PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Agmon, IC				Agmon, Ilana C.			A model for the role of isomerization in nascent peptide movement through the ribosomal tunnel	FASEB JOURNAL			English	Article						translation; translation arrest; origin of life	CIS-TRANS ISOMERIZATION; STRUCTURAL BASIS; CIS/TRANS ISOMERIZATION; TRANSFERASE CENTER; TRANSFER-RNA; TRANSLOCATION; CONFORMATION; NUCLEOTIDES; DYNAMICS	The ribosome is a molecular machine whose manner of controlling the progression of the nascent chain through the ribosomal exit tunnel is currently unknown. A novel model for the mechanism driving the nascent chain motion is hereby presented, in which the similar to 180 degrees rotatory motion performed by each C-terminal amino acid of the nascent chain during its translocation from the A site to the P site, is suggested to twist the newly formed peptide bond into cis conformation. By catalyzing the cis to trans isomerization, the ribosome is proposed to release the potential energy stored within the cis conformer and to utilize it to push the chain down the tunnel, thus operating as a molecular motor. This hypothetical isomerization mechanism is supported by its ability to provide an explanation for the peculiar conduct observed in translational events of nascent chains with C-terminal prolines: the slow peptide bond formation with puromycin, translation arrest, and tmRNA tagging.-Agmon, I. C. A model for the role of isomerization in nascent peptide movement through the ribosomal tunnel. FASEB J. 26, 2277-2282 (2012). www.fasebj.org	[Agmon, Ilana C.] Technion Israel Inst Technol, Inst Adv Studies Theoret Chem, Schulich Fac Chem, IL-32000 Haifa, Israel; [Agmon, Ilana C.] Hebrew Univ Jerusalem, Fritz Haber Res Ctr Mol Dynam, IL-91904 Jerusalem, Israel	Technion Israel Institute of Technology; Hebrew University of Jerusalem	Agmon, IC (corresponding author), Technion Israel Inst Technol, Inst Adv Studies Theoret Chem, Schulich Fac Chem, IL-32000 Haifa, Israel.	chilana@tx.technion.ac.il			Elsa Fendler Research Fund	Elsa Fendler Research Fund	Thanks are due to Noam Adir for the helpful discussion. This work was supported by a Technion Vice President grant from the Elsa Fendler Research Fund.	Agmon F, 2005, BIOL CHEM, V386, P833, DOI 10.1515/BC.2005.098; Agmon I, 2006, ISR J ECOL EVOL, V52, P359, DOI 10.1560/IJEE_52_3-4_359; Agmon I, 2009, INT J MOL SCI, V10, P2921, DOI 10.3390/ijms10072921; Bashan A, 2003, MOL CELL, V11, P91, DOI 10.1016/S1097-2765(03)00009-1; Bhushan S, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000581; Bhushan S, 2010, MOL CELL, V40, P138, DOI 10.1016/j.molcel.2010.09.009; BIRGE RR, 1981, BIOPHYS J, V34, P517, DOI 10.1016/S0006-3495(81)84865-5; Bokov K, 2009, NATURE, V457, P977, DOI 10.1038/nature07749; Chirkova A, 2010, NUCLEIC ACIDS RES, V38, P4844, DOI 10.1093/nar/gkq213; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Green R, 1997, J MOL BIOL, V266, P40, DOI 10.1006/jmbi.1996.0780; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Hugel T, 2002, SCIENCE, V296, P1103, DOI 10.1126/science.1069856; Kern D, 1997, J AM CHEM SOC, V119, P8403, DOI 10.1021/ja970606w; Kramer G, 2001, INT J BIOCHEM CELL B, V33, P541, DOI 10.1016/S1357-2725(01)00044-9; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; Lu JL, 2007, J MOL BIOL, V371, P1378, DOI 10.1016/j.jmb.2007.06.038; Mankin AS, 2006, TRENDS BIOCHEM SCI, V31, P11, DOI 10.1016/j.tibs.2005.11.007; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Moore PB, 2003, ANNU REV BIOCHEM, V72, P813, DOI 10.1146/annurev.biochem.72.110601.135450; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Mulder FAA, 2004, BIOCHEMISTRY-US, V43, P5930, DOI 10.1021/bi0495331; Murthy VL, 1999, J MOL BIOL, V291, P313, DOI 10.1006/jmbi.1999.2958; PICKING WD, 1991, J BIOL CHEM, V266, P1534; Reimer U, 2002, BIOPHYS CHEM, V96, P203, DOI 10.1016/S0301-4622(02)00013-3; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Schmid FX, 2002, ADV PROTEIN CHEM, V59, P243; Schuette JC, 2009, EMBO J, V28, P755, DOI 10.1038/emboj.2009.26; Seidelt B, 2009, SCIENCE, V326, P1412, DOI 10.1126/science.1177662; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Tchaicheeyan O, 2004, FASEB J, V18, P783, DOI 10.1096/fj.03-1027hyp; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Vazquez-Laslop N, 2008, MOL CELL, V30, P190, DOI 10.1016/j.molcel.2008.02.026; Vologodskii A, 2006, PHYS LIFE REV, V3, P119, DOI 10.1016/j.plrev.2006.02.002; Voorhees RM, 2009, NAT STRUCT MOL BIOL, V16, P528, DOI 10.1038/nsmb.1577; Wohlgemuth I, 2008, J BIOL CHEM, V283, P32229, DOI 10.1074/jbc.M805316200; Yang R, 2009, J BACTERIOL, V191, P3445, DOI 10.1128/JB.00096-09; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	41	1	1	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2277	2282		10.1096/fj.11-197657	http://dx.doi.org/10.1096/fj.11-197657			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22389440				2022-12-28	WOS:000305017200006
J	Calve, S; Simon, HG				Calve, Sarah; Simon, Hans-Georg			Biochemical and mechanical environment cooperatively regulate skeletal muscle regeneration	FASEB JOURNAL			English	Article						extracellular matrix; polydimethylsiloxane; live cell imaging; newt; tenascin-C	EXTRACELLULAR-MATRIX; LIMB REGENERATION; BIOMECHANICAL PROPERTIES; PERSISTENCE LENGTH; GROWTH-FACTORS; NEWT LIMB; CELLS; HYALURONAN; ELASTICITY; BEHAVIOR	During forelimb regeneration in the newt Notophthalmus viridescens, the dynamic expression of a transitional matrix rich in hyaluronic acid, tenascin-C, and fibronectin controls muscle cell behavior in vivo and in vitro. However, the influence of extracellular matrix (ECM) remodeling on tissue stiffness and the cellular response to mechanical variations during regeneration was unknown. By measuring the transverse stiffness of tissues in situ, we found undifferentiated regenerative blastemas were less stiff than differentiated stump muscle (13.3 +/- 1.6 vs. 16.6 +/- 1.2 kPa). To directly determine how ECM and stiffness combine to affect skeletal muscle fragmentation, migration, and fusion, we coated silicone-based substrates ranging from 2 to 100 kPa with matrices representative of transitional (tenascin-C and fibronectin) and differentiated environments (laminin and Matrigel). Using live-cell imaging, we found softer tenascin-C-coated substrates significantly enhanced migration and fragmentation of primary newt muscle cells. In contrast, stiffer substrates coated with laminin, Matrigel, or fibronectin increased differentiation while suppressing migration and fragmentation. These data support our in vivo observations that a transitional matrix of reduced stiffness regulates muscle plasticity and progenitor cell recruitment into the regenerative blastema. These new findings will enable the determination of how biochemical and mechanical cues from the ECM control genetic pathways that drive regeneration.-Calve, S., Simon, H.-G. Biochemical and mechanical environment cooperatively regulate skeletal muscle regeneration. FASEB J. 26, 2538-2545 (2012). www.fasebj.org	[Calve, Sarah; Simon, Hans-Georg] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Dept Pediat, Chicago, IL 60614 USA	Northwestern University; Feinberg School of Medicine	Simon, HG (corresponding author), Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Dept Pediat, 2300 Childrens Plaza,M-C 204, Chicago, IL 60614 USA.	hgsimon@northwestern.edu			U.S. Defense Advanced Research Projects Agency [BAA04-12 Addendum B]; Chicago Community Trust; U.S. National Institutes of Health	U.S. Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Chicago Community Trust; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. K. Shull and K. Otim (Department of Materials Science and Engineering, Northwestern University) for assistance with mechanical testing. The authors also thank all members of the H.-G. S. laboratory for helpful discussions. The authors are grateful to Dr. C. Huppenbauer and M. Tjepkema (W. Nuhsbaum Inc., McHenry, IL, USA) for expert technical support. This work was supported by the U.S. Defense Advanced Research Projects Agency, Restorative Injury Repair BAA04-12 Addendum B (to H.-G. S.), Searle Funds at The Chicago Community Trust (to H.-G. S.), and the U.S. National Institutes of Health T90 Regenerative Medicine Training	Boonen KJM, 2009, AM J PHYSIOL-CELL PH, V296, pC1338, DOI 10.1152/ajpcell.00015.2009; Bosboom EMH, 2001, J BIOMECH, V34, P1365, DOI 10.1016/S0021-9290(01)00083-5; Bouchiat C, 1999, BIOPHYS J, V76, P409, DOI 10.1016/S0006-3495(99)77207-3; Calve S, 2010, IUTAM BOOKSER, V16, P257, DOI 10.1007/978-90-481-3348-2_22; Calve S, 2011, DEV DYNAM, V240, P1233, DOI 10.1002/dvdy.22530; Calve S, 2010, DEV BIOL, V344, P259, DOI 10.1016/j.ydbio.2010.05.007; Candiello J, 2007, FEBS J, V274, P2897, DOI 10.1111/j.1742-4658.2007.05823.x; CHALKLEY DT, 1954, J MORPHOL, V94, P21, DOI 10.1002/jmor.1050940103; Collinsworth AM, 2002, AM J PHYSIOL-CELL PH, V283, pC1219, DOI 10.1152/ajpcell.00502.2001; Darling EM, 2010, BIOPHYS J, V98, P2848, DOI 10.1016/j.bpj.2010.03.037; Defranchi E, 2005, MICROSC RES TECHNIQ, V67, P27, DOI 10.1002/jemt.20177; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Grounds Miranda D., 2008, V3, P269; Hakim CH, 2011, J APPL PHYSIOL, V110, P1656, DOI 10.1152/japplphysiol.01425.2010; Han L, 2011, ANNU REV MATER RES, V41, P133, DOI 10.1146/annurev-matsci-062910-100431; Han R, 2009, P NATL ACAD SCI USA, V106, P12573, DOI 10.1073/pnas.0906545106; Jarvinen TAH, 2003, J CELL SCI, V116, P857, DOI 10.1242/jcs.00303; Kjaer M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003; Kragl M, 2009, NATURE, V460, P60, DOI 10.1038/nature08152; Kumar A, 2004, PLOS BIOL, V2, P1168, DOI 10.1371/journal.pbio.0020218; Kumar A, 2007, NAT PROTOC, V2, P939, DOI 10.1038/nprot.2007.134; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Luo ZP, 2004, BIORHEOLOGY, V41, P247; Macfelda K, 2007, ARTIF ORGANS, V31, P4, DOI 10.1111/j.1525-1594.2007.00334.x; Mackey AL, 2011, FASEB J, V25, P1943, DOI 10.1096/fj.10-176487; MALEY MAL, 1995, EXP CELL RES, V219, P169, DOI 10.1006/excr.1995.1217; MESCHER AL, 1988, DIFFERENTIATION, V38, P161, DOI 10.1111/j.1432-0436.1988.tb00210.x; Morrison JI, 2006, J CELL BIOL, V172, P433, DOI 10.1083/jcb.200509011; Nemir S, 2010, ANN BIOMED ENG, V38, P2, DOI 10.1007/s10439-009-9811-1; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Ogneva IV, 2010, BIOPHYS J, V98, P418, DOI 10.1016/j.bpj.2009.10.028; Okita M, 2004, J MUSCLE RES CELL M, V25, P159, DOI 10.1023/B:JURE.0000035851.12800.39; Ren KF, 2010, ACTA BIOMATER, V6, P4238, DOI 10.1016/j.actbio.2010.06.014; REPESH LA, 1982, DIFFERENTIATION, V22, P125, DOI 10.1111/j.1432-0436.1982.tb01236.x; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sanes JR, 2003, J BIOL CHEM, V278, P12601, DOI 10.1074/jbc.R200027200; Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524-475X.2009.00466.x; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Serrano AL, 2011, CURR TOP DEV BIOL, V96, P167, DOI 10.1016/B978-0-12-385940-2.00007-3; Shull KR, 2002, MAT SCI ENG R, V36, P1, DOI 10.1016/S0927-796X(01)00039-0; Sivakumar L, 2010, BIOMATERIALS, V31, P4802, DOI 10.1016/j.biomaterials.2010.02.070; Tassava Roy A., 1996, Wound Repair and Regeneration, V4, P75, DOI 10.1046/j.1524-475X.1996.40113.x; TOOLE BP, 1971, DEV BIOL, V25, P57, DOI 10.1016/0012-1606(71)90019-4; Vinarsky V, 2005, DEV BIOL, V279, P86, DOI 10.1016/j.ydbio.2004.12.003; Walthall JC, 2006, ANAT REC PART A, V288A, P46, DOI 10.1002/ar.a.20279	48	60	60	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2538	2545		10.1096/fj.11-200162	http://dx.doi.org/10.1096/fj.11-200162			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415307	Green Published, Green Submitted			2022-12-28	WOS:000305017200030
J	Lorenzato, A; Martino, C; Dani, N; Oligschlager, Y; Ferrero, AM; Biglia, N; Calogero, R; Olivero, M; Di Renzo, MF				Lorenzato, Annalisa; Martino, Cosimo; Dani, Nadia; Oligschlaeger, Yvonne; Ferrero, Anna Maria; Biglia, Nicoletta; Calogero, Raffaele; Olivero, Martina; Di Renzo, Maria Flavia			The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C	FASEB JOURNAL			English	Article						receptor tyrosine kinases; MET receptor; hepatocyte growth factor; nuclear import	HEPATOCYTE GROWTH-FACTOR; CHROMOSOME SEGREGATION; TUMOR-SUPPRESSOR; IMPORTIN-ALPHA; HUMAN HOMOLOG; EXPRESSION; CARCINOMA; CISPLATIN; CSE1; CSE1L/CAS	The cellular apoptosis susceptibility gene CAS/CSE1L is overexpressed in cancer, although it was originally identified as a gene that renders cells vulnerable to apoptotic stimuli. CAS/CSE1L has roles in the nucleocytoplasmic recycling of importin-alpha and in the regulation of gene expression, cell migration, and secretion. We identified CAS/CSE1L as a survival factor for ovarian cancer cells in vitro and in vivo. In 3/3 ovarian cancer cell lines, CAS/CSE1L was down-modulated by the unorthodox proapoptotic signaling of the MET receptor. CAS/CSE1L knockdown with RNA interference committed the ovarian cancer cells to death, but not immortalized normal cells and breast and colon cancer cells. In 70 and 95% of these latter cells, respectively, CAS/CSE1L was localized in the cytoplasm, while it accumulated in the nucleus in >90% of ovarian cancer cells. Nuclear localization depended on AKT, which was constitutively active in ovarian cancer cells. In the nucleus, CAS/CSE1L regulated the expression of the proapoptotic Ras-association domain family 1 gene products RASSF1C and RASSF1A, which mediated death signals evoked by depletion of CAS/CSE1L. Our data show that CAS/CSE1L protects ovarian cancer cells from death through transcriptional suppression of a proapoptotic gene and suggest that the localization of CAS/CSE1L dictates its function.-Lorenzato, A., Martino, C., Dani, N., Oligschlager, Y., Ferrero, A. M., Biglia, N., Calogero, R., Olivero, M., Di Renzo, M. F. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB J. 26, 2446-2456 (2012). www.fasebj.org	[Di Renzo, Maria Flavia] Univ Turin, Sch Med, Canc Genet Lab, Dept Oncol Sci,IRCC, I-10060 Turin, Italy; [Ferrero, Anna Maria; Biglia, Nicoletta] Azienda Sanit Osped ASO Ordine Mauriziano, Dept Obstet & Gynaecol, Turin, Italy; [Lorenzato, Annalisa; Martino, Cosimo; Dani, Nadia; Oligschlaeger, Yvonne; Olivero, Martina; Di Renzo, Maria Flavia] Inst Canc Res Candiolo, Candiolo, Italy; [Calogero, Raffaele] ASO San Luigi Gonzaga, Dept Clin & Biol Sci, Genom & Bioinformat Unit, Orbassano, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; IRCCS Fondazione del Piemonte per l'Oncologia	Di Renzo, MF (corresponding author), Univ Turin, Sch Med, Canc Genet Lab, Dept Oncol Sci,IRCC, SP 142,Km 3-95, I-10060 Turin, Italy.	mariaflavia.direnzo@unito.it	Calogero, Raffaele/K-9428-2019; Biglia, Nicoletta/F-8801-2013; DI RENZO, Maria Flavia/B-6091-2012; olivero, martina/J-4811-2018; Ferrero, Annamaria/AAI-6572-2020	Calogero, Raffaele/0000-0002-2848-628X; Biglia, Nicoletta/0000-0003-1009-5309; DI RENZO, Maria Flavia/0000-0002-5093-3373; olivero, martina/0000-0002-6815-3498; Ferrero, Annamaria/0000-0002-2909-3699; Martino, Cosimo/0000-0002-7286-9755; Lorenzato, Annalisa/0000-0002-9324-2337	Italian Association for Cancer Research; Fondazione Cassa di Risparmio delle Provincie Lombarde (CARIPLO); Italian Ministry of Health; Regione Piemonte	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio delle Provincie Lombarde (CARIPLO)(Fondazione Cariplo); Italian Ministry of Health(Ministry of Health, Italy); Regione Piemonte(Regione Piemonte)	The authors are extremely grateful to Dr. Simona Pavan, who generously made available the results of her experiments on CAS/CSE1L and chemotherapeutics in ovarian cancer. They also thank Dr. Barbara Canepa for scientific collaboration, and Lidia Giraudo Diego for her enthusiastic help in performing experiments. The authors are indebted to Prof. Guido Serini for help in performing immunofluorescence experiments with confocal microscopy, and to Prof. Luca Primo for advice on expressing active AKT. This study is supported by grants of the Italian Association for Cancer Research and Fondazione Cassa di Risparmio delle Provincie Lombarde (CARIPLO) to M. F. D., of the Italian Ministry of Health to M. F. D. and N.B., and of Regione Piemonte to M. F. D. and R.C.	Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Bagnat M, 2010, CURR BIOL, V20, P1840, DOI 10.1016/j.cub.2010.09.012; Bardella C, 2007, CLIN CANCER RES, V13, P2191, DOI 10.1158/1078-0432.CCR-06-1915; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Bera TK, 2001, MOL CELL BIOL, V21, P7020, DOI 10.1128/MCB.21.20.7020-7024.2001; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Brustmann H, 2004, GYNECOL ONCOL, V92, P268, DOI 10.1016/j.ygyno.2003.10.029; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Calleros L, 2009, CARCINOGENESIS, V30, P1670, DOI 10.1093/carcin/bgp188; Capelson M, 2010, CELL, V140, P372, DOI 10.1016/j.cell.2009.12.054; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Coltella N, 2006, INT J CANCER, V118, P2981, DOI 10.1002/ijc.21766; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040; Kodiha M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008420; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Liao CF, 2008, BMB REP, V41, P210, DOI 10.5483/BMBRep.2008.41.3.210; Liao CF, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-15; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Ogryzko VV, 1997, BIOCHEMISTRY-US, V36, P9493, DOI 10.1021/bi970236o; Olivero M, 2006, MOL CANCER THER, V5, P1126, DOI 10.1158/1535-7163.MCT-06-0013; Ouellet V, 2006, INT J CANCER, V119, P599, DOI 10.1002/ijc.21902; Peiro G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Royer B, 2005, ANTI-CANCER DRUG, V16, P1009, DOI 10.1097/01.cad.0000176505.94175.d4; Samouelian V, 2004, CANCER CHEMOTH PHARM, V54, P497, DOI 10.1007/s00280-004-0843-9; Scherf U, 1996, P NATL ACAD SCI USA, V93, P2670, DOI 10.1073/pnas.93.7.2670; Smith JA, 2005, GYNECOL ONCOL, V98, P141, DOI 10.1016/j.ygyno.2005.02.006; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Tai CJ, 2010, EXP CELL RES, V316, P2969, DOI 10.1016/j.yexcr.2010.07.019; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Tommasi S, 2005, CANCER RES, V65, P92; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tsai CSS, 2010, AM J PATHOL, V176, P1619, DOI 10.2353/ajpath.2010.090467; Tsao TY, 2009, MOL CELL BIOCHEM, V327, P163, DOI 10.1007/s11010-009-0054-0; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Yasuda Y, 2012, EMBO J, V31, P83, DOI 10.1038/emboj.2011.360; Yoon SO, 2008, MOL CELL, V29, P362, DOI 10.1016/j.molcel.2007.12.024	49	27	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2446	2456		10.1096/fj.11-195982	http://dx.doi.org/10.1096/fj.11-195982			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22389439				2022-12-28	WOS:000305017200022
J	Chen, ZM; Janes, K; Chen, C; Doyle, T; Bryant, L; Tosh, DK; Jacobson, KA; Salvemini, D				Chen, Zhoumou; Janes, Kali; Chen, Collin; Doyle, Tim; Bryant, Leesa; Tosh, Dilip K.; Jacobson, Kenneth A.; Salvemini, Daniela			Controlling murine and rat chronic pain through A(3) adenosine receptor activation	FASEB JOURNAL			English	Article						IB-MECA; MRS1898; paclitaxel; oxaliplatin; bortezomib	ISCHEMIC BRAIN-INJURY; SYNAPTIC-TRANSMISSION; RHEUMATOID-ARTHRITIS; INTERNATIONAL UNION; TARGET; CLASSIFICATION; A(3)-RECEPTORS; PHARMACOLOGY; NOMENCLATURE; OXALIPLATIN	Clinical management of chronic neuropathic pain is limited by marginal effectiveness and unacceptable side effects of current drugs. We demonstrate A(3) adenosine receptor (A(3)AR) agonism as a new target-based therapeutic strategy. The development of mechanoallodynia in a well-characterized mouse model of neuropathic pain following chronic constriction injury of the sciatic nerve was rapidly and dose-dependently reversed by the A(3)AR agonists: IB-MECA, its 2-chlorinated analog (Cl-IB-MECA), and the structurally distinct MRS1898. These effects were naloxone insensitive and thus are not opioid receptor mediated. IB-MECA was >= 1.6-fold more efficacious than morphine and >5-fold more potent. In addition, IB-MECA was equally efficacious as gabapentin (Neurontin) or amitriptyline, but respectively >350- and >75-fold more potent. Besides its potent standalone ability to reverse established mechanoallodynia, IB-MECA significantly increased the antiallodynic effects of all 3 analgesics. Moreover, neuropathic pain development in rats caused by widely used chemotherapeutics in the taxane (paclitaxel), platinum-complex (oxaliplatin), and proteasome-inhibitor (bortezomib) classes was blocked by IB-MECA without antagonizing their antitumor effect. A(3)AR agonist effects were blocked with A(3)AR antagonist MRS1523, but not with A(1)AR (DPCPX) or A(2)AAR (SCH-442416) antagonists. Our findings provide the scientific rationale and pharmacological basis for therapeutic development of A(3)AR agonists for chronic pain.-Chen, Z., Janes, K., Chen, C., Doyle, T., Bryant, L., Tosh, D. K., Jacobson, K. A., Salvemini, D. Controlling murine and rat chronic pain through A(3) adenosine receptor activation. FASEB J. 26, 1855-1865 (2012). www.fasebj.org	[Chen, Zhoumou; Janes, Kali; Chen, Collin; Doyle, Tim; Bryant, Leesa; Salvemini, Daniela] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; [Tosh, Dilip K.; Jacobson, Kenneth A.] NIDDK, NIH, Bethesda, MD USA	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Salvemini, D (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	salvemd@slu.edu	Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	U.S. National Institutes of Health (NIH) [R01 DA024074]; St. Louis University; NIH National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK031117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA024074] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Louis University; NIH National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors are grateful to Dr. Gary Bennett, (McGill University, Montreal, QC, Canada) for critically reviewing our work. This work was supported by U.S. National Institutes of Health (NIH) grant R01 DA024074 (D. S.), St. Louis University President Research Funds (D. S.), and the NIH National Institute of Diabetes and Digestive and Kidney Diseases Intramural Program (K.A.J.). The authors report no conflicts of interest.	Abbracchio MP, 1997, BIOCHEM BIOPH RES CO, V241, P297, DOI 10.1006/bbrc.1997.7705; Bennett GJ, 2010, ONCOLOGIST, V15, P9, DOI 10.1634/theoncologist.2009-S503; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Cata JP, 2006, MINERVA ANESTESIOL, V72, P151; Chen GJ, 2006, J NEUROSCI RES, V84, P1848, DOI 10.1002/jnr.21071; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Farquhar-Smith Paul, 2011, Curr Opin Support Palliat Care, V5, P1, DOI 10.1097/SPC.0b013e328342f9cc; Fedorova IM, 2003, CELL MOL NEUROBIOL, V23, P431, DOI 10.1023/A:1023601007518; Finnerup NB, 2010, PAIN, V150, P573, DOI 10.1016/j.pain.2010.06.019; Fishman P, 2003, CURR TOP MED CHEM, V3, P463, DOI 10.2174/1568026033392147; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Fishman P, 2012, DRUG DISCOV TODAY, V17, P359, DOI 10.1016/j.drudis.2011.10.007; FOLEY KM, 1995, ANTI-CANCER DRUG, V6, P4, DOI 10.1097/00001813-199504003-00002; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Gao ZG, 2009, PURINERG SIGNAL, V5, P31, DOI 10.1007/s11302-008-9107-1; Ge ZD, 2006, J PHARMACOL EXP THER, V319, P1200, DOI 10.1124/jpet.106.111351; Giannaccini G, 2008, NEUROCHEM RES, V33, P852, DOI 10.1007/s11064-007-9525-4; Hentschel S, 2003, RESTOR NEUROL NEUROS, V21, P55; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; Jacobson KA, 1998, TRENDS PHARMACOL SCI, V19, P184, DOI 10.1016/S0165-6147(98)01203-6; Jacobson KA, 2011, ADV PHARMACOL, V61, P187, DOI 10.1016/B978-0-12-385526-8.00007-2; Joseph EK, 2004, EUR J NEUROSCI, V20, P2896, DOI 10.1111/j.1460-9568.2004.03750.x; Kiesman William F, 2009, Handb Exp Pharmacol, P25, DOI 10.1007/978-3-540-89615-9_2; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016; Kriedt Christopher L, 2010, J Exp Ther Oncol, V8, P287; Kumar V, 2009, EUR J PHARMACOL, V616, P7, DOI 10.1016/j.ejphar.2009.05.005; Li AH, 1998, J MED CHEM, V41, P3186, DOI 10.1021/jm980093j; Lopes LV, 2003, NEUROREPORT, V14, P1645, DOI 10.1097/00001756-200308260-00021; Loram LC, 2009, J NEUROSCI, V29, P14015, DOI 10.1523/JNEUROSCI.3447-09.2009; Ndengele MM, 2009, J PHARMACOL EXP THER, V329, P64, DOI 10.1124/jpet.108.146290; Ochaion A, 2009, CELL IMMUNOL, V258, P115, DOI 10.1016/j.cellimm.2009.03.020; PELLATDECEUNYNK C, 1995, BLOOD, V86, P4001, DOI 10.1182/blood.V86.10.4001.bloodjournal86104001; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Ru F, 2011, AM J PHYSIOL-GASTR L, V300, pG485, DOI 10.1152/ajpgi.00361.2010; Rubaj A, 2003, BEHAV BRAIN RES, V141, P11, DOI 10.1016/S0166-4328(02)00314-5; Shah MR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-84; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; Silverman MH, 2008, J RHEUMATOL, V35, P41; Taliani S, 2010, CURR TOP MED CHEM, V10, P942, DOI 10.2174/156802610791293109; Tchilibon S, 2005, J MED CHEM, V48, P1745, DOI 10.1021/jm049580r; Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V367, P157, DOI 10.1016/S0014-2999(98)00977-7; Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wunderlich JE, 2008, AM J PHYSIOL-GASTR L, V294, pG554, DOI 10.1152/ajpgi.00500.2007; Yi DH, 1997, ARCH BIOCHEM BIOPHYS, V344, P253, DOI 10.1006/abbi.1997.0218; Yoon MH, 2005, ANESTH ANALG, V101, P1417, DOI 10.1213/01.ANE.0000180994.10087.6F; Zhang M, 2010, NEUROCHEM INT, V56, P35, DOI 10.1016/j.neuint.2009.08.011; Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016; Zheng J, 2007, AM J PHYSIOL-HEART C, V293, pH3685, DOI 10.1152/ajpheart.00819.2007; Zylka MJ, 2011, TRENDS MOL MED, V17, P188, DOI 10.1016/j.molmed.2010.12.006	58	83	83	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1855	1865		10.1096/fj.11-201541	http://dx.doi.org/10.1096/fj.11-201541			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22345405	Green Published			2022-12-28	WOS:000303680800014
J	Chen, JR; Zhang, J; Lazarenko, OP; Kang, P; Blackburn, ML; Ronis, MJJ; Badger, TM; Shankar, K				Chen, Jin-Ran; Zhang, Jian; Lazarenko, Oxana P.; Kang, Ping; Blackburn, Michael L.; Ronis, Martin J. J.; Badger, Thomas M.; Shankar, Kartik			Inhibition of fetal bone development through epigenetic down-regulation of HoxA10 in obese rats fed high-fat diet	FASEB JOURNAL			English	Article						osteoblast; methylation; osteogenesis; free fatty acid	VITAMIN-D STATUS; DNA METHYLATION; OSTEOPOROSIS; OSTEOBLASTOGENESIS; ORIGINS; DISEASE; LINEAGE; CELLS; ACIDS; MASS	Epidemiological studies show that maternal obesity during intrauterine and early postnatal life increases the risk of low bone mass and fracture later in life. Here, we show that bone development is inhibited in gestational embryonic day 18.5 (E18.5) embryos from rat dams made obese by feeding a high-fat diet (HFD). Moreover, fetal rat osteogenic calvarial cells (FOCCs) from these obese dams have significantly less potential to develop into mature osteoblasts compared to cells from AIN-93G diet-fed controls. Profiling of transcriptional genes for osteogenesis revealed a profound decrease in the homeodomain-containing factor A10 (HoxA10) in FOCCs from fetuses of HFD-induced obese dams. Significant methylation of the HoxA10 promoter was found in those FOCCs, as well as in mouse ST2 cells treated with a mixture of free fatty acids similar to that found in serum from HFD-induced obese rats. This was accompanied by lower expression of osteogenic markers, but higher levels of PPAR gamma. Control FOCCs depleted of the HoxA10 gene (shRNA) ex vivo behave similarly to cells from fetuses of obese dams; conversely, overexpression of HoxA10 gene in FOCCs from HFD rats exhibit the same phenotype as controls. Treatment of FOCCs from control rats or of ST2 cells with an artificial mixture of free fatty acids significantly down-regulated HoxA10 protein expression, and cells exhibited adipocyte-like properties. These results suggest that maternal obesity impairs fetal skeletal development through down-regulation of the HoxA10 gene, which may lead to an increase in the prevalence of low bone mass in the offspring later in life.-Chen, J.-R., Zhang, J., Lazarenko, O. P., Kang, P., Blackburn, M. L., Ronis, M. J. J., Badger, T. M., Shankar, K. Inhibition of fetal bone development through epigenetic down-regulation of HoxA10 in obese rats fed high-fat diet. FASEB J. 26, 1131-1141 (2012). www.fasebj.org	[Chen, Jin-Ran; Zhang, Jian; Lazarenko, Oxana P.; Kang, Ping; Blackburn, Michael L.; Ronis, Martin J. J.; Badger, Thomas M.; Shankar, Kartik] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; [Chen, Jin-Ran; Zhang, Jian; Ronis, Martin J. J.; Badger, Thomas M.; Shankar, Kartik] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Chen, JR (corresponding author), Arkansas Childrens Nutr Ctr, 15 Childrens Way,Slot 512-20B, Little Rock, AR 72202 USA.	chenjinran@uams.edu		Shankar, Kartik/0000-0002-7964-9026	U.S. Department of Agriculture/Agriculture Research Service [CRIS 6251-51000-006-03s]	U.S. Department of Agriculture/Agriculture Research Service(United States Department of Agriculture (USDA))	This work was supported by U.S. Department of Agriculture/Agriculture Research Service grant CRIS 6251-51000-006-03s to the Arkansas Children's Nutrition Center.	Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137; Chen JR, 2010, J BONE MINER RES, V25, P1117, DOI 10.1002/jbmr.7; Cooper C, 2009, ADV EXP MED BIOL, V646, P31, DOI 10.1007/978-1-4020-9173-5_3; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Dunn GA, 2011, ENDOCRINOLOGY, V152, P2228, DOI 10.1210/en.2010-1461; ELPHICK MC, 1975, J PHYSIOL-LONDON, V252, P29, DOI 10.1113/jphysiol.1975.sp011132; Gicquel C, 2008, BEST PRACT RES CL EN, V22, P1, DOI 10.1016/j.beem.2007.07.009; Gluckman PD, 2007, BIOESSAYS, V29, P145, DOI 10.1002/bies.20522; Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979; Gordon JAR, 2011, CELLS TISSUES ORGANS, V194, P146, DOI 10.1159/000324790; Gordon JAR, 2010, MOL CELL BIOL, V30, P3531, DOI 10.1128/MCB.00889-09; Greco EA, 2010, INT J CLIN PRACT, V64, P817, DOI 10.1111/j.1742-1241.2009.02301.x; Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544-06; Hassan MQ, 2009, CELLS TISSUES ORGANS, V189, P122, DOI 10.1159/000151453; Herrera BM, 2011, MATURITAS, V69, P41, DOI 10.1016/j.maturitas.2011.02.018; Hombria JCG, 2003, DIFFERENTIATION, V71, P461, DOI 10.1046/j.1432-0436.2003.7108004.x; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Javaid MK, 2002, BEST PRACT RES CL EN, V16, P349, DOI 10.1053/beem.2002.0199; King JC, 2006, ANNU REV NUTR, V26, P271, DOI 10.1146/annurev.nutr.24.012003.132249; Lanham SA, 2008, OSTEOPOROSIS INT, V19, P157, DOI 10.1007/s00198-007-0448-3; Leucht P, 2008, DEVELOPMENT, V135, P2845, DOI 10.1242/dev.023788; Liang C, 2009, BIRTH DEFECTS RES B, V86, P362, DOI 10.1002/bdrb.20204; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Mahon P, 2010, J BONE MINER RES, V25, P14, DOI 10.1359/jbmr.090701; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Menegola E, 2001, TERATOLOGY, V64, P125, DOI 10.1002/tera.1055; Premaor MO, 2010, J BONE MINER RES, V25, P292, DOI 10.1359/jbmr.091004; Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070; Shankar K, 2010, ENDOCRINOLOGY, V151, P153, DOI 10.1210/en.2009-0840; Viljakainen HT, 2010, J CLIN ENDOCR METAB, V95, P1749, DOI 10.1210/jc.2009-1391; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813	36	39	40	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1131	1141		10.1096/fj.11-197822	http://dx.doi.org/10.1096/fj.11-197822			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22131269				2022-12-28	WOS:000300949300017
J	Douard, V; Suzuki, T; Sabbagh, Y; Lee, J; Shapses, S; Lin, S; Ferraris, RP				Douard, Veronique; Suzuki, Takuji; Sabbagh, Yves; Lee, Jacklyn; Shapses, Sue; Lin, Sheldon; Ferraris, Ronaldo P.			Dietary fructose inhibits lactation-induced adaptations in rat 1,25-(OH)(2)D-3 synthesis and calcium transport	FASEB JOURNAL			English	Article						bone; intestine; kidney; parathyroid hormone; vitamin D	VITAMIN-D-RECEPTOR; BONE-MINERAL DENSITY; KAPPA-B; MICE; INDUCTION; KNOCKOUT; GENES; IDENTIFICATION; CONSUMPTION; HOMEOSTASIS	We recently showed that excessive fructose consumption, already associated with numerous metabolic abnormalities, reduces rates of intestinal Ca2+ transport. Using a rat lactation model with increased Ca2+ requirements, we tested the hypothesis that mechanisms underlying these inhibitory effects of fructose involve reductions in renal synthesis of 1,25-(OH)(2)D-3. Pregnant and virgin (control) rats were fed isocaloric fructose or, as controls, glucose, and starch diets from d2 of gestation to the end of lactation. Compared to virgins, lactating dams fed glucose or starch had higher rates of intestinal transcellular Ca2+ transport, elevated intestinal and renal expression of Ca2+ channels, Ca2+-binding proteins, and CaATPases, as well as increased levels of 25-(OH)D-3 and 1,25-(OH)(2)D-3. Fructose consumption prevented almost all of these lactation-induced increases, and reduced vitamin D receptor binding to promoter regions of Ca2+ channels and binding proteins. Changes in 1,25-(OH)(2)D-3 level were tightly correlated with alterations in expression of 1 alpha-hydroxylase but not with levels of parathyroid hormone and of 24-hydroxylase. Bone mineral density, content, and mechanical strength each decreased with lactation, but then fructose exacerbated these effects. When Ca2+ requirements increase during lactation or similar physiologically challenging conditions, excessive fructose consumption may perturb Ca2+ homeostasis because of fructose-induced reductions in synthesis of 1,25-(OH)(2)D-3.-Douard, V., Suzuki, T., Sabbagh, Y., Lee, J., Shapses, S., Lin, S., Ferraris, R. P. Dietary fructose inhibits lactation-induced adaptations in rat 1,25-(OH)(2)D-3 synthesis and calcium transport. FASEB J. 26, 707-721 (2012). www.fasebj.org	[Douard, Veronique; Suzuki, Takuji; Lee, Jacklyn; Ferraris, Ronaldo P.] UMDNJ New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07101 USA; [Lin, Sheldon] UMDNJ New Jersey Med Sch, Dept Orthoped, Newark, NJ 07101 USA; [Suzuki, Takuji] Univ Shizuoka, Grad Sch Nutr & Environm Sci, Lab Nutr Physiol, Shizuoka 4228526, Japan; [Sabbagh, Yves] Genzyme Corp, Renal & Endocrine Sci Grp, Framingham, MA 01701 USA; [Shapses, Sue] Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Shizuoka; Sanofi-Aventis; Genzyme Corporation; Rutgers State University New Brunswick	Ferraris, RP (corresponding author), UMDNJ New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,MSB H621, Newark, NJ 07101 USA.	ferraris@umdnj.edu	Sabbagh, Yves/I-9792-2019; Douard, veronique/AAU-6271-2020	Sabbagh, Yves/0000-0001-5339-6705; Shapses, Sue/0000-0002-3128-2325; Suzuki, Takuji/0000-0002-7257-6792	National Science Foundation [IOS-1121049]; U.S. National Institutes of Health [DK-075617, AG-12161]; Foundation of the University of Medicine and Dentistry of New Jersey (UMDNJ); Institut Benjamin Delessert; Japan Society for the Promotion of Science [20-11635]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK075617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012161, R01AG012161] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation of the University of Medicine and Dentistry of New Jersey (UMDNJ); Institut Benjamin Delessert; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the National Science Foundation (IOS-1121049 to R. P. F.), the U.S. National Institutes of Health (DK-075617 to R. P. F. and AG-12161 to S. A. S.), the Foundation of the University of Medicine and Dentistry of New Jersey (UMDNJ; to R. P. F.), and Institut Benjamin Delessert (to V. D.), and a Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (20-11635 to T. S.). This study was presented at the Annual Meeting of the Federation of American Societies for Experimental Biology (April 2010; Anaheim, CA, USA). The authors are grateful to Prof. Sylvia Christakos (UMDNJ) for the CaBP28k antibody and for valuable discussion, and to Dr. K. Mochizuki for technical advice, as well as to A. Asgerally, H. Ambia-Sobhan, Dr. J. D. Bogden, M. Chi, A. Hamzelou, F. Kemp, Dr. D. Lagunoff, and D. Paglia for technical help.	Abrams SA, 2007, AM J CLIN NUTR, V85, p604S, DOI 10.1093/ajcn/85.2.604S; Ajibade DV, 2010, ENDOCRINOLOGY, V151, P2974, DOI 10.1210/en.2010-0033; Al-Zube L, 2009, J ORTHOP RES, V27, P1074, DOI 10.1002/jor.20842; Benn BS, 2008, ENDOCRINOLOGY, V149, P3196, DOI 10.1210/en.2007-1655; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; Boass A, 1996, J BONE MINER RES, V11, P1640; Bray GA, 2004, AM J CLIN NUTR, V79, P537; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; Douard V, 2008, J PHYSIOL-LONDON, V586, P3657, DOI 10.1113/jphysiol.2008.155226; Douard V, 2008, ENDOCRINOLOGY, V149, P409, DOI 10.1210/en.2007-0906; Douard V, 2010, J AM SOC NEPHROL, V21, P261, DOI 10.1681/ASN.2009080795; Ebert R, 2004, MOL ENDOCRINOL, V18, P2440, DOI 10.1210/me.2002-0441; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Gezmish O, 2010, REPROD SCI, V17, P168, DOI 10.1177/1933719109349536; Gkika D, 2006, J AM SOC NEPHROL, V17, P3020, DOI 10.1681/ASN.2006060676; Hache S, 2011, J CELL MOL MED, V15, P654, DOI 10.1111/j.1582-4934.2010.01039.x; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Horst RL, 2005, J MAMMARY GLAND BIOL, V10, P141, DOI 10.1007/s10911-005-5397-x; Johnson LE, 2001, J NUTR, V131, P1787, DOI 10.1093/jn/131.6.1787; Kawashima Y, 2009, BONE, V44, P648, DOI 10.1016/j.bone.2008.12.012; Kellett GL, 2011, NUTR REV, V69, P347, DOI 10.1111/j.1753-4887.2011.00395.x; Kirchner S, 2008, AM J CLIN NUTR, V87, P1028, DOI 10.1093/ajcn/87.4.1028; Lee GS, 2007, J BONE MINER RES, V22, P1968, DOI 10.1359/JBMR.070801; McGartland C, 2003, J BONE MINER RES, V18, P1563, DOI 10.1359/jbmr.2003.18.9.1563; Meyer MB, 2007, J BIOL CHEM, V282, P22344, DOI 10.1074/jbc.M703475200; Mochizuki K, 2010, MOL NUTR FOOD RES, V54, P1445, DOI 10.1002/mnfr.200900467; Nakayama T, 2010, AM J PHYSIOL-RENAL, V298, pF712, DOI 10.1152/ajprenal.00433.2009; PATEL S, 1988, KIDNEY INT, V34, P224, DOI 10.1038/ki.1988.168; Rohacs T, 2007, PFLUG ARCH EUR J PHY, V453, P753, DOI 10.1007/s00424-006-0153-7; Ross AC, 2011, DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN D, P35; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Singh P, 2004, ASSAY DRUG DEV TECHN, V2, P161, DOI 10.1089/154065804323056503; Suzuki T, 2011, BIOCHEM J, V435, P43, DOI 10.1042/BJ20101987; Tappy L, 2010, PHYSIOL REV, V90, P23, DOI 10.1152/physrev.00019.2009; Tjaderhane L, 1998, J NUTR, V128, P1807, DOI 10.1093/jn/128.10.1807; Tsai J, 2009, AM J PHYSIOL-GASTR L, V296, pG1287, DOI 10.1152/ajpgi.90540.2008; Tucker KL, 2006, AM J CLIN NUTR, V84, P936, DOI 10.1093/ajcn/84.4.936; Van Cromphaut SJ, 2003, J BONE MINER RES, V18, P1725, DOI 10.1359/jbmr.2003.18.10.1725; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Weiler H, 2005, CAN MED ASSOC J, V172, P757, DOI 10.1503/cmaj.1040508; Wuest M, 2011, NUCL MED BIOL, V38, P461, DOI 10.1016/j.nucmedbio.2010.11.004; Xue YB, 2009, GASTROENTEROLOGY, V136, P1317, DOI 10.1053/j.gastro.2008.12.051; ZERNICKE RF, 1995, BONE, V16, P25, DOI 10.1016/S8756-3282(00)80007-1	44	18	18	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					707	721		10.1096/fj.11-190264	http://dx.doi.org/10.1096/fj.11-190264			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038050	Green Published			2022-12-28	WOS:000300485700022
J	Sekiyama, E; Saint-Geniez, M; Yoneda, K; Hisatomi, T; Nakao, S; Walshe, TE; Maruyama, K; Hafezi-Moghadam, A; Miller, JW; Kinoshita, S; D'Amore, PA				Sekiyama, Eiichi; Saint-Geniez, Magali; Yoneda, Kazuhito; Hisatomi, Toshio; Nakao, Shintaro; Walshe, Tony E.; Maruyama, Kazuichi; Hafezi-Moghadam, Ali; Miller, Joan W.; Kinoshita, Shigeru; D'Amore, Patricia A.			Heat treatment of retinal pigment epithelium induces production of elastic lamina components and antiangiogenic activity	FASEB JOURNAL			English	Article						choroidal neovascularization; transpupillary thermotherapy; endostatin; thrombospondin-1; elastin	CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; BRUCHS MEMBRANE; IN-VIVO; EXPRESSION; ANGIOGENESIS; ENDOSTATIN; CELLS; EYES; CHORIOCAPILLARIS	Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. In advanced AMD, new vessels from choriocapillaris (CC) invade through the Bruch's membrane (BrM) into the retina, forming choroidal neovascularization (CNV). BrM, an elastic lamina that is located between the retinal pigment epithelium (RPE) and CC, is thought to act as a physical and functional barrier against CNV. The BrM of patients with early AMD are characterized by decreased levels of antiangiogenic factors, including endostatin, thrombospondin-1 (TSP-1), and pigment epithelium-derived factor (PEDF), as well as by degeneration of the elastic layer. Motivated by a previous report that heat increases elastin expression in human skin, we examined the effect of heat on human ARPE-19 cell production of BrM components. Heat treatment stimulated the production of BrM components, including TSP-1, PEDF, and tropoelastin in vitro and increased the antiangiogenic activity of RPE measured in a mouse corneal pocket assay. The effect of heat on experimental CNV was investigated by pretreating the retina with heat via infrared diode laser prior to the induction of CNV. Heat treatment blocked the development of experimental CNV in vivo. These findings suggest that heat treatment may restore BrM integrity and barrier function against new vessel growth.-Sekiyama, E., Saint-Geniez, M., Yoneda, K., Hisatomi, T., Nakao, S., Walshe, T. E., Maruyama, K., Hafezi-Moghadam, A., Miller, J. W., Kinoshita, S., D'Amore, P. A. Heat treatment of retinal pigment epithelium induces production of elastic lamina components and anti-angiogenic activity. FASEB J. 26, 567-575 (2012). www.fasebj.org	[Sekiyama, Eiichi; Saint-Geniez, Magali; Walshe, Tony E.; Maruyama, Kazuichi; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; [Sekiyama, Eiichi; Saint-Geniez, Magali; Walshe, Tony E.; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; [D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Pathol, Boston, MA 02114 USA; [Hisatomi, Toshio; Nakao, Shintaro; Hafezi-Moghadam, Ali; Miller, Joan W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA; [Yoneda, Kazuhito; Maruyama, Kazuichi; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Grad Sch Med, Kyoto, Japan	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Kyoto Prefectural University of Medicine	D'Amore, PA (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	patricia.damore@schepens.harvard.edu	SAINT-GENIEZ, MAGALI/P-3509-2019; Maruyama, Kazuichi/GRX-8129-2022; Walshe, Tony/AAJ-8833-2020; D'Amore, Patricia A/G-5660-2017	SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; Maruyama, Kazuichi/0000-0001-6283-5466; D'Amore, Patricia A/0000-0001-9652-8974; Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697	Grants-in-Aid for Scientific Research [22791679] Funding Source: KAKEN; NATIONAL EYE INSTITUTE [R01EY015435] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY015435] Funding Source: Medline	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573; Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862; Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670; Chen Z, 2005, J INVEST DERMATOL, V124, P70, DOI 10.1111/j.0022-202X.2004.23550.x; Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1; COCKBURN CG, 1991, MATRIX, V11, P168, DOI 10.1016/S0934-8832(11)80155-1; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Hirabayashi Yoshifumi, 2003, Medical Electron Microscopy, V36, P139, DOI 10.1007/s00795-003-0218-z; Kang JH, 2006, FEBS LETT, V580, P510, DOI 10.1016/j.febslet.2005.12.065; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X; Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com; Mitola S, 2006, CIRC RES, V98, P45, DOI 10.1161/01.RES.0000199355.32422.7b; Nakao S, 2007, AM J PATHOL, V171, P1058, DOI 10.2353/ajpath.2007.070172; Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019; Reichel E., 2005, INVEST OPHTH VIS SCI, V46, P2311; Roth JM, 2005, AM J PATHOL, V166, P901, DOI 10.1016/S0002-9440(10)62310-3; Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x; School S., 2008, INVEST OPHTH VIS SCI, V49, P1750; Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130; Taddei L, 1999, BIOCHEM BIOPH RES CO, V263, P340, DOI 10.1006/bbrc.1999.1342; Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005; West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025; WOLTER JR, 1955, ARCH OPHTHALMOL-CHIC, V53, P208, DOI 10.1001/archopht.1955.00930010210005; Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508	26	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					567	575		10.1096/fj.11-184127	http://dx.doi.org/10.1096/fj.11-184127			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22067481	hybrid, Green Published			2022-12-28	WOS:000300485700010
J	Huang, R; Cheung, NKV; Vider, J; Cheung, IY; Gerald, WL; Tickoo, SK; Holland, EC; Blasberg, RG				Huang, Ruimin; Cheung, Nai-Kong V.; Vider, Jelena; Cheung, Irene Y.; Gerald, William L.; Tickoo, Satish K.; Holland, Eric C.; Blasberg, Ronald G.			MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas	FASEB JOURNAL			English	Article						transcriptional regulation; survival	C-MYC; SELF-RENEWAL; TARGET GENE; N-MYC; TRANSGENIC MICE; BREAST-CANCER; STEM-CELLS; EXPRESSION; SENESCENCE; HETEROGENEITY	The BMI1 gene is overexpressed in similar to 90% of human neuroblastomas. However, little is known about the regulation of BMI1 expression. Using microarray and immunohistochemical analysis, we show that BMI1 expression correlated with MYCN levels in MYCN-amplified human neuroblastomas, and with MYC levels in the MYCN-nonamplified group. We further demonstrated that BMI1 is a direct target gene of MYCN/MYC in 3 neuroblastoma cell lines: BE (2)-C, LAN1, and SH-SY5Y. Overexpression of MYCN or MYC transactivated the BMI1 promoter and up-regulated BMI1 gene expression. shRNA-mediated knockdown of MYCN or MYC decreased BMI1 gene expression. Chromatin immunoprecipitation and point-mutation assays revealed that both MYCN and MYC bind to the E-box within the BMI1 promoter. Overexpression of BMI1, MYCN, and MYC independently increased both cell proliferation and tumor growth. Conversely, specific inhibition of BMI1, MYCN, and MYC decreased tumor cell proliferation and tumor growth. Interestingly, BMI1 suppression in MYCN/MYC-overexpressing cells resulted in significantly greater inhibition compared to that in mock-transduced and parental cells. Our results indicate that MYCN and MYC regulate BMI1 gene expression at the transcriptional level and that dysregulation of the BMI1 gene mediated by MYCN or MYC overexpression, confers increased cell proliferation during neuroblastoma genesis and tumor progression.-Huang, R., Cheung, N.-K. V., Vider, J., Cheung, I. Y., Gerald, W. L., Tickoo, S. K., Holland, E. C., Blasberg, R. G. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J. 25, 4138-4149 (2011). www.fasebj.org	[Blasberg, Ronald G.] Mem Sloan Kettering Canc Ctr, Dept Neurol, Mol Pharmacol & Chem Program, New York, NY 10065 USA; [Cheung, Nai-Kong V.; Cheung, Irene Y.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Gerald, William L.; Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Holland, Eric C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA; [Blasberg, Ronald G.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Blasberg, RG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurol, Mol Pharmacol & Chem Program, Box 52,1275 York Ave, New York, NY 10065 USA.	blasberg@neuro1.mskcc.org	Vider, Jelena/AAW-8577-2020; Vider, Jelena/B-9663-2011	Vider, Jelena/0000-0003-1696-9812	Small Animal Imaging Core; U.S. National Institutes of Health [R01-CA102673, P50-CA086438, P01-CA106450]; NATIONAL CANCER INSTITUTE [R01CA102673, P01CA106450, P50CA086438] Funding Source: NIH RePORTER	Small Animal Imaging Core; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. David Cobrinik for the valuable comments on the manuscript. The authors thank Drs. Michael Cole (Dartmouth Medical School, Lebanon, NH, USA), Jan Jacob Schuringa (University Medical Center Groningen, Groningen, The Netherlands), and Anna Marie Kenney (Vanderbilt University Medical Center, Nashville, TN, USA) for their plasmids. The authors thank Katerina Dyomina, Hong-Fen Guo, Yi Feng, and Jim Finney for technical assistance. The authors thank the Small Animal Imaging Core for their support. This work was supported by U.S. National Institutes of Health grants R01-CA102673 and P50-CA086438 (R.G.B.) and P01-CA106450 (N-K.V.C. and W.L.G.).	Alaminos M, 2005, PEDIATR BLOOD CANCER, V45, P909, DOI 10.1002/pbc.20505; Alaminos M, 2003, CANCER RES, V63, P4538; Castleberry RP, 1997, EUR J CANCER, V33, P1430, DOI 10.1016/S0959-8049(97)00308-0; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; GAZITT Y, 1992, CANCER RES, V52, P2957; Giannini G, 2005, CANCER RES, V65, P8308, DOI 10.1158/0008-5472.CAN-05-0607; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Iyengar RV, 2001, CANCER RES, V61, P3045; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Malynn BA, 2000, GENE DEV, V14, P1390; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Mora J, 2001, BRIT J CANCER, V85, P182, DOI 10.1054/bjoc.2001.1849; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rizo A, 2008, BLOOD, V111, P2621, DOI 10.1182/blood-2007-08-106666; Ross RA, 2004, JNCI-J NATL CANCER I, V96, P1192, DOI 10.1093/jnci/djh262; Sawa M, 2005, INT J HEMATOL, V82, P42, DOI 10.1532/IJH97.05013; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SLAVC I, 1990, CANCER RES, V50, P1459; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Zhe Xiaoning, 1999, Chinese Medical Sciences Journal, V14, P102	37	60	63	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4138	4149		10.1096/fj.11-185033	http://dx.doi.org/10.1096/fj.11-185033			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21856782	Green Published			2022-12-28	WOS:000298138100008
J	Trapani, L; Melli, L; Segatto, M; Trezza, V; Campolongo, P; Jozwiak, A; Swiezewska, E; Pucillo, LP; Moreno, S; Fanelli, F; Linari, M; Pallottini, V				Trapani, Laura; Melli, Luca; Segatto, Marco; Trezza, Viviana; Campolongo, Patrizia; Jozwiak, Adam; Swiezewska, Ewa; Pucillo, Leopoldo Paolo; Moreno, Sandra; Fanelli, Francesca; Linari, Marco; Pallottini, Valentina			Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions	FASEB JOURNAL			English	Article						cholesterol; statins	COENZYME-A REDUCTASE; SHORTENING VELOCITY; PLASMA-CHOLESTEROL; STATIN THERAPY; COA REDUCTASE; OLDER-ADULTS; BODY-SIZE; RAT; SIMVASTATIN; FIBERS	The rate-limiting step of cholesterol bio-synthetic pathway is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme reductase (HGMR), whose inhibitors, the statins, widely used in clinical practice to treat hypercholesterolemia, often cause myopathy, and rarely rhabdomyolysis. All studies to date are limited to the definition of statin-induced myotoxicity omitting to investigate whether and how HMGR inhibition influences muscle functions. To this end, 3-mo-old male rats (Rattus norvegicus) were treated for 3 wk with a daily intraperitoneal injection of simvastatin (1.5 mg/kg/d), and biochemical, morphological, mechanical, and functional analysis were performed on extensor digitorum longus (EDL) muscle. Our results show that EDL muscles from simvastatin-treated rats exhibited reduced HMGR activity; a 15% shift from the fastest myosin heavy-chain (MHC) isoform IIb to the slower IIa/x; and reduced power output and unloaded shortening velocity, by 41 and 23%, respectively, without any change in isometric force and endurance. Moreover, simvastatin-treated rats showed a decrease of maximum speed reached and the latency to fall off the rotaroad (similar to = 30%). These results indicate that the molecular mechanism of the impaired muscle function following statin treatment could be related to the plasticity of fast MHC isoform expression.-Trapani, L., Melli, L., Segatto, M., Trezza, V., Campolongo, P., Jozwiak, A., Swiezewska, E., Pucillo, L. P., Moreno, S., Fanelli, F., Linari, M., Pallottini, V. Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions. FASEB J. 25, 4037-4047 (2011). www.fasebj.org	[Trapani, Laura; Segatto, Marco; Trezza, Viviana; Moreno, Sandra; Fanelli, Francesca; Pallottini, Valentina] Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; [Melli, Luca; Linari, Marco] Univ Florence, Dept Evolutionary Biol, Florence, Italy; [Campolongo, Patrizia] Univ Roma La Sapienza, Dept Physiol & Pharmacol, Rome, Italy; [Jozwiak, Adam; Swiezewska, Ewa] Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland; [Pucillo, Leopoldo Paolo] Natl Inst Infect Dis, Rome, Italy	Roma Tre University; University of Florence; Sapienza University Rome; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Pallottini, V (corresponding author), Univ Roma Tre, Dept Biol, Viale Marconi 446, I-00146 Rome, Italy.	vpallott@uniroma3.it	Segatto, Marco/AHD-3607-2022; Trezza, Viviana/K-4418-2016; Moreno, Sandra/D-4254-2014; Jozwiak, Adam/E-7717-2011; Campolongo, Patrizia/D-4628-2009; Pallottini, Valentina/AAA-3218-2021	Jozwiak, Adam/0000-0002-7666-7747; Campolongo, Patrizia/0000-0002-2827-8755; Pallottini, Valentina/0000-0003-2511-6168; moreno, sandra/0000-0002-1079-3222; LINARI, MARCO/0000-0001-6512-4897; Swiezewska, Ewa/0000-0002-3439-8948; Segatto, Marco/0000-0003-0465-9470				Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Bottinelli R, 2000, PROG BIOPHYS MOL BIO, V73, P195, DOI 10.1016/S0079-6107(00)00006-7; Bozzo C, 2003, AM J PHYSIOL-CELL PH, V285, pC575, DOI 10.1152/ajpcell.00441.2002; Brown MS, 2004, ATHEROSCLEROSIS SUPP, V5, P57, DOI 10.1016/j.atherosclerosissup.2004.08.024; BRUSCALUPI G, 1985, CELL MOL BIOL, V31, P365; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; CHAO Y, 1991, EUR J CLIN PHARMACOL, V40, pS11, DOI 10.1007/BF01409400; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; Draeger A, 2006, J PATHOL, V210, P94, DOI 10.1002/path.2018; Dubroca C, 2007, CARDIOVASC RES, V73, P190, DOI 10.1016/j.cardiores.2006.10.020; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; Ginsberg HN, 1998, AM J CARDIOL, V81, p32B, DOI 10.1016/S0002-9149(98)00035-6; Istvan ES, 2000, BBA-MOL CELL BIOL L, V1529, P9, DOI 10.1016/S1388-1981(00)00134-7; Izumo N, 2001, METHOD FIND EXP CLIN, V23, P389, DOI 10.1358/mf.2001.23.7.662123; Kou R, 2009, J BIOL CHEM, V284, P14734, DOI 10.1074/jbc.M808664200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martini C, 2009, J CELL PHYSIOL, V220, P524, DOI 10.1002/jcp.21810; Ogura Takeharu, 2007, Journal of Toxicological Sciences, V32, P57, DOI 10.2131/jts.32.57; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Pellegrino MA, 2003, J PHYSIOL-LONDON, V546, P677, DOI 10.1113/jphysiol.2002.027375; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Puthoff ML, 2007, PHYS THER, V87, P1334, DOI 10.2522/ptj.20060176; ROME LC, 1990, J PHYSIOL-LONDON, V431, P173, DOI 10.1113/jphysiol.1990.sp018325; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schreiber DH, 2006, J EMERG MED, V31, P177, DOI 10.1016/j.jemermed.2005.08.020; Scott D, 2009, QJM-INT J MED, V102, P625, DOI 10.1093/qjmed/hcp093; Sirvent P, 2005, BIOCHEM BIOPH RES CO, V338, P1426, DOI 10.1016/j.bbrc.2005.10.108; Tang PH, 2001, CLIN CHEM, V47, P256; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Viccica G, 2007, J Endocrinol Invest, V30, P8; von Tresckow B, 2007, HAEMATOL-HEMATOL J, V92, P682, DOI 10.3324/haematol.11020; Voss J, 2003, EUR J PHARMACOL, V482, P215, DOI 10.1016/j.ejphar.2003.10.007; Wang WX, 2010, J MOL MED, V88, P309, DOI 10.1007/s00109-009-0561-1; Westwood FR, 2005, TOXICOL PATHOL, V33, P246, DOI 10.1080/01926230590908213; Yokoyama M, 2007, J LIPID RES, V48, P646, DOI 10.1194/jlr.M600301-JLR200	39	17	19	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					4037	4047		10.1096/fj.11-184218	http://dx.doi.org/10.1096/fj.11-184218			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21798954	Green Submitted			2022-12-28	WOS:000296723100027
J	Moreno, M; Silvestri, E; De Matteis, R; de Lange, P; Lombardi, A; Glinni, D; Senese, R; Cioffi, F; Salzano, AM; Scaloni, A; Lanni, A; Goglia, F				Moreno, Maria; Silvestri, Elena; De Matteis, Rita; de lange, Pieter; Lombardi, Assunta; Glinni, Daniela; Senese, Rosalba; Cioffi, Federica; Salzano, Anna Maria; Scaloni, Andrea; Lanni, Antonia; Goglia, Fernando			3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations	FASEB JOURNAL			English	Article						thyroid hormone; metabolism; proteomics	AKT/PROTEIN KINASE-B; PROTEIN-KINASE; ACID-METABOLISM; GLYCOGEN-SYNTHESIS; GLUCOSE-TRANSPORT; WEIGHT-LOSS; AMINO-ACID; OBESITY; CELLS; RED	The worldwide prevalence of obesity-associated pathologies, including type 2 diabetes, requires thorough investigation of mechanisms and interventions. Recent studies have highlighted thyroid hormone analogs and derivatives as potential agents able to counteract such pathologies. In this study, in rats receiving a high-fat diet (HFD), we analyzed the effects of a 4-wk daily administration of a naturally occurring iodothyronine, 3,5-diiodo-L-thyronine (T2), on the gastrocnemius muscle metabolic/structural phenotype and insulin signaling. The HFD-induced increases in muscle levels of fatty acid translocase (3-fold; P<0.05) and TGs (2-fold, P<0.05) were prevented by T2 (each; P<0.05 vs. HFD). T2 increased insulin-stimulated Akt phosphorylation levels (similar to 2.5-fold; P<0.05 vs. HFD). T2 induced these effects while sparing muscle mass and without cardiac hypertrophy. T2 increased the muscle contents of fast/glycolytic fibers (2-fold; P<0.05 vs. HFD) and sarcolemmal glucose transporter 4 (3-fold; P<0.05 vs. HFD). Adipocyte differentiation-related protein was predominantly present within the slow/oxidative fibers in HFD-T2. In T2-treated rats (vs. HFD), glycolytic enzymes and associated components were up-regulated (proteomic analysis, significance limit: 2-fold; P<0.05), as was phosphofructokinase activity (by 1.3-fold; P<0.05), supporting the metabolic shift toward a more glycolytic phenotype. These results highlight T2 as a potential therapeutic approach to the treatment of diet-induced metabolic dysfunctions.-Moreno, M., Silvestri, E., De Matteis, R., de Lange, P., Lombardi, A., Glinni, D., Senese, R., Cioffi, F., Salzano, A. M., Scaloni, A., Lanni, A., Goglia, F. 3,5-Diiodo-L-thyronine prevents high-fat diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. FASEB J. 25, 3312-3324 (2011). www.fasebj.org	[Moreno, Maria; Silvestri, Elena; Glinni, Daniela; Goglia, Fernando] Univ Sannio, Dipartimento Sci Biol Geol & Ambiente, I-82100 Benevento, Italy; [De Matteis, Rita] Univ Urbino Carlo Bo, Dipartimento Sci Biomol, Urbino, Italy; [de lange, Pieter; Senese, Rosalba; Cioffi, Federica; Lanni, Antonia] Univ Naples 2, Dipartimento Sci Vita, Caserta, Italy; [Lombardi, Assunta] Univ Naples Federico II, Sez Fisiol & Igiene, Dipartimento Sci Biol, Naples, Italy; [Salzano, Anna Maria; Scaloni, Andrea] CNR, Inst Sistema Produz Anim Ambiente Mediterraneo 2, Lab Prote & Spettrometria Massa, Naples, Italy	University of Sannio; University of Urbino; Universita della Campania Vanvitelli; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR)	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol Geol & Ambiente, Via Portarsa 11, I-82100 Benevento, Italy.	goglia@unisannio.it	Salzano, Anna Maria/C-7139-2012; cioffi, federica/AAB-8161-2019; de Lange, Pieter/GXA-3052-2022; De+Matteis, Rita/AAG-6904-2019	Salzano, Anna Maria/0000-0001-7192-8760; cioffi, federica/0000-0002-1530-8556; SENESE, Rosalba/0000-0003-1571-0980; MORENO, Maria/0000-0002-6218-5501; Scaloni, Andrea/0000-0001-9362-8515; DE MATTEIS, Rita/0000-0003-4665-4547; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR) Cofinanziamento (COFIN) [20089SRS2X]; MIUR Fondo Investimento Ricerca di Base (FIRB) Medical Research in Italy (MERIT) [RBNE08YFN3_003]; Regione Campania; Regione Campania Rete di Spettrometria di Massa	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR) Cofinanziamento (COFIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); MIUR Fondo Investimento Ricerca di Base (FIRB) Medical Research in Italy (MERIT); Regione Campania(Regione Campania); Regione Campania Rete di Spettrometria di Massa	This work was partially supported by the following grants: Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR) Cofinanziamento (COFIN) 2008 Protocol 20089SRS2X, MIUR Fondo Investimento Ricerca di Base (FIRB) Medical Research in Italy (MERIT) RBNE08YFN3_003, Regione Campania 2008, and Regione Campania Rete di Spettrometria di Massa.	Albright A, 2000, MED SCI SPORT EXER, V32, P1345; Behan WMH, 2002, J CLIN PATHOL, V55, P375, DOI 10.1136/jcp.55.5.375; Belfort R, 2005, DIABETES, V54, P1640, DOI 10.2337/diabetes.54.6.1640; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; Chabowski A, 2006, AM J PHYSIOL-ENDOC M, V291, pE675, DOI 10.1152/ajpendo.00096.2006; de Lange P, 2008, ENDOCRINOLOGY, V149, P6462, DOI 10.1210/en.2008-0202; DeFronzo RA, 2009, DIABETES CARE, V32, pS157, DOI 10.2337/dc09-S302; Dimitriadis G, 1997, EUR J CLIN INVEST, V27, P475, DOI 10.1046/j.1365-2362.1997.1380688.x; DIMITRIADIS GD, 1989, BIOCHEM J, V257, P369, DOI 10.1042/bj2570369; Fluck M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Izumiya Y, 2008, CELL METAB, V7, P159, DOI 10.1016/j.cmet.2007.11.003; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Koopman R, 2001, HISTOCHEM CELL BIOL, V116, P63; Lanni A, 2005, FASEB J, V19, DOI 10.1096/fj.05.3977fje; Levin MC, 2007, AM J PHYSIOL-ENDOC M, V293, pE1772, DOI 10.1152/ajpendo.00158.2007; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Minnaard R, 2009, J CLIN ENDOCR METAB, V94, P4077, DOI 10.1210/jc.2009-0352; Miyabara EH, 2005, CELL TISSUE RES, V321, P233, DOI 10.1007/s00441-005-1119-3; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; OPIE LH, 1967, BIOCHEM J, V103, P391, DOI 10.1042/bj1030391; OPPENHEIMER JH, 1991, J CLIN INVEST, V87, P125, DOI 10.1172/JCI114961; Phillips SA, 2005, OBES RES, V13, P1321, DOI 10.1038/oby.2005.160; Pimenta AS, 2008, J CELL PHYSIOL, V217, P478, DOI 10.1002/jcp.21520; Qian WJ, 2005, J PROTEOME RES, V4, P53, DOI 10.1021/pr0498638; RANDLE PJ, 1963, LANCET, V1, P785; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schmitz KH, 2007, AM J CLIN NUTR, V86, P566, DOI 10.1093/ajcn/86.3.566; Scippa GS, 2010, ELECTROPHORESIS, V31, P497, DOI 10.1002/elps.200900459; Silvestri E, 2007, J PROTEOME RES, V6, P3187, DOI 10.1021/pr0701299; Son NH, 2010, J CLIN INVEST, V120, P3443, DOI 10.1172/JCI40905; Stump CS, 2006, ANN MED, V38, P389, DOI 10.1080/07853890600888413; Talamo F, 2003, PROTEOMICS, V3, P440, DOI 10.1002/pmic.200390059; Tanner CJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE1191, DOI 10.1152/ajpendo.00416.2001; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Loon LJC, 2006, PFLUG ARCH EUR J PHY, V451, P606, DOI 10.1007/s00424-005-1509-0; Watt MJ, 2009, CLIN EXP PHARMACOL P, V36, P5, DOI 10.1111/j.1440-1681.2008.05075.x; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; WEINSTEIN SP, 1991, ENDOCRINOLOGY, V129, P455, DOI 10.1210/endo-129-1-455	45	65	67	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3312	3324		10.1096/fj.11-181982	http://dx.doi.org/10.1096/fj.11-181982			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21670063				2022-12-28	WOS:000295356400004
J	Seib, KL; Pigozzi, E; Muzzi, A; Gawthorne, JA; Delany, I; Jennings, MP; Rappuoli, R				Seib, Kate L.; Pigozzi, Eva; Muzzi, Alessandro; Gawthorne, Jayde A.; Delany, Isabel; Jennings, Michael P.; Rappuoli, Rino			A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44	FASEB JOURNAL			English	Article						DNA methyltransferase; meningococcal infection; phase variation; phasevarion; virulence	RESTRICTION-MODIFICATION SYSTEM; PHASE VARIATION; HAEMOPHILUS-INFLUENZAE; TRANSCRIPTOME ANALYSIS; OXIDATIVE STRESS; CONTINGENCY LOCI; IDENTIFICATION; DISEASE; VACCINE; SEROGROUP	Neisseria meningitidis is a major cause of septicemia and meningitis. The hypervirulent clonal complex 41/44 (cc41/44) has emerged as the predominant cause of serogroup B meningococcal disease, having been responsible for recent outbreaks and epidemics worldwide. However, the meningococcal factors that enable transition from asymptomatic carriage to rapidly progressing disease are poorly understood. Here we describe a novel phase-variable DNA methyltransferase, ModD, which was identified in the genome sequence of a New Zealand epidemic isolate. Investigation of the distribution of modD in the wider meningococcal population, by PCR and sequence analysis of genetically diverse N. meningitidis strains, revealed the presence of modD in 20/27 strains in cc41/44, but in only 2/47 strains from other clonal complexes, indicating a significant association of modD with cc41/44 (Fisher's exact P value = 3 x 10(-10)). The modD gene contains 5'-ACCGA-3' repeats that mediate phase variation, leading to reversible on/off switching of modD expression. Microarray analysis of modD-on/off variants revealed that ModD regulates expression of multiple genes involved in colonization, infection, and protection against host defenses, with increased catalase expression in the modD-on variant conferring increased resistance to oxidative stress. The modulation of gene expression via the ModD phase-variable regulon (phasevarion), and its significant association with the cc41/44, suggest a role in the fitness and/or pathogenesis of strains belonging to the cc41/44.-Seib, K. L., Pigozzi, E., Muzzi, A., Gawthorne, J. A., Delany, I., Jennings, M. P., Rappuoli, R. A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44. FASEB J. 25, 3622-3633 (2011). www.fasebj.org	[Seib, Kate L.] Novartis Vaccines, Microbial Mol Biol, I-53100 Siena, Italy; [Gawthorne, Jayde A.; Jennings, Michael P.] Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia	Novartis; Griffith University	Seib, KL (corresponding author), Novartis Vaccines, Microbial Mol Biol, Via Fiorentina 1, I-53100 Siena, Italy.	kate.seib@novartis.com	Jennings, Michael P/G-4822-2013; Seib, Kate L/B-4670-2015	Jennings, Michael P/0000-0002-1027-4684; Seib, Kate L/0000-0002-7094-3528	Novartis Vaccines; Australian National Health and Medical Research Council [565526]	Novartis Vaccines; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Maria Scarselli, Yogitha Srikhanta, Duccio Medini, Sonia Budroni, Davide Serruto, Mariagrazia Pizza, Maurizio Comanducci, and Richard Moxon for useful discussions. The authors thank Stefania Bambini and Maurizio Comanducci (Novartis Vaccines) for providing meningococcal strains, Yogitha Srikhanta (Institute for Glycomics, Griffith University) for providing gonococcal FA1090 ModB1-on and Delta modB1 strains, Laura Fantappie' for help with microarray analysis, and the Australian Equine Genetics Research Centre for help with GeneScan fragment analysis. This work was supported by Novartis Vaccines (general support and a Novartis fellowship from the Ph.D. program in Cellular Biology of the University of Padova to E.P.) and the Australian National Health and Medical Research Council (C.J. Martin Fellowship to K. L. S.; program grant 565526 to M.P.J.).	Adamczyk-Poplawska M, 2009, FEMS MICROBIOL LETT, V300, P25, DOI 10.1111/j.1574-6968.2009.01760.x; Bambini S, 2009, VACCINE, V27, P2794, DOI 10.1016/j.vaccine.2009.02.098; Bart A, 2001, INFECT IMMUN, V69, P1816, DOI 10.1128/IAI.69.3.1816-1820.2001; Bayliss CD, 2001, J CLIN INVEST, V107, P657, DOI 10.1172/JCI12557; Bayliss CD, 2009, FEMS MICROBIOL REV, V33, P504, DOI 10.1111/j.1574-6976.2009.00162.x; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; Bille E, 2005, J EXP MED, V201, P1905, DOI 10.1084/jem.20050112; Buckee CO, 2008, P NATL ACAD SCI USA, V105, P15082, DOI 10.1073/pnas.0712019105; Budroni S, 2011, P NATL ACAD SCI USA, V108, P4494, DOI 10.1073/pnas.1019751108; Casadesus J, 2006, MICROBIOL MOL BIOL R, V70, P830, DOI 10.1128/MMBR.00016-06; Caugant DA, 2008, INFECT GENET EVOL, V8, P558, DOI 10.1016/j.meegid.2008.04.002; de Vries N, 2002, J BACTERIOL, V184, P6615, DOI 10.1128/JB.184.23.6615-6624.2002; Delany I, 2006, J BACTERIOL, V188, P2483, DOI 10.1128/JB.188.7.2483-2492.2006; Dietrich G, 2003, J BACTERIOL, V185, P155, DOI 10.1128/JB.185.1.155-164.2003; Echenique-Rivera H, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002027; Elias J, 2010, EMERG INFECT DIS, V16, P464, DOI 10.3201/eid1603.091102; Exley RM, 2009, INFECT IMMUN, V77, P45, DOI 10.1128/IAI.00968-08; Fantappie L, 2011, MOL MICROBIOL, V80, P507, DOI 10.1111/j.1365-2958.2011.07592.x; Fox KL, 2007, NUCLEIC ACIDS RES, V35, P5242, DOI 10.1093/nar/gkm571; Frigimelica E, 2008, J INFECT DIS, V197, P1124, DOI 10.1086/533456; Grifantini R, 2003, P NATL ACAD SCI USA, V100, P9542, DOI 10.1073/pnas.1033001100; Grifantini R, 2002, NAT BIOTECHNOL, V20, P914, DOI 10.1038/nbt728; Guckenberger M, 2002, J BACTERIOL, V184, P2546, DOI 10.1128/JB.184.9.2546-2551.2002; Harrison LH, 2010, J INFECT DIS, V201, P1208, DOI 10.1086/651505; Harrison OB, 2009, J INFECT DIS, V200, P94, DOI 10.1086/599377; Heusipp G, 2007, INT J MED MICROBIOL, V297, P1, DOI 10.1016/j.ijmm.2006.10.002; Holst J, 2009, VACCINE, V27, pB3, DOI 10.1016/j.vaccine.2009.04.071; Ieva R, 2008, MOL MICROBIOL, V70, P1152, DOI 10.1111/j.1365-2958.2008.06468.x; Jolley KA, 2000, J CLIN MICROBIOL, V38, P4492, DOI 10.1128/JCM.38.12.4492-4498.2000; Leuzzi R, 2005, MOL MICROBIOL, V58, P669, DOI 10.1111/j.1365-2958.2005.04859.x; Levy C, 2010, PEDIATR INFECT DIS J, V29, P618, DOI 10.1097/INF.0b013e3181d3ce32; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Makarova KS, 2001, GENOME BIOL, V2; Martin P, 2003, MOL MICROBIOL, V50, P245, DOI 10.1046/j.1365-2958.2003.03678.x; Oster P, 2005, VACCINE, V23, P2191, DOI 10.1016/j.vaccine.2005.01.063; Peiser L, 2006, INFECT IMMUN, V74, P5191, DOI 10.1128/IAI.00124-06; Racloz VN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-175; Redaschi N, 1996, J MOL BIOL, V257, P790, DOI 10.1006/jmbi.1996.0202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOLTEN RJPM, 1993, CLIN INFECT DIS, V16, P237, DOI 10.1093/clind/16.2.237; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; Seib KL, 2011, INFECT IMMUN, V79, P970, DOI 10.1128/IAI.00891-10; Seib KL, 2010, VACCINE, V28, P2416, DOI 10.1016/j.vaccine.2009.12.082; Seib KL, 2004, J INFECT DIS, V190, P136, DOI 10.1086/421299; Seib KL, 2002, FEMS IMMUNOL MED MIC, V32, P159; Skoglund A, 2007, J BACTERIOL, V189, P8914, DOI 10.1128/JB.00108-07; Snyder LAS, 2005, PLASMID, V54, P191, DOI 10.1016/j.plasmid.2005.04.005; Srikhanta YN, 2005, P NATL ACAD SCI USA, V102, P5547, DOI 10.1073/pnas.0501169102; Srikhanta YN, 2010, NAT REV MICROBIOL, V8, P196, DOI 10.1038/nrmicro2283; Srikhanta YN, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000400; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Sun YH, 2000, NAT MED, V6, P1269, DOI 10.1038/81380; van der Ende A, 2000, INFECT IMMUN, V68, P6685, DOI 10.1128/IAI.68.12.6685-6690.2000; Wion D, 2006, NAT REV MICROBIOL, V4, P183, DOI 10.1038/nrmicro1350; Wu HJ, 2006, MOL MICROBIOL, V60, P401, DOI 10.1111/j.1365-2958.2006.05079.x; Yazdankhah SP, 2004, J CLIN MICROBIOL, V42, P5146, DOI 10.1128/JCM.42.11.5146-5153.2004	56	33	34	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3622	3633		10.1096/fj.11-183590	http://dx.doi.org/10.1096/fj.11-183590			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21680891				2022-12-28	WOS:000295356400032
J	Bouchecareilh, M; Higa, A; Fribourg, S; Moenner, M; Chevet, E				Bouchecareilh, Marion; Higa, Arisa; Fribourg, Sebastien; Moenner, Michel; Chevet, Eric			Peptides derived from the bifunctional kinase/RNase enzyme IRE1 alpha modulate IRE1 alpha activity and protect cells from endoplasmic reticulum stress	FASEB JOURNAL			English	Article						RIDD; UPR; alphascreen	UNFOLDED PROTEIN; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; MESSENGER-RNAS; ACTIVATION; ATF6; TRANSCRIPTION; SURVIVAL; DELIVERY; DOMAIN	Activation of the bifunctional kinase/RNase enzyme IRE1 alpha is part of an adaptive response triggered on accumulation of misfolded proteins in the endoplasmic reticulum (ER). To facilitate recovery of ER homeostasis, IRE1 alpha molecules oligomerize, allowing for their transautophosphorylation and endoribonuclease activation. These, in turn, induce the activation of specific transcriptional and post-transcriptional programs. To identify novel and selective modulators of IRE1 alpha activity, we investigated IRE1 alpha oligomerization properties using IRE1 alpha-derived peptides identified through an activity-based in vitro assay. We then used these peptides to probe IRE1 alpha activity in vitro and in vivo using both cultured human hepatocellular carcinoma-derived HuH7 cells and Caenorhabditis elegans experimental systems. We identified a peptide derived from the kinase domain of human IRE1 alpha, which promoted IRE1 alpha oligomerization in vitro, enhanced its Xbp1 mRNA cleavage activity in vitro (1.7 x) in cell culture (1.8 x) and in vivo (1.3 x), and attenuated both ER stress-mediated JNK activation and regulated IRE1-dependent mRNA decay (RIDD). This was accompanied by a 2.5-fold increase in survival on tunicamycin-induced ER stress and reduced apoptosis by 1.4-fold in cells expressing this peptide. Hence, targeted and selective activation of the catalytic properties of IRE1 alpha may consequently define new strategies to protect cells from deleterious effects of ER stress signaling.-Bouchecareilh, M., Higa, A., Fribourg, S., Moenner, M., Chevet, E. Peptides derived from the bifunctional kinase/RNase enzyme IRE1 alpha modulate IRE1 alpha activity and protect cells from endoplasmic reticulum stress. FASEB J. 25, 3115-3129 (2011). www.fasebj.org	[Bouchecareilh, Marion; Higa, Arisa; Chevet, Eric] Univ Bordeaux 2, INSERM, U1053, F-33076 Bordeaux, France; [Bouchecareilh, Marion; Fribourg, Sebastien; Chevet, Eric] Univ Bordeaux Segalen, Bordeaux, France; [Bouchecareilh, Marion; Moenner, Michel] INSERM, Talence, France; [Bouchecareilh, Marion; Moenner, Michel] Univ Bordeaux, Talence, France; [Fribourg, Sebastien] Inst Europeen Chim & Biol, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Chevet, E (corresponding author), Univ Bordeaux 2, INSERM, U1053, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	eric.chevet@u-bordeaux2.fr	chevet, eric/E-4992-2016; Fribourg, Sebastien/M-7418-2014	chevet, eric/0000-0001-5855-4522; Fribourg, Sebastien/0000-0003-4112-7510	Marie Curie International Reintegration; Fondation pour la Recherche Medicale; Institut Federatif de Recherche [66]; Association pour la Recherche sur le Cancer; Avenir (Institut National de la Sante et de la Recherche Medicale)-Institut National du Cancer; Conseil Regional d'Aquitaine	Marie Curie International Reintegration(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut Federatif de Recherche; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Avenir (Institut National de la Sante et de la Recherche Medicale)-Institut National du Cancer(Institut National de la Sante et de la Recherche Medicale (Inserm)Institut National du Cancer (INCA) France); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine)	The authors are grateful to Nathalie Dugot-Senant for technical help with confocal microscopy as well as J. Rosenbaum, V. Moreau, P. Cameron, E. Marza, N. Dejeans, S. Taouji, and M. Dominguez for critical reading of the manuscript. This work was funded by a Marie Curie International Reintegration grant; grants from the Fondation pour la Recherche Medicale, the Institut Federatif de Recherche 66, from and the Association pour la Recherche sur le Cancer; and an Avenir (Institut National de la Sante et de la Recherche Medicale)-Institut National du Cancer program grant to E. C. M. B. was supported by a Ph.D. fellowship from the Conseil Regional d'Aquitaine and a fellowship from the Fondation pour la Recherche Medicale.	Aragon T, 2009, NATURE, V457, P736, DOI 10.1038/nature07641; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Bouchecareilh M, 2010, J BIOMOL SCREEN, V15, P406, DOI 10.1177/1087057110363823; Caruso ME, 2008, MOL CELL BIOL, V28, P4261, DOI 10.1128/MCB.02252-07; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; Delom F, 2007, BIOCHEM BIOPH RES CO, V352, P587, DOI 10.1016/j.bbrc.2006.11.046; Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014; Jenna S, 2005, MOL BIOL CELL, V16, P1629, DOI 10.1091/mbc.E04-08-0760; Kanemoto S, 2005, BIOCHEM BIOPH RES CO, V331, P1146, DOI 10.1016/j.bbrc.2005.04.039; Korennykh AV, 2009, NATURE, V457, P687, DOI 10.1038/nature07661; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lee KPK, 2008, CELL, V132, P89, DOI 10.1016/j.cell.2007.10.057; Lee KPK, 2011, METHOD ENZYMOL, V490, P271, DOI 10.1016/B978-0-12-385114-7.00016-7; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Urano F, 2002, J CELL BIOL, V158, P639, DOI 10.1083/jcb.200203086; Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737; Wiseman RL, 2010, MOL CELL, V38, P291, DOI 10.1016/j.molcel.2010.04.001	34	56	58	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3115	3129		10.1096/fj.11-182931	http://dx.doi.org/10.1096/fj.11-182931			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21680894				2022-12-28	WOS:000294435200025
J	Domanskyi, A; Geissler, C; Vinnikov, IA; Alter, H; Schober, A; Vogt, MA; Gass, P; Parlato, R; Schutz, G				Domanskyi, Andrii; Geissler, Christin; Vinnikov, Ilya A.; Alter, Heike; Schober, Andreas; Vogt, Miriam A.; Gass, Peter; Parlato, Rosanna; Schuetz, Guenther			Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models	FASEB JOURNAL			English	Article						neurodegeneration; mTOR; mouse	TUMOR-SUPPRESSOR GENE; NIGROSTRIATAL SYSTEM; NUCLEOLAR DISRUPTION; MAMMALIAN TARGET; CRE RECOMBINASE; MOTOR DEFICITS; ANIMAL-MODELS; CELL-DEATH; MICE; BRAIN	Parkinson's disease (PD) is a progressive age-related movement disorder that results primarily from the selective loss of midbrain dopaminergic (DA) neurons. Symptoms of PD can be induced by genetic mutations or by DA neuron-specific toxins. A specific ablation of an essential factor controlling ribosomal RNA transcription, TifIa, in adult mouse DA neurons represses mTOR signaling and leads to progressive neurodegeneration and PD-like phenotype. Using an inducible Cre system in adult mice, we show here that the specific ablation of Pten in adult mouse DA neurons leads to activation of mTOR pathway and is neuroprotective in genetic (TifIa deletion) and neurotoxin-induced (MPTP or 6OHDA) mouse models of PD. Adult mice with DA neuron-specific Pten deletion exhibit elevated expression of tyrosine hydroxylase, a rate-limiting enzyme in the dopamine biosynthesis pathway, associated with increased striatal dopamine content, and increased mRNA levels of Foxa2, Pitx3, En1, Nurr1, and Lmx1b-the essential factors for maintaining physiological functions of adult DA neurons. Pten deletion attenuates the loss of tyrosine hydroxylase-positive cells after 6OHDA treatment, restores striatal dopamine in TifIa-knockout and MPTP-treated mice, and rescues locomotor impairments caused by TifIa loss. Inhibition of Pten-dependent functions in adult DA neurons may represent a promising PD therapy.-Domanskyi, A., Geissler, C., Vinnikov, I. A., Alter, H., Schober, A., Vogt, M. A., Gass, P., Parlato, R., Schutz, G. Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J. 25, 2898-2910 (2011). www.fasebj.org	[Domanskyi, Andrii; Geissler, Christin; Vinnikov, Ilya A.; Alter, Heike; Parlato, Rosanna; Schuetz, Guenther] German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany; [Schober, Andreas] Univ Freiburg, Dept Mol Embryol, Inst Anat & Cell Biol 2, Freiburg, Germany; [Vogt, Miriam A.; Gass, Peter] Univ Heidelberg, Cent Inst Mental Hlth, RG Anim Models Psychiat, D-6800 Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Schutz, G (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 1, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	g.schuetz@dkfz.de	Domanskyi, Andrii/H-3437-2012; Parlato, Rosanna/G-8768-2015; Parlato, Rosanna/AAH-4429-2020	Domanskyi, Andrii/0000-0002-4755-5981; Parlato, Rosanna/0000-0001-6682-9645; Vogt, Miriam Annika/0000-0002-3400-5067; Vinnikov, Ilya/0000-0003-0488-8484	Deutsche Forschungsgemeinschaft [SFB 488, SFB 636]; Fonds der Chemischen Industrie; European Union [LSHM-CT-2005-018652 (CRESCENDO)]; Bundesministerium fur Bildung und Forschung [FZK 01GS08153, 01GS08142, 0313074C (HepatoSys)]; Helmholtz Gemeinschaft Deutscher Forschungszentren, through Initiative CoReNe and Alliance HelMA; Deutsche Krebshilfe [108567]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); European Union(European Commission); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Helmholtz Gemeinschaft Deutscher Forschungszentren, through Initiative CoReNe and Alliance HelMA(Helmholtz Association); Deutsche Krebshilfe(Deutsche Krebshilfe)	The authors thank R. Hertel for HPLC-ED. This work was supported by the Deutsche Forschungsgemeinschaft, through Collaborative Research Centers SFB 488 and SFB 636; the Fonds der Chemischen Industrie; the European Union, through grant LSHM-CT-2005-018652 (CRESCENDO); the Bundesministerium fur Bildung und Forschung, through NGFNplus grants FZK 01GS08153 and 01GS08142 and project 0313074C (HepatoSys); the Helmholtz Gemeinschaft Deutscher Forschungszentren, through Initiative CoReNe and Alliance HelMA; and the Deutsche Krebshilfe, through project 108567.	Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Burke RE, 2004, CELL TISSUE RES, V318, P63, DOI 10.1007/s00441-004-0908-4; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chang N, 2007, TRENDS NEUROSCI, V30, P581, DOI 10.1016/j.tins.2007.08.006; Cheng HC, 2011, J NEUROSCI, V31, P2125, DOI 10.1523/JNEUROSCI.5519-10.2011; Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Diaz-Ruiz O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007027; Ekstrand MI, 2009, PARKINSONISM RELAT D, V15, pS185, DOI 10.1016/S1353-8020(09)70811-9; Engblom D, 2008, NEURON, V59, P497, DOI 10.1016/j.neuron.2008.07.010; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Ferri ALM, 2007, DEVELOPMENT, V134, P2761, DOI 10.1242/dev.000141; Fraser MM, 2008, NEUROSCIENCE, V151, P476, DOI 10.1016/j.neuroscience.2007.10.048; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Inzelberg R, 2007, NEUROLOGY, V69, P1542, DOI 10.1212/01.wnl.0000277638.63767.b8; Jacobs FMJ, 2009, DEVELOPMENT, V136, P531, DOI 10.1242/dev.029769; Kadkhodaei B, 2009, J NEUROSCI, V29, P15923, DOI 10.1523/JNEUROSCI.3910-09.2009; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kittappa R, 2007, PLOS BIOL, V5, P2875, DOI 10.1371/journal.pbio.0050325; Klein C, 2007, CURR OPIN NEUROL, V20, P453, DOI 10.1097/WCO.0b013e3281e6692b; Le WD, 2008, J NEUROL SCI, V273, P29, DOI 10.1016/j.jns.2008.06.007; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lewek MD, 2010, GAIT POSTURE, V31, P256, DOI 10.1016/j.gaitpost.2009.10.013; Lin W, 2009, DEV BIOL, V333, P386, DOI 10.1016/j.ydbio.2009.07.006; Liu BS, 2010, STROKE, V41, P1018, DOI 10.1161/STROKEAHA.110.579011; Malagelada C, 2006, J NEUROSCI, V26, P9996, DOI 10.1523/JNEUROSCI.3292-06.2006; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; OTTO D, 1990, J NEUROSCI, V10, P1912; Parkitna Jan Rodriguez, 2009, V530, P325, DOI 10.1007/978-1-59745-471-1_17; Parlato R, 2008, J NEUROSCI, V28, P12759, DOI 10.1523/JNEUROSCI.2439-08.2008; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Rieker C, 2011, J NEUROSCI, V31, P453, DOI 10.1523/JNEUROSCI.0590-10.2011; Ries V, 2006, P NATL ACAD SCI USA, V103, P18757, DOI 10.1073/pnas.0606401103; Schober A, 2004, CELL TISSUE RES, V318, P215, DOI 10.1007/s00441-004-0938-y; Schober A, 2007, NEUROBIOL DIS, V25, P378, DOI 10.1016/j.nbd.2006.10.005; Sgado P, 2006, P NATL ACAD SCI USA, V103, P15242, DOI 10.1073/pnas.0602116103; Sha D, 2010, HUM MOL GENET, V19, P352, DOI 10.1093/hmg/ddp501; Smidt MP, 2007, NAT REV NEUROSCI, V8, P21, DOI 10.1038/nrn2039; Sonnier L, 2007, J NEUROSCI, V27, P1063, DOI 10.1523/JNEUROSCI.4583-06.2007; Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979; Tain LS, 2009, NAT NEUROSCI, V12, P1129, DOI 10.1038/nn.2372; Terzioglu M, 2008, FEBS J, V275, P1384, DOI 10.1111/j.1742-4658.2008.06302.x; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Van Diepen MT, 2008, DEV NEUROSCI-BASEL, V30, P59, DOI 10.1159/000109852; Xu PY, 2002, NEUROLOGY, V58, P881, DOI 10.1212/WNL.58.6.881; Yogev G, 2007, EXP BRAIN RES, V177, P336, DOI 10.1007/s00221-006-0676-3; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zaborszky L, 2001, BEHAV GENET, V31, P47, DOI 10.1023/A:1010257808945; Zhang C, 2005, MOL CELL BIOL, V25, P6899, DOI 10.1128/MCB.25.16.6899-6911.2005; Zheng KN, 2003, ARCH NEUROL-CHICAGO, V60, P722, DOI 10.1001/archneur.60.5.722; Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5; Zhu Y, 2007, NEUROCHEM INT, V50, P507, DOI 10.1016/j.neuint.2006.10.010	64	90	94	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2898	2910		10.1096/fj.11-181958	http://dx.doi.org/10.1096/fj.11-181958			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21593433	Bronze			2022-12-28	WOS:000294435200006
J	Holloway, C; Cochlin, L; Codreanu, I; Bloch, E; Fatemian, M; Szmigielski, C; Atherton, H; Heather, L; Francis, J; Neubauer, S; Robbins, P; Montgomery, H; Clarke, K				Holloway, Cameron; Cochlin, Lowri; Codreanu, Ion; Bloch, Edward; Fatemian, Marzieh; Szmigielski, Cezary; Atherton, Helen; Heather, Lisa; Francis, Jane; Neubauer, Stefan; Robbins, Peter; Montgomery, Hugh; Clarke, Kieran			Normobaric hypoxia impairs human cardiac energetics	FASEB JOURNAL			English	Article						cardiac energy metabolism; cardiac diastolic function; hypoxic chamber	MAGNETIC-RESONANCE-SPECTROSCOPY; HIGH-ALTITUDE; HEART; TOLERANCE; MAMMALS; HIF-1	Hypoxia causes left ventricular dysfunction in the human heart, but the biochemical mechanism is poorly understood. Here, we tested whether short-term normobaric hypoxia leads to changes in cardiac energetics and early cardiac dysfunction. Healthy male volunteers (n = 12, age 24 +/- 2 yr) were exposed to normobaric hypoxia in a purpose-built hypoxic chamber. The partial pressure of oxygen during end-tidal expiration (P(ET)O(2)) was kept between 50 and 60 mmHg, and peripheral oxygen saturation (SaO(2)) was kept above 80%. Cardiac morphology and function were assessed using magnetic resonance imaging and echocardiography, both before and after 20 h of hypoxic exposure, and high-energy phosphate metabolism [measured as the phosphocreatine (PCr)/ATP ratio] was measured using (31)P magnetic resonance spectroscopy. During hypoxia, PETO(2) and SaO(2) averaged 55 +/- 1 mmHg and 83.6 +/- 0.4%, respectively. Hypoxia caused a 15% reduction in cardiac PCr/ATP (from 2.0 +/- 0.1 to 1.7 +/- 0.1, P<0.01) and reduced diastolic function (measured as E/E ', rising from 6.1 +/- 0.4 to 7.5 +/- 0.7, P<0.01). Normobaric hypoxia causes a rapid decrease in high-energy phosphate metabolism in the human cardiac left ventricle, which may lead to a decline in diastolic function. These findings are important in understanding the response of normal individuals to environmental hypoxia, and to situations in which disease reduces cardiac oxygen delivery.-Holloway, C., Cochlin, L., Codreanu, I., Bloch, E., Fatemian, M., Szmigielski, C., Atherton, H., Heather, L., Francis, J., Neubauer, S., Robbins, P., Montgomery, H., Clarke, K. Normobaric hypoxia impairs human cardiac energetics. FASEB J. 25, 3130-3135 (2011). www.fasebj.org	[Holloway, Cameron; Cochlin, Lowri; Codreanu, Ion; Bloch, Edward; Fatemian, Marzieh; Atherton, Helen; Heather, Lisa; Robbins, Peter; Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Holloway, Cameron; Cochlin, Lowri; Codreanu, Ion; Szmigielski, Cezary; Francis, Jane; Neubauer, Stefan] Univ Oxford, Univ Oxford Ctr Clin Magnet Resonance Res, Oxford OX1 3PT, England; [Montgomery, Hugh] UCL, Inst Sport Exercise & Hlth, London, England; [Montgomery, Hugh] UCL, Univ Coll London Inst Human Hlth & Performance, London, England	University of Oxford; University of Oxford; University of London; University College London; University of London; University College London	Holloway, C (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,Parks Rd, Oxford OX1 3PT, England.	cameron.holloway@dpag.ox.ac.uk	Codreanu, Ion/AAS-4378-2020; Montgomery, Hugh/L-1229-2019; Robbins, Peter/C-7846-2016; Montgomery, Hugh/C-2592-2008	Codreanu, Ion/0000-0002-2644-5572; Szmigielski, Cezary/0000-0002-0837-6323; Bloch, Edward/0000-0002-0799-3258; Heather, Lisa/0000-0002-7246-1338; Robbins, Peter/0000-0002-4975-0609; Montgomery, Hugh/0000-0001-8797-5019; Neubauer, Stefan/0000-0001-9017-5645	British Heart Foundation (BHF); BHF Centre of Research Excellence, Oxford, UK; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: researchfish	British Heart Foundation (BHF)(British Heart Foundation); BHF Centre of Research Excellence, Oxford, UK; British Heart Foundation(British Heart Foundation)	The authors thank Emma Carter for plasma metabolite analysis and Dr Robert Olszewski for assistance with the echocardiography. The authors are also very thankful to Federico Formenti and David O'Connor for their assistance with running the hypoxic chamber. The British Heart Foundation (BHF) supported this work. S.N. acknowledges support from the BHF Centre of Research Excellence, Oxford, UK.	Allemann Y, 2004, AM J PHYSIOL-HEART C, V286, pH856, DOI 10.1152/ajpheart.00518.2003; Andrews MT, 2004, BIOCHEM SOC T, V32, P1021, DOI 10.1042/BST0321021; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; BALASUBRAMANIAN V, 1978, CIRCULATION, V57, P1180, DOI 10.1161/01.CIR.57.6.1180; BOTTOMLEY PA, 1992, MAGNET RESON MED, V24, P384, DOI 10.1002/mrm.1910240220; Boussuges A, 2000, AM J RESP CRIT CARE, V161, P264, DOI 10.1164/ajrccm.161.1.9902096; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P1215, DOI 10.1073/pnas.93.3.1215; HOLLOWAY CJ, AM J CLIN NUTR, V93, P748; HOLLOWAY CJ, FASEB J, V25, P792; HOWARD LSGE, 1995, J APPL PHYSIOL, V78, P1088, DOI 10.1152/jappl.1995.78.3.1088; Hudsmith LE, 2008, NAT CLIN PRACT CARD, V5, pS49, DOI 10.1038/ncpcardio1158; Hudsmith LE, 2006, J MAGN RESON IMAGING, V24, P312, DOI 10.1002/jmri.20638; Jung WI, 2000, CIRCULATION, V101, pE121, DOI 10.1161/01.CIR.101.12.e121; Kelly DP, 2008, NAT GENET, V40, P132, DOI 10.1038/ng0208-132; Kjaergaard J, 2006, EUR J APPL PHYSIOL, V98, P411, DOI 10.1007/s00421-006-0299-1; KOLLER EA, 1991, EUR J APPL PHYSIOL O, V62, P228, DOI 10.1007/BF00643747; Murray AJ, 2004, LANCET, V364, P1786, DOI 10.1016/S0140-6736(04)17402-3; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Rader DJ, 2008, NATURE, V451, P904, DOI 10.1038/nature06796; Rajabi M, 2007, HEART FAIL REV, V12, P331, DOI 10.1007/s10741-007-9034-1; Ramirez JM, 2007, ANNU REV PHYSIOL, V69, P113, DOI 10.1146/annurev.physiol.69.031905.163111; Robson MD, 2005, MAGNET RESON MED, V53, P267, DOI 10.1002/mrm.20344; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shen WQ, 1999, CIRCULATION, V100, P2113, DOI 10.1161/01.CIR.100.20.2113; Tyler DJ, 2009, NMR BIOMED, V22, P405, DOI 10.1002/nbm.1350	29	27	29	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3130	3135		10.1096/fj.11-183426	http://dx.doi.org/10.1096/fj.11-183426			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21646398				2022-12-28	WOS:000294435200026
J	Townsend, D; Yasuda, S; McNally, E; Metzger, JM				Townsend, DeWayne; Yasuda, Soichiro; McNally, Elizabeth; Metzger, Joseph M.			Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex	FASEB JOURNAL			English	Article						muscular dystrophy; hemodynamics; cellular compliance; cardiac fibrosis	GIRDLE MUSCULAR-DYSTROPHY; NITRIC-OXIDE SYNTHASE; GAMMA-SARCOGLYCAN; BETA-SARCOGLYCAN; SMOOTH-MUSCLE; SKELETAL-MUSCLE; PROTEIN; DEFICIENCY; MUTATIONS; DISRUPTION	Duchenne muscular dystrophy (DMD) and limb girdle muscular dystrophy (LGMD) 2C-F result from the loss of dystrophin and the sarcoglycans, respectively. Dystrophin, a cytoskeletal protein, is closely associated with the membrane-bound sarcoglycan complex. Despite this tight biochemical association, the function of dystrophin and the sarcoglycan subunits may differ. The loss of dystrophin in skeletal muscle results in muscle that is highly susceptible to contraction-induced damage, but the skeletal muscle of mice lacking gamma- or delta-sarcoglycan are less susceptible. Using mouse models of DMD, LGMD-2C, and LGMD-2F, we demonstrate that isolated cardiac myocytes from mice lacking either gamma- or delta-sarcoglycan have normal compliance. In contrast, dystrophin-deficient myocytes display poor passive compliance and are susceptible to terminal contracture following mild passive extensions. Mice deficient in dystrophin and, less so, delta-sarcoglycan have reduced survival during in vivo dobutamine stress testing compared to controls. Catheter-based hemodynamic studies show deficits in both baseline and dobutamine-stimulated cardiac function in all of the dystrophic mice compared to control mice, with dystrophin-deficient mice having the poorest function. In contrast, histopathology showed increased fibrosis in the sarcoglycan-deficient hearts, but not in hearts lacking dystrophin. In summary, this study provides important insights into the unique mechanisms of disease underlying these different models of inherited dystrophic cardiomyopathy and supports a model where dystrophin, but not the sarcoglycans, protects the cardiac myocyte against mechanical damage.-Townsend, D., Yasuda, S., McNally, E., Metzger, J. M. Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J. 25, 3106-3114 (2011). www.fasebj.org	[Townsend, DeWayne; Yasuda, Soichiro; Metzger, Joseph M.] Univ Minnesota, Dept Integrat Biol & Physiol, Minneapolis, MN 55455 USA; [McNally, Elizabeth] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Chicago	Townsend, D (corresponding author), Univ Minnesota, Dept Integrat Biol & Physiol, 6-125 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	town0045@umn.edu	McNally, Elizabeth/W-4909-2019	McNally, Elizabeth/0000-0002-1221-719X	Muscular Dystrophy Association [68419]; U.S. National Institutes of Health [HL61322, HL102066, HL086790]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086790, K08HL102066, R01HL061322] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the Muscular Dystrophy Association (68419 to D. T.) and the U.S. National Institutes of Health (HL61322 to E. M., HL102066 to D. T., and HL086790 to J.M.).	Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Barton ER, 2010, J BIOL CHEM, V285, P17263, DOI 10.1074/jbc.M109.063990; Barton ER, 2006, AM J PHYSIOL-CELL PH, V290, pC411, DOI 10.1152/ajpcell.00192.2005; Bies RD, 1997, J MOL CELL CARDIOL, V29, P3175, DOI 10.1006/jmcc.1997.0568; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Bosser G, 2004, AM J CARDIOL, V93, P724, DOI 10.1016/j.amjcard.2003.12.005; BRUTSAERT DL, 1989, PHYSIOL REV, V69, P1228, DOI 10.1152/physrev.1989.69.4.1228; Bushby KMD, 1999, HUM MOL GENET, V8, P1875, DOI 10.1093/hmg/8.10.1875; Chen JW, 2007, BBA-MOL BASIS DIS, V1772, P570, DOI 10.1016/j.bbadis.2007.01.014; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Duchenne, 1867, Br Med J, V2, P541; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 2003, P NATL ACAD SCI USA, V100, P8910, DOI 10.1073/pnas.1537554100; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Gavillet B, 2006, CIRC RES, V99, P407, DOI 10.1161/01.RES.0000237466.13252.5e; Griffin MA, 2005, J CELL SCI, V118, P1405, DOI 10.1242/jcs.01717; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Hainsey TA, 2003, NEUROMUSCULAR DISORD, V13, P294, DOI 10.1016/S0960-8966(02)00286-9; Heydemann A, 2005, NEUROMUSCULAR DISORD, V15, P601, DOI 10.1016/j.nmd.2005.05.004; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Iwata Y, 2005, MOL CELL BIOCHEM, V268, P59, DOI 10.1007/s11010-005-2998-z; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Li DJ, 2009, HUM MOL GENET, V18, P1209, DOI 10.1093/hmg/ddp015; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Markham LW, 2006, J AM SOC ECHOCARDIOG, V19, P865, DOI 10.1016/j.echo.2006.02.003; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Norwood F, 2007, EUR J NEUROL, V14, P1305, DOI 10.1111/j.1468-1331.2007.01979.x; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Politano L, 2001, NEUROMUSCULAR DISORD, V11, P178, DOI 10.1016/S0960-8966(00)00174-7; Pratali L, 2001, AM J CARDIOL, V88, P1374, DOI 10.1016/S0002-9149(01)02116-6; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Ross J, 1883, Br Med J, V1, P200; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Sen S, 2011, EUR J CELL BIOL, V90, P249, DOI 10.1016/j.ejcb.2010.06.005; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Townsend D, 2008, MOL THER, V16, P832, DOI 10.1038/mt.2008.52; Townsend D, 2007, MOL THER, V15, P1086, DOI 10.1038/sj.mt.6300144; Trabelsi M, 2008, EUR J HUM GENET, V16, P793, DOI 10.1038/ejhg.2008.9; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; Vatta M, 2004, J AM COLL CARDIOL, V43, P811, DOI 10.1016/j.jacc.2003.09.052; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; Wheeler MT, 2004, AM J PATHOL, V164, P1063, DOI 10.1016/S0002-9440(10)63193-8; Williams JC, 2006, J BIOL CHEM, V281, P23341, DOI 10.1074/jbc.M513341200; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	57	32	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3106	3114		10.1096/fj.10-178913	http://dx.doi.org/10.1096/fj.10-178913			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21665956	Green Published			2022-12-28	WOS:000294435200024
J	Abramov, JP; Wells, PG				Abramov, Julia P.; Wells, Peter G.			Embryonic catalase protects against endogenous and phenytoin-enhanced DNA oxidation and embryopathies in acatalasemic and human catalase-expressing mice	FASEB JOURNAL			English	Article						teratology; birth defects; oxidative stress; hydrogen peroxide; protein therapy	P-GLYCOPROTEIN EXPRESSION; BLOOD-BRAIN-BARRIER; SUPEROXIDE-DISMUTASE; NEURODEVELOPMENTAL DEFICITS; BIRTH-WEIGHT; EMBRYOPROTECTIVE ROLE; MOLECULAR MECHANISM; IN-VIVO; DAMAGE; INJURY	Oxidative stress and reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), which is detoxified by catalase, are implicated in fetal death and birth defects. However, embryonic levels of catalase are only similar to 5% of adult activity, and its protective role is not understood completely. Herein, we used mutant catalase-deficient mice [acatalasemic (aCat)] and transgenic mice expressing human catalase (hCat), which, respectively, exhibited 40-50% reductions and 2-fold elevations in the activities of embryonic and fetal brain catalase, to show that embryonic catalase protects the embryo from both physiological oxidative stress and the ROS-initiating anti-epileptic drug phenytoin. Compared to wild-type (WT) catalase-normal controls, both untreated and phenytoin-exposed aCat mice exhibited a 30% increase in embryonic DNA oxidation and a > 2-fold increase in embryopathies, both of which were completely blocked by protein therapy with exogenous catalase. Conversely, compared to WT controls, untreated and, to a lesser extent, phenytoin-exposed hCat mice were protected, with untreated hCat embryos exhibiting a 40% decrease in embryonic DNA oxidation and up to a 67% decrease in embryopathies. Embryonic catalase accordingly plays an important protective role, and both physiological and phenytoin-enhanced oxidative stress can be embryopathic.-Abramov, J. P., Wells, P. G. Embryonic catalase protects against endogenous and phenytoin-enhanced DNA oxidation and embryopathies in acatalasemic and human catalase-expressing mice. FASEB J. 25, 2188-2200 (2011). www.fasebj.org	[Abramov, Julia P.; Wells, Peter G.] Univ Toronto, Fac Pharm, Toronto, ON M5S 3M2, Canada; [Wells, Peter G.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 3M2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 144 Coll St, Toronto, ON M5S 3M2, Canada.	pg.wells@utoronto.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank Dr. Arlan Richardson (University of Texas Health Science Center, San Antonio, TX, USA) for generously providing a breeding pair of the transgenic hCat mice. Preliminary reports of this research were presented at the 2007 and 2009 annual meetings of the Teratology Society (USA; refs 57, 58) and the 2009 annual meeting of the Society of Toxicology (USA; ref. 59). These studies were supported by a grant from the Canadian Institutes of Health Research.	Abel KM, 2010, ARCH GEN PSYCHIAT, V67, P923, DOI 10.1001/archgenpsychiatry.2010.100; Abramov JP, 2011, TOXICOL SCI, V120, P428, DOI 10.1093/toxsci/kfr007; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; BARROW MV, 1969, J MORPHOL, V127, P291, DOI 10.1002/jmor.1051270303; Beyerlein A, 2010, AM J CLIN NUTR, V92, P585, DOI 10.3945/ajcn.2009.29116; Ceckova-Novotna M, 2006, REPROD TOXICOL, V22, P400, DOI 10.1016/j.reprotox.2006.01.007; Danielsson BR, 1997, TERATOLOGY, V56, P271, DOI 10.1002/(SICI)1096-9926(199710)56:4<271::AID-TERA6>3.0.CO;2-1; DAS DK, 1991, FREE RADICAL RES COM, V12-3, P653; ELHAGE S, 1990, DEV GENET, V11, P149, DOI 10.1002/dvg.1020110205; ELMAZAR MMA, 1981, TERATOLOGY, V24, P115, DOI 10.1002/tera.1420240202; ERICKSON UJ, 1991, DIABETOLOGIA, V34, P325; ESPEEL M, 1993, CELL TISSUE RES, V272, P89, DOI 10.1007/BF00323574; Fattal-Valevski A, 2009, J CHILD NEUROL, V24, P846, DOI 10.1177/0883073808331082; Fromm MF, 2002, ADV DRUG DELIVER REV, V54, P1295, DOI 10.1016/S0169-409X(02)00064-9; Gaetani GF, 1996, BLOOD, V88, P1084; GUPTA BL, 1973, J MICROCHEM, V18, P363; Halliwell B., 2007, FREE RADICALS BIOL M; HANSEN DK, 1991, P SOC EXP BIOL MED, V197, P361; Himpel S, 2006, J NEURAL TRANSM, V113, P295, DOI 10.1007/s00702-005-0330-4; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; Indredavik MS, 2005, PEDIATR NEUROL, V33, P259, DOI 10.1016/j.pediatrneurol.2005.05.002; Ishii K, 1996, JPN J CANCER RES, V87, P680, DOI 10.1111/j.1349-7006.1996.tb00277.x; Jeng W, 2005, FREE RADICAL BIO MED, V39, P317, DOI 10.1016/j.freeradbiomed.2005.03.015; Jeng W, 2006, FASEB J, V20, P638, DOI 10.1096/fj.05-5271com; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Kim PM, 1996, MOL PHARMACOL, V49, P172; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; LUM JT, 1985, J CHROMATOGR, V338, P242, DOI 10.1016/0378-4347(85)80093-1; Mahmood B, 2001, J INVEST MED, V49, P250, DOI 10.2310/6650.2001.33969; McCallum GP, 2011, ANTIOXID REDOX SIGN, V14, P747, DOI 10.1089/ars.2009.2946; Nair MKC, 2009, INDIAN PEDIATR, V46, pS71; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; ODA T, 1992, TRANSPLANT P, V24, P797; OGATA M, 1991, HUM GENET, V86, P331; Ou P, 1996, J PHARMACOL EXP THER, V277, P945; PADMANABHAN RV, 1985, AM REV RESPIR DIS, V132, P264; Perstin J, 2007, BIRTH DEFECTS RES A, V79, P418; Perstin J, 2009, BIRTH DEFECTS RES A, V85, P398; PERSTIN J, 2009, TOXICOL SCI S, V108, P355; PERSTIN JP, 2010, TOXICOL LETT S, V196, pP204; Potschka H, 2001, EPILEPSIA, V42, P1231, DOI 10.1046/j.1528-1157.2001.01901.x; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Reuner G, 2009, EARLY HUM DEV, V85, P409, DOI 10.1016/j.earlhumdev.2009.01.007; Roberts G, 2007, MATERN CHILD HLTH J, V11, P161, DOI 10.1007/s10995-006-0158-z; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Tsai CE, 2002, BIOL NEONATE, V81, P58, DOI 10.1159/000047185; VORHEES CV, 1983, J PHARMACOL EXP THER, V227, P274; VORHEES CV, 1994, ENVIRON HEALTH PERSP, V102, P145, DOI 10.2307/3431832; Wang DH, 1996, ARCH TOXICOL, V70, P189, DOI 10.1007/s002040050259; Watson RE, 2006, BIRTH DEFECTS RES B, V77, P471, DOI 10.1002/bdrb.20090; Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061; Wells PG, 2010, BIRTH DEFECTS RES C, V90, P103, DOI 10.1002/bdrc.20177; Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Winn LM, 1995, EUR J NEUROL, V2, P5; WINN LM, 1995, MOL PHARMACOL, V48, P112; Wong AW, 2008, J NEUROSCI, V28, P9047, DOI 10.1523/JNEUROSCI.2557-08.2008; Yamada K, 1997, ANTICANCER RES, V17, P2041	59	33	34	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2188	2200		10.1096/fj.11-182444	http://dx.doi.org/10.1096/fj.11-182444			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478259				2022-12-28	WOS:000292242200011
J	Nichenametla, SN; Lazarus, P; Richie, JP				Nichenametla, Sailendra N.; Lazarus, Philip; Richie, John P., Jr.			A GAG trinucleotide-repeat polymorphism in the gene for glutathione biosynthetic enzyme, GCLC, affects gene expression through translation	FASEB JOURNAL			English	Article						gamma-glutamylcysteine ligase; short tandem repeats; 5 ' untranslated region	LIGASE CATALYTIC SUBUNIT; FRAGILE-X-SYNDROME; PREMUTATION CARRIERS; MESSENGER-RNA; HUMAN-DISEASE; ASSOCIATION; REGION; CELL; ELEMENTS; BINDING	A guanine-adenine-guanine (GAG) repeat polymorphism with 5 different alleles (4, 7, 8, 9, and 10 repeats) in the 5' untranslated region (UTR) of GCLC has been associated with altered GCL activity and glutathione (GSH) levels. We investigated whether this polymorphism affects either transcription or translation using luciferase reporter constructs containing variant GCLC 5' UTRs. Higher luciferase activity was observed in HepG2 and human embryonic kidney 293 (HEK293) cells transfected with constructs containing either 8 or 9 repeats than in constructs containing 4, 7, or 10 repeats (P < 0.05). In cell-free lysates, GAG repeat number had no effect on luciferase mRNA yield. In vitro translation of mRNAs from luciferase constructs resulted in differences similar to those found in cell cultures (P < 0.05). A similar association of GAG repeat with GCLC phenotype was observed in vivo in healthy adults, as individuals with GAG-7/7 genotype had lower GCL activity and GSH levels in lymphocytes compared to those with GAG-9/9 (P < 0.05). Higher GCL activity and GSH levels observed in red blood cells (RBCs) from individuals with GAG-7/7 compared to GAG-9/9 are likely due to differences in GCL regulation in RBCs. Altogether, these results suggest that GAG polymorphism affects GCLC expression via translation, and thus may be associated with altered risk for GSH-related diseases and toxicities.-Nichenametla, S. N., Lazarus, P., Richie, J. P., Jr. A GAG trinucleotide-repeat polymorphism in the gene for glutathione biosynthetic enzyme, GCLC, affects gene expression through translation. FASEB J. 25, 2180-2187 (2011). www.fasebj.org	[Nichenametla, Sailendra N.; Lazarus, Philip; Richie, John P., Jr.] Penn State Univ, Coll Med, Penn State Canc Inst, Mol Epidemiol & Canc Control Program, Hershey, PA USA; [Nichenametla, Sailendra N.; Lazarus, Philip; Richie, John P., Jr.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Lazarus, Philip] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Richie, JP (corresponding author), Penn State Coll Med, Penn State Canc Inst, H069,500 Univ Dr, Hershey, PA 17033 USA.	jrichie@psu.edu	Nichenametla, Sailendra Nath/B-2733-2009	Nichenametla, Sailendra Nath/0000-0002-5969-3572; Richie, John/0000-0001-8239-2850	U. S. National Institutes of Health [P01-CA68384, R01-DE13158]; NATIONAL CANCER INSTITUTE [P01CA068384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013158] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported in part by Public Health Service grants P01-CA68384 (P.L., principal investigator; J.P.R, project leader) and R01-DE13158 (P.L.) from the U. S. National Institutes of Health.	Bekris LM, 2007, EXP CLIN ENDOCR DIAB, V115, P221, DOI 10.1055/s-2007-970574; Bekris LM, 2006, J OCCUP ENVIRON MED, V48, P599, DOI 10.1097/01.jom.0000201845.02369.ba; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Butticaz C, 2011, FREE RADICAL BIO MED, V50, P617, DOI 10.1016/j.freeradbiomed.2010.12.002; Chave Karen J., 1997, Biochemical Society Transactions, V25, p53S; Custodio HM, 2004, ARCH ENVIRON HEALTH, V59, P588, DOI 10.1080/00039890409603438; Ellouk-Achard S, 1995, Arch Toxicol Suppl, V17, P209; Ennis S, 2006, EUR J HUM GENET, V14, P253, DOI 10.1038/sj.ejhg.5201510; Fairbanks VF, 1987, FUNDAMENTALS CLIN CH, P789; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Gysin R, 2007, P NATL ACAD SCI USA, V104, P16621, DOI 10.1073/pnas.0706778104; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; Iglesias AR, 2004, GENE, V341, P149, DOI 10.1016/j.gene.2004.06.035; Jollow D J, 1980, Arch Toxicol Suppl, V3, P95; JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1; Kleinman WA, 2000, BIOCHEM PHARMACOL, V60, P19, DOI 10.1016/S0006-2952(00)00293-8; Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8; Kumari S, 2007, NAT CHEM BIOL, V3, P218, DOI 10.1038/nchembio864; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lu SC, 2000, CURR TOP CELL REGUL, V36, P95; Maiti A K, 2001, BMC Mol Biol, V2, P11, DOI 10.1186/1471-2199-2-11; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Nenonen HA, 2011, INT J ANDROL, V34, P327, DOI 10.1111/j.1365-2605.2010.01084.x; Nichenarnetla SN, 2008, FREE RADICAL BIO MED, V45, P645, DOI 10.1016/j.freeradbiomed.2008.05.012; Nuttall SL, 1998, LANCET, V351, P645, DOI 10.1016/S0140-6736(05)78428-2; Ohashi Y, 2004, ONCOGENE, V23, P7772, DOI 10.1038/sj.onc.1208058; Peprah E, 2010, J HUM GENET, V55, P66, DOI 10.1038/jhg.2009.121; Raca G, 2000, NUCLEIC ACIDS RES, V28, P3943, DOI 10.1093/nar/28.20.3943; Richie JP, 1996, CLIN CHEM, V42, P64; Schenborn ET., 1995, PROMEGA NOTES, V50, P2; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Sulek Anna, 2004, Journal of Applied Genetics, V45, P101; Syagailo YV, 2002, GENE, V294, P259, DOI 10.1016/S0378-1119(02)00798-9; Tew KD, 1996, MOL PHARMACOL, V50, P149; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X; Unt E, 2008, J SPORT SCI MED, V7, P344; Vassos E, 2008, J PSYCHIATR RES, V42, P544, DOI 10.1016/j.jpsychires.2007.05.008; Vina J., 1990, GLUTATHIONE METABOLI; VOGT BL, 1993, BIOCHEM PHARMACOL, V46, P257, DOI 10.1016/0006-2952(93)90412-P; Walsh AC, 2001, TOXICOL SCI, V61, P218, DOI 10.1093/toxsci/61.2.218; Yang P, 2004, CARCINOGENESIS, V25, P1935, DOI 10.1093/carcin/bgh203; Zitouni K, 2005, DIABETES CARE, V28, P1698, DOI 10.2337/diacare.28.7.1698	48	14	14	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2180	2187		10.1096/fj.10-174011	http://dx.doi.org/10.1096/fj.10-174011			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21444626	Green Published			2022-12-28	WOS:000292242200010
J	Cozzi, R; Nuccitelli, A; D'Onofrio, M; Necchi, F; Rosini, R; Zerbini, F; Biagini, M; Norais, N; Beier, C; Telford, JL; Grandi, G; Assfalg, M; Zacharias, M; Maione, D; Rinaudo, CD				Cozzi, Roberta; Nuccitelli, Annalisa; D'Onofrio, Mariapina; Necchi, Francesca; Rosini, Roberto; Zerbini, Francesca; Biagini, Massimiliano; Norais, Nathalie; Beier, Christian; Telford, John L.; Grandi, Guido; Assfalg, Michael; Zacharias, Martin; Maione, Domenico; Rinaudo, C. Daniela			New insights into the role of the glutamic acid of the E-box motif in group B Streptococcus pilus 2a assembly	FASEB JOURNAL			English	Article						isopeptide bonds; molecular dynamic simulations; NMR spectroscopy; backbone protein	GRAM-POSITIVE BACTERIA; INTRAMOLECULAR ISOPEPTIDE BONDS; MOLECULAR-DYNAMICS METHOD; CORYNEBACTERIUM-DIPHTHERIAE; STABILIZING ISOPEPTIDE; PROTEIN; SURFACE; WATER; AGALACTIAE; VACCINE	Group B Streptococcus pili are covalently linked structures assembled via a sortase-catalyzed transpeptidation mechanism involving specific residues and motifs. A sequence element containing a conserved glutamic acid, called the E-box, has been described to be involved in pilus formation. Although it is known that the glutamic acid is involved in stabilizing the internal isopeptide bonds, its role in pilus assembly still needs to be investigated. Using site-specific mutagenesis and complementation studies of knockout strains, we found that the E-box glutamic residue of the backbone and the major ancillary proteins is essential for pilus protein polymerization. NMR analysis revealed that the mutation of this residue seriously affected the folding of the protein. By contrast, the mutation of the lysine involved in the same isopeptide bond did not engender a structural destabilization, and the native fold was preserved. Moreover, molecular dynamics simulations on the E-box-containing domain of the backbone protein showed that the E-box glutamic acid is necessary to maintain the appropriate dryness of the domain core and that its mutation favors an unfolded state. The data provide the first direct evidence that the E-box has an additional and key role in maintaining the correct protein fold independently of isopeptide bond formation.-Cozzi, R., Nuccitelli, A., D'Onofrio, M., Necchi, F., Rosini, R., Zerbini, F., Biagini, M., Norais, N., Beier, C., Telford, J. L., Grandi, G., Assfalg, M., Zacharias, M., Maione, D., Rinaudo, C. D. New insights into the role of the glutamic acid of the E-box motif in group B Streptococcus pilus 2a assembly. FASEB J. 26, 2008-2018 (2012). www.fasebj.org	[Cozzi, Roberta; Nuccitelli, Annalisa; Necchi, Francesca; Rosini, Roberto; Zerbini, Francesca; Biagini, Massimiliano; Norais, Nathalie; Telford, John L.; Grandi, Guido; Maione, Domenico; Rinaudo, C. Daniela] Novartis Vaccines & Diagnost, I-53100 Siena, Italy; [D'Onofrio, Mariapina; Assfalg, Michael] Univ Verona, Dept Biotechnol, Nucl Magnet Resonance Lab, I-37100 Verona, Italy; [Beier, Christian; Zacharias, Martin] Tech Univ Munich, Dept Phys, D-8000 Munich, Germany	Novartis; University of Verona; Technical University of Munich; University of Munich	Rinaudo, CD (corresponding author), Novartis Vaccines & Diagnost, Via Fiorentina 1, I-53100 Siena, Italy.	daniela.rinaudo@novartis.com	Telford, John Laird/ABG-8144-2020	D'ONOFRIO, Mariapina/0000-0002-8699-0847; Assfalg, Michael/0000-0001-9331-3169; Grandi, Guido/0000-0001-9724-2185				Alegre-Cebollada J, 2010, J BIOL CHEM, V285, P11235, DOI 10.1074/jbc.M110.102962; Ball P, 2003, NATURE, V423, P25, DOI 10.1038/423025a; Budzik JM, 2008, P NATL ACAD SCI USA, V105, P10215, DOI 10.1073/pnas.0803565105; Budzik JM, 2009, P NATL ACAD SCI USA, V106, P19992, DOI 10.1073/pnas.0910887106; Chandler D, 2002, NATURE, V417, P491, DOI 10.1038/417491a; Cheung MS, 2002, P NATL ACAD SCI USA, V99, P685, DOI 10.1073/pnas.022387699; Cozzi R, 2011, FASEB J, V25, P1874, DOI 10.1096/fj.10-174797; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; Eggers DK, 2001, J MOL BIOL, V314, P911, DOI 10.1006/jmbi.2001.5166; Hendrickx APA, 2011, NAT REV MICROBIOL, V9, P166, DOI 10.1038/nrmicro2520; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung TT, 2004, MOL MICROBIOL, V53, P251, DOI 10.1111/j.1365-2958.2004.04117.x; Izore T, 2010, STRUCTURE, V18, P106, DOI 10.1016/j.str.2009.10.019; Johri AK, 2006, NAT REV MICROBIOL, V4, P932, DOI 10.1038/nrmicro1552; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kang HJ, 2007, SCIENCE, V318, P1625, DOI 10.1126/science.1145806; Kang HJ, 2011, TRENDS BIOCHEM SCI, V36, P227, DOI 10.1016/j.tibs.2010.09.007; Kang HJ, 2009, P NATL ACAD SCI USA, V106, P16967, DOI 10.1073/pnas.0906826106; Kang HJ, 2009, J BIOL CHEM, V284, P20729, DOI 10.1074/jbc.M109.014514; Klock Heath E., 2009, V498, P91, DOI 10.1007/978-1-59745-196-3_6; Konto-Ghiorghi Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000422; Krishnan V, 2007, STRUCTURE, V15, P893, DOI 10.1016/j.str.2007.06.015; Kwan AH, 2011, FEBS J, V278, P687, DOI 10.1111/j.1742-4658.2011.08004.x; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Mandlik A, 2008, TRENDS MICROBIOL, V16, P33, DOI 10.1016/j.tim.2007.10.010; Margarit I, 2009, J INFECT DIS, V199, P108, DOI 10.1086/595564; Nobbs AH, 2008, INFECT IMMUN, V76, P3550, DOI 10.1128/IAI.01613-07; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851; Nuccitelli A, 2011, P NATL ACAD SCI USA, V108, P10278, DOI 10.1073/pnas.1106590108; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Proft T, 2009, CELL MOL LIFE SCI, V66, P613, DOI 10.1007/s00018-008-8477-4; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; Spraggon G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010919; Ton-That H, 2003, MOL MICROBIOL, V50, P1429, DOI 10.1046/j.1365-2958.2003.03782.x; Ton-That H, 2004, TRENDS MICROBIOL, V12, P228, DOI 10.1016/j.tim.2004.03.004; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Vengadesan K, 2011, J MOL BIOL, V407, P731, DOI 10.1016/j.jmb.2011.02.024; Yeates TO, 2007, SCIENCE, V318, P1558, DOI 10.1126/science.1151398; Young T, 2010, PROTEINS, V78, P1856, DOI 10.1002/prot.22699	43	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2008	2018		10.1096/fj.11-196378	http://dx.doi.org/10.1096/fj.11-196378			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253480	Green Submitted			2022-12-28	WOS:000303680800027
J	Gupta, V; Discenza, M; Guyon, JR; Kunkel, LM; Beggs, AH				Gupta, Vandana; Discenza, Marie; Guyon, Jeffrey R.; Kunkel, Louis M.; Beggs, Alan H.			alpha-Actinin-2 deficiency results in sarcomeric defects in zebrafish that cannot be rescued by alpha-actinin-3 revealing functional differences between sarcomeric isoforms	FASEB JOURNAL			English	Article						skeletal muscle; cytoskeletal; myofibrillogenesis; gene duplication; evolution	ALPHA-ACTININ GENE; EXPRESSION; PROTEINS; MUTATIONS; CLONING; MUTANT; CELLS; MYOFIBRILLOGENESIS; CARDIOMYOPATHY; LOCALIZATION	alpha-Actinins are actin-binding proteins that can be broadly divided into Ca2+-sensitive cytoskeletal and Ca2+-insensitive sarcomeric isoforms. To date, little is known about functional differences between the isoforms due to their indistinguishable activities in most in vitro assays. To identify functional differences in vivo between sarcomeric isoforms, we employed computational and molecular approaches to characterize the zebrafish (Danio rerio) genome, which contains orthologoues of each human alpha-actinin gene, including duplicated copies of actn3. Each isoform exhibits a distinct and unique pattern of gene expression as assessed by mRNA in situ hybridization, largely sharing similar expression profiles as seen in humans. The spatial conservation of expression of these genes from lower invertebrates to humans suggests that regulation and subsequent functions of these genes are conserved during evolution. Morpholino-based knockdown of the sarcomeric isoform, actn2, leads to skeletal muscle, cardiac, and ocular defects evident over the first week of development. Remarkably, despite the high degree of sequence conservation between actn2 and actn3, the phenotypes of alpha-actinin-2 deficient zebrafish can be rescued by overexpression of alpha-actinin-2 but not by alpha-actinin-3 mRNAs from zebrafish or human. These data provide functional evidence that the primary sequences of alpha-actinin-2 and alpha-actinin-3 evolved differences to optimize their functions.-Gupta, V., Discenza, M., Guyon, J. R., Kunkel, L. M., Beggs, A. H. alpha-Actinin-2 deficiency results in sarcomeric defects in zebrafish that cannot be rescued by alpha-actinin-3 revealing functional differences between sarcomeric isoforms. FASEB J. 26, 1892-1908 (2012). www.fasebj.org	[Gupta, Vandana; Discenza, Marie; Guyon, Jeffrey R.; Kunkel, Louis M.; Beggs, Alan H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res,Div Genet, Boston, MA 02115 USA; [Gupta, Vandana; Discenza, Marie; Guyon, Jeffrey R.; Kunkel, Louis M.; Beggs, Alan H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res,Genom Program, Boston, MA 02115 USA; [Guyon, Jeffrey R.] Ted Stevens Marine Res Inst, Auke Bay Labs, Natl Marine Fisheries Serv, Juneau, AK USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA	Beggs, AH (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res,Div Genet, CLSB 15026,300 Longwood Ave, Boston, MA 02115 USA.	beggs@enders.tch.harvard.edu		Beggs, Alan/0000-0001-8818-0568; Gupta, Vandana/0000-0002-4057-8451	U.S. National Institute for Child Health and Human Development; U.S. National Institutes of Health (NIH) [NIH-P30-HD-18655]; NIH, National Institute of Arthritis and Musculoskeletal and Skin Disease [R01 AR044345]; Muscular Dystrophy Association [MDA201302]; Lee and Penny Anderson Family Foundation; William Hearst Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044345] Funding Source: NIH RePORTER	U.S. National Institute for Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute of Arthritis and Musculoskeletal and Skin Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Muscular Dystrophy Association(Muscular Dystrophy Association); Lee and Penny Anderson Family Foundation; William Hearst Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors gratefully thank Dr. Genri Kawahara and Dr. Yukio Nakamura (Children's Hospital Boston, Boston, MA, USA) for sharing reagents. The authors thank Ryan Darnall for technical help in these studies and Dr. Yi Zhao for help with zebrafish genomic analysis. The authors thank members of the A. H. B. and L. M. K. laboratories for critically reading the manuscript. The authors also thank Chris Lawrence and Jason Best (Zebrafish Facility, Children's Hospital Boston) for sharing their wonderful expertise with zebrafish. Antibodies F59 and F310 (developed by F. E. Stockdale) and MF20 (developed by D. A. Fischman) were obtained from the Developmental Studies Hybridoma Bank supported under the auspices of the U.S. National Institute for Child Health and Human Development and maintained by The University of Iowa Department of Biology (Iowa City, IA, USA). Confocal microscopy was performed at Children's Hospital Boston Intellectual and Developmental Disability Research Center imaging core, supported by U.S. National Institutes of Health (NIH) grant NIH-P30-HD-18655. This work was supported by funding from the NIH, National Institute of Arthritis and Musculoskeletal and Skin Disease (R01 AR044345), the Muscular Dystrophy Association (MDA201302), and the Lee and Penny Anderson Family Foundation to A. H. B. and a William Hearst Foundation fellowship to V.G.	ARIKAWA K, 1989, J COMP NEUROL, V288, P640, DOI 10.1002/cne.902880410; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Berman Y, 2010, PHYSIOLOGY, V25, P250, DOI 10.1152/physiol.00008.2010; Broderick MJF, 2005, ADV PROTEIN CHEM, V70, P203, DOI 10.1016/S0065-3233(04)70007-8; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Cabello N, 2007, J BIOL CHEM, V282, P12143, DOI 10.1074/jbc.M608880200; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; Chiu C, 2010, J AM COLL CARDIOL, V55, P1127, DOI 10.1016/j.jacc.2009.11.016; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; Gupta V, 2011, HUM MOL GENET, V20, P1712, DOI 10.1093/hmg/ddr047; Guyon JR, 2007, BBA-MOL BASIS DIS, V1772, P205, DOI 10.1016/j.bbadis.2006.07.003; Henry CA, 2005, ZEBRAFISH, V2, P7, DOI 10.1089/zeb.2005.2.7; Hirata H, 2007, DEVELOPMENT, V134, P2771, DOI 10.1242/dev.004531; Holterhoff CK, 2009, DEV DYNAM, V238, P2936, DOI 10.1002/dvdy.22123; Huang W, 2009, DEV BIOL, V331, P237, DOI 10.1016/j.ydbio.2009.04.039; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kremerskothen J, 2002, BIOCHEM BIOPH RES CO, V295, P678, DOI 10.1016/S0006-291X(02)00734-9; MacArthur DG, 2007, NAT GENET, V39, P1261, DOI 10.1038/ng2122; Mills MA, 2001, HUM MOL GENET, V10, P1335, DOI 10.1093/hmg/10.13.1335; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; North KN, 1999, NAT GENET, V21, P353, DOI 10.1038/7675; O'Sullivan ML, 2011, AM J VET RES, V72, P932, DOI 10.2460/ajvr.72.7.932; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; SANGER JM, 1986, J CELL BIOL, V102, P2053, DOI 10.1083/jcb.102.6.2053; Sanger JW, 2009, CELL MOTIL CYTOSKEL, V66, P556, DOI 10.1002/cm.20365; SCHLEICHER M, 1988, J CELL SCI, V90, P59; SCHULTHEISS T, 1992, P NATL ACAD SCI USA, V89, P9282, DOI 10.1073/pnas.89.19.9282; Sjoblom B, 2008, CELL MOL LIFE SCI, V65, P2688, DOI 10.1007/s00018-008-8080-8; Steffen LS, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-79; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Usmanova A, 1998, COMP BIOCHEM PHYS B, V120, P693, DOI 10.1016/S0305-0491(98)10065-2; Westerfield M, 2007, ZEBRAFISH BOOK; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Yao J, 2004, PLOS BIOL, V2, P787, DOI 10.1371/journal.pbio.0020167; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	38	26	26	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1892	1908		10.1096/fj.11-194548	http://dx.doi.org/10.1096/fj.11-194548			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253474	Green Published			2022-12-28	WOS:000303680800018
J	Preidis, GA; Saulnier, DM; Blutt, SE; Mistretta, TA; Riehle, KP; Major, AM; Venable, SF; Finegold, MJ; Petrosino, JF; Conner, ME; Versalovic, J				Preidis, Geoffrey A.; Saulnier, Delphine M.; Blutt, Sarah E.; Mistretta, Toni-Ann; Riehle, Kevin P.; Major, Angela M.; Venable, Susan F.; Finegold, Milton J.; Petrosino, Joseph F.; Conner, Margaret E.; Versalovic, James			Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine	FASEB JOURNAL			English	Article						animal models; cell movement; epithelium; metagenome	INTEGRIN-LINKED KINASE; LACTOBACILLUS-REUTERI; NECROTIZING ENTEROCOLITIS; ESCHERICHIA-COLI; CROHNS-DISEASE; HOST; HOMEOSTASIS; BACTERIA; PREBIOTICS; EXPRESSION	Beneficial microbes and probiotics show promise for the treatment of pediatric gastrointestinal diseases. However, basic mechanisms of probiosis are not well understood, and most investigations have been performed in germ-free or microbiome-depleted animals. We sought to functionally characterize probiotic-host interactions in the context of normal early development. Outbred CD1 neonatal mice were orally gavaged with one of two strains of human-derived Lactobacillus reuteri or an equal volume of vehicle. Transcriptome analysis was performed on enterocyte RNA isolated by laser-capture microdissection. Enterocyte migration and proliferation were assessed by labeling cells with 5-bromo-2'-deoxyuridine, and fecal microbial community composition was determined by 16S metagenomic sequencing. Probiotic ingestion altered gene expression in multiple canonical pathways involving cell motility. L. reuteri strain DSM 17938 dramatically increased enterocyte migration (3-fold), proliferation (34%), and crypt height (29%) compared to vehicle-treated mice, whereas strain ATCC PTA 6475 increased cell migration (2-fold) without affecting crypt proliferative activity. In addition, both probiotic strains increased the phylogenetic diversity and evenness between taxa of the fecal microbiome 24 h after a single probiotic gavage. These experiments identify two targets of probiosis in early development, the intestinal epithelium and the gut microbiome, and suggest novel mechanisms for probiotic strain-specific effects.-Preidis, G. A., Saulnier, D. M., Blutt, S. E., Mistretta, T.-A., Riehle, K. P., Major, A. M., Venable, S. F., Finegold, M. J., Petrosino, J. F., Conner, M. E., Versalovic, J. Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. FASEB J. 26, 1960-1969 (2012). www.fasebj.org	[Versalovic, James] Texas Childrens Hosp, Feigin Ctr, Dept Pathol, Houston, TX 77030 USA; [Preidis, Geoffrey A.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Preidis, Geoffrey A.; Saulnier, Delphine M.; Mistretta, Toni-Ann; Venable, Susan F.; Finegold, Milton J.; Conner, Margaret E.; Versalovic, James] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Blutt, Sarah E.; Petrosino, Joseph F.; Conner, Margaret E.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Riehle, Kevin P.] Baylor Coll Med, Bioinformat Res Lab, Houston, TX 77030 USA; [Petrosino, Joseph F.] Human Genome Sequencing Ctr, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Versalovic, J (corresponding author), Texas Childrens Hosp, Feigin Ctr, Dept Pathol, Ste 830,1102 Bates Ave, Houston, TX 77030 USA.	jamesv@bcm.edu	Conner, Margaret E./I-7230-2019; SAULNIER, Delphine DM/C-1307-2013; Preidis, Geoffrey A./W-5538-2019; Petrosino, Joseph F./AAF-1621-2019	Preidis, Geoffrey A./0000-0002-2206-6452; Riehle, Kevin/0000-0003-4888-2404	U.S. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) [F30 DK081269, R01 DK065075, UH3 DK083990, P30 DK56338]; National Institute of Allergy and Infectious Diseases (NIAID) [RO1 AI24998]; National Center for Complementary and Alternative Medicine (NCCAM) [R01 AT004326]; Biogaia AB; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT004326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338, R01DK065075, F30DK081269, UH3DK083990] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Biogaia AB; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the U.S. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) F30 DK081269 (G. A. P.), R01 DK065075 (J.V.), UH3 DK083990 (J.V.), and P30 DK56338 (M.J.F. and J.V.); by the National Institute of Allergy and Infectious Diseases (NIAID) RO1 AI24998 (M. E. C.); and by the National Center for Complementary and Alternative Medicine (NCCAM) R01 AT004326 (J.V.). J.V. received an unrestricted grant from Biogaia AB; he acts as an advisor and consultant to Danone. The other authors declare no conflicts of interest.	AlFaleh K, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005496.pub2, 10.1097/AOG.0b013e3181726f2f]; AlFaleh K, 2011, COCHRANE DB SYST REV, DOI [10.1097/AOG.0b013e3181726f2f, 10.1002/14651858.CD005496.pub3]; Allen SJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003048.pub3; Banasaz M, 2002, APPL ENVIRON MICROB, V68, P3031, DOI 10.1128/AEM.68.6.3031-3034.2002; Aponte GB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007401.pub2; Boshuizen JA, 2003, J VIROL, V77, P13005, DOI 10.1128/JVI.77.24.13005-13016.2003; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; CHAO A, 1984, SCAND J STAT, V11, P265; Cliffe LJ, 2005, SCIENCE, V308, P1463, DOI 10.1126/science.1108661; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Cox MJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011044, 10.1371/journal.pone.0008745]; Deshpande G, 2010, PEDIATRICS, V125, P921, DOI 10.1542/peds.2009-1301; Food and Agricultural Organization of the United Nations and World Health Organization, 2001, HLTH NUTR PROP PROB; Frese SA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001314; FULLER R, 1989, J APPL BACTERIOL, V66, P365; Gallis Jean-Louis, 2007, BMC Physiology, V7, P8, DOI 10.1186/1472-6793-7-8; Kim M, 2009, NATURE, V459, P578, DOI 10.1038/nature07952; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; MacKenzie DA, 2010, MICROBIOL-SGM, V156, P3368, DOI 10.1099/mic.0.043265-0; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Martin FPJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb4100190; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Preidis GA, 2011, GASTROENTEROLOGY, V140, P8, DOI 10.1053/j.gastro.2010.11.010; Preidis GA, 2009, GASTROENTEROLOGY, V136, P2015, DOI 10.1053/j.gastro.2009.01.072; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Saulnier DM, 2011, GASTROENTEROLOGY, V141, P1782, DOI 10.1053/j.gastro.2011.06.072; Saulnier DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018783; Savino F, 2007, PEDIATRICS, V119, pE124, DOI 10.1542/peds.2006-1222; Savino F, 2010, PEDIATRICS, V126, pE526, DOI 10.1542/peds.2010-0433; Shanahan F, 2010, GASTROENTEROLOGY, V139, P1808, DOI 10.1053/j.gastro.2010.10.025; Shannon C.E., 1963, MATH THEORY COMMUNIC; Shornikova AV, 1997, PEDIATR INFECT DIS J, V16, P1103, DOI 10.1097/00006454-199712000-00002; Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176-199704000-00008; Soll RF, 2010, PEDIATRICS, V125, P1071, DOI 10.1542/peds.2010-0643; Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Swidsinski A, 2008, INFLAMM BOWEL DIS, V14, P147, DOI 10.1002/ibd.20330; Swidsinski A, 2009, INFLAMM BOWEL DIS, V15, P359, DOI 10.1002/ibd.20763; Tarnow-Mordi WO, 2010, PEDIATRICS, V125, P1068, DOI 10.1542/peds.2009-2151; Thomas DW, 2010, PEDIATRICS, V126, P1217, DOI 10.1542/peds.2010-2548; Tobe T, 2006, P NATL ACAD SCI USA, V103, P14941, DOI 10.1073/pnas.0604891103; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; van Baarlen P, 2009, P NATL ACAD SCI USA, V106, P2371, DOI 10.1073/pnas.0809919106; Walker MR, 2009, J PATHOL, V217, P169, DOI 10.1002/path.2474; Walter J, 2011, P NATL ACAD SCI USA, V108, P4645, DOI 10.1073/pnas.1000099107; Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yan F, 2007, GASTROENTEROLOGY, V132, P562, DOI 10.1053/j.gastro.2006.11.022; Zhang W, 2008, VACCINE, V26, P3655, DOI 10.1016/j.vaccine.2008.04.070	54	74	84	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1960	1969		10.1096/fj.10-177980	http://dx.doi.org/10.1096/fj.10-177980			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22267340	Green Published			2022-12-28	WOS:000303680800023
J	Velders, M; Schleipen, B; Fritzemeier, KH; Zierau, O; Diel, P				Velders, Martina; Schleipen, Burkhardt; Fritzemeier, Karl H.; Zierau, Oliver; Diel, Patrick			Selective estrogen receptor-beta activation stimulates skeletal muscle growth and regeneration	FASEB JOURNAL			English	Article						notexin; satellite cells	NECROSIS-FACTOR-ALPHA; MYOGENIC SATELLITE CELLS; FACTOR-I; NEUTROPHIL INFILTRATION; SARCOPLASMIC-RETICULUM; ER-ALPHA; EXPRESSION; RAT; INJURY; OVARIECTOMY	There is increasing evidence suggesting that estrogens augment skeletal muscle regeneration processes after injury. To study the contribution of estrogen receptors alpha and beta (ER alpha and ER beta) during muscle regeneration, skeletal muscles of ovariectomized (OVX) rats, as well as ER alpha- and ER beta-knockout (alpha Erko and beta Erko) mice, were injured with a myotoxin (notexin). OVX rats were simultaneously treated with the ER-selective ligands genistein, ER alpha agonist 16 alpha-LE2 (alpha), ER beta agonist 8 beta-VE2 (beta), or 17 beta-estradiol (E-2). OVX rats showed significantly elevated serum creatine kinase (CK) activity after muscle injury compared to intact sham-treated animals. Treatment with ER ligands significantly reduced CK activity. TNF-alpha, IL-10, and MCP-1 expression served to characterize immune responses. Treatment with all ER ligands, but particularly E-2 and beta, reduced TNF-alpha, but elevated MCP-1 and IL-10 expression. PCNA and MyoD expression served to define satellite cell activation and proliferation and were found to be up-regulated by beta and E-2. To further study muscle regeneration responses, expression of the embryonic myosin heavy chain (MHC) was analyzed. Beta and E-2 but not alpha increased embryonic MHC expression compared to OVX. The absence of ER beta in beta Erko mice negatively affected CK activity levels and expression of satellite cell and muscle regeneration markers (MHC embryonic, MyoD, Pax7) compared with alpha Erko and wild-type mice. In a classic Hershberger assay using male rats, beta stimulated muscle growth, accompanied by a strong induction of IGF-1 expression. Our data provide evidence that ER beta signaling is involved in the regulation of skeletal muscle growth and regeneration by stimulating anabolic pathways, activating satellite cells and modulating immune responses.-Velders, M., Schleipen, B., Fritzemeier, K. H., Zierau, O., Diel, P. Selective estrogen receptor-beta activation stimulates skeletal muscle growth and regeneration. FASEB J. 26, 1909-1920 (2012). www.fasebj.org	[Diel, Patrick] German Sports Univ, Deutsch Sporthsch Koln, Dept Mol & Cellular Sports Med, Inst Sports Med, D-50933 Cologne, Germany; [Fritzemeier, Karl H.] Bayer Schering Pharma AG, Berlin, Germany; [Zierau, Oliver] Tech Univ Dresden, Inst Zool, Dept Mol Cell Physiol & Endocrinol, D-01062 Dresden, Germany	German Sport University Cologne; Bayer AG; Bayer Healthcare Pharmaceuticals; Technische Universitat Dresden	Diel, P (corresponding author), German Sports Univ, Deutsch Sporthsch Koln, Dept Mol & Cellular Sports Med, Inst Sports Med, Sportpk Mungersdorf 6, D-50933 Cologne, Germany.	diel@dshs-koeln.de						AMELINK GJ, 1986, J NEUROL SCI, V76, P61, DOI 10.1016/0022-510X(86)90142-5; AMELINK GJ, 1990, ACTA PHYSIOL SCAND, V138, P115, DOI 10.1111/j.1748-1716.1990.tb08823.x; BAR PDR, 1995, BIOCHEM SOC T, V23, pS236; BAR PR, 1988, LIFE SCI, V42, P2677, DOI 10.1016/0024-3205(88)90243-3; Bar PR, 1997, BIOCHEM SOC T, V25, P50; Belcastro AN, 1998, MOL CELL BIOCHEM, V179, P135, DOI 10.1023/A:1006816123601; Borski RJ, 1996, ENDOCRINOLOGY, V137, P3253, DOI 10.1210/en.137.8.3253; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Coletti D, 2005, GENESIS, V43, P120, DOI 10.1002/gene.20160; Cvoro A, 2008, J IMMUNOL, V180, P630, DOI 10.4049/jimmunol.180.1.630; Enns DL, 2008, ACTA PHYSIOL, V194, P81, DOI 10.1111/j.1748-1716.2008.01861.x; Enns DL, 2008, J APPL PHYSIOL, V104, P347, DOI 10.1152/japplphysiol.00128.2007; Feng X, 2004, ACTA PHARMACOL SIN, V25, P1489; Fritzemeier KH, 2004, E SCHERING RES FDN W, V46, P127; HARRIS JB, 1981, TOXICON, V19, P419, DOI 10.1016/0041-0101(81)90046-5; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hegele-Hartung C, 2004, P NATL ACAD SCI USA, V101, P5129, DOI 10.1073/pnas.0306720101; HELMKE S, 1986, MEMBRANE BIOCHEM, V6, P239, DOI 10.3109/09687688609065451; Hertrampf T, 2007, BONE, V40, P1529, DOI 10.1016/j.bone.2007.02.006; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Jiang JMY, 2008, J NUTR, V138, P2106, DOI 10.3945/jn.108.093781; JIANG YL, 1992, J IMMUNOL, V148, P2423; Johansen JA, 2007, J NEUROENDOCRINOL, V19, P823, DOI 10.1111/j.1365-2826.2007.01592.x; Johnson BJ, 1996, J ANIM SCI, V74, P363; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; KOOT RW, 1991, J STEROID BIOCHEM, V40, P689, DOI 10.1016/0960-0760(91)90292-D; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MacNeil LG, 2011, AM J PHYSIOL-REG I, V300, pR1443, DOI 10.1152/ajpregu.00689.2009; Martinez CO, 2010, AM J PHYSIOL-REG I, V299, pR832, DOI 10.1152/ajpregu.00797.2009; Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Mau M, 2008, PEDIATR RES, V63, P39, DOI 10.1203/PDR.0b013e31815b8e60; McClung JM, 2006, J APPL PHYSIOL, V100, P2012, DOI 10.1152/japplphysiol.01583.2005; McCormick KM, 2004, J MUSCLE RES CELL M, V25, P21, DOI 10.1023/B:JURE.0000021398.78327.39; MCLENNAN IS, 1993, CELL TISSUE RES, V272, P193, DOI 10.1007/BF00323586; Milanesi L, 2008, J CELL BIOCHEM, V104, P1254, DOI 10.1002/jcb.21706; Milanesi L, 2009, STEROIDS, V74, P489, DOI 10.1016/j.steroids.2009.01.005; Moresi V, 2008, STEM CELLS, V26, P997, DOI 10.1634/stemcells.2007-0493; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; NG RH, 1980, P NATL ACAD SCI-BIOL, V77, P1346, DOI 10.1073/pnas.77.3.1346; Pedraza-Alva G, 2009, BIOCHEM BIOPH RES CO, V389, P360, DOI 10.1016/j.bbrc.2009.08.153; Peterson JM, 2006, J APPL PHYSIOL, V101, P1394, DOI 10.1152/japplphysiol.01453.2005; Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje; PLUSKAL MG, 1978, CLIN EXP PHARMACOL P, V5, P131, DOI 10.1111/j.1440-1681.1978.tb00663.x; Rehfeldt C, 2009, J AGR FOOD CHEM, V57, P852, DOI 10.1021/jf803039b; Rigoni M, 2008, J BIOL CHEM, V283, P34013, DOI 10.1074/jbc.M803243200; Schmalbruch H, 2000, MUSCLE NERVE, V23, P617, DOI 10.1002/(SICI)1097-4598(200004)23:4<617::AID-MUS22>3.0.CO;2-Y; Shirernan PK, 2007, J LEUKOCYTE BIOL, V81, P775, DOI 10.1189/jlb.0506356; Sitnick M, 2006, J APPL PHYSIOL, V100, P286, DOI 10.1152/japplphysiol.00869.2005; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Sorensen MB, 2001, OBES RES, V9, P622, DOI 10.1038/oby.2001.81; Stupka N, 2001, J APPL PHYSIOL, V91, P1828, DOI 10.1152/jappl.2001.91.4.1828; Sugiura T, 2006, J PHYSIOL SCI, V56, P393, DOI 10.2170/physiolsci.RP006906; Thomas A, 2010, ACTA PHYSIOL, V198, P81, DOI 10.1111/j.1748-1716.2009.02033.x; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tiidus PM, 2005, ACTA PHYSIOL SCAND, V184, P67, DOI 10.1111/j.1365-201X.2005.01427.x; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; Tournadre Anne, 2007, Curr Rheumatol Rep, V9, P286, DOI 10.1007/s11926-007-0046-6; Tsai WJA, 2007, EXP BIOL MED, V232, P1314, DOI 10.3181/0704-RM-92; Walsh MC, 2006, OSTEOPOROSIS INT, V17, P61, DOI 10.1007/s00198-005-1900-x; WARHOL MJ, 1985, AM J PATHOL, V118, P331; Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02-0187fje; Whiting KP, 2000, LIFE SCI, V67, P743, DOI 10.1016/S0024-3205(00)00669-X; Wiik A, 2003, ACTA PHYSIOL SCAND, V179, P381, DOI 10.1046/j.0001-6772.2003.01186.x; Wiik A, 2005, HISTOCHEM CELL BIOL, V124, P161, DOI 10.1007/s00418-005-0030-z; Wiik A, 2009, HISTOCHEM CELL BIOL, V131, P181, DOI 10.1007/s00418-008-0512-x; Zierau O, 2008, MOL CELL ENDOCRINOL, V294, P92, DOI 10.1016/j.mce.2008.08.008; Zoth N, 2010, J STEROID BIOCHEM, V122, P100, DOI 10.1016/j.jsbmb.2010.03.029	73	104	106	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1909	1920		10.1096/fj.11-194779	http://dx.doi.org/10.1096/fj.11-194779			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278942				2022-12-28	WOS:000303680800019
J	Werthmann, RC; Volpe, S; Lohse, MJ; Calebiro, D				Werthmann, Ruth C.; Volpe, Silvia; Lohse, Martin J.; Calebiro, Davide			Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells	FASEB JOURNAL			English	Article						G-protein-coupled receptor; fluorescence resonance energy transfer; fluorescence imaging	PARATHYROID-HORMONE RECEPTOR; BINDING	G-protein-coupled receptors (GPCRs) have long been believed to activate G proteins only on the cell surface. However, we have recently shown that, in thyroid cells, the GPCR for the thyroid-stimulating hormone (TSH) can continue stimulating cAMP production after cointernalization with TSH. cAMP signaling by internalized TSH receptors (TSHRs) was persistent, whereas that by cell-surface TSHRs was apparently transient, but the reasons for the transient signaling by cell-surface TSHRs were not investigated. Here, we developed and used fluorescence resonance energy transfer (FRET)-based methods to precisely compare the kinetics of TSH binding and dissociation from cell-surface TSHRs with those of the subsequent termination of cAMP signaling directly in living cells. Our results indicate that both TSH binding to human TSHRs expressed in a human embryonic kidney cell line (HEK 293) and the ensuing cAMP signals are rapidly and fully reversible (t(1/2,off) = 2.96 +/- 1.04 and 2.70 +/- 0.73 min, respectively). The FRET measurement of TSH binding was specific, as shown by the lack of a detectable interaction between TSH and the beta(2)-adrenergic receptor expressed in control cells. Enhancing TSHR internalization by beta-arrestin 2 overexpression did not modify the reversibility of TSHR-cAMP signaling. These findings strengthen the view that the cointernalization of TSH-TSHR complexes to a signaling compartment present in thyroid, but not in HEK 293 cells, is responsible for persistent cAMP signaling.-Werthmann, R. C., Volpe, S., Lohse, M. J., Calebiro, D. Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J. 26, 2043-2048 (2012). www.fasebj.org	[Werthmann, Ruth C.; Volpe, Silvia; Lohse, Martin J.; Calebiro, Davide] Univ Wurzburg, Deutsch Forsch Gemeinschaft, Res Ctr Expt Biomed, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; [Lohse, Martin J.; Calebiro, Davide] Univ Wurzburg, Deutsch Forsch Gemeinschaft, Res Ctr Expt Biomed, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Deutsch Forsch Gemeinschaft, Res Ctr Expt Biomed, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de; davide.calebiro@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510; calebiro, davide/0000-0002-3811-1553	Deutsche Forschungsgemeinschaft [CA 1014/1-1]; European Research Council	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission)	The authors thank Bianca Klupfel and Christian Dees for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (grant CA 1014/1-1) and the European Research Council (advanced grant Topas).	Alberti L, 2002, J CLIN ENDOCR METAB, V87, P2549, DOI 10.1210/jc.87.6.2549; Borner S, 2011, NAT PROTOC, V6, P427, DOI 10.1038/nprot.2010.198; Calebiro D, 2010, J MOL ENDOCRINOL, V45, P1, DOI 10.1677/JME-10-0014; Calebiro D, 2010, TRENDS PHARMACOL SCI, V31, P221, DOI 10.1016/j.tips.2010.02.002; Calebiro D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000172; Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102; Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545; Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206; Frenzel R, 2006, ENDOCRINOLOGY, V147, P3114, DOI 10.1210/en.2005-0687; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; Neumann S, 2010, FASEB J, V24, P3992, DOI 10.1096/fj.10-161745; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Powell-Jones C. H. J., 1979, J BIOL CHEM, V10, P4001; RAPOPORT B, 1976, ENDOCRINOLOGY, V98, P1189, DOI 10.1210/endo-98-5-1189; SALTIEL AR, 1982, MOL CELL ENDOCRINOL, V28, P299, DOI 10.1016/0303-7207(82)90128-9; Van Sande J, 2003, J CLIN ENDOCR METAB, V88, P5366, DOI 10.1210/jc.2003-030664	18	46	46	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2043	2048		10.1096/fj.11-195248	http://dx.doi.org/10.1096/fj.11-195248			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22291442				2022-12-28	WOS:000303680800030
J	McAlpine, SM; Issekutz, TB; Marshall, JS				McAlpine, Sarah M.; Issekutz, Thomas B.; Marshall, Jean S.			Virus stimulation of human mast cells results in the recruitment of CD56(+) T cells by a mechanism dependent on CCR5 ligands	FASEB JOURNAL			English	Article						chemotaxis; chemokines; innate immunity; allergy	CHEMOKINE RECEPTOR EXPRESSION; HEPATITIS-C VIRUS; IMMUNE-RESPONSES; CORD BLOOD; NK CELLS; KEY ROLE; ACTIVATION; REOVIRUS; LYMPHOCYTES; INFECTION	The trafficking of effector cells to sites of infection is crucial for antiviral responses. However, the mechanisms of recruitment of the interferon-gamma-producing and cytotoxic CD56(+) T cells are poorly understood. Human mast cells are sentinel cells found in the skin and airway and produce selected proinflammatory mediators in response to multiple pathogen-associated signals. The role of human mast cell-derived chemokines in T-cell recruitment to virus infection was examined. Supernatants from primary human cord blood-derived mast cells (CBMCs) infected with mammalian reovirus were examined for chemokine production and utilized in chemotaxis assays. Virus-infected CBMCs produced several chemokines, including CCL3, CCL4, and CCL5. Supernatants from reovirus-infected CBMCs selectively induced the chemotaxis of CD8(+) T cells (10 +/- 1%) and CD3(+) CD56(+) T cells (19 +/- 5%). CD56(+) T-cell migration was inhibited by pertussis toxin (65 +/- 9%) and met-RAN-TES (56 +/- 7%), a CCR1/CCR5 antagonist. CD56(+) T cells expressed CCR5, but little CCR1. The depletion of CCL3, CCL4, and CCL5 from reovirus-infected CBMC supernatants significantly (41 +/- 10%) inhibited CD56(+) T-cell chemotaxis. This study demonstrates a novel role for mast cells and CCR5 in CD56(+) T-cell trafficking and suggests that human mast cells enhance immunity to viruses through the selective recruitment of cytotoxic effector cells to virus infection sites. These findings could be exploited to enhance local T-cell responses in chronic viral infection and malignancies at mast cell-rich sites.-McAlpine, S. M., Issekutz, T. B., Marshall, J. S. Virus stimulation of human mast cells results in the recruitment of CD56(+) T cells by a mechanism dependent on CCR5 ligands. FASEB J. 26, 1280-1289 (2012). www.fasebj.org	[McAlpine, Sarah M.; Issekutz, Thomas B.; Marshall, Jean S.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada; [McAlpine, Sarah M.; Issekutz, Thomas B.; Marshall, Jean S.] Dalhousie Univ, Dalhousie Inflammat Grp, Halifax, NS B3H 1X5, Canada; [Issekutz, Thomas B.] Dalhousie Univ, Dept Pediat, Halifax, NS B3H 1X5, Canada; [Issekutz, Thomas B.; Marshall, Jean S.] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 1X5, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University	Marshall, JS (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Rm 7C,5850 Coll St, Halifax, NS B3H 1X5, Canada.	jean.marshall@dal.ca	MARSHALL, JEAN/K-4014-2012	Marshall, Jean S./0000-0002-5642-1379; McAlpine, Sarah M/0000-0002-9298-9682; Issekutz, Thomas/0000-0001-5486-9463	Canadian Institutes of Health Research; Canadian Cancer Society Research Institute	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	The authors thank Dr. Patrick Lee (Dalhousie University) for supplying reovirus for these studies and Dr. Ian Haidl (Dalhousie University) for his experimental advice and revision of the manuscript. This study was supported by grants from the Canadian Institutes of Health Research and the Canadian Cancer Society Research Institute. The authors also thank Yi-Song Wei, Nong Xu, Sarah Roberts, Sarah Bugden, Pamela Gallant and Sandy Edgar for their excellent technical assistance.	Albarran B, 2005, APMIS, V113, P526, DOI 10.1111/j.1600-0463.2005.apm_191.x; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Boisvert J, 2003, J HEPATOL, V38, P67, DOI 10.1016/S0168-8278(02)00328-8; Brainard DM, 2007, J VIROL, V81, P8439, DOI 10.1128/JVI.00199-07; Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167; Burke SM, 2008, BLOOD, V111, P5467, DOI 10.1182/blood-2007-10-118547; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006; Doherty DG, 1999, J IMMUNOL, V163, P2314; Dunne J, 2001, J IMMUNOL, V167, P3129, DOI 10.4049/jimmunol.167.6.3129; Faint JM, 2001, J IMMUNOL, V167, P212, DOI 10.4049/jimmunol.167.1.212; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Golden-Mason L, 2007, J VIROL, V81, P9292, DOI 10.1128/JVI.00834-07; Gurish MF, 2006, J ALLERGY CLIN IMMUN, V117, P1285, DOI 10.1016/j.jaci.2006.04.017; Hess C, 2004, BLOOD, V104, P3463, DOI 10.1182/blood-2004-03-1067; Jin YD, 1998, HUM IMMUNOL, V59, P352, DOI 10.1016/S0198-8859(98)00030-5; Kato M, 2004, INT ARCH ALLERGY IMM, V134, P37, DOI 10.1159/000077791; Kelly-Rogers J, 2006, HUM IMMUNOL, V67, P863, DOI 10.1016/j.humimm.2006.08.292; King CA, 2000, J VIROL, V74, P7146, DOI 10.1128/JVI.74.15.7146-7150.2000; King CA, 2002, J VIROL, V76, P8408, DOI 10.1128/JVI.76.16.8408-8419.2002; Kohlmeier JE, 2008, IMMUNITY, V29, P101, DOI 10.1016/j.immuni.2008.05.011; Kohlmeier JE, 2009, J IMMUNOL, V183, P4378, DOI 10.4049/jimmunol.0902022; Komatsu K, 2008, CURR EYE RES, V33, P736, DOI 10.1080/02713680802344716; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Maginnis MS, 2008, J VIROL, V82, P3181, DOI 10.1128/JVI.01612-07; Maginnis MS, 2006, J VIROL, V80, P2760, DOI 10.1128/JVI.80.6.2760-2770.2006; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Metz M, 2007, TRENDS IMMUNOL, V28, P234, DOI 10.1016/j.it.2007.03.003; MOSS J, 1984, J RECEPTOR RES, V4, P459, DOI 10.3109/10799898409042567; Musha N, 1998, CLIN EXP IMMUNOL, V113, P220; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; ORTALDO JR, 1991, CELL IMMUNOL, V136, P486, DOI 10.1016/0008-8749(91)90369-M; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Saito H, 1996, J IMMUNOL, V157, P343; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schaller MA, 2008, AM J PATHOL, V172, P386, DOI 10.2353/ajpath.2008.070537; SCHMIDTWOLF IGH, 1994, BRIT J HAEMATOL, V87, P453, DOI 10.1111/j.1365-2141.1994.tb08297.x; St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108; Stelekati E, 2009, IMMUNITY, V31, P665, DOI 10.1016/j.immuni.2009.08.022; Takayama E, 2003, IMMUNOLOGY, V108, P211, DOI 10.1046/j.1365-2567.2003.01575.x; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Ye L, 2009, HEPATOLOGY, V49, P753, DOI 10.1002/hep.22715	48	28	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1280	1289		10.1096/fj.11-188979	http://dx.doi.org/10.1096/fj.11-188979			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22125314				2022-12-28	WOS:000300949300030
J	Kleiman, A; Hubner, S; Parkitna, JMR; Neumann, A; Hofer, S; Weigand, MA; Bauer, M; Schmid, W; Schutz, G; Libert, C; Reichardt, HM; Tuckermann, JP				Kleiman, Anna; Huebner, Sabine; Parkitna, Jan M. Rodriguez; Neumann, Anita; Hofer, Stefan; Weigand, Markus A.; Bauer, Michael; Schmid, Wolfgang; Schuetz, Guenter; Libert, Claude; Reichardt, Holger M.; Tuckermann, Jan P.			Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages	FASEB JOURNAL			English	Article						IL-1 beta; GR; CLP	DNA-BINDING; INFLAMMATORY RESPONSES; GENE-EXPRESSION; MAP KINASE; KAPPA-B; REPRESSION; MICE; PHOSPHATASE-1; DEXAMETHASONE; ACTIVATION	Sepsis is controlled by endogenous glucocorticoids (GCs). Previous studies provided evidence that crosstalk of the monomeric GC receptor (GR) with proinflammatory transcription factors is the crucial mechanism underlying the suppressive GC effect. Here we demonstrate that mice with a dimerization-deficient GR (GR(dim)) are highly susceptible to sepsis in 2 different models, namely cecal ligation and puncture and lipopolysaccharide (LPS)-induced septic shock. TNF-alpha is normally regulated in these mice, but down-regulation of IL-6 and IL-1 beta is diminished. LPS-treated macrophages derived from GR(dim) mice are largely resistant to GC actions in vitro in terms of morphology, surface marker expression, and gene expression. Treatment with recombinant IL-1 receptor antagonist improved survival of GR(dim) mice and mice lacking the GR in macrophages (GR(LysMCre)) mice. This suggests that regulation of IL-1 beta in macrophages by GCs is pivotal to control sepsis.-Kleiman, A., Hubner, S., Rodriguez Parkitna, J. M., Neumann, A., Hofer, S., Weigand, M. A., Bauer, M., Schmid, W., Schutz, G., Libert, C., Reichardt, H. M., Tuckermann, J. P. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26, 722-729 (2012). www.fasebj.org	[Kleiman, Anna; Huebner, Sabine; Neumann, Anita; Tuckermann, Jan P.] Fritz Lipmann Inst, Leibniz Inst Age Res, D-07745 Jena, Germany; [Parkitna, Jan M. Rodriguez; Schmid, Wolfgang; Schuetz, Guenter] German Canc Res Ctr, Div Mol Biol Cell 1, D-6900 Heidelberg, Germany; [Hofer, Stefan] Univ Heidelberg, Dept Anesthesiol, Heidelberg, Germany; [Weigand, Markus A.] Univ Giessen, Giessen, Germany; [Bauer, Michael] Univ Klinikum Jena, Ctr Sepsis Control & Care, Jena, Germany; [Libert, Claude] Univ Ghent VIB, Dept Mol Biomed Res, Ghent, Belgium; [Reichardt, Holger M.] Univ Gottingen, Dept Cellular & Mol Immunol, Sch Med, Gottingen, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Friedrich Schiller University of Jena; Flanders Institute for Biotechnology (VIB); Ghent University; University of Gottingen	Tuckermann, JP (corresponding author), Fritz Lipmann Inst, Leibniz Inst Age Res, Beutenbergstr 11, D-07745 Jena, Germany.	j.tuckermann@fli-leibniz.de	Rodriguez, Jan/I-2910-2012; Reichardt, Holger/AAF-3048-2020	Rodriguez, Jan/0000-0003-0367-2331; Reichardt, Holger/0000-0003-4647-057X; Bauer, Michael/0000-0002-1521-3514; Vettorazzi, Dr. Sabine/0000-0001-8667-9488	Deutsche Forschungsgemeinschaft [Tu220/3, Re1631/7-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Katrin Buder for excellent technical assistance, Dr. Walther Richter (Elektronenmikroskopisches Zentrum, Friedrich Schiller University, Jena, Germany) for scanning electron microscopy, Dr. Michael Kiehntopf (Institute for Clinical Chemistry and Laboratory Diagnostics, University Clinics Jena, Jena, Germany) for performing corticosterone measurements, and Dr. Katrin Ittrich for cluster analysis of gene expression profiles. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Tu220/3 to J.P.T. and Re1631/7-1 to H.M.R.). The authors declare no conflicts of interest.	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Baschant U, 2010, J STEROID BIOCHEM, V120, P69, DOI 10.1016/j.jsbmb.2010.03.058; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; Bhattacharyya S, 2007, BLOOD, V109, P4313, DOI 10.1182/blood-2006-10-048215; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Ghadially H, 2005, J IMMUNOL, V174, P5620, DOI 10.4049/jimmunol.174.9.5620; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003; Kleiman A, 2007, MOL CELL ENDOCRINOL, V275, P98, DOI 10.1016/j.mce.2007.05.009; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Mahony D, 1999, EUR J BIOCHEM, V263, P765, DOI 10.1046/j.1432-1327.1999.00552.x; Moreno Rui, 2006, Curr Infect Dis Rep, V8, P346, DOI 10.1007/s11908-006-0044-2; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Nussler AK, 2006, NAT PROTOC, V1, P2223, DOI 10.1038/nprot.2006.341; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Prigent H, 2004, CRIT CARE, V8, P243, DOI 10.1186/cc2878; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919; Rivers EP, 2001, CHEST, V119, P889, DOI 10.1378/chest.119.3.889; Surjit M, 2011, CELL, V145, P224, DOI 10.1016/j.cell.2011.03.027; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Wust S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008202; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	32	114	115	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					722	729		10.1096/fj.11-192112	http://dx.doi.org/10.1096/fj.11-192112			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22042221				2022-12-28	WOS:000300485700023
J	Baker, JG; Kemp, P; March, J; Fretwell, L; Hill, SJ; Gardiner, SM				Baker, Jillian G.; Kemp, Philip; March, Julie; Fretwell, Laurice; Hill, Stephen J.; Gardiner, Sheila M.			Predicting in vivo cardiovascular properties of beta-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses	FASEB JOURNAL			English	Article						beta-adrenoceptor; partial agonism; intrinsic sympathomimetic activity; heart rate; vascular conductance	INTRINSIC SYMPATHOMIMETIC ACTIVITY; CHRONIC HEART-FAILURE; ADRENOCEPTOR ANTAGONISTS; RECEPTOR-BINDING; PROVIDE EVIDENCE; AGONIST ACTIONS; GUINEA-PIG; CARVEDILOL; BUCINDOLOL; NEBIVOLOL	beta-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which these properties are manifest in vivo is less clear. Conscious freely moving rats, instrumented for measurement of heart rate (beta 1; HR) and hindquarters vascular conductance (beta 2; HVC) were used to measure receptor selectivity and ligand efficacy in vivo. CGP 20712A caused a dose-dependent decrease in basal HR (P<0.05, ANOVA) at 5 doses between 6.7 and 670 mu g/kg (i.v.) and shifted the dose-response curve for isoprenaline to higher agonist concentrations without altering HVC responses. In contrast, at doses of 67 mu g/kg (i.v.) and above, ICI 118551 substantially reduced the HVC response to isoprenaline without affecting HR responses. ZD 7114, xamoterol, and bucindolol significantly increased basal HR (Delta HR: +122 +/- 12, +129 +/- 11, and +59 +/- 11 beats/min, respectively; n=6), whereas other beta-blockers caused significant reductions (all at 2 mg/kg i.v.). The agonist effects of xamoterol and ZD 7114 were equivalent to that of the highest dose of isoprenaline. Bucindolol, however, significantly antagonized the response to the highest doses isoprenaline. An excellent correlation was obtained between in vivo and in vitro measures of beta 1-adrenoceptor efficacy (R-2=0.93; P<0.0001).-Baker, J. G., Kemp, P., March, J., Fretwell, L., Hill, S. J., Gardiner, S. M. Predicting in vivo cardiovascular properties of beta-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J. 25, 4486-4497 (2011). www.fasebj.org	[Baker, Jillian G.; Kemp, Philip; March, Julie; Fretwell, Laurice; Hill, Stephen J.; Gardiner, Sheila M.] Univ Nottingham, Inst Cell Signalling, Sch Biomed Sci, Sch Med, Nottingham NG7 2UH, England; [Baker, Jillian G.] Univ Nottingham, Sch Med, Inst Cell Signalling, Queens Med Ctr,Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Baker, JG (corresponding author), Univ Nottingham, Sch Med, Inst Cell Signalling, Queens Med Ctr,Sch Biomed Sci, C Floor, Nottingham NG7 2UH, England.	jillian.baker@nottingham.ac.uk	Hill, Stephen J/M-6243-2018; Hill, Stephen/N-6753-2013	Hill, Stephen J/0000-0002-4424-239X; Hill, Stephen/0000-0002-4424-239X; Fretwell, Laurice/0000-0001-7860-8751; baker, jillian/0000-0003-2371-8202	Wellcome Trust [073377/Z/03/Z]; Medical Research Council [G0800006] Funding Source: researchfish; MRC [G0800006] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	J.G.B. thanks the Wellcome Trust for her Clinician Scientist Fellowship (073377/Z/03/Z). The authors thank June McCulloch and Marleen Groenen technical assistance in running the cAMP chromatography columns. The authors declare no conflicts of interest.	Andreka P, 2002, CIRCULATION, V105, P2429, DOI 10.1161/01.CIR.0000016050.79810.18; [Anonymous], 1990, Lancet, V336, P1; Arch JRS, 2004, BRIT J PHARMACOL, V143, P517, DOI 10.1038/sj.bjp.0705991; Aronow WS, 2010, EXPERT OPIN PHARMACO, V11, P2599, DOI 10.1517/14656566.2010.482561; Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1435, DOI 10.1001/jama.287.11.1435; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Baker JG, 2005, BRIT J PHARMACOL, V144, P317, DOI 10.1038/sj.bjp.0706048; Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; Baker JG, 2003, MOL PHARMACOL, V63, P1312, DOI 10.1124/mol.63.6.1312; Baker JG, 2005, J PHARMACOL EXP THER, V313, P1163, DOI 10.1124/jpet.104.082875; Baker JG, 2011, TRENDS PHARMACOL SCI, V32, P227, DOI 10.1016/j.tips.2011.02.010; Baker JG, 2010, BRIT J PHARMACOL, V160, P1048, DOI 10.1111/j.1476-5381.2010.00754.x; Bangalore S, 2007, J AM COLL CARDIOL, V50, P563, DOI 10.1016/j.jacc.2007.04.060; Basile JN, 2010, AM J MED, V123, pS9, DOI 10.1016/j.amjmed.2010.04.013; BLACK JW, 1965, BRIT J PHARM CHEMOTH, V25, P577, DOI 10.1111/j.1476-5381.1965.tb01782.x; Bundkirchen A, 2002, J PHARMACOL EXP THER, V300, P794, DOI 10.1124/jpet.300.3.794; Cruickshank JM, 2007, INT J CARDIOL, V120, P10, DOI 10.1016/j.ijcard.2007.01.069; Cruickshank JM, 2009, J AM COLL CARDIOL, V53, P2105, DOI 10.1016/j.jacc.2008.11.066; DONALDSON J, 1988, BIOCHEM PHARMACOL, V37, P715, DOI 10.1016/0006-2952(88)90146-3; Echahidi N, 2008, J AM COLL CARDIOL, V51, P793, DOI 10.1016/j.jacc.2007.10.043; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Ellison KE, 2005, DRUGS, V65, P787, DOI 10.2165/00003495-200565060-00006; FEELY J, 1984, DRUGS, V27, P425, DOI 10.2165/00003495-198427050-00003; Flather MD, 2005, EUR HEART J, V26, P215, DOI 10.1093/eurheartj/ehi118; Galandrin S, 2008, MOL PHARMACOL, V74, P162, DOI 10.1124/mol.107.043893; Galandrin S, 2006, MOL PHARMACOL, V70, P1575, DOI 10.1124/mol.106.026716; Granneman JG, 2001, AM J PHYSIOL-ENDOC M, V280, pE199, DOI 10.1152/ajpendo.2001.280.2.E199; Gray RN, 1999, DRUG TREATMENTS PREV; Hjalmarson A, 1999, LANCET, V353, P2001; Hoffmann C, 2004, N-S ARCH PHARMACOL, V369, P151, DOI 10.1007/s00210-003-0860-y; Hollenberg NK, 2005, AM J HYPERTENS, V18, p165S, DOI 10.1016/j.amjhyper.2005.09.010; JASPER JR, 1990, MOL PHARMACOL, V37, P44; JASPER JR, 1988, FASEB J, V2, P2891, DOI 10.1096/fasebj.2.13.2901994; Joseph SS, 2003, N-S ARCH PHARMACOL, V368, P496, DOI 10.1007/s00210-003-0835-z; Karter Yesari, 2007, Recent Pat Cardiovasc Drug Discov, V2, P152; Kaumann AJ, 2008, PHARMACOL THERAPEUT, V118, P303, DOI 10.1016/j.pharmthera.2008.03.009; Kountz DS, 2009, POSTGRAD MED, V121, P14, DOI 10.3810/pgm.2009.01.1951; Lechat P, 1999, LANCET, V353, P9; Limmroth V, 2001, BRIT J CLIN PHARMACO, V52, P237, DOI 10.1046/j.0306-5251.2001.01459.x; Lipsic E, 2010, EXPERT OPIN PHARMACO, V11, P983, DOI 10.1517/14656561003694650; Maack C, 2003, CIRCULATION, V108, P348, DOI 10.1161/01.CIR.0000080325.94345.8B; Maack C, 2000, BRIT J PHARMACOL, V130, P1131, DOI 10.1038/sj.bjp.0703400; Metra M, 2004, HEART FAIL REV, V9, P123, DOI 10.1023/B:HREV.0000046367.99002.a4; Molenaar P, 2003, BRIT J PHARMACOL, V140, P1, DOI 10.1038/sj.bjp.0705420; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; PAUWELS PJ, 1991, BIOCHEM PHARMACOL, V42, P1683, DOI 10.1016/0006-2952(91)90502-V; PAUWELS PJ, 1988, MOL PHARMACOL, V34, P843; PEET M, 1981, J CLIN HOSP PHARM, V6, P155, DOI 10.1111/j.1365-2710.1981.tb00988.x; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Smith C, 1999, CARDIOVASC DRUG THER, V13, P123, DOI 10.1023/A:1007784109255; Stamper RL, 2002, SURV OPHTHALMOL, V47, P63, DOI 10.1016/S0039-6257(01)00286-7; SWEDBERG K, 1979, LANCET, V1, P1374; Uitti RJ, 1998, GERIATRICS, V53, P46; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WALTER M, 1984, N-S ARCH PHARMACOL, V327, P159, DOI 10.1007/BF00500912; Willette RN, 1999, J PHARMACOL EXP THER, V289, P48; Wollert KC, 2002, CIRCULATION, V106, P2164, DOI 10.1161/01.CIR.0000038702.35084.D6	57	16	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4486	4497		10.1096/fj.11-192435	http://dx.doi.org/10.1096/fj.11-192435			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21865315	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000298138100039
J	Turan, S; Bode, J				Turan, Soeren; Bode, Juergen			Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications	FASEB JOURNAL			English	Review						Ser/Tyr-dependent integrases; PhiC31; Cre; F1p	EMBRYONIC STEM-CELLS; IN-VIVO EVALUATION; CASSETTE EXCHANGE; DNA-BINDING; PHI-C31 INTEGRASE; MAMMALIAN-CELLS; FLP-RECOMBINASE; HIGH-EFFICIENCY; HOMOLOGOUS RECOMBINATION; GENE	Site-specific recombinases (SSRs) enable novel tag-and-target as well as tag-and-exchange strategies for tailoring mammalian genomes. If used in combination with homologous recombination, which per se is inefficient but can serve to introduce SSR sites, the tagged locus lends itself to repeated modification at largely increased efficiency and specificity. The more conventional SSR-based genetic modifications enable straightforward integration of a transgene with efficiencies depending on both the target locus and the vector composition. Only the more recent tag-and-exchange strategies in conjunction with advanced selection principles enable the clean replacement of a genomically anchored cassette by a donor cassette with the related architecture. Meanwhile this recombinase-mediated cassette exchange (RMCE) concept could be verified for two classes of SSRs, belonging to either the Tyr or the Ser family. Certain members of these open different fields of application that will be discussed with reference to the molecular properties of the respective enzymes. A major aim of our review is to characterize the RMCE-relevant components and describe their optimal utilization in the fields of gene therapy and molecular genomics. Early contributions to the field of experimental animal models will be mentioned considering in vivo modifications enabled by microinjection into oocytes.-Turan, S., Bode, J. Site-specific recombinases: from tag-and-target-to tag-and-exchange-based genomic modifications. FASEB J. 25, 4088-4107 (2011). www.fasebj.org	[Turan, Soeren; Bode, Juergen] Hannover Med Sch, Inst Expt Hematol, D-30625 Hannover, Germany	Hannover Medical School	Bode, J (corresponding author), Hannover Med Sch, Inst Expt Hematol OE6960, Carl Neuberg Str 1, D-30625 Hannover, Germany.	bode.juergen@mh-hannover.de			University of Leeds, Leeds, UK; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; College of Medical, Veterinary, and Life Sciences, Glasgow, UK; Medical School Hannover, Hannover, Germany; CliniGene Network of Excellence (European Commission) [LSHBCT-2006-018933]; PERSIST (Persisting Transgenesis); Excellence Initiative REBIRTH (Regenerative Biology to Reconstructive Therapy); Optimierung konventioneller and innovativer Transplantate [SFB 738]; Bundesministerium fur Bildung und Forshung (Germany)	University of Leeds, Leeds, UK; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; College of Medical, Veterinary, and Life Sciences, Glasgow, UK; Medical School Hannover, Hannover, Germany; CliniGene Network of Excellence (European Commission)(European CommissionEuropean Commission Joint Research Centre); PERSIST (Persisting Transgenesis); Excellence Initiative REBIRTH (Regenerative Biology to Reconstructive Therapy); Optimierung konventioneller and innovativer Transplantate; Bundesministerium fur Bildung und Forshung (Germany)(Federal Ministry of Education & Research (BMBF))	When we took the challenge to compare the two (Ser-Int and Tyr-Int) branches of site-specific recombinases that are currently available for gene-targeting and replacement, we had to rely on current trends and yet unpublished information, especially from the Ser-Int field. Our efforts were greatly supported by then nonaccessible information from Monica Hollstein (University of Leeds, Leeds, UK), Ben Davies (Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK), and W. Marshall Stark (College of Medical, Veterinary, and Life Sciences, Glasgow, UK). The Tyr branch, on the other hand, was enriched by Barry Rosen (Wellcome Trust Sanger Institute, Cambridge, UK), Harald von Melchner (University of Frankfurt am Main, Frankfurt am Main, Germany), Yuri Voziyanov (Louisiana Tech University, Ruston, LA, USA), and Ezra Yagil (Tel Aviv University, Tel Aviv, Israel). With regard to multiplexing and flirting-RMCE approaches, we greatly profited from ongoing projects and discussions with members of the Institute of Experimental Hematology at Hannover Medical School, our new home since 2009. Supported by Christopher Baum (Medical School Hannover, Hannover, Germany), the transfer of current project ideas from basic science to application has come within reach. Cooperative work in the authors' laboratory was supported by the CliniGene Network of Excellence (European Commission FP6 Research Program, contract LSHBCT-2006-018933), the PERSIST (Persisting Transgenesis) Seventh Framework Programme, the Excellence Initiative REBIRTH (Regenerative Biology to Reconstructive Therapy), the SFB 738 (Optimierung konventioneller and innovativer Transplantate), and a ReGene (Regenerative Medicine and Biology) grant, provided by the Bundesministerium fur Bildung und Forshung (Germany).	Akoplan A, 2005, ADV GENET, V55, P1, DOI 10.1016/S0065-2660(05)55001-6; Baer A, 2001, CURR OPIN BIOTECH, V12, P473, DOI 10.1016/S0958-1669(00)00248-2; Bateman JR, 2006, GENETICS, V173, P769, DOI 10.1534/genetics.106.056945; Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787; Bode H, 2003, N COMP BIOC, V38, P551; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Broll S, 2010, J MOL BIOL, V395, P950, DOI 10.1016/j.jmb.2009.11.066; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chalberg TW, 2006, J MOL BIOL, V357, P28, DOI 10.1016/j.jmb.2005.11.098; Chavez CL, 2011, CURR GENE THER, V11, P375; Chen CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023376; Chen YT, 2000, GENESIS, V28, P31, DOI 10.1002/1526-968X(200009)28:1<31::AID-GENE40>3.0.CO;2-K; Connelly JP, 2010, MOL THER, V18, P1103, DOI 10.1038/mt.2010.57; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; Ehrhardt A, 2005, MOL THER, V11, P695, DOI 10.1016/j.ymthe.2005.01.010; Ehrhardt A, 2006, HUM GENE THER, V17, P1077, DOI 10.1089/hum.2006.17.1077; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Galla M, 2008, J VIROL, V82, P3069, DOI 10.1128/JVI.01880-07; Galla M, 2011, NUCLEIC ACIDS RES, V39, P7147, DOI 10.1093/nar/gkr384; Goetze S, 2005, MOL CELL BIOL, V25, P2260, DOI 10.1128/MCB.25.6.2260-2272.2005; Gordley RM, 2009, P NATL ACAD SCI USA, V106, P5053, DOI 10.1073/pnas.0812502106; Grandjean M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr436; Grindley NDF, 2006, ANNU REV BIOCHEM, V75, P567, DOI 10.1146/annurev.biochem.73.011303.073908; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Hitz C, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm475; Iqbal K, 2009, BIOTECHNIQUES, V47, P959, DOI 10.2144/000113270; Keravala A, 2011, GENE THER, V18, P842, DOI 10.1038/gt.2011.31; Keravala A, 2006, MOL GENET GENOMICS, V276, P135, DOI 10.1007/s00438-006-0129-5; Khaleel T, 2011, MOL MICROBIOL, V80, P1450, DOI 10.1111/j.1365-2958.2011.07696.x; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Li ZH, 2011, GENE, V484, P48, DOI 10.1016/j.gene.2011.05.020; LYZNIK LA, 1993, NUCLEIC ACIDS RES, V21, P969, DOI 10.1093/nar/21.4.969; Maetzig T, 2011, VIRUSES-BASEL, V3, P677, DOI 10.3390/v3060677; Malchin N, 2011, MOL GENET GENOMICS, V285, P403, DOI 10.1007/s00438-011-0614-3; Malchin N, 2010, J MOL MICROB BIOTECH, V19, P117, DOI 10.1159/000321497; McEwan AR, 2011, NUCLEIC ACIDS RES, V39, P6137, DOI 10.1093/nar/gkr220; McEwan AR, 2009, NUCLEIC ACIDS RES, V37, P4764, DOI 10.1093/nar/gkp485; Mielke C, 1996, BIOCHEMISTRY-US, V35, P2239, DOI 10.1021/bi952393y; Monetti C, 2011, METHODS, V53, P380, DOI 10.1016/j.ymeth.2010.12.023; Ohtsuka M, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq860; Osterwalder M, 2010, NAT METHODS, V7, P893, DOI 10.1038/nmeth.1521; Paques F, 2007, CURR GENE THER, V7, P49, DOI 10.2174/156652307779940216; Pfeiffer BD, 2010, GENETICS, V186, P735, DOI 10.1534/genetics.110.119917; Preuss E, 2010, HUM GENE THER, V21, P929, DOI 10.1089/hum.2009.042; Qiao JH, 2009, J MOL BIOL, V390, P579, DOI 10.1016/j.jmb.2009.05.012; Rajewsky K, 2007, EUR J IMMUNOL, V37, pS134, DOI 10.1002/eji.200737819; Ramachandra CJA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr409; Raymond CS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000162; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; Roebroek AJM, 2006, MOL CELL BIOL, V26, P605, DOI 10.1128/MCB.26.2.605-616.2006; Roebroek AJM, 2011, METHODS MOL BIOL, V693, P277, DOI 10.1007/978-1-60761-974-1_16; Rubera I, 2002, GENESIS, V32, P173, DOI 10.1002/gene.10040; Sangiorgi E, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn627; Sarkar I, 2007, SCIENCE, V316, P1912, DOI 10.1126/science.1141453; Schebelle L, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq044; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P12746, DOI 10.1021/bi00209a003; Schleef M, 2010, CURR GENE THER, V10, P487, DOI 10.2174/156652310793797711; Schnutgen F, 2011, METHODS, V53, P347, DOI 10.1016/j.ymeth.2010.12.037; Schnutgen F, 2011, NAT METHODS, V8, P103, DOI 10.1038/nmeth0211-103; Sclimenti CR, 2001, NUCLEIC ACIDS RES, V29, P5044, DOI 10.1093/nar/29.24.5044; Seibler J, 1997, BIOCHEMISTRY-US, V36, P1740, DOI 10.1021/bi962443e; Shultz JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018077; Siegal ML, 1996, GENETICS, V144, P715; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smith MCM, 2010, BIOCHEM SOC T, V38, P388, DOI 10.1042/BST0380388; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; STACEY A, 1994, MOL CELL BIOL, V14, P1009, DOI 10.1128/MCB.14.2.1009; Stark WM, 2011, BIOCHEM SOC T, V39, P617, DOI 10.1042/BST0390617; Stoll SM, 2002, J BACTERIOL, V184, P3657, DOI 10.1128/JB.184.13.3657-3663.2002; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Suzuki E, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1280; Tasic B, 2011, P NATL ACAD SCI USA, V108, P7902, DOI 10.1073/pnas.1019507108; Thomson JG, 2003, GENESIS, V36, P162, DOI 10.1002/gene.10211; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Toledo F, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl518; Torres R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019794; Turan S, 2011, J MOL BIOL, V407, P193, DOI 10.1016/j.jmb.2011.01.004; Turan S, 2010, J MOL BIOL, V402, P52, DOI 10.1016/j.jmb.2010.07.015; Voelkel C, 2010, P NATL ACAD SCI USA, V107, P7805, DOI 10.1073/pnas.0914517107; Wei QX, 2011, CELL CYCLE, V10, P1261, DOI 10.4161/cc.10.8.15303; Woodard LE, 2010, GENE THER, V17, P217, DOI 10.1038/gt.2009.136; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Zhang L, 2008, J BACTERIOL, V190, P6392, DOI 10.1128/JB.00777-08; Zhang L, 2010, J MOL CELL BIOL, V2, P264, DOI 10.1093/jmcb/mjq025	87	42	62	1	44	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4088	4107		10.1096/fj.11-186940	http://dx.doi.org/10.1096/fj.11-186940			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21891781				2022-12-28	WOS:000298138100004
J	Engel, D; Beckers, L; Wijnands, E; Seijkens, T; Lievens, D; Drechsler, M; Gerdes, N; Soehnlein, O; Daemen, MJAP; Stan, RV; Biessen, EAL; Lutgens, E				Engel, David; Beckers, Linda; Wijnands, Erwin; Seijkens, Tom; Lievens, Dirk; Drechsler, Maik; Gerdes, Norbert; Soehnlein, Oliver; Daemen, Mat J. A. P.; Stan, Radu V.; Biessen, Erik A. L.; Lutgens, Esther			Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response	FASEB JOURNAL			English	Article						cholesterol; lipoproteins; endothelial cells; hematopoietic and nonhematopoietic compartment	NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; NEOINTIMA FORMATION; GENETIC ABLATION; IMMUNE-RESPONSE; IN-VIVO; EXPRESSION; DEFECTS; MICE; ACTIVATION	Caveolin-1 plays a crucial role in atherosclerosis, which is mainly attributed to its effects on low-density-lipoprotein (LDL) transcytosis. However, caveolin-1 has also been implicated in the regulation of inflammation. We investigated the effects of caveolin-1 deficiency in atherosclerosis with its accompanying changes in plaque- and lymphoid-related immunology and inflammation. Cav1(-/-)Apoe(-/-) mice exhibited a 15-fold reduction in plaque size with plaques containing fewer macrophages, T cells, and neutrophils. Intravital microscopy revealed 83% less leukocyte adhesion to the vessel wall in Cav1(-/-)Apoe(-/-) mice, which could be attributed to reduced endothelial chemokine ligand-2 (CCL-2/MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) expression. Caveolin-1 deficiency resulted in a 57% increase in regulatory T cells and a 4% decrease in CD4(+) effector T cells in lymphoid organs. Bone marrow transplantations revealed that Cav1(-/-)Apoe(-/-) mice receiving Cav1(+/+)Apoe(-/-) or Cav1(-/-)Apoe(-/-) bone marrow presented 4- to 4.5-fold smaller plaques with no additional phenotypic changes. In contrast, atherosclerosis was not affected in Cav1(+/+) Apoe(-/-) recipients receiving Cav1(-/-)Apoe(-/-) or Cav1(+/+) Apoe(-/-) bone marrow. However, the presence of Cav1(-/-) Apoe(-/-) bone marrow was associated with an anti-inflammatory T-cell profile. Our study reveals that nonhematopoietic caveolin-1 determines plaque size, whereas hematopoietic caveolin-1 regulates lymphoid immune-modulation. However, both are required for phenotypic modulation of plaques.-Engel, D., Beckers, L., Wijnands, E., Seijkens, T., Lievens, D., Drechsler, M., Gerdes, N., Soehnlein, O., Daemen, M. J. A. P., Stan, R. V., Biessen, E. A. L., Lutgens, E. Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response. FASEB J. 25, 3838-3848 (2011). www.fasebj.org	[Engel, David; Beckers, Linda; Wijnands, Erwin; Seijkens, Tom; Gerdes, Norbert; Soehnlein, Oliver; Biessen, Erik A. L.; Lutgens, Esther] Univ Maastricht, Dept Pathol, Cardiovasc Res Inst Maastricht CARIM, NL-6229 HX Maastricht, Netherlands; [Lievens, Dirk; Drechsler, Maik; Gerdes, Norbert; Soehnlein, Oliver; Lutgens, Esther] Univ Munich, Inst Cardiovasc Prevent, Munich, Germany; [Daemen, Mat J. A. P.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Stan, Radu V.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA	Maastricht University; University of Munich; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Dartmouth College	Engel, D (corresponding author), Univ Maastricht, Dept Pathol, Cardiovasc Res Inst Maastricht CARIM, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands.	david.engel@maastrichtuniversity.nl	Gerdes, Norbert/E-2787-2010; Lutgens, Esther/E-2919-2010; Stan, Radu/AAE-7574-2021; Drechsler, Maik/C-3829-2008	Gerdes, Norbert/0000-0002-4546-7208; Lutgens, Esther/0000-0002-2609-5744; Stan, Radu/0000-0003-2969-1725; Daemen, Mat/0000-0003-1076-199X; Seijkens, Tom/0000-0001-6370-1267; Biessen, Erik/0000-0002-6454-8548	Netherlands Organization for Scientific Research; Netherlands Heart Foundation; Humboldt Foundation; Deutsche Forschungsgemeinschaft (DFG) [SO873/3-1]; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092085, R01HL065418, R01HL083249] Funding Source: NIH RePORTER	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Heart Foundation(Netherlands Heart Foundation); Humboldt Foundation(Alexander von Humboldt Foundation); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Netherlands Organization for Scientific Research (VIDI grant to E.L.), the Netherlands Heart Foundation (established investigator grant to E.L.), the Humboldt Foundation (Sofja Kovalevskaja grant to E.L.), and the Deutsche Forschungsgemeinschaft (DFG grant SO873/3-1).	Ait-Oufella H, 2006, NAT MED, V12, P178, DOI 10.1038/nm1343; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Chang SH, 2009, AM J PATHOL, V175, P1768, DOI 10.2353/ajpath.2009.090171; Chen SF, 2010, J CELL BIOCHEM, V109, P356, DOI 10.1002/jcb.22407; Chidlow JH, 2010, CARDIOVASC RES, V86, P219, DOI 10.1093/cvr/cvq075; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Donners MMPC, 2008, BLOOD, V111, P4596, DOI 10.1182/blood-2007-05-088906; Donners MMPC, 2005, AM J TRANSPLANT, V5, P1204, DOI 10.1111/j.1600-6143.2005.00821.x; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Drechsler M, 2010, CIRCULATION, V122, P1837, DOI 10.1161/CIRCULATIONAHA.110.961714; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fernandez-Hernando C, 2010, AM J PATHOL, V177, P998, DOI 10.2353/ajpath.2010.091287; Fernandez-Hernando C, 2009, CELL METAB, V10, P48, DOI 10.1016/j.cmet.2009.06.003; Feron O, 2001, CIRCULATION, V103, P113; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; Frank PG, 2004, ARTERIOSCL THROM VAS, V24, P98, DOI 10.1161/01.ATV.0000101182.89118.E5; Frank PG, 2008, AM J PHYSIOL-CELL PH, V295, pC242, DOI 10.1152/ajpcell.00185.2008; Frank PG, 2006, AM J PHYSIOL-HEART C, V291, pH677, DOI 10.1152/ajpheart.01092.2005; Fu CL, 2010, BBA-MOL CELL BIOL L, V1801, P702, DOI 10.1016/j.bbalip.2010.04.001; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gargalovic P, 2003, J LIPID RES, V44, P1622, DOI 10.1194/jlr.M300140-JLR200; Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853; Han SG, 2010, TOXICOL APPL PHARM, V246, P74, DOI 10.1016/j.taap.2010.04.009; Harris J, 2002, IMMUNOLOGY, V105, P190, DOI 10.1046/j.1365-2567.2002.01362.x; Harris J, 2002, TRENDS IMMUNOL, V23, P158, DOI 10.1016/S1471-4906(01)02161-5; Hassan GS, 2006, AM J PHYSIOL-HEART C, V290, pH2393, DOI 10.1152/ajpheart.01161.2005; Hassan GS, 2004, BIOCHEMISTRY-US, V43, P8312, DOI 10.1021/bi049609t; Hnasko Robert, 2003, Mol Interv, V3, P445, DOI 10.1124/mi.3.8.445; Hu GC, 2008, AM J PHYSIOL-LUNG C, V294, pL178, DOI 10.1152/ajplung.00263.2007; Lin WW, 2006, J HISTOCHEM CYTOCHEM, V54, P897, DOI 10.1369/jhc.5A6869.2006; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Medina FA, 2006, INFECT IMMUN, V74, P6665, DOI 10.1128/IAI.00949-06; Mercier I, 2009, AM J PATHOL, V174, P1172, DOI 10.2353/ajpath.2009.080882; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Oh YS, 2008, DIABETOLOGIA, V51, P1025, DOI 10.1007/s00125-008-0993-0; Ohnuma Kei, 2006, Mod Rheumatol, V16, P3; Park DS, 2002, AM J PATHOL, V160, P2207, DOI 10.1016/S0002-9440(10)61168-6; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Rodriguez-Feo JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002612; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schwencke C, 2005, CARDIOVASC RES, V68, P128, DOI 10.1016/j.cardiores.2005.05.004; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Wang XM, 2009, J IMMUNOL, V182, P3809, DOI 10.4049/jimmunol.0712437; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Yu J, 2006, J CLIN INVEST, V116, P1284, DOI 10.1172/JCI27100; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799; Zulli A, 2006, J HISTOCHEM CYTOCHEM, V54, P151, DOI 10.1369/jhc.5A6677.2005	49	35	37	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3838	3848		10.1096/fj.11-183350	http://dx.doi.org/10.1096/fj.11-183350			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21795505	Green Published			2022-12-28	WOS:000296723100009
J	Jia, JJ; Yao, W; Guan, M; Dai, WW; Shahnazari, M; Kar, R; Bonewald, L; Jiang, JX; Lane, NE				Jia, Junjing; Yao, Wei; Guan, Min; Dai, Weiwei; Shahnazari, Mohammad; Kar, Rekha; Bonewald, Lynda; Jiang, Jean X.; Lane, Nancy E.			Glucocorticoid dose determines osteocyte cell fate	FASEB JOURNAL			English	Article						osteoporosis; apoptosis; autophagy; antioxidant; MLO-Y4 cell; LC3	INDUCED BONE LOSS; PARATHYROID-HORMONE TREATMENT; CONTROLLED CLINICAL-TRIAL; ERECT BIPEDAL STANCE; OXIDATIVE STRESS; INDUCED OSTEOPOROSIS; INDUCED AUTOPHAGY; MULTIFUNCTIONAL CELLS; CANCELLOUS BONE; TREATED MICE	In response to cellular insult, several pathways can be activated, including necrosis, apoptosis, and autophagy. Because glucocorticoids (GCs) have been shown to induce both osteocyte apoptosis and autophagy, we sought to determine whether osteocyte cell fate in the presence of GCs was dose dependent by performing in vivo and in vitro studies. Male Swiss-Webster mice were treated with slow-release prednisolone pellets at 1.4, 2.8, and 5.6 mg/kg/d for 28 d. An osteocyte cell line, MLO-Y4 cells, was treated with various doses of dexamethasone. We found that GC treatments dose dependently decreased activation of antioxidant-, autophagy-, and antiapoptosis-focused RT-PCR gene pathways in mouse cortical bone. The activation of antioxidant genes was correlated with autophagy gene expression after the GC treatments. The presence of osteocyte autophagy, as detected by immunostaining for LC3, increased similar to 50% at the distal femur cortical bone region but not at trabecular bone region at the 1.4 and 2.8 mg/kg/d GC dose levels. The number of apoptotic osteocytes was increased at the cortical bone region by similar to 40% initially observed at the 2.8 mg/kg/d dose level. In addition, the presence of the osteocyte autophagy was associated with an increased protein level of cathepsin K in vitro after the GC treatments. In summary, we found that GC treatment dose-dependently decreased antioxidant gene expression, with lower GC doses activating autophagy, whereas a higher dose increased apoptosis. These data suggest that autophagy may provide a mechanism for osteocytes to survive the stress after GC exposure and provide further insight into how GCs alter bone cell fate.-Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., Lane, N. E. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 25, 3366-3376 (2011). www.fasebj.org	[Jia, Junjing; Yao, Wei; Guan, Min; Dai, Weiwei; Shahnazari, Mohammad; Lane, Nancy E.] Univ Calif Davis, Med Ctr, Dept Med, Sacramento, CA 95817 USA; [Kar, Rekha; Jiang, Jean X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Bonewald, Lynda] Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio; University of Missouri System; University of Missouri Kansas City	Lane, NE (corresponding author), Univ Calif Davis, Med Ctr, Dept Med, 4800 2nd Ave,Suite 2600, Sacramento, CA 95817 USA.	nelane@ucdavis.edu	Bonewald, Lynda/Q-3638-2019; Yao, Wei/O-8187-2019; Shahnazari, Mohammad Reza/AAU-8573-2020; yao, wei/GVS-3913-2022	Yao, Wei/0000-0002-1198-1161; Shahnazari, Mohammad Reza/0000-0001-8647-5426; yao, wei/0000-0002-1198-1161; Jiang, Jean/0000-0002-2185-5716; Guan, Min/0000-0003-3851-8553	U.S. National Institutes of Health [1K12-HD05195801, R01-AR043052-07, K24-AR048841, 5R21-AR57515-2, P01-AR46798]; National Institute of Child Health and Human Development; Office of Research on Women's Health; Office of Dietary Supplements; National Institute of Aging; Welch Foundation [AQ-1507]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD051958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043052, K24AR048841, R21AR057515, P01AR046798] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); Office of Dietary Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Welch Foundation(The Welch Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Frank Chuang (Center for Biophotonics and Science Technology, University of California at Davis Medical Center) for generously providing GFP-tagged LC3 expression vector and photographing the cells. This work was funded by U.S. National Institutes of Health grants 1K12-HD05195801 (cofunded by the National Institute of Child Health and Human Development, the Office of Research on Women's Health, the Office of Dietary Supplements, and the National Institute of Aging), R01-AR043052-07, K24-AR048841, 5R21-AR57515-2, and P01-AR46798 (to L. F.B. and J.X.J), and Welch Foundation grant AQ-1507 (to J.X.J.).	Adcock Ian M, 2005, Proc Am Thorac Soc, V2, P313, DOI 10.1513/pats.200504-035SR; Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200; Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010-0189; Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017; Bardeguez AD, 1997, AM J OBSTET GYNECOL, V176, P158, DOI 10.1016/S0002-9378(97)80029-4; BELANGER LF, 1969, CALC TISS RES, V4, P1, DOI 10.1007/BF02279101; BOASS A, 1981, ENDOCRINOLOGY, V109, P505, DOI 10.1210/endo-109-2-505; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Bonewald L., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P331; Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97; Chen JL, 2009, AUTOPHAGY, V5, P244, DOI 10.4161/auto.5.2.7549; Chiodini I, 1998, J CLIN ENDOCR METAB, V83, P1863, DOI 10.1210/jc.83.6.1863; Edinger AL, 2009, BIOCHEM SOC T, V37, P253, DOI 10.1042/BST0370253; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Evans BJ, 2006, BLOOD, V107, P3593, DOI 10.1182/blood-2005-09-3695; Feng JQ, 2009, CURR OPIN NEPHROL HY, V18, P285, DOI 10.1097/MNH.0b013e32832c224f; Ferioli ME, 1999, BIOCHEM PHARMACOL, V58, P1907, DOI 10.1016/S0006-2952(99)00280-4; Fukumoto S, 2009, MOL CELL ENDOCRINOL, V310, P63, DOI 10.1016/j.mce.2008.08.031; Fukumoto S, 2009, TRENDS ENDOCRIN MET, V20, P230, DOI 10.1016/j.tem.2009.02.001; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; HARMAN D, 1988, MOL CELL BIOCHEM, V84, P155, DOI 10.1007/BF00421050; HARMAN D, 1992, ANN NY ACAD SCI, V673, P126, DOI 10.1111/j.1749-6632.1992.tb27444.x; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; JEE WSS, 1991, ANAT RECORD, V230, P332, DOI 10.1002/ar.1092300306; JEE WSS, 1990, ANAT REC, V227, P418, DOI 10.1002/ar.1092270405; Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518; Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474-9726.2010.00616.x; Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; KE HZ, 1993, BONE, V14, P481, DOI 10.1016/8756-3282(93)90183-B; Komatsu F, 2007, J GERONTOL A-BIOL, V62, P459, DOI 10.1093/gerona/62.4.459; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46; Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103; Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017; Lee CW, 2006, WORLD J SURG, V30, P2217, DOI 10.1007/s00268-006-0143-0; Lester DR, 1996, CLIN ORTHOP RELAT R, P271; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024; Martinet W, 2009, CLIN SCI, V116, P697, DOI 10.1042/CS20080508; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; Ogasawara M, 1999, ENDOCR J, V46, P99, DOI 10.1507/endocrj.46.99; Ong SLH, 2008, CLIN EXP PHARMACOL P, V35, P477, DOI 10.1111/j.1440-1681.2008.04900.x; Orzechowski A, 2002, J VET MED A, V49, P256, DOI 10.1046/j.1439-0442.2002.00443.x; Planey SL, 2003, CANCER RES, V63, P172; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Qing H, 2009, INT J ORAL SCI, V1, P59, DOI 10.4248/ijos.09019; RASMUSSEN P, 1977, CALC TISS RES, V23, P95, DOI 10.1007/BF02012772; Rowe PSN, 2006, BONE, V39, P773, DOI 10.1016/j.bone.2006.04.012; Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408; Saag Kenneth G, 2002, Curr Rheumatol Rep, V4, P218, DOI 10.1007/s11926-002-0068-z; Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200; Srinivas V, 2009, CELL CYCLE, V8, P391, DOI 10.4161/cc.8.3.7545; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Teti A, 2009, BONE, V44, P11, DOI 10.1016/j.bone.2008.09.017; Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016; Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283; Walther FJ, 1998, J APPL PHYSIOL, V85, P273, DOI 10.1152/jappl.1998.85.1.273; Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155; Weinstein RS, 2007, NAT CLIN PRACT ENDOC, V3, P86, DOI 10.1038/ncpendmet0372; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160; Yao W, 2000, BONE, V27, P667, DOI 10.1016/S8756-3282(00)00377-X; Yao W, 2000, J BONE MINER RES, V15, P1158, DOI 10.1359/jbmr.2000.15.6.1158; Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954; Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454; Yao W, 2007, BONE, V41, P804, DOI 10.1016/j.bone.2007.06.021; Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719	79	109	126	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3366	3376		10.1096/fj.11-182519	http://dx.doi.org/10.1096/fj.11-182519			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21705669	Green Published			2022-12-28	WOS:000295356400009
J	Chan, SL; Cipolla, MJ				Chan, Siu-Lung; Cipolla, Marilyn J.			Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-gamma	FASEB JOURNAL			English	Article						hypertrophy; middle cerebral arteries; myogenic reactivity	PPAR-GAMMA; MYOGENIC REACTIVITY; CEREBRAL ARTERIOLES; RENAL VASODILATION; CEREBROVASCULAR RESISTANCE; VASCULAR DYSFUNCTION; PREGNANCY; RATS; MICE; HYPERFILTRATION	Brain parenchymal arterioles (PAs), but not pial arteries, undergo hypotrophic outward remodeling during pregnancy that involves peroxisome proliferator-activated receptor-gamma (PPAR gamma) activation. Relaxin, a peptide hormone produced during pregnancy, is involved in systemic and renal artery remodeling and activates PPAR gamma in vitro. Thus, we hypothesized that relaxin is involved in the selective outward remodeling of PAs through a PPAR gamma-dependent mechanism. Nonpregnant rats were treated with relaxin (4 mu g/h, osmotic minipump), relaxin plus PPAR gamma inhibitor GW9662 (10 mg/kg/d), or vehicle for 10 d. Vascular function and structure were compared in isolated and pressurized middle cerebral arteries (MCAs) and PAs taken from the same animals. Relaxin treatment increased serum relaxin to the level of pregnancy (54 ng/ml) and increased passive wall thickness (hypertrophy; 70 +/- 5 vs. 54 +/- 4 mu m in vehicle; P<0.05) and inner diameter (outward remodeling; 10.6 +/- 0.5 vs. 8.0 +/- 0.6 mu m in vehicle; P<0.05) in PAs, but not in MCAs. This hypertrophic outward remodeling was prevented by GW9662 that had diameters (57 +/- 3 mu m) and wall thickness (8.6 +/- 1.0 mu m) similar to vehicle. GW9662 also prevented relaxin-induced changes in PPAR gamma target gene expression. These results suggest that relaxin produced during pregnancy may be partly responsible for selective remodeling of PAs during pregnancy through a mechanism involving PPAR gamma.-Chan, S.-L., Cipolla, M. J. Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-gamma. FASEB J. 25, 3229-3239 (2011). www.fasebj.org	[Chan, Siu-Lung; Cipolla, Marilyn J.] Univ Vermont, Dept Neurol, Burlington, VT 05401 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Obstet Gynecol & Reprod Sci, Burlington, VT 05401 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Pharmacol, Burlington, VT 05401 USA	University of Vermont; University of Vermont; University of Vermont	Cipolla, MJ (corresponding author), Univ Vermont, Dept Neurol, 89 Beaumont Ave,C454 Given, Burlington, VT 05401 USA.	marilyn.cipolla@uvm.edu	Chan, Siu-Lung/I-3023-2019	Chan, Siu-Lung/0000-0001-7564-3287	U.S. National Institutes of Health [NS045940]; American Recovery and Reinvestment Act supplement [NS045940-05S1]; American Heart Association [0540081N]; Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL095488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045940] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Recovery and Reinvestment Act supplement; American Heart Association(American Heart Association); Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Dennis Stewart (Corthera, Inc., San Carlos, CA, USA) and Novartis Pharmaceuticals (Basel, Switzerland) for providing recombinant human relaxin-2. The authors thank Mr. Timothy Hunter, Ms. Mary Lou Shane, and the Vermont Cancer Center DNA analysis facility at the University of Vermont for their technical expertise and help with PCR. The authors also thank Ms. Julie Sweet for technical expertise with the PA experiments. The authors gratefully acknowledge the continued support from the U.S. National Institutes of Health (NS045940), the American Recovery and Reinvestment Act supplement (NS045940-05S1), the American Heart Association Established Investigator Award (0540081N), and the Totman Medical Research Trust. Recombinant human relaxin-2 was a gift from Corthera Inc. and Novartis Pharmaceuticals.	Arck P, 2010, BIOL REPROD, V83, P168, DOI 10.1095/biolreprod.110.083550; BANI D, 2008, HLTH RISK MANAG, V4, P515; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Baumbach Gary L., 2000, Journal of Hypertension, V18, pS7; Baumbach GL, 1996, HYPERTENSION, V27, P159, DOI 10.1161/01.HYP.27.2.159; BAUMBACH GL, 1989, J PHYSIOL-LONDON, V416, P123, DOI 10.1113/jphysiol.1989.sp017753; Baumbach GL, 2004, CIRC RES, V95, P822, DOI 10.1161/01.RES.0000146279.11923.14; Baumbach GL, 2003, HYPERTENSION, V41, P50, DOI 10.1161/01.HYP.0000042427.05390.5C; Beyer AM, 2008, HYPERTENSION, V51, P867, DOI 10.1161/HYPERTENSIONAHA.107.103648; CHAN SL, 2010, FRONT VASC PHYSL, V1, P12; Chillon JM, 1999, HYPERTENSION, V33, P856, DOI 10.1161/01.HYP.33.3.856; Cipolla MJ, 2008, MICROCIRCULATION, V15, P495, DOI 10.1080/10739680801986742; Cipolla MJ, 2008, REPROD SCI, V15, p288A; Cipolla MJ, 2008, FASEB J, V22; Cipolla MJ, 2011, J APPL PHYSIOL, V110, P329, DOI 10.1152/japplphysiol.01159.2010; Cipolla MJ, 2009, REPROD SCI, V16, p91A; Cipolla MJ, 2009, STROKE, V40, P1451, DOI 10.1161/STROKEAHA.108.535435; Cipolla MJ, 2004, J CARDIOVASC PHARM, V44, P1, DOI 10.1097/00005344-200407000-00001; CIPOLLA MJ, 2010, FASEB J, V24; Conrad KP, 2004, AM J PHYSIOL-REG I, V287, pR250, DOI 10.1152/ajpregu.00672.2003; Conrad KP, 2004, ENDOCRINOLOGY, V145, P3289, DOI 10.1210/en.2003-1612; Danielson LA, 2003, J APPL PHYSIOL, V95, P1509, DOI 10.1152/japplphysiol.00545.2003; Debrah DO, 2006, ENDOCRINOLOGY, V147, P5126, DOI 10.1210/en.2006-0567; Debrah DO, 2005, J APPL PHYSIOL, V98, P1013, DOI 10.1152/japplphysiol.01083.2004; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; DESAN PH, 1988, PHARMACOL BIOCHEM BE, V30, P563, DOI 10.1016/0091-3057(88)90066-4; Diep QN, 2002, CIRCULATION, V105, P2296, DOI 10.1161/01.CIR.0000016049.86468.23; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Fournier T, 2008, CURR MED CHEM, V15, P3011, DOI 10.2174/092986708786848677; Gregg C, 2009, J NEUROL SCI, V285, P22, DOI 10.1016/j.jns.2009.06.040; Halabi CM, 2008, CELL METAB, V7, P215, DOI 10.1016/j.cmet.2007.12.008; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jeyabalan A, 2003, CIRC RES, V93, P1249, DOI 10.1161/01.RES.0000104086.43830.6C; Jeyabalan A, 2006, J APPL PHYSIOL, V100, P1955, DOI 10.1152/japplphysiol.01330.2005; Jeyabalan A, 2007, ENDOCRINOLOGY, V148, P189, DOI 10.1210/en.2006-0989; Li Y, 2005, REGUL PEPTIDES, V132, P41, DOI 10.1016/j.regpep.2005.09.009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Novak J, 2001, J CLIN INVEST, V107, P1469, DOI 10.1172/JCI11975; Novak J, 2002, AM J PHYSIOL-REG I, V283, pR349, DOI 10.1152/ajpregu.00635.2001; Pohl U, 2000, ACTA PHYSIOL SCAND, V168, P505, DOI 10.1046/j.1365-201x.2000.00702.x; Samuel CS, 2006, KIDNEY INT, V69, P1498, DOI 10.1038/sj.ki.5000264; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; SHERWOOD OD, 1994, PHYSL REPRODUCTION, V1, P861; Singh S, 2010, MOL CELL ENDOCRINOL, V315, P239, DOI 10.1016/j.mce.2009.08.014; Sugawara A, 2001, ENDOCRINOLOGY, V142, P3125, DOI 10.1210/en.142.7.3125; Teerlink JR, 2009, LANCET, V373, P1429, DOI 10.1016/S0140-6736(09)60622-X; Toth B, 2007, AM J REPROD IMMUNOL, V58, P289, DOI 10.1111/j.1600-0897.2007.00514.x; Tsai YS, 2004, J CLIN INVEST, V114, P240, DOI 10.1172/JCI200420964; Unemori E, 2009, ANN NY ACAD SCI, V1160, P381, DOI 10.1111/j.1749-6632.2009.03838.x; Waite LL, 2005, J CLIN ENDOCR METAB, V90, P620, DOI 10.1210/jc.2004-0849; Wieser F, 2008, PPAR RES, V2008, DOI 10.1155/2008/527048; Williams KP, 1998, AM J OBSTET GYNECOL, V179, P1200, DOI 10.1016/S0002-9378(98)70131-0	52	40	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3229	3239		10.1096/fj.10-175471	http://dx.doi.org/10.1096/fj.10-175471			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21602449	Green Published			2022-12-28	WOS:000294435200035
J	Hellriegel, C; Caiolfa, VR; Corti, V; Sidenius, N; Zamai, M				Hellriegel, Christian; Caiolfa, Valeria R.; Corti, Valeria; Sidenius, Nicolai; Zamai, Moreno			Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane	FASEB JOURNAL			English	Article						fluorescence microscopy; GPI-anchored proteins; ligand binding; receptor dimerization	RECEPTOR-RELATED-PROTEIN; FLUORESCENCE CORRELATION SPECTROSCOPY; PHOTON-COUNTING HISTOGRAM; EPIDERMAL-GROWTH-FACTOR; UROKINASE RECEPTOR; PLASMINOGEN-ACTIVATOR; LIVING CELLS; IN-VIVO; BINDING; COMPLEX	We studied the molecular forms of the GPI-anchored urokinase plasminogen activator receptor (uPAR-mEGFP) in the human embryo kidney (HEK293) cell membrane and demonstrated that the binding of the amino-terminal fragment (ATF) of urokinase plasminogen activator is sufficient to induce the dimerization of the receptor. We followed the association kinetics and determined precisely the dimeric stoichiometry of uPAR-mEGFP complexes by applying number and brightness (N&B) image analysis. N&B is a novel fluctuation-based approach for measuring the molecular brightness of fluorophores in an image time sequence in live cells. Because N&B is very sensitive to long-term temporal fluctuations and photobleaching, we have introduced a filtering protocol that corrects for these important sources of error. Critical experimental parameters in N&B analysis are illustrated and analyzed by simulation studies. Control experiments are based on mEGFP-GPI, mEGFP-mEGFP-GPI, and mCherry-GPI, expressed in HEK293. This work provides a first direct demonstration of the dimerization of uPAR in live cells. We also provide the first methodological guide on N&B to discern minor changes in molecular composition such as those due to dimerization events, which are involved in fundamental cell signaling mechanisms.-Hellriegel, C., Caiolfa, V. R., Corti, V., Sidenius, N., Zamai, M. Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane. FASEB J. 25, 2883-2897 (2011). www.fasebj.org	[Hellriegel, Christian; Caiolfa, Valeria R.; Zamai, Moreno] Natl Ctr Cardiovasc Res CNIC, Microscopy & Dynam Imaging Unit, Madrid, Spain; [Caiolfa, Valeria R.; Corti, Valeria; Zamai, Moreno] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy; [Caiolfa, Valeria R.; Zamai, Moreno] Ist Sci San Raffaele, Italian Inst Technol Network Res, Unit Mol Neurosci, I-20132 Milan, Italy; [Sidenius, Nicolai] Italian Canc Res Fdn FIRX, Inst Mol Oncol IFOM, Milan, Italy	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IFOM - FIRC Institute of Molecular Oncology	Zamai, M (corresponding author), Natl Ctr Cardiovasc Res, Microscopy & Dynam Imaging Unit, Melchor Fernandez Almagro 3, ES-28029 Madrid, Spain.	valeria.caiolfa@hsr.it; mzamai@cnic.es	Zamai, Moreno/H-5923-2015; Hellriegel, Christian/B-8263-2014; Sidenius, Nicolai/M-9643-2015; Caiolfa, Valeria R./H-2769-2015	Zamai, Moreno/0000-0002-2222-6815; Sidenius, Nicolai/0000-0002-7825-7629; Caiolfa, Valeria R./0000-0003-4814-6490	Cariplo Foundation; Italian Association for Cancer Research (AIRC); Spanish Ministry of Science and Innovation; Pro-CNIC Foundation; National Center for Research Resources of the U.S. National Institutes of Health [PHS 5 P41-RR003155]; UCI; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003155] Funding Source: NIH RePORTER	Cariplo Foundation(Fondazione Cariplo); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Pro-CNIC Foundation; National Center for Research Resources of the U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); UCI; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors are grateful to Elvira Arza for technical help. The authors thank Enrico Gratton for the valuable discussion. The authors acknowledge the financial support from the Cariplo Foundation (V. R. C. and N.S.) and the Italian Association for Cancer Research (AIRC; N.S.). CNIC is supported by the Spanish Ministry of Science and Innovation and by the Pro-CNIC Foundation. Raw data in Figs. 4 and 5 were acquired at the Laboratory for Fluorescence Dynamics (LFD) at the University of California, Irvine (UCI; Irvine, CA, USA). The LFD is supported jointly by the National Center for Research Resources of the U.S. National Institutes of Health (PHS 5 P41-RR003155) and UCI.	APPELLA E, 1987, ANN NY ACAD SCI, V511, P192, DOI 10.1111/j.1749-6632.1987.tb36247.x; Barinka C, 2006, J MOL BIOL, V363, P482, DOI 10.1016/j.jmb.2006.08.063; Bdeir K, 2003, BLOOD, V102, P3600, DOI 10.1182/blood-2003-03-0949; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; Blasi F, 2010, FEBS LETT, V584, P1923, DOI 10.1016/j.febslet.2009.12.039; Caiolfa VR, 2007, J CELL BIOL, V179, P1067, DOI 10.1083/jcb.200702151; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Cortese K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003730; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Dalal RB, 2008, MICROSC RES TECHNIQ, V71, P69, DOI 10.1002/jemt.20526; Digman MA, 2008, BIOPHYS J, V94, P2320, DOI 10.1529/biophysj.107.114645; Digman MA, 2009, P NATL ACAD SCI USA, V106, P2170, DOI 10.1073/pnas.0806036106; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Hellriegel C, 2009, J R SOC INTERFACE, V6, pS3, DOI 10.1098/rsif.2008.0313.focus; Huang MD, 2005, ACTA CRYSTALLOGR D, V61, P697, DOI 10.1107/S0907444905014174; Jo M, 2007, ONCOGENE, V26, P2585, DOI 10.1038/sj.onc.1210066; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LINDEMANN B, 1969, MED BIOL ENG, V7, P239, DOI 10.1007/BF02474182; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058; Mallengo G, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2940570; Maupas-Schwalm F, 2009, CELL SIGNAL, V21, P1925, DOI 10.1016/j.cellsig.2009.08.010; Muller JD, 2000, BIOPHYS J, V78, P474, DOI 10.1016/S0006-3495(00)76610-0; Nagy P, 2010, P NATL ACAD SCI USA, V107, P16524, DOI 10.1073/pnas.1002642107; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Ossato G, 2010, BIOPHYS J, V98, P3078, DOI 10.1016/j.bpj.2010.02.058; Perroud TD, 2005, CHEMPHYSCHEM, V6, P905, DOI 10.1002/cphc.200400547; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QIAN H, 1990, P NATL ACAD SCI USA, V87, P5479, DOI 10.1073/pnas.87.14.5479; Sahores M, 2008, BBA-BIOMEMBRANES, V1778, P250, DOI 10.1016/j.bbamem.2007.09.030; Sanchez-Andres A, 2005, BIOPHYS J, V89, P3531, DOI 10.1529/biophysj.105.067082; Schriebl K, 2006, PROTEIN EXPRES PURIF, V49, P265, DOI 10.1016/j.pep.2006.05.018; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Unruh JR, 2008, BIOPHYS J, V95, P5385, DOI 10.1529/biophysj.108.130310; Zacharias DA, 2006, METHOD BIOCHEM ANAL, V47, P83	43	32	33	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2883	2897		10.1096/fj.11-181537	http://dx.doi.org/10.1096/fj.11-181537			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21602447	Green Published			2022-12-28	WOS:000294435200005
J	Chin, KT; Kang, GX; Qu, JX; Gardner, LB; Coetzee, WA; Zito, E; Fishman, GI; Ron, D				Chin, King-Tung; Kang, Guoxin; Qu, Jiaxiang; Gardner, Lawrence B.; Coetzee, William A.; Zito, Ester; Fishman, Glenn I.; Ron, David			The sarcoplasmic reticulum luminal thiol oxidase ERO1 regulates cardiomyocyte excitation-coupled calcium release and response to hemodynamic load	FASEB JOURNAL			English	Article						disulfide bonds; endoplasmic reticulum; heart failure	OXIDATIVE STRESS; PROTEIN; GENE; HOMEOSTASIS; MECHANISMS; PATHWAYS; HYPOXIA; CELLS; HEART; SERCA	Two related ER oxidation 1 (ERO1) proteins, ERO1 alpha and ERO1 beta, dynamically regulate the redox environment in the mammalian endoplasmic reticulum (ER). Redox changes in cysteine residues on intralumenal loops of calcium release and reuptake channels have been implicated in altered calcium release and reuptake. These findings led us to hypothesize that altered ERO1 activity may affect cardiac functions that are dependent on intracellular calcium flux. We established mouse lines with loss of function insertion mutations in Ero1l and Ero1lb encoding ERO1 alpha and ERO1 beta. The peak amplitude of calcium transients in homozygous Ero1 alpha mutant adult cardiomyocytes was reduced to 42.0 +/- 2.2% (n = 10, P <= 0.01) of values recorded in wild-type cardiomyocytes. Decreased ERO1 activity blunted cardiomyocyte inotropic response to adrenergic stimulation and sensitized mice to adrenergic blockade. Whereas all 12 wild-type mice survived challenge with 4 mg/kg esmolol, 6 of 8 compound Ero1l and Ero1lb mutant mice succumbed to this level of beta adrenergic blockade (P <= 0.01). In addition, mice lacking ERO1 alpha were partially protected against progressive heart failure in a transaortic constriction model [at 10 wk postprocedure, fractional shortening was 0.31 +/- 0.02 in the mutant (n = 20) vs. 0.23 +/- 0.03 in the wild type (n = 18); P <= 0.01]. These findings establish a role for ERO1 in calcium homeostasis and suggest that modifying the lumenal redox environment may affect the progression of heart failure.Chin, K. T., Kang, G., Qu, J., Gardner, L. B., Coetzee, W. A., Zito, E., Fishman, G. I., Ron, R. The sarcoplasmic reticulum luminal thiol oxidase ERO1 regulates cardiomyocyte excitation-coupled calcium release and response to hemodynamic load. FASEB J. 25, 2583-2591 (2011). www.fasebj.org	[Kang, Guoxin] NYU, Sch Med, Leon H Charney Div Cardiol, Dept Med, New York, NY 10016 USA; [Chin, King-Tung; Zito, Ester; Ron, David] NYU, Sch Med, Kimmel Ctr Biol & Med, Skirball Inst, New York, NY 10016 USA; [Ron, David] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Coetzee, William A.] NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; [Ron, David] Univ Cambridge, Inst Metab Sci, Cambridge, England	New York University; New York University; New York University; New York University; University of Cambridge	Fishman, GI (corresponding author), NYU, Sch Med, Leon H Charney Div Cardiol, Dept Med, 522 1st Ave,Smilow 801, New York, NY 10016 USA.	glenn.fishman@med.nyu.edu; dr360@medschl.cam.ac.uk	Zito, Ester/ABB-9687-2020; Zito, Ester/AAA-7246-2020	Coetzee, William/0000-0003-1522-8326; Ron, David/0000-0002-3014-5636; Gardner, Lawrence/0000-0003-0191-0172; Fishman, Glenn/0000-0002-2366-8527	U.S. National Institutes of Health [ES08681, DK47119, DK075311, R01HL82727, R01HL081336, S10RR026881]; EMBO [ALTF649-2008]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026881] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081336, T32HL007151, R01HL082727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081641, R01DK075311, R01DK047119, R29DK047119, R37DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; Medical Research Council [G0600717B] Funding Source: researchfish	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EMBO(European Molecular Biology Organization (EMBO)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank S. James Remington (University of Oregon, Eugene, OR, USA) for the roGFP_iE. This study was supported by U.S. National Institutes of Health grants ES08681, DK47119, and DK075311 to D.R. and R01HL82727, R01HL081336, and S10RR026881 to G.I.F., and EMBO long-term fellowship ALTF649-2008 to E.Z. D.R. is a Wellcome Trust Principal Research Fellow.	Appenzeller-Herzog C, 2010, EMBO J, V29, P3318, DOI 10.1038/emboj.2010.203; Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455; Blais JD, 2010, J BIOL CHEM, V285, P20993, DOI 10.1074/jbc.M110.126599; Dibb KM, 2007, CELL CALCIUM, V42, P503, DOI 10.1016/j.ceca.2007.04.002; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Fu HY, 2010, CIRCULATION, V122, P361, DOI 10.1161/CIRCULATIONAHA.109.917914; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Hamada H, 2004, MOL CELL BIOL, V24, P8007, DOI 10.1128/MCB.24.18.8007-8017.2004; Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI [10.1089/ars.2009.2466, 10.1089/ARS.2009.2466]; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Kang GX, 2010, CIRC RES, V107, P512, DOI 10.1161/CIRCRESAHA.110.221481; Krishnan J, 2009, CELL METAB, V9, P512, DOI 10.1016/j.cmet.2009.05.005; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Lohman JR, 2008, BIOCHEMISTRY-US, V47, P8678, DOI 10.1021/bi800498g; LOMPRE AM, 1994, J MOL CELL CARDIOL, V26, P1109, DOI 10.1006/jmcc.1994.1130; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325; Meyers MB, 2003, J BIOL CHEM, V278, P28865, DOI 10.1074/jbc.M302009200; Nass RD, 2008, NAT CLIN PRACT CARD, V5, P196, DOI 10.1038/ncpcardio1130; O'Neill SC, 2004, J PHYSIOL-LONDON, V559, P121, DOI 10.1113/jphysiol.2003.058917; Okada K, 2004, CIRCULATION, V110, P705, DOI 10.1161/01.CIR.0000137836.95625.D4; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Qu JX, 2009, CIRC RES, V104, P365, DOI 10.1161/CIRCRESAHA.108.184044; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sevier CS, 2008, BBA-MOL CELL RES, V1783, P549, DOI 10.1016/j.bbamcr.2007.12.011; Tavender TJ, 2010, J CELL SCI, V123, P2672, DOI 10.1242/jcs.067843; Tien AC, 2008, J CELL BIOL, V182, P1113, DOI 10.1083/jcb.200805001; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Zito E, 2010, MOL CELL, V40, P787, DOI 10.1016/j.molcel.2010.11.010; Zito E, 2010, J CELL BIOL, V188, P821, DOI 10.1083/jcb.200911086	33	41	41	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2583	2591		10.1096/fj.11-184622	http://dx.doi.org/10.1096/fj.11-184622			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507899	Green Published, Green Submitted			2022-12-28	WOS:000293337800009
J	Sarkar, A; Zhang, M; Liu, SH; Sarkar, S; Brunicardi, FC; Berger, DH; Belaguli, NS				Sarkar, Aloke; Zhang, Mao; Liu, Shi-He; Sarkar, Swapna; Brunicardi, F. Charles; Berger, David H.; Belaguli, Narasimhaswamy S.			Serum response factor expression is enriched in pancreatic beta cells and regulates insulin gene expression	FASEB JOURNAL			English	Article						Pdx-1; knock-in; LacZ	TRANSCRIPTION FACTOR; FACTOR-BINDING; E-BOX; ACTIVATION; ELEMENT; SRF; CARG; PROLIFERATION; PROTEINS; PROMOTER	Serum response factor (SRF) is an essential regulator of myogenic and neurogenic genes and the ubiquitously expressed immediate-early genes. The purpose of this study is to determine SRF expression pattern in murine pancreas and examine the role of SRF in pancreatic gene expression. Immunohistochemical analysis of wild-type pancreas and LacZ staining of pancreas from SRF LacZ knock-in animals showed that SRF expression is restricted to beta cells. SRF bound to the rat insulin promoter II (RIP II) serum response element, an element conserved in both rat I and murine I and II insulin promoters. SRF activated RIP II, and SRF binding to RIP II and the exon 5-encoded 64-aa subdomain of SRF was required for this activation. Transient or stable knockdown of SRF leads to down-regulation of insulin gene expression, suggesting that SRF is required for insulin gene expression. Further, SRF physically interacted with the pancreas and duodenum homeobox-1 (Pdx-1) and synergistically activated RIP II. Elevated glucose concentration down-regulated SRF binding to RIP II SRE, and this down-regulation was associated with decreased RIP II activity and increased SRF phosphorylation on serine 103. Together, our results demonstrate that SRF is a glucose concentration-sensitive regulator of insulin gene expression.-Sarkar, A., Zhang, M., Liu, S.-H., Sarkar, S., Brunicardi, F. C., Berger, D. H., Belaguli, N. S. Serum response factor expression is enriched in pancreatic beta cells and regulates insulin gene expression. FASEB J. 25, 2592-2603 (2011). www.fasebj.org	[Belaguli, Narasimhaswamy S.] Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine	Belaguli, NS (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.	elaguli@bcm.edu			American Diabetes Association [1-06-RA-10]	American Diabetes Association(American Diabetes Association)	The authors thank Dr. Christopher Newgard (Duke University, Durham, NC, USA) for the generous gift of INS-1 823/13 cells. Thanks to Dr. Patricia Castro for help with quantitative PCR and Dr. Pradip Saha for islet isolation. This work was supported by the American Diabetes Association (research award 1-06-RA-10 to N.S.B).	Andrali SS, 2008, BIOCHEM J, V415, P1, DOI 10.1042/BJ20081029; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Baker DL, 1998, NUCLEIC ACIDS RES, V26, P1092, DOI 10.1093/nar/26.4.1092; Barron MR, 2005, J BIOL CHEM, V280, P11816, DOI 10.1074/jbc.M412408200; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHEN YR, 1995, MOL CELL BIOL, V15, P4631; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Contreras JL, 2001, TRANSPLANTATION, V71, P1015, DOI 10.1097/00007890-200104270-00001; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; Escalante R, 2003, EUKARYOT CELL, V2, P1327, DOI 10.1128/EC.2.6.1327-1335.2003; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gurzov EN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003030; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kaneto H, 2008, ENDOCR J, V55, P235, DOI 10.1507/endocrj.K07E-041; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; LIU SH, 1993, J BIOL CHEM, V268, P21147; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Miralles F, 2006, LAB INVEST, V86, P1020, DOI 10.1038/labinvest.3700457; Nilsson M, 2007, NUCLEIC ACIDS RES, V35, P4858, DOI 10.1093/nar/gkm492; Niu Z, 2005, J BIOL CHEM, V280, P32531, DOI 10.1074/jbc.M501372200; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Pino MF, 2005, MOL ENDOCRINOL, V19, P1343, DOI 10.1210/me.2003-0493; Rene C, 2005, NUCLEIC ACIDS RES, V33, P5271, DOI 10.1093/nar/gki837; Schratt G, 2004, EMBO J, V23, P1834, DOI 10.1038/sj.emboj.7600188; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sun K, 2009, HEPATOLOGY, V49, P1645, DOI 10.1002/hep.22834; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Wang ZX, 2009, J CELL SCI, V122, P893, DOI 10.1242/jcs.034355; Zhang SX, 2005, J BIOL CHEM, V280, P19115, DOI 10.1074/jbc.M413793200	50	11	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2592	2603		10.1096/fj.10-173757	http://dx.doi.org/10.1096/fj.10-173757			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21525490				2022-12-28	WOS:000293337800010
J	Plaideau, C; Liu, JM; Hartleib-Geschwindner, J; Bastin-Coyette, L; Bontemps, F; Oscarsson, J; Hue, L; Rider, MH				Plaideau, Catheline; Liu, Jianming; Hartleib-Geschwindner, Judith; Bastin-Coyette, Laurent; Bontemps, Francoise; Oscarsson, Jan; Hue, Louis; Rider, Mark H.			Overexpression of AMP-metabolizing enzymes controls adenine nucleotide levels and AMPK activation in HEK293T cells	FASEB JOURNAL			English	Article						adenylate energy charge; cN-1A; control coefficient	PROTEIN-KINASE; ADENYLATE DEAMINASE; SKELETAL-MUSCLE; ENERGY-CHARGE; YEAST SNF1; PHOSPHORYLATION; INSULIN; CONTRACTION; EXERCISE; HEART	We investigated whether overexpression of AMP-metabolizing enzymes in intact cells would modulate oligomycin-induced AMPK activation. Human embryonic kidney (HEK) 293T cells were transiently transfected with increasing amounts of plasmid vectors to obtain a graded increase in overexpression of AMP-deaminase (AMPD) 1, AMPD2, and soluble 5'-nucleotidase IA (cN-IA) for measurements of AMPK activation and total intracellular adenine nucleotide levels induced by oligomycin treatment. Overexpression of AMPD1 and AMPD2 slightly decreased AMP levels and oligomycin-induced AMPK activation. Increased overexpression of cN-IA led to reductions in the oligomycin-induced increases in AMP and ADP concentrations by similar to 70 and 50%, respectively, concomitant with a 50% decrease in AMPK activation. The results support the view that a rise in ADP as well as AMP is important for activation of AMPK, which can thus be regulated by the adenylate energy charge. The control coefficient of cN-IA on AMP was 0.3-0.7, whereas the values for AMPD1 and AMPD2 were <0.1, suggesting that in this model cN-IA exerts a large proportion of control over intracellular AMP. Therefore, small molecule inhibition of cN-IA could be a strategy for AMPK activation.-Plaideau, C., Liu, J., Hartleib-Geschwindner, J., Bastin-Coyette, L., Bontemps, F., Oscarsson, J., Hue, L., Rider, M. H. Overexpression of AMP-metabolizing enzymes controls adenine nucleotide levels and AMPK activation in HEK293T cells. FASEB J. 26, 2685-2694 (2012). www.fasebj.org	[Plaideau, Catheline; Bastin-Coyette, Laurent; Bontemps, Francoise; Hue, Louis; Rider, Mark H.] Catholic Univ Louvain, Duve Inst, B-1200 Brussels, Belgium; [Liu, Jianming; Hartleib-Geschwindner, Judith; Oscarsson, Jan] AstraZeneca Res & Dev, Molndal, Sweden	Universite Catholique Louvain; AstraZeneca	Rider, MH (corresponding author), Catholic Univ Louvain, Duve Inst, Ave Hippocrate 75,Bte B1-74-02, B-1200 Brussels, Belgium.	mark.rider@uclouvain.be			Interuniversity Attraction Poles Program-Belgian Science Policy [P6/28]; Directorate General Higher Education and Scientific Research, French Community of Belgium; Fund for Medical Scientific Research (Belgium); EXGENESIS from European Commission [LSHM-CT-2004-005272]; Fund for Scientific Research in Industry and Agriculture (FRIA; Belgium)	Interuniversity Attraction Poles Program-Belgian Science Policy(Belgian Federal Science Policy Office); Directorate General Higher Education and Scientific Research, French Community of Belgium; Fund for Medical Scientific Research (Belgium)(Fonds de la Recherche Scientifique - FNRS); EXGENESIS from European Commission; Fund for Scientific Research in Industry and Agriculture (FRIA; Belgium)(Fonds de la Recherche Scientifique - FNRS)	The authors thank Roxane Jacobs for her expert technical assistance. This work was supported by the Interuniversity Attraction Poles Program-Belgian Science Policy (P6/28), the Directorate General Higher Education and Scientific Research, French Community of Belgium, the Fund for Medical Scientific Research (Belgium), and the EXGENESIS Integrated Project (LSHM-CT-2004-005272) from the European Commission. C. P. was supported by the Fund for Scientific Research in Industry and Agriculture (FRIA; Belgium).	ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BAUSCHJURKEN MT, 1995, ARCH BIOCHEM BIOPHYS, V321, P372, DOI 10.1006/abbi.1995.1407; BELSHAM GJ, 1980, BIOCHEM J, V192, P457, DOI 10.1042/bj1920457; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; Bontemps F, 2000, BIOCHEM PHARMACOL, V59, P1237, DOI 10.1016/S0006-2952(00)00258-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabarcas SM, 2010, CURR MOL MED, V10, P741; CHAPMAN AG, 1973, J BIOL CHEM, V248, P8309; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Francis SH, 2011, HANDB EXP PHARMACOL, V204, P47, DOI [10.1007/978-3-642-17969-3_2, 10.1007/978-3-642-13443-2_4]; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Haas AL, 2003, BIOCHEM BIOPH RES CO, V305, P421, DOI 10.1016/S0006-291X(03)00787-3; HALFMAN CJ, 1982, BIOCHEM J, V203, P339, DOI 10.1042/bj2030339; Hancock CR, 2006, J APPL PHYSIOL, V100, P406, DOI 10.1152/japplphysiol.00885.2005; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; Hunter RW, 2011, DIABETES, V60, P766, DOI 10.2337/db10-1148; Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kulkarni SS, 2011, J BIOL CHEM, V286, P34567, DOI 10.1074/jbc.M111.268292; Lai YC, 2010, J APPL PHYSIOL, V108, P1106, DOI 10.1152/japplphysiol.00401.2009; Mahnke-Zizelman DK, 1998, J BIOL CHEM, V273, P35118, DOI 10.1074/jbc.273.52.35118; MahnkeZizelman DK, 1997, BIOCHEM J, V326, P521, DOI 10.1042/bj3260521; Mantovani J, 2011, FEBS LETT, V585, P967, DOI 10.1016/j.febslet.2010.12.015; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; MCGILVERY RW, 1974, J BIOL CHEM, V249, P5845; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; Neumann D., 2007, MOL SYSTEMS BIOENERG, P303; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; OGASAWARA N, 1975, FEBS LETT, V58, P245, DOI 10.1016/0014-5793(75)80270-5; OGASAWARA N, 1978, EUR J BIOCHEM, V87, P297, DOI 10.1111/j.1432-1033.1978.tb12378.x; REN JM, 1990, J APPL PHYSIOL, V69, P919, DOI 10.1152/jappl.1990.69.3.919; Richter EA, 2009, BIOCHEM J, V418, P261, DOI 10.1042/BJ20082055; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC287, DOI 10.1152/ajpcell.1992.263.2.C287; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC294, DOI 10.1152/ajpcell.1992.263.2.C294; Rush JWE, 1998, AM J PHYSIOL-CELL PH, V274, pC465, DOI 10.1152/ajpcell.1998.274.2.C465; Saha AK, 2010, DIABETES, V59, P2426, DOI 10.2337/db09-1870; SAHLIN K, 1990, INT J SPORTS MED, V11, pS62, DOI 10.1055/s-2007-1024856; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Scott JW, 2008, CHEM BIOL, V15, P1220, DOI 10.1016/j.chembiol.2008.10.005; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Teijeira S, 2009, CLIN NEUROPATHOL, V28, P136; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Wegener G, 1996, EXPERIENTIA, V52, P404, DOI 10.1007/BF01919307; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xiao B, 2007, NATURE, V449, P496, DOI 10.1038/nature06161; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zhang SJ, 2008, ACTA PHYSIOL, V192, P413, DOI 10.1111/j.1748-1716.2007.01767.x	58	21	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2685	2694		10.1096/fj.11-198168	http://dx.doi.org/10.1096/fj.11-198168			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415305				2022-12-28	WOS:000305017200044
J	Bosmann, M; Grailer, JJ; Zhu, KT; Matthay, MA; Sarma, JV; Zetoune, FS; Ward, PA				Bosmann, Markus; Grailer, Jamison J.; Zhu, Ketong; Matthay, Michael A.; Sarma, J. Vidya; Zetoune, Firas S.; Ward, Peter A.			Anti-inflammatory effects of beta(2) adrenergic receptor agonists in experimental acute lung injury	FASEB JOURNAL			English	Article						albuterol; formoterol; macrophages; neutrophils; JNK	BRONCHIAL EPITHELIAL-CELLS; RESPIRATORY-DISTRESS-SYNDROME; CONTROLLED CLINICAL-TRIAL; ALVEOLAR FLUID CLEARANCE; PULMONARY-EDEMA; COMPLEMENT ACTIVATION; ENDOTHELIAL-CELLS; CYTOKINE RELEASE; RAT LUNGS; SALMETEROL	These studies were undertaken to extend emerging evidence that beta(2) adrenergic receptor (beta(2)AR) agonists, in addition to their bronchorelaxing effects, may have broad anti-inflammatory effects in the lung following onset of experimental acute lung injury (ALI). Young male C57BL/6 mice (25 g) developed ALI following airway deposition of bacterial LPS or IgG immune complexes in the absence or presence of appropriate stereoisomers (enantiomers) of beta(2)AR agonists, albuterol or formoterol. Endpoints included albumin leak into lung and buildup of polymorphonuclear neutrophils and cytokines/chemokines in bronchoalveolar fluids. Both beta(2)AR agonists suppressed lung inflammatory parameters (IC50=10(-7) M). Similar effects of beta(2)AR agonists on mediator release were found when mouse macrophages were stimulated in vitro with LPS. The protective effects were associated with reduced activation (phosphorylation) of JNK but not of other signaling proteins. Collectively, these data suggest that beta(2)AR agonists have broad anti-inflammatory effects in the setting of ALI. While beta(2)AR agonists suppress JNK activation, the extent to which this can explain the blunted lung inflammatory responses in the ALI models remains to be determined.-Bosmann, M., Grailer, J. J., Zhu, K., Matthay, M A., Vidya Sarma, J., Zetoune, F. S., Ward, P. A. Anti-inflammatory effects of beta(2) adrenergic receptor agonists in experimental acute lung injury. FASEB J. 26, 2137-2144 (2012). www.fasebj.org	[Bosmann, Markus; Grailer, Jamison J.; Zhu, Ketong; Sarma, J. Vidya; Zetoune, Firas S.; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Matthay, Michael A.] Univ Calif San Francisco, Dept Med & Anesthesia, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd,Box 5602, Ann Arbor, MI 48109 USA.	pward@umich.edu		Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health [GM-29507, GM-61656, NHLBI-T32-HL007517-29, HL-51856, HL-51854]; Deutsche Forschungsgemeinschaft [571701, BO 3482/1-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051856, T32HL007517, R01HL051854, R01HL051856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R01GM029507, R37GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants to P.A.W. (GM-29507, GM-61656), J.J.G. (NHLBI-T32-HL007517-29), and M.A.M. (HL-51856, HL-51854) and by a Deutsche Forschungsgemeinschaft grant to M.B. (project 571701, BO 3482/1-1). The authors declare no conflicts of interest. The authors acknowledge the excellent staff support of Beverly Schumann, Sue Scott, and Robin Kunkel.	Atabai K, 2002, INTENS CARE MED, V28, P705, DOI 10.1007/s00134-002-1282-x; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bloemen PGM, 1997, AM J PHYSIOL-LUNG C, V272, pL580, DOI 10.1152/ajplung.1997.272.4.L580; Bosmann M, 2011, FASEB J, V25, P4222, DOI 10.1096/fj.11-191205; Bosmann M, 2011, SHOCK, V36, P396, DOI 10.1097/SHK.0b013e3182295f5f; Chen FS, 2006, ANN THORAC SURG, V82, P465, DOI 10.1016/j.athoracsur.2006.01.010; Cobelens PM, 2002, J IMMUNOL, V169, P5028, DOI 10.4049/jimmunol.169.9.5028; Dhingra VK, 2001, ANESTHESIOLOGY, V95, P947, DOI 10.1097/00000542-200110000-00025; Donnelly LE, 2010, EUR RESPIR J, V36, P178, DOI 10.1183/09031936.00158008; Dutta EJ, 2002, MED CLIN N AM, V86, P991, DOI 10.1016/S0025-7125(02)00031-7; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Levitt JE, 2009, CHEST, V135, P936, DOI 10.1378/chest.08-2346; Manocha S, 2006, CRIT CARE, V10, DOI 10.1186/cc3971; Maris NA, 2005, AM J RESP CRIT CARE, V172, P878, DOI 10.1164/rccm.200503-451OC; Matthay MA, 2006, AM J RESP CRIT CARE, V173, P254, DOI 10.1164/rccm.rccm2511003; Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E; Mutlu GM, 2005, AM J PHYSIOL-LUNG C, V289, pL685, DOI 10.1152/ajplung.00247.2005; Mutlu GM, 2008, AM J RESP CELL MOL, V38, P127, DOI 10.1165/rcmb.2007-0198TR; Oddera S, 1998, J ASTHMA, V35, P401, DOI 10.3109/02770909809048948; Perkins GD, 2004, CRIT CARE, V8, P25, DOI 10.1186/cc2417; Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC; Queen LR, 2006, J PHYSIOL-LONDON, V576, P585, DOI 10.1113/jphysiol.2006.115998; Rittirsch D, 2008, J IMMUNOL, V180, P7664, DOI 10.4049/jimmunol.180.11.7664; Roux FJ, 1996, AM J RESP CRIT CARE, V153, P1489, DOI 10.1164/ajrccm.153.5.8630591; Sabatini F, 2003, RESP MED, V97, P1052, DOI 10.1016/S0954-6111(03)00137-9; Sakuma T, 1997, AM J RESP CRIT CARE, V155, P506, DOI 10.1164/ajrccm.155.2.9032186; SAKUMA T, 1994, AM J RESP CRIT CARE, V150, P305, DOI 10.1164/ajrccm.150.2.8049807; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; Scola AM, 2009, BRIT J PHARMACOL, V158, P267, DOI 10.1111/j.1476-5381.2009.00178.x; Shanley TP, 1997, J IMMUNOL, V158, P3439; Spoelstra FM, 2002, THORAX, V57, P237, DOI 10.1136/thorax.57.3.237; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; WHELAN CJ, 1993, BRIT J PHARMACOL, V110, P613, DOI 10.1111/j.1476-5381.1993.tb13855.x; ZINK S, 1995, AM J PHYSIOL-CELL PH, V269, pC1209, DOI 10.1152/ajpcell.1995.269.5.C1209	42	71	76	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2137	2144		10.1096/fj.11-201640	http://dx.doi.org/10.1096/fj.11-201640			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22318967	Green Published, Green Submitted			2022-12-28	WOS:000303680800039
J	Yang, XS; Li, Q; Lin, X; Ma, YL; Yue, XJ; Tao, ZY; Wang, F; Mckeehan, WL; Wei, L; Schwartz, RJ; Chang, J				Yang, Xiangsheng; Li, Qi; Lin, Xi; Ma, Yanlin; Yue, Xiaojing; Tao, Zhenyin; Wang, Fen; Mckeehan, Wallace L.; Wei, Lei; Schwartz, Robert J.; Chang, Jiang			Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1	FASEB JOURNAL			English	Article						myocardial fibrosis; transgenic mice; serum response factor; TGF beta 1	SERUM RESPONSE FACTOR; NF-KAPPA-B; LONG-TERM INHIBITION; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MYOCARDIAL-INFARCTION; MEDIATED ACTIVATION; CASPASE-3 CLEAVAGE; CARDIAC FIBROSIS; ACTIN DYNAMICS	We have previously found that in failing human hearts, Rho-associated coiled-coil protein kinase 1 (ROCK1) is processed by caspase-3 into an active isoform, ROCK Delta 1. The purpose of the current investigation was to elucidate the pathological consequences of truncated ROCK1 accumulation in the heart, the associated molecular mechanism of ROCK Delta 1-mediated cardiac phenotype, and the molecular signaling between Rho kinase activation in cardiomyocytes and extracellular matrix response. We generated transgenic mice expressing ROCK Delta 1 in cardiomyocytes to mimic the situation observed in human heart disease, whereas an additional kinase-deficient mouse was generated as a control. The ROCK Delta 1 transgenic mice developed fibrotic cardiomyopathy with diastolic dysfunction. Transgenic hearts displayed activated TGF beta 1 and NF-kappa B signaling and a release of a subset of cytokines and were susceptible to angiotensin II stress. Treatment with a Rho kinase inhibitor attenuated the fibrotic phenotype. Cardiac fibroblasts differentiated into myofibroblasts when cocultured with transgenic cardiomyocytes but not with wild-type cardiomyocytes. Inhibitors of Rho kinase as well as TGF beta R1 and NF-kappa B decreased these effects. The serum response factor-dependent TGF beta 1 regulation was shown to be responsible for the Rho kinase-mediated activation of TGF beta 1 signaling. We conclude that ROCK Delta 1 is a novel fibrotic factor. Activation of TGF beta 1 and NF-kappa B signaling contributes to the Rho kinase-mediated pathological fibrosis.-Yang, X., Li, Q., Lin, X., Ma, Y., Yue, X., Tao, Z., Wang, F., Mckeehan, W. L., Wei, L., Schwartz, R. J., Chang, J. Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1. FASEB J. 26, 2105-2116 (2012). www.fasebj.org	[Yang, Xiangsheng; Lin, Xi; Yue, Xiaojing; Tao, Zhenyin; Wang, Fen; Mckeehan, Wallace L.; Chang, Jiang] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; [Li, Qi; Ma, Yanlin; Chang, Jiang] Hainan Med Coll, Affiliated Hosp, Hainan Prov Key Lab Human Reprod Med & Genet Res, Hainan, Peoples R China; [Wei, Lei] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA; [Schwartz, Robert J.] Univ Houston, Dept Biol & Biochem, Houston, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Hainan Medical University; Indiana University System; Indiana University Bloomington; University of Houston System; University of Houston	Chang, J (corresponding author), Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	jchang@ibt.tamhsc.edu	Lin, Xi/K-2473-2015	Lin, Xi/0000-0002-9034-7117; Chang, Jiang/0000-0003-3707-7557	U.S. National Heart, Lung, and Blood Institute [R01-HL-102314, R21-HL-094844, K02-HL-098956]; American Heart Association [0855030F]; National Science Foundation of China [NSFC 30860103]; NATIONAL CANCER INSTITUTE [P50CA140388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL094844, R01HL072897, R01HL102314, P01HL085098, K02HL098956] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Dr. Vladimir N. Potaman and Alexis M. Boggs for editorial assistance on the manuscript. This work was supported by U.S. National Heart, Lung, and Blood Institute grants R01-HL-102314, R21-HL-094844, and K02-HL-098956 and American Heart Association grant-in-aid 0855030F (to J.C.); and National Science Foundation of China grant NSFC 30860103 (to Q.L.). The authors declare no conflicts of interest.	Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Chang J, 2003, CIRCULATION, V108, P407, DOI 10.1161/01.CIR.0000084502.02147.83; Chang J, 2006, P NATL ACAD SCI USA, V103, P14495, DOI 10.1073/pnas.0601911103; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Cowell CF, 2009, J CELL BIOCHEM, V106, P714, DOI 10.1002/jcb.22067; Deten A, 2002, CARDIOVASC RES, V55, P329, DOI 10.1016/S0008-6363(02)00413-3; Dorn GW, 2009, CARDIOVASC RES, V81, P465, DOI 10.1093/cvr/cvn243; Hattori T, 2004, CIRCULATION, V109, P2234, DOI 10.1161/01.CIR.0000127939.16111.58; Haudek SB, 2009, CARDIOVASC RES, V83, P511, DOI 10.1093/cvr/cvp135; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; Kobayashi N, 2002, CARDIOVASC RES, V55, P757, DOI 10.1016/S0008-6363(02)00457-1; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; Leask A, 2007, CARDIOVASC RES, V74, P207, DOI 10.1016/j.cardiores.2006.07.012; Lemarie A, 2008, J IMMUNOL, V180, P6010, DOI 10.4049/jimmunol.180.9.6010; LI G, 1998, CIRCULATION, V98, P149; Li GM, 1998, CIRCULATION, V98, pII144; Li MX, 2005, CIRCULATION, V111, P2494, DOI 10.1161/01.CIR.0000165117.71483.0C; Li Q, 2010, AM J PHYSIOL-HEART C, V298, pH1340, DOI 10.1152/ajpheart.00592.2009; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Lin X, 2012, MOL CELL BIOL, V32, P297, DOI 10.1128/MCB.05484-11; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Onai Y, 2007, AM J PHYSIOL-HEART C, V292, pH530, DOI 10.1152/ajpheart.00549.2006; Peng FF, 2008, DIABETES, V57, P1683, DOI 10.2337/db07-1149; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Rodriguez PL, 2007, CELL SIGNAL, V19, P2361, DOI 10.1016/j.cellsig.2007.07.021; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Small EM, 2010, CIRC RES, V107, P294, DOI 10.1161/CIRCRESAHA.110.223172; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; WALTENBERGER J, 1993, AM J PATHOL, V142, P71; Wiebel FF, 2002, GENESIS, V32, P124, DOI 10.1002/gene.10049; Zhai YS, 2008, EUR J PHARMACOL, V587, P196, DOI 10.1016/j.ejphar.2008.03.006; Zhang YM, 2006, FASEB J, V20, P916, DOI 10.1096/fj.05-5129com	38	27	34	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2105	2116		10.1096/fj.11-201319	http://dx.doi.org/10.1096/fj.11-201319			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278938	Green Published			2022-12-28	WOS:000303680800036
J	Tal, TL; Franzosa, JA; Tilton, SC; Philbrick, KA; Iwaniec, UT; Turner, RT; Waters, KM; Tanguay, RL				Tal, Tamara L.; Franzosa, Jill A.; Tilton, Susan C.; Philbrick, Kenneth A.; Iwaniec, Urszula T.; Turner, Russell T.; Waters, Katrina M.; Tanguay, Robert L.			MicroRNAs control neurobehavioral development and function in zebrafish	FASEB JOURNAL			English	Article						miR-9; miR-153; skeletal development	ETHANOL EXPOSURE; CONDITIONAL LOSS; GENE-EXPRESSION; BRAIN; ALCOHOL; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; MORPHOGENESIS; VARIANCE	microRNAs (miRNAs) have emerged as regulators of a broad spectrum of neurodevelopmental processes, including brain morphogenesis, neuronal differentiation, and survival. While the role of miRNAs in establishing and maintaining the developing nervous system is widely appreciated, the developmental neurobehavioral role of miRNAs has yet to be defined. Here we show that transient disruption of brain morphogenesis by ethanol exposure results in behavioral hyperactivity in larval zebrafish challenged with changes in lighting conditions. Aberrations in swimming activity persist in juveniles that were developmentally exposed to ethanol. During early neurogenesis, multiple gene expression profiling studies revealed widespread changes in mRNA and miRNA abundance in ethanol-exposed embryos. Consistent with a role for miRNAs in neurobehavioral development, target prediction analyses identified multiple miRNAs misexpressed in the ethanol-exposed cohorts that were also predicted to target inversely expressed transcripts known to influence brain morphogenesis. In vivo knockdown of miR9/9* or miR-153c persistently phenocopied the effect of ethanol on larval and juvenile swimming behavior. Structural analyses performed on adults showed that repression of miR-153c during development impacts craniofacial skeletal development. Together, these data support an integral role for miRNAs in the establishment of vertebrate neurobehavioral and skeletal systems.-Tal, T. L., Franzosa, J. A., Tilton, S. C., Philbrick, K. A., Iwaniec, U. T., Turner, R. T., Waters, K. M., Tanguay, R. L. MicroRNAs control neurobehavioral development and function in zebrafish. FASEB J. 26, 1452-1461 (2012). www.fasebj.org	[Tal, Tamara L.; Franzosa, Jill A.; Tanguay, Robert L.] Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, Corvallis, OR 97333 USA; [Philbrick, Kenneth A.; Iwaniec, Urszula T.; Turner, Russell T.] Oregon State Univ, Skeletal Biol Lab, Corvallis, OR 97333 USA; [Tilton, Susan C.; Waters, Katrina M.] Pacific NW Natl Lab, Computat Biol & Bioinformat Grp, Richland, WA 99352 USA	Oregon State University; Oregon State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Tanguay, RL (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, 28645 E HWY 34, Corvallis, OR 97333 USA.	robert.tanguay@oregonstate.edu	Tal, Tamara/O-5414-2019	Tal, Tamara/0000-0001-8365-9385; Waters, Katrina/0000-0003-4696-5396; Philbrick, Kenneth/0000-0003-1424-6987	U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center [ES00210]; NIEHS [T32ES7060]; Oregon State University (OSU) Linus Pauling Institute; Superfund Basic Research Program [NIEHS P42 ES016465]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210, P42ES016465, T32ES007060] Funding Source: NIH RePORTER	U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Oregon State University (OSU) Linus Pauling Institute; Superfund Basic Research Program; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by U.S. National Institute of Environmental Health Sciences (NIEHS) Environmental Health Sciences Core Center grant ES00210, NIEHS training grant T32ES7060, an Oregon State University (OSU) Linus Pauling Institute grant to R. L. T., and Superfund Basic Research Program grant NIEHS P42 ES016465 to R. L. T. and K. M. W. The authors declare no conflicts of interest. The authors are grateful to Katrine Saili and Britton Goodale for their critical review of the manuscript. The authors are grateful to Carrie Barton, Cari Buchner, Brittany McCauslin, and the staff at the OSU Sinnhuber Aquatic Research Laboratory for exemplary fish husbandry and technical expertise. The authors thank Dawn Olsen for her assistance with skeletal analysis, Hao Truong for developing custom PERL software used to process locomotion data, and Gregory Gonnerman for providing body length measurements for the juvenile locomotion studies.	Ali Shaukat, 2011, PLoS One, V6, pe20037, DOI 10.1371/journal.pone.0020037; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bilotta J, 2004, NEUROTOXICOL TERATOL, V26, P737, DOI 10.1016/j.ntt.2004.06.011; Blaser R. E., PHARM BIOCH BEHAV, V95, P278; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burgess HA, 2007, J EXP BIOL, V210, P2526, DOI 10.1242/jeb.003939; Carvan MJ, 2004, NEUROTOXICOL TERATOL, V26, P757, DOI 10.1016/j.ntt.2004.06.016; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P529; Cogswell JP, 2008, J ALZHEIMERS DIS, V14, P27, DOI 10.3233/jad-2008-14103; Cowmeadow RB, 2005, ALCOHOL CLIN EXP RES, V29, P1777, DOI 10.1097/01.alc.0000183232.56788.62; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; Davis TH, 2008, J NEUROSCI, V28, P4322, DOI 10.1523/JNEUROSCI.4815-07.2008; Delaloy C, 2010, CELL STEM CELL, V6, P323, DOI 10.1016/j.stem.2010.02.015; Echevarria DJ, 2011, REV NEUROSCIENCE, V22, P85, DOI 10.1515/RNS.2011.010; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Emran Farida, 2008, J Vis Exp, DOI 10.3791/923; Fernandes Y, 2009, ALCOHOL CLIN EXP RES, V33, P601, DOI 10.1111/j.1530-0277.2008.00874.x; Gao FB, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-25; Gao XL, 2004, BIOPOLYMERS, V73, P579, DOI 10.1002/bip.20005; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; HAGINS WA, 1970, BIOPHYS J, V10, P380, DOI 10.1016/S0006-3495(70)86308-1; Haramati S, 2010, P NATL ACAD SCI USA, V107, P13111, DOI 10.1073/pnas.1006151107; Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107; Hoyme HE, 2005, PEDIATRICS, V115, P39, DOI 10.1542/peds.2004-0259; Huang TW, 2010, J MOL CELL BIOL, V2, P152, DOI 10.1093/jmcb/mjq008; Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106; Irons TD, 2010, NEUROTOXICOL TERATOL, V32, P84, DOI 10.1016/j.ntt.2009.04.066; Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; KIMMEL CB, 1993, ANNU REV NEUROSCI, V16, P707, DOI 10.1146/annurev.ne.16.030193.003423; Kocerha J, 2009, P NATL ACAD SCI USA, V106, P3507, DOI 10.1073/pnas.0805854106; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Leucht C, 2008, NAT NEUROSCI, V11, P641, DOI 10.1038/nn.2115; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Ling KH, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-176; MacPhail RC, 2009, NEUROTOXICOLOGY, V30, P52, DOI 10.1016/j.neuro.2008.09.011; Marrs JA, 2010, ALCOHOL, V44, P707, DOI 10.1016/j.alcohol.2009.03.004; Maurel DB, 2012, OSTEOPOROSIS INT, V23, P1, DOI 10.1007/s00198-011-1787-7; Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008; Pietrzykowski AZ, 2008, NEURON, V59, P274, DOI 10.1016/j.neuron.2008.05.032; Pinter R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010021; Reimers MJ, 2006, NEUROTOXICOL TERATOL, V28, P497, DOI 10.1016/j.ntt.2006.05.007; Reimers MJ, 2004, NEUROTOXICOL TERATOL, V26, P769, DOI 10.1016/j.ntt.2004.06.012; Rihel J, 2010, SCIENCE, V327, P348, DOI 10.1126/science.1183090; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sathyan P, 2007, J NEUROSCI, V27, P8546, DOI 10.1523/JNEUROSCI.1269-07.2007; Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823; Staddon JER, 2010, J EXP ANAL BEHAV, V94, P261, DOI 10.1901/jeab.2010.94-261; Tonelli DD, 2008, DEVELOPMENT, V135, P3911, DOI 10.1242/dev.025080; Treistman SN, 2009, TRENDS NEUROSCI, V32, P629, DOI 10.1016/j.tins.2009.08.001; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wolman M, 2012, DEV NEUROBIOL, V72, P366, DOI 10.1002/dneu.20872; Zehir A, 2010, DEV BIOL, V340, P459, DOI 10.1016/j.ydbio.2010.01.039	57	58	60	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1452	1461		10.1096/fj.11-194464	http://dx.doi.org/10.1096/fj.11-194464			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22253472	Green Published			2022-12-28	WOS:000302359700008
J	Tarcic, G; Avraham, R; Pines, G; Amit, I; Shay, T; Lu, YL; Zwang, Y; Katz, M; Ben-Chetrit, N; Jacob-Hirsch, J; Virgilio, L; Rechavi, G; Mavrothalassitis, G; Mills, GB; Domany, E; Yarden, Y				Tarcic, Gabi; Avraham, Roi; Pines, Gur; Amit, Ido; Shay, Tal; Lu, Yiling; Zwang, Yaara; Katz, Menachem; Ben-Chetrit, Nir; Jacob-Hirsch, Jasmine; Virgilio, Laura; Rechavi, Gideon; Mavrothalassitis, George; Mills, Gordon B.; Domany, Eytan; Yarden, Yosef			EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF	FASEB JOURNAL			English	Article						growth factor; phosphorylation; transcription; negative feedback	TRANSCRIPTION FACTOR EGR1; EARLY GROWTH RESPONSE-1; MEDIATED MOTILITY; FEEDBACK LOOP; MAP KINASE; IN-VIVO; PROTEIN; CANCER; P53; CONTRIBUTES	The signaling pathways that commit cells to migration are incompletely understood. We employed human mammary cells and two stimuli: epidermal growth factor (EGF), which induced cellular migration, and serum factors, which stimulated cell growth. In addition to strong activation of ERK by EGF, and AKT by serum, early transcription remarkably differed: while EGF induced early growth response-1 (EGR1), and this was required for migration, serum induced c-Fos and FosB to enhance proliferation. We demonstrate that induction of EGR1 involves ERK-mediated down-regulation of microRNA-191 and phosphorylation of the ETS2 repressor factor (ERF) repressor, which subsequently leaves the nucleus. Unexpectedly, knockdown of ERF inhibited migration, which implies migratory roles for exported ERF molecules. On the other hand, chromatin immunoprecipitation identified a subset of direct EGR1 targets, including EGR1 autostimulation and SERPINB2, whose transcription is essential for EGF-induced cell migration. In summary, EGR1 and the EGF-ERK-ERF axis emerge from our study as major drivers of growth factor-induced mammary cell migration.-Tarcic, G., Avraham, R., Pines, G., Amit, I., Shay, T., Lu, Y., Zwang, Y., Katz, M., Ben-Chetrit, N., Jacob-Hirsch, J., Virgilio, L., Rechavi, G., Mavrothalassitis, G., Mills, G. B., Domany, E., Yarden, Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 26, 1582-1592 (2012). www.fasebj.org	[Tarcic, Gabi; Avraham, Roi; Pines, Gur; Amit, Ido; Zwang, Yaara; Katz, Menachem; Ben-Chetrit, Nir; Yarden, Yosef] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Shay, Tal; Domany, Eytan] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; [Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Jacob-Hirsch, Jasmine; Rechavi, Gideon] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, IL-52621 Tel Hashomer, Israel; [Jacob-Hirsch, Jasmine; Rechavi, Gideon] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Virgilio, Laura; Mavrothalassitis, George] Univ Crete, Sch Med, Iraklion, Greece; [Virgilio, Laura; Mavrothalassitis, George] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece	Weizmann Institute of Science; Weizmann Institute of Science; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012; Pines, Gur/X-7501-2019; DOMANY, EYTAN/K-1560-2012; Shay, Tal/J-4028-2016	Pines, Gur/0000-0002-1757-6722; Shay, Tal/0000-0003-0755-1350; Avraham, Roi/0000-0002-9098-3885	U.S. National Cancer Institute [CA072981, CA121994-01, CA120248-01]; European Commission; German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; M. D. Moross Institute for Cancer Research; Susan G. Komen Foundation; NATIONAL CANCER INSTITUTE [R21CA120248, P50CA098258, R37CA072981, R01CA072981, P30CA016672, K23CA121994] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Commission(European CommissionEuropean Commission Joint Research Centre); German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; M. D. Moross Institute for Cancer Research; Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge research funding by the U.S. National Cancer Institute (CA072981, CA121994-01, and CA120248-01); the European Commission; the German-Israeli Project Cooperation; the Israel Cancer Research Fund; the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; the Kekst Family Institute for Medical Genetics; the Kirk Center for Childhood Cancer and Immunological Disorders; the Women's Health Research Center, funded by the Bennett-Pritzker Endowment Fund; the Marvelle Koffler Program for Breast Cancer Research; the Leir Charitable Foundation; the M. D. Moross Institute for Cancer Research; and The Susan G. Komen Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. E. D. is the recipient of the Henry J. Leir Professorial Chair.	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; Cermak V, 2010, CELL MOL LIFE SCI, V67, P3557, DOI 10.1007/s00018-010-0395-6; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Cohen-Saidon C, 2009, MOL CELL, V36, P885, DOI 10.1016/j.molcel.2009.11.025; Collins S, 2008, EUR J IMMUNOL, V38, P528, DOI 10.1002/eji.200737157; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; Damm S, 2010, J INVEST DERMATOL, V130, P1893, DOI 10.1038/jid.2010.45; de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200; Fitzgerald JS, 2005, CHEM IMMUNOL ALLERGY, V88, P181, DOI 10.1159/000087834; Gilles C, 1999, J CELL SCI, V112, P4615; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kasneci A, 2009, CARDIOVASC RES, V81, P695, DOI 10.1093/cvr/cvn357; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kholodenko BN, 2010, NAT REV MOL CELL BIO, V11, P414, DOI 10.1038/nrm2901; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Laufs S, 2006, CELL CYCLE, V5, P1760; Lawson MA, 2007, MOL ENDOCRINOL, V21, P1175, DOI 10.1210/me.2006-0392; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; McCawley LJ, 1997, ENDOCRINOLOGY, V138, P121, DOI 10.1210/en.138.1.121; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morishige M, 2008, NAT CELL BIOL, V10, P85, DOI 10.1038/ncb1672; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; SCHLEGEL J, 1994, J NEURO-ONCOL, V22, P201, DOI 10.1007/BF01052920; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; TAIT L, 1990, CANCER RES, V50, P6087; Tang C, 2010, ELECTROPHORESIS, V31, P2936, DOI 10.1002/elps.201000094; von Kriegsheim A, 2009, NAT CELL BIOL, V11, P1458, DOI 10.1038/ncb1994; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Xian CJ, 2004, FRONT BIOSCI-LANDMRK, V9, P85, DOI 10.2741/1210; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	55	71	72	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1582	1592		10.1096/fj.11-194654	http://dx.doi.org/10.1096/fj.11-194654			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198386	Green Published			2022-12-28	WOS:000302359700020
J	Hesdorffer, CS; Malchinkhuu, E; Biragyn, A; Mabrouk, OS; Kennedy, RT; Madara, K; Taub, DD; Longo, DL; Schwartz, JB; Ferrucci, L; Goetzl, EJ				Hesdorffer, Charles S.; Malchinkhuu, Enkhzol; Biragyn, Arya; Mabrouk, Omar S.; Kennedy, Robert T.; Madara, Karen; Taub, Dennis D.; Longo, Dan L.; Schwartz, Janice B.; Ferrucci, Luigi; Goetzl, Edward J.			Distinctive immunoregulatory effects of adenosine on T cells of older humans	FASEB JOURNAL			English	Article						cytokines; cellular antigens; chemotaxis; immunosenescence; immunodeficiency	EXPRESSION; LYMPHOCYTES; ACTIVATION; CD39; INTERLEUKIN-2; CD73	A role for adenosine in immunosenescence was investigated in T cells from older (>= 65 yr) and younger (24-45 yr) healthy humans. Adenosine concentrations in cultures of activated T cells were significantly higher (P<0.0001) for older (145 +/- 47 nM, mean +/- SD) than younger (58 +/- 5.5 nM) subjects. Expression of the activation coreceptor CD28 was suppressed significantly by 0.1 to 1 mu M exogenous adenosine, with greater effects of 1 mu M (P<0.01) on T cells of younger (mean suppression of 67 and 65% for CD4 and CD8 T cells, respectively) than older (means of 42 and 46%) subjects. T-cell chemotaxis to CCL21 was suppressed significantly by 0.3 and 1 mu M exogenous adenosine, with mean maximum decreases of 39 and 49%, respectively, for younger subjects and 28 and 31% for older subjects. Generation of IL-2 and IFN-gamma by T cells of younger and older subjects was suppressed substantially only at adenosine levels of 3 mu M or higher. Lower baseline expression of CD28 and chemotaxis to CCL21 and S1P for T cells from older subjects attributable to endogenous adenosine were reversed completely by two different A(2A) adenosine receptor antagonists without affecting T cells of younger subjects. Adenosine is an endogenous T-cell immunosuppressor in older humans, and A(2A) antagonists reverse adenosine-induced T-cell deficiencies of aging.-Hesdorffer, H. S., Malchinkhuu, E., Biragyn, A., Mabrouk, O. S., Kennedy, R. T., Madara, K., Taub, D. D., Longo, D. L., Schwartz, J. B., Ferrucci, L., Goetzl, E. J. Distinctive immunoregulatory effects of adenosine on T cells of older humans. FASEB J. 26, 1301-1310 (2012). www.fasebj.org	[Goetzl, Edward J.] JHSF, Geriatr Res Ctr, Geriatr Res Labs, San Francisco, CA 94112 USA; [Hesdorffer, Charles S.; Malchinkhuu, Enkhzol; Biragyn, Arya; Madara, Karen; Taub, Dennis D.; Longo, Dan L.; Ferrucci, Luigi; Goetzl, Edward J.] NIA, NIH, Baltimore, MD 21224 USA; [Mabrouk, Omar S.; Kennedy, Robert T.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), JHSF, Geriatr Res Ctr, Geriatr Res Labs, 302 Silver Ave, San Francisco, CA 94112 USA.	edward.goetzl@ucsf.edu	Longo, Dan L./F-6022-2011; Schwartz, Janice/K-6354-2019; Malchinkhuu, Enkhzol/AAH-4600-2019; Kennedy, Robert/G-9095-2016	Kennedy, Robert/0000-0003-2447-7471; Malchinkhuu, Enkhzol/0000-0003-0744-079X	U.S. National Institute on Aging; Jewish Home of San Francisco; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB003320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000104, ZIAAG000443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007268] Funding Source: NIH RePORTER	U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Jewish Home of San Francisco; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was supported by the intramural research program of the U.S. National Institute on Aging and endowment funds of the Jewish Home of San Francisco. The authors are grateful to Judith H. Goetzl for preparation of the figures and tables. C. S. H., E. M., A. B., O.S.M., R. T. K., J.B.S., and E.J.G. designed research; C. S. H., K. M., J.B.S., and L. F. evaluated and selected subjects; C. S. H., E. M., O.S.M., D. D. T., and E.J.G. performed laboratory research; C. S. H., E. M., O.S.M., D. L. L., L. F., and E.J.G. analyzed data and wrote the paper.	Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Algars A, 2011, BLOOD, V117, P4387, DOI 10.1182/blood-2010-11-321646; Blay J, 1997, CANCER RES, V57, P2602; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Butler JJ, 2003, J CELL BIOCHEM, V89, P975, DOI 10.1002/jcb.10562; Caruso C, 1996, IMMUNOL RES, V15, P84, DOI 10.1007/BF02918286; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; DOSREIS GA, 1986, CELL IMMUNOL, V101, P213, DOI 10.1016/0008-8749(86)90199-1; El Yacoubi M, 2001, BRIT J PHARMACOL, V134, P68, DOI 10.1038/sj.bjp.0704240; Ernst PB, 2010, J IMMUNOL, V185, P1993, DOI 10.4049/jimmunol.1000108; Gessi S, 2007, PURINERG SIGNAL, V3, P109, DOI 10.1007/s11302-006-9042-y; GILLIS S, 1981, J CLIN INVEST, V67, P937, DOI 10.1172/JCI110143; Grahler MH, 2005, J IMMUNOL, V174, P1997; Himer L, 2010, FASEB J, V24, P2631, DOI 10.1096/fj.10-155192; Hoskin DW, 2008, INT J ONCOL, V32, P527; Huang MC, 2011, CLIN IMMUNOL, V138, P201, DOI 10.1016/j.clim.2010.11.002; Kase H., 1999, ADENOSINE RECEPTORS; Olkhanud PB, 2011, CANCER RES, V71, P3505, DOI 10.1158/0008-5472.CAN-10-4316; Parish ST, 2010, J IMMUNOL, V184, P2847, DOI 10.4049/jimmunol.0903647; Rea IM, 1996, GERONTOLOGY, V42, P69, DOI 10.1159/000213775; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Shook BC, 2010, J MED CHEM, V53, P8104, DOI 10.1021/jm100971t; Takedachi M, 2008, J IMMUNOL, V180, P6288, DOI 10.4049/jimmunol.180.9.6288; Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013; Zheng YH, 2000, FASEB J, V14, P2387; Zhoua Q, 2009, AM J TRANSPLANT, V9, P2303, DOI 10.1111/j.1600-6143.2009.02777.x	26	11	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1301	1310		10.1096/fj.11-197046	http://dx.doi.org/10.1096/fj.11-197046			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22121051	Green Published, Green Submitted			2022-12-28	WOS:000300949300032
J	Charan, RA; Hanson, R; Clemens, PR				Charan, Rakshita A.; Hanson, Ryan; Clemens, Paula R.			Deubiquitinating enzyme A20 negatively regulates NF-kappa B signaling in skeletal muscle in mdx mice	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; inflammation; regeneration; differentiation; TNFAIP3	DUCHENNE MUSCULAR-DYSTROPHY; ZINC-FINGER PROTEIN; CELL-DIFFERENTIATION; GENE-PRODUCTS; MOUSE MUSCLE; NECROSIS; ACTIVATION; EXPRESSION; FIBERS; DEATH	Duchenne muscular dystrophy (DMD) is caused by the lack of a functional dystrophin protein that results in muscle fiber membrane disruption and, ultimately, degeneration. Regeneration of muscle fibers fails progressively, and muscle tissue is replaced with connective tissue. As a result, DMD causes progressive limb muscle weakness and cardiac and respiratory failure. The absence of dystrophin from muscle fibers triggers the chronic activation of the nuclear factor of kappa B (NF-kappa B). Chronic activation of NF-kappa B in muscle leads to infiltration of macrophages, up-regulation of the ubiquitin-proteosome system, and down-regulation of the helix-loop-helix muscle regulatory factor, MyoD. These processes, triggered by NF-kappa B activation, promote muscle degeneration and failure of muscle regeneration. A20 (TNFAIP3) is a critical negative regulator of NF-kappa B. In this study, we characterize the role of A20 in regulating NF-kappa B activation in skeletal muscle, identifying a novel role in muscle regeneration. A20 is highly expressed in regenerating muscle fibers, and knockdown of A20 impairs muscle differentiation in vitro, which suggests that A20 expression is critically important for regeneration of dystrophic muscle tissue. Furthermore, down-regulation of the classic pathway of NF-kappa B activation is associated with up-regulation of the alternate pathway in regenerating muscle fibers, suggesting a mechanism by which A20 promotes muscle regeneration. These results demonstrate the important role of A20 in muscle fiber repair and suggest the potential of A20 as a therapeutic target to ameliorate the pathology and clinical symptoms of DMD.-Charan, R. A., Hanson, R., Clemens, P. R. Deubiquitinating enzyme A20 negatively regulates NF-kappa B signaling in skeletal muscle in mdx mice. FASEB J. 26, 587-595 (2012). www.fasebj.org	[Charan, Rakshita A.; Hanson, Ryan; Clemens, Paula R.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA; [Charan, Rakshita A.; Clemens, Paula R.] Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clemens, PR (corresponding author), Univ Pittsburgh, Dept Neurol, Sch Med, S520 Biomed Sci Tower,203 Lothrop St, Pittsburgh, PA 15213 USA.	pclemens@pitt.edu		Hanson, Ryan/0000-0002-2564-3710	VA Merit Review grant; University of Pittsburgh	VA Merit Review grant(US Department of Veterans Affairs); University of Pittsburgh(University of Pittsburgh)	The authors thank Daniel Reay and Gabriela Niizawa for technical assistance and advice. This work was supported by a VA Merit Review grant and University of Pittsburgh departmental funds. The authors take full responsibility for the contents of this paper, which do not represent the views of the Department of Veterans Affairs or the U.S. Government.	Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556; Bakkar N, 2008, J CELL BIOL, V180, P787, DOI 10.1083/jcb.200707179; Bakkar N, 2010, PHYSIOL REV, V90, P495, DOI 10.1152/physrev.00040.2009; Batchelor CL, 2006, TRENDS CELL BIOL, V16, P198, DOI 10.1016/j.tcb.2006.02.001; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; Dahlman JM, 2010, J BIOL CHEM, V285, P5479, DOI 10.1074/jbc.M109.075606; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Grounds MD, 2004, FASEB J, V18, P676, DOI 10.1096/fj.03-1024com; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hnia K, 2008, AM J PATHOL, V172, P1509, DOI 10.2353/ajpath.2008.071009; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Jiang ZL, 2006, FASEB J, V20, P2570, DOI 10.1096/fj.06-6347fje; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kumamoto T, 2000, ACTA NEUROPATHOL, V100, P595, DOI 10.1007/s004010000229; Kunter U, 2005, KIDNEY INT, V68, P1520, DOI 10.1111/j.1523-1755.2005.00564.x; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Monici MC, 2003, NEUROLOGY, V60, P993, DOI 10.1212/01.WNL.0000049913.27181.51; Nordquist J, 2007, MOL MED, V13, P461, DOI 10.2119/2006-00066.Nordquist; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Pan Y, 2008, MOL CELLS, V25, P531; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Tran TM, 2009, APOPTOSIS, V14, P320, DOI 10.1007/s10495-009-0311-4; Verstrepen L, 2010, BIOCHEM PHARMACOL, V80, P2009, DOI 10.1016/j.bcp.2010.06.044; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	38	11	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					587	595		10.1096/fj.11-189829	http://dx.doi.org/10.1096/fj.11-189829			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22012122				2022-12-28	WOS:000300485700012
J	Chipumuro, E; Henriksen, MA				Chipumuro, Edmond; Henriksen, Melissa A.			The ubiquitin hydrolase USP22 contributes to 3 '-end processing of JAK-STAT-inducible genes	FASEB JOURNAL			English	Article						epigenetics; histone modifications; chromatin; transcription; interferon-gamma	RNA-POLYMERASE-II; HISTONE H2B UBIQUITYLATION; STEM-CELL MARKER; MESSENGER-RNA; CHROMATIN MODIFICATIONS; TRANSCRIPTION ELONGATION; POLY(A) SIGNAL; END FORMATION; P-TEFB; COMPLEX	The JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway drives cellular growth, differentiation, and the immune response. STAT-activated gene expression is both rapid and transient and requires dynamic post-translational modification of the chromatin template. We previously showed that monoubiquitination of histone H2B (ubH2B) is highly dynamic at the STAT1 target gene, interferon regulatory factor 1 (IRF1), suggesting that a deubiquitinase is recruited during gene activation. Here, we report that RNAi-mediated knockdown of the ubiquitin hydrolase, USP22, results in 2-fold higher ubH2B, and 2-fold lower transcriptional elongation at IRF1. We also demonstrate that USP22 depletion diminishes 3'-end cleavage/polyadenylation by 2- to 3-fold. Furthermore, the polyadenylation factor CPSF73 is not effectively recruited, and serine 2 phosphorylation (Ser2P) of the C-terminal domain of RNA polymerase II is also disrupted. The transcriptional and processing defects observed in the USP22-knockdown cells are reversed by transient USP22 overexpression. Together, these results suggest that ubH2B helps recruit polyadenylation factors to STAT1-activated genes. We propose a working model, wherein a cycle of H2B ubiquitination/deubiquitination specifies Ser2P to regulate elongation and 3'-end processing of JAK-STAT-inducible mRNAs. These results further elaborate USP22 function and its role as a putative cancer stem cell marker.-Chipumuro, E., Henriksen, M. A. The ubiquitin hydrolase USP22 contributes to 3'-end processing of JAK-STAT inducible genes. FASEB J. 26, 842-854 (2012). www.fasebj.org	[Chipumuro, Edmond; Henriksen, Melissa A.] Univ Virginia, Dept Biol, 485 McCormick Rd, Charlottesville, VA 22903 USA	University of Virginia	Henriksen, MA (corresponding author), Univ Virginia, Dept Biol, 485 McCormick Rd, Charlottesville, VA 22903 USA.	mah2hx@virginia.edu						Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Ansari A, 2005, GENE DEV, V19, P2969, DOI 10.1101/gad.1362305; Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Buro Lauren J, 2010, J Vis Exp, DOI 10.3791/2053; Buro LJ, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-16; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Glover-Cutter K, 2008, NAT STRUCT MOL BIOL, V15, P71, DOI 10.1038/nsmb1352; Hampsey M, 2011, ADV ENZYME REGUL, V51, P118, DOI 10.1016/j.advenzreg.2010.10.001; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hershkovits G, 2006, P NATL ACAD SCI USA, V103, P9808, DOI 10.1073/pnas.0602014103; Jaehning JA, 2010, BBA-GENE REGUL MECH, V1799, P379, DOI 10.1016/j.bbagrm.2010.01.001; Khaladkar M, 2011, RNA BIOL, V8, P529, DOI 10.4161/rna.8.3.15194; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lang G, 2011, MOL CELL BIOL, V31, P3734, DOI 10.1128/MCB.05231-11; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li B, 2009, J BIOL CHEM, V284, P7970, DOI 10.1074/jbc.M808220200; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; Millevoi S, 2010, NUCLEIC ACIDS RES, V38, P2757, DOI 10.1093/nar/gkp1176; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; Nag A, 2006, RNA, V12, P1534, DOI 10.1261/rna.103206; Nakanishi S, 2009, J CELL BIOL, V186, P371, DOI 10.1083/jcb.200906005; O'Sullivan JM, 2004, NAT GENET, V36, P1014, DOI 10.1038/ng1411; Orozco IJ, 2002, J BIOL CHEM, V277, P42899, DOI 10.1074/jbc.M207415200; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Spies N, 2009, MOL CELL, V36, P245, DOI 10.1016/j.molcel.2009.10.008; Suganuma T, 2008, CELL, V135, P604, DOI 10.1016/j.cell.2008.10.036; Tomson BN, 2011, GENETICS, V188, P273, DOI 10.1534/genetics.111.128645; Wagner EJ, 2007, MOL CELL, V28, P692, DOI 10.1016/j.molcel.2007.10.009; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014; Wood A, 2006, CELL CYCLE, V5, P1066, DOI 10.4161/cc.5.10.2769; Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08; WYCE A, 2004, NOVART FDN SYMP, V259, P73; WYCE A, 2004, NOVART FDN SYMP, V259, P163; Wyce A, 2007, MOL CELL, V27, P275, DOI 10.1016/j.molcel.2007.01.035; Wyce Anastasia, 2004, Novartis Found Symp, V259, P63; Zhang XY, 2008, CELL CYCLE, V7, P1522, DOI 10.4161/cc.7.11.5962; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	69	29	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					842	854		10.1096/fj.11-189498	http://dx.doi.org/10.1096/fj.11-189498			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22067483				2022-12-28	WOS:000300485700035
J	Renner, P; Roger, T; Bochud, PY; Sprong, T; Sweep, FCGJ; Bochud, M; Faust, SN; Haralambous, E; Betts, H; Chanson, AL; Reymond, MK; Mermel, E; Erard, V; van Deuren, M; Read, RC; Levin, M; Calandra, T				Renner, Pascal; Roger, Thierry; Bochud, Pierre-Yves; Sprong, Tom; Sweep, Fred C. G. J.; Bochud, Murielle; Faust, Saul N.; Haralambous, Elene; Betts, Helen; Chanson, Anne-Laure; Reymond, Marlies Knaup; Mermel, Elliot; Erard, Veronique; van Deuren, Marcel; Read, Robert C.; Levin, Michael; Calandra, Thierry			A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease	FASEB JOURNAL			English	Article						sepsis; Neisseria meningitidis; gene polymorphism; cytokine	JUVENILE IDIOPATHIC ARTHRITIS; INNATE IMMUNE-RESPONSES; TOLL-LIKE RECEPTOR-4; P38 MAP KINASE; FACTOR MIF; PROMOTER POLYMORPHISM; REGULATORY ROLE; SEVERE SEPSIS; SEPTIC SHOCK; KAPPA-B	Macrophage migration inhibitory factor (MIF) is an abundantly expressed proinflammatory cytokine playing a critical role in innate immunity and sepsis and other inflammatory diseases. We examined whether functional MIF gene polymorphisms (-794 CATT5-8 microsatellite and -173 G/C SNP) were associated with the occurrence and outcome of meningococcal disease in children. The CATT5 allele was associated with the probability of death predicted by the Pediatric Index of Mortality 2 (P = 0.001), which increased in correlation with the CATT5 copy number (P = 0.04). The CATT5 allele, but not the -173 G/C alleles, was also associated with the actual mortality from meningoccal sepsis [OR 2.72 (1.2-6.4), P = 0.02]. A family-based association test (i.e., transmission disequilibrium test) performed in 240 trios with 1 afflicted offspring indicated that CATT5 was a protective allele (P = 0.02) for the occurrence of meningococcal disease. At baseline and after stimulation with Neisseria meningitidis in THP-1 monocytic cells or in a whole-blood assay, CATT5 was found to be a low-expression MIF allele (P = 0.005 and P = 0.04 for transcriptional activity; P = 0.09 and P = 0.09 for MIF production). Taken together, these data suggest that polymorphisms of the MIF gene affecting MIF expression are associated with the occurrence, severity, and outcome of meningococcal disease in children.-Renner, P., Roger, T., Bochud, P.-Y., Sprong, T., Sweep, F. C. G. J., Bochud, M., Faust, S. N., Haralambous, E., Betts, H., Chanson, A.-L., Reymond, M. K., Mermel, E., Erard, V., van Deuren, M., Read, R. C., Levin, M., Calandra, T. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J. 26, 907-916 (2012). www.fasebj.org	[Renner, Pascal; Roger, Thierry; Bochud, Pierre-Yves; Chanson, Anne-Laure; Reymond, Marlies Knaup; Mermel, Elliot; Erard, Veronique; Calandra, Thierry] CHU Vaudois, Infect Dis Serv, Dept Med, CH-1011 Lausanne, Switzerland; [Bochud, Murielle] CHU Vaudois, Inst Social & Prevent Med, CH-1011 Lausanne, Switzerland; [Bochud, Murielle] Univ Lausanne, Lausanne, Switzerland; [Sprong, Tom; van Deuren, Marcel] Radboud Univ Nijmegen, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Sprong, Tom; van Deuren, Marcel] Radboud Univ Nijmegen, Nijmegen Inst Infect Inflammat & Immun N4I, NL-6525 ED Nijmegen, Netherlands; [Sweep, Fred C. G. J.] Radboud Univ Nijmegen, Dept Lab Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Sprong, Tom] Canisius Wilhelmina Ziekenhuis Nijmegen, Dept Internal Med, Nijmegen, Netherlands; [Faust, Saul N.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Sprong, Tom] Canisius Wilhelmina Ziekenhuis Nijmegen, Dept Med Microbiol, Nijmegen, Netherlands; [Faust, Saul N.] Southampton Univ Hosp, Natl Hlth Serv Fdn Trust, Southampton, Hants, England; [Faust, Saul N.] Wellcome Trust Res Labs, Clin Res Facil, Southampton, Hants, England; [Haralambous, Elene] Imperial Coll London St Marys Campus, Dept Pediat, London, England; [Betts, Helen; Levin, Michael] Imperial Coll London St Marys Campus, Div Infect Dis, Dept Med, London, England; [Read, Robert C.] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England; [Read, Robert C.] Sheffield Teaching Hosp Fdn Trust, Sheffield, S Yorkshire, England	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Canisius-Wilhelmina Hospital; University of Southampton; Canisius-Wilhelmina Hospital; University of Southampton; Imperial College London; Imperial College London; University of Sheffield	Calandra, T (corresponding author), CHU Vaudois, Infect Dis Serv, Dept Med, BH 10-555,Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	thierry.calandra@chuv.ch	Bochud, Murielle/A-3981-2010; Deuren, Marcel/O-1846-2013; Sweep, C.G.J./H-8096-2014; Calandra, Thierry/D-9017-2015; Faust, Saul/J-9779-2014; Bochud, Pierre-Yves/ABE-5979-2020; Roger, Thierry/G-2007-2012	Bochud, Murielle/0000-0002-5727-0218; Sweep, C.G.J./0000-0003-1103-3070; Calandra, Thierry/0000-0003-3051-1285; Faust, Saul/0000-0003-3410-7642; Roger, Thierry/0000-0002-9358-0109; Bochud, Pierre-Yves/0000-0002-2208-4757; Levin, Michael/0000-0003-2767-6919	Swiss National Science Foundation [3100_066972, 310000_118266]; Leenaards Foundation; Santos-Suarez Foundation for Medical Research; Meningitis Research Foundation, UK; Baxter AG (Vienna); University of Lausanne	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Leenaards Foundation; Santos-Suarez Foundation for Medical Research; Meningitis Research Foundation, UK(Meningitis Research Foundation (MRF)); Baxter AG (Vienna); University of Lausanne	The authors thank Francisca Tilves Pazos for blood drawing. This work was supported by the Swiss National Science Foundation (grants 3100_066972 and 310000_118266 to T. C.), the Leenaards Foundation (T. R. and T. C.), the Santos-Suarez Foundation for Medical Research (T. C.), and the Meningitis Research Foundation, UK (M. L.). T. C. has received research funding from and has been a consultant for Baxter AG (Vienna). E. M. was supported by the Summer Undergraduate Research (SUR) program of the University of Lausanne.	Aeberli D, 2006, FEBS LETT, V580, P974, DOI 10.1016/j.febslet.2006.01.027; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218; Awandare GA, 2006, GENES IMMUN, V7, P568, DOI 10.1038/sj.gene.6364332; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Balding J, 2003, GENES IMMUN, V4, P533, DOI 10.1038/sj.gene.6364020; Baugh JA, 2002, GENES IMMUN, V3, P170, DOI 10.1038/sj.gene.6363867; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Patrick KBA, 2008, J REPROD IMMUNOL, V77, P142, DOI 10.1016/j.jri.2007.07.004; Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Brouwer MC, 2009, LANCET INFECT DIS, V9, P31, DOI 10.1016/S1473-3099(08)70261-5; Bucala R, 2007, IMMUNITY, V26, P281, DOI 10.1016/j.immuni.2007.03.005; Burger-Kentischer A, 2006, ATHEROSCLEROSIS, V184, P28, DOI 10.1016/j.atherosclerosis.2005.03.028; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Daun JM, 2000, AM J PHYSIOL-REG I, V279, pR1043, DOI 10.1152/ajpregu.2000.279.3.R1043; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640; Delaloye J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000480; Doernberg S, 2011, CYTOKINE, V53, P292, DOI 10.1016/j.cyto.2010.12.010; Donn R, 2004, ARTHRITIS RHEUM-US, V50, P1604, DOI 10.1002/art.20178; Donn R, 2002, ARTHRITIS RHEUM-US, V46, P2402, DOI 10.1002/art.10492; Donn RP, 2001, ARTHRITIS RHEUM-US, V44, P1782, DOI 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#; Emonts M, 2003, LANCET INFECT DIS, V3, P565, DOI 10.1016/S1473-3099(03)00740-0; Emonts M, 2007, CLIN INFECT DIS, V44, P1321, DOI 10.1086/514344; Endler G, 2006, CLIN CHEM, V52, P511, DOI 10.1373/clinchem.2005.058537; Filip AM, 2009, J BIOL CHEM, V284, P7977, DOI 10.1074/jbc.M808620200; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818; Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007; Gregersen PK, 2003, ARTHRITIS RHEUM-US, V48, P1171, DOI 10.1002/art.10880; Greven D, 2010, EXPERT OPIN THER TAR, V14, P253, DOI 10.1517/14728220903551304; Haralambous E, 2003, CRIT CARE MED, V31, P2788, DOI 10.1097/01.CCM.0000100122.57249.5D; Haralambous E, 2003, EPIDEMIOL INFECT, V130, P413, DOI 10.1017/S0950268803008513; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kim KS, 2003, NAT REV NEUROSCI, V4, P376, DOI 10.1038/nrn1103; Kim KS, 2010, LANCET INFECT DIS, V10, P32, DOI 10.1016/S1473-3099(09)70306-8; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Laird NM, 2006, NAT REV GENET, V7, P385, DOI 10.1038/nrg1839; Le Roy D, 2001, J IMMUNOL, V167, P2759, DOI 10.4049/jimmunol.167.5.2759; Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022; Lehmann LE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-100; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Leng L, 2009, CYTOKINE, V48, P177, DOI 10.1016/j.cyto.2009.07.002; Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318; Lugrin J, 2009, BBA-MOL CELL RES, V1793, P1749, DOI 10.1016/j.bbamcr.2009.09.007; Martin RJL, 2010, DIABETIC MED, V27, P143, DOI 10.1111/j.1464-5491.2009.02916.x; Maxime V, 2005, J INFECT DIS, V191, P138, DOI 10.1086/426401; McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Plant BJ, 2005, AM J RESP CRIT CARE, V172, P1412, DOI 10.1164/rccm.200412-1714OC; Radstake TRDJ, 2005, ARTHRITIS RHEUM, V52, P3020, DOI 10.1002/art.21285; Renner P, 2005, CLIN INFECT DIS, V41, pS513, DOI 10.1086/432009; Roger T, 2005, EUR J IMMUNOL, V35, P3405, DOI 10.1002/eji.200535413; Roger T, 2005, BIOCHEM J, V387, P355, DOI 10.1042/BJ20041243; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Roger T, 2007, EUR J IMMUNOL, V37, P3509, DOI 10.1002/eji.200737357; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Santos LL, 2004, J RHEUMATOL, V31, P1038; Schwartz V, 2009, FEBS LETT, V583, P2749, DOI 10.1016/j.febslet.2009.07.058; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Smirnova I, 2003, P NATL ACAD SCI USA, V100, P6075, DOI 10.1073/pnas.1031605100; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Sprong T, 2007, SHOCK, V27, P482, DOI 10.1097/01.shk.0000246898.65692.34; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Veillat V, 2009, FERTIL STERIL, V91, P2148, DOI 10.1016/j.fertnstert.2008.05.017; Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097; Wright V, 2009, VACCINE, V27, pB90, DOI 10.1016/j.vaccine.2009.05.002; Yende S, 2009, FASEB J, V23, P2403, DOI 10.1096/fj.09-129445	79	42	42	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					907	916		10.1096/fj.11-195065	http://dx.doi.org/10.1096/fj.11-195065			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	21990375				2022-12-28	WOS:000300485700040
J	Zwaenepoel, O; Tzenaki, N; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA				Zwaenepoel, Olivier; Tzenaki, Niki; Vergetaki, Aikaterini; Makrigiannakis, Antonis; Vanhaesebroeck, Bart; Papakonstanti, Evangelia A.			Functional CSF-1 receptors are located at the nuclear envelope and activated via the p110 delta isoform of PI 3-kinase	FASEB JOURNAL			English	Article						nucleus; CSF-1R; p110 delta; PI3K; Rab5	COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; FMS PROTOONCOGENE PRODUCT; SMALL GTPASE RAB5; C-FMS; KINASE INHIBITOR; GROWTH-FACTOR; AUTOANTIGEN EEA1; EXPRESSION; CANCER	Colony stimulating factor-1 (CSF-1) and its receptor (CSF-1R) are key regulators of macrophage biology, and their elevated expression in cancer cells has been linked to poor prognosis. CSF-1Rs are thought to function at the plasma membrane. We show here that functional CSF-1Rs are present at the nuclear envelope of various cell types, including primary macrophages, human cancer cell lines, and primary human carcinomas. In response to CSF-1, added to intact cells or isolated nuclei, nucleus-associated CSF-1R became phosphorylated and triggered the phosphorylation of Akt and p27 inside the nucleus. Extracellularly added CSF-1 was also found to colocalize with nucleus-associated CSF-1Rs. All these activities were found to depend selectively on the activity of the p110 delta isoform of phosphoinositide 3-kinase (PI3K). This finding was related to the p110 delta-dependent translocation of exogenous CSF-1 to the nucleus-associated CSF-1Rs, correlating with a prominent role of p110 delta in activation of the Rab5 GTPase, a key regulator of the endocytic trafficking. siRNA-silencing of Rab5a phenocopied p110 delta inactivation and nuclear CSF-1 signaling. Our work demonstrates for the first time the presence of functional nucleus-associated CSF-1Rs, which are activated by extracellular CSF-1 by a mechanism that involves p110 delta and Rab5 activity. These findings may have important implications in cancer development.-Zwaenepoel, O., Tzenaki, N., Vergetaki A., Makrigiannakis, A., Vanhaesebroeck, B., Papakonstanti, E. A. Functional CSF-1 receptors are located at the nuclear envelope and activated via the p110 delta isoform of PI 3-kinase. FASEB J. 26, 691-706 (2012). www.fasebj.org	[Zwaenepoel, Olivier; Tzenaki, Niki; Papakonstanti, Evangelia A.] Univ Crete, Dept Biochem, Sch Med, GR-71110 Iraklion, Greece; [Vergetaki, Aikaterini; Makrigiannakis, Antonis] Univ Crete, Dept Obstet & Gynecol, Sch Med, GR-71110 Iraklion, Greece; [Vanhaesebroeck, Bart] Univ London, Ctr Cell Signalling, Barts Canc Inst, London, England	University of Crete; University of Crete; University of London; Queen Mary University London	Papakonstanti, EA (corresponding author), Univ Crete, Dept Biochem, Sch Med, GR-71110 Iraklion, Greece.	epapak@med.uoc.gr		Makrigiannakis, Antonis/0000-0002-8475-1500; Papakonstanti, Evangelia/0000-0002-7119-6026	European Reintegration Grant [MERG-CT-2006-044916]; Research Committee of the University of Crete [KA 2564, KA 2999, KA 3001]	European Reintegration Grant; Research Committee of the University of Crete	The authors thank Christian Rommel, Thomas Ruckle, and Montserrat Camps (Merck, Geneva, Switzerland) and Kevan Shokat (University of California, San Francisco, California, USA) for pharmacological agents. The authors are also grateful to E. Richard Stanley (Albert Einstein College of Medicine, New York, NY, USA) for providing MacCsf1r<SUP>+/+</SUP> and MacCsf1r<SUP>-/-</SUP> cell lines; Guangpu Li (University of Oklahoma, Norman, OK, USA) for the pGEX/R5BD construct; Jozsef Konya (University of Debrecen, Debrecen, Hungary) for Caski, Hela, and C33-A cell lines; Ines Koch (Charite University Hospital, Berlin, Germany) for CAOV3, OVCAR3, and ES2 cell lines; and Nicholas Pavlidis (Medical School, University of Ioannina, Ioannina, Greece) for the breast cancer tissue. O.Z. is supported by European Reintegration Grant (MERG-CT-2006-044916). N.T. is supported by the Research Committee of the University of Crete (KA 2999). This work was supported by the European Reintegration grant (MERG-CT-2006-044916) awarded to E. P. and by the Research Committee of the University of Crete (KA 2564, KA 2999, KA 3001).	Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Cress AE, 2000, BIOTECHNIQUES, V29, P776, DOI 10.2144/00294st03; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; Huang H, 2008, BIOORG MED CHEM LETT, V18, P2355, DOI 10.1016/j.bmcl.2008.02.070; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Illig CR, 2008, BIOORG MED CHEM LETT, V18, P1642, DOI 10.1016/j.bmcl.2008.01.059; Irvine KM, 2006, FASEB J, V20, P1921, DOI 10.1096/fj.06-5848fje; KACINSKI BM, 1989, YALE J BIOL MED, V62, P379; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kirma N, 2007, CANCER RES, V67, P1918, DOI 10.1158/0008-5472.CAN-06-1991; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Liu J, 2007, MOL BIOL CELL, V18, P1375, DOI 10.1091/mbc.E06-08-0725; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; Martelli AM, 2006, CELL SIGNAL, V18, P1101, DOI 10.1016/j.cellsig.2006.01.011; Martelli AM, 2004, PHARMACOL THERAPEUT, V101, P47, DOI 10.1016/j.pharmthera.2003.10.003; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Murayama T, 1999, CIRCULATION, V99, P1740, DOI 10.1161/01.CIR.99.13.1740; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Ohno H, 2006, MOL CANCER THER, V5, P2634, DOI 10.1158/1535-7163.MCT-05-0313; Okkenhaug K, 2002, SCIENCE, V297, P1031; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763; Patch RJ, 2007, BIOORG MED CHEM LETT, V17, P6070, DOI 10.1016/j.bmcl.2007.09.057; Patel S, 2009, CURR TOP MED CHEM, V9, P599, DOI 10.2174/156802609789007327; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; Robertson D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-13; Rosenfeld JL, 2001, J CELL SCI, V114, P4499; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smalley TL, 2007, BIOORG MED CHEM LETT, V17, P6257, DOI 10.1016/j.bmcl.2007.09.009; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STUURMAN N, 1990, J BIOL CHEM, V265, P5460; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Toy EP, 2009, NEOPLASIA, V11, P136, DOI 10.1593/neo.81150; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; Wainszelbaum MJ, 2006, EXP CELL RES, V312, P2238, DOI 10.1016/j.yexcr.2006.03.025; Wall MJ, 2008, BIOORG MED CHEM LETT, V18, P2097, DOI 10.1016/j.bmcl.2008.01.088; Wesche J, 2000, BIOCHEMISTRY-US, V39, P15091, DOI 10.1021/bi001831k; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; Yu WF, 2008, J LEUKOCYTE BIOL, V84, P852, DOI 10.1189/jlb.0308171	59	8	8	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					691	706		10.1096/fj.11-189753	http://dx.doi.org/10.1096/fj.11-189753			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22084313				2022-12-28	WOS:000300485700021
J	Baker, PJ				Baker, Phillip J.			The pain of "chronic Lyme disease": moving the discourse in a different direction	FASEB JOURNAL			English	Article						antibiotic therapy; diagnosis; diagnostic tests		About 30% of the population of the United States suffers from acute or chronic pain, often of unknown cause. Among this group might be included patients with symptoms claimed to be caused by a poorly defined condition called "chronic Lyme disease" in which chronic pain is a major contributor. Since there is no evidence to indicate that chronic Lyme disease is due to a persistent infection and that extended antibiotic therapy is beneficial and safe, this condition should not be viewed solely as an infectious disease problem. Rather, it should be considered within the context of a broad-based, multidisciplinary approach to determining the cause of chronic pain per se and developing more effective strategies for its treatment as outlined in a recent report on pain issued by the Institute of Medicine.-Baker, P. J. The pain of "chronic Lyme disease": moving the discourse in a different direction. FASEB J. 26, 11-12 (2012). www.fasebj.org	Amer Lyme Dis Fdn, Lyme, CT 06371 USA		Baker, PJ (corresponding author), Amer Lyme Dis Fdn, POB 466, Lyme, CT 06371 USA.	executivedir@aldf.com						[Anonymous], 2011, REL PAIN AM BLUEP TR; Fallon BA, 2008, NEUROLOGY, V70, P992, DOI 10.1212/01.WNL.0000284604.61160.2d; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Krupp LB, 2003, NEUROLOGY, V60, P1923, DOI 10.1212/01.WNL.0000071227.23769.9E; Kugeler KJ, 2011, CLIN INFECT DIS, V52, P364, DOI 10.1093/cid/ciq157; Schoen RT, 2011, NAT REV RHEUMATOL, V7, P179, DOI 10.1038/nrrheum.2010.209; Wormser GP, 2006, CLIN INFECT DIS, V43, P1089, DOI 10.1086/508667	8	6	8	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					11	12		10.1096/fj.11-192898	http://dx.doi.org/10.1096/fj.11-192898			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21900506	hybrid, Green Published			2022-12-28	WOS:000299202200003
J	Lin, YH; Jones, BW; Liu, AH; Tucker, JF; Rapp, K; Luo, L; Baehr, W; Bernstein, PS; Watt, CB; Yang, JH; Shaw, MV; Marc, RE				Lin, Yanhua; Jones, Bryan W.; Liu, Aihua; Tucker, James F.; Rapp, Kevin; Luo, Ling; Baehr, Wolfgang; Bernstein, Paul S.; Watt, Carl B.; Yang, Jia-Hui; Shaw, Marguerite V.; Marc, Robert E.			Retinoid receptors trigger neuritogenesis in retinal degenerations	FASEB JOURNAL			English	Article						retinoic acid; Ca2+/calmodulin-dependent protein kinase II; ionotropic glutamate receptor	CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-II; RETINITIS-PIGMENTOSA; ALL-TRANS; MOUSE RETINA; LIGHT DAMAGE; X-RECEPTOR; PHOTORECEPTOR DEGENERATIONS; MACULAR DEGENERATION; SYNAPTIC PLASTICITY	Anomalous neuritogenesis is a hallmark of neurodegenerative disorders, including retinal degenerations, epilepsy, and Alzheimer's disease. The neuritogenesis processes result in a partial reinnervation, new circuitry, and functional changes within the deafferented retina and brain regions. Using the light-induced retinal degeneration (LIRD) mouse model, which provides a unique platform for exploring the mechanisms underlying neuritogenesis, we found that retinoid X receptors (RXRs) control neuritogenesis. LIRD rapidly triggered retinal neuron neuritogenesis and up-regulated several key elements of retinoic acid (RA) signaling, including retinoid X receptors (RXRs). Exogenous RA initiated neuritogenesis in normal adult retinas and primary retinal cultures and exacerbated it in LIRD retinas. However, LIRD-induced neuritogenesis was partly attenuated in retinol dehydrogenase knockout (Rdh12(-/-)) mice and by aldehyde dehydrogenase inhibitors. We further found that LIRD rapidly increased the expression of glutamate receptor 2 and beta Ca2+/calmodulin-dependent protein kinase II (beta CaMKII). Pull-down assays demonstrated interaction between beta CaMKII and RXRs, suggesting that CaMKII pathway regulates the activities of RXRs. RXR antagonists completely prevented and RXR agonists were more effective than RA in inducing neuritogenesis. Thus, RXRs are in the final common path and may be therapeutic targets to attenuate retinal remodeling and facilitate global intervention methods in blinding diseases and other neurodegenerative disorders.-Lin, Y., Jones, B. W., Liu, A., Tucker, J. F., Rapp, K., Luo, L., Baehr, W., Bernstein, P. S., Watt, C. B., Yang, J.-H., Shaw, M. V., Marc, R. E. Retinoid receptors trigger neuritogenesis in retinal degenerations. FASEB J. 26, 81-92 (2012). www.fasebj.org	[Lin, Yanhua; Jones, Bryan W.; Liu, Aihua; Tucker, James F.; Rapp, Kevin; Luo, Ling; Baehr, Wolfgang; Bernstein, Paul S.; Watt, Carl B.; Yang, Jia-Hui; Shaw, Marguerite V.; Marc, Robert E.] Univ Utah, Dept Ophthalmol, John A Moran Eye Ctr, Sch Med, Salt Lake City, UT 84132 USA; [Baehr, Wolfgang] Univ Utah, Dept Neurobiol & Anat, Hlth Sci Ctr, Salt Lake City, UT 84132 USA; [Baehr, Wolfgang] Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Marc, RE (corresponding author), Univ Utah, Dept Ophthalmol, John A Moran Eye Ctr, Sch Med, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.	robert.marc@hsc.utah.edu		Jones, Bryan/0000-0001-5527-6643	U.S. National Eye Institute [EY002576, EY015128, EY014800, EY08123, EY019298]; Research to Prevent Blindness; Edward N. and Della L. Thome Memorial Foundation; Moran Eye Center Tiger Team; Fight For Sight; Knights Templar Eye Foundation; International Retinal Research Foundation; Foundation Fighting Blindness, Inc. (Columbia, MD, USA); NATIONAL EYE INSTITUTE [R01EY008123, R01EY002576, R01EY015128, P30EY014800, R01EY019298] Funding Source: NIH RePORTER	U.S. National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Edward N. and Della L. Thome Memorial Foundation; Moran Eye Center Tiger Team; Fight For Sight; Knights Templar Eye Foundation; International Retinal Research Foundation; Foundation Fighting Blindness, Inc. (Columbia, MD, USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This project was supported by U.S. National Eye Institute grants EY002576, EY015128, and EY014800 Vision Core (R. E. M.), EY08123 and EY019298 (W. B.); Research to Prevent Blindness (R. E. M. and B.W.J.); the Edward N. and Della L. Thome Memorial Foundation (B.W.J.), a Moran Eye Center Tiger Team Translational Medicine Award (B.W.J.), Fight For Sight (Y.H.L.), the Knights Templar Eye Foundation (Y.H.L.), the International Retinal Research Foundation (Y.H.L.), and a center grant by the Foundation Fighting Blindness, Inc. (Columbia, MD, USA), to the University of Utah. The authors thank Changjiang Zou for assisting with cell culture and immunoprecipitation; Dr. Ning Tian and Dr. Yingbin Fu for advice on manuscript revision; Cecilia Gerstner for breeding the Rdh12 mutation mice; Dr. Bala Ambati for assistance with retinal injection; Dr. Felix Vazquez-Chona for advice on manuscript organization; and Drew Ferrell for assistance on imaging.	Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; Aoto J, 2008, NEURON, V60, P308, DOI 10.1016/j.neuron.2008.08.012; Applebury ML, 2000, NEURON, V27, P513, DOI 10.1016/S0896-6273(00)00062-3; Bastie JN, 2001, FEBS LETT, V507, P67, DOI 10.1016/S0014-5793(01)02938-6; Beltowski J, 2008, CARDIOVASC THER, V26, P297, DOI 10.1111/j.1755-5922.2008.00062.x; Benav H, 2010, IEEE ENG MED BIO, P5919, DOI 10.1109/IEMBS.2010.5627549; Berry DC, 2010, J BIOL CHEM, V285, P15324, DOI 10.1074/jbc.M110.110635; Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897; Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2; Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Cvekl A, 2009, EXP EYE RES, V89, P280, DOI 10.1016/j.exer.2009.04.012; Dadon-Nachum M, 2011, J MOL NEUROSCI, V43, P470, DOI 10.1007/s12031-010-9467-1; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Deller T, 2006, ADV EXP MED BIOL, V557, P101; Dmetrichuk JM, 2005, DEV BIOL, V281, P112, DOI 10.1016/j.ydbio.2005.02.019; Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69; Duncan T, 1999, MOL VIS, V5, pU1; Duncan T, 2006, PHOTOCHEM PHOTOBIOL, V82, P741, DOI 10.1562/2005-10-05-RA-712; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elliott RC, 2003, J NEUROSCI, V23, P2218; Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fujikado T, 2011, INVEST OPHTH VIS SCI, V52, P4726, DOI 10.1167/iovs.10-6836; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Guizzetti M, 2008, J BIOL CHEM, V283, P31884, DOI 10.1074/jbc.M801316200; Gupta A, 2006, CANCER RES, V66, P8100, DOI 10.1158/0008-5472.CAN-05-4519; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Horsager A, 2010, INVEST OPHTH VIS SCI, V51, P1223, DOI 10.1167/iovs.09-3746; Hyatt GA, 1997, INVEST OPHTH VIS SCI, V38, P1471; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; Jones BW, 2006, ADV EXP MED BIOL, V572, P405; Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006; Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703; Kikonyogo A, 1999, EUR J BIOCHEM, V262, P704, DOI 10.1046/j.1432-1327.1999.00415.x; Koulen P, 1998, J NEUROSCI, V18, P10136; LARNER AJ, 1995, SEIZURE, V4, P249, DOI 10.1016/S1059-1311(95)80001-8; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Liets LC, 2006, P NATL ACAD SCI USA, V103, P12156, DOI 10.1073/pnas.0605211103; Liu LO, 2000, MOL BRAIN RES, V82, P150, DOI 10.1016/S0169-328X(00)00203-5; Liu SH, 2004, NEURON, V43, P43, DOI 10.1016/j.neuron.2004.06.017; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Maden M, 2007, NAT REV NEUROSCI, V8, P755, DOI 10.1038/nrn2212; Maeda A, 2006, J BIOL CHEM, V281, P37697, DOI 10.1074/jbc.M608375200; Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200; Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Marc RE, 2000, J COMP NEUROL, V425, P560, DOI 10.1002/1096-9861(20001002)425:4<560::AID-CNE7>3.0.CO;2-D; Marc RE, 2010, ENCY EYE, P414; Marc Robert E., 2006, P33, DOI 10.1007/0-387-28190-8_3; Marc RE, 2008, MOL VIS, V14, P782; Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032; Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Nahoum V, 2007, P NATL ACAD SCI USA, V104, P17323, DOI 10.1073/pnas.0705356104; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004; Pan F, 2010, J COMP NEUROL, V518, P911, DOI 10.1002/cne.22254; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Puthussery T, 2009, EUR J NEUROSCI, V29, P1533, DOI 10.1111/j.1460-9568.2009.06728.x; Rongo C, 1999, NATURE, V402, P195, DOI 10.1038/46065; SCHEIBEL AB, 1978, EXP NEUROL, V60, P1, DOI 10.1016/0014-4886(78)90164-4; Si JT, 2007, J CLIN INVEST, V117, P1412, DOI 10.1172/JCI30779; Sigulinsky CL, 2008, DEV BIOL, V317, P560, DOI 10.1016/j.ydbio.2008.02.055; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Strettoi E, 2002, J NEUROSCI, V22, P5492; Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010; Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006; Uehara H, 2010, VISION RES, V50, P674, DOI 10.1016/j.visres.2009.12.003; Wasowicz M, 2002, INVEST OPHTH VIS SCI, V43, P813; Weiler R, 1998, P NATL ACAD SCI USA, V95, P7139, DOI 10.1073/pnas.95.12.7139; WEILER R, 1995, EUR J NEUROSCI, V7, P1914, DOI 10.1111/j.1460-9568.1995.tb00713.x; Yang PB, 2010, EXP EYE RES, V91, P727, DOI 10.1016/j.exer.2010.08.022; Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149; Zhang HB, 2011, NAT NEUROSCI, V14, P874, DOI 10.1038/nn.2835; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	84	21	24	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					81	92		10.1096/fj.11-192914	http://dx.doi.org/10.1096/fj.11-192914			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21940995	Green Published			2022-12-28	WOS:000299202200010
J	Baker, JM; De Lisio, M; Parise, G				Baker, J. M.; De Lisio, Michael; Parise, Gianni			Endurance exercise training promotes medullary hematopoiesis	FASEB JOURNAL			English	Article						bone marrow; blood; mesenchymal; cytokine; skeletal muscle	COLONY-STIMULATING FACTOR; MESENCHYMAL STEM-CELLS; BONE-MARROW ADIPOCYTES; HUMAN SKELETAL-MUSCLE; ADIPOSE-TISSUE; MESSENGER-RNA; GM-CSF; ERYTHROPOIETIN; PROGENITORS; EXPRESSION	Endurance exercise is a poorly defined yet powerful mediator of hematopoiesis. The purpose of this study was to directly investigate the effects of endurance exercise training on hematopoiesis and to identify potential mechanisms responsible for any observed changes. Four-week-old male C57Bl/6 mice were trained on a treadmill at progressive speeds over a 10-wk period. Tissues were harvested 2 d following the final training session. Flow cytometry, the cobblestone area-forming cell assay, and the methycellulose colony-forming unit assay were used to assess medullary and mobilized hematopoietic stem and progenitor cells. Quantitative real-time PCR and Western blots were used to measure hematopoietic cytokine production. Histochemistry was also used to assess adaptations to exercise in the bone marrow niche. Depending on the cell type, endurance training increased medullary and mobilized hematopoietic stem and progenitor cell content from 50 to 800%. Training also reduced marrow cavity fat by 78%. Skeletal muscle hematopoietic cytokine expression was also increased at least 60% by training. Sedentary mice served as controls for the above experiments. In conclusion, endurance exercise training greatly promotes hematopoiesis and does so through improvements in medullary niche architecture as well as increased skeletal muscle hematopoietic cytokine production.-Baker, J. M., De Lisio, M., Parise, G. Endurance exercise training promotes medullary hematopoiesis. FASEB J. 25, 4348-4357 (2011). www.fasebj.org	[Baker, J. M.; De Lisio, Michael; Parise, Gianni] McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada; [Parise, Gianni] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Parise, G (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada.	pariseg@mcmaster.ca			Canadian Institutes of Health Research (CIHR) [96344]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Authorship contribution was as follows: J.B. designed and performed experiments, analyzed data, and wrote the manuscript; M. D. designed and performed experiments and analyzed data; G. P. designed experiments, supervised the project, and edited the manuscript. The authors declare no competing financial interests. This study was supported by Canadian Institutes of Health Research (CIHR) grant 96344 (to G.P.). M.D. was supported by a CIHR Canadian Graduate Scholarship.	Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Belaid-Choucair Z, 2008, STEM CELLS, V26, P1556, DOI 10.1634/stemcells.2008-0068; Bonsignore MR, 2010, J APPL PHYSIOL, V109, P60, DOI 10.1152/japplphysiol.01344.2009; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CARRINGTON PA, 1991, BLOOD, V77, P34; CONVERTINO V A, 1991, Medicine and Science in Sports and Exercise, V23, P1338; Corre J, 2006, J CELL PHYSIOL, V208, P282, DOI 10.1002/jcp.20655; D'Andrea Alan D, 2002, Hematology Am Soc Hematol Educ Program, P58; David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006-1704; Donnelly S, 2001, AM J KIDNEY DIS, V38, P415, DOI 10.1053/ajkd.2001.26111; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002; Iwamoto J, 2001, J Orthop Sci, V6, P128; Kim DH, 2008, AM J PHYSIOL-ENDOC M, V295, pE1038, DOI 10.1152/ajpendo.00061.2008; KRICUN ME, 1985, SKELETAL RADIOL, V14, P10, DOI 10.1007/BF00361188; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malm C, 1999, J APPL PHYSIOL, V86, P461, DOI 10.1152/jappl.1999.86.2.461; Margeli A, 2005, J CLIN ENDOCR METAB, V90, P3914, DOI 10.1210/jc.2004-2346; McKay BR, 2008, J PHYSIOL-LONDON, V586, P5549, DOI 10.1113/jphysiol.2008.160176; Menuki K, 2008, BONE, V43, P613, DOI 10.1016/j.bone.2008.04.022; Miharada K, 2008, J CELL PHYSIOL, V215, P526, DOI 10.1002/jcp.21334; Morici G, 2005, AM J PHYSIOL-REG I, V289, pR1496, DOI 10.1152/ajpregu.00338.2005; Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099; NIENHUIS AW, 1987, J CLIN INVEST, V80, P573, DOI 10.1172/JCI113106; Pedersen B K, 1999, J Sci Med Sport, V2, P234, DOI 10.1016/S1440-2440(99)80176-5; Pedersen BK, 2007, J APPL PHYSIOL, V103, P1093, DOI 10.1152/japplphysiol.00080.2007; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; PIROSO E, 1991, AM J HEMATOL, V36, P105, DOI 10.1002/ajh.2830360208; ROZMAN C, 1993, MED CLIN-BARCELONA, V101, P441; Rundqvist H, 2009, EUR J ENDOCRINOL, V161, P427, DOI 10.1530/EJE-09-0342; Schodel J, 2009, AM J PATHOL, V174, P1663, DOI 10.2353/ajpath.2009.080687; Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008-0687; Shin JW, 2008, WORLD J GASTROENTERO, V14, P2323, DOI 10.3748/wjg.14.2323; Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021-9290(03)00110-6; Spivak JL, 2005, NAT REV CANCER, V5, P543, DOI 10.1038/nrc1648; Steensberg A, 2007, FASEB J, V21, P2683, DOI 10.1096/fj.06-7477com; Sugita S, 2007, OBESITY, V15, P1988, DOI 10.1038/oby.2007.237; SUKI W, 1960, AM J PHYSIOL, V199, P629, DOI 10.1152/ajplegacy.1960.199.4.629; Sun XJ, 2008, TISSUE ENG PT A, V14, P391, DOI 10.1089/tea.2006.0429; TAN CC, 1992, AM J PHYSIOL, V263, pF474, DOI 10.1152/ajprenal.1992.263.3.F474; TAVASSOLI M, 1974, BLOOD, V43, P33, DOI 10.1182/blood.V43.1.33.33; Trudel G, 2009, J APPL PHYSIOL, V107, P540, DOI 10.1152/japplphysiol.91530.2008; van Os Ronald P., 2008, V430, P143, DOI 10.1007/978-1-59745-182-6_10; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; Wilber RL, 2001, SPORTS MED, V31, P249, DOI 10.2165/00007256-200131040-00002; Wingard JR, 2010, INFECT DIS CLIN N AM, V24, P257, DOI 10.1016/j.idc.2010.01.010; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348	51	50	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4348	4357		10.1096/fj.11-189043	http://dx.doi.org/10.1096/fj.11-189043			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21868472	Bronze			2022-12-28	WOS:000298138100026
J	Harrington, JK; Chahboune, H; Criscione, JM; Li, AY; Hibino, N; Yi, T; Villalona, GA; Kobsa, S; Meijas, D; Duncan, DR; Devine, L; Papademetri, X; Shin'oka, T; Fahmy, TM; Breuer, CK				Harrington, Jamie K.; Chahboune, Halima; Criscione, Jason M.; Li, Alice Y.; Hibino, Narutoshi; Yi, Tai; Villalona, Gustavo A.; Kobsa, Serge; Meijas, Dane; Duncan, Daniel R.; Devine, Lesley; Papademetri, Xenophon; Shin'oka, Toshiharu; Fahmy, Tarek M.; Breuer, Christopher K.			Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI	FASEB JOURNAL			English	Article						ultrasmall superparamagnetic iron oxide nanoparticles; cellular magnetic resonance imaging; cell tracking	MESENCHYMAL STEM-CELLS; MAGNETIC-RESONANCE TRACKING; BONE-MARROW-CELLS; IN-VIVO DETECTION; CONTRAST AGENTS; LABELED CELLS; MOUSE MODEL; BLOOD-VESSELS; CELLULAR MRI; NANOPARTICLES	A major limitation of tissue engineering research is the lack of noninvasive monitoring techniques for observations of dynamic changes in single tissue-engineered constructs. We use cellular magnetic resonance imaging (MRI) to track the fate of cells seeded onto functional tissue-engineered vascular grafts (TEVGs) through serial imaging. After in vitro optimization, murine macrophages were labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles and seeded onto scaffolds that were surgically implanted as inferior vena cava interposition grafts in SCID/bg mice. Serial MRI showed the transverse relaxation times (T-2) were significantly lower immediately following implantation of USPIO-labeled scaffolds (T-2=44 +/- 6.8 vs. 71 +/- 10.2 ms) but increased rapidly at 2 h to values identical to control implants seeded with unlabeled macrophages (T-2=63 +/- 12 vs. 63 +/- 14 ms). This strongly indicates the rapid loss of seeded cells from the scaffolds, a finding verified using Prussian blue staining for iron containing macrophages on explanted TEVGs. Our results support a novel paradigm where seeded cells are rapidly lost from implanted scaffolds instead of developing into cells of the neovessel, as traditionally thought. Our findings confirm and validate this paradigm shift while demonstrating the first successful application of noninvasive MRI for serial study of cellular-level processes in tissue engineering.-Harrington, J. K., Chahboune, H., Criscione, J. M., Li, A. Y., Hibino, N., Yi, T., Villalona, G. A., Kobsa, S., Meijas, D., Duncan, D. R., Devine, L., Papademetri, X., Shin'oka, T., Fahmy, T. M., Breuer, C. K. Determining the fate of seeded cells in venous tissue engineered vascular grafts using serial MRI. FASEB J. 25, 4150-4161 (2011). www.fasebj.org	[Harrington, Jamie K.; Li, Alice Y.; Hibino, Narutoshi; Yi, Tai; Villalona, Gustavo A.; Meijas, Dane; Duncan, Daniel R.; Shin'oka, Toshiharu; Fahmy, Tarek M.; Breuer, Christopher K.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06510 USA; [Papademetri, Xenophon] Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06510 USA; [Devine, Lesley] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; [Chahboune, Halima; Criscione, Jason M.; Kobsa, Serge; Papademetri, Xenophon; Fahmy, Tarek M.] Yale Univ, Dept Biomed Engn, New Haven, CT 06510 USA; [Fahmy, Tarek M.] Yale Univ, Dept Chem Engn, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Breuer, CK (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, 10 Amistad St,Amistad Bldg,Rm 301 C, New Haven, CT 06510 USA.	christopher.breuer@yale.edu		Breuer, Christopher/0000-0003-0987-3898; Duncan, Daniel/0000-0003-4771-8901	Howard Hughes Medical Institute; Yale University Department of Surgery; Yale University Office of Student Research; U.S. National Institutes of Health (NIH) [UL1RR024139, R01-HL098228, K08HL083980]; NIH; Gunze Ltd.; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098228, K08HL083980] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Yale University Department of Surgery; Yale University Office of Student Research; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gunze Ltd.; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Research support was provided through the Howard Hughes Medical Institute, the Yale University Department of Surgery Ohse Grant Program, the Yale University Office of Student Research, and the U.S. National Institutes of Health (NIH; grants UL1RR024139, R01-HL098228, and K08HL083980). This work was performed as part of an NIH-sponsored Howard Hughes Medical Institute Medical Research Training Fellowship. Gunze Ltd. has provided research support for the clinical trial evaluating the use of tissue-engineered vascular grafts. None of the funding for the work done in this manuscript was provided by Gunze Ltd.	Anzai Y, 1997, J MAGN RESON IMAGING, V7, P75, DOI 10.1002/jmri.1880070111; Arbab AS, 2008, REGEN MED, V3, P199, DOI 10.2217/17460751.3.2.199; Brennan M. P., 2008, T M AM SURG ASS, V126, P20; Bulte JWM, 2004, CURR PHARM BIOTECHNO, V5, P567; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Burtea C., 2010, CONTRAST MEDIA MOL I, DOI [10.1002/cmmi.423, DOI 10.1002/CMMI.423]; Burtea Carmen, 2008, V185, P135, DOI 10.1007/978-3-540-72718-7_7; Crich SG, 2004, MAGN RESON MED, V51, P938, DOI 10.1002/mrm.20072; de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154; Feigenbaum GS, 2009, J AM COLL CARDIOL, V54, P1627, DOI 10.1016/j.jacc.2009.05.067; Foster-Gareau P, 2003, MAGN RESON MED, V49, P968, DOI 10.1002/mrm.10417; Gentles TL, 1997, J THORAC CARDIOV SUR, V114, P392, DOI 10.1016/S0022-5223(97)70184-3; Giannico S, 2006, J AM COLL CARDIOL, V47, P2065, DOI 10.1016/j.jacc.2005.12.065; Heymer A, 2008, BIOMATERIALS, V29, P1473, DOI 10.1016/j.biomaterials.2007.12.003; Heyn C, 2005, MAGN RESON MED, V53, P312, DOI 10.1002/mrm.20356; Hibino N, 2011, FASEB J, V25, P2731, DOI 10.1096/fj.11-182246; Hibino N, 2010, J THORAC CARDIOV SUR, V139, P431, DOI 10.1016/j.jtcvs.2009.09.057; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Hjortnaes J, 2010, TISSUE ENG PART C-ME, V16, P597, DOI [10.1089/ten.tec.2009.0466, 10.1089/ten.TEC.2009.0466]; Ito A, 2005, TISSUE ENG, V11, P1553, DOI 10.1089/ten.2005.11.1553; Kim SJ, 2008, J THORAC CARDIOV SUR, V136, P108, DOI 10.1016/j.jtcvs.2007.12.032; Kraitchman DL, 2008, J MAGN RESON IMAGING, V27, P299, DOI 10.1002/jmri.21263; Kubinova S, 2010, MINIM INVASIV THER, V19, P144, DOI 10.3109/13645706.2010.481398; Liu W, 2009, EUR J RADIOL, V70, P258, DOI 10.1016/j.ejrad.2008.09.021; Lopez-Soler RI, 2007, J SURG RES, V139, P1, DOI 10.1016/j.jss.2006.07.040; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; Matsumura G, 2003, BIOMATERIALS, V24, P2303, DOI 10.1016/S0142-9612(03)00043-7; Matsumura G, 2006, TISSUE ENG, V12, P3075, DOI 10.1089/ten.2006.12.3075; Metz S, 2004, EUR RADIOL, V14, P1851, DOI 10.1007/s00330-004-2405-2; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Mirensky TL, 2010, J PEDIATR SURG, V45, P1299, DOI 10.1016/j.jpedsurg.2010.02.102; Mohs AM, 2007, EXPERT OPIN DRUG DEL, V4, P149, DOI 10.1517/17425247.4.2.149; Muller K, 2007, BIOMATERIALS, V28, P1629, DOI 10.1016/j.biomaterials.2006.12.002; Nelson GN, 2008, FASEB J, V22, P3888, DOI 10.1096/fj.08-107367; Nelson GN, 2008, ARCH SURG-CHICAGO, V143, P488, DOI 10.1001/archsurg.143.5.488; Nitzsche H, 2009, TISSUE ENG PART C-ME, V15, P513, DOI [10.1089/ten.tec.2008.0488, 10.1089/ten.TEC.2008.0488]; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; Perea H, 2007, J TISSUE ENG REGEN M, V1, P318, DOI 10.1002/term.32; Poirier-Quinot M, 2010, TISSUE ENG PART C-ME, V16, P185, DOI [10.1089/ten.tec.2009.0015, 10.1089/ten.TEC.2009.0015]; Rogers WJ, 2006, NAT CLIN PRACT CARD, V3, P554, DOI 10.1038/ncpcardio0659; Roh JD, 2008, BIOMATERIALS, V29, P1454, DOI 10.1016/j.biomaterials.2007.11.041; Roh JD, 2010, P NATL ACAD SCI USA, V107, P4669, DOI 10.1073/pnas.0911465107; Saldanha KJ, 2008, EUR CELLS MATER, V16, P17, DOI 10.22203/eCM.v016a03; Saldanha KJ, 2011, MAGN RESON IMAGING, V29, P40, DOI 10.1016/j.mri.2010.07.015; SAMANEK M, 1992, PEDIATR CARDIOL, V13, P152; Shapiro EM, 2006, MAGN RESON MED, V55, P242, DOI 10.1002/mrm.20718; Shapiro EM, 2007, CONTRAST MEDIA MOL I, V2, P147, DOI 10.1002/cmmi.134; Shimizu K, 2007, J BIOSCI BIOENG, V103, P472, DOI 10.1263/jbb.103.472; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Strijkers GJ, 2007, ANTI-CANCER AGENT ME, V7, P291, DOI 10.2174/187152007780618135; Terrovitis JV, 2006, TISSUE ENG, V12, P2765, DOI 10.1089/ten.2006.12.2765; Trivedi RA, 2004, STROKE, V35, P1631, DOI 10.1161/01.STR.0000131268.50418.b7; Villalona GA, 2010, TISSUE ENG PART B-RE, V16, P341, DOI [10.1089/ten.teb.2009.0527, 10.1089/ten.TEB.2009.0527]; Watanabe M, 2001, TISSUE ENG, V7, P429, DOI 10.1089/10763270152436481; Yamanami M, 2010, J BIOMED MATER RES B, V92B, P156, DOI 10.1002/jbm.b.31501; Zhang ZL, 2004, MAGN RESON MATER PHY, V17, P201, DOI 10.1007/s10334-004-0054-8	57	43	44	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4150	4161		10.1096/fj.11-185140	http://dx.doi.org/10.1096/fj.11-185140			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21846838	Green Published			2022-12-28	WOS:000298138100009
J	Martin, GM				Martin, George M.			The biology of aging: 1985-2010 and beyond	FASEB JOURNAL			English	Review						dietary restriction; evolutionary biology; epigenetic drift; geriatric pathology; health span; life span	EXTENDS LIFE-SPAN; DIETARY RESTRICTION; CELLULAR SENESCENCE; EXTENSION; LONGEVITY; GENE; RESVERATROL; RAPAMYCIN; CELLS; TELOMERASE	In this contribution to the series of reflective essays celebrating the 25th anniversary of The FASEB Journal, our task is to assess the growth of research on the biology of aging during this period and to suggest where we might be heading during the next 25 yr. A review of the literature suggests a healthy acceleration of progress during the past decade, perhaps largely due to progress on the genetics of longevity of model organisms. Progress on the genetics of health span in these model organisms has lagged, however. Research on the genetic basis of the remarkable interspecific variations in life span has only recently begun to be seriously addressed. The spectacular advances in genomics should greatly accelerate progress. Research on environmental effects on life span and health span needs to be accelerated. Stochastic variations in gene expression in aging have only recently been addressed. These can lead to random departures from homeostasis during aging.-Martin, G. M. The biology of aging: 1985-2010 and beyond. FASEB J. 25, 3756-3762 (2011). www.fasebj.org	[Martin, George M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Martin, George M.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Martin, George M.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles	Martin, GM (corresponding author), Univ Washington, Dept Pathol, Rm K-543,Hlth Sci Bldg,1959 NE Pacific St, Seattle, WA 98195 USA.	gmmartin@uw.edu			NCI NIH HHS [R24CA078088, R24 CA078088] Funding Source: Medline; NIA NIH HHS [P01 AG001751, R01AG019711, P01AG001751, R01 AG019711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA078088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019711, P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexeyev MF, 2009, FEBS J, V276, P5768, DOI 10.1111/j.1742-4658.2009.07269.x; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Austad S.N., 1997, WHY WE AGE WHAT SCI; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bernhard D, 2007, EXP GERONTOL, V42, P160, DOI 10.1016/j.exger.2006.09.016; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cao K, 2011, J CLIN INVEST, V121, P2833, DOI 10.1172/JCI43578; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Douglas PM, 2010, J CELL BIOL, V190, P719, DOI 10.1083/jcb.201005144; Edrey YH, 2011, ILAR J, V52, P41, DOI 10.1093/ilar.52.1.41; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Everitt AV, 2010, CALORIE RESTRICTION, AGING AND LONGEVITY, P1, DOI 10.1007/978-90-481-8556-6; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; FRIEDMAN DB, 1988, GENETICS, V118, P75; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kirkwood TBL, 2005, MECH AGEING DEV, V126, P439, DOI 10.1016/j.mad.2004.09.008; Kitazoe Y., 2011, GENOME BIOL EVOL; Kudlow BA, 2007, NAT REV MOL CELL BIO, V8, P394, DOI 10.1038/nrm2161; Lapointe J, 2010, CELL MOL LIFE SCI, V67, P1, DOI 10.1007/s00018-009-0138-8; Le Bourg E, 2010, AGEING RES REV, V9, P289, DOI 10.1016/j.arr.2010.01.001; Liao CY, 2011, AGING CELL, V10, P629, DOI 10.1111/j.1474-9726.2011.00702.x; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Martin G M, 1987, Prog Clin Biol Res, V228, P25; Martin GM, 2007, ANN NY ACAD SCI, V1100, P14, DOI 10.1196/annals.1395.002; Martin George M, 2002, Sci Aging Knowledge Environ, V2002, pvp2, DOI 10.1126/sageke.2002.9.vp2; Martin GM, 2009, AGING CELL, V8, P761, DOI 10.1111/j.1474-9726.2009.00515.x; Martin GM, 1996, HUM MOL GENET, V5, P215, DOI 10.1093/hmg/5.2.215; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Olshansky SJ, 2009, MILBANK Q, V87, P842, DOI 10.1111/j.1468-0009.2009.00581.x; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Pajcini KV, 2010, CELL STEM CELL, V7, P198, DOI 10.1016/j.stem.2010.05.022; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Perez VI, 2009, BBA-GEN SUBJECTS, V1790, P1005, DOI 10.1016/j.bbagen.2009.06.003; Pollard KS, 2006, NATURE, V443, P167, DOI 10.1038/nature05113; Poon PC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000356; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Rao RD, 2004, CURR CANCER DRUG TAR, V4, P621, DOI 10.2174/1568009043332718; Rea SL, 2005, NAT GENET, V37, P894, DOI 10.1038/ng1608; Ristow M, 2011, FREE RADICAL BIO MED, V51, P327, DOI 10.1016/j.freeradbiomed.2011.05.010; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003; Smith ED, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-49; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Wadman M, 2010, NATURE, V468, P148, DOI 10.1038/468148a; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Ziv E, 2011, AGEING RES REV, V10, P201, DOI 10.1016/j.arr.2010.09.002	71	56	64	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3756	3762		10.1096/fj.11-1102.ufm	http://dx.doi.org/10.1096/fj.11-1102.ufm			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	22046003	Green Published			2022-12-28	WOS:000296723100001
J	Rakotomamonjy, J; Levenes, C; Baulieu, EE; Schumacher, M; Ghoumari, AM				Rakotomamonjy, Jennifer; Levenes, Carole; Baulieu, Etienne Emile; Schumacher, Michael; Ghoumari, Abdel M.			Novel protective effect of mifepristone on detrimental GABA(A) receptor activity to immature Purkinje neurons	FASEB JOURNAL			English	Article						resting potential; neuroprotection; ionotropic receptor; RU486	TEMPORAL-LOBE EPILEPSY; CELL-DEATH; HIPPOCAMPAL-NEURONS; IN-VITRO; EXCITATORY ACTIONS; CUSHINGS-SYNDROME; CLIMBING FIBERS; RAT; APOPTOSIS; SURVIVAL	Immature Purkinje neurons are particularly vulnerable cells. They survive in cerebellar slice cultures under treatment by the synthetic steroid mifepristone (RU486) that depolarizes them at this age. The present study aims at understanding the mechanism underlying this neuroprotective effect. In the developing cerebellum, the role of gamma-aminobutyric acid (GABA) in neuron survival is unknown. In 3-d-old mouse cerebellar slice cultures, we show that GABA(A) receptor activation is depolarizing and excitatory. Antagonists of GABA(A) receptors rescue Purkinje neurons, demonstrating that GABA is endogenously released in this preparation and is toxic. Mifepristone likely protects these neurons by reversing GABA(A) receptor-mediated chloride fluxes and reducing their driving force. Neuroprotection by mifepristone is dose-dependently decreased by the agonist of GABA(A) receptors muscimol and by caffeine, an agonist of internal calcium store release. Moreover, the survival induced by neomycin, an inhibitor of calcium release, is partially reversed by muscimol. The p38 mitogen-activated protein kinase (MAPK) inhibitor SB239063 also rescues Purkinje neurons. In summary, we propose that when GABA is depolarizing, mifepristone protects Purkinje neurons by shunting GABA responses and probably chloride fluxes, by inhibiting p38 MAPK activity and likely internal calcium store release. A new and nonhormonal effect of mifepristone is thus revealed.-Rakotomamonjy, J., Levenes, C., Baulieu, E. E., Schumacher, M., Ghoumari, A. M. Novel protective effect of mifepristone on detrimental GABA(A) receptor activity to immature Purkinje neurons. FASEB J. 25, 3999-4010 (2011). www.fasebj.org	[Rakotomamonjy, Jennifer; Baulieu, Etienne Emile; Schumacher, Michael; Ghoumari, Abdel M.] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Rakotomamonjy, Jennifer; Baulieu, Etienne Emile; Schumacher, Michael; Ghoumari, Abdel M.] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Levenes, Carole] Univ Paris 05, Inst Neurosci Cognit IMC, CNRS, UMR8119, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Ghoumari, AM (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	abdel.ghoumari@inserm.fr	Schumacher, Michael/G-3581-2013	Schumacher, Michael/0000-0001-6117-5371; Rakotomamonjy, Jennifer/0000-0002-6375-0920; Levenes, Carole/0000-0002-1345-180X				BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Bosman LWJ, 2009, NEUROSCIENCE, V162, P612, DOI 10.1016/j.neuroscience.2009.01.032; Castinetti F, 2009, EUR J ENDOCRINOL, V160, P1003, DOI 10.1530/EJE-09-0098; Cerminara NL, 2004, J NEUROSCI, V24, P4510, DOI 10.1523/JNEUROSCI.4530-03.2004; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; CHERUBINI E, 1990, INT J DEV NEUROSCI, V8, P481, DOI 10.1016/0736-5748(90)90080-L; Cohen I, 2003, BIOL CELL, V95, P329, DOI 10.1016/S0248-4900(03)00081-9; Conti R, 2004, J NEUROSCI, V24, P6946, DOI 10.1523/JNEUROSCI.1397-04.2004; DRENGLER SM, 1993, BRAIN RES, V615, P175, DOI 10.1016/0006-8993(93)91129-G; Dusart I, 1997, J NEUROSCI, V17, P3710; Eilers J, 2001, J PHYSIOL-LONDON, V536, P429, DOI 10.1111/j.1469-7793.2001.0429c.xd; Fredriksson A, 2007, ANESTHESIOLOGY, V107, P427, DOI 10.1097/01.anes.0000278892.62305.9c; Ghoumari AM, 2006, FASEB J, V20, P1377, DOI 10.1096/fj.05-5832com; Ghoumari AM, 2000, EUR J NEUROSCI, V12, P2935, DOI 10.1046/j.1460-9568.2000.00186.x; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Honegger P, 1998, DEV BRAIN RES, V105, P219, DOI 10.1016/S0165-3806(97)00194-6; Ikonomidou C, 2009, BRAIN DEV-JPN, V31, P488, DOI 10.1016/j.braindev.2009.02.006; Jankowski J, 2009, CEREBELLUM, V8, P277, DOI 10.1007/s12311-009-0093-9; Johanssen S, 2007, EUR J ENDOCRINOL, V157, P561, DOI 10.1530/EJE-07-0458; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kahraman S, 2008, J NEUROSURG ANESTH, V20, P233, DOI 10.1097/ANA.0b013e31817ec34d; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Kim DY, 2008, EPILEPSIA, V49, P861, DOI 10.1111/j.1528-1167.2007.01455.x; Lukasiuk K, 2000, J NEUROCHEM, V74, P2445, DOI 10.1046/j.1471-4159.2000.0742445.x; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Meldrum BS, 2007, NEUROTHERAPEUTICS, V4, P18, DOI 10.1016/j.nurt.2006.11.010; Nunez JL, 2003, EXP NEUROL, V181, P258, DOI 10.1016/S0014-4886(03)00053-0; Oomen CA, 2007, EUR J NEUROSCI, V26, P3395, DOI 10.1111/j.1460-9568.2007.05972.x; Palma E, 2006, P NATL ACAD SCI USA, V103, P8465, DOI 10.1073/pnas.0602979103; Repici M, 2011, CEREBELLUM, V10, P281, DOI 10.1007/s12311-010-0244-z; SERAFINI R, 1995, J PHYSIOL-LONDON, V488, P371, DOI 10.1113/jphysiol.1995.sp020973; Sotelo C, 2008, J COMP NEUROL, V506, P240, DOI 10.1002/cne.21501; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Watt AJ, 2009, NAT NEUROSCI, V12, P463, DOI 10.1038/nn.2285; Wei L, 2004, PFLUG ARCH EUR J PHY, V448, P325, DOI 10.1007/s00424-004-1277-2; Young AH, 2004, NEUROPSYCHOPHARMACOL, V29, P1538, DOI 10.1038/sj.npp.1300471; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360; Yuzaki M, 1996, J NEUROSCI, V16, P4651	42	9	10	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3999	4010		10.1096/fj.11-183384	http://dx.doi.org/10.1096/fj.11-183384			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21795502				2022-12-28	WOS:000296723100024
J	An, J; Golech, S; Klaewsongkram, J; Zhang, YQ; Subedi, K; Huston, GE; Wood, WH; Wersto, RP; Becker, KG; Swain, SL; Weng, NP				An, Jie; Golech, Susanne; Klaewsongkram, Jettanong; Zhang, Yongqing; Subedi, Kalpana; Huston, Gail E.; Wood, William H., III; Wersto, Robert P.; Becker, Kevin G.; Swain, Susan L.; Weng, Nanping			Kruppel-like factor 4 (KLF4) directly regulates proliferation in thymocyte development and IL-17 expression during Th17 differentiation	FASEB JOURNAL			English	Article						transcription factor; T-cell homeostasis; autoimmune disease	T-CELL DEVELOPMENT; ROR-GAMMA-T; TRANSCRIPTION FACTOR; DOWN-REGULATION; T-H-17 CELLS; TGF-BETA; LINEAGE; SURVIVAL; ALPHA; GROWTH	Kruppel-like factor 4 (KLF4), a transcription factor, plays a key role in the pluripotency of stem cells. We sought to determine the function of KLF4 in T-cell development and differentiation by using T-cell-specific Klf4-knockout (KO) mice. We found that KLF4 was highly expressed in thymocytes and mature T cells and was rapidly down-regulated in mature T cells after activation. In Klf4-KO mice, we observed a modest reduction of thymocytes (27%) due to the reduced proliferation of double-negative (DN) thymocytes. We demonstrated that a direct repression of Cdkn1b by KLF4 was a cause of decreased DN proliferation. During in vitro T-cell differentiation, we observed significant reduction of IL-17-expressing CD4(+) T cells (Th17; 24%) but not in other types of Th differentiation. The reduction of Th17 cells resulted in a significant attenuation of the severity (35%) of experimental autoimmune encephalomyelitis in vivo in Klf4-KO mice as compared with the Klf4 wild-type littermates. Finally, we demonstrated that KLF4 directly binds to the promoter of Il17a and positively regulates its expression. In summary, these findings identify KLF4 as a critical regulator in T-cell development and Th17 differentiation.-An, J., Golech, S., Klaewsongkram, J., Zhang, Y., Subedi, K., Huston, G. E., Wood, W. H., III, Wersto, R. P., Becker, K. G., Swain, S. L., Weng, N. Kruppel-like factor 4 (KLF4) directly regulates proliferation in thymocyte development and IL-17 expression during Th17 differentiation. FASEB J. 25, 3634-3645 (2011). www.fasebj.org	[An, Jie; Golech, Susanne; Klaewsongkram, Jettanong; Subedi, Kalpana; Weng, Nanping] NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA; [Zhang, Yongqing; Wood, William H., III; Becker, Kevin G.] NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA; [Wersto, Robert P.] NIA, Flow Cytometry Unit, NIH, Baltimore, MD 21224 USA; [Huston, Gail E.] Trudeau Inst, New York, NY USA; [Swain, Susan L.] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Trudeau Institute; University of Massachusetts System; University of Massachusetts Worcester	Weng, NP (corresponding author), 251 Bayview Blvd,Ste 100, Baltimore, MD 21224 USA.	wengn@mail.nih.gov	Klaewsongkram, Jettanong/AAI-6245-2021; Weng, Nan-ping/AAC-5037-2020	Klaewsongkram, Jettanong/0000-0001-6063-2403; Becker, Kevin/0000-0002-6794-6656; Subedi, kalpana/0000-0002-1808-3268	National Institute on Aging; National Institute on Aging, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046530, R01AI076534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000757, ZICAG000618, ZICAG000616] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Drs. Richard Hodes and Joyti Sen for critical reading of the manuscript, Andrea Wurster and Qing Yu for help with Th2- and Th17-cell differentiation, Jun Ho Lee for help with the EAE mouse model, Cuong Nguyen and Tonya Wolf of the Flow Cytometry Unit for cell sorting, the staff of the National Institute on Aging animal facility for support and assistance, and Ana Lustig for proofreading the manuscript. This research was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. J.A and S. G. designed and performed experiments, analyzed the data, and contributed to the writing of the manuscript. J.K., Y.Z., K.S., G.E.H., W.H.W., R.P.W., and K.G.B. contributed to some of the experiments and data analysis. S.L.S and N.W. directed the experiments and wrote the manuscript. N.W. conceived the research, designed the experiments, and funded the research. The authors declare no competing financial interests.	Araki Y, 2008, J IMMUNOL, V180, P8102, DOI 10.4049/jimmunol.180.12.8102; Beeton Christine, 2007, J Vis Exp, P527, DOI 10.3791/527; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; David-Fung ES, 2009, DEV BIOL, V325, P444, DOI 10.1016/j.ydbio.2008.10.021; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hayday AC, 2007, NAT IMMUNOL, V8, P137, DOI 10.1038/ni1436; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Klaewsongkram J, 2007, J IMMUNOL, V179, P4679, DOI 10.4049/jimmunol.179.7.4679; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Laky K, 2007, J EXP MED, V204, P2115, DOI 10.1084/jem.20070550; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lebson L, 2010, J IMMUNOL, V185, P7161, DOI 10.4049/jimmunol.1002750; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Martinez GJ, 2010, J BIOL CHEM, V285, P29039, DOI 10.1074/jbc.C110.155820; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Moisan J, 2007, J EXP MED, V204, P2825, DOI 10.1084/jem.20070994; Mosmann TR, 2005, J IMMUNOL, V175, P5; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Reynolds JM, 2010, IMMUNITY, V32, P692, DOI 10.1016/j.immuni.2010.04.010; ROWLAND BD, 2005, NAT CELL BIOL; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Sebzda E, 2008, NAT IMMUNOL, V9, P292, DOI 10.1038/ni1565; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tabrizifard S, 2004, J IMMUNOL, V173, P1094, DOI 10.4049/jimmunol.173.2.1094; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VONBOEHMER H, 1992, BONE MARROW TRANSPL, V9, P46; Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953; Wolfer A, 2002, IMMUNITY, V16, P869, DOI 10.1016/S1074-7613(02)00330-8; Xi HK, 2004, J IMMUNOL, V172, P964, DOI 10.4049/jimmunol.172.2.964; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zamisch M, 2009, J EXP MED, V206, P2685, DOI 10.1084/jem.20092024; Zhang FP, 2008, NAT IMMUNOL, V9, P1297, DOI 10.1038/ni.1663; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou MX, 2007, J IMMUNOL, V178, P5496, DOI 10.4049/jimmunol.178.9.5496; Zhu JF, 2009, J EXP MED, V206, P329, DOI 10.1084/jem.20081666	51	42	50	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3634	3645		10.1096/fj.11-186924	http://dx.doi.org/10.1096/fj.11-186924			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21685331	Green Published			2022-12-28	WOS:000295356400033
J	Andreo, U; Elkind, J; Blachford, C; Cederbaum, AI; Fisher, EA				Andreo, Ursula; Elkind, Josh; Blachford, Courtney; Cederbaum, Arthur I.; Fisher, Edward A.			Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells	FASEB JOURNAL			English	Article						polyunsaturated fatty acids; lipid peroxides; VLDL	APOLIPOPROTEIN-B; LIPID-PEROXIDATION; DISMUTASE MIMETICS; OMEGA-3-FATTY-ACIDS; SECRETION; PATHWAY; DISEASE; PROTEIN; ACID	VLDL is produced by the liver. Its major protein is apoB100. Docosahexaenoic acid (DHA), a dietary polyunsaturated fatty acid (PUFA), reduces VLDL levels and is used therapeutically for hypertriglyceridemia. In model systems, DHA lowers VLDL secretion by inducing presecretory apoB100 degradation, a process dependent on PUFA-derived lipid peroxides. We hypothesized that superoxide (SO) was a major participant in DHA-induced apoB100 degradation, given its promotion of lipid peroxidation. SO levels in a model of VLDL metabolism, rat hepatoma McArdle cells, were either decreased by a mimetic of superoxide dismutase 1 (SOD1) or by overexpressing SOD1 or increased by SOD1 siRNA. ApoB100 recovery was assessed by immunoprecipitation, SO by 2-hydroxyethidine, and lipid peroxides by thiobarbituric acid reactive substances. The SOD1 mimetic or SOD1 overexpression reduced SO and inhibited apoB100 degradation in DHA-treated cells by up to 100%. Surprisingly, silencing SOD1 did not increase DHA-induced degradation, although levels of SO were higher (+44%); those of lipid peroxides were similar, and their reduction by alpha-tocopherol decreased degradation by 50%. SO is required for lipid peroxidation in DHA-induced apoB100 degradation, but it is the peroxide level that has a tighter relationship to the level of degradation and the regulation of VLDL production.-Andreo, U., Elkind, J., Blachford, C., Cederbaum, A. I., Fisher, E. A. Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells. FASEB J. 25, 3554-3560 (2011). www.fasebj.org	[Andreo, Ursula; Elkind, Josh; Blachford, Courtney; Fisher, Edward A.] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol,Marc & Ruti Bell Progr, New York, NY 10016 USA; [Andreo, Ursula; Elkind, Josh; Blachford, Courtney; Fisher, Edward A.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Cederbaum, Arthur I.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA; [Fisher, Edward A.] Univ Oxford, Dept Cardiovasc Med, Oxford, England	New York University; New York University; Icahn School of Medicine at Mount Sinai; University of Oxford	Fisher, EA (corresponding author), NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol,Marc & Ruti Bell Progr, Smilow 7,522 1st Ave, New York, NY 10016 USA.	edward.fisher@nyumc.org	Fisher, Edward/ABE-7469-2020	Fisher, Edward/0000-0001-9802-143X	U.S. National Institutes of Health (NIH) [HL-58541]; American Heart Association [0825883D]; NIH [AA-017425, AA-018790]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA018790, R01AA017425] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by U.S. National Institutes of Health (NIH) grant HL-58541 (to E.A.F.), American Heart Association postdoctoral fellowship 0825883D (to U.A.), and NIH grants AA-017425 and AA-018790 (to A.I.C.). The authors thank Dr Jacek Zielonka for the 2-hydroxyethidium measurements that were performed at the Free Radical Research Center (Medical College of Wisconsin, Milwaukee, WI, USA), Lisa Grauer (New York University) for help in the manuscript preparation, and Dr. Charles (Liang) Guo (New York University) for helpful discussions.	BELOQUI O, 1986, BIOCHEM PHARMACOL, V35, P2663, DOI 10.1016/0006-2952(86)90172-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caro AA, 2001, MOL PHARMACOL, V60, P742; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 2008, AUTOPHAGY, V4, P721, DOI 10.4161/auto.6346; FRUEBIS J, 1992, P NATL ACAD SCI USA, V89, P10588, DOI 10.1073/pnas.89.22.10588; Gauuan PJF, 2002, BIOORGAN MED CHEM, V10, P3013, DOI 10.1016/S0968-0896(02)00153-0; Ginsberg HN, 2009, J LIPID RES, V50, pS162, DOI 10.1194/jlr.R800090-JLR200; Harris WS, 2008, ATHEROSCLEROSIS, V197, P12, DOI 10.1016/j.atherosclerosis.2007.11.008; Harris WS, 2006, CURR OPIN LIPIDOL, V17, P387, DOI 10.1097/01.mol.0000236363.63840.16; Kris-Etherton PM, 2003, ARTERIOSCL THROM VAS, V23, P151, DOI 10.1161/01.ATV.0000057393.97337.AE; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu Y, 2008, FREE RADICAL BIO MED, V44, P723, DOI 10.1016/j.freeradbiomed.2007.11.004; Pan MH, 2008, P NATL ACAD SCI USA, V105, P5862, DOI 10.1073/pnas.0707460104; Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197; Perez MJ, 2003, HEPATOLOGY, V38, P1146, DOI 10.1053/jhep.2003.50479; PUNTARULO S, 1989, BIOCHEM PHARMACOL, V38, P2911, DOI 10.1016/0006-2952(89)90449-8; REUBEN MA, 1988, J LIPID RES, V29, P1337; Smith C., 2005, MARKS BASIC MED BIOC, P439; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890; Tran K, 2006, BBA-MOL CELL BIOL L, V1761, P463, DOI 10.1016/j.bbalip.2006.03.018; Trova MP, 2003, BIOORGAN MED CHEM, V11, P2695, DOI 10.1016/S0968-0896(03)00272-4; Uchiyama S, 2006, J BIOL CHEM, V281, P31713, DOI 10.1074/jbc.M603422200; WANG HX, 1994, J BIOL CHEM, V269, P18514; Zielonka J, 2008, NAT PROTOC, V3, P8, DOI 10.1038/nprot.2007.473	26	17	17	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3554	3560		10.1096/fj.11-182725	http://dx.doi.org/10.1096/fj.11-182725			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21757500	Green Published			2022-12-28	WOS:000295356400025
J	Sarig, H; Ohana, D; Epand, RF; Mor, A; Epand, RM				Sarig, Hadar; Ohana, Dafna; Epand, Raquel F.; Mor, Amram; Epand, Richard M.			Functional studies of cochleate assemblies of an oligo-acyl-lysyl with lipid mixtures for combating bacterial multidrug resistance	FASEB JOURNAL			English	Article						drug encapsulation in lipids; drug delivery; drug synergy; membrane fusion	LYSINE OLIGOMERS; STAPHYLOCOCCUS-AUREUS; EFFLUX; PROTEINS; TRANSPORTER; FAMILY; PUMPS	The cationic antimicrobial oligo-acyl-lysyls (OAKs) interact with lipid mixtures mimicking the composition of bacterial cytoplasmic membranes. We have reported the ability of one such OAK, C(12)K-7 alpha(8), to cluster anionic lipids and to promote a structural change with lipid bilayers to form rolled cylindrical structures or cochleates, without requiring divalent cations for their assembly. These assemblies can be exploited for drug delivery, permitting their synergistic use with antibiotics in systemic therapy to increase efficacy and reduce toxicity. Our previous studies of the biophysical properties of these systems led us to select mixtures with the goal of optimizing their potential for enhancing effectiveness in combating bacterial multidrug resistance. Here, we further investigate the properties of such mixtures that result in enhanced in vivo activity. The role of erythromycin in the assembly of cochleates with OAK in the gel and the liquid crystalline states were assessed, as well as the encapsulation efficiency of the systems chosen. In addition, we found that erythromycin did not undermine the ability of OAKs to induce fusion of vesicles, fusion being an essential component of cochleate formation. The in vivo activity of the new assemblies tested resulted in higher survival rates of animals infected with multidrug resistant bacteria.-Sarig, H., Ohana, D., Epand, R. F., Mor, A., Epand, R. M. Functional studies of cochleate assemblies of an oligo-acyl-lysyl with lipid mixtures for combating bacterial multidrug resistance. FASEB J. 25, 3336-3343 (2011). www.fasebj.org	[Epand, Raquel F.; Epand, Richard M.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Sarig, Hadar; Ohana, Dafna; Mor, Amram] Technion Israel Inst Technol, Dept Biotechnol & Food Engn, Haifa, Israel	McMaster University; Technion Israel Institute of Technology	Epand, RM (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada.	amor@tx.technion.ac.il; epand@mcmaster.ca	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	Canadian Institute of Health Research [MOP 86608]; Israel Science Foundation [283/08]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Israel Science Foundation(Israel Science Foundation)	This research was partly supported by the Canadian Institute of Health Research (grant MOP 86608) and the Israel Science Foundation (grant 283/08).	DeMarco CE, 2007, ANTIMICROB AGENTS CH, V51, P3235, DOI 10.1128/AAC.00430-07; Epand RF, 2011, J PHYS CHEM B, V115, P2287, DOI 10.1021/jp111242q; Epand RM, 2008, J AM CHEM SOC, V130, P14346, DOI 10.1021/ja8062327; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; KATES M, 1993, LIPIDS, V28, P877, DOI 10.1007/BF02537494; Li XZ, 2009, DRUGS, V69, P1555, DOI 10.2165/11317030-000000000-00000; Livne L, 2010, FASEB J, V24, P5092, DOI 10.1096/fj.10-167809; Miyamae S, 2001, ANTIMICROB AGENTS CH, V45, P3341, DOI 10.1128/AAC.45.12.3341-3346.2001; Mor A, 2010, ADV M C M, P100, DOI 10.1079/9781845936570.0100; Morita Y, 2000, J BACTERIOL, V182, P6694, DOI 10.1128/JB.182.23.6694-6697.2000; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 2009, ANNU REV BIOCHEM, V78, P119, DOI 10.1146/annurev.biochem.78.082907.145923; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; Prinz WA, 2009, CRIT REV BIOCHEM MOL, V44, P278, DOI 10.1080/10409230903183472; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2008, CHEM BIOL, V15, P354, DOI 10.1016/j.chembiol.2008.03.006; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023	21	18	18	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3336	3343		10.1096/fj.11-183764	http://dx.doi.org/10.1096/fj.11-183764			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21676947				2022-12-28	WOS:000295356400006
J	Lim, SK; Orhant-Prioux, M; Toy, W; Tan, KY; Lim, YP				Lim, Shen Kiat; Orhant-Prioux, Magali; Toy, Weiyi; Tan, Kah Yap; Lim, Yoon Pin			Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway	FASEB JOURNAL			English	Article						WBP2; ER alpha; EGFR; beta-catenin; crosstalk	YES-ASSOCIATED PROTEIN; GROWTH-FACTOR RECEPTOR; NUCLEAR RECEPTORS; WNT/BETA-CATENIN; BETA-CATENIN; ACTIVATION; KINASE; SRC; CELLS; YAP	WW-binding protein 2 (WBP2) has been demonstrated in different studies to be a tyrosine kinase substrate, to activate estrogen receptor alpha (ER alpha)/progesterone receptor (PR) transcription, and to play a role in breast cancer. However, the role of WBP2 tyrosine phosphorylation in regulating ER alpha function and breast cancer biology is unknown. Here, we established WBP2 as a tyrosine phosphorylation target of estrogen signaling via EGFR crosstalk. Using dominant-negative, constitutively active mutants, RNAi, and pharmacological studies, we demonstrated that phosphorylation of WBP2 at Tyr192 and Tyr231 could be regulated by c-Src and c-Yes kinases. We further showed that abrogating WBP2 phosphorylation impaired >60% of ER alpha reporter activity, putatively by blocking nuclear entry of WBP2 and its interaction with ER alpha. Compared to vector control, overexpression of WBP2 and its phospho-mimic mutant in MCF7 cells resulted in larger tumors in mice, induced loss of cell-cell adhesion, and enhanced cell proliferation, anchorage-independent growth, migration, and invasion in both estrogen-dependent and -independent manners, events of which could be substantially abolished by overexpression of the phosphorylation-defective mutant. Hormone independence of cells expressing WBP2 phospho-mimic mutant was associated with heightened ER alpha and Wnt reporter activities. Wnt/beta-catenin inhibitor FH535 blocked phospho-WBP2-mediated cancer cell growth more pronouncedly than tamoxifen and fulvestrant, in part by reducing the expression of ER alpha. Wnt pathway is likely to be a critical component in WBP2-mediated breast cancer biology.-Lim, S. K., Orhant-Prioux, M., Toy, W., Tan, K. Y., Lim, Y. P. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway. FASEB J. 25, 3004-3018 (2011). www.fasebj.org	[Lim, Shen Kiat; Toy, Weiyi; Tan, Kah Yap; Lim, Yoon Pin] Natl Univ Singapore, Fac Sci, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore; [Lim, Shen Kiat; Orhant-Prioux, Magali; Toy, Weiyi; Tan, Kah Yap; Lim, Yoon Pin] Natl Univ Singapore, Fac Sci, Canc Sci Inst, Singapore 117597, Singapore; [Lim, Yoon Pin] Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117597, Singapore; [Lim, Yoon Pin] Agcy Sci & Technol, Bioinformat Inst, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lim, YP (corresponding author), Natl Univ Singapore, Fac Sci, Yong Loo Lin Sch Med, Dept Biochem, MD4A,02-05,8 Med Dr, Singapore 117597, Singapore.	bchlyp@nus.edu.sg	Toy, Weiyi/ABH-3914-2020		Singapore Biomedical Research Council; Agency for Science, Technology, and Research	Singapore Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); Agency for Science, Technology, and Research(Agency for Science Technology & Research (A*STAR))	The authors thank Dr. Siew Pang Chan (senior lecturer, Division of Health Sciences, La Trobe University, Melbourne, VIC, Australia; and statistics editor, Cochrane Consumers & Collaboration Group) for his assistance in statistical analysis in the xenograft studies. The work is funded by the Singapore Biomedical Research Council and Agency for Science, Technology, and Research.	Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Callige Mathilde, 2006, Nucl Recept Signal, V4, pe004; Chan SW, 2011, ONCOGENE, V30, P600, DOI 10.1038/onc.2010.438; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395-MCP200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; Fox EM, 2009, STEROIDS, V74, P622, DOI 10.1016/j.steroids.2008.10.014; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; KARIAGINA A, HORM CANC, V1, P229; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lim YP, 2003, MOL CANCER THER, V2, P1369; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Migliaccio A, 2006, ANN NY ACAD SCI, V1089, P194, DOI 10.1196/annals.1386.006; Mohinta S, 2007, FRONT BIOSCI-LANDMRK, V12, P4020, DOI 10.2741/2368; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oh AS, 2008, MOL CELL BIOL, V28, P6580, DOI 10.1128/MCB.00118-08; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; Talukder AH, 2008, ONCOGENE, V27, P5233, DOI 10.1038/onc.2008.151; TOY W, CELL SIGNAL, V22, P437; Toy W, 2010, CELL SIGNAL, V22, P437, DOI 10.1016/j.cellsig.2009.10.015; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073	50	40	43	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3004	3018		10.1096/fj.10-169136	http://dx.doi.org/10.1096/fj.10-169136			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21642474				2022-12-28	WOS:000294435200016
J	Manns, J; Daubrawa, M; Driessen, S; Paasch, F; Hoffmann, N; Loffler, A; Lauber, K; Dieterle, A; Alers, S; Iftner, T; Schulze-Osthoff, K; Stork, B; Wesselborg, S				Manns, Joachim; Daubrawa, Merle; Driessen, Stefan; Paasch, Florian; Hoffmann, Nadine; Loeffler, Antje; Lauber, Kirsten; Dieterle, Alexandra; Alers, Sebastian; Iftner, Thomas; Schulze-Osthoff, Klaus; Stork, Bjoern; Wesselborg, Sebastian			Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1	FASEB JOURNAL			English	Article						UCN-01; apoptosome; mitochondria; Bcl-2	CELL-DEATH; CYTOCHROME-C; PHASE-I; PHOSPHORYLATION; MITOCHONDRIAL; UCN-01; 7-HYDROXYSTAUROSPORINE; PROCASPASE-9; MODULATION; MELANOMA	The protein kinase inhibitor staurosporine is one of the most potent and frequently used proapoptotic stimuli, although its mechanism of action is poorly understood. Here, we show that staurosporine as well as its analog 7-hydroxystaurosporine (UCN-01) not only trigger the classical mitochondrial apoptosis pathway but, moreover, activate an additional novel intrinsic apoptosis pathway. Unlike conventional anticancer drugs, staurosporine and UCN-01 induced apoptosis in a variety of tumor cells overexpressing the apoptosis inhibitors Bcl-2 and Bcl-xL. Furthermore, activation of this novel intrinsic apoptosis pathway by staurosporine did not rely on Apaf-1 and apoptosome formation, an essential requirement for the mitochondrial pathway. Nevertheless, as demonstrated in caspase-9-deficient murine embryonic fibroblasts, human lymphoma cells, and chicken DT40 cells, stauro-sporine-induced apoptosis was essentially mediated by caspase-9. Our results therefore suggest that, in addition to the classical cytochrome c/Apaf-1-dependent pathway of caspase-9 activation, staurosporine can induce caspase-9 activation and apoptosis independently of the apoptosome. Since staurosporine derivatives have proven efficacy in clinical trials, activation of this novel pathway might represent a powerful target to induce apoptosis in multidrug-resistant tumor cells.-Manns, J., Daubrawa, M., Driessen, S., Paasch, F., Hoffmann, N., Loffler, A., Lauber, K., Dieterle, A., Alers, S., Iftner, T., Schulze-Osthoff, K., Stork, B., Wesselborg, S. Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1. FASEB J. 25, 3250-3261 (2011). www.fasebj.org	[Manns, Joachim; Daubrawa, Merle; Driessen, Stefan; Paasch, Florian; Hoffmann, Nadine; Loeffler, Antje; Lauber, Kirsten; Dieterle, Alexandra; Alers, Sebastian; Stork, Bjoern; Wesselborg, Sebastian] Univ Tubingen, Dept Internal Med 1, Tubingen, Germany; [Iftner, Thomas] Univ Tubingen, Div Expt Virol, Inst Med Virol & Epidemiol Viral Dis, Tubingen, Germany; [Schulze-Osthoff, Klaus] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	sebastian.wesselborg@uni-tuebingen.de	Schulze-Osthoff, Klaus/N-9025-2013; Manns, J/AAA-4986-2020; Stork, Björn/C-2160-2011; Iftner, Thomas/ABF-9029-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Stork, Björn/0000-0002-4167-7806; Wesselborg, Sebastian/0000-0002-5236-942X; Alers, Sebastian/0000-0002-9813-9451; Alers, Alexandra Maria/0000-0002-7863-3559	Deutsche Forschungsgemeinschaft [We 1801/2-4, GRK 1302, SFB 685, SFB 773]; Interdisciplinary Center of Clinical Research Tubingen (IZKF) [01KS9602, 1866-0-0]; Wilhelm Sander-Stiftung [2004.099.1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Center of Clinical Research Tubingen (IZKF); Wilhelm Sander-Stiftung	The authors thank Claus Belka (Ludwig-Maximilians University, Munich, Germany), John Blenis (Harvard Medical School, Boston, MA, USA), Simone Fulda (Universtitatsklinikum Ulm, Ulm, Germany), Marja Jaattela (Danish Cancer Society, Copenhagen, Denmark), Ottmar Janssen (University of Kiel, Kiel, Germany), Maria S. Soengas (University of Michigan, Ann Arbor, MI, USA), Edward A. Sausville (National Cancer Institute, Rockville, MD, USA), Andreas Strasser (Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia), Henning Walczak (Imperial College London, London, UK), and the Drug Synthesis and Chemistry Branch (Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA) for providing valuable cell lines and reagents. This work was supported by grants from the Deutsche Forschungsgemeinschaft We 1801/2-4 (S.W.), GRK 1302 (B. S., K.S.O., S. W.), SFB 685 (K. L., K.S.O., S. W.), SFB 773 (B. S., K.S.O., S. W., T. I.), the Interdisciplinary Center of Clinical Research Tubingen (IZKF; Fo. 01KS9602 to S. W.; Fo. 1866-0-0 to B. S.) and the Wilhelm Sander-Stiftung (2004.099.1; S.W.).	Aleo E, 2006, CANCER RES, V66, P9235, DOI 10.1158/0008-5472.CAN-06-0702; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dees EC, 2005, CLIN CANCER RES, V11, P664; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Harkin ST, 1998, MOL PHARMACOL, V54, P663; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Kawabe T, 2004, MOL CANCER THER, V3, P513; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200; McDonnell MA, 2008, J BIOL CHEM, V283, P20149, DOI 10.1074/jbc.M802846200; Milleron RS, 2006, J BIOL CHEM, V281, P16991, DOI 10.1074/jbc.M512754200; Nagasaka A, 2010, CELL DEATH DIFFER, V17, P931, DOI 10.1038/cdd.2009.186; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Raina D, 2005, J BIOL CHEM, V280, P11147, DOI 10.1074/jbc.M413787200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rudner J, 2001, J CELL SCI, V114, P4161; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Seifert A, 2008, FEBS J, V275, P6268, DOI 10.1111/j.1742-4658.2008.06751.x; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Waibel M, 2007, APOPTOSIS, V12, P623, DOI 10.1007/s10495-006-0006-z; Walensky LD, 2006, CELL DEATH DIFFER, V13, P1339, DOI 10.1038/sj.cdd.4401992; Wilson WH, 2000, CLIN CANCER RES, V6, P415; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zanon M, 2004, CANCER RES, V64, P7386, DOI 10.1158/0008-5472.CAN-04-1640; Zhang XD, 2004, MOL CANCER THER, V3, P187	51	68	71	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3250	3261		10.1096/fj.10-177527	http://dx.doi.org/10.1096/fj.10-177527			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21659556				2022-12-28	WOS:000294435200037
J	Zhou, QY; Pardo, A; Konigshoff, M; Eickelberg, O; Budinger, GRS; Thavarajah, K; Gottardi, CJ; Jones, J; Varga, J; Selman, M; Sznajder, JI; Raj, JU; Zhou, GF				Zhou, Qiyuan; Pardo, Annie; Koenigshoff, Melanie; Eickelberg, Oliver; Budinger, G. R. Scott; Thavarajah, Krishna; Gottardi, Cara J.; Jones, Jonathan; Varga, John; Selman, Moises; Sznajder, Jacob I.; Raj, J. Usha; Zhou, Guofei			Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis	FASEB JOURNAL			English	Article						idiopathic pulmonary fibrosis; extracellular matrix; integrin alpha 5 beta 1; focal adhesion kinase	GROWTH-FACTOR-BETA; PULMONARY-FIBROSIS; TGF-BETA; MATRIX DEPOSITION; HIF-ALPHA; IN-VIVO; INTEGRIN; FIBRONECTIN; ACTIVATION; INTEGRIN-ALPHA-V-BETA-6	Idiopathic pulmonary fibrosis (IPF) is characterized by exaggerated fibroblast proliferation and accumulation of collagens and fibronectin. The extracellular fibronectin and collagen network is regulated by von Hippel-Lindau protein (pVHL). However, it is unknown whether pVHL contributes to pulmonary fibrosis. We found that lungs from patients with IPF expressed increased levels of pVHL in fibroblastic foci. Bleomycin treatment also induced pVHL in lung fibroblasts, but not in alveolar type II cells. Overexpression of pVHL increased lung fibroblast proliferation, protein abundance of fibronectin and collagen, and extracellular fibronectin. In addition, overexpression of pVHL induced expression of the alpha 5 integrin subunit. Overexpression of pVHL did not alter hypoxia-inducible factor luciferase reporter activity and mRNA expression of vascular endothelial growth factor. Fibroblasts overexpressing pVHL were more sensitive to RGD peptide-mediated reduction in proliferation. Activating alpha 5 and beta 1 integrin increased proliferation of fibroblasts overexpressing pVHL and those cells were more resistant to the inhibition of alpha 5 integrin. Overexpression of pVHL also increased activation of focal adhesion kinase (FAK). Moreover, suppression of pVHL prevented TGF-beta 1-induced proliferation of mouse embryonic fibroblasts. Taken together, our results indicate that elevated expression of pVHL results in the aberrant fibronectin expression, activation of integrin/FAK signaling, fibroblast proliferation, and fibrosis.-Zhou, Q., Pardo, A., Konigshoff, M., Eickelberg, O., Budinger, G. R. S., Thavarajah, K., Gottardi, C. J., Jones, J., Varga, J., Selman, M., Sznajder, J. I., Raj, J. U., Zhou, G. Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis. FASEB J. 25, 3032-3044 (2011). www.fasebj.org	[Zhou, Qiyuan; Raj, J. Usha; Zhou, Guofei] Univ Illinois, Dept Pediat, Chicago, IL 60612 USA; [Pardo, Annie] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico; [Koenigshoff, Melanie; Eickelberg, Oliver] Univ Munich, Comprehens Pneumol Ctr, Neuherberg, Germany; [Koenigshoff, Melanie; Eickelberg, Oliver] Helmholtz Zentrum Munchen, Inst Lung Biol & Dis, Neuherberg, Germany; [Budinger, G. R. Scott; Thavarajah, Krishna; Gottardi, Cara J.; Sznajder, Jacob I.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Jones, Jonathan] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL USA; [Varga, John] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA; [Selman, Moises] Inst Nacl Enfermedades Resp, Tlalpan, Mexico	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Universidad Nacional Autonoma de Mexico; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Zhou, GF (corresponding author), Univ Illinois, Dept Pediat, 840 S Wood St,Ste 1206,M-C 856, Chicago, IL 60612 USA.	guofei@uic.edu	Varga, John/AAK-6472-2021; Eickelberg, Oliver/A-5461-2013; Jones, Jonathan C R/T-9467-2017; Gottardi, Cara J./AAU-4691-2021	Eickelberg, Oliver/0000-0001-7170-0360; Jones, Jonathan C R/0000-0002-1496-4922; Gottardi, Cara J./0000-0003-0912-7617	U.S. National Institutes of Health [HL-071643, HL-093014, AR-042309]; Parker B. Francis foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643, R01HL093014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309, R56AR042309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013995] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by U.S. National Institutes of Health grants HL-071643, HL-093014 (J.I.S.), and AR-042309 (J.V.), and a Parker B. Francis foundation fellowship (G.Z.). The authors greatly appreciate Ms. Christine Y. Kim for her insightful reading of their manuscript.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Budinger GRS, 2006, P NATL ACAD SCI USA, V103, P4604, DOI 10.1073/pnas.0507604103; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; du Bois RM, 2010, NAT REV DRUG DISCOV, V9, P129, DOI 10.1038/nrd2958; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Fontana L, 2005, FASEB J, V19, P1798, DOI 10.1096/fj.05-4134com; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Hickey MM, 2010, J CLIN INVEST, V120, P827, DOI 10.1172/JCI36362; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Horowitz JC, 2007, CELL SIGNAL, V19, P761, DOI 10.1016/j.cellsig.2006.10.001; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jatta K, 2009, J CLIN PATHOL, V62, P70, DOI 10.1136/jcp.2008.057190; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Lei L, 2008, MOL CELL BIOL, V28, P3790, DOI 10.1128/MCB.01580-07; Liu J, 2005, CELL METAB, V2, P165, DOI 10.1016/j.cmet.2005.08.006; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Meighan CM, 2008, CURR OPIN CELL BIOL, V20, P520, DOI 10.1016/j.ceb.2008.05.010; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pardo A, 2005, PLOS MED, V2, P891, DOI 10.1371/journal.pmed.0020251; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009	40	18	19	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3032	3044		10.1096/fj.10-177824	http://dx.doi.org/10.1096/fj.10-177824			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21642472	Green Published			2022-12-28	WOS:000294435200018
J	Zhou, XD; Hu, XY; He, WX; Tang, XY; Shi, Q; Zhang, ZH; Yan, RQ				Zhou, Xiangdong; Hu, Xiangyou; He, Wanxia; Tang, Xiaoying; Shi, Qi; Zhang, Zhuohua; Yan, Riqiang			Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition	FASEB JOURNAL			English	Article						Alzheimer's disease; reticulon; BACE1	BETA-PEPTIDE GENERATION; ALZHEIMERS-DISEASE; AXONAL REGENERATION; GENETIC DELETION; ALPHA-SECRETASE; GAMMA-SECRETASE; NERVOUS-SYSTEM; A-BETA; BACE1; INHIBITION	Excessive production or accumulation of beta-amyloid (A beta) peptides in human brains leads to increased amyloid deposition and cognitive dysfunction, which are invariable pathological features in patients with Alzheimer's disease (AD). Many cellular factors can regulate the production of A beta. In this study, we show that a family of proteins named Nogo receptor proteins (NgR1 to NgR3) regulates A beta production via interaction with amyloid precursor protein (APP). Further mapping of the interacting domain indicates that a small region adjacent to the BACE1 cleavage site of APP mediates interaction of APP with Nogo receptor proteins. Our results also indicate that increased interaction between Nogo receptor and APP reduces surface expression of APP and favors processing of APP by BACE1. When NgR2 was ablated in AD transgenic mice expressing Swedish APP and PS1 Delta E9, amyloid deposition was clearly reduced (0.66% of total measured area in APP(swe)/PS1 Delta E9/NgR2(-/-) mice vs. 0.76% of total measured area in APP(swe)/PS1 Delta E9 mice). Our results demonstrate that down-regulation of NgR expression is a potential approach for inhibiting amyloid deposition in AD patients.-Zhou, X., Hu, X., He, W., Tang, X., Shi, Q., Zhang, Z., Yan, R. Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition. FASEB J. 25, 3146-3156 (2011). www.fasebj.org	[Zhou, Xiangdong; Hu, Xiangyou; He, Wanxia; Tang, Xiaoying; Shi, Qi; Yan, Riqiang] Cleveland Clin, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; [Zhang, Zhuohua] Cent S Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China	Cleveland Clinic Foundation; Central South University	Yan, RQ (corresponding author), Cleveland Clin, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.	yanr@ccf.org		Yan, Riqiang/0000-0001-7195-7617	American Health Assistance Foundation [A2006-060]; National Institute on Aging [AG025493]; NATIONAL INSTITUTE ON AGING [R01AG025493] Funding Source: NIH RePORTER	American Health Assistance Foundation(BrightFocus Foundation); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Chris Nelson for critical reading of this manuscript. This work was fully supported by the American Health Assistance Foundation to R.Y. (A2006-060) between 2006 and 2009. R.Y. is also supported by the National Institute on Aging (AG025493).	Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Budel S, 2008, J NEUROSCI, V28, P13161, DOI 10.1523/JNEUROSCI.3828-08.2008; Cafferty WBJ, 2010, J NEUROSCI, V30, P6825, DOI 10.1523/JNEUROSCI.6239-09.2010; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Deuss M, 2008, CURR ALZHEIMER RES, V5, P187, DOI 10.2174/156720508783954686; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harrison KD, 2009, CELL METAB, V10, P208, DOI 10.1016/j.cmet.2009.07.003; He WX, 2007, J BIOL CHEM, V282, P29144, DOI 10.1074/jbc.M704181200; He WX, 2006, J MOL BIOL, V363, P625, DOI 10.1016/j.jmb.2006.07.094; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Lauren J, 2003, MOL CELL NEUROSCI, V24, P581, DOI 10.1016/S1044-7431(03)00199-4; Lee JK, 2010, NEURON, V66, P663, DOI 10.1016/j.neuron.2010.05.002; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Luo XY, 2010, INT J CLIN EXP PATHO, V3, P618; Majercak J, 2006, P NATL ACAD SCI USA, V103, P17967, DOI 10.1073/pnas.0605461103; Murayama KS, 2006, EUR J NEUROSCI, V24, P1237, DOI 10.1111/j.1460-9568.2006.05005.x; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Pignot V, 2003, J NEUROCHEM, V85, P717, DOI 10.1046/j.1471-4159.2003.01710.x; Prior M, 2010, NEUROSCI BIOBEHAV R, V34, P1201, DOI 10.1016/j.neubiorev.2010.01.017; Qahwash I, 2004, J BIOL CHEM, V279, P39010, DOI 10.1074/jbc.M407101200; Shi Q, 2009, J NEUROSCI, V29, P9163, DOI 10.1523/JNEUROSCI.5741-08.2009; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Strittmatter SM, 2002, J MOL NEUROSCI, V19, P117, DOI 10.1007/s12031-002-0021-7; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009; Voineskos AN, 2009, J NEUROSCI, V29, P5045, DOI 10.1523/JNEUROSCI.0477-09.2009; Wang RS, 2006, J BIOL CHEM, V281, P15330, DOI 10.1074/jbc.M512574200; Willi R, 2010, J NEUROSCI, V30, P556, DOI 10.1523/JNEUROSCI.4393-09.2010; Wojcik S, 2007, ACTA NEUROPATHOL, V114, P517, DOI 10.1007/s00401-007-0281-y; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang YS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-12-234	46	29	32	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3146	3156		10.1096/fj.11-184325	http://dx.doi.org/10.1096/fj.11-184325			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21670066	Green Published			2022-12-28	WOS:000294435200028
J	Kubota, H; Wu, X; Goodyear, SM; Avarbock, MR; Brinster, RL				Kubota, Hiroshi; Wu, Xin; Goodyear, Shaun M.; Avarbock, Mary R.; Brinster, Ralph L.			Glial cell line-derived neurotrophic factor and endothelial cells promote self-renewal of rabbit germ cells with spermatogonial stem cell properties	FASEB JOURNAL			English	Article						spermatogenesis; testis; growth factors	IN-VITRO; MOUSE TESTES; UNDIFFERENTIATED SPERMATOGONIA; LENTIVIRAL VECTOR; TRANSPLANTATION; CULTURE; MICE; RAT; EXPRESSION; FATE	Previous studies suggest that exogenous factors crucial for spermatogonial stem cell (SSC) self-renewal are conserved among several mammalian species. Since glial cell line-derived neurotrophic factor (GDNF) and fibroblast growth factor 2 (FGF2) are critical for rodent SSC self-renewal, we hypothesized that they might promote self-renewal of nonrodent SSCs. Therefore, we cultured testicular germ cells from prepubertal rabbits in the presence of GDNF and FGF2 and found they proliferated indefinitely as cellular clumps that displayed characteristics previously identified for rodent SSCs. The rabbit germ cells could not be maintained on mouse embryonic fibroblast (STO) feeders that support rodent SSC self-renewal in vitro but were rather supported on mouse yolk sac-derived endothelial cell (C166) feeder layers. Proliferation of rabbit germ cells was dependent on GDNF. Of critical importance was that clump-forming rabbit germ cells colonized seminiferous tubules of immunodeficient mice, proliferated for at least 6 mo, while retaining an SSC phenotype in the testes of recipient mice, indicating that they were rabbit SSCs. This study demonstrates that GDNF is a mitogenic factor promoting self-renewal that is conserved between rodent and rabbit SSCs; with an evolutionary separation of similar to 60 million years. These findings provide a foundation to study the mechanisms governing SSC self-renewal in nonrodent species.-Kubota, H., Wu, X., Goodyear, S. M., Avarbock, M. R., Brinster, R. L. Glial cell line-derived neurotrophic factor and endothelial cells promote self-renewal of rabbit germ cells with spermatogonial stem cell properties. FASEB J. 25, 2604-2614 (2011). www.fasebj.org	[Kubota, Hiroshi; Wu, Xin; Goodyear, Shaun M.; Avarbock, Mary R.; Brinster, Ralph L.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Brinster, RL (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3850 Baltimore Ave, Philadelphia, PA 19104 USA.	cpope@vet.upenn.edu	wu, xin/A-3010-2011; KUBOTA, Hiroshi/N-7832-2019	Brinster, Ralph/0000-0003-1408-7656; Goodyear, Shaun/0000-0003-0217-0890; wu, xin/0000-0001-7938-9407	U.S. National Institute of Child Health and Human Development [HD 052728]; Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD052728] Funding Source: NIH RePORTER	U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Dr. Zhiyv Niu for helpful comments on the manuscript, Drs. L. Wang and J. Johnston for construction and production of lentivirus vectors at the Penn Vector Core, C. Freeman and R. Naroznowski for assistance with animal maintenance and experimentation, and J. Hayden for photography. Financial support for the research was from the U.S. National Institute of Child Health and Human Development (HD 052728) and the Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation.	Aponte PM, 2008, REPRODUCTION, V136, P543, DOI 10.1530/REP-07-0419; Brinster RL, 2007, SCIENCE, V316, P404, DOI 10.1126/science.1137741; Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; De Rooij DG, 2000, J ANDROL, V21, P776; Dobrinski I, 1999, BIOL REPROD, V61, P1331, DOI 10.1095/biolreprod61.5.1331; Dobrinski I, 2000, MOL REPROD DEV, V57, P270, DOI 10.1002/1098-2795(200011)57:3&lt;270::AID-MRD9&gt;3.0.CO;2-Z; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; Hamra FK, 2005, P NATL ACAD SCI USA, V102, P17430, DOI 10.1073/pnas.0508780102; Hamra FK, 2002, P NATL ACAD SCI USA, V99, P14931, DOI 10.1073/pnas.222561399; He ZP, 2010, BIOL REPROD, V82, P363, DOI 10.1095/biolreprod.109.078550; Hermann BP, 2009, HUM REPROD, V24, P1704, DOI 10.1093/humrep/dep073; Kanatsu-Shinohara M, 2004, BIOL REPROD, V70, P70, DOI 10.1095/biolreprod.103.020867; Kanatsu-Shinohara M, 2003, BIOL REPROD, V69, P612, DOI 10.1095/biolreprod.103.017012; Kanatsu-Shinohara M, 2008, BIOL REPROD, V78, P611, DOI 10.1095/biolreprod.107.065615; Kanatsu-Shinohara M, 2006, P NATL ACAD SCI USA, V103, P8018, DOI 10.1073/pnas.0601139103; Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664; Kubota H, 2006, NAT CLIN PRACT ENDOC, V2, P99, DOI 10.1038/ncpendmet0098; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207; Kubota H, 2008, METHOD CELL BIOL, V86, P59, DOI 10.1016/S0091-679X(08)00004-6; Kubota H, 2009, BIOL REPROD, V81, P293, DOI 10.1095/biolreprod.109.075960; Lu LS, 1996, P NATL ACAD SCI USA, V93, P14782, DOI 10.1073/pnas.93.25.14782; Matzuk MM, 2004, P NATL ACAD SCI USA, V101, P16395, DOI 10.1073/pnas.0407344101; McKenna MC, 1997, CLASSIFICATION MAMMA; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Nagano M, 2002, FERTIL STERIL, V78, P1225, DOI 10.1016/S0015-0282(02)04345-5; Nagano M, 2001, BIOL REPROD, V64, P1409, DOI 10.1095/biolreprod64.5.1409; Nagano MC, 2003, BIOL REPROD, V69, P701, DOI 10.1095/biolreprod.103.016352; Nakagawa T, 2010, SCIENCE, V328, P62, DOI 10.1126/science.1182868; Naughton CK, 2006, BIOL REPROD, V74, P314, DOI 10.1095/biolreprod.105.047365; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Reding SC, 2010, REPRODUCTION, V139, P893, DOI 10.1530/REP-09-0513; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Ryu BY, 2005, P NATL ACAD SCI USA, V102, P14302, DOI 10.1073/pnas.0506970102; Sadri-Ardekani H, 2009, JAMA-J AM MED ASSOC, V302, P2127, DOI 10.1001/jama.2009.1689; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Spinnler K, 2010, HUM REPROD, V25, P2181, DOI 10.1093/humrep/deq170; Viglietto G, 2000, INT J ONCOL, V16, P689; Wu X, 2009, P NATL ACAD SCI USA, V106, P21672, DOI 10.1073/pnas.0912432106; Yoshida S, 2007, SCIENCE, V317, P1722, DOI 10.1126/science.1144885	50	47	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2604	2614		10.1096/fj.10-175802	http://dx.doi.org/10.1096/fj.10-175802			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21525489	Green Published			2022-12-28	WOS:000293337800011
J	Li, ZJ; Burns, AR; Miller, SB; Smith, CW				Li, Zhijie; Burns, Alan R.; Miller, Sarah Byeseda; Smith, C. Wayne			CCL20, gamma delta T cells, and IL-22 in corneal epithelial healing	FASEB JOURNAL			English	Article						ICAM-1; IL-17A; IL-23R; neutrophils; platelets	ENDOTHELIAL GROWTH-FACTOR; STIMULATES AXONAL OUTGROWTH; SPINAL-CORD-INJURY; MHC CLASS-II; CHEMOKINE RECEPTOR; NEUROTROPHIC KERATOPATHY; ANTIMICROBIAL PEPTIDES; INTRACELLULAR POOL; HUMAN NEUTROPHILS; DENDRITIC CELLS	After corneal epithelial abrasion, leukocytes and platelets rapidly enter the corneal stroma, and CCR6(+) IL-17(+) gamma delta T cells migrate into the epithelium. gamma delta T-cell-deficient (TCR delta(-/-)) mice have significantly reduced inflammation and epithelial wound healing. Epithelial CCL20 mRNA increased 19-fold at 3 h, and protein increased similar to 16-fold at 6 h after injury. Systemic or topical treatment of wild-type C57BL/6 mice with anti-CCL20 reduced gamma delta T-cell accumulation in the cornea by > 50% with a concomitant decrease in epithelial healing and stromal inflammation. In addition to CCR6 and IL-17, corneal gamma delta T cells stained positively for ROR gamma t, IL-23R, and IL-22. Anti-IL-22 reduced peak cell division of the healing epithelium by 52%. Treatment of TCR delta(-/-) mice with rIL-22 significantly promoted wound closure, with peak epithelial cell division increased > 3-fold. In addition, rIL-22 restored neutrophil and platelet influx in the TCR delta(-/-) mice to wildtype levels and increased CXCL1 production by wounded corneal explants > 2-fold. These results indicate that an important aspect of the healing response to corneal epithelial abrasion includes CCL20-dependent influx of CCR6(+) IL-17(+) IL-22(+) gamma delta T cells and that IL-22 contributes to the inflammatory response and promotes epithelial healing.-Li, Z., Burns, A. R., Byeseda Miller, S., Smith, C. W. CCL20, gamma delta T cells, and IL-22 in corneal epithelial healing. FASEB J. 25, 2659-2668 (2011). www.fasebj.org	[Smith, C. Wayne] Baylor Coll Med, Dept Pediat, Sect Leukocyte Biol, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Smith, C. Wayne] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Li, Zhijie] Jinan Univ, Minist Educ, Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Li, Zhijie] Jinan Univ, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China; [Burns, Alan R.] Univ Houston, Coll Optometry, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Jinan University; Jinan University; University of Houston System; University of Houston	Smith, CW (corresponding author), Baylor Coll Med, Dept Pediat, Sect Leukocyte Biol, Childrens Nutr Res Ctr, 1100 Bates,Rm 6014, Houston, TX 77030 USA.	cwsmith@bcm.tmc.edu			U.S. National Institutes of Health [EY-018239, EY-00751, EY-017120]; National Natural Science Foundation of China [39970250, 30772387, 81070703]; NATIONAL EYE INSTITUTE [P30EY007551, R01EY017120, R01EY018239] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by U.S. National Institutes of Health grants EY-018239, EY-00751, and EY-017120 and National Natural Science Foundation of China grants 39970250, 30772387, and 81070703.	ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Braun RK, 2008, INFLAMMATION, V31, P167, DOI 10.1007/s10753-008-9062-6; Byeseda SE, 2009, AM J PATHOL, V175, P571, DOI 10.2353/ajpath.2009.090112; Chinnery HR, 2007, INVEST OPHTH VIS SCI, V48, P1568, DOI 10.1167/iovs.06-0746; Cole N, 2000, IMMUNOL CELL BIOL, V78, P1, DOI 10.1046/j.1440-1711.2000.00860.x; Cooper D, 2003, AM J PHYSIOL-GASTR L, V284, pG1027, DOI 10.1152/ajpgi.00457.2002; Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391; Dovi JV, 2003, J LEUKOCYTE BIOL, V73, P448, DOI 10.1189/jlb.0802406; Eppley BL, 2004, PLAST RECONSTR SURG, V114, P1502, DOI 10.1097/01.PRS.0000138251.07040.51; FERRARI G, 2010, INVEST OPHTHALMOL VI; Gagen D, 2010, EXP EYE RES, V91, P676, DOI 10.1016/j.exer.2010.08.007; Gan L, 1999, INVEST OPHTH VIS SCI, V40, P575; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; Gong Y, 2010, CELL TISSUE RES, V339, P437, DOI 10.1007/s00441-009-0908-5; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Grenier A, 2002, BLOOD, V99, P2997, DOI 10.1182/blood.V99.8.2997; Haas JD, 2009, EUR J IMMUNOL, V39, P3488, DOI 10.1002/eji.200939922; Hamrah P, 2003, J LEUKOCYTE BIOL, V74, P172, DOI 10.1189/jlb.1102544; Havran WL, 2010, J IMMUNOL, V184, P5423, DOI 10.4049/jimmunol.0902733; Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; Huang LC, 2007, CURR EYE RES, V32, P595, DOI 10.1080/02713680701446653; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin YP, 2007, MOL VIS, V13, P626; KAREY KP, 1989, BLOOD, V74, P1093; Knickelbein JE, 2009, OPHTHALMOL EYE DIS, V1, P45; Laurence A, 2008, NAT MED, V14, P247, DOI 10.1038/nm0308-247; Lee EJ, 2010, INVEST OPHTH VIS SCI, V51, P2101, DOI 10.1167/iovs.08-2213; Li Z, 2007, AM J PATHOL, V171, P838, DOI 10.2353/ajpath.2007.070008; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P4794, DOI 10.1167/iovs.06-0381; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P1947, DOI 10.1167/iovs.05-1193; Li ZJ, 2011, AM J PATHOL, V178, P1106, DOI 10.1016/j.ajpath.2010.12.001; Li ZJ, 2004, J APPL PHYSIOL, V97, P641, DOI 10.1152/japplphysiol.00200.2004; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Nagano T, 2003, INVEST OPHTH VIS SCI, V44, P3810, DOI 10.1167/iovs.03-0189; Nishida T, 2009, CURR OPIN OPHTHALMOL, V20, P276, DOI 10.1097/ICU.0b013e32832b758f; O'Brien RL, 2009, EUR J IMMUNOL, V39, P662, DOI 10.1002/eji.200839120; Ouyang WJ, 2010, CYTOKINE GROWTH F R, V21, P435, DOI 10.1016/j.cytogfr.2010.10.007; Pereira HA, 2004, INVEST OPHTH VIS SCI, V45, P4284, DOI 10.1167/iovs.03-1052; Petrescu MS, 2007, INVEST OPHTH VIS SCI, V48, P5023, DOI 10.1167/iovs.07-0562; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Robker RL, 2004, OBES RES, V12, P936, DOI 10.1038/oby.2004.114; Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Scapini P, 2004, J IMMUNOL, V172, P5034, DOI 10.4049/jimmunol.172.8.5034; Scapini P, 1999, J IMMUNOL METHODS, V232, P121, DOI 10.1016/S0022-1759(99)00170-2; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Shirane J, 2004, CURR EYE RES, V28, P297, DOI 10.1076/ceyr.28.5.297.28682; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Taichman NS, 1997, J LEUKOCYTE BIOL, V62, P397, DOI 10.1002/jlb.62.3.397; Toulon A, 2009, J EXP MED, V206, P743, DOI 10.1084/jem.20081787; Valeri CR, 2006, TRANSFUSION, V46, P225, DOI 10.1111/j.1537-2995.2006.00705.x; von Vietinghoff S, 2009, J IMMUNOL, V183, P865, DOI 10.4049/jimmunol.0804080; Witherden DA, 2010, SCIENCE, V329, P1205, DOI 10.1126/science.1192698; Yamagami S, 2005, INVEST OPHTH VIS SCI, V46, P1201, DOI 10.1167/iovs.04-0658; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yin ZN, 2002, J IMMUNOL, V168, P1566, DOI 10.4049/jimmunol.168.4.1566; Yu CQ, 2008, INVEST OPHTH VIS SCI, V49, P3870, DOI 10.1167/iovs.07-1418; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	67	77	82	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2659	2668		10.1096/fj.11-184804	http://dx.doi.org/10.1096/fj.11-184804			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21518851	Green Published			2022-12-28	WOS:000293337800016
J	Jiang, XF; Pan, H; Nabhan, JF; Krishnan, R; Koziol-White, C; Panettieri, RA; Lu, Q				Jiang, Xiaofeng; Pan, Hui; Nabhan, Joseph F.; Krishnan, Ramaswamy; Koziol-White, Cynthia; Panettieri, Reynold A.; Lu, Quan			A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in beta 2-adrenergic receptor internalization and down-regulation	FASEB JOURNAL			English	Article						alendronate; beta-agonist; genetic screen; short-hairpin RNA	AIRWAY SMOOTH-MUSCLE; HUMAN BETA(1)-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; RAB GTPASES; MOLECULAR-MECHANISMS; MAMMALIAN-CELLS; 7-TRANSMEMBRANE RECEPTORS; MEVALONATE PATHWAY; ENDOCYTIC PATHWAY	The beta 2-adrenergic receptor (beta 2AR) plays important physiological roles in the heart and lung and is the primary target of beta-agonists, the mainstay asthma drugs. Activation of beta 2AR by beta-agonists is attenuated by receptor down-regulation, which ensures transient stimulation of the receptor but reduces the efficacy of beta-agonists. Here we report the identification, through a functional genome-wide RNA interference (RNAi) screen, of new genes critically involved in beta 2AR down-regulation. We developed a lentivirus-based RNAi library consisting of 26-nt short-hairpin RNAs (shRNAs). The library was generated enzymatically from a large collection of expressed sequence tag (EST) DNAs corresponding to similar to 20,000 human genes and contains on average similar to 6 highly potent shRNAs (>75% knockdown efficiency) for each gene. Using this novel shRNA library, together with a robust cell model for beta 2AR expression, we performed fluorescence-activated cell sorting and isolated cells that, as a consequence of shRNA-mediated gene inactivation, exhibited defective agonist-induced down-regulation. The screen discovered several previously unrecognized beta 2AR regulators, including farnesyl diphosphate synthase (FDPS). We showed that inactivation of FDPS by shRNA, small interfering RNA, or the highly specific pharmaceutical inhibitor alendronate inhibited beta 2AR down-regulation. Notably, in human airway smooth muscle cells, the physiological target of beta-agonists, alendronate treatment functionally reversed agonist-induced endogenous beta 2AR loss as indicated by an increase in cAMP production. FDPS inactivation interfered with beta 2AR internalization into endosomes through disrupting the membrane localization of the Rab5 small GTPase. Furthermore, Rab5 overexpression reversed the deficient receptor down-regulation induced by alendronate, suggesting that FDPS regulates receptor down-regulation in a Rab5-dependent manner. Together, our findings reveal a FDPS-dependent mechanism in the internalization and down-regulation of beta 2AR, identify FDPS as a potential target for improving the therapeutic efficacy of beta-agonists, and demonstrate the utility of the unique EST-derived shRNA library for functional genetics studies.-Jiang, X., Pan, H., Nabhan, J. F., Krishnan, R., Koziol-White, C., Panettieri, R. A., Lu, Q. A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in beta 2-adrenergic receptor internalization and down-regulation. FASEB J. 26, 1995-2007 (2012). www.fasebj.org	[Jiang, Xiaofeng; Pan, Hui; Nabhan, Joseph F.; Lu, Quan] Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, Boston, MA 02115 USA; [Lu, Quan] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Krishnan, Ramaswamy] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Vasc Biol Res Ctr, Boston, MA 02215 USA; [Koziol-White, Cynthia; Panettieri, Reynold A.] Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania	Lu, Q (corresponding author), Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	qlu@hsph.harvard.edu	panettieri, reynold/AAG-9485-2019		American Lung Association Biomedical Research; Harvard-National Institute of Environmental Health Sciences (NIEHS) Center [P30ES000002]; NIEHS [P42ES016454]; U.S. National Institutes of Health (NIH) [HL097796, P30ES013508]; NIH [5T32HL7118-35]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097796, T32HL007118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES016454, P30ES013508, P30ES000002] Funding Source: NIH RePORTER	American Lung Association Biomedical Research; Harvard-National Institute of Environmental Health Sciences (NIEHS) Center; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Drs. Lester Kobzik and Marianne Wessling-Resnick for critical reading of the manuscript. The authors are also grateful for the advice and help from other members of the Q.L. laboratory. Q.L. was supported by an American Lung Association Biomedical Research grant, a Harvard-National Institute of Environmental Health Sciences (NIEHS) Center grant (P30ES000002), and a NIEHS Super-fund Research Program grant (P42ES016454). R.A.P. was supported by U.S. National Institutes of Health (NIH) grants HL097796 and P30ES013508. X.J. was supported by a NIH training grant (5T32HL7118-35).	Abramson Michael J, 2003, Am J Respir Med, V2, P287; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Billington CK, 2003, RESP RES, V4; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chang ACY, 2006, J VIROL, V80, P8705, DOI 10.1128/JVI.00475-06; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cooper PR, 2009, AM J PHYSIOL-LUNG C, V297, pL530, DOI 10.1152/ajplung.00133.2009; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dohlman HG, 2002, NATURE, V418, P591, DOI 10.1038/418591a; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fellmann C, 2011, MOL CELL, V41, P733, DOI 10.1016/j.molcel.2011.02.008; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Haney S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-19; Haney S, 2006, CLIN REV ALLERG IMMU, V31, P181, DOI 10.1385/CRIAI:31:2:181; Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830; Insel PA, 2005, ANN NY ACAD SCI, V1047, P166, DOI 10.1196/annals.1341.015; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Laporte JD, 1998, AM J PHYSIOL-LUNG C, V275, pL491, DOI 10.1152/ajplung.1998.275.3.L491; Liang W, 2004, J BIOL CHEM, V279, P46882, DOI 10.1074/jbc.M406501200; Liang W, 2003, J BIOL CHEM, V278, P39773, DOI 10.1074/jbc.M304482200; LIGGETT SB, 1991, PHARMACOL RES, V24, P29, DOI 10.1016/1043-6618(91)90119-I; Lipworth BJ, 1997, DRUG SAFETY, V16, P295, DOI 10.2165/00002018-199716050-00002; Lu Q, 2004, P NATL ACAD SCI USA, V101, P17246, DOI 10.1073/pnas.0407794101; Moncke-Buchner E, 2004, J BIOTECHNOL, V114, P99, DOI 10.1016/j.jbiotec.2004.06.014; Moore PE, 2000, AM J RESP CRIT CARE, V162, P2117, DOI 10.1164/ajrccm.162.6.9909046; Moore RH, 2004, J CELL SCI, V117, P3107, DOI 10.1242/jcs.01168; Moore RH, 1999, EUR J PHARMACOL, V369, P113, DOI 10.1016/S0014-2999(99)00055-2; Nabhan JF, 2010, EMBO REP, V11, P605, DOI 10.1038/embor.2010.80; Nelson HS, 2006, ANN INTERN MED, V145, P706, DOI 10.7326/0003-4819-145-9-200611070-00017; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Parent A, 2009, BIOCHEM J, V418, P163, DOI 10.1042/BJ20080867; Penn Raymond B, 2008, Proc Am Thorac Soc, V5, P47, DOI 10.1513/pats.200705-054VS; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pontier SM, 2008, J BIOL CHEM, V283, P24659, DOI 10.1074/jbc.M800778200; Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731; Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078-0432.CCR-06-0843; Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006-2023H; Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Sharma S, 2008, J ALLERGY CLIN IMMUN, V122, P921, DOI 10.1016/j.jaci.2008.09.004; Shenoy SK, 2005, NAT CELL BIOL, V7, P1159, DOI 10.1038/ncb1205-1159; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shenoy SK, 2008, J BIOL CHEM, V283, P22166, DOI 10.1074/jbc.M709668200; Shenoy SK, 2007, CIRC RES, V100, P1142, DOI 10.1161/01.RES.0000261939.88744.5a; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Shore SA, 2003, RESP PHYSIOL NEUROBI, V137, P179, DOI 10.1016/S1569-9048(03)00146-0; Shore SA, 2003, J CLIN INVEST, V112, P495, DOI 10.1172/JCI200319642; Shtutman M, 2010, P NATL ACAD SCI USA, V107, P7377, DOI 10.1073/pnas.1003055107; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Tantisira KG, 2005, CURR OPIN MOL THER, V7, P209; Tattersfield AE, 2002, LANCET, V360, P1313, DOI 10.1016/S0140-6736(02)11312-2; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Walker J. K., BR J PHARM, V163, P18; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Williams BR, 2000, MOL PHARMACOL, V58, P421, DOI 10.1124/mol.58.2.421; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Xiao K., J BIOL CHEM, V286, P12785; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	83	8	10	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1995	2007		10.1096/fj.11-193870	http://dx.doi.org/10.1096/fj.11-193870			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278941	Green Published			2022-12-28	WOS:000303680800026
J	Lasagna-Reeves, CA; Castillo-Carranza, DL; Sengupta, U; Sarmiento, J; Troncoso, J; Jackson, GR; Kayed, R				Lasagna-Reeves, Cristian A.; Castillo-Carranza, Diana L.; Sengupta, Urmi; Sarmiento, Jose; Troncoso, Juan; Jackson, George R.; Kayed, Rakez			Identification of oligomers at early stages of tau aggregation in Alzheimer's disease	FASEB JOURNAL			English	Article						neurodegeneration; conformational antibodies; tauopathies; protein misfolding	RESONANCE ENERGY-TRANSFER; PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; CEREBROSPINAL-FLUID; TRANSGENIC MICE; MOUSE MODEL; CELL-DEATH; A-BETA; EXTRACELLULAR TAU; NEURITIC PLAQUES	Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease (AD); however, the relationship between NFTs and disease progression remains controversial. Analyses of tau animal models suggest that phenotypes coincide with accumulation of soluble aggregated tau species but not the accumulation of NFTs. The pathological role of prefilamentous tau aggregates, e. g., tau oligomeric intermediates, is poorly understood, in part because of methodological challenges. Here, we engineered a novel tau oligomer-specific antibody, T22, and used it to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain. We found that tau oligomers in human AD brain samples were 4-fold higher than those in the controls. We also revealed the role of oligomeric tau conformers in pretangles, neuritic plaques, and neuropil threads in the frontal cortex tissue from AD brains; this analysis uncovers a consistent code that governs tau oligomerization with regard to degree of neuronal cytopathology. These data are the first to characterize the role of tau oligomers in the natural history of NFTs, and they highlight the suitability of tau oligomers as therapeutic targets in AD and related tauopathies.-Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Troncoso, J., Jackson, G. R., Kayed, R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959 (2012). www.fasebj.org	[Lasagna-Reeves, Cristian A.; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, George P & Cynthia Woods Mitchell Ctr Neurodegene, Galveston, TX 77555 USA; [Lasagna-Reeves, Cristian A.; Castillo-Carranza, Diana L.; Sengupta, Urmi; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurol, Galveston, TX USA; [Sarmiento, Jose; Jackson, George R.; Kayed, Rakez] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX USA; [Troncoso, Juan] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University	Kayed, R (corresponding author), Univ Texas Med Branch, George P & Cynthia Woods Mitchell Ctr Neurodegene, 301 Univ Blvd,Med Res Bldg,Room 10-138C, Galveston, TX 77555 USA.	rakayed@utmb.edu	Lasagna-Reeves, Cristian/ABE-2001-2021	Castillo-Carranza, Diana/0000-0003-2511-949X	Cullen Family Trust for Health Care; Alzheimer's Drug Discovery Foundation; Mitchell Center for Neurodegenerative Diseases; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	Cullen Family Trust for Health Care; Alzheimer's Drug Discovery Foundation; Mitchell Center for Neurodegenerative Diseases; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Bridget E. Hawkins for her suggestions and critical reading of the manuscript. The authors are grateful to Prof. Carl Cotman [University of California-Irvine (UCI), Irvine, CA, USA] and the UCI-Alzheimer's Disease Research Center brain bank for providing brain samples, Dr. Marcos Guerrero-Munoz for his help in the purification and characterization of tau oligomers, and Dr. Adriana Paulucci for her help in using the confocal and image analyses. This work was supported by the Cullen Family Trust for Health Care, the Alzheimer's Drug Discovery Foundation, and the Mitchell Center for Neurodegenerative Diseases. R. K. is the founder of ConImm, Inc. and has patent applications on the compositions and methods related to tau oligomers.	Adalbert R, 2009, BRAIN, V132, P402, DOI 10.1093/brain/awn312; Alonso AD, 2008, CURR ALZHEIMER RES, V5, P375, DOI 10.2174/156720508785132307; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Andreasen N, 1999, NEUROSCI LETT, V273, P5, DOI 10.1016/S0304-3940(99)00617-5; Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Avila J, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00049; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Blom ES, 2009, DEMENT GERIATR COGN, V27, P458, DOI 10.1159/000216841; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAAK H, 1988, NEUROPATH APPL NEURO, V14, P39, DOI 10.1111/j.1365-2990.1988.tb00864.x; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Brunden KR, 2008, J ALZHEIMERS DIS, V14, P393; Brundin P, 2010, NAT REV MOL CELL BIO, V11, P301, DOI 10.1038/nrm2873; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Campioni S, 2010, NAT CHEM BIOL, V6, P140, DOI [10.1038/NCHEMBIO.283, 10.1038/nchembio.283]; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Caughey B, 2009, ANNU REV BIOCHEM, V78, P177, DOI 10.1146/annurev.biochem.78.082907.145410; Chatterjee S, 2009, HUM MOL GENET, V18, P164, DOI 10.1093/hmg/ddn326; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Cripps D, 2006, J BIOL CHEM, V281, P10825, DOI 10.1074/jbc.M512786200; Delacourte A, 2002, EXP GERONTOL, V37, P1291, DOI 10.1016/S0531-5565(02)00141-9; Diaz-Hernandez M, 2010, J BIOL CHEM, V285, P32539, DOI 10.1074/jbc.M110.145003; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Duyckaerts C, 2011, ACTA NEUROPATHOL, V121, P145, DOI 10.1007/s00401-010-0794-7; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Galasko D, 1997, NEUROLOGY, V48, P632, DOI 10.1212/WNL.48.3.632; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Gomez-Ramos A, 2008, MOL CELL NEUROSCI, V37, P673, DOI 10.1016/j.mcn.2007.12.010; Gomez-Ramos A, 2006, FEBS LETT, V580, P4842, DOI 10.1016/j.febslet.2006.07.078; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hernandez F, 2010, CURR ALZHEIMER RES, V7, P670, DOI 10.2174/156720510793611583; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Kayed R, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-57; Kayed R, 2009, CURR OPIN IMMUNOL, V21, P359, DOI 10.1016/j.coi.2009.05.001; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knowles RB, 1999, J NEUROPATH EXP NEUR, V58, P1090, DOI 10.1097/00005072-199910000-00007; Lace G, 2009, BRAIN, V132, P1324, DOI 10.1093/brain/awp059; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2011, J BIOL CHEM, V286, P22122, DOI 10.1074/jbc.M111.236257; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Lin YT, 2007, J NEUROCHEM, V103, P802, DOI 10.1111/j.1471-4159.2007.04792.x; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Margittai M, 2006, J BIOL CHEM, V281, P37820, DOI 10.1074/jbc.M605336200; Marx J, 2007, SCIENCE, V316, P1416, DOI 10.1126/science.316.5830.1416; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Meraz-Rios MA, 2010, J NEUROCHEM, V112, P1353, DOI 10.1111/j.1471-4159.2009.06511.x; Mocanu MM, 2008, J NEUROSCI, V28, P737, DOI 10.1523/JNEUROSCI.2824-07.2008; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Oddo S, 2006, J BIOL CHEM, V281, P39413, DOI 10.1074/jbc.M608485200; Paquet D, 2009, J CLIN INVEST, V119, P1382, DOI 10.1172/JCI37537; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Reifert J, 2011, J BIOL CHEM, V286, P20797, DOI 10.1074/jbc.M111.234674; Rostagno A., 2009, CURR PROTOC CELL BIO, P31; Sahara N, 2007, EUR J NEUROSCI, V25, P3020, DOI 10.1111/j.1460-9568.2007.05555.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sharma N, 2001, ACTA NEUROPATHOL, V102, P329; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Small SA, 2008, NEURON, V60, P534, DOI 10.1016/j.neuron.2008.11.007; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Spires-Jones TL, 2011, J MOL NEUROSCI, V45, P438, DOI 10.1007/s12031-011-9566-7; Sydow A, 2011, J NEUROSCI, V31, P2511, DOI 10.1523/JNEUROSCI.5245-10.2011; Talmat-Amar Y, 2011, HUM MOL GENET, V20, P3738, DOI 10.1093/hmg/ddr290; Uchihara T, 2001, ACTA NEUROPATHOL, V101, P535; Umahara T, 2002, NEUROPATHOLOGY, V22, P9, DOI 10.1046/j.0919-6544.2002.00422.x; Vidal R, 2000, ACTA NEUROPATHOL, V100, P1, DOI 10.1007/s004010051186; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yoshida M, 2006, NEUROPATHOLOGY, V26, P457, DOI 10.1111/j.1440-1789.2006.00743.x; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	99	322	327	2	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1946	1959		10.1096/fj.11-199851	http://dx.doi.org/10.1096/fj.11-199851			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253473	Green Published			2022-12-28	WOS:000303680800022
J	Levett, DZ; Radford, EJ; Menassa, DA; Graber, EF; Morash, AJ; Hoppeler, H; Clarke, K; Martin, DS; Ferguson-Smith, AC; Montgomery, HE; Grocott, MPW; Murray, AJ				Levett, Denny Z.; Radford, Elizabeth J.; Menassa, David A.; Graber, E. Franziska; Morash, Andrea J.; Hoppeler, Hans; Clarke, Kieran; Martin, Daniel S.; Ferguson-Smith, Anne C.; Montgomery, Hugh E.; Grocott, Michael P. W.; Murray, Andrew J.		Caudwell Xtreme Everest Res Grp	Acclimatization of skeletal muscle mitochondria to high-altitude hypoxia during an ascent of Everest	FASEB JOURNAL			English	Article						metabolism; energetics	ACTIVATED RECEPTOR-ALPHA; UNCOUPLING PROTEIN-3; HYPOBARIC HYPOXIA; OXYGEN-TRANSPORT; GENE-EXPRESSION; MOUNT EVEREST; RAT-HEART; METABOLISM; ADAPTATION; UCP3	Ascent to high altitude is associated with a fall in the partial pressure of inspired oxygen (hypobaric hypoxia). For oxidative tissues such as skeletal muscle, resultant cellular hypoxia necessitates acclimatization to optimize energy metabolism and restrict oxidative stress, with changes in gene and protein expression that alter mitochondrial function. It is known that lowlanders returning from high altitude have decreased muscle mitochondrial densities, yet the underlying transcriptional mechanisms and time course are poorly understood. To explore these, we measured gene and protein expression plus ultrastructure in muscle biopsies of lowlanders at sea level and following exposure to hypobaric hypoxia. Subacute exposure (19 d after initiating ascent to Everest base camp, 5300 m) was not associated with mitochondrial loss. After 66 d at altitude and ascent beyond 6400 m, mitochondrial densities fell by 21%, with loss of 73% of subsarcolemmal mitochondria. Correspondingly, levels of the transcriptional coactivator PGC-1 alpha fell by 35%, suggesting down-regulation of mitochondrial biogenesis. Sustained hypoxia also decreased expression of electron transport chain complexes I and IV and UCP3 levels. We suggest that during subacute hypoxia, mitochondria might be protected from oxidative stress. However, following sustained exposure, mitochondrial biogenesis is deactivated and uncoupling down-regulated, perhaps to improve the efficiency of ATP production.-Levett, D. Z., Radford, E. J., Menassa, D. A., Graber, E. F., Morash, A. J., Hoppeler, H., Clarke, K., Martin, D. C., Ferguson-Smith, A. C., Montgomery, H. E., Grocott, M. P. W., Murray, A. J., Caudwell Xtreme Everest Research Group. Acclimatization of skeletal muscle mitochondria to high-altitude hypoxia during an ascent of Everest. FASEB J. 26, 1431-1441 (2012). www.fasebj.org	[Radford, Elizabeth J.; Menassa, David A.; Morash, Andrea J.; Ferguson-Smith, Anne C.; Murray, Andrew J.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Levett, Denny Z.; Martin, Daniel S.; Grocott, Michael P. W.] UCL, Inst Child Hlth, Ctr Altitude Space & Extreme Environm Med, London, England; [Graber, E. Franziska; Hoppeler, Hans] Univ Bern, Dept Anat, Inst Anat, CH-3000 Bern, Switzerland; [Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England; [Montgomery, Hugh E.] UCL, Inst Human Hlth & Performance, London, England; [Montgomery, Hugh E.] Inst Sport Exercise & Hlth, London, England	University of Cambridge; University of London; University College London; University of Bern; University of Oxford; University of London; University College London	Murray, AJ (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Downing St, Cambridge CB2 3EG, England.	ajm267@cam.ac.uk	Menassa, David/L-8726-2019; Murray, Andrew/B-3130-2010; Morash, Andrea/F-2835-2013; Montgomery, Hugh/L-1229-2019; Grocott, Michael/C-4394-2008; Martin, Daniel S/F-7997-2010; Levett, Denny/D-2239-2017; Levett, Denny Zelda Hope/AAY-4627-2021; Levett, Denny/F-4474-2011; Montgomery, Hugh/C-2592-2008	Murray, Andrew/0000-0002-0929-9315; Morash, Andrea/0000-0001-8486-4567; Grocott, Michael/0000-0002-9484-7581; Levett, Denny/0000-0002-8418-1675; Levett, Denny Zelda Hope/0000-0002-8418-1675; Levett, Denny/0000-0002-8418-1675; Martin, Daniel/0000-0001-6220-8235; Ferguson-Smith, Anne/0000-0002-7608-5894; Menassa, David/0000-0002-5984-8407; Montgomery, Hugh/0000-0001-8797-5019; Radford, Elizabeth/0000-0002-7829-5422	entrepreneur John Caudwell (BOC Medical, now part of Linde Gas Therapeutics); Lilly Critical Care; London Clinic; Smiths Medical; Deltex Medical; Rolex Foundation; Association of Anesthetists of Great Britain; Association of Anesthetists of Ireland; UK Intensive Care Foundation; Sir Halley Stuart Trust; Research Councils UK; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: researchfish	entrepreneur John Caudwell (BOC Medical, now part of Linde Gas Therapeutics); Lilly Critical Care; London Clinic; Smiths Medical; Deltex Medical; Rolex Foundation; Association of Anesthetists of Great Britain; Association of Anesthetists of Ireland; UK Intensive Care Foundation; Sir Halley Stuart Trust; Research Councils UK(UK Research & Innovation (UKRI)); British Heart Foundation(British Heart Foundation)	Caudwell Xtreme Everest (CXE) is a project coordinated by the UCL Centre for Altitude, Space, and Extreme Environment Medicine, with the aim of conducting research into hypoxia and human performance at high altitude to improve understanding of hypoxia in critical illness. The research was funded by unrestricted grants from a variety of sources, none of which are public, including the entrepreneur John Caudwell (BOC Medical, now part of Linde Gas Therapeutics), Lilly Critical Care, the London Clinic, Smiths Medical, Deltex Medical, and the Rolex Foundation. Specific grants were awarded by the Association of Anesthetists of Great Britain and Ireland, the UK Intensive Care Foundation, and the Sir Halley Stuart Trust. The CXE volunteers who trekked to EBC also kindly donated to support the research. The CXE Research Group contributed to the design and conduct of experiments. The members of the CXE Research Group are listed on the project's website (http://www.xtreme-everest.co.uk). In particular, the authors thank Prof. Chris Imray and Prof. David Howard for collecting muscle biopsies at EBC, Adolfo Odriozola for preparing ultrathin sections of biopsies and producing some of the EM images included in this article, and the CXE Project Manager, Kay Mitchell, for her tireless work that made the expedition possible. A.J.M. thanks the Research Councils UK for supporting his academic fellowship and the Department of Physiology, Development, and Neuroscience, University of Cambridge, for welcoming him so warmly as a new member of the academic staff.	Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; BOYER SJ, 1984, J APPL PHYSIOL, V57, P1580, DOI 10.1152/jappl.1984.57.5.1580; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Carre JE, 2010, AM J RESP CRIT CARE, V182, P745, DOI 10.1164/rccm.201003-0326OC; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; Edwards LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010681; Essop MF, 2004, BIOCHEM BIOPH RES CO, V314, P561, DOI 10.1016/j.bbrc.2003.12.121; Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345; Ferretti G, 2003, EUR J APPL PHYSIOL, V90, P344, DOI 10.1007/s00421-003-0923-2; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Gilde AJ, 2003, CIRC RES, V92, P518, DOI 10.1161/01.RES.0000060700.55247.7C; Gore CJ, 2007, MED SCI SPORT EXER, V39, P1600, DOI 10.1249/mss.0b013e3180de49d3; GREEN HJ, 1992, J APPL PHYSIOL, V73, P2701, DOI 10.1152/jappl.1992.73.6.2701; Grocott M, 2007, CRIT CARE, V11, DOI 10.1186/cc5142; Grocott MPW, 2009, NEW ENGL J MED, V360, P140, DOI 10.1056/NEJMoa0801581; Holloway CJ, 2011, FASEB J, V25, P792, DOI 10.1096/fj.10-172999; HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462; HOPPELER H, 1986, INT J SPORTS MED, V7, P187, DOI 10.1055/s-2008-1025758; Houle-Leroy P, 2000, J APPL PHYSIOL, V89, P1608, DOI 10.1152/jappl.2000.89.4.1608; Howald H, 2003, EUR J APPL PHYSIOL, V90, P360, DOI 10.1007/s00421-003-0872-9; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Khosravi Maryam, 2009, Expert Rev Respir Med, V3, P561, DOI 10.1586/ers.09.56; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Koves TR, 2005, AM J PHYSIOL-CELL PH, V288, pC1074, DOI 10.1152/ajpcell.00391.2004; Levett DZH, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-98; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Ljubicic V, 2004, J APPL PHYSIOL, V97, P976, DOI 10.1152/japplphysiol.00336.2004; Lu ZP, 2008, J BIOL CHEM, V283, P23410, DOI 10.1074/jbc.M801236200; McCarthy J, 2011, J CELL PHYSIOL, V226, P2457, DOI 10.1002/jcp.22592; McClelland GB, 2005, J EXP BIOL, V208, P515, DOI 10.1242/jeb.01423; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Murray AJ, 2005, DIABETES, V54, P3496, DOI 10.2337/diabetes.54.12.3496; Murray AJ, 2008, J MOL CELL CARDIOL, V44, P694, DOI 10.1016/j.yjmcc.2008.01.008; Murray AJ, 2009, GENOME MED, V1, DOI 10.1186/gm117; Murray AJ, 2009, FASEB J, V23, P4353, DOI 10.1096/fj.09-139691; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Peacock AJ, 1998, BRIT MED J, V317, P1063; Raguso CA, 2004, CURR OPIN CLIN NUTR, V7, P411, DOI 10.1097/01.mco.0000134372.78438.09; REYNAFARJE B, 1962, J APPL PHYSIOL, V17, P301, DOI 10.1152/jappl.1962.17.2.301; SEMENZA GL, 2007, SCI STKE, pCM8, DOI DOI 10.1126/STKE.4072007CM8; Shukla V, 2005, NUTR NEUROSCI, V8, P161, DOI 10.1080/10284150500132823; SUTTON JR, 1988, J APPL PHYSIOL, V64, P1309, DOI 10.1152/jappl.1988.64.4.1309; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Vock R, 1996, J EXP BIOL, V199, P1675; WEST JB, 1983, J APPL PHYSIOL, V54, P1188, DOI 10.1152/jappl.1983.54.5.1188; Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	53	106	114	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1431	1441		10.1096/fj.11-197772	http://dx.doi.org/10.1096/fj.11-197772			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22186874	Bronze			2022-12-28	WOS:000302359700006
J	Apidianakis, Y; Que, YA; Xu, WH; Tegos, GP; Zimniak, P; Hamblin, MR; Tompkins, RG; Xiao, WZ; Rahme, LG				Apidianakis, Yiorgos; Que, Yok-Ai; Xu, Weihong; Tegos, George P.; Zimniak, Piotr; Hamblin, Michael R.; Tompkins, Ronald G.; Xiao, Wenzhong; Rahme, Laurence G.			Down-regulation of glutatione S-transferase alpha 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection	FASEB JOURNAL			English	Article						reactive oxygen species; oxidative stress; 4-hydroxynonenal; lipid peroxidation; trauma; biomarker	BURN WOUND INFECTIONS; PSEUDOMONAS-AERUGINOSA; LIPID-PEROXIDATION; SKELETAL-MUSCLE; OXIDATIVE STRESS; GENE-EXPRESSION; TRAUMA; CONJUGATION; PRODUCTS; ENZYME	Patients with severe burns are highly susceptible to bacterial infection. While immunosuppression facilitates infection, the contribution of soft tissues to infection beyond providing a portal for bacterial entry remains unclear. We showed previously that glutathione S-transferase S1 (gstS1), an enzyme with conjugating activity against the lipid peroxidation by-product 4-hydroxynonenal (4HNE), is important for resistance against wound infection in Drosophila muscle. The importance of the mammalian functional counterpart of GstS1 in the context of wounds and infection has not been investigated. Here we demonstrate that the presence of a burn wound dramatically affects expression of both human (hGSTA4) and mouse (mGsta4) 4HNE scavengers. hGSTA4 is down-regulated significantly within 1 wk of thermal burn injury in the muscle and fat tissues of patients from the large-scale collaborative Inflammation and the Host Response to Injury multicentered study. Similarly, mGsta4, the murine GST with the highest catalytic efficiency for 4HNE, is down-regulated to approximately half of normal levels in mouse muscle immediately postburn. Consequently, 4HNE protein adducts are increased 4- to 5-fold in mouse muscle postburn. Using an open wound infection model, we show that deletion of mGsta4 renders mice more susceptible to infection with the prevalent wound pathogen Pseudomonas aeruginosa, while muscle hGSTA4 expression negatively correlates with burn wound infection episodes per patient. Our data suggest that hGSTA4 down-regulation and the concomitant increase in 4HNE adducts in human muscle are indicative of susceptibility to infection in individuals with severely thermal injuries.-Apidianakis, Y., Que, Y.-A., Xu, W., Tegos, G. P., Zimniak, P., Hamblin, M. R., Tompkins, R. G., Xiao, W., Rahme, L. G. Down-regulation of glutatione S-transferase alpha 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection. FASEB J. 26, 730-737 (2012). www.fasebj.org	[Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Xiao, Wenzhong; Rahme, Laurence G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Xiao, Wenzhong; Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; [Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Rahme, Laurence G.] Shriners Burn Inst, Boston, MA 02114 USA; [Xu, Weihong; Xiao, Wenzhong] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; [Zimniak, Piotr] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; [Zimniak, Piotr] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA; [Tegos, George P.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Stanford University; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of New Mexico; University of New Mexico	Rahme, LG (corresponding author), Massachusetts Gen Hosp, Dept Surg, Thier 340, Boston, MA 02114 USA.	rahme@amber.mgh.harvard.edu	Xu, Weihong/C-4175-2012; Que, Yok Ai/AAE-5474-2020; Hamblin, Mike/AAB-2511-2022; Apidianakis, Yiorgos/ABF-7464-2020; Hamblin, Michael R/H-2758-2019	Xu, Weihong/0000-0002-3988-3571; Que, Yok Ai/0000-0001-9443-6101; Apidianakis, Yiorgos/0000-0002-7465-3560; Hamblin, Michael R/0000-0001-6431-4605; xiao, wenzhong/0000-0003-4944-6380	Shriners research grants [87100, 85600]; U.S. National Institutes of Health (NIH) [U54 GM-062119]; Swiss National Science Foundation/Swiss Medical Association [PASMP3-123226]; SICPA Foundation; NIH [AG-032643, AI050875]; U.S. Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R33AI105902, R01AI050875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032643] Funding Source: NIH RePORTER	Shriners research grants; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation/Swiss Medical Association(Swiss National Science Foundation (SNSF)); SICPA Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by Shriners research grants 87100 and 85600 and by the U.S. National Institutes of Health (NIH) Inflammation and the Host Response to Injury Large Scale Collaborative Project, U54 GM-062119. Y.A.Q. was supported by a Swiss National Science Foundation/Swiss Medical Association grant PASMP3-123226) and a grant from the SICPA Foundation. P.Z. was supported by NIH grant AG-032643 and by a U.S. Department of Veterans Affairs Research Career Scientist Award and M. R. H. by NIH grant AI050875.	Apidianakis Y, 2005, P NATL ACAD SCI USA, V102, P2573, DOI 10.1073/pnas.0409588102; Apidianakis Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001356; Astrakas LG, 2005, FASEB J, V19, P1431, DOI 10.1096/fj.04-2005com; Board PG, 2007, EXPERT OPIN DRUG MET, V3, P421, DOI 10.1517/17425255.3.3.421; Chai J, 2000, CHINESE MED J-PEKING, V113, P1142; Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Evers LH, 2010, EXP DERMATOL, V19, P777, DOI 10.1111/j.1600-0625.2010.01105.x; Finnerty CC, 2008, MOL MED, V14, P553, DOI 10.2119/2007-00132.Finnerty; Hamblin MR, 2003, J INFECT DIS, V187, P1717, DOI 10.1086/375244; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Horke S, 2010, BIOCHEM J, V426, P73, DOI 10.1042/BJ20091414; Horton JW, 2003, TOXICOLOGY, V189, P75, DOI 10.1016/S0300-483X(03)00154-9; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Lau GW, 2003, INFECT IMMUN, V71, P4059, DOI 10.1128/IAI.71.7.4059-4066.2003; Padfield KE, 2006, J TRAUMA, V61, P280, DOI 10.1097/01.ta.0000230567.56797.6c; Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102; Parihar A, 2008, BURNS, V34, P6, DOI 10.1016/j.burns.2007.04.009; Polavarapu N, 2008, J CRANIOFAC SURG, V19, P899, DOI 10.1097/SCS.0b013e318175b4f0; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Singh SP, 2010, J GERONTOL A-BIOL, V65, P14, DOI 10.1093/gerona/glp165; Singh SP, 2001, EUR J BIOCHEM, V268, P2912, DOI 10.1046/j.1432-1327.2001.02179.x; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Yang YS, 2003, ACTA BIOCHIM POL, V50, P319; Zaborina O, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030035; Zhou BY, 2010, P NATL ACAD SCI USA, V107, P9923, DOI 10.1073/pnas.1002757107	26	19	19	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					730	737		10.1096/fj.11-192484	http://dx.doi.org/10.1096/fj.11-192484			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038048	Green Published			2022-12-28	WOS:000300485700024
J	Csoka, B; Selmeczy, Z; Koscso, B; Nemeth, ZH; Pacher, P; Murray, PJ; Kepka-Lenhart, D; Morris, SM; Gause, WC; Leibovich, SJ; Hasko, G				Csoka, Balazs; Selmeczy, Zsolt; Koscso, Balazs; Nemeth, Zoltan H.; Pacher, Pal; Murray, Peter J.; Kepka-Lenhart, Diane; Morris, Sidney M., Jr.; Gause, William C.; Leibovich, S. Joseph; Hasko, Gyoergy			Adenosine promotes alternative macrophage activation via A(2A) and A(2B) receptors	FASEB JOURNAL			English	Article						cancer; helminth infection; inflammation; wound healing; obesity	HUMAN MAST-CELLS; C/EBP-BETA; IL-10 PRODUCTION; GENE-EXPRESSION; IFN-GAMMA; TNF-ALPHA; ARGINASE; MECHANISM; INFLAMMATION; INFECTIONS	Adenosine has been implicated in suppressing the proinflammatory responses of classically activated macrophages induced by Th1 cytokines. Alternative macrophage activation is induced by the Th2 cytokines interleukin (IL)-4 and IL-13; however, the role of adenosine in governing alternative macrophage activation is unknown. We show here that adenosine treatment of IL-4- or IL-13-activated macrophages augments the expression of alternative macrophage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage galactose-type C-type lectin-1. The stimulatory effect of adenosine required primarily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased both arginase activity (EC50 = 261.8 nM) and TIMP-1 production (EC50 = 80.67 nM), and both pharmacologic and genetic blockade of A(2B) receptors prevented the effect of NECA. A(2A) receptors also contributed to the adenosine augmentation of IL-4-induced TIMP-1 release, as both adenosine and NECA were less efficacious in augmenting TIMP-1 release by A(2A) receptor-deficient than control macrophages. Of the transcription factors known to drive alternative macrophage activation, CCAAT-enhancer-binding protein beta was required, while cAMP response element-binding protein and signal transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine. We propose that adenosine receptor activation suppresses inflammation and promotes tissue restitution, in part, by promoting alternative macrophage activation.-Csoka, B., Selmeczy, Z., Koscso, B., Nemeth, Z. H., Pacher, P., Murray, P. J., Kepka-Lenhart, D., Morris S. M., Jr., Gause, W. C., Leibovich, S. J., Hasko, G. Adenosine promotes alternative macrophage activation via A(2A) and A(2B) receptors. FASEB J. 26, 376-386 (2012). www.fasebj.org	[Csoka, Balazs; Selmeczy, Zsolt; Koscso, Balazs; Nemeth, Zoltan H.; Hasko, Gyoergy] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; [Gause, William C.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; [Gause, William C.] Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Immun & Inflammat, Newark, NJ 07103 USA; [Leibovich, S. Joseph] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; [Nemeth, Zoltan H.] Morristown Mem Hosp, Dept Surg, Morristown, NJ USA; [Pacher, Pal] NIAAA, Bethesda, MD 90034 USA; [Murray, Peter J.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Murray, Peter J.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Kepka-Lenhart, Diane; Morris, Sidney M., Jr.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Hasko, Gyoergy] Univ Debrecen, Dept Med Chem, Med & Hlth Sci Ctr, Debrecen, Hungary	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Atlantic Health System; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); St Jude Children's Research Hospital; St Jude Children's Research Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Debrecen	Hasko, G (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.	haskoge@umdnj.edu	Murray, Peter J/K-4725-2018; Morris, Sidney M/I-3440-2015; Pacher, Pal/B-6378-2008	Murray, Peter J/0000-0001-6329-9802; Pacher, Pal/0000-0001-7036-8108; Koscso, Balazs/0000-0001-9676-2066; Leibovich, Samuel Joseph/0000-0002-6692-7322; Csoka, Balazs/0000-0002-7562-1130	U.S. National Institutes of Health (NIH) [R01GM66189, R01GM57384]; NIH, National Institute on Alcohol Abuse and Alcoholism; Hungarian Research Fund [CK 78275]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189, R56GM066189, R01GM057384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000375] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Hungarian Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by U.S. National Institutes of Health (NIH) grants R01GM66189 and R01GM57384, and the NIH Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism, as well as the Hungarian Research Fund (CK 78275). The authors declare no competing financial interests.	Albina JE, 2005, SHOCK, V23, P168, DOI 10.1097/01.shk.0000148054.74268.e2; ALBINA JE, 1990, J IMMUNOL, V144, P3877; Belikoff BG, 2011, J IMMUNOL, V186, P2444, DOI 10.4049/jimmunol.1001567; Blackburn Michael R, 2009, Handb Exp Pharmacol, P215, DOI 10.1007/978-3-540-89615-9_8; Chen HJ, 2009, EXP HEMATOL, V37, P533, DOI 10.1016/j.exphem.2009.02.001; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; Csoka B, 2007, PURINERG SIGNAL, V3, P447, DOI 10.1007/s11302-007-9075-x; Csoka B, 2007, BLOOD, V110, P2685, DOI 10.1182/blood-2007-01-065870; Csoka B, 2010, J IMMUNOL, V185, P542, DOI 10.4049/jimmunol.0901295; Deszo EL, 2004, CELL SIGNAL, V16, P271, DOI 10.1016/S0898-6568(03)00137-2; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; Erdely A, 2006, AM J PHYSIOL-LUNG C, V290, pL534, DOI 10.1152/ajplung.00326.2005; FEOKTISTOV I, 1993, MOL PHARMACOL, V43, P909; Feoktistov I, 1999, MOL PHARMACOL, V55, P726; Feoktistov I, 1998, BIOCHEM PHARMACOL, V55, P627, DOI 10.1016/S0006-2952(97)00512-1; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gorgoni B, 2002, J IMMUNOL, V168, P4055, DOI 10.4049/jimmunol.168.8.4055; Gough MJ, 2001, CANCER RES, V61, P7240; Gray MJ, 2005, GENE, V353, P98, DOI 10.1016/j.gene.2005.04.004; Hart ML, 2009, J IMMUNOL, V182, P3965, DOI 10.4049/jimmunol.0802193; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hasko G, 2009, TRENDS IMMUNOL, V30, P263, DOI 10.1016/j.it.2009.04.001; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hasko G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003; Hunt AE, 2002, CYTOKINE, V18, P295, DOI 10.1006/cyto.2002.1043; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Kim CH, 2009, J CELL BIOCHEM, V108, P974, DOI 10.1002/jcb.22330; Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Kuroda E, 2002, J IMMUNOL, V168, P5477, DOI 10.4049/jimmunol.168.11.5477; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Munder M, 1998, J IMMUNOL, V160, P5347; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; Nemeth ZH, 2003, BIOCHEM BIOPH RES CO, V312, P883, DOI 10.1016/j.bbrc.2003.11.006; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; Qualls JE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000955; Raes G, 2005, J LEUKOCYTE BIOL, V77, P321, DOI 10.1189/jlb.0304212; Ratthe C, 2007, J LEUKOCYTE BIOL, V81, P1287, DOI 10.1189/jlb.0306209; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Ryzhov S, 2008, J PHARMACOL EXP THER, V324, P694, DOI 10.1124/jpet.107.131540; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Van Ginderachter JA, 2006, IMMUNOBIOLOGY, V211, P487, DOI 10.1016/j.imbio.2006.06.002; Welch JS, 2002, J BIOL CHEM, V277, P42821, DOI 10.1074/jbc.M205873200; Wilson JM, 2009, J IMMUNOL, V182, P4616, DOI 10.4049/jimmunol.0801279; Xaus J, 1999, J IMMUNOL, V162, P3607; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933	57	253	261	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					376	386		10.1096/fj.11-190934	http://dx.doi.org/10.1096/fj.11-190934			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21926236	Green Published			2022-12-28	WOS:000299202200037
J	Koning, H; Sayers, I; Stewart, CE; de Jong, D; ten Hacken, NHT; Postma, DS; van Oosterhout, AJM; Nawijn, MC; Koppelman, GH				Koning, Henk; Sayers, Ian; Stewart, Ceri E.; de Jong, Debora; ten Hacken, Nick H. T.; Postma, Dirkje S.; van Oosterhout, Antoon J. M.; Nawijn, Martijn C.; Koppelman, Gerard H.			Characterization of protocadherin-1 expression in primary bronchial epithelial cells: association with epithelial cell differentiation	FASEB JOURNAL			English	Article						asthma; brush; rapid amplification of cDNA ends; air-liquid interface; splice variants	MUCOCILIARY DIFFERENTIATION; DELTA-PROTOCADHERINS; DYSREGULATED REPAIR; LARGE FAMILY; ORGANIZATION; EVOLUTION; ISOFORMS; ALPHA(+); ADHESION; GROWTH	Protocadherin-1 (PCDH1) is a novel susceptibility gene for asthma that is expressed in airway epithelium. We aimed to characterize PCDH1 mRNA transcripts and protein expression in primary bronchial epithelial cells and to determine regulation of PCDH1 during mucociliary differentiation. Total RNA and protein were isolated from human primary bronchial epithelial cells. PCDH1 transcripts were characterized by rapid amplification of cDNA ends in bronchial epithelial cells of 4 subjects. PCDH1 expression was quantified by quantitative RT-PCR and Western blotting in bronchial epithelial cells directly ex vivo and after air liquid interface (ALI) or submerged culture. We identified 5 novel exons on the 5' end and 1 exon on the 3' end of PCDH1. Novel transcripts showed major variation in expression of intracellular conserved motifs. Expression levels of PCDH1 transcripts encoding exon 1-2 were 4-fold higher, and transcripts encoding exon 3-4 were 15-fold higher in freshly isolated bronchial epithelial cells than in submerged cultures. PCDH1 mRNA (3 to 8-fold) and protein levels (2- to 3-fold) were strongly up-regulated during mucociliary differentiation of primary bronchial epithelial cells in ALI cultures. In summary, PCDH1 transcripts display remarkable variability in expression of conserved intracellular signaling domains. Enhanced PCDH1 expression levels strongly correlate with differentiation of bronchial epithelial cells.-Koning, H., Sayers, I., Stewart, C. E., de Jong, D., ten Hacken, N. H. T., Postma, D. S., van Oosterhout, A. J. M., Nawijn, M. C., Koppelman, G. H. Characterization of protocadherin-1 expression in primary bronchial epithelial cells: association with epithelial cell differentiation. FASEB J. 26, 439-448 (2012). www.fasebj.org	[Koppelman, Gerard H.] Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Koning, Henk; de Jong, Debora; van Oosterhout, Antoon J. M.; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, Lab Allergol & Pulm Dis, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands; [ten Hacken, Nick H. T.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen Res Inst Asthma & COPD GRIAC, NL-9700 RB Groningen, Netherlands; [Sayers, Ian; Stewart, Ceri E.] Univ Nottingham, Div Therapeut & Mol Med, Nottingham Resp Biomed Res Unit, Queens Med Ctr, Nottingham NG7 2RD, England	University of Groningen; University of Groningen; University of Groningen; University of Nottingham	Koppelman, GH (corresponding author), Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Univ Med Ctr Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands.	g.h.koppelman@umcg.nl	Koppelman, Gerard/AAG-9187-2020	Stewart, Ceri/0000-0002-6214-2237; Nawijn, Martijn/0000-0003-3372-6521; Sayers, Ian/0000-0001-5601-5410; Koppelman, Gerard/0000-0001-8567-3252	Jan Kornelis de Cock Stichting; GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community); European Commission; Stichting Astma Bestrijding; Netherlands Asthma Foundation [3.2.09.055]; ZonMW Veni Koppelman [916.56.091]	Jan Kornelis de Cock Stichting; GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community); European Commission(European CommissionEuropean Commission Joint Research Centre); Stichting Astma Bestrijding; Netherlands Asthma Foundation; ZonMW Veni Koppelman	The authors thank Dr. C. van Kooten (Leiden University Hospital, Leiden, The Netherlands) for providing mouse L-cell fibroblasts, and D. C. Gruenert (Department of Medicine, University of Vermont, Burlington, VT, USA, and University of California, San Francisco, CA, USA) for providing the bronchial epithelial cell-line 16HBE14o<SUP>-</SUP>. Furthermore, the authors thank all subjects who contributed to this study and J. Noordhoek for technical assistance. This work was supported by Jan Kornelis de Cock Stichting, GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community), a European Commission FP6 grant, Stichting Astma Bestrijding, Netherlands Asthma Foundation Grant 3.2.09.055, and ZonMW Veni Koppelman (916.56.091).	Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Blanco-Arias P, 2004, MAMM GENOME, V15, P41, DOI 10.1007/s00335-003-3028-7; Borger P, 2002, J HEART LUNG TRANSPL, V21, P567, DOI 10.1016/S1053-2498(01)00418-1; Bouillot S, 2011, J BIOL CHEM, V286, P15195, DOI 10.1074/jbc.M111.230045; Broekema M, 2009, AM J RESP CRIT CARE, V180, P1170, DOI 10.1164/rccm.200906-0828OC; Carrasquillo MM, 2009, NAT GENET, V41, P192, DOI 10.1038/ng.305; Ciana A, 2010, CELL BIOL INT, V34, P669, DOI 10.1042/CBI20090067; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; DEJONG PM, 1993, IN VITRO CELL DEV-AN, V29A, P379, DOI 10.1007/BF02633985; Demontis F, 2006, DEV GENES EVOL, V216, P737, DOI 10.1007/s00427-006-0097-0; Fitsialos G, 2007, J BIOL CHEM, V282, P15090, DOI 10.1074/jbc.M606094200; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Heijink IH, 2010, EUR RESPIR J, V35, P894, DOI 10.1183/09031936.00065809; Hormi-Carver KK, 2004, DEV DYNAM, V229, P791, DOI 10.1002/dvdy.10497; Huang YT, 2009, J CLIN ONCOL, V27, P2660, DOI 10.1200/JCO.2008.18.7906; Hulpiau P, 2011, MOL BIOL EVOL, V28, P647, DOI 10.1093/molbev/msq233; Hulpiau P, 2009, INT J BIOCHEM CELL B, V41, P349, DOI 10.1016/j.biocel.2008.09.027; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Kim SY, 2011, CELL ADHES MIGR, V5, P97, DOI 10.4161/cam.5.2.14374; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Krahn MP, 2010, J BIOL CHEM, V285, P13193, DOI 10.1074/jbc.M109.080051; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006; Parker J, 2010, PEDIATR RES, V67, P17, DOI 10.1203/PDR.0b013e3181c0b200; Redies C, 2005, CELL MOL LIFE SCI, V62, P2840, DOI 10.1007/s00018-005-5320-z; Redies C, 2008, DEV DYNAM, V237, P2496, DOI 10.1002/dvdy.21650; Reiss K, 2006, J BIOL CHEM, V281, P21735, DOI 10.1074/jbc.M602663200; Romagnoli M, 1999, RESP MED, V93, P461, DOI 10.1016/S0954-6111(99)90088-4; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheth B, 1997, DEVELOPMENT, V124, P2027; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; Vanhalst K, 2005, CELL MOL LIFE SCI, V62, P1247, DOI 10.1007/s00018-005-5021-7; VIGNOLA AM, 1993, ALLERGY, V48, P32, DOI 10.1111/j.1398-9995.1993.tb04696.x; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; Yoshida K, 1999, FEBS LETT, V460, P93, DOI 10.1016/S0014-5793(99)01309-5; Yoshida K, 1998, GENOMICS, V49, P458, DOI 10.1006/geno.1998.5271; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003	45	25	26	2	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					439	448		10.1096/fj.11-185207	http://dx.doi.org/10.1096/fj.11-185207			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21982948				2022-12-28	WOS:000299202200043
J	Park, JS; Lee, WC; Yeo, KJ; Ryu, KS; Kumarasiri, M; Hesek, D; Lee, M; Mobashery, S; Song, JH; Kim, SI; Lee, JC; Cheong, C; Jeon, YH; Kim, HY				Park, Jeong Soon; Lee, Woo Cheol; Yeo, Kwon Joo; Ryu, Kyoung-Seok; Kumarasiri, Malika; Hesek, Dusan; Lee, Mijoon; Mobashery, Shahriar; Song, Jung Hyun; Kim, Seung Il; Lee, Je Chul; Cheong, Chaejoon; Jeon, Young Ho; Kim, Hye-Yeon			Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane	FASEB JOURNAL			English	Article						diaminopimelate; lysine; molecular recognition; nosocomial pathogen	ACINETOBACTER-BAUMANNII; ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; GENETIC ALGORITHM; CRYSTAL-STRUCTURE; FLAGELLAR MOTOR; NMR SYSTEM; RECOGNITION; VESICLES; CRYSTALLOGRAPHY	The outer membrane protein A (OmpA) plays important roles in anchoring of the outer membrane to the bacterial cell wall. The C-terminal periplasmic domain of OmpA (OmpA-like domain) associates with the peptidoglycan (PGN) layer noncovalently. However, there is a paucity of information on the structural aspects of the mechanism of PGN recognition by OmpA-like domains. To elucidate this molecular recognition process, we solved the high-resolution crystal structure of an OmpA-like domain from Acinetobacter baumannii bound to diaminopimelate (DAP), a unique bacterial amino acid from the PGN. The structure clearly illustrates that two absolutely conserved Asp271 and Arg286 residues are the key to the binding to DAP of PGN. Identification of DAP as the central anchoring site of PGN to OmpA is further supported by isothermal titration calorimetry and a pulldown assay with PGN. An NMR-based computational model for complexation between the PGN and OmpA emerged, and this model is validated by determining the crystal structure in complex with a synthetic PGN fragment. These structural data provide a detailed glimpse of how the anchoring of OmpA to the cell wall of gram-negative bacteria takes place in a DAP-dependent manner.-Park, J. S., Lee, W. C., Yeo, K. J., Ryu, K.-S., Kumarasiri, M., Hesek, D., Lee, M., Mobashery, S., Song, J. H., Lim, S. I., Lee, J. C., Cheong, C., Jeon, Y. H., Kim, H.-Y. Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane. FASEB J. 26, 219-228 (2012). www.fasebj.org	[Park, Jeong Soon; Lee, Woo Cheol; Yeo, Kwon Joo; Ryu, Kyoung-Seok; Song, Jung Hyun; Cheong, Chaejoon; Jeon, Young Ho; Kim, Hye-Yeon] Korea Basic Sci Inst, Div Magnet Resonance Res, Ochang, South Korea; [Kumarasiri, Malika; Hesek, Dusan; Lee, Mijoon; Mobashery, Shahriar] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Kim, Seung Il] Korea Basic Sci Inst, Div Life Sci, Taejon, South Korea; [Lee, Je Chul] Kyungpook Natl Univ, Sch Med, Dept Microbiol, Taegu, South Korea; [Cheong, Chaejoon] Univ Sci & Technol, Dept Bioanalyt Sci, Taejon, South Korea; [Jeon, Young Ho] Korea Univ, Coll Pharm, Jochiwon, South Korea	Korea Basic Science Institute (KBSI); University of Notre Dame; Korea Basic Science Institute (KBSI); Kyungpook National University; Korea University	Kim, HY (corresponding author), Korea Basic Sci Inst, Div Magnet Resonance Res, 804-1 Ochang, Chungbuk 363883, South Korea.	yhjeon@korea.ac.kr; hyeyeon@kbsi.re.kr	Cheong, Chaejoon/GWC-3135-2022; Lee, Mijoon/AFK-1543-2022	Lee, Mijoon/0000-0001-7432-0427; Park, Jeong Soon/0000-0002-8239-1978	Korean Membrane Protein Initiative of Korean Ministry of Education, Science, and Technology; Global Frontier Project [NRF-M1AXA002-2010-0029765]; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090348] Funding Source: NIH RePORTER	Korean Membrane Protein Initiative of Korean Ministry of Education, Science, and Technology; Global Frontier Project; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank the staff of beamline 17A at the Photon Factory (Tsukuba, Japan) and Yeon-Gil Kim, Kyung-Jin Kim, and Ghyung-Hwa Kim of beamlines 4A and 6C1 at the Pohang Accelerator Laboratory (Pohang, Korea) for help with X-ray data collection. We are grateful to Myung Hee Kim at the Korea Research Institute of Bioscience and Biotechnology (Daejeon, Korea) for the use of isothermal titration calorimetry (VP-ITC) and assistance in ITC data analysis. This work was supported by the Korean Membrane Protein Initiative program of the Korean Ministry of Education, Science, and Technology (to H.-Y.K.) and Global Frontier Project grant NRF-M1AXA002-2010-0029765 (to Y.H.J.). The work in the United States was supported by the National Institutes of Health (to S. M.). The coordinates and structural factors of AbOmpA-PD native structure and structures in complex with DAP and compound 5 have been deposited in the PDB under the access codes of 3TD3, 3TD4, and 3TD5, respectively.	Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BLAIR DF, 1991, J BACTERIOL, V173, P4049, DOI 10.1128/jb.173.13.4049-4055.1991; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Cascales E, 2004, MOL MICROBIOL, V51, P873, DOI 10.1046/j.1365-2958.2003.03881.x; Case D, 2006, AMBER 9; Cho S, 2007, P NATL ACAD SCI USA, V104, P8761, DOI 10.1073/pnas.0701453104; Choi CH, 2005, CELL MICROBIOL, V7, P1127, DOI 10.1111/j.1462-5822.2005.00538.x; Clavel T, 1998, MOL MICROBIOL, V29, P359, DOI 10.1046/j.1365-2958.1998.00945.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEMOT R, 1994, MOL MICROBIOL, V12, P333; Dijkshoorn L, 2007, NAT REV MICROBIOL, V5, P939, DOI 10.1038/nrmicro1789; Dramsi S, 2008, FEMS MICROBIOL REV, V32, P307, DOI 10.1111/j.1574-6976.2008.00102.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gaddy JA, 2009, INFECT IMMUN, V77, P3150, DOI 10.1128/IAI.00096-09; Goddard T. D., 2006, SPARKY 3; Gootz TD, 2010, CRIT REV IMMUNOL, V30, P79, DOI 10.1615/CritRevImmunol.v30.i1.60; Grizot S, 2004, MOL MICROBIOL, V51, P1027, DOI 10.1111/j.1365-2958.2003.03903.x; Hamid N, 2008, CLIN VACCINE IMMUNOL, V15, P1461, DOI 10.1128/CVI.00093-08; HANCOCK REW, 1994, N COMP BIOC, V27, P263, DOI DOI 10.1016/S0167-7306(08)60415-9; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Jin JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017027; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jyothisri K, 1999, FEBS LETT, V443, P57, DOI 10.1016/S0014-5793(98)01679-2; Kim KA, 2004, FEBS LETT, V565, P181, DOI 10.1016/j.febslet.2004.03.062; KOEBNIK R, 1995, MOL MICROBIOL, V16, P1269, DOI 10.1111/j.1365-2958.1995.tb02348.x; Kojima S, 2009, MOL MICROBIOL, V73, P710, DOI 10.1111/j.1365-2958.2009.06802.x; Kuehn MJ, 2005, GENE DEV, V19, P2645, DOI 10.1101/gad.1299905; Kulp A, 2010, ANNU REV MICROBIOL, V64, P163, DOI 10.1146/annurev.micro.091208.073413; Kwon SO, 2009, FEMS MICROBIOL LETT, V297, P150, DOI 10.1111/j.1574-6968.2009.01669.x; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; Larbig M, 2001, VACCINE, V19, P2291, DOI 10.1016/S0264-410X(00)00550-8; Lee EY, 2007, PROTEOMICS, V7, P3143, DOI [10.1002/pmic.200700196, 10.1002/pmic.200790083]; Lee MJ, 2009, J AM CHEM SOC, V131, P8742, DOI 10.1021/ja9025566; Leone P, 2008, MOL IMMUNOL, V45, P2521, DOI 10.1016/j.molimm.2008.01.015; Meroueh SO, 2006, P NATL ACAD SCI USA, V103, P4404, DOI 10.1073/pnas.0510182103; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsons LM, 2006, BIOCHEMISTRY-US, V45, P2122, DOI 10.1021/bi052227i; Roujeinikova A, 2008, P NATL ACAD SCI USA, V105, P10348, DOI 10.1073/pnas.0803039105; Smith SGJ, 2007, FEMS MICROBIOL LETT, V273, P1, DOI 10.1111/j.1574-6968.2007.00778.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THORNE KJI, 1973, J BACTERIOL, V116, P410, DOI 10.1128/JB.116.1.410-417.1973; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; Vollmer W, 2008, FEMS MICROBIOL REV, V32, P149, DOI 10.1111/j.1574-6976.2007.00094.x	50	119	125	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					219	228		10.1096/fj.11-188425	http://dx.doi.org/10.1096/fj.11-188425			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965596	Green Published			2022-12-28	WOS:000299202200023
J	Rahman, NA; Bennink, HJTC; Chrusciel, M; Sharp, V; Zimmerman, Y; Dina, R; Li, XD; Ellonen, A; Rivero-Muller, A; Dilworth, S; Ghaem-Maghami, S; Vainio, O; Huhtaniemi, I				Rahman, Nafis A.; Bennink, Herjan J. T. Coelingh; Chrusciel, Marcin; Sharp, Victoria; Zimmerman, Yvette; Dina, Roberto; Li, Xiangdong; Ellonen, Antti; Rivero-Mueller, Adolfo; Dilworth, Stephen; Ghaem-Maghami, Sadaf; Vainio, Olli; Huhtaniemi, Ilpo			A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3	FASEB JOURNAL			English	Article						granulosa cell; target-defined tumor associated antigen; vaccine	GRANULOSA-CELL TUMORS; FOLLICLE-STIMULATING-HORMONE; SIMIAN-VIRUS-40 T-ANTIGEN; GONADAL TUMORIGENESIS; MICE BEARING; FUSION GENE; INHIBIN; GONADOTROPIN; ESTABLISHMENT; SPECIFICITY	We tested the principle of treating malignant ovarian tumors by vaccination against their ectopically expressed protein, zona pellucida glycoprotein (ZP) 3, using as the experimental model the granulosa cell tumors that develop in transgenic mice expressing the simian virus 40 T-antigen under the inhibin-alpha promoter (inh alpha/Tag). We found high ZP3 expression in granulosa cell tumors of the transgenic mice, in human surface ovarian cancer and granulosa cell lines, and in human granulosa cell tumors and their metastases. Early preventive immunization (between 2 and 5.5 mo of age) of transgenic mice with recombinant human (rh) ZP3 prevented ovarian tumorigenesis, and delayed therapeutic immunization (between 4.5 and 7 mo) reduced weights of existing tumors by 86 and 75%, respectively (P<0.001), compared to vehicle-treated control mice. No objective side effects of the immunizations were observed. Liver metastases were found in nontreated/vehicletreated controls (n = 7/39), but none following active rhZP3 immunizations (n = 0/36; P<0.05). Immunization with rhZP3 was highly effective, as demonstrated by the induction of anti-ZP3 antibodies, as well as proliferative responses to the ZP3 antigen. These results signal rhZP3 immunization as a novel strategy to be developed for the immunotherapy of ovarian granulosa cell tumors, as well as for that of other malignancies that may express ZP3.-Rahman, N. A., Coelingh Bennink, H. J. T., Chrusciel, M., Sharp, V., Zimmerman, Y., Dina, R., Li, X., Ellonen, A., Rivero-Muller, A., Dilworth, S., Ghaem-Maghami, S., Vainio, O., Huhtaniemi, I. A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J. 26, 324-333 (2012). www.fasebj.org	[Rahman, Nafis A.; Chrusciel, Marcin; Ellonen, Antti; Rivero-Mueller, Adolfo; Huhtaniemi, Ilpo] Univ Turku, Dept Physiol, Turku 20540, Finland; [Rahman, Nafis A.] Florida Int Univ, Coll Med, Dept Cell Biol, Miami, FL 33199 USA; [Rahman, Nafis A.] Florida Int Univ, Coll Med, Dept Human Mol Genet, Miami, FL 33199 USA; [Rahman, Nafis A.] Florida Int Univ, Coll Med, Dept Obstet & Gynecol, Miami, FL 33199 USA; [Bennink, Herjan J. T. Coelingh; Zimmerman, Yvette] Pantarhei Biosci BV, NL-3701 Zeist, Netherlands; [Sharp, Victoria; Dilworth, Stephen; Huhtaniemi, Ilpo] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Inst Reprod & Dev Biol, London, England; [Dina, Roberto; Ghaem-Maghami, Sadaf] Univ London Imperial Coll Sci Technol & Med, Dept Gynecol Oncol, Inst Reprod & Dev Biol, London, England; [Li, Xiangdong] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100094, Peoples R China; [Vainio, Olli] Univ Oulu, Oulu Univ Hosp, Dept Microbiol & Immunol, Oulu, Finland; [Vainio, Olli] Univ Oulu, Oulu Univ Hosp, Clin Microbiol Lab, Oulu, Finland	University of Turku; State University System of Florida; Florida International University; State University System of Florida; Florida International University; State University System of Florida; Florida International University; Imperial College London; Imperial College London; China Agricultural University; University of Oulu; University of Oulu	Rahman, NA (corresponding author), Univ Turku, Dept Physiol, Turku 20540, Finland.	nafis.rahman@utu.fi; hcb@pantarheibio.com	Rivero-Muller, Adolfo/A-5120-2008	Rivero-Muller, Adolfo/0000-0002-9794-802X; Ghaem-Maghami, Sadaf/0000-0002-7369-5080; Li, Xiangdong/0000-0003-2261-2393	Pantarhei Bioscience	Pantarhei Bioscience	This study was supported by an unrestricted grant from Pantarhei Bioscience. The authors thank Drs. Yoshihiro Nishi and Toshihiko Yanase (Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka, Japan) for providing the KGN human granulosa cancer cell line. H. C. B. is the inventor of the treatment concept; N.A.R., H. C. B., and I. H. designed the research; N.A.R., M. C., V. S., R. D., A. E., and X. L. performed the experiments; V. S., S. D., and I. H. produced the rhZP3 protein; N.A.R., H. C. B, Y.Z., A. R. M., S. G. M., O.V., and I. H. analyzed and interpreted the results; and N.A.R., H. C. B., and I. H. wrote the manuscript. H. C. B. and Y.Z. are employees, and H. C. B. is a shareholder, of Pantarhei Bioscience, the company developing the treatment of ovarian granulosa cell cancer by ZP3 immunization. The other authors declare no conflicts of interest.	Amling CL, 2001, CURR PROB CANCER, V25, P219; BEAMER WG, 1986, JNCI-J NATL CANCER I, V77, P1117; BLAAKAER J, 1995, EUR J OBSTET GYN R B, V59, P53, DOI 10.1016/0028-2243(95)93678-H; Boggess JF, 1997, GYNECOL ONCOL, V64, P64, DOI 10.1006/gyno.1996.4520; COOKE I, 1995, BRIT J CANCER, V71, P1046, DOI 10.1038/bjc.1995.201; Cronje HS, 1999, AM J OBSTET GYNECOL, V180, P323, DOI 10.1016/S0002-9378(99)70207-3; Gupta SK, 1997, HUM REPROD UPDATE, V3, P311, DOI 10.1093/humupd/3.4.311; HAAVISTO AM, 1993, ENDOCRINOLOGY, V132, P1687, DOI 10.1210/en.132.4.1687; Harris JD, 1999, PROTEIN EXPRES PURIF, V16, P298, DOI 10.1006/prep.1999.1060; Honda S, 1997, Int J Urol, V4, P68, DOI 10.1111/j.1442-2042.1997.tb00143.x; Hung CF, 2008, IMMUNOL REV, V222, P43, DOI 10.1111/j.1600-065X.2008.00622.x; JOBLING T, 1994, GYNECOL ONCOL, V55, P285, DOI 10.1006/gyno.1994.1291; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; Kananen K, 1996, MOL CELL ENDOCRINOL, V119, P135, DOI 10.1016/0303-7207(96)03802-6; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; KAYE SB, 1986, GYNECOL ONCOL, V24, P261, DOI 10.1016/0090-8258(86)90035-1; Koukourakis GV, 2008, INTEGR CANCER THER, V7, P204, DOI 10.1177/1534735408322845; Kristensen GB, 1997, LANCET, V349, P113, DOI 10.1016/S0140-6736(96)06071-0; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; Li JY, 2007, J GENE MED, V9, P1095, DOI 10.1002/jgm.1069; LOU YH, 1993, J IMMUNOL, V151, P5790; MAHIBROWN CA, 1988, AM J REPROD IMMUNOL, V18, P94; MALMSTROM H, 1994, GYNECOL ONCOL, V52, P50, DOI 10.1006/gyno.1994.1010; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MILLAR SE, 1989, SCIENCE, V246, P935, DOI 10.1126/science.2479101; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; PATERSON M, 1992, BIOL REPROD, V46, P523, DOI 10.1095/biolreprod46.4.523; Paterson M, 1998, AM J REPROD IMMUNOL, V40, P198; Pectasides D, 2008, ANTICANCER RES, V28, P1421; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; Rahman NA, 1998, MOL CELL ENDOCRINOL, V145, P167, DOI 10.1016/S0303-7207(98)00184-1; Rahman NA, 2001, BIOL REPROD, V64, P1122, DOI 10.1095/biolreprod64.4.1122; Rath A, 2003, VACCINE, V21, P1913, DOI 10.1016/S0264-410X(02)00824-1; RHIM SH, 1992, J CLIN INVEST, V89, P28, DOI 10.1172/JCI115572; Riggs DR, 1997, CANCER, V79, P1987, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1987::AID-CNCR21>3.0.CO;2-Q; Rilianawati, 1999, MOL CELL ENDOCRINOL, V149, P9, DOI 10.1016/S0303-7207(99)00004-0; Savage P, 1998, Clin Oncol (R Coll Radiol), V10, P242, DOI 10.1016/S0936-6555(98)80008-3; Sole K., 2006, NAT CLIN PRACT UROL, V3, P292; Trope C, 1997, SEMIN ONCOL, V24, P1; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; Wassarman Paul M., 2008, V475, P99, DOI 10.1007/978-1-59745-250-2_6; Wassarman PM, 2004, CYTOGENET GENOME RES, V105, P228, DOI 10.1159/000078193	45	7	9	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					324	333		10.1096/fj.11-192468	http://dx.doi.org/10.1096/fj.11-192468			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21974931				2022-12-28	WOS:000299202200032
J	Schreurs, MPH; Houston, EM; May, V; Cipolla, MJ				Schreurs, Malou P. H.; Houston, Emily M.; May, Victor; Cipolla, Marilyn J.			The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy	FASEB JOURNAL			English	Article						cerebral endothelium; circulating angiogenic factors; gestation; sFlt1	FACTOR RECEPTOR-2; SOLUBLE FLT-1; NITRIC-OXIDE; VEGF; PERMEABILITY; EXPRESSION; RAT; VASODILATOR; INDUCTION; NEURONS	Vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) are increased in the maternal circulation during pregnancy. These factors may increase blood-brain barrier (BBB) permeability, yet brain edema does not normally occur during pregnancy. We therefore hypothesized that in pregnancy, the BBB adapts to high levels of these permeability factors. We investigated the influence of pregnancy-related circulating factors on VEGF-induced BBB permeability by perfusing cerebral veins with plasma from nonpregnant (NP) or late-pregnant (LP) rats (n=6/group) and measuring permeability in response to VEGF. The effect of VEGF, PLGF, and VEGF-receptor (VEGFR) activation on BBB permeability was also determined. Results showed that VEGF significantly increased permeability (x10(7) mu m(3)/min) from 9.7 +/- 3.5 to 21.0 +/- 1.5 (P<0.05) in NP veins exposed to NP plasma, that was prevented when LP veins were exposed to LP plasma; (9.7 +/- 3.8; P>0.05). Both LP plasma and soluble FMS-like tyrosine-kinase 1 (sFlt1) in NP plasma abolished VEGF-induced BBB permeability in NP veins (9.5 +/- 2.9 and 12 +/- 2.6; P>0.05). PLGF significantly increased BBB permeability in NP plasma (18 +/- 1.4; P<0.05), and required only VEGFR1 activation, whereas VEGF-induced BBB permeability required both VEGFR1 and VEGFR2. Our findings suggest that VEGF and PLGF enhance BBB permeability through different VEGFR pathways and that circulating sFlt1 prevents VEGF- and PLGF-induced BBB permeability during pregnancy.-Schreurs, M. P. H., Houston, E. M., May, V., Cipolla, M. J. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy. FASEB J. 26, 355-362 (2012). www.fasebj.org	[Schreurs, Malou P. H.; Houston, Emily M.; Cipolla, Marilyn J.] Univ Vermont, Dept Neurol, Coll Med, Burlington, VT 05405 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Obstet Gynecol & Reprod Sci, Coll Med, Burlington, VT 05405 USA; [Cipolla, Marilyn J.] Univ Vermont, Dept Pharmacol, Coll Med, Burlington, VT 05405 USA; [May, Victor] Univ Vermont, Dept Anat & Neurobiol, Coll Med, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Cipolla, MJ (corresponding author), Univ Vermont, Dept Neurol, Coll Med, 89 Beaumont Ave, Burlington, VT 05405 USA.	marilyn.cipolla@uvm.edu			U.S. National Institute of Neurological Disorders and Stroke [RO1 NS045940]; Neural Environment Cluster supplement [RO1 NS045940-06S1]; ARRA [RO1 NS045940-05S1]; U.S. National Heart, Lung, and Blood Institute [PO1 HL095488]; Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL095488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045940] Funding Source: NIH RePORTER	U.S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Neural Environment Cluster supplement; ARRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Totman Medical Research Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors gratefully acknowledge the support of U.S. National Institute of Neurological Disorders and Stroke grant RO1 NS045940, the Neural Environment Cluster supplement RO1 NS045940-06S1, and ARRA supplement RO1 NS045940-05S1. The authors also gratefully acknowledge the support of U.S. National Heart, Lung, and Blood Institute grant PO1 HL095488 and of the Totman Medical Research Trust.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Amburgey OA, 2010, HYPERTENSION, V56, P1003, DOI 10.1161/HYPERTENSIONAHA.110.158931; Ananth S. Karumanchi, 2009, ANNU REV PATHOL-MECH, V5, P173; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Banks RE, 1998, MOL HUM REPROD, V4, P377, DOI 10.1093/molehr/4.4.377; Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579; Celia G, 2005, J VASC RES, V42, P47, DOI 10.1159/000082976; Chrusciel M, 2011, REPROD DOMEST ANIM, V46, P434, DOI 10.1111/j.1439-0531.2010.01686.x; Cindrova-Davies T, 2011, CARDIOVASC RES, V89, P671, DOI 10.1093/cvr/cvq346; Cipolla MJ, 2007, HYPERTENSION, V50, P14, DOI 10.1161/HYPERTENSIONAHA.106.079442; Cipolla Marilyn J, 2011, Fetal Matern Med Rev, V22, P91, DOI 10.1017/S0965539511000040; Espinoza J, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2009.10.891; Euser AG, 2007, HYPERTENSION, V49, P334, DOI 10.1161/01.HYP.0000255791.54655.29; Evans P, 1997, CLIN SCI, V92, P567, DOI 10.1042/cs0920567; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; Foidart JM, 2009, J REPROD IMMUNOL, V82, P106, DOI 10.1016/j.jri.2009.09.001; Girard BM, 2002, REGUL PEPTIDES, V109, P89, DOI 10.1016/S0167-0115(02)00191-X; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013; Karumanchi SA, 2008, CURR HYPERTENS REP, V10, P305, DOI 10.1007/s11906-008-0057-3; Klinger MB, 2008, J COMP NEUROL, V507, P1379, DOI 10.1002/cne.21627; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Makrydimas G, 2008, PRENATAL DIAG, V28, P175, DOI 10.1002/pd.1916; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148; MAYHAN WG, 1995, BRAIN RES, V686, P99, DOI 10.1016/0006-8993(95)00460-8; Maynard SE, 2005, PEDIATR RES, V57, p1R, DOI 10.1203/01.PDR.0000159567.85157.B7; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; Odorisio T, 2002, J CELL SCI, V115, P2559; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Osol G, 2008, AM J PHYSIOL-HEART C, V294, pH1381, DOI 10.1152/ajpheart.00922.2007; Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516; Rajakumar A, 2009, PLACENTA, V30, P25, DOI 10.1016/j.placenta.2008.10.006; Roberts TJM, 2009, AM J PHYSIOL-HEART C, V297, pH1347, DOI 10.1152/ajpheart.00630.2009; Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Tripathi R, 2009, YONSEI MED J, V50, P656, DOI 10.3349/ymj.2009.50.5.656; Vaisbuch E., 2010, AM J OBSTET GYNECOL, V204, p152e151; Valdes G., PLACENTA S2, V32, pS170; Valdes G, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477-7827-6-13; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zygmunt M, 2003, EUR J OBSTET GYN R B, V110, pS10, DOI 10.1016/S0301-2115(03)00168-4	45	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					355	362		10.1096/fj.11-191916	http://dx.doi.org/10.1096/fj.11-191916			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21911594	Green Published			2022-12-28	WOS:000299202200035
J	Tocchini-Valentini, GP; Tocchini-Valentini, MA				Tocchini-Valentini, Glauco P.; Tocchini-Valentini, Marta A.			Comparative Anatomy: Giorgione's Venus, Connoisseur Morelli, and the Reverend Bayes	FASEB JOURNAL			English	Editorial Material									[Tocchini-Valentini, Glauco P.] CNR, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR)	Tocchini-Valentini, GP (corresponding author), CNR, Rome, Italy.							Bayes T., 1764, PHILOS T ROY SOC LON, V53, P370, DOI [10.1098/rstl.1763.0053, DOI 10.1098/RSTL.1763.0053]; Conan Doyle A, 1924, MEMORIES ADVENTURES, p[25, 74]; Freud S, 1976, MOSE MICHELANGELO, P36; Friedlander M. J, 1919, KUNSTKENNER, P24; Ginzburg C, 1986, MITI EMBLEMI SPIE MO, P159; Lermolieff I., 1880, WERKE ITALIENISCHER, P1; Lermolieff Ivan, 1880, WERKE ITALIENISCHER; Morelli G., 1883, ITALIAN MASTERS GERM; Wind E, 1972, ARTE ANARCHIA, P52	9	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					5	8		10.1096/fj.12-0102ufm	http://dx.doi.org/10.1096/fj.12-0102ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	22215794				2022-12-28	WOS:000299202200002
J	Mihlan, M; Blom, AM; Kupreishvili, K; Lauer, N; Stelzner, K; Bergstrom, F; Niessen, HWM; Zipfel, PF				Mihlan, Michael; Blom, Anna M.; Kupreishvili, Koba; Lauer, Nadine; Stelzner, Kristin; Bergstrom, Frida; Niessen, Hans W. M.; Zipfel, Peter F.			Monomeric C-reactive protein modulates classic complement activation on necrotic cells	FASEB JOURNAL			English	Article						cell death; C1q; C4b-binding protein; myocardial infarction	HEMOLYTIC-UREMIC SYNDROME; FACTOR-H; C4B-BINDING PROTEIN; APOPTOTIC CELLS; ENDOTHELIAL-CELLS; MYOCARDIAL-INFARCTION; HUMAN-DISEASES; 2 PARTS; PATHWAY; PHAGOCYTOSIS	The acute-phase protein C-reactive protein (CRP) recruits C1q to the surface of damaged cells and thereby initiates complement activation. However, CRP also recruits complement inhibitors, such as C4b-binding protein (C4bp) and factor H, which both block complement progression at the level of C3 and inhibits inflammation. To define how CRP modulates the classic complement pathway, we studied the interaction of CRP with the classic pathway inhibitor C4bp. Monomeric CRP (mCRP), but not pentameric CRP (pCRP), binds C4bp and enhances degradation of C4b and C3b. Both C1q, the initiator, and C4bp, the inhibitor of the classic pathway, compete for mCRP binding, and this competition adjusts the local balance of activation and inhibition. After attachment of pCRP to the surface of necrotic rat myocytes, generation of mCRP was demonstrated over a period of 18 h. Similarly, a biological role for mCRP, C1q, and C4bp in the disease setting of acute myocardial infarction was revealed. In this inflamed tissue, mCRP, pCRP, C4bp, C1q, and C4d were detected in acetone-fixed and in unfixed tissue. Protein levels were enhanced 6 h to 5 d after infarction. Thus, mCRP bound to damaged cardiomyocytes recruits C1q to activate and also C4bp to control the classic complement pathway.-Mihlan, M., Blom, A. M., Kupreishvili, K., Lauer, N., Stelzner, K., Bergstro " m, F., Niessen, H. W. M., Zipfel, P. F. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J. 25, 4198-4210 (2011). www.fasebj.org	[Mihlan, Michael; Lauer, Nadine; Stelzner, Kristin; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany; [Blom, Anna M.; Bergstrom, Frida] Lund Univ, Dept Lab Med, Malmo, Sweden; [Kupreishvili, Koba; Niessen, Hans W. M.] Vrije Univ Med Ctr Amsterdam, Dept Pathol, Amsterdam, Netherlands; [Zipfel, Peter F.] Univ Jena, Jena, Germany	Hans Knoll Institute (HKI); Lund University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Friedrich Schiller University of Jena	Zipfel, PF (corresponding author), Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11A, D-07745 Jena, Germany.	peter.zipfel@hki-jena.de	Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734; Mihlan, Michael/0000-0002-3946-6583; Niessen, Hans/0000-0001-9404-9822	Deutsche Forschungsgemeinschaft [Zi432-9/1]; Swedish Research Council [K2009-68X-14928-06-3]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Swedish Research Council(Swedish Research CouncilEuropean Commission)	The authors thank Steffi Halbich for expert assistance with surface plasmon resonance. The work was supported by the Deutsche Forschungsgemeinschaft (Zi432-9/1) and Swedish Research Council (K2009-68X-14928-06-3).	BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BERMAN S, 1986, J IMMUNOL, V136, P1354; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x; Blom AM, 2004, ARCH IMMUNOL THER EX, V52, P83; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; Eisenhardt SU, 2009, TRENDS CARDIOVAS MED, V19, P232, DOI 10.1016/j.tcm.2010.02.002; Fraser DA, 2010, J NEUROCHEM, V112, P733, DOI 10.1111/j.1471-4159.2009.06494.x; Fraser DA, 2009, J IMMUNOL, V183, P6175, DOI 10.4049/jimmunol.0902232; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200; Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069; Hellwage J, 1997, IMMUNOPHARMACOLOGY, V38, P149, DOI 10.1016/S0162-3109(97)00075-1; Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com; Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73; Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68; Lagrand WK, 1997, CIRCULATION, V95, P97, DOI 10.1161/01.CIR.95.1.97; Luo SS, 2011, J BIOL CHEM, V286, P8021, DOI 10.1074/jbc.M110.130138; Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Mevorach D, 2010, APOPTOSIS, V15, P1114, DOI 10.1007/s10495-010-0530-8; Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103; Mihlan M, 2009, MOL IMMUNOL, V46, P335, DOI 10.1016/j.molimm.2008.10.029; Mold C, 2001, J IMMUNOL, V166, P1200, DOI 10.4049/jimmunol.166.2.1200; MOLD C, 1984, J IMMUNOL, V133, P882; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028; Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012; Slevin M, 2010, BRAIN PATHOL, V20, P151, DOI 10.1111/j.1750-3639.2008.00256.x; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200; Trouw LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002886; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620	51	79	83	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4198	4210		10.1096/fj.11-186460	http://dx.doi.org/10.1096/fj.11-186460			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21856781				2022-12-28	WOS:000298138100013
J	Mendelson, A; Frank, E; Allred, C; Jones, E; Chen, M; Zhao, WL; Mao, JJ				Mendelson, Avital; Frank, Eric; Allred, Chad; Jones, Elena; Chen, Mo; Zhao, Wenli; Mao, Jeremy J.			Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells in vitro	FASEB JOURNAL			English	Article						tissue engineering; TGF-beta 3; SDF-1; chondrocytes	GROWTH-FACTOR; ARTICULAR-CARTILAGE; PROGENITOR CELLS; STROMAL CELLS; TISSUE; DIFFERENTIATION; REGENERATION; SCAFFOLDS; REPAIR; MICROSPHERES	Cell transplantation has been well explored for cartilage regeneration. We recently showed that the entire articular surface of a synovial joint can regenerate by endogenous cell homing and without cell transplantation. However, the sources of endogenous cells that regenerate articular cartilage remain elusive. Here, we studied whether cytokines not only chemotactically recruit adipose stem cells (ASCs), mesenchymal stem cells (MSCs), and synovium stem cells (SSCs) but also induce chondrogenesis of the recruited cells. Recombinant human transforming growth factor-beta 3 (TGF-beta 3; 100 ng) and/or recombinant human stromal derived factor-1 beta (SDF-1 beta; 100 ng) was control released into an acellular collagen sponge cube with underlying ASCs, MSCs, or SSCs in monolayer culture. Although all cell types randomly migrated into the acellular collagen sponge cube, TGF-beta 3 and/or SDF-1 beta recruited significantly more cells than the cytokine-free control group. In 6 wk, TGF-beta 3 alone recruited substantial numbers of ASCs (558 +/- 65) and MSCs (302 +/- 52), whereas codelivery of TGF-beta 3 and SDF-1 beta was particularly chemotactic to SSCs (400 +/- 120). Proliferation of the recruited cells accounted for some, but far from all, of the observed cellularity. TGF-beta 3 and SDF-1 beta codelivery induced significantly higher aggrecan gene expression than the cytokine-free group for ASCs, MSCs, and SSCs. Type II collagen gene expression was also significantly higher for ASCs and SSCs by SDF-1 and TGF-beta 3 codelivery. Remarkably, the expression of aggrecan and type II collagen was detected among all cell types. Thus, homing of multiple stem/progenitor cell populations may potentially serve as an alternative or adjunctive approach to cell transplantation for cartilage regeneration.-Mendelson, A., Frank, E., Allred, C., Jones, E., Chen, M., Zhao, W., Mao, J. J. Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells in vitro. FASEB J. 25, 3496-3504 (2011). www.fasebj.org	[Mendelson, Avital; Frank, Eric; Allred, Chad; Chen, Mo; Zhao, Wenli; Mao, Jeremy J.] Columbia Univ, Med Ctr, Tissue Engn & Regenerat Med Lab, New York, NY 10032 USA; [Mendelson, Avital; Mao, Jeremy J.] Columbia Univ, Dept Biomed Engn, New York, NY 10032 USA; [Jones, Elena] Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England	Columbia University; Columbia University; University of Leeds	Mao, JJ (corresponding author), Columbia Univ, Med Ctr, Tissue Engn & Regenerat Med Lab, 630 W 168 St,PH7E-CDM, New York, NY 10032 USA.	jmao@columbia.edu	Jones, Elena/F-3136-2010	Mendelson, Avital/0000-0002-1120-9593; Jones, Elena/0000-0001-9365-2283	U.S. National Institutes of Health [RC2-D-E020767, R01-EB-0062621]	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Ryan V. Maneevese, Brian H. Sybo, Brandon R. Knapp, Stephanie Bohaczuk, and Andrew Chang for technical assistance. Adipose stem cells were a generous gift from Dr. Jeffrey M. Gimble (Pennington Biomedical Research Center, Louisiana State University, Baton Rogue, LA, USA). The present study is funded in part by U.S. National Institutes of Health grants RC2-D-E020767 and R01-EB-0062621.	Agrawal V, 2010, P NATL ACAD SCI USA, V107, P3351, DOI 10.1073/pnas.0905851106; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alhadlaq A, 2004, ANN BIOMED ENG, V32, P911, DOI 10.1023/B:ABME.0000032454.53116.ee; Awad HA, 2004, BIOMATERIALS, V25, P3211, DOI 10.1016/j.biomaterials.2003.10.045; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bladergroen BA, 2009, TISSUE ENG PT A, V15, P1591, DOI 10.1089/ten.tea.2008.0348; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; Chen T, 2007, STEM CELLS, V25, P392, DOI 10.1634/stemcells.2006-0145; Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood-2008-10-184754; Chung C, 2008, ADV DRUG DELIVER REV, V60, P243, DOI 10.1016/j.addr.2007.08.027; De Bari C, 2001, ARTHRITIS RHEUM-US, V44, P1928, DOI 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P; De Bari C, 2008, ARTHRITIS RHEUM, V58, P240, DOI 10.1002/art.23143; Dowthwaite GP, 2004, J CELL SCI, V117, P889, DOI 10.1242/jcs.00912; Fan HB, 2006, J BIOMED MATER RES A, V77A, P785, DOI 10.1002/jbm.a.30647; Fodor William L, 2003, Reprod Biol Endocrinol, V1, P102, DOI 10.1186/1477-7827-1-102; Gao J, 2007, P I MECH ENG H, V221, P441, DOI 10.1243/09544119JEIM257; He XZ, 2010, INT J PHARMACEUT, V390, P107, DOI 10.1016/j.ijpharm.2009.12.063; Hildner F, 2010, J BIOMED MATER RES A, V94A, P978, DOI 10.1002/jbm.a.32761; Jones E, 2010, ANN RHEUM DIS, V69, P450, DOI 10.1136/ard.2008.106435; Jones EA, 2004, ARTHRITIS RHEUM-US, V50, P817, DOI 10.1002/art.20203; Karystinou A, 2009, RHEUMATOLOGY, V48, P1057, DOI 10.1093/rheumatology/kep192; Kim JY, 2010, TISSUE ENG PT A, V16, P3023, DOI [10.1089/ten.tea.2010.0181, 10.1089/ten.TEA.2010.0181]; Kim J, 2009, ARCH PHARM RES, V32, P117, DOI 10.1007/s12272-009-1125-1; Kimura Y, 2003, BIOMATERIALS, V24, P2513, DOI 10.1016/S0142-9612(03)00049-8; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; Kumar A, 2007, CR BIOL, V330, P485, DOI 10.1016/j.crvi.2007.01.006; Lee CH, 2009, TISSUE ENG PT A, V15, P3923, DOI 10.1089/ten.TEA.2008.0653; Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230; Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140-6736(10)60668-X; Lepperdinger G, 2008, EXP GERONTOL, V43, P1018, DOI 10.1016/j.exger.2008.07.004; Li Y, 2007, BIOCHEM BIOPH RES CO, V356, P780, DOI 10.1016/j.bbrc.2007.03.049; Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818; Mao JJ, 2010, TISSUE ENG PART B-RE, V16, P257, DOI 10.1089/ten.TEB.2009.0496; Mao JJ, 2005, BIOL CELL, V97, P289, DOI 10.1042/BC20040100; Marion NW, 2006, METHOD ENZYMOL, V420, P339, DOI 10.1016/S0079-6879(06)20016-8; Mazzetti E, 2004, ARTHRITIS RHEUM-US, V50, P112, DOI 10.1002/art.11474; Moioli E. K., TISSUE ENG A, V16, P3299; Pelus LM, 2008, LEUKEMIA, V22, P466, DOI 10.1038/sj.leu.2405021; Raghunath J, 2005, CURR OPIN BIOTECH, V16, P503, DOI 10.1016/j.copbio.2005.08.004; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Schaefer D, 2002, ARTHRITIS RHEUM-US, V46, P2524, DOI 10.1002/art.10493; Schantz JT, 2007, TISSUE ENG, V13, P2615, DOI 10.1089/ten.2006.0438; Shen WL, 2010, BIOMATERIALS, V31, P7239, DOI 10.1016/j.biomaterials.2010.05.040; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Thangarajah H, 2009, STEM CELLS, V27, P266, DOI 10.1634/stemcells.2008-0276; Thorpe SD, 2010, ANN BIOMED ENG, V38, P2896, DOI 10.1007/s10439-010-0059-6; Varshney RR, 2010, BIOMATERIALS, V31, P6876, DOI 10.1016/j.biomaterials.2010.05.038; Yun K, 2008, J BIOSCI BIOENG, V105, P122, DOI 10.1263/jbb.105.122; Zheng Z, 2011, J INVEST DERMATOL, V131, P769, DOI 10.1038/jid.2010.381	49	54	59	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3496	3504		10.1096/fj.10-176305	http://dx.doi.org/10.1096/fj.10-176305			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746864	Green Published			2022-12-28	WOS:000295356400020
J	Bertero, T; Gastaldi, C; Bourget-Ponzio, I; Imbert, V; Loubat, A; Selva, E; Busca, R; Mari, B; Hofman, P; Barbry, P; Meneguzzi, G; Ponzio, G; Rezzonico, R				Bertero, Thomas; Gastaldi, Cecile; Bourget-Ponzio, Isabelle; Imbert, Veronique; Loubat, Agnes; Selva, Eric; Busca, Roser; Mari, Bernard; Hofman, Paul; Barbry, Pascal; Meneguzzi, Guerrino; Ponzio, Gilles; Rezzonico, Roger			miR-483-3p controls proliferation in wounded epithelial cells	FASEB JOURNAL			English	Article						microRNA; skin; MK2; YAP1	IN-VITRO; EPIDERMAL-KERATINOCYTES; HUMAN FIBROBLASTS; MICRORNAS; EXPRESSION; INHIBITION; IDENTIFICATION; BINDING; TARGET; GENES	The mechanisms that regulate keratinocyte migration and proliferation in wound healing remain largely unraveled, notably regarding possible involvements of microRNAs (miRNAs). Here we disclose upregulation of miR-483-3p in 2 distinct models of wound healing: scratch-injured cultures of human keratinocytes and wounded skin in mice. miR-483-3p accumulation peaks at the final stage of the wound closure process, consistent with a role in the arrest of "healing" progression. Using an in vitro wound-healing model, videomicroscopy, and 5-bromo-2'-uridine incorporation, we observed that overexpression of miR-483-3p inhibits keratinocyte migration and proliferation, whereas delivery of anti-miR-483-3p oligonucleotides sustains keratinocyte proliferation beyond the closure of the wound, compared with irrelevant anti-miR treatment. Expression profiling of keratinocytes transfected with miR-483-3p identified 39 transcripts that were both predicted targets of miR-483-3p and down-regulated after miR-483-3p overexpression. Luciferase reporter assays, Western blot analyses, and silencing by specific siRNAs finally established that kinase MK2, cell proliferation marker MKI67, and transcription factor YAP1 are direct targets of miR-483-3p that control keratinocyte proliferation. miR-483-3p-mediated down-regulation of MK2, MKI67, and YAP1 thus represents a novel mechanism controlling keratinocyte growth arrest at the final steps of reepithelialization.-Bertero, T., Gastaldi, C., Bourget-Ponzio, I., Imbert, V., Loubat, A., Selva, E., Busca, R., Mari, B., Hofman, P., Barbry, P., Meneguzzi, G., Ponzio, G., Rezzonico, R. miR-483-3p controls proliferation in wounded epithelial cells. FASEB J. 25, 3092-3105 (2011). www.fasebj.org	[Bertero, Thomas; Gastaldi, Cecile; Bourget-Ponzio, Isabelle; Loubat, Agnes; Busca, Roser; Meneguzzi, Guerrino; Ponzio, Gilles; Rezzonico, Roger] Fac Med Nice, INSERM, U634, IFR50, F-06107 Nice 02, France; [Bertero, Thomas; Gastaldi, Cecile; Bourget-Ponzio, Isabelle; Imbert, Veronique; Loubat, Agnes; Selva, Eric; Busca, Roser; Mari, Bernard; Hofman, Paul; Barbry, Pascal; Meneguzzi, Guerrino; Ponzio, Gilles; Rezzonico, Roger] Univ Nice Sophia Antipolis, Nice, France; [Imbert, Veronique] Fac Med Nice, INSERM, U895, C3M, F-06034 Nice, France; [Mari, Bernard; Barbry, Pascal] CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; [Selva, Eric; Hofman, Paul] Pasteur Hosp, Fac Med, INSERM,ERI21, Lab Clin & Expt Pathol & Human Biobank,EA4319, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Rezzonico, R (corresponding author), Fac Med Nice, INSERM, U634, IFR50, 28 Ave Valombrose, F-06107 Nice 02, France.	rezzonic@unice.fr	Mari, Bernard P/GVS-3100-2022; REZZONICO, Roger/N-9626-2016; Barbry, Pascal/O-5021-2016; Hofman, Paul/P-7654-2018; Mari, Bernard P/F-8960-2013; Ponzio, Gilles/Q-1256-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Imbert, Véronique/I-6093-2016	Mari, Bernard P/0000-0002-0422-9182; REZZONICO, Roger/0000-0002-8460-1641; Barbry, Pascal/0000-0001-9632-6483; Hofman, Paul/0000-0003-0431-9353; Mari, Bernard P/0000-0002-0422-9182; Ponzio, Gilles/0000-0003-2741-0248; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Imbert, Véronique/0000-0003-2103-6718; Meneguzzi, Guerrino/0000-0002-1609-6540; BOURGET, Isabelle/0000-0001-6369-8176; BERTERO, Thomas/0000-0002-4801-9902	Association pour la Recherche sur le Cancer (ARC) [3840]; French Society of Dermatology (SFD) [2005]; EC [FP7/2007-2011, 201279]; INSERM/Provence-Alpes-Cote d'Azur region	Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); French Society of Dermatology (SFD); EC(European CommissionEuropean Commission Joint Research Centre); INSERM/Provence-Alpes-Cote d'Azur region(Institut National de la Sante et de la Recherche Medicale (Inserm)Region Provence-Alpes-Cote d'Azur)	The authors thank N. Techer and L. Fantin for skillful technical assistance. This work was supported by the Association pour la Recherche sur le Cancer (ARC; grant 3840), the French Society of Dermatology (SFD; grant 2005) and the EC Seventh Framework Program FP7/2007-2011 under grant 201279. C. G. was recipient of an INSERM/Provence-Alpes-Cote d'Azur region fellowship. The authors declare no conflicts of interest.	Banerjee J, 2011, PHYSIOL GENOMICS, V43, P543, DOI 10.1152/physiolgenomics.00157.2010; Biswas S, 2010, P NATL ACAD SCI USA, V107, P6976, DOI 10.1073/pnas.1001653107; Blakytny Robert, 2000, Journal of Pathology, V190, P589, DOI 10.1002/(SICI)1096-9896(200004)190:5<589::AID-PATH553>3.0.CO;2-T; Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762; D'Addario I, 2010, HISTOCHEM CELL BIOL, V134, P265, DOI 10.1007/s00418-010-0728-4; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fitsialos G, 2008, J CELL SCI, V121, P2992, DOI 10.1242/jcs.029256; Fitsialos G, 2007, J BIOL CHEM, V282, P15090, DOI 10.1074/jbc.M606094200; Fu HJ, 2005, FEBS LETT, V579, P3849, DOI 10.1016/j.febslet.2005.05.064; Gu J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r42; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kausch I, 2003, INT J CANCER, V105, P710, DOI 10.1002/ijc.11111; Krutzfeldt J, 2006, NAT GENET, V38, pS14, DOI 10.1038/ng1799; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Loryman C, 2008, WOUND REPAIR REGEN, V16, P45, DOI 10.1111/j.1524-475X.2007.00290.x; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luscher-Firzlaff J, 2008, CANCER RES, V68, P749, DOI 10.1158/0008-5472.CAN-07-3158; Moreilhon C, 2005, PHYSIOL GENOMICS, V20, P244, DOI 10.1152/physiolgenomics.00135.2004; Muller-Decker K, 2005, J INVEST DERMATOL, V124, P553, DOI 10.1111/j.0022-202X.2004.23598.x; Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/NMETH.1294, 10.1038/nmeth.1294]; Pottier N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006718; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Shilo S, 2007, DNA CELL BIOL, V26, P227, DOI 10.1089/dna.2006.0568; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J INVEST DERMATOL, V130, P124, DOI 10.1038/jid.2009.294; Tang J, 2008, ONCOGENE, V27, P6635, DOI 10.1038/onc.2008.262; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Tzur G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007511; van Dongen S, 2008, NAT METHODS, V5, P1023, DOI 10.1038/nmeth.1267; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yu J, 2010, FASEB J, V24, P3950, DOI 10.1096/fj.10-157404; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zheng JN, 2006, LIFE SCI, V78, P724, DOI 10.1016/j.lfs.2005.05.064; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zibert JR, 2010, J DERMATOL SCI, V58, P177, DOI 10.1016/j.jdermsci.2010.03.004	51	74	78	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3092	3105		10.1096/fj.10-168401	http://dx.doi.org/10.1096/fj.10-168401			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21676945				2022-12-28	WOS:000294435200023
J	Jousse, C; Parry, L; Lambert-Langlais, S; Maurin, AC; Averous, J; Bruhat, A; Carraro, V; Tost, J; Letteron, P; Chen, P; Jockers, R; Launay, JM; Mallet, J; Fafournoux, P				Jousse, Celine; Parry, Laurent; Lambert-Langlais, Sarah; Maurin, Anne-Catherine; Averous, Julien; Bruhat, Alain; Carraro, Valerie; Tost, Jorg; Letteron, Philippe; Chen, Patty; Jockers, Ralf; Launay, Jean-Marie; Mallet, Jacques; Fafournoux, Pierre			Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome	FASEB JOURNAL			English	Article						nutritional programming; epigenetic; food intake; maternal imprinting	NUTRITION TRANSITION; ENERGY HOMEOSTASIS; DNA METHYLATION; OBESITY; LIFE; DISEASE; HYPOTHALAMUS; EPIGENETICS; EPIGENOME; PROMOTER	Transient environmental influences, such as perinatal nutritional stress, may induce deleterious metabolic symptoms that last for the entire life of individuals, implying that epigenetic modifications play an important role in this process. We have investigated, in mice, the consequences of maternal undernutrition during gestation and lactation on DNA methylation and expression of the leptin gene, which plays a major regulatory role in coordinating nutritional state with many aspects of mammalian biology. We show that animals born to mothers fed a low-protein-diet (F1-LPD group) have a lower body weight/adiposity and exhibit a higher food intake than animals born to mothers fed a control diet (F1-CD group). These modifications persisted throughout life and were associated with lower levels of leptin mRNA and protein in starved F1-LPD mice, emphasizing that maternal protein-undernutrition affects the balance between food intake and energy expenditure in adults. Moreover, this nutritional stress resulted in the removal of methyls at CpGs located in the promoter of leptin, causing a permanent specific modification in the dynamics of the expression of leptin, which exhibits a stronger induction in the F1-LPD than in F1-CD mice in response to a meal. This study is an example of a molecular rationale linking transient environmental influences to permanent phenotypic consequences.-Jousse, C., Parry, L., Lambert-Langlais, S., Maurin, A. C., Averous, J., Bruhat, A., Carraro, V., Tost, J., Letteron, P., Chen, P., Jockers, R., Launay, J. M., Mallet, J., Fafournoux, P. Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome. FASEB J. 25, 3271-3278 (2011). www.fasebj.org	[Jousse, Celine; Parry, Laurent; Lambert-Langlais, Sarah; Maurin, Anne-Catherine; Averous, Julien; Bruhat, Alain; Carraro, Valerie; Fafournoux, Pierre] INRA, UMR Unite Nutr Humaine 1019, F-63122 St Genes Champanelle, France; [Jousse, Celine; Fafournoux, Pierre] CNRS, Paris, France; [Tost, Jorg] CEA, Inst Genom, Lab Epigenet, Ctr Natl Genotypage, Evry, France; [Letteron, Philippe] INSERM, U773, Fac Med Xavier Bichat CRB3, Paris, France; [Chen, Patty; Jockers, Ralf] CNRS, INSERM, U1016, UMR 8104,Inst Cochin, Paris, France; [Launay, Jean-Marie] Univ Paris 05, Hop Lariboisiere, AP HP, Serv Biochim & Biol Mol,EA 3621,Fac Pharm, Paris, France; [Mallet, Jacques] Univ Paris 06, Hop La Pitie Salpetriere, CNRS,UMR 7091, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, Paris, France	INRAE; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Fafournoux, P (corresponding author), INRA, UMR Nutr Humaine 1019, F-63122 St Genes Champanelle, France.	pierre.fafournoux@clermont.inra.fr	Jockers, Ralf/P-2272-2017; Jockers, Ralf/Q-2100-2019; Tost, Joerg/H-7129-2019	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750; Tost, Joerg/0000-0002-2683-0817	Agence Nationale de la Recherche Epidiabesity	Agence Nationale de la Recherche Epidiabesity(French National Research Agency (ANR))	The authors thank Anne Terrisse for animal care and Rolando Meloni and Nicole Faucon for critical reading of the manuscript. Funding for this project has been supplied by Agence Nationale de la Recherche Epidiabesity.	BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9; Bluher Susann, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P458, DOI 10.1097/MED.0b013e3282f1cfdc; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Burdge GC, 2010, ANNU REV NUTR, V30, P315, DOI 10.1146/annurev.nutr.012809.104751; Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310; Cooney CA, 2002, J NUTR, V132, p2393S; Desai M, 1997, AM J PHYSIOL-GASTR L, V273, pG899, DOI 10.1152/ajpgi.1997.273.4.G899; Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Holness MJ, 2000, BIOCHEM J, V349, P657, DOI 10.1042/bj3490657; Igoudjil A, 2007, ANTIVIR THER, V12, P389; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008; Lam QLK, 2007, CELL MOL IMMUNOL, V4, P1; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Lu XY, 2007, CURR OPIN PHARMACOL, V7, P648, DOI 10.1016/j.coph.2007.10.010; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Muhlhausler BS, 2004, J NEUROENDOCRINOL, V16, P502, DOI 10.1111/j.1365-2826.2004.01197.x; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V270, pE559, DOI 10.1152/ajpendo.1996.270.4.E559; Petry C J, 2001, Int J Exp Diabetes Res, V2, P139; Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]; Rees WD, 2000, J NUTR, V130, P1821, DOI 10.1093/jn/130.7.1821; Rutten BPF, 2009, SCHIZOPHRENIA BULL, V35, P1045, DOI 10.1093/schbul/sbp104; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Singhal A, 2002, AM J CLIN NUTR, V75, P993, DOI 10.1093/ajcn/75.6.993; Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009; Thompson MP, 1996, BIOCHEM BIOPH RES CO, V224, P332, DOI 10.1006/bbrc.1996.1029; Thompson SL, 2001, TOXICOL LETT, V120, P143, DOI 10.1016/S0378-4274(01)00292-2; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378	36	113	119	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3271	3278		10.1096/fj.11-181792	http://dx.doi.org/10.1096/fj.11-181792			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21670064	Bronze			2022-12-28	WOS:000294435200039
J	Seriwatanachai, D; Densmore, MJ; Sato, T; Correa, D; Neff, L; Baron, R; Lanske, B				Seriwatanachai, Dutmanee; Densmore, Michael J.; Sato, Tadatoshi; Correa, Diego; Neff, Lynn; Baron, Roland; Lanske, Beate			Deletion of Zfp521 rescues the growth plate phenotype in a mouse model of Jansen metaphyseal chondrodysplasia	FASEB JOURNAL			English	Article						chondrocyte; endochondral bone formation; PTHrP; JMC; zinc finger protein	HORMONE-RELATED PEPTIDE; ENDOCHONDRAL BONE-FORMATION; PARATHYROID-HORMONE; PTH/PTHRP RECEPTOR; SKELETAL DEVELOPMENT; INDIAN HEDGEHOG; IN-VITRO; CHONDROCYTE MATURATION; TARGETED EXPRESSION; MICE	Jansen metaphyseal chondrodysplasia (JMC) is caused by a constitutively activating mutation of the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (PTHR1) and is characterized by widening of the metaphyses, reduction of long bone length, and short stature. A transgenic mouse expressing this mutation under the collagen alpha 1(II) promoter has been generated to investigate the mechanisms responsible for this chondrodysplasia. We recently identified zinc finger protein 521 (Zfp521) as a downstream target gene of PTHrP signaling. Interestingly, loss of Zfp521 from chondrocytes leads to reduced cell proliferation and increased differentiation in the growth plate. Thus, we hypothesized that specifically ablating Zfp521 from Jansen chondrocytes could sufficiently rescue the chondrodysplasia phenotype. Our results show that Zfp521 expression is up-regulated in Jansen mouse growth plate chondrocytes and that PTHR1 is required for Zfp521 expression. Its ablation from Jansen chondrocytes restored normal cell differentiation, thus initiating chondrocyte apoptosis at the chondro-osseous junction, leading to partial rescue of endochondral bone formation shown by proper bone length. This study provides the first genetic evidence that Zfp521 is required downstream of PTHR1 signaling to act on chondrocyte proliferation, differentiation, and cell death.-Seriwatanachai, D., Densmore, M. J., Sato, T., Correa, D., Neff, L., Baron, R., Lanske, B. Deletion of Zfp521 rescues the growth plate phenotype in a mouse model of Jansen metaphyseal chondrodysplasia. FASEB J. 25, 3057-3067 (2011). www.fasebj.org	[Seriwatanachai, Dutmanee; Densmore, Michael J.; Sato, Tadatoshi; Lanske, Beate] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; [Correa, Diego; Neff, Lynn; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA; [Baron, Roland] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02115 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital	Lanske, B (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, Res & Educ Bldg,Rm 303,188 Longwood Ave, Boston, MA 02115 USA.	beate_lanske@hsdm.harvard.edu	Seriwatanachai, Dutmanee/K-3423-2019	Seriwatanachai, Dutmanee/0000-0001-8955-1324; Lanske, Beate/0000-0003-4638-804X	U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR050560, AR057769]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050560, R01AR057769] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Drs. Neal G. Copeland, Soren Warming, Riku Kiviranta, and Yukiko Maeda for helpful suggestions. This work was supported by U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases grants AR050560 (B. L.) and AR057769 (R. B.).	Al Kaissi A, 2005, Australas Radiol, V49, P57, DOI 10.1111/j.1440-1673.2005.01395.x; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Correa D, 2010, DEV CELL, V19, P533, DOI 10.1016/j.devcel.2010.09.008; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Guo J, 2006, DEV BIOL, V292, P116, DOI 10.1016/j.ydbio.2005.12.044; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kobayashi T, 2002, DEVELOPMENT, V129, P2977; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415-09; Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Long FX, 2001, DEVELOPMENT, V128, P5099; Maeda Y, 2010, BONE, V46, P472, DOI 10.1016/j.bone.2009.09.009; Minagawa M, 1997, ENDOCR J, V44, P493, DOI 10.1507/endocrj.44.493; Nakamata T, 2003, J BONE MINER RES, V18, P97, DOI 10.1359/jbmr.2003.18.1.97; Provot S, 2006, DEVELOPMENT, V133, P651, DOI 10.1242/dev.02258; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Soegiarto DW, 2001, ENDOCRINOLOGY, V142, P5303, DOI 10.1210/en.142.12.5303; VWEN SF, 2000, CANCER GENE THER, V7, P1469; Wu M, 2009, BONE, V44, P528, DOI 10.1016/j.bone.2008.11.011	27	20	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3057	3067		10.1096/fj.11-183277	http://dx.doi.org/10.1096/fj.11-183277			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21642473	Green Published, Bronze			2022-12-28	WOS:000294435200020
J	Lowenstein, J				Lowenstein, Jerome			The anglerfish and uremic	FASEB JOURNAL			English	Article							RESIDUAL RENAL-FUNCTION; ORGANIC ANION TRANSPORTERS; INDOXYL SULFATE; RELATIVE CONTRIBUTION; GENE-EXPRESSION; DIALYSIS; INDUCTION; ADEQUACY; KIDNEY		NYU, Sch Med, Div Nephrol, New York, NY 10016 USA	New York University	Lowenstein, J (corresponding author), NYU, Sch Med, Div Nephrol, 530 1st Ave,4D, New York, NY 10016 USA.	jerome.lowenstein@nyumc.org		Lowenstein, Jerome/0000-0002-2090-2015				Aoyama I, 2003, AM J KIDNEY DIS, V41, pS8, DOI 10.1053/ajkd.2003.50075; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Beyenbach KW, 2004, AM J PHYSIOL-RENAL, V286, pF811, DOI 10.1152/ajprenal.00351.2003; BOWMER CJ, 1982, BIOCHEM PHARMACOL, V31, P319, DOI 10.1016/0006-2952(82)90177-0; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Deguchi T, 2004, KIDNEY INT, V65, P162, DOI 10.1111/j.1523-1755.2004.00354.x; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Enomoto A, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022017.96399.B2; EVENEPOEL P, 2009, KIDNEY INT S114, V76, P512; Grantham JJ, 2002, AM J PHYSIOL-RENAL, V282, pF1, DOI 10.1152/ajprenal.2002.282.1.F1; Himmelfarb J, 2006, CLIN J AM SOC NEPHRO, V1, P896, DOI 10.2215/CJN.10911105; Launay-Vacher V, 2006, NEPHRON PHYSIOL, V103, P97, DOI 10.1159/000092212; LOWENSTEIN J, 1985, B MOUNT DESERT BIOL, V25, P66; Marquez IO, 2011, CLIN J AM SOC NEPHRO, V6, P290, DOI 10.2215/CJN.06100710; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Miyazaki T, 2000, NEPHROL DIAL TRANSPL, V15, P1773, DOI 10.1093/ndt/15.11.1773; Motojima M, 2003, KIDNEY INT, V63, P1671, DOI 10.1046/j.1523-1755.2003.00906.x; Ogu C C, 2000, Proc (Bayl Univ Med Cent), V13, P421; OLIVER J, 1950, J UROLOGY, V63, P373, DOI 10.1016/S0022-5347(17)68776-7; Oliver J., 1939, ARCHITECTURE KIDNEY; Rettig RA, 2011, NEW ENGL J MED, V364, P596, DOI 10.1056/NEJMp1014193; Schroeder JC, 2010, BIOCHEMISTRY-US, V49, P393, DOI 10.1021/bi901786x; Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297; Sekine T, 2006, AM J PHYSIOL-RENAL, V290, pF251, DOI 10.1152/ajprenal.00439.2004; Smith HW, 1941, PORTER LECT SERIES, V9; Smith HW., 1951, KIDNEY STRUCTURE FUN, P552; Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93; Toyohara T, 2009, J AM SOC NEPHROL, V20, P2546, DOI 10.1681/ASN.2009070696; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Wang AYM, 2006, KIDNEY INT, V69, P1726, DOI 10.1038/sj.ki.5000382; Yu M, 2011, CLIN J AM SOC NEPHRO, V6, P30, DOI 10.2215/CJN.05340610	31	20	21	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1781	1785		10.1096/fj.11-0602ufm	http://dx.doi.org/10.1096/fj.11-0602ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21622695				2022-12-28	WOS:000291023800002
J	Zhang, X; Zhang, Y; Tao, B; Teng, L; Li, YW; Cao, R; Gui, Q; Ye, MD; Mou, XZ; Cheng, HQ; Hu, H; Zhou, R; Wu, XM; Xie, QM; Ning, W; Lai, MD; Shen, HH; Feng, GS; Ke, YH				Zhang, Xue; Zhang, Yun; Tao, Bo; Teng, Li; Li, Yanwei; Cao, Rui; Gui, Qiu; Ye, Madong; Mou, Xiaozhou; Cheng, Hongqiang; Hu, Hu; Zhou, Ren; Wu, Ximei; Xie, Qiangmin; Ning, Wen; Lai, Maode; Shen, Huahao; Feng, Gen-Sheng; Ke, Yuehai			Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis	FASEB JOURNAL			English	Article						Abca3; TTF-1; FGFs; surfactant proteins; IPF	TYROSINE-PHOSPHATASE; GROWTH-FACTOR; PROTEIN-A; CELLS; APOPTOSIS; MICE; STEM; PATHOGENESIS; MUTATIONS; DELETION	Type II alveolar epithelial (AT-II) cells produce pulmonary surfactant proteins that are essential for alveolar function. AT-II is a major target in lung injury, and ineffective repair of damaged alveolar epithelia has been postulated to cause pulmonary fibrosis. Previous studies have shown that tyrosine phosphatase Shp2 is expressed highly in the embryonic lung epithelial buds, and Shp2 activity is required for FGF-induced lung branching morphogenesis. To investigate in vivo function of pulmonary Shp2, we generated alveoli epithelia-specific Shp2-knockout (Shp2(Delta/Delta)) mice. Shp2(Delta/Delta) mice exhibit marked reduction in surfactant proteins, disorganized lamellar bodies, increased alveolar epithelial apoptosis, and interstitial pulmonary fibrosis without preceding inflammation. Mechanistically, Shp2 acts to mediate expression of thyroid transcription factor 1 (TTF1) and ATP-binding cassette subfamily A member 3 (ABCA3). Shp2 also plays a central role in mediating FGF/GAB/ERK activity, required for epithelial repair program. Together, our results identify a novel role of tyrosine phosphatase Shp2 in surfactant homeostasis, and deregulation of Shp2 triggers spontaneous pulmonary fibrosis with minimal inflammation.-Zhang, X., Zhang, Y., Tao, B., Teng, L., Li, Y., Cao, R., Gui, Q., Ye, M., Mou, X., Cheng, H., Hu, H., Zhou, R., Wu, X., Xie, Q., Ning, W., Lai, M., Shen, H., Feng, G.-S., Ke, Y. Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis. FASEB J. 26, 2338-2350 (2012). www.fasebj.org	[Zhang, Xue; Zhang, Yun; Tao, Bo; Teng, Li; Li, Yanwei; Cao, Rui; Gui, Qiu; Ye, Madong; Mou, Xiaozhou; Cheng, Hongqiang; Hu, Hu; Zhou, Ren; Wu, Ximei; Lai, Maode; Ke, Yuehai] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Xue; Zhang, Yun; Tao, Bo; Teng, Li; Li, Yanwei; Cao, Rui; Gui, Qiu; Ye, Madong; Mou, Xiaozhou; Cheng, Hongqiang; Hu, Hu; Zhou, Ren; Wu, Ximei; Lai, Maode; Ke, Yuehai] Zhejiang Univ, Sch Med, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Xue; Zhang, Yun; Tao, Bo; Teng, Li; Li, Yanwei; Cao, Rui; Gui, Qiu; Ye, Madong; Mou, Xiaozhou; Cheng, Hongqiang; Hu, Hu; Zhou, Ren; Wu, Ximei; Xie, Qiangmin; Lai, Maode; Shen, Huahao; Ke, Yuehai] Zhejiang Univ, Sch Med, Inst Resp Dis, Hangzhou 310058, Zhejiang, Peoples R China; [Ning, Wen] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Feng, Gen-Sheng] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Feng, Gen-Sheng] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Zhejiang University; Zhejiang University; Zhejiang University; Nankai University; University of California System; University of California San Diego; University of California System; University of California San Diego	Ke, YH (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, POB 59,866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	yke@zju.edu.cn	Xie, Qiang-min/AAV-7711-2021; li, yan/GTI-4638-2022	Wu, Ximei/0000-0002-3316-893X; Cheng, Hongqiang/0000-0001-9662-1570; Xie, qiang-min/0000-0002-7975-9962	National Basic Research Program of China (973 Program) [2009CB522103]; National Natural Science Foundation of China [30871291, 30971504, 30900849]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors thank L. Lu and D. Wang for critical review of the manuscript and for helpful comments; J. A. Whitsett (College of Medicine, University of Cincinnati, Cincinnati, OH, USA) for SP-C-rtTA<SUP>tg</SUP>/<SUP>-</SUP> and (tetO)<INF>7</INF>CMV-Cre<SUP>tg/-</SUP> transgenic mice; L. Wang for conducting electronic microscopy; A. Chen, Dr. X Qin, (Zhejiang University School of Medicine, Hangzhou, China) and M. Chen (Zhejiang University of Traditional Chinese Medicine, Hangzhou, China) for their technical assistance. This work was supported by National Basic Research Program of China (973 Program) grant 2009CB522103 to Y.K., and National Natural Science Foundation of China grants 30871291 and 30971504 to Y.K., and 30900849 to X.Z.	Allam JS, 2006, CURR OPIN PULM MED, V12, P312, DOI 10.1097/01.mcp.0000239546.24831.61; Aoki Y, 2000, FASEB J, V14, P1965, DOI 10.1096/fj.00-0105com; Atabai K, 2002, AM J PHYSIOL-LUNG C, V283, pL163, DOI 10.1152/ajplung.00396.2001; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Boggaram V, 2009, CLIN SCI, V116, P27, DOI 10.1042/CS20080068; Cai ZG, 2011, MOL CELL BIOL, V31, P2973, DOI 10.1128/MCB.05054-11; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Cushing MC, 2008, FASEB J, V22, P1769, DOI 10.1096/fj.07-087627; Deng YM, 2006, EUR J PHARMACOL, V547, P125, DOI 10.1016/j.ejphar.2006.07.002; Devendra G, 2002, RESPIR RES, V3, DOI 10.1186/rr168; du Bois RM, 2010, NAT REV DRUG DISCOV, V9, P129, DOI 10.1038/nrd2958; El Firar A, 2009, FASEB J, V23, P4069, DOI 10.1096/fj.09-131367; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Galambos C, 2010, AM J RESP CRIT CARE, V182, P549, DOI 10.1164/rccm.201002-0167CR; Gharaee-Kermani M, 2005, AM J PATHOL, V166, P1593, DOI 10.1016/S0002-9440(10)62470-4; Gupte VV, 2009, AM J RESP CRIT CARE, V180, P424, DOI 10.1164/rccm.200811-1794OC; Hamvas A, 2007, NEONATOLOGY, V91, P311, DOI 10.1159/000101347; Hardie WD, 2009, AM J PATHOL, V175, P3, DOI 10.2353/ajpath.2009.081170; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Horowitz A, 2009, CIRC RES, V104, pE21, DOI 10.1161/CIRCRESAHA.108.191494; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; Ke YH, 2007, MOL CELL BIOL, V27, P6706, DOI 10.1128/MCB.01225-07; Ke YH, 2006, J BIOL CHEM, V281, P34374, DOI 10.1074/jbc.M607325200; Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Lawson WE, 2005, AM J PATHOL, V167, P1267, DOI 10.1016/S0002-9440(10)61214-X; Lee YH, 2010, J CELL SCI, V123, P1634, DOI 10.1242/jcs.063545; Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005; Morimoto M, 2009, DEV BIOL, V325, P171, DOI 10.1016/j.ydbio.2008.10.013; Mulugeta S, 2005, AM J RESP CELL MOL, V32, P521, DOI 10.1165/rcmb.2005-0009OC; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Perl AKT, 2011, AM J RESP CRIT CARE, V183, P511, DOI 10.1164/rccm.201005-0744OC; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Ramos C, 2010, AM J PHYSIOL-LUNG C, V299, pL222, DOI 10.1152/ajplung.00070.2010; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Selman M, 2003, HUM GENET, V113, P542, DOI 10.1007/s00439-003-1015-4; Selman M, 2008, PLOS MED, V5, P373, DOI 10.1371/journal.pmed.0050062; Sisson TH, 2010, AM J RESP CRIT CARE, V181, P254, DOI 10.1164/rccm.200810-1615OC; Stahlman MT, 2000, LAB INVEST, V80, P395, DOI 10.1038/labinvest.3780044; Strieter RM, 2009, CHEST, V136, P1364, DOI 10.1378/chest.09-0510; Tefft D, 2005, DEV BIOL, V282, P422, DOI 10.1016/j.ydbio.2005.03.022; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; van Moorsel CHM, 2010, AM J RESP CRIT CARE, V182, P1419, DOI 10.1164/rccm.200906-0953OC; VERDER H, 1994, NEW ENGL J MED, V331, P1051, DOI 10.1056/NEJM199410203311603; Weichert N, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-4; White MK, 2001, EXP CELL RES, V263, P183, DOI 10.1006/excr.2000.5120; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Yang WT, 2006, DEV CELL, V10, P317, DOI 10.1016/j.devcel.2006.01.002; Zhu HH, 2011, BLOOD, V117, P5350, DOI 10.1182/blood-2011-01-333476; Zoz DF, 2011, AM J MED SCI, V341, P435, DOI 10.1097/MAJ.0b013e31821a9d8e	55	48	51	3	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2338	2350		10.1096/fj.11-200139	http://dx.doi.org/10.1096/fj.11-200139			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362894				2022-12-28	WOS:000305017200012
J	Foller, M; Hermann, A; Gu, SC; Alesutan, I; Qadri, SM; Borst, O; Schmidt, EM; Schiele, F; vom Hagen, JM; Saft, C; Schols, L; Lerche, H; Stournaras, C; Storch, A; Lang, F				Foeller, Michael; Hermann, Andreas; Gu, Shuchen; Alesutan, Ioana; Qadri, Syed M.; Borst, Oliver; Schmidt, Eva-Maria; Schiele, Franziska; vom Hagen, Jennifer Mueller; Saft, Carsten; Schoels, Ludger; Lerche, Holger; Stournaras, Christos; Storch, Alexander; Lang, Florian			Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis	FASEB JOURNAL			English	Article						cytoskeleton; erythrocyte; PI3K; PAK1; Bad	GRANULE EXOCYTOSIS; CANCER CELLS; PROTEIN; CYTOSKELETON; KINASE; GENE; APOPTOSIS; DYNAMICS; BAD; PHOSPHORYLATION	Chorea-acanthocytosis is an inevitably lethal genetic disease characterized by a progressive hyperkinetic movement disorder and cognitive and behavioral abnormalities as well as acanthocytosis. The disease is caused by loss-of-function mutations of the gene encoding vacuolar protein sorting-associated protein 13A (VPS13A) or chorein, a protein with unknown function expressed in various cell types. How chorein deficiency leads to the pathophysiology of chorea-acanthocytosis remains enigmatic. Here we show decreased phosphoinositide-3-kinase (PI3K)-p85-subunit phosphorylation, ras-related C3 botunlinum toxin substrate 1 (Rac1) activity, and p21 protein-activated kinase 1 (PAK1) phosphorylation as well as depolymerized cortical actin in erythrocytes from patients with chorea-acanthocytosis and in K562-erythrocytic cells following chorein silencing. Pharmacological inhibition of PI3K, Rac1, or PAK1 similarly triggered actin depolymerization. Moreover, in K562 cells, both chorein silencing and PAK1 inhibition with IPA-3 decreased phosphorylation of Bad, a Bcl2-associated protein, promoting apoptosis by forming mitochondrial pores, followed by mitochondrial depolarization, DNA fragmentation, and phosphatidylserine exposure at the cell surface, all hallmarks of apoptosis. Our observations reveal chorein as a novel powerful regulator of cytoskeletal architecture and cell survival, thus explaining erythrocyte misshape and possibly neurodegeneration in chorea-acanthocytosis.-Fller, M., Hermann, A., Gu, S., Alesutan, I., Qadri, S. M., Borst, O., Schmidt, E.-M., Schiele, F., Muller vom Hagen, J., Saft, C., Schls, L., Lerche, H., Stournaras, C., Storch, A., Lang, F. Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis. FASEB J. 26, 1526-1534 (2012). www.fasebj.org	[Lang, Florian] Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany; [Schiele, Franziska; vom Hagen, Jennifer Mueller; Schoels, Ludger; Lerche, Holger] Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; [Schiele, Franziska; vom Hagen, Jennifer Mueller; Schoels, Ludger; Lerche, Holger] Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; [Hermann, Andreas; Storch, Alexander] Tech Univ Dresden, Dept Neurol, Div Neurodegenerat Dis, Dresden, Germany; [Saft, Carsten] Ruhr Univ Bochum, Dept Neurol, Bochum, Germany; [Stournaras, Christos] Univ Crete, Sch Med, Dept Biochem, Iraklion, Greece; [Storch, Alexander] German Ctr Neurodegenerat Dis DZNE, Dresden, Germany; [Schoels, Ludger] DZNE, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Technische Universitat Dresden; Ruhr University Bochum; University of Crete; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technische Universitat Dresden; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Lang, F (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	lang@uni-tuebingen.de	Hermann, Andreas/D-4213-2017; Schöls, Ludger/ABB-2482-2021	Hermann, Andreas/0000-0002-7364-7791; Schöls, Ludger/0000-0001-7774-5025; Saft, Carsten/0000-0002-3983-7292; Borst, Oliver/0000-0003-4002-4085	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft [GRK 1302, SFB 773, LA 315/13-3]; Neuroacanthocytosis Advocacy (London, UK); Advocacy for Neuroacanthocytosis Patients; ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA) [BMBF 01GM1003]	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Neuroacanthocytosis Advocacy (London, UK); Advocacy for Neuroacanthocytosis Patients; ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA)	The authors thank all patients and their families as well as the healthy control subjects for participation. The authors acknowledge the meticulous preparation of the manuscript by Tanja Loch and Lejla Subasic. This study was supported by the Carl-Zeiss-Stiftung and the Deutsche Forschungsgemeinschaft, GRK 1302, SFB 773, LA 315/13-3, and the Neuroacanthocytosis Advocacy (London, UK). Western blot analysis for chorein was performed by Dr. Benedikt Bader with the financial support of the Advocacy for Neuroacanthocytosis Patients and of the ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA; BMBF 01GM1003) in the laboratories of Profs. Hans Kretzschmar (Department of Neuropathology) and Adrian Danek (Department of Neurology) at Ludwig-Maximilians-Universitat (Munich, Germany).	Andrade AL, 2010, J PHYSIOL-LONDON, V588, P1499, DOI 10.1113/jphysiol.2010.187609; Arboleda G, 2009, BRAIN RES REV, V59, P333, DOI 10.1016/j.brainresrev.2008.10.001; Barzilai A, 2010, APOPTOSIS, V15, P1371, DOI 10.1007/s10495-010-0501-0; Bausen M, 2006, MOL CELL NEUROSCI, V31, P376, DOI 10.1016/j.mcn.2005.11.004; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dobson-Stone C, 2004, ANN NEUROL, V56, P299, DOI 10.1002/ana.20200; Dobson-Stone C, 2002, EUR J HUM GENET, V10, P773, DOI 10.1038/sj.ejhg.5200866; Dobson-Stone C, 1993, GENEREVIEWS; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Eliyahu E, 2005, REPRODUCTION, V129, P161, DOI 10.1530/rep.1.00424; European Molecular Biology Laboratory-European Bioinformatics Institute, 2011, INTACT DAT; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Keller H, 2002, EXP CELL RES, V277, P161, DOI 10.1006/excr.2002.5552; Kreis P, 2008, J NEUROCHEM, V106, P1184, DOI 10.1111/j.1471-4159.2008.05474.x; Kurano Y, 2007, BIOCHEM BIOPH RES CO, V353, P431, DOI 10.1016/j.bbrc.2006.12.059; Lang F, 2008, CELL PHYSIOL BIOCHEM, V22, P373, DOI 10.1159/000185448; Malacombe M, 2006, BBA-MOL CELL RES, V1763, P1175, DOI 10.1016/j.bbamcr.2006.09.004; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mitchell T, 2008, AM J PHYSIOL-CELL PH, V295, pC1354, DOI 10.1152/ajpcell.00239.2008; Mohiddin SA, 2002, TEX HEART I J, V29, P290; Onabajo OO, 2008, J IMMUNOL, V180, P6685, DOI 10.4049/jimmunol.180.10.6685; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Papakonstanti EA, 2008, FEBS LETT, V582, P2120, DOI 10.1016/j.febslet.2008.02.064; Papakonstanti EA, 2002, MOL BIOL CELL, V13, P2946, DOI 10.1091/mbc.02-01-0599; Papakonstanti EA, 1996, BIOCHEM J, V315, P241, DOI 10.1042/bj3150241; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Papakonstanti EA, 2007, METHOD ENZYMOL, V428, P227, DOI 10.1016/S0076-6879(07)28012-7; Polzien L, 2011, J BIOL CHEM, V286, P17934, DOI 10.1074/jbc.M110.177345; Rodrigues GR, 2008, MOVEMENT DISORD, V23, P2090, DOI 10.1002/mds.22305; Saiki S, 2007, MOVEMENT DISORD, V22, P848, DOI 10.1002/mds.21437; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Tomemori Y, 2005, J NEUROCHEM, V92, P759, DOI 10.1111/j.1471-4159.2004.02924.x; Tomiyasu A, 2011, AM J MED GENET B, V156B, P620, DOI 10.1002/ajmg.b.31206; Ueno S, 2001, NAT GENET, V28, P121, DOI 10.1038/88825; Walterfang M, 2011, PSYCHIAT RES-NEUROIM, V192, P29, DOI 10.1016/j.pscychresns.2010.10.006; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wu CG, 2007, PROTEOMICS, V7, P1775, DOI 10.1002/pmic.200601006; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zappulla Donatella, 2008, J Cardiometab Syndr, V3, P30, DOI 10.1111/j.1559-4572.2008.07263.x	47	53	53	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1526	1534		10.1096/fj.11-198317	http://dx.doi.org/10.1096/fj.11-198317			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22227296				2022-12-28	WOS:000302359700015
J	Meliopoulos, VA; Andersen, LE; Birrer, KF; Simpson, KJ; Lowenthal, JW; Bean, AGD; Stambas, J; Stewart, CR; Tompkins, SM; van Beusechem, VW; Fraser, I; Mhlanga, M; Barichievy, S; Smith, Q; Leake, D; Karpilow, J; Buck, A; Jona, G; Tripp, RA				Meliopoulos, Victoria A.; Andersen, Lauren E.; Birrer, Katherine F.; Simpson, Kaylene J.; Lowenthal, John W.; Bean, Andrew G. D.; Stambas, John; Stewart, Cameron R.; Tompkins, S. Mark; van Beusechem, Victor W.; Fraser, Iain; Mhlanga, Musa; Barichievy, Samantha; Smith, Queta; Leake, Devin; Karpilow, Jon; Buck, Amy; Jona, Ghil; Tripp, Ralph A.			Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens	FASEB JOURNAL			English	Review						antivirals; HTS; genome; pathway; meta-analysis	MICROARRAY EXPERIMENT MIAME; PROTEIN-KINASE; VIRUS-REPLICATION; NS1 PROTEIN; MINIMUM INFORMATION; SIGNAL-TRANSDUCTION; CELL TRANSCRIPTOMES; DENDRITIC CELLS; STRANDED-RNA; GENOME	Influenza virus encodes only 11 viral proteins but replicates in a broad range of avian and mammalian species by exploiting host cell functions. Genome-wide RNA interference (RNAi) has proven to be a powerful tool for identifying the host molecules that participate in each step of virus replication. Meta-analysis of findings from genome-wide RNAi screens has shown influenza virus to be dependent on functional nodes in host cell pathways, requiring a wide variety of molecules and cellular proteins for replication. Because rapid evolution of the influenza A viruses persistently complicates the effectiveness of vaccines and therapeutics, a further understanding of the complex host cell pathways coopted by influenza virus for replication may provide new targets and strategies for antiviral therapy. RNAi genome screening technologies together with bioinformatics can provide the ability to rapidly identify specific host factors involved in resistance and susceptibility to influenza virus, allowing for novel disease intervention strategies.-Meliopoulos, V. A., Andersen, L. E., Birrer, K. F., Simpson, K. J., Lowenthal, J. W., Bean, A. G. D., Stambas, J., Stewart, C. R., Tompkins, S. M., van Beusechem, V. W., Fraser, I., Mhlanga, M., Barichievy, S., Smith, Q., Leake, D., Karpilow, J., Buck, A., Jona, G., Tripp, R. A. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J. 26, 1372-1386 (2012). www.fasebj.org	[Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Anim Hlth Res Ctr, Athens, GA 30602 USA; [Birrer, Katherine F.; Lowenthal, John W.; Bean, Andrew G. D.; Stewart, Cameron R.] Commonwealth Sci & Ind Res Org, Australian Anim Hlth Lab, Geelong, Vic, Australia; [Simpson, Kaylene J.] Peter MacCallum Canc Ctr, Victorian Ctr Funct Genom, Melbourne, Vic, Australia; [Birrer, Katherine F.; Stambas, John] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia; [van Beusechem, Victor W.] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; [Fraser, Iain] NIAID, Lab Syst Biol, NIH, Bethesda, MD 20892 USA; [Mhlanga, Musa; Barichievy, Samantha] CSIR, Synthet Biol Emerging Res Area, Gene Express & Biophys Grp, Pretoria, South Africa; [Smith, Queta; Leake, Devin; Karpilow, Jon] Thermo Fisher Sci, Lafayette, CO USA; [Simpson, Kaylene J.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Buck, Amy] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland; [Jona, Ghil] Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel	University System of Georgia; University of Georgia; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Peter Maccallum Cancer Center; Deakin University; Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Council for Scientific & Industrial Research (CSIR) - South Africa; Thermo Fisher Scientific; University of Melbourne; University of Edinburgh; Weizmann Institute of Science	Tripp, RA (corresponding author), Univ Georgia, Dept Infect Dis, Anim Hlth Res Ctr, 111 Carlton St, Athens, GA 30602 USA.	ratripp@uga.edu	lowenthal, john w/G-4459-2010; Fraser, Iain DC/L-4735-2017; Mhlanga, Musa/D-1283-2011; Tompkins, Stephen/A-3317-2008; Stewart, Cameron R/E-6823-2011	lowenthal, john w/0000-0002-0548-2497; Fraser, Iain DC/0000-0003-2272-3907; Mhlanga, Musa/0000-0003-1381-3409; Tompkins, Stephen/0000-0002-1523-5588; Stewart, Cameron/0000-0002-3395-7859; Jona, Ghil/0000-0002-4526-6182; Buck, Amy/0000-0003-2645-7191; Tripp, Ralph/0000-0002-2924-9956; Stambas, John/0000-0002-5690-2551; Simpson, Kaylene/0000-0001-9136-1781	BBSRC [BB/G01552X/1] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001106, ZIAAI001107] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/G01552X/1] Funding Source: Medline; Intramural NIH HHS [ZIA AI001106-04, ZIA AI001107-04] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bagasra O, 2004, J MOL HISTOL, V35, P545; Bankhead A, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-80; Barchet W, 2005, EUR J IMMUNOL, V35, P236, DOI 10.1002/eji.200425583; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Blair CD, 2011, FUTURE MICROBIOL, V6, P265, DOI [10.2217/fmb.11.11, 10.2217/FMB.11.11]; Blakely K, 2011, METHODS MOL BIOL, V781, P161, DOI 10.1007/978-1-61779-276-2_9; Borjabad A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002213; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brazma A, 2009, THESCIENTIFICWORLDJO, V9, P420, DOI 10.1100/tsw.2009.57; Bredenbeek PJ, 2006, VIROLOGY, V345, P299, DOI 10.1016/j.virol.2005.12.001; Bruce EA, 2010, J VIROL, V84, P5848, DOI 10.1128/JVI.00307-10; Calderwood MA, 2007, P NATL ACAD SCI USA, V104, P7606, DOI 10.1073/pnas.0702332104; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CONSTANTINESCU SN, 1991, FEBS LETT, V292, P31, DOI 10.1016/0014-5793(91)80826-O; Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443; de Chassey B, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.66; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Eberle F, 2008, J IMMUNOL, V180, P3229, DOI 10.4049/jimmunol.180.5.3229; Ehrhardt C, 2007, J VIROL, V81, P3058, DOI 10.1128/JVI.02082-06; Ehrhardt C, 2006, CELL MICROBIOL, V8, P1336, DOI 10.1111/j.1462-5822.2006.00713.x; Eierhoff T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001099; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fraser IDC, 2009, NAT IMMUNOL, V10, P327, DOI 10.1038/ni.1711; Friedman AA, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002029; Ganter B, 2008, CURR OPIN DRUG DISC, V11, P86; Geisbert TW, 2011, J VIROL, V85, P4222, DOI 10.1128/JVI.02407-10; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; Geiss GK, 2001, J VIROL, V75, P4321, DOI 10.1128/JVI.75.9.4321-4331.2001; Genovesio A, 2011, J BIOMOL SCREEN, V16, P945, DOI 10.1177/1087057111415521; Genovesio A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019733; Glaab E, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-597; Gobeil S, 2008, GENE DEV, V22, P2932, DOI 10.1101/gad.1714608; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Haney SA, 2007, PHARMACOGENOMICS, V8, P1037, DOI 10.2217/14622416.8.8.1037; Hao LH, 2008, NATURE, V454, P890, DOI 10.1038/nature07151; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Held K, 2011, J VIROL, V85, P9680, DOI 10.1128/JVI.00874-11; Hirsch AJ, 2010, FUTURE MICROBIOL, V5, P303, DOI 10.2217/FMB.09.121; Hoffmann HH, 2008, ANTIVIR RES, V80, P124, DOI 10.1016/j.antiviral.2008.05.008; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hughes RA, 2011, METHOD ENZYMOL, V498, P277, DOI 10.1016/B978-0-12-385120-8.00012-7; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jianu R, 2010, IEEE T VIS COMPUT GR, V16, P609, DOI 10.1109/TVCG.2009.106; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karlas A, 2010, NATURE, V463, P818, DOI 10.1038/nature08760; Khodarev NN, 1999, P NATL ACAD SCI USA, V96, P12062, DOI 10.1073/pnas.96.21.12062; Khor R, 2003, TRAFFIC, V4, P857, DOI 10.1046/j.1398-9219.2003.0140.x; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kisielow M, 2002, BIOCHEM J, V363, P1, DOI 10.1042/0264-6021:3630001; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Komar N, 2008, EMERG INFECT DIS, V14, P1176, DOI 10.3201/eid1407.080161; Kramer A, 2008, P NATL ACAD SCI USA, V105, P11236, DOI 10.1073/pnas.0801967105; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; Kumar N, 2008, J VIROL, V82, P9880, DOI 10.1128/JVI.00909-08; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lazrak A, 2009, FASEB J, V23, P3829, DOI 10.1096/fj.09-135590; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lefebvre G, 2011, J VIROL, V85, P6205, DOI 10.1128/JVI.00252-11; Legendre M, 2010, GENOME RES, V20, P664, DOI 10.1101/gr.102582.109; Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x; Ludwig S, 2004, FEBS LETT, V561, P37, DOI 10.1016/S0014-5793(04)00108-5; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Marjuki H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-134; Marjuki H, 2006, J BIOL CHEM, V281, P16707, DOI 10.1074/jbc.M510233200; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Nagata K, 2008, REV MED VIROL, V18, P247, DOI 10.1002/rmv.575; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0; Pache L, 2011, METHODS, V53, P3, DOI 10.1016/j.ymeth.2010.07.009; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Pleschka S, 2008, BIOL CHEM, V389, P1273, DOI 10.1515/BC.2008.145; Porotto M, 2009, J VIROL, V83, P5148, DOI 10.1128/JVI.00164-09; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Robbins M, 2007, MOL THER, V15, P1663, DOI 10.1038/sj.mt.6300240; Root CN, 2000, J GEN VIROL, V81, P2697, DOI 10.1099/0022-1317-81-11-2697; Rossman JS, 2011, VIROLOGY, V411, P229, DOI 10.1016/j.virol.2010.12.003; Ruan L, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-35; Sakurai K., 2010, CURR PROTOC CELL BIO, V47, P2711; Santhakumar D, 2010, P NATL ACAD SCI USA, V107, P13830, DOI 10.1073/pnas.1008861107; Satoh J, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-17; Schulte J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023841; Severson WE, 2008, J BIOMOL SCREEN, V13, P879, DOI 10.1177/1087057108323123; Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018; Shih SR, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-13; Sieczkarski SB, 2005, ARCH VIROL, V150, P1783, DOI 10.1007/s00705-005-0558-1; Sigoillot FD, 2011, ACS CHEM BIOL, V6, P47, DOI 10.1021/cb100358f; Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013; Sioud M, 2007, BIOCHEM BIOPH RES CO, V361, P122, DOI 10.1016/j.bbrc.2007.06.177; Snead NM, 2010, WIRES RNA, V1, P117, DOI 10.1002/wrna.14; Su B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008495; Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305; Tirabassi R, 2011, J VIROL, V85, P11938, DOI 10.1128/JVI.05443-11; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Tripp RA, 2009, METHODS MOL BIOL, V555, P43, DOI 10.1007/978-1-60327-295-7_4; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vermeulen A, 2007, RNA, V13, P723, DOI 10.1261/rna.448107; von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; World Health Organization, 2009, OV PAND H1N1 2009 WH; World Health Organization, 2009, SEAS INFL; Wu JQ, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-18; Wu SH, 2011, CURR OPIN INFECT DIS, V24, P235, DOI 10.1097/QCO.0b013e328344c0e3; Wurzer WJ, 2004, J BIOL CHEM, V279, P30931, DOI 10.1074/jbc.M403258200; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Yang ZL, 2010, P NATL ACAD SCI USA, V107, P11513, DOI 10.1073/pnas.1006594107; Yeh MH, 2011, INT J ONCOL, V39, P1221, DOI 10.3892/ijo.2011.1100; Yore MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022862; Zhang WJ, 2011, VACCINE, V29, P8032, DOI 10.1016/j.vaccine.2011.08.054; Zhang WL, 2008, J VIROL, V82, P12221, DOI 10.1128/JVI.01557-08; Zhou Z, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-384	136	37	42	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1372	1386		10.1096/fj.11-193466	http://dx.doi.org/10.1096/fj.11-193466			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22247330	Green Published			2022-12-28	WOS:000302359700001
J	Davis, SP; Amrein, M; Gillrie, MR; Lee, K; Muruve, DA; Ho, M				Davis, Shevaun P.; Amrein, Matthias; Gillrie, Mark R.; Lee, Kristine; Muruve, Daniel A.; Ho, May			Plasmodium falciparum-induced CD36 clustering rapidly strengthens cytoadherence via p130CAS-mediated actin cytoskeletal rearrangement	FASEB JOURNAL			English	Article						adhesion; endothelium; malaria; pathogenesis	INTERCELLULAR-ADHESION MOLECULE-1; CELL FORCE SPECTROSCOPY; HUMAN CEREBRAL MALARIA; RED-BLOOD-CELLS; INFECTED ERYTHROCYTES; IN-VIVO; MICROVASCULAR ENDOTHELIUM; TYROSINE PHOSPHORYLATION; SEQUESTRATION; MIGRATION	The adhesion of infected red blood cells (IRBCs) to microvascular endothelium is critical in the pathogenesis of severe malaria. Here we used atomic force and confocal microscopy to examine the adhesive forces between IRBCs and human dermal microvascular endothelial cells. Initial contact of the cells generated a mean +/- SD adhesion force of 167 +/- 208 pN from the formation of single or multiple bonds with CD36. The strength of adhesion increased by 5-to 6-fold within minutes of contact through a signaling pathway initiated by CD36 ligation by live IRBCs, or polystyrene beads coated with anti-CD36 or PpMC-179, a recombinant peptide representing the minimal binding domain of the parasite ligand PfEMP1 to CD36. Engagement of CD36 led to localized phosphorylation of Src family kinases and the adaptor protein p130CAS, resulting in actin recruitment and CD36 clustering by 50-60% of adherent beads. Uninfected red blood cells or IgGcoated beads had no effect. Inhibition of the increase in adhesive strength by the Src family kinase inhibitor PP1 or gene silencing of p130CAS decreased adhesion by 39 +/- 12 and 48 +/- 20%, respectively, at 10 dyn/cm2 in a flow chamber assay. Modulation of adhesive strength at PfEMP1-CD36-actin cytoskeleton synapses could be a novel target for antiadhesive therapy.Davis, S. P., Amrein, M., Gillrie, M. R., Lee, K., Muruve, D. A., Ho, M. Plasmodium falciparum-induced CD36 clustering rapidly strengthens cytoadherence via p130CAS-mediated actin cytoskeletal rearrangement. FASEB J. 26, 1119-1130 (2012). www.fasebj.org	[Davis, Shevaun P.; Gillrie, Mark R.; Lee, Kristine; Ho, May] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB T2N 4N1, Canada; [Amrein, Matthias] Univ Calgary, Dept Anat & Cell Biol, Calgary, AB T2N 4N1, Canada; [Muruve, Daniel A.; Ho, May] Univ Calgary, Dept Med, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Ho, M (corresponding author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	mho@ucalgary.ca			Canadian Institutes of Health Research (CIHR) [MT14104, MGC-48374]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This research was supported by a grant (MT14104) to M. H. and a group grant (MGC-48374) from the Canadian Institutes of Health Research (CIHR). M. H. is a scientist and D. A. M. is a senior scholar of Alberta Innovates-Health Solutions, Canada. M. R. G. is supported by a CIHR M.D./Ph.D. studentship. The authors are grateful to Dr. Carolyn Lane (Valley View Family Practice Clinic, Calgary, AB, Canada) for providing skin specimens, Dr. Ciaran Brady [National Institute of Allergy and Infectious Diseases (NAIAD), U.S. National Institutes of Health, Bethesda, MD, USA] for the PpMC-179 peptide, Dr. Dror I. Baruch (NAIAD) for the mAb (clone 4B3) against PpMC-179, Dr. Richard M. Fairhurst (NAIAD) for the parasite line 7G8, and Dr. John F. Elliott (University of Alberta, Edmonton, AB, Canada) for the human CD36 plasmid.	Allingham MJ, 2007, J IMMUNOL, V179, P4053, DOI 10.4049/jimmunol.179.6.4053; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Baruch DI, 1997, BLOOD, V90, P3766, DOI 10.1182/blood.V90.9.3766; Carman CV, 2003, J IMMUNOL, V171, P6135, DOI 10.4049/jimmunol.171.11.6135; Chaudhuri O, 2009, NAT METHODS, V6, P383, DOI [10.1038/NMETH.1320, 10.1038/nmeth.1320]; Cholera R, 2008, P NATL ACAD SCI USA, V105, P991, DOI 10.1073/pnas.0711401105; Collins RF, 2009, J BIOL CHEM, V284, P30288, DOI 10.1074/jbc.M109.045104; Dondorp AM, 2008, J INFECT DIS, V197, P79, DOI 10.1086/523762; Dondorp AM, 2007, J INFECT DIS, V196, P460, DOI 10.1086/519287; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Evans IM, 2011, MOL CELL BIOL, V31, P1174, DOI 10.1128/MCB.00903-10; Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631; Helenius J, 2008, J CELL SCI, V121, P1785, DOI 10.1242/jcs.030999; Ho M, 2000, J EXP MED, V192, P1205, DOI 10.1084/jem.192.8.1205; Ho M, 2005, INFECT IMMUN, V73, P8179, DOI 10.1128/IAI.73.12.8179-8187.2005; Imai Y, 2011, J BIOMECH, V44, P1553, DOI 10.1016/j.jbiomech.2011.02.084; Jambou R, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001021; Jaqaman K, 2011, CELL, V146, P593, DOI 10.1016/j.cell.2011.06.049; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Kaczmarek E, 2005, THROMB HAEMOSTASIS, V93, P735, DOI 10.1160/TH04-09-0576; Kang S, 2009, LANGMUIR, V25, P9656, DOI 10.1021/la902247w; Li A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016929; Lipowsky H. H., 1995, PHYSL PATHOPHYSIOLOG, P140; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; Marchiafava E., 1894, 2 MONOGRAPHS MALAIRA, P1; Nourshargh S, 2010, NAT REV MOL CELL BIO, V11, P366, DOI 10.1038/nrm2889; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Rowe JA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001082; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; Stuart LM, 2007, J BIOL CHEM, V282, P27392, DOI 10.1074/jbc.M702887200; TURNER GDH, 1994, AM J PATHOL, V145, P1057; WARRELL DA, 1988, LANCET, V2, P534; WHITE NJ, 1985, LANCET, V1, P776; Yang L, 2006, J IMMUNOL, V177, P6440, DOI 10.4049/jimmunol.177.9.6440; Yipp BG, 2000, BLOOD, V96, P2292, DOI 10.1182/blood.V96.6.2292.h8002292_2292_2298; Yipp BG, 2003, BLOOD, V101, P2850, DOI 10.1182/blood-2002-09-2841; Yipp BG, 2003, BLOOD, V101, P331, DOI 10.1182/blood-2002-06-1725; Yipp BG, 2007, MICROCIRCULATION, V14, P593, DOI 10.1080/10739680701404705	38	20	21	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1119	1130		10.1096/fj.11-196923	http://dx.doi.org/10.1096/fj.11-196923			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22106368	Green Published			2022-12-28	WOS:000300949300016
J	Afshar, Y; Jeong, JW; Roqueiro, D; DeMayo, F; Lydon, J; Radtke, F; Radnor, R; Miele, L; Fazleabas, A				Afshar, Yalda; Jeong, Jae-Wook; Roqueiro, Damian; DeMayo, Franco; Lydon, John; Radtke, Freddy; Radnor, Rachel; Miele, Lucio; Fazleabas, Asgerally			Notch1 mediates uterine stromal differentiation and is critical for complete decidualization in the mouse	FASEB JOURNAL			English	Article						implantation; endometrium; reproduction	PAPIO-ANUBIS UTERUS; CHORIONIC-GONADOTROPIN; ESTROGEN-RECEPTOR; CROSS-TALK; IN-VIVO; EXPRESSION; APOPTOSIS; PATHWAY; ACTIVATION; MECHANISMS	Uterine receptivity implies a dialogue between the hormonally primed maternal endometrium and the free-floating blastocyst. Endometrial stromal cells proliferate, avert apoptosis, and undergo decidualization in preparation for implantation; however, the molecular mechanisms that underlie differentiation into the decidual phenotype remain largely undefined. The Notch family of transmembrane receptors transduce extracellular signals responsible for cell survival, cell-to-cell communication, and differentiation, all fundamental processes for decidualization and pregnancy. Using a murine artificial decidualization model, pharmacological inhibition of Notch signaling by gamma-secretase inhibition resulted in a significantly decreased deciduoma. Furthermore, a progesterone receptor (PR)-Cre Notch1 bigenic (Notch1d/d) confirmed a Notch1-dependent hypomorphic decidual phenotype. Microarray and pathway analysis, following Notch1 ablation, demonstrated significantly altered signaling repertoire. Concomitantly, hierarchical clustering demonstrated Notch1-dependent differences in gene expression. Uteri deprived of Notch1 signaling demonstrated decreased cellular proliferation; namely, reduced proliferation-specific antigen, Ki67, altered p21, cdk6, and cyclinD activity and an increased apoptotic-profile, cleaved caspase-3, Bad, and attenuated Bcl2. The results demonstrate that the preimplantation uterus relies on Notch signaling to inhibit apoptosis of stromal fibroblasts and regulate cell cycle progression, which together promotes successful decidualization. In summary, Notch1 signaling modulates multiple signaling mechanisms crucial for decidualization and these studies provide additional perspectives to the coordination of multiple signaling modalities required during decidualization.-Afshar, Y., Jeong, J.-W., Roqueiro, D., DeMayo, F., Lydon, J., Radtke, F., Radnor, R., Miele, L., Fazleabas, A. Notch1 mediates uterine stromal differentiation and is critical for complete decidualization in the mouse. FASEB J. 26, 282-294 (2012). www.fasebj.org	[Fazleabas, Asgerally] Michigan State Univ, Ctr Womens Hlth, Van Andel Inst, Dept Obstet & Gynecol & Reprod Biol, Grand Rapids, MI 49503 USA; [Afshar, Yalda] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60680 USA; [Roqueiro, Damian] Univ Illinois, Dept Bioengn, Chicago, IL USA; [DeMayo, Franco; Lydon, John] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Radtke, Freddy] Ecole Polytech Fed Lausanne, Lausanne, Switzerland; [Miele, Lucio] Univ Mississippi, Inst Canc, Jackson, MS 39216 USA	Michigan State University; Van Andel Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Mississippi	Fazleabas, A (corresponding author), Michigan State Univ, Ctr Womens Hlth, Van Andel Inst, Dept Obstet & Gynecol & Reprod Biol, 333 Bostwick Ave NE,Rm 4027, Grand Rapids, MI 49503 USA.	asgi@hc.msu.edu	Roqueiro, Damian/AAE-2240-2020; Radtke, Freddy/Q-3198-2017; DeMayo, Francesco/C-6255-2019	Radtke, Freddy/0000-0003-4315-4045; Afshar, Yalda/0000-0003-3807-7022; DeMayo, Francesco/0000-0002-9480-7336; Miele, Lucio/0000-0002-5853-7287; Roqueiro, Damian/0000-0002-9195-5915	U.S. National Institutes of Health [RO1HD42280, TL1RR029879, R01HD057873, R01HD042311, U54HD0077495];  [RO1CA077530]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R03HD077495, R01HD057873, R01HD042311, R01HD042280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077530] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029879] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors thank Patty Mavrogianis and Zuzana Harrison (University of Illinois) for technical assistance; Barbara Osborn (University of Massachusetts, Amherst, MA, USA) for the GSI chow; and the University of Illinois at Chicago Biological Research Laboratory for wild-type pregnant mice. Funding support was provided by grants from the U.S. National Institutes of Health: RO1HD42280 (A. T. F.), TL1RR029879 (Y.A.), R01HD057873 (J.J.), R01HD042311 and U54HD0077495 (F. D.), and RO1CA077530 (J.L.). All gene expression data, cluster groups, and functional categories have been placed on the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under accession number GSE31244 and are available online in their entirety (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31244).	Akcali KC, 1996, ENDOCRINOLOGY, V137, P3123, DOI 10.1210/en.137.7.3123; Aoyama K, 2007, STEM CELLS, V25, P2488, DOI 10.1634/stemcells.2007-0102; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Banaszak S, 2000, BIOL REPROD, V63, P820, DOI 10.1095/biolreprod63.3.820; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brosens JJ, 2006, J MOL ENDOCRINOL, V36, P389, DOI 10.1677/jme.1.02060; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buzzio OL, 2006, ENDOCRINOLOGY, V147, P3870, DOI 10.1210/en.2006-0167; Carlson ME, 2007, CURR OPIN PHARMACOL, V7, P303, DOI 10.1016/j.coph.2007.02.004; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; De Falco M, 2007, PLACENTA, V28, P118, DOI 10.1016/j.placenta.2006.03.010; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Fazleabas AT, 1999, P NATL ACAD SCI USA, V96, P2543, DOI 10.1073/pnas.96.5.2543; FINN CA, 1971, ADV REPROD PHYSIOL, V5, P1; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Hahne F, 2008, USE R, P1, DOI 10.1007/978-0-387-77240-0_1; Hao L, 2010, ONCOGENE, V29, P201, DOI 10.1038/onc.2009.323; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jabbour HN, 2001, REPRODUCTION, V121, P197, DOI 10.1530/rep.0.1210197; Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467; Jasinska A, 2006, ENDOCRINOLOGY, V147, P4112, DOI 10.1210/en.2005-1577; JAYATILAK PG, 1984, BIOL REPROD, V31, P556, DOI 10.1095/biolreprod31.3.556; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; Kluppel M, 2005, BIOESSAYS, V27, P115, DOI 10.1002/bies.20187; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; Lee K, 2006, J STEROID BIOCHEM, V102, P41, DOI 10.1016/j.jsbmb.2006.09.006; Lee K, 2006, NAT GENET, V38, P1204, DOI 10.1038/ng1874; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Minter LM, 2005, NAT IMMUNOL, V6, P680, DOI 10.1038/ni1209x; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mohamed OA, 2005, P NATL ACAD SCI USA, V102, P8579, DOI 10.1073/pnas.0500612102; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mukherjee A, 2006, J STEROID BIOCHEM, V102, P22, DOI 10.1016/j.jsbmb.2006.09.007; Nickoloff BJ, 2005, J INVEST DERM SYMP P, V10, P95, DOI 10.1111/j.1087-0024.2005.200404.x; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Noseda M, 2006, CIRC RES, V98, P1468, DOI 10.1161/01.RES.0000229683.81357.26; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Rizzo P, 2009, ADV ENZYME REGUL, V49, P134, DOI 10.1016/j.advenzreg.2009.01.008; Rubel CA, 2010, SEMIN REPROD MED, V28, P27, DOI 10.1055/s-0029-1242990; Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood-2008-03-144980; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Suarez-Huerta N, 2000, CELL PROLIFERAT, V33, P101, DOI 10.1046/j.1365-2184.2000.00169.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TARANTINO S, 1992, ENDOCRINOLOGY, V130, P2354, DOI 10.1210/en.130.4.2354; Tong W, 1999, MOL CELL BIOL, V19, P2251; Vaskivuo TE, 2000, MOL CELL ENDOCRINOL, V165, P75, DOI 10.1016/S0303-7207(00)00261-6; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wu Xia, 2004, Zhonghua Yi Xue Za Zhi, V84, P1018; Xie HR, 2008, DEVELOPMENT, V135, P717, DOI 10.1242/dev.015339	79	75	80	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					282	294		10.1096/fj.11-184663	http://dx.doi.org/10.1096/fj.11-184663			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21990372	Green Published			2022-12-28	WOS:000299202200029
J	Zhang, HJ; Gu, S; Al-Sabeq, B; Wang, S; He, J; Tam, A; Cifelli, C; Mathalone, N; Tirgari, S; Boyd, S; Heximer, SP				Zhang, Hangjun; Gu, Steven; Al-Sabeq, Basil; Wang, Sean; He, Janet; Tam, Alex; Cifelli, Carlo; Mathalone, Nurit; Tirgari, Sam; Boyd, Shelley; Heximer, Scott P.			Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression	FASEB JOURNAL			English	Article						G-protein signaling; regulators of G-protein signaling; vascular smooth muscle development	GTPASE-ACTIVATING PROTEINS; CARDIAC NEURAL CREST; SMOOTH-MUSCLE-CELLS; DNA METHYLATION; SIGNALING RGS; BINDING; DIFFERENTIATION; TRANSCRIPTION; REGULATORS; GROWTH	Cells from multiple origins contribute to vascular smooth muscle cell (VSMC) development. Phenotypic heterogeneity of VSMCs is associated with their point of developmental origin; however, the mechanisms driving such differences are unknown. We here examined the mechanisms controlling vascular bed-specific differences in Rgs5 expression during development. Rgs5 levels were similar across different regions of the vasculature in neonatal animals but were > 15-fold higher in descending aortas compared with carotid arteries of adult mice. Thus, vessel bed-specific changes in regulation of Rgs5 expression occurred during vessel maturation. Examination of adult Rgs5-LacZ reporter mice revealed lower Rgs5 expression in VSMCs originating from the third (carotid artery) branchial arch compared with those originating in the fourth and sixth (aortic B segment, right subclavian, and ductus arteriosus) branchial arches. Indeed, a mosaic Rgs5 expression pattern, with discreet LacZ boundaries between VSMCs derived from different developmental origins, was observed. Furthermore, Rgs5-LacZ expression was correlated with the site of VSMC origin (splanchic mesoderm approximate to local mesenchyme > somites > proepicardium > mesothelium). Surprisingly, Rgs5 reporter activity in cultured carotid artery-and descending aorta-derived cells did not recapitulate the differences observed in vivo. Consistent with a developmental origin-specific epigenetic mechanism driving the observed expression differences in vivo, the Rgs5 promoter showed increased methylation on CpG dinucleotides in carotid arteries compared with that in descending aortas in adult but not in neonatal mice. In vitro methylation of the Rgs5 promoter confirmed that its activity is sensitive to transcriptional down-regulation by CpG methylation. These data suggest that an origin-dependent epigenetic program regulates vascular bed- and maturation state-dependent regulation of VSMC-specific gene transcription.-Zhang, H., Gu, S., Al-Sabeq, B., Wang, S., He, J., Tam, A., Cifelli, C., Mathalone, N., Tirgari, S., Boyd, S., Heximer, S. P. Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression. FASEB J. 26, 181-191 (2012). www.fasebj.org	[Zhang, Hangjun; Gu, Steven; Al-Sabeq, Basil; Wang, Sean; He, Janet; Tam, Alex; Cifelli, Carlo; Tirgari, Sam; Heximer, Scott P.] Univ Toronto, Dept Physiol Heart & Stroke, Toronto, ON M5S 1A8, Canada; [Zhang, Hangjun; Gu, Steven; Al-Sabeq, Basil; Wang, Sean; He, Janet; Tam, Alex; Cifelli, Carlo; Tirgari, Sam; Heximer, Scott P.] Univ Toronto, Richard Lewar Ctr Excellence Cardiovasc Res, Toronto, ON M5S 1A8, Canada; [Mathalone, Nurit; Boyd, Shelley] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON M5S 1A8, Canada; [Mathalone, Nurit; Boyd, Shelley] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Heximer, SP (corresponding author), Univ Toronto, Dept Physiol Heart & Stroke, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	scott.heximer@utoronto.ca		Al-Sabeq, Basil/0000-0001-8880-0165				Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Berger M, 2005, BLOOD, V105, P1094, DOI 10.1182/blood-2004-06-2315; Bergwerff M, 1999, CARDIOVASC RES, V44, P185, DOI 10.1016/S0008-6363(99)00186-8; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Cho H, 2008, MOL CELL BIOL, V28, P2590, DOI 10.1128/MCB.01889-07; Christ B, 2004, ANAT EMBRYOL, V208, P333, DOI 10.1007/s00429-004-0408-z; Cifelli C, 2008, CIRC RES, V103, P527, DOI 10.1161/CIRCRESAHA.108.180984; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Esner M, 2006, DEVELOPMENT, V133, P737, DOI 10.1242/dev.02226; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hamzah J, 2008, NATURE, V453, P410, DOI 10.1038/nature06868; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kapoor M, 2008, J CLIN INVEST, V118, P3279, DOI 10.1172/JCI35381; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Larminie C, 2004, MOL BRAIN RES, V122, P24, DOI 10.1016/j.molbrainres.2003.11.014; Madura JA, 1996, J VASC RES, V33, P53; Majesky MW, 2007, ARTERIOSCL THROM VAS, V27, P1248, DOI 10.1161/ATVBAHA.107.141069; Nakamura T, 2006, CIRC RES, V98, P1547, DOI 10.1161/01.RES.0000227505.19472.69; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nisancioglu MH, 2008, MOL CELL BIOL, V28, P2324, DOI 10.1128/MCB.01252-07; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Seki N, 1998, J HUM GENET, V43, P202, DOI 10.1007/s100380050071; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; WALDO KL, 1993, ANAT RECORD, V237, P385, DOI 10.1002/ar.1092370312; Waldo KL, 1999, DEV BIOL, V208, P307, DOI 10.1006/dbio.1999.9219; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	42	22	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					181	191		10.1096/fj.11-185454	http://dx.doi.org/10.1096/fj.11-185454			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965603				2022-12-28	WOS:000299202200019
J	Zaika, E; Wei, JX; Yin, DP; Andl, C; Moll, U; El-Rifai, W; Zaika, AI				Zaika, Elena; Wei, Jinxiong; Yin, Dengping; Andl, Claudia; Moll, Ute; El-Rifai, Wael; Zaika, Alexander I.			p73 protein regulates DNA damage repair	FASEB JOURNAL			English	Article						p53; p63; bile acids	KINASE C-ABL; APOPTOTIC RESPONSE; BILE-ACIDS; P53; EXPRESSION; DELTA-NP73; REFLUX; CANCER; P63; ADENOCARCINOMAS	Although the p53 tumor suppressor is relatively well characterized, much less is known about the functions of other members of the p53 family, p73 and p63. Here, we present evidence that in specific pathological conditions caused by exposure of normal cells to bile acids in acidic conditions, p73 protein plays the predominant role in the DNA damage response. These pathological conditions frequently occur during gastric reflux in the human esophagus and are associated with progression to esophageal adenocarcinoma. We found that despite strong DNA damage induced by bile acid exposure, only p73 (but not p53 and p63) is selectively activated in a c-Abl kinase-dependent manner. The activated p73 protein induces DNA damage repair. Using a human DNA repair PCR array, we identified multiple DNA repair genes affected by p73. Two glycosylases involved in base excision repair, SMUG1 and MUTYH, were characterized and found to be transcriptionally regulated by p73 in DNA damage conditions. Using a surgical procedure in mice, which recapitulates bile acid exposure, we found that p73 deficiency is associated with increased DNA damage. These findings were further investigated with organotypic and traditional cell cultures. Collectively our studies demonstrate that p73 plays an important role in the regulation of DNA damage repair.-Zaika, E., Wei, J., Yin, D., Andl, C., Moll, U., El-Rifai, W., Zaika, A. I. p73 protein regulates DNA damage repair. FASEB J. 25, 4406-4414 (2011). www.fasebj.org	[Zaika, Elena; Wei, Jinxiong; Yin, Dengping; Andl, Claudia; El-Rifai, Wael; Zaika, Alexander I.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [El-Rifai, Wael; Zaika, Alexander I.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Moll, Ute] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zaika, AI (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg & Canc Biol, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	alexander.zaika@vanderbilt.edu			U.S. National Cancer Institute [NIH R01CA138833, NIH R01CA108956, NIH R01CA106176]; NATIONAL CANCER INSTITUTE [R01CA108956, R01CA106176, R01CA138833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK075379] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the U.S. National Cancer Institute, grants NIH R01CA138833, NIH R01CA108956, and NIH R01CA106176. The authors thank Dr. P. Williams for valuable discussion of the manuscript.	Agami R, 1999, NATURE, V399, P809; ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Belyi VA, 2009, P NATL ACAD SCI USA, V106, P17609, DOI 10.1073/pnas.0910634106; Bernal C, 2008, BIOL RES, V41, P303, DOI [10.4067/S0716-97602008000300007, /S0716-97602008000300007]; Bernstein H, 2009, WORLD J GASTROENTERO, V15, P3329, DOI 10.3748/wjg.15.3329; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Christmann M, 2005, ONCOGENE, V24, P8304, DOI 10.1038/sj.onc.1208994; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Dent J, 2005, GUT, V54, P710, DOI 10.1136/gut.2004.051821; Dvorak K, 2007, GUT, V56, P763, DOI 10.1136/gut.2006.103697; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gong JG, 1999, NATURE, V399, P806; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kauer WKH, 1997, SURGERY, V122, P874, DOI 10.1016/S0039-6060(97)90327-5; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Li Y, 2007, DIS ESOPHAGUS, V20, P372, DOI 10.1111/j.1442-2050.2007.00713.x; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Lin YL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000680; Maley CC, 2005, SEMIN CANCER BIOL, V15, P474, DOI 10.1016/j.semcancer.2005.06.004; Masuda N, 2003, CANCER SCI, V94, P612, DOI 10.1111/j.1349-7006.2003.tb01491.x; Melhado Rachel E, 2010, Cancers (Basel), V2, P1379, DOI 10.3390/cancers2031379; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Poulsen MLM, 2008, CURR GENOMICS, V9, P420, DOI 10.2174/138920208785699562; Qiao DH, 2001, CARCINOGENESIS, V22, P957, DOI 10.1093/carcin/22.6.957; Roman S, 2007, AM J PHYSIOL-GASTR L, V293, pG45, DOI 10.1152/ajpgi.00583.2006; Souza R. F., 2002, SURG ONCOL CLIN N AM, V11, pviii; Souza Rhonda F, 2002, Surg Oncol Clin N Am, V11, P257, DOI 10.1016/S1055-3207(02)00003-0; Speit G, 1998, MUTAT RES-GEN TOX EN, V412, P187, DOI 10.1016/S1383-5718(97)00199-X; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; STONER GD, 1991, CANCER RES, V51, P365; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Theisen J, 2005, ANN SURG, V241, P63, DOI 10.1097/01.sla.0000150072.55037.e3; Tomkova K, 2006, ONCOGENE, V25, P6032, DOI 10.1038/sj.onc.1209610; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm AE, 2010, ONCOGENE, V29, P5861, DOI 10.1038/onc.2010.319; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Vilgelm AE, 2010, MOL CANCER THER, V9, P693, DOI 10.1158/1535-7163.MCT-09-0912; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Wei A, 2008, GASTROENTEROLOGY, V134, P1412, DOI 10.1053/j.gastro.2008.01.072; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011572; Yokozaki H, 1999, INT J CANCER, V83, P192, DOI 10.1002/(SICI)1097-0215(19991008)83:2<192::AID-IJC8>3.0.CO;2-E; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhang HY, 2009, CANCER RES, V69, P9083, DOI 10.1158/0008-5472.CAN-09-2518	50	30	31	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4406	4414		10.1096/fj.11-192815	http://dx.doi.org/10.1096/fj.11-192815			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21891782	Green Published			2022-12-28	WOS:000298138100031
J	Young, JC; Major, AT; Miyamoto, Y; Loveland, KL; Jans, DA				Young, Julia C.; Major, Andrew T.; Miyamoto, Yoichi; Loveland, Kate L.; Jans, David A.			Distinct effects of importin alpha 2 and alpha 4 on Oct3/4 localization and expression in mouse embryonic stem cells	FASEB JOURNAL			English	Article						differentiation; embryoid body; nuclear transport; importin/karyopherin	NUCLEAR-MEMBRANE; NUCLEOCYTOPLASMIC TRANSPORT; CELLULAR-DIFFERENTIATION; EARLY EMBRYOGENESIS; ES CELLS; PROTEIN; SIGNAL; SPERMATOGENESIS; PLURIPOTENCY; SUBUNITS	The cellular repertoire of importin (IMP) proteins that mediates nuclear import of transcription factors and chromatin remodeling agents is critical to processes such as differentiation and transformation. This study identifies for the first time independent roles for specific IMP alpha s in murine embryonic stem cells (mESCs), showing that mESC differentiation is accompanied by dynamic changes in the levels of transcripts encoding the IMPs, IMP alpha 3, IMP alpha 4, IMP beta 1, and IPO5. Of these, only IMP alpha 4 was maintained at higher levels in differentiating mESCs, correlating with the finding that IMP alpha 4 overexpression induced a significant decrease in Oct3/4 protein levels compared to control transfections. In parallel, IMP alpha 4 protein showed a unique and striking shift in subcellular localization from the nucleus to the cytoplasm during differentiation, which is consistent with activation of a role in nuclear import of differentiation factors. Overexpression of a dominant-negative IMP alpha 2 isoform, when assessed against adjacent untransfected or IMP alpha 2 transfected cells, led to both a significant reduction in endogenous Oct3/4 protein levels and inhibition of Oct3/4 nuclear localization, suggesting that IMP alpha 2-mediated delivery of Oct3/4 to the nucleus contributes directly to maintenance of mESC pluripotency. These findings implicate IMP alpha 2 and IMP alpha 4 in specific but distinct roles in the fate choice between pluripotency and commitment to differentiation.-Young, J. C., Major, A. T., Miyamoto, Y., Loveland, K. L., Jans, D. A. Distinct effects of importin alpha 2 and alpha 4 on Oct3/4 localization and expression in mouse embryonic stem cells. FASEB J. 25, 3958-3965 (2011). www.fasebj.org	[Young, Julia C.; Miyamoto, Yoichi; Loveland, Kate L.; Jans, David A.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; [Young, Julia C.; Major, Andrew T.; Miyamoto, Yoichi; Loveland, Kate L.; Jans, David A.] Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, Vic 3168, Australia; [Major, Andrew T.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic 3168, Australia	Monash University; Monash University; Monash University	Loveland, KL (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3168, Australia.	kate.loveland@monash.edu	Major, Andrew T./B-8469-2016; Loveland, Kate L/X-4404-2019	Major, Andrew T./0000-0001-9036-6652; Loveland, Kate L/0000-0002-5750-8046; Young, Julia/0000-0001-7219-7824; Jans, David/0000-0001-5115-4745	Australian Research Council [348239, DPO878102]; National Health and Medical Research Council [545917, 384109, APP1002486]	Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work received grant support from the Australian Research Council (COE#348239 and #DPO878102) and National Health and Medical Research Council (ID#545917, ID#384109 and APP1002486). The authors acknowledge the excellent technical assistance of Chin Wong.	Argentaro A, 2003, J BIOL CHEM, V278, P33839, DOI 10.1074/jbc.M302078200; Desbaillets I, 2000, EXP PHYSIOL, V85, P645, DOI 10.1017/S0958067000021047; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Fulcher AJ, 2010, FASEB J, V24, P1454, DOI 10.1096/fj.09-136564; Geles KG, 2002, MOL BIOL CELL, V13, P3138, DOI 10.1091/mbc.E02-02-0069; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Harel A, 2003, MOL BIOL CELL, V14, P4387, DOI 10.1091/mbc.E03-05-0275; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hogarth C, 2005, BIOESSAYS, V27, P1011, DOI 10.1002/bies.20289; Hogarth CA, 2006, DEV DYNAM, V235, P253, DOI 10.1002/dvdy.20569; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Koike M, 2007, J BIOSCI BIOENG, V104, P294, DOI 10.1263/jbb.104.294; Li XQ, 2008, J GENET GENOMICS, V35, P723, DOI 10.1016/S1673-8527(08)60227-1; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Loveland K. L., 2006, EXPRESSION NUCL TRAN; Loveland KL, 2005, ANN NY ACAD SCI, V1061, P173, DOI 10.1196/annals.1336.018; Lusk CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Nakamura T, 2007, NAT CELL BIOL, V9, P64, DOI 10.1038/ncb1519; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okada N, 2008, J CELL MOL MED, V12, P1863, DOI 10.1111/j.1582-4934.2008.00437.x; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Roth DM, 2011, J BIOL CHEM, V286, P14335, DOI 10.1074/jbc.M110.210302; Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Yasuhara N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521; Yasuharaa N, 2009, SEMIN CELL DEV BIOL, V20, P590, DOI 10.1016/j.semcdb.2009.05.003	30	31	31	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3958	3965		10.1096/fj.10-176941	http://dx.doi.org/10.1096/fj.10-176941			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21840941	Bronze			2022-12-28	WOS:000296723100020
J	Besaratinia, A; Yoon, JI; Schroeder, C; Bradforth, SE; Cockburn, M; Pfeifer, GP				Besaratinia, Ahmad; Yoon, Jae-in; Schroeder, Christi; Bradforth, Stephen E.; Cockburn, Myles; Pfeifer, Gerd P.			Wavelength dependence of ultraviolet radiation-induced DNA damage as determined by laser irradiation suggests that cyclobutane pyrimidine dimers are the principal DNA lesions produced by terrestrial sunlight	FASEB JOURNAL			English	Article						carcinogenesis; mutagenesis	UV-LIGHT; IN-VIVO; 2-PHOTON IONIZATION; MAMMALIAN-CELLS; SINGLET OXYGEN; ACTION SPECTRA; SKIN-CANCER; REPAIR; MUTATIONS; PHOTOPRODUCTS	To elucidate the involvement of specific ultraviolet (UV) wavelengths in solar mutagenesis, we used a laser system to investigate the induction of DNA damage, both in the overall genome and at the nucleotide resolution level, in the genomic DNA of transgenic Big Blue mouse fibroblasts irradiated with a series of UV wavelengths, inclusive of UVC (lambda<280 nm), UVB (lambda=280-320 nm), and UVA (lambda>320 nm). Subsequently, we sought correlation between the locations of UV-induced DNA lesions in the cII transgene of irradiated DNA samples and the frequency distribution and codon position of the induced cII mutations in counterpart mouse cells irradiated with simulated sunlight. Using a combination of enzymatic digestion assays coupled with gel electrophoresis, immunodot blot assays, and DNA footprinting assays, we demonstrated a unique wavelength-dependent formation of photodimeric lesions, i.e., cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts [(6-4) PPs], based on direct UV absorption of DNA, in irradiated mouse genomic DNA, which could partially explain the induction of mutations in mouse cells irradiated with simulated sunlight. Most notably, there was a divergence of CPD and (6-4) PP formation at an irradiation wavelength of 296 nm in mouse genomic DNA. Whereas substantial formation of (6-4) PPs was detectable in samples irradiated at this wavelength, which intensified as the irradiation wavelength decreased, only small quantities of these lesions were found in samples irradiated at wavelengths of 300-305 nm, with no detectable level of (6-4) PPs in samples irradiated with longer wavelengths. Although CPD formation followed the same pattern of increase with decreasing wavelengths of irradiation, there were substantial levels of CPDs in samples irradiated with UVB wavelengths borderlined with UVA, and small but detectable levels of these lesions in samples irradiated with longer wavelengths. Because the terrestrial sunlight spectrum rolls off sharply at wavelengths similar to 300 nm, our findings suggest that CPDs are the principal lesion responsible for most DNA damage-dependent biological effects of sunlight.-Besaratinia, A., Yoon, J. -I., Schroeder, C., Bradforth, S. E., Cockburn, M., Pfeifer, G. P. Wavelength dependence of ultraviolet radiation-induced DNA damage as determined by laser irradiation suggests that cyclobutane pyrimidine dimers are the principal DNA lesions produced by terrestrial sunlight. FASEB J. 25, 3079-3091 (2011). www.fasebj.org	[Besaratinia, Ahmad; Yoon, Jae-in; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Schroeder, Christi; Bradforth, Stephen E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Cockburn, Myles] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	City of Hope; Beckman Research Institute of City of Hope; University of Southern California; University of Southern California	Besaratinia, A (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ania@coh.org	Bradforth, Stephen E/B-5186-2008; Bradforth, Stephen/GSM-7470-2022	Bradforth, Stephen E/0000-0002-6164-3347; Besaratinia, Ahmad/0000-0001-7231-228X	American Cancer Society [RSG-11-083-01-CNE]; National Institute of Environmental Health Sciences [ES06070]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by grants from the American Cancer Society (RSG-11-083-01-CNE) to A. B., and the National Institute of Environmental Health Sciences (ES06070) to G. P. P.	Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Besaratinia A, 2008, FASEB J, V22, P2379, DOI 10.1096/fj.07-105437; Besaratinia A, 2006, CARCINOGENESIS, V27, P1526, DOI 10.1093/carcin/bgi311; Besaratinia A, 2009, GASTROENTEROLOGY, V137, P1127, DOI 10.1053/j.gastro.2009.06.002; Besaratinia A, 2009, METHODS, V48, P35, DOI 10.1016/j.ymeth.2009.02.008; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Cadet J, 2006, PHOTOCHEM PHOTOBIOL, V82, P1219, DOI 10.1562/2006-06-09-IR-914; Cadet J, 2009, PHOTOCH PHOTOBIO SCI, V8, P903, DOI 10.1039/b905343n; CHEN HH, 2001, SCI STKE, pPL1; Courdavault S, 2005, DNA REPAIR, V4, P836, DOI 10.1016/j.dnarep.2005.05.001; Courdavault S, 2004, MUTAT RES-FUND MOL M, V556, P135, DOI 10.1016/j.mrfmmm.2004.07.011; Dahle J, 2008, CANCER LETT, V267, P18, DOI 10.1016/j.canlet.2008.03.002; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DROUIN R, 1996, TECHNOLOGIES DETECTI, V1, P37; Elles CG, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2217738; FREYER GA, 1995, MOL CELL BIOL, V15, P4572; Friedberg EC, 2005, DNA REPAIR MUTAGENES; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; HAMER DH, 1975, CHROMOSOMA, V49, P243, DOI 10.1007/BF00361069; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; Jacovides CP, 1998, THEOR APPL CLIMATOL, V59, P107, DOI 10.1007/s007040050016; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; Jiang Y, 2009, BIOPHYS J, V96, P1151, DOI 10.1016/j.bpj.2008.10.030; Kappes UP, 2006, J INVEST DERMATOL, V126, P667, DOI 10.1038/sj.jid.5700093; Kappes UP, 2005, RADIAT RES, V164, P440, DOI 10.1667/RR3434.1; Kaur B, 1998, BIOCHEMISTRY-US, V37, P11599, DOI 10.1021/bi981008c; KELFKENS G, 1990, PHOTOCHEM PHOTOBIOL, V52, P819, DOI 10.1111/j.1751-1097.1990.tb08687.x; Komura J, 1998, NUCLEIC ACIDS RES, V26, P1807, DOI 10.1093/nar/26.7.1807; Kozmin S, 2005, P NATL ACAD SCI USA, V102, P13538, DOI 10.1073/pnas.0504497102; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; Marguet S, 2006, J PHYS CHEM B, V110, P11037, DOI 10.1021/jp062578m; Mathonnet R, 2003, P NATL ACAD SCI USA, V100, P7219, DOI 10.1073/pnas.123216100; McCulloch SD, 2006, DNA REPAIR, V5, P1373, DOI 10.1016/j.dnarep.2006.06.003; McMillan TJ, 2008, J PHARM PHARMACOL, V60, P969, DOI 10.1211/jpp.60.8.0004; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1987, PHOTOCHEM PHOTOBIOL, V45, P781, DOI 10.1111/j.1751-1097.1987.tb07882.x; MITCHELL DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P741, DOI 10.1111/j.1751-1097.1991.tb02084.x; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Mouret S, 2006, P NATL ACAD SCI USA, V103, P13765, DOI 10.1073/pnas.0604213103; Palmer CM, 1997, PHOTOCHEM PHOTOBIOL, V65, P543, DOI 10.1111/j.1751-1097.1997.tb08602.x; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; PFLAUM M, 1994, CARCINOGENESIS, V15, P297, DOI 10.1093/carcin/15.2.297; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; Runger TM, 2008, PHOTODERMATOL PHOTO, V24, P2, DOI 10.1111/j.1600-0781.2008.00319.x; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; Slavicek P, 2009, J AM CHEM SOC, V131, P6460, DOI 10.1021/ja8091246; SUTHERLAND JC, 1981, RADIAT RES, V86, P399, DOI 10.2307/3575456; Tanford C., 1961, PHYS CHEM MACROMOLEC; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; Tyrrell RM, 2000, METHOD ENZYMOL, V319, P290; von Thaler AK, 2010, EXP DERMATOL, V19, P81, DOI 10.1111/j.1600-0625.2009.01025.x; Vreeswijk MPG, 2009, MUTAT RES-FUND MOL M, V663, P7, DOI 10.1016/j.mrfmmm.2008.12.007; Willis C E, 1988, Appl Theor Electrophor, V1, P11; Woodhead A D, 1999, J Epidemiol, V9, pS102; Woollons A, 1999, BRIT J DERMATOL, V140, P1023; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; ZHANG Y, J PHYS CHEM B, V115, P1889	72	99	101	0	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3079	3091		10.1096/fj.11-187336	http://dx.doi.org/10.1096/fj.11-187336			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21613571	Green Published			2022-12-28	WOS:000294435200022
J	Ilatovskaya, DV; Pavlov, TS; Levchenko, V; Negulyaev, YA; Staruschenko, A				Ilatovskaya, Daria V.; Pavlov, Tengis S.; Levchenko, Vladislav; Negulyaev, Yuri A.; Staruschenko, Alexander			Cortical actin binding protein cortactin mediates ENaC activity via Arp2/3 complex	FASEB JOURNAL			English	Article						aldosterone; epithelial transport; endocytosis	EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; TYROSINE PHOSPHORYLATION; MEMBRANE DYNAMICS; N-WASP; LOCALIZATION; CYTOSKELETON; ASSOCIATION; ACTIVATION; EXPRESSION	Epithelial Na+ channel (ENaC) activity is regulated, in part, by the cortical cytoskeleton. Here we demonstrate that cortactin is highly expressed in the kidney cortex and polarized epithelial cells, and is localized to the cortical collecting duct. Coexpression of cortactin with ENaC decreases ENaC activity, as measured in patch-clamp experiments. Biotinylation experiments and single-channel analysis reveal that cortactin decreases ENaC activity via affecting channel open probability (P-o). Knockdown of cortactin in mpkCCD(c14) principal cells results in an increase in ENaC activity and sodium reabsorption. Coimmuno-precipitation analysis shows direct interactions between cortactin and all three ENaC subunits in cultured and native cells. To address the question of what mechanism underlies the action of cortactin on ENaC activity, we assayed the effects of various mutants of cortactin. The data show that only a cortactin mutant unable to bind Arp2/3 complex does not influence ENaC activity. Furthermore, inhibitor of the Arp2/3 complex CK-0944666 precludes the effect of cortactin. Depolymerization of the actin microfilaments and inhibition of the Arp2/3 complex does not result in the loss of association between ENaC and cortactin. Thus, these results indicate that cortactin is functionally important for ENaC activity and that Arp2/3 complex is involved in this mechanism.-Ilatovskaya, D. V., Pavlov, T. S., Levchenko, V., Negulyaev, Y. A., Staruschenko, A. Cortical actin binding protein cortactin mediates ENaC activity via Arp2/3 complex. FASEB J. 25, 2688-2699 (2011). www.fasebj.org	[Ilatovskaya, Daria V.; Pavlov, Tengis S.; Levchenko, Vladislav; Staruschenko, Alexander] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Staruschenko, Alexander] Med Coll Wisconsin, Kidney Dis Ctr, Milwaukee, WI 53226 USA; [Negulyaev, Yuri A.] Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Medical College of Wisconsin; Medical College of Wisconsin; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Staruschenko, A (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	staruschenko@mcw.edu	Negulyaev, Yuri/N-6531-2015	Negulyaev, Yuri/0000-0002-1773-9798; Staruschenko, Alexander/0000-0002-5190-8356; Ilatovskaya, Daria/0000-0003-4832-4170	American Heart Association [0730111N]; American Society of Nephrology; SR Foundation; Russian Foundation for Basic Research [RFBR-10-04-00995]; Russian Academy of Sciences	American Heart Association(American Heart Association); American Society of Nephrology; SR Foundation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Russian Academy of Sciences(Russian Academy of Sciences)	The authors thank Drs. A. Sorokin and M. Hodges (Medical College of Wisconsin, Milwaukeee, WI, USA) for helpful discussions and critical reading of the manuscript. The authors are grateful to Dr. J. T. Parsons (University of Virginia, Charlottesville, VA, USA) and Dr. A. D. Morielli (University of Vermont, Burlington, VT, USA) for providing cortactin constructs used in this study and Dr. L. G. Palmer (Weill Medical College of Cornell University, New York, NY, USA) for ENaC antibodies. This research was supported by American Heart Association grant 0730111N, an American Society of Nephrology Carl W. Gottschalk Research Scholar grant, and an S&R Foundation Ryuji Ueno award (to A.S.); Russian Foundation for Basic Research grant RFBR-10-04-00995 and the Molecular and Cell Biology Program of the Russian Academy of Sciences (to Y.A.N. and D.V.I.). Glen Slocum and Christine Duris are recognized for excellent technical assistance with immunohistochemistry experiments. Dr. A. Karpushev is recognized for initial help with biochemistry experiments.	Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; Bhalla V, 2008, J AM SOC NEPHROL, V19, P1845, DOI 10.1681/ASN.2008020225; Blanchoin L, 2009, CHEM BIOL, V16, P1125, DOI 10.1016/j.chembiol.2009.11.001; Butterworth MB, 2009, AM J PHYSIOL-RENAL, V296, pF10, DOI 10.1152/ajprenal.90248.2008; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; Condliffe SB, 2004, J BIOL CHEM, V279, P10085, DOI 10.1074/jbc.M313592200; Connors EC, 2008, J BIOL CHEM, V283, P3445, DOI 10.1074/jbc.M708875200; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Edinger RS, 2009, J BIOL CHEM, V284, P150, DOI 10.1074/jbc.M807358200; Frindt G, 2008, J GEN PHYSIOL, V131, P617, DOI 10.1085/jgp.200809989; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Gumz ML, 2010, BBA-GENE REGUL MECH, V1799, P622, DOI 10.1016/j.bbagrm.2010.09.003; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Karpushev AV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008827; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Levchenko V, 2010, J CELL PHYSIOL, V223, P252, DOI 10.1002/jcp.22033; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Mazzochi C, 2006, AM J PHYSIOL-RENAL, V291, pF1113, DOI 10.1152/ajprenal.00195.2006; Mazzochi C, 2006, J BIOL CHEM, V281, P6528, DOI 10.1074/jbc.M509386200; MCDONALD FJ, 1995, BIOCHEM J, V312, P491, DOI 10.1042/bj3120491; Mooren OL, 2009, J BIOL CHEM, V284, P23995, DOI 10.1074/jbc.M109.024398; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; Nolen BJ, 2009, NATURE, V460, P1031, DOI 10.1038/nature08231; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Pavlov TS, 2010, J AM SOC NEPHROL, V21, P833, DOI 10.1681/ASN.2009080885; Pochynyuk O, 2007, J BIOL CHEM, V282, P14576, DOI 10.1074/jbc.M701348200; Pochynyuk O, 2006, J BIOL CHEM, V281, P26520, DOI 10.1074/jbc.M603716200; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Soderling SH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.255pe5; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Staruschenko A, 2007, J AM SOC NEPHROL, V18, P1652, DOI 10.1681/ASN.2007010020; Staruschenko Alexander, 2006, V337, P3; Tian L, 2008, J BIOL CHEM, V283, P3067, DOI 10.1074/jbc.M706826200; Tian LJ, 2006, FASEB J, V20, P2588, DOI 10.1096/fj.06-6152fje; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Williams MR, 2007, P NATL ACAD SCI USA, V104, P17412, DOI 10.1073/pnas.0703865104; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	60	35	37	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2688	2699		10.1096/fj.10-167262	http://dx.doi.org/10.1096/fj.10-167262			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21536685				2022-12-28	WOS:000293337800018
J	Shen, WJ; Liu, LF; Patel, S; Kraemer, FB				Shen, Wen-Jun; Liu, Li-Fen; Patel, Shailja; Kraemer, Fredric B.			Hormone-sensitive lipase-knockout mice maintain high bone density during aging	FASEB JOURNAL			English	Article						osteoblastogenesis; bone marrow adipocytes	PPAR-GAMMA; LEPTIN REGULATION; FATTY-ACIDS; BETA-CELL; MARROW; EXPRESSION; DIFFERENTIATION; OSTEOBLASTS; METABOLISM; ROLES	We tested the hypothesis that the actions of hormone-sensitive lipase (HSL) affect the microenvironment of the bone marrow and that removal of HSL function by gene deletion maintains high bone mass in aging mice. We compared littermate control wild-type (WT) and HSL-/- mice during aging for changes in serum biochemical values, trabecular bone density using micro-computed tomography, bone histomorphometry, and characteristics of primary bone marrow cells and preosteoblasts. There is a regulated expression of HSL and genes involved in lipid metabolism in the bone marrow during aging. HSL-/- mice have increased serum levels of insulin and osteocalcin with decreased leptin levels. Compared with the marked adipocyte infiltration in WT bone marrow (65% by area) at 14 mo, HSL-/- mice have fewer (16%, P < 0.05) and smaller adipocytes in bone marrow. While peak bone density is similar, HSL-/- mice maintain a higher bone density (bone volume/total volume 6.1%) with age than WT mice (2.6%, P < 0.05). Primary osteo-blasts from HSL-/- mice show increased growth rates and higher osteogenic potential, manifested by increased expression of Runx2 (3.5-fold, P < 0.05) and osteocalcin (4-fold, P < 0.05). The absence of HSL directs cells within the bone marrow toward osteoblast differentiation and favors the maintenance of bone density with aging.-Shen, W.-J., Liu, L.-F., Patel, S., Kraemer, F. B. Hormone-sensitive lipase-knockout mice maintain high bone density during aging. FASEB J. 25, 2722-2730 (2011). www.fasebj.org	[Shen, Wen-Jun; Liu, Li-Fen; Patel, Shailja; Kraemer, Fredric B.] Stanford Univ, Div Endocrinol, Stanford, CA 94305 USA; [Shen, Wen-Jun; Liu, Li-Fen; Patel, Shailja; Kraemer, Fredric B.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Kraemer, FB (corresponding author), Stanford Univ, Div Endocrinol, S-025,300 Pasteur Dr, Stanford, CA 94305 USA.	fbk@stanford.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	U.S. Department of Veterans Affairs (Office of Research and Development, Medical Research Service); U.S. National Institutes of Health (NIH) [R01 AG028098]	U.S. Department of Veterans Affairs (Office of Research and Development, Medical Research Service)(US Department of Veterans Affairs); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported in part by the U.S. Department of Veterans Affairs (Office of Research and Development, Medical Research Service) and by U.S. National Institutes of Health (NIH) grant R01 AG028098. W.J.S. designed and performed experiments and wrote the manuscript; L.F.L. and S.P. performed experiments; F.B.K. designed the experiments and wrote the manuscript.	Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004-0735; Araneta MRG, 2009, J BONE MINER RES, V24, P2016, DOI [10.1359/JBMR.090519, 10.1359/jbmr.090519]; Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031; BENNETT JH, 1991, J CELL SCI, V99, P131; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Chen TL, 2007, STEM CELLS DEV, V16, P371, DOI 10.1089/scd.2006.0037; Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777; Gimble JM, 1996, MOL PHARMACOL, V50, P1087; Harada K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1182, DOI 10.1152/ajpendo.00259.2003; Hinoi E, 2009, ANN NY ACAD SCI, V1173, pE20, DOI 10.1111/j.1749-6632.2009.05061.x; Hinoi E, 2008, J CELL BIOL, V183, P1235, DOI 10.1083/jcb.200809113; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894; Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008; Kawai M, 2009, NAT REV RHEUMATOL, V5, P365, DOI 10.1038/nrrheum.2009.102; Kolditz CI, 2010, CURR OPIN CLIN NUTR, V13, P377, DOI 10.1097/MCO.0b013e32833bed6a; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Kraemer FB, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-12; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Liu LF, 2010, J CELL PHYSIOL, V225, P837, DOI 10.1002/jcp.22291; Magni P, 2010, CURR MOL MED, V10, P522; Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756-3282(00)00252-0; Mertelsmann R, 2000, J HEMATOTH STEM CELL, V9, P957, DOI 10.1089/152581600750062417; Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474-9728.2004.00127.x; Morioka T, 2007, J CLIN INVEST, V117, P2860, DOI 10.1172/JCI30910; Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RAISZ LG, 1995, J NUTR, V125, pS2024, DOI 10.1093/jn/125.suppl_7.2024S; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Reid IR, 2010, ARCH BIOCHEM BIOPHYS, V503, P20, DOI 10.1016/j.abb.2010.06.027; Rosen CJ, 2010, CELL, V142, P198, DOI 10.1016/j.cell.2010.07.001; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Shen WJ, 2011, BBA-MOL CELL BIOL L, V1811, P9, DOI 10.1016/j.bbalip.2010.10.001; Shen WJ, 1998, BIOCHEMISTRY-US, V37, P8973, DOI 10.1021/bi980545u; SUMIDA C, 1993, PROSTAG LEUKOTR ESS, V48, P117, DOI 10.1016/0952-3278(93)90019-S; Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137; Tokuzawa Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001019; Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693; Wang SP, 2008, MOL GENET METAB, V95, P117, DOI 10.1016/j.ymgme.2008.06.012; Watkins BA, 2001, J AM COLL NUTR, V20, p410S, DOI 10.1080/07315724.2001.10719177; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zimmermann R, 2009, BBA-MOL CELL BIOL L, V1791, P494, DOI 10.1016/j.bbalip.2008.10.005	52	6	6	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2722	2730		10.1096/fj.11-181016	http://dx.doi.org/10.1096/fj.11-181016			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21566206	Green Published			2022-12-28	WOS:000293337800021
J	Bose, K; Meinke, G; Bohm, A; Baleja, JD				Bose, Kakoli; Meinke, Gretchen; Bohm, Andrew; Baleja, James D.			Design and characterization of an enhanced repressor of human papillomavirus E2 protein	FASEB JOURNAL			English	Article						crystallography; protein-DNA interaction; subunit interface; transactivation	DNA-BINDING DOMAIN; BOVINE PAPILLOMAVIRUS; TRANSCRIPTIONAL ACTIVATION; TRANSFORMED CELLS; CRYSTAL-STRUCTURE; TYPE-16; STABILITY; CHROMATIN; TRANSACTIVATOR; DISCRIMINATION	Papillomaviruses are causative agents of cervical and anogenital cancers. The viral E2 protein mediates viral DNA replication and transactivation of viral oncogenes and thus represents a specific target for therapeutic intervention. Short forms of E2, E2R, contain only the C-terminal dimerization domain, and repress the normal function of E2 due to formation of an inactive heterodimer. Using structure-guided design, we replaced conserved residues at the dimer interface to design a heterodimer with increased stability. One E2R mutant in which histidine was replaced by a glutamate residue showed preferential heterodimer formation in vitro, as well as an increase in plasticity at the interface, as a result of histidine-glutamate pair formation, as observed spectroscopically and in the crystal structure, determined to 2.2-angstrom resolution. In addition, the enhanced E2R showed greater repression of transcription from E2-responsive reporter plasmids in mammalian cell culture. Recent advances in protein delivery into the cell raise the possibility of using exogenously added proteins as therapeutic agents. More generally, this approach may be used to target the subunit interfaces of any multisubunit protein having a similar mechanism of action.-Bose, K., Meinke, G., Bohm, A., Baleja, J. D. Design and characterization of an enhanced repressor of human papillomavirus E2 protein. FASEB J. 25, 2354-2361 (2011). www.fasebj.org	[Bose, Kakoli; Meinke, Gretchen; Bohm, Andrew; Baleja, James D.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Bose, Kakoli] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India	Tufts University; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital	Baleja, JD (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.	jim.baleja@tufts.edu			U.S. National Institutes of Health (NIH) [CA97992]; Lifespan/Tufts/Brown Center for AIDS Research [NIH P30AI042853]; NATIONAL CANCER INSTITUTE [K07CA097992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lifespan/Tufts/Brown Center for AIDS Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Drs. Brian Schaffhausen and Shaida Andrabi (Tufts University School of Medicine, Boston, MA, USA) for providing space, reagents, and advice for mammalian cell culture studies and Drs. Elliot Androphy and Xiaoyu Wang (University of Massachusetts Medical School, Worcester, MA, USA) for plasmids and protocols. This project was funded by U.S. National Institutes of Health (NIH) grant CA97992 and the Lifespan/Tufts/Brown Center for AIDS Research (NIH P30AI042853).	Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104; Abroi A, 2004, J VIROL, V78, P2100, DOI 10.1128/JVI.78.4.2100-2113.2004; Alloul N, 1999, J GEN VIROL, V80, P2461, DOI 10.1099/0022-1317-80-9-2461; Amoutzias GD, 2008, TRENDS BIOCHEM SCI, V33, P220, DOI 10.1016/j.tibs.2008.02.002; BARSOUM J, 1992, J VIROL, V66, P3941, DOI 10.1128/JVI.66.6.3941-3945.1992; Baxter MK, 2005, J VIROL, V79, P4806, DOI 10.1128/JVI.79.8.4806-4818.2005; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Bolon DN, 2005, P NATL ACAD SCI USA, V102, P12724, DOI 10.1073/pnas.0506124102; Bose K, 2005, PROTEIN SCI, V14, P24; Bose K, 2007, BIOCHEMISTRY-US, V46, P1402, DOI 10.1021/bi0611255; Bussiere DE, 1998, ACTA CRYSTALLOGR D, V54, P1367, DOI 10.1107/S0907444998005587; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; Dell G, 2003, J MOL BIOL, V334, P979, DOI 10.1016/j.jmb.2003.10.009; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eliseo T, 2009, J MOL BIOL, V388, P327, DOI 10.1016/j.jmb.2009.03.013; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Grossel MJ, 1996, VIROLOGY, V217, P301, DOI 10.1006/viro.1996.0117; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; Kumar RA, 2007, J VIROL, V81, P2213, DOI 10.1128/JVI.01746-06; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LAMBERT PF, 1989, J VIROL, V63, P3151, DOI 10.1128/JVI.63.7.3151-3154.1989; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; McLaughlin-Drubin ME, 2004, VIROLOGY, V321, P173, DOI 10.1016/j.virol.2003.12.019; McPhillips MG, 2005, J VIROL, V79, P8920, DOI 10.1128/JVI.79.14.8920-8932.2005; MEISLER M, 2004, THESIS TUFTS U BOSTO, P34; Mok YK, 1996, PROTEIN SCI, V5, P310; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; NADRA A, 2006, J BIOMOL NMR, V30, P211; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011; Pepinsky RB, 1997, J VIROL, V71, P828, DOI 10.1128/JVI.71.1.828-831.1997; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rocchia W, 2002, J COMPUT CHEM, V23, P128, DOI 10.1002/jcc.1161; SANDERS CM, 1995, VIROLOGY, V211, P418, DOI 10.1006/viro.1995.1424; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Soeda E, 2006, VIROLOGY, V351, P29, DOI 10.1016/j.virol.2006.03.016; Speck L M, 2006, Skin Therapy Lett, V11, P1; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; Veeraraghavan S, 1998, J BIOMOL NMR, V11, P457, DOI 10.1023/A:1008237029912; Veeraraghavan S, 1999, BIOCHEMISTRY-US, V38, P16115, DOI 10.1021/bi991633x; Wang XY, 2009, J VIROL, V83, P2274, DOI 10.1128/JVI.01791-08; Xi LF, 2009, CANCER EPIDEM BIOMAR, V18, P2507, DOI 10.1158/1055-9965.EPI-09-0482; Yan JP, 2010, J VIROL, V84, P76, DOI 10.1128/JVI.01647-09	49	1	2	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2354	2361		10.1096/fj.10-176461	http://dx.doi.org/10.1096/fj.10-176461			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21482558	Green Published			2022-12-28	WOS:000292242200027
J	Hoff, M; Balfanz, S; Ehling, P; Gensch, T; Baumann, A				Hoff, Max; Balfanz, Sabine; Ehling, Petra; Gensch, Thomas; Baumann, Arnd			A single amino acid residue controls Ca2+ signaling by an octopamine receptor from Drosophila melanogaster	FASEB JOURNAL			English	Article						biogenic amine; G-protein-coupled receptor; inositol-1,4,5-trisphosphate; learning and memory; oscillation	PROTEIN-COUPLED RECEPTORS; CALCIUM OSCILLATIONS; LOCUST FLIGHT; PHOSPHORYLATION; DESENSITIZATION; TRAFFICKING; MECHANISMS; SEQUENCES; BEHAVIOR; FAMILY	Rhythmic activity of cells and cellular networks plays an important role in physiology. In the nervous system oscillations of electrical activity and/or second messenger concentrations are important to synchronize neuronal activity. At the molecular level, rhythmic activity can be initiated by different routes. We have recently shown that an octopamine-activated G-protein-coupled receptor (GPCR; DmOct alpha 1Rb, CG3856) from Drosophila initiates Ca2+ oscillations. Here, we have unraveled the molecular basis of cellular Ca2+ signaling controlled by the DmOct alpha 1Rb receptor using a combination of pharmacological intervention, site-directed mutagenesis, and functional cellular Ca2+ imaging on heterologously expressed receptors. Phosphorylation of a single amino acid residue in the third intracellular loop of the GPCR by PKC is necessary and sufficient to desensitize the receptor. From its desensitized state, DmOct alpha 1Rb is resensitized by dephosphorylation, and a new Ca2+ signal occurs on octopamine stimulation. Our findings show that transient changes of the receptor's surface profile have a strong effect on its physiological signaling properties. We expect that the detailed knowledge of DmOct alpha 1Rb-dependent signal transduction fosters the identification of specific drugs that can be used for GPCR-mediated pest control, since octopamine serves important physiological and behavioral functions in arthropods.-Hoff M., Balfanz, S., Ehling, P., Gensch, T., Baumann, A. A single amino acid residue controls Ca2+ signaling by an octopamine receptor from Drosophila melanogaster. FASEB J. 25, 2484-2491 (2011). www.fasebj.org	[Hoff, Max; Balfanz, Sabine; Gensch, Thomas; Baumann, Arnd] Inst Complex Syst, Julich, Germany; [Ehling, Petra] Univ Munster, Inst Phys, D-4400 Munster, Germany	University of Munster	Baumann, A (corresponding author), Forschungszentrum Juelich, Inst Complex Syst Zellulaere Biophys ICS 4, D-52425 Julich, Germany.	a.baumann@fz-juelich.de	Baumann, Arnd/I-7941-2013	Baumann, Arnd/0000-0001-9456-7275; Balfanz, Sabine/0000-0002-7082-3999	Deutsche Forschungsgemeinschaft [Ba 1541/3-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors gratefully acknowledge the assistance of Joachim Schmitz in the cell culture and Dr. M. Krahling during the initial phases of pharmacological tests on DmOct alpha 1Rb. The authors also thank Dr. D. Kaschuba and A. Meisenberg for comments on the manuscript. The work was supported in part by a Deutsche Forschungsgemeinschaft grant to A. B. (Ba 1541/3-1).	Balfanz S, 2005, J NEUROCHEM, V93, P440, DOI 10.1111/j.1471-4159.2005.03034.x; Burchett SA, 2006, PROG NEUROBIOL, V79, P223, DOI 10.1016/j.pneurobio.2006.07.003; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Deng XX, 2009, J BIOL CHEM, V284, P22501, DOI 10.1074/jbc.R109.018655; Fain GL, 2010, CURR BIOL, V20, pR114, DOI 10.1016/j.cub.2009.12.006; Farooqui T, 2007, NEUROCHEM RES, V32, P1511, DOI 10.1007/s11064-007-9344-7; Gehret AU, 2010, BIOCHEM J, V428, P235, DOI 10.1042/BJ20100139; Han KA, 1998, J NEUROSCI, V18, P3650; Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830; Harrisingh MC, 2007, J NEUROSCI, V27, P12489, DOI 10.1523/JNEUROSCI.3680-07.2007; Hauser F, 2008, FRONT NEUROENDOCRIN, V29, P142, DOI 10.1016/j.yfrne.2007.10.003; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee HG, 2003, DEV BIOL, V264, P179, DOI 10.1016/j.ydbio.2003.07.018; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LIVINGSTONE MS, 1980, SCIENCE, V208, P76, DOI 10.1126/science.208.4439.76; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MALAMUD JG, 1988, J COMP PHYSIOL A, V162, P827, DOI 10.1007/BF00610971; Maqueira B, 2005, J NEUROCHEM, V94, P547, DOI 10.1111/j.1471-4159.2005.03251.x; Menzel R, 2006, CELL, V124, P237, DOI 10.1016/j.cell.2006.01.011; Nakahara K, 1997, J NEUROCHEM, V69, P1467; ORCHARD I, 1993, ANNU REV ENTOMOL, V38, P227, DOI 10.1146/annurev.en.38.010193.001303; Prossnitz ER, 2004, LIFE SCI, V75, P893, DOI 10.1016/j.lfs.2004.04.003; Putney JW, 2009, IMMUNOL REV, V231, P10, DOI 10.1111/j.1600-065X.2009.00810.x; Roeder T, 2003, ARCH INSECT BIOCHEM, V54, P1, DOI 10.1002/arch.10102; Roper SD, 2007, PFLUG ARCH EUR J PHY, V454, P759, DOI 10.1007/s00424-007-0247-x; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Sambrook J., 2001, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheiner R, 2006, CURR NEUROPHARMACOL, V4, P259, DOI 10.2174/157015906778520791; Stengl M, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00133; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Tobin AB, 2008, TRENDS PHARMACOL SCI, V29, P413, DOI 10.1016/j.tips.2008.05.006; Touhara K, 2009, ANNU REV PHYSIOL, V71, P307, DOI 10.1146/annurev.physiol.010908.163209; Verlinden H, 2010, J INSECT PHYSIOL, V56, P854, DOI 10.1016/j.jinsphys.2010.05.018; Wolfe BL, 2007, TRAFFIC, V8, P462, DOI 10.1111/j.1600-0854.2007.00551.x; Wong YH, 2007, NUCLEIC ACIDS RES, V35, pW588, DOI 10.1093/nar/gkm322	39	19	19	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2484	2491		10.1096/fj.11-180703	http://dx.doi.org/10.1096/fj.11-180703			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478261	Green Published			2022-12-28	WOS:000292242200038
J	Kwan, R; Hanada, S; Harada, M; Strnad, P; Li, DH; Omary, MB				Kwan, Raymond; Hanada, Shinichiro; Harada, Masaru; Strnad, Pavel; Li, Daniel H.; Omary, M. Bishr			Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation	FASEB JOURNAL			English	Article						intermediate filaments; steatohepatitis; transglutaminase 2	SIMPLE EPITHELIAL KERATINS; GRISEOFULVIN-FED MICE; TRANSGLUTAMINASE ACTIVITY; INFRARED-SPECTROSCOPY; ALCOHOLIC HEPATITIS; OXIDATIVE STRESS; MULTIPLE SITES; HUMAN-DISEASE; CROSS-LINKS; MOUSE-LIVER	Mallory-Denk bodies (MDBs) are hepatocyte inclusions that are associated with poor liver disease prognosis. The intermediate filament protein keratin 8 (K8) and its cross-linking by transglutaminase-2 (TG2) are essential for MDB formation. K8 hyperphosphorylation occurs in association with liver injury and MDB formation, but the link between keratin phosphorylation and MDB formation is unknown. We used a mutational approach to identify K8 Q70 as a residue that is important for K8 cross-linking to itself and other liver proteins. K8 cross-linking is markedly enhanced on treating cells with a phosphatase inhibitor and decreases dramatically on K8 S74A or Q70N mutation in the presence of phosphatase inhibition. K8 Q70 cross-linking, in the context of synthetic peptides or intact proteins transfected into cells, is promoted by phosphorylation at K8 S74 or by an S74D substitution and is inhibited by S74A mutation. Transgenic mice that express K8 S74A or a K8 G62C liver disease variant that inhibits K8 S74 phosphorylation have a markedly reduced ability to form MDBs. Our findings support a model in which the stress-triggered phosphorylation of K8 S74 induces K8 cross-linking by TG2, leading to MDB formation. These findings may extend to neuropathies and myopathies that are characterized by intermediate filament-containing inclusions.-Kwan, R., Hanada, S., Harada, M., Strnad, P., Li, D. H., Omary, M. B. Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation. FASEB J. 26, 2318-2326 (2012). www.fasebj.org	[Kwan, Raymond; Omary, M. Bishr] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Hanada, Shinichiro] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 830, Japan; [Harada, Masaru] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 3, Kitakyushu, Fukuoka 807, Japan; [Strnad, Pavel] Univ Ulm, Dept Internal Med 1, Ulm, Germany; [Li, Daniel H.] AnaSpec, Fremont, CA USA	University of Michigan System; University of Michigan; Kurume University; University of Occupational & Environmental Health - Japan; Ulm University	Kwan, R (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 7744 Med Sci Bldg 2,1301 E Catherine, Ann Arbor, MI 48109 USA.	raykwan@umich.edu		Omary, Bishr/0000-0002-8624-2347	U.S. National Institutes of Health (NIH) [R01 DK-52951]; U.S. Department of Veterans Affairs; NIH Michigan Gastrointestinal Peptide Research Center [P30 DK34933]; German Research Foundation [STR 1095/2-1]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052951, P30DK034933] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NIH Michigan Gastrointestinal Peptide Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by U.S. National Institutes of Health (NIH) grant R01 DK-52951, by the U.S. Department of Veterans Affairs (M. B. O.), and by NIH Michigan Gastrointestinal Peptide Research Center grant P30 DK34933. P. S. is supported by the Emmy Noether Program of the German Research Foundation (STR 1095/2-1). The authors are grateful to Dr. Chaitan Khosla (Stanford University, Stanford, CA, USA) for providing TG2 and thank Dr. Sujith Weerasinghe (University of Michigan) for performing mouse hepatocyte isolations.	Armstrong RA, 2006, EUR J NEUROL, V13, P528, DOI 10.1111/j.1468-1331.2006.01284.x; BONAR L, 1969, P SOC EXP BIOL MED, V131, P1373; CADRIN M, 1992, J HEPATOL, V14, P226, DOI 10.1016/0168-8278(92)90162-I; CADRIN M, 1991, EXP MOL PATHOL, V55, P170, DOI 10.1016/0014-4800(91)90050-8; Cortez-Pinto H, 2003, DIGEST DIS SCI, V48, P1909, DOI 10.1023/A:1026152415917; de Lima VM, 2008, J HEPATOL, V49, P1055, DOI 10.1016/j.jhep.2008.07.024; DENK H, 1975, LAB INVEST, V32, P773; DENK H, 1984, LIVER, V4, P208; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; Goebel HH, 2003, MUSCLE NERVE, V27, P527, DOI 10.1002/mus.10322; Hanada S, 2010, GASTROENTEROLOGY, V138, P1607, DOI 10.1053/j.gastro.2009.12.055; Harada M, 2008, HEPATOLOGY, V47, P2026, DOI 10.1002/hep.22294; Harada M, 2007, HEPATOLOGY, V45, P88, DOI 10.1002/hep.21471; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Jeitner TM, 2001, J NEUROCHEM, V79, P1109, DOI 10.1046/j.1471-4159.2001.00673.x; KACHI K, 1993, EXP MOL PATHOL, V59, P197, DOI 10.1006/exmp.1993.1039; Ku NO, 2006, J CELL BIOL, V174, P115, DOI 10.1083/jcb.200602146; Ku NO, 2004, METHOD CELL BIOL, V78, P489; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; Lesort M, 2000, J NEUROCHEM, V75, P1951, DOI 10.1046/j.1471-4159.2000.0751951.x; Liem RKH, 2009, J CLIN INVEST, V119, P1814, DOI 10.1172/JCI38003; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Mahajan V, 2011, GASTROENTEROLOGY, V141, P1080, DOI 10.1053/j.gastro.2011.05.039; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Nakamichi I, 2005, J CELL BIOL, V171, P931, DOI 10.1083/jcb.200507093; Nemes Z, 2009, J BIOL CHEM, V284, P27252, DOI 10.1074/jbc.M109.033969; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Omary MB, 2009, J CLIN INVEST, V119, P1794, DOI 10.1172/JCI37762; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Rakoski MO, 2011, CLIN GASTROENTEROL H, V9, P902, DOI 10.1016/j.cgh.2011.07.006; Riley NE, 2002, EXP MOL PATHOL, V72, P17, DOI 10.1006/exmp.2001.2413; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; Schmid AW, 2009, J BIOL CHEM, V284, P13128, DOI 10.1074/jbc.M809067200; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455; Siegel M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001861; Snider NT, 2011, J BIOL CHEM, V286, P2273, DOI 10.1074/jbc.M110.171314; Stamnaes J, 2010, J BIOL CHEM, V285, P25402, DOI 10.1074/jbc.M109.097162; Stmad P, 2008, HEPATOLOGY, V48, P931, DOI 10.1002/hep.22430; Strnad P, 2006, FEBS LETT, V580, P2351, DOI 10.1016/j.febslet.2006.03.051; Strnad P, 2007, GASTROENTEROLOGY, V132, P1515, DOI 10.1053/j.gastro.2007.02.020; Strnad R, 2008, BBA-MOL BASIS DIS, V1782, P764, DOI 10.1016/j.bbadis.2008.08.008; Stumptner C, 2000, AM J PATHOL, V156, P77, DOI 10.1016/S0002-9440(10)64708-6; Sugimura Y, 2006, J BIOL CHEM, V281, P17699, DOI 10.1074/jbc.M513538200; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tao GZ, 2006, EXP CELL RES, V312, P411, DOI 10.1016/j.yexcr.2005.11.010; Tatsukawa H, 2009, GASTROENTEROLOGY, V136, P1783, DOI 10.1053/j.gastro.2009.01.007; TAZAWA J, 1983, HEPATOLOGY, V3, P989; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Toivola DM, 2002, MOL BIOL CELL, V13, P1857, DOI 10.1091/mbc.01-12-0591; YOKOO H, 1982, GASTROENTEROLOGY, V83, P109; Zainelli GM, 2003, J NEUROPATH EXP NEUR, V62, P14, DOI 10.1093/jnen/62.1.14; ZATLOUKAL K, 1992, LAB INVEST, V66, P774; ZATLOUKAL K, 1989, LAB INVEST, V61, P603; Zatloukal K, 2000, AM J PATHOL, V156, P1263, DOI 10.1016/S0002-9440(10)64997-8; Zatloukal K, 2007, EXP CELL RES, V313, P2033, DOI 10.1016/j.yexcr.2007.04.024	58	22	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2318	2326		10.1096/fj.11-198580	http://dx.doi.org/10.1096/fj.11-198580			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362895	Green Submitted, Green Published			2022-12-28	WOS:000305017200010
J	Schmetterer, KG; Neunkirchner, A; Pickl, WF				Schmetterer, Klaus G.; Neunkirchner, Alina; Pickl, Winfried F.			Naturally occurring regulatory T cells: markers, mechanisms, and manipulation	FASEB JOURNAL			English	Review						FOXP3; immunomodulation; tolerance	TOLEROGENIC DENDRITIC CELLS; VERSUS-HOST-DISEASE; TRANS-RETINOIC ACID; ANTIGEN-SPECIFIC TOLERANCE; DE-NOVO GENERATION; EX-VIVO EXPANSION; LATENT TGF-BETA; IN-VITRO; CUTTING EDGE; PERIPHERAL-BLOOD	Naturally occurring CD4(+)CD25(high) fork-Head box protein 3 (FOXP3)(+) regulatory T cells (nTregs) are key mediators of immunity, which orchestrate and maintain tolerance to self and foreign antigens. In the recent 1.5 decades, a multitude of studies have aimed to define the phenotype and function of nTregs and to assess their therapeutic potential for modulating immune mediated disorders such as auto-immunity, allergy, and episodes of transplant rejection. In this review, we summarize the current knowledge on the biology of nTregs. We address the exact definition of nTregs by specific markers and combinations thereof, which is a prerequisite for the state-of-the-art isolation of defined nTreg populations. Furthermore, we discuss the mechanism by which nTregs mediate immunosuppression and how this knowledge might translate into novel therapeutic modalities. With first clinical studies of nTreg-based therapies being finished, questions concerning the reliable sources of nTregs arebecoming more and more eminent. Consequently, approaches allowing conversion of CD4(+) T cells into nTregs by coculture with antigen-presenting cells, cytokines, and/or pharmacological agents are discussed. In addition, genetic engineering approaches for the generation of antigen-specific nTregs are described.-Schmetterer, K. G., Neunkirchner, A., Pickl, W. F. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 26, 2253-2276 (2012). www.fasebj.org	[Schmetterer, Klaus G.; Neunkirchner, Alina; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Neunkirchner, Alina; Pickl, Winfried F.] Christian Doppler Lab Immunmodulat, Vienna, Austria	Medical University of Vienna	Pickl, WF (corresponding author), Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at		Pickl, Winfried F./0000-0003-0430-4952; Schmetterer, Klaus/0000-0001-9328-4871	Austrian Science Fund (FWF) [SFB F1816-B13, SFB F4609-B19]; Christian Doppler Laboratory for Immunomodulation, Christian Doppler Society	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Christian Doppler Laboratory for Immunomodulation, Christian Doppler Society	The authors thank Drs. Steinberger and Wojta-Stremayr for critically reading the manuscript. This work was supported by the Austrian Science Fund (FWF), grants SFB F1816-B13 and SFB F4609-B19; and by the Christian Doppler Laboratory for Immunomodulation, Christian Doppler Society. The authors declare no conflicts of interest.	Aarts-Riemens T, 2008, EUR J IMMUNOL, V38, P1381, DOI 10.1002/eji.200737590; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Allan SE, 2008, IMMUNOL REV, V223, P391, DOI 10.1111/j.1600-065X.2008.00634.x; Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Anderson AE, 2008, J LEUKOCYTE BIOL, V84, P124, DOI 10.1189/jlb.1107744; Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; Anz D, 2011, INT J CANCER, V129, P2417, DOI 10.1002/ijc.25902; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Arazi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008447; Aricha R, 2008, J IMMUNOL, V180, P2132, DOI 10.4049/jimmunol.180.4.2132; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baecher-Allan C, 2006, IMMUNOL REV, V212, P203, DOI 10.1111/j.0105-2896.2006.00417.x; Baecher-Allan C, 2006, J IMMUNOL, V176, P4622, DOI 10.4049/jimmunol.176.8.4622; Baeke F, 2011, J IMMUNOL, V186, P132, DOI 10.4049/jimmunol.1000695; Bardel E, 2008, J IMMUNOL, V181, P6898, DOI 10.4049/jimmunol.181.10.6898; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Begum-Haque S, 2008, J NEUROIMMUNOL, V204, P58, DOI 10.1016/j.jneuroim.2008.07.018; Beiras-Fernandez A, 2003, Exp Clin Transplant, V1, P79; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Bilsborough J, 2003, IMMUNOLOGY, V108, P481, DOI 10.1046/j.1365-2567.2003.01606.x; Bluestone JA, 2005, NAT REV IMMUNOL, V5, P343, DOI 10.1038/nri1574; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Bresson D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Broady R, 2009, BLOOD, V114, P5003, DOI 10.1182/blood-2009-04-214437; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Brusko TM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011726; Buckland M, 2006, AM J TRANSPLANT, V6, P2046, DOI 10.1111/j.1600-6143.2006.01450.x; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; BUONAVISTA N, 1992, GENOMICS, V13, P856, DOI 10.1016/0888-7543(92)90169-S; Camisaschi C, 2010, J IMMUNOL, V184, P6545, DOI 10.4049/jimmunol.0903879; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen HW, 2006, CLIN IMMUNOL, V119, P21, DOI 10.1016/j.clim.2005.11.003; Chen LC, 2009, J IMMUNOL, V183, P4094, DOI 10.4049/jimmunol.0901081; Chen ML, 2008, J IMMUNOL, V180, P7327, DOI 10.4049/jimmunol.180.11.7327; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen X, 2006, EUR J IMMUNOL, V36, P2139, DOI 10.1002/eji.200635873; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cui GL, 2009, CELL RES, V19, P574, DOI 10.1038/cr.2009.12; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dejean AS, 2009, NAT IMMUNOL, V10, P504, DOI 10.1038/ni.1729; Dominguez MD, 2011, AUTOIMMUNITY, V44, P471, DOI 10.3109/08916934.2010.550590; Delgado M, 2005, J LEUKOCYTE BIOL, V78, P1327, DOI 10.1189/jlb.0605299; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; DING L, 1993, J IMMUNOL, V151, P1224; DiPaolo RJ, 2007, J IMMUNOL, V179, P4685, DOI 10.4049/jimmunol.179.7.4685; Earle KE, 2005, CLIN IMMUNOL, V115, P3, DOI 10.1016/j.clim.2005.02.017; Efimova O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016013; Elinav E, 2009, GASTROENTEROLOGY, V136, P1721, DOI 10.1053/j.gastro.2009.01.049; Elpek KG, 2007, J IMMUNOL, V179, P7295, DOI 10.4049/jimmunol.179.11.7295; Ermann J, 2005, BLOOD, V105, P2220, DOI 10.1182/blood-2004-05-2044; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fantini MC, 2006, GUT, V55, P671, DOI 10.1136/gut.2005.072801; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Feng XM, 2008, BLOOD, V111, P3675, DOI 10.1182/blood-2008-01-130146; Fernandez-Martin A, 2006, EUR J IMMUNOL, V36, P318, DOI 10.1002/eji.200535430; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Freeman GJ, 2006, J EXP MED, V203, P2223, DOI 10.1084/jem.20061800; Fu S, 2004, AM J TRANSPLANT, V4, P65, DOI 10.1046/j.1600-6143.2003.00293.x; Garg SK, 2011, ANTIOXID REDOX SIGN, V15, P39, DOI 10.1089/ars.2010.3496; Garin MI, 2007, BLOOD, V109, P2058, DOI 10.1182/blood-2006-04-016451; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368; Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Godfrey WR, 2004, BLOOD, V104, P453, DOI 10.1182/blood-2004-01-0151; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Gonzalez-Rey E, 2006, BLOOD, V107, P3632, DOI 10.1182/blood-2005-11-4497; Gonzalez-Rey E, 2006, ARTHRITIS RHEUM-US, V54, P864, DOI 10.1002/art.21652; Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Guo Z, 2008, INT IMMUNOL, V20, P307, DOI 10.1093/intimm/dxm143; Haque R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2983; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Henry E, 2008, J IMMUNOL, V181, P7230, DOI 10.4049/jimmunol.181.10.7230; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hock BD, 2001, INT IMMUNOL, V13, P959, DOI 10.1093/intimm/13.7.959; Hoffmann P, 2004, BLOOD, V104, P895, DOI 10.1182/blood-2004-01-0086; Hombach AA, 2009, GENE THER, V16, P1088, DOI 10.1038/gt.2009.75; Hong J, 2005, P NATL ACAD SCI USA, V102, P6449, DOI 10.1073/pnas.0502187102; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Horwitz DA, 2008, EUR J IMMUNOL, V38, P912, DOI 10.1002/eji.200738109; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Huang H, 2010, J IMMUNOL, V185, P5003, DOI 10.4049/jimmunol.0903446; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; Iruretagoyena MI, 2006, J PHARMACOL EXP THER, V318, P59, DOI 10.1124/jpet.106.103259; Itoh M, 1999, J IMMUNOL, V162, P5317; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jee Y, 2007, CLIN IMMUNOL, V125, P34, DOI 10.1016/j.clim.2007.05.020; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Jiang SP, 2003, BLOOD, V102, P2180, DOI 10.1182/blood-2003-04-1164; Joetham A, 2008, J IMMUNOL, V180, P7117, DOI 10.4049/jimmunol.180.11.7117; Joetham A, 2011, J IMMUNOL, V186, P113, DOI 10.4049/jimmunol.1001663; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Kanamaru F, 2004, J IMMUNOL, V172, P7306, DOI 10.4049/jimmunol.172.12.7306; Kang HK, 2005, J IMMUNOL, V174, P3247, DOI 10.4049/jimmunol.174.6.3247; Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kitazawa Y, 2007, TRANSPLANTATION, V83, P774, DOI 10.1097/01.tp.0000256293.90270.e8; Kleinewietfeld M, 2005, BLOOD, V105, P2877, DOI 10.1182/blood-2004-07-2505; Kober J, 2008, EUR J IMMUNOL, V38, P2678, DOI 10.1002/eji.200838250; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Koenen HJPM, 2003, J IMMUNOL, V171, P6431, DOI 10.4049/jimmunol.171.12.6431; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kubach J, 2007, BLOOD, V110, P1550, DOI 10.1182/blood-2007-01-069229; Kuczma M, 2009, J IMMUNOL, V183, P3118, DOI 10.4049/jimmunol.0900514; Kueng HJ, 2010, FASEB J, V24, P1572, DOI 10.1096/fj.09-137281; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; La Cava A, 2004, J IMMUNOL, V173, P3542, DOI 10.4049/jimmunol.173.5.3542; LaCorcia G, 2009, TRANSPLANTATION, V87, P966, DOI 10.1097/TP.0b013e31819c84b8; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Li XL, 2010, AM J RESP CELL MOL, V42, P190, DOI 10.1165/rcmb.2009-0023OC; Liang BT, 2008, J IMMUNOL, V180, P5916, DOI 10.4049/jimmunol.180.9.5916; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Lipscomb MW, 2010, EUR J IMMUNOL, V40, P480, DOI 10.1002/eji.200939667; Liu T, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-40; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Long SA, 2008, J AUTOIMMUN, V30, P293, DOI 10.1016/j.jaut.2007.12.012; Lopez M, 2006, J AM SOC NEPHROL, V17, P2844, DOI 10.1681/ASN.2006050422; Lu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015150; Luhder F, 1998, J EXP MED, V187, P427, DOI 10.1084/jem.187.3.427; Mahnke K, 2007, EUR J IMMUNOL, V37, P2117, DOI 10.1002/eji.200636841; Maldonado RA, 2010, ADV IMMUNOL, V108, P111, DOI [10.1016/B978-0-12-380995-7.00004-5, 10.1016/S0065-2776(10)08004_1]; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170; Maynard CL, 2009, J EXP MED, V206, P343, DOI 10.1084/jem.20080950; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Mekala DJ, 2005, BLOOD, V105, P2090, DOI 10.1182/blood-2004-09-3579; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mellor AL, 2011, J IMMUNOL, V186, P4535, DOI 10.4049/jimmunol.1002937; Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440-1711.2003.t01-1-01177.x; Moldaver D, 2011, ALLERGY, V66, P784, DOI 10.1111/j.1398-9995.2011.02610.x; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Niedbala W, 2007, EUR J IMMUNOL, V37, P3021, DOI 10.1002/eji.200737810; NISHIZUK.Y, 1969, SCIENCE, V166, P753, DOI 10.1126/science.166.3906.753; Oberle N, 2007, J IMMUNOL, V179, P3578, DOI 10.4049/jimmunol.179.6.3578; Ohkura N, 2010, SEMIN IMMUNOPATHOL, V32, P95, DOI 10.1007/s00281-010-0200-5; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Okamura T, 2009, P NATL ACAD SCI USA, V106, P13974, DOI 10.1073/pnas.0906872106; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Onodera T, 2009, J IMMUNOL, V183, P5608, DOI 10.4049/jimmunol.0804116; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Paas-Rozner M, 2003, P NATL ACAD SCI USA, V100, P6676, DOI 10.1073/pnas.1131898100; Pacholczyk R, 2008, IMMUNOLOGY, V125, P450, DOI 10.1111/j.1365-2567.2008.02992.x; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123; Paust S, 2004, P NATL ACAD SCI USA, V101, P10398, DOI 10.1073/pnas.0403342101; Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044; Perrin PJ, 1996, J IMMUNOL, V157, P1333; Popow I, 2012, TRANSPLANTATION, V93, P32, DOI 10.1097/TP.0b013e31823bb664; Pozo D, 2009, J IMMUNOL, V183, P4346, DOI 10.4049/jimmunol.0900400; Qin HY, 2006, INT IMMUNOL, V18, P1001, DOI 10.1093/intimm/dxl035; Raimondi G, 2006, J IMMUNOL, V176, P2808, DOI 10.4049/jimmunol.176.5.2808; Rao PE, 2005, J IMMUNOL, V174, P1446, DOI 10.4049/jimmunol.174.3.1446; Reinwald S, 2008, J IMMUNOL, V180, P5890, DOI 10.4049/jimmunol.180.9.5890; Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006; Ristich V, 2005, EUR J IMMUNOL, V35, P1133, DOI 10.1002/eji.200425741; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; Ruzek MC, 2008, BLOOD, V111, P1726, DOI 10.1182/blood-2007-08-106526; SAKAGUCHI S, 1982, J EXP MED, V156, P1565, DOI 10.1084/jem.156.6.1565; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Santodomingo-Garzon T, 2009, HEPATOLOGY, V49, P1267, DOI 10.1002/hep.22761; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4; Schmetterer KG, 2011, J ALLERGY CLIN IMMUN, V127, P238, DOI 10.1016/j.jaci.2010.10.023; Scholler N, 2002, J IMMUNOL, V168, P2599, DOI 10.4049/jimmunol.168.6.2599; Schreiber TH, 2010, J CLIN INVEST, V120, P3629, DOI 10.1172/JCI42933; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Selvaraj RK, 2008, J IMMUNOL, V180, P2830, DOI 10.4049/jimmunol.180.5.2830; Seyer M, 2010, EUR J IMMUNOL, V40, P321, DOI 10.1002/eji.200939527; Sharabi A, 2008, J IMMUNOL, V181, P3243, DOI 10.4049/jimmunol.181.5.3243; Sharabi A, 2006, P NATL ACAD SCI USA, V103, P8810, DOI 10.1073/pnas.0603201103; Sharabi A, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3076; Sharabi A, 2010, J AUTOIMMUN, V34, P87, DOI 10.1016/j.jaut.2009.06.002; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Singh AK, 2009, TRANSPL P, V41, P418, DOI 10.1016/j.transproceed.2008.10.079; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Srivastava MK, 2010, CANCER RES, V70, P68, DOI 10.1158/0008-5472.CAN-09-2587; Stockinger B, 2001, NAT IMMUNOL, V2, P757, DOI 10.1038/ni0901-757; Stockis J, 2009, EUR J IMMUNOL, V39, P3315, DOI 10.1002/eji.200939684; Strauss L, 2009, J IMMUNOL, V182, P1469, DOI 10.4049/jimmunol.182.3.1469; Su H, 2008, BRIT J DERMATOL, V158, P1197, DOI 10.1111/j.1365-2133.2008.08555.x; Suffia I, 2005, J IMMUNOL, V174, P5444, DOI 10.4049/jimmunol.174.9.5444; Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dxl060; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Szanya V, 2002, J IMMUNOL, V169, P2461, DOI 10.4049/jimmunol.169.5.2461; Szymczak-Workman AL, 2011, J IMMUNOL, V187, P4416, DOI 10.4049/jimmunol.1100548; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Taylor A, 2009, MOL IMMUNOL, V46, P622, DOI 10.1016/j.molimm.2008.07.031; TEITELBAUM D, 1971, European Journal of Immunology, V1, P242, DOI 10.1002/eji.1830010406; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Torres-Aguilar H, 2010, J IMMUNOL, V184, P1765, DOI 10.4049/jimmunol.0902133; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Tran DQ, 2009, BLOOD, V113, P5125, DOI 10.1182/blood-2009-01-199950; Tuyaerts S, 2007, J LEUKOCYTE BIOL, V82, P93, DOI 10.1189/jlb.0906568; Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103; Valmori D, 2006, J IMMUNOL, V177, P944, DOI 10.4049/jimmunol.177.2.944; Verginis P, 2005, J IMMUNOL, V174, P7433, DOI 10.4049/jimmunol.174.11.7433; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Waldmann H, 2005, CURR TOP MICROBIOL, V293, P249, DOI 10.1007/3-540-27702-1_11; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang J, 2009, J IMMUNOL, V183, P4119, DOI 10.4049/jimmunol.0901065; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Wang R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002705; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weber SE, 2006, J IMMUNOL, V176, P4730, DOI 10.4049/jimmunol.176.8.4730; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391; Yan ZH, 2010, J BIOL CHEM, V285, P41525, DOI 10.1074/jbc.M110.189944; Yan ZH, 2009, NAT CHEM BIOL, V5, P721, DOI 10.1038/nchembio.212; Yang H, 2010, INFLAMM RES, V59, P197, DOI 10.1007/s00011-009-0087-6; Zhang H, 2005, NAT MED, V11, P1238, DOI 10.1038/nm1312; Zhang P, 2007, SCAND J IMMUNOL, V66, P435, DOI 10.1111/j.1365-3083.2007.01994.x; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; Zhao DC, 2008, BLOOD, V112, P2129, DOI 10.1182/blood-2008-02-140277; Zheng SG, 2004, J IMMUNOL, V172, P1531, DOI 10.4049/jimmunol.172.3.1531; Zheng SG, 2011, ARTHRITIS RHEUM-US, V63, pS334; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Zheng SG, 2006, J IMMUNOL, V176, P3321, DOI 10.4049/jimmunol.176.6.3321; Zheng XF, 2010, J IMMUNOL, V184, P6457, DOI 10.4049/jimmunol.0901717; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zhou XH, 2010, J IMMUNOL, V185, P2675, DOI 10.4049/jimmunol.1000598; Zhoua Q, 2009, AM J TRANSPLANT, V9, P2303, DOI 10.1111/j.1600-6143.2009.02777.x; Zozulya AL, 2009, J NEUROSCI, V29, P140, DOI 10.1523/JNEUROSCI.2199-08.2009	272	121	128	2	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2253	2276		10.1096/fj.11-193672	http://dx.doi.org/10.1096/fj.11-193672			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362896				2022-12-28	WOS:000305017200005
J	Louwette, S; Labarque, V; Wittevrongel, C; Thys, C; Metz, J; Gijsbers, R; Debyser, Z; Arnout, J; Van Geet, C; Freson, K				Louwette, Sophie; Labarque, Veerle; Wittevrongel, Christine; Thys, Chantal; Metz, Juriaan; Gijsbers, Rik; Debyser, Zeger; Arnout, Jef; Van Geet, Chris; Freson, Kathleen			Regulator of G-protein signaling 18 controls megakaryopoiesis and the cilia-mediated vertebrate mechanosensory system	FASEB JOURNAL			English	Article						thrombocyte formation; zebrafish; hair cells; inner ear; neuromast migration; noncanonical Wnt	HEMATOPOIETIC STEM-CELLS; ZEBRAFISH DANIO-RERIO; NEGATIVE REGULATOR; B-LYMPHOCYTES; RGS PROTEINS; LATERAL-LINE; EXPRESSION; MATURATION; MUTATIONS; PLATELETS	RGS18 was originally identified as a R4 subfamily member of regulators of G-protein signaling (RGS) with specific expression in hematopoietic progenitors, myeloerythroid cells, and megakaryocytes, though its physiological role in hematopoiesis remained unknown. Here, we show that lentiviral RGS18 overexpression during differentiation of mouse Sca1(+) hematopoietic stem cells induced a 50% increase of megakaryocyte proliferation. RGS18 depletion in zebrafish results in thrombocytopenia, as 66 to 88% of the embryos lack thrombocytes after injection of an ATG or splice-blocking morpholino, respectively. These embryos have no defects in early hematopoiesis, erythropoiesis, or leukocyte number and migration. In addition, all RGS18 depleted embryos have curly tails and an almost absent response to acoustic stimuli. In situ hybridization in zebrafish, Xenopus, and mouse embryos shows RGS18 expression in thrombocytes and/or hematological tissues but also in brain and otic vesicles. RGS18 interferes with development of cilia in hair cells of the inner ear and neuromast cells. On the basis of literature evidence that RGS-R4 members interact with the G-protein-modulated Wnt/calcium pathway, Wnt5b-but not Wnt5a-depleted embryos phenocopy all RGS18 knockdown effects. In summary, our study is the first to show that RGS18 regulates megakaryopoiesis but also reveals its unexpected role in ciliogenesis, at least in lower vertebrates, via interference with Wnt signaling.-Louwette, S., Labarque, V., Wittevrongel, C., Thys, C., Metz, J., Gijsbers, R., Debyser, Z., Arnout, J., Van Geet, C., Freson, K. Regulator of G-protein signaling 18 controls megakaryopoiesis and the cilia-mediated vertebrate mechanosensory system. FASEB J. 26, 2125-2136 (2012). www.fasebj.org	[Labarque, Veerle; Van Geet, Chris] Univ Leuven, Dept Pediat, Louvain, Belgium; [Louwette, Sophie; Wittevrongel, Christine; Thys, Chantal; Arnout, Jef; Van Geet, Chris; Freson, Kathleen] Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium; [Gijsbers, Rik; Debyser, Zeger] Univ Leuven, Lab Mol Virol & Gene Therapy, Louvain, Belgium; [Metz, Juriaan] Radboud Univ Nijmegen, Dept Anim Physiol, Inst Water & Wetland Res, NL-6525 ED Nijmegen, Netherlands	KU Leuven; KU Leuven; KU Leuven; Radboud University Nijmegen	Freson, K (corresponding author), Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Campus Gasthuisberg,O&N1,Herestr 49,Box 911, B-3000 Louvain, Belgium.	kathleen.freson@med.kuleuven.be	Metz, Juriaan R./A-3290-2012	Metz, Juriaan R./0000-0002-1515-1958; freson, kathleen/0000-0002-4381-2442	KU Leuven [EF/05/013]; FWO-Vlaanderen [G.0490.10N, G.0743.09]; Research Council of the University of Leuven (Onderzoeksraad KU Leuven, Leuven, Belgium) [GOA/2009/13]	KU Leuven(KU Leuven); FWO-Vlaanderen(FWO); Research Council of the University of Leuven (Onderzoeksraad KU Leuven, Leuven, Belgium)	C.V.G. is a holder of a clinical-fundamental research mandate of the Fund for Scientific Research-Flanders (FWO-Vlaanderen; Belgium) and of the Bayer and Norbert Heimburger (CSL Behring) chairs. This article was supported by the Excellentie financiering KU Leuven (EF/05/013), by research grants G.0490.10N and G.0743.09 from the FWO-Vlaanderen; and by GOA/2009/13 from the Research Council of the University of Leuven (Onderzoeksraad KU Leuven, Leuven, Belgium).	Beadling C, 1999, J IMMUNOL, V162, P2677; Berthebaud M, 2005, BLOOD, V106, P2962, DOI 10.1182/blood-2005-02-0526; Chen D, 2007, EXP HEMATOL, V35, P1344, DOI 10.1016/j.exphem.2007.06.004; De Waele L., PEDIAT RES, V67, P314; Delvaeye M, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-25; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; Faber J., 1994, SYSTEMATICAL CHRONOL; Freisinger C. M., PLOS GENET, V6; Freson K, 2008, BLOOD, V111, P1885, DOI 10.1182/blood-2007-06-098558; Gagnon AW, 2002, CELL SIGNAL, V14, P595, DOI 10.1016/S0898-6568(02)00012-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Hughes I, 2004, DEV BIOL, V276, P391, DOI 10.1016/j.ydbio.2004.09.001; Ibrahimi A, 2009, HUM GENE THER, V20, P845, DOI 10.1089/hum.2008.188; Jagadeeswaran P, 1999, BLOOD CELL MOL DIS, V25, P239, DOI 10.1006/bcmd.1999.0249; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kim SD, 2006, PLATELETS, V17, P493, DOI 10.1080/09537100600758123; KORZH V, 1993, DEVELOPMENT, V118, P417; Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063; Lin HF, 2005, BLOOD, V106, P3803, DOI 10.1182/blood-2005-01-0179; Liu JX, 2009, J BIOL CHEM, V284, P16679, DOI 10.1074/jbc.M109.009654; Moratz C, 2000, J IMMUNOL, V164, P1829, DOI 10.4049/jimmunol.164.4.1829; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Nicolson T, 2005, ANNU REV GENET, V39, P9, DOI 10.1146/annurev.genet.39.073003.105049; Noe L, 2010, J THROMB HAEMOST, V8, P1594, DOI 10.1111/j.1538-7836.2010.03885.x; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156; Pizard A, 2004, CURR PROTOC MOL BIOL, V14, p14.9, DOI 10.1002/0471142727.mb1409-66; Popper AN, 2000, PHILOS T ROY SOC B, V355, P1277, DOI 10.1098/rstb.2000.0683; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Riley BB, 1997, DEV BIOL, V191, P191, DOI 10.1006/dbio.1997.8736; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Santos F, 2006, HEARING RES, V213, P25, DOI 10.1016/j.heares.2005.12.009; Schmid A., BIOL CELL, V103, P159; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; Sercan Z., LEUK RES, V34, P946; Van Geet C, 2009, J THROMB HAEMOST, V7, P282, DOI 10.1111/j.1538-7836.2009.03399.x; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Whitfield TT, 1996, DEVELOPMENT, V123, P241; Wu CL, 2000, DEVELOPMENT, V127, P2773	42	20	20	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2125	2136		10.1096/fj.11-198739	http://dx.doi.org/10.1096/fj.11-198739			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22308195				2022-12-28	WOS:000303680800038
J	Thompson, AJ; McGonigle, I; Duke, R; Johnston, GAR; Lummis, SCR				Thompson, Andrew J.; McGonigle, Ian; Duke, Rujee; Johnston, Graham A. R.; Lummis, Sarah C. R.			A single amino acid determines the toxicity of Ginkgo biloba extracts	FASEB JOURNAL			English	Article						Cys-loop receptor; picrotoxin; antagonist	DROSOPHILA GABA RECEPTOR; BINDING; RDL; PICROTOXININ; ANTAGONIST; MUTATIONS; FIPRONIL	Ginkgo biloba extracts are currently used for a wide range of health-related conditions. Some of the medical benefits of these extracts are controversial, but their lack of toxicity in humans is not in doubt. These extracts are, however, highly toxic to insects. Their active components (ginkgolides and bilobalide) have structures similar to the convulsant picrotoxin, a GABA(A) receptor antagonist, so their lack of toxicity in mammals is puzzling. Here, we show that the different compositions of insect and vertebrate GABA receptor pores are responsible for the differing toxicities. Insect GABA receptors contain Ala at their 2' position in the pore. Substitution with Val, which is the equivalent residue in vertebrate GABA(A) receptor alpha-subunits, decreases ginkgolide potency by up to 10,000-fold. The reverse mutation in vertebrate GABA(A) alpha 1 subunits increased the sensitivity of alpha 1 beta 2 and alpha 1 beta 2 gamma 2 receptors to ginkgolides. Mutant cycle analysis demonstrates a strong interaction between the ginkgolides and the 2' residue, a result supported by in silico docking of compounds into a model of the pore. We conclude that the insecticidal activity of G. biloba extracts can be attributed to their effects at insect GABA receptors, and the presence of a Val at the 2' position in vertebrate GABA(A) receptors explains why these compounds are not similarly toxic to humans.-Thompson, A. J., McGonigle, I., Duke, R., Johnston, G. A. R., Lummis, S. C. R. A single amino acid determines the toxicity of Ginkgo biloba extracts. FASEB J. 26, 1884-1891 (2012). www.fasebj.org	[Thompson, Andrew J.; McGonigle, Ian; Lummis, Sarah C. R.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Duke, Rujee; Johnston, Graham A. R.] Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Cambridge; University of Sydney	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk	Johnston, Graham/AAJ-9569-2021; Johnston, Graham AR/B-9827-2009	Johnston, Graham/0000-0001-8872-4078; McGonigle, Ian/0000-0003-0837-080X; Thompson, Andrew/0000-0002-7046-6792	University of Sydney	University of Sydney(University of Sydney)	The authors thank The Wellcome Trust (81925; S. C. R. L., A.J.T.; S. C. R. L. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science), the UK Medical Research Council (I. M. held a MRC studentship), the National Health and Medical Research Council of Australia (R. D.; G.A.R.J.) and the University of Sydney (a travel grant to S. C. R. L.). A.J.T. and I. M. conducted the experiments; R. D. and G.A.R.J. contributed new reagents or analytic tools; A.J.T. and S. C. R. L. performed data analysis; A.J.T., S. C. R. L., I. M., R. D., and G.A.R.J. wrote or contributed to the writing of the manuscript; A.J.T. and S. C. R. L. participated in research design; S. C. R. L. and G.A.R.J. acquired funding for the research. The authors declare no conflicts of interest.	Ahlemeyer B, 2003, CELL MOL LIFE SCI, V60, P1779, DOI 10.1007/s00018-003-3080-1; Ahn YJ, 1997, ACS SYM SER, V658, P90; Buckingham SD, 2005, MOL PHARMACOL, V68, P942, DOI 10.1124/mol.105.015313; Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; Drieu K, 2000, PROSTAG LEUKOTR ESS, V63, P293, DOI 10.1054/plef.2000.0217; Erkkila BE, 2008, BIOPHYS J, V94, P4299, DOI 10.1529/biophysj.107.118455; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Harrison JB, 1996, CELL TISSUE RES, V284, P269, DOI 10.1007/s004410050587; Heads JA, 2008, J NEUROCHEM, V105, P1418, DOI 10.1111/j.1471-4159.2008.05244.x; Hori T., 1997, GINKGO BILOBA GLOBAL; Horovitz A, 1996, FOLD DES, V1, pR121, DOI 10.1016/S1359-0278(96)00056-9; Jensen AA, 2010, J BIOL CHEM, V285, P10141, DOI 10.1074/jbc.M109.079319; Le Goff G, 2005, J NEUROCHEM, V92, P1295, DOI 10.1111/j.1471-4159.2004.02922.x; Ludmerer SW, 2002, BIOCHEMISTRY-US, V41, P6548, DOI 10.1021/bi015920o; MILLAR NS, 1994, P ROY SOC B-BIOL SCI, V258, P307, DOI 10.1098/rspb.1994.0178; MILLER TA, 1979, PESTIC BIOCHEM PHYS, V10, P128, DOI 10.1016/0048-3575(79)90014-2; OLSEN RW, 1982, ANNU REV PHARMACOL, V22, P245, DOI 10.1146/annurev.pa.22.040182.001333; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sedelnikova A, 2006, J PHYSIOL-LONDON, V577, P569, DOI 10.1113/jphysiol.2006.120287; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sieghart W, 2006, ADV PHARMACOL, V54, P231, DOI 10.1016/S1054-3589(06)54010-4; Thompson AJ, 2011, J PHYSIOL-LONDON, V589, P4243, DOI 10.1113/jphysiol.2011.208439; Thompson AJ, 2011, MOL PHARMACOL, V80, P183, DOI 10.1124/mol.111.071415; Thompson AJ, 2010, Q REV BIOPHYS, V43, P449, DOI 10.1017/S0033583510000168; Tomlin C D S, 2006, PESTICIDE MANUAL WOR, P462; Woelkart K, 2010, PHYTOTHER RES, V24, P445, DOI 10.1002/ptr.3074; Xie JS, 2008, J CHROMATOGR B, V864, P87, DOI 10.1016/j.jchromb.2008.01.045; Zhao XL, 2003, J PHARMACOL EXP THER, V306, P914, DOI 10.1124/jpet.103.051839	28	16	17	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1884	1891		10.1096/fj.11-192765	http://dx.doi.org/10.1096/fj.11-192765			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253475	Green Published, hybrid			2022-12-28	WOS:000303680800017
J	Yung, HW; Cox, M; van Patot, MT; Burton, GJ				Yung, Hong Wa; Cox, Mathew; van Patot, Martha Tissot; Burton, Graham J.			Evidence of endoplasmic reticulum stress and protein synthesis inhibition in the placenta of non-native women at high altitude	FASEB JOURNAL			English	Article						AKT-mTOR signaling; birth weight; hypoxia; pregnancy	INTRAUTERINE GROWTH RESTRICTION; HUMAN TERM PLACENTAE; OXIDATIVE STRESS; GENE-EXPRESSION; IN-VIVO; OXYGEN DELIVERY; CHRONIC HYPOXIA; KINASE B; TRANSLATION; PHOSPHORYLATION	Pregnancy at high altitude is associated with a reduction in birth weight of similar to 100 g/1000 m of ascent. The underlying mechanisms are unclear but may involve alteration in energy-demanding activities, such as protein synthesis. To test this hypothesis, both in vivo and in vitro approaches were used. Placental tissues from pregnant women residing at 3100 m were studied, and placental cells were incubated under hypoxia. In the 3100-m placentas, we observed dilation of endoplasmic reticulum (ER) cisternae, increased phosphorylation of eukaryotic initiation factor 2 subunit alpha (P-eIF2 alpha), reduced AKT phosphorylation, and reduced P-4E-BP1 but increased 4E-BP1 protein compared to sea level controls. These findings suggest the presence of ER stress and protein synthesis inhibition. Hypoxia (1% O-2) reduced proliferation of trophoblast-like JEG-3 cells, BeWo cells, and placental fibroblasts by similar to 40, similar to 60, and similar to 18%, respectively. Sublethal dosage of salubrinal, an eIF2 alpha phosphatase inhibitor, increased P-eIF2 alpha and reduced BeWo cell and placental fibroblast proliferation by similar to 50%. Administration of the PI-3K inhibitor LY294002 also reduced JEG-3 proliferation. Our results demonstrate that exposure to chronic hypobaric hypoxia causes mild placental ER stress, which, in turn, modulates protein synthesis and slows proliferation. These effects may account for the reduced placental villous volume, and contribute to the low birth weight that typifies high-altitude populations.-Yung, H. W., Cox, M., Tissot van Patot, M., Burton, G. J. Evidence of endoplasmic reticulum stress and protein synthesis inhibition in the placenta of non-native women at high altitude. FASEB J. 26, 1970-1981 (2012). www.fasebj.org	[Burton, Graham J.] Univ Cambridge, Physiol Lab, Ctr Trophoblast Res, Cambridge CB2 3EG, England	University of Cambridge	Burton, GJ (corresponding author), Univ Cambridge, Physiol Lab, Ctr Trophoblast Res, Downing St, Cambridge CB2 3EG, England.	gjb2@cam.ac.uk		Tissot van Patot, Martha/0000-0002-2934-366X	Wellcome Trust [084804/2/08/Z]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by the Wellcome Trust (084804/2/08/Z).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bastide A, 2008, NUCLEIC ACIDS RES, V36, P2434, DOI 10.1093/nar/gkn093; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Carter AM, 2000, PLACENTA, V21, pS31, DOI 10.1053/plac.1999.0513; Choi SJ, 2007, AM J OBSTET GYNECOL, V196, P45, DOI 10.1016/j.ajog.2006.08.029; Cindrova-Davies T, 2007, AM J PATHOL, V171, P1168, DOI 10.2353/ajpath.2007.070528; Cindrova-Davies T, 2007, AM J PATHOL, V170, P1511, DOI 10.2353/ajpath.2007.061035; Colleoni F, 2011, PLACENTA, V32, pA46; Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235; Espinoza J, 2001, PLACENTA, V22, P606, DOI 10.1053/plac.2001.0696; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Giussani DA, 2001, PEDIATR RES, V49, P490, DOI 10.1203/00006450-200104000-00009; Giussani DA, 2007, J PHYSIOL-LONDON, V585, P911, DOI 10.1113/jphysiol.2007.141572; Illsley NP, 2010, INT J DEV BIOL, V54, P409, DOI 10.1387/ijdb.082798ni; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iwawaki T, 2009, P NATL ACAD SCI USA, V106, P16657, DOI 10.1073/pnas.0903775106; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; JACKSON MR, 1987, PLACENTA, V8, P487, DOI 10.1016/0143-4004(87)90077-4; JACKSON MR, 1987, J ANAT, V152, P173; Jan E, 2001, COLD SPRING HARB SYM, V66, P285, DOI 10.1101/sqb.2001.66.285; Julian CG, 2007, ARCH DIS CHILD-FETAL, V92, P372, DOI 10.1136/adc.2006.109579; Julian CG, 2009, AM J PHYSIOL-REG I, V296, pR1564, DOI 10.1152/ajpregu.90945.2008; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Keyes LE, 2003, PEDIATR RES, V54, P20, DOI 10.1203/01.PDR.0000069846.64389.DC; Kim YK, 2002, BIOCHEM BIOPH RES CO, V297, P224, DOI 10.1016/S0006-291X(02)02154-X; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Krampl E, 2000, ULTRASOUND OBST GYN, V16, P9, DOI 10.1046/j.1469-0705.2000.00156.x; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Moore LG, 1998, YEARB PHYS ANTHROPOL, V41, P25; Moore LG, 2001, AM J HUM BIOL, V13, P635, DOI 10.1002/ajhb.1102; Moore LG, 2001, AM J PHYS ANTHROPOL, V114, P42, DOI 10.1002/1096-8644(200101)114:1<42::AID-AJPA1004>3.0.CO;2-B; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Postigo L, 2009, J PHYSIOL-LONDON, V587, P693, DOI 10.1113/jphysiol.2008.163634; Raman L, 2005, DEV BRAIN RES, V156, P202, DOI 10.1016/j.devbrainres.2005.02.013; RESHETNIKOVA OS, 1994, AM J OBSTET GYNECOL, V171, P1560, DOI 10.1016/0002-9378(94)90402-2; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SIEMS WG, 1992, CELL BIOCHEM FUNCT, V10, P61, DOI 10.1002/cbf.290100110; Soma Hiroaki, 2005, Medical Molecular Morphology, V38, P92, DOI 10.1007/s00795-004-0259-y; van Patot MCT, 2009, PLACENTA, V30, P523, DOI 10.1016/j.placenta.2009.04.002; van Patot MCT, 2010, AM J PHYSIOL-REG I, V298, pR166, DOI 10.1152/ajpregu.00383.2009; Walsh B, 2001, J PHYSIOL-LONDON, V537, P971; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Yamaguchi S, 2008, CELL METAB, V7, P269, DOI 10.1016/j.cmet.2008.01.008; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Yung HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017894; Yung HW, 2008, AM J PATHOL, V173, P451, DOI 10.2353/ajpath.2008.071193; Yung HW, 2007, FASEB J, V21, P872, DOI 10.1096/fj.06-6054com; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	58	76	78	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1970	1981		10.1096/fj.11-190082	http://dx.doi.org/10.1096/fj.11-190082			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22267338	Green Published, hybrid			2022-12-28	WOS:000303680800024
J	Bansal, S; Srivastava, A; Mukherjee, G; Pandey, R; Verma, AK; Mishra, P; Kundu, B				Bansal, Saurabh; Srivastava, Ankit; Mukherjee, Goutam; Pandey, Ramendra; Verma, Anita Kamra; Mishra, Prashant; Kundu, Bishwajit			Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action	FASEB JOURNAL			English	Article						Pyroccocus furiosus; leukemia; stability; MD simulation; catalytic triad	ESCHERICHIA-COLI-ASPARAGINASE; CAROTOVORA L-ASPARAGINASE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ENGINEERING RESISTANCE; CONFORMATIONAL-CHANGES; THERMAL-STABILITY; PROTEIN; PURIFICATION; EXPRESSION	Thermophilic L-asparaginases display high stability and activity at elevated temperatures. However, they are of limited use in leukemia therapy because of their low substrate affinity and reduced activity under physiological conditions. In an attempt to combine stability with activity at physiological conditions, 3 active-site mutants of Pyrococcus furiosus L-asparaginase (PfA) were developed. The mutants, specifically K274E, showed improved enzymatic properties at physiological conditions as compared to the wild type. All variants were thermodynamically stable and resistant to proteolytic digestion. None of the enzymes displayed glutaminase activity, a highly desirable therapeutic property. All variants showed higher and significant killing of human cell lines HL60, MCF7, and K562 as compared to the Escherichia coli L-asparaginase. Our study revealed that increased substrate accessibility through the active site loop plays a major role in determining activity. A new mechanistic insight has been proposed based on molecular dynamics simulated structures, where dynamic flipping of a critical Tyr residue is responsible for the activity of thermophilic L-asparaginases. Our study not only resulted in development of PfA mutants with combination of desirable properties but also gave a mechanistic insight about their activity.-Bansal, S., Srivastava, A., Mukherjee, G., Pandey, R., Verma, A. K., Mishra, P., Kundu, B. Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action. FASEB J. 26, 1161-1171 (2012). www.fasebj.org	[Bansal, Saurabh; Mishra, Prashant] Indian Inst Technol Delhi, Dept Biochem Engn & Biotechnol, New Delhi, India; [Srivastava, Ankit; Kundu, Bishwajit] Indian Inst Technol Delhi, Kusuma Sch Biol Sci, New Delhi, India; [Mukherjee, Goutam] Indian Inst Technol Delhi, Supercomp Facil Bioinformat & Computat Biol, New Delhi, India; [Pandey, Ramendra; Verma, Anita Kamra] Univ Delhi, Kirorimal Coll, Dept Zool, New Delhi, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; University of Delhi	Kundu, B (corresponding author), Indian Inst Technol, Sch Biol Sci, Hauz Khas, New Delhi 110016, India.	bkundu@bioschool.iitd.ac.in	Bansal, Saurabh/I-8051-2019; Mukherjee, Goutam/B-6478-2017; Verma, Anita Kamra/GNW-5479-2022; Pandey, Ramendra pati/AAE-6970-2021; Bansal, Saurabh/S-9094-2016; verma, Anita/AAU-2760-2021; Mishra, Prashant/R-4701-2019	Bansal, Saurabh/0000-0002-0574-4063; Mukherjee, Goutam/0000-0002-4620-2770; Verma, Anita Kamra/0000-0001-6341-5930; Bansal, Saurabh/0000-0002-0574-4063; Pandey, Ramendrapati/0000-0002-5196-6468; Mukherjee, Babul/0000-0003-2422-1601; Kundu, Bishwajit/0000-0002-5786-3144	Indian Institute of Technology Delhi; Council of Scientific and Industrial Research, Government of India; supercomputing facility of the Indian Institute of Technology Delhi	Indian Institute of Technology Delhi; Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India); supercomputing facility of the Indian Institute of Technology Delhi	S. B. acknowledges the Indian Institute of Technology Delhi and the Council of Scientific and Industrial Research, Government of India, for providing financial and infrastructural support. The authors are thankful for the support of the supercomputing facility of the Indian Institute of Technology Delhi. The authors also thank Dr. P. Guptasarma, Dr. K. K. Pandey, and Ms. Rachana for helping at different phases of the work.	AMMON HL, 1988, J BIOL CHEM, V263, P150; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Avramis VI, 2006, INT J NANOMED, V1, P241; Balcao VM, 2001, BIOTECHNOL PROGR, V17, P537, DOI 10.1021/bp000163r; Bansal S, 2010, BIOCHEMISTRY-MOSCOW+, V75, P375, DOI 10.1134/S0006297910030144; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Case D, 2006, AMBER 9; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CURRAN MP, 1985, ARCH BIOCHEM BIOPHYS, V241, P571, DOI 10.1016/0003-9861(85)90582-X; CURTHOYS NP, 1974, J BIOL CHEM, V249, P3261; DAVIDSON L, 1977, J BACTERIOL, V129, P1379, DOI 10.1128/JB.129.3.1379-1386.1977; de Champdore Marcella, 2006, Reviews in Environmental Science and Bio/Technology, V5, P233, DOI 10.1007/s11157-006-0009-9; DeLano W.L, PYMOL MOL GRAPHICS S; Derst C, 2000, PROTEIN SCI, V9, P2009, DOI 10.1110/ps.9.10.2009; DUNLOP PC, 1975, J BACTERIOL, V122, P1017, DOI 10.1128/JB.122.3.1017-1024.1975; Duval M, 2002, BLOOD, V99, P2734, DOI 10.1182/blood.V99.8.2734; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Graham ML, 2003, ADV DRUG DELIVER REV, V55, P1293, DOI 10.1016/S0169-409X(03)00110-8; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guo L, 2000, BIOCHEM BIOPH RES CO, V276, P197, DOI 10.1006/bbrc.2000.3434; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Keating M J, 1993, Leuk Lymphoma, V10 Suppl, P153, DOI 10.3109/10428199309149129; Khushoo A, 2004, PROTEIN EXPRES PURIF, V38, P29, DOI 10.1016/j.pep.2004.07.009; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kotzia GA, 2005, J BIOTECHNOL, V119, P309, DOI 10.1016/j.jbiotec.2005.04.016; Kotzia GA, 2007, BIOCHEM J, V404, P337, DOI 10.1042/BJ20061708; Kotzia GA, 2007, J BIOTECHNOL, V127, P657, DOI 10.1016/j.jbiotec.2006.07.037; Kotzia GA, 2009, FEBS J, V276, P1750, DOI 10.1111/j.1742-4658.2009.06910.x; Kukurova K, 2009, MOL NUTR FOOD RES, V53, P1532, DOI 10.1002/mnfr.200800600; Kwon YM, 2009, J CONTROL RELEASE, V139, P182, DOI 10.1016/j.jconrel.2009.06.027; Lam SY, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001027; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li LZ, 2007, ENZYME MICROB TECH, V41, P523, DOI 10.1016/j.enzmictec.2007.04.004; Lubkowski J, 1996, EUR J BIOCHEM, V241, P201, DOI 10.1111/j.1432-1033.1996.0201t.x; Mishra A, 2006, APPL BIOCHEM BIOTECH, V135, P33, DOI 10.1385/ABAB:135:1:33; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muller HJ, 1998, CRIT REV ONCOL HEMAT, V28, P97, DOI 10.1016/S1040-8428(98)00015-8; Narta UK, 2007, CRIT REV ONCOL HEMAT, V61, P208, DOI 10.1016/j.critrevonc.2006.07.009; NEWSTED WJ, 1995, ENZYME MICROB TECH, V17, P757, DOI 10.1016/0141-0229(95)91162-R; Oettgen H F, 1970, Recent Results Cancer Res, V33, P219; Offman MN, 2011, BLOOD, V117, P1614, DOI 10.1182/blood-2010-07-298422; Oza VP, 2009, J INTEGR PLANT BIOL, V51, P201, DOI 10.1111/j.1744-7909.2008.00779.x; Palm GJ, 1996, FEBS LETT, V390, P211, DOI 10.1016/0014-5793(96)00660-6; Papageorgiou AC, 2008, FEBS J, V275, P4306, DOI 10.1111/j.1742-4658.2008.06574.x; Pedreschi F, 2008, FOOD CHEM, V109, P386, DOI 10.1016/j.foodchem.2007.12.057; Polizzi KM, 2007, CURR OPIN CHEM BIOL, V11, P220, DOI 10.1016/j.cbpa.2007.01.685; Pritsa AA, 2001, MOL CELL BIOCHEM, V216, P93, DOI 10.1023/A:1011066129771; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanches M, 2007, CURR CHEM BIOL, V1, P75, DOI DOI 10.2174/2212796810701010075; Soares AL, 2002, INT J PHARMACEUT, V237, P163, DOI 10.1016/S0378-5173(02)00046-7; Stecher A L, 1999, Pharm Acta Helv, V74, P1, DOI 10.1016/S0031-6865(99)00009-6; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; van den Berg H, 2011, LEUKEMIA LYMPHOMA, V52, P168, DOI 10.3109/10428194.2010.537796; Vemparala S, 2011, BBA-PROTEINS PROTEOM, V1814, P630, DOI 10.1016/j.bbapap.2011.03.012; Verma N, 2007, CRIT REV BIOTECHNOL, V27, P45, DOI 10.1080/07388550601173926; Wolf-Watz M, 2004, NAT STRUCT MOL BIOL, V11, P945, DOI 10.1038/nsmb821; Xiao GS, 1996, BBA-PROTEIN STRUCT M, V1294, P1; Yao M, 2005, ACTA CRYSTALLOGR D, V61, P294, DOI 10.1107/S0907444904032950; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; ZHOU HM, 1993, BIOCHEM J, V291, P103, DOI 10.1042/bj2910103	64	47	52	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1161	1171		10.1096/fj.11-191254	http://dx.doi.org/10.1096/fj.11-191254			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22166247				2022-12-28	WOS:000300949300019
J	Cai, LF; Pan, CG; Xu, L; Shui, Y; Liu, KL; Jiang, SB				Cai, Lifeng; Pan, Chungen; Xu, Liang; Shui, Yuan; Liu, Keliang; Jiang, Shibo			Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination	FASEB JOURNAL			English	Article						peptide; gp41; TLT; T20; T1144	VIRUS TYPE-1 GP41; PEPTIDE INHIBITOR; MEMBRANE-FUSION; ENFUVIRTIDE; RESISTANT; REPLICATION; DESIGN; TARGET; IDENTIFICATION; GLYCOPROTEIN	We previously reported that the combinatorial use of T20 and T1144, the first and next generations of HIV fusion inhibitors, containing different functional domains resulted in synergistic anti-HIV-1 effect, but this effect diminished when T20 and T1144 were covalently linked together. To elucidate the mechanism underlying this synergistic anti-HIV-1 effect, we studied the interactions between T20 and T1144 either in a mixture state or in a covalently linked state. T20 alone in solution was largely featureless, while T1144 alone was in alpha-helical trimeric conformation. When mixed in solution, T20 and T1144 showed a loose and transient interaction, with a moderate 10% alpha-helical content increase, but this interaction was greatly enhanced in the linked state, and T20 and T1144 showed similar to 100% alpha-helical content. These results suggested that the loose and transient interaction between T20 and T1144 may destabilize the T1144 trimer, which makes its otherwise shielded binding sites more accessible to N-terminal heptad repeat (NHR) and increases its associating rate, thus increasing its anti-HIV-1 potency against the temporarily exposed target in NHR and causing the synergistic anti-HIV-1 effect. However, the strong interaction between T20 and T1144 in the covalently linked state may shield their NHR-binding sites, resulting in reduction of the synergistic effect.-Cai, L., Pan, C., Xu, L., Shui, Y., Liu, K., Jiang, S. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 ef-fect resulting from their combination. FASEB J. 26, 1018 -1026 (2012). www.fasebj.org	[Cai, Lifeng; Pan, Chungen; Shui, Yuan; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA; [Cai, Lifeng; Xu, Liang; Liu, Keliang] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China; [Pan, Chungen] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Human Virol, Minist Educ,Key Lab Trop Dis Control, Guangzhou 510275, Guangdong, Peoples R China; [Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Inst Med Microbiol, Minist Educ,Minist Hlth,Key Lab Med Mol Virol, Shanghai 200433, Peoples R China	New York Blood Center; Academy of Military Medical Sciences - China; Sun Yat Sen University; Fudan University	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.	keliangliu@yahoo.com; sjiang@nybloodcenter.org	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135; Xu, Liang/0000-0001-8946-8280	U.S. National Institutes of Health [AI046221]; National Natural Science Foundation of China [81072581, 81173098]; National Science and Technology Major Project of Original New Drug Research Key Technology grant [2009ZX09301-002]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221, R21AI046221] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of Original New Drug Research Key Technology grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by U.S. National Institutes of Health grant AI046221 to S.J., National Natural Science Foundation of China grants 81072581 to L. C. and 81173098 to S.J., and National Science and Technology Major Project of Original New Drug Research Key Technology grant 2009ZX09301-002 to K.L.	Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289; Cai LF, 2009, ANTIMICROB AGENTS CH, V53, P2444, DOI 10.1128/AAC.00150-09; CASE DA, 2004, AMBER 8; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Delmedico M, 2006, 13 C RETR OPP INF DE; Dong MX, 2010, EUR J MED CHEM, V45, P4096, DOI 10.1016/j.ejmech.2010.05.070; Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Kahle KM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000674; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu J, 2010, J VIROL, V84, P201, DOI 10.1128/JVI.01558-09; Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08; Nishikawa H, 2008, BIOORGAN MED CHEM, V16, P9184, DOI 10.1016/j.bmc.2008.09.018; Nishikawa H, 2009, INT J BIOCHEM CELL B, V41, P891, DOI 10.1016/j.biocel.2008.08.039; Oishi S, 2008, J MED CHEM, V51, P388, DOI 10.1021/jm701109d; Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J; Pan CG, 2011, J BIOL CHEM, V286, P28425, DOI 10.1074/jbc.M111.241992; Pan CG, 2009, J VIROL, V83, P7862, DOI 10.1128/JVI.00168-09; Pan C, 2009, AIDS, V23, P639, DOI 10.1097/QAD.0b013e328325a4cd; Steger HK, 2006, J BIOL CHEM, V281, P25813, DOI 10.1074/jbc.M601457200; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537	29	15	16	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1018	1026		10.1096/fj.11-195289	http://dx.doi.org/10.1096/fj.11-195289			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22085645	Green Published			2022-12-28	WOS:000300949300007
J	Hutchison, S; Benson, RA; Gibson, VB; Pollock, AH; Garside, P; Brewer, JM				Hutchison, Sharon; Benson, Robert A.; Gibson, Vivienne B.; Pollock, Abigail H.; Garside, Paul; Brewer, James M.			Antigen depot is not required for alum adjuvanticity	FASEB JOURNAL			English	Article						vaccine; in vivo	CD4 T-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSE; SELF-TOLERANCE; IN-VIVO; ABSENCE; INJECTION; COMPLEX	Alum adjuvants have been in continuous clinical use for more than 80 yr. While the prevailing theory has been that depot formation and the associated slow release of antigen and/or inflammation are responsible for alum enhancement of antigen presentation and subsequent T-and B-cell responses, this has never been formally proven. To examine antigen persistence, we used the chimeric fluorescent protein E alpha GFP, which allows assessment of antigen presentation in situ, using the Y-Ae antibody. We demonstrate that alum and/or CpG adjuvants induced similar uptake of antigen, and in all cases, GFP signal did not persist beyond 24 h in draining lymph node antigen-presenting cells. Antigen presentation was first detectable on B cells within 6-12 h of antigen administration, followed by conventional dendritic cells (DCs) at 12-24 h, then finally plasmacytoid DCs at 48 h or later. Again, alum and/or CpG adjuvants did not have an effect on the magnitude or sequence of this response; furthermore, they induced similar antigen-specific T-cell activation in vivo. Notably, removal of the injection site and associated alum depot, as early as 2 h after administration, had no appreciable effect on antigen-specific T- and B-cell responses. This study clearly rules out a role for depot formation in alum adjuvant activity.-Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., Brewer, J. M. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272-1279 (2012). www.fasebj.org	[Hutchison, Sharon; Benson, Robert A.; Gibson, Vivienne B.; Pollock, Abigail H.; Garside, Paul; Brewer, James M.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow	Brewer, JM (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, Sir Graeme Davies Bldg,120 Univ Ave, Glasgow G12 8TA, Lanark, Scotland.	james.brewer@glasgow.ac.uk	Brewer, James/A-7186-2010	Brewer, James/0000-0001-7933-0915; Hutchison, Sharon/0000-0002-8932-8349; Benson, Robert/0000-0003-3687-0481	UK Biotechnology and Biological Sciences Research Council; Wellcome Trust; BBSRC [BB/E00069X/2, BB/E00069X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E00069X/1, BB/E00069X/2] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by grants from the UK Biotechnology and Biological Sciences Research Council and The Wellcome Trust.	Allenspach EJ, 2008, IMMUNITY, V29, P795, DOI 10.1016/j.immuni.2008.08.013; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Benson RA, 2010, J IMMUNOL, V184, P6378, DOI 10.4049/jimmunol.0903951; Brewer JM, 2006, IMMUNOL LETT, V102, P10, DOI 10.1016/j.imlet.2005.08.002; Brewer JM, 1999, J IMMUNOL, V163, P6448; Catron DM, 2004, IMMUNITY, V21, P341, DOI 10.1016/j.immuni.2004.08.007; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Glenny AT, 1931, J PATHOL BACTERIOL, V34, P267, DOI 10.1002/path.1700340214; Glenny AT, 1925, J PATHOL BACTERIOL, V28, P273, DOI 10.1002/path.1700280217; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hansen B, 2007, VACCINE, V25, P6618, DOI 10.1016/j.vaccine.2007.06.049; Harrison WT, 1935, AM J PUBLIC HEALTH N, V25, P298, DOI 10.2105/AJPH.25.3.298; Hawkins ED, 2007, NAT PROTOC, V2, P2057, DOI 10.1038/nprot.2007.297; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Holt L.B., 1950, DEV DIPHTHERIA PROPH; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Jongbloed SL, 2009, J IMMUNOL, V182, P963, DOI 10.4049/jimmunol.182.2.963; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kreig A. M., 1995, NATURE, V374, P546; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; MURPHY DB, 1992, J IMMUNOL, V148, P3483; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Oakley C. L., 1966, BIOGR MEMS FELL R SO, V12, P163; Obst R, 2005, J EXP MED, V201, P1555, DOI 10.1084/jem.20042521; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Rush CM, 2010, METHODS MOL BIOL, V626, P169, DOI 10.1007/978-1-60761-585-9_12; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; WARD JR, 1962, ARTHRITIS RHEUM, V5, P557, DOI 10.1002/art.1780050604; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; WEISSBURG RP, 1995, PHARMACEUT RES, V12, P1439, DOI 10.1023/A:1016266916893; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228	36	138	148	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1272	1279		10.1096/fj.11-184556	http://dx.doi.org/10.1096/fj.11-184556			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22106367	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000300949300029
J	Kozminsky-Atias, A; Zilberberg, N				Kozminsky-Atias, Adi; Zilberberg, Noam			Molding the business end of neurotoxins by diversifying evolution	FASEB JOURNAL			English	Article						active surface; ion channels; multigene families	ALPHA-LIKE TOXIN; SCORPION BETA-TOXINS; MULTIPLE SEQUENCE ALIGNMENT; MOLECULAR EVOLUTION; ADAPTIVE EVOLUTION; CHANNEL SELECTIVITY; POSITIVE SELECTION; FUNCTIONAL SURFACE; RAPID EVOLUTION; SODIUM-CHANNELS	A diverse range of organisms utilize neurotoxins that target specific ion channels and modulate their activity. Typically, toxins are clustered into several multigene families, providing an organism with the upper hand in the never-ending predator-prey arms race. Several gene families, including those encoding certain neurotoxins, have been subject to diversifying selection forces, resulting in rapid gene evolution. Here we sought a spatial pattern in the distribution of both diversifying and purifying selection forces common to neurotoxin gene families. Utilizing the mechanistic empirical combination model, we analyzed various toxin families from different phyla affecting various receptors and relying on diverse modes of action. Through this approach, we were able to detect clear correlations between the pharmacological surface of a toxin and rapidly evolving domains, rich in positively selected residues. On the other hand, patches of negatively selected residues were restricted to the nontoxic face of the molecule and most likely help in stabilizing the tertiary structure of the toxin. We thus propose a mutual evolutionary strategy of venomous animals in which adaptive molecular evolution is directed toward the toxin active surface. Furthermore, we propose that the binding domains of unstudied toxins could be readily predicted using evolutionary considerations.-Kozminsky-Atias, A., Zilberberg, N. Molding the business end of neurotoxins by diversifying evolution. FASEB J. 26, 576-586 (2012). www.fasebj.org	[Kozminsky-Atias, Adi; Zilberberg, Noam] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Zilberberg, N (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	noamz@bgu.ac.il	Zilberberg, Noam/F-2005-2012	Zilberberg, Noam/0000-0002-7848-2391	Israel Science Foundation [1237/10]	Israel Science Foundation(Israel Science Foundation)	The authors are grateful to Ariel Novoplansky and Moran Gershoni for helpful discussions. This work was supported by a grant from the Israel Science Foundation (1237/10) to N.Z.	Alape-Giron A, 1999, EUR J BIOCHEM, V259, P225, DOI 10.1046/j.1432-1327.1999.00021.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Chen J, 2008, CELL MOL LIFE SCI, V65, P2431, DOI 10.1007/s00018-008-8135-x; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; Cohen L, 2008, J BIOL CHEM, V283, P15169, DOI 10.1074/jbc.M801229200; Cohen L, 2006, FASEB J, V20, P1933, DOI 10.1096/fj.05-5545fje; Conticello SG, 2001, MOL BIOL EVOL, V18, P120, DOI 10.1093/oxfordjournals.molbev.a003786; Darbon H, 1999, J Soc Biol, V193, P445; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Demuth JP, 2009, BIOESSAYS, V31, P29, DOI 10.1002/bies.080085; Doron-Faigenboim A, 2007, MOL BIOL EVOL, V24, P388, DOI 10.1093/molbev/msl175; Duda TF, 2000, MOL BIOL EVOL, V17, P1286, DOI 10.1093/oxfordjournals.molbev.a026412; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; Froy O, 1998, FASEB J, V12, P1793, DOI 10.1096/fasebj.12.15.1793; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; Gibbs HL, 2008, J MOL EVOL, V66, P151, DOI 10.1007/s00239-008-9067-7; Gordon D, 2007, TOXICON, V49, P452, DOI 10.1016/j.toxicon.2006.11.016; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Gruber J, 2007, ACTA CRYSTALLOGR D, V63, P50, DOI 10.1107/S0907444906046762; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Gurevitz M, 2007, TOXICON, V49, P473, DOI 10.1016/j.toxicon.2006.11.015; HSEU TH, 1977, J MOL EVOL, V10, P167, DOI 10.1007/BF01751810; Hughes A.L., 1999, ADAPTIVE EVOLUTION G; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Juarez P, 2008, MOL BIOL EVOL, V25, P2391, DOI 10.1093/molbev/msn179; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Karbat I, 2004, J BIOL CHEM, V279, P31679, DOI 10.1074/jbc.M402048200; Karbat I, 2007, FEBS J, V274, P1918, DOI 10.1111/j.1742-4658.2007.05737.x; Karbat I, 2007, J MOL BIOL, V366, P586, DOI 10.1016/j.jmb.2006.10.085; Kini RM, 2005, TOXICON, V45, P1147, DOI 10.1016/j.toxicon.2005.02.018; Kini RM, 1999, J MOL EVOL, V48, P125, DOI 10.1007/PL00006450; Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Kordis D, 2000, GENE, V261, P43, DOI 10.1016/S0378-1119(00)00490-X; Kozminsky-Atias A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-333; Lee CW, 2004, BIOCHEMISTRY-US, V43, P890, DOI 10.1021/bi0353373; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; Li M, 2005, MOL BIOL EVOL, V22, P934, DOI 10.1093/molbev/msi077; Liang SP, 2004, TOXICON, V43, P575, DOI 10.1016/j.toxicon.2004.02.005; Liao Z, 2007, PROTEOMICS, V7, P1892, DOI 10.1002/pmic.200600785; Liu LH, 2005, FASEB J, V19, P594, DOI 10.1096/fj.04-2485fje; Lynch VJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-2; Madaoui H, 2008, P NATL ACAD SCI USA, V105, P7708, DOI 10.1073/pnas.0707032105; Mebs D, 2001, TOXICON, V39, P87, DOI 10.1016/S0041-0101(00)00155-0; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Petan T, 2002, BIOCHEM J, V363, P353, DOI 10.1042/0264-6021:3630353; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Prijatelj P, 2006, BIOCHIMIE, V88, P69, DOI 10.1016/j.biochi.2005.06.015; Prijatelj P, 2008, TOXICON, V51, P1520, DOI 10.1016/j.toxicon.2008.03.031; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Saul FA, 2010, J STRUCT BIOL, V169, P360, DOI 10.1016/j.jsb.2009.10.010; Schnur E, 2008, BIOCHEMISTRY-US, V47, P911, DOI 10.1021/bi701323k; Servent D, 2000, EUR J PHARMACOL, V393, P197, DOI 10.1016/S0014-2999(00)00095-9; Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016; Stern A, 2007, NUCLEIC ACIDS RES, V35, pW506, DOI 10.1093/nar/gkm382; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; Tamiya T, 2006, MOL DIVERS, V10, P529, DOI 10.1007/s11030-006-9049-x; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tian CH, 2008, TOXICON, V51, P555, DOI 10.1016/j.toxicon.2007.11.010; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Valdez-Cruz NA, 2004, BIOCHIMIE, V86, P387, DOI 10.1016/j.biochi.2004.05.005; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; Wang CG, 2003, BIOCHEMISTRY-US, V42, P4699, DOI 10.1021/bi0270438; Wang JM, 2004, J GEN PHYSIOL, V123, P455, DOI 10.1085/jgp.200309005; Weinberger H, 2010, MOL BIOL EVOL, V27, P1025, DOI 10.1093/molbev/msp310; Ye X, 2005, J MOL BIOL, V353, P788, DOI 10.1016/j.jmb.2005.08.068; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	86	21	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					576	586		10.1096/fj.11-187179	http://dx.doi.org/10.1096/fj.11-187179			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22009937				2022-12-28	WOS:000300485700011
J	Krumpochova, P; Sapthu, S; Brouwers, JF; de Haas, M; de Vos, R; Borst, P; van de Wetering, K				Krumpochova, Petra; Sapthu, Sunny; Brouwers, Jos F.; de Haas, Marcel; de Vos, Ric; Borst, Piet; van de Wetering, Koen			Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays	FASEB JOURNAL			English	Article						metabolomics; LC/MS; phytoestrogens; knockout mice	TANDEM MASS-SPECTROMETRY; MULTIDRUG-RESISTANCE PROTEIN; MRP2; METABOLISM; DISEASE; GENE; RATS; MICE; GLUCURONIDES; MUTATION	The ATP-binding cassette (ABC) genes encode the largest family of transmembrane proteins. ABC transporters translocate a wide variety of substrates across membranes, but their physiological function is often incompletely understood. We describe a new method to study the substrate spectrum of ABC transporters: We incubate extracts of mouse urine with membrane vesicles prepared from Spodoptera frugiperda Sf9 insect cells overproducing an ABC transporter and determine the compounds transported into the vesicles by LC/MS-based metabolomics. We illustrate the power of this simple "transportomics" approach using ABCC2, a protein present at sites of uptake and elimination. We identified many new substrates of ABCC2 in urine. These included glucuronides of plant-derived xenobiotics, a class of compounds to which humans are exposed on a daily basis. Moreover, we show that the excretion of these compounds in vivo depends on ABCC2: compared to wildtype mice, the urinary excretion of several glucuronides was increased up to 20-fold in Abcc2(-/-) mice. Transportomics has broad applicability, as it is not restricted to urine and can be applied to other ATP-dependent transport proteins as well.-Krumpochova, P., Sapthu, S., Brouwers, J. F., de Haas, M., de Vos, R., Borst, P., van de Wetering, K. Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays. FASEB J. 26, 738-747 (2012). www.fasebj.org	[Krumpochova, Petra; Sapthu, Sunny; de Haas, Marcel; Borst, Piet; van de Wetering, Koen] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Brouwers, Jos F.] Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, Utrecht, Netherlands; [de Vos, Ric] Plant Res Int, Wageningen, Netherlands; [de Vos, Ric] Netherlands Metabol Ctr, Leiden, Netherlands	Netherlands Cancer Institute; Utrecht University	van de Wetering, K (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	k.vd.wetering@nki.nl	Brouwers, Jos F/AAH-1444-2019; De Vos, Ric/F-5012-2017	Brouwers, Jos F/0000-0003-2924-3279; 	ZonMw (TOP) [40-00812-98-07-028]; Netherlands Metabolomics Centre, under the Netherlands Genomics Initiative	ZonMw (TOP); Netherlands Metabolomics Centre, under the Netherlands Genomics Initiative	The authors thank Ton Schrauwers for excellent biotechnical assistance and their colleagues Alfred Schinkel, Jos Jonkers, and Robert Jansen (The Netherlands Cancer Institute), Ronald Oude Elferink (Division of Experimental Hepatology, University of Amsterdam, Amsterdam, The Netherlands), Jos Beijnen (Division of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, Amsterdam, The Netherlands), and Hiroyuki Kusuhara (Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan) for fruitful discussions and critical reading of the manuscript. The experimental work in the authors' laboratory is supported by ZonMw (TOP grant 40-00812-98-07-028, to K. V. and P. B.). R. D. gets additional financial support from The Netherlands Metabolomics Centre, which is under the auspices of the Netherlands Genomics Initiative. The authors declare no conflicts of interest.	Borst P, 2006, CANCER LETT, V234, P51, DOI 10.1016/j.canlet.2005.05.051; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Buchler M, 1996, J BIOL CHEM, V271, P15091; Ci L, 2007, MOL PHARMACOL, V71, P1591, DOI 10.1124/mol.106.031823; Dieckhaus CM, 2005, CHEM RES TOXICOL, V18, P630, DOI 10.1021/tx049741u; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; ELFERINK RPJO, 1991, BIOCHEM J, V274, P281, DOI 10.1042/bj2740281; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Jager W, 1997, HEPATOLOGY, V26, P1467; Jansen GHE, 2005, ARCH BIOCHEM BIOPHYS, V435, P74, DOI 10.1016/j.abb.2004.12.015; Jemnitz K, 2010, DRUG METAB REV, V42, P402, DOI 10.3109/03602530903491741; Katona M, 2009, RAPID COMMUN MASS SP, V23, P3372, DOI 10.1002/rcm.4259; Kruh GD, 2007, CANCER METAST REV, V26, P5, DOI 10.1007/s10555-007-9039-1; Lafaye A, 2004, J MASS SPECTROM, V39, P655, DOI 10.1002/jms.635; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Maher JM, 2005, DRUG METAB DISPOS, V33, P947, DOI 10.1124/dmd.105.003780; Nies AT, 2007, PFLUG ARCH EUR J PHY, V453, P643, DOI 10.1007/s00424-006-0109-y; Novakova L, 2009, ANAL CHIM ACTA, V656, P8, DOI 10.1016/j.aca.2009.10.004; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Qu J, 2001, J CHROMATOGR A, V928, P155, DOI 10.1016/S0021-9673(01)01111-6; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; van de Wetering K, 2007, MOL PHARMACOL, V72, P387, DOI 10.1124/mol.107.035592; Van De Wetering K, 2009, GASTROENTEROLOGY, V137, P1725, DOI 10.1053/j.gastro.2009.06.052; Vlaming MLH, 2006, J PHARMACOL EXP THER, V318, P319, DOI 10.1124/jpet.106.101774	26	48	50	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					738	747		10.1096/fj.11-195743	http://dx.doi.org/10.1096/fj.11-195743			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22034653	hybrid			2022-12-28	WOS:000300485700025
J	Toll, L; Khroyan, TV; Sonmez, K; Ozawa, A; Lindberg, I; McLaughlin, JP; Eans, SO; Shahien, AA; Kapusta, DR				Toll, Lawrence; Khroyan, Taline V.; Sonmez, Kemal; Ozawa, Akihiko; Lindberg, Iris; McLaughlin, Jay P.; Eans, Shainnel O.; Shahien, Amir A.; Kapusta, Daniel R.			Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception	FASEB JOURNAL			English	Article						antinociception; neuropeptide	CORTICOTROPIN-RELEASING HORMONE; BARRINGTONS NUCLEUS; IN-VIVO; RAT; RECEPTOR; NEURONS; SYSTEM; IDENTIFICATION; NEUROPEPTIDE; AGONIST	Computational methods have led two groups to predict the endogenous presence of a highly conserved, amidated, 14-aa neuropeptide called either spexin or NPQ. NPQ/spexin is part of a larger prohormone that contains 3 sets of RR residues, suggesting that it could yield more than one bioactive peptide; however, no in vivo activity has been demonstrated for any peptide processed from this precursor. Here we demonstrate biological activity for two peptides present within proNPQ/spexin. NPQ/spexin (NWTPQAM-LYLKGAQ-NH2) and NPQ 53-70 (FISDQSRRKDLS-DRPLPE) have differing renal and cardiovascular effects when administered intracerebroventricularly or intravenously into rats. Intracerebroventricular injection of NPQ/spexin produced a 13 +/- 2 mmHg increase in mean arterial pressure, a 38 +/- 8 bpm decrease in heart rate, and a profound decrease in urine flow rate. Intracerebroventricular administration of NPQ 53-70 produced a 26 +/- 9 bpm decrease in heart rate with no change in mean arterial pressure, and a marked increase in urine flow rate. Intraventricular NPQ/spexin and NPQ 53-70 also produced antinociceptive activity in the warm water tail withdrawal assay in mice (ED50 < 30 and 10 nmol for NPQ/spexin and NPQ 53-70, respectively). We conclude that newly identified peptides derived from the NPQ/spexin precursor contribute to CNS-mediated control of arterial blood pressure and salt and water balance and modulate nociceptive responses.-Toll, L., Khroyan, T. V., Sonmez, K., Ozawa, A., Lindberg, I., McLaughlin, J. P., Eans, S. O., Shahien, A. A., Kapusta, D. R. Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception. FASEB J. 26, 947-954 (2012). www.fasebj.org	[Toll, Lawrence; McLaughlin, Jay P.; Eans, Shainnel O.] Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA; [Sonmez, Kemal] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Ozawa, Akihiko; Lindberg, Iris] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Toll, Lawrence; Khroyan, Taline V.] SRI Int, Menlo Pk, CA USA; [Shahien, Amir A.; Kapusta, Daniel R.] Louisiana State Univ, Dept Pharmacol & Expt Therapeut, Hlth Sci Ctr, New Orleans, LA USA	Torrey Pines Institute for Molecular Studies, Florida; Oregon Health & Science University; University System of Maryland; University of Maryland Baltimore; SRI International; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Toll, L (corresponding author), Torrey Pines Inst Mol Studies, 11350 SW Village Pkwy, Port St Lucie, FL 34987 USA.	ltoll@tpims.org	Ozawa, Akihiko/U-4426-2019; Sonmez, Kemal/ABF-3992-2020; Lindberg, Iris/Q-3825-2019	Sonmez, Kemal/0000-0002-2816-6438; 	U.S. National Institutes of Health (NIH) [R21-DA016629]; American Heart Association [0855293E]; NIH [P20-RR018766, DA027170]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027170, R21DA016629, R01DA005084] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health (NIH) grant R21-DA016629 to L. T., American Heart Association grant 0855293E and NIH grant P20-RR018766 to D. R. K., and NIH grant DA027170 to I.L.	CAMERON A, 2001, ENZYMES; Cano G, 2000, J AUTONOM NERV SYST, V79, P117, DOI 10.1016/S0165-1838(99)00101-0; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DiBona GF, 2001, ANN NY ACAD SCI, V940, P395; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Kacprzak MM, 2004, J BIOL CHEM, V279, P36788, DOI 10.1074/jbc.M400484200; Kapusta DR, 2005, J PHARMACOL EXP THER, V314, P643, DOI 10.1124/jpet.104.082768; Kapusta DR, 1996, LIFE SCI, V60, pPL15, DOI 10.1016/S0024-3205(96)00593-0; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; McLaughlin JP, 1999, J PHARMACOL EXP THER, V289, P304; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mirabeau O, 2007, GENOME RES, V17, P320, DOI 10.1101/gr.5755407; Mutt V, 1980, BIOCHEM SOC T, V8, P11, DOI 10.1042/bst0080011; PAVCOVICH LA, 1995, NEUROSCI LETT, V196, P185, DOI 10.1016/0304-3940(95)11873-U; Porzionato A, 2010, J HISTOCHEM CYTOCHEM, V58, P825, DOI 10.1369/jhc.2010.956300; Reilley KJ, 2010, AAPS J, V12, P318, DOI 10.1208/s12248-010-9191-3; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Rouzade-Dominguez ML, 2003, EUR J NEUROSCI, V18, P3325, DOI 10.1111/j.1460-9568.2003.03072.x; Rucinski M, 2010, PEPTIDES, V31, P676, DOI 10.1016/j.peptides.2009.12.025; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SMYTH DG, 1989, J NEUROCHEM, V53, P489, DOI 10.1111/j.1471-4159.1989.tb07360.x; Sonmez K, 2007, INT CONF ACOUST SPEE, P377; Sonmez K, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000258; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Sved AF, 2002, PHYSIOL BEHAV, V77, P737, DOI 10.1016/S0031-9384(02)00927-7; VALENTINO RJ, 1994, NEUROSCIENCE, V62, P125, DOI 10.1016/0306-4522(94)90320-4; Valentino RJ, 2000, J COMP NEUROL, V417, P399; VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86; Xu YL, 2007, J COMP NEUROL, V500, P84, DOI 10.1002/cne.21159; YI Z, 1993, J BIOL CHEM, V268, P5615	32	60	67	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					947	954		10.1096/fj.11-192831	http://dx.doi.org/10.1096/fj.11-192831			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038051	Green Published			2022-12-28	WOS:000300485700044
J	Martin, DDO; Ahpin, CY; Heit, RJ; Perinpanayagam, MA; Yap, MC; Veldhoen, RA; Goping, IS; Berthiaume, LG				Martin, Dale D. O.; Ahpin, Chrisselle Y.; Heit, Ryan J.; Perinpanayagam, Maneka A.; Yap, Megan C.; Veldhoen, Richard A.; Goping, Ing Swie; Berthiaume, Luc G.			Tandem reporter assay for myristoylated proteins post-translationally (TRAMPP) identifies novel substrates for post-translational myristoylation: PKC epsilon, a case study	FASEB JOURNAL			English	Article						apoptosis; caspases	KINASE-C-EPSILON; BAX-DEPENDENT APOPTOSIS; N-MYRISTOYLATION; PROTEOLYTIC ACTIVATION; MUTANT HUNTINGTIN; CASPASE CLEAVAGE; RAPID DETECTION; HUMAN GELSOLIN; AMINO-ACIDS; PHOSPHORYLATION	Myristoylation, the addition of a 14-carbon fatty acid to the N-terminal glycine of a protein, is key to protein-membrane and protein-protein interactions. Typically, myristoylation occurs cotranslationally; however, post-translational myristoylation of caspase-cleaved proteins is now emerging as a well-established protein modification and as a novel regulator of apoptosis. To identify additional post-translationally myristoylated proteins, we engineered a plasmid vector encoding for a caspase-cleavable reporter protein named tandem reporter assay for myristoylation of proteins post-translationally (TRAMPP). pTRAMPP consists of tdTomato-DEVD-"test myristoylation sequence"-enhanced green fluorescent protein (EGFP). After induction of apoptosis, the reporter protein is cleaved by caspases, which frees a new N-terminal glycine residue attached to EGFP that can be myristoylated. We used pTRAMPP in appropriately transfected cells to identify 7 post-translationally myristoylated proteins. First, we confirmed the post-translational myristoylation of two previously identified putative substrates, cytoplasmic dynein intermediate chain 2A and PKC epsilon (ctPKC epsilon), and identified 5 more caspase-cleaved potential substrates for myristoylation that include the antiapoptotic regulator of apoptosis, Mcl-1, and the causative agent of Huntington's disease, huntingtin protein. Further investigation revealed that post-translationally myristoylated ctPKC epsilon localized to membranes and increased Erk signaling and degradation of the proapoptotic protein Bim, which prevented a significant loss of mitochondrial potential of 17% over nonmyristoylated ctPKC epsilon in HeLa cells in the presence of apoptotic stimuli. Taken together, these findings suggest a possible antiapoptotic role for post-translationally myristoylated caspase-cleaved ctPKC epsilon. Martin, D. D. O., Ahpin, C. Y., Heit, R. J., Perinpanayagam, M. A., Yap, M. C., Veldhoen, R. A., Goping, I. S., Berthiaume, L. G. Tandem reporter assay for myristoylated proteins post-translationally (TRAMPP) identifies novel substrates for post-translational myristoylation: PKC epsilon, a case study. FASEB J. 26, 13-28 (2012). www.fasebj.org	[Martin, Dale D. O.; Ahpin, Chrisselle Y.; Heit, Ryan J.; Perinpanayagam, Maneka A.; Yap, Megan C.; Berthiaume, Luc G.] Univ Alberta, Dept Cell Biol, Sch Mol & Syst Med, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada; [Veldhoen, Richard A.; Goping, Ing Swie] Univ Alberta, Dept Biochem, Sch Mol & Syst Med, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berthiaume, LG (corresponding author), Univ Alberta, Dept Cell Biol, Sch Mol & Syst Med, Fac Med & Dent, 5-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	luc.berthiaume@ualberta.ca	Veldhoen, Richard/M-8168-2019; Martin, Dale/L-6351-2015	Veldhoen, Richard/0000-0003-4643-2960; Berthiaume, Luc/0000-0003-0926-059X	Alberta Cancer Research Institute (ACRI) [24425]; Canadian Institutes of Health Research; Alberta Heritage Foundation Medical Research	Alberta Cancer Research Institute (ACRI); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation Medical Research(Alberta Heritage Foundation for Medical Research)	This work was supported by an Alberta Cancer Research Institute (ACRI) grant (24425) to L.G.B. D.D.O.M. held a Canada Graduate Scholarships Doctoral Award from the Canadian Institutes of Health Research and a Medical Research Studentship Incentive Award from Alberta Heritage Foundation Medical Research. C.Y.A. and M.A.P. held a Summer Studentship and a Graduate Studentship, respectively, from ACRI.	Ai HW, 2008, NAT METHODS, V5, P401, DOI [10.1038/nmeth.1207, 10.1038/NMETH.1207]; Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; Aslan JE, 2009, TRAFFIC, V10, P1390, DOI 10.1111/j.1600-0854.2009.00951.x; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Bologna G, 2004, PROTEOMICS, V4, P1626, DOI 10.1002/pmic.200300783; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Charron G, 2009, J AM CHEM SOC, V131, P4967, DOI 10.1021/ja810122f; Chen HJ, 2006, GENE DEV, V20, P1933, DOI 10.1101/gad.1411206; Dasgupta S, 2011, BBA-MOL BASIS DIS, V1812, P495, DOI 10.1016/j.bbadis.2011.01.001; Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038; Ducker CE, 2005, MOL CANCER RES, V3, P463, DOI 10.1158/1541-7786.MCR-05-0037; Ehrnhoefer DE, 2011, NEUROSCIENTIST, V17, P475, DOI 10.1177/1073858410390378; Eisenhaber B, 2004, PROTEOMICS, V4, P1614, DOI 10.1002/pmic.200300781; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fryer JD, 2006, NAT NEUROSCI, V9, P1088, DOI 10.1038/nn0906-1088; Garczarczyk D, 2009, CELL SIGNAL, V21, P745, DOI 10.1016/j.cellsig.2009.01.017; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; GUASCH RM, 1993, EXP CELL RES, V207, P136, DOI 10.1006/excr.1993.1172; Hang HC, 2007, J AM CHEM SOC, V129, P2744, DOI 10.1021/ja0685001; Hannoush AN, 2010, NAT CHEM BIOL, V6, P498, DOI [10.1038/NCHEMBIO.388, 10.1038/nchembio.388]; Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KRONEBUSCH PJ, 1987, J CELL SCI, V88, P25; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Lane JD, 2001, J CELL BIOL, V153, P1415, DOI 10.1083/jcb.153.7.1415; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leverrier S, 2002, BIOCHEM J, V368, P905, DOI 10.1042/BJ20021253; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Mahrus S, 2008, CELL, V134, P866, DOI 10.1016/j.cell.2008.08.012; Martin DDO, 2008, FASEB J, V22, P797, DOI 10.1096/fj.07-9198com; Martin DDO, 2011, BIOCHIMIE, V93, P18, DOI 10.1016/j.biochi.2010.10.018; MATHESON AT, 1975, CAN J BIOCHEM CELL B, V53, P1323, DOI 10.1139/o75-179; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sakurai N, 2006, J BIOL CHEM, V281, P14288, DOI 10.1074/jbc.M510338200; Sallese M, 2006, EMBO J, V25, P2663, DOI 10.1038/sj.emboj.7601172; Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749; Selvakumar P, 2006, FEBS LETT, V580, P2021, DOI 10.1016/j.febslet.2006.02.076; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tyas L, 2000, EMBO REP, V1, P266, DOI 10.1093/embo-reports/kvd050; Utsumi T, 2004, EUR J BIOCHEM, V271, P863, DOI 10.1111/j.1432-1033.2004.03991.x; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Vilas GL, 2006, P NATL ACAD SCI USA, V103, P6542, DOI 10.1073/pnas.0600824103; Wellington CL, 2002, J NEUROSCI, V22, P7862; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Wright MM, 2004, BIOCHEM CELL BIOL, V82, P18, DOI 10.1139/o03-092; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Wyllie AH, 1999, BRIT J CANCER, V80, P34; Xu TR, 2009, J CELL BIOCHEM, V106, P633, DOI 10.1002/jcb.22043; Yap MC, 2010, J LIPID RES, V51, P1566, DOI 10.1194/jlr.D002790; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yim H, 2006, J CELL BIOL, V174, P77, DOI 10.1083/jcb.200509141; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	63	18	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					13	28		10.1096/fj.11-182360	http://dx.doi.org/10.1096/fj.11-182360			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965604				2022-12-28	WOS:000299202200004
J	Noujaim, SF; Kaur, K; Milstein, M; Jones, JM; Furspan, P; Jiang, D; Auerbach, DS; Herron, T; Meisler, MH; Jalife, J				Noujaim, Sami F.; Kaur, Kuljeet; Milstein, Michelle; Jones, Julie M.; Furspan, Philip; Jiang, Daniel; Auerbach, David S.; Herron, Todd; Meisler, Miriam H.; Jalife, Jose			A null mutation of the neuronal sodium channel Na(V)1.6 disrupts action potential propagation and excitation-contraction coupling in the mouse heart	FASEB JOURNAL			English	Article						ataxia3; brain-type sodium channels; hyperkalemia; optical mapping	RAT VENTRICULAR MYOCYTES; MOLECULAR-BASIS; SINOATRIAL NODE; SCN8A; BRAIN; REQUIREMENT; ARRHYTHMIAS; MECHANISMS; SUBUNITS; EPILEPSY	Evidence supports the expression of brain-type sodium channels in the heart. Their functional role, however, remains controversial. We used global Na(V)1.6-null mice to test the hypothesis that Na(V)1.6 contributes to the maintenance of propagation in the myocardium and to excitation-contraction (EC) coupling. We demonstrated expression of transcripts encoding full-length Na(V)1.6 in isolated ventricular myocytes and confirmed the striated pattern of Na(V)1.6 fluorescence in myocytes. On the ECG, the PR and QRS intervals were prolonged in the null mice, and the Ca2+ transients were longer in the null cells. Under patch clamping, at holding potential (HP) = -120 mV, the peak I-Na was similar in both phenotypes. However, at HP = -70 mV, the peak I-Na was smaller in the nulls. In optical mapping, at 4 mM [K+](o), 17 null hearts showed slight (7%) reduction of ventricular conduction velocity (CV) compared to 16 wild-type hearts. At 12 mM [K+](o), CV was 25% slower in a subset of 9 null vs. 9 wild-type hearts. These results highlight the importance of neuronal sodium channels in the heart, whereby Na(V)1.6 participates in EC coupling, and represents an intrinsic depolarizing reserve that contributes to excitation.-Noujaim, S. F., Kaur, K., Milstein, M., Jones, J. M., Furspan, P., Jiang, D., Auerbach, D. S., Herron, T., Meisler, M. H., Jalife, J. A null mutation of the neuronal sodium channel Na(V)1.6 disrupts action potential propagation and excitation-contraction coupling in the mouse heart. FASEB J. 26, 63-72 (2012). www.fasebj.org	[Noujaim, Sami F.; Kaur, Kuljeet; Milstein, Michelle; Furspan, Philip; Jiang, Daniel; Auerbach, David S.; Herron, Todd; Jalife, Jose] Univ Michigan, Ctr Arrhythmia Res, Ann Arbor, MI 48108 USA; [Jones, Julie M.; Meisler, Miriam H.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48108 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Jalife, J (corresponding author), Univ Michigan, Ctr Arrhythmia Res, 5025 Venture Dr, Ann Arbor, MI 48108 USA.	jjalife@umich.edu	Auerbach, David/AAA-5466-2020; Jalife, Jose/L-4833-2015; Kaur, Kuljeet/R-4564-2017; Jalife, Jose/AAJ-9156-2021	Auerbach, David/0000-0001-9198-3847; Jalife, Jose/0000-0003-0080-3500; Kaur, Kuljeet/0000-0002-8075-5678; Jalife, Jose/0000-0003-0080-3500; Furspan, Philip/0000-0001-9306-3403; Jiang, Daniel/0000-0001-5021-8225	U.S. National Heart, Blood, and Lung Institute [P01-HL039707, P01-HL087226, K99-HL105574]; Leducq Foundation; National Institute of Neurological Disorders and Stroke [R01-NS34509]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL105574, P01HL087226, P01HL039707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509] Funding Source: NIH RePORTER	U.S. National Heart, Blood, and Lung Institute; Leducq Foundation(Leducq Foundation); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by U.S. National Heart, Blood, and Lung Institute grants P01-HL039707 and P01-HL087226 (J.J.) and K99-HL105574 (S.F.N.), the Leducq Foundation (J.J.), and National Institute of Neurological Disorders and Stroke grant R01-NS34509 (M. M.). The authors thank Dr. Nidhi Talwar (Center for Statistical Consultation and Research, University of Michigan).	Brette F, 2006, CIRC RES, V98, P667, DOI 10.1161/01.RES.0000209963.02720.70; Brette F, 2006, BIOCHEM BIOPH RES CO, V348, P1163, DOI 10.1016/j.bbrc.2006.07.189; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; Catterall WA, 2008, J NEUROSCI, V28, P11768, DOI 10.1523/JNEUROSCI.3901-08.2008; Cerrone M, 2007, CIRC RES, V101, P1039, DOI 10.1161/CIRCRESAHA.107.148064; Chen Y, 2008, MOL CELL NEUROSCI, V38, P607, DOI 10.1016/j.mcn.2008.05.009; Christidis D, 2006, SEIZURE-EUR J EPILEP, V15, P64, DOI 10.1016/j.seizure.2005.10.002; Cote PD, 2005, J NEUROSCI, V25, P5046, DOI 10.1523/JNEUROSCI.4692-04.2005; De Repentigny Y, 2001, HUM MOL GENET, V10, P1819, DOI 10.1093/hmg/10.17.1819; Du Y, 2007, PFLUG ARCH EUR J PHY, V454, P451, DOI 10.1007/s00424-007-0216-4; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Haufe V, 2007, J MOL CELL CARDIOL, V42, P469, DOI 10.1016/j.yjmcc.2006.12.005; Haufe V, 2005, CARDIOVASC RES, V65, P117, DOI 10.1016/j.cardiores.2004.08.017; HEINEMANN SH, 1992, PFLUG ARCH EUR J PHY, V422, P90, DOI 10.1007/BF00381519; Kleber AG, 2004, PHYSIOL REV, V84, P431, DOI 10.1152/physrev.00025.2003; Lopez-Santiago Luis F, 2007, J Mol Cell Cardiol, V43, P636, DOI 10.1016/j.yjmcc.2007.07.062; Maier SKG, 2004, CIRCULATION, V109, P1421, DOI 10.1161/01.CIR.0000121421.61896.24; Maier SKG, 2003, P NATL ACAD SCI USA, V100, P3507, DOI 10.1073/pnas.2627986100; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; Meisler MH, 2005, J CLIN INVEST, V115, P2010, DOI 10.1172/JCI25466; Meisler MH, 2004, GENETICA, V122, P37, DOI 10.1007/s10709-004-1441-9; Meisler MH, 2010, J PHYSIOL-LONDON, V588, P1841, DOI 10.1113/jphysiol.2010.188482; Morley GE, 2000, J CARDIOVASC ELECTR, V11, P375, DOI 10.1111/j.1540-8167.2000.tb01811.x; Morley GE, 1999, J CARDIOVASC ELECTR, V10, P1361, DOI 10.1111/j.1540-8167.1999.tb00192.x; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Noujaim SF, 2007, J PHYSIOL-LONDON, V578, P315, DOI 10.1113/jphysiol.2006.121475; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Priori SG, 2004, ANN NY ACAD SCI, V1015, P96, DOI 10.1196/annals.1302.008; Sauer AJ, 2007, J AM COLL CARDIOL, V49, P329, DOI 10.1016/j.jacc.2006.08.057; Sharkey LM, 2009, J NEUROSCI, V29, P2733, DOI 10.1523/JNEUROSCI.6026-08.2009; Song LS, 2006, P NATL ACAD SCI USA, V103, P4305, DOI 10.1073/pnas.0509324103; Torres NS, 2010, J PHYSIOL-LONDON, V588, P4249, DOI 10.1113/jphysiol.2010.194688; Trudeau MM, 2006, J MED GENET, V43, P527, DOI 10.1136/jmg.2005.035667; Vaidya D, 1999, CIRC RES, V85, P174, DOI 10.1161/01.RES.85.2.174; Vaitkevicius R, 2009, HEART RHYTHM, V6, P221, DOI 10.1016/j.hrthm.2008.10.027; YU FH, 2004, SCI STKE	37	47	49	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					63	72		10.1096/fj.10-179770	http://dx.doi.org/10.1096/fj.10-179770			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21948246	Green Published, Green Submitted			2022-12-28	WOS:000299202200008
J	Alkelai, A; Lupoli, S; Greenbaum, L; Giegling, I; Kohn, Y; Sarner-Kanyas, K; Ben-Asher, E; Lancet, D; Rujescu, D; Macciardi, F; Lerer, B				Alkelai, Anna; Lupoli, Sara; Greenbaum, Lior; Giegling, Ina; Kohn, Yoav; Sarner-Kanyas, Kyra; Ben-Asher, Edna; Lancet, Doron; Rujescu, Dan; Macciardi, Fabio; Lerer, Bernard			Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample	FASEB JOURNAL			English	Article						GWAS; LRRFIP1; TDT; association	GENOME-WIDE ASSOCIATION; DIAGNOSTIC CRITERIA; CHROMOSOME 6Q23; COMMON VARIANTS; FLIP-FLOP; GENE; AHI1; LINKAGE; EXPRESSION; CANDIDATE	While the use of population-based samples is a common strategy in genome-wide association studies (GWASs), family-based samples have considerable advantages, such as robustness against population stratification and false-positive associations, better quality control, and the possibility to check for both linkage and association. In a genome-wide linkage study of schizophrenia in Arab-Israeli families with multiple affected individuals, we previously reported significant evidence for a susceptibility locus at chromosome 6q23.2-q24.1 and suggestive evidence at chromosomes 10q22.3-26.3, 2q36.1-37.3 and 7p21.1-22.3. To identify schizophrenia susceptibility genes, we applied a family-based GWAS strategy in an enlarged, ethnically homogeneous, Arab-Israeli family sample. We performed genome-wide single nucleotide polymorphism (SNP) genotyping and single SNP transmission disequilibrium test association analysis and found genome-wide significant association (best value of P=1.22x10-(11)) for 8 SNPs within or near highly reasonable functional candidate genes for schizophrenia. Of particular interest are a group of SNPs within and flanking the transcriptional factor LRRFIP1 gene. To determine replicability of the significant associations beyond the Arab-Israeli population, we studied the association of the significant SNPs in a German case-control validation sample and found replication of associations near the UGT1 subfamily and EFHD1 genes. Applying an exploratory homozygosity mapping approach as a complementary strategy to identify schizophrenia susceptibility genes in our Arab Israeli sample, we identified 8 putative disease loci. Overall, this GWAS, which emphasizes the important contribution of family based studies, identifies promising candidate genes for schizophrenia.-Alkelai, A., Lupoli, S., Greenbaum, L., Giegling, I., Kohn, Y., Sarner-Kanyas, K., Ben-Asher, E., Lancet, D., Rujescu, D., Macciardi, F., Lerer, B. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J. 25, 4011-4023 (2011). www.fasebj.org	[Alkelai, Anna; Greenbaum, Lior; Kohn, Yoav; Sarner-Kanyas, Kyra; Lerer, Bernard] Hadassah Hebrew Univ, Med Ctr, Dept Psychiat, Biol Psychiat Lab, IL-91120 Jerusalem, Israel; [Lupoli, Sara] Ist Sci San Raffaele, Inst Expt Neurol INSPE, I-20132 Milan, Italy; [Lupoli, Sara; Macciardi, Fabio] Univ Milan, Dept Med Surg & Dent, Milan, Italy; [Giegling, Ina; Rujescu, Dan] Univ Munich, Div Mol & Clin Neurobiol, Munich, Germany; [Giegling, Ina; Rujescu, Dan] Univ Munich, Dept Psychiat, D-8000 Munich, Germany; [Ben-Asher, Edna; Lancet, Doron] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; [Macciardi, Fabio] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA	Hebrew University of Jerusalem; Hadassah University Medical Center; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Munich; University of Munich; Weizmann Institute of Science; University of California System; University of California Irvine	Lerer, B (corresponding author), Hadassah Hebrew Univ, Med Ctr, Dept Psychiat, Biol Psychiat Lab, IL-91120 Jerusalem, Israel.	lerer@cc.huji.ac.il	Macciardi, Fabio/N-3768-2014; Giegling, Ina/ABA-3677-2021; Rujescu, Dan/GRS-3875-2022	Macciardi, Fabio/0000-0003-0537-4266; 	Israel Science Foundation (Israel Academy of Sciences) [348/09]; EU [FP7-ICT-2007-216088]; Crown Genome Center	Israel Science Foundation (Israel Academy of Sciences)(Israel Science Foundation); EU(European Commission); Crown Genome Center	This work was supported by the Israel Science Foundation (Israel Academy of Sciences, grant 348/09), the 7th EU project POCEMON [FP7-ICT-2007-216088], and the The Crown Genome Center at the Weizmann Institute of Science. The authors thank Dr. Adnan Hamdan for assistance in recruitment of the samples.	Alkelai A, 2009, AM J MED GENET B, V150B, P914, DOI 10.1002/ajmg.b.30918; Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; Alvarez Retuerto AI, 2008, HUM MOL GENET, V17, P3887, DOI 10.1093/hmg/ddn291; Amann-Zalcenstein D, 2006, EUR J HUM GENET, V14, P1111, DOI 10.1038/sj.ejhg.5201675; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BARON M, 1994, PSYCHIATR GENET, V4, P43, DOI 10.1097/00041444-199421000-00007; Benyamin B, 2009, PHARMACOGENOMICS, V10, P181, DOI 10.2217/14622416.10.2.181; Benzel I, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-31; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Carroll LS, 2009, GENOME MED, V1, DOI 10.1186/gm102; Cohen-Woods S, 2009, ACTA PSYCHIAT SCAND, V120, P355, DOI 10.1111/j.1600-0447.2009.01465.x; de Leon J, 2003, INT J NEUROPSYCHOPH, V6, P57, DOI 10.1017/S1461145703003249; Dixon-Salazar T, 2004, AM J HUM GENET, V75, P979, DOI 10.1086/425985; Duan JB, 2010, BRAIN RES BULL, V83, P93, DOI 10.1016/j.brainresbull.2010.04.009; Falk RE, 2007, AM J MED GENET C, V145C, P357, DOI 10.1002/ajmg.c.30153; Fan JB, 2006, METHOD ENZYMOL, V410, P57, DOI 10.1016/S0076-6879(06)10003-8; Geschwind DH, 2007, CURR OPIN NEUROBIOL, V17, P103, DOI 10.1016/j.conb.2007.01.009; Gonzalez N, 2008, CURR OPIN ENDOCRINOL, V15, P58, DOI 10.1097/MED.0b013e3282f3709b; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Ingason A, 2007, EUR J HUM GENET, V15, P988, DOI 10.1038/sj.ejhg.5201848; Ingason A, 2010, HUM MOL GENET, V19, P1379, DOI 10.1093/hmg/ddq009; Jaber L, 2000, CLIN GENET, V58, P106, DOI 10.1034/j.1399-0004.2000.580203.x; JABER L, 1994, ARCH PEDIAT ADOL MED, V148, P412, DOI 10.1001/archpedi.1994.02170040078013; Kirov G, 2009, MOL PSYCHIATR, V14, P796, DOI 10.1038/mp.2008.33; Klei L, 2005, HUM GENET, V117, P349, DOI 10.1007/s00439-005-1320-1; Knight HM, 2008, EUR J HUM GENET, V16, P750, DOI 10.1038/ejhg.2008.11; Kohn Y, 2005, MOL PSYCHIATR, V10, P1062, DOI 10.1038/sj.mp.4001738; Laird NM, 2009, STAT SCI, V24, P388, DOI 10.1214/08-STS280; Laird NM, 2006, NAT REV GENET, V7, P385, DOI 10.1038/nrg1839; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Lencz T, 2007, P NATL ACAD SCI USA, V104, P19942, DOI 10.1073/pnas.0710021104; Lerer B, 2003, MOL PSYCHIATR, V8, P488, DOI 10.1038/sj.mp.4001322; Levi A, 2005, EUR J HUM GENET, V13, P763, DOI 10.1038/sj.ejhg.5201406; Lieberman JA, 2006, J CLIN PSYCHIAT, V67, P983, DOI 10.4088/JCP.0806e07; Lim C, 2009, ANN ACAD MED SINGAP, V38, P402; Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133; Mah S, 2006, MOL PSYCHIATR, V11, P471, DOI 10.1038/sj.mp.4001785; Morar B, 2007, AM J MED GENET B, V144B, P318, DOI 10.1002/ajmg.b.30451; Morrow EM, 2008, SCIENCE, V321, P218, DOI 10.1126/science.1157657; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; Owen MJ, 2010, ARCH GEN PSYCHIAT, V67, P667, DOI 10.1001/archgenpsychiatry.2010.69; Paunio T, 2001, HUM MOL GENET, V10, P3037, DOI 10.1093/hmg/10.26.3037; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rapoport JL, 2005, MOL PSYCHIATR, V10, P434, DOI 10.1038/sj.mp.4001642; Rikiyama T, 2003, BBA-GENE STRUCT EXPR, V1629, P15, DOI 10.1016/S0167-4781(03)00156-8; Rivero O., PLOS ONE, V5; Rudan I, 2006, NAT GENET, V38, P1224, DOI 10.1038/ng1106-1224; Schwab SG, 2009, CURR OPIN PSYCHIATR, V22, P147, DOI 10.1097/YCO.0b013e328325a598; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Shifman S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040028; Slonimsky A, 2010, SCHIZOPHR RES, V120, P159, DOI 10.1016/j.schres.2010.03.041; SPITZER REJ, 1977, SCHEDULE AFFECTIVE D; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; Steemers FJ, 2005, PHARMACOGENOMICS, V6, P777, DOI 10.2217/14622416.6.7.777; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; Sullivan PF, 2007, BIOL PSYCHIAT, V61, P1121, DOI 10.1016/j.biopsych.2006.11.010; Suriano AR, 2005, MOL CELL BIOL, V25, P9073, DOI 10.1128/MCB.25.20.9073-9081.2005; Tominaga M, 2002, BIOCHEM BIOPH RES CO, V297, P473, DOI 10.1016/S0006-291X(02)02225-8; Torri F, 2010, FASEB J, V24, P3066, DOI 10.1096/fj.09-152611; van den Oord EJCG, 2008, ARCH GEN PSYCHIAT, V65, P1062, DOI 10.1001/archpsyc.65.9.1062; Van Steen Kristel, 2005, Hum Genomics, V2, P67; Vardi-Saliternik R, 2002, ANN HUM BIOL, V29, P422, DOI 10.1080/03014460110100928; Wijsman EM, 2003, MOL PSYCHIATR, V8, P695, DOI 10.1038/sj.mp.4001356; Wong AHC, 2003, NEUROSCI BIOBEHAV R, V27, P269, DOI 10.1016/S0149-7634(03)00035-6; Woods BT, 1998, AM J PSYCHIAT, V155, P1661, DOI 10.1176/ajp.155.12.1661; Wray NR, 2010, SCHIZOPHRENIA BULL, V36, P14, DOI 10.1093/schbul/sbp137; Yamada K, 2002, NEUROSCI LETT, V330, P163, DOI 10.1016/S0304-3940(02)00771-1; Zaykin DV, 2008, AM J HUM GENET, V82, P794, DOI 10.1016/j.ajhg.2008.02.001; Zlotogora J, 2010, HUM GENET, V128, P473, DOI 10.1007/s00439-010-0890-8; Zlotogora J, 2009, ISR MED ASSOC J, V11, P373	76	22	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					4011	4023		10.1096/fj.11-184937	http://dx.doi.org/10.1096/fj.11-184937			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21795503				2022-12-28	WOS:000296723100025
J	Barbieri, SS; Amadio, P; Gianellini, S; Zacchi, E; Weksler, BB; Tremoli, E				Barbieri, Silvia S.; Amadio, Patrizia; Gianellini, Sara; Zacchi, Elena; Weksler, Babette B.; Tremoli, Elena			Tobacco smoke regulates the expression and activity of microsomal prostaglandin E synthase-1: role of prostacyclin and NADPH-oxidase	FASEB JOURNAL			English	Article						prostanoids; reactive oxygen species; endothelial cells; signal transduction	SMOOTH-MUSCLE-CELLS; CIGARETTE-SMOKE; ENDOTHELIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; SUPEROXIDE GENERATION; VASCULAR ENDOTHELIUM; INTERLEUKIN-1-BETA; ATHEROSCLEROSIS; ACTIVATION; DISEASE	Tobacco smoke (TS) interacts with interleukin-1 beta (IL-1 beta) to modulate generation of reactive oxygen species (ROS) and expression of cyclooxygenase-2. We explored molecular mechanisms by which TS/IL-1 beta alters expression and activity of microsomal-prostaglandin E synthase-1 (mPGES-1) and of prostacyclin synthase (PGIS) in mouse cardiac endothelial cells. TS (EC(50) similar to 5 puffs/L) interacting with IL-1 beta (2 mu g/L) up-regulates PGE(2) production and mPGES-1 expression, reaching a plateau at 4-6 h, but down-regulates prostacyclin (PGI(2)) release by increasing IL-1 beta-mediated PGIS tyrosine nitration. Inhibition of NADPH-oxidase, achieved pharmacologically and/or by silencing its catalytic subunit p47phox, or exogenous PGI(2) (carbaprostacyclin; IC(50) similar to 5 mu M) prevents production of both ROS and PGE(2), and negatively modulates mPGES-1 expression induced by TS/IL-1 beta. Moreover, inhibiting PGI(2), either using PGIS siRNA and/or CAY10441 (EC(50) similar to 20 nM), a PGI(2) receptor antagonist, increases NADPH-oxidase activation, mPGES-1 synthesis, and PGE(2) production. Finally, lower PGI(2) levels associated with higher PGIS tyrosine nitration, p47phox translocation to the membrane (an index of activation of NADPH-oxidase), and mPGES-1 expression and activity were detected in cardiovascular tissues of ApoE(-/-) mice exposed to cigarette smoke compared to control mice. In conclusion, cigarette smoke in association with cytokines alters the balance between PGI(2)/PGE(2), reducing PGI(2) production and increasing synthesis and activity of mPGES-1 via NADPH-oxidase activation, predisposing to development of pathological conditions.-Barbieri, S. S., Amadio, P., Gianellini, S., Zacchi, E., Weksler, B. B., Tremoli, E. Tobacco smoke regulates the expression and activity of microsomal prostaglandin E synthase-1: role of prostacyclin and NADPH-oxidase. FASEB J. 25, 3731-3740 (2011). www.fasebj.org	[Barbieri, Silvia S.; Tremoli, Elena] IRCCS, Ctr Cardiol Monzino, I-20138 Milan, Italy; [Amadio, Patrizia; Gianellini, Sara; Zacchi, Elena; Tremoli, Elena] Univ Milan, Dept Pharmacol Sci, Milan, Italy; [Weksler, Babette B.] Cornell Univ, Div Hematol Med Oncol, Weill Med Coll, New York, NY 10021 USA	IRCCS Centro Cardiologico Monzino; University of Milan; Cornell University	Barbieri, SS (corresponding author), IRCCS, Ctr Cardiol Monzino, Via Parea 4, I-20138 Milan, Italy.	silviabarbieri@yahoo.com	Barbieri, Silvia Stella/K-2130-2018; Amadio, Patrizia/K-3937-2018; TREMOLI, ELENA/I-8126-2018	Barbieri, Silvia Stella/0000-0002-7486-2637; Amadio, Patrizia/0000-0002-7439-2778; TREMOLI, ELENA/0000-0002-0929-6106	Reti [FIRB-2005-RBPR05NWWC]	Reti	The authors are grateful to Dr. A. Ieraci and Dr. D. Baldassarre for useful comments after reading this manuscript. This work was supported by Reti FIRB-2005-RBPR05NWWC.	Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Barbieri SS, 2008, ARTERIOSCL THROM VAS, V28, P732, DOI 10.1161/ATVBAHA.107.159434; Barbieri SS, 2007, FASEB J, V21, P1831, DOI 10.1096/fj.06-7557com; Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Castro P, 2004, EUR J PHARMACOL, V498, P279, DOI 10.1016/j.ejphar.2004.07.047; Chang TC, 2005, J BIOL CHEM, V280, P36567, DOI 10.1074/jbc.M504280200; Chattopadhyay M, 2010, J PHARMACOL EXP THER, V335, P443, DOI 10.1124/jpet.110.171017; Cheng SE, 2010, FREE RADICAL BIO MED, V48, P1410, DOI 10.1016/j.freeradbiomed.2010.02.026; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Chung KF, 2004, NEW ENGL J MED, V351, P1459; Churg A, 2009, AM J RESP CELL MOL, V40, P482, DOI 10.1165/rcmb.2008-0038OC; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1925, DOI 10.1161/01.ATV.0000177814.41505.41; Csiszar A, 2009, FRONT BIOSCI-LANDMRK, V14, P3128, DOI 10.2741/3440; Cyrus T, 2010, ATHEROSCLEROSIS, V208, P376, DOI 10.1016/j.atherosclerosis.2009.08.008; Dworakowski R, 2008, PHARMACOL REP, V60, P21; Ekberg-Jansson A, 2001, RESP MED, V95, P363, DOI 10.1053/rmed.2001.1050; Gross ND, 2005, CLIN CANCER RES, V11, P6087, DOI 10.1158/1078-0432.CCR-05-0733; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977; Lau PP, 2006, ARTERIOSCL THROM VAS, V26, P143, DOI 10.1161/01.ATV.0000193510.19000.10; Lin CC, 2010, FREE RADICAL BIO MED, V48, P240, DOI 10.1016/j.freeradbiomed.2009.10.047; Mahfouz M, 2006, J ENVIRON PATHOL TOX, V25, P585, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i3.30; MONCADA S, 1981, CLIN RES PROC, V17, P687; Muzaffar S, 2004, CIRCULATION, V110, P1140, DOI 10.1161/01.CIR.0000139851.50067.E4; Nana-Sinkam SP, 2007, AM J RESP CRIT CARE, V175, P676, DOI 10.1164/rccm.200605-724OC; Niu XL, 2010, CIRCULATION, V121, P549, DOI 10.1161/CIRCULATIONAHA.109.908319; Oda K, 2007, HUM MOL GENET, V16, P592, DOI 10.1093/hmg/ddl483; Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006; Pauwels NS, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-134; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; REINDERS JH, 1986, ARTERIOSCLEROSIS, V6, P15, DOI 10.1161/01.ATV.6.1.15; Ryder MI, 2002, ORAL MICROBIOL IMMUN, V17, P331, DOI 10.1034/j.1399-302X.2002.170601.x; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Shin VY, 2004, TOXICOL APPL PHARM, V195, P103, DOI 10.1016/j.taap.2003.10.009; UMEKI S, 1994, INT J BIOCHEM, V26, P1003, DOI 10.1016/0020-711X(94)90071-X; Vendrov AE, 2007, ARTERIOSCL THROM VAS, V27, P2714, DOI 10.1161/ATVBAHA.107.152629; Wang M, 2008, J INTERN MED, V263, P500, DOI 10.1111/j.1365-2796.2008.01938.x; Wang M, 2006, P NATL ACAD SCI USA, V103, P14507, DOI 10.1073/pnas.0606586103; Wu KK, 1996, ANNU REV MED, V47, P315; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	43	13	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3731	3740		10.1096/fj.11-181776	http://dx.doi.org/10.1096/fj.11-181776			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21737615				2022-12-28	WOS:000295356400041
J	Candido, ED; Pinto, MFS; Pelegrini, PB; Lima, TB; Silva, ON; Pogue, R; Grossi-de-Sa, MF; Franco, OL				Candido, Elizabete de Souza; Soares Pinto, Michelle Flaviane; Pelegrini, Patricia Barbosa; Lima, Thais Bergamin; Silva, Osmar Nascimento; Pogue, Robert; Grossi-de-Sa, Maria Fatima; Franco, Octavio Luiz			Plant storage proteins with antimicrobial activity: novel insights into plant defense mechanisms	FASEB JOURNAL			English	Review						biotechnological potential; pathogen attack; drug development	SERINE-PROTEASE INHIBITOR; GLYCINE-RICH PROTEINS; LIPID ACYL HYDROLASE; KUNITZ TRYPSIN-INHIBITOR; NAPIN-LIKE POLYPEPTIDE; GENE-EXPRESSION; ANTIFUNGAL PEPTIDE; DISEASE RESISTANCE; PHOSPHOLIPASE A(2); CRYSTAL-STRUCTURE	Storage proteins perform essential roles in plant survival, acting as molecular reserves important for plant growth and maintenance, as well as being involved in defense mechanisms by virtue of their properties as insecticidal and antimicrobial proteins. These proteins accumulate in storage vacuoles inside plant cells, and, in response to determined signals, they may be used by the different plant tissues in response to pathogen attack. To shed some light on these remarkable proteins with dual functions, storage proteins found in germinative tissues, such as seeds and kernels, and in vegetative tissues, such as tubercles and leaves, are extensively discussed here, along with the related mechanisms of protein expression. Among these proteins, we focus on 2S albumins, Kunitz proteinase inhibitors, plant lectins, glycine-rich proteins, vicilins, patatins, tarins, and ocatins. Finally, the potential use of these molecules in development of drugs to combat human and plant pathogens, contributing to the development of new biotechnology-based medications and products for agribusiness, is also presented.-De Souza Candido, E., Pinto, M. F. S., Pelegrini, P. B., Lima, T. B., Silva, O. N., Pogue, R., Grossi-de-Sa, M. F., Franco, O. L. Plant storage proteins with antimicrobial activity: novel insights into plant defense mechanisms. FASEB J. 25, 3290-3305 (2011). www.fasebj.org	[Candido, Elizabete de Souza; Soares Pinto, Michelle Flaviane; Lima, Thais Bergamin; Silva, Osmar Nascimento; Pogue, Robert; Grossi-de-Sa, Maria Fatima; Franco, Octavio Luiz] Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, BR-70790160 Brasilia, DF, Brazil; [Pelegrini, Patricia Barbosa; Grossi-de-Sa, Maria Fatima] Empresa Brasileira Pesquisa Agr Recursos Genet &, Lab Interacao Mol Planta Praga, Brasilia, DF, Brazil; [Silva, Osmar Nascimento; Franco, Octavio Luiz] Univ Fed Juiz de Fora, Programa Posgrad Imunol Genet & Biotecnol, Juiz De Fora, Brazil	Universidade Catolica de Brasilia; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade Federal de Juiz de Fora	Franco, OL (corresponding author), Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Campus Avancado Asa Norte,SGAN 916 Ave W5, BR-70790160 Brasilia, DF, Brazil.	ocfranco@gmail.com	Pogue, Robert/C-3860-2016; Grossi-de-Sa, Maria Fatima/N-7856-2017; Silva, Osmar N./B-3183-2012; Silva, Osmar/M-3270-2019; Franco, Octavio L/T-3020-2017; Cândido, Elizabete/F-3347-2019; Pelegrini, Patrícia/U-2882-2019	Pogue, Robert/0000-0002-8789-3512; Silva, Osmar N./0000-0003-2148-131X; Silva, Osmar/0000-0003-2148-131X; Cândido, Elizabete/0000-0002-3126-029X; GROSSI-DE-SA, MARIA FATIMA/0000-0001-8184-9599; Franco, Octavio/0000-0001-9546-0525	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; Universidade Catolica de Brasilia; Fundacao de Apoio a Pesquisa do Distrito Federal	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Universidade Catolica de Brasilia; Fundacao de Apoio a Pesquisa do Distrito Federal(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Universidade Catolica de Brasilia, and the Fundacao de Apoio a Pesquisa do Distrito Federal.	Agizzio AP, 2003, ARCH BIOCHEM BIOPHYS, V416, P188, DOI 10.1016/S0003-9861(03)00313-8; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Azarkan M, 2006, BBA-PROTEINS PROTEOM, V1764, P1063, DOI 10.1016/j.bbapap.2006.02.014; Banerji S, 2004, MICROBIOL-SGM, V150, P522, DOI 10.1099/mic.0.26957-0; Barciszewski J, 2000, J PROTEIN CHEM, V19, P249, DOI 10.1023/A:1007085627485; Bauw G, 2006, FEBS J, V273, P3569, DOI 10.1111/j.1742-4658.2006.05364.x; BEZERRA IC, 1995, PLANT MOL BIOL, V28, P137, DOI 10.1007/BF00042045; Bolon YT, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-41; BOURNE Y, 1994, J BIOL CHEM, V269, P9429; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Carrillo MGC, 2009, RICE, V2, P67, DOI 10.1007/s12284-009-9024-0; Carvalho AD, 2009, PEPTIDES, V30, P1007, DOI 10.1016/j.peptides.2009.01.018; CHAPIN FS, 1990, ANNU REV ECOL SYST, V21, P423, DOI 10.1146/annurev.ecolsys.21.1.423; Chen AP, 2007, J PLANT RES, V120, P337, DOI 10.1007/s10265-006-0058-8; Costa FT, 2007, CURR MICROBIOL, V55, P162, DOI 10.1007/s00284-007-0131-0; Delrot S, 2001, PLANT NITROGEN, P213; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEWALD DB, 1994, PLANT PHYSIOL, V104, P439, DOI 10.1104/pp.104.2.439; Dhondt S, 2000, PLANT J, V23, P431, DOI 10.1046/j.1365-313x.2000.00802.x; Ee KY, 2009, J AGR FOOD CHEM, V57, P7022, DOI 10.1021/jf900923t; Egorov TA, 2005, PEPTIDES, V26, P2064, DOI 10.1016/j.peptides.2005.03.007; Ezcurra I, 1999, PLANT MOL BIOL, V40, P699, DOI 10.1023/A:1006206124512; Flores T, 2002, PLANT PHYSIOL, V128, P1291, DOI 10.1104/pp.010541; Gomes VM, 1997, J AGR FOOD CHEM, V45, P4110, DOI 10.1021/jf960942g; Gomes VM, 1998, BBA-GEN SUBJECTS, V1379, P207, DOI 10.1016/S0304-4165(97)00100-1; Guani-Guerra E, 2009, ANN ALLERG ASTHMA IM, V103, pA71; Guerriero G, 2009, NEW PHYTOL, V184, P552, DOI 10.1111/j.1469-8137.2009.02977.x; Guimaraes RL, 2001, PHYSIOL PLANTARUM, V111, P182, DOI 10.1034/j.1399-3054.2001.1110208.x; Hansen D, 2007, BIOCHEM BIOPH RES CO, V360, P735, DOI 10.1016/j.bbrc.2007.06.144; HATTORI T, 1991, PLANT CELL PHYSIOL, V32, P79; Hernandez-Nistal J, 2009, PLANT PHYSIOL BIOCH, V47, P181, DOI 10.1016/j.plaphy.2008.11.009; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; Holdsworth MJ, 2008, NEW PHYTOL, V179, P33, DOI 10.1111/j.1469-8137.2008.02437.x; Jean-Francois F, 2008, BIOPHYS J, V95, P5748, DOI 10.1529/biophysj.108.136655; Jurgens G, 2004, ANNU REV CELL DEV BI, V20, P481, DOI 10.1146/annurev.cellbio.20.082503.103057; Kawagoe Y, 1996, PLANT SCI, V116, P47, DOI 10.1016/0168-9452(96)04366-X; Kim JY, 2009, INT J MOL SCI, V10, P2860, DOI 10.3390/ijms10062860; Kim JY, 2005, BIOCHEM BIOPH RES CO, V330, P921, DOI 10.1016/j.bbrc.2005.03.057; Kim MH, 2006, BIOCHEM BIOPH RES CO, V346, P681, DOI 10.1016/j.bbrc.2006.05.186; Kim YS, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-36; Konarev AV, 2008, PHYTOCHEMISTRY, V69, P2482, DOI 10.1016/j.phytochem.2008.07.001; Kroj T, 2003, DEVELOPMENT, V130, P6065, DOI 10.1242/dev.00814; Kubo S, 2008, INT J PEPT RES THER, V14, P341, DOI 10.1007/s10989-008-9146-z; Lara P, 2003, J BIOL CHEM, V278, P21003, DOI 10.1074/jbc.M210538200; Li GF, 2001, PLANT MOL BIOL, V46, P121, DOI 10.1023/A:1010693703421; Li SS, 2003, PHYTOCHEMISTRY, V63, P249, DOI 10.1016/S0031-9422(03)00116-X; Liu YL, 2005, PLANT PHYSIOL, V139, P1545, DOI 10.1104/pp.105.066837; Lopes JLS, 2009, PHYTOCHEMISTRY, V70, P871, DOI 10.1016/j.phytochem.2009.04.009; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; MACEDO MLR, 1993, COMP BIOCHEM PHYS C, V105, P89, DOI 10.1016/0742-8413(93)90063-Q; Major IT, 2008, PLANT PHYSIOL, V146, P888, DOI 10.1104/pp.107.106229; Mangeon A, 2010, PLANT SIGNAL BEHAV, V5, P99, DOI 10.4161/psb.5.2.10336; Mansfeld J, 2009, BIOTECHNOL LETT, V31, P1373, DOI 10.1007/s10529-009-0034-1; Marcus JP, 1999, PLANT J, V19, P699, DOI 10.1046/j.1365-313x.1999.00569.x; MASON HS, 1992, PLANT PHYSIOL, V98, P859, DOI 10.1104/pp.98.3.859; Migliolo L, 2010, J MOL GRAPH MODEL, V29, P148, DOI 10.1016/j.jmgm.2010.05.006; MIGNERY GA, 1984, NUCLEIC ACIDS RES, V12, P7987, DOI 10.1093/nar/12.21.7987; MIGNERY GA, 1988, GENE, V62, P27, DOI 10.1016/0378-1119(88)90577-X; Monke G, 2004, PLANTA, V219, P158, DOI 10.1007/s00425-004-1206-9; MonteNeshich DC, 1995, PLANT SCI, V112, P149, DOI 10.1016/0168-9452(95)04257-1; Moreno F Javier, 2008, Open Biochem J, V2, P16, DOI 10.2174/1874091X00802010016; Mousavi A, 2005, APPL BIOCHEM BIOTECH, V120, P169, DOI 10.1385/ABAB:120:3:169; Muntz K, 1998, PLANT MOL BIOL, V38, P77, DOI 10.1023/A:1006020208380; Naqvi SMS, 1998, PLANT MOL BIOL, V37, P571, DOI 10.1023/A:1006031316476; Neumann U, 2003, ANN BOT-LONDON, V92, P167, DOI 10.1093/aob/mcg134; Ngai PHK, 2004, J PEPT RES, V64, P202, DOI 10.1111/j.1399-3011.2004.00186.x; Ngai PHK, 2004, PEPTIDES, V25, P171, DOI 10.1016/j.peptides.2003.12.012; Nomata T, 2004, PLANT CELL PHYSIOL, V45, P48, DOI 10.1093/pcp/pch005; Oliveira AS, 2002, PESTIC BIOCHEM PHYS, V72, P122, DOI 10.1006/pest.2001.2591; Park M, 2004, PLANT PHYSIOL, V134, P625, DOI 10.1104/pp.103.030635; Park Y, 2005, J AGR FOOD CHEM, V53, P6491, DOI 10.1021/jf0505123; Pelegrini PB, 2006, BBA-PROTEINS PROTEOM, V1764, P1141, DOI 10.1016/j.bbapap.2006.04.010; Pelegrini PB, 2008, PEPTIDES, V29, P1271, DOI 10.1016/j.peptides.2008.03.013; Perez-de-Luque A, 2009, PEST MANAG SCI, V65, P540, DOI 10.1002/ps.1732; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; Pouvreau L, 2003, J AGR FOOD CHEM, V51, P5001, DOI 10.1021/jf0212486; Reidt W, 2000, PLANT J, V21, P401, DOI 10.1046/j.1365-313x.2000.00686.x; Ribeiro SM, 2011, PEPTIDES, V32, P868, DOI 10.1016/j.peptides.2010.10.011; Ribeiro SFF, 2007, TOXICON, V50, P600, DOI 10.1016/j.toxicon.2007.05.005; Ringli C, 2001, CELL MOL LIFE SCI, V58, P1430, DOI 10.1007/PL00000786; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; Senda K, 1996, PLANT CELL PHYSIOL, V37, P347, DOI 10.1093/oxfordjournals.pcp.a028952; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Shutov AD, 2003, J EXP BOT, V54, P1645, DOI 10.1093/jxb/erg165; SINGH J, 1993, PHYTOCHEMISTRY, V33, P979, DOI 10.1016/0031-9422(93)85007-E; Speranskaya AS, 2006, BIOCHEMISTRY-MOSCOW+, V71, P1176, DOI 10.1134/S0006297906110022; Speransky Anna S., 2007, Biotechnology Journal, V2, P1417, DOI 10.1002/biot.200700022; STRICKLAND JA, 1995, PLANT PHYSIOL, V109, P667, DOI 10.1104/pp.109.2.667; Stupar RM, 2006, GENETICS, V172, P1263, DOI 10.1534/genetics.105.051219; Tonon C, 2001, PLANT PHYSIOL BIOCH, V39, P849, DOI 10.1016/S0981-9428(01)01311-0; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; Vashishta A, 2006, BBA-PROTEINS PROTEOM, V1764, P847, DOI 10.1016/j.bbapap.2006.03.010; Verdier J, 2008, PLANT CELL PHYSIOL, V49, P1263, DOI 10.1093/pcp/pcn116; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; Vincentz M, 1997, PLANT MOL BIOL, V34, P879, DOI 10.1023/A:1005874404706; WALSH TA, 1991, PLANT PHYSIOL, V97, P15, DOI 10.1104/pp.97.1.15; Wang HX, 2003, PEPTIDES, V24, P969, DOI 10.1016/S0196-9781(03)00191-8; Wang X, 2001, BIOCHEM BIOPH RES CO, V282, P1224, DOI 10.1006/bbrc.2001.4716; Wright CS, 1997, CURR OPIN STRUC BIOL, V7, P631, DOI 10.1016/S0959-440X(97)80071-1; Yang XY, 2007, APPL ENVIRON MICROB, V73, P939, DOI 10.1128/AEM.02016-06; Yap KL, 2003, J MOL BIOL, V328, P193, DOI 10.1016/S0022-2836(03)00271-7; YOULE RJ, 1981, AM J BOT, V68, P44, DOI 10.2307/2442990	104	82	86	1	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3290	3305		10.1096/fj.11-184291	http://dx.doi.org/10.1096/fj.11-184291			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746866				2022-12-28	WOS:000295356400002
J	Pergola, C; Rogge, A; Dodt, G; Northoff, H; Weinigel, C; Barz, D; Radmark, O; Sautebin, L; Werz, O				Pergola, Carlo; Rogge, Anja; Dodt, Gabriele; Northoff, Hinnak; Weinigel, Christina; Barz, Dagmar; Radmark, Olof; Sautebin, Lidia; Werz, Oliver			Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes	FASEB JOURNAL			English	Article						sex hormones; inflammation; extracellular signal-regulated kinases; 5-lipoxygenase	BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE; 5-LIPOXYGENASE; ACTIVATION; GENERATION; CALCIUM; MEN; ATHEROSCLEROSIS; INFLAMMATION; STIMULATION	Sex disparities in inflammation have been reported, but the cellular and molecular basis for these discrepancies is unknown. Monocytes are central effector cells in immunity and possess high capacities to produce proinflammatory leukotrienes (LTs). Here, we investigated sex differences in the activation of 5-lipoxygenase (5-LO), the key enzyme in LT biosynthesis, in human peripheral monocytes. In cells from females, 5-LO product formation was 1.8-fold higher than in cells from males, as evaluated by HPLC. When female monocytes were resuspended in plasma from males, 5-LO products were significantly lower than in female plasma. Interestingly, 5 alpha-dihydrotestosterone (5 alpha-DHT, 10 nM) repressed LT synthesis in female cells down to the levels observed in males, while estradiol (100 nM) was without effect, and progesterone (100 nM) caused only a slight inhibition. 5 alpha-DHT (10 nM) caused ERK phosphorylation and inhibition of phospholipase D (PLD), as evaluated by Western blot and measurement of PLD activity via radioenzymatic diacylglyceride (DAG) and nonradioactive choline assays. Accordingly, PLD activity and DAG formation were 1.4- to 1.8-fold lower in male vs. female monocytes connected to increased ERK phosphorylation. Our data indicate that ERK activation by androgens in monocytes represses PLD activity, resulting in impaired 5-LO product formation due to lack of activating DAGs.-Pergola, C., Rogge, A., Dodt, G., Northoff, H., Weinigel, C., Barz, D., Radmark, O., Sautebin, L., Werz, O. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB J. 25, 3377-3387 (2011). www.fasebj.org	[Pergola, Carlo; Rogge, Anja; Werz, Oliver] Univ Jena, Inst Pharm, Dept Pharmaceut & Med Chem, D-07743 Jena, Germany; [Dodt, Gabriele] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany; [Northoff, Hinnak] Univ Tubingen Hosp, Inst Clin & Expt Transfus Med, Tubingen, Germany; [Weinigel, Christina; Barz, Dagmar] Univ Hosp Jena, Inst Transfus Med, Jena, Germany; [Radmark, Olof] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden; [Sautebin, Lidia] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy	Friedrich Schiller University of Jena; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Friedrich Schiller University of Jena; Karolinska Institutet; University of Naples Federico II	Werz, O (corresponding author), Univ Jena, Inst Pharm, Dept Pharmaceut & Med Chem, Philosophenweg 14, D-07743 Jena, Germany.	oliver.werz@uni-jena.de			Deutsche Forschungsgemeinschaft; Carl-Zeiss stipend	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Carl-Zeiss stipend	The authors thank Bianca Jazzar for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft. C.P. received a Carl-Zeiss stipend. The authors declare no conflicts of interest.	Albert D, 2003, BBA-MOL CELL BIOL L, V1631, P85, DOI 10.1016/S1388-1981(02)00359-1; Albert D, 2008, J LEUKOCYTE BIOL, V83, P1019, DOI 10.1189/jlb.0807531; Arain FA, 2009, CIRC J, V73, P1774, DOI 10.1253/circj.CJ-09-0588; Bae YS, 2000, J IMMUNOL, V164, P4089, DOI 10.4049/jimmunol.164.8.4089; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Chiang N, 2006, ARTERIOSCL THROM VAS, V26, pE14, DOI 10.1161/01.ATV.0000196729.98651.bf; Choi BG, 2007, ENDOCRIN METAB CLIN, V36, P365, DOI 10.1016/j.ecl.2007.03.011; Cutolo M, 2005, ARTHRITIS RES THER, V7, pR1124, DOI 10.1186/ar1791; CUTOLO M, 1991, ARTHRITIS RHEUM, V34, P1, DOI 10.1002/art.1780340102; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; English KM, 2000, EUR HEART J, V21, P890, DOI 10.1053/euhj.1999.1873; Esser J, 2010, BIOCHEM J, V425, P265, DOI 10.1042/BJ20090856; Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002-0164; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Goetzl EJ, 2010, FASEB J, V24, P3580, DOI 10.1096/fj.10-160911; Gosselin J, 1997, BLOOD, V89, P2122, DOI 10.1182/blood.V89.6.2122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Horning C, 2005, J BIOL CHEM, V280, P26913, DOI 10.1074/jbc.M500068200; Kanda N, 1997, ARTHRITIS RHEUM-US, V40, P1703, DOI 10.1002/art.1780400921; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; Malkin CJ, 2003, J ENDOCRINOL, V178, P373, DOI 10.1677/joe.0.1780373; MIYAGI M, 1993, J PERIODONTOL, V64, P1075, DOI 10.1902/jop.1993.64.11.1075; Morishita M, 1999, J PERIODONTOL, V70, P757, DOI 10.1902/jop.1999.70.7.757; Murray AJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.122re4; O'Connor MF, 2007, AM J PHYSIOL-REG I, V293, pR145, DOI 10.1152/ajpregu.00752.2006; Osman M, 2003, ARCH DIS CHILD, V88, P587, DOI 10.1136/adc.88.7.587; Paruch S, 2005, FASEB J, V19, P142, DOI 10.1096/fj.05-3881fje; Pergola C, 2008, P NATL ACAD SCI USA, V105, P19881, DOI 10.1073/pnas.0809120105; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Poeckel D, 2009, J BIOL CHEM, V284, P21077, DOI 10.1074/jbc.M109.000901; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; Rosano GMC, 1999, CIRCULATION, V99, P1666, DOI 10.1161/01.CIR.99.13.1666; SONDELL K, 1990, MECH AGEING DEV, V51, P55, DOI 10.1016/0047-6374(90)90161-8; Surette ME, 1996, J LEUKOCYTE BIOL, V59, P709, DOI 10.1002/jlb.59.5.709; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	43	67	67	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3377	3387		10.1096/fj.11-182758	http://dx.doi.org/10.1096/fj.11-182758			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21693622				2022-12-28	WOS:000295356400010
J	Xu, Z; Adrover, M; Pastore, A; Prigent, S; Mouthon, F; Comoy, E; Rezaei, H; Deslys, JP				Xu, Zhou; Adrover, Miquel; Pastore, Annalisa; Prigent, Stephanie; Mouthon, Franck; Comoy, Emmanuel; Rezaei, Human; Deslys, Jean-Philippe			Mechanistic insights into cellular alteration of prion by poly-D-lysine: the role of H2H3 domain	FASEB JOURNAL			English	Article						misfolding; amyloid; PrP conversion	HETERONUCLEAR CORRELATION SPECTRA; SCRAPIE PRION; BRANCHED POLYAMINES; NMR-SPECTROSCOPY; PROTEIN; CELLS; IDENTIFICATION; THERAPEUTICS; AGGREGATION; CHAPERONE	Misfolding of the prion protein (PrP) is the central feature of prion diseases. The conversion of the normal alpha-helical PrP(C) into a pathological beta-enriched PrP(Sc) constitutes an early event in the infectious process. Several hypotheses, involving different regions of the protein, endeavor to delineate the structural mechanism underlying this change of conformation. All current working hypotheses, however, are based on biophysical and modeling studies, the biological relevance of which still needs to be assessed. We have studied the effect of positively charged polymers on the conversion, using polylysine as a model system, and have investigated a possible mechanism of structural stabilization. We have shown that poly-D-lysine removes proteinase K-resistant PrP from prion-infected SN56 neuroblastoma cells without affecting PrP(C). The effect is enantiospecific since the levorotary isomer, poly-L-lysine, has a markedly weaker effect, likely because of its higher susceptibility to degradation. In vitro cross-linking and NMR studies confirm a direct interaction between polylysine and PrP, which mainly maps to the PrP region containing helices 2 and 3 (H2H3). Interaction prevents conformational conversion and protein aggregation. Our results establish a central role of H2H3 in PrP(Sc) amyloidogenesis and replication and provide biological relevance for the pathological misfolding of this domain.-Xu, Z., Adrover, M., Pastore, A., Prigent, S., Mouthon, F., Comoy, E., Rezaei, H., Deslys, J. -P. Mechanistic insights into cellular alteration of prion by poly-D-lysine: the role of H2H3 domain. FASEB J. 25, 3426-3435 (2011). www.fasebj.org	[Pastore, Annalisa; Prigent, Stephanie; Rezaei, Human] INRA, Equipe Biol Physicochim Prions, F-78350 Jouy En Josas, France; [Xu, Zhou; Mouthon, Franck; Comoy, Emmanuel; Deslys, Jean-Philippe] Commiss Energie Atom, Serv Etud Prions & Infect Atyp, Inst Emerging Dis & Innovat Therapies, F-92265 Fontenay Aux Roses, France; [Adrover, Miquel] Univ Illes Balears, Dept Quim, Inst Univ Invest Ciencies Salut, E-07071 Palma de Mallorca, Spain; [Pastore, Annalisa] Natl Inst Med Res, Med Res Council, London NW7 1AA, England	INRAE; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Universitat de les Illes Balears; MRC National Institute for Medical Research; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Rezaei, H (corresponding author), INRA, Equipe Biol Physicochim Prions, F-78350 Jouy En Josas, France.	human.rezaei@jouy.inra.fr; jpdeslys@cea.fr	Xu, Zhou/F-8513-2011	Xu, Zhou/0000-0001-9468-1406; Adrover, Miquel/0000-0002-4211-9013	MRC [MC_U117584256, MC_U117533887] Funding Source: UKRI; Medical Research Council [MC_U117584256, MC_U117533887] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adrover M, 2010, J BIOL CHEM, V285, P21004, DOI 10.1074/jbc.M110.111815; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chakroun N, 2010, FASEB J, V24, P3222, DOI 10.1096/fj.09-153924; Cobb NJ, 2007, P NATL ACAD SCI USA, V104, P18946, DOI 10.1073/pnas.0706522104; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Eghiaian F, 2007, P NATL ACAD SCI USA, V104, P7414, DOI 10.1073/pnas.0607745104; Goddard D., 2008, SPARKY 3; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kocisko DA, 2006, ANTIMICROB AGENTS CH, V50, P1034, DOI 10.1128/AAC.50.3.1034-1044.2006; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Li AM, 2007, EMBO J, V26, P548, DOI 10.1038/sj.emboj.7601507; Magalhaes AC, 2005, J NEUROSCI, V25, P5207, DOI 10.1523/JNEUROSCI.0653-05.2005; Marc D, 2007, CELL MOL LIFE SCI, V64, P815, DOI 10.1007/s00018-007-6370-1; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Nguyen KV, 2002, BIOCHEM BIOPH RES CO, V291, P764, DOI 10.1006/bbrc.2002.6514; Nicoll AJ, 2010, P NATL ACAD SCI USA, V107, P17610, DOI 10.1073/pnas.1009062107; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rezaei H, 2000, EUR J BIOCHEM, V267, P2833, DOI 10.1046/j.1432-1033.2000.01347.x; Schanda P, 2005, J BIOMOL NMR, V33, P199, DOI 10.1007/s10858-005-4425-x; Schatzl HM, 1997, J VIROL, V71, P8821; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/awl150; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Vogtherr M, 2003, J MED CHEM, V46, P3563, DOI 10.1021/jm034093h	41	10	10	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3426	3435		10.1096/fj.11-187534	http://dx.doi.org/10.1096/fj.11-187534			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21697549				2022-12-28	WOS:000295356400014
J	Harris, F; Dennison, SR; Phoenix, DA				Harris, Frederick; Dennison, Sarah R.; Phoenix, David A.			Aberrant action of amyloidogenic host defense peptides: a new paradigm to investigate neurodegenerative disorders?	FASEB JOURNAL			English	Article						Alzheimer's disease; membrane interaction	ALZHEIMERS-DISEASE; ANTIMICROBIAL PEPTIDES; MEMBRANE INTERACTIONS; BETA PEPTIDE; ION CHANNELS; DOMAIN-V; PROTEIN; BINDING; AGGREGATION; BACTERIAL	Host defense peptides (HDPs) are components of the innate immune system with activity against a broad range of microbes. In some cases, it appears that this activity is mediated by the ability of these peptides to permeabilize microbial membranes via the formation of amyloid associated structures. Recent evidence suggests that the naturally occurring function of the A beta 40 and A beta 42 peptides, which are causative agents of Alzheimer's disease, may be to serve as amyloidogenic HDPs. Here, it is hypothesized that the neurotoxicity of these peptides is related to aberrant use of their amyloid-mediated antimicrobial mechanisms, which provides the as yet unexplored paradigm of a relationship among HDPs, neurodegenerative disorders, and other conditions that could contribute to their understanding and remediation.-Harris, F., Dennison, S. R., Phoenix, D. A. Aberrant action of amyloidogenic host defense peptides: a new paradigm to investigate neurodegenerative disorders? FASEB J. 26, 1776-1781 (2012). www.fasebj.org	[Phoenix, David A.] Univ Cent Lancashire, Vice Chancellors Off, Preston PR1 2HE, Lancs, England; [Harris, Frederick] Univ Cent Lancashire, Sch Forens & Invest Sci, Preston PR1 2HE, Lancs, England; [Dennison, Sarah R.] Univ Cent Lancashire, Sch Pharm & Biomed Sci, Preston PR1 2HE, Lancs, England	University of Central Lancashire; University of Central Lancashire; University of Central Lancashire	Phoenix, DA (corresponding author), Univ Cent Lancashire, Vice Chancellors Off, Preston PR1 2HE, Lancs, England.	daphoenix@uclan.ac.uk	Phoenix, David A/F-8719-2011	Phoenix, David A/0000-0003-4865-6132				Araki-Sasaki K, 2009, CORNEA, V28, pS80, DOI 10.1097/ICO.0b013e3181aea04d; Arispe N, 2007, BBA-BIOMEMBRANES, V1768, P1952, DOI 10.1016/j.bbamem.2007.03.014; Auvynet C, 2008, FEBS J, V275, P4134, DOI 10.1111/j.1742-4658.2008.06554.x; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Bechinger B, 2011, J PEPT SCI, V17, P306, DOI 10.1002/psc.1343; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5414, DOI 10.1046/j.1432-1033.2002.03225.x; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Brorsson AC, 2010, FRONT BIOSCI-LANDMRK, V15, P373; Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09; Butterfield SM, 2010, ANGEW CHEM INT EDIT, V49, P5628, DOI 10.1002/anie.200906670; Chauhan A, 2000, NEUROCHEM RES, V25, P423, DOI 10.1023/A:1007509608440; Dennison SR, 2005, BIOPHYS J, V88, P3008, DOI 10.1529/biophysj.104.049957; Dennison SR, 2005, PROTEIN PEPTIDE LETT, V12, P31, DOI 10.2174/0929866053406084; Diaz JC, 2009, P NATL ACAD SCI USA, V106, P3348, DOI 10.1073/pnas.0813355106; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Eckert GP, 2010, CURR PROTEIN PEPT SC, V11, P319, DOI 10.2174/138920310791330668; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Gossler-Schofberger R, 2009, FEBS J, V276, P5849, DOI 10.1111/j.1742-4658.2009.07266.x; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009; Harris F, 2013, MED RES REV, V33, P190, DOI 10.1002/med.20252; Harris F, 2009, CURR PROTEIN PEPT SC, V10, P585, DOI 10.2174/138920309789630589; Jang H, 2008, BIOPHYS J, V95, P4631, DOI 10.1529/biophysj.108.134551; Jang H, 2011, BIOPHYS J, V100, P1775, DOI 10.1016/j.bpj.2011.01.072; Kagan BL, 2010, ADV EXP MED BIOL, V677, P150; Kawahara Masahiro, 2011, Int J Alzheimers Dis, V2011, P304583, DOI 10.4061/2011/304583; Kawahara M, 2010, CURR PHARM DESIGN, V16, P2779, DOI 10.2174/138161210793176545; Kinnunen, 2009, OPEN BIOL J, V2, P163; Kobayashi N, 2008, BIOCONTROL SCI, V13, P49, DOI 10.4265/bio.13.49; Lashuel HA, 2006, Q REV BIOPHYS, V39, P167, DOI 10.1017/S0033583506004422; Lee SJ, 2011, NEUROSCI RES, V70, P339, DOI 10.1016/j.neures.2011.05.008; Ludolph AC, 2009, EUR J NEUROL, V16, P297, DOI 10.1111/j.1468-1331.2008.02513.x; Mahalka AK, 2009, BBA-BIOMEMBRANES, V1788, P1600, DOI 10.1016/j.bbamem.2009.04.012; Moir R. D., 2011, SOC NEUR ABSTR VIEW, V41; Nair RR, 2011, AFR J BIOTECHNOL, V10, P2366; Nicolas P, 2009, BBA-BIOMEMBRANES, V1788, P1537, DOI 10.1016/j.bbamem.2008.09.006; Nicolson GL, 2008, LABMEDICINE, V39, P291, DOI 10.1309/96M3BWYP42L11BFU; Nilsson MR, 2003, BIOCHEMISTRY-US, V42, P375, DOI 10.1021/bi0204746; Papaleo E, 2011, CURR COMPUT-AID DRUG, V7, P23, DOI 10.2174/157340911793743574; Pasupuleti M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007358; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Sanchez-Portocarrero J, 2000, DIAGN MICR INFEC DIS, V37, P169, DOI 10.1016/S0732-8893(00)00140-1; Shanmugam G, 2011, BIOPHYS CHEM, V155, P104, DOI 10.1016/j.bpc.2011.03.005; Smith DG, 2010, J ALZHEIMERS DIS, V19, P1387, DOI 10.3233/JAD-2010-1334; Sood R, 2008, BBA-BIOMEMBRANES, V1778, P983, DOI 10.1016/j.bbamem.2007.11.016; Sood R, 2007, J FLUORESC, V17, P223, DOI 10.1007/S10895-007-0161-9; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Starakis Ioannis, 2011, Cardiovascular & Hematological Disorders - Drug Targets, V11, P40; Steiner JA, 2011, CELL DEATH DIFFER, V18, P1425, DOI 10.1038/cdd.2011.53; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Takahashi T, 2010, J MOL CELL BIOL, V2, P180, DOI 10.1093/jmcb/mjq005; Torrent M, 2010, BIOMACROMOLECULES, V11, P1983, DOI 10.1021/bm100334u; Wang LG, 2010, NEUROSCI LETT, V481, P164, DOI 10.1016/j.neulet.2010.06.079; Welzel AT, 2011, IRISH J MED SCI, V180, P15, DOI 10.1007/s11845-010-0606-z; Wong PT, 2009, J MOL BIOL, V386, P81, DOI 10.1016/j.jmb.2008.11.060; Yoshiike Y, 2007, NEUROMOL MED, V9, P270, DOI 10.1007/s12017-007-0003-6; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhao H, 2006, BBA-BIOMEMBRANES, V1758, P1461, DOI 10.1016/j.bbamem.2006.03.037; Zhao HX, 2005, BIOCHEMISTRY-US, V44, P2857, DOI 10.1021/bi048510j; Zhao HX, 2002, J BIOL CHEM, V277, P25170, DOI 10.1074/jbc.M203186200	61	26	26	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1776	1781		10.1096/fj.11-199208	http://dx.doi.org/10.1096/fj.11-199208			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22308196				2022-12-28	WOS:000303680800005
J	Shamri, R; Melo, RCN; Young, KM; Bivas-Benita, M; Xenakis, JJ; Spencer, LA; Weller, PF				Shamri, Revital; Melo, Rossana C. N.; Young, Kristen M.; Bivas-Benita, Maytal; Xenakis, Jason J.; Spencer, Lisa A.; Weller, Peter F.			CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules	FASEB JOURNAL			English	Article						piecemeal degranulation; airway inflammation; cationic proteins; granulocytes	RESPIRATORY SYNCYTIAL VIRUS; MAJOR BASIC-PROTEIN; CATIONIC PROTEIN; PULMONARY INFLAMMATION; AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; DEGRANULATION; MICE; RELEASE; ACTIVATION	Rapid secretion of eosinophil-associated RNases (EARs), such as the human eosinophilic cationic protein (ECP), from intracellular granules is central to the role of eosinophils in allergic diseases and host immunity. Our knowledge regarding allergic inflammation has advanced based on mouse experimental models. However, unlike human eosinophils, capacities of mouse eosinophils to secrete granule proteins have been controversial. To study mechanisms of mouse eosinophil secretion and EAR release, we combined an RNase assay of mouse EARs with ultrastructural studies. In vitro, mouse eosinophils stimulated with the chemokine eotaxin-1 (CCL11) secreted enzymatically active EARs (EC50 5 nM) by piecemeal degranulation. In vivo, in a mouse model of allergic airway inflammation, increased airway eosinophil infiltration (24-fold) correlated with secretion of active RNases (3-fold). Moreover, we found that eosinophilic inflammation in mice can involve eosinophil cytolysis and release of cell-free granules. Cell-free mouse eosinophil granules expressed functional CCR3 receptors and secreted their granule proteins, including EAR and eosinophil peroxidase in response to CCL11. Collectively, these data demonstrate chemokine-dependent secretion of EARs from both intact mouse eosinophils and their cell-free granules, findings pertinent to understanding the pathogenesis of eosinophil-associated diseases, in which EARs are key factors.-Shamri, R., Melo, R. C. N., Young, K. M., B.-B, M., Xenakis, J. J., Spencer, L. A., Weller, P. F. CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules. FASEB J. 26, 2084-2093 (2012). www.fasebj.org	[Shamri, Revital; Melo, Rossana C. N.; Young, Kristen M.; Xenakis, Jason J.; Spencer, Lisa A.; Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Allergy & Inflammat,Dept Med, Boston, MA 02215 USA; [Bivas-Benita, Maytal] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis,Dept Med, Boston, MA 02215 USA; [Weller, Peter F.] Univ Fed Juiz de Fora, Dept Biol, Lab Cellular Biol, Juiz De Fora, MG, Brazil	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universidade Federal de Juiz de Fora	Weller, PF (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Allergy & Inflammat,Dept Med, Boston, MA 02215 USA.	pweller@bidmc.harvard.edu	Melo, Rossana C. N./B-8248-2013	Melo, Rossana C. N./0000-0003-1736-0806	U.S. National Institutes of Health [R01/R37 AI020241, R01 AI051645, R01 HL095699]; Conselho Nacional de Pesquisa Cinetifica e Tecnologica (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020241, R01AI051645, R01AI020241] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Conselho Nacional de Pesquisa Cinetifica e Tecnologica (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Dr. James J. Lee (Mayo Clinic Arizona, Scottsdale, AZ, USA) for providing anti-mouse MBP. The authors also thank Dr. Ionita Ghiran and Dr. Roi Gazit for editorial assistance. This study was funded by grants from the U.S. National Institutes of Health to P.F.W. (R01/R37 AI020241 and R01 AI051645) and L.A.S. (R01 HL095699), and from Conselho Nacional de Pesquisa Cinetifica e Tecnologica (CNPq) and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) to R.C.N.M.	Adamko DJ, 2004, J IMMUNOL METHODS, V291, P101, DOI 10.1016/j.jim.2004.05.003; Alexander B, 1999, J PHARMACOL TOXICOL, V41, P55, DOI 10.1016/S1056-8719(98)00038-0; Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209; Bivas-Benita M, 2005, EUR J PHARM BIOPHARM, V61, P214, DOI 10.1016/j.ejpb.2005.04.009; Boix E, 2001, METHOD ENZYMOL, V341, P287, DOI 10.1016/S0076-6879(01)41159-1; Bystrom J, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-10; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Clark K, 2004, J LEUKOCYTE BIOL, V75, P1001, DOI 10.1189/jlb.0803391; Cormier SA, 2001, MAMM GENOME, V12, P352, DOI 10.1007/s003350020007; De Marinis E, 2009, IUBMB LIFE, V61, P62, DOI 10.1002/iub.149; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; Dvorak AM, 2000, CHEM IMMUNOL, V76, P1; El-Shazly A, 1998, INT ARCH ALLERGY IMM, V117, P55, DOI 10.1159/000053573; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Garcia NV, 2011, J IMMUNOL, V187, P2268, DOI 10.4049/jimmunol.1101008; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; Garvey TL, 2005, J IMMUNOL, V175, P4735, DOI 10.4049/jimmunol.175.7.4735; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Lee JJ, 2005, CLIN EXP ALLERGY, V35, P986, DOI 10.1111/j.1365-2222.2005.02302.x; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; Melo RCN, 2005, TRAFFIC, V6, P1047, DOI 10.1111/j.1600-0854.2005.00344.x; Melo RCN, 2005, TRAFFIC, V6, P866, DOI 10.1111/j.1600-0854.2005.00322.x; Melo RCN, 2010, MICROSC MICROANAL, V16, P653, DOI 10.1017/S1431927610093864; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; Moqbel R, 1999, CLIN EXP ALLERGY, V29, P1017; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Neves JS, 2010, J ALLERGY CLIN IMMUN, V125, P477, DOI 10.1016/j.jaci.2009.11.029; Neves JS, 2009, CURR OPIN IMMUNOL, V21, P694, DOI 10.1016/j.coi.2009.07.011; Neves JS, 2009, J IMMUNOL METHODS, V344, P64, DOI 10.1016/j.jim.2009.03.006; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879; Ochkur SI, 2012, J IMMUNOL METHODS, V375, P138, DOI 10.1016/j.jim.2011.10.002; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P117, DOI 10.1016/S0165-6147(97)01042-0; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; REIMERT CM, 1993, J IMMUNOL METHODS, V166, P183, DOI 10.1016/0022-1759(93)90359-F; Rosenberg HF, 2008, CURR PHARM BIOTECHNO, V9, P135, DOI 10.2174/138920108784567236; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Shamri R, 2011, CELL TISSUE RES, V343, P57, DOI 10.1007/s00441-010-1049-6; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Stelts D, 1998, AM J RESP CELL MOL, V18, P463, DOI 10.1165/ajrcmb.18.4.2957; Toyoda M, 1996, AM J DERMATOPATH, V18, P49, DOI 10.1097/00000372-199602000-00008; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Xu X, 2000, CLIN EXP ALLERGY, V30, P794; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027	53	37	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2084	2093		10.1096/fj.11-200246	http://dx.doi.org/10.1096/fj.11-200246			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22294786	Green Published			2022-12-28	WOS:000303680800034
J	Goudet, C; Vilar, B; Courtiol, T; Deltheil, T; Bessiron, T; Brabet, I; Oueslati, N; Rigault, D; Bertrand, HO; McLean, H; Daniel, H; Amalric, M; Acher, F; Pin, JP				Goudet, Cyril; Vilar, Bruno; Courtiol, Tiphanie; Deltheil, Thierry; Bessiron, Thomas; Brabet, Isabelle; Oueslati, Nadia; Rigault, Delphine; Bertrand, Hugues-Olivier; McLean, Heather; Daniel, Herve; Amalric, Marianne; Acher, Francine; Pin, Jean-Philippe			A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential	FASEB JOURNAL			English	Article						mGluR; drug development; Parkinson's disease	POSITIVE ALLOSTERIC MODULATION; MOLECULAR DETERMINANTS; BINDING DOMAIN; ACTIVATION; RECOGNITION; ACID; DOCKING; MGLUR4; CHARMM; SITE	Metabotropic glutamate (mGlu) receptors are promising targets to treat numerous brain disorders. So far, allosteric modulators are the only subtype selective ligands, but pure agonists still have strong therapeutic potential. Here, we aimed at investigating the possibility of developing subtype-selective agonists by extending the glutamate-like structure to hit a nonconsensus binding area. We report the properties of the first mGlu4-selective orthosteric agonist, derived from a virtual screening hit, LSP4-2022 using cell-based assays with recombinant mGlu receptors [EC50: 0.11 +/- 0.02, 11.6 +/- 1.9, 29.2 +/- 4.2 mu M (n>19) in calcium assays on mGlu4, mGlu7, and mGlu8 receptors, respectively, with no activity at the group I and -II mGlu receptors at 100 mu M]. LSP4-2022 inhibits neurotransmission in cerebellar slices from wild-type but not mGlu4 receptor-knockout mice. In vivo, it possesses antiparkinsonian properties after central or systemic administration in a haloperidol-induced catalepsy test, revealing its ability to cross the blood-brain barrier. Site-directed mutagenesis and molecular modeling was used to identify the LSP4-2022 binding site, revealing interaction with both the glutamate binding site and a variable pocket responsible for selectivity. These data reveal new approaches for developing selective, hydrophilic, and brain-penetrant mGlu receptor agonists, offering new possibilities to design original bioactive compounds with therapeutic potential.-Goudet, C., Vilar, B., Courtiol, T., Deltheil, T., Bessiron, T., Brabet, I., Oueslati, N., Rigault, D., Bertrand, H.-O., McLean, H., Daniel, H., Amalric, M., Acher, F., Pin, J.-P. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype-selective ligands with therapeutic potential. FASEB J. 26, 1682-1693 (2012). www.fasebj.org	[Goudet, Cyril; Vilar, Bruno; Brabet, Isabelle; Oueslati, Nadia; Pin, Jean-Philippe] Univ Montpellier, CNRS, INSERM, U661,UMR5203,Inst Genom Fonct, F-34094 Montpellier, France; [Courtiol, Tiphanie; Rigault, Delphine; Acher, Francine] Univ Paris 05, CNRS, UMR8601, Lab Chim & Biochim Pharmacol & Toxicol, F-75270 Paris, France; [Deltheil, Thierry; Amalric, Marianne] Aix Marseille Univ, CNRS, UMR6155, Lab Neurobiol Cognit, Marseille, France; [Bessiron, Thomas; McLean, Heather; Daniel, Herve] Univ Paris 11, CNRS, Lab Pharmacol & Biochim Synapse, Inst Biochim & Biophys Mol & Cellulaire,UMR8619, F-91405 Orsay, France; [Bertrand, Hugues-Olivier] Parc Club Univ, Accelrys SARL, Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Goudet, C (corresponding author), Univ Montpellier, CNRS, INSERM, U661,UMR5203,Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier, France.	cyril.goudet@igf.cnrs.fr; francine.acher@parisdescartes.fr	Goudet, Cyril/AAE-3415-2020; Pin, Jean-Philippe/Y-6668-2019	Goudet, Cyril/0000-0002-8255-3535; Pin, Jean-Philippe/0000-0002-1423-345X; Vilar, Bruno/0000-0001-6155-4080; Amalric, Marianne/0000-0002-9915-6763	Fondation pour la Recherche Medicale [INE20050303431]; Agence Nationale pour la Recherche [ANR-05-NEUR-0121-04, ANR-07-NEURO-047-01, ANR-08-NEUR-006]; CNRS (Direction de l'Innovation et des Relations avec les Entreprises); Ministere de l'Education Nationale, de la Recherche et de la Technologie; Societe Francaise d'Etude et de Traitement de la Douleur; Institut UPSA de la Douleur	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Agence Nationale pour la Recherche(French National Research Agency (ANR)); CNRS (Direction de l'Innovation et des Relations avec les Entreprises); Ministere de l'Education Nationale, de la Recherche et de la Technologie; Societe Francaise d'Etude et de Traitement de la Douleur; Institut UPSA de la Douleur	This work was supported by the Fondation pour la Recherche Medicale (INE20050303431), by the Agence Nationale pour la Recherche directly (ANR-05-NEUR-0121-04 and ANR-07-NEURO-047-01) or as part of the Era-net Neuron program (ANR-08-NEUR-006), by the CNRS (Direction de l'Innovation et des Relations avec les Entreprises, to T.C.), by the Ministere de l'Education Nationale, de la Recherche et de la Technologie (scholarships to T. B. and B. V.), and by the Societe Francaise d'Etude et de Traitement de la Douleur and the Institut UPSA de la Douleur. The calcium measurements were performed using the ARPEGE (Pharmacology Screening-Interactome) platform facility at the Institute of Functional Genomics (Montpellier, France). The authors thank Emmanuel Bourinet for his help in developing the electrophysiological assay of mGlu receptor activity, Pr. Terrance P. Snutch (University of British Columbia, Vancouver, BC, Canada) for kindly providing the cDNAs of the different Cav subunits, Dr. Gregory Stewart for critical reading of the manuscript, Dr. Gerard Sadoc (Unite de Neurosciences Integratives et Computationnelles, UPR CNRS 2191, Institut Alfred Fessard, Gif-sur-Yvette, France) for providing the Acquis1 software employed in these studies, C. Vol for her involvement in the ARPEGE facility and in the J.P.P. research laboratory, and Dr. L. Prezeau for his constant support. B. V., I. B., and N.O. performed the pharmacological and mutagenesis studies under the direct supervision of C. G., who designed the study and analyzed data. T. C. and D. R. synthesized the molecules under the supervision of F. A. T. B. and H. M. L. performed the slice recordings under the supervision of H. D. T. D. performed the in vivo experiments under the supervision of M. A. H.O.B. was in charge of the molecular modeling, and F. A. analyzed the models. C. G. and J.P.P. wrote the manuscript, and C. G., F. A., and J.P.P. supervised the entire project.	Abitbol K, 2008, J NEUROCHEM, V105, P2069, DOI 10.1111/j.1471-4159.2008.05290.x; Acher FC, 2005, BIOPOLYMERS, V80, P357, DOI 10.1002/bip.20229; Antony J, 2009, FASEB J, V23, P442, DOI 10.1096/fj.08-114751; Atluri PP, 1996, J NEUROSCI, V16, P5661; Bertrand HO, 2002, J MED CHEM, V45, P3171, DOI 10.1021/jm010323l; Bessis AS, 2000, PROTEIN SCI, V9, P2200, DOI 10.1110/ps.9.11.2200; Beurrier C, 2009, FASEB J, V23, P3619, DOI 10.1096/fj.09-131789; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Daniel H, 2001, J PHYSIOL-LONDON, V537, P793; Duty S, 2010, BRIT J PHARMACOL, V161, P271, DOI 10.1111/j.1476-5381.2010.00882.x; Frauli M, 2007, MOL PHARMACOL, V71, P704, DOI 10.1124/mol.106.030254; Garavito RM, 2003, ANNU REV BIOPH BIOM, V32, P183, DOI 10.1146/annurev.biophys.32.110601.141906; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C, 2009, BRAIN RES REV, V60, P43, DOI 10.1016/j.brainresrev.2008.12.007; Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Hermit MB, 2004, EUR J PHARMACOL, V486, P241, DOI 10.1016/j.ejphar.2003.12.033; Kniazeff J, 2011, PHARMACOL THERAPEUT, V130, P9, DOI 10.1016/j.pharmthera.2011.01.006; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lennon SM, 2010, EUR J PHARMACOL, V649, P29, DOI 10.1016/j.ejphar.2010.08.038; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; Lopez S, 2007, J NEUROSCI, V27, P6701, DOI 10.1523/JNEUROSCI.0299-07.2007; Maj M, 2003, NEUROPHARMACOLOGY, V45, P895, DOI 10.1016/S0028-3908(03)00271-5; Mathiesen JM, 2003, BRIT J PHARMACOL, V138, P1026, DOI 10.1038/sj.bjp.0705159; Mitsukawa K, 2005, P NATL ACAD SCI USA, V102, P18712, DOI 10.1073/pnas.0508063102; Muto T, 2007, P NATL ACAD SCI USA, V104, P3759, DOI 10.1073/pnas.0611577104; Niswender CM, 2008, MOL PHARMACOL, V74, P1345, DOI 10.1124/mol.108.049551; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Ogawa H, 2010, PROTEIN SCI, V19, P544, DOI 10.1002/pro.332; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Palucha-Poniewiera A, 2009, PROG NEURO-PSYCHOPH, V33, P1454, DOI 10.1016/j.pnpbp.2009.07.029; Parmentier ML, 2000, NEUROPHARMACOLOGY, V39, P1119, DOI 10.1016/S0028-3908(99)00204-X; Patil ST, 2007, NAT MED, V13, P1102, DOI 10.1038/nm1632; Rosemond E, 2004, MOL PHARMACOL, V66, P834, DOI 10.1124/mol.104.002956; Rosemond E, 2002, J BIOL CHEM, V277, P7333, DOI 10.1074/jbc.M110476200; Selvam C, 2010, J MED CHEM, V53, P2797, DOI 10.1021/jm901523t; Servant G, 2011, TRENDS PHARMACOL SCI, V32, P631, DOI 10.1016/j.tips.2011.06.007; Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Wellendorph P, 2009, BRIT J PHARMACOL, V156, P869, DOI 10.1111/j.1476-5381.2008.00078.x; Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	46	78	78	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1682	1693		10.1096/fj.11-195941	http://dx.doi.org/10.1096/fj.11-195941			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223752				2022-12-28	WOS:000302359700029
J	Liu, CH; Ren, JQ; You, ZR; Yang, JS; Liu, CM; Uppal, R; Liu, PK				Liu, Christina H.; Ren, Jia Q.; You, Zerong; Yang, Jinsheng; Liu, Charng-Ming; Uppal, Ritika; Liu, Philip K.			Noninvasive detection of neural progenitor cells in living brains by MRI	FASEB JOURNAL			English	Article						angiogenesis; drug delivery; pericyte; pharmacokinetics	ENDOTHELIAL GROWTH-FACTOR; CARDIOPULMONARY-RESUSCITATION; CEREBRAL-ISCHEMIA; GENE TRANSCRIPTS; CARDIAC-ARREST; PERICYTES; DAMAGE; ANGIOGENESIS; TRAFFICKING; AMPHETAMINE	The presence of pericytes in brain regions undergoing repair is evident of the recruitment of bone marrow-derived multipotent regenerative cells to the neurovascular unit during angiogenesis. At present, post mortem sampling is the only way to identify them. Therefore, such cell typing is inadequate for preserving neural progenitor cells for any meaningful stem cell therapy. We aimed to target cerebral pericytes in vivo using dual gene transcript-targeted MRI (GT-tMRI) in male C57black6 mice after a 60-min bilateral carotid artery occlusion (BCAO). We attached super-paramagnetic iron oxide nanoparticles (SPIONs) to phosphorothioate-modified micro-DNA that targets actin or nestin mRNA. Because BCAO compromises the blood-brain barrier (BBB) and induces expression of alpha-smooth muscle (alpha SM)-actin and nestin antigens by pericytes in new vessels, we delivered pericyte-specific magnetic resonance contrast agents (SPION-actin or SPION-nestin at 4 mg Fe/kg) by i.p. injection to C57black6 mice that had experienced BCAO. We demonstrated that the surge in cerebral iron content by inductively coupled plasma-mass spectrometry matched the increase in the frequency of relaxivity. We also found that SPION-nestin was colocalized in alpha SM-actin- and nestin-expressing pericytes in BCAO-treated C57black6 or transgenic mice [B6.Cg-Tg(CAG-mRFP1) 1F1Hadj/J, expressing red fluorescent protein by actin promoter]. We identified pericytes in the repair patch in living brains after BCAO with a voxel size of 0.03 mm(3). The presence of electron-dense nanoparticles in vascular pericytes in the region of BBB injury led us to draw the conclusion that GT-tMRI can noninvasively reveal neural progenitor cells during vascularization.-Liu, C. H., Ren, J. Q., You, Z., Yang, J., Liu, C.-M., Uppal, R., Liu, P. K. Noninvasive detection of neural progenitor cells in living brains by MRI. FASEB J. 26, 1652-1662 (2012). www.fasebj.org	[Liu, Christina H.; Ren, Jia Q.; Yang, Jinsheng; Liu, Charng-Ming; Uppal, Ritika; Liu, Philip K.] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; [You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Liu, PK (corresponding author), Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.	philipl@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X	American Heart Association [2060416]; U.S. National Institutes of Health [AT004974, DA026108, DA029889, EB013768]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB013768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA029889, R01DA026108] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank M. McKee for assistance in TEM and N. Eusemann for help with editing. This project was supported by grants from the American Heart Association (grant 2060416) and the U.S. National Institutes of Health (grant AT004974 to J.Q.R. and grants DA026108, DA029889, and EB013768 to P.K.L.).	Abrahams JM, 2009, NEUROL RES, V31, P528, DOI 10.1179/174313209X380801; Alliot F, 1999, J NEUROSCI RES, V58, P367; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; Cobbs CS, 1998, NEUROSCI LETT, V249, P79, DOI 10.1016/S0304-3940(98)00377-2; Cui JK, 1999, J NEUROCHEM, V73, P1164, DOI 10.1046/j.1471-4159.1999.0731164.x; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Fischer AJ, 2010, GLIA, V58, P633, DOI 10.1002/glia.20950; Fitzgerald ML, 2007, J LIPID RES, V48, P621, DOI 10.1194/jlr.M600449-JLR200; Fornai F, 2004, PSYCHOPHARMACOLOGY, V173, P353, DOI 10.1007/s00213-003-1708-3; Greenberg DA, 1998, DRUG NEWS PERSPECT, V11, P265, DOI 10.1358/dnp.1998.11.5.657287; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Hughes S, 2004, INVEST OPHTH VIS SCI, V45, P2795, DOI 10.1167/iovs.03-1312; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; Kokovay E, 2006, J CEREBR BLOOD F MET, V26, P545, DOI 10.1038/sj.jcbfm.9600214; Krupinski J, 2008, FRONT BIOSCI-LANDMRK, V13, P6472, DOI 10.2741/3167; Lee HJ, 2002, J NUCL MED, V43, P948; Lee JH, 2010, NATURE, V465, P788, DOI 10.1038/nature09108; Liu CH, 2008, FASEB J, V22, P1193, DOI 10.1096/fj.07-9557com; Liu CH, 2007, FASEB J, V21, P3004, DOI 10.1096/fj.07-8203com; Liu CH, 2007, MOL IMAGING, V6, P156, DOI 10.2310/7290.2007.00011; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; Liu CH, 2009, J NEUROSCI, V29, P10663, DOI 10.1523/JNEUROSCI.2167-09.2009; Liu CH, 2009, J NEUROSCI, V29, P3508, DOI 10.1523/JNEUROSCI.5332-08.2009; Liu PK, 1996, J NEUROSCI, V16, P6795; Malberg JE, 1998, J NEUROSCI, V18, P5086; Minamishima S, 2011, CIRCULATION, V124, P1645, DOI 10.1161/CIRCULATIONAHA.111.025395; Minamishima S, 2009, CIRCULATION, V120, P888, DOI 10.1161/CIRCULATIONAHA.108.833491; MULDOON LL, 1995, AM J PATHOL, V147, P1840; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; Rodriguez-Baeza A, 1998, ANAT RECORD, V252, P176, DOI 10.1002/(SICI)1097-0185(199810)252:2<176::AID-AR3>3.0.CO;2-1; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Tagawa A, 2005, J CELL BIOL, V170, P769, DOI 10.1083/jcb.200506103; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhu M., BIOMED PHARMACOTHER, V64, P208	38	22	22	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1652	1662		10.1096/fj.11-199547	http://dx.doi.org/10.1096/fj.11-199547			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198388	Bronze, Green Published			2022-12-28	WOS:000302359700026
J	Woo, JA; Roh, SE; Lakshmana, MK; Kang, DE				Woo, Jung A.; Roh, Seung-Eon; Lakshmana, Madepalli K.; Kang, David E.			Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly	FASEB JOURNAL			English	Article						APP; LRP; RanBPM; integrin; adhesion	AMYLOID PRECURSOR PROTEIN; NEURITE OUTGROWTH; CELL-SURVIVAL; ACTIVATION; APP; TRAFFICKING; GENERATION; MIGRATION; MEMBRANE; PATHWAY	Accumulation of the amyloid beta (A beta) peptide derived from the amyloid precursor protein (APP) plays a central role in the pathogenesis of Alzheimer's disease (AD). We previously reported that the scaffolding protein RanBP9 is markedly increased in AD brains and promotes A beta generation by scaffolding APP/BACE1/LRP complexes together and accelerating APP endocytosis. Because APP, LRP, and RanBP9 all physically interact with beta-integrins, we investigated whether RanBP9 alters integrin-dependent cell adhesion and focal adhesion signaling. Here, we show that RanBP9 overexpression dramatically disrupts integrin-dependent cell attachment and spreading in NIH3T3 and hippocampus-derived HT22 cells, concomitant with strongly decreased Pyk2/paxillin signaling and talin/vinculin localization in focal adhesion complexes. Conversely, RanBP9 knockdown robustly promotes cell attachment, spreading, and focal adhesion signaling and assembly. Cell surface biotinylation and endocytosis assays reveal that RanBP9 overexpression and RanBP9 siRNA potently reduces and increases surface beta 1-integrin and LRP by accelerating and inhibiting their endocytosis, respectively. Primary hippocampal neurons derived from RanBP9-transgenic mice also demonstrate severely reduced levels of surface beta 1-integrin, LRP, and APP, as well as neurite arborization. Therefore, these data indicate that RanBP9 simultaneously inhibits cell-adhesive processes and enhances A beta generation by accelerating APP, LRP, and beta 1-integrin endocytosis.-Woo, J.A., Roh, S.-E., Lakshmana, M. K., Kang, D. E. Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly. FASEB J. 26, 1672-1681 (2012). www.fasebj.org	[Lakshmana, Madepalli K.; Kang, David E.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Woo, Jung A.; Roh, Seung-Eon; Kang, David E.] Seoul Natl Univ, Coll Med, World Class Univ, Neurocyt Program, Seoul, South Korea	University of California System; University of California San Diego; Seoul National University (SNU)	Kang, DE (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dekang@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X; Woo, Jung A/0000-0002-9194-1361	American Health Assistance Foundation [A2007-05]; Alzheimer's Association [IIRG-08-91662]; U.S. National Institutes of Health/National Institute on Aging [1R01AG033055-01A1, 1K02AG031920-10A1, 1R03AG032064-01, 1R01AG036859-01]; World Class University from National Research Foundation of Korea; NATIONAL INSTITUTE ON AGING [R01AG033055, R03AG032064, R01AG036859, K02AG031920] Funding Source: NIH RePORTER	American Health Assistance Foundation; Alzheimer's Association(Alzheimer's Association); U.S. National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); World Class University from National Research Foundation of Korea(National Research Foundation of Korea); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Elisabetta Bianchi (Pasteur Institute, Paris, France) for the RanBP9 monoclonal antibody and Dr. Mark Ginsberg (University of California, San Diego, CA, USA) for talin-GFP construct, as well as helpful discussions. This work was supported in part by the American Health Assistance Foundation (A2007-05, D.E.K.), the Alzheimer's Association (IIRG-08-91662, D.E.K.), the U.S. National Institutes of Health/National Institute on Aging (1R01AG033055-01A1 and 1K02AG031920-10A1, D.E.K.; 1R03AG032064-01 and 1R01AG036859-01, M.K.L.), and by a World Class University-Neurocytomics Project grant from the National Research Foundation of Korea (D.E.K.).	Akkawi S, 2006, AM J PHYSIOL-HEART C, V291, pH1351, DOI 10.1152/ajpheart.01042.2005; Anderson KL, 2004, J NEUROSCI RES, V75, P688, DOI 10.1002/jnr.20018; Becchetti A, 2010, INT REV CEL MOL BIO, V279, P135, DOI 10.1016/S1937-6448(10)79005-5; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; De Strooper B, 2000, J CELL SCI, V113, P1857; Denti S, 2004, J BIOL CHEM, V279, P13027, DOI 10.1074/jbc.M313515200; Hoe HS, 2009, J NEUROSCI, V29, P7459, DOI 10.1523/JNEUROSCI.4872-08.2009; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Hu K, 2007, J CLIN INVEST, V117, P3821, DOI 10.1172/JCI32301; Lakshmana MK, 2010, FASEB J, V24, P119, DOI 10.1096/fj.09-136457; Lakshmana MK, 2009, J BIOL CHEM, V284, P11863, DOI 10.1074/jbc.M807345200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Vachon P. H., 2011, J SIGNAL TRANSDUCT, V2011; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Waldron E, 2008, NEUROBIOL DIS, V31, P188, DOI 10.1016/j.nbd.2008.04.006; Wang QW, 2008, NEUROBIOL AGING, V29, P1485, DOI 10.1016/j.neurobiolaging.2007.03.018; Wright S, 2007, NEUROBIOL AGING, V28, P226, DOI 10.1016/j.neurobiolaging.2005.12.002; Yoon IS, 2007, FASEB J, V21, P2742, DOI 10.1096/fj.07-8114com; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	27	41	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1672	1681		10.1096/fj.11-194423	http://dx.doi.org/10.1096/fj.11-194423			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223749	Green Published			2022-12-28	WOS:000302359700028
J	Niespodziana, K; Napora, K; Cabauatan, C; Focke-Tejkl, M; Keller, W; Niederberger, V; Tsolia, M; Christodoulou, I; Papadopoulos, NG; Valenta, R				Niespodziana, Katarzyna; Napora, Kamila; Cabauatan, Clarissa; Focke-Tejkl, Margarete; Keller, Walter; Niederberger, Verena; Tsolia, Maria; Christodoulou, Ioannis; Papadopoulos, Nikolaos G.; Valenta, Rudolf			Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections	FASEB JOURNAL			English	Article						asthma; rhinovirus infection	COMMON COLD VIRUS; NEUTRALIZATION; EXACERBATIONS; RECEPTOR; BACTERIA; ASTHMA	Rhinoviruses (RVs) are the primary cause of upper respiratory tract infections, generally known as the common cold. Moreover, RV infections can trigger severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD). We expressed the 4 major RV capsid proteins, VP1-VP4, in Escherichia coli and used these proteins as well as recombinant and synthetic VP1 fragments to study and map antibody responses in RV-infected humans. VP1, which on infection binds to ICAM 1, was identified as a major target for the memory immune response, residing in the IgG1 subclass and IgA class. Interestingly, this response was mainly directed against an N-terminal 20mer peptide in VP1, P1a, which becomes exposed on intact RV only when it docks to its receptor ICAM 1. Molecular modeling using the 3-dimensional RV capsid structures revealed that P1a was localized inside the capsid and outside the areas involved in receptor binding or RV neutralization. Our results suggest misdirection of antibody responses against a nonprotective epitope as a mechanism how RV escapes immunity and causes recurrent infections. Based on these findings, it may be possible to design vaccines against RV infections and RV-induced respiratory diseases.-Niespodziana, K., Napora, K., Cabauatan, C., Focke-Tejkl, M., Keller, W., Niederberger, V., Tsolia, M., Christodoulou, I., Papadopoulos, N. G., Valenta, R. Misdirected antibody responses against an N-terminal epitope on human RV VP1 as explanation for recurrent RV infections. FASEB J. 26, 1001-1008 (2012). www.fasebj.org	[Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, A-1090 Vienna, Austria; [Keller, Walter] Karl Franzens Univ Graz, Inst Chem, Graz, Austria; [Tsolia, Maria; Christodoulou, Ioannis; Papadopoulos, Nikolaos G.] Univ Athens, Pediat Clin 2, Allergy Res Ctr, Athens, Greece	Medical University of Vienna; Medical University of Vienna; University of Graz; National & Kapodistrian University of Athens	Valenta, R (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	N.G., Papadopoulos/L-8670-2013; Keller, Walter/AAW-1501-2021; Papadopoulos, Nikolaos/ABE-1774-2021	N.G., Papadopoulos/0000-0002-4448-3468; Keller, Walter/0000-0002-2261-958X; Papadopoulos, Nikolaos/0000-0002-4448-3468; Cabauatan, Clarissa/0000-0001-8404-7065; Valenta, Rudolf/0000-0001-5944-3365; Niespodziana, Katarzyna/0000-0003-0700-965X; Papadopoulos, Nikolaos/0000-0002-2508-3872	Austrian Science Fund (FWF) [DK-W1212-B13, F1805, F1818]; Biomay (Vienna, Austria); Christian Doppler Research Association (Austria); European Commission [260895]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Biomay (Vienna, Austria); Christian Doppler Research Association (Austria); European Commission(European CommissionEuropean Commission Joint Research Centre)	This study is supported by grants DK-W1212-B13, F1805, and F1818 of the Austrian Science Fund (FWF); by a research grant from Biomay (Vienna, Austria); by the Christian Doppler Research Association (Austria); and by the European Commission's Seventh Framework program under grant agreement 260895 (PreDicta). N.G.P is coordinator of the PreDicta Consortium.	ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BARCLAY WS, 1989, EPIDEMIOL INFECT, V103, P659, DOI 10.1017/S095026880003106X; Braciale T. J., 2007, FIELDS VIROLOGY; Che ZW, 1998, J VIROL, V72, P4610, DOI 10.1128/JVI.72.6.4610-4622.1998; Donaldson GC, 2003, EUR RESPIR J, V22, P931, DOI 10.1183/09031936.03.00038303; Edlmayr J, 2011, EUR RESPIR J, V37, P44, DOI 10.1183/09031936.00149109; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Katpally U, 2009, J VIROL, V83, P7040, DOI 10.1128/JVI.00557-09; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774; LI QH, 1994, J VIROL, V68, P3965, DOI 10.1128/JVI.68.6.3965-3970.1994; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Papadopoulos NG, 2001, QJM-INT J MED, V94, P1, DOI 10.1093/qjmed/94.1.1; ROSSMANN M G, 1989, Viral Immunology, V2, P143, DOI 10.1089/vim.1989.2.143; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; Rotbart HA, 2000, ARCH FAM MED, V9, P913, DOI 10.1001/archfami.9.9.913; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; Spyridaki IS, 2009, J VIROL METHODS, V156, P102, DOI 10.1016/j.jviromet.2008.10.027; Stripeli F, 2010, EUR J CLIN MICROBIOL, V29, P683, DOI 10.1007/s10096-010-0914-2	25	40	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1001	1008		10.1096/fj.11-193557	http://dx.doi.org/10.1096/fj.11-193557			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22121050				2022-12-28	WOS:000300949300005
J	Sundvik, M; Kudo, H; Toivonen, P; Rozov, S; Chen, YC; Panula, P				Sundvik, Maria; Kudo, Hisaaki; Toivonen, Pauliina; Rozov, Stanislav; Chen, Yu-Chia; Panula, Pertti			The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish	FASEB JOURNAL			English	Article						locomotor activity; sleep disorders; dorsal telencephalon; tracing	H-3 RECEPTOR; HISTIDINE-DECARBOXYLASE; LARVAL ZEBRAFISH; CSF HISTAMINE; SLEEP; NARCOLEPSY; BRAIN; ACTIVATION; OREXINS; IDENTIFICATION	The histaminergic and hypocretin/orexin (hcrt) neurotransmitter systems play crucial roles in alertness/wakefulness in rodents. We elucidated the role of histamine in wakefulness and the interaction of the histamine and hcrt systems in larval zebrafish. Translation inhibition of histidine decarboxylase (hdc) with morpholino oligonucleotides (MOs) led to a behaviorally measurable decline in light-associated activity, which was partially rescued by hdc mRNA injections and mimicked by histamine receptor H1 (Hrh1) antagonist pyrilamine treatment. Histamine-immunoreactive fibers targeted the dorsal telencephalon, an area that expresses histamine receptors hrh1 and hrh3 and contains predominantly glutamatergic neurons. Tract tracing with DiI revealed that projections from dorsal telencephalon innervate the hcrt and histaminergic neurons. Translation inhibition of hdc decreased the number of hcrt neurons in a Hrh1-dependent manner. The reduction was rescued by overexpression of hdc mRNA. hdc mRNA injection alone led to an up-regulation of hcrt neuron numbers. These results suggest that histamine is essential for the development of a functional and intact hcrt system and that histamine has a bidirectional effect on the development of the hcrt neurons. In summary, our findings provide evidence that these two systems are linked both functionally and developmentally, which may have important implications in sleep disorders and narcolepsy.-Sundvik, M., Kudo, H., Toivonen, P., Rozov, S., Chen, Y.-C., Panula, P. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J. 25, 4338-4347 (2011). www.fasebj.org	[Panula, Pertti] Univ Helsinki, Fac Med, Ctr Neurosci, FIN-00290 Helsinki, Finland; [Sundvik, Maria; Kudo, Hisaaki; Toivonen, Pauliina; Rozov, Stanislav; Chen, Yu-Chia; Panula, Pertti] Univ Helsinki, Inst Biomed, FIN-00290 Helsinki, Finland; [Toivonen, Pauliina] Univ Helsinki, Dept Biosci, FIN-00290 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Panula, P (corresponding author), Univ Helsinki, Fac Med, Ctr Neurosci, POB 63,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	pertti.panula@helsinki.fi		Panula, Pertti/0000-0002-1189-5132; Rozov, Stanislav/0000-0002-0352-5502	Academy of Finland [116177, 207352]; Finnish Technology Development Fund (TEKES); Sigrid Juselius Foundation; Helsinki Biomedical Graduate School	Academy of Finland(Academy of Finland); Finnish Technology Development Fund (TEKES); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Helsinki Biomedical Graduate School	The authors thank Dr. Shin-ichi Higashijima (National Institutes of Natural Sciences, Okazaki Institute for Integrative Bioscience, Okazaki, Japan) for kindly providing the gad1, gad2, skc17a6a, slc17a6b, and slc17a7 constructs; Henri Koivula and Susanna Norrbacka for excellent fish care; Anna Lehtonen for technical assistance; and Dr. Saara Nuutinen and Dr. Piotr Podlasz for constructive discussions and comments on the manuscript. This study was funded by the Academy of Finland (grants 116177 and 207352), the Finnish Technology Development Fund (TEKES), and the Sigrid Juselius Foundation. M.S. was supported by the Helsinki Biomedical Graduate School. The authors declare no conflicts of interest.	Anaclet C, 2009, J NEUROSCI, V29, P14423, DOI 10.1523/JNEUROSCI.2604-09.2009; AUVINEN S, 1988, J COMP NEUROL, V276, P289, DOI 10.1002/cne.902760211; Bayer L, 2001, EUR J NEUROSCI, V14, P1571, DOI 10.1046/j.0953-816x.2001.01777.x; Burgess HA, 2009, GENES BRAIN BEHAV, V8, P500, DOI 10.1111/j.1601-183X.2009.00499.x; Burgess HA, 2007, J EXP BIOL, V210, P2526, DOI 10.1242/jeb.003939; Burgess HA, 2007, J NEUROSCI, V27, P4984, DOI 10.1523/JNEUROSCI.0615-07.2007; Burgess HA, 2010, CURR BIOL, V20, P381, DOI 10.1016/j.cub.2010.01.022; Chen YC, 2009, HISTOCHEM CELL BIOL, V132, P375, DOI 10.1007/s00418-009-0619-8; Cirelli C, 2009, NAT REV NEUROSCI, V10, P549, DOI 10.1038/nrn2683; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Eisen JS, 2008, DEVELOPMENT, V135, P1735, DOI 10.1242/dev.001115; Emran Farida, 2008, J Vis Exp, DOI 10.3791/923; Eriksson KS, 1998, EUR J NEUROSCI, V10, P3799, DOI 10.1046/j.1460-9568.1998.00394.x; Eriksson KS, 2001, J NEUROSCI, V21, P9273, DOI 10.1523/JNEUROSCI.21-23-09273.2001; Gahtan E, 2005, J NEUROSCI, V25, P9294, DOI 10.1523/JNEUROSCI.2678-05.2005; Guo RX, 2009, BRIT J PHARMACOL, V157, P104, DOI 10.1111/j.1476-5381.2009.00205.x; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Haas HL, 2008, PHYSIOL REV, V88, P1183, DOI 10.1152/physrev.00043.2007; Higashijima S, 2004, J COMP NEUROL, V480, P1, DOI 10.1002/cne.20278; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; Jin CY, 2009, BRIT J PHARMACOL, V157, P118, DOI 10.1111/j.1476-5381.2009.00149.x; Kanbayashi T, 2009, SLEEP, V32, P181, DOI 10.1093/sleep/32.2.181; Kaslin J, 2004, J NEUROSCI, V24, P2678, DOI 10.1523/JNEUROSCI.4908-03.2004; Kaslin J, 2001, J COMP NEUROL, V440, P342, DOI 10.1002/cne.1390; Keegan BR, 2002, DEVELOPMENT, V129, P1623; Kobbert C, 2000, PROG NEUROBIOL, V62, P327, DOI 10.1016/S0301-0082(00)00019-8; Kudo H, 2009, ENDOCRINOLOGY, V150, P1393, DOI 10.1210/en.2008-1301; Lin JS, 1996, J NEUROSCI, V16, P1523; Lin L, 2002, PEPTIDES, V23, P2203, DOI 10.1016/S0196-9781(02)00251-6; MONTI JM, 1986, J NEURAL TRANSM, V66, P1, DOI 10.1007/BF01262953; MONTI JM, 1991, EUR J PHARMACOL, V205, P283, DOI 10.1016/0014-2999(91)90911-9; Moree WJ, 2009, J MED CHEM, V52, P5307, DOI 10.1021/jm900933k; Mueller T, 2008, J COMP NEUROL, V507, P1245, DOI 10.1002/cne.21604; Naumann EA, 2010, NAT NEUROSCI, V13, P513, DOI 10.1038/nn.2518; Nishino S, 2009, SLEEP, V32, P175, DOI 10.1093/sleep/32.2.175; OMalley DM, 1996, NEURON, V17, P1145, DOI 10.1016/S0896-6273(00)80246-9; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; PANULA P, 1990, NEUROSCIENCE, V34, P127, DOI 10.1016/0306-4522(90)90307-P; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; Passani MB, 2004, TRENDS PHARMACOL SCI, V25, P618, DOI 10.1016/j.tips.2004.10.003; Vargas JP, 2009, BRAIN RES BULL, V79, P436, DOI 10.1016/j.brainresbull.2009.05.008; Peitsaro N, 2003, J NEUROCHEM, V86, P432, DOI 10.1046/j.1471-4159.2003.01850.x; Peitsaro N, 2007, BIOCHEM PHARMACOL, V73, P1205, DOI 10.1016/j.bcp.2007.01.014; Perala N, 2010, DEV DYNAM, V239, P2722, DOI 10.1002/dvdy.22397; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Pillot C, 2002, NEUROSCIENCE, V114, P173, DOI 10.1016/S0306-4522(02)00135-5; Prober DA, 2006, J NEUROSCI, V26, P13400, DOI 10.1523/JNEUROSCI.4332-06.2006; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sallinen V, 2009, J NEUROCHEM, V108, P719, DOI 10.1111/j.1471-4159.2008.05793.x; Sallinen V, 2009, J NEUROCHEM, V109, P403, DOI 10.1111/j.1471-4159.2009.05986.x; Scammell TE, 2009, SLEEP, V32, P133, DOI 10.1093/sleep/32.2.133; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; WATANABE T, 1984, BRAIN RES, V295, P13, DOI 10.1016/0006-8993(84)90811-4; Yamanaka A, 2002, BIOCHEM BIOPH RES CO, V290, P1237, DOI 10.1006/bbrc.2001.6318; Yokogawa T, 2007, PLOS BIOL, V5, P2379, DOI 10.1371/journal.pbio.0050277	57	59	62	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4338	4347		10.1096/fj.11-188268	http://dx.doi.org/10.1096/fj.11-188268			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885652				2022-12-28	WOS:000298138100025
J	Vida, G; Pena, G; Kanashiro, A; Thompson-Bonilla, MD; Palange, D; Deitch, EA; Ulloa, L				Vida, Gergely; Pena, Geber; Kanashiro, Alexandre; Thompson-Bonilla, Maria del Rocio; Palange, David; Deitch, Edwin A.; Ulloa, Luis			beta 2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system	FASEB JOURNAL			English	Article						sepsis; septic shock; parasympathetic nervous system; vagus nerve; inflammation; cytokine	CHOLINERGIC ANTIINFLAMMATORY PATHWAY; TUMOR-NECROSIS-FACTOR; NICOTINIC ACETYLCHOLINE-RECEPTOR; SEPTIC SHOCK; VAGUS NERVE; HOST RESPONSE; SEVERE SEPSIS; PROTEIN; STIMULATION; MODULATION	The nervous system is classically organized into sympathetic and parasympathetic systems acting in opposition to maintain physiological homeostasis. Here, we report that both systems converge in the activation of beta 2-adrenoceptors of splenic regulatory lymphocytes to control systemic inflammation. Vagus nerve stimulation fails to control serum TNF levels in either beta 2-knockout or lymphocyte-deficient nude mice. Unlike typical suppressor CD25(+) cells, the transfer of CD4(+)CD25(-) regulatory lymphocytes reestablishes the anti-inflammatory potential of the vagus nerve and beta 2-agonists to control inflammation in both beta 2-knockout and nude mice. beta 2-Agonists inhibit cytokine production in splenocytes (IC50 similar to 1 mu M) and prevent systemic inflammation in wild-type but not in beta 2-knockout mice. beta 2-Agonists rescue wild-type mice from established polymicrobial peritonitis in a clinically relevant time frame. Regulatory lymphocytes reestablish the anti-inflammatory potential of beta 2-agonists to control systemic inflammation, organ damage, and lethal endotoxic shock in beta 2-knockout mice. These results indicate that beta 2-adrenoceptors in regulatory lymphocytes are critical for the anti-inflammatory potential of the parasympathetic vagus nerve, and they represent a potential pharmacological target for sepsis. Vida, G., Pena, G., Kanashiro, A., del Rocio Thompson-Bonilla, M., Palange, D., Deitch, E. A., Ulloa, L. beta 2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J. 25, 4476-4485 (2011). www.fasebj.org	[Vida, Gergely; Pena, Geber; Kanashiro, Alexandre; Thompson-Bonilla, Maria del Rocio; Palange, David; Deitch, Edwin A.; Ulloa, Luis] Univ Med & Dent New Jersey, New Jersey Med Sch, Lab Immun & Infect, Dept Surg, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Ulloa, L (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Lab Immun & Infect, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.	mail@luisulloa.com	Ulloa, Luis/AAE-8751-2019; pena, Geber/AAD-5890-2019; Kanashiro, Alexandre/AAX-3823-2020; Kanashiro, Alexandre/C-9435-2012	Ulloa, Luis/0000-0002-7702-7549; Kanashiro, Alexandre/0000-0003-0367-7503; Kanashiro, Alexandre/0000-0003-0367-7503	Hungarian Rosztoczy Foundation; Brazilian Fundacao ao Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Mexican National Council for Science and Technology (CONACyT); Department of Surgery of the New Jersey Medical School; U.S. National Institutes of Health [RO1-GM084125]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084125] Funding Source: NIH RePORTER	Hungarian Rosztoczy Foundation; Brazilian Fundacao ao Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Mexican National Council for Science and Technology (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Department of Surgery of the New Jersey Medical School; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Brian Kobilka (Stanford University, Stanford, CA, USA) for his collaboration with the beta 2KO mice. G.V. was supported by the Hungarian Rosztoczy Foundation, A.K. was supported by the Brazilian Fundacao ao Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), and M.R.T. was supported by the Mexican National Council for Science and Technology (CONACyT). L.U. is supported by the faculty program of the Department of Surgery of the New Jersey Medical School, and the U.S. National Institutes of Health (RO1-GM084125).	Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006; Altavilla D, 2006, SHOCK, V25, P500, DOI 10.1097/01.shk.0000209539.91553.82; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2007, JAMA-J AM MED ASSOC, V298, P456, DOI 10.1001/jama.298.4.456; Bernik TR, 2002, J VASC SURG, V36, P1231, DOI 10.1067/mva.2002.129643; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Cai BL, 2009, J CELL MOL MED, V13, P3774, DOI 10.1111/j.1582-4934.2008.00550.x; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Crandall M, 2009, MOL MED, V15, P263, DOI 10.2119/molmed.2009.00029; Crassous PA, 2007, CURR TOP MED CHEM, V7, P187, DOI 10.2174/156802607779318190; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264; de Montmollin E, 2009, CRIT CARE, V13, DOI 10.1186/cc8026; Eijkelkamp N, 2004, J NEUROIMMUNOL, V150, P3, DOI 10.1016/j.jneuroim.2004.01.001; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; Felten S Y, 1998, Adv Pharmacol, V42, P583; FLOOD JF, 1987, SCIENCE, V236, P832, DOI 10.1126/science.3576201; Hasko G, 1998, J NEUROIMMUNOL, V88, P57, DOI 10.1016/S0165-5728(98)00073-3; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Javed U, 2009, CARDIOL REV, V17, P287, DOI 10.1097/CRD.0b013e3181bdf63e; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LEVINE JD, 1988, P NATL ACAD SCI USA, V85, P4553, DOI 10.1073/pnas.85.12.4553; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Nakada TA, 2010, AM J RESP CRIT CARE, V181, P143, DOI 10.1164/rccm.200903-0332OC; Nakamura A, 2004, J AM SOC NEPHROL, V15, P316, DOI 10.1097/01.ASN.0000111247.76908.59; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; O'Mahony C, 2009, AM J PHYSIOL-REG I, V297, pR1118, DOI 10.1152/ajpregu.90904.2008; Oberbeck R, 2009, CURR MED CHEM, V16, P1082, DOI 10.2174/092986709787581770; Ortega VE, 2010, CURR OPIN PHARMACOL, V10, P246, DOI 10.1016/j.coph.2010.04.009; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Sanders VM, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P63; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Small KM, 2003, ANNU REV PHARMACOL, V43, P381, DOI 10.1146/annurev.pharmtox.43.100901.135823; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; Tracey KJ, 2010, NAT IMMUNOL, V11, P561, DOI 10.1038/ni0710-561; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003; Ulloa L, 2009, CURR PHARM DESIGN, V15, P1918, DOI 10.2174/138161209788453248; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; VANDERPOLL T, 1994, INFECT IMMUN, V62, P2046, DOI 10.1128/IAI.62.5.2046-2050.1994; Venet F, 2008, J LEUKOCYTE BIOL, V83, P523, DOI 10.1189/jlb.0607371; Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248	57	107	121	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4476	4485		10.1096/fj.11-191007	http://dx.doi.org/10.1096/fj.11-191007			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21840939	Green Published			2022-12-28	WOS:000298138100038
J	Feldner, A; Otto, H; Rewerk, S; Hecker, M; Korff, T				Feldner, Anja; Otto, Hannes; Rewerk, Stephan; Hecker, Markus; Korff, Thomas			Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein-1	FASEB JOURNAL			English	Article						smooth muscle cells; MMP-2; gelatinase activity; circumferential wall tension	SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTOR; RODENT MODEL; LEUKOCYTE CONCENTRATION; VEINS; EXPRESSION; METALLOPROTEINASES; PATHOGENESIS; DISEASE; FIBERS	An increase in circumferential wall tension (CWT) is an important determinant of vascular remodeling during hypertension or arteriosclerosis but also arteriogenesis. Although pivotal for such processes, the effect of this biomechanical force on venous remodeling has not yet been delineated. To this end, we raised the filling pressure in veins of the mouse auricle, which led to a 2.5-fold enlargement of these blood vessels within 4 d along with an increase in smooth muscle cell proliferation, matrix metalloproteinase 2 (MMP-2) expression and gelatinase activity. These changes were likewise observed in tissue samples of human varicose veins. Topical treatment of the auricles with a decoy oligonucleotide- neutralizing activator protein 1 (AP-1) inhibited these effects. Likewise, proliferation, MMP-2 expression, and gelatinase activity in both native and cultured venous smooth muscle cells exposed to enhanced stretch was decreased by up to 80% through inhibiting AP-1. In contrast, mutant control oligonucleotides had no effect on smooth muscle cell activation. These findings indicate that an increase in venous filling pressure and thus CWT is sufficient to activate AP-1, which, in turn, triggers varicose remodeling through fuelling MMP-2 activity and smooth muscle cell hyperplasia in the venous vessel wall.-Feldner, A., Otto, H., Rewerk, S., Hecker, M., Korff, T. Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein-1. FASEB J. 25, 3613-3621 (2011). www.fasebj.org	[Feldner, Anja; Otto, Hannes; Hecker, Markus; Korff, Thomas] Univ Heidelberg, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, D-69120 Heidelberg, Germany; [Rewerk, Stephan] Ctr Vasc Med, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Korff, T (corresponding author), Univ Heidelberg, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, Neuenheimer Feld 230, D-69120 Heidelberg, Germany.	korff@physiologie.uni-heidelberg.de						Aunapuu M, 2005, VASA-J VASCULAR DIS, V34, P170, DOI 10.1024/0301-1526.34.3.170; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; Bergan JJ, 2008, J VASC SURG, V47, P183, DOI 10.1016/j.jvs.2007.09.028; Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; BURKITT DP, 1976, LANCET, V2, P202; Demicheva E, 2008, CIRC RES, V103, P477, DOI 10.1161/CIRCRESAHA.108.177782; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Hahn TL, 1999, J SURG RES, V81, P38, DOI 10.1006/jsre.1998.5518; Hahn TL, 2000, J SURG RES, V88, P150, DOI 10.1006/jsre.1999.5766; *I AN LAB RES, 1996, NIH PUBL, V8523; Ishikawa Y, 2000, VIRCHOWS ARCH, V437, P138, DOI 10.1007/s004280000200; Kowalewski R, 2004, INT ANGIOL, V23, P164; Lalka SG, 1998, J SURG RES, V74, P59, DOI 10.1006/jsre.1997.5189; Lee AJ, 2003, J CLIN EPIDEMIOL, V56, P171, DOI 10.1016/S0895-4356(02)00518-8; Lim CS, 2009, BRIT J SURG, V96, P1231, DOI 10.1002/bjs.6798; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; NORTH KAK, 1958, CIRC RES, V6, P721, DOI 10.1161/01.RES.6.6.721; Pascarella L, 2005, J VASC SURG, V41, P303, DOI 10.1016/j.jvs.2004.10.038; Porto LC, 2002, ANGIOLOGY, V53, P131; Raffetto JD, 2008, PHLEBOLOGY, V23, P85, DOI 10.1258/phleb.2007.007027; Sansilvestri-Morel P, 2002, CIRCULATION, V106, P479, DOI 10.1161/01.CIR.0000022846.22923.46; Somers P, 2006, ANGIOLOGY, V57, P546, DOI 10.1177/0003319706293115; Wali MA, 2002, INT ANGIOL, V21, P337; Woodside KJ, 2003, J VASC SURG, V38, P162, DOI 10.1016/S0741-5214(03)00134-4; Wu X, 2007, AM J PHYSIOL-ENDOC M, V293, pE1789, DOI 10.1152/ajpendo.00249.2007; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1	27	23	25	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3613	3621		10.1096/fj.11-185975	http://dx.doi.org/10.1096/fj.11-185975			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21685329				2022-12-28	WOS:000295356400031
J	Sumoza-Toledo, A; Lange, I; Cortado, H; Bhagat, H; Mori, Y; Fleig, A; Penner, R; Partida-Sanchez, S				Sumoza-Toledo, Adriana; Lange, Ingo; Cortado, Hanna; Bhagat, Harivadan; Mori, Yasuo; Fleig, Andrea; Penner, Reinhold; Partida-Sanchez, Santiago			Dendritic cell maturation and chemotaxis is regulated by TRPM2-mediated lysosomal Ca2+ release	FASEB JOURNAL			English	Article						ADP-ribose; calcium signaling; IP3R; SOCE	CYCLIC ADP-RIBOSE; TRPM2 CHANNELS; NEUTROPHIL GRANULOCYTES; HYDROGEN-PEROXIDE; BETA-CELLS; CALCIUM; MIGRATION; ACTIVATION; MONOCYTES; RECEPTOR	Chemokines induce calcium (Ca2+) signaling and chemotaxis in dendritic cells (DCs), but the molecular players involved in shaping intracellular Ca2+ changes remain to be characterized. Using siRNA and knockout mice, we show that in addition to inositol 1,4,5-trisphosphate (IP3)-mediated Ca2+ release and store-operated Ca2+ entry (SOCE), the transient receptor potential melastatin 2 (TRPM2) channel contributes to Ca2+ release but not Ca2+ influx in mouse DCs. Consistent with these findings, TRPM2 expression in DCs is restricted to endolysosomal vesicles, whereas in neutrophils, the channel localizes to the plasma membrane. TRPM2-deficient DCs show impaired maturation and severely compromised chemokine-activated directional migration as well as bacterial-induced DC trafficking to the draining lymph nodes. Defective DC chemotaxis is due to perturbed chemokine-receptor-initiated Ca2+ signaling mechanisms, which include suppression of TRPM2-mediated Ca2+ release and secondary modification of SOCE. DCs deficient in both TRPM2 and IP3 receptor signaling lose their ability to perform chemotaxis entirely. These results highlight TRPM2 as a key player regulating DC chemotaxis through its function as Ca2+ release channel and confirm ADP-ribose as a novel second messenger for intracellular Ca2+ mobilization.-Sumoza-Toledo, A., Lange, I., Cortado, H., Bhagat, H., Mori, Y., Fleig, A., Penner, R., Partida-Sanchez, S. Dendritic cell maturation and chemotaxis is regulated by TRPM2-mediated lysosomal Ca2+ release. FASEB J. 25, 3529-3542 (2011). www.fasebj.org	[Sumoza-Toledo, Adriana; Cortado, Hanna; Bhagat, Harivadan; Partida-Sanchez, Santiago] Nationwide Childrens Hosp, Res Inst, Ctr Microbial Pathogenesis, Columbus, OH 43205 USA; [Sumoza-Toledo, Adriana; Lange, Ingo; Fleig, Andrea; Penner, Reinhold] Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, Honolulu, HI USA; [Sumoza-Toledo, Adriana; Lange, Ingo; Fleig, Andrea; Penner, Reinhold] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Sumoza-Toledo, Adriana; Cortado, Hanna; Bhagat, Harivadan; Partida-Sanchez, Santiago] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Mori, Yasuo] Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Kyoto, Japan	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; The Queen's Medical Center; University of Hawaii System; University System of Ohio; Ohio State University; Kyoto University	Partida-Sanchez, S (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Microbial Pathogenesis, 700 Childrens Dr, Columbus, OH 43205 USA.	rpenner@hawaii.edu; santiago.partida-sanchez@nationwidechildrens.org	Partida-Sanchez, Santiago/B-7523-2008; Sumoza-Toledo, Adriana/D-5083-2013	Partida-Sanchez, Santiago/0000-0003-2996-9440; Sumoza-Toledo, Adriana/0000-0002-8366-2047; Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537; Lange, Ingo/0000-0002-6703-0015	Research Institute at Nationwide Children's Hospital; U.S. National Institutes of Health [GM063954, GM078195]; U.S. National Institute of Allergy and Infectious Diseases [R01AI092117]; Queen Emma Research Foundation; Research Centers in Minority Institutions; Centers of Biomedical Research Excellence [G12-RR003061, P20-RR016453]; COBRE [2P20RR018727-06]; Grants-in-Aid for Scientific Research [20249015] Funding Source: KAKEN; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003061, P20RR016453, P20RR018727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI092117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM078195, R01GM063954] Funding Source: NIH RePORTER	Research Institute at Nationwide Children's Hospital(Ohio State University); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Queen Emma Research Foundation; Research Centers in Minority Institutions(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Centers of Biomedical Research Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); COBRE; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank S. Johne for technical support. This work was supported by the Research Institute at Nationwide Children's Hospital (S.P.-S. and A.S.-T.), U.S. National Institutes of Health grants GM063954 (R.P.) and GM078195 (A.F.), U.S. National Institute of Allergy and Infectious Diseases grant R01AI092117 (S.P.-S), and The Queen Emma Research Foundation (A.S.-T.). The John A. Burns School of Medicine (JABSOM) Histology and Imaging Core facility is supported by both Research Centers in Minority Institutions and Centers of Biomedical Research Excellence grants (G12-RR003061 and P20-RR016453). The JABSOM Molecular and Cellular Immunology Core facility is supported by COBRE grant 2P20RR018727-06. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicting financial interests.	Bai L, 2009, P NATL ACAD SCI USA, V106, P10254, DOI 10.1073/pnas.0901228106; Barbet G, 2008, NAT IMMUNOL, V9, P1148, DOI 10.1038/ni.1648; Beck A, 2006, FASEB J, V20, P962, DOI 10.1096/fj.05-5538fje; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Calcraft PJ, 2009, NATURE, V459, P596, DOI 10.1038/nature08030; Cheng H, 2007, CELL CALCIUM, V41, P51, DOI 10.1016/j.ceca.2006.04.032; Choi EY, 2009, FRONT BIOSCI-LANDMRK, V14, P1596, DOI 10.2741/3327; Christensen KA, 2002, J CELL SCI, V115, P599; Colvin RA, 2010, NAT IMMUNOL, V11, P495, DOI 10.1038/ni.1878; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Du JY, 2009, P NATL ACAD SCI USA, V106, P7239, DOI 10.1073/pnas.0811725106; Dunzendorfer S, 2000, IMMUNOL LETT, V71, P5, DOI 10.1016/S0165-2478(99)00161-3; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P159, DOI 10.1080/10799890600637506; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Hsu SF, 2001, J IMMUNOL, V166, P6126, DOI 10.4049/jimmunol.166.10.6126; Kennedy AD, 2009, IMMUNOL RES, V43, P25, DOI 10.1007/s12026-008-8049-6; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Koski GK, 1999, BLOOD, V94, P1359, DOI 10.1182/blood.V94.4.1359.416k25_1359_1371; Lange I, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000278; Lange I, 2008, CELL CALCIUM, V44, P604, DOI 10.1016/j.ceca.2008.05.001; Laszlo C, 2009, J GEN PHYSIOL, V133, P189, DOI 10.1085/jgp.200810109; Massullo P, 2006, SEMIN CELL DEV BIOL, V17, P654, DOI 10.1016/j.semcdb.2006.11.006; Matzner N, 2008, J IMMUNOL, V181, P6803, DOI 10.4049/jimmunol.181.10.6803; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; O'Connell PJ, 2002, FEBS LETT, V512, P67, DOI 10.1016/S0014-5793(01)03321-X; Olah ME, 2009, J PHYSIOL-LONDON, V587, P965, DOI 10.1113/jphysiol.2008.162289; Partida-Sanchez S, 2007, J IMMUNOL, V179, P7827, DOI 10.4049/jimmunol.179.11.7827; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Qamar S, 2007, BIOCHEM SOC T, V35, P124, DOI 10.1042/BST0350124; Randolph GJ, 2008, ANNU REV IMMUNOL, V26, P293, DOI 10.1146/annurev.immunol.26.021607.090254; Roederer M, 2001, CYTOMETRY, V45, P47, DOI 10.1002/1097-0320(20010901)45:1<47::AID-CYTO1143>3.0.CO;2-A; Rottembourg D, 2010, J IMMUNOL, V184, P7100, DOI 10.4049/jimmunol.0803935; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Seale AP, 2004, CELL PHYSIOL BIOCHEM, V14, P155, DOI 10.1159/000078107; Selvatici R, 2006, EUR J PHARMACOL, V534, P1, DOI 10.1016/j.ejphar.2006.01.034; Starkus JG, 2010, J PHYSIOL-LONDON, V588, P1227, DOI 10.1113/jphysiol.2010.187476; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Stolk M, 2006, J LEUKOCYTE BIOL, V80, P651, DOI 10.1189/jlb.1205739; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yang W, 2010, J BIOL CHEM, V285, P30411, DOI 10.1074/jbc.M110.139774; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	50	99	103	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3529	3542		10.1096/fj.10-178483	http://dx.doi.org/10.1096/fj.10-178483			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21753080	Green Published			2022-12-28	WOS:000295356400023
J	Huebbe, P; Nebel, A; Siegert, S; Moehring, J; Boesch-Saadatmandi, C; Most, E; Pallauf, J; Egert, S; Muller, MJ; Schreiber, S; Nothlings, U; Rimbach, G				Huebbe, Patricia; Nebel, Almut; Siegert, Sabine; Moehring, Jennifer; Boesch-Saadatmandi, Christine; Most, Erika; Pallauf, Josef; Egert, Sarah; Mueller, Manfred James; Schreiber, Stefan; Noethlings, Ute; Rimbach, Gerald			APOE epsilon 4 is associated with higher vitamin D levels in targeted replacement mice and humans	FASEB JOURNAL			English	Article						apolipoprotein E; epsilon 4 allele; global allele distribution; evolutionary advantage	APOLIPOPROTEIN-E GENOTYPE; GENOME-WIDE ASSOCIATION; CARDIOVASCULAR-DISEASE; D INSUFFICIENCY; E GENE; ALLELE; RISK; ATHEROSCLEROSIS; PREVENTION; INFLAMMATION	The allele epsilon 4 of apolipoprotein E (APOE), which is a key regulator of lipid metabolism, represents a risk factor for cardiovascular diseases and Alzheimer's disease. Despite its adverse effects, the allele is common and shows a nonrandom global distribution that is thought to be the result of evolutionary adaptation. One hypothesis proposes that the APOE epsilon 4 allele protects against vitamin D deficiency. Here we present, for the first time, experimental and epidemiological evidence that the APOE epsilon 4 allele is indeed associated with higher serum vitamin D [25(OH) D] levels. In APOE4 targeted replacement mice, significantly higher 25(OH) D levels were found compared with those in APOE2 and APOE3 mice (70.9 vs. 41.8 and 27.8 nM, P<0.05). Furthermore, multivariate adjusted models show a positive association of the APOE epsilon 4 allele with 25(OH) D levels in a small collective of human subjects (n = 93; P = 0.072) and a general population sample (n = 699; P = 0.003). The novel link suggests epsilon 4 as a modulator of vitamin D status. Although this result agrees well with evolutionary aspects, it appears contradictory with regard to chronic diseases, especially cardiovascular disease. Large prospective cohort studies are now needed to investigate the potential implications of this finding for chronic disease risks.-Huebbe, P., Nebel, A., Siegert, S., Moehring, J., Boesch-Saadatmandi, C., Most, E., Pallauf, J., Egert, S., Muller, M. J., Schreiber, S., Nothlings, U., Rimbach, G. APOE epsilon 4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J. 25, 3262-3270 (2011). www.fasebj.org	[Nebel, Almut] Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; [Huebbe, Patricia; Moehring, Jennifer; Boesch-Saadatmandi, Christine; Egert, Sarah; Mueller, Manfred James; Rimbach, Gerald] Univ Kiel, Inst Human Nutr & Food Sci, D-24105 Kiel, Germany; [Siegert, Sabine; Noethlings, Ute] Univ Kiel, Epidemiol Sect, Inst Expt Med, D-24105 Kiel, Germany; [Most, Erika; Pallauf, Josef] Univ Giessen, Inst Anim Nutr & Nutr Physiol, Giessen, Germany; [Schreiber, Stefan] Univ Hosp Schleswig Holstein, Clin Internal Med 1, Kiel, Germany; [Schreiber, Stefan; Noethlings, Ute] Univ Hosp Schleswig Holstein, PopGen Biobank, Kiel, Germany	University of Kiel; University of Kiel; University of Kiel; Justus Liebig University Giessen; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Nebel, A (corresponding author), Univ Kiel, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany.	a.nebel@mucosa.de	Rimbach, Gerald/A-7178-2011; Nebel, Almut/E-4196-2010; Nöthlings, Ute/B-2713-2010	Rimbach, Gerald/0000-0001-7888-4684; Bosch, Christine/0000-0001-6705-5709	Deutsche Forschungsgemeinschaft; German Federal Ministry of Research and Education	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Research and Education	This study was supported by the Deutsche Forschungsgemeinschaft Excellence Cluster Inflammation at Interfaces and through grants from the German Federal Ministry of Research and Education. P. H. performed the mouse study (sample collection, PCR analyses, total hepatic bile acid analysis) and analyzed the data of the mouse study. J.M., C.B.-S., and P. H. measured the serum 25(OH) D levels in both murine and human samples. E. M. and J.P. did the calcium analysis in bones. S. E. and M.J.M. recruited and phenotyped the MSX subjects. S.Sc. and U.N. established and maintained the PopGen study population. C.B.-S. genotyped the MSX, and A.N. genotyped the PopGen samples. S. Si. and U.N. analyzed the data. G. R., A.N., and U.N. designed the study and coordinated the project. A.N., P. H., U.N., and G. R. wrote the manuscript.	Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155; Anderson JL, 2010, AM J CARDIOL, V106, P963, DOI 10.1016/j.amjcard.2010.05.027; Borradale D, 2009, NUTR RES REV, V22, P118, DOI 10.1017/S0954422409990102; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAIGER SP, 1975, P NATL ACAD SCI USA, V72, P2076, DOI 10.1073/pnas.72.6.2076; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; Dietrich M, 2005, LIPIDS, V40, P329, DOI 10.1007/s11745-006-1390-4; Egert S, 2009, BRIT J NUTR, V102, P1065, DOI 10.1017/S0007114509359127; Engelman CD, 2010, J STEROID BIOCHEM, V122, P186, DOI 10.1016/j.jsbmb.2010.06.013; Finch CE, 2010, P NATL ACAD SCI USA, V107, P1718, DOI 10.1073/pnas.0909606106; Finch CE, 2004, Q REV BIOL, V79, P3, DOI 10.1086/381662; Fujita H, 2006, J HISTOCHEM CYTOCHEM, V54, P933, DOI 10.1369/jhc.6A6944.2006; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; Gaedicke S, 2008, FEBS LETT, V582, P3542, DOI 10.1016/j.febslet.2008.09.032; Geleijnse JM, 2011, AM J HYPERTENS, V24, P253, DOI 10.1038/ajh.2010.199; Gerdes LU, 2003, CLIN CHEM LAB MED, V41, P628, DOI 10.1515/CCLM.2003.094; Gerdes LU, 2001, J BONE MINER RES, V16, P1906, DOI 10.1359/jbmr.2001.16.10.1906; HANLON CS, 1995, ATHEROSCLEROSIS, V112, P85, DOI 10.1016/0021-9150(94)05402-5; Hofmann AF, 1999, NEWS PHYSIOL SCI, V14, P24, DOI 10.1152/physiologyonline.1999.14.1.24; Holick MF, 2004, AM J CLIN NUTR, V79, P362; Holick MF, 2011, CURR DRUG TARGETS, V12, P4; Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435; Jofro-Monseny L, 2007, BIOCHEM BIOPH RES CO, V357, P319, DOI 10.1016/j.bbrc.2007.03.150; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Krawczak M, 2006, COMMUNITY GENET, V9, P55, DOI 10.1159/000090694; Kuhlmann I, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-8; Lucotte G, 1997, HUM BIOL, V69, P253; Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200; Nebel A, 2005, P NATL ACAD SCI USA, V102, P7906, DOI 10.1073/pnas.0408670102; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Oria RB, 2010, BRAZ J MED BIOL RES, V43, P249, DOI 10.1590/S0100-879X2010007500003; Payami H, 2005, HUM GENET, V118, P322, DOI 10.1007/s00439-005-0057-1; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Singh PP, 2006, ANN HUM BIOL, V33, P279, DOI 10.1080/03014460600594513; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Walter A, 2000, J VET MED A, V47, P367, DOI 10.1046/j.1439-0442.2000.00301.x; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Will C, 2008, PERITON DIALYSIS INT, V28, P577; Yuen AWC, 2010, MED HYPOTHESES, V74, P39, DOI 10.1016/j.mehy.2009.08.007; Zerwekh JE, 2008, AM J CLIN NUTR, V87, p1087S, DOI 10.1093/ajcn/87.4.1087S; Zittermann A, 2005, BRIT J NUTR, V94, P483, DOI 10.1079/BJN20051544; Zittermann A, 2006, PROG BIOPHYS MOL BIO, V92, P39, DOI 10.1016/j.pbiomolbio.2006.02.001	45	62	64	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3262	3270		10.1096/fj.11-180935	http://dx.doi.org/10.1096/fj.11-180935			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21659554				2022-12-28	WOS:000294435200038
J	Rong, MQ; Chen, JJ; Tao, H; Wu, YY; Jiang, P; Lu, M; Su, HB; Chi, YP; Cai, TF; Zhao, LQ; Zeng, XZ; Xiao, YC; Liang, SP				Rong, Mingqiang; Chen, Jinjun; Tao, Huai; Wu, Yuanyuan; Jiang, Peng; Lu, Ming; Su, Haibo; Chi, Yupeng; Cai, Tianfu; Zhao, Liqun; Zeng, Xiongzhi; Xiao, Yucheng; Liang, Songping			Molecular basis of the tarantula toxin jingzhaotoxin-III (beta-TRTX-Cj1 alpha) interacting with voltage sensors in sodium channel subtype Nav1.5	FASEB JOURNAL			English	Article						spider toxin; mutation	BETA-SCORPION TOXIN; DOMAIN-II; PROTX-II; CHILOBRACHYS-JINGZHAO; GATING-MODIFIERS; SCANNING MUTAGENESIS; CALCIUM-CHANNELS; ALPHA-SUBUNIT; NA+ CHANNELS; ACTIVATION	With conserved structural scaffold and divergent electrophysiological functions, animal toxins are considered powerful tools for investigating the basic structure-function relationship of voltage-gated sodium channels. Jingzhaotoxin-III (beta-TRTX-Cj1 alpha) is a unique sodium channel gating modifier from the tarantula Chilobrachys jingzhao, because the toxin can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes. However, the molecular basis of JZTX-III interaction with sodium channels remains unknown. In this study, we showed that JZTX-III was efficiently expressed by the secretory pathway in yeast. Alanine-scanning analysis indicated that 2 acidic residues (Asp1, Glu3) and an exposed hydrophobic patch, formed by 4 Trp residues (residues 8, 9, 28 and 30), play important roles in the binding of JZTX-III to Nav1.5. JZTX-III docked to the Nav1.5 DIIS3-S4 linker. Mutations S799A, R800A, and L804A could additively reduce toxin sensitivity of Nav1.5. We also demonstrated that the unique Arg800, not emerging in other sodium channel subtypes, is responsible for JZTX-III selectively interacting with Nav1.5. The reverse mutation D816R in Nav1.7 greatly increased the sensitivity of the neuronal subtype to JZTX-III. Conversely, the mutation R800D in Nav1.5 decreased JZTX-III's IC50 by 72-fold. Therefore, our results indicated that JZTX-III is a site 4 toxin, but does not possess the same critical residues on sodium channels as other site 4 toxins. Our data also revealed the underlying mechanism for JZTX-III to be highly specific for the cardiac sodium channel.-Rong, M., Chen, J., Tao, H., Wu, Y., Jiang, P., Lu, M., Su, H., Chi, Y., Cai, T., Zhao, L., Zeng, X., Xiao, Y., Liang, S. Molecular basis of the tarantula toxin jing-zhaotoxin-III (beta-TRTX-Cj1 alpha) interacting with voltage sensors in sodium channel subtype Nav1.5. FASEB J. 25, 3177-3185 (2011). www.fasebj.org	[Rong, Mingqiang; Tao, Huai; Wu, Yuanyuan; Jiang, Peng; Lu, Ming; Su, Haibo; Chi, Yupeng; Cai, Tianfu; Zhao, Liqun; Zeng, Xiongzhi; Xiao, Yucheng; Liang, Songping] Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, Minist Educ, Changsha 410081, Hunan, Peoples R China; [Chen, Jinjun] Hunan Agr Univ, Coll Biol Sci & Technol, Changsha, Hunan, Peoples R China	Hunan Normal University; Hunan Agricultural University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, Minist Educ, Changsha 410081, Hunan, Peoples R China.	liangsp@hunnu.edu.cn	Xiao, Yucheng/H-3600-2012	Lu, Ming/0000-0003-3768-7267	National 973 Project of China [2010CB529801, 2009BC526510]; Hunan Provincial Education Department [07A035, 10B049]; Chinese Ministry of Education [208096]; Huo Ying Dong Education Foundation [111023]; Program for New Century Excellent Talents in University [NCET-07-0279]; National Natural Science Foundation of China [30900242, 3100047]; Hunan Education Department of Science and Technology [10C0961]	National 973 Project of China(National Basic Research Program of China); Hunan Provincial Education Department(Hunan Provincial Education Department); Chinese Ministry of Education(Ministry of Education, China); Huo Ying Dong Education Foundation; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Education Department of Science and Technology	This work was supported by grants from the National 973 Project of China (2010CB529801, 2009BC526510), the Science Research Fund of the Hunan Provincial Education Department (07A035, 10B049), the Key Project of Chinese Ministry of Education (208096), the Huo Ying Dong Education Foundation (111023), the Program for New Century Excellent Talents in University (NCET-07-0279), the National Natural Science Foundation of China (30900242), the National Natural Science Foundation of China (grant. 3100047), and the Hunan Education Department of Science and Technology Research Project (10C0961).	Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; Campos FV, 2007, J GEN PHYSIOL, V130, P257, DOI 10.1085/jgp.200609719; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Chanda B, 2002, J GEN PHYSIOL, V120, P629, DOI 10.1085/jgp.20028679; Chen J, 2008, CELL MOL LIFE SCI, V65, P2431, DOI 10.1007/s00018-008-8135-x; Chen JJ, 2009, PEPTIDES, V30, P1042, DOI 10.1016/j.peptides.2009.02.018; Clare JJ, 2010, EXPERT OPIN INV DRUG, V19, P45, DOI 10.1517/13543780903435340; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2006, J BIOL CHEM, V281, P20673, DOI 10.1074/jbc.M603212200; Deng MC, 2009, NEUROPHARMACOLOGY, V57, P77, DOI 10.1016/j.neuropharm.2009.04.009; Dutertre S, 2010, J BIOL CHEM, V285, P13315, DOI 10.1074/jbc.R109.076596; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Halai R, 2009, J BIOL CHEM, V284, P20275, DOI 10.1074/jbc.M109.015339; Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735; King GF, 2008, TOXICON, V52, P264, DOI 10.1016/j.toxicon.2008.05.020; Krafte DS, 2008, CURR OPIN PHARMACOL, V8, P50, DOI 10.1016/j.coph.2007.09.007; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Liao Z, 2007, TOXICON, V50, P135, DOI 10.1016/j.toxicon.2007.03.006; Lopreato GF, 2001, P NATL ACAD SCI USA, V98, P7588, DOI 10.1073/pnas.131171798; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; OGATA N, 1993, J PHYSIOL-LONDON, V466, P9; Priest BT, 2007, TOXICON, V49, P194, DOI 10.1016/j.toxicon.2006.09.014; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Saez NJ, 2010, TOXINS, V2, P2851, DOI 10.3390/toxins2122851; Schmalhofer WA, 2008, MOL PHARMACOL, V74, P1476, DOI 10.1124/mol.108.047670; Smith JJ, 2007, J BIOL CHEM, V282, P12687, DOI 10.1074/jbc.M610462200; Smith JJ, 2005, J BIOL CHEM, V280, P11127, DOI 10.1074/jbc.M412552200; Sokolov S, 2008, MOL PHARMACOL, V73, P1020, DOI 10.1124/mol.107.041046; Spencer CI, 2009, TOXICON, V53, P78, DOI 10.1016/j.toxicon.2008.10.015; Tedford HW, 2004, J BIOL CHEM, V279, P44133, DOI 10.1074/jbc.M404006200; Wang JM, 2004, J GEN PHYSIOL, V123, P455, DOI 10.1085/jgp.200309005; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637; Xiao YC, 2004, J BIOL CHEM, V279, P26220, DOI 10.1074/jbc.M401387200; Xiao YC, 2005, J BIOL CHEM, V280, P12069, DOI 10.1074/jbc.M411651200; Xiao YC, 2008, J BIOL CHEM, V283, P27300, DOI 10.1074/jbc.M708447200; Xiao YC, 2010, MOL PHARMACOL, V78, P1124, DOI 10.1124/mol.110.066332; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	41	29	32	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3177	3185		10.1096/fj.10-178848	http://dx.doi.org/10.1096/fj.10-178848			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21665957				2022-12-28	WOS:000294435200030
J	Buxbaum, JN; Tagoe, C; Gallo, G; Walker, JR; Kurian, S; Salomon, DR				Buxbaum, Joel N.; Tagoe, Clement; Gallo, Gloria; Walker, John R.; Kurian, Sunil; Salomon, Daniel R.			Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?	FASEB JOURNAL			English	Article						protein misfolding diseases; microarrays	ENDOPLASMIC-RETICULUM STRESS; RESPONSE ACTIVATOR PXBP1(S); HEAT-SHOCK RESPONSE; POLYNEUROPATHY; GENE; TRB3; TRANSMISSION; PROTEOSTASIS; REGULATOR; DISEASES	In the human systemic amyloidoses caused by mutant or wild-type transthyretin (TTR), deposition occurs at a distance from the site of synthesis. The TTR synthesized and secreted by the hepatocyte circulates in plasma, then deposits in target tissues far from the producing cell, a pattern reproduced in mice transgenic for multiple copies of the human wild-type TTR gene. By 2 yr of age, half of the transgenic males show cardiac deposition resembling human senile systemic amyloidosis. However, as early as 3 mo of age, when there are no deposits, cardiac gene transcription differs from that of nontransgenic littermates, primarily in the expression of a large number of genes associated with inflammation and the immune response. At 24 mo, the hearts with histologically proven TTR deposits show expression of stress response genes, exuberant mitochondrial gene transcription, and increased expression of genes associated with apoptosis, relative to the hearts without TTR deposition. These 24-mo-old hearts with TTR deposits also show a decrease in transcription of inflammatory genes relative to that in the younger transgenic mice. After 2 yr of expressing large amounts of human TTR, the livers of the transgenic mice without cardiac deposition display chaperone gene expression and evidence of an activated unfolded protein response, while the livers of animals with cardiac TTR deposition display neither, showing increased transcription of interferon-responsive inflammatory genes and those encoding an antioxidant response. With time, in animals with cardiac deposition, it appears that hepatic proteostatic capacity is diminished, exposing the heart to a greater load of misfolded TTR with subsequent extracellular deposition. Hence systemic (cardiac) TTR deposition may be the direct result of the diminution in the distant chaperoning capacity of the liver related to age or long-standing exposure to misfolded TTR, or both.-Buxbaum, J. N., Tagoe, C., Gallo, G., Walker, J. R., Kurian, S., Salomon, D. R. Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J. 26, 2283-2293 (2012). www.fasebj.org	[Buxbaum, Joel N.; Kurian, Sunil; Salomon, Daniel R.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Tagoe, Clement] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Gallo, Gloria] NYU, Sch Med, Dept Pathol, New York, NY USA; [Walker, John R.] Novartis Fdn, Funct Genom Inst, La Jolla, CA USA	Scripps Research Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; New York University; Novartis	Buxbaum, JN (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,Mail Code MEM-230, La Jolla, CA 92037 USA.	jbux@scripps.edu	Salomon, Daniel/E-9380-2012; Kurian, Sunil/C-4493-2008	Kurian, Sunil/0000-0002-7782-7263	U.S. National Institutes of Health [R01 AG30027]; NATIONAL INSTITUTE ON AGING [R01AG030027] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The work was supported by U.S. National Institutes of Health grant R01 AG30027 (J.N.B.).	Araki S, 2000, NEUROPATHOLOGY, V20, pS47; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buxbaum JN, 2007, PROTEIN MISFOLDING A, P259; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; HOFER PA, 1975, ACTA PATH MICRO IM A, VA 83, P309; Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266; Llado L, 2010, LIVER TRANSPLANT, V16, P1386, DOI 10.1002/lt.22174; Madrazo JA, 2008, J MOL CELL CARDIOL, V44, P968, DOI 10.1016/j.yjmcc.2008.03.021; Ord D, 2007, EXP CELL RES, V313, P3556, DOI 10.1016/j.yexcr.2007.07.017; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844; Reixach N, 2008, J BIOL CHEM, V283, P2098, DOI 10.1074/jbc.M708028200; Santos SD, 2008, J NEUROPATH EXP NEUR, V67, P449, DOI 10.1097/NEN.0b013e31816fd648; Santos SD, 2010, NEUROBIOL AGING, V31, P280, DOI 10.1016/j.neurobiolaging.2008.04.001; Sato T, 2007, EMBO J, V26, P2501, DOI 10.1038/sj.emboj.7601685; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Shoag J, 2010, ARTERIOSCL THROM VAS, V30, P662, DOI 10.1161/ATVBAHA.108.181636; Sipe JD, 2010, AMYLOID, V17, P101, DOI 10.3109/13506129.2010.526812; Sousa MM, 2004, FASEB J, V18, P124, DOI 10.1096/fj.04-2022fje; Stangou AJ, 2005, NEW ENGL J MED, V352, P2356, DOI 10.1056/NEJM200506023522219; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Takei Y, 2007, LIVER TRANSPLANT, V13, P215, DOI 10.1002/lt.20954; Teixeira PF, 2006, J BIOL CHEM, V281, P21998, DOI 10.1074/jbc.M602302200; Teng MH, 2001, LAB INVEST, V81, P385, DOI 10.1038/labinvest.3780246; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P269, DOI 10.1080/10409230500315352; Wiseman RL, 2007, CELL, V131, P809, DOI 10.1016/j.cell.2007.10.025; Yamamoto S, 2007, TRANSPL INT, V20, P926, DOI 10.1111/j.1432-2277.2007.00516.x; YI S, 1991, AM J PATHOL, V138, P403; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshida H, 2009, CELL STRUCT FUNCT, V34, P1, DOI 10.1247/csf.06028; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; Zhang K, 2006, HANDB EXP PHARM, V172, P69	37	41	41	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2283	2293		10.1096/fj.11-189571	http://dx.doi.org/10.1096/fj.11-189571			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362898	Green Published			2022-12-28	WOS:000305017200007
J	Schallreuter, KU; Salem, MAEL; Gibbons, NCJ; Martinez, A; Slominski, R; Ludemann, J; Rokos, H				Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Martinez, Aurora; Slominski, Radomir; Luedemann, Juergen; Rokos, Hartmut			Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 1: epidermal H2O2/ONOO--mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels	FASEB JOURNAL			English	Article						MITF; calcium channel; hydrogen peroxide; peroxynitrite	HYDROGEN-PEROXIDE H2O2; SUPPORTS OXIDATIVE STRESS; CATALASE GENE; DNA-DAMAGE; COMPUTER-SIMULATION; ANTIOXIDANT ENZYMES; AUTOIMMUNE-DISEASE; CALCIUM IMBALANCE; VITAMIN-C; IN-VIVO	Vitiligo is characterized by a progressive loss of inherited skin color. The cause of the disease is still unknown. To date, there is accumulating in vivo and in vitro evidence for massive oxidative stress via hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) in the skin of affected individuals. Autoimmune etiology is the favored theory. Since depletion of the essential amino acid L-tryptophan (Trp) affects immune response mechanisms, we here looked at epidermal Trp metabolism via tryptophan hydroxylase (TPH) with its downstream cascade, including serotonin and melatonin. Our in situ immunofluorescence and Western blot data reveal significantly lower TPH1 expression in patients with vitiligo. Expression is also low in melanocytes and keratinocytes under in vitro conditions. Although in vivo Fourier transform-Raman spectroscopy proves the presence of 5-hydroxytryptophan, epidermal TPH activity is completely absent. Regulation of TPH via microphthalmia-associated transcription factor and L-type calcium channels is severely affected. Moreover, dopa decarboxylase (DDC) expression is significantly lower, in association with decreased serotonin and melatonin levels. Computer simulation supports H2O2/ONOO--mediated oxidation/nitration of TPH1 and DDC, affecting, in turn, enzyme functionality. Taken together, our data point to depletion of epidermal Trp by Fenton chemistry and exclude melatonin as a relevant contributor to epidermal redox balance and immune response in vitiligo.-Schallreuter, K. U., Salem, M. A. E. L., Gibbons, N. C. J., Martinez, A., Slominski, R., Ludemann, J., Rokos, H. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 1: epidermal H2O2/ONOO--mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels. FASEB J. 26, 2457-2470 (2012). www.fasebj.org	[Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Slominski, Radomir] Univ Bradford, Ctr Skin Sci, Dept Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England; [Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Rokos, Hartmut] Ernst Moritz Arndt Univ Greifswald, Inst Pigmentary Disorders, Greifswald, Germany; [Luedemann, Juergen] Ernst Moritz Arndt Univ Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany; [Martinez, Aurora] Univ Bergen, Dept Biochem, Bergen, Norway	University of Bradford; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; University of Bergen	Schallreuter, KU (corresponding author), Univ Bradford, Ctr Skin Sci, Dept Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk	Martinez, Aurora/M-3088-2019	Martinez, Aurora/0000-0003-1643-6506	Deutsche Vitiligo Verein eV (Hamburg, Germany)	Deutsche Vitiligo Verein eV (Hamburg, Germany)	The authors thank the participating patients for their patience during this long-lasting international collaborative investigation. The work has been supported by private donations to K.U.S. and by the Deutsche Vitiligo Verein eV (Hamburg, Germany).	Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; ARONOFF S, 1965, SCIENCE, V150, P72, DOI 10.1126/science.150.3692.72; Barbosa R, 2008, LIFE SCI, V82, P529, DOI 10.1016/j.lfs.2007.12.011; Burkhard P, 2001, NAT STRUCT BIOL, V8, P963, DOI 10.1038/nsb1101-963; CALANCHINIPOSTIZZI E, 1987, DERMATOLOGICA, V174, P266, DOI 10.1159/000249197; Casp CB, 2002, PIGM CELL RES, V15, P62, DOI 10.1034/j.1600-0749.2002.00057.x; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; Dell'Anna M. L., 2006, J INVEST DERMATOL S3, V126, P403; Dell'Anna ML, 2003, PIGM CELL RES, V16, P553, DOI 10.1034/j.1600-0749.2003.00087.x; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x; Fischer TW, 2006, FASEB J, V20, P1564, DOI 10.1096/fj.05-5227fje; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; FLATMARK T, 1980, ANAL BIOCHEM, V107, P71, DOI 10.1016/0003-2697(80)90494-7; Gavalas NG, 2006, BIOCHEM BIOPH RES CO, V345, P1586, DOI 10.1016/j.bbrc.2006.05.063; Gibbons NQ, 2006, J INVEST DERMATOL, V126, P2576, DOI 10.1038/sj.jid.5700612; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; Gitto E, 2001, J PHARM PHARMACOL, V53, P1393, DOI 10.1211/0022357011777747; Gomez M, 2005, FREE RADICAL BIO MED, V38, P104, DOI 10.1016/j.freeradbiomed.2004.10.009; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Ishii S, 1996, J BIOCHEM, V120, P369; Jin Y, 2010, NAT GENET, V42, P576, DOI 10.1038/ng.602; KIISTALA U, 1968, J INVEST DERMATOL, V50, P129, DOI 10.1038/jid.1968.15; Kitamura R, 2004, J PATHOL, V202, P463, DOI 10.1002/path.1538; Konakchieva R, 1995, J NEUROIMMUNOL, V63, P125, DOI 10.1016/0165-5728(95)00135-2; LISSONI P, 1993, CANCER-AM CANCER SOC, V71, P2076, DOI 10.1002/1097-0142(19930315)71:6<2076::AID-CNCR2820710624>3.0.CO;2-I; Lopez-Burillo S, 2003, J PINEAL RES, V34, P269, DOI 10.1034/j.1600-079X.2003.00041.x; LOPEZGONZALEZ MA, 1992, NEUROSCI LETT, V136, P150, DOI 10.1016/0304-3940(92)90036-7; Maresca V, 1997, J INVEST DERMATOL, V109, P310, DOI 10.1111/1523-1747.ep12335801; Marles LK, 2003, EXP DERMATOL, V12, P61, DOI 10.1034/j.1600-0625.2003.120108.x; McKinney J, 2001, BIOCHEMISTRY-US, V40, P15591, DOI 10.1021/bi015722x; Morii E, 2001, BLOOD, V97, P2038, DOI 10.1182/blood.V97.7.2038; MORREY KM, 1994, J IMMUNOL, V153, P2671; ORECCHIA G, 1994, DERMATOLOGY, V189, P350, DOI 10.1159/000246877; Park HH, 2006, EXP DERMATOL, V15, P377, DOI 10.1111/j.0906-6705.2006.00423.x; Pey AL, 2006, FASEB J, V20, P2130, DOI 10.1096/fj.06-5835fje; PIOLI C, 1993, INT J IMMUNOPHARMACO, V15, P463, DOI 10.1016/0192-0561(93)90060-C; Poon Angela M. S., 1994, Biological Signals, V3, P107; Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rokos H, 2002, BIOCHEM BIOPH RES CO, V292, P805, DOI 10.1006/bbrc.2002.6727; Rokos H, 2008, J RAMAN SPECTROSC, V39, P1214, DOI 10.1002/jrs.1968; Salem MMAEL, 2009, FASEB J, V23, P3790, DOI 10.1096/fj.09-132621; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2007, BIOCHEM BIOPH RES CO, V360, P70, DOI 10.1016/j.bbrc.2007.05.218; Schallreuter KU, 2008, INT J DERMATOL, V47, P743, DOI 10.1111/j.1365-4632.2008.03660.x; Schallreuter KU, 2008, J INVEST DERMATOL, V128, P808, DOI 10.1038/sj.jid.5701100; Schallreuter KU, 2006, J INVEST DERMATOL, V126, P1036, DOI 10.1038/sj.jid.5700257; Schallreuter KU, 2012, FASEB J, V26, P2471, DOI 10.1096/fj.11-201897; Schallreuter KU, 1996, ARCH DERMATOL RES, V288, P14, DOI 10.1007/BF02505037; SCHALLREUTER KU, 1991, J INVEST DERMATOL, V97, P1081, DOI 10.1111/1523-1747.ep12492612; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; SCHALLREUTER KU, 1994, BBA-MOL BASIS DIS, V1226, P181, DOI 10.1016/0925-4439(94)90027-2; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2002, DERMATOLOGY, V204, P194, DOI 10.1159/000057881; Shalbaf M, 2008, EXP DERMATOL, V17, P761, DOI 10.1111/j.1600-0625.2008.00697.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; SLOMINSKI A, 1989, J ROY SOC MED, V82, P539, DOI 10.1177/014107688908200911; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Slominski A, 2008, EXP DERMATOL, V17, P148, DOI 10.1111/j.1600-0625.2007.00666_5.x; Spencer JD, 2007, J INVEST DERMATOL, V127, P411, DOI 10.1038/sj.jid.5700538; Spritz RA, 2012, J INVEST DERMATOL, V132, P268, DOI 10.1038/jid.2011.321; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; Tomas-Zapico C, 2005, J PINEAL RES, V39, P99, DOI 10.1111/j.1600-079X.2005.00248.x; Wajs E, 1995, EUR J ENDOCRINOL, V133, P754, DOI 10.1530/eje.0.1330754; Wang L, 2002, BIOCHEMISTRY-US, V41, P12569, DOI 10.1021/bi026561f; Winiarska K, 2006, J PINEAL RES, V40, P168, DOI 10.1111/j.1600-079X.2005.00295.x; Wood JM, 2009, FASEB J, V23, P2065, DOI 10.1096/fj.08-125435; Wood JM, 2008, EXP DERMATOL, V17, P366, DOI 10.1111/j.1600-0625.2008.00699.x; Yannay-Cohen N, 2009, MOL CELL, V34, P603, DOI 10.1016/j.molcel.2009.05.019; Zmijewski MA, 2009, MOL CELL ENDOCRINOL, V307, P211, DOI 10.1016/j.mce.2009.04.010	80	34	35	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2457	2470		10.1096/fj.11-197137	http://dx.doi.org/10.1096/fj.11-197137			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415302				2022-12-28	WOS:000305017200023
J	Schallreuter, KU; Salem, MAEL; Gibbons, NCJ; Maitland, DJ; Marsch, E; Elwary, SMA; Healey, AR				Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Maitland, Derek J.; Marsch, Elke; Elwary, Souna M. A.; Healey, Andrew R.			Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: epidermal H2O2/ONOO--mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling	FASEB JOURNAL			English	Article						peroxynitrite; Treg; IDO; hydrogen peroxide	SUPPORTS OXIDATIVE STRESS; REGULATORY T-CELLS; H2O2 ACCUMULATION; NITRIC-OXIDE; IN-VIVO; SKIN; IDENTIFICATION; PATHOGENESIS; EXPRESSION; TOLERANCE	Vitiligo is characterized by a mostly progressive loss of the inherited skin color. The cause of the disease is still unknown, despite accumulating in vivo and in vitro evidence of massive oxidative stress via hydrogen peroxide (H2O2) and peroxynitrite (ONOO-) in the skin of affected individuals. The most favored hypothesis is based on autoimmune mechanisms. Since depletion of the essential amino acid L-tryptophan (Trp) severely affects various immune responses, we here looked at Trp metabolism and signaling in these patients. Our in vivo and in vitro data revealed total absence of epidermal Trp hydroxylase activities and the presence of H2O2/ONOO- deactivated indoleamine 2,3-dioxygenase. Aryl hydrocarbon receptor signaling is severely impaired despite the ligand (Trp dimer) being formed, as shown by mass spectrometry. Loss of this signal is supported by the absence of downstream signals (COX-2 and CYP1A1) as well as regulatory T-lymphocytes and by computer modeling. In vivo Fourier transform Raman spectroscopy confirmed the presence of Trp metabolites together with H2O2 supporting deprivation of the epidermal Trp pool by Fenton chemistry. Taken together, our data support a long-expressed role for in loco redox balance and a distinct immune response. These insights could open novel treatment strategies for this disease.-Schallreuter, K. U., Salem, M. A. E. L., Gibbons, N.C.J., Maitland, D. J., Marsch, E., Elwary, S., Healey, A. R. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: epidermal H2O2/ONOO--mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling. FASEB J. 26, 2471-2485 (2012). www.fasebj.org	[Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Elwary, Souna M. A.] Univ Bradford, Ctr Skin Sci, Dept Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England; [Schallreuter, Karin U.; Salem, Mohamed A. E. L.; Gibbons, Nick C. J.; Marsch, Elke; Elwary, Souna M. A.] Univ Greifswald, Inst Pigmentary Disorders, Greifswald, Germany; [Maitland, Derek J.] Univ Bradford, Dept Chem & Forens Sci, Bradford BD7 1DP, W Yorkshire, England; [Healey, Andrew R.] Univ Bradford, Analyt Ctr, Bradford BD7 1DP, W Yorkshire, England	University of Bradford; Ernst Moritz Arndt Universitat Greifswald; University of Bradford; University of Bradford	Schallreuter, KU (corresponding author), Univ Bradford, Ctr Skin Sci, Dept Clin & Expt Dermatol, Bradford BD7 1DP, W Yorkshire, England.	k.schallreuter@bradford.ac.uk			Deutsche Vitiligo Verein eV (Hamburg, Germany)	Deutsche Vitiligo Verein eV (Hamburg, Germany)	This research was kindly supported by the Deutsche Vitiligo Verein eV (Hamburg, Germany) and by a grant to K. U. S. and by private donations. The authors are grateful for excellent technical support by Ms. M. A. T. el Sayed.	Afzali B, 2007, CLIN EXP IMMUNOL, V148, P32, DOI 10.1111/j.1365-2249.2007.03356.x; Basak PY, 2009, J AM ACAD DERMATOL, V60, P256, DOI 10.1016/j.jaad.2008.09.048; CALANCHINIPOSTIZZI E, 1987, DERMATOLOGICA, V174, P266, DOI 10.1159/000249197; Dyer JM, 2006, PHOTOCH PHOTOBIO SCI, V5, P698, DOI 10.1039/b603030k; Esser C, 2009, TRENDS IMMUNOL, V30, P447, DOI 10.1016/j.it.2009.06.005; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Fujigaki H, 2006, J IMMUNOL, V176, P372, DOI 10.4049/jimmunol.176.1.372; GRIMES PE, 1986, J AM ACAD DERMATOL, V14, P196, DOI 10.1016/S0190-9622(86)70021-2; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Jux B, 2011, J INVEST DERMATOL, V131, P203, DOI 10.1038/jid.2010.269; KIISTALA U, 1968, J INVEST DERMATOL, V50, P129, DOI 10.1038/jid.1968.15; King NJC, 2007, INT J BIOCHEM CELL B, V39, P2167, DOI 10.1016/j.biocel.2007.01.004; Klarquist J, 2010, PIGM CELL MELANOMA R, V23, P276, DOI 10.1111/j.1755-148X.2010.00688.x; Marles LK, 2003, EXP DERMATOL, V12, P61, DOI 10.1034/j.1600-0625.2003.120108.x; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Nguyen NT, 2010, P NATL ACAD SCI USA, V107, P19961, DOI 10.1073/pnas.1014465107; Pandini A, 2007, BIOCHEMISTRY-US, V46, P696, DOI 10.1021/bi061460t; Parrish J. A., 1979, DERMATOLOGY GENERAL, P942; Pey AL, 2006, FASEB J, V20, P2130, DOI 10.1096/fj.06-5835fje; Pingle Shubhangi K, 2008, Indian J Occup Environ Med, V12, P107, DOI 10.4103/0019-5278.44690; Poljak A, 2006, ARCH BIOCHEM BIOPHYS, V450, P9, DOI 10.1016/j.abb.2006.03.003; Rannug U, 1995, CHEM BIOL, V2, P841, DOI 10.1016/1074-5521(95)90090-X; Rokos H, 2008, J RAMAN SPECTROSC, V39, P1214, DOI 10.1002/jrs.1968; Salem MMAEL, 2009, FASEB J, V23, P3790, DOI 10.1096/fj.09-132621; Samelson-Jones BJ, 2006, BIOCHEMISTRY-US, V45, P8527, DOI 10.1021/bi060143j; Schallreuter KU, 2008, EXP DERMATOL, V17, P139, DOI [10.1111/j.1600-0625.2007.00666_1.x, 10.1111/j.1600-0625.2007.00666.x]; Schallreuter KU, 2008, INT J DERMATOL, V47, P743, DOI 10.1111/j.1365-4632.2008.03660.x; Schallreuter KU, 2007, LIFE SCI, V80, P2221, DOI 10.1016/j.lfs.2007.01.028; Schallreuter KU, 2012, FASEB J, V26, P2457, DOI 10.1096/fj.11-197137; Schallreuter KU, 1996, ARCH DERMATOL RES, V288, P14, DOI 10.1007/BF02505037; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2002, DERMATOLOGY, V204, P194, DOI 10.1159/000057881; Schallreuter KU, 2001, J INVEST DERMATOL, V116, P167, DOI 10.1046/j.1523-1747.2001.00220.x; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schroecksnadel K, 2006, CLIN RHEUMATOL, V25, P334, DOI 10.1007/s10067-005-0056-6; Shalbaf M, 2008, EXP DERMATOL, V17, P761, DOI 10.1111/j.1600-0625.2008.00697.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Stevens EA, 2009, IMMUNOLOGY, V127, P299, DOI 10.1111/j.1365-2567.2009.03054.x; Sugimoto H, 2006, P NATL ACAD SCI USA, V103, P2611, DOI 10.1073/pnas.0508996103; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Wang CQF, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025832, 10.1371/journal.pone.0018907]; Wood JM, 2009, FASEB J, V23, P2065, DOI 10.1096/fj.08-125435	51	48	52	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2471	2485		10.1096/fj.11-201897	http://dx.doi.org/10.1096/fj.11-201897			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415306				2022-12-28	WOS:000305017200024
J	Mogilenko, DA; Orlov, SV; Trulioff, AS; Ivanov, AV; Nagumanov, VK; Kudriavtsev, IV; Shavva, VS; Tanyanskiy, DA; Perevozchikov, AP				Mogilenko, Denis A.; Orlov, Sergey V.; Trulioff, Andrey S.; Ivanov, Andrey V.; Nagumanov, Vadim K.; Kudriavtsev, Igor V.; Shavva, Vladimir S.; Tanyanskiy, Dmitry A.; Perevozchikov, Andrej P.			Endogenous apolipoprotein A-I stabilizes ATP-binding cassette transporter A1 and modulates Toll-like receptor 4 signaling in human macrophages	FASEB JOURNAL			English	Article						TNF-alpha; IL-1 beta; NOS2; LPS; lipid rafts	HIGH-DENSITY-LIPOPROTEIN; NECROSIS-FACTOR-ALPHA; WHITE BLOOD-CELLS; E MESSENGER-RNA; INFLAMMATORY RESPONSE; CHOLESTEROL EFFLUX; LIPID RAFTS; TNF-ALPHA; APOA-I; EXPRESSION	Apolipoprotein A-I (ApoA-I) is the main functional protein component of human high-density lipoproteins. ApoA-I shows various anti-inflammatory and atheroprotective properties toward macrophages; however, endogenous apoA-I expression has not been investigated in macrophages. We have shown that endogenous apoA-I gene is expressed in human macrophages at both mRNA and protein levels. Endogenous ApoA-I is localized in intracellular vesicles and at the external side of the plasma membrane in association with ATP-binding cassette transporter A1 (ABCA1) and lipid rafts in macrophages. We have shown that endogenous ApoA-I stabilizes ABCA1, moreover, down-regulation of ApoA-I by siRNA results in an increase of Toll-like receptor 4 (TLR4) mRNA and membrane surface protein expression, as well as an enhancement of bacterial lipopolysaccharide (LPS)-induced expression of tumor necrosis factor-alpha (TNF-alpha), interleukin 1 alpha (IL-1 beta), and inducible nitric oxide synthase (NOS2) genes in human macrophages. TNF-alpha stimulates ApoA-I expression and secretion (1.2 +/- 0.2 vs. 4.3 +/- 0.9 ng/mg total protein) in macrophages. Obtained results suggest that endogenous ApoA-I has anti-inflammatory properties, presumably due to ABCA1 stabilization in macrophages; these results elucidate the cell type-specific mechanism of the TNF-alpha-mediated regulation of apoA-I gene expression in monocytes and macrophages.-Mogilenko, D. A., Orlov, S. V., Trulioff, A. S., Ivanov, A. V., Nagumanov, V. K., Kudriavtsev, I. V., Shavva, V. S., Tanyanskiy, D. A., Perevozchikov, A. P. Endogenous apolipoprotein A-I stabilizes ATP-binding cassette transporter A1 and modulates Toll-like receptor 4 signaling in human macrophages. FASEB J. 26, 2019-2030 (2012). www.fasebj.org	[Mogilenko, Denis A.; Orlov, Sergey V.; Tanyanskiy, Dmitry A.; Perevozchikov, Andrej P.] Russian Acad Med Sci, Inst Expt Med, Dept Biochem, St Petersburg 197376, Russia; [Trulioff, Andrey S.] Russian Acad Med Sci, Inst Expt Med, Dept Immunol, St Petersburg 197376, Russia; [Mogilenko, Denis A.; Orlov, Sergey V.; Shavva, Vladimir S.; Perevozchikov, Andrej P.] St Petersburg State Univ, Dept Embryol, St Petersburg, Russia; [Nagumanov, Vadim K.; Kudriavtsev, Igor V.] St Petersburg State Univ, Dept Cytol & Histol, St Petersburg, Russia; [Ivanov, Andrey V.] NW Reg Med Ctr, St Petersburg, Russia	Institute of Experimental Medicine; Russian Academy of Medical Sciences; Institute of Experimental Medicine; Russian Academy of Medical Sciences; Saint Petersburg State University; Saint Petersburg State University	Mogilenko, DA (corresponding author), Russian Acad Med Sci, Inst Expt Med, Dept Biochem, Acad Pavlov St 12, St Petersburg 197376, Russia.	denis@iem.sp.ru; serge@iem.sp.ru; app@iem.sp.ru	Perevozchikov, Andrej/M-9744-2015; Orlov, Sergey V./N-6823-2014; Kudryavtsev, Igor/D-2124-2013; Tanyanskiy, Dmitry/G-3307-2015; Mogilenko, Denis/H-4436-2013; Mogilenko, Denis/ABE-9454-2021; Ivanov, Andrei/J-6062-2015; Trulioff, Andrey/AAF-5844-2021	Perevozchikov, Andrej/0000-0001-7049-3224; Orlov, Sergey V./0000-0002-3134-1989; Kudryavtsev, Igor/0000-0001-7204-7850; Tanyanskiy, Dmitry/0000-0002-5321-8834; Mogilenko, Denis/0000-0001-5427-5243; Ivanov, Andrei/0000-0002-1676-7754; Trulioff, Andrey/0000-0002-7495-446X; Shavva, Vladimir S./0000-0002-5080-8636	Russian Fund of Basic Research [09-04-01301, 11-04-02012-a]	Russian Fund of Basic Research(Russian Foundation for Basic Research (RFBR))	The authors thank C. Benken (St. Petersburg State University, St. Petersburg, Russia) and Dr. S. A. Podzorova (Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg, Russia) for methodological assistance with the LSCM, Dr. E. B. Dizhe (Institute of Experimental Medicine, Russian Academy of Medical Sciences, Russia) for methodological assistance with HepG2 cell cultivation, and Dr. A. D. Denisenko (Institute of Experimental Medicine) for helpful discussions and reviewing the manuscript. The work has been supported by the Russian Fund of Basic Research (grants 09-04-01301 and 11-04-02012-a).	Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; Bresnihan B, 2004, ARTHRITIS RES THER, V6, pR563, DOI 10.1186/ar1443; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; DUAN HW, 1995, J CLIN INVEST, V96, P915, DOI 10.1172/JCI118139; EGGERMAN TL, 1991, J LIPID RES, V32, P821; EPAND RM, 1994, ARTERIOSCLER THROMB, V14, P1775, DOI 10.1161/01.ATV.14.11.1775; Feig JE, 2011, P NATL ACAD SCI USA, V108, P7166, DOI 10.1073/pnas.1016086108; Gaus K, 2004, FASEB J, V18, P574, DOI 10.1096/fj.03-0486fje; Hozoji M, 2008, J BIOL CHEM, V283, P30057, DOI 10.1074/jbc.M804599200; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; Major AS, 2001, ARTERIOSCL THROM VAS, V21, P1790, DOI 10.1161/hq1101.097798; Martinez-Lopez E, 2007, LIVER INT, V27, P930, DOI 10.1111/j.1478-3231.2007.01509.x; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; Mogilenko DA, 2010, BIOCHEM BIOPH RES CO, V402, P477, DOI 10.1016/j.bbrc.2010.10.053; Mogilenko DA, 2009, BIOCHEMISTRY-US, V48, P11950, DOI 10.1021/bi9015742; Murphy AJ, 2008, ARTERIOSCL THROM VAS, V28, P2071, DOI 10.1161/ATVBAHA.108.168690; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Nuno-Gonzalez P, 2005, BBA-MOL BASIS DIS, V1740, P350, DOI 10.1016/j.bbadis.2004.11.003; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Orlov SV, 2010, BIOCHEM BIOPH RES CO, V398, P224, DOI 10.1016/j.bbrc.2010.06.064; Rye KA, 2008, ARTERIOSCL THROM VAS, V28, P1890, DOI 10.1161/ATVBAHA.108.173575; Song H, 1998, CYTOKINE, V10, P275, DOI 10.1006/cyto.1997.0291; Srivastava R, 2000, MOL CELL BIOCHEM, V209, P131, DOI 10.1023/A:1007111830472; Su YR, 2008, ARTERIOSCL THROM VAS, V28, P1439, DOI 10.1161/ATVBAHA.107.160093; Suzuki M, 2010, CIRCULATION, V122, P1919, DOI 10.1161/CIRCULATIONAHA.110.961193; Tang CR, 2009, J BIOL CHEM, V284, P32336, DOI 10.1074/jbc.M109.047472; Tedla N, 2004, IMMUNOLOGY, V113, P338, DOI 10.1111/j.1365-2567.2004.01972.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang X, 2007, CURR OPIN CARDIOL, V22, P368, DOI 10.1097/HCO.0b013e3281ec5113; WU AL, 1979, J BIOL CHEM, V254, P7316; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zhu X, 2008, J BIOL CHEM, V283, P22930, DOI 10.1074/jbc.M801408200; Zhu XW, 2010, J LIPID RES, V51, P3196, DOI 10.1194/jlr.M006486	40	35	41	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2019	2030		10.1096/fj.11-193946	http://dx.doi.org/10.1096/fj.11-193946			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22271762				2022-12-28	WOS:000303680800028
J	Tradtrantip, L; Zhang, H; Anderson, MO; Saadoun, S; Phuan, PW; Papadopoulos, MC; Bennett, JL; Verkman, AS				Tradtrantip, Lukmanee; Zhang, Hua; Anderson, Marc O.; Saadoun, Samira; Phuan, Puay-Wah; Papadopoulos, Marios C.; Bennett, Jeffrey L.; Verkman, A. S.			Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica	FASEB JOURNAL			English	Article						water channel; Devic's disease; drug discovery; autoantibody	ORTHOGONAL ARRAYS; IN-VITRO; IMMUNOGLOBULIN-G; WATER TRANSPORT; SINGLE; BRAIN; ANTIBODIES; QUERCETIN; DISEASE; CELLS	Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of spinal cord and optic nerve caused by pathogenic autoantibodies (NMO-IgG) against astrocyte aquaporin-4 (AQP4). We developed a high-throughput screen to identify blockers of NMO-IgG binding to human AQP4 using a human recombinant monoclonal NMO-IgG and transfected Fisher rat thyroid cells stably expressing human M23-AQP4. Screening of similar to 60,000 compounds yielded the antiviral arbidol, the flavonoid tamarixetin, and several plant-derived berbamine alkaloids, each of which blocked NMO-IgG binding to AQP4 without affecting AQP4 expression, array assembly, or water permeability. The compounds inhibited NMO-IgG binding to AQP4 in NMO patient sera and blocked NMO-IgG-dependent complement-and cell-mediated cytotoxicity with IC50 down to similar to 5 mu M. Docking computations identified putative sites of blocker binding at the extracellular surface of AQP4. The blockers did not affect complement-dependent cytotoxicity caused by anti-GD3 antibody binding to ganglioside GD3. The blockers reduced by >80% the severity of NMO lesions in an ex vivo spinal cord slice culture model of NMO and in mice in vivo. Our results provide proof of concept for a small-molecule blocker strategy to reduce NMO pathology. Small-molecule blockers may also be useful for other autoimmune diseases caused by binding of pathogenic autoantibodies to defined targets.-Tradtrantip, L., Zhang, H., Anderson, M. O., Saadoun, S., Phuan, P.-W., Papadopoulos, M. C., Bennett, J. L., Verkman, A. S. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 26, 2197-2208 (2012). www.fasebj.org	[Tradtrantip, Lukmanee; Zhang, Hua; Phuan, Puay-Wah; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Tradtrantip, Lukmanee; Zhang, Hua; Phuan, Puay-Wah; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Anderson, Marc O.] San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA; [Saadoun, Samira; Papadopoulos, Marios C.] Univ London, Acad Neurosurg Unit, London, England; [Bennett, Jeffrey L.] Univ Colorado Denver, Dept Neurol, Aurora, CO USA; [Bennett, Jeffrey L.] Univ Colorado Denver, Dept Ophthalmol, Aurora, CO USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California State University System; San Francisco State University; University of London; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu		Saadoun, Samira/0000-0002-5480-5678; Papadopoulos, Marios/0000-0001-9174-4176	Guthy-Jackson Charitable Foundation; U.S. National Institutes of Health [EY13574, EB00415, DK35124, HL73856, DK86125, DK72517]; National Multiple Sclerosis Society [RG4320]; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, P30DK072517, RC1DK086125, R37DK035124] Funding Source: NIH RePORTER	Guthy-Jackson Charitable Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Guthy-Jackson Charitable Foundation (to A.S.V., M.C.P., and J.L.B.); grants EY13574, EB00415, DK35124, HL73856, DK86125, and DK72517 from the U.S. National Institutes of Health (to A.S.V.); and grant RG4320 from the National Multiple Sclerosis Society (to J.L.B.).	Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Bennett JL, 2009, ANN NEUROL, V66, P617, DOI 10.1002/ana.21802; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658; Boriskin YS, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-56; Bradl M, 2009, ANN NEUROL, V66, P630, DOI 10.1002/ana.21837; Chai HF, 2006, BIOORGAN MED CHEM, V14, P911, DOI 10.1016/j.bmc.2005.08.041; Crane JM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.227298; Crane JM, 2009, J BIOL CHEM, V284, P35850, DOI 10.1074/jbc.M109.071670; Crane JM, 2009, J CELL SCI, V122, P813, DOI 10.1242/jcs.042341; Cree B, 2008, CURR NEUROL NEUROSCI, V8, P427, DOI 10.1007/s11910-008-0066-2; de Boer VCJ, 2005, J NUTR, V135, P1718, DOI 10.1093/jn/135.7.1718; Glushkov R. G., 1992, Drugs of the Future, V17, P1079; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hinson SR, 2007, NEUROLOGY, V69, P2221, DOI 10.1212/01.WNL.0000289761.64862.ce; Ho JD, 2009, P NATL ACAD SCI USA, V106, P7437, DOI 10.1073/pnas.0902725106; Jarius S, 2008, NAT CLIN PRACT NEURO, V4, P202, DOI 10.1038/ncpneuro0764; Jarius S, 2010, NAT REV NEUROL, V6, P383, DOI 10.1038/nrneurol.2010.72; Jin BJ, 2011, BIOPHYS J, V100, P2936, DOI 10.1016/j.bpj.2011.05.012; Kinoshita M, 2009, BIOCHEM BIOPH RES CO, V386, P623, DOI 10.1016/j.bbrc.2009.06.085; Lavillette D, 2006, J BIOL CHEM, V281, P3909, DOI 10.1074/jbc.M509747200; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Li LH, 2011, FASEB J, V25, P1556, DOI 10.1096/fj.10-177279; LI Q, 1981, Chinese Journal of Tuberculosis and Respiratory Diseases, V4, P321; LIU CX, 1991, PHYTOTHER RES, V5, P228, DOI 10.1002/ptr.2650050508; Liu MY, 2009, CLIN THER, V31, P784, DOI 10.1016/j.clinthera.2009.04.016; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Mader S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010455; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marignier R, 2010, BRAIN, V133, P2578, DOI 10.1093/brain/awq177; Nielsen S, 1997, J NEUROSCI, V17, P171; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Parratt JDE, 2010, MULT SCLER J, V16, P1156, DOI 10.1177/1352458510382324; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Ren YP, 2008, J IMMUNOL, V181, P1491, DOI 10.4049/jimmunol.181.2.1491; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2012, ANN NEUROL, V71, P323, DOI 10.1002/ana.22686; Saadoun S, 2010, BRAIN, V133, P349, DOI 10.1093/brain/awp309; Schulz HU, 2005, ARZNEIMITTELFORSCH, V55, P561; Tajima M, 2010, J BIOL CHEM, V285, P8163, DOI 10.1074/jbc.M109.093948; Tradtrantip L, 2012, ANN NEUROL, V71, P314, DOI 10.1002/ana.22657; van der Woude H, 2004, CHEM RES TOXICOL, V17, P1520, DOI 10.1021/tx049826v; Verkman AS, 2011, ACTA PHARMACOL SIN, V32, P702, DOI 10.1038/aps.2011.27; Wei YL, 2009, ACTA PHARMACOL SIN, V30, P451, DOI 10.1038/aps.2009.19; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8; Wolburg H, 2011, INT REV CEL MOL BIO, V287, P1, DOI 10.1016/B978-0-12-386043-9.00001-3; Xu WL, 2006, LEUKEMIA RES, V30, P407, DOI 10.1016/j.leukres.2005.08.005; Yang BX, 2008, BIOORGAN MED CHEM, V16, P7489, DOI 10.1016/j.bmc.2008.06.005; Zhang H, 2011, ANN NEUROL, V70, P943, DOI 10.1002/ana.22551	52	63	70	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2197	2208		10.1096/fj.11-201608	http://dx.doi.org/10.1096/fj.11-201608			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22319008	Green Published			2022-12-28	WOS:000303680800045
J	Serhan, CN; Dalli, J; Karamnov, S; Choi, A; Park, CK; Xu, ZZ; Ji, RR; Zhu, M; Petasis, NA				Serhan, Charles N.; Dalli, Jesmond; Karamnov, Sergey; Choi, Alexander; Park, Chul-Kyu; Xu, Zhen-Zhong; Ji, Ru-Rong; Zhu, Min; Petasis, Nicos A.			Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain	FASEB JOURNAL			English	Article						DHA metabolome; eicosanoids; inflammation resolution; neutrophils; resolvins	DOCOSAHEXAENOIC ACID; INFLAMMATORY PAIN; RESOLUTION-PHASE; LIPID MEDIATORS; RESOLVINS; MECHANISMS; ASPIRIN; BIOSYNTHESIS; PROTECTINS; SENSATION	Self-resolving inflammatory exudates and lipid mediator metabolomics recently uncovered a new family of potent anti-inflammatory and proresolving mediators biosynthesized by macrophages (M Phi s), denoted maresins. Here we determined that maresin 1 (MaR1) produced by human M Phi s from endogenous docosahexaenoic acid (DHA) matched synthetic 7R,14S-dihydroxydocosa-4Z, 8E, 10E, 12Z, 16Z, 19Z-hexaenoic acid. The MaR1 alcohol groups and Z/E geometry of conjugated double bonds were matched using isomers prepared by total organic synthesis. MaR1's potent defining actions were confirmed with synthetic MaR1, i.e., limiting poly-morphonuclear neutrophil (PMN) infiltration in murine peritonitis (ng/mouse range) as well as enhancing human macrophage uptake of apoptotic PMNs. At 1 nM, MaR1 was slightly more potent than resolvin D1 in stimulating human M Phi efferocytosis, an action not shared by leukotriene B-4. MaR1 also accelerated surgical regeneration in planaria, increasing the rate of head reappearance. On injury of planaria, MaR1 was biosynthesized from deuterium-labeled (d(5))-DHA that was blocked with lipoxygenase (LOX) inhibitor. MaR1 dose-dependently inhibited TRPV1 currents in neurons, blocked capsaicin (100 nM)-induced inward currents (IC50 0.49 +/- 0.02 nM), and reduced both inflammation- and chemotherapy-induced neuropathic pain in mice. These results demonstrate the potent actions of MaR1 in regulating inflammation resolution, tissue regeneration, and pain resolution. These findings suggest that chemical signals are shared in resolution cellular trafficking, a key process in tissue regeneration. Moreover, immunoresolvents of the innate immune response, such as MaR1, offer new opportunities for assessing M Phi s and their local DHA metabolome in the return to tissue homeostasis.-Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C.-K., Xu, Z.-Z., Ji, R.-R., Zhu, M., Petasis, N. A. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26, 1755-1765 (2012). www.fasebj.org	[Serhan, Charles N.; Dalli, Jesmond; Karamnov, Sergey; Choi, Alexander] Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; [Park, Chul-Kyu; Xu, Zhen-Zhong; Ji, Ru-Rong] Brigham & Womens Hosp, Pain Res Ctr, Sensory Plast Lab, Boston, MA 02115 USA; [Serhan, Charles N.; Dalli, Jesmond; Karamnov, Sergey; Choi, Alexander; Park, Chul-Kyu; Xu, Zhen-Zhong; Ji, Ru-Rong] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; [Zhu, Min; Petasis, Nicos A.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Petasis, Nicos A.] Univ So Calif, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California; University of Southern California	Serhan, CN (corresponding author), Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, 77 Ave Louis Pasteur,HIM 829, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Ji, Ru-Rong/L-7070-2017; Petasis, Nicos/B-3162-2009; Karamnov, Sergey/ABD-6350-2020; Karamnov, Sergey/D-7554-2016	Ji, Ru-Rong/0000-0002-9355-3688; Petasis, Nicos/0000-0002-8864-4446; Karamnov, Sergey/0000-0002-4198-7548; Xu, Zhen-Zhong/0000-0001-6578-211X; Dalli, Jesmond/0000-0001-6328-3640	U.S. National Institutes of Health [1P01GM095467, 1R01DE019938, 1R01NS067686]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS067686] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Mary Halm Small for expert assistance in manuscript preparation, Thad W. Vickery for technical assistance, and Dr. Rong Yang for initial LC-MS/MS methods to isolate isomers of MaR1 and related structures. The authors also thank Iris Kao for assistance in the initial planaria experiments. The work was supported in part by U.S. National Institutes of Health grants 1P01GM095467 (C.N.S., N.A.P.), 1R01DE019938 (C.N.S.), and 1R01NS067686 (R.R.J., C.N.S.). The authors report no conflicts of interest.	Bang S, 2010, BRIT J PHARMACOL, V161, P707, DOI 10.1111/j.1476-5381.2010.00909.x; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Cotran R S, 1982, Monogr Pathol, P18; Dai Y, 2007, J CLIN INVEST, V117, P1979, DOI 10.1172/JCI30951; De Caterina R, 2011, NEW ENGL J MED, V364, P2439, DOI 10.1056/NEJMra1008153; Fredman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024422; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Hong S, 2005, PROSTAG OTH LIPID M, V78, P107, DOI 10.1016/j.prostaglandins.2005.04.004; Huang LA, 2011, PAIN, V152, P557, DOI 10.1016/j.pain.2010.11.021; Joseph EK, 2004, EUR J NEUROSCI, V20, P2896, DOI 10.1111/j.1460-9568.2004.03750.x; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Lima-Garcia JF, 2011, BRIT J PHARMACOL, V164, P278, DOI 10.1111/j.1476-5381.2011.01345.x; Majno G., 1982, CURRENT TOPICS INFLA; Majno G., 2004, CELLS TISSUES DIS PR; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Oh SF, 2011, BBA-MOL CELL BIOL L, V1811, P737, DOI 10.1016/j.bbalip.2011.06.007; Oh SF, 2011, J CLIN INVEST, V121, P569, DOI 10.1172/JCI42545; Pellettieri J, 2010, DEV BIOL, V338, P76, DOI 10.1016/j.ydbio.2009.09.015; Price Sarah, 2010, Nat Rev Rheumatol, V6, P379, DOI 10.1038/nrrheum.2010.88; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Raatz SK, 2011, J AGR FOOD CHEM, V59, P11278, DOI 10.1021/jf202576k; Rossi A, 2008, RESOLUTION INFLAMMAT; Rowley A. F., 1998, EICOSANOIDS RELATED; Russell DG, 2009, PHAGOCYTE-PATHOGEN INTERACTIONS: MACROPHAGES AND THE HOST RESPONSE TO INFECTION, pXIII; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sasaki K, 2011, CHEM-ASIAN J, V6, P534, DOI 10.1002/asia.201000494; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Serhan CN, 2011, CURR TOP MED CHEM, V11, P629; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Tian HB, 2011, J BIOL CHEM, V286, P4443, DOI 10.1074/jbc.M110.100388; Xu ZZ, 2011, BRIT J PHARMACOL, V164, P274, DOI 10.1111/j.1476-5381.2011.01348.x; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364; Yang R., 2011, CURR PROTOC IMMUNOL, V95; Zak DE, 2009, IMMUNOL REV, V227, P264, DOI 10.1111/j.1600-065X.2008.00721.x; Zayas RM, 2010, DEV DYNAM, V239, P2888, DOI 10.1002/dvdy.22427	48	308	316	8	109	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1755	1765		10.1096/fj.11-201442	http://dx.doi.org/10.1096/fj.11-201442			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22253477	Green Published			2022-12-28	WOS:000302359700036
J	Moan, J; Nielsen, KP; Juzeniene, A				Moan, Johan; Nielsen, Kristian Pagh; Juzeniene, Asta			Immediate pigment darkening: its evolutionary roles may include protection against folate photosensitization	FASEB JOURNAL			English	Article						UVA; human skin color	HUMAN SKIN; ACTION SPECTRA; ERYTHEMA; 5-METHYLTETRAHYDROFOLATE; ULTRAVIOLET; UVA; MELANOGENESIS; RADIATION; MELANIN; PHOTODEGRADATION	The evolution of dark human skin colors in tropical areas is possibly related to photoprotection of folates. However, natural folates absorb mainly UVB radiation, and too little UVB can penetrate down to folates in dermal vessels to cause serious damage. However, endogenous photosensitizers, like riboflavin and uroporphyrin, absorbing UVA and visible light, can cause photosensitization of folates. Immediate pigment darkening (IPD), generated by UVA, has an absorption spectrum covering those of the endogenous photosensitizers. IPD is most prominent for darker skin types, which were typical for populations living under tropical solar fluences. We here propose that the biological role of IPD is protection of folates against photodegradation, which would be of large evolutionary importance for early hominids.-Moan, J., Nielsen, K. P., Juzeniene, A. Immediate pigment darkening: its evolutionary roles may include protection against folate photosensitization. FASEB J. 26, 971-975 (2012). www.fasebj.org	[Moan, Johan; Juzeniene, Asta] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Montebello, Norway; [Moan, Johan] Univ Oslo, Inst Phys, Oslo, Norway; [Nielsen, Kristian Pagh] Danish Meteorol Inst, Copenhagen, Denmark	University of Oslo; University of Oslo; Danish Meteorological Institute DMI	Juzeniene, A (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, N-0310 Oslo, Norway.	asta.juzeniene@rr-research.no		Juzeniene, Asta/0000-0001-9426-0062				Agar N, 2005, MUTAT RES-FUND MOL M, V571, P121, DOI 10.1016/j.mrfmmm.2004.11.016; AGIN PP, 1985, PHOTODERMATOLOGY, V2, P288; AMBACH W, 1993, EXPERIENTIA, V49, P747, DOI 10.1007/BF01923543; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; [Anonymous], 1979, DTSCH NOR, P1; AULETTA M, 1986, J INVEST DERMATOL, V86, P649, DOI 10.1111/1523-1747.ep12275683; Baier J, 2006, BIOPHYS J, V91, P1452, DOI 10.1529/biophysj.106.082388; BLACK G, 1985, J INVEST DERMATOL, V85, P448, DOI 10.1111/1523-1747.ep12277170; BRANDA RF, 1978, SCIENCE, V201, P625, DOI 10.1126/science.675247; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Charkoudian N, 2003, MAYO CLIN PROC, V78, P603, DOI 10.4065/78.5.603; Freesemann AG, 1998, EUR J BIOCHEM, V257, P149, DOI 10.1046/j.1432-1327.1998.2570149.x; Honigsmann H, 2002, PHOTODERMATOL PHOTO, V18, P75, DOI 10.1034/j.1600-0781.2002.180204.x; HONIGSMANN H, 1986, J INVEST DERMATOL, V87, P648, DOI 10.1111/1523-1747.ep12456326; Hustad S, 2002, CLIN CHEM, V48, P1571; IRWIN C, 1993, PHOTOCHEM PHOTOBIOL, V57, P504, DOI 10.1111/j.1751-1097.1993.tb02326.x; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Juzeniene A., 2006, FREE RADIC BIOL MED, V5, P215; Juzeniene A, 2010, J PHOTOCH PHOTOBIO B, V101, P111, DOI 10.1016/j.jphotobiol.2010.01.013; Juzeniene A, 2009, FREE RADICAL BIO MED, V47, P1199, DOI 10.1016/j.freeradbiomed.2009.07.030; KOLLIAS N, 1985, J INVEST DERMATOL, V85, P38, DOI 10.1111/1523-1747.ep12275011; MENON IA, 1990, CLIN CHIM ACTA, V186, P375, DOI 10.1016/0009-8981(90)90323-K; Nielsen KP, 2004, PHOTOCHEM PHOTOBIOL, V80, P450, DOI 10.1562/0031-8655(2004)080<0450:RSOPAN>2.0.CO;2; Ou-Yang H, 2004, J INVEST DERMATOL, V122, P492, DOI 10.1046/j.0022-202X.2004.22247.x; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PATHAK MA, 1962, J INVEST DERMATOL, V39, P435, DOI 10.1038/jid.1962.136; Routaboul C, 1999, EUR J DERMATOL, V9, P95; Shaheen M., 2006, EGYPT DERMATOL ONLIN, V2, P1; Steindal AH, 2008, PHOTOCH PHOTOBIO SCI, V7, P814, DOI 10.1039/b718907a; Steindal AH, 2006, PHOTOCHEM PHOTOBIOL, V82, P1651, DOI 10.1562/2006-06-09-RA-915; Suh KS, 2007, SKIN RES TECHNOL, V13, P360, DOI 10.1111/j.1600-0846.2007.00238.x; Tam TTT, 2009, J PHOTOCH PHOTOBIO B, V94, P201, DOI 10.1016/j.jphotobiol.2008.12.003; Welzel J, 2004, BRIT J DERMATOL, V150, P220, DOI 10.1111/j.1365-2133.2004.05810.x; WIJESEKERA TP, 1985, ADV EXP MED BIOL, V193, P229; Wolber R, 2008, PIGM CELL MELANOMA R, V21, P487, DOI 10.1111/j.1755-148X.2008.00470.x; Wondrak GT, 2006, PHOTOCH PHOTOBIO SCI, V5, P215, DOI 10.1039/b504573h; Yamashita T, 2007, EXP DERMATOL, V16, P905, DOI 10.1111/j.1600-0625.2007.00604.x; Young A.R, 2001, COMP PHOTO, P359; Young AR, 1998, J INVEST DERMATOL, V111, P982, DOI 10.1046/j.1523-1747.1998.00436.x	39	18	19	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					971	975		10.1096/fj.11-195859	http://dx.doi.org/10.1096/fj.11-195859			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22159146				2022-12-28	WOS:000300949300002
J	Qaisar, R; Renaud, G; Morine, K; Barton, ER; Sweeney, HL; Larsson, L				Qaisar, Rizwan; Renaud, Guillaume; Morine, Kevin; Barton, Elisabeth R.; Sweeney, H. Lee; Larsson, Lars			Is functional hypertrophy and specific force coupled with the addition of myonuclei at the single muscle fiber level?	FASEB JOURNAL			English	Article						IGF-1; myosin; myostatin	SATELLITE CELL-PROLIFERATION; RAT SOLEUS MUSCLE; GROWTH-FACTOR-I; EXPRESSION; MYOSIN; SLOW; MASS; CONTRACTILE; INHIBITION; ACTIVATION	Muscle force is typically proportional to muscle size, resulting in constant force normalized to muscle fiber cross-sectional area (specific force). Mice overexpressing insulin-like growth factor-1 (IGF-1) exhibit a proportional gain in muscle force and size, but not the myostatin-deficient mice. In an attempt to explore the role of the cytoplasmic volume supported by individual myonuclei [myonuclear domain (MND) size] on functional capacity of skeletal muscle, we have investigated specific force in relation to MND and the content of the molecular motor protein, myosin, at the single muscle fiber level from myostatin-knockout (Mstn(-/-)) and IGF1-overexpressing (mIgf1(-/-)) mice. We hypothesize that the addition of extra myonuclei is a prerequisite for maintenance of specific force during muscle hypertrophy. A novel algorithm was used to measure individual MNDs in 3 dimensions along the length of single muscle fibers from the fast-twitch extensor digitorum longus and the slow-twitch soleus muscle. A significant effect of the size of individual MNDs in hypertrophic muscle fibers on both specific force and myosin content was observed. This effect was muscle cell type specific and suggested there is a critical volume individual myonuclei can support efficiently. The large MNDs found in fast muscles of Mstn(-/)-mice were correlated with the decrement in specific force and myosin content in Mstn(-/)-muscles. Thus, myostatin inhibition may not be able to maintain the appropriate MND for optimal function.-Qaisar, R., Renaud, G., Morine, K., Barton, E. R., Sweeney, H. L., Larsson, L. Is functional hypertrophy and specific force coupled with the addition of myonuclei at the single muscle fiber level? FASEB J. 26, 1077-1085 (2012). www.fasebj.org	[Qaisar, Rizwan; Renaud, Guillaume; Larsson, Lars] Uppsala Univ, Dept Neurosci, SE-75185 Uppsala, Sweden; [Morine, Kevin; Sweeney, H. Lee] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; [Barton, Elisabeth R.] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Larsson, Lars] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA	Uppsala University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Larsson, L (corresponding author), Uppsala Univ, Dept Neurosci, SE-75185 Uppsala, Sweden.	lars.larsson@neurofys.uu.se	Larsson, Lars/AAY-1347-2021	Larsson, Lars/0000-0003-3722-035X; Qaisar, Rizwan/0000-0001-8485-7172	Swedish Research Council [8651]; European Commission [CT-223756, COST CM1001]; King Gustaf V and Queen Victoria's Foundation; Association Francaise contre les Myopathies; Higher Education Commission (HEC) of Pakistan; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); King Gustaf V and Queen Victoria's Foundation; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Higher Education Commission (HEC) of Pakistan(Higher Education Commission of Pakistan); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors are grateful to Yvette Hedstrom, Rebeca Corpeno, and Ann-Marie Gustafson for excellent technical assistance and to Dr. Julien Ochala for invaluable help and support during experiments and constructive criticism of the manuscript. This study was supported by grants from the Swedish Research Council (8651), the European Commission (MyoAge, EC Fp7 CT-223756 and COST CM1001), King Gustaf V and Queen Victoria's Foundation, and Association Francaise contre les Myopathies to L. L., and the Higher Education Commission (HEC) of Pakistan to R.Q.	ALLEN DL, 1995, J APPL PHYSIOL, V78, P1969, DOI 10.1152/jappl.1995.78.5.1969; ALLEN RE, 1989, J CELL PHYSIOL, V138, P311, DOI 10.1002/jcp.1041380213; Amthor H, 2007, P NATL ACAD SCI USA, V104, P1835, DOI 10.1073/pnas.0604893104; Amthor H, 2009, P NATL ACAD SCI USA, V106, P7479, DOI 10.1073/pnas.0811129106; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; Bruusgaard JC, 2006, J APPL PHYSIOL, V100, P2024, DOI 10.1152/japplphysiol.00913.2005; Bruusgaard JC, 2003, J PHYSIOL-LONDON, V551, P467, DOI 10.1113/jphysiol.2003.045328; Colombini B, 2009, J MUSCLE RES CELL M, V30, P199, DOI 10.1007/s10974-009-9187-8; Cristea A, 2011, SARCOPENIA-AGE-RELATED MUSCLE WASTING AND WEAKNESS: MECHANISMS AND TREATMENTS, P55, DOI 10.1007/978-90-481-9713-2_4; Cristea A, 2010, AGING CELL, V9, P685, DOI 10.1111/j.1474-9726.2010.00594.x; Del Prete Z, 2008, ANN BIOMED ENG, V36, P1281, DOI 10.1007/s10439-008-9496-x; DODSON MV, 1985, ENDOCRINOLOGY, V117, P2357, DOI 10.1210/endo-117-6-2357; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Frontera WR, 1997, MUSCLE NERVE, V20, P948, DOI 10.1002/(SICI)1097-4598(199708)20:8<948::AID-MUS3>3.0.CO;2-6; Gonzalez E, 2003, J PHYSIOL-LONDON, V552, P833, DOI 10.1113/jphysiol.2003.048165; Haidet AM, 2008, P NATL ACAD SCI USA, V105, P4318, DOI 10.1073/pnas.0709144105; HANZLIKOVA V, 1975, CELL TISSUE RES, V160, P411; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; LEWIS SEM, 1984, BIOCHEM J, V217, P517, DOI 10.1042/bj2170517; Liu JX, 2009, EXP PHYSIOL, V94, P117, DOI 10.1113/expphysiol.2008.043877; Martyn DA, 2007, BIOPHYS J, V92, P4379, DOI 10.1529/biophysj.106.096768; Matsakas A, 2009, NEUROMUSCULAR DISORD, V19, P489, DOI 10.1016/j.nmd.2009.06.367; McCarthy JJ, 2007, J APPL PHYSIOL, V103, P1102; McCarthy JJ, 2007, J APPL PHYSIOL, V103, P1100, DOI 10.1152/japplphysiol.00101.2007a; MCDONALD KS, 1995, J APPL PHYSIOL, V79, P1796, DOI 10.1152/jappl.1995.79.5.1796; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Mendias CL, 2006, J APPL PHYSIOL, V101, P898, DOI 10.1152/japplphysiol.00126.2006; Morine KJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009176; Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Paul AC, 2002, J CELL BIOL, V156, P751, DOI 10.1083/jcb.200105147; Quinn LS, 2007, AM J PHYSIOL-ENDOC M, V293, pE1538, DOI 10.1152/ajpendo.00160.2007; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; Seow CY, 1997, J PHYSIOL-LONDON, V501, P149, DOI 10.1111/j.1469-7793.1997.149bo.x; SNOW MH, 1990, ANAT REC, V227, P437, DOI 10.1002/ar.1092270407; Thompson LV, 2006, J APPL PHYSIOL, V101, P1581, DOI 10.1152/japplphysiol.00426.2006; TSENG BS, 1994, CELL TISSUE RES, V275, P39, DOI 10.1007/BF00305374; Wada KI, 2003, JPN J PHYSIOL, V53, P145; Watt KI, 2010, MUSCLE NERVE, V41, P624, DOI 10.1002/mus.21573; Welle S, 2006, AM J PHYSIOL-ENDOC M, V290, pE409, DOI 10.1152/ajpendo.00433.2005; Welle S, 2007, AM J PHYSIOL-ENDOC M, V292, pE985, DOI 10.1152/ajpendo.00531.2006; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	46	47	47	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1077	1085		10.1096/fj.11-192195	http://dx.doi.org/10.1096/fj.11-192195			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22125316	Green Submitted, Green Published			2022-12-28	WOS:000300949300012
J	Seebohm, G; Strutz-Seebohm, N; Ursu, ON; Preisig-Muller, R; Zuzarte, M; Hill, EV; Kienitz, MC; Bendahhou, S; Fauler, M; Tapken, D; Decher, N; Collins, A; Jurkat-Rott, K; Steinmeyer, K; Lehmann-Horn, F; Daut, J; Tavare, JM; Pott, L; Bloch, W; Lang, F				Seebohm, Guiscard; Strutz-Seebohm, Nathalie; Ursu, Oana N.; Preisig-Mueller, Regina; Zuzarte, Marylou; Hill, Elaine V.; Kienitz, Marie-Cecile; Bendahhou, Said; Fauler, Michael; Tapken, Daniel; Decher, Niels; Collins, Anthony; Jurkat-Rott, Karin; Steinmeyer, Klaus; Lehmann-Horn, Frank; Daut, Juergen; Tavare, Jeremy M.; Pott, Lutz; Bloch, Wilhelm; Lang, Florian			Altered stress stimulation of inward rectifier potassium channels in Andersen-Tawil syndrome	FASEB JOURNAL			English	Article						oocytes; PIP2; trafficking; PIP5K3; Kir2	INDUCIBLE KINASE ISOFORMS; RECTIFYING K+ CHANNELS; VENTRICULAR MYOCYTES; HEART-FAILURE; DIFFERENTIAL SENSITIVITY; PERIODIC PARALYSIS; KIR2.1 CHANNELS; MUTATIONS; PROTEIN; I-K1	Inward rectifier potassium channels of the Kir2 subfamily are important determinants of the electrical activity of brain and muscle cells. Genetic mutations in Kir2.1 associate with Andersen-Tawil syndrome (ATS), a familial disorder leading to stress-triggered periodic paralysis and ventricular arrhythmia. To identify the molecular mechanisms of this stress trigger, we analyze Kir channel function and localization electrophysiologically and by time-resolved confocal microscopy. Furthermore, we employ a mathematical model of muscular membrane potential. We identify a novel corticoid signaling pathway that, when activated by glucocorticoids, leads to enrichment of Kir2 channels in the plasma membranes of mammalian cell lines and isolated cardiac and skeletal muscle cells. We further demonstrate that activation of this pathway can either partly restore (40% of cases) or further impair (20% of cases) the function of mutant ATS channels, depending on the particular Kir2.1 mutation. This means that glucocorticoid treatment might either alleviate or deteriorate symptoms of ATS depending on the patient's individual Kir2.1 genotype. Thus, our findings provide a possible explanation for the contradictory effects of glucocorticoid treatment on symptoms in patients with ATS and may open new pathways for the design of personalized medicines in ATS therapy.-Seebohm, G., Strutz-Seebohm, N., Ursu, O. N., Preisig-Muller, R., Zuzarte, M., Hill, E. V., Kienitz, M.-C., Bendahhou, S., Fauler, M., Tapken, D., Decher, N., Collins, A., Jurkat-Rott, K., Steinmeyer, K., Lehmann-Horn, F., Daut, J., Tavare, J. M., Pott, L., Bloch, W., Lang, F. Altered stress stimulation of inward rectifier potassium channels in Andersen-Tawil syndrome. FASEB J. 26, 513-522 (2012). www.fasebj.org	[Seebohm, Guiscard] Ruhr Univ Bochum, Dept Biochem 1, Cat Channel Grp, D-44780 Bochum, Germany; [Kienitz, Marie-Cecile; Pott, Lutz] Ruhr Univ Bochum, Dept Cellular Physiol, D-44780 Bochum, Germany; [Ursu, Oana N.; Lang, Florian] Univ Tubingen, Inst Physiol 1, Tubingen, Germany; [Preisig-Mueller, Regina; Zuzarte, Marylou; Daut, Juergen] Univ Marburg, Inst Physiol, Marburg, Germany; [Hill, Elaine V.; Tavare, Jeremy M.] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; [Bendahhou, Said] Univ Nice Sophia Antipolis, Unite Mixte Rech UMR 6097, Ctr Natl Rech Sci CNRS Transport Ion Aspects Norm, Nice, France; [Fauler, Michael; Jurkat-Rott, Karin; Lehmann-Horn, Frank] Univ Ulm, Div Neurophysiol, Ulm, Germany; [Tapken, Daniel] Univ Copenhagen, Dept Med Chem, Fac Pharmaceut Sci, Copenhagen, Denmark; [Collins, Anthony] Queens Univ Belfast, Ctr Vis & Vasc Sci, Inst Clin Sci, Belfast, Antrim, North Ireland; [Steinmeyer, Klaus] Sanofi Aventis, Therapeut Strateg Unit TSU Aging, Frankfurt, Germany; [Bloch, Wilhelm] German Sport Univ Cologne, Cologne, Germany	Ruhr University Bochum; Ruhr University Bochum; Eberhard Karls University of Tubingen; Philipps University Marburg; University of Bristol; UDICE-French Research Universities; Universite Cote d'Azur; Ulm University; University of Copenhagen; Queens University Belfast; Sanofi-Aventis; German Sport University Cologne	Seebohm, G (corresponding author), Ruhr Univ Bochum, Dept Biochem 1, Cat Channel Grp, Univ Str 150, D-44780 Bochum, Germany.	guiscard.seebohm@gmx.de	Decher, Niels/AAF-5002-2020	Pott, Lutz/0000-0002-4000-4132; Tapken, Daniel/0000-0002-0166-0751	Deutsche Forschungsgemeinschaft [SE1077/3, STR649/1-1, La315/4-5, DE1482/2-1, DE1482/3-2, TP A4, SFB593]; P. E. Kempkes Foundation [16/06]; Association Francaise contre les Myopathies; Medical Research Council [G7708269] Funding Source: researchfish; MRC [G7708269] Funding Source: UKRI	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); P. E. Kempkes Foundation; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Deutsche Forschungsgemeinschaft (grants SE1077/3 to G.S., STR649/1-1 to N.S., La315/4-5 to F. L., DE1482/2-1 and DE1482/3-2 to N.D., and TP A4, SFB593 to J.D.), the P. E. Kempkes Foundation (grant 16/06 to R. P. M.), and the Association Francaise contre les Myopathies (grant to S. B.). F. L. H. is an endowed Senior Research Professor of the Gemeinnutzige Hertie-Stiftung. The authors declare no conflicts of interest.	ANDERSEN ED, 1971, ACTA PAEDIATR SCAND, V60, P559, DOI 10.1111/j.1651-2227.1971.tb06990.x; Arteaga MF, 2006, P NATL ACAD SCI USA, V103, P11178, DOI 10.1073/pnas.0604816103; BECHEM M, 1983, EUR J CELL BIOL, V31, P366; Beckmann C, 2008, CELL PHYSIOL BIOCHEM, V21, P259, DOI 10.1159/000129381; Bendahhou S, 2007, HUM MOL GENET, V16, P900, DOI 10.1093/hmg/ddm034; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Collins A, 2005, MOL PHARMACOL, V67, P1214, DOI 10.1124/mol.104.008292; Collins A, 2002, J BIOL CHEM, V277, P35815, DOI 10.1074/jbc.M206032200; Dart C, 2001, J BIOL CHEM, V276, P20499, DOI 10.1074/jbc.M101425200; Decher N, 2007, CARDIOVASC RES, V75, P748, DOI 10.1016/j.cardiores.2007.05.010; Donaldson MR, 2003, NEUROLOGY, V60, P1811, DOI 10.1212/01.WNL.0000072261.14060.47; Dunker N, 2002, MECH DEVELOP, V113, P111, DOI 10.1016/S0925-4773(02)00015-1; Han W, 2001, CIRCULATION, V104, P2095, DOI 10.1161/hc4201.097134; Jones MC, 2006, CURR OPIN CELL BIOL, V18, P549, DOI 10.1016/j.ceb.2006.08.003; Jones SVP, 2003, MOL PHARMACOL, V64, P987, DOI 10.1124/mol.64.4.987; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Leyland ML, 2004, J BIOL CHEM, V279, P43427, DOI 10.1074/jbc.M407575200; Liu Y, 2001, MOL PHARMACOL, V59, P1061, DOI 10.1124/mol.59.5.1061; Lodge NJ, 1997, J MOL CELL CARDIOL, V29, P3211, DOI 10.1006/jmcc.1997.0548; Lopatin AN, 2001, J MOL CELL CARDIOL, V33, P625, DOI 10.1006/jmcc.2001.1344; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Preisig-Muller R, 2002, P NATL ACAD SCI USA, V99, P7774, DOI 10.1073/pnas.102609499; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Romanenko VG, 2004, BIOPHYS J, V87, P3850, DOI 10.1529/biophysj.104.043273; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Sansone V, 1997, ANN NEUROL, V42, P305, DOI 10.1002/ana.410420306; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seebohm G, 2005, CELL PHYSIOL BIOCHEM, V16, P255, DOI 10.1159/000089851; Seebohm G, 2008, CIRC RES, V103, P1451, DOI 10.1161/CIRCRESAHA.108.177360; Seemann G, 2007, AM J PHYSIOL-HEART C, V292, pH549, DOI 10.1152/ajpheart.00701.2006; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Strutz-Seebohm N, 2005, J PHYSIOL-LONDON, V565, P391, DOI 10.1113/jphysiol.2004.079624; TAWIL R, 1994, ANN NEUROL, V35, P326, DOI 10.1002/ana.410350313; Tristani-Firouzi M, 2002, J CLIN INVEST, V110, P381, DOI 10.1172/JCI200215183; Vicente R, 2004, FEBS LETT, V572, P189, DOI 10.1016/j.febslet.2004.07.030; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Xiao J, 2003, NAT NEUROSCI, V6, P811, DOI 10.1038/nn1090; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zitron E, 2004, CARDIOVASC RES, V63, P520, DOI 10.1016/j.cardiores.2004.02.015	43	15	18	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					513	522		10.1096/fj.11-189126	http://dx.doi.org/10.1096/fj.11-189126			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22002906				2022-12-28	WOS:000300485700005
J	Diaz-Vera, J; Camacho, M; Machado, JD; Dominguez, N; Montesinos, MS; Hernandez-Fernaud, JR; Lujan, R; Borges, R				Diaz-Vera, Jesica; Camacho, Marcial; David Machado, Jose; Dominguez, Natalia; Montesinos, Monica S.; Hernandez-Fernaud, Juan R.; Lujan, Rafael; Borges, Ricardo			Chromogranins A and B are key proteins in amine accumulation, but the catecholamine secretory pathway is conserved without them	FASEB JOURNAL			English	Article						adrenal; amperometry; chromaffin cells	GRANULE BIOGENESIS; TARGETED ABLATION; CHROMAFFIN CELLS; EXOCYTOSIS; FIBRINOGEN; AMPEROMETRY; ASSAY; GENE	Chromogranins are the main soluble proteins in the large dense core secretory vesicles (LDCVs) found in aminergic neurons and chromaffin cells. We recently demonstrated that chromogranins A and B each regulate the concentration of adrenaline in chromaffin granules and its exocytosis. Here we have further studied the role played by these proteins by generating mice lacking both chromogranins. Surprisingly, these animals are both viable and fertile. Although chromogranins are thought to be essential for their biogenesis, LDCVs were evident in these mice. These vesicles do have a somewhat atypical appearance and larger size. Despite their increased size, single-cell amperometry recordings from chromaffin cells showed that the amine content in these vesicles is reduced by half. These data demonstrate that although chromogranins regulate the amine concentration in LDCVs, they are not completely essential, and other proteins unrelated to neurosecretion, such as fibrinogen, might compensate for their loss to ensure that vesicles are generated and the secretory pathway conserved.-DiazVera, J., Camacho, M., Machado, J. D., Dominguez, N., Montesinos, M. S., Hernandez-Fernaud, J. R., Lujan, R., Borges, R. Chromogranins A and B are key proteins in amine accumulation, but the catecholamine secretory pathway is conserved without them. FASEB J. 26, 430-438 (2012). www.fasebj.org	[Diaz-Vera, Jesica; Camacho, Marcial; David Machado, Jose; Dominguez, Natalia; Montesinos, Monica S.; Hernandez-Fernaud, Juan R.; Borges, Ricardo] Univ La Laguna, Fac Med, Unidad Farmacol, ES-38071 Tenerife, Spain; [Lujan, Rafael] Univ Castilla La Mancha, Fac Med, Dept Ciencias Med, Albacete, Spain	Universidad de la Laguna; Universidad de Castilla-La Mancha	Borges, R (corresponding author), Univ La Laguna, Fac Med, Unidad Farmacol, ES-38071 Tenerife, Spain.	rborges@ull.es	Diaz Vera, Jesica/N-3082-2015; Fernaud, Juan Ramon Hernandez/H-9190-2015; Lujan, Rafael/G-2555-2015; Borges, Ricardo/N-3250-2014; Machado, José David/N-5210-2014; Dominguez, Natalia/ABG-7769-2020	Diaz Vera, Jesica/0000-0002-0750-8267; Fernaud, Juan Ramon Hernandez/0000-0003-2807-0601; Borges, Ricardo/0000-0003-3413-4392; Machado, José David/0000-0003-3531-7051; Camacho Perez, Marcial/0000-0002-2367-1259; Lujan Miras, Rafael/0000-0003-2001-9545; Dominguez, Natalia/0000-0002-2615-3414	Spanish Ministry of Science and Innovation (MICINN); Consolider contract [CSD2008-00005]; Spanish Ministry of Science and Innovation [BFU2010-15822]; Canary Islands Agency for Research, Innovation and Information Society [PI2007/017]	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Consolider contract; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Canary Islands Agency for Research, Innovation and Information Society	J.D.V. and N.D. are the recipients of a FPU fellowship from the Spanish Ministry of Science and Innovation (MICINN). J.D.M. holds a Consolider contract (CSD2008-00005). This work was supported by the Spanish Ministry of Science and Innovation (BFU2010-15822) and Consolider (R. B.), and the Canary Islands Agency for Research, Innovation and Information Society PI2007/017 (J.D.M.). The authors are grateful to Daniel O'Connor and Sushil Mahata (University of California, San Diego, CA, USA) for providing the CgA<SUP>-/-</SUP> mice, and to Wieland Huttner and Federico Callegari (Max Planck Institute of Molecular Biology and Genetics, Dresden, Germany) for providing the CgB<SUP>-/-</SUP> mice. Agustin Castaneyra and Emilia Carmona helped to obtain the immunocytochemistry images. The authors also thank the personnel of the animal house of the University of La Laguna for maintaining the mouse strains. Discussions with Humberto Viveros, Lucio Diaz-Flores, Reiner Fischer-Colbrie, and Mark Sefton were whole-heartedly appreciated. The authors declare no conflicts of interest.	BORGES R, 1986, J NEUROSCI METH, V16, P289, DOI 10.1016/0165-0270(86)90054-3; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; Borges R, 2010, J NEUROCHEM, V114, P335, DOI 10.1111/j.1471-4159.2010.06786.x; Colliver TL, 2001, J NEUROSCI METH, V105, P95, DOI 10.1016/S0165-0270(00)00359-9; Courel M, 2010, J BIOL CHEM, V285, P10030, DOI 10.1074/jbc.M109.064196; Crivellato E, 2003, ANAT REC PART A, V270A, P103, DOI 10.1002/ar.a.10013; Dernick G, 2005, NAT METHODS, V2, P699, DOI 10.1038/nmeth0905-699; Diaz-Vera J, 2010, J NEUROSCI, V30, P950, DOI 10.1523/JNEUROSCI.2894-09.2010; Everse SJ, 1998, BIOCHEMISTRY-US, V37, P8637, DOI 10.1021/bi9804129; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; Helle KB, 2000, ADV EXP MED BIOL, V482, P3; Hendy GN, 2006, MOL ENDOCRINOL, V20, P1935, DOI 10.1210/me.2005-0398; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; Kim T, 2005, J NEUROSCI, V25, P6958, DOI 10.1523/JNEUROSCI.1058-05.2005; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Machado David J., 2008, V440, P297, DOI 10.1007/978-1-59745-178-9_23; Machado JD, 2000, J BIOL CHEM, V275, P20274, DOI 10.1074/jbc.M000930200; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Martini S, 2007, BIOMACROMOLECULES, V8, P2689, DOI 10.1021/bm070273n; Montesinos MS, 2008, J NEUROSCI, V28, P3350, DOI 10.1523/JNEUROSCI.5292-07.2008; Mosharov EV, 2003, J NEUROSCI, V23, P5835; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; NAGATSU T, 1979, ANAL BIOCHEM, V93, P82, DOI 10.1016/S0003-2697(79)80119-0; Obermuller S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008936; SantoDomingo J, 2008, EUR J NEUROSCI, V28, P1265, DOI 10.1111/j.1460-9568.2008.06440.x; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Zhang JZ, 1996, J BIOL CHEM, V271, P12674, DOI 10.1074/jbc.271.21.12674; Zhang JZ, 1996, J BIOL CHEM, V271, P30083, DOI 10.1074/jbc.271.47.30083	35	38	38	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					430	438		10.1096/fj.11-181941	http://dx.doi.org/10.1096/fj.11-181941			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21990378				2022-12-28	WOS:000299202200042
J	Butikofer, L; Zurlinden, A; Bolliger, MF; Kunz, B; Sonderegger, P				Buetikofer, Lukas; Zurlinden, Andreas; Bolliger, Marc F.; Kunz, Beat; Sonderegger, Peter			Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia	FASEB JOURNAL			English	Article						proteolysis; muscle atrophy; neurotrypsin-overexpressing mice; neurotrypsin-deficient mice	ACETYLCHOLINE-RECEPTOR DISTRIBUTION; SKELETAL-MUSCLE FIBERS; WHOLE VASTUS LATERALIS; MOTOR UNITS; AGE-CHANGES; FAST-TWITCH; ENZYME-ACTIVITY; SOLEUS MUSCLE; TOTAL NUMBER; RAT	Etiology and pathogenesis of sarcopenia, the progressive decline in skeletal muscle mass and strength that occurs with aging, are still poorly understood. We recently found that overexpression of the neural serine protease neurotrypsin in motoneurons resulted in the degeneration of their neuromuscular junctions (NMJ) within days. Therefore, we wondered whether neurotrypsin-dependent NMJ degeneration also affected the structure and function of the skeletal muscles. Using histological and functional analyses of neurotrypsin-overexpressing and neurotrypsin-deficient mice, we found that overexpression of neurotrypsin in motoneurons installed the full sarcopenia phenotype in young adult mice. Characteristic muscular alterations included a reduced number of muscle fibers, increased heterogeneity of fiber thickness, more centralized nuclei, fiber-type grouping, and an increased proportion of type I fibers. As in age-dependent sarcopenia, excessive fragmentation of the NMJ accompanied the muscular alterations. These results suggested the destabilization of the NMJ through proteolytic cleavage of agrin at the onset of a pathogenic pathway ending in sarcopenia. Studies of neurotrypsin-deficient and agrin-overexpressing mice revealed that old-age sarcopenia also develops without neurotrypsin and is not prevented by elevated levels of agrin. Our results define neurotrypsin-and age-dependent sarcopenia as the common final outcome of 2 etiologically distinct entities.-Butikofer, L., Zurlinden, A., Bolliger, M. F., Kunz, B., Sonderegger, P. Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia. FASEB J. 25, 4378-4393 (2011). www.fasebj.org	[Buetikofer, Lukas; Zurlinden, Andreas; Bolliger, Marc F.; Kunz, Beat; Sonderegger, Peter] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Sonderegger, P (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter.sonderegger@bioc.uzh.ch		Butikofer, Lukas/0000-0002-0801-746X	Swiss National Science Foundation; National Center of Competence in Research, Neural Plasticity and Repair, of the Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Center of Competence in Research, Neural Plasticity and Repair, of the Swiss National Science Foundation(Swiss National Science Foundation (SNSF))	The authors thank Urs Ziegler for help with microscopy and image analysis and Monika Dilkin for mouse care and husbandry. The authors thank Pico Caroni (Friedrich Miescher Institute, Basel, Switzerland) for providing the mouse line expressing synaptophysin-GFP in neurons and Silvia Arber (Friedrich Miescher Institute) and Thomas M. Jessell (Columbia University, New York, NY, USA) for providing the Hb9-Cre mouse line. The work was supported by grants of the Swiss National Science Foundation and the National Center of Competence in Research, Neural Plasticity and Repair, of the Swiss National Science Foundation. P. S. is a cofounder and minor shareholder (<0.5%) of Neurotune AG.	Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8; ALNAQEEB MA, 1987, J ANAT, V153, P31; ANIANSSON A, 1992, J APPL PHYSIOL, V73, P812, DOI 10.1152/jappl.1992.73.3.812; ANSVED T, 1989, J NEUROL SCI, V93, P105, DOI 10.1016/0022-510X(89)90165-2; BaliceGordon RJ, 1997, MUSCLE NERVE, pS83; Blondet B, 2002, BRAIN RES, V930, P53, DOI 10.1016/S0006-8993(01)03405-9; Bolliger MF, 2010, J CELL SCI, V123, P3944, DOI 10.1242/jcs.072090; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; CACCIA MR, 1979, MUSCLE NERVE, V2, P202, DOI 10.1002/mus.880020308; CARDASIS CA, 1987, MUSCLE NERVE, V10, P200, DOI 10.1002/mus.880100303; CARLSON BM, 1995, J GERONTOL A-BIOL, V50, P96; Carter EE, 2010, EXP GERONTOL, V45, P662, DOI 10.1016/j.exger.2010.04.001; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; COURTNEY J, 1981, J PHYSIOL-LONDON, V320, P435, DOI 10.1113/jphysiol.1981.sp013960; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; Dalton BH, 2008, MUSCLE NERVE, V38, P1108, DOI 10.1002/mus.20984; DAW CK, 1988, J APPL PHYSIOL, V64, P2428, DOI 10.1152/jappl.1988.64.6.2428; De Paola V, 2003, NAT NEUROSCI, V6, P491, DOI 10.1038/nn1046; Delbono O, 2003, AGING CELL, V2, P21, DOI 10.1046/j.1474-9728.2003.00011.x; Deschenes MR, 2010, EXP GERONTOL, V45, P389, DOI 10.1016/j.exger.2010.03.007; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; DOHERTY TJ, 1993, J APPL PHYSIOL, V74, P868, DOI 10.1152/jappl.1993.74.2.868; Edstrom E, 2007, PHYSIOL BEHAV, V92, P129, DOI 10.1016/j.physbeh.2007.05.040; EDSTROM L, 1987, J PHYSIOL-LONDON, V392, P129, DOI 10.1113/jphysiol.1987.sp016773; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; Gallegly JC, 2004, J APPL PHYSIOL, V97, P1082, DOI 10.1152/japplphysiol.00006.2004; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Greenlund LJS, 2003, MECH AGEING DEV, V124, P287, DOI 10.1016/S0047-6374(02)00196-3; Hamada K, 2004, FASEB J, V18, P264, DOI 10.1096/fj.03-1286fje; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; HASHIZUME K, 1988, J COMP NEUROL, V269, P425, DOI 10.1002/cne.902690309; Hegedus J, 2007, NEUROBIOL DIS, V28, P154, DOI 10.1016/j.nbd.2007.07.003; Hepple RT, 2004, J GERONTOL A-BIOL, V59, P108; Hepple Russell T, 2006, Sci Aging Knowledge Environ, V2006, ppe3, DOI 10.1126/sageke.2006.3.pe3; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; ISHIHARA A, 1987, BRAIN RES, V435, P355, DOI 10.1016/0006-8993(87)91624-6; ISHIHARA A, 1988, BRAIN RES, V446, P195, DOI 10.1016/0006-8993(88)91315-7; JAKOBSSON F, 1990, ACTA NEUROPATHOL, V80, P459, DOI 10.1007/BF00294604; Janssen I, 2002, J AM GERIATR SOC, V50, P889, DOI 10.1046/j.1532-5415.2002.50216.x; JENNEKENS FG, 1971, J NEUROL SCI, V14, P245, DOI 10.1016/0022-510X(71)90215-2; Kamel HK, 2003, NUTR REV, V61, P157, DOI 10.1301/nr.2003.may.157-167; Kano Y, 2002, J GERONTOL A-BIOL, V57, pB422, DOI 10.1093/gerona/57.12.B422; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; Larkin LM, 2003, MECH AGEING DEV, V124, P653, DOI 10.1016/S0047-6374(02)00190-2; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; LEXELL J, 1987, ACTA NEUROPATHOL, V75, P109, DOI 10.1007/BF00687070; LEXELL J, 1991, J ANAT, V174, P239; LEXELL J, 1991, ACTA NEUROPATHOL, V81, P377, DOI 10.1007/BF00293457; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LEXELL J, 1986, J NEUROL SCI, V72, P211, DOI 10.1016/0022-510X(86)90009-2; Lin WC, 2005, NEURON, V46, P569, DOI 10.1016/j.neuron.2005.04.002; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; Marques MJ, 2007, ANAT REC, V290, P846, DOI 10.1002/ar.20525; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Minatel E, 2001, MUSCLE NERVE, V24, P410, DOI 10.1002/1097-4598(200103)24:3<410::AID-MUS1014>3.0.CO;2-0; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Monemi M, 1999, J MUSCLE RES CELL M, V20, P351, DOI 10.1023/A:1005421604314; Narita S, 1999, NEUROREPORT, V10, P3233, DOI 10.1097/00001756-199910190-00020; ODA K, 1984, J NEUROL SCI, V66, P327, DOI 10.1016/0022-510X(84)90021-2; Picard Martin, 2010, Aging Cell, V9, P1032, DOI 10.1111/j.1474-9726.2010.00628.x; Reif R, 2007, FASEB J, V21, P3468, DOI 10.1096/fj.07-8800com; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; ROBBINS N, 1985, J NEUROCYTOL, V14, P1019, DOI 10.1007/BF01224810; Roubenoff R, 2000, J GERONTOL A-BIOL, V55, pM716, DOI 10.1093/gerona/55.12.M716; Roubenoff R, 2003, CURR OPIN CLIN NUTR, V6, P295, DOI 10.1097/01.mco.0000068965.34812.62; Rowan SL, 2011, EXP GERONTOL, V46, P660, DOI 10.1016/j.exger.2011.03.005; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SCELSI R, 1980, ACTA NEUROPATHOL, V51, P99, DOI 10.1007/BF00690450; Stephan A, 2008, FASEB J, V22, P1861, DOI 10.1096/fj.07-100008; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2	75	88	92	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4378	4393		10.1096/fj.11-191262	http://dx.doi.org/10.1096/fj.11-191262			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885656				2022-12-28	WOS:000298138100029
J	Asai, M; Yagishita, S; Iwata, N; Saido, TC; Ishiura, S; Maruyama, K				Asai, Masashi; Yagishita, Sosuke; Iwata, Nobuhisa; Saido, Takaomi C.; Ishiura, Shoichi; Maruyama, Kei			An alternative metabolic pathway of amyloid precursor protein C-terminal fragments via cathepsin B in a human neuroglioma model	FASEB JOURNAL			English	Article						Alzheimer's disease; CA-074Me; gamma-secretase; phosphorylation	GAMMA-SECRETASE INHIBITORS; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; BETA-SECRETASE; WILD-TYPE; APP; PHOSPHORYLATION; ENZYME; FAMILY; TRAFFICKING	gamma-Secretase catalyzes the cleavage of the intramembrane region of the Alzheimer amyloid precursor protein (APP), generating p3, amyloid-beta peptide (A beta), and the APP intracellular domain (AICD). Although a gamma-secretase inhibitor has been shown to cause an accumulation of the APP C-terminal fragments (CTFs) alpha and beta and to decrease levels of p3 or A beta and AICD, we found that treatment with a lysosomotropic weak base, such as chloroquine or ammonium chloride, caused simultaneous accumulation of both CTFs and AICD, suggesting that lysosomal proteases are also involved in processing of APP. This observation was reinforced by the results that cysteine protease inhibitor E-64d and cathepsin B specific inhibitor CA-074Me caused the accumulation of both CTFs and AICD with no change in known secretase activities. gamma-Secretase preferentially cleaved phosphorylated CTFs to produce A beta, but cathepsin B degraded CTFs regardless of phosphorylation. Our results suggest that cathepsin B plays novel roles in the metabolism of APP and that an inhibition of APP phosphorylation is an attractive therapeutic target for Alzheimer's disease.-Asai, M., Yagishita, S., Iwata, N., Saido, T. C., Ishiura, S., Maruyama, K. An alternative metabolic pathway of amyloid precursor protein C-terminal fragments via cathepsin B in a human neuroglioma model. FASEB J. 25, 3720-3730 (2011). www.fasebj.org	[Asai, Masashi; Maruyama, Kei] Saitama Med Univ, Dept Pharmacol, Fac Med, Moroyama, Saitama 3500495, Japan; [Asai, Masashi; Iwata, Nobuhisa; Saido, Takaomi C.] RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, Saitama, Japan; [Yagishita, Sosuke; Ishiura, Shoichi] Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo, Japan; [Iwata, Nobuhisa] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan	Saitama Medical University; RIKEN; University of Tokyo; Nagasaki University	Asai, M (corresponding author), Saitama Med Univ, Dept Pharmacol, Fac Med, 38 Moro Hongo, Moroyama, Saitama 3500495, Japan.	asai@saitama-med.ac.jp	Asai, Masashi/AAB-7672-2022; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Asai, Masashi/0000-0001-6392-0910; Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	Regional Innovation Cluster Program (City Area Type; Central Saitama Area); Shimabara Science Promotion Foundation; Japan Society for the Promotion of Science [20590260]	Regional Innovation Cluster Program (City Area Type; Central Saitama Area); Shimabara Science Promotion Foundation; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank Dr. Raphael Kopan (Washington University, St. Louis, MO, USA) for providing a plasmid (Delta EMV: pCS2/Notch<SUP>Delta E</SUP>), Dr. Bart De Strooper (Katholieke Universiteit Leuven, Leuven, Belgium) for providing PS1 and PS2 double-knockout MEF PS1<SUP>-/-</SUP>PS2<SUP>-/-</SUP> cells, and Drs. Taisuke Tomita and Takeshi Iwatsubo (The University of Tokyo, Tokyo, Japan) for providing mNotch<SUP>Delta E</SUP>-N2a cells. The authors also thank Dr. Kazumi Ishidoh (Tokushima Bunri University, Tokushima, Japan) for his valuable advice. This work was supported by the Regional Innovation Cluster Program (City Area Type; Central Saitama Area), the Shimabara Science Promotion Foundation, and a Grant-in-Aid for Scientific Research (C; 20590260) from the Japan Society for the Promotion of Science.	Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Asai M, 2007, BIOCHEM BIOPH RES CO, V352, P498, DOI 10.1016/j.bbrc.2006.11.043; Asai M, 2010, J NEUROSCI RES, V88, P3588, DOI 10.1002/jnr.22503; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; DICE JF, 1990, CRIT REV THER DRUG, V7, P211; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eisele YS, 2007, MOL BIOL CELL, V18, P3591, DOI 10.1091/mbc.E07-01-0035; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guha S, 2008, INDIAN J BIOCHEM BIO, V45, P75; Ha SD, 2008, J IMMUNOL, V181, P690, DOI 10.4049/jimmunol.181.1.690; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Hook VYH, 2008, J BIOL CHEM, V283, P7745, DOI 10.1074/jbc.M708362200; Hook VYH, 2009, BIOCHEM BIOPH RES CO, V386, P284, DOI 10.1016/j.bbrc.2009.05.131; Jacobsen KT, 2009, CELL MOL LIFE SCI, V66, P2299, DOI 10.1007/s00018-009-0020-8; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim SH, 1996, J NEUROCHEM, V67, P1172; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Klein DM, 2009, J PHARMACOL EXP THER, V328, P813, DOI 10.1124/jpet.108.147082; Kouchi Z, 1999, BIOCHEM BIOPH RES CO, V254, P804, DOI 10.1006/bbrc.1998.9977; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Marks N, 2008, NEUROCHEM INT, V52, P184, DOI 10.1016/j.neuint.2007.06.020; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Mueller-Steiner S, 2006, NEURON, V51, P703, DOI 10.1016/j.neuron.2006.07.027; Nakanishi H, 2003, AGEING RES REV, V2, P367, DOI 10.1016/S1568-1637(03)00027-8; Panza F, 2009, DRUG AGING, V26, P537, DOI 10.2165/11315770-000000000-00000; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Sun BG, 2008, NEURON, V60, P247, DOI 10.1016/j.neuron.2008.10.001; Suzuki T, 2008, J BIOL CHEM, V283, P29633, DOI 10.1074/jbc.R800003200; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Tomita T, 2009, EXPERT REV NEUROTHER, V9, P661, DOI [10.1586/ern.09.24, 10.1586/ERN.09.24]; Van Acker GJD, 2002, AM J PHYSIOL-GASTR L, V283, pG794, DOI 10.1152/ajpgi.00363.2001; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; Vingtdeux V, 2007, NEUROBIOL DIS, V25, P686, DOI 10.1016/j.nbd.2006.09.019; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Yagishita S, 2008, J BIOL CHEM, V283, P733, DOI 10.1074/jbc.M707103200; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	47	28	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3720	3730		10.1096/fj.11-182154	http://dx.doi.org/10.1096/fj.11-182154			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746863				2022-12-28	WOS:000295356400040
J	Goursaud, S; Focant, MC; Berger, JV; Nizet, Y; Maloteaux, JM; Hermans, E				Goursaud, Stephanie; Focant, Marylene C.; Berger, Julie V.; Nizet, Yannick; Maloteaux, Jean-Marie; Hermans, Emmanuel			The VPAC(2) agonist peptide histidine isoleucine (PHI) up-regulates glutamate transport in the corpus callosum of a rat model of amyotrophic lateral sclerosis (hSOD1(G93A)) by inhibiting caspase-3 mediated inactivation of GLT-1a	FASEB JOURNAL			English	Article						astrocytes; neurodegenerative disease; splice variants; white matter	CYCLASE-ACTIVATING POLYPEPTIDE; POSTNATAL EXCITOTOXIC DAMAGE; WHITE-MATTER; INTESTINAL-PEPTIDE; MULTIPLE-SCLEROSIS; ALTERED EXPRESSION; ISCHEMIC-INJURY; BRAIN-LESIONS; SPINAL-CORD; ASTROCYTES	Degeneration of corpus callosum appears in patients with amyotrophic lateral sclerosis (ALS) before clinical signs of upper motor neuron death. Considering the ALS-associated impairment of astrocytic glutamate uptake, we have characterized the expression and activity of the glutamate transporter isoforms GLT-1a and GLT-1b in the corpus callosum of transgenic rats expressing a mutated form of the human superoxide dismutase 1 (hSOD1(G93A)). We have also studied the effect of peptide histidine isoleucine (PHI), a vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating polypeptide (PACAP) receptor 2 (VPAC(2)) agonist on glutamate transporters both in vivo and in callosal astrocytes. Before the onset of motor symptoms, the expression of both transporter isoforms was correlated with a constitutive activity of caspase-3. This enzyme participates in the down-regulation of GLT-1 in ALS, and here we demonstrated its involvement in the selective degradation of GLT-1a in the white matter. A single stereotactic injection of PHI into the corpus callosum of symptomatic rats decreased caspase-3 activity and promoted GLT-1a expression and uptake activity. Together, with evidence for a reduced expression of prepro-VIP/PHI mRNA in the corpus callosum of transgenic animals, these data shed light on the modulatory role of the VIP/PHI system on the glutamatergic transmission in ALS.-Goursaud, S., Focant, M. C., Berger, J. V., Nizet, Y., Maloteaux, J.-M., Hermans, E. The VPAC(2) agonist peptide histidine isoleucine (PHI) up-regulates glutamate transport in the corpus callosum of a rat model of amyotrophic lateral sclerosis (hSOD1(G93A)) by inhibiting caspase-3 mediated inactivation of GLT-1a. FASEB J. 25, 3674-3686 (2011). www.fasebj.org	[Goursaud, Stephanie; Focant, Marylene C.; Berger, Julie V.; Maloteaux, Jean-Marie; Hermans, Emmanuel] Catholic Univ Louvain, Grp Neuropharmacol, Inst Neurosci, B-1200 Brussels, Belgium; [Nizet, Yannick] Catholic Univ Louvain, Expt Surg Lab, Inst Expt & Clin Res, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Hermans, E (corresponding author), Catholic Univ Louvain, Grp Neuropharmacol, Inst Neurosci, 54-10 Av,Hippocrate 54, B-1200 Brussels, Belgium.	emmanuel.hermans@uclouvain.be	Hermans, Emmanuel/A-1654-2015; Hermans, Emmanuel/V-3040-2019		National Fund for Scientific Research (Belgium, Conventions des Fonds de la Recherche Scientifique Medicale) [3.4560.07, 1.5.109.09.F]; DIANE research program of Belgium's Walloon region; Queen Elisabeth Medical Foundation; Association Belge pour les Maladies Neuromusculaires	National Fund for Scientific Research (Belgium, Conventions des Fonds de la Recherche Scientifique Medicale); DIANE research program of Belgium's Walloon region; Queen Elisabeth Medical Foundation; Association Belge pour les Maladies Neuromusculaires	This work was supported by the National Fund for Scientific Research (Belgium, Conventions des Fonds de la Recherche Scientifique Medicale 3.4560.07 and Credit au chercheur 1.5.109.09.F), by the DIANE research program of Belgium's Walloon region, by the Queen Elisabeth Medical Foundation, and by the Association Belge pour les Maladies Neuromusculaires. The authors thank A. Lebbe and R. Lenaert for their excellent technical assistance.	Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Bartels C, 2008, NEUROMUSCULAR DISORD, V18, P398, DOI 10.1016/j.nmd.2008.02.005; Bassan M, 2008, EUR J NEUROSCI, V27, P66, DOI 10.1111/j.1460-9568.2007.05986.x; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Boston-Howes W, 2006, J BIOL CHEM, V281, P14076, DOI 10.1074/jbc.M600653200; Botia B, 2008, J MOL NEUROSCI, V36, P61, DOI 10.1007/s12031-008-9075-5; Chen A, 2008, BRAIN RES, V1201, P187, DOI 10.1016/j.brainres.2008.01.066; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; Dejda A, 2005, PHARMACOL REP, V57, P307; Dracheva S, 2003, J NEUROCHEM, V87, P1402, DOI 10.1046/j.1471-4159.2003.02115.x; Favrais G, 2007, PEPTIDES, V28, P1727, DOI 10.1016/j.peptides.2007.06.022; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Filippini N, 2010, NEUROLOGY, V75, P1645, DOI 10.1212/WNL.0b013e3181fb84d1; Focant MC, 2011, NEUROCHEM INT, V58, P751, DOI 10.1016/j.neuint.2011.02.023; Gibb SL, 2007, J BIOL CHEM, V282, P32480, DOI 10.1074/jbc.M704314200; Goursaud S, 2008, J NEUROCHEM, V105, P1165, DOI 10.1111/j.1471-4159.2008.05231.x; Goursaud S, 2009, NEUROCHEM INT, V55, P28, DOI 10.1016/j.neuint.2009.02.003; Goursaud S, 2009, J NEUROCHEM, V108, P1442, DOI 10.1111/j.1471-4159.2009.05889.x; Gozes I, 1996, P NATL ACAD SCI USA, V93, P427, DOI 10.1073/pnas.93.1.427; Hassel B, 2003, J NEUROCHEM, V87, P230, DOI 10.1046/j.1471-4159.2003.01984.x; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P70, DOI 10.1016/j.bcp.2005.04.025; Holmseth S, 2009, NEUROSCIENCE, V162, P1055, DOI 10.1016/j.neuroscience.2009.03.048; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Iwasaki Y, 2001, NEUROL RES, V23, P851, DOI 10.1179/016164101101199298; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lee SH, 2008, NEUROPHARMACOLOGY, V55, P1329, DOI 10.1016/j.neuropharm.2008.08.028; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Maragakis NJ, 2004, ANN NEUROL, V55, P469, DOI 10.1002/ana.20003; Massie A, 2010, NEUROCHEM INT, V57, P572, DOI 10.1016/j.neuint.2010.07.004; Matsumoto A, 2006, J NEUROSCI RES, V83, P119, DOI 10.1002/jnr.20708; Rangon CM, 2005, J PHARMACOL EXP THER, V314, P745, DOI 10.1124/jpet.105.086405; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Reglodi D, 2006, ANN NY ACAD SCI, V1070, P518, DOI 10.1196/annals.1317.072; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sach M, 2004, BRAIN, V127, P340, DOI 10.1093/brain/awh041; Sathasivam S, 2005, NEUROPATH APPL NEURO, V31, P467, DOI 10.1111/j.1365-2990.2005.00658.x; Senda J, 2009, AMYOTROPH LATERAL SC, V10, P288, DOI 10.3109/17482960802651717; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Sun W, 2006, INT IMMUNOL, V18, P1691, DOI 10.1093/intimm/dxl103; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; Tekkok SB, 2007, J CEREBR BLOOD F MET, V27, P1540, DOI 10.1038/sj.jcbfm.9600455; Trotti, 1999, Nat Neurosci, V2, P848, DOI 10.1038/12227; Turner MR, 2009, LANCET NEUROL, V8, P94, DOI 10.1016/S1474-4422(08)70293-X; Underwood CK, 2011, NEUROIMAGE, V55, P455, DOI 10.1016/j.neuroimage.2010.12.044; Vanoni C, 2004, J CELL SCI, V117, P5417, DOI 10.1242/jcs.01411; Vermeiren C, 2006, J NEUROCHEM, V96, P719, DOI 10.1111/j.1471-4159.2005.03577.x; WERDELIN L, 1989, ACTA NEUROL SCAND, V79, P177, DOI 10.1111/j.1600-0404.1989.tb03735.x; Wittstock M, 2007, CLIN NEUROPHYSIOL, V118, P301, DOI 10.1016/j.clinph.2006.09.026; Wolswijk G, 2000, BRAIN, V123, P105, DOI 10.1093/brain/123.1.105; Yang YJ, 2010, GLIA, V58, P277, DOI 10.1002/glia.20922; Yang YJ, 2009, NEURON, V61, P880, DOI 10.1016/j.neuron.2009.02.010; Yasuda M, 1995, NEUROPEPTIDES, V29, P325, DOI 10.1016/0143-4179(95)90003-9; Zhou JZ, 2004, J NEUROSCI, V24, P6301, DOI 10.1523/JNEUROSCI.1404-04.2004; ZHOU Y, 1995, NEUROSCI LETT, V195, P89, DOI 10.1016/0304-3940(94)11787-J	59	12	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3674	3686		10.1096/fj.11-182337	http://dx.doi.org/10.1096/fj.11-182337			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21730107				2022-12-28	WOS:000295356400036
J	Jegot, G; Derache, C; Castella, S; Lahouassa, H; Pitois, E; Jourdan, ML; Remold-O'Donnell, E; Kellenberger, C; Gauthier, F; Korkmaz, B				Jegot, Gwenhael; Derache, Chrystelle; Castella, Sandrine; Lahouassa, Hichem; Pitois, Elodie; Jourdan, Marie Lise; Remold-O'Donnell, Eileen; Kellenberger, Christine; Gauthier, Francis; Korkmaz, Brice			A substrate-based approach to convert SerpinB1 into a specific inhibitor of proteinase 3, the Wegener's granulomatosis autoantigen	FASEB JOURNAL			English	Article						neutrophil; serine protease; drug design	HUMAN POLYMORPHONUCLEAR NEUTROPHILS; CATHEPSIN-G; ELASTASE INHIBITOR; ALPHA-1-ANTITRYPSIN DEFICIENCY; ALPHA-1-PROTEASE INHIBITOR; SERINE PROTEINASES; CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; IN-VIVO; SURFACE	The physiological and pathological functions of proteinase 3 (PR3) are not well understood due to its close similarity to human neutrophil elastase (HNE) and the lack of a specific inhibitor. Based on structural analysis of the active sites of PR3 and HNE, we generated mutants derived from the polyvalent inhibitor SerpinB1 (monocyte/neutrophil elastase inhibitor) that specifically inhibit PR3 and that differ from wt-SerpinB1 by only 3 or 4 residues in the reactive center loop. The rate constant of association between the best SerpinB1 mutant and PR3 is 1.4 x 10(7) M(-1) . s(-1), which is similar to 100-fold higher than that observed with wt-SerpinB1 and compares with that of alpha 1-protease inhibitor (alpha 1-PI) toward HNE. SerpinB1(S/DAR) is cleaved by HNE, but due to differences in rate, inhibition of PR3 by SerpinB1(S/DAR) is only minimally affected by the presence of HNE even when the latter is in excess. SerpinB1(S/DAR) inhibits soluble PR3 and also membrane-bound PR3 at the surface of activated neutrophils. Moreover, SerpinB1(S/DAR) clears induced PR3 from the surface of activated neutrophils. Overall, these specific inhibitors of PR3 will be valuable for defining biological functions of the protease and may prove useful as therapeutics for PR3-related inflammatory diseases, such as Wegener's granulomatosis.-Jegot, G., Derache, C., Castella, S., Lahouassa, H., Pitois, E., Jourdan, M. L., Remold-O'Donnell, E., Kellenberger, C., Gauthier, F., Korkmaz, B. A substrate-based approach to convert SerpinB1 into a specific inhibitor of proteinase 3, the Wegener's granulomatosis autoantigen. FASEB J. 25, 3019-3031 (2011). www.fasebj.org	[Korkmaz, Brice] Univ Tours, Fac Med, INSERM, U618, F-37032 Tours, France; [Derache, Chrystelle] CNRS, Ctr Biophys Mol, Orleans, France; [Jourdan, Marie Lise] Ctr Hosp Reg Univ, Tours, France; [Remold-O'Donnell, Eileen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA; [Kellenberger, Christine] CNRS, UMR, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Centre National de la Recherche Scientifique (CNRS); CHU Tours; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Centre National de la Recherche Scientifique (CNRS)	Korkmaz, B (corresponding author), Univ Tours, Fac Med, INSERM, U618, F-37032 Tours, France.	brice.korkmaz@inserm.fr	kellenberger, christine/AAV-9304-2020	KORKMAZ, BRICE/0000-0002-5159-8706	Region Centre; Fonds Europeen de Developpement Regional	Region Centre(Region Centre-Val de Loire); Fonds Europeen de Developpement Regional	This work was supported by Region Centre and the Fonds Europeen de Developpement Regional (Projet INFINHI). B. K. acknowledges the Fondation Pour La Recherche Medicale (FRM). The authors thank Dr. Dieter Jenne (Max Planck Institute of Neurobiology, Martinsried, Germany) for sending proteinase 3 plasmid, Dr. Michele Brillard-Bourdet for sequence analyses, Dr. Martine Cadene (Centre de Biophysique Moleculaire, Orleans, France) for performing MALDI-TOF mass spectrometry analysis, and Dr. Herve Watier and Dr. Danielle Degenne (Centre Hospitalier Regional Universitaire, Tours, France) for providing WG blood samples. The authors appreciatively acknowledge contributions of Dr. Nicolas Guyot, Marine Sigismeau, and Lise Vanderlynden to early phases of this work.	Askew YS, 2001, J BIOL CHEM, V276, P49320, DOI 10.1074/jbc.M108879200; Attucci S, 2002, BIOCHEM J, V366, P965, DOI 10.1042/BJ20020321; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; Chughtai B, 2004, J AEROSOL MED, V17, P289, DOI 10.1089/jam.2004.17.289; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; COOLEY J, 2010, EUR RESP J; CSERNOK E, 1990, AM J PATHOL, V137, P1113; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; Dou DF, 2010, BIOORGAN MED CHEM, V18, P1093, DOI 10.1016/j.bmc.2009.12.057; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Felber LM, 2006, FEBS J, V273, P2505, DOI 10.1111/j.1742-4658.2006.05257.x; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Groutas WC, 1997, BIOCHEM BIOPH RES CO, V233, P697, DOI 10.1006/bbrc.1997.6526; HALBWACHSMECARELLI L, 1995, FEBS LETT, V374, P29, DOI 10.1016/0014-5793(95)01073-N; HATTAR K, EUR RESP J, V36, P187; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Inoue Y, 2006, J TRAUMA, V60, P936, DOI 10.1097/01.ta.0000217271.25809.a0; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; Kallenberg CGM, 2008, J AUTOIMMUN, V30, P29, DOI 10.1016/j.jaut.2007.11.005; Kallenberg CGM, 2006, NAT CLIN PRACT RHEUM, V2, P661, DOI 10.1038/ncprheum0355; Kalupov T, 2009, J BIOL CHEM, V284, P34084, DOI 10.1074/jbc.M109.042903; Koehl C, 2003, J BIOL CHEM, V278, P12609, DOI 10.1074/jbc.M210074200; Korkmaz B, 2002, J BIOL CHEM, V277, P39074, DOI 10.1074/jbc.M202918200; Korkmaz B, 2005, J IMMUNOL, V175, P3329, DOI 10.4049/jimmunol.175.5.3329; Korkmaz B, 2005, AM J RESP CELL MOL, V32, P553, DOI 10.1165/rcmb.2004-0374OC; Korkmaz B, 2004, AM J RESP CELL MOL, V30, P801, DOI 10.1165/rcmb.2003-0139OC; Korkmaz B, 2008, NAT PROTOC, V3, P991, DOI 10.1038/nprot.2008.63; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Korkmaz B, 2007, J BIOL CHEM, V282, P1989, DOI 10.1074/jbc.M608700200; Korkmaz B, 2010, PHARMACOL REV, V62, P726, DOI 10.1124/pr.110.002733; Korkmaz B, 2009, J BIOL CHEM, V284, P19896, DOI 10.1074/jbc.M901471200; Kuhl A, 2010, J IMMUNOL, V185, P387, DOI 10.4049/jimmunol.0903887; Kuraki T, 2002, AM J RESP CRIT CARE, V166, P496, DOI 10.1164/rccm.2103118; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; Moreau T, 2008, BIOCHIMIE, V90, P284, DOI 10.1016/j.biochi.2007.09.007; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Pendergraft WF, 2004, KIDNEY INT, V65, P75, DOI 10.1111/j.1523-1755.2004.00364.x; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Preston GA, 2002, J AM SOC NEPHROL, V13, P2840, DOI 10.1097/01.ASN.0000034911.03334.C3; Quinn Derek J, 2010, Open Respir Med J, V4, P20, DOI 10.2174/1874306401004020020; Ralston DR, 1997, J CLIN INVEST, V100, P1416, DOI 10.1172/JCI119662; REMOLDODONNELL E, 1989, J EXP MED, V169, P1071, DOI 10.1084/jem.169.3.1071; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Rooney CP, 2001, AM J RESP CELL MOL, V24, P747, DOI 10.1165/ajrcmb.24.6.4147; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 2004, J BIOL CHEM, V279, P29981, DOI 10.1074/jbc.M401913200; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Sugawara S, 2005, CRIT REV IMMUNOL, V25, P343, DOI 10.1615/CritRevImmunol.v25.i5.10; Van Rossum AP, 2005, KIDNEY INT, V68, P537, DOI 10.1111/j.1523-1755.2005.00431.x; van Rossum AP, 2004, J LEUKOCYTE BIOL, V76, P1162, DOI 10.1189/jlb.0604319; Vong L, 2007, J BIOL CHEM, V282, P29998, DOI 10.1074/jbc.M702876200; Voynow JA, 2008, INT J BIOCHEM CELL B, V40, P1238, DOI 10.1016/j.biocel.2008.03.003; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A	59	11	14	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3019	3031		10.1096/fj.10-176552	http://dx.doi.org/10.1096/fj.10-176552			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21670065				2022-12-28	WOS:000294435200017
J	Zhao, WA; Loh, W; Droujinine, IA; Teo, WS; Kumar, N; Schafer, S; Cui, CH; Zhang, L; Sarkar, D; Karnik, R; Karp, JM				Zhao, Weian; Loh, Weili; Droujinine, Ilia A.; Teo, Weisuong; Kumar, Namit; Schafer, Sebastian; Cui, Cheryl H.; Zhang, Liang; Sarkar, Debanjan; Karnik, Rohit; Karp, Jeffrey M.			Mimicking the inflammatory cell adhesion cascade by nucleic acid aptamer programmed cell-cell interactions	FASEB JOURNAL			English	Article						mesenchymal stem cell; homing; trafficking; cell therapy	MESENCHYMAL STEM-CELLS; L-SELECTIN; P-SELECTIN; BONE-MARROW; DNA APTAMER; TRAFFICKING; LIGANDS; RNA; ENRICHMENT; EXPRESSION	Nature has evolved effective cell adhesion mechanisms to deliver inflammatory cells to inflamed tissue; however, many culture-expanded therapeutic cells are incapable of targeting diseased tissues following systemic infusion, which represents a great challenge in cell therapy. Our aim was to develop simple approaches to program cell-cell interactions that would otherwise not exist toward cell targeting and understanding the complex biology of cell-cell interactions. We employed a chemistry approach to engineer P-or L-selectin binding nucleic acid aptamers onto mesenchymal stem cells (MSCs) to enable them to engage inflamed endothelial cells and leukocytes, respectively. We show for the first time that engineered cells with a single artificial adhesion ligand can recapitulate 3 critical cell interactions in the inflammatory cell adhesion cascade under dynamic flow conditions. Aptamer-engineered MSCs adhered on respective selectin surfaces under static conditions >10 times more efficiently than controls including scrambled-DNA modified MSCs. Significantly, engineered MSCs can be directly captured from the flow stream by selectin surfaces or selectin-expressing cells under flow conditions (<= 2dyn/cm(2)). The simple chemistry approach and the versatility of aptamers permit the concept of engineered cell-cell interactions to be generically applicable for targeting cells to diseased tissues and elucidating the biology of cell-cell interactions.-Zhao, W., Loh, W., Droujinine, I. A., Teo, W., Kumar, N., Schafer, S., Cui, C. H., Zhang, L., Sarkar, D., Karnik, R., Karp, J. M. Mimicking the inflammatory cell adhesion cascade by nucleic acid aptamer programmed cell-cell interactions. FASEB J. 25, 3045-3056 (2011). www.fasebj.org	[Karp, Jeffrey M.] Harvard Univ, Sch Med, PRB, Cambridge, MA 02139 USA; [Zhao, Weian; Loh, Weili; Droujinine, Ilia A.; Teo, Weisuong; Kumar, Namit; Schafer, Sebastian; Cui, Cheryl H.; Zhang, Liang; Sarkar, Debanjan; Karp, Jeffrey M.] Brigham & Womens Hosp, Ctr Regenerat Therapeut, Cambridge, MA USA; [Zhao, Weian; Loh, Weili; Droujinine, Ilia A.; Teo, Weisuong; Kumar, Namit; Schafer, Sebastian; Cui, Cheryl H.; Zhang, Liang; Sarkar, Debanjan; Karp, Jeffrey M.] Brigham & Womens Hosp, Dept Med, Cambridge, MA USA; [Zhao, Weian; Loh, Weili; Droujinine, Ilia A.; Teo, Weisuong; Kumar, Namit; Schafer, Sebastian; Cui, Cheryl H.; Zhang, Liang; Sarkar, Debanjan; Karp, Jeffrey M.] Harvard Stem Cell Inst, Cambridge, MA USA; [Zhao, Weian; Loh, Weili; Droujinine, Ilia A.; Teo, Weisuong; Kumar, Namit; Schafer, Sebastian; Cui, Cheryl H.; Zhang, Liang; Sarkar, Debanjan; Karp, Jeffrey M.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Karnik, Rohit] MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Karp, JM (corresponding author), Harvard Univ, Sch Med, PRB, Rm 313,65 Landsdowne St, Cambridge, MA 02139 USA.	jkarp@rics.bwh.harvard.edu	Sarkar, Debanjan/C-6093-2017	Sarkar, Debanjan/0000-0002-6666-3152; Schafer, Sebastian/0000-0002-6909-8275; KUMAR, NAMIT/0000-0002-5084-3490	National Institute of Health (NIH) [HL-097172, HL-095722, DE-019191]; American Heart Association [0970178N]; International Human Frontier Science Program Organization; NIH National Center for Research Resources [P40RR017447]; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR017447] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095722, R21HL097172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE019191] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); International Human Frontier Science Program Organization(Human Frontier Science Program); NIH National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Uli von Andrian for helpful discussions. This work was supported by National Institute of Health (NIH) grants HL-097172, HL-095722, and DE-019191 (to J.M.K.) and by American Heart Association grant 0970178N (to J.M.K). W.Z. is supported by an International Human Frontier Science Program Organization postdoctoral fellowship. Primary human MSCs were obtained from the Center for Gene Therapy (Texas A&M, College Station, TX, USA), which received funding through NIH National Center for Research Resources grant P40RR017447.	Ankrum J, 2010, TRENDS MOL MED, V16, P203, DOI 10.1016/j.molmed.2010.02.005; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Chandra RA, 2006, ANGEW CHEM INT EDIT, V45, P896, DOI 10.1002/ANIE.200502421; De Bank PA, 2007, BIOTECHNOL BIOENG, V97, P1617, DOI 10.1002/bit.21343; Detzer A, 2009, CURR TOP MED CHEM, V9, P1109, DOI 10.2174/156802609789630884; Diacovo TG, 1998, J EXP MED, V187, P197, DOI 10.1084/jem.187.2.197; Dimitroff CJ, 2001, J BIOL CHEM, V276, P47623, DOI 10.1074/jbc.M105997200; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FLEMING T, 2002, CELL CELL INTERACTIO; Gartner ZJ, 2009, P NATL ACAD SCI USA, V106, P4606, DOI 10.1073/pnas.0900717106; Guo KT, 2006, STEM CELLS, V24, P2220, DOI 10.1634/stemcells.2006-0015; Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092; Hodgkinson CP, 2010, HUM GENE THER, V21, P1513, DOI 10.1089/hum.2010.165; Hsiao SC, 2009, LANGMUIR, V25, P6985, DOI 10.1021/la900150n; Huang J, 2010, CIRC RES, V106, P1753, DOI 10.1161/CIRCRESAHA.109.196030; Hui EE, 2007, P NATL ACAD SCI USA, V104, P5722, DOI 10.1073/pnas.0608660104; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Jenison RD, 1998, ANTISENSE NUCLEIC A, V8, P265, DOI 10.1089/oli.1.1998.8.265; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Laird DJ, 2008, CELL, V132, P612, DOI 10.1016/j.cell.2008.01.041; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liu JW, 2009, CHEM REV, V109, P1948, DOI 10.1021/cr030183i; Ludwig RJ, 2004, J INVEST DERMATOL, V122, P830, DOI 10.1111/j.0022-202X.2004.22318.x; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Oh Hana, 2008, J Vis Exp, DOI 10.3791/745; Phillips JA, 2009, ANAL CHEM, V81, P1033, DOI 10.1021/ac802092j; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763; Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703; Sarkar D, 2008, BIOCONJUGATE CHEM, V19, P2105, DOI 10.1021/bc800345q; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; SIMON SI, 1993, BLOOD, V82, P1097; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Veedu RN, 2009, RNA BIOL, V6, P321, DOI 10.4161/rna.6.3.8807; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3; Wu YR, 2010, P NATL ACAD SCI USA, V107, P5, DOI 10.1073/pnas.0909611107; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; ZHAO W, 2010, MATER TODAY, V13, P14021; Zhao W, 2008, CHEMBIOCHEM, V9, P2363, DOI 10.1002/cbic.200800282; Zhao WA, 2008, ANGEW CHEM INT EDIT, V47, P6330, DOI 10.1002/anie.200705982; Zhao WA, 2008, J AM CHEM SOC, V130, P3610, DOI 10.1021/ja710241b; Zhao WA, 2007, CHEMBIOCHEM, V8, P727, DOI 10.1002/cbic.200700014	53	32	33	4	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3045	3056		10.1096/fj.10-178384	http://dx.doi.org/10.1096/fj.10-178384			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21653192	Green Published			2022-12-28	WOS:000294435200019
J	Harris, NC; Paavonen, K; Davydova, N; Roufail, S; Sato, T; Zhang, YF; Karnezis, T; Stacker, SA; Achen, MG				Harris, Nicole C.; Paavonen, Karri; Davydova, Natalia; Roufail, Sally; Sato, Teruhiko; Zhang, You-Fang; Karnezis, Tara; Stacker, Steven A.; Achen, Marc G.			Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer	FASEB JOURNAL			English	Article						VEGF-D; metastasis; lymphangiogenesis; angiogenesis; neuropilin	VEGF-D; PROPROTEIN CONVERTASES; FACTOR-C; TUMOR LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MOLECULAR CONTROL; FACTOR RECEPTOR-3; BREAST-CANCER; IN-VIVO; CELLS	VEGF-D is a mitogen for endothelial cells that promotes tumor growth and metastatic spread in animal models, and expression of which correlates with lymph node metastasis in some human cancers. It is secreted from the cell as a full-length form with propeptides flanking a central region containing binding sites for VEGFR-2 and VEGFR-3, receptors that signal for angiogenesis and lymphangiogenesis. The propeptides can be cleaved from VEGF-D, enhancing affinity for VEGFR-2 and VEGFR-3 in vitro; however, the importance of this processing in cancer is unclear. To explore the necessity of processing for the effects of VEGF-D in cancer, we use a mutant full-length form that cannot be processed, and show that, in contrast to full-length VEGF-D that is processed, this mutant does not promote tumor growth and lymph node metastasis in a mouse tumor model. Processing of VEGF-D is required for tumor angiogenesis, lymphangiogenesis, and recruitment of tumor-associated macrophages. These observations may be explained by the requirement of processing for VEGF-D to bind neuropilin receptors and activate VEGFR-2. Our results indicate that proteolytic processing is necessary for VEGF-D to promote the growth and spread of cancer, and suggest that enzymes catalyzing this processing could be targets for antimetastatic therapeutics.-Harris, N. C., Paavonen, K., Davydova, N., Roufail, S., Sato, T., Zhang, Y. -F., Karnezis, T., Stacker, S. A., Achen, M. G. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J. 25, 2615-2625 (2011). www.fasebj.org	[Harris, Nicole C.; Davydova, Natalia; Roufail, Sally; Zhang, You-Fang; Karnezis, Tara; Stacker, Steven A.; Achen, Marc G.] Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia; [Harris, Nicole C.] Univ Melbourne, Dept Surg, Royal Melbourne Hosp, Parkville, Vic 3052, Australia; [Harris, Nicole C.; Paavonen, Karri; Davydova, Natalia; Roufail, Sally; Sato, Teruhiko; Zhang, You-Fang; Karnezis, Tara; Stacker, Steven A.; Achen, Marc G.] Univ Melbourne, Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic, Australia	Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne	Achen, MG (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	marc.achen@petermac.org		Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273	National Health and Medical Research Council of Australia; Melbourne Research Scholarship; Victorian Government, Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Melbourne Research Scholarship; Victorian Government, Australia	This work was supported by a Program Grant and Research Fellowships (to M.G.A. and S.A.S.) from the National Health and Medical Research Council of Australia, a Melbourne Research Scholarship (to N.C.H.), and funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. M.G.A. and S.A.S. are consultants to Vegenics Ltd., a company developing anticancer therapeutics.	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Achen MG, 2006, INT J CANCER, V119, P1755, DOI 10.1002/ijc.21899; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Baldwin ME, 2002, BIOESSAYS, V24, P1030, DOI 10.1002/bies.10173; Baldwin ME, 2001, J BIOL CHEM, V276, P44307, DOI 10.1074/jbc.M106188200; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Bassi DE, 2010, NEOPLASIA, V12, P516, DOI 10.1593/neo.92030; Bassi DE, 2005, MOL CARCINOGEN, V44, P151, DOI 10.1002/mc.20134; Bhardwaj S, 2003, HUM GENE THER, V14, P1451, DOI 10.1089/104303403769211664; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Goldman J, 2007, FASEB J, V21, P1003, DOI 10.1096/fj.06-6656com; Gordon EJ, 2008, DEV DYNAM, V237, P1901, DOI 10.1002/dvdy.21605; Haiko P, 2008, MOL CELL BIOL, V28, P4843, DOI 10.1128/MCB.02214-07; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Karpanen T, 2001, CANCER RES, V61, P1786; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kopfstein L, 2007, AM J PATHOL, V170, P1348, DOI 10.2353/ajpath.2007.060835; Laakkonen P, 2007, CANCER RES, V67, P593, DOI 10.1158/0008-5472.CAN-06-3567; Leppanen VM, 2011, BLOOD, V117, P1507, DOI 10.1182/blood-2010-08-301549; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; Nilsson I, 2010, EMBO J, V29, P1377, DOI 10.1038/emboj.2010.30; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rutanen J, 2003, CARDIOVASC RES, V59, P971, DOI 10.1016/S0008-6363(03)00518-2; Rutanen J, 2004, CIRCULATION, V109, P1029, DOI 10.1161/01.CIR.0000115519.03688.A2; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shayan R, 2006, CARCINOGENESIS, V27, P1729, DOI 10.1093/carcin/bgl031; Shojaei F, 2007, LAB INVEST, V87, P227, DOI 10.1038/labinvest.3700526; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tuttle TM, 2004, AM SURGEON, V70, P407; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Von Marschall Z, 2005, INT J ONCOL, V27, P669; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137	50	30	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2615	2625		10.1096/fj.10-179788	http://dx.doi.org/10.1096/fj.10-179788			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21515745				2022-12-28	WOS:000293337800012
J	Hibino, N; Villalona, G; Pietris, N; Duncan, DR; Schoffner, A; Roh, JD; Yi, T; Dobrucki, LW; Mejias, D; Sawh-Martinez, R; Harrington, JK; Sinusas, A; Krause, DS; Kyriakides, T; Saltzman, WM; Pober, JS; Shin'oka, T; Breuer, CK				Hibino, Narutoshi; Villalona, Gustavo; Pietris, Nicholas; Duncan, Daniel R.; Schoffner, Adam; Roh, Jason D.; Yi, Tai; Dobrucki, Lawrence W.; Mejias, Dane; Sawh-Martinez, Rajendra; Harrington, Jamie K.; Sinusas, Albert; Krause, Diane S.; Kyriakides, Themis; Saltzman, W. Mark; Pober, Jordan S.; Shin'oka, Toshiharu; Breuer, Christopher K.			Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel	FASEB JOURNAL			English	Article						bone marrow chimera; composite vascular implant; microcomputed tomography angiography	BONE-MARROW; AUTOGRAFTS; CELLS; INFLAMMATION	We developed a tissue-engineered vascular graft composed of biodegradable scaffold seeded with autologous bone marrow-derived mononuclear cells (BMMCs) that is currently in clinical trial and developed analogous mouse models to study mechanisms of neovessel formation. We previously reported that seeded human BMMCs were rapidly lost after implantation into immunodeficient mice as host macrophages invaded the graft. As a consequence, the resulting neovessel was entirely of host cell origin. Here, we investigate the source of neotissue cells in syngeneic BMMC-seeded grafts, implanted into immunocompetent mouse recipients. We again find that seeded BMMCs are lost, declining to 0.02% at 14 d, concomitant with host macrophage invasion. In addition, we demonstrate using sex-mismatched chimeric hosts that bone marrow is not a significant source of endothelial or smooth muscle cells that comprise the neovessel. Furthermore, using composite grafts formed from seeded scaffold anastomosed to sex-mismatched natural vessel segments, we demonstrate that the adjacent vessel wall is the principal source of these endothelial and smooth muscle cells, forming 93% of proximal neotissue. These findings have important implications regarding fundamental mechanisms underlying neotissue formation; in this setting, the tissue-engineered construct functions by mobilizing the body's innate healing capabilities to "regenerate" neotissue from preexisting committed tissue cells.-Hibino, N., Villalona, G., Pietris, N., Duncan, D. R., Schoffner, A., Roh, J. D., Yi, T., Dobrucki, L. W., Mejias, D., Sawh-Martinez, R., Harrington, J. K., Sinusas, A., Krause, D. S., Kyriakides, T., Saltzman, W. M., Pober, J. S., Shin'oka, T., Breuer, C. K. Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J. 25, 2731-2739 (2011). www.fasebj.org	[Hibino, Narutoshi; Villalona, Gustavo; Pietris, Nicholas; Duncan, Daniel R.; Schoffner, Adam; Roh, Jason D.; Yi, Tai; Dobrucki, Lawrence W.; Mejias, Dane; Sawh-Martinez, Rajendra; Harrington, Jamie K.; Sinusas, Albert; Krause, Diane S.; Kyriakides, Themis; Saltzman, W. Mark; Pober, Jordan S.; Shin'oka, Toshiharu; Breuer, Christopher K.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT USA	Yale University	Breuer, CK (corresponding author), 10 Amistad St,Amistad Bldg,Rm 301 C, New Haven, CT 06510 USA.	christopher.breuer@yale.edu	Sinusas, Albert J/A-7235-2009; Dobrucki, Wawrzyniec L/D-3987-2009; Sawh-Martinez, Rajendra/AAF-4842-2021	Dobrucki, Wawrzyniec L/0000-0002-6807-217X; Sawh-Martinez, Rajendra/0000-0002-8363-3529; Breuer, Christopher/0000-0003-0987-3898; Duncan, Daniel/0000-0003-4771-8901	U.S. National Institutes of Health (NIH) [AR46032]; Howard Hughes Medical Institute; Doris Duke Charitable Foundation;  [NIH K08HL083980];  [NIH R01HL098228];  [NIH UL1RR024139];  [NIH P30DK072442]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL083980, R01HL098228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072442] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); ; ; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Lin Wang for assisting with Y chromosome FISH analysis. Histological processing and embedding was done by the Yale Core Center for Musculoskeletal Disorders [U.S. National Institutes of Health (NIH) grant AR46032]. Research support was provided through the following grants: NIH K08HL083980, NIH R01HL098228, NIH UL1RR024139, and NIH P30DK072442; a Howard Hughes Medical Institute grant; and a Doris Duke Charitable Foundation Clinical Scientist Development Award. Gunze Ltd. has provided research support for the clinical trial evaluating the use of the use of tissue-engineered vascular grafts. None of the funding for the work done in this study was provided by Gunze Ltd.	Brennan MP, 2008, ANN SURG, V248, P370, DOI 10.1097/SLA.0b013e318184dcbd; Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106; Hibino N, 2005, J THORAC CARDIOV SUR, V129, P1064, DOI 10.1016/j.jtcvs.2004.10.030; Hibino N, 2010, J THORAC CARDIOV SUR, V139, P431, DOI 10.1016/j.jtcvs.2009.09.057; Jones RJ, 1996, BLOOD, V88, P487, DOI 10.1182/blood.V88.2.487.bloodjournal882487; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; Roh JD, 2008, BIOMATERIALS, V29, P1454, DOI 10.1016/j.biomaterials.2007.11.041; Roh JD, 2007, TISSUE ENG, V13, P2743, DOI 10.1089/ten.2007.0171; Roh JD, 2010, P NATL ACAD SCI USA, V107, P4669, DOI 10.1073/pnas.0911465107; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Shinoka T, 1998, J THORAC CARDIOV SUR, V115, P536, DOI 10.1016/S0022-5223(98)70315-0; Vacanti JP, 1999, LANCET, V354, pSI32; VILLALONA GA, TISSUE ENG B, V16, P341	16	112	118	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2731	2739		10.1096/fj.11-182246	http://dx.doi.org/10.1096/fj.11-182246			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21566209	Green Published			2022-12-28	WOS:000293337800022
J	Hulsmans, M; De Keyzer, D; Holvoet, P				Hulsmans, Maarten; De Keyzer, Dieuwke; Holvoet, Paul			MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis	FASEB JOURNAL			English	Review						cardiovascular diseases; metabolic syndrome; vascular tissue; adipose tissue; microvesicles	C-REACTIVE PROTEIN; ADIPOSE-TISSUE MACROPHAGES; CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; ADIPOCYTE DIFFERENTIATION; INSULIN-RESISTANCE; METABOLIC SYNDROME; GENE-EXPRESSION; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE	A primary event in atherogenesis is the infiltration of activated inflammatory cells into the arterial wall. There they secrete reactive oxygen species and oxidize lipoproteins, inducing foam cell formation and endothelial cell apoptosis, which in turn lead to plaque growth, erosion, and rupture. In addition, there is evidence that this vicious circle between oxidative stress and inflammation occurs not only in the diseased arterial wall but also in adipose tissues in obesity. In this condition, oxidative stress and inflammation impair adipocyte maturation, resulting in defective insulin action and adipocytokine signaling. This observation raises questions regarding what molecules are probably common regulators of these pathogenic processes in adipose and vascular tissues. Candidates are small, noncoding, microRNAs (miRs) that control gene expression by inducing mRNA degradation or blocking translation. This review summarizes recent insights into the roles of miRs in regulation of oxidative stress and inflammation in vascular and adipose tissues. It emphasizes the role of miR-containing microvesicles in the interaction between inflammatory cells and endothelial cells within these tissues and in communication between these tissues, possibly explaining the similarity and the simultaneity of molecular changes and interactions in adipose and vascular tissues.-Hulsmans, M., De Keyzer, D., Holvoet, P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J. 25, 2515-2527 (2011). www.fasebj.org	[Hulsmans, Maarten; De Keyzer, Dieuwke; Holvoet, Paul] Katholieke Univ Leuven, Dept Cardiovasc Dis, Atherosclerosis & Metab Unit, B-3000 Louvain, Belgium	KU Leuven	Holvoet, P (corresponding author), Katholieke Univ Leuven, Dept Cardiovasc Dis, Atherosclerosis & Metab Unit, Herestr 49,O&N1,PB 705, B-3000 Louvain, Belgium.	paul.holvoet@med.kuleuven.be	Xie, Huangming/B-2260-2012; HOLVOET, PAUL/T-8434-2017; Hulsmans, Maarten/AAI-9547-2020	HOLVOET, PAUL/0000-0001-9201-0772; Hulsmans, Maarten/0000-0003-1009-658X	Belgian Federal Government [P06/30]; Katholieke Universiteit Leuven [PF/10/014]; Fonds voor Wetenschappelijk Onderzoek-Vlaanderen [G.0846.11]	Belgian Federal Government; Katholieke Universiteit Leuven(KU Leuven); Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO)	Funding was provided by the Interuniversitaire Attractiepolen Programma of the Belgian Federal Government (P06/30), the Bijzonder Onderzoeksfonds of the Katholieke Universiteit Leuven (PF/10/014), and the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (G.0846.11 and Vascular Biology Network).	Akao Y, 2011, MOL THER, V19, P395, DOI 10.1038/mt.2010.254; Alevizos I, 2010, NAT REV RHEUMATOL, V6, P391, DOI 10.1038/nrrheum.2010.81; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Andreasen D, 2010, METHODS, V50, pS6, DOI 10.1016/j.ymeth.2010.01.006; Aoki N, 2010, ENDOCRINOLOGY, V151, P2567, DOI 10.1210/en.2009-1023; Barbato C, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/803069; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BASTIDA E, 1984, BLOOD, V64, P177; Bonauer A, 2010, CURR DRUG TARGETS, V11, P943, DOI 10.2174/138945010791591313; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; BORK S, 2010, J CELL PHYSL, DOI DOI 10.1002/JCP.22557; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Butler J, 2006, J AM COLL CARDIOL, V47, P1595, DOI 10.1016/j.jacc.2005.12.046; Ceolotto G, 2011, AM J HYPERTENS, V24, P241, DOI 10.1038/ajh.2010.211; Chang CL, 2011, ENDOCRINOLOGY, V152, P384, DOI 10.1210/en.2010-0493; Chen DL, 2010, J CELL PHYSIOL, V225, P296, DOI 10.1002/jcp.22234; Chen T, 2009, CARDIOVASC RES, V83, P131, DOI 10.1093/cvr/cvp121; Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09; Cipolletta C, 2005, DIABETES, V54, P2779, DOI 10.2337/diabetes.54.9.2779; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; COLE JE, 2010, MEDIAT INFLAMM, P393; Conen D, 2009, CIRCULATION, V120, P1041, DOI 10.1161/CIRCULATIONAHA.109.863092; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Corsten MF, 2010, CIRC-CARDIOVASC GENE, V3, P499, DOI 10.1161/CIRCGENETICS.110.957415; Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065; de Ferranti S, 2008, CLIN CHEM, V54, P945, DOI 10.1373/clinchem.2007.100156; de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057; DeClercq Vanessa, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P228, DOI 10.2174/187152908785849080; Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]; Deng G, 2010, INT J OBESITY, V34, P165, DOI 10.1038/ijo.2009.205; Dentelli P, 2010, ARTERIOSCL THROM VAS, V30, P1562, DOI 10.1161/ATVBAHA.110.206201; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Dong SM, 2009, J BIOL CHEM, V284, P29514, DOI 10.1074/jbc.M109.027896; Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799; Dyce PW, 2010, HISTOL HISTOPATHOL, V25, P505, DOI 10.14670/HH-25.505; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Ella L, 2009, CELL DEATH DIFFER, V16, P1590, DOI 10.1038/cdd.2009.153; Estep M, 2010, ALIMENT PHARM THER, V32, P487, DOI 10.1111/j.1365-2036.2010.04366.x; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566; Fleissner F, 2010, CIRC RES, V107, P138, DOI 10.1161/CIRCRESAHA.110.216770; Fonseca V, 2004, ENDOCR REV, V25, P153, DOI 10.1210/er.2002-0034; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Forrest ARR, 2010, LEUKEMIA, V24, P460, DOI 10.1038/leu.2009.246; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Gerin I, 2010, AM J PHYSIOL-ENDOC M, V299, pE198, DOI 10.1152/ajpendo.00179.2010; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; Guo M, 2010, IMMUNOL CELL BIOL, V88, P555, DOI 10.1038/icb.2010.16; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; He AB, 2007, MOL ENDOCRINOL, V21, P2785, DOI 10.1210/me.2007-0167; Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153; Heneghan HM, 2010, OBES REV, V11, P354, DOI 10.1111/j.1467-789X.2009.00659.x; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Ho L, 2010, EXP GERONTOL, V45, P15, DOI 10.1016/j.exger.2009.09.007; Holvoet P, 2004, DIABETES, V53, P1068, DOI 10.2337/diabetes.53.4.1068; Holvoet P, 2008, JAMA-J AM MED ASSOC, V299, P2287, DOI 10.1001/jama.299.19.2287; Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107; Huang RS, 2010, J INVEST MED, V58, P961, DOI 10.231/JIM.0b013e3181ff46d7; Hulsmans M, 2010, J CELL MOL MED, V14, P70, DOI 10.1111/j.1582-4934.2009.00978.x; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Ito T, 2010, BIOCHEM BIOPH RES CO, V398, P735, DOI 10.1016/j.bbrc.2010.07.012; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098; Kartha RV, 2010, J CARDIOVASC TRANSL, V3, P256, DOI 10.1007/s12265-010-9172-z; Keophiphath M, 2009, MOL ENDOCRINOL, V23, P11, DOI 10.1210/me.2008-0183; Kim SY, 2010, BIOCHEM BIOPH RES CO, V392, P323, DOI 10.1016/j.bbrc.2010.01.012; Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235; Kinoshita M, 2010, MOL ENDOCRINOL, V24, P1978, DOI 10.1210/me.2010-0054; Kloting N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004699; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lee EK, 2011, MOL CELL BIOL, V31, P626, DOI 10.1128/MCB.00894-10; Leeper NJ, 2011, J CELL PHYSIOL, V226, P1035, DOI 10.1002/jcp.22422; Li GX, 2011, J CELL BIOCHEM, V112, P1318, DOI 10.1002/jcb.23045; Lia D, 2010, J HYPERTENS, V28, P1646, DOI 10.1097/HJH.0b013e32833a4922; Lin Q, 2009, FEBS J, V276, P2348, DOI 10.1111/j.1742-4658.2009.06967.x; Lin Y, 2009, J BIOL CHEM, V284, P7903, DOI 10.1074/jbc.M806920200; Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003; Ling HY, 2009, CLIN EXP PHARMACOL P, V36, pe32, DOI 10.1111/j.1440-1681.2009.05207.x; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Luo NL, 2010, DIABETES, V59, P791, DOI 10.2337/db09-1338; Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107; Martin MM, 2007, J BIOL CHEM, V282, P24262, DOI 10.1074/jbc.M701050200; Mathivanan S, 2010, MOL CELL PROTEOMICS, V9, P197, DOI 10.1074/mcp.M900152-MCP200; Matkovich SJ, 2009, CIRCULATION, V119, P1263, DOI 10.1161/CIRCULATIONAHA.108.813576; Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456; Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629; Nakamachi Y, 2009, ARTHRITIS RHEUM-US, V60, P1294, DOI 10.1002/art.24475; Ndumele Chiadi E, 2006, J Cardiometab Syndr, V1, P190; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Ogawa R, 2010, BIOCHEM BIOPH RES CO, V398, P723, DOI 10.1016/j.bbrc.2010.07.008; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Ohtani K, 2011, BASIC RES CARDIOL, V106, P5, DOI 10.1007/s00395-010-0139-7; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Orom UA, 2006, GENE, V372, P137, DOI 10.1016/j.gene.2005.12.031; Ortega FJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009022; Pamukcu B, 2010, ANN MED, V42, P394, DOI 10.3109/07853890.2010.497767; Park K, 2009, DIABETES CARE, V32, P1302, DOI 10.2337/dc09-0259; Parra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013005; Pena AS, 2010, INT J PEDIATR OBES, V5, P185, DOI 10.3109/17477160903111748; Phalon C, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001584; Ploner A, 2009, RNA, V15, P1797, DOI 10.1261/rna.1740009; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Poller W, 2010, CARDIOVASC RES, V86, P353, DOI 10.1093/cvr/cvq056; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Prieur X, 2011, DIABETES, V60, P797, DOI 10.2337/db10-0705; Ran JM, 2010, DIABETES RES CLIN PR, V88, P177, DOI 10.1016/j.diabres.2010.01.021; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Reilly MP, 2005, CIRCULATION, V111, P932, DOI 10.1161/01.CIR.0000155620.10387.43; Ribas J, 2010, CELL CYCLE, V9, P923, DOI 10.4161/cc.9.5.10930; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ronald JA, 2009, CIRCULATION, V120, P592, DOI 10.1161/CIRCULATIONAHA.108.813998; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Sayed D, 2010, J BIOL CHEM, V285, P20281, DOI 10.1074/jbc.M110.109207; Sethi JK, 2007, J LIPID RES, V48, P1253, DOI 10.1194/jlr.R700005-JLR200; Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019; Shibata SI, 2009, INT J ONCOL, V34, P1433, DOI 10.3892/ijo_00000272; Simak J, 2006, TRANSFUS MED REV, V20, P1, DOI 10.1016/j.tmrv.2005.08.001; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Strum JC, 2009, MOL ENDOCRINOL, V23, P1876, DOI 10.1210/me.2009-0117; Sun TW, 2009, MOL ENDOCRINOL, V23, P925, DOI 10.1210/me.2008-0298; Takahashi Y, 2010, CLIN SCI, V119, P395, DOI 10.1042/CS20100003; Tsimikas S, 2006, J AM COLL CARDIOL, V47, pC19, DOI 10.1016/j.jacc.2005.10.066; Tuccoli A, 2006, CELL CYCLE, V5, P2473, DOI 10.4161/cc.5.21.3422; van Rooij E, 2011, CIRC RES, V108, P219, DOI 10.1161/CIRCRESAHA.110.227496; Vickers Kasey C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P150, DOI 10.1097/MED.0b013e32833727a1; Villeneuve LM, 2010, DIABETES, V59, P2904, DOI 10.2337/db10-0208; Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105; Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684; Weber M, 2010, BIOCHEM BIOPH RES CO, V393, P643, DOI 10.1016/j.bbrc.2010.02.045; Wong P, 2010, CANCER RES, V70, P3833, DOI 10.1158/0008-5472.CAN-09-3268; Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08-1299; Yang Z, 2011, STEM CELLS DEV, V20, P259, DOI 10.1089/scd.2010.0072; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zheng LA, 2010, BIOCHEM BIOPH RES CO, V400, P483, DOI 10.1016/j.bbrc.2010.08.067; Zhu N, 2011, ATHEROSCLEROSIS, V215, P286, DOI 10.1016/j.atherosclerosis.2010.12.024	144	182	193	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2515	2527		10.1096/fj.11-181149	http://dx.doi.org/10.1096/fj.11-181149			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507901				2022-12-28	WOS:000293337800003
J	Karmouty-Quintana, H; Zhong, HY; Acero, L; Weng, TT; Melicoff, E; West, JD; Hemnes, A; Grenz, A; Eltzschig, HK; Blackwell, TS; Xia, Y; Johnston, RA; Zeng, DW; Belardinelli, L; Blackburn, MR				Karmouty-Quintana, Harry; Zhong, Hongyan; Acero, Luis; Weng, Tingting; Melicoff, Ernestina; West, James D.; Hemnes, Anna; Grenz, Almut; Eltzschig, Holger K.; Blackwell, Timothy S.; Xia, Yang; Johnston, Richard A.; Zeng, Dewan; Belardinelli, Luiz; Blackburn, Michael R.			The A(2B) adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease	FASEB JOURNAL			English	Article						vascular remodeling; fibrosis; G-protein coupled receptors; purinergic signaling; smooth muscle; interleukin-6	ARTERIAL-HYPERTENSION; INCREASED ENDOTHELIN-1; GENE-TRANSFER; FIBROSIS; INFLAMMATION; SMOOTH; MICE; GROWTH; HYPERRESPONSIVENESS; INTERLEUKIN-6	Development of pulmonary hypertension is a common and deadly complication of interstitial lung disease. Little is known regarding the cellular and molecular mechanisms that lead to pulmonary hypertension in patients with interstitial lung disease, and effective treatment options are lacking. The purpose of this study was to examine the adenosine 2B receptor (A(2B)R) as a regulator of vascular remodeling and pulmonary hypertension secondary to pulmonary fibrosis. To accomplish this, cellular and molecular changes in vascular remodeling were monitored in mice exposed to bleomycin in conjunction with genetic removal of the A(2B)R or treatment with the A(2B)R antagonist GS-6201. Results demonstrated that GS-6201 treatment or genetic removal of the A(2B)R attenuated vascular remodeling and hypertension in our model. Furthermore, direct A(2B)R activation on vascular cells promoted interleukin-6 and endothelin-1 release. These studies identify a novel mechanism of disease progression to pulmonary hypertension and support the development of A(2B)R antagonists for the treatment of pulmonary hypertension secondary to interstitial lung disease.-Karmouty-Quintana, H., Zhong, H., Acero, L., Weng, T., Melicoff, E., West, J. D., Hemnes, A., Grenz, A., Eltzschig, H. K., Blackwell, T. S., Xia, Y., Johnston, R. A., Zeng, D., Belardinelli, L., Blackburn, M. R. The A(2B) adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J. 26, 2546-2557 (2012). www.fasebj.org	[Karmouty-Quintana, Harry; Acero, Luis; Weng, Tingting; Melicoff, Ernestina; Xia, Yang; Blackburn, Michael R.] Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Johnston, Richard A.] Univ Texas Med Sch Houston, Dept Pediat, Houston, TX 77030 USA; [Zhong, Hongyan; Zeng, Dewan; Belardinelli, Luiz] Gilead Sci Inc, Palo Alto, CA USA; [Melicoff, Ernestina] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [West, James D.; Hemnes, Anna; Blackwell, Timothy S.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Grenz, Almut; Eltzschig, Holger K.] Univ Colorado Denver, Dept Anesthesiol, Aurora, CO USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Gilead Sciences; Baylor College of Medicine; Vanderbilt University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Blackburn, MR (corresponding author), Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	West, James/E-2960-2010; Karmouty-Quintana, Harry/ABC-9144-2020	West, James/0000-0002-6004-0202; Karmouty-Quintana, Harry/0000-0003-4753-9823; Blackburn, Michael/0000-0002-1394-9966; Melicoff, Ernestina/0000-0001-5696-7112; Johnston, Richard/0000-0003-0686-5139	Gilead Sciences Inc.; American Heart Association [11POST7580121]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098294, R01HL085317, R01HL070952] Funding Source: NIH RePORTER	Gilead Sciences Inc.(Gilead Sciences); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a research contract from Gilead Sciences Inc. (to M. R. B.). In addition, H. K.-Q. was supported in part by an American Heart Association South-West Affiliate postdoctoral fellowship (11POST7580121).	Aherne CM, 2011, BBA-BIOMEMBRANES, V1808, P1329, DOI 10.1016/j.bbamem.2010.05.016; Archer SL, 2010, CIRCULATION, V121, P2045, DOI 10.1161/CIRCULATIONAHA.108.847707; Ask K, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-16; Behr J, 2008, EUR RESPIR J, V31, P1357, DOI 10.1183/09031936.00171307; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Cacoub P, 1997, CARDIOVASC RES, V33, P196, DOI 10.1016/S0008-6363(96)00189-7; Chaouat A, 2009, CHEST, V136, P678, DOI 10.1378/chest.08-2420; Chua F, 2005, AM J RESP CELL MOL, V33, P9, DOI 10.1165/rcmb.2005-0062TR; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Clozel M, 2005, ANN MED, V37, P2, DOI 10.1080/07853890410018925; Csoka B, 2007, BLOOD, V110, P2685, DOI 10.1182/blood-2007-01-065870; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Galie N, 2004, CARDIOVASC RES, V61, P227, DOI 10.1016/j.cardiores.2003.11.026; Grobe AC, 2006, AM J PHYSIOL-LUNG C, V290, pL1069, DOI 10.1152/ajplung.00408.2005; Hamada K, 2007, CHEST, V131, P650, DOI 10.1378/chest.06-1466; Hemnes AR, 2008, AM J PHYSIOL-LUNG C, V294, pL24, DOI 10.1152/ajplung.00245.2007; Hopkins N, 2002, J ANAT, V201, P335, DOI 10.1046/j.1469-7580.2002.00096.x; Johnston RA, 2008, J APPL PHYSIOL, V104, P1727, DOI 10.1152/japplphysiol.00075.2008; Kalla RV, 2009, PURINERG SIGNAL, V5, P21, DOI 10.1007/s11302-008-9119-x; Kamezaki F, 2008, AM J RESP CRIT CARE, V177, P219, DOI 10.1164/rccm.200702-264OC; Kelland NF, 2010, J VASC RES, V47, P16, DOI 10.1159/000231717; Knight DA, 2003, PHARMACOL THERAPEUT, V99, P327, DOI 10.1016/S0163-7258(03)00095-0; Koupenova M, 2012, CIRCULATION, V125, P354, DOI 10.1161/CIRCULATIONAHA.111.057596; Lettieri CJ, 2006, CHEST, V129, P746, DOI 10.1378/chest.129.3.746; Leuchte HH, 2006, AM J RESP CRIT CARE, V173, P744, DOI 10.1164/rccm.200510-1545OC; Morrell NW, 2001, CIRCULATION, V104, P790, DOI 10.1161/hc3201.094152; Nadrous HF, 2005, CHEST, V128, P2393, DOI 10.1378/chest.128.4.2393; Nathan SD, 2007, AM J RESP CRIT CARE, V175, P875, DOI 10.1164/rccm.200608-1153CC; Ortiz LA, 2002, AM J PHYSIOL-LUNG C, V282, pL1209, DOI 10.1152/ajplung.00144.2001; Pardo A, 2005, PLOS MED, V2, P891, DOI 10.1371/journal.pmed.0020251; Park SH, 1997, AM J RESP CRIT CARE, V156, P600, DOI 10.1164/ajrccm.156.2.9607123; Rubens C, 2001, CHEST, V120, P1562, DOI 10.1378/chest.120.5.1562; Ryu JH, 2002, MAYO CLIN PROC, V77, P1221, DOI 10.4065/77.11.1221; Schroll S, 2010, RESP PHYSIOL NEUROBI, V170, P32, DOI 10.1016/j.resp.2009.11.005; Selman M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000482; Shahar I, 1999, INT J IMMUNOPHARMACO, V21, P759, DOI 10.1016/S0192-0561(99)00056-9; Shalaby KH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-82; Shao DM, 2011, PHARMACOL RES, V63, P504, DOI 10.1016/j.phrs.2011.03.003; Shetty Nagalakshmi, 2011, Inflammation & Allergy Drug Targets, V10, P19; Shorr AF, 2003, CHEST, V124, P922, DOI 10.1378/chest.124.3.922; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Sime PJ, 2001, CLIN IMMUNOL, V99, P308, DOI 10.1006/clim.2001.5008; SOFIA M, 1995, SARCOIDOSIS, V12, P118; Steiner MK, 2009, CIRC RES, V104, P236, DOI 10.1161/CIRCRESAHA.108.182014; STELZNER TJ, 1992, AM J PHYSIOL, V262, pL614, DOI 10.1152/ajplung.1992.262.5.L614; Stenmark KR, 2009, AM J PHYSIOL-LUNG C, V297, pL1013, DOI 10.1152/ajplung.00217.2009; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Terashita K, 2006, RESPIROLOGY, V11, P145, DOI 10.1111/j.1440-1843.2006.00826.x; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Tofovic SP, 2009, VASC PHARMACOL, V51, P190, DOI 10.1016/j.vph.2009.06.002; Van Rheen Z, 2011, AM J RESP CELL MOL, V44, P500, DOI 10.1165/rcmb.2010-0065OC; Weitzenblum E, 2009, SEMIN RESP CRIT CARE, V30, P458, DOI 10.1055/s-0029-1233315; West J, 2008, AM J PHYSIOL-LUNG C, V295, pL744, DOI 10.1152/ajplung.90255.2008; Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105; Yang ZH, 1999, CIRCULATION, V100, P5, DOI 10.1161/01.CIR.100.1.5; Zaynagetdinov R, 2010, AM J RESP CELL MOL, V42, P564, DOI 10.1165/rcmb.2008-0391OC; Zhong HY, 2005, AM J RESP CELL MOL, V32, P2, DOI 10.1165/rcmb.2004-0103OC; Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907; Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224; Zhou Y, 2009, PHARMACOL THERAPEUT, V123, P105, DOI 10.1016/j.pharmthera.2009.04.003	65	71	74	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2546	2557		10.1096/fj.11-200907	http://dx.doi.org/10.1096/fj.11-200907			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415303	Green Published			2022-12-28	WOS:000305017200031
J	Xu, HB; Wang, XL; Pahar, B; Alvarez, X; Rasmussen, KK; Lackner, AA; Veazey, RS				Xu, Huanbin; Wang, Xiaolei; Pahar, Bapi; Alvarez, Xavier; Rasmussen, Kelsi K.; Lackner, Andrew A.; Veazey, Ronald S.			Rapid down-regulation of gamma(c) on T cells in early SIV infection correlates with impairment of T-cell function	FASEB JOURNAL			English	Article						cytokine; CD4(+); T cell; HIV; intestine; mucosal immunology	IMMUNODEFICIENCY-VIRUS-INFECTION; TRIPLE COMBINATION THERAPY; HIV-1 INFECTION; IN-VIVO; INTERLEUKIN-7 RECEPTOR; HOMEOSTATIC PROLIFERATION; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; CD127 EXPRESSION; CHAIN CYTOKINES	The common gamma(c) subunit molecule is shared among all gamma(c) cytokines and clearly involved in T-cell function, but its role in HIV infection and immunity is not well understood. Here, we examined expression and function of gamma(c) on T cells during SIV infection in Rhesus macaques. Surface gamma(c) distribution was differentially expressed on CD4(+) and CD8(+) T cells, and CD4(+) naive/memory cell populations in various lymphoid tissues of normal macaques. However, surface gamma(c) expression was rapidly and significantly down-regulated on T cells in acute infection with pathogenic SIV, compared to infection with a less virulent SHIV or controls and did not recover on CD8(+) T cells in the chronic stage. Moreover, the peripheral and CD4(+) T cell loss was inversely correlated with gamma(+)(c) CD8(+) T cells in individual tissues. gamma(+)(c) T cells were mainly functional as evidenced by higher cytokine secretion and proliferative capacity. Further in vitro experiments found that surface gamma(c) expression could be down-regulated following high level of IL-7 treatment by both internalization and shedding. Down-regulation of gamma(c) during early HIV/SIV infection may inhibit T-cell function, particularly of CD8(+) T cells, and, may be linked with immune failure and loss of viral containment.-Xu, H., Wang, X., Pahar, B., Alvarez, X., Rasmussen, K. K., Lackner, A. A., Veazey, R. S. Rapid down-regulation of gamma(c) on T cells in early SIV infection correlates with impairment of T-cell function. FASEB J. 26, 2294-2305 (2012). www.fasebj.org	[Xu, Huanbin; Wang, Xiaolei; Pahar, Bapi; Alvarez, Xavier; Rasmussen, Kelsi K.; Lackner, Andrew A.; Veazey, Ronald S.] Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA 70433 USA	Tulane University	Veazey, RS (corresponding author), Tulane Natl Primate Res Ctr, Div Comparat Pathol, 18703 3 Rivers Rd, Covington, LA 70433 USA.	rveazey@tulane.edu	Xu, Huanbin/S-4870-2019; Pahar, Bapi/AFM-3129-2022	Pahar, Bapi/0000-0003-1949-973X	U.S. National Institutes of Health [AI49080, AI084793, U19 AI084793, U19 AI76982, RR000164]; Tulane University (New Orleans, LA, USA); NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084793, U19AI076982, R01AI049080] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011104] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tulane University (New Orleans, LA, USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Julie Bruhn, Calvin Lanclos, and Desiree Waguespachek for flow cytometry support and Janell LeBlanc, Maryjane Dodd, Linda Green, and Maury Duplantis for technical support. This work was supported by U.S. National Institutes of Health grants AI49080, AI084793, U19 AI084793, U19 AI76982, and RR000164, and a Faculty Enhancement grant from Tulane University (New Orleans, LA, USA). The authors declare no conflict of interests.	Alpdogan O, 2005, TRENDS IMMUNOL, V26, P56, DOI 10.1016/j.it.2004.11.002; Alves NL, 2007, IMMUNOL LETT, V108, P113, DOI 10.1016/j.imlet.2006.11.006; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Bani L, 1997, EUR J IMMUNOL, V27, P2188, DOI 10.1002/eji.1830270911; Bradley LM, 2005, TRENDS IMMUNOL, V26, P172, DOI 10.1016/j.it.2005.01.004; CARINI C, 1994, EUR J IMMUNOL, V24, P2927, DOI 10.1002/eji.1830241202; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; Chattopadhyay S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007382; Cohen T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001085; D'Souza WN, 2003, J IMMUNOL, V171, P5727, DOI 10.4049/jimmunol.171.11.5727; David D, 1998, P NATL ACAD SCI USA, V95, P11348, DOI 10.1073/pnas.95.19.11348; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Fluur C, 2007, J IMMUNOL, V178, P5340, DOI 10.4049/jimmunol.178.8.5340; Fry TJ, 2003, BLOOD, V101, P2294, DOI 10.1182/blood-2002-07-2297; Giliani S, 2005, IMMUNOL REV, V203, P110, DOI 10.1111/j.0105-2896.2005.00234.x; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Gougeon ML, 2010, J INTERN MED, V267, P502, DOI 10.1111/j.1365-2796.2010.02221.x; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Jaleco S, 2003, J IMMUNOL, V171, P61, DOI 10.4049/jimmunol.171.1.61; Juffroy O, 2010, J VIROL, V84, P96, DOI 10.1128/JVI.01475-09; Kim HP, 2006, CYTOKINE GROWTH F R, V17, P349, DOI 10.1016/j.cytogfr.2006.07.003; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Lazarevic V, 2005, INFECT IMMUN, V73, P2910, DOI 10.1128/IAI.73.5.2910-2922.2005; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leone A, 2009, CURR HIV RES, V7, P83, DOI 10.2174/157016209787048519; Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253; Llano A, 2001, J VIROL, V75, P10319, DOI 10.1128/JVI.75.21.10319-10325.2001; Maeurer MJ, 2000, INFECT IMMUN, V68, P2962, DOI 10.1128/IAI.68.5.2962-2970.2000; Masse GX, 2007, EUR J IMMUNOL, V37, P2606, DOI 10.1002/eji.200737234; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; Mitsuyasu R, 2007, ARCH INTERN MED, V167, P597, DOI 10.1001/archinte.167.6.597; Monteiro M, 2007, BLOOD, V109, P2863, DOI 10.1182/blood-2006-06-027060; Muthukumar A, 2004, BLOOD, V103, P973, DOI 10.1182/blood-2003-03-0874; Napolitano LA, 2001, NAT MED, V7, P73, DOI 10.1038/83381; Pahwa R, 2006, J INFECT DIS, V193, P879, DOI 10.1086/500471; Pahwa S, 2007, IMMUNOL RES, V38, P373, DOI 10.1007/s12026-007-0036-9; Paiardini M, 2005, J IMMUNOL, V174, P2900, DOI 10.4049/jimmunol.174.5.2900; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Park JH, 2004, IMMUNITY, V21, P289, DOI 10.1016/j.immuni.2004.07.016; Parkin NT, 1999, J INFECT DIS, V180, P865, DOI 10.1086/314928; Prlic M, 2003, J EXP MED, V197, P967, DOI 10.1084/jem.20021847; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Rose T, 2009, J IMMUNOL, V182, P7389, DOI 10.4049/jimmunol.0900190; Sasson SC, 2006, CURR DRUG TARGETS, V7, P1571, DOI 10.2174/138945006779025365; Sasson SC, 2006, J INFECT DIS, V193, P505, DOI 10.1086/499309; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Sereti I, 2005, J CLIN INVEST, V115, P1839, DOI 10.1172/JCI24307; Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601; Shi M, 2009, J IMMUNOL, V183, P4493, DOI 10.4049/jimmunol.0804339; Sirskyj D, 2008, CYTOKINE, V43, P1, DOI 10.1016/j.cyto.2008.03.001; Veazey RS, 2000, J VIROL, V74, P11001, DOI 10.1128/JVI.74.23.11001-11007.2000; Vranjkovic A, 2007, INT IMMUNOL, V19, P1329, DOI 10.1093/intimm/dxm102; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Xu HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017965; Xu HB, 2010, J IMMUNOL, V185, P7340, DOI 10.4049/jimmunol.1001642; Youle M, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010003	60	3	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2294	2305		10.1096/fj.11-195180	http://dx.doi.org/10.1096/fj.11-195180			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22375017	Green Published			2022-12-28	WOS:000305017200008
J	Pacios, S; Kang, J; Galicia, J; Gluck, K; Patel, H; Ovaydi-Mandel, A; Petrov, S; Alawi, F; Graves, DT				Pacios, Sandra; Kang, Jun; Galicia, Johnah; Gluck, Kenneth; Patel, Hemal; Ovaydi-Mandel, Amy; Petrov, Sophia; Alawi, Faizan; Graves, Dana T.			Diabetes aggravates periodontitis by limiting repair through enhanced inflammation	FASEB JOURNAL			English	Article						bone formation; cytokine; growth factor; inhibitor	TUMOR-NECROSIS-FACTOR; BONE LOSS; FACTOR-ALPHA; DESTRUCTION; INHIBITION; RESORPTION; CYTOKINES; HEALTH	Periodontitis is the most common lytic bone disease and one of the first clinical manifestations of diabetes. Diabetes increases the risk of periodontitis. The aim of the present study was to examine mechanisms by which diabetes aggravates periodontitis. Ligature-induced periodontitis was examined in Goto-Kakizaki rats with type 2 diabetes. A tumor necrosis factor (TNF)-specific-inhibitor, pegsunercept, was applied to diabetic rats after the onset of periodontal disease. Interferon-gamma (IFN-gamma), TNF-alpha, interleukin-1 beta (IL-1 beta), fibroblast growth factor-2 (FGF-2), transforming growth factor beta-1 (TGF beta-1), bone morphogenetic protein-2 (BMP-2), and BMP-6 were measured by real-time RT-PCR, and histological sections were examined for leukocyte infiltration and several parameters related to bone resorption and formation. Inflammation was prolonged in diabetic rats and was reversed by the TNF inhibitor, which reduced cytokine mRNA levels, leukocyte infiltration, and osteoclasts. In contrast, new bone and osteoid formation and osteoblast numbers were increased significantly vs. untreated diabetic animals. TNF inhibition in diabetic animals also reduced apoptosis, increased proliferation of bone-lining cells, and increased mRNA levels of FGF-2, TGF beta-1, BMP-2, and BMP-6. Thus, diabetes prolongs inflammation and osteoclastogenesis in periodontitis and through TNF limits the normal reparative process by negatively modulating factors that regulate bone.-Pacios, S., Kang, J., Galicia, J., Gluck, K., Patel, H., Ovaydi-Mandel, A., Petrov, S., Alawi, F., Graves, D. T. Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J. 26, 1423-1430 (2012). www.fasebj.org	[Pacios, Sandra; Kang, Jun; Galicia, Johnah; Patel, Hemal; Graves, Dana T.] Univ Penn, Dept Periodont, Sch Dent Med, Philadelphia, PA 19104 USA; [Alawi, Faizan] Univ Penn, Dept Pathol, Sch Dent Med, Philadelphia, PA 19104 USA; [Pacios, Sandra] Univ Int Catalunya, Dept Periodont, Sch Dent Med, Sant Cugat Del Valles, Spain; [Kang, Jun] Peking Univ, Dept Periodont, Sch Stomatol, Beijing 100871, Peoples R China; [Kang, Jun] Peking Univ, Dept Periodont, Hosp Stomatol, Beijing 100871, Peoples R China; [Gluck, Kenneth; Ovaydi-Mandel, Amy; Petrov, Sophia] Univ Med & Dent New Jersey, New Jersey Dent Sch, Dept Periodont, Newark, NJ 07103 USA	University of Pennsylvania; University of Pennsylvania; Universitat Internacional de Catalunya (UIC); Peking University; Peking University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Graves, DT (corresponding author), Univ Penn, Dept Periodont, Sch Dent Med, 240 S 40th St,Levy 122, Philadelphia, PA 19104 USA.	dtgraves@dental.upenn.edu		Galicia, Johnah/0000-0003-1908-5801	U.S. National Institute of Dental and Craniofacial Research [DE018307, DE0DE17732]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018307] Funding Source: NIH RePORTER	U.S. National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Tesfahun Desta (University of Medicine and Dentistry of New Jersey) for help in the experiments and Sunitha Batchu (University of Pennsylvania School of Dental Medicine) for help in preparing the manuscript. This work was supported by the U.S. National Institute of Dental and Craniofacial Research, grants DE018307 and DE0DE17732.	Assuma R, 1998, J IMMUNOL, V160, P403; Baker PJ, 1999, INFECT IMMUN, V67, P2804, DOI 10.1128/IAI.67.6.2804-2809.1999; Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954; Delima AJ, 2002, J INFECT DIS, V186, P511, DOI 10.1086/341778; Fantuzzi F, 2008, EXPERT OPIN THER TAR, V12, P1085, DOI 10.1517/14728222.12.9.1085 ; Garlet GP, 2007, CLIN EXP IMMUNOL, V147, P128, DOI 10.1111/j.1365-2249.2006.03260.x; Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236; Graves DT, 2008, FRONT BIOSCI-LANDMRK, V13, P1227, DOI 10.2741/2757; Graves DT, 2005, J DENT RES, V84, P324, DOI 10.1177/154405910508400406; Graves DT, 2001, J DENT RES, V80, P1875, DOI 10.1177/00220345010800100301; Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200; Han XZ, 2006, J IMMUNOL, V176, P625, DOI 10.4049/jimmunol.176.1.625; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; HAVELL EA, 1989, J IMMUNOL, V143, P2894; Kim EY, 2006, J IMMUNOL, V176, P1026, DOI 10.4049/jimmunol.176.2.1026; Kumar PS, 2006, J CLIN MICROBIOL, V44, P3665, DOI 10.1128/JCM.00317-06; Lalla E, 2000, J CLIN INVEST, V105, P1117, DOI 10.1172/JCI8942; Lamster IB, 2008, J AM DENT ASSOC, V139, p19S, DOI 10.14219/jada.archive.2008.0363; Lencel P, 2011, BONE, V48, P242, DOI 10.1016/j.bone.2010.09.001; Liu R, 2006, J DENT RES, V85, P510, DOI 10.1177/154405910608500606; Miheller P, 2007, INFLAMM BOWEL DIS, V13, P1379, DOI 10.1002/ibd.20234; Naguib G, 2004, J INVEST DERMATOL, V123, P87, DOI 10.1111/j.0022-202X.2004.22711.x; Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027; ROVIN SHELDON, 1966, J PERIODONTAL RES, V1, P193, DOI 10.1111/j.1600-0765.1966.tb01860.x; Salvi GE, 1997, J CLIN PERIODONTOL, V24, P8, DOI 10.1111/j.1600-051X.1997.tb01178.x; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763; WILLIAMS RC, 1985, SCIENCE, V227, P640, DOI 10.1126/science.3969553; Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139	32	105	109	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1423	1430		10.1096/fj.11-196279	http://dx.doi.org/10.1096/fj.11-196279			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22179526	Green Published, Bronze			2022-12-28	WOS:000302359700005
J	Aliprantis, AO; Stolina, M; Kostenuik, PJ; Poliachik, SL; Warner, SE; Bain, SD; Gross, TS				Aliprantis, Antonios O.; Stolina, Marina; Kostenuik, Paul J.; Poliachik, Sandra L.; Warner, Sarah E.; Bain, Steven D.; Gross, Ted S.			Transient muscle paralysis degrades bone via rapid osteoclastogenesis	FASEB JOURNAL			English	Article						homeostasis; botulinum toxin A; NFATc1; RANKL	GENE-RELATED PEPTIDE; SPINAL-CORD-INJURY; BOTULINUM TOXIN INJECTION; KAPPA-B LIGAND; SYMPATHETIC INNERVATION; RECEPTOR ACTIVATOR; GROWING RABBITS; OSTEOPOROSIS; MICE; RAT	A unilateral injection of botulinum toxin A (BTxA) in the calf induces paralysis and profound loss of ipsalateral trabecular bone within days. However, the cellular mechanism underlying acute muscle paralysis-induced bone loss (MPIBL) is poorly understood. We hypothesized that MPIBL arises via rapid and extensive osteoclastogenesis. We performed a series of in vivo experiments to explore this thesis. First, we observed elevated levels of the proosteoclastogenic cytokine receptor activator for nuclear factor-kappa B ligand (RANKL) within the proximal tibia metaphysis at 7 d after muscle paralysis (+113%, P<0.02). Accordingly, osteoclast numbers were increased 122% compared with the contralateral limb at 5 d after paralysis (P=0.04) and MPIBL was completely blocked by treatment with human recombinant osteoprotegerin (hrOPG). Further, conditional deletion of nuclear factor of activated T-cells c1 (NFATc1), the master regulator of osteoclastogenesis, completely inhibited trabecular bone loss (-2.2 +/- 11.9%, P<0.01). All experiments included negative control assessments of contralateral limbs and/or within-animal pre-and postintervention imaging. In summary, transient muscle paralysis induced acute RANKL-mediated osteoclastogenesis resulting in profound local bone resorption. Elucidation of the pathways that initiate osteoclastogenesis after paralysis may identify novel targets to inhibit bone loss and prevent fractures.-Aliprantis, A. O., Stolina, M., Kostenuik, P. J., Poliachik, S. L., Warner, S. E., Bain, S. D., Gross, T. S. Transient muscle paralysis degrades bone via rapid osteoclastogenesis. FASEB J. 26, 1110-1118 (2012). www.fasebj.org	[Poliachik, Sandra L.; Warner, Sarah E.; Bain, Steven D.; Gross, Ted S.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98104 USA; [Aliprantis, Antonios O.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02115 USA; [Aliprantis, Antonios O.] Harvard Univ, Sch Publ Hlth, Dept Infect Dis & Immunol, Boston, MA 02115 USA; [Stolina, Marina; Kostenuik, Paul J.] Amgen Inc, Metab Disorders, Thousand Oaks, CA 91320 USA	University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Amgen	Gross, TS (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, Box 359798,325 9th Ave, Seattle, WA 98104 USA.	tgross@u.washington.edu			Burroughs Wellcome Fund Career Award for Medical Scientists; U.S. National Institute of Arthritis and Metabolic Diseases [K08-AR-54859, AR-45665, AR-60304]; Amgen; Sigvard T. Hansen, Jr. Endowed Chair; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060304, R01AR045665, K08AR054859] Funding Source: NIH RePORTER	Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); U.S. National Institute of Arthritis and Metabolic Diseases; Amgen(Amgen); Sigvard T. Hansen, Jr. Endowed Chair; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported, in part, by a Burroughs Wellcome Fund Career Award for Medical Scientists (to A.O.A.), U.S. National Institute of Arthritis and Metabolic Diseases grants K08-AR-54859 (to A.O.A.), AR-45665 (to T. S. G.), and AR-60304 (to T. S. G.); a grant from Amgen (to T. S. G.); and the Sigvard T. Hansen, Jr. Endowed Chair (T. S. G.). A.O.A., S. L. P., S. E. W., and S. D. B. report no conflicts of interest. T. S. G. received funding from Amgen that, in part, supported this work. M. S. and P.J.K. are employees of Amgen and have equity ownership in Amgen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Arthritis and Metabolic Diseases or the U.S. National Institutes of Health.	Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Ausk B. J., 2011, 56 ANN M ORTH RES SO, P2260; Ausk BJ, 2012, BONE, V50, P14, DOI 10.1016/j.bone.2011.08.028; Bain S. D., 2009, J BONE MINER RES, V24, pS96; Blouin S, 2007, OSTEOPOROSIS INT, V18, P85, DOI 10.1007/s00198-006-0197-8; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Castro MJ, 1999, J APPL PHYSIOL, V86, P350, DOI 10.1152/jappl.1999.86.1.350; Chenu C, 2005, JOINT BONE SPINE, V72, P481, DOI 10.1016/j.jbspin.2005.10.007; Cooper C, 2010, OSTEOPOROSIS INT, V21, P425, DOI 10.1007/s00198-010-1251-0; Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302; Frost HM, 1999, AM J HUM BIOL, V11, P437; Garland DE, 2008, J SPINAL CORD MED, V31, P543, DOI 10.1080/10790268.2008.11753650; Geusens P, 2009, CLIN INTERV AGING, V4, P241; Goto Tetsuya, 2001, Medical Electron Microscopy, V34, P77; Gracia-Marco L, 2011, EUR J APPL PHYSIOL, V111, P2671, DOI 10.1007/s00421-011-1897-0; HAMBLETON P, 1992, J NEUROL, V239, P16, DOI 10.1007/BF00839205; Hansen RB, 2007, SCAND J UROL NEPHROL, V41, P115, DOI 10.1080/00365590600991383; Imai S, 1997, J BONE MINER RES, V12, P1018, DOI 10.1359/jbmr.1997.12.7.1018; JAWORSKI ZFG, 1981, J ANAT, V133, P397; Judex S, 2004, J BONE MINER RES, V19, P607, DOI 10.1359/JBMR.040110; Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kwon TG, 2007, J ORAL MAXIL SURG, V65, P1530, DOI 10.1016/j.joms.2006.10.059; Lang AM, 2003, ARCH PHYS MED REHAB, V84, pS69, DOI 10.1053/apmr.2003.50121; Larson CM, 2000, J PEDIATR ORTHOPED, V20, P71, DOI 10.1097/00004694-200001000-00016; Lewis SJG, 2001, ACTA NEUROL SCAND, V103, P320, DOI 10.1034/j.1600-0404.2001.103005320.x; Libouban H, 2008, MICRON, V39, P998, DOI 10.1016/j.micron.2007.09.006; Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306-4522(02)00165-3; MANNI E, 1989, DOC OPHTHALMOL, V72, P189, DOI 10.1007/BF00156709; Manske SL, 2010, BONE, V46, P24, DOI 10.1016/j.bone.2009.10.016; Marenzana M, 2007, BONE, V41, P206, DOI 10.1016/j.bone.2007.04.184; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Morey-Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001; Mori T, 1999, BIOCHEM BIOPH RES CO, V262, P418, DOI 10.1006/bbrc.1999.1220; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Negishi-Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600-065X.2009.00821.x; Ominsky MS, 2007, OSTEOPOROSIS INT, V18, P1073, DOI 10.1007/s00198-007-0363-7; Parfitt AM, 1983, BONE HISTOMORPHOMETR; Poliachik SL, 2010, BONE, V46, P18, DOI 10.1016/j.bone.2009.10.025; Prasad J., 2011, 33 AM SOC BON MIN RE; Rantalainen T, 2011, BONE, V48, P786, DOI 10.1016/j.bone.2010.11.013; Rauch F., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P264; Rauch F, 2004, BONE, V34, P771, DOI 10.1016/j.bone.2004.01.022; Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059; Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919; Saxena R, 2011, J BONE MINER METAB, V29, P111, DOI 10.1007/s00774-010-0201-4; Sayer AA, 2008, J NUTR HEALTH AGING, V12, P427, DOI 10.1007/BF02982703; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; SHAW NJ, 1994, ARCH DIS CHILD, V71, P235, DOI 10.1136/adc.71.3.235; Shiotani A, 2001, J ELECTRON MICROSC, V50, P365, DOI 10.1093/jmicro/50.4.365; Sievanen H., ARCH BIOCH BIOPHYS, V503, P146; Singh JA, 2010, THER ADV MUSCULOSKEL, V2, P105, DOI 10.1177/1759720X09357113; Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105-2896.2009.00849.x; Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601; Takahashi N, 2003, METH MOLEC MED, V80, P129; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Tang-Liu DDS, 2003, TOXICON, V42, P461, DOI 10.1016/S0041-0101(03)00196-X; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121; Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756-3282(99)00210-0; Usas A, 2007, BIOMATERIALS, V28, P5401, DOI 10.1016/j.biomaterials.2007.09.008; Vickerman L, 2011, DEV BIOL, V350, P323, DOI 10.1016/j.ydbio.2010.11.031; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8; Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009; Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006; Wright DE, 2002, J NEUROBIOL, V50, P198, DOI 10.1002/neu.10024; Yoshinaga Y, 2007, J PERIODONTAL RES, V42, P402, DOI 10.1111/j.1600-0765.2007.00960.x; ZAIDI M, 1987, J ENDOCRINOL, V115, P511, DOI 10.1677/joe.0.1150511; ZANCHETTA JR, 1995, BONE, V16, pS393, DOI 10.1016/S8756-3282(95)80505-2	74	29	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1110	1118		10.1096/fj.11-196642	http://dx.doi.org/10.1096/fj.11-196642			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22125315	Green Published			2022-12-28	WOS:000300949300015
J	Ben Khalifa, N; Tyteca, D; Marinangeli, C; Depuydt, M; Collet, JF; Courtoy, PJ; Renauld, JC; Constantinescu, S; Octave, JN; Kienlen-Campard, P				Ben Khalifa, Naouel; Tyteca, Donatienne; Marinangeli, Claudia; Depuydt, Mathieu; Collet, Jean-Francois; Courtoy, Pierre J.; Renauld, Jean-Christophe; Constantinescu, Stefan; Octave, Jean-Noel; Kienlen-Campard, Pascal			Structural features of the KPI domain control APP dimerization, trafficking, and processing	FASEB JOURNAL			English	Article						Alzheimer; APP; dimerization; BiFC; beta-amyloid	AMYLOID PRECURSOR PROTEIN; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; BETA-PROTEIN; GAMMA-SECRETASE; LIVING CELLS; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; INHIBITOR DOMAIN	The two major isoforms of human APP, APP695 and APP751, differ by the presence of a Kunitz-type protease inhibitor (KPI) domain in the extracellular region. APP processing and function is thought to be regulated by homodimerization. We used bimolecular fluorescence complementation (BiFC) to study dimerization of different APP isoforms and mutants. APP751 was found to form significantly more homodimers than APP695. Mutation of dimerization motifs in the TM domain did not affect fluorescence complementation, but native folding of KPI is critical for APP751 homodimerization. APP751 and APP695 dimers were mostly localized at steady state in the Golgi region, suggesting that most of the APP751 and 695 dimers are in the secretory pathway. Mutation of the KPI led to the retention of the APP homodimers in the endoplasmic reticulum. We finally showed that APP751 is more efficiently processed through the nonamyloidogenic pathway than APP695. These findings provide new insight on the particular role of KPI domain in APP dimerization. The correlation observed between dimerization, subcellular localization, and processing suggests that dimerization acts as an efficient regulator of APP trafficking in the secretory compartments that has major consequences on its processing.-Ben Khalifa, N., Tyteca, D., Marinangeli, C., Depuydt, M., Collet, J.-F., Courtoy, P. J., Renauld, J.-C., Constantinescu, S. N., Octave, J.-N., Kienlen-Campard, P. Structural features of the KPI domain control APP dimerization, trafficking, and processing. FASEB J. 26, 855-867 (2012). www.fasebj.org	[Ben Khalifa, Naouel; Marinangeli, Claudia; Octave, Jean-Noel; Kienlen-Campard, Pascal] Catholic Univ Louvain, Inst Neurosci, B-1200 Brussels, Belgium; [Tyteca, Donatienne; Collet, Jean-Francois; Courtoy, Pierre J.; Renauld, Jean-Christophe; Constantinescu, Stefan] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium; [Depuydt, Mathieu; Collet, Jean-Francois] Walloon Excellence Life Sci & Biotechnol Welbio, Brussels, Belgium; [Renauld, Jean-Christophe; Constantinescu, Stefan] Ludwig Inst Canc Res, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; WELBIO; Ludwig Institute for Cancer Research	Kienlen-Campard, P (corresponding author), Catholic Univ Louvain, Inst Neuroscience IoNS, UCL5410,Av Hippocrate 54, B-1200 Brussels, Belgium.	pascal.kienlen-campard@uclouvain.be	Collet, Jean Francois/F-2105-2010; Renauld, Jean-Christophe/B-7268-2012	Collet, Jean-Francois/0000-0001-8069-7036; Constantinescu, Stefan N./0000-0002-8599-2699; Depuydt, Matthieu/0000-0002-4069-3521; Kienlen-Campard, Pascal/0000-0003-1086-2942; Renauld, Jean-Christophe/0000-0003-1736-2131	Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FNS-FNRS); Neurodegeneration and Inflamation (DIANE) Program of Excellence Region Wallonne; Region Bruxelloise; Loterie Nationale; Interuniversity Attraction Pole Programme-Belgian Science Policy [P6/05, P6/43]; Foundation for Research on Alzheimer Disease; Fonds Speciaux de Recherches	Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FNS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Neurodegeneration and Inflamation (DIANE) Program of Excellence Region Wallonne; Region Bruxelloise(Innoviris); Loterie Nationale; Interuniversity Attraction Pole Programme-Belgian Science Policy(Belgian Federal Science Policy Office); Foundation for Research on Alzheimer Disease; Fonds Speciaux de Recherches	The authors thank L. El Haylani for excellent technical support; T. Lac, M. Lemaire, B. Tasiaux, and Y. Marchand for technical or typing assistance. The authors gratefully acknowledge B. de Strooper (Katholieke Universiteit Leuven-Vlaams Instituut voor Biotechnologie, Leuven, Belgium) for providing the APP-knockout MEF cells and Carmela R. Abraham (Boston University, Boston, MA, USA) for the YFP fusion plasmids. This work was supported by grants from Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FNS-FNRS; to J.F.C.), Neurodegeneration and Inflamation (DIANE) Program of Excellence Region Wallonne (to P.J.C. and J.N.O.), Region Bruxelloise, Loterie Nationale (to P.J.C.), the Interuniversity Attraction Pole Programme-Belgian Science Policy (network P6/05, to J.F.C.; and P6/43, to J.N.O. and P. K. C.), the Foundation for Research on Alzheimer Disease (SAO-FRMA; to P. K. C.), and Fonds Speciaux de Recherches (to P. K. C.). J.F.C. and S.N.C. are research associates of the FRS-FNRS. M. D. is a research fellow of the Fonds pour la Formation a la Recherche dans l'Industrie et l'Agriculture.	Akman G, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-12; Bai Y, 2008, MOL CELL PROTEOMICS, V7, P15, DOI 10.1074/mcp.M700077-MCP200; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Ben Khalifa N, 2010, CELL ADHES MIGR, V4, P268, DOI 10.4161/cam.4.2.11476; BUSH AI, 1993, J BIOL CHEM, V268, P16109; Chang JY, 2000, FEBS LETT, V473, P183, DOI 10.1016/S0014-5793(00)01515-5; Chen CD, 2006, J NEUROCHEM, V97, P30, DOI 10.1111/j.1471-4159.2006.03705.x; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Dahms SO, 2010, P NATL ACAD SCI USA, V107, P5381, DOI 10.1073/pnas.0911326107; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; Dulubova I, 2004, BIOCHEMISTRY-US, V43, P9583, DOI 10.1021/bi049041o; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOJOBORI T, 1994, PHILOS T ROY SOC B, V344, P411, DOI 10.1098/rstb.1994.0080; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; Gralle M, 2006, J MOL BIOL, V357, P493, DOI 10.1016/j.jmb.2005.12.053; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Huysseune S, 2009, FASEB J, V23, P4158, DOI 10.1096/fj.09-140012; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; Kaden D, 2008, J BIOL CHEM, V283, P7271, DOI 10.1074/jbc.M708046200; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kerppola TK, 2008, ANNU REV BIOPHYS, V37, P465, DOI 10.1146/annurev.biophys.37.032807.125842; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kienlen-Campard P, 2008, J BIOL CHEM, V283, P7733, DOI 10.1074/jbc.M707142200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; MARKS CB, 1987, SCIENCE, V235, P1370, DOI 10.1126/science.2435002; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Menendez-Gonzalez M, 2005, NEURODEGENER DIS, V2, P277, DOI 10.1159/000092315; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Miyashita N, 2009, J AM CHEM SOC, V131, P3438, DOI 10.1021/ja809227c; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; Octave JN, 1995, ACTA NEUROL BELG, V95, P197; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Santos SF, 2009, J NEUROSCI, V29, P4708, DOI 10.1523/JNEUROSCI.4917-08.2009; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Siemes C, 2006, EXP CELL RES, V312, P1939, DOI 10.1016/j.yexcr.2006.02.025; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; TANZI RE, 1993, MOL BRAIN RES, V18, P246, DOI 10.1016/0169-328X(93)90196-V; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Tyteca D, 2010, BBA-BIOMEMBRANES, V1798, P909, DOI 10.1016/j.bbamem.2010.01.021; Vincenz C, 2008, P NATL ACAD SCI USA, V105, P16572, DOI 10.1073/pnas.0805317105; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	64	33	34	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					855	867		10.1096/fj.11-190207	http://dx.doi.org/10.1096/fj.11-190207			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22085646				2022-12-28	WOS:000300485700036
J	Rosenblatt-Velin, N; Ogay, S; Felley, A; Stanford, WL; Pedrazzini, T				Rosenblatt-Velin, Nathalie; Ogay, Sandy; Felley, Allison; Stanford, William L.; Pedrazzini, Thierry			Cardiac dysfunction and impaired compensatory response to pressure overload in mice deficient in stem cell antigen-1	FASEB JOURNAL			English	Article						heart; regeneration; precursors; differentiation	PROGENITOR CELLS; MYOCARDIAL REGENERATION; SMOOTH-MUSCLE; HEART-DISEASE; NULL MICE; MULTIPOTENT; SCA-1; DIFFERENTIATION; CARDIOMYOCYTES; REPAIR	Stem cell antigen-1 (Sca-1) has been used to identify cardiac stem cells in the mouse heart. To investigate the function of Sca-1 in aging and during the cardiac adaptation to stress, we used Sca-1-deficient mice. These mice developed dilated cardiomyopathy [end-diastolic left ventricular diameter at 18 wk of age: wild-type (WT) mice, 4.2 mm +/- 0.3; Sca-1-knockout (Sca-1-KO) mice, 4.6 mm +/- 0.1; ejection fraction: WT mice, 51.1 +/- 2.7%; Sca-1-KO mice, 42.9 +/- 2.7%]. Furthermore, the hearts of mice lacking Sca-1 demonstrated exacerbated susceptibility to pressure overload [ejection fraction after transaortic constriction (TAC): WT mice, 43.5 +/- 3.2%; Sca-1-KO mice, 30.8% +/- 4.0] and increased apoptosis, as shown by the 2.5-fold increase in TUNEL(+) cells in Sca-1-deficient hearts under stress. Sca-1 deficiency affected primarily the nonmyocyte cell fraction. Indeed, the number of Nkx2.5(+) nonmyocyte cells, which represent a population of cardiac precursor cells (CPCs), was 2-fold smaller in Sca-1 deficient neonatal hearts. In vitro, the ability of CPCs to differentiate into cardiomyocytes was not affected by Sca-1 deletion. In contrast, these cells demonstrated unrestricted differentiation into cardiomyocytes. Interestingly, proliferation of cardiac nonmyocyte cells in response to stress, as judged by BrdU incorporation, was higher in mice lacking Sca-1 (percentages of BrdU(+) cells in the heart after TAC: WT mice, 4.4 +/- 2.1%; Sca-1-KO mice, 19.3 +/- 4.2%). These data demonstrate the crucial role of Sca-1 in the maintenance of cardiac integrity and suggest that Sca-1 restrains spontaneous differentiation in the precursor population. The absence of Sca-1 results in uncontrolled precursor recruitment, exhaustion of the precursor pool, and cardiac dysfunction.-Rosenblatt-Velin, N., Ogay, S., Felley, A., Stanford, W. L., Pedrazzini, T. Cardiac dysfunction and impaired compensatory response to pressure overload in mice deficient in stem cell antigen-1. FASEB J. 26, 229-239 (2012). www.fasebj.org	[Rosenblatt-Velin, Nathalie; Ogay, Sandy; Pedrazzini, Thierry] Univ Lausanne, Sch Med, Expt Cardiol Unit, Dept Med, CH-1011 Lausanne, Switzerland; [Felley, Allison] Univ Lausanne, Cardiovasc Assessment Facil, CH-1011 Lausanne, Switzerland; [Stanford, William L.] Ottawa Hosp Res Inst, Sprott Ctr Stem Cell Res, Ottawa, ON, Canada	University of Lausanne; University of Lausanne; University of Ottawa; Ottawa Hospital Research Institute	Pedrazzini, T (corresponding author), Univ Lausanne, Sch Med, Expt Cardiol Unit, Dept Med, Rue Bugnon 27, CH-1011 Lausanne, Switzerland.	thierry.pedrazzini@chuv.ch		Rosenblatt, Nathalie/0000-0003-2011-2862; Stanford, William/0000-0002-5813-8016	Swiss National Science Foundation [PMPDB-110269, PMPDB-118627, 320000-114026]; Canadian Institutes of Health Research [FRN 62788]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the Swiss National Science Foundation (PMPDB-110269 and PMPDB-118627 to N.R. and 320000-114026 to T. P.), and Sca-1 research in the W. L. S. laboratory is supported by the Canadian Institutes of Health Research (FRN 62788). The authors are grateful to Francois Feihl and Bernard Waeber for critical reading of the manuscript and Jeff Kiernan for helpful discussions. The authors declare no conflicts of interest.	Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Bersell K, 2009, CELL, V138, P257, DOI 10.1016/j.cell.2009.04.060; Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100; Boudoulas KD, 2009, DIS MODEL MECH, V2, P344, DOI 10.1242/dmm.000240; Bradfute SB, 2005, EXP HEMATOL, V33, P836, DOI 10.1016/j.exphem.2005.04.001; Bu L, 2009, NATURE, V460, P113, DOI 10.1038/nature08191; Cai CL, 2008, NATURE, V454, P104, DOI 10.1038/nature06969; Epting CL, 2004, J CELL SCI, V117, P6185, DOI 10.1242/jcs.01548; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Gonzales C, 2009, EXP CELL RES, V315, P3077, DOI 10.1016/j.yexcr.2009.09.006; Holmes C, 2007, STEM CELLS, V25, P1339, DOI 10.1634/stemcells.2006-0644; Hsieh PCH, 2007, NAT MED, V13, P970, DOI 10.1038/nm1618; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Kafadar KA, 2009, DEV BIOL, V326, P47, DOI 10.1016/j.ydbio.2008.10.036; Kajstura J, 2010, CIRC RES, V107, P1374, DOI 10.1161/CIRCRESAHA.110.231498; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Lu G, 2009, CIRCULATION, V119, P2587, DOI 10.1161/CIRCULATIONAHA.108.827691; Martin CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028; Matsuura K, 2009, J CLIN INVEST, V119, P2204, DOI 10.1172/JCI37456; Mercola M, 2011, GENE DEV, V25, P299, DOI 10.1101/gad.2018411; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Petersen BE, 2003, HEPATOLOGY, V37, P632, DOI 10.1053/jhep.2003.50104; Rosenblatt-Velin N, 2005, J CLIN INVEST, V115, P1724, DOI 10.1172/JCI23418; Stanford WL, 1997, J EXP MED, V186, P705, DOI 10.1084/jem.186.5.705; Sturzu AC, 2011, CIRC RES, V108, P353, DOI 10.1161/CIRCRESAHA.110.227066; Tateishi K, 2007, J CELL SCI, V120, P1791, DOI 10.1242/jcs.006122; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Urbanek K, 2005, P NATL ACAD SCI USA, V102, P8692, DOI 10.1073/pnas.0500169102; Urbanek K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI 10.1073/pnas.1832855100; Urbanek K, 2006, P NATL ACAD SCI USA, V103, P9226, DOI 10.1073/pnas.0600635103; Wang XH, 2006, STEM CELLS, V24, P1779, DOI 10.1634/stemcells.2005-0386; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; YUTOKU M, 1974, J IMMUNOL, V112, P1774; Zhang YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012559	39	18	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					229	239		10.1096/fj.11-189605	http://dx.doi.org/10.1096/fj.11-189605			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21957128				2022-12-28	WOS:000299202200024
J	Bosmann, M; Patel, VR; Russkamp, NF; Pache, F; Zetoune, FS; Sarma, JV; Ward, PA				Bosmann, Markus; Patel, Vinay R.; Russkamp, Norman F.; Pache, Florence; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.			MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a via the Akt signaling pathway	FASEB JOURNAL			English	Article						macrophages; endotoxemia; endotoxic shock; cecal ligation and puncture; polymicrobial sepsis	COMPLEMENT FRAGMENTS; DENDRITIC CELLS; RECEPTOR; EXPRESSION; ACTIVATION; CYTOKINE; DIFFERENTIATION; GRANULOCYTE; MACROPHAGES; NEUTROPHILS	The interleukin-17 (IL-17) family of cytokines plays important roles in innate immune defenses against bacterial and fungal pathogens. While much is known about IL-17A, much less information is available about the IL-17F isoform. Here, we investigated gene expression and release of IL-17F and its regulation by the complement system. IL-17F was produced in mouse peritoneal elicited macrophages after TLR4 activation by LPS, peaking after 12 h. This effect was completely dependent on the presence of the adaptor protein MyD88. The copresence of the complement activation product, C5a (EC50 = 10 nM), amplified IL-17F production via the receptor C5aR. In vitro signaling studies indicated that LPS or C5a, or the combination, caused phosphorylation of Akt occurring at threonine 308 but not at serine 473. Treatment of macrophages with pharmacologic inhibitors of PI3K-Akt greatly reduced production of IL-17F as well as mRNA for IL-17F. In endotoxemia, C5a levels peaked at 6 h, while IL-17F levels peaked between 6-12 h. Full in vivo production of IL-17F during endotoxemia required C5a. A similar result was found in the cecal ligation and puncture sepsis model. These data suggest that maximal production of IL-17F requires complement activation and presence of C5a.-Bosmann, M., Patel, V. R., Russkamp, N. F., Pache, F., Zetoune, F. S., Sarma, J. V., Ward, P. A. MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a via the Akt signaling pathway. FASEB J. 25, 4222-4232 (2011). www.fasebj.org	[Bosmann, Markus; Patel, Vinay R.; Russkamp, Norman F.; Pache, Florence; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu		Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health [GM-29507, GM-61656]; Deutsche Forschungsgemeinschaft [571701, BO 3482/1-1]; Boehringer Ingelheim Fonds; Studienstiftung des deutschen Volkes; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R01GM029507, R37GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Boehringer Ingelheim Fonds(Boehringer Ingelheim); Studienstiftung des deutschen Volkes; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the U.S. National Institutes of Health (grants GM-29507 and GM-61656 to P.A.W.), along with the Deutsche Forschungsgemeinschaft (project 571701, BO 3482/1-1, to M.B.), the Boehringer Ingelheim Fonds (to N.F.R.), and the Studienstiftung des deutschen Volkes (to F.P.). The authors cordially thank Rachel Voight, Mike Haggadone, and Fabien Meta for technical assistance, as well as Beverly Schumann, Sue Scott, and Robin Kunkel for assistance in the preparation of the manuscript.	Atefi G, 2011, FASEB J, V25, P2500, DOI 10.1096/fj.11-183236; Bosmann M., 2011, SHOCK; Chang SH, 2007, CELL RES, V17, P435, DOI 10.1038/cr.2007.35; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Da Silva CA, 2008, J IMMUNOL, V181, P4279, DOI 10.4049/jimmunol.181.6.4279; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; Fujishima S, 2010, ARCH DERMATOL RES, V302, P499, DOI 10.1007/s00403-010-1033-8; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gu Y, 2008, EUR J IMMUNOL, V38, P1807, DOI 10.1002/eji.200838331; Guo RF, 2006, J LEUKOCYTE BIOL, V80, P1575, DOI 10.1189/jlb.0106065; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hajishengallis G, 2010, TRENDS IMMUNOL, V31, P154, DOI 10.1016/j.it.2010.01.002; Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lalli PN, 2008, BLOOD, V112, P1759, DOI 10.1182/blood-2008-04-151068; Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu JG, 2007, J EXP MED, V204, P141, DOI 10.1084/jem.20061440; Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105; Nataf S, 1999, J IMMUNOL, V162, P4018; Niederbichler AD, 2006, J EXP MED, V203, P53, DOI 10.1084/jem.20051207; Nonaka M, 2004, MOL IMMUNOL, V40, P897, DOI 10.1016/j.molimm.2003.10.009; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Patel SN, 2008, J EXP MED, V205, P1133, DOI 10.1084/jem.20072248; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Reiman R, 2002, EUR J IMMUNOL, V32, P1157, DOI 10.1002/1521-4141(200204)32:4<1157::AID-IMMU1157>3.3.CO;2-D; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Riedemann NC, 2003, IMMUNITY, V19, P193, DOI 10.1016/S1074-7613(03)00206-1; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Seki E, 2001, J IMMUNOL, V166, P2651, DOI 10.4049/jimmunol.166.4.2651; Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001; STRIETER RM, 1992, AM J PATHOL, V141, P397; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Ward PA, 2010, THESCIENTIFICWORLDJO, V10, P2395, DOI 10.1100/tsw.2010.216; Ward PA, 2010, J INNATE IMMUN, V2, P439, DOI 10.1159/000317194; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weaver DJ, 2010, EUR J IMMUNOL, V40, P710, DOI 10.1002/eji.200939333; WEBSTER RO, 1982, J CLIN INVEST, V70, P1177, DOI 10.1172/JCI110716; Wittmann M, 1999, J IMMUNOL, V162, P6763; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519	54	25	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4222	4232		10.1096/fj.11-191205	http://dx.doi.org/10.1096/fj.11-191205			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21859896	Green Submitted, Green Published			2022-12-28	WOS:000298138100015
J	Hoog, G; Zarrizi, R; von Stedingk, K; Jonsson, K; Alvarado-Kristensson, M				Hoog, Greta; Zarrizi, Reihaneh; von Stedingk, Kristoffer; Jonsson, Kristina; Alvarado-Kristensson, Maria			Nuclear localization of gamma-tubulin affects E2F transcriptional activity and S-phase progression	FASEB JOURNAL			English	Article						cell cycle progression; signal transduction; cell signaling	CELL-CYCLE; CENTROSOME; EXPRESSION; PROLIFERATION; COMPLEXES; FAMILY; GENES; PHOSPHORYLATION; IDENTIFICATION; PROTEINS	We show that the centrosome- and microtubule-regulating protein gamma-tubulin interacts with E2 promoter binding factors (E2Fs) to modulate E2F transcriptional activity and thereby control cell cycle progression. gamma-Tubulin contains a C-terminal signal that results in its translocation to the nucleus during late G(1) to early S phase. gamma-Tubulin mutants showed that the C terminus interacts with the transcription factor E2F1 and that the E2F1-gamma-tubulin complex is formed during the G(1)/S transition, when E2F1 is transcriptionally active. Furthermore, E2F transcriptional activity is altered by reduced expression of gamma-tubulin or by complex formation between gamma-tubulin and E2F1, E2F2, or E2F3, but not E2F6. In addition, the gamma-tubulin C terminus encodes a DNA-binding domain that interacts with E2F-regulated promoters, resulting in gamma-tubulin-mediated transient activation of E2Fs. Thus, we report a novel mechanism regulating the activity of E2Fs, which can help explain how these proteins affect cell cycle progression in mammalian cells.-Hoog, G., Zarrizi, R., von Stedingk, K., Jonsson, K., Alvarado-Kristensson, M. Nuclear localization of gamma-tubulin affects E2F transcriptional activity and S-phase progression. FASEB J. 25, 3815-3827 (2011). www.fasebj.org	[Hoog, Greta; Zarrizi, Reihaneh; von Stedingk, Kristoffer; Jonsson, Kristina; Alvarado-Kristensson, Maria] Lund Univ, Ctr Mol Pathol, Dept Lab Med, Skane Univ Hosp, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Alvarado-Kristensson, M (corresponding author), Lund Univ, Ctr Mol Pathol, SUS, Entrance 78,Floor 2, SE-20502 Malmo, Sweden.	maria.alvarado-kristensson@med.lu.se	Alvarado-Kristensson, Maria T./C-4543-2014	Eklund, Greta/0000-0002-2498-7765; Alvarado Kristensson, Maria Teresa/0000-0003-0598-7986	Royal Physiographic Society (Lund, Sweden); Ake Wiberg Foundations; Thelma Zoegas Foundation; Per-Eric Foundation; Ulla Schyberg Foundation; O. E. and Edla Johansson Foundation; Gradfordska, H. and G. Jeassons Foundation; O. and E. Ericsson Foundation; Gyllenstiernska Krapperupsstiftelsen; Universitetssjukhuset Malmo Allmana Sjukhus (U-MAS); U-MAS Cancer Research Fund; Swedish Research Council; Swedish Society for Medical Research	Royal Physiographic Society (Lund, Sweden); Ake Wiberg Foundations; Thelma Zoegas Foundation; Per-Eric Foundation; Ulla Schyberg Foundation; O. E. and Edla Johansson Foundation; Gradfordska, H. and G. Jeassons Foundation; O. and E. Ericsson Foundation; Gyllenstiernska Krapperupsstiftelsen; Universitetssjukhuset Malmo Allmana Sjukhus (U-MAS); U-MAS Cancer Research Fund; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society for Medical Research	The authors thank Jiri Bartek (Institute of Cancer Biology, Danish Cancer Society, Yang Shi (Harvard Medical School, Boston, MA, USA), Kristian Helin (Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark), Marc van de Wetering (Hubrecht Laboratory, Centre for Biomedical Genetics, Utrecht, The Netherlands), Joseph R. Nevins (Duke University, Durham, NC, USA), Robert A. Weinberg (Massachusetts Institute of Technology, Cambridge, MA, USA), and David M. Livingston (Dana-Farber Cancer Institute, Boston, MA, USA) for reagents, and P. Odman for editorial assistance. This work was supported by grants from the Royal Physiographic Society (Lund, Sweden); the Ake Wiberg, Thelma Zoegas, Per-Eric and Ulla Schyberg, O. E. and Edla Johansson, Gradfordska, H. and G. Jeassons, and O. and E. Ericsson Foundations; Gyllenstiernska Krapperupsstiftelsen; Universitetssjukhuset Malmo Allmana Sjukhus (U-MAS) and the U-MAS Cancer Research Fund; and the Swedish Research Council. A fellowship from the Swedish Society for Medical Research provided additional support. The authors declare no conflicts of interest.	Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Alvarado-Kristensson M, 2009, NAT CELL BIOL, V11, P1081, DOI 10.1038/ncb1921; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; [Anonymous], Q01094 E2F1 HUMAN UN; Black EP, 2005, P NATL ACAD SCI USA, V102, P15948, DOI 10.1073/pnas.0504300102; Carrera AC, 2009, CELL CYCLE, V8, P4005, DOI 10.4161/cc.8.24.10178; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geng Y, 1996, ONCOGENE, V12, P1173; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jamshidi-Parsian A, 2005, GENE, V344, P67, DOI 10.1016/j.gene.2004.09.030; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lesca C, 2005, ONCOGENE, V24, P5165, DOI 10.1038/sj.onc.1208723; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Moudjou M, 1996, J CELL SCI, V109, P875; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Muller H, 2006, SCIENCE, V314, P654, DOI 10.1126/science.1132834; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wan ZH, 2010, J CLIN INVEST, V120, P3530, DOI 10.1172/JCI41805; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3	36	43	43	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3815	3827		10.1096/fj.11-187484	http://dx.doi.org/10.1096/fj.11-187484			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21788450	Green Published, hybrid			2022-12-28	WOS:000296723100007
J	Zakharian, E; Cao, C; Rohacs, T				Zakharian, Eleonora; Cao, Chike; Rohacs, Tibor			Intracellular ATP supports TRPV6 activity via lipid kinases and the generation of PtdIns(4,5)P-2	FASEB JOURNAL			English	Article						transient receptor potential channel; phosphoinositides	PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CALCIUM-CHANNEL; TRPM8 CHANNELS; VANILLOID RECEPTOR; CATION CHANNEL; ION CHANNELS; PHOSPHOINOSITIDES; DESENSITIZATION; FAMILY; PIP2	Transient receptor potential vanilloid 6 (TRPV6) channels play an important role in Ca2+ absorption in the intestines. Both phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P-2] and cytoplasmic ATP have been proposed to be important for maintaining TRPV6 activity. To evaluate whether PtdIns(4,5)P-2 and ATP affect channel activity directly or indirectly, we have used a dual approach, examining channel activity in excised patches and planar lipid bilayers. In excised inside-out patch-clamp measurements, ATP reactivated the human TRPV6 channels after current rundown only in the presence of Mg2+. The effect of MgATP was inhibited by 3 structurally different compounds that inhibit type III phosphatidylinositol 4-kinases (PI4Ks). PtdIns(4,5)P-2 also activated TRPV6 in excised patches, while its precursor PtdIns(4)P had only minimal effect. These data demonstrate that MgATP provides substrate for lipid kinases, allowing the resynthesis of PtdIns(4,5)P-2. To determine whether PtdIns(4,5)P-2 is a direct activator of TRPV6, we purified and reconstituted the channel protein in planar lipid bilayers. The reconstituted channel showed high activity in the presence of PtdIns(4,5)P-2, while PtdIns(4)P induced only minimal activity. Our data establish PtdIns(4,5)P-2 as a direct activator of TRPV6 and demonstrate that intracellular ATP regulates the channel indirectly as a substrate for type III PI4Ks.-Zakharian, E., Cao, C., Rohacs, T. Intracellular ATP supports TRPV6 activity via lipid kinases and the generation of PtdIns(4,5)P-2. FASEB J. 25, 3915-3928 (2011). www.fasebj.org	[Rohacs, Tibor] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rohacs, T (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,MSB H631, Newark, NJ 07103 USA.	tibor.rohacs@umdnj.edu			U.S. National Institutes of Health [NS-055159, GM-093290]; University of Medicine and Dentistry of New Jersey Foundation; American Heart Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055159] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Medicine and Dentistry of New Jersey Foundation; American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health grants NS-055159 and GM-093290 and by a grant from the University of Medicine and Dentistry of New Jersey Foundation (to T.R.) and by a Scientist Development grant from the American Heart Association (to E.Z). The authors thank Dr. Tamas Balla for insightful discussions and comments on the manuscript and Dr. Joshua Berlin for careful reading of and commenting on the manuscript. The clone for the human TRPV6 was generously provided by Dr. T. V. McDonald (Albert Einstein College of Medicine, New York, NY, USA).	Akey JM, 2006, HUM MOL GENET, V15, P2106, DOI 10.1093/hmg/ddl134; Al-Ansary D, 2010, FASEB J, V24, P425, DOI 10.1096/fj.09-141481; Balla A, 2008, BIOCHEMISTRY-US, V47, P1599, DOI 10.1021/bi7017927; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; D'Avanzo N, 2010, J BIOL CHEM, V285, P37129, DOI 10.1074/jbc.C110.186692; Daniels RL, 2009, J BIOL CHEM, V284, P1570, DOI 10.1074/jbc.M807270200; Derler I, 2006, J PHYSIOL-LONDON, V577, P31, DOI 10.1113/jphysiol.2006.118661; Grycova L, 2007, ARCH BIOCHEM BIOPHYS, V465, P389, DOI 10.1016/j.abb.2007.06.035; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hughes DA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001686; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Korzeniowski MK, 2009, J BIOL CHEM, V284, P21027, DOI 10.1074/jbc.M109.012252; Kwak J, 2000, J NEUROSCI, V20, P8298, DOI 10.1523/JNEUROSCI.20-22-08298.2000; Leal-Pinto E, 2010, J BIOL CHEM, V285, P39790, DOI 10.1074/jbc.M110.151373; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Liu BY, 2005, J NEUROSCI, V25, P4835, DOI 10.1523/JNEUROSCI.1296-05.2005; Logothetis DE, 2007, PFLUG ARCH EUR J PHY, V455, P1, DOI 10.1007/s00424-007-0311-6; Lukacs V, 2007, J NEUROSCI, V27, P7070, DOI 10.1523/JNEUROSCI.1866-07.2007; Mercado J, 2010, J NEUROSCI, V30, P13338, DOI 10.1523/JNEUROSCI.2108-10.2010; Murata Y, 2007, J PHYSIOL-LONDON, V583, P875, DOI 10.1113/jphysiol.2007.134775; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2008, EMBO J, V27, P2809, DOI 10.1038/emboj.2008.217; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Nilius B, 2010, PFLUG ARCH EUR J PHY, V460, P437, DOI 10.1007/s00424-010-0788-2; OROURKE B, 1993, BIOCHEM PHARMACOL, V46, P1103, DOI 10.1016/0006-2952(93)90456-7; Phelps CB, 2008, BIOCHEMISTRY-US, V47, P2476, DOI 10.1021/bi702109w; Phelps CB, 2010, J BIOL CHEM, V285, P731, DOI 10.1074/jbc.M109.052548; Rohacs T, 2002, METHOD ENZYMOL, V345, P71; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Rohacs T, 2009, CELL CALCIUM, V45, P554, DOI 10.1016/j.ceca.2009.03.011; Suchyna TM, 2009, BIOPHYS J, V97, P738, DOI 10.1016/j.bpj.2009.05.018; Suh BC, 2008, ANNU REV BIOPHYS, V37, P175, DOI 10.1146/annurev.biophys.37.032807.125859; Suzuki Y, 2008, HUM MOL GENET, V17, P1613, DOI 10.1093/hmg/ddn048; Thyagarajan B, 2008, J BIOL CHEM, V283, P14980, DOI 10.1074/jbc.M704224200; Thyagarajan B, 2009, MOL PHARMACOL, V75, P608, DOI 10.1124/mol.108.052449; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Toth B, 2006, J BIOL CHEM, V281, P36369, DOI 10.1074/jbc.M604935200; Toth B, 2010, J BIOL CHEM, V285, P30091, DOI 10.1074/jbc.M109.066464; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Wu LJ, 2010, PHARMACOL REV, V62, P381, DOI 10.1124/pr.110.002725; Yao J, 2009, PLOS BIOL, V7, P350, DOI 10.1371/journal.pbio.1000046; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zakharian E, 2010, J NEUROSCI, V30, P12526, DOI 10.1523/JNEUROSCI.3189-10.2010; Zakharian E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005404	53	36	37	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3915	3928		10.1096/fj.11-184630	http://dx.doi.org/10.1096/fj.11-184630			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21810903	Green Published			2022-12-28	WOS:000296723100016
J	De Amicis, F; Giordano, F; Vivacqua, A; Pellegrino, M; Panno, ML; Tramontano, D; Fuqua, SAW; Ando, S				De Amicis, Francesca; Giordano, Francesca; Vivacqua, Adele; Pellegrino, Michele; Panno, Maria Luisa; Tramontano, Donatella; Fuqua, Suzanne A. W.; Ando, Sebastiano			Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38(MAPK)/CK2 signaling in human breast cancer cells	FASEB JOURNAL			English	Article						tamoxifen resistance; ER alpha; promoter	TRANSCRIPTIONAL REPRESSION; MUTANT P53; PROTEIN; APOPTOSIS; GROWTH; COREPRESSOR; SUPPRESSION; ACTIVATION; PATHWAY; AGONIST/ANTAGONIST	Agents to counteract acquired resistance to hormonal therapy for breast cancer would substantially enhance the long-term benefits of hormonal therapy. In the present study, we demonstrate how resveratrol (Res) inhibits human breast cancer cell proliferation, including MCF-7 tamoxifen-resistant cells (IC50 values for viability were in the 30-45 mu M range). We show that Res, through p38(MAPK) phosphorylation, causes induction of p53, which recruits at the estrogen receptor alpha (ER alpha) proximal promoter, leading to an inhibition of ER alpha expression in terms of mRNA and protein content. These events appear specifically p53 dependent, since they are drastically abrogated with p53-targeting siRNA. Coimmunoprecipitation assay showed specific interaction between p53, the Sin3A corepressor, and histone deacetylase 1 (HDAC1), which was phosphorylated. The enhancement of the tripartite complex p53/Sin3A/HDAC1, together with NF-Y on Res treatment, was confirmed by chromatin immunoprecipitation analyses, with a concomitant release of Sp1 and RNA polymerase II, thereby inhibiting the cell transcriptional machinery. The persistence of such effects in MCF-7 tamoxifen-resistant cells at a higher extent than parental MCF-7 cells addresses how Res may be considered a useful pharmacological tool to be exploited in the adjuvant settings for treatment of breast cancer developing hormonal resistance.-De Amicis, F., Giordano, F., Vivacqua, A., Pellegrino, M., Panno, M. L., Tramontano, D., Fuqua, S. A. W., Ando, S. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38(MAPK)/CK2 signaling in human breast cancer cells. FASEB J. 25, 3695-3707 (2011). www.fasebj.org	[Ando, Sebastiano] Univ Calabria, Fac Pharm Nutr & Hlth Sci, Ctr Sanit, I-87030 Arcavacata Di Rende, CS, Italy; [De Amicis, Francesca; Vivacqua, Adele] Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy; [Giordano, Francesca; Pellegrino, Michele; Panno, Maria Luisa; Ando, Sebastiano] Univ Calabria, Dept Cellular Biol, I-87030 Arcavacata Di Rende, CS, Italy; [Tramontano, Donatella] Univ Naples Federico II, Dept Cellular & Mol Pathol L Califano, Naples, Italy; [Fuqua, Suzanne A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	University of Calabria; University of Calabria; University of Calabria; University of Naples Federico II; Baylor College of Medicine	Ando, S (corresponding author), Univ Calabria, Fac Pharm Nutr & Hlth Sci, Ctr Sanit, I-87030 Arcavacata Di Rende, CS, Italy.	sebastiano.ando@unical.it	vivacqua, adele/I-2771-2015; Tramontano, Donatella/AAS-1740-2020	vivacqua, adele/0000-0001-5333-8396; Pellegrino, Michele/0000-0002-4046-4243; GIORDANO, Francesca/0000-0002-7621-1969; De Amicis, Francesca/0000-0001-7079-1037; Tramontano, Donatella/0000-0002-9308-034X	Nazionale-Ministro dell'Istruzione, dell'Universita e della Ricerca; U.S. National Institutes of Health/National Cancer Institute [R01 CA72038]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	Nazionale-Ministro dell'Istruzione, dell'Universita e della Ricerca; U.S. National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Programma di Ricerca di Rilevante Interesse Nazionale-Ministro dell'Istruzione, dell'Universita e della Ricerca, Ex 60%-2010, and U.S. National Institutes of Health/National Cancer Institute grant R01 CA72038 to S.A.W.F.	AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Azios NG, 2007, NEOPLASIA, V9, P147, DOI 10.1593/neo.06778; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243; De Amicis F, 2009, MOL ENDOCRINOL, V23, P454, DOI 10.1210/me.2008-0267; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; Diel P, 2002, TOXICOL LETT, V127, P217, DOI 10.1016/S0378-4274(01)00503-3; Duval D, 2004, CELL DEATH DIFFER, V11, P331, DOI 10.1038/sj.cdd.4401337; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Ferry-Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Frech MS, 2005, CANCER RES, V65, P681; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giordano C, 2010, BREAST CANCER RES TR, V119, P71, DOI 10.1007/s10549-009-0334-0; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guvakova MA, 1997, CANCER RES, V57, P2606; Hildesheim J, 2005, J BIOL CHEM, V280, P17221, DOI 10.1074/jbc.M410440200; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsieh TC, 1999, INT J ONCOL, V15, P245; HU XF, 1993, INT J CANCER, V55, P873, DOI 10.1002/ijc.2910550529; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; LEVESQUE MA, 1994, BREAST CANCER RES TR, V30, P179, DOI 10.1007/BF00666062; Lin HY, 2006, FASEB J, V20, P1742, DOI 10.1096/fj.06-5743fje; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Moore L, 2007, MECH AGEING DEV, V128, P717, DOI 10.1016/j.mad.2007.10.011; Mukherjee S, 2010, DOSE-RESPONSE, V8, P478, DOI 10.2203/dose-response.09-015.Mukherjee; Panno ML, 2009, CURR CANCER DRUG TAR, V9, P469, DOI 10.2174/156800909788486786; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Santen RJ, 2005, ENDOCR-RELAT CANCER, V12, pS61, DOI 10.1677/erc.1.01018; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stewart JR, 2000, BIOCHEM PHARMACOL, V60, P1355, DOI 10.1016/S0006-2952(00)00450-0; Sun JM, 2007, J BIOL CHEM, V282, P33227, DOI 10.1074/jbc.M703549200; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Vivacqua A, 2009, MOL ENDOCRINOL, V23, P1815, DOI 10.1210/me.2009-0120; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	55	60	61	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3695	3707		10.1096/fj.10-178871	http://dx.doi.org/10.1096/fj.10-178871			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21737614	Green Published			2022-12-28	WOS:000295356400038
J	Borgeson, E; Docherty, NG; Murphy, M; Rodgers, K; Ryan, A; O'Sullivan, TP; Guiry, PJ; Goldschmeding, R; Higgins, DF; Godson, C				Boergeson, Emma; Docherty, Neil G.; Murphy, Madeline; Rodgers, Karen; Ryan, Aidan; O'Sullivan, Tim P.; Guiry, Patrick J.; Goldschmeding, Roel; Higgins, Debra F.; Godson, Catherine			Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis	FASEB JOURNAL			English	Article						eicosanoids; unilateral ureteric obstruction; TGF-beta; tubulointerstial fibrosis	UNILATERAL URETERAL OBSTRUCTION; IN-VIVO; TGF-BETA; TUBULOINTERSTITIAL FIBROSIS; MESENCHYMAL TRANSITION; INTERSTITIAL FIBROSIS; APOPTOTIC NEUTROPHILS; SYNTHETIC ANALOG; LIPID MEDIATORS; GENE-EXPRESSION	Unresolved inflammation underlies the development of fibrosis and organ failure. Here, we investigate the potential of the proresolving eicosanoid lipoxinA(4) (LXA(4)) and its synthetic analog benzo-LXA(4) to prophylactically modulate fibrotic and inflammatory responses in a model of early renal fibrosis, unilateral ureteric obstruction (UUO). Male Wistar rats (Animalia, Chordata, Rattus norvegicus) were injected intravenously with vehicle (0.1% ethanol), LXA(4) (45 mu g/250-g rat), or benzo-LXA(4) (15 mu g/250-g rat) 15 min prior to surgery and sacrificed 3 d postligation. Renal gene and protein expression, collagen deposition, macrophage infiltration, and apoptosis were analyzed using manipulated kidneys from sham operations as control. Lipoxins (LXs) attenuated collagen deposition and renal apoptosis (P<0.05) and shifted the inflammatory milieu toward resolution, inhibiting TNF-alpha and IFN-gamma expression, while stimulating proresolving IL-10. LXs attenuated UUO-induced activation of MAP kinases, Akt, and Smads (P<0.05) in injured kidneys. We explored whether the underlying mechanism reflected LX-induced modulation of fibroblast activation. Using cultured rat renal NRK-49F fibroblasts, we report that LXA(4) (1 nM) inhibits TGF-beta 1 (10 ng/ml)-induced activation of Smad2 and MAP-kinases (P<0.05), and furthermore, LXA(4) reduced TGF-beta 1-stimulated PAI-1 luciferase activation (P<0.05) relative to vehicle-stimulated cells. We propose that LXs may represent a potentially useful and novel therapeutic strategy for consideration in the context of renal fibrosis.-Borgeson, E., Docherty, N. G., Murphy, M., Rodgers, K., Ryan, A., O'Sullivan, T. P., Guiry, P. J., Goldschmeding, R., Higgins, D. F., Godson, C. Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J. 25, 2967-2979 (2011). www.fasebj.org	[Boergeson, Emma; Murphy, Madeline; Rodgers, Karen; Ryan, Aidan; Higgins, Debra F.; Godson, Catherine] Univ Coll Dublin, Sch Med & Med Sci, UCD Conway Inst, Diabet Res Ctr, Dublin 2, Ireland; [O'Sullivan, Tim P.; Guiry, Patrick J.] Univ Coll Dublin, Ctr Synth & Chem Biol, Dublin 2, Ireland; [Docherty, Neil G.] Trinity Coll Dublin, Sch Med, Dept Physiol, Dublin, Ireland; [Goldschmeding, Roel] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	University College Dublin; University College Dublin; Trinity College Dublin; Utrecht University; Utrecht University Medical Center	Godson, C (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, UCD Conway Inst, UCD Diabet Res Ctr, Dublin 2, Ireland.	catherine.godson@ucd.ie	Borgeson, Emma/O-3128-2017; O'Sullivan, Timothy/ABF-6865-2021; O'Sullivan, Timothy/J-1710-2012; Goldschmeding, Roel/I-1723-2014	Borgeson, Emma/0000-0002-2290-9472; O'Sullivan, Timothy/0000-0001-6649-331X; O'Sullivan, Timothy/0000-0001-6649-331X; Docherty, Neil/0000-0002-0961-2607; Godson, Catherine/0000-0003-0655-1041	Irish Research Council for Science, Engineering, and Technology; Science Foundation Ireland; Health Research Board; Government of Ireland Programme for Research in Third-Level Institutions	Irish Research Council for Science, Engineering, and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Government of Ireland Programme for Research in Third-Level Institutions	The authors thank Prof. Finian Martin for helpful suggestions during the work. E. B. is a recipient of an Irish Research Council for Science, Engineering, and Technology Embark postgraduate research scholarship. Work in C. G.'s laboratory is supported by Science Foundation Ireland, the Health Research Board, and the Government of Ireland Programme for Research in Third-Level Institutions. The authors acknowledge the excellent support of Andrew Gaffney, technical help of the UCD Conway Institute Transcriptomics Core facility and staff at the UCD Biomedical animal facility, Dionne van der Gizel (University of Utrecht), and Dr. Simon Curran (UCD Diabetes Research Centre).	BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; Baker N, 2009, J IMMUNOL, V182, P3819, DOI 10.4049/jimmunol.0803175; Borgeson E, 2010, THESCIENTIFICWORLDJO, V10, P1370, DOI 10.1100/tsw.2010.120; Bottinger EP, 2007, SEMIN NEPHROL, V27, P309, DOI 10.1016/j.semnephrol.2007.02.009; Cao Q, 2010, J AM SOC NEPHROL, V21, P933, DOI 10.1681/ASN.2009060592; Cheng S, 2006, FASEB J, V20, P1898, DOI 10.1096/fj.06-5898fje; Chevalier RL, 2009, KIDNEY INT, V75, P1145, DOI 10.1038/ki.2009.86; Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220; de Vries WB, 2010, PEDIATR RES, V67, P72, DOI 10.1203/PDR.0b013e3181bf570d; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Docherty NG, 2009, KIDNEY INT, V75, P205, DOI 10.1038/ki.2008.482; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF4, DOI 10.1152/ajprenal.00045.2005; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; Duffield JS, 2011, J AM SOC NEPHROL, V22, P199, DOI 10.1681/ASN.2010121301; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Duffy CD, 2010, CHEMMEDCHEM, V5, P517, DOI 10.1002/cmdc.200900533; Garcia-Sanchez O, 2010, KIDNEY INT, V77, P950, DOI 10.1038/ki.2010.88; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Grumbach Y, 2009, AM J PHYSIOL-LUNG C, V296, pL101, DOI 10.1152/ajplung.00018.2008; Hewitson TD, 2010, ENDOCRINOLOGY, V151, P4938, DOI 10.1210/en.2010-0286; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Kieran NE, 2003, KIDNEY INT, V64, P480, DOI 10.1046/j.1523-1755.2003.00106.x; Lee SB, 2010, KIDNEY INT, V78, pS22, DOI 10.1038/ki.2010.418; Leonard MO, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015795.74094.91; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma FY, 2009, AM J PHYSIOL-RENAL, V296, pF177, DOI 10.1152/ajprenal.90498.2008; Maderna P, 2005, PROSTAG LEUKOTR ESS, V73, P179, DOI 10.1016/j.plefa.2005.05.004; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; Martins V, 2009, J IMMUNOL, V182, P5374, DOI 10.4049/jimmunol.0802259; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murphy M, 2008, BIOCHEM SOC T, V36, P941, DOI 10.1042/BST0360941; Murphy M, 2008, J AM SOC NEPHROL, V19, P1672, DOI 10.1681/ASN.2007101080; O'Sullivan TP, 2007, J MED CHEM, V50, P5894, DOI 10.1021/jm060270d; Okada H, 2005, CURR MOL MED, V5, P467, DOI 10.2174/1566524054553478; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; Petasis NA, 2008, BIOORG MED CHEM LETT, V18, P1382, DOI 10.1016/j.bmcl.2008.01.013; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Rodriguez-Pena AB, 2008, KIDNEY INT, V74, P196, DOI 10.1038/ki.2008.160; Rooney B, 2011, FEBS LETT, V585, P531, DOI 10.1016/j.febslet.2011.01.004; Schieppati A, 2005, KIDNEY INT, V68, pS7, DOI 10.1111/j.1523-1755.2005.09801.x; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Sun YP, 2009, PROSTAG LEUKOTR ESS, V81, P357, DOI 10.1016/j.plefa.2009.09.004; Sung SA, 2007, NEPHRON EXP NEPHROL, V105, pE1, DOI 10.1159/000096859; Suzuki Hitoe, 2004, Clin Exp Nephrol, V8, P188; Wada T, 2004, J AM SOC NEPHROL, V15, P940, DOI 10.1097/01.ASN.0000120371.09769.80; Wang Y, 2007, KIDNEY INT, V72, P290, DOI 10.1038/sj.ki.5002275; Wang YP, 2011, J AM SOC NEPHROL, V22, P21, DOI 10.1681/ASN.2010030269; Willoughby DA, 2000, INT J IMMUNOPHARMACO, V22, P1131, DOI 10.1016/S0192-0561(00)00064-3; Wu SH, 2010, AM J NEPHROL, V32, P122, DOI 10.1159/000315121; Xia Z, 2008, AM J NEPHROL, V28, P34, DOI 10.1159/000108759; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Yanagita M, 2006, KIDNEY INT, V70, P989, DOI 10.1038/sj.ki.5001731; Yoo KH, 2006, KIDNEY INT, V70, P1735, DOI 10.1038/sj.ki.5000357	63	86	95	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2967	2979		10.1096/fj.11-185017	http://dx.doi.org/10.1096/fj.11-185017			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21628447				2022-12-28	WOS:000294435200012
J	Robinson, MM; Turner, SM; Hellerstein, MK; Hamilton, KL; Miller, BF				Robinson, Matthew M.; Turner, Scott M.; Hellerstein, Marc K.; Hamilton, Karyn L.; Miller, Benjamin F.			Long-term synthesis rates of skeletal muscle DNA and protein are higher during aerobic training in older humans than in sedentary young subjects but are not altered by protein supplementation	FASEB JOURNAL			English	Article						stable isotope tracer; kinetics; deuterium oxide; heavy water; endurance; satellite cell	IN-VIVO; RESISTANCE EXERCISE; SATELLITE CELLS; MITOCHONDRIAL BIOGENESIS; NITROGEN-BALANCE; DOSE-RESPONSE; TURNOVER; INGESTION; MASS; MEN	Consuming protein following exercise has been shown to stimulate protein synthesis acutely in skeletal muscle and has been recommended to prevent sarcopenia. It is not known, however, whether acute stimulation persists long term or includes muscle cell division. We asked here whether consuming protein following exercise during aerobic training increases long-term protein and DNA synthesis rates in skeletal muscle of adult humans. Sixteen previously untrained participants (50 +/- 8 yr) consumed either a carbohydrate or carbohydrate and protein drink following each session during 6 wk of treadmill training. A younger untrained group provided a nonexercising comparison. Participants were administered heavy water ((H2O)-H-2; deuterium oxide) continuously for 6 wk to isotopically label newly synthesized skeletal muscle proteins and DNA. Muscle biopsies were performed after 6 wk of training. Contrary to acute studies, consuming protein after exercise did not increase skeletal muscle protein synthesis rates. In contrast, muscle protein synthesis, DNA, and phospholipid synthesis were significantly higher in the older exercise groups than the younger sedentary group. The higher DNA replication rate could not be attributed to mitochondrial DNA and may be due to satellite cell activation. We conclude that postexercise protein supplementation does not increase rates of mixed protein synthesis over 6 wk and that aerobic exercise may stimulate long-term cell division (DNA synthesis) in skeletal muscle of humans. Measurements of long-term synthesis rates provide important insights into aging and exercise adaptations.-Robinson, M. M., Turner, S. M., Hellerstein, M. K., Hamilton, K. L., Miller, B. F. Long-term synthesis rates of skeletal muscle DNA and protein are higher during aerobic training in older humans than in sedentary young subjects but are not altered by protein supplementation. FASEB J. 25, 3240-3249 (2011). www.fasebj.org	[Robinson, Matthew M.; Hamilton, Karyn L.; Miller, Benjamin F.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA; [Turner, Scott M.; Hellerstein, Marc K.] KineMed Inc, Emeryville, CA USA; [Hellerstein, Marc K.] Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	Colorado State University; University of California System; University of California Berkeley	Miller, BF (corresponding author), Colorado State Univ, Dept Hlth & Exercise Sci, 200 Moby B Complex, Ft Collins, CO 80523 USA.	benjamin.f.miller@colostate.edu		Miller, Benjamin/0000-0003-1647-0122	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK048520]; Colorado State University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Colorado State University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors appreciate the enthusiasm of all the study participants during the project and thank everyone who helped with exercise training and heavy water preparation: Jon Land, Kyle Barnes, Karen Warnersdorfer, Rebecca Peterson, Carrie Sousek, Shannon Wells, and the Adult Fitness Program at Colorado State University. The authors also thank Christopher Bell, Rebecca Scalzo, and Garrett Peltonen for providing the sedentary control data and Wyatt Voyles for providing medical oversight. Claire Emson and Kelvin Li (KineMed Inc.) provided technical expertise for deuterium analysis. Funding for the project was provided to B. F. M. by U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases pilot grant P30 DK048520 and Colorado State University.	Beccafico S, 2011, AGE, V33, P523, DOI 10.1007/s11357-010-9197-x; Busch R, 2007, NAT PROTOC, V2, P3045, DOI 10.1038/nprot.2007.420; Busch R, 2006, BBA-GEN SUBJECTS, V1760, P730, DOI 10.1016/j.bbagen.2005.12.023; Crameri RM, 2007, J PHYSIOL-LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827; Cristea A, 2010, AGING CELL, V9, P685, DOI 10.1111/j.1474-9726.2010.00594.x; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Esmarck B, 2001, J PHYSIOL-LONDON, V535, P301, DOI 10.1111/j.1469-7793.2001.00301.x; Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059, DOI 10.1093/gerona/61.10.1059; Harber MP, 2010, AM J PHYSIOL-REG I, V299, pR1254, DOI 10.1152/ajpregu.00348.2010; Harber MP, 2009, AM J PHYSIOL-REG I, V296, pR708, DOI [10.1152/ajpregu.00354.2009, 10.1152/ajpregu.90906.2008]; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; Henderson GC, 2009, FASEB J, V23, P631, DOI 10.1096/fj.08-117200; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Hughes VA, 2002, AM J CLIN NUTR, V76, P473, DOI 10.1093/ajcn/76.2.473; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Jordan LY, 2010, J GERONTOL A-BIOL, V65, P1068, DOI 10.1093/gerona/glq123; Koopman R, 2005, AM J PHYSIOL-ENDOC M, V288, pE645, DOI 10.1152/ajpendo.00413.2004; Koopman R, 2009, J APPL PHYSIOL, V106, P2040, DOI 10.1152/japplphysiol.91551.2008; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Kumar V, 2009, J PHYSIOL-LONDON, V587, P211, DOI 10.1113/jphysiol.2008.164483; Levenhagen DK, 2001, AM J PHYSIOL-ENDOC M, V280, pE982, DOI 10.1152/ajpendo.2001.280.6.E982; Liu XG, 2009, EMBO J, V28, P3074, DOI 10.1038/emboj.2009.255; Menshikova EV, 2007, J APPL PHYSIOL, V103, P21, DOI 10.1152/japplphysiol.01228.2006; Menshikova EV, 2006, J GERONTOL A-BIOL, V61, P534, DOI 10.1093/gerona/61.6.534; Miller BF, 2007, EXERC SPORT SCI REV, V35, P50, DOI 10.1097/jes.0b013e31803eac78; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Moore DR, 2009, AM J CLIN NUTR, V89, P161, DOI 10.3945/ajcn.2008.26401; MOSS FP, 1971, ANAT REC, V170, P421, DOI 10.1002/ar.1091700405; Murphy C, 2010, APPL PHYSIOL NUTR ME, V35, P583, DOI 10.1139/H10-047; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; Pennings B, 2011, AM J CLIN NUTR, V93, P322, DOI 10.3945/ajcn.2010.29649; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Previs SF, 2004, AM J PHYSIOL-ENDOC M, V286, pE665, DOI 10.1152/ajpendo.00271.2003; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; Roberts MD, 2010, MED SCI SPORT EXER, V42, P1861, DOI 10.1249/MSS.0b013e3181da8a29; Robinson MM, 2009, J APPL PHYSIOL, V107, P8, DOI 10.1152/japplphysiol.00343.2009; Roohk DJ, 2010, J PHARMACOL EXP THER, V333, P281, DOI 10.1124/jpet.109.162487; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Schultz E, 1996, DEV BIOL, V175, P84, DOI 10.1006/dbio.1996.0097; Shefer G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013307; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Szuhai K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e13; Thornell LE, 2003, SCAND J MED SCI SPOR, V13, P48, DOI 10.1034/j.1600-0838.2003.20285.x; Tipton KD, 2001, AM J PHYSIOL-ENDOC M, V281, pE197, DOI 10.1152/ajpendo.2001.281.2.E197; Tipton KD, 2007, AM J PHYSIOL-ENDOC M, V292, pE71, DOI 10.1152/ajpendo.00166.2006; TODD KS, 1984, J NUTR, V114, P2107, DOI 10.1093/jn/114.11.2107; Turner SM, 2003, AM J PHYSIOL-ENDOC M, V285, pE790, DOI 10.1152/ajpendo.00402.2002; Verdijk LB, 2009, AM J CLIN NUTR, V89, P608, DOI 10.3945/ajcn.2008.26626; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Wilkes EA, 2009, AM J CLIN NUTR, V90, P1343, DOI 10.3945/ajcn.2009.27543; Wilkinson SB, 2008, J PHYSIOL-LONDON, V586, P3701, DOI 10.1113/jphysiol.2008.153916	54	101	106	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3240	3249		10.1096/fj.11-186437	http://dx.doi.org/10.1096/fj.11-186437			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21613572	Green Published			2022-12-28	WOS:000294435200036
J	Ko, JK; Choi, KH; Zhao, XL; Komazaki, S; Pan, Z; Weisleder, N; Ma, JJ				Ko, Jae-Kyun; Choi, Kyoung-Han; Zhao, Xiaoli; Komazaki, Shinji; Pan, Zui; Weisleder, Noah; Ma, Jianjie			A versatile single-plasmid system for tissue-specific and inducible control of gene expression in transgenic mice	FASEB JOURNAL			English	Article						cre; doxycycline; junctophilin; muscle; shRNA	OPERATED CA2+ ENTRY; RNA-INTERFERENCE; MAMMALIAN-CELLS; SKELETAL-MUSCLE; JUNCTOPHILIN TYPE-1; CHANNEL FUNCTION; U6 PROMOTER; DEFICIENCY; TRANSLATION; EFFICIENCY	We describe a novel transgenic system for tissue-specific and inducible control of gene expression in mice. The system employs a tetracycline-responsive CMV promoter that controls transcription of a short-hairpin RNA (shRNA) that remains nonfunctional until an interrupting reporter cassette is excised by Cre recombinase. Insertion of Dicer and Drosha RNase processing sites within the shRNA allows generation of siRNA to knock down a target gene efficiently. Tissue-specific shRNA expression is achieved through the use of appropriate inducer mice with tissue-specific expression of Cre. We applied this system to regulate expression of junctophilins (JPs), genes essential for maintenance of membrane ultrastructure and Ca(2+) signaling in muscle. Transgenic mice with skeletal muscle-specific expression of shRNA against JP mRNAs displayed no basal change of JP expression before treatment with doxycycline (Dox), while inducible and reversible knockdown of JPs was achieved by feeding mice with Dox-containing water. Dox-induced knockdown of JPs led to abnormal junctional membrane structure and Ca(2+) signaling in adult muscle fibers, consistent with essential roles of JPs in muscle development and function. This transgenic approach can be applied for inducible and reversible gene knockdown or gene overexpression in many different tissues, thus providing a versatile system for elucidating the physiological gene function in viable animal models.- Ko, J. -K., Choi, K. -H., Zhao, X., Komazaki, S., Pan, Z., Weisleder, N., Ma, J. A versatile single-plasmid system for tissue-specific and inducible control of gene expression in transgenic mice. FASEB J. 25, 2638 -2649 (2011). www.fasebj.org	[Ko, Jae-Kyun; Choi, Kyoung-Han; Zhao, Xiaoli; Pan, Zui; Weisleder, Noah; Ma, Jianjie] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; [Komazaki, Shinji] Saitama Med Sch, Dept Anat, Saitama, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Saitama Medical University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	Weisleder, Noah L/A-7098-2013	Weisleder, Noah L/0000-0002-2619-8022; Weisleder, Noah/0000-0003-2710-3088; Pan, Zui/0000-0003-4105-901X	U.S. National Institutes of Health [RO1-HL069000, RO1-AG028614, K99/R00-AR054793, AHA 10SDG2630086]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K99AR054793, R00AR054793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028614] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by U.S. National Institutes of Health grants RO1-HL069000 and RO1-AG028614 to J.M., K99/R00-AR054793 to N.W., and AHA 10SDG2630086 to X. Z.	Chang HS, 2004, AM J PATHOL, V165, P1535, DOI 10.1016/S0002-9440(10)63411-6; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferrer-Martinez A, 2006, GENE, V384, P145, DOI 10.1016/j.gene.2006.07.042; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; Gupta S, 2004, P NATL ACAD SCI USA, V101, P1927, DOI 10.1073/pnas.0306111101; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Henriksen JR, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm193; Hirata Y, 2006, BIOPHYS J, V90, P4418, DOI 10.1529/biophysj.105.076570; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Komazaki S, 2003, FEBS LETT, V542, P69, DOI 10.1016/S0014-5793(03)00340-5; Komazaki S, 2002, FEBS LETT, V524, P225, DOI 10.1016/S0014-5793(02)03042-9; Landstrom AP, 2007, J MOL CELL CARDIOL, V42, P1026, DOI 10.1016/j.yjmcc.2007.04.006; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LI H, 2010, J BIOL CHEM; Lin XY, 2004, FEBS LETT, V577, P376, DOI 10.1016/j.febslet.2004.10.033; Mao H, 1998, ANN BIOMED ENG, V26, P666, DOI 10.1114/1.124; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; RAYMOND F, BMC GENOMICS, V11, P125; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Silva J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tiscornia G, 2004, P NATL ACAD SCI USA, V101, P7347, DOI 10.1073/pnas.0402107101; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Woo JS, 2010, BIOCHEM J, V427, P125, DOI 10.1042/BJ20091225; Zhao XL, 2008, AGING CELL, V7, P561, DOI 10.1111/j.1474-9726.2008.00408.x; Zhao XL, 2006, J BIOL CHEM, V281, P33477, DOI 10.1074/jbc.M602306200; Zhu Z, 2002, SEMIN CELL DEV BIOL, V13, P121, DOI 10.1016/S1084-9521(02)00018-6; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200	41	18	19	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2638	2649		10.1096/fj.11-181560	http://dx.doi.org/10.1096/fj.11-181560			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21518849	Green Published			2022-12-28	WOS:000293337800014
J	Canal, F; Palygin, O; Pankratov, Y; Correa, SAL; Muller, J				Canal, Frederic; Palygin, Oleg; Pankratov, Yuriy; Correa, Sonia A. L.; Mueller, Juergen			Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons	FASEB JOURNAL			English	Article						signaling; ERK1/2; dendritic spine; long-term potentiation	LONG-TERM POTENTIATION; SIGNAL-REGULATED KINASE; NEUROFIBROMATOSIS TYPE-1; PHOSPHORYLATION SITES; RECEPTOR TRAFFICKING; DOCKING SITES; GENE ENCODES; MOUSE MODEL; C-ELEGANS; RAS	ERK1/2 is required for certain forms of synaptic plasticity, including the long-term potentiation of synaptic strength. However, the molecular mechanisms regulating synaptically localized ERK1/2 signaling are poorly understood. Here, we show that the MAPK scaffold protein kinase suppressor of Ras 1 (KSR1) is directly phosphorylated by the downstream kinase ERK1/2. Quantitative Western blot analysis further demonstrates that expression of mutated, feedback-deficient KSR1 promotes sustained ERK1/2 activation in HEK293 cells in response to EGF stimulation, compared to a more transient activation in control cells expressing wild-type KSR1. Immunocytochemistry and confocal imaging of primary hippocampal neurons from newborn C57BL6 mice further show that feedback phosphorylation of KSR1 significantly reduces its localization to dendritic spines. This effect can be reversed by tetrodotoxin (1 mu M) or PD184352 (2 mu M) treatment, further suggesting that neuronal activity and phosphorylation by ERK1/2 lead to KSR1 removal from the postsynaptic compartment. Consequently, electrophysiological recordings in hippocampal neurons expressing wild-type or feedback-deficient KSR1 demonstrate that KSR1 feedback phosphorylation restricts the potentiation of excitatory postsynaptic currents. Our findings, therefore, suggest that feedback phosphorylation of the scaffold protein KSR1 prevents excessive ERK1/2 signaling in the postsynaptic compartment and thus contributes to maintaining physiological levels of synaptic excitability.-Canal, F., Palygin, O., Pankratov, Y., Correa, S. A. L., Muller, J. Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons. FASEB J. 25, 2362-2372 (2011). www.fasebj.org	[Canal, Frederic; Mueller, Juergen] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Palygin, Oleg; Pankratov, Yuriy; Correa, Sonia A. L.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick; University of Warwick	Muller, J (corresponding author), Univ Warwick, Warwick Med Sch, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.	jurgen.muller@warwick.ac.uk	Palygin, Oleg/AAT-3047-2020	Palygin, Oleg/0000-0002-3680-5527; Correa, Sonia AL/0000-0002-7434-1073; Muller, Jurgen/0000-0002-5487-0736	UK Medical Research Council (MRC) [G0600790]; North West Cancer Research Fund; University of Warwick [08141]; Biotechnology and Biological Sciences Research Council (BBSRC) [BB/H0183441/1]; BBSRC [BB/H018344/1, BB/F021445/1] Funding Source: UKRI; MRC [G0600790] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/H018344/1, BB/F021445/1] Funding Source: researchfish; Medical Research Council [G0600790] Funding Source: researchfish	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Cancer Research Fund; University of Warwick; Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Bruno Frenguelli for critical reading of the manuscript. This work was funded by the UK Medical Research Council (MRC; G0600790). J.M. was supported by the North West Cancer Research Fund during parts of this study. S. A. L. C. is a Warwick Research Fellow supported by Researcher Development Fund (RDF; 08141; University of Warwick) and Biotechnology and Biological Sciences Research Council (BBSRC; BB/H0183441/1) awards.	Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Brown MD, 2009, CELL SIGNAL, V21, P462, DOI 10.1016/j.cellsig.2008.11.013; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Cohen E, 2008, BRAIN RES, V1235, P21, DOI 10.1016/j.brainres.2008.06.022; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; Correa SAL, 2009, J CELL SCI, V122, P4186, DOI 10.1242/jcs.058420; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dudek SM, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0002.2001; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fitzjohn SM, 2001, NEUROPHARMACOLOGY, V41, P693, DOI 10.1016/S0028-3908(01)00128-9; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Gerdjikov TV, 2004, BEHAV NEUROSCI, V118, P740, DOI 10.1037/0735-7044.118.4.740; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kim JH, 2003, J NEUROSCI, V23, P1119; Komiyama NH, 2002, J NEUROSCI, V22, P9721; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McKay MM, 2009, P NATL ACAD SCI USA, V106, P11022, DOI 10.1073/pnas.0901590106; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2003, EMBO J, V22, P4431, DOI 10.1093/emboj/cdg426; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; Pankratov Y, 2007, J GEN PHYSIOL, V129, P257, DOI 10.1085/jgp.200609693; Pankratov YV, 2003, BIOPHYS J, V85, P3375, DOI 10.1016/S0006-3495(03)74757-2; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Shalin SC, 2006, NEURON, V50, P765, DOI 10.1016/j.neuron.2006.04.029; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; Stricker C, 1996, J PHYSIOL-LONDON, V490, P443, DOI 10.1113/jphysiol.1996.sp021156; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	45	14	14	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2362	2372		10.1096/fj.10-173153	http://dx.doi.org/10.1096/fj.10-173153			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21471251				2022-12-28	WOS:000292242200028
J	Rodriguez-Cuenca, S; Carobbio, S; Vidal-Puig, A				Rodriguez-Cuenca, Sergio; Carobbio, Stefania; Vidal-Puig, Antonio			Ablation of Pparg2 impairs lipolysis and reveals murine strain differences in lipolytic responses	FASEB JOURNAL			English	Article						adipose tissue; insulin resistance	ADIPOSE-TISSUE LIPOLYSIS; ACTIVATED-RECEPTOR-GAMMA; DIET-INDUCED OBESITY; LIPID DROPLETS; INSULIN SENSITIVITY; ADIPOCYTE LIPOLYSIS; TRIGLYCERIDE LIPASE; EXPRESSION; RESISTANCE; PERILIPIN	We investigate the role of PPARg2 as a regulator of lipolysis and its interaction with specific genetic backgrounds as determinants of the severity of the metabolic phenotype. This question was prompted by our previous characterization of Pparg2-knockout (KO) mice that revealed striking genetic background differences in the severity of their adipose tissue development impairment and dysfunction. Analysis is done of pharmacological lipolytic responses combined with protein and mRNA expression analysis in isolated adipocytes from the gonadal pad of Pparg2-KO mice in 2 different backgrounds (129S6/SvEv and C57BL/6). We provide evidence of the prolipolytic role of PPARg2 and how these effects are modulated by genetic background, leading to differential severity of metabolic syndrome. Specifically, ablation of Pparg2 reduced both basal and stimulated lipolysis as a result of impaired beta(3)-AR signaling, a general defect at downstream lipases, and increased insulin-mediated antilipolytic action. Of note, the C57BL/6 Pparg2-KO mice exhibited more active lipolytic response to catecholamines than 129S6/SvEv Pparg2-KO mice with respect to their wild-type controls. Pparg2-KO mice exhibit metabolic inflexibility resulting from the combined effects of impaired lipid deposition coupled with impaired lipolytic lipid mobilization. The genetic background-dependent differences in lipolysis may account for Pparg2-KO background-specific differences in the severity of their metabolic disturbances. Our findings identify the isoform Pparg2 as an integrator of the adipose lipid metabolism coordinating both anabolic and catabolic processes.-Rodriguez-Cuenca, S., Carobbio, S., Vidal-Puig, A. Ablation of Pparg2 impairs lipolysis and reveals murine strains differences in lipolytic responses. FASEB J. 26, 1835-1844 (2012). www.fasebj.org	[Rodriguez-Cuenca, Sergio; Carobbio, Stefania; Vidal-Puig, Antonio] Univ Cambridge, Addenbrookes Hosp, NIHR Cambridge Biomed Res Ctr, Dept Clin Biochem,Metab Res Labs,Inst Metab Sci, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Rodriguez-Cuenca, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, NIHR Cambridge Biomed Res Ctr, Dept Clin Biochem,Metab Res Labs,Inst Metab Sci, Cambridge CB2 0QQ, England.	sr441@medschl.cam.ac.uk; ajv22@medschl.cam.ac.uk	carobbio, stefania/E-7095-2018	Vidal-Puig, Antonio/0000-0003-4220-9577	Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome (HEPADIP) project; Wellcome Trust; UK Medical Research Council [HEALTH-F4-2008-223450]; British Heart Foundation; Medical Research Council [G0802051, G0600717B] Funding Source: researchfish; MRC [G0802051] Funding Source: UKRI	Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome (HEPADIP) project; Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Dr. Gema Medina-Gomez (Institute of Metabolic Sciences, University of Cambridge) for providing access to the Pparg2-KO line. The authors also thank Janice Carter, Dan Hart, Sarah Grocott, and Helen Westby for husbandry of the Pparg2-KO colony. This work was funded by the Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome (HEPADIP) project, a Wellcome Trust Insulin Resistance Program grant, UK Medical Research Council Programme grants FP7-MITIN (HEALTH-F4-2008-223450) and FP7-BetaBAT, and the British Heart Foundation.	Ahmad F, 2009, BIOCHEM J, V424, P399, DOI 10.1042/BJ20090842; Almind K, 2004, DIABETES, V53, P3274, DOI 10.2337/diabetes.53.12.3274; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Dalen KT, 2004, DIABETES, V53, P1243, DOI 10.2337/diabetes.53.5.1243; Deng T, 2006, ENDOCRINOLOGY, V147, P875, DOI 10.1210/en.2005-0623; Ducharme NA, 2008, ENDOCRINOLOGY, V149, P942, DOI 10.1210/en.2007-1713; Festuccia WT, 2006, DIABETOLOGIA, V49, P2427, DOI 10.1007/s00125-006-0336-y; Granneman JG, 2009, J BIOL CHEM, V284, P34538, DOI 10.1074/jbc.M109.068478; Gray SL, 2007, NUTR REV, V65, pS7, DOI [10.1111/j.1753-4887.2007.tb00331.x, 10.1301/nr.2007.jun.S7-S12]; Harris C. A., J LIPID RES, V52, P657; Jaworski K, 2007, AM J PHYSIOL-GASTR L, V293, pG1, DOI 10.1152/ajpgi.00554.2006; Kershaw EE, 2007, AM J PHYSIOL-ENDOC M, V293, pE1736, DOI 10.1152/ajpendo.00122.2007; Kim JY, 2006, AM J PHYSIOL-ENDOC M, V291, pE115, DOI 10.1152/ajpendo.00317.2005; Langin D, 2006, CR BIOL, V329, P598, DOI 10.1016/j.crvi.2005.10.008; Medina-Gomez G, 2005, DIABETES, V54, P1706, DOI 10.2337/diabetes.54.6.1706; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Puri V, 2008, P NATL ACAD SCI USA, V105, P7833, DOI 10.1073/pnas.0802063105; RODBELL M, 1964, J BIOL CHEM, V239, P375; Snyder PB, 2005, J LIPID RES, V46, P494, DOI 10.1194/jlr.M400362-JLR200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Thiele C, 2008, CURR OPIN CELL BIOL, V20, P378, DOI 10.1016/j.ceb.2008.05.009; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101	25	11	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1835	1844		10.1096/fj.11-193631	http://dx.doi.org/10.1096/fj.11-193631			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22319009				2022-12-28	WOS:000303680800012
J	Lam, V; Su, JD; Koprowski, S; Hsu, AN; Tweddell, JS; Rafiee, P; Gross, GJ; Salzman, NH; Baker, JE				Lam, Vy; Su, Jidong; Koprowski, Stacy; Hsu, Anna; Tweddell, James S.; Rafiee, Parvaneh; Gross, Garrett J.; Salzman, Nita H.; Baker, John E.			Intestinal microbiota determine severity of myocardial infarction in rats	FASEB JOURNAL			English	Article						bacteria; leptin; probiotics; biomarkers; cytokines	CORONARY-HEART-DISEASE; CHLAMYDIA-PNEUMONIAE; GUT MICROBIOTA; RIBOSOMAL-RNA; HELICOBACTER-PYLORI; DNA EXTRACTION; PCR ASSAYS; LACTOBACILLUS; METABOLISM; ATHEROSCLEROSIS	Signals from the intestinal microbiota are important for normal host physiology; alteration of the microbiota (dysbiosis) is associated with multiple disease states. We determined the effect of antibiotic-induced intestinal dysbiosis on circulating cytokine levels and severity of ischemia/reperfusion injury in the heart. Treatment of Dahl S rats with a minimally absorbed antibiotic vancomycin, in the drinking water, decreased circulating leptin levels by 38%, resulted in smaller myocardial infarcts (27% reduction), and improved recovery of postischemic mechanical function (35%) as compared with untreated controls. Vancomycin altered the abundance of intestinal bacteria and fungi, measured by 16S and 18S ribosomal DNA quantity. Pretreatment with leptin (0.12 mu g/kg i.v.) 24 h before ischemia/reperfusion abolished cardioprotection produced by vancomycin treatment. Dahl S rats fed the commercially available probiotic product Goodbelly, which contains the leptin-suppressing bacteria Lactobacillus plantarum 299v, also resulted in decreased circulating leptin levels by 41%, smaller myocardial infarcts (29% reduction), and greater recovery of postischemic mechanical function (23%). Pretreatment with leptin (0.12 mu g/kg i.v.) abolished cardioprotection produced by Goodbelly. This proof-of-concept study is the first to identify a mechanistic link between changes in intestinal microbiota and myocardial infarction and demonstrates that a probiotic supplement can reduce myocardial infarct size.-Lam, V., Su, J., Koprowski, S., Hsu, A., Tweddell, J. S., Rafiee, P., Gross, G. J., Salzman, N. H., Baker, J. E. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26, 1727-1735 (2012). www.fasebj.org	[Lam, Vy; Su, Jidong; Koprowski, Stacy; Tweddell, James S.; Baker, John E.] Med Coll Wisconsin, Childrens Res Inst, Div Cardiothorac Surg, Milwaukee, WI 53226 USA; [Hsu, Anna; Gross, Garrett J.; Baker, John E.] Med Coll Wisconsin, Childrens Res Inst, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Rafiee, Parvaneh] Med Coll Wisconsin, Childrens Res Inst, Div Colorectal Surg, Milwaukee, WI 53226 USA; [Baker, John E.] Med Coll Wisconsin, Childrens Res Inst, Dept Biochem, Milwaukee, WI 53226 USA; [Salzman, Nita H.] Med Coll Wisconsin, Childrens Res Inst, Dept Pediat, Div Gastroenterol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Baker, JE (corresponding author), Med Coll Wisconsin, Childrens Res Inst, Div Cardiothorac Surg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jbaker@mcw.edu	Baker, John/V-8897-2019	Baker, John/0000-0001-7899-3266; Salzman, Nita/0000-0003-0939-6139	U.S. National Institutes of Health [HL-54075, AI-080363, AI-057757, HL-074317]; Foundation for Heart Science; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI057757, R01AI080363, R01AI057757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099526] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for Heart Science; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Ravinder Singh (Mayo Laboratories, Rochester, MN, USA) for determining vancomycin levels in blood; Michael Hayward (Medical College of Wisconsin) for guidance with the PCR determinations; and Dr. Jeffrey I. Gordon (Washington University School of Medicine, St. Louis, MO, USA) for providing genomic DNA from M. smithii. This work was supported by U.S. National Institutes of Health grants HL-54075 and AI-080363 (to J.E.B.), AI-057757 (to N.H.S.), and HL-074317 (to G.J.G.) and by the Foundation for Heart Science (to V.L.). J.E.B. has filed a provisional patent application based on the findings of this study. J.E.B. holds an equity interest in Microbiota Diagnostics, a limited-liability corporation formed to develop the findings of this study.	Ahmad S, 2002, J CLIN MICROBIOL, V40, P2483, DOI 10.1128/JCM.40.7.2483-2489.2002; Armougom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007125; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Baker JE, 2000, AM J PHYSIOL-HEART C, V278, pH1395, DOI 10.1152/ajpheart.2000.278.4.H1395; Baker JE, 2008, CARDIOVASC RES, V77, P44, DOI 10.1093/cvr/cvm026; Baker JE, 2007, J CARDIOVASC PHARM, V49, P337, DOI 10.1097/FJC.0b013e318040cf81; Cannon CP, 2005, NEW ENGL J MED, V352, P1646, DOI 10.1056/NEJMoa043528; Chang HW, 2007, J MICROBIOL METH, V71, P191, DOI 10.1016/j.mimet.2007.08.013; Costa C, 2002, J CLIN MICROBIOL, V40, P2224, DOI 10.1128/JCM.40.6.2224-2227.2002; Crawford PA, 2009, P NATL ACAD SCI USA, V106, P11276, DOI 10.1073/pnas.0902366106; Croswell A, 2009, INFECT IMMUN, V77, P2741, DOI 10.1128/IAI.00006-09; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Epstein SE, 1996, LANCET, V348, pS13, DOI 10.1016/S0140-6736(96)98005-8; Fryer RM, 2001, J PHARMACOL EXP THER, V296, P642; Gross ER, 2003, J MOL CELL CARDIOL, V35, P985, DOI 10.1016/S0022-2828(03)00183-4; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85; Kubota H., APPL ENV MICROBIOL, V76, P5440; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; Loscalzo J, 2011, CIRC RES, V109, P127, DOI 10.1161/RES.0b013e3182290620; Madan M, 2007, ATHEROSCLEROSIS, V190, P62, DOI 10.1016/j.atherosclerosis.2006.02.026; Matsuda K, 2009, APPL ENVIRON MICROB, V75, P1961, DOI 10.1128/AEM.01843-08; Molin G, 2001, AM J CLIN NUTR, V73, p380S, DOI 10.1093/ajcn/73.2.380s; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Muller A, 1999, CLIN DIAGN LAB IMMUN, V6, P243; Naruszewicz M, 2002, AM J CLIN NUTR, V76, P1249, DOI 10.1093/ajcn/76.6.1249; Nicholson JK, 2005, NAT REV MICROBIOL, V3, P431, DOI 10.1038/nrmicro1152; O'Connor CM, 2003, JAMA-J AM MED ASSOC, V290, P1459, DOI 10.1001/jama.290.11.1459; Ombrouck C, 1997, J CLIN MICROBIOL, V35, P652, DOI 10.1128/JCM.35.3.652-655.1997; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Purdham DM, 2008, AM J PHYSIOL-HEART C, V295, pH441, DOI 10.1152/ajpheart.91537.2007; Purdham DM, 2004, AM J PHYSIOL-HEART C, V287, pH2877, DOI 10.1152/ajpheart.00499.2004; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rajesh KG, 2003, CARDIOVASC RES, V59, P297, DOI 10.1016/S0008-6363(03)00358-4; Ren J, 2008, OBESITY, V16, P2417, DOI 10.1038/oby.2008.381; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Shi Y, 2005, J MOL CELL CARDIOL, V38, P625, DOI 10.1016/j.yjmcc.2005.02.005; Smith CCT, 2011, PHARMACOL THERAPEUT, V129, P206, DOI 10.1016/j.pharmthera.2010.09.003; Smith CCT, 2010, AM J PHYSIOL-HEART C, V299, pH1265, DOI 10.1152/ajpheart.00092.2010; Song YL, 2000, FEMS MICROBIOL LETT, V187, P167, DOI 10.1016/S0378-1097(00)00196-8; Stone AFM, 2002, CIRCULATION, V106, P1219, DOI 10.1161/01.CIR.0000027820.66786.CF; Takemura N, 2010, EXP BIOL MED, V235, P849, DOI 10.1258/ebm.2010.009377; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; VANKUPPEVELD FJM, 1992, APPL ENVIRON MICROB, V58, P2606, DOI 10.1128/AEM.58.8.2606-2615.1992; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wolfrum S, 2002, CARDIOVASC RES, V55, P583, DOI 10.1016/S0008-6363(02)00408-X; Yap IKS, 2008, J PROTEOME RES, V7, P3718, DOI 10.1021/pr700864x	49	176	192	0	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1727	1735		10.1096/fj.11-197921	http://dx.doi.org/10.1096/fj.11-197921			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22247331	Green Published			2022-12-28	WOS:000302359700033
J	Bortolussi, G; Zentilin, L; Baj, G; Giraudi, P; Bellarosa, C; Giacca, M; Tiribelli, C; Muro, AF				Bortolussi, Giulia; Zentilin, Lorena; Baj, Gabriele; Giraudi, Pablo; Bellarosa, Cristina; Giacca, Mauro; Tiribelli, Claudio; Muro, Andres F.			Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer	FASEB JOURNAL			English	Article						kernicterus; phototherapy; UGT1A1	UDP-GLUCURONOSYLTRANSFERASE DEFICIENCY; INDUCED CEREBELLAR HYPOPLASIA; GUNN RAT; UGT1 LOCUS; EDA EXON; HYPERBILIRUBINEMIA; MICE; FIBRONECTIN; KERNICTERUS; GENOME	Crigler-Najjar type I (CNI) syndrome is a recessively inherited disorder characterized by severe unconjugated hyperbilirubinemia caused by uridine diphosphoglucuronosyltransferase 1A1 (UGT1A1) deficiency. The disease is lethal due to bilirubin-induced neurological damage unless phototherapy is applied from birth. However, treatment becomes less effective during growth, and liver transplantation is required. To investigate the pathophysiology of the disease and therapeutic approaches in mice, we generated a mouse model by introducing a premature stop codon in the UGT1a1 gene, which results in an inactive enzyme. Homozygous mutant mice developed severe jaundice soon after birth and died within 11 d, showing significant cerebellar alterations. To rescue neonatal lethality, newborns were injected with a single dose of adeno-associated viral vector 9 (AAV9) expressing the human UGT1A1. Gene therapy treatment completely rescued all AAV-treated mutant mice, accompanied by lower plasma bilirubin levels and normal brain histology and motor coordination. Our mouse model of CNI reproduces genetic and phenotypic features of the human disease. We have shown, for the first time, the full recovery of the lethal effects of neonatal hyperbilirubinemia. We believe that, besides gene-addition-based therapies, our mice could represent a very useful model to develop and test novel technologies based on gene correction by homologous recombination.-Bortolussi, G., Zentilin, L., Baj, G., Giraudi, P., Bellarosa, C., Giacca, M., Tiribelli, C., Muro, A. F. Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer. FASEB J. 26, 1052-1063 (2012). www.fasebj.org	[Bortolussi, Giulia; Zentilin, Lorena; Giacca, Mauro; Muro, Andres F.] Int Ctr Genet Engn & Biotechnol, I-34149 Trieste, Italy; [Baj, Gabriele] Univ Trieste, Dept Life Sci, Ctr Neurosci, Basic Res & Integrat Neurosci BRAIN, Trieste, Italy; [Tiribelli, Claudio] Univ Trieste, Dept Med Sci, Trieste, Italy; [Giraudi, Pablo; Bellarosa, Cristina; Tiribelli, Claudio] Fdn Italiana Fegato, Ctr Studi Fegato, Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste; University of Trieste	Muro, AF (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34149 Trieste, Italy.	muro@icgeb.org	Muro, Andrés F/K-3156-2016; Giacca, Mauro/J-9287-2016; Baj, Gabriele/H-4228-2012; Tiribelli, Claudio/A-4716-2014	Muro, Andrés F/0000-0002-9628-0494; Giacca, Mauro/0000-0003-2927-7225; Baj, Gabriele/0000-0002-2625-9454; Bortolussi, Giulia/0000-0001-9470-0902; Tiribelli, Claudio/0000-0001-6596-7595	Telethon [GGP10051]; Friuli-Venezia Giulia Regional Grant	Telethon(Fondazione Telethon); Friuli-Venezia Giulia Regional Grant	This work was supported by Telethon (GGP10051) and by Friuli-Venezia Giulia Regional Grant to AFM. The authors thank M. Dappas and M. Zotti for help with AAV preparation, M. Sturnega and S. Artico for help with animal care, E. Tongiorgi for microscope resources, M. Rossi for help in determination of Ugt1a1 activity, and the integrants of the Mouse Molecular Genetics Group for critical reading of the manuscript.	Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Chauhan AK, 2005, BEHAV BRAIN RES, V161, P31, DOI 10.1016/j.bbr.2005.02.020; Chowdhury J. R., 1986, BILE PIGMENTS JAUNDI, P317; CHOWDHURY JR, 1993, ADV VET SCI COMP MED, V37, P149; CRIGLER JF, 1952, PEDIATRICS, V10, P169; DOBBS RH, 1975, ARCH DIS CHILD, V50, P833, DOI 10.1136/adc.50.11.833; Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978-1-59745-471-1_23; DOUMAS BT, 1985, CLIN CHEM, V31, P1779; Emi Y, 2002, ARCH BIOCHEM BIOPHYS, V405, P163, DOI 10.1016/S0003-9861(02)00351-X; Flageul M, 2009, J GENE MED, V11, P689, DOI 10.1002/jgm.1343; Fonnum F, 2000, TOXICOL LETT, V112, P9, DOI 10.1016/S0378-4274(99)00246-5; Fujiwara R, 2010, P NATL ACAD SCI USA, V107, P5024, DOI 10.1073/pnas.0913290107; GeorgesLabouesse EN, 1996, DEV DYNAM, V207, P145, DOI 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H; GORDON ER, 1984, J BIOL CHEM, V259, P5500; Gunn CH, 1938, J HERED, V29, P137, DOI 10.1093/oxfordjournals.jhered.a104478; Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; Iyanagi T, 1998, BBA-MOL BASIS DIS, V1407, P173, DOI 10.1016/S0925-4439(98)00044-1; Jia Z, 2005, MOL THER, V12, P860, DOI 10.1016/j.ymthe.2005.04.023; Kadakol A, 2000, HUM MUTAT, V16, P297, DOI 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z; KEINO H, 1989, NEUROSCI RES, V6, P209, DOI 10.1016/0168-0102(89)90060-6; Li HJ, 2011, NATURE, V475, P217, DOI 10.1038/nature10177; Lin SZ, 2005, EUR J NEUROSCI, V22, P21, DOI 10.1111/j.1460-9568.2005.04182.x; Miranda PSM, 2009, CURR GENE THER, V9, P72; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Nguyen N, 2008, J BIOL CHEM, V283, P7901, DOI 10.1074/jbc.M709244200; Ogura T, 2006, J GENE MED, V8, P990, DOI 10.1002/jgm.916; Pacak Christina A, 2008, Genet Vaccines Ther, V6, P13, DOI 10.1186/1479-0556-6-13; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; SCHUTTA HS, 1967, J NEUROPATH EXP NEUR, V26, P377, DOI 10.1097/00005072-196707000-00003; Seppen J, 2006, MOL THER, V13, P1085, DOI 10.1016/j.ymthe.2006.01.014; Shapiro SM, 2006, CLIN PERINATOL, V33, P387, DOI 10.1016/j.clp.2006.03.010; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strauss KA, 2006, EUR J PEDIATR, V165, P306, DOI 10.1007/s00431-005-0055-2; Watchko JF, 2006, NEUROMOL MED, V8, P513, DOI 10.1385/NMM:8:4:513; Yamamura H, 1993, Nagoya J Med Sci, V55, P11; Zentilin L, 2001, J VIROL, V75, P12279, DOI 10.1128/JVI.75.24.12279-12287.2001	38	53	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1052	1063		10.1096/fj.11-195461	http://dx.doi.org/10.1096/fj.11-195461			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22094718	Green Published, hybrid			2022-12-28	WOS:000300949300010
J	Colom, B; Poitelon, Y; Huang, WL; Woodfin, A; Averill, S; Del Carro, U; Zambroni, D; Brain, SD; Perretti, M; Ahluwalia, A; Priestley, JV; Chavakis, T; Imhof, BA; Feltri, ML; Nourshargh, S				Colom, Bartomeu; Poitelon, Yannick; Huang, Wenlong; Woodfin, Abigail; Averill, Sharon; Del Carro, Ubaldo; Zambroni, Desiree; Brain, Susan D.; Perretti, Mauro; Ahluwalia, Amrita; Priestley, John V.; Chavakis, Triantafyllos; Imhof, Beat A.; Feltri, M. Laura; Nourshargh, Sussan			Schwann cell-specific JAM-C-deficient mice reveal novel expression and functions for JAM-C in peripheral nerves	FASEB JOURNAL			English	Article						adhesion molecules; tight junctions; peripheral nerves	JUNCTIONAL-ADHESION-MOLECULE; MYELINATED AXONS; TRANSENDOTHELIAL MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; TIGHT JUNCTIONS; IN-VIVO; RECEPTOR; PROTEINS; INTEGRIN; GROWTH	Junctional adhesion molecule-C (JAM-C) is an adhesion molecule expressed at junctions between adjacent endothelial and epithelial cells and implicated in multiple inflammatory and vascular responses. In addition, we recently reported on the expression of JAM-C in Schwann cells (SCs) and its importance for the integrity and function of peripheral nerves. To investigate the role of JAM-C in neuronal functions further, mice with a specific deletion of JAM-C in SCs (JAM-C SC KO) were generated. Compared to wild-type (WT) controls, JAM-C SC KO mice showed electrophysiological defects, muscular weakness, and hypersensitivity to mechanical stimuli. In addressing the underlying cause of these defects, nerves from JAM-C SC KO mice were found to have morphological defects in the paranodal region, exhibiting increased nodal length as compared to WTs. The study also reports on previously undetected expressions of JAM-C, namely on perineural cells, and in line with nociception defects of the JAM-C SC KO animals, on finely myelinated sensory nerve fibers. Collectively, the generation and characterization of JAM-C SC KO mice has provided unequivocal evidence for the involvement of SC JAM-C in the fine organization of peripheral nerves and in modulating multiple neuronal responses.-Colom, B., Poitelon, Y., Huang, W., Woodfin, A., Averill, S., Del Carro, U., Zambroni, D., Brain, S. D., Perretti, M., Ahluwalia, A., Priestley, J. V., Chavakis, T., Imhof, B. A., Feltri, M. L., Nourshargh, S. Schwann cell-specific JAM-C-deficient mice reveal novel expression and functions for JAM-C in peripheral nerves. FASEB J. 26, 1064-1076 (2012). www.fasebj.org	[Colom, Bartomeu; Woodfin, Abigail; Perretti, Mauro; Ahluwalia, Amrita; Nourshargh, Sussan] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; [Huang, Wenlong; Averill, Sharon; Priestley, John V.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Neurosci & Trauma, London EC1M 6BQ, England; [Poitelon, Yannick; Del Carro, Ubaldo; Zambroni, Desiree; Feltri, M. Laura] Ist Sci San Raffaele, Dept Genet & Cell Biol, I-20132 Milan, Italy; [Poitelon, Yannick; Del Carro, Ubaldo; Zambroni, Desiree; Feltri, M. Laura] Ist Sci San Raffaele, Dept Neurol, I-20132 Milan, Italy; [Brain, Susan D.] Kings Coll London, Div Cardiovasc, London WC2R 2LS, England; [Brain, Susan D.] Kings Coll London, Ctr Integrat Biomed, London WC2R 2LS, England; [Chavakis, Triantafyllos] Univ Dresden, Dept Med, Dresden, Germany; [Chavakis, Triantafyllos] Univ Dresden, Dept Physiol, Dresden, Germany; [Imhof, Beat A.] Ctr Med Univ Geneva, Geneva, Switzerland	University of London; Queen Mary University London; University of London; Queen Mary University London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; King's College London; University of London; King's College London; Technische Universitat Dresden; Technische Universitat Dresden; University of Geneva	Nourshargh, S (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	s.nourshargh@qmul.ac.uk	Zambroni, Desiree/AAN-4003-2020; Del Carro, Ubaldo/AAO-3457-2020; Feltri, Maria Laura/J-5286-2018; Colom, Bartomeu/AAA-7539-2019; Colom, Bartomeu/A-6905-2013; Brain, Susan/L-3681-2013; Chavakis, Triantafyllos/ABE-8845-2020; Huang, Wenlong/P-2025-2016	Zambroni, Desiree/0000-0003-4027-1094; Del Carro, Ubaldo/0000-0003-3301-5412; Nourshargh, Sussan/0000-0001-5677-1806; Colom, Bartomeu/0000-0001-6256-6462; Brain, Susan/0000-0002-9684-8342; Poitelon, Yannick/0000-0001-9868-1569; AHLUWALIA, Amrita/0000-0001-7626-6399	Wellcome Trust [081172/Z/06/Z]; Swiss National Science Foundation [310030-120184]; Deutsche Forschungsgemeinschaft; Center for Regenerative Therapies Dresden; U.S. National Institute of Neurological Disorders and Stroke [R01NS045630]; Telethon Italia [GGP08021]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045630] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Center for Regenerative Therapies Dresden; U.S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon Italia(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by the Wellcome Trust (081172/Z/06/Z to S.N.). The study was also supported by the Swiss National Science Foundation (310030-120184 to B. A. I.), the Deutsche Forschungsgemeinschaft and the Center for Regenerative Therapies Dresden (to T. C.), the U.S. National Institute of Neurological Disorders and Stroke (R01NS045630 to M. L. F.), and Telethon Italia (GGP08021 to M. L. F.). The authors thank Stefania Saccucci for superb technical assistance.	Alanne MH, 2009, J HISTOCHEM CYTOCHEM, V57, P523, DOI 10.1369/jhc.2009.951681; Angelow S, 2007, AM J PHYSIOL-RENAL, V293, pF166, DOI 10.1152/ajprenal.00087.2007; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Baum AE, 2008, MOL PSYCHIATR, V13, P197, DOI 10.1038/sj.mp.4002012; Betanzos A, 2009, BIOL CELL, V101, P441, DOI 10.1042/BC20080130; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Bradfield PF, 2007, ARTERIOSCL THROM VAS, V27, P2104, DOI 10.1161/ATVBAHA.107.147694; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; FANNON AM, 1995, J CELL BIOL, V129, P189, DOI 10.1083/jcb.129.1.189; Feltri ML, 1999, ANN NY ACAD SCI, V883, P116, DOI 10.1111/j.1749-6632.1999.tb08574.x; Fullerton JM, 2010, BIOL PSYCHIAT, V67, P478, DOI 10.1016/j.biopsych.2009.10.022; Gliki G, 2004, NATURE, V431, P320, DOI 10.1038/nature02877; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Imhof BA, 2007, J PATHOL, V212, P198, DOI 10.1002/path.2163; Inoue H, 1997, EUR J PHARMACOL, V333, P231, DOI 10.1016/S0014-2999(97)01040-6; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Keiper T, 2005, FASEB J, V19, P2078, DOI 10.1096/fj.05-4196fje; Lamagna C, 2005, MOL BIOL CELL, V16, P4992, DOI 10.1091/mbc.E05-04-0310; Lamagna C, 2005, CANCER RES, V65, P5703, DOI 10.1158/0008-5472.CAN-04-4012; Langer HF, 2011, CANCER RES, V71, P4096, DOI 10.1158/0008-5472.CAN-10-2794; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154; Morris AP, 2006, CELL COMMUN ADHES, V13, P233, DOI 10.1080/15419060600877978; Occhi S, 2005, J NEUROSCI, V25, P9418, DOI 10.1523/JNEUROSCI.2068-05.2005; Ody C, 2007, LEUKEMIA, V21, P1285, DOI 10.1038/sj.leu.2404689; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Palmer G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2223; Parmantier E, 1999, NEURON, V23, P713, DOI 10.1016/S0896-6273(01)80030-1; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Poliak S, 2002, J CELL BIOL, V159, P361, DOI 10.1083/jcb.200207050; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; Praetor A, 2009, BLOOD, V113, P1919, DOI 10.1182/blood-2008-06-159574; Priestley JV, 2002, CAN J PHYSIOL PHARM, V80, P495, DOI 10.1139/y02-034; Quattrini A, 1996, GLIA, V17, P294, DOI 10.1002/(SICI)1098-1136(199608)17:4<294::AID-GLIA4>3.0.CO;2-#; Salzer JL, 2008, GLIA, V56, P1532, DOI 10.1002/glia.20750; Sandri C, 1977, Prog Brain Res, V46, P1; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Scheiermann C, 2007, SCIENCE, V318, P1472, DOI 10.1126/science.1149276; Scheiermann C, 2009, ARTERIOSCL THROM VAS, V29, P1509, DOI 10.1161/ATVBAHA.109.187559; Scherer SS, 1995, J NEUROSCI, V15, P8281; SCHNAPP B, 1976, NEUROSCIENCE, V1, P459, DOI 10.1016/0306-4522(76)90097-X; Shagdarsuren E, 2009, ARTERIOSCL THROM VAS, V29, P1161, DOI 10.1161/ATVBAHA.109.187898; Sherman DL, 2005, NAT REV NEUROSCI, V6, P683, DOI 10.1038/nrn1743; THOMAS PK, 1963, J ANAT, V97, P35; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vonlaufen A, 2006, J PATHOL, V209, P540, DOI 10.1002/path.2007; Weber C, 2007, NAT REV IMMUNOL, V7, P467, DOI 10.1038/nri2096; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Zimmerli C, 2009, J IMMUNOL, V182, P4728, DOI 10.4049/jimmunol.0803892	52	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1064	1076		10.1096/fj.11-196220	http://dx.doi.org/10.1096/fj.11-196220			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22090315	Green Published, hybrid			2022-12-28	WOS:000300949300011
J	Pederson, T				Pederson, Thoru			Paul Doty and the Modern Era of DNA as a Molecule	FASEB JOURNAL			English	Editorial Material									Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Cell & Dev Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Cell & Dev Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						Alberts B, 2004, NATURE, V431, P1041, DOI 10.1038/4311041a; BHORJEE JS, 1972, P NATL ACAD SCI USA, V69, P3345, DOI 10.1073/pnas.69.11.3345; Fresco J. R, 2012, ASBMB TODAY      FEB, P10; Gratzer W, 2012, CURR BIOL, V22, pR39, DOI 10.1016/j.cub.2011.12.044; Hill R. J., 1971, J MOL BIOL, V61, P442; Meselson M, 2012, SCIENCE, V335, P181, DOI 10.1126/science.1218031; Rice SA, 2012, NATURE, V481, P266, DOI 10.1038/481266a; ZUBAY G, 1959, J MOL BIOL, V1, P1, DOI 10.1016/S0022-2836(59)80002-4	8	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					967	968		10.1096/fj.12-0301ufm	http://dx.doi.org/10.1096/fj.12-0301ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22379190				2022-12-28	WOS:000300949300001
J	Zampell, JC; Yan, A; Avraham, T; Daluvoy, S; Weitman, ES; Mehrara, BJ				Zampell, Jamie C.; Yan, Alan; Avraham, Tomer; Daluvoy, Sanjay; Weitman, Evan S.; Mehrara, Babak J.			HIF-1 alpha coordinates lymphangiogenesis during wound healing and in response to inflammation	FASEB JOURNAL			English	Article						hypoxia inducible factor-1 alpha; CD4 cells; hypoxia	GROWTH FACTOR-C; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; VEGF-C; LYMPHATIC REGENERATION; INTERSTITIAL FLOW; BREAST-CANCER; EXPRESSION; HIF; SKIN; YC-1	This study aimed to investigate the mechanisms that coordinate lymphangiogenesis. Using mouse models of lymphatic regeneration and inflammatory lymphangiogenesis, we explored the hypothesis that hypoxia inducible factor-alpha (HIF-1 alpha) is a central regulator of lymphangiogenesis. We show that HIF-1 alpha inhibition by small molecule inhibitors (YC-1 and 2-methyoxyestradiol) results in delayed lymphatic repair, decreased local vascular endothelial growth factor-C (VEGF-C) expression, reduced numbers of VEGF-C+ cells, and reductions in inflammatory lymphangiogenesis. Using transgenic HIF1 alpha/luciferase mice to image HIF-1 alpha expression in real time in addition to Western blot analysis and pimonidazole staining for cellular hypoxia, we demonstrate that hypoxia stabilizes HIF-1 alpha during initial stages of wound repair (1-2 wk); whereas inflammation secondary to gradients of lymphatic fluid stasis stabilizes HIF-1 alpha thereafter (3-6 wk). In addition, we show that CD4(+) cellmediated inflammation is necessary for this response and regulates HIF-1 alpha expression by macrophages, as CD4deficient or CD4-depleted mice demonstrate 2-fold reductions in HIF-1 alpha expression as compared to wild-types. In summary, we show that HIF-1 alpha is a critical coordinator of lymphangiogenesis by regulating the expression of lymphangiogenic cytokines as part of an early response mechanism to hypoxia, inflammation, and lymphatic fluid stasis.-Zampell, J. C., Yan, A., Avraham, T., Daluvoy, S., Weitman, E. S., Mehrara, B. J. HIF-1 alpha coordinates lymphangiogenesis during wound healing and in response to inflammation. FASEB J. 26, 1027-1039 (2012). www. fasebj. org	[Mehrara, Babak J.] Mem Sloan Kettering Canc Ctr, Div Plast & Reconstruct Surg, New York, NY 10065 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Mehrara, BJ (corresponding author), Mem Sloan Kettering Canc Ctr, Div Plast & Reconstruct Surg, 1275 York Ave,Rm MRI 1005, New York, NY 10065 USA.	mehrarab@mskcc.org			U.S. National Institutes of Health (NIH) [NIH CA 009501]; Plastic Surgery Education Foundation; George Washington University; Society of Memorial Sloan; Division of Plastic Surgery, Memorial Sloan-Kettering; NIH [R24 CA83084, P30 CA08748]; NATIONAL CANCER INSTITUTE [T32CA009501, P30CA008748, R24CA083084] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Plastic Surgery Education Foundation; George Washington University; Society of Memorial Sloan; Division of Plastic Surgery, Memorial Sloan-Kettering; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a U.S. National Institutes of Health (NIH) T32 grant (NIH CA 009501; J.Z.), a Plastic Surgery Education Foundation grant (J.Z., T. A.), a George Washington University surgical research grant (S. D.), a Society of Memorial Sloan-Kettering grant (B.J.M.), and the Division of Plastic Surgery, Memorial Sloan-Kettering. Technical services provided by the Small-Animal Imaging Core Facility, supported by NIH Small-Animal Imaging Research Program (SAIRP) grant R24 CA83084 and NIH Center grant P30 CA08748, are acknowledged. J.Z. performed experiments and writing. A.Y. performed T-cell depletion and CD4-knockout experiments. T. A. participated in study design and transgenic mouse experiments. S. D. performed experiments. E. W. performed experiments and edited manuscript. B.J.M. designed research and wrote the manuscript. The authors declare no conflicts of interest.	Avraham T, 2010, AM J PATHOL, V177, P3202, DOI 10.2353/ajpath.2010.100594; Avraham T, 2009, PLAST RECONSTR SURG, V124, P438, DOI 10.1097/PRS.0b013e3181adcf4b; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; Clavin NW, 2008, AM J PHYSIOL-HEART C, V295, pH2113, DOI 10.1152/ajpheart.00879.2008; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Goldman J, 2005, CIRC RES, V96, P1193, DOI 10.1161/01.RES.0000168918.27576.78; Goldman J, 2007, AM J PHYSIOL-HEART C, V292, pH2176, DOI 10.1152/ajpheart.01011.2006; Halin C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811; Katsuta M, 2005, EXP MOL PATHOL, V78, P123, DOI 10.1016/j.yexmp.2004.11.002; Li SH, 2008, MOL CANCER THER, V7, P3729, DOI 10.1158/1535-7163.MCT-08-0074; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Petrek JA, 1998, CANCER-AM CANCER SOC, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Rosenberger Christian, 2009, V466, P161, DOI 10.1007/978-1-59745-352-3_12; Rutkowski JM, 2006, AM J PHYSIOL-HEART C, V291, pH1402, DOI 10.1152/ajpheart.00038.2006; Saaristo A, 2004, FASEB J, V18, P1707, DOI 10.1096/fj.04-1592fje; Safran M, 2006, P NATL ACAD SCI USA, V103, P105, DOI 10.1073/pnas.0509459103; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Scortegagna M, 2008, BLOOD, V111, P3343, DOI 10.1182/blood-2007-10-115758; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shin DH, 2007, CANCER LETT, V255, P107, DOI 10.1016/j.canlet.2007.03.026; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Sun HL, 2007, ONCOGENE, V26, P3941, DOI 10.1038/sj.onc.1210169; Swartz MA, 1996, AM J PHYSIOL-HEART C, V270, pH324, DOI 10.1152/ajpheart.1996.270.1.H324; Thangarajah H, 2009, P NATL ACAD SCI USA, V106, P13505, DOI 10.1073/pnas.0906670106; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zampell JC, 2011, AM J PHYSIOL-CELL PH, V300, pC1107, DOI 10.1152/ajpcell.00378.2010; Zhao Q, 2007, PANCREAS, V34, P242, DOI 10.1097/01.mpa.0000250135.95144.b6	35	55	56	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1027	1039		10.1096/fj.11-195321	http://dx.doi.org/10.1096/fj.11-195321			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22067482	Green Published			2022-12-28	WOS:000300949300008
J	Farrar, CA; Keogh, B; McCormack, W; O'Shaughnessy, A; Parker, A; Reilly, M; Sacks, SH				Farrar, Conrad A.; Keogh, Brian; McCormack, William; O'Shaughnessy, Aisling; Parker, Andrew; Reilly, Mary; Sacks, Steven H.			Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury	FASEB JOURNAL			English	Article						kidney; Toll-like receptor	TOLL-LIKE RECEPTORS; INNATE IMMUNE-RESPONSE; ACUTE REJECTION; P-SELECTIN; COMPLEMENT; ACTIVATION; KIDNEY; EXPRESSION; CELLS; C3	Toll-like receptors (TLRs) are important molecules involved in the activation of innate and subsequent development of adaptive immunity. TLRs are ligated by exogenous ligands from pathogens and by endogenous ligands released in inflammatory diseases. Activation of TLR leads to activation of NF-kappa B and release of proinflammatory cytokines, such as IL-6 and TNF-alpha. TLRs play an important role in the pathogenesis of renal diseases. Increased expression of TLRs have been associated with ischemic kidney damage, acute kidney injury, end-stage renal failure, acute renal transplant rejection, and delayed allograft function. OPN301 is a mouse anti-human TLR2 antibody that cross-reacts with mouse TLR2. We show that inhibition of TLR2 promotes graft function in an isograft model of renal transplantation. Recipient mice were treated intravenously with OPN301 before reperfusion of the transplanted kidney that had been subjected to 30 min of cold ischemia. After 5 d, the residual native kidney was removed, and renal transplant function was assessed 24 h later by measurement of blood urea nitrogen. Renal function in both saline-and isotype-treated mice was similar, with significant improvement in OPN301-treated mice (isotypetreated vs. OPN301-treated: 33.9 +/- 3.2 vs. 19.8 +/- 1.9 mu M; P<0.01). The histopathological appearance corresponded with renal functional results. In OPN301-treated recipients, renal structure was well preserved, whereas in the saline-treated group, tubular injury was severe, with marked tubular thinning, epithelial shedding, cast formation and necrosis. Inhibition of TLR2 also leads to a decrease in C3d deposition, although it is unclear whether this is due directly to TLR2 inhibition or a decrease in renal inflammation. This study shows that inhibition of TLR2 with a therapeutic agent (OPN301) provides significant protection from ischemia/reperfusion injury in amodel of kidney transplantation.-Farrar, C. A., Keogh, B., McCormack, W., O'Shaughnessy, A., Parker, A., Reilly, M., Sacks, S. H. Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J. 26, 799-807 (2012). www.fasebj.org	[Sacks, Steven H.] Kings Coll London, Sch Med Guys, Div Transplantat Immunol & Mucosal Biol, MRC Ctr Transplantat,Dept Nephrol & Transplantat, London SE1 9RT, England; [Sacks, Steven H.] Guys Hosp, St Thomas Hosp, London SE1 9RT, England; [Keogh, Brian; McCormack, William; O'Shaughnessy, Aisling; Parker, Andrew; Reilly, Mary] Trinity Coll Dublin, Inst Mol Med, Trinity Ctr Hlth Sci, St James Hosp, Dublin, Ireland	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Trinity College Dublin	Sacks, SH (corresponding author), Kings Coll London, Sch Med Guys, Div Transplantat Immunol & Mucosal Biol, MRC Ctr Transplantat,Dept Nephrol & Transplantat, London SE1 9RT, England.	steven.sacks@kcl.ac.uk		McCormack, William/0000-0003-3748-5729; Sacks, Steven/0000-0001-6361-9095	Medical Research Council Centre for Transplantation; Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre; St. Thomas' National Health Service (NHS) Foundation Trust; King's College London; King's College Hospital NHS Foundation Trust; National Institute for Health Research [NF-SI-0510-10142] Funding Source: researchfish	Medical Research Council Centre for Transplantation(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); St. Thomas' National Health Service (NHS) Foundation Trust; King's College London; King's College Hospital NHS Foundation Trust; National Institute for Health Research(National Institute for Health Research (NIHR))	The authors acknowledge the support of the Medical Research Council Centre for Transplantation and acknowledge financial support from the Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Anders HJ, 2007, CURR OPIN NEPHROL HY, V16, P177, DOI 10.1097/MNH.0b013e32803fb767; Arslan F, 2010, CIRCULATION, V121, P80, DOI 10.1161/CIRCULATIONAHA.109.880187; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; Breslin JW, 2008, SHOCK, V29, P349, DOI 10.1097/shk.0b013e3181454975; Damman J, 2011, AM J TRANSPLANT, V11, P660, DOI 10.1111/j.1600-6143.2011.03475.x; Farrar CA, 2004, AM J PATHOL, V164, P133, DOI 10.1016/S0002-9440(10)63104-5; Farrar CA, 2006, FASEB J, V20, P217, DOI 10.1096/fj.05-4747com; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Gerondakis S, 2007, IMMUNOL CELL BIOL, V85, P471, DOI 10.1038/sj.icb.7100097; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Hadley JS, 2007, SHOCK, V27, P466, DOI 10.1097/01.shk.0000245033.69977.c5; Halloran PF, 1997, TRANSPL P, V29, P79, DOI 10.1016/S0041-1345(96)00015-2; He HZ, 2002, TRANSPLANTATION, V73, P853, DOI 10.1097/00007890-200203270-00005; Hoffmann U, 2011, NEPHROL DIAL TRANSPL, V26, P1080, DOI 10.1093/ndt/gfq420; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Land Walter Gottlieb, 2006, Exp Clin Transplant, V4, P406; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; Morris PJ, 1999, LANCET, V354, P1147, DOI 10.1016/S0140-6736(99)01104-6; Pagtalunan ME, 1999, J AM SOC NEPHROL, V10, P366; Pope MR, 2010, MOL IMMUNOL, V48, P356, DOI 10.1016/j.molimm.2010.07.004; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Pulskens WP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003596; Raymond Tracy, 2007, Proc Am Thorac Soc, V4, P635, DOI 10.1513/pats.200706-067TH; Shigeoka AA, 2007, J IMMUNOL, V178, P6252, DOI 10.4049/jimmunol.178.10.6252; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; TROPPMANN C, 1995, TRANSPLANTATION, V59, P962, DOI 10.1097/00007890-199504150-00007; Wang MY, 2011, CELL MOL IMMUNOL, V8, P265, DOI 10.1038/cmi.2011.1; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636; ZHANG Z, 1995, MICROSURG, V16, P103, DOI 10.1002/micr.1920160212; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	38	61	70	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					799	807		10.1096/fj.11-195396	http://dx.doi.org/10.1096/fj.11-195396			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22042224				2022-12-28	WOS:000300485700031
J	Seifert, EL; Caron, AZ; Morin, K; Coulombe, J; He, XH; Jardine, K; Dewar-Darch, D; Boekelheide, K; Harper, ME; McBurney, MW				Seifert, Erin L.; Caron, Annabelle Z.; Morin, Katy; Coulombe, Josee; He, Xiao Hong; Jardine, Karen; Dewar-Darch, Danielle; Boekelheide, Kim; Harper, Mary-Ellen; McBurney, Michael W.			SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice	FASEB JOURNAL			English	Article						sirtuin; knock-in; metabolism	LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; SIR2-ALPHA PROTEIN; DEACETYLASE SIRT1; CELL-SURVIVAL; GENE; AUTOPHAGY; MECHANISM; NAD; RESVERATROL	The protein encoded by the sirt1 gene is an enzyme, SirT1, that couples the hydrolysis of NAD(+) to the deacetylation of acetyl-lysine residues in substrate proteins. Mutations of the sirt1 gene that fail to encode protein have been introduced into the mouse germ line, and the animals homozygous for these null mutations have various physiological abnormalities. To determine which of the characteristics of these sirt1(-/-) mice are a consequence of the absence of the catalytic activity of the SirT1 protein, we created a mouse strain carrying a point mutation (H355Y) that ablates the catalytic activity but does not affect the amount of the SirT1 protein. Mice carrying point mutations in both sirt1 genes, sirt1(Y/Y), have a phenotype that is overlapping but not identical to that of the sirt1-null animals. The sirt1(Y/Y) phenotype is significantly milder than that seen in the sirt1(-/-) animals. For example, female sirt1(Y/Y) animals are fertile, while sirt1(-/-) females are sterile. On the other hand, both sirt1(-/-) and sirt1(Y/Y) male mice are sterile and hypermetabolic. We report that sirt1(Y/Y) mice respond aberrantly to caloric restriction, although the effects are more subtle than seen in sirt1(-/-) mice. Thus, the SirT1 protein has functions that can be attributed to the catalytic activity of the protein, as well as other functions that are conferred by the protein itself.-Seifert, E. L., Caron, A. Z., Morin, K., Coulombe, J., Hong He, X., Jardine, K., Dewar-Darch, D., Boekelheide, K., Harper, M.-E., McBurney, M. W. SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice. FASEB J. 26, 555-566 (2012). www.fasebj.org	[Seifert, Erin L.; Caron, Annabelle Z.; Morin, Katy; Coulombe, Josee; He, Xiao Hong; Jardine, Karen; Dewar-Darch, Danielle; McBurney, Michael W.] Univ Ottawa, Ottawa Hosp Res Inst, Program Canc Therapeut, Ottawa, ON K1H 8L6, Canada; [Seifert, Erin L.; Caron, Annabelle Z.; Morin, Katy; Coulombe, Josee; He, Xiao Hong; Jardine, Karen; Dewar-Darch, Danielle; McBurney, Michael W.] Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada; [Morin, Katy; Harper, Mary-Ellen; McBurney, Michael W.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L6, Canada; [Boekelheide, Kim] Brown Univ, Dept Pathol & Lab Med, Sch Med, Warren Alpert Med Sch, Providence, RI 02912 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Brown University	McBurney, MW (corresponding author), Univ Ottawa, Ottawa Hosp Res Inst, Program Canc Therapeut, 501 Smyth Rd,Box 926, Ottawa, ON K1H 8L6, Canada.	mmcburney@ohri.ca		Harper, Mary-Ellen/0000-0003-3864-5886	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the Canadian Institutes of Health Research. The authors acknowledge the help of Ryan Tuen and Andrea Robinson, who worked on this project during their coop work terms; Dr. Ruth Slack and members of her laboratory, who helped establish cultures of cortical neurons; and Dr. Robert Screaton, in whose laboratory the enzyme assays were performed.	ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Avalos JL, 2004, MOL CELL, V13, P639, DOI 10.1016/S1097-2765(04)00082-6; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Ghosh HS, 2007, BIOCHEM J, V408, P105, DOI 10.1042/BJ20070817; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Huber JL, 2010, FUTURE MED CHEM, V2, P1751, DOI 10.4155/FMC.10.257; Hwang JW, 2010, ARCH BIOCHEM BIOPHYS, V500, P203, DOI 10.1016/j.abb.2010.05.013; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kolthur-Seetharam U, 2009, BIOL REPROD, V80, P384, DOI 10.1095/biolreprod.108.070193; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Liang FX, 2009, NAT REV ENDOCRINOL, V5, P367, DOI 10.1038/nrendo.2009.101; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McBurney MW, 2003, MOL CANCER RES, V1, P402; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Powell MJ, 2011, CANCER RES, V71, P964, DOI 10.1158/0008-5472.CAN-10-3172; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wu CS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002000; Zhang DY, 2009, J BIOL CHEM, V284, P20917, DOI 10.1074/jbc.M109.020073	54	47	51	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					555	566		10.1096/fj.11-193979	http://dx.doi.org/10.1096/fj.11-193979			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22006156				2022-12-28	WOS:000300485700009
J	Muthu, P; Wang, L; Yuan, CC; Kazmierczak, K; Huang, WR; Hernandez, OM; Kawai, M; Irving, TC; Szczesna-Cordary, D				Muthu, Priya; Wang, Li; Yuan, Chen-Ching; Kazmierczak, Katarzyna; Huang, Wenrui; Hernandez, Olga M.; Kawai, Masataka; Irving, Thomas C.; Szczesna-Cordary, Danuta			Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction	FASEB JOURNAL			English	Article						cross-bridge kinetics; FHC-linked ELC mutation; myofilament lattice spacing; transgenic mice	FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; N-TERMINAL EXTENSION; ACTIN-BINDING SITE; MOLECULAR MOTORS; SKELETAL-MUSCLE; CROSS-BRIDGES; SUDDEN-DEATH; HUMAN HEART; LEVER-ARM; MUTATIONS	The myosin essential light chain (ELC) is a structural component of the actomyosin cross-bridge, but its function is poorly understood, especially the role of the cardiac specific N-terminal extension in modulating actomyosin interaction. Here, we generated transgenic (Tg) mice expressing the A57G (alanine to glycine) mutation in the cardiac ELC known to cause familial hypertrophic cardiomyopathy (FHC). The function of the ELC N-terminal extension was investigated with the Tg-Delta 43 mouse model, whose myocardium expresses a truncated ELC. Low-angle X-ray diffraction studies on papillary muscle fibers in rigor revealed a decreased interfilament spacing (similar to 1.5 nm) and no alterations in cross-bridge mass distribution in Tg-A57G mice compared to Tg-WT, expressing the full-length nonmutated ELC. The truncation mutation showed a 1.3-fold increase in I(1,1)/I(1,0), indicating a shift of cross-bridge mass from the thick filament backbone toward the thin filaments. Mechanical studies demonstrated increased stiffness in Tg-A57G muscle fibers compared to Tg-WT or Tg-Delta 43. The equilibrium constant for the cross-bridge force generation step was smallest in Tg-Delta 43. These results support an important role for the N-terminal ELC extension in prepositioning the cross-bridge for optimal force production. Subtle changes in the ELC sequence were sufficient to alter cross-bridge properties and lead to pathological phenotypes.-Muthu, P., Wang, L., Yuan, C.-C., Kazmierczak, K., Huang, W., Hernandez, O. M., Kawai, M., Irving, T. C., Szczesna-Cordary, D. Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction. FASEB J. 25, 4394-4405 (2011). www.fasebj.org	[Muthu, Priya; Kazmierczak, Katarzyna; Huang, Wenrui; Hernandez, Olga M.; Szczesna-Cordary, Danuta] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Wang, Li; Kawai, Masataka] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA USA; [Yuan, Chen-Ching; Irving, Thomas C.] IIT, Ctr Synchrotron Radiat Res & Instrumentat, Chicago, IL 60616 USA; [Yuan, Chen-Ching; Irving, Thomas C.] IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	University of Miami; University of Iowa; Illinois Institute of Technology; Illinois Institute of Technology	Szczesna-Cordary, D (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6113,R-189, Miami, FL 33136 USA.	dszczesna@med.miami.edu		Kawai, Masataka/0000-0002-3219-3527	U.S. National Institutes of Health (NIH) [HL071778, HL090786, HL070041]; American Heart Association [10POST3420009]; U.S. DOE [AC02-06CH11357]; NIH [RR-08630]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008630] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778, R01HL108343, R01HL090786, R01HL070041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103622] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); U.S. DOE(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health (NIH) grants HL071778 and HL090786 (D.S.C.) and HL070041 (M.K.); and American Heart Association grant 10POST3420009 (P.M.). The authors thank Hsiao Man Hsu for help with X-ray experiments. Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under contract DE-AC02-06CH11357. BioCAT is an NIH-supported research center (RR-08630). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Center for Research Resources or the NIH.	Aydt EM, 2007, J STRUCT BIOL, V159, P158, DOI 10.1016/j.jsb.2007.04.002; Bai F, 2011, BIOPHYS J, V100, P1014, DOI 10.1016/j.bpj.2011.01.001; Colson BA, 2010, J PHYSIOL-LONDON, V588, P981, DOI 10.1113/jphysiol.2009.183897; COOKE R, 1980, BIOCHEMISTRY-US, V19, P2265, DOI 10.1021/bi00551a042; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Farman GP, 2009, J STRUCT BIOL, V168, P240, DOI 10.1016/j.jsb.2009.07.020; Fischetti R, 2004, J SYNCHROTRON RADIAT, V11, P399, DOI 10.1107/S0909049504016760; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Geeves MA, 2002, NATURE, V415, P129, DOI 10.1038/415129a; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; Huxley AF, 1998, NATURE, V396, P317, DOI 10.1038/24503; Irving T, 2001, J MUSCLE RES CELL M, V22, P675, DOI 10.1023/A:1016336024366; Irving TC, 2000, AM J PHYSIOL-HEART C, V279, pH2568, DOI 10.1152/ajpheart.2000.279.5.H2568; IRVING TC, 1989, J MUSCLE RES CELL M, V10, P385, DOI 10.1007/BF01758435; Kaski JP, 2009, CIRC-CARDIOVASC GENE, V2, P436, DOI 10.1161/CIRCGENETICS.108.821314; KAWAI M, 1991, BIOPHYS J, V59, P329, DOI 10.1016/S0006-3495(91)82227-5; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; KAWAI M, 1993, CIRC RES, V73, P35, DOI 10.1161/01.RES.73.1.35; Kazmierczak K, 2009, J MOL BIOL, V387, P706, DOI 10.1016/j.jmb.2009.02.006; Knowles AC, 2008, BIOPHYS J, V95, P3882, DOI 10.1529/biophysj.108.131508; Lee WH, 2001, AM HEART J, V141, P184, DOI 10.1067/mhj.2001.112487; Lowey S, 2007, J MOL BIOL, V371, P902, DOI 10.1016/j.jmb.2007.05.080; Lu XY, 2010, J MUSCLE RES CELL M, V31, P93, DOI 10.1007/s10974-010-9213-x; Maron Barry J, 2002, Card Electrophysiol Rev, V6, P100, DOI 10.1023/A:1017903709361; Miller MS, 2011, BIOPHYS J, V100, P1737, DOI 10.1016/j.bpj.2011.02.028; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Miyanishi T, 2002, BIOCHEMISTRY-US, V41, P5429, DOI 10.1021/bi0118355; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; Morita H, 2008, NEW ENGL J MED, V358, P1899, DOI 10.1056/NEJMoa075463; Olson TM, 2002, CIRCULATION, V105, P2337, DOI 10.1161/01.CIR.0000018444.47798.94; Pant K, 2009, FASEB J, V23, P3571, DOI 10.1096/fj.08-126672; PARKER VP, 1985, MOL CELL BIOL, V5, P3058, DOI 10.1128/MCB.5.11.3058; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Seebohm B, 2009, BIOPHYS J, V97, P806, DOI 10.1016/j.bpj.2009.05.023; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; Squire J., 1981, STRUCTURAL BASIS MUS, P543; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; Szczesna-Cordary D, 2005, J CELL SCI, V118, P3675, DOI 10.1242/jcs.02492; Timson DJ, 1999, J BIOL CHEM, V274, P18271, DOI 10.1074/jbc.274.26.18271; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; Wang Y, 2006, J MOL BIOL, V361, P286, DOI 10.1016/j.jmb.2006.06.018; WINSTANLEY MA, 1977, FEBS LETT, V77, P239, DOI 10.1016/0014-5793(77)80242-1; Zhao Y, 1996, AM J PHYSIOL-HEART C, V271, pH1394, DOI 10.1152/ajpheart.1996.271.4.H1394	48	37	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4394	4405		10.1096/fj.11-191973	http://dx.doi.org/10.1096/fj.11-191973			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885653	Green Published			2022-12-28	WOS:000298138100030
J	Pucci, L; Grazioso, G; Dallanoce, C; Rizzi, L; De Micheli, C; Clementi, F; Bertrand, S; Bertrand, D; Longhi, R; De Amici, M; Gotti, C				Pucci, Luca; Grazioso, Giovanni; Dallanoce, Clelia; Rizzi, Luca; De Micheli, Carlo; Clementi, Francesco; Bertrand, Sonia; Bertrand, Daniel; Longhi, Renato; De Amici, Marco; Gotti, Cecilia			Engineering of alpha-conotoxin MII-derived peptides with increased selectivity for native alpha 6 beta 2*nicotinic acetylcholine receptors	FASEB JOURNAL			English	Article						molecular modeling; striatum; binding assays; neurotransmitter release	NEURONAL NICOTINIC RECEPTORS; RAT STRIATAL SYNAPTOSOMES; VENTRAL TEGMENTAL AREA; 3 BETA 2; PARKINSONS-DISEASE; HIPPOCAMPAL SYNAPTOSOMES; DOPAMINERGIC TERMINALS; MOLECULAR-DYNAMICS; NACHR SUBTYPES; RELEASE	alpha 6 beta 2* Nicotinic acetylcholine receptors are expressed in selected central nervous system areas, where they are involved in striatal dopamine (DA) release and its behavioral consequences, and other still uncharacterized brain activities. alpha 6 beta 2* receptors are selectively blocked by the alpha-conotoxins MII and PIA, which bear a characteristic N-terminal amino acid tail [arginine (R), aspartic acid (D), and proline (P)]. We synthesized a group of PIA-related peptides in which R1 was mutated or the RDP motif gradually removed. Binding and striatal DA release assays of native rat alpha 6 beta 2* receptors showed that the RDP sequence, and particularly residue R1, is essential for the activity of PIA. On the basis of molecular modeling analyses, we synthesized a hybrid peptide (RDP-MII) that had increased potency (7-fold) and affinity (13-fold) for alpha 6 beta 2* receptors but not for the very similar alpha 3 beta 2* subtype. As docking studies also suggested that E11 of MII might be a key residue engendering alpha 6 beta 2* vs. alpha 3 beta 2* selectivity, we prepared MII[E11R] and RDP-MII[E11R] peptides. Their affinity and potency for native alpha 6 beta 2* receptors were similar to those of their parent analogues, whereas, for the oocyte expressed rat alpha 3 beta 2* subtype, they showed a 31- and 14-fold lower affinity and 21- and 3.5-fold lower potency. Thus, MII[E11R] and RDP-MII[E11R] are potent antagonists showing a degree of alpha 6 beta 2* vs. alpha 3 beta 2* selectivity in vivo.-Pucci, L., Grazioso, G., Dallanoce, C., Rizzi, L., De Micheli, C., Clementi, F., Bertrand, S., Bertrand, D., Longhi, R., De Amici, M., Gotti, C. Engineering of alpha-conotoxin MII-derived peptides with increased selectivity for native alpha 6 beta 2* nicotinic acetylcholine receptors. FASEB J. 25, 3775-3789 (2011). www.fasebj.org	[Pucci, Luca; Clementi, Francesco; Gotti, Cecilia] Univ Milan, CNR, Ist Neurosci, Dipartimento Farmacol Chemioterapia & Tossicol Me, I-20133 Milan, Italy; [Pucci, Luca; Clementi, Francesco; Gotti, Cecilia] Univ Milan, CNR, Ist Neurosci Farmacol Cellulare & Mol, I-20133 Milan, Italy; [Grazioso, Giovanni; Dallanoce, Clelia; Rizzi, Luca; De Micheli, Carlo] Univ Milan, Dipartimento Sci Farmaceut Pietro Pratesi, I-20133 Milan, Italy; [Bertrand, Sonia; Bertrand, Daniel] HiQScreen Sarl, Geneva, Switzerland; [Longhi, Renato; De Amici, Marco] CNR, Ist Chim Riconoscimento Mol, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Gotti, C (corresponding author), Univ Milan, CNR, Ist Neurosci, Dipartimento Farmacol Chemioterapia & Tossicol Me, Via Vanvitelli 32, I-20133 Milan, Italy.	c.gotti@in.cnr.it	Grazioso, Giovanni/AFU-7952-2022; DE MICHELI, CARLO/A-9656-2011; De Amici, Marco/F-9684-2015	Grazioso, Giovanni/0000-0002-3261-9356; DE MICHELI, CARLO/0000-0003-3549-4365; Dallanoce, Clelia/0000-0002-7383-1484; De Amici, Marco/0000-0002-0236-0662	Italian FIRB [RBNE03H5Y]; PRIN [20072BTSR2]; EC from Regione Lombardia [ID 16983]; Associazione Oasi Maria SS (Troina, Italy)	Italian FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); EC from Regione Lombardia; Associazione Oasi Maria SS (Troina, Italy)	This research was financially supported by the Italian FIRB grant RBNE03H5Y to C.D.M. and PRIN grant 20072BTSR2 to F.C. and M.D.A. An EC Neurocypres grant, TERDISMENTAL grant ID 16983 SAL-50 from Regione Lombardia to C.G., and a grant from the Associazione Oasi Maria SS (Troina, Italy) to F.C. are also gratefully acknowledged.	Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Azam L, 2008, J BIOL CHEM, V283, P11625, DOI 10.1074/jbc.M710288200; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Azam L, 2010, FASEB J, V24, P5113, DOI 10.1096/fj.10-166272; Barik J, 2006, MOL PHARMACOL, V69, P618, DOI 10.1124/mol.105.018184; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bordia T, 2007, MOL PHARMACOL, V72, P52, DOI 10.1124/mol.107.035998; Brunzell DH, 2010, NEUROPSYCHOPHARMACOL, V35, P665, DOI 10.1038/npp.2009.171; Capelli AM, 2011, BRIT J PHARMACOL, V163, P313, DOI 10.1111/j.1476-5381.2011.01213.x; Case D, 2006, AMBER 9; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; Chi SW, 2005, BIOCHEM BIOPH RES CO, V338, P1990, DOI 10.1016/j.bbrc.2005.10.176; Clarke PBS, 1996, BRIT J PHARMACOL, V117, P595, DOI 10.1111/j.1476-5381.1996.tb15232.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cox BC, 2008, J NEUROCHEM, V105, P1924, DOI 10.1111/j.1471-4159.2008.05282.x; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; David R, 2010, EUR J NEUROSCI, V31, P978, DOI 10.1111/j.1460-9568.2010.07133.x; De Biasi M, 2002, J NEUROBIOL, V53, P568, DOI 10.1002/neu.10145; Dowell C, 2003, J NEUROSCI, V23, P8445; Drenan RM, 2008, NEURON, V60, P123, DOI 10.1016/j.neuron.2008.09.009; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FORNASARI D, 1990, NEUROSCI LETT, V111, P351, DOI 10.1016/0304-3940(90)90287-J; Gotti C, 2006, CURR PHARM DESIGN, V12, P407, DOI 10.2174/138161206775474486; Gotti C, 2005, MOL PHARMACOL, V68, P1162, DOI 10.1124/mol.105.015925; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Gotti C, 2010, J NEUROSCI, V30, P5311, DOI 10.1523/JNEUROSCI.5095-09.2010; Grady SR, 2007, BIOCHEM PHARMACOL, V74, P1235, DOI 10.1016/j.bcp.2007.07.032; Grady SR, 2009, J NEUROSCI, V29, P2272, DOI 10.1523/JNEUROSCI.5121-08.2009; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Harvey SC, 1996, J NEUROSCI, V16, P3798; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hogg RC, 2008, J NEUROSCI METH, V169, P65, DOI 10.1016/j.jneumeth.2007.11.028; Janes RW, 2005, CURR OPIN PHARMACOL, V5, P280, DOI 10.1016/j.coph.2005.01.013; Jensen AA, 2005, J MED CHEM, V48, P4705, DOI 10.1021/jm040219e; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Kulak JM, 1997, J NEUROSCI, V17, P5263; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Lai A, 2005, MOL PHARMACOL, V67, P1639, DOI 10.1124/mol.104.006429; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lomazzo E, 2010, J NEUROCHEM, V115, P625, DOI 10.1111/j.1471-4159.2010.06967.x; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; Moretti M, 2004, MOL PHARMACOL, V66, P85, DOI 10.1124/mol.66.1.85; Moretti M, 2010, MOL PHARMACOL, V78, P287, DOI 10.1124/mol.110.064071; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Papke RL, 2008, NEUROPHARMACOLOGY, V54, P1189, DOI 10.1016/j.neuropharm.2008.03.010; Parker MJ, 1998, MOL PHARMACOL, V54, P1132, DOI 10.1124/mol.54.6.1132; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sidhpura N, 2007, EUR J PHARMACOL, V567, P102, DOI 10.1016/j.ejphar.2007.03.052; Turner JR, 2005, J NEUROSCI, V25, P9258, DOI 10.1523/JNEUROSCI.2112-05.2005; Turner M, 2009, BIOORGAN MED CHEM, V17, P5894, DOI 10.1016/j.bmc.2009.07.005; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Whiteaker P, 2002, J NEUROSCI, V22, P2522, DOI 10.1523/JNEUROSCI.22-07-02522.2002; Xiao YX, 2004, J PHARMACOL EXP THER, V310, P98, DOI 10.1124/jpet.104.066787; Yang KC, 2009, ACTA PHARMACOL SIN, V30, P740, DOI 10.1038/aps.2009.63; Zoli M, 2002, J NEUROSCI, V22, P8785	66	32	34	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3775	3789		10.1096/fj.10-179853	http://dx.doi.org/10.1096/fj.10-179853			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21778325				2022-12-28	WOS:000296723100004
J	Edin, ML; Wang, ZJ; Bradbury, JA; Graves, JP; Lih, FB; DeGraff, LM; Foley, JF; Torphy, R; Ronnekleiv, OK; Tomer, KB; Lee, CR; Zeldin, DC				Edin, Matthew L.; Wang, ZhongJing; Bradbury, J. Alyce; Graves, Joan P.; Lih, Fred B.; DeGraff, Laura M.; Foley, Julie F.; Torphy, Robert; Ronnekleiv, Oline K.; Tomer, Kenneth B.; Lee, Craig R.; Zeldin, Darryl C.			Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart	FASEB JOURNAL			English	Article						CYP2J2; EETs; reactive oxygen species; leukotoxin; Langendorff	SOLUBLE EPOXIDE HYDROLASE; EPOXYEICOSATRIENOIC ACIDS; ARACHIDONIC-ACID; LINOLEIC-ACID; MYOCARDIAL-INFARCTION; POSTISCHEMIC RECOVERY; ATHEROSCLEROSIS RISK; CONTRACTILE FUNCTION; GENETIC-VARIATION; DISEASE RISK	Cytochrome P450 (CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosatrienoic acids (EETs) from arachidonic acid. Mice with expression of CYP2J2 in cardiomyocytes (alpha MHC-CYP2J2 Tr) or treated with synthetic EETs have increased functional recovery after ischemia/reperfusion (I/R); however, no studies have examined the role of cardiomyocyte-vs. endothelial-derived EETs or compared the effects of different CYP epoxygenase isoforms in the ischemic heart. We generated transgenic mice with increased endothelial EET biosynthesis (Tie2-CYP2C8 Tr and Tie2-CYP2J2 Tr) or EET hydrolysis (Tie2-sEH Tr). Compared to wild-type (WT), alpha MHC-CYP2J2 Tr hearts showed increased recovery of left ventricular developed pressure (LVDP) and decreased infarct size after I/R. In contrast, LVDP recovery and infarct size were unchanged in Tie2-CYP2J2 Tr and Tie2-sEH Tr hearts. Surprisingly, compared to WT, Tie2-CYP2C8 Tr hearts had significantly reduced LVDP recovery (from 21 to 14%) and increased infarct size after I/R (from 51 to 61%). Tie2-CYP2C8 Tr hearts also exhibited increased reactive oxygen species (ROS) generation, dihydroxyoctadecenoic acid (DiHOME) formation, and coronary resistance after I/R. ROS scavengers and CYP2C8 inhibition reversed the detrimental effects of CYP2C8 expression in Tie2-CYP2C8 Tr hearts. Treatment of WT hearts with 250 nM 9,10-DiHOME decreased LVDP recovery compared to vehicle (16 vs. 31%, respectively) and increased coronary resistance after I/R. These data demonstrate that increased ROS generation and enhanced DiHOME synthesis by endothelial CYP2C8 impair functional recovery and mask the beneficial effects of increased EET production following I/R.-Edin, M. L., Wang, Z. J., Bradbury, J. A., Graves, J. P., Lih, F. B., DeGraff, L. M., Foley, J. F., Torphy, R., Ronnekleiv, O. K., Tomer, K. B., Lee, C. R., Zeldin, D. C. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J. 25, 3436-3447 (2011). www.fasebj.org	[Edin, Matthew L.; Wang, ZhongJing; Bradbury, J. Alyce; Graves, Joan P.; Lih, Fred B.; DeGraff, Laura M.; Foley, Julie F.; Torphy, Robert; Tomer, Kenneth B.; Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; [Ronnekleiv, Oline K.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA; [Ronnekleiv, Oline K.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA; [Lee, Craig R.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Oregon Health & Science University; Oregon Health & Science University; University of North Carolina; University of North Carolina Chapel Hill	Zeldin, DC (corresponding author), 111 TW Alexander Dr,Bldg 101,Rm A222, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Edin, Matthew/AAI-1934-2019; Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Lee, Craig/0000-0003-3595-5301; Edin, Matthew/0000-0002-7042-500X; Torphy, Robert J/0000-0003-3941-0886	NIH, NIEHS [Z01 ES050167, Z01 ES025034, R01 GM088199]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIGES102505, ZIAES050167, ZIAES025034] Funding Source: NIH RePORTER	NIH, NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr. Bruce Hammock (University of California, Davis, CA, USA) for providing the sEH antibody, Dr. Joyce Goldstein [U.S. National Institutes of Health (NIH)/National Institute for Environmental Health Sciences (NIEHS), Research Triangle Park, NC, USA] for providing the CYP2C8 antibody, and Dr. Tom Sato (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing the Tie2 promoter construct. The authors also thank staff at Xenogen Biosciences (Cranberry, NJ, USA) for assistance with pronuclear injections and staff in the NIEHS Laboratory of Experimental Pathology (Natasha Clayton and Tiwanda Masinde) for assistance with immunohistochemistry. This work was supported with funds from the Intramural Research Program of the NIH, NIEHS, to K.B.T. (Z01 ES050167), D.C.Z. (Z01 ES025034), and C.R.L. (R01 GM088199).	Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chaudhary KR, 2010, J CARDIOVASC PHARM, V55, P67, DOI 10.1097/FJC.0b013e3181c37d69; Chaudhary KR, 2009, CARDIOVASC RES, V83, P362, DOI 10.1093/cvr/cvp134; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JY, 1999, MOL PHARMACOL, V55, P288, DOI 10.1124/mol.55.2.288; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; Deng YM, 2011, FASEB J, V25, P703, DOI 10.1096/fj.10-171488; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; FUKUSHIMA A, 1988, CARDIOVASC RES, V22, P213, DOI 10.1093/cvr/22.3.213; Granville DJ, 2004, P NATL ACAD SCI USA, V101, P1321, DOI 10.1073/pnas.0308185100; Greene JF, 2000, CHEM RES TOXICOL, V13, P217, DOI 10.1021/tx990162c; Gross GJ, 2010, AM J PHYSIOL-HEART C, V298, pH2201, DOI 10.1152/ajpheart.00815.2009; Gross GJ, 2009, CURR OPIN INVEST DR, V10, P253; Gustafsson AB, 2008, CARDIOVASC RES, V77, P334, DOI 10.1093/cvr/cvm005; HANAKI Y, 1991, JPN J MED, V30, P224; Hunter AL, 2005, VASC PHARMACOL, V43, P213, DOI 10.1016/j.vph.2005.07.005; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Katragadda D, 2009, J MOL CELL CARDIOL, V46, P867, DOI 10.1016/j.yjmcc.2009.02.028; King LM, 2002, MOL PHARMACOL, V61, P840, DOI 10.1124/mol.61.4.840; King Lorraine M, 2005, Pharmacogenet Genomics, V15, P7, DOI 10.1097/01213011-200501000-00002; Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8; KONKEL A, BIOCH BIOPHYS ACTA, V1814, P210; KOSAKA K, 1994, MOL CELL BIOCHEM, V139, P141, DOI 10.1007/BF01081737; Kusmic C, 2006, AM J PHYSIOL-HEART C, V291, pH1814, DOI 10.1152/ajpheart.00220.2006; Lee CR, 2006, HUM MOL GENET, V15, P1640, DOI 10.1093/hmg/ddl085; Lee CR, 2007, PHARMACOGENET GENOM, V17, P349, DOI 10.1097/FPC.0b013e32809913ea; Lee CR, 2010, FASEB J, V24, P3770, DOI 10.1096/fj.10-160119; Li PL, 1997, CIRC RES, V80, P877; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Marciante KD, 2008, PHARMACOGENET GENOM, V18, P535, DOI 10.1097/FPC.0b013e3282fd1287; Michaelis UR, 2005, J CELL SCI, V118, P5489, DOI 10.1242/jcs.02674; Mitchell Lex A, 2002, Cardiovasc Toxicol, V2, P219; Mobert J, 1997, J CARDIOVASC PHARM, V29, P789, DOI 10.1097/00005344-199706000-00012; Moran JH, 1997, TOXICOL APPL PHARM, V146, P53, DOI 10.1006/taap.1997.8197; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; Nithipatikom K, 2006, AM J PHYSIOL-HEART C, V291, pH537, DOI 10.1152/ajpheart.00071.2006; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Seubert J, 2004, CIRC RES, V95, P506, DOI 10.1161/01.RES.0000139436.89654.c8; Seubert JM, 2007, PROSTAG OTH LIPID M, V82, P50, DOI 10.1016/j.prostaglandins.2006.05.017; Seubert JM, 2006, CIRC RES, V99, P442, DOI 10.1161/01.RES.0000237390.92932.37; SIEGFRIED MR, 1990, LIFE SCI, V46, P427, DOI 10.1016/0024-3205(90)90086-7; Spector AA, 2007, AM J PHYSIOL-CELL PH, V292, pC996, DOI 10.1152/ajpcell.00402.2006; Spiecker M, 2004, CIRCULATION, V110, P2132, DOI 10.1161/01.CIR.0000143832.91812.60; SUGIYAMA S, 1987, LIFE SCI, V40, P225, DOI 10.1016/0024-3205(87)90336-5; Theken KN, 2007, PHARMACOGENOMICS, V8, P1369, DOI 10.2217/14622416.8.10.1369; Viswanathan S, 2003, J AM COLL NUTR, V22, P502, DOI 10.1080/07315724.2003.10719328; Wang Y, 2005, J PHARMACOL EXP THER, V314, P522, DOI 10.1124/jpet.105.083477; Wen X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/dmd.30.6.631; Wong PYK, 1997, J LIPID MEDIAT CELL, V16, P155, DOI 10.1016/S0929-7855(97)00005-9; Yang BC, 2001, MOL PHARMACOL, V60, P310, DOI 10.1124/mol.60.2.310; Yasar U, 2003, PHARMACOGENETICS, V13, P715, DOI [10.1097/00008571-200312000-00002, 10.1097/01.fpc.0000054141.14659.28]; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438	56	94	98	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3436	3447		10.1096/fj.11-188300	http://dx.doi.org/10.1096/fj.11-188300			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21697548	Green Published			2022-12-28	WOS:000295356400015
J	Vincents, B; Guentsch, A; Kostolowska, D; von Pawel-Rammingen, U; Eick, S; Potempa, J; Abrahamson, M				Vincents, Bjarne; Guentsch, Arndt; Kostolowska, Dominika; von Pawel-Rammingen, Ulrich; Eick, Sigrun; Potempa, Jan; Abrahamson, Magnus			Cleavage of IgG(1) and IgG(3) by gingipain K from Porphyromonas gingivalis may compromise host defense in progressive periodontitis	FASEB JOURNAL			English	Article						cysteine proteases; cysteine peptidases; host-pathogen interactions; enzyme kinetics; immunoglobulin G; native substrates	STEADY-STATE KINETICS; CYSTEINE PROTEINASES; BACTERIAL PROTEINASES; CREVICULAR FLUID; IMMUNOGLOBULIN-G; VIRULENCE FACTORS; CYSTATIN C; INACTIVATION; DEGRADATION; RESPONSES	Degradation of immunoglobulins is an effective strategy of bacteria to evade the immune system. We have tested whether human IgG is a substrate for gingipain K of Porphyromonas gingivalis and found that the enzyme can hydrolyze subclass 1 and 3 of human IgG. The heavy chain of IgG(1) was cleaved at a single site within the hinge region, generating Fab and Fc fragments. IgG(3) was also cleaved within the heavy chain, but at several sites around the CH2 region. Investigation of the enzyme kinetics of IgG proteolysis by gingipain K, using FPLC- and isothermal titration calorimetry-based assays followed by Hill plots, revealed non-Michaelis-Menten kinetics involving a mechanism of positive cooperativity. In ex vivo studies, it was shown that gingipain K retained its IgG hydrolyzing activity in human plasma despite the high content of natural protease inhibitors; that IgG(1) cleavage products were detected in gingival crevicular fluid samples from patients with severe periodontitis; and that gingipain K treatment of serum samples from patients with high antibody titers against P. gingivalis significantly hindered opsonin-dependent phagocytosis of clinical isolates of P. gingivalis by neutrophils. Altogether, these findings underline a biological function of gingipain K as an IgG protease of pathophysiological importance.-Vincents, B., Guentsch, A., Kostolowska, D., von Pawel-Rammingen, U., Eick, S., Potempa, J., Abrahamson, M. Cleavage of IgG(1) and IgG(3) by gingipain K from Porphyromonas gingivalis may compromise host defense in progressive periodontitis. FASEB J. 25, 3741-3750 (2011). www.fasebj.org	[Vincents, Bjarne; Abrahamson, Magnus] Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem & Pharmacol, SE-22185 Lund, Sweden; [Guentsch, Arndt] Univ Hosp Jena, Dept Conservat Dent, Jena, Germany; [Kostolowska, Dominika; Potempa, Jan] Jagiellonian Univ, Dept Microbiol, Fac Biochem Biophys & Biotechnol, Krakow, Poland; [von Pawel-Rammingen, Ulrich] Umea Univ, Dept Mol Biol, Umea, Sweden; [Eick, Sigrun] Univ Bern, Dept Periodontol, Lab Oral Microbiol, Bern, Switzerland; [Potempa, Jan] Univ Louisville, Sch Dent, Ctr Oral Hlth & System Dis, Louisville, KY 40202 USA	Lund University; Skane University Hospital; Friedrich Schiller University of Jena; Jagiellonian University; Umea University; University of Bern; University of Louisville	Abrahamson, M (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem & Pharmacol, SE-22185 Lund, Sweden.	jspote01@louisville.edu; magnus.abrahamson@med.lu.se	Abrahamson, Magnus/CAG-9507-2022; Potempa, Jan/AAA-6850-2021; Guentsch, Arndt/N-4427-2015; Guentsch, Arndt/AAE-9389-2020	Guentsch, Arndt/0000-0001-8989-1441; Guentsch, Arndt/0000-0001-8989-1441; Potempa, Jan/0000-0002-3600-7461	Foundation for Polish Science [DPS/424-329/10]; Ministry of Science and Higher Education (Warsaw, Poland) [1642/B/P01/2008/35]; European Commission [FP7-HEALTH-2010-261460]; U.S. National Institutes of Health [DE 09761]; Swedish Research Council [14800, 14767, 09915]; Commission of the European Communities; Crafoord and A. Osterberg foundations; Royal Physiographic Society (Lund, Sweden); Faculty of Medicine at Lund University; European Union [POIG.02.01.00-12-064/08]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER	Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); Ministry of Science and Higher Education (Warsaw, Poland)(Ministry of Science and Higher Education, Poland); European Commission(European CommissionEuropean Commission Joint Research Centre); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); Commission of the European Communities(European Commission); Crafoord and A. Osterberg foundations; Royal Physiographic Society (Lund, Sweden); Faculty of Medicine at Lund University; European Union(European Commission); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors are grateful to Dr. Peter Westh (Roskilde University, Roskilde, Denmark) for use of his ITC equipment and helpful comments. J.P. acknowledges support from Foundation for Polish Science (TEAM project DPS/424-329/10). This study was partially supported by funding from the Ministry of Science and Higher Education (Warsaw, Poland; 1642/B/P01/2008/35), the European Commission (FP7-HEALTH-2010-261460; Gums and Joints), and the U.S. National Institutes of Health (DE 09761), and by grants from the Swedish Research Council (14800, 14767, and 09915), the Commission of the European Communities, the Crafoord and A. Osterberg foundations; the Royal Physiographic Society (Lund, Sweden), the Faculty of Medicine at Lund University, and Insamlingsstiftelsen at Umea University. The Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University is a beneficiary of structural funds from the European Union (POIG.02.01.00-12-064/08; Molecular Biotechnology for Health).	Abrahamson M, 1997, J CLIN PATHOL-MOL PA, V50, P291, DOI 10.1136/mp.50.6.291; Ashimoto A, 1996, ORAL MICROBIOL IMMUN, V11, P266, DOI 10.1111/j.1399-302X.1996.tb00180.x; CORNISHBOWDEN A, 1987, BIOCHEM EDUC, V15, P144, DOI 10.1016/0307-4412(87)90048-3; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; Curtis MA, 2002, INFECT IMMUN, V70, P6968, DOI 10.1128/IAI.70.12.6968-6975.2002; Dias IHK, 2008, INFECT IMMUN, V76, P317, DOI 10.1128/IAI.00618-07; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; Eley BM, 2003, PERIODONTOL 2000, V31, P105, DOI 10.1034/j.1600-0757.2003.03107.x; Ermert D, 2009, J INNATE IMMUN, V1, P181, DOI 10.1159/000205281; FRENCH M, 1986, MONOGR ALLERGY, V19, P100; Gibson FC, 2005, J PERIODONTOL, V76, P1629, DOI 10.1902/jop.2005.76.10.1629; Guentsch A, 2009, J PERIODONTAL RES, V44, P368, DOI 10.1111/j.1600-0765.2008.01113.x; Guentsch A, 2011, J PERIODONTOL, V82, P1051, DOI 10.1902/jop.2011.100565; Guo YH, 2010, PERIODONTOL 2000, V54, P15, DOI 10.1111/j.1600-0757.2010.00377.x; Imamura T, 2003, CURR PROTEIN PEPT SC, V4, P443, DOI 10.2174/1389203033487027; Inagaki S, 2003, J PERIODONTOL, V74, P1432, DOI 10.1902/jop.2003.74.10.1432; Inomata M, 2009, J PERIODONTOL, V80, P1511, DOI 10.1902/jop.2009.090114; Janeway C., 1994, IMMUNOBIOLOGY IMMUNE; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Katz J, 2002, INFECT IMMUN, V70, P2512, DOI 10.1128/IAI.70.5.2512-2518.2002; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; Kinane DF, 1999, CLIN EXP IMMUNOL, V115, P534; Lamster IB, 2007, ANN NY ACAD SCI, V1098, P216, DOI 10.1196/annals.1384.027; Lefranc M. P., 2009, NUCLEIC ACIDS RES, V32, pD160; Mahtout H, 2009, ORAL MICROBIOL IMMUN, V24, P396, DOI 10.1111/j.1399-302X.2009.00532.x; Medina E, 2009, J INNATE IMMUN, V1, P176, DOI 10.1159/000203699; Mezyk-Kopec R, 2005, INFECT IMMUN, V73, P1506, DOI 10.1128/IAI.73.3.1506-1514.2005; Mikolajczyk-Pawlinska J, 1998, FEBS LETT, V440, P282, DOI 10.1016/S0014-5793(98)01461-6; NILSSON T, 1985, INFECT IMMUN, V50, P467, DOI 10.1128/IAI.50.2.467-471.1985; O'Brien-Simpson NM, 2000, INFECT IMMUN, V68, P2704, DOI 10.1128/IAI.68.5.2704-2712.2000; Oleksy A, 2002, MICROB PATHOGENESIS, V32, P173, DOI 10.1006/mpat.2002.0491; PIKE R, 1994, J BIOL CHEM, V269, P406; Potempa J, 1997, BIOL CHEM, V378, P223, DOI 10.1515/bchm.1997.378.3-4.223; Potempa J, 1998, J BIOL CHEM, V273, P21648, DOI 10.1074/jbc.273.34.21648; Potempa J, 2003, CURR PROTEIN PEPT SC, V4, P397, DOI 10.2174/1389203033487036; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Potempa J, 2009, J INNATE IMMUN, V1, P70, DOI 10.1159/000181144; Puklo M, 2008, ORAL MICROBIOL IMMUN, V23, P328, DOI 10.1111/j.1399-302X.2008.00433.x; Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segel I.H., 1975, ENZYME KINETICS; Sheets SA, 2005, INFECT IMMUN, V73, P1543, DOI 10.1128/IAI.73.3.1543-1552.2005; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; Takeuchi Y, 2006, ORAL MICROBIOL IMMUN, V21, P314, DOI 10.1111/j.1399-302X.2006.00296.x; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; Toh ECY, 2011, ANTIMICROB AGENTS CH, V55, P1155, DOI 10.1128/AAC.00466-10; Travis J, 2000, BBA-PROTEIN STRUCT M, V1477, P35, DOI 10.1016/S0167-4838(99)00278-2; Vincents B, 2004, BIOCHEMISTRY-US, V43, P15540, DOI 10.1021/bi048284d; Vincents B, 2008, CHEM BIOL, V15, P960, DOI 10.1016/j.chembiol.2008.07.021; VLUG A, 1994, ANN BIOL CLIN-PARIS, V52, P561; von Pawel-Rammingen U, 2003, CURR OPIN MICROBIOL, V6, P50, DOI 10.1016/S1369-5274(03)00003-1; von Pawel-Rammingen U, 2002, EMBO J, V21, P1607, DOI 10.1093/emboj/21.7.1607; Willemoes M, 2002, EUR J BIOCHEM, V269, P4772, DOI 10.1046/j.1432-1033.2002.03175.x; WILTON JMA, 1993, ARCH ORAL BIOL, V38, P55, DOI 10.1016/0003-9969(93)90155-F; Yasuhara R, 2009, BIOCHEM J, V419, P159, DOI 10.1042/BJ20081469	55	40	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3741	3750		10.1096/fj.11-187799	http://dx.doi.org/10.1096/fj.11-187799			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21768393	Green Published			2022-12-28	WOS:000295356400042
J	Watson, MJ; Worthington, EN; Clunes, LA; Rasmussen, JE; Jones, L; Tarran, R				Watson, Michael J.; Worthington, Erin N.; Clunes, Lucy A.; Rasmussen, Julia E.; Jones, Lisa; Tarran, Robert			Defective adenosine-stimulated cAMP production in cystic fibrosis airway epithelia: a novel role for CFTR in cell signaling	FASEB JOURNAL			English	Article						chloride; ion channel; G protein-coupled receptor; 2nd messenger	TRANSMEMBRANE CONDUCTANCE REGULATOR; PLASMA-MEMBRANE; 2B RECEPTOR; TRAFFICKING; EXPRESSION; SECRETION; COMPLEXES; DOMAIN; LUNGS	Adenosine (ADO) is an extracellular signaling molecule that is an important regulator of innate lung defense. On binding ADO, the A2B receptor (A2BR) stimulates cAMP production to activate the CFTR Cl- channel, increase ciliary beating, and initiate cytokine secretion. We tested the hypothesis that CFTR served as a positive regulator of the A2BRs. We found that A2BR and CFTR coimmunoprecipitated. They also underwent ADO-dependent Forster resonance energy transfer (FRET), which increased from 5% in the absence of agonist to 18% with 100 mu M ADO (EC50 1.7 mu M), suggesting that they dynamically associate in the plasma membrane. In contrast, despite colocalization, no FRET was observed between CFTR and GAP43. The interaction between A2BR and CFTR had some specificity: A2BR-stimulated but not forskolin-stimulated cAMP production was similar to 50% greater in the presence of CFTR, due to a CFTR-dependent increase in plasma membrane A2BR levels. These CFTR-dependent increases in A2BR levels and cAMP production resulted in significantly enhanced ciliary beating and increased cytokine secretion in normal compared to cystic fibrosis airway epithelia. Thus, we hypothesize that CFTR regulates A2BR levels in the plasma membrane to modulate cell signaling and to enhance selective components of the innate lung defense system.-Watson, M. J., Worthington, E. N., Clunes, L. A., Rasmussen, J. E., Jones, L., Tarran, R. Defective adenosine-stimulated cAMP production in cystic fibrosis airway epithelia: a novel role for CFTR in cell signaling. FASEB J. 25, 2996-3003 (2011). www.fasebj.org	[Watson, Michael J.; Worthington, Erin N.; Clunes, Lucy A.; Rasmussen, Julia E.; Jones, Lisa; Tarran, Robert] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Tarran, R (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, 7125 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	tarran@med.unc.edu		Watson, Michael/0000-0002-3715-3153	U.S. National Institutes of Health [P50HL084934, R01HL74158-3, P30DK34987]; British American Tobacco; Cystic Fibrosis Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084934, R01HL074158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); British American Tobacco; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Claire Brown (McGill University, Montreal, QC, Canada) for the GAP43 construct and Drs. Tamas Hegudus, Martina Gentzsch and Jack Riordan [University of North Carolina (UNC)-Chapel Hill] for providing the CFTRcfp construct and the BHK cell lines. The authors also thank Drs. Eduardo Lazarowski and Jack Stutts for critical reading of this manuscript. The help of the UNC Immunotechnology Core and the UNC CF Center Molecular and Tissue Culture Cores is gratefully acknowledged. This study was supported by U.S. National Institutes of Health grants P50HL084934, R01HL74158-3, and P30DK34987, by British American Tobacco, and by the Cystic Fibrosis Foundation.	ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Antonioli L, 2008, PHARMACOL THERAPEUT, V120, P233, DOI 10.1016/j.pharmthera.2008.08.010; Berdiev BK, 2007, J BIOL CHEM, V282, P36481, DOI 10.1074/jbc.M708089200; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRUNTON LL, 2003, SCI STKE, pPE44; Bucheimer RE, 2004, J PHYSIOL-LONDON, V555, P311, DOI 10.1113/jphysiol.2003.056697; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Carnpodonico VL, 2008, TRENDS MOL MED, V14, P120, DOI 10.1016/j.molmed.2008.01.002; Chmiel JF, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-8; CHOLON DM, AM J PHYSL LUNG CELL, V298, pL304; Cobb BR, 2002, AM J PHYSIOL-LUNG C, V282, pL12, DOI 10.1152/ajplung.2002.282.1.L12; Com Gulnur, 2009, Handb Exp Pharmacol, P363, DOI 10.1007/978-3-540-89615-9_12; Cooper DMF, 2006, TRENDS PHARMACOL SCI, V27, P426, DOI 10.1016/j.tips.2006.06.002; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gentzsch M, 2007, J CELL SCI, V120, P447, DOI 10.1242/jcs.03350; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Guggino William B, 2004, Proc Am Thorac Soc, V1, P28, DOI 10.1513/pats.2306011; Haggie PM, 2006, MOL BIOL CELL, V17, P4937, DOI 10.1091/mbc.E06-08-0670; Haggie PM, 2004, J BIOL CHEM, V279, P5494, DOI 10.1074/jbc.M312445200; Harris A, 1993, Semin Cell Biol, V4, P37, DOI 10.1006/scel.1993.1005; Ho K, 1998, CURR OPIN NEPHROL HY, V7, P49, DOI 10.1097/00041552-199801000-00009; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Li CY, 2007, CELL, V131, P940, DOI 10.1016/j.cell.2007.09.037; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Nichols D, 2008, CLIN REV ALLERG IMMU, V34, P146, DOI 10.1007/s12016-007-8039-9; Penmatsa H, 2010, MOL BIOL CELL, V21, P1097, DOI 10.1091/mbc.E09-08-0655; Quinton PM, 2008, LANCET, V372, P415, DOI 10.1016/S0140-6736(08)61162-9; Rollins BM, 2008, AM J RESP CELL MOL, V39, P190, DOI 10.1165/rcmb.2007-0450OC; Sheridan JT, 2011, J BIOL CHEM, V286, P1381, DOI 10.1074/jbc.M110.174847; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sitaraman SV, 2000, AM J PHYSIOL-CELL PH, V278, pC1230, DOI 10.1152/ajpcell.2000.278.6.C1230; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Sun Y, 2008, J IMMUNOL, V180, P4173, DOI 10.4049/jimmunol.180.6.4173; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; Thelin WR, 2007, J CLIN INVEST, V117, P364, DOI 10.1172/JCI30376; Turnbull EL, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S11; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Wang LX, 2004, AM J PHYSIOL-GASTR L, V287, pG1100, DOI 10.1152/ajpgi.00164.2004	44	19	19	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2996	3003		10.1096/fj.11-186080	http://dx.doi.org/10.1096/fj.11-186080			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21628448	Green Published			2022-12-28	WOS:000294435200015
J	Perez-Tilve, D; Heppner, K; Kirchner, H; Lockie, SH; Woods, SC; Smiley, DL; Tschop, M; Pfluger, P				Perez-Tilve, Diego; Heppner, Kristy; Kirchner, Henriette; Lockie, Sarah H.; Woods, Stephen C.; Smiley, David L.; Tschoep, Matthias; Pfluger, Paul			Ghrelin-induced adiposity is independent of orexigenic effects	FASEB JOURNAL			English	Article						brain; metabolism; melanocortin	LIPID-METABOLISM; SKELETAL-MUSCLE; INDUCED OBESITY; NEUROPEPTIDE-Y; ENERGY-BALANCE; OLDER-ADULTS; RATS; NEURONS; BRAIN; SECRETAGOGUE	Ghrelin is a hormone produced predominantly by the stomach that targets a number of specific areas in the central nervous system to promote a positive energy balance by increasing food intake and energy storage. In that respect, similarities exist with the effects of consuming a high-fat diet (HFD), which also increases caloric intake and the amount of stored calories. We determined whether the effects of ghrelin on feeding and adiposity are influenced by the exposure to an HFD. Chronic intracerebroventricular ghrelin (2.5 nmol/d) increased feeding in lean rats fed a low-fat control diet (CD) [192 +/- 5 g (ghrelin + CD) vs. 152 +/- 5 g (control i.c.v. saline + CD), P < 0.001], but the combination of ghrelin plus HFD did not result in significantly greater hyperphagia [150 +/- 7 g (ghrelin + HFD) vs. 136 +/- 4 g (saline + HFD)]. Despite failing to increase food intake in rats fed the HFD, ghrelin nonetheless increased adiposity [fat mass increase of 14 +/- 2 g (ghrelin + HFD) vs. 1 +/- 1 g (saline + HFD), P < 0.001] up-regulating the gene expression of lipogenic enzymes in white adipose tissue. Our findings demonstrate that factors associated with high-fat feeding functionally interact with pathways regulating the effect of ghrelin on food intake. We conclude that ghrelin's central effects on nutrient intake and nutrient partitioning can be separated and suggest an opportunity to identify respective independent neuronal pathways.-Perez-Tilve, D., Heppner, K., Kirchner, H., Lockie, S. H., Woods, S. C., Smiley, D. L., Tschop, M., and Pfluger, P. Ghrelin-induced adiposity is independent of orexigenic effects. FASEB J. 25, 2814-2822 (2011). www.fasebj.org	[Perez-Tilve, Diego; Heppner, Kristy; Kirchner, Henriette; Tschoep, Matthias; Pfluger, Paul] Univ Cincinnati, Dept Internal Med, Metab Dis Inst, Cincinnati, OH 45237 USA; [Woods, Stephen C.] Univ Cincinnati, Dept Psychiat, Metab Dis Inst, Cincinnati, OH 45237 USA; [Lockie, Sarah H.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Smiley, David L.] Indiana Univ, Dept Chem, Bloomington, IN USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Monash University; Indiana University System; Indiana University Bloomington	Perez-Tilve, D (corresponding author), Univ Cincinnati, Dept Internal Med, Metab Dis Inst, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	pereztdo@ucmail.uc.edu	Lockie, Sarah/M-1415-2019; Pfluger, Paul T/A-3770-2019; Tschoep, Matthias H/I-5443-2014	Pfluger, Paul T/0000-0002-8118-7588; Perez-Tilve, Diego/0000-0002-0351-4133; Tschoep, Matthias/0000-0002-4744-371X; Lockie, Sarah/0000-0002-3833-4714	U.S. National Institutes of Health [DK077975]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017844, R01DK077975] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the U.S. National Institutes of Health (DK077975).	Barazzoni R, 2005, AM J PHYSIOL-ENDOC M, V288, pE228, DOI 10.1152/ajpendo.00115.2004; Bouret SG, 2008, CELL METAB, V7, P179, DOI 10.1016/j.cmet.2007.12.001; Briggs DI, 2010, ENDOCRINOLOGY, V151, P4745, DOI 10.1210/en.2010-0556; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; Clegg DJ, 2003, DIABETES, V52, P682, DOI 10.2337/diabetes.52.3.682; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Davies JS, 2009, MOL ENDOCRINOL, V23, P914, DOI 10.1210/me.2008-0432; Egecioglu E, 2010, ADDICT BIOL, V15, P304, DOI 10.1111/j.1369-1600.2010.00216.x; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Faulconbridge LF, 2005, DIABETES, V54, P1985, DOI 10.2337/diabetes.54.7.1985; Gardiner JV, 2010, GASTROENTEROLOGY, V138, P2468, DOI 10.1053/j.gastro.2010.02.012; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Iwakura H, 2007, AM J PHYSIOL-ENDOC M, V293, pE819, DOI 10.1152/ajpendo.00681.2006; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lall S, 2001, BIOCHEM BIOPH RES CO, V280, P132, DOI 10.1006/bbrc.2000.4065; Nass R, 2008, ANN INTERN MED, V149, P601, DOI 10.7326/0003-4819-149-9-200811040-00003; Nogueiras R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JCI31743; Perreault M, 2004, INT J OBESITY, V28, P879, DOI 10.1038/sj.ijo.0802640; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rosenbaum M, 2005, J CLIN INVEST, V115, P3579, DOI 10.1172/JCI25977; Sangiao-Alvarellos S, 2009, ENDOCRINOLOGY, V150, P4562, DOI 10.1210/en.2009-0482; Shimbara T, 2004, NEUROSCI LETT, V369, P75, DOI 10.1016/j.neulet.2004.07.060; Strassburg S, 2008, AM J PHYSIOL-ENDOC M, V295, pE78, DOI 10.1152/ajpendo.00040.2008; Svensson J, 1998, J CLIN ENDOCR METAB, V83, P362, DOI 10.1210/jc.83.2.362; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Tong QC, 2008, NAT NEUROSCI, V11, P998, DOI 10.1038/nn.2167; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Untergasser A, 2007, NUCLEIC ACIDS RES, V35, pW71, DOI 10.1093/nar/gkm306; van den Top M, 2004, NAT NEUROSCI, V7, P493, DOI 10.1038/nn1226; White HK, 2009, J CLIN ENDOCR METAB, V94, P1198, DOI 10.1210/jc.2008-0632; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823	33	83	84	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2814	2822		10.1096/fj.11-183632	http://dx.doi.org/10.1096/fj.11-183632			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21543764	Green Published			2022-12-28	WOS:000293337800029
J	Piedfer, M; Dauzonne, D; Tang, RP; N'Guyen, J; Billard, C; Bauvois, B				Piedfer, Marion; Dauzonne, Daniel; Tang, Ruoping; N'Guyen, Juliette; Billard, Christian; Bauvois, Brigitte			Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells	FASEB JOURNAL			English	Article						AML; APN; antibody; inhibitor; Bcl-2 family	P38 MAP KINASE; N CD13; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LEUKEMIC-CELLS; KAPPA-B; APOPTOSIS; INHIBITION; PATHWAYS; SURVIVAL	The transmembrane metalloprotease aminopeptidase-N (APN)/CD13 is overexpressed in various solid and hematological malignancies in humans, including acute myeloid leukemia (AML) and is thought to influence tumor progression. Here, we investigated the contribution of APN/CD13 to the regulation of growth and survival processes in AML cells in vitro. Anti-CD13 monoclonal antibodies MY7 and SJ1D1 (which do not inhibit APN activity) and WM15 (an APN-blocking antibody) inhibited the growth of the AML cell line U937 and induced apoptosis, as evidenced by cell accumulation in the sub-G(1) phase, DNA fragmentation, and phosphatidylserine externalization. Isotype-matched IgG1 and the APN/CD13 enzymatic inhibitors bestatin and 2',3-dinitroflavone-8-acetic acid, were ineffective. Internalization of CD13-MY7 complex into cells was followed by mitochondrial membrane depolarization, Bcl-2 and Mcl-1 down-regulation, Bax up-regulation, caspase-9, caspase-8, and caspase-3 activation, and cleavage of the caspase substrate PARP-1. The broad-spectrum caspase inhibitor Z-VAD-fmk and the caspase-9- and caspase-8-specific inhibitors significantly attenuated apoptosis. CD13 ligation also induced apoptosis and PARP-1 cleavage in primary AML blasts, whereas normal blood cells were not affected. Overall, these data provide new evidence that CD13 can serve as a target for inducing caspase-dependent apoptosis in AML (independently of its APN activity). These findings may have implications for tumor biology and treatment.-Piedfer, M., Dauzonne, D., Tang, R., N'Guyen, J., Billard, C., Bauvois, B. Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 25, 2831-2842 (2011). www.fasebj.org	[Piedfer, Marion; Billard, Christian; Bauvois, Brigitte] INSERM, Ctr Rech Cordeliers, U872, F-75270 Paris 06, France; [Piedfer, Marion; Billard, Christian; Bauvois, Brigitte] Univ Paris 06, UMRS 872, Paris, France; [Piedfer, Marion; Billard, Christian; Bauvois, Brigitte] Univ Paris 05, UMRS 872, Paris, France; [Dauzonne, Daniel] Inst Curie, CNRS 176, Paris, France; [Tang, Ruoping] Hop St Antoine, Dept Hematol, F-75571 Paris, France; [N'Guyen, Juliette] Hop Cochin, Dept Malad Infect, F-75674 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), INSERM, Ctr Rech Cordeliers, U872, 15 Rue Ecole Med, F-75270 Paris 06, France.	brigitte.bauvois@crc.jussieu.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922	Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer; Ligue contre le Cancer (Comite de Paris)	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue contre le Cancer (Comite de Paris)(Ligue nationale contre le cancer)	This work was funded by grants from the Institut National de la Sante et de la Recherche Medicale, the Association pour la Recherche sur le Cancer, and the Ligue contre le Cancer (Comite de Paris). The authors thank Fanny Fava for technical assistance. The authors declare no conflicting financial interests.	Afonina IS, 2010, IMMUNOL REV, V235, P105, DOI 10.1111/j.0105-2896.2010.00908.x; ASHMUN RA, 1990, BLOOD, V75, P462; Bauvois B, 2006, MED RES REV, V26, P88, DOI 10.1002/med.20044; Bauvois B, 2003, J MED CHEM, V46, P3900, DOI 10.1021/jm021109f; Bauvois B, 1996, EXP CELL RES, V222, P209, DOI 10.1006/excr.1996.0026; Bauvois B, 2000, ONCOGENE, V19, P265, DOI 10.1038/sj.onc.1203292; Bernardi P., 2007, V45, P481; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; BRELJAK D, 2003, HAEMA, V6, P453; Bremer E, 2006, TRENDS MOL MED, V12, P382, DOI 10.1016/j.molmed.2006.06.002; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Bulat N, 2009, BRAIN RES BULL, V80, P251, DOI 10.1016/j.brainresbull.2009.07.007; Chowdhury I, 2008, COMP BIOCHEM PHYS B, V151, P10, DOI 10.1016/j.cbpb.2008.05.010; Cowburn AS, 2006, J BIOL CHEM, V281, P12458, DOI 10.1074/jbc.M511277200; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FAVALORO EJ, 1988, BRIT J HAEMATOL, V69, P163, DOI 10.1111/j.1365-2141.1988.tb07618.x; FAVALORO EJ, 1991, IMMUNOL CELL BIOL, V69, P253, DOI 10.1038/icb.1991.36; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gredmark S, 2004, J IMMUNOL, V173, P4897, DOI 10.4049/jimmunol.173.8.4897; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; INO K, 1994, JPN J CANCER RES, V85, P927, DOI 10.1111/j.1349-7006.1994.tb02970.x; King ME, 2007, ONCOLOGIST, V12, P14, DOI 10.1634/theoncologist.12-S2-14; Lai A, 2010, MOL CELL BIOCHEM, V343, P191, DOI 10.1007/s11010-010-0513-7; Lendeckel U, 2000, ADV EXP MED BIOL, V477, P1; Lohn M, 1997, ADV EXP MED BIOL, V421, P85; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Martelli AM, 2007, EUR J HISTOCHEM, V51, P125; Mason KD, 2006, BLOOD REV, V20, P71, DOI 10.1016/j.blre.2005.08.002; Mina-Osorio P, 2005, J LEUKOCYTE BIOL, V77, P1008, DOI 10.1189/jlb.1204714; Mina-Osorio P, 2008, TRENDS MOL MED, V14, P361, DOI 10.1016/j.molmed.2008.06.003; Mina-Osorio P, 2008, J LEUKOCYTE BIOL, V84, P448, DOI 10.1189/jlb.1107802; Mina-Osorio P, 2006, J LEUKOCYTE BIOL, V79, P719, DOI 10.1189/jlb.0705425; Nguyen J, 2006, IMMUNOL LETT, V106, P34, DOI 10.1016/j.imlet.2006.04.003; Park C, 2008, TOXICOL APPL PHARM, V227, P219, DOI 10.1016/j.taap.2007.10.003; Pasqualini R, 2000, CANCER RES, V60, P722; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Plesa C, 2008, CANCER-AM CANCER SOC, V112, P572, DOI 10.1002/cncr.23219; Quiney C, 2006, LEUKEMIA, V20, P491, DOI 10.1038/sj.leu.2404098; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Santos AN, 2000, CELL IMMUNOL, V201, P22, DOI 10.1006/cimm.2000.1629; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Song G, 2010, CURR CANCER DRUG TAR, V10, P584, DOI 10.2174/156800910791859515; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wickstrom M, 2011, CANCER SCI, V102, P501, DOI 10.1111/j.1349-7006.2010.01826.x; Xie J, 2005, EXP HEMATOL, V33, P564, DOI 10.1016/j.exphem.2005.03.001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	59	40	45	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2831	2842		10.1096/fj.11-181396	http://dx.doi.org/10.1096/fj.11-181396			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21566207	Green Published			2022-12-28	WOS:000293337800031
J	Davis, PM				Davis, Philip M.			Open access, readership, citations: a randomized controlled trial of scientific journal publishing	FASEB JOURNAL			English	Article						bibliometric analysis; science communication	USAGE STATISTICS; DOWNLOADS; SCIENCE; WEB	Does free access to journal articles result in greater diffusion of scientific knowledge? Using a randomized controlled trial of open access publishing, involving 36 participating journals in the sciences, social sciences, and humanities, we report on the effects of free access on article downloads and citations. Articles placed in the open access condition (n = 712) received significantly more downloads and reached a broader audience within the first year, yet were cited no more frequently, nor earlier, than subscription-access control articles (n = 2533) within 3 yr. These results may be explained by social stratification, a process that concentrates scientific authors at a small number of elite research universities with excellent access to the scientific literature. The real beneficiaries of open access publishing may not be the research community but communities of practice that consume, but rarely contribute to, the corpus of literature.-Davis, P. M. Open access, readership, citations: a randomized controlled trial of scientific journal publishing. FASEB J. 25, 2129-2134 (2011). www.fasebj.org	Cornell Univ, Dept Commun, Ithaca, NY 14853 USA	Cornell University	Davis, PM (corresponding author), Cornell Univ, Dept Commun, Ithaca, NY 14853 USA.	pmd8@cornell.edu	Davis, Philip M/A-5693-2009	Davis, Philip M/0000-0002-1893-5360	Andrew W. Mellon Foundation, Scholarly Communications and Information Technology Section; Cornell University	Andrew W. Mellon Foundation, Scholarly Communications and Information Technology Section; Cornell University	This study was funded by the Andrew W. Mellon Foundation, Scholarly Communications and Information Technology Section. The author thanks the following at Cornell University for support and mentorship: Bruce Lewenstein, Tarleton Gillespie, Jeremy Birnholtz, and Dan Simon (faculty advisors); Matthew Connolly (programmer); and James Booth (statistician), The study would not have been possible without the participation from the American Association for the Advancement of Science (AAAS), the American Heart Association (AHA), the American Physiological Society (APS), Duke University Press, the Federation of American Societies for Experimental Biology (FASEB), the Genetics Society of America (GSA), Sage Publications, and High-Wire Press.	Archambault E, 2009, J AM SOC INF SCI TEC, V60, P1320, DOI 10.1002/asi.21062; Biagioli M, 2003, SCI AUTHORSHIP CREDI; Bjork BC, 2009, INFORM RES, V14; BROADUS RN, 1983, J AM SOC INFORM SCI, V34, P132, DOI 10.1002/asi.4630340206; Brody T, 2006, J AM SOC INF SCI TEC, V57, P1060, DOI 10.1002/asi.20373; Cole J. R., 1973, SOCIAL STRATIFICATIO; Craig ID, 2007, J INFORMETR, V1, P239, DOI 10.1016/j.joi.2007.04.001; Crane D., 1972, INVISIBLE COLL DIFFU; Cronin B., 1995, SCHOLARS COURTESY RO; Davis PM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a568; Davis PM, 2007, SCIENTOMETRICS, V71, P203, DOI 10.1007/s11192-007-1661 -8; Davis PM, 2006, J AM SOC INF SCI TEC, V57, P1243, DOI 10.1002/asi.20405; Davis Philip M, 2010, Physiologist, V53, P200; DAVIS PM, 2011, J MED LIBR IN PRESS, V99; Evans JA, 2009, SCIENCE, V323, P1025, DOI 10.1126/science.1154562; EYSENBACH G, 2008, BMJ; Eysenbach G, 2006, PLOS BIOL, V4, P692, DOI 10.1371/journal.pbio.0040157; Franck G, 1999, SCIENCE, V286, P53, DOI 10.1126/science.286.5437.53; GARFIELD E, 1955, SCIENCE, V122, P108, DOI 10.1126/science.122.3159.108; Gaule P, 2009, J AM SOC INF SCI TEC, V60, P2548, DOI 10.1002/asi.21195; Hagstrom W., 1965, SCI COMMUNITY; HOWARD J, 2010, CHRON HIGHER ED 0613; *ISI, 2004, IMP OP ACC J CIT STU; Kurtz MJ, 2005, INFORM PROCESS MANAG, V41, P1395, DOI 10.1016/j.ipm.2005.03.010; MCCABE MJ, 2011, DID ONLINE ACCESS J; Moed HF, 2005, J AM SOC INF SCI TEC, V56, P1088, DOI 10.1002/asi.20200; NIH (Natl. Inst. Health), 2008, REV POL ENH PUBL ACC; Perneger TV, 2004, BRIT MED J, V329, P546, DOI 10.1136/bmj.329.7465.546; PRICE DJD, 1965, SCIENCE, V149, P510; RICHARDSON M, 2001, NAT WEB DEBATES; Simkin MV, 2007, J AM SOC INF SCI TEC, V58, P1661, DOI 10.1002/asi.20653; WAGNER AB, 2010, ISSUES SCI TECH LIBR, V60; Wren JD, 2005, BRIT MED J, V330, P1128, DOI 10.1136/bmj.38422.611736.E0; PUBGET SEARCH ENGINE	35	151	156	2	84	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2129	2134		10.1096/fj.11-183988	http://dx.doi.org/10.1096/fj.11-183988			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21450907				2022-12-28	WOS:000292242200005
J	Banfi, A; von Degenfeld, G; Gianni-Barrera, R; Reginato, S; Merchant, MJ; McDonald, DM; Blau, HM				Banfi, Andrea; von Degenfeld, Georges; Gianni-Barrera, Roberto; Reginato, Silvia; Merchant, Milton J.; McDonald, Donald M.; Blau, Helen M.			Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB	FASEB JOURNAL			English	Article						ischemia; gene therapy; adenoviral vectors	FUNCTIONAL VESSEL GROWTH; GENE-THERAPY; PERICYTE COVERAGE; FLOW-CYTOMETRY; BLOOD-FLOW; PURIFICATION; VASCULATURE; RECRUITMENT; COMBINATION; DETERMINES	Therapeutic angiogenesis by delivery of vascular growth factors is an attractive strategy for treating debilitating occlusive vascular diseases, yet clinical trials have thus far failed to show efficacy. As a result, limb amputation remains a common outcome for muscle ischemia due to severe atherosclerotic disease, with an overall incidence of 100 per million people in the United States per year. A challenge has been that the angiogenic master regulator vascular endothelial growth factor (VEGF) induces dysfunctional vessels, if expressed outside of a narrow dosage window. We tested the hypothesis that codelivery of platelet-derived growth factor-BB (PDGF-BB), which recruits pericytes, could induce normal angiogenesis in skeletal muscle irrespective of VEGF levels. Coexpression of VEGF and PDGF-BB encoded by separate vectors in different cells or in the same cells only partially corrected aberrant angiogenesis. In marked contrast, coexpression of both factors in every cell at a fixed relative level via a single bicistronic vector led to robust, uniformly normal angiogenesis, even when VEGF expression was high and heterogeneous. Notably, in an ischemic hindlimb model, single-vector expression led to efficient growth of collateral arteries, revascularization, increased blood flow, and reduced tissue damage. Furthermore, these results were confirmed in a clinically applicable gene therapy approach by adenoviral-mediated delivery of the bicistronic vector. We conclude that coordinated expression of VEGF and PDGF-BB via a single vector constitutes a novel strategy for harnessing the potency of VEGF to induce safe and efficacious angiogenesis.-Banfi, A., von Degenfeld, G., Gianni-Barrera, R., Reginato, S., Merchant, M. J., McDonald, D. M., Blau, H. M. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J. 26, 2486-2497 (2012). www.fasebj.org	[Blau, Helen M.] Stanford Univ, Baxter Lab Stem Cell Biol, Inst Regenerat Med & Stem Cell Biol, Dept Microbiol & Immunol,Sch Med, Stanford, CA 94305 USA; [Banfi, Andrea; Gianni-Barrera, Roberto; Reginato, Silvia] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Banfi, Andrea; Gianni-Barrera, Roberto; Reginato, Silvia] Univ Basel Hosp, Dept Surg, CH-4031 Basel, Switzerland; [McDonald, Donald M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [McDonald, Donald M.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [McDonald, Donald M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Stanford University; University of Basel; University of Basel; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Blau, HM (corresponding author), Stanford Univ, Baxter Lab Stem Cell Biol, Inst Regenerat Med & Stem Cell Biol, Dept Microbiol & Immunol,Sch Med, CCSR 4216,269 Campus Dr, Stanford, CA 94305 USA.	abanfi@uhbs.ch; hblau@stanford.edu	Gianni-Barrera, Roberto/ACU-4280-2022; Banfi, Andrea/B-8720-2008	Gianni-Barrera, Roberto/0000-0001-6303-4513; Banfi, Andrea/0000-0001-5737-8811	American Heart Association [043031]; Swiss National Science Foundation [310030-127426]; EU [CP-IP 214402]; Deutsche-Forschungsgemeinschaft [DE 740/1-1]; U.S. National Institutes of Health (NIH) [HL-24136, HL-59157, CA-082923]; NIH [AG-009521, HL-065572, AG-020961, AG-024987]; Baxter Foundation; NATIONAL CANCER INSTITUTE [R01CA082923] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096113, P01HL024136, R01HL059157, R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521, R01AG024987, R01AG020961] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EU(European Commission); Deutsche-Forschungsgemeinschaft(German Research Foundation (DFG)); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baxter Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank N. Di Maggio (Basel University Hospital, Basel, Switzerland) for critical comments on the manuscript, P. Lindblom (Karolinska Institute, Stockholm, Sweden) for the hPDGFb cDNA, and L. T. Williams (University of California, San Francisco, CA, USA) for the sPDGFR-beta cDNA. This work was supported by an American Heart Association Scientist Development grant (043031), a Swiss National Science Foundation grant (310030-127426), and the EU FP7 grant ANGIOSCAFF (CP-IP 214402) to A. B.; by a Deutsche-Forschungsgemeinschaft grant (DE 740/1-1) to G. V. D.; by U.S. National Institutes of Health (NIH) grants HL-24136, HL-59157 and CA-082923 to D. M. M.; and by NIH grants AG-009521, HL-065572, AG-020961, and AG-024987 and support from the Baxter Foundation to H. M. B. The authors declare no conflicts of interest.	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Bamberg F, 2012, INVEST RADIOL, V47, P71, DOI 10.1097/RLI.0b013e31823fd42b; Banfi Andrea, 2005, Curr Atheroscler Rep, V7, P227, DOI 10.1007/s11883-005-0011-7; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Drake CJ, 1999, J HISTOCHEM CYTOCHEM, V47, P1351, DOI 10.1177/002215549904701101; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424; Gueret V, 2002, CYTOTECHNOLOGY, V38, P87, DOI 10.1023/A:1021106116887; Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386; Karvinen H, 2010, CURR OPIN PHARMACOL, V10, P208, DOI 10.1016/j.coph.2010.01.004; Korpisalo P, 2008, CIRC RES, V103, P1092, DOI 10.1161/CIRCRESAHA.108.182287; Korpisalo P, 2010, INTEGR BIOL-UK, V2, P102, DOI 10.1039/b921869f; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Misteli H, 2010, STEM CELLS, V28, P611, DOI 10.1002/stem.291; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Pries AR, 2010, NAT REV CANCER, V10, P587, DOI 10.1038/nrc2895; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rissanen TT, 2005, CIRCULATION, V112, P3937, DOI 10.1161/CIRCULATIONAHA.105.543124; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; von Degenfeld G, 2006, FASEB J, V20, P2657, DOI 10.1096/fj.06-6568fje; Yla-Herttuala S, 2004, TRENDS CARDIOVAS MED, V14, P295, DOI 10.1016/j.tcm.2004.09.001; Yla-Herttuala S, 2007, J AM COLL CARDIOL, V49, P1015, DOI 10.1016/j.jacc.2006.09.053	32	67	71	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2486	2497		10.1096/fj.11-197400	http://dx.doi.org/10.1096/fj.11-197400			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22391130	Green Published			2022-12-28	WOS:000305017200025
J	Tzenaki, N; Andreou, M; Stratigi, K; Vergetaki, A; Makrigiannakis, A; Vanhaesebroeck, B; Papakonstanti, EA				Tzenaki, Niki; Andreou, Margarita; Stratigi, Kalliopi; Vergetaki, Aikaterini; Makrigiannakis, Antonis; Vanhaesebroeck, Bart; Papakonstanti, Evangelia A.			High levels of p110 delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110 delta inhibitors through PTEN activation	FASEB JOURNAL			English	Article						breast; prostate	GENETIC ALTERATIONS; PATHWAY; PIK3CA; CANCER; MUTATIONS; SUBUNIT; PHOSPHORYLATION; TRANSFORMATION; STABILITY; ONCOGENE	Class IA PI3K isoforms have divergent, nonredundant cell biological roles. In untransformed cells and tissues, p110 alpha and p110 beta are ubiquitously expressed, whereas p110 delta expression is highly enriched in leukocytes. High levels of p110 delta expression have been documented in some solid tumor cell lines, but the functional role is unknown. This study aimed to elucidate the link between elevated expression of p110 delta PI3K and cancer. We report that in breast and prostate cancer cells that contain leukocyte levels of p110 delta, p110 delta activity dampens the activity of the PTEN tumor suppressor. Indeed, inactivation of p110 delta in these cells led to PTEN activation, suppression of Akt phosphorylation, and inhibition of cell proliferation, with inhibition of PTEN activity being able to counterbalance p110 delta inactivation. Likewise, forced overexpression of p110 delta in cells with low p110 delta expression reduced PTEN activity, resulting in increased Akt phosphorylation. Our data indicate that the oncogenic potential of p110 delta PI3K overexpression might at least partially act through PTEN inactivation, and that p110 delta-selective PI3K inhibitors can have a dual antitumor mechanism, namely by directly inhibiting p110 delta signaling and by a broader inhibition of class I PI3K activity through PTEN activation. These data may have important implications in the intervention of breast cancer.-Tzenaki, N., Andreou, M., Stratigi, K., Vergetaki, A., Makrigiannakis, A., Vanhaesebroeck, B., Papakonstanti, E. A. High levels of p110 delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110 delta inhibitors through PTEN activation. FASEB J. 26, 2498-2508 (2012). www.fasebj.org	[Tzenaki, Niki; Andreou, Margarita; Stratigi, Kalliopi; Papakonstanti, Evangelia A.] Univ Crete, Dept Biochem, Sch Med, GR-71110 Iraklion, Greece; [Vergetaki, Aikaterini; Makrigiannakis, Antonis] Univ Crete, Dept Obstet & Gynecol, Sch Med, GR-71110 Iraklion, Greece; [Vanhaesebroeck, Bart] Univ London, Ctr Cell Signalling, Barts Canc Inst, London, England	University of Crete; University of Crete; University of London; Queen Mary University London	Papakonstanti, EA (corresponding author), Univ Crete, Dept Biochem, Sch Med, GR-71110 Iraklion, Greece.	epapak@med.uoc.gr		Makrigiannakis, Antonis/0000-0002-8475-1500; Papakonstanti, Evangelia/0000-0002-7119-6026	Research Committee of University of Crete [KA 2564, KA 2999, KA 3506, KA 3001]; Cancer Research UK [C23338/A10200]; European Reintegration grant [MERG-CT-2006-044916]	Research Committee of University of Crete; Cancer Research UK(Cancer Research UK); European Reintegration grant	The authors thank Christian Rommel, Thomas Ruckle, and Montserrat Camps (Merck, Geneva, Switzerland) as well as Kevan Shokat (University of California, San Francisco, CA, USA) for pharmacological agents. The authors are also grateful to Jozsef Konya (University of Debrecen, Debrecen, Hungary) for cervical cancer cell lines, Ines Koch (Charite University Hospital, Berlin, Germany) for ovarian cancer cell lines, Antonio Bilancio and Ciro Abbondanza (II Universita' di Napoli, Naples, Italy) for the ZR-75 cell line, El-Nasir Lalani and Hanna Romanska (University of Birmingham, Birmingham, UK) for prostate cancer cell lines, Nicholas Pavlidis (Medical School, University of Ioannina, Ioannina, Greece) for the human cancer tissues, Tim Fenton (Ludwig Institute for Cancer Research, University of California, San Diego, CA, USA) for pBabe-puro p110 delta construct and Gemma Nock (Centre for Cell Signaling, Barts Cancer Institute, Queen Mary, University of London) for transfection experiments. N.T. is supported by the Research Committee of the University of Crete (KA 2999). This work was supported by the European Reintegration grant (MERG-CT-2006-044916) awarded to E. A. P. and by the Research Committee of the University of Crete (KA 2564, KA 2999, KA 3506, and KA 3001). Part of this work was supported by Cancer Research UK (C23338/A10200).	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Chagpar RB, 2010, P NATL ACAD SCI USA, V107, P5471, DOI 10.1073/pnas.0908899107; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145; Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Rabinovsky R, 2009, MOL CELL BIOL, V29, P5377, DOI 10.1128/MCB.01649-08; Robertson D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-13; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanchez T, 2005, P NATL ACAD SCI USA, V102, P4312, DOI 10.1073/pnas.0409784102; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sawyer C, 2003, CANCER RES, V63, P1667; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Whitehead MA, 2012, BIOCHEM J, V443, P857, DOI 10.1042/BJ20112214; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660; Zhang XX, 2011, MOL CELL, V41, P567, DOI 10.1016/j.molcel.2011.01.026	40	33	34	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2498	2508		10.1096/fj.11-198192	http://dx.doi.org/10.1096/fj.11-198192			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22391131				2022-12-28	WOS:000305017200026
J	Wann, AKT; Zuo, N; Haycraft, CJ; Jensen, CG; Poole, CA; McGlashan, SR; Knight, MM				Wann, Angus K. T.; Zuo, Ning; Haycraft, Courtney J.; Jensen, Cynthia G.; Poole, C. Anthony; McGlashan, Susan R.; Knight, Martin M.			Primary cilia mediate mechanotransduction through control of ATP-induced Ca2+ signaling in compressed chondrocytes	FASEB JOURNAL			English	Article						cartilage; extracellular matrix; polycystin-1; polycystin-2; purine receptors	POLYCYSTIC KIDNEY-DISEASE; ARTICULAR CHONDROCYTES; DYNAMIC COMPRESSION; INTRACELLULAR CA2+; MDCK CELLS; AGAROSE CONSTRUCTS; COLLECTING DUCT; CARTILAGE; MICE; GENE	We investigated the role of the chondrocyte primary cilium in mechanotransduction events related to cartilage extracellular matrix synthesis. We generated conditionally immortalized wild-type (WT) and IFT88(orpk) (ORPK) mutant chondrocytes that lack primary cilia and assessed intracellular Ca2+ signaling, extracellular matrix synthesis, and ATP release in response to physiologically relevant compressive strains in a 3-dimensional chondrocyte culture system. All conditions were compared to unloaded controls. We found that cilia were required for compression-induced Ca2+ signaling mediated by ATP release, and an associated up-regulation of aggrecan mRNA and sulfated glycosaminosglycan secretion. However, chondrocyte cilia were not the initial mechanoreceptors, since both WT and ORPK cells showed mechanically induced ATP release. Rather, we found that primary cilia were required for downstream ATP reception, since ORPK cells did not elicit a Ca2+ response to exogenous ATP even though WT and ORPK cells express similar levels of purine receptors. We suggest that purinergic Ca2+ signaling may be regulated by polycystin-1, since ORPK cells only expressed the C-terminal tail. This is the first study to demonstrate that primary cilia are essential organelles for cartilage mechanotransduction, as well as identifying a novel role for primary cilia not previously reported in any other cell type, namely cilia-mediated control of ATP reception.-Wann, A. K. T., Zuo, N., Haycraft, C. J., Jensen, C. G., Poole, C. A., McGlashan, S. R., Knight, M. M. Primary cilia mediate mechanotransduction through control of ATP-induced Ca2+ signaling in compressed chondrocytes. FASEB J. 26, 1663-1671 (2012). www.fasebj.org	[Zuo, Ning; Jensen, Cynthia G.; McGlashan, Susan R.] Univ Auckland, Dept Anat Radiol, Auckland 1023, New Zealand; [Wann, Angus K. T.; Knight, Martin M.] Queen Mary Univ London, Sch Engn & Mat Sci, London, England; [Haycraft, Courtney J.] Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA; [Poole, C. Anthony] Univ Otago, Dept Med, Dunedin Sch Med, Otago, New Zealand	University of Auckland; University of London; Queen Mary University London; Medical University of South Carolina; University of Otago	McGlashan, SR (corresponding author), Univ Auckland, Dept Anat Radiol, Private Bag 92019, Auckland 1023, New Zealand.	s.mcglashan@auckland.ac.nz		Knight, Martin/0000-0003-3755-1597; McGlashan, Susan/0000-0002-8666-2456	Wellcome Trust; Royal Society of New Zealand; Marsden Fast Start grant; Arthritis New Zealand; Auckland Medical Research Foundation; U.S. National Institutes of Health, National Center for Research Resources (NIH/NCRR) [5P20RR017696]; EPSRC [EP/E046975/1] Funding Source: UKRI; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038] Funding Source: NIH RePORTER; Engineering and Physical Sciences Research Council [EP/E046975/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Royal Society of New Zealand(Royal Society of New Zealand); Marsden Fast Start grant(Royal Society of New ZealandMarsden Fund (NZ)); Arthritis New Zealand; Auckland Medical Research Foundation; U.S. National Institutes of Health, National Center for Research Resources (NIH/NCRR); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by a Wellcome Trust project grant (A. W. and N.Z.). Additional support was provided by a Royal Society of New Zealand Marsden Fast Start grant, Arthritis New Zealand, and the Auckland Medical Research Foundation (N.Z., S.R.M., and C.A.P.), and by the U.S. National Institutes of Health, National Center for Research Resources (NIH/NCRR 5P20RR017696; C.J.H.). The authors are grateful to Devina Jethwa (Queen Mary University of London, London, UK) for support in analyzing ATP-induced calcium transients.	Buckwalter JA, 2006, BIORHEOLOGY, V43, P603; Chapin HC, 2010, MOL BIOL CELL, V21, P4338, DOI 10.1091/mbc.E10-05-0407; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Chowdhury TT, 2006, J CELL PHYSIOL, V209, P845, DOI 10.1002/jcp.20768; Chowdhury TT, 2006, BIORHEOLOGY, V43, P413; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Egorova AD, 2011, CIRC RES, V108, P1093, DOI 10.1161/CIRCRESAHA.110.231860; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Garcia M, 2010, J ORTHOP RES, V28, P510, DOI 10.1002/jor.21025; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; GUILAK F, 1995, J ORTHOP RES, V13, P410, DOI 10.1002/jor.1100130315; Hooper KM, 2005, AM J PHYSIOL-RENAL, V289, pF521, DOI 10.1152/ajprenal.00355.2004; Hovater MB, 2008, PURINERG SIGNAL, V4, P155, DOI 10.1007/s11302-007-9072-0; Iomini C, 2004, J CELL BIOL, V164, P811, DOI 10.1083/jcb.200312133; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jensen CG, 2004, CELL BIOL INT, V28, P101, DOI 10.1016/j.cellbi.2003.11.007; Kaushik AP, 2009, J ORTHOP RES, V27, P1093, DOI 10.1002/jor.20855; Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469-7580.2008.01021.x; Knight MM, 1998, BBA-MOL CELL RES, V1405, P67, DOI 10.1016/S0167-4889(98)00102-5; Koolpe M, 1997, J ORTHOP RES, V15, P204, DOI 10.1002/jor.1100150208; Lee DA, 1997, J ORTHOP RES, V15, P181, DOI 10.1002/jor.1100150205; Lee DA, 1995, IN VITRO CELL DEV-AN, V31, P828; Liu W, 2005, AM J PHYSIOL-RENAL, V289, pF978, DOI 10.1152/ajprenal.00260.2004; Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104; Masyuk AI, 2006, GASTROENTEROLOGY, V131, P911, DOI 10.1053/j.gastro.2006.07.003; Mauck RL, 2002, ANN BIOMED ENG, V30, P1046, DOI 10.1114/1.1512676; McGlashan SR, 2007, MATRIX BIOL, V26, P234, DOI 10.1016/j.matbio.2006.12.003; McGlashan SR, 2006, J HISTOCHEM CYTOCHEM, V54, P1005, DOI 10.1369/jhc.5A6866.2006; McGlashan SR, 2010, CELL BIOL INT, V34, P441, DOI 10.1042/CBI20090094; Millward-Sadler SJ, 2004, BIORHEOLOGY, V41, P567; MOSKALEWSKI S, 1975, EXP CELL RES, V95, P440, DOI 10.1016/0014-4827(75)90569-8; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111; Palmer GD, 2001, OSTEOARTHR CARTILAGE, V9, P761, DOI 10.1053/joca.2001.0473; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pedersen LB, 2008, DEV DYNAM, V237, P1993, DOI 10.1002/dvdy.21521; Pingguan-Murphy B, 2006, J CELL PHYSIOL, V209, P389, DOI 10.1002/jcp.20747; Pingguan-Murphy B, 2005, ARCH BIOCHEM BIOPHYS, V444, P45, DOI 10.1016/j.abb.2005.09.015; Poole CA, 1997, CELL BIOL INT, V21, P483, DOI 10.1006/cbir.1997.0177; Poole CA, 2001, J ANAT, V199, P393, DOI 10.1046/j.1469-7580.2001.19940393.x; POOLE CA, 1985, CELL MOTIL CYTOSKEL, V5, P175, DOI 10.1002/cm.970050302; Praetorius HA, 2009, ACTA PHYSIOL, V197, P241, DOI 10.1111/j.1748-1716.2009.02002.x; Praetorius HA, 2009, PURINERG SIGNAL, V5, P433, DOI 10.1007/s11302-009-9146-2; Roberts SR, 2001, J APPL PHYSIOL, V90, P1385, DOI 10.1152/jappl.2001.90.4.1385; Satir P, 2007, ANNU REV PHYSIOL, V69, P377, DOI 10.1146/annurev.physiol.69.040705.141236; Sharma N, 2011, MOL BIOL CELL, V22, P806, DOI 10.1091/mbc.E10-03-0269; Song B, 2007, DEV BIOL, V305, P202, DOI 10.1016/j.ydbio.2007.02.003; URBAN JPG, 1994, BRIT J RHEUMATOL, V33, P901; Wang SX, 2007, MOL CELL BIOL, V27, P3241, DOI 10.1128/MCB.00072-07; Weber KH, 2008, AM J PHYSIOL-RENAL, V294, pF1279, DOI 10.1152/ajprenal.00348.2007; Wheatley DN, 2000, BIOL CELL, V92, P573, DOI 10.1016/S0248-4900(00)01108-4; Wildman SS, 2003, AM J PHYSIOL-RENAL, V285, pF1168, DOI 10.1152/ajprenal.00171.2003; Woodward O. M., 2011, PLOS ONE, V5; Yoder BK, 1997, AM J PATHOL, V150, P2231; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001; Zhang QH, 2003, DEV DYNAM, V227, P78, DOI 10.1002/dvdy.10289	59	123	124	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1663	1671		10.1096/fj.11-193649	http://dx.doi.org/10.1096/fj.11-193649			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223751	Green Published			2022-12-28	WOS:000302359700027
J	Franco, HL; Rubel, CA; Large, MJ; Wetendorf, M; Fernandez-Valdivia, R; Jeong, JW; Spencer, TE; Behringer, RR; Lydon, JP; DeMayo, FJ				Franco, Heather L.; Rubel, Cory A.; Large, Michael J.; Wetendorf, Margeaux; Fernandez-Valdivia, Rodrigo; Jeong, Jae-Wook; Spencer, Thomas E.; Behringer, Richard R.; Lydon, John P.; DeMayo, Francesco J.			Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function	FASEB JOURNAL			English	Article						embryo implantation; proliferation; adenogenesis	FEMALE REPRODUCTIVE-TRACT; INDIAN HEDGEHOG; PROMOTER ACTIVITY; ESTROGEN; IMPLANTATION; PROLIFERATION; EXPRESSION; UTERUS; DECIDUALIZATION; RESPONSIVENESS	The ovarian steroid progesterone, acting through the progesterone receptor (PR), coordinates endometrial epithelial-stromal cell communication, which is critical for its development and function. PR expression in these cellular compartments is under tight temporal and endocrine control. Although ex vivo studies demonstrated the importance of stromal PR expression, they failed to show a role for epithelial PR in uterine function. Here, the in vivo role of PR in the uterine epithelium is defined using floxed PR (PRf/f) mice crossed to Wnt7a-Cre mice. Progesterone was unable to stimulate the expression of its epithelial target genes, including Ihh, in the Wnt7a-Cre(+)PR(f/-) mice. Analysis was conducted on Ihh to determine whether PR directly regulates epithelial gene transcription. ChIP-on-chip analysis identified PR binding sites in the 5'-flanking region of Ihh. Cotransfection of the proximal Ihh promoter with PR demonstrated that PR directly regulates Ihh transcription. Female Wnt7a-Cre(+)PR(f/-) mice are infertile due to defects in embryo attachment, stromal cell decidualization, and the inability to cease estrogen-induced epithelial cell proliferation. Finally, progesterone was unable to inhibit neonatal endometrial glandular development in Wnt7a-Cre(+)PR(f/-) mice. Thus, epithelial PR is necessary for the regulation of progesterone epithelial target gene expression, as well as uterine function and development.-Franco, H. L., Rubel, C. A., Large, M. J., Wetendorf, M., Fernandez-Valdivia, R., Jeong, J.-W., Spencer, T. E., Behringer, R. R., Lydon, J. P., DeMayo, F. J. Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. FASEB J. 26, 1218-1227 (2012). www.fasebj.org	[Franco, Heather L.; Rubel, Cory A.; Large, Michael J.; Wetendorf, Margeaux; Lydon, John P.; DeMayo, Francesco J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wetendorf, Margeaux] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; [Fernandez-Valdivia, Rodrigo] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA; [Behringer, Richard R.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Jeong, Jae-Wook] Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA; [Spencer, Thomas E.] Washington State Univ, Dept Anim Sci, Pullman, WA 99164 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Michigan State University; Washington State University	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	fdemayo@bcm.tmc.edu	Spencer, Thomas/AAD-6434-2020; DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Large, Michael/0000-0002-0170-3918; Marbrey, Margeaux/0000-0002-0473-9422; Spencer, Thomas/0000-0003-2815-766X	U.S. National Institutes of Health (NIH) [R01HD042311, R01HD057873, R01CA77530, HD30284]; Reproductive Biology Training grant [5T32HD07165]; Baylor Research Advocates for Student Scientists; Winter-man Foundation; Houston Livestock Show and Rodeo Scholarship Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165, R01HD042311, R01HD030284, R01HD057873] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077530] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Reproductive Biology Training grant; Baylor Research Advocates for Student Scientists; Winter-man Foundation; Houston Livestock Show and Rodeo Scholarship Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Sungnam Cho, Jie Yang, Genpathway, Inc., and Grant Orvis for technical assistance and Janet DeMayo for manuscript preparation. This work was supported by U.S. National Institutes of Health (NIH) grants R01HD042311 (to F.J.D.), R01HD057873 (to J.W.J.), R01CA77530 (to J.P.L), and HD30284 (to R. R. B.), and Reproductive Biology Training grant 5T32HD07165 and a scholarship from Baylor Research Advocates for Student Scientists, supported, in part, by the Winter-man Foundation and the Houston Livestock Show and Rodeo Scholarship Fund (to H.L.F.).	BARTOL FF, 1988, J ANIM SCI, V66, P3000; Chen B, 2005, MOL ENDOCRINOL, V19, P1978, DOI 10.1210/me.2004-0274; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; Fernandez-Valdivia R, 2010, GENESIS, V48, P106, DOI 10.1002/dvg.20586; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Franco HL, 2010, BIOL REPROD, V82, P991, DOI 10.1095/biolreprod.109.081513; Franco HL, 2010, BIOL REPROD, V82, P783, DOI 10.1095/biolreprod.109.080259; Gao JG, 2001, MOL CELL ENDOCRINOL, V176, P97, DOI 10.1016/S0303-7207(01)00450-6; Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289; Gray CA, 2001, BIOL REPROD, V64, P797, DOI 10.1095/biolreprod64.3.797; Gray CA, 2001, BIOL REPROD, V64, P1608, DOI 10.1095/biolreprod64.6.1608; Gray CA, 2001, BIOL REPROD, V65, P1311, DOI 10.1095/biolreprod65.5.1311; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; Kurita T, 1998, ENDOCRINOLOGY, V139, P4708, DOI 10.1210/en.139.11.4708; Large MJ, 2012, MOL CELL ENDOCRINOL, V358, P155, DOI 10.1016/j.mce.2011.07.027; Lee K, 2006, NAT GENET, V38, P1204, DOI 10.1038/ng1874; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma WG, 2003, P NATL ACAD SCI USA, V100, P2963, DOI 10.1073/pnas.0530162100; MARTIN L, 1973, J ENDOCRINOL, V57, P549, DOI 10.1677/joe.0.0570549; Matsumoto H, 2002, DEV BIOL, V245, P280, DOI 10.1006/dbio.2002.0645; Pan HY, 2006, P NATL ACAD SCI USA, V103, P14021, DOI 10.1073/pnas.0601271103; Rubel CA, 2010, SEMIN REPROD MED, V28, P27, DOI 10.1055/s-0029-1242990; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; Simon L, 2009, ENDOCRINOLOGY, V150, P3871, DOI 10.1210/en.2008-1691; Spencer TE, 2004, BIOL REPROD, V71, P2, DOI 10.1095/biolreprod.103.024133; Stewart CA, 2011, BIOL REPROD, V85, P954, DOI 10.1095/biolreprod.111.091470; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takamoto N, 2005, MOL ENDOCRINOL, V19, P2299, DOI 10.1210/me.2005-0019; Takamoto N, 2002, MOL ENDOCRINOL, V16, P2338, DOI 10.1210/me.2001-0154; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; Tang MY, 2002, MOL CELL ENDOCRINOL, V192, P45, DOI 10.1016/S0303-7207(02)00111-9; Tong W, 1999, MOL CELL BIOL, V19, P2251; Tseng L, 2003, DNA CELL BIOL, V22, P633, DOI 10.1089/104454903770238102; Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808; Winuthayanon W, 2010, P NATL ACAD SCI USA, V107, P19272, DOI 10.1073/pnas.1013226107; Yang ZM, 1996, MOL REPROD DEV, V43, P470	43	104	110	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1218	1227		10.1096/fj.11-193334	http://dx.doi.org/10.1096/fj.11-193334			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22155565	Green Published			2022-12-28	WOS:000300949300024
J	Kemmner, W; Kessel, P; Sanchez-Ruderisch, H; Moller, H; Hinderlich, S; Schlag, PM; Detjen, K				Kemmner, Wolfgang; Kessel, Pia; Sanchez-Ruderisch, Hugo; Moeller, Heinz; Hinderlich, Stephan; Schlag, Peter M.; Detjen, Katharina			Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells	FASEB JOURNAL			English	Article						anoikis; unfolded protein response; sialylation; chemoresistance	TUMOR-SUPPRESSOR P16(INK4A); UNFOLDED PROTEIN RESPONSE; SIALIC-ACID BIOSYNTHESIS; DEPENDENT INDUCTION; EXPRESSION; GENE; CANCER; PROLIFERATION; ANOIKIS; SIALYLTRANSFERASE	Early invasive growth and metastasis are features of pancreatic cancer that rely on its resistance to anoikis, an apoptosis program activated on loss of matrix anchorage. How anoikis is regulated is unclear. UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine-kinase (GNE) was silenced, or p16 was overexpressed, in human pancreatic carcinoma cells. Gene expression profiling, enzymatic assays, Western blotting, and cell cycle analysis were conducted. Silencing of GNE, the key enzyme of sialic acid biosynthesis, sensitizes pancreatic cancer cells to anoikis. Accordingly, we observed a loss of GNE enzyme activity in cells, which became anoikis susceptible after transfection with the tumor suppressor p16. Similarly, studies of another cell line with low GNE activity revealed strong anoikis susceptibility, confirming the association of low GNE activity and anoikis susceptibility. Gene expression profiling demonstrated that the loss of GNE triggered the transcriptional activation of the ATF4-ATF3-CHOP pathway, leading to apoptosis in the framework of the unfolded protein response. In silico analysis showed that GNE up-regulation occurred predominantly in pancreatic cancer but also in other malignancies. Delineation of GNE-dependent signaling pathways may provide targets that control anchorage dependence and/or restore drug efficacy, which is of utmost relevance for the treatment of pancreatic cancer.-Kemmner, W., Kessel, P., Sanchez-Ruderisch, H., Moller, H., Hinderlich, S., Schlag, P. M., Detjen, K. Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells. FASEB J. 26, 938-946 (2012). www.fasebj.org	[Kemmner, Wolfgang; Kessel, Pia; Schlag, Peter M.] Max Delbrueck Ctr Mol Med, Res Grp Surg Oncol, ECRC, Charite Campus Buch, D-13125 Berlin, Germany; [Sanchez-Ruderisch, Hugo; Detjen, Katharina] Charite Campus Virchow Klinikum, Med Klin Schwerpunkt Hepatol & Gastroenterol, Berlin, Germany; [Moeller, Heinz; Hinderlich, Stephan] Technik Berlin Univ Appl Sci, Dept Life Sci & Technol, Beuth Hsch, Berlin, Germany; [Kemmner, Wolfgang; Schlag, Peter M.] Charite Comprehens Canc Ctr, Charite Campus Mitte, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berliner Hochschule fur Technik; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kemmner, W (corresponding author), Max Delbrueck Ctr Mol Med, Res Grp Surg Oncol, ECRC, Charite Campus Buch, Robert Roessle Str 10, D-13125 Berlin, Germany.	wkemmner@mdc-berlin.de		Sanchez Ruderisch, Hugo/0000-0001-9315-4508				Andre S, 2007, FEBS J, V274, P3233, DOI 10.1111/j.1742-4658.2007.05851.x; Astrosini C, 2008, INT J CANCER, V123, P409, DOI 10.1002/ijc.23466; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GESSNER P, 1993, CANCER LETT, V75, P143, DOI 10.1016/0304-3835(93)90056-F; Giordanengo V, 2004, FASEB J, V18, P1961, DOI 10.1096/fj.04-2467fje; Gjymishka A, 2009, BIOCHEM J, V417, P695, DOI 10.1042/BJ20081706; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; KAKU M, 1980, GANN, V71, P596; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Krause S, 2005, EXP CELL RES, V304, P365, DOI 10.1016/j.yexcr.2004.11.010; Lata S, 2008, SCIENCE, V321, P1354, DOI 10.1126/science.1161070; Lin SQ, 2002, EXP CELL RES, V276, P101, DOI 10.1006/excr.2002.5521; Lubomierski N, 2001, CANCER RES, V61, P5905; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mungrue IN, 2009, J IMMUNOL, V182, P466, DOI 10.4049/jimmunol.182.1.466; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Oetke C, 2003, BIOCHEM BIOPH RES CO, V308, P892, DOI 10.1016/S0006-291X(03)01471-2; Oetke C, 2002, J BIOL CHEM, V277, P6688, DOI 10.1074/jbc.M109973200; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ortiz-Zapater E, 2007, AM J PATHOL, V170, P1573, DOI 10.2353/ajpath.2007.060850; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sanchez-Ruderisch H, 2011, CELL DEATH DIFFER, V18, P806, DOI 10.1038/cdd.2010.148; Schauer R, 2009, CURR OPIN STRUC BIOL, V19, P507, DOI 10.1016/j.sbi.2009.06.003; Schneider F, 2001, CANCER RES, V61, P4605; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Su N, 2008, J BIOL CHEM, V283, P35106, DOI 10.1074/jbc.M806874200; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Wang ZY, 2006, J BIOL CHEM, V281, P27016, DOI 10.1074/jbc.M604903200; Weidemann W, 2010, GLYCOBIOLOGY, V20, P107, DOI 10.1093/glycob/cwp153; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	37	18	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					938	946		10.1096/fj.11-186700	http://dx.doi.org/10.1096/fj.11-186700			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22049060				2022-12-28	WOS:000300485700043
J	Fiume, R; Ramazzotti, G; Faenza, I; Piazzi, M; Bavelloni, A; Billi, AM; Cocco, L				Fiume, Roberta; Ramazzotti, Giulia; Faenza, Irene; Piazzi, Manuela; Bavelloni, Alberto; Billi, Anna Maria; Cocco, Lucio			Nuclear PLCs affect insulin secretion by targeting PPAR gamma in pancreatic beta cells	FASEB JOURNAL			English	Article						PLC beta 1; PLC delta 4; phosphoinositides; diabetes	PHOSPHOLIPASE-C ACTIVATION; PROTEIN-KINASE-C; GLUCOSE; PHOSPHOINOSITIDES; RECEPTOR; ISLETS; DIFFERENTIATION; PLC-BETA(1); EXPRESSION; FEEDBACK	Type 2 diabetes is a heterogeneous disorder caused by concomitant impairment of insulin secretion by pancreatic beta cells and of insulin action in peripheral target tissues. Studies with inhibitors and agonists established a role for PLC in the regulation of insulin secretion but did not distinguish between effects due to nuclear or cytoplasmic PLC signaling pathways that act in a distinct fashion. We report that in MIN6 beta cells, PLC beta 1 localized in both nucleus and cytoplasm, PLC delta 4 in the nucleus, and PLC gamma 1 in the cytoplasm. By silencing each isoform, we observed that they all affected glucose-induced insulin release both at basal and high glucose concentrations. To elucidate the molecular basis of PLC regulation, we focused on peroxisome proliferator-activated receptor-gamma (PPAR gamma), a nuclear receptor transcription factor that regulates genes critical to beta-cell maintenance and functions. Silencing of PLC beta 1 and PLC delta 4 resulted in a decrease in the PPAR gamma mRNA level. By means of a PPAR gamma-promoter-luciferase assay, the decrease could be attributed to a PLC action on the PPAR gamma-promoter region. The effect was specifically observed on silencing of the nuclear and not the cytoplasmic PLC. These findings highlight a novel pathway by which nuclear PLCs affect insulin secretion and identify PPAR gamma as a novel molecular target of nuclear PLCs.-Fiume, R., Ramazzotti, G., Faenza, I., Piazzi, M., Bavelloni, A., Billi, A. M., Cocco, L. Nuclear PLCs affect insulin secretion by targeting PPAR gamma in pancreatic beta cells. FASEB J. 26, 203-210 (2012). www.fasebj.org	[Fiume, Roberta; Ramazzotti, Giulia; Faenza, Irene; Piazzi, Manuela; Billi, Anna Maria; Cocco, Lucio] Univ Bologna, Cellular Signaling Lab, Dept Human Anat, Bologna, Italy; [Bavelloni, Alberto] Rizzoli Orthoped Inst, Lab Musculoskeletal Cell Biol, Bologna, Italy	University of Bologna; IRCCS Istituto Ortopedico Rizzoli	Cocco, L (corresponding author), Via Irnerio 48, I-40126 Bologna, Italy.	lucio.cocco@unibo.it	Cocco, Lucio/AAI-2206-2020; Piazzi, Manuela/K-2147-2016; RAMAZZOTTI, GIULIA/AGZ-9499-2022; Faenza, Irene/AAC-4606-2022; Ramazzotti, Giulia/AAC-4597-2022; Bavelloni, Alberto/E-5726-2019; Piazzi, Manuela/AAD-5016-2020	Cocco, Lucio/0000-0002-9206-8277; Piazzi, Manuela/0000-0002-9072-2757; RAMAZZOTTI, GIULIA/0000-0001-9684-714X; Faenza, Irene/0000-0002-5227-3567; Bavelloni, Alberto/0000-0002-6467-1431; Piazzi, Manuela/0000-0002-9072-2757; FIUME, ROBERTA/0000-0001-7757-4000	Italian Ministero dell'Istruzione, dell'Universit a e della Ricerca (MIUR)-Fondo FIRB; Carisbo Foundation, Bologna, Italy	Italian Ministero dell'Istruzione, dell'Universit a e della Ricerca (MIUR)-Fondo FIRB; Carisbo Foundation, Bologna, Italy(Fondazione Carisbo)	The authors thank Dr. Sun Sik Bae (MRC for Ischemic Tissue Regeneration, Pusan National University, Busan, Korea) for the generous gift of the plasmids encoding PPAR-gamma promoter and the PPAR-gamma responsive element (PPRE); and Dr. Susumu Seino (Kobe University, Kobe, Japan) for the generous gift of MIN6m9 cells. This work was supported by Italian Ministero dell'Istruzione, dell'Universit a e della Ricerca (MIUR)-Fondo FIRB and Carisbo Foundation, Bologna, Italy.	Chang TJ, 2009, DIABETOLOGIA, V52, P1112, DOI 10.1007/s00125-009-1337-4; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Faenza I, 2002, BBA-MOL CELL RES, V1589, P305, DOI 10.1016/S0167-4889(02)00192-1; Faenza I, 2007, ENDOCRINOLOGY, V148, P1108, DOI 10.1210/en.2006-1003; Follo MY, 2009, P NATL ACAD SCI USA, V106, P16811, DOI 10.1073/pnas.0907109106; Follo MY, 2009, J CLIN ONCOL, V27, P782, DOI 10.1200/JCO.2008.19.3748; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; Gupta D, 2010, DIABETES OBES METAB, V12, P1036, DOI 10.1111/j.1463-1326.2010.01299.x; Kim SP, 2010, BIOCHEM BIOPH RES CO, V399, P55, DOI 10.1016/j.bbrc.2010.07.038; Kumar V, 2008, J BIOL CHEM, V283, P14072, DOI 10.1074/jbc.M708551200; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger B, 2010, FASEB J, V24, P1824, DOI 10.1096/fj.09-148072; Leibiger IB, 2010, BIOCHEM BIOPH RES CO, V396, P111, DOI 10.1016/j.bbrc.2010.02.174; Leibiger IB, 2008, ANNU REV NUTR, V28, P233, DOI 10.1146/annurev.nutr.28.061807.155530; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Nakamichi Y, 2003, BIOCHEM BIOPH RES CO, V306, P832, DOI 10.1016/S0006-291X(03)01045-3; Ramazzotti G, 2008, CELL SIGNAL, V20, P2013, DOI 10.1016/j.cellsig.2008.07.009; Ramazzotti G, 2011, J CELL PHYSIOL, V226, P14, DOI 10.1002/jcp.22334; Suh PG, 2008, BMB REP, V41, P415, DOI 10.5483/BMBRep.2008.41.6.415; Thore S, 2005, J CELL SCI, V118, P4463, DOI 10.1242/jcs.02577; World Health Organization, HLTH TOP DIAB; Yamazaki H, 2006, AM J PHYSIOL-ENDOC M, V290, pE26, DOI 10.1152/ajpendo.00149.2005; Yamazaki H, 2010, J NUTR SCI VITAMINOL, V56, P1, DOI 10.3177/jnsv.56.1; Zawalich WS, 2008, METABOLISM, V57, P290, DOI 10.1016/j.metabol.2007.09.015; Zawalich WS, 2006, METABOLISM, V55, P35, DOI 10.1016/j.metabol.2005.06.023	28	21	25	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					203	210		10.1096/fj.11-186510	http://dx.doi.org/10.1096/fj.11-186510			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21974932				2022-12-28	WOS:000299202200021
J	Ko, IK; Ju, YM; Chen, T; Atala, A; Yoo, JJ; Lee, SJ				Ko, In Kap; Ju, Young Min; Chen, Timothy; Atala, Anthony; Yoo, James J.; Lee, Sang Jin			Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration	FASEB JOURNAL			English	Article						cell-free scaffold; substance P; stromal-derived factor-1 alpha	MUSCLE REGENERATION; HEMATOPOIETIC PROGENITOR; SUBSTANCE-P; BONE-MARROW; MOBILIZATION; RECRUITMENT	Whereas the conventional tissue engineering strategy involves the use of scaffolds combined with appropriate cell types to restore normal functions, the concept of in situ tissue regeneration uses host responses to a target-specific scaffold to mobilize host cells to a site of injury without the need for cell seeding. For this purpose, local delivery of bioactive molecules from scaffolds has been generally used. However, this approach has limited stem cell recruitment into the implants. Thus, we developed a combination of systemic delivery of substance P (SP) and local release of stromal-derived factor-1 alpha (SDF-1 alpha) from an implant. In this study, we examined whether this combined system would significantly enhance recruitment of host stem cells into the implants. Flow cytometry and immunohistochemistry for CD29/CD45, CD146/alpha-smooth muscle actin, and c-kit demonstrated that this system significantly increased the number of stem cell-like cells within the implants when compared with other systems. In vitro culture of the cells that had infiltrated into the scaffolds from the combined system confirmed that host stem cells were recruited into these implants and indicated that they were capable of differentiation into multiple lineages. These results indicate that this combined system may lead to more efficient tissue regeneration.-Ko, I. K., Ju, Y. M., Chen, T., Atala, A., Yoo, J. J., Lee, S. J. Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration. FASEB J. 26, 158 -168 (2012). www.fasebj.org	[Ko, In Kap; Ju, Young Min; Chen, Timothy; Atala, Anthony; Yoo, James J.; Lee, Sang Jin] Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA	Wake Forest University	Lee, SJ (corresponding author), Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sjlee@wakehealth.edu	Yoo, James J./L-4850-2017; Lee, Sang Jin/S-4056-2019	Lee, Sang Jin/0000-0002-3899-1909; Atala, Anthony/0000-0001-8186-2160	Armed Forces Institute of Regenerative Medicine [X81XWH-08-2-0032]	Armed Forces Institute of Regenerative Medicine	The authors thank Drs. John Jackson and Jennifer Olson for editorial assistance with this manuscript and Dr. Youngsook Son (Kyung Hee University, Seoul, South Korea) for providing valuable information on the CD29 antibody. This study was supported in part by the Armed Forces Institute of Regenerative Medicine (X81XWH-08-2-0032).	An YS, 2011, J CELL PHYSIOL, V226, P1204, DOI 10.1002/jcp.22447; Bladergroen BA, 2009, TISSUE ENG PT A, V15, P1591, DOI 10.1089/ten.tea.2008.0348; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hong HS, 2009, NAT MED, V15, P425, DOI 10.1038/nm.1909; Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Kim JY, 2010, TISSUE ENG PT A, V16, P3023, DOI [10.1089/ten.tea.2010.0181, 10.1089/ten.TEA.2010.0181]; Ko IK, 2010, MOL THER, V18, P1365, DOI 10.1038/mt.2010.54; Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338; Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140-6736(10)60668-X; Lee SJ, 2008, REJUV RES, V11, P747, DOI 10.1089/rej.2008.0691; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; Thevenot PT, 2010, BIOMATERIALS, V31, P3997, DOI 10.1016/j.biomaterials.2010.01.144; Vishalakumar S, 2006, CELL SIGNAL, V18, P422, DOI 10.1016/j.cellsig.2005.05.002; Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	22	68	69	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					158	168		10.1096/fj.11-182998	http://dx.doi.org/10.1096/fj.11-182998			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965595				2022-12-28	WOS:000299202200017
J	Mailloux, RJ; Adjeitey, CNK; Xuan, JY; Harper, ME				Mailloux, Ryan J.; Adjeitey, Cyril Nii-Klu; Xuan, Jian Ying; Harper, Mary-Ellen			Crucial yet divergent roles of mitochondrial redox state in skeletal muscle vs. brown adipose tissue energetics	FASEB JOURNAL			English	Article						glutathione; thermogenesis; uncoupling proteins	COMPLEX-I; REVERSIBLE GLUTATHIONYLATION; PROTEIN GLUTATHIONYLATION; OXIDATIVE-PHOSPHORYLATION; UNCOUPLING PROTEIN; PROTON LEAK; CELL; IDENTIFICATION; DEHYDROGENASE; GLUTAREDOXIN	Reduced glutathione (GSH) is the major determinant of redox balance in mitochondria and as such is fundamental in the control of cellular bioenergetics. GSH is also the most important nonprotein antioxidant molecule in cells. Surprisingly, the effect of redox environment has never been examined in skeletal muscle and brown adipose tissue (BAT), two tissues that have exceptional dynamic range and that are relevant to the development of obesity and related diseases. Here, we show that the redox environment plays crucial, yet divergent, roles in modulating mitochondrial bioenergetics in skeletal muscle and BAT. Skeletal muscle mitochondria were found to naturally have a highly reduced environment (GSH/GSSG approximate to 46), and this was associated with fairly high (similar to 40%) rates of state 4 (nonphosphorylating) respiration and decreased reactive oxygen species (ROS) emission. The deglutathionylation of uncoupling protein 3 (UCP3) following an increase in the reductive potential of mitochondria results in a further increase in nonphosphorylating respiration (similar to 20% in situ). BAT mitochondria were found to have a much more oxidized status (GSH/GSSG approximate to 13) and had basal reactive oxygen species emission that was higher (similar to 250% increase in ROS generation) than that in skeletal muscle mitochondria. When redox status was subsequently increased (i.e., more reduced), UCP1-mediated uncoupling was more sensitive to GDP inhibition. Surprisingly, BAT was found to be devoid of glutaredoxin-2 (Grx2) expression, while there was abundant expression in skeletal muscle. Taken together, these findings reveal the importance of redox environment in controlling bioenergetic functions in both tissues, and the highly unique characteristics of BAT in this regard.-Mailloux, R. J., Adjeitey, C. N.-K., Xuan, J. Y., and Harper, M.-E. Crucial yet divergent roles of mitochondrial redox state in skeletal muscle vs. brown adipose tissue energetics. FASEB J. 26, 363-375 (2012). www.fasebj.org	[Mailloux, Ryan J.; Adjeitey, Cyril Nii-Klu; Xuan, Jian Ying; Harper, Mary-Ellen] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Harper, ME (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	maryellen.harper@uottawa.ca		Mailloux, Ryan/0000-0003-3986-9830; Harper, Mary-Ellen/0000-0003-3864-5886	Canadian Institutes of Health Research (CIHR); CIHR (Institute of Nutrition, Metabolism, and Diabetes)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR (Institute of Nutrition, Metabolism, and Diabetes)(Canadian Institutes of Health Research (CIHR))	The authors thank Mahmoud Salkhordeh for the isolation and purification of the primary myoblasts. R.J.M. was funded by a postdoctoral fellowship provided by the Canadian Institutes of Health Research (CIHR). Operating funding for this research was provided by CIHR (Institute of Nutrition, Metabolism, and Diabetes; to M. E. H.).	Applegate MAB, 2008, BIOCHEMISTRY-US, V47, P473, DOI 10.1021/bi7017464; Azzu V, 2010, TRENDS BIOCHEM SCI, V35, P298, DOI 10.1016/j.tibs.2009.11.001; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Caprioli Joseph, 2009, Trans Am Ophthalmol Soc, V107, P161; Chen YR, 2007, J BIOL CHEM, V282, P32640, DOI 10.1074/jbc.M702294200; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; DEQUIROGA GB, 1991, BIOCHEM J, V277, P289, DOI 10.1042/bj2770289; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Garcia J, 2010, J BIOL CHEM, V285, P39646, DOI 10.1074/jbc.M110.164160; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOUBERN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P334, DOI 10.1016/0005-2728(90)90038-6; Harper ME, 2008, ANNU REV NUTR, V28, P13, DOI 10.1146/annurev.nutr.28.061807.155357; HAUGAARD N, 1969, BIOCHEM PHARMACOL, V18, P2385, DOI 10.1016/0006-2952(69)90353-0; Hill BG, 2010, BBA-BIOENERGETICS, V1797, P285, DOI 10.1016/j.bbabio.2009.11.005; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Hurd TR, 2008, J BIOL CHEM, V283, P24801, DOI 10.1074/jbc.M803432200; Hurd TR, 2005, ANTIOXID REDOX SIGN, V7, P999, DOI 10.1089/ars.2005.7.999; Kil IS, 2005, J BIOL CHEM, V280, P10846, DOI 10.1074/jbc.M411306200; Mailloux R. J., 2011, BIOCHEM J, V437, P21865; Mailloux RJ, 2011, J BIOL CHEM, V286, P21865, DOI 10.1074/jbc.M111.240242; Mailloux RJ, 2010, FASEB J, V24, P2495, DOI 10.1096/fj.09-151803; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Mieyal JJ, 2008, ANTIOXID REDOX SIGN, V10, P1941, DOI 10.1089/ars.2008.2089; Mracek T, 2009, ARCH BIOCHEM BIOPHYS, V481, P30, DOI 10.1016/j.abb.2008.10.011; Naoi M, 2009, J NEURAL TRANSM, V116, P1371, DOI 10.1007/s00702-009-0309-7; Nedergaard J, 2010, ANN NY ACAD SCI, V1212, pE20, DOI 10.1111/j.1749-6632.2010.05905.x; Nicholls DG, 1999, J BIOENERG BIOMEMBR, V31, P399, DOI 10.1023/A:1005436121005; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Oelkrug R, 2010, J BIOL CHEM, V285, P21961, DOI 10.1074/jbc.M110.122861; Parker N, 2009, J BIOENERG BIOMEMBR, V41, P335, DOI 10.1007/s10863-009-9232-8; Petrovic V, 2010, GENES NUTR, V5, P225, DOI 10.1007/s12263-009-0162-1; Queiroga CSF, 2010, J BIOL CHEM, V285, P17077, DOI 10.1074/jbc.M109.065052; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Rolfe DFS, 1996, BBA-BIOENERGETICS, V1276, P45, DOI 10.1016/0005-2728(96)00029-1; Rolfe DFS, 1996, AM J PHYSIOL-CELL PH, V271, pC1380, DOI 10.1152/ajpcell.1996.271.4.C1380; SASTRE J, 1989, LIFE SCI, V45, P183, DOI 10.1016/0024-3205(89)90293-2; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seifert EL, 2010, J BIOL CHEM, V285, P5748, DOI 10.1074/jbc.M109.026203; SHAKED Z, 1980, BIOCHEMISTRY-US, V19, P4156, DOI 10.1021/bi00559a004; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Wu HL, 2010, BBA-BIOENERGETICS, V1797, P1705, DOI 10.1016/j.bbabio.2010.06.003	55	48	49	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					363	375		10.1096/fj.11-189639	http://dx.doi.org/10.1096/fj.11-189639			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21940996				2022-12-28	WOS:000299202200036
J	Shi, J; Ju, M; Abramowitz, J; Large, WA; Birnbaumer, L; Albert, AP				Shi, Jian; Ju, Min; Abramowitz, Joel; Large, William A.; Birnbaumer, Lutz; Albert, Anthony P.			TRPC1 proteins confer PKC and phosphoinositol activation on native heteromeric TRPC1/C5 channels in vascular smooth muscle: comparative study of wild-type and TRPC1(-/-) mice	FASEB JOURNAL			English	Article						Ca2+; signaling; hypertension; transgenic	CA2+-PERMEABLE CATION CHANNEL; OPERATED CA2+ CHANNELS; KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ANGIOTENSIN-II; ENTRY; DESENSITIZATION; IDENTIFICATION; ENDOTHELIN-1; INVOLVEMENT	Ca2+-permeable cation channels consisting of canonical transient receptor potential 1 (TRPC1) proteins mediate Ca2+ influx pathways in vascular smooth muscle cells (VSMCs), which regulate physiological and pathological functions. We investigated properties conferred by TRPC1 proteins to native single TRPC channels in acutely isolated mesenteric artery VSMCs from wildtype (WT) and TRPC1-deficient (TRPC1(-/-)) mice using patch-clamp techniques. In WT VSMCs, the intracellular Ca2+ store-depleting agents cyclopiazonic acid (CPA) and 1,2-bis-(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM) both evoked channel currents, which had unitary conductances of similar to 2 pS. In TRPC1(-/-) VSMCs, CPA-induced channel currents had 3 subconductance states of 14, 32, and 53 pS. Passive depletion of intracellular Ca2+ stores activated whole-cell cation currents in WT but not TRPC1(-/-) VSMCs. Differential blocking actions of anti-TRPC antibodies and coimmunoprecipitation studies revealed that CPA induced heteromeric TRPC1/C5 channels in WT VSMCs and TRPC5 channels in TRPC1(-/-) VSMCs. CPA-evoked TRPC1/C5 channel activity was prevented by the protein kinase C (PKC) inhibitor chelerythrine. In addition, the PKC activator phorbol 12,13-dibutyrate (PDBu), a PKC catalytic subunit, and phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-trisphosphate (PIP3) activated TRPC1/C5 channel activity, which was prevented by chelerythrine. In contrast, CPA-evoked TRPC5 channel activity was potentiated by chelerythrine, and inhibited by PDBu, PIP2, and PIP3. TRPC5 channels in TRPC1(-/-) VSMCs were activated by increasing intracellular Ca2+ concentrations ([Ca2+](i)), whereas increasing [Ca2+](i) had no effect in WT VSMCs. We conclude that agents that deplete intracellular Ca2+ stores activate native heteromeric TRPC1/C5 channels in VSMCs, and that TRPC1 subunits are important in determining unitary conductance and conferring channel activation by PKC, PIP2, and PIP3.-Shi, J., Ju, M., Abramowitz, J., Large, W. A., Birnbaumer, L., Albert, A. P. TRPC1 proteins confer PKC and phosphoinositol activation on native heteromeric TRPC1/C5 channels in vascular smooth muscle: comparative study of wild-type and TRPC1(-/-) mice. FASEB J. 26, 409-419 (2012). www.fasebj.org	[Shi, Jian; Ju, Min; Large, William A.; Albert, Anthony P.] Univ London, Div Biomed Sci, London SW17 0RE, England; [Abramowitz, Joel; Birnbaumer, Lutz] Natl Inst Environm Hlth Sci, Neurobiol Lab, Res Triangle Pk, NC USA	University of London; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Albert, AP (corresponding author), Univ London, Div Biomed Sci, London SW17 0RE, England.	aalbert@sgul.ac.uk	Abramowitz, Joel/A-2620-2015	Albert, Anthony/0000-0002-3596-9634	British Heart Foundation; Biotechnology and Biological Sciences Research Council [BB/J007226/1] Funding Source: researchfish; BBSRC [BB/J007226/1] Funding Source: UKRI; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101684] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the British Heart Foundation.	Abramowitz J, 2009, FASEB J, V23, P297, DOI 10.1096/fj.08-119495; Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Albert AP, 2007, J PHYSIOL-LONDON, V583, P25, DOI 10.1113/jphysiol.2007.137802; Albert AP, 2011, ADV EXP MED BIOL, V704, P391, DOI 10.1007/978-94-007-0265-3_22; Albert AP, 2009, CURR MED CHEM, V16, P1158, DOI 10.2174/092986709787581815; Albert AP, 2006, J PHYSIOL-LONDON, V571, P361, DOI 10.1113/jphysiol.2005.102780; Albert AP, 2002, J PHYSIOL-LONDON, V538, P717, DOI 10.1113/jphysiol.2001.013101; Alfonso S, 2008, CELL CALCIUM, V43, P375, DOI 10.1016/j.ceca.2007.07.004; Bergdahl A, 2005, AM J PHYSIOL-CELL PH, V288, pC872, DOI 10.1152/ajpcell.00334.2004; Berra-Romani R, 2008, AM J PHYSIOL-CELL PH, V295, pC779, DOI 10.1152/ajpcell.00173.2008; Bird GS, 2008, METHODS, V46, P204, DOI 10.1016/j.ymeth.2008.09.009; Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928; Bisaillon JM, 2010, AM J PHYSIOL-CELL PH, V298, pC993, DOI 10.1152/ajpcell.00325.2009; Blair NT, 2009, J GEN PHYSIOL, V133, P525, DOI 10.1085/jgp.200810153; Desai BN, 2005, PFLUG ARCH EUR J PHY, V451, P11, DOI 10.1007/s00424-005-1429-z; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Dietrich A, 2010, THROMB HAEMOSTASIS, V103, P262, DOI 10.1160/TH09-08-0517; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Gross SA, 2009, J BIOL CHEM, V284, P34423, DOI 10.1074/jbc.M109.018192; Ju M, 2010, J PHYSIOL-LONDON, V588, P1419, DOI 10.1113/jphysiol.2009.185256; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kim BJ, 2008, BIOL PHARM BULL, V31, P1733, DOI 10.1248/bpb.31.1733; Kwan HY, 2009, CIRC RES, V104, P670, DOI 10.1161/CIRCRESAHA.108.188748; Large WA, 2009, CELL CALCIUM, V45, P574, DOI 10.1016/j.ceca.2009.02.007; Ma R, 2002, AM J PHYSIOL-CELL PH, V283, pC1390, DOI 10.1152/ajpcell.00141.2002; Ma R, 2001, J BIOL CHEM, V276, P25759, DOI 10.1074/jbc.M011241200; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Peppiatt-Wildman CM, 2007, J PHYSIOL-LONDON, V580, P755, DOI 10.1113/jphysiol.2006.126656; Plant TD, 2005, N-S ARCH PHARMACOL, V371, P266, DOI 10.1007/s00210-005-1055-5; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Saleh SN, 2006, J PHYSIOL-LONDON, V577, P479, DOI 10.1113/jphysiol.2006.119305; Saleh SN, 2008, J PHYSIOL-LONDON, V586, P2463, DOI 10.1113/jphysiol.2008.152157; Saleh SN, 2009, J PHYSIOL-LONDON, V587, P5361, DOI 10.1113/jphysiol.2009.180331; Saleh SN, 2009, J PHYSIOL-LONDON, V587, P531, DOI 10.1113/jphysiol.2008.166678; Shi J, 2010, J PHYSIOL-LONDON, V588, P3671, DOI 10.1113/jphysiol.2010.194621; Sours-Brorhers S, 2009, EXP BIOL MED, V234, P673, DOI 10.3181/0809-RM-279; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2009, PFLUG ARCH EUR J PHY, V457, P757, DOI 10.1007/s00424-008-0550-1; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Wolfle SE, 2010, CLIN EXP PHARMACOL P, V37, P536, DOI [10.1111/j.1440-1681.2010.05350.x, 10.1111/j.1440-1681.2009.05350.x]; Xie A, 2007, J CEREBR BLOOD F MET, V27, P1692, DOI 10.1038/sj.jcbfm.9600471; Xu SZ, 2006, AM J PHYSIOL-HEART C, V291, pH2653, DOI 10.1152/ajpheart.00495.2006; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zhang W, 2011, CIRC RES, V109, P534, DOI 10.1161/CIRCRESAHA.111.246777; Zhu MH, 2005, AM J PHYSIOL-CELL PH, V289, pC591, DOI 10.1152/ajpcell.00440.2004	47	42	48	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					409	419		10.1096/fj.11-185611	http://dx.doi.org/10.1096/fj.11-185611			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21968068	Green Published			2022-12-28	WOS:000299202200040
J	Chen, GP; Howe, AG; Xu, G; Frohlich, O; Klein, JD; Sands, JM				Chen, Guangping; Howe, Ashley G.; Xu, Gang; Froehlich, Otto; Klein, Janet D.; Sands, Jeff M.			Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization	FASEB JOURNAL			English	Article						glycosylation; apical membrane; trafficking; lectin; sucrose gradient centrifugation	MEMBRANE ACCUMULATION; COLLECTING DUCT; CL-COTRANSPORTER; EPITHELIAL-CELLS; APICAL MEMBRANE; RAT-KIDNEY; GLYCOSYLATION; VASOPRESSIN; PHOSPHORYLATION; LOCALIZATION	The UT-A1 urea transporter is a glycoprotein with two different glycosylated forms of 97 and 117 kDa. In this study, we found the 117-kDa UT-A1 preferentially resides in lipid rafts, suggesting that the glycosylation status may interfere with UT-A1 lipid raft trafficking. This was confirmed by a site-directed mutagenesis study in MDCK cells. The nonglycosylated UT-A1 showed reduced localization in lipid rafts. By using sugar-specific binding lectins, we further found that the UT-A1 in nonlipid rafts contained a high amount of mannose, as detected by concanavalin A, while the UT-A1 in lipid rafts was the mature N-acetylglucosamine-containing form, as detected by wheat germ agglutinin. In the inner medulla (IM) of diabetic rats, the more abundant 117-kDa UT-A1 in lipid rafts was the mature glycosylation form, with high amounts of N-acetylglucosamine and sialic acid. In contrast, in the IM of normal rats, the predominant 97-kDa UT-A1 was the form enriched in mannose. Functionally, inhibition of glycosylation by tunicamycin or elimination of the glycosylation sites by mutation significantly reduced UT-A1 activity in oocytes. Taken together, our study reveals a new role of N-linked glycosylation in regulating UT-A1 activity by promoting UT-A1 trafficking into membrane lipid raft subdomains.-Chen, G., Howe, A. G., Xu, G., Frohlich, O., Klein, J. D., Sands, J. M. Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization. FASEB J. 25, 4531-4539 (2011). www.fasebj.org	[Chen, Guangping; Howe, Ashley G.; Xu, Gang; Klein, Janet D.; Sands, Jeff M.] Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA; [Froehlich, Otto; Sands, Jeff M.] Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University; Emory University	Chen, GP (corresponding author), WMRB Rm 338,1639 Pierce Dr, Atlanta, GA 30322 USA.	gchen3@emory.edu			U.S. National Institutes of Health [R01-DK087838, R21-DK080431, R01-DK41707]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041707, R21DK080431, R01DK087838] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants R01-DK087838 and R21-DK080431 (to G.C.), and R01-DK41707 (to J.M.S.).	Blount MA, 2008, AM J PHYSIOL-RENAL, V295, pF295, DOI 10.1152/ajprenal.00102.2008; Bradford AD, 2001, AM J PHYSIOL-RENAL, V281, pF133, DOI 10.1152/ajprenal.2001.281.1.F133; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen G, 2008, AM J PHYSIOL-RENAL, V295, pF1528, DOI 10.1152/ajprenal.90482.2008; Chen GP, 2006, J BIOL CHEM, V281, P27436, DOI 10.1074/jbc.M605525200; Dart C, 2010, J PHYSIOL-LONDON, V588, P3169, DOI 10.1113/jphysiol.2010.191585; Dennis JW, 2009, TRAFFIC, V10, P1569, DOI 10.1111/j.1600-0854.2009.00981.x; Fattakhova G, 2006, TRAFFIC, V7, P673, DOI 10.1111/j.1600-0854.2006.00423.x; Feng XY, 2009, AM J PHYSIOL-RENAL, V296, pF1514, DOI 10.1152/ajprenal.00068.2009; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; Frohlich O, 2004, AM J PHYSIOL-CELL PH, V286, pC1264, DOI 10.1152/ajpcell.00499.2003; Haeuptle MA, 2009, HUM MUTAT, V30, P1628, DOI 10.1002/humu.21126; Hartmann AM, 2009, J NEUROCHEM, V111, P321, DOI 10.1111/j.1471-4159.2009.06343.x; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Hill WG, 2007, J BIOL CHEM, V282, P37402, DOI 10.1074/jbc.M704084200; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Huang Haidong, 2010, J Epithel Biol Pharmacol, V3, P34; Huang HD, 2010, AM J PHYSIOL-RENAL, V299, pF1389, DOI 10.1152/ajprenal.00718.2009; Huang P, 2008, BIOCHEM BIOPH RES CO, V365, P82, DOI 10.1016/j.bbrc.2007.10.128; Kanno T, 2010, NEUROCHEM RES, V35, P782, DOI 10.1007/s11064-010-0135-1; Kim D, 2003, AM J PHYSIOL-RENAL, V285, pF303, DOI 10.1152/ajprenal.00438.2002; Klein JD, 2006, J AM SOC NEPHROL, V17, P2680, DOI 10.1681/ASN.2006030246; Klein JD, 2010, AM J PHYSIOL-RENAL, V298, pF935, DOI 10.1152/ajprenal.00682.2009; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Lee TK, 2003, AM J PHYSIOL-GASTR L, V285, pG371, DOI 10.1152/ajpgi.00358.2002; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; Morenilla-Palao C, 2009, J BIOL CHEM, V284, P9215, DOI 10.1074/jbc.M807228200; Murtazina R, 2006, J BIOL CHEM, V281, P17845, DOI 10.1074/jbc.M601740200; Nielsen S, 1996, P NATL ACAD SCI USA, V93, P5495, DOI 10.1073/pnas.93.11.5495; Pech V, 2005, AM J PHYSIOL-RENAL, V289, pF531, DOI 10.1152/ajprenal.00125.2005; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Saldova R, 2011, GLYCOBIOLOGY, V21, P195, DOI 10.1093/glycob/cwq147; Sands JM, 2003, J MEMBRANE BIOL, V191, P149, DOI 10.1007/s00232-002-1053-1; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977; Vagin O, 2009, AM J PHYSIOL-RENAL, V296, pF459, DOI 10.1152/ajprenal.90340.2008; Welker P, 2008, AM J PHYSIOL-RENAL, V295, pF789, DOI 10.1152/ajprenal.90227.2008; Xiong YN, 2009, BIOCHEM BIOPH RES CO, V384, P32, DOI 10.1016/j.bbrc.2009.04.044; Zhang C, 2002, AM J PHYSIOL-RENAL, V282, pF85, DOI 10.1152/ajprenal.0054.2001	42	31	36	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4531	4539		10.1096/fj.11-185991	http://dx.doi.org/10.1096/fj.11-185991			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21965602	Green Published			2022-12-28	WOS:000298138100043
J	Mesnard, L; Rafat, C; Vandermeersch, S; Hertig, A; Cathelin, D; Xu-Dubois, YC; Jouanneau, C; Keller, AC; Ribeil, JA; Leite-de-Moraes, MC; Rondeau, E				Mesnard, Laurent; Rafat, Cedric; Vandermeersch, Sophie; Hertig, Alexandre; Cathelin, Dominique; Xu-Dubois, Yi-Chun; Jouanneau, Chantal; Keller, Alexandre Castro; Ribeil, Jean-Antoine; Leite-de-Moraes, Maria C.; Rondeau, Eric			Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis	FASEB JOURNAL			English	Article						complement system; mouse model; PAI-1; Kidney	PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTI-GBM GLOMERULONEPHRITIS; DISEASED HUMAN KIDNEYS; S-PROTEIN VITRONECTIN; EXPRESSION IN-VIVO; CRESCENTIC GLOMERULONEPHRITIS; NEPHROTOXIC NEPHRITIS; GLOMERULAR INJURY; BIOLOGICAL ROLE; MESSENGER-RNA	During human glomerulonephritis, the severity of injuries correlates with glomerular fibrin deposits, which are tightly regulated by the intraglomerular fibrinolytic system. Here, we evaluated the role of vitronectin (VTN; also known as complement S protein), the principal cofactor of the plasminogen activator inhibitor-1 (PAI-1), in a mouse model of acute glomerulonephritis. We found that in mice subjected to nephrotoxic serum, the absence of VTN resulted in a lower glomerular PAI-1 activity and a higher glomerular fibrinolytic activity. Challenged VTN-/- mice displayed significantly less fibrin deposits, proteinuria, and renal failure than their wild-type counterparts. Notably, this protective effect afforded by VTN deficiency was still observed after a C3 depletion. Finally, the injection of VTN+/+ serum in VTN-/- mice induced the glomerular deposition of VTN, increased PAI-1 deposition, decreased glomerular fibrinolytic activity, and aggravated glomerular injury. As in mice, abundant glomerular VTN deposits were also observed in patients with severe glomerulonephritis. Here, we show that plasma-exchange therapy, admittedly beneficial in this clinical context, induces a significant depletion in circulating VTN, which might modulate PAI-1 activity locally and accelerate the clearance of fibrin deposits in the glomeruli. Collectively, these results demonstrate that VTN exerts a deleterious role independently from complement, by directing PAI-dependent fibrinolysis in the glomerular compartment.-Mesnard, L., Rafat, C., Vandermeersch, S., Hertig, A., Cathelina, D., Xu-Dubois, Y. -C., Jouanneau, C., Castro Keller, A., Ribeil, J. -A., Leite-de-Moraes, M. C., Rondeau, E. Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis. FASEB J. 25, 3543-3553 (2011). www.fasebj.org	[Mesnard, Laurent; Rafat, Cedric; Vandermeersch, Sophie; Hertig, Alexandre; Cathelin, Dominique; Xu-Dubois, Yi-Chun; Jouanneau, Chantal; Rondeau, Eric] Univ Paris 06, INSERM, UMR S702, Hop Tenon, F-75020 Paris, France; [Mesnard, Laurent; Rafat, Cedric; Hertig, Alexandre; Rondeau, Eric] Univ Paris 06, Hop Tenon, APHP, F-75020 Paris, France; [Keller, Alexandre Castro; Ribeil, Jean-Antoine; Leite-de-Moraes, Maria C.] Hop Necker Enfants Malad, CNRS, UMR 8147, Paris, France; [Ribeil, Jean-Antoine] Hop Necker Enfants Malad, APHP, Fac Med Rene Descartes, Dept Biotherapie, Paris, France; [Keller, Alexandre Castro] Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universidade Federal de Sao Paulo (UNIFESP)	Mesnard, L (corresponding author), Univ Paris 06, INSERM, UMR S702, Hop Tenon, 4 Rue Chine, F-75020 Paris, France.	laurent.mesnard@tnn.aphp.fr; eric.rondeau@tnn.aphp.fr	Ribeil, Jean-Antoine/AAK-7979-2020; Keller, Alexandre C/E-4621-2012; de Moraes, Maria Leite/AAV-9159-2020; Ribeil, Jean-Antoine/F-7896-2017	Ribeil, Jean-Antoine/0000-0002-4549-4783; Keller, Alexandre C/0000-0002-7827-0292; de Moraes, Maria Leite/0000-0002-2891-2269; Ribeil, Jean-Antoine/0000-0002-5733-9123; VANDERMEERSCH, sophie/0000-0001-6021-1334	Institut National de la Sante et de la Recherche Medicale (INSERM); Faculte de Medecine Pierre et Marie Curie; Academie de Medecine; European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/07120-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) in Brazil [501848/2009-6]	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Faculte de Medecine Pierre et Marie Curie; Academie de Medecine; European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) in Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was financially supported by the Institut National de la Sante et de la Recherche Medicale (INSERM) and by the Faculte de Medecine Pierre et Marie Curie. L.M. is a research fellow of INSERM. C.R. received grants from the Academie de Medecine. D.C. is recipient of a grant from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). A.C.K. is recipient of grants from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2007/07120-0) and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq 501848/2009-6) in Brazil. The authors thank Chantal, Carole, Corinne, Ismael, and Mariam for their technical assistance. The authors thank Caroline Martin and Claude Kitou for providing animal housing. The authors are grateful to Prof. B. P Morgan and Dr. T. Hughes (Cardiff University, Cardiff, UK), who provided antibodies against C9, DAF, and CD59a.	BARIETY J, 1989, CLIN EXP IMMUNOL, V75, P76; De Prada NA, 2002, EUR J BIOCHEM, V269, P184, DOI 10.1046/j.0014-2956.2002.02639.x; Drew AF, 2001, AM J PHYSIOL-RENAL, V281, pF1157, DOI 10.1152/ajprenal.0002.2001; Elberg G, 2006, NEPHRON EXP NEPHROL, V102, pE113, DOI 10.1159/000090070; FALK RJ, 1987, AM J PATHOL, V127, P182; Farrehi PM, 1998, CIRCULATION, V97, P1002; GIROUX L, 1979, LAB INVEST, V40, P415; Grandaliano G, 2000, AM J KIDNEY DIS, V35, P726, DOI 10.1016/S0272-6386(00)70022-9; Henseleit U, 1995, Exp Dermatol, V4, P249; Hertig A, 2004, J AM SOC NEPHROL, V15, P844, DOI 10.1097/01.ASN.0000115400.52705.83; Hertig A, 2003, FASEB J, V17, P1904, DOI 10.1096/fj.03-0084fje; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Huang YF, 2009, AM J PHYSIOL-RENAL, V297, pF1045, DOI 10.1152/ajprenal.00024.2009; Kitching AR, 2003, J AM SOC NEPHROL, V14, P1487, DOI 10.1097/01.ASN.0000065550.13931.00; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Lin F, 2004, J IMMUNOL, V172, P2636, DOI 10.4049/jimmunol.172.4.2636; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; MALLIAROS J, 1993, KIDNEY INT, V44, P557, DOI 10.1038/ki.1993.281; Mesnard L, 2009, J AM SOC NEPHROL, V20, P1282, DOI 10.1681/ASN.2008040433; MORLEY AR, 1985, J PATHOL, V145, P315, DOI 10.1002/path.1711450405; OGAWA T, 1994, NEPHRON, V68, P87, DOI 10.1159/000188225; OKADA M, 1993, VIRCHOWS ARCH A, V422, P367, DOI 10.1007/BF01605455; Osmers I, 2006, MOL IMMUNOL, V43, P1722, DOI 10.1016/j.molimm.2005.10.004; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; PODOR TJ, 1992, ANN NY ACAD SCI, V667, P173, DOI 10.1111/j.1749-6632.1992.tb51609.x; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Preissner KT, 1996, SEMIN THROMB HEMOST, V22, P165, DOI 10.1055/s-2007-999005; RONDEAU E, 1990, CLIN NEPHROL, V33, P55; SALANT DJ, 1988, METHOD ENZYMOL, V162, P421; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1994, J BIOL CHEM, V269, P19836; Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787; Stoop AA, 2000, ARTERIOSCL THROM VAS, V20, P1143, DOI 10.1161/01.ATV.20.4.1143; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; Turnberg D, 2003, J AM SOC NEPHROL, V14, P2271, DOI 10.1097/01.ASN.0000083901.47783.2E; Tuzun E, 2003, J IMMUNOL, V171, P3847, DOI 10.4049/jimmunol.171.7.3847; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANDIJK H, 1980, J IMMUNOL METHODS, V36, P29, DOI 10.1016/0022-1759(80)90091-5; VASSALLI P, 1964, ANN NY ACAD SCI, V116, P1052, DOI 10.1111/j.1749-6632.1964.tb52567.x; WARDLE EN, 1974, CLIN NEPHROL, V2, P85; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Xie C, 2004, J IMMUNOL, V172, P5047, DOI 10.4049/jimmunol.172.8.5047; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	48	7	7	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3543	3553		10.1096/fj.11-180752	http://dx.doi.org/10.1096/fj.11-180752			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21764994				2022-12-28	WOS:000295356400024
J	Bascove, M; Gueguinou, N; Schaerlinger, B; Gauquelin-Koch, G; Frippiat, JP				Bascove, Matthieu; Gueguinou, Nathan; Schaerlinger, Berenice; Gauquelin-Koch, Guillemette; Frippiat, Jean-Pol			Decrease in antibody somatic hypermutation frequency under extreme, extended spaceflight conditions	FASEB JOURNAL			English	Article						microgravity; immune response; immunoglobulin; affinity maturation; B lymphocytes	AMPHIBIAN PLEURODELES-WALTL; INDUCED CYTIDINE DEAMINASE; IMMUNOGLOBULIN HEAVY-CHAINS; T-CELL-ACTIVATION; GENE-EXPRESSION; AFFINITY MATURATION; HUMAN-LYMPHOCYTES; SPACE-FLIGHT; TERM SPACEFLIGHT; ANTIGEN RECEPTOR	Somatic hypermutation diversifies antibody binding sites by introducing point mutations in the variable domains of rearranged immunoglobulin genes. In this study, we analyzed somatic hypermutation in variable heavy-chain (VH) domains of specific IgM antibodies of the urodele amphibian Pleurodeles waltl, immunized either on Earth or onboard the Mir space station. To detect somatic hypermutation, we aligned the variable domains of IgM heavy-chain transcripts with the corresponding VH gene. We also quantified NF-kappa B and activation-induced cytidine deaminase transcripts. Results were compared with those obtained using control animals immunized on Earth. Our data show that, as in most species of ectotherms, somatic hypermutation in P. waltl exhibits a mutational bias toward G and C bases. Furthermore, we show for the first time that somatic hypermutation occurs in space following immunization but at a lower frequency. This decrease is not due to a decrease in food intake or of the B-cell receptor/antigen interaction or to the absence of the germinal center-associated nuclear protein. It likely results from the combination of several spaceflight-associated changes, such as the severe reduction in T-cell activation, important perturbations of the cytoskeleton, and changes in the distribution of lymphocyte subpopulations and adhesion molecule expression.-Bascove, M., Gueguinou, N., Schaerlinger, B., Gauquelin-Koch, G., Frippiat, J.-P. Decrease in antibody somatic hypermutation frequency under extreme, extended spaceflight conditions. FASEB J. 25, 2947-2955 (2011). www.fasebj.org	[Frippiat, Jean-Pol] Nancy Univ, Fac Med Dev & Immunogenet, JE 2537, F-54500 Vandoeuvre Les Nancy, France; [Gauquelin-Koch, Guillemette] French Natl Space Agcy, Paris, France	Universite de Lorraine	Frippiat, JP (corresponding author), Nancy Univ, Fac Med Dev & Immunogenet, JE 2537, 9 Ave Foret Haye, F-54500 Vandoeuvre Les Nancy, France.	jean-pol.frippiat@scbiol.uhp-nancy.fr	Schaerlinger, Berenice/AAU-8024-2021	Schaerlinger, Berenice/0000-0002-7449-2752; Frippiat, Jean-Pol/0000-0002-4027-6269	French National Space Agency (CNES); National Research Agency [ANR NT09-632666]; French Ministry of Higher Education and Research; University of Nancy	French National Space Agency (CNES)(Centre National D'etudes Spatiales); National Research Agency(French National Research Agency (ANR)); French Ministry of Higher Education and Research; University of Nancy	The authors thank the French cosmonaut J.-P. Haignere for performing the Genesis experiment onboard the Mir space station; Prof. A. Dalloul for critical reading and suggestions; our Russian colleagues for the preparation of the space mission; and the French National Space Agency (CNES), the National Research Agency (ANR NT09-632666), the French Ministry of Higher Education and Research, and the University of Nancy for financial support.	Baqai FP, 2009, J APPL PHYSIOL, V106, P1935, DOI 10.1152/japplphysiol.91361.2008; Bascove M, 2010, MOL IMMUNOL, V47, P1640, DOI 10.1016/j.molimm.2010.01.005; Bascove M, 2009, FASEB J, V23, P1607, DOI 10.1096/fj.08-121327; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; Boxio R, 2005, J APPL PHYSIOL, V98, P905, DOI 10.1152/japplphysiol.00957.2004; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; COGOLIGREUTER M, 2004, J GRAVIT PHYSL, V11, P53; Criscitiello MF, 2007, EUR J IMMUNOL, V37, P2683, DOI 10.1002/eji.200737263; Crucian BE, 2000, J INTERF CYTOK RES, V20, P547, DOI 10.1089/10799900050044741; Crucian BE, 2008, AVIAT SPACE ENVIR MD, V79, P835, DOI 10.3357/ASEM.2276.2008; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Diaz M, 1999, INT IMMUNOL, V11, P825, DOI 10.1093/intimm/11.5.825; Dorner T, 1997, J IMMUNOL, V158, P2779; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; Flajnik MF, 2010, NAT REV GENET, V11, P47, DOI 10.1038/nrg2703; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GONZALEZFERNANDEZ A, 1994, P NATL ACAD SCI USA, V91, P12614, DOI 10.1073/pnas.91.26.12614; GOULD CL, 1987, AVIAT SPACE ENVIR MD, V58, P983; Gridley DS, 2009, J APPL PHYSIOL, V106, P194, DOI 10.1152/japplphysiol.91126.2008; GROVE DS, 1995, EXP CELL RES, V219, P102, DOI 10.1006/excr.1995.1210; Gueguinou N, 2009, J LEUKOCYTE BIOL, V86, P1027, DOI 10.1189/jlb.0309167; Hashemi BB, 1999, FASEB J, V13, P2071, DOI 10.1096/fasebj.13.14.2071; HINDSFREY KR, 1993, J EXP MED, V178, P815, DOI 10.1084/jem.178.3.815; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; Hughes-Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883; Ichiki AT, 1996, J LEUKOCYTE BIOL, V60, P37, DOI 10.1002/jlb.60.1.37; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Kuwahara K, 2004, P NATL ACAD SCI USA, V101, P1010, DOI 10.1073/pnas.0307609100; Langerak P, 2007, J EXP MED, V204, P1989, DOI 10.1084/jem.20070902; Lebsack TW, 2010, J CELL BIOCHEM, V110, P372, DOI 10.1002/jcb.22547; Lee SS, 2002, IMMUNITY, V16, P571, DOI 10.1016/S1074-7613(02)00300-X; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Litman GW, 2010, NAT REV IMMUNOL, V10, P543, DOI 10.1038/nri2807; Maccarrone M, 2003, J LEUKOCYTE BIOL, V73, P472, DOI 10.1189/jlb.0602295; Marr S, 2007, J IMMUNOL, V179, P6783, DOI 10.4049/jimmunol.179.10.6783; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; Maul RW, 2011, NAT IMMUNOL, V12, P70, DOI 10.1038/ni.1970; Maule Jake, 2003, J Gravit Physiol, V10, P47; Meloni MA, 2006, PROTOPLASMA, V229, P243, DOI 10.1007/s00709-006-0210-2; Meloni MA, 2011, CYTOSKELETON, V68, P125, DOI 10.1002/cm.20499; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; Mognato M, 2009, MUTAT RES-FUND MOL M, V663, P32, DOI 10.1016/j.mrfmmm.2009.01.002; PARVARI R, 1990, P NATL ACAD SCI USA, V87, P3072, DOI 10.1073/pnas.87.8.3072; Pecaut MJ, 2003, J APPL PHYSIOL, V94, P2085, DOI 10.1152/japplphysiol.01052.2002; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Schaerlinger B, 2008, MOL IMMUNOL, V45, P776, DOI 10.1016/j.molimm.2007.06.356; Shen HM, 2006, J IMMUNOL, V177, P5386, DOI 10.4049/jimmunol.177.8.5386; Sonnenfeld G, 1992, J APPL PHYSIOL, V73, p191S; Stowe RP, 1999, J LEUKOCYTE BIOL, V65, P179, DOI 10.1002/jlb.65.2.179; Tian J, 2010, J APPL PHYSIOL, V108, P162, DOI 10.1152/japplphysiol.00730.2009; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vernikos J, 1996, BIOESSAYS, V18, P1029, DOI 10.1002/bies.950181215; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; WILSON M, 1992, EMBO J, V11, P4337, DOI 10.1002/j.1460-2075.1992.tb05533.x; Wilson M, 1995, DEV IMMUNOL, V4, P227, DOI 10.1155/1995/38639; Yang FX, 2006, J IMMUNOL, V176, P1655, DOI 10.4049/jimmunol.176.3.1655; YELAMOS J, 1995, NATURE, V376, P225	63	30	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2947	2955		10.1096/fj.11-185215	http://dx.doi.org/10.1096/fj.11-185215			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21593434				2022-12-28	WOS:000294435200010
J	Martin, A; Liu, SG; David, V; Li, H; Karydis, A; Feng, JQ; Quarles, LD				Martin, Aline; Liu, Shiguang; David, Valentin; Li, Hua; Karydis, Anastasios; Feng, Jian Q.; Quarles, L. Darryl			Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling	FASEB JOURNAL			English	Article						XLH; ARHR; hypophosphatemia; osteomalacia; microarray	MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PARATHYROID-HORMONE; MINERALIZATION DEFECT; PHOSPHATE-TRANSPORT; GENE-EXPRESSION; PATHOGENIC ROLE; FIBROBLAST-GROWTH-FACTOR-23; OSTEOMALACIA; METABOLISM; KLOTHO	Fibroblastic growth factor 23 (FGF23) is a circulating phosphaturic hormone. Inactivating mutations of the endopeptidase PHEX or the SIBLING protein DMP1 result in equivalent intrinsic bone mineralization defects and increased Fgf23 expression in osteocytes. The mechanisms whereby PHEX and DMP1 regulate Fgf23 expression are unknown. We examined the possibility that PHEX and DMP1 regulate Fgf23 through a common pathway by analyzing the phenotype of compound Phex and Dmp1 mutant mice (Hyp/Dmp1(-/-)). Compared to single-mutant littermates, compound-mutant Hyp/Dmp1(-/-) mice displayed nonadditive elevations of serum FGF23 (1912 +/- 183, 1715 +/- 178, and 1799 +/- 181 pg/ml), hypophosphatemia (Pi: 6.0 +/- 0.3, 5.8 +/- 0.2, and 5.4 +/- 0.1 mg/dl), and severity of rickets/osteomalacia (bone mineral density: -36, -36, and -30%). Microarray analysis of long bones identified gene expression profiles implicating common activation of the FGFR pathway in all the mutant groups. Furthermore, inhibiting FGFR signaling using SU5402 in Hyp- and Dmp1(-/-)-derived bone marrow stromal cells prevented the increase in Fgf23 mRNA expression (129- and 124-fold increase in Hyp and Dmp1(-/-) vs. 1.3-fold in Hyp+SU5402 and 2.5-fold in Dmp1(-/-)+SU5402, P < 0.05). For all analyses, samples collected from nonmutant wild-type littermates served as controls. These findings indicate that PHEX and DMP1 control a common pathway regulating bone mineralization and FGF23 production, the latter involving activation of the FGFR signaling in osteocytes.-Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., Quarles, L. D. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway. FASEB J. 25, 2551-2562 (2011). www.fasebj.org	[Martin, Aline; David, Valentin; Li, Hua; Karydis, Anastasios; Quarles, L. Darryl] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Liu, Shiguang] Genzyme Corp, Framingham, MA 01701 USA; [Feng, Jian Q.] Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA	University of Tennessee System; University of Tennessee Health Science Center; Sanofi-Aventis; Genzyme Corporation; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Quarles, LD (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coleman Coll Med Bldg,Ste B216,956 Court Ave, Memphis, TN 38163 USA.	amarti71@uthsc.edu		Quarles, L. Darryl/0000-0002-5082-7896	U.S. National Institutes of Health from the National Institute of Arthritis and Musculoskeletal and Skin Diseases [RO1-AR45955]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045955, R56AR045955] Funding Source: NIH RePORTER	U.S. National Institutes of Health from the National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U.S. National Institutes of Health grant RO1-AR45955 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors thank Drs. Ivan Gerling, Weikuan Gu, and Yan Jiao for their help and advice on microarray analysis and Jianping Zhou for his technical expertise.	Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004-0233; Beret-Pages A, 2004, BONE, V35, P455, DOI 10.1016/j.bone.2004.04.002; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105; Carpenter TO, 2005, J CLIN ENDOCR METAB, V90, P1012, DOI 10.1210/jc.2004-0357; David V, 2009, ENDOCRINOLOGY, V150, P4012, DOI 10.1210/en.2009-0216; Dunham-Ems SM, 2009, MOL BIOL CELL, V20, P2401, DOI 10.1091/mbc.E08-06-0600; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004-1039; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; Guo R, 2001, AM J PHYSIOL-ENDOC M, V281, pE837, DOI 10.1152/ajpendo.2001.281.4.E837; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; *I LAB AN RES, 1996, PUBL NIH, V8623; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Kawata T, 2007, J AM SOC NEPHROL, V18, P2683, DOI 10.1681/ASN.2006070783; Kolek OI, 2005, AM J PHYSIOL-GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003-1768; Li H, 2011, AM J PHYSIOL-ENDOC M, V300, pE508, DOI 10.1152/ajpendo.00499.2010; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Liu SG, 2005, J AM SOC NEPHROL, V16, P1645, DOI 10.1681/ASN.2004121060; Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200; Liu SG, 2008, AM J PHYSIOL-ENDOC M, V295, pE254, DOI 10.1152/ajpendo.90201.2008; Liu SG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1636, DOI 10.1152/ajpendo.00396.2007; Liu SG, 2007, J ENDOCRINOL, V192, P261, DOI 10.1677/joe.1.07059; Liu SG, 2006, J AM SOC NEPHROL, V17, P1305, DOI 10.1681/ASN.2005111185; Liu SG, 2006, AM J PHYSIOL-ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006; Liu SG, 2009, MOL ENDOCRINOL, V23, P1505, DOI 10.1210/me.2009-0085; Lotinun S, 2002, ENDOCRINE, V17, P29, DOI 10.1385/ENDO:17:1:29; Lu YB, 2009, CELLS TISSUES ORGANS, V189, P175, DOI 10.1159/000151727; Martin A, 2008, ENDOCRINOLOGY, V149, P1757, DOI 10.1210/en.2007-1205; Martin A, 2008, J BONE MINER RES, V23, P2040, DOI 10.1359/JBMR.080708; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mori S, 2008, J BIOL CHEM, V283, P18066, DOI 10.1074/jbc.M801213200; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Nauman EA, 2003, CALCIFIED TISSUE INT, V73, P147, DOI 10.1007/s00223-002-1033-6; Nishida Y, 2006, KIDNEY INT, V70, P2141, DOI 10.1038/sj.ki.5002000; Perwad F, 2005, ENDOCRINOLOGY, V146, P5358, DOI 10.1210/en.2005-0777; Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004; Quarles LD, 2008, J CLIN INVEST, V118, P3820, DOI 10.1172/JCI36479; Rowe PSN, 2006, BONE, V39, P773, DOI 10.1016/j.bone.2006.04.012; Saji F, 2009, NEPHRON PHYSIOL, V111, P59, DOI 10.1159/000210389; Samadfam R, 2009, ENDOCRINOLOGY, V150, P4835, DOI 10.1210/en.2009-0472; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2005, AM J PHYSIOL-RENAL, V289, pF1088, DOI 10.1152/ajprenal.00474.2004; Stevens DA, 2003, MOL ENDOCRINOL, V17, P1751, DOI 10.1210/me.2003-0137; Suzuki M, 2008, MOL ENDOCRINOL, V22, P1006, DOI 10.1210/me.2007-0313; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tebben PJ, 2004, MAYO CLIN PROC, V79, P1508, DOI 10.4065/79.12.1508; Tomoe Y, 2010, AM J PHYSIOL-RENAL, V298, pF1341, DOI 10.1152/ajprenal.00375.2009; Tsuji K, 2010, J BONE MINER RES, V25, P1711, DOI 10.1002/jbmr.65; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Xiao LP, 2010, J BIOL CHEM, V285, P2834, DOI 10.1074/jbc.M109.030577; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Zhang B, 2010, ORAL DIS, V16, P453, DOI 10.1111/j.1601-0825.2010.01656.x	61	177	183	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2551	2562		10.1096/fj.10-177816	http://dx.doi.org/10.1096/fj.10-177816			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507898	Green Published			2022-12-28	WOS:000293337800006
J	Woo, KC; Kim, TD; Lee, KH; Kim, DY; Kim, S; Lee, HR; Kang, HJ; Chung, SJ; Senju, S; Nishimura, Y; Kim, KT				Woo, Kyung-Chul; Kim, Tae-Don; Lee, Kyung-Ha; Kim, Do-Yeon; Kim, Sangjune; Lee, Hwa-Rim; Kang, Hyo-Jin; Chung, Sang J.; Senju, Satoru; Nishimura, Yasuharu; Kim, Kyong-Tai			Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs	FASEB JOURNAL			English	Article						circadian rhythm; untranslated region	N-ACETYLTRANSFERASE; 3'-UNTRANSLATED REGION; QUALITY-CONTROL; SKI COMPLEX; MOUSE; DECAY; DEGRADATION; EXPRESSION; KSRP; IDENTIFICATION	Eukaryotic mRNA turnover is among most critical mechanisms that affect mRNA abundance and are regulated by mRNA-binding proteins and the cytoplasmic exosome. A functional protein, guanosinetriphosphate-binding protein 1 (GTPBP1), which associates with both the exosome and target mRNAs, was identified. The overexpression of GTPBP1 accelerated the target mRNA decay, whereas the reduction of the GTPBP1 expression with RNA interference stabilized the target mRNA. GTPBP1 has a putative guanosinetriphosphate (GTP)-binding domain, which is found in members of the G-protein family and Ski7p, a well-known core factor of the exosome-mediated mRNA turnover pathway in yeast. Analyses of protein interactions and mRNA decay demonstrated that GTPBP1 modulates mRNA degradation via GTP-binding-dependent target loading. Moreover, GTPBP1-knockout models displayed multiple mRNA decay defects, including elevated nocturnal levels of Aanat mRNA in pineal glands, and retarded degradation of TNF-alpha mRNA in lipopolysaccharide-treated splenocytes. The results of this study suggest that GTPBP1 is a regulator and adaptor of the exosome-mediated mRNA turnover pathway.-Woo, K.-C., Kim, T.-D., Lee, K.-H., Kim, D.-Y. Kim, S., Lee, H.-R., Kang, H.-J., Chung, S. J., Senju, S., Nishimura, Yasuharu, Kim, K.-T. Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs. FASEB J. 25, 2757-2769 (2011). www.fasebj.org	[Woo, Kyung-Chul; Lee, Kyung-Ha; Kim, Do-Yeon; Kim, Sangjune; Lee, Hwa-Rim; Kim, Kyong-Tai] Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang, South Korea; [Kim, Kyong-Tai] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Kang, Hyo-Jin; Chung, Sang J.] Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, Taejon, South Korea; [Kim, Tae-Don] Korea Res Inst Biosci & Biotechnol, Cell Therapy Res Ctr, Taejon, South Korea; [Kang, Hyo-Jin; Chung, Sang J.] Korea Univ Sci & Technol, Nanobiotechnol Div, Taejon, South Korea; [Senju, Satoru; Nishimura, Yasuharu] Kumamoto Univ, Grad Sch Med Sci, Dept Immunogenet, Kumamoto, Japan	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kumamoto University	Kim, KT (corresponding author), POSTECH, Dept Life Sci, San 31, Pohang 790784, South Korea.	ktk@postech.ac.kr	Lee, Kyung-Ha/GRY-2640-2022; Kim, Do-Yeon/B-1877-2009	Lee, Kyung-Ha/0000-0003-0515-7392; Kang, Hyo Jin/0000-0001-7104-8456; Kim, Sangjune/0000-0003-3052-3163; Kim, Tae-Don/0000-0002-5910-4264; KIM, KYONG-TAI/0000-0001-7292-2627	National Research Foundation of Korea [20100030004, 20100000250, 20100002146, 20100019706]; Brain Korea 21 program; World Class University [R31-10105]; Korean Ministry of Education, Science, and Technology; Pohang University of Science and Technology Biotechnology Research Center	National Research Foundation of Korea(National Research Foundation of Korea); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); World Class University; Korean Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Pohang University of Science and Technology Biotechnology Research Center	The authors thank Dr. C. S. Lee and Dr. S. H. Ha for critical comments, Dr. Kyung-Yeol Lee (Chonbuk National University, Jeanju, Korea) for the pCY2-TNF-alpha ARE, and Dr. K. J. Kim for the hnRNP Q437 purification. This work was supported by grants from the National Research Foundation of Korea (20100030004, 20100000250, 20100002146, and 20100019706), the Brain Korea 21 program, the World Class University program (R31-10105), and the Regional Core Research Program/Antiaging and Well-being Research Center funded by the Korean Ministry of Education, Science, and Technology. This work was also supported by Pohang University of Science and Technology Biotechnology Research Center.	Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; Benard L, 1999, J VIROL, V73, P2893, DOI 10.1128/JVI.73.4.2893-2900.1999; Bosgraaf L, 2003, BBA-MOL CELL RES, V1643, P5, DOI 10.1016/j.bbamcr.2003.08.008; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Chae HD, 1999, NEUROCHEM INT, V35, P447, DOI 10.1016/S0197-0186(99)00086-8; Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017; Coon SL, 2006, MOL CELL ENDOCRINOL, V252, P2, DOI 10.1016/j.mce.2006.03.039; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Diaz-Moreno I, 2009, NAT STRUCT MOL BIOL, V16, P238, DOI 10.1038/nsmb.1558; Fritz DT, 2004, CELL BIOCHEM BIOPHYS, V41, P265, DOI 10.1385/CBB:41:2:265; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; Garcia-Mayoral MF, 2008, NUCLEIC ACIDS RES, V36, P5290, DOI 10.1093/nar/gkn509; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Guo JH, 2009, CELL, V138, P1236, DOI 10.1016/j.cell.2009.06.043; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Isken O, 2007, GENE DEV, V21, P1833, DOI 10.1101/gad.1566807; Kim TD, 2007, GENE DEV, V21, P797, DOI 10.1101/gad.1519507; Kim TD, 2005, MOL CELL BIOL, V25, P3232, DOI 10.1128/MCB.25.8.3232-3246.2005; Kojima S, 2003, BIOCHEM BIOPH RES CO, V301, P1, DOI 10.1016/S0006-291X(02)02938-8; Kojima S, 2007, P NATL ACAD SCI USA, V104, P1859, DOI 10.1073/pnas.0607567104; Kudo H, 2000, BIOCHEM BIOPH RES CO, V272, P456, DOI 10.1006/bbrc.2000.2763; Kwak E, 2006, J BIOL CHEM, V281, P19100, DOI 10.1074/jbc.M511927200; Kwon MC, 2008, EMBO J, V27, P642, DOI 10.1038/sj.emboj.7601986; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Mitchell P, 2003, MOL CELL, V11, P1405, DOI 10.1016/S1097-2765(03)00190-4; Murakoshi H, 2004, P NATL ACAD SCI USA, V101, P7317, DOI 10.1073/pnas.0401354101; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Roseboom PH, 1998, MOL BRAIN RES, V63, P189, DOI 10.1016/S0169-328X(98)00273-3; Rudoni S, 2001, BBA-MOL CELL RES, V1538, P181, DOI 10.1016/S0167-4889(01)00067-2; Ruggiero T, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-28; Schmid M, 2008, TRENDS BIOCHEM SCI, V33, P501, DOI 10.1016/j.tibs.2008.07.003; Senju S, 1997, BIOCHEM BIOPH RES CO, V231, P360, DOI 10.1006/bbrc.1997.6103; Senju S, 2000, MOL CELL BIOL, V20, P6195, DOI 10.1128/MCB.20.17.6195-6200.2000; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; UKAITADENUMA M, 2008, NAT CELL BIOL; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Woo KC, 2009, NUCLEIC ACIDS RES, V37, P26, DOI 10.1093/nar/gkn893; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	47	20	28	3	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2757	2769		10.1096/fj.10-178715	http://dx.doi.org/10.1096/fj.10-178715			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21515746				2022-12-28	WOS:000293337800024
J	Rossi, CA; Flaibani, M; Blaauw, B; Pozzobon, M; Figallo, E; Reggiani, C; Vitiello, L; Elvassore, N; De Coppi, P				Rossi, Carlo Alberto; Flaibani, Marina; Blaauw, Bert; Pozzobon, Michela; Figallo, Elisa; Reggiani, Carlo; Vitiello, Libero; Elvassore, Nicola; De Coppi, Paolo			In vivo tissue engineering of functional skeletal muscle by freshly isolated satellite cells embedded in a photopolymerizable hydrogel	FASEB JOURNAL			English	Article						muscle ablation; muscle reconstruction; biocompatible scaffold; cell transplantation	DIFFERENTIATION; TRANSPLANTATION; ACTIVATION; SCAFFOLDS	The success of skeletal muscle reconstruction depends on finding the most effective, clinically suitable strategy to engineer myogenic cells and biocompatible scaffolds. Satellite cells (SCs), freshly isolated or transplanted within their niche, are presently considered the best source for muscle regeneration. Here, we designed and developed the delivery of either SCs or muscle progenitor cells (MPCs) via an in situ photo-cross-linkable hyaluronan-based hydrogel, hyaluronic acid-photoinitiator (HA-PI) complex. Partially ablated tibialis anterior (TA) of C57BL/6J mice engrafted with freshly isolated satellite cells embedded in hydrogel showed a major improvement in muscle structure and number of new myofibers, compared to muscles receiving hydrogel + MPCs or hydrogel alone. Notably, SCs embedded in HA-PI also promoted functional recovery, as assessed by contractile force measurements. Tissue reconstruction was associated with the formation of both neural and vascular networks and the reconstitution of a functional SC niche. This innovative approach could overcome previous limitations in skeletal muscle tissue engineering.-Rossi, C. A., Flaibani, M., Blaauw, B., Pozzobon, M., Figallo, E., Reggiani, C., Vitiello, L., Elvassore, N., De Coppi, P. In vivo tissue engineering of functional skeletal muscle by freshly isolated satellite cells embedded in a photopolymerizable hydrogel. FASEB J. 25, 2296-2304 (2011). www.fasebj.org	[Rossi, Carlo Alberto; De Coppi, Paolo] UCL, Inst Child Hlth, Surg Unit, London WC1N 1EH, England; [Rossi, Carlo Alberto; Pozzobon, Michela; De Coppi, Paolo] Univ Padua, Dept Pediat, Stem Cell Lab, I-35131 Padua, Italy; [Flaibani, Marina; Figallo, Elisa; Elvassore, Nicola] Univ Padua, Dept Chem Engn, I-35131 Padua, Italy; [Blaauw, Bert; Reggiani, Carlo] Univ Padua, Dept Human Anat & Physiol, I-35131 Padua, Italy; [Vitiello, Libero] Univ Padua, Dept Biol, I-35131 Padua, Italy; [Flaibani, Marina; Blaauw, Bert; Elvassore, Nicola] Venetian Inst Mol Med, Padua, Italy	University of London; University College London; University of Padua; University of Padua; University of Padua; University of Padua; Veneto Institute Molecular Medicine	De Coppi, P (corresponding author), UCL, Inst Child Hlth, Surg Unit, 30 Guilford St, London WC1N 1EH, England.	nicola.elvassore@unipd.it; p.decoppi@ich.ucl.ac.uk	Pozzobon, Michela/X-7504-2019; blaauw, bert/A-7614-2014; Pozzobon, Michela/G-7974-2018; Vitiello, Libero/AAJ-6962-2021	Pozzobon, Michela/0000-0001-9213-402X; blaauw, bert/0000-0002-3893-1463; Pozzobon, Michela/0000-0001-9213-402X; Vitiello, Libero/0000-0003-0017-0838; Flaibani, Marina/0000-0001-6284-5699; De Coppi, Paolo/0000-0002-1659-0207; BLAAUW, BERT/0000-0002-4167-5106	Fondazione Telethon (Rome, Italy) [GGP07216]; Fondazione Il Sangue (Milan, Italy); Fondazione Citta della Speranza (Malo, Vicenza, Italy) [08/02]; Great Ormond Street Hospital Charity; Great Ormond Street Hospital Childrens Charity [V1230] Funding Source: researchfish	Fondazione Telethon (Rome, Italy)(Fondazione Telethon); Fondazione Il Sangue (Milan, Italy); Fondazione Citta della Speranza (Malo, Vicenza, Italy); Great Ormond Street Hospital Charity; Great Ormond Street Hospital Childrens Charity	The authors gratefully acknowledge Fidia Advanced Biopolymers (Abano Terme, Padua, Italy) for providing HA-PI. This work has been supported by Fondazione Telethon (Rome, Italy; grant GGP07216), Fondazione Il Sangue (Milan, Italy) and Fondazione Citta della Speranza (Malo, Vicenza, Italy; grant 08/02). P. D. C. has been supported by the Great Ormond Street Hospital Charity. C. A. R., M. F., M. P., C. R., L. V., N.E. and P. D. C. designed the experiments; C. A. R., M. F., B. B., E. F., and L. V. performed the experiments; C. A. R., L. V., N.E., and P. D. C. wrote the article. The authors declare no competing financial interests.	BEAUCHAMP JR, 2000, J CELL BIOL, V22, P1113; Beier JP, 2006, PLAST RECONSTR SURG, V118, P1113, DOI 10.1097/01.prs.0000221007.97115.1d; Blaauw B, 2008, HUM MOL GENET, V17, P3686, DOI 10.1093/hmg/ddn264; Blau HM, 2008, NEW ENGL J MED, V359, P1403, DOI 10.1056/NEJMcibr0805708; Boldrin L, 2007, TISSUE ENG, V13, P253, DOI 10.1089/ten.2006.0093; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Carnio S, 2011, J TISSUE ENG REGEN M, V5, P1, DOI 10.1002/term.282; CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228; CLELAND RL, 1970, BIOPOLYMERS, V9, P799, DOI 10.1002/bip.1970.360090706; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; De Coppi P, 2005, TISSUE ENG, V11, P1034, DOI 10.1089/ten.2005.11.1034; De Coppi P, 2006, TISSUE ENG, V12, P1929, DOI 10.1089/ten.2006.12.1929; de Jong SJ, 2001, J CONTROL RELEASE, V71, P261, DOI 10.1016/S0168-3659(01)00228-0; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; Giraud MN, 2008, ARTIF ORGANS, V32, P692, DOI 10.1111/j.1525-1594.2008.00595.x; Hathcock JJ, 2000, J BIOMAT SCI-POLYM E, V11, P1211, DOI 10.1163/156856200744282; Huang LK, 1997, PHARMACEUT RES, V14, P475, DOI 10.1023/A:1012199500072; Malm C, 2001, ACTA PHYSIOL SCAND, V171, P233, DOI 10.1046/j.1365-201x.2001.00825.x; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; REVELL PA, 2005, J MATER SCI-MATER M, V18, P303; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; Rossi CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008523; Rossi CA, 2010, ORGANOGENESIS, V6, P167, DOI 10.4161/org.6.3.12419; Rumsey JW, 2008, BIOMATERIALS, V29, P994, DOI 10.1016/j.biomaterials.2007.10.042; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; SCHIAFFINO S, 1986, EXP CELL RES, V163, P211, DOI 10.1016/0014-4827(86)90574-4; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Serena E, 2008, NEUROL RES, V30, P207, DOI 10.1179/174313208X281109; Yan W, 2007, TISSUE ENG, V13, P2781, DOI 10.1089/ten.2006.0408	32	144	149	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2296	2304		10.1096/fj.10-174755	http://dx.doi.org/10.1096/fj.10-174755			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21450908				2022-12-28	WOS:000292242200021
J	Chen, BY; Li, Y; Jiang, SX; Xie, YP; Guo, A; Kutschke, W; Zimmerman, K; Weiss, RM; Miller, FJ; Anderson, ME; Song, LS				Chen, Biyi; Li, Yue; Jiang, Shuxia; Xie, Yu-Ping; Guo, Ang; Kutschke, William; Zimmerman, Kathy; Weiss, Robert M.; Miller, Francis J.; Anderson, Mark E.; Song, Long-Sheng			beta-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction	FASEB JOURNAL			English	Article						heart failure; beta-AR blockers	CHRONIC HEART-FAILURE; VENTRICULAR MYOCYTES; CA2+ RELEASE; ADRENOCEPTOR ANTAGONISTS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTORS; REDUCED SYNCHRONY; CARDIAC MYOCYTES; RAT-HEART; CARVEDILOL	beta-Adrenergic receptor (AR) blockers provide substantial clinical benefits, including improving overall survival and left ventricular (LV) function following myocardial infarction (MI), though the mechanisms remain incompletely defined. The transverse-tubule (T-tubule) system of ventricular myocytes is an important determinant of cardiac excitation-contraction function. T-tubule remodeling occurs early during LV failure. We hypothesized that beta-AR blockers prevent T-tubule remodeling and thereby provide therapeutic benefits. A murine model of MI was utilized to examine the effect of beta-AR blockers on T-tubule remodeling following LV MI. We applied the in situ imaging of T-tubule structure from Langendorff-perfused intact hearts with laser scanning confocal microscopy. We found that MI caused remarkable T-tubule remodeling near the infarction border zone and moderate LV remodeling remote from the MI. Metoprolol and carvedilol administered 6 d after MI for 4 wk each increased the T-tubule integrity at the remote and border zones. At the molecular level, both beta-AR blockers restored border and remote zone expression of junctophilin-2 (JP-2), which is involved in T-tubule organization and formation of the T-tubule/sarcoplasmic reticulum junctions. In contrast, beta-AR blockers had no significant effects on caveolin-3 expression. In summary, our data show that beta-AR antagonists can protect against T-tubule remodeling after MI, suggesting a novel therapeutic mechanism of action for this drug class. Preservation of JP-2 expression may contribute to the beneficial effects of metoprolol and carvedilol on T-tubule remodeling.-Chen, B., Li, Y., Jiang, S., Xie, Y.-P., Guo, A., Kutschke, W., Zimmerman, K., Weiss, R. M., Miller, F. J., Anderson, M. E., Song, L.-S. beta-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. FASEB J. 26, 2531-2537 (2012). www.fasebj.org	[Chen, Biyi; Li, Yue; Jiang, Shuxia; Xie, Yu-Ping; Guo, Ang; Kutschke, William; Weiss, Robert M.; Miller, Francis J.; Anderson, Mark E.; Song, Long-Sheng] Univ Iowa, Dept Internal Med, Div Cardiovasc Med, Carver Coll Med, Iowa City, IA 52242 USA; [Zimmerman, Kathy; Miller, Francis J.] Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Song, LS (corresponding author), Univ Iowa, Dept Internal Med, Div Cardiovasc Med, Carver Coll Med, Iowa City, IA 52242 USA.	long-sheng-song@uiowa.edu	Miller Jr, Francis/N-7312-2015; Chen, Biyi/AAF-3077-2021; Guo, Ang/M-3549-2013; Miller, Francis J/F-3801-2017	Miller Jr, Francis/0000-0001-5822-0549; Guo, Ang/0000-0002-5551-2279; Miller, Francis J/0000-0001-5822-0549; Song, Long-Sheng/0000-0002-6035-8106; Weiss, Robert/0000-0003-1307-2647	U.S. National Institutes of Health [NIH R01 HL090905, RR026293]; American Heart Association [0635056N, 11POST7640011]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026293] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090905] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grants NIH R01 HL090905 (L. S. S.) and RR026293 (R. M. W.) and American Heart Association Scientific Development grant 0635056N (L. S. S.). S. J. was supported in part by an American Heart Association postdoctoral fellowship award (11POST7640011). The authors declare no conflicts of interest.	Bartholomeu JB, 2008, J MOL CELL CARDIOL, V45, P240, DOI 10.1016/j.yjmcc.2008.05.011; Bito V, 2008, CARDIOVASC RES, V77, P315, DOI 10.1093/cvr/cvm063; Brette F, 2005, J MOL CELL CARDIOL, V39, P804, DOI 10.1016/j.yjmcc.2005.08.005; Brette F, 2004, J MOL CELL CARDIOL, V36, P265, DOI 10.1016/j.yjmcc.2003.11.002; Brette F, 2003, CIRC RES, V92, P1182, DOI 10.1161/01.RES.0000074908.17214.FD; Colucci WS, 2007, CIRCULATION, V116, P49, DOI 10.1161/CIRCULATIONAHA.106.666016; Crossman DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017901; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; Doughty RN, 2004, CIRCULATION, V109, P201, DOI 10.1161/01.CIR.0000108928.25690.94; EPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Francis J, 2001, AM J PHYSIOL-REG I, V281, pR1734, DOI 10.1152/ajpregu.2001.281.5.R1734; Franzini-Armstrong C, 1999, FASEB J, V13, pS266, DOI 10.1096/fasebj.13.9002.S266; Gheorghiade M, 2003, CIRCULATION, V107, P1570, DOI 10.1161/01.CIR.0000065187.80707.18; HALL SA, 1995, J AM COLL CARDIOL, V25, P1154, DOI 10.1016/0735-1097(94)00543-Y; Heinzel FR, 2008, CIRC RES, V102, P338, DOI 10.1161/CIRCRESAHA.107.160085; Ibrahim M, 2010, FASEB J, V24, P3321, DOI 10.1096/fj.10-156638; Janosi A, 2003, AM HEART J, V146, P721, DOI 10.1016/S0002-8703(03)00163-7; Kemi OJ, 2011, J CELL PHYSIOL, V226, P2235, DOI 10.1002/jcp.22559; Khattar RS, 2001, AM HEART J, V142, P704, DOI 10.1067/mhj.2001.116768; Landstrom AP, 2011, CIRC-HEART FAIL, V4, P214, DOI 10.1161/CIRCHEARTFAILURE.110.958694; Louch WE, 2006, J PHYSIOL-LONDON, V574, P519, DOI 10.1113/jphysiol.2006.107227; Lyon AR, 2009, P NATL ACAD SCI USA, V106, P6854, DOI 10.1073/pnas.0809777106; Maczewski M, 2008, CARDIOVASC RES, V79, P42, DOI 10.1093/cvr/cvn057; Minamisawa S, 2004, BIOCHEM BIOPH RES CO, V325, P852, DOI 10.1016/j.bbrc.2004.10.107; Minetti C, 2002, AM J PATHOL, V160, P265, DOI 10.1016/S0002-9440(10)64370-2; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Rehsia NS, 2010, EXP CLIN CARDIOL, V15, pE86; Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49; Song LS, 2006, P NATL ACAD SCI USA, V103, P4305, DOI 10.1073/pnas.0509324103; Song LS, 2005, ANN NY ACAD SCI, V1047, P99, DOI 10.1196/annals.1341.009; Song LS, 2001, CIRC RES, V88, P794, DOI 10.1161/hh0801.090461; Sun YL, 2005, CHEST, V128, P1812, DOI 10.1378/chest.128.3.1812; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; van Oort RJ, 2011, CIRCULATION, V123, P979, DOI 10.1161/CIRCULATIONAHA.110.006437; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Wei S, 2000, J AM COLL CARDIOL, V36, P276, DOI 10.1016/S0735-1097(00)00671-9; Wei S, 2010, CIRC RES, V107, P520, DOI 10.1161/CIRCRESAHA.109.212324; Wu CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024404; Xie YP, 2012, HYPERTENSION, V59, P355, DOI 10.1161/HYPERTENSIONAHA.111.180968; Xu M, 2007, PLOS BIOL, V5, P203, DOI 10.1371/journal.pbio.0050021; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215; Ziman AP, 2010, J MOL CELL CARDIOL, V48, P379, DOI 10.1016/j.yjmcc.2009.09.016	45	48	49	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2531	2537		10.1096/fj.11-199505	http://dx.doi.org/10.1096/fj.11-199505			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22375019	Green Published, Bronze			2022-12-28	WOS:000305017200029
J	Salah, Z; Uziely, B; Jaber, M; Maoz, M; Cohen, I; Hamburger, T; Maly, B; Peretz, T; Bar-Shavit, R				Salah, Zaidoun; Uziely, Beatrice; Jaber, Mohammad; Maoz, Miriam; Cohen, Irit; Hamburger, Tamar; Maly, Bella; Peretz, Tamar; Bar-Shavit, Rachel			Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen	FASEB JOURNAL			English	Article						thrombin; tumor; ERE; tissue microarray	TRANSCRIPTIONAL REGULATION; TISSUE MICROARRAYS; GROWTH-FACTOR; IDENTIFICATION; ALPHA; PHOSPHORYLATION; OVEREXPRESSION; COAGULATION; RESISTANCE; PATHWAYS	A pivotal role is attributed to the estrogenreceptor (ER) pathway in mediating the effect of estrogen in breast cancer progression. Yet the precise mechanisms of cancer development by estrogen remain poorly understood. Advancing tumor categorization a step forward, and identifying cellular gene fingerprints to accompany histopathological assessment may provide targets for therapy as well as vehicles for evaluating the response to treatment. We report here that in breast carcinoma, estrogen may induce tumor development by eliciting protease-activated receptor-1 (PAR(1)) gene expression. Induction of PAR(1) was shown by electrophoretic mobility shift assay, luciferase reporter gene driven by the hPar(1) promoter, and chromatin-immunoprecipitation analyses. Functional estrogen regulation of hPar1 in breast cancer was demonstrated by an endothelial tube-forming network. Notably, tissue-microarray analyses from an established cohort of women diagnosed with invasive breast carcinoma exhibited a significantly shorter disease-free (P =0.006) and overall (P=0.02) survival of patients that were positive for ER and PAR(1), compared to ER-positive but PAR(1)-negative patients. We propose that estrogen transcriptionally regulates hPar(1), culminating in an aggressive gene imprint in breast cancer. While ER+ patients are traditionally treated with hormone therapy, the presence of PAR(1) identifies a group of patients that requires additional treatment, such as anti-PAR(1) biological vehicles or chemotherapy.-Salah, Z., Uziely, B., Jaber, M., Maoz, M., Cohen, I., Hamburger, T., Maly, B., Peretz, T., B.-S, R. Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen. FASEB J. 26, 2031-2042 (2012). www.fasebj.org	[Salah, Zaidoun; Uziely, Beatrice; Jaber, Mohammad; Maoz, Miriam; Cohen, Irit; Hamburger, Tamar; Peretz, Tamar; Bar-Shavit, Rachel] Hadassah Hebrew Univ Hosp, Sharett Inst Oncol, IL-91120 Jerusalem, Israel; [Maly, Bella] Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Bar-Shavit, R (corresponding author), Hadassah Hebrew Univ Hosp, Sharett Inst Oncol, POB 12000, IL-91120 Jerusalem, Israel.	rachel.bar-shavit@ekmd.huji.ac.il			Israel Scientific Foundation (ISF); Ministry of Industry and Trade	Israel Scientific Foundation (ISF)(Israel Science Foundation); Ministry of Industry and Trade	This work was supported in part by funds from the Israel Scientific Foundation (ISF) and the Ministry of Industry and Trade, Nofar project (to R.B.).	ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Applanat MP, 2008, ADV EXP MED BIOL, V617, P437, DOI 10.1007/978-0-387-69080-3_42; Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Charpentier AH, 2000, CANCER RES, V60, P5977; Clarke RB, 1997, CANCER RES, V57, P4987; Cohen I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011135; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Creighton CJ, 2008, CANCER RES, V68, P7493, DOI 10.1158/0008-5472.CAN-08-1404; DANIEL CW, 1987, CANCER RES, V47, P6052; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; McDonnell DP, 2010, CURR OPIN PHARMACOL, V10, P620, DOI 10.1016/j.coph.2010.09.007; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; RICKLES FR, 1983, BLOOD, V62, P14; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Salah Z, 2008, ONCOGENE, V27, P6866, DOI 10.1038/onc.2008.324; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Schiff R, 2005, BREAST CANCER RES, V7, P205, DOI 10.1186/bcr1287; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; Song RXD, 2006, ENDOCR-RELAT CANCER, V13, pS3, DOI 10.1677/erc.1.01322; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKELING AE, 1992, CANCER SURV, V14, P71; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; White HD, 2011, AM HEART J, V161, P450, DOI 10.1016/j.ahj.2010.10.043; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yang E, 2009, CANCER RES, V69, P6223, DOI 10.1158/0008-5472.CAN-09-0187; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com	49	12	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2031	2042		10.1096/fj.11-194704	http://dx.doi.org/10.1096/fj.11-194704			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22291441				2022-12-28	WOS:000303680800029
J	Lefebvre, J; Ancot, F; Leroy, C; Muharram, G; Lemiere, A; Tulasne, D				Lefebvre, Jonathan; Ancot, Frederic; Leroy, Catherine; Muharram, Ghaffar; Lemiere, Arnaud; Tulasne, David			Met degradation: more than one stone to shoot a receptor down	FASEB JOURNAL			English	Review						receptor tyrosine kinase; hepatocyte growth factor; cleavages; caspase; metalloprotease; gamma-secretase	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; FATTY-ACID SYNTHASE; C-MET; DOWN-REGULATION; ONCOGENIC ACTIVATION; SOMATIC MUTATIONS; CASPASE CLEAVAGE; DOCKING SITE	The receptor tyrosine kinase Met and its high-affinity ligand, the hepatocyte growth factor/scatter factor (HGF/SF), are essential to embryonic development. Deregulation of their signaling is associated with tumorigenesis and metastasis, notably through receptor overexpression. It is thus important to understand the mechanisms controlling Met expression. The ligand-dependent internalization of Met and its subsequent degradation in the lysosomal compartment are well described. This process is known to attenuate downstream Met signaling pathways. Yet internalized Met takes part directly in intracellular signaling by chaperoning signaling factors in the course of its trafficking. Furthermore, recent studies describe various new degradation mechanisms of membrane-anchored Met, involving proteolytic cleavages or association with novel partners. Although all these degradations are ligand-independent, they share, to different extents, some common features with canonical HGF/SF-dependent degradation. Interestingly, activated Met variants display resistance to degradation, suggesting defective degradation is involved in tumorigenesis. Conversely, forced degradation of Met through reinduction of one or more degradation pathways is a promising therapeutic strategy.-Lefebvre, J., Ancot, F., Leroy, C., Mu-harram, G., Lemiere, A., Tulasne, D. Met degradation: more than one stone to shoot a receptor down. FASEB J. 26, 1387-1399 (2012). www.fasebj.org	[Lefebvre, Jonathan; Ancot, Frederic; Leroy, Catherine; Muharram, Ghaffar; Lemiere, Arnaud; Tulasne, David] Univ Lille Nord France, Inst Federatif Rech IFR 142, Unite Mixte Rech UMR 8161, CNRS,Inst Pasteur Lille,Inst Biol Lille, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Tulasne, D (corresponding author), Inst Pasteur, CNRS, Inst Biol Lille, UMR 8161, BP 447, F-59021 Lille, France.	david.tulasne@ibl.fr	Tulasne, David/AAR-5287-2020; Tulasne, David/A-8705-2008; Muharram, Ghaffar/I-6686-2017	Tulasne, David/0000-0002-6764-7242; Muharram, Ghaffar/0000-0003-4309-8450	Centre National de la Recherche Scientifique; Institut Pasteur de Lille; Institut National de la Sante et de la Recherche Medicale; Ligue contre le Cancer, comite Nord; Association pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Agence Nationale pour la Recherche; French Research and Technology Ministry	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue contre le Cancer, comite Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Agence Nationale de la Recherche(French National Research Agency (ANR)); Agence Nationale pour la Recherche(French National Research Agency (ANR)); French Research and Technology Ministry	This work was supported by the Centre National de la Recherche Scientifique, the Institut Pasteur de Lille, and the Institut National de la Sante et de la Recherche Medicale, and by grants from the Ligue contre le Cancer, comite Nord, the Association pour la Recherche sur le Cancer, and the Agence Nationale de la Recherche, Young Investigator Program. F. A. was supported by a fellowship from the Association pour la Recherche sur le Cancer, A. L. and G. M. by the Agence Nationale pour la Recherche, J.L. by a grant from the French Research and Technology Ministry.	Abella JV, 2009, AM J PHYSIOL-ENDOC M, V296, pE973, DOI 10.1152/ajpendo.90857.2008; Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Ancot F, 2009, ONCOGENE, V28, P2185, DOI 10.1038/onc.2009.88; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Buraschi Simone, 2010, J Biol Chem, V285, P42075, DOI 10.1074/jbc.M110.172841; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Coleman DT, 2009, MOL CANCER THER, V8, P214, DOI 10.1158/1535-7163.MCT-08-0722; de Melker AA, 2004, J BIOL CHEM, V279, P55465, DOI 10.1074/jbc.M409765200; Deheuninck J, 2008, BIOCHEM BIOPH RES CO, V367, P573, DOI 10.1016/j.bbrc.2007.12.177; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Ferraris DM, 2010, J MOL BIOL, V395, P522, DOI 10.1016/j.jmb.2009.10.074; Foveau B, 2007, CELL DEATH DIFFER, V14, P752, DOI 10.1038/sj.cdd.4402080; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; GALVANI AP, 1995, BIOCHEM PHARMACOL, V50, P959, DOI 10.1016/0006-2952(95)00219-P; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gillooly DJ, 2003, HISTOCHEM CELL BIOL, V120, P445, DOI 10.1007/s00418-003-0591-7; Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Goormachtigh G, 2011, BIOCHEM BIOPH RES CO, V411, P780, DOI 10.1016/j.bbrc.2011.07.024; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; LONGATI P, 1994, ONCOGENE, V9, P49; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Madshus IH, 2009, J CELL SCI, V122, P3433, DOI 10.1242/jcs.050260; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; McShane MP, 2008, J CELL BIOL, V182, P823, DOI 10.1083/jcb.200807165; Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Niemann HH, 2007, CELL, V130, P235, DOI 10.1016/j.cell.2007.05.037; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Parachoniak CA, 2009, J BIOL CHEM, V284, P8382, DOI 10.1074/jbc.M807607200; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; Qin SA, 2010, J CLIN INVEST, V120, P3617, DOI 10.1172/JCI41531; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Traub LM, 2009, NAT REV MOL CELL BIO, V10, P583, DOI 10.1038/nrm2751; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Uddin S, 2010, MOL CANCER THER, V9, P1244, DOI 10.1158/1535-7163.MCT-09-1061; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Veiga E, 2005, NAT CELL BIOL, V7, P894, DOI 10.1038/ncb1292; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yant J, 1998, EXP CELL RES, V241, P476, DOI 10.1006/excr.1998.4028; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	84	41	42	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1387	1399		10.1096/fj.11-197723	http://dx.doi.org/10.1096/fj.11-197723			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223753				2022-12-28	WOS:000302359700002
J	Zuo, DM; Yu, XF; Guo, CQ; Yi, HF; Chen, X; Conrad, DH; Guo, TL; Chen, ZL; Fisher, PB; Subjeck, JR; Wang, XY				Zuo, Daming; Yu, Xiaofei; Guo, Chunqing; Yi, Huanfa; Chen, Xing; Conrad, Daniel H.; Guo, Tai L.; Chen, Zhengliang; Fisher, Paul B.; Subjeck, John R.; Wang, Xiang-Yang			Molecular chaperoning by glucose-regulated protein 170 in the extracellular milieu promotes macrophage-mediated pathogen sensing and innate immunity	FASEB JOURNAL			English	Article						TLR9; endocytosis; CpG-ODN	HEAT-SHOCK PROTEINS; TOLL-LIKE RECEPTORS; PLASMACYTOID DENDRITIC CELLS; ENDOPLASMIC-RETICULUM; BACTERIAL-DNA; LISTERIA-MONOCYTOGENES; HSP70 SUPERFAMILY; MAMMALIAN-CELLS; STRESS-PROTEINS; NITRIC-OXIDE	Recognition of pathogen-associated molecular patterns by innate immune receptors is essential for host defense responses. Although extracellular stress proteins are considered as indicators of the stressful conditions (e. g., infection or cell injury), the exact roles of these molecules in the extracellular milieu remain less defined. We found that glucose-regulated protein 170 (Grp170), the largest stress protein and molecular chaperone, is highly efficient in binding CpG oligodeoxynucleotides (CpG-ODN), the microbial DNA mimetic sensed by toll-like receptor 9 (TLR9). Extracellular Grp170 markedly potentiates the endocytosis and internalization of CpG-ODN by mouse bone marrow-derived macrophages and directly interacts with endosomal TLR9 on cell entry. These molecular collaborations result in the synergistic activation of the MyD88-dependent signaling and enhanced production of proinflammatory cytokines and nitric oxide in mouse primary macrophages as well as human THP-1 monocyte-derived macrophages, suggesting that Grp170 released from injured cells facilitates the sensing of pathogen-associated "danger" signals by intracellular receptors. This CpG-ODN chaperone complex-promoted innate immunity confers increased resistance in mice to infection of Listeria monocytogenes compared with CpG-ODN treatment alone. Our studies reveal a previously unrecognized attribute of Grp170 as a superior DNA-binding chaperone capable of amplifying TLR9 activation on pathogen recognition, which provides a conceptual advance in understanding the dynamics of ancient chaperoning functions inside and outside the cell.-Zuo, D., Yu, X., Guo, C., Yi, H., Chen, X., Conrad, D. H., Guo, T. L., Chen, Z., Fisher, P. B., Subjeck, J. R., Wang, X.-Y. Molecular chaperoning by glucose-regulated protein 170 in the extracellular milieu promotes macrophage-mediated pathogen sensing and innate immunity. FASEB J. 26, 1493-1505 (2012). www.fasebj.org	[Zuo, Daming; Yu, Xiaofei; Guo, Chunqing; Yi, Huanfa; Fisher, Paul B.; Wang, Xiang-Yang] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Conrad, Daniel H.] Virginia Commonwealth Univ, Sch Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA; [Guo, Tai L.] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Zuo, Daming; Yu, Xiaofei; Guo, Chunqing; Yi, Huanfa; Fisher, Paul B.; Wang, Xiang-Yang] Virginia Commonwealth Univ, Sch Med, Inst Mol Med, Richmond, VA 23298 USA; [Zuo, Daming; Yu, Xiaofei; Guo, Chunqing; Yi, Huanfa; Fisher, Paul B.; Wang, Xiang-Yang] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; [Zuo, Daming; Chen, Zhengliang] So Med Univ, Dept Immunol, Guangzhou, Guangdong, Peoples R China; [Chen, Xing; Subjeck, John R.] Roswell Pk Canc Inst, Dept Cellular Stress Biol, Buffalo, NY 14263 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Southern Medical University - China; Roswell Park Cancer Institute	Wang, XY (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, POB 980033, Richmond, VA 23298 USA.	xywang@vcu.edu	GUO, CHUNQING/F-4524-2014; Yu, Xiaofei/N-7860-2013; Zuo, Daming/AAO-8461-2021; Yu, Xiaofei/C-2893-2014	Yu, Xiaofei/0000-0003-3119-4920; Yu, Xiaofei/0000-0002-4944-1865; chen, zhengliang/0000-0002-2657-7970	U.S. National Institutes of Health (NIH) [CA-154708, CA-129111]; American Cancer Society; NIH [CA-099326, CA-097318, N01ES5538]; U.S. National Cancer Institute Cancer Center [P30 CA-16059]; NATIONAL CANCER INSTITUTE [P30CA016059, R01CA097318, R01CA129111, R01CA154708, R01CA099326] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Cancer Institute Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by U.S. National Institutes of Health (NIH) grants CA-154708 and CA-129111 and an American Cancer Society Scholarship (to X.Y.W), NIH grant CA-099326 (to J.R.S), NIH grant CA-097318 (to P. B. F.), and NIH grant N01ES5538 and U.S. National Cancer Institute Cancer Center support grant P30 CA-16059 to Virginia Commonwealth University Massey Cancer Center. X.Y.W is a Harrison Endowed Scholar. P. B. F holds the Thelma New-meyer Corman Endowed Chair at the Virginia Commonwealth University Massey Cancer Center. Author contributions were as follows: D.Z. and X.Y.W. designed research; D.Z., X.Y., H.Y., C. G., X. C., D. H. C., and T. L. G. performed experiments; D.Z., D. H. C., T. L. G., P. B. F., J.R.S., and X.Y.W. analyzed data; X.Y. W., P. B. F., J.R.S., and D.Z. wrote the manuscript. The authors declare no competing financial interests.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Berwin B, 2001, J BIOL CHEM, V276, P21083, DOI 10.1074/jbc.M101836200; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Calderwood SK, 2007, ANN NY ACAD SCI, V1113, P28, DOI 10.1196/annals.1391.019; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; Facciponte JG, 2007, EUR J IMMUNOL, V37, P2268, DOI 10.1002/eji.200737127; Gong JL, 2009, J IMMUNOL, V183, P3092, DOI 10.4049/jimmunol.0901235; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Henderson B, 2010, CELL STRESS CHAPERON, V15, P123, DOI 10.1007/s12192-009-0137-6; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Ito S, 2005, INFECT IMMUN, V73, P3803, DOI 10.1128/IAI.73.6.3803-3805.2005; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 1998, J IMMUNOL, V161, P2428; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Liu B, 2003, P NATL ACAD SCI USA, V100, P15824, DOI 10.1073/pnas.2635458100; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Osterloh A, 2007, J BIOL CHEM, V282, P4669, DOI 10.1074/jbc.M608666200; Park J, 2003, BIOCHEMISTRY-US, V42, P14893, DOI 10.1021/bi030122e; Park JE, 2006, CANCER RES, V66, P1161, DOI 10.1158/0008-5472.CAN-05-2609; Prescott J, 2006, CANCER LETT, V231, P12, DOI 10.1016/j.canlet.2004.12.037; Rajaiah R, 2009, AUTOIMMUN REV, V8, P388, DOI 10.1016/j.autrev.2008.12.004; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; Theriault JR, 2006, J IMMUNOL, V177, P8604, DOI 10.4049/jimmunol.177.12.8604; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Wang X.-Y., 2007, PROTEIN REV, V7; Wang XY, 2006, J IMMUNOL, V177, P1543, DOI 10.4049/jimmunol.177.3.1543; Wang XY, 2010, J IMMUNOL, V184, P6309, DOI 10.4049/jimmunol.0903891; Wang XY, 2003, CANCER RES, V63, P2553; Warger T, 2006, J BIOL CHEM, V281, P22545, DOI 10.1074/jbc.M502900200; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005	48	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1493	1505		10.1096/fj.11-197707	http://dx.doi.org/10.1096/fj.11-197707			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22207611	Green Published			2022-12-28	WOS:000302359700012
J	Barajas-Espinosa, A; Ni, NC; Yan, D; Zarini, S; Murphy, RC; Funk, CD				Barajas-Espinosa, Alma; Ni, Nathan C.; Yan, Dong; Zarini, Simona; Murphy, Robert C.; Funk, Colin D.			The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy	FASEB JOURNAL			English	Article						inflammation; pericyte	VASCULAR-PERMEABILITY; MOUSE MODEL; RAT RETINA; 5-LIPOXYGENASE; PERICYTES; EXPRESSION; CYSLT(1); CELLS; DEGENERATION; CAPILLARIES	Leukotrienes have been implicated in the pathogenesis of degenerative diabetic retinopathy, with research focusing primarily on leukotriene B4, with little attention devoted to the cysteinyl leukotrienes (cysLTs), which act through cysLT receptors (CysLT1R and CysLT2R). We demonstrate here the presence of CysLT2R in pericytes and endothelial cells of superficial retinal vasculature using an indirect assay by assessment of beta-galactosidase expression in CysLT2R-knockout (KO) mice. Retinal damage was induced in KO and wild-type (WT) mice using an established oxygen-induced retinopathy (OIR) model. CysLT2R expression following OIR was intensely upregulated compared to sham-treated controls. Staining with Griffonia simplicifolia lectin revealed enhanced tissue damage (as assessed by vasoobliteration/ vasoproliferation) in KO mice compared to WT controls, yet the opposite was true with respect to retinal edema. However, vascular endothelial growth factor receptor 1 (VEGFR1) transcripts were increased by OIR similarly with respect to genotype. Intravitreal application of exogenous cysLTs elicited greater vasculature leakage (assessed ex vivo) in eyes from WT mice compared to KO mice. While mRNA encoding enzymes for various components of the leukotriene cascade were detected in sham-and OIR-treated retinas, only prostaglandins and hydroxyeicosatetraenoic acids, but not leukotrienes, were detected in A23187-treated retina preparations. Together, these results implicate the CysLT2R in the progression of ischemic retinopathy.-Barajas-Espi-nosa, A., Ni, N. C., Yan, D., Zarini, S., Murphy, R. C., Funk, C. D. The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy. FASEB J. 26, 1100-1109 (2012). www.fasebj.org	[Barajas-Espinosa, Alma; Ni, Nathan C.; Yan, Dong; Funk, Colin D.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada; [Zarini, Simona; Murphy, Robert C.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA	Queens University - Canada; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Funk, CD (corresponding author), Queens Univ, Dept Biomed & Mol Sci, 18 Stuart St,433 Botterell Hall, Kingston, ON K7L 3N6, Canada.	funkc@queensu.ca	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Zarini, Simona/0000-0002-7460-3299; Funk, Colin/0000-0001-7029-4233	CIHR [MOP-68930]; Canada Research Chairs program; Heart and Stroke Foundation of Ontario; CONACyT	CIHR(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs program(Canada Research Chairs); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The authors thank Tim St Amand and Laurel Ballantyne for their help with retina tissue processing, staining, and animal care; Dr. Lois Smith (Department of Ophthalmology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA) for the SWIFT software; and Dr. Satoshi Ishii (University of Tokyo, Tokyo, Japan) for supplying the CysLT<INF>2</INF>R-KO embryos. This work is supported by CIHR grant MOP-68930, Canada Research Chairs program, Heart and Stroke Foundation of Ontario Career Investigator Award (C. D. F.), and a CONACyT International Fellowship Award (A.B.-E.).	Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P433, DOI 10.1136/bjo.38.7.433; Barajas-Espinosa A, 2011, AM J PATHOL, V178, P2682, DOI 10.1016/j.ajpath.2011.02.041; BAZAN NG, 1987, J NEUROSCI RES, V18, P591, DOI 10.1002/jnr.490180412; Chan-Ling T, 2004, AM J PATHOL, V165, P1301, DOI 10.1016/S0002-9440(10)63389-5; Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0; Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Claxton S, 2003, EXP EYE RES, V77, P305, DOI 10.1016/S0014-4835(03)00153-2; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DEOLIVEIRA F, 1966, BRIT J OPHTHALMOL, V50, P134, DOI 10.1136/bjo.50.3.134; Finkensieper A, 2010, CARDIOVASC RES, V86, P37, DOI 10.1093/cvr/cvp385; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Hui YQ, 2004, CIRCULATION, V110, P3360, DOI 10.1161/01.CIR.0000147775.50954.AA; Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798; Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817; McMurdo L, 1998, J PHARMACOL EXP THER, V285, P1255; Moos MPW, 2008, FASEB J, V22, P4352, DOI 10.1096/fj.08-113274; Ni NC, 2011, J PHARMACOL EXP THER, V339, P768, DOI 10.1124/jpet.111.186031; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Poeckel D, 2009, J BIOL CHEM, V284, P21077, DOI 10.1074/jbc.M109.000901; REINBOTH JJ, 1995, CURR EYE RES, V14, P1001, DOI 10.3109/02713689508998521; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571; SCHONFELD W, 1988, IMMUNOLOGY, V65, P529; Sheng WW, 2006, BIOCHEM BIOPH RES CO, V346, P19, DOI 10.1016/j.bbrc.2006.05.023; Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808; Silverman W. A., 1980, RETROLENTAL FIBROPLA; SKALLI O, 1989, J HISTOCHEM CYTOCHEM, V37, P315, DOI 10.1177/37.3.2918221; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 2002, ACTA PAEDIATR, V91, P26, DOI 10.1080/08035250260095771; Stahl A, 2010, AM J PATHOL, V177, P2715, DOI 10.2353/ajpath.2010.100526; SZABO ME, 1991, INVEST OPHTH VIS SCI, V32, P1471; Talahalli R, 2010, INVEST OPHTH VIS SCI, V51, P1699, DOI 10.1167/iovs.09-3557; Terry TL., 1942, AM J OPHTHALMOL, V25, P203, DOI DOI 10.1016/S0002-9394(42)92088-9; TSOPANOGLOU NE, 1994, EUR J PHARMACOL, V258, P151, DOI 10.1016/0014-2999(94)90068-X; Ulyatt C, 2011, BIOCHEM BIOPH RES CO, V404, P774, DOI 10.1016/j.bbrc.2010.12.057; WILLIAMSON JR, 1980, MICROVASC RES, V20, P233, DOI 10.1016/0026-2862(80)90010-2; Yuan YM, 2009, J PHARMACOL SCI, V109, P285, DOI 10.1254/jphs.08321FP	48	18	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1100	1109		10.1096/fj.11-195792	http://dx.doi.org/10.1096/fj.11-195792			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22131271				2022-12-28	WOS:000300949300014
J	Higuchi, M; Iwata, N; Matsuba, Y; Takano, J; Suemoto, T; Maeda, J; Ji, B; Ono, M; Staufenbiel, M; Suhara, T; Saido, TC				Higuchi, Makoto; Iwata, Nobuhisa; Matsuba, Yukio; Takano, Jiro; Suemoto, Takahiro; Maeda, Jun; Ji, Bin; Ono, Maiko; Staufenbiel, Matthias; Suhara, Tetsuya; Saido, Takaomi C.			Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology	FASEB JOURNAL			English	Article						amyloid precursor protein; APP; amyloid beta peptide; A beta; humans; mice	AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; BETA-PEPTIDE; SYNAPTIC ACTIVITY; A-BETA; MEDIATED DEGRADATION; CELL-DEATH; ACTIVATION; TAU; PLAQUES	The mechanism by which amyloid-beta peptide (A beta) accumulation causes neurodegeneration in Alzheimer's disease (AD) remains unresolved. Given that A beta perturbs calcium homeostasis in neurons, we investigated the possible involvement of calpain, a calcium-activated neutral protease. We first demonstrated close postsynaptic association of calpain activation with A beta plaque formation in brains from both patients with AD and transgenic (Tg) mice overexpressing amyloid precursor protein (APP). Using a viral vector-based tracer, we then showed that axonal termini were dynamically misdirected to calpain activation-positive A beta plaques. Consistently, cerebrospinal fluid from patients with AD contained a higher level of calpain-cleaved spectrin than that of controls. Genetic deficiency of calpastatin (CS), a calpain-specific inhibitor protein, augmented A beta amyloidosis, tau phosphorylation, microgliosis, and somatodendritic dystrophy, and increased mortality in APP-Tg mice. In contrast, brain-specific CS overexpression had the opposite effect. These findings implicate that calpain activation plays a pivotal role in the A beta-triggered pathological cascade, highlighting a target for pharmacological intervention in the treatment of AD.-Higuchi, M., Iwata, N., Matsuba, Y., Takano, J., Suemoto, T., Maeda, J., Ji, B., Ono, M., Staufenbiel, M., Suhara, T., Saido, T. C. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 26, 1204-1217 (2012). www.fasebj.org	[Higuchi, Makoto; Iwata, Nobuhisa; Matsuba, Yukio; Takano, Jiro; Suemoto, Takahiro; Saido, Takaomi C.] Rikagaku Kenkyujo RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama, Japan; [Higuchi, Makoto; Maeda, Jun; Ji, Bin; Suhara, Tetsuya] Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 260, Japan; [Ono, Maiko; Staufenbiel, Matthias] Novartis Inst Biomed Res Basel, Basel, Switzerland	RIKEN; National Institutes for Quantum Science & Technology; Novartis	Saido, TC (corresponding author), RIKEN Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	saido@brain.riken.jp	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	RIKEN BSI; Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labor, and Welfare of Japan	RIKEN BSI; Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	The authors thank Misaki Sekiguchi, Ryo Fujioka, and Takashi Okauchi for technical assistance. The authors also thank Sangram Sisodia for critical reading of the manuscript. This work was supported by research grants from RIKEN BSI, grants-in-aid for the Molecular Imaging Program, Scientific Research (B) from the Ministry of Education, Culture, Sports, Science, and Technology, and grants from the Ministry of Health, Labor, and Welfare of Japan.	Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; Diaz-Villasenor A, 2008, TOXICOL APPL PHARM, V231, P291, DOI 10.1016/j.taap.2008.05.018; Dong YZ, 2006, FASEB J, V20, P331, DOI 10.1096/fj.05-4524fje; Evans JS, 2007, J NEUROCHEM, V103, P849, DOI 10.1111/j.1471-4159.2007.04815.x; Fifre A, 2006, J BIOL CHEM, V281, P229, DOI 10.1074/jbc.M507378200; Fukura H, 1996, J NEUROCHEM, V67, P1426; GEDDES JW, 1986, EXP NEUROL, V94, P767, DOI 10.1016/0014-4886(86)90254-2; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomez-Ramos A, 2006, FEBS LETT, V580, P4842, DOI 10.1016/j.febslet.2006.07.078; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hayashi T, 2004, NEUROL RES, V26, P827, DOI 10.1179/016164104X3770; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Higuchi M, 2005, NAT NEUROSCI, V8, P527, DOI 10.1038/nn1422; Higuchi M, 2002, NEURON, V35, P433, DOI 10.1016/S0896-6273(02)00789-4; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Koffie RM, 2009, P NATL ACAD SCI USA, V106, P4012, DOI 10.1073/pnas.0811698106; Kuchibhotla KV, 2008, NEURON, V59, P214, DOI 10.1016/j.neuron.2008.06.008; Liang B, 2010, J BIOL CHEM, V285, P27737, DOI 10.1074/jbc.M110.117960; Liu J, 2008, SCI SIGNAL, V1, DOI [10.1126/stke.114re1, 10.1126/scisignal.123tr3]; Lu XY, 2000, NEUROSCI LETT, V286, P149, DOI 10.1016/S0304-3940(00)01101-0; Maeda J, 2007, J NEUROSCI, V27, P10957, DOI 10.1523/JNEUROSCI.0673-07.2007; Marshall C, 2005, MOL ENDOCRINOL, V19, P213, DOI 10.1210/me.2004-0064; MASLIAH E, 1991, NEURON, V6, P729, DOI 10.1016/0896-6273(91)90170-5; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Ohbayashi K, 1998, J NEUROSCI RES, V51, P682, DOI 10.1002/(SICI)1097-4547(19980315)51:6<682::AID-JNR3>3.0.CO;2-7; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Phinney AL, 1999, J NEUROSCI, V19, P8552; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; Saido TC, 2006, NEUROSCI RES, V54, P235, DOI 10.1016/j.neures.2005.12.015; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Tomioka M, 2002, MOL BRAIN RES, V108, P18, DOI 10.1016/S0169-328X(02)00486-2; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang K. K. W., 1992, CALPAIN PHARM TOXICO, P77; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	62	71	73	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1204	1217		10.1096/fj.11-187740	http://dx.doi.org/10.1096/fj.11-187740			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22173972				2022-12-28	WOS:000300949300023
J	Kuusisto, HV; Wagstaff, KM; Alvisi, G; Roth, DM; Jans, DA				Kuusisto, Henna V.; Wagstaff, Kylie M.; Alvisi, Gualtiero; Roth, Daniela M.; Jans, David A.			Global enhancement of nuclear localization-dependent nuclear transport in transformed cells	FASEB JOURNAL			English	Article						importins; exportins; neoplastic transformation; isogenic; specific drug delivery	HORMONE-RELATED PROTEIN; GENE-EXPRESSION; IMPORTIN-ALPHA; BREAST-CANCER; DIFFERENTIAL EXPRESSION; MODULAR TRANSPORTERS; OVARIAN-CARCINOMA; TARGETING SIGNAL; CSE1L/CAS GENE; MESSENGER-RNA	Fundamental to eukaryotic cell function, nucleocytoplasmic transport can be regulated at many levels, including through modulation of the importin/exportin (Imp/Exp) nuclear transport machinery itself. Although Imps/Exps are overexpressed in a number of transformed cell lines and patient tumor tissues, the efficiency of nucleocytoplasmic transport in transformed cell types compared with nontransformed cells has not been investigated. Here we use quantitative live cell imaging of 3 isogenic nontransformed/transformed cell pairs to show that nuclear accumulation of nuclear localization signal (NLS)-containing proteins, but not their NLS-mutated derivatives, is increased up to 7-fold in MCF10CA1h human epithelial breast carcinoma cells and in simian virus 40 (SV40)-transformed fibroblasts of human and monkey origin, compared with their nontransformed counterparts. The basis for this appears to be a significantly faster rate of nuclear import in transformed cell types, as revealed by analysis using fluorescence recovery after photobleaching for the human MCF10A/MCF10CA1h cell pair. Nuclear accumulation of NLS/nuclear export signal-containing (shuttling) proteins was also enhanced in transformed cell types, experiments using the nuclear export inhibitor leptomycin B demonstrating that efficient Exp-1-mediated nuclear export was not impaired in transformed compared with nontransformed cells. Enhanced nuclear import and export efficiencies were found to correlate with 2- to 4-fold higher expression of specific Imps/Exps in transformed cells, as indicated by quantitative Western blot analysis, with ectopic expression of Imps able to enhance NLS nuclear accumulation levels up to 5-fold in nontransformed MCF10A cells. The findings indicate that transformed cells possess altered nuclear transport properties, most likely due to the overexpression of Imps/Exps. The findings have important implications for the development of tumor-specific drug nanocarriers in anticancer therapy.-Kuusisto, H. V., Wagstaff, K. M., Alvisi, G., Roth, D. M., Jans, D. A. Global enhancement of nuclear localization-dependent nuclear transport in transformed cells. FASEB J. 26, 1181-1193 (2012). www.fasebj.org	[Kuusisto, Henna V.; Wagstaff, Kylie M.; Alvisi, Gualtiero; Roth, Daniela M.; Jans, David A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signalling Lab, Clayton, Vic 3800, Australia	Monash University	Jans, DA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Nucl Signalling Lab, Clayton, Vic 3800, Australia.	david.jans@monash.edu	Alvisi, Gualtiero/F-9915-2012	Wagstaff, Kylie/0000-0003-4791-1410; Alvisi, Gualtiero/0000-0002-8177-3616; Jans, David/0000-0001-5115-4745	National Health and Medical Research Council (Australia) [436614, 384105]	National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council (Australia; grant 436614 and fellowship 384105). The authors thank Cassandra David for skilled technical assistance and Caroline Garrett (Sussex Centre for Genome Damage and Stability, Sussex, UK) and Steven Santner (Karmanos Cancer Institute, Detroit, MI, USA) for the 1BR3/1BR3N and MCF10A/CA1h cell lines, respectively. All microscopic imaging was conducted using microscopes provided by the Monash Micro Imaging facility (Monash University, Clayton, VIC, Australia). The authors declare no conflicts of interest.	Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; Alvisi G, 2006, TRAFFIC, V7, P1322, DOI 10.1111/j.1600-0854.2006.00477.x; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Behrens P, 2001, ANTICANCER RES, V21, P2413; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; Brustmann H, 2004, GYNECOL ONCOL, V92, P268, DOI 10.1016/j.ygyno.2003.10.029; Cardarelli F, 2007, MOL THER, V15, P1313, DOI 10.1038/sj.mt.6300172; Chahine MN, 2009, PHARMACOL REV, V61, P358, DOI 10.1124/pr.108.000620; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Dankof A, 2007, VIRCHOWS ARCH, V451, P877, DOI 10.1007/s00428-007-0513-5; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FELDHERR CM, 1992, P NATL ACAD SCI USA, V89, P11002, DOI 10.1073/pnas.89.22.11002; Forwood JK, 2002, BIOCHEMISTRY-US, V41, P9333, DOI 10.1021/bi025548s; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fulcher AJ, 2011, BBA-MOL CELL RES, V1813, P2176, DOI 10.1016/j.bbamcr.2011.03.019; Ghildyal R, 2009, J VIROL, V83, P5353, DOI 10.1128/JVI.02374-08; Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577; Gluz O, 2008, INT J CANCER, V123, P1433, DOI 10.1002/ijc.23628; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gu LL, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-17; Hakata Y, 2002, J VIROL, V76, P8079, DOI 10.1128/JVI.76.16.8079-8089.2002; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Hogarth CA, 2006, DEV DYNAM, V235, P253, DOI 10.1002/dvdy.20569; Hosokawa K, 2008, NEUROSCIENCE, V157, P864, DOI 10.1016/j.neuroscience.2008.09.045; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; Jensen JB, 2011, EUR UROL, V59, P841, DOI 10.1016/j.eururo.2011.01.048; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kirschbaum-Slager N, 2005, PHYSIOL GENOMICS, V21, P423, DOI 10.1152/physiolgenomics.00237.2004; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kohler M, 2002, CELL PHYSIOL BIOCHEM, V12, P335; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kuusisto HV, 2008, INT J CANCER, V123, P2965, DOI 10.1002/ijc.23884; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Loveland KL, 2006, BIOL REPROD, V74, P67, DOI 10.1095/biolreprod.105.042341; Mortezavi A., CLIN CANC RES, V17, P1111; Moseley GW, 2007, MOL BIOL CELL, V18, P3204, DOI 10.1091/mbc.E07-01-0030; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NAKASHIMA T, 1994, EUR ARCH OTO-RHINO-L, V251, pS87, DOI 10.1007/BF02565228; Noske A, 2008, CANCER-AM CANCER SOC, V112, P1733, DOI 10.1002/cncr.23354; Pache JC, 2006, ENDOCRINOLOGY, V147, P990, DOI 10.1210/en.2005-0663; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Rosenkranz AA, 2003, FASEB J, V17, P1121, DOI 10.1096/fj.02-0888fje; Roth DM, 2007, TRAFFIC, V8, P673, DOI 10.1111/j.1600-0854.2007.00564.x; Roth DM, 2011, J BIOL CHEM, V286, P14335, DOI 10.1074/jbc.M110.210302; Sakai M, 2010, ANTICANCER RES, V30, P851; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sato F, 2006, BIOCHEM BIOPH RES CO, V342, P465, DOI 10.1016/j.bbrc.2006.01.177; Smith ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009295; Sobolev AS, 2009, J BUON, V14, pS33; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; SOULE HD, 1990, CANCER RES, V50, P6075; Tachibana T, 1999, FEBS LETT, V442, P235, DOI 10.1016/S0014-5793(98)01664-0; Timney BL, 2006, J CELL BIOL, V175, P579, DOI 10.1083/jcb.200608141; Truant R, 1999, MOL CELL BIOL, V19, P1210; Van der Watt PJ, 2009, INT J CANCER, V124, P1829, DOI 10.1002/ijc.24146; Wagstaff KM, 2006, ANAL BIOCHEM, V348, P49, DOI 10.1016/j.ab.2005.10.029; Wagstaff KM, 2009, EUR J PHARMACOL, V625, P174, DOI 10.1016/j.ejphar.2009.06.069; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wellmann A, 2001, INT J MOL MED, V7, P489; Wu MS, 2005, WORLD J GASTROENTERO, V11, P7405, DOI 10.3748/wjg.v11.i47.7405; Yang WD, 2006, J CELL BIOL, V174, P951, DOI 10.1083/jcb.200605053; Yasuhara, 2007, NAT CELL BIOL, V9, P479; Yasuhara N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521; Yoshitake K, 2011, ANN SURG ONCOL, V18, P2093, DOI 10.1245/s10434-011-1569-7; Young JC, 2011, FASEB J, V25, P3958, DOI 10.1096/fj.10-176941; Zheng M, 2010, OBSTET GYNECOL, V116, P884, DOI 10.1097/AOG.0b013e3181f104ce	81	44	47	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1181	1193		10.1096/fj.11-191585	http://dx.doi.org/10.1096/fj.11-191585			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22155563	Green Submitted			2022-12-28	WOS:000300949300021
J	Magzoub, M; Miranker, AD				Magzoub, Mazin; Miranker, Andrew D.			Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide	FASEB JOURNAL			English	Article						Alzheimer's disease; amylin; Parkinson's disease	BETA-CELL APOPTOSIS; ENDOPLASMIC-RETICULUM STRESS; ALPHA-HELICAL STATES; HUMAN AMYLIN; NMR-SPECTROSCOPY; INTRACELLULAR AMYLOIDOGENESIS; MEMBRANE DISRUPTION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DIABETES-MELLITUS	Islet amyloid polypeptide (IAPP) is a peptide hormone cosecreted with insulin by pancreatic beta-cells. In type II diabetes, IAPP aggregates in a process that is associated with beta-cell dysfunction and loss of beta-cell mass. The relationship between IAPP's conformational landscape and its capacity to mediate cell death remains poorly understood. We have addressed these unknowns by comparing the cytotoxic effects of sequence variants with differing alpha-helical and amyloid propensities. IAPP was previously shown to oligomerize cooperatively on binding to lipid bilayers. Here, comparable transitions are evident in cell culture and are associated with a change in subcellular localization to the mitochondria under toxic conditions. Notably, we find that this toxic gain of function maps to IAPP's capacity to adopt aggregated membrane-bound alpha-helical, and not beta-sheet, states. Our findings suggest that upon alpha-helical mediated oligomerization, IAPP acquires cell-penetrating peptide (CPP) properties, facilitating access to the mitochondrial compartment, resulting in its dysfunction.-Magzoub, M. Miranker, A. D. Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB J. 26, 1228-1238 (2012). www.fasebj.org	[Magzoub, Mazin; Miranker, Andrew D.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Miranker, AD (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 260 Whitney Ave, New Haven, CT 06520 USA.	andrew.miranker@yale.edu			U.S. National Institutes of Health [DK079829, GM094693]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK079829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094693] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Gary W. Cline and Rebecca Pongratz (Department of Internal Medicine, Yale University) for the gift of INS-1 cells, valuable discussions, and technical assistance with cell culture. The authors thank A. Trexler for assistance with the FCS, Dr. V. Horsley and Dr. K. Nelson for assistance with FACS, Dr. J. Wolenski for assistance with confocal imaging, and N. Last and Dr. G. W. Cline for critical reading of the manuscript. This work was supported by grants from the U.S. National Institutes of Health (DK079829 and GM094693).	Apostolidou M, 2008, J BIOL CHEM, V283, P17205, DOI 10.1074/jbc.M801383200; Bai JZ, 1999, BIOCHEM J, V343, P53, DOI 10.1042/0264-6021:3430053; Brender JR, 2008, BIOCHEMISTRY-US, V47, P12680, DOI 10.1021/bi801427c; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509; Casas S, 2007, DIABETES, V56, P2284, DOI 10.2337/db07-0178; Clark A, 2004, DIABETOLOGIA, V47, P157, DOI 10.1007/s00125-003-1304-4; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Du DG, 2011, BIOCHEMISTRY-US, V50, P1607, DOI 10.1021/bi1013744; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Gurlo T, 2010, AM J PATHOL, V176, P861, DOI 10.2353/ajpath.2010.090532; Haataja L, 2008, ENDOCR REV, V29, P303, DOI 10.1210/er.2007-0037; Hebda JA, 2009, CHEM BIOL, V16, P943, DOI 10.1016/j.chembiol.2009.08.013; Hebda JA, 2009, ANNU REV BIOPHYS, V38, P125, DOI 10.1146/annurev.biophys.050708.133622; Hiddinga HJ, 1999, AM J PATHOL, V154, P1077, DOI 10.1016/S0002-9440(10)65360-6; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hoppener JWM, 1999, DIABETOLOGIA, V42, P427, DOI 10.1007/s001250051175; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kapurniotu A, 2001, BIOPOLYMERS, V60, P438, DOI 10.1002/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A; Knight JD, 2006, BIOCHEMISTRY-US, V45, P9496, DOI 10.1021/bi060579z; Konarkowska B, 2006, FEBS J, V273, P3614, DOI 10.1111/j.1742-4658.2006.05367.x; Koo BW, 2008, PROTEIN ENG DES SEL, V21, P147, DOI 10.1093/protein/gzm076; Last NB, 2011, P NATL ACAD SCI USA, V108, P9460, DOI 10.1073/pnas.1102356108; Li XL, 2011, INT J BIOCHEM CELL B, V43, P525, DOI 10.1016/j.biocel.2010.12.008; Lim YA, 2008, FEBS LETT, V582, P2188, DOI 10.1016/j.febslet.2008.05.006; Lim YA, 2010, PROTEOMICS, V10, P1621, DOI 10.1002/pmic.200900651; Lin CY, 2007, DIABETES, V56, P1324, DOI 10.2337/db06-1579; Liu ML, 2005, EXP MOL MED, V37, P559, DOI 10.1038/emm.2005.69; Luca S, 2007, BIOCHEMISTRY-US, V46, P13505, DOI 10.1021/bi701427q; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583505004014; Matveyenko AV, 2006, DIABETES, V55, P2106, DOI 10.2337/db05-1672; Matveyenko AV, 2009, DIABETES, V58, P906, DOI 10.2337/db08-1464; McNeil PL, 2002, J CELL SCI, V115, P873; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MCNEIL PL, 1989, METHOD CELL BIOL, V29, P153; Meier JJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE1317, DOI 10.1152/ajpendo.00082.2006; Middleton ER, 2010, BIOPHYS J, V99, P2279, DOI 10.1016/j.bpj.2010.07.056; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura K, 2011, J BIOL CHEM, V286, P20710, DOI 10.1074/jbc.M110.213538; Nakamura K, 2008, J NEUROSCI, V28, P12305, DOI 10.1523/JNEUROSCI.3088-08.2008; Nanga RPR, 2009, J AM CHEM SOC, V131, P8252, DOI 10.1021/ja9010095; Nanga RPR, 2008, BIOCHEMISTRY-US, V47, P12689, DOI 10.1021/bi8014357; Nath A, 2011, ANGEW CHEM INT EDIT, V50, P10859, DOI 10.1002/anie.201102887; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; OBRIEN T, 1995, AM J PATHOL, V147, P609; Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254; Patil SM, 2009, J BIOL CHEM, V284, P11982, DOI 10.1074/jbc.M809085200; Potter KJ, 2010, P NATL ACAD SCI USA, V107, P4305, DOI 10.1073/pnas.0909024107; Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315; Ritzel RA, 2003, DIABETES, V52, P1701, DOI 10.2337/diabetes.52.7.1701; Rumora L, 2002, BIOL CHEM, V383, P1751, DOI 10.1515/BC.2002.196; Ruschak AM, 2007, P NATL ACAD SCI USA, V104, P12341, DOI 10.1073/pnas.0703306104; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Soong R, 2009, J AM CHEM SOC, V131, P7079, DOI 10.1021/ja900285z; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Tschop M, 2001, EXP CLIN ENDOCR DIAB, V109, P307, DOI 10.1055/s-2001-17297; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Williamson JA, 2007, PROTEIN SCI, V16, P110, DOI 10.1110/ps.062486907; Williamson JA, 2009, J MOL BIOL, V393, P383, DOI 10.1016/j.jmb.2009.07.077; Wiltzius JJW, 2009, PROTEIN SCI, V18, P1521, DOI 10.1002/pro.145	71	69	70	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1228	1238		10.1096/fj.11-194613	http://dx.doi.org/10.1096/fj.11-194613			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22183778	Green Published			2022-12-28	WOS:000300949300025
J	Simiele, F; Recchiuti, A; Mattoscio, D; De Luca, A; Cianci, E; Franchi, S; Gatta, V; Parolari, A; Werba, JP; Camera, M; Favaloro, B; Romano, M				Simiele, Felice; Recchiuti, Antonio; Mattoscio, Domenico; De Luca, Antonella; Cianci, Eleonora; Franchi, Sara; Gatta, Valentina; Parolari, Alessandro; Werba, Jose Pablo; Camera, Marina; Favaloro, Bartolo; Romano, Mario			Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity	FASEB JOURNAL			English	Article						lipoxin A(4) receptor; inflammation; Sp1; polymorphism; methylation	FORMYL-PEPTIDE RECEPTOR; LIPOXIN A(4) RECEPTOR; ACUTE INFLAMMATORY RESPONSES; 5-LIPOXYGENASE PROMOTER; 15-EPI-LIPOXIN A(4); LEUKOTRIENE B-4; SEVERE ASTHMA; UP-REGULATION; ASPIRIN; EXPRESSION	Lipoxin (LX) A(4), a main endogenous stop-signal of inflammation, activates the G-protein-coupled receptor FPR2/ALX, which triggers potent anti-inflammatory signaling in vivo. Thus, the regulation of FPR2/ALX expression may have pathophysiological and therapeutic relevance. Here, we mapped a nucleotide sequence with strong FPR2/ALX promoter activity. Chromatin immuno-precipitation revealed specificity protein 1 (Sp1) binding to the core promoter. Site-directed mutagenesis of the Sp1 cis-acting element and Sp1 overexpression established that this transcription factor is key for maximal promoter activity, which is instead suppressed by DNA methylation. LXA4 enhanced FPR2/ALX promoter activity (+74%) and mRNA expression (+87.5%) in MDA-MB231 cells. A single nucleotide mutation (A/G) was detected in the core promoter of one subject with history of cardiovascular disease and of his two daughters. This mutation reduced by similar to 35-90% the promoter activity in vitro. Moreover, neutrophils from individuals carrying the A/G variant displayed similar to 10- and 3-fold reduction in FPR2/ALX mRNA and protein, respectively, compared with cells from their relatives or healthy volunteers expressing the wild-type allele. These results uncover FPR2/ALX transcriptional regulation and provide the first evidence of mutations that affect FPR2/ALX transcription, thus opening new opportunities for the understanding of the LXA4-FPR2/ALX axis in human disease-Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Parolari, A., Werba, J. P., Camera, M., Favaloro, B., Romano, M. Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 26, 1323-1333 (2012). www.fasebj.org	[Romano, Mario] G DAnnunzio Uni Fdn, Dept Biomed Sci, Ctr Excellence Aging, CeSI, I-66013 Chieti, Italy; [Cianci, Eleonora] G DAnnunzio Uni Fdn, Dept Med & Aging Sci, Ctr Excellence Aging, I-66013 Chieti, Italy; [Franchi, Sara; Gatta, Valentina] G DAnnunzio Uni Fdn, Dept Oral Sci Nano & Biotechnol, Ctr Excellence Aging, I-66013 Chieti, Italy; [Parolari, Alessandro; Werba, Jose Pablo; Camera, Marina] IRCCS, Ctr Cardiol Monzino, Milan, Italy; [Camera, Marina] Univ Milan, Dept Pharmacol Sci, Milan, Italy; [Parolari, Alessandro] Univ Milan, Dept Cardiovasc Sci, Milan, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; IRCCS Centro Cardiologico Monzino; University of Milan; University of Milan	Romano, M (corresponding author), G DAnnunzio Uni Fdn, Dept Biomed Sci, Ctr Excellence Aging, CeSI, Via Colle Ara, I-66013 Chieti, Italy.	mromano@unich.it	Camera, Marina/AAC-4741-2022; Mattoscio, Domenico/K-1411-2018; Romano, Mario/I-7986-2012; Recchiuti, Antonio/K-7670-2016; Gatta, Valentina/G-5765-2014; Werba, José Pablo/AAC-8973-2019; PAROLARI, ALESSANDRO/AAB-1763-2021	Mattoscio, Domenico/0000-0002-2149-2855; Romano, Mario/0000-0001-8512-1458; Recchiuti, Antonio/0000-0002-1409-5261; Werba, José Pablo/0000-0001-7188-1157; PAROLARI, ALESSANDRO/0000-0002-6954-0422; GATTA, Valentina/0000-0002-9999-5823	Italian Foundation for Cystic Fibrosis Research [FFC 15/2007]; EU	Italian Foundation for Cystic Fibrosis Research; EU(European Commission)	The authors thank investigators and personnel of the Polimorfismi Genici in Ambito Cardiovascolare (POGEAC) Study Group (F. Alamanni, M. Amato, M. Brambilla, P. Canzano, G. Polvani, G. Pompilio, L. Rossetti, and M. Zanobini, Centro Cardiologico Monzino IRCCS; and E. Tremoli, Universita degli Studi di Milano and Centro Cardiologico Monzino IRCCS) and the Functional Genomic Unit (Chieti, Italy) for recruiting subjects and collecting DNA samples for this study. The authors thank the Heart Surgeons of the Centro Cardiologico Monzino IRCSS for patient selection and Irene Recchia, Veronica Cecilia Mari, Antonella Pompei, and Cesidio Giuliani for technical support. A special thanks to Dr. Dieter Steinhilber for helpful discussion and valuable advice. This work was supported by grant FFC 15/2007 from the Italian Foundation for Cystic Fibrosis Research and from the EU VI framework program, EICOSANOX (to M. R). A European patent application relative to data reported in this manuscript has been filed (11425283.6). The authors declare no conflicts of interest.	BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; Birnbaum Y, 2006, CIRCULATION, V114, P929, DOI 10.1161/CIRCULATIONAHA.106.629907; Bonnans C, 2006, AM J PATHOL, V168, P1064, DOI 10.2353/ajpath.2006.051056; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BOYUM A, 1968, J CLIN LAB INVEST S, V97, P77; Chan MMY, 2010, J IMMUNOL, V184, P6418, DOI 10.4049/jimmunol.0903816; Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Hecht I, 2009, J PHARMACOL EXP THER, V328, P426, DOI 10.1124/jpet.108.145821; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; Katryniok C., BIOCHIM BIOPHYS ACTA, V1801, P49; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Morris T, 2010, P NATL ACAD SCI USA, V107, P8842, DOI 10.1073/pnas.1000373107; Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; Ndlovu M. N., TRENDS BIOCH SCI, V36, P381; PEREZ HD, 1992, GENE, V118, P303, DOI 10.1016/0378-1119(92)90208-7; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Planaguma A, 2010, MUCOSAL IMMUNOL, V3, P270, DOI 10.1038/mi.2009.141; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Qiu H, 2006, P NATL ACAD SCI USA, V103, P6913, DOI 10.1073/pnas.0602208103; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; Romano M, 2007, THESCIENTIFICWORLDJO, V7, P1393, DOI 10.1100/tsw.2007.186; Romano M, 2010, THESCIENTIFICWORLDJO, V10, P1048, DOI 10.1100/tsw.2010.113; Sawmynaden P, 2006, BIOCHEM BIOPH RES CO, V349, P1351, DOI 10.1016/j.bbrc.2006.08.179; Schnur N, 2007, BBA-MOL CELL BIOL L, V1771, P1271, DOI 10.1016/j.bbalip.2007.08.003; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; SERHAN CN, 1984, BIOCHEM BIOPH RES CO, V118, P943, DOI 10.1016/0006-291X(84)91486-4; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578	44	50	51	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1323	1333		10.1096/fj.11-198069	http://dx.doi.org/10.1096/fj.11-198069			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22131270				2022-12-28	WOS:000300949300034
J	Jaiswal, R; Gong, J; Sambasivam, S; Combes, V; Mathys, JM; Davey, R; Grau, GER; Bebawy, M				Jaiswal, Ritu; Gong, Joyce; Sambasivam, Shwetha; Combes, Valery; Mathys, Jean-Marie; Davey, Ross; Grau, Georges E. R.; Bebawy, Mary			Microparticle-associated nucleic acids mediate trait dominance in cancer	FASEB JOURNAL			English	Article						multidrug resistance; P-glycoprotein; multidrug resistance-associated protein 1; intercellular transfer	P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; BREAST-CANCER; IN-VITRO; DIAGNOSTIC BIOMARKERS; CROSS-RESISTANCE; DRUG-RESISTANCE; TUMOR-CELLS; EXPRESSION; MICROVESICLES	Drug resistance is a major cause of cancer treatment failure, with multidrug resistance (MDR) being the most serious, whereby cancer cells display cross-resistance to structurally and functionally unrelated drugs. MDR is caused by overexpression of the efflux transporters P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1). These transporters act to maintain sublethal intracellular drug concentrations within the cancer cell, making the population treatment unresponsive. Recently, we discovered a novel nongenetic basis to MDR whereby microparticles (MPs) transfer P-gp intercellularly from MDR donor cells to drug-sensitive recipient cells. MPs isolated from MDR leukemia and breast cancer cells were cocultured with their drug-sensitive counterparts. P-gp transfer was assessed by direct immunolabeling, and acquired transcripts and regulatory microRNAs by quantitative real-time PCR. We show that MDR MPs incorporate nucleic acids; MPs change recipient cells' transcriptional environment to reflect donor MDR phenotype, and distinct pathways exist among cancers of different origin that may be dependent on donor cells' ABCB1 overexpression. We demonstrate that this pathway exists for both hematological and nonhematological malignancies. By conferring MDR and "retemplating" the transcriptional landscape of recipient cells, MPs provide a novel pathway, having implications in the dissemination and acquisition of deleterious traits in clinical oncology.-Jaiswal, R., Gong, J., Sambasivam, S., Combes, V., Mathys, J.-M., Davey, R., Grau, G. E. R., Bebawy, M. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J. 26, 420-429 (2012). www.fasebj.org	[Jaiswal, Ritu; Gong, Joyce; Sambasivam, Shwetha; Bebawy, Mary] Univ Technol Sydney, Sch Pharm, Grad Sch Hlth, Sydney, NSW 2007, Australia; [Jaiswal, Ritu; Gong, Joyce; Combes, Valery; Grau, Georges E. R.] Univ Sydney, Vasc Immunol Unit, Sydney Med Sch, Sydney, NSW 2006, Australia; [Jaiswal, Ritu; Gong, Joyce; Combes, Valery; Grau, Georges E. R.] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Mathys, Jean-Marie] Royal Prince Alfred Hosp, Dept Mol & Clin Genet, Camperdown, NSW 2050, Australia; [Davey, Ross] Kolling Inst, Bill Walsh Canc Res Labs, St Leonards, NSW, Australia	University of Technology Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney; Kolling Institute of Medical Research	Bebawy, M (corresponding author), Univ Technol Sydney, Sch Pharm, Grad Sch Hlth, Level 5,Bldg 4,POB 123, Sydney, NSW 2007, Australia.	georges.grau@sydney.edu.au; mary.bebawy@uts.edu.au	Grau, Georges/AGR-7139-2022	Grau, Georges/0000-0002-0442-0462; Combes, Valery/0000-0003-2178-3596; Bebawy, Mary/0000-0003-2606-921X; Jaiswal, Ritu/0000-0002-8691-1352	New South Wales Cancer Council [571016]; National Health and Medical Research Council [1007613]	New South Wales Cancer Council(Cancer Council New South Wales); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank the following funding bodies for supporting this work: New South Wales Cancer Council (571016) and National Health and Medical Research Council (1007613) for research grants (to M. B., G. E. R. G., and V. C.).	Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9; Bebawy M, 1999, ANAL BIOCHEM, V268, P270, DOI 10.1006/abio.1998.3087; Bebawy M, 2001, BRIT J CANCER, V85, P1998, DOI 10.1054/bjoc.2001.2184; Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76; Bianco F, 2009, EMBO J, V28, P1043, DOI 10.1038/emboj.2009.45; BIEDLER JL, 1970, CANCER RES, V30, P1174; Camussi G, 2011, AM J CANCER RES, V1, P98; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Distler JHW, 2006, AUTOIMMUNITY, V39, P683, DOI 10.1080/08916930601061538; Donmez Y, 2011, CANCER CHEMOTH PHARM, V67, P823, DOI 10.1007/s00280-010-1385-y; Freyssinet JM, 2003, J THROMB HAEMOST, V1, P1655, DOI 10.1046/j.1538-7836.2003.00309.x; GOASGUEN JE, 1993, BLOOD, V81, P2394; Gong J, 2012, CANCER TREAT REV, V38, P226, DOI 10.1016/j.ctrv.2011.06.005; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Lane JD, 2005, J CELL SCI, V118, P4059, DOI 10.1242/jcs.02529; Lee G, 2004, PHARM RES-DORDR, V21, P1313, DOI 10.1023/B:PHAM.0000036905.82914.8e; Levchenko A, 2005, P NATL ACAD SCI USA, V102, P1933, DOI 10.1073/pnas.0401851102; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liang ZX, 2010, BIOCHEM PHARMACOL, V79, P817, DOI 10.1016/j.bcp.2009.10.017; LINN SC, 1995, ANN ONCOL, V6, P679, DOI 10.1093/oxfordjournals.annonc.a059284; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Longo-Sorbello GSA, 2001, HAEMATOLOGICA, V86, P121; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mi Y, 2007, BRIT J CANCER, V97, P934, DOI 10.1038/sj.bjc.6603985; Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285; Nooter K, 1997, LANCET, V349, P1885, DOI 10.1016/S0140-6736(05)63876-7; Oerlemans R, 2006, ARTHRITIS RHEUM-US, V54, P557, DOI 10.1002/art.21569; Reich CF, 2009, EXP CELL RES, V315, P760, DOI 10.1016/j.yexcr.2008.12.014; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Schiller M, 2008, CELL DEATH DIFFER, V15, P183, DOI 10.1038/sj.cdd.4402239; Shi HC, 2008, CANCER INVEST, V26, P344, DOI 10.1080/07357900701788072; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smalley DM, 2007, THROMB HAEMOSTASIS, V97, P67, DOI 10.1160/TH06-02-0066; Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Tesselaar MET, 2009, J THROMB HAEMOST, V7, P1421, DOI 10.1111/j.1538-7836.2009.03504.x; Tsang WP, 2008, APOPTOSIS, V13, P1215, DOI 10.1007/s10495-008-0256-z; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007	44	91	92	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					420	429		10.1096/fj.11-186817	http://dx.doi.org/10.1096/fj.11-186817			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965597				2022-12-28	WOS:000299202200041
J	Dumont, M; Stack, C; Elipenahli, C; Jainuddin, S; Gerges, M; Starkova, NN; Yang, LC; Starkov, AA; Beal, F				Dumont, Magali; Stack, Cliona; Elipenahli, Ceyhan; Jainuddin, Shari; Gerges, Meri; Starkova, Natalia N.; Yang, Lichuan; Starkov, Anatoly A.; Beal, Flint			Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice	FASEB JOURNAL			English	Article						tauopathy; exploration; tangles	LIPID-PEROXIDATION PRODUCT; MOUSE MODEL; NEURODEGENERATIVE TAUOPATHIES; ALZHEIMERS-DISEASE; PROTEIN; CELLS	Abnormal tau accumulation can lead to the development of neurodegenerative diseases. P301S mice overexpress the human tau mutated gene, resulting in tau hyperphosphorylation and tangle formation. Mice also develop synaptic deficits and microglial activation prior to any neurodegeneration and tangles. Oxidative stress can also affect tauopathy. We studied the role of oxidative stress in relationship to behavioral abnormalities and disease progression in P301S mice at 2, 7, and 10 mo of age. At 7 mo of age, P301S mice had behavioral abnormalities, such as hyperactivity and disinhibition. At the same age, we observed increased carbonyls in P301S mitochondria (similar to 215 and 55% increase, males/females), and deregulation in the activity and content of mitochondrial enzymes involved in reactive oxygen species formation and energy metabolism, such as citrate synthase (similar to 19 and similar to 5% decrease, males/females), MnSOD (similar to 16% decrease, males only), cytochrome C (similar to 19% decrease, females only), and cytochrome C oxidase (similar to 20% increase, females only). These changes in mitochondria proteome appeared before tau hyperphosphorylation and tangle formation, which were observed at 10 mo and were associated with GSK3 beta activation. At that age, mitochondria proteome deregulation became more apparent in male P301S mitochondria. The data strongly suggest that oxidative stress and mitochondrial abnormalities appear prior to tau pathology.-Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, M. N., Yang, L., Starkov, A. A., Beal, F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 25, 4063-4072 (2011). www.fasebj.org	[Dumont, Magali; Stack, Cliona; Elipenahli, Ceyhan; Jainuddin, Shari; Gerges, Meri; Starkova, Natalia N.; Yang, Lichuan; Starkov, Anatoly A.; Beal, Flint] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA	Cornell University	Dumont, M (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, 525 E 68th St,Rm A569A, New York, NY 10065 USA.	mad2138@med.cornell.edu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; DUMONT, MAGALI/0000-0001-9990-6512	National Institute of Aging [PO AG014930]; NATIONAL INSTITUTE ON AGING [P01AG014930] Funding Source: NIH RePORTER	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Tau Consortium. The authors thank Dr. Peter Davies (Albert Einstein College of Medicine, Manhasset, NY, USA) for providing the tau antibodies (CP13, PHF1, MC1, and DA9). A. A. S was supported by the National Institute of Aging (PO AG014930).	Agarwal R, 2002, J CHROMATOGR B, V775, P121, DOI 10.1016/S1570-0232(02)00273-8; ARRIGONI O, 1962, NATURE, V193, P1256, DOI 10.1038/1931256a0; Cente M, 2006, EUR J NEUROSCI, V24, P1085, DOI 10.1111/j.1460-9568.2006.04986.x; Chen JQ, 2009, BBA-MOL CELL RES, V1793, P1540, DOI 10.1016/j.bbamcr.2009.06.001; Chou JL, 2011, J PROTEOMICS, V74, P466, DOI 10.1016/j.jprot.2010.12.012; Correia Sonia C, 2010, Curr Aging Sci, V3, P113; David DC, 2005, J BIOL CHEM, V280, P23802, DOI 10.1074/jbc.M500356200; Dias-Santagata D, 2007, J CLIN INVEST, V117, P236, DOI 10.1172/JCI28769; Du H, 2010, P NATL ACAD SCI USA, V107, P18670, DOI 10.1073/pnas.1006586107; Dumont M, 2010, NEUROCHEM INT, V56, P345, DOI 10.1016/j.neuint.2009.11.006; Eckert A, 2008, J MOL MED, V86, P1255, DOI 10.1007/s00109-008-0391-6; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Gasparini L, 2007, NEURODEGENER DIS, V4, P236, DOI 10.1159/000101848; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gomez-Ramos A, 2003, J NEUROSCI RES, V71, P863, DOI 10.1002/jnr.10525; Hernandez F, 2010, EXP NEUROL, V223, P322, DOI 10.1016/j.expneurol.2009.09.011; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hoover BR, 2010, NEURON, V68, P1067, DOI 10.1016/j.neuron.2010.11.030; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Lee VMY, 2005, BBA-MOL BASIS DIS, V1739, P251, DOI 10.1016/j.bbadis.2004.06.014; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu Q, 2005, FREE RADICAL BIO MED, V38, P746, DOI 10.1016/j.freeradbiomed.2004.11.005; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Misiak M, 2010, BBA-BIOENERGETICS, V1797, P1178, DOI 10.1016/j.bbabio.2010.04.009; Noble W, 2010, CNS NEUROL DISORD-DR, V9, P403, DOI 10.2174/187152710791556131; Perez M, 2000, FEBS LETT, V486, P270, DOI 10.1016/S0014-5793(00)02323-1; Scattoni ML, 2010, BEHAV BRAIN RES, V208, P250, DOI 10.1016/j.bbr.2009.12.002; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Starkov AA, 2010, METHODS MOL BIOL, V648, P245, DOI 10.1007/978-1-60761-756-3_16; Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015; Thomas B, 2012, ANTIOXID REDOX SIGN, V16, P855, DOI 10.1089/ars.2010.3849; Yoshiyama Y, 2001, Curr Neurol Neurosci Rep, V1, P413, DOI 10.1007/s11910-001-0100-0; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	38	87	88	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					4063	4072		10.1096/fj.11-186650	http://dx.doi.org/10.1096/fj.11-186650			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21825035	Green Published			2022-12-28	WOS:000296723100029
J	Lu, HY; Huang, DP; Ransohoff, RM; Zhou, L				Lu, Haiyan; Huang, Danping; Ransohoff, Richard M.; Zhou, Lan			Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair	FASEB JOURNAL			English	Article						chemokine; inflammation; IGF-1	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CHEMOKINE RECEPTOR 2; GROWTH-FACTOR-I; CHEMOATTRACTANT PROTEIN-1; IGF-I; ALTERED INFLAMMATION; BONE-MARROW; CCR2-/-MICE; REGENERATION; MACROPHAGES	CC chemokine ligand 2 (CCL2), a ligand of CC chemokine receptor 2 (CCR2), is essential to mount an adequate inflammatory response to repair acute skeletal muscle injury. We studied the mechanisms by which CCL2 regulates muscle inflammation and regeneration. Mobilization of monocytes/macrophages (MOs/MPs) but not lymphocytes or neutrophils was impaired from bone marrow to blood and from blood to injured muscles in Ccl2(-/-) mice. This was accompanied by poor phagocytosis, reduced up-regulation of insulin-like growth factor-1 (IGF-1), and impaired muscle regeneration. Bone marrow transfer from wild-type mice to irradiated Ccr2(-/-) but not Ccl2(-/-) mice restored muscle inflammation. Intravenously injected CCL2-deficient bone marrow monocytes could not enter wild-type injured muscles as well as wild-type bone marrow monocytes. Intravenously injected wild-type bone marrow monocytes could not enter CCL2-deficient injured muscles as well as wild-type injured muscles. CCL2 stimulated IGF-1 expression by wild-type but not CCR2-deficient intramuscular macrophages. A single intramuscular injection of IGF-1, but not PBS, markedly improved muscle regeneration in Ccl2(-/-) mice. We conclude that CCL2 is a major ligand of CCR2 to recruit MOs/MPs into injured muscles to conduct phagocytosis and produce IGF-1 for injury repair. CCL2 needs to be expressed by bone marrow cells, circulating monocytes, and injured muscle tissue cells to recruit MOs/MPs into injured muscles. CCL2/CCR2 signaling also up-regulates IGF-1 expression by intramuscular macrophages to promote acute skeletal muscle injury repair.-Lu, H., Huang, D., Ransohoff, R. M., Zhou, L. Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J. 25, 3344-3355 (2011). www.fasebj.org	[Lu, Haiyan; Huang, Danping; Ransohoff, Richard M.; Zhou, Lan] Cleveland Clin, Neuroinflammat Res Ctr, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; [Ransohoff, Richard M.; Zhou, Lan] Cleveland Clin, Dept Neurol, Neurol Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Zhou, L (corresponding author), Cleveland Clin, Neuroinflammat Res Ctr, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave S90, Cleveland, OH 44195 USA.	zhoul2@ccf.org			U.S. National Institutes of Health [K08 NS049346]; Muscular Dystrophy Association (MDA) [91682, K24 51400]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS049346] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study is supported by U.S. National Institutes of Health grant K08 NS049346 (L.Z.) and Muscular Dystrophy Association grants MDA#91682 (L.Z.) and K24 51400 (R.M.R.). The authors thank Drs. Liping Liu, Georgian Cheng, and Ping Huang and the Flow Cytometry Core of the Cleveland Clinic for superb technical support.	Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Belperio JA, 2001, J CLIN INVEST, V108, P547, DOI 10.1172/JCI12214; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Chazaud B, 2003, J CELL BIOL, V163, P1133, DOI 10.1083/jcb.200212046; Contreras-Shannon V, 2007, AM J PHYSIOL-CELL PH, V292, pC953, DOI 10.1152/ajpcell.00154.2006; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Giunti S, 2010, CURR VASC PHARMACOL, V8, P849, DOI 10.2174/157016110793563816; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hayashi S, 2004, HISTOCHEM CELL BIOL, V122, P427, DOI 10.1007/s00418-004-0704-y; Heinemeier KM, 2009, J APPL PHYSIOL, V106, P178, DOI 10.1152/japplphysiol.91092.2008; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Laudanna C, 2006, THROMB HAEMOSTASIS, V95, P5, DOI 10.1160/TH05-07-0482; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LIU L, J NEUROSCI, V30, P9074; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu HY, 2011, FASEB J, V25, P358, DOI 10.1096/fj.10-171579; MARTINEZ CO, 2010, AM J PHYSIOL, V299, P832; Maus U, 2002, AM J PHYSIOL-HEART C, V283, pH2584, DOI 10.1152/ajpheart.00349.2002; Moore BB, 2005, AM J PATHOL, V166, P675, DOI 10.1016/S0002-9440(10)62289-4; Musaro A, 2005, ARCH ITAL BIOL, V143, P243; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Ochoa O, 2007, AM J PHYSIOL-REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Shahrara S, 2008, J IMMUNOL, V180, P3447, DOI 10.4049/jimmunol.180.5.3447; Shavlakadze T, 2010, BIOGERONTOLOGY, V11, P363, DOI 10.1007/s10522-009-9260-0; Shireman PK, 2006, J SURG RES, V134, P145, DOI 10.1016/j.jss.2005.12.003; Shirernan PK, 2007, J LEUKOCYTE BIOL, V81, P775, DOI 10.1189/jlb.0506356; Summan M, 2003, J INTERF CYTOK RES, V23, P237, DOI 10.1089/107999003321829953; Sun DX, 2009, FASEB J, V23, P382, DOI 10.1096/fj.07-095901; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Xia MD, 2009, EXPERT OPIN THER PAT, V19, P295, DOI 10.1517/13543770902755129; Zhou L, 2006, NEUROMUSCULAR DISORD, V16, P32, DOI 10.1016/j.nmd.2005.09.009	48	152	155	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3344	3355		10.1096/fj.10-178939	http://dx.doi.org/10.1096/fj.10-178939			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21697550	Green Published			2022-12-28	WOS:000295356400007
J	May, LT; Bridge, LJ; Stoddart, LA; Briddon, SJ; Hill, SJ				May, Lauren T.; Bridge, Lloyd J.; Stoddart, Leigh A.; Briddon, Stephen J.; Hill, Stephen J.			Allosteric interactions across native adenosine-A(3) receptor homodimers: quantification using single-cell ligand-binding kinetics	FASEB JOURNAL			English	Article						dissociation; cooperativity; GPCRs	PROTEIN-COUPLED RECEPTORS; DRUG DISCOVERY; LIVING CELLS; MUSCARINIC RECEPTORS; TARGETS; COOPERATIVITY; ACTIVATION; OLIGOMERS; MODEL; GPCR	A growing awareness indicates that many G-protein-coupled receptors (GPCRs) exist as homodimers, but the extent of the cooperativity across the dimer interface has been largely unexplored. Here, measurement of the dissociation kinetics of a fluorescent agonist (ABA-X-BY630) from the human A(1) or A(3) adenosine receptors expressed in CHO-K1 cells has provided evidence for highly cooperative interactions between protomers of the A(3)-receptor dimer in single living cells. In the absence of competitive ligands, the dissociation rate constants of ABA-X-BY630 from A(1) and A(3) receptors were 1.45 +/- 0.05 and 0.57 +/- 0.07 min(-1), respectively. At the A(3) receptor, this could be markedly increased by both orthosteric agonists and antagonists [15-, 9-, and 19-fold for xanthine amine congener (XAC), 5'-(N-ethyl carboxamido)adenosine (NECA), and adenosine, respectively] and reduced by coexpression of a nonbinding (N250A) A(3)-receptor mutant. The changes in ABA-X-BY630 dissociation were much lower at the A(1) receptor (1.5-, 1.4-, and 1.5-fold). Analysis of the pEC(50) values of XAC, NECA, and adenosine for the ABA-X-BY630-occupied A(3)-receptor dimer yielded values of 6.0 +/- 0.1, 5.9 +/- 0.1, and 5.2 +/- 0.1, respectively. This study provides new insight into the spatial and temporal specificity of drug action that can be provided by allosteric modulation across a GPCR homodimeric interface.-May, L. T., Bridge, L. J., Stoddart, L. A., Briddon, S. J., Hill, S. J. Allosteric interactions across native adenosine-A(3) receptor homodimers: quantification using single-cell ligand-binding kinetics. FASEB J. 25, 3465-3476 (2011). www.fasebj.org	[May, Lauren T.; Bridge, Lloyd J.; Stoddart, Leigh A.; Briddon, Stephen J.; Hill, Stephen J.] Univ Nottingham, Sch Biomed Sci, Inst Cell Signalling, Nottingham NG7 2UH, England	University of Nottingham	Hill, SJ (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England.	stephen.hill@nottingham.ac.uk	Hill, Stephen/N-6753-2013; Hill, Stephen J/M-6243-2018	Hill, Stephen/0000-0002-4424-239X; Hill, Stephen J/0000-0002-4424-239X; May, Lauren/0000-0002-4412-1707; Stoddart, Leigh/0000-0002-4469-0600; Briddon, Stephen/0000-0001-8514-0827	UK Biotechnology and Biological Sciences Research Council [BB/D008522]; UK Medical Research Council [G0800006]; Biotechnology and Biological Sciences Research Council [BB/D008522/1] Funding Source: researchfish; Medical Research Council [G0800006] Funding Source: researchfish; BBSRC [BB/D008522/1] Funding Source: UKRI; MRC [G0800006] Funding Source: UKRI	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank N.D. Holliday for useful discussions. This work was supported by the UK Biotechnology and Biological Sciences Research Council (BB/D008522) and the UK Medical Research Council (G0800006). L.T.M. is an Australian National Health and Medical Research Council Postdoctoral Research Fellow. L.T.M. designed and performed kinetic fluorescent ligand-binding assays and analysis. L.J.B. developed and performed parameter estimation methods. L.A.S., S.J.B., and S.J.H. generated the AR constructs. S.J.B. performed the BiFC experiments. L.T.M., L.J.B., S.J.B., and S.J.H. designed experiments and interpreted results. All authors participated in the writing and editing of the manuscript. S.J.H. managed the overall project.	Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Armstrong D, 2001, J BIOL CHEM, V276, P22621, DOI 10.1074/jbc.M006936200; ATTWOOD TK, 1994, PROTEIN ENG, V7, P195, DOI 10.1093/protein/7.2.195; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Birdsall NJM, 2010, TRENDS PHARMACOL SCI, V31, P499, DOI 10.1016/j.tips.2010.08.003; Birdsall NJM, 2005, MINI-REV MED CHEM, V5, P523, DOI 10.2174/1389557054023251; Bortolato A, 2009, CURR PHARM DESIGN, V15, P4017, DOI 10.2174/138161209789824768; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brea J, 2009, MOL PHARMACOL, V75, P1380, DOI 10.1124/mol.108.054395; Briddon SJ, 2008, BBA-MOL CELL RES, V1783, P2262, DOI 10.1016/j.bbamcr.2008.07.006; Casado V, 2009, PHARMACOL THERAPEUT, V124, P248, DOI 10.1016/j.pharmthera.2009.07.005; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; Christopoulos A, 1997, BIOCHEM PHARMACOL, V53, P795, DOI 10.1016/S0006-2952(96)00814-3; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Cordeaux Y, 2008, FASEB J, V22, P850, DOI 10.1096/fj.07-8180com; Cordeaux Y, 2000, MOL PHARMACOL, V58, P1075, DOI 10.1124/mol.58.5.1075; Durroux T, 2005, TRENDS PHARMACOL SCI, V26, P376, DOI 10.1016/j.tips.2005.05.006; Franco R, 2005, TRENDS BIOCHEM SCI, V30, P360, DOI 10.1016/j.tibs.2005.05.010; Franco R, 2006, MOL PHARMACOL, V69, P1905, DOI 10.1124/mol.105.020685; Gao ZG, 2002, J BIOL CHEM, V277, P19056, DOI 10.1074/jbc.M110960200; Gao ZG, 2008, PHARMACOL RES, V57, P303, DOI 10.1016/j.phrs.2008.02.008; Han Y, 2009, NAT CHEM BIOL, V5, P688, DOI 10.1038/nchembio.199; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Kenakin T, 2002, TRENDS PHARMACOL SCI, V23, P275, DOI 10.1016/S0165-6147(02)02036-9; Kenakin T, 2007, TRENDS PHARMACOL SCI, V28, P407, DOI 10.1016/j.tips.2007.06.009; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; Kuszak AJ, 2009, J BIOL CHEM, V284, P26732, DOI 10.1074/jbc.M109.026922; May LT, 2010, MOL PHARMACOL, V77, P678, DOI 10.1124/mol.109.063065; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; May LT, 2010, MOL PHARMACOL, V78, P511, DOI 10.1124/mol.110.064493; Middleton RJ, 2007, J MED CHEM, V50, P782, DOI 10.1021/jm061279i; Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Rose RH, 2010, BRIT J PHARMACOL, V159, P738, DOI 10.1111/j.1476-5381.2009.00480.x; Rovira X, 2009, BRIT J PHARMACOL, V156, P28, DOI 10.1111/j.1476-5381.2008.00031.x; Rovira X, 2010, TRENDS PHARMACOL SCI, V31, P15, DOI 10.1016/j.tips.2009.10.008; Smith NJ, 2010, PHARMACOL REV, V62, P701, DOI 10.1124/pr.110.002667; Springael JY, 2007, PHARMACOL THERAPEUT, V115, P410, DOI 10.1016/j.pharmthera.2007.06.004; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004; Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	47	74	74	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3465	3476		10.1096/fj.11-186296	http://dx.doi.org/10.1096/fj.11-186296			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21715680	Green Published			2022-12-28	WOS:000295356400017
J	Tang, HB; Lee, M; Budak, MT; Pietras, N; Hittinger, S; Vu, M; Khuong, A; Hoang, CD; Hussain, SNA; Levine, S; Shrager, JB				Tang, Huibin; Lee, Myung; Budak, Murat T.; Pietras, Nicole; Hittinger, Scott; Vu, Michael; Khuong, Andy; Hoang, Chuong D.; Hussain, Sabah N. A.; Levine, Sanford; Shrager, Joseph B.			Intrinsic apoptosis in mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis	FASEB JOURNAL			English	Article						oxidative stress; skeletal muscle; dysfunction; atrophy; respiratory muscle	MUSCLE PROTEIN-DEGRADATION; CONTRACTILE PROPERTIES; OXIDATIVE STRESS; SKELETAL-MUSCLE; GENE-EXPRESSION; WEANING FAILURE; DYSFUNCTION; ACTIVATION; ATROPHY; TERM	Mechanical ventilation (MV) is a life-saving measure in many critically ill patients. However, prolonged MV results in diaphragm dysfunction that contributes to the frequent difficulty in weaning patients from the ventilator. The molecular mechanisms underlying ventilator-induced diaphragm dysfunction (VIDD) remain poorly understood. We report here that MV induces myonuclear DNA fragmentation (3-fold increase; P<0.01) and selective activation of caspase 9 (P<0.05) and Bcl2-interacting mediator of cell death (Bim; 2- to 7-fold increase; P<0.05) in human diaphragm. MV also statistically significantly down-regulates mitochondrial gene expression and induces oxidative stress. In cultured muscle cells, we show that oxidative stress activates each of the catabolic pathways thought to underlie VIDD: apoptotic (P<0.05), proteasomal (P<0.05), and autophagic (P<0.01). Further, silencing Bim expression blocks (P<0.05) oxidative stress-induced apoptosis. Overlapping the gene expression profiles of MV human diaphragm and H2O2-treated muscle cells, we identify Fos, FoxO1, and Stat3 as regulators of Bim expression as well as of expression of the catabolic markers atrogin and LC3. We thus identify a novel Fos/FoxO1/Stat3-Bim intrinsic apoptotic pathway and establish the centrality of oxidative stress in the development of VIDD. This information may help in the design of specific drugs to prevent this condition.-Tang, H., Lee, M., Budak, M. T., Pietras, N., Hittinger, S., Vu, M., Khuong, A., Hoang, C. D., Hussain, S. N. A., Levine, S., Shrager, J. B. Intrinsic apoptosis in mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis. FASEB J. 25, 2921-2936 (2011). www.fasebj.org	[Tang, Huibin; Lee, Myung; Pietras, Nicole; Hittinger, Scott; Vu, Michael; Khuong, Andy; Hoang, Chuong D.; Shrager, Joseph B.] Stanford Univ, Sch Med, Dept Cardiothorac Surg, Div Thorac Surg, Stanford, CA 94305 USA; [Tang, Huibin; Lee, Myung; Pietras, Nicole; Hittinger, Scott; Vu, Michael; Khuong, Andy; Hoang, Chuong D.; Shrager, Joseph B.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA; [Budak, Murat T.; Levine, Sanford] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; [Budak, Murat T.; Levine, Sanford] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Hussain, Sabah N. A.] McGill Univ, Royal Victoria Hosp, Div Resp, Montreal, PQ H3A 1A1, Canada; [Hussain, Sabah N. A.] McGill Univ, Royal Victoria Hosp, Crit Care Div, Montreal, PQ H3A 1A1, Canada	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Shrager, JB (corresponding author), Stanford Univ, Sch Med, Dept Cardiothorac Surg, Div Thorac Surg, 300 Pasteur Dr, Stanford, CA 94305 USA.	shrager@stanford.edu	Hussain, Sabah/ABC-5315-2021; Budak, Murat/I-8358-2013	Budak, Murat/0000-0002-5059-9651	Veterans Affairs; U.S. National Institutes of Health [HL078834]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078834] Funding Source: NIH RePORTER	Veterans Affairs(US Department of Veterans Affairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Kevin Hoang (summer student at University of California, San Diego, CA, USA) and Donna Minagawa (Stanford University) for technical assistance and Xiaohua Zhang (Stanford University) for assistance in bioinformatics analysis. This research was supported by a Veterans Affairs merit review grant awarded to J.B.S. and also in part by U.S. National Institutes of Health grant HL078834. The authors declare that they have no financial relationship with a commercial entity.	Afessa B, 1999, CHEST, V116, P456, DOI 10.1378/chest.116.2.456; Alia I, 2000, CRIT CARE, V4, P72, DOI 10.1186/cc660; Anzueto A, 1997, CRIT CARE MED, V25, P1187, DOI 10.1097/00003246-199707000-00021; Argiles JA, 2008, INT J BIOCHEM CELL B, V40, P1674, DOI 10.1016/j.biocel.2008.02.001; Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Buczko W, 2009, HEALTH CARE FINANC R, V31, P1; Capdevila X, 2003, INTENS CARE MED, V29, P103, DOI 10.1007/s00134-002-1548-3; Cattapan SE, 2003, THORAX, V58, P58, DOI 10.1136/thorax.58.1.58; Cholette J, 2009, CRIT CARE MED, V37, pA434, DOI 10.1097/CCM.0b013e3181b6e760; Criswell DS, 2003, CHEST, V124, P2302, DOI 10.1378/chest.124.6.2302; Dasgupta A, 1999, CHEST, V116, P447, DOI 10.1378/chest.116.2.447; DeRuisseau KC, 2005, AM J RESP CRIT CARE, V172, P1267, DOI 10.1164/rccm.200503-403OC; DeRuisseau KC, 2005, J APPL PHYSIOL, V98, P1314, DOI 10.1152/japplphysiol.00993.2004; Douglas SL, 2002, CRIT CARE MED, V30, P2655, DOI 10.1097/00003246-200212000-00008; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Du J, 2005, EUR J CLIN INVEST, V35, P157, DOI 10.1111/j.1365-2362.2005.01473.x; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Falk DJ, 2006, J APPL PHYSIOL, V101, P1017, DOI 10.1152/japplphysiol.00104.2006; Gayan-Ramirez G, 2002, EUR RESPIR J, V20, P1579, DOI 10.1183/09031936.02.00063102; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Jang SW, 2007, J BIOL CHEM, V282, P30836, DOI 10.1074/jbc.M704542200; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; Laghi F, 1998, J APPL PHYSIOL, V85, P1103, DOI 10.1152/jappl.1998.85.3.1103; Laghi F, 2003, AM J RESP CRIT CARE, V167, P120, DOI 10.1164/rccm.200210-1246OC; LEBOURDELLES G, 1994, AM J RESP CRIT CARE, V149, P1539, DOI 10.1164/ajrccm.149.6.8004310; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Levine S, 2011, AM J RESP CRIT CARE, V183, P483, DOI 10.1164/rccm.200910-1487OC; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; Martin AD, 2002, CHEST, V122, P192, DOI 10.1378/chest.122.1.192; McClung JM, 2008, AM J PHYSIOL-REG I, V294, pR1608, DOI 10.1152/ajpregu.00044.2008; McClung JM, 2007, J PHYSIOL-LONDON, V585, P203, DOI 10.1113/jphysiol.2007.141119; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; McClung JM, 2009, CRIT CARE MED, V37, P1373, DOI 10.1097/CCM.0b013e31819cef63; Modawal A, 2002, ARCH PHYS MED REHAB, V83, P154, DOI 10.1053/apmr.2002.29614; Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006; Muscedere JG, 2008, J CRIT CARE, V23, P5, DOI 10.1016/j.jcrc.2007.11.012; Nguyen T, 2005, J APPL PHYSIOL, V98, P2004, DOI 10.1152/japplphysiol.00767.2004; Pilcher DV, 2005, THORAX, V60, P187, DOI 10.1136/thx.2004.026500; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Purro A, 2000, AM J RESP CRIT CARE, V161, P1115, DOI 10.1164/ajrccm.161.4.9812160; Racz GZ, 2003, AM J RESP CRIT CARE, V168, P297, DOI 10.1164/rccm.200206-541OC; Restrepo MI, 2010, INFECT CONT HOSP EP, V31, P509, DOI 10.1086/651669; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sassoon CSH, 2002, J APPL PHYSIOL, V92, P2585, DOI 10.1152/japplphysiol.01213.2001; Sassoon CSH, 2004, AM J RESP CRIT CARE, V170, P626, DOI 10.1164/rccm.200401-042OC; Scheinhorn D J, 2000, Respir Care Clin N Am, V6, P437, DOI 10.1016/S1078-5337(05)70080-0; Scheinhorn DJ, 2001, CHEST, V120, p482S, DOI 10.1378/chest.120.6_suppl.482S; Scheinhorn DJ, 2002, CRIT CARE CLIN, V18, P569, DOI 10.1016/S0749-0704(02)00016-7; Scheinhorn DJ, 1997, CHEST, V111, P1654, DOI 10.1378/chest.111.6.1654; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Shanely RA, 2003, CHEST, V123, P195, DOI 10.1378/chest.123.1.195; Shanely RA, 2002, AM J RESP CRIT CARE, V166, P1369, DOI 10.1164/rccm.200202-088OC; Sprague SS, 2003, PHYS THER, V83, P171, DOI 10.1093/ptj/83.2.171; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; SWARTZ MA, 1985, CHEST, V88, P736, DOI 10.1378/chest.88.5.736; Testelmans D, 2006, CRIT CARE MED, V34, P3018, DOI 10.1097/01.CCM.0000245783.28478.AD; Vassilakopoulos T, 2006, CRIT CARE, V10, DOI 10.1186/cc3917; Watson AC, 2001, CRIT CARE MED, V29, P1325, DOI 10.1097/00003246-200107000-00005; Zergeroglu MA, 2003, J APPL PHYSIOL, V95, P1116, DOI 10.1152/japplphysiol.00824.2002; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Zhu E, 2005, J APPL PHYSIOL, V99, P747, DOI 10.1152/japplphysiol.00126.2005	67	57	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2921	2936		10.1096/fj.11-183798	http://dx.doi.org/10.1096/fj.11-183798			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21597002	Green Published			2022-12-28	WOS:000294435200008
J	Ganesh, K; Neuberger, MS				Ganesh, Karuna; Neuberger, Michael S.			The relationship between hypothesis and experiment in unveiling the mechanisms of antibody gene diversification	FASEB JOURNAL			English	Review						immunoglobulin; activation-induced deaminase; somatic hypermutation; B lymphocytes	SINGLE-STRANDED-DNA; B-CELL LINE; CYTIDINE DEAMINASE AID; BENCE-JONES PROTEINS; CLASS-SWITCH RECOMBINATION; AMINO-ACID SEQUENCE; SOMATIC HYPERMUTATION; V(D)J RECOMBINATION; SELECTION THEORY; VARIABLE GENES	The origin of antibody diversity has intrigued scientists for nearly a century. We now know that the diversity is achieved through a 2-stage process. Gene rearrangement (catalyzed by the RAG1/2 recombinase) allows the production of a primary repertoire of antibodies; targeted deamination of cytosines within these rearranged antibody genes (catalyzed by the DNA deaminase AID) then allows them to be further diversified and matured by somatic hypermutation, gene conversion, and class-switch recombination. Here we review the history of the uncovering of some of these processes, contrasting the relative importance of hypothesis and methodological developments in driving the research at different periods of the work.-Ganesh, K., Neuberger, M. S. Unraveling the roles of gene rearrangement and targeted deanimation in antibody gene diversification. FASEB J. 25, 1123-1132 (2011). www.fasebj.org	[Neuberger, Michael S.] MRC, Mol Biol Lab, Div Prot & Nucle Acid Chem, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology	Neuberger, MS (corresponding author), MRC, Mol Biol Lab, Div Prot & Nucle Acid Chem, Hills Rd, Cambridge CB2 0QH, England.	msn@mrc-lmb.cam.ac.uk			MRC [MC_U105178806] Funding Source: UKRI; Medical Research Council [MC_U105178806] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; BREINL F, 1930, Z PHYSL CHEM, V192, P42; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; BURNET F. M., 1963, P7; Burnet FM, 1949, PRODUCTION ANTIBODIE; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; COHN M, 1994, ANNU REV IMMUNOL, V12, P1; Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; Denepoux S, 1997, IMMUNITY, V6, P35, DOI 10.1016/S1074-7613(00)80240-X; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; EDELMAN GM, 1994, GENETICS, V138, P975; FAGRAEUS A, 1948, J IMMUNOL, V58, P1; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0; HAUROWITZ FELIC, 1963, P22; HILSCHMANN N, 1965, P NATL ACAD SCI USA, V53, P1403, DOI 10.1073/pnas.53.6.1403; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; JERNE NK, 1967, COLD SPRING HARB SYM, V32, P591; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; Jordan MA, 2008, IMMUNOL CELL BIOL, V86, P72, DOI 10.1038/sj.icb.7100140; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; LANDSTEINER K, 1933, SPEZIFIZITAT SEROLOG; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LEDERBERG J, 1988, ANN NY ACAD SCI, V546, P175; LENNOX ES, 1967, ANNU REV BIOCHEM, V36, P365, DOI 10.1146/annurev.bi.36.070167.002053; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Lombard M, 2007, REV SCI TECH OIE, V26, P29, DOI 10.20506/rst.26.1.1724; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; Martomo SA, 2005, J IMMUNOL, V174, P7787, DOI 10.4049/jimmunol.174.12.7787; MILSTEIN C, 1966, NATURE, V209, P370, DOI 10.1038/209370a0; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Neuberger MS, 2008, IMMUNOL CELL BIOL, V86, P124, DOI 10.1038/sj.icb.7100160; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Neuberger MS, 1999, COLD SPRING HARB SYM, V64, P211, DOI 10.1101/sqb.1999.64.211; NOSSAL GJV, 1958, NATURE, V181, P1419, DOI 10.1038/1821383a0; NOSSAL GJV, 1989, IMMUNOLOGY 1930 1980, P41; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Pasteur L, 1880, CR HEBD ACAD SCI, V90, P239; Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018; PERUTZ M, 1994, LIVING MOL; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Popper K. R., 1963, CONJECTURES REFUTAT; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SECHER DS, 1977, IMMUNOL REV, V36, P51, DOI 10.1111/j.1600-065X.1977.tb00382.x; Silverstein AM, 2003, NAT IMMUNOL, V4, P3, DOI 10.1038/ni0103-3; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; TALMAGE DW, 1986, ANNU REV IMMUNOL, V4, P1; THUCYDIDES, 1972, HIST PELOPONNESIAN W, P154; TITANI K, 1966, SCIENCE, V152, P1513, DOI 10.1126/science.152.3728.1513; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDENT DC, 1995, CELL, V81, P925; WABL MR, 1984, P NATL ACAD SCI-BIOL, V81, P867, DOI 10.1073/pnas.81.3.867; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; Wang M, 2010, J EXP MED, V207, P141, DOI 10.1084/jem.20092238; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Weill JC, 1996, IMMUNOL TODAY, V17, P92, DOI 10.1016/0167-5699(96)80586-X; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	75	12	12	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2011	25	4					1123	1132		10.1096/fj.11-0402ufm	http://dx.doi.org/10.1096/fj.11-0402ufm			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	742ZA	21454370				2022-12-28	WOS:000288982800002
J	Byun, EH; Kim, WS; Kim, JS; Jung, ID; Park, YM; Kim, HJ; Cho, SN; Shin, SJ				Byun, Eui-Hong; Kim, Woo Sik; Kim, Jong-Seok; Jung, In Duk; Park, Yeong-Min; Kim, Hwa-Jung; Cho, Sang-Nae; Shin, Sung Jae			Mycobacterium tuberculosis Rv0577, a novel TLR2 agonist, induces maturation of dendritic cells and drives Th1 immune response	FASEB JOURNAL			English	Article						Toll-like receptor; tuberculosis; surface molecules; proinflammatory cytokines; memory T cell	ANTIGEN ESAT-6; T-CELLS; PROTEIN; MEMORY; EXPRESSION; INFECTION; CFP32; IDENTIFICATION; RECEPTORS; INDUCTION	Tuberculosis (TB) caused by Mycobacterium tuberculosis constitutes an ongoing threat to global health. An antigen that can induce dendritic cell (DC) maturation and lead to enhanced cellular immunity is crucial to the development of an effective TB vaccine. Here, we investigated the functional roles and the related signaling mechanism of the Rv0577 protein, a M. tuberculosis complex-restricted secreted protein involved in the methylglyoxal detoxification pathway. Rv0577 recognizes Toll-like receptor 2 (TLR2) and functionally induces DC maturation by augmenting the expression of cell surface molecules (CD80, CD86, and MHC class I and II) and proinflammatory cytokine production (TNF-alpha, IL-1 beta, IL-6, and IL-12p70) in DCs on MyD88-dependent signaling, mitogen-activated protein kinases, and nuclear factor kappa B signaling pathways. In addition, Rv0577-treated DCs activated naive T cells, effectively polarized CD4(+) and CD8(+) T cells to secrete IFN-gamma and IL-2, and induced T-cell proliferation, indicating that this protein possibly contributes to Th1-polarization of the immune response. More important, unlike LPS, Rv0577-treated DCs specifically induced the proliferation of memory CD4(+)/CD8(+) CD44(high) CD62L(low) T cells in the spleen of M. tuberculosis-infected mice in a TLR2-dependent manner. Taken together, these findings suggest that Rv0577 may regulate innate and adaptive immunity by interacting with TLR2, a finding that could be helpful in the design of new TB vaccines.-Byun, E.-H., Kim, W. S., Kim, J.-S., Jung, I. D., Park, Y.-M., Kim, H.-J., Cho, S.-N., Shin, S. J. Mycobacterium tuberculosis Rv0577, a novel TLR2 agonist, induces maturation of dendritic cells and drives Th1 immune response. FASEB J. 26, 2695-2711 ( 2012). www.fasebj.org	[Byun, Eui-Hong; Kim, Woo Sik; Kim, Jong-Seok; Kim, Hwa-Jung; Shin, Sung Jae] Chungnam Natl Univ, Dept Microbiol, Coll Med, Taejon 301747, South Korea; [Byun, Eui-Hong; Kim, Woo Sik; Kim, Jong-Seok; Kim, Hwa-Jung; Shin, Sung Jae] Chungnam Natl Univ, Res Inst Med Sci, Coll Med, Taejon 301747, South Korea; [Jung, In Duk; Park, Yeong-Min] Pusan Natl Univ, Dept Microbiol & Immunol, Sch Med, Yangsan, South Korea; [Cho, Sang-Nae] Yonsei Univ, Coll Med, Dept Microbiol, Inst Immunol & Immunol Dis, Seoul, South Korea	Chungnam National University; Chungnam National University; Pusan National University; Pusan National University Hospital; Yonsei University; Yonsei University Health System	Shin, SJ (corresponding author), Chungnam Natl Univ, Dept Microbiol, Coll Med, Taejon 301747, South Korea.	sjshin@cnu.ac.kr		Kim, Hwa-Jung/0000-0002-1127-0909	National Research Foundation of Korea (NRF); Korea government (MEST) [2011-0017906]; Ministry for Health and Welfare, Republic of Korea [11203901_26555]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Ministry for Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST; 2011-0017906) and by a grant from the National Research and Development Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (11203901_26555).	AbouZeid C, 1997, INFECT IMMUN, V65, P1856, DOI 10.1128/IAI.65.5.1856-1862.1997; ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; Andreu N, 2004, FEMS MICROBIOL LETT, V231, P283, DOI 10.1016/S0378-1097(04)00008-4; Bansal K, 2010, J BIOL CHEM, V285, P36511, DOI 10.1074/jbc.M110.158055; Bansal K, 2010, J IMMUNOL, V184, P3495, DOI 10.4049/jimmunol.0903299; Basu S, 2007, J BIOL CHEM, V282, P1039, DOI 10.1074/jbc.M604379200; Benabdesselem C, 2007, MOL BIOTECHNOL, V35, P41, DOI 10.1385/MB:35:1:41; Benabdesselem C, 2006, J CLIN MICROBIOL, V44, P3086, DOI 10.1128/JCM.02672-05; Bertholet S, 2008, J IMMUNOL, V181, P7948, DOI 10.4049/jimmunol.181.11.7948; Byun EH, 2012, J MOL MED, V90, P285, DOI 10.1007/s00109-011-0819-2; Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002; Cho DH, 2006, PROTEOMICS, V6, P5785, DOI 10.1002/pmic.200600207; COOPER AM, 1995, CURR OPIN IMMUNOL, V7, P512, DOI 10.1016/0952-7915(95)80096-4; Cowley SC, 2005, J EXP MED, V202, P309, DOI 10.1084/jem.20050569; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Drage MG, 2010, NAT STRUCT MOL BIOL, V17, P1088, DOI 10.1038/nsmb.1869; Druszczynska M, 2011, POSTEP HIG MED DOSW, V65, P28, DOI 10.5604/17322693.931545; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Esser MT, 2003, VACCINE, V21, P419, DOI 10.1016/S0264-410X(02)00407-3; Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027; Gerberick GF, 1997, TOXICOL APPL PHARM, V146, P1, DOI 10.1006/taap.1997.8218; Giri PK, 2010, PROTEOMICS, V10, P3190, DOI 10.1002/pmic.200900840; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Gruppo V, 2002, MICROBIOL-SGM, V148, P2959, DOI 10.1099/00221287-148-10-2959; Hogevold HE, 1997, PERFUSION-UK, V12, P9, DOI 10.1177/026765919701200103; Huard RC, 2003, INFECT IMMUN, V71, P6871, DOI 10.1128/IAI.71.12.6871-6883.2003; Jeong YI, 2009, J BIOL CHEM, V284, P3700, DOI 10.1074/jbc.M807328200; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Khan N, 2008, CELL MICROBIOL, V10, P1711, DOI 10.1111/j.1462-5822.2008.01161.x; Lee JS, 2009, INFECT IMMUN, V77, P2979, DOI 10.1128/IAI.01411-08; Lipscomb MF, 2002, PHYSIOL REV, V82, P97, DOI 10.1152/physrev.00023.2001; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Mukhopadhyay S, 2011, TUBERCULOSIS, V91, P441, DOI 10.1016/j.tube.2011.04.004; Nair S, 2009, J IMMUNOL, V183, P6269, DOI 10.4049/jimmunol.0901367; Narayana Y, 2007, CLIN VACCINE IMMUNOL, V14, P1334, DOI 10.1128/CVI.00181-07; ORME IM, 1993, J INFECT DIS, V167, P1481, DOI 10.1093/infdis/167.6.1481; Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468; Pecora ND, 2006, J IMMUNOL, V177, P422, DOI 10.4049/jimmunol.177.1.422; Pethe K, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1060; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sousa CRE, 2001, IMMUNITY, V14, P495; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Steinman RM, 1999, J LEUKOCYTE BIOL, V66, P205, DOI 10.1002/jlb.66.2.205; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P841, DOI 10.1111/j.1348-0421.2003.tb03450.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Wang BL, 2007, CLIN VACCINE IMMUNOL, V14, P902, DOI 10.1128/CDLI.00077-07	51	66	75	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2695	2711		10.1096/fj.11-199588	http://dx.doi.org/10.1096/fj.11-199588			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415304				2022-12-28	WOS:000305017200045
J	Seiferth, A; Ruhs, S; Mildenberger, S; Gekle, M; Grossmann, C				Seiferth, Anja; Ruhs, Stefanie; Mildenberger, Sigrid; Gekle, Michael; Grossmann, Claudia			The phosphatase calcineurin PP2BA beta mediates part of mineralocorticoid receptor transcriptional activity	FASEB JOURNAL			English	Article						aldosterone; steroid hormone; transcription factor CREB; transcription factor NFaT	GROWTH-FACTOR RECEPTOR; A-BETA; CARDIAC-HYPERTROPHY; ESTROGEN-RECEPTOR; SMOOTH-MUSCLE; IN-VITRO; ALDOSTERONE; INHIBITION; ACTIVATION; APOPTOSIS	Recently it was shown that the mineralocorticoid receptor (MR) may exert part of its transcriptional activity by mediation of calcineurin (PP2B). Here we investigated the mechanism of interaction of MR with calcineurin and provide a new MR signaling pathway with potential physiological and pathophysiological relevance. MR -> calcineurin crosstalk was assessed in a heterologous expression system (human embryonic kidney cells), which provides the opportunity for detailed mechanistic investigation. SiRNA knockdown experiments show that activated MR, but not GR, reduces CREB-and enhances NFaT-mediated transcriptional activation via the catalytic calcineurin subunit PP2BA beta but not via PP2BA alpha. Altered PP2BA beta expression, elevated cytosolic Ca2+, activation of mitogen-activated kinase [p38, extracellular signal-regulated kinase (ERK) 1/2], or protein kinase C do not seem to be involved, whereas inhibition of the chaperone heat-shock protein 90 (HSP90) abrogated the effect of MR. Coimmunoprecipitation indicates the existence of protein complexes harboring MR and PP2BA beta independent of MR activation but dependent on HSP90. Activated MR alters the subcellular distribution of PP2BA beta, enhancing its nuclear fraction, and reduces mRNA expression of the endogenous inhibitor CAIN (calcineurin inhibitor) but not of RCAN1 (regulator of calcineurin). Overall, transcriptional relevant MR -> calcineurin crosstalk occurs via the catalytic subunit PP2BA beta, enables glucocorticoid response element-independent genomic signaling of MR, and is of potential pathophysiological relevance. Mechanistically, the crosstalk results from HSP90-mediated cytosolic protein complex formation, altered subcellular distribution, and altered endogenous inhibitor expression.-Seiferth, A., Ruhs, S., Mildenberger, S., Gekle, M., Grossmann, C. The phosphatase calcineurin PP2BA beta mediates part of mineralocorticoid receptor. FASEB J. 26, 2327-2337 (2012). www.fasebj.org	[Seiferth, Anja; Ruhs, Stefanie; Mildenberger, Sigrid; Gekle, Michael; Grossmann, Claudia] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, D-06112 Halle, Saale, Germany	Martin Luther University Halle Wittenberg	Gekle, M (corresponding author), Univ Halle Wittenberg, Julius Bernstein Inst Physiol, Magdeburger Str 6, D-06112 Halle, Saale, Germany.	michael.gekle@medizin.uni-halle.de			Deutsche Forschungsgemeinschaft [Ge 905/13-1, Ge 905/14-1]; Medical School, Universitat Halle-Wittenberg	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Medical School, Universitat Halle-Wittenberg	This study was supported by the Deutsche Forschungsgemeinschaft (grants Ge 905/13-1 and 14-1) and the Wilhelm-Roux program of the Medical School, Universitat Halle-Wittenberg. The authors declare no conflicts of interest.	ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bueno OF, 2004, CIRC RES, V94, P91, DOI 10.1161/01.RES.0000107197.99679.77; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chan MC, 2011, MOL CELL BIOL, V31, P517, DOI 10.1128/MCB.00884-10; Dickhout JG, 2011, CIRC RES, V108, P629, DOI 10.1161/CIRCRESAHA.110.226803; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 1996, P NATL ACAD SCI USA, V93, P10500, DOI 10.1073/pnas.93.19.10500; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; Grossmann C, 2005, MOL ENDOCRINOL, V19, P1697, DOI 10.1210/me.2004-0469; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Grossmann C, 2010, STEROIDS, V75, P539, DOI 10.1016/j.steroids.2009.10.006; Grossmann C, 2010, FASEB J, V24, P2010, DOI 10.1096/fj.09-146985; Guo XX, 2011, BIOCHEM BIOPH RES CO, V407, P807, DOI 10.1016/j.bbrc.2011.03.104; Hallhuber M, 2006, CIRC RES, V99, P626, DOI 10.1161/01.RES.0000243208.59795.d8; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; Jabr RI, 2007, AM J PHYSIOL-CELL PH, V292, pC2213, DOI 10.1152/ajpcell.00139.2005; Krug AW, 2003, J BIOL CHEM, V278, P43060, DOI 10.1074/jbc.M308134200; Kupatt C, 2004, ARTERIOSCL THROM VAS, V24, P1435, DOI 10.1161/01.ATV.0000134300.87476.d1; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Li HM, 2011, TRENDS CELL BIOL, V21, P91, DOI 10.1016/j.tcb.2010.09.011; Liu JO, 2003, BIOCHEM BIOPH RES CO, V311, P1103, DOI 10.1016/j.bbrc.2003.10.020; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Mano A, 2004, CIRCULATION, V110, P317, DOI 10.1161/01.CIR.0000135599.33787.CA; Min LJ, 2009, J MOL CELL CARDIOL, V47, P798, DOI 10.1016/j.yjmcc.2009.09.006; Nilsson-Berglund LM, 2010, ARTERIOSCL THROM VAS, V30, P218, DOI 10.1161/ATVBAHA.109.199299; Orie NN, 2009, BRIT J PHARMACOL, V157, P554, DOI 10.1111/j.1476-5381.2009.00221.x; Pedram A, 2008, ENDOCRINOLOGY, V149, P3361, DOI 10.1210/en.2008-0133; Peng YD, 2010, CELL BIOL INT, V34, P447, DOI 10.1042/CBI20090301; Pfau A, 2007, MOL CELL ENDOCRINOL, V264, P35, DOI 10.1016/j.mce.2006.10.002; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Ritter O, 2003, TRENDS MOL MED, V9, P313, DOI 10.1016/S1471-4914(03)00114-X; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sharp SY, 2007, CANCER RES, V67, P2206, DOI 10.1158/0008-5472.CAN-06-3473; Shibasaki F, 2002, J BIOCHEM, V131, P1, DOI 10.1093/oxfordjournals.jbchem.a003063; Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800; Takeda Y, 2002, CIRCULATION, V105, P677, DOI 10.1161/hc0602.104675; Thomas W, 2007, BIOCHEM SOC T, V35, P1049, DOI 10.1042/BST0351049; Tumlin JA, 1997, J CLIN INVEST, V99, P1217, DOI 10.1172/JCI119278; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Wohlfarth V, 2003, KIDNEY INT, V63, pS103, DOI 10.1046/j.1523-1755.63.s84.13.x	44	6	6	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2327	2337		10.1096/fj.11-199976	http://dx.doi.org/10.1096/fj.11-199976			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22345406				2022-12-28	WOS:000305017200011
J	Counotte, DS; Goriounova, NA; Moretti, M; Smoluch, MT; Irth, H; Clementi, F; Schoffelmeer, ANM; Mansvelder, HD; Smit, AB; Gotti, C; Spijker, S				Counotte, Danielle S.; Goriounova, Natalia A.; Moretti, Milena; Smoluch, Marek T.; Irth, Hubertus; Clementi, Francesco; Schoffelmeer, Anton N. M.; Mansvelder, Huibert D.; Smit, August B.; Gotti, Cecilia; Spijker, Sabine			Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex	FASEB JOURNAL			English	Article						neurophysiology; membrane expression; immunoprecipitation; epibatidine binding; IPSC amplitude; pyramidal neurons	CONDITIONED PLACE PREFERENCE; ACETYLCHOLINE-RECEPTORS; CHOLINERGIC SYSTEMS; CIGARETTE-SMOKING; UP-REGULATION; ADULT RATS; GLUTAMATE RELEASE; BINDING-SITES; BRAIN; SUBTYPES	Adolescence is a critical developmental period during which most adult smokers initiate their habit. Adolescents are more vulnerable than adults to nicotine's long-term effects on addictive and cognitive behavior. We investigated whether adolescent nicotine exposure in rats modifies expression of nicotinic acetylcholine receptors (nAChRs) in medial prefrontal cortex (mPFC) in the short and/or long term, and whether this has functional consequences. Using receptor binding studies followed by immunoprecipitation of nAChR subunits, we showed that adolescent nicotine exposure, as compared with saline, caused an increase in mPFC nAChRs containing alpha 4 or beta 2 subunits (24 and 18%, respectively) 24 h after the last injection. Nicotine exposure in adulthood had no such effect. This increase was transient and was not observed 5 wk following either adolescent or adult nicotine exposure. In line with increased nAChRs expression 1 d after adolescent nicotine exposure, we observed a 34% increase in amplitude of nicotine-induced spontaneous inhibitory postsynaptic currents in layer II/III mPFC pyramidal neurons. These effects were transient and specific, and observed only acutely after adolescent nicotine exposure, but not after 5 wk, and no changes were observed in adult-exposed animals. The acute nicotine-induced increase in alpha 4 beta 2-containing receptors in adolescents interferes with the normal developmental decrease (37%) of these receptors from early adolescence (postnatal day 34) to adulthood (postnatal day 104) in the mPFC. Together, this suggests that these receptors play a role in mediating the acute rewarding effects of nicotine and may underlie the increased sensitivity of adolescents to nicotine.-Counotte, D. S., Goriounova, N. A., Moretti, M., Smoluch, M. T., Irth, H., Clementi, F., Schoffelmeer, A. N. M., Mansvelder, H. D., Smit, A. B., Gotti, C., Spijker, S. Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex. FASEB J. 26, 1810-1820 (2012). www.fasebj.org	[Counotte, Danielle S.; Smit, August B.; Spijker, Sabine] Vrije Univ Amsterdam, Med Ctr, Dept Mol & Cellular Neurobiol, Amsterdam, Netherlands; [Goriounova, Natalia A.; Mansvelder, Huibert D.] Vrije Univ Amsterdam, Med Ctr, Ctr Neurogen & Cognit Res, Dept Integrat Neurophysiol, Amsterdam, Netherlands; [Schoffelmeer, Anton N. M.] Vrije Univ Amsterdam, Med Ctr, Dept Anat & Neurosci, Amsterdam, Netherlands; [Smoluch, Marek T.; Irth, Hubertus] Vrije Univ Amsterdam, Dept Analyt Chem & Appl Spect, Amsterdam, Netherlands; [Moretti, Milena; Clementi, Francesco; Gotti, Cecilia] Univ Milan, Inst Neurosci, Dept Med Pharmacol, CNR, Milan, Italy	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Spijker, S (corresponding author), De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	s.spijker@vu.nl	Smoluch, Marek/AAN-8306-2021; Spijker, Sabine/F-2300-2011; Mansvelder, Huibert/N-6138-2018; Goriounova, Natalia/ABE-6759-2020; Smoluch, Marek/AGA-6079-2022	Smoluch, Marek/0000-0002-9481-988X; Mansvelder, Huibert/0000-0003-1365-5340; Spijker, Sabine/0000-0002-6814-2019; Goriounova, Natalia/0000-0002-5917-983X	Netherlands Organisation for Scientific Research (NWO-ZonMW) TOP [91206148]; European Union [HEALTH-F2-2008-202088]; Italian PRIN [2009R7WCZS]	Netherlands Organisation for Scientific Research (NWO-ZonMW) TOP; European Union(European Commission); Italian PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	The authors thank Martin Giera for his expertise with the extraction method to measure plasma nicotine levels. The authors also thank Rob Binnekade, Mathijs Stegeman, Dustin Schetters, and Yvar van Mourik for their excellent technical assistance in the behavioral paradigm. Funding was received from the Netherlands Organisation for Scientific Research (NWO-ZonMW) TOP project 91206148 (D. S. C., N.A.G., S. S., H. D. M., and A. B. S.), the European Union Seventh Framework Programme under grant agreement HEALTH-F2-2008-202088 (NeuroCypres project; A. B. S. and C. G.), and from the Italian PRIN 2009R7WCZS (C. G.). The authors report no conflicts of interest.	Abreu-Villaca Y, 2003, NEUROPSYCHOPHARMACOL, V28, P1935, DOI 10.1038/sj.npp.1300221; Adriani W, 2003, J NEUROSCI, V23, P4712; Barron Susan, 2005, Alcohol Clin Exp Res, V29, P1720, DOI 10.1097/01.alc.0000179220.79356.e5; Belluzzi JD, 2004, PSYCHOPHARMACOLOGY, V174, P389, DOI 10.1007/s00213-003-1758-6; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; Brielmaier JM, 2007, NEUROTOXICOL TERATOL, V29, P74, DOI 10.1016/j.ntt.2006.09.023; Britton AF, 2007, J PHARMACOL EXP THER, V320, P871, DOI 10.1124/jpet.106.112730; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Chassin L, 1996, HEALTH PSYCHOL, V15, P478, DOI 10.1037/0278-6133.15.6.478; Couey JJ, 2007, NEURON, V54, P73, DOI 10.1016/j.neuron.2007.03.006; Counotte DS, 2011, DEV COGN NEUROS-NETH, V1, P430, DOI 10.1016/j.dcn.2011.05.010; Counotte DS, 2011, NAT NEUROSCI, V14, P417, DOI 10.1038/nn.2770; Counotte DS, 2010, EUR J NEUROSCI, V32, P1452, DOI 10.1111/j.1460-9568.2010.07404.x; Counotte DS, 2009, NEUROPSYCHOPHARMACOL, V34, P299, DOI 10.1038/npp.2008.96; Doura MB, 2008, BRAIN RES, V1215, P40, DOI 10.1016/j.brainres.2008.03.056; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gotti C, 2007, BIOCHEM PHARMACOL, V74, P1102, DOI 10.1016/j.bcp.2007.05.023; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Govind AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Grady SR, 2009, J NEUROSCI, V29, P2272, DOI 10.1523/JNEUROSCI.5121-08.2009; HILL P, 1983, J CHRON DIS, V36, P439, DOI 10.1016/0021-9681(83)90136-4; Iniguez SD, 2009, NEUROPSYCHOPHARMACOL, V34, P1609, DOI 10.1038/npp.2008.220; ISAAC PF, 1972, NATURE, V236, P308, DOI 10.1038/236308a0; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Konradsson-Geuken A, 2009, SYNAPSE, V63, P1069, DOI 10.1002/syn.20693; Kota D, 2009, BIOCHEM PHARMACOL, V78, P873, DOI 10.1016/j.bcp.2009.06.099; Kuryatov A, 2008, MOL PHARMACOL, V74, P132, DOI 10.1124/mol.108.046789; Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI 10.1038/sj.npp.1300032; Livingstone PD, 2009, EUR J NEUROSCI, V29, P539, DOI 10.1111/j.1460-9568.2009.06613.x; Marks MJ, 2006, MOL PHARMACOL, V70, P947, DOI 10.1124/mol.106.025338; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Moretti M, 2010, MOL PHARMACOL, V78, P287, DOI 10.1124/mol.110.064071; Novick L F, 2000, J Public Health Manag Pract, V6, pvi; O'Dell LE, 2009, NEUROPHARMACOLOGY, V56, P263, DOI 10.1016/j.neuropharm.2008.07.039; O'Dell LE, 2006, PSYCHOPHARMACOLOGY, V186, P612, DOI 10.1007/s00213-006-0383-6; PAULY JR, 1991, J PHARMACOL EXP THER, V258, P1127; Rogers SW, 1998, J NEUROSCI, V18, P4825; RUSSELL MAH, 1980, BMJ-BRIT MED J, V280, P972, DOI 10.1136/bmj.280.6219.972; Schramm-Sapyta NL, 2009, PSYCHOPHARMACOLOGY, V206, P1, DOI 10.1007/s00213-009-1585-5; SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/science.6828889; Shram MJ, 2006, PSYCHOPHARMACOLOGY, V186, P201, DOI 10.1007/s00213-006-0373-8; Slotkin TA, 2004, TOXICOL APPL PHARM, V198, P132, DOI 10.1016/j.taap.2003.06.001; Slotkin TA, 2008, BRAIN RES BULL, V76, P152, DOI 10.1016/j.brainresbull.2007.12.009; Torres OV, 2008, PHARMACOL BIOCHEM BE, V90, P658, DOI 10.1016/j.pbb.2008.05.009; Trauth JA, 1999, BRAIN RES, V851, P9, DOI 10.1016/S0006-8993(99)01994-0; Tumkosit P, 2006, MOL PHARMACOL, V70, P1358, DOI 10.1124/mol.106.027326; Van den Oever MC, 2008, NAT NEUROSCI, V11, P1053, DOI 10.1038/nn.2165; Vastola BJ, 2002, PHYSIOL BEHAV, V77, P107, DOI 10.1016/S0031-9384(02)00818-1; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	52	34	34	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1810	1820		10.1096/fj.11-198994	http://dx.doi.org/10.1096/fj.11-198994			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22308197	Green Accepted			2022-12-28	WOS:000303680800009
J	Rasmussen, P; Nordsborg, N; Taudorf, S; Sorensen, H; Berg, RMG; Jacobs, RA; Bailey, DM; Olsen, NV; Secher, NH; Moller, K; Lundby, C				Rasmussen, Peter; Nordsborg, Nikolai; Taudorf, Sarah; Sorensen, Henrik; Berg, Ronan M. G.; Jacobs, Robert A.; Bailey, Damian M.; Olsen, Niels V.; Secher, Niels H.; Moller, Kirsten; Lundby, Carsten			Brain and skin do not contribute to the systemic rise in erythropoietin during acute hypoxia in humans	FASEB JOURNAL			English	Article						cerebrospinal fluid; O-2 sensing; synthesis; epidermal	OXYGEN; EXERCISE	Erythropoietin (EPO) preserves arterial oxygen content by controlling red blood cell and plasma volumes. Synthesis of EPO was long thought to relate inversely to renal oxygenation, but in knockout mice, brain and skin have been identified as essential for the acute hypoxic EPO response. Whether these findings apply to humans remains unknown. We exposed healthy young subjects to hypoxia (equivalent to 3800 m) and measured EPO in arterial and jugular venous plasma and in cerebrospinal fluid. To examine the role of the skin for EPO production during hypoxia, subjects were exposed to 8 h of hypobaric hypoxia with or without breathing oxygen-enriched air to ensure systemic normoxemia. With 9 h of hypoxia, arterial EPO increased (from 6.0+/-2.2 to 22.0+/-6.0 mU/ml, n=11, P<0.0001) and jugular venous EPO displayed a similar response (to 22.2+/-6.0 mU/ml, n=11). Thus, the arterio-jugular venous EPO difference was unaffected by hypoxia and also in cerebrospinal fluid EPO remained stable following hypoxic exposure (0.33+/-0.15 mU/ml, n=9 in normoxia vs. 0.41+/-0.20 mU/ml, n=9 in hypoxia, P=0.40). No change in plasma EPO was observed when only skin was exposed to hypobaric hypoxia (n=8). Thus, neither dermal oxygen exposure nor cerebral EPO production appears to be important for the systemic EPO response to acute hypoxia in healthy humans.-Rasmussen, P., Nordsborg, N., Taudorf, S., Sorensen, H., Berg, R. M. G., Jacobs, R. A., Bailey, D. M., Olsen, N. V., Secher, N. H., Moller, K., Lundby, C. Brain and skin do not contribute to the systemic rise in erythropoietin during acute hypoxia in humans. FASEB J. 26, 1831-1834 (2012). www.fasebj.org	[Rasmussen, Peter; Jacobs, Robert A.; Lundby, Carsten] Univ Zurich, Dept Physiol, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Rasmussen, Peter; Secher, Niels H.; Lundby, Carsten] Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; [Taudorf, Sarah; Berg, Ronan M. G.; Moller, Kirsten] Rigshosp, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; [Sorensen, Henrik; Olsen, Niels V.; Secher, Niels H.; Moller, Kirsten] Rigshosp, Dept Anesthesiol, DK-2100 Copenhagen, Denmark; [Moller, Kirsten] Bispebjerg Hosp, Dept Anesthesiol, DK-2400 Copenhagen, Denmark; [Rasmussen, Peter; Olsen, Niels V.; Moller, Kirsten] Univ Copenhagen, Dept Neurosci & Pharmacol, DK-1168 Copenhagen, Denmark; [Nordsborg, Nikolai] Univ Copenhagen, Dept Sports & Exercise Sci, DK-1168 Copenhagen, Denmark; [Bailey, Damian M.] Univ Glamorgan, Fac Hlth Sci & Sport, Neurovasc Res Lab, Cardiff, S Glam, Wales	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen; University of South Wales	Lundby, C (corresponding author), Univ Zurich, Dept Physiol, Zurich Ctr Integrat Human Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	carsten.lundby@access.uzh.ch	Sørensen, Henrik/H-8404-2013; Ernst-Rasmussen, Peter Bonde/B-8203-2013; Bailey, Damian Miles/AAQ-1840-2020; Jacobs, Robert A/G-8439-2015; Moller, Kirsten/A-4751-2009; Nordsborg, Nikolai/O-6173-2014	Sørensen, Henrik/0000-0003-0819-106X; Ernst-Rasmussen, Peter Bonde/0000-0003-1761-4562; Jacobs, Robert A/0000-0003-0180-8266; Moller, Kirsten/0000-0003-3058-1072; Nordsborg, Nikolai/0000-0001-7077-9265; Berg, Ronan/0000-0002-5757-9506	Danish National Research Council [10-094110, 22-04-0413, 504-14, DG 02-512-555]; Anti-Doping Denmark; Copenhagen Hospital Corporation; Laerdal Foundation; AP Moller Foundation; Jens la Cour Foundation; Larsen Foundation; Hojmosegaard Foundation; P. Carl Petersen Foundation; Novo Nordisk Foundation; Lundbeck Foundation; Commission of the European Communities [LSHM-CT-2004-005272 EXGENESIS]; Hypoxianet.com [COST-STSM-TD0901-8234]	Danish National Research Council(Danmarks Grundforskningsfond); Anti-Doping Denmark; Copenhagen Hospital Corporation; Laerdal Foundation; AP Moller Foundation; Jens la Cour Foundation; Larsen Foundation; Hojmosegaard Foundation; P. Carl Petersen Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Commission of the European Communities(European Commission); Hypoxianet.com	This study was supported by grants from the Danish National Research Council (10-094110, 22-04-0413, 504-14, and DG 02-512-555), Anti-Doping Denmark, the Copenhagen Hospital Corporation, the Laerdal Foundation, the AP Moller Foundation, the Jens la Cour Foundation, the Larsen Foundation, the Hojmosegaard Foundation, the P. Carl Petersen Foundation, the Novo Nordisk Foundation, the Lundbeck Foundation, the Commission of the European Communities (contract LSHM-CT-2004-005272 EXGENESIS), and Hypoxianet.com (COST-STSM-TD0901-8234). The authors acknowledge the skillful assistance of Niels J. Aachmann-Andersen, Thomas Bonne, Birgit H. Hansen, and Merete Nielsen. The authors declare no conflicts of interest.	ABBRECHT PH, 1966, AM J PHYSIOL, V210, P237, DOI 10.1152/ajplegacy.1966.210.2.237; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bodo E, 2007, FASEB J, V21, P3346, DOI 10.1096/fj.07-8628com; Boutin AT, 2008, CELL, V133, P223, DOI 10.1016/j.cell.2008.02.038; GONZALEZ NC, 1991, J APPL PHYSIOL, V71, P1041, DOI 10.1152/jappl.1991.71.3.1041; KNAUPP W, 1992, J APPL PHYSIOL, V73, P837, DOI 10.1152/jappl.1992.73.3.837; Lundby C, 2007, J PHYSIOL-LONDON, V578, P309, DOI 10.1113/jphysiol.2006.122689; Olsen NV, 2011, J PHYSIOL-LONDON, V589, P1273, DOI 10.1113/jphysiol.2010.194241; Pellegri G, 1996, MOL BRAIN RES, V38, P191, DOI 10.1016/0169-328X(95)00305-C; Rasmussen P, 2010, J APPL PHYSIOL, V109, P476, DOI 10.1152/japplphysiol.00234.2010; Rasmussen P, 2007, J CEREBR BLOOD F MET, V27, P1082, DOI 10.1038/sj.jcbfm.9600416; Robach P, 2007, BLOOD, V109, P4724, DOI 10.1182/blood-2006-08-040006; Simmons GH, 2007, J APPL PHYSIOL, V103, P608, DOI 10.1152/japplphysiol.01443.2006; Weidemann A, 2009, J CLIN INVEST, V119, P3373, DOI 10.1172/JCI39378	14	10	10	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1831	1834		10.1096/fj.11-191692	http://dx.doi.org/10.1096/fj.11-191692			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22321729				2022-12-28	WOS:000303680800011
J	Mijouin, L; Rosselin, M; Bottreau, E; Pizarro-Cerda, J; Cossart, P; Velge, P; Wiedemann, A				Mijouin, Lily; Rosselin, Manon; Bottreau, Elisabeth; Pizarro-Cerda, Javier; Cossart, Pascale; Velge, Philippe; Wiedemann, Agnes			Salmonella enteritidis Rck-mediated invasion requires activation of Rac1, which is dependent on the class I PI 3-kinases-Akt signaling pathway	FASEB JOURNAL			English	Article						bacterial internalization; phosphoinositides	GROUP-B STREPTOCOCCUS; PROTEIN-KINASE B; EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; LISTERIA-MONOCYTOGENES; PHOSPHATIDYLINOSITOL 3-KINASE; YERSINIA-PSEUDOTUBERCULOSIS; BACTERIAL INVASION; E-CADHERIN; AKT	The Salmonella outer membrane protein Rck mediates a Zipper-like entry mechanism controlled by Rac, the Arp2/3 complex, and actin polymerization. However, little is known about the early steps leading to Rac activation and Rck-mediated internalization. The use of pharmacological inhibitors or PI 3-kinase dominant-negative mutant induced more than 80% less invasion without affecting attachment. Moreover, Rck-mediated internalization caused an increase in the association of p85 with at least one tyrosine-phosphorylated protein, indicating that class I PI 3-kinase activity was stimulated. We also report that this PI 3-kinase activity is essential for Rac1 activation. However, Rac recruitment at the Rck-mediated entry site was independent of its activation. Using a pharmacological approach or Akt-knockout cells, we also demonstrated that Akt was phosphorylated in response to Rck-mediated internalization as demonstrated by immunoblotting analysis and that all three Akt isoforms were required during this process. Overall, our results describe a signaling pathway involving tyrosine phosphorylation, class I PI 3-kinase, Akt activation, and Rac activation, leading to Rck-dependent Zipper entry. The specificity of this signaling pathway with regard to that of the type 3 secretion system, which is the other invasion process of Salmonella, is discussed.-Mijouin, L., Rosselin, M., Bottreau, E., Pizarro-Cerda, J., Cossart, P., Velge, P., Wiedemann, A. Salmonella enteritidis Rck-mediated invasion requires activation of Rac1, which is dependent on the class I PI 3-kinases-Akt signaling pathway. FASEB J. 26, 1569-1581 (2012). www.fasebj.org	[Mijouin, Lily; Rosselin, Manon; Bottreau, Elisabeth; Velge, Philippe; Wiedemann, Agnes] INRA, Infectiol Anim & Sante Publ UR1282, Nouzilly, France; [Mijouin, Lily; Rosselin, Manon; Bottreau, Elisabeth; Velge, Philippe; Wiedemann, Agnes] Univ Tours, Agents Transmissibles & Infectiol IFR136, Tours, France; [Pizarro-Cerda, Javier; Cossart, Pascale] Inst Pasteur, Unite Interact Bacteries Cellules, Paris, France	INRAE; Universite de Tours; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Wiedemann, A (corresponding author), INRA Tours Nouzilly, UR Infectiol Anim & Sante Publ 1282, F-37380 Nouzilly, France.	awiedemann@tours.inra.fr	velge, philippe/AAK-4165-2021	Wiedemann, Agnes/0000-0001-8237-3545	Region Centre [2008-00036085]; Delegation Regionale a la Recherche et a la Technologie du Centre [1634-32245]; Institut National de la Recherche Agronomique	Region Centre(Region Centre-Val de Loire); Delegation Regionale a la Recherche et a la Technologie du Centre; Institut National de la Recherche Agronomique	This work was supported by the Region Centre and performed within the SAVIRE project, funded by the Delegation Regionale a la Recherche et a la Technologie du Centre (FEDER; 1634-32245) and by the Region Centre (2008-00036085). M. R. holds a doctoral fellowship funded by the Region Centre and the Institut National de la Recherche Agronomique. The authors thank Dr. Keith Ireton (Institut Pasteur) for donating plasmids.	Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bonazzi M, 2008, CELL MICROBIOL, V10, P2208, DOI 10.1111/j.1462-5822.2008.01200.x; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burnham CAD, 2007, MICROBIOL-SGM, V153, P4240, DOI 10.1099/mic.0.2007/008417-0; Burnham CAD, 2007, FEMS MICROBIOL LETT, V272, P8, DOI 10.1111/j.1574-6968.2007.00768.x; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Clark CS, 2007, INFECT IMMUN, V75, P2531, DOI 10.1128/IAI.01866-06; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Cougoule C, 2006, J BIOL CHEM, V281, P8756, DOI 10.1074/jbc.M513731200; Eitel J, 2005, CELL MICROBIOL, V7, P63, DOI 10.1111/j.1462-5822.2004.00434.x; Eitel J, 2002, INFECT IMMUN, V70, P4880, DOI 10.1128/IAI.70.9.4880-4891.2002; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HEFFERNAN EJ, 1994, INFECT IMMUN, V62, P5183, DOI 10.1128/IAI.62.11.5183-5186.1994; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hilbi H, 2006, CELL MICROBIOL, V8, P1697, DOI 10.1111/j.1462-5822.2006.00793.x; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Huang FC, 2005, FEMS MICROBIOL LETT, V243, P265, DOI 10.1016/j.femsle.2004.12.013; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kierbel A, 2005, MOL BIOL CELL, V16, P2577, DOI 10.1091/mbc.E04-08-0717; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; Knodler LA, 2005, J BIOL CHEM, V280, P9058, DOI 10.1074/jbc.M412588200; Liao Y, 2010, AM J TRANSL RES, V2, P19; Mallo GV, 2008, J CELL BIOL, V182, P741, DOI 10.1083/jcb.200804131; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Pizarro-Cerda J, 2007, CELL MICROBIOL, V9, P2381, DOI 10.1111/j.1462-5822.2007.00967.x; ROSENSHINE I, 1994, INFECT IMMUN, V62, P4969, DOI 10.1128/IAI.62.11.4969-4974.1994; Rosselin M, 2010, CELL RES, V20, P647, DOI 10.1038/cr.2010.45; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlumberger MC, 2006, CURR OPIN MICROBIOL, V9, P46, DOI 10.1016/j.mib.2005.12.006; Seveau S, 2007, CELL MICROBIOL, V9, P790, DOI 10.1111/j.1462-5822.2006.00832.x; Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Uliczka F, 2009, CELL MICROBIOL, V11, P1782, DOI 10.1111/j.1462-5822.2009.01371.x; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Velge P, 2005, VET RES, V36, P267, DOI 10.1051/vetres:2005005; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200	49	19	22	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1569	1581		10.1096/fj.11-189647	http://dx.doi.org/10.1096/fj.11-189647			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22210834				2022-12-28	WOS:000302359700019
J	Schreiber, G; Barberis, M; Scolari, S; Klaus, C; Herrmann, A; Klipp, E				Schreiber, Gabriele; Barberis, Matteo; Scolari, Silvia; Klaus, Christine; Herrmann, Andreas; Klipp, Edda			Unraveling interactions of cell cycle-regulating proteins Sic1 and B-type cyclins in living yeast cells: a FLIM-FRET approach	FASEB JOURNAL			English	Article						Saccharomyces cerevisiae; Forster resonance energy transfer; fluorescence lifetime imaging microscopy; Cdk1-Clb complexes; Cdk inhibitor	INFLUENZA-VIRUS HEMAGGLUTININ; KINASE INHIBITOR SIC1; S-PHASE; CDK INHIBITOR; DNA-REPLICATION; IN-VITRO; PHOSPHORYLATION; PROTEOLYSIS; DEGRADATION; TRANSITION	Sic1, cyclin-dependent kinase inhibitor of budding yeast, is synthesized in anaphase and largely degraded at the S-phase onset to regulate timing of DNA synthesis. Sic1 interacts with phase-specific B-type cyclin (Clb)-kinase (Cdk1) complexes, central regulators in cell cycle control. Its appearance is timed to mediate reduction in kinase activities at appropriate stages. Clbs are unstable proteins with extremely short half-lives. Interactions of Sic1 with Clbs have been detected both in vitro and in vivo by high-throughput genome-wide screenings. Furthermore, we have recently shown that Sic1 regulates waves of Clbs, acting as a timer in their appearance, thus controlling Cdk1-Clbs activation. The molecular mechanism is not yet fully understood but is hypothesized to occur via stoichiometric binding of Sic1 to Cdk1-Clb complexes. Using Forster resonance energy transfer (FRET) via fluorescence lifetime imaging microscopy (FLIM), we showed association of Sic1 to Clb cyclins in living yeast cells. This finding is consistent with the notion that inhibition of kinase activity can occur over the whole cell cycle progression despite variable Sic1 levels. Specifically, Sic1/Clb3 interaction was observed for the first time, and Sic1/Clb2 and Sic1/Clb5 pairs were confirmed, but no Sic1/Clb4 interaction was found, which suggests that, despite high functional homology between Clbs, only some of them can target Sic1 function in vivo.-Schreiber, G., Barberis, M., Scolari, S., Klaus, C., Herrmann, A., Klipp, E. Unraveling interactions of cell cycle-regulating proteins Sic1 and B-type cyclins in living yeast cells: a FLIM-FRET approach. FASEB J. 26, 546-554 (2012). www.fasebj.org	[Schreiber, Gabriele; Barberis, Matteo; Scolari, Silvia; Klaus, Christine; Herrmann, Andreas; Klipp, Edda] Humboldt Univ, Dept Biol, D-10115 Berlin, Germany	Humboldt University of Berlin	Barberis, M (corresponding author), Humboldt Univ, Dept Biol, Invalidenstr 42, D-10115 Berlin, Germany.	matteo.barberis@biologie.hu-berlin.de; edda.klipp@rz.hu-berlin.de		Barberis, Matteo/0000-0001-5640-7422	European Commission, Experimental Network for Functional Integration (ENFIN) [LSHG-CT-2005-518254]; UNICELLSYS [HEALTH-2007-201142]; Deutsche Forschungsgemeinschaft [GRK-1121, Sonderforschungsbereich 740]	European Commission, Experimental Network for Functional Integration (ENFIN); UNICELLSYS; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Rodrigo F. de Almeida for fruitful discussions on the data. This work was supported by grants from the European Commission, Experimental Network for Functional Integration (ENFIN; contract LSHG-CT-2005-518254) and UNICELLSYS (contract HEALTH-2007-201142), to E. K., from Deutsche Forschungsgemeinschaft (GRK-1121) to A. H., and from Sonderforschungsbereich 740 to A.H. and E.K.	AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Archambault V, 2004, MOL CELL, V14, P699, DOI 10.1016/j.molcel.2004.05.025; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bailly E, 1999, MOL CELL BIOL, V19, P6872; Barberis M, 2005, BIOCHEM BIOPH RES CO, V336, P1040, DOI 10.1016/j.bbrc.2005.08.224; Barberis M, 2005, BIOCHEM J, V387, P639, DOI 10.1042/BJ20041299; Barberis M., 2012, ADV SYSTEMS BIOL ADV, V736; Barberis M, 2012, BIOTECHNOL ADV, V30, P108, DOI 10.1016/j.biotechadv.2011.09.004; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495; Collins SR, 2007, MOL CELL PROTEOMICS, V6, P439, DOI 10.1074/mcp.M600381-MCP200; Cross FR, 2000, MOL CELL BIOL, V20, P4782, DOI 10.1128/MCB.20.13.4782-4790.2000; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Engel S, 2010, BIOCHEM J, V425, P567, DOI 10.1042/BJ20091388; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Futcher B, 1996, YEAST, V12, P1635; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; Hofman EG, 2008, J CELL SCI, V121, P2519, DOI 10.1242/jcs.028753; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Kishi T, 2008, P NATL ACAD SCI USA, V105, P14497, DOI 10.1073/pnas.0806253105; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Komakhin R A, 2008, Mol Biol (Mosk), V42, P494; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Lackowicz JR, 2006, PRINCIPLES FLUORESCE; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Lleres David, 2007, Curr Protoc Cytom, VChapter 12, DOI 10.1002/0471142956.cy1210s42; Lleres D, 2009, J CELL BIOL, V187, P481, DOI 10.1083/jcb.200907029; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Miller A, 2010, J BIOL CHEM, V285, P35142, DOI 10.1074/jbc.M110.166918; Morgan D. O., 2007, PRIMERS BIOL SERIES; Morgan DO, 2002, NATURE, V418, P495, DOI 10.1038/418495a; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nair DK, 2006, OPT EXPRESS, V14, P12217, DOI 10.1364/OE.14.012217; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Parsons M, 2005, MOL CELL BIOL, V25, P1680, DOI 10.1128/MCB.25.5.1680-1695.2005; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rossi RL, 2005, CELL CYCLE, V4, P1798, DOI 10.4161/cc.4.12.2189; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Scolari S, 2009, J BIOL CHEM, V284, P15708, DOI 10.1074/jbc.M900437200; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Stuart D, 1998, GENE DEV, V12, P2698, DOI 10.1101/gad.12.17.2698; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Toone WM, 1997, ANNU REV MICROBIOL, V51, P125, DOI 10.1146/annurev.micro.51.1.125; Toyn JH, 1997, GENETICS, V145, P85; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vogel Steven S, 2006, Sci STKE, V2006, pre2; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	62	12	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					546	554		10.1096/fj.11-192518	http://dx.doi.org/10.1096/fj.11-192518			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22002907				2022-12-28	WOS:000300485700008
J	Wang, H; Shi, BZ; Zhang, QL; Jiang, H; Hu, SW; Kong, J; Yao, M; Yang, SL; Li, ZH				Wang, Hai; Shi, Bizhi; Zhang, Qingli; Jiang, Hua; Hu, Suwen; Kong, Juan; Yao, Ming; Yang, Shengli; Li, Zonghai			Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation	FASEB JOURNAL			English	Article						target therapy; C225; LAMP-1	INTRACELLULAR TRAFFICKING; KINASE-ACTIVITY; CANCER-CELLS; EGFR; MONOCLONAL-ANTIBODY-806; IDENTIFICATION; PROLIFERATION; CARCINOMA; APOPTOSIS; CETUXIMAB	We recently isolated an exon-4-deleted epidermal growth factor receptor (EGFR) variant, termed de4 EGFR. Because the extracellular domain alteration of receptors often influences the antitumor effect of therapeutic antibodies, it is essential to test the sensitivity of de4 EGFR(+) tumors to anti-EGFR antibodies. Therefore, in this study, the antitumor activities of mAb CH12, an anti-EGFRvIII antibody developed in our laboratory, as well as a U. S. Food and Drug Administration-approved anti-EGFR antibody, cetuximab (C225), were characterized on de4 EGFR(+) models. The results of FACS assays showed that CH12 bound to de4 EGFR with a higher avidity than did C225. Interestingly, CH12, but not C225, significantly inhibited the metastasis and growth of U87MG-de4 EGFR xenografts, with a growth-inhibition ratio of 46.48% in vivo, and prolonged the survival of the tumor-bearing mice by 37.2%. Treatment with CH12 significantly suppressed tumor proliferation and angiogenesis with increased tumor apoptosis. Mechanistically, de4 EGFR protein expression was virtually undetectable in the U87MG-de4 EGFR xenografts treated with CH12. This may account for the observed reduction of Akt and Erk phosphorylation, cyclin D1, Bcl-2, and Bcl-x(L) expression and the increase of p27 and E-cadherin expression. Intriguingly, LAMP-1, a major component of the lysosome, was significantly up-regulated in the CH12-treated group but not in the C225-treated group, suggesting its contribution to the degradation of de4 EGFR. Taken together, our data demonstrated that mAb CH12 is a promising therapeutic agent for treating de4 EGFR(+) gliomas.-Wang, H., Shi, B., Zhang, Q., Jiang, H., Hu, S., Kong, J., Yao, M., Yang, S., Li, Z. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. FASEB J. 26, 73-80 (2012). www.fasebj.org	[Wang, Hai; Shi, Bizhi; Jiang, Hua; Hu, Suwen; Kong, Juan; Yao, Ming; Yang, Shengli; Li, Zonghai] Shanghai Jiao Tong Univ, Key Lab Oncogenes & Related Genes, Renji Hosp, Sch Med,Shanghai Canc Inst, Shanghai 200032, Peoples R China; [Zhang, Qingli] Univ S China, Sch Med, Canc Res Inst, Hengyang City, Peoples R China	Shanghai Jiao Tong University; University of South China	Li, ZH (corresponding author), Shanghai Jiao Tong Univ, Key Lab Oncogenes & Related Genes, Renji Hosp, Sch Med,Shanghai Canc Inst, Shanghai 200032, Peoples R China.	zonghaili@shsmu.edu.cn			National Basic Research Program [2010CB529902]; National Natural Science Foundation of China [81071746]; Shanghai Science and Technology Committee [10431903700]; State Key Laboratory of Oncogenes and Related Genes [91-10-06]	National Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); State Key Laboratory of Oncogenes and Related Genes	This study was supported by the National Basic Research Program (grant 2010CB529902), the National Natural Science Foundation of China (81071746), the Key Program Project of the Shanghai Science and Technology Committee (10431903700), and the research fund of the State Key Laboratory of Oncogenes and Related Genes (91-10-06).	Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Huang SM, 1999, CANCER RES, V59, P1935; Huang ZQ, 2003, J SURG RES, V111, P274, DOI 10.1016/S0022-4804(03)00076-3; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jiang H, 2011, J BIOL CHEM, V286, P5913, DOI 10.1074/jbc.M110.192252; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; Johns TG, 2004, J BIOL CHEM, V279, P30375, DOI 10.1074/jbc.M401218200; Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luwor RB, 2001, CANCER RES, V61, P5355; Margineanu Eliana, 2008, Rev Med Chir Soc Med Nat Iasi, V112, P432; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Perera RM, 2007, NEOPLASIA, V9, P1099, DOI 10.1593/neo.07721; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Scott AM, 2007, P NATL ACAD SCI USA, V104, P4071, DOI 10.1073/pnas.0611693104; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Wang H, 2011, NEOPLASIA, V13, P461, DOI 10.1593/neo.101744; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242	25	10	12	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					73	80		10.1096/fj.11-191064	http://dx.doi.org/10.1096/fj.11-191064			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21917986				2022-12-28	WOS:000299202200009
J	De Rienzo, G; Bishop, JA; Mao, YW; Pan, LY; Ma, TP; Moens, CB; Tsai, LH; Sive, H				De Rienzo, Gianluca; Bishop, Joshua A.; Mao, Yingwei; Pan, Luyuan; Ma, Taylur P.; Moens, Cecilia B.; Tsai, Li-Huei; Sive, Hazel			Disc1 regulates both beta-catenin-mediated and noncanonical Wnt signaling during vertebrate embryogenesis	FASEB JOURNAL			English	Article						Disc1; zebrafish; brain; neurons; GSK3 beta; pcp; mutant	SCHIZOPHRENIA 1; CELL POLARITY; ZEBRAFISH; EXPRESSION; MECHANISM; BRAIN; DISRUPTED-IN-SCHIZOPHRENIA-1; XENOPUS; ABNORMALITIES; GASTRULATION	Disc1 is a schizophrenia risk gene that engages multiple signaling pathways during neurogenesis and brain development. Using the zebrafish as a tool, we analyze the function of zebrafish Disc1 (zDisc1) at the earliest stages of brain and body development. We define a "tool" as a biological system that gives insight into mechanisms underlying a human disorder, although the system does not phenocopy the disorder. A zDisc1 peptide binds to GSK3 beta, and zDisc1 directs early brain development and neurogenesis, by promoting beta-catenin-mediated Wnt signaling and inhibiting GSK3 beta activity. zDisc1 loss-of-function embryos additionally display a convergence and extension phenotype, demonstrated by abnormal movement of dorsolateral cells during gastrulation, through changes in gene expression, and later through formation of abnormal, U-shaped muscle segments, and a truncated tail. These phenotypes are caused by alterations in the noncanonical Wnt pathway, via Daam and Rho signaling. The convergence and extension phenotype can be rescued by a dominant negative GSK3 beta construct, suggesting that zDisc1 inhibits GSK3 beta activity during noncanonical Wnt signaling. This is the first demonstration that Disc1 modulates the noncanonical Wnt pathway and suggests a previously unconsidered mechanism by which Disc1 may contribute to the etiology of neuropsychiatric disorders.-De Rienzo, G., Bishop, J. A., Mao, Y., Pan, L., Ma, T. P., Moens, C. B., Tsai, L. H., Sive, H. Disc1 regulates both beta-catenin-mediated and noncanonical Wnt signaling during vertebrate embryogenesis. FASEB J. 25, 4184 -4197 (2011). www.fasebj.org	[De Rienzo, Gianluca; Sive, Hazel] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Bishop, Joshua A.; Tsai, Li-Huei] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA; [Bishop, Joshua A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Mao, Yingwei] Penn State Univ, Dept Biol, State Coll, PA USA; [Pan, Luyuan; Ma, Taylur P.; Moens, Cecilia B.] Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Div Basic Sci, Seattle, WA 98104 USA; [Tsai, Li-Huei] Howard Hughes Med Inst, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, Cambridge, MA USA; [Sive, Hazel] MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Northwell Health; Massachusetts Institute of Technology (MIT)	Sive, H (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sive@wi.mit.edu	Moens, Cecilia/AAN-1536-2020	Sive, Hazel/0000-0002-4890-424X; Moens, Cecilia/0000-0002-1099-0728	Stanley Medical Research Institute; U.S. National Institutes of Health (NIH) [R01 HG002995]; NIH [RO1 MH091115]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD076585] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH091115] Funding Source: NIH RePORTER	Stanley Medical Research Institute; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank the members of the H.S. laboratory for discussion, and Olivier Paugois for expert fish husbandry. The authors are grateful to Ed Scolnick, Stephen Haggarty, Pamela Sklar, and other members of the Stanley Center for input. The authors thank the following colleagues for generous gifts of reagents, as noted in Materials and Methods: Anand Chandrasekhar (University of Missouri, Columbia, MO, USA), Jeremy Green (Dana-Farber Cancer Institute, Boston, MA, USA), Raymond Habas (Temple University, Philadelphia, PA, USA), Stephen Haggarty (Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA), Xi He (Harvard Medical School, Cambridge, MA, USA), David Kimelman (University of Washington, Seattle, WA, USA), Jim Smith (Gurdon Institute, Cambridge, UK), Randall Moon (University of Washington School of Medicine, Seattle, WA, USA), Steven Wilson (University College London, London, UK), Rudi Winklbauer (University of Toronto, Toronto, ON, Canada), and Karen Symes (Boston University, Boston, MA, USA). This work was supported by the Stanley Medical Research Institute, via a grant to the Stanley Center for Psychiatric Research at the Broad Institute. The Disc1<SUP>fh291</SUP> and Disc1<SUP>fh292</SUP> mutants were identified with the support of U.S. National Institutes of Health (NIH) grant R01 HG002995 to C.B.M. This work was partially supported by NIH grant RO1 MH091115 to L.-H.T.	Bingham SM, 2010, DEV NEUROBIOL, V70, P87, DOI 10.1002/dneu.20761; Brandon NJ, 2009, J NEUROSCI, V29, P12768, DOI 10.1523/JNEUROSCI.3355-09.2009; Brandon NJ, 2004, MOL CELL NEUROSCI, V25, P42, DOI 10.1016/j.mcn.2003.09.009; Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024; Domingos PM, 2001, DEV BIOL, V239, P148, DOI 10.1006/dbio.2001.0431; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Draper BW, 2004, METHOD CELL BIOL, V77, P91; Drerup CM, 2009, DEVELOPMENT, V136, P2623, DOI 10.1242/dev.030577; Duan X, 2007, CELL, V130, P1146, DOI 10.1016/j.cell.2007.07.010; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Ftouh S, 2005, J NEUROCHEM, V94, P520, DOI 10.1111/j.1471-4159.2005.03239.x; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Gutzman Jennifer H, 2009, J Vis Exp, DOI 10.3791/1218; Gutzman JH, 2010, DEVELOPMENT, V137, P795, DOI 10.1242/dev.042705; Harvey SA, 2010, DEVELOPMENT, V137, P1127, DOI 10.1242/dev.046318; Hayashi-Takagi A, 2010, NAT NEUROSCI, V13, P327, DOI 10.1038/nn.2487; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOLM PJ, 1995, DEV BIOL, V171, P267, DOI 10.1006/dbio.1995.1279; Korth C, 2009, REV NEUROSCIENCE, V20, P321; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; Li SD, 2011, P NATL ACAD SCI USA, V108, P2264, DOI 10.1073/pnas.1013170108; Liu W., 2007, P NATL ACAD SCI USA, V105, P210; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Marley A., 2010, PLOS ONE, V28, P5; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Millar JK, 2007, J PHYSIOL-LONDON, V584, P401, DOI 10.1113/jphysiol.2007.140210; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Pletnikov MV, 2008, MOL PSYCHIATR, V13, P173, DOI [10.1038/sj.mp.4002079, 10.1038/sj.mp.4002144]; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Porteous DJ, 2006, TRENDS MOL MED, V12, P255, DOI 10.1016/j.molmed.2006.04.009; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Rohde LA, 2007, INT REV CYTOL, V261, P159, DOI 10.1016/S0074-7696(07)61004-3; Roszko I, 2009, SEMIN CELL DEV BIOL, V20, P986, DOI 10.1016/j.semcdb.2009.09.004; Shinoda T, 2007, J NEUROSCI, V27, P4, DOI 10.1523/JNEUROSCI.3825-06.2007; Shkumatava A, 2009, GENE DEV, V23, P466, DOI 10.1101/gad.1745709; Singh KK, 2010, NEURON, V67, P33, DOI 10.1016/j.neuron.2010.06.002; Sive H, 2011, DIS MODEL MECH, V4, P137, DOI 10.1242/dmm.007666; Thermes V, 2002, MECH DEVELOP, V118, P91, DOI 10.1016/S0925-4773(02)00218-6; van de Water S, 2001, DEVELOPMENT, V128, P3877; Vivancos V, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-7; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wiellette EL, 2003, DEVELOPMENT, V130, P3821, DOI 10.1242/dev.00572; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wood JD, 2009, HUM MOL GENET, V18, P391, DOI 10.1093/hmg/ddn361; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	51	31	31	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4184	4197		10.1096/fj.11-186239	http://dx.doi.org/10.1096/fj.11-186239			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21859895	Green Published			2022-12-28	WOS:000298138100012
J	Guan, YJ; Yang, X; Wei, L; Chen, Q				Guan, Ying-Jie; Yang, Xu; Wei, Lei; Chen, Qian			MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4	FASEB JOURNAL			English	Article						mechanotransduction; HDAC4; Indian hedgehog	CARTILAGE MATRIX PROTEIN; INDIAN-HEDGEHOG; CELL-ADHESION; GROWTH-PLATE; EXPRESSION; PROLIFERATION; MECHANOTRANSDUCTION; HYPERTROPHY; MATURATION; BONE	Mechanical stress plays an essential role in tissue development and remodeling. In this study, we determined the role of microRNA in chondrocyte mechanotransduction. Using microarray, we identified miR-365 as a mechanoresponsive microRNA in parallel to mechanical induction of Indian hedgehog (Ihh) in primary chicken chondrocytes cultured in 3-dimensional collagen scaffoldings under cyclic loading (1 Hz, 5% elongation). Interestingly, expression of miR-365 is elevated in the prehypertrophic zone of the growth plate, coinciding with the Ihh expression region in vivo. MiR-365 significantly stimulates chondrocyte proliferation and differentiation. MiR-365 increases expression of Ihh and the hypertrophic marker type X collagen, whereas anti-miR-365 inhibits the expression of these genes. We identified histone deacetylase 4 (HDAC4), an inhibitor of chondrocyte hypertrophy, as a target of miR-365. MiR-365 inhibits both endogenous HDAC4 protein levels as well as the activity of a reporter gene bearing the 3'-untranslated region of HDAC4 mRNA. Conversely, inhibition of endogenous miR-365 relieves the repression of HDAC4. Mutation of the miR-365 binding site in HDAC4 mRNA abolishes miR-365-mediated repression of the reporter gene activity. Overexpression of HDAC4 reverses miR-365 stimulation of chondrocyte differentiation markers including Ihh, Col X, and Runx2. Moreover, inhibition of miR-365 abolishes mechanical stimulation of chondrocyte differentiation. Taken together, miR-365 is the first identified mechanically responsive microRNA that regulates chondrocyte differentiation via directly targeting HDAC4.-Guan, Y.-J., Yang, X., Wei, L., Chen, Q. MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4. FASEB J. 25, 4457-4466 (2011). www.fasebj.org	[Guan, Ying-Jie; Yang, Xu; Wei, Lei; Chen, Qian] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Cell & Mol Biol Lab,Dept Orthopaed, Providence, RI 02903 USA; [Yang, Xu] Qingdao Univ, Affiliated Hosp, Coll Med, Dept Orthopaed, Qingdao 266071, Peoples R China	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Qingdao University	Chen, Q (corresponding author), Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Cell & Mol Biol Lab,Dept Orthopaed, 1 Hoppin St,Ste 402, Providence, RI 02903 USA.	qian_chen@brown.edu	Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	U.S. National Institutes of Health [AG 017021, AG 014399, AR 059142, RR024484]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014399, R29AG014399, R01AG017021] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Gary Stein (University of Massachusetts Medical School, Worcester, MA, USA) and Dr. Da-Zhi Wang (Children's Hospital Boston and Harvard Medical School, Boston, MA, USA) for providing plasmid constructs, and Paul Shultz for critical reading of the manuscript. This study is supported by U.S. National Institutes of Health grants AG 017021, AG 014399, AR 059142 and RR024484.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chan Shih-Peng, 2006, RNA Biol, V3, P97; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; COHEN B, 1992, J ORTHOPAED RES, V10, P263, DOI 10.1002/jor.1100100214; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Dunn W, 2009, ARTHRITIS RHEUM-US, V60, P2333, DOI 10.1002/art.24678; Guo L, 2009, PHOTOCHEM PHOTOBIOL, V85, P765, DOI 10.1111/j.1751-1097.2008.00482.x; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023; Kanbe K, 2007, J BONE MINER RES, V22, P318, DOI 10.1359/JBMR.061104; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397; Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200; LIU M, 1992, AM J PHYSIOL, V263, pL376; Maes OC, 2009, J CELL PHYSIOL, V221, P109, DOI 10.1002/jcp.21834; Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; Miyaki S., GENES DEV, V24, P1173; Mohamed J. S., J BIOL CHEM, V285, P29336; Qin B, 2011, BIOCHEM BIOPH RES CO, V410, P127, DOI 10.1016/j.bbrc.2011.05.118; Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028; Tang GH, 2004, J DENT RES, V83, P434, DOI 10.1177/154405910408300516; Teague EMCO, 2009, MOL ENDOCRINOL, V23, P265, DOI 10.1210/me.2008-0387; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wang KC, P NATL ACAD SCI US, V107, P3234; Wang X. Y., MOL CELL BIOCH, V345, P283; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Wu QQ, 2001, J BIOL CHEM, V276, P35290, DOI 10.1074/jbc.M101055200; Xu Z, 2011, J BIOL CHEM, V286, P21401, DOI 10.1074/jbc.M110.198630; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	37	116	122	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4457	4466		10.1096/fj.11-185132	http://dx.doi.org/10.1096/fj.11-185132			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21856783	Green Published			2022-12-28	WOS:000298138100036
J	Willis, DN; Liu, BY; Ha, MA; Jordt, SE; Morris, JB				Willis, Daniel N.; Liu, Boyi; Ha, Michael A.; Jordt, Sven-Eric; Morris, John B.			Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants	FASEB JOURNAL			English	Article						chemosensation; sensory nerves; TRP channels	SENSORY IRRITATION; TOBACCO-SMOKE; METABOLIC-ACTIVATION; VANILLOID RECEPTOR; RISK-ASSESSMENT; COLD RECEPTOR; TRP CHANNELS; TRACT UPTAKE; VAPORS; ACID	Menthol, the cooling agent in peppermint, is added to almost all commercially available cigarettes. Menthol stimulates olfactory sensations, and interacts with transient receptor potential melastatin 8 (TRPM8) ion channels in cold-sensitive sensory neurons, and transient receptor potential ankyrin 1 (TRPA1), an irritant-sensing channel. It is highly controversial whether menthol in cigarette smoke exerts pharmacological actions affecting smoking behavior. Using plethysmography, we investigated the effects of menthol on the respiratory sensory irritation response in mice elicited by smoke irritants (acrolein, acetic acid, and cyclohexanone). Menthol, at a concentration (16 ppm) lower than in smoke of mentholated cigarettes, immediately abolished the irritation response to acrolein, an agonist of TRPA1, as did eucalyptol (460 ppm), another TRPM8 agonist. Menthol's effects were reversed by a TRPM8 antagonist, AMTB. Menthol's effects were not specific to acrolein, as menthol also attenuated irritation responses to acetic acid, and cyclohexanone, an agonist of the capsaicin receptor, TRPV1. Menthol was efficiently absorbed in the respiratory tract, reaching local concentrations sufficient for activation of sensory TRP channels. These experiments demonstrate that menthol and eucalyptol, through activation of TRPM8, act as potent counterirritants against a broad spectrum of smoke constituents. Through suppression of respiratory irritation, menthol may facilitate smoke inhalation and promote nicotine addiction and smoking-related morbidities.-Willis, D. N., Liu, B., Ha, M. A., Jordt, S.-E., Morris, J. B. Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants. FASEB J. 25, 4434-4444 (2011). www.fasebj.org	[Liu, Boyi; Jordt, Sven-Eric] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Willis, Daniel N.; Ha, Michael A.; Morris, John B.] Univ Connecticut, Sch Pharm, Dept Pharmaceut Sci, Toxicol Program, Storrs, CT USA	Yale University; University of Connecticut	Jordt, SE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	sven.jordt@yale.edu	Liu, Boyi/J-5396-2014; Liu, Boyi/C-9181-2012; Jordt, Sven-Eric/ABE-6517-2020	Jordt, Sven-Eric/0000-0001-6171-5622	U.S. National Institutes of Health [R01HL105365, R01ES015056]; American Asthma Foundation [07-0212]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105635, U01HL105365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015056] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by U.S. National Institutes of Health grants R01HL105365 (to J.B.M. and S.E.J.) and R01ES015056 (to S.E.J.), and by the American Asthma Foundation (07-0212 to S.E.J.).	Agency for Toxic Substances and Disease Registry, 2007, TOX PROF ACR; Alarie Y, 1973, CRC Crit Rev Toxicol, V2, P299, DOI 10.3109/10408447309082020; Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; Bautista DM, 2007, NATURE, V448, P204, DOI 10.1038/nature05910; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Behrendt HJ, 2004, BRIT J PHARMACOL, V141, P737, DOI 10.1038/sj.bjp.0705652; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bessac BF, 2009, FASEB J, V23, P1102, DOI 10.1096/fj.08-117812; Bessac BF, 2008, PHYSIOLOGY, V23, P360, DOI 10.1152/physiol.00026.2008; Bi XH, 2005, CHEMOSPHERE, V61, P1512, DOI 10.1016/j.chemosphere.2005.04.057; Blot WJ, 2011, JNCI-J NATL CANCER I, V103, P810, DOI 10.1093/jnci/djr102; Brown RP, 1997, TOXICOL IND HEALTH, V13, P407, DOI 10.1177/074823379701300401; Deering-Rice CE, 2011, CHEM RES TOXICOL, V24, P950, DOI 10.1021/tx200123z; DeSesa CR, 2008, TOXICOL SCI, V104, P198, DOI 10.1093/toxsci/kfn061; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; Escalera J, 2008, J BIOL CHEM, V283, P24136, DOI 10.1074/jbc.M710280200; GERDE P, 1991, TOXICOL APPL PHARM, V109, P276, DOI 10.1016/0041-008X(91)90175-E; Harrington AM, 2011, PAIN, V152, P1459, DOI 10.1016/j.pain.2011.01.027; Hazari MS, 2011, ENVIRON HEALTH PERSP, V119, P951, DOI 10.1289/ehp.1003200; Honore P, 2002, PAIN, V96, P99, DOI 10.1016/S0304-3959(01)00434-1; Igaz P, 2008, CURR MED CHEM, V15, P2734, DOI 10.2174/092986708786242921; JOHANSON G, 1991, ANN OCCUP HYG, V35, P323, DOI 10.1093/annhyg/35.3.323; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Karashima Y, 2007, J NEUROSCI, V27, P9874, DOI 10.1523/JNEUROSCI.2221-07.2007; Klausner K., 2010, MENTHOL CIGARETTES I; Lanosa MJ, 2010, TOXICOL SCI, V115, P589, DOI 10.1093/toxsci/kfq057; Lashinger ESR, 2008, AM J PHYSIOL-RENAL, V295, pF803, DOI 10.1152/ajprenal.90269.2008; LAUDE EA, 1994, PULM PHARMACOL, V7, P179, DOI 10.1006/pulp.1994.1021; Lawrence D, 2011, TOBACCO INDUCED D S1, V9, pS3, DOI [10.1186/1617-9625-9-S1-S3, DOI 10.1186/1617-9625-9-S1-S3]; Levy DT, 2011, AM J PUBLIC HEALTH, V101, P1241, DOI 10.2105/AJPH.2011.300178; Lin YS, 2010, J APPL PHYSIOL, V108, P1293, DOI 10.1152/japplphysiol.01048.2009; Macpherson LJ, 2006, MOL CELL NEUROSCI, V32, P335, DOI 10.1016/j.mcn.2006.05.005; McCoy DD, 2011, AM J PHYSIOL-REG I, V300, pR1278, DOI 10.1152/ajpregu.00631.2010; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MEDINSKY MA, 1993, FUND APPL TOXICOL, V20, P265, DOI 10.1006/faat.1993.1035; Mendiondo MS, 2010, ADDICTION, V105, P124, DOI 10.1111/j.1360-0443.2010.03202.x; MORICE AH, 1994, THORAX, V49, P1024, DOI 10.1136/thx.49.10.1024; Morris JB, 1999, INHAL TOXICOL, V11, P943, DOI 10.1080/089583799196727; Morris JB, 2000, TOXICOL SCI, V54, P222, DOI 10.1093/toxsci/54.1.222; Morris JB, 2003, J APPL PHYSIOL, V94, P1563, DOI 10.1152/japplphysiol.00572.2002; Morris JB, 2010, TARG ORG T, P99; Morris JB, 2009, TOXICOL SCI, V111, P383, DOI 10.1093/toxsci/kfp138; Morris JB, 2009, TOXICOL SCI, V108, P173, DOI 10.1093/toxsci/kfn222; Muscat JE, 2009, CANCER EPIDEM BIOMAR, V18, P35, DOI 10.1158/1055-9965.EPI-08-0744; Nielsen GD, 2007, REGUL TOXICOL PHARM, V48, P6, DOI 10.1016/j.yrtph.2006.11.005; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perfetti R., 2009, CHEM COMPONENTS TOBA, P215; Proudfoot CJ, 2006, CURR BIOL, V16, P1591, DOI 10.1016/j.cub.2006.07.061; Rising Joshua, 2011, Tob Induc Dis, V9 Suppl 1, pS4, DOI 10.1186/1617-9625-9-S1-S4; ROSSI M, 1983, J MED CHEM, V26, P1246, DOI 10.1021/jm00363a008; Silver WL, 2006, CHEM SENSES, V31, P807, DOI 10.1093/chemse/bjl022; STEDMAN RL, 1968, CHEM REV, V68, P153, DOI 10.1021/cr60252a002; Stott WT, 1983, J APPL TOXICOL, V3, P310, DOI 10.1002/jat.2550030607; Su T, 2000, CANCER RES, V60, P5074; Symanowicz PT, 2004, NEUROSCI LETT, V362, P150, DOI 10.1016/j.neulet.2004.03.016; ThorntonManning JR, 1997, MUTAT RES-FUND MOL M, V380, P43, DOI 10.1016/S0027-5107(97)00126-7; Tobacco Industry Stakeholders, 2011, MENTH CIG DISPR IMP; Tobacco Products Scientific Advisory Committee to the Food and Drug Administration, 2011, MENTH CIG PUBL HLTH; Vaughan RP, 2006, TOXICOL SCI, V93, P411, DOI 10.1093/toxsci/kfl061; VIJAYARAGHAVAN R, 1993, ARCH TOXICOL, V67, P478, DOI 10.1007/BF01969919; Vogt-Eisele AK, 2007, BRIT J PHARMACOL, V151, P530, DOI 10.1038/sj.bjp.0707245; Williams JM, 2007, NICOTINE TOB RES, V9, P873, DOI 10.1080/14622200701484995; YAMAGUCHI T, 1994, DRUG METAB DISPOS, V22, P616	64	128	132	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4434	4444		10.1096/fj.11-188383	http://dx.doi.org/10.1096/fj.11-188383			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21903934	Green Published			2022-12-28	WOS:000298138100034
J	Jankowski, V; Tolle, M; Santos, RAS; Gunthner, T; Krause, E; Beyermann, M; Welker, P; Bader, M; Pinheiro, SVB; Sampaio, WO; Lautner, R; Kretschmer, A; van der Giet, M; Zidek, W; Jankowski, J				Jankowski, Vera; Toelle, Markus; Santos, Robson A. S.; Guenthner, Thomas; Krause, Eberhard; Beyermann, Michael; Welker, Pia; Bader, Michael; Brant Pinheiro, Sergio Veloso; Sampaio, Walkyria O.; Lautner, Roberto; Kretschmer, Axel; van der Giet, Markus; Zidek, Walter; Jankowski, Joachim			Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects	FASEB JOURNAL			English	Article						amino acid exchange; vascular tone	HUMAN ENDOTHELIAL-CELLS; RECEPTOR MAS; PROTEIN; EXPRESSION; MOUSE; GENE; RAT	The family of angiotensin peptides has been steadily growing in recent years. Most are fragments of angiotensin II (Ang II) with different affinities to the known angiotensin receptors. Here, we describe a novel endogenous Ang II-like octapeptide in plasma from healthy humans and patients with end-stage renal failure, which acts as a stronger agonist at Mas receptors than Ang 1-7. Chromatographic purification and structural analysis by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) revealed an Ang II-like octapeptide, angioprotectin, with the sequence Pro-Glu-Val-Tyr-Ile-His-Pro-Phe, which differs from Ang II in Pro(1) and Glu(2) instead of Asp(1) and Arg(2). Pro-Glu-Val-Tyr-Ile-His-Pro-Phe in angioprotectin is most likely generated enzymatically from Ang II. Angioprotectin antagonized the contractile actions of Ang II on rat aortic rings. The physiological antagonism of vasoconstrictor actions of Ang II by angioprotectin is mediated by the Mas receptor. Angioprotectin has a stronger affinity to the Mas receptor than Ang-1-7. Plasma concentrations were similar to 15% of plasma Ang II concentrations in healthy volunteers and up to 50% in patients with renal failure. A commercially available Ang II antibody did not discriminate between angioprotectin and Ang II; thus, angioprotectin can contribute to Ang II concentrations measured by antibody-based assays. This novel peptide is likely to be a relevant component of the human renin-angiotensin-system.-Jankowski, V., Tolle, M., Santos, R. A. S., Gunthner, T., Krause, E., Beyermann, M., Welker, P., Bader, M., Pinheiro, S. V. B., Sampaio, W. O., Lautner, R., Kretschmer, A., van der Giet, M., Zidek, W., Jankowski, J. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J. 25, 2987-2995 (2011). www.fasebj.org	[Jankowski, Vera; Toelle, Markus; Guenthner, Thomas; van der Giet, Markus; Zidek, Walter; Jankowski, Joachim] Charite, Med Klin 4, D-12200 Berlin, Germany; [Welker, Pia] Charite, Inst Vegetat Anat, D-12200 Berlin, Germany; [Santos, Robson A. S.; Brant Pinheiro, Sergio Veloso; Sampaio, Walkyria O.; Lautner, Roberto] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil; [Krause, Eberhard; Beyermann, Michael] Forschungsinst Mol Pharmakol, Berlin, Germany; [Bader, Michael] Max Delbrueck Ctr Mol Med, Berlin, Germany; [Kretschmer, Axel] Bayer Schering Pharma, Wuppertal, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universidade Federal de Minas Gerais; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Bayer AG; Bayer Healthcare Pharmaceuticals	Jankowski, J (corresponding author), Charite, Med Klin 4, Hindenburgdamm 30, D-12200 Berlin, Germany.	joachim.jankowski@charite.de	Tölle, Markus/GPP-7157-2022; Bader, Michael/K-2124-2013; PINHEIRO, SERGIO V B/T-8307-2019; Santos, Robson A S/C-9336-2011; Lautner, Roberto/G-9503-2012	Santos, Robson A S/0000-0001-8738-5852; van der Giet, Markus/0000-0003-3590-5451; Bader, Michael/0000-0003-4780-4164	German Federal Ministry of Education and Research [NGFN/01GR0807]; Sonnenfeld Foundation; European Union [FP7-HEALTH-2009-2.4.5-2]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Sonnenfeld Foundation; European Union(European Commission)	The authors thank M. Witt (Bruker-Daltonics, Bremen, Germany) for accumulation of FT-mass spectra. The authors were supported by a grant from the German Federal Ministry of Education and Research (NGFN/01GR0807 to J.J.), a grant from the Sonnenfeld Foundation (to J.J.), and grant FP7-HEALTH-2009-2.4.5-2 from the European Union to the SysKid Consortium.	AMBROZ C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P107, DOI 10.1016/0167-4889(91)90248-V; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS30; Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Douglas SA, 2000, BRIT J PHARMACOL, V131, P1262, DOI 10.1038/sj.bjp.0703690; Gobom J, 2001, ANAL CHEM, V73, P434, DOI 10.1021/ac001241s; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; Jankowski V, 2005, HYPERTENSION, V46, P591, DOI 10.1161/01.HYP.0000177436.09733.d4; Jankowski V, 2007, ARTERIOSCL THROM VAS, V27, P297, DOI 10.1161/01.ATV.0000253889.09765.5f; Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D; Lyngso C, 2009, MOL CELL ENDOCRINOL, V302, P203, DOI 10.1016/j.mce.2008.09.018; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; Pinheiro SVB, 2004, HYPERTENSION, V44, P490, DOI 10.1161/01.HYP.0000141438.64887.42; Sampaio WO, 2007, HYPERTENSION, V50, P1093, DOI 10.1161/HYPERTENSIONAHA.106.084848; Santos RAS, 2000, REGUL PEPTIDES, V91, P45, DOI 10.1016/S0167-0115(00)00138-5; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Santos RAS, 2008, EXP PHYSIOL, V93, P519, DOI 10.1113/expphysiol.2008.042002; Tallant EA, 2005, AM J PHYSIOL-HEART C, V289, pH1560, DOI 10.1152/ajpheart.00941.2004; van Kats JP, 2001, KIDNEY INT, V60, P2311, DOI 10.1046/j.1523-1755.2001.00049.x; Walther T, 1998, J BIOL CHEM, V273, P11867, DOI 10.1074/jbc.273.19.11867; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	22	31	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2987	2995		10.1096/fj.11-185470	http://dx.doi.org/10.1096/fj.11-185470			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21628446				2022-12-28	WOS:000294435200014
J	Xu, CF; Liu, J; Hsu, LC; Luo, YP; Xiang, R; Chuang, TH				Xu, Congfeng; Liu, Jin; Hsu, Li-Chung; Luo, Yunping; Xiang, Rong; Chuang, Tsung-Hsien			Functional interaction of heat shock protein 90 and Beclin 1 modulates Toll-like receptor-mediated autophagy	FASEB JOURNAL			English	Article						ubiquitination; pattern recognition receptor; innate immunity	PATTERN-RECOGNITION RECEPTORS; ENTERICA SEROVAR TYPHIMURIUM; HSP90 CHAPERONE MACHINERY; INNATE IMMUNE-RESPONSE; SIGNALING PATHWAYS; UBIQUITINATION; CELLS; DEGRADATION; MACROPHAGES; DISRUPTION	Autophagy is one of the downstream effector mechanisms for elimination of intracellular microbes following activation of the Toll-like receptors (TLRs). Although the detailed molecular mechanism for this cellular process is still unclear, Beclin 1, a key molecule for autophagy, has been suggested to play a role. Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the stability of signaling proteins. Herein, we show that Hsp90 forms a complex with Beclin 1 through an evolutionarily conserved domain to maintain the stability of Beclin 1. In monocytic cells, geldanamycin (GA), an Hsp90 inhibitor, effectively promoted proteasomal degradation of Beclin 1 in a concentration-dependent (EC50 100 nM) and time-dependent (t(50) 2 h) manner. In contrast, KNK437/Hsp inhibitor I had no effect. Hsp90 specifically interacted with Beclin 1 but not with other adapter proteins in the TLR signalsome. Treatment of cells with GA inhibited TLR3- and TLR4-mediated autophagy. In addition, S. typhimurium infection-induced autophagy was blocked by GA treatment. This further suggested a role of the Hsp90/Beclin 1 in controlling autophagy in response to microbial infections. Taken together, our data revealed that by maintaining the homeostasis of Beclin 1, Hsp90 plays a novel role in TLR-mediated autophagy.-Xu, C., Liu, J., Hsu, L. -C., Luo, Y., Xiang, R., Chuang, T. -H. Functional interaction of Hsp90 and Beclin 1 modulates Toll-like receptor-mediated autophagy. FASEB J. 25, 2700-2710 (2011). www.fasebj.org	[Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Miaoli County, Taiwan; [Xu, Congfeng; Liu, Jin; Chuang, Tsung-Hsien] Sanford Burnham Med Res Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA USA; [Hsu, Li-Chung] Natl Taiwan Univ, Inst Mol Med, Taipei 10764, Taiwan; [Luo, Yunping] Peking Union Med Coll, Dept Immunol, Sch Basic Med, Beijing 100021, Peoples R China; [Xiang, Rong] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Xiang, Rong] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China	National Health Research Institutes - Taiwan; Sanford Burnham Prebys Medical Discovery Institute; National Taiwan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Scripps Research Institute; Nankai University	Chuang, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Miaoli County, Taiwan.	thchuang@nhri.org.tw	Xu, Congfeng/E-4806-2013; Chuang, Tsung-Hsien/F-9679-2010	Xu, Congfeng/0000-0002-8009-4865; Hsu, Li-Chung/0000-0001-7206-5231	National Science Council [NSC-98-2628-B-002-034-MY3]; National Natural Science Foundation of China [NSFC30671938, NSFC30830096, NBRP973-2007CB914804]; California Tobacco-Related Disease Research Program [16RT-0103]; U.S. National Institutes of Health [GM069652]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069652] Funding Source: NIH RePORTER	National Science Council(Ministry of Science and Technology, Taiwan); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); California Tobacco-Related Disease Research Program(University of California System); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Science Council grant NSC-98-2628-B-002-034-MY3 (L.C.H.), National Natural Science Foundation of China grants NSFC30671938 (Y.L.) and NSFC30830096, NBRP973-2007CB914804 (R.X.), California Tobacco-Related Disease Research Program grant 16RT-0103 (T.H.C.), and U.S. National Institutes of Health grant GM069652 (T.H.C.).	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Birmingham CL, 2006, AUTOPHAGY, V2, P156, DOI 10.4161/auto.2825; Birmingham CL, 2009, METHOD ENZYMOL, V452, P325, DOI 10.1016/S0076-6879(08)03620-3; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Chang ZY, 2009, SCI CHINA SER C, V52, P515, DOI 10.1007/s11427-009-0084-6; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40; Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31; Deretic V, 2009, CURR OPIN IMMUNOL, V21, P53, DOI 10.1016/j.coi.2009.02.002; Ding XD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005949; Fang SP, 2009, CELL IMMUNOL, V259, P49, DOI 10.1016/j.cellimm.2009.05.012; Fearns C, 2006, J BIOL CHEM, V281, P34592, DOI 10.1074/jbc.M604019200; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hsu HY, 2007, MOL PHARMACOL, V71, P344, DOI 10.1124/mol.106.024240; Huang J, 2009, CURR TOP MICROBIOL, V335, P189, DOI 10.1007/978-3-642-00302-8_9; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Jeong JH, 2008, J CELL BIOCHEM, V105, P585, DOI 10.1002/jcb.21859; Kamynina E, 2007, MOL CELL BIOL, V27, P1809, DOI 10.1128/MCB.01051-06; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Kimura S, 2009, METHOD ENZYMOL, V452, P1, DOI 10.1016/S0076-6879(08)03601-X; Komander D, 2009, BIOCHEM SOC T, V37, P937, DOI 10.1042/BST0370937; Korolchuk VI, 2010, FEBS LETT, V584, P1393, DOI 10.1016/j.febslet.2009.12.047; Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272; Lee J, 2009, BIOCHEM J, V421, P301, DOI 10.1042/BJ20090013; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Long J, 2008, J BIOL CHEM, V283, P5427, DOI 10.1074/jbc.M704973200; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Muenz C, 2009, ANNU REV IMMUNOL, V27, P423, DOI 10.1146/annurev.immunol.021908.132537; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Orvedahl A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com; Pratt WB, 2008, J BIOL CHEM, V283, P22885, DOI 10.1074/jbc.R800023200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200; Shi LJ, 2009, MOL IMMUNOL, V46, P541, DOI 10.1016/j.molimm.2008.07.019; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007; Stravopodis DJ, 2007, CURR MED CHEM, V14, P3122, DOI 10.2174/092986707782793925; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Wertz IE, 2010, CELL DEATH DIFFER, V17, P14, DOI 10.1038/cdd.2009.168; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Xiong HB, 2005, J BIOL CHEM, V280, P23531, DOI 10.1074/jbc.M414296200; Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853	56	69	69	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2700	2710		10.1096/fj.10-167676	http://dx.doi.org/10.1096/fj.10-167676			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21543763	Green Published			2022-12-28	WOS:000293337800019
J	Changeux, JP; Lou, HC				Changeux, Jean-Pierre; Lou, Hans C.			Emergent pharmacology of conscious experience: new perspectives in substance addiction	FASEB JOURNAL			English	Review						global neuronal workspace; self-awareness; self-regulation; GABA; interneurons; acetylcholine; dopamine	PONTINE RETICULAR-FORMATION; RAT HIPPOCAMPAL SLICE; NICOTINIC RECEPTORS; PREFRONTAL CORTEX; NEURAL SYNCHRONY; DECISION-MAKING; NETWORK OSCILLATIONS; MOLECULAR-BIOLOGY; GABA(A) RECEPTORS; WORKING-MEMORY	We here review experimental findings relevant for the pharmacology of conscious experience, an issue largely neglected in pharmacological research. First, we focus on self-awareness, a pivotal component of conscious experience and its integration within the global neuronal network (GNW), a theoretical concept that unifies convergent approaches on the neural bases of conscious processing. We report recent evidence to show that self-awareness mobilizes a paralimbic circuitry of gamma synchrony, and that such synchrony is, in particular, regulated by GABA interneurons under the control of acetylcholine and dopamine. Recent data illustrate that these neurotransmitters establish a causal relationship with the control of self-awareness. The hypothesis is presented that not only is self-awareness chemically regulated, but the reverse may be true. Long-term deficit in self-control of drug intake would result in compulsive substance use, accompanied, in particular, with lesions of the paralimbic circuitry of self-awareness, leading to aggravation of substance abuse, resulting in addiction in a vicious circle. Finally, we propose that the emergent pharmacology of conscious experience may provide new perspectives, not only in substance addiction but also in the many other pathological conditions with deficient self-awareness.-Changeux, J. -P., Lou, H. C. Emergent pharmacology of conscious experience: new perspectives in substance addiction. FASEB J. 25, 2098-2108 (2011). www.fasebj.org	[Changeux, Jean-Pierre] Inst Pasteur, 28 Rue Docteur Roux, F-75724 Paris 15, France; [Changeux, Jean-Pierre] Coll France, F-75231 Paris, France; [Lou, Hans C.] Aarhus Univ, Ctr Funktionelt Integrativ Neurovidenskab, DK-8000 Aarhus, Denmark	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; PSL Research University Paris; College de France; Aarhus University	Changeux, JP (corresponding author), Inst Pasteur, 28 Rue Docteur Roux, F-75724 Paris 15, France.	changeux@noos.fr; hansLou1@gmail.com			College de France; Institut Pasteur; Skaggs Research Foundation at University of California-San Diego School of Pharmacy; Lundbeck Foundation; National Research Council	College de France; Institut Pasteur(European Commission); Skaggs Research Foundation at University of California-San Diego School of Pharmacy; Lundbeck Foundation(Lundbeckfonden); National Research Council	A preliminary version of this article was presented by H.C.L. at the Nobel symposium "The Enlightened Brain" on the occasion of the 200th anniversary of the Karolinska Institutet, Stockholm. The authors are indebted to Professor Hugo Lagercrantz of the organizing committee for prompting their collaboration, and to many colleagues for discussions and presubmission reviews, including Associate Professors Vagn Andersen and Jorgen Scheel-Kruger, and Professors Leif Ostergaard, Olivier George, George Koob, Sylvie Granon, and Pierre-Jean Corringer. This work was supported by College de France, Institut Pasteur, the Skaggs Research Foundation at University of California-San Diego School of Pharmacy (J.P.C.), the Lundbeck Foundation, and the National Research Council (H.C.L.).	Ashtari M, 2008, J PSYCHIATR RES, V43, P189, DOI 10.1016/j.jpsychires.2008.12.002; Baars B.J., 1989, COGNITIVE THEORY CON; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Blakemore SJ, 1998, NEUROPSYCHOLOGIA, V36, P521, DOI 10.1016/S0028-3932(97)00145-0; Bocquet N, 2007, NATURE, V445, P116, DOI 10.1038/nature05371; Cabanac M, 2009, BEHAV BRAIN RES, V198, P267, DOI 10.1016/j.bbr.2008.11.028; CAMACHOARROYO I, 1991, NEUROSCI LETT, V129, P95, DOI 10.1016/0304-3940(91)90728-C; Changeux JP, 2006, PHILOS T R SOC B, V361, P2239, DOI 10.1098/rstb.2006.1832; Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849; Clauss RP, 2010, MED HYPOTHESES, V75, P287, DOI 10.1016/j.mehy.2010.03.005; Clayton T, 2007, CURR MED CHEM, V14, P2755, DOI 10.2174/092986707782360097; Comoli E, 2003, NAT NEUROSCI, V6, P974, DOI 10.1038/nn1113; Cumyn L, 2009, CAN J PSYCHIAT, V54, P673, DOI 10.1177/070674370905401004; Damasio AR, 1998, PHILOS T ROY SOC B, V353, P1879, DOI 10.1098/rstb.1998.0339; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Dehaene S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/pnas.1332574100; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Demiralp T, 2007, CEREB CORTEX, V17, P1007, DOI 10.1093/cercor/bhl011; Dommett E, 2005, SCIENCE, V307, P1476, DOI 10.1126/science.1107026; Ehrsson HH, 2007, P NATL ACAD SCI USA, V104, P9828, DOI 10.1073/pnas.0610011104; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Faulkner HJ, 1998, BRIT J PHARMACOL, V125, P483, DOI 10.1038/sj.bjp.0702113; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Fisch L, 2009, NEURON, V64, P562, DOI 10.1016/j.neuron.2009.11.001; Flint RR, 2010, J NEUROSCI, V30, P12301, DOI 10.1523/JNEUROSCI.1119-10.2010; Fox JE, 1998, NEUROSCI LETT, V257, P101, DOI 10.1016/S0304-3940(98)00812-X; Franks NP, 2011, CAN J ANESTH, V58, P139, DOI 10.1007/s12630-010-9420-3; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Fuchs EC, 2007, NEURON, V53, P591, DOI 10.1016/j.neuron.2007.01.031; Gaillard R, 2009, PLOS BIOL, V7, P472, DOI 10.1371/journal.pbio.1000061; Galarreta M, 2001, NAT REV NEUROSCI, V2, P425, DOI 10.1038/35077566; Gallagher S, 2000, TRENDS COGN SCI, V4, P14, DOI 10.1016/S1364-6613(99)01417-5; Gardiner JM, 2001, PHILOS T R SOC B, V356, P1351, DOI 10.1098/rstb.2001.0955; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; Glass JM, 2009, ADDICTION, V104, P38, DOI 10.1111/j.1360-0443.2008.02415.x; Gonzalez-Burgos G, 2008, SCHIZOPHRENIA BULL, V34, P944, DOI 10.1093/schbul/sbn070; Gotti C, 2009, BIOCHEM PHARMACOL, V78, P703, DOI 10.1016/j.bcp.2009.05.024; Granon S, 2003, P NATL ACAD SCI USA, V100, P9596, DOI 10.1073/pnas.1533498100; GRANON S, 1995, PSYCHOPHARMACOLOGY, V119, P139, DOI 10.1007/BF02246154; Gross DW, 1999, NEUROSCIENCE, V94, P1005, DOI 10.1016/S0306-4522(99)00343-7; Hartley AA, 2000, MICROSC RES TECHNIQ, V51, P45, DOI 10.1002/1097-0029(20001001)51:1<45::AID-JEMT5>3.3.CO;2-F; Heath CJ, 2010, NEUROPSYCHOPHARMACOL, V35, P2324, DOI 10.1038/npp.2010.130; Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004; Jacobsen LK, 2007, J NEUROSCI, V27, P13491, DOI 10.1523/JNEUROSCI.2402-07.2007; Jeon J, 2010, J NEUROSCI, V30, P2396, DOI 10.1523/JNEUROSCI.3843-09.2010; Kawai H, 2007, NAT NEUROSCI, V10, P1168, DOI 10.1038/nn1956; Kjaer TW, 2000, CONSCIOUS COGN, V9, pS59; Kjaer TW, 2002, NEUROIMAGE, V17, P1080, DOI 10.1006/nimg.2002.1230; Kjaer TW, 2002, COGNITIVE BRAIN RES, V13, P255, DOI 10.1016/S0926-6410(01)00106-9; Kjaer TW, 2001, CONSCIOUS COGN, V10, P356, DOI 10.1006/ccog.2001.0509; Kroner S, 2007, CEREB CORTEX, V17, P1020, DOI 10.1093/cercor/bhl012; Kwan VSY, 2007, EXP BRAIN RES, V182, P379, DOI 10.1007/s00221-007-0992-2; Lagercrantz H, 2009, PEDIATR RES, V65, P255, DOI 10.1203/PDR.0b013e3181973b0d; Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI 10.1038/sj.npp.1300032; Lena C, 2004, J NEUROSCI, V24, P5711, DOI 10.1523/JNEUROSCI.3882-03.2004; LENA C, 1993, J NEUROSCI, V13, P2680, DOI 10.1523/JNEUROSCI.13-06-02680.1993; Li GD, 2006, J NEUROSCI, V26, P11599, DOI 10.1523/JNEUROSCI.3467-06.2006; LIBET B, 1982, HUM NEUROBIOL, V2, P35; Liu HH, 2008, AM J DRUG ALCOHOL AB, V34, P562, DOI 10.1080/00952990802295238; Lou HC, 2011, J VISION, V11, DOI 10.1167/11.2.15; Lou HC, 2010, EXP BRAIN RES, V207, P27, DOI 10.1007/s00221-010-2425-x; Lou HC, 2010, HUM BRAIN MAPP, V31, P185, DOI 10.1002/hbm.20855; Lou HC, 1999, HUM BRAIN MAPP, V7, P98; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; Maguire EA, 1999, BRAIN, V122, P1839, DOI 10.1093/brain/122.10.1839; Mameli-Engvall M, 2006, NEURON, V50, P911, DOI 10.1016/j.neuron.2006.05.007; Marks GA, 2008, NEUROSCIENCE, V156, P1, DOI 10.1016/j.neuroscience.2008.06.067; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Melloni L, 2011, J NEUROSCI, V31, P1386, DOI 10.1523/JNEUROSCI.4570-10.2011; Northoff G, 2004, TRENDS COGN SCI, V8, P102, DOI 10.1016/j.tics.2004.01.004; Nury H, 2011, NATURE, V469, P428, DOI 10.1038/nature09647; Nyakale NE, 2010, ARZNEIMITTELFORSCH, V60, P177, DOI 10.1055/s-0031-1296269; Olsen RW, 2011, CAN J ANESTH, V58, P206, DOI 10.1007/s12630-010-9429-7; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rochat P, 1998, EXP BRAIN RES, V123, P102, DOI 10.1007/s002210050550; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; RODRIGUEZ R, 2004, J NEUROSCI 24, V103, P69; Salo R, 2009, BIOL PSYCHIAT, V65, P706, DOI 10.1016/j.biopsych.2008.11.026; Salo R, 2009, BIOL PSYCHIAT, V65, P122, DOI 10.1016/j.biopsych.2008.08.004; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Schmitt GJE, 2006, EUR ARCH PSY CLIN N, V256, P115, DOI 10.1007/s00406-005-0618-2; Simeone TA, 2003, J CHILD NEUROL, V18, P39, DOI 10.1177/08830738030180012101; Sohal VS, 2009, NATURE, V459, P698, DOI 10.1038/nature07991; Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927; Uhlhaas PJ, 2010, TRENDS COGN SCI, V14, P72, DOI 10.1016/j.tics.2009.12.002; Vanini G, 2008, ANESTHESIOLOGY, V109, P978, DOI 10.1097/ALN.0b013e31818e3b1b; Vazquez J, 2004, J NEUROPHYSIOL, V92, P2198, DOI 10.1152/jn.00099.2004; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V91, P213, DOI 10.1016/j.drugalcdep.2007.05.025; VIDAL C, 1993, NEUROSCIENCE, V56, P23, DOI 10.1016/0306-4522(93)90558-W; Vogeley K, 2004, J COGNITIVE NEUROSCI, V16, P817, DOI 10.1162/089892904970799; Vohs KD, 2008, J PERS SOC PSYCHOL, V94, P883, DOI 10.1037/0022-3514.94.5.883; VOLKOW ND, 1992, SYNAPSE, V12, P86; Wang JJ, 2009, NMR BIOMED, V22, P516, DOI 10.1002/nbm.1363; Werner G, 2007, J PHYSIOL-PARIS, V101, P273, DOI 10.1016/j.jphysparis.2007.12.001; Wiklund A, 2008, ANESTHESIOLOGY, V109, P790, DOI 10.1097/ALN.0b013e31818a379a; Williams LM, 2009, J PSYCHIATR NEUROSCI, V34, P21; Williams LM, 2006, J PSYCHIATR NEUROSCI, V31, P181; Wong JYF, 2003, EUR J PHARMACOL, V472, P39, DOI 10.1016/S0014-2999(03)01862-4; Yamasaki M, 2010, J NEUROSCI, V30, P4408, DOI 10.1523/JNEUROSCI.5719-09.2010; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yuen EY, 2009, J NEUROSCI, V29, P550, DOI 10.1523/JNEUROSCI.5050-08.2009	107	19	19	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2098	2108		10.1096/fj.11-0702ufm	http://dx.doi.org/10.1096/fj.11-0702ufm			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21719514				2022-12-28	WOS:000292242200002
J	Sartorius, T; Lutz, SZ; Hoene, M; Waak, J; Peter, A; Weigert, C; Rammensee, HG; Kahle, PJ; Haring, HU; Hennige, AM				Sartorius, Tina; Lutz, Stefan Z.; Hoene, Miriam; Waak, Jens; Peter, Andreas; Weigert, Cora; Rammensee, Hans-Georg; Kahle, Philipp J.; Haering, Hans-Ulrich; Hennige, Anita M.			Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and osteopontin and alter sleep architecture	FASEB JOURNAL			English	Article						locomotion; TLR2/4	INTRAMYOCELLULAR LIPID-CONTENT; ADIPOSE-TISSUE; FATTY-ACIDS; BETA-CELLS; IRS-2 EXPRESSION; MICE LACKING; RESISTANCE; OBESITY; MUTATION; HYPERINSULINEMIA	Impaired insulin action in the brain represents an early step in the progression toward type 2 diabetes, and elevated levels of saturated free fatty acids are known to impair insulin action in prediabetic subjects. One potential mediator that links fatty acids to inflammation and insulin resistance is the Toll-like receptor (TLR) family. Therefore, C3H/HeJ/TLR2-KO (TLR2/4-deficient) mice were fed a high-fat diet (HFD), and insulin action in the brain as well as cortical and locomotor activity was analyzed by using telemetric implants. TLR2/4-deficient mice were protected from HFD-induced glucose intolerance and insulin resistance in the brain and displayed an improvement in cortical and locomotor activity that was not observed in C3H/HeJ mice. Sleep recordings revealed a 42% increase in rapid eye movement sleep in the deficient mice during daytime, and these mice spent 41% more time awake during the night period. Treatment of control mice with a neutralizing IL-6 antibody improved insulin action in the brain as well as cortical activity and diminished osteopontin protein to levels of the TLR2/4-deficient mice. Together, our data suggest that the lack of functional TLR2/4 protects mice from a fat-mediated impairment in insulin action, brain activity, locomotion, and sleep architecture by an IL-6/osteopontin-dependent mechanism.-Sartorius, T., Lutz, S. Z., Hoene, M., Waak, J., Peter, A., Weigert, C., Rammensee, H.-G., Kahle, P. J., Haring, H.-U., Hennige, A. M. Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and osteopontin and alter sleep architecture. FASEB J. 26, 1799-1809 (2012). www.fasebj.org	[Sartorius, Tina; Lutz, Stefan Z.; Hoene, Miriam; Peter, Andreas; Weigert, Cora; Haering, Hans-Ulrich; Hennige, Anita M.] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, D-72076 Tubingen, Germany; [Waak, Jens; Kahle, Philipp J.] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat, Lab Funct Neurogenet, D-72076 Tubingen, Germany; [Waak, Jens; Kahle, Philipp J.] Univ Tubingen, German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany; [Rammensee, Hans-Georg] Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen	Haring, HU (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Vasc Dis Nephrol & Clin C, Otfried Mueller Str 10, D-72076 Tubingen, Germany.	hans-ulrich.haering@med.uni-tuebingen.de			Deutsche Forschungsgemeinschaft [HE 3653/3-1]; German Federal Ministry of Education and Research (BMBF) [DLR01GI0925]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This study was supported in part by a grant from the Deutsche Forschungsgemeinschaft (HE 3653/3-1) and the German Federal Ministry of Education and Research (BMBF; DLR01GI0925) to the German Center for Diabetes Research (DZDeV). The authors gratefully acknowledge the helpful contribution to a more precise analysis of sleep parameters of Dr. Sonja Binder and Dr. Manfred Hallschmid (Department of Neuroendocrinology, University of Luebeck, Luebeck, Germany). The authors thank Lucy Liaw (Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA) for providing the OPN-null mice, and Dr. Johannes M. Weiss (Department of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany) for assistance. The authors also thank A. Janessa, E. Metzinger, D. Neuscheler, and H. Runge for excellent technical assistance.	Arruda AP, 2011, ENDOCRINOLOGY, V152, P1314, DOI 10.1210/en.2010-0659; Awazawa M, 2011, CELL METAB, V13, P401, DOI 10.1016/j.cmet.2011.02.010; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Baracchi F, 2008, BRAIN BEHAV IMMUN, V22, P982, DOI 10.1016/j.bbi.2008.02.001; Benarroch EE, 2010, NEUROLOGY, V74, P919, DOI 10.1212/WNL.0b013e3181d3e44b; Bertola A, 2009, DIABETES, V58, P125, DOI 10.2337/db08-0400; Brechtel K, 2001, MAGNET RESON MED, V45, P179, DOI 10.1002/1522-2594(200102)45:2<179::AID-MRM1023>3.0.CO;2-D; Caricilli AM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001212; Chapman J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013959; Di Gregorio GB, 2004, AM J PHYSIOL-ENDOC M, V287, pE182, DOI 10.1152/ajpendo.00189.2003; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Ellingsgaard H, 2008, P NATL ACAD SCI USA, V105, P13163, DOI 10.1073/pnas.0801059105; Fessler MB, 2009, CURR OPIN LIPIDOL, V20, P379, DOI 10.1097/MOL.0b013e32832fa5c4; Guthoff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019482; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Hanisch UK, 2008, TRENDS NEUROSCI, V31, P176, DOI 10.1016/j.tins.2008.01.005; Hanley AJG, 2004, DIABETES, V53, P1773, DOI 10.2337/diabetes.53.7.1773; Heni M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021594; Hennige AM, 2009, DIABETOLOGIA, V52, P2416, DOI 10.1007/s00125-009-1522-5; Hennige AM, 2005, DIABETES, V54, P361, DOI 10.2337/diabetes.54.2.361; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kiefer FW, 2010, DIABETES, V59, P935, DOI 10.2337/db09-0404; Konner AC, 2011, TRENDS ENDOCRIN MET, V22, P16, DOI 10.1016/j.tem.2010.08.007; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Mo L, 2007, AM J PHYSIOL-RENAL, V293, pF1935, DOI 10.1152/ajprenal.00383.2007; Nomiyama T, 2007, J CLIN INVEST, V117, P2877, DOI 10.1172/JCI31986; Ogawa W, 2008, SCIENCE, V322, P1483, DOI 10.1126/science.1167571; Oliveira AG, 2011, DIABETES, V60, P784, DOI 10.2337/db09-1907; Perseghin G, 1997, DIABETES, V46, P1001, DOI 10.2337/diabetes.46.6.1001; Plum L, 2005, TRENDS ENDOCRIN MET, V16, P59, DOI 10.1016/j.tem.2005.01.008; Poggi M, 2007, DIABETOLOGIA, V50, P1267, DOI 10.1007/s00125-007-0654-8; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Ropelle ER, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000465; Samuvel DJ, 2010, J BIOL CHEM, V285, P3916, DOI 10.1074/jbc.M109.033951; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Sinton CM, 1999, J SLEEP RES, V8, P197, DOI 10.1046/j.1365-2869.1999.00158.x; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Tschritter O, 2007, DIABETOLOGIA, V50, P2602, DOI 10.1007/s00125-007-0839-1; Tschritter O, 2009, DIABETOLOGIA, V52, P169, DOI 10.1007/s00125-008-1187-5; Tschritter O, 2006, P NATL ACAD SCI USA, V103, P12103, DOI 10.1073/pnas.0604404103; Tschritter O, 2009, J CLIN ENDOCR METAB, V94, P4600, DOI 10.1210/jc.2009-0469; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75	49	28	30	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1799	1809		10.1096/fj.11-191023	http://dx.doi.org/10.1096/fj.11-191023			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278939				2022-12-28	WOS:000303680800008
J	Townsend, KL; Suzuki, R; Huang, TL; Jing, EX; Schulz, TJ; Lee, K; Taniguchi, CM; Espinoza, DO; McDougall, LE; Zhang, HB; He, TC; Kokkotou, E; Tseng, YH				Townsend, Kristy L.; Suzuki, Ryo; Huang, Tian Lian; Jing, Enxuan; Schulz, Tim J.; Lee, Kevin; Taniguchi, Cullen M.; Espinoza, Daniel O.; McDougall, Lindsay E.; Zhang, Hongbin; He, Tong-Chuan; Kokkotou, Efi; Tseng, Yu-Hua			Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway	FASEB JOURNAL			English	Article						hypothalamus; p70S6K	NEUROTROPHIC FACTOR; MAMMALIAN TARGET; TRANSLATION MACHINERY; NERVOUS-SYSTEM; FOOD-INTAKE; STEM-CELLS; RAT MODEL; LEPTIN; EXPRESSION; DIFFERENTIATION	Body weight is regulated by coordinating energy intake and energy expenditure. Transforming growth factor beta (TGF beta)/bone morphogenetic protein (BMP) signaling has been shown to regulate energy balance in lower organisms, but whether a similar pathway exists in mammals is unknown. We have previously demonstrated that BMP7 can regulate brown adipogenesis and energy expenditure. In the current study, we have uncovered a novel role for BMP7 in appetite regulation. Systemic treatment of diet-induced obese mice with BMP7 resulted in increased energy expenditure and decreased food intake, leading to a significant reduction in body weight and improvement of metabolic syndrome. Similar degrees of weight loss with reduced appetite were also observed in BMP7-treated ob/ob mice, suggesting a leptin-independent mechanism utilized by BMP7. Intracerebroventricular administration of BMP7 to mice led to an acute decrease in food intake, which was mediated, at least in part, by a central rapamycin-sensitive mTOR-p70S6 kinase pathway. Together, these results underscore the importance of BMP7 in regulating both food intake and energy expenditure, and suggest new therapeutic approaches for obesity and its comorbidities.-Townsend, K. L., Suzuki, R., Huang, T. L., Jing, E., Schulz, T. J., Lee, K., Taniguchi, C. M., Espinoza, D. O., McDougall, L. E., Zhang, H., He, T.-C., Kokkotou, E., Tseng, Y.-H. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J. 26, 2187-2196 (2012). www.fasebj.org	[Townsend, Kristy L.; Suzuki, Ryo; Huang, Tian Lian; Jing, Enxuan; Schulz, Tim J.; Lee, Kevin; Taniguchi, Cullen M.; Espinoza, Daniel O.; McDougall, Lindsay E.; Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; [He, Tong-Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Chicago, IL 60637 USA; [Kokkotou, Efi] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Chicago; University of Chicago Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Tseng, YH (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.	ekokkoto@caregroup.harvard.edu; yu-hua.tseng@joslin.harvard.edu	Schulz, Tim/F-4842-2013; Tseng, Yu-Hua/G-7003-2015; Suzuki, Ryo/AAA-2736-2019	Schulz, Tim/0000-0002-8413-3972; Suzuki, Ryo/0000-0002-2965-6906; Lee, Kevin/0000-0002-1528-7417; Taniguchi, Cullen/0000-0002-8052-3316	U.S. National Institutes of Health (NIH) [NIH R01 DK077097, UL1 RR 025758-01]; Eli Lilly Research Foundation; Harvard Stem Cell Institute [NIH R01 DK080058]; NIH [T32-DK007260-33, F32-DK091996]; Joslin Diabetes and Endocrinology Center; National Institute of Diabetes and Digestive and Kidney Diseases [P30-DK036836]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, F32DK091996, R01DK077097, T32DK007260, P30DK036836, R01DK080058] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eli Lilly Research Foundation(Eli Lilly); Harvard Stem Cell Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Joslin Diabetes and Endocrinology Center; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by U.S. National Institutes of Health (NIH) grants NIH R01 DK077097 and UL1 RR 025758-01 (Harvard Catalyst/The Harvard Clinical and Translational Science Center) and research grants from the Eli Lilly Research Foundation and Harvard Stem Cell Institute (to Y.-H.T.) and NIH R01 DK080058 (to E.K.). K.L.T. was supported by NIH T32-DK007260-33 and F32-DK091996. The Joslin Physiology and Special Assay Cores were supported by the Joslin Diabetes and Endocrinology Center, grant P30-DK036836 from the National Institute of Diabetes and Digestive and Kidney Diseases. The authors thank C. R. Kahn (Joslin Diabetes Center) for helpful discussion, and Andre Kleinridders (Joslin Diabetes Center) for technical advice. The authors declare no conflicts of interest. K.L.T. wrote the manuscript and conducted several of the experiments. R.S. performed most of the i.c.v. experiments. T.L.H. performed several of the in vitro and in vivo experiments. E.J. did the immunohistochemical staining. T.J.S. performed some of the LacZ staining and assisted with some of the i.c.v. studies. K.L. did the in situ hybridization and part of the LacZ staining. D.O.E. performed some of the in vitro studies and assisted with some of the i.c.v. studies. C.M.T. did the adenovirus experiments. L.E.M. assisted with the animal studies and RNA extractions. T.-C.H. provided the adenovirus and technical expertise. E.K. and Y.-H.T. designed the studies, performed the key experiments, and wrote the manuscript.	Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Ballard SL, 2010, DEV BIOL, V337, P375, DOI 10.1016/j.ydbio.2009.11.011; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Blouet C, 2008, CELL METAB, V8, P459, DOI 10.1016/j.cmet.2008.10.004; Bluher S, 2009, AM J CLIN NUTR, V89, p991S, DOI 10.3945/ajcn.2008.26788E; Bottcher Y, 2009, DIABETES, V58, P2119, DOI 10.2337/db08-1458; Boon M. R., 2011, CYTOKINE GROWTH F R, V7, P1; Cannon CM, 2005, EUR J NEUROSCI, V21, P2600, DOI 10.1111/j.1460-9568.2005.04077.x; Chai BX, 2010, PEPTIDES, V31, P1888, DOI 10.1016/j.peptides.2010.06.028; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; Charytoniuk DA, 2000, NEUROSCIENCE, V100, P33, DOI 10.1016/S0306-4522(00)00246-3; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chou J, 2006, J NEUROL SCI, V240, P21, DOI 10.1016/j.jns.2005.08.015; Coll AP, 2007, CELL, V129, P251, DOI 10.1016/j.cell.2007.04.001; Cordeira JW, 2010, J NEUROSCI, V30, P2533, DOI 10.1523/JNEUROSCI.5768-09.2010; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Cota D, 2008, J NEUROSCI, V28, P7202, DOI 10.1523/JNEUROSCI.1389-08.2008; Dattatreyamurty B, 2001, EXP NEUROL, V172, P273, DOI 10.1006/exnr.2001.7728; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; Farooqi IS, 2007, SCIENCE, V317, P1355, DOI 10.1126/science.1144599; Fulton S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006; Godin RE, 1998, DEVELOPMENT, V125, P3473; Hayes MR, 2010, CELL METAB, V11, P77, DOI 10.1016/j.cmet.2009.10.009; Johnen H, 2007, NAT MED, V13, P1333, DOI 10.1038/nm1677; Langenfeld EM, 2005, MOL CANCER RES, V3, P679, DOI 10.1158/1541-7786.MCR-05-0124; Lebrun B, 2006, AUTON NEUROSCI-BASIC, V126, P30, DOI 10.1016/j.autneu.2006.02.027; Leinninger GM, 2011, CELL METAB, V14, P313, DOI 10.1016/j.cmet.2011.06.016; Liao L, 2007, J PROTEOME RES, V6, P1059, DOI 10.1021/pr060358f; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Mori H, 2009, CELL METAB, V9, P362, DOI 10.1016/j.cmet.2009.03.005; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Ohyama K, 2008, DEVELOPMENT, V135, P3325, DOI 10.1242/dev.027078; PERIDES G, 1995, NEUROSCI LETT, V187, P21, DOI 10.1016/0304-3940(95)11327-S; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; Sabo JK, 2009, NEUROSIGNALS, V17, P255, DOI 10.1159/000231892; Schleinitz D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016155; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Schulz TJ, 2009, CYTOKINE GROWTH F R, V20, P523, DOI 10.1016/j.cytogfr.2009.10.019; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Shimizu H, 2007, J ENDOCRINOL, V193, P1, DOI 10.1677/JOE-06-0144; Soderstrom S, 1999, J NEUROSCI RES, V56, P482; Son JW, 2011, ENDOCR J, V58, P39, DOI 10.1507/endocrj.K10E-248; Stoica L, 2011, P NATL ACAD SCI USA, V108, P3791, DOI 10.1073/pnas.1014715108; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101; Tobin JF, 2006, DRUG DISCOV TODAY, V11, P405, DOI 10.1016/j.drudis.2006.03.016; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Vacher CM, 2008, FEBS LETT, V582, P3832, DOI 10.1016/j.febslet.2008.10.018; Villanueva EC, 2009, ENDOCRINOLOGY, V150, P4541, DOI 10.1210/en.2009-0642; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Yadav H, 2011, CELL METAB, V14, P67, DOI 10.1016/j.cmet.2011.04.013; You YJ, 2008, CELL METAB, V7, P249, DOI 10.1016/j.cmet.2008.01.005; Zamani N, 2011, ENDOCR REV, V32, P387, DOI 10.1210/er.2010-0018; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	60	75	83	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2187	2196		10.1096/fj.11-199067	http://dx.doi.org/10.1096/fj.11-199067			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22331196	Green Published			2022-12-28	WOS:000303680800044
J	Singh, AK; Spiessberger, B; Zheng, W; Xiao, F; Lukowski, R; Wegener, JW; Weinmeister, P; Saur, D; Klein, S; Schemann, M; Krueger, D; Seidler, U; Hofmann, F				Singh, Anurag Kumar; Spiessberger, Beate; Zheng, Wen; Xiao, Fang; Lukowski, Robert; Wegener, Joerg W.; Weinmeister, Pascal; Saur, Dieter; Klein, Sabine; Schemann, Michael; Krueger, Dagmar; Seidler, Ursula; Hofmann, Franz			Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid	FASEB JOURNAL			English	Article						peptic ulcer; knockout mouse models; N. vagus; proton pump inhibitor	NITRIC-OXIDE; SMALL-INTESTINE; HCO3-SECRETION; VILLIN GENE; PROTEIN; EXPRESSION; CFTR; BRAIN; MICE; PROSTAGLANDIN	Brief contact of the duodenal mucosa with luminal acid elicits a long-lasting bicarbonate (HCO3-) secretory response, which is believed to be the primary protective mechanism against mucosal damage. Here, we show that cGMP-dependent protein kinase type I-knockout (cGKI(-/-)) mice are unable to respond to a physiological H+ stimulus with a HCO3- secretory response and spontaneously develop duodenal ulcerations. Smooth muscle-selective cGKI knock-in rescued the motility disturbance but not the defective HCO3- secretion. Proton-induced HCO3- secretion was not attenuated by selective inactivation of the cGKI gene in interstitial cells of Cajal or in enterocytes, but was abolished by inactivation of cGKI in neurons (ncGKI(-/-)). cGKI was expressed in the brainstem nucleus tractus solitarius that connects the afferent with the efferent N. vagus. Accordingly, truncation of the subdiaphragmal N. vagus significantly diminished proton-induced HCO3- secretion in wild-type mice, whereas stimulation of the subdiaphragmal N. vagus elicited a similar HCO3- secretory response in cGKI(-/-), ncGKI(-/-) and wild-type mice. These findings show that protection of the duodenum from acid injury requires neuronal cGKI.-Singh, A. K., Spiessberger, B., Zheng, W., Xiao, F., Lukowski, R., Wegener, J. W., Weinmeister, P., Saur, D., Klein, S., Schemann, M., Krueger, D., Seidler, U., Hofmann, F. Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid. FASEB J. 26, 1745-1754 (2012). www.fasebj.org	[Spiessberger, Beate; Lukowski, Robert; Wegener, Joerg W.; Weinmeister, Pascal; Hofmann, Franz] Tech Univ Munich, Inst Pharmakol & Toxikol, Forschergrp 923, D-80802 Munich, Germany; [Singh, Anurag Kumar; Zheng, Wen; Xiao, Fang; Lukowski, Robert; Seidler, Ursula] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-3000 Hannover, Germany; [Klein, Sabine] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-80802 Munich, Germany; [Schemann, Michael; Krueger, Dagmar] Tech Univ Munich, Wissensch Zentrum Weihenstephan, Freising Weihenstephan, Germany	Technical University of Munich; Hannover Medical School; Technical University of Munich; Technical University of Munich	Hofmann, F (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Forschergrp 923, FOR 923,Biedersteiner Str 29, D-80802 Munich, Germany.	franz.hofmann@mytum.de	Saur, Dieter/G-4629-2011; Saur, Dieter/O-8355-2015; Seidler, Ursula/HII-8049-2022	Saur, Dieter/0000-0001-5874-0210; Seidler, Ursula/0000-0002-9600-2769; Wegener, Jorg/0000-0002-8129-1537; Schemann, Michael/0000-0003-1007-9843; Singh, Anurag Kumar/0000-0003-0818-0993	Deutsche Forschungsgemeinschaft [DFG HO579/17-1, HO579/19-1, DFG SE 460/13-4, SE 460/9-6, SFB621/C9, DFG SA 1374/1-2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Teodora Kennel, Uschi Gotz, and Regina Engelhardt for expert technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft to F.H. (DFG HO579/17-1 and HO579/19-1), U.S. (DFG SE 460/13-4, SE 460/9-6, and SFB621/C9), and D.S. (DFG SA 1374/1-2).	Akiba Y, 2005, AM J PHYSIOL-GASTR L, V289, pG753, DOI 10.1152/ajpgi.00130.2005; Akiba Y, 2001, J CLIN INVEST, V108, P1807, DOI 10.1172/JCI12218; Allen A, 2005, AM J PHYSIOL-CELL PH, V288, pC1, DOI 10.1152/ajpcell.00102.2004; BALLESTEROS MA, 1991, AM J PHYSIOL, V261, pG327, DOI 10.1152/ajpgi.1991.261.2.G327; Bilski J, 1994, J Physiol Pharmacol, V45, P541; Ehrlich A, 1999, METHOD FIND EXP CLIN, V21, P47, DOI 10.1358/mf.1999.21.1.527018; Feil S, 2005, NEUROSCIENCE, V135, P863, DOI 10.1016/j.neuroscience.2005.06.051; Foller M, 2008, P NATL ACAD SCI USA, V105, P6771, DOI 10.1073/pnas.0708940105; Francis S. H., PHYSL REV, V91, P651; Geiselhoringer A, 2004, FEBS LETT, V575, P19, DOI 10.1016/j.febslet.2004.08.030; HEYLINGS JR, 1984, AM J PHYSIOL, V246, pG235, DOI 10.1152/ajpgi.1984.246.3.G235; Hirokawa M, 2004, GASTROENTEROLOGY, V127, P1162, DOI 10.1053/j.gastro.2004.06.057; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Holm M, 1998, ACTA PHYSIOL SCAND, V162, P461; Holm M, 2001, DIGEST DIS SCI, V46, P1765, DOI 10.1023/A:1010674109111; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG629, DOI 10.1152/ajpgi.1998.275.4.G629; ISENBERG JI, 1986, GASTROENTEROLOGY, V91, P370, DOI 10.1016/0016-5085(86)90571-8; JONSON C, 1986, ACTA PHYSIOL SCAND, V128, P65, DOI 10.1111/j.1748-1716.1986.tb07950.x; Kaunitz J D, 2001, JOP, V2, P268; Konturek PC, 2004, EUR J PHARMACOL, V499, P15, DOI 10.1016/j.ejphar.2004.06.060; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Lukowski R, 2010, P NATL ACAD SCI USA, V107, P5646, DOI 10.1073/pnas.1001360107; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Nagl F, 2009, LAB INVEST, V89, p141A; Nayeb-Hashemi H, 2009, CURR OPIN GASTROEN, V25, P537, DOI 10.1097/MOG.0b013e328330da7b; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Plante L, 2004, J REPROD MED, V49, P825; Sanders KM, 2007, J PHYSIOL-LONDON, V578, P33, DOI 10.1113/jphysiol.2006.122473; Schubert ML, 2008, GASTROENTEROLOGY, V134, P1842, DOI 10.1053/j.gastro.2008.05.021; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; Singh AK, 2008, ACTA PHYSIOL, V193, P357, DOI 10.1111/j.1748-1716.2008.01854.x; Singh AK, 2010, AM J PHYSIOL-CELL PH, V298, pC1057, DOI 10.1152/ajpcell.00454.2009; Singh AK, 2009, J CLIN INVEST, V119, P540, DOI 10.1172/JCI35541; Sugamoto S, 2001, DIGEST DIS SCI, V46, P1208, DOI 10.1023/A:1010603026913; Takeuchi K, 1999, GASTROENTEROLOGY, V117, P1128, DOI 10.1016/S0016-5085(99)70398-7; Travagli RA, 2006, ANNU REV PHYSIOL, V68, P279, DOI 10.1146/annurev.physiol.68.040504.094635; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Weber S, 2007, CIRC RES, V101, P1096, DOI 10.1161/CIRCRESAHA.107.154351; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	43	15	15	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1745	1754		10.1096/fj.11-200394	http://dx.doi.org/10.1096/fj.11-200394			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22253479				2022-12-28	WOS:000302359700035
J	Ezzat, K; Helmfors, H; Tudoran, O; Juks, C; Lindberg, S; Padari, K; El-Andaloussi, S; Pooga, M; Langel, U				Ezzat, Kariem; Helmfors, Henrik; Tudoran, Oana; Juks, Carmen; Lindberg, Staffan; Padari, Kaert; El-Andaloussi, Samir; Pooga, Margus; Langel, Ulo			Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides	FASEB JOURNAL			English	Article						drug delivery; splice correction; cellular uptake	PHOSPHOROTHIOATE-STIMULATED UPTAKE; ARGININE-RICH PEPTIDES; SERUM-FREE MEDIUM; IN-VITRO; SURFACE RECEPTOR; NUCLEIC-ACIDS; PLASMID DNA; DELIVERY; TRANSFECTION; COMPLEXES	Cell-penetrating peptides (CPPs) are short cationic peptides that penetrate cells by interacting with the negatively charged plasma membrane; however, the detailed uptake mechanism is not clear. In contrary to the conventional mode of action of CPPs, we show here that a CPP, PepFect14 (PF14), forms negatively charged nanocomplexes with oligonucleotides and their uptake is mediated by class-A scavenger receptors (SCARAs). Specific inhibitory ligands of SCARAs, such as fucoidin, polyinosinic acid, and dextran sulfate, totally inhibit the activity of PF14-oligonucleotide nanocomplexes in the HeLa pLuc705 splice-correction cell model, while nonspecific, chemically related molecules do not. Furthermore, RNA interference (RNAi) knockdown of SCARA subtypes (SCARA3 and SCARA5) that are expressed in this cell line led to a significant reduction of the activity to < 50%. In line with this, immunostaining shows prevalent colocalization of the nanocomplexes with the receptors, and electron microscopy images show no binding or internalization of the nanocomplexes in the presence of the inhibitory ligands. Interestingly, naked oligonucleotides also colocalize with SCARAs when used at high concentrations. These results demonstrate the involvement of SCARA3 and SCARA5 in the uptake of PF14-oligonucleotide nanocomplexes and suggest for the first time that some CPP-based systems function through scavenger receptors, which could yield novel possibilities to understand and improve the transfection by CPPs.-Ezzat, K., Helmfors, H., Tudoran, O., Juks, C., Lindberg, S., Padari, K., El-Andaloussi, S., Pooga, M., Langel, U. Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J. 26, 1172-1180 (2012). www.fasebj.org	[Ezzat, Kariem; Helmfors, Henrik; Lindberg, Staffan; Langel, Ulo] Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden; [Tudoran, Oana] Chiricuta Canc Inst, Dept Funct Genom & Expt Pathol, Cluj Napoca, Romania; [Juks, Carmen; Padari, Kaert; Pooga, Margus] Univ Tartu, Inst Mol & Cell Biol, Dept Dev Biol, EE-50090 Tartu, Estonia; [Langel, Ulo] Univ Tartu, Inst Technol, Mol Biotechnol Lab, EE-50090 Tartu, Estonia; [El-Andaloussi, Samir] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England; [El-Andaloussi, Samir] Karolinska Inst, Dept Lab Med, Huddinge, Sweden	Stockholm University; Oncology Institute Prof. Dr. Ion Chiricuta; University of Tartu; University of Tartu; University of Oxford; Karolinska Institutet	Ezzat, K (corresponding author), Stockholm Univ, Dept Neurochem, 21A Svante Arrhenius Vag, S-10691 Stockholm, Sweden.	kariem@neurochem.su.se	Pooga, Margus/A-8575-2011; Ezzat, Kariem/O-6593-2019; Ezzat, Kariem/D-1436-2015	Pooga, Margus/0000-0003-4532-4087; Ezzat, Kariem/0000-0003-4186-0675; Helmfors, Henrik/0000-0001-9912-4887; Langel, Ulo/0000-0001-6107-0844; Lindberg, Staffan/0000-0001-7746-8574	Swedish Research Council (VR-NT); SSF (Sweden-Japan); Center for Biomembrane Research, Stockholm; European Union; Estonian Science Foundation (ESF) [7058]; Estonian government [SF0180027s08, 0180019s11]	Swedish Research Council (VR-NT)(Swedish Research Council); SSF (Sweden-Japan)(Swedish Foundation for Strategic Research); Center for Biomembrane Research, Stockholm; European Union(European Commission); Estonian Science Foundation (ESF); Estonian government	The authors thank all the contributing funding agencies. This work was supported by the Swedish Research Council (VR-NT); by SSF (Sweden-Japan); by the Center for Biomembrane Research, Stockholm; by the European Union through the European Regional Development Fund through the Center of Excellence in Chemical Biology, Estonia: by the Estonian Science Foundation (ESF; grant 7058); and by the targeted financing grants SF0180027s08 and 0180019s11 from the Estonian government.	Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299; Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005; Detzer A, 2009, CURR TOP MED CHEM, V9, P1109, DOI 10.2174/156802609789630884; DeWitte-Orr SJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000829; Ezzat K, 2011, NUCLEIC ACIDS RES, V39, P5284, DOI 10.1093/nar/gkr072; Ezzat K, 2010, CURR PHARM DESIGN, V16, P1167, DOI 10.2174/138161210790963832; Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Jarver P, 2010, TRENDS PHARMACOL SCI, V31, P528, DOI 10.1016/j.tips.2010.07.006; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; Koller E, 2011, NUCLEIC ACIDS RES, V39, P4795, DOI 10.1093/nar/gkr089; Lehto T, 2011, MOL THER, V19, P1457, DOI 10.1038/mt.2011.10; Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028; Limmon GV, 2008, FASEB J, V22, P159, DOI 10.1096/fj.07-8348com; Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729; Mae M, 2009, EXPERT OPIN DRUG DEL, V6, P1195, DOI 10.1517/17425240903213688; Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025; Mescalchin A, 2007, EXPERT OPIN BIOL TH, V7, P1531, DOI 10.1517/14712598.7.10.1531; Murphy JE, 2005, ATHEROSCLEROSIS, V182, P1, DOI 10.1016/j.atherosclerosis.2005.03.036; Nagayama S, 2007, INT J PHARMACEUT, V329, P192, DOI 10.1016/j.ijpharm.2006.08.025; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Oskolkov N, 2011, INT J PEPT RES THER, V17, P147, DOI 10.1007/s10989-011-9252-1; Overhoff M, 2005, EMBO REP, V6, P1176, DOI 10.1038/sj.embor.7400535; Patel PC, 2010, BIOCONJUGATE CHEM, V21, P2250, DOI 10.1021/bc1002423; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Pluddemann A, 2007, METHODS, V43, P207, DOI 10.1016/j.ymeth.2007.06.004; Pluddemann A, 2009, J INNATE IMMUN, V1, P153, DOI 10.1159/000155227; Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439; Sewell KL, 2002, J PHARMACOL EXP THER, V303, P1334, DOI 10.1124/jpet.102.036749; Sobal G, 2002, J RECEPT SIGNAL TR R, V22, P459, DOI 10.1081/RRS-120014614; Son KK, 2000, BBA-BIOMEMBRANES, V1468, P6, DOI 10.1016/S0005-2736(00)00311-4; Son KK, 2000, BBA-BIOMEMBRANES, V1468, P11, DOI 10.1016/S0005-2736(00)00312-6; Son KK, 2001, BBA-BIOMEMBRANES, V1511, P201, DOI 10.1016/S0005-2736(01)00297-8; Son KK, 2000, BBA-BIOMEMBRANES, V1466, P11, DOI 10.1016/S0005-2736(00)00176-0; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; Takagi H, 2002, J CELL SCI, V115, P3309; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Verdurmen WPR, 2011, TRENDS PHARMACOL SCI, V32, P116, DOI 10.1016/j.tips.2010.11.005; Yacyshyn BR, 2002, GUT, V51, P30, DOI 10.1136/gut.51.1.30; Yanyan JY, 2006, J BIOL CHEM, V281, P11834, DOI 10.1074/jbc.M507599200	43	108	110	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1172	1180		10.1096/fj.11-191536	http://dx.doi.org/10.1096/fj.11-191536			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22138034				2022-12-28	WOS:000300949300020
J	Roy, SG; Raikhel, AS				Roy, Saurabh G.; Raikhel, Alexander S.			Nutritional and hormonal regulation of the TOR effector 4E-binding protein (4E-BP) in the mosquito Aedes aegypti	FASEB JOURNAL			English	Article						amino acids; insulin; translation; blood-feeding insect	TRANSLATION INITIATION; JUVENILE-HORMONE; INSULIN; DROSOPHILA; DOWNSTREAM; FOXO; STRESS; TARGET; VITELLOGENIN; TRANSDUCTION	Mosquitoes require blood for egg development, and, as a consequence, they transmit pathogens of devastating diseases. Target of rapamycin (TOR) signaling is a key pathway linking blood feeding and egg development in the mosquito Aedes aegypti. We show that the regulation of the TOR effector translational repressor 4E-BP is finely tuned to the nutritional requirements of the female mosquito, and it occurs at transcriptional and post-translational levels. Immediately after blood feeding, 4E-BP became hyperphosphorylated, suggesting rapid inhibition of its translational repression function. 4E-BP was highly phosphorylated after in vitro incubation of the fat body in the presence of amino acids; this phosphorylation was rapamycin insensitive, in contrast to another TOR target, S6K, phosphorylation of which was rapamycin sensitive. A high level of 4E-BP phosphorylation was also elicited by insulin. Rapamycin and the PI3K inhibitor LY294002 blocked insulin-mediated 4E-BP phosphorylation. RNA-interference depletion of the insulin receptor or Akt resulted in severe reduction of 4E-BP phosphorylation. Phosphorylation and stability of 4E-BP was dependent on its partner eIF4E translation initiation factor. Silencing of 4E-BP resulted in reduction of the life span of adult female mosquitoes. This study demonstrates a dual nutritional and hormonal control of 4E-BP and its role in mosquito egg development.-Roy, S. G., Raikhel, A. S. Nutritional and hormonal regulation of the TOR effector 4E-binding protein (4E-BP) in the mosquito Aedes aegypti. FASEB J. 26, 1334-1342 (2012). www.fasebj.org	[Raikhel, Alexander S.] Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, 900 Univ Ave, Riverside, CA 92521 USA.	araikhel@ucr.edu			U.S. National Institutes of Health [R37 AI24716]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by U.S. National Institutes of Health grant R37 AI24716 (to A. S. R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The nucleotide sequence of A. aegypti 4E-BP reported in this article has been submitted to the GenBank databank with the accession number FJ392868.	Attardo GM, 2006, J EXP BIOL, V209, P3071, DOI 10.1242/jeb.02349; Brandon MC, 2008, INSECT BIOCHEM MOLEC, V38, P916, DOI 10.1016/j.ibmb.2008.07.003; Brown MR, 2008, P NATL ACAD SCI USA, V105, P5716, DOI 10.1073/pnas.0800478105; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Corby-Harris V, 2010, PLOS PATHOG, V6, DOI [10.1371/journal.ppat.1001003, 10.1371/annotation/738ac91f-8c41-4bf5-9a39-bddf0b777a89]; Corona M, 2007, P NATL ACAD SCI USA, V104, P7128, DOI 10.1073/pnas.0701909104; Demontis F, 2010, CELL, V143, P813, DOI 10.1016/j.cell.2010.10.007; Gulia-Nuss M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020401; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hansen IA, 2007, INSECT BIOCHEM MOLEC, V37, P985, DOI 10.1016/j.ibmb.2007.05.008; Hansen IA, 2011, J BIOL CHEM, V286, P10803, DOI 10.1074/jbc.M110.179739; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hay N, 2011, BBA-MOL CELL RES, V1813, P1965, DOI 10.1016/j.bbamcr.2011.03.013; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; Kramer JM, 2008, GENOME, V51, P668, DOI 10.1139/G08-047; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; MADER S, 1995, MOL CELL BIOL, V15, P4990; Maestro JL, 2009, J BIOL CHEM, V284, P5506, DOI 10.1074/jbc.M807042200; Park JH, 2006, J BIOL CHEM, V281, P11167, DOI 10.1074/jbc.M601517200; Parthasarathy R, 2011, INSECT BIOCHEM MOLEC, V41, P294, DOI 10.1016/j.ibmb.2011.01.006; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Raikhel Alexander S., 2005, P329; Roy SG, 2007, INSECT BIOCHEM MOLEC, V37, P1317, DOI 10.1016/j.ibmb.2007.08.004; Roy SG, 2011, INSECT BIOCHEM MOLEC, V41, P62, DOI 10.1016/j.ibmb.2010.10.001; Russell SJ, 2007, NAT REV MOL CELL BIO, V8, P681, DOI 10.1038/nrm2234; Sim C, 2008, P NATL ACAD SCI USA, V105, P6777, DOI 10.1073/pnas.0802067105; SONDERGAARD L, 1995, MOL GEN GENET, V248, P25, DOI 10.1007/BF02456610; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005	34	31	33	2	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1334	1342		10.1096/fj.11-189969	http://dx.doi.org/10.1096/fj.11-189969			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22159149	Green Published			2022-12-28	WOS:000300949300035
J	Sassi, Y; Abi-Gerges, A; Fauconnier, J; Mougenot, N; Reiken, S; Haghighi, K; Kranias, EG; Marks, AR; Lacampagne, A; Engelhardt, S; Hatem, SN; Lompre, AM; Hulot, JS				Sassi, Yassine; Abi-Gerges, Aniella; Fauconnier, Jeremy; Mougenot, Nathalie; Reiken, Steven; Haghighi, Kobra; Kranias, Evangelia G.; Marks, Andrew R.; Lacampagne, Alain; Engelhardt, Stefan; Hatem, Stephane N.; Lompre, Anne-Marie; Hulot, Jean-Sebastien			Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes	FASEB JOURNAL			English	Article						cyclic nucleotides; MRP proteins; phosphodiesterases	SIGNAL-TRANSDUCTION; CELLULAR EXPORT; CA2+ CHANNELS; HEART; RESISTANCE; TRANSPORTER; EPAC; PUMP; ATP; COMPARTMENTATION	Recent studies indicate that members of the multidrug-resistance protein (MRP) family belonging to ATP binding cassette type C (ABCC) membrane proteins extrude cyclic nucleotides from various cell types. This study aimed to determine whether MRP proteins regulate cardiac cAMP homeostasis. Here, we demonstrate that MRP4 is the predominant isoform present at the plasma membrane of cardiacmyocytes and that it mediates the efflux of cAMP in these cells. MRP4-deficient mice displayed enhanced cardiac myocyte cAMP formation, contractility, and cardiac hypertrophy at 9 mo of age, an effect that was compensated transiently by increased phosphodiesterase expression at young age. These findings suggest that cAMP extrusion via MRP4 acts together with phosphodiesterases to control cAMP levels in cardiac myocytes.-Sassi, Y., Abi-Gerges, A., Fauconnier, J., Mougenot, N., Reiken, S., Haghighi, K., Kranias, E. G., Marks, A. R., Lacampagne, A., Engelhardt, S., Hatem, S. N., Lompre, A.-M., Hulot, J. S. Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 26, 1009-1017 (2012). www.fasebj.org	[Hulot, Jean-Sebastien] Univ Paris 06, Fac Med Pitie Salpetriere, INSERM, UMR S 956, F-75013 Paris, France; [Sassi, Yassine; Engelhardt, Stefan] Tech Univ Munich, Inst Pharmakol & Toxikol, Munich, Germany; [Fauconnier, Jeremy; Lacampagne, Alain] Univ Montpellier, INSERM, U1046, F-34059 Montpellier, France; [Mougenot, Nathalie] Univ Paris 06, INSERM, IFR CMV 14, F-75013 Paris, France; [Reiken, Steven; Marks, Andrew R.] Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Clyde & Helen Wu Ctr Mol Cardiol, New York, NY 10032 USA; [Haghighi, Kobra; Kranias, Evangelia G.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; [Hulot, Jean-Sebastien] Mt Sinai Sch Med, Cardiovasc Res Ctr, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Technical University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Columbia University; University System of Ohio; University of Cincinnati; Icahn School of Medicine at Mount Sinai	Hulot, JS (corresponding author), Univ Paris 06, Fac Med Pitie Salpetriere, INSERM, UMR S 956, 91 Bvd Hop, F-75013 Paris, France.	jean-sebastien.hulot@psl.aphp.fr	Lacampagne, Alain/S-3719-2016; Hulot, Jean-Sébastien/A-2278-2016; Hatem, Stephane/D-1016-2017; Abi-Gerges, Aniella/AAH-5250-2020; LOMPRE, Anne-Marie/H-2872-2013; Engelhardt, Stefan/AAA-9329-2019	Lacampagne, Alain/0000-0003-0264-1787; Hulot, Jean-Sébastien/0000-0001-5463-6117; Abi-Gerges, Aniella/0000-0001-9974-4023; Engelhardt, Stefan/0000-0001-5378-8661; Sassi, Yassine/0000-0002-7807-1728; hatem, stephane/0000-0002-9790-0755	Agence Nationale de la Recherche (ANR) [09JCJC0112]; Fondation de France [2006005606]; Fondation Leducq through CAERUS network [05CVD03]; U.S. National Institutes of Health [NIH HL26057, HL64018]; French Ministere de l'Education Nationale et de la Recherche Scientifique (MENRS); Fondation pour la Recherche Medicale (FRM); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061503, R01HL026057, R37HL026057, R01HL064018] Funding Source: NIH RePORTER	Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Fondation de France(Fondation de France); Fondation Leducq through CAERUS network(Leducq Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); French Ministere de l'Education Nationale et de la Recherche Scientifique (MENRS); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Prof. Piet Borst (NKI-Amsterdam, Amsterdam, The Netherlands) for helpful discussions and Dr. Chen Yan (University of Rochester, Rochester, NY, USA) for providing the PDE3A antibody. This work was supported by grants from the Agence Nationale de la Recherche (ANR; 09JCJC0112) and Fondation de France (2006005606) to J.S.H., by the Fondation Leducq through the CAERUS network (research agreement 05CVD03 to A.-M. L., A. R. M., and E. G. K.), and by the U.S. National Institutes of Health (grants NIH HL26057 and HL64018). Y.S. is the recipient of a Ph.D. fellowship from the French Ministere de l'Education Nationale et de la Recherche Scientifique (MENRS) and from Fondation pour la Recherche Medicale (FRM). J.S.H, S.N.H., A.-M. L. and S. E. were involved in the development of the overall study design. Y.S. planned and performed most of the experiments; A. A. G. assisted in in vitro experiments; J.F. performed the evaluation in isolated cardiac myocytes with the help of Y.S. and A. L.; Y.S., J.S.H., and N.M. performed the in vivo evaluations in mice; S. R. performed the RyR2 immunoblots. J.S.H, Y.S., S.N.H., and A.-M. L wrote the manuscript with the help of A. R. M., S. E., and A. L.; A. R. M., E. G. K., K. H., and S.N.H. assisted in conceptual aspects of the studies and interpretation of the data. All authors discussed results and contributed intellectually to the manuscript.	Abi-Char J, 2007, J PHYSIOL-LONDON, V582, P1205, DOI 10.1113/jphysiol.2007.134809; Abi-Gerges A, 2009, CIRC RES, V105, P784, DOI 10.1161/CIRCRESAHA.109.197947; Akanuma S, 2010, J PHARMACOL EXP THER, V333, P912, DOI 10.1124/jpet.109.165332; Balijepalli RC, 2006, P NATL ACAD SCI USA, V103, P7500, DOI 10.1073/pnas.0503465103; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Boixel C, 2001, CIRC RES, V89, P607, DOI 10.1161/hh1901.096702; Borst P, 2007, PFLUG ARCH EUR J PHY, V453, P661, DOI 10.1007/s00424-006-0054-9; Bristow MR, 1998, LANCET, V352, P8; Cazorla O, 2009, P NATL ACAD SCI USA, V106, P14144, DOI 10.1073/pnas.0812536106; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Copsel S, 2011, J BIOL CHEM, V286, P6979, DOI 10.1074/jbc.M110.166868; Dazert P, 2003, AM J PATHOL, V163, P1567, DOI 10.1016/S0002-9440(10)63513-4; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Wolf CJF, 2007, FEBS J, V274, P439, DOI 10.1111/j.1742-4658.2006.05591.x; El-Haou S, 2009, CIRC RES, V104, P758, DOI 10.1161/CIRCRESAHA.108.191007; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Fauconnier J, 2007, DIABETES, V56, P1136, DOI 10.2337/db06-0739; Feldman DS, 2005, NAT CLIN PRACT CARD, V2, P475, DOI 10.1038/ncpcardio0309; Fischmeister R, 2006, CIRC RES, V99, P816, DOI 10.1161/01.RES.0000246118.98832.04; GAUDIN C, 1995, J CLIN INVEST, V95, P1676, DOI 10.1172/JCI117843; Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200; HAMET P, 1989, J BIOL CHEM, V264, P12364; Hara Y, 2011, J CLIN INVEST, V121, P2888, DOI 10.1172/JCI45023; Henaff M, 2001, FASEB J, V15, P99, DOI 10.1096/fj.01-0389fje; Houslay MD, 2007, CIRC RES, V100, P950, DOI 10.1161/01.RES.0000261934.56938.38; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KAPOOR A K, 1977, Indian Journal of Physiology and Pharmacology, V21, P133; Leggas M, 2004, MOL CELL BIOL, V24, P7612, DOI 10.1128/MCB.24.17.7612-7621.2004; Li CY, 2007, CELL, V131, P940, DOI 10.1016/j.cell.2007.09.037; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Metrich M, 2008, CIRC RES, V102, P959, DOI 10.1161/CIRCRESAHA.107.164947; Metrich M, 2010, PFLUG ARCH EUR J PHY, V459, P535, DOI 10.1007/s00424-009-0747-y; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; Nikolaev VO, 2006, CIRC RES, V99, P1084, DOI 10.1161/01.RES.0000250046.69918.d5; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Ritter CA, 2005, DRUG METAB REV, V37, P253, DOI 10.1081/DMR-200047984; Rodriguez MR, 2011, GASTROENTEROLOGY, V140, P1292, DOI 10.1053/j.gastro.2010.12.053; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; Russel FGM, 2008, TRENDS PHARMACOL SCI, V29, P200, DOI 10.1016/j.tips.2008.01.006; Sassi Y, 2008, J CLIN INVEST, V118, P2747, DOI 10.1172/JCI35067; Takahashi K, 2002, HEART VESSELS, V16, P249, DOI 10.1007/s003800200032; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Yan C, 2007, CIRC RES, V100, P489, DOI 10.1161/01.RES.0000258451.44949.d7; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	51	50	52	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1009	1017		10.1096/fj.11-194027	http://dx.doi.org/10.1096/fj.11-194027			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22090316	Green Published			2022-12-28	WOS:000300949300006
J	Balghi, H; Robert, R; Rappaz, B; Zhang, XX; Wohlhuter-Haddad, A; Evagelidis, A; Luo, YS; Goepp, J; Ferraro, P; Romeo, P; Trebak, M; Wiseman, PW; Thomas, DY; Hanrahan, JW				Balghi, Haouaria; Robert, Renaud; Rappaz, Benjamin; Zhang, Xuexin; Wohlhuter-Haddad, Adeline; Evagelidis, Alexandra; Luo, Yishan; Goepp, Julie; Ferraro, Pasquale; Romeo, Philippe; Trebak, Mohamed; Wiseman, Paul W.; Thomas, David Y.; Hanrahan, John W.			Enhanced Ca2+ entry due to Orai1 plasma membrane insertion increases IL-8 secretion by cystic fibrosis airways	FASEB JOURNAL			English	Article						calcium influx; calcium channels; cystic fibrosis transmembrane conductance regulator; CFTR; cytokine	TRANSMEMBRANE CONDUCTANCE REGULATOR; NF-KAPPA-B; EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; CHANNEL FUNCTION; T-CELL; I-CRAC; FLUORESCENCE PROPERTIES; INFLAMMATORY RESPONSES; CFTR TRAFFICKING	Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). The most common mutation, Delta F508, causes retention of CFTR in the endoplasmic reticulum (ER). Some CF abnormalities can be explained by altered Ca2+ homeostasis, although it remains unknown how CFTR influences calcium signaling. This study examined the novel hypothesis that store-operated calcium entry (SOCE) through Orai1 is abnormal in CF. The significance of Orai1-mediated SOCE for increased interleukin-8 (IL-8) expression in CF was also investigated. CF and non-CF human airway epithelial cell line and primary cells (obtained at lung transplantation) were used in Ca2+ imaging, electrophysiology, and fluorescence imaging experiments to explore differences in Orai1 function in CF vs. non-CF cells. Protein expression and localization was assessed by Western blots, cell surface biotinylation, ELISA, and image correlation spectroscopy (ICS). We show here that store-operated Ca2+ entry (SOCE) is elevated in CF human airway epithelial cells (hAECs; similar to 1.8- and similar to 2.5-fold for total Ca-i(2+) increase and Ca2+ influx rate, respectively, and similar to 2-fold increase in the I-CRAC current) and is caused by increased exocytotic insertion (similar to 2-fold) of Orai1 channels into the plasma membrane, which is normalized by rescue of Delta F508-CFTR trafficking to the cell surface. Augmented SOCE in CF cells is a major factor leading to increased IL-8 secretion (similar to 2-fold). CFTR normally down-regulates the Orai1/stromal interaction molecule 1 (STIM1) complex, and loss of this inhibition due to the absence of CFTR at the plasma membrane helps to explain the potentiated inflammatory response in CF cells.-Balghi, H., Robert, R., Rappaz, B., Zhang, X., Wohlhuter-Haddad, A., Evagelidis, A., Luo, Y., Goepp, J., Ferraro, P., Romeo, P., Trebak, M., Wiseman, P. W., Thomas, D. Y., Hanrahan, J. W. Enhanced Ca2+ entry due to Orai1 plasma membrane insertion increases IL-8 secretion by cystic fibrosis airways. FASEB J. 25, 4274-4291 (2011). www.fasebj.org	[Balghi, Haouaria; Robert, Renaud; Wohlhuter-Haddad, Adeline; Evagelidis, Alexandra; Luo, Yishan; Goepp, Julie; Hanrahan, John W.] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Rappaz, Benjamin; Wiseman, Paul W.] McGill Univ, Dept Phys, Montreal, PQ, Canada; [Wiseman, Paul W.] McGill Univ, Dept Chem, Montreal, PQ, Canada; [Thomas, David Y.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Hanrahan, John W.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; [Zhang, Xuexin; Trebak, Mohamed] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; [Ferraro, Pasquale] Ctr Hosp Univ Montrel, Div Thorac Surg, Montreal, PQ, Canada; [Romeo, Philippe] Univ Montreal, Montreal Heart Inst, Dept Pathol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; Albany Medical College; Universite de Montreal	Balghi, H (corresponding author), 3655 Promenade Sir William Osler,McIntyre Med Bld, Montreal, PQ H3G 1Y6, Canada.	haouaria.balghi@mail.mcgill.ca	Rappaz, Benjamin/C-1881-2014; Zhang, Xuexin/I-7600-2013; Hanrahan, John/AGG-1926-2022; Trebak, Mohamed/E-7405-2014; 张学新, XUEXIN ZHANG/AAD-7645-2019; Thomas, David/M-7661-2017	Rappaz, Benjamin/0000-0002-8744-600X; Hanrahan, John/0000-0001-9080-2039; 张学新, XUEXIN ZHANG/0000-0001-8276-3885; Wohlhuter-Haddad, Adeline/0000-0002-2323-8092; Thomas, David/0000-0002-8854-762X	Cystic Fibrosis Canada (CFC); Canadian Institutes of Health Research (CIHR); U.S. National Institutes of Health [1R01HL097111, 5K22ES014729]; CFC; Swiss National Science Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES014729] Funding Source: NIH RePORTER	Cystic Fibrosis Canada (CFC); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CFC; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors are grateful to Richard S. Lewis (Stanford University School of Medicine, Stanford, CA, USA) for generously providing the STIM1-GFP and Orai1-mCherry plasmids. The authors thank the staff of the McGill University Life Sciences Complex Imaging Facility for excellent technical help and discussion and also the McGill University electron microscopy facility for the technical assistance. This work was supported by Cystic Fibrosis Canada (CFC) and Canadian Institutes of Health Research (CIHR). Part of this work was supported by U.S. National Institutes of Health grants 1R01HL097111 and 5K22ES014729 to M.T. H.B. is supported by a CFC fellowship and B.R. by a Swiss National Science Foundation fellowship. The authors have declared no conflicts of interest.	Antigny F, 2008, CELL CALCIUM, V43, P175, DOI 10.1016/j.ceca.2007.05.002; Antigny F, 2011, AM J RESP CELL MOL, V44, P83, DOI 10.1165/rcmb.2009-0347OC; Antigny F, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-70; Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; Comeau JWD, 2006, BIOPHYS J, V91, P4611, DOI 10.1529/biophysj.106.089441; Di Sabatino A, 2009, J IMMUNOL, V183, P3454, DOI 10.4049/jimmunol.0802887; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Divangahi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000586; Dudez T, 2008, BBA-MOL CELL RES, V1783, P779, DOI 10.1016/j.bbamcr.2008.01.007; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Fu Z, 2007, AM J PHYSIOL-LUNG C, V292, pL353, DOI 10.1152/ajplung.00042.2006; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; Gadsby DC, 2006, NATURE, V440, P477, DOI 10.1038/nature04712; Galan C, 2009, ARCH BIOCHEM BIOPHYS, V490, P137, DOI 10.1016/j.abb.2009.08.007; Gallagher AM, 2001, AM J PHYSIOL-GASTR L, V281, pG681, DOI 10.1152/ajpgi.2001.281.3.G681; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Gwack Y, 2008, MOL CELL BIOL, V28, P5209, DOI 10.1128/MCB.00360-08; Hanrahan John W, 2004, Proc Am Thorac Soc, V1, P17, DOI 10.1513/pats.2306009; Hong JH, 2011, TRAFFIC, V12, P232, DOI 10.1111/j.1600-0854.2010.01138.x; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Illek B, 2008, CELL PHYSIOL BIOCHEM, V22, P57, DOI 10.1159/000149783; KNOWLES MR, 1986, CLIN CHEST MED, V7, P285; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; LLOYDSTILL JD, 1994, DIGEST DIS SCI, V39, P880, DOI 10.1007/BF02087437; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Machen TE, 2006, AM J PHYSIOL-CELL PH, V291, pC218, DOI 10.1152/ajpcell.00605.2005; Martin ACL, 2009, MOL PHARMACOL, V75, P830, DOI 10.1124/mol.108.051748; McCarl CA, 2010, J IMMUNOL, V185, P5845, DOI 10.4049/jimmunol.1001796; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Michoud MC, 2009, AM J RESP CELL MOL, V40, P217, DOI 10.1165/rcmb.2006-0444OC; Motiani RK, 2010, J BIOL CHEM, V285, P19173, DOI 10.1074/jbc.M110.102582; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Otsuguro KI, 2008, J BIOL CHEM, V283, P10026, DOI 10.1074/jbc.M707306200; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Peters KW, 2001, PFLUG ARCH EUR J PHY, V443, pS65, DOI 10.1007/s004240100647; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Randell SH, 2001, IN VITRO CELL DEV-AN, V37, P480; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Ribeiro Carla Maria Pedrosa, 2006, Drugs R D, V7, P17, DOI 10.2165/00126839-200607010-00002; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Roussel L., BIOCH BIOPHYS RES CO, V391, P505; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Walsh CM, 2010, BIOCHEM J, V425, P159, DOI 10.1042/BJ20090884; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; Wiseman PW, 2000, J MICROSC-OXFORD, V200, P14, DOI 10.1046/j.1365-2818.2000.00736.x; Woodard GE, 2008, AM J PHYSIOL-CELL PH, V294, pC1323, DOI 10.1152/ajpcell.00071.2008; Yu F, 2010, J CELL BIOL, V191, P523, DOI 10.1083/jcb.201006022; Yuan JP, 2007, NAT CELL BIOL, V9, P636, DOI 10.1038/ncb1590; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103	67	47	48	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4274	4291		10.1096/fj.11-187682	http://dx.doi.org/10.1096/fj.11-187682			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21873556	Green Published			2022-12-28	WOS:000298138100020
J	Malawista, SE; de Boisfleury, AC; Naccache, PH				Malawista, Stephen E.; de Boisfleury, Anne Chevance; Naccache, Paul H.			Inflammatory Gout: Observations over a Half-Century	FASEB JOURNAL			English	Article							INDUCED NEUTROPHIL ACTIVATION; MONOSODIUM URATE CRYSTALS; ENDOGENOUS PYROGEN PRODUCTION; SYNOVIAL FLUID; ARTHRITIS; IDENTIFICATION; STIMULATION; COMPLEMENT; RESOLUTION; RESPONSES	This is a discussion of acute gouty arthritis, seen for over 50 years of engagement. It addresses the evolution of our current understanding of the interaction between urate crystals and key cellular components of the gouty inflammatory paroxysm, with new material on pathogenesis. FASEB J. 25, 4073-4078 (2011). www.fasebj.org	[Malawista, Stephen E.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; [Malawista, Stephen E.; de Boisfleury, Anne Chevance] Hop La Pitie Salpetriere, Ctr Ecol Cellulaire, Paris, France; [Naccache, Paul H.] Univ Laval, Dept Microbiol Infectiol & Immunol, Ctr Rech, Ctr Rech Rhumatol & Immunol,CHUQ, Quebec City, PQ, Canada	Yale University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Laval University	Malawista, SE (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208031,300 Cedar St, New Haven, CT 06520 USA.	stephen.malawista@yale.edu			NIH/NIAMS [AR053495]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR053495] Funding Source: NIH RePORTER	NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by NIH/NIAMS AR053495.	AGUDELO CA, 1973, HUM PATHOL, V4, P265, DOI 10.1016/S0046-8177(73)80013-9; DEBOISFLEURYCHEVANCE A, 1989, BLOOD CELLS, V15, P315; Desaulniers P, 2006, J RHEUMATOL, V33, P928; Desaulniers P, 2001, J LEUKOCYTE BIOL, V70, P659; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; Dinarello CA, 2010, ARTHRITIS RHEUM-US, V62, P3140, DOI 10.1002/art.27663; DUFF GW, 1983, T ASSOC AM PHYSICIAN, V96, P234; Faires J., 1962, LANCET, V280, P682; Garrod Archibald E., 1876, TREATISE GOUT RHEUMA; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; HOWELL RR, 1963, ARTHRITIS RHEUM-US, V6, P97, DOI 10.1002/art.1780060202; Joosten LAB, 2010, ARTHRITIS RHEUM-US, V62, P3237, DOI 10.1002/art.27667; MALAWIST.SE, 1965, ANN INTERN MED, V62, P648, DOI 10.7326/0003-4819-62-4-648; Malawista S. E., 1977, ARTHRITIS RHEUM, V20, pS241; MALAWISTA SE, 1985, ARTHRITIS RHEUM, V28, P1039, DOI 10.1002/art.1780280911; Martin WJ, 2010, IMMUNOL CELL BIOL, V88, P15, DOI 10.1038/icb.2009.89; Martinon F, 2006, J CLIN INVEST, V116, P2073, DOI 10.1172/JCI29404; MCCARTY DJ, 1962, AM J MED SCI, V243, P288, DOI 10.1097/00000441-196203000-00003; MCCARTY DJ, 1961, ANN INTERN MED, V54, P452, DOI 10.7326/0003-4819-54-3-452; PEKIN TJ, 1964, J CLIN INVEST, V43, P1372, DOI 10.1172/JCI105013; Popa-Nita O, 2007, J LEUKOCYTE BIOL, V82, P763, DOI 10.1189/jlb.0307174; Popa-Nita O, 2010, IMMUNOL CELL BIOL, V88, P32, DOI 10.1038/icb.2009.98; Ropes M., 1953, SYNOVIAL FLUID CHANG, P92; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P469; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; TERKELTAUB R, 1983, ARTHRITIS RHEUM, V26, P775, DOI 10.1002/art.1780260612; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tramontini N, 2004, ARTHRITIS RHEUM-US, V50, P2633, DOI 10.1002/art.20386; Yagnik DR, 2004, ARTHRITIS RHEUM-US, V50, P2273, DOI 10.1002/art.20317	29	25	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4073	4078		10.1096/fj.11-1201ufm	http://dx.doi.org/10.1096/fj.11-1201ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	22131362	Green Published			2022-12-28	WOS:000298138100001
J	Hupkes, M; Jonsson, MKB; Scheenen, WJ; van Rotterdam, W; Sotoca, AM; van Someren, EP; van der Heyden, MAG; van Veen, TA; van Ravestein-van Os, RI; Bauerschmidt, S; Piek, E; Ypey, DL; van Zoelen, EJ; Dechering, KJ				Hupkes, Marlinda; Jonsson, Malin K. B.; Scheenen, Wim J.; van Rotterdam, Walter; Sotoca, Ana M.; van Someren, Eugene P.; van der Heyden, Marcel A. G.; van Veen, Toon A.; van Ravestein-van Os, Roselinde I.; Bauerschmidt, Susanne; Piek, Ester; Ypey, Dirk L.; van Zoelen, Everardus J.; Dechering, Koen J.			Epigenetics: DNA demethylation promotes skeletal myotube maturation	FASEB JOURNAL			English	Article						5-azacytidine; C2C12 myogenesis; sarcomere development; spontaneous myotube contractions	C2C12 MOUSE MYOTUBES; EMBRYONIC STEM-CELLS; MYOBLAST DIFFERENTIATION; MUSCLE DIFFERENTIATION; CALCIUM TRANSIENTS; ELECTRICAL-STIMULATION; DENERVATED MUSCLE; CANCER-THERAPY; IN-VITRO; METHYLATION	Mesenchymal progenitor cells can be differentiated in vitro into myotubes that exhibit many characteristic features of primary mammalian skeletal muscle fibers. However, in general, they do not show the functional excitation-contraction coupling or the striated sarcomere arrangement typical of mature myofibers. Epigenetic modifications have been shown to play a key role in regulating the progressional changes in transcription necessary for muscle differentiation. In this study, we demonstrate that treatment of murine C2C12 mesenchymal progenitor cells with 10 mu M of the DNA methylation inhibitor 5-azacytidine (5AC) promotes myogenesis, resulting in myotubes with enhanced maturity as compared to untreated myotubes. Specifically, 5AC treatment resulted in the up-regulation of muscle genes at the myoblast stage, while at later stages nearly 50% of the 5AC-treated myotubes displayed a mature, well-defined sarcomere organization, as well as spontaneous contractions that coincided with action potentials and intracellular calcium transients. Both the percentage of striated myotubes and their contractile activity could be inhibited by 20 nM TTX, 10 mu M ryanodine, and 100 mu M nifedipine, suggesting that action potential-induced calcium transients are responsible for these characteristics. Our data suggest that genomic demethylation induced by 5AC overcomes an epigenetic barrier that prevents untreated C2C12 myotubes from reaching full maturity.-Hupkes, M., Jonsson, M. K. B., Scheenen, W. J., van Rotterdam, W., Sotoca, A. M., van Someren, E. P., van der Heyden, M. A. G., van Veen, T. A., van Ravestein-van Os, R. I., Bauerschmidt, S., Piek, E., Ypey, D. L., van Zoelen, E. J., Dechering, K. J. Epigenetics: DNA demethylation promotes skeletal myotube maturation. FASEB J. 25, 3861-3872 (2011). www.fasebj.org	[Hupkes, Marlinda; van Rotterdam, Walter; Sotoca, Ana M.; van Someren, Eugene P.; Piek, Ester; van Zoelen, Everardus J.; Dechering, Koen J.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Cell & Appl Biol, Fac Sci, NL-6525 AJ Nijmegen, Netherlands; [Scheenen, Wim J.] Radboud Univ Nijmegen, Dept Cellular Anim Physiol, Donders Ctr Neurosci, Fac Sci, NL-6525 AJ Nijmegen, Netherlands; [Jonsson, Malin K. B.; van der Heyden, Marcel A. G.; van Veen, Toon A.] Univ Med Ctr Utrecht, Dept Med Physiol, Div Heart & Lungs, Utrecht, Netherlands; [van Someren, Eugene P.] TNO, Dept Microbiol & Syst Biol, NL-3700 AJ Zeist, Netherlands; [van Ravestein-van Os, Roselinde I.; Bauerschmidt, Susanne; Dechering, Koen J.] Merck Res Labs, Oss, Netherlands; [Ypey, Dirk L.] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Netherlands Organization Applied Science Research; Merck & Company; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hupkes, M (corresponding author), Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Cell & Appl Biol, Fac Sci, Heyendaalseweg 135, NL-6525 AJ Nijmegen, Netherlands.	m.hupkes@science.ru.nl	Scheenen, Wim/E-3674-2012; van Zoelen, Everardus J./D-9192-2012	van der Heyden, Marcel/0000-0002-4225-7942; Jonsson, Malin/0000-0003-2986-2889	Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) [018.002.035]; Merck Sharp & Dohme (Oss, the Netherlands)	Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)(Netherlands Organization for Scientific Research (NWO)); Merck Sharp & Dohme (Oss, the Netherlands)(Netherlands GovernmentMerck & Company)	The authors thank Elisabeth Pierson (Department of General Instruments, Radboud University Nijmegen) for her expert assistance with the confocal and the DIC microscopes. This work was supported by a Casimir grant from the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO; project 018.002.035) and by Merck Sharp & Dohme (Oss, the Netherlands).	Aguirre-Arteta AM, 2000, CELL GROWTH DIFFER, V11, P551; Allegrucci C, 2007, HUM MOL GENET, V16, P1253, DOI 10.1093/hmg/ddm074; Almirza WHM, 2010, CELL CALCIUM, V47, P544, DOI 10.1016/j.ceca.2010.05.004; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berendse M, 2003, EXP CELL RES, V291, P435, DOI 10.1016/j.yexcr.2003.07.004; Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Brunk BP, 1996, DEV BIOL, V177, P490, DOI 10.1006/dbio.1996.0180; Buckingham M, 2006, CURR OPIN GENET DEV, V16, P525, DOI 10.1016/j.gde.2006.08.008; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Collas P, 2009, BBA-GEN SUBJECTS, V1790, P900, DOI 10.1016/j.bbagen.2008.10.006; Cooper ST, 2004, CELL MOTIL CYTOSKEL, V58, P200, DOI 10.1002/cm.20010; Cornelisse LN, 2002, J NEUROENDOCRINOL, V14, P778, DOI 10.1046/j.1365-2826.2002.00838.x; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; De Deyne PG, 2000, AM J PHYSIOL-CELL PH, V279, pC1801, DOI 10.1152/ajpcell.2000.279.6.C1801; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Ferrari MB, 1998, J CELL BIOL, V141, P1349, DOI 10.1083/jcb.141.6.1349; Ferrari MB, 2006, CELL BIOCHEM BIOPHYS, V45, P317, DOI 10.1385/CBB:45:3:317; Fujita H, 2007, EXP CELL RES, V313, P1853, DOI 10.1016/j.yexcr.2007.03.002; Fuso A, 2010, CELL CYCLE, V9, P3965, DOI 10.4161/cc.9.19.13193; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; GIOVANNELLI A, 1995, CELL CALCIUM, V18, P41, DOI 10.1016/0143-4160(95)90044-6; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Gowher H, 2004, CANCER BIOL THER, V3, P1062, DOI 10.4161/cbt.3.11.1308; GRASSI F, 1993, PFLUG ARCH EUR J PHY, V422, P591, DOI 10.1007/BF00374007; GROUSELLE M, 1991, PFLUG ARCH EUR J PHY, V418, P40, DOI 10.1007/BF00370450; Guasconi V, 2009, TRENDS CELL BIOL, V19, P286, DOI 10.1016/j.tcb.2009.03.002; Harris BN, 2005, CELL MOTIL CYTOSKEL, V60, P129, DOI 10.1002/cm.20054; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hupkes M, 2011, BBA-MOL CELL RES, V1813, P839, DOI 10.1016/j.bbamcr.2011.01.022; Jost JP, 2001, NUCLEIC ACIDS RES, V29, P4452, DOI 10.1093/nar/29.21.4452; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kablar B, 1999, DEV BIOL, V206, P219, DOI 10.1006/dbio.1998.9126; Kislinger T, 2005, MOL CELL PROTEOMICS, V4, P887, DOI 10.1074/mcp.M400182-MCP200; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Komashko Vitalina M, 2010, Epigenetics, V5, P229; Kontrogianni-Konstantopoulos A, 2006, AM J PHYSIOL-CELL PH, V290, pC626, DOI 10.1152/ajpcell.00442.2005; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; Lee KH, 1999, EXP CELL RES, V252, P401, DOI 10.1006/excr.1999.4648; Lee S, 2006, SEPAR SCI TECHNOL, V41, P1, DOI 10.1080/01496390500446426; Li HY, 2004, DEV DYNAM, V229, P231, DOI 10.1002/dvdy.10428; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; Lorenzon P, 2000, J PHYSIOL-LONDON, V525, P499, DOI 10.1111/j.1469-7793.2000.00499.x; Lorenzon P, 1997, EUR J NEUROSCI, V9, P800, DOI 10.1111/j.1460-9568.1997.tb01429.x; Lucarelli M, 2001, J BIOL CHEM, V276, P7500, DOI 10.1074/jbc.M008234200; Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Palacios D, 2006, J CELL PHYSIOL, V207, P1, DOI 10.1002/jcp.20489; Palacios D, 2010, MOL CELL BIOL, V30, P3805, DOI 10.1128/MCB.00050-10; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; Park H, 2008, J TISSUE ENG REGEN M, V2, P279, DOI 10.1002/term.93; Perdiguero E, 2009, EPIGENETICS-US, V4, P541, DOI 10.4161/epi.4.8.10258; Porter GA, 2002, J BIOL CHEM, V277, P28942, DOI 10.1074/jbc.M203961200; PURVES D, 1974, J PHYSIOL-LONDON, V239, P125, DOI 10.1113/jphysiol.1974.sp010559; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; SZENTGYORGYI AG, 1975, BIOPHYS J, V15, P707, DOI 10.1016/S0006-3495(75)85849-8; SZYF M, 1992, J BIOL CHEM, V267, P12831; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TESSERAUX I, 1987, N-S ARCH PHARMACOL, V336, P232, DOI 10.1007/BF00165810; Thelen MHM, 1997, BIOCHEM J, V321, P845, DOI 10.1042/bj3210845; THESLEFF S, 1975, J PHYSIOL-LONDON, V244, P313, DOI 10.1113/jphysiol.1975.sp010800; van Veen TAB, 2000, CARDIOVASC RES, V46, P496, DOI 10.1016/S0008-6363(00)00047-X; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Weng L, 2006, BIOINFORMATICS, V22, P1111, DOI 10.1093/bioinformatics/btl045; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zebedin E, 2007, AM J PHYSIOL-HEART C, V292, pH439, DOI 10.1152/ajpheart.00119.2006	75	55	58	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3861	3872		10.1096/fj.11-186122	http://dx.doi.org/10.1096/fj.11-186122			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21795504				2022-12-28	WOS:000296723100011
J	Esposito, D; Komarnytsky, S; Shapses, S; Raskin, I				Esposito, Debora; Komarnytsky, Slavko; Shapses, Sue; Raskin, Ilya			Anabolic effect of plant brassinosteroid	FASEB JOURNAL			English	Article						homobrassinolide; protein synthesis; muscle mass	GROWTH-FACTOR-I; ANDROGEN RECEPTOR; PROTEIN-SYNTHESIS; INSULIN; METABOLISM; EXPRESSION; VIRUS; VITRO; PHYTOECDYSTEROIDS; BRASSINOLIDE	Brassinosteroids are plant-derived polyhydroxylated derivatives of 5a-cholestane, structurally similar to cholesterol-derived animal steroid hormones and insect ecdysteroids, with no known function in mammals. 28-Homobrassinolide (HB), a steroidal lactone with potent plant growth-promoting property, stimulated protein synthesis and inhibited protein degradation in L6 rat skeletal muscle cells (EC50 4 mu M) mediated in part by PI3K/Akt signaling pathway. Oral administration of HB (20 or 60 mg/kg/d for 24 d) to healthy rats fed normal diet (protein content 23.9%) increased food intake, body weight gain, lean body mass, and gastrocnemius muscle mass as compared with vehicle-treated controls. The effect of HB administration increased slightly in animals fed a high-protein diet (protein content 39.4%). Both oral (up to 60 mg/kg) and subcutaneous (up to 4 mg/kg) administration of HB showed low androgenic activity when tested in the Hershberger assay. Moreover, HB showed no direct binding to the androgen receptor in vitro. HB treatment was also associated with an improved physical fitness of untrained healthy rats, as evident from a 6.7% increase in lower extremity strength, measured by grip test. In the gastrocnemius muscle of castrated animals, HB treatment significantly increased the number of type IIa and IIb fibers and the cross-sectional area of type I and type IIa fibers. These findings suggest that oral application of HB triggers selective anabolic response with minimal or no androgenic side-effects and begin to elucidate the putative cellular targets for plant brassinosteroids in mammals.-Esposito, D., Komarnytsky, S., Shapses, S., Raskin, I. Anabolic effect of plant brassinosteroid. FASEB J. 25, 3708-3719 (2011). www.fasebj.org	[Esposito, Debora; Komarnytsky, Slavko; Raskin, Ilya] Rutgers State Univ, Sch Environm & Biol Sci, Biotech Ctr, New Brunswick, NJ 08903 USA; [Shapses, Sue] Rutgers State Univ, Sch Environm & Biol Sci, Dept Nutr Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Komarnytsky, S (corresponding author), N Carolina State Univ, Plants Human Hlth Inst, FBNS, 600 Laureate Way, Kannapolis, NC 28081 USA.	komarnytsky@ncsu.edu	Komarnytsky, Slavko/A-9575-2009	Komarnytsky, Slavko/0000-0003-4665-4993; Shapses, Sue/0000-0002-3128-2325	U.S. National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome [1-P50 AT002776-01]; Fogarty International Center of the National Institutes of Health [U01 TW006674]; FOGARTY INTERNATIONAL CENTER [U01TW006674] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER	U.S. National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. David Lagunoff (New Jersey Medical School-University of Medicine and Dentistry of New Jersey, Newark, NJ, USA) for muscle histology and microscopic imaging. This work was supported in part by the U.S. National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome, grant 1-P50 AT002776-01, and Fogarty International Center of the National Institutes of Health grant U01 TW006674 for the International Cooperative Biodiversity Groups and Rutgers University.	Atherton PJ, 2010, AMINO ACIDS, V38, P1533, DOI 10.1007/s00726-009-0377-x; Bajguz A, 2000, PLANT PHYSIOL BIOCH, V38, P209, DOI 10.1016/S0981-9428(00)00733-6; Bajguz A, 2003, PHYTOCHEMISTRY, V62, P1027, DOI 10.1016/S0031-9422(02)00656-8; Bathori M, 2008, CURR MED CHEM, V15, P75, DOI 10.2174/092986708783330674; Castilla V, 2005, ANTIVIR RES, V68, P88, DOI 10.1016/j.antiviral.2005.07.007; CHANG CS, 1987, J STEROID BIOCHEM, V27, P123, DOI 10.1016/0022-4731(87)90303-7; Clouse SD, 2002, VITAM HORM, V65, P195, DOI 10.1016/S0083-6729(02)65065-4; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; Dhaubhadel S, 2002, PLANT J, V29, P681, DOI 10.1046/j.1365-313X.2002.01257.x; DOUGLAS RG, 1991, J CLIN INVEST, V88, P614, DOI 10.1172/JCI115346; Fawcett J, 2001, ARCH BIOCHEM BIOPHYS, V385, P357, DOI 10.1006/abbi.2000.2160; Feldkoren BI, 2005, J STEROID BIOCHEM, V94, P481, DOI 10.1016/j.jsbmb.2004.12.036; Frost RA, 2007, J APPL PHYSIOL, V103, P378, DOI 10.1152/japplphysiol.00089.2007; Fujioka S, 2003, ANNU REV PLANT BIOL, V54, P137, DOI 10.1146/annurev.arplant.54.031902.134921; Gorelick-Feldman J, 2008, J AGR FOOD CHEM, V56, P3532, DOI 10.1021/jf073059z; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HARPER JMM, 1987, J ENDOCRINOL, V112, P87, DOI 10.1677/joe.0.1120087; HERSHBERGER LG, 1953, P SOC EXP BIOL MED, V83, P175; IKEKAWA N, 1984, J CHROMATOGR, V290, P289, DOI 10.1016/S0021-9673(01)93583-6; Jean C, 2001, J NUTR, V131, P91, DOI 10.1093/jn/131.1.91; Kartal G, 2009, PLANT GROWTH REGUL, V58, P261, DOI 10.1007/s10725-009-9374-z; Kim TW, 2009, NAT CELL BIOL, V11, P1254, DOI 10.1038/ncb1970; Kizelsztein P, 2009, AM J PHYSIOL-ENDOC M, V296, pE433, DOI 10.1152/ajpendo.90772.2008; Kuhn CM, 2002, RECENT PROG HORM RES, V57, P411, DOI 10.1210/rp.57.1.411; Kulaeva O. N., 2009, BRASSINOSTEROIDS, P141; Kuzmitskii BB, 1991, TECHNICAL REPORT, P1; Layman DK, 2003, J NUTR, V133, P411, DOI 10.1093/jn/133.2.411; Li BG, 2005, INT J BIOCHEM CELL B, V37, P2207, DOI 10.1016/j.biocel.2005.04.008; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Malikova J, 2008, PHYTOCHEMISTRY, V69, P418, DOI 10.1016/j.phytochem.2007.07.028; MANDEL JL, 1974, NATURE, V251, P618, DOI 10.1038/251618a0; Massey A. P., 2003, SYNTHESIS-STUTTGART, P0426; Michelini FM, 2008, J STEROID BIOCHEM, V108, P164, DOI 10.1016/j.jsbmb.2007.10.002; Michelini FM, 2004, STEROIDS, V69, P713, DOI 10.1016/j.steroids.2004.04.011; Mohler ML, 2009, J MED CHEM, V52, P3597, DOI 10.1021/jm900280m; Montgomery J. L., 2002, Methods in Cell Science, V24, P123, DOI 10.1023/A:1024498316958; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murkunde YV, 2010, INT J TOXICOL, V29, P517, DOI 10.1177/1091581810375620; Mussig C, 2005, PLANT BIOLOGY, V7, P110, DOI 10.1055/s-2005-837493; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nemhauser JL, 2004, J EXP BOT, V55, P265, DOI 10.1093/jxb/erh024; Oehme I, 2006, CELL DEATH DIFFER, V13, P189, DOI 10.1038/sj.cdd.4401730; Pushkala K, 2001, CYTOBIOS, V106, P201; Rahman F, 2007, TRENDS ENDOCRIN MET, V18, P371, DOI 10.1016/j.tem.2007.09.004; Romanutti C, 2007, INT J ANTIMICROB AG, V29, P311, DOI 10.1016/j.ijantimicag.2006.11.005; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; TAKATSUTO S, 1984, J CHEM SOC PERK T 1, P439, DOI 10.1039/p19840000439; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Wachsman MB, 2000, ANTIVIR CHEM CHEMOTH, V11, P71, DOI 10.1177/095632020001100107; Wachsman Monica B., 2002, Antiviral Chemistry & Chemotherapy, V13, P61; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Watanabe T, 2000, J CHEM RES, P18; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200	59	25	26	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3708	3719		10.1096/fj.11-181271	http://dx.doi.org/10.1096/fj.11-181271			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746867	Green Published			2022-12-28	WOS:000295356400039
J	Liu, ZH; Ciappio, ED; Crott, JW; Brooks, RS; Nesvet, J; Smith, DE; Choi, SW; Mason, JB				Liu, Zhenhua; Ciappio, Eric D.; Crott, Jimmy W.; Brooks, Ryan S.; Nesvet, Jared; Smith, Donald E.; Choi, Sang-Woon; Mason, Joel B.			Combined inadequacies of multiple B vitamins amplify colonic Wnt signaling and promote intestinal tumorigenesis in BAT-LacZ X Apc1638N mice	FASEB JOURNAL			English	Article						colorectal cancer; folate; methylation	EPIGENETIC INACTIVATION; DIETARY-FOLATE; DNA METHYLATION; CANCER; DEFICIENCY; APC; RISK; GENE; EXPRESSION; MUTATION	The Wnt pathway is a pivotal signaling cascade in colorectal carcinogenesis. The purpose of this work is to determine whether depletion of folate and other metabolically related B vitamins induces in vivo activation of intestinal Wnt signaling and whether this occurs in parallel with increased tumorigenesis. A hybrid mouse was created by crossing a Wnt-reporter animal (BAT-LacZ) with a model of colorectal cancer (Apc1638N). A mild depletion of folate and vitamins B-2, B-6, and B-12 was induced over 16 wk, and the control animals in each instance were pair fed a diet containing the basal requirement of these nutrients. The multiplicity of macroscopic tumors and aberrant crypt foci both increased by similar to 50% in the hybrid mice fed the depletion diet (P<0.05). A 4-fold elevation in Wnt signaling was produced by the depletion diet (P<0.05) and was accompanied by significant changes in the expression of a number of Wnt-related genes in a pattern consistent with its activation. Proliferation and apoptosis of the colonic mucosa both changed in a protrans-formational direction (P<0.05). In summary, mild depletion of multiple B vitamins produces in vivo activation of colonic Wnt signaling, implicating it as a key pathway by which B-vitamin inadequacies enhance intestinal tumorigenesis.-Liu, Z., Ciappio, E. D., Crott, J. W., Brooks, R. S., Nesvet, J., Smith, D. E., Choi, S.-W., Mason, J. B. Combined inadequacies of multiple B vitamins amplify colonic Wnt signaling and promote intestinal tumorigenesis in BAT-LacZ X Apc1638N mice. FASEB J. 25, 3136-3145 (2011). www.fasebj.org	[Liu, Zhenhua] Tufts Univ, USDA Human Nutr Res Ctr Aging, Vitamins & Carcinogenesis Lab, Boston, MA 02111 USA; [Smith, Donald E.] Tufts Univ, Comparat Biol Unit, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Liu, Zhenhua; Crott, Jimmy W.; Choi, Sang-Woon; Mason, Joel B.] Tufts Univ, Tufts Med Ctr, Ctr Canc, Boston, MA 02111 USA; [Ciappio, Eric D.; Mason, Joel B.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA; [Mason, Joel B.] Tufts Univ, Div Clin Nutr & Gastroenterol, Tufts Med Ctr, Boston, MA 02111 USA; [Nesvet, Jared] Univ Rochester, Dept Biochem & Biophys, Rochester, NY USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; Tufts Medical Center; Tufts University; Tufts University; Tufts Medical Center; Tufts University; University of Rochester	Liu, ZH (corresponding author), Tufts Univ, USDA Human Nutr Res Ctr Aging, Vitamins & Carcinogenesis Lab, 711 Washington St, Boston, MA 02111 USA.	zhenhua.liu@tufts.edu			Prevent Cancer Foundation; U.S. National Institutes of Health [R21 ES019102]; USDA Agricultural Research Service [1950-074-01S]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES019102] Funding Source: NIH RePORTER	Prevent Cancer Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by the Prevent Cancer Foundation (to Z.L.), U.S. National Institutes of Health grant R21 ES019102 (to J.B.M.), and the USDA Agricultural Research Service (agreement 1950-074-01S). Any opinions, findings, conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Arnold CN, 2004, CANCER BIOL THER, V3, P960, DOI 10.4161/cbt.3.10.1113; Bailey RL, 2010, AM J CLIN NUTR, V91, P231, DOI 10.3945/ajcn.2009.28427; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Carter M, 2005, P NATL ACAD SCI USA, V102, P12843, DOI 10.1073/pnas.0501963102; Choi SW, 2004, J NUTR, V134, P750, DOI 10.1093/jn/134.4.750; Choi SW, 2003, J NUTR, V133, P1206, DOI 10.1093/jn/133.4.1206; CLIFFORD AJ, 1989, J NUTR, V119, P1956, DOI 10.1093/jn/119.12.1956; Davies PS, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-57; Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002; EUSSEN SJ, CANC EPIDEMIOL BIOMA, V19, P2549; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fuchs CS, 2002, CANCER EPIDEM BIOMAR, V11, P227; GIOVANNUCCI E, 2002, J NUTR, V132, P2355; Han SP, 2009, INT J MOL MED, V23, P321, DOI 10.3892/ijmm_00000134; Henderson L., 2004, NATL DIET NUTR SURVE; Kathe SD, 2004, J BIOL CHEM, V279, P18511, DOI 10.1074/jbc.M313598200; Katula KS, 2007, J NUTR BIOCHEM, V18, P541, DOI 10.1016/j.jnutbio.2006.11.002; Kim YI, 2004, ENVIRON MOL MUTAGEN, V44, P10, DOI 10.1002/em.20025; Kim YI, 2000, GASTROENTEROLOGY, V119, P151, DOI 10.1053/gast.2000.8518; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; Liu ZH, 2007, J NUTR, V137, P2701, DOI 10.1093/jn/137.12.2701; Mackey AD, 2003, J NUTR, V133, P1362; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mason JB, 2009, NUTR REV, V67, P206, DOI 10.1111/j.1753-4887.2009.00190.x; NICHOALDS GE, 1974, CLIN CHEM, V20, P624; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBROIN S, 1992, J CLIN PATHOL, V45, P344, DOI 10.1136/jcp.45.4.344; Planells E, 2003, EUR J CLIN NUTR, V57, P777, DOI 10.1038/sj.ejcn.1601610; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Song J, 2000, CANCER RES, V60, P5434; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932; Wei EK, 2005, J NATL CANCER I, V97, P684, DOI 10.1093/jnci/dji116; Yang K, 1998, CANCER RES, V58, P5713; Yang WC, 2001, CANCER RES, V61, P565; Yates CA, 2001, BRIT J NUTR, V86, P593, DOI 10.1079/BJN2001420; Ye F, 2009, NAT NEUROSCI, V12, P829, DOI 10.1038/nn.2333	50	13	14	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3136	3145		10.1096/fj.11-184143	http://dx.doi.org/10.1096/fj.11-184143			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21646397	Green Published			2022-12-28	WOS:000294435200027
J	Cotan, D; Cordero, MD; Garrido-Maraver, J; Oropesa-Avila, M; Rodriguez-Hernandez, A; Izquierdo, LG; De la Mata, M; De Miguel, M; Lorite, JB; Infante, ER; Jackson, S; Navas, P; Sanchez-Alcazar, JA				Cotan, David; Cordero, Mario D.; Garrido-Maraver, Juan; Oropesa-Avila, Manuel; Rodriguez-Hernandez, Angeles; Gomez Izquierdo, Lourdes; De la Mata, Mario; De Miguel, Manuel; Bautista Lorite, Juan; Rivas Infante, Eloy; Jackson, Sandra; Navas, Placido; Sanchez-Alcazar, Jose A.			Secondary coenzyme Q(10) deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts	FASEB JOURNAL			English	Article						autophagy; free radicals; mitochondrial diseases	STROKE-LIKE EPISODES; TRANSFER RNALEU(UUR) GENE; PERMEABILITY TRANSITION; LACTIC-ACIDOSIS; PROTEIN-SYNTHESIS; TRANSFER-RNA; CELL-DEATH; AUTOPHAGY; MUTATION; DNA	Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a mitochondrial disease most usually caused by point mutations in tRNA genes encoded by mtDNA. Here, we report on how this mutation affects mitochondrial function in primary fibroblast cultures established from 2 patients with MELAS who harbored the A3243G mutation. Both mitochondrial respiratory chain enzyme activities and coenzyme Q(10) (CoQ) levels were significantly decreased in MELAS fibroblasts. A similar decrease in mitochondrial membrane potential was found in intact MELAS fibroblasts. Mitochondrial dysfunction was associated with increased oxidative stress and the activation of mitochondrial permeability transition (MPT), which triggered the degradation of impaired mitochondria. Furthermore, we found defective autophagosome elimination in MELAS fibroblasts. Electron and fluorescence microscopy studies confirmed a massive degradation of mitochondria and accumulation of autophagosomes, suggesting mitophagy activation and deficient autophagic flux. Transmitochondrial cybrids harboring the A3243G mutation also showed CoQ deficiency and increased autophagy activity. All these abnormalities were partially restored by CoQ supplementation. Autophagy in MELAS fibroblasts was also abolished by treatment with antioxidants or cyclosporine, suggesting that both reactive oxygen species and MPT participate in this process. Furthermore, prevention of autophagy in MELAS fibroblasts resulted in apoptotic cell death, suggesting a protective role of autophagy in MELAS fibroblasts.-Cotan, D., Cordero, M. D., Garrido-Maraver, J., Oropesa-Avila, M., Rodriguez-Hernandez, A., Gomez Izquierdo, L., De la Mata, M., De Miguel, M., Bautista Lorite, J., Rivas Infante, E., Jackson, S., Navas, P., Sanchez-Alcazar, J. A. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J. 25, 2669-2687 (2011). www.fasebj.org	[Cotan, David; Cordero, Mario D.; Garrido-Maraver, Juan; Oropesa-Avila, Manuel; Rodriguez-Hernandez, Angeles; De la Mata, Mario; Navas, Placido; Sanchez-Alcazar, Jose A.] Univ Pablo Olavide, Consejo Super Invest Cient, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain; [Cotan, David; Cordero, Mario D.; Garrido-Maraver, Juan; Oropesa-Avila, Manuel; Rodriguez-Hernandez, Angeles; De la Mata, Mario; Navas, Placido; Sanchez-Alcazar, Jose A.] Univ Pablo Olavide, Consejo Super Invest Cient, Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Seville 41013, Spain; [Gomez Izquierdo, Lourdes] Hosp Virgen Rocio, Dept Anat Patol, Seville, Spain; [De Miguel, Manuel] Univ Seville, Fac Med, Dept Citol & Histol Normal & Patol, Seville, Spain; [Bautista Lorite, Juan] Hosp Sagrado Corazon, Seville, Spain; [Jackson, Sandra] Uniklinikum CG Carus, Dept Neurol, Dresden, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; Universidad Pablo de Olavide; Virgen del Rocio University Hospital; University of Sevilla; Technische Universitat Dresden	Sanchez-Alcazar, JA (corresponding author), Univ Pablo Olavide, Consejo Super Invest Cient, Ctr Andaluz Biol Desarrollo, Carretera Utrera Km 1, Seville 41013, Spain.	jasanalc@upo.es	De-Miguel, Manuel/B-3713-2017; NAVAS, PLACIDO/R-5943-2019; GARRIDO-MARAVER, JUAN/S-3846-2016; IBIS, TERAPIA CELULA/P-3297-2015; Sanchéz-Alcázar, José A. A/L-4925-2014; IBIS, NEUROCIENCIAS/C-2262-2016; Rodríguez-Hernández, Ángeles/K-9717-2015; DE LA MATA, MARIO DE-LA-MATA MARIODELAMATA/O-8844-2015; Cordero, Mario D./L-8006-2014; De la Mata, Mario/I-8800-2017; IBIS, ENF. RESPIRATO/P-3887-2015	De-Miguel, Manuel/0000-0002-6751-1695; NAVAS, PLACIDO/0000-0002-4115-7966; GARRIDO-MARAVER, JUAN/0000-0003-4534-4109; Sanchéz-Alcázar, José A. A/0000-0001-9705-1469; Rodríguez-Hernández, Ángeles/0000-0003-1846-0606; DE LA MATA, MARIO DE-LA-MATA MARIODELAMATA/0000-0003-1640-7887; Cordero, Mario D./0000-0003-0151-3644; De la Mata, Mario/0000-0003-1640-7887; Gomez-Izquierdo, Lourdes/0000-0001-5918-2134; Rivas Infante, Eloy/0000-0001-6014-8048	Ministerio de Sanidad, Spain [FIS PI080500, FIS EC08/00076]; Asociacion de Enfermos de Patologia Mitocondrial (AEPMI); Fundacion Espanola de Enfermedades Lisosomales (FEEL); Colegio Oficial de Farmaceuticos de Sevilla	Ministerio de Sanidad, Spain(Spanish Government); Asociacion de Enfermos de Patologia Mitocondrial (AEPMI); Fundacion Espanola de Enfermedades Lisosomales (FEEL); Colegio Oficial de Farmaceuticos de Sevilla	This work was supported by Ministerio de Sanidad, Spain, grants FIS PI080500 and FIS EC08/00076, and by Asociacion de Enfermos de Patologia Mitocondrial (AEPMI) and Fundacion Espanola de Enfermedades Lisosomales (FEEL). M. de la Mata is the recipient of a fellowship from Colegio Oficial de Farmaceuticos de Sevilla. This group was founded by the Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII). The authors thank Pilar Jaraquemada, Loren Valbuena, Jose Maria Sanabria, Miguel Angel Martin, and Alberto Blazquez for their collaboration on the manuscript.	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006; Armstrong JS, 2003, J BIOL CHEM, V278, P49079, DOI 10.1074/jbc.M307841200; Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Cordero MD, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2918; Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje; Davidson MM, 2009, MITOCHONDRION, V9, P463, DOI 10.1016/j.mito.2009.08.006; de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x; Forte M, 2005, J BIOENERG BIOMEMBR, V37, P121, DOI 10.1007/s10863-005-6565-9; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Gottlieb RA, 2010, ANNU REV PHYSIOL, V72, P45, DOI 10.1146/annurev-physiol-021909-135757; Gu YP, 2004, FEBS LETT, V577, P357, DOI 10.1016/j.febslet.2004.10.040; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Molyneux Sarah L, 2008, Clin Biochem Rev, V29, P71; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; PLOMP PJAM, 1989, J BIOL CHEM, V264, P6699; Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092; Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113; Rodriguez-Hernandez A, 2009, AUTOPHAGY, V5, P19, DOI 10.4161/auto.5.1.7174; Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Sasarman F, 2008, HUM MOL GENET, V17, P3697, DOI 10.1093/hmg/ddn265; SCHELLENS JPM, 1991, HISTOCHEM J, V23, P460, DOI 10.1007/BF01041376; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011; Tafrechi RSJ, 2005, MUTAT RES-FUND MOL M, V578, P43, DOI 10.1016/j.mrfmmm.2005.02.002; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vergarajauregui S, 2008, HUM MOL GENET, V17, P2723, DOI 10.1093/hmg/ddn174; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	106	108	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2669	2687		10.1096/fj.10-165340	http://dx.doi.org/10.1096/fj.10-165340			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21551238				2022-12-28	WOS:000293337800017
J	Neves, AA; Stockmann, H; Harmston, RR; Pryor, HJ; Alam, IS; Ireland-Zecchini, H; Lewis, DY; Lyons, SK; Leeper, FJ; Brindle, KM				Neves, Andre A.; Stoeckmann, Henning; Harmston, Rebecca R.; Pryor, Helen J.; Alam, Israt S.; Ireland-Zecchini, Heather; Lewis, David Y.; Lyons, Scott K.; Leeper, Finian J.; Brindle, Kevin M.			Imaging sialylated tumor cell glycans in vivo	FASEB JOURNAL			English	Article						sialic acid; metabolic labeling; fluorescence imaging; SPECT	FREE CLICK CHEMISTRY; SIALIC-ACID; LIVING ANIMALS; CANCER METASTASIS; BREAST-CANCER; GLYCOSYLATION; EXPRESSION; CARCINOMA; SURVIVAL; ADENOCARCINOMA	Cell surface glycans are involved in numerous physiological processes that involve cell-cell interactions and migration, including lymphocyte trafficking and cancer metastasis. We have used a bioorthogonal metabolic labeling strategy to detect cell surface glycans and demonstrate, for the first time, fluorescence and radionuclide imaging of sialylated glycans in a murine tumor model in vivo. Peracetylated azido-labeled N-acetyl-mannosamine, injected intraperitoneally, was used as the metabolic precursor for the biosynthesis of 5-azidoneuraminic, or azidosialic acid. Azidosialic acid-labeled cell surface glycans were then reacted, by Staudinger ligation, with a biotinylated phosphine injected intraperitoneally, and the biotin was detected by subsequent intravenous injection of a fluorescent or radiolabeled avidin derivative. At 24 h after administration of NeutrAvidin, labeled with either a far-red fluorophore or (111)In, there was a significant azido-labeled N-acetyl-mannosamine-dependent increase in tumor-to-tissue contrast, which was detected using optical imaging or single-photon-emission computed tomography (SPECT), respectively. The technique has the potential to translate to the clinic, where, given the prognostic relevance of altered sialic acid expression in cancer, it could be used to monitor disease progression.-Neves, A. A., Stockmann, H., Harmston, R. R., Pryor, H. J., Alam, I. S., Ireland-Zecchini, H., Lewis, D. Y., Lyons, S. K., Leeper, F. J., Brindle, K. M. Imaging sialylated tumor cell glycans in vivo. FASEB J. 25, 2528-2537 (2011). www.fasebj.org	[Brindle, Kevin M.] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; [Stoeckmann, Henning; Leeper, Finian J.] Univ Cambridge, Dept Chem, Cambridge CB2 1GA, England; [Neves, Andre A.; Stoeckmann, Henning; Harmston, Rebecca R.; Pryor, Helen J.; Alam, Israt S.; Ireland-Zecchini, Heather; Lewis, David Y.; Lyons, Scott K.; Brindle, Kevin M.] Li Ka Shing Ctr, Cambridge Res Inst, Canc Res UK, Cambridge, England	University of Cambridge; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.	kmb1001@cam.ac.uk	Lewis, David/AAN-9235-2021; Leeper, Finian/B-4842-2012; Neves, Andre/B-8397-2011; Stockmann, Henning/A-1891-2012	Neves, Andre/0000-0003-2740-5166; Lyons, Scott/0000-0003-0139-6054; Lewis, David/0000-0001-9329-1326; Leeper, Finian James/0000-0003-3408-5199; Stockmann, Henning/0000-0002-2409-5476	Cancer Research UK; Cancer Research UK [6934] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	H.S. and I.S.A. were recipients of Cancer Research UK Ph.D. studentships. A.A.N. thanks Kwasi Agyei-Owusu, James Kelly, and Hiral Bhalara for advice on synthetic methods. The authors thank De-En Hu and Sarah Fawcett for support with animal procedures, Mikko Kettunen for advice on imaging, and Joan Boren for support on flow cytometric imaging. The authors acknowledge Kishor Solanki, Chandra Solanki, and Sarah Heard (Nuclear Medicine Department, Addenbrooke's Hospital, Cambridge, UK) for kind logistical support in the SPECT studies. This work was supported by a Cancer Research UK program grant to K.M.B. The authors declare no competing financial interests.	Baskin JM, 2007, P NATL ACAD SCI USA, V104, P16793, DOI 10.1073/pnas.0707090104; Becker A, 2000, PHOTOCHEM PHOTOBIOL, V72, P234, DOI 10.1562/0031-8655(2000)072<0234:MCAFOI>2.0.CO;2; BERNACKI RJ, 1977, SCIENCE, V195, P577, DOI 10.1126/science.835014; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; BRENNAN MJ, 1986, INFECT IMMUN, V52, P840, DOI 10.1128/IAI.52.3.840-845.1986; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Chang PV, 2010, P NATL ACAD SCI USA, V107, P1821, DOI 10.1073/pnas.0911116107; Chiang CH, 2010, J CELL PHYSIOL, V223, P492, DOI 10.1002/jcp.22068; DENNIS J, 1982, NATURE, V300, P274, DOI 10.1038/300274a0; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Du J, 2009, GLYCOBIOLOGY, V19, P1382, DOI 10.1093/glycob/cwp115; Dube DH, 2006, P NATL ACAD SCI USA, V103, P4819, DOI 10.1073/pnas.0506855103; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; Fukuda M, 1996, CANCER RES, V56, P2237; Goetz M, 2010, GASTROENTEROLOGY, V138, P828, DOI 10.1053/j.gastro.2010.01.009; Gold DV, 2007, CLIN CANCER RES, V13, P7380, DOI 10.1158/1078-0432.CCR-07-1488; Granovsky M, 2000, NAT MED, V6, P306; Hedlund M, 2008, CANCER RES, V68, P388, DOI 10.1158/0008-5472.CAN-07-1340; Hsiung PL, 2008, NAT MED, V14, P454, DOI 10.1038/nm1692; Igarashi Y, 2010, J BIOCHEM, V147, P3, DOI 10.1093/jb/mvp195; INOKUCHI J, 1990, CANCER RES, V50, P6731; Jung T, 2010, METHODS MOL BIOL, V594, P173, DOI 10.1007/978-1-60761-411-1_13; Kobayashi H, 2004, CLIN CANCER RES, V10, P7712, DOI 10.1158/1078-0432.CCR-04-1175; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Laughlin ST, 2008, SCIENCE, V320, P664, DOI 10.1126/science.1155106; Laughlin ST, 2009, ACS CHEM BIOL, V4, P1068, DOI 10.1021/cb900254y; Laughlin ST, 2009, P NATL ACAD SCI USA, V106, P12, DOI 10.1073/pnas.0811481106; Lemieux GA, 1999, J AM CHEM SOC, V121, P4278, DOI 10.1021/ja984228m; Leroy X, 2006, ANN PATHOL, V26, P257, DOI 10.1016/S0242-6498(06)70718-0; Luchansky SJ, 2004, BIOCHEMISTRY-US, V43, P12358, DOI 10.1021/bi049274f; Luker GD, 2008, J NUCL MED, V49, P1, DOI 10.2967/jnumed.107.045799; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417; Medarova Z, 2009, CANCER RES, V69, P1182, DOI 10.1158/0008-5472.CAN-08-2001; Medina LA, 2004, NUCL MED BIOL, V31, P41, DOI 10.1016/S0969-8051(03)00122-7; MILES DW, 1994, BRIT J CANCER, V70, P1272, DOI 10.1038/bjc.1994.486; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MURAYAMA K, 1986, CANCER RES, V46, P1395; NAKAMORI S, 1993, CANCER RES, V53, P3632; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Prescher JA, 2004, NATURE, V430, P873, DOI 10.1038/nature02791; Satoh H, 1997, CLIN CANCER RES, V3, P495; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Schauer R, 2004, ZOOLOGY, V107, P49, DOI 10.1016/j.zool.2003.10.002; Schneider F, 2001, CANCER RES, V61, P4605; Sletten EM, 2009, ANGEW CHEM INT EDIT, V48, P6974, DOI 10.1002/anie.200900942; Stockmann H, 2011, CHEM SCI, V2, P932, DOI 10.1039/c0sc00631a; Szymanski CM, 2005, NAT REV MICROBIOL, V3, P225, DOI 10.1038/nrmicro1100; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Varki A, 2008, TRENDS MOL MED, V14, P351, DOI 10.1016/j.molmed.2008.06.002; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9; Wahrenbrock MG, 2006, CANCER RES, V66, P2433, DOI 10.1158/0008-5472.CAN-05-3851; Yu CJ, 1996, ONCOLOGY, V53, P118	54	64	65	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2528	2537		10.1096/fj.10-178590	http://dx.doi.org/10.1096/fj.10-178590			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21493886				2022-12-28	WOS:000293337800004
J	Atefi, G; Zetoune, FS; Herron, TJ; Jalife, J; Bosmann, M; Al-Aref, R; Sarma, JV; Ward, PA				Atefi, Gelareh; Zetoune, Firas S.; Herron, Todd J.; Jalife, Jose; Bosmann, Markus; Al-Aref, Rami; Sarma, J. Vidya; Ward, Peter A.			Complement dependency of cardiomyocyte release of mediators during sepsis	FASEB JOURNAL			English	Article						cytokines; cytokine receptors; C5a; IL-17A; cardiomyopathy	NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; MITOCHONDRIAL DYSFUNCTION; TNF-ALPHA; CALCIUM; C5A; INTERLEUKIN-1-BETA; PATHOGENESIS; ACTIVATION	We have recently shown that antibody-induced blockade of C5a, C5a receptors, or IL-17A greatly reduced the harmful outcomes of sepsis. In the current study, normal cardiomyocytes from young (300 g) male Sprague-Dawley rats responded in vitro to C5a (ED50 = 55 nM) with release of IL-6 and TNF alpha, peaking between 2 to 8 h. Neutralizing antibodies to mouse C5a or IL-17A (ED50 = 40 mu g for each, based on improved survival) reduced spontaneous in vitro release of cardiosuppressive cytokines and chemokines in cardiomyocytes obtained from mice with polymicrobial sepsis. A non-neutralizing C5a antibody had no such effects. Cardiomyocytes from septic mice (C57B1/6) showed increased mRNA for TNFR1, IL-6 (gp80), and C5aR at 6 h after sepsis. Cardiomyocytes from septic C5aR(-/-) or C5L2(-/-) mice did not show spontaneous in vitro release of cytokines and chemokines. These data suggest that cardiomyocytes from septic mice release suppressive cytokines in a C5a-, C5aR-, and IL-17A-dependent manner, followed by mediator reactivity with receptors on cardiomyocytes, resulting in defective contractility and relaxation. These data may be relevant to a strategy for the treatment of heart dysfunction developing during sepsis.-Atefi, G., Zetoune, F. S., Herron, T. J., Jalife, J., Bosmann, M., Chen, A., Al-Aref, R., Sarma, J. V., Ward, P. A. Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB J. 25, 2500-2508 (2011). www.fasebj.org	[Atefi, Gelareh; Zetoune, Firas S.; Bosmann, Markus; Al-Aref, Rami; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Herron, Todd J.; Jalife, Jose] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Herron, Todd J.; Jalife, Jose] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd,Box 5602, Ann Arbor, MI 48109 USA.	pward@umich.edu	Jalife, Jose/L-4833-2015; Jalife, Jose/AAJ-9156-2021	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500; Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health [GM-61656, GM-29507, HL-31963, NHLBI-T32-HL007517-28]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963, T32HL007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029507, R01GM061656, R37GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was sponsored by U.S. National Institutes of Health grants GM-61656, GM-29507, and HL-31963 to P. A. W. and NHLBI-T32-HL007517-28 to G. A.	Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Ballard-Croft C, 2004, J APPL PHYSIOL, V97, P1470, DOI 10.1152/japplphysiol.01149.2003; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; Buras JA, 2004, IMMUNOBIOLOGY, V209, P629, DOI 10.1016/j.imbio.2004.09.004; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; CLOWES GHA, 1966, ANN SURG, V163, P866, DOI 10.1097/00000658-196606000-00008; Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; Flierl MA, 2008, MOL MED, V14, P327, DOI 10.2119/2007-00130.Flierl; Gellerich FN, 2002, BIOSCIENCE REP, V22, P99, DOI 10.1023/A:1016017224003; Harrois A, 2009, CURR OPIN ANESTHESIO, V22, P143, DOI 10.1097/ACO.0b013e328328d1cc; Herron TJ, 2007, CIRC RES, V100, P1182, DOI 10.1161/01.RES.0000264102.00706.4e; Huber-Lang MS, 2001, FASEB J, V15, P568; Janssen SPM, 2005, CIRCULATION, V111, P996, DOI 10.1161/01.CIR.0000156469.96135.0D; Joulin O, 2007, PHYSIOL RES, V56, P291, DOI 10.33549/physiolres.930946; Kumar A, 2007, CRIT CARE MED, V35, P358, DOI 10.1097/01.CCM.0000254341.87098.A4; Maass DL, 2002, SHOCK, V18, P360, DOI 10.1097/00024382-200210000-00012; Maass DL, 2002, SHOCK, V17, P293, DOI 10.1097/00024382-200204000-00009; Niederbichler AD, 2006, J EXP MED, V203, P53, DOI 10.1084/jem.20051207; Pacher P, 2007, CARDIOVASC DRUG REV, V25, P235, DOI 10.1111/j.1527-3466.2007.00018.x; PARRILLO JE, 1985, J CLIN INVEST, V76, P1539, DOI 10.1172/JCI112135; Rabuel C, 2006, INTENS CARE MED, V32, P799, DOI 10.1007/s00134-006-0142-5; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Singh MV, 2009, J CLIN INVEST, V119, P986, DOI 10.1172/JCI35814; Soriano FG, 2006, CRIT CARE MED, V34, P1073, DOI 10.1097/01.CCM.0000206470.47721.8D; Thompson M, 2000, PEDIATR RES, V47, P669, DOI 10.1203/00006450-200005000-00019; Ward PA, 2009, NAT MED, V15, P497, DOI 10.1038/nm0509-497	30	42	43	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2500	2508		10.1096/fj.11-183236	http://dx.doi.org/10.1096/fj.11-183236			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478262	Green Submitted, Green Published			2022-12-28	WOS:000292242200040
J	Xiao, ZS; Dallas, M; Qiu, N; Nicolella, D; Cao, L; Johnson, M; Bonewald, L; Quarles, LD				Xiao, Zhousheng; Dallas, Mark; Qiu, Ni; Nicolella, Daniel; Cao, Li; Johnson, Mark; Bonewald, Lynda; Quarles, L. Darryl			Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice	FASEB JOURNAL			English	Article						polycystin-1; mechanical loading; fluid flow	POLYCYSTIC KIDNEY-DISEASE; FLUID SHEAR; ESTROGEN-RECEPTOR; MECHANICAL STRAIN; GENE-PRODUCT; BONE-CELLS; IN-VIVO; PARATHYROID-HORMONE; EARLY RESPONSES; PRIMARY CILIUM	We investigated whether polycystin-1 is a bone mechanosensor. We conditionally deleted Pkd1 in mature osteoblasts/osteocytes by crossing Dmp1-Cre with Pkd1(flox/m1Bei) mice, in which the m1Bei allele is nonfunctional. We assessed in wild-type and Pkd1-deficient mice the response to mechanical loading in vivo by ulna loading and ex vivo by measuring the response of isolated osteoblasts to fluid shear stress. We found that conditional Pkd1 heterozygotes (Dmp1-Cre; Pkd1(flox/+)) and null mice (Pkd1(Dmp1-cKO)) exhibited a similar to 40 and similar to 90% decrease, respectively, in functional Pkd1 transcripts in bone. Femoral bone mineral density (12 vs. 27%), trabecular bone volume (32 vs. 48%), and cortical thickness (6 vs. 17%) were reduced proportionate to the reduction of Pkd1 gene dose, as were mineral apposition rate (MAR) and expression of Runx2-II, Osteocalcin, Dmp1, and Phex. Anabolic load-induced periosteal lamellar MAR (0.58 +/- 0.14; Pkd1(Dmp1-cKO) vs. 1.68 +/- 0.34 mu m/d; control) and increases in Cox-2, c-Jun, Wnt10b, Axin2, and Runx2-II gene expression were significantly attenuated in Pkd1(Dmp1-cKO) mice compared with controls. Application of fluid shear stress to immortalized osteoblasts from Pkd1(null/null) and Pkd1(m1Bei/m1Bei)-derived osteoblasts failed to elicit the increments in cytosolic calcium observed in wild-type controls. These data indicate that polycystin-1 is essential for the anabolic response to skeletal loading in osteoblasts/osteocytes.-Xiao, Z., Dallas, M., Qiu, N., Nicolella, D., Cao, L., Johnson, M., Bonewald, L., Quarles, L. D. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J. 25, 2418-2432 (2011). www.fasebj.org	[Xiao, Zhousheng; Qiu, Ni; Cao, Li; Quarles, L. Darryl] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38165 USA; [Dallas, Mark; Johnson, Mark; Bonewald, Lynda] Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO USA; [Nicolella, Daniel] SW Res Inst, San Antonio, TX USA	University of Tennessee System; University of Tennessee Health Science Center; University of Missouri System; University of Missouri Kansas City; Southwest Research Institute	Xiao, ZS (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38165 USA.	zxiao2@uthsc.edu; dquarles@uthsc.edu	Bonewald, Lynda/Q-3638-2019	xiao, zhousheng/0000-0002-3363-5673; Quarles, L. Darryl/0000-0002-5082-7896	U.S. National Institutes of Health [R01-DK083303, R21-AR056794, P01-AR46798]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR046798, R21AR056794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083303] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants R01-DK083303 to L. D. Q., R21-AR056794 to Z.S.X., and P01-AR46798 to L.F.B.	Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200; Akhter MP, 2004, BONE, V35, P162, DOI 10.1016/j.bone.2004.02.018; Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200; Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388; Bonewald L. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P239; Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224; Bonewald LF, 2007, CELL METAB, V5, P410, DOI 10.1016/j.cmet.2007.05.008; Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Bravenboer N, 2001, J ORTHOP RES, V19, P945, DOI 10.1016/S0736-0266(01)00026-2; Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200; Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH-24.1593; Chen YJ, 2008, CONNECT TISSUE RES, V49, P7, DOI 10.1080/03008200701818561; Cherian PP, 2003, J BIOL CHEM, V278, P43146, DOI 10.1074/jbc.M302993200; Cowin SC, 1998, BONE, V22, p119S, DOI 10.1016/S8756-3282(98)00011-8; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Garcia M, 2010, J ORTHOP RES, V28, P510, DOI 10.1002/jor.21025; Gattone VH, 2009, J AM SOC NEPHROL, V20, P1527, DOI 10.1681/ASN.2008090927; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Grimston SK, 2008, J BONE MINER RES, V23, P879, DOI [10.1359/jbmr.080222, 10.1359/JBMR.080222]; Gu GL, 2005, BIOCHEM BIOPH RES CO, V335, P1095, DOI 10.1016/j.bbrc.2005.06.211; Haasper C, 2008, EXP TOXICOL PATHOL, V59, P355, DOI [10.1016/j.etp.2007.11.013, 10.1016/j.etp.2007.11.008]; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; Hou B, 2009, BONE, V44, P1121, DOI 10.1016/j.bone.2009.02.018; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Hughes-Fulford Millie, 2004, Sci STKE, V2004, pRE12; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087; Jansen JHW, 2010, J ORTHOP RES, V28, P390, DOI 10.1002/jor.20991; Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135; Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756-3282(00)00421-X; Kamioka H, 2006, J BONE MINER RES, V21, P1012, DOI 10.1359/JBMR.060408; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Knight MM, 2009, J ANAT, V214, P275, DOI 10.1111/j.1469-7580.2008.01021.x; Kwan KM, 2002, GENESIS, V32, P49, DOI 10.1002/gene.10068; LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021-9290(87)90026-1; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200; Lee KCL, 2002, BONE, V31, P407, DOI 10.1016/S8756-3282(02)00842-6; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; Liu SG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1636, DOI 10.1152/ajpendo.00396.2007; Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404; MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009; Malhas AN, 2002, J AM SOC NEPHROL, V13, P19, DOI 10.1681/ASN.V13119; MATTHEWS JL, 1981, CLIN ORTHOP RELAT R, P27; McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175; McGlashan SR, 2010, CELL BIOL INT, V34, P441, DOI 10.1042/CBI20090094; MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111; Nauli SM, 2006, J AM SOC NEPHROL, V17, P1015, DOI 10.1681/ASN.2005080830; Nims N, 2003, BIOCHEMISTRY-US, V42, P13035, DOI 10.1021/bi035074c; Oswald E. S., 2006, C P IEEE ENG MED BIO, V1, P3659; Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Paterson AD, 2002, AM J KIDNEY DIS, V40, P16, DOI 10.1053/ajkd.2002.33908; Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284; Pavik I, 2011, KIDNEY INT, V79, P234, DOI 10.1038/ki.2010.375; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05-4221fje; Puri S, 2004, J BIOL CHEM, V279, P55455, DOI 10.1074/jbc.M402905200; Qian F, 2005, J BIOL CHEM, V280, P40723, DOI 10.1074/jbc.M509650200; Ramage L, 2009, SCAND J MED SCI SPOR, V19, P457, DOI 10.1111/j.1600-0838.2009.00912.x; Rath B, 2008, J BIOMECH, V41, P1095, DOI 10.1016/j.jbiomech.2007.11.024; Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756-3282(96)00260-8; Rios HF, 2008, J PERIODONTOL, V79, P1480, DOI [10.1902/jop.2008.070624, 10.1902/jop.2008.070624 ]; Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200; Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545; Robling AG, 2002, FASEB J, V16, P324, DOI 10.1096/fj.02-0393fje; Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200; Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198-010-1194-5; Rowe PSN, 2004, CRIT REV ORAL BIOL M, V15, P264, DOI 10.1177/154411130401500503; Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028; SANTOS A, 2003, BIOCHEM BIOPH RES CO, V391, P364; Sato N, 2009, J DENT RES, V88, P812, DOI 10.1177/0022034509343101; Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200; Sen B, 2009, J BIOL CHEM, V284, P34607, DOI 10.1074/jbc.M109.039453; Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045; Silva MJ, 2000, J BIOMECH, V33, P231, DOI 10.1016/S0021-9290(99)00158-X; Skerry TM, 2008, ARCH BIOCHEM BIOPHYS, V473, P117, DOI 10.1016/j.abb.2008.02.028; Starremans PG, 2008, KIDNEY INT, V73, P1394, DOI 10.1038/ki.2008.111; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Tanaka SM, 2002, FASEB J, V16, P313, DOI 10.1096/fj.02-0561fje; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; TURCO AE, 1993, J MED GENET, V30, P419, DOI 10.1136/jmg.30.5.419; VAILAS AC, 1990, FASEB J, V4, P47, DOI 10.1096/fasebj.4.1.2295378; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Wilson PD, 1999, LAB INVEST, V79, P1311; Xiao Y, 2010, MOL CELL BIOCHEM, V339, P155, DOI 10.1007/s11010-009-0379-8; Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200; Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200; Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906; Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047; Zerath E, 1998, ADV SPACE RES, V21, P1049, DOI 10.1016/S0273-1177(98)00026-X; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	105	83	86	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2418	2432		10.1096/fj.10-180299	http://dx.doi.org/10.1096/fj.10-180299			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21454365	Green Published			2022-12-28	WOS:000292242200033
J	Pederson, T				Pederson, Thoru			Eric Kandel and Charlie Rose: a stylish synapse review of The Brain Series, televised on The Charlie Rose Show, syndicated by the Public Broadcasting System, now available on DVD	FASEB JOURNAL			English	Editorial Material									[Pederson, Thoru] Univ Massachusetts, Sch Med, Program Cell & Dev Dynam, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Program Cell & Dev Dynam, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu							0	1	1	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1438	1440		10.1096/fj.11-0503ufm	http://dx.doi.org/10.1096/fj.11-0503ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21532052				2022-12-28	WOS:000290023800002
J	Dallas, MR; Liu, GS; Chen, WC; Thomas, SN; Wirtz, D; Huso, DL; Konstantopoulos, K				Dallas, Matthew R.; Liu, Guosheng; Chen, Wei-Chiang; Thomas, Susan N.; Wirtz, Denis; Huso, David L.; Konstantopoulos, Konstantinos			Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis	FASEB JOURNAL			English	Article						CEA; cytoplasmic compliance; migration	COLORECTAL-CARCINOMA CELLS; VARIANT ISOFORMS; BREAST-CANCER; DECREASED EXPRESSION; HEPATIC METASTASIS; HOMOTYPIC ADHESION; IN-VITRO; INVASION; INHIBITION; PROGNOSIS	After separating from a primary tumor, metastasizing cells enter the circulatory system and interact with host cells before lodging in secondary organs. Previous studies have implicated the surface glycoproteins CD44 and carcinoembryonic antigen (CEA) in adhesion, migration, and invasion, suggesting that they may influence metastatic progression. To elucidate the role of these multifunctional molecules while avoiding the potential drawbacks of ectopic expression or monoclonal antibody treatments, we silenced the expression of CD44 and/or CEA in LS174T colon carcinoma cells and analyzed their ability to metastasize in 2 independent mouse models. Quantitative PCR revealed that CD44 knockdown increased lung and liver metastasis >10-fold, while metastasis was decreased by >50% following CEA knockdown. These findings were corroborated by in vitro experiments assessing the metastatic potential of LS174T cells. Cell migration was decreased as a result of silencing CEA but was enhanced in CD44-knockdown cells. In addition, CD44 silencing promoted homotypic aggregation of LS147T cells, a phenotype that was reversed by additional CEA knockdown. Finally, CD44-knockdown cells exhibited greater mechanical compliance than control cells, a property that correlates with increased metastatic potential. Collectively, these data indicate that CEA, but not CD44, is a viable target for therapeutics aimed at curbing colon carcinoma metastasis.-Dallas, M. R., Liu, G., Chen, W.-C., Thomas, S. N., Wirtz, D., Huso, D. L., Konstantopoulos, K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J. 26, 2648-2656 (2012). www.fasebj.org	[Dallas, Matthew R.; Chen, Wei-Chiang; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Dallas, Matthew R.; Chen, Wei-Chiang; Wirtz, Denis; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Dallas, Matthew R.; Chen, Wei-Chiang; Wirtz, Denis; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA; [Dallas, Matthew R.; Chen, Wei-Chiang; Wirtz, Denis; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Liu, Guosheng; Huso, David L.] Johns Hopkins Med Inst, Dept Mol & Comparat Pathol, Baltimore, MD 21205 USA; [Liu, Guosheng; Huso, David L.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Thomas, Susan N.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Georgia; Georgia Institute of Technology	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	konstant@jhu.edu	Thomas, Susan/A-9947-2009; Thomas, Susan/B-4592-2016; Konstantopoulos, Konstantinos/A-7045-2011	Thomas, Susan/0000-0003-4651-232X; 	U.S. National Institutes of Health/National Cancer Institute [R01-CA-101135, U54-CA-143868]; NATIONAL CANCER INSTITUTE [R01CA101135, U54CA143868] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by U.S. National Institutes of Health/National Cancer Institute grants R01-CA-101135 and U54-CA-143868. The authors thank Philip Yang for critical input to this work.	Alves CS, 2009, J BIOL CHEM, V284, P1177, DOI 10.1074/jbc.M805144200; Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420; Choi SH, 2000, INT J CANCER, V85, P523, DOI 10.1002/(SICI)1097-0215(20000215)85:4<523::AID-IJC13>3.0.CO;2-6; Cross SE, 2007, NAT NANOTECHNOL, V2, P780, DOI 10.1038/nnano.2007.388; De Marzo AM, 1998, PROSTATE, V34, P162; Edmiston KH, 1997, CANCER RES, V57, P4432; Fang DD, 2010, BRIT J CANCER, V102, P1265, DOI 10.1038/sj.bjc.6605610; Gangopadhyay A, 1998, CLIN EXP METASTAS, V16, P703, DOI 10.1023/A:1006576627429; Gangopadhyay A, 1996, CANCER RES, V56, P4805; Gao AC, 1997, CANCER RES, V57, P846; GOLDENBERG DM, 1976, J NATL CANCER I, V57, P11, DOI 10.1093/jnci/57.1.11; Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; HASHINO J, 1994, CLIN EXP METASTAS, V12, P324, DOI 10.1007/BF01753839; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Jessup JM, 2004, CLIN EXP METASTAS, V21, P709, DOI 10.1007/s10585-004-7705-z; Jessup JM, 2004, INT J CANCER, V111, P332, DOI 10.1002/ijc.20264; Jothy S, 2003, CLIN EXP METASTAS, V20, P195, DOI 10.1023/A:1022931016285; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Kim HR, 2004, CANCER RES, V64, P4569, DOI 10.1158/0008-5472.CAN-04-0202; KITSUKI H, 1995, CANCER LETT, V88, P7, DOI 10.1016/0304-3835(94)03605-I; Klingbeil P, 2009, MOL CANCER RES, V7, P168, DOI 10.1158/1541-7786.MCR-08-0207; Li Y, 2010, CANCER RES, V70, P8159, DOI 10.1158/0008-5472.CAN-10-1073; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Louderbough JMV, 2011, MOL CANCER RES, V9, P1573, DOI 10.1158/1541-7786.MCR-11-0156; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; Morrin M, 2002, INT J COLORECTAL DIS, V17, P30, DOI 10.1007/s003840100335; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; Murray EW, 1998, J BIOL CHEM, V273, P25279, DOI 10.1074/jbc.273.39.25279; Napier SL, 2007, J BIOL CHEM, V282, P3433, DOI 10.1074/jbc.M607219200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Noordzij MA, 1999, INT J CANCER, V84, P478, DOI 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-N; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; Swaminathan V, 2011, CANCER RES, V71, P5075, DOI 10.1158/0008-5472.CAN-11-0247; Terpe HJ, 1996, AM J PATHOL, V148, P453; Thomas SN, 2008, J BIOL CHEM, V283, P15647, DOI 10.1074/jbc.M800543200; UPDYKE TV, 1986, CLIN EXP METASTAS, V4, P273, DOI 10.1007/BF00133592; Weg-Remers S, 1998, EUR J CANCER, V34, P1607, DOI 10.1016/S0959-8049(98)00177-4; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Wirtz D, 2009, ANNU REV BIOPHYS, V38, P301, DOI 10.1146/annurev.biophys.050708.133724; Yang XR, 2010, GUT, V59, P953, DOI 10.1136/gut.2008.176271; Yoshioka T, 1998, JPN J CANCER RES, V89, P177, DOI 10.1111/j.1349-7006.1998.tb00546.x; Yuce I, 2011, AM J OTOLARYNG, V32, P141, DOI 10.1016/j.amjoto.2010.01.001; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940	51	36	39	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2648	2656		10.1096/fj.12-203786	http://dx.doi.org/10.1096/fj.12-203786			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415308	Green Published			2022-12-28	WOS:000305017200040
J	Xu, XR; Gammon, MD; Hernandez-Vargas, H; Herceg, Z; Wetmur, JG; Teitelbaum, SL; Bradshaw, PT; Neugut, AI; Santella, RM; Chen, J				Xu, Xinran; Gammon, Marilie D.; Hernandez-Vargas, Hector; Herceg, Zdenko; Wetmur, James G.; Teitelbaum, Susan L.; Bradshaw, Patrick T.; Neugut, Alfred I.; Santella, Regina M.; Chen, Jia			DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study	FASEB JOURNAL			English	Article						epigenetics; biomarker; 1-carbon metabolism	ONE-CARBON METABOLISM; RISK-FACTORS; LONG-ISLAND; HYPOMETHYLATION; POLYMORPHISM; SUSCEPTIBILITY; LEUKOCYTES; BIOMARKER; LINE-1; MTHFR	Our purpose was to identify epigenetic markers of breast cancer risk, which can be reliably measured in peripheral blood and are amenable for large population screening. We used 2 independent assays, luminometric methylation assay (LUMA) and long interspersed elements-1 (LINE-1) to measure "global methylation content" in peripheral blood DNA from a well-characterized population-based case-control study. We examined associations between methylation levels and breast cancer risk among 1055 cases and 1101 controls and potential influences of 1-carbon metabolism on global methylation. Compared with women in the lowest quintile of LUMA methylation, those in the highest quintile had a 2.41-fold increased risk of breast cancer (95% confidence interval: 1.83-3.16; P, trend<0.0001). The association did not vary by other key tumor characteristics and lifestyle risk factors. Consistent with LUMA findings, genome-wide methylation profiling of a subset of samples revealed greater promoter hypermethylation in breast cancer case participants (P=0.04); higher LUMA was associated with higher promoter methylation in the controls (P=0.05). LUMA levels were also associated with functional sodium nitroprusside in key 1-carbon metabolizing genes, MTHFR C677T (P=0.001) and MTRR A66G (P=0.018). LINE-1 methylation was associated with neither breast cancer risk nor 1-carbon metabolism. Our results show that global promoter hypermethylation measured in peripheral blood was associated with breast cancer risk.-Xu, X., Gammon, M. D., Hernandez-Vargas, H., Herceg, Z., Wetmur, J. G., Teitelbaum, S. L., Bradshaw, P. T., Neugut, A. I., Santella, R. M., Chen, J. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J. 26, 2657-2666 (2012). www.fasebj.org	[Xu, Xinran; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Xu, Xinran] Tongji Univ, Shanghai E Hosp, Sch Med, Res Ctr Translat Med,Minist Educ, Shanghai 200120, Peoples R China; [Xu, Xinran] Tongji Univ, Shanghai E Hosp, Sch Med, Minist Educ,Key Lab Arrhythmias, Shanghai 200120, Peoples R China; [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA; [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA; [Hernandez-Vargas, Hector; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Tongji University; Tongji University; University of North Carolina; University of North Carolina Chapel Hill; Columbia University; Columbia University; Columbia University; World Health Organization; International Agency for Research on Cancer (IARC)	Chen, J (corresponding author), Mt Sinai Sch Med, Dept Prevent Med, Box 1057,1 Gustave L Levy Pl, New York, NY 10029 USA.	xu_xinran@hotmail.com; jia.chen@mssm.edu	Bradshaw, Patrick/AAJ-7529-2021	Bradshaw, Patrick/0000-0001-7761-3129; Hernandez-Vargas, Hector/0000-0001-6045-2103; Xu, Xinran/0000-0001-6435-8181	U.S. National Cancer Institute [R01CA109753, 3R01CA109753-04S1]; Department of Defense [BC031746, W81XWH-06-1-0298]; National Cancer Institute; National Institute of Environmental Health and Sciences [UO1CA/ES66572, UO1CA66572, P30CA013696, P30ES009089, P30ES10126]; NATIONAL CANCER INSTITUTE [R01CA109753, U01CA066572, P30CA013696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health and Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grants from the U.S. National Cancer Institute (R01CA109753 and 3R01CA109753-04S1) and in part by grants from Department of Defense (BC031746 and W81XWH-06-1-0298) and National Cancer Institute and National Institute of Environmental Health and Sciences (UO1CA/ES66572, UO1CA66572, P30CA013696, P30ES009089, and P30ES10126). The authors acknowledge the invaluable help of Dr. Thomas Kraus, who performed cell fractionation, and Alexander Rialdi, who performed the LUMA assay for the fractionated cells.	Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Brody T., 1994, NUTR BIOCH; Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006; Castro R, 2004, J MED GENET, V41, P454, DOI 10.1136/jmg.2003.017244; Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cho YH, 2010, ANTICANCER RES, V30, P2489; Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143; Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602; Estecio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926; Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677; Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485; Graziano F, 2006, INT J CANCER, V118, P628, DOI 10.1002/ijc.21397; Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590; Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636; Karimi M, 2006, EPIGENETICS-US, V1, P45; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961; Matthews RG, 2007, CLIN CHEM LAB MED, V45, P1700, DOI 10.1515/CCLM.2007.324; McKay JA, 2011, MOL NUTR FOOD RES, V55, P1026, DOI 10.1002/mnfr.201100008; Medvedeva YA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-48; Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; RUSSO J, 1998, FRONT BIOSCI, V3, P944, DOI DOI 10.2741/A335; Sohn KJ, 2009, INT J CANCER, V124, P1999, DOI 10.1002/ijc.24003; Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656; Willett W., 2012, NUTR EPIDEMIOLOGY; Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; Xu XR, 2007, CARCINOGENESIS, V28, P1504, DOI 10.1093/carcin/bgm061; Xu XR, 2007, AM J CLIN NUTR, V85, P1098, DOI 10.1093/ajcn/85.4.1098; Xu XR, 2009, FASEB J, V23, P4022, DOI 10.1096/fj.09-136507; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Zeisel SH, 2003, J NUTR, V133, P1302	41	68	71	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2657	2666		10.1096/fj.11-197251	http://dx.doi.org/10.1096/fj.11-197251			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22371529	Green Published			2022-12-28	WOS:000305017200041
J	Kajla, S; Mondol, AS; Nagasawa, A; Zhang, YG; Kato, M; Matsuno, K; Yabe-Nishimura, C; Kamata, T				Kajla, Seheli; Mondol, Abdus S.; Nagasawa, Atsushi; Zhang, Yugen; Kato, Masayoshi; Matsuno, Kuniharu; Yabe-Nishimura, Chihiro; Kamata, Tohru			A crucial role for Nox 1 in redox-dependent regulation of Wnt-beta-catenin signaling	FASEB JOURNAL			English	Article						NADPH oxidase; Rac1; nucleoredoxin; reactive oxygen species	HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; NADPH OXIDASE-1; COLON-CANCER; RAS; SUPEROXIDE; EXPRESSION; TRANSFORMATION; GROWTH; TIAM1	Canonical Wnt signaling critically regulates cell fate and proliferation in developmental stages and adult tissues. Redox regulation through nucleoredoxin (NRX) has recently been identified in canonical Wnt signaling. However, the source of reactive oxygen species (ROS) affecting the redox state of NRX remains elusive. Our principal aim in this study was to investigate whether superoxide-generating NADPH oxidase1 (Nox1) is involved in NRX-regulated Wnt signaling in intestinal and colon epithelial cells. Here, we demonstrate that Wnt treatment of mouse intestinal cells induces production of ROS through Nox1. This Nox1 action is regulated by Rac1 GTPase through Wnt-induced activation of the Rac1 guanine nucleotide exchange factor Vav2 by Src-mediated tyrosine phosphorylation. Nox1-generated ROS oxidize and inactivate NRX, thereby releasing the NRX-dependent suppression of Wnt-beta-catenin signaling through dissociation of NRX from Dvl. Nox1 small-interference RNA inhibits cell response to Wnt, including stabilization of beta-catenin, expression of cyclin D1 and c-Myc via the TCF transcription factor, and accelerated cell proliferation. Nox1 mediates Wnt-induced cell growth in colon cancer cells with the normal Wnt pathway, but not in APC-deficient colon cancer cells, which are constitutively active in Wnt signaling. Together, these results suggest the mediating role of Nox1 in redox-dependent regulation of canonical Wnt-beta-catenin signaling and provide further insight into the regulatory mechanism of the Wnt pathway.-Kajla, S., Mondol, A. S., Nagasawa, A., Zhang, Y., Kato, M., Matsuno, K., Yabe-Nishimura, C., Kamata, T. A crucial role for Nox 1 in redox-dependent regulation of Wnt-beta-catenin signaling. FASEB J. 26, 2049-2059 (2012). www.fasebj.org	[Kajla, Seheli; Mondol, Abdus S.; Nagasawa, Atsushi; Zhang, Yugen; Kato, Masayoshi; Kamata, Tohru] Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; [Matsuno, Kuniharu; Yabe-Nishimura, Chihiro] Kyoto Prefectural Univ Med, Dept Pharmacol, Kyoto, Japan	Shinshu University; Kyoto Prefectural University of Medicine	Kamata, T (corresponding author), Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kamatat@shinshu-u.ac.jp			Ministry of Science and Culture of Japan	Ministry of Science and Culture of Japan	The authors thank Dr. M. Kawakubo, Department of Laboratory Medicine, Shinshu University for technical assistance. The authors are grateful to F. Ushiyama for assistance in manuscript preparation. This work was supported by a grant on Cancer Research in Applied Areas from the Ministry of Science and Culture of Japan (T.K.).	Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BOLEN JB, 1987, ONCOGENE RES, V1, P149; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Coant N, 2010, MOL CELL BIOL, V30, P2636, DOI 10.1128/MCB.01194-09; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Gianni D, 2008, MOL BIOL CELL, V19, P2984, DOI 10.1091/mbc.E08-02-0138; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Komatsu D, 2008, ONCOGENE, V27, P4724, DOI 10.1038/onc.2008.102; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Laurent E, 2008, INT J CANCER, V123, P100, DOI 10.1002/ijc.23423; Liu JY, 2009, J CELL SCI, V122, P324, DOI 10.1242/jcs.033720; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Matsuno K, 2005, CIRCULATION, V112, P2677, DOI 10.1161/CIRCULATIONAHA.105.573709; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200; Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Szanto I, 2005, J PATHOL, V207, P164, DOI 10.1002/path.1824; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; Yokoyama N, 2009, J CELL SCI, V122, P4439, DOI 10.1242/jcs.051847; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	36	82	83	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2049	2059		10.1096/fj.11-196360	http://dx.doi.org/10.1096/fj.11-196360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278940				2022-12-28	WOS:000303680800031
J	Dancyger, AM; King, JJ; Quinlan, MJ; Fifield, H; Tucker, S; Saunders, HL; Berru, M; Magor, BG; Martin, A; Larijani, M				Dancyger, Alex M.; King, Justin J.; Quinlan, Matthew J.; Fifield, Heather; Tucker, Stephanie; Saunders, Holly L.; Berru, Maribel; Magor, Bradley G.; Martin, Alberto; Larijani, Mani			Differences in the enzymatic efficiency of human and bony fish AID are mediated by a single residue in the C terminus modulating single-stranded DNA binding	FASEB JOURNAL			English	Article						antibody diversification; DNA mutating enzymes; mechanisms of enzyme thermosensitivity	INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; ACTIVATION-INDUCED DEAMINASE; APOBEC3G CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; PSYCHROPHILIC ENZYMES; SOMATIC HYPERMUTATION; AID/APOBEC FAMILY; EVOLUTION; ISOTYPE	Activation-induced cytidine deaminase (AID) mediates antibody diversification by deaminating deoxycytidines to deoxyuridine within immunoglobulin genes. However, it also generates genome-wide DNA lesions, leading to transformation. Though the biochemical properties of AID have been described, its 3-dimensional structure has not been determined. Hence, to investigate the relationship between the primary structure and biochemical characteristics of AID, we compared the properties of human and bony fish AID, since these are most divergent in amino acid sequence. We show that AIDs of various species have different catalytic rates that are thermosensitive and optimal at native physiological temperatures. Zebrafish AID is severalfold more catalytically robust than human AID, while catfish AID is least active. This disparity is mediated by a single amino acid difference in the C terminus. Using functional assays supported by models of AID core and surface structure, we show that this residue modulates activity by affecting ssDNA binding. Furthermore, the cold-adapted catalytic rates of fish AID result from increased ssDNA binding affinity at lower temperatures. Our work suggests that AID may generate DNA damage with variable efficiencies in different organisms, identifies residues critical in regulating AID activity, and provides insights into the evolution of the APOBEC family of enzymes.-Dancyger, A. M., King, J. J., Quinlan, M. J., Fifield, H., Tucker, S., Saunders, H. L., Berru, M., Magor, B. G., Martin, A., Larijani, M. Differences in the enzymatic efficiency of human and bony fish AID are mediated by a single residue in the C terminus modulating single-stranded DNA binding. FASEB J. 26, 1517-1525 (2012). www.fasebj.org	[Larijani, Mani] Mem Univ Newfoundland, Hlth Sci Ctr, Fac Med, Program Immunol & Infect Dis,Div Biomed Sci, St John, NF A1B 3V6, Canada; [Saunders, Holly L.; Magor, Bradley G.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada; [Berru, Maribel; Martin, Alberto] Univ Toronto, Dept Immunol, Toronto, ON, Canada	Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Alberta; University of Toronto	Larijani, M (corresponding author), Mem Univ Newfoundland, Hlth Sci Ctr, Fac Med, Program Immunol & Infect Dis,Div Biomed Sci, Rm 1809A, St John, NF A1B 3V6, Canada.	mlarijani@mun.ca	Magor, Bradley/M-6352-2017	Magor, Bradley/0000-0003-4819-8530; Martin, Alberto/0000-0002-0795-0418	Canadian Instiutes of Health Research (CIHR) [MOP111132, MOP66965]; Natural Sciences and Engineering Research Council of Canada; Canada Research Chair award	Canadian Instiutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by operating grants from the Canadian Instiutes of Health Research (CIHR) to M. L. (MOP111132) and A. M. (MOP66965), and from the Natural Sciences and Engineering Research Council of Canada to B. M. A. D. is supported by a CIHR fellowship. A. M. is supported by a Canada Research Chair award. M. L. is supported by a CIHR New Investigator award.	Barreto VM, 2011, DEV COMP IMMUNOL, V35, P991, DOI 10.1016/j.dci.2011.02.005; Barreto VM, 2005, J EXP MED, V202, P733, DOI 10.1084/jem.20051378; Barreto VM, 2005, TRENDS IMMUNOL, V26, P90, DOI 10.1016/j.it.2004.12.004; Basu U, 2008, MOL CELL, V32, P285, DOI 10.1016/j.molcel.2008.08.019; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Chen KM, 2008, NATURE, V452, P116, DOI 10.1038/nature06638; Coker HA, 2007, DNA REPAIR, V6, P235, DOI 10.1016/j.dnarep.2006.10.001; Coker HA, 2006, METHOD ENZYMOL, V408, P156, DOI 10.1016/S0076-6879(06)08010-4; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Conticello Silvestro G, 2007, Adv Immunol, V94, P37, DOI 10.1016/S0065-2776(06)94002-4; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; Danilova N, 2005, NAT IMMUNOL, V6, P295, DOI 10.1038/ni1166; Durandy A, 2006, HUM MUTAT, V27, P1185, DOI 10.1002/humu.20414; Feller G, 2003, NAT REV MICROBIOL, V1, P200, DOI 10.1038/nrmicro773; Flajnik MF, 2010, NAT REV GENET, V11, P47, DOI 10.1038/nrg2703; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Hansen JD, 2005, P NATL ACAD SCI USA, V102, P6919, DOI 10.1073/pnas.0500027102; Holden LG, 2008, NATURE, V456, P121, DOI 10.1038/nature07357; Ichikawa HT, 2006, J IMMUNOL, V177, P355, DOI 10.4049/jimmunol.177.1.355; Kohli RM, 2010, J BIOL CHEM, V285, P40956, DOI 10.1074/jbc.M110.177402; Langlois MA, 2005, NUCLEIC ACIDS RES, V33, P1913, DOI 10.1093/nar/gki343; Larijani M, 2005, IMMUNOGENETICS, V56, P840, DOI 10.1007/s00251-004-0748-0; Larijani M, 2007, MOL CELL BIOL, V27, P8038, DOI 10.1128/MCB.01046-07; Larijani M, 2007, MOL CELL BIOL, V27, P20, DOI 10.1128/MCB.00824-06; Marshall CJ, 1997, TRENDS BIOTECHNOL, V15, P359, DOI 10.1016/S0167-7799(97)01086-X; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Mussmann R, 1997, EUR J IMMUNOL, V27, P2610, DOI 10.1002/eji.1830271021; Nakatani M, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-177; Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Pham P, 2007, DNA REPAIR, V6, P689, DOI 10.1016/j.dnarep.2007.01.001; Prochnow C, 2007, NATURE, V445, P447, DOI 10.1038/nature05492; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Saunders HL, 2004, DEV COMP IMMUNOL, V28, P657, DOI 10.1016/j.dci.2004.01.002; Saunders HL, 2010, DEV COMP IMMUNOL, V34, P669, DOI 10.1016/j.dci.2010.01.013; Shandilya SMD, 2010, STRUCTURE, V18, P28, DOI 10.1016/j.str.2009.10.016; Shen HM, 2004, P NATL ACAD SCI USA, V101, P12997, DOI 10.1073/pnas.0404974101; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Stavnezer J, 2004, SEMIN IMMUNOL, V16, P257, DOI 10.1016/j.smim.2004.08.005; Steinke D, 2006, J MOL EVOL, V62, P772, DOI 10.1007/s00239-005-0170-8; Wakae K, 2006, INT IMMUNOL, V18, P41, DOI 10.1093/intimm/dxh347; Wang M, 2010, J EXP MED, V207, P141, DOI 10.1084/jem.20092238; Wang M, 2009, NAT STRUCT MOL BIOL, V16, P769, DOI 10.1038/nsmb.1623; Yu KF, 2004, J BIOL CHEM, V279, P6496, DOI 10.1074/jbc.M311616200; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406; Zhao YF, 2005, DEV COMP IMMUNOL, V29, P61, DOI 10.1016/j.dci.2004.05.005	49	17	18	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1517	1525		10.1096/fj.11-198135	http://dx.doi.org/10.1096/fj.11-198135			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198384				2022-12-28	WOS:000302359700014
J	Pierdominici, M; Vomero, M; Barbati, C; Colasanti, T; Maselli, A; Vacirca, D; Giovannetti, A; Malorni, W; Ortona, E				Pierdominici, Marina; Vomero, Marta; Barbati, Cristiana; Colasanti, Tania; Maselli, Angela; Vacirca, Davide; Giovannetti, Antonello; Malorni, Walter; Ortona, Elena			Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus	FASEB JOURNAL			English	Review						innate and adaptive immune responses; T-cell homeostasis; cell fate; rapamycin	CHAPERONE-MEDIATED AUTOPHAGY; GENOME-WIDE ASSOCIATION; CLASS-II PRESENTATION; T-CELL-ACTIVATION; APOPTOTIC CELLS; LYMPHOCYTE HOMEOSTASIS; THYMIC EPITHELIUM; MAMMALIAN TARGET; XENO-CANNIBALISM; INDUCE AUTOPHAGY	Autophagy is a lysosome-mediated catabolic process that allows cells to degrade unwanted cytoplasmic constituents and to recycle nutrients. Autophagy is also involved in innate and adaptive immune responses, playing a key role in interactions against microbes, in antigen processing for major histocompatibility complex (MHC) presentation, and in lymphocyte development, survival, and proliferation. Over recent years, perturbations in autophagy have been implicated in a number of diseases, including autoimmunity. Systemic lupus erythematosus (SLE) is a multifactorial disease characterized by autoimmune responses against self-antigens generated by dying cells. Genome-wide association studies have linked several single-nucleotide polymorphisms (SNPs) in the autophagy-related gene Atg5 to SLE susceptibility. Loss of Atg5-dependent effects, including clearance of dying cells and cell antigen presentation, might contribute to the autoimmunity and inflammation associated with SLE. Moreover, activation of the mammalian target of rapamycin (mTOR), a key player in the autophagy regulation, has recently been demonstrated in SLE, confirming an altered autophagy pathway in this disease. In the present review, we summarize the autophagy mechanisms, their molecular regulation, and their relevance in immunity and autoimmunity. The potential of targeting autophagy pathway in SLE, by developing innovative therapeutic approaches, has finally been discussed.-Pierdominici, M., Vomero, M., Barbati, C., Colasanti, T., Maselli, A., Vacirca, D., Giovannetti, A., Malorni, W., Ortona, E. Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J. 26, 1400-1412 (2012). www.fasebj.org	[Malorni, Walter] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy; [Pierdominici, Marina; Vomero, Marta; Barbati, Cristiana; Colasanti, Tania; Maselli, Angela; Vacirca, Davide; Ortona, Elena] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Barbati, Cristiana; Colasanti, Tania; Malorni, Walter; Ortona, Elena] Ist San Raffaele Sulmona, Sulmona, Italy; [Giovannetti, Antonello] Sapienza Univ Rome, Div Clin Immunol, Dept Clin Med, Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Sapienza University Rome	Malorni, W (corresponding author), Ist Super Sanita, Dept Therapeut Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	COLASANTI, Tania/AAF-4074-2022; Vomero, Marta/AAC-6074-2022; Giovannetti, Antonello/E-7736-2012; COLASANTI, Tania/AFI-8434-2022; ortona, elena/J-6395-2016; Pierdominici, Marina/J-6436-2016	COLASANTI, Tania/0000-0002-4413-1817; Vomero, Marta/0000-0001-9744-5628; COLASANTI, Tania/0000-0002-4413-1817; ortona, elena/0000-0001-9845-8105; Pierdominici, Marina/0000-0002-6372-3754; malorni, walter/0000-0002-1223-7000	Ministero della Salute	Ministero della Salute(Ministry of Health, Italy)	This study is supported by grants from Ministero della Salute (W.M. and E.O.).	Alirezaei M, 2009, AUTOPHAGY, V5, P152, DOI 10.4161/auto.5.2.7348; Arsov I, 2011, J IMMUNOL, V186, P2201, DOI 10.4049/jimmunol.1002223; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Baldo P, 2008, CURR CANCER DRUG TAR, V8, P647, DOI 10.2174/156800908786733513; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Bijl M, 2006, ANN RHEUM DIS, V65, P57, DOI 10.1136/ard.2005.035733; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cao WP, 2008, NAT IMMUNOL, V9, P1157, DOI 10.1038/ni.1645; Chaturvedi A, 2008, IMMUNITY, V28, P799, DOI 10.1016/j.immuni.2008.03.019; Cheallaigh CN, 2011, CLIN EXP IMMUNOL, V164, P291, DOI 10.1111/j.1365-2249.2011.04381.x; Chemali M, 2011, CELL MOL LIFE SCI, V68, P1533, DOI 10.1007/s00018-011-0660-3; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Deretic V, 2011, IMMUNOL REV, V240, P92, DOI 10.1111/j.1600-065X.2010.00995.x; DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437; Dongre AR, 2001, EUR J IMMUNOL, V31, P1485, DOI 10.1002/1521-4141(200105)31:5<1485::AID-IMMU1485>3.0.CO;2-A; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Fernandez D, 2006, ARTHRITIS RHEUM-US, V54, P2983, DOI 10.1002/art.22085; Fernandez D, 2010, DISCOV MED, V9, P173; Fernandez D, 2009, AUTOIMMUN REV, V8, P184, DOI 10.1016/j.autrev.2008.07.041; Fernandez DR, 2009, J IMMUNOL, V182, P2063, DOI 10.4049/jimmunol.0803600; Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071; Gaipl US, 2007, J AUTOIMMUN, V28, P114, DOI 10.1016/j.jaut.2007.02.005; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Giovannetti A, 2008, CURR PHARM DESIGN, V14, P253; Gualtierotti R, 2010, AUTOIMMUN REV, V10, P3, DOI 10.1016/j.autrev.2010.09.007; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Harr MW, 2010, AUTOPHAGY, V6, P912, DOI 10.4161/auto.6.7.13290; Hartford CM, 2007, CLIN PHARMACOL THER, V82, P381, DOI 10.1038/sj.clpt.6100317; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Jia W, 2011, J IMMUNOL, V186, P5313, DOI 10.4049/jimmunol.1002404; Jia W, 2011, J IMMUNOL, V186, P1564, DOI 10.4049/jimmunol.1001822; Kasai M, 2009, J IMMUNOL, V183, P7278, DOI 10.4049/jimmunol.0804087; Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155; Kiss E, 2010, AUTOIMMUN REV, V9, P195, DOI 10.1016/j.autrev.2009.07.004; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kovacs JR, 2012, CELL DEATH DIFFER, V19, P144, DOI 10.1038/cdd.2011.78; Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702; La Cava A, 2009, LUPUS, V18, P196, DOI 10.1177/0961203308098191; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li WM, 2011, CELL MOL LIFE SCI, V68, P749, DOI 10.1007/s00018-010-0565-6; Lista P, 2011, J CELL MOL MED, V15, P1443, DOI 10.1111/j.1582-4934.2011.01293.x; LONG EO, 1994, J IMMUNOL, V153, P1487; Longatti A, 2009, CELL DEATH DIFFER, V16, P956, DOI 10.1038/cdd.2009.39; Lugini L, 2006, CANCER RES, V66, P3629, DOI 10.1158/0008-5472.CAN-05-3204; Malorni W, 2007, AUTOPHAGY, V3, P75, DOI 10.4161/auto.3439; Matarrese P, 2012, AGE, V34, P1341, DOI 10.1007/s11357-011-9307-4; McLeod IX, 2010, CELL MOL IMMUNOL, V7, P104, DOI 10.1038/cmi.2009.115; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P222, DOI 10.1002/art.27233; Mijaljica D, 2011, AUTOPHAGY, V7, P673, DOI 10.4161/auto.7.7.14733; Miller BC, 2008, AUTOPHAGY, V4, P309, DOI 10.4161/auto.5474; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mormone E, 2006, J NEUROCHEM, V98, P1090, DOI 10.1111/j.1471-4159.2006.03998.x; Munz C, 2010, CURR OPIN IMMUNOL, V22, P89, DOI 10.1016/j.coi.2010.01.016; Muller S, 2008, ARTHRITIS RHEUM-US, V58, P3873, DOI 10.1002/art.24027; Nagata S, 2010, CELL, V140, P619, DOI 10.1016/j.cell.2010.02.014; Nagy G, 2005, CRIT REV IMMUNOL, V25, P123, DOI 10.1615/CritRevImmunol.v25.i2.30; Nagy G, 2004, J IMMUNOL, V173, P3676, DOI 10.4049/jimmunol.173.6.3676; Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208; Ohl K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/432595; Orme J, 2012, AUTOIMMUN REV, V11, P365, DOI 10.1016/j.autrev.2011.10.010; Page N, 2011, ANN RHEUM DIS, V70, P837, DOI 10.1136/ard.2010.139832; Peng YF, 2011, J CLIN INVEST, V121, P2221, DOI 10.1172/JCI43254; Pierdominici M, 2011, CURR PHARM DESIGN, V17, P3888, DOI 10.2174/138161211798357809; Pua HH, 2007, AUTOPHAGY, V3, P266, DOI 10.4161/auto.3908; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Pua HH, 2009, CURR TOP MICROBIOL, V335, P85, DOI 10.1007/978-3-642-00302-8_4; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Ramos-Barron A, 2007, LUPUS, V16, P775, DOI 10.1177/0961203307081401; Ronnblom L, 2011, SEMIN IMMUNOL, V23, P113, DOI 10.1016/j.smim.2011.01.009; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Towns R, 2005, AUTOPHAGY, V1, P163, DOI 10.4161/auto.1.3.2068; Turzanski J, 2009, BRIT J HAEMATOL, V145, P137, DOI 10.1111/j.1365-2141.2008.07555.x; Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579; Walsh CM, 2010, IMMUNOL REV, V236, P95, DOI 10.1111/j.1600-065X.2010.00919.x; Wang YJ, 2008, J BIOL CHEM, V283, P4766, DOI 10.1074/jbc.M706666200; WARNER LM, 1994, ARTHRITIS RHEUM, V37, P289, DOI 10.1002/art.1780370219; Watanabe K, 2008, BIOCHEM BIOPH RES CO, V374, P274, DOI 10.1016/j.bbrc.2008.07.013; WEISSMANN G, 1964, LANCET, V2, P1373; Wu SP, 2011, DISCOV MED, V11, P325; Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003; Yildirim-Toruner C, 2011, J ALLERGY CLIN IMMUN, V127, P303, DOI 10.1016/j.jaci.2010.12.1087; Younes A, 2011, ONCOLOGIST, V16, P730, DOI 10.1634/theoncologist.2010-0318; Zhou DL, 2004, IMMUNOL RES, V30, P279, DOI 10.1385/IR:30:3:279; Zhou XJ, 2011, ANN RHEUM DIS, V70, P1330, DOI 10.1136/ard.2010.140111; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	100	111	120	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1400	1412		10.1096/fj.11-194175	http://dx.doi.org/10.1096/fj.11-194175			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22247332				2022-12-28	WOS:000302359700003
J	Roldan, M; Macias-Gonzalez, M; Garcia, R; Tinahones, FJ; Martin, M				Roldan, Mar; Macias-Gonzalez, Manuel; Garcia, Regina; Tinahones, Francisco J.; Martin, Miguel			Obesity short-circuits stemness gene network in human adipose multipotent stem cells	FASEB JOURNAL			English	Article						multilineage differentiation; Wnt; Notch; Sonic Hedgehog; microRNAs	ADIPOCYTE DIFFERENTIATION; WNT; EXPRESSION; INSULIN; TISSUE; OSTEOBLASTOGENESIS; PROLIFERATION; PREADIPOCYTES; ADIPOGENESIS; INHIBITION	The discovery of adipose multipotent stem cells has provided new insights to explore cellular mechanisms involved in adipose tissue function. In the present work, we aimed to evaluate how the adipogenic environment influences the stemness of the resident multipotent stem cells. To achieve this goal, human omental multipotent stem cells (hO-MSCs) were isolated, expanded, and characterized in both healthy lean and morbidly obese individuals. We observed decreased cell proliferation, premature senescence, and increased cytokine secretion associated with increasing body mass index of the patients. Consistent with the latter finding, the hO-MSCs derived from patients with morbid obesity lose their multilineage differentiation capacity associated with a dysregulation in the Wnt, Notch, and Sonic Hedgehog signaling pathways. Moreover, microRNAs involved in the regulation of stemness, cell differentiation, and senescence were also up-regulated in obese individuals. Altogether, our data show that obesity causes a general short circuit in the stemness gene network of hO-MSCs.-Roldan, M., Macias-Gonzalez, M., Garcia, R., Tinahones, F. J., Martin, M. Obesity short-circuits stemness gene network in human adipose multipotent stem cells. FASEB J. 25, 4111-4126 (2011). www.fasebj.org	[Roldan, Mar; Macias-Gonzalez, Manuel; Garcia, Regina; Martin, Miguel] Hosp Univ Virgen de la Victoria, Fdn Inst Mediterraneo Avance Biotecnol & Invest S, Malaga, Spain; [Garcia, Regina] Hosp Univ Virgen de la Victoria, Serv Hematol, Malaga, Spain; [Tinahones, Francisco J.] Hosp Univ Virgen de la Victoria, Serv Endocrinol & Nutr, Malaga, Spain; [Roldan, Mar; Martin, Miguel] Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Dept Stem Cells, Seville, Spain; [Macias-Gonzalez, Manuel; Tinahones, Francisco J.] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain	Universidad de Malaga; Universidad de Malaga; Universidad de Malaga; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Martin, M (corresponding author), CABIMER, Andalusian Ctr Mol Biol & Regenerat Med, Dept Stem Cells, Edificio CABIMER,Avda Amer Vespucio S-N,Parque Ci, Seville 41092, Spain.	miguel.martin@cabimer.es	Duarte, Graziela Biude Silva/Q-7728-2016; Tinahones, Francisco José/AAB-2882-2020; MACIAS-GONZALEZ, MANUEL/E-7584-2016	MACIAS-GONZALEZ, MANUEL/0000-0002-6475-4704; Tinahones, Francisco J/0000-0001-6871-4403	Consejeria de Salud-Junta de Andalucia [PI-0253, PI-0020, P08-CTS-04369]; Spanish Ministry of Science and Innovation (MICINN) [RYC-2006-001013]; Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria (ISCIII-FIS) [PI070953, PS09/00997]	Consejeria de Salud-Junta de Andalucia(Junta de Andalucia); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria (ISCIII-FIS)	The authors thank Dr. Jose Maria Perez-Pomares, Dr. Javier Garcia-Castro, and Dr. Rene Rodriguez for valuable scientific input to this work, and Dr. Jose Rivas (Hospital Universitario Virgen de la Victoria, Malaga, Spain) for providing the adipose tissue biopsies. This work was funded by the Consejeria de Salud-Junta de Andalucia, grants PI-0253 (to M.M.), PI-0020 (to M.M. and M.M.-G.), and P08-CTS-04369 (to F.J.T.); the Spanish Ministry of Science and Innovation (MICINN), grant RYC-2006-001013 (to M.M.); and the Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria (ISCIII-FIS), grants PI070953 (to M.M.-G.) and PS09/00997 (to F.J.T.). The authors declare no conflicts of interest.	Armoni M, 2006, J BIOL CHEM, V281, P19881, DOI 10.1074/jbc.M600320200; Baglioni S, 2009, FASEB J, V23, P3494, DOI 10.1096/fj.08-126946; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Cleveland-Donovan K, 2010, ENDOCRINOLOGY, V151, P3752, DOI 10.1210/en.2010-0043; de la Fuente R, 2004, EXP CELL RES, V297, P313, DOI 10.1016/j.yexcr.2004.02.026; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; El-Zaatari M, 2007, BRIT J CANCER, V96, P1855, DOI 10.1038/sj.bjc.6603782; Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007-0974; Gerin I, 2009, J BIOL CHEM, V284, P10755, DOI 10.1074/jbc.M809115200; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Gustafson B, 2006, J BIOL CHEM, V281, P9507, DOI 10.1074/jbc.M512077200; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; Hellingman C. A., 2009, TISSUE ENG PART A, V17, P1157; Isakson P, 2009, DIABETES, V58, P1550, DOI 10.2337/db08-1770; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200; Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Kim SH, 2009, BIOCHEM BIOPH RES CO, V386, P532, DOI 10.1016/j.bbrc.2009.06.071; Ling HY, 2009, CLIN EXP PHARMACOL P, V36, pe32, DOI 10.1111/j.1440-1681.2009.05207.x; Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Maes OC, 2009, J CELL PHYSIOL, V221, P109, DOI 10.1002/jcp.21834; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Ogle BM, 2005, NAT REV MOL CELL BIO, V6, P567, DOI 10.1038/nrm1678; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289; Qian SW, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-47; Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-320; Rogler CE, 2009, HEPATOLOGY, V50, P575, DOI 10.1002/hep.22982; ROSS SE, 2000, SCIENCE, V0289, P00950, DOI [DOI 10.1126/SCIENCE.289.5481.950, DOI 10.1126/science.289.5481.950, 10.1126/science.289.5481.950]; Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708; Sengenes C, 2005, J CELL PHYSIOL, V205, P114, DOI 10.1002/jcp.20381; Shockley KR, 2007, PPAR RES, V2007, DOI 10.1155/2007/81219; Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Virtue S, 2008, PLOS BIOL, V6, P1819, DOI 10.1371/journal.pbio.0060237; Vujovic S, 2007, CELL PROLIFERAT, V40, P185, DOI 10.1111/j.1365-2184.2007.00426.x; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	43	86	88	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4111	4126		10.1096/fj.10-171439	http://dx.doi.org/10.1096/fj.10-171439			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21846837				2022-12-28	WOS:000298138100006
J	Rudrabhatla, P; Jaffe, H; Pant, HC				Rudrabhatla, Parvathi; Jaffe, Howard; Pant, Harish C.			Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs	FASEB JOURNAL			English	Article						Tau; sarkosyl; AD brain	PAIRED HELICAL FILAMENTS; NEUROFILAMENT PROTEIN; PYRAMIDAL NEURONS; HYPERPHOSPHORYLATED-TAU; QUANTITATIVE-ANALYSIS; COGNITIVE IMPAIRMENT; STEREOLOGIC ANALYSIS; VULNERABLE SUBSET; DISEASE; ANTIBODIES	Alzheimer's disease (AD) is a neurodegenerative disorder characterized by brain pathology of intracellular neurofibrillary tangles (NFTs) and extracellular amyloid plaques. NFTs contain aberrantly hyperphosphorylated Tau as paired helical filaments (PHFs). Although NFs have been shown immunohistologically to be part of NFTs, there has been debate that the identity of NF proteins in NFTs is due to the cross-reactivity of phosphorylated NF antibodies with phospho-Tau. Here, we provide direct evidence on the identity of NFs in NFTs by immunochemical and mass spectrometric analysis. We have purified sarkosyl-insoluble NFTs and performed liquid chromatography/tandem mass spectrometry of NFT tryptic digests. The phosphoproteomics of NFTs clearly identified NF-M phosphopeptides SPVPKS*PVEEAK, corresponding to Ser685, and KAES*PVKEEAVAEVVTITK, corresponding to Ser736, and an NF-H phosphopeptide, EPDDAKAKEPS*KP, corresponding to Ser942. Western blotting of purified tangles with SMI31 showed a 150-kDa band corresponding to phospho-NF-M, while RT97 antibodies detected phospho-NF-H. The proteomics analysis also identified an NF-L peptide (ALYEQEIR, EAEEEKKVEGAGEEQAAAK) and another intermediate filament protein, vimentin (FADLSEAANR). Mass spectrometry revealed Tau phosphopeptides corresponding to Thr231, Ser235, Thr181, Ser184, Ser185, Thr212, Thr217, Ser396, and Ser403. And finally, phosphopeptides corresponding to MAP1B (corresponding to Ser1270, Ser1274, and Ser1779) and MAP2 (corresponding to Thr350, Ser1702, and Ser1706) were identified. In corresponding matched control preparations of PHF/NFTs, none of these phosphorylated neuronal cytoskeletal proteins were found. These studies independently demonstrate that NF proteins are an integral part of NFTs in AD brains.-Rudrabhatla, P., Jaffe, H., Pant, H. C. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs. FASEB J. 25, 3896-3905 (2011). www.fasebj.org	[Pant, Harish C.] NINDS, Cytoskeletal Regulatory Prot Sect, Neurochem Lab, NIH, Bethesda, MD 20892 USA; [Jaffe, Howard] NINDS, Prot Peptide Sequencing Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Pant, HC (corresponding author), NINDS, Cytoskeletal Regulatory Prot Sect, Neurochem Lab, NIH, Bldg 49,Rm 2A28, Bethesda, MD 20892 USA.	panth@ninds.nih.gov		Rudrabhatla, Parvathi/0000-0002-7537-3130	U.S. National Institute of Neurological Disorders and Stroke, National Institutes of Health; Dr. Philip Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725] Funding Source: NIH RePORTER	U.S. National Institute of Neurological Disorders and Stroke, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Dr. Philip Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by the grants from the U.S. National Institute of Neurological Disorders and Stroke, National Institutes of Health. The authors acknowledge the Harvard Brain Resource Center (Boston, MA, USA) and the National Institute of Child Health and Human Development Brain and Tissue Bank (Bethesda, MD, USA) for providing human brain tissue. The authors thank Dr. Philip Grant for extensive editing and reviewing the manuscript.	Alonso AD, 2006, P NATL ACAD SCI USA, V103, P8864, DOI 10.1073/pnas.0603214103; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Ayala-Grosso C, 2006, NEUROSCIENCE, V141, P863, DOI 10.1016/j.neuroscience.2006.04.041; BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; Bussiere T, 2003, J COMP NEUROL, V463, P281, DOI 10.1002/cne.10760; Bussiere T, 2003, NEUROSCIENCE, V117, P577, DOI 10.1016/S0306-4522(02)00942-9; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; Dosemeci A, 2010, BIOCHEM BIOPH RES CO, V391, P78, DOI 10.1016/j.bbrc.2009.10.167; GAMBETTI P, 1983, LAB INVEST, V49, P430; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M., 1997, MOL GENETIC BASIS NE, P613; GomezIsla T, 1996, J NEUROSCI, V16, P4491; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1984, ACTA NEUROPATHOL, V62, P259, DOI 10.1007/BF00687607; GRUNDKEIQBAL I, 1979, ANN NEUROL, V6, P532, DOI 10.1002/ana.410060612; Guillozet AL, 2003, ARCH NEUROL-CHICAGO, V60, P729, DOI 10.1001/archneur.60.5.729; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; HOF PR, 1990, J COMP NEUROL, V301, P44, DOI 10.1002/cne.903010105; HOF PR, 1990, J COMP NEUROL, V301, P55, DOI 10.1002/cne.903010106; IHARA Y, 1981, P JPN ACAD B-PHYS, V57, P152, DOI 10.2183/pjab.57.152; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; IQBAL K, 1974, BRAIN RES, V77, P337, DOI 10.1016/0006-8993(74)90798-7; ISHII T, 1979, ACTA NEUROPATHOL, V48, P105, DOI 10.1007/BF00691151; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Kelleher I, 2007, J NEUROCHEM, V103, P2256, DOI 10.1111/j.1471-4159.2007.04930.x; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Kimura T, 2007, EMBO J, V26, P5143, DOI 10.1038/sj.emboj.7601917; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOSIK KS, 1984, BIOCHEM INT, V9, P483; KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; MILLER CCJ, 1986, EMBO J, V5, P269, DOI 10.1002/j.1460-2075.1986.tb04209.x; Mitchell TW, 2002, ANN NEUROL, V51, P182, DOI 10.1002/ana.10086; Morrison JH, 2002, PROG BRAIN RES, V136, P467; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; PERRY G, 1985, P NATL ACAD SCI USA, V82, P3916, DOI 10.1073/pnas.82.11.3916; Rudrabhatla P, 2011, ADV NEUROBIOL, V3, P627, DOI 10.1007/978-1-4419-6787-9_26; Rudrabhatla P, 2010, FASEB J, V24, P4396, DOI 10.1096/fj.10-157859; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Shea TB, 1997, J NEUROSCI RES, V48, P515, DOI 10.1002/(SICI)1097-4547(19970615)48:6<515::AID-JNR4>3.0.CO;2-D; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Wu J, 2007, J PROTEOME RES, V6, P4684, DOI 10.1021/pr070481m	54	79	84	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3896	3905		10.1096/fj.11-181297	http://dx.doi.org/10.1096/fj.11-181297			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21828286	Green Published			2022-12-28	WOS:000296723100014
J	Huang, WC; Tsai, CC; Chen, CL; Chen, TY; Chen, YP; Lin, YS; Lu, PJ; Lin, CM; Wang, SH; Tsao, CW; Wang, CY; Cheng, YL; Hsieh, CY; Tseng, PC; Lin, CF				Huang, Wei-Ching; Tsai, Cheng-Chieh; Chen, Chia-Ling; Chen, Tsai-Yun; Chen, Ya-Ping; Lin, Yee-Shin; Lu, Pei-Jung; Lin, Chun-Mao; Wang, Shwu-Huey; Tsao, Chiung-Wen; Wang, Chi-Yun; Cheng, Yi-Lin; Hsieh, Chia-Yuan; Tseng, Po-Chun; Lin, Chiou-Feng			Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis	FASEB JOURNAL			English	Article						drug resistance; gatekeeper mutation; ceramide	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; TYROSINE PHOSPHORYLATION; MEMBRANE PERMEABILIZATION; GLYCOLIPID BIOSYNTHESIS; SPHINGOSINE 1-PHOSPHATE; DRUG-RESISTANCE; BREAST-CANCER; IMATINIB; CELLS	Inactivation of glycogen synthase kinase (GSK)-3 has been implicated in cancer progression. Previously, we showed an abundance of inactive GSK-3 in the human chronic myeloid leukemia (CML) cell line. CML is a hematopoietic malignancy caused by an oncogenic Bcr-Abl tyrosine kinase. In Bcr-Abl signaling, the role of GSK-3 is not well defined. Here, we report that enforced expression of constitutively active GSK-3 reduced proliferation and increased Bcr-Abl inhibitioninduced apoptosis by nearly 1-fold. Bcr-Abl inhibition activated GSK-3 and GSK-3-dependent apoptosis. Inactivation of GSK-3 by Bcr-Abl activity is, therefore, confirmed. To reactivate GSK-3, we used glucosylceramide synthase (GCS) inhibitor PDMP to accumulate endogenous ceramide, a tumor-suppressor sphingolipid and a potent GSK-3 activator. We found that either PDMP or silence of GCS increased Bcr-Abl inhibitioninduced GSK-3 activation and apoptosis. Furthermore, PDMP sensitized the most clinical problematic drug-resistant CML T315I mutant to Bcr-Abl inhibitor GNF2-, imatinib-, or nilotinib-induced apoptosis by >5-fold. Combining PDMP and GNF-2 eliminated transplanted-CML-T315I-mutants in vivo and dose dependently sensitized primary cells from CML T315I patients to GNF-2-induced proliferation inhibition and apoptosis. The synergistic efficacy was Bcr-Abl restricted and correlated to increased intracellular ceramide levels and acted through GSK-3-mediated apoptosis. This study suggests a feasible novel anti-CML strategy by accumulating endogenous ceramide to reactivate GSK-3 and abrogate drug resistance.-Huang, W.-C., Tsai, C.-C., Chen, C.-L., Chen, T.-Y., Chen, Y.-P., Lin, Y.-S., Lu, P.-J., Lin, C.-M., Wang, S.-W., Tsao, C.-W., Wang, C.-Y., Cheng, Y.-L., Hsieh, C.-Y., Tseng, P.-C., Lin, C.-F. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. FASEB J. 25, 3661-3673 (2011). www.fasebj.org	[Huang, Wei-Ching; Tsai, Cheng-Chieh; Chen, Ya-Ping; Lu, Pei-Jung; Wang, Chi-Yun; Cheng, Yi-Lin; Hsieh, Chia-Yuan; Tseng, Po-Chun; Lin, Chiou-Feng] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 701, Taiwan; [Huang, Wei-Ching; Tsai, Cheng-Chieh; Lin, Yee-Shin; Lu, Pei-Jung; Wang, Chi-Yun; Lin, Chiou-Feng] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; [Huang, Wei-Ching; Chen, Chia-Ling; Lin, Yee-Shin; Lin, Chiou-Feng] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 701, Taiwan; [Chen, Tsai-Yun; Chen, Ya-Ping] Natl Cheng Kung Univ, Dept Internal Med, Coll Med, Tainan 701, Taiwan; [Cheng, Yi-Lin] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, Tainan 701, Taiwan; [Tsai, Cheng-Chieh; Tsao, Chiung-Wen] Chung Hwa Univ Med Technol, Dept Nursing, Tainan, Taiwan; [Lin, Chun-Mao] Taipei Med Univ, Grad Inst Med Sci, Taipei, Taiwan; [Wang, Shwu-Huey] Taipei Med Univ, Core Facil Ctr, Off Res & Dev, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chung Hua University; Taipei Medical University; Taipei Medical University	Lin, CF (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 701, Taiwan.	cflin@mail.ncku.edu.tw		Wang, Chi-Yun/0000-0003-0317-5378; Lin, Chun-Mao/0000-0002-8366-4026; Chen, Ya-Ping/0000-0001-6748-7448; Huang, Wei-Ching/0000-0003-1255-2067	National Health Research Institutes [NHRI-EX99-9917NC]; National Science Council, Taiwan [NSC 96-2320-B-006-018-MY3]; National Cheng Kung University	National Health Research Institutes(National Health Research Institutes, Japan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University	The authors thank the Immunobiology Core Laboratory, Research Center of Clinical Medicine, National Cheng Kung University Hospital, for providing services that include training, technical support, and assistance with experimental design and data analysis using Flow Cytometry Core facilities. The authors thank Dr. Huey-Kang Sytwu (Graduate Institute of Life Science, National Defense Medical Center, Taiwan) for materials for and assistance with lentiviral-based shRNA experiments. The authors thank Dr. Cheng-Ta Yang (Department of Respiratory Care, College of Medicine, Chang Gung University, Taoyuan, Taiwan) for the kind gift of gefitinibresistant H1975 cells. Use of the API 4000 triple-quadrupole mass spectrometer was supported by Yung Shin Pharmaceutical Co. (Taiwan). This work was supported by grants NHRI-EX99-9917NC from the National Health Research Institutes and NSC 96-2320-B-006-018-MY3 from the National Science Council, Taiwan, and by the Landmark Project C020 of National Cheng Kung University.	ABE A, 1995, J LIPID RES, V36, P611; Adrian FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Basu M, 1998, ACTA BIOCHIM POL, V45, P327, DOI 10.18388/abp.1998_4228; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; Chen CL, 2008, BLOOD, V111, P4365, DOI 10.1182/blood-2007-08-106336; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Huang WC, 2009, J PHARMACOL EXP THER, V329, P524, DOI 10.1124/jpet.108.148122; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kantarjian HM, 2003, BLOOD, V101, P97, DOI 10.1182/blood-2002-02-0545; Kockeritz L, 2006, CURR DRUG TARGETS, V7, P1377, DOI 10.2174/1389450110607011377; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li QF, 2007, ONCOGENE, V26, P7904, DOI 10.1038/sj.onc.1210587; Lin CF, 2007, J CELL SCI, V120, P2935, DOI 10.1242/jcs.03473; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Mian AA, 2009, LEUKEMIA, V23, P2242, DOI 10.1038/leu.2009.194; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Puissant A, 2010, LEUKEMIA, V24, P115, DOI 10.1038/leu.2009.233; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rayasam GV, 2009, BRIT J PHARMACOL, V156, P885, DOI 10.1111/j.1476-5381.2008.00085.x; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Saddoughi Sahar A., 2008, V49, P413, DOI 10.1007/978-1-4020-8831-5_16; Salas A, 2011, BLOOD, V117, P5941, DOI 10.1182/blood-2010-08-300772; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sawafuji K, 2003, LEUKEMIA LYMPHOMA, V44, P1987, DOI 10.1080/1042819031000122033; Schiffmann S, 2009, J LIPID RES, V50, P32, DOI 10.1194/jlr.M800122-JLR200; Shaner RL, 2009, J LIPID RES, V50, P1692, DOI 10.1194/jlr.D800051-JLR200; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Tamborini E, 2006, ONCOGENE, V25, P6140, DOI 10.1038/sj.onc.1209639; TENHOEVE J, 1994, BLOOD, V84, P1731; Tsai CC, 2009, J IMMUNOL, V183, P856, DOI 10.4049/jimmunol.0804033; von Bubnoff N, 2005, LEUKEMIA, V19, P286, DOI 10.1038/sj.leu.2403600; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; Wang SH, 2011, J LIPID RES, V52, P471, DOI 10.1194/jlr.M011015; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675	57	34	37	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3661	3673		10.1096/fj.10-180190	http://dx.doi.org/10.1096/fj.10-180190			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21705667				2022-12-28	WOS:000295356400035
J	Barthet, G; Shioi, J; Shao, ZP; Ren, YM; Georgakopoulos, A; Robakis, NK				Barthet, Gael; Shioi, Junichi; Shao, Zhiping; Ren, Yimin; Georgakopoulos, Anastasios; Robakis, Nikolaos K.			Inhibitors of gamma-secretase stabilize the complex and differentially affect processing of amyloid precursor protein and other substrates	FASEB JOURNAL			English	Article						Alzheimer's disease; A beta; presenilin; N-cadherin	C-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; PRESENILIN; BETA; NICASTRIN; BINDING; TARGET; APH-1; GLYCOSYLATION; TOLERABILITY	gamma-Secretase inhibitors (GSIs) are drugs used in research to inhibit production of A beta and in clinical trials to treat Alzheimer's disease (AD). They inhibit proteolytic activities of gamma-secretase noncompetitively by unknown mechanisms. Here, we used cortical neuronal cultures expressing endogenous levels of enzymes and substrates to study the effects of GSIs on the structure and function of gamma-secretase. We show that GSIs stabilize the interactions between the C-terminal fragment of presenilin (PS-CTF), the central component of the gamma-secretase complex, and its partners the APH-1/nicastrin and PS1-NTF/PEN-2 subcomplexes. This stabilization dose-dependently correlates with inhibition of N-cadherin cleavage, a process limited by enzyme availability. In contrast, production of amyloid precursor protein (APP) intracellular domain (AICD) is insensitive to low concentrations of GSIs and is limited by substrate availability. Interestingly, APP is processed by both PS1- and PS2-containing gamma-secretase complexes, while N-cadherin and ephrinB1 are processed only by PS1-containing complexes. Paradoxically, low concentrations of GSIs specifically increased the levels of A beta without affecting its catabolism, indicating increased A beta production. Our data reveal a mechanism of gamma-secretase inhibition by GSIs and provide evidence that distinct gamma-secretase complexes process specific substrates. Furthermore, our observations have implications for GSIs as therapeutics because processing of functionally important substrates may be inhibited at lower concentrations than A beta.-Barthet, G., Shioi, J., Shao, Z., Ren, Y., Georgakopoulos, A., Robakis, N. K. Inhibitors of gamma-secretase stabilize the complex and differentially affect processing of amyloid precursor protein and other substrates. FASEB J. 25, 2937-2946 (2011). www.fasebj.org	[Robakis, Nikolaos K.] NYU, Mt Sinai Sch Med, Dept Psychiat, Ctr Mol Biol & Genet Neurodegenerat, New York, NY 10029 USA; [Robakis, Nikolaos K.] NYU, Mt Sinai Sch Med, Dept Neurosci, Ctr Mol Biol & Genet Neurodegenerat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Robakis, NK (corresponding author), NYU, Mt Sinai Sch Med, Dept Psychiat, Ctr Mol Biol & Genet Neurodegenerat, 1 Gustave L Levy Pl,Box 1229, New York, NY 10029 USA.	nikos.robakis@mssm.edu	Robakis, Nikolaos/AAA-1838-2021	Barthet, Gael/0000-0003-4025-1616; Georgakopoulos, Anastasios/0000-0001-8241-6306	U.S. National Institutes of Health [AG-017926, NS047229, AG-008200]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG017926, RF1AG008200, R01AG008200, R01AG017926] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institutes of Health grants AG-017926, NS047229, and AG-008200.	Agiostratidou G, 2006, J NEUROCHEM, V96, P1182, DOI 10.1111/j.1471-4159.2005.03616.x; AHN K, 2010, P NATL ACAD SCI USA, P1; Burton CR, 2008, J BIOL CHEM, V283, P22992, DOI 10.1074/jbc.M804175200; Cervantes S, 2004, J BIOL CHEM, V279, P36519, DOI 10.1074/jbc.M404832200; Cummings J, 2010, BIOL PSYCHIAT, V68, P876, DOI 10.1016/j.biopsych.2010.09.020; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Georgakopoulos A, 2006, EMBO J, V25, P1242, DOI 10.1038/sj.emboj.7601031; He G, 2010, NATURE, V467, P95, DOI 10.1038/nature09325; Herl L, 2006, BIOCHEM BIOPH RES CO, V340, P668, DOI 10.1016/j.bbrc.2005.12.063; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Kouchi Z, 2009, J BIOL CHEM, V284, P1954, DOI 10.1074/jbc.M806250200; Kounnas MZ, 2010, NEURON, V67, P769, DOI 10.1016/j.neuron.2010.08.018; Lanz TA, 2006, J PHARMACOL EXP THER, V319, P924, DOI 10.1124/jpet.106.110700; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Martone RL, 2009, J PHARMACOL EXP THER, V331, P598, DOI 10.1124/jpet.109.152975; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Morohashi Y, 2006, J BIOL CHEM, V281, P14670, DOI 10.1074/jbc.M513012200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660; Steiner H, 2008, J BIOL CHEM, V283, P34677, DOI 10.1074/jbc.M709067200; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Waldron E, 2008, EXP CELL RES, V314, P2419, DOI 10.1016/j.yexcr.2008.05.003; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200	34	21	22	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2937	2946		10.1096/fj.11-183806	http://dx.doi.org/10.1096/fj.11-183806			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21597003	Green Published			2022-12-28	WOS:000294435200009
J	Larsen, FJ; Schiffer, TA; Sahlin, K; Ekblom, B; Weitzberg, E; Lundberg, JO				Larsen, Filip J.; Schiffer, Tomas A.; Sahlin, Kent; Ekblom, Bjorn; Weitzberg, Eddie; Lundberg, Jon O.			Mitochondrial oxygen affinity predicts basal metabolic rate in humans	FASEB JOURNAL			English	Article						proton leak; cytochrome c oxidase; efficiency	CYTOCHROME-C-OXIDASE; DIETARY NITRATE SUPPLEMENTATION; HUMAN SKELETAL-MUSCLE; NITRIC-OXIDE; CYCLING EFFICIENCY; ENERGY-EXPENDITURE; CELLULAR RESPIRATION; WORLD-CLASS; IN-VIVO; EXERCISE	The basal metabolic rate (BMR) is referred to as the minimal rate of metabolism required to support basic body functions. It is well known that individual BMR varies greatly, even when correcting for body weight, fat content, and thyroid hormone levels, but the mechanistic determinants of this phenomenon remain unknown. Here, we show in humans that mass-related BMR correlates strongly to the mitochondrial oxygen affinity (p50(mito); R-2 = 0.66, P = 0.0004) measured in isolated skeletal muscle mitochondria. A similar relationship was found for oxygen affinity and efficiency during constant-load submaximal exercise (R-2 = 0.46, P = 0.007). In contrast, BMR did not correlate to overall mitochondrial density or to proton leak. Mechanistically, part of the p50(mito) seems to be controlled by the excess of cytochrome c oxidase (COX) protein and activity relative to other mitochondrial proteins. This is illustrated by the 5-fold increase in p50(mito) after partial cyanide inhibition of COX at doses that do not affect maximal mitochondrial electron flux through the ETS. These data suggest that the interindividual variation in BMR in humans is primarily explained by differences in mitochondrial oxygen affinity. The implications of these findings are discussed in terms of a trade-off between aerobic efficiency and power.-Larsen, F. J., Schiffer, T. A., Sahlin, K., Ekblom, B., Weitzberg, E., Lundberg, J. O. Mitochondrial oxygen affinity predicts basal metabolic rate in humans. FASEB J. 25, 2843-2852 (2011). www.fasebj.org	[Larsen, Filip J.; Schiffer, Tomas A.; Sahlin, Kent; Ekblom, Bjorn; Weitzberg, Eddie; Lundberg, Jon O.] Karolinska Inst, Dept Physiol & Pharmacol, S-11486 Stockholm, Sweden; [Larsen, Filip J.; Sahlin, Kent; Ekblom, Bjorn] Karolinska Inst, Swedish Sch Sport & Hlth Sci, S-11486 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish School of Sport & Health Sciences	Larsen, FJ (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-11486 Stockholm, Sweden.	filip.larsen@ki.se	Schiffer, Tomas/X-1343-2018	Schiffer, Tomas/0000-0002-9077-2682; Lundberg, Jon/0000-0002-0174-5210				ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; Astrand PO, 2003, TXB WORK PHYSL PHYSL, V4th; Bailey SJ, 2010, J APPL PHYSIOL, V109, P135, DOI 10.1152/japplphysiol.00046.2010; Befroy DE, 2008, P NATL ACAD SCI USA, V105, P16701, DOI 10.1073/pnas.0808889105; BESCOS R, 2011, MED SCI SPORTS EXERC; BIENFAIT HF, 1975, BIOCHIM BIOPHYS ACTA, V376, P446, DOI 10.1016/0005-2728(75)90166-8; Boushel R, 2011, MITOCHONDRION, V11, P303, DOI 10.1016/j.mito.2010.12.006; BROUWER E, 1957, ACTA PHYSIOL PHARM N, V6, P795; Cooper CE, 2003, BBA-BIOENERGETICS, V1607, P27, DOI 10.1016/j.bbabio.2003.08.003; COYLE EF, 1992, MED SCI SPORT EXER, V24, P782; DANFORTH E, 1984, CLIN ENDOCRINOL META, V13, P581, DOI 10.1016/S0300-595X(84)80039-0; Darveau CA, 2002, NATURE, V417, P166, DOI 10.1038/417166a; GAESSER GA, 1975, J APPL PHYSIOL, V38, P1132, DOI 10.1152/jappl.1975.38.6.1132; Gnaiger E, 1998, J EXP BIOL, V201, P1129; Gnaiger E, 2003, ADV EXP MED BIOL, V543, P39; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; Johnstone AM, 2005, AM J CLIN NUTR, V82, P941, DOI 10.1093/ajcn/82.5.941; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; KARLSSON J, 1967, J APPL PHYSIOL, V22, P1061, DOI 10.1152/jappl.1967.22.6.1061; Lansley KE, 2011, J APPL PHYSIOL, V110, P591, DOI 10.1152/japplphysiol.01070.2010; Lanza IR, 2010, AM J PHYSIOL-REG I, V299, pR1415, DOI 10.1152/ajpregu.00225.2010; Larsen FJ, 2007, ACTA PHYSIOL, V191, P59, DOI 10.1111/j.1748-1716.2007.01713.x; Larsen FJ, 2011, CELL METAB, V13, P149, DOI 10.1016/j.cmet.2011.01.004; Larsen FJ, 2010, FREE RADICAL BIO MED, V48, P342, DOI 10.1016/j.freeradbiomed.2009.11.006; Leavesley HB, 2008, TOXICOL SCI, V101, P101, DOI 10.1093/toxsci/kfm254; Lucia A, 2002, MED SCI SPORT EXER, V34, P2079, DOI 10.1249/01.MSS.0000039306.92778.DF; Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Mole PA, 1999, AM J PHYSIOL-REG I, V277, pR173, DOI 10.1152/ajpregu.1999.277.1.R173; MORGAN DW, 1994, INT J SPORTS MED, V15, P426, DOI 10.1055/s-2007-1021082; Moseley L, 2004, INT J SPORTS MED, V25, P374, DOI 10.1055/s-2004-815848; Nickleberry BL, 1996, MED SCI SPORT EXER, V28, P1396, DOI 10.1097/00005768-199611000-00008; Pecina P, 2004, AM J PHYSIOL-CELL PH, V287, pC1384, DOI 10.1152/ajpcell.00286.2004; Pierre S, 2006, EUR J APPL PHYSIOL, V97, P133, DOI 10.1007/s00421-006-0132-x; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5; Richardson RS, 1999, J APPL PHYSIOL, V87, P325, DOI 10.1152/jappl.1999.87.1.325; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; Rolfe DFS, 1996, AM J PHYSIOL-CELL PH, V271, pC1380, DOI 10.1152/ajpcell.1996.271.4.C1380; Scandurra FM, 2010, ADV EXP MED BIOL, V662, P7, DOI 10.1007/978-1-4419-1241-1_2; SCHOLANDER PF, 1950, BIOL BULL, V99, P259, DOI 10.2307/1538742; Scott GR, 2011, MOL BIOL EVOL, V28, P351, DOI 10.1093/molbev/msq205; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Speakman JR, 2003, P NUTR SOC, V62, P621, DOI 10.1079/PNS2003282; STEINLECHNERMAR.R, 2006, AM J PHYSIOL, V271, pC2053; SUAREZ RK, 1992, EXPERIENTIA, V48, P565, DOI 10.1007/BF01920240; SULLIVAN MJ, 1994, J APPL PHYSIOL, V77, P2194, DOI 10.1152/jappl.1994.77.5.2194; Vanhatalo A, 2010, AM J PHYSIOL-REG I, V299, pR1121, DOI 10.1152/ajpregu.00206.2010; Verkhovsky MI, 1996, NATURE, V380, P268, DOI 10.1038/380268a0	50	48	50	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2843	2852		10.1096/fj.11-182139	http://dx.doi.org/10.1096/fj.11-182139			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21576503				2022-12-28	WOS:000293337800032
J	Urayama, A; Morales, R; Niehoff, ML; Banks, WA; Soto, C				Urayama, Akihiko; Morales, Rodrigo; Niehoff, Michael L.; Banks, William A.; Soto, Claudio			Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake	FASEB JOURNAL			English	Article						PrPSc; pharmacokinetics; blood-brain barrier	BLOOD-BRAIN-BARRIER; RECEPTOR-MEDIATED TRANSPORT; CYCLIC AMPLIFICATION; PRESYMPTOMATIC DETECTION; SCRAPIE INFECTIVITY; LYSOSOMAL-ENZYME; PROTEIN; NEUROINVASION; PERMEABILITY; REPLICATION	Prion diseases are infectious neurodegenerative disorders associated with the misfolded prion protein (PrPSc), which appears to be the sole component of the infectious agent (termed prion). To produce disease, prions have to be absorbed into the body and reach sufficient quantities in the brain. Very little is known about the biological mechanisms controlling the initial fate of prions. Here, we studied the systemic pharmacokinetics and biodistribution of PrPSc in vivo. After an intravenous injection of highly purified radiolabeled or native unlabeled PrPSc, the protein was eliminated rapidly from the serum (half-life of 3.24 h), mostly through tissue uptake. The quantity of intact PrPSc reaching the brain was similar to 0.2% of the injected dose per gram of brain tissue (ID/g). The highest levels were found in liver (similar to 20% ID/g), spleen (similar to 13% ID/g), and kidney (similar to 7.4% ID/g). Cell surface PrPC does not appear to play a role in PrPSc pharmacokinetics, since the infectious protein distributed similarly in wild-type and PrP-null mice. To measure tissue uptake kinetics and biodistribution accurately, vascular space in tissues was measured with radioactively labeled albumin coinjected with radioactively labeled PrPSc. Our results provide a fundamental pharmacokinetic characterization of PrPSc in vivo, which may be relevant to estimate tissue risks and mechanisms of prion neuroinvasion and to identify novel therapeutic strategies.-Urayama, A., Morales, R., Niehoff, M. L., Banks, W. A., Soto, C. Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake FASEB J. 25, 2792-2803 (2011). www.fasebj.org	[Urayama, Akihiko; Morales, Rodrigo; Soto, Claudio] Univ Texas Houston, Med Sch Houston, Dept Neurol, Mitchell Ctr Alzheimers Dis & Related Brain Disor, Houston, TX 77030 USA; [Niehoff, Michael L.] Vet Affairs Med Ctr St Louis, GRECC, St Louis, MO USA; [Niehoff, Michael L.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO USA; [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA; [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA	University of Texas System; University of Texas Health Science Center Houston; Geriatric Research Education & Clinical Center; Saint Louis University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Urayama, A (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Neurol, Mitchell Ctr Alzheimers Dis & Related Brain Disor, MSE R468,6431 Fannin St, Houston, TX 77030 USA.	akihiko.urayama@uth.tmc.edu; claudio.soto@uth.tmc.edu	Morales, Rodrigo/K-7173-2015; Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619	U.S. National Institutes of Health [R01 NS050547, P01 AI77774]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI077774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050547] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by U.S. National Institutes of Health grant R01 NS050547 (to W.A.B. and C.S.) and P01 AI77774 (to C.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A.U. designed the study, performed the bulk of the experiments, analyzed all data, wrote the manuscript, and managed the peer review process. R.M.L. helped on the characterization of iodinated PrP<SUP>Sc</SUP>. M.L.N. contributed to HPLC analysis. W.A.B. analyzed all data and critically reviewed the manuscript. C.S. developed the hypothesis, wrote the manuscript, and supervised the entire research project and the peer review process.	Aguzzi A, 2003, BRIT MED BULL, V66, P141, DOI 10.1093/bmb/66.1.141; Aguzzi A, 1997, LANCET, V349, P742, DOI 10.1016/S0140-6736(97)22011-8; Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; ALLEN L, 1982, J CLIN PHARMACOL, V22, pS1; Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Baldauf E, 1997, J GEN VIROL, V78, P1187, DOI 10.1099/0022-1317-78-5-1187; Banks WA, 2009, EXP NEUROL, V218, P162, DOI 10.1016/j.expneurol.2009.04.025; Banks WA, 2004, BIOCHEM BIOPH RES CO, V318, P125, DOI 10.1016/j.bbrc.2004.04.009; Banks WA, 1998, PEPTIDES, V19, P883, DOI 10.1016/S0196-9781(98)00018-7; Banks WA, 2001, PSYCHONEUROIMMUNOLOG, V2, P483; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; Bolton DC, 1998, J GEN VIROL, V79, P2557, DOI 10.1099/0022-1317-79-10-2557; Brandner S, 2000, EXP PHYSIOL, V85, P705, DOI 10.1111/j.1469-445X.2000.02091.x; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; Brown P, 2005, VOX SANG, V89, P63, DOI 10.1111/j.1423-0410.2005.00683.x; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2005, NAT MED, V11, P982, DOI 10.1038/nm1286; Castilla J, 2008, EMBO J, V27, P2557, DOI 10.1038/emboj.2008.181; Castilla J, 2008, CELL, V134, P757, DOI 10.1016/j.cell.2008.07.030; Castilla J, 2006, METHOD ENZYMOL, V412, P3, DOI 10.1016/s0076-6879(06)12001-7; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Chen BA, 2010, NAT METHODS, V7, P519, DOI [10.1038/NMETH.1465, 10.1038/nmeth.1465]; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; DEDRICK RL, 1973, BIOCHEM PHARMACOL, V22, P2405, DOI 10.1016/0006-2952(73)90342-0; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; GITLIN D, 1958, NATURE, V181, P1064, DOI 10.1038/1811064b0; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; Head MW, 2004, AM J PATHOL, V164, P143, DOI 10.1016/S0002-9440(10)63105-7; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hetz C, 2003, TRENDS MOL MED, V9, P237, DOI 10.1016/S1471-4914(03)00069-8; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; Kruger D, 2009, VET RES, V40, DOI 10.1051/vetres:2008042; Luhr KM, 2002, J VIROL, V76, P12259, DOI 10.1128/JVI.76.23.12259-12264.2002; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; PODUSLO JF, 1994, P NATL ACAD SCI USA, V91, P5705, DOI 10.1073/pnas.91.12.5705; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Rodriguez EM, 2010, PEPTIDES, V31, P757, DOI 10.1016/j.peptides.2010.01.003; Saa P, 2006, J BIOL CHEM, V281, P35245, DOI 10.1074/jbc.M603964200; Saa P, 2006, SCIENCE, V313, P92, DOI 10.1126/science.1129051; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Scherbel C, 2006, VET RES, V37, P695, DOI 10.1051/vetres:2006024; SISO S, 2010, INTERDISCIP PERSPECT, P747; Soto C, 2005, FEBS LETT, V579, P638, DOI 10.1016/j.febslet.2004.12.035; Urayama A, 2004, P NATL ACAD SCI USA, V101, P12658, DOI 10.1073/pnas.0405042101; Urayama A, 2007, P NATL ACAD SCI USA, V104, P12873, DOI 10.1073/pnas.0705611104; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582	51	13	13	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2792	2803		10.1096/fj.11-180729	http://dx.doi.org/10.1096/fj.11-180729			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21555356	Green Published			2022-12-28	WOS:000293337800027
J	Baillet, A; Xu, R; Grichine, A; Berthier, S; Morel, F; Paclet, MH				Baillet, Athan; Xu, Rang; Grichine, Alexei; Berthier, Sylvie; Morel, Francoise; Paclet, Marie-Helene			Coupling of 6-phosphogluconate dehydrogenase with NADPH oxidase in neutrophils: Nox2 activity regulation by NADPH availability	FASEB JOURNAL			English	Article						phox; siRNA transfection; cytochrome b(558)	CHRONIC GRANULOMATOUS-DISEASE; IMMORTALIZED B-LYMPHOCYTES; CYTOCHROME B(558); RESPIRATORY BURST; GLUCOSE-TRANSPORT; CYTOSOLIC SUBUNIT; N-TERMINUS; ACTIVATION; BINDING; P67(PHOX)	It is well known that activation of the phagocyte NADPH oxidase requires the association of cytosolic proteins (p67-phox, p47-phox, p40-phox, and Rac) with the membrane cytochrome b(558), leading to its conformation change. Recently, the phagocyte NADPH oxidase complex was isolated in a constitutively active form. In this complex, 6-phosphogluconate dehydrogenase (6PGDH), an enzyme involved in the production of intracellular NADPH, was identified. This protein was absent from the oxidase complex isolated from B lymphocytes, suggesting a specific interaction with the neutrophil NADPH oxidase. To clarify the implication of 6PGDH in the NADPH oxidase activity, a siRNA approach was conducted in neutrophil-like PLB985 cells. NADPH oxidase activity of siRNA-transfected cells was shown to be decreased. Similar results were obtained in vitro, after reconstitution of oxidase activity with subcellular fractions isolated from siRNA-transfected cells. Interestingly, the Michaelis constant (Km) of Nox2 for NADPH increases in 6PGDH-depleted cells. Moreover, 6PGDH coimmunoprecipitated with oxidase cytosolic factors from cytosol of stimulated cells. Data suggested that the affinity of Nox2 for NADPH is increased in the presence of 6PGDH on cell stimulation. The present work proposes a new way of NADPH oxidase activity regulation by modulating Nox2 affinity for NADPH.-Baillet, A., Xu, R., Grichine, A., Berthier, S., Morel, F., Paclet, M.-H. Coupling of 6-phosphogluconate dehydrogenase with NADPH oxidase in neutrophils: Nox2 activity regulation by NADPH availability. FASEB J. 25, 2333-2343 (2011). www.fasebj.org	[Paclet, Marie-Helene] UJF, CHU Albert Michallon, CNRS, GREPI TIMC IMAG UMR 5525, F-38043 Grenoble 9, France; [Baillet, Athan] CHU Grenoble, Clin Rheumatol, F-38043 Grenoble, France; [Berthier, Sylvie; Paclet, Marie-Helene] CHU Grenoble, Inst Biol & Pathol, Lab Biochim Enzymes & Prot, F-38043 Grenoble, France; [Grichine, Alexei] UJF, Inst Albert Bonniot, INSERM, U823, La Tronche, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Paclet, MH (corresponding author), UJF, CHU Albert Michallon, CNRS, GREPI TIMC IMAG UMR 5525, 6Eme Etage Unite E,BP 217, F-38043 Grenoble 9, France.	mhpaclet@chu-grenoble.fr	Grichine, Alexei/M-3923-2013; Grichine, Alexei/P-8377-2019; Paclet, Marie-Hélène/AAS-5029-2020	Grichine, Alexei/0000-0002-7335-9706; Grichine, Alexei/0000-0002-7335-9706; 	Ministere de l'Enseignement Superieur de la Recherche et Technologie, Paris; Region Rhone Alpes, Programme MIRA; Programme Emergence; Groupement des Entreprises Francaises dans la Lutte contre le Cancer, Delegation de Grenoble; Fondation pour la Recherche Medicale, Isere; Regionale de la Recherche Clinique; Association Francaise; la Ligue Nationale contre le Cancer; Societe Francaise de Rhumatologie	Ministere de l'Enseignement Superieur de la Recherche et Technologie, Paris; Region Rhone Alpes, Programme MIRA(Region Auvergne-Rhone-Alpes); Programme Emergence; Groupement des Entreprises Francaises dans la Lutte contre le Cancer, Delegation de Grenoble; Fondation pour la Recherche Medicale, Isere(Fondation pour la Recherche Medicale); Regionale de la Recherche Clinique; Association Francaise; la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Societe Francaise de Rhumatologie	This work was supported by grants from the Ministere de l'Enseignement Superieur de la Recherche et Technologie, Paris; the Region Rhone Alpes, Programme MIRA 2001 and Programme Emergence 2003; the Groupement des Entreprises Francaises dans la Lutte contre le Cancer, Delegation de Grenoble; the Fondation pour la Recherche Medicale, Isere; the Direction Regionale de la Recherche Clinique; the Association Francaise; la Ligue Nationale contre le Cancer; and the Societe Francaise de Rhumatologie.	Baciou L, 2009, FEBS LETT, V583, P3225, DOI 10.1016/j.febslet.2009.09.011; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; Campion Y, 2007, BIOCHIMIE, V89, P1145, DOI 10.1016/j.biochi.2007.01.010; Campion Y, 2009, J INNATE IMMUN, V1, P556, DOI 10.1159/000231977; COTTON DJ, 1983, J INFECT DIS, V148, P194, DOI 10.1093/infdis/148.2.194; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Dang PMC, 1999, BIOCHEMISTRY-US, V38, P5746, DOI 10.1021/bi982750f; Dang PMC, 2000, BIOCHEMISTRY-US, V39, P3069, DOI 10.1021/bi9919807; He WW, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-38; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Kindzelskii AL, 2004, J IMMUNOL, V172, P6373, DOI 10.4049/jimmunol.172.10.6373; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINASCHEK G, 1992, EUR J CELL BIOL, V58, P418; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; Nauseef WM, 2008, SEMIN IMMUNOPATHOL, V30, P195, DOI 10.1007/s00281-008-0117-4; Paclet MH, 2007, FASEB J, V21, P1244, DOI 10.1096/fj.06-6852com; Paclet MH, 2004, BIOCHEM J, V382, P981, DOI 10.1042/BJ20040954; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; Segal BH, 2009, CELL MOL LIFE SCI, V66, P553, DOI 10.1007/s00018-009-8506-y; Smith RM, 1996, J CLIN INVEST, V98, P977, DOI 10.1172/JCI118882; SMITH RM, 1989, J BIOL CHEM, V264, P12243; Tan AS, 1998, BLOOD, V91, P649, DOI 10.1182/blood.V91.2.649.649_649_655; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; WEISDORF DJ, 1982, BLOOD, V60, P888; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288	32	12	14	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2333	2343		10.1096/fj.10-173807	http://dx.doi.org/10.1096/fj.10-173807			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21444627				2022-12-28	WOS:000292242200025
J	Kasaikina, MV; Kravtsova, MA; Lee, BC; Seravalli, J; Peterson, DA; Walter, J; Legge, R; Benson, AK; Hatfield, DL; Gladyshev, VN				Kasaikina, Marina V.; Kravtsova, Marina A.; Lee, Byung Cheon; Seravalli, Javier; Peterson, Daniel A.; Walter, Jens; Legge, Ryan; Benson, Andrew K.; Hatfield, Dolph L.; Gladyshev, Vadim N.			Dietary selenium affects host selenoproteome expression by influencing the gut microbiota	FASEB JOURNAL			English	Article						selenoproteins; germ-free mice; high-throughput sequencing	HUMAN HEALTH; DISEASE; MICE; BACTERIA; METABOLISM; MODULATION; OBESITY; COLON	Colonization of the gastrointestinal tract and composition of the microbiota may be influenced by components of the diet, including trace elements. To understand how selenium regulates the intestinal microflora, we used high-throughput sequencing to examine the composition of gut microbiota of mice maintained on selenium-deficient, selenium-sufficient, and selenium-enriched diets. The microbiota diversity increased as a result of selenium in the diet. Specific phylotypes showed differential effects of selenium, even within a genus, implying that selenium had unique effects across microbial taxa. Conventionalized germfree mice subjected to selenium diets gave similar results and showed an increased diversity of the bacterial population in animals fed with higher levels of selenium. Germ-free mice fed selenium diets modified their selenoproteome expression similar to control mice but showed higher levels and activity of glutathione peroxidase 1 and methionine-R-sulfoxide reductase 1 in the liver, suggesting partial sequestration of selenium by the gut microorganisms, limiting its availability for the host. These changes in the selenium status were independent of the levels of other trace elements. The data show that dietary selenium affects both composition of the intestinal microflora and colonization of the gastrointestinal tract, which, in turn, influence the host selenium status and selenoproteome expression.-Kasaikina, M. V., Kravtsova, M. A., Lee, B. C., Seravalli, J., Peterson, D. A., Walter, J., Legge, R., Benson, A. K., Hatfield, D. L., Gladyshev, V. N. Dietary selenium affects host selenoproteome expression by influencing the gut microbiota. FASEB J. 25, 2492-2499 (2011). www.fasebj.org	[Kasaikina, Marina V.; Lee, Byung Cheon; Gladyshev, Vadim N.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Kasaikina, Marina V.; Lee, Byung Cheon; Gladyshev, Vadim N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kasaikina, Marina V.; Kravtsova, Marina A.; Lee, Byung Cheon; Seravalli, Javier; Gladyshev, Vadim N.] Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; [Kasaikina, Marina V.; Kravtsova, Marina A.; Lee, Byung Cheon; Seravalli, Javier; Gladyshev, Vadim N.] Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68583 USA; [Peterson, Daniel A.; Walter, Jens; Legge, Ryan; Benson, Andrew K.] Univ Nebraska, Dept Food Sci & Technol, Lincoln, NE 68583 USA; [Hatfield, Dolph L.] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, New Res Bldg,Rm 435,77 Ave Louis Pasteur, Boston, MA 02115 USA.	vgladyshev@rics.bwh.harvard.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013; Walter, Jens/AAA-7636-2020	Walter, Jens/0000-0003-1754-172X; Gladyshev, Vadim/0000-0002-0372-7016; Benson, Andrew/0000-0001-6330-0252; Lee, Byung Cheon/0000-0003-1467-1940	U.S. National Institutes of Health (NIH) [GM061603, AG021518]; Center for Cancer Research, National Cancer Institute, NIH; NATIONAL CANCER INSTITUTE [ZIABC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021518] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Cancer Research, National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by U.S. National Institutes of Health (NIH) grants GM061603 and AG021518 (to V.N.G.) and the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH (to D.L.H.).	Baesman SA, 2007, APPL ENVIRON MICROB, V73, P2135, DOI 10.1128/AEM.02558-06; Bosschaerts T, 2008, J IMMUNOL, V180, P6168, DOI 10.4049/jimmunol.180.9.6168; Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026; Fava F, 2006, CURR MED CHEM, V13, P3005, DOI 10.2174/092986706778521814; Flint HJ, 2007, ENVIRON MICROBIOL, V9, P1101, DOI 10.1111/j.1462-2920.2007.01281.x; Fukushima K, 2003, SCAND J GASTROENTERO, V38, P626, DOI 10.1080/00365510310000376; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Hattori M, 2009, DNA RES, V16, P1, DOI 10.1093/dnares/dsn033; Hoffmann PR, 2007, NUCLEIC ACIDS RES, V35, P3963, DOI 10.1093/nar/gkm355; Hrdina J, 2009, J NUTR BIOCHEM, V20, P638, DOI 10.1016/j.jnutbio.2008.06.009; Irons R, 2006, J NUTR, V136, P1311, DOI 10.1093/jn/136.5.1311; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Mostert V, 2001, BIOFACTORS, V14, P135, DOI 10.1002/biof.5520140118; Novoselov SV, 2010, ANTIOXID REDOX SIGN, V12, P829, DOI 10.1089/ars.2009.2895; Novoselov SV, 2005, ONCOGENE, V24, P8003, DOI 10.1038/sj.onc.1208940; Oh PL, 2010, ISME J, V4, P377, DOI 10.1038/ismej.2009.123; Possemiers S, 2009, CURR PHARM DESIGN, V15, P2051, DOI 10.2174/138161209788489159; Rock C, 2009, BIOMETALS, V22, P995, DOI 10.1007/s10534-009-9251-2; Schomburg L, 2009, BBA-GEN SUBJECTS, V1790, P1453, DOI 10.1016/j.bbagen.2009.03.015; Stolz JE, 2006, ANNU REV MICROBIOL, V60, P107, DOI 10.1146/annurev.micro.60.080805.142053; Takaishi H, 2008, INT J MED MICROBIOL, V298, P463, DOI 10.1016/j.ijmm.2007.07.016; Tannock GW, 2008, TRENDS MICROBIOL, V16, P488, DOI 10.1016/j.tim.2008.07.005; Tompkins GR, 2001, CURR MICROBIOL, V43, P38, DOI 10.1007/s002840010257; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Yi YS, 2003, BBA-MOL BASIS DIS, V1638, P249, DOI 10.1016/S0925-4439(03)00090-5	27	128	130	10	76	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2492	2499		10.1096/fj.11-181990	http://dx.doi.org/10.1096/fj.11-181990			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21493887	Green Published, Green Submitted			2022-12-28	WOS:000292242200039
J	Sittig, LJ; Shukla, PK; Herzing, LBK; Redei, EE				Sittig, Laura J.; Shukla, Pradeep K.; Herzing, Laura B. K.; Redei, Eva E.			Strain-specific vulnerability to alcohol exposure in utero via hippocampal parent-of-origin expression of deiodinase-III	FASEB JOURNAL			English	Article						fetal alcohol spectrum disorder; thyroid hormone; imprinting; neurodevelopment; social interaction; memory	TYPE-3 IODOTHYRONINE DEIODINASE; SPATIAL WORKING-MEMORY; ACUTE ETHANOL EXPOSURE; THYROID-HORMONE LEVELS; SPECTRUM DISORDERS; MAGNETIC-RESONANCE; MONOALLELIC EXPRESSION; ANTISENSE TRANSCRIPTS; ALLELIC EXPRESSION; MOUSE-BRAIN	Prenatal exposure to alcohol is thought to be the most prevalent nongenetic cause of a wide range of neurodevelopmental deficits. Insufficient thyroid hormone levels are one mechanism that hampers development of the alcohol-exposed brain, and we hypothesized that altered dosage of the imprinted thyroid hormone-inactivating gene deiodinase-III (Dio3) is responsible. To follow parent-of-origin allelic expression of Dio3 in the fetal and adult offspring of alcohol-consuming and control dams, we reciprocally crossed 2 polymorphic rat strains. In the frontal cortex, prenatal alcohol exposure altered imprinting patterns and total expression of Dio3 in the fetus and produced a permanent hypothyroid milieu in the adult. In the hippocampus, alcohol affected the paternal and total expression of Dio3 in the fetus and in the adult male, where thyroid hormone levels were concomitantly increased. Hippocampus-dependent behavioral deficits were identified exclusively in males, suggesting they are dependent on aberrant allelic Dio3 expression. None of these effects were observed in offspring of the reciprocal cross. Thus, genetic background and sex modify vulnerability to prenatal alcohol via brain region-specific expression of Dio3. This finding implies that phenotypic heterogeneity in human fetal alcohol spectrum disorder can be linked to genetic vulnerability in affected brain regions.-Sittig, L. J., Shukla, P. K., Herzing, L. B. K., Redei, E. E. Strain-specific vulnerability to alcohol exposure in utero via hippocampal parent-of-origin expression of deiodinase-III. FASEB J. 25, 2313-2324 (2011). www.fasebj.org	[Sittig, Laura J.; Shukla, Pradeep K.; Redei, Eva E.] Northwestern Univ, Feinberg Sch Med, Asher Ctr, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Herzing, Laura B. K.] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Dept Pediat, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Redei, EE (corresponding author), Northwestern Univ, Feinberg Sch Med, Asher Ctr, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.	e-redei@northwestern.edu			U.S. National Institutes of Health (NIH) [RO1 AA017978, RO1 AA013452]; NIH [F31 AA018251]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017978, R01AA013452, F31AA018251] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The authors thank Dr. Jelena Radulovic for helpful discussions. The authors thank Daniel Schaffer, Brian Andrus, Kanchi Batra, Timothy Ullmann, and Kristen Dennis for help in technical aspects of the study. The work was funded by U.S. National Institutes of Health (NIH) grants RO1 AA017978 and RO1 AA013452 to E.E.R. L.J.S. is a predoctoral fellow funded by NIH grant F31 AA018251.	Aird F, 1997, ALCOHOL CLIN EXP RES, V21, P1560, DOI 10.1111/j.1530-0277.1997.tb04490.x; Altman J. B. S., 1995, ATLAS PRENATAL RAT B; Arfsten DP, 2004, INT J TOXICOL, V23, P47, DOI 10.1080/10915810490265450; ASTLEY SJ, 2009, ALCOHOL CLIN EXP RES, V16, pE178; Astley SJ, 2009, ALCOHOL CLIN EXP RES, V33, P1671, DOI 10.1111/j.1530-0277.2009.01004.x; Bianco AC, 2006, J CLIN INVEST, V116, P2571, DOI 10.1172/JCI29812; Bitanihirwe BKY, 2010, NEUROPSYCHOPHARMACOL, V35, P2462, DOI 10.1038/npp.2010.129; Boehm SL, 1997, ALCOHOL, V14, P389, DOI 10.1016/S0741-8329(97)87950-5; BONTHIUS DJ, 1990, ALCOHOL CLIN EXP RES, V14, P107, DOI 10.1111/j.1530-0277.1990.tb00455.x; Boyles AL, 2010, AM J EPIDEMIOL, V172, P924, DOI 10.1093/aje/kwq226; Calfa G, 2007, BEHAV BRAIN RES, V181, P23, DOI 10.1016/j.bbr.2007.03.020; Cheema ZF, 2000, ALCOHOL CLIN EXP RES, V24, P535, DOI 10.1111/j.1530-0277.2000.tb02022.x; CHRISTOFFEL KK, 1975, J PEDIATR-US, V87, P963, DOI 10.1016/S0022-3476(75)80919-X; Croteau S, 2005, MAMM GENOME, V16, P127, DOI 10.1007/s00335-004-2434-9; Das UG, 2004, ALCOHOL CLIN EXP RES, V28, P1598, DOI 10.1097/01.ALC.0000141816.14776.97; Downing C, 1999, BEHAV GENET, V29, P31, DOI 10.1023/A:1021485821842; Downing C, 2009, ALCOHOL CLIN EXP RES, V33, P1238, DOI 10.1111/j.1530-0277.2009.00949.x; Edwards CA, 2008, PLOS BIOL, V6, P1292, DOI 10.1371/journal.pbio.0060135; Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262; Green CR, 2009, J CHILD PSYCHOL PSYC, V50, P688, DOI 10.1111/j.1469-7610.2008.01990.x; Gregg C, 2010, SCIENCE, V329, P682, DOI 10.1126/science.1190831; Gregg C, 2010, SCIENCE, V329, P643, DOI 10.1126/science.1190830; Haycock PC, 2009, BIOL REPROD, V81, P607, DOI 10.1095/biolreprod.108.074690; Hellemans KGC, 2010, NEUROSCI BIOBEHAV R, V34, P791, DOI 10.1016/j.neubiorev.2009.06.004; Hellemans KGC, 2010, ALCOHOL CLIN EXP RES, V34, P633, DOI 10.1111/j.1530-0277.2009.01132.x; Herman LE, 2008, J POPUL THER CLIN PH, V15, pE411; Hernandez A, 2004, GENOMICS, V83, P413, DOI 10.1016/j.ygeno.2003.08.024; Hernandez A, 2002, ENDOCRINOLOGY, V143, P4483, DOI 10.1210/en.2002-220800; Hernandez A, 2010, ENDOCRINOLOGY, V151, P5550, DOI 10.1210/en.2010-0450; Hofmann CE, 2007, ALCOHOL CLIN EXP RES, V31, P345, DOI 10.1111/j.1530-0277.2006.00316.x; Hogart A, 2008, HUM GENET, V124, P235, DOI 10.1007/s00439-008-0546-0; Huang SA, 2002, J CLIN ENDOCR METAB, V87, P4457, DOI 10.1210/jc.2002-020627; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Jacobsen LK, 2007, J NEUROSCI, V27, P13491, DOI 10.1523/JNEUROSCI.2402-07.2007; Keen CL, 2010, BIOFACTORS, V36, P125, DOI 10.1002/biof.89; Kelly SJ, 2009, ALCOHOL ALCOHOLISM, V44, P555, DOI 10.1093/alcalc/agp061; Kilts CD, 2006, NEUROPSYCHOPHARMACOL, V31, P2243, DOI 10.1038/sj.npp.1301053; Kim CK, 1997, BEHAV NEUROSCI, V111, P985, DOI 10.1037/0735-7044.111.5.985; KOTKOSKIE LA, 1988, ALCOHOL CLIN EXP RES, V12, P831, DOI 10.1111/j.1530-0277.1988.tb01355.x; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lan N, 2006, J NEUROENDOCRINOL, V18, P672, DOI 10.1111/j.1365-2826.2006.01462.x; Lewis A, 2005, CURR BIOL, V15, pR291, DOI 10.1016/j.cub.2005.04.003; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Louis C, 2008, PHARMACOL BIOCHEM BE, V89, P36, DOI 10.1016/j.pbb.2007.10.020; Malisza KL, 2005, PEDIATR RES, V58, P1150, DOI 10.1203/01.pdr.0000185479.92484.a1; McCarver DG, 1997, J PHARMACOL EXP THER, V283, P1095; Meintjes EM, 2010, ALCOHOL CLIN EXP RES, V34, P1450, DOI 10.1111/j.1530-0277.2010.01230.x; MEYER LS, 1986, TERATOLOGY, V34, P1, DOI 10.1002/tera.1420340102; MILLER MW, 1995, ALCOHOL CLIN EXP RES, V19, P1359, DOI 10.1111/j.1530-0277.1995.tb01625.x; Miller MW, 1995, ALCOHOL CLIN EXP RES, V19, P1500, DOI 10.1111/j.1530-0277.1995.tb01014.x; Mueller BR, 2008, J NEUROSCI, V28, P9055, DOI 10.1523/JNEUROSCI.1424-08.2008; O'Hare ED, 2009, HUM BRAIN MAPP, V30, P3200, DOI 10.1002/hbm.20741; Paxinos G., 1998, RAT BRAIN STEROTAXIC; PRACYK JB, 1992, J DEV PHYSIOL, V18, P105; Ranade SC, 2008, NEUROSCIENCE, V152, P859, DOI 10.1016/j.neuroscience.2008.01.002; Rasmussen C, 2005, ALCOHOL CLIN EXP RES, V29, P1359, DOI 10.1097/01.alc.0000175040.91007.d0; Royo H, 2007, MOL BIOL CELL, V18, P2817, DOI 10.1091/mbc.E06-10-0920; Schaefer HS, 2006, BIOL PSYCHIAT, V60, P974, DOI 10.1016/j.biopsych.2006.03.024; SCHAPIRO MB, 1984, NEUROBEH TOXICOL TER, V6, P351; Schlotz W, 2009, BRAIN BEHAV IMMUN, V23, P905, DOI 10.1016/j.bbi.2009.02.001; Shukla PK, 2011, ALCOHOL CLIN EXP RES, V35, P559, DOI 10.1111/j.1530-0277.2010.01373.x; Shukla PK, 2010, PSYCHONEUROENDOCRINO, V35, P791, DOI 10.1016/j.psyneuen.2009.10.019; Sinha P, 1997, ENDOCRINOLOGY, V138, P4792, DOI 10.1210/en.138.11.4792; Sittig LJ, 2011, MOL PSYCHIATR, V16, P786, DOI 10.1038/mp.2011.19; Sittig LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010058; Spadoni AD, 2009, ALCOHOL CLIN EXP RES, V33, P2067, DOI 10.1111/j.1530-0277.2009.01046.x; Spohr HL, 2007, J PEDIATR-US, V150, P175, DOI 10.1016/j.jpeds.2006.11.044; Stoler JM, 2002, J PEDIATR-US, V141, P780, DOI 10.1067/mpd.2002.128112; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; STREISSGUTH AP, 1980, SCIENCE, V209, P353, DOI 10.1126/science.6992275; SULIK KK, 1983, AM J ANAT, V166, P257, DOI 10.1002/aja.1001660303; Takahashi N, 2010, J BIOL CHEM, V285, P26121, DOI 10.1074/jbc.M109.075325; Thomas SE, 1998, ALCOHOL CLIN EXP RES, V22, P528, DOI 10.1111/j.1530-0277.1998.tb03684.x; Tsai CE, 2002, CURR BIOL, V12, P1221, DOI 10.1016/S0960-9822(02)00951-X; Tu HM, 1999, ENDOCRINOLOGY, V140, P784, DOI 10.1210/en.140.2.784; Turner JD, 2008, NUCLEIC ACIDS RES, V36, P7207, DOI 10.1093/nar/gkn897; WALKER P, 1985, CAN J PHYSIOL PHARM, V63, P279, DOI 10.1139/y85-050; WEINBERG J, 1992, ALCOHOL, V9, P219, DOI 10.1016/0741-8329(92)90057-H; WEINBERG J, 1984, NEUROBEH TOXICOL TER, V6, P261; WEST JR, 1986, NEUROTOXICOLOGY, V7, P245; Wilcoxon JS, 2005, MOL PSYCHIATR, V10, P961, DOI 10.1038/sj.mp.4001694; Wilcoxon JS, 2004, AM J PHYSIOL-ENDOC M, V287, pE318, DOI 10.1152/ajpendo.00022.2004; Wilcoxon JS, 2003, AM J PHYSIOL-ENDOC M, V285, pE31, DOI 10.1152/ajpendo.00552.2002; Wilkinson LS, 2007, NAT REV NEUROSCI, V8, P832, DOI 10.1038/nrn2235; Williams GR, 2008, J NEUROENDOCRINOL, V20, P784, DOI 10.1111/j.1365-2826.2008.01733.x; Willoughby KA, 2008, J INT NEUROPSYCH SOC, V14, P1022, DOI 10.1017/S1355617708081368	86	34	36	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2313	2324		10.1096/fj.10-179234	http://dx.doi.org/10.1096/fj.10-179234			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21429942	Green Published			2022-12-28	WOS:000292242200023
J	Westendorp, B; Major, JL; Nader, M; Salih, M; Leenen, FHH; Tuana, BS				Westendorp, Bart; Major, Jennifer L.; Nader, Moni; Salih, Maysoon; Leenen, Frans H. H.; Tuana, Balwant S.			The E2F6 repressor activates gene expression in myocardium resulting in dilated cardiomyopathy	FASEB JOURNAL			English	Article						connexin-43; micro-RNA; transcription factors; transgenic mice	CONNEXIN43 EXPRESSION; INDUCED APOPTOSIS; GAP-JUNCTIONS; MAP KINASE; PROTEIN; FAMILY; PROLIFERATION; INHIBITION; MUTATION; HEART	The E2F/Rb pathway regulates cardiac growth and development and holds great potential as a therapeutic target. The E2F6 repressor is a unique E2F member that acts independently of pocket proteins. Forced expression of E2F6 in mouse myocardium induced heart failure and mortality, with severity of symptoms correlating to E2F6 levels. Echocardiography demonstrated a 37% increase (P<0.05) in left ventricular end-diastolic diameter and reduced ejection fraction (<40%, P<0.05) in young transgenic (Tg) mice. Microarray and qPCR analysis revealed a paradoxical increase in E2F-responsive genes, which regulate the cell cycle, without changes in cardiomyocyte cell number or size in Tg mice. Young adult Tg mice displayed a 75% (P<0.01) decrease in gap junction protein connexin-43, resulting in abnormal electrocardiogram including a 24% (P<0.05) increase in PR interval. Further, mir-206, which targets connexin-43, was up-regulated 10-fold (P<0.05) in Tg myocardium. The mitogen-activated protein kinase pathway, which regulates the levels of miR-206 and connexin-43, was activated in Tg hearts. Thus, deregulated E2F6 levels evoked abnormal gene expression at transcriptional and post-transcriptional levels, leading to cardiac remodeling and dilated cardiomyopathy. The data highlight an unprecedented role for the strict regulation of the E2F pathway in normal postnatal cardiac function.-Westen-dorp, B., Major, J. L., Nader, M., Salih, M., Leenen, F. H. H., Tuana, B. S. The E2F6 repressor activates gene expression in myocardium resulting in dilated cardiomyopathy. FASEB J. 26, 2569-2579 (2012). www.fasebj.org	[Westendorp, Bart; Major, Jennifer L.; Nader, Moni; Salih, Maysoon; Leenen, Frans H. H.; Tuana, Balwant S.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; [Westendorp, Bart; Nader, Moni; Leenen, Frans H. H.; Tuana, Balwant S.] Univ Ottawa, Hypertens Unit, Inst Heart, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa; University of Ottawa Heart Institute	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	btuana@uottawa.ca	Major, Jennifer/K-7268-2019	Nader, Moni/0000-0003-2138-5213; Westendorp, Bart/0000-0003-1043-3638	Canadian Institutes of Health Research [57809]; Heart and Stroke Foundation of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	This work was supported by an operating grant from the Canadian Institutes of Health Research (57809) to B. S. T. B. W. and M. N. were supported by postdoctoral research fellowships from the Heart and Stroke Foundation of Canada. F. H. H. L. holds the Pfizer Chair in Hypertension Research, an endowed chair supported by Pfizer Canada, the University of Ottawa Heart Institute Foundation, and the Canadian Institutes of Health Research. The authors declare no conflicts of interest.	Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006; Anderson C, 2006, NUCLEIC ACIDS RES, V34, P5863, DOI 10.1093/nar/gkl743; Asp P, 2009, GENE DEV, V23, P37, DOI 10.1101/gad.1727309; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Barth AS, 2006, J AM COLL CARDIOL, V48, P1610, DOI 10.1016/j.jacc.2006.07.026; Baudet S, 2000, CARDIOVASC RES, V46, P17, DOI 10.1016/S0008-6363(00)00015-8; Berman SD, 2009, P NATL ACAD SCI USA, V106, P14932, DOI 10.1073/pnas.0902408106; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chang AN, 2005, HEART FAIL REV, V10, P225, DOI 10.1007/s10741-005-5252-6; Cox B, 2006, NAT PROTOC, V1, P1872, DOI 10.1038/nprot.2006.273; Dahme T, 2002, EUR J BIOCHEM, V269, P5030, DOI 10.1046/j.1432-1033.2002.03210.x; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Divakaran V, 2008, CIRC RES, V103, P1072, DOI 10.1161/CIRCRESAHA.108.183087; Ebelt H, 2005, CIRC RES, V96, P509, DOI 10.1161/01.RES.0000159705.17322.57; Ebelt H, 2008, CARDIOVASC RES, V80, P219, DOI 10.1093/cvr/cvn194; Gard JJ, 2005, CARDIOVASC RES, V67, P539, DOI 10.1016/j.cardiores.2005.04.004; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Ivanova IA, 2009, ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kalma Y, 2004, ENDOCRINOLOGY, V145, P1617, DOI 10.1210/en.2003-1051; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; King JC, 2008, CELL CYCLE, V7, P3775, DOI 10.4161/cc.7.23.7240; Kitamura H, 2003, CIRC J, V67, P1017, DOI 10.1253/circj.67.1017; Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010; Luk A, 2009, J CLIN PATHOL, V62, P219, DOI 10.1136/jcp.2008.060731; MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486-2497.2005; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Melcon G, 2006, HUM MOL GENET, V15, P637, DOI 10.1093/hmg/ddi479; Movassagh M, 2006, J PHARM PHARMACOL, V58, P73, DOI 10.1211/jpp.58.1.0009; Muchir A, 2007, HUM MOL GENET, V16, P1884, DOI 10.1093/hmg/ddm137; Muchir A, 2007, J CLIN INVEST, V117, P1282, DOI 10.1172/JCI29042; Muchir A, 2009, HUM MOL GENET, V18, P241, DOI 10.1093/hmg/ddn343; Nader M., AM J PHYSL IN PRESS, V287, pH2468; Park JH, 2008, CELL PROLIFERAT, V41, P786, DOI 10.1111/j.1365-2184.2008.00552.x; Sdek P, 2011, J CELL BIOL, V194, P407, DOI 10.1083/jcb.201012049; Severs NJ, 2008, CARDIOVASC RES, V80, P9, DOI 10.1093/cvr/cvn133; Shan ZX, 2010, FEBS LETT, V584, P3592, DOI 10.1016/j.febslet.2010.07.027; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Sirnes S, 2009, BIOCHEM BIOPH RES CO, V382, P41, DOI 10.1016/j.bbrc.2009.02.141; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Sun LP, 2010, CHINESE MED J-PEKING, V123, P1058, DOI 10.3760/cma.j.issn.0366-6999.2010.08.015; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Thomas PD, 2003, NUCLEIC ACIDS RES, V31, P334, DOI 10.1093/nar/gkg115; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; van Amerongen MJ, 2010, CARDIOVASC RES, V86, P92, DOI 10.1093/cvr/cvp383; Vanderheyden M, 2008, J AM COLL CARDIOL, V51, P129, DOI 10.1016/j.jacc.2007.07.087; Vara D, 2003, J BIOL CHEM, V278, P21388, DOI 10.1074/jbc.M212612200; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; Wohlschlaeger J, 2010, J HEART LUNG TRANSPL, V29, P117, DOI 10.1016/j.healun.2009.09.017; Wu W, 2011, CIRCULATION, V123, P53, DOI 10.1161/CIRCULATIONAHA.110.970673; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yang WW, 2007, CELL DEATH DIFFER, V14, P807, DOI 10.1038/sj.cdd.4402062; Yang WW, 2008, MOL BIOL CELL, V19, P3691, DOI 10.1091/mbc.E08-02-0171	60	13	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2569	2579		10.1096/fj.11-203174	http://dx.doi.org/10.1096/fj.11-203174			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22403008				2022-12-28	WOS:000305017200033
J	Rehman, J; Zhang, HJ; Toth, PT; Zhang, YM; Marsboom, G; Hong, ZG; Salgia, R; Husain, AN; Wietholt, C; Archer, SL				Rehman, Jalees; Zhang, Hannah J.; Toth, Peter T.; Zhang, Yanmin; Marsboom, Glenn; Hong, Zhigang; Salgia, Ravi; Husain, Aliya N.; Wietholt, Christian; Archer, Stephen L.			Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer	FASEB JOURNAL			English	Article						fusion; Drp-1; mitofusin-2	DYNAMIN-RELATED PROTEIN-1; APOPTOSIS; DRP1; EXPRESSION; FUSION; METABOLISM; PROLIFERATION; DIVISION; GROWTH; OPA1	Mitochondria exist in dynamic networks that undergo fusion and fission. Mitochondrial fusion and fission are mediated by several GTPases in the outer mitochondrial membrane, notably mitofusin-2 (Mfn-2), which promotes fusion, and dynamin-related protein (Drp-1), which promotes fission. We report that human lung cancer cell lines exhibit an imbalance of Drp-1/Mfn-2 expression, which promotes a state of mitochondrial fission. Lung tumor tissue samples from patients demonstrated a similar increase in Drp-1 and decrease in Mfn-2 when compared to adjacent healthy lung. Complementary approaches to restore mitochondrial network formation in lung cancer cells by overexpression of Mfn-2, Drp-1 inhibition, or Drp-1 knock-down resulted in a marked reduction of cancer cell proliferation and an increase in spontaneous apoptosis. The number of cancer cells in S phase decreased from 32.4 +/- 0.6 to 6.4 +/- 0.3% with Drp-1 inhibition (P<0.001). In a xenotransplantation model, Mfn-2 gene therapy or Drp-1 inhibition could regress tumor growth. The tumor volume decreased from 205.6 +/- 59 to 70.6 +/- 15 mm(3) (P<0.05) with Mfn-2 overexpression and from 186.0 +/- 19 to 87.0 +/- 6 mm(3) (P<0.01) with therapeutic Drp-1 inhibition. Impaired fusion and enhanced fission contribute fundamentally to the proliferation/apoptosis imbalance in cancer and constitute promising novel therapeutic targets.-Rehman, J., Zhang, H. J., Toth, P. T., Zhang, Y., Marsboom, G., Hong, Z., Salgia, R., Husain, A. N., Wietholt, C., Archer, S. L. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 26, 2175-2186 (2012). www.fasebj.org	[Zhang, Hannah J.; Toth, Peter T.; Marsboom, Glenn; Hong, Zhigang; Wietholt, Christian; Archer, Stephen L.] Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; [Salgia, Ravi] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Husain, Aliya N.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Rehman, Jalees; Zhang, Yanmin] Univ Illinois, Dept Med, Cardiol Sect, Chicago, IL USA; [Rehman, Jalees; Zhang, Yanmin] Univ Illinois, Dept Pharmacol, Chicago, IL USA	University of Chicago; University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Archer, SL (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, 5841 S Maryland Ave,MC6080, Chicago, IL 60637 USA.	sarcher@medicine.bsd.uchicago.edu	Rehman, Jalees/J-8258-2012; Archer, Stephen L/C-3621-2013; Rehman, Jalees/GVU-1981-2022	Rehman, Jalees/0000-0002-2787-9292; Rehman, Jalees/0000-0002-2787-9292; Marsboom, Glenn/0000-0001-6309-7557; Toth, Peter/0000-0003-2168-0124	Harold Hines Jr. Chair in Medicine; U.S. National Institutes of Health (NIH) [NIH-RO1-HL071115, 1RC1HL099462-01, NIH-K08-HL080082, NIH-R01-GM094220, NIH-R01-CA125541-04, NIH-R01-CA 129501-02]; NATIONAL CANCER INSTITUTE [R01CA125541, R01CA129501] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL080082, RC1HL099462, R01HL071115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094220] Funding Source: NIH RePORTER	Harold Hines Jr. Chair in Medicine; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported in part by the Harold Hines Jr. Chair in Medicine and U.S. National Institutes of Health (NIH) grants NIH-RO1-HL071115 (S.A.), 1RC1HL099462-01 (S.A), NIH-K08-HL080082 (J.R.), NIH-R01-GM094220 (J.R.), NIH-R01-CA125541-04 (R.S.), and NIH-R01-CA 129501-02 (R.S.). The authors thank the following colleagues for providing the tools to study mitochondrial networking: Dr. Richard Youle (NIH, Bethesda, MD, USA) for the mito-PA-GFP plasmid, Dr. Michael Frohman (Stony Brook University, Stony Brook, NY, USA) for the mito-DS-Red plasmid, Dr. S. James Remington (University of Oregon, Eugene, OR, USA) for the redox-sensitive ro-GFP plasmid, Dr. Kuang-Hueih Chen (NIH) for the adenovirus containing rat mitofusin-2 cDNA, and Dr. Frederick E. (Rick) Domann, Jr. and Dr. Shawn Flanagan (University of Iowa, Iowa City, IA, USA) for the adenovirus containing the cDNA of human mitochondrially targeted catalase.	Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chang CR, 2010, ANN NY ACAD SCI, V1201, P34, DOI 10.1111/j.1749-6632.2010.05629.x; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chiang YY, 2009, MODERN PATHOL, V22, P1139, DOI 10.1038/modpathol.2009.83; Choi SY, 2006, NAT CELL BIOL, V8, P1255, DOI 10.1038/ncb1487; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Fueger BJ, 2006, J NUCL MED, V47, P999; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gogvadze V, 2009, APOPTOSIS, V14, P624, DOI 10.1007/s10495-009-0323-0; Hanson GT, 2004, J BIOL CHEM, V279, P13044, DOI 10.1074/jbc.M312846200; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; HUDSON HM, 1994, IEEE T MED IMAGING, V13, P601, DOI 10.1109/42.363108; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106; Ong LC, 2008, ACTA RADIOL, V49, P1145, DOI 10.1080/02841850802482486; Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152; Pan XC, 2004, PHYS MED BIOL, V49, P4349, DOI 10.1088/0031-9155/49/18/011; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Wu L, 2008, MOL CANCER THER, V7, P222, DOI 10.1158/1535-7163.MCT-07-0382; Zhao J, 2011, EMBO J, V30, P2762, DOI 10.1038/emboj.2011.198	35	379	386	2	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2175	2186		10.1096/fj.11-196543	http://dx.doi.org/10.1096/fj.11-196543			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22321727	Green Published			2022-12-28	WOS:000303680800043
J	Cao, PX; Sun, WY; Kramp, K; Zheng, MH; Salom, D; Jastrzebska, B; Jin, H; Palczewski, K; Feng, ZY				Cao, Pengxiu; Sun, Wenyu; Kramp, Kristopher; Zheng, Maohua; Salom, David; Jastrzebska, Beata; Jin, Hui; Palczewski, Krzysztof; Feng, Zhaoyang			Light-sensitive coupling of rhodopsin and melanopsin to G(i/o) and G(q) signal transduction in Caenorhabditis elegans	FASEB JOURNAL			English	Article						optogenetics; G-protein signaling	OPTICAL CONTROL; HETEROLOGOUS EXPRESSION; NEURAL ACTIVITY; RECEPTOR; PATHWAY; IDENTIFICATION; ACTIVATION; G(Q)ALPHA; BEHAVIOR; GENE	Activation of G-protein-coupled receptors (GPCRs) initiates signal transduction cascades that affect many physiological responses. The worm Caenorhabditis elegans expresses >1000 of these receptors along with their cognate heterotrimeric G proteins. Here, we report properties of 9-cis-retinal regenerated bovine opsin [(b)isoRho] and human melanopsin [(h)Mo], two light-activated, heterologously expressed GPCRs in the nervous system of C. elegans with various genetically engineered alterations. Profound transient photoactivation of G(i/o) signaling by (b)isoRho led to a sudden and transient loss of worm motility dependent on cyclic adenosine monophosphate, whereas transient photoactivation of G(q) signaling by (h)Mo enhanced worm locomotion dependent on phospholipase C beta. These transgenic C. elegans models provide a unique way to study the consequences of G(i/o) and G(q) signaling in vivo with temporal and spatial precision and, by analogy, their relationship to human neuromotor function.-Cao, P., Sun, W., Kramp, K., Zheng, M., Salom, D., Jastrzebska, B., Jin, H., Palczewski, K., Feng, Z. Light-sensitive coupling of rhodopsin and melanopsin to G(i/o) and G(q) signal transduction in Caenorhabditis elegans. FASEB J. 26, 480-491 (2012). www.fasebj.org	[Palczewski, Krzysztof; Feng, Zhaoyang] Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; [Sun, Wenyu; Salom, David; Palczewski, Krzysztof] Polgenix Inc, Cleveland, OH USA; [Feng, Zhaoyang] Xi An Jiao Tong Univ, Dept Physiol, Coll Med, Xian 710049, Peoples R China	Case Western Reserve University; Xi'an Jiaotong University	Palczewski, K (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu; zxf17@case.edu	Cao, Pengxiu/I-5378-2012; Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526; CAO, PENGXIU/0000-0002-5900-5645; Kramp, Kristopher/0000-0003-2121-9274; Salom, David/0000-0002-3208-1509	U.S. National Institutes of Health [GM083241, EY008061, EY009339, P30 EY11373]; Mt. Sinai Health Care Foundation; National Institute of General Medical Sciences [GM074945]; Polgenix, Inc.; NATIONAL EYE INSTITUTE [R01EY009339, R01EY008061, P30EY011373, R29EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083241, U54GM074945] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mt. Sinai Health Care Foundation; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Polgenix, Inc.; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank L. T. Webster for critical comments on the manuscript. This research was supported in part by grants GM083241 (to Z.F.), EY008061, EY009339 and P30 EY11373 (to K. P., co-principal investigator) from the U.S. National Institutes of Health, and Mt. Sinai Health Care Foundation Scholars Program in the Basic Science (to Z.F.). Research was also supported by a U54 award to the New York SGX Research Center for Structural Genomics (NYSGXRC) from the National Institute of General Medical Sciences (GM074945; principal investigator: Stephen K. Burley) under a contract to Polgenix, Inc. D. S. and W. S. are employees of Polgenix, Inc. K.P. is CSO at Polgenix, Inc. P.C., K.K., B.J., H.J., and Z.F. report no conflicts of interest. The Z.F. laboratory received support from Polgenix, Inc.	Airan RD, 2009, NATURE, V458, P1025, DOI 10.1038/nature07926; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bastiani Carol, 2006, WormBook, P1; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Charlie NK, 2006, GENETICS, V173, P111, DOI 10.1534/genetics.105.054007; Cho SW, 2005, MOL CELLS, V19, P149; Chow BY, 2010, NATURE, V463, P98, DOI 10.1038/nature08652; Darby C, 2001, INFECT IMMUN, V69, P6271, DOI 10.1128/IAI.69.10.6271-6275.2001; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; Edwards SL, 2008, PLOS BIOL, V6, P1715, DOI 10.1371/journal.pbio.0060198; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng ZY, 2006, CELL, V127, P621, DOI 10.1016/j.cell.2006.09.035; Gutierrez DV, 2011, J BIOL CHEM, V286, P25848, DOI 10.1074/jbc.M111.253674; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Han X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000299; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hsu AL, 2009, NEUROBIOL AGING, V30, P1498, DOI 10.1016/j.neurobiolaging.2007.12.007; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; Kiser P. D., 2011, BIOCHIM BIOPHYS ACTA; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Leifer AM, 2011, NAT METHODS, V8, P147, DOI 10.1038/NMETH.1554; Li W, 2006, NATURE, V440, P684, DOI 10.1038/nature04538; Liu J, 2010, NAT NEUROSCI, V13, P715, DOI 10.1038/nn.2540; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; OKKEMA PG, 1993, GENETICS, V135, P385; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Pierce-Shimomura JT, 2008, P NATL ACAD SCI USA, V105, P20982, DOI 10.1073/pnas.0810359105; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Ryu MH, 2010, J BIOL CHEM, V285, P41501, DOI 10.1074/jbc.M110.177600; Salom D, 2012, FASEB J, V26, P492, DOI 10.1096/fj.11-197780; Salom D, 2008, BIOCHEMISTRY-US, V47, P13296, DOI 10.1021/bi8018527; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Stiernagle Theresa, 2006, WormBook, P1; Stirman JN, 2011, NAT METHODS, V8, P153, DOI 10.1038/NMETH.1555; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; Terakita A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-213; Tesmer JJG, 2010, NAT STRUCT MOL BIOL, V17, P650, DOI 10.1038/nsmb0610-650; van der Linden AM, 2003, CURR BIOL, V13, P516, DOI 10.1016/S0960-9822(03)00164-7; von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005; Walker MT, 2008, P NATL ACAD SCI USA, V105, P8861, DOI 10.1073/pnas.0711397105; Ward A, 2008, NAT NEUROSCI, V11, P916, DOI 10.1038/nn.2155; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; Weissenberger S, 2011, J NEUROCHEM, V116, P616, DOI 10.1111/j.1471-4159.2010.07148.x; Yabe T, 2005, DEVELOPMENT, V132, P3197, DOI 10.1242/dev.01909; Yau DM, 2003, P NATL ACAD SCI USA, V100, P14748, DOI 10.1073/pnas.2533143100; Ye HF, 2011, SCIENCE, V332, P1565, DOI 10.1126/science.1203535; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936; Zhang SJ, 2011, J NEUROSCI METH, V197, P315, DOI 10.1016/j.jneumeth.2011.02.014	60	20	23	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					480	491		10.1096/fj.11-197798	http://dx.doi.org/10.1096/fj.11-197798			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22090313	Green Published			2022-12-28	WOS:000300485700002
J	Oztokatli, H; Hornberg, M; Berghard, A; Bohm, S				Oztokatli, Hande; Hornberg, Maria; Berghard, Anna; Bohm, Staffan			Retinoic acid receptor and CNGA2 channel signaling are part of a regulatory feedback loop controlling axonal convergence and survival of olfactory sensory neurons	FASEB JOURNAL			English	Article						retinoids; neuronal activity; caspase-3; Kirrel-2; Neuropilin-1	VOMERONASAL NEURONS; ODORANT RECEPTORS; ADULT MICE; SYSTEM; BULB; EXPRESSION; MAP; PROJECTIONS; MOUSE; DIFFERENTIATION	Little is known about the identities and functions of extracellular signaling molecules that work in concert with neuronal activity to regulate refinement and maintenance of the mouse olfactory sensory map. We show that expression of a dominant negative retinoic acid receptor (RAR) in olfactory sensory neurons (OSNs) increased the number of glomeruli that incorrectly contained OSN axons expressing different odorant receptors. This phenotype became apparent postnatally, coincided with increased cell death, and was preceded by increased Neuropilin-1 and reduced Kirrel-2 expressions. Kirrel-2-mediated cell adhesion influences odorant receptor-specific axonal convergence and is regulated by odorant receptor signaling via the olfactory cyclic nucleotide-gated (CNG) ion channel. Accordingly, we found that inhibited RAR function correlated with reduced CNG channel expression. Naris occlusion experiments and analysis of CNG channel-deficient mice further indicated that RAR-regulated CNG channel levels influenced the intrinsic neuronal activity required for cell survival in the absence of odor stimulation. Finally, we showed that CNG channel activity regulated expression of the retinoic acid-degrading enzyme Cyp26B1. Combined, these results identify a novel homeostatic feedback mechanism involving retinoic acid metabolism and CNG channel activity, which influences glomerular homogeneity and maintenance of precisely connected OSNs.-Oztokatli, H., Hornberg, M., Berghard, A., Bohm, S. Retinoic acid receptor and CNGA2 channel signaling are part of a regulatory feedback loop controlling axonal convergence and survival of olfactory sensory neurons. FASEB J. 26, 617-627 (2012). www.fasebj.org	[Oztokatli, Hande; Hornberg, Maria; Berghard, Anna; Bohm, Staffan] Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden	Umea University	Bohm, S (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	staffan.bohm@molbiol.umu.se			Swedish Medical Science Research Council [K2008-63X-20726-01-3]; Swedish Research Council FORMAS [221-2006-419]	Swedish Medical Science Research Council; Swedish Research Council FORMAS(Swedish Research CouncilSwedish Research Council Formas)	The authors thank Dr. Viktoria Vedin for expert advice on immunohistochemistry; Dr. Jorg Strotmann (University of Hohenheim, Stuttgart, Germany) for allowing the authors to use MOL2.3-IRES-GFP-IRES-tauLacZ mice and for the gift of the anti-MOR256-17 antibody; and Dr. Peter Mombaerts (Max-Planck-Institut fur Biophysik, Frankfurt, Germany) for the P2-IRES-tauLacZ, OMP-tauLacZ, and OCNC1 mutant strains. This work was supported by the Swedish Medical Science Research Council (K2008-63X-20726-01-3) and Swedish Research Council FORMAS (221-2006-419 to A.B.).	Aoto J, 2008, NEURON, V60, P308, DOI 10.1016/j.neuron.2008.08.012; Baker H, 1999, J NEUROSCI, V19, P9313; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; Billig GM, 2011, NAT NEUROSCI, V14, P763, DOI 10.1038/nn.2821; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chesler AT, 2007, P NATL ACAD SCI USA, V104, P1039, DOI 10.1073/pnas.0609215104; Conzelmann S, 2000, EUR J NEUROSCI, V12, P3926, DOI 10.1046/j.1460-9568.2000.00286.x; Cutforth T, 2003, CELL, V114, P311, DOI 10.1016/S0092-8674(03)00568-3; Dal Col JA, 2007, DEVELOPMENT, V134, P2481, DOI 10.1242/dev.006346; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; Di Schiavi E, 2005, EUR J NEUROSCI, V21, P3291, DOI 10.1111/j.1460-9568.2005.04164.x; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Greer PL, 2008, NEURON, V59, P846, DOI 10.1016/j.neuron.2008.09.002; Hagglund M, 2006, J NEUROSCI, V26, P3281, DOI 10.1523/JNEUROSCI.4955-05.2006; Henion TR, 2011, J NEUROSCI, V31, P6576, DOI 10.1523/JNEUROSCI.0224-11.2011; Hornberg M, 2009, J NEUROCHEM, V110, P1263, DOI 10.1111/j.1471-4159.2009.06216.x; Imai T, 2006, SCIENCE, V314, P657, DOI 10.1126/science.1131794; Imai T, 2009, SCIENCE, V325, P585, DOI 10.1126/science.1173596; Ishii T, 2004, J NEUROCYTOL, V33, P657, DOI 10.1007/s11068-005-3334-y; Jones SV, 2008, J NEUROSCI, V28, P13106, DOI 10.1523/JNEUROSCI.4465-08.2008; Kerr MA, 2006, NAT NEUROSCI, V9, P484, DOI 10.1038/nn1673; Langton S, 2008, DEV BIOL, V315, P331, DOI 10.1016/j.ydbio.2007.12.021; Lin CW, 2010, NEURON, V65, P32, DOI 10.1016/j.neuron.2009.12.001; Lin DM, 2000, NEURON, V26, P69, DOI 10.1016/S0896-6273(00)81139-3; Maden M, 2007, NAT REV NEUROSCI, V8, P755, DOI 10.1038/nrn2212; Maritan M, 2009, P NATL ACAD SCI USA, V106, P3537, DOI 10.1073/pnas.0813224106; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Munger SD, 2009, ANNU REV PHYSIOL, V71, P115, DOI 10.1146/annurev.physiol.70.113006.100608; Murphy GJ, 2003, NEURON, V37, P639, DOI 10.1016/S0896-6273(03)00057-6; Niederreither K, 2002, MECH DEVELOP, V110, P165, DOI 10.1016/S0925-4773(01)00561-5; Norlin EM, 2001, MOL CELL NEUROSCI, V18, P283, DOI 10.1006/mcne.2001.1019; Pun RYK, 2003, BIOPHYS J, V84, P3425, DOI 10.1016/S0006-3495(03)70064-2; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Schwarting GA, 2004, EUR J NEUROSCI, V19, P1800, DOI 10.1111/j.1460-9568.2004.03304.x; Serizawa S, 2006, CELL, V127, P1057, DOI 10.1016/j.cell.2006.10.031; Strotmann J, 2004, J NEUROSCI, V24, P7754, DOI 10.1523/JNEUROSCI.2588-04.2004; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VERHAAGEN J, 1989, J NEUROSCI, V9, P683; Yu CR, 2004, NEURON, V42, P553, DOI 10.1016/S0896-6273(04)00224-7; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X; Zou DJ, 2004, SCIENCE, V304, P1976, DOI 10.1126/science.1093468; Zou DJ, 2007, J NEUROSCI, V27, P6675, DOI 10.1523/JNEUROSCI.0699-07.2007; Zou DJ, 2009, NAT REV NEUROSCI, V10, P611, DOI 10.1038/nrn2666	47	16	17	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					617	627		10.1096/fj.11-192450	http://dx.doi.org/10.1096/fj.11-192450			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22009938	Green Published			2022-12-28	WOS:000300485700015
J	Herring, A; Donath, A; Yarmolenko, M; Uslar, E; Conzen, C; Kanakis, D; Bosma, C; Worm, K; Paulus, W; Keyvani, K				Herring, Arne; Donath, Anja; Yarmolenko, Maksym; Uslar, Ellen; Conzen, Catharina; Kanakis, Dimitrios; Bosma, Claudius; Worm, Karl; Paulus, Werner; Keyvani, Kathy			Exercise during pregnancy mitigates Alzheimer-like pathology in mouse offspring	FASEB JOURNAL			English	Article						maternal running; progeny; APP processing and amyloid; inflammation; plasticity	AMYLOID-BETA-PEPTIDE; ENVIRONMENTAL ENRICHMENT; LIPOPROTEIN RECEPTORS; REELIN EXPRESSION; PHYSICAL-ACTIVITY; OXIDATIVE DAMAGE; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; DISEASE	Physical activity protects brain function in healthy individuals and those with Alzheimer's disease (AD). Evidence for beneficial effects of parental exercise on the health status of their progeny is sparse and limited to nondiseased individuals. Here, we questioned whether maternal running interferes with offspring's AD-like pathology and sought to decipher the underlying mechanisms in TgCRND8 mice. Maternal stimulation was provided by voluntary wheel running vs. standard housing during pregnancy. Following 5 mo of standard housing of transgenic and wild-type offspring, their brains were examined for AD-related pathology and/or plasticity changes. Running during pregnancy reduced beta-amyloid (A beta) plaque burden (-35%, P = 0.017) and amyloidogenic APP processing in transgenic offspring and further improved the neurovascular function by orchestrating different A beta transporters and increasing angiogenesis (+29%, P = 0.022). This effect was accompanied by diminished inflammation, as indicated by reduced microgliosis (-20%, P = 0.002) and down-regulation of other proinflammatory mediators, and resulted in less oxidative stress, as nitrotyrosine levels declined (-28%, P = 0.029). Moreover, plasticity changes (in terms of up-regulation of reelin, synaptophysin, and ARC) were found not only in transgenic but also in wild-type offspring. We conclude that exercise during pregnancy provides long-lasting protection from neurodegeneration and improves brain plasticity in the otherwise unstimulated progeny.-Herring, A., Donath, A., Yarmolenko, M., Uslar, E., Conzen, C., Kanakis, D., Bosma, C., Worm, K., Paulus, W., Keyvani, K. Exercise during pregnancy mitigates Alzheimer-like pathology in mouse offspring. FASEB J. 26, 117-128 (2012). www.fasebj.org	[Herring, Arne; Donath, Anja; Yarmolenko, Maksym; Uslar, Ellen; Conzen, Catharina; Kanakis, Dimitrios; Bosma, Claudius; Worm, Karl; Keyvani, Kathy] Univ Hosp Essen, Inst Pathol & Neuropathol, D-45122 Essen, Germany; [Paulus, Werner] Univ Hosp Muenster, Inst Neuropathol, Munster, Germany	University of Duisburg Essen; University of Munster	Keyvani, K (corresponding author), Univ Hosp Essen, Inst Pathol & Neuropathol, Hufelandstr 55, D-45122 Essen, Germany.	kathy.keyvani@uk-essen.de			Innovative Medical Research (IMF) [KE 110711]	Innovative Medical Research (IMF)	The authors thank A. Wagner, D. Bergmann, A. Kurowski, and J. Scheich for technical assistance and David Westaway (University of Toronto, Toronto, ON, Canada) for providing TgCRND8 mice. This work was supported by a grant from Innovative Medical Research (IMF; KE 110711).	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Ambree O, 2006, AM J PATHOL, V169, P544, DOI 10.2353/ajpath.2006.051107; Arai JA, 2009, J NEUROSCI, V29, P1496, DOI 10.1523/JNEUROSCI.5057-08.2009; Becker M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012793; Bell RD, 2007, J CEREBR BLOOD F MET, V27, P909, DOI 10.1038/sj.jcbfm.9600419; Bick-Sander A, 2006, P NATL ACAD SCI USA, V103, P3852, DOI 10.1073/pnas.0502644103; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Botella-Lopez A, 2006, P NATL ACAD SCI USA, V103, P5573, DOI 10.1073/pnas.0601279103; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chin J, 2007, J NEUROSCI, V27, P2727, DOI 10.1523/JNEUROSCI.3758-06.2007; Ciaccio C, 2009, J MOL BIOL, V385, P1556, DOI 10.1016/j.jmb.2008.11.025; Clapp JF, 1996, J PEDIATR-US, V129, P856, DOI 10.1016/S0022-3476(96)70029-X; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Herring A, 2008, BRAIN PATHOL, V18, P32, DOI 10.1111/j.1750-3639.2007.00094.x; Herring A, 2011, NEUROBIOL DIS, V42, P530, DOI 10.1016/j.nbd.2011.03.007; Herring A, 2010, BRAIN PATHOL, V20, P166, DOI 10.1111/j.1750-3639.2008.00257.x; Herring A, 2009, EXP NEUROL, V216, P184, DOI 10.1016/j.expneurol.2008.11.027; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Hoe HS, 2006, J BIOL CHEM, V281, P35176, DOI 10.1074/jbc.M602162200; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Kim H, 2007, INT J DEV NEUROSCI, V25, P243, DOI 10.1016/j.ijdevneu.2007.03.003; Kocherhans S, 2010, J NEUROSCI, V30, P9228, DOI 10.1523/JNEUROSCI.0418-10.2010; Kuhnke D, 2007, BRAIN PATHOL, V17, P347, DOI 10.1111/j.1750-3639.2007.00075.x; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Liu HL, 2011, BEHAV BRAIN RES, V218, P308, DOI 10.1016/j.bbr.2010.12.030; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Pan WH, 2004, J CELL SCI, V117, P5071, DOI 10.1242/jcs.01381; Parachikova A, 2008, NEUROBIOL DIS, V30, P121, DOI 10.1016/j.nbd.2007.12.008; Plath N, 2006, NEURON, V52, P437, DOI 10.1016/j.neuron.2006.08.024; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Reddy PH, 2006, J NEUROCHEM, V96, P1, DOI 10.1111/j.1471-4159.2005.03530.x; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144; Senechal Y, 2007, J NEUROCHEM, V102, P1928, DOI 10.1111/j.1471-4159.2007.04672.x; Song MK, 2009, BRIT J PHARMACOL, V158, P442, DOI 10.1111/j.1476-5381.2009.00201.x; Stengel A, 2010, ENDOCRINOLOGY, V151, P4224, DOI 10.1210/en.2010-0195; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Um HS, 2008, INT J MOL MED, V22, P529, DOI 10.3892/ijmm_00000052; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Walker DG, 2006, J LEUKOCYTE BIOL, V79, P596, DOI 10.1189/jlb.0705377; Weissgerber TL, 2006, APPL PHYSIOL NUTR ME, V31, P661, DOI [10.1139/H06-060, 10.1139/h06-060]; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; Wolf SA, 2006, BIOL PSYCHIAT, V60, P1314, DOI 10.1016/j.biopsych.2006.04.004; Yamashita N, 1999, J EXP MED, V189, P1699, DOI 10.1084/jem.189.11.1699; Zhao ST, 2006, J COMP NEUROL, V495, P1, DOI 10.1002/cne.20846; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001	53	64	65	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					117	128		10.1096/fj.11-193193	http://dx.doi.org/10.1096/fj.11-193193			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21948247				2022-12-28	WOS:000299202200013
J	Morin, A; Fritsch, L; Mathieu, JRR; Gilbert, C; Guarmit, B; Firlej, V; Gallou-Kabani, C; Vieillefond, A; Delongchamps, NB; Cabon, F				Morin, Aurelie; Fritsch, Lauriane; Mathieu, Jacques R. R.; Gilbert, Cristele; Guarmit, Basma; Firlej, Virginie; Gallou-Kabani, Catherine; Vieillefond, Annick; Delongchamps, Nicolas Barry; Cabon, Florence			Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence	FASEB JOURNAL			English	Article						pyrimidine biosynthesis; nuclear translocation	PYRIMIDINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN; EXPRESSION; PURIFICATION; URIDINE	Markers of prostate tumor recurrence after radical prostatectomy are lacking and highly demanded. The androgen receptor (AR) is a nuclear receptor that plays a pivotal role in normal and cancerous prostate tissue. AR interacts with a number of proteins modulating its stability, localization, and activity. To test the hypothesis that an increased expression of AR partners might foster tumor development, we immunopurified AR partners in human tumors xeno-grafted into mice. One of the identified AR partners was the multifunctional enzyme carbamoyl-phosphate synthetase II, aspartate transcarbamylase, and dihydro-orotase (CAD), which catalyzes the 3 initial steps of pyrimidine biosynthesis. We combined experiments in C4-2, LNCaP, 22RV1, and PC3 human prostate cell lines and analysis of frozen radical prostatectomy samples to study the CAD-AR interaction. We show here that in prostate tumor cells, CAD fosters AR translocation into the nucleus and stimulates its transcriptional activity. Notably, in radical prostatectomy specimens, CAD expression was not correlated with proliferation markers, but a higher CAD mRNA level was associated with local tumor extension (P=0.049) and cancer relapse (P=0.017). These results demonstrate an unsuspected function for a key metabolic enzyme and identify CAD as a potential predictive marker of cancer relapse.-Morin, A., Fritsch, L., Mathieu, J. R. R., Gilbert, C., Guarmit, B., Firlej, V., Gallou-Kabani, C., Vieillefond, A., Delongchamps, N. B., Cabon, F. Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J. 26, 460-467 (2012). www.fasebj.org	[Morin, Aurelie; Mathieu, Jacques R. R.; Gilbert, Cristele; Firlej, Virginie; Delongchamps, Nicolas Barry; Cabon, Florence] Univ Paris 11, FRE3239, CNRS, Villejuif, France; [Fritsch, Lauriane] Univ Paris Diderot, CNRS, Unite Mixte Rech UMR 7216, Paris, France; [Guarmit, Basma] Ctr Mediterraneen Med Mol, INSERM, U895, Nice, France; [Gallou-Kabani, Catherine; Cabon, Florence] SeleXel, Toulouse, France; [Vieillefond, Annick; Delongchamps, Nicolas Barry] Paris Descartes Univ, Cochin Hosp, Dept Urol & Pathol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Cabon, F (corresponding author), INSERM, UMR1037, 1 Ave Jean Poulhes, F-31403 Toulouse 4, France.	florence.cabon@inserm.fr	Firlej, Virginie/R-2065-2018; Firlej, Virginie/AFQ-6362-2022; Delongchamps, Nicolas Barry/AAE-8651-2020; Cabon, Florence/B-3284-2013	Firlej, Virginie/0000-0003-4132-0695; Cabon, Florence/0000-0002-6149-082X				Ameyar-Zazoua M, 2009, J BIOL CHEM, V284, P27974, DOI 10.1074/jbc.M109.037929; Bettoun D. J., 2005, J BIOL CHEM; Borley N, 2009, ASIAN J ANDROL, V11, P74, DOI 10.1038/aja.2008.19; Brizova H, 2010, VIRCHOWS ARCH, V456, P671, DOI 10.1007/s00428-010-0922-8; CHAPARIAN MG, 1988, FASEB J, V2, P2982, DOI 10.1096/fasebj.2.14.2903106; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chi KN, 2009, EUR UROL, V56, P594, DOI 10.1016/j.eururo.2009.06.027; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; Colombel M, 2005, CANCER RES, V65, P300; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; KARLE JM, 1984, J BIOL CHEM, V259, P67; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Qiu YQ, 2008, ASIAN J ANDROL, V10, P855, DOI 10.1111/j.1745-7262.2008.00428.x; REARDON MA, 1987, BIOCHEM BIOPH RES CO, V147, P494, DOI 10.1016/S0006-291X(87)80148-1; Sigoillot FD, 2005, J BIOL CHEM, V280, P25611, DOI 10.1074/jbc.M504581200; Sigoillot FD, 2004, INT J CANCER, V109, P491, DOI 10.1002/ijc.11717; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; TESSERA L, 1995, ANTICANCER RES, V15, P189; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441	25	15	15	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					460	467		10.1096/fj.11-191296	http://dx.doi.org/10.1096/fj.11-191296			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21982950				2022-12-28	WOS:000299202200045
J	El-Armouche, A; Wittkopper, K; Fuller, W; Howie, J; Shattock, MJ; Pavlovic, D				El-Armouche, Ali; Wittkoepper, Katrin; Fuller, William; Howie, Jacqueline; Shattock, Michael J.; Pavlovic, Davor			Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase	FASEB JOURNAL			English	Article						sodium pump; FXYD1; beta-adrenergic signaling; heart failure	PROTEIN PHOSPHATASE-1; HEART-FAILURE; NA+ CONCENTRATION; PUMP FUNCTION; PHOSPHORYLATION; CONTRACTILITY; EXPRESSION; MYOCYTES; ACTIVATION; SERINE-68	Cardiac Na/K-ATPase (NKA) is regulated by its accessory protein phospholemman (PLM). Whereas kinase-induced PLM phosphorylation has been shown to mediate NKA stimulation, the role of endogenous phosphatases is presently unknown. We investigated the role of protein phosphatase-1 (PP-1) on PLM phosphorylation and NKA activity in rat cardiomyocytes and failing human hearts. Incubation of rat cardiomyocytes with the chemical PP-1/PP-2A inhibitor okadaic acid or the specific PP-1-inhibitor peptide (I-1ct) identified PLM phosphorylation at Ser-68 as the main substrate for PP-1. Moreover, myocytes adenovirally overexpressing PP-1 inhibitor-1 protein (I-1,Ad-I-1/eGFP) showed a 70% increase in PLM Ser-68 phosphorylation and 65% increase in NKA current, compared with enhanced green fluorescence protein (eGFP)-infected controls (Ad-eGFP), using Western blotting and voltage clamping, respectively. Notably, in left ventricular myocardium from patients with heart failure, PLM Ser-68 phosphorylation was similar to 50% lower (n=7) than in nonfailing controls (n=7). We provide the first physiological and biochemical evidence that PLM phosphorylation and cardiac Na/K-ATPase activity are negatively regulated by PP-1 and that this regulatory mechanism could be counteracted by I-1. This novel mechanism is markedly perturbed in failing hearts favoring PLM dephosphorylation and NKA deactivation and thus may contribute to maladaptive hypertrophy and arrhythmogenesis via chronically higher intracellular Na and Ca concentrations.-El-Armouche, A., Wittkopper, K., Fuller, W., Howie, J., Shattock, M. J., Pavlovic, D. Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J. 25, 4467-4475 (2011). www.fasebj.org	[El-Armouche, Ali; Wittkoepper, Katrin] Univ Med Ctr Gottingen, Ctr Heart, Dept Pharmacol, Gottingen, Germany; [Fuller, William; Howie, Jacqueline] Univ Dundee, Ctr Cardiovasc & Lung Biol, Dundee, Scotland; [Shattock, Michael J.; Pavlovic, Davor] Kings Coll London, Div Cardiovasc, London SE1 7EH, England	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Dundee; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England.	michael.shattock@kcl.ac.uk	El-Armouche, Ali/H-3161-2018	El-Armouche, Ali/0000-0003-2514-9429; Pavlovic, Davor/0000-0002-3171-3551; Fuller, William/0000-0002-5883-4433; Shattock, Michael/0000-0001-6242-7585	British Heart Foundation; Medical Research Council; Deutsche Forschungsgemeinschaft; German Heart Foundation; MRC [G0700903] Funding Source: UKRI; British Heart Foundation [RG/07/001/22628] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Heart Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation)	The authors thank Shiney Reiji for expert help with the isolation of the myocytes and Susanne Lutz for technical advice for adenovirus generation. This work was supported by grants from the British Heart Foundation, the Medical Research Council, the Deutsche Forschungsgemeinschaft, and the German Heart Foundation. The authors have no conflicts of interest to disclose.	ALLEN PD, 1992, BASIC RES CARDIOL, V87, P87; Baartscheer A, 2003, CARDIOVASC RES, V57, P1015, DOI 10.1016/S0008-6363(02)00809-X; Berry RG, 2007, CARDIOVASC RES, V73, P92, DOI 10.1016/j.cardiores.2006.11.006; Bers DM, 2006, J PHARMACOL SCI, V100, P315, DOI 10.1254/jphs.CPJ06001X; Bers DM, 2009, TRENDS CARDIOVAS MED, V19, P111, DOI 10.1016/j.tcm.2009.07.001; Bollen M, 2010, TRENDS BIOCHEM SCI, V35, P450, DOI 10.1016/j.tibs.2010.03.002; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Carr AN, 2001, J PHYSIOL-LONDON, V534, P357, DOI 10.1111/j.1469-7793.2001.00357.x; Despa S, 2002, CIRCULATION, V105, P2543, DOI 10.1161/01.CIR.0000016701.85760.97; Despa S, 2008, CIRCULATION, V117, P1849, DOI 10.1161/CIRCULATIONAHA.107.754051; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; El-Armouche A, 2008, CARDIOVASC RES, V80, P396, DOI 10.1093/cvr/cvn208; El-Armouche A, 2006, CIRCULATION, V114, P670, DOI 10.1161/CIRCULATIONAHA.106.636845; El-Armouche A, 2006, BIOCHEM BIOPH RES CO, V346, P700, DOI 10.1016/j.bbrc.2006.05.182; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Fuller W, 2009, AM J PHYSIOL-CELL PH, V296, pC1346, DOI 10.1152/ajpcell.00523.2008; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; Han F, 2006, CIRC RES, V99, P1376, DOI 10.1161/01.RES.0000251667.73461.fb; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hedou GF, 2008, J NEUROSCI, V28, P154, DOI 10.1523/JNEUROSCI.4109-07.2008; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; LEE CO, 1982, BIOPHYS J, V40, P185, DOI 10.1016/S0006-3495(82)84474-3; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Nicklin S A, 1999, Methods Mol Med, V30, P271, DOI 10.1385/1-59259-247-3:271; Nicolaou P, 2009, J MOL CELL CARDIOL, V47, P365, DOI 10.1016/j.yjmcc.2009.05.010; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Pavlovic D, 2007, FASEB J, V21, P1539, DOI 10.1096/fj.06-7269com; Pavlovic D, 2010, EXP PHYSIOL, V95, P518, DOI 10.1113/expphysiol.2009.052126; Pieske B, 2002, CIRCULATION, V106, P447, DOI 10.1161/01.CIR.0000023042.50192.F4; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Schwinger RHG, 1999, CIRCULATION, V99, P2105, DOI 10.1161/01.CIR.99.16.2105; Semb SO, 1998, J MOL CELL CARDIOL, V30, P1311; Shattock MJ, 2009, CURR OPIN PHARMACOL, V9, P160, DOI 10.1016/j.coph.2008.12.015; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Verdonck F, 2003, CARDIOVASC RES, V57, P1035, DOI 10.1016/S0008-6363(02)00734-4; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wittkopper K, 2010, BASIC RES CARDIOL, V105, P569, DOI 10.1007/s00395-010-0107-2; Wittopper K, 2010, J CLIN INVEST, V120, P617, DOI 10.1172/JCI40545; Zalk R, 2007, ANNU REV BIOCHEM, V76, P367, DOI 10.1146/annurev.biochem.76.053105.094237	47	29	30	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4467	4475		10.1096/fj.11-184903	http://dx.doi.org/10.1096/fj.11-184903			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21849407				2022-12-28	WOS:000298138100037
J	Vivarini, AD; Pereira, RDS; Teixeira, KLD; Calegari-Silva, TC; Bellio, M; Laurenti, MD; Corbett, CEP; Gomes, CMD; Soares, RP; Silva, AM; Silveira, FT; Lopes, UG				Vivarini, Aislan de Carvalho; Santos Pereira, Renata de Meirelles; Dias Teixeira, Karina Luiza; Calegari-Silva, Teresa Cristina; Bellio, Maria; Laurenti, Marcia Dalastra; Pereira Corbett, Carlos Eduardo; de Castro Gomes, Claudia Maria; Soares, Rodrigo Pedro; Silva, Aristobolo Mendes; Silveira, Fernando Tobias; Lopes, Ulisses Gazos			Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2	FASEB JOURNAL			English	Article						interferon-1; Toll-like receptor 2; SOD1	PROTOZOAN PARASITE LEISHMANIA; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; VIRAL-INFECTION; I INTERFERON; RECEPTOR 2; IFN-BETA; LIPOPHOSPHOGLYCAN; MACROPHAGES; ACTIVATION	We investigated the type I interferon (IFN-1)/PKR axis in the outcome of the Leishmania (Leishmania) amazonensis infection, along with the underlying mechanisms that trigger and sustain this signaling pathway. Reporter assays of cell extracts from RAW-264.7 macrophages infected with L. (L.) amazonensis or HEK-293T cells cotransfected with TLR2 and PKR promoter constructions were employed. Primary macrophages of TLR2-knockout (KO) or IFNR-KO mice were infected, and the levels of PKR, IFN-1, and superoxide dismutase 1 (SOD1) transcript levels were investigated and compared. Immunohistochemical analysis of human biopsy lesions was evaluated for IFN-1 and PKR-positive cells. Leishmania infection increased the expression of PKR and IFN-beta on induction of PKR-promoter activity. The observed effects required the engagement of TLR2. TLR2-KO macrophages expressed low IFN-beta and PKR levels postinfection with a reduced parasite load. We also revealed the requirement of PKR signaling for Leishmania-induced IFN-1 expression, responsible for sustaining PKR expression and enhancing infection. Moreover, during infection, SOD1 transcripts increased and were also enhanced when IFN-1 was added to the cultures. Remarkably, SOD1 expression was abrogated in infected, dominant-negative PKR-expressing cells. Finally, lesions of patients with anergic diffuse cutaneous leishmaniasis exhibited higher levels of PKR/IFN1-expressing cells compared to those with single cutaneous leishmaniasis. In summary, we demonstrated the mechanisms and relevance of the IFN-1/PKR axis in the Leishmania infection.-De Carvalho Vivarini, A., Pereira, R. M. S., Dias Teixeira, K. L., Calegari-Silva, T. C., Bellio, M., Laurenti, M. D., Corbett, C. E. P., de Castro Gomes, C. M., Soares, R. P., Mendes Silva, A., Silveira, F. T., Lopes, U. G. Human cutaneous leish-maniasis: interferon-dependent expression of double-stranded RNA-kinase (PKR) via TLR2. FASEB J. 25, 4162-4173 (2011). www.fasebj.org	[Lopes, Ulisses Gazos] Univ Fed Rio de Janeiro, Ilha Fundao, Inst Biofis Carlos Chagas Filho, Lab Parasitol Mol,CCS, BR-21940902 Rio De Janeiro, Brazil; [Bellio, Maria] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21940902 Rio De Janeiro, Brazil; [Laurenti, Marcia Dalastra; Pereira Corbett, Carlos Eduardo; de Castro Gomes, Claudia Maria] Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil; [Soares, Rodrigo Pedro] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil; [Silva, Aristobolo Mendes] Univ Fed Minas Gerais, Inst Ciencias Biol, Lab Genes Inflamatorios, Belo Horizonte, MG, Brazil; [Silveira, Fernando Tobias] Minist Saude, Inst Evandro Chagas, Lab Leishmaniose, Belem, Para, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais; Instituto Evandro Chagas	Lopes, UG (corresponding author), Univ Fed Rio de Janeiro, Ilha Fundao, Inst Biofis Carlos Chagas Filho, Lab Parasitol Mol,CCS, Av Carlos Chagas Filho S-N, BR-21940902 Rio De Janeiro, Brazil.	lopesu@biof.ufrj.br	Pereira, Renata/V-6194-2019; Corbett, Carlos E P/R-7090-2018; Silva, Aristobolo/CAF-4874-2022; Silva, Aristóbolo/AAA-2239-2021; Lopes, Ulisses/N-4416-2013; Silveira, Fernando Tobias/AAE-5767-2021; Vivarini, Áislan/G-3249-2015; Lopes, Ulisses Gazos/T-6634-2019; Bellio, Maria/N-8525-2018; Dias Teixeira, Karina/J-4918-2017; Laurenti, Marcia Dalastra/C-4734-2012	Silva, Aristóbolo/0000-0001-7473-7433; Silveira, Fernando Tobias/0000-0002-0412-6060; Vivarini, Áislan/0000-0002-2629-257X; Bellio, Maria/0000-0002-3360-2740; Dias Teixeira, Karina/0000-0002-6115-6768; Calegari Silva, Teresa Cristina/0000-0002-1656-3460; Pereira, Renata/0000-0002-7719-8356; Pereira Corbett, Carlos Eduardo/0000-0003-1587-3085	Instituto Nacional de Ciencia e Tecnologia-Pesquisa Translacional em Saude e Ambiente na Regiao Amazonica (INCT-IMPeTAM); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	Instituto Nacional de Ciencia e Tecnologia-Pesquisa Translacional em Saude e Ambiente na Regiao Amazonica (INCT-IMPeTAM); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	The authors especially thank Paulo Cordeiro for his technical assistance. The authors are most grateful to Dr. Charles Samuel (University of California, Santa Barbara, CA, USA) for providing the PKR-promoter constructs used in this study. The authors are in debt to Dr. Marcelo Torres Bozza (Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil) for providing the IFNRA-KO mice and Judy Grevan and James Scott-Browne (La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA) for editing the manuscript. This work was supported by the Instituto Nacional de Ciencia e Tecnologia-Pesquisa Translacional em Saude e Ambiente na Regiao Amazonica (INCT-IMPeTAM), Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico (CNPq), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP).	Akuffo H, 1997, J INFECT DIS, V175, P737, DOI 10.1093/infdis/175.3.737; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Barbalat R, 2009, NAT IMMUNOL, V10, P1200, DOI 10.1038/ni.1792; Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Bonfim G., 1996, EXP PARASITOL, V84, P188; Brittingham A, 1996, PARASITOL TODAY, V12, P444, DOI 10.1016/0169-4758(96)10067-3; Cabanski M, 2008, AM J RESP CELL MOL, V38, P26, DOI 10.1165/rcmb.2007-0010OC; Chai Y, 2011, MOL BIOL REP, V38, P139, DOI 10.1007/s11033-010-0087-1; Cheung BKW, 2005, J IMMUNOL, V175, P7218, DOI 10.4049/jimmunol.175.11.7218; Cohen-Chalamish S, 2009, NAT CHEM BIOL, V5, P896, DOI 10.1038/nchembio.234; Das S, 2006, J BIOL CHEM, V281, P3244, DOI 10.1074/jbc.M510612200; de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Dietrich N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010250; Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634; Gregory DJ, 2005, PARASITOLOGY, V130, pS27, DOI 10.1017/S0031182005008139; Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326; Kamhawi S, 2004, CELL, V119, P329, DOI 10.1016/j.cell.2004.10.009; Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394; Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Lykens JE, 2010, J IMMUNOL, V184, P877, DOI 10.4049/jimmunol.0902346; Mattner J, 2004, J IMMUNOL, V172, P7574, DOI 10.4049/jimmunol.172.12.7574; Mattner J, 2000, EUR J IMMUNOL, V30, P2257, DOI 10.1002/1521-4141(2000)30:8&lt;2257::AID-IMMU2257&gt;3.0.CO;2-U; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Pereira RMS, 2010, FASEB J, V24, P617, DOI 10.1096/fj.09-140053; Perry AK, 2005, CELL RES, V15, P407, DOI 10.1038/sj.cr.7290309; Pindel A, 2011, J INTERF CYTOK RES, V31, P59, DOI 10.1089/jir.2010.0099; Schriefer A, 2008, CURR OPIN INFECT DIS, V21, P483, DOI 10.1097/QCO.0b013e32830d0ee8; Schulz O, 2010, CELL HOST MICROBE, V7, P354, DOI 10.1016/j.chom.2010.04.007; Shankar AH, 1996, EXP PARASITOL, V84, P136, DOI 10.1006/expr.1996.0099; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x; Silveira FT, 1998, PARASITE IMMUNOL, V20, P19, DOI 10.1046/j.1365-3024.1998.00126.x; Soares RPP, 2002, MOL BIOCHEM PARASIT, V121, P213, DOI 10.1016/S0166-6851(02)00033-6; Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772; Vargas-Inchaustegui DA, 2009, INFECT IMMUN, V77, P2948, DOI 10.1128/IAI.00154-09; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; *WHO, 2010, LEISHM BURD DIS; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wilson J, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000179	45	46	47	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4162	4173		10.1096/fj.11-185165	http://dx.doi.org/10.1096/fj.11-185165			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21846836				2022-12-28	WOS:000298138100010
J	Polge, C; Heng, AE; Jarzaguet, M; Ventadour, S; Claustre, A; Combaret, L; Bechet, D; Matondo, M; Uttenweiler-Joseph, S; Monsarrat, B; Attaix, D; Taillandier, D				Polge, Cecile; Heng, Anne-Elisabeth; Jarzaguet, Marianne; Ventadour, Sophie; Claustre, Agnes; Combaret, Lydie; Bechet, Daniel; Matondo, Mariette; Uttenweiler-Joseph, Sandrine; Monsarrat, Bernard; Attaix, Didier; Taillandier, Daniel			Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1	FASEB JOURNAL			English	Article						proteasome; C2C12	RING FINGER PROTEINS; SKELETAL-MUSCLE; UBIQUITIN LIGASE; SOLEUS MUSCLE; STRIATED-MUSCLE; ATROPHY; PROTEASOME; DEGRADATION; ACTIVATION; EXPRESSION	Muscle atrophy prevails in numerous diseases (cancer cachexia, renal failure, infections, etc.), mainly results from elevated proteolysis, and is accelerated by bed rest. This largely contributes to increased health costs. Devising new strategies to prevent muscle wasting is a major clinical challenge. The ubiquitin proteasome system (UPS) degrades myofibrillar proteins, but the precise mechanisms responsible for actin breakdown are surprisingly poorly characterized. We report that chimeric flag-actin was destabilized and polyubiquitinylated in stably transfected C2C12 myotubes treated with the catabolic agent dexamethasone (1 mu M) and that only proteasome inhibitors blocked its breakdown. Actin polyubiquitinylation was also detected in wild-type C2C12 myotubes and human muscle biopsies from control participants and patients with cancer. The muscle-specific E3 ubiquitin ligase MuRF1 is up-regulated in catabolic conditions and polyubiquitinylates components of the thick filament. We also demonstrate that recombinant GST-MuRF1 physically interacted and polyubiquitinylated actin in vitro and that MuRF1 is a critical component for actin breakdown, since MuRF1 siRNA stabilized flag-actin. These data identify unambiguously the abundant contractile protein actin as a target of the UPS in skeletal muscle both in vitro and in vivo, further supporting the need for new strategies blocking specifically the activation of this pathway in muscle wasting conditions.-Polge, C., Heng, A.-E., Jarzaguet, M., Ventadour, S., Claustre, A., Combaret, L., Bechet, D., Matondo, M., Uttenweiler-Joseph, S., Monsarrat, B., Attaix, D., Taillandier, D. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790-3802 (2011). www.fasebj.org	[Polge, Cecile; Heng, Anne-Elisabeth; Jarzaguet, Marianne; Ventadour, Sophie; Claustre, Agnes; Combaret, Lydie; Bechet, Daniel; Attaix, Didier; Taillandier, Daniel] INRA, UMR 1019, UNH, Ctr Rech Nutr Humaine CNRH Auvergne, F-63000 Clermont Ferrand, France; [Polge, Cecile; Heng, Anne-Elisabeth; Jarzaguet, Marianne; Ventadour, Sophie; Claustre, Agnes; Combaret, Lydie; Bechet, Daniel; Attaix, Didier; Taillandier, Daniel] Univ Auvergne, Clermont Univ, UNH, Clermont Ferrand, France; [Heng, Anne-Elisabeth] Hyg Hosp REUNNIRH, Serv Nephrol Reanimat Med, Clermont Ferrand, France; [Matondo, Mariette; Uttenweiler-Joseph, Sandrine; Monsarrat, Bernard] CNRS, Toulouse, France; [Uttenweiler-Joseph, Sandrine; Monsarrat, Bernard; Attaix, Didier] Univ Toulouse 3, Univ Toulouse, IPBS, F-31062 Toulouse, France	INRAE; Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Taillandier, D (corresponding author), INRA, CRNH Auvergne, Unite Nutr Humaine, BP10448, F-63000 Clermont Ferrand, France.	daniel.taillandier@clermont.inra.fr	Matondo, Mariette/AAA-4163-2020; Bechet, Daniel/AAU-2874-2020; Polge, Cécile/AAM-2467-2020; Attaix, Didier/H-5247-2011	Matondo, Mariette/0000-0003-3958-7710; Bechet, Daniel/0000-0002-3812-8099; Polge, Cécile/0000-0002-8730-5776; Taillandier, Daniel/0000-0003-4520-0551; Attaix, Didier/0000-0002-0429-9957; Combaret, Lydie/0000-0001-6550-8700; Uttenweiler, Sandrine/0000-0001-9019-4766	Institut National de la Recherche Agronomique; Association Francaise contre les Myopathies	Institut National de la Recherche Agronomique; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	The authors thank Prof. Martin Rechsteiner and Dr. Patrick Young for the generous gift of the MLG clone. The authors are grateful to Dr. May Morris for providing the CADY peptide used for the KO experiments. This work was supported by grants to D.T., C.P., and/or D.A. from the Institut National de la Recherche Agronomique and the Association Francaise contre les Myopathies.	Adegoke OAJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE482, DOI 10.1152/ajpendo.00097.2002; Attaix D, 2005, ESSAYS BIOCHEM, V41, P173, DOI 10.1042/EB0410173; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; CAMPOS Y, PLOS ONE, V5, pE9866; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Chen CS, 2007, FEBS LETT, V581, P1124, DOI 10.1016/j.febslet.2007.02.018; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Cosper PF, 2011, CANCER RES, V71, P1710, DOI 10.1158/0008-5472.CAN-10-3145; Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215; Dammer EB, 2011, J BIOL CHEM, V286, P10457, DOI 10.1074/jbc.M110.149633; Dimitrova LN, 2009, J BIOL CHEM, V284, P10343, DOI 10.1074/jbc.M808840200; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Fielitz J, 2007, J CLIN INVEST, V117, P2486, DOI 10.1172/JCI32827; Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gregorio CC, 2005, J MUSCLE RES CELL M, V26, P389, DOI 10.1007/s10974-005-9021-x; Heng AE, 2008, INT J BIOCHEM CELL B, V40, P2544, DOI 10.1016/j.biocel.2008.04.013; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Kaneko-Oshikawa C, 2005, MOL CELL BIOL, V25, P10953, DOI 10.1128/MCB.25.24.10953-10964.2005; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Krawiec BJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE1555, DOI 10.1152/ajpendo.00622.2006; Kudryashova E, 2005, J MOL BIOL, V354, P413, DOI 10.1016/j.jmb.2005.09.068; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Lagirand-Cantaloube J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004973; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Locke M, 2009, HUM MOL GENET, V18, P2344, DOI 10.1093/hmg/ddp167; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Menconi M, 2008, J CELL BIOCHEM, V105, P353, DOI 10.1002/jcb.21833; Nastasi T, 2004, DEV CELL, V6, P269, DOI 10.1016/S1534-5807(04)00020-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sassone J, 2006, EUR J HISTOCHEM, V50, P109; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stawiecka-Mirota M, 2008, EXP CELL RES, V314, P3318, DOI 10.1016/j.yexcr.2008.08.017; Taillandier D, 2003, INT J BIOCHEM CELL B, V35, P665, DOI 10.1016/S1357-2725(03)00004-9; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Tsapara A, 1999, FEBS LETT, V455, P117, DOI 10.1016/S0014-5793(99)00848-0; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Vazeille E, 2008, AM J PHYSIOL-ENDOC M, V295, pE1181, DOI 10.1152/ajpendo.90532.2008; Ventadour S, 2007, J BIOL CHEM, V282, P5302, DOI 10.1074/jbc.M610005200	46	102	112	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3790	3802		10.1096/fj.11-180968	http://dx.doi.org/10.1096/fj.11-180968			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21764995				2022-12-28	WOS:000296723100005
J	Wang, Q; Levay, K; Chanturiya, T; Dvoriantchikova, G; Anderson, KL; Bianco, SDC; Ueta, CB; Molano, RD; Pileggi, A; Gurevich, EV; Gavrilova, O; Slepak, VZ				Wang, Qiang; Levay, Konstantin; Chanturiya, Tatyana; Dvoriantchikova, Galina; Anderson, Karen L.; Bianco, Suzy D. C.; Ueta, Cintia B.; Molano, R. Damaris; Pileggi, Antonello; Gurevich, Eugenia V.; Gavrilova, Oksana; Slepak, Vladlen Z.			Targeted deletion of one or two copies of the G protein beta subunit G beta 5 gene has distinct effects on body weight and behavior in mice	FASEB JOURNAL			English	Article						RGS protein; obesity; insulin; pancreas; RGS7	RGS PROTEINS; REGULATORS; RECEPTOR; FAMILY; COMPLEX; DOMAIN; SELECTIVITY; ACTIVATION; MODULATOR; SURVIVAL	We investigated the physiological role of G beta 5, a unique G protein beta subunit that dimerizes with regulators of G protein signaling (RGS) proteins of the R7 family instead of G gamma. G beta 5 is essential for stability of these complexes, so that its knockout (KO) causes degradation of the entire G beta 5-R7 family. We report that the G beta 5-KO mice remain leaner than the wild type (WT) throughout their lifetime and are resistant to a high-fat diet. They have a 5-fold increase in locomotor activity, increased thermogenesis, and lower serum insulin, all of which correlate with a higher level of secreted epinephrine. Heterozygous (HET) mice are 2-fold more active than WT mice. Surprisingly, with respect to body weight, the HET mice display a phenotype opposite to that of the KO mice: by the age of 6 mo, they are >= 15% heavier than the WT and have increased adiposity, insulin resistance, and liver steatosis. These changes occur in HET mice fed a normal diet and without apparent hyperphagia, mimicking basic characteristics of human metabolic syndrome. We conclude that even a partial reduction in G beta 5-R7 level can perturb normal animal metabolism and behavior. Our data on G beta 5 haploinsufficient mice may explain earlier observations of genetic linkage between R7 family mutations and obesity in humans.-Wang, Q., Levay, K., Chanturiya, T., Dvoriantchikova, G., Anderson, K. L., Bianco, S. D. C., Ueta, C. B., Molano, R. D., Pileggi, A., Gurevich, E. V., Gavrilova, O., and Slepak, V. Z. Targeted deletion of one or two copies of the G protein beta subunit G beta 5 gene has distinct effects on body weight and behavior in mice. FASEB J. 25, 3949-3957 (2011). www.fasebj.org	[Wang, Qiang; Levay, Konstantin; Bianco, Suzy D. C.; Slepak, Vladlen Z.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Dvoriantchikova, Galina] Univ Miami, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA; [Anderson, Karen L.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA; [Bianco, Suzy D. C.; Ueta, Cintia B.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA; [Molano, R. Damaris; Pileggi, Antonello] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA; [Pileggi, Antonello] Univ Miami, Miller Sch Med, Dept Surg, Div Cellular Transplantat, Miami, FL 33136 USA; [Chanturiya, Tatyana; Gavrilova, Oksana] NIDDK, Mouse Metab Core Lab, NIH, Bethesda, MD USA; [Gurevich, Eugenia V.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Vanderbilt University	Slepak, VZ (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	v.slepak@miami.edu	Molano, Ruth Damaris/B-8633-2015; Pileggi, Antonello/A-2394-2008; Ueta, Cintia/D-6832-2013; Bianco, Suzy D.C./E-8892-2010	Molano, Ruth Damaris/0000-0002-6132-8750; Pileggi, Antonello/0000-0001-7819-2813; Bianco, Suzy D.C./0000-0003-3794-9853	U.S. National Institutes of Health (NIH) [GM 060019, 1R01 EB008009, NS065868]; Juvenile Diabetes Research Foundation; NIH [DK70460, NIHU42 RR016603]; City of Hope (Duarte, CA, USA); NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB008009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZICDK070002, U01DK070460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065868] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); City of Hope (Duarte, CA, USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Ching-Kang Chen (Virginia Commonwealth University, Richmond, VA, USA) for G beta 5-KO mice and Drs. Yossef Itzhak, Ronald Goldberg, Alessia Fornoni, and Valery Shestopalov for providing necessary equipment and invaluable critical discussions. The authors are also grateful to Darla Karpinsky, Elsie Zahr-Akrawi, Maite Lopez, Yelena Gadea, and Susana Villate for technical assistance. This study was supported by U.S. National Institutes of Health (NIH) grants GM 060019 (V.Z.S), 1R01 EB008009, and NS065868 (E.V.G) and by the Juvenile Diabetes Research Foundation (A.P.). Pancreatic islets were obtained through the support of NIH grants DK70460 and NIHU42 RR016603 and the City of Hope (Duarte, CA, USA).	Aissani B, 2006, OBESITY, V14, P1605, DOI 10.1038/oby.2006.185; Anderson GR, 2009, CELL BIOCHEM BIOPHYS, V54, P33, DOI 10.1007/s12013-009-9052-9; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berney T, 2003, TRANSPLANTATION, V76, P1669, DOI 10.1097/01.TP.0000092525.17025.D0; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Cao Y, 2009, J NEUROSCI, V29, P9301, DOI 10.1523/JNEUROSCI.1367-09.2009; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Chidiac P, 2003, RECEPTOR CHANNEL, V9, P135, DOI 10.3109/10606820308244; Cone RD, 2000, J CLIN INVEST, V106, P185, DOI 10.1172/JCI10628; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gautam D., ENDOCRINOLOGY, V151, P5185; Gautam D, 2006, CELL METAB, V4, P363, DOI 10.1016/j.cmet.2006.09.008; Gavrilova O, 2000, DIABETES, V49, P1910, DOI 10.2337/diabetes.49.11.1910; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Itoh M, 2006, J NEUROCHEM, V99, P1505, DOI 10.1111/j.1471-4159.2006.04220.x; Jayaraman M, 2009, TRENDS PHARMACOL SCI, V30, P17, DOI 10.1016/j.tips.2008.10.002; Jones MB, 2004, MOL INTERV, V4, P200, DOI 10.1124/mi.4.4.4; Kong K. C., P NATL ACAD SCI US, V107, P21181; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018-004-4462-3; Molano RD, 2003, DIABETES, V52, P957, DOI 10.2337/diabetes.52.4.957; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Oswal A, 2007, OBES REV, V8, P293, DOI 10.1111/j.1467-789X.2007.00378.x; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Posokhova E, 2010, CIRC RES, V107, P1350, DOI 10.1161/CIRCRESAHA.110.224212; Psifogeorgou K, 2007, J NEUROCHEM, V103, P617, DOI 10.1111/j.1471-4159.2007.04812.x; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Sandiford SL, 2009, BIOCHEMISTRY-US, V48, P2282, DOI 10.1021/bi801989c; Sibbel SP, 2011, OBESITY, V19, P1433, DOI 10.1038/oby.2010.333; Slepak V. Z., 2009, STRUCTURE FUNCTION L, V86; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Witherow DS, 2003, RECEPTOR CHANNEL, V9, P205, DOI 10.1080/10606820390203848; Yang JQ, 2010, CIRC RES, V107, P1345, DOI 10.1161/CIRCRESAHA.110.224220; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100; Zahr E, 2007, TRANSPLANTATION, V84, P1576, DOI 10.1097/01.tp.0000296035.48728.28	42	24	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3949	3957		10.1096/fj.11-190157	http://dx.doi.org/10.1096/fj.11-190157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21804131	Green Published			2022-12-28	WOS:000296723100019
J	Kashimada, K; Svingen, T; Feng, CW; Pelosi, E; Bagheri-Fam, S; Harley, VR; Schlessinger, D; Bowles, J; Koopman, P				Kashimada, Kenichi; Svingen, Terje; Feng, Chun-Wei; Pelosi, Emanuele; Bagheri-Fam, Stefan; Harley, Vincent R.; Schlessinger, David; Bowles, Josephine; Koopman, Peter			Antagonistic regulation of Cyp26b1 by transcription factors SOX9/SF1 and FOXL2 during gonadal development in mice	FASEB JOURNAL			English	Article						Forkhead box protein L2; germ cells; meiosis; retinoic acid; sex determination	STEROIDOGENIC FACTOR-I; GERM-CELL FATE; SEX DETERMINATION; RETINOIC-ACID; GENE-TRANSCRIPTION; TESTIS DEVELOPMENT; NUCLEAR RECEPTOR; MOUSE; DIFFERENTIATION; EXPRESSION	Sex determination in fetal germ cells depends on a balance between exposure to retinoic acid (RA) and the degradation of RA achieved by the testis-specific expression of the catabolic cytochrome P450 enzyme, CYP26B1. Therefore, identification of factors regulating the expression of the Cyp26b1 gene is an important goal in reproductive biology. We used in situ hybridization to demonstrate that Cyp26b1 and transcription factor genes steroidogenic factor-1 (Sf1) and Sry-related HMG box 9 (Sox9) are coexpressed in Sertoli cells, whereas Cyp26b1 and Sf1 are coexpressed in Leydig cells in mouse fetal testes. In the mouse gonadal somatic cell line TM3, transfection of constructs expressing SOX9 and SF1 activated Cyp26b1 expression, independently of the positive regulator RA. In embryonic gonads deficient in SOX9 or SF1, Cyp26b1 expression was decreased relative to wild-type (WT) controls, as measured by quantitative RT-PCR (qRT-PCR). Furthermore, qRT-PCR showed that Cyp26b1 up-regulation by SOX9/SF1 was attenuated by the ovarian transcription factor Forkhead box L2 (FOXL2) in TM3 cells, whereas in Foxl2-null mice, Cyp26b1 expression in XX gonads was increased similar to 20-fold relative to WT controls. These data support the hypothesis that SOX9 and SF1 ensure the male fate of germ cells by up-regulating Cyp26b1 and that FOXL2 acts to antagonize Cyp26b1 expression in ovaries.-Kashimada, K., Svingen, T., Feng, C.-W., Pelosi, E., Bagheri-Fam, S., Harley, V. R., Schlessinger, D., Bowles, J., Koopman, P. Antagonistic regulation of Cyp26b1 by transcription factors SOX9/SF1 and FOXL2 during gonadal development in mice. FASEB J. 25, 3561-3569 (2011). www.fasebj.org	[Kashimada, Kenichi; Svingen, Terje; Feng, Chun-Wei; Bowles, Josephine; Koopman, Peter] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Pelosi, Emanuele; Schlessinger, David] NIA, NIH, Biomed Res Ctr, Intramural Res Program,Lab Genet, Baltimore, MD 21224 USA; [Bagheri-Fam, Stefan; Harley, Vincent R.] Prince Henrys Inst Med Res, Clayton, Vic, Australia	University of Queensland; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Prince Henry's Institute of Medical Research	Koopman, P (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	p.koopman@imb.uq.edu.au	Pelosi, Emanuele/D-2015-2017; Harley, Vincent/B-8092-2018; Svingen, Terje/A-5283-2010; Bowles, Josephine/B-6583-2013; Feng, Chun-Wei/I-8575-2017; Bowles, Josephine/AAG-4903-2020; Koopman, Peter A/C-9416-2009	Pelosi, Emanuele/0000-0003-1890-9821; Harley, Vincent/0000-0002-2405-1262; Svingen, Terje/0000-0003-4650-7651; Bowles, Josephine/0000-0003-2867-7438; Feng, Chun-Wei/0000-0001-9510-1012; Bowles, Josephine/0000-0003-2867-7438; Koopman, Peter A/0000-0001-6939-0914; Kashimada, Kenichi/0000-0003-2505-5932	Australian Research Council (ARC); National Health and Medical Research Council of Australia; U.S. National Institutes of Health, National Institute on Aging; NATIONAL INSTITUTE ON AGING [ZIAAG000647] Funding Source: NIH RePORTER	Australian Research Council (ARC)(Australian Research Council); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); U.S. National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank R. Chandraratna and K. Yin Tsang (Vitae Pharmaceuticals, Fort Washington, PA, USA) for providing AGN193109, Ken-Ichirou Morohashi (Kyushu University, Fukuoka, Japan) for providing SF1 antibody, and Sally L. Dunwoodie (Victor Chang Cardiac Research Institute, Sydney, NSW, Australia) for providing Cited2-knockout mice. The authors also thank C. Spiller and C. Harris for technical support. This work was supported by research grants from the Australian Research Council (ARC), the National Health and Medical Research Council of Australia, and the Intramural Research Program of the U.S. National Institutes of Health, National Institute on Aging. P.K. is a Federation Fellow of the ARC.	Agarwal C, 1996, J BIOL CHEM, V271, P12209, DOI 10.1074/jbc.271.21.12209; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Barrionuevo F, 2006, BIOL REPROD, V74, P195, DOI 10.1095/biolreprod.105.045930; Barrionuevo F, 2009, DEV BIOL, V327, P301, DOI 10.1016/j.ydbio.2008.12.011; Beverdam A, 2003, CYTOGENET GENOME RES, V101, P242, DOI 10.1159/000074344; Bowles J, 2006, SCIENCE, V312, P596, DOI 10.1126/science.1125691; Bowles J, 2010, DEV CELL, V19, P440, DOI 10.1016/j.devcel.2010.08.010; Bowles J, 2009, DEV DYNAM, V238, P2073, DOI 10.1002/dvdy.22024; Buaas FW, 2009, HUM MOL GENET, V18, P2989, DOI 10.1093/hmg/ddp237; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chuma S, 2001, DEV BIOL, V229, P468, DOI 10.1006/dbio.2000.9989; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; de Santa Barbara P, 1998, J BIOL CHEM, V273, P29654; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Garcia-Ortiz JE, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-36; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HILSCHER B, 1974, CELL TISSUE RES, V154, P443, DOI 10.1007/BF00219667; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; Kashimada K, 2011, ENDOCRINOLOGY, V152, P272, DOI 10.1210/en.2010-0636; Kent J, 1996, DEVELOPMENT, V122, P2813; Kim Y, 2006, DEV DYNAM, V235, P2292, DOI 10.1002/dvdy.20894; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koubova J, 2006, P NATL ACAD SCI USA, V103, P2474, DOI 10.1073/pnas.0510813103; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; MacLean G, 2007, ENDOCRINOLOGY, V148, P4560, DOI 10.1210/en.2007-0492; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; McLaren A, 1984, Symp Soc Exp Biol, V38, P7; McLaren A, 2003, DEV BIOL, V262, P1, DOI 10.1016/S0012-1606(03)00214-8; McLaren A, 1995, PHILOS T R SOC B, V350, P229, DOI 10.1098/rstb.1995.0156; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nef Serge, 2009, Journal of Biology (London), V8, P74, DOI 10.1186/jbiol173; Ottolenghi C, 2007, HUM MOL GENET, V16, P2795, DOI 10.1093/hmg/ddm235; Ottolenghi C, 2007, BIOESSAYS, V29, P15, DOI 10.1002/bies.20515; Pailhoux E, 2001, NAT GENET, V29, P453, DOI 10.1038/ng769; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Park M, 2010, MOL ENDOCRINOL, V24, P1024, DOI 10.1210/me.2009-0375; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Reijntjes S, 2005, DEV BIOL, V285, P224, DOI 10.1016/j.ydbio.2005.06.019; Sadovsky Y, 1998, J SOC GYNECOL INVEST, V5, P6, DOI 10.1016/S1071-5576(97)00096-8; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Schepers G, 2003, J BIOL CHEM, V278, P28101, DOI 10.1074/jbc.M304067200; Schmidt D, 2004, DEVELOPMENT, V131, P933, DOI 10.1242/dev.00969; Sekido R, 2008, NATURE, V453, P930, DOI 10.1038/nature06944; Svingen T, 2009, SEX DEV, V3, P194, DOI 10.1159/000228720; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Val P, 2007, DEVELOPMENT, V134, P2349, DOI 10.1242/dev.004390; Wang DS, 2007, MOL ENDOCRINOL, V21, P712, DOI 10.1210/me.2006-0248; Wilhelm D, 2005, DEV BIOL, V287, P111, DOI 10.1016/j.ydbio.2005.08.039; Wilhelm D, 2007, J BIOL CHEM, V282, P10553, DOI 10.1074/jbc.M609578200; Wilhelm D, 2007, PHYSIOL REV, V87, P1, DOI 10.1152/physrev.00009.2006; Wilhelm D, 2009, MECH DEVELOP, V126, P324, DOI 10.1016/j.mod.2009.02.006; Wilson MJ, 2005, J BIOL CHEM, V280, P5917, DOI 10.1074/jbc.M412806200; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0	56	65	67	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3561	3569		10.1096/fj.11-184333	http://dx.doi.org/10.1096/fj.11-184333			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21757499	Green Published			2022-12-28	WOS:000295356400026
J	Hughes-Fulford, M				Hughes-Fulford, Millie			To infinity ... and beyond! Human spaceflight and life science	FASEB JOURNAL			English	Review						spaceflight; osteoporosis; microgravity; red blood cell anemia; immunosuppression	EPSTEIN-BARR-VIRUS; RED-CELL MASS; LONG-DURATION SPACEFLIGHT; SPACE-FLIGHT; GENE-EXPRESSION; BLOOD-CELLS; T-LYMPHOCYTES; MICROGRAVITY; NEOCYTOLYSIS; ASTRONAUTS		[Hughes-Fulford, Millie] VAMC, Dept Vet Affairs Med Ctr, Dept Res, Hughes Fulford Lab, San Francisco, CA 94121 USA; [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA; [Hughes-Fulford, Millie] No Calif Inst Res & Educ, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Northern California Institute for Research & Education	Hughes-Fulford, M (corresponding author), VAMC, Dept Vet Affairs Med Ctr, Dept Res, Hughes Fulford Lab, Code 151F,4150 Clement St, San Francisco, CA 94121 USA.	millie.hughes-fulford@ucsf.edu		Hughes-Fulford, Millie/0000-0002-0756-068X	NIA NIH HHS [UH3 AG037628] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [UH3AG037628] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alfrey CP, 1996, MED SCI SPORT EXER, V28, pS42; Alfrey CP, 1997, LANCET, V349, P1389, DOI 10.1016/S0140-6736(96)09208-2; Alfrey CP, 1996, J APPL PHYSIOL, V81, P98, DOI 10.1152/jappl.1996.81.1.98; ARNAUD C, 1992, SPACELAB LIFE SCI 1; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; COGOLI A, 1993, J LEUKOCYTE BIOL, V53, P569, DOI 10.1002/jlb.53.5.569; Cogoli A, 1996, J Gravit Physiol, V3, P1; Cogoli A, 1997, Adv Space Biol Med, V6, P33, DOI 10.1016/S1569-2574(08)60077-5; Cogoli A, 1997, Gravit Space Biol Bull, V10, P5; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CRISWELLHUDAK BS, 1991, EXP GERONTOL, V26, P289, DOI 10.1016/0531-5565(91)90022-E; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; HAWKINS WR, 1975, NASA SP, V368, P43; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; Hughes-Fulford M, 1998, Gravit Space Biol Bull, V11, P51; Hughes-Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883; Hughes-Fulford Millie, 2004, Sci STKE, V2004, pRE12; HUGHESFULFORD, 2011, J IMMUNOL, V186, P16; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HUGHESFULFORD M, 2011, IAA HUM SPAC S; Kimsey S., 1977, BIOMEDICAL RESULTS S, P249; Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307; Lang TF, 2006, J BONE MINER RES, V21, P1224, DOI 10.1359/JBMR.060509; LEACH CS, 1991, J CLIN PHARMACOL, V31, P921, DOI 10.1002/j.1552-4604.1991.tb03650.x; Leach CS, 1977, BIOMEDICAL RESULTS S, P204; LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157; LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33; Lewis ML, 2001, FASEB J, V15, P1783, DOI 10.1096/fj.00-0820fje; Mehta SK, 2000, J INFECT DIS, V182, P1761, DOI 10.1086/317624; Mehta SK, 2004, J MED VIROL, V72, P174, DOI 10.1002/jmv.10555; Nicogossian AE., 1989, SPACE PHYSL MED, V2nd/4th Edition; Payne DA, 1999, AVIAT SPACE ENVIR MD, V70, P1211; Pierson DL, 2005, BRAIN BEHAV IMMUN, V19, P235, DOI 10.1016/j.bbi.2004.08.001; REITZ G, 1995, RADIAT ENVIRON BIOPH, V34, P139, DOI 10.1007/BF01211539; Rice L, 2005, CELL PHYSIOL BIOCHEM, V15, P245, DOI 10.1159/000087234; Rice L, 2000, PFLUG ARCH EUR J PHY, V441, pR91, DOI 10.1007/s004240000333; Rice L, 2001, ANN INTERN MED, V134, P652, DOI 10.7326/0003-4819-134-8-200104170-00010; Rice L, 1999, AM J KIDNEY DIS, V33, P59, DOI 10.1016/S0272-6386(99)70258-1; Schatten H, 2001, ACTA ASTRONAUT, V49, P399, DOI 10.1016/S0094-5765(01)00116-3; Sibonga JD, 2007, BONE, V41, P973, DOI 10.1016/j.bone.2007.08.022; Stowe RP, 2000, NEUROIMMUNOMODULAT, V8, P51, DOI 10.1159/000026453; Stowe RP, 2001, PSYCHOSOM MED, V63, P891, DOI 10.1097/00006842-200111000-00007; Stowe RP, 2001, AVIAT SPACE ENVIR MD, V72, P884; Tjandrawinata RR, 1997, ADV EXP MED BIOL, V407, P163; Trial J, 2001, J INVEST MED, V49, P335, DOI 10.2310/6650.2001.33899; UDDEN MM, 1995, J LAB CLIN MED, V125, P442; Vassy J., 2001, FASEB Journal, V15, P1104; VERNE J, 1888, EARTH MOON; Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140-6736(00)02217-0; VOGEL JM, 1975, ACTA ASTRONAUT, V2, P129, DOI 10.1016/0094-5765(75)90049-1; Williams D, 2009, CAN MED ASSOC J, V180, P1317, DOI 10.1503/cmaj.090628; Wilson JW, 2007, P NATL ACAD SCI USA, V104, P16299, DOI 10.1073/pnas.0707155104	53	34	36	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2858	2864		10.1096/fj.11-0902ufm	http://dx.doi.org/10.1096/fj.11-0902ufm			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21880668	Green Published			2022-12-28	WOS:000294435200002
J	Toulorge, D; Guerreiro, S; Hild, A; Maskos, U; Hirsch, EC; Michel, PP				Toulorge, Damien; Guerreiro, Serge; Hild, Audrey; Maskos, Uwe; Hirsch, Etienne C.; Michel, Patrick P.			Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+	FASEB JOURNAL			English	Article						calcium; dopaminergic; excitability; nicotinic acetylcholine receptors	PARKINSONS-DISEASE; NIGROSTRIATAL DAMAGE; CALCIUM-CHANNELS; RAT MIDBRAIN; RECEPTORS; ACETYLCHOLINE; STIMULATION; ACTIVATION; PROTECTS; DEGENERATION	Epidemiological and experimental evidence indicates that nicotine is protective for Parkinson disease vulnerable dopamine neurons, but the underlying mechanism of this effect remains only partly characterized. To address this question, we established rat midbrain cultures maintained in experimental conditions that favor the selective and spontaneous loss of dopamine neurons. We report here that nicotine afforded neuroprotection to dopamine neurons (EC50 = 0.32 mu M) but only in a situation where cytosolic Ca2+ (Ca2+ (cyt)) was slightly and chronically elevated above control levels by concurrent depolarizing treatments. By a pharmacological approach, we demonstrated that the rise in Ca2+ (cyt) was necessary to sensitize dopamine neurons to the action of nicotine through a mechanism involving alpha-bungarotoxin-sensitive (presumably alpha 7) nicotinic acetylcholine receptors (nAChRs) and secondarily T-type voltage-gated calcium channels. Confirming the role played by alpha 7 nAChRs in this effect, nicotine had no protective action in midbrain cultures prepared from genetically engineered mice lacking this receptor subtype. Signaling studies revealed that Ca2+ (cyt) elevations evoked by nicotine and concomitant depolarizing treatments served to activate a survival pathway involving the calcium effector protein calmodulin and phosphatidylinositol 3-kinase. Collectively, our data support the idea that the protective action of nicotine for dopamine neurons is activity-dependent and gated by Ca2+ (cyt).-Toulorge, D., Guerreiro, S., Hild, A., Maskos, U., Hirsch, E. C., Michel, P. P. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J. 25, 2563-2573 (2011). www.fasebj.org	[Toulorge, Damien; Guerreiro, Serge; Hild, Audrey; Hirsch, Etienne C.; Michel, Patrick P.] Univ Paris 06, Inst Cerveau & Moelle Epiniere, Ctr Rech, Unite Mixte Rech S975, Paris, France; [Toulorge, Damien; Guerreiro, Serge; Hild, Audrey; Hirsch, Etienne C.; Michel, Patrick P.] Inst Natl Sante & Rech Med, U975, Paris, France; [Toulorge, Damien; Guerreiro, Serge; Hild, Audrey; Hirsch, Etienne C.; Michel, Patrick P.] Ctr Natl Rech Sci, Unite Mixte Rech 7225, Paris, France; [Maskos, Uwe] Inst Pasteur, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Michel, PP (corresponding author), Hop La Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, 47 Bd Hop, F-75013 Paris, France.	patrick-pierre.michel@upmc.fr	Hirsch, Etienne/AAC-7655-2019; Michel, Patrick Pierre/J-5248-2019	Hirsch, Etienne/0000-0003-4823-276X; Michel, Patrick Pierre/0000-0001-5607-3119; Guerreiro, Serge/0000-0003-1744-6351; Toulorge, Damien/0000-0002-9651-8132	Rotary International through the fundraising campaign Espoir en Tete; Fondation pour la Recherche sur le Cerveau (FRC); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Pierre et Marie Curie-Paris; Fondation pour la Recherche Medicale (FRM)	Rotary International through the fundraising campaign Espoir en Tete; Fondation pour la Recherche sur le Cerveau (FRC); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Pierre et Marie Curie-Paris; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	The authors thank Christian Lobsiger for helpful discussions throughout the course of this work. The authors gratefully acknowledge the technical assistance of Aurelien Dauphin for confocal imaging. This work received financial support from Rotary International through the fundraising campaign Espoir en Tete, Fondation pour la Recherche sur le Cerveau (FRC), Institut National de la Sante et de la Recherche Medicale (INSERM), and Universite Pierre et Marie Curie-Paris 6. D.T. was supported by Fondation pour la Recherche Medicale (FRM).	Abin-Carriquiry JA, 2008, EUR J PHARMACOL, V589, P80, DOI 10.1016/j.ejphar.2008.05.013; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Dagher A, 2009, NEURON, V61, P502, DOI 10.1016/j.neuron.2009.01.031; Darcy DP, 2009, J NEUROSCI, V29, P2510, DOI 10.1523/JNEUROSCI.5333-08.2009; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Douhou A, 2001, J NEUROCHEM, V78, P163, DOI 10.1046/j.1471-4159.2001.00401.x; Forster GL, 2003, EUR J NEUROSCI, V17, P751, DOI 10.1046/j.1460-9568.2003.02511.x; Guerreiro S, 2008, MOL PHARMACOL, V74, P980, DOI 10.1124/mol.108.048207; HALVORSEN SW, 1986, J NEUROSCI, V6, P3405; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Karachi C, 2010, J CLIN INVEST, V120, P2745, DOI 10.1172/JCI42642; Katsuki H, 2001, NEUROSCI LETT, V300, P166, DOI 10.1016/S0304-3940(01)01570-1; Kawai H, 2002, J NEUROSCI, V22, P7903; Khwaja M, 2007, J NEUROCHEM, V100, P180, DOI 10.1111/j.1471-4159.2006.04177.x; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Liss B, 2005, NAT NEUROSCI, V8, P1742, DOI 10.1038/nn1570; Liu QS, 1999, J NEUROPHYSIOL, V82, P1124, DOI 10.1152/jn.1999.82.3.1124; Livingstone PD, 2009, BIOCHEM PHARMACOL, V78, P744, DOI 10.1016/j.bcp.2009.06.004; Marinelli M, 2000, J NEUROSCI, V20, P8876; Maskos U, 2010, J NEUROCHEM, V114, P641, DOI 10.1111/j.1471-4159.2010.06798.x; Michel PP, 2007, J NEUROCHEM, V101, P289, DOI 10.1111/j.1471-4159.2006.04424.x; Michel PP, 1997, J NEUROCHEM, V69, P1499; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; Neuhoff H, 2002, J NEUROSCI, V22, P1290, DOI 10.1523/JNEUROSCI.22-04-01290.2002; Quik M, 2007, TRENDS PHARMACOL SCI, V28, P229, DOI 10.1016/j.tips.2007.03.001; Radcliffe PM, 2009, J NEUROCHEM, V109, P1272, DOI 10.1111/j.1471-4159.2009.06056.x; Ries V, 2006, P NATL ACAD SCI USA, V103, P18757, DOI 10.1073/pnas.0606401103; Salthun-Lassalle B, 2004, J NEUROSCI, V24, P5922, DOI 10.1523/JNEUROSCI.5668-03.2004; Sato A, 2006, J CELL PHYSIOL, V209, P172, DOI 10.1002/jcp.20719; Thacker EL, 2007, NEUROLOGY, V68, P764, DOI 10.1212/01.wnl.0000256374.50227.4b; Toulorge D, 2010, J NEUROCHEM, V114, P553, DOI 10.1111/j.1471-4159.2010.06785.x; Traver S, 2006, MOL PHARMACOL, V70, P30, DOI 10.1124/mol.106.022715; Tsuneki H, 2000, EUR J NEUROSCI, V12, P2475, DOI 10.1046/j.1460-9568.2000.00138.x; Turner TJ, 2004, J NEUROSCI, V24, P11328, DOI 10.1523/JNEUROSCI.1559-04.2004; Visanji NP, 2006, NEUROPHARMACOLOGY, V51, P506, DOI 10.1016/j.neuropharm.2006.04.015; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734	39	61	67	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2563	2573		10.1096/fj.11-182824	http://dx.doi.org/10.1096/fj.11-182824			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507900	Bronze			2022-12-28	WOS:000293337800007
J	Johnston, TH; Millar, Z; Huot, P; Wagg, K; Thiele, S; Salomonczyk, D; Yong-Kee, CJ; Gandy, MN; McIldowie, M; Lewis, KD; Gomez-Ramirez, J; Lee, J; Fox, SH; Martin-Iverson, M; Nash, JE; Piggott, MJ; Brotchie, JM				Johnston, Tom H.; Millar, Zak; Huot, Philippe; Wagg, Keith; Thiele, Sherri; Salomonczyk, Danielle; Yong-Kee, Christopher J.; Gandy, Michael N.; McIldowie, Matthew; Lewis, Katie D.; Gomez-Ramirez, Jordi; Lee, Joohyung; Fox, Susan H.; Martin-Iverson, Mathew; Nash, Joanne E.; Piggott, Matthew J.; Brotchie, Jonathan M.			A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates	FASEB JOURNAL			English	Article						drug of abuse; translational medicine; methylenedioxymethamphetamine; ecstasy	3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; INDUCED DYSKINESIA; ECSTASY; SEROTONIN; DRUG; RATS; NOREPINEPHRINE; NEUROTOXICITY; FENFLURAMINE; INHIBITOR	Treatment of Parkinson's disease with dopaminergic agents, such as L-DOPA, is frequently compromised by disabling side effects, particularly dyskinesia and a shortening in duration of antiparkinsonian action. Studies in animal models and anecdotal evidence from a patient with Parkinson's disease show that the illicit drug ecstasy (MDMA) can alleviate these side effects, though with many drawbacks (e.g., psychoactivity). MDMA itself thus has little therapeutic potential. On the basis of known structure-psychoactivity relationships, we designed a series of alpha-substituted MDMA analogues, one of which, bearing an alpha-cyclopropyl substituent (UWA-101), enhanced the quality of L-DOPA actions in animal models. Indeed, UWA-101 was more effective than MDMA. Unlike MDMA, UWA-101 did not reduce viability of serotonergic cells, exhibit psychoactive properties, or reduce food intake, and did not substitute for MDMA in drug discrimination assays. UWA-101 displayed a unique receptor/transporter binding profile relative to MDMA, with a >5-fold decrease in affinity for NET and 5-HT2A receptors and a 10-fold increase in affinity for DAT. Furthermore, in a functional reuptake assay, UWA-101 inhibited both 5-HT and dopamine reuptake, while having no effect on the reuptake of noradrenaline. UWA-101 is the first selective DAT/SERT inhibitor described with comparable affinities for these two sites. These data identify a new class of therapeutic in Parkinson's disease and highlight the potential benefits of studying illicit drugs that in themselves would never be considered safe for longterm therapy.-Johnston, T. H., Millar, Z., Huot, P., Wagg, K., Thiele, S., Salomonczyk, D., Yong-Kee, C. J., Gandy, M. N., McIldowie, M., Lewis, K. D., Gomez-Ramirez, J., Lee, J., Fox, S. H., Martin-Iverson, M., Nash, J. E., Piggott, M. J., Brotchie, J. M. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. FASEB J. 26, 2154-2163 (2012). www.fasebj.org	[Johnston, Tom H.; Huot, Philippe; Gomez-Ramirez, Jordi; Lee, Joohyung; Brotchie, Jonathan M.] Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S7, Canada; [Fox, Susan H.] Univ Hlth Network, Toronto Western Hosp, Movement Disorders Clin, Toronto, ON M5T 2S7, Canada; [Millar, Zak; Martin-Iverson, Mathew] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Gandy, Michael N.; McIldowie, Matthew; Lewis, Katie D.; Piggott, Matthew J.] Univ Western Australia, Sch Biomed Biomol & Chem Sci, Perth, WA 6009, Australia; [Wagg, Keith] Australian Natl Univ, Dept Chem, Canberra, ACT, Australia; [Thiele, Sherri; Salomonczyk, Danielle; Yong-Kee, Christopher J.; Nash, Joanne E.] Univ Toronto Scarborough, Dept Biol Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Western Australia; University of Western Australia; Australian National University; University of Toronto; University Toronto Scarborough	Brotchie, JM (corresponding author), Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, 399 Bathurst St,MC-11-419, Toronto, ON M5T 2S7, Canada.	matthew.piggott@uwa.edu.au; brotchie@uhnres.utoronto.ca	Piggott, Matthew/K-6990-2019; Johnston, Tom H/D-2531-2018; Piggott, Matthew J/A-3251-2008	Johnston, Tom H/0000-0002-1537-8175; Piggott, Matthew/0000-0002-5857-7051; Lee, Joohyung/0000-0002-4277-3680; Brotchie, Jonathan/0000-0003-2337-0816; Martin-Iverson, Mathew/0000-0003-4855-6748	University of Western Australia; Edmond J. Safra Philanthropic Foundation; Parkinson Society Canada	University of Western Australia; Edmond J. Safra Philanthropic Foundation; Parkinson Society Canada	The authors thank the Brain Foundation (M.J.P.), the Natural Sciences and Engineering Research Council of Canada (J.E.N.), Krembil Neuroscience Fund (J.M.B.), and Johnson & Johnson Corporate Office of Science and Technology. M.N.G and K.D.L were recipients of a University of Western Australia Postgraduate Scholarship and Australian Postgraduate Award, respectively. P.H. was supported by fellowships from the Edmond J. Safra Philanthropic Foundation and the Parkinson Society Canada.	BATTAGLIA G, 1988, EUR J PHARMACOL, V149, P159, DOI 10.1016/0014-2999(88)90056-8; Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Bernschneider-Reif S, 2006, PHARMAZIE, V61, P966; Bishop C, 2006, EUR J NEUROSCI, V23, P2669, DOI 10.1111/j.1460-9568.2006.04790.x; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Capela JP, 2007, NEUROTOXICOLOGY, V28, P868, DOI 10.1016/j.neuro.2007.04.005; Carta M, 2007, BRAIN, V130, P1819, DOI 10.1093/brain/awm082; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Colombo G, 1996, J NEUROSCI METH, V67, P83, DOI 10.1016/0165-0270(95)00154-9; Conductier G, 2005, NEUROPSYCHOPHARMACOL, V30, P1056, DOI 10.1038/sj.npp.1300662; CORRIGALL WA, 1992, PHARMACOL BIOCHEM BE, V41, P165, DOI 10.1016/0091-3057(92)90077-S; Fabbrini G, 2007, MOVEMENT DISORD, V22, P1379, DOI 10.1002/mds.21475; Gandy MN, 2010, MEDCHEMCOMM, V1, P287, DOI 10.1039/c0md00108b; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; Hansard MJ, 2002, J PHARMACOL EXP THER, V303, P952, DOI 10.1124/jpet.102.039743; Hince DA, 2005, BEHAV NEUROSCI, V119, P66, DOI 10.1037/0735-7044.119.1.66; HOFFMAN HS, 1980, PSYCHOL REV, V87, P175, DOI 10.1037/0033-295X.87.2.175; Huot P, 2011, J NEUROSCI, V31, P7190, DOI 10.1523/JNEUROSCI.1171-11.2011; Iravani MM, 2003, J NEUROSCI, V23, P9107; Johnston TH, 2005, EXP NEUROL, V191, P243, DOI 10.1016/j.expneurol.2004.10.002; KEHNE JH, 1992, J PHARMACOL EXP THER, V260, P78; Lane EL, 2005, J PHARMACOL EXP THER, V312, P1124, DOI 10.1124/jpet.104.076554; Liechti ME, 2000, NEUROPSYCHOPHARMACOL, V23, P396, DOI 10.1016/S0893-133X(00)00126-3; Munoz A, 2008, BRAIN, V131, P3380, DOI 10.1093/brain/awn235; Poewe W, 2009, NEUROLOGY, V72, pS65, DOI 10.1212/WNL.0b013e31819908ce; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; Ricaurte GA, 2000, TOXICOL LETT, V112, P143, DOI 10.1016/S0378-4274(99)00216-7; Shulgin A. T., 1991, PHENETHYL AMINES I H; Verrico CD, 2007, PSYCHOPHARMACOLOGY, V189, P489, DOI 10.1007/s00213-005-0174-5; Visanji NP, 2009, NEUROBIOL DIS, V35, P184, DOI 10.1016/j.nbd.2008.11.010; Wasik AM, 2012, INVEST NEW DRUG, V30, P1471, DOI 10.1007/s10637-011-9730-5; Yoneda F, 2001, BIOORGAN MED CHEM, V9, P1197, DOI 10.1016/S0968-0896(01)00002-5	32	14	14	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2154	2163		10.1096/fj.11-195016	http://dx.doi.org/10.1096/fj.11-195016			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22345403				2022-12-28	WOS:000303680800041
J	Huttemann, M; Lee, I; Malek, MH				Huettemann, Maik; Lee, Icksoo; Malek, Moh H.			(-)-Epicatechin maintains endurance training adaptation in mice after 14 days of detraining	FASEB JOURNAL			English	Article						angiogenesis; exercise; flavanol; muscle physiology	CYTOCHROME-C-OXIDASE; SKELETAL-MUSCLE; MITOCHONDRIAL BIOGENESIS; EXERCISE CAPACITY; OXIDATIVE STRESS; FIBER-TYPE; PGC-1-ALPHA; EXPRESSION; PHOSPHORYLATION; CAPILLARIZATION	The purpose of this study was to determine whether (-)-epicatechin (mainly found in cocoa) could attenuate detraining effects in the hindlimb muscles of mice. Thirty-two male mice were randomized into 4 groups: control, trained, trained with 14 d of detraining and vehicle (DT-14-W), and trained with 14 d of detraining and (-)-epicatechin [DT-14-(-)-Epi]. DT-14-(-)-Epi received (-)-epicatechin (1.0 mg/kg2X/d), whereas water was given to the DT-14-W group. The latter 3 groups performed 5 wk of endurance training 5X/wk. Hindlimb muscles were harvested, and Western blots, as well as enzyme analyses, were performed. Training significantly increased capillary-to-fiber ratio (approximate to 78.8%), cytochrome-c oxidase (approximate to 35%), and activity (approximate to 144%) compared to controls. These adaptations returned to control levels for the DT-14-W group, whereas the DT-14-(-)-Epi group was able to maintain capillary-to-fiber ratio (approximate to 44%), CcO protein expression (approximate to 45%), and activity (approximate to 108%) above control levels. In addition, the increase in capillarity was related to decreased protein expression of thrombospondin-1, an antiangiogenic regulator. Furthermore, there were no significant differences in endurance capacity between the trained and DT-14-(-)-Epi groups. Our data suggest that (-)-epicatechin may be a suitable compound to maintain exercise-induced improved capillarity and mitochondrial capacity, even when exercise regimens are discontinued.-Huttemann, M., Lee, I., Malek, M. H. (-)-Epicatechin maintains endurance training adaptation in mice after 14 d of detraining. FASEB J. 26, 1413-1422 (2012). www.fasebj.org	[Malek, Moh H.] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Integrat Physiol Exercise Lab, Detroit, MI 48201 USA; [Huettemann, Maik; Lee, Icksoo] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Malek, MH (corresponding author), Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Integrat Physiol Exercise Lab, 259 Mack Ave,Rm 2248, Detroit, MI 48201 USA.	en7488@wayne.edu	Malek, Moh/E-2321-2013	Huttemann, Maik/0000-0001-6310-7081	U.S. National Institutes of Health [GM089900]; Wayne State University; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089900] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wayne State University; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by funding from the U.S. National Institutes of Health (GM089900, M. H.) and startup funds from Wayne State University (M.H.M.).	Al-Gayyar MMH, 2011, DIABETOLOGIA, V54, P669, DOI 10.1007/s00125-010-1994-3; Augusto V, 2004, BRAZ J MORPHOL SCIS, V21, P89; Baltes-Breitwisch MM, 2010, REPRODUCTION, V140, P319, DOI 10.1530/REP-09-0456; Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628; Betik AC, 2008, EXP PHYSIOL, V93, P863, DOI 10.1113/expphysiol.2008.042069; Chabi B, 2009, J APPL PHYSIOL, V107, P1730, DOI 10.1152/japplphysiol.91451.2008; COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857; DUDLEY GA, 1982, J APPL PHYSIOL, V53, P844, DOI 10.1152/jappl.1982.53.4.844; El-Remessy AB, 2007, FASEB J, V21, P2528, DOI 10.1096/fj.06-7854com; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; Geng TY, 2010, AM J PHYSIOL-CELL PH, V298, pC572, DOI 10.1152/ajpcell.00481.2009; GOLLNICK PD, 1969, AM J PHYSIOL, V216, P1502, DOI 10.1152/ajplegacy.1969.216.6.1502; GUTH L, 1970, EXP NEUROL, V28, P365, DOI 10.1016/0014-4886(70)90244-X; Hepple RT, 1997, CAN J APPL PHYSIOL, V22, P11, DOI 10.1139/h97-002; Hepple RT, 1997, J APPL PHYSIOL, V82, P1305, DOI 10.1152/jappl.1997.82.4.1305; Hepple RT, 2001, J APPL PHYSIOL, V91, P2150, DOI 10.1152/jappl.2001.91.5.2150; HOUSTON ME, 1979, ACTA PHYSIOL SCAND, V105, P163, DOI 10.1111/j.1748-1716.1979.tb06328.x; Huttemann M, 2000, BBA-GENE STRUCT EXPR, V1492, P252, DOI 10.1016/S0167-4781(00)00087-7; Huttemann M, 2007, BBA-MOL CELL RES, V1773, P1701, DOI 10.1016/j.bbamcr.2007.10.001; Ishihara A, 1998, J APPL PHYSIOL, V84, P2183, DOI 10.1152/jappl.1998.84.6.2183; Keppel G., 2004, DESIGN ANAL RES HDB; Kleiner S, 2009, J BIOL CHEM, V284, P18624, DOI 10.1074/jbc.M109.008797; Kressler J, 2011, MED SCI SPORT EXER, V43, P2396, DOI 10.1249/MSS.0b013e31822495a7; Lee I, 2005, J BIOL CHEM, V280, P6094, DOI 10.1074/jbc.M411335200; Lehnen AM, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-67; Li L, 2011, DIABETES, V60, P157, DOI 10.2337/db10-0331; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Malek MH, 2010, EXP PHYSIOL, V95, P359, DOI 10.1113/expphysiol.2009.050369; Malek MH, 2009, EXP PHYSIOL, V94, P749, DOI 10.1113/expphysiol.2008.045989; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nogueira L, 2011, J PHYSIOL-LONDON, V589, P4615, DOI 10.1113/jphysiol.2011.209924; Olfert IM, 2011, MICROCIRCULATION, V18, P316, DOI 10.1111/j.1549-8719.2011.00092.x; Olfert IM, 2009, J PHYSIOL-LONDON, V587, P1755, DOI 10.1113/jphysiol.2008.164384; Pae MY, 2012, J NUTR BIOCHEM, V23, P526, DOI 10.1016/j.jnutbio.2011.02.006; Pinho R. A., 2011, EUR J APPL PHYSL; ROSENBLATT JD, 1987, STAIN TECHNOL, V62, P85, DOI 10.3109/10520298709107973; Roudier E, 2010, J PHYSIOL-LONDON, V588, P4579, DOI 10.1113/jphysiol.2010.193243; Ryan MJ, 2010, J GERONTOL A-BIOL, V65, P815, DOI 10.1093/gerona/glq080; Safdar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010778; SOUSSI B, 1989, ACTA PHYSIOL SCAND, V135, P373, DOI 10.1111/j.1748-1716.1989.tb08590.x; van Praag H, 2007, J NEUROSCI, V27, P5869, DOI 10.1523/JNEUROSCI.0914-07.2007; Wagner PD, 1996, ANNU REV PHYSIOL, V58, P21, DOI 10.1146/annurev.physiol.58.1.21; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; Wong LE, 2009, J APPL PHYSIOL, V106, P1660, DOI 10.1152/japplphysiol.91233.2008; Wong YT, 2009, FREE RADICAL BIO MED, V46, P799, DOI 10.1016/j.freeradbiomed.2008.12.016; 류경렬, 2006, Endocrinology and Metabolism, V21, P302	46	32	32	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1413	1422		10.1096/fj.11-196154	http://dx.doi.org/10.1096/fj.11-196154			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22179525	Green Published			2022-12-28	WOS:000302359700004
J	Burgoyne, JR; Haeussler, DJ; Kumar, V; Ji, YH; Pimental, DR; Zee, RS; Costello, CE; Lin, C; McComb, ME; Cohen, RA; Bachschmid, MM				Burgoyne, Joseph R.; Haeussler, Dagmar J.; Kumar, Vikas; Ji, Yuhan; Pimental, David R.; Zee, Rebecca S.; Costello, Cathrine E.; Lin, Cheng; McComb, Mark E.; Cohen, Richard A.; Bachschmid, Markus M.			Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis	FASEB JOURNAL			English	Article						growth factor signaling; high-fat high-glucose diet; oxidative post-translational modifications; reactive oxygen species; reactive nitrogen species	ACTIVATED PROTEIN-KINASE; H-RAS; S-GLUTATHIOLATION; PLASMA-MEMBRANE; PALMITATE TURNOVER; POLYBASIC DOMAIN; NAD(P)H OXIDASE; BETA-CELL; LOCALIZATION; MECHANISMS	Here we demonstrate a new paradigm in redox signaling, whereby oxidants resulting from metabolic stress directly alter protein palmitoylation by oxidizing reactive cysteine thiolates. In mice fed a high-fat, high-sucrose diet and in cultured endothelial cells (ECs) treated with high palmitate and high glucose (HPHG), there was decreased HRas palmitoylation on Cys181/184 (61 +/- 24% decrease for cardiac tissue and 38 +/- 7.0% in ECs). This was due to oxidation of Cys181/184, detected using matrix-assisted laser desorption/ionization time of flight (MALDI TOF)-TOF. Decrease in HRas palmitoylation affected its compartmentalization and Ras binding domain binding activity, with a shift from plasma membrane tethering to Golgi localization. Loss of plasma membrane-bound HRas decreased growth factor-stimulated ERK phosphorylation (84 +/- 8.6% decrease) and increased apoptotic signaling (24 +/- 6.5-fold increase) after HPHG treatment that was prevented by overexpressing wild-type but not C181/184S HRas. The essential role of HRas in metabolic stress was made evident by the similar effects of expressing an inactive dominant negative N17-HRas or a MEK inhibitor. Furthermore, the relevance of thiol oxidation was demonstrated by overexpressing manganese superoxide dismutase, which improved HRas palmitoylation and ERK phosphorylation, while lessening apoptosis in HPHG treated ECs.-Burgoyne, J. R., Haeussler, D. J., Kumar, V., Ji, Y., Pimental, D. R., Zee, R. S., Costello, C. E., Lin, C., McComb, M. E., Cohen, R. A., Bachschmid, M. M. Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis. FASEB J. 26, 832-841 (2012). www.fasebj.org	[Burgoyne, Joseph R.; Pimental, David R.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Myocardial Unit, Boston, MA 02118 USA; [Ji, Yuhan; Costello, Cathrine E.; Lin, Cheng; McComb, Mark E.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Cardiovasc Prote Ctr, Boston, MA 02118 USA	Boston University; Boston University	Burgoyne, JR (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Myocardial Unit, Boston, MA 02118 USA.	jrburgoy@bu.edu; bach@bu.edu	McComb, Mark E/I-3193-2014	/0000-0002-1070-6408; /0000-0002-4249-485X; Zee, Rebecca/0000-0002-4235-8778; Costello, Catherine/0000-0003-1594-5122; Burgoyne, Joseph/0000-0001-7325-7382; Bachschmid, Markus Michael/0000-0002-0748-5528	U.S. National Institutes of Health (NIH) [PO1-HL-068758, R37-HL-04017]; NIH [HL-007969-06A1]; National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services [HHSN268201000031C]; Wellcome Trust [085483/Z/08/Z]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758, R01HL031607, R37HL104017, T32HL007969, K08HL004017] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services; Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health (NIH) grants PO1-HL-068758 and R37-HL-04017 and NIH predoctoral training grant HL-007969-06A1, as well as by the National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services, under contract HHSN268201000031C. This work was also supported by a Sir Henry Wellcome postdoctoral fellowship from The Wellcome Trust (sponsor reference 085483/Z/08/Z; to J.R.B.). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the awarding offices.	Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001; Baker TL, 2003, J BIOL CHEM, V278, P19292, DOI 10.1074/jbc.M206956200; Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Charles RL, 2008, PROTEOM CLIN APPL, V2, P823, DOI 10.1002/prca.200780104; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Clavreul N, 2006, FASEB J, V20, P518, DOI 10.1096/fj.05-4875fje; Dietrich LEP, 2004, EMBO REP, V5, P1053, DOI 10.1038/sj.embor.7400277; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Grines CL, 2002, CIRCULATION, V105, P1291, DOI 10.1161/hc1102.105595; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Haeussler DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023160; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Kumar P, 2007, CANCER RES, V67, P1193, DOI 10.1158/0008-5472.CAN-06-2265; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Misaki R, 2010, J CELL BIOL, V191, P23, DOI 10.1083/jcb.200911143; Oeste CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015866; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Schreyer SA, 2003, ATHEROSCLEROSIS, V171, P49, DOI 10.1016/j.atherosclerosis.2003.07.010; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zee RS, 2010, ANTIOXID REDOX SIGN, V13, P1023, DOI 10.1089/ars.2010.3251	37	42	42	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					832	841		10.1096/fj.11-189415	http://dx.doi.org/10.1096/fj.11-189415			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22085642	Green Published			2022-12-28	WOS:000300485700034
J	Hu, JX; Thor, D; Zhou, YR; Liu, T; Wang, Y; McMillin, SM; Mistry, R; Challiss, RAJ; Costanzi, S; Wess, J				Hu, Jianxin; Thor, Doreen; Zhou, Yaru; Liu, Tong; Wang, Yan; McMillin, Sara M.; Mistry, Rajendra; Challiss, R. A. John; Costanzi, Stefano; Wess, Juergen			Structural aspects of M-3 muscarinic acetylcholine receptor dimer formation and activation	FASEB JOURNAL			English	Article						G-protein-coupled receptor; GPCR; disulfidescanning mutagenesis	PROTEIN-COUPLED RECEPTOR; CROSS-LINKING STRATEGY; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; DRUG DISCOVERY; GPCR; DIMERIZATION; AGONIST; INTERFACE	To explore the structural mechanisms underlying the assembly and activation of family A GPCR dimers, we used the rat M-3 muscarinic acetylcholine receptor (M3R) as a model system. Studies with Cys-substituted mutant M3Rs expressed in COS-7 cells led to the identification of several mutant M3Rs that exclusively existed as cross-linked dimers under oxidizing conditions. The cross-linked residues were located at the bottom of transmembrane domain 5 (TM5) and within the N-terminal portion of the third intracellular loop (i3 loop). Studies with urea-stripped membranes demonstrated that M3R disulfide cross-linking did not require the presence of heterotrimeric G proteins. Molecular modeling studies indicated that the cross-linking data were in excellent agreement with the existence of a low-energy M3R dimer characterized by a TM5-TM5 interface. [S-35]GTP gamma S binding/G alpha(q/11) immunoprecipitation assays revealed that an M3R dimer that was cross-linked within the N-terminal portion of the i3 loop (264C) was functionally severely impaired (similar to 50% reduction in receptor-G-protein coupling, as compared to control M3R). These data support the novel concept that agonist-induced activation of M3R dimers requires a conformational change of the N-terminal segment of the i3 loop. Given the high degree of structural homology among family A GPCRs, these findings should be of broad significance.-Hu, J., Thor, D., Zhou, Y., Liu, T., Wang, Y., McMillin, S. M., Mistry, R., Challiss, R. A. J., Costanzi, S., Wess, J. Structural aspects of M-3 muscarinic acetylcholine receptor dimer formation and activation. FASEB J. 26, 604-616 (2012). www.fasebj.org	[Wess, Juergen] NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; [Costanzi, Stefano] NIDDK, Lab Biol Modeling, Bethesda, MD 20892 USA; [Zhou, Yaru] Hebei Med Univ, Dept Endocrinol, Hosp 3, Shijiazhuang, Peoples R China; [Mistry, Rajendra; Challiss, R. A. John] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Hebei Medical University; University of Leicester	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Thor, Doreen/P-6778-2019; Costanzi, Stefano/G-8990-2013	Thor, Doreen/0000-0002-9522-5098; Challiss, John/0000-0001-5506-2848; Costanzi, Stefano/0000-0003-3183-7332	U.S. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK031129, ZIADK013025] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by the Intramural Research Program of the U.S. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The authors thank Ms. Vanivilasini Balachandran and Mr. Zifan Xiang (NIH, NIDDK) for excellent technical assistance.	Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/NCHEMBIO.396, 10.1038/nchembio.396]; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; [Anonymous], 2010, MOL OP ENV MOE VERS; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Choe HW, 2011, NATURE, V471, P651, DOI 10.1038/nature09789; Costanzi S, 2008, J MED CHEM, V51, P2907, DOI 10.1021/jm800044k; Costanzi S, 2010, CHIM OGGI, V28, P26; Filizola M, 2005, FEBS J, V272, P2926, DOI 10.1111/j.1742-4658.2005.04730.x; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Goin JC, 2006, J BIOL CHEM, V281, P5416, DOI 10.1074/jbc.M507476200; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hu JX, 2010, NAT CHEM BIOL, V6, P541, DOI [10.1038/NCHEMBIO.385, 10.1038/nchembio.385]; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Li JH, 2007, J BIOL CHEM, V282, P26284, DOI 10.1074/jbc.M704875200; McMillin SM, 2011, J BIOL CHEM, V286, P28584, DOI 10.1074/jbc.M111.259788; Michino M, 2009, NAT REV DRUG DISCOV, V8, P455, DOI 10.1038/nrd2877; Milligan G, 2007, BBA-BIOMEMBRANES, V1768, P825, DOI 10.1016/j.bbamem.2006.09.021; Palczewski K, 2010, TRENDS BIOCHEM SCI, V35, P595, DOI 10.1016/j.tibs.2010.05.002; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Rovira X, 2010, TRENDS PHARMACOL SCI, V31, P15, DOI 10.1016/j.tips.2009.10.008; Song GJ, 2007, P NATL ACAD SCI USA, V104, P18303, DOI 10.1073/pnas.0702857104; Standfuss J, 2011, NATURE, V471, P656, DOI 10.1038/nature09795; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; White JF, 2007, P NATL ACAD SCI USA, V104, P12199, DOI 10.1073/pnas.0705312104; Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	38	34	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					604	616		10.1096/fj.11-191510	http://dx.doi.org/10.1096/fj.11-191510			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22031716	Green Published			2022-12-28	WOS:000300485700014
J	Salom, D; Cao, PX; Sun, WY; Kramp, K; Jastrzebska, B; Jin, H; Feng, ZY; Palczewski, K				Salom, David; Cao, Pengxiu; Sun, Wenyu; Kramp, Kristopher; Jastrzebska, Beata; Jin, Hui; Feng, Zhaoyang; Palczewski, Krzysztof			Heterologous expression of functional G-protein-coupled receptors in Caenorhabditis elegans	FASEB JOURNAL			English	Article						native GPCR; purification; membrane proteins	RHODOPSIN MONOCLONAL-ANTIBODIES; STRUCTURAL GENOMICS; MEMBRANE-PROTEINS; LIGHT; PURIFICATION; ENVIRONMENT; ACTIVATION; BINDING	New strategies for expression, purification, functional characterization, and structural determination of membrane-spanning G-protein-coupled receptors (GPCRs) are constantly being developed because of their importance to human health. Here, we report a Caenorhabditis elegans heterologous expression system able to produce milligram amounts of functional native and engineered GPCRs. Both bovine opsin [(b)opsin] and human adenosine A(2A) subtype receptor [(h) A(2A)R] expressed in neurons or muscles of C. elegans were localized to cell membranes. Worms expressing these GPCRs manifested changes in motor behavior in response to light and ligands, respectively. With a newly devised protocol, 0.6-1 mg of purified homogenous 9-cis-retinal-bound bovine isorhodopsin [(b)isoRho] and ligand-bound (h) A(2A)R were obtained from C. elegans from one 10-L fermentation at low cost. Purified recombinant (b) isoRho exhibited its signature absorbance spectrum and activated its cognate G-protein transducin in vitro at a rate similar to native rhodopsin (Rho) obtained from bovine retina. Generally high expression levels of 11 native and mutant GPCRs demonstrated the potential of this C. elegans system to produce milligram quantities of high-quality GPCRs and possibly other membrane proteins suitable for detailed characterization.-Salom, D., Cao, P., Sun, W., Kramp, K., Jastrzebska, B., Jin, H., Feng, Z., Palczewski, K. Heterologous expression of functional G-protein-coupled receptors in Caenorhabditis elegans. FASEB J. 26, 492-502 (2012). www.fasebj.org	[Feng, Zhaoyang; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Salom, David; Sun, Wenyu; Palczewski, Krzysztof] Polgenix Inc, Cleveland, OH USA; [Feng, Zhaoyang] Xi An Jiao Tong Univ, Dept Physiol, Coll Med, Xian 710049, Peoples R China	Case Western Reserve University; Xi'an Jiaotong University	Feng, ZY (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	zxf17@case.edu; kxp65@case.edu	Cao, Pengxiu/I-5378-2012	CAO, PENGXIU/0000-0002-5900-5645; Kramp, Kristopher/0000-0003-2121-9274; Salom, David/0000-0002-3208-1509	U.S. National Institutes of Health [EY-008061, EY-009339, P30 EY-11373]; Mt. Sinai Health Care Foundation; National Institute of General Medical Sciences [GM074945]; Polgenix, Inc.; NATIONAL EYE INSTITUTE [R29EY008061, P30EY011373, R01EY009339, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074945] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mt. Sinai Health Care Foundation; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Polgenix, Inc.; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank L. T. Webster, Jr., and members of the K. P. laboratory for critical comments on the manuscript. The authors thank Dr. I. Katsura (Graduate University for Advanced Studies, Mishima, Japan) for P<INF>H20</INF> DNA and M. H. Zheng for technical assistance. This research was supported in part by grants EY-008061, EY-009339, and P30 EY-11373 (to K. P.) from the U.S. National Institutes of Health, and Mt. Sinai Health Care Foundation Scholars Program in the Basic Science (to Z.F.). Research was also supported by a U54 award to the New York SGX Research Center for Structural Genomics (NYSGXRC) from the National Institute of General Medical Sciences (GM074945; principal investigator: Stephen K. Burley) under a contract to Polgenix, Inc. D. S. and W. S. are employees of Polgenix, Inc. K. P. is CSO at Polgenix Inc. P.C., K.K., B.J., H.J., and Z.F. report no conflicts of interest. The Z.F. laboratory received support from Polgenix, Inc.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Baker M, 2010, NATURE, V465, P823, DOI 10.1038/465823a; Baker M, 2010, NAT METHODS, V7, P429, DOI 10.1038/nmeth0610-429; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Cao PX, 2012, FASEB J, V26, P480, DOI 10.1096/fj.11-197798; Dror RO, 2009, P NATL ACAD SCI USA, V106, P4689, DOI 10.1073/pnas.0811065106; FABIAN TJ, 1994, J GERONTOL, V49, pB145, DOI 10.1093/geronj/49.4.B145; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng ZY, 2006, CELL, V127, P621, DOI 10.1016/j.cell.2006.09.035; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; Gottschalk A, 2006, J NEUROSCI METH, V154, P68, DOI 10.1016/j.jneumeth.2005.11.016; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; Klammt Christian, 2007, V375, P57; Lee JK, 2010, CURR OPIN STRUC BIOL, V20, P464, DOI 10.1016/j.sbi.2010.05.004; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lodowski DT, 2009, PHOTOCHEM PHOTOBIOL, V85, P425, DOI 10.1111/j.1751-1097.2008.00516.x; Lundstrom K, 2007, J CELL MOL MED, V11, P224, DOI 10.1111/j.1582-4934.2007.00028.x; Lundstrom K, 2005, TRENDS BIOTECHNOL, V23, P103, DOI 10.1016/j.tibtech.2004.12.006; Lundstrom Kenneth, 2006, Journal of Structural and Functional Genomics, V7, P77, DOI 10.1007/s10969-006-9011-2; Lundstrom K, 2006, CURR PROTEIN PEPT SC, V7, P465, DOI 10.2174/138920306778559403; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Markkanen PMH, 2008, J BIOL CHEM, V283, P29086, DOI 10.1074/jbc.M801880200; Milligan G, 2007, ERNST SCHERING FOUND, V2, P145, DOI 10.1007/2789_2006_007; Mustafi D, 2009, MOL PHARMACOL, V75, P1, DOI 10.1124/mol.108.051938; O'Malley MA, 2007, J STRUCT BIOL, V159, P166, DOI 10.1016/j.jsb.2007.05.001; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; OKKEMA PG, 1993, GENETICS, V135, P385; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Panneels V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018478; Parrill AL, 2008, CHEMMEDCHEM, V3, P1021, DOI 10.1002/cmdc.200800070; Provasi D, 2010, BIOPHYS J, V98, P2347, DOI 10.1016/j.bpj.2010.01.047; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; Salom D.L.N., 2005, G PROTEIN COUPLED RE, P1; Salom D, 2008, BIOCHEMISTRY-US, V47, P13296, DOI 10.1021/bi8018527; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; Sprang SR, 2011, NATURE, V469, P172, DOI 10.1038/469172a; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Stiernagle Theresa, 2006, WormBook, P1; Topiol S, 2009, BIOCHEM PHARMACOL, V78, P11, DOI 10.1016/j.bcp.2009.02.012; Vanni S, 2009, BIOCHEMISTRY-US, V48, P4789, DOI 10.1021/bi900299f; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Vilaro MT, 2002, NEUROPHARMACOLOGY, V42, P60, DOI 10.1016/S0028-3908(01)00154-X; Ward A, 2008, NAT NEUROSCI, V11, P916, DOI 10.1038/nn.2155; Yabe T, 2005, DEVELOPMENT, V132, P3197, DOI 10.1242/dev.01909; Zhang SJ, 2011, J NEUROSCI METH, V197, P315, DOI 10.1016/j.jneumeth.2011.02.014	51	15	16	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					492	502		10.1096/fj.11-197780	http://dx.doi.org/10.1096/fj.11-197780			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22090314	Green Published			2022-12-28	WOS:000300485700003
J	He, P; Liu, Q; Wu, J; Shen, Y				He, Ping; Liu, Qiang; Wu, Jie; Shen, Yong			Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons	FASEB JOURNAL			English	Article						clustering; inflammation; neurodysfunction; neurodegeneration; excitotoxicity	TUMOR-NECROSIS-FACTOR; LONG-TERM POTENTIATION; IONOTROPIC GLUTAMATE RECEPTORS; ACTIVITY-DEPENDENT REGULATION; CULTURED HIPPOCAMPAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE	The distribution of postsynaptic glutamate receptors has been shown to be regulated by proimmunocytokine tumor necrosis factor alpha (TNF-alpha) signaling. The role of TNF-alpha receptor subtypes in mediating glutamate receptor expression, trafficking, and function still remains unclear. Here, we report that TNF receptor subtypes (TNFR1 and TNFR2) differentially modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) clustering and function in cultured cortical neurons. We find that genetic deletion of TNFR1 decreases surface expression and synaptic localization of the AMPAR GluA1 subunit, reduces the frequency of miniature excitatory postsynaptic current (mEPSC), and reduces AMPA-induced maximal whole-cell current. In addition, these results are not observed in TNFR2-deleted neurons. The decreased AMPAR expression and function in TNFR1-deleted cells are not significantly restored by short (2 h) or long (24 h) term exposure to TNF-alpha. In TNFR2-deleted cells, TNF-alpha promotes AMPAR trafficking to the synapse and increases mEPSC frequency. In the present study, we find no significant change in the GluN1 subunit of NMDAR clusters, location, and mEPSC. This includes applying or withholding the TNF-alpha treatment in both TNFR1- and TNFR2-deleted neurons. Our results indicate that TNF receptor subtype 1 but not 2 plays a critical role in modulating AMPAR clustering, suggesting that targeting TNFR1 gene might be a novel approach to preventing neuronal AMPAR-mediated excitotoxicity.-He, P., Liu, Q., Wu, J., Shen, Y. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J. 26, 334-345 (2012). www.fasebj.org	[He, Ping; Shen, Yong] Roskamp Inst, Ctr Adv Therapeut Strategies Brain Disorders, Sarasota, FL 34243 USA; [He, Ping; Shen, Yong] Sun Hlth Res Inst, Haldeman Lab Mol & Cellular Neurobiol, Sun City, AZ USA; [Liu, Qiang; Wu, Jie] St Josephs Hosp, Div Neurol, Barrow Neurol Inst, Phoenix, AZ 85013 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Shen, Y (corresponding author), Roskamp Inst, Ctr Adv Therapeut Strategies Brain Disorders, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	jie.wu@chw.edu; yshen@rfdn.org	Liu, Qiang/HHZ-3181-2022		U.S. National Institutes of Health [NIH NIAAG025888]; Alzheimer's Association; Arizona Biomedical Research Commission	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); Arizona Biomedical Research Commission	This work is supported by the U.S. National Institutes of Health, grant NIH NIAAG025888 (Y.S.); an Alzheimer's Association Zenith Award (Y.S.); and a grant from the Arizona Biomedical Research Commission (Y.S.). The authors thank Harrison Stratton for his editorial assistance.	Adesnik H, 2005, NEURON, V48, P977, DOI 10.1016/j.neuron.2005.11.030; Akassoglou K, 1997, J IMMUNOL, V158, P438; Allison DW, 1998, J NEUROSCI, V18, P2423; Alvarez A, 2007, NEUROBIOL AGING, V28, P533, DOI 10.1016/j.neurobiolaging.2006.02.012; Bats C, 2007, NEURON, V53, P719, DOI 10.1016/j.neuron.2007.01.030; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beique JC, 2006, P NATL ACAD SCI USA, V103, P19535, DOI 10.1073/pnas.0608492103; Bessler H, 1999, BIOMED PHARMACOTHER, V53, P141, DOI 10.1016/S0753-3322(99)80079-1; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Cheng X, 2010, J ALZHEIMERS DIS, V19, P621, DOI 10.3233/JAD-2010-1253; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dakoji S, 2003, NEUROPHARMACOLOGY, V45, P849, DOI 10.1016/S0028-3908(03)00267-3; Diem R, 2001, J NEUROSCI, V21, P2058, DOI 10.1523/JNEUROSCI.21-06-02058.2001; Ehlers MD, 2007, NEURON, V54, P447, DOI 10.1016/j.neuron.2007.04.010; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; El-Hussein AE, 2000, SCIENCE, V290, P1364; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Furukawa K, 1998, J NEUROCHEM, V70, P1876; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grell M, 1996, J INFLAMM, V47, P8; Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; He P, 2009, J NEUROSCI, V29, P6545, DOI 10.1523/JNEUROSCI.0421-09.2009; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim MJ, 2007, NEURON, V56, P488, DOI 10.1016/j.neuron.2007.09.007; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kobayashi T, 1998, EUR J PHARMACOL, V363, P1, DOI 10.1016/S0014-2999(98)00774-2; Lebrun-Julien F, 2009, J NEUROSCI, V29, P5536, DOI 10.1523/JNEUROSCI.0831-09.2009; Leonoudakis D, 2008, J NEUROSCI, V28, P2119, DOI 10.1523/JNEUROSCI.5159-07.2008; Leonoudakis D, 2004, NEURON GLIA BIOL, V1, P263, DOI 10.1017/S1740925X05000608; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; Lissin DV, 1999, J NEUROSCI, V19, P1263; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Ogoshi F, 2005, EXP NEUROL, V193, P384, DOI 10.1016/j.expneurol.2004.12.026; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Patel JR, 2008, J NEUROSCI RES, V86, P2303, DOI 10.1002/jnr.21663; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Prange O, 2001, J NEUROSCI, V21, P9325, DOI 10.1523/JNEUROSCI.21-23-09325.2001; Raine CS, 1998, REV NEUROL-FRANCE, V154, P577; Rao A, 1998, J NEUROSCI, V18, P1217; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Rumbaugh G, 2003, J NEUROSCI, V23, P4567; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shen Y, 2006, TRENDS MOL MED, V12, P574, DOI 10.1016/j.molmed.2006.10.002; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; Wu J, 2004, J BIOL CHEM, V279, P37842, DOI 10.1074/jbc.M400335200; Wu LJ, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-40; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Youn DH, 2008, J NEUROSCI RES, V86, P2867, DOI 10.1002/jnr.21726; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	82	62	65	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					334	345		10.1096/fj.11-192716	http://dx.doi.org/10.1096/fj.11-192716			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21982949	Green Published			2022-12-28	WOS:000299202200033
J	Koeberle, A; Shindou, H; Harayama, T; Yuki, K; Shimizu, T				Koeberle, Andreas; Shindou, Hideo; Harayama, Takeshi; Yuki, Koichi; Shimizu, Takao			Polyunsaturated fatty acids are incorporated into maturating male mouse germ cells by lysophosphatidic acid acyltransferase 3	FASEB JOURNAL			English	Article						lipidomics; phospholipids; spermatocytes	LIPID-COMPOSITION; LONG-CHAIN; ACYL-COA; LYSOPHOSPHOLIPID ACYLTRANSFERASE; RAT TESTES; TESTICULAR LIPIDS; SERTOLI-CELLS; METABOLISM; MICE; IDENTIFICATION	Long-chain polyunsaturated fatty acids (PUFAs) accumulate in mammalian testis during puberty and are essential for fertility. To investigate whether lysophospholipid acyltransferases determine the PUFA composition of testicular phospholipids during pubertal development, we compared their mRNA expression, in vitro activity, and specificity with the lipidomic profile of major phospholipids. The accumulation of PUFAs in phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine correlated with an induced lysophosphatidic acid acyltransferase (LPAAT)3 mRNA expression, increased microsomal LPAAT3 activity, and shift of LPAAT specificity to PUFA-coenzyme A. LPAAT3 was induced during germ cell maturation, as shown by immunofluorescence microscopy. Accordingly, differentiation of mouse GC-2spd(ts) spermatocytes into spermatides up-regulated LPAAT3 mRNA, increased the amount of polyunsaturated phospholipids, and shifted the specificity for the incorporation of deuterium-labeled docosahexaenoic acid toward phosphatidylcholine and phosphatidylethanolamine. Stable knockdown of LPAAT3 in GC-2spd(ts) cells significantly decreased microsomal LPAAT3 activity, reduced levels of polyunsaturated phosphatidylethanolamine species, and impaired cell proliferation/survival during geneticin selection. We conclude that the induction of LPAAT3 during germ cell development critically contributes to the accumulation of PUFAs in testicular phospholipids, thereby possibly affecting sperm cell production.-Koeberle, A., Shindou, H., Harayama, T., Yuki, K., Shimizu, T. Polyunsaturated fatty acids are incorporated into maturating male mouse germ cells by lysophosphatidic acid acyltransferase 3. FASEB J. 26, 169-180 (2012). www.fasebj.org	[Shimizu, Takao] Univ Tokyo, Dept Biochem & Mol Biol, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Shimizu, T (corresponding author), Univ Tokyo, Dept Biochem & Mol Biol, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Koeberle, Andreas/ABB-2356-2020; Harayama, Takeshi/AAD-8852-2022; Shimizu, Takao/AAV-7052-2021	Koeberle, Andreas/0000-0001-6269-5088; Harayama, Takeshi/0000-0003-2255-4197; 	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; Japan Society for Promotion of Sciences; Center for NanoBio Integration at the University of Tokyo; Ministry of Health and Labor; MEXT; Uehara Memorial Foundation; Cell Science Research Foundation; Japan Society for the Promotion of Science; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for Promotion of Sciences(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center for NanoBio Integration at the University of Tokyo; Ministry of Health and Labor; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (to T. S.) and a Global COE Program (The University of Tokyo) from the Japan Society for Promotion of Sciences (to T. S.). T. S. and H. S. were supported by the Center for NanoBio Integration at the University of Tokyo. H. S. was supported by Health and Labor Sciences research grants (Research on Allergic Disease and Immunology) from the Ministry of Health and Labor, a Grant-in-Aid for Young Scientists (B) from MEXT, and grants from the Uehara Memorial Foundation and the Cell Science Research Foundation. T. H. was supported by research fellowships from the Japan Society for the Promotion of Science for Young Scientists. A. K. received a stipend from Takeda Science Foundation.	AHLUWALIA B, 1966, LIPIDS, V1, P197, DOI 10.1007/BF02531872; BECKMAN JK, 1980, LIPIDS, V15, P389, DOI 10.1007/BF02534061; BECKMAN JK, 1979, LIPIDS, V14, P262, DOI 10.1007/BF02533912; BIERI JG, 1965, COMP BIOCHEM PHYSIOL, V15, P275, DOI 10.1016/0010-406X(65)90131-3; BLANK ML, 1985, BIOCHIM BIOPHYS ACTA, V833, P366, DOI 10.1016/0005-2760(85)90092-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cao JS, 2008, J BIOL CHEM, V283, P19049, DOI 10.1074/jbc.M800364200; CONIGLIO JG, 1975, BIOL REPROD, V12, P255, DOI 10.1095/biolreprod12.2.255; DAVIS JT, 1966, BIOCHEM J, V98, P342, DOI 10.1042/bj0980342; DIX JA, 1990, BIOCHEMISTRY-US, V29, P1949, DOI 10.1021/bi00459a041; Furland NE, 2007, BIOL REPROD, V77, P181, DOI 10.1095/biolreprod.106.056556; Gijon MA, 2008, J BIOL CHEM, V283, P30235, DOI 10.1074/jbc.M806194200; Hishikawa D, 2008, P NATL ACAD SCI USA, V105, P2830, DOI 10.1073/pnas.0712245105; HOFMANN MC, 1994, P NATL ACAD SCI USA, V91, P5533, DOI 10.1073/pnas.91.12.5533; Hollenback D, 2006, J LIPID RES, V47, P593, DOI 10.1194/jlr.M500435-JLR200; Huyghe S, 2006, ENDOCRINOLOGY, V147, P2228, DOI 10.1210/en.2005-1571; Jain S, 2009, J LIPID RES, V50, P1563, DOI 10.1194/jlr.M800398-JLR200; JOHNSON LA, 1975, J ANIM SCI, V40, P108, DOI 10.2527/jas1975.401108x; Kazachkov M, 2008, LIPIDS, V43, P895, DOI 10.1007/s11745-008-3233-y; Koeberle A, 2010, FASEB J, V24, P4929, DOI 10.1096/fj.10-162818; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; LACY D, 1962, BRIT MED BULL, V18, P205, DOI 10.1093/oxfordjournals.bmb.a069979; Lin DS, 2004, J LIPID RES, V45, P529, DOI 10.1194/jlr.M300374-JLR200; LYNCH KM, 1951, ENDOCRINOLOGY, V49, P8, DOI 10.1210/endo-49-1-8; Moreno RD, 2006, MOL REPROD DEV, V73, P1430, DOI 10.1002/mrd.20581; Nakanishi H, 2006, J BIOL CHEM, V281, P20140, DOI 10.1074/jbc.M600225200; NISSEN HP, 1983, ANDROLOGIA, V15, P264; Oresti GM, 2010, J LIPID RES, V51, P2909, DOI 10.1194/jlr.M006429; Retterstol K, 2001, LIPIDS, V36, P601, DOI 10.1007/s11745-001-0763-z; Retterstol K, 2001, REPRODUCTION, V121, P881, DOI 10.1530/reprod/121.6.881; Roqueta-Rivera M, 2010, J LIPID RES, V51, P360, DOI 10.1194/jlr.M001180; Saether T, 2003, BIOL REPROD, V69, P117, DOI 10.1095/biolreprod.102.014035; Schmidt JA, 2009, J CELL BIOL, V186, P211, DOI 10.1083/jcb.200904147; SEBOKOVA E, 1988, AM J PHYSIOL, V255, pE442, DOI 10.1152/ajpendo.1988.255.4.E442; Shindou H, 2007, J BIOL CHEM, V282, P6532, DOI 10.1074/jbc.M609641200; Shindou H, 2009, J BIOL CHEM, V284, P1, DOI 10.1074/jbc.R800046200; Soupene E, 2008, P NATL ACAD SCI USA, V105, P88, DOI 10.1073/pnas.0709737104; Stoffel W, 2008, EMBO J, V27, P2281, DOI 10.1038/emboj.2008.156; Stroud CK, 2009, J LIPID RES, V50, P1870, DOI 10.1194/jlr.M900039-JLR200; Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005; Wathes DC, 2007, BIOL REPROD, V77, P190, DOI 10.1095/biolreprod.107.060558; Yang YZ, 2004, J BIOL CHEM, V279, P55866, DOI 10.1074/jbc.M406710200; Ye XQ, 2008, BIOL REPROD, V79, P328, DOI 10.1095/biolreprod.108.068783; Yuki K, 2009, J LIPID RES, V50, P860, DOI 10.1194/jlr.M800468-JLR200; Zanetti SR, 2007, CANCER RES, V67, P6973, DOI 10.1158/0008-5472.CAN-07-0376; Zhao Y, 2008, J BIOL CHEM, V283, P8258, DOI 10.1074/jbc.M710422200	46	42	43	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					169	180		10.1096/fj.11-184879	http://dx.doi.org/10.1096/fj.11-184879			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21968070				2022-12-28	WOS:000299202200018
J	Foulds, PG; Mitchell, JD; Parker, A; Turner, R; Green, G; Diggle, P; Hasegawa, M; Taylor, M; Mann, D; Allsop, D				Foulds, Penelope G.; Mitchell, J. Douglas; Parker, Angela; Turner, Roisin; Green, Gerwyn; Diggle, Peter; Hasegawa, Masato; Taylor, Mark; Mann, David; Allsop, David			Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease	FASEB JOURNAL			English	Article						Lewy body; oligomer; immunoassay; immunoblot	LEWY BODY; NEURODEGENERATIVE DISORDERS; CLINICAL-DIAGNOSIS; DEMENTIA; SER-129; BODIES; OLIGOMERS; MUTATION; MODEL; CSF	Parkinson's disease (PD) is characterized by the presence of Lewy bodies containing phosphorylated and aggregated alpha-synuclein (alpha-syn). alpha-Syn is present in human body fluids, including blood plasma, and is a potential biomarker for PD. Immunoassays for total and oligomeric forms of both normal and phosphorylated (at Ser-129) alpha-syn have been used to assay plasma samples from a longitudinal cohort of 32 patients with PD (sampled at mo 0, 1, 2, 3), as well as single plasma samples from a group of 30 healthy control participants. The levels of alpha-syn in plasma varied greatly between individuals, but were remarkably consistent over time within the same individual with PD. The mean level of phospho-alpha-syn was found to be higher (P=0.053) in the PD samples than the controls, whereas this was not the case for total alpha-syn (P=0.244), oligo-alpha-syn (P=0.221), or oligo-phospho-alpha-syn (P=0.181). Immunoblots of plasma revealed bands (at 21, 24, and 50-60 kDa) corresponding to phosphorylated alpha-syn. Thus, phosphorylated alpha-syn can be detected in blood plasma and shows more promise as a diagnostic marker than the nonphosphorylated protein. Longitudinal studies undertaken over a more extended time period will be required to determine whether alpha-syn can act as a marker of disease progression.-Foulds, P. G., Mitchell, J. D., Parker, A., Turner, R., Green, G., Diggle, P., Hasegawa, M., Taylor, M., Mann, D., Allsop, D. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25, 4127-4137 (2011). www.fasebj.org	[Foulds, Penelope G.; Taylor, Mark; Allsop, David] Univ Lancaster, Sch Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4AY, England; [Green, Gerwyn; Diggle, Peter] Univ Lancaster, Sch Hlth & Med, Div Hlth Res, Lancaster LA1 4AY, England; [Mitchell, J. Douglas; Parker, Angela; Turner, Roisin] Royal Preston Hosp, Preston, Lancs, England; [Hasegawa, Masato] Tokyo Inst Psychiat, Dept Mol Neurobiol, Tokyo, Japan; [Mann, David] Univ Manchester, Hope Hosp, Sch Community Based Med, Neurodegenerat & Mental Hlth Res Grp, Salford M6 8HD, Lancs, England	Lancaster University; Lancaster University; Royal Preston Hospital; Tokyo Institute of Psychiatry; University of Manchester	Allsop, D (corresponding author), Univ Lancaster, Sch Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4AY, England.	d.allsop@lancaster.ac.uk	Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575; Diggle, Peter/0000-0003-3521-5020	UK Medical Research Council [G0601364]; MRC [G0601364] Funding Source: UKRI; Medical Research Council [G0601364] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors dedicate this paper to the memory of Prof. John Douglas Mitchell. The authors are grateful to the UK Medical Research Council for financial support (grant award G0601364). The authors thank all of the medical, nursing, and administrative staff of Dementias and Neurodegenerative Diseases Research Network North West, who assisted with the recruitment of patients and the collection and preparation of samples. We also wish to acknowledge and thank all the Consultant Neurologists and their staff within the North West Region of Great Britain who took part in this study, particularly Prof. J. Barrett (Arrowe Park Hospital, Wirral) and Drs. M. Kellett (Salford Royal Hospitals National Health Service Foundation Trust), S. N. H. Naqvi (Chorley and South Ribble District General Hospital), J. Raw (Fairfield General Hospital, Bury), M. J. Steiger (The Walton Centre, Liverpool), P. Tidswell (Royal Blackburn Hospital), C. J. Turnbull (Arrowe Park Hospital, Wirral), and J. Vassallo (Royal Oldham Hospital), for their enthusiasm for, and commitment to, the project. The authors thank students H. Sheldon, S. Macari, E. Mooney, and H. Kennedy from Lancaster Girls Grammar School for their help with the immunoblotting, and Mrs K. Lamb for her assistance in preparing the recombinant proteins.	Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Angot E, 2009, PARKINSONISM RELAT D, V15, pS143, DOI 10.1016/S1353-8020(09)70802-8; Barbour R, 2008, NEURODEGENER DIS, V5, P55, DOI 10.1159/000112832; Brooks DJ, 2010, J NUCL MED, V51, P596, DOI 10.2967/jnumed.108.059998; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; de Lau LML, 2006, ARCH NEUROL-CHICAGO, V63, P362, DOI 10.1001/archneur.63.3.noc50312; Duran R, 2010, MOVEMENT DISORD, V25, P489, DOI 10.1002/mds.22928; El-Agnaf OMA, 2004, FASEB J, V18, P1315, DOI 10.1096/fj.03-1346fje; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com; Eller M, 2009, NAT REV NEUROL, V5, P561, DOI 10.1038/nrneurol.2009.135; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Foulds P, 2010, NAT REV NEUROL, V6, P359, DOI 10.1038/nrneurol.2010.78; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Gorbatyuk OS, 2008, P NATL ACAD SCI USA, V105, P763, DOI 10.1073/pnas.0711053105; Hong Z, 2010, BRAIN, V133, P713, DOI 10.1093/brain/awq008; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Irvine GB, 2008, MOL MED, V14, P451, DOI 10.2119/2007-00100.Irvine; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee PH, 2006, J NEURAL TRANSM, V113, P1435, DOI 10.1007/s00702-005-0427-9; Li QX, 2007, EXP NEUROL, V204, P583, DOI 10.1016/j.expneurol.2006.12.006; Lo Bianco C, 2002, P NATL ACAD SCI USA, V99, P10813, DOI 10.1073/pnas.152339799; Machiya Y, 2010, J BIOL CHEM, V285, P40732, DOI 10.1074/jbc.M110.141952; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuda N, 2010, J ALZHEIMERS DIS, V19, P1, DOI 10.3233/JAD-2010-1231; Mollenhauer B, 2008, EXP NEUROL, V213, P315, DOI 10.1016/j.expneurol.2008.06.004; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; Parkkinen L, 2008, ACTA NEUROPATHOL, V115, P399, DOI 10.1007/s00401-008-0346-6; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qing H, 2009, BIOCHEM BIOPH RES CO, V387, P149, DOI 10.1016/j.bbrc.2009.06.142; Reesink FE, 2010, J ALZHEIMERS DIS, V22, P87, DOI 10.3233/JAD-2010-100186; Sasakawa H, 2007, BIOCHEM BIOPH RES CO, V363, P795, DOI 10.1016/j.bbrc.2007.09.048; Savitt JM, 2006, J CLIN INVEST, V116, P1744, DOI 10.1172/JCI29178; Schapira AHV, 1999, BRIT MED J, V318, P311, DOI 10.1136/bmj.318.7179.311; Shi M, 2010, NEUROSCI LETT, V480, P78, DOI 10.1016/j.neulet.2010.06.009; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suchowersky O, 2006, NEUROLOGY, V66, P968, DOI 10.1212/01.wnl.0000215437.80053.d0; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Tokuda T, 2010, NEUROLOGY, V75, P1766, DOI 10.1212/WNL.0b013e3181fd613b; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Wider C, 2010, MOVEMENT DISORD, V25, pS15, DOI 10.1002/mds.22723; Zaccai J, 2005, AGE AGEING, V34, P561, DOI 10.1093/ageing/afi190; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	54	143	152	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4127	4137		10.1096/fj.10-179192	http://dx.doi.org/10.1096/fj.10-179192			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21865317				2022-12-28	WOS:000298138100007
J	Wong, VW; Paterno, J; Sorkin, M; Glotzbach, JP; Levi, K; Januszyk, M; Rustad, KC; Longaker, MT; Gurtner, GC				Wong, Victor W.; Paterno, Josemaria; Sorkin, Michael; Glotzbach, Jason P.; Levi, Kemal; Januszyk, Michael; Rustad, Kristine C.; Longaker, Michael T.; Gurtner, Geoffrey C.			Mechanical force prolongs acute inflammation via T-cell-dependent pathways during scar formation	FASEB JOURNAL			English	Article						wound healing; mechanotransduction; fibrosis; microarray	POSTBURN HYPERTROPHIC SCAR; FOCAL ADHESION KINASE; GENE-EXPRESSION; SKIN FIBROSIS; DERMAL FIBROBLASTS; RENAL FIBROSIS; SCLEROTIC SKIN; ANIMAL-MODEL; MECHANOTRANSDUCTION; ACTIVATION	Mechanical force significantly modulates both inflammation and fibrosis, yet the fundamental mechanisms that regulate these interactions remain poorly understood. Here we performed microarray analysis to compare gene expression in mechanically loaded wounds vs. unloaded control wounds in an established murine hypertrophic scar (HTS) model. We identified 853 mechanically regulated genes (false discovery rate <2) at d 14 postinjury, a subset of which were enriched for T-cell-regulated pathways. To substantiate the role of T cells in scar mechanotransduction, we applied the HTS model to T-cell-deficient mice and wild-type mice. We found that scar formation in T-cell-deficient mice was reduced by almost 9-fold (P < 0.001) with attenuated epidermal (by 2.6-fold, P < 0.01) and dermal (3.9-fold, P < 0.05) proliferation. Mechanical stimulation was highly associated with sustained T-cell-dependent Th2 cytokine (IL-4 and IL-13) and chemokine (MCP-1) signaling. Further, T-cell-deficient mice failed to recruit systemic inflammatory cells such as macrophages or monocytic fibroblast precursors in response to mechanical loading. These findings indicate that T-cell-regulated fibrogenic pathways are highly mechanoresponsive and suggest that mechanical forces induce a chronic-like inflammatory state through immune-dependent activation of both local and systemic cell populations.-Wong, V. W., Paterno, J., Sorkin, M., Glotzbach, J. P., Levi, K., Januszyk, M., Rustad, K. C., Longaker, M. T., Gurtner, G. C. Mechanical force prolongs acute inflammation via T-cell-dependent pathways during scar formation. FASEB J. 25, 4498-4510 (2011). www.fasebj.org	[Wong, Victor W.; Paterno, Josemaria; Sorkin, Michael; Glotzbach, Jason P.; Januszyk, Michael; Rustad, Kristine C.; Longaker, Michael T.; Gurtner, Geoffrey C.] Stanford Univ, Dept Surg, Hagey Lab Pediat Regenerat Med, Stanford, CA 94305 USA; [Levi, Kemal] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Gurtner, GC (corresponding author), Stanford Univ, Dept Surg, Hagey Lab Pediat Regenerat Med, 257 Campus Dr,GK-201, Stanford, CA 94305 USA.	ggurtner@stanford.edu	Glotzbach, Jason P./O-4394-2019	Glotzbach, Jason P./0000-0002-8002-9422; Levi, Kemal/0000-0001-9760-166X				Aarabi S, 2007, FASEB J, V21, P3250, DOI 10.1096/fj.07-8218com; Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P99, DOI 10.1080/09674845.2004.11732652; Aliprantis AO, 2007, P NATL ACAD SCI USA, V104, P2827, DOI 10.1073/pnas.0700021104; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Boyce DE, 2001, BRIT J PLAST SURG, V54, P511, DOI 10.1054/bjps.2001.3638; Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332; Castagnoli C, 1997, BURNS, V23, P565, DOI 10.1016/S0305-4179(97)00070-3; Chatzizisis YS, 2007, J AM COLL CARDIOL, V49, P2379, DOI 10.1016/j.jacc.2007.02.059; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Davison SP, 2007, PLAST RECONSTR SURG, V119, P110, DOI 10.1097/01.prs.0000244846.11400.68; Distler JHW, 2009, RHEUMATOLOGY, V48, P98, DOI 10.1093/rheumatology/ken401; Distler JHW, 2006, ARTHRITIS RHEUM-US, V54, P214, DOI 10.1002/art.21497; Eckes B, 2006, J INVEST DERM SYMP P, V11, P66, DOI 10.1038/sj.jidsymp.5650003; Ferreira AM, 2006, J INVEST DERMATOL, V126, P1900, DOI 10.1038/sj.jid.5700302; Ferretti M, 2006, J IMMUNOL, V177, P8757, DOI 10.4049/jimmunol.177.12.8757; Gawronska-Kozak B, 2006, WOUND REPAIR REGEN, V14, P265, DOI 10.1111/j.1743-6109.2006.00121.x; Gawronska-Kozak B, 2011, MATRIX BIOL, V30, P290, DOI 10.1016/j.matbio.2011.04.004; Gieni RS, 2008, J CELL BIOCHEM, V104, P1964, DOI 10.1002/jcb.21364; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gurtner G. C., 2011, ANN SURG, DOI [10.1097/SLA.0b013e31822b8b2f, DOI 10.1097/SLA.0B013E31822B8B2F]; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Iniguez MA, 1999, J IMMUNOL, V163, P111; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; Kessler-Becker D, 2004, BIOCHEM J, V379, P351, DOI 10.1042/BJ20031371; Lakos G, 2006, PATHOBIOLOGY, V73, P224, DOI 10.1159/000098208; Lin Y, 1997, J IMMUNOL, V158, P5658; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013; Makino A, 2007, BIORHEOLOGY, V44, P221; MATTANA J, 1995, AM J PATHOL, V147, P529; Mecklenburg L, 2005, EXP DERMATOL, V14, P797, DOI 10.1111/j.1600-0625.2005.00362.x; Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007; Morisugi T, 2010, J BIOCHEM, V147, P633, DOI 10.1093/jb/mvp210; Morrison J, 2000, LAB INVEST, V80, P881, DOI 10.1038/labinvest.3780092; Niedermeier M, 2009, P NATL ACAD SCI USA, V106, P17892, DOI 10.1073/pnas.0906070106; Ogawa R, 2008, MED HYPOTHESES, V71, P493, DOI 10.1016/j.mehy.2008.05.020; Ostergaard HL, 2005, IMMUNOL RES, V31, P267, DOI 10.1385/IR:31:3:267; Paddock HN, 2003, J BURN CARE REHABIL, V24, P371, DOI 10.1097/01.BCR.0000095508.96754.E0; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Paterno J, 2011, WOUND REPAIR REGEN, V19, P49, DOI 10.1111/j.1524-475X.2010.00643.x; Pignata C, 2009, ADV EXP MED BIOL, V665, P195; Ricardo SD, 2008, J CLIN INVEST, V118, P3522, DOI 10.1172/JCI36150; Shao DD, 2008, J LEUKOCYTE BIOL, V83, P1323, DOI 10.1189/jlb.1107782; Shynlova O, 2008, J IMMUNOL, V181, P1470, DOI 10.4049/jimmunol.181.2.1470; Simon BA, 2006, AM J PHYSIOL-LUNG C, V291, pL851, DOI 10.1152/ajplung.00463.2005; Simonian PL, 2006, J IMMUNOL, V177, P4436, DOI 10.4049/jimmunol.177.7.4436; Strieter RM, 2007, J CLIN INVEST, V117, P549, DOI 10.1172/JCI30562; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tapmeier TT, 2010, KIDNEY INT, V78, P351, DOI 10.1038/ki.2010.177; Tredget EE, 2006, J INTERF CYTOK RES, V26, P179, DOI 10.1089/jir.2006.26.179; Tsou R, 2000, J BURN CARE REHABIL, V21, P541, DOI 10.1097/00004630-200021060-00012; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wada T, 2007, KIDNEY INT, V72, P269, DOI 10.1038/sj.ki.5002325; WALLACE VA, 1994, EUR J IMMUNOL, V24, P1463, DOI 10.1002/eji.1830240634; Wang JF, 2007, WOUND REPAIR REGEN, V15, P113, DOI 10.1111/j.1524-475X.2006.00192.x; Wang JF, 2007, J INTERF CYTOK RES, V27, P921, DOI 10.1089/jir.2007.0008; Wang JF, 2007, WOUND REPAIR REGEN, V15, P530, DOI 10.1111/j.1524-475X.2007.00261.x; Wang JF, 2011, WOUND REPAIR REGEN, V19, P274, DOI 10.1111/j.1524-475X.2011.00672.x; Wang Z, 2006, J CELL PHYSIOL, V206, P510, DOI 10.1002/jcp.20486; Wittmann M, 2006, CURR OPIN ALLERGY CL, V6, P329, DOI 10.1097/01.all.0000244792.95615.3a; Wong VW, 2011, TISSUE ENG PT A, V17, P631, DOI [10.1089/ten.tea.2010.0298, 10.1089/ten.TEA.2010.0298]; Wu J, 2004, J TRAUMA, V57, P1276, DOI 10.1097/01.TA.0000108997.49513.DC; Wu YJ, 2010, STEM CELLS, V28, P905, DOI 10.1002/stem.420; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yamamoto T, 2004, ARCH DERMATOL RES, V295, P453, DOI 10.1007/s00403-003-0439-y; Yamamoto T, 2001, J INVEST DERMATOL, V117, P999, DOI 10.1046/j.0022-202x.2001.01509.x; Yang DY, 2007, PLAST RECONSTR SURG, V119, P104, DOI 10.1097/01.prs.0000244828.80490.62; Yano S, 2004, J INVEST DERMATOL, V122, P783, DOI 10.1111/j.0022-202X.2004.22328.x; Zeisberg M, 2001, CURR OPIN NEPHROL HY, V10, P315, DOI 10.1097/00041552-200105000-00004	73	83	106	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4498	4510		10.1096/fj.10-178087	http://dx.doi.org/10.1096/fj.10-178087			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21911593				2022-12-28	WOS:000298138100040
J	Manthey, HD; Thomas, AC; Shiels, IA; Zernecke, A; Woodruff, TM; Rolfe, B; Taylor, SM				Manthey, Helga D.; Thomas, Anita C.; Shiels, Ian A.; Zernecke, Alma; Woodruff, Trent M.; Rolfe, Barbara; Taylor, Stephen M.			Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice	FASEB JOURNAL			English	Article						macrophage; C5a receptor; PMX53	E-DEFICIENT MICE; GENE-EXPRESSION; IN-VIVO; DIETARY-CHOLESTEROL; ENDOTHELIAL-CELLS; REGULATOR CD59; COMPONENT C5A; RECEPTOR; LESIONS; C5L2	The complement C5a receptor, CD88, is present on many of the cells found within human atherosclerotic plaques, but little is known about the role of C5a in atherogenesis. Using real-time PCR, we determined that ApoE(-/-) mice fed a normal diet express more aortic CD88 mRNA compared with controls, and this increase coincides with atherosclerotic lesion development (P<0.001 for 3- vs. 25-wk-old animals). Conversely, mRNA expression of the alternative C5a receptor, C5L2, in aortas of ApoE(-/-) mice, was lower than controls at all time points. Using immunohistochemistry, we confirmed the presence of CD88 on macrophages, smooth muscle cells, and activated endothelial cells in plaques from brachiocephalic arteries. Treatment of ApoE(-/-) mice with a CD88 antagonist (PMX53; 3 mg/kg s.c. 3 x /wk plus 1 mg/kg/d p.o.) for 25 wk reduced lesion size and lipid content in the plaque by similar to 40% (P<0.05). Our study provides evidence for a proatherogenic role for C5a and identifies the CD88 antagonist PMX53 as a potential antiatherosclerotic drug.-Manthey, H. D., Thomas, A. C., Shiels, I. A., Zernecke, A., Woodruff, T. M., Rolfe, B., Taylor, S. M. Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice. FASEB J. 25, 2447-2455 (2011). www.fasebj.org	[Manthey, Helga D.; Zernecke, Alma; Rolfe, Barbara] Univ Wurzburg, Rudolf Virchow Zentrum, DFG Forschungszentrum Experimentelle Biomed, D-97080 Wurzburg, Germany; [Manthey, Helga D.; Shiels, Ian A.; Woodruff, Trent M.; Taylor, Stephen M.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Thomas, Anita C.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia; [Thomas, Anita C.] Univ Bristol, Bristol Heart Inst, Bristol, Avon, England	University of Wurzburg; University of Queensland; University of Queensland; University of Bristol	Manthey, HD (corresponding author), Univ Wurzburg, Rudolf Virchow Zentrum, DFG Forschungszentrum Experimentelle Biomed, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	helga.manthey@uni-wuerzburg.de	Woodruff, Trent/AAS-4629-2020; Thomas, Anita C/E-1743-2011; Woodruff, Trent M/B-4861-2009	Woodruff, Trent/0000-0003-1382-911X; Thomas, Anita C/0000-0002-3792-2653; Woodruff, Trent M/0000-0003-1382-911X; Rolfe, Barbara/0000-0002-0468-1371	Australia National Health and Medical Research Council; British Heart Foundation; Deutsche Forschungsgemeinschaft [ZE827/4-1]	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); British Heart Foundation(British Heart Foundation); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Australia National Health and Medical Research Council. A. C. T. is supported by funding from the British Heart Foundation and A.Z. by the Deutsche Forschungsgemeinschaft (ZE827/4-1). The authors thank Tyson Moore, Michael Morgan, Jackie Costello, and Mike Wu for technical assistance with dosing mice and Bob Simpson and Johanna Barclay for technical assistance with real-time PCR experiments. The authors also thank Dr. Peter Monk (University of Sheffield, Sheffield, UK) for supplying the anti-mouse C5L2 antibody and Promics Ltd (Brisbane, QLD, Australia) for supplying the CD88 antagonist, PMX53, used in these studies.	Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2; Ali K, 2005, CIRC RES, V97, P922, DOI 10.1161/01.RES.0000187467.67684.43; Bamberg CE, 2010, J BIOL CHEM, V285, P7633, DOI 10.1074/jbc.M109.092106; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; Dawson TC, 1999, ATHEROSCLEROSIS, V143, P205; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Grainger DJ, 2004, J IMMUNOL, V173, P6366, DOI 10.4049/jimmunol.173.10.6366; Guo RF, 2004, SHOCK, V21, P1, DOI 10.1097/01.shk.0000105502.75189.5e; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Haskard DO, 2008, CURR OPIN LIPIDOL, V19, P478, DOI 10.1097/MOL.0b013e32830f4a06; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Kiernan J.A., 1999, HISTOLOGICAL HISTOCH, V3rd ed; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Koehl J, 2006, CURR OPIN MOL THER, V8, P529; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Niculescu F, 1999, MOL IMMUNOL, V36, P949, DOI 10.1016/S0161-5890(99)00117-0; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Ohta H, 2005, ATHEROSCLEROSIS, V180, P11, DOI 10.1016/j.atherosclerosis.2004.11.016; Oksjoki R, 2007, ATHEROSCLEROSIS, V195, P90, DOI 10.1016/j.atherosclerosis.2006.12.016; Patel S, 2001, BIOCHEM BIOPH RES CO, V286, P164, DOI 10.1006/bbrc.2001.5276; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Schmiedt W, 1998, ARTERIOSCL THROM VAS, V18, P1790, DOI 10.1161/01.ATV.18.11.1790; SEIFERT PS, 1990, J EXP MED, V172, P547, DOI 10.1084/jem.172.2.547; SEIFERT PS, 1989, LAB INVEST, V60, P747; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shagdarsuren E, 2010, CIRCULATION, V122, P1026, DOI 10.1161/CIRCULATIONAHA.110.954370; Speidl WS, 2011, FASEB J, V25, P35, DOI 10.1096/fj.10-156083; Speidl WS, 2005, EUR HEART J, V26, P2294, DOI 10.1093/eurheartj/ehi339; Thomas AC, 2010, J VASC RES, V47, P299, DOI 10.1159/000265564; Tous M, 2006, BIOCHEM BIOPH RES CO, V340, P1078, DOI 10.1016/j.bbrc.2005.12.109; Vischer UM, 1998, THROMB HAEMOSTASIS, V80, P1002; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9; Woodruff TM, 2006, DRUG FUTURE, V31, P325, DOI 10.1358/dof.2006.031.04.980656; Woodruff TM, 2008, J IMMUNOL, V181, P8727, DOI 10.4049/jimmunol.181.12.8727; Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363; Wu GX, 2009, CIRC RES, V104, P550, DOI 10.1161/CIRCRESAHA.108.191361; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Yun S, 2008, ARTERIOSCL THROM VAS, V28, P1714, DOI 10.1161/ATVBAHA.108.169912	48	69	70	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2447	2455		10.1096/fj.10-174284	http://dx.doi.org/10.1096/fj.10-174284			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21490292				2022-12-28	WOS:000292242200035
J	Bu, WM; Liu, RY; Cheung-Lau, JC; Dmochowski, IJ; Loll, PJ; Eckenhoff, RG				Bu, Weiming; Liu, Renyu; Cheung-Lau, Jasmina C.; Dmochowski, Ivan J.; Loll, Patrick J.; Eckenhoff, Roderic G.			Ferritin couples iron and fatty acid metabolism	FASEB JOURNAL			English	Article						arachidonic acid; X-ray crystallography; calorimetry; ferrihydrite	SERUM FERRITIN; FERROXIDASE KINETICS; ANESTHETIC BINDING; OXIDATIVE STRESS; HUMAN H; SITE; EXPRESSION; PROTEINS; DISEASE; MEN	A physiological relationship between iron, oxidative injury, and fatty acid metabolism exists, but transduction mechanisms are unclear. We propose that the iron storage protein ferritin contains fatty acid binding sites whose occupancy modulates iron uptake and release. Using isothermal microcalorimetry, we found that arachidonic acid binds ferritin specifically and with 60 mu M affinity. Arachidonate binding by ferritin enhanced iron mineralization, decreased iron release, and protected the fatty acid from oxidation. Cocrystals of arachidonic acid and horse spleen apoferritin diffracted to 2.18 angstrom and revealed specific binding to the 2-fold intersubunit pocket. This pocket shields most of the fatty acid and its double bonds from solvent but allows the arachidonate tail to project well into the ferrihydrite mineralization site on the ferritin L-subunit, a structural feature that we implicate in the effects on mineralization by demonstrating that the much shorter saturated fatty acid, caprylate, has no significant effects on mineralization. These combined effects of arachidonate binding by ferritin are expected to lower both intracellular free iron and free arachidonate, thereby providing a previously unrecognized mechanism for limiting lipid peroxidation, free radical damage, and proinflammatory cascades during times of cellular stress.-Bu, W., Liu, R., Cheung-Lau, J. C., Dmochowski, I. J., Loll, P. J., Eckenhoff, R. G. Ferritin couples iron and fatty acid metabolism. FASEB J. 26, 2394-2400 (2012). www.fasebj.org	[Bu, Weiming; Liu, Renyu; Eckenhoff, Roderic G.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Cheung-Lau, Jasmina C.; Dmochowski, Ivan J.] Univ Penn, Sch Arts & Sci, Dept Chem, Philadelphia, PA 19104 USA; [Loll, Patrick J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Drexel University	Eckenhoff, RG (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,305 John Morgan, Philadelphia, PA 19104 USA.	roderic.eckenhoff@uphs.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X	U.S. National Institutes of Health National Institute of General Medical Sciences [P0155876]; Austin Lamont Endowment; National Science Foundation [CHE 0548188]	U.S. National Institutes of Health National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Austin Lamont Endowment; National Science Foundation(National Science Foundation (NSF))	This work was supported by U.S. National Institutes of Health National Institute of General Medical Sciences grant P0155876, the Austin Lamont Endowment (R. G. E.), and National Science Foundation CAREER Award CHE 0548188 (I.J.D.). The authors appreciate the technical support of David Liang. The authors declare no conflicts of interest.	ARAUJO FB, 1995, ATHEROSCLEROSIS, V117, P61, DOI 10.1016/0021-9150(94)05558-Z; Baldi A, 2005, CLIN CANCER RES, V11, P3175, DOI 10.1158/1078-0432.CCR-04-0631; Bar-Or D, 2001, BIOCHEM BIOPH RES CO, V284, P856, DOI 10.1006/bbrc.2001.5042; Bou-Abdallah F, 2004, BIOCHEMISTRY-US, V43, P4332, DOI 10.1021/bi0498813; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Burke JE, 2009, J LIPID RES, V50, pS237, DOI 10.1194/jlr.R800033-JLR200; Chmurzynska A, 2006, J APPL GENET, V47, P39, DOI 10.1007/BF03194597; Crichton RR, 2010, BBA-GEN SUBJECTS, V1800, P706, DOI 10.1016/j.bbagen.2010.03.019; Curry S, 2009, DRUG METAB PHARMACOK, V24, P342, DOI 10.2133/dmpk.24.342; Elia G, 1999, EUR J BIOCHEM, V264, P736, DOI 10.1046/j.1432-1327.1999.00610.x; Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200; Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561; Giordani A, 2000, J PHOTOCH PHOTOBIO B, V54, P43, DOI 10.1016/S1011-1344(99)00154-2; Haldar S, 2011, J BIOL CHEM, V286, P25620, DOI 10.1074/jbc.M110.205278; HEMPSTEAD PD, 1994, FEBS LETT, V350, P258, DOI 10.1016/0014-5793(94)00781-0; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Hermans MP, 2010, DIABETIC MED, V27, P417, DOI 10.1111/j.1464-5491.2010.02979.x; Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486; Kell DB, 2010, ARCH TOXICOL, V84, P825, DOI 10.1007/s00204-010-0577-x; Knuiman MW, 2003, AM J EPIDEMIOL, V158, P144, DOI 10.1093/aje/kwg121; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; Liu RY, 2005, FASEB J, V19, P567, DOI 10.1096/fj.04-3171com; Mackenzie EL, 2008, BIOCHEM J, V411, P107, DOI 10.1042/BJ20071544; Ortiz E, 2004, J NEUROSCI RES, V77, P681, DOI 10.1002/jnr.20207; PRECIGOUX G, 1994, ACTA CRYSTALLOGR D, V50, P739, DOI 10.1107/S0907444994003227; SUN S, 1992, J BIOL CHEM, V267, P25160; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; Tsuji Y, 2005, ONCOGENE, V24, P7567, DOI 10.1038/sj.onc.1208901; Vedula LS, 2009, J BIOL CHEM, V284, P24176, DOI 10.1074/jbc.M109.017814; Wang ZM, 2006, ACTA CRYSTALLOGR D, V62, P800, DOI 10.1107/S0907444906018294; Zacharski LR, 2007, JAMA-J AM MED ASSOC, V297, P603, DOI 10.1001/jama.297.6.603; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; Zimmerman AW, 2001, INT J BIOCHEM CELL B, V33, P865, DOI 10.1016/S1357-2725(01)00070-X	34	26	26	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2394	2400		10.1096/fj.11-198853	http://dx.doi.org/10.1096/fj.11-198853			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362897	Green Published			2022-12-28	WOS:000305017200017
J	Hifumi, E; Honjo, E; Fujimoto, N; Arakawa, M; Nishizono, A; Uda, T				Hifumi, Emi; Honjo, Eijiro; Fujimoto, Naoko; Arakawa, Mitsue; Nishizono, Akira; Uda, Taizo			Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics	FASEB JOURNAL			English	Article						germline gene; rabies virus; infection	MONOCLONAL-ANTIBODIES; ABILITY; HYDROLYSIS; SUBUNITS; PEPTIDE; HIV-1; GP41	The ultimate goal of catalytic antibody research is to develop new patient therapies that use the advantages offered by human catalytic antibodies. The establishment of a high-throughput method for obtaining valuable candidate catalytic antibodies must be accelerated to achieve this objective. In this study, based on our concept that we can find antibody light chains with a high probability of success if they include a serine protease-like catalytic triad composed of Ser, His, and Asp on a variable region of the antibody structure, we amplified and cloned DNAs encoding human antibody light chains from germline genes of subgroup II by seminested PCR using two primer sets designed for this purpose. Seven DNA fragments encoding light chains in 17 clones were derived from germline gene A18b, 6 DNA fragments from A3/A19, 2 DNA fragments from A17, and a clone DNA fragment from A5 and O11/O1. All light chains expressed in Escherichia coli and highly purified under nondenaturing conditions exhibited amidolytic activity against synthetic peptides. Some of the light chains exhibited unique features that suppressed the infectious activity of the rabies virus. Furthermore, the survival rate of mice in which a lethal level of the rabies virus was coinoculated directly into the brain with light chain 18 was significantly improved. In the case of humans, these results demonstrate that high-throughput selection of light chains possessing catalytic functions and specificity for a target molecule can be attained from a light-chain DNA library amplified from germline genes belonging to subgroup II.-Hifumi, E., Honjo, E., Fujimoto, N., Arakawa, M., Nishizono, A., Uda, T. Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics. FASEB J. 26, 1607-1615 (2012). www.fasebj.org	[Honjo, Eijiro; Fujimoto, Naoko; Uda, Taizo] Oita Univ, Fac Engn, Dept Appl Biochem, Oita 8701192, Japan; [Hifumi, Emi] Oita Univ, Res Ctr Appl Med Engn, Oita 8701192, Japan; [Honjo, Eijiro; Fujimoto, Naoko; Uda, Taizo] Oita Univ, Fac Med, Dept Nursing, Yufu, Japan; [Nishizono, Akira] Oita Univ, Fac Med, Dept Microbiol, Yufu, Japan; [Hifumi, Emi; Honjo, Eijiro; Fujimoto, Naoko; Arakawa, Mitsue; Nishizono, Akira; Uda, Taizo] Japan Sci & Technol Agcy Core Res Evolut Sci & Te, Kawaguchi, Saitama, Japan	Oita University; Oita University; Oita University; Oita University; Japan Science & Technology Agency (JST)	Uda, T (corresponding author), Oita Univ, Fac Engn, Dept Appl Biochem, 700 Dan Noharu, Oita 8701192, Japan.	uda@oita-u.ac.jp		Uda, Taizo/0000-0001-8146-7902	Japan Science and Technology Agency (Core Research for Evolutional Science and Technology, Establishment of Innovative Manufacturing Technology Based on Nanoscience)	Japan Science and Technology Agency (Core Research for Evolutional Science and Technology, Establishment of Innovative Manufacturing Technology Based on Nanoscience)	This study was supported by the Japan Science and Technology Agency (Core Research for Evolutional Science and Technology, Establishment of Innovative Manufacturing Technology Based on Nanoscience). The authors thank Mr. Masashi Kanda and Mr. Hiroyuki Sakata for their assistance with this study.	ANCHIN JM, 1994, J MOL GRAPHICS, V12, P257, DOI 10.1016/0263-7855(94)80102-9; GAO QS, 1994, J BIOL CHEM, V269, P32389; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; Hifumi E, 2002, J IMMUNOL METHODS, V269, P283, DOI 10.1016/S0022-1759(02)00242-9; Hifumi E, 2000, APPL BIOCHEM BIOTECH, V83, P209, DOI 10.1385/ABAB:83:1-3:209; Hifumi E, 2008, J BIOL CHEM, V283, P899, DOI 10.1074/jbc.M705674200; Hifumi E, 2010, FEBS J, V277, P3823, DOI 10.1111/j.1742-4658.2010.07785.x; Hollfelder F, 1996, NATURE, V383, P60, DOI 10.1038/383060a0; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; LAUTNERRIESKE A, 1992, EUR J IMMUNOL, V22, P1023, DOI 10.1002/eji.1830220422; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; Matsumoto T, 2010, MICROBIOL IMMUNOL, V54, P673, DOI 10.1111/j.1348-0421.2010.00262.x; MEI S, 1991, J BIOL CHEM, V266, P15571; Mitsuda Y, 2004, BIOTECHNOL BIOENG, V86, P217, DOI 10.1002/bit.20031; Okochi N, 2007, APPL MICROBIOL BIOT, V77, P597, DOI 10.1007/s00253-007-1197-0; Paul S, 2004, J BIOL CHEM, V279, P39611, DOI 10.1074/jbc.M406719200; Paul S, 2010, J CLIN IMMUNOL, V30, pS43, DOI 10.1007/s10875-010-9414-5; Planque S, 2008, AUTOIMMUN REV, V7, P473, DOI 10.1016/j.autrev.2008.04.002; Ramsland R. A., 2006, BIOCHEM J, V396, P473; Sharma V, 2009, J BIOL CHEM, V284, P33079, DOI 10.1074/jbc.M109.036087; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535; SUN M, 1994, J IMMUNOL, V153, P5121; Uda T, 2004, J BIOSCI BIOENG, V97, P143, DOI 10.1016/S1389-1723(04)70183-8	27	25	26	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1607	1615		10.1096/fj.11-195339	http://dx.doi.org/10.1096/fj.11-195339			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22205784				2022-12-28	WOS:000302359700022
J	Hirota, N; Risse, PA; Novali, M; McGovern, T; Al-Alwan, L; McCuaig, S; Proud, D; Hayden, P; Hamid, Q; Martin, JG				Hirota, Nobuaki; Risse, Paul-Andre; Novali, Mauro; McGovern, Toby; Al-Alwan, Laila; McCuaig, Sarah; Proud, David; Hayden, Patrick; Hamid, Qutayba; Martin, James G.			Histamine may induce airway remodeling through release of epidermal growth factor receptor ligands from bronchial epithelial cells	FASEB JOURNAL			English	Article						amphiregulin; heparin-binding epidermal growth factor-like growth factor; HB-EGF; proliferation; migration; goblet cell differentiation	ALPHA-CONVERTING-ENZYME; SMOOTH-MUSCLE; EGF RECEPTOR; HB-EGF; MAST-CELL; PROLIFERATION; AMPHIREGULIN; EXPRESSION; ACTIVATION; ASTHMA	Asthma is a chronic inflammatory disease that is associated with airway remodeling, including hyperplasia of airway epithelial cells and airway smooth muscle cells, and goblet cell differentiation. We wished to address the potential role of histamine, a key biogenic amine involved in allergic reactions, in airway remodeling through the epidermal growth factor receptor (EGFR) pathway. Here, we demonstrate that histamine releases 2 EGFR ligands, amphiregulin and heparin-binding epidermal growth factor-like growth factor (HB-EGF), from airway epithelial cells. Amphiregulin and HB-EGF were expressed in airway epithelium of patients with asthma. Histamine up-regulated their mRNA expression (amphiregulin 3.2-fold, P<0.001; HB-EGF 2.3-fold, P<0.05) and triggered their release (amphiregulin EC50 0.50 mu M, 31.2 +/- 2.7 pg/ml with 10 mu M histamine, P<0.01; HB-EGF EC50 0.54 mu M, 78.5 +/- 1.8 pg/ml with 10 mu M histamine, P<0.001) compared to vehicle control (amphiregulin 19.3 +/- 0.9 pg/ml; HB-EGF 60.2 +/- 1.0 pg/ml), in airway epithelial cells. Histamine increased EGFR phosphorylation (2.1-fold by Western blot analysis) and induced goblet cell differentiation (CLCA1 up-regulation by real-time qPCR) in normal human bronchial epithelial (NHBE) cells. Moreover, amphiregulin and HB-EGF caused proliferation and migration of both NHBE cells and human airway smooth muscle cells. These results suggest that histamine may induce airway remodeling via the epithelial-derived EGFR ligands amphiregulin and HB-EGF.-Hirota, N., Risse, P.-A., Novali, M., McGovern, T., Al-Alwan, L., McCuaig, S., Proud, D., Hayden, P., Hamid, Q., Martin, J. G. Histamine may induce airway remodeling through release of epidermal growth factor receptor ligands from bronchial epithelial cells. FASEB J. 26, 1704-1716 (2012). www.fasebj.org	[Hirota, Nobuaki; Risse, Paul-Andre; Novali, Mauro; McGovern, Toby; Al-Alwan, Laila; McCuaig, Sarah; Hamid, Qutayba; Martin, James G.] McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; [Proud, David] Univ Calgary, Fac Med, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Hayden, Patrick] MatTek Corp, Ashland, ME USA	McGill University; University of Calgary; MatTek Corporation	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.	james.martin@mcgill.ca		Martin, James/0000-0001-7574-5363; Hayden, Patrick/0000-0001-8977-1845	Richard and Edith Strauss Canada Foundation; Canadian Institutes of Health Research [MOP-93747]; Strauss Canada Foundation; Canadian Thoracic Society	Richard and Edith Strauss Canada Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Strauss Canada Foundation; Canadian Thoracic Society	The authors thank Dr. Muhannad Hassan for his technical support with immunostaining. The authors also thank Ms. Jamilah P. Saeed and laboratory members for technical advice and useful discussions. The authors also acknowledge the assistance of Dr. R. Olivenstein and the Difficult Asthma Program (McGill University). This work was supported in part by The Richard and Edith Strauss Canada Foundation and by Canadian Institutes of Health Research grant MOP-93747. N.H. was supported by a fellowship from the Strauss Canada Foundation. T. M. was supported by a studentship of the Canadian Thoracic Society.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Baginski TK, 2006, AM J RESP CELL MOL, V35, P165, DOI 10.1165/rcmb.2005-0259OC; Bara I, 2010, EUR RESPIR J, V36, P1174, DOI 10.1183/09031936.00019810; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Carrasco-Garcia E, 2011, EXP CELL RES, V317, P1476, DOI 10.1016/j.yexcr.2011.03.015; Cheng KR, 2007, BIOCHEM PHARMACOL, V73, P1001, DOI 10.1016/j.bcp.2006.11.028; Chhabra J, 2007, EUR RESPIR J, V29, P861, DOI 10.1183/09031936.00106306; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-0266OC; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Damera G, 2009, AM J PHYSIOL-LUNG C, V296, pL674, DOI 10.1152/ajplung.90585.2008; Deshmukh HS, 2005, AM J RESP CRIT CARE, V171, P305, DOI 10.1164/rccm.200408-1003OC; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Enomoto Y, 2009, J ALLERGY CLIN IMMUN, V124, P913, DOI 10.1016/j.jaci.2009.08.044; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8; Goncharova EA, 2006, NAT PROTOC, V1, P2933, DOI 10.1038/nprot.2006.434; Gooz M, 2006, J BIOL CHEM, V281, P21004, DOI 10.1074/jbc.M512096200; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kasina S, 2009, CELL PROLIFERAT, V42, P799, DOI 10.1111/j.1365-2184.2009.00645.x; Kim KW, 2009, CHEST, V136, P805, DOI 10.1378/chest.08-2972; Kunzmann S, 2007, J ALLERGY CLIN IMMUN, V119, P1398, DOI 10.1016/j.jaci.2007.02.018; Le Cras TD, 2011, AM J PHYSIOL-LUNG C, V300, pL414, DOI 10.1152/ajplung.00346.2010; Liles JS, 2010, CANCER BIOL THER, V10, P555, DOI 10.4161/cbt.10.6.12532; Liu K, 2008, J BIOL CHEM, V283, P9977, DOI 10.1074/jbc.M710257200; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McGovern T, 2010, AM J PHYSIOL-LUNG C, V299, pL808, DOI 10.1152/ajplung.00438.2009; Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028; Nopp A, 2010, ALLERGY, V65, P56, DOI 10.1111/j.1398-9995.2009.02144.x; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Ornskov D, 2007, BIOCHEM BIOPH RES CO, V354, P885, DOI 10.1016/j.bbrc.2007.01.047; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; Park SJ, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-78; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rocks N, 2008, CELL PROLIFERAT, V41, P988, DOI 10.1111/j.1365-2184.2008.00557.x; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Shah BH, 2004, TRENDS ENDOCRIN MET, V15, P47, DOI 10.1016/j.tem.2004.01.004; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Shiomi T., 2010, AM J RESP CELL MOL B; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tamaoka M, 2008, EUR RESPIR J, V32, P1213, DOI 10.1183/09031936.00166907; Ueno Y, 2008, INT J CANCER, V123, P340, DOI 10.1002/ijc.23465; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang Q, 2010, J IMMUNOL, V185, P834, DOI 10.4049/jimmunol.0901490; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Willmarth NE, 2009, CELL SIGNAL, V21, P212, DOI 10.1016/j.cellsig.2008.10.003; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	64	48	49	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1704	1716		10.1096/fj.11-197061	http://dx.doi.org/10.1096/fj.11-197061			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22247333				2022-12-28	WOS:000302359700031
J	Zhang, HL; Limphong, P; Pieper, J; Liu, Q; Rodesch, CK; Christians, E; Benjamin, IJ				Zhang, Huali; Limphong, Pattraranee; Pieper, Joel; Liu, Qiang; Rodesch, Christopher K.; Christians, Elisabeth; Benjamin, Ivor J.			Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity	FASEB JOURNAL			English	Article						redox potential; thioredoxin; roGFPs; reactive oxygen species	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; FLUORESCENT PROTEIN INDICATORS; REDOX STATE; SACCHAROMYCES-CEREVISIAE; THIOREDOXIN SYSTEMS; N-ACETYLCYSTEINE; CARCINOMA-CELLS; APOPTOSIS; INVOLVEMENT; RESISTANCE	To investigate the effects of the predominant nonprotein thiol, glutathione (GSH), on redox homeostasis, we employed complementary pharmacological and genetic strategies to determine the consequences of both loss-and gain-of-function GSH content in vitro. We monitored the redox events in the cytosol and mitochondria using reduction-oxidation sensitive green fluorescent protein (roGFP) probes and the level of reduced/oxidized thioredoxins (Trxs). Either H2O2 or the Trx reductase inhibitor 1-chloro-2,4-dinitrobenzene (DNCB), in embryonic rat heart (H9c2) cells, evoked 8 or 50 mV more oxidizing glutathione redox potential, E-hc (GSSG/2GSH), respectively. In contrast, N-acetyl-L-cysteine (NAC) treatment in H9c2 cells, or overexpression of either the glutamate cysteine ligase (GCL) catalytic subunit (GCLC) or GCL modifier subunit (GCLM) in human embryonic kidney 293 T (HEK293T) cells, led to 3- to 4-fold increase of GSH and caused 7 or 12 mV more reducing Ehc, respectively. This condition paradoxically increased the level of mitochondrial oxidation, as demonstrated by redox shifts in mitochondrial roGFP and Trx2. Lastly, either NAC treatment (EC50 4 mM) or either GCLC or GCLM overexpression exhibited increased cytotoxicity and the susceptibility to the more reducing milieu was achieved at decreased levels of ROS. Taken together, our findings reveal a novel mechanism by which GSH-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity.-Zhang, H., Limphong, P., Pieper, J., Liu, Q., Rodesch, C. K., Christians, E., Benjamin, I. J. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J. 26, 1442-1451 (2012). www.fasebj.org	[Zhang, Huali; Limphong, Pattraranee; Pieper, Joel; Liu, Qiang; Christians, Elisabeth; Benjamin, Ivor J.] Univ Utah, Sch Med, Lab Cardiac Dis Redox Signaling & Cell Regenerat, Div Cardiol, Salt Lake City, UT 84132 USA; [Rodesch, Christopher K.] Univ Utah, Sch Med, Cell Imaging Lab, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Benjamin, IJ (corresponding author), Univ Utah, Sch Med, Dept Internal Med, 30 N 1900 E,Rm 4A100, Salt Lake City, UT 84132 USA.	ivor.benjamin@hsc.utah.edu			U.S. National Heart, Lung, and Blood Institute (NHLBI) [2 R01 HL063834-06, 5R01HL074370-03]; U.S. National Institutes of Health [NIH 5DP1OD006438-02]; NIH [1RO1HL66701]; Leducq Transatlantic Network of Excellence; American Heart Association [09POST2251058]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074370, R01HL063834, DP1HL117650] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006438] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leducq Transatlantic Network of Excellence; American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the U.S. National Heart, Lung, and Blood Institute (NHLBI; ARRA award 2 R01 HL063834-06 and grant 5R01HL074370-03 to I.J.B.), a 2009 U.S. National Institutes of Health Director's Pioneer (NIH 5DP1OD006438-02), Veterans Affairs Merit Review award (NIH 1RO1HL66701 I.J.B.), and the Leducq Transatlantic Network of Excellence. H.Z. was supported by an American Heart Association postdoctoral fellowship (09POST2251058).	Adeyemo D, 2001, CANCER LETT, V164, P77, DOI 10.1016/S0304-3835(00)00720-5; Albrecht SC, 2011, CELL METAB, V14, P819, DOI 10.1016/j.cmet.2011.10.010; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; BAILEY HH, 1992, CANCER RES, V52, P5115; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Dikalov S, 2007, HYPERTENSION, V49, P717, DOI 10.1161/01.HYP.0000258594.87211.6b; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Gutscher M, 2008, NAT METHODS, V5, P553, DOI 10.1038/NMETH.1212; Halvey PJ, 2005, BIOCHEM J, V386, P215, DOI 10.1042/BJ20041829; Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122; Hanson GT, 2004, J BIOL CHEM, V279, P13044, DOI 10.1074/jbc.M312846200; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; Hu JJ, 2008, J BIOL CHEM, V283, P29126, DOI 10.1074/jbc.M803028200; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jones DP, 2006, CHEM-BIOL INTERACT, V163, P38, DOI 10.1016/j.cbi.2006.07.008; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Menon SG, 2007, CANCER RES, V67, P6392, DOI 10.1158/0008-5472.CAN-07-0225; Merten KE, 2006, J PHARMACOL EXP THER, V319, P934, DOI 10.1124/jpet.106.108845; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Pimentel D, 2012, ANTIOXID REDOX SIGN, V16, P524, DOI 10.1089/ars.2011.4336; Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200; Rajasekaran NS, 2007, CELL, V130, P427, DOI 10.1016/j.cell.2007.06.044; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Trotter EW, 2002, MOL MICROBIOL, V46, P869, DOI 10.1046/j.1365-2958.2002.03216.x; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang X, 2010, HYPERTENSION, V55, P1412, DOI 10.1161/HYPERTENSIONAHA.109.147066	42	117	124	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1442	1451		10.1096/fj.11-199869	http://dx.doi.org/10.1096/fj.11-199869			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22202674	Green Published			2022-12-28	WOS:000302359700007
J	Bailey, AR; Hou, HY; Obregon, DF; Tian, J; Zhu, YY; Zou, Q; Nikolic, WV; Bengtson, M; Mori, T; Murphy, T; Tan, J				Bailey, Antoinette R.; Hou, Huayan; Obregon, Demian F.; Tian, Jun; Zhu, Yuyan; Zou, Qiang; Nikolic, William V.; Bengtson, Michael; Mori, Takashi; Murphy, Tanya; Tan, Jun			Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-alpha : implications for autism	FASEB JOURNAL			English	Article						T cells; sAPP-alpha; transgenic mice	NERVE GROWTH-FACTOR; NEGATIVE SELECTION; CELL DEVELOPMENT; SPECTRUM DISORDERS; SECRETED FORMS; ACTIVE DOMAIN; RETT-SYNDROME; CHILDREN; RECEPTOR; DISEASE	Abnormalities in T-lymphocyte populations and function are observed in autism. Soluble amyloid precursor protein alpha (sAPP-alpha) is elevated in some patients with autism and is known to be produced by immune cells. In light of the well-established role of sAPP-alpha in proliferation, growth, and survival of neurons, we hypothesized an analogous role in the immune system. Thus, we explored whether sAPP-alpha could modulate immune development and function, especially aspects of the pinnacle cell of the adaptive arm of the immune system: the T cell. To do this, we generated mice overexpressing human sAPP-alpha and characterized elements of T-cell development, signal transduction, cytokine production, and innate/adaptive immune functions. Here, we report that transgenic sAPP-alpha-overexpressing (TgsAPP-alpha) mice displayed increased proportions of CD8(+) T cells, while effector memory T cells were decreased in the thymus. Overall apoptotic signal transduction was decreased in the thymus, an effect that correlated with dramatic elevations in Notch1 activation; while active-caspase-3/total-caspase-3 and Bax/Bcl-2 ratios were decreased. Greater levels of IFN-gamma, IL-2, and IL-4 were observed after ex vivo challenge of TgsAPP-alpha mouse splenocytes with T-cell mitogen. Finally, after immunization, splenocytes from TgsAPP-alpha mice displayed decreased levels IFN-gamma, IL-2, and IL-4, as well as suppressed ZAP70 activation, after recall antigen stimulation. Given elevated levels of circulating sAPP-alpha in some patients with autism, sAPP-alpha could potentially drive aspects of immune dysfunction observed in these patients, including dysregulated T-cell apoptosis, aberrant PI3K/AKT signaling, cytokine alterations, and impaired T-cell recall stimulation.-Bailey, A. R., Hou, H., Obregon, D. F., Tian, J., Zhu, Y., Zou, Q., Nikolic, W. V., Bengtson, M., Mori, T., Murphy, T., Tan, J. Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-alpha : implications for autism. FASEB J. 26, 1040-1051 (2012). www.fasebj.org	[Bailey, Antoinette R.; Hou, Huayan; Obregon, Demian F.; Tian, Jun; Zhu, Yuyan; Zou, Qiang; Bengtson, Michael; Tan, Jun] Univ S Florida, Coll Med, All Childrens Hosp, Rashid Lab Dev Neurobiol,Silver Child Dev Ctr,Dep, Tampa, FL 33613 USA; [Murphy, Tanya] Univ S Florida, Coll Med, All Childrens Hosp, Rothman Ctr Neuropsychiat,Dept Pediat, Tampa, FL 33613 USA; [Nikolic, William V.] Univ Kragujevac, Fac Med, Dept Genet, Kragujevac, Serbia; [Mori, Takashi] Saitama Med Ctr, Dept Biomed Sci, Kawagoe, Saitama, Japan; [Mori, Takashi] Saitama Med Ctr, Dept Pathol, Kawagoe, Saitama, Japan; [Mori, Takashi] Saitama Med Univ, Kawagoe, Saitama, Japan	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Kragujevac; Saitama Medical University; Saitama Medical University; Saitama Medical University	Tan, J (corresponding author), Univ S Florida, Coll Med, Dept Psychiat & Neurosci, Rashid Lab Dev Neurobiol,Silver Child Dev Ctr, 3515 E Fletcher Ave, Tampa, FL 33613 USA.	jtan@hsc.usf.edu	Tan, Jun/I-5339-2012; Murphy, Tanya K/J-7079-2013; Nikolic, William/H-4672-2013	Nikolic, William/0000-0002-7670-6910	Silver Foundation; U.S. National Institutes of Health/National Institute of Mental Health [R21MH087849]; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH087849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032432] Funding Source: NIH RePORTER	Silver Foundation; U.S. National Institutes of Health/National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Silver Foundation and the U.S. National Institutes of Health/National Institute of Mental Health (R21MH087849, J.T.). J.T. holds the Sliver Chair in Developmental Neurobiology. T. M. holds the Rothman Chair for Neuropsychiatry. The authors particularly thank Steven Barger (University of Arkansas, Little Rock, AR, USA) for providing the sAPP-alpha DNA construct and Danielle T. Sutton for her helpful advice and discussion. The authors also thank Frank Fernandez for his support.	APA, 2000, DIAGN STAT MAN MENT; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Ashwood P, 2004, AUTOIMMUN REV, V3, P557, DOI 10.1016/j.autrev.2004.07.036; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P840, DOI 10.1016/j.bbi.2010.09.002; Atladottir HO, 2010, ARCH PEDIAT ADOL MED, V164, P470, DOI 10.1001/archpediatrics.2010.9; Bailey AR, 2008, INT J CLIN EXP MED, V1, P338; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Bullido MJ, 1996, BBA-MOL CELL RES, V1313, P54, DOI 10.1016/0167-4889(96)00015-8; Copanaki E, 2010, MOL CELL NEUROSCI, V44, P386, DOI 10.1016/j.mcn.2010.04.007; Denney DR, 1996, J AUTISM DEV DISORD, V26, P87, DOI 10.1007/BF02276236; DWYER JM, 1981, CLIN EXP IMMUNOL, V46, P237; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fiumara A, 1999, PEDIATR NEUROL, V21, P619, DOI 10.1016/S0887-8994(99)00053-3; FUKUYAMA R, 1994, MOL CHEM NEUROPATHOL, V23, P93, DOI 10.1007/BF02815403; Goines P, 2010, CURR OPIN NEUROL, V23, P111, DOI 10.1097/WCO.0b013e3283373514; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; Gupta S, 1996, J AUTISM DEV DISORD, V26, P439, DOI 10.1007/BF02172828; Gupta S, 1998, J NEUROIMMUNOL, V85, P106, DOI 10.1016/S0165-5728(98)00021-6; Gupta S, 2010, J CLIN IMMUNOL, V30, pS90, DOI 10.1007/s10875-010-9402-9; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hong R, 2001, Chest Surg Clin N Am, V11, P295; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Kadlecek TA, 1998, J IMMUNOL, V161, P4688; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.3.CO;2-2; MASLIAH E, 1992, BRAIN RES, V593, P323, DOI 10.1016/0006-8993(92)91329-D; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; Mostafa G. A., 1925, J CHILD NEUROL, V25, P328; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Niehus R, 2006, J DEV BEHAV PEDIATR, V27, pS120, DOI 10.1097/00004703-200604002-00010; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; Nishino M, 2006, RADIOGRAPHICS, V26, P335, DOI 10.1148/rg.262045213; PLIOPLYS AV, 1994, NEUROPSYCHOBIOLOGY, V29, P12, DOI 10.1159/000119056; Ray B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020405; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; ROCH JM, 1993, ANN NY ACAD SCI, V695, P149, DOI 10.1111/j.1749-6632.1993.tb23044.x; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Sokol DK, 2011, NEUROLOGY, V76, P1344, DOI 10.1212/WNL.0b013e3182166dc7; Sokol DK, 2006, J CHILD NEUROL, V21, P444, DOI 10.1177/08830738060210062201; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stern L, 2005, ANN ALLERG ASTHMA IM, V95, P558, DOI 10.1016/S1081-1206(10)61019-8; STUBBS EG, 1977, J AUTISM CHILD SCHIZ, V7, P49, DOI 10.1007/BF01531114; Suh YH, 1997, ARCH GERONTOL GERIAT, V24, P1, DOI 10.1016/S0167-4943(96)00721-2; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Tong Wei-Gang, 2010, Epigenetics, V5, P499; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Von Boehmer H, 2004, ADV IMMUNOL, V84, P201, DOI 10.1016/S0065-2776(04)84006-9; Wang HP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002279; WARREN RP, 1990, IMMUNOL INVEST, V19, P245, DOI 10.3109/08820139009041839; WARREN RP, 1986, J AUTISM DEV DISORD, V16, P189, DOI 10.1007/BF01531729; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; YONK LJ, 1990, IMMUNOL LETT, V25, P341, DOI 10.1016/0165-2478(90)90205-5; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	57	14	14	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1040	1051		10.1096/fj.11-195438	http://dx.doi.org/10.1096/fj.11-195438			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22085641	Green Published			2022-12-28	WOS:000300949300009
J	Huang, JS; Jia, YZ; Fu, T; Viswakarma, N; Bai, L; Rao, MS; Zhu, YJ; Borensztajn, J; Reddy, JK				Huang, Jiansheng; Jia, Yuzhi; Fu, Tao; Viswakarma, Navin; Bai, Liang; Rao, M. Sambasiva; Zhu, Yijun; Borensztajn, Jayme; Reddy, Janardan K.			Sustained activation of PPAR alpha by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice	FASEB JOURNAL			English	Article						fatty acyl-CoA oxidase-1; Acox1 deficiency; endoplasmic reticulum stress; liver tumors	ACYL-COA OXIDASE; LEPTIN-DEFICIENT MICE; RECEPTOR-ALPHA; PEROXISOME PROLIFERATORS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; GLUCOSE-TOLERANCE; BODY-WEIGHT; LIVER; GAMMA	Obesity, a major health concern, results from an imbalance between energy intake and expenditure. Leptin-deficient ob/ob mice are paradigmatic of obesity, resulting from excess energy intake and storage. Mice lacking acyl-CoA oxidase 1 (Acox1), the first enzyme of the peroxisomal fatty acid beta-oxidation system, are characterized by increased energy expenditure and a lean body phenotype caused by sustained activation of peroxisome proliferator-activated receptor alpha (PPAR alpha) by endogenous ligands in liver that remain unmetabolized in the absence of Acox1. We generated ob/ob mice deficient in Acox1 (Acox1(-/-)) to determine how the activation of PPAR alpha by endogenous ligands might affect the obesity of ob/ob mice. In contrast to Acox1(-/-) (14.3 +/- 1.2 g at 6 mo) and the Acox1-deficient (ob/ob) double-mutant mice (23.8 +/- 4.6 g at 6 mo), the ob/ob mice are severely obese (54.3 +/- 3.2 g at 6 mo) and had significantly more (P<0.01) epididymal fat content. The resistance of Acox1(-/-)/ob/ob mice to obesity is due to increased PPAR alpha-mediated up-regulation of genes involved in fatty acid oxidation in liver. Activation of PPAR alpha in Acox1-deficient ob/ob mice also reduces serum glucose and insulin (P<0.05) and improves glucose tolerance and insulin sensitivity. Further, PPAR alpha activation reduces hepatic steatosis and increases hepatocellular regenerative response in Acox1(-/-)/ob/ob mice at a more accelerated pace than in mice lacking only Acox1. However, Acox1(-/-)/ob/ob mice manifest hepatic endoplasmic reticulum (ER) stress and also develop hepatocellular carcinomas (8 of 8 mice) similar to those observed in Acox1(-/-) mice (10 of 10 mice), but unlike in ob/ob (0 of 14 mice) and OB/OB (0 of 6 mice) mice, suggesting that superimposed ER stress and PPAR alpha activation contribute to carcinogenesis in a fatty liver. Finally, absence of Acox1 in ob/ob mice can impart resistance to high-fat diet (60% fat)-induced obesity, and their liver had significantly (P<0.01) more cell proliferation. These studies with Acox1(-/-)/ob/ob mice indicate that sustained activation of lipid-sensing nuclear receptor PPAR alpha attenuates obesity and restores glucose homeostasis by ameliorating insulin resistance but increases the risk for liver cancer development, in part related to excess energy combustion.-Huang, J., Jia, Y., Fu, T., Viswakarma, N., Bai, L., Sambasiva Rao, M., Zhu, Y., Borensztajn, J., Reddy, J. K. Sustained activation of PPAR alpha by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J. 26, 628-638 (2012). www.fasebj.org	[Huang, Jiansheng; Jia, Yuzhi; Fu, Tao; Viswakarma, Navin; Bai, Liang; Rao, M. Sambasiva; Zhu, Yijun; Borensztajn, Jayme; Reddy, Janardan K.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			U.S. National Institutes of Health [GM23750, DK083163]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083163, R56DK083163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported, in part, by U.S. National Institutes of Health grants GM23750 and DK083163 to J.K.R. The authors thank Dr. Aurore Vluggens for her gracious and generous assistance in the analysis of liver tumors.	Abdelkarim M, 2010, J BIOL CHEM, V285, P36759, DOI 10.1074/jbc.M110.166231; Badman MK, 2009, AM J PHYSIOL-ENDOC M, V297, pE1197, DOI 10.1152/ajpendo.00357.2009; Bai LA, 2011, HEPATOLOGY, V53, P1164, DOI 10.1002/hep.24155; Caldwell SH, 2004, GASTROENTEROLOGY, V127, pS97, DOI 10.1053/j.gastro.2004.09.021; Chakravarthy MV, 2009, CELL, V138, P476, DOI 10.1016/j.cell.2009.05.036; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chen H, 2010, ENDOCRINOLOGY, V151, P3115, DOI 10.1210/en.2009-1366; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Dentin R, 2006, DIABETES, V55, P2159, DOI 10.2337/db06-0200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fu T, 2006, BIOCHEM BIOPH RES CO, V341, P1172, DOI 10.1016/j.bbrc.2006.01.071; Goruppi S, 2010, J BIOL CHEM, V285, P1577, DOI 10.1074/jbc.R109.080887; Gurevich-Panigrahi T, 2009, CURR MED CHEM, V16, P506, DOI 10.2174/092986709787315568; Han DH, 2004, AM J PHYSIOL-ENDOC M, V286, pE347, DOI 10.1152/ajpendo.00434.2003; Holt LJ, 2009, MOL ENDOCRINOL, V23, P1406, DOI 10.1210/me.2008-0386; Huang JS, 2007, HEPATOLOGY, V46, P147, DOI 10.1002/hep.21632; Huang JS, 2011, AM J PATHOL, V179, P703, DOI 10.1016/j.ajpath.2011.04.030; Huang JS, 2010, AM J PHYSIOL-GASTR L, V299, pG1211, DOI 10.1152/ajpgi.00322.2010; Ip E, 2004, HEPATOLOGY, V39, P1286, DOI 10.1002/hep.20170; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jia YZ, 2004, J BIOL CHEM, V279, P24427, DOI 10.1074/jbc.M402391200; Matsumoto K, 2007, J BIOL CHEM, V282, P17053, DOI 10.1074/jbc.M701956200; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Matsusue K, 2008, CELL METAB, V7, P302, DOI 10.1016/j.cmet.2008.03.003; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Ohnishi M, 2011, FASEB J, V25, P2031, DOI 10.1096/fj.10-167056; Orellana-Gavalda JM, 2011, HEPATOLOGY, V53, P821, DOI 10.1002/hep.24140; Oyadomari S, 2008, CELL METAB, V7, P520, DOI 10.1016/j.cmet.2008.04.011; Park SH, 2010, J BIOL CHEM, V285, P35330, DOI 10.1074/jbc.M110.136259; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Pyper Sean R, 2010, Nucl Recept Signal, V8, pe002, DOI 10.1621/nrs.08002; Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006-0541; Rao MS, 2002, IN VIVO, V16, P145; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Segal-Lieberman G, 2003, P NATL ACAD SCI USA, V100, P10085, DOI 10.1073/pnas.1633636100; Shah YA, 2007, MOL CELL BIOL, V27, P4238, DOI 10.1128/MCB.00317-07; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vluggens A, 2010, LAB INVEST, V90, P696, DOI 10.1038/labinvest.2010.46; Yanagitani K, 2011, SCIENCE, V331, P586, DOI 10.1126/science.1197142; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zadravec D, 2010, FASEB J, V24, P4366, DOI 10.1096/fj.09-152298; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	55	69	71	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					628	638		10.1096/fj.11-194019	http://dx.doi.org/10.1096/fj.11-194019			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22009939	Green Published			2022-12-28	WOS:000300485700016
J	Purushotham, A; Xu, Q; Li, XL				Purushotham, Aparna; Xu, Qing; Li, Xiaoling			Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding	FASEB JOURNAL			English	Article						sirtuin; oxidative stress; GL/FFA cycle; phospholipid/lysolipid; testosterone	ACTIVATED PROTEIN-KINASE; HEPATIC GENE-EXPRESSION; PANCREATIC BETA-CELLS; INSULIN-RESISTANCE; GLUCOSE-HOMEOSTASIS; MAMMALIAN SIRTUINS; CIRCADIAN CONTROL; LIPID-METABOLISM; SKELETAL-MUSCLE; DISEASE	SIRT1 is a highly-conserved NAD(+)-dependent protein deacetylase that plays essential roles in the regulation of energy metabolism, genomic stability, and stress response. Although the functions of SIRT1 in many organs have been extensively studied in tissue-specific knockout mouse models, the systemic role of SIRT1 is still largely unknown as a result of severe developmental defects that result from whole-body knockout in mice. Here, we investigated the systemic functions of SIRT1 in metabolic homeostasis by utilizing a whole-body SIRT1 heterozygous mouse model. These mice are phenotypically normal under standard feeding conditions. However, when chronically challenged with a 40% fat diet, they become obese and insulin resistant, display increased serum cytokine levels, and develop hepatomegaly. Hepatic metabolomic analyses revealed that SIRT1 heterozygous mice have elevated gluconeogenesis and oxidative stress. Surprisingly, they are depleted of glycerolipid metabolites and free fatty acids, yet accumulate lysolipids. Moreover, high-fat feeding induces elevation of serum testosterone levels and enlargement of seminal vesicles in SIRT1 heterozygous males. Microarray analysis of liver mRNA indicates that they have altered expression of genes involved in steroid metabolism and glycerolipid metabolism. Taken together, our findings indicate that SIRT1 plays a vital role in the regulation of systemic energy and steroid hormone homeostasis.-Purushotham, A., Xu, Q., Li, X. Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding. FASEB J. 26, 656-667 (2012). www.fasebj.org	[Purushotham, Aparna; Xu, Qing; Li, Xiaoling] Natl Inst Environm Hlth Sci, Lab Signal Transduct, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Li, XL (corresponding author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	lix3@niehs.nih.gov	Li, Xiaoling/A-2994-2015	Li, Xiaoling/0000-0001-5920-7784	U.S. National Institutes of Health, NIEHS [Z01 ES102205]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZICES102445, ZIAES102205] Funding Source: NIH RePORTER	U.S. National Institutes of Health, NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Drs. Anton Jetten, Stephen Shears, John Cidlowski, and members of the X. L. laboratory for critical reading of the manuscript, and Dr. Michael W. McBurney (University of Ottawa, Ottawa, ON, Canada) for providing the SIRT1-null allele. The authors also thank the National Institute of Environmental Health Sciences (NIEHS) Laboratory of Experimental Pathology for histological staining and serum hormone ELISA; the NIEHS microarray facility for performing the microarray experiments, and Liwen Liu for analyzing the microarray data. This research was supported by the Intramural Research Program of the U.S. National Institutes of Health, NIEHS to X. L. (Z01 ES102205).	ABBASZADE IG, 1995, MOL ENDOCRINOL, V9, P1214, DOI 10.1210/me.9.9.1214; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Baptiste CG, 2010, J STEROID BIOCHEM, V122, P42, DOI 10.1016/j.jsbmb.2009.12.010; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Cakir I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008322; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Cheng H. L., 2003, P NATL ACAD SCI US; Cohen DE, 2009, GENE DEV, V23, P2812, DOI 10.1101/gad.1839209; DANNO H, 1992, J NUTR SCI VITAMINOL, V38, P517, DOI 10.3177/jnsv.38.517; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Delic D, 2010, J MOL ENDOCRINOL, V45, P379, DOI 10.1677/JME-10-0026; Dietrich MO, 2010, J NEUROSCI, V30, P11815, DOI 10.1523/JNEUROSCI.2234-10.2010; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2008, CELL CYCLE, V7, P3669, DOI 10.4161/cc.7.23.7164; Guillen N, 2009, PHYSIOL GENOMICS, V37, P187, DOI 10.1152/physiolgenomics.90339.2008; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Iwabu M, 2010, NATURE, V464, P1313, DOI 10.1038/nature08991; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032; Li XL, 2011, INT J BIOL SCI, V7, P575, DOI 10.7150/ijbs.7.575; Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Ohta T, 2009, TOXICOL PATHOL, V37, P521, DOI 10.1177/0192623309336152; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Park CHJ, 1996, MOL CELL ENDOCRINOL, V116, P157, DOI 10.1016/0303-7207(95)03707-1; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; Ponugoti B, 2010, J BIOL CHEM, V285, P33959, DOI 10.1074/jbc.M110.122978; Prentki M, 2008, ENDOCR REV, V29, P647, DOI 10.1210/er.2008-0007; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Qiao AJ, 2011, HEPATOLOGY, V54, P509, DOI 10.1002/hep.24402; Ramadori G, 2010, CELL METAB, V12, P78, DOI 10.1016/j.cmet.2010.05.010; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257; Ruderman NB, 2010, AM J PHYSIOL-ENDOC M, V298, pE751, DOI 10.1152/ajpendo.00745.2009; Satoh A, 2010, J NEUROSCI, V30, P10220, DOI 10.1523/JNEUROSCI.1385-10.2010; Schug TT, 2011, ANN MED, V43, P198, DOI 10.3109/07853890.2010.547211; Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	65	43	45	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					656	667		10.1096/fj.11-195172	http://dx.doi.org/10.1096/fj.11-195172			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22006157	Green Published			2022-12-28	WOS:000300485700018
J	Motallebzadeh, R; Rehakova, S; Conlon, TM; Win, TS; Callaghan, CJ; Goddard, M; Bolton, EM; Ruddle, NH; Bradley, JA; Pettigrew, GJ				Motallebzadeh, Reza; Rehakova, Sylvia; Conlon, Thomas M.; Win, Thet Su; Callaghan, Chris J.; Goddard, Martin; Bolton, Eleanor M.; Ruddle, Nancy H.; Bradley, J. Andrew; Pettigrew, Gavin J.			Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses	FASEB JOURNAL			English	Article						chronic rejection; vasculopathy	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOLLICULAR DENDRITIC CELLS; NONOBESE DIABETIC MICE; B-CELLS; GERMINAL-CENTERS; BETA-RECEPTOR; CHRONIC REJECTION; SURFACE LYMPHOTOXIN; SJOGRENS-SYNDROME	Tertiary lymphoid organs (TLOs) may develop within allografts, but their contribution to graft rejection remains unclear. Here, we study a mouse model of autoantibody-mediated cardiac allograft vasculopathy to clarify the alloimmune responses mediated by intragraft TLOs and whether blocking lymphotoxin-beta-receptor (LT beta R) signaling, a pathway essential for lymphoid organogenesis, abrogates TLO development. TLOs (defined as discrete lymphoid aggregates associated with high endothelial venules) were detectable in 9 of 13 heart allografts studied and were predominantly B cell in composition, harboring germinal-center activity. These are most likely manifestations of the humoral autoimmunity triggered in this model after transplantation; TLOs did not develop if autoantibody production was prevented. Treatment with inhibitory LT beta R-Ig fusion protein virtually abolished allograft TLO formation (mean TLOs/heart: 0.2 vs. 2.2 in control recipients; P = 0.02), with marked attenuation of the autoantibody response. Recipients primed for autoantibody before transplantation rejected grafts rapidly, but this accelerated rejection was prevented by postoperative administration of LT beta R-Ig (median survival time: 18 vs. > 50 d, respectively, P = 0.003). Our results provide the first demonstration that TLOs develop within chronically rejecting heart allografts, are predominantly B cell in origin, and can be targeted pharmacologically to inhibit effector humoral responses.-Motallebzadeh, R., Rehakova, S., Conlon, T. M., Win, T. S., Callaghan, C. J., Goddard, M., Bolton, E. M., Ruddle, N. H., Bradley, J. A., Pettigrew, G. J. Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. FASEB J. 26, 51-62 (2012). www.fasebj.org	[Motallebzadeh, Reza; Rehakova, Sylvia; Conlon, Thomas M.; Win, Thet Su; Callaghan, Chris J.; Bolton, Eleanor M.; Bradley, J. Andrew; Pettigrew, Gavin J.] Univ Cambridge, Dept Surg, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England; [Ruddle, Nancy H.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	University of Cambridge; Yale University	Pettigrew, GJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Surg, Hills Rd, Cambridge CB2 2QQ, England.	gjp25@cam.ac.uk	Motallebzadeh, Reza/AAF-5515-2021	Motallebzadeh, Reza/0000-0002-5399-9546; Conlon, Thomas/0000-0002-4316-6612; pettigrew, gavin/0000-0003-3724-9945; Bolton, Eleanor/0000-0002-7253-6045	Wellcome Trust; Raymond and Beverly Sackler Scholarship; British Heart Foundation [PG/10/002/28143] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Raymond and Beverly Sackler Scholarship; British Heart Foundation(British Heart Foundation)	The authors thank Dr. J. Browning (Biogen Idec, Cambridge, MA, USA) for providing LT beta R-Ig and MOPC-21 fusion proteins. R.M. was suported by a clinical research fellowship from the Wellcome Trust and the Raymond and Beverly Sackler Scholarship.	Allen CDC, 2008, SEMIN IMMUNOL, V20, P14, DOI 10.1016/j.smim.2007.12.001; Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Armengol MP, 2001, AM J PATHOL, V159, P861, DOI 10.1016/S0002-9440(10)61762-2; Baddoura FK, 2005, AM J TRANSPLANT, V5, P510, DOI 10.1111/j.1600-6143.2004.00714.x; BRADLEY DS, 1994, J IMMUNOL, V152, P1960; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; Cassese G, 2001, EUR J IMMUNOL, V31, P2726, DOI 10.1002/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; Columba-Cabezas S, 2006, J NEUROIMMUNOL, V179, P76, DOI 10.1016/j.jneuroim.2006.06.015; Cuff CA, 1998, J IMMUNOL, V161, P6853; Cyster JG, 2000, IMMUNOL REV, V176, P181; Deteix C, 2010, J IMMUNOL, V184, P5344, DOI 10.4049/jimmunol.0902999; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Endres R, 1999, J EXP MED, V189, P159, DOI 10.1084/jem.189.1.159; Fava RA, 2003, J IMMUNOL, V171, P115, DOI 10.4049/jimmunol.171.1.115; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Gatumu MK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2617; Gommerman JL, 2003, J CLIN INVEST, V112, P755, DOI 10.1172/JCI200318648; Gommerman JL, 2002, J CLIN INVEST, V110, P1359, DOI 10.1172/JCI200215975; Humby F, 2009, PLOS MED, V6, P59, DOI 10.1371/journal.pmed.0060001; Kim HJ, 1999, J IMMUNOL, V162, P3053; Kranich J, 2008, J EXP MED, V205, P1293, DOI 10.1084/jem.20071019; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Liao S, 2006, J IMMUNOL, V177, P3369, DOI 10.4049/jimmunol.177.5.3369; Luther SA, 2003, J EXP MED, V197, P1191, DOI 10.1084/jem.20021294; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Motallebzadeh R, 2008, TRANSPLANTATION, V85, P309, DOI 10.1097/TP.0b013e318162d2d0; Mounzer RH, 2010, BLOOD, V116, P2173, DOI 10.1182/blood-2009-12-256065; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; RADIO SJ, 1991, MODERN PATHOL, V4, P654; RANDEN I, 1992, J IMMUNOL, V148, P3296; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Sims GP, 2001, J IMMUNOL, V167, P1935, DOI 10.4049/jimmunol.167.4.1935; Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019; Stott DI, 1998, J CLIN INVEST, V102, P938, DOI 10.1172/JCI3234; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Stuht S, 2007, AM J TRANSPLANT, V7, P377, DOI 10.1111/j.1600-6143.2006.01638.x; Suzuki J, 2003, AM J TRANSPLANT, V3, P968, DOI 10.1034/j.1600-6143.2003.00164.x; Thaunat O, 2005, P NATL ACAD SCI USA, V102, P14723, DOI 10.1073/pnas.0507223102; Ware CF, 2008, IMMUNOL REV, V223, P186, DOI 10.1111/j.1600-065X.2008.00629.x; Win TS, 2009, CIRC-HEART FAIL, V2, P361, DOI 10.1161/CIRCHEARTFAILURE.108.827139; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327; Zarkhin V, 2008, KIDNEY INT, V74, P664, DOI 10.1038/ki.2008.249	52	50	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					51	62		10.1096/fj.11-186973	http://dx.doi.org/10.1096/fj.11-186973			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21926237				2022-12-28	WOS:000299202200007
J	Fidler, JA; Treleaven, CM; Frakes, A; Tamsett, TJ; McCrate, M; Cheng, SH; Shihabuddin, LS; Kaspar, BK; Dodge, JC				Fidler, Jonathan A.; Treleaven, Christopher M.; Frakes, Ashley; Tamsett, Thomas J.; McCrate, Mary; Cheng, Seng H.; Shihabuddin, Lamya S.; Kaspar, Brian K.; Dodge, James C.			Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone	FASEB JOURNAL			English	Article						ALS; motor neuron disease; MND; glucocorticoid; allostasis; cacostasis	MOTOR-NEURON DEGENERATION; BLOOD-BRAIN-BARRIER; SALIVARY CORTISOL; ALS PATIENTS; SPINAL-CORD; SURVIVAL; MICE; HOMEOSTASIS; DEPRESSION; EXERCISE	Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron cell loss, muscular atrophy, and a shortened life span. Survival is highly variable, as some patients die within months, while others live for many years. Exposure to stress or the development of a nonoptimal stress response to disease might account for some of this variability. We show in the SOD1(G93A) mouse model of ALS that recurrent exposure to restraint stress led to an earlier onset of astrogliosis and microglial activation within the spinal cord, accelerated muscular weakness, and a significant decrease in median survival (105 vs. 122 d) when compared to non-stressed animals. Moreover, during normal disease course, ALS mice display a cacostatic stress response by developing an aberrant serum corticosterone circadian rhythm. Interestingly, we also found that higher corticosterone levels were significantly correlated with both an earlier onset of paralysis (males: r(2)=0.746; females: r(2)=0.707) and shorter survival times (males: r(2)=0.680; females: r(2)=0.552) in ALS mice. These results suggest that stress is capable of accelerating disease progression and that strategies that modulate glucocorticoid metabolism might be a viable treatment approach for ALS.-Fidler, J. A., Treleaven, C. M., Frakes, A., Tamsett, T. J., McCrate, M., Cheng, S. H., Shihabuddin, L. S., Kaspar, B. K., Dodge, J. C. Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone. FASEB J. 25, 4369-4377 (2011). www.fasebj.org	[Fidler, Jonathan A.; Treleaven, Christopher M.; Tamsett, Thomas J.; Cheng, Seng H.; Shihabuddin, Lamya S.; Dodge, James C.] Genzyme Corp, Framingham, MA 01701 USA; [Frakes, Ashley; McCrate, Mary; Kaspar, Brian K.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Frakes, Ashley; McCrate, Mary; Kaspar, Brian K.] Ohio State Univ, Coll Med, Integrated Biomed Grad Program, Columbus, OH 43210 USA	Sanofi-Aventis; Genzyme Corporation; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Dodge, JC (corresponding author), Genzyme Corp, 49 New York Ave, Framingham, MA 01701 USA.	jim.dodge@genzyme.com	Kaspar, Brian/E-3349-2011; Cheng, Seng H/AAC-6564-2022		U.S. National Institutes of Health [R01NS064492, RC2NS069476-01]; ALS; Muscular Dystrophy Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064492, T32NS077984, RC2NS069476] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ALS; Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Ms. Amy Eagle for her technical assistance. This work was funded, in part, by grants from the U.S. National Institutes of Health (R01NS064492 and RC2NS069476-01), Project ALS, and the Muscular Dystrophy Association to B. K. K.	BERTEL O, 1991, BRAIN RES, V566, P54, DOI 10.1016/0006-8993(91)91680-Y; Bouteloup C, 2009, J NEUROL, V256, P1236, DOI 10.1007/s00415-009-5100-z; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Charmandari E, 2005, ANNU REV PHYSIOL, V67, P259, DOI 10.1146/annurev.physiol.67.040403.120816; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; Czaplinski A, 2006, ARCH NEUROL-CHICAGO, V63, P1139, DOI 10.1001/archneur.63.8.1139; Deniselle MCG, 1997, J STEROID BIOCHEM, V60, P205, DOI 10.1016/S0960-0760(96)00193-8; Dodge JC, 2008, MOL THER, V16, P1056, DOI 10.1038/mt.2008.60; Dodge JC, 2010, MOL THER, V18, P2075, DOI 10.1038/mt.2010.206; Dumas TC, 2010, J NEUROSCI, V30, P1712, DOI 10.1523/JNEUROSCI.4402-09.2010; Dupuis L, 2004, P NATL ACAD SCI USA, V101, P11159, DOI 10.1073/pnas.0402026101; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Garbuzova-Davis S, 2007, BRAIN RES, V1157, P126, DOI 10.1016/j.brainres.2007.04.044; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hamadeh MJ, 2005, MUSCLE NERVE, V31, P214, DOI 10.1002/mus.20255; Hunter M D, 1993, Disabil Rehabil, V15, P119; Iellamo F, 2003, J SPORT MED PHYS FIT, V43, P539; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kim KS, 2006, J NEUROSCI RES, V83, P497, DOI 10.1002/jnr.20754; Kimura K, 1999, J NEUROL SCI, V164, P37, DOI 10.1016/S0022-510X(99)00044-1; KRAEMER WJ, 1992, INT J SPORTS MED, V13, P103, DOI 10.1055/s-2007-1021240; KRAEMER WJ, 1995, J APPL PHYSIOL, V78, P976, DOI 10.1152/jappl.1995.78.3.976; Magnus T, 2008, GLIA, V56, P200, DOI 10.1002/glia.20604; Mastorakos George, 2005, Hormones (Athens), V4, P73; MCDONALD ER, 1994, ARCH NEUROL-CHICAGO, V51, P17, DOI 10.1001/archneur.1994.00540130027010; McElhiney MC, 2009, J NEUROL NEUROSUR PS, V80, P1146, DOI 10.1136/jnnp.2008.163246; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Morselli LL, 2006, CLIN ENDOCRINOL, V65, P385, DOI 10.1111/j.1365-2265.2006.02609.x; Nagao M, 1998, J NEUROPATH EXP NEUR, V57, P329, DOI 10.1097/00005072-199804000-00004; NELSON JF, 1995, NEUROBIOL AGING, V16, P837, DOI 10.1016/0197-4580(95)00072-M; OCONNOR PJ, 1989, PSYCHONEUROENDOCRINO, V14, P303, DOI 10.1016/0306-4530(89)90032-2; Ohno T, 2001, AUTON NEUROSCI-BASIC, V88, P94, DOI 10.1016/S1566-0702(01)00217-X; Paccotti P, 2005, INT J SPORTS MED, V26, P747, DOI 10.1055/s-2004-830449; Patacchioli FR, 2003, J ENDOCRINOL INVEST, V26, pRC23, DOI 10.1007/BF03349149; Patel BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009386; PERNA FM, 1995, INT J BEHAV MED, V2, P13, DOI 10.1207/s15327558ijbm0201_2; Pradat PF, 2010, AMYOTROPH LATERAL SC, V11, P166, DOI 10.3109/17482960902822960; RAPS D, 1971, EXPERIENTIA, V27, P339, DOI 10.1007/BF02138184; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; Sapolsky RM, 2000, NEUROBIOL DIS, V7, P540, DOI 10.1006/nbdi.2000.0350; Sato Y, 1997, EUR NEUROL, V37, P225, DOI 10.1159/000117447; Sorrells SF, 2007, BRAIN BEHAV IMMUN, V21, P259, DOI 10.1016/j.bbi.2006.11.006; Tanskanen MM, 2011, J STRENGTH COND RES, V25, P787, DOI 10.1519/JSC.0b013e3181c1fa5d; Tateno M, 2009, HUM MOL GENET, V18, P942, DOI 10.1093/hmg/ddn422; Toepfer M, 1999, AMYOTROPH LATERAL SC, V1, P15; Vignola A, 2008, EUR J NEUROL, V15, P1231, DOI 10.1111/j.1468-1331.2008.02303.x; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; Wheaton MW, 2007, NEUROLOGY, V69, P1411, DOI 10.1212/01.wnl.0000277422.11236.2c; Wilczak N, 2003, LANCET, V361, P1007, DOI 10.1016/S0140-6736(03)12828-0; Yang WW, 2011, EXP NEUROL, V227, P287, DOI 10.1016/j.expneurol.2010.11.019; Zhong ZH, 2008, NAT NEUROSCI, V11, P420, DOI 10.1038/nn2073; ZIEGLER MG, 1980, NEUROLOGY, V30, P98, DOI 10.1212/WNL.30.1.98	56	23	25	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4369	4377		10.1096/fj.11-190819	http://dx.doi.org/10.1096/fj.11-190819			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21876068	Green Published			2022-12-28	WOS:000298138100028
J	Wan, NK; Yao, Z; Finkbeiner, WE; Verkman, AS				Wan Namkung; Yao, Zhen; Finkbeiner, Walter E.; Verkman, A. S.			Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction	FASEB JOURNAL			English	Article						CaCC; cystic fibrosis; dry mouth; intestinal motility; drug discovery	CA2+-ACTIVATED CL-CHANNELS; CYSTIC-FIBROSIS; INTERSTITIAL-CELLS; FLUID SECRETION; ACINAR-CELLS; GLAND-CELLS; IN-VITRO; INHIBITORS; EXPRESSION; THERAPY	TMEM16A (ANO1) is a calcium-activated chloride channel (CaCC) expressed in secretory epithelia, smooth muscle, and other tissues. Cell-based functional screening of similar to 110,000 compounds revealed compounds that activated TMEM16A CaCC conductance without increasing cytoplasmic Ca2+. By patch-clamp, N-aroylaminothiazole "activators" (E-act) strongly increased Cl- current at 0 Ca2+, whereas tetrazolylbenzamide "potentiators" (Fact) were not active at 0 Ca2+ but reduced the EC50 for Ca2+-dependent TMEM16A activation. Of 682 analogs tested, the most potent activator (E-act) and potentiator (F-act) produced large and more sustained CaCC Cl- currents than general agonists of Ca2+ signaling, with EC50 3-6 mu M and Cl- conductance comparable to that induced transiently by Ca2+-elevating purinergic agonists. Analogs of activators were identified that fully inhibited TMEM16A Cl- conductance, providing further evidence for direct TMEM16A binding. The TMEM16A activators increased CaCC conductance in human salivary and airway submucosal gland epithelial cells, and IL-4 treated bronchial cells, and stimulated submucosal gland secretion in human bronchi and smooth muscle contraction in mouse intestine. Small-molecule, TMEM16A-targeted activators may be useful for drug therapy of cystic fibrosis, dry mouth, and gastrointestinal hypomotility disorders, and for pharmacological dissection of TMEM16A function.-Namkung, W., Yao, Z., Finkbeiner, W. E., Verkman, A. S. Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J. 25, 4048-4062 (2011). www.fasebj.org	[Wan Namkung; Yao, Zhen; Verkman, A. S.] Univ Calif San Francisco, Dept Med & Physiol, San Francisco, CA 94143 USA; [Finkbeiner, Walter E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med & Physiol, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu			NIH [DK72517, HL73856, DK35124, DK86125, EB00415, EY13574]; Cystic Fibrosis Foundation; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, RC1DK086125, P30DK072517, R37DK035124] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Dennis W. Nielson (Department of Pediatrics, University of California, San Francisco) and Dr. Jae-Woo Lee (Department of Anesthesia and Perioperative Care, University of California, San Francisco) for human airway tissues. This work was supported by NIH grants DK72517, HL73856, DK35124, DK86125, EB00415, and EY13574 and Research Development Program and Drug Discovery grants from the Cystic Fibrosis Foundation.	Boucher RC, 2007, ANNU REV MED, V58, P157, DOI 10.1146/annurev.med.58.071905.105316; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Cheng JF, 2006, J MED CHEM, V49, P1517, DOI 10.1021/jm050109n; De la Fuente R, 2008, MOL PHARMACOL, V73, P758, DOI 10.1124/mol.107.043208; DiMauro EF, 2006, J MED CHEM, V49, P5671, DOI 10.1021/jm0605482; Donaldson SH, 2007, CHEST, V132, P1631, DOI 10.1378/chest.07-0288; Dutta AK, 2011, J BIOL CHEM, V286, P766, DOI 10.1074/jbc.M110.164970; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; Ferrera L, 2010, PHYSIOLOGY, V25, P357, DOI 10.1152/physiol.00030.2010; Finkbeiner WE, 2010, IN VITRO CELL DEV-AN, V46, P450, DOI 10.1007/s11626-009-9262-x; Fischer H, 2010, AM J PHYSIOL-LUNG C, V299, pL585, DOI 10.1152/ajplung.00421.2009; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; Gomez-Pinilla PJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1370, DOI 10.1152/ajpgi.00074.2009; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; Hwang SJ, 2009, J PHYSIOL-LONDON, V587, P4887, DOI 10.1113/jphysiol.2009.176198; Kashyap P, 2011, NEUROGASTROENT MOTIL, V23, P760, DOI 10.1111/j.1365-2982.2011.01729.x; KAWAMATSU Y, 1981, EUR J MED CHEM, V16, P355; Kellerman D, 2008, PULM PHARMACOL THER, V21, P600, DOI 10.1016/j.pupt.2007.12.003; Lee K, 2010, EUR J MED CHEM, V45, P5420, DOI 10.1016/j.ejmech.2010.09.002; Lee RJ, 2010, AM J PHYSIOL-LUNG C, V298, pL210, DOI 10.1152/ajplung.00342.2009; Levin MH, 2006, J BIOL CHEM, V281, P25803, DOI 10.1074/jbc.M604332200; Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Manoury B, 2010, J PHYSIOL-LONDON, V588, P2305, DOI 10.1113/jphysiol.2010.189506; Mokale SN, 2010, EUR J MED CHEM, V45, P3096, DOI 10.1016/j.ejmech.2010.03.043; Munchhof MJ, 2009, BIOORG MED CHEM LETT, V19, P1428, DOI 10.1016/j.bmcl.2009.01.032; Namkung W, 2011, J BIOL CHEM, V286, P2365, DOI 10.1074/jbc.M110.175109; Namkung W, 2010, FASEB J, V24, P4178, DOI 10.1096/fj.10-160648; Nichols KK, 2004, EXPERT OPIN INV DRUG, V13, P47, DOI 10.1517/13543784.13.1.47; Rock JR, 2008, DEV BIOL, V321, P141, DOI 10.1016/j.ydbio.2008.06.009; Rock JR, 2009, J BIOL CHEM, V284, P14875, DOI 10.1074/jbc.C109.000869; Romanenko VG, 2010, J BIOL CHEM, V285, P12990, DOI 10.1074/jbc.M109.068544; Satoh A, 2009, BIOORG MED CHEM LETT, V19, P5464, DOI 10.1016/j.bmcl.2009.07.097; Scheiff AB, 2010, BIOORGAN MED CHEM, V18, P2195, DOI 10.1016/j.bmc.2010.01.072; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Shipps GW, 2005, BIOORG MED CHEM LETT, V15, P115, DOI 10.1016/j.bmcl.2004.10.024; Sloane PA, 2010, CURR OPIN PULM MED, V16, P591, DOI 10.1097/MCP.0b013e32833f1d00; Stadelmann B, 2010, J ANTIMICROB CHEMOTH, V65, P512, DOI 10.1093/jac/dkp490; Steiner I, 2008, N-S ARCH PHARMACOL, V378, P323, DOI 10.1007/s00210-008-0293-8; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; White April F, 2006, Med Chem, V2, P499, DOI 10.2174/157340606778250180; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313	46	142	148	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					4048	4062		10.1096/fj.11-191627	http://dx.doi.org/10.1096/fj.11-191627			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21836025	Green Published			2022-12-28	WOS:000296723100028
J	Georgakopoulos, A; Xu, JD; Xu, CJ; Mauger, G; Barthet, G; Robakis, NK				Georgakopoulos, Anastasios; Xu, Jindong; Xu, Chijie; Mauger, Gweltas; Barthet, Gael; Robakis, Nikolaos K.			Presenilin1/gamma-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein	FASEB JOURNAL			English	Article						Alzheimer disease; PAG/Cbp; Src kinases	LONG-TERM POTENTIATION; T-CELL-ACTIVATION; TRANSMEMBRANE ADAPTER; SYNAPSE FORMATION; REVERSE SIGNALS; SRC KINASE; C-SRC; HIPPOCAMPAL; PLASTICITY; CSK	Reverse signaling through the ephrinB ligands is important for several morphogenetic events, such as axon guidance, neuronal plasticity, spine maturation, and synaptogenesis. Signaling is initiated by binding of EphB receptors to ephrinB ligands, stimulating their tyrosine phosphorylation via an unclear mechanism. Here we show that this mechanism involves presenilin1 (PS1)/gamma-secretase regulation of phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein (PAG/Cbp), an adaptor protein that controls the activity of Src kinases. Using immunoprecipitation and Western blot of mouse primary neuronal and human embryonic kidney (HEK293) cell extracts overexpressing PAG/Cbp, we show that EphB2 induces tyrosine dephosphorylation of PAG/Cbp in a gamma-secretase-dependent manner. In these cells, PAG/Cbp dephosphorylation is promoted by the PS1/gamma-secretase-produced fragment of ephrinB2 cleavage (ephrinB2/CTF2), which forms complexes with PAG/Cbp when introduced exogenously. EphB2-induced tyrosine phosphorylation of ephrinB2 depends on PAG/Cbp because EphB2 cannot increase ephrinB2 phosphorylation in cells treated with anti-PAG siRNA or in PAG/Cbp-knockout (KO) cells. Furthermore, in contrast to WT PS1, familial Alzheimer disease (FAD) PS1 mutants expressed in PS1-KO mouse embryonic fibroblasts inhibited both the EphB2-induced dephosphorylation of PAG/Cbp and the phosphorylation of ephrinB2. PS1 FAD mutations may thus inhibit the function of ephrinB in the brain, promoting neurodegeneration in Alzheimer disease.-Georgakopoulos, A., Xu, J., Xu, C., Mauger, G., Barthet, G., Robakis, N. K. Presenilin1/gamma-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J. 25, 3594-3604 (2011). www.fasebj.org	[Georgakopoulos, Anastasios] NYU, Dept Psychiat, Mt Sinai Sch Med, Ctr Mol Biol & Genet Neurodegenerat, New York, NY 10029 USA; NYU, Dept Neurosci, Mt Sinai Sch Med, Ctr Mol Biol & Genet Neurodegenerat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Georgakopoulos, A (corresponding author), NYU, Dept Psychiat, Mt Sinai Sch Med, Ctr Mol Biol & Genet Neurodegenerat, 1 Gustave L Levy Pl,Box 1229, New York, NY 10029 USA.	tassos.georgakopoulos@mssm.edu	Robakis, Nikolaos/AAA-1838-2021	Georgakopoulos, Anastasios/0000-0001-8241-6306; Barthet, Gael/0000-0003-4025-1616	U.S. National Institutes of Health [P50 AG005138, AG008200, AG017926]; Alzheimer's Association [IIRG-07-59620]; NATIONAL INSTITUTE ON AGING [R01AG017926, P50AG005138, R01AG008200, R37AG017926] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work has been supported by U.S. National Institutes of Health grants P50 AG005138 to A.G. and AG008200 and AG017926 to N.K.R. and by Alzheimer's Association grant IIRG-07-59620 to A.G.	Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; Aoto J, 2007, J NEUROSCI, V27, P7508, DOI 10.1523/JNEUROSCI.0705-07.2007; Baki L, 2008, J NEUROSCI, V28, P483, DOI 10.1523/JNEUROSCI.4067-07.2008; Bouzioukh F, 2007, J NEUROSCI, V27, P11279, DOI 10.1523/JNEUROSCI.3393-07.2007; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Georgakopoulos A, 2006, EMBO J, V25, P1242, DOI 10.1038/sj.emboj.7601031; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Grunwald IC, 2004, NAT NEUROSCI, V7, P33, DOI 10.1038/nn1164; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Horejsi V, 2004, IMMUNOL LETT, V92, P43, DOI 10.1016/j.imlet.2003.10.013; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; Khanna S, 2007, J BIOL CHEM, V282, P23482, DOI 10.1074/jbc.M611269200; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; McCarthy JV, 2009, CELL MOL LIFE SCI, V66, P1534, DOI 10.1007/s00018-009-8435-9; OKADA M, 1989, J BIOL CHEM, V264, P20886; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Rodenas-Ruano A, 2006, DEV BIOL, V292, P34, DOI 10.1016/j.ydbio.2006.01.004; Segura I, 2007, NAT NEUROSCI, V10, P301, DOI 10.1038/nn1858; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Svec A, 2008, PATHOL RES PRACT, V204, P785, DOI 10.1016/j.prp.2008.06.006; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tomita T, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-2; Xu JD, 2009, J BIOL CHEM, V284, P27220, DOI 10.1074/jbc.M109.048728; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	35	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3594	3604		10.1096/fj.11-187856	http://dx.doi.org/10.1096/fj.11-187856			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746865	Green Published			2022-12-28	WOS:000295356400029
J	Mustafi, D; Kevany, BM; Genoud, C; Okano, K; Cideciyan, AV; Sumaroka, A; Roman, AJ; Jacobson, SG; Engel, A; Adams, MD; Palczewski, K				Mustafi, Debarshi; Kevany, Brian M.; Genoud, Christel; Okano, Kiichiro; Cideciyan, Artur V.; Sumaroka, Alexander; Roman, Alejandro J.; Jacobson, Samuel G.; Engel, Andreas; Adams, Mark D.; Palczewski, Krzysztof			Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration	FASEB JOURNAL			English	Article						Nrl; RNA-Seq; vision	SCANNING-ELECTRON-MICROSCOPY; EXPRESSED SEQUENCE TAGS; GENE-EXPRESSION; EYE DEVELOPMENT; TRANSCRIPTION FACTORS; LAMINAR ARCHITECTURE; SERIAL ANALYSIS; SURFACE-CHARGE; GANGLION-CELL; 6 FAMILY	Enhanced S-cone syndrome (ESCS), featuring an excess number of S cones, manifests as a progressive retinal degeneration that leads to blindness. Here, through optical imaging, we identified an abnormal interface between photoreceptors and the retinal pigment epithelium (RPE) in 9 patients with ESCS. The neural retina leucine zipper transcription factor-knockout (Nrl(-/-)) mouse model demonstrates many phenotypic features of human ESCS, including unstable S-cone-positive photoreceptors. Using massively parallel RNA sequencing, we identified 6203 differentially expressed transcripts between wild-type (Wt) and Nrl(-/-) mouse retinas, with 6 highly significant differentially expressed genes of the Pax, Notch, and Wnt canonical pathways. Changes were also obvious in expression of 30 genes involved in the visual cycle and 3 key genes in photoreceptor phagocytosis. Novel high-resolution (100 nm) imaging and reconstruction of Nrl(-/-) retinas revealed an abnormal packing of photoreceptors that contributed to buildup of photoreceptor deposits. Furthermore, lack of phagosomes in the RPE layer of Nrl(-/-) retina revealed impairment in phagocytosis. Cultured RPE cells from Wt and Nrl(-/-) mice illustrated that the phagocytotic defect was attributable to the aberrant interface between ESCS photoreceptors and the RPE. Overcoming the retinal phagocytosis defect could arrest the progressive degenerative component of this disease.-Mustafi, D., Kevany, B. M., Genoud, C., Okano, K., Cideciyan, A. V., Sumaroka, A., Roman, A. J., Jacobson, S. G. Engel, A., Adams, M. D., Palczewski, K. Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. FASEB J. 25, 3157-3176 (2011). www.fasebj.org	[Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; [Adams, Mark D.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; [Adams, Mark D.; Palczewski, Krzysztof] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Genoud, Christel] Friedrich Miescher Inst, Electron Microscopy Facil, CH-4002 Basel, Switzerland; [Cideciyan, Artur V.; Sumaroka, Alexander; Roman, Alejandro J.; Jacobson, Samuel G.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; [Engel, Andreas] Univ Basel, ME Muller Inst, Ctr Cellular Imaging & Nanoanalyt, Basel, Switzerland	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Friedrich Miescher Institute for Biomedical Research; University of Pennsylvania; Pennsylvania Medicine; University of Basel	Palczewski, K (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu	Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Jacobson, Samuel/0000-0003-2122-169X; Mustafi, Debarshi/0000-0002-9164-7488; genoud, christel/0000-0002-0933-9911	U.S. National Institutes of Health (NIH) [EY009339, EY019478]; Foundation Fighting Blindness; NIH [T32 GM007250, T32 EY007157]; Maurice E. Muller Foundation of Switzerland; National Institute of Diabetes and Digestive and Kidney Diseases [DK-007319]; NATIONAL EYE INSTITUTE [R01EY009339, R01EY019478, T32EY007157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness(European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Maurice E. Muller Foundation of Switzerland; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Anand Swaroop (National Eye Institute) for helpful discussions and Dr. Leslie T. Webster Jr., Dr. Yoshikazu Imanishi, Dr. Michael E. Maguire and Dr. Akiko Maeda (Case Western Reserve University) for valuable comments about the manuscript. The authors thank Dr. Russell Van Gelder (University of Washington, Seatttle, WA, USA) for providing the scanning electron microscope for imaging and Dr. David Williams and Dr. Tanja Diemer (University of California, Los Angeles, CA, USA) for graciously offering to demonstrate their RPE isolation technique. The authors also thank Dr. Yan Liang, Dr. Hisashi Fujioka, Dr. Heather Holdaway, Dr. Glenn Lobo, Neil Molyneaux, Satsumi Roos, Simone Edelheit, Pamela Supelak, Sungho Lee (Case Western Reserve University), and Christopher Bleck (University of Basel, Basel, Switzerland) for sample preparation, imaging assistance, data analysis help and useful discussions. This research was supported by U.S. National Institutes of Health (NIH) grants EY009339 and EY019478, and by a grant from Foundation Fighting Blindness. D. M. was supported in part by Case Western Reserve University (CWRU) Medical Scientist Training Program grant T32 GM007250 from NIH, Visual Sciences Training grant T32 EY007157 from NIH, and the Maurice E. Muller Foundation of Switzerland. B. M. K. was supported by a CWRU Department of Nutrition Metabolic Training grant postdoctoral fellowship award from National Institute of Diabetes and Digestive and Kidney Diseases grant DK-007319. K. P. is John H. Hord Professor of Pharmacology.	ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110; Alfano G, 2005, HUM MOL GENET, V14, P913, DOI 10.1093/hmg/ddi084; ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Bonilha VL, 2009, OPHTHALMIC GENET, V30, P172, DOI 10.3109/13816810903176765; BRAY DF, 1993, MICROSC RES TECHNIQ, V26, P489, DOI 10.1002/jemt.1070260603; Brown NL, 2001, DEVELOPMENT, V128, P2497; Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265; Chen JC, 2007, INVEST OPHTH VIS SCI, V48, P2799, DOI 10.1167/iovs.06-0922; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457; Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105; Coleman JA, 2009, J BIOL CHEM, V284, P32670, DOI 10.1074/jbc.M109.047415; Conte I, 2010, DEVELOPMENT, V137, P2307, DOI 10.1242/dev.045294; Corbo JC, 2005, PLOS GENET, V1, P140, DOI 10.1371/journal.pgen.0010011; Corbo JC, 2007, P NATL ACAD SCI USA, V104, P12069, DOI 10.1073/pnas.0705465104; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Daniele LL, 2005, INVEST OPHTH VIS SCI, V46; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; Denk W, 2004, PLOS BIOL, V2, P1900, DOI 10.1371/journal.pbio.0020329; Denoeud F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r175; Diemer T, 2008, ADV EXP MED BIOL, V613, P321, DOI 10.1007/978-0-387-74904-4_37; Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005; Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438; Farjo R, 2006, J CELL BIOL, V173, P59, DOI 10.1083/jcb.200509036; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Gehring WJ, 2005, J HERED, V96, P171, DOI 10.1093/jhered/esi027; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Han XW, 2009, P NATL ACAD SCI USA, V106, P12741, DOI 10.1073/pnas.0902417106; Haynes T, 2007, P NATL ACAD SCI USA, V104, P20380, DOI 10.1073/pnas.0708202104; HOOD DC, 1995, VISION RES, V35, P1473, DOI 10.1016/0042-6989(95)98727-Q; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; IMMEL JH, 1985, CELL TISSUE RES, V239, P667; Jacobson SG, 2009, INVEST OPHTH VIS SCI, V50, P1886, DOI 10.1167/iovs.08-3122; JACOBSON SG, 1989, EXP EYE RES, V48, P679, DOI 10.1016/0014-4835(89)90009-2; Jacobson SG, 2004, HUM MOL GENET, V13, P1893, DOI 10.1093/hmg/ddh198; JACOBSON SG, 1990, INVEST OPHTH VIS SCI, V31, P827; JACOBSON SG, 1991, AM J OPHTHALMOL, V111, P446, DOI 10.1016/S0002-9394(14)72379-7; Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245; Jadhav AP, 2006, P NATL ACAD SCI USA, V103, P18998, DOI 10.1073/pnas.0608155103; Karner CM, 2011, DEVELOPMENT, V138, P1247, DOI 10.1242/dev.057646; Karner CM, 2009, NAT GENET, V41, P793, DOI 10.1038/ng.400; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009; Kumar JP, 2009, CELL MOL LIFE SCI, V66, P565, DOI 10.1007/s00018-008-8335-4; Levine EM, 1997, J NEUROSCI, V17, P6277; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Milam AH, 2002, P NATL ACAD SCI USA, V99, P473, DOI 10.1073/pnas.022533099; Mollema N, 2010, EXP EYE RES, V91, P116, DOI 10.1016/j.exer.2010.04.013; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Murali D, 2005, DEV BIOL, V283, P671; Mustafi D, 2011, J NEUROSCI METH, V198, P70, DOI 10.1016/j.jneumeth.2011.03.013; Nagalakshmi U, 2008, SCIENCE, V320, P1344, DOI 10.1126/science.1158441; Nelson BR, 2007, DEV BIOL, V304, P479, DOI 10.1016/j.ydbio.2007.01.001; Nishiguchi KM, 2004, P NATL ACAD SCI USA, V101, P17819, DOI 10.1073/pnas.0408183101; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROMAN AJ, 1991, EXP EYE RES, V53, P685, DOI 10.1016/0014-4835(91)90230-C; ROMAN AJ, 1991, INVEST OPHTH VIS SCI, V32, P1138; Rouquette J, 2009, CHROMOSOME RES, V17, P801, DOI 10.1007/s10577-009-9070-x; Sakagami K, 2009, J NEUROSCI, V29, P6932, DOI 10.1523/JNEUROSCI.0289-09.2009; Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799; Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880; Vance JE, 2005, PROG LIPID RES, V44, P207, DOI 10.1016/j.plipres.2005.05.001; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155; Wang NK, 2009, BRIT J OPHTHALMOL, V93, P1234, DOI 10.1136/bjo.2008.153577; Wang WH, 2001, MOL VIS, V7, P89; Wang YP, 2005, DEVELOPMENT, V132, P5103, DOI 10.1242/dev.02096; Wang YP, 2002, NAT NEUROSCI, V5, P831, DOI 10.1038/nn911; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006; Wenzel A, 2007, INVEST OPHTH VIS SCI, V48, P534, DOI 10.1167/iovs.06-0652; Wright Alan F, 2004, Hum Mutat, V24, P439, DOI 10.1002/humu.9285; Wu JQ, 2010, P NATL ACAD SCI USA, V107, P5254, DOI 10.1073/pnas.0914114107; Yaron O, 2006, DEVELOPMENT, V133, P1367, DOI 10.1242/dev.02311; Yetemian RM, 2010, INVEST OPHTH VIS SCI, V51, P6196, DOI 10.1167/iovs.10-5452; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yeung T, 2009, J CELL BIOL, V185, P917, DOI 10.1083/jcb.200903020; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Yu JD, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r65	98	69	71	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3157	3176		10.1096/fj.11-186767	http://dx.doi.org/10.1096/fj.11-186767			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21659555	Green Published			2022-12-28	WOS:000294435200029
J	Vaneycken, I; Devoogdt, N; Van Gassen, N; Vincke, C; Xavier, C; Wernery, U; Muyldermans, S; Lahoutte, T; Caveliers, V				Vaneycken, Ilse; Devoogdt, Nick; Van Gassen, Naomi; Vincke, Cecile; Xavier, Catarina; Wernery, Ulrich; Muyldermans, Serge; Lahoutte, Tony; Caveliers, Vicky			Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer	FASEB JOURNAL			English	Article						tracer development; SPECT	SINGLE-CHAIN FV; ANKYRIN REPEAT PROTEINS; PINHOLE SPECT/MICRO-CT; ANTIBODY FRAGMENTS; HER-2 OVEREXPRESSION; AFFIBODY MOLECULE; METASTATIC SITES; AFFINITY; THERAPY; MICE	Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)-status in breast cancer patients is possible via noninvasive imaging, provided adequate tracers are used. In this study, we describe the generation of a panel of 38 nanobodies, small HER2-binding fragments that are derived from heavy-chain-only antibodies raised in an immunized dromedary. In search of a lead compound, a subset of nanobodies was biochemically characterized in depth and preclinically tested for use as tracers for imaging of xenografted tumors. The selected compound, 2Rs15d, was found to be stable and to interact specifically with HER2 recombinant protein and HER2-expressing cells in ELISA, surface plasmon resonance, flow cytometry, and radioligand binding studies with low nanomolar affinities, and did not compete with anti-HER2 therapeutic antibodies trastuzumab and pertuzumab. Single-photon-emission computed tomography (SPECT) imaging quantification and biodistribution analyses showed that Tc-99m-labeled 2Rs15d has a high tumor uptake in 2 HER2(+) tumor models, fast blood clearance, low accumulation in nontarget organs except kidneys, and high concomitant tumor-to-blood and tumor-to-muscle ratios at 1 h after intravenous injection. These values were dramatically lower for an irrelevant control Tc-99m-nanobody and for Tc-99m-2Rs15d targeting a HER2(-) tumor.-Vaneycken, I., Devoogdt, N., Van Gassen, N., Vincke, C., Xavier, C., Wernery, U., Muyldermans, S., Lahoutte, T., Caveliers, V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 25, 2433-2446 (2011). www.fasebj.org	[Vaneycken, Ilse; Devoogdt, Nick; Xavier, Catarina; Lahoutte, Tony; Caveliers, Vicky] Vrije Univ Brussel, In Vivo Cellular & Mol Imaging ICMI Lab, B-1090 Brussels, Belgium; [Van Gassen, Naomi; Vincke, Cecile; Muyldermans, Serge] Vrije Univ Brussel, Lab Cellular & Mol Immunol, B-1090 Brussels, Belgium; [Lahoutte, Tony; Caveliers, Vicky] Univ Ziekenhuis St Rafael, Dept Nucl Med, Brussels, Belgium; [Van Gassen, Naomi; Vincke, Cecile; Muyldermans, Serge] VIB, Dept Mol & Cellular Interact, Brussels, Belgium; [Wernery, Ulrich] Cent Vet Res Lab, Dubai, U Arab Emirates	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB)	Vaneycken, I (corresponding author), Vrije Univ Brussel, In Vivo Cellular & Mol Imaging Lab, Laarbeeklaan 103, B-1090 Brussels, Belgium.	ilse.vaneycken@gmail.com	Lahoutte, Tony/O-6381-2016; Muyldermans, Serge V/C-6418-2016; Devoogdt, Nick/H-5156-2013; Muyldermans, Serge/AAC-7374-2019; Xavier, Catarina/D-8080-2015; Vincke, Cecile/C-6590-2016	Muyldermans, Serge V/0000-0002-3678-3575; Devoogdt, Nick/0000-0001-9220-4833; Muyldermans, Serge/0000-0002-3678-3575; Xavier, Catarina/0000-0001-9006-1074; Vincke, Cecile/0000-0003-0681-7444; Lahoutte, Tony/0000-0002-1773-8664; Caveliers, Vicky/0000-0002-4301-5902	Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy	Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy(Belgian Federal Science Policy Office)	The authors thank Cindy Peleman and Isabel Remory for their technical assistance with the small-animal pinhole SPECT/microCT and the cell culturing. The research at ICMI is funded by the Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy. T. L. is a Senior Clinical Investigator of the Research Foundation, Flanders (FWO), Belgium.	Adams GP, 2001, CANCER RES, V61, P4750; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Ahlgren S, 2010, J NUCL MED, V51, P1131, DOI 10.2967/jnumed.109.073346; Behr TM, 2001, EUR J NUCL MED, V28, P976; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Cortez-Retamozo V, 2008, CURR RADIOPHARM, V1, P37, DOI 10.2174/1874471010801010037; De Groeve K, 2010, J NUCL MED, V51, P782, DOI 10.2967/jnumed.109.070078; Gainkam LOT, 2008, J NUCL MED, V49, P788, DOI 10.2967/jnumed.107.048538; Gainkam LOT, 2011, CONTRAST MEDIA MOL I, V6, P85, DOI 10.1002/cmmi.408; Gancberg D, 2002, ANN ONCOL, V13, P1036, DOI 10.1093/annonc/mdf252; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Hait W.N., 2008, MOL BASIS CANC, V3rd ed., P571; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hanna W, 2007, BREAST J, V13, P122, DOI 10.1111/j.1524-4741.2007.00396.x; Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2; Hicks DG, 2008, AM J CLIN PATHOL, V129, P263, DOI 10.1309/99AE032R9FM8WND1; Huang L, 2008, MOL IMAGING BIOL, V10, P167, DOI 10.1007/s11307-008-0133-8; McLarty K, 2009, J NUCL MED, V50, P1848, DOI 10.2967/jnumed.109.067231; Nielsen UB, 2000, CANCER RES, V60, P6434; Orlova A, 2006, CANCER RES, V66, P4339, DOI 10.1158/0008-5472.CAN-05-3521; Orlova A, 2009, J NUCL MED, V50, P417, DOI 10.2967/jnumed.108.057919; Robinson MK, 2005, CANCER RES, V65, P1471, DOI 10.1158/0008-5472.CAN-04-2008; Saerens D, 2005, J MOL BIOL, V352, P597, DOI 10.1016/j.jmb.2005.07.038; Tang Y, 2005, NUCL MED COMMUN, V26, P427, DOI 10.1097/00006231-200505000-00006; Tolmachev V, 2008, CURR PHARM DESIGN, V14, P2999, DOI 10.2174/138161208786404290; Vaneycken I, 2010, J NUCL MED, V51, P1099, DOI 10.2967/jnumed.109.069823; Vegt E, 2010, J NUCL MED, V51, P1049, DOI 10.2967/jnumed.110.075101; Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; Willuda J, 1999, CANCER RES, V59, P5758; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zahnd C, 2006, J BIOL CHEM, V281, P35167, DOI 10.1074/jbc.M602547200; Zahnd C, 2010, CANCER RES, V70, P1595, DOI 10.1158/0008-5472.CAN-09-2724; Zidan J, 2005, BRIT J CANCER, V93, P552, DOI 10.1038/sj.bjc.6602738	34	198	223	4	112	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2433	2446		10.1096/fj.10-180331	http://dx.doi.org/10.1096/fj.10-180331			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478264				2022-12-28	WOS:000292242200034
J	Zhang, SZ; Zheng, MQ; Kibe, R; Huang, YP; Marrero, L; Warren, S; Zieske, AW; Iwakuma, T; Kolls, JK; Cui, Y				Zhang, Shuzhong; Zheng, Mingquan; Kibe, Ryoko; Huang, Yunping; Marrero, Luis; Warren, Samantha; Zieske, Arthur W.; Iwakuma, Tomoo; Kolls, Jay K.; Cui, Yan			Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis	FASEB JOURNAL			English	Article						IL-17; IL-6; CD45.1; inflammatory cytokines	NF-KAPPA-B; T-CELLS; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; TUMOR-SUPPRESSOR; POINT MUTATION; T-H-17 CELLS; TH17 CELLS; P53; INFLAMMATION	Emerging evidence suggests that the tumor suppressor p53 is also a crucial regulator for many physiological processes. Previous observations indicate that p53 suppresses inflammation by inhibiting inflammatory antigen-presenting cells. To investigate the potential role of p53 in autoimmune effector T cells, we generated p53(null)CD45.1 mice by crossing p53(null)CD45.2 and CD45.1 mice. We demonstrate that p53(null)CD45.1 mice spontaneously developed autoimmunity, with a significant increase in IL-17-producing Th17 effectors in their lymph nodes (4.7 +/- 1.0%) compared to the age-matched counterparts (1.9 +/- 0.8% for p53(null)CD45.2, 1.1 +/- 0.2% for CD45.1, and 0.5 +/- 0.1% for CD45.2 mice). Likewise, p53(null)CD45.1 mice possess highly elevated serum levels of inflammatory cytokines IL-17 and IL-6. This enhanced Th17 response results largely from an increased sensitivity of p53(null)CD45.1 T cells to IL-6-induced STAT3 phosphorylation. Administration of STAT3 inhibitor S31-201 (IC50 of 38.0 +/- 7.2 mu M for IL-6-induced STAT3 phosphorylation), but not PBS control, to p53(null)CD45.1 mice suppressed Th17 effectors and alleviated autoimmune pathology. This is the first report revealing that p53 activity in T cells suppresses autoimmunity by controlling Th17 effectors. This study suggests that p53 serves as a guardian of immunological functions and that the p53-STAT3-Th17 axis might be a therapeutic target for autoimmunity.-Zhang, S., Zheng, M., Kibe, R., Huang, Y., Marrero, L., Warren, S., Zieske, A. W., Iwakuma, T., Kolls, J. K., Cui, Y. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 25, 2387-2398 (2011). www.fasebj.org	[Zhang, Shuzhong; Kibe, Ryoko; Huang, Yunping; Marrero, Luis; Warren, Samantha; Cui, Yan] Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; [Zheng, Mingquan; Iwakuma, Tomoo; Kolls, Jay K.; Cui, Yan] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA 70112 USA; [Iwakuma, Tomoo; Kolls, Jay K.; Cui, Yan] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Zieske, Arthur W.] Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Cui, Y (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Dept Microbiol Immunol & Parasitol, 533 Bolivar St, New Orleans, LA 70112 USA.	ycui@lsuhsc.edu	Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304; Cui, Yan/0000-0002-2800-6039	Louisiana Gene Therapy Research Consortium; Louisiana Cancer Research Consortium; U.S. National Institutes of Health [CA112065, P20RR021970]; NATIONAL CANCER INSTITUTE [R01CA112065] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021970] Funding Source: NIH RePORTER	Louisiana Gene Therapy Research Consortium; Louisiana Cancer Research Consortium; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors give special thanks to Dr. Defu Zheng for constructive suggestions; Drs. Alistair Ramsay, Augusto Ochoa, Paulo Rodriguez, and Daitoku Sakamuro for critical reading; Dr. Heidi Davis for editorial assistance; and Dr. Zaili Chen, Dr. Weitao Huang, and Ms. Candice Pereira for technical assistance. This work is supported in part by research funding from the Louisiana Gene Therapy Research Consortium and the Louisiana Cancer Research Consortium, grants from the U.S. National Institutes of Health to Y.C. (CA112065 and P20RR021970).	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Aparicio S, 2009, CELL, V138, P1060, DOI 10.1016/j.cell.2009.09.004; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Chen Z, 2008, IMMUNOL RES, V41, P87, DOI 10.1007/s12026-007-8014-9; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Diveu C, 2008, CURR OPIN IMMUNOL, V20, P663, DOI 10.1016/j.coi.2008.09.003; Do HT, 2006, J IMMUNOL, V176, P931, DOI 10.4049/jimmunol.176.2.931; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Hussain SP, 2000, CANCER RES, V60, P3333; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Lin JY, 2002, CANCER RES, V62, P376; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Okuda Y, 2003, J NEUROIMMUNOL, V135, P29, DOI 10.1016/S0165-5728(02)00428-9; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palmer MT, 2010, NAT IMMUNOL, V11, P36, DOI 10.1038/ni.1802; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Puzio-Kuter AM, 2009, NAT BIOTECHNOL, V27, P914, DOI 10.1038/nbt1009-914; RASCHKE WC, 1995, IMMUNOGENETICS, V41, P144, DOI 10.1007/BF00182327; Salvador JM, 2005, NAT IMMUNOL, V6, P396, DOI 10.1038/ni1176; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Steinman L, 2010, NAT IMMUNOL, V11, P41, DOI 10.1038/ni.1803; Tak PP, 2000, IMMUNOL TODAY, V21, P78, DOI 10.1016/S0167-5699(99)01552-2; Tapinos NI, 1999, ARTHRITIS RHEUM-US, V42, P1466, DOI 10.1002/1529-0131(199907)42:7<1466::AID-ANR21>3.0.CO;2-L; Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Vang T, 2008, ANNU REV IMMUNOL, V26, P29, DOI 10.1146/annurev.immunol.26.021607.090418; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Windhagen A, 2007, CLIN EXP IMMUNOL, V150, P509, DOI 10.1111/j.1365-2249.2007.03508.x; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yao QP, 2001, MOL THER, V3, P901, DOI 10.1006/mthe.2001.0343; ZEBEDEE SL, 1991, EUR J IMMUNOGENET, V18, P155, DOI 10.1111/j.1744-313X.1991.tb00015.x; Zheng SJ, 2005, DIABETES, V54, P1423, DOI 10.2337/diabetes.54.5.1423; Zhou L, 2009, CURR OPIN IMMUNOL, V21, P146, DOI 10.1016/j.coi.2009.03.001	60	37	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2387	2398		10.1096/fj.10-175299	http://dx.doi.org/10.1096/fj.10-175299			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21471252	Green Published			2022-12-28	WOS:000292242200030
J	Chang, IA; Oh, MJ; Kim, MH; Park, SK; Kim, BG; Namgung, U				Chang, In Ae; Oh, Myung-Jin; Kim, Min Hee; Park, Seung-Kiel; Kim, Byung G.; Namgung, Uk			Vimentin phosphorylation by Cdc2 in Schwann cell controls axon growth via beta 1-integrin activation	FASEB JOURNAL			English	Article						implantation; neurite outgrowth; preinjury; regeneration; sciatic nerve	NEURONAL PROCESS OUTGROWTH; FIBRILLARY ACIDIC PROTEIN; SPINAL-CORD-INJURY; EXTRACELLULAR-MATRIX; INTERMEDIATE-FILAMENTS; CONDITIONING-LESION; SENSORY AXONS; SCIATIC-NERVE; INTEGRIN; KINASE	Although preconditioning injury on the peripheral nerve induces axonal regenerative capacity in neurons, it is not known whether similar lesion effects occur in glial cells. Here we demonstrate that Schwann cells are activated by peripheral nerve preinjury and primed to mediate axon regeneration. Cdc2, which was induced from Schwann cells after sciatic nerve injury, phosphorylated vimentin almost exclusively in the distal nerve area. Phospho-vimentin-positive Schwann cells showed increased migration activity and were in close contact with process outgrowth of co-cultured neurons. Vimentin phosphorylation by Cdc2 was involved in beta 1-integrin activation leading to FAK phoshorylation and associated with Erk1/2 activation in Schwann cells. Neurite outgrowth of dorsal root ganglion neurons was increased by co-culture with activated Schwann cells, in which phospho-vimentin signaling was transmitted into beta 1-integrin activation. Then neurite outgrowth was suppressed by genetic depletion of phospho-vimentin and beta 1 integrin as well as inhibition of vimentin phosphorylation by Cdc2 inhibitor purvalanol A. The sciatic nerve graft harboring activated Schwann cells into the spinal cord induced Schwann cell migration beyond the graft-host barrier and facilitated regeneration of spinal axons, which was inhibited by purvalanol A pretreatment of the graft. This is the first report to our knowledge demonstrating that activation of phospho-vimentin linked to beta 1-integrin pathway may mediate transcellular signaling to promote axon growth.-Chang, I. A., Oh, M.-J., Kim, M. H., Park, S.-K., Kim, B. G., Namgung, U. Vimentin phosphorylation by Cdc2 in Schwann cell controls axon growth via beta 1-integrin activation. FASEB J. 26, 2401-2413 (2012). www.fasebj.org	[Chang, In Ae; Oh, Myung-Jin; Kim, Min Hee; Namgung, Uk] Daejeon Univ, Dept Oriental Med, Taejon 300716, South Korea; [Park, Seung-Kiel] Chungnam Natl Univ, Coll Med, Dept Biochem, Taejon, South Korea; [Kim, Byung G.] Ajou Univ, Sch Med, Brain Dis Res Ctr, Inst Med Sci, Suwon 441749, South Korea; [Kim, Byung G.] Ajou Univ, Sch Med, Dept Neurol, Suwon 441749, South Korea	Daejeon University; Chungnam National University; Ajou University; Ajou University	Namgung, U (corresponding author), Daejeon Univ, Dept Oriental Med, Taejon 300716, South Korea.	unamgung@dju.kr	Kim, Byung Gon/L-6884-2019	Kim, Byung Gon/0000-0003-2233-9569	National Research Foundation (NRF); Ministry of Education, Science and Technology, Korea [2010-0023869]; MEST [20090081466]	National Research Foundation (NRF); Ministry of Education, Science and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea)	The authors thank Heesup Lee for technical assistance, Dr. Eun-hye Joe (Ajou University, Suwon, Korea) for vimentin antibody, and the Korea Basic Science Institute for the use of their confocal microscope facility. This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Education, Science and Technology, Korea (2010-0023869) to U.N. and MEST (20090081466) to B.G.K.	Afshari FT, 2010, J NEUROSCI, V30, P4246, DOI 10.1523/JNEUROSCI.3351-09.2010; Anthis NJ, 2011, TRENDS BIOCHEM SCI, V36, P191, DOI 10.1016/j.tibs.2010.11.002; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; BIGNAMI A, 1982, DEV BIOL, V91, P286, DOI 10.1016/0012-1606(82)90035-5; BIXBY JL, 1988, J CELL BIOL, V107, P353, DOI 10.1083/jcb.107.1.353; BODEGA G, 1994, HISTOCHEMISTRY, V102, P113, DOI 10.1007/BF00269015; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chernousov MA, 2003, EXP CELL RES, V291, P514, DOI 10.1016/S0014-4827(03)00409-9; Condic ML, 1997, NATURE, V389, P852, DOI 10.1038/39878; DAHL D, 1981, EUR J CELL BIOL, V24, P191; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DELEON M, 1991, J NEUROSCI RES, V29, P437; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; Ekstrom PAR, 2003, MOL CELL NEUROSCI, V22, P383, DOI 10.1016/S1044-7431(02)00034-9; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fawcett J. W., 2001, BRAIN DAMAGE BRAIN R, P145; Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Gschwendtner A, 2003, MOL CELL NEUROSCI, V24, P307, DOI 10.1016/S1044-7431(03)00167-2; Han IS, 2007, J CELL SCI, V120, P246, DOI 10.1242/jcs.03322; Hill CE, 2007, EUR J NEUROSCI, V26, P1433, DOI 10.1111/j.1460-9568.2007.05771.x; Hines JH, 2010, NAT NEUROSCI, V13, P829, DOI 10.1038/nn.2554; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Ide C, 1996, NEUROSCI RES, V25, P101; Inoue G, 2010, GLIA, V58, P399, DOI 10.1002/glia.20931; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Kamei Y, 1998, GLIA, V23, P191, DOI 10.1002/(SICI)1098-1136(199807)23:3<191::AID-GLIA2>3.0.CO;2-8; Kim H, 2010, EXP CELL RES, V316, P1829, DOI 10.1016/j.yexcr.2010.02.007; LEFCORT F, 1992, DEVELOPMENT, V116, P767; Lemons ML, 2008, EXP NEUROL, V209, P343, DOI 10.1016/j.expneurol.2007.05.027; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; NEUBERGER TJ, 1989, J NEUROCYTOL, V18, P695, DOI 10.1007/BF01187088; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Oh MJ, 2009, J NEUROTRAUM, V26, P2071, DOI [10.1089/neu.2008.0800, 10.1089/neu.2008-0800]; OUDEGA M, 1994, EXP NEUROL, V129, P194, DOI 10.1006/exnr.1994.1161; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pereira JA, 2009, J CELL BIOL, V185, P147, DOI 10.1083/jcb.200809008; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Pietri T, 2004, DEVELOPMENT, V131, P3871, DOI 10.1242/dev.01264; Polinsky M, 2000, J NEUROSCI, V20, P1044, DOI 10.1523/JNEUROSCI.20-03-01044.2000; Previtali SC, 2001, PROG NEUROBIOL, V64, P35, DOI 10.1016/S0301-0082(00)00045-9; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; RICHARDSON PM, 1984, NATURE, V309, P791, DOI 10.1038/309791a0; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sandrow HR, 2008, EXP NEUROL, V210, P489, DOI 10.1016/j.expneurol.2007.11.029; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Seo TB, 2006, MED SCI SPORT EXER, V38, P1267, DOI 10.1249/01.mss.0000227311.00976.68; Seo TB, 2009, J NEUROTRAUM, V26, P1733, DOI 10.1089/neu.2008-0711; Sihag RK, 2007, EXP CELL RES, V313, P2098, DOI 10.1016/j.yexcr.2007.04.010; Smith DS, 1997, J NEUROSCI, V17, P646; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tan CL, 2011, J NEUROSCI, V31, P6289, DOI 10.1523/JNEUROSCI.0008-11.2011; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091	69	40	41	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2401	2413		10.1096/fj.11-199018	http://dx.doi.org/10.1096/fj.11-199018			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22371530				2022-12-28	WOS:000305017200018
J	Natsuizaka, M; Naganuma, S; Kagawa, S; Ohashi, S; Ahmadi, A; Subramanian, H; Chang, S; Nakagawa, KJ; Ji, XJ; Liebhaber, SA; Klein-Szanto, AJ; Nakagawa, H				Natsuizaka, Mitsuteru; Naganuma, Seiji; Kagawa, Shingo; Ohashi, Shinya; Ahmadi, Azal; Subramanian, Harry; Chang, Sanders; Nakagawa, Kei J.; Ji, Xinjun; Liebhaber, Stephen A.; Klein-Szanto, Andres J.; Nakagawa, Hiroshi			Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1 alpha-mediated mRNA transcription and continuous protein synthesis	FASEB JOURNAL			English	Article						cap-dependent translation; internal ribosome entry site	FACTOR-BINDING PROTEIN-3; INDUCIBLE FACTOR (HIF)-1-ALPHA; RIBOSOME ENTRY SITES; GENE-EXPRESSION; TRANSLATIONAL CONTROL; RESPONSIVE ELEMENT; CANDIDATE GENES; BREAST-CANCER; STEM-CELL; P53	Insulin-like growth factor binding protein (IGFBP)-3 regulates cell proliferation and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. We have investigated how the hypoxic tumor microenvironment in ESCC fosters the induction of IGFBP3. RNA interference experiments revealed that hypoxia-inducible factor (HIF)-1 alpha, but not HIF-2 alpha, regulates IGFBP3 mRNA induction. By chromatin immunoprecipitation and transfection assays, HIF-1 alpha was found to transactivate IGFBP3 through a novel hypoxia responsive element (HRE) located at 57 kb upstream from the transcription start site. Metabolic labeling experiments demonstrated hypoxia-mediated inhibition of global protein synthesis. 7-Methyl GTP-cap binding assays suggested that hypoxia suppresses cap-dependent translation. Experiments using pharmacological inhibitors for mammalian target of rapamycin (mTOR) suggested that a relatively weak mTOR activity may be sufficient for cap-dependent translation of IGFBP3 under hypoxic conditions. Bicistronic RNA reporter transfection assays did not validate the possibility of an internal ribosome entry site as a potential mechanism for cap-independent translation for IGFBP3 mRNA. Finally, IGFBP3 mRNA was found enriched to the polysomes. In aggregate, our study establishes IGFBP3 as a direct HIF-1 alpha target gene and that polysome enrichment of IGFBP3 mRNA may permit continuous translation under hypoxic conditions.-Natsuizaka, M., Naganuma, S., Kagawa, S., Ohashi, S., Ahmadi, A., Subramanian, H., Chang, S., Nakagawa, K. J., Ji, X., Liebhaber, S. A., Klein-Szanto, A. J., Nakagawa, H. Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1 alpha-mediated mRNA transcription and continuous protein synthesis. FASEB J. 26, 2620-2630 (2012). www.fasebj.org	[Natsuizaka, Mitsuteru; Naganuma, Seiji; Kagawa, Shingo; Ohashi, Shinya; Ahmadi, Azal; Subramanian, Harry; Chang, Sanders; Nakagawa, Kei J.; Nakagawa, Hiroshi] Univ Penn, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA; [Natsuizaka, Mitsuteru; Naganuma, Seiji; Kagawa, Shingo; Ohashi, Shinya; Ahmadi, Azal; Subramanian, Harry; Chang, Sanders; Nakagawa, Kei J.; Nakagawa, Hiroshi] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Ji, Xinjun; Liebhaber, Stephen A.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; [Klein-Szanto, Andres J.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Ohashi, Shinya] Kitano Hosp, Div Gastroenterol & Hepatol, Ctr Digest Dis, Tazuke Kofukai Med Res Inst, Osaka, Japan	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Fox Chase Cancer Center; Kitano Hospital	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, Dept Med, 638 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu	Ohashi, Shinya/AAD-8920-2022; Natsuizaka, Mitsuteru/F-7300-2012	Natsuizaka, Mitsuteru/0000-0002-1819-1955; Subramanian, Harry/0000-0001-9173-6248; Chang, Sanders/0000-0003-3543-0310	U.S. National Institute of Health (NIH) [R01DK077005, P01CA098101, P30-DK050306, R37-HL65449-MERIT]; University of Pennsylvania University Research Foundation; Japan Society for the Promotion of Science [21790382]; American Gastroenterological Association (AGA) Research Foundation; NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases [P30-DK050306]; AGA-Broad Foundation; NATIONAL CANCER INSTITUTE [P01CA098101, P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL065449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077005, P30DK050306] Funding Source: NIH RePORTER	U.S. National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania University Research Foundation; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); American Gastroenterological Association (AGA) Research Foundation; NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGA-Broad Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported in part by U.S. National Institute of Health (NIH) grants R01DK077005 (to M. N., S. K., S. O., and H. N.), P01CA098101 (to H. N., M. N., S. K., S. O., and A. J. P. K.), P30-DK050306 (to A. A., H. S., S. C., and K. J. N.), R37-HL65449-MERIT (to S. A. L.); a University of Pennsylvania University Research Foundation Award (to H. N.); Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists B-21790382 (to S. N.); an American Gastroenterological Association (AGA) Research Foundation Student Fellowship Award (to S. C.) and an AGA-Broad Foundation Student Research Fellowship Award (to K. J. N.); and the NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306) and its core facilities (Molecular Pathology and Imaging, Cell Culture, and Molecular Biology and Gene Expression). The authors thank James J. Lee and Daniela Budo for technical assistance; Dr. Frank S. Lee (University of Pennsylvania) and Dr. David Feldman and Dr. Peter Sarnow (Stanford University, Palo Alto, CA, USA) for reagents; Dr. Regina M. Young and Dr. Phyllis A. Gimotty (University of Pennsylvania) for discussions; and Dr. Louis del Peso (Universidad Autonoma de Madrid, Madrid, Spain) for in silico screening of IGFBP3 HREs and discussions. The authors are appreciative of discussions with members of the laboratory of Dr. Anil K. Rustgi and his editorial help.	Azuma Y, 2003, CLIN CANCER RES, V9, P4944; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carter MS, 2000, J BIOL CHEM, V275, P28301; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Chang KH, 2007, P NATL ACAD SCI USA, V104, P10595, DOI 10.1073/pnas.0702072104; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P4203, DOI 10.1002/art.23074; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feldser D, 1999, CANCER RES, V59, P3915; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gharib SA, 2005, PHYSIOL GENOMICS, V22, P14, DOI 10.1152/physiolgenomics.00265.2004; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HINTZ RL, 1991, J UROLOGY, V146, P1160, DOI 10.1016/S0022-5347(17)38031-X; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Katsuta M, 2005, EXP MOL PATHOL, V78, P123, DOI 10.1016/j.yexmp.2004.11.002; Kimura S, 2004, EUR J CANCER, V40, P1904, DOI 10.1016/j.ejca.2004.04.035; Koong AC, 2000, CANCER RES, V60, P883; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Kurokawa T, 2003, BRIT J CANCER, V89, P1042, DOI 10.1038/sj.bjc.6601186; Le Jan S, 2006, FEBS LETT, V580, P3395, DOI 10.1016/j.febslet.2006.05.011; Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326; Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347; Lofqvist C, 2007, P NATL ACAD SCI USA, V104, P10589, DOI 10.1073/pnas.0702031104; Matsuyama T, 2005, CANCER SCI, V96, P176, DOI 10.1111/j.1349-7006.2005.00025.x; McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; Peng LH, 2004, MOL ENDOCRINOL, V18, P1109, DOI 10.1210/me.2003-0344; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ragel BT, 2007, NEUROSURG REV, V30, P181, DOI 10.1007/s10143-007-0070-z; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Takaoka M, 2004, CANCER RES, V64, P7711, DOI 10.1158/0008-5472.CAN-04-0715; Takaoka M, 2006, AM J PHYSIOL-GASTR L, V290, pG404, DOI 10.1152/ajpgi.00344.2005; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Xia XB, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-r113; Young RM, 2008, J BIOL CHEM, V283, P16309, DOI 10.1074/jbc.M710079200; Yu F, 2001, CANCER RES, V61, P4136	56	37	39	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2620	2630		10.1096/fj.11-198598	http://dx.doi.org/10.1096/fj.11-198598			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415309	Green Published			2022-12-28	WOS:000305017200037
J	Lin, PH; Zhu, H; Cai, CX; Wang, XH; Cao, CM; Xiao, RP; Pan, Z; Weisleder, N; Takeshima, H; Ma, JJ				Lin, Peihui; Zhu, Hua; Cai, Chuanxi; Wang, Xianhua; Cao, Chunmei; Xiao, Ruiping; Pan, Zui; Weisleder, Noah; Takeshima, Hiroshi; Ma, Jianjie			Nonmuscle myosin IIA facilitates vesicle trafficking for MG53-mediated cell membrane repair	FASEB JOURNAL			English	Article						confocal imaging; nucleation; COS-7 cells	MUSCULAR-DYSTROPHY; DYSFERLIN; MG53; CAVEOLIN-3; EXOCYTOSIS	Repair of injury to the plasma membrane is an essential mechanism for maintenance of cellular homeostasis and integrity that involves coordinated movement of intracellular vesicles to membrane injury sites to facilitate patch formation. We have previously identified MG53 as an essential component of the cell membrane repair machinery. In order for MG53 and intracellular vesicles to translocate to membrane injury sites, motor proteins must be involved. Here, we show that nonmuscle myosin type IIA (NM-IIA) interacts with MG53 to regulate vesicle trafficking during cell membrane repair. In cells that are deficient for NM-IIA expression, MG53 cannot translocate to acute injury sites, whereas rescue of NM-IIA expression in these cells can restore MG53-mediated membrane repair. Compromised cell membrane repair is observed in cells with RNAi-mediated knockdown of NM-IIA expression, or following pharmacological alteration of NM-IIA motor function. Together, our data reveal NM-IIA as a key cytoskeleton motor protein that facilitates vesicle trafficking during MG53-mediated cell membrane repair.-Lin, P., Zhu, H., Cai, C., Wang, X., Cao, C., Xiao, R., Pan, Z., Weisleder, N., Takeshima, H., Ma, J. Nonmuscle myosin IIA facilitates vesicle trafficking for MG53-mediated cell membrane repair. FASEB J. 26, 1875-1883 (2012). www.fasebj.org	[Lin, Peihui; Zhu, Hua; Cai, Chuanxi; Pan, Zui; Weisleder, Noah; Ma, Jianjie] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; [Wang, Xianhua; Cao, Chunmei; Xiao, Ruiping] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; [Takeshima, Hiroshi] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Peking University; Kyoto University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	maj2@umdnj.edu	Xiao, Rui-Ping/AAE-2629-2019; Lin, Pei-Hui/I-3011-2015; Zhu, Hua/G-4409-2010; Weisleder, Noah L/A-7098-2013; Yimei, Wang/AAE-4083-2019; Cai, Chuanxi/AAW-1488-2020	Lin, Pei-Hui/0000-0002-3894-5099; Weisleder, Noah L/0000-0002-2619-8022; Pan, Zui/0000-0003-4105-901X; Takeshima, Hiroshi/0000-0003-4525-3725; Zhu, Hua/0000-0001-7136-7326; Weisleder, Noah/0000-0003-2710-3088	U.S. National Institute of Health [R01-HL069000, R01-AR061385]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061385] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by U.S. National Institute of Health grants R01-HL069000 and R01-AR061385 to J.M.	Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2010, MUSCLE NERVE, V42, P22, DOI 10.1002/mus.21645; Bement WM, 2007, CURR OPIN CELL BIOL, V19, P95, DOI 10.1016/j.ceb.2006.12.001; Bement WM, 1999, CURR BIOL, V9, P579, DOI 10.1016/S0960-9822(99)80261-9; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Cai CX, 2009, J BIOL CHEM, V284, P15894, DOI 10.1074/jbc.M109.009589; Cai CX, 2009, J BIOL CHEM, V284, P3314, DOI 10.1074/jbc.M808866200; Cai CX, 2009, NAT CELL BIOL, V11, P56, DOI 10.1038/ncb1812; Cao CM, 2010, CIRCULATION, V121, P2565, DOI 10.1161/CIRCULATIONAHA.110.954628; Chase TH, 2009, AM J PATHOL, V175, P2299, DOI 10.2353/ajpath.2009.080930; Cheung A, 2002, NAT CELL BIOL, V4, P83, DOI 10.1038/ncb734; Chung LTK, 2010, BIOCHEM BIOPH RES CO, V391, P995, DOI 10.1016/j.bbrc.2009.12.004; Clark AG, 2009, CURR BIOL, V19, P1389, DOI 10.1016/j.cub.2009.06.044; Duan R, 2009, DEV BIOL, V325, P374, DOI 10.1016/j.ydbio.2008.10.035; Gazzerro E, 2010, EUR J HUM GENET, V18, P137, DOI 10.1038/ejhg.2009.103; Glover L, 2007, TRAFFIC, V8, P785, DOI 10.1111/j.1600-0854.2007.00573.x; Han R, 2007, CURR OPIN CELL BIOL, V19, P409, DOI 10.1016/j.ceb.2007.07.001; Hernandez-Deviez DJ, 2008, J BIOL CHEM, V283, P6476, DOI 10.1074/jbc.M708776200; Hirata Y, 2006, BIOPHYS J, V90, P4418, DOI 10.1529/biophysj.105.076570; Idone V, 2008, TRENDS CELL BIOL, V18, P552, DOI 10.1016/j.tcb.2008.09.001; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; LaPlaca M. C., 2009, C P IEEE ENG MED BIO, V2009, P1113; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Li Y, 2008, DNA CELL BIOL, V27, P117, DOI 10.1089/dna.2007.0661; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Miserey-Lenkei S, 2010, NAT CELL BIOL, V12, P645, DOI 10.1038/ncb2067; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang XH, 2010, CIRC RES, V107, P76, DOI 10.1161/CIRCRESAHA.109.215822; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Wilson CA, 2010, NATURE, V465, P373, DOI 10.1038/nature08994; Zhu H, 2011, J BIOL CHEM, V286, P12820, DOI 10.1074/jbc.C111.221440	33	52	54	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1875	1883		10.1096/fj.11-188599	http://dx.doi.org/10.1096/fj.11-188599			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253476	Green Published			2022-12-28	WOS:000303680800016
J	Nahmod, KA; Walther, T; Cambados, N; Fernandez, N; Meiss, R; Tappenbeck, N; Wang, Y; Raffo, D; Simian, M; Schwiebs, A; Pozner, RG; Bass, JIF; Pozzi, AG; Geffner, JR; Kordon, EC; Schere-Levy, C				Nahmod, Karen A.; Walther, Thomas; Cambados, Nadia; Fernandez, Natalia; Meiss, Roberto; Tappenbeck, Nils; Wang, Yong; Raffo, Diego; Simian, Marina; Schwiebs, Anja; Pozner, Roberto G.; Fuxman Bass, Juan I.; Pozzi, Andrea G.; Geffner, Jorge R.; Kordon, Edith C.; Schere-Levy, Carolina			AT(1) receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system	FASEB JOURNAL			English	Article						AKT; angiotensin II; apoptosis; metalloproteases; STAT3	SMOOTH-MUSCLE-CELLS; II TYPE-1 RECEPTOR; NF-KAPPA-B; EPITHELIAL-CELLS; BREAST-CANCER; MICE LACKING; CARDIOVASCULAR-DISEASE; RAT CARDIOMYOCYTES; MESSENGER-RNA; IN-VITRO	Angiotensin II (AngII), the main effector peptide of the renin-angiotensin system (RAS), participates in multiple biological processes, including cell growth, apoptosis, and tissue remodeling. Since AngII activates, in different cell types, signal transducing pathways that are critical for mammary gland postlactational regression, we investigated the role of the RAS during this process. We found that exogenous administration of AngII in mammary glands of lactating Balb/c mice induced epithelium apoptosis [2.9+/-0.5% (control) vs. 9.6+/-1.1% (AngII); P < 0.001] and activation of the proapoptotic factor STAT3, an effect inhibited by irbesartan, an AT(1) receptor blocker. Subsequently, we studied the expression kinetics of RAS components during involution. We found that angiotensin-converting enzyme (ACE) mRNA expression peaked 6 h after weaning (5.7-fold; P<0.01), while induction of angiotensinogen and AT(1) and AT(2) receptors expression was detected 96 h after weaning (6.2-, 10-, and 6.2-fold increase, respectively; P<0.01). To assess the role of endogenously generated AngII, mice were treated with losartan, an AT(1) receptor blocker, during mammary involution. Mammary glands from losartan-treated mice showed activation of the survival factors AKT and BCL-(XL), significantly lower LIF and TNF-alpha mRNA expression (P<0.05), reduced apoptosis [12.1+/-2.1% (control) vs. 4.8+/-0.7% (losartan); P<0.001] and shedding of epithelial cells, inhibition of MMP-9 activity in a dose-dependent manner (80%; P<0.05; with losartan IC50 value of 6.9 mg/kg/d] and lower collagen deposition and adipocyte invasion causing a delayed involution compared to vehicle-treated mice. Furthermore, mammary glands of forced weaned AT(1A)- and/or AT(1B)-deficient mice exhibited retarded apoptosis of epithelial cells [6.3+/-0.95% (WT) vs. 3.3+/-0.56% (AT(1A)/AT(1B) DKO); P<0.05] with remarkable delayed postlactational regression compared to wild-type animals. Taken together, these results strongly suggest that AngII, via the AT(1) receptor, plays a major role in mouse mammary gland involution identifying a novel role for the RAS.-Nahmod, K. A., Walther, T., Cambados, N., Fernandez, N., Meiss, R., Tappenbeck, N., Wang, Y., Raffo, D., Simian, M., Schwiebs, A., Pozner, R. G., Fuxman Bass, J. I., Pozzi, A. G., Geffner, J. R., Kordon, E. C., Schere-Levy, C. AT(1) receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system. FASEB J. 26, 1982-1994 (2012). www.fasebj.org	[Nahmod, Karen A.; Meiss, Roberto; Pozner, Roberto G.; Fuxman Bass, Juan I.; Geffner, Jorge R.] Natl Acad Med Buenos Aires, Inst Hematol Res, Buenos Aires, DF, Argentina; [Walther, Thomas; Tappenbeck, Nils; Wang, Yong; Schwiebs, Anja] Univ Giessen, Dept Expt Cardiol, Giessen, Germany; [Walther, Thomas; Tappenbeck, Nils; Wang, Yong; Schwiebs, Anja] Univ Hull, Hull York Med Sch, Ctr Cardiovasc & Metab Res, Kingston Upon Hull HU6 7RX, N Humberside, England; [Cambados, Nadia; Fernandez, Natalia; Pozzi, Andrea G.; Kordon, Edith C.; Schere-Levy, Carolina] Univ Buenos Aires, Fac Exact & Nat Sci, Consejo Nacl Invest Cient & Tecn CONICET, Inst Physiol Mol Biol & Neurosci, RA-1428 Buenos Aires, DF, Argentina; [Raffo, Diego; Simian, Marina] Univ Buenos Aires, Res Area, Inst Oncol Angel H Roffo, RA-1428 Buenos Aires, DF, Argentina	Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; Justus Liebig University Giessen; University of Hull; University of York - UK; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Schere-Levy, C (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, IFIBYNE CONICET, RA-1428 Buenos Aires, DF, Argentina.	caschere@fibertel.com.ar		Fernandez, Natalia Brenda/0000-0001-9170-2101; Simian, Marina/0000-0003-2070-3793	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) [PICT 2008-1979, PICT 31948, PICT 00325]; Roemmers Foundation; Consejo Nacional de Investigaciones Cientificas y Tecnicas [PIP 112-200801-00859]; Ministerio de Ciencia, Tecnologia e Innovacion Productiva-Deutscher Akademischer Austausch Dienst [DA0809]; Susan G. Komen for the Cure Foundation [BCTR0600341]	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); Roemmers Foundation; Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio de Ciencia, Tecnologia e Innovacion Productiva-Deutscher Akademischer Austausch Dienst; Susan G. Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation)	The authors thank Dr. Monica Vermeulen for helping with in vivo experiments, Dr. Nancy Hynes (Friedrich Meischer Institute, Basel, Switzerland) for providing the HC11 cell line, and Dr. Omar Coso (University of Buenos Aires) for kindly providing some of the antibodies used for signal transduction studies. The authors are grateful to Beatriz Loria for excellent technical assistance. This work was supported by research grants awarded to K.N. from Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT; PICT 2008-1979) and Roemmers Foundation (2009); to C. S. L. from ANPCyT (PICT 31948) and Consejo Nacional de Investigaciones Cientificas y Tecnicas (PIP 112-200801-00859); to T. W. and C. S. L. from Ministerio de Ciencia, Tecnologia e Innovacion Productiva-Deutscher Akademischer Austausch Dienst (DA0809); and to M. S. from ANPCyT (PICT 00325) and the Susan G. Komen for the Cure Foundation (BCTR0600341). The authors declare no conflicts of interest.	Baxter FO, 2006, DEVELOPMENT, V133, P3485, DOI 10.1242/dev.02502; Browatzki M, 2005, J VASC RES, V42, P415, DOI 10.1159/000087451; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clauser E, 1996, EUR J ENDOCRINOL, V134, P403, DOI 10.1530/eje.0.1340403; Crandall DL, 1999, ENDOCRINOLOGY, V140, P154, DOI 10.1210/en.140.1.154; De Paepe B, 2001, HISTOCHEM CELL BIOL, V116, P247, DOI 10.1007/s004180100313; Diep QN, 2001, HYPERTENSION, V37, P604, DOI 10.1161/01.HYP.37.2.604; Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009; Gembardt F, 2008, FASEB J, V22, P3068, DOI 10.1096/fj.08-108316; Gross V, 2000, KIDNEY INT, V57, P191, DOI 10.1046/j.1523-1755.2000.00820.x; Guo RW, 2008, REGUL PEPTIDES, V147, P37, DOI 10.1016/j.regpep.2007.12.005; Herr D, 2008, GYNECOL ONCOL, V109, P418, DOI 10.1016/j.ygyno.2008.02.019; Ibanez P, 2007, J GASTROEN HEPATOL, V22, P846, DOI 10.1111/j.1440-1746.2006.04700.x; Inwang ER, 1997, BRIT J CANCER, V75, P1279, DOI 10.1038/bjc.1997.217; Kodama H, 1998, CIRC RES, V82, P244; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; Kosugi M, 2006, CLIN CANCER RES, V12, P2888, DOI 10.1158/1078-0432.CCR-05-2213; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Luchtefeld M, 2005, BIOCHEM BIOPH RES CO, V328, P183, DOI 10.1016/j.bbrc.2004.12.152; Lund LR, 1996, DEVELOPMENT, V122, P181; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; NAHMOD VE, 1978, SCIENCE, V202, P1091, DOI 10.1126/science.152460; Oliverio MI, 1998, P NATL ACAD SCI USA, V95, P15496, DOI 10.1073/pnas.95.26.15496; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; Quaglino A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-55; Rahman M, 2004, EUR J PHARMACOL, V485, P243, DOI 10.1016/j.ejphar.2003.11.074; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Roks AJM, 2003, J HYPERTENS, V21, P1269, DOI 10.1097/00004872-200307000-00013; Sadoshima J, 2000, CIRC RES, V86, P1187, DOI 10.1161/01.RES.86.12.1187; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Levy CS, 2010, J CELL BIOCHEM, V110, P857, DOI 10.1002/jcb.22595; Schere-Levy C, 2003, EXP CELL RES, V282, P35, DOI 10.1006/excr.2002.5666; Schorr K, 1999, CANCER RES, V59, P2541; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Silver RB, 2004, P NATL ACAD SCI USA, V101, P13607, DOI 10.1073/pnas.0403208101; Sutherland KD, 2007, J MAMMARY GLAND BIOL, V12, P15, DOI 10.1007/s10911-007-9034-8; Tahmasebi M, 2006, BRIT J CANCER, V95, P67, DOI 10.1038/sj.bjc.6603213; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; Tybitanclova K, 2005, MOL CELL ENDOCRINOL, V244, P42, DOI 10.1016/j.mce.2005.01.015; Unger T, 2002, AM J CARDIOL, V89, p10A; Unger T, 2002, AM J CARDIOL, V89, p3A; VINSON GP, 1995, MOL MED TODAY, V1, P35, DOI 10.1016/1357-4310(95)80018-2; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Wang JM, 2003, J CARDIOVASC PHARM, V41, P593, DOI 10.1097/00005344-200304000-00012; Watson Christine J., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000196; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Yvan-Charvet L, 2011, KIDNEY INT, V79, P162, DOI 10.1038/ki.2010.391; Zampetaki A, 2005, AM J PHYSIOL-HEART C, V288, pH2946, DOI 10.1152/ajpheart.00919.2004; Zhang LP, 2005, ARTERIOSCL THROM VAS, V25, P1148, DOI 10.1161/01.ATV.0000164624.00099.e7; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330; Zhao YB, 2010, J CELL PHYSIOL, V225, P168, DOI 10.1002/jcp.22209; Zhou YB, 2005, J MOL CELL CARDIOL, V38, P693, DOI 10.1016/j.yjmcc.2005.02.009; Zhuo JL, 1998, J HYPERTENS, V16, P2027, DOI 10.1097/00004872-199816121-00026; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	59	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1982	1994		10.1096/fj.11-191932	http://dx.doi.org/10.1096/fj.11-191932			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22286690				2022-12-28	WOS:000303680800025
J	Begum, G; Stevens, A; Smith, EB; Connor, K; Challis, JRG; Bloomfield, F; White, A				Begum, Ghazala; Stevens, Adam; Smith, Emma Bolton; Connor, Kristin; Challis, John R. G.; Bloomfield, Frank; White, Anne			Epigenetic changes in fetal hypothalamic energy regulating pathways are associated with maternal undernutrition and twinning	FASEB JOURNAL			English	Article						proopiomelanocortin; glucocorticoid receptor; methylation analysis	THRIFTY PHENOTYPE HYPOTHESIS; PERICONCEPTIONAL UNDERNUTRITION; DNA METHYLATION; GENE-EXPRESSION; BIRTH-WEIGHT; GLUCOCORTICOID REGULATION; PROOPIOMELANOCORTIN GENE; CHROMATIN-STRUCTURE; ADRENAL AXIS; ADULT HEALTH	Undernutrition during pregnancy is implicated in the programming of offspring for the development of obesity and diabetes. We hypothesized that maternal programming causes epigenetic changes in fetal hypothalamic pathways regulating metabolism. This study used sheep to examine the effect of moderate maternal undernutrition (60 d before to 30 d after mating) and twinning to investigate changes in the key metabolic regulators proopiomelanocortin (POMC) and the glucocorticoid receptor (GR) in fetal hypothalami. Methylation of the fetal hypothalamic POMC promoter was reduced in underfed singleton, fed twin, and underfed twin groups (60, 73, and 63% decrease, respectively). This was associated with reduced DNA methyltransferase activity and altered histone methylation and acetylation. Methylation of the hypothalamic GR promoter was decreased in both twin groups and in maternally underfed singleton fetuses (52, 65, and 55% decrease, respectively). This correlated with changes in histone methylation and acetylation and increased GR mRNA expression in the maternally underfed singleton group. Alterations in GR were hypothalamic specific, with no changes in hippocampi. Unaltered levels of OCT4 promoter methylation indicated gene-specific effects. In conclusion, twinning and periconceptional undernutrition are associated with epigenetic changes in fetal hypothalamic POMC and GR genes, potentially resulting in altered energy balance regulation in the offspring.-Begum, G., Stevens, A., Smith, E. B., Connor, K., Challis, J. R. G., Bloomfield, F., White, A. Epigenetic changes in fetal hypothalamic energy regulating pathways are associated with maternal undernutrition and twinning. FASEB J. 26, 1694-1703 (2012). www.fasebj.org	[White, Anne] Univ Manchester, Fac Life Sci, Manchester Acad Hlth Sci Ctr, Manchester M13 9PT, Lancs, England; [Stevens, Adam; White, Anne] Univ Manchester, Fac Med & Human Sci, Dept Endocrinol & Diabet, Manchester M13 9PT, Lancs, England; [Bloomfield, Frank] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; [Bloomfield, Frank] Univ Auckland, Dept Paediat, Auckland, New Zealand; [Connor, Kristin; Bloomfield, Frank] Natl Res Ctr Growth & Dev, Auckland, New Zealand; [Connor, Kristin; Challis, John R. G.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	University of Manchester; University of Manchester; University of Auckland; University of Auckland; University of Auckland; University of Toronto	White, A (corresponding author), Univ Manchester, Fac Life Sci, Manchester Acad Hlth Sci Ctr, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	awhite@manchester.ac.uk	Stevens, Adam/AAB-6301-2020; Challis, John RG/E-7419-2014; Stevens, Adam/D-6476-2012; White, Anne/G-7717-2015	Stevens, Adam/0000-0002-1950-7325; Stevens, Adam/0000-0002-1950-7325; White, Anne/0000-0002-7686-2884; Bloomfield, Frank/0000-0001-6424-6577; Begum, Ghazala/0000-0002-8445-1815	UK National Institute of Health Research Manchester Biomedical Research Center; Health Research Council of New Zealand; New Zealand National Research Centre for Growth and Development; Canadian Institutes for Health Research	UK National Institute of Health Research Manchester Biomedical Research Center; Health Research Council of New Zealand(Health Research Council of New Zealand); New Zealand National Research Centre for Growth and Development; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	The study was supported by the UK National Institute of Health Research Manchester Biomedical Research Center, the Health Research Council of New Zealand, the New Zealand National Research Centre for Growth and Development, and the Canadian Institutes for Health Research (to J.R.G.C.). The authors also thank Ngapouri Research Station staff and Hui Hui Phua for technical assistance.	Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BEAULIEU S, 1988, MOL ENDOCRINOL, V2, P727, DOI 10.1210/mend-2-8-727; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; Buckler JMH, 2004, ANN HUM BIOL, V31, P311, DOI 10.1080/03014460410001670120; Coupe B, 2010, ENDOCRINOLOGY, V151, P702, DOI 10.1210/en.2009-0893; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; de Souza FSJ, 2005, MOL CELL BIOL, V25, P3076, DOI 10.1128/MCB.25.8.3076-3086.2005; Delahaye F, 2008, ENDOCRINOLOGY, V149, P470, DOI 10.1210/en.2007-1263; Dennis JH, 2007, GENOME RES, V17, P928, DOI 10.1101/gr.5636607; Edwards LJ, 2002, BIOL REPROD, V66, P1562, DOI 10.1095/biolreprod66.5.1562; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Geng CD, 2008, MOL ENDOCRINOL, V22, P2624, DOI 10.1210/me.2008-0157; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Gupta S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000134; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004; Ikenasio-Thorpe BA, 2007, J ENDOCRINOL, V193, P31, DOI 10.1677/joe.1.07017; Langlais D, 2011, MOL ENDOCRINOL, V25, P348, DOI 10.1210/me.2010-0422; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marino JS, 2011, TRENDS ENDOCRIN MET, V22, P275, DOI 10.1016/j.tem.2011.03.001; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Monrad RN, 2009, J CLIN ENDOCR METAB, V94, P2394, DOI 10.1210/jc.2008-1858; Muhlhausler BS, 2004, J NEUROENDOCRINOL, V16, P502, DOI 10.1111/j.1365-2826.2004.01197.x; Newell-Price J, 2003, J ENDOCRINOL, V177, P365, DOI 10.1677/joe.0.1770365; Ohlsson R, 2010, CHROMOSOMA, V119, P351, DOI 10.1007/s00412-010-0262-0; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; Poulsen P, 2009, DIABETES, V58, P1350, DOI 10.2337/db08-1714; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; Rumball CWH, 2008, J PHYSIOL-LONDON, V586, P1399, DOI 10.1113/jphysiol.2007.144071; Rumball CWH, 2009, PEDIATR RES, V66, P605, DOI 10.1203/PDR.0b013e3181bbde72; Schneider E, 2010, NUCLEIC ACIDS RES, V38, P3880, DOI 10.1093/nar/gkq126; Schwartz J, 1998, AM J PHYSIOL-REG I, V274, pR1, DOI 10.1152/ajpregu.1998.274.1.R1; Sebert SP, 2009, ENDOCRINOLOGY, V150, P634, DOI 10.1210/en.2008-0542; Stevens A, 2011, EUR J PHARMACOL, V660, P194, DOI 10.1016/j.ejphar.2010.10.111; Stevens A, 2010, ENDOCRINOLOGY, V151, P3652, DOI 10.1210/en.2010-0094; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Symonds ME, 2009, P NUTR SOC, V68, P173, DOI 10.1017/S0029665109001049; The NS, 2010, AM J EPIDEMIOL, V172, P549, DOI 10.1093/aje/kwq169; Todd SE, 2009, PEDIATR RES, V65, P409, DOI 10.1203/PDR.0b013e3181975efa; Turner BM, 2009, PHILOS T R SOC B, V364, P3403, DOI 10.1098/rstb.2009.0125; van Dommelen P, 2008, ACTA PAEDIATR, V97, P1099, DOI 10.1111/j.1651-2227.2008.00853.x; Wardlaw SL, 1998, NEUROENDOCRINOLOGY, V67, P51, DOI 10.1159/000054298; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Zakrzewska KE, 1999, ENDOCRINOLOGY, V140, P3183, DOI 10.1210/en.140.7.3183	54	85	87	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1694	1703		10.1096/fj.11-198762	http://dx.doi.org/10.1096/fj.11-198762			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223754	Green Published			2022-12-28	WOS:000302359700030
J	Yamashita, T; Fujimiya, M; Nagaishi, K; Ataka, K; Tanaka, M; Yoshida, H; Tsuchihashi, K; Shimamoto, K; Miura, T				Yamashita, Tomohisa; Fujimiya, Mineko; Nagaishi, Kanna; Ataka, Koji; Tanaka, Marenao; Yoshida, Hideaki; Tsuchihashi, Kazufumi; Shimamoto, Kazuaki; Miura, Tetsuji			Fusion of bone marrow-derived cells with renal tubules contributes to renal dysfunction in diabetic nephropathy	FASEB JOURNAL			English	Article						mice; TNF-alpha; streptozotocin; high-fat diet	MULTIPOTENT STROMAL CELLS; NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELLS; TNF-ALPHA; STEM-CELLS; ALBUMIN; GLOMERULI; PATHWAY; MICE; RATS	Although diabetic nephropathy (DN) is a major cause of end-stage renal disease, the mechanism of dysfunction has not yet been clarified. We previously reported that in diabetes proinsulin-producing bone marrow-derived cells (BMDCs) fuse with hepatocytes and neurons. Fusion cells are polyploidy and produce tumor necrosis factor (TNF)-alpha, ultimately causing diabetic complications. In this study, we assessed whether the same mechanism is involved in DN. We performed bone marrow transplantation from male GFP-Tg mice to female C57BL/6J mice and produced diabetes by streptozotocin (STZ) or a high-fat diet. In diabetic kidneys, massive infiltration of BMDCs and tubulointerstitial injury were prominent. BMDCs and damaged tubular epithelial cells were positively stained with proinsulin and TNF-alpha. Cell fusion between BMDCs and renal tubules was confirmed by the presence of Y chromosome. Of tubular epithelial cells, 15.4% contain Y chromosomes in STZ-diabetic mice, 8.6% in HFD-diabetic mice, but only 1.5% in nondiabetic mice. Fusion cells primarily expressed TNF-alpha and caspase-3 in diabetic kidney. These in vivo findings were confirmed by in vitro coculture experiments between isolated renal tubular cells and BMDCs. It was concluded that cell fusion between BMDCs and renal tubular epithelial cells plays a crucial role in DN.-Yamashita, T. Fujimiya, M., Nagaishi, K., Ataka, K., Tanaka, M., Yoshida, H., Tsuchihashi, K., Shimamoto, K., Miura, T. Fusion of bone marrow-derived cells with renal tubules contributes to renal dysfunction in diabetic nephropathy. FASEB J. 26, 1559-1568 (2012). www.fasebj.org	[Fujimiya, Mineko; Nagaishi, Kanna; Ataka, Koji] Sapporo Med Univ, Sch Med, Dept Anat 2, Sapporo, Hokkaido 0608543, Japan; [Yamashita, Tomohisa; Tanaka, Marenao; Yoshida, Hideaki; Tsuchihashi, Kazufumi; Shimamoto, Kazuaki; Miura, Tetsuji] Sapporo Med Univ, Sch Med, Dept Internal Med 2, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University; Sapporo Medical University	Fujimiya, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Anat 2, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	fujimiya@sapmed.ac.jp	Yamashita, Tomohisa/AAU-9554-2020; Marenao, Tanaka/ABA-4054-2020	Yamashita, Tomohisa/0000-0001-9808-7623; Ataka, Koji/0000-0002-2572-5572; Tanaka, Marenao/0000-0002-6575-9996	Ministry of Education, Culture, Sports, Science, and Technology, Japan [21390054]; Akiyama Life Science Foundation	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Akiyama Life Science Foundation	The authors are thankful for the help of Dr. Sugaya (CIMIC Co., Ltd., Tokyo, Japan) in mProx24 cell culture and for technical assistance of Ms. Asami Ogawa. This work was supported by a Grant-in-Aid for Scientific Research 21390054 (to M. F.) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan and by Akiyama Life Science Foundation (to M.F.).	Birn H, 2006, KIDNEY INT, V69, P440, DOI 10.1038/sj.ki.5000141; BOHLE A, 1991, PATHOL RES PRACT, V187, P251; Camargo FD, 2004, J CLIN INVEST, V113, P1266, DOI 10.1172/JCI200421301; Cameron NE, 2008, CURR DRUG TARGETS, V9, P60, DOI 10.2174/138945008783431718; Christensen EI, 2009, PFLUG ARCH EUR J PHY, V458, P1039, DOI 10.1007/s00424-009-0685-8; Curril IM, 2010, FASEB J, V24, P4856, DOI 10.1096/fj.09-152991; Dong X, 2007, KIDNEY INT, V71, P619, DOI 10.1038/sj.ki.5002132; Ezquer F, 2009, BIOL BLOOD MARROW TR, V15, P1354, DOI 10.1016/j.bbmt.2009.07.022; Fujimiya M, 2007, P NATL ACAD SCI USA, V104, P4030, DOI 10.1073/pnas.0700220104; Guo GJ, 1999, AM J PHYSIOL-RENAL, V277, pF766, DOI 10.1152/ajprenal.1999.277.5.F766; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Hills CE, 2010, AM J NEPHROL, V31, P68, DOI 10.1159/000256659; Jefferson JA, 2008, KIDNEY INT, V74, P22, DOI 10.1038/ki.2008.128; JEVNIKAR AM, 1991, KIDNEY INT, V40, P203, DOI 10.1038/ki.1991.201; Joussen AM, 2009, MOL VIS, V15, P1418; Kalantarinia K, 2003, KIDNEY INT, V64, P1208, DOI 10.1046/j.1523-1755.2003.00237.x; Kamijo A, 2002, KIDNEY INT, V62, P1628, DOI 10.1046/j.1523-1755.2002.00618.x; Kojima H, 2004, P NATL ACAD SCI USA, V101, P2458, DOI 10.1073/pnas.0308690100; Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103; Li L, 2007, J AM SOC NEPHROL, V18, P3067, DOI 10.1681/ASN.2007030284; Meldrum KK, 2007, AM J PHYSIOL-REG I, V292, pR1456, DOI 10.1152/ajpregu.00620.2005; Munusamy S, 2009, FREE RADICAL BIO MED, V46, P1149, DOI 10.1016/j.freeradbiomed.2009.01.022; NAKAMURA T, 1993, DIABETES, V42, P450, DOI 10.2337/diabetes.42.3.450; Navarro-Gonzalez JF, 2008, J AM SOC NEPHROL, V19, P433, DOI 10.1681/ASN.2007091048; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Peti-Peterdi J, 2009, AM J PHYSIOL-RENAL, V296, pF1255, DOI 10.1152/ajprenal.00144.2009; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Russo LM, 2009, J AM SOC NEPHROL, V20, P489, DOI 10.1681/ASN.2008050503; Saito A, 2005, NEPHROLOGY, V10, pS26, DOI 10.1111/j.1440-1797.2005.00453.x; Satoh Jo, 2003, Exp Diabesity Res, V4, P65, DOI 10.1155/EDR.2003.65; Striker G E, 1970, Hum Pathol, V1, P615, DOI 10.1016/S0046-8177(70)80060-0; Sugimoto H, 1999, DIABETOLOGIA, V42, P878, DOI 10.1007/s001250051241; Takaya K, 2003, AM J PHYSIOL-RENAL, V284, pF1037, DOI 10.1152/ajprenal.00230.2002; Tanaka M, 2008, INFLAMM RES, V57, P593, DOI 10.1007/s00011-008-7171-1; Tanner GA, 2009, AM J PHYSIOL-RENAL, V296, pF1258, DOI 10.1152/ajprenal.90638.2008; Terashima T, 2005, P NATL ACAD SCI USA, V102, P12525, DOI 10.1073/pnas.0505717102; U.S. Renal Data System, 2010, ANN DAT REP 2010; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Zhang B, 2007, KIDNEY INT, V72, P37, DOI 10.1038/sj.ki.5002242; Zheng F, 2004, DIABETES, V53, P2420, DOI 10.2337/diabetes.53.9.2420; Zhou H, 2009, CHINESE MED J-PEKING, V122, P2573, DOI 10.3760/cma.j.issn.0366-6999.2009.21.009	42	15	17	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1559	1568		10.1096/fj.11-183194	http://dx.doi.org/10.1096/fj.11-183194			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198389				2022-12-28	WOS:000302359700018
J	Kaliappan, K; Choudhury, NR; Suyal, G; Mukherjee, SK				Kaliappan, Kosalai; Choudhury, Nirupam Roy; Suyal, Geetika; Mukherjee, Sunil Kumar			A novel role for RAD54: this host protein modulates geminiviral DNA replication	FASEB JOURNAL			English	Article						electron microscopy; RAD54; rolling circle; yeast nuclear extract	YELLOW MOSAIC-VIRUS; MODEL SYSTEM; SACCHAROMYCES-CEREVISIAE; ROLLING-CIRCLE; REP PROTEIN; HOMOLOGOUS RECOMBINATION; PLANT-CELLS; ARABIDOPSIS-THALIANA; VIRAL-DNA; YEAST	Geminiviruses primarily encode only few factors, such as replication initiator protein (Rep), and need various host cellular machineries for rolling-circle replication (RCR) and/or recombination-dependent replication (RDR). We have identified a host factor, RAD54, in a screen for Repinteracting partners and observed its role in DNA replication of the geminivirus mungbean yellow mosaic India virus (MYMIV). We identified the interacting domains ScRAD54 and MYMIV-Rep and observed that ScRAD54 enhanced MYMIV-Rep nicking, ATPase, and helicase activities. An in vitro replication assay demonstrated that the geminiviral DNA replication reaction depends on the viral Rep protein, viral origin of replication sequences, and host cellcycle proteins. Rad54-deficient yeast nuclear extract did not support in vitro viral DNA replication, while exogenous addition of the purified ScRAD54 protein enhanced replication. The role of RAD54 in in planta replication was confirmed by the transient replication assay; i.e., agroinoculation studies. RAD54 is a well-known recombination/repair protein that uses its DNA-dependent ATPase activity in conjunction with several other host factors. However, this study demonstrates for the first time that the eukaryotic rolling-circle replicon depends on the RAD54 protein.-Kaliappan, K., Choudhury, N. R., Suyal, G., Mukherjee, S. K. A novel role for RAD54: this host protein modulates geminiviral DNA replication. FASEB J. 26, 1142-1160 (2012). www.fasebj.org	[Kaliappan, Kosalai; Choudhury, Nirupam Roy; Suyal, Geetika; Mukherjee, Sunil Kumar] Int Ctr Genet Engn & Biotechnol, Plant Mol Biol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Mukherjee, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Plant Mol Biol Grp, Aruna Asaf Ali Marg, New Delhi 110067, India.	sunilm@icgeb.res.in			Council of Scientific and Industrial Research (New Delhi, India); Department of Biotechnology (Ministry of Science and Technology, New Delhi, India); UMDNJ	Council of Scientific and Industrial Research (New Delhi, India)(Council of Scientific & Industrial Research (CSIR) - India); Department of Biotechnology (Ministry of Science and Technology, New Delhi, India)(Department of Biotechnology (DBT) India); UMDNJ	The authors thank Dr. Tom Ellenberger (Harvard Medical School, Boston, MA, USA) and Dr. Patrick Sung (Yale University, New Haven, CT, USA) for the Rad54 constructs. The assistance of Dr. Ashish Nandi and Mr. Swadhin Swain (Jawaharlal Nehru University, New Delhi, India) in the Arabidopsis work is greatly appreciated. The authors thank Dr. Subhasis Biswas [University of Medicine and Dentistry of New Jersey (UMDNJ), Stratford, NJ, USA] for his help and the space he provided for the in vitro replication experiments. The authors thank Mr. Rajeev Mishra (Banaras Hindu University, Varanasi, India), Mr. Somyadeep Nandi (Jawaharlal Nehru University) and Dr. Esther E. Biswas (Thomas Jefferson University, Philadelphia, PA, USA) for their assistance and help. This work was partly supported by the Council of Scientific and Industrial Research (New Delhi, India), the Department of Biotechnology (Ministry of Science and Technology, New Delhi, India), and UMDNJ, through research fellowships to K. K.	Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Ahlquist P, 2006, NAT REV MICROBIOL, V4, P371, DOI 10.1038/nrmicro1389; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Alves-Rodrigues I, 2006, VIRUS RES, V120, P49, DOI 10.1016/j.virusres.2005.11.018; Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Arguello-Astorga G, 2004, J VIROL, V78, P4817, DOI 10.1128/JVI.78.9.4817-4826.2004; Ascencio-Ibanez JT, 2008, PLANT PHYSIOL, V148, P436, DOI 10.1104/pp.108.121038; Bagewadi B, 2004, J VIROL, V78, P11890, DOI 10.1128/JVI.78.21.11890-11903.2004; Bass HW, 2000, J CELL SCI, V113, P1149; Bisaro D. M., 1994, Homologous recombination and gene silencing in plants., P39; Castillo AG, 2004, J VIROL, V78, P2758, DOI 10.1128/JVI.78.6.2758-2769.2004; Choudhury NR, 2006, NUCLEIC ACIDS RES, V34, P6362, DOI 10.1093/nar/gkl903; COELLO P, 1992, PLANT MOL BIOL, V20, P1159, DOI 10.1007/BF00028902; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gutierrez C, 2000, EMBO J, V19, P792, DOI 10.1093/emboj/19.5.792; Hanley-Bowdoin L, 2000, CRIT REV BIOCHEM MOL, V35, P105; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; James P, 1996, GENETICS, V144, P1425; Jeske H, 2001, EMBO J, V20, P6158, DOI 10.1093/emboj/20.21.6158; Klutstein M, 2008, GENETICS, V178, P2389, DOI 10.1534/genetics.108.086777; Kong LJ, 2000, EMBO J, V19, P3485, DOI 10.1093/emboj/19.13.3485; Kong LJ, 2002, PLANT CELL, V14, P1817, DOI 10.1105/tpc.003681; Longo VD, 2002, CELL MOL LIFE SCI, V59, P903, DOI 10.1007/s00018-002-8477-8; Luque A, 2002, VIROLOGY, V302, P83, DOI 10.1006/viro.2002.1599; Mansoor S, 2003, TRENDS PLANT SCI, V8, P128, DOI 10.1016/S1360-1385(03)00007-4; Matulova P, 2009, J BIOL CHEM, V284, P7733, DOI 10.1074/jbc.M806192200; Mitkova AV, 2005, J BIOL CHEM, V280, P6285, DOI 10.1074/jbc.M410129200; NAGAR S, 1995, PLANT CELL, V7, P705, DOI 10.1105/tpc.7.6.705; Nagy PD, 2008, ANNU REV PHYTOPATHOL, V46, P217, DOI 10.1146/annurev.phyto.121407.093958; Osakabe K, 2006, PLANT J, V48, P827, DOI 10.1111/j.1365-313X.2006.02927.x; Pandey P, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-152; Pant V, 2001, J GEN VIROL, V82, P2559, DOI 10.1099/0022-1317-82-10-2559; Perego P, 2000, PHARMACOL REV, V52, P477; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Raghavan V, 2004, J VIROL, V78, P2405, DOI 10.1128/JVI.78.5.2405-2413.2004; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Raschle M, 2004, J BIOL CHEM, V279, P51973, DOI 10.1074/jbc.M410101200; Replansky T, 2008, TRENDS ECOL EVOL, V23, P494, DOI 10.1016/j.tree.2008.05.005; RUSHING AE, 1987, PHYTOPATHOLOGY, V77, P1231, DOI 10.1094/Phyto-77-1231; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; Shaked H, 2005, P NATL ACAD SCI USA, V102, P12265, DOI 10.1073/pnas.0502601102; Siggers KA, 2008, CELL HOST MICROBE, V4, P8, DOI 10.1016/j.chom.2008.06.004; Simon JA, 2004, NAT REV CANCER, V4, P481, DOI 10.1038/nrc1372; Singh D. K., 2007, COMMUNICATING CURREN, P155; Singh DK, 2008, VIROLOGY, V380, P75, DOI 10.1016/j.virol.2008.07.010; Singh DK, 2007, NUCLEIC ACIDS RES, V35, P755, DOI 10.1093/nar/gkl1088; STANLEY J, 1995, VIROLOGY, V206, P707, DOI 10.1016/S0042-6822(95)80093-X; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Tittel-Elmer M, 2009, EMBO J, V28, P1142, DOI 10.1038/emboj.2009.60; Urena DE, 2011, J MOL BIOL, V405, P77, DOI 10.1016/j.jmb.2010.10.042; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; XIE Q, 1995, EMBO J, V14, P4073, DOI 10.1002/j.1460-2075.1995.tb00079.x; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	64	22	27	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1142	1160		10.1096/fj.11-188508	http://dx.doi.org/10.1096/fj.11-188508			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22171001				2022-12-28	WOS:000300949300018
J	Klymiuk, N; Bocker, W; Schonitzer, V; Bahr, A; Radic, T; Frohlich, T; Wunsch, A; Kessler, B; Kurome, M; Schilling, E; Herbach, N; Wanke, R; Nagashima, H; Mutschler, W; Arnold, GJ; Schwinzer, R; Schieker, M; Wolf, E				Klymiuk, Nikolai; Boecker, Wolfgang; Schoenitzer, Veronika; Baehr, Andrea; Radic, Tamara; Froehlich, Thomas; Wuensch, Annegret; Kessler, Barbara; Kurome, Mayuko; Schilling, Eleonore; Herbach, Nadja; Wanke, Ruediger; Nagashima, Hiroshi; Mutschler, Wolf; Arnold, Georg J.; Schwinzer, Reinhard; Schieker, Matthias; Wolf, Eckhard			First inducible transgene expression in porcine large animal models	FASEB JOURNAL			English	Article						tet-on system; RANKL; CTLA-4Ig	OSTEOCLAST DIFFERENTIATION; CELLS; PIGS; OSTEOPROTEGERIN; INTERFERENCE; DISRUPTION; LIGAND; WOMEN; BONE; MICE	The purpose of this study was to establish inducible transgene expression in pigs, a model organism with great promise for experimental physiology and translational medicine, using the binary tet-on system. This expression system is activated by doxycycline (dox) via the tet-controlled transactivator (TA). Binding of TA to the transactivator response element (TRE) results in transcription of downstream genes. First, we cloned transgenic founder pigs expressing TA under the control of the CMV enhancer/chicken beta-actin promoter (CAG). Then, cells from CAG-TA transgenic founders were nucleofected with TRE-controlled expression vectors for either porcine cytotoxic T-lymphocyte associated antigen 4-Fc domain of immunoglobulin G1 (CTLA-4Ig) or soluble receptor activator of NF-kappa B ligand (RANKL), and double-transgenic offspring were cloned. Dox administration resulted in a dose-dependent increase in expression of CTLA-4Ig or RANKL, in nucleofected cells and in transgenic pigs, while in the absence of dox, the levels of both proteins were below the detection limit. Inducible transgene expression was reproduced in double-transgenic offspring generated by cloning or breeding. Our strategy revealed the first two examples of inducible transgene expression in pigs. The CAG-TA transgenic pigs generated in this study constitute an interesting basis for future pig models with inducible transgene expression.- Klymiuk, N., Bocker, W., Schonitzer, V., Bahr, A., Radic, T., Frohlich, T., Wunsch, A., Kessler, B., Kurome, M., Schilling, E., Herbach, N., Wanke, R., Nagashima, H., Mutschler, W., Arnold, G. J., Schwinzer, R., Schieker, M., Wolf, E. First inducible transgene expression in porcine large animal models. FASEB J. 26, 1086-1099 (2012). www.fasebj.org	[Klymiuk, Nikolai; Baehr, Andrea; Wuensch, Annegret; Kessler, Barbara; Kurome, Mayuko; Schilling, Eleonore; Wolf, Eckhard] Univ Munich, Chair Mol Anim Breeding & Biotechnol, Munich, Germany; [Klymiuk, Nikolai; Froehlich, Thomas; Arnold, Georg J.; Wolf, Eckhard] Univ Munich, Lab Funct Genome Anal LAFUGA, Gene Ctr, Munich, Germany; [Boecker, Wolfgang; Schoenitzer, Veronika; Radic, Tamara; Mutschler, Wolf; Schieker, Matthias] Univ Munich, Klinikum Innenstadt, Dept Surg, D-8000 Munich, Germany; [Herbach, Nadja; Wanke, Ruediger] Univ Munich, Inst Vet Pathol, Munich, Germany; [Nagashima, Hiroshi] Meiji Univ, Sch Agr, Dept Life Sci, Lab Dev Engn, Kawasaki, Kanagawa, Japan; [Schwinzer, Reinhard] Hannover Med Sch, Transplant Lab, D-30623 Hannover, Germany	University of Munich; University of Munich; University of Munich; University of Munich; Meiji University; Hannover Medical School	Wolf, E (corresponding author), Ludwig Maximilians Univ Munchen, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.	ewolf@lmb.uni-muenchen.de	Fröhlich, Thomas/C-6735-2011; Klymiuk, Nikolai/AAB-8345-2022; Schieker, Matthias/AGZ-2030-2022; Schieker, Matthias/J-6511-2015	Fröhlich, Thomas/0000-0002-4709-3211; Klymiuk, Nikolai/0000-0003-3532-1659; Schieker, Matthias/0000-0002-1230-3653; Schieker, Matthias/0000-0002-1230-3653; Nagashima, Hiroshi/0000-0001-9940-8783; Herbach, Nadja/0000-0001-5893-0356; Wolf, Eckhard/0000-0002-0430-9510; Wanke, Rudiger/0000-0002-0153-224X	Deutsche Forschungsgemeinschaft [FOR 535, FOR 793]; Bayerische Forschungsstiftung (FORZebRA); Bundesministerium fur Bildung und Forschung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bayerische Forschungsstiftung (FORZebRA); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	The authors thank Wiebke Baars, Miwako Kosters, Christian Erdle, and Sigfried Elsner for competent technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft (FOR 535, Xenotransplantation; FOR 793, Mechanisms of Fracture Healing in Osteoporosis), the Bayerische Forschungsstiftung (FORZebRA), and the Bundesministerium fur Bildung und Forschung (Leading Edge Cluster Munich: m<SUP>4</SUP>, Personalized Medicine and Targeted Therapies).	Aigner B, 2010, J MOL MED, V88, P653, DOI 10.1007/s00109-010-0610-9; Besenfelder U, 1997, THERIOGENOLOGY, V47, P1051, DOI 10.1016/S0093-691X(97)00062-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000053299; Frohlich T, 2011, METHODS MOL BIOL, V790, P141, DOI 10.1007/978-1-61779-319-6_11; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716; Kues WA, 2006, FASEB J, V20, P1200, DOI 10.1096/fj.05-5415fje; Kulkarni RN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001027; Kurome M, 2006, TRANSGENIC RES, V15, P229, DOI 10.1007/s11248-006-0004-5; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Meier C, 2006, CLIN LAB, V52, P1; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Pearce AI, 2007, EUR CELLS MATER, V13, P1; Phelps CJ, 2009, XENOTRANSPLANTATION, V16, P477, DOI 10.1111/j.1399-3089.2009.00533.x; Plege A, 2009, TRANSPLANTATION, V87, P975, DOI 10.1097/TP.0b013e31819c85e8; Renner S, 2010, DIABETES, V59, P1228, DOI 10.2337/db09-0519; Rogers CS, 2008, SCIENCE, V321, P1837, DOI 10.1126/science.1163600; Saunders TL, 2011, METHODS MOL BIOL, V693, P103, DOI 10.1007/978-1-60761-974-1_7; Shearwin KE, 2005, TRENDS GENET, V21, P339, DOI 10.1016/j.tig.2005.04.009; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uemura H, 2008, J ENDOCRINOL INVEST, V31, P163, DOI 10.1007/BF03345584; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wine JJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001130; Yin XJ, 2002, BIOL REPROD, V67, P442, DOI 10.1095/biolreprod67.2.442	30	44	47	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1086	1099		10.1096/fj.11-185041	http://dx.doi.org/10.1096/fj.11-185041			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22138035	Bronze			2022-12-28	WOS:000300949300013
J	Reed, SA; Sandesara, PB; Senf, SM; Judge, AR				Reed, Sarah A.; Sandesara, Pooja B.; Senf, Sarah M.; Judge, Andrew R.			Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy	FASEB JOURNAL			English	Article						cancer; sepsis; satellite cells; myostatin; protein synthesis	MOUSE SKELETAL-MUSCLE; NF-KAPPA-B; CANCER CACHEXIA; GENE-EXPRESSION; WEIGHT-LOSS; PROTEIN-DEGRADATION; UBIQUITIN LIGASES; SATELLITE CELLS; MESSENGER-RNA; SEPSIS	Cachexia is characterized by inexorable muscle wasting that significantly affects patient prognosis and increases mortality. Therefore, understanding the molecular basis of this muscle wasting is of significant importance. Recent work showed that components of the forkhead box O (FoxO) pathway are increased in skeletal muscle during cachexia. In the current study, we tested the physiological significance of FoxO activation in the progression of muscle atrophy associated with cachexia. FoxO-DNA binding dependent transcription was blocked in the muscles of mice through injection of a dominant negative (DN) FoxO expression plasmid prior to inoculation with Lewis lung carcinoma cells or the induction of sepsis. Expression of DN FoxO inhibited the increased mRNA levels of atrogin-1, MuRF1, cathepsin L, and/or Bnip3 and inhibited muscle fiber atrophy during cancer cachexia and sepsis. Interestingly, during control conditions, expression of DN FoxO decreased myostatin expression, increased MyoD expression and satellite cell proliferation, and induced fiber hypertrophy, which required de novo protein synthesis. Collectively, these data show that FoxO-DNA binding-dependent transcription is necessary for normal muscle fiber atrophy during cancer cachexia and sepsis, and further suggest that basal levels of FoxO play an important role during normal conditions to depress satellite cell activation and limit muscle growth.-Reed, S. A., Sandesara, P. B., Senf, S. F., Judge, A. R. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 26, 987-1000 (2012). www.fasebj.org	[Reed, Sarah A.; Sandesara, Pooja B.; Judge, Andrew R.] Univ Florida, Dept Phys Therapy, Gainesville, FL 32611 USA; [Senf, Sarah M.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Judge, AR (corresponding author), Univ Florida, Dept Phys Therapy, 101 S Newell Dr, Gainesville, FL 32611 USA.	arjudge@phhp.ufl.edu		Judge, Sarah/0000-0002-3974-0247; Reed, Sarah A/0000-0002-9961-6280	Bankhead Coley Cancer Research Program [09BN-09]; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases [R03AR056418, R01AR060209]; U.S. National Institute of Child Health and Human Development [T32-HD-043730]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043730] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR056418, R01AR060209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	Bankhead Coley Cancer Research Program; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by Bankhead Coley Cancer Research Program grant 09BN-09, and U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases grants R03AR056418 and R01AR060209 (to A.R.J.). S. M. S. is supported by U.S. National Institute of Child Health and Human Development grant T32-HD-043730.	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Alamdari N, 2010, AM J PHYSIOL-REG I, V299, pR509, DOI 10.1152/ajpregu.00858.2009; Allen DL, 2007, AM J PHYSIOL-CELL PH, V292, pC188, DOI 10.1152/ajpcell.00542.2005; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Asp ML, 2010, INT J CANCER, V126, P756, DOI 10.1002/ijc.24784; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; COSTELLI P, 1993, J CLIN INVEST, V92, P2783, DOI 10.1172/JCI116897; Crossland H, 2008, J PHYSIOL-LONDON, V586, P5589, DOI 10.1113/jphysiol.2008.160150; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Durieux AC, 2007, ENDOCRINOLOGY, V148, P3140, DOI 10.1210/en.2006-1500; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Fareed MU, 2006, AM J PHYSIOL-REG I, V290, pR1589, DOI 10.1152/ajpregu.00668.2005; Favier FB, 2008, PFLUG ARCH EUR J PHY, V456, P587, DOI 10.1007/s00424-007-0423-z; Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033; Fearon KC, 2006, AM J CLIN NUTR, V83, P1345, DOI 10.1093/ajcn/83.6.1345; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fortunati N, 2007, ONCOL REP, V18, P1521; Frost RA, 2007, AM J PHYSIOL-ENDOC M, V292, pE501, DOI 10.1152/ajpendo.00359.2006; HALLANGERAS M, 1990, SURGERY, V108, P460; HARVEY KB, 1979, CANCER, V43, P2065, DOI 10.1002/1097-0142(197905)43:5+<2065::AID-CNCR2820430714>3.0.CO;2-1; Hasselgren PO, 2005, INT J BIOCHEM CELL B, V37, P2156, DOI 10.1016/j.biocel.2005.01.017; HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Krzystek-Korpacka M, 2007, CLIN BIOCHEM, V40, P1353, DOI 10.1016/j.clinbiochem.2007.07.013; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Li P, 2007, AM J PATHOL, V170, P599, DOI 10.2353/ajpath.2007.060505; Lipina C, 2010, FEBS LETT, V584, P2403, DOI 10.1016/j.febslet.2010.04.039; Liu CM, 2007, CANCER GENE THER, V14, P945, DOI 10.1038/sj.cgt.7701091; Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; MATTHYS P, 1991, EUR J CANCER, V27, P182, DOI 10.1016/0277-5379(91)90483-T; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Menconi MJ, 2010, AM J PHYSIOL-ENDOC M, V299, pE533, DOI 10.1152/ajpendo.00596.2009; Minnaard R, 2005, MUSCLE NERVE, V31, P339, DOI 10.1002/mus.20268; Moylan JS, 2008, AM J PHYSIOL-CELL PH, V295, pC986, DOI 10.1152/ajpcell.00041.2008; Murton AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006945; Nystrom GJ, 2008, INT J CLIN EXP MED, V1, P50; Opal SM, 2010, CONTRIB NEPHROL, V167, P14, DOI 10.1159/000315915; Penner CG, 2001, BIOCHEM BIOPH RES CO, V281, P1331, DOI 10.1006/bbrc.2001.4497; Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Poylin V, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/317851; Reed SA, 2011, BIOCHEM BIOPH RES CO, V405, P491, DOI 10.1016/j.bbrc.2011.01.059; Ross PJ, 2004, BRIT J CANCER, V90, P1905, DOI 10.1038/sj.bjc.6601781; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sartori R, 2009, AM J PHYSIOL-CELL PH, V296, pC1248, DOI 10.1152/ajpcell.00104.2009; Schertzer JD, 2006, MOL THER, V13, P795, DOI 10.1016/j.ymthe.2005.09.019; Schertzer Jonathan D., 2008, V433, P115, DOI 10.1007/978-1-59745-237-3_7; Schmitt TL, 2007, J MOL MED, V85, P647, DOI 10.1007/s00109-007-0177-2; Schulze PC, 2005, CIRC RES, V97, P418, DOI 10.1161/01.RES.0000179580.72375.c2; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163; Senf SM, 2010, AM J PHYSIOL-CELL PH, V298, pC38, DOI 10.1152/ajpcell.00315.2009; Smith IJ, 2010, INT J BIOCHEM CELL B, V42, P701, DOI 10.1016/j.biocel.2010.01.006; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; VAUGHAN GM, 1982, J TRAUMA, V22, P263, DOI 10.1097/00005373-198204000-00001; Vigano A, 2000, ARCH INTERN MED, V160, P861, DOI 10.1001/archinte.160.6.861; Waddell DS, 2008, AM J PHYSIOL-ENDOC M, V295, pE785, DOI 10.1152/ajpendo.00646.2007; Wang AYM, 2004, J AM SOC NEPHROL, V15, P3134, DOI 10.1097/01.ASN.0000144206.29951.B2; Welle S, 2011, AM J PHYSIOL-ENDOC M, V300, pE993, DOI 10.1152/ajpendo.00509.2010; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Wu AL, 2008, ENDOCRINOLOGY, V149, P1407, DOI 10.1210/en.2007-1470; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226; Yamazaki Y, 2010, BIOCHEM J, V427, P171, DOI 10.1042/BJ20091346; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	78	140	146	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					987	1000		10.1096/fj.11-189977	http://dx.doi.org/10.1096/fj.11-189977			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22102632	Green Published			2022-12-28	WOS:000300949300004
J	Radulescu, AE; Shields, D				Radulescu, Andreea E.; Shields, Dennis			Clathrin is required for postmitotic Golgi reassembly	FASEB JOURNAL			English	Article						mitosis; remodeling; spindle poles; centrosome	VESICLE-TETHERING PROTEIN; CELL-FREE SYSTEM; PLASMA-MEMBRANE; MITOTIC SPINDLE; APPARATUS; CYTOKINESIS; MITOSIS; ORGANIZATION; INHERITANCE; BIOGENESIS	During the G2-M transition, the highly organized Golgi apparatus undergoes reversible fragmentation through unstacking of the cisternal ribbon and disassembly into radially dispersed vesicles and tubules. These Golgi-derived fragments redistribute randomly within the cytoplasm, partition stochastically, and in telophase coalesce to generate a functionally and structurally intact Golgi complex. Here we identified a novel step in postmitotic Golgi reassembly that requires the clathrin heavy chain (CHC). We used siRNA-mediated CHC knockdown, biochemistry, and morphological analysis and showed that the spindle-and spindle pole-associated clathrin pools are membrane-bound and required for postmitotic Golgi reassembly. The results presented here show that clathrin remains associated with the spindle poles throughout mitosis and that this clathrin pool is distinct from the previously characterized spindle-associated population. We suggest that clathrin may provide a template for postmitotic Golgi reassembly and cisternal remodeling. In absence of the CHC, the Golgi apparatus remained disconnected and disordered and failed to regain its characteristic perinuclear, lace-like morphology. Our findings build on previous independent reports that clathrin is required for Golgi reassembly following disruption with pharmacological agents and for mitotic chromosome congression.-Radulescu, A. E., Shields, D. Clathrin is required for postmitotic Golgi reassembly. FASEB J. 26, 129-136 (2012). www.fasebj.org	[Radulescu, Andreea E.; Shields, Dennis] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA; [Shields, Dennis] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Radulescu, AE (corresponding author), 1300 Morris Pk Ave,Chanin 505, Bronx, NY 10461 USA.	aradulescu@ucsd.edu			U.S. National Institutes of Health [DK21860]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This article is dedicated to the memory of Dr. Dennis Shields (1948-2008). The authors thank Drs. Silvia Corvera (University of Massachusetts Medical School, Worcester, MA, USA), Yanzhuang Wang (University of Michigan, Ann Arbor, MI, USA), and Sylvie Urbe (University of Liverpool, School of Biomedical Sciences, Liverpool, UK) for very generous gifts of antibodies and Dr. James Keen (Thomas Jefferson University, Philadelphia, PA, USA) for the CLCdsRed plasmid. The authors thank Dr. Shaeri Mukherjee for helpful suggestions with the manuscript. This work was supported by U.S. National Institutes of Health grant DK21860 to D.S.	Bard F, 2006, ANNU REV CELL DEV BI, V22, P439, DOI 10.1146/annurev.cellbio.21.012704.133126; Blomberg-Wirschell M, 1998, METHOD ENZYMOL, V298, P228, DOI 10.1016/S0076-6879(98)98022-3; Booth D. G., EMBO J, V30, P906; Borlido J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003115; Boucrot E, 2007, P NATL ACAD SCI USA, V104, P7939, DOI 10.1073/pnas.0702511104; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Gerald NJ, 2001, CELL MOTIL CYTOSKEL, V48, P213, DOI 10.1002/1097-0169(200103)48:3<213::AID-CM1010>3.0.CO;2-V; Guo YS, 2008, MOL BIOL CELL, V19, P2830, DOI 10.1091/mbc.E07-12-1236; Jiang S, 2006, MOL BIOL CELL, V17, P4105, DOI 10.1091/mbc.E05-12-1112; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; KURIYAMA R, 1984, J CELL SCI, V66, P265; Lehtonen S, 2008, MOL BIOL CELL, V19, P2949, DOI 10.1091/mbc.E07-05-0521; Liu ZH, 2009, J CELL BIOL, V186, P473, DOI 10.1083/jcb.200902071; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Lowe M, 2007, NAT REV MOL CELL BIO, V8, P429, DOI 10.1038/nrm2179; MARO B, 1985, J EMBRYOL EXP MORPH, V90, P287; Marra P, 2007, MOL BIOL CELL, V18, P1595, DOI 10.1091/mbc.E06-10-0886; McNiven MA, 2006, SCIENCE, V313, P1591, DOI 10.1126/science.1118133; Misteli T, 1996, FEBS LETT, V389, P66, DOI 10.1016/0014-5793(96)00518-2; Morita E., P NATL ACAD SCI US, V107, P12889; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Okamoto CT, 2000, AM J PHYSIOL-CELL PH, V279, pC369, DOI 10.1152/ajpcell.2000.279.2.C369; Puri S, 2004, J CELL SCI, V117, P451, DOI 10.1242/jcs.00863; Puthenveedu MA, 2006, NAT CELL BIOL, V8, P238, DOI 10.1038/ncb1366; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Radulescu AE, 2007, MOL BIOL CELL, V18, P94, DOI 10.1091/mbc.E06-06-0532; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; Shimizu H, 2009, J CELL SCI, V122, P3145, DOI 10.1242/jcs.052795; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Warner AK, 2006, TRAFFIC, V7, P205, DOI 10.1111/j.1600-0854.2005.00377.x; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162	42	7	7	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					129	136		10.1096/fj.10-167684	http://dx.doi.org/10.1096/fj.10-167684			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965600	Green Published			2022-12-28	WOS:000299202200014
J	Szabo, ER; Cservenak, M; Dobolyi, A				Szabo, Eva Rebeka; Cservenak, Melinda; Dobolyi, Arpad			Amylin is a novel neuropeptide with potential maternal functions in the rat	FASEB JOURNAL			English	Article						preoptic area; hypothalamus; postpartum mother; peptide expression	MEDIAL PREOPTIC AREA; AMYLOID POLYPEPTIDE AMYLIN; GENE-RELATED PEPTIDE; TUBEROINFUNDIBULAR PEPTIDE; STRIA TERMINALIS; BRAIN-REGIONS; BED NUCLEUS; 39 RESIDUES; C-FOS; BEHAVIOR	Amylin, a 37-aa pancreatic peptide, was found to be expressed in the preoptic area of mother rats in our recent microarray study. Here, we report a marked increase in amylin expression around parturition and show that amylin mRNA level remains elevated as long as the pups are not removed from the dams. Amylin expression is also induced in maternally behaving (sensitized) nonlactating but not in nonsensitized nulliparous females or in females that did not become maternal despite the sensitization procedure. Immunohistochemistry verified the increased amylin peptide expression in maternally behaving rats and demonstrated the same expression pattern of amylin as in situ hybridization histochemistry. Ovariectomy had no effect on the activation of amylin neurons, suggesting sexual steroid-independent mechanisms. In subsequent functional experiments, mothers were separated from their pups for 22 h. On return of the pups, neuronal activation was found in the mother's preoptic area, with a distribution pattern similar to amylin-expressing neurons. Subsequent double labeling revealed that 86-93% of amylin neurons were activated by pup exposure. The results implicate amylin in the control of maternal adaptations, possibly exerting its actions on maternal behaviors via amylin receptors present in brain regions to which preoptic neurons project.-Szabo, E. R., Cservenak, M., Dobolyi, A. Amylin is a novel neuropeptide with potential maternal functions in the rat. FASEB J. 26, 272-281 (2012). www.fasebj.org	Semmelweis Univ, Neuromorphol & Neuroendocrine Res Lab, Dept Anat Histol & Embryol, H-1094 Budapest, Hungary; Hungarian Acad Sci, Budapest, Hungary	Semmelweis University; Hungarian Academy of Sciences	Dobolyi, A (corresponding author), Semmelweis Univ, Neuromorphol Lab, Dept Anat Histol & Embryol, Tuzolto U 58, H-1094 Budapest, Hungary.	dobolyi@ana.sote.hu	Dobolyi, Arpad/AAE-5913-2020; Cservenak, Melinda/AAF-3072-2020	Cservenak, Melinda/0000-0002-6899-9944	Hungarian Academy of Sciences; NFM-OTKA [NNF2 85612, NKTH-OTKA K67646, OTKA K100319, NKTH TECH_09_A1]	Hungarian Academy of Sciences(Hungarian Academy of Sciences); NFM-OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	Grant support was provided by the Bolyai Janos Fellowship grant from the Hungarian Academy of Sciences, as well as NFM-OTKA NNF2 85612, NKTH-OTKA K67646, OTKA K100319, and NKTH TECH_09_A1 grants. The authors thank Prof. Miklos Palkovits for critically reading the manuscript and Eva Renner for help in the combination of in situ hybridization and immunocytochemistry procedures. The authors also appreciate the technical assistance of Nikolett Hanak and Szilvia Deak. American Journal Experts is acknowledged for English editing. The authors declare no conflicts of interest.	Augustine RA, 2008, J PHYSIOL-LONDON, V586, P387, DOI 10.1113/jphysiol.2007.146316; Becskei C, 2004, BRAIN RES, V1030, P221, DOI 10.1016/j.brainres.2004.10.012; Bosch OJ, 2010, J NEUROENDOCRINOL, V22, P420, DOI 10.1111/j.1365-2826.2010.01984.x; Bosch OJ, 2008, P NATL ACAD SCI USA, V105, P17139, DOI 10.1073/pnas.0807412105; Burbach JPH, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P3055; Carter C S, 2001, Prog Brain Res, V133, P241; Coolen LM, 1998, J COMP NEUROL, V397, P421, DOI 10.1002/(SICI)1096-9861(19980803)397:3<421::AID-CNE8>3.0.CO;2-4; Cservenak M, 2010, ENDOCRINOLOGY, V151, P5830, DOI 10.1210/en.2010-0767; Dobolyi A, 2005, J COMP NEUROL, V489, P92, DOI 10.1002/cne.20618; Dobolyi A, 2011, J NEUROENDOCRINOL, V23, P1002, DOI 10.1111/j.1365-2826.2011.02127.x; Dobolyi A, 2002, P NATL ACAD SCI USA, V99, P1651, DOI 10.1073/pnas.042416199; Dobolyi A, 2008, J COMP NEUROL, V507, P1393, DOI 10.1002/cne.21621; Dobolyi A, 2009, J NEUROCHEM, V111, P1490, DOI 10.1111/j.1471-4159.2009.06422.x; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P957, DOI 10.1037/h0036414; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gebre-Medhin S, 1998, MOL BRAIN RES, V63, P180, DOI 10.1016/S0169-328X(98)00269-1; GRAY P, 1984, BEHAV NEUROSCI, V98, P703, DOI 10.1037/0735-7044.98.4.703; Hay DL, 2004, BIOCHEM SOC T, V32, P865, DOI 10.1042/BST0320865; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Kinsley CH, 2008, J NEUROENDOCRINOL, V20, P515, DOI 10.1111/j.1365-2826.2008.01667.x; Knobil E., 2006, KNOBIL NEILLS PHYSL, V2; Lamming G. E., 1994, MARSHALLS PHYSL REPR, V3; LEFFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127, DOI 10.1073/pnas.86.9.3127; Leng G, 2008, CURR OPIN PHARMACOL, V8, P731, DOI 10.1016/j.coph.2008.07.001; Li C, 1999, NEUROSCIENCE, V94, P117, DOI 10.1016/S0306-4522(99)00236-5; Lin SH, 1998, BRAIN RES, V787, P226, DOI 10.1016/S0006-8993(97)01484-4; Lonstein JS, 1998, NEUROSCIENCE, V82, P267; Lutz TA, 2001, INT J OBESITY, V25, P1005, DOI 10.1038/sj.ijo.0801664; Lutz TA, 2006, PHYSIOL BEHAV, V89, P465, DOI 10.1016/j.physbeh.2006.04.001; Mallikarjun PK, 2005, J R SOC PROMO HEALTH, V125, P221, DOI 10.1177/146642400512500514; McNeilly AS, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P2511; MULDER H, 1995, J NEUROSCI, V15, P7625; Numan M, 1997, J NEUROENDOCRINOL, V9, P369, DOI 10.1046/j.1365-2826.1997.t01-1-00597.x; NUMAN M, 1986, ANN NY ACAD SCI, V474, P226, DOI 10.1111/j.1749-6632.1986.tb28014.x; Numan M, 1997, ANN NY ACAD SCI, V807, P101, DOI 10.1111/j.1749-6632.1997.tb51915.x; Numan M., 2003, HORM BR BEHAV; Numan M, 2010, BEHAV NEUROSCI, V124, P715, DOI 10.1037/a0021548; Potes CS, 2010, PHYSIOL BEHAV, V100, P511, DOI 10.1016/j.physbeh.2010.03.001; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; ROSENBLATT JS, 1967, SCIENCE, V156, P1512, DOI 10.1126/science.156.3781.1512; Rushing PA, 2001, ENDOCRINOLOGY, V142, P5035, DOI 10.1210/en.142.11.5035; SEXTON PM, 1994, NEUROSCIENCE, V62, P553, DOI 10.1016/0306-4522(94)90388-3; SHEWARD WJ, 1994, NEUROSCI LETT, V181, P31, DOI 10.1016/0304-3940(94)90553-3; SIMERLY RB, 1986, J COMP NEUROL, V246, P312, DOI 10.1002/cne.902460304; SIMERLY RB, 1988, J COMP NEUROL, V270, P209, DOI 10.1002/cne.902700205; Smith MS, 2002, FRONT NEUROENDOCRIN, V23, P225, DOI 10.1016/S0091-3022(02)00002-X; Stack EC, 2000, BEHAV NEUROSCI, V114, P609, DOI 10.1037/0735-7044.114.3.609; Tohyama M., 1998, ATLAS NEUROACTIVE SU; Wayneforth H, 1992, EXPT SURG TECHNIQUES; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Woodside B, 2007, PHYSIOL BEHAV, V91, P375, DOI 10.1016/j.physbeh.2007.04.015; Young Andrew, 2005, Adv Pharmacol, V52, P19, DOI 10.1016/S1054-3589(05)52002-7	52	38	38	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					272	281		10.1096/fj.11-191841	http://dx.doi.org/10.1096/fj.11-191841			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965599				2022-12-28	WOS:000299202200028
J	Roepke, TK; Kanda, VA; Purtell, K; King, EC; Lerner, DJ; Abbott, GW				Roepke, Torsten K.; Kanda, Vikram A.; Purtell, Kerry; King, Elizabeth C.; Lerner, Daniel J.; Abbott, Geoffrey W.			KCNE2 forms potassium channels with KCNA3 and KCNQ1 in the choroid plexus epithelium	FASEB JOURNAL			English	Article						MiRP1; cerebrospinal fluid; polarized trafficking; central nervous system; ventricles	DISRUPTION; EXPRESSION; BRAIN; MINK; AQUAPORIN-1; CONTRIBUTE; SUBUNIT; MIRP1	Cerebrospinal fluid (CSF) is crucial for normal function and mechanical protection of the CNS. The choroid plexus epithelium (CPe) is primarily responsible for secreting CSF and regulating its composition by mechanisms currently not fully understood. Previously, the heteromeric KCNQ1-KCNE2 K+ channel was functionally linked to epithelial processes including gastric acid secretion and thyroid hormone biosynthesis. Here, using Kcne2(-/-) tissue as a negative control, we found cerebral expression of KCNE2 to be markedly enriched in the CPe apical membrane, where we also discovered expression of KCNQ1. Targeted Kcne2 gene deletion in C57B6 mice increased CPe outward K+ current 2-fold. The Kcne2 deletion-enhanced portion of the current was inhibited by XE991 (10 mu M) and margatoxin (10 mu M) but not by dendrotoxin (100 nM), indicating that it arose from augmentation of KCNQ subfamily and KCNA3 but not KCNA1 K+ channel activity. Kcne2 deletion in C57B6 mice also altered the polarity of CPe KCNQ1 and KCNA3 trafficking, hyperpolarized the CPe membrane by 9 +/- 2 mV, and increased CSF [Cl-] by 14% compared with wild-type mice. These findings constitute the first report of CPe dysfunction caused by cation channel gene disruption and suggest that KCNE2 influences blood-CSF anion flux by regulating KCNQ1 and KCNA3 in the CPe.-Roepke, T. K., Kanda, V. A., Purtell, K., King, E. C., Lerner, D. J., Abbott, G. W. KCNE2 forms potassium channels with KCNA3 and KCNQ1 in the choroid plexus epithelium. FASEB J. 25, 4264-4273 (2011). www.fasebj.org	[Roepke, Torsten K.; Kanda, Vikram A.; Purtell, Kerry; King, Elizabeth C.; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; [Roepke, Torsten K.; King, Elizabeth C.; Lerner, Daniel J.; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University	Abbott, GW (corresponding author), Weill Cornell Med Coll, Dept Pharmacol, Box 70,1300 York Ave, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X	U.S. National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) [R01-HL079275]; American Heart Association [0855756D]; Irma T. Hirschl Career Scientist Award; NIH [T32-GM073546]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM073546] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); Irma T. Hirschl Career Scientist Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful for expert assistance from K. La Perle, L. Cohen-Gould (Director of the Electron Microscopy and Histology Core Facility at Weill Cornell Medical College), M. S. Jiao, and the Molecular Cytology Core Facility of Memorial Sloan-Kettering Cancer Center. The authors thank Antonio Felipe (Universitat de Barcelona, Barcelona, Spain), Neil Harrison (Columbia University, New York, NY, USA), and Charles Inturrisi (Weill Cornell Medical College, New York, NY, USA) for advice, reagents, and other resources. This work was supported by the U.S. National Heart, Lung, and Blood Institute, National Institutes of Health (NIH; R01-HL079275), the American Heart Association (grant-in-aid 0855756D), and an Irma T. Hirschl Career Scientist Award (to G. W. A.). K.P. was supported by an NIH predoctoral training grant (T32-GM073546).	Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; AMES A, 1965, J PHYSIOL-LONDON, V181, P506, DOI 10.1113/jphysiol.1965.sp007779; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Goldman AM, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000289; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; Heron SE, 2010, EPILEPSIA, V51, P293, DOI 10.1111/j.1528-1167.2009.02317.x; Hunter NL, 2007, DEVELOPMENT, V134, P3449, DOI 10.1242/dev.003095; Jacobs S, 2008, P NATL ACAD SCI USA, V105, P311, DOI 10.1073/pnas.0705487105; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Lewis A, 2004, J BIOL CHEM, V279, P7884, DOI 10.1074/jbc.M310501200; LINDVALLAXELSSON M, 1989, EXP BRAIN RES, V77, P605; Liu Li, 2008, J Vis Exp, DOI 10.3791/960; Loerch PM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003329; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; Millar Ian D, 2007, Cerebrospinal Fluid Res, V4, P8, DOI 10.1186/1743-8454-4-8; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; Roepke TK, 2008, FASEB J, V22, P3648, DOI 10.1096/fj.08-110171; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Roepke TK, 2011, FASEB J, V25, P727, DOI 10.1096/fj.10-173682; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Serot JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS515, DOI 10.2741/1085; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sole L, 2009, J CELL SCI, V122, P3738, DOI 10.1242/jcs.056689; Speake T, 2003, BBA-BIOMEMBRANES, V1609, P80, DOI 10.1016/S0005-2736(02)00658-2; Speake T, 2004, AM J PHYSIOL-CELL PH, V286, pC611, DOI 10.1152/ajpcell.00292.2003; Tam GWC, 2010, BIOCHEM SOC T, V38, P445, DOI 10.1042/BST0380445; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tinel N, 2000, FEBS LETT, V480, P137, DOI 10.1016/S0014-5793(00)01918-9; VermaKurvari S, 1997, MOL BRAIN RES, V46, P54, DOI 10.1016/S0169-328X(96)00271-9; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511	30	34	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4264	4273		10.1096/fj.11-187609	http://dx.doi.org/10.1096/fj.11-187609			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21859894	Green Published, Green Submitted			2022-12-28	WOS:000298138100019
J	Tang, HF; Yan, CG; Cao, J; Sarma, JV; Haura, EB; Wu, M; Gao, HW				Tang, Huifang; Yan, Chunguang; Cao, Jay; Sarma, J. Vidya; Haura, Eric B.; Wu, Min; Gao, Hongwei			An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation	FASEB JOURNAL			English	Article						signal transducer and activator of transcription; ALI	ACUTE LUNG INJURY; NECROSIS-FACTOR-ALPHA; FC-GAMMA RECEPTORS; MONOCYTIC CELLS; IN-VIVO; ACTIVATION; EXPRESSION; OVEREXPRESSION; HOMEOSTASIS; EPITHELIUM	Growing evidence suggests that transcription factor signal transducer and activator of transcription (Stat) 3 may play an important regulatory role during inflammation. However, the function of Stat3 in acute lung injury (ALI) is largely unknown. In the current study, by using an adenoviral vector expressing a dominant-negative Stat3 isoform (Ad-Stat3-EVA), we determined the role of Stat3 in IgG immune complex (IC)-induced inflammatory responses and injury in the lung from C57BL/6J mice. We show that IgG IC-induced DNA binding activity of Stat3 in the lung was significantly inhibited by Stat3-EVA. We demonstrate that both lung vascular permeability (albumin leak) and lung myeloperoxidase accumulation in the Ad-Stat-EVA treated mice were substantially reduced when compared with values in mice receiving control virus (Ad-GFP) during the injury. Furthermore, intratracheal administration of Ad-Stat3-EVA caused significant decreases in the contents of neutrophils, inflammatory cytokines (TNF-alpha and IL-6), chemokines [ keratinocyte cell-derived chemokine, macrophage inflammatory protein (MIP)-1 alpha, and MIP-1 beta], and complement component C5a in bronchoalveolar lavage fluids. Using Stat3-specific small interfering RNA, we show that knocking down Stat3 expression in alveolar macrophages (MH-S cells) significantly reduced the production of proinflammatory mediators on IgG IC stimulation. These data suggest that Stat3 plays an essential role in the pathogenesis of IgG IC-induced ALI by mediating the acute inflammatory responses in the lung and alveolar macrophages.-Tang, H., Yan, C., Cao, J., Sarma, J. V., Haura, E. B., Wu, M., Gao, H. An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J. 25, 4292-4300 (2011). www.fasebj.org	[Tang, Huifang; Yan, Chunguang; Gao, Hongwei] Harvard Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Brigham & Womens Hosp,Ctr Expt Therapeut & Reperf, Boston, MA 02115 USA; [Tang, Huifang] Zhejiang Univ, Sch Med, State Food & Drug Adm China, Zhejiang Resp Drugs Res Lab, Hangzhou 310003, Zhejiang, Peoples R China; [Cao, Jay] ARS, USDA, Grand Forks Human Nutr Res Ctr, Grand Forks, ND USA; [Sarma, J. Vidya] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Haura, Eric B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Yan, Chunguang; Wu, Min] Univ N Dakota, Dept Biochem & Mol Biol, Grand Forks, ND 58201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Zhejiang University; United States Department of Agriculture (USDA); University of Michigan System; University of Michigan; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of North Dakota Grand Forks	Gao, HW (corresponding author), Harvard Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Brigham & Womens Hosp,Ctr Expt Therapeut & Reperf, Boston, MA 02115 USA.	hgao@zeus.bwh.harvard.edu	Tang, Huifang/ADI-7037-2022		U.S. National Institutes of Health [5R01-HL-092905-04, 3R01-HL-092905-02S1]; U.S. Department of Agriculture, Agricultural Research Service (ARS) [CRIS 5450-51000-046-00D]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092905] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Agriculture, Agricultural Research Service (ARS)(United States Department of Agriculture (USDA)USDA Agricultural Research Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Peter A. Ward (University of Michigan, Ann Arbor, MI, USA) and Dr. Richard C. Schwartz (Michigan State University, Lansing, MI, USA) for constant encouragement and advice. The authors also thank Dr. Wei Zhang for preparing the adenovirus. This research was supported by U.S. National Institutes of Health grants 5R01-HL-092905-04 and 3R01-HL-092905-02S1 (to H.G.) and the U.S. Department of Agriculture, Agricultural Research Service (ARS) program, CRIS 5450-51000-046-00D (to J.C.). The authors declare no competing financial interests.	BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cappelletti M, 1996, CELL DEATH DIFFER, V3, P29; Chouchakova N, 2001, J IMMUNOL, V166, P5193, DOI 10.4049/jimmunol.166.8.5193; Crockett Elahe T, 2004, BMC Clin Pathol, V4, P2, DOI 10.1186/1472-6890-4-2; Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037, DOI 10.1152/ajplung.2001.281.5.L1037; Fernandez N, 2002, EUR J IMMUNOL, V32, P383, DOI 10.1002/1521-4141(200202)32:2<383::AID-IMMU383>3.0.CO;2-9; Fernandez N, 2002, J IMMUNOL, V169, P3321, DOI 10.4049/jimmunol.169.6.3321; Fu XY, 2006, CELL RES, V16, P214, DOI 10.1038/sj.cr.7310029; Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155; Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612; Gao HW, 2004, J IMMUNOL, V172, P7703, DOI 10.4049/jimmunol.172.12.7703; Guo RF, 2002, AM J PATHOL, V161, P275, DOI 10.1016/S0002-9440(10)64179-X; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Ikegami M, 2008, J APPL PHYSIOL, V104, P1753, DOI 10.1152/japplphysiol.00875.2007; Kumar V, 2006, J CLIN INVEST, V116, P512, DOI 10.1172/JCI25536; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; Lentsch AB, 1999, AM J RESP CELL MOL, V20, P692, DOI 10.1165/ajrcmb.20.4.3414; Lian XM, 2005, J IMMUNOL, V174, P7250, DOI 10.4049/jimmunol.174.11.7250; Matsuzaki Y, 2006, J IMMUNOL, V177, P527, DOI 10.4049/jimmunol.177.1.527; Meng ZH, 2001, AM J PHYSIOL-CELL PH, V280, pC343, DOI 10.1152/ajpcell.2001.280.2.C343; MULLIGAN MS, 1993, AM J PATHOL, V142, P1739; Nguyen-Jackson H, 2010, BLOOD, V115, P3354, DOI 10.1182/blood-2009-08-240317; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Quinton LJ, 2008, AM J RESP CELL MOL, V38, P699, DOI 10.1165/rcmb.2007-0365OC; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Rittirsch D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000464; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Severgnini M, 2005, AM J RESP CRIT CARE, V171, P858, DOI 10.1164/rccm.200407-981OC; SHANLEY TP, 1995, J IMMUNOL, V154, P4793; Shanley TP, 1997, J IMMUNOL, V158, P3439; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sun L, 2009, FASEB J, V23, P3808, DOI 10.1096/fj.09-133694; Trcka J, 2002, IMMUNITY, V16, P861, DOI 10.1016/S1074-7613(02)00327-8; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje	36	14	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4292	4300		10.1096/fj.11-187955	http://dx.doi.org/10.1096/fj.11-187955			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21859893	Green Published, Green Submitted			2022-12-28	WOS:000298138100021
J	Kaplan, D				Kaplan, David			Social Choice at NIH: the principle of complementarity	FASEB JOURNAL			English	Editorial Material							STATISTICAL-ANALYSIS		Case Western Reserve Univ, Dept Pathol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital	Kaplan, D (corresponding author), Case Western Reserve Univ, Dept Pathol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.	david.kaplan@case.edu						Arrow KJ, 1950, J POLIT ECON, V58, P328, DOI 10.1086/256963; Johnson VE, 2008, P NATL ACAD SCI USA, V105, P11076, DOI 10.1073/pnas.0804538105; Kaplan D, 2007, FASEB J, V21, P305, DOI 10.1096/fj.07-0204ufm; Kaplan D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002761; National Science Foundation, 2017, ENH SUPP TRANSF RES; National Science Foundation, 2007, IMP NOT 130 TRANSF R; *PROG, 1997, M PEER REV OV GROUP; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; [No title captured]	9	4	4	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3763	3764		10.1096/fj.11-191015	http://dx.doi.org/10.1096/fj.11-191015			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21798955				2022-12-28	WOS:000296723100002
J	Rogel, MR; Soni, PN; Troken, JR; Sitikov, A; Trejo, HE; Ridge, KM				Rogel, Micah R.; Soni, Pritin N.; Troken, James R.; Sitikov, Albert; Trejo, Humberto E.; Ridge, Karen M.			Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells	FASEB JOURNAL			English	Article						TGF-beta 1; migration; scratch wound assay; intermediate filaments; lung injury	GROWTH-FACTOR-BETA; KERATIN INTERMEDIATE-FILAMENTS; TGF-BETA; IN-VITRO; P21-ACTIVATED KINASE; PULMONARY-FIBROSIS; ASSEMBLY DYNAMICS; GENE-EXPRESSION; PHOSPHORYLATION; MIGRATION	The physiological and pathophysiological implications of the expression of vimentin, a type III intermediate filament protein, in alveolar epithelial cells (AECs) are unknown. We provide data demonstrating that vimentin is regulated by TGF beta 1, a major cytokine released in response to acute lung injury and that vimentin is required for wound repair and remodeling of the alveolar epithelium. Quantitative real-time PCR shows a 16-fold induction of vimentin mRNA in TGF beta 1-treated transformed AECs. Luciferase assays identify a Smad-binding element in the 5' promoter of vimentin responsible for TGF beta 1-induced transcription. Notably, TGF beta 1 induces vimentin protein expression in AECs, which is associated with a 2.5-fold increase in cell motility, resulting in increased rates of migration and wound closure. These effects are independent of cell proliferation. TGF beta 1-mediated vimentin protein expression, cell migration, and wound closure are prevented by a pharmacological inhibitor of the Smad pathway and by expression of Ad-shRNA against vimentin. Conversely, overexpression of mEmerald-vimentin is sufficient for increased cell-migration and wound-closure rates. These results demonstrate that vimentin is required and sufficient for increased wound repair in an in vitro model of lung injury.-Rogel, M. R., Soni, P. N., Troken, J. R., Sitikov, A., Trejo, H. E., Ridge, K. M. Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J. 25, 3873-3883 (2011). www.fasebj.org	[Ridge, Karen M.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Rogel, Micah R.] Northwestern Univ, Dept Biomed Engn, Chicago, IL 60611 USA; [Ridge, Karen M.] Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Ridge, Karen M.] Dept Vet Affairs, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Northwestern University	Ridge, KM (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, 240 E Huron St,McGaw M328, Chicago, IL 60611 USA.	kridge@northwestern.edu		Trejo BIttar, Humberto/0000-0003-2701-6531	U.S. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NIH-NHLBI) [PO1 HL71643, T32-076139-02]; Department of Veterans Affairs; American Heart Association (AHA) [10PRE4210064]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079190, P01HL071643] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NIH-NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Veterans Affairs(US Department of Veterans Affairs); American Heart Association (AHA)(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Robert D. Goldman (Northwestern University, Evanston, IL, USA) for the mEmerald-vimentin vector construct, Dr. Robert B. Hamanaka for technical help and suggestions, and Mr. Luke Skertich for assistance with wound closure data analysis. This work was supported by grants from the U.S. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (PO1 HL71643 NIH-NHLBI), the Department of Veterans Affairs (MERIT Award), the Training Program in Lung Science (T32-076139-02 NIH-NHLBI; to M.R.R.), and the American Heart Association (AHA 10PRE4210064; to M.R.R.).	ADAMSON IYR, 1990, AM J PATHOL, V137, P385; Barberis L, 2009, EUR J IMMUNOL, V39, P1136, DOI 10.1002/eji.200838884; Bargagna-Mohan P, 2007, CHEM BIOL, V14, P623, DOI 10.1016/j.chembiol.2007.04.010; Bargagna-Mohan P, 2010, J BIOL CHEM, V285, P7657, DOI 10.1074/jbc.M109.093765; Bergeron A, 2003, EUR RESPIR J, V22, P69, DOI 10.1183/09031936.03.00014703; Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brown MJ, 2001, J IMMUNOL, V166, P6640, DOI 10.4049/jimmunol.166.11.6640; Buisson AC, 1996, LAB INVEST, V74, P658; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75; Draper BK, 2003, J CELL BIOCHEM, V89, P1126, DOI 10.1002/jcb.10584; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Farooqui R, 2005, J CELL SCI, V118, P51, DOI 10.1242/jcs.01577; Geiser T, 2000, AM J PHYSIOL-LUNG C, V279, pL1184, DOI 10.1152/ajplung.2000.279.6.L1184; Gilles C, 1999, J CELL SCI, V112, P4615; Godsel LM, 2005, J CELL BIOL, V171, P1045, DOI 10.1083/jcb.200510038; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Khalil N, 1996, AM J RESP CELL MOL, V14, P131, DOI 10.1165/ajrcmb.14.2.8630262; Khalil N, 1996, AM J RESP CELL MOL, V15, P252, DOI 10.1165/ajrcmb.15.2.8703482; KHERADMAND F, 1994, AM J PHYSIOL-LUNG C, V267, pL728, DOI 10.1152/ajplung.1994.267.6.L728; Lesur O, 1996, AM J PHYSIOL-LUNG C, V270, pL311, DOI 10.1152/ajplung.1996.270.3.L311; Li QF, 2006, J BIOL CHEM, V281, P34716, DOI 10.1074/jbc.M607715200; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; Savla U, 2004, J APPL PHYSIOL, V96, P566, DOI 10.1152/japplphysiol.00510.2003; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; Sivaramakrishnan S, 2009, MOL BIOL CELL, V20, P2755, DOI 10.1091/mbc.E08-10-1028; SUNDARRAJ N, 1992, CELL TISSUE RES, V267, P347, DOI 10.1007/BF00302973; Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Uhal BD, 1997, AM J PHYSIOL-LUNG C, V272, pL1031, DOI 10.1152/ajplung.1997.272.6.L1031; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Wu YZ, 2007, BBA-MOL CELL RES, V1773, P427, DOI 10.1016/j.bbamcr.2006.11.017; Yoon KH, 2001, J CELL BIOL, V153, P503, DOI 10.1083/jcb.153.3.503; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; ZAHM JM, 1991, AM J RESP CELL MOL, V5, P242, DOI 10.1165/ajrcmb/5.3.242	52	82	84	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3873	3883		10.1096/fj.10-170795	http://dx.doi.org/10.1096/fj.10-170795			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21803859	Green Published			2022-12-28	WOS:000296723100012
J	Mathew, B; Jacobson, JR; Berdyshev, E; Huang, Y; Sun, XG; Zhao, YT; Gerhold, LM; Siegler, J; Evenoski, C; Wang, T; Zhou, T; Zaidi, R; Moreno-Vinasco, L; Bittman, R; Chen, CT; LaRiviere, PJ; Sammani, S; Lussier, YA; Dudek, SM; Natarajan, V; Weichselbaum, RR; Garcia, JGN				Mathew, Biji; Jacobson, Jeffrey R.; Berdyshev, Evgeny; Huang, Yong; Sun, Xiaoguang; Zhao, Yutong; Gerhold, Lynnette M.; Siegler, Jessica; Evenoski, Carrie; Wang, Ting; Zhou, Tong; Zaidi, Rafe; Moreno-Vinasco, Liliana; Bittman, Robert; Chen, Chin Tu; LaRiviere, Patrick J.; Sammani, Saad; Lussier, Yves A.; Dudek, Steven M.; Natarajan, Viswanathan; Weichselbaum, Ralph R.; Garcia, Joe G. N.			Role of sphingolipids in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogs	FASEB JOURNAL			English	Article						gene dysregulation; S1P receptors; fTysiponate; FTY720	ENDOTHELIAL-CELLS; ACID SPHINGOMYELINASE; BARRIER ENHANCEMENT; INDUCED APOPTOSIS; GENE-EXPRESSION; VASCULAR LEAK; CERAMIDE; PNEUMONITIS; RECEPTOR; ACTIVATION	Clinically significant radiation-induced lung injury (RILI) is a common toxicity in patients administered thoracic radiotherapy. Although the molecular etiology is poorly understood, we previously characterized a murine model of RILI in which alterations in lung barrier integrity surfaced as a potentially important pathobiological event and genome-wide lung gene mRNA levels identified dysregulation of sphingolipid metabolic pathway genes. We hypothesized that sphingolipid signaling components serve as modulators and novel therapeutic targets of RILI. Sphingolipid involvement in murine RILI was confirmed by radiation-induced increases in lung expression of sphingosine kinase (SphK) isoforms 1 and 2 and increases in the ratio of ceramide to sphingosine 1-phosphate (S1P) and dihydro-S1P (DHS1P) levels in plasma, bronchoalveolar lavage fluid, and lung tissue. Mice with a targeted deletion of SphK1 (SphK1(-/-)) or with reduced expression of S1P receptors (S1PR1(+/-), S1PR2(-/-), and S1PR3(-/-)) exhibited marked RILI susceptibility. Finally, studies of 3 potent vascular barrier-protective S1P analogs, FTY720, (S)-FTY720-phosphonate (fTyS), and SEW-2871, identified significant RILI attenuation and radiation-induced gene dysregulation by the phosphonate analog, fTyS (0.1 and 1 mg/kg i.p., 2x/wk) and to a lesser degree by SEW-2871 (1 mg/kg i.p., 2x/wk), compared with those in controls. These results support the targeting of S1P signaling as a novel therapeutic strategy in RILI.-Mathew, B., Jacobson, J. R., Berdyshev, E., Huang, Y., Sun, X., Zhao, Y., Gerhold, L. M., Siegler, J., Evenoski, C., Wang, T., Zhou, T., Zaidi, R., Moreno-Vinasco, L., Bittman, R., Chen, C. T., LaRiviere, P. J., Sammani, S., Lussier, Y. A., Dudek, S. M., Natarajan, V., Weichselbaum, R. R., Garcia, J. G. N. Role of sphingolipids in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogs. FASEB J. 25, 3388-3400 (2011). www. fasebj. org	[Garcia, Joe G. N.] Univ Illinois, Dept Med Pharmacol & Bioengn, Inst Personalized Resp Med, Sect Pulm Crit Care & Sleep Med, Chicago, IL 60612 USA; [Natarajan, Viswanathan] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; [Huang, Yong; Lussier, Yves A.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Gerhold, Lynnette M.; Chen, Chin Tu; LaRiviere, Patrick J.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA; [Weichselbaum, Ralph R.] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637 USA; [Bittman, Robert] CUNY, Queens Coll, Dept Chem & Biochem, Flushing, NY USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Chicago; University of Chicago; City University of New York (CUNY) System; Queens College NY (CUNY)	Garcia, JGN (corresponding author), Univ Illinois, Dept Med Pharmacol & Bioengn, Inst Personalized Resp Med, Sect Pulm Crit Care & Sleep Med, 1737 W Polk St,305D AOB, Chicago, IL 60612 USA.	jggarcia@uic.edu	Chen, Chin-Tu/K-3393-2014; Lussier, Yves/N-4891-2017	Lussier, Yves/0000-0001-9854-1005	U.S. National Institutes of Health [R01 HL079396, P01 HL098050, HL083187, HL58094, HL09805, K22 LM008308-04, 5U54CA121852-05]; NATIONAL CANCER INSTITUTE [U54CA121852, R01CA134680] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL098050, R24HL083187, R01HL079396] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K22LM008308] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	The authors are grateful to Eddie T. Chiang for outstanding technical assistance. This work was supported by U.S. National Institutes of Health grants R01 HL079396 (V.N.), P01 HL098050 (V.N., J.G.N., S.D., J.R.J., and R.R.W.), HL083187 (R.B.), HL58094, HL09805, K22 LM008308-04, and 5U54CA121852-05. Microarray data have been submitted to the Gene Expression Omnibus repository of the National Center for Biotechnology Information (GSE25295).	Anscher MS, 1998, INT J RADIAT ONCOL, V41, P1029, DOI 10.1016/S0360-3016(98)00154-0; Benson HL, 2011, AM J RESP CELL MOL, V44, P700, DOI 10.1165/rcmb.2010-0125OC; Berdyshev EV, 2005, ANAL BIOCHEM, V339, P129, DOI 10.1016/j.ab.2004.12.006; Berdyshev EV, 2006, CELL SIGNAL, V18, P1779, DOI 10.1016/j.cellsig.2006.01.018; Camp SM, 2009, J PHARMACOL EXP THER, V331, P54, DOI 10.1124/jpet.109.153544; Carruthers SA, 2004, BRIT J CANCER, V90, P2080, DOI 10.1038/sj.bjc.6601751; Chen YY, 2002, SEMIN RADIAT ONCOL, V12, P26, DOI 10.1053/srao.2002.31360; Deng XZ, 2008, SCIENCE, V322, P110, DOI 10.1126/science.1158111; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3501, DOI 10.1016/j.bmcl.2004.04.070; Hong JH, 1999, INT J RADIAT BIOL, V75, P1421, DOI 10.1080/095530099139287; Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kolosova IA, 2008, AM J PHYSIOL-LUNG C, V294, pL319, DOI 10.1152/ajplung.00283.2007; Kong FM, 2005, SEMIN ONCOL, V32, pS42, DOI 10.1053/j.seminoncol.2005.03.009; Korthagen NM, 2010, CLIN EXP IMMUNOL, V161, P342, DOI 10.1111/j.1365-2249.2010.04181.x; Kovarik JM, 2004, THER DRUG MONIT, V26, P585, DOI 10.1097/00007691-200412000-00001; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Li C., 2001, GENOME BIOL, V2, DOI [10.1186/gb-2001-2-8-research0032, DOI 10.1186/GB-2001-2-8-RESEARCH0032]; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Lu XQ, 2009, J ORG CHEM, V74, P3192, DOI 10.1021/jo900023u; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McBride WH, 2000, INT J RADIAT BIOL, V76, P517, DOI 10.1080/095530000138529; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Meyer NJ, 2009, FASEB J, V23, P1325, DOI 10.1096/fj.08-119073; Michael JM, 1997, CANCER RES, V57, P3600; Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006; Ogata T, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-26; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; PEZNER RD, 1984, CHEST, V85, P816, DOI 10.1378/chest.85.6.816; Pollack A, 2009, CLIN CANCER RES, V15, P5478, DOI 10.1158/1078-0432.CCR-08-2704; Rabbani ZN, 2010, RADIAT RES, V173, P165, DOI 10.1667/RR1816.1; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; Sammani S, 2010, AM J RESP CELL MOL, V43, P394, DOI 10.1165/rcmb.2009-0223OC; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Singleton P. A., 2010, AM J PHYSIOL-LUNG C, V104, P978; Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Undas Anetta, 2002, Clin Lab, V48, P287; Viemann D, 2007, BLOOD, V109, P2453, DOI 10.1182/blood-2006-08-040444; von Bismarck P, 2008, AM J RESP CRIT CARE, V177, P1233, DOI 10.1164/rccm.200705-752OC; von Bismarck P, 2007, CRIT CARE MED, V35, P2309, DOI 10.1097/01.CCM.0000281472.47067.45; Zhao YT, 2007, J BIOL CHEM, V282, P14165, DOI 10.1074/jbc.M701279200	57	45	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3388	3400		10.1096/fj.11-183970	http://dx.doi.org/10.1096/fj.11-183970			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21712494	Green Published			2022-12-28	WOS:000295356400011
J	Dong, YF; Kataoka, K; Tokutomi, Y; Nako, H; Nakamura, T; Toyama, K; Sueta, D; Koibuchi, N; Yamamoto, E; Ogawa, H; Kim-Mitsuyama, S				Dong, Yi-Fei; Kataoka, Keiichiro; Tokutomi, Yoshiko; Nako, Hisato; Nakamura, Taishi; Toyama, Kensuke; Sueta, Daisuke; Koibuchi, Nobutaka; Yamamoto, Eiichiro; Ogawa, Hisao; Kim-Mitsuyama, Shokei			Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid-beta; inflammation; oxidative stress; cognitive function; blood-brain barrier	AMYLOID BETA-PROTEIN; BLOOD-PRESSURE; NITRIC-OXIDE; MEMORY; DEMENTIA; BRAIN; ACE; HYPERTENSION; ASSOCIATION; DEPOSITION	The purpose of this work was to test whether brain-penetrating angiotensin-converting enzyme (ACE) inhibitors (e. g., perindopril), as opposed to non-brain-penetrating ACE inhibitors (e. g., enalapril and imidapril), may reduce the cognitive decline and brain injury in Alzheimer's disease (AD). We first compared the effect of perindopril, enalapril, and imidapril on cognitive impairment and brain injury in a mouse model of AD induced by intracerebroventricular (i.c.v.) injection of amyloid-beta (A beta)(1-40). Perindopril, with significant inhibition of hippocampal ACE, significantly prevented cognitive impairment in this AD mouse model. This beneficial effect was attributed to the suppression of microglia/astrocyte activation and the attenuation of oxidative stress caused by iNOS induction and extracellular superoxide dismutase down-regulation. In contrast, neither enalapril nor imidapril prevented cognitive impairment and brain injury in this AD mouse. We next examined the protective effects of perindopril on cognitive impairment in PS2APP-transgenic mice overexpressing A beta in the brain. Perindopril, without affecting brain A beta deposition, significantly suppressed the increase in hippocampal ACE activity and improved cognition in PS2APP-transgenic mice, being associated with the suppression of hippocampal astrocyte activation and attenuation of superoxide. Our data demonstrated that the brain-penetrating ACE inhibitor perindopril, as compared to non-brain-penetrating ACE inhibitors, protected against cognitive impairment and brain injury in experimental AD models.-Dong, Y. -F., Kataoka, K., Tokutomi, Y., Nako, H., Nakamura, T., Toyama, K., Sueta, D., Koibuchi, N., Yamamoto, E., Ogawa, H., Kim-Mitsuyama, S. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 25, 2911-2920 (2011). www.fasebj.org	[Dong, Yi-Fei; Kataoka, Keiichiro; Tokutomi, Yoshiko; Nako, Hisato; Nakamura, Taishi; Toyama, Kensuke; Sueta, Daisuke; Koibuchi, Nobutaka; Yamamoto, Eiichiro; Kim-Mitsuyama, Shokei] Kumamoto Univ, Grad Sch Med Sci, Dept Pharmacol & Mol Therapeut, Kumamoto 8608556, Japan; [Ogawa, Hisao] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Kim-Mitsuyama, S (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Pharmacol & Mol Therapeut, 1-1-1 Honjyo, Kumamoto 8608556, Japan.	kimmitsu@gpo.kumamoto-u.ac.jp	Nakamura, Taishi/O-9297-2019	Nakamura, Taishi/0000-0002-1205-3252	Japan Ministry of Education, Culture, Sports, Science, and Technology; Grants-in-Aid for Scientific Research [23390058] Funding Source: KAKEN	Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Ministry of Education, Culture, Sports, Science, and Technology.	Alkam T, 2007, BEHAV BRAIN RES, V180, P139, DOI 10.1016/j.bbr.2007.03.001; ARREGUI A, 1982, J NEUROCHEM, V38, P1490, DOI 10.1111/j.1471-4159.1982.tb07930.x; Dong YF, 2010, DIABETOLOGIA, V53, P180, DOI 10.1007/s00125-009-1575-5; Eckman EA, 2006, J BIOL CHEM, V281, P30471, DOI 10.1074/jbc.M605827200; Germano C, 2005, NEUROPSYCHOL REV, V15, P1, DOI 10.1007/s11065-005-3583-7; Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Kehoe PG, 2007, LANCET NEUROL, V6, P373, DOI 10.1016/S1474-4422(07)70077-7; Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; Malinski T, 2007, J ALZHEIMERS DIS, V11, P207; Mamiya T, 2001, BRIT J PHARMACOL, V134, P1597, DOI 10.1038/sj.bjp.0704429; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; Miners S, 2009, AM J TRANSL RES, V1, P163; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Oba R, 2005, EUR J NEUROSCI, V21, P733, DOI 10.1111/j.1460-9568.2005.03912.x; Ohrui T, 2004, NEUROLOGY, V63, P1324, DOI 10.1212/01.WNL.0000140705.23869.E9; Ohrui T, 2004, J AM GERIATR SOC, V52, P649, DOI 10.1111/j.1532-5415.2004.52178_7.x; Oyama F, 1998, J NEUROCHEM, V71, P313; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Richards JG, 2003, J NEUROSCI, V23, P8989; Shibata M, 2004, STROKE, V35, P2598, DOI 10.1161/01.STR.0000143725.19053.60; Sink KM, 2009, ARCH INTERN MED, V169, P1195, DOI 10.1001/archinternmed.2009.175; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Tran MH, 2003, MOL PSYCHIATR, V8, P407, DOI 10.1038/sj.mp.4001240; Tran MH, 2001, FASEB J, V15, P1407, DOI 10.1096/fj.00-0719fje; Tzourio C, 2003, ARCH INTERN MED, V163, P1069; Van Dam D, 2006, NAT REV DRUG DISCOV, V5, P956, DOI 10.1038/nrd2075; Wright JW, 2010, EXP NEUROL, V223, P326, DOI 10.1016/j.expneurol.2009.09.012; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yamamoto E, 2007, ARTERIOSCL THROM VAS, V27, P556, DOI 10.1161/01.ATV.0000254855.24394.f9	35	107	109	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2911	2920		10.1096/fj.11-182873	http://dx.doi.org/10.1096/fj.11-182873			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21593435				2022-12-28	WOS:000294435200007
J	Wen, JM; Grenz, A; Zhang, YJ; Dai, YB; Kellems, RE; Blackburn, MR; Eltzschig, HK; Xia, Y				Wen, Jiaming; Grenz, Almut; Zhang, Yujin; Dai, Yingbo; Kellems, Rodney E.; Blackburn, Michael R.; Eltzschig, Holger K.; Xia, Yang			A(2B) adenosine receptor contributes to penile erection via PI3K/AKT signaling cascade-mediated eNOS activation	FASEB JOURNAL			English	Article						shear stress; vascular tone; CD73; erectile function	DEAMINASE-DEFICIENT MICE; NITRIC-OXIDE SYNTHASE; AKT-DEPENDENT PHOSPHORYLATION; ENDOTHELIAL-CELLS; PULMONARY-FIBROSIS; ADENINE-NUCLEOTIDES; CORPUS CAVERNOSUM; PRIAPISM; TISSUE; ESTABLISHMENT	Normal penile erection is under the control of multiple factors and signaling pathways. Although adenosine signaling is implicated in normal and abnormal penile erection, the exact role and the underlying mechanism for adenosine signaling in penile physiology remain elusive. Here we report that shear stress leads to increased adenosine release from endothelial cells. Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for the production of elevated adenosine from ATP released by shear-stressed endothelial cells. Mechanistically, we demonstrate that shear stress-mediated elevated adenosine functions through the adenosine A(2B) receptor (A(2B)R) to activate the PI3K/AKT signaling cascade and subsequent increased endothelial nitric oxide synthase (eNOS) phosphorylation. These in vitro studies led us to discover further that adenosine was induced during sustained penile erection and contributes to PI3K/AKT activation and subsequent eNOS phosphorylation via A(2B)R signaling in intact animal. Finally, we demonstrate that lowering adenosine in wild-type mice or genetic deletion of A(2B)R in mutant mice significantly attenuated PI3K/AKT activation, eNOS phosphorylation, and subsequent impaired penile erection featured with the reduction of ratio of maximal intracavernosal pressure to systemic arterial pressure from 0.49 +/- 0.03 to 0.41 +/- 0.05 and 0.38 +/- 0.04, respectively (both P < 0.05). Overall, using biochemical, cellular, genetic, and physiological approaches, our findings reveal that adenosine is a novel molecule signaling via A(2B)R activation, contributing to penile erection via PI3K/AKT-dependent eNOS activation. These studies suggest that this signaling pathway may be a novel therapeutic target for erectile disorders.-Wen, J., Grenz, A., Zhang, Y., Dai, Y., Kellems, R. E., Blackburn, M. R., Eltzschig, H. K., Xia, Y. A(2B) adenosine receptor contributes to penile erection via PI3K/AKT signaling cascade-mediated eNOS activation. FASEB J. 25, 2823-2830 (2011). www.fasebj.org	[Wen, Jiaming; Zhang, Yujin; Dai, Yingbo; Kellems, Rodney E.; Blackburn, Michael R.; Xia, Yang] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, Houston, TX USA; [Wen, Jiaming; Dai, Yingbo] Cent S Univ, Xiangya Hosp 3, Dept Urol, Changsha, Hunan, Peoples R China; [Grenz, Almut; Eltzschig, Holger K.] Univ Colorado, Dept Anesthesiol, Denver, CO 80202 USA	University of Texas System; University of Texas Health Science Center Houston; Central South University; University of Colorado System; University of Colorado Denver	Xia, Y (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Biochem & Mol Biol, 6431 Fannin St,MSB 6-200, Houston, TX 77030 USA.	yang.xia@uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	U.S. National Institute of Health [DK077748, DK083559, HL070952, HL092188]; China Scholarship Council [2008637068]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092188, R01HL070952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083559, R21DK077748] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institute of Health grants DK077748 and DK083559 (to Y.X.), HL070952 (to M.R.B.), and HL092188 (to H.E.) and China Scholarship Council grant 2008637068 (to J.W.). The authors declare no conflicts of interest.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Bivalacqua TJ, 2009, J SEX MED, V6, P2494, DOI 10.1111/j.1743-6109.2009.01359.x; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; Burnett AL, 2003, J ANDROL, V24, pS2; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Champion HC, 2005, P NATL ACAD SCI USA, V102, P1661, DOI 10.1073/pnas.0407183102; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; da Silva CG, 2009, CIRCULATION, V119, P871, DOI 10.1161/CIRCULATIONAHA.108.764571; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Faria M, 2006, J PHARMACOL EXP THER, V319, P405, DOI 10.1124/jpet.106.107821; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Filippi S, 2000, INT J ANDROL, V23, P210, DOI 10.1046/j.1365-2605.2000.00232.x; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Fredholm BB, 2001, PHARMACOL REV, V53, P527; GORDON EL, 1986, J BIOL CHEM, V261, P5496; Gorman MW, 2003, LUMINESCENCE, V18, P173, DOI 10.1002/bio.721; Hurt KJ, 2002, P NATL ACAD SCI USA, V99, P4061, DOI 10.1073/pnas.052712499; Kilic S, 1994, Int J Impot Res, V6, P191; Lin CS, 2005, J SEX MED, V2, P478, DOI 10.1111/j.1743-6109.2005.00080.x; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; Lue TF, 2000, NEW ENGL J MED, V342, P1802, DOI 10.1056/NEJM200006153422407; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; Noto T, 2001, EUR J PHARMACOL, V425, P51, DOI 10.1016/S0014-2999(01)01167-0; Phatarpekar PV, 2010, J SEX MED, V7, P3553, DOI 10.1111/j.1743-6109.2009.01555.x; Schilder RJ, 2008, J CLIN ONCOL, V26, P3418, DOI 10.1200/JCO.2007.14.3420; Shalev M, 1999, J UROLOGY, V161, P955, DOI 10.1016/S0022-5347(01)61828-7; Sharifzadeh M, 1995, GEN PHARMACOL-VASC S, V26, P1785, DOI 10.1016/0306-3623(95)00114-X; Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]; Stiles Gary L., 1997, P29; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; Xie DH, 2005, J SEX MED, V2, P634, DOI 10.1111/j.1743-6109.2005.00111.x; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yonezawa Akihiko, 2002, Nihon Rinsho, V60 Suppl 6, P52; Zhang YJ, 2011, NAT MED, V17, P79, DOI 10.1038/nm.2280; Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224	41	33	35	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2823	2830		10.1096/fj.11-181057	http://dx.doi.org/10.1096/fj.11-181057			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21566208	Green Published			2022-12-28	WOS:000293337800030
J	Zhang, HM; Hao, Q				Zhang, HongMin; Hao, Quan			Crystal structure of NDM-1 reveals a common beta-lactam hydrolysis mechanism	FASEB JOURNAL			English	Article						New Delhi metallo-beta-lactamase; antibiotic resistance; ampicillin; inhibitor design	PSEUDOMONAS-AERUGINOSA; BACILLUS-CEREUS; CLINICAL ISOLATE; ACTIVE-SITE; INHIBITION; GENE; CATALYSIS; ARP/WARP; COMPLEX; CLONING	Metallo-beta-lactamases (MBLs) hydrolyze most beta-lactam antibiotics, and bacteria containing this kind of enzyme pose a serious threat to the public health. The newly identified New Delhi MBL (NDM-1) is a new member of this family that shows tight binding to penicillin and cephalosporins. The rapid dissemination of NDM-1 in clinically relevant bacteria has become a global concern. However, no clinically useful inhibitors against MBLs exist, partly due to the lack of knowledge about the catalysis mechanism of this kind of enzyme. Here we report the crystal structure of this novel enzyme in complex with a hydrolyzed ampicillin at its active site at 1.3-angstrom resolution. Structural comparison with other MBLs revealed a new hydrolysis mechanism applicable to all three subclasses of MBLs, which might help the design of mechanism based inhibitors.-Zhang, H.-M., Hao, Q. Crystal structure of NDM-1 reveals a common beta-lactam hydrolysis mechanism. FASEB J. 25, 2574-2582 (2011). www.fasebj.org	[Zhang, HongMin; Hao, Quan] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Zhang, HM (corresponding author), L4-55,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	hzhang20@hku.hk; qhao@hku.hk	Zhang, Hongmin/C-4503-2009; Hao, Quan/C-4304-2009; Zhang, Hongmin/S-9953-2017	Zhang, Hongmin/0000-0001-6357-4106; Zhang, Hongmin/0000-0003-4356-3615; Hao, Quan/0000-0002-9642-0514	Research Grant Council of Hong Kong [HKU765909M, HKU785110M]	Research Grant Council of Hong Kong(Hong Kong Research Grants Council)	This work was supported by Research Grant Council of Hong Kong grants HKU765909M and HKU785110M to Q.H. and H.-M.Z. The crystallographic data were collected at the Shanghai Synchrotron Radiation Facility (Shanghai, China).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bush K, 2010, ANTIMICROB AGENTS CH, V54, P969, DOI 10.1128/AAC.01009-09; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Dal Peraro M, 2007, J AM CHEM SOC, V129, P2808, DOI 10.1021/ja0657556; DAVIES RB, 1974, BIOCHEM J, V143, P129, DOI 10.1042/bj1430129; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Drawz SM, 2010, CLIN MICROBIOL REV, V23, P160, DOI 10.1128/CMR.00037-09; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Gonzalez JM, 2007, J MOL BIOL, V373, P1141, DOI 10.1016/j.jmb.2007.08.031; Gonzalez JM, 2010, BIOCHEMISTRY-US, V49, P7930, DOI 10.1021/bi100894r; Hu ZX, 2008, J AM CHEM SOC, V130, P14207, DOI 10.1021/ja8035916; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; Lienard BMR, 2008, ORG BIOMOL CHEM, V6, P2282, DOI 10.1039/b802311e; Malakhov Michael P., 2004, Journal of Structural and Functional Genomics, V5, P75, DOI 10.1023/B:JSFG.0000029237.70316.52; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MI, 1999, CURR PHARM DESIGN, V5, P895; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Poirel L, 2000, ANTIMICROB AGENTS CH, V44, P891, DOI 10.1128/AAC.44.4.891-897.2000; Poirel L, 2010, ANTIMICROB AGENTS CH, V54, P4914, DOI 10.1128/AAC.00878-10; RASMUSSEN BA, 1990, ANTIMICROB AGENTS CH, V34, P1590, DOI 10.1128/AAC.34.8.1590; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Simona F, 2009, J BIOL CHEM, V284, P28164, DOI 10.1074/jbc.M109.049502; Spencer J, 2006, ANGEW CHEM INT EDIT, V45, P1022, DOI 10.1002/anie.200502984; Spencer J, 2005, J AM CHEM SOC, V127, P14439, DOI 10.1021/ja0536062; Tomatis PE, 2008, P NATL ACAD SCI USA, V105, P20605, DOI 10.1073/pnas.0807989106; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Walsh TR, 1996, J ANTIMICROB CHEMOTH, V37, P423, DOI 10.1093/jac/37.3.423; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Yamaguchi Y, 2005, J BIOL CHEM, V280, P20824, DOI 10.1074/jbc.M414314200; Yamaguchi Y, 2007, J MED CHEM, V50, P6647, DOI 10.1021/jm701031n; Yong Dongeun, 2009, Antimicrob Agents Chemother, V53, P5046, DOI 10.1128/AAC.00774-09	47	194	211	0	68	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2574	2582		10.1096/fj.11-184036	http://dx.doi.org/10.1096/fj.11-184036			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507902				2022-12-28	WOS:000293337800008
J	Nie, YH; Ma, RC; Chan, JCN; Xu, HY; Xu, G				Nie, Yaohui; Ma, Ronald C.; Chan, Juliana C. N.; Xu, Haiyan; Xu, Gang			Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes	FASEB JOURNAL			English	Article						G-protein-coupled receptor; cAMP-PKA pathway; IKK beta; JNK; inflammatory cytokines	GASTRIC-INHIBITORY POLYPEPTIDE; LIPOPROTEIN-LIPASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE; TYPE-2 DIABETES-MELLITUS; HYPERGLYCEMIC OB/OB MICE; TUMOR-NECROSIS-FACTOR; 3T3-L1 CELLS; HIGH-FAT; GLYCEMIC CONTROL; ADIPOSE-TISSUE	Glucose-dependent insulinotropic peptide (GIP) exerts multiple biological effects via the G-protein-coupled receptor GIPR, including glucose-stimulated insulin production and secretion, cell proliferation, and antiapoptosis in pancreatic beta-cells. In an obese state, the circulating level of GIP is elevated. GIPR-knockout mice are resistant to high-fat-diet-induced obesity. The rising evidence suggests a potential role of GIP in adipocyte biology and lipid metabolism. In our study, we overexpressed GIPR in 3T3-L1 CAR adipocytes and demonstrated that GIP impaired the physiological functions of adipocytes as a consequence of increased production of inflammatory cytokines and chemokines and phosphorylation of IkB kinase (IKK)-beta through activation of the cAMP-PKA pathway. Activation of Jun N-terminal kinase (JNK) pathway was also observed during GIP-induced inflammatory responses in adipocytes. The inhibition of JNK blocked GIP-stimulated secretion of inflammatory cytokines and chemokines, as well as phosphorylation of IKK beta. In addition, GIP-induced inflammatory response increased basal glucose uptake but inhibited insulin-stimulated glucose uptake. Moreover, GIP-induced adipocyte inflammation impaired insulin signaling in adipocytes as demonstrated by a reduction of AKT phosphorylation. Our results suggest that GIP might be one of the stimuli attributable to obesity-induced insulin resistance via the induction of adipocyte inflammation.-Nie, Y., Ma, R. C., Chan, J. C., Xu, H., Xu, G. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 26, 2383-2393 (2012). www.fasebj.org	[Nie, Yaohui; Ma, Ronald C.; Chan, Juliana C. N.; Xu, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Ma, Ronald C.; Chan, Juliana C. N.; Xu, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Shatin, Hong Kong, Peoples R China; [Ma, Ronald C.; Chan, Juliana C. N.; Xu, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Nie, Yaohui; Xu, Haiyan] Hallett Ctr Diabet & Endocrinol, Dept Med, Brown Med Sch, Providence, RI USA; [Xu, Gang] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Brown University; Chinese University of Hong Kong, Shenzhen	Xu, G (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	gangxu@cuhk.edu.hk	Chan, Juliana/B-7918-2016; Ma, Ronald/C-2788-2009	Chan, Juliana/0000-0003-1325-1194; Ma, Ronald/0000-0002-1227-803X	Hong Kong Government Research Grant Committee [478110]; National Natural Science of Foundation of China [81170722]; American Heart Association	Hong Kong Government Research Grant Committee; National Natural Science of Foundation of China(National Natural Science Foundation of China (NSFC)); American Heart Association(American Heart Association)	The authors thank the other members of their laboratory for support and helpful discussions. This work was supported by the Hong Kong Government Research Grant Committee (478110) and the National Natural Science of Foundation of China (81170722; to G. X.). The work was also supported by an American Heart Association Scientist Development grant (to H. X.).	Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; BAILEY CJ, 1986, ACTA ENDOCRINOL-COP, V112, P224, DOI 10.1530/acta.0.1120224; Choy Mary, 2007, Cardiol Rev, V15, P264, DOI 10.1097/CRD.0b013e318123f771; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826, DOI 10.1210/jcem-37-5-826; DUPRE J, 1976, METABOLISM, V25, P1197, DOI 10.1016/S0026-0495(76)80002-9; ECKEL RH, 1979, DIABETES, V28, P1141, DOI 10.2337/diabetes.28.12.1141; EGAN JM, 1994, ENDOCRINOLOGY, V135, P2070, DOI 10.1210/en.135.5.2070; ELLIOTT RM, 1993, J ENDOCRINOL, V138, P159, DOI 10.1677/joe.0.1380159; Fan R, 2010, DIABETES OBES METAB, V12, P815, DOI 10.1111/j.1463-1326.2010.01238.x; Fineman MS, 2003, DIABETES CARE, V26, P2370, DOI 10.2337/diacare.26.8.2370; FLATT PR, 1984, J ENDOCRINOL, V101, P249, DOI 10.1677/joe.0.1010249; Gloerich M, 2010, ANNU REV PHARMACOL, V50, P355, DOI 10.1146/annurev.pharmtox.010909.105714; Green BD, 2004, CURR PHARM DESIGN, V10, P3651, DOI 10.2174/1381612043382774; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Iltz JL, 2006, CLIN THER, V28, P652, DOI 10.1016/j.clinthera.2006.05.006; Irwin N, 2007, DIABETES-METAB RES, V23, P572, DOI 10.1002/dmrr.729; Jiao P, 2009, DIABETES, V58, P104, DOI 10.2337/db07-1344; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; KAWAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P331, DOI 10.1093/oxfordjournals.jbchem.a121917; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; Kim SJ, 2007, J BIOL CHEM, V282, P34139, DOI 10.1074/jbc.M704896200; Kim SJ, 2007, J BIOL CHEM, V282, P8557, DOI 10.1074/jbc.M609088200; Kim SJ, 2010, J LIPID RES, V51, P3145, DOI 10.1194/jlr.M006841; KNAPPER JME, 1995, J NUTR, V125, P183; Kolterman OG, 2003, J CLIN ENDOCR METAB, V88, P3082, DOI 10.1210/jc.2002-021545; McClean PL, 2007, AM J PHYSIOL-ENDOC M, V293, pE1746, DOI 10.1152/ajpendo.00460.2007; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Mohammad S, 2011, J BIOL CHEM, V286, P43062, DOI 10.1074/jbc.M111.289009; MORGAN LM, 1988, BRIT J NUTR, V60, P29, DOI 10.1079/BJN19880073; Mottillo E. P., BIOCH BIOPHYS ACTA, V1801, P1048; Nie YH, 2009, J CELL MOL MED, V13, P3051, DOI 10.1111/j.1582-4934.2008.00382.x; Orlicky DJ, 2001, J LIPID RES, V42, P910; Qi L, 2009, CELL METAB, V9, P277, DOI 10.1016/j.cmet.2009.01.006; RABEN A, 1994, AM J PHYSIOL-ENDOC M, V267, pE549, DOI 10.1152/ajpendo.1994.267.4.E549; Raz I, 2006, DIABETOLOGIA, V49, P2564, DOI 10.1007/s00125-006-0416-z; ROUST LR, 1988, AM J PHYSIOL, V254, pE767, DOI 10.1152/ajpendo.1988.254.6.E767; Ruan H, 2003, J BIOL CHEM, V278, P47585, DOI 10.1074/jbc.M305257200; RUIZGRANDE C, 1992, PEPTIDES, V13, P13, DOI 10.1016/0196-9781(92)90134-O; SEMB H, 1987, J BIOL CHEM, V262, P8390; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; SIEGEL EG, 1985, DIABETOLOGIA, V28, P857, DOI 10.1007/BF00291078; Song DH, 2007, GASTROENTEROLOGY, V133, P1796, DOI 10.1053/j.gastro.2007.09.005; Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686; Tchivileva IE, 2009, MOL IMMUNOL, V46, P2256, DOI 10.1016/j.molimm.2009.04.008; Villanueva-Penacarrillo ML, 2001, HORM METAB RES, V33, P73, DOI 10.1055/s-2001-12428; WASADA T, 1981, J CLIN INVEST, V68, P1106, DOI 10.1172/JCI110335; Weaver RE, 2008, INT J OBESITY, V32, P1705, DOI 10.1038/ijo.2008.148; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yip RGC, 1998, ENDOCRINOLOGY, V139, P4004, DOI 10.1210/en.139.9.4004	54	37	41	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2383	2393		10.1096/fj.11-196782	http://dx.doi.org/10.1096/fj.11-196782			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22366643				2022-12-28	WOS:000305017200016
J	Ceraudo, E; Hierso, R; Tan, YV; Murail, S; Rouyer-Fessard, C; Nicole, P; Robert, JC; Jamin, N; Neumann, JM; Robberecht, P; Laburthe, M; Couvineau, A				Ceraudo, Emilie; Hierso, Regine; Tan, Yossan-Var; Murail, Samuel; Rouyer-Fessard, Christiane; Nicole, Pascal; Robert, Jean-Claude; Jamin, Nadege; Neumann, Jean-Michel; Robberecht, Patrick; Laburthe, Marc; Couvineau, Alain			Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction	FASEB JOURNAL			English	Article						VIP; GPCR; inflammatory diseases; binding site	PROTEIN-COUPLED-RECEPTOR; VASOACTIVE-INTESTINAL-PEPTIDE; CLASS-B GPCR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; MOLECULAR RECOGNITION; SELECTIVE ANTAGONIST; ECTODOMAIN COMPLEX; LIGAND-BINDING; VIP1 RECEPTOR	Vasoactive intestinal peptide (VIP) plays a major role in pathophysiology. Our previous studies demonstrated that the VIP sequence 6-28 interacts with the N-terminal ectodomain (N-ted) of its receptor, VPAC1. Probes for VIP and receptor antagonist PG97-269 were synthesized with a photolabile residue/Bpa at various positions and used to explore spatial proximity with VPAC1. PG97-269 probes with Bpa at position 0, 6, and 24 behaved as high-affinity receptor antagonists (K-i=12, 9, and 7 nM, respectively). Photolabeling experiments revealed that the [Bpa(0)]-VIP probe was in physical contact with VPAC1 Q(135), while [Bpa(0)]-PG97-269 was covalently bound to G(62) residue of N-ted, indicating different binding sites. In contrast, photolabeling with [Bpa(6)]-and [Bpa(24)]-PG97-269 showed that the distal domains of PG97-269 interacted with N-ted, as we previously showed for VIP. Substitution with alanine of the K-143, T-144, and T-147 residues located in the first transmembrane domain of VPAC1 induced a loss of receptor affinity (IC50=1035, 874, and 2070 nM, respectively), and pharmacological studies using VIP2-28 indicated that these three residues play an important role in VPAC1 interaction with the first histidine residue of VIP. These data demonstrate that VIP and PG97-269 bind to distinct domains of VPAC1.-Ceraudo, E., Hierso, R., Tan, Y.-V., Murail, S., Rouyer-Fessard C., Nicole, P., Robert, J.-C., Jamin, N., Neumann, J.-M., Robberecht, P., Laburthe, M., Couvineau, A. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J. 26, 2060-2071 (2012). www.fasebj.org	[Ceraudo, Emilie; Hierso, Regine; Tan, Yossan-Var; Rouyer-Fessard, Christiane; Nicole, Pascal; Robert, Jean-Claude; Laburthe, Marc; Couvineau, Alain] Univ Paris 07, Fac Med Xavier Bichat, Inst Natl Sante & Rech Med INSERM 773, Ctr Rech Biomed Bichat Beaujon, F-75018 Paris, France; [Murail, Samuel; Jamin, Nadege; Neumann, Jean-Michel] Ctr Etud Saclay, CNRS,SB2SM, URA 2096,DSV,Inst Biol & Technol Saclay iBiTecS, Commissariat Energie Atom & Energies Alternat CEA, F-91191 Gif Sur Yvette, France; [Robberecht, Patrick] Univ Libre Brussels, Brussels, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles	Couvineau, A (corresponding author), Univ Paris 07, INSERM, U773, CRB3, 16 Rue Henri Huchard, F-75018 Paris, France.	alain.couvineau@inserm.fr	couvineau, alain/T-3466-2019; couvineau, alain/G-3641-2013; Jamin, Nadege/AAA-7067-2021; Murail, Samuel/AAC-3897-2019	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; Murail, Samuel/0000-0002-3842-5333	Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique; Universite Paris 7; Association de Recherche sur la Polyarthrite; Fondation pour la Recherche Medicale [FDT20070910820]; Interuniversity Poles of Attraction from the Universite Libre de Bruxelles (Brussels, Belgium)	Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique(Institut National de la Sante et de la Recherche Medicale (Inserm)Centre National de la Recherche Scientifique (CNRS)); Universite Paris 7; Association de Recherche sur la Polyarthrite; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Interuniversity Poles of Attraction from the Universite Libre de Bruxelles (Brussels, Belgium)	This work was supported by the Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, the Universite Paris 7, and a grant from the Association de Recherche sur la Polyarthrite. E.C. is supported by grant FDT20070910820 from the Fondation pour la Recherche Medicale and by an Interuniversity Poles of Attraction Program from the Universite Libre de Bruxelles (Brussels, Belgium).	Boeckler F, 2005, J MED CHEM, V48, P694, DOI 10.1021/jm049612a; Ceraudo E, 2008, MOL ENDOCRINOL, V22, P147, DOI 10.1210/me.2007-0361; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Chugunov AO, 2010, MOL PHARMACOL, V78, P394, DOI 10.1124/mol.110.063578; COUVINEAU A, 1984, BIOCHEM BIOPH RES CO, V121, P493, DOI 10.1016/0006-291X(84)90209-2; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; Couvineau A, 2010, NEUROPEPTIDES, V44, P127, DOI 10.1016/j.npep.2009.11.008; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Couvineau A, 2008, J MOL NEUROSCI, V36, P249, DOI 10.1007/s12031-008-9072-8; De Vries SJ, 2007, PROTEINS, V69, P726, DOI 10.1002/prot.21723; Dejda A, 2005, PHARMACOL REP, V57, P307; Delgado M, 2004, PHARMACOL REV, V56, P249, DOI 10.1124/pr.56.2.7; Dong M, 2011, J BIOL CHEM, V286, P23888, DOI 10.1074/jbc.M111.245969; Du K, 1997, BIOCHEM BIOPH RES CO, V230, P289, DOI 10.1006/bbrc.1996.5949; Du K, 2002, J BIOL CHEM, V277, P37016, DOI 10.1074/jbc.M203049200; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Grace CRR, 2007, P NATL ACAD SCI USA, V104, P4858, DOI 10.1073/pnas.0700682104; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Heyda J, 2010, J PHYS CHEM B, V114, P8744, DOI 10.1021/jp101031v; Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359-6446(05)03370-2; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Koth CM, 2010, BIOCHEMISTRY-US, V49, P1862, DOI 10.1021/bi901848m; Kumar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019682; Laburthe M, 2007, PEPTIDES, V28, P1631, DOI 10.1016/j.peptides.2007.04.026; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; Neumann JM, 2008, TRENDS BIOCHEM SCI, V33, P314, DOI 10.1016/j.tibs.2008.05.001; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parthier C, 2007, P NATL ACAD SCI USA, V104, P13942, DOI 10.1073/pnas.0706404104; Pioszak AA, 2008, J BIOL CHEM, V283, P32900, DOI 10.1074/jbc.M805749200; Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Runge S, 2008, J BIOL CHEM, V283, P11340, DOI 10.1074/jbc.M708740200; SALOMON R, 1993, AM J PHYSIOL, V264, pE294, DOI 10.1152/ajpendo.1993.264.2.E294; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Sun CH, 2007, P NATL ACAD SCI USA, V104, P7875, DOI 10.1073/pnas.0611397104; Tan YV, 2006, J BIOL CHEM, V281, P12792, DOI 10.1074/jbc.M513305200; Tan YV, 2004, J BIOL CHEM, V279, P38889, DOI 10.1074/jbc.M404460200; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; ter Haar E, 2010, STRUCTURE, V18, P1083, DOI 10.1016/j.str.2010.05.014; Underwood CR, 2010, J BIOL CHEM, V285, P723, DOI 10.1074/jbc.M109.033829; Vaudry H, 2006, ANN NY ACAD SCI, V1070, P1; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Wittelsberger A, 2006, BIOCHEMISTRY-US, V45, P2027, DOI 10.1021/bi051833a; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Wuthrich K., 1986, PROTEINS, V1, P34	49	19	19	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2060	2071		10.1096/fj.11-196444	http://dx.doi.org/10.1096/fj.11-196444			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22291440				2022-12-28	WOS:000303680800032
J	Klein, J; Jupp, S; Moulos, P; Fernandez, M; Buffin-Meyer, B; Casemayou, A; Chaaya, R; Charonis, A; Bascands, JL; Stevens, R; Schanstra, JP				Klein, Julie; Jupp, Simon; Moulos, Panagiotis; Fernandez, Myriem; Buffin-Meyer, Benedicte; Casemayou, Audrey; Chaaya, Rana; Charonis, Aristidis; Bascands, Jean-Loup; Stevens, Robert; Schanstra, Joost P.			The KUPKB: a novel Web application to access multiomics data on kidney disease	FASEB JOURNAL			English	Article						renal pathophysiology; genomics; proteomics; bioinformatics; experimental data	TO-MESENCHYMAL TRANSITION; FIBROSIS; BIOINFORMATICS; CALRETICULIN; KNOWLEDGE; PATHWAYS; RESOURCE; ONTOLOGY; CELLS	The information gathered from the large number of omics experiments in renal biology is under-explored, as it is scattered over many publications or held in supplemental data. To address this, we have developed an open-source Kidney and Urinary Pathway Knowledge Base (KUPKB) that facilitates simple exploration of these omics data. The KUPKB currently comprises 220 data sets (miRNA, mRNA, proteins, and metabolites) extracted from existing publications or databases. Researchers can explore the integrated data using the iKUP browser, and a simple template is provided to submit new omics data sets to the knowledge base. As an example of iKUP's use, we show how we identified, in silico, calreticulin as a protein induced in human interstitial fibrosis and tubular atrophy (IFTA) in chronic kidney transplant rejection; a link that would have been difficult to establish using existing Web-based tools. Using immunohistochemistry, we validated in vivo this in silico result in human and rat biopsies of IFTA, thus identifying calreticulin as a potential new player in chronic kidney transplant rejection. The KUPKB provides a simple tool that enables users to quickly survey a wide range of omics data sets and has been shown to facilitate rapid hypothesis generation in the context of renal pathophysiology.-Klein, J., Jupp, S., Moulos, P., Fernandez, M., Buffin-Meyer, B., Casemayou, A., Chaaya, R., Charonis, A., Bascands, J.-L., Stevens, R., Schanstra, J. P. The KUPKB: a novel Web application to access multiomics data on kidney disease. FASEB J. 26, 2145-2153 (2012). www.fasebj.org	[Klein, Julie; Moulos, Panagiotis; Fernandez, Myriem; Buffin-Meyer, Benedicte; Casemayou, Audrey; Chaaya, Rana; Bascands, Jean-Loup; Schanstra, Joost P.] Inst Cardiovasc & Metab Dis, INSERM, U1048, F-31432 Toulouse 4, France; [Klein, Julie; Moulos, Panagiotis; Fernandez, Myriem; Buffin-Meyer, Benedicte; Casemayou, Audrey; Chaaya, Rana; Bascands, Jean-Loup; Schanstra, Joost P.] Univ Toulouse 3, F-31062 Toulouse, France; [Jupp, Simon; Stevens, Robert] Univ Manchester, Sch Comp Sci, Manchester, Lancs, England; [Charonis, Aristidis] Acad Athens, Biomed Res Fdn, Ctr Basic Res 1, Sect Histol, Athens, Greece	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Manchester; Academy of Athens	Klein, J (corresponding author), Inst Cardiovasc & Metab Dis, INSERM, U1048, 1 Ave Jean Poulhes, F-31432 Toulouse 4, France.	julie.klein64@gmail.com; joost-peter.schanstra@inserm.fr	Schanstra, Joost P/X-7724-2018; Moulos, Panagiotis/E-2335-2018; Klein, Julie/ABE-2622-2020; Buffin-Meyer, Bénédicte/X-7705-2018; Bascands, Jean-loup/G-3260-2013; Klein, Julie/M-7088-2017	Schanstra, Joost P/0000-0002-7471-372X; Moulos, Panagiotis/0000-0002-4199-0333; Klein, Julie/0000-0002-3279-0559; Buffin-Meyer, Bénédicte/0000-0002-4805-1558; Klein, Julie/0000-0002-3279-0559; Bascands, Jean-loup/0000-0002-1667-5913; Jupp, Simon/0000-0002-0643-3144; Charonis, Aristidis/0000-0001-9956-732X	FP7-PEOPLE-2009-IAPP program Protoclin [GA 251368]; INSERM; Direction Regional Clinique [Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France); Direction de la Recherche Medicale et Innovation (CHU de Toulouse) under the Contrat Hospitalier de Recherche Translationnelle;  [EU/FP7/ICT-2007.4.4 e-LICO]	FP7-PEOPLE-2009-IAPP program Protoclin; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Direction Regional Clinique [Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France); Direction de la Recherche Medicale et Innovation (CHU de Toulouse) under the Contrat Hospitalier de Recherche Translationnelle; 	The authors thank EuroKUP members for participating in the KUPO day, in particular Antonia Vlahou, Jorgen Frokaier, Alberto Ortiz, and Harry Holthofer for useful suggestions; Michael Wicks and Duncan Davidson (Medical Research Council Human Genetics Unit, Edinburgh, UK) for supplying the EuReGene data set; the RF lab (http://www.renalfibrosis.fr) for continuous support and constructive comments; and Aureja Steponaviciute. and Aurelien Despierris for artistic participation in designing the logo and website. The authors thank Celine Gales [Institut National de la Sante et de la Recherche Medicale (INSERM) 1048, Team 8, Toulouse, France] for providing the rabbit anti-HA antibody and Laurent Sicard for help with immunohistology. This work is funded by the EU/FP7/ICT-2007.4.4 e-LICO project (http://www.e-lico.eu) and by the FP7-PEOPLE-2009-IAPP program Protoclin (GA 251368). J.L.B. acknowledges support by INSERM and the Direction Regional Clinique [Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France) under the Interface program. J.P.S. was supported by INSERM and the Direction de la Recherche Medicale et Innovation (CHU de Toulouse) under the Contrat Hospitalier de Recherche Translationnelle program. S.J., J.K., A.C., J.-L.B., and J.P.S. are members of COST action EuroKUP (http://www.eurokup.org). The KUPKB is available online (http://www.kupkb.org).	Barati MT, 2007, AM J PHYSIOL-RENAL, V293, pF1157, DOI 10.1152/ajprenal.00411.2006; Bard J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-r21; Baron D, 2011, BIOINFORMATICS, V27, P725, DOI 10.1093/bioinformatics/btq710; Belleau F, 2008, J BIOMED INFORM, V41, P706, DOI 10.1016/j.jbi.2008.03.004; Chaaya R, 2011, NEPHROL DIAL TRANSPL, V26, P489, DOI 10.1093/ndt/gfq445; Chatziioannou A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-354; Chen YX, 2010, AM J NEPHROL, V31, P24, DOI 10.1159/000253865; Davidson S B, 1995, J Comput Biol, V2, P557, DOI 10.1089/cmb.1995.2.557; European Molecular Biology Laboratory-European Bioinformatics Institute, MICROCOSM TARG VERS; Goble C, 2008, J BIOMED INFORM, V41, P687, DOI 10.1016/j.jbi.2008.01.008; Harding SD, 2011, DEVELOPMENT, V138, P2845, DOI 10.1242/dev.063594; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hayamizu TF, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r29; Hills CE, 2010, MOL ENDOCRINOL, V24, P822, DOI 10.1210/me.2009-0391; Jupp Simon, 2011, J Biomed Semantics, V2 Suppl 2, pS7, DOI 10.1186/2041-1480-2-S2-S7; Klein J, 2010, J AM SOC NEPHROL, V21, P1157, DOI 10.1681/ASN.2009090887; Kypreou KP, 2008, PROTEOMICS, V8, P2407, DOI 10.1002/pmic.200700831; Laughery MD, 2007, AM J PHYSIOL-RENAL, V292, pF1718, DOI 10.1152/ajprenal.00360.2006; Miyamoto M, 2007, J PROTEOME RES, V6, P3680, DOI 10.1021/pr070203n; Mueller CFH, 2008, BIOCHEM BIOPH RES CO, V370, P669, DOI 10.1016/j.bbrc.2008.04.011; Nakorchevsky A, 2010, J AM SOC NEPHROL, V21, P362, DOI 10.1681/ASN.2009060628; *NAT CTR BIOT INF, HOMOLOGENE; Pisitkun T, 2006, PHYSIOL GENOMICS, V25, P263, DOI 10.1152/physiolgenomics.00214.2005; Rajasekaran SA, 2010, MOL CANCER THER, V9, P1515, DOI 10.1158/1535-7163.MCT-09-0832; Renal GO Working Group, GO ANN REN SYST; Ruttenberg A. R. J., 2008, PROTOTYPE KNOWLDEGE; Shadbolt N, 2006, IEEE INTELL SYST, V21, P96, DOI 10.1109/MIS.2006.62; Stevens RD, 2004, BIOINFORMATICS, V20, P303, DOI 10.1093/bioinformatics/bth944; Stevens R, 2007, INT J HUM-COMPUT ST, V65, P583, DOI 10.1016/j.ijhcs.2007.03.006; The National Center for Biotechnology Information, ENTR GEN; Universal Protein Resource Consortium, UNIPROT KNOWL BAS; Weiss RH, 2012, NAT REV NEPHROL, V8, P22, DOI 10.1038/nrneph.2011.152; World Wide Web Consortium, W3C REC; Xu YF, 2009, J NEPHROL, V22, P403; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	35	27	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2145	2153		10.1096/fj.11-194381	http://dx.doi.org/10.1096/fj.11-194381			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22345404				2022-12-28	WOS:000303680800040
J	Siggens, L; Figg, N; Bennett, M; Foo, R				Siggens, Lee; Figg, Nichola; Bennett, Martin; Foo, Roger			Nutrient deprivation regulates DNA damage repair in cardiomyocytes via loss of the base-excision repair enzyme OGG1	FASEB JOURNAL			English	Article						8-oxoG; cardiomyopathy; oxidative genomic damage; heart failure	CARDIAC MYOCYTE APOPTOSIS; HEART-FAILURE; CELL-DEATH; OXIDATIVE STRESS; HEMODYNAMIC STRESS; PRESSURE-OVERLOAD; AUTOPHAGY; DISEASE; MECHANISMS; HYPERTROPHY	Oxidative stress contributes to the pathogenesis of many diseases, including heart failure, but the role and regulation of oxidative DNA damage in many cases have not been studied. Here, we set out to examine how oxidative DNA damage is regulated in cardiomyocytes. Compared to normal healthy controls, human hearts in end-stage cardiomyopathy (EsCM) showed a high degree of DNA damage by histological evidence of damage markers, including 8-oxoG and gamma H2AX (8-oxoG: 4.7 +/- 0.88 vs. 99.9 +/- 0.11%; gamma H2AX: 2.1 +/- 0.33 vs. 85.0 +/- 13.8%; P<0.01) This raised the possibility that defective DNArepair may be partly responsible. Indeed, nutrient deprivation led to impaired base-excision repair (BER) in cardiomyocytes in vitro, accompanied by loss of the BER enzyme OGG1, while BER activity was rescued by recombinant OGG1 (control vs. nutrient deprived vs. nutrient deprived + OGG1; 100 +/- 2.96 vs. 68.2 +/- 7.53 vs. 94.0 +/- 0.72%; ANOVA, P<0.01). Hearts from humans with EsCM and two murine models of myocardial stress also showed a loss of OGG1 protein. OGG1 loss was inhibited by the autophagy inhibitor bafilomycin and in autophagy-deficient Atg5(-/-) mouse embryonic fibroblasts. However, pharmacological activation of autophagy, itself, did not induce OGG1 loss, suggesting that autophagy is necessary but not sufficient for OGG1 turnover, and OGG1 loss requires concurrent nutrient deprivation. Finally, we found that the role of autophagy in nutrient starvation is complex, since it balanced the positive effects of ROS inhibition against the negative effect of OGG1 loss. Therefore, we have identified a central role for OGG1 in regulating DNA repair in cardiomyopathy. The manipulation of OGG1 may be used in future studies to examine the direct contribution of oxidative DNA damage to the progression of heart failure.-Siggens, L., Figg, N., Bennett, M., Foo, R. Nutrient deprivation regulates DNA damage repair in cardiomyocytes via loss of the base-excision repair enzyme OGG1. FASEB J. 26, 2117-2124 (2012). www.fasebj.org	[Siggens, Lee; Figg, Nichola; Bennett, Martin; Foo, Roger] Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Foo, R (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Addenbrookes Ctr Clin Invest Bldg,Level 6, Cambridge CB2 0QQ, England.	rsyf2@cam.ac.uk		Bennett, Martin/0000-0002-2565-1825; Siggens, Lee/0000-0001-7277-3633; Foo, Roger/0000-0002-8079-4618	Wellcome Trust; British Heart Foundation (BHF); UK National Institute for Health Research Cambridge Biomedical Research Centre; MRC [G1000847, G0800784] Funding Source: UKRI; British Heart Foundation [RG/08/009/25841] Funding Source: researchfish; Medical Research Council [G1000847, G0800784] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation (BHF)(British Heart Foundation); UK National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	L.S. is supported by a Wellcome Trust Studentship in Metabolic and Cardiovascular Disease, M.R.B. is supported by a British Heart Foundation (BHF) professorship, and R.S.F. is supported by a BHF intermediate fellowship. This study is also supported by the UK National Institute for Health Research Cambridge Biomedical Research Centre.	Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bozkurt B, 2010, HEART FAIL REV, V15, P331, DOI 10.1007/s10741-009-9140-3; Choy MK, 2010, GENOME MED, V2, DOI 10.1186/gm158; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; Foo RSY, 2007, J BIOL CHEM, V282, P5529, DOI 10.1074/jbc.M609046200; Foo RSY, 2006, J CELL PHYSIOL, V209, P1, DOI 10.1002/jcp.20723; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Gottlieb RA, 2010, ANNU REV PHYSIOL, V72, P45, DOI 10.1146/annurev-physiol-021909-135757; Hare JM, 2001, CIRC RES, V89, P198, DOI 10.1161/res.89.3.198; Hill JW, 2008, DNA REPAIR, V7, P648, DOI 10.1016/j.dnarep.2008.01.003; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Knaapen MWM, 2001, CARDIOVASC RES, V51, P304, DOI 10.1016/S0008-6363(01)00290-5; Kubota C, 2010, J BIOL CHEM, V285, P667, DOI 10.1074/jbc.M109.053058; Lammens K, 2011, CELL, V145, P54, DOI 10.1016/j.cell.2011.02.038; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mirbahai L, 2010, DNA REPAIR, V9, P144, DOI 10.1016/j.dnarep.2009.11.009; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Movassagh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008564; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Oka S, 2008, EMBO J, V27, P421, DOI 10.1038/sj.emboj.7601975; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Sano M, 2007, NATURE, V446, P444, DOI 10.1038/nature05602; Saxowsky TT, 2008, P NATL ACAD SCI USA, V105, P18877, DOI 10.1073/pnas.0806464105; Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005; Tachibana H, 2005, CIRCULATION, V111, P591, DOI 10.1161/01.CIR.0000142291.70954.DF; Takemura G, 2009, AUTOPHAGY, V5, P1034, DOI 10.4161/auto.5.7.9297; Tang JB, 2010, MOL CANCER RES, V8, P67, DOI 10.1158/1541-7786.MCR-09-0411; Webster KA, 2007, ANTIOXID REDOX SIGN, V9, P1303, DOI 10.1089/ars.2007.1730; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523	38	44	46	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2117	2124		10.1096/fj.11-197525	http://dx.doi.org/10.1096/fj.11-197525			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22302830	Green Accepted			2022-12-28	WOS:000303680800037
J	Hwang, SY; Putney, JW				Hwang, Sung-Yong; Putney, James W.			Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1	FASEB JOURNAL			English	Article						store-operated channels; bone remodeling; osteoporosis; receptor activator of nuclear factor kappa B ligand; tartrate-resistant acid phosphatase	KAPPA-B LIGAND; T-CELLS C1; BONE-RESORPTION; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; SIGNALING PATHWAY; PROTEIN-KINASE; NUCLEAR FACTOR	Bone diseases such as postmenopausal osteoporosis are primarily caused by excessive formation and activity of osteoclasts (OCLs). Receptor activator of nuclear factor-kappa B ligand (RANKL) is a key initiating cytokine for OCL differentiation and function. RANKL induces calcium (Ca2+) oscillations, resulting in selective and robust induction of nuclear factor of activated T cells c1 (NFATc1), a Ca2+-responsive transcription factor that drives osteoclastogenesis. Store-operated Ca2+ entry (SOCE) is a major Ca2+ influx pathway in most nonexcitable cell types and is activated by any stimulus that depletes Ca2+ stores in the endoplasmic reticulum. Although the role of Orai1, a SOCE channel in the plasma membrane, in maintaining Ca2+ oscillations and transactivation of NFAT in other cell types is well known, its contribution to osteoclastogenesis remains unclear. We show here that silencing of the Orai1 gene with viral delivery of shRNA reduces SOCE and inhibits RANKL-induced osteoclastogenesis of RAW264.7 cells, a murine monocyte/macrophage cell line, by suppressing the induction of NFATc1. This was accompanied by defective induction of OCL-specific genes, such as tartrate-resistant acid phosphatase and immunoreceptor OCL-associated receptor, which are known to be direct transcriptional targets of NFATc1 during osteoclastogenesis. In addition, maturation of OCLs was abrogated by defective cell fusion of pre-OCLs depleted of Orai1, consistent with defective RANKL-mediated induction of d2 isoform of vacuolar ATPase V-o domain that is involved in cell fusion of pre-OCLs. We found that the functional bone resorbing capacity was severely impaired in OCLs depleted of Orai1, potentially related to the observed decrease in the induction of cathepsin K, a major bone matrix degrading protease. Our results indicate that Orai1 plays a critical role in the differentiation and function of OCLs, suggesting that Orai1 might be a potential therapeutic target for the treatment or prevention of bone loss caused by OCLs.-Hwang, S.-Y., Putney, J. W. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J. 26, 1484 -1492 (2012). www.fasebj.org	[Hwang, Sung-Yong; Putney, James W.] NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hwang, SY (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	hwangs3@niehs.nih.gov	Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789	U.S. National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by the Intramural Research Program of the U.S. National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS). The authors thank Dr. Xiaoling Li and Dr. Robert Oakley for helpful comments. The authors thank Dr. Gary Bird for technical advice and helpful discussion. The authors also thank Dr. Charles Romeo and Dr. Negin Martin (Viral Vector Core, NIEHS) for lentivirus preparations.	Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; Blair H. C., 2007, V45, P539; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; FALLON MD, 1983, LAB INVEST, V49, P159; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Fujikawa Y, 1996, BRIT J RHEUMATOL, V35, P213; Gelb BD, 1996, BIOCHEM MOL MED, V59, P200, DOI 10.1006/bmme.1996.0088; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Hwang SY, 2011, BBA-MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Kar P, 2011, J BIOL CHEM, V286, P14795, DOI 10.1074/jbc.M111.220582; Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Lin JT, 2004, CLIN ORTHOP RELAT R, P126, DOI 10.1097/01.blo.0000132404.30139.f2; Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Mentaverri R, 2003, CELL CALCIUM, V34, P169, DOI 10.1016/S0143-4160(03)00080-0; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mohamed SGK, 2005, BIOCHEM BIOPH RES CO, V329, P839, DOI 10.1016/j.bbrc.2005.02.049; Novack DV, 2008, ANNU REV PATHOL-MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; Wedel B, 2007, J PHYSIOL-LONDON, V579, P679, DOI 10.1113/jphysiol.2006.125641; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593; Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423	48	48	49	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1484	1492		10.1096/fj.11-194399	http://dx.doi.org/10.1096/fj.11-194399			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198385	Green Published			2022-12-28	WOS:000302359700011
J	Grubb, DR; Luo, JT; Yu, YL; Woodcock, EA				Grubb, David R.; Luo, Jieting; Yu, Yen Lin; Woodcock, Elizabeth A.			Scaffolding protein Homer 1c mediates hypertrophic responses downstream of Gq in cardiomyocytes	FASEB JOURNAL			English	Article						Shank3; alpha(1)-adrenergic receptor; phospholipase C beta 1b	CARDIAC-HYPERTROPHY; MYOCARDIAL HYPERTROPHY; PRESSURE-OVERLOAD; SHANK FAMILY; HEART; CA2+; ACTIVATION; SKELETAL; CHANNELS; BRAIN	Activation of the heterotrimeric G protein, Gq, causes cardiomyocyte hypertrophy in vivo and in cell models. Responses to activated Gq in cardiomyocytes are mediated exclusively by phospholipase C beta 1b (PLC beta 1b), because it localizes at the sarcolemma by binding to Shank3, a high-molecular-weight (MW) scaffolding protein. Shank3 can bind to the Homer family of low-MW scaffolding proteins that fine tune Ca2+ signaling by facilitating crosstalk between Ca2+ channels at the cell surface with those on intracellular Ca2+ stores. Activation of alpha(1)-adrenergic receptors, expression of constitutively active G alpha q (G alpha qQL), or PLC beta 1b initiated cardiomyocyte hypertrophy and increased Homer 1c mRNA expression, by 1.6 +/- 0.18-, 1.9 +/- 0.17-, and 1.5 +/- 0.07-fold, respectively (means +/- SE, 6 independent experiments, P<0.05). Expression of Homer 1c induced an increase in cardiomyocyte area from 853 +/- 27 to 1146 +/- 31 mu m(2) (P<0.05); furthermore, expression of dominant-negative Homer (Homer 1a) reversed the increase in cell size caused by alpha(1)-adrenergic agonist or PLC beta 1b treatment (1503 +/- 48 to 996 +/- 28 and 1626 +/- 48 to 828 +/- 31 mu m(2), respectively, P<0.05). Homer proteins were localized near the sarcolemma, associated with Shank3 and phospholipase C beta 1b. We conclude that Gq-mediated hypertrophy involves activation of PLC beta 1b scaffolded onto a Shank3/Homer complex. Signaling downstream of Homer 1c is necessary and sufficient for Gq-initiated hypertrophy.-Grubb, D. R., Luo, J., Yu, Y. L., Woodcock, E. A. Scaffolding protein Homer 1c mediates hypertrophic responses downstream of Gq in cardiomyocytes. FASEB J. 26, 596-603 (2012). www.fasebj.org	[Grubb, David R.; Luo, Jieting; Yu, Yen Lin; Woodcock, Elizabeth A.] Baker IDI Heart & Diabet Inst, Mol Cardiol Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker IDI Heart & Diabet Inst, Mol Cardiol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@bakeridi.edu.au			National Health and Medical Research Council (NHMRC) of Australia [526621, 526623]; Australian National Heart Foundation [GM08-3695]; Victorian government	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian National Heart Foundation(National Heart Foundation of Australia); Victorian government	This work was supported by grants in aid from the National Health and Medical Research Council (NHMRC) of Australia (526621 and 526623), as well as the Australian National Heart Foundation (GM08-3695). E. A. W. is a Principal Research Fellow of the NHMRC (586621). This work was supported, in part, by the Victorian government's Operational Infrastructure Support Program. The authors thank Monash Medical Imaging (Monash University, Melbourne, VIC, Australia) for confocal microscopy.	Abe H, 2003, MOL CELL NEUROSCI, V23, P157, DOI 10.1016/S1044-7431(03)00052-6; Agrawal R, 2010, PHARMACOL RES, V61, P269, DOI 10.1016/j.phrs.2009.11.012; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Backs J, 2009, P NATL ACAD SCI USA, V106, P2342, DOI 10.1073/pnas.0813013106; Catalucci D, 2008, FRONT BIOSCI-LANDMRK, V13, P312, DOI 10.2741/2681; Ciruela F, 2000, MOL CELL NEUROSCI, V15, P36, DOI 10.1006/mcne.1999.0808; Dorn GW, 2004, ANN NY ACAD SCI, V1015, P225, DOI 10.1196/annals.1302.019; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Eder P, 2011, CIRC RES, V108, P265, DOI 10.1161/CIRCRESAHA.110.225888; Ehrengruber MU, 2004, MOL NEUROBIOL, V29, P213, DOI 10.1385/MN:29:3:213; Fan GF, 2005, J BIOL CHEM, V280, P40337, DOI 10.1074/jbc.M506810200; Filtz TM, 2009, FASEB J, V23, P3564, DOI 10.1096/fj.09-133983; Gasperini R, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-29; Grubb DR, 2008, FASEB J, V22, P2768, DOI 10.1096/fj.07-102558; Grubb DR, 2011, FASEB J, V25, P1040, DOI 10.1096/fj.10-171470; Huang GN, 2008, SCIENCE, V319, P476, DOI 10.1126/science.1151227; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Minakami R, 2000, BIOCHEM BIOPH RES CO, V272, P466, DOI 10.1006/bbrc.2000.2777; Molkentin JD, 2006, J CLIN INVEST, V116, P623, DOI 10.1172/JCI27824; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Peterson FC, 2009, FRONT BIOSCI-LANDMRK, V14, P833, DOI 10.2741/3281; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Seth M, 2009, CIRC RES, V105, P1023, DOI 10.1161/CIRCRESAHA.109.206581; Sheng M, 2000, J CELL SCI, V113, P1851; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Stiber JA, 2005, DEV BIOL, V287, P213, DOI 10.1016/j.ydbio.2005.06.030; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Volpe P, 2004, BIOCHEM BIOPH RES CO, V316, P884, DOI 10.1016/j.bbrc.2004.02.132; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Worley PF, 2007, CELL CALCIUM, V42, P363, DOI 10.1016/j.ceca.2007.05.007; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	37	16	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					596	603		10.1096/fj.11-190330	http://dx.doi.org/10.1096/fj.11-190330			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22012123				2022-12-28	WOS:000300485700013
J	Muller, GA; Hansen, U; Xu, Z; Griswold, B; Talan, MI; McDonnell, NB; Briest, W				Mueller, Gerd A.; Hansen, Uwe; Xu, Zhi; Griswold, Benjamin; Talan, Mark I.; McDonnell, Nazli B.; Briest, Wilfried			Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts	FASEB JOURNAL			English	Article						extracellular matrix; collagen; RNA interference	SYNDROME TYPE-IV; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; MARFAN-SYNDROME; RNAI; HAPLOINSUFFICIENCY; DISCRIMINATION; BIOGENESIS; DEATH; MODEL	The vascular type of the Ehlers-Danlos syndrome (vEDS) is caused by dominant-negative mutations in the procollagen type III (COL3A1) gene. Patients with this autosomal dominant disorder have a shortened life expectancy due to complications from ruptured vessels or hollow organs. We tested the effectiveness of allele-specific RNA interference (RNAi) to reduce the mutated phenotype in fibroblasts. Small-interfering RNAs (siRNAs) discriminating between wild-type and mutant COL3A1 allele were identified by a luciferase reporter gene assay and in primary fibroblasts from a normal donor and a patient with vEDS. The best discriminative siRNA with the mutation at position 10 resulted in >90% silencing of the mutant allele without affecting the wild-type allele. Transmission and immunogold electron microscopy of extracted extracellular matrices from untreated fibroblasts of the patient with vEDS revealed structurally abnormal fibrils. After siRNA treatment, collagen fibrils became similar to fibrils from fibroblasts of normal and COL3A1 haploinsufficient donors. In addition, it was shown that expression of mutated COL3A1 activates the unfolded protein response and that reduction of the amount of mutated protein by siRNA reduces cellular stress. Taken together, the results provide evidence that allele-specific siRNAs are able to reduce negative effects of mutated COL3A1 proteins. Thus, the application of allele-specific RNAi may be a promising direction for future personalized therapies to reduce the severity of vEDS.-Muller, G. A., Hansen, U., Xu, Z., Griswold, B., Talan, M. I., McDonnell, N. B., Briest, W. Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts. FASEB J. 26, 668-677 (2012). www.fasebj.org	[Mueller, Gerd A.; Talan, Mark I.; Briest, Wilfried] NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA; [Xu, Zhi; Griswold, Benjamin; McDonnell, Nazli B.] NIA, Clin Invest Lab, Baltimore, MD 21224 USA; [Hansen, Uwe] Univ Hosp Munster, Inst Physiol Chem & Pathobiochem, Munster, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Munster	Briest, W (corresponding author), Fritz Lipmann Inst, Leibniz Inst Age Res, Beutenbergstr 11, D-07745 Jena, Germany.	wilfried.briest@arcor.de	Müller, Gerd Armin/AAO-6714-2021; Briest, Wilfried/AAE-5820-2019; Müller, Gerd Armin/GYU-9447-2022; Xu, Zhi/I-2546-2012	Müller, Gerd Armin/0000-0002-4967-2487; Briest, Wilfried/0000-0003-4556-4849; Müller, Gerd Armin/0000-0002-4967-2487; 	U.S. National Institutes of Health, National Institute on Aging (NIA; Bethesda, MD, USA); NATIONAL INSTITUTE ON AGING [ZIAAG000865, ZIAAG000666] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute on Aging (NIA; Bethesda, MD, USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The work was fully funded by the Intramural Research Program of the U.S. National Institutes of Health, National Institute on Aging (NIA; Bethesda, MD, USA). The authors are indebted to Shannon Marshall (NIA), Gerburg Hoelscher (University Hospital of Munster), and Barbara Schedding (University Hospital of Munster) for expert technical assistance. The authors owe special thanks to Kenneth R. Boheler (NIA) for helpful discussions.	Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; Bommiasamy H, 2009, J CELL SCI, V122, P1626, DOI 10.1242/jcs.045625; Briest W, 2011, J PHARMACOL EXP THER, V337, P621, DOI 10.1124/jpet.110.177782; Callewaert B, 2008, BEST PRACT RES CL RH, V22, P165, DOI 10.1016/j.berh.2007.12.005; Du Q, 2005, NUCLEIC ACIDS RES, V33, P1671, DOI 10.1093/nar/gki312; Firtina Z, 2009, J BIOL CHEM, V284, P35872, DOI 10.1074/jbc.M109.060384; Germain DP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-32; HAUSSER I, 1994, HUM GENET, V93, P394; Hickerson RP, 2008, J INVEST DERMATOL, V128, P594, DOI 10.1038/sj.jid.5701060; Huang H, 2009, NUCLEIC ACIDS RES, V37, P7560, DOI 10.1093/nar/gkp835; Khalique Z, 2009, EUR J VASC ENDOVASC, V38, P608, DOI 10.1016/j.ejvs.2009.07.009; Klootwijk RD, 2008, FASEB J, V22, P3846, DOI 10.1096/fj.08-110890; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Leistritz DF, 2011, GENET MED, V13, P717, DOI 10.1097/GIM.0b013e3182180c89; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Millington-Ward S, 2004, EUR J HUM GENET, V12, P864, DOI 10.1038/sj.ejhg.5201230; Ohnishi Yusuke, 2006, J RNAi Gene Silencing, V2, P154; Ohnishi Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002248; Ong KT, 2010, LANCET, V376, P1476, DOI 10.1016/S0140-6736(10)60960-9; Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001; Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030; Plancke A, 2009, EUR J HUM GENET, V17, P1411, DOI 10.1038/ejhg.2009.76; Pyeritz RE, 2000, NEW ENGL J MED, V342, P730, DOI 10.1056/NEJM200003093421009; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schwarz DS, 2006, PLOS GENET, V2, P1307, DOI 10.1371/journal.pgen.0020140; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarze U, 2001, AM J HUM GENET, V69, P989, DOI 10.1086/324123; Sorensen S, 2006, J BIOL CHEM, V281, P468, DOI 10.1074/jbc.M507071200; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Stenson P. D, 2009, HUMAN GENE MUTATION, V2010; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Than Naing B., 2010, 60 ANN M AM SOC HUM; Watanabe Atsushi, 2008, Journal of Nippon Medical School, V75, P254, DOI 10.1272/jnms.75.254; Whiteman P, 2007, HUM MOL GENET, V16, P907, DOI 10.1093/hmg/ddm035; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373	37	15	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					668	677		10.1096/fj.11-182162	http://dx.doi.org/10.1096/fj.11-182162			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038052	Green Published			2022-12-28	WOS:000300485700019
J	Pandini, A; Fornili, A; Fraternali, F; Kleinjung, J				Pandini, Alessandro; Fornili, Arianna; Fraternali, Franca; Kleinjung, Jens			Detection of allosteric signal transmission by information-theoretic analysis of protein dynamics	FASEB JOURNAL			English	Article						structural alphabet; networks; molecular simulation; two-component systems	MOLECULAR-DYNAMICS; CONFORMATIONAL-CHANGE; RECEIVER DOMAIN; LOCAL MOTIONS; ACTIVATION; RESOLUTION; MECHANISM; MODELS; TRANSITIONS; SIMULATIONS	Allostery offers a highly specific way to modulate protein function. Therefore, understanding this mechanism is of increasing interest for protein science and drug discovery. However, allosteric signal transmission is difficult to detect experimentally and to model because it is often mediated by local structural changes propagating along multiple pathways. To address this, we developed a method to identify communication pathways by an information-theoretical analysis of molecular dynamics simulations. Signal propagation was described as information exchange through a network of correlated local motions, modeled as transitions between canonical states of protein fragments. The method was used to describe allostery in two-component regulatory systems. In particular, the transmission from the allosteric site to the signaling surface of the receiver domain NtrC was shown to be mediated by a layer of hub residues. The location of hubs preferentially connected to the allosteric site was found in close agreement with key residues experimentally identified as involved in the signal transmission. The comparison with the networks of the homologues CheY and FixJ highlighted similarities in their dynamics. In particular, we showed that a preorganized network of fragment connections between the allosteric and functional sites exists already in the inactive state of all three proteins.-Pandini, A., Fornili, A., Fraternali, F., Kleinjung, J. Detection of allosteric signal transmission by information-theoretic analysis of protein dynamics. FASEB J. 26, 868-881 (2012). www.fasebj.org	[Pandini, Alessandro; Kleinjung, Jens] Natl Inst Med Res, MRC, Div Math Biol, London NW7 1AA, England; [Pandini, Alessandro; Fornili, Arianna; Fraternali, Franca] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; [Fraternali, Franca] Thomas Young Ctr Theory & Simulat Mat, London, England	MRC National Institute for Medical Research; University of London; King's College London	Kleinjung, J (corresponding author), Natl Inst Med Res, MRC, Div Math Biol, Mill Hill, London NW7 1AA, England.	apandin@nimr.mrc.ac.uk; jkleinj@nimr.mrc.ac.uk	Fraternali, Franca/D-4410-2011; Pandini, Alessandro/P-5200-2019; Pandini, Alessandro/F-9854-2012; Fraternali, Franca/C-8912-2009	Pandini, Alessandro/0000-0002-4158-233X; Pandini, Alessandro/0000-0002-4158-233X; Fraternali, Franca/0000-0002-3143-6574; Kleinjung, Jens/0000-0002-7875-5724	European Community [PIEF-GA-2008-220256]; Medical Research Council [U117581331]; Leverhulme Trust [F/07040/AL]; Biotechnology and Biological Sciences Research Council [BB/I023291/1]; Biotechnology and Biological Sciences Research Council [BB/H018409/1] Funding Source: researchfish; BBSRC [BB/H018409/1, BB/I023291/1] Funding Source: UKRI	European Community(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Leverhulme Trust(Leverhulme Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This research was supported by a Marie Curie Intra European Fellowship within the 7th European Community Framework Programme (PIEF-GA-2008-220256 to A. P.), the Medical Research Council (U117581331 to A. P. and J.K.), the Leverhulme Trust (F/07040/AL to A. F. and F. F.) and the Biotechnology and Biological Sciences Research Council (BB/I023291/1 to A. P. and F.F.).	AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Bourret RB, 2010, CURR OPIN MICROBIOL, V13, P142, DOI 10.1016/j.mib.2010.01.015; Bourret RB, 2010, CURR OPIN MICROBIOL, V13, P113, DOI 10.1016/j.mib.2010.02.003; Chennubhotla C, 2007, PLOS COMPUT BIOL, V3, P1716, DOI 10.1371/journal.pcbi.0030172; COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625; Cover TM, 1991, ELEMENTS INFORM THEO; Crooks GE, 2004, PROTEINS, V57, P804, DOI 10.1002/prot.20262; Csardi G., 2006, INTERJOURNALCOMPLEX, V1695, P1, DOI DOI 10.3724/SP.J.1087.2009.02191; Daily MD, 2008, PROTEINS, V71, P455, DOI 10.1002/prot.21800; Daily MD, 2007, PROTEINS, V67, P385, DOI 10.1002/prot.21300; del Sol A, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100063; del Sol A, 2009, STRUCTURE, V17, P1042, DOI 10.1016/j.str.2009.06.008; Duarte JM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-283; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fanelli F, 2010, FASEB J, V24, P3196, DOI 10.1096/fj.09-151084; Gardino AK, 2009, CELL, V139, P1109, DOI 10.1016/j.cell.2009.11.022; Genoni A, 2010, BIOCHEMISTRY-US, V49, P4283, DOI 10.1021/bi100569u; Ghosh A, 2007, P NATL ACAD SCI USA, V104, P15711, DOI 10.1073/pnas.0704459104; Gotoh Y, 2010, CURR OPIN MICROBIOL, V13, P232, DOI 10.1016/j.mib.2010.01.008; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; Gunasekaran K, 2004, PROTEINS, V57, P433, DOI 10.1002/prot.20232; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hess B, 2000, PHYS REV E, V62, P8438, DOI 10.1103/PhysRevE.62.8438; HOCKNEY RW, 1974, J COMPUT PHYS, V14, P148, DOI 10.1016/0021-9991(74)90010-2; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Itoh K, 2010, P NATL ACAD SCI USA, V107, P7775, DOI 10.1073/pnas.0912978107; Kar G, 2010, CURR OPIN PHARMACOL, V10, P715, DOI 10.1016/j.coph.2010.09.002; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kidd BA, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000484; Kormos BL, 2006, J AM CHEM SOC, V128, P8992, DOI 10.1021/ja0606071; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Laio A, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/12/126601; Lee GM, 2009, SCIENCE, V324, P213, DOI 10.1126/science.1169378; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lei M, 2009, J MOL BIOL, V392, P823, DOI 10.1016/j.jmb.2009.06.065; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Ma L, 2007, J AM CHEM SOC, V129, P10261, DOI 10.1021/ja073059f; McClendon CL, 2009, J CHEM THEORY COMPUT, V5, P2486, DOI 10.1021/ct9001812; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; Morra G, 2010, J CHEM THEORY COMPUT, V6, P2978, DOI 10.1021/ct100334n; Morra G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000323; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Noe F, 2008, CURR OPIN STRUC BIOL, V18, P154, DOI 10.1016/j.sbi.2008.01.008; Otten R, 2010, J AM CHEM SOC, V132, P17004, DOI 10.1021/ja107410x; Pandini A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-97; PARK BH, 1995, J MOL BIOL, V249, P493, DOI 10.1006/jmbi.1995.0311; Park S, 2002, FASEB J, V16, P1964, DOI 10.1096/fj.02-0395fje; Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702; Pioszak AA, 2004, J BACTERIOL, V186, P5730, DOI 10.1128/JB.186.17.5730-5740.2004; Poirot O, 2003, NUCLEIC ACIDS RES, V31, P3503, DOI 10.1093/nar/gkg522; Reeder SB, 2005, MAGNET RESON MED, V54, P748, DOI 10.1002/mrm.20636; Roche P, 2002, PROTEIN SCI, V11, P2622, DOI 10.1110/ps.0218802; Roulston MS, 1999, PHYSICA D, V125, P285, DOI 10.1016/S0167-2789(98)00269-3; Schrodinger L, 2009, PYMOL MOL GRAPH SYST; Schuster M, 2001, P NATL ACAD SCI USA, V98, P6003, DOI 10.1073/pnas.101571298; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI DOI 10.1002/J.1538-7305.1948.TB01338.X; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Skiena S. S., 2008, ALGORITHM DESIGN MAN; Stacklies Wolfram, 2009, PLoS Comput Biol, V5, pe1000574, DOI 10.1371/journal.pcbi.1000574; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Takeuchi M, 2001, ACCOUNTS CHEM RES, V34, P865, DOI 10.1021/ar0000410; Tsai CJ, 2008, J MOL BIOL, V378, P1, DOI 10.1016/j.jmb.2008.02.034; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; WEBER G, 1972, BIOCHEMISTRY-US, V11, P864, DOI 10.1021/bi00755a028; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751; Zheng WJ, 2006, P NATL ACAD SCI USA, V103, P7664, DOI 10.1073/pnas.0510426103; ZWEIG MH, 1993, CLIN CHEM, V39, P561	79	88	88	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					868	881		10.1096/fj.11-190868	http://dx.doi.org/10.1096/fj.11-190868			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22071506	Green Published			2022-12-28	WOS:000300485700037
J	Schneider, DJ; Wu, MH; Le, TT; Cho, SH; Brenner, MB; Blackburn, MR; Agarwal, SK				Schneider, Daniel J.; Wu, Minghua; Le, Thuy T.; Cho, Seo-Hee; Brenner, Michael B.; Blackburn, Michael R.; Agarwal, Sandeep K.			Cadherin-11 contributes to pulmonary fibrosis: potential role in TGF-beta production and epithelial to mesenchymal transition	FASEB JOURNAL			English	Article						macrophage; extracellular matrix; lung; alveolar; fibroblast	GROWTH-FACTOR-BETA; GENE-EXPRESSION; N-CADHERIN; CELLS; TGF-BETA-1; INFLAMMATION; MECHANISMS; DISEASE; DIFFERENTIATION; MYOFIBROBLASTS	Pulmonary fibrosis, characterized by excess deposition of extracellular matrix by myofibroblasts, is a serious component of chronic lung diseases. Cadherin-11 (CDH11) is increased in wound healing and fibrotic skin. We hypothesized that CDH11 is increased in pulmonary fibrosis and contributes its development. CDH11 expression was assessed in lung tissue from idiopathic pulmonary fibrosis patients. The role of CDH11 in lung fibrosis was determined using the bleomycin model of pulmonary fibrosis, and in vitro analyses were performed on A549 cells during the process of epithelial to mesenchymal transition (EMT). Immunohistochemical studies demonstrated CDH11 expression on fibroblasts, epithelial cells, and alveolar macrophages of patients with pulmonary fibrosis and mice given bleomycin. Interestingly, CDH11-deficient mice had decreased fibrotic endpoints in the bleomycin model of pulmonary fibrosis compared to wild-type mice. Furthermore, anti-CDH11-neutralizing monoclonal antibodies successfully treated established pulmonary fibrosis induced by bleomycin. TGF-beta levels were reduced in bronchoalveolar lavage (BAL) fluid, BAL cells, and primary alveolar macrophages from CDH11-deficient mice. Mechanistic studies demonstrated that TGF-beta up-regulated CDH11 expression on A549 cells, and inhibition of CDH11 expression using siRNA reduced TGF-beta -induced EMT. Together, these results identify CDH11 as a novel therapeutic target for pulmonary fibrosis. Schneider, D. J., Wu, M., Le, T. T., Cho, S.-H., Brenner, M. B., Blackburn, M. R., Agarwal, S. K. Cadherin-11 contributes to pulmonary fibrosis: potential role in TGF beta production and epithelial to mesenchymal transition. FASEB J. 26, 503-512 (2012). www.fasebj.org	[Schneider, Daniel J.; Le, Thuy T.; Blackburn, Michael R.] Univ Texas Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX USA; [Wu, Minghua; Agarwal, Sandeep K.] Univ Texas Hlth Sci Ctr, Div Rheumatol & Clin Immunogenet, Dept Internal Med, Houston, TX USA; [Cho, Seo-Hee] Univ Texas Hlth Sci Ctr, Dept Pediat, Pediat Res Ctr, Houston, TX USA; [Brenner, Michael B.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA; [Brenner, Michael B.] Harvard Univ, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Sch Med, Boston, MA 02115 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Agarwal, SK (corresponding author), Baylor Coll Med, Dept Med, Sect Allergy Immunol & Rheumatol, Biol Inflammat Ctr, 1 Baylor Plaza,Suite 672E,MS BCM285, Houston, TX 77030 USA.	skagarwa@bcm.edu		Blackburn, Michael/0000-0002-1394-9966	U.S. National Institutes of Health (NIH) [HL095401, HL70952]; NIH [TL1RR024147, 5T32AR052283-03, K08AR054404]; Scleroderma Foundation; Synovex Corporation; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024147] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL095401, R01HL070952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR054404, T32AR052283] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scleroderma Foundation; Synovex Corporation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by U.S. National Institutes of Health (NIH) grants HL095401 and HL70952 (M. R. B), NIH training awards TL1RR024147 (D.J.S.) and 5T32AR052283-03 (M. W.), and NIH grant K08AR054404 and a Scleroderma Foundation New Investigator Award (S. K. A.). The authors declare that M. B. B. owns equity options and has received consulting fees from Synovex Corporation.	Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Borchers A, 2001, DEVELOPMENT, V128, P3049; Cai GQ, 2010, EXP CELL RES, V316, P1600, DOI 10.1016/j.yexcr.2010.01.021; Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002-9440(10)64282-4; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cutroneo KR, 2007, WOUND REPAIR REGEN, V15, pS54, DOI 10.1111/j.1524-475X.2007.00226.x; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Forino M, 2006, INT J EXP PATHOL, V87, P197, DOI 10.1111/j.1365-2613.2006.00479.x; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gardner H, 2006, ARTHRITIS RHEUM-US, V54, P1961, DOI 10.1002/art.21894; Hinz B, 2004, MOL BIOL CELL, V15, P4310, DOI 10.1091/mbc.E04-05-0386; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Horikawa K, 1999, DEV BIOL, V215, P182, DOI 10.1006/dbio.1999.9463; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jeffery PK, 1999, CLIN EXP ALLERGY, V29, P14, DOI 10.1046/j.1365-2222.1999.00004.x-i2; Kam Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004580; Kasper M, 1996, HISTOL HISTOPATHOL, V11, P463; Katzenstein ALA, 2002, AM J SURG PATHOL, V26, P1567, DOI 10.1097/00000478-200212000-00004; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; Kiener HP, 2009, ARTHRITIS RHEUM-US, V60, P1305, DOI 10.1002/art.24453; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nagatoya K, 2002, KIDNEY INT, V61, P1684, DOI 10.1046/j.1523-1755.2002.00328.x; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olson AL, 2007, AM J RESP CRIT CARE, V176, P277, DOI 10.1164/rccm.200701-044OC; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Pishvaian MJ, 1999, CANCER RES, V59, P947; Pozharskaya V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007559; Raghu G, 2006, AM J RESP CRIT CARE, V174, P810, DOI 10.1164/rccm.200602-163OC; Reneker LW, 2010, BRAIN RES BULL, V81, P287, DOI 10.1016/j.brainresbull.2009.10.019; Roy SG, 2001, INT J BIOCHEM CELL B, V33, P723, DOI 10.1016/S1357-2725(01)00041-3; Salazar KD, 2009, AM J PHYSIOL-LUNG C, V297, pL1002, DOI 10.1152/ajplung.90347.2008; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schneider DJ, 2010, FASEB J, V24, P70, DOI 10.1096/fj.09-140772; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Takao S, 2000, Hum Cell, V13, P15; Valencia X, 2004, J EXP MED, V200, P1673, DOI 10.1084/jem.20041545; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Whitfield ML, 2003, P NATL ACAD SCI USA, V100, P12319, DOI 10.1073/pnas.1635114100; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Xiao YQ, 2008, J IMMUNOL, V181, P3575, DOI 10.4049/jimmunol.181.5.3575; Yu Q, 2000, GENE DEV, V14, P163; Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224	63	106	113	1	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					503	512		10.1096/fj.11-186098	http://dx.doi.org/10.1096/fj.11-186098			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	21990376	Green Published			2022-12-28	WOS:000300485700004
J	Chattergoon, NN; Giraud, GD; Louey, S; Stork, P; Fowden, AL; Thornburg, KL				Chattergoon, Natasha N.; Giraud, George D.; Louey, Samantha; Stork, Philip; Fowden, Abigail L.; Thornburg, Kent L.			Thyroid hormone drives fetal cardiomyocyte maturation	FASEB JOURNAL			English	Article						proliferation; sheep fetus; p21	SIGNAL-REGULATED KINASE; CELL-CYCLE ACTIVITY; INTRAUTERINE GROWTH RESTRICTION; ATRIAL-NATRIURETIC-FACTOR; ACTIVATED PROTEIN-KINASE; CARDIAC-MUSCLE-CELLS; MEK-ERK PATHWAY; SARCOPLASMIC-RETICULUM; POSTNATAL-DEVELOPMENT; SHEEP CARDIOMYOCYTES	Tri-iodo-L-thyronine (T-3) suppresses the proliferation of near-term serum-stimulated fetal ovine cardiomyocytes in vitro. Thus, we hypothesized that T-3 is a major stimulant of cardiomyocyte maturation in vivo. We studied 3 groups of sheep fetuses on gestational days 125-130 (term similar to 145 d): a T-3-infusion group, to mimic fetal term levels (plasma T-3 levels increased from similar to 0.1 to similar to 1.0 ng/ml; t(1/2) similar to 24 h); a thyroidectomized group, to produce low thyroid hormone levels; and a vehicle-infusion group, to serve as intact controls. At 130 d of gestation, sections of left ventricular freewall were harvested, and the remaining myocardium was enzymatically dissociated. Proteins involved in cell cycle regulation (p21, cyclin D1), proliferation (ERK), and hypertrophy (mTOR) were measured in left ventricular tissue. Evidence that elevated T-3 augmented the maturation rate of cardiomyocytes included 14% increased width, 31% increase in binucleation, 39% reduction in proliferation, 150% reduction in cyclin D1 protein, and 500% increase in p21 protein. Increased expression of phospho-mTOR, ANP, and SERCA2a also suggests that T-3 promotes maturation and hypertrophy of fetal cardiomyocytes. Thyroidectomized fetuses had reduced cell cycle activity and binucleation. These findings support the hypothesis that T-3 is a prime driver of prenatal cardiomyocyte maturation.-Chattergoon, N. N., Giraud, G. D., Louey, S., Stork, P., Fowden, A. L., Thornburg, K. L. Thyroid hormone drives fetal cardiomyocyte maturation FASEB J. 26, 397-408 (2012). www.fasebj.org	[Chattergoon, Natasha N.; Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA; [Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA; [Giraud, George D.; Louey, Samantha; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA; [Stork, Philip] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA; [Fowden, Abigail L.] Univ Cambridge, Physiol Lab, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; University of Cambridge	Thornburg, KL (corresponding author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH15H, Portland, OR 97239 USA.	thornbur@ohsu.edu	Louey, Samantha/A-1381-2009	Louey, Samantha/0000-0002-2628-0085	U.S. National Institute of Child Health and Human Development [P01 HD 34430]; National Heart, Lung, and Blood Institute (NHLBI) [R21 HL093617, T32HL094294]; National Institutes of Health [R01 HL102763]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD034430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102763, T32HL094294, R21HL093617] Funding Source: NIH RePORTER	U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Mr. Robert Webber and Ms. Loni Socha for excellent technical assistance. The authors appreciate support from the M. Lowell Edwards Endowment. This study was supported by funds from U.S. National Institute of Child Health and Human Development grant P01 HD 34430, National Heart, Lung, and Blood Institute (NHLBI) grant R21 HL093617, and National Institutes of Health grant R01 HL102763. N.N.C. was supported by NHLBI training grant T32HL094294.	ANVERSA P, 1978, LAB INVEST, V38, P597; ANVERSA P, 1980, CIRC RES, V46, P495, DOI 10.1161/01.RES.46.4.495; Barbera A, 2000, AM J PHYSIOL-REG I, V279, pR1157, DOI 10.1152/ajpregu.2000.279.4.R1157; Barker DJP, 2010, EUR J HEART FAIL, V12, P819, DOI 10.1093/eurjhf/hfq069; BECKS GP, 1991, MED CLIN N AM, V75, P121, DOI 10.1016/S0025-7125(16)30475-8; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Bianco AC, 2006, J CLIN INVEST, V116, P2571, DOI 10.1172/JCI29812; Boluyt MO, 2004, CARDIOVASC DRUG THER, V18, P257, DOI 10.1023/B:CARD.0000041245.61136.56; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; BREALL JA, 1984, J CLIN INVEST, V73, P1418, DOI 10.1172/JCI111346; Brown DD, 2007, DEV BIOL, V306, P20, DOI 10.1016/j.ydbio.2007.03.021; Bubb KJ, 2007, J PHYSIOL-LONDON, V578, P871, DOI 10.1113/jphysiol.2006.121160; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Burrell JH, 2003, ANAT REC PART A, V274A, P952, DOI 10.1002/ar.a.10110; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Casey BM, 2005, OBSTET GYNECOL, V105, P239, DOI 10.1097/01.AOG.0000152345.99421.22; CASTRO R, 1988, Pediatric Research, V23, p274A; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; Chan S, 2003, J CLIN ENDOCR METAB, V88, P4488, DOI 10.1210/jc.2003-030228; Chan SY, 2006, J ENDOCRINOL, V189, P465, DOI 10.1677/joe.1.06582; Chan SY, 2009, NAT CLIN PRACT ENDOC, V5, P45, DOI 10.1038/ncpendmet1026; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; Chattergoon NN, 2007, J ENDOCRINOL, V192, pR1, DOI 10.1677/JOE-06-0114; Chen CH, 2011, NEUROTOX RES, V20, P15, DOI 10.1007/s12640-010-9214-y; Chen D, 1999, J IMMUNOL, V163, P5796; CHEUNG CY, 1987, AM J PHYSIOL, V252, pE279, DOI 10.1152/ajpendo.1987.252.2.E279; CHEUNG CY, 1993, AM J OBSTET GYNECOL, V169, P1345, DOI 10.1016/0002-9378(93)90303-Z; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; CHOPRA IJ, 1978, ENDOCRINOLOGY, V103, P393, DOI 10.1210/endo-103-2-393; Chuderland D, 2005, MOL BIOTECHNOL, V29, P57, DOI 10.1385/MB:29:1:57; Chuderland D, 2008, J BIOL CHEM, V283, P11176, DOI 10.1074/jbc.M709030200; Davis PJ, 2002, THYROID, V12, P459, DOI 10.1089/105072502760143827; DILLMANN WH, 1985, MED CLIN N AM, V69, P849, DOI 10.1016/S0025-7125(16)30993-2; Dillmann WH, 2002, THYROID, V12, P447, DOI 10.1089/105072502760143809; Fisher DA, 1997, CLIN OBSTET GYNECOL, V40, P16, DOI 10.1097/00003081-199703000-00005; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Forhead AJ, 2003, J PHYSIOL-LONDON, V548, P941, DOI 10.1113/jphysiol.2002.035816; Forhead AJ, 2002, J ENDOCRINOL, V173, P143, DOI 10.1677/joe.0.1730143; Forhead AJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE80, DOI 10.1152/ajpendo.00284.2001; Forhead AJ, 2006, ENDOCRINOLOGY, V147, P5988, DOI 10.1210/en.2006-0712; Gardner DG, 2003, TRENDS ENDOCRIN MET, V14, P411, DOI 10.1016/S1043-2760(03)00113-9; Gezmish O, 2010, REPROD SCI, V17, P168, DOI 10.1177/1933719109349536; Giraud GD, 2006, ENDOCRINOLOGY, V147, P3643, DOI 10.1210/en.2006-0061; Glinoer D, 2000, THYROID, V10, P871, DOI 10.1089/thy.2000.10.871; Goldenthal MJ, 2005, J MOL CELL CARDIOL, V39, P319, DOI 10.1016/j.yjmcc.2005.03.016; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; Higuchi R, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e57; HIRAKOW R, 1980, ACTA ANAT, V108, P144; HOPKINS PS, 1972, J ENDOCRINOL, V54, P55, DOI 10.1677/joe.0.0540055; Hume R, 2004, J CLIN ENDOCR METAB, V89, P4097, DOI 10.1210/jc.2004-0573; Jonker SS, 2007, J APPL PHYSIOL, V102, P1130, DOI 10.1152/japplphysiol.00937.2006; Jonker SS, 2007, AM J PHYSIOL-REG I, V292, pR913, DOI 10.1152/ajpregu.00484.2006; Kahaly GJ, 2005, ENDOCR REV, V26, P704, DOI 10.1210/er.2003-0033; Kawa MP, 2010, EUR J ENDOCRINOL, V162, P295, DOI 10.1530/EJE-09-0875; Kawamura Y, 2010, CIRC J, V74, P1442, DOI 10.1253/circj.CJ-09-0793; Kenessey A, 2006, J BIOL CHEM, V281, P20666, DOI 10.1074/jbc.M512671200; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuzman JA, 2005, J MOL CELL CARDIOL, V39, P841, DOI 10.1016/j.yjmcc.2005.07.019; Kuzman JA, 2005, J MOL CELL CARDIOL, V39, P251, DOI 10.1016/j.yjmcc.2005.03.020; Li GH, 2004, AM J PHYSIOL-HEART C, V286, pH1712, DOI 10.1152/ajpheart.00898.2003; Li GH, 2003, J SOC GYNECOL INVEST, V10, P265, DOI 10.1016/S1071-5576(03)00074-1; Louey S, 2007, J PHYSIOL-LONDON, V580, P639, DOI 10.1113/jphysiol.2006.122200; Macchia PE, 2000, MOL MED TODAY, V6, P36, DOI 10.1016/S1357-4310(99)01620-2; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; Muslin AJ, 2005, TRENDS CARDIOVAS MED, V15, P225, DOI 10.1016/j.tcm.2005.06.008; Niswander KR, 1972, COLLABORATIVE PERINA, P246; O'Tierney PF, 2010, J PHYSIOL-LONDON, V588, P2879, DOI 10.1113/jphysiol.2010.191098; O'Tierney PF, 2010, AM J PHYSIOL-REG I, V299, pR573, DOI 10.1152/ajpregu.00754.2009; OPPENHEIMER JH, 1978, CLIN ENDOCRINOL META, V7, P145, DOI 10.1016/S0300-595X(78)80040-1; PINSON CW, 1991, CIRC RES, V68, P947, DOI 10.1161/01.RES.68.4.947; POLK DH, 1995, REPROD FERT DEVELOP, V7, P469, DOI 10.1071/RD9950469; Radetti G, 2002, Minerva Pediatr, V54, P383; RAKUSAN K, 1984, GROWTH HEART HLTH DI, P25; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; SCHELLENBERG JC, 1987, J PERINAT MED, V15, P447, DOI 10.1515/jpme.1987.15.5.447; Seely BL, 1994, MATERNAL FETAL MED P, P979; SMOLICH JJ, 1989, AM J PHYSIOL, V257, pH1, DOI 10.1152/ajpheart.1989.257.1.H1; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Sundgren NC, 2003, AM J PHYSIOL-REG I, V285, pR1481, DOI 10.1152/ajpregu.00232.2003; Sundgren NC, 2003, J PHYSIOL-LONDON, V548, P881, DOI 10.1113/jphysiol.2003.038778; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Thomas TA, 2005, AM J PHYSIOL-HEART C, V288, pH2118, DOI 10.1152/ajpheart.01000.2004; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; Thornburg K. L., 2009, FETAL MED; Thornburg K, 2011, PROG BIOPHYS MOL BIO, V106, P289, DOI 10.1016/j.pbiomolbio.2010.11.010; Ueyama T, 2000, J MOL CELL CARDIOL, V32, P947, DOI 10.1006/jmcc.2000.1135; van Tuyl M, 2004, DEV BIOL, V272, P104, DOI 10.1016/j.ydbio.2004.03.042; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714	91	107	110	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					397	408		10.1096/fj.10-179895	http://dx.doi.org/10.1096/fj.10-179895			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21974928	Green Published			2022-12-28	WOS:000299202200039
J	de Morree, A; Droog, M; Moursel, LG; Bisschop, IJM; Impagliazzo, A; Frants, RR; Klooster, R; van der Maarel, SM				de Morree, Antoine; Droog, Marjolein; Moursel, Laure Grand; Bisschop, Ilona J. M.; Impagliazzo, Antonietta; Frants, Rune R.; Klooster, Rinse; van der Maarel, Silvere M.			Self-regulated alternative splicing at the AHNAK locus	FASEB JOURNAL			English	Article						LGMD; muscle differentiation; RNA expression	MYELINATING SCHWANN-CELLS; DYSFERLIN PROTEIN COMPLEX; DESMOYOKIN/AHNAK PROTEIN; MAXIMUM-LIKELIHOOD; SKELETAL-MUSCLE; PERIAXIN; GENE; EXPRESSION; SELECTION; DOMAIN	AHNAK is a 700-kDa protein involved in cytoarchitecture and calcium signaling. It is secondarily reduced in muscle of dysferlinopathy patients and accumulates in muscle of calpainopathy patients, both affected by a muscular dystrophy. AHNAK directly interacts with dysferlin. This interaction is lost on cleavage of AHNAK by the protease calpain 3, explaining the molecular observations in patients. Currently, little is known of AHNAK regulation. We describe the self-regulation of multiple mRNA transcripts emanating from the AHNAK locus in muscle cells. We show that the AHNAK gene consists of a 17-kb exon flanked by multiple small exons. This genetic structure is shared by AHNAK2 and Periaxin, which share a common ancestor. Two major AHNAK transcripts are differentially expressed during muscle differentiation that encode for a small (17-kDa) and a large (700-kDa) protein isoform. These proteins interact in the cytoplasm, but the small AHNAK is also present in the nucleus. During muscle differentiation the small AHNAK is strongly increased, thereby establishing a positive feedback loop to regulate mRNA splicing of its own locus. A small 17-kDa isoform of Periaxin similarly traffics between the cytoplasm and the nucleus to regulate mRNA splicing. Thus, AHNAK constitutes a novel mechanism in post-transcriptional control of gene expression.-De Morree, A., Droog, M., Grand Moursel, L., Bisschop, I. J. M., Impagliazzo, A., Frants, R., Klooster, R., van der Maarel, S. M. Self-regulated alternative splicing at the AHNAK locus. FASEB J. 26, 93-103 (2012). www.fasebj.org	[van der Maarel, Silvere M.] Leiden Univ, Med Ctr, Ctr Human Genet, Dept Human Genet, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Maarel, SM (corresponding author), Leiden Univ, Med Ctr, Ctr Human Genet, Dept Human Genet, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	maarel@lumc.nl	Moursel, Laure Grand/M-4194-2019; van der Maarel, Silvere/X-3631-2018; Grand Moursel, Laure/H-7061-2018	Moursel, Laure Grand/0000-0002-8696-7145; van der Maarel, Silvere/0000-0001-8103-711X; Grand Moursel, Laure/0000-0002-8696-7145; de Morree, Antoine/0000-0002-8316-4531				Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Alvarez J, 2004, J BIOL CHEM, V279, P12456, DOI 10.1074/jbc.M312177200; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; de Morree A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013854; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gentil EJ, 2005, J CELL PHYSIOL, V203, P362, DOI 10.1002/jcp.20232; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Haase H, 2005, FASEB J, V19, P1969, DOI 10.1096/fj.05-3997com; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hestand MS, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq602; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Huang YC, 2008, HUM MOL GENET, V17, P1855, DOI 10.1093/hmg/ddn081; Huang YC, 2007, FASEB J, V21, P732, DOI 10.1096/fj.06-6628com; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kijima K, 2004, J HUM GENET, V49, P376, DOI 10.1007/s10038-004-0162-3; Klooster R, 2009, J IMMUNOL METHODS, V342, P1, DOI 10.1016/j.jim.2008.10.009; Kolodziejski PJ, 2003, P NATL ACAD SCI USA, V100, P14263, DOI 10.1073/pnas.2435290100; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Matza D, 2008, IMMUNITY, V28, P64, DOI 10.1016/j.immuni.2007.11.020; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Saavedra JT, 2008, J NEUROSCI METH, V174, P25, DOI 10.1016/j.jneumeth.2008.06.029; Salim C, 2009, GLIA, V57, P535, DOI 10.1002/glia.20782; Sherman DL, 2000, J BIOL CHEM, V275, P4537, DOI 10.1074/jbc.275.7.4537; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Sun SY, 2010, NAT STRUCT MOL BIOL, V17, P306, DOI 10.1038/nsmb.1750; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; Talavera G, 2007, SYST BIOL, V56, P564, DOI 10.1080/10635150701472164	36	17	18	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					93	103		10.1096/fj.11-187971	http://dx.doi.org/10.1096/fj.11-187971			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21940993				2022-12-28	WOS:000299202200011
J	Chateau, A; van Schaik, W; Six, A; Aucher, W; Fouet, A				Chateau, Alice; van Schaik, Willem; Six, Anne; Aucher, Willy; Fouet, Agnes			CodY regulation is required for full virulence and heme iron acquisition in Bacillus anthracis	FASEB JOURNAL			English	Article						anthrax; capsule; toxin; dissemination	GRAM-POSITIVE BACTERIA; TOXIN GENE-EXPRESSION; CAPSULE SYNTHESIS; STREPTOCOCCUS-PNEUMONIAE; PROTEIN; ATXA; GROWTH; TRANSACTIVATOR; IDENTIFICATION; TRANSCRIPTION	Capsule and toxin are the major virulence factors of Bacillus anthracis. The B. anthracis pleiotropic regulator CodY activates toxin gene expression by post-translationally regulating the accumulation of the global regulator AtxA. However, the role of CodY on B. anthracis capsulation and virulence of encapsulated strains has been unknown. The role of CodY in B. anthracis virulence was studied in mouse and guinea pig models. Spore outgrowth and dissemination of the vegetative cells was followed in mice by bioluminescent imaging. We also determined the state of capsulation and the iron requirement for growth of the codY mutant. In all models tested, the codY mutant strain was strongly attenuated compared to the wildtype strain and, in mice, also compared to the atxA strain. The disruption of codY did not affect either ex vivo or in vivo capsulation, whereas atxA deletion affected ex vivo capsulation only. The disruption of codY led to a delayed initiation of dissemination but similar kinetics of subsequent spread of the bacilli. The codY mutant cannot grow on heme iron as sole iron source, whereas the parental and complemented strains can. The lack of CodY-mediated transcription weakens virulence by controlling iron acquisition and synthesis of toxin, but without modifying capsulation.-Chateau, A., van Schaik, W., Six, A., Aucher, W., Fouet, A. CodY regulation is required for full virulence and heme iron acquisition in Bacillus anthracis. FASEB J. 25, 4445-4456 (2011). www.fasebj.org	[Fouet, Agnes] Inst Cochin Barrier & Pathogens, INSERM, U1016, F-75014 Paris, France; [Chateau, Alice; van Schaik, Willem; Six, Anne; Aucher, Willy; Fouet, Agnes] Inst Pasteur, Unite Toxines & Pathogenie Bacteriennes, F-75015 Paris, France; [Chateau, Alice; Six, Anne; Fouet, Agnes] Inst Pasteur, Lab Pathogenie Toxi Infect Bacteriennes, F-75015 Paris, France; [Fouet, Agnes] CNRS, UMR 8104, Paris, France; [van Schaik, Willem] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands; [Fouet, Agnes] Univ Paris 05, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; UDICE-French Research Universities; Universite Paris Cite	Fouet, A (corresponding author), Inst Cochin Barrier & Pathogens, INSERM, U1016, Rm 206,22 Rue Mechain, F-75014 Paris, France.	agnes.fouet@inserm.fr	CHATEAU, Alice/AAU-7791-2021	van Schaik, Willem/0000-0001-5832-0988; Fouet, Agnes/0000-0001-7715-9157; CHATEAU, Alice/0000-0002-7288-4744	Direction Generale de l'Armement; EMBO; Agence Nationale de la Recherche [ANR-09-MIEN-010-02]	Direction Generale de l'Armement; EMBO(European Molecular Biology Organization (EMBO)); Agence Nationale de la Recherche(French National Research Agency (ANR))	The authors thank M. Haustant for technical assistance. Financial support was provided by a fellowship from the Direction Generale de l'Armement (A.C.) and an EMBO Long Term Fellowship (W.V.S.) and by the Agence Nationale de la Recherche, ANR-09-MIEN-010-02.	Abergel RJ, 2006, P NATL ACAD SCI USA, V103, P18499, DOI 10.1073/pnas.0607055103; Baldari CT, 2006, TRENDS IMMUNOL, V27, P434, DOI 10.1016/j.it.2006.07.002; Bennett HJ, 2007, MOL MICROBIOL, V63, P1453, DOI 10.1111/j.1365-2958.2007.05597.x; Berthier M, 1996, LANCET, V347, P828, DOI 10.1016/S0140-6736(96)90901-0; Bertin M, 2010, RES MICROBIOL, V161, P249, DOI 10.1016/j.resmic.2010.03.003; Bourgogne A, 2003, INFECT IMMUN, V71, P2736, DOI 10.1128/IAI.71.5.2736-2743.2003; Brossier F, 2002, INFECT IMMUN, V70, P661; Candela T, 2005, J BACTERIOL, V187, P7765, DOI 10.1128/JB.187.22.7765-7772.2005; Candela T, 2005, MOL MICROBIOL, V57, P717, DOI 10.1111/j.1365-2958.2005.04718.x; Carlson PE, 2010, MOL MICROBIOL, V75, P900, DOI 10.1111/j.1365-2958.2009.07025.x; Carlson PE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006988; Caymaris S, 2010, MOL MICROBIOL, V78, P344, DOI 10.1111/j.1365-2958.2010.07339.x; Cendrowski S, 2004, MOL MICROBIOL, V51, P407, DOI 10.1046/j.1365-2958.2003.03861.x; Chiang C, 2011, J BACTERIOL, V193, P52, DOI 10.1128/JB.01656-09; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; Daou N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000675; Davison S, 2005, J BACTERIOL, V187, P6742, DOI 10.1128/JB.187.19.6742-6749.2005; Drysdale M, 2004, J BACTERIOL, V186, P307, DOI 10.1128/JB.186.2.307-315.2004; Duguid J. P., 1951, J PATHOL BACTERIOL, V63, P675; Dumetz F, 2011, AM J PATHOL, V178, P2523, DOI 10.1016/j.ajpath.2011.02.027; Fabian M, 2009, J BIOL CHEM, V284, P32138, DOI 10.1074/jbc.M109.040915; Fouet A, 2006, CURR OPIN MICROBIOL, V9, P160, DOI 10.1016/j.mib.2006.02.009; Fouet A, 1996, INFECT IMMUN, V64, P4928, DOI 10.1128/IAI.64.12.4928-4932.1996; Fouet A, 2010, RES MICROBIOL, V161, P735, DOI 10.1016/j.resmic.2010.09.006; Fouet A, 2009, MOL ASPECTS MED, V30, P374, DOI 10.1016/j.mam.2009.07.001; Gat O, 2008, MOL MICROBIOL, V70, P983, DOI 10.1111/j.1365-2958.2008.06460.x; Gimenez AP, 2004, J IMMUNOL, V173, P521, DOI 10.4049/jimmunol.173.1.521; Glomski IJ, 2007, PLOS PATHOG, V3, P699, DOI 10.1371/journal.ppat.0030076; Glomski IJ, 2007, INFECT IMMUN, V75, P4754, DOI 10.1128/IAI.00575-07; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; Guignot J, 1997, FEMS MICROBIOL LETT, V147, P203, DOI 10.1111/j.1574-6968.1997.tb10242.x; Hendriksen WT, 2008, J BACTERIOL, V190, P590, DOI 10.1128/JB.00917-07; Honsa ES, 2011, BIOMETALS, V24, P533, DOI 10.1007/s10534-011-9413-x; Hotta K, 2010, MICROBIOL-SGM, V156, P1918, DOI 10.1099/mic.0.039404-0; Jones MB, 2010, VIRULENCE, V1, P72, DOI 10.4161/viru.1.2.10752; Kern JW, 2008, MOL MICROBIOL, V68, P504, DOI 10.1111/j.1365-2958.2008.06169.x; KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/jb.176.3.586-595.1994; Lee JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020777; Lemos JA, 2008, J BACTERIOL, V190, P5291, DOI 10.1128/JB.00288-08; MAKINO S, 1989, J BACTERIOL, V171, P722, DOI 10.1128/jb.171.2.722-730.1989; Malke H, 2007, J MED MICROBIOL, V56, P707, DOI 10.1099/jmm.0.46984-0; Maresso AW, 2006, J BACTERIOL, V188, P8145, DOI 10.1128/JB.01011-06; Maresso AW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000132; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Mignot T, 2003, MOL MICROBIOL, V47, P917, DOI 10.1046/j.1365-2958.2003.03345.x; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Namy O, 1999, FEMS MICROBIOL LETT, V173, P297, DOI 10.1111/j.1574-6968.1999.tb13517.x; PEZARD C, 1993, J GEN MICROBIOL, V139, P2459, DOI 10.1099/00221287-139-10-2459; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Preisz H., 1909, Z IMMUNITAT FORSCH, V5, P341; REED L. J., 1938, AMER JOUR HYG, V27, P493; RISTROPH JD, 1983, INFECT IMMUN, V39, P483, DOI 10.1128/IAI.39.1.483-486.1983; Saile E, 2002, J BACTERIOL, V184, P370, DOI 10.1128/JB.184.2.370-380.2002; Scorpio A, 2007, ANTIMICROB AGENTS CH, V51, P215, DOI 10.1128/AAC.00706-06; SIRARD JC, 1994, J BACTERIOL, V176, P5188, DOI 10.1128/jb.176.16.5188-5192.1994; Skaar EP, 2006, J BACTERIOL, V188, P1071, DOI 10.1128/JB.188.3.1071-1080.2006; SMITH H, 1955, BRIT J EXP PATHOL, V36, P323; Sonenshein AL, 2005, CURR OPIN MICROBIOL, V8, P203, DOI 10.1016/j.mib.2005.01.001; Stauff DL, 2009, MOL MICROBIOL, V72, P763, DOI 10.1111/j.1365-2958.2009.06684.x; Stenz L, 2011, FEMS IMMUNOL MED MIC, V62, P123, DOI 10.1111/j.1574-695X.2011.00812.x; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Strauch MA, 2005, MICROBIOL-SGM, V151, P1751, DOI 10.1099/mic.0.27803-0; Tarlovsky Y, 2010, J BACTERIOL, V192, P3503, DOI 10.1128/JB.00054-10; TRIEUCUOT P, 1991, GENE, V106, P21, DOI 10.1016/0378-1119(91)90561-O; TRIEUCUOT P, 1987, MICROBIOL SCI, V4, P263; Tsvetanova B, 2007, MOL MICROBIOL, V63, P644, DOI 10.1111/j.1365-2958.2006.05543.x; Uchida I, 1997, MOL MICROBIOL, V23, P1229, DOI 10.1046/j.1365-2958.1997.3041667.x; UCHIDA I, 1993, J BACTERIOL, V175, P5329, DOI 10.1128/JB.175.17.5329-5338.1993; Unge A, 1999, APPL ENVIRON MICROB, V65, P813; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Schaik W, 2009, INFECT IMMUN, V77, P4437, DOI 10.1128/IAI.00716-09; VIETRI NJ, 1995, GENE, V152, P1, DOI 10.1016/0378-1119(94)00662-C; Welkos S. L., 1991, BACILLUS ANTHRACIS M, V10, P183; Wilson AC, 2009, MOL MICROBIOL, V72, P109, DOI 10.1111/j.1365-2958.2009.06627.x; Wilson MK, 2010, BIOMETALS, V23, P129, DOI 10.1007/s10534-009-9272-x	76	32	32	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4445	4456		10.1096/fj.11-188912	http://dx.doi.org/10.1096/fj.11-188912			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21911592				2022-12-28	WOS:000298138100035
J	Chen, YN; Shen, A; Rider, PJ; Yu, Y; Wu, KL; Mu, YX; Hao, Q; Liu, YL; Gong, H; Zhu, Y; Liu, FY; Wu, JG				Chen, Yanni; Shen, Ao; Rider, Paul J.; Yu, Yi; Wu, Kailang; Mu, Yongxin; Hao, Qian; Liu, Yingle; Gong, Hao; Zhu, Ying; Liu, Fenyong; Wu, Jianguo			A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication	FASEB JOURNAL			English	Article						chronic infection; liver disease; hepatocellular carcinoma; viral infection; miR-122; therapeutic agent	IDENTIFICATION	Regulated gene expression and progeny production are essential for persistent and chronic infection by human pathogens, such as hepatitis B virus (HBV), which affects >400 million people worldwide and is a major cause of liver disease. In this study, we provide the first direct evidence that a liver-specific microRNA, miR-122, binds to a highly conserved HBV pregenomic RNA sequence via base-pairing interactions and inhibits HBV gene expression and replication. The miR-122 target sequence is located at the coding region of the mRNA for the viral polymerase and the 3' untranslated region of the mRNA for the core protein. In cultured cells, HBV gene expression and replication reduces with increased expression of miR-122, and the expression of miR-122 decreases in the presence of HBV infection and replication. Furthermore, analyses of clinical samples demonstrated an inverse linear correlation in vivo between the miR-122 level and the viral loads in the peripheral blood mononuclear cells of HBV-positive patients. Our results suggest that miR-122 may down-regulate HBV replication by binding to the viral target sequence, contributing to the persistent/chronic infection of HBV, and that HBV-induced modulation of miR-122 expression may represent a mechanism to facilitate viral pathogenesis.-Chen, Y., Shen, A., Rider, P. J., Yu, Y., Wu, K., Mu, Y., Hao, Q, Liu, Y., Gong, H., Zhu, Y., Liu, F., Wu, J. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J. 25, 4511-4521 (2011). www.fasebj.org	[Shen, Ao; Rider, Paul J.; Gong, Hao; Liu, Fenyong] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA; [Chen, Yanni; Shen, Ao; Yu, Yi; Wu, Kailang; Mu, Yongxin; Hao, Qian; Liu, Yingle; Zhu, Ying; Liu, Fenyong; Wu, Jianguo] Wuhan Univ, Wuhan Inst Biotechnol, Chinese French Liver Dis Res Inst, State Key Lab Virol,Zhongnan Hosp, Wuhan 430072, Peoples R China; [Chen, Yanni; Shen, Ao; Yu, Yi; Wu, Kailang; Mu, Yongxin; Hao, Qian; Liu, Yingle; Zhu, Ying; Liu, Fenyong; Wu, Jianguo] Wuhan Univ, Wuhan Inst Biotechnol, Chinese French Liver Dis Res Inst, Coll Life Sci,Zhongnan Hosp, Wuhan 430072, Peoples R China	University of California System; University of California Berkeley; Wuhan University; Wuhan University	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.	liu_fy@berkeley.edu; jwu@whu.edu.cn	mu, yongxin/G-1882-2014	mu, yongxin/0000-0002-5569-5255; Wu, Jianguo/0000-0002-8326-2895; SHEN, AO/0000-0002-1559-3895	National Mega Project on Major Infectious Diseases Prevention and Treatment [2008ZX10002-009]; National Basic Research Program of China (973 Program) [2011CB504800, 2012CB518900]; National Mega Project on Major Drug Development [2009ZX09301-012]; Major State Basic Research Development Program of China [2005CB522901, 2007CB512803]; National Natural Science Foundation of China [30730001, 81171525, 30570070, 31100128, 81030031]; Program for Changjiang Scholars and Innovative Research Team in Universities [IRT0745]; U.S. National Institutes of Health [AI041927, AI050468, DE014842]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041927, R01AI050468] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014842] Funding Source: NIH RePORTER	National Mega Project on Major Infectious Diseases Prevention and Treatment; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Mega Project on Major Drug Development; Major State Basic Research Development Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars and Innovative Research Team in Universities(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors are indebted to Gerry Abenes, Naresh Sunkara, and Ed Yang for technical assistance and valuable suggestions. This work has been supported by research grants from the National Mega Project on Major Infectious Diseases Prevention and Treatment (2008ZX10002-009), National Basic Research Program of China (973 Program; 2011CB504800 and 2012CB518900), National Mega Project on Major Drug Development (2009ZX09301-012), Major State Basic Research Development Program of China (2005CB522901 and 2007CB512803), National Natural Science Foundation of China (30730001, 81171525, 30570070, 31100128, and 81030031), and Program for Changjiang Scholars and Innovative Research Team in Universities (IRT0745). This research has been supported by grants from the U.S. National Institutes of Health (AI041927, AI050468, and DE014842).	Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Belongia E A, 2008, NIH Consens State Sci Statements, V25, P1; Bennasser Yamina, 2004, Retrovirology, V1, P43, DOI 10.1186/1742-4690-1-43; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Fu HJ, 2005, FEBS LETT, V579, P3849, DOI 10.1016/j.febslet.2005.05.064; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Jackson Richard J, 2007, Sci STKE, V2007, pre1, DOI 10.1126/stke.3672007re1; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moazed D, 2009, NATURE, V457, P413, DOI 10.1038/nature07756; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Ramezani A, 2008, J GASTROEN HEPATOL, V23, P1716, DOI 10.1111/j.1440-1746.2008.05482.x; Seegar C., 2007, FIELDS VIROLOGY, P2978; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243; Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576; Sullivan CS, 2005, MOL CELL, V20, P3, DOI 10.1016/j.molcel.2005.09.012; Tan AT, 2008, J VIROL, V82, P10986, DOI 10.1128/JVI.01124-08; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Wu KL, 2005, VIRUS RES, V112, P100, DOI 10.1016/j.virusres.2005.04.001	33	141	154	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4511	4521		10.1096/fj.11-187781	http://dx.doi.org/10.1096/fj.11-187781			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21903935	Green Published			2022-12-28	WOS:000298138100041
J	Lopez-Vales, R; Ghasemlou, N; Redensek, A; Kerr, BJ; Barbayianni, E; Antonopoulou, G; Baskakis, C; Rathore, KI; Constantinou-Kokotou, V; Stephens, D; Shimizu, T; Dennis, EA; Kokotos, G; David, S				Lopez-Vales, Ruben; Ghasemlou, Nader; Redensek, Adriana; Kerr, Bradley J.; Barbayianni, Efrosini; Antonopoulou, Georgia; Baskakis, Constantinos; Rathore, Khizr I.; Constantinou-Kokotou, Violetta; Stephens, Daren; Shimizu, Takao; Dennis, Edward A.; Kokotos, George; David, Samuel			Phospholipase A(2) superfamily members play divergent roles after spinal cord injury	FASEB JOURNAL			English	Article						CNS injury; secondary damage; lipid metabolismw; prostaglandin receptors	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GROUP-IVA; ADULT-MOUSE; 2-OXOAMIDE INHIBITORS; REGULATORY FUNCTIONS; CONTUSION INJURY; MICE DEFICIENT; IN-VIVO; LYSOPHOSPHATIDYLCHOLINE; RECOVERY	Spinal cord injury (SCI) results in permanent loss of motor functions. A significant aspect of the tissue damage and functional loss may be preventable as it occurs, secondary to the trauma. We show that the phospholipase A(2) (PLA(2)) superfamily plays important roles in SCI. PLA(2) enzymes hydrolyze membrane glycerophospholipids to yield a free fatty acid and lysophospholipid. Some free fatty acids (arachidonic acid) give rise to eicosanoids that promote inflammation, while some lysophospholipids (lysophosphatidylcholine) cause demyelination. We show in a mouse model of SCI that two cytosolic forms [calcium-dependent PLA(2) group IVA (cPLA(2) GIVA) and calcium-independent PLA(2) group VIA (iPLA(2) GVIA)], and a secreted form [secreted PLA(2) group IIA (sPLA(2) GIIA)] are up-regulated. Using selective inhibitors and null mice, we show that these PLA(2)s play differing roles. cPLA(2) GIVA mediates protection, whereas sPLA(2) GIIA and, to a lesser extent, iPLA(2) GVIA are detrimental. Furthermore, completely blocking all three PLA(2)s worsens outcome, while the most beneficial effects are seen by partial inhibition of all three. The partial inhibitor enhances expression of cPLA(2) and mediates its beneficial effects via the prostaglandin EP1 receptor. These findings indicate that drugs that inhibit detrimental forms of PLA(2) (sPLA(2) and iPLA(2)) and up-regulate the protective form (cPLA(2)) may be useful for the treatment of SCI.-Lopez-Vales, R., Ghasemlou, N., Redensek, A., Kerr, B. J., Barbayianni, E., Antonopoulou, G., Baskakis, C., Rathore, K. I., Constantinou-Kokotou, V., Stephens, D., Shimizu, T., Dennis, E. A., Kokotos, G., David, S. Phospholipase A2 superfamily members play divergent roles after spinal cord injury. FASEB J. 25, 4240-4252 (2011). www.fasebj.org	[Lopez-Vales, Ruben; Ghasemlou, Nader; Redensek, Adriana; Kerr, Bradley J.; Rathore, Khizr I.; David, Samuel] McGill Univ, Ctr Hlth, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; [Lopez-Vales, Ruben] Univ Autonoma Barcelona, Ctr Inves Biomed Red Enfermedades Neurodegenerat, Inst Neurociencies, Dept Biol Cellular Fisiol & Immunol, Bellaterra, Spain; [Barbayianni, Efrosini; Antonopoulou, Georgia; Baskakis, Constantinos; Kokotos, George] Univ Athens, Dept Chem, GR-10680 Athens, Greece; [Constantinou-Kokotou, Violetta] Agr Univ Athens, Chem Labs, Athens, Greece; [Stephens, Daren; Dennis, Edward A.] Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan	McGill University; Autonomous University of Barcelona; National & Kapodistrian University of Athens; Agricultural University of Athens; University of California System; University of California San Diego; University of Tokyo	David, S (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Ctr Res Neurosci, Livingston Hall,Rm L7-210,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	sam.david@mcgill.ca	Dennis, Edward A./M-5554-2019; Baskakis, Constantinos/F-3350-2011; Lopez-Vales, Ruben/E-2150-2011; Ghasemlou, Nader/AAB-5673-2022; Shimizu, Takao/AAV-7052-2021	Dennis, Edward A./0000-0003-3738-3140; Lopez-Vales, Ruben/0000-0001-7615-9550; Ghasemlou, Nader/0000-0002-1696-7342; 	Canadian Institutes of Health Research (CIHR); Wings for Life (Austria); European Social Fund and National Resources (EPEAEK); U.S. National Institutes of Health [RO1 GM20508, R01 GM64611]; CIHR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020501, R01GM064611] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Wings for Life (Austria); European Social Fund and National Resources (EPEAEK); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Hiba Kazak and Eva Santos-Nogueira for technical assistance and Margaret Attiwell for help with preparing the illustrations. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Wings for Life (Austria) to S.D.; from the European Social Fund and National Resources (EPEAEK program) to G.K.; and from the U.S. National Institutes of Health (RO1 GM20508 and R01 GM64611) to E.A.D. R.L.V. was the recipient of a CIHR postdoctoral fellowship.	Antonopoulou G, 2008, BIOORGAN MED CHEM, V16, P10257, DOI 10.1016/j.bmc.2008.10.046; Arai K, 2001, EUR J NEUROSCI, V13, P2319, DOI 10.1046/j.0953-816x.2001.01623.x; Baskakis C, 2008, J MED CHEM, V51, P8027, DOI 10.1021/jm800649q; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Casas J, 2006, J BIOL CHEM, V281, P6106, DOI 10.1074/jbc.M505230200; Forlenza OV, 2007, PROSTAG LEUKOTR ESS, V76, P47, DOI 10.1016/j.plefa.2006.10.002; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Ghasemlou N, 2005, EXP NEUROL, V196, P9, DOI 10.1016/j.expneurol.2005.05.017; Ghomashchi F, 1999, BBA-BIOMEMBRANES, V1420, P45, DOI 10.1016/S0005-2736(99)00056-5; Hains BC, 2001, J NEUROTRAUM, V18, P409, DOI 10.1089/089771501750170994; HALL SM, 1971, J CELL SCI, V9, P769; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Huang WL, 2009, J NEUROTRAUM, V26, P1429, DOI [10.1089/neu.2008.0835, 10.1089/neu.2008-0835]; Ikeda-Matsuo Y, 2006, P NATL ACAD SCI USA, V103, P11790, DOI 10.1073/pnas.0604400103; Kalyvas A, 2004, NEURON, V41, P323, DOI 10.1016/S0896-6273(04)00003-0; Kalyvas A, 2009, BRAIN, V132, P1221, DOI 10.1093/brain/awp002; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kokotos G, 2004, J MED CHEM, V47, P3615, DOI 10.1021/jm030485c; Kokotos G, 2002, J MED CHEM, V45, P2891, DOI 10.1021/jm025538p; Kwon BK, 2005, SPINE, V30, pS3, DOI 10.1097/01.brs.0000175186.17923.87; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Lopez-Vales R, 2006, SPINE, V31, P1100; Lopez-Vales R, 2008, BRAIN, V131, P2620, DOI 10.1093/brain/awn188; Marusic S, 2005, J EXP MED, V202, P841, DOI 10.1084/jem.20050665; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Offer S, 2005, AM J PHYSIOL-LUNG C, V288, pL523, DOI 10.1152/ajplung.00199.2004; Oikawa Y, 2005, FEBS LETT, V579, P3975, DOI 10.1016/j.febslet.2005.06.024; Ousman SS, 2000, GLIA, V30, P92, DOI 10.1002/(SICI)1098-1136(200003)30:1<92::AID-GLIA10>3.0.CO;2-W; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Rocha PN, 2003, SPRINGER SEMIN IMMUN, V25, P215, DOI 10.1007/s00281-003-0132-4; RYBORG AK, 1994, ARCH DERMATOL RES, V286, P462, DOI 10.1007/BF00371572; Ryborg AK, 2000, ACTA DERM-VENEREOL, V80, P242; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Six DA, 2007, J MED CHEM, V50, P4222, DOI 10.1021/jm0613673; Stephens D, 2006, J MED CHEM, V49, P2821, DOI 10.1021/jm050993h; Tabuchi S, 2003, ACT NEUR S, V86, P169; Titsworth WL, 2007, EXP NEUROL, V207, P150, DOI 10.1016/j.expneurol.2007.06.010; Titsworth WL, 2009, GLIA, V57, P1521, DOI 10.1002/glia.20867; Trigueros SDA, 2003, MOL CELL NEUROSCI, V24, P753, DOI 10.1016/S1044-7431(03)00241-0; Yaksh TL, 2006, J PHARMACOL EXP THER, V316, P466, DOI 10.1124/jpet.105.091686	47	41	44	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4240	4252		10.1096/fj.11-183186	http://dx.doi.org/10.1096/fj.11-183186			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21868473	Green Published, Green Submitted			2022-12-28	WOS:000298138100017
J	Zhu, N; Feng, XC; He, CY; Gao, HW; Yang, LF; Ma, QJ; Guo, L; Qiao, Y; Yang, H; Ma, TH				Zhu, Na; Feng, Xuechao; He, Chengyan; Gao, Hongwen; Yang, Longfei; Ma, Qingjie; Guo, Lei; Qiao, Ying; Yang, Hong; Ma, Tonghui			Defective macrophage function in aquaporin-3 deficiency	FASEB JOURNAL			English	Article						aquaglyceroporin; water transport; phagocytosis; migration; innate immunity	WATER PERMEABILITY; DENDRITIC CELLS; GENE DISRUPTION; PHAGOCYTIC CUP; GLYCEROL; MICE; MIGRATION; CHANNELS; AQUAGLYCEROPORINS; INVOLVEMENT	Macrophages play an essential role in innate immunity. We found that mouse resident peritoneal macrophages (mRPMs) express the aquaglyceroporin aquaporin-3 (AQP3) in a plasma membrane pattern. AQP3-deficient (AQP3(-/-)) mice showed significantly greater mortality than wild-type (AQP3(+/+)) mice in a model of bacterial peritonitis. To establish the cellular mechanism of the peritonitis phenotype, measurements were made of mRPM phagocytosis, migration, and water/glycerol permeability. We found significantly impaired engulfment of Escherichia coli and chicken erythrocytes in AQP3(-/-) vs. AQP3(+/+) mRPMs, as well as impaired migration of AQP3(-/-) mRPMs in response to a chemotactic stimulus. In AQP3(+/+) mRPMs, AQP3 was polarized to pseudopodia at the leading edge during migration and around the phagocytic cup during engulfment. Water and glycerol permeabilities in mRPMs from AQP3(-/-) mice were reduced compared to mRPMs from AQP3(+/+) mice. Cellular glycerol and ATP content were remarkably lower in AQP3(-/-) vs. AQP3(+/+) mRPMs, and glycerol supplementation partially rescued the reduced ATP content and impaired function of AQP3(-/-) mRPMs. These data implicate AQP3 as a novel determinant in macrophage immune function by a cellular mechanism involving facilitated water and glycerol transport, and consequent phagocytic and migration activity. This is the first study demonstrating involvement of an aquaporin in innate immunity. Our results suggest AQP3 as a novel therapeutic target in modulating the immune response in various infectious and inflammatory conditions.-Zhu, N., Feng, X., He, C., Gao, H., Yang, L., Ma, Q., Guo, L., Qiao, Y., Yang, Y., Ma, T. Defective macrophage function in aquaporin-3 deficiency. FASEB J. 25, 4233-4239 (2011). www.fasebj.org	[Zhu, Na; Feng, Xuechao; Gao, Hongwen; Yang, Longfei; Guo, Lei; Qiao, Ying; Yang, Hong; Ma, Tonghui] Jilin Univ, Bethune Hosp 2, Cent Res Lab, Changchun 130041, Peoples R China; [He, Chengyan; Ma, Qingjie] Jilin Univ, China Japan Union Hosp, Changchun 130041, Peoples R China; [Zhu, Na] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Biotech Ctr Viral Dis Emergency, Beijing, Peoples R China; [Yang, Hong] Liaoning Normal Univ, Sch Life Sci, Dalian, Peoples R China	Jilin University; Jilin University; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Liaoning Normal University	Ma, TH (corresponding author), Jilin Univ, Bethune Hosp 2, Cent Res Lab, Changchun 130041, Peoples R China.	math108@gmail.com	Yang, Longfei/B-4223-2018	Yang, Longfei/0000-0003-4153-9670; Ma, Tonghui/0000-0001-9338-1030; feng, xuechao/0000-0003-2444-3757	National Natural Science Fund for Distinguished Young Scholars [30325011]; National Natural Science Fund [30670477, 30770493]; National Basic Research Program of China (973) [2009CB521908]	National Natural Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Fund(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973)(National Basic Research Program of China)	The authors are grateful to Prof. Alan Verkman (University of California, San Francisco, CA, USA) for critical reading of the manuscript and helpful suggestions. The authors thank Mr. Qingyan Li and Ms. Lianhui Dou for mouse breeding. This work was supported by the National Natural Science Fund for Distinguished Young Scholars (grant 30325011), the National Natural Science Fund (grants 30670477 and 30770493), and the National Basic Research Program of China (973; grant 2009CB521908). The authors paid to use the animal facility of Northeast Normal University (NENU; Changchun, China) for breeding and maintenance of the transgenic mice and performing the animal procedures used in this study. The authors and grant support in this project have no other relations with NENU.	BABA H, 1995, NUTRITION, V11, P149; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Brisson D, 2001, BIOESSAYS, V23, P534, DOI 10.1002/bies.1073; Chen Q, 2011, CELL RES, V21, P922, DOI 10.1038/cr.2010.169; Chen ZH, 2011, RESP PHYSIOL NEUROBI, V176, P110, DOI 10.1016/j.resp.2011.02.001; Chi Y, 2011, AGING CELL, V10, P368, DOI 10.1111/j.1474-9726.2011.00677.x; Clarke M, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-154; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Hara-Chikuma M, 2006, CELL MOL LIFE SCI, V63, P1386, DOI 10.1007/s00018-006-6028-4; Hara-Chikuma M, 2008, MOL CELL BIOL, V28, P326, DOI 10.1128/MCB.01482-07; Holevinsky KO, 1998, BIOPHYS J, V75, P2577, DOI 10.1016/S0006-3495(98)77703-3; Ishibashi K, 2009, CLIN EXP NEPHROL, V13, P107, DOI 10.1007/s10157-008-0118-6; Kida H, 2005, J MEMBRANE BIOL, V208, P55, DOI 10.1007/s00232-005-0819-7; Lee WL, 2007, MOL BIOL CELL, V18, P2883, DOI 10.1091/mbc.E06-05-0450; Li YH, 2009, INT J BIOCHEM CELL B, V41, P2466, DOI 10.1016/j.biocel.2009.07.017; Lignot JH, 2002, J EXP BIOL, V205, P2653; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Liu YJ, 2009, BIOL CELL, V101, P133, DOI 10.1042/BC20080083; Loitto VM, 2009, CELL MOTIL CYTOSKEL, V66, P237, DOI 10.1002/cm.20357; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Maeda N, 2008, NAT CLIN PRACT ENDOC, V4, P627, DOI 10.1038/ncpendmet0980; Maeda Norikazu, 2009, Handb Exp Pharmacol, P233, DOI 10.1007/978-3-540-79885-9_12; Mao JW, 2005, CELL RES, V15, P371, DOI 10.1038/sj.cr.7290304; Maree AFM, 2005, J THEOR BIOL, V233, P533, DOI 10.1016/j.jtbi.2004.10.030; Moon C, 2004, AM J HEMATOL, V75, P128, DOI 10.1002/ajh.10476; Niedergang F, 2004, CURR OPIN CELL BIOL, V16, P422, DOI 10.1016/j.ceb.2004.06.006; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; PILKIS SJ, 1976, J BIOL CHEM, V251, P7841; Rojek A, 2008, ANNU REV PHYSIOL, V70, P301, DOI 10.1146/annurev.physiol.70.113006.100452; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Tollis S, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-149; Verkman A. S., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000690; Wang GF, 2008, CLIN EXP IMMUNOL, V153, P410, DOI 10.1111/j.1365-2249.2008.03702.x; Yeung CH, 2009, BIOL REPROD, V80, P350, DOI 10.1095/biolreprod.108.071928; Yeung T, 2006, CURR OPIN CELL BIOL, V18, P429, DOI 10.1016/j.ceb.2006.06.006; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	42	44	47	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4233	4239		10.1096/fj.11-182808	http://dx.doi.org/10.1096/fj.11-182808			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21865318				2022-12-28	WOS:000298138100016
J	Wang, MY; Ji, SR; Bai, CJ; El Kebir, D; Li, HY; Shi, JM; Zhu, W; Costantino, S; Zhou, HH; Potempa, LA; Zhao, J; Filep, JG; Wu, Y				Wang, Ming-Yu; Ji, Shang-Rong; Bai, Cai-Juan; El Kebir, Driss; Li, Hai-Yun; Shi, Jing-Ming; Zhu, Wei; Costantino, Santiago; Zhou, Hai-Hong; Potempa, Lawrence A.; Zhao, Jing; Filep, Janos G.; Wu, Yi			A redox switch in C-reactive protein modulates activation of endothelial cells	FASEB JOURNAL			English	Article						thioredoxin; coronary artery disease; inflammation; pathology	E-DEFICIENT MICE; HUMAN NEUTROPHILS; THIOREDOXIN; ATHEROSCLEROSIS; DISSOCIATION; LESIONS	C-reactive protein (CRP) has been implicated in the regulation of inflammation underlying coronary artery disease; however, little is known about the molecular mechanisms responsible for the expression of its pro-or anti-inflammatory activities. Here, we have identified the intrasubunit disulfide bond as a conserved switch that controls the structure and functions of CRP. Conformational rearrangement in human pentameric CRP to monomeric CRP (mCRP) is the prerequisite for this switch to be activated by reducing agents, including thioredoxin. Immunohistochemical analysis revealed 36-79% colocalization of thioredoxin and mCRP in human advanced coronary atherosclerotic lesions. Nonreduced mCRP was largely inert in activating human coronary artery endothelial cells (HCAECs), whereas reduced or cysteine-mutated mCRP evoked marked release of IL-8 and monocyte chemoattractant protein-1 from HCAECs, with similar to 50% increase at a concentration of 1 mu g/ml. Reduced mCRP was similar to 4 to 40-fold more potent than mCRP in up-regulating adhesion molecule expression, promoting U937 monocyte adhesion to HCAECs, and inducing cytokine release from rabbit arteries ex vivo and in mice. These actions were primarily due to unlocking the lipid raft interaction motif. Therefore, expression of proinflammatory properties of CRP on endothelial cells requires sequential conformational changes, i.e., loss of pentameric symmetry followed by reduction of the intrasubunit disulfide bond.-Wang M-Y., Ji, S-R., Bai, C-J., El Kebir, D., Li, H-Y., Shi, J-M., Zhu, W., Costantino, S., Zhou, H-H., Potempa, L. A., Zhao, J., Filep, J. G., Wu, Y. A redox switch in C-reactive protein modulates activation of endothelial cells. FASEB J. 25, 3186-3196 (2011). www.fasebj.org	[Wang, Ming-Yu; Ji, Shang-Rong; Bai, Cai-Juan; Li, Hai-Yun; Shi, Jing-Ming; Zhu, Wei; Zhou, Hai-Hong; Zhao, Jing; Filep, Janos G.; Wu, Yi] Lanzhou Univ, Minist Educ Key Lab Arid & Grassland Ecol, Inst Biophys, Lanzhou 730000, Peoples R China; [Wang, Ming-Yu; Ji, Shang-Rong; Bai, Cai-Juan; Li, Hai-Yun; Shi, Jing-Ming; Zhu, Wei; Zhou, Hai-Hong; Zhao, Jing; Wu, Yi] Lanzhou Univ, Hosp 2, Lanzhou 730000, Peoples R China; [El Kebir, Driss; Costantino, Santiago; Filep, Janos G.] Univ Montreal, Res Ctr, Maisonneuve Rosemont Hosp, Montreal, PQ, Canada; [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA	Lanzhou University; Lanzhou University; Universite de Montreal	Filep, JG (corresponding author), Lanzhou Univ, Minist Educ Key Lab Arid & Grassland Ecol, Inst Biophys, Tianshui Nanlu 222, Lanzhou 730000, Peoples R China.	janos.g.filep@umontreal.ca; wuy@lzu.edu.cn	Costantino, Santiago/ABD-5472-2020; Shi, Jing-Ming/ACS-3321-2022	Costantino, Santiago/0000-0002-2454-2635; Shi, Jing-Ming/0000-0002-8185-3130; Wang, Ming-Yu/0000-0002-6622-5996; Wu, Yi/0000-0003-0365-5590; Li, Haiyun/0000-0002-7458-7399; Ji, Shang-Rong/0000-0001-8595-3756	National Natural Science Foundation of China (NSFC) [30930024, 30770451, 30870495]; NSFC-Canadian Institutes of Health Research (CIHR) [30711120578, CCI-85707]; CIHR [MOP-94851]; Ministry of Science and Technology of China (MOST) [2011CB910500]; New Century Excellent Talents in University of China (NCET) [NCET-07-0392]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC-Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Ministry of Science and Technology of China (MOST)(Ministry of Science and Technology, China); New Century Excellent Talents in University of China (NCET)(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants from the National Natural Science Foundation of China (NSFC; 30930024, 30770451, and 30870495), NSFC-Canadian Institutes of Health Research (CIHR; 30711120578 and CCI-85707), CIHR (MOP-94851), Ministry of Science and Technology of China (MOST; 2011CB910500), and the Program for New Century Excellent Talents in University of China (NCET; NCET-07-0392). The authors declare no conflicts of interest.	Burke-Gaffney A, 2005, TRENDS PHARMACOL SCI, V26, P398, DOI 10.1016/j.tips.2005.06.005; Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009; Ciubotaru I, 2005, EXP BIOL MED, V230, P762, DOI 10.1177/153537020523001010; Devaraj S, 2006, ATHEROSCLEROSIS, V184, P48, DOI 10.1016/j.atherosclerosis.2005.03.031; Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611; Filep JG, 2009, CIRC RES, V105, P109, DOI 10.1161/CIRCRESAHA.109.202010; Heuertz RM, 2005, INT J BIOCHEM CELL B, V37, P320, DOI 10.1016/j.biocel.2004.07.002; Hirschfield GM, 2005, P NATL ACAD SCI USA, V102, P8309, DOI 10.1073/pnas.0503202102; Hoshino Y, 2007, ANTIOXID REDOX SIGN, V9, P689, DOI 10.1089/ars.2007.1575; Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com; Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962; Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73; Ji SR, 2006, INT J BIOCHEM CELL B, V38, P648, DOI 10.1016/j.biocel.2005.11.004; Kemp M, 2008, FREE RADICAL BIO MED, V44, P921, DOI 10.1016/j.freeradbiomed.2007.11.008; Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB; Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68; Koike T, 2009, CIRCULATION, V120, P2088, DOI 10.1161/CIRCULATIONAHA.109.872796; Kovacs A, 2007, P NATL ACAD SCI USA, V104, P13768, DOI 10.1073/pnas.0706027104; Miyamoto S, 2003, AM HEART J, V146, P465, DOI 10.1016/S0002-8703(03)00311-9; Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359; Mukherjee A, 2008, BRIT J RADIOL, V81, pS57, DOI 10.1259/bjr/34180435; Nishihira K, 2008, ATHEROSCLEROSIS, V201, P360, DOI 10.1016/j.atherosclerosis.2008.03.005; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Pagliei S, 2002, EUR CYTOKINE NETW, V13, P261; Paul A, 2004, CIRCULATION, V109, P647, DOI 10.1161/01.CIR.0000114526.50618.24; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schroeder BO, 2011, NATURE, V469, P419, DOI 10.1038/nature09674; Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028; Schwedler SB, 2005, CIRCULATION, V112, P1016, DOI 10.1161/CIRCULATIONAHA.105.556530; Schwedler SB, 2009, CLIN CHEM, V55, P1728, DOI 10.1373/clinchem.2009.125732; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Singh SK, 2008, ANN MED, V40, P110, DOI 10.1080/07853890701749225; Taylor KE, 2007, IMMUNOLOGY, V120, P404, DOI 10.1111/j.1365-2567.2006.02516.x; Teupser D, 2011, J BIOL CHEM, V286, P6272, DOI 10.1074/jbc.M110.161414; Verma S, 2006, CIRCULATION, V113, P2135; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Watanabe R, 2010, PHARMACOL THERAPEUT, V127, P261, DOI 10.1016/j.pharmthera.2010.04.004; Wu Y, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1377, DOI 10.1023/A:1021862027061; Xu SZ, 2008, NATURE, V451, P69, DOI 10.1038/nature06414; Yamawaki H, 2003, CIRC RES, V93, P1029, DOI 10.1161/01.RES.0000102869.39150.23; YING SC, 1989, J IMMUNOL, V143, P221; Yoshida S, 1999, J IMMUNOL, V163, P351; [赵晶 ZHAO Jing], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P87; Zhou AW, 2010, NATURE, V468, P108, DOI 10.1038/nature09505	46	63	72	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3186	3196		10.1096/fj.11-182741	http://dx.doi.org/10.1096/fj.11-182741			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21670067				2022-12-28	WOS:000294435200031
J	Lee, CJJ; Goncalves, LL; Wells, PG				Lee, Crystal J. J.; Goncalves, Luisa L.; Wells, Peter G.			Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism	FASEB JOURNAL			English	Article						2-phthalimidoglutaramic acid; 2-phthalimidoglutaric acid; otic vesicle development; 8-oxoguanine	OXIDATIVE DNA-DAMAGE; CATALYZED BIOACTIVATION; TERATOGENIC ACTIVITY; CHIRAL INVERSION; SCORING SYSTEM; SERUM-ALBUMIN; IN-VIVO; PHENYTOIN; LIMB; GLUTATHIONE	Thalidomide (TD) causes birth defects in humans and rabbits via several potential mechanisms, including bioactivation by embryonic prostaglandin H synthase (PHS) enzymes to a reactive intermediate that enhances reactive oxygen species (ROS) formation. We show herein that TD in rabbit embryo culture produces relevant embryopathies, including decreases in head/brain development by 28% and limb bud growth by 71% (P<0.05). Two TD hydrolysis products, 2-phthalimidoglutaramic acid (PGMA) and 2-phthalimidoglutaric acid (PGA), were similarly embryopathic, attenuating otic vesicle (ear) and limb bud formation by up to 36 and 77%, respectively (P<0.05). TD, PGMA, and PGA all increased embryonic DNA oxidation measured as 8-oxoguanine (8-oxoG) by up to 2-fold (P<0.05). Co- or pretreatment with the PHS inhibitors eicosatetraynoic acid (ETYA) or acetylsalicylic acid (ASA), or the free-radical spin trap phenyl-butylnitrone (PBN), completely blocked embryonic 8-oxoG formation and/or embryopathies initiated by TD, PGMA, and PGA. This is the first demonstration of limb bud embryopathies initiated by TD, as well as its hydrolysis products, in a mammalian embryo culture model of a species susceptible to TD in vivo, indicating that all likely contribute to TD teratogenicity in vivo, in part through PHS-dependent, ROS-mediated mechanisms.-Lee, C. J. J., Goncalves, L. L., Wells, P. G. Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. FASEB J. 25, 2468-2483 (2011). www.fasebj.org	[Lee, Crystal J. J.; Goncalves, Luisa L.; Wells, Peter G.] Univ Toronto, Fac Pharm, Toronto, ON M5S 3M2, Canada; [Wells, Peter G.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 3M2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 144 Coll St, Toronto, ON M5S 3M2, Canada.	pg.wells@utoronto.ca	Gonçalves, Luisa/A-4120-2016	Gonçalves, Luisa/0000-0002-3654-8612; Goncalves, Luisa/0000-0002-2385-7395	Canadian Institutes of Health Research (CIHR); Canadian Rx&D Health Research Foundation	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Rx&D Health Research Foundation	The authors thank Dr. Edward Carney, technician Valerie Marshall, and their colleagues at Dow Chemical Co. for their training and guidance in the techniques for rabbit embryo culture; University of Toronto veterinarian Dr. Kate Banks for her expertise and advice, and animal technicians Sara Johnson and Erin Dunning for the high quality of their care for the rabbits. Funding for this research was provided by the Canadian Institutes of Health Research (CIHR). C.J.J.L. was supported by a doctoral award jointly funded by CIHR and the Canadian Rx&D Health Research Foundation. A preliminary report of this research was presented at the 2009 annual meeting of the Teratology Society (USA; ref. 77).	Arlen RR, 1996, J PHARMACOL EXP THER, V277, P1649; Ballmaier D, 2006, TOXICOLOGY, V221, P166, DOI 10.1016/j.tox.2006.01.009; Beaudoin S, 2003, FETAL DIAGN THER, V18, P422, DOI 10.1159/000073136; BRAUN AG, 1986, TOXICOL APPL PHARM, V82, P175, DOI 10.1016/0041-008X(86)90449-7; Carney EW, 2007, BIRTH DEFECTS RES B, V80, P213, DOI 10.1002/bdrb.20118; Castilla EE, 1996, TERATOLOGY, V54, P273, DOI 10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DELAHUNT CS, 1964, SCIENCE, V146, P1300, DOI 10.1126/science.146.3649.1300; Eriksson T, 1998, CHIRALITY, V10, P223, DOI 10.1002/(SICI)1520-636X(1998)10:3<223::AID-CHIR4>3.0.CO;2-A; FABRO S, 1967, BIOCHEM J, V104, P565, DOI 10.1042/bj1040565; FABRO S, 1967, BIOCHEM J, V104, P570, DOI 10.1042/bj1040570; FABRO S, 1964, NATURE, V201, P1125, DOI 10.1038/2011125a0; FABRO S, 1965, BRIT J PHARM CHEMOTH, V25, P352, DOI 10.1111/j.1476-5381.1965.tb02055.x; FABRO S, 1966, J PATHOL BACTERIOL, V91, P511, DOI 10.1002/path.1700910227; Franks ME, 2004, LANCET, V363, P1802, DOI 10.1016/S0140-6736(04)16308-3; FRITZ H, 1966, J REPROD FERTIL, V11, P157; GORDON GB, 1981, P NATL ACAD SCI-BIOL, V78, P2545, DOI 10.1073/pnas.78.4.2545; Halliwell B., 2007, FREE RADICALS BIOL M; HANLEY TR, 1984, TOXICOL APPL PHARM, V75, P409, DOI 10.1016/0041-008X(84)90178-9; Hansen JM, 2002, J PHARMACOL EXP THER, V300, P768, DOI 10.1124/jpet.300.3.768; Hansen JM, 2002, DEV DYNAM, V225, P186, DOI 10.1002/dvdy.10150; Hansen JM, 1999, REPROD TOXICOL, V13, P547, DOI 10.1016/S0890-6238(99)00053-2; HENDRICKX AG, 1973, TERATOLOGY, V7, P151, DOI 10.1002/tera.1420070206; Huang PHT, 1997, TERATOGEN CARCIN MUT, V17, P1, DOI 10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L; HUANG PHT, 1990, TERATOGEN CARCIN MUT, V10, P281, DOI 10.1002/tcm.1770100402; Huang PHT, 1999, PHARMACOL TOXICOL, V85, P103, DOI 10.1111/j.1600-0773.1999.tb00074.x; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jansen MS, 2004, P NATL ACAD SCI USA, V101, P7199, DOI 10.1073/pnas.0402014101; Kastritis E, 2007, BEST PRACT RES CL HA, V20, P681, DOI 10.1016/j.beha.2007.09.001; Kennedy JC, 2004, MOL PHARMACOL, V66, P404; KING FE, 1949, J CHEM SOC, P3315, DOI 10.1039/jr9490003315; Knobloch J, 2008, MOL CELL BIOL, V28, P529, DOI 10.1128/MCB.00533-07; Knobloch J, 2007, FASEB J, V21, P1410, DOI 10.1096/fj.06-7603com; Knobloch J, 2008, MOL PHARMACEUT, V5, P1138, DOI 10.1021/mp8001232; KOCHERBECKER U, 1982, NATURWISSENSCHAFTEN, V69, P191, DOI 10.1007/BF00364900; LECK IM, 1962, BMJ-BRIT MED J, V2, P14, DOI 10.1136/bmj.2.5296.16; Lee CJJ, 2009, BIRTH DEFECTS RES A, V85, P400; Lee CJJ, 2011, TOXICOL SCI, V122, P146, DOI 10.1093/toxsci/kfr084; Lee CJJ, 2011, TOXICOL SCI, V122, P157, DOI 10.1093/toxsci/kfr086; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; Matthews SJ, 2003, CLIN THER, V25, P342, DOI 10.1016/S0149-2918(03)80085-1; MCBRIDE WG, 1961, LANCET, V2, P1358; MCBRIDE WG, 1977, TERATOLOGY, V16, P79, DOI 10.1002/tera.1420160113; MEISE W, 1973, EXPERIENTIA, V29, P423, DOI 10.1007/BF01926758; Miller MT, 1999, TERATOLOGY, V60, P306, DOI 10.1002/(SICI)1096-9926(199911)60:5<306::AID-TERA11>3.0.CO;2-Y; MIRANDA AF, 1994, TOXICOL APPL PHARM, V124, P230, DOI 10.1006/taap.1994.1027; Neubert R, 1995, LIFE SCI, V58, P295, DOI 10.1016/0024-3205(95)02290-2; Nicolai S, 1997, BIOCHEM PHARMACOL, V53, P1553, DOI 10.1016/S0006-2952(97)00096-8; OCKENFELS H, 1970, EXPERIENTIA, V26, P1236, DOI 10.1007/BF01897987; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Pitt JA, 1999, TERATOLOGY, V59, P88, DOI 10.1002/(SICI)1096-9926(199902)59:2<88::AID-TERA3>3.0.CO;2-7; Pitt JA, 1999, TERATOLOGY, V59, P102, DOI 10.1002/(SICI)1096-9926(199902)59:2<102::AID-TERA4>3.0.CO;2-6; Ramkissoon A, 2011, FREE RADICAL BIO MED, V50, P295, DOI 10.1016/j.freeradbiomed.2010.11.010; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Reist M, 1998, CHEM RES TOXICOL, V11, P1521, DOI 10.1021/tx9801817; Sauer H, 2000, AM J PATHOL, V156, P151, DOI 10.1016/S0002-9440(10)64714-1; Schuler-Faccini L, 2007, BIRTH DEFECTS RES A, V79, P671, DOI 10.1002/bdra.20384; SCHUMACHER H, 1968, J PHARMACOL EXP THER, V160, P189; SCHUMACHER H, 1965, BRIT J PHARM CHEMOTH, V25, P324, DOI 10.1111/j.1476-5381.1965.tb02053.x; SCHUMACHER H, 1965, BRIT J PHARM CHEMOTH, V25, P338, DOI 10.1111/j.1476-5381.1965.tb02054.x; SCHUMACHER HJ, 1970, J PHARMACOL EXP THER, V173, P265; SCOTT WJ, 1977, TERATOLOGY, V16, P333, DOI 10.1002/tera.1420160313; Silverstein R., 1977, SPECTROMETRIC IDENTI; SOMERS GF, 1962, LANCET, V1, P912; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; STROMLAND K, 1993, ACTA OPHTHALMOL, V71, P238; TAKEMORI S, 1976, ARCH OTOLARYNGOL, V102, P425; Therapontos C, 2009, P NATL ACAD SCI USA, V106, P8573, DOI 10.1073/pnas.0901505106; Walker SL, 2007, LEPROSY REV, V78, P197; Webster WS, 1997, INT J DEV BIOL, V41, P329; Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263; WILLIAMS RT, 1968, ARCH ENVIRON HEALTH, V16, P493, DOI 10.1080/00039896.1968.10665097; Winn LM, 2002, TOXICOL APPL PHARM, V184, P144, DOI 10.1006/taap.2002.9504; Wong AW, 2008, J NEUROSCI, V28, P9047, DOI 10.1523/JNEUROSCI.2557-08.2008; WUEST HM, 1964, LIFE SCI, V3, P721, DOI 10.1016/0024-3205(64)90025-6; YU WK, 1995, TOXICOL APPL PHARM, V131, P1, DOI 10.1006/taap.1995.1040	77	28	36	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2468	2483		10.1096/fj.10-178814	http://dx.doi.org/10.1096/fj.10-178814			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21502285				2022-12-28	WOS:000292242200037
J	Youssef, J; Chen, P; Shenoy, VB; Morgan, JR				Youssef, Jacquelyn; Chen, Peng; Shenoy, Vivek B.; Morgan, Jeffrey R.			Mechanotransduction is enhanced by the synergistic action of heterotypic cell interactions and TGF-beta 1	FASEB JOURNAL			English	Article						3-dimensional cell culture; cell-cell adhesion; cellular mechanics; multicellular aggregate; wound healing	GROWTH-FACTOR-BETA; ADHESION MOLECULES; MECHANICAL CONTROL; TISSUE; CONTRACTION; MYOFIBROBLASTS; EXPRESSION; MATRIX; FIBROBLASTS	With the use of planar substrates and collagen gels, the field of mechanotransduction has focused on the role of extracellular matrix stiffness, mechanical tension, and TGF-beta 1 in generating a more contractile fibroblast. However, little is known about the role of cell-cell interactions in inducing cellular contraction. We used 3-dimensional self-assembled microtissues, in which cell-cell interactions dominate, and a recently developed cell power assay (an assay for mechanotransduction) to quantify the effects of TGF-beta 1 vs. the heterotypic cell interface on the power exerted by pure normal human fibroblast (NHF) and pure rat hepatocyte 35 (H35) microtissues and their mixes. As a control, we found that TGF-beta 1 only doubled the power output of pure NHF and pure H35 microtissues, whereas the heterotypic environment resulted in a 5-fold increase in cell power (0.24 +/- 0.05 to 1.17 +/- 0.13 fJ/h). Seeding TGF-beta 1-treated NHFs with untreated H35 cells demonstrated that the heterotypic environment and TGF-beta 1 synergistically increase cell power by 22x by maximizing heterotypic cell interactions. Using a mathematical simulation of stress generation, we showed that tensile forces can be enhanced by heterotypic cell interactions. These data render a new understanding of how heterotypic cell interactions may increase cellular force generation during wound healing.-Youssef, J., Chen, P., Shenoy, V. B., Morgan, J. R. Mechanotransduction is enhanced by the synergistic action of heterotypic cell interactions and TGF-beta 1. FASEB J. 26, 2522-2530 (2012). www.fasebj.org	[Morgan, Jeffrey R.] Brown Univ, Biomed Ctr, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; [Youssef, Jacquelyn; Morgan, Jeffrey R.] Brown Univ, Ctr Biomed Engn, Providence, RI 02912 USA; [Chen, Peng; Shenoy, Vivek B.] Brown Univ, Sch Engn, Providence, RI 02912 USA	Brown University; Brown University; Brown University	Morgan, JR (corresponding author), Brown Univ, Biomed Ctr, Dept Mol Pharmacol Physiol & Biotechnol, G-B 393,171 Meeting St, Providence, RI 02912 USA.	jeffrey_morgan@brown.edu	Chen, Peng/F-9418-2010; Shenoy, Vivek/ABD-5075-2021	Chen, Peng/0000-0002-6930-1675; Morgan, Jeffrey/0000-0002-7546-3443	National Science Foundation (NSF) [DMR-0520651, CMMI-1129172]; U.S. National Institutes of Health [NIH R01-EB008664-01A1]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB008664] Funding Source: NIH RePORTER; Div Of Civil, Mechanical, & Manufact Inn [1129172] Funding Source: National Science Foundation	National Science Foundation (NSF)(National Science Foundation (NSF)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Div Of Civil, Mechanical, & Manufact Inn(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was funded in part by the Materials Research Science and Engineering Centers Program of the National Science Foundation (NSF) under award DMR-0520651, NSF CMMI-1129172, and U.S. National Institutes of Health grant NIH R01-EB008664-01A1. J. R. M. has an equity interest in MicroTissues, Inc. This relationship has been reviewed and managed by Brown University in accordance with its conflict of interest policies.	ALBELDA SM, 1993, LAB INVEST, V68, P4; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Carlsson AE, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.051912; Chen CS, 2004, ANNU REV BIOMED ENG, V6, P275, DOI 10.1146/annurev.bioeng.6.040803.140040; Chen JX, 2007, CELL MOTIL CYTOSKEL, V64, P248, DOI 10.1002/cm.20178; Chen P, 2011, SOFT MATTER, V7, P355, DOI 10.1039/c0sm00908c; Dean DM, 2007, FASEB J, V21, P4005, DOI 10.1096/fj.07-8710com; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Fernandez-Gonzalez R, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2101pe78; Freyman TM, 2001, BIOMATERIALS, V22, P2883, DOI 10.1016/S0142-9612(01)00034-5; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2004, MOL BIOL CELL, V15, P4310, DOI 10.1091/mbc.E04-05-0386; Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03-05-0328; Hinz Boris, 2009, Curr Rheumatol Rep, V11, P120; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Krieg M, 2008, NAT CELL BIOL, V10, P429, DOI 10.1038/ncb1705; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; MacKintosh FC, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.018104; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Mammoto T, 2010, DEVELOPMENT, V137, P1407, DOI 10.1242/dev.024166; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; Omelchenko T, 2001, P NATL ACAD SCI USA, V98, P8632, DOI 10.1073/pnas.151247698; Park JS, 2000, BIOL PHARM BULL, V23, P1517; ROBERTS AB, 1990, ANN NY ACAD SCI, V580, P225, DOI 10.1111/j.1749-6632.1990.tb17931.x; Timoshenko S.P., 1970, THEORY ELASTICITY; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Youssef J, 2011, P NATL ACAD SCI USA, V108, P6993, DOI 10.1073/pnas.1102559108; Zemel A, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.021905	32	11	12	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2522	2530		10.1096/fj.11-199414	http://dx.doi.org/10.1096/fj.11-199414			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22375018	Green Published			2022-12-28	WOS:000305017200028
J	Goplen, N; Karim, Z; Guo, L; Zhuang, YH; Huang, H; Gorska, MM; Gelfand, E; Pages, G; Pouyssegur, J; Alam, R				Goplen, Nicholas; Karim, Zunayet; Guo, Lei; Zhuang, Yonghua; Huang, Hua; Gorska, Magdalena M.; Gelfand, Erwin; Pages, Gilles; Pouyssegur, Jacques; Alam, Rafeul			ERK1 is important for Th2 differentiation and development of experimental asthma	FASEB JOURNAL			English	Article						apoptosis; IgE; mitogen-activated protein kinase; transcription factor	ACTIVATED PROTEIN-KINASE; THYMIC STROMAL LYMPHOPOIETIN; T-CELL-ACTIVATION; AIRWAY INFLAMMATION; MAP KINASE; IL-4 EXPRESSION; B-LYMPHOCYTES; PATHWAY; RESPONSES; TRANSCRIPTION	The ERK1/2 signaling pathway regulates a variety of T-cell functions. We observed dynamic changes in the expression of ERK1/2 during T-helper cell differentiation. Specifically, the expression of ERK1/2 was decreased and increased by IL-12 and IL-4, respectively. To address this subject further, we examined the specific role of ERK1 in Th2 differentiation and development of experimental asthma using ERK1(-/-) mice. ERK1(-/-) mice were unable to mount airway inflammation and hyperreactivity in two different models of asthma, acute and chronic. ERK1(-/-) mice had reduced expression of Th2 cytokines IL-4 and IL-5 but not IL-17A or IFN-gamma. They had reduced levels of allergen-specific IgE and blood eosinophils. T cells from immunized ERK1(-/-) mice manifested reduced proliferation in response to the sensitizing allergen. ERK1(-/-) T cells had reduced and short-lived expression of JunB following TCR stimulation, which likely contributed to their impaired Th2 differentiation. Immunized ERK1(-/-) mice showed reduced numbers of CD44(high) CD4 T cells in the spleen. In vitro studies demonstrated that Th2 but not Th1 cells from ERK1(-/-) mice had reduced numbers of CD44(high) cells. Finally, CD4 T cells form ERK1(-/-) mice expressed higher levels of BIM under growth factor-deprived conditions and reduced Mcl-1 on stimulation. As a result, the survival of CD4 T cells, especially CD44(high) Th2 cells, was much reduced in ERK1(-/-) mice. We conclude that ERK1 plays a nonredundant role in Th2 differentiation and development of experimental asthma. ERK1 controls Th2 differentiation and survival through its effect on JunB and BIM, respectively.-Goplen, N., Karim, Z., Guo, L., Zhuang, Y., Huang, H., Gorska, M. M., Gelfand, E., Pages, G., Pouyssegur, J., Alam, R. ERK1 is important for Th2 differentiation and development of experimental asthma. FASEB J. 26, 1934-1945 (2012). www.fasebj.org	[Goplen, Nicholas; Karim, Zunayet; Guo, Lei; Zhuang, Yonghua; Huang, Hua; Gorska, Magdalena M.; Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Gelfand, Erwin] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Huang, Hua; Gorska, Magdalena M.; Gelfand, Erwin; Alam, Rafeul] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Pages, Gilles; Pouyssegur, Jacques] Univ Nice Sophia Antipolis, Inst Signaling Dev Biol & Canc Res, Nice, France	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; UDICE-French Research Universities; Universite Cote d'Azur	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org	Zhuang, Yonghua/A-2946-2013; Pages, Gilles/N-7135-2017	Zhuang, Yonghua/0000-0002-1822-2395; Huang, Hua/0000-0001-7317-8983	U.S. National Institutes of Health [RO1 AI68088, AI091614, PPG HL36577]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068088, R01AI091614] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by U.S. National Institutes of Health grants RO1 AI68088, AI091614, and PPG HL36577. The authors declare no conflict of interest.	Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Agrawal A, 2006, J IMMUNOL, V176, P5788, DOI 10.4049/jimmunol.176.10.5788; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; D'Souza WN, 2008, J IMMUNOL, V181, P7617, DOI 10.4049/jimmunol.181.11.7617; Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Dzhagalov I, 2008, J IMMUNOL, V181, P521, DOI 10.4049/jimmunol.181.1.521; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Gorska MM, 2010, J IMMUNOL, V184, P4488, DOI 10.4049/jimmunol.0903115; Hartenstein B, 2002, EMBO J, V21, P6321, DOI 10.1093/emboj/cdf648; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Jorritsma PJ, 2003, J IMMUNOL, V170, P2427, DOI 10.4049/jimmunol.170.5.2427; Le VTK, 2008, J GEN VIROL, V89, P2416, DOI 10.1099/vir.0.2008/001669-0; Legewie S, 2007, BIOPHYS J, V93, P2279, DOI 10.1529/biophysj.107.109132; Lelliott A, 2012, EUR J PHARMACOL, V674, P407, DOI 10.1016/j.ejphar.2011.10.042; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Liu WM, 2010, MOL CELL BIOL, V30, P1783, DOI 10.1128/MCB.01003-09; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mostecki J, 2011, J IMMUNOL, V187, P2794, DOI 10.4049/jimmunol.0902569; Nakazawa T, 2008, J NEUROSCI RES, V86, P136, DOI 10.1002/jnr.21472; Nekrasova T, 2005, J IMMUNOL, V175, P2374, DOI 10.4049/jimmunol.175.4.2374; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; O'Shaughnessy EC, 2011, CELL, V144, P119, DOI 10.1016/j.cell.2010.12.014; Ohnishi H, 2009, J ALLERGY CLIN IMMUN, V123, P249, DOI 10.1016/j.jaci.2008.10.054; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; Shibata Y, 2002, J IMMUNOL, V169, P2134, DOI 10.4049/jimmunol.169.4.2134; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Tam NWN, 1999, EUR J BIOCHEM, V262, P149, DOI 10.1046/j.1432-1327.1999.00360.x; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Tewfik MA, 2009, ALLERGY, V64, P746, DOI 10.1111/j.1398-9995.2008.01889.x; Tong JK, 2010, AM J RESP CELL MOL, V43, P342, DOI 10.1165/rcmb.2008-0454OC; Tripathi P, 2012, IMMUNOL CELL BIOL, V90, P676, DOI 10.1038/icb.2011.87; Wensveen FM, 2010, IMMUNITY, V32, P754, DOI 10.1016/j.immuni.2010.06.005; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yuan TL, 2011, CURR BIOL, V21, P173, DOI 10.1016/j.cub.2010.12.047; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	53	29	34	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1934	1945		10.1096/fj.11-196477	http://dx.doi.org/10.1096/fj.11-196477			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22262639	Green Published			2022-12-28	WOS:000303680800021
J	Arslan, MA; Chikina, M; Csermely, P; Soti, C				Arslan, Mehmet Alper; Chikina, Maria; Csermely, Peter; Soti, Csaba			Misfolded proteins inhibit proliferation and promote stress-induced death in SV40-transformed mammalian cells	FASEB JOURNAL			English	Article						HSF1; Hsp70; sirtuin	HEAT-SHOCK FACTOR-1; CHLORAMPHENICOL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; MEDIATED TRANSCRIPTION; POLYGLUTAMINE PROTEIN; MOLECULAR CHAPERONES; COMMON MECHANISM; ALPHA-SYNUCLEIN; C. ELEGANS; SIRT1	Protein misfolding is implicated in neurodegenerative diseases and occurs in aging. However, the contribution of the misfolded ensembles to toxicity remains largely unknown. Here we introduce 2 primate cell models of destabilized proteins devoid of specific cellular functions and interactors, as bona fide misfolded proteins, allowing us to isolate the gain-of-function of non-native structures. Both GFP-degron and a mutant chloramphenicol-acetyltransferase fused to GFP (GFP-Delta 9CAT) form perinuclear aggregates, are degraded by the proteasome, and colocalize with and induce the chaperone Hsp70 (HSPA1A/B) in COS-7 cells. We find that misfolded proteins neither significantly compromise chaperone-mediated folding capacity nor induce cell death. However, they do induce growth arrest in cells that are unable to degrade them and promote stress-induced death upon proteasome inhibition by MG-132 and heat shock. Finally, we show that overexpression of all heat-shock factor-1 (HSF1) and Hsp70 proteins, as well as wild-type and deacetylase-deficient (H363Y) SIRT1, rescue survival upon stress, implying a noncatalytic action of SIRT1 in response to protein misfolding. Our study establishes a novel model and extends our knowledge on the mechanism of the function-independent proteotoxicity of misfolded proteins in dividing cells.-Arslan, M. A., Chikina, M., Csermely, P., Soti, C. Misfolded proteins inhibit proliferation and promote stress-induced death in SV40-transformed mammalian cells. FASEB J. 26, 766-777 (2012). www.fasebj.org	[Arslan, Mehmet Alper; Chikina, Maria; Csermely, Peter; Soti, Csaba] Semmelweis Univ, Dept Med Chem, H-1094 Budapest, Hungary	Semmelweis University	Soti, C (corresponding author), Semmelweis Univ, Dept Med Chem, Tuzolto U 37-47, H-1094 Budapest, Hungary.	csaba.soti@eok.sote.hu	Sőti, Csaba/O-6070-2017; Csermely, Peter/J-2067-2017; Arslan, Mehmet Alper/HDO-4459-2022	Sőti, Csaba/0000-0002-4057-7678; Csermely, Peter/0000-0001-9234-0659; Arslan, Mehmet Alper/0000-0002-3113-7195	EU [FP6-518230 PRO-TEOMAGE, FP7-200970 WhyWeAge, TAMOP-4.2.2/B-10/1-2010-0013]; Hungarian Science Foundation and Norway [NNF-78794]; Hungarian Science Foundation [OTKA K69105, OTKA-K83314]	EU(European Commission); Hungarian Science Foundation and Norway; Hungarian Science Foundation(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	The authors thank Kerstin Bellman (Heinrich-Heine University, Dusseldorf, Germany), Laszlo Buday (Semmelweis University, Budapest, Hungary), Heim Cohen (Bar-Ilan University, Ramat-Gan, Israel), Laszlo Hunyady (Semmelweis University), Richard I. Morimoto (Northwestern University, Evanston, IL, USA), Lea Sistonen (Abo Akademi University, Turku, Finland), Elizabeth Sztul (University of Alabama, Birmingham, AL, USA), and Richard Voellmy (University of Miami, Miami, FL, USA) for generously sharing reagents. The authors are indebted to Gergely Imre, Akos Putics, and Minh Tu Nguyen for experimental help, Beata Gilanyi for technical help, and the members of the Stress Group and the anonymous reviewers of this manuscript for helpful comments and suggestions. This work was supported by research grants from the EU (FP6-518230 PRO-TEOMAGE, FP7-200970 WhyWeAge, TAMOP-4.2.2/B-10/1-2010-0013), from a joint grant of the Hungarian Science Foundation and Norway Grants (NNF-78794), and from the Hungarian Science Foundation (OTKA K69105 and OTKA-K83314). C. S. is a Bolyai Research Scholar of the Hungarian Academy of Sciences.	Albani D, 2009, J NEUROCHEM, V110, P1445, DOI 10.1111/j.1471-4159.2009.06228.x; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Batulan Z, 2003, J NEUROSCI, V23, P5789; Ben-Zvi A, 2009, P NATL ACAD SCI USA, V106, P14914, DOI 10.1073/pnas.0902882106; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bett JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005128; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Drummond DA, 2008, CELL, V134, P341, DOI 10.1016/j.cell.2008.05.042; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Fu LW, 2005, NEUROBIOL DIS, V20, P656, DOI 10.1016/j.nbd.2005.05.015; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Geiler-Samerotte KA, 2011, P NATL ACAD SCI USA, V108, P680, DOI 10.1073/pnas.1017570108; Ghosh HS, 2007, BIOCHEM J, V408, P105, DOI 10.1042/BJ20070817; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Kanfi Y, 2010, AGING CELL, V9, P162, DOI 10.1111/j.1474-9726.2009.00544.x; Kern A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008568; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee JW, 2006, NATURE, V443, P50, DOI 10.1038/nature05096; Link CD, 2006, J BIOL CHEM, V281, P1808, DOI 10.1074/jbc.M505581200; Metzger MB, 2008, J BIOL CHEM, V283, P32302, DOI 10.1074/jbc.M806424200; Metzger MB, 2009, MOL BIOL CELL, V20, P1006, DOI 10.1091/mbc.E08-02-0140; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Ng PC, 2006, ANNU REV GENOM HUM G, V7, P61, DOI 10.1146/annurev.genom.7.080505.115630; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844; ROBBEN J, 1993, J BIOL CHEM, V268, P24555; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shaw W V, 1975, Methods Enzymol, V43, P737; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; Sugio A, 2009, PLANT CELL, V21, P642, DOI 10.1105/tpc.108.062596; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Trotter EW, 2002, J BIOL CHEM, V277, P44817, DOI 10.1074/jbc.M204686200; Trotter EW, 2001, P NATL ACAD SCI USA, V98, P7313, DOI 10.1073/pnas.121172998; Vaitiekunaite R, 2007, MECH AGEING DEV, V128, P650, DOI 10.1016/j.mad.2007.09.004; Van der Schueren J, 1998, PROTEIN ENG, V11, P1211, DOI 10.1093/protein/11.12.1211; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; Voellmy R, 2007, ADV EXP MED BIOL, V594, P89; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Westerheide SD, 2009, SCIENCE, V323, P1063, DOI 10.1126/science.1165946; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200	59	16	18	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					766	777		10.1096/fj.11-186197	http://dx.doi.org/10.1096/fj.11-186197			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22049061				2022-12-28	WOS:000300485700028
J	Blache, D; Gautier, T; Tietge, UJF; Lagrost, L				Blache, Denis; Gautier, Thomas; Tietge, Uwe J. F.; Lagrost, Laurent			Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism	FASEB JOURNAL			English	Article						thrombosis; oxidative stress	INTIMA-MEDIA THICKNESS; GROUP-II; GROUP-V; SECRETORY PHOSPHOLIPASE-A2; CHOLESTEROL ACCUMULATION; POTENTIAL INVOLVEMENT; OXIDATIVE STRESS; APOLIPOPROTEIN-E; CORONARY EVENTS; LIPID PEROXIDES	Plasma activity of secretory phospholipase A2 (sPLA2) increases in patients with cardiovascular disease. The present study investigated whether platelet-released sPLA2 induces low-density lipoprotein (LDL) and high-density lipoprotein (HDL) modifications that translate into changes in lipoprotein function. Activated but not resting platelets induced oxidative modifications of human native LDLs and HDLs, which render these particles dysfunctional. Platelet-incubated LDLs stimulated the incorporation of cholesterol oleate into macrophages, and modified HDLs lost their cholesterol efflux capacity and antioxidant properties. In vitro and ex vivo experiments showed that lysophophatidylcholine accumulated in the platelet-modified LDLs and HDLs of mice expressing sPLA2 (Balb/c and transgenic C57Bl/6 mice expressing human sPLA2) but not in the lipoproteins of naturally sPLA2-deficient mice (C57Bl/6). Unlike C57Bl/6 mice, Balb/c mice injected with leptin (67 mu g/mouse, i.p.) as an in vivo prothrombotic agent displayed increased plasma sPLA2 activity, reduced clotting time, higher plasma levels of oxidation products, increased production of nonesterified fatty acids, and more substantial platelet-mediated modification of lipoproteins. These effects were blocked completely by injection of the platelet inhibitor ticlopidine (5 mg/kg, i.p.) or by a sPLA2 inhibitor (LY311727, 3 mg/kg, i.p.). These results demonstrate that stimulated platelets are major contributors to plasma sPLA2 activity in vivo and account to a large extent for the adverse modification of circulating lipoproteins.-Blache, D., Gautier, T., Tietge, U.J.F., Lagrost, L. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism. FASEB J. 26, 927-937 (2012). www.fasebj.org	[Blache, Denis] Univ Bourgogne, INSERM, Res Ctr, Fac Med,UMR 866, F-21079 Dijon, France; [Tietge, Uwe J. F.] Univ Groningen, Dept Pediat, Ctr Liver Digest & Metab Dis, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Groningen	Blache, D (corresponding author), Univ Bourgogne, INSERM, Res Ctr, Fac Med,UMR 866, 7 Blvd Jeanne Arc,BP 87900, F-21079 Dijon, France.	dblache@u-bourgogne.fr	Gautier, Thomas/Q-5371-2018	Gautier, Thomas/0000-0003-1119-7382	Institut National de la Sante et de la Recherche Medicale (INSERM); Conseil Regional de Bourgogne; Universite de Bourgogne; Netherlands Organization for Scientific Research [917-56-358]	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); Universite de Bourgogne; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	The authors thank Benoit Larnaudie for helpful initial studies and Philip Bastable for manuscript editing. This work was supported in part by the Institut National de la Sante et de la Recherche Medicale (INSERM), the Conseil Regional de Bourgogne, the Universite de Bourgogne, and by a grant from the Netherlands Organization for Scientific Research (VIDI grant 917-56-358 to U.J.F.T).	Ansell BJ, 2007, CURR OPIN LIPIDOL, V18, P427, DOI 10.1097/MOL.0b013e3282364a17; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; AVIRAM M, 1990, ARTERIOSCLEROSIS, V10, P559, DOI 10.1161/01.ATV.10.4.559; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERLINER JA, 1992, DIABETES, V41, P74, DOI 10.2337/diab.41.2.S74; Blache D, 1998, J AM OIL CHEM SOC, V75, P107, DOI 10.1007/s11746-998-0019-6; Blache D, 2002, FREE RADICAL BIO MED, V33, P1670, DOI 10.1016/S0891-5849(02)01139-5; BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5; BLACHE D, 1995, AM J PHYSIOL-HEART C, V268, pH679, DOI 10.1152/ajpheart.1995.268.2.H679; Blache D, 2006, FREE RADICAL BIO MED, V41, P277, DOI 10.1016/j.freeradbiomed.2006.04.008; Bodary PF, 2005, ARTERIOSCL THROM VAS, V25, P119, DOI 10.1161/01.ATV.0000173306.47722.ec; Boyanovsky BB, 2009, CARDIOVASC DRUG THER, V23, P61, DOI 10.1007/s10557-008-6134-7; Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9; Carnevale R, 2007, FASEB J, V21, P927, DOI 10.1096/fj.06-6908com; Corsonello A, 2004, INT J OBESITY, V28, P979, DOI 10.1038/sj.ijo.0802722; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; ELSAADANI M, 1989, J LIPID RES, V30, P627; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; Garces F, 2010, OBESITY, V18, P2023, DOI 10.1038/oby.2010.9; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Gesquiere L, 1999, FREE RADICAL BIO MED, V27, P134, DOI 10.1016/S0891-5849(99)00055-6; Gesquiere L, 2000, FREE RADICAL BIO MED, V29, P181, DOI 10.1016/S0891-5849(00)00337-3; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; Gesquiere L, 1997, FREE RADICAL BIO MED, V23, P541, DOI 10.1016/S0891-5849(97)00114-7; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; Hatch F T, 1968, Adv Lipid Res, V6, P1; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; HurtCamejo E, 1997, ATHEROSCLEROSIS, V132, P1, DOI 10.1016/S0021-9150(97)00085-3; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; Jaross W, 2002, EUR J CLIN INVEST, V32, P383, DOI 10.1046/j.1365-2362.2002.01000.x; Jawien J, 2007, EUR J PHARMACOL, V556, P129, DOI 10.1016/j.ejphar.2006.11.028; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Koenig W, 2009, EUR HEART J, V30, P2742, DOI 10.1093/eurheartj/ehp302; Korotaeva AA, 2010, PROSTAG OTH LIPID M, V91, P38, DOI 10.1016/j.prostaglandins.2009.12.004; Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d; Kugiyama K, 2000, AM J CARDIOL, V86, P718, DOI 10.1016/S0002-9149(00)01069-9; Kugiyama K, 1999, CIRCULATION, V100, P1280, DOI 10.1161/01.CIR.100.12.1280; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; Leinonen ES, 2004, J INTERN MED, V256, P119, DOI 10.1111/j.1365-2796.2004.01350.x; Leite JO, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-7; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; Magrioti V, 2010, EXPERT OPIN THER PAT, V20, P1, DOI 10.1517/13543770903463905; Mallat Z, 2007, ARTERIOSCL THROM VAS, V27, P1177, DOI 10.1161/ATVBAHA.107.139352; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Mattsson N, 2010, ARTERIOSCL THROM VAS, V30, P1861, DOI 10.1161/ATVBAHA.110.204669; MOUNIER C, 1994, BBA-LIPID LIPID MET, V1214, P88, DOI 10.1016/0005-2760(94)90013-2; Oorni K, 2009, CURR OPIN LIPIDOL, V20, P421, DOI 10.1097/MOL.0b013e32832fa14d; POLETTE A, 1992, ATHEROSCLEROSIS, V96, P171, DOI 10.1016/0021-9150(92)90063-M; Porela P, 2000, BASIC RES CARDIOL, V95, P413, DOI 10.1007/s003950070041; Rauch U, 2001, ANN INTERN MED, V134, P224, DOI 10.7326/0003-4819-134-3-200102060-00014; Rosenblat M, 1999, J BIOL CHEM, V274, P13790, DOI 10.1074/jbc.274.20.13790; Rosengren B, 2006, ARTERIOSCL THROM VAS, V26, P1579, DOI 10.1161/01.ATV.0000221231.56617.67; Rosenson RS, 2009, LANCET, V373, P649, DOI 10.1016/S0140-6736(09)60403-7; Sato H, 2008, J BIOL CHEM, V283, P33483, DOI 10.1074/jbc.M804628200; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Singh Uma, 2006, Pathophysiology, V13, P129, DOI 10.1016/j.pathophys.2006.05.002; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; Tietge UJF, 2003, AM J PHYSIOL-ENDOC M, V285, pE403, DOI 10.1152/ajpendo.00576.2002; van der Giet M, 2010, J MOL MED, V88, P75, DOI 10.1007/s00109-009-0543-3; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zusman RM, 1999, CLIN CARDIOL, V22, P559, DOI 10.1002/clc.4960220905	63	18	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					927	937		10.1096/fj.11-191593	http://dx.doi.org/10.1096/fj.11-191593			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22042222				2022-12-28	WOS:000300485700042
J	Hoermann, G; Cerny-Reiterer, S; Herrmann, H; Blatt, K; Bilban, M; Gisslinger, H; Gisslinger, B; Mullauer, L; Kralovics, R; Mannhalter, C; Valent, P; Mayerhofer, M				Hoermann, Gregor; Cerny-Reiterer, Sabine; Herrmann, Harald; Blatt, Katharina; Bilban, Martin; Gisslinger, Heinz; Gisslinger, Bettina; Muellauer, Leonhard; Kralovics, Robert; Mannhalter, Christine; Valent, Peter; Mayerhofer, Matthias			Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms	FASEB JOURNAL			English	Article						cancer; cytokines; microenvironment; fibrosis	TYROSINE KINASE JAK2; CELL-LINE; POLYCYTHEMIA-VERA; CD34(+) CELLS; HEMATOPOIETIC PROGENITORS; PRIMARY MYELOFIBROSIS; SIGNAL-TRANSDUCTION; COLLAGEN PRODUCTION; MOUSE MODEL; M RECEPTOR	The JAK2 mutation V617F is detectable in a majority of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). Enforced expression of JAK2 V617F in mice induces myeloproliferation and bone marrow (BM) fibrosis, suggesting a causal role for the JAK2 mutant in the pathogenesis of MPNs. However, little is known about mechanisms and effector molecules contributing to JAK2 V617F-induced myeloproliferation and fibrosis. We show that JAK2 V617F promotes expression of oncostatin M (OSM) in neoplastic myeloid cells. Correspondingly, OSM mRNA levels were increased in the BM of patients with MPNs (median 287% of ABL, range 22-1450%) compared to control patients (median 59% of ABL, range 12-264%; P < 0.0001). OSM secreted by JAK2 V617F+ cells stimulated growth of fibroblasts and microvascular endothelial cells and induced the production of angiogenic and profibrogenic cytokines (HGF, VEGF, and SDF-1) in BM fibroblasts. All effects of MPN cell-derived OSM were blocked by a neutralizing anti-OSM antibody, whereas the production of OSM in MPN cells was suppressed by a pharmacologic JAK2 inhibitor or RNAi-mediated knockdown of JAK2. In summary, JAK2 V617F-mediated up-regulation of OSM may contribute to fibrosis, neoangiogenesis, and the cytokine storm observed in MPNs, suggesting that OSM might serve as a novel therapeutic target molecule in these neoplasms.-Hoermann, G., Cerny-Reiterer, S., Herrmann, H., Blatt, K., Bilban, M., Gisslinger, H., Gisslinger, B., Mullauer, L., Kralovics, R., Mannhalter, C., Valent, P., Mayerhofer, M. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 26, 894 -906 (2012). www.fasebj.org	[Hoermann, Gregor; Bilban, Martin; Mannhalter, Christine; Mayerhofer, Matthias] Med Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria; [Cerny-Reiterer, Sabine; Blatt, Katharina; Gisslinger, Heinz; Gisslinger, Bettina; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria; [Kralovics, Robert] Ctr Mol Med, Vienna, Austria; [Cerny-Reiterer, Sabine; Herrmann, Harald; Valent, Peter] Ludwig Boltzmann Cluster Oncol, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute	Mayerhofer, M (corresponding author), Med Univ Vienna, Dept Lab Med, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	matthias.mayerhofer@meduniwien.ac.at	Müllauer, Leonhard/GSN-9884-2022; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Hoermann, Gregor/B-8832-2016; Hermann, Harald/E-7073-2018	Müllauer, Leonhard/0000-0002-3399-078X; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Hoermann, Gregor/0000-0002-7374-4380; Hermann, Harald/0000-0002-5095-4641; Bilban, Martin/0000-0001-7043-7142; Mannhalter, Christine/0000-0001-7667-8078; Kralovics, Robert/0000-0002-6997-8539	City of Vienna; Austrian Society of Laboratory Medicine and Clinical Chemistry	City of Vienna; Austrian Society of Laboratory Medicine and Clinical Chemistry	This study was supported by the Medical Scientific Fund of the Mayor of the City of Vienna and a grant from the Austrian Society of Laboratory Medicine and Clinical Chemistry. The authors thank Andreas Spittler and Gunther Hofbauer (Core Facility Flow Cytometry/Cell Sorting, Medical University of Vienna) and Marion Groger and Sabine Rauscher (Core Facility Imaging, Medical University of Vienna) for help with cell sorting and microscopy, respectively. G. H., S.C.-R., H. H., K. B., M. B., B. G., and M. M. performed experiments and analyzed the data. H. G., L. M., R. K., and C. M. contributed and analyzed patient samples and patient data. G. H., P. V., and M. M. designed the study and wrote the manuscript. The authors declare no conflicts of interest.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Akada H, 2010, BLOOD, V115, P3589, DOI 10.1182/blood-2009-04-215848; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; Bogani C, 2008, STEM CELLS, V26, P1920, DOI 10.1634/stemcells.2008-0377; Boissinot M, 2011, ONCOGENE, V30, P990, DOI 10.1038/onc.2010.479; Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; Funakoshi-Tago M, 2010, J BIOL CHEM, V285, P5296, DOI 10.1074/jbc.M109.040733; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; Guglielmelli P, 2007, STEM CELLS, V25, P165, DOI 10.1634/stemcells.2006-0351; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Harir N, 2007, BLOOD, V109, P1678, DOI 10.1182/blood-2006-01-029918; Hoermann G, 2011, AM J PATHOL, V178, P2344, DOI 10.1016/j.ajpath.2011.01.020; Hohensinner PJ, 2009, FASEB J, V23, P774, DOI 10.1096/fj.08-108035; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Koskela K, 2000, EUR J HAEMATOL, V65, P52, DOI 10.1034/j.1600-0609.2000.90167.x; Kota J, 2008, LEUKEMIA, V22, P1828, DOI 10.1038/leu.2008.236; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2008, BLOOD, V112, P2190, DOI 10.1182/blood-2008-03-077966; Levy MT, 2000, J HEPATOL, V32, P218, DOI 10.1016/S0168-8278(00)80066-5; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Luzina IG, 2003, ARTHRITIS RHEUM-US, V48, P2262, DOI 10.1002/art.11080; Manicourt DH, 2000, ARTHRITIS RHEUM, V43, P281, DOI 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063; Mayerhofer M, 2008, BLOOD, V111, P2200, DOI 10.1182/blood-2006-11-055723; Menon MP, 2006, J CLIN INVEST, V116, P683, DOI 10.1172/JCI25227; Michiels JJ, 2007, LEUKEMIA RES, V31, P1031, DOI 10.1016/j.leukres.2007.01.021; Migliaccio AR, 2008, EXP HEMATOL, V36, P158, DOI 10.1016/j.exphem.2007.10.001; Minehata K, 2006, INT J HEMATOL, V84, P319, DOI 10.1532/IJH97.06090; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Shide K, 2008, LEUKEMIA, V22, P87, DOI 10.1038/sj.leu.2405043; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Spivak Jerry L, 2003, Hematology Am Soc Hematol Educ Program, P200; Su L, 2000, J BIOL CHEM, V275, P12661, DOI 10.1074/jbc.275.17.12661; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Tauber S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-200; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Uozumi K, 2000, LEUKEMIA, V14, P142, DOI 10.1038/sj.leu.2401608; Urbanska-Rys H, 2000, EUR CYTOKINE NETW, V11, P443; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; WALLACE PM, 1995, BLOOD, V86, P1310, DOI 10.1182/blood.V86.4.1310.bloodjournal8641310; Wallace PM, 1995, ANN NY ACAD SCI, V762, P42; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	65	35	37	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					894	906		10.1096/fj.11-193078	http://dx.doi.org/10.1096/fj.11-193078			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22051730				2022-12-28	WOS:000300485700039
J	Zeng, S; Zhang, QY; Huang, JZ; Vedantham, S; Rosario, R; Ananthakrishnan, R; Yan, SF; Ramasamy, R; DeMatteo, RP; Emond, JC; Friedman, RA; Schmidt, AM				Zeng, Shan; Zhang, Qing Yin; Huang, Jianzhong; Vedantham, Srinivasan; Rosario, Rosa; Ananthakrishnan, Radha; Yan, Shi Fang; Ramasamy, Ravichandran; DeMatteo, Ronald P.; Emond, Jean C.; Friedman, Richard A.; Schmidt, Ann Marie			Opposing roles of RAGE and Myd88 signaling in extensive liver resection	FASEB JOURNAL			English	Article						nuclear factor-kappa B; Pim1; inflammation; proliferation; stat 3 phosphorylation	NF-KAPPA-B; SERINE/THREONINE KINASE PIM-1; MICE LACKING; IN-VIVO; C-MYC; REGENERATION; ACTIVATION; EXPRESSION; INTERLEUKIN-6; NECROSIS	In extensive liver resection secondary to primary or metastatic liver tumors, or in living donor liver transplantation, strategies to quell deleterious inflammatory responses and facilitate regeneration are essential. The receptor for advanced glycation end-products (RAGE) and myeloid differentiating factor 88 (Myd88) are implicated in the inflammatory response. To establish the contributions of RAGE vs. Myd88 signaling in extensive liver resection, we probed the effect of RAGE and/or Myd88, the latter primarily a key transducer of major toll-like receptors and also implicated in interleukin-1 (Il1) signaling, in a murine model of extensive (85%) hepatectomy. We report that, although Myd88 is thoroughly essential for survival via regulation of NF-kappa B and TNF-alpha, deletion of RAGE significantly improved survival compared to wild-type, Myd88-null, or RAGE-null/Myd88-null mice. RAGE opposes Myd88 signaling at multiple levels: by suppression of p65 levels, thereby reducing activation of NF-kappa B and consequent production of cyclin D1, and by suppression of Il6-mediated phosphorylation of Stat3, thereby down-regulating Pim1 and suppressing the hyperplastic response. Further, RAGE-dependent suppression of glyoxalase1, a detoxification pathway for pre-AGEs, enhances AGE levels and suppresses Il6 action. We conclude that blockade of RAGE may rescue liver remnants from the multiple signals that preclude adaptive proliferation triggered primarily by Myd88 signaling pathways.-Zeng, S., Zhang, Q. Y., Huang, J., Vedantham, S., Rosario, R., Ananthakrishnan, R., Yan, S. F., Ramasamy, R., DeMatteo, R. P., Emond, J. C., Friedman, R. A., Schmidt, A. M. Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J. 26, 882-893 (2012). www.fasebj.org	[Zeng, Shan; DeMatteo, Ronald P.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Vedantham, Srinivasan; Rosario, Rosa; Ananthakrishnan, Radha; Yan, Shi Fang; Ramasamy, Ravichandran; Schmidt, Ann Marie] NYU, Div Endocrinol, Dept Med, Sch Med, New York, NY 10016 USA; [Zeng, Shan; Zhang, Qing Yin; Huang, Jianzhong; Emond, Jean C.] Columbia Univ, Dept Surg, Coll Phys & Surg, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Coll Phys & Surg, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Coll Phys & Surg, Dept Biomed Informat, New York, NY USA	Memorial Sloan Kettering Cancer Center; New York University; Columbia University; Columbia University; Columbia University	Zeng, S (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA.	zengs@mskcc.org; annmarie.schmidt@nyumc.org		Ramasamy, Ravichandran/0000-0002-3666-3346	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068346] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK068346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Bachmann M, 2006, INT J BIOCHEM CELL B, V38, P430, DOI 10.1016/j.biocel.2005.10.010; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bair WB, 2010, MELANOMA RES, V20, P85, DOI 10.1097/CMR.0b013e3283364903; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Buckley AR, 2000, J NEUROIMMUNOL, V109, P40, DOI 10.1016/S0165-5728(00)00301-5; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cataldegirmen G, 2005, J EXP MED, V201, P473, DOI 10.1084/jem.20040934; Chen XG, 2010, J INTERF CYTOK RES, V30, P525, DOI 10.1089/jir.2009.0111; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CUYPERS HT, 1984, CELL, V37, P141; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Hanse EA, 2009, CELL CYCLE, V8, P2802, DOI 10.4161/cc.8.17.9465; Jin X, 2007, HEPATOLOGY, V46, P802, DOI 10.1002/hep.21728; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kluwe J, 2009, J MOL MED, V87, P125, DOI 10.1007/s00109-008-0426-z; Koniaris LG, 2003, J AM COLL SURGEONS, V197, P634, DOI 10.1016/S1072-7515(03)00374-0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Meloche J, 2011, ARTERIOSCL THROM VAS, V31, P2114, DOI 10.1161/ATVBAHA.111.230573; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nihira K, 2010, CELL DEATH DIFFER, V17, P689, DOI 10.1038/cdd.2009.174; OHMORI S, 1987, J CHROMATOGR-BIOMED, V414, P149, DOI 10.1016/0378-4347(87)80033-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Panis Y, 1997, SURGERY, V121, P142, DOI 10.1016/S0039-6060(97)90283-X; Ramasamy R, 2009, J LEUKOCYTE BIOL, V86, P505, DOI 10.1189/jlb.0409230; Samstein B, 2001, ANNU REV MED, V52, P147, DOI 10.1146/annurev.med.52.1.147; Sowa JP, 2008, WORLD J GASTROENTERO, V14, P7093, DOI 10.3748/wjg.14.7093; Stout BA, 2004, J IMMUNOL, V173, P6409, DOI 10.4049/jimmunol.173.10.6409; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Wang Z, 2001, J Vet Sci, V2, P167; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Yamada Y, 1998, AM J PATHOL, V152, P1577; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	42	25	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					882	893		10.1096/fj.11-192997	http://dx.doi.org/10.1096/fj.11-192997			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22075646	Green Published			2022-12-28	WOS:000300485700038
J	Satyanarayana, A; Klarmann, KD; Gavrilova, O; Keller, JR				Satyanarayana, Ande; Klarmann, Kimberly D.; Gavrilova, Oksana; Keller, Jonathan R.			Ablation of the transcriptional regulator Id1 enhances energy expenditure, increases insulin sensitivity, and protects against age and diet induced insulin resistance, and hepatosteatosis	FASEB JOURNAL			English	Article						PGC1a; UCP1; adipogenesis; brown adipose tissue; thermogenesis	WHITE ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; IN-VIVO; MELANOCORTIN SYSTEM; HEPATIC STEATOSIS; INDUCED OBESITY; LEAN PHENOTYPE; DEFICIENT MICE; KNOCKOUT MICE; BROWN FAT	Obesity is a major health concern that contributes to the development of diabetes, hyperlipidemia, coronary artery disease, and cancer. Id proteins are helix-loop-helix transcription factors that regulate the proliferation and differentiation of cells from multiple tissues, including adipocytes. We screened mouse tissues for the expression of Id1 and found that Id1 protein is highly expressed in brown adipose tissue (BAT) and white adipose tissue (WAT), suggesting a role for Id1 in adipogenesis and cell metabolism. Id1(-/-) mice are viable but show a significant reduction in fat mass (P<0.005) over the life of the animal that was not due to decreased number of adipocytes. Analysis of Id1(-/-) mice revealed higher energy expenditure, increased lipolysis, and fatty acid oxidation, resulting in reduced triglyceride accumulation in WAT compared to Id1(+/+) mice. Serum levels of triglycerides (193.9 +/- 32.2 vs. 86.5 +/- 33.8, P<0.0005), cholesterol (189.4 +/- 33.8 vs. 110.6 +/- 8.23, P<0.0005) and leptin (1263 +/- 835 vs. 222 +/- 260, P<0.005) were significantly lower in aged Id1(-/-) mice compared to Id1(+/+) mice. Id1-deficient mice have higher resting (P<0.005) and total (P<0.05) O-2 consumption and lower respiratory exchange ratio (P<0.005), confirming that Id1(-/-) mice use a higher proportion of lipid as an energy source for the increased energy expenditure. The expression of PGC1 alpha and UCP1 were 2- to 3-fold up-regulated in Id1(-/-) BAT, suggesting that loss of Id1 increases thermogenesis. As a consequence of higher energy expenditure and reduced fat mass, Id1(-/-) mice displayed enhanced insulin sensitivity. Id1 deficiency protected mice against age-and high-fat-diet-induced adiposity, insulin resistance, and hepatosteatosis. Our findings suggest that Id1 plays a critical role in the regulation of energy homeostasis and could be a potential target in the treatment of insulin resistance and fatty liver disease.-Satyanarayana, A., Klarmann, K. D., Gavrilova, 1 O., Keller, J. R. Ablation of the transcriptional regulator Id1 enhances energy expenditure, increases insulin sensitivity, and protects against age and diet-induced insulin resistance and hepatosteatosis. FASEB J. 26, 309-323 (2012). www.fasebj.org	[Satyanarayana, Ande; Klarmann, Kimberly D.; Keller, Jonathan R.] NCI, Basic Res Program, SAIC Frederick, Ctr Canc Res, Frederick, MD 21701 USA; [Gavrilova, Oksana] Natl Inst Diabet Digest & Kidney Dis, Mouse Metab Core Lab, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Keller, JR (corresponding author), Inst Frederick, Basic Res Program, SAIC Frederick, Ctr Canc Res, Bldg 560-12-03,1050 Boyles St, Frederick, MD 21702 USA.	kellerjo@mail.nih.gov	Keller, Jonathan R./O-6677-2018		National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZICDK070002] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Robert Benezra (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for providing the Id1-knockout mice. The authors thank Steven Stull and Juanita Mercado for animal care; Tatyana Chanturiya and William Jou for technical help; and Roberta Smith and the Pathology/Histotechnology Laboratory, NCI-Frederick, for tissue sectioning and staining. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. The authors declare no competing financial interests.	Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; ATRENS DM, 1993, BRAIN RES, V630, P238, DOI 10.1016/0006-8993(93)90662-7; Baggio Laurie L, 2002, Treat Endocrinol, V1, P117, DOI 10.2165/00024677-200201020-00005; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Budhiraja S, 2009, FUND CLIN PHARMACOL, V23, P149, DOI 10.1111/j.1472-8206.2009.00667.x; Butler AA, 2006, PEPTIDES, V27, P281, DOI 10.1016/j.peptides.2005.02.029; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Chen M, 2010, CELL METAB, V11, P320, DOI 10.1016/j.cmet.2010.02.013; Chen M, 2009, CELL METAB, V9, P548, DOI 10.1016/j.cmet.2009.05.004; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Conarello SL, 2007, DIABETOLOGIA, V50, P142, DOI 10.1007/s00125-006-0481-3; D'Agostino D, 2002, J BIOL CHEM, V277, P7170, DOI 10.1074/jbc.M108328200; Das UN, 2010, NUTRITION, V26, P459, DOI 10.1016/j.nut.2009.09.020; de Ferranti S, 2008, CLIN CHEM, V54, P945, DOI 10.1373/clinchem.2007.100156; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Fan W, 2005, PEPTIDES, V26, P1800, DOI 10.1016/j.peptides.2004.11.033; Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001; Florez-Duquet M, 1998, PHYSIOL REV, V78, P339, DOI 10.1152/physrev.1998.78.2.339; FOLEY JE, 1980, DIABETOLOGIA, V19, P234, DOI 10.1007/BF00275275; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Gantois I, 2007, P NATL ACAD SCI USA, V104, P4182, DOI 10.1073/pnas.0611625104; Gautam D, 2006, CELL METAB, V4, P363, DOI 10.1016/j.cmet.2006.09.008; Guesdon B, 2010, BEHAV BRAIN RES, V207, P14, DOI 10.1016/j.bbr.2009.09.032; Hansen JB, 2006, BIOCHEM J, V398, P153, DOI 10.1042/BJ20060402; Heron-Milhavet L, 2004, ENDOCRINOLOGY, V145, P4667, DOI 10.1210/en.2003-1543; Hulver MW, 2004, P NUTR SOC, V63, P375, DOI 10.1079/PNS2004351; Hurov JB, 2007, P NATL ACAD SCI USA, V104, P5680, DOI 10.1073/pnas.0701179104; Iwen KAH, 2008, J ENDOCRINOL, V196, P465, DOI 10.1677/JOE-07-0299; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kajimura S, 2010, CELL METAB, V11, P257, DOI 10.1016/j.cmet.2010.03.005; Kanzaki M, 2001, CELL BIOCHEM BIOPHYS, V35, P191, DOI 10.1385/CBB:35:2:191; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Kim A, 2010, MOL NUTR FOOD RES, V54, P1361, DOI 10.1002/mnfr.200900317; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Klaus S, 1997, BIOESSAYS, V19, P215, DOI 10.1002/bies.950190307; Langin D, 2006, PHARMACOL RES, V53, P482, DOI 10.1016/j.phrs.2006.03.009; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; List EO, 2011, ENDOCR REV, V32, P356, DOI 10.1210/er.2010-0009; Murad JM, 2010, J BIOL CHEM, V285, P24164, DOI 10.1074/jbc.M110.128744; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ordovas JM, 1999, CURR OPIN LIPIDOL, V10, P15, DOI 10.1097/00041433-199902000-00004; Park KW, 2008, MOL ENDOCRINOL, V22, P2038, DOI 10.1210/me.2007-0454; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Postic C, 2008, DIABETES METAB, V34, P643, DOI 10.1016/S1262-3636(08)74599-3; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ricquier D, 2005, P NUTR SOC, V64, P47, DOI 10.1079/PNS2004408; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schroeder-Gloeckler JM, 2007, J BIOL CHEM, V282, P15717, DOI 10.1074/jbc.M701329200; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Su PY, 2011, J PHARMACOL EXP THER, V337, P822, DOI 10.1124/jpet.111.178970; Suh HC, 2008, ONCOGENE, V27, P5612, DOI 10.1038/onc.2008.175; Sun L, 2008, P NATL ACAD SCI USA, V105, P3339, DOI 10.1073/pnas.0800165105; Szekely Miklos, 2010, Front Biosci (Schol Ed), V2, P1009; Tedesco L, 2010, DIABETES, V59, P2826, DOI 10.2337/db09-1881; Tomimoto S, 2008, J PHARMACOL SCI, V107, P41, DOI 10.1254/jphs.FP0072173; Verty ANA, 2010, ENDOCRINOLOGY, V151, P4236, DOI 10.1210/en.2009-1235; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wielinga PY, 2010, PHYSIOL BEHAV, V101, P45, DOI 10.1016/j.physbeh.2010.04.012; Wilding JPH, 2002, DIABETIC MED, V19, P619, DOI 10.1046/j.1464-5491.2002.00790.x; Ye JM, 2001, AM J PHYSIOL-ENDOC M, V280, pE562, DOI 10.1152/ajpendo.2001.280.4.E562; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	75	29	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					309	323		10.1096/fj.11-190892	http://dx.doi.org/10.1096/fj.11-190892			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21990377	Green Published, Bronze			2022-12-28	WOS:000299202200031
J	Balut, CM; Loch, CM; Devor, DC				Balut, Corina M.; Loch, Christian M.; Devor, Daniel C.			Role of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1	FASEB JOURNAL			English	Article						TUBEs; DUB Chip; PR-619	CA2+-ACTIVATED K+ CHANNEL; PROTEIN-COUPLED RECEPTORS; DEUBIQUITINATING ENZYMES; UBIQUITIN ISOPEPTIDASE; SMALL-CONDUCTANCE; DOWN-REGULATION; CELL-SURFACE; TRAFFICKING; DEGRADATION; GROWTH	We recently demonstrated that plasma membrane KCa3.1 is rapidly endocytosed and targeted for lysosomal degradation via a Rab7- and ESCRT-dependent pathway. Herein, we assess the role of ubiquitylation in this process. Using a biotin ligase acceptor peptide (BLAP)-tagged KCa3.1, in combination with tandem ubiquitin binding entities (TUBEs), we demonstrate that KCa3.1 is polyubiquitylated following endocytosis. Hypertonic sucrose inhibited KCa3.1 endocytosis and resulted in a significant decrease in channel ubiquitylation. Inhibition of the ubiquitin-activating enzyme (E1) with UBEI-41 resulted in reduced KCa3.1 ubiquitylation and internalization. The general deubiquitylase (DUB) inhibitor, PR-619 attenuated KCa3.1 degradation, indicative of deubiquitylation being required for lysosomal delivery. Using the DUB Chip, a protein microarray containing 35 DUBs, we demonstrate a time-dependent association between KCa3.1 and USP8 following endocytosis, which was confirmed by coimmunoprecipitation. Further, overexpression of wild-type USP8 accelerates channel deubiquitylation, while either a catalytically inactive mutant USP8 or siRNA-mediated knockdown of USP8 enhanced accumulation of ubiquitylated KCa3.1, thereby inhibiting channel degradation. In summary, by combining BLAP-tagged KCa3.1 with TUBEs and DUB Chip methodologies, we demonstrate that polyubiquitylation mediates the targeting of membrane KCa3.1 to the lysosomes and also that USP8 regulates the rate of KCa3.1 degradation by deubiquitylating KCa3.1 prior to lysosomal delivery.-Balut, C. M., Loch, C. M., Devor, D. C. Role of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1. FASEB J. 25, 3938-3948 (2011). www.fasebj.org	[Balut, Corina M.; Devor, Daniel C.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; [Loch, Christian M.] LifeSensors Inc, Malvern, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S331 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu			U.S. National Institutes of Health [HL083060, HL092157]; American Heart Fellowship [0825542D]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083060, R01HL092157] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Fellowship(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors gratefully acknowledge Dr. Patrick H. Thibodeau for scientific discussions and for kindly helping with BirA purification. The authors also acknowledge Dr. Kirk Hamilton for critically reading the manuscript and for many helpful discussions. This work was supported by U.S. National Institutes of Health grants (HL083060, HL092157) to D.C.D. and an American Heart Fellowship (0825542D) to C.M.B.	Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Balut CM, 2010, AM J PHYSIOL-CELL PH, V299, pC1015, DOI 10.1152/ajpcell.00120.2010; Balut CM, 2010, FUTURE MED CHEM, V2, P707, DOI [10.4155/fmc.10.182, 10.4155/FMC.10.182]; Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735; Chen JX, 2009, TRAFFIC, V10, P1488, DOI 10.1111/j.1600-0854.2009.00961.x; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Cottrell GS, 2007, J BIOL CHEM, V282, P12260, DOI 10.1074/jbc.M606338200; Davies BA, 2009, CHEM REV, V109, P1575, DOI 10.1021/cr800473s; Farr GA, 2009, J CELL BIOL, V186, P269, DOI 10.1083/jcb.200901021; Gao YJ, 2008, J BIOL CHEM, V283, P9049, DOI 10.1074/jbc.M708022200; Gao YJ, 2010, J BIOL CHEM, V285, P17938, DOI 10.1074/jbc.M109.086553; Hasdemir B, 2007, J BIOL CHEM, V282, P29646, DOI 10.1074/jbc.M702974200; Hasdemir B, 2009, J BIOL CHEM, V284, P28453, DOI 10.1074/jbc.M109.025692; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hislop JN, 2011, TRAFFIC, V12, P137, DOI 10.1111/j.1600-0854.2010.01121.x; Hislop JN, 2009, J BIOL CHEM, V284, P19361, DOI 10.1074/jbc.M109.001644; Hjerpe R, 2009, EMBO REP, V10, P1250, DOI 10.1038/embor.2009.192; Jones HM, 2005, J BIOL CHEM, V280, P37257, DOI 10.1074/jbc.M508601200; Jones HM, 2004, J BIOL CHEM, V279, P15531, DOI 10.1074/jbc.M400069200; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Lamb CA, 2010, TRAFFIC, V11, P1445, DOI 10.1111/j.1600-0854.2010.01113.x; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Loch CM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002402; Millard SM, 2006, J CELL BIOL, V173, P463, DOI 10.1083/jcb.200602082; Mizuno E, 2006, TRAFFIC, V7, P1017, DOI 10.1111/j.1600-0854.2006.00452.x; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tian XF, 2011, ASSAY DRUG DEV TECHN, V9, P165, DOI 10.1089/adt.2010.0317; Tu LW, 1999, BIOPHYS J, V76, P2004, DOI 10.1016/S0006-3495(99)77358-3; Tuteja D, 2010, CIRC RES, V107, P851, DOI 10.1161/CIRCRESAHA.109.215269; Wulff H, 2007, CURR MED CHEM, V14, P1437, DOI 10.2174/092986707780831186	41	45	45	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3938	3948		10.1096/fj.11-187005	http://dx.doi.org/10.1096/fj.11-187005			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21828287	Green Published			2022-12-28	WOS:000296723100018
J	Ermak, G; Pritchard, MA; Dronjak, S; Niu, B; Davies, KJA				Ermak, Gennady; Pritchard, Melanie A.; Dronjak, Sladjana; Niu, Brenda; Davies, Kelvin J. A.			Do RCAN1 proteins link chronic stress with neurodegeneration?	FASEB JOURNAL			English	Article						glucocorticoids; tau	AMYOTROPHIC-LATERAL-SCLEROSIS; SYNDROME CRITICAL REGION-1; ALZHEIMERS-DISEASE; DOWN-SYNDROME; OXIDATIVE STRESS; RAT-BRAIN; DSCR1 ADAPT78; TAU-PROTEIN; CALCINEURIN; EXPRESSION	It has long been suspected that chronic stress can exacerbate, or even cause, disease. We now propose that the RCAN1 gene, which can generate several RCAN1 protein isoforms, may be at least partially responsible for this phenomenon. We review data showing that RCAN1 proteins can be induced by multiple stresses, and present new data also implicating psychosocial/emotional stress in RCAN1 induction. We further show that transgenic mice overexpressing the RCAN1-1L protein exhibit accumulation of hyperphosphorylated tau protein (AT8 antibody), an early precursor to the formation of neurofibrillary tangles and neurodegeneration of the kind seen in Alzheimer disease. We propose that, although transient induction of the RCAN1 gene might protect cells against acute stress, persistent stress may cause chronic RCAN1 overexpression, resulting in serious side effects. Chronically elevated levels of RCAN1 proteins may promote or exacerbate various diseases, including tauopathies such as Alzheimer disease. We propose that the mechanism by which stress can lead to these diseases involves the inhibition of calcineurin and the induction of GSK-3 beta by RCAN1 proteins. Both inhibition of calcineurin and induction of GSK-3 beta contribute to accumulation of phosphorylated tau, formation of neurofibrillary tangles, and eventual neurodegeneration.-Ermak, G., Pritchard, M. A., Dronjak, S., Niu, B., Davies, K. J. A. Do RCAN1 proteins link chronic stress with neurodegeneration? FASEB J. 25, 3306-3311 (2011). www.fasebj.org	[Ermak, Gennady; Niu, Brenda; Davies, Kelvin J. A.] Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Davis Sch Gerontol, Los Angeles, CA 90089 USA; [Ermak, Gennady; Niu, Brenda; Davies, Kelvin J. A.] Univ So Calif, Div Mol & Computat Biol, Dornsife Coll Letters Arts & Sci, Los Angeles, CA 90089 USA; [Pritchard, Melanie A.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Dronjak, Sladjana] Inst Nucl Sci Vinca, Lab Mol Biol & Endocrinol, Belgrade, Serbia	University of Southern California; University of Southern California; Monash University; University of Belgrade	Davies, KJA (corresponding author), Univ So Calif, Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003; Dronjak Cucakovic, Sladjana/0000-0002-4334-8002	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES003598, R01ES003598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG016256] Funding Source: Medline; NIEHS NIH HHS [R56 ES003598, R01 ES003598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Chang KT, 2005, NAT NEUROSCI, V8, P1577, DOI 10.1038/nn1564; Chang KT, 2003, P NATL ACAD SCI USA, V100, P15794, DOI 10.1073/pnas.2536696100; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Cho YJ, 2005, ARCH BIOCHEM BIOPHYS, V439, P121, DOI 10.1016/j.abb.2005.05.002; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; Cook CN, 2005, J ALZHEIMERS DIS, V8, P63; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06-7246com; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2006, FEBS J, V273, P2100, DOI 10.1111/j.1742-4658.2006.05217.x; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Garver TD, 1999, MOL PHARMACOL, V55, P632; Gavrilovic L, 2010, NEUROIMMUNOMODULAT, V17, P265, DOI 10.1159/000290042; GOLDKUHL R, EUR SURG RES, V44, P117; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harris CD, 2007, FEBS J, V274, P1715, DOI 10.1111/j.1742-4658.2007.05717.x; Hirakawa Yasuko, 2009, J Mol Signal, V4, P6, DOI 10.1186/1750-2187-4-6; Iqbal K, 2008, J CELL MOL MED, V12, P38, DOI 10.1111/j.1582-4934.2008.00225.x; Jeong YH, 2006, FASEB J, V20, P729, DOI 10.1096/fj.05-4265fje; Joels M, 2008, EUR J PHARMACOL, V583, P312, DOI 10.1016/j.ejphar.2007.11.064; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Keating DJ, 2008, HUM MOL GENET, V17, P1020, DOI 10.1093/hmg/ddm374; KORNEYEV A, 1995, NEUROSCI LETT, V191, P19, DOI 10.1016/0304-3940(95)11546-3; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; Ladner CJ, 1996, J NEUROPATH EXP NEUR, V55, P924, DOI 10.1097/00005072-199608000-00008; Martinez A, 2008, J ALZHEIMERS DIS, V15, P181; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; Michtalik HJ, 2004, FREE RADICAL BIO MED, V37, P454, DOI 10.1016/j.freeradbiomed.2004.05.014; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Papasozomenos SC, 1996, J NEUROCHEM, V66, P1140; Piazza O, 2004, CURR MED RES OPIN, V20, P505, DOI 10.1185/030079904125003296; Poppek D, 2006, BIOCHEM J, V400, P511, DOI 10.1042/BJ20060463; Porta S, 2007, HUM MOL GENET, V16, P1039, DOI 10.1093/hmg/ddm049; U M, 2004, LEUKEMIA, V18, P1850, DOI 10.1038/sj.leu.2403516; Wang YL, 2002, AM J PHYSIOL-HEART C, V283, pH533, DOI 10.1152/ajpheart.00002.2002; Wilson RS, 2005, NEUROLOGY, V64, P380, DOI 10.1212/01.WNL.0000149525.53525.E7; WOON FL, PROG NEUROPSYCHOPHAR, V34, P1181; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Yanagisawa M, 1999, FEBS LETT, V461, P329, DOI 10.1016/S0014-5793(99)01480-5	44	35	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3306	3311		10.1096/fj.11-185728	http://dx.doi.org/10.1096/fj.11-185728			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21680892	Green Published, Green Submitted			2022-12-28	WOS:000295356400003
J	Hyldahl, RD; Xin, L; Hubal, MJ; Moeckel-Cole, S; Chipkin, S; Clarkson, PM				Hyldahl, Robert D.; Xin, Ling; Hubal, Monica J.; Moeckel-Cole, Stephanie; Chipkin, Stuart; Clarkson, Priscilla M.			Activation of nuclear factor-kappa B following muscle eccentric contractions in humans is localized primarily to skeletal muscle-residing pericytes	FASEB JOURNAL			English	Article						regeneration; inflammation	SATELLITE CELLS; GENE-EXPRESSION; LENGTHENING CONTRACTIONS; CANCER CACHEXIA; STEM-CELLS; EXERCISE; REGENERATION; RESPONSES; MACROPHAGES; MECHANISMS	Limited data exist on the molecular mechanisms that govern skeletal muscle regeneration in humans. This study characterized the early molecular alterations in humans to eccentric contractions (ECs), a stimulus known to induce a muscle regenerative response. Thirty-five subjects completed 100 ECs of the knee extensors with 1 leg, and muscle biopsies were taken from both legs 3 h post-EC. The sample from the non-EC leg served as the control. We first conducted a well-powered transcriptomic screen and network analysis. Our screen identified significant changes in several transcripts with functions relating to inflammation, cell growth, and proliferation. Network analysis then identified the transcription factor NF-kappa B as a key molecular element affected by ECs. A transcription factor ELISA, using nuclear extracts from EC and control muscle samples, showed a 1.6-fold increase in NF-kappa B DNA binding activity following ECs. Immunohistochemical experiments localized the majority of NF-kappa B-positive nuclei to cells in the interstitium, which stained positive for the pericyte markers NG2 proteoglycan and alkaline phosphatase. Our results provide the first evidence of NF-kappa B activation in human muscle following ECs and suggest a novel role for muscle residing pericytes in the early adaptive response to ECs.-Hyldahl, R. D., Xin, L., Hubal, M. J., Moeckel-Cole, S., Chipkin, S., Clarkson, P. M. Activation of nuclear factor-kappa B following muscle eccentric contractions in humans is localized primarily to skeletal muscle-residing pericytes. FASEB J. 25, 2956-2966 (2011). www.fasebj.org	[Clarkson, Priscilla M.] Univ Massachusetts, Dept Kinesiol, Muscle Biol & Imaging Lab, Amherst, MA 01003 USA; [Hubal, Monica J.] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA	University of Massachusetts System; University of Massachusetts Amherst; Children's National Health System	Clarkson, PM (corresponding author), Univ Massachusetts, Dept Kinesiol, Muscle Biol & Imaging Lab, Totman Bldg,30 Eastman Ln, Amherst, MA 01003 USA.	rhyldahl@kin.umass.edu	Hyldahl, Robert/AAZ-3960-2020	Hubal, Monica/0000-0001-6579-6036; Chipkin, Stuart/0000-0003-2114-9480	Interleukin Genetics	Interleukin Genetics	The authors thank Karen Riska and Brittany Rahmberg (University of Massachusetts, Amherst, MA, USA) and Valerie Greger and Karen Shaver (Interleukin Genetics, Waltham, MA, USA) for valuable contributions to the study design and human subject work; President and Chief Scientific Officer Kenneth S. Kornman of Interleukin Genetics for support of this study; and Dr. Terrance Partridge for insight into the interpretation of the IHC images. This research was supported by Interleukin Genetics.	Abou-Khalil R, 2009, CELL STEM CELL, V5, P298, DOI 10.1016/j.stem.2009.06.001; Boldrin L, 2010, J HISTOCHEM CYTOCHEM, V58, P941, DOI 10.1369/jhc.2010.956201; Bryan BA, 2008, METHOD ENZYMOL, V443, P315, DOI 10.1016/S0076-6879(08)02016-8; Chen YW, 2003, J APPL PHYSIOL, V95, P2485, DOI 10.1152/japplphysiol.01161.2002; Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06-08-0693; CHURCH JCT, 1970, J EMBRYOL EXP MORPH, V23, P531; Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Dahlman JM, 2010, J BIOL CHEM, V285, P5479, DOI 10.1074/jbc.M109.075606; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; DIMARIO J, 1988, DIFFERENTIATION, V39, P42, DOI 10.1111/j.1432-0436.1988.tb00079.x; Durham WJ, 2004, J APPL PHYSIOL, V97, P1740, DOI 10.1152/japplphysiol.00088.2004; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Ho RC, 2005, AM J PHYSIOL-CELL PH, V289, pC794, DOI 10.1152/ajpcell.00632.2004; Hubal MJ, 2008, AM J PHYSIOL-REG I, V294, pR1628, DOI 10.1152/ajpregu.00853.2007; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kirillova I, 2007, DEV BIOL, V311, P449, DOI 10.1016/j.ydbio.2007.08.056; Klossner S, 2007, PFLUG ARCH EUR J PHY, V455, P555, DOI 10.1007/s00424-007-0303-6; Kostek MC, 2007, PHYSIOL GENOMICS, V31, P42, DOI 10.1152/physiolgenomics.00151.2006; Lauritzen F, 2009, J APPL PHYSIOL, V107, P1923, DOI 10.1152/japplphysiol.00148.2009; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Liao P, 2010, AM J PHYSIOL-REG I, V298, pR599, DOI 10.1152/ajpregu.00480.2009; Lima-Cabello E, 2010, J APPL PHYSIOL, V108, P575, DOI 10.1152/japplphysiol.00816.2009; Liu YW, 2007, CELL MOL LIFE SCI, V64, P3282, DOI 10.1007/s00018-007-7375-5; Mahoney DJ, 2008, AM J PHYSIOL-REG I, V294, pR1901, DOI 10.1152/ajpregu.00847.2007; Mahoney DJ, 2004, PHYSIOL GENOMICS, V18, P226, DOI 10.1152/physiolgenomics.00067.2004; Maruhashi Y, 2007, J PHYSIOL SCI, V57, P211, DOI 10.2170/physiolsci.RP013006; McKay BR, 2010, J PHYSIOL-LONDON, V588, P3307, DOI 10.1113/jphysiol.2010.190876; Mckay BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006027; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; O'Reilly C, 2008, MUSCLE NERVE, V38, P1434, DOI 10.1002/mus.21146; Paulsen G, 2010, MED SCI SPORT EXER, V42, P75, DOI 10.1249/MSS.0b013e3181ac7adb; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; Sekine O, 2002, J BIOL CHEM, V277, P36631, DOI 10.1074/jbc.M206266200; Shefer G, 2006, DEV BIOL, V294, P50, DOI 10.1016/j.ydbio.2006.02.022; Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406; Shireman PK, 2006, J SURG RES, V134, P145, DOI 10.1016/j.jss.2005.12.003; Tantiwong P, 2010, AM J PHYSIOL-ENDOC M, V299, pE794, DOI 10.1152/ajpendo.00776.2009; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; UEDA A, 1994, J IMMUNOL, V153, P2052; Wang H., 2007, Autonomic & Autacoid Pharmacology, V27, P1, DOI 10.1111/j.1474-8673.2006.00381.x; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011	45	44	44	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2956	2966		10.1096/fj.10-177105	http://dx.doi.org/10.1096/fj.10-177105			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21602448				2022-12-28	WOS:000294435200011
J	Bolscher, JGM; Oudhoff, MJ; Nazmi, K; Antos, JM; Guimaraes, CP; Spooner, E; Haney, EF; Vallejo, JJG; Vogel, HJ; van't Hof, W; Ploegh, HL; Veerman, ECI				Bolscher, Jan G. M.; Oudhoff, Menno J.; Nazmi, Kamran; Antos, John M.; Guimaraes, Carla P.; Spooner, Eric; Haney, Evan F.; Vallejo, Juan J. Garcia; Vogel, Hans J.; van't Hof, Wim; Ploegh, Hidde L.; Veerman, Enno C. I.			Sortase A as a tool for high-yield histatin cyclization	FASEB JOURNAL			English	Article						intramolecular transpeptidation; wound closure stimulating peptide	GRAM-POSITIVE BACTERIA; MEDIATED LIGATION; SURFACE-PROTEINS; MOTIF	Cyclic peptides are highly valued tools in biomedical research. In many cases, they show higher receptor affinity, enhanced biological activity, and improved serum stability. Technical difficulties in producing cyclic peptides, especially larger ones, in appreciable yields have precluded a prolific use in biomedical research. Here, we describe a novel and efficient cyclization method that uses the peptidyl-transferase activity of the Staphylococcus aureus enzyme sortase A to cyclize linear synthetic precursor peptides. As a model, we used histatin 1, a 38-mer salivary peptide with motogenic activity. Chemical cyclization of histatin 1 resulted in <= 3% yields, whereas sortase-mediated cyclization provided a yield of > 90%. The sortase-cyclized peptide displayed a maximum wound closure activity at 10 nM, whereas the linear peptide displayed maximal activity at 10 mu M. Circular dichroism and NMR spectroscopic analysis of the linear and cyclic peptide in solution showed no evidence for conformational changes, suggesting that structural differences due to cyclization only became manifest when these peptides were located in the binding domain of the receptor. The sortase-based cyclization technology provides a general method for easy and efficient manufacturing of large cyclic peptides.-Bolscher, J. G. M., Oudhoff, M. J., Nazmi, K., Antos, J. M., Guimaraes, C. P., Spooner, E., Haney, E. F., Garcia-Vallejo, J. J., Vogel, H. J., van't Hof, W., Ploegh, H. L., Veerman. E. C. I. Sortase A as a tool for high-yield histatin cyclization. FASEB J. 25, 2650 -2658 (2011). www.fasebj.org	[Bolscher, Jan G. M.; Oudhoff, Menno J.; Nazmi, Kamran; van't Hof, Wim; Veerman, Enno C. I.] Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent Amsterdam, NL-1081 LA Amsterdam, Netherlands; [Bolscher, Jan G. M.; Oudhoff, Menno J.; Nazmi, Kamran; van't Hof, Wim; Veerman, Enno C. I.] Vrije Univ VU Amsterdam, NL-1081 LA Amsterdam, Netherlands; [Vallejo, Juan J. Garcia] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Antos, John M.; Guimaraes, Carla P.; Spooner, Eric; Ploegh, Hidde L.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA; [Ploegh, Hidde L.] MIT, Dept Biol, Cambridge, MA USA; [Haney, Evan F.; Vogel, Hans J.] Univ Calgary, Dept Biol Sci, Biochem Res Grp, Calgary, AB T2N 1N4, Canada	Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Calgary	Bolscher, JGM (corresponding author), Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent Amsterdam, Gustav Mahlerlaan 3004, NL-1081 LA Amsterdam, Netherlands.	j.bolscher@acta.nl	Haney, Evan/S-5501-2019; Garcia-Vallejo, Juan/H-4162-2012; Bolscher, Jan/ABF-6102-2021; Vallejo, Juan Garcia/AAA-3765-2020	Haney, Evan/0000-0003-3645-770X; Garcia-Vallejo, Juan/0000-0001-6238-7069; Bolscher, Jan/0000-0001-5669-6164; Oudhoff, Menno/0000-0002-1180-8975	Skeletal Tissue Engineering Group Amsterdam; European Molecular Biology Organization; Journal of Cell Science	Skeletal Tissue Engineering Group Amsterdam; European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Journal of Cell Science	This work was supported by the Skeletal Tissue Engineering Group Amsterdam and travel funds of the European Molecular Biology Organization and Journal of Cell Science.	Antos JM, 2009, J AM CHEM SOC, V131, P10800, DOI 10.1021/ja902681k; Antos JM, 2009, J BIOL CHEM, V284, P16028, DOI 10.1074/jbc.M901752200; Brewer D, 2002, BIOCHEMISTRY-US, V41, P5526, DOI 10.1021/bi015926d; Cascales L, 2010, ORG BIOMOL CHEM, V8, P5035, DOI 10.1039/c0ob00139b; Melino S, 1999, BIOCHEMISTRY-US, V38, P9626, DOI 10.1021/bi990212c; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Nguyen LT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012684; Oudhoff MJ, 2008, FASEB J, V22, P3805, DOI 10.1096/fj.08-112003; Oudhoff MJ, 2009, FASEB J, V23, P3928, DOI 10.1096/fj.09-137588; Popp MW, 2007, NAT CHEM BIOL, V3, P707, DOI 10.1038/nchembio.2007.31; Popp MW, 2011, P NATL ACAD SCI USA, V108, P3169, DOI 10.1073/pnas.1016863108; Pritz S, 2007, J ORG CHEM, V72, P3909, DOI 10.1021/jo062331l; Proft T, 2010, BIOTECHNOL LETT, V32, P1, DOI 10.1007/s10529-009-0116-0; Rydengard V, 2006, FEBS J, V273, P2399, DOI 10.1111/j.1742-4658.2006.05246.x; Tanaka T, 2008, CHEMBIOCHEM, V9, P802, DOI 10.1002/cbic.200700614; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; Tsukiji S, 2009, CHEMBIOCHEM, V10, P787, DOI 10.1002/cbic.200800724; Zhou HX, 2010, BIOPHYS J, V98, pL15, DOI 10.1016/j.bpj.2009.11.029	18	71	79	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2650	2658		10.1096/fj.11-182212	http://dx.doi.org/10.1096/fj.11-182212			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21525488				2022-12-28	WOS:000293337800015
J	Sen, GL				Sen, George L.			Remembering one's identity: the epigenetic basis of stem cell fate decisions	FASEB JOURNAL			English	Review						DNA methylation; differentiation; histone modification	CPG-BINDING-PROTEIN; DNA METHYLATION; HEMATOPOIETIC STEM; SELF-RENEWAL; DEVELOPMENTAL REGULATORS; DEMETHYLASE JMJD3; MOUSE DEVELOPMENT; GENE-EXPRESSION; POLYCOMB; METHYLTRANSFERASE	Stem cells serve a vital role in multicellular organisms by constantly replenishing tissue with their differentiated progeny during normal homeostasis or damage. How these cells maintain their identities throughout the life of an organism is an area of intense research. In this review, we explore recent emerging evidence that stem cell fate decisions are based on their epigenome and specific epigenetic factors.-Sen, G. L. Remembering one's identity: the epigenetic basis of stem cell fate decisions. FASEB J. 25, 2123-2128 (2011). www.fasebj.org	[Sen, George L.] Univ Calif San Diego, Dept Med, Dept Cellular & Mol Med, Div Dermatol,Program Stem Cell Biol, San Diego, CA 92103 USA	University of California System; University of California San Diego	Sen, GL (corresponding author), 9500 Gilman Dr,MC 0869, La Jolla, CA 92093 USA.	gsen@ucsd.edu						Alison MR, 2009, J PATHOL, V217, P144, DOI 10.1002/path.2498; Barr H, 2007, MOL CELL BIOL, V27, P3750, DOI 10.1128/MCB.02204-06; Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Blelloch R, 2006, STEM CELLS, V24, P2007, DOI 10.1634/stemcells.2006-0050; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Jiricny J, 2008, CELL, V135, P1167, DOI 10.1016/j.cell.2008.12.008; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li XK, 2008, J BIOL CHEM, V283, P27644, DOI 10.1074/jbc.M804899200; Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; Tadokoro Y, 2007, J EXP MED, V204, P715, DOI 10.1084/jem.20060750; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Yu JY, 2008, GENE DEV, V22, P1987, DOI 10.1101/gad.1689808; Zammit PS, 2008, J CELL SCI, V121, P2975, DOI 10.1242/jcs.019661	60	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2123	2128		10.1096/fj.11-182774	http://dx.doi.org/10.1096/fj.11-182774			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21441350				2022-12-28	WOS:000292242200004
J	Serhan, CN				Serhan, Charles N.			The resolution of inflammation: the devil in the flask and in the details	FASEB JOURNAL			English	Editorial Material						anti-inflammatory drugs; small molecule therapeutics; eicosanoids; omega-3 PUFA; leukocytes	TRIGGERED 15-EPI-LIPOXIN A(4); LIPOXIN A(4); LIPID MEDIATORS; NONPHLOGISTIC PHAGOCYTOSIS; APOPTOTIC NEUTROPHILS; ASPIRIN TREATMENT; CYCLOOXYGENASE; INHIBITORS; RESOLVINS; IMPACT		[Serhan, Charles N.] Brigham & Womens Hosp, Harvard Inst Med, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; [Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 77 Ave Louis Pasteur,HIM 829, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita M, 2006, J BIOL CHEM, V281, P22847, DOI 10.1074/jbc.M603766200; Avicenna, 1999, CANON MED; Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Bernard C., 1957, INTRO LIT CORRES TON; BEVERIDGE WIB, 1950, ART SCI INVESTIGATIO; Brooks DW, 2009, EYE DOC NEWS; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Cotran RS, 1994, ROBBINS PATHOLOGIC B; Damjanov I, 2010, AM J PATHOL, V177, P2150, DOI 10.2353/ajpath.2010.100879; Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Flower RJ, 2006, BRIT J PHARMACOL, V147, pS182, DOI 10.1038/sj.bjp.0706506; Friedman M., 1998, MED 10 GREATEST DISC; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; HASLETT C, 1988, MOL CELLULAR BIOL WO; Hassan IR, 2009, J IMMUNOL, V182, P3223, DOI 10.4049/jimmunol.0802064; Houck J. C., 1979, CHEM MESSENGERS INFL; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; LANDS WEM, 2005, FISH OMEGA 2 HUMAN H; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liu YQ, 1999, J IMMUNOL, V162, P3639; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Majno G., 1982, CURRENT TOPICS INFLA; Majno G., 2004, CELLS TISSUES DIS PR; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Morris T, 2010, P NATL ACAD SCI USA, V107, P8842, DOI 10.1073/pnas.1000373107; Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Robbins SL, 1979, PATHOLOGIC BASIS DIS, V2nd; Rossi A, 2008, RESOLUTION INFLAMMAT; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; Savill J, 2007, IMMUNITY, V27, P830, DOI 10.1016/j.immuni.2007.12.002; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SAVILL JS, 1989, J CLIN INVEST, V84, P1518, DOI 10.1172/JCI114328; SCHMELZER K, 2007, METHOD ENZYMOL, V432, P247; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan Charles N., 2002, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V1, P177, DOI 10.2174/1568014023355881; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P139, DOI 10.1016/j.plefa.2005.07.001; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SERHAN CN, 2011, CHEM REV; Simopoulos Artemis P., 1999, Journal of the American College of Nutrition, V18, P487, DOI 10.1046/j.1440-6047.1999.00123.x; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675; Taber CW, 1970, TABERS CYCLOPEDIC ME; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Vandivier RW, 2006, CHEST, V129, P1673, DOI 10.1378/chest.129.6.1673; Vane JR, 2001, THERAPEUTIC ROLES SE; Vane JR, 1982, PRIX NOBEL NOBEL PRI, P181; VONEULER US, 1978, EXCITEMENT FASCINATI, V2, P675; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123	76	126	129	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2011	25	5					1441	1448		10.1096/fj.11-0502ufm	http://dx.doi.org/10.1096/fj.11-0502ufm			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	21532053	Green Published			2022-12-28	WOS:000290023800003
J	Hasan, S; Santhi, N; Lazar, AS; Slak, A; Lo, JN; von Schantz, M; Archer, SN; Johnston, JD; Dijk, DJ				Hasan, Sibah; Santhi, Nayantara; Lazar, Alpar S.; Slak, Ana; Lo, June; von Schantz, Malcolm; Archer, Simon N.; Johnston, Jonathan D.; Dijk, Derk-Jan			Assessment of circadian rhythms in humans: comparison of real-time fibroblast reporter imaging with plasma melatonin	FASEB JOURNAL			English	Article						sleep; PER3; Bmal1; lentivirus; clock genes	SLEEP-PHASE SYNDROME; INTRINSIC PERIOD; GENE-EXPRESSION; LENGTH POLYMORPHISM; DIURNAL PREFERENCE; SHIFT WORK; CKI-DELTA; CLOCK; PER3; ENTRAINMENT	We compared the period of the rhythm of plasma melatonin, driven by the hypothalamic circadian pacemaker, to in vitro periodicity in cultured peripheral fibroblasts to assess the effects on these rhythms of a polymorphism of PER3 (rs57875989), which is associated with sleep timing. In vitro circadian period was determined using luminometry of cultured fibroblasts, in which the expression of firefly luciferase was driven by the promoter of the circadian gene Arntl (Bmal1). The period of the melatonin rhythm was assessed in a 9-d forced desynchrony protocol, minimizing confounding effects of sleep-wake and light-dark cycles on circadian rhythmicity. In vitro periods (32 participants, 24.61 +/- 0.33 h, mean +/- SD) were longer than in vivo periods (31 participants, 24.16 +/- 0.17 h; P<0.0001) but did not differ between PER3 genotypes (P>0.4). Analyses of replicate in vitro assessments demonstrated that circadian period was reproducible within individuals (intraclass correlation = 0.62), but in vivo and in vitro period assessments did not correlate (P>0.9). In accordance with circadian entrainment theory, in vivo period correlated with the timing of melatonin (P<0.05) at baseline and with diurnal preference (P<0.05). Individual circadian rhythms can be reliably assessed in fibroblasts but may not correlate with physiological rhythms driven by the central circadian pacemaker.-Hasan, S., Santhi, N., Lazar, A. S., Slak, A., Lo, J., von Schantz, M., Archer, S. N., Johnston, J. D., Dijk, D.-J. Assessment of circadian rhythms in humans: comparison of real-time fibroblast reporter imaging with plasma melatonin. FASEB J. 26, 2414-2423 (2012). www.fasebj.org	[Hasan, Sibah; Santhi, Nayantara; Lazar, Alpar S.; Slak, Ana; Lo, June; von Schantz, Malcolm; Archer, Simon N.; Johnston, Jonathan D.; Dijk, Derk-Jan] Univ Surrey, Fac Hlth & Med Sci, Surrey Sleep Res Ctr, Guildford GU2 7XH, Surrey, England; [von Schantz, Malcolm; Archer, Simon N.; Johnston, Jonathan D.; Dijk, Derk-Jan] Univ Surrey, Fac Hlth & Med Sci, Dept Biochem & Physiol, Guildford GU2 7XH, Surrey, England	University of Surrey; University of Surrey	Dijk, DJ (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Surrey Sleep Res Ctr, Egerton Rd, Guildford GU2 7XH, Surrey, England.	d.j.dijk@surrey.ac.uk	Johnston, Jonathan D/H-6363-2011; von Schantz, Malcolm/C-5962-2014; Johnston, Jonathan/AAS-6969-2021	Johnston, Jonathan D/0000-0001-8083-9794; von Schantz, Malcolm/0000-0002-9911-9436; Santhi, Nayantara/0000-0003-4568-1447; Lazar, Alpar/0000-0003-3147-8229	UK Biotechnology and Biological Sciences Research Council [BB/F022883/1]; BBSRC [BB/F022883/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F022883/1] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Prof. S. A. Brown (Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland) for generously providing the lentiviral plasmids, Dr. E. Maywood (Medical Research Council Laboratory of Molecular Biology, Cambridge, UK) for providing training related to the real-time luminometry technique, Dr. W. Qasim and E. Chan (Institute of Child Health, University College London, London, UK) for training in lentivirus production, P. McGabe for statistical advice, and the staff of the Surrey Clinical Research Centre for their help. This research was supported by the UK Biotechnology and Biological Sciences Research Council, grant BB/F022883/1.	Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Akashi M, 2010, P NATL ACAD SCI USA, V107, P15643, DOI 10.1073/pnas.1003878107; [Anonymous], [No title captured], DOI [DOI 10.1126/SCIENCE.284.5423.2177, 10.1126/science.284.5423.2177]; Archer SN, 2008, SLEEP, V31, P608, DOI 10.1093/sleep/31.5.608; Archer SN, 2010, SLEEP, V33, P695, DOI 10.1093/sleep/33.5.695; Archer SN, 2003, SLEEP, V26, P413, DOI 10.1093/sleep/26.4.413; ASCHOFF J, 1965, SCIENCE, V148, P1427, DOI 10.1126/science.148.3676.1427; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Barion A, 2011, DM-DIS MON, V57, P423, DOI 10.1016/j.disamonth.2011.06.003; Boggild H, 1999, SCAND J WORK ENV HEA, V25, P85, DOI 10.5271/sjweh.410; Brown SA, 2005, PLOS BIOL, V3, P1813, DOI 10.1371/journal.pbio.0030338; Brown SA, 2008, P NATL ACAD SCI USA, V105, P1602, DOI 10.1073/pnas.0707772105; CARSKADON MA, 1980, SLEEP, V2, P309; Clendenen Tess V, 2010, BMC Res Notes, V3, P302, DOI 10.1186/1756-0500-3-302; Czeisler CA, 2000, SCIENCE, V288, P1174; Daan S, 2000, J BIOL RHYTHM, V15, P195, DOI 10.1177/074873040001500301; Davis S, 2006, CANCER CAUSE CONTROL, V17, P539, DOI 10.1007/s10552-005-9010-9; Dijk DJ, 2010, SLEEP MED REV, V14, P151, DOI 10.1016/j.smrv.2009.07.002; DIJK DJ, 1995, J NEUROSCI, V15, P3526; Duffy JF, 2011, P NATL ACAD SCI USA, V108, P15602, DOI 10.1073/pnas.1010666108; Duffy JF, 1996, J PHYSIOL-LONDON, V495, P289, DOI 10.1113/jphysiol.1996.sp021593; Duffy JF, 2001, BEHAV NEUROSCI, V115, P895, DOI 10.1037//0735-7044.115.4.895; Ebisawa T, 2001, EMBO REP, V2, P342, DOI 10.1093/embo-reports/kve070; Guo HG, 2006, J NEUROSCI, V26, P6406, DOI 10.1523/JNEUROSCI.4676-05.2006; HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649; Hasan S, 2011, AM J PHYSIOL-REG I, V301, pR1821, DOI 10.1152/ajpregu.00260.2011; Hastings MH, 2008, CURR BIOL, V18, pR805, DOI 10.1016/j.cub.2008.07.021; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Klerman EB, 2002, J BIOL RHYTHM, V17, P181, DOI 10.1177/074873002129002474; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271, DOI 10.1152/ajpregu.1996.270.1.R271; Kornmann B, 2007, PLOS BIOL, V5, P179, DOI 10.1371/journal.pbio.0050034; Kowalska E, 2007, COLD SPRING HARB SYM, V72, P301, DOI 10.1101/sqb.2007.72.014; Lazar AS, 2012, CHRONOBIOL INT, V29, P131, DOI 10.3109/07420528.2011.641193; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee HM, 2011, P NATL ACAD SCI USA, V108, P16451, DOI 10.1073/pnas.1107178108; Lee SK, 2011, BIOCHEM BIOPH RES CO, V416, P337, DOI 10.1016/j.bbrc.2011.11.037; LEWY AJ, 1983, J CLIN ENDOCR METAB, V56, P1103, DOI 10.1210/jcem-56-6-1103; Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763; Loop S, 2005, FEBS J, V272, P3714, DOI 10.1111/j.1742-4658.2005.04798.x; McDearmon EL, 2006, SCIENCE, V314, P1304, DOI 10.1126/science.1132430; Meng QJ, 2008, NEURON, V58, P78, DOI 10.1016/j.neuron.2008.01.019; Munch M, 2005, NEUROBIOL AGING, V26, P1307, DOI 10.1016/j.neurobiolaging.2005.03.004; Pagani L, 2011, P NATL ACAD SCI USA, V108, P7218, DOI 10.1073/pnas.1008882108; Pagani L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013376; Peirson SN, 2006, BIOCHEM BIOPH RES CO, V351, P800, DOI 10.1016/j.bbrc.2006.10.118; Pendergast JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030254; Pendergast JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008552; Pereira DS, 2005, SLEEP, V28, P29; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; Reddy AB, 2011, EMBO REP, V12, P612, DOI 10.1038/embor.2011.123; Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106; Schibler U, 2003, J BIOL RHYTHM, V18, P250, DOI 10.1177/0748730403018003007; Sharma VK, 1998, NATURWISSENSCHAFTEN, V85, P183, DOI 10.1007/s001140050481; Shearman LP, 2000, MOL CELL BIOL, V20, P6269, DOI 10.1128/MCB.20.17.6269-6275.2000; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 2008, TRENDS ENDOCRIN MET, V19, P17, DOI 10.1016/j.tem.2007.10.007; Stratmann M, 2006, J BIOL RHYTHM, V21, P494, DOI 10.1177/0748730406293889; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Takano A, 2004, J BIOL CHEM, V279, P32578, DOI 10.1074/jbc.M403433200; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; van der Veen DR, 2010, J BIOL RHYTHM, V25, P3, DOI 10.1177/0748730409356680; Vandewalle G, 2009, J NEUROSCI, V29, P7948, DOI 10.1523/JNEUROSCI.0229-09.2009; Viola AU, 2007, CURR BIOL, V17, P613, DOI 10.1016/j.cub.2007.01.073; Viola AU, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.024; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wright KP, 2005, J BIOL RHYTHM, V20, P168, DOI 10.1177/0748730404274265; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453; Yagita K, 2000, GENE DEV, V14, P1353; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682	70	48	58	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2414	2423		10.1096/fj.11-201699	http://dx.doi.org/10.1096/fj.11-201699			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22371527	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000305017200019
J	Kang, HW; Niepel, MW; Han, SX; Kawano, Y; Cohen, DE				Kang, Hye Won; Niepel, Michele W.; Han, Shuxin; Kawano, Yuki; Cohen, David E.			Thioesterase superfamily member 2/acyl-CoA thioesterase 13 (Them2/Acot13) regulates hepatic lipid and glucose metabolism	FASEB JOURNAL			English	Article						free fatty acid; liver; obesity	PHOSPHATIDYLCHOLINE TRANSFER PROTEIN/STARD2; ACYL-COA THIOESTERASES; BETA-OXIDATION; FATTY-ACIDS; PPAR-ALPHA; MICE; RECEPTOR; IDENTIFICATION; PEROXISOMES; CHAIN	Members of the acyl-CoA thioesterase (Acot) gene family catalyze the hydrolysis of fatty acyl-CoAs, but their biological functions remain unknown. Thioesterase superfamily member 2 (Them2; synonym Acot13) is a broadly expressed mitochondria-associated Acot. Them2 was previously identified as an interacting protein of phosphatidylcholine transfer protein (PC-TP). Pctp(-/-) mice exhibit altered fatty acid metabolism that is accompanied by reduced hepatic glucose production. To examine the role of Them2 in regulating hepatic lipid and glucose homeostasis, we generated Them2(-/-) mice. In livers of Them2(-/-) mice compared with Them2(+/+) controls, a 1.9-fold increase in the K-m of mitochondrial thioesterase activity was accompanied by a 28% increase in fatty acyl-CoA concentration. A reciprocal 23% decrease in free fatty acid concentration was associated with reduced activation of peroxisome proliferator-activated receptor alpha. However, fatty acid oxidation rates were preserved in livers of Them2(-/-) mice, suggesting that Them2 functions to limit beta-oxidation. Hepatic glucose production was also decreased by 45% in the setting of reduced hepatocyte nuclear factor 4 alpha (HNF4 alpha) expression. When fed a high-fat diet, Them2(-/-) mice were resistant to increases in hepatic glucose production and steatosis. These findings reveal key roles for Them2 in the regulation of hepatic metabolism, which are potentially mediated by PC-TP-Them2 interactions.-Kang, H. W., Niepel, M. W., Han, S., Kawano, Y., Cohen, D. E. Thioesterase superfamily member 2/acyl-CoA thioesterase 13 (Them2/Acot13) regulates hepatic lipid and glucose metabolism. FASEB J. 26, 2209-2221 (2012). www.fasebj.org	[Kang, Hye Won; Niepel, Michele W.; Han, Shuxin; Kawano, Yuki; Cohen, David E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Cohen, DE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gastroenterol, 77 Ave Louis Pasteur,HIM 941, Boston, MA 02115 USA.	dcohen@partners.org			U.S. National Institutes of Health [DK-56626, DK-48873]; Harvard Digestive Diseases Center [P30 DK34854]; American Heart Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056626, P30DK034854, R01DK048873, R29DK048873, R37DK048873] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Digestive Diseases Center; American Heart Association(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants DK-56626 and DK-48873 (to D.E.C.) and Harvard Digestive Diseases Center (P30 DK34854). H.W.K. is a recipient of a Founders Affiliate Postdoctoral Fellowship from the American Heart Association. The authors thank Drs. Oliver J. Haworth and Vasile Pavlov for assisting with measurements of hepatic triglyceride secretion in mice, Drs. Elizabeth Newberry and Nicholas Davidson for advice on measuring fecal fat contents, and Dr. Richard Mitchell for interpretation of intestinal histopathology.	Ayala JE, 2010, DIS MODEL MECH, V3, P525, DOI 10.1242/dmm.006239; Brocker Chad, 2010, Hum Genomics, V4, P411; Cao J, 2009, BIOCHEMISTRY-US, V48, P1293, DOI 10.1021/bi801879z; Cheng ZY, 2011, ANTIOXID REDOX SIGN, V14, P649, DOI 10.1089/ars.2010.3370; Cheng ZJ, 2006, BIOCHEM BIOPH RES CO, V350, P850, DOI 10.1016/j.bbrc.2006.09.105; Cox B, 2006, NAT PROTOC, V1, P1872, DOI 10.1038/nprot.2006.273; de Brouwer APM, 2002, EXP CELL RES, V274, P100, DOI 10.1006/excr.2001.5460; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dongol B, 2007, J LIPID RES, V48, P1781, DOI 10.1194/jlr.M700119-JLR200; Ellis JM, 2010, CELL METAB, V12, P53, DOI 10.1016/j.cmet.2010.05.012; Fisher FM, 2011, ENDOCRINOLOGY, V152, P2996, DOI 10.1210/en.2011-0281; Forwood JK, 2007, P NATL ACAD SCI USA, V104, P10382, DOI 10.1073/pnas.0700974104; He JH, 2011, EXP BIOL MED, V236, P1116, DOI 10.1258/ebm.2011.011128; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hunt MC, 2006, FASEB J, V20, P1855, DOI 10.1096/fj.06-6042com; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hyogo H, 2002, J BIOL CHEM, V277, P34117, DOI 10.1074/jbc.M203912200; Jump DB, 2011, CURR OPIN CLIN NUTR, V14, P115, DOI 10.1097/MCO.0b013e328342991c; Kaiyala KJ, 2010, DIABETES, V59, P1657, DOI 10.2337/db09-1582; Kang HW, 2010, TRENDS ENDOCRIN MET, V21, P449, DOI 10.1016/j.tem.2010.02.001; Kang HW, 2010, BBA-MOL CELL BIOL L, V1801, P496, DOI 10.1016/j.bbalip.2009.12.013; Kang HW, 2009, J LIPID RES, V50, P2212, DOI 10.1194/jlr.M900013-JLR200; Kanno K, 2007, J BIOL CHEM, V282, P30728, DOI 10.1074/jbc.M703745200; Kirkby B, 2010, PROG LIPID RES, V49, P366, DOI 10.1016/j.plipres.2010.04.001; Kliewer SA, 2010, AM J CLIN NUTR, V91, p254S, DOI 10.3945/ajcn.2009.28449B; Li LO, 2010, BBA-MOL CELL BIOL L, V1801, P246, DOI 10.1016/j.bbalip.2009.09.024; Li LO, 2009, J BIOL CHEM, V284, P27816, DOI 10.1074/jbc.M109.022467; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Newberry EP, 2006, HEPATOLOGY, V44, P1191, DOI 10.1002/hep.21369; Poupon V, 1999, J BIOL CHEM, V274, P19188, DOI 10.1074/jbc.274.27.19188; Scapa EF, 2008, FASEB J, V22, P2579, DOI 10.1096/fj.07-105395; Shishova EY, 2011, HEPATOLOGY, V54, P664, DOI 10.1002/hep.24393; Su X, 2009, TRENDS ENDOCRIN MET, V20, P72, DOI 10.1016/j.tem.2008.11.001; Wei J, 2009, BIOCHEM J, V421, P311, DOI 10.1042/BJ20090039; Westin MAK, 2008, CELL MOL LIFE SCI, V65, P982, DOI 10.1007/s00018-008-7576-6; Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200; Westin MAK, 2007, J BIOL CHEM, V282, P26707, DOI 10.1074/jbc.M703718200; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Yuan XH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005609	40	46	47	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2209	2221		10.1096/fj.11-202853	http://dx.doi.org/10.1096/fj.11-202853			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22345407	Green Published			2022-12-28	WOS:000303680800046
J	Satou, R; Miyata, K; Gonzalez-Villalobos, RA; Ingelfinger, JR; Navar, LG; Kobori, H				Satou, Ryousuke; Miyata, Kayoko; Gonzalez-Villalobos, Romer A.; Ingelfinger, Julie R.; Navar, L. Gabriel; Kobori, Hiroyuki			Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells	FASEB JOURNAL			English	Article						kidney; inflammation; hypertension	MESSENGER-RNA; INTRARENAL ANGIOTENSINOGEN; AUGMENTS ANGIOTENSINOGEN; GENE; TRANSCRIPTION; RECEPTOR; TRANSDUCTION; INVOLVEMENT; ACTIVATION; PHYSIOLOGY	Renal inflammation modulates angiotensinogen (AGT) production in renal proximal tubular cells (RPTCs) via inflammatory cytokines, including interleukin-6, tumor necrosis factor alpha, and interferon-gamma (IFN-gamma). Among these, the effects of IFN-gamma on AGT regulation in RPTCs are incompletely delineated. This study aimed to elucidate mechanisms by which IFN-gamma regulates AGT expression in RPTCs. RPTCs were incubated with or without IFN-gamma up to 48 h. AGT expression, STAT1 and STAT3 activities, and SOCS1 expression were evaluated. RNA interference studies against STAT1, SOCS1, and STAT3 were performed to elucidate a signaling cascade. IFN-gamma decreased AGT expression at 6 h (0.61 +/- 0.05, ratio to control) and 12 h (0.47 +/- 0.03). In contrast, longer exposure for 24 and 48 h increased AGT expression (1.76 +/- 0.18, EC50 +/- 3.4 ng/ml, and 1.45 +/- 0.08, respectively). IFN-gamma treatment for 6 h strongly induced STAT1 phosphorylation and SOCS1 augmentation, and decreased STAT3 activity. However, STAT1 phosphorylation and SOCS1 augmentation waned at 24 h, while STAT3 activity increased. RNA interference studies revealed that activation of STAT1-SOCS1 axis decreased STAT3 activity. Thus, IFN-gamma biphasically regulates AGT expression in RPTCs via STAT3 activity modulated by STAT1-SOCS1 axis, suggesting the STAT1-SOCS1 axis is important in IFN-gamma-induced activation of the intrarenal renin-angiotensin system.-Satou, R., Miyata, K., Gonzalez-Villalobos, R. A., Ingelfinger, J. R., Navar, L. G., Kobori, H. Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB J. 26, 1821-1830 (2012). www.fasebj.org	[Satou, Ryousuke; Miyata, Kayoko; Navar, L. Gabriel; Kobori, Hiroyuki] Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; [Satou, Ryousuke; Miyata, Kayoko; Navar, L. Gabriel; Kobori, Hiroyuki] Tulane Univ, Hlth Sci Ctr, Hypertens & Renal Ctr Excellence, New Orleans, LA 70112 USA; [Gonzalez-Villalobos, Romer A.] Cedars Sinai Med Ctr, Dept Biomed Sci & Pathol, Los Angeles, CA 90048 USA; [Gonzalez-Villalobos, Romer A.] Cedars Sinai Med Ctr, Dept Lab Med, Los Angeles, CA 90048 USA; [Ingelfinger, Julie R.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA	Tulane University; Tulane University; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Satou, R (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Physiol, 1430 Tulane Ave,SL39-M720, New Orleans, LA 70112 USA.	rsato@tulane.edu	Kobori, Hiroyuki/F-1994-2014	Kobori, Hiroyuki/0000-0001-5128-5059	U.S. National Institute of Diabetes and Digestive and Kidney Diseases [R01DK072408, K99DK083455]; National Center for Research Resources [P20RR017659]; National Heart, Lung, and Blood Institute [R01HL026371]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017659] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072408, K99DK083455] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge the valuable comments and excellent technical assistance of Dr. Maki Urushihara, Dr. Masumi Kamiyama, Dr. Daisuke Inui, Dr. Omar W. Acres, Ms. Akemi Katsurada, and Ms. Ayumi Kitano (Tulane University). This study was supported by grants from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072408 and K99DK083455), the National Center for Research Resources (P20RR017659), and the National Heart, Lung, and Blood Institute (R01HL026371). The authors declare no conflicts of interest.	AMEZAGA MA, 1992, BLOOD, V79, P735; Cheon H, 2009, P NATL ACAD SCI USA, V106, P9373, DOI 10.1073/pnas.0903487106; Crowley SD, 2008, AM J PHYSIOL-RENAL, V295, pF515, DOI 10.1152/ajprenal.00527.2007; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DiGiandomenico A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.1162191; DZAU VJ, 1994, CIRCULATION, V89, P493, DOI 10.1161/01.CIR.89.1.493; Fujimoto M, 2003, TRENDS IMMUNOL, V24, P659, DOI 10.1016/j.it.2003.10.008; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; Gonzalez-Villalobos RA, 2008, AM J PHYSIOL-RENAL, V295, pF772, DOI 10.1152/ajprenal.00019.2008; Gonzalez-Villalobos RA, 2011, J AM SOC NEPHROL, V22, P449, DOI 10.1681/ASN.2010060624; Ingelfinger JR, 1999, AM J PHYSIOL-RENAL, V276, pF218, DOI 10.1152/ajprenal.1999.276.2.F218; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; Jain S, 2007, AM J PHYSIOL-CELL PH, V293, pC401, DOI 10.1152/ajpcell.00433.2006; Jain S, 2006, BBA-GENE STRUCT EXPR, V1759, P340, DOI 10.1016/j.bbaexp.2006.07.003; Katsurada A, 2007, AM J PHYSIOL-RENAL, V293, pF956, DOI 10.1152/ajprenal.00090.2007; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kobori H, 2005, J AM SOC NEPHROL, V16, P2073, DOI 10.1681/ASN.2004080676; Kobori H, 2001, J AM SOC NEPHROL, V12, P431, DOI 10.1681/ASN.V123431; Kobori H, 2008, AM J PHYSIOL-RENAL, V294, pF1257, DOI 10.1152/ajprenal.00588.2007; Kobori H, 2007, AM J PHYSIOL-RENAL, V293, pF938, DOI 10.1152/ajprenal.00146.2007; Kobori H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3; Kobori H, 2009, HYPERTENSION, V53, P344, DOI 10.1161/HYPERTENSIONAHA.108.123802; Krejci P, 2009, CELL SIGNAL, V21, P151, DOI 10.1016/j.cellsig.2008.10.006; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Navar LG, 2011, CURR OPIN PHARMACOL, V11, P180, DOI 10.1016/j.coph.2011.01.009; Navar LG, 2011, HYPERTENSION, V57, P355, DOI 10.1161/HYPERTENSIONAHA.110.163519; Ortiz-Munoz G, 2010, J AM SOC NEPHROL, V21, P763, DOI 10.1681/ASN.2009060625; Park YJ, 2007, BIOCHEM BIOPH RES CO, V363, P361, DOI 10.1016/j.bbrc.2007.08.195; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Qing Y, 2005, J BIOL CHEM, V280, P1849, DOI 10.1074/jbc.M409863200; Ray S, 2005, GASTROENTEROLOGY, V129, P1616, DOI 10.1053/j.gastro.2005.07.055; Re RN, 2004, MED CLIN N AM, V88, P19, DOI 10.1016/S0025-7125(03)00124-X; Sachetelli S, 2006, KIDNEY INT, V69, P1016, DOI 10.1038/sj.ki.5000210; Saha B, 2010, CYTOKINE, V50, P1, DOI 10.1016/j.cyto.2009.11.021; Satou R, 2008, AM J PHYSIOL-RENAL, V295, pF283, DOI 10.1152/ajprenal.00047.2008; Satou R, 2010, AM J PHYSIOL-CELL PH, V299, pC750, DOI 10.1152/ajpcell.00078.2010; Satou R, 2009, MOL CELL ENDOCRINOL, V311, P24, DOI 10.1016/j.mce.2009.06.013; Shi YH, 2010, AM J NEPHROL, V31, P380, DOI 10.1159/000286559; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; TAMURA K, 1992, JPN HEART J, V33, P113; TERADA Y, 1993, KIDNEY INT, V43, P1251, DOI 10.1038/ki.1993.177; Tsuboi H, 2011, INT J RHEUM DIS, V14, P86, DOI 10.1111/j.1756-185X.2010.01575.x	44	49	50	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1821	1830		10.1096/fj.11-195198	http://dx.doi.org/10.1096/fj.11-195198			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22302831	Green Published			2022-12-28	WOS:000303680800010
J	Chan, KSK; Xu, J; Wardan, H; McColl, B; Orkin, S; Vadolas, J				Chan, Kasey S. K.; Xu, Jian; Wardan, Hady; McColl, Bradley; Orkin, Stuart; Vadolas, Jim			Generation of a genomic reporter assay system for analysis of gamma- and beta-globin gene regulation	FASEB JOURNAL			English	Article							SICKLE-CELL-DISEASE; FETAL-HEMOGLOBIN INDUCTION; SOLUBLE GUANYLYL CYCLASE; ERYTHROID-CELLS; EXPRESSION; BCL11A; HYDROXYUREA; THALASSEMIA; LOCUS; MICE	A greater understanding of the regulatory mechanisms that govern gamma-globin expression in humans, especially the switching from gamma- to beta-globin, which occurs after birth, would help to identify new therapeutic targets for patients with beta-hemoglobinopathy. To further elucidate the mechanisms involved in gamma-globin expression, a novel fluorescent-based cellular reporter assay system was developed. Using homologous recombination, two reporter genes, DsRed and EGFP, were inserted into a 183-kb intact human beta-globin locus under the control of (G)gamma- or (A)gamma-globin promoter and beta-globin promoter, respectively. The modified constructs were stably transfected into adult murine erythroleukaemic (MEL) cells and human embryonic or fetal erythroleukemic (K562) cells, allowing for rapid and simultaneous analysis of fetal and adult globin gene expression according to their developmental stage-specific expression. To demonstrate the utility of this system, we performed RNA interference (RNAi)-mediated knockdown of BCL11A in the presence or absence of known fetal hemoglobin inducers and demonstrated functional derepression of a gamma-globin-linked reporter in an adult erythroid environment. Our results demonstrate that the cellular assay system represents a promising approach to perform genetic and functional genomic studies to identify and evaluate key factors associated with gamma-globin gene suppression.-Chan, K. S. K., Xu, J., Wardan, H., McColl, B., Orkin, S., Vadolas, J. Generation of a genomic reporter assay system for analysis of gamma- and beta-globin gene regulation. FASEB J. 26, 1736-1744 (2012). www.fasebj.org	[Chan, Kasey S. K.; Wardan, Hady; McColl, Bradley; Vadolas, Jim] Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Parkville, Vic 3052, Australia; [Chan, Kasey S. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Chan, Kasey S. K.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Xu, Jian; Orkin, Stuart] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; [Xu, Jian; Orkin, Stuart] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Vadolas, J (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Grp, Flemington Rd, Parkville, Vic 3052, Australia.	jim.vadolas@mcri.edu.au		Vadolas, Jim/0000-0002-3072-3512	Australia National Health and Medical Research Council; Murdoch Childrens Research Institute; Victorian Government; Thalassaemia Australia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK093543] Funding Source: NIH RePORTER	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Murdoch Childrens Research Institute; Victorian Government; Thalassaemia Australia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The Australia National Health and Medical Research Council, the Murdoch Childrens Research Institute, the Victorian Government's Operational Infrastructure Support Program, and Thalassaemia Australia supported this work. The authors declare no conflicts of interest.	Atweh GF, 1999, BLOOD, V93, P1790; Banzon V, 2011, EXP HEMATOL, V39, P26, DOI 10.1016/j.exphem.2010.10.003; Boosalis MS, 2011, BLOOD CELL MOL DIS, V47, P107, DOI 10.1016/j.bcmd.2011.04.008; Borg J, 2010, NAT GENET, V42, P801, DOI 10.1038/ng.630; Bradner JE, 2010, P NATL ACAD SCI USA, V107, P12617, DOI 10.1073/pnas.1006774107; CIOE L, 1981, CANCER RES, V41, P237; Cokic VP, 2008, BLOOD, V111, P1117, DOI 10.1182/blood-2007-05-088732; Cokic VP, 2003, J CLIN INVEST, V111, P231, DOI 10.1172/JCI200316672; Cui SAY, 2011, MOL CELL BIOL, V31, P3298, DOI 10.1128/MCB.05310-11; Fathallah H, 2009, BLOOD CELL MOL DIS, V43, P58, DOI 10.1016/j.bcmd.2009.02.006; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; Howden SE, 2008, GENE THER, V15, P1372, DOI 10.1038/gt.2008.84; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; LEY TJ, 1983, BLOOD, V62, P370; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Mabaera R, 2008, EXP HEMATOL, V36, P1057, DOI 10.1016/j.exphem.2008.06.014; Migliaccio G, 2005, BLOOD CELL MOL DIS, V34, P174, DOI 10.1016/j.bcmd.2004.11.005; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Rees DC, 2011, HAEMATOL-HEMATOL J, V96, P488, DOI 10.3324/haematol.2011.041988; Sankaran VG, 2011, NEW ENGL J MED, V365, P807, DOI 10.1056/NEJMoa1103070; Sankaran VG, 2009, NATURE, V460, P1093, DOI 10.1038/nature08243; Sankaran VG, 2008, SCIENCE, V322, P1839, DOI 10.1126/science.1165409; Saunthararajah Y, 2004, SEMIN HEMATOL, V41, P11, DOI 10.1053/j.seminhematol.2004.08.003; SINGER D, 1974, P NATL ACAD SCI USA, V71, P2668, DOI 10.1073/pnas.71.7.2668; Skarpidi E, 2000, BLOOD, V96, P321, DOI 10.1182/blood.V96.1.321.013k48_321_326; Thein SL, 2007, P NATL ACAD SCI USA, V104, P11346, DOI 10.1073/pnas.0611393104; Thein SL, 2009, HUM MOL GENET, V18, pR216, DOI 10.1093/hmg/ddp401; Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105; Vadolas J, 2005, BBA-GENE STRUCT EXPR, V1728, P150, DOI 10.1016/j.bbaexp.2005.02.008; Vadolas J, 2002, BLOOD, V100, P4209, DOI 10.1182/blood-2001-12-0365; van Dijk TB, 2010, BLOOD, V116, P4349, DOI 10.1182/blood-2010-03-274399; Wilber A, 2011, BLOOD, V117, P2817, DOI 10.1182/blood-2010-08-300723; Xu J, 2011, SCIENCE, V334, P993, DOI 10.1126/science.1211053; Xu J, 2010, GENE DEV, V24, P783, DOI 10.1101/gad.1897310; YARBRO JW, 1992, SEMIN ONCOL, V19, P1	37	17	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1736	1744		10.1096/fj.11-199356	http://dx.doi.org/10.1096/fj.11-199356			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22267339	Green Published			2022-12-28	WOS:000302359700034
J	Rodger, J; Mo, C; Wilks, T; Dunlop, SA; Sherrard, RM				Rodger, Jennifer; Mo, Christina; Wilks, Tenelle; Dunlop, Sarah A.; Sherrard, Rachel M.			Transcranial pulsed magnetic field stimulation facilitates reorganization of abnormal neural circuits and corrects behavioral deficits without disrupting normal connectivity	FASEB JOURNAL			English	Article						rTMS; topography; ephrin; plasticity; BDNF; neuromodulation	THETA-BURST STIMULATION; RAT SUPERIOR COLLICULUS; PRIMARY MOTOR CORTEX; FREQUENCY ELECTROMAGNETIC-FIELDS; EXPERIENCE-DEPENDENT PLASTICITY; OPTIC-NERVE REGENERATION; SPINAL-CORD-INJURY; ENVIRONMENTAL ENRICHMENT; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY	Although the organization of neuronal circuitry is shaped by activity patterns, the capacity to modify and/or optimize the structure and function of whole projection pathways using external stimuli is poorly defined. We investigate whether neuronal activity induced by pulsed magnetic fields (PMFs) alters brain structure and function. We delivered low-intensity PMFs to the posterior cranium of awake, unrestrained mice (wild-type and ephrin-A2A5(-/-)) that have disorganized retinocollicular circuitry and associated visuomotor deficits. Control groups of each genotype received sham stimulation. Following daily stimulation for 14 d, we measured biochemical, structural (anterograde tracing), and functional (electrophysiology and behavior) changes in the retinocollicular projection. PMFs induced BDNF, GABA, and nNOS expression in the superior colliculus and retina of wild-type and ephrin-A2A5(-/-) mice. Furthermore, in ephrin-A2A5(-/-) mice, PMFs corrected abnormal neuronal responses and selectively removed inaccurate ectopic axon terminals to improve structural and functional organization of their retinocollicular projection and restore normal visual tracking behavior. In contrast, PMFs did not alter the structure or function of the normal projection in wild-type mice. Sham PMF stimulation had no effect on any mice. Thus, PMF-induced biochemical changes are congruent with its capacity to facilitate beneficial reorganization of abnormal neural circuits without disrupting normal connectivity and function.-Rodger, J., Mo, C., Wilks, T., Dunlop, S. A., Sherrard, R. M. Transcranial pulsed magnetic field stimulation facilitates reorganization of abnormal neural circuits and corrects behavioral deficits without disrupting normal connectivity. FASEB J. 26, 1593-1606 (2012). www.fasebj.org	[Rodger, Jennifer; Mo, Christina; Wilks, Tenelle; Dunlop, Sarah A.] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Sherrard, Rachel M.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia; [Sherrard, Rachel M.] Univ Paris 06, Paris, France; [Sherrard, Rachel M.] CNRS, Unite Mixte Rech 7102, Paris, France	University of Western Australia; University of Western Australia; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol M317, Crawley, WA 6009, Australia.	jennifer.rodger@uwa.edu.au	Sherrard, Rachel/Y-1355-2019; Rodger, Jennifer/H-5735-2014; Dunlop, Sarah A/G-9357-2013; Sherrard, Rachel M/D-5446-2013	Sherrard, Rachel/0000-0002-6595-3545; Rodger, Jennifer/0000-0003-3413-4229; Dunlop, Sarah/0000-0002-1306-3962; Mo, Christina/0000-0001-6725-7239	Western Australian State Government; Raine Foundation (Western Australia); National Health and Medical Research Council Australia; Ecole de Neuroscience de Paris	Western Australian State Government; Raine Foundation (Western Australia); National Health and Medical Research Council Australia(National Health and Medical Research Council (NHMRC) of Australia); Ecole de Neuroscience de Paris	The authors thank Michael Archer, Stephanie Grehl, Marissa Penrose, and Clarissa Goh for technical assistance, Prof. Lindy Fitzgerald for advice on behavioral analysis, and Dr. Robert Woodward and Prof. Don Robertson for advice on measuring magnetic fields. The authors also thank Prof. A. J. Bower for his helpful comments on the manuscript. This work was funded by the Neurotrauma Research Program (Western Australian State Government), the Raine Foundation (Western Australia), and the National Health and Medical Research Council Australia. Travel funds were provided by the Ecole de Neuroscience de Paris.	Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015; Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; Allen EA, 2007, SCIENCE, V317, P1918, DOI 10.1126/science.1146426; Arias-Carrion O, 2004, J NEUROSCI RES, V78, P16, DOI 10.1002/jnr.20235; Arias-Carrion Oscar, 2008, Int Arch Med, V1, P2, DOI 10.1186/1755-7682-1-2; Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; Aydin-Abidin S, 2006, J PHYSIOL-LONDON, V574, P443, DOI 10.1113/jphysiol.2006.108464; Baeken C, 2008, CLIN NEUROPHYSIOL, V119, P568, DOI 10.1016/j.clinph.2007.11.044; BALKEMA GW, 1981, J NEUROSCI, V1, P1320; BARKER AT, 1985, LANCET, V1, P1106; Ben-Shachar D, 1999, BRAIN RES, V816, P78, DOI 10.1016/S0006-8993(98)01119-6; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Berretta N, 2008, PROG NEUROBIOL, V84, P343, DOI 10.1016/j.pneurobio.2007.12.004; Brighina F, 2009, CEREBELLUM, V8, P260, DOI 10.1007/s12311-008-0090-4; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Cao LX, 2007, CURR BIOL, V17, P911, DOI 10.1016/j.cub.2007.04.040; Capone F, 2009, J NEURAL TRANSM, V116, P257, DOI 10.1007/s00702-009-0184-2; Cheetham Ce, 2007, Adv Clin Neurosci Rehabil, V7, P8; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cline H, 2003, TRENDS NEUROSCI, V26, P655, DOI 10.1016/j.tins.2003.10.005; Cotelli M, 2008, EUR J NEUROL, V15, P1286, DOI 10.1111/j.1468-1331.2008.02202.x; Daskalakis ZJ, 2008, CAN J PSYCHIAT, V53, P555, DOI 10.1177/070674370805300902; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Marco S, 2009, J NEUROSCI, V29, P13691, DOI 10.1523/JNEUROSCI.3854-09.2009; Dontchev VD, 2002, J NEUROSCI, V22, P6659; DRAGER UC, 1975, J NEUROPHYSIOL, V38, P690, DOI 10.1152/jn.1975.38.3.690; DRAGER UC, 1976, J NEUROPHYSIOL, V39, P91, DOI 10.1152/jn.1976.39.1.91; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Ernst AF, 1999, J NEUROSCI, V19, P229, DOI 10.1523/JNEUROSCI.19-01-00229.1999; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Fernandez EA, 2010, JARO-J ASSOC RES OTO, V11, P235, DOI 10.1007/s10162-009-0204-9; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Frost DO, 2001, PROG BRAIN RES, V134, P35; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; Gangitano M, 2002, CLIN NEUROPHYSIOL, V113, P1249, DOI 10.1016/S1388-2457(02)00109-8; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; HARVEY AR, 1990, J COMP NEUROL, V298, P281, DOI 10.1002/cne.902980303; Hausmann A, 2000, MOL BRAIN RES, V76, P355, DOI 10.1016/S0169-328X(00)00024-3; Haustead DJ, 2008, J NEUROSCI, V28, P7376, DOI 10.1523/JNEUROSCI.1135-08.2008; HIRAI H, 1993, BRAIN RES, V629, P23, DOI 10.1016/0006-8993(93)90476-4; Huang L, 2001, J NEUROPHYSIOL, V86, P1179, DOI 10.1152/jn.2001.86.3.1179; Huang YZ, 2009, CLIN NEUROPHYSIOL, V120, P796, DOI 10.1016/j.clinph.2009.01.003; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Ikeda T, 2005, BIOCHEM BIOPH RES CO, V327, P218, DOI 10.1016/j.bbrc.2004.12.009; Isa T, 1998, J NEUROSCI, V18, P8496; Jiang B, 2004, EUR J NEUROSCI, V20, P709, DOI 10.1111/j.1460-9568.2004.03523.x; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Keck ME, 2000, EUR J NEUROSCI, V12, P3713, DOI 10.1046/j.1460-9568.2000.00243.x; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kole MHP, 1999, BRAIN RES, V826, P309, DOI 10.1016/S0006-8993(99)01257-3; Le Roux N, 2009, NEUROSCIENCE, V163, P942, DOI 10.1016/j.neuroscience.2009.07.010; Lee MC, 2010, NEURON, V66, P859, DOI 10.1016/j.neuron.2010.05.015; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Li YX, 1998, J NEUROSCI, V18, P10231; Lien CC, 2006, NAT NEUROSCI, V9, P372, DOI 10.1038/nn1649; Lin HY, 2011, BIOELECTROMAGNETICS, V32, P552, DOI 10.1002/bem.20668; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Maccabee P. J., 1991, MAGNETIC MOTOR STIMU, P340; Martiny K, 2010, BIOL PSYCHIAT, V68, P163, DOI 10.1016/j.biopsych.2010.02.017; McAllister SM, 2009, CLIN NEUROPHYSIOL, V120, P820, DOI 10.1016/j.clinph.2009.02.003; McBain VA, 2003, INVEST OPHTH VIS SCI, V44, P540, DOI 10.1167/iovs.02-0570; MCILWAIN JT, 1975, J NEUROPHYSIOL, V38, P219, DOI 10.1152/jn.1975.38.2.219; McLaughlin T, 2003, NEURON, V40, P1147, DOI 10.1016/S0896-6273(03)00790-6; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Morgado-Valle C, 1998, CELL TISSUE RES, V291, P217, DOI 10.1007/s004410050992; Mu Y, 2006, NEURON, V50, P115, DOI 10.1016/j.neuron.2006.03.009; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; Namiki S, 2005, J PHYSIOL-LONDON, V566, P849, DOI 10.1113/jphysiol.2005.088799; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Noda, 2000, Pathophysiology, V7, P127, DOI 10.1016/S0928-4680(00)00039-0; Pascual-Leone A, 2006, PROG BRAIN RES, V157, P315, DOI 10.1016/S0079-6123(06)57019-0; Payne BR, 1996, P NATL ACAD SCI USA, V93, P290, DOI 10.1073/pnas.93.1.290; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Post A, 2001, J PSYCHIATR RES, V35, P193, DOI 10.1016/S0022-3956(01)00023-1; Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460; Reber M, 2004, NATURE, V431, P847, DOI 10.1038/nature02957; Rodger J, 2005, MOL CELL NEUROSCI, V30, P452, DOI 10.1016/j.mcn.2005.08.009; Rodger J, 2004, MOL CELL NEUROSCI, V25, P56, DOI 10.1016/j.mcn.2003.09.010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; SCHMIDT JT, 1985, CELL MOL NEUROBIOL, V5, P65, DOI 10.1007/BF00711086; SCHNEIDER GE, 1969, SCIENCE, V163, P895, DOI 10.1126/science.163.3870.895; Sefton A.J., 2004, RAT NERVOUS SYSTEM, P1083; Sherrard RM, 2009, DEV NEUROBIOL, V69, P647, DOI 10.1002/dneu.20730; Siebner HR, 2009, CORTEX, V45, P1035, DOI 10.1016/j.cortex.2009.02.007; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Singh KK, 2008, NAT NEUROSCI, V11, P649, DOI 10.1038/nn.2114; Sivakumaran S, 2009, J NEUROSCI, V29, P2637, DOI 10.1523/JNEUROSCI.5019-08.2009; Sun P, 2011, J NEUROSCI, V31, P16464, DOI 10.1523/JNEUROSCI.1542-11.2011; Szapacs ME, 2004, J NEUROSCI METH, V140, P81, DOI 10.1016/j.jneumeth.2004.03.026; Thickbroom GW, 2007, EXP BRAIN RES, V180, P583, DOI 10.1007/s00221-007-0991-3; Thickbroom GW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-4; Trippe J, 2009, EXP BRAIN RES, V199, P411, DOI 10.1007/s00221-009-1961-8; Valero-Cabre A, 2006, EXP BRAIN RES, V172, P14, DOI 10.1007/s00221-005-0307-4; Valero-Cabre A, 2005, EXP BRAIN RES, V163, P1, DOI 10.1007/s00221-004-2140-6; Valero-Cabre A, 2005, IEEE ENG MED BIOL, V24, P29, DOI 10.1109/MEMB.2005.1384097; Valero-Cabre A, 2008, EUR J NEUROSCI, V27, P765, DOI 10.1111/j.1460-9568.2008.06045.x; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Varani K, 2002, BRIT J PHARMACOL, V136, P57, DOI 10.1038/sj.bjp.0704695; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; WEISSMAN JD, 1992, ELECTROEN CLIN NEURO, V85, P215, DOI 10.1016/0168-5597(92)90135-X; Wilks TA, 2010, EUR J NEUROSCI, V31, P613, DOI 10.1111/j.1460-9568.2010.07111.x; Zabouri N, 2011, J COMP NEUROL, V519, P1258, DOI 10.1002/cne.22534; Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154	119	65	67	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1593	1606		10.1096/fj.11-194878	http://dx.doi.org/10.1096/fj.11-194878			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223750				2022-12-28	WOS:000302359700021
J	Wang, SB; Hu, KM; Seamon, KJ; Mani, V; Chen, YD; Gronert, K				Wang, Samantha B.; Hu, Kyle M.; Seamon, Kyle J.; Mani, Vinidhra; Chen, Yangdi; Gronert, Karsten			Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea	FASEB JOURNAL			English	Article						17 beta-estradiol; lipoxin A(4); ER beta; ER alpha; 15-LOX; sex-specific	DRY EYE; MEIBOMIAN GLAND; SJOGRENS-SYNDROME; GENE-EXPRESSION; MESSENGER-RNAS; RECEPTOR ALX; INFLAMMATION; LIPOXINS; RESOLUTION; RESPONSES	Estrogen receptors (ERs) are expressed in leukocytes and in every ocular tissue. However, sex-specific differences and the role of estradiol in ocular inflammatory-reparative responses are not well understood. We found that female mice exhibited delayed corneal epithelial wound closure and attenuated polymorphonuclear (PMN) leukocyte responses, a phenotype recapitulated by estradiol treatment both in vivo (topically in male mice) and in vitro (corneal epithelial cell wound healing). The cornea expresses 15-lipoxygenase (15-LOX) and receptors for lipoxin A(4) (LXA(4)), which have been implicated in an intrinsic lipid circuit that regulates corneal inflammation and wound healing. Delayed epithelial wound healing correlated with lower expression of 15-LOX in the regenerated epithelium of female mice. Estradiol in vitro and in vivo down-regulated epithelial 15-LOX expression and LXA(4) formation, while estradiol abrogation of epithelial wound healing was completely reversed by treatment with LXA(4). More important, ER beta and ER alpha selectively regulated epithelial wound healing, PMN cell recruitment, and activity of the intrinsic 15-LOX/LXA(4) circuit. Our results demonstrate for the first time a sex-specific difference in the corneal reparative response, which is mediated by ER beta and ER alpha selective regulation of the epithelial and PMN 15-LOX/LXA(4) circuit. These findings may provide novel insights into the etiology of sex-specific ocular inflammatory diseases.-Wang, S. B., Hu, K. M., Seamon, K. J., Mani, V., Chen, Y., Gronert, K. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J. 26, 1506-1516 (2012). www.fasebj.org	[Wang, Samantha B.; Hu, Kyle M.; Seamon, Kyle J.; Mani, Vinidhra; Chen, Yangdi; Gronert, Karsten] Univ Calif Berkeley, Sch Optometry, Vis Sci Program, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gronert, K (corresponding author), Univ Calif Berkeley, Sch Optometry, Vis Sci Program, 594 Minor Hall,MC 2020, Berkeley, CA 94720 USA.	kgronert@berkeley.edu			U.S. National Eye Institute [EY016136, P30EY003176]; Hellman's Family Faculty; University of California, Berkeley; NATIONAL EYE INSTITUTE [R01EY016136, P30EY003176, R01EY022208] Funding Source: NIH RePORTER	U.S. National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Hellman's Family Faculty; University of California, Berkeley(University of California System); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported in part by U.S. National Eye Institute grants EY016136 and P30EY003176 and a Hellman's Family Faculty Fund grant from the University of California, Berkeley.	Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; Barabino Stefano, 2007, Chem Immunol Allergy, V92, P176, DOI 10.1159/000099268; Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635; Biteman B, 2007, FASEB J, V21, P2257, DOI 10.1096/fj.06-7918com; Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; COLES N, 1988, Investigative Ophthalmology and Visual Science, V29, P48; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Gilliver SC, 2010, J STEROID BIOCHEM, V120, P105, DOI 10.1016/j.jsbmb.2009.12.015; Godson C, 2000, Curr Opin Investig Drugs, V1, P380; Gronert K, 2005, PROSTAG LEUKOTR ESS, V73, P221, DOI 10.1016/j.plefa.2005.05.009; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 2008, MOL INTERV, V8, P28, DOI 10.1124/mi.8.1.7; Gronert K, 2010, EXP EYE RES, V91, P478, DOI 10.1016/j.exer.2010.07.004; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jin YP, 2009, INVEST OPHTH VIS SCI, V50, P4743, DOI 10.1167/iovs.08-2462; Karim MJ, 2009, J OCUL PHARMACOL TH, V25, P483, DOI [10.1089/jop.2008.0134, 10.1089/jop.2009.0134]; Kenchegowda S, 2011, INVEST OPHTH VIS SCI, V52, P2240, DOI 10.1167/iovs.10-6199; Kenchegowda S, 2010, J LIPID RES, V51, P879, DOI 10.1194/jlr.R001347; Krishnan T, 2012, BRIT J OPHTHALMOL, V96, P137, DOI 10.1136/bjophthalmol-2011-300441; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Leedom AJ, 2010, AM J PATHOL, V176, P74, DOI 10.2353/ajpath.2010.090678; Leitman DC, 2010, CURR OPIN PHARMACOL, V10, P629, DOI 10.1016/j.coph.2010.09.009; Li Z, 2007, AM J PATHOL, V171, P838, DOI 10.2353/ajpath.2007.070008; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P4794, DOI 10.1167/iovs.06-0381; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P1947, DOI 10.1167/iovs.05-1193; Liclican EL, 2010, INVEST OPHTH VIS SCI, V51, P6311, DOI 10.1167/iovs.10-5455; Liclican EL, 2010, THESCIENTIFICWORLDJO, V10, P1029, DOI 10.1100/tsw.2010.99; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Russell R, 2011, FASEB J, V25, P4326, DOI 10.1096/fj.11-187658; Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571; Sator MO, 1998, BRIT J OBSTET GYNAEC, V105, P100, DOI 10.1111/j.1471-0528.1998.tb09358.x; Schaumberg DA, 2002, ADV EXP MED BIOL, V506, P989; Schaumberg DA, 2001, JAMA-J AM MED ASSOC, V286, P2114, DOI 10.1001/jama.286.17.2114; Schirra F, 2006, CORNEA, V25, P438, DOI 10.1097/01.ico.0000183664.80004.44; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Seta F, 2006, AM J PATHOL, V169, P1612, DOI 10.2353/ajpath.2006.060555; Sharma GD, 2005, J BIOL CHEM, V280, P7917, DOI 10.1074/jbc.M408852200; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Sullivan DA, 2004, DRY EYE AND OCULAR SURFACE DISORDERS, P165; Sullivan DA, 2002, LUPUS, V11, P667, DOI 10.1191/0961203302lu275oa; Sullivan David A, 2004, Ocul Surf, V2, P92; Suzuki T, 2005, CORNEA, V24, P1004, DOI 10.1097/01.ico.0000160973.04072.a5; Suzuki T, 2002, ANN NY ACAD SCI, V966, P223, DOI 10.1111/j.1749-6632.2002.tb04218.x; Suzuki T, 2001, CURR EYE RES, V22, P28, DOI 10.1076/ceyr.22.1.28.6980; Suzuki T, 2008, INVEST OPHTH VIS SCI, V49, P1797, DOI 10.1167/iovs.07-1458; Suzuki T, 2006, CORNEA, V25, P454; Tachibana M, 2000, INVEST OPHTH VIS SCI, V41, P668; Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833; Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x	56	68	71	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1506	1516		10.1096/fj.11-198036	http://dx.doi.org/10.1096/fj.11-198036			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22186873	Green Published			2022-12-28	WOS:000302359700013
J	Nordmann, A; Wixler, L; Boergeling, Y; Wixler, V; Ludwig, S				Nordmann, Alexandra; Wixler, Ludmilla; Boergeling, Yvonne; Wixler, Viktor; Ludwig, Stephan			A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication	FASEB JOURNAL			English	Article						cellular innate immune response; interferon; large GTPases	INFLUENZA-A VIRUS; VESICULAR STOMATITIS-VIRUS; NUCLEOTIDE-BINDING; INTERFERON-GAMMA; GTPASE; ACTIVATION; EXPRESSION; FAMILY; PROLIFERATION; INDUCTION	Guanylate-binding proteins (GBPs) belong to the family of large GTPases that are induced in response to interferons. GBPs contain an N-terminal globular GTPase domain and a C-terminal alpha-helical regulatory domain that are connected by a short middle domain. Antiviral activity against vesicular stomatitis virus and encephalomyocarditis virus has been shown for hGBP-1; however, no anti-influenza virus properties for GBPs have been described to date. Here we show that hGBP-1 and hGBP-3 possess anti-influenza viral activity. Furthermore, we have identified a novel splice variant of hGBP-3, named hGBP-3 Delta C, with a largely modified C-terminal alpha-helical domain. While all three GBP isoforms were up-regulated on influenza virus infection, hGBP-3 Delta C showed the most prominent antiviral activity in epithelial cells. Mutational analysis of hGBPs revealed that the globular domain is the principal antiviral effector domain, and GTP-binding, but not hydrolysis, is necessary for antiviral action. Furthermore, we showed that hGBP-3 Delta C strongly represses the activity of the viral polymerase complex, which results in decreased synthesis of viral vRNA, cRNA, mRNA, and viral proteins, as well.-Nordmann, A., Wixler, L., Boergeling, Y., Wixler, V., Ludwig, S. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J. 26, 1290-1300 (2012). www.fasebj.org	[Nordmann, Alexandra; Wixler, Ludmilla; Boergeling, Yvonne; Wixler, Viktor; Ludwig, Stephan] Univ Munster, IMV, Ctr Mol Biol Inflammat ZMBE, D-48149 Munster, Germany	University of Munster	Ludwig, S (corresponding author), Univ Munster, IMV, Ctr Mol Biol Inflammat ZMBE, Von Esmarch Str 56, D-48149 Munster, Germany.	ludwigs@uni-muenster.de		Ludwig, Stephan/0000-0003-4490-3052	Deutsche Forschungsgemeinschaft [DFG Lu477/13-1]; International Max Planck Research School (IMPRS) International Graduate School Muenster (Muenster, Germany); German Ministry of Education and Research (BMBF)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); International Max Planck Research School (IMPRS) International Graduate School Muenster (Muenster, Germany); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by the Deutsche Forschungsgemeinschaft (grant DFG Lu477/13-1) and the Graduate Program Cell Dynamics and Disease (CEDAD)-International Max Planck Research School (IMPRS) International Graduate School Muenster (Muenster, Germany). The Institute of Molecular Virology Muenster is a member of the Flu Research Net, a nationwide research network on zoonotic influenza sponsored by the German Ministry of Education and Research (BMBF).	Abdullah N, 2009, J MOL BIOL, V386, P690, DOI 10.1016/j.jmb.2008.12.060; Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; Carr SM, 2006, VIROLOGY, V344, P492, DOI 10.1016/j.virol.2005.08.041; Carter CC, 2005, ARCH VIROL, V150, P1213, DOI 10.1007/s00705-004-0489-2; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; Cheung TKW, 2007, ANN NY ACAD SCI, V1102, P1, DOI 10.1196/annals.1408.001; Degrandi D, 2007, J IMMUNOL, V179, P7729, DOI 10.4049/jimmunol.179.11.7729; Dudek SE, 2010, J VIROL, V84, P9439, DOI 10.1128/JVI.00533-10; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Fellenberg F, 2004, J INVEST DERMATOL, V122, P1510, DOI 10.1111/j.0022-202X.2004.22613.x; Fodor E, 2002, J VIROL, V76, P8989, DOI 10.1128/JVI.76.18.8989-9001.2002; Ghosh A, 2006, NATURE, V440, P101, DOI 10.1038/nature04510; Gorbacheva VY, 2002, J BIOL CHEM, V277, P6080, DOI 10.1074/jbc.M110542200; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Haller O, 2007, MICROBES INFECT, V9, P1636, DOI 10.1016/j.micinf.2007.09.010; Itsui Y, 2009, HEPATOLOGY, V50, P1727, DOI 10.1002/hep.23195; Kim BH, 2011, SCIENCE, V332, P717, DOI 10.1126/science.1201711; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lubeseder-Martellato C, 2002, AM J PATHOL, V161, P1749, DOI 10.1016/S0002-9440(10)64452-5; Messmer-Blust AF, 2010, MOL BIOL CELL, V21, P2514, DOI 10.1091/mbc.E09-04-0344; Olszewski MA, 2006, J INTERF CYTOK RES, V26, P328, DOI 10.1089/jir.2006.26.328; Pleschka S, 1996, J VIROL, V70, P4188, DOI 10.1128/JVI.70.6.4188-4192.1996; Praefcke GJK, 2004, J MOL BIOL, V344, P257, DOI 10.1016/j.jmb.2004.09.026; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Tietzel I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006499; Tripal P, 2007, J INTERF CYTOK RES, V27, P44, DOI 10.1089/jir.2007.0086; Vopel T, 2010, J MOL BIOL, V400, P63, DOI 10.1016/j.jmb.2010.04.053; Wehner M, 2010, FEBS J, V277, P1597, DOI 10.1111/j.1742-4658.2010.07586.x	32	67	72	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1290	1300		10.1096/fj.11-189886	http://dx.doi.org/10.1096/fj.11-189886			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22106366				2022-12-28	WOS:000300949300031
J	Loubet, D; Dakowski, C; Pietri, M; Pradines, E; Bernard, S; Callebert, J; Ardila-Osorio, H; Mouillet-Richard, S; Launay, JM; Kellermann, O; Schneider, B				Loubet, Damien; Dakowski, Caroline; Pietri, Mathea; Pradines, Elodie; Bernard, Sophie; Callebert, Jacques; Ardila-Osorio, Hector; Mouillet-Richard, Sophie; Launay, Jean-Marie; Kellermann, Odile; Schneider, Benoit			Neuritogenesis: the prion protein controls beta 1 integrin signaling activity	FASEB JOURNAL			English	Article						Rho kinase; focal adhesions; actin cytoskeleton; neurite sprouting; neuronal differentiation	FOCAL ADHESION KINASE; NEURITE OUTGROWTH; LIPID RAFTS; TYROSINE PHOSPHORYLATION; NEURONAL POLARIZATION; ACTIN CYTOSKELETON; GENE-EXPRESSION; STRESS FIBERS; RHO FAMILY; DIFFERENTIATION	Cytoskeleton modifications are required for neuronal stem cells to acquire neuronal polarization. Little is known, however, about mechanisms that orchestrate cytoskeleton remodeling along neuritogenesis. Here, we show that the silencing of the cellular prion protein (PrPC) impairs the initial sprouting of neurites upon induction of differentiation of the 1C11 neuroectodermal cell line, indicating that PrPC is necessary to neuritogenesis. Such PrPC function relies on its capacity to negatively regulate the clustering, activation, and signaling activity of beta 1 integrins at the plasma membrane. beta 1 Integrin aggregation caused by PrPC depletion triggers overactivation of the RhoA-Rho kinase-LIMK-cofilin pathway, which, in turn, alters the turnover of focal adhesions, increases the stability of actin microfilaments, and in fine impairs neurite formation. Inhibition of Rho kinases is sufficient to compensate for the lack of PrPC and to restore neurite sprouting. We also observe an increased secretion of fibronectin in the surrounding milieu of PrPC-depleted 1C11 cells, which likely self-sustains beta 1 integrin signaling overactivation and contributes to neuritogenesis defect. Our overall data reveal that PrPC contributes to the acquisition of neuronal polarization by modulating beta 1 integrin activity, cell interaction with fibronectin, and cytoskeleton dynamics.-Loubet, D., Dakowski, C., Pietri, M., Pradines, E., Bernard, S., Callebert, J., Ardila-Osorio, H., Mouillet-Richard, S., Launay, J. M., Kellermann, O., Schneider, B. Neuritogenesis: the prion protein controls beta 1 integrin signaling activity. FASEB J. 26, 678-690 (2012). www.fasebj.org	[Schneider, Benoit] Univ Paris 05, INSERM, UMR S 747, F-75006 Paris, France; [Loubet, Damien; Dakowski, Caroline; Pietri, Mathea; Pradines, Elodie; Ardila-Osorio, Hector; Mouillet-Richard, Sophie; Kellermann, Odile; Schneider, Benoit] INSERM, Unite Mixte Rech Sante UMR S 747, Paris, France; [Bernard, Sophie] CNRS, Unite Mixte Rech UMR 8194, Paris, France; [Bernard, Sophie] Univ Paris 05, UMR 8194, F-75006 Paris, France; [Callebert, Jacques; Launay, Jean-Marie] Hop Lariboisiere, Assistance Publ Hop Paris, Serv Biochim, F-75475 Paris, France; [Launay, Jean-Marie] F Hoffmann La Roche, Pharma Res Dept, Basel, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Roche Holding	Schneider, B (corresponding author), Univ Paris 05, INSERM, UMR S 747, 45 Rue St Peres, F-75006 Paris, France.	benoit.schneider@parisdescartes.fr	Mouillet, Sophie/E-4960-2017; callebert, jacques/L-4569-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; PIETRI, Mathea/0000-0002-1819-2878; ARDILA OSORIO, Hector/0000-0002-1198-6843; Schneider, Benoit/0000-0002-1377-2670	Agence Nationale pour la Recherche; INSERM; La Ligue Nationale Contre le Cancer	Agence Nationale pour la Recherche(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	The authors thank J.-M. Petit (Plateforme d'Imagerie des Saints-Peres, Paris, France) for fluorescence image acquisition and processing. The authors acknowledge M. Briley and S. Blanquet for critical reading of the manuscript. This work was supported by Agence Nationale pour la Recherche and INSERM. D. L. was funded by La Ligue Nationale Contre le Cancer.	Alenghat FJ, 2009, J CELL BIOCHEM, V106, P529, DOI 10.1002/jcb.22001; Andressen C, 2005, EUR J CELL BIOL, V84, P973, DOI 10.1016/j.ejcb.2005.09.017; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Chadi S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-448; Chen ZL, 2009, DEV BIOL, V327, P158, DOI 10.1016/j.ydbio.2008.12.006; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dubash AD, 2007, J CELL SCI, V120, P3989, DOI 10.1242/jcs.003806; Endo M, 2003, J NEUROSCI, V23, P2527; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Gupton SL, 2010, DEV CELL, V18, P725, DOI [10.1016/j.devcel.2010.02.017, 10.1016/j.devce1.2010.02.017]; Hajj GNM, 2009, J COMP NEUROL, V517, P371, DOI 10.1002/cne.22157; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Hynds DL, 2001, J NEUROSCI RES, V66, P630, DOI 10.1002/jnr.10020; Kanaani J, 2005, J NEUROCHEM, V95, P1373, DOI 10.1111/j.1471-4159.2005.03469.x; Kim S, 2010, NAT REV MOL CELL BIO, V11, P75, DOI 10.1038/nrm2818; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lathia JD, 2007, J COMP NEUROL, V505, P630, DOI 10.1002/cne.21520; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lewis V, 2011, FRONT BIOSCI-LANDMRK, V16, P151, DOI 10.2741/3681; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Ma W, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-90; Malaga-Trillo E, 2009, PLOS BIOL, V7, P576, DOI 10.1371/journal.pbio.1000055; Martins VR, 2010, CURR ISSUES MOL BIOL, V12, P63; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mouillet-Richard S, 1999, MICROBES INFECT, V1, P969, DOI 10.1016/S1286-4579(99)80514-0; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Naruse K, 1998, ONCOGENE, V17, P455, DOI 10.1038/sj.onc.1201950; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Pantera B, 2009, J NEUROCHEM, V110, P194, DOI 10.1111/j.1471-4159.2009.06123.x; Park JH, 2011, J CELL PHYSIOL, V226, P267, DOI 10.1002/jcp.22338; Pellegrin S, 2007, J CELL SCI, V120, P3491, DOI 10.1242/jcs.018473; Pietri M, 2006, J BIOL CHEM, V281, P28470, DOI 10.1074/jbc.M602774200; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Robles E, 2006, NAT NEUROSCI, V9, P1274, DOI 10.1038/nn1762; Roman J, 2005, AM J PHYSIOL-LUNG C, V288, pL975, DOI 10.1152/ajplung.00003.2004; Sakudo A, 2007, MICROBIOL IMMUNOL, V51, P1, DOI 10.1111/j.1574-695X.2007.00284.x; Salani B, 2009, BIOCHEM BIOPH RES CO, V380, P489, DOI 10.1016/j.bbrc.2009.01.102; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Seidenfaden R, 2006, NEUROCHEM INT, V49, P1, DOI 10.1016/j.neuint.2005.12.011; Sfakianos MK, 2007, J NEUROSCI, V27, P10982, DOI 10.1523/JNEUROSCI.0793-07.2007; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Steele AD, 2007, PRION, V1, P83, DOI 10.4161/pri.1.2.4346; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Thoumine O, 2008, CELL ADHES MIGR, V2, P263, DOI 10.4161/cam.2.4.7274; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Watts JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000608; Witte H, 2008, J CELL BIOL, V180, P619, DOI 10.1083/jcb.200707042; Witte H, 2008, CURR OPIN NEUROBIOL, V18, P479, DOI 10.1016/j.conb.2008.09.019; Young R, 2009, FEBS LETT, V583, P3296, DOI 10.1016/j.febslet.2009.09.027; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792	64	78	79	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					678	690		10.1096/fj.11-185579	http://dx.doi.org/10.1096/fj.11-185579			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038049				2022-12-28	WOS:000300485700020
J	Dalli, J; Jones, CP; Cavalcanti, DM; Farsky, SH; Perretti, M; Rankin, SM				Dalli, Jesmond; Jones, Carla P.; Cavalcanti, Danielle M.; Farsky, Sandra H.; Perretti, Mauro; Rankin, Sara M.			Annexin A1 regulates neutrophil clearance by macrophages in the mouse bone marrow	FASEB JOURNAL			English	Article						CXCR4; neutrophil homeostasis	APOPTOTIC NEUTROPHILS; DEPENDENT PHAGOCYTOSIS; VITRONECTIN RECEPTOR; GENE-EXPRESSION; IN-VIVO; PHOSPHATIDYLSERINE; CELLS; HETEROGENEITY; GRANULOCYTES; MOBILIZATION	Under homeostatic conditions, a proportion of senescent CXCR4(hi) neutrophils home from the circulation back to the bone marrow, where they are phagocytosed by bone marrow macrophages. In this study, we have identified an unexpected role for the anti-inflammatory molecule annexin A1 (AnxA1) as a critical regulator of this process. We first observed that AnxA1(-/-) mice have significantly increased neutrophil numbers in their bone marrow while having normal levels of GM and G colony-forming units, monocytes, and macrophages. Although AnxA1(-/-) mice have more neutrophils in the bone marrow, a greater proportion of these cells are senescent, as determined by their higher levels of CXCR4 expression and annexin V binding. Consequently, bone marrow neutrophils from AnxA1(-/-) mice exhibit a reduced migratory capacity in vitro. Studies conducted in vitro also show that expression of AnxA1 is required for bone marrow macrophages, but not peritoneal macrophages, to phagocytose apoptotic neutrophils. Moreover, in vivo experiments indicate a defect in clearance of wild-type neutrophils in the bone marrow of AnxA1(-/-) mice. Thus, we conclude that expression of AnxA1 by resident macrophages is a critical determinant for neutrophil clearance in the bone marrow.-Dalli, J., Jones, C. P., Cavalcanti, D. M., Farsky, S. H., Perretti, M., Rankin, S. M. Annexin A1 regulates neutrophil clearance by macrophages in the mouse bone marrow. FASEB J. 26, 387-396 (2012). www.fasebj.org	[Jones, Carla P.; Rankin, Sara M.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England; [Cavalcanti, Danielle M.; Farsky, Sandra H.] Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, Brazil; [Dalli, Jesmond; Cavalcanti, Danielle M.; Perretti, Mauro] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London, England	Imperial College London; Universidade de Sao Paulo; University of London; Queen Mary University London	Rankin, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.rankin@imperial.ac.uk	Farsky, Sandra HP/C-4044-2012	Jones, Carla P/0000-0002-4329-3267; Dalli, Jesmond/0000-0001-6328-3640	Wellcome Trust [086867/Z/08, 0851851/Z/08]; William Harvey Research Foundation; National Institute for Health Research (UK)	Wellcome Trust(Wellcome TrustEuropean Commission); William Harvey Research Foundation; National Institute for Health Research (UK)(National Institute for Health Research (NIHR))	The authors acknowledge the support of the Wellcome Trust (086867/Z/08 and 0851851/Z/08) and the William Harvey Research Foundation. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institute for Health Research (UK). J.D. performed research and collected, analyzed, and interpreted data, and contributed to paper preparation; D. M. C. performed research and collected data; S. F. analyzed and interpreted data; C.J. performed research and collected data; M. P. designed research, analyzed and interpreted data, and contributed to paper preparation; and S. R. designed research, analyzed and interpreted data, and wrote the paper. The authors declare no competing financial interests.	BICKNELL S, 1994, AM J RESP CELL MOL, V10, P16, DOI 10.1165/ajrcmb.10.1.8292377; Bottcher A, 2006, ARTHRITIS RHEUM-US, V54, P927, DOI 10.1002/art.21660; Burdon PCE, 2008, BRIT J HAEMATOL, V142, P100, DOI 10.1111/j.1365-2141.2008.07018.x; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Dalli J, 2008, BLOOD, V112, P2512, DOI 10.1182/blood-2008-02-140533; Damazo AS, 2006, J IMMUNOL, V176, P4410, DOI 10.4049/jimmunol.176.7.4410; Damazo AS, 2005, AM J PATHOL, V166, P1607, DOI 10.1016/S0002-9440(10)62471-6; El Kebir D, 2008, J LEUKOCYTE BIOL, V84, P600, DOI 10.1189/jlb.1107765; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Fox S, 2010, J INNATE IMMUN, V2, P216, DOI 10.1159/000284367; Furze RC, 2008, IMMUNOLOGY, V125, P281, DOI 10.1111/j.1365-2567.2008.02950.x; Furze RC, 2008, FASEB J, V22, P3111, DOI 10.1096/fj.08-109876; Gastardelo TS, 2009, AM J PATHOL, V174, P177, DOI 10.2353/ajpath.2009.080342; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gorgani NN, 2008, IMMUNOL CELL BIOL, V86, P246, DOI 10.1038/sj.icb.7100131; Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; Jitkaew S, 2009, J LEUKOCYTE BIOL, V85, P427, DOI 10.1189/jlb.0408232; Jung T, 2010, METHODS MOL BIOL, V594, P173, DOI 10.1007/978-1-60761-411-1_13; Kamal AM, 2005, MEM I OSWALDO CRUZ, V100, P39, DOI 10.1590/S0074-02762005000900008; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lovas K, 1996, EUR J HAEMATOL, V56, P221; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; McColl A, 2009, J IMMUNOL, V183, P2167, DOI 10.4049/jimmunol.0803503; Nagase H, 2002, J LEUKOCYTE BIOL, V71, P711; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; OSMOND DG, 1994, IMMUNOL REV, V142, P209, DOI 10.1111/j.1600-065X.1994.tb00891.x; Pederzoli-Ribeil M, 2010, BLOOD, V116, P4288, DOI 10.1182/blood-2010-02-270520; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017; Rankin SM, 2010, J LEUKOCYTE BIOL, V88, P241, DOI 10.1189/jlb.0210112; Sadahira Y, 1999, PATHOL INT, V49, P841, DOI 10.1046/j.1440-1827.1999.00954.x; SAVERYMUTTU SH, 1985, BRIT J HAEMATOL, V61, P675, DOI 10.1111/j.1365-2141.1985.tb02882.x; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Scannell M, 2007, J IMMUNOL, V178, P4595, DOI 10.4049/jimmunol.178.7.4595; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Solito E, 2003, FASEB J, V17, P1544, DOI 10.1096/fj.02-0941fje; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Suratt BT, 2001, AM J PHYSIOL-LUNG C, V281, pL913, DOI 10.1152/ajplung.2001.281.4.L913; Takahashi K, 1996, PATHOL INT, V46, P473, DOI 10.1111/j.1440-1827.1996.tb03641.x; THAKUR ML, 1977, J NUCL MED, V18, P1014; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Wolach B, 2007, EXP HEMATOL, V35, P541, DOI 10.1016/j.exphem.2006.12.008; Yona S, 2004, BRIT J PHARMACOL, V142, P890, DOI 10.1038/sj.bjp.0705858; Yona S, 2006, BRIT J PHARMACOL, V148, P469, DOI 10.1038/sj.bjp.0706730	49	57	59	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					387	396		10.1096/fj.11-182089	http://dx.doi.org/10.1096/fj.11-182089			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21957127	Green Published, hybrid			2022-12-28	WOS:000299202200038
J	Kumita, JR; Helmfors, L; Williams, J; Luheshi, LM; Menzer, L; Dumoulin, M; Lomas, DA; Crowther, DC; Dobson, CM; Brorsson, AC				Kumita, Janet R.; Helmfors, Linda; Williams, Jocy; Luheshi, Leila M.; Menzer, Linda; Dumoulin, Mireille; Lomas, David A.; Crowther, Damian C.; Dobson, Christopher M.; Brorsson, Ann-Christin			Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster	FASEB JOURNAL			English	Article						quality control system; ER stress; xbp1-EGFP	HEREDITARY RENAL AMYLOIDOSIS; ENDOPLASMIC-RETICULUM STRESS; CAMELID ANTIBODY FRAGMENT; ALZHEIMERS-DISEASE; GENE-EXPRESSION; FOLDING PROCESS; MODEL; DEGENERATION; STABILITY; FIBRILS	We have created a Drosophila model of lysozyme amyloidosis to investigate the in vivo behavior of disease-associated variants. To achieve this objective, wild-type (WT) protein and the amyloidogenic variants F57I and D67H were expressed in Drosophila melanogaster using the UAS-gal4 system and both the ubiquitous and retinal expression drivers Act5C-gal4 and gmr-gal4. The nontransgenic w(1118) Drosophila line was used as a control throughout. We utilized ELISA experiments to probe lysozyme protein levels, scanning electron microscopy for eye phenotype classification, and immunohistochemistry to detect the unfolded protein response (UPR) activation. We observed that expressing the destabilized F57I and D67H lysozymes triggers UPR activation, resulting in degradation of these variants, whereas the WT lysozyme is secreted into the fly hemolymph. Indeed, the level of WT was up to 17 times more abundant than the variant proteins. In addition, the F57I variant gave rise to a significant disruption of the eye development, and this correlated to pronounced UPR activation. These results support the concept that the onset of familial amyloid disease is linked to an inability of the UPR to degrade completely the amyloidogenic lysozymes prior to secretion, resulting in secretion of these destabilized variants, thereby leading to deposition and associated organ damage.-Kumita, J. R., Helmfors, L., Williams, J., Luheshi, L. M., Menzer, L., Dumoulin, M., Lomas, D. A., Crowther, D. C., Dobson, C. M., Brorsson, A.-C. Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster. FASEB J. 26, 192-202 (2012). www.fasebj.org	[Helmfors, Linda; Brorsson, Ann-Christin] Linkoping Univ, Dept Phys Chem & Biol, Div Mol Biotechnol, SE-58183 Linkoping, Sweden; [Kumita, Janet R.; Luheshi, Leila M.; Dobson, Christopher M.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; [Williams, Jocy] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Crowther, Damian C.] Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; [Menzer, Linda; Dumoulin, Mireille] Univ Liege, Lab Enzymol & Prot Folding, Ctr Prot Engn, Inst Chem B6c, Liege, Belgium; [Lomas, David A.; Crowther, Damian C.] Cambridge Inst Med Res, Cambridge, England	Linkoping University; University of Cambridge; University of Cambridge; University of Cambridge; University of Liege; University of Cambridge	Brorsson, AC (corresponding author), Linkoping Univ, Dept Phys Chem & Biol, Div Mol Biotechnol, SE-58183 Linkoping, Sweden.	anki@ifm.liu.se	Kumita, Janet/AAO-5254-2021		Swedish Research Council; Biotechnology and Biological Sciences Research Council [BB/E019927/1, BBH0038431]; Wellcome Trust; Leverhulme Trust; European Commission [LSHM-CT-2006-037525/EURAMY]; Medical Research Council [G0700990]; VINNOVA; BBSRC [BB/H003843/1] Funding Source: UKRI; MRC [G0700990, G0901786, MC_G1000734] Funding Source: UKRI; Alzheimers Research UK [ART-SRF2010-2] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/H003843/1] Funding Source: researchfish; Medical Research Council [G0901786, MC_G1000734] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust); Leverhulme Trust(Leverhulme Trust); European Commission(European CommissionEuropean Commission Joint Research Centre); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); VINNOVA(Vinnova); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Prof. Bengt-Harald Jonsson for valuable discussions and Mildred Otieno for technical assistance. This work was supported in part by the Swedish Research Council (A.-C.B.) and in part by a grant from the Biotechnology and Biological Sciences Research Council (BB/E019927/1 to C. M. D. and J.R.K.; and BBH0038431 to C. M. D., D. C. C., and D. A. L.), the Wellcome and Leverhulme Trusts (to C. M. D.), and the European Commission (project LSHM-CT-2006-037525/EURAMY to C. M. D. and M. D.). D. C. C. and L. M. L. were supported by the Medical Research Council (G0700990). L. H. is enrolled in the multidisciplinary graduate school Forum Scientium at Linkoping University and in the VINNOVA-supported program AgoraLink. M. D. is a Research Associate of the Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (Belgium), and D. C. C. is an Alzheimer's Research UK Senior Research Fellow.	Berg I, 2009, NEURODEGENER DIS, V6, P127, DOI 10.1159/000213761; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Canet D, 1999, BIOCHEMISTRY-US, V38, P6419, DOI 10.1021/bi983037t; Chamberlain AK, 2001, PROTEIN SCI, V10, P2525, DOI 10.1110/ps.ps.28101; Chan PH, 2008, BIOCHEMISTRY-US, V47, P11041, DOI 10.1021/bi8005797; Crowther DC, 2005, NEUROSCIENCE, V132, P123, DOI 10.1016/j.neuroscience.2004.12.025; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; De Felice FG, 2004, FASEB J, V18, P1099, DOI 10.1096/fj.03-1072fje; Dumoulin M, 2005, J MOL BIOL, V346, P773, DOI 10.1016/j.jmb.2004.11.020; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; Dumoulin M, 2006, ACCOUNTS CHEM RES, V39, P603, DOI 10.1021/ar050070g; Esposito G, 2003, J BIOL CHEM, V278, P25910, DOI 10.1074/jbc.M211000200; Finelli A, 2004, MOL CELL NEUROSCI, V26, P365, DOI 10.1016/j.mcn.2004.03.001; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; Frare E, 2009, J MOL BIOL, V387, P17, DOI 10.1016/j.jmb.2009.01.049; Funahashi J, 1996, J BIOCHEM, V120, P1216; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; Gillmore JD, 1999, NEPHROL DIAL TRANSPL, V14, P2639, DOI 10.1093/ndt/14.11.2639; Green C, 2000, GENETICS, V156, P1117; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; Hagan CL, 2010, PROTEIN ENG DES SEL, V23, P499, DOI 10.1093/protein/gzq023; Hirota-Nakaoka N, 2003, J BIOCHEM, V134, P159, DOI 10.1093/jb/mvg124; HOOKE SD, 1994, BIOCHEMISTRY-US, V33, P5867, DOI 10.1021/bi00185a026; HOOKE SD, 1995, J AM CHEM SOC, V117, P7548, DOI 10.1021/ja00133a030; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Johnson RJK, 2005, J MOL BIOL, V352, P823, DOI 10.1016/j.jmb.2005.07.040; Kumita JR, 2007, J MOL BIOL, V369, P157, DOI 10.1016/j.jmb.2007.02.095; Kumita JR, 2006, FEBS J, V273, P711, DOI 10.1111/j.1742-4658.2005.05099.x; Lee YC, 2002, ANAL BIOCHEM, V310, P223, DOI 10.1016/S0003-2697(02)00320-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; Oberstein A, 2005, NAT METHODS, V2, P583, DOI 10.1038/NMETH775; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Pokrzywa M, 2007, EUR J NEUROSCI, V26, P913, DOI 10.1111/j.1460-9568.2007.05728.x; PORSTMANN B, 1989, CLIN BIOCHEM, V22, P349, DOI 10.1016/S0009-9120(89)80031-1; Rocken Christoph, 2006, Hum Mutat, V27, P119, DOI 10.1002/humu.9393; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Takano K, 2001, EUR J BIOCHEM, V268, P155, DOI 10.1046/j.1432-1327.2001.01863.x; Valleix S, 2002, KIDNEY INT, V61, P907, DOI 10.1046/j.1523-1755.2002.00205.x; Wain R, 2005, J MOL BIOL, V351, P662, DOI 10.1016/j.jmb.2005.06.035; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Whyteside G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022692; Yazaki M, 2003, KIDNEY INT, V63, P1652, DOI 10.1046/j.1523-1755.2003.00904.x; Yerbury JJ, 2009, J BIOL CHEM, V284, P4246, DOI 10.1074/jbc.M807242200	53	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					192	202		10.1096/fj.11-185983	http://dx.doi.org/10.1096/fj.11-185983			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965601	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000299202200020
J	Lund, LM; Kerr, JP; Lupinetti, J; Zhang, YH; Russell, MA; Bloch, RJ; Bond, M				Lund, Linda M.; Kerr, Jaclyn P.; Lupinetti, Jenna; Zhang, Yinghua; Russell, Mary A.; Bloch, Robert J.; Bond, Meredith			Synemin isoforms differentially organize cell junctions and desmin filaments in neonatal cardiomyocytes	FASEB JOURNAL			English	Article						Z disk; sarcolemma; intermediate filaments; rat	HEART-MUSCLE CELLS; CULTURED CARDIAC MYOCYTES; MICE LACKING DESMIN; INTERMEDIATE-FILAMENTS; PROTEIN SYNEMIN; SKELETAL-MUSCLE; AREA COMPOSITA; INTERCALATED DISKS; PLECTIN ISOFORMS; ALPHA-SYNEMIN	Intermediate filaments (IFs) in cardiomyocytes consist primarily of desmin, surround myofibrils at Z disks, and transmit forces from the contracting myofilaments to the cell surface through costameres at the sarcolemma and desmosomes at intercalated disks. Synemin is a type IV IF protein that forms filaments with desmin and also binds alpha-actinin and vinculin. Here we examine the roles and expression of the alpha and beta forms of synemin in developing rat cardiomyocytes. Quantitative PCR showed low levels of expression for both synemin mRNAs, which peaked at postnatal day 7. Synemin was concentrated at sites of cell-cell adhesion and at Z disks in neonatal cardiomyocytes. Overexpression of the individual isoforms showed that alpha-synemin preferentially localized to cell-cell junctions, whereas beta-synemin was primarily at the level of Z disks. An siRNA targeted to both synemin isoforms reduced protein expression in cardiomyocytes by 70% and resulted in a failure of desmin to align with Z disks and disrupted cell-cell junctions, with no effect on sarcomeric organization. Solubility assays showed that beta-synemin was soluble and interacted with sarcomeric alpha-actinin by coimmunoprecipitation, while alpha-synemin and desmin were insoluble. We conclude that beta-synemin mediates the association of desmin IFs with Z disks, whereas alpha-synemin stabilizes junctional complexes between cardiomyocytes.-Lund, L. M., Kerr, J. P., Lupinetti, J., Zhang, Y., Russell, M. A., Bloch, R. J., Bond, M. Synemin isoforms differentially organize cell junctions and desmin filaments in neonatal cardiomyocytes. FASEB J. 26, 137-148 (2012). www.fasebj.org	[Lund, Linda M.; Kerr, Jaclyn P.; Lupinetti, Jenna; Zhang, Yinghua; Bloch, Robert J.; Bond, Meredith] Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; [Russell, Mary A.] Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA	University System of Maryland; University of Maryland Baltimore; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Lund, LM (corresponding author), Univ Maryland, Dept Physiol, Sch Med, 655 W Baltimore St, Baltimore, MD 21201 USA.	llund001@umaryland.edu		Russell, Mary A/0000-0001-5677-8194; Kerr, Jaclyn/0000-0002-1416-276X	U.S. National Institutes of Health [NIH RO1-02520711, NIH RO1 AR055928RO1]; Muscular Dystrophy Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055928] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Shirley Gaa and Dr. Terry B. Rogers for preparations of cardiomyocytes, Gloria Vives-Rodriguez for technical assistance, and Maureen O'Donnell for help with TaqMan assays and data analysis. This work was supported by U.S. National Institutes of Health grants NIH RO1-02520711 (to M.B.) and NIH RO1 AR055928RO1 (to R.J.B.) and by The Muscular Dystrophy Association (R.J.B.).	BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bhosle RC, 2006, BIOCHEM BIOPH RES CO, V346, P768, DOI 10.1016/j.bbrc.2006.05.192; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; Capetanaki Y, 2007, EXP CELL RES, V313, P2063, DOI 10.1016/j.yexcr.2007.03.033; Franke WW, 2007, EUR J CELL BIOL, V86, P127, DOI 10.1016/j.ejcb.2006.11.003; Franke WW, 2006, EUR J CELL BIOL, V85, P69, DOI 10.1016/j.ejcb.2005.11.003; Fuchs P, 1999, HUM MOL GENET, V8, P2461, DOI 10.1093/hmg/8.13.2461; GONCHAROVA EJ, 1992, DEVELOPMENT, V114, P173; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; Herrmann H, 2003, CELL MOL LIFE SCI, V60, P1607, DOI 10.1007/s00018-003-3004-0; Hijikata T, 2008, J CELL SCI, V121, P2062, DOI 10.1242/jcs.021634; Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2; Izmiryan A, 2010, NEUROCHEM RES, V35, P881, DOI 10.1007/s11064-009-0111-9; Izmiryan A, 2009, EXP CELL RES, V315, P769, DOI 10.1016/j.yexcr.2008.12.009; Jing RF, 2005, GLIA, V50, P107, DOI 10.1002/glia.20158; Jing RF, 2007, J CELL SCI, V120, P1267, DOI 10.1242/jcs.03423; Khanamiryan L, 2008, BIOCHEMISTRY-US, V47, P9531, DOI 10.1021/bi800912w; Kim HD, 1996, ANAT RECORD, V246, P271, DOI 10.1002/(SICI)1097-0185(199610)246:2<271::AID-AR13>3.0.CO;2-L; Konieczny P, 2008, J CELL BIOL, V181, P667, DOI 10.1083/jcb.200711058; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Lovering RM, 2011, AM J PHYSIOL-CELL PH, V300, pC803, DOI 10.1152/ajpcell.00394.2010; LU MH, 1992, J CELL BIOL, V117, P1007, DOI 10.1083/jcb.117.5.1007; Luo Y, 2003, J CELL SCI, V116, P1471, DOI 10.1242/jcs.00339; Milner DJ, 1999, J MOL CELL CARDIOL, V31, P2063, DOI 10.1006/jmcc.1999.1037; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Mizuno Y, 2004, MUSCLE NERVE, V30, P337, DOI 10.1002/mus.20111; Mizuno Y, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-8; O'Neill A, 2002, MOL BIOL CELL, V13, P2347, DOI 10.1091/mbc.01-12-0576; Pieperhoff S, 2010, EUR J CELL BIOL, V89, P365, DOI 10.1016/j.ejcb.2009.11.025; Rezniczek GA, 2003, HUM MOL GENET, V12, P3181, DOI 10.1093/hmg/ddg345; Russell MA, 2006, ARCH BIOCHEM BIOPHYS, V456, P204, DOI 10.1016/j.abb.2006.06.010; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; Shiraishi I, 1997, J MOL CELL CARDIOL, V29, P2041, DOI 10.1006/jmcc.1997.0438; SMOLICH JJ, 1995, REPROD FERT DEVELOP, V7, P451, DOI 10.1071/RD9950451; Sun N, 2008, EXP CELL RES, V314, P1839, DOI 10.1016/j.yexcr.2008.01.034; Sun N, 2008, BIOCHEM J, V409, P657, DOI 10.1042/BJ20071188; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; Tokuyasu D., 1985, ANN NY ACAD SCI, V455, P200; TOKUYASU KT, 1983, J CELL BIOL, V96, P1727, DOI 10.1083/jcb.96.6.1727; TOKUYASU KT, 1983, J CELL BIOL, V96, P1736, DOI 10.1083/jcb.96.6.1736; Ursitti JA, 2004, J BIOL CHEM, V279, P41830, DOI 10.1074/jbc.M400128200; Uyama N, 2006, GUT, V55, P1276, DOI 10.1136/gut.2005.078865; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wright G, 2002, AM J PHYSIOL-HEART C, V282, pH872, DOI 10.1152/ajpheart.00256.2001	48	12	12	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					137	148		10.1096/fj.10-179408	http://dx.doi.org/10.1096/fj.10-179408			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21982947	Green Published			2022-12-28	WOS:000299202200015
J	Momken, I; Stevens, L; Bergouignan, A; Desplanches, D; Rudwill, F; Chery, I; Zahariev, A; Zahn, S; Stein, TP; Sebedio, JL; Pujos-Guillot, E; Falempin, M; Simon, C; Coxam, V; Andrianjafiniony, T; Gauquelin-Koch, G; Picquet, F; Blanc, S				Momken, Iman; Stevens, Laurence; Bergouignan, Audrey; Desplanches, Dominique; Rudwill, Floriane; Chery, Isabelle; Zahariev, Alexandre; Zahn, Sandrine; Stein, T. Peter; Sebedio, Jean Louis; Pujos-Guillot, Estelle; Falempin, Maurice; Simon, Chantal; Coxam, Veronique; Andrianjafiniony, Tany; Gauquelin-Koch, Guillemette; Picquet, Florence; Blanc, Stephane			Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat	FASEB JOURNAL			English	Article						sedentary behavior; polyphenol; spaceflight; weightlessness	HUMAN SKELETAL-MUSCLE; BED-REST; OXIDATIVE STRESS; SOLEUS MUSCLE; SPACE-FLIGHT; ENERGY-EXPENDITURE; INSULIN-RESISTANCE; PROTEIN-SYNTHESIS; VITAMIN-E; GASTROCNEMIUS-MUSCLES	Long-term spaceflight induces hypokinesia and hypodynamia, which, along microgravity per se, result in a number of significant physiological alterations, such as muscle atrophy, force reduction, insulin resistance, substrate use shift from fats to carbohydrates, and bone loss. Each of these adaptations could turn to serious health deterioration during the longterm spaceflight needed for planetary exploration. We hypothesized that resveratrol (RES), a natural polyphenol, could be used as a nutritional countermeasure to prevent muscle metabolic and bone adaptations to 15 d of rat hindlimb unloading. RES treatment maintained a net protein balance, soleus muscle mass, and soleus muscle maximal force contraction. RES also fully maintained soleus mitochondrial capacity to oxidize palmitoyl-carnitine and reversed the decrease of the glutathione vs. glutathione disulfide ratio, a biomarker of oxidative stress. At the molecular level, the protein content of Sirt-1 and COXIV in soleus muscle was also preserved. RES further protected whole-body insulin sensitivity and lipid trafficking and oxidation, and this was likely associated with the maintained expression of FAT/CD36, CPT-1, and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) in muscle. Finally, chronic RES supplementation maintained the bone mineral density and strength of the femur. For the first time, we report a simple countermeasure that prevents the deleterious adaptations of the major physiological functions affected by mechanical unloading. RES could thus be envisaged as a nutritional countermeasure for spaceflight but remains to be tested in humans.-Momken, I., Stevens, L., Bergouignan, A., Desplanches, D., Rudwill, F., Chery, I., Zahariev, A., Zahn, S., Stein, T. P., Sebedio, J. L., Pujos-Guillot, E., Falempin, M., Simon, C., Coxam, V., Andrianjafiniony, T., Gauquelin-Koch, G., Picquet, F., Blanc, S. Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat. FASEB J. 25, 3646-3660 (2011). www.fasebj.org	[Momken, Iman; Bergouignan, Audrey; Rudwill, Floriane; Chery, Isabelle; Zahariev, Alexandre; Zahn, Sandrine; Blanc, Stephane] Univ Strasbourg, CNRS, IPHC, UMR 7178, Strasbourg, France; [Stevens, Laurence; Falempin, Maurice; Picquet, Florence] Univ Lille 1, Lab Activite Phys Muscle & Sante, Lille, France; [Desplanches, Dominique; Andrianjafiniony, Tany] Univ Lyon 1, CNRS, UMR 5534, F-69622 Villeurbanne, France; [Stein, T. Peter] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA; [Sebedio, Jean Louis; Pujos-Guillot, Estelle] Univ Auvergne, UMR 1019, INRA, Clermont Ferrand, France; [Simon, Chantal] Fac Med Lyon Sud, INSERM, U870, INRA 1235, Lyon, France; [Coxam, Veronique] UMR 1019 Alimentat Squelette & Metab, Unite Nutr Humaine, St Genes Champanelle, France; [Gauquelin-Koch, Guillemette] CNES, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Rutgers State University New Brunswick; Rutgers State University Medical Center; INRAE; Universite Clermont Auvergne (UCA); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm)	Blanc, S (corresponding author), CNRS 7178, IPHC, Dept Ecol, 23 Rue Becquerel, F-67087 Strasbourg, France.	stephane.blanc@iphc.cnrs.fr	Stein, T. Peter/R-4244-2019; , simon/B-2895-2011; Bergouignan, Audrey/A-2750-2016	, simon/0000-0002-7820-3233; Bergouignan, Audrey/0000-0002-1266-5144; PUJOS-GUILLOT, Estelle/0000-0002-4693-5712	National Centre of French Space Study (CNES)	National Centre of French Space Study (CNES)(Centre National D'etudes Spatiales)	This work was supported by the National Centre of French Space Study (CNES) and a research fellowship to I. M. The authors appreciate the great help and guidance of Dr. Anne Garnier for RT-qPCR quantification and analysis. The authors thank Steven Wingling and Cedric Falter for their technical assistance. The authors also thank Antoine Stier and Celine Bret for their involvement in the cardiovascular tests as part of their bachelor of sciences degree.	ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BALDWIN KM, 1993, J APPL PHYSIOL, V75, P2466, DOI 10.1152/jappl.1993.75.6.2466; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Belavy DL, 2011, OSTEOPOROSIS INT, V22, P1581, DOI 10.1007/s00198-010-1371-6; Bergouignan A, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010027; Bergouignan A, 2010, J CLIN ENDOCR METAB, V95, P1045, DOI 10.1210/jc.2009-1005; Bergouignan A, 2009, DIABETES, V58, P367, DOI 10.2337/db08-0263; Blanc S, 2002, COMP BIOCHEM PHYS A, V131, P683, DOI 10.1016/S1095-6433(01)00519-0; Blanc S, 2000, AM J PHYSIOL-REG I, V279, pR1964, DOI 10.1152/ajpregu.2000.279.6.R1964; Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008-5472.CAN-05-0651; Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cavanagh Peter R, 2005, Gravit Space Biol Bull, V18, P39; CHEN H, 1995, FREE RADICAL RES, V22, P177, DOI 10.3109/10715769509147537; CONCON JM, 1973, ANAL BIOCHEM, V53, P35, DOI 10.1016/0003-2697(73)90405-3; Csiszar A, 2009, AM J PHYSIOL-HEART C, V297, pH13, DOI 10.1152/ajpheart.00368.2009; Csukly K, 2005, EUR J APPL PHYSIOL, V95, P243, DOI 10.1007/s00421-005-1391-7; Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003; Falempin M, 1997, MUSCLE NERVE, V20, P172; Falempin M, 1999, J APPL PHYSIOL, V87, P3, DOI 10.1152/jappl.1999.87.1.3; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fitts RH, 2007, AM J PHYSIOL-CELL PH, V293, pC313, DOI 10.1152/ajpcell.00573.2006; Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823; Fortney SM, 1998, AVIAT SPACE ENVIR MD, V69, P137; Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Giroud S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008823; Gleeson M, 2000, J PHYSIOL-LONDON, V529, P1, DOI 10.1111/j.1469-7793.2000.00001.x; GOLDSPINK DF, 1986, PFLUG ARCH EUR J PHY, V407, P333, DOI 10.1007/BF00585311; GREENLEAF JE, 1989, J APPL PHYSIOL, V67, P507, DOI 10.1152/jappl.1989.67.2.507; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Heer M, 2002, NUTRITION, V18, P853, DOI 10.1016/S0899-9007(02)00905-X; Helge JW, 2003, J PHYSIOL-LONDON, V546, P299, DOI 10.1113/jphysiol.2002.030437; Hilder TL, 2005, J APPL PHYSIOL, V99, P2181, DOI 10.1152/japplphysiol.00743.2005; HOWELL RR, 1961, J CLIN INVEST, V40, P2076, DOI 10.1172/JCI104433; Iwamoto Jun, 2005, Keio Journal of Medicine, V54, P55, DOI 10.2302/kjm.54.55; Jackson JR, 2010, AM J PHYSIOL-REG I, V299, pR1572, DOI 10.1152/ajpregu.00489.2010; JASPERS SR, 1986, MUSCLE NERVE, V9, P554, DOI 10.1002/mus.880090613; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; KONDO H, 1993, AM J PHYSIOL, V265, pE839, DOI 10.1152/ajpendo.1993.265.6.E839; la Porte C, 2010, CLIN PHARMACOKINET, V49, P449, DOI 10.2165/11531820-000000000-00000; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307; Lawler JM, 2003, FREE RADICAL BIO MED, V35, P9, DOI 10.1016/S0891-5849(03)00186-2; LEBLANC A, 1992, ACTA ASTRONAUT, V27, P89, DOI 10.1016/0094-5765(92)90182-I; LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33; Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105; Lew PS, 2009, CAN J PHYSIOL PHARM, V87, P839, DOI 10.1139/Y09-074; MACHO L, 1992, ACTA ASTRONAUT, V27, P51, DOI 10.1016/0094-5765(92)90175-I; Morey E R, 1979, Physiologist, V22, pS23; Morris CA, 2005, J APPL PHYSIOL, V99, P1719, DOI 10.1152/japplphysiol.01419.2004; Muller FL, 2008, BIOCHEM J, V409, P491, DOI 10.1042/BJ20071162; Murase T, 2009, BIOGERONTOLOGY, V10, P423, DOI 10.1007/s10522-008-9177-z; Paddon-Jones D, 2004, AM J PHYSIOL-ENDOC M, V286, pE321, DOI 10.1152/ajpendo.00368.2003; Paddon-Jones D, 2006, J CLIN ENDOCR METAB, V91, P4836, DOI 10.1210/jc.2006-0651; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Picquet F, 2003, EXP NEUROL, V182, P186, DOI 10.1016/S0014-4886(03)00111-0; PIERCE S, 1978, BIOCHIM BIOPHYS ACTA, V523, P27, DOI 10.1016/0005-2744(78)90005-0; RACETTE SB, 1994, AM J PHYSIOL-ENDOC M, V267, pE585, DOI 10.1152/ajpendo.1994.267.4.E585; Rathbone CR, 2009, EUR J CELL BIOL, V88, P35, DOI 10.1016/j.ejcb.2008.08.003; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Ryan MJ, 2010, J GERONTOL A-BIOL, V65, P815, DOI 10.1093/gerona/glq080; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; SANTIDRIAN S, 1981, METABOLISM, V30, P798, DOI 10.1016/0026-0495(81)90026-3; Servais S, 2007, FREE RADICAL BIO MED, V42, P627, DOI 10.1016/j.freeradbiomed.2006.12.001; SHANGRAW RE, 1988, AM J PHYSIOL, V255, pE548, DOI 10.1152/ajpendo.1988.255.4.E548; Smith BJ, 2005, CALCIFIED TISSUE INT, V76, P272, DOI 10.1007/s00223-004-0269-8; Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105; SOUTHORN BG, 1990, BIOCHEM J, V272, P187, DOI 10.1042/bj2720187; Stein T P, 2002, J Gravit Physiol, V9, pP165; Stein T P, 1999, J Gravit Physiol, V6, pP85; Stein TP, 2005, J NUTR, V135, p1824S, DOI 10.1093/jn/135.7.1824S; Stein TP, 2002, J NUTR BIOCHEM, V13, P471, DOI 10.1016/S0955-2863(02)00195-X; STEIN TP, 1994, AVIAT SPACE ENVIR MD, V65, P1091; STUART CA, 1993, EXP TOXICOL PATHOL, V45, P291; STUART CA, 1988, METABOLISM, V37, P802, DOI 10.1016/0026-0495(88)90018-2; Supornsilchai V, 2005, HORM RES, V64, P280, DOI 10.1159/000089487; Trappe S, 2008, AM J PHYSIOL-REG I, V294, pR939, DOI 10.1152/ajpregu.00761.2007; Trappe S, 2009, J APPL PHYSIOL, V106, P1159, DOI 10.1152/japplphysiol.91578.2008; Ungvari Z, 2009, AM J PHYSIOL-HEART C, V297, pH1876, DOI 10.1152/ajpheart.00375.2009; VEKSLER V, 1994, MOL CELL BIOCHEM, V133, P287, DOI 10.1007/BF01267961; Williams LD, 2009, FOOD CHEM TOXICOL, V47, P2170, DOI 10.1016/j.fct.2009.06.002; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; YAMASHITA H, 1995, J APPL PHYSIOL, V78, P384, DOI 10.1152/jappl.1995.78.2.384; Yimlamai T, 2005, J APPL PHYSIOL, V99, P71, DOI 10.1152/japplphysiol.00448.2004; Zange J, 2009, EUR J APPL PHYSIOL, V105, P271, DOI 10.1007/s00421-008-0899-z	87	132	136	0	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3646	3660		10.1096/fj.10-177295	http://dx.doi.org/10.1096/fj.10-177295			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21715682				2022-12-28	WOS:000295356400034
J	Schulz, P; Fischer, C; Detjen, KM; Rieke, S; Hilfenhaus, G; von Marschall, Z; Bohmig, M; Koch, I; Kehrberger, J; Hauff, P; Thierauch, KH; Alves, F; Wiedenmann, B; Scholz, A				Schulz, Petra; Fischer, Christian; Detjen, Katharina M.; Rieke, Svenja; Hilfenhaus, Georg; von Marschall, Zofia; Boehmig, Michael; Koch, Inga; Kehrberger, Jenny; Hauff, Peter; Thierauch, Karl Heinz; Alves, Frauke; Wiedenmann, Bertram; Scholz, Arne			Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer	FASEB JOURNAL			English	Article						lymphangiogenesis; animal model; orthotopic	PHASE-III TRIAL; TUMOR ANGIOGENESIS; DIFFERENTIAL EXPRESSION; SERUM ANGIOPOIETIN-2; DISEASE PROGRESSION; ENDOTHELIAL-CELLS; IN-VIVO; GROWTH; RECEPTOR; COMBINATION	Lymphatic metastasis constitutes a critical route of disease dissemination, which limits the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). As lymphangiogenesis has been implicated in stimulation of lymphatic metastasis by vascular endothelial growth factor-C (VEGF-C) and VEGF-D, we studied the effect of the angioregulatory growth factor angiopoietin-2 (Ang-2) on PDAC progression. Ang-2 was found to be expressed in transformed cells of human PDAC specimens, with corresponding Tie-2 receptors present on blood and lymphatic endothelium. In vitro in PDAC cells, Ang-2 was subject to autocrine/paracrine TGF-beta stimulation (2-fold induction, P=0.0106) acting on the -61- to +476-bp element of the human Ang-2 promoter. In turn, Ang-2 regulated the expression of genes involved in cell motility and tumor suppression. Orthotopic PDAC xenografts with forced expression of Ang-2, but not Ang-1, displayed increased blood and lymphatic vessel density, and an enhanced rate of lymphatic metastasis (6.7- to 9.1-fold, P<0.01), which was prevented by sequestration of Ang-2 via coexpression of soluble Tie-2. Notably, elevated circulating Ang-2 in patients with PDAC correlated with the extent of lymphatic metastasis. Furthermore, median survival was reduced from 28.4 to 7.7 mo in patients with circulating Ang-2 >= 75th percentile (P=0.0005). These findings indicate that Ang-2 participates in the control of lymphatic metastasis, constitutes a noninvasive prognostic biomarker, and may provide an accessible therapeutic target in PDAC.-Schulz, P., Fischer, C., Detjen, K. M., Rieke, S., Hilfenhaus, G., von Marschall, Z., Bohmig, M., Koch, I., Kehrberger, J., Hauff, P., Thierauch, K.-H., Alves, F., Wiedenmann, B., Scholz, A. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J. 25, 3325-3335 (2011). www.fasebj.org	[Schulz, Petra; Fischer, Christian; Detjen, Katharina M.; Rieke, Svenja; Hilfenhaus, Georg; von Marschall, Zofia; Boehmig, Michael; Koch, Inga; Kehrberger, Jenny; Wiedenmann, Bertram; Scholz, Arne] Charite, Campus Virchow Klinikum, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; [Fischer, Christian; Detjen, Katharina M.; Hilfenhaus, Georg] Charite, Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Hauff, Peter; Thierauch, Karl Heinz] Bayer Schering Pharma AG, Global Drug Discovery, Berlin, Germany; [Alves, Frauke] Univ Gottingen, Klin Hamatol & Onkol, Gottingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Bayer AG; Bayer Healthcare Pharmaceuticals; University of Gottingen	Detjen, KM (corresponding author), Charite, Campus Virchow Klinikum, Med Klin Schwerpunkt Hepatol & Gastroenterol, Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.detjen@charite.de		Hilfenhaus, Georg/0000-0001-8764-077X; Wiedenmann, Bertram/0000-0002-7890-2552	Deutsche Forschungsgemeinschaft (DFG); Experimental and Clinical Research Center (Charite-Universitatsmedizin, Berlin, Germany); Speidel scholarship; Sonnenfeld Stiftung; Muggenburg Stiftung	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Experimental and Clinical Research Center (Charite-Universitatsmedizin, Berlin, Germany); Speidel scholarship; Sonnenfeld Stiftung; Muggenburg Stiftung	A.S. was supported by a grant from Deutsche Forschungsgemeinschaft (DFG), P.S. was supported by a DFG scholarship, C.F. was supported by a grant from the Experimental and Clinical Research Center (Charite-Universitatsmedizin, Berlin, Germany), G.H. was supported by a Speidel scholarship, and K.M.D. and B.W. were supported by Sonnenfeld Stiftung and Muggenburg Stiftung. The authors thank Annett Rexin, Nicole Thiele, and Martina Welzel for expert technical support. This work was designed and initiated by Prof. Stefan Rosewicz (August 13, 1960 to May 20, 2004).	Ahmad SA, 2001, CANCER RES, V61, P1255; Audero E, 2001, ARTERIOSCL THROM VAS, V21, P536, DOI 10.1161/01.ATV.21.4.536; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Brown JL, 2010, MOL CANCER THER, V9, P145, DOI 10.1158/1535-7163.MCT-09-0554; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Chen XY, 2009, NEUROSCI RES, V64, P348, DOI 10.1016/j.neures.2009.04.007; Detjen KM, 2010, CLIN CANCER RES, V16, P420, DOI 10.1158/1078-0432.CCR-09-1924; Durkin AJ, 2004, J AM COLL SURGEONS, V199, P724, DOI 10.1016/j.jamcollsurg.2004.07.021; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004; Fischer C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Hashizume H, 2010, CANCER RES, V70, P2213, DOI 10.1158/0008-5472.CAN-09-1977; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Helfrich I, 2009, CLIN CANCER RES, V15, P1384, DOI 10.1158/1078-0432.CCR-08-1615; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Jo MJ, 2009, ANN SURG ONCOL, V16, P2052, DOI 10.1245/s10434-009-0474-9; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Karlan BY, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.5000; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Koch M, 2009, J PATHOL, V219, P356, DOI 10.1002/path.2605; Kumpers P, 2008, BLOOD, V112, P2139, DOI 10.1182/blood-2007-12-130021; Kurahara H, 2004, CLIN CANCER RES, V10, P8413, DOI 10.1158/1078-0432.CCR-04-0379; Lee OH, 2006, NEOPLASIA, V8, P419, DOI 10.1593/neo.06109; Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684; Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019; Mita AC, 2010, CLIN CANCER RES, V16, P3044, DOI 10.1158/1078-0432.CCR-09-3368; Morrissey C, 2008, CLIN EXP METASTAS, V25, P377, DOI 10.1007/s10585-007-9116-4; Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030; Park JH, 2007, CHEST, V132, P200, DOI 10.1378/chest.06-2915; Reiss Y, 2009, J PATHOL, V217, P571, DOI 10.1002/path.2484; Sarraf-Yazdi S, 2008, J SURG RES, V146, P16, DOI 10.1016/j.jss.2007.04.028; Schulz P, 2008, BRIT J CANCER, V99, P110, DOI 10.1038/sj.bjc.6604457; Seraj MJ, 2000, CANCER RES, V60, P2764; Sfiligoi C, 2003, INT J CANCER, V103, P466, DOI 10.1002/ijc.10851; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558; Smith RA, 2008, DIGEST SURG, V25, P226, DOI 10.1159/000140961; Sotgia F, 2006, AM J PATHOL, V168, P292, DOI 10.2353/ajpath.2006.050429; Stoeltzing O, 2003, CANCER RES, V63, P3370; Stoeltzing O, 2002, BRIT J CANCER, V87, P1182, DOI 10.1038/sj.bjc.6600598; Stratmann A, 2001, INT J CANCER, V91, P273, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q; Tian S, 2002, BRIT J CANCER, V86, P645, DOI 10.1038/sj.bjc.6600082; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; Villeneuve J, 2008, BRAIN PATHOL, V18, P401, DOI 10.1111/j.1750-3639.2008.00139.x; Von Marschall Z, 2005, INT J ONCOL, V27, P669; Wang J, 2005, BIOCHEM BIOPH RES CO, V337, P386, DOI 10.1016/j.bbrc.2005.09.051; Yoshiji H, 2005, GUT, V54, P1768, DOI 10.1136/gut.2005.067900; Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08	53	50	53	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3325	3335		10.1096/fj.11-182287	http://dx.doi.org/10.1096/fj.11-182287			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21685330				2022-12-28	WOS:000295356400005
J	Bussolati, B; Grange, C; Camussi, G				Bussolati, Benedetta; Grange, Cristina; Camussi, Giovanni			Tumor exploits alternative strategies to achieve vascularization	FASEB JOURNAL			English	Review						angiogenesis; vasculogenesis; exosomes; antiangiogenic therapy	MICROVASCULAR ENDOTHELIAL-CELLS; BONE-MARROW; HORIZONTAL TRANSFER; GENE-EXPRESSION; MESSENGER-RNA; MULTIPLE-MYELOMA; DOWN-REGULATION; IN-VIVO; MICROVESICLES; ANGIOGENESIS	Neoangiogenesis is crucial for solid tumor growth and invasion, as the vasculature provides metabolic support and access to the circulation. Current antiangiogenic therapies have been designed on the assumption that endothelial cells forming the tumor vasculature exhibit genetic stability. Recent studies demonstrate that this is not the case. Tumor endothelial cells possess a distinct phenotype, differing from normal endothelial cells at both molecular and functional levels. This challenges the concept that tumor angiogenesis exclusively depends on normal endothelial cell recruitment from the surrounding vascular network. Indeed, recent data suggest alternative strategies for tumor vascularization. It has been reported that tumor vessels may derive from an intratumor embryonic-like vasculogenesis. This condition might be due to differentiation of normal stem and progenitor cells of hematopoietic origin or resident in tissues. Cancer stem cells may also participate in tumor vasculogenesis by virtue of their stem and progenitor cell properties. Finally, normal endothelial cells might be reprogrammed to a proangiogenic or dedifferentiated phenotype by genetic information transmitted from the tumor trough apoptotic bodies, or following mRNA and microRNA transfer by exosomes and microvesicles. In this review, we discuss the different aspects of intratumor angiogenesis and vasculogenesis, the known mechanisms involved, and the possible implications for the response to antiangiogenic therapy.-Bussolati, B., Grange, C., Camussi, G. Tumor exploits alternative strategies to achieve vascularization. FASEB J. 25, 2874-2882 (2011). www.fasebj.org	[Camussi, Giovanni] Univ Turin, Res Ctr Expt Med, Dept Internal Med, I-10126 Turin, Italy; Univ Turin, Ctr Mol Biotechnol, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy	University of Turin; University of Turin	Camussi, G (corresponding author), Univ Turin, Res Ctr Expt Med, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Camussi, Giovanni/J-7624-2016; Bussolati, Benedetta/AAA-9058-2022	Camussi, Giovanni/0000-0003-2795-232X; Bussolati, Benedetta/0000-0002-3663-5134; GRANGE, CRISTINA/0000-0002-6960-5476	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG8912]; Italian Ministry of University and Research (MIUR) [Prin08]; Regione Piemonte; Nano-IgT; Piattaforme Biotecnologiche; Pi-Stem project	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Regione Piemonte(Regione Piemonte); Nano-IgT; Piattaforme Biotecnologiche; Pi-Stem project	The authors thank Dr. Justin Mason (Imperial College, London, UK) for the helpful suggestions and Danilo Bozzetto for art graphics. This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), project IG8912; by the Italian Ministry of University and Research (MIUR), Prin08; and by Regione Piemonte, Nano-IgT, and Piattaforme Biotecnologiche, Pi-Stem project.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Akino T, 2009, AM J PATHOL, V175, P2657, DOI 10.2353/ajpath.2009.090202; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Amin DN, 2006, CANCER RES, V66, P2173, DOI 10.1158/0008-5472.CAN-05-3387; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9; Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Bussolati B, 2006, EXP CELL RES, V312, P913, DOI 10.1016/j.yexcr.2005.12.004; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Bussolati B, 2006, J MOL MED-JMM, V84, P852, DOI 10.1007/s00109-006-0075-z; Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x; Calzi SL, 2010, MICROVASC RES, V79, P207, DOI 10.1016/j.mvr.2010.02.011; Camussi G, 2011, AM J CANCER RES, V1, P98; Castellana D, 2009, CANCER RES, V69, P785, DOI 10.1158/0008-5472.CAN-08-1946; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; Collino F, 2009, EXP CELL RES, V315, P2982, DOI 10.1016/j.yexcr.2009.06.010; De Bock K, 2011, CURR OPIN GENET DEV, V21, P73, DOI 10.1016/j.gde.2010.10.008; Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709; Dudley AC, 2010, BLOOD, V116, P3367, DOI 10.1182/blood-2010-02-271122; Dudley AC, 2009, CELL CYCLE, V8, P236, DOI 10.4161/cc.8.2.7413; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; El Hallani S, 2010, BRAIN, V133, P973, DOI 10.1093/brain/awq044; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fonsato V, 2006, AM J PATHOL, V168, P706, DOI 10.2353/ajpath.2006.050776; Fonsato V, 2008, BLOOD, V111, P2806, DOI 10.1182/blood-2007-04-085555; Grange C, 2006, ONCOL REP, V15, P381; Gunsilius E, 2000, LANCET, V355, P1688, DOI 10.1016/S0140-6736(00)02241-8; Hida K, 2005, CANCER RES, V65, P2507, DOI 10.1158/0008-5472.CAN-05-0002; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hida K, 2008, CANCER SCI, V99, P459, DOI 10.1111/j.1349-7006.2007.00704.x; Hill PA, 2010, PATHOLOGY, V42, P479, DOI 10.3109/00313025.2010.494284; Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556; Kim CW, 2002, CANCER RES, V62, P6312; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Kurosu T, 2011, BRIT J CANCER, V104, P819, DOI 10.1038/bjc.2011.20; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Mangieri D, 2008, J CELL MOL MED, V12, P1023, DOI 10.1111/j.1582-4934.2008.00152.x; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marhaba R, 2008, CURR MOL MED, V8, P784, DOI 10.2174/156652408786733667; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Miebach S, 2006, J NEURO-ONCOL, V76, P39, DOI 10.1007/s11060-005-3674-6; Millimaggi D, 2007, NEOPLASIA, V9, P349, DOI 10.1593/neo.07133; Muralidharan-Chari V, 2010, J CELL SCI, V123, P1603, DOI 10.1242/jcs.064386; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Narayana A, 2009, J NEUROSURG, V110, P173, DOI 10.3171/2008.4.17492; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976; Patenaude A, 2010, MICROVASC RES, V79, P217, DOI 10.1016/j.mvr.2010.01.007; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Pezzolo A, 2011, CELL RES, V21, P1470, DOI 10.1038/cr.2011.38; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; RIBATTI D, 2010, J ANGIOGENES RES, V10, P2; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rigolin GM, 2006, BLOOD, V107, P2531, DOI 10.1182/blood-2005-04-1768; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Sheldon H, 2010, BLOOD, V116, P2385, DOI 10.1182/blood-2009-08-239228; Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; St Croix B, 2000, SCIENCE, V289, P1197; Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Virrey JJ, 2009, J NEURO-ONCOL, V95, P13, DOI 10.1007/s11060-009-9891-7; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wysoczynski M, 2009, INT J CANCER, V125, P1595, DOI 10.1002/ijc.24479; Xiong YQ, 2009, CLIN CANCER RES, V15, P4838, DOI 10.1158/1078-0432.CCR-08-2780; Yao XH, 2011, PROTEIN CELL, V2, P266, DOI 10.1007/s13238-011-1041-2; Zambidis ET, 2007, ANN NY ACAD SCI, V1106, P223, DOI 10.1196/annals.1392.010	89	72	73	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2874	2882		10.1096/fj.10-180323	http://dx.doi.org/10.1096/fj.10-180323			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21628445				2022-12-28	WOS:000294435200004
J	Wei, L; Salahura, G; Boncompagni, S; Kasischke, KA; Protasi, F; Sheu, SS; Dirksen, RT				Wei, Lan; Salahura, Gheorghe; Boncompagni, Simona; Kasischke, Karl A.; Protasi, Feliciano; Sheu, Shey-Shing; Dirksen, Robert T.			Mitochondrial superoxide flashes: metabolic biomarkers of skeletal muscle activity and disease	FASEB JOURNAL			English	Article						excitation-contraction coupling; reactive oxygen species; electron transport chain; permeability transition pore; adenine nucleotide translocase	PERMEABILITY TRANSITION; REACTIVE OXYGEN; CYCLOPHILIN-D; OXIDATIVE STRESS; CA2+ RELEASE; DYNAMICS; CALCIUM; DEATH	Mitochondrial superoxide flashes (mSOFs) are stochastic events of quantal mitochondrial superoxide generation. Here, we used flexor digitorum brevis muscle fibers from transgenic mice with muscle-specific expression of a novel mitochondrial-targeted superoxide biosensor (mt-cpYFP) to characterize mSOF activity in skeletal muscle at rest, following intense activity, and under pathological conditions. Results demonstrate that mSOF activity in muscle depended on electron transport chain and adenine nucleotide translocase functionality, but it was independent of cyclophilin-D-mediated mitochondrial permeability transition pore activity. The diverse spatial dimensions of individual mSOF events were found to reflect a complex underlying morphology of the mitochondrial network, as examined by electron microscopy. Muscle activity regulated mSOF activity in a biphasic manner. Specifically, mSOF frequency was significantly increased following brief tetanic stimulation (18.1 +/- 1.6 to 22.3 +/- 2.0 flashes/1000 mu m(2).100 s before and after 5 tetani) and markedly decreased (to 7.7 +/- 1.6 flashes/1000 mu m(2).100 s) following prolonged tetanic stimulation (40 tetani). A significant temperature-dependent increase in mSOF frequency (11.9 +/- 0.8 and 19.8 +/- 2.6 flashes/1000 mu m(2).100 s at 23 degrees C and 37 degrees C) was observed in fibers from RYR1(Y522S/WT) mice, a mouse model of malignant hyperthermia and heat-induced hypermetabolism. Together, these results demonstrate that mSOF activity is a highly sensitive biomarker of mitochondrial respiration and the cellular metabolic state of muscle during physiological activity and pathological oxidative stress.-Wei, L., Salahura, G., Boncompagni, S., Kasischke, K. A., Protasi, F., Sheu, S.-S., Dirksen, R. T. Mitochondrial superoxide flashes: metabolic biomarkers of skeletal muscle activity and disease. FASEB J. 25, 3068-3078 (2011). www.fasebj.org	[Wei, Lan; Sheu, Shey-Shing; Dirksen, Robert T.] Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Salahura, Gheorghe; Kasischke, Karl A.] Univ Rochester, Med Ctr, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Boncompagni, Simona; Protasi, Feliciano] Univ Gabriele dAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Boncompagni, Simona; Protasi, Feliciano] Univ Gabriele dAnnunzio, Ctr Res Aging, Chieti, Italy	University of Rochester; University of Rochester; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Dirksen, RT (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	robert_dirksen@urmc.rochester.edu	Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601; Kasischke, Karl/0000-0003-0582-4319	U.S. National Institutes of Health [AR44657, HL033333]; Italian Telethon ONLUS Foundation [GGP08153]; Academia Dei Lincea; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044657] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Telethon ONLUS Foundation(Fondazione Telethon); Academia Dei Lincea; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Jeffery D. Molkentin (University of Cincinnati, Cincinnati, OH, USA) for providing the CypD<SUP>-/-</SUP> mice and skeletal muscle-specific vector used to generate the mt-cpYFP transgenic mice used in this study. The authors also thank Linda Groom (University of Rochester Medical Center) for generating the muscle-specific mt-cpYFP construct used to make the transgenic mice used in this study. The authors thank Dr. Susan L. Hamilton (Baylor College of Medicine, Houston, TX, USA) for constructive comments on the manuscript and for providing access to the RYR1<SUP>Y522S/WT</SUP> mice used in this work. The 2-photon imaging studies were performed in the Multiphoton Core Facility of the University of Rochester Medical Center. This research was supported by U.S. National Institutes of Health grants AR44657 (to R. T. D.) and HL033333 (to S. S. S.), Italian Telethon ONLUS Foundation grant GGP08153 (to F. P.), and the Academia Dei Lincea Fund (to L. W.).	Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Andronache Z, 2009, P NATL ACAD SCI USA, V106, P4531, DOI 10.1073/pnas.0812661106; Aon MA, 2004, P NATL ACAD SCI USA, V101, P4447, DOI 10.1073/pnas.0307156101; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; Balaban RS, 2002, J MOL CELL CARDIOL, V34, P1259, DOI 10.1006/jmcc.2002.2082; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Boncompagni S, 2009, P NATL ACAD SCI USA, V106, P21996, DOI 10.1073/pnas.0911496106; Boncompagni S, 2009, MOL BIOL CELL, V20, P1058, DOI 10.1091/mbc.E08-07-0783; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Chelu MG, 2006, FASEB J, V20, P329, DOI 10.1096/fj.05-4497fje; Di Meo S, 2001, BIOL SIGNAL RECEPT, V10, P125; DiFranco M, 2006, PROTEIN EXPRES PURIF, V47, P281, DOI 10.1016/j.pep.2005.10.018; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dudkina NV, 2010, BBA-BIOENERGETICS, V1797, P664, DOI 10.1016/j.bbabio.2009.12.013; Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042; ERNSTER L, 1981, J CELL BIOL, V91, pS227, DOI 10.1083/jcb.91.3.227s; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Jackson MJ, 2007, J APPL PHYSIOL, V102, P1664, DOI 10.1152/japplphysiol.01102.2006; Jackson MJ, 2002, MOL ASPECTS MED, V23, P209, DOI 10.1016/S0098-2997(02)00018-3; JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9; Moylan JS, 2007, MUSCLE NERVE, V35, P411, DOI 10.1002/mus.20743; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Pouvreau S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013035; Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rudolf R, 2004, J CELL BIOL, V166, P527, DOI 10.1083/jcb.200403102; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Smith MA, 2006, RESP PHYSIOL NEUROBI, V151, P229, DOI 10.1016/j.resp.2005.12.011; Wang W, 2008, CELL, V134, P279, DOI 10.1016/j.cell.2008.06.017; Won JH, 2007, AM J PHYSIOL-GASTR L, V293, pG1166, DOI 10.1152/ajpgi.00352.2007; Zhou LF, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000657	37	78	82	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3068	3078		10.1096/fj.11-187252	http://dx.doi.org/10.1096/fj.11-187252			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21646399	Green Published			2022-12-28	WOS:000294435200021
J	Guillaumond, F; Boyer, B; Becquet, D; Guillen, S; Kuhn, L; Garin, J; Belghazi, M; Bosler, O; Franc, JL; Francois-Bellan, AM				Guillaumond, Fabienne; Boyer, Benedicte; Becquet, Denis; Guillen, Severine; Kuhn, Lauriane; Garin, Jerome; Belghazi, Maya; Bosler, Olivier; Franc, Jean-Louis; Francois-Bellan, Anne-Marie			Chromatin remodeling as a mechanism for circadian prolactin transcription: rhythmic NONO and SFPQ recruitment to HLTF	FASEB JOURNAL			English	Article						helicase-like-transcription factor; PIT-1; paraspeckle proteins; pituitary gland	GENE-EXPRESSION; HISTONE ACETYLATION; E-BOX; BINDING; CLOCK; HORMONE; BASAL; ACTIVATOR; PROMOTER; COREPRESSOR	Most clock-controlled genes (CCGs) lack the specific E-box response element necessary for direct circadian regulation. This is the case for the prolactin (Prl) gene, the expression of which oscillates in individual lactotrope pituitary cells. To characterize the processes underlying this oscillation, we used a lactotrope cell line (GH4C1 cells). In these cells, Prl gene expression fluctuated significantly during 24 h (P = 0.0418). Circadian Prl transcription depended on an interaction between the pituitary-specific transcription factor, PIT-1, and the helicase-like transcription factor (HLTF), a SWI/SNF chromatin remodeler, shown here to bind the Prl promoter on an E-box that differs from the specific E-box preferentially bound by clock proteins. Circadian Prl transcription was further accompanied by marked daily chromatin transitions. While neither HLTF nor PIT-1 was rhythmically expressed, NONO and SFPQ, identified as HLTF-associated proteins by mass spectrometry, displayed a circadian pattern and bound rhythmically to the Prl promoter. Furthermore, NONO and SFPQ were functionally involved in circadian Prl transcription since overexpression of both proteins greatly reduced Prl promoter activity (P < 0.001) and disrupted its circadian pattern. A mechanism involving a rhythm in paraspeckle protein recruitment is proposed to explain how the core oscillator can generate a circadian pattern of CCGs lacking the specific E-box response element.-Guillaumond, F., Boyer, B., Becquet, D., Guillen, S., Kuhn, L., Garin, J., Belghazi, M., Bosler, O., Franc, J. L., Franc, ois-Bellan, A. M. Chromatin remodeling as a mechanism for circadian prolactin transcription: rhythmic NONO and SFPQ recruitment to HLTF. FASEB J. 25, 2740-2756 (2011). www.fasebj.org	[Boyer, Benedicte; Becquet, Denis; Guillen, Severine; Bosler, Olivier; Franc, Jean-Louis; Francois-Bellan, Anne-Marie] Univ Aix Marseille 2, Ctr Rech Neurobiol & Neurophysiol Marseille CRN2M, Ctr Natl Rech Sci CNRS, Unite Mixte Rech UMR 6231, F-13344 Marseille 15, France; [Guillaumond, Fabienne] Univ Aix Marseille 3, Inst Sci Mol Marseille ISM2, UMR6263, Marseille, France; [Garin, Jerome] Plateforme Etud Dynam Proteomes EDyP Serv, Grenoble, France; [Belghazi, Maya] Inst Federatif Rech IFR, Ctr Anal Prote Marseille, Marseille, France; [Kuhn, Lauriane] Plateforme Prote Esplanade Inst Biol Mol & Cellul, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Francois-Bellan, AM (corresponding author), Univ Aix Marseille 2, CNRS, CRN2M, Fac Med Nord,UMR 6231, Bd Pierre Dramard CS 80011, F-13344 Marseille 15, France.	anne-marie.francois@univmed.fr	Becquet, Denis/E-3675-2010; François-Bellan, anne-marie/D-3116-2017; francois, anne-marie/H-1193-2011; Guillaumond, Fabienne/E-8265-2017; Franc, Jean-Louis/C-8861-2009	Becquet, Denis/0000-0001-8232-7418; François-Bellan, anne-marie/0000-0002-3278-4642; Guillaumond, Fabienne/0000-0001-7456-7315; Franc, Jean-Louis/0000-0002-2900-5468; Kuhn, Lauriane/0000-0002-2637-1024	National Research Agency [ANR-08-GENO-026-01]	National Research Agency(French National Research Agency (ANR))	The authors are indebted to Dr. Alexandra Belayew (University of Leuven, Leuven, Belgium) for generous gifts of monoclonal antiserum to HLTF and plasmid pCIneo-His6-HLTF and to Dr. Hiroshi Hosoda (Tokyo University of Agriculture, Tokyo, Japan) for supplying plasmid construct of R91A, a dominant negative mutant of BMAL1. The authors also thank Dr. Raymond Miquelis for useful advice in proteomic analysis and Gary Burkhart for editing. This work was supported by grants from the National Research Agency (ANR-08-GENO-026-01).	Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; Becquet D, 2001, MOL CELL ENDOCRINOL, V175, P93, DOI 10.1016/S0303-7207(01)00393-8; Belden WJ, 2007, MOL CELL, V25, P587, DOI 10.1016/j.molcel.2007.01.010; BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; Bose S, 2010, ENDOCRINOLOGY, V151, P2287, DOI 10.1210/en.2009-1252; Brooks YS, 2009, J BIOL CHEM, V284, P18033, DOI 10.1074/jbc.M109.006999; Brown SA, 2005, SCIENCE, V308, P693, DOI 10.1126/science.1107373; Caccavelli L, 1998, MOL ENDOCRINOL, V12, P1215, DOI 10.1210/me.12.8.1215; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Dennis Jr G, 2003, GENOME BIOL, V4, P3, DOI [10.1186/gb-2003-4-5-p3, DOI 10.1186/GB-2003-4-5-P3]; Ding H, 1996, DNA CELL BIOL, V15, P429, DOI 10.1089/dna.1996.15.429; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Fox AH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000687; Hosoda H, 2004, GENE, V338, P235, DOI 10.1016/j.gene.2004.05.022; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; HUGHES M, 2007, COLD SPRING HARB SYM, V72, P381; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Ito T, 2008, BIOCHEM J, V411, P201, DOI 10.1042/BJ20071075; Izumo M, 2003, P NATL ACAD SCI USA, V100, P16089, DOI 10.1073/pnas.2536313100; Leclerc GM, 2005, ENDOCRINOLOGY, V146, P2782, DOI 10.1210/en.2005-0100; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Mahajan MC, 2002, BLOOD, V99, P348, DOI 10.1182/blood.V99.1.348; Masri S, 2010, NAT NEUROSCI, V13, P1324, DOI 10.1038/nn.2668; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; Onishi Y, 2008, MOL CELL BIOL, V28, P3477, DOI 10.1128/MCB.02227-07; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; Pellegrini I, 2006, MOL ENDOCRINOL, V20, P3212, DOI 10.1210/me.2006-0122; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Qi Y, 2008, P NATL ACAD SCI USA, V105, P2481, DOI 10.1073/pnas.0712196105; Quentien MH, 2002, J BIOL CHEM, V277, P44408, DOI 10.1074/jbc.M207824200; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Sato TK, 2006, NAT GENET, V38, P312, DOI 10.1038/ng1745; Shimizu F, 2007, J NEUROCHEM, V103, P1834, DOI 10.1111/j.1471-4159.2007.04900.x; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Triqueneaux G, 2004, J MOL ENDOCRINOL, V33, P585, DOI 10.1677/jme.1.01554; Yamajuku D, 2010, NUCLEIC ACIDS RES, V38, P7964, DOI 10.1093/nar/gkq678; ZHANG GH, 1994, NATURE, V372, P809; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	41	29	30	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2740	2756		10.1096/fj.10-178616	http://dx.doi.org/10.1096/fj.10-178616			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507896				2022-12-28	WOS:000293337800023
J	Battista, N; Meloni, MA; Bari, M; Mastrangelo, N; Galleri, G; Rapino, C; Dainese, E; Agro, AF; Pippia, P; Maccarrone, M				Battista, Natalia; Meloni, Maria A.; Bari, Monica; Mastrangelo, Nicolina; Galleri, Grazia; Rapino, Cinzia; Dainese, Enrico; Agro, Alessandro Finazzi; Pippia, Proto; Maccarrone, Mauro			5-Lipoxygenase-dependent apoptosis of human lymphocytes in the International Space Station: data from the ROALD experiment	FASEB JOURNAL			English	Article						fatty acids; immunosuppression; lipoxygenase pathway; space environment	IN-VITRO; MICROGRAVITY; SPACEFLIGHT; CELLS; LIPOXYGENASES; CYTOSKELETON; INVOLVEMENT; SUPPRESSION; ACTIVATION; EXPRESSION	The functional adaptation of the immune system to the surrounding environment is also a fundamental issue in space. It has been suggested that a decreased number of lymphocytes might be a cause of immunosuppression, possibly due to the induction of apoptosis. Early activation of 5-lipoxygenase (5-LOX) might play a central role in the initiation of the apoptotic program. The goal of the role of apoptosis in lymphocyte depression (ROALD) experiment, flown on the International Space Station as part of the BIO-4 mission of the European Space Agency, was to ascertain the induction of apoptosis in human lymphocytes under authentic microgravity, and to elucidate the possible involvement of 5-LOX. Our results demonstrate that exposure of human lymphocytes to microgravity for 48 h onboard the ISS remarkably increased apoptotic hallmarks such as DNA fragmentation (similar to 3-fold compared to ground-based controls) and cleaved-poly (ADP-ribose) polymerase (PARP) protein expression (similar to 3-fold), as well as mRNA levels of apoptosis-related markers such as p53 (similar to 3-fold) and calpain (similar to 4-fold); these changes were paralleled by an early increase of 5-LOX activity (similar to 2-fold). Our findings provide a molecular background for the immune dysfunction observed in astronauts during space missions, and reveal potential new markers to monitor health status of ISS crew members.-Battista, N., Meloni, M. A., Bari, M., Mastrangelo, N., Galleri, G., Rapino, C., Dainese, E., Finazzi Agro, A., Pippia, P., Maccarrone, M. 5-Lipoxygenase-dependent apoptosis of human lymphocytes in the International Space Station: data from the ROALD experiment. FASEB J. 26, 1791-1798 (2012). www.fasebj.org	[Battista, Natalia; Rapino, Cinzia; Dainese, Enrico; Maccarrone, Mauro] Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; [Meloni, Maria A.; Galleri, Grazia; Pippia, Proto] Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy; [Bari, Monica; Mastrangelo, Nicolina; Agro, Alessandro Finazzi] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; [Maccarrone, Mauro] Univ Roma Tor Vergata, Ctr Space Biomed, Rome, Italy; [Maccarrone, Mauro] Santa Lucia Fdn, Rome, Italy	University of Teramo; University of Sassari; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.	mmaccarrone@unite.it	Galleri, Grazia/AAD-3278-2021; Maccarrone, Mauro/K-5398-2012; Battista, Natalia/AAC-2529-2019	Galleri, Grazia/0000-0001-5379-9387; Maccarrone, Mauro/0000-0002-3990-2963; Dainese, Enrico/0000-0001-7163-9344; Battista, Natalia/0000-0002-1936-6710	Zero g Life Tec, Zurich, Switzerland; Agenzia Spaziale Italiana; Fondazione Banco di Sardegna	Zero g Life Tec, Zurich, Switzerland; Agenzia Spaziale Italiana(Agenzia Spaziale Italiana (ASI)); Fondazione Banco di Sardegna(Fondazione Banco di Sardegna)	The authors are grateful to Dr. Augusto Cogoli (Zero g Life Tec, Zurich, Switzerland) for his continuing support to the ROALD project; and to Dr. Natalie Leys [Belgian Nuclear Research Center (SCK.CEN), Mol, Belgium], Dr. Raimondo Fortezza (Mars Center, Naples, Italy), and all members of Kayser Italia, ESA, Energia, and NASA who have been involved in the different phases of the ROALD experiment. This work was supported by Agenzia Spaziale Italiana (Disturbi del Controllo Motorio e Cardiorespiratorio and From Molecules to Man projects, 2006-2009; to A. F. A. and M. M.), and in part by Fondazione Banco di Sardegna (to P.P.).	Allen DL, 2009, J APPL PHYSIOL, V106, P582, DOI 10.1152/japplphysiol.90780.2008; Arneth B. M., 2010, CURR PROTOC CYTOM, V51, P6281; Bai SS, 2011, IMMUNOL INVEST, V40, P535, DOI 10.3109/08820139.2011.568032; Bakos A, 2001, J GRAVIT PHYSL, V8, P69; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Battista N., 2007, J GRAVIT PHYSL, V14, P131; Berger W, 2007, INT J CLIN PRACT, V61, P663, DOI 10.1111/j.1742-1241.2007.01320.x; Bocan TMA, 1998, ATHEROSCLEROSIS, V136, P203, DOI 10.1016/S0021-9150(97)00204-9; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chang H, 2011, J CELL BIOCHEM, V112, P571, DOI 10.1002/jcb.22947; Cho YJ, 2011, CELL MOL LIFE SCI, V68, P1883, DOI 10.1007/s00018-011-0666-x; Chu J, 2011, AM J PATHOL, V178, P1762, DOI 10.1016/j.ajpath.2010.12.032; Claria J, 2006, RECENT PAT ANTI-CANC, V1, P369, DOI 10.2174/157489206778776961; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cooper D, 2001, IN VITRO CELL DEV-AN, V37, P63; Crucian B, 2009, J LEUKOCYTE BIOL, V86, P1017, DOI 10.1189/jlb.0709500; Dainese E, 2010, FASEB J, V24, P1725, DOI 10.1096/fj.09-141390; Fitzgerald W, 2009, IN VITRO CELL DEV-AN, V45, P622, DOI 10.1007/s11626-009-9225-2; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Heitz F, 2010, EXPERT REV ANTICANC, V10, P1125, DOI 10.1586/ERA.10.53; Kumari R, 2009, J CELL BIOCHEM, V107, P723, DOI 10.1002/jcb.22171; Lewis Marian L, 2002, Adv Space Biol Med, V8, P77; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Liggieri L, 1997, J COLLOID INTERF SCI, V186, P46, DOI 10.1006/jcis.1996.4580; Lovat PE, 2002, CANCER RES, V62, P5158; Maccarrone M, 2001, J IMMUNOL, V166, P7183, DOI 10.4049/jimmunol.166.12.7183; Maccarrone M, 2003, J LEUKOCYTE BIOL, V73, P472, DOI 10.1189/jlb.0602295; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; Maccarrone M, 2001, BIOPHYS CHEM, V90, P301, DOI 10.1016/S0301-4622(01)00160-0; Maccarrone M, 2009, CELL CYCLE, V8, P3, DOI 10.4161/cc.8.1.7671; Meloni MA, 2011, CYTOSKELETON, V68, P125, DOI 10.1002/cm.20499; Melstrom LG, 2008, CLIN CANCER RES, V14, P6525, DOI 10.1158/1078-0432.CCR-07-4631; Mic FA, 1999, CELL DEATH DIFFER, V6, P593; Ming Y., 2009, FASEB J, V23, pLB97; Moreno JJ, 2009, BIOCHEM PHARMACOL, V77, P1, DOI 10.1016/j.bcp.2008.07.033; Nieves D, 2006, BIOCHEM PHARMACOL, V72, P1022, DOI 10.1016/j.bcp.2006.07.021; Ohnishi T, 1999, MUTAT RES-FUND MOL M, V430, P271, DOI 10.1016/S0027-5107(99)00138-4; Pasquariello N, 2009, J BIOL CHEM, V284, P29413, DOI 10.1074/jbc.M109.044412; Pietsch J, 2011, CURR MOL MED, V11, P350, DOI 10.2174/156652411795976600; Plett PA, 2004, EXP HEMATOL, V32, P773, DOI 10.1016/j.exphem.2004.03.014; Pompeia C, 2002, BIOL CELL, V94, P251, DOI 10.1016/S0248-4900(02)01200-5; Ritz BW, 2006, FASEB J, V20, P305, DOI 10.1096/fj.04-3122fje; Scadding GW, 2010, CURR OPIN ALLERGY CL, V10, P370, DOI 10.1097/ACI.0b013e32833bfa20; Schatten H, 2001, ACTA ASTRONAUT, V49, P399, DOI 10.1016/S0094-5765(01)00116-3; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Sharma CS, 2008, MOL CELL BIOCHEM, V313, P71, DOI 10.1007/s11010-008-9743-3; Simons DM, 2006, J APPL PHYSIOL, V100, P1287, DOI 10.1152/japplphysiol.00887.2005; Storr SJ, 2011, NAT REV CANCER, V11, P364, DOI 10.1038/nrc3050; Tamma R, 2009, FASEB J, V23, P2549, DOI 10.1096/fj.08-127951; Vernikos J, 2010, GERONTOLOGY, V56, P157, DOI 10.1159/000252852; Walther I, 1998, FEBS LETT, V436, P115, DOI 10.1016/S0014-5793(98)01107-7; Wang JH, 2009, NEUROCHEM INT, V55, P710, DOI 10.1016/j.neuint.2009.07.002; Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335	55	37	40	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1791	1798		10.1096/fj.11-199406	http://dx.doi.org/10.1096/fj.11-199406			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253478				2022-12-28	WOS:000303680800007
J	Lakshmana, MK; Hayes, CD; Bennett, SP; Bianchi, E; Reddy, KM; Koo, EH; Kang, DE				Lakshmana, Madepalli K.; Hayes, Crystal D.; Bennett, Steven P.; Bianchi, Elisabetta; Reddy, Konda M.; Koo, Edward H.; Kang, David E.			Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain	FASEB JOURNAL			English	Article						Alzheimer's disease; transgenic mice; null mice; synapses	PRECURSOR-PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; BINDING PROTEIN; DENSITY; DOMAIN; BACE1; INTERACTS; RELEASE; PROMOTE	We previously reported that RanBP9 binds low-density lipoprotein receptor-related protein (LRP), amyloid precursor protein (APP), and BACE1 and robustly increased A beta generation in a variety of cell lines and primary neuronal cultures. To confirm the physiological/pathological significance of this phenotype in vivo, we successfully generated transgenic mice overexpressing RanBP9 as well as RanBP9-null mice. Here we show that RanBP9 overexpression resulted in > 2-fold increase in A beta 40 levels as early as 4 mo of age. A sustained increase in A beta 40 levels was seen at 12 mo of age in both CHAPS-soluble and formic acid (FA)-soluble brain fractions. In addition, A beta 42 levels were also significantly increased in FA-soluble fractions at 12 mo of age. More important, increased A beta levels were translated to increased deposition of amyloid plaques. In addition, RanBP9 overexpression significantly decreased the levels of synaptophysin and PSD-95 proteins. Conversely, RanBP9-null mice showed increased levels of synaptophysin, PSD-95, and drebrin A protein levels. Given that loss of synapses is the best pathological correlate of cognitive deficits in Alzheimer's disease (AD), increased A beta levels by RanBP9 observed in the present study provides compelling evidence that RanBP9 may indeed play a key role in the etiology of AD. If so, RanBP9 provides a great opportunity to develop novel therapy for AD.-Lakshmana, M. K., Hayes, C. D., Bennett, S. P., Bianchi, E., Reddy, K. M., Koo, E. H., Kang, D. E. Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J. 26, 2072-2083 (2012). www.fasebj.org	[Lakshmana, Madepalli K.; Hayes, Crystal D.; Bennett, Steven P.] Torrey Pines Inst Mol Studies, Neurobiol Sect, Port St Lucie, FL 34987 USA; [Koo, Edward H.; Kang, David E.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Bianchi, Elisabetta] Inst Pasteur, Dept Immunol, Lab Immuneregulat, F-75724 Paris, France; [Reddy, Konda M.] Univ Cent Florida, Orlando, FL 32816 USA; [Kang, David E.] Seoul Natl Univ, Coll Med, World Class Univ Neurocyt Program, Seoul, South Korea	Torrey Pines Institute for Molecular Studies, Florida; University of California System; University of California San Diego; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; State University System of Florida; University of Central Florida; Seoul National University (SNU)	Lakshmana, MK (corresponding author), Torrey Pines Inst Mol Studies, Neurobiol Sect, 11350 SW Village Pkwy, Port St Lucie, FL 34987 USA.	mlakshmana@tpims.org; dekang@ucsd.edu	Kang, David E./E-5234-2012; Bennett, Steven/GLV-6597-2022	Kang, David E./0000-0002-7132-821X	U.S. National Institute of Aging/National Institutes of Health [1R03AG032064-01, 1R01AG036859-01, 1R01AG033055-01A1, 1K02AG031920-10A1]; National Research Foundation -World Class University -Neurocytomics (Korea); NATIONAL INSTITUTE ON AGING [K02AG031920, R01AG033055, R01AG036859, R03AG032064] Funding Source: NIH RePORTER	U.S. National Institute of Aging/National Institutes of Health; National Research Foundation -World Class University -Neurocytomics (Korea); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institute of Aging/National Institutes of Health grants to M.L.K. (1R03AG032064-01 and 1R01AG036859-01) and D.E.K. (1R01AG033055-01A1 and 1K02AG031920-10A1) and by a National Research Foundation -World Class University -Neurocytomics (Korea) grant to D.E.K.	Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bowman AL, 2008, MOL BIOL CELL, V19, P3782, DOI 10.1091/mbc.E08-03-0237; Cheng L, 2005, J NEUROCHEM, V94, P1102, DOI 10.1111/j.1471-4159.2005.03254.x; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Cole SL, 2008, J BIOL CHEM, V283, P29621, DOI 10.1074/jbc.R800015200; Counts SE, 2006, J NEUROPATH EXP NEUR, V65, P592, DOI 10.1097/00005072-200606000-00007; Cummings J, 2010, BIOL PSYCHIAT, V68, P876, DOI 10.1016/j.biopsych.2010.09.020; Dansereau DA, 2008, J CELL BIOL, V182, P963, DOI 10.1083/jcb.200711046; De Strooper B, 2000, J CELL SCI, V113, P1857; Denti S, 2004, J BIOL CHEM, V279, P13027, DOI 10.1074/jbc.M313515200; Extance A, 2010, NAT REV DRUG DISCOV, V9, P749, DOI 10.1038/nrd3288; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Harigaya Y, 1996, J NEUROSCI RES, V43, P87, DOI 10.1002/jnr.490430111; Hatanpaa K, 1999, J NEUROPATH EXP NEUR, V58, P637, DOI 10.1097/00005072-199906000-00008; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lakshmana MK, 2010, FASEB J, V24, P119, DOI 10.1096/fj.09-136457; Lakshmana MK, 2009, J BIOL CHEM, V284, P11863, DOI 10.1074/jbc.M807345200; Lakshmana MK, 2008, J CELL MOL MED, V12, P2665, DOI 10.1111/j.1582-4934.2008.00320.x; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Menon RP, 2004, J MOL BIOL, V343, P43, DOI 10.1016/j.jmb.2004.08.024; Murrin LC, 2007, J NEUROIMMUNE PHARM, V2, P290, DOI 10.1007/s11481-007-9079-x; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Quast T, 2003, FASEB J, V17, P1739, DOI 10.1096/fj.02-1059fje; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Togashi H, 2006, J NEUROSCI, V26, P4961, DOI 10.1523/JNEUROSCI.0704-06.2006; Valiyaveettil M, 2008, J CELL BIOL, V182, P727, DOI 10.1083/jcb.200801133; Yoon IS, 2007, FASEB J, V21, P2742, DOI 10.1096/fj.07-8114com; Yoon IS, 2005, J BIOL CHEM, V280, P20140, DOI 10.1074/jbc.M413729200	39	29	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2072	2083		10.1096/fj.11-196709	http://dx.doi.org/10.1096/fj.11-196709			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22294787	Green Published			2022-12-28	WOS:000303680800033
J	Magnone, M; Sturla, L; Jacchetti, E; Scarfi, S; Bruzzone, S; Usai, C; Guida, L; Salis, A; Damonte, G; De Flora, A; Zocchi, E				Magnone, Mirko; Sturla, Laura; Jacchetti, Emanuela; Scarfi, Sonia; Bruzzone, Santina; Usai, Cesare; Guida, Lucrezia; Salis, Annalisa; Damonte, Gianluca; De Flora, Antonio; Zocchi, Elena			Autocrine abscisic acid plays a key role in quartz-induced macrophage activation	FASEB JOURNAL			English	Article						inflammation; NF kappa B; TNF alpha; PGE(2); LANCL2	NECROSIS-FACTOR-ALPHA; CYCLIC ADP-RIBOSE; MURINE MACROPHAGES; LIPID-PEROXIDATION; SCAVENGER RECEPTOR; IN-VITRO; KAPPA-B; EXPRESSION; SILICA; LUNG	Inhalation of quartz induces silicosis, a lung disease where alveolar macrophages release inflammatory mediators, including prostaglandin-E-2 (PGE(2)) and tumor necrosis factor alpha (TNF-alpha). Here we report the pivotal role of abscisic acid (ABA), a recently discovered human inflammatory hormone, in silica-induced activation of murine RAW264.7 macrophages and of rat alveolar macrophages (AMs). Stimulation of both RAW264.7 cells and AMs with quartz induced a significant increase of ABA release (5- and 10-fold, respectively), compared to untreated cells. In RAW264.7 cells, autocrine ABA released after quartz stimulation sequentially activates the plasma membrane receptor LANCL2 and NADPH oxidase, generating a Ca2+ influx resulting in NF kappa B nuclear translocation and PGE(2) and TNF-alpha release (3-, 2-, and 3.5-fold increase, respectively, compared to control, un-stimulated cells). Quartz-stimulated RAW264.7 cells silenced for LANCL2 or preincubated with a monoclonal antibody against ABA show an almost complete inhibition of NF kappa B nuclear translocation and PGE(2) and TNF-alpha release compared to controls electroporated with a scramble oligonucleotide or preincubated with an unrelated antibody. AMs showed similar early and late ABA-induced responses as RAW264.7 cells. These findings identify ABA and LANCL2 as key mediators in quartz-induced inflammation, providing possible new targets for antisilicotic therapy.-Magnone, M., Sturla, L., Jacchetti, E., Scarf, S., Bruzzone, S., Usai, C., Guida, L., Salis, A., Damonte, G., De Flora, A., Zocchi, E. Autocrine abscisic acid plays a key role in quartz-induced macrophage activation. FASEB J. 26, 1261-1271 (2012). www.fasebj.org	[Magnone, Mirko; Sturla, Laura; Scarfi, Sonia; Bruzzone, Santina; Guida, Lucrezia; Salis, Annalisa; Damonte, Gianluca; De Flora, Antonio; Zocchi, Elena] Univ Genoa, Biochem Sect, Dept Expt Med DIMES, I-16132 Genoa, Italy; [Magnone, Mirko; Sturla, Laura; Scarfi, Sonia; Bruzzone, Santina; Guida, Lucrezia; Salis, Annalisa; Damonte, Gianluca; De Flora, Antonio; Zocchi, Elena] Univ Genoa, CEBR, I-16132 Genoa, Italy; [Jacchetti, Emanuela; Usai, Cesare] CNR, Inst Biophys, Genoa, Italy; [Scarfi, Sonia; Zocchi, Elena] Adv Biotechnol Ctr CBA, Genoa, Italy	University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Magnone, M (corresponding author), Univ Genoa, Biochem Sect, DIMES, Viale Benedetto XV 1, I-16132 Genoa, Italy.	mirko.magnone@unige.it; ezocchi@unige.it	Bruzzone, Santina/A-4264-2015; Scarfi, Sonia/AAJ-2387-2020; JACCHETTI, Emanuela/AAP-2453-2021; Salis, Annalisa/R-9241-2018	Bruzzone, Santina/0000-0003-2034-3716; Scarfi, Sonia/0000-0002-7079-6919; JACCHETTI, Emanuela/0000-0001-5990-001X; Usai, Cesare/0000-0001-8863-7759; Salis, Annalisa/0000-0002-3082-2908	Italian Ministry of Education, University and Scientific Research; University of Genova; Fondazione Cassa di Risparmio di Genova e Imperia; Compagnia di S. Paolo; European Community; Regione Liguria	Italian Ministry of Education, University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); University of Genova; Fondazione Cassa di Risparmio di Genova e Imperia; Compagnia di S. Paolo(Compagnia di San Paolo); European Community(European Commission); Regione Liguria(Regione Liguria)	This work was supported in part by the Italian Ministry of Education, University and Scientific Research, by the University of Genova, by the Fondazione Cassa di Risparmio di Genova e Imperia, by the Compagnia di S. Paolo, by the European Community, and by Regione Liguria. The authors declare no conflicts of interest.	Aitken RJ, 2007, MOL HUM REPROD, V13, P203, DOI 10.1093/molehr/gal119; Albrecht C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-129; Albrecht C, 2004, AM J RESP CELL MOL, V31, P292, DOI 10.1165/rcmb.2003-0300OC; Bapat S, 2002, J AM SOC NEPHROL, V13, P2990, DOI 10.1097/01.ASN.0000036870.58561.81; Bodrato N, 2009, J BIOL CHEM, V284, P14777, DOI 10.1074/jbc.M802604200; Bruzzone S, 2008, J BIOL CHEM, V283, P32188, DOI 10.1074/jbc.M802603200; Bruzzone S, 2007, P NATL ACAD SCI USA, V104, P5759, DOI 10.1073/pnas.0609379104; Campa VM, 2005, INFLAMM RES, V54, P328, DOI 10.1007/s00011-005-1359-4; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; Chen F., 2007, AM J PHYSIOL-LUNG C, V272, pL779; Chen J, 2010, BLOOD, V115, P4237, DOI 10.1182/blood-2009-11-255323; CLAUDIO E, 1995, AM J RESP CELL MOL, V13, P547, DOI 10.1165/ajrcmb.13.5.7576690; Di Giuseppe M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005689; Ding M, 2002, INT IMMUNOPHARMACOL, V2, P173, DOI 10.1016/S1567-5769(01)00170-9; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381, DOI 10.1165/ajrcmb/2.4.381; El-Benna J, 2009, EXP MOL MED, V41, P217, DOI 10.3858/emm.2009.41.4.058; Finney-Hayward TK, 2010, AM J RESP CELL MOL, V43, P296, DOI 10.1165/rcmb.2008-0373OC; GABOR S, 1975, ARCH ENVIRON HEALTH, V30, P499, DOI 10.1080/00039896.1975.10666761; Garcia YJ, 2005, J NEUROSCI METH, V144, P127, DOI 10.1016/j.jneumeth.2004.10.018; Gozal E, 2002, AM J RESP CELL MOL, V27, P91, DOI 10.1165/ajrcmb.27.1.4790; Hannigan MO, 2004, CURR TOP MICROBIOL, V282, P165; KREYLING WG, 1992, ENVIRON HEALTH PERSP, V97, P121, DOI 10.2307/3431339; Lysko PG, 1999, J PHARMACOL EXP THER, V289, P1277; Magnone M, 2009, J BIOL CHEM, V284, P17808, DOI 10.1074/jbc.M809546200; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; Nambara E, 2005, ANNU REV PLANT BIOL, V56, P165, DOI 10.1146/annurev.arplant.56.032604.144046; NYBERG P, 1991, ENVIRON RES, V55, P157, DOI 10.1016/S0013-9351(05)80172-0; Orfila C, 1998, HISTOCHEM J, V30, P857, DOI 10.1023/A:1003485312164; Puce S, 2004, J BIOL CHEM, V279, P39783, DOI 10.1074/jbc.M405348200; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; Roca J, 2004, J ANDROL, V25, P397; RUOTSALAINEN M, 1995, TOXICOL LETT, V78, P195, DOI 10.1016/0378-4274(95)03255-J; Scarfi S, 2007, FEBS J, V274, P60, DOI 10.1111/j.1742-4658.2006.05564.x; Scarfi S, 2009, STEM CELLS, V27, P2469, DOI 10.1002/stem.173; Scarfi S, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-25; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507; Sturla L, 2009, J BIOL CHEM, V284, P28045, DOI 10.1074/jbc.M109.035329; Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855; Tarnok A, 1997, ANAL CELL PATHOL, V15, P61, DOI 10.1155/1997/539384; Vidyashankar S, 2010, MOL CELL BIOCHEM, V333, P41, DOI 10.1007/s11010-009-0202-6; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Warheit DB, 2007, TOXICOL SCI, V95, P270, DOI 10.1093/toxsci/kfl128; Wehrhahn J, 2010, J IMMUNOL, V184, P2386, DOI 10.4049/jimmunol.0902474; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Zeidler PC, 2003, J TOXICOL ENV HEAL A, V66, P995, DOI 10.1080/15287390306395; ZHANG Y, 1993, J IMMUNOL, V150, P4188; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, P NATL ACAD SCI USA, V98, P14859, DOI 10.1073/pnas.261448698	50	32	35	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1261	1271		10.1096/fj.11-187351	http://dx.doi.org/10.1096/fj.11-187351			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22042223				2022-12-28	WOS:000300949300028
J	Blanchet, E; Bertrand, C; Annicotte, JS; Schlernitzauer, A; Pessemesse, L; Levin, J; Fouret, G; Feillet-Coudray, C; Bonafos, B; Fajas, L; Cabello, G; Wrutniak-Cabello, C; Casas, F				Blanchet, Emilie; Bertrand, Christelle; Annicotte, Jean Sebastien; Schlernitzauer, Audrey; Pessemesse, Laurence; Levin, Jonathan; Fouret, Gilles; Feillet-Coudray, Christine; Bonafos, Beatrice; Fajas, Lluis; Cabello, Gerard; Wrutniak-Cabello, Chantal; Casas, Francois			Mitochondrial T3 receptor p43 regulates insulin secretion and glucose homeostasis	FASEB JOURNAL			English	Article						thyroid hormone; mitochondria	THYROID-HORMONE-RECEPTOR; BETA-CELL FUNCTION; MYOBLAST DIFFERENTIATION; C-ERB; RESPIRATORY-CHAIN; EXPRESSION; ALPHA; OVEREXPRESSION; IDENTIFICATION; PROTEIN	Thyroid hormone is a major determinant of energy expenditure and a key regulator of mitochondrial activity. We have previously identified a mitochondrial triiodothyronine receptor (p43) that acts as a mitochondrial transcription factor of the organelle genome, which leads, in vitro and in vivo, to a stimulation of mitochondrial biogenesis. Here we generated mice specifically lacking p43 to address its physiological influence. We found that p43 is required for normal glucose homeostasis. The p43(-/-) mice had a major defect in insulin secretion both in vivo and in isolated pancreatic islets and a loss of glucose-stimulated insulin secretion. Moreover, a high-fat/high-sucrose diet elicited more severe glucose intolerance than that recorded in normal animals. In addition, we observed in p43(-/-) mice both a decrease in pancreatic islet density and in the activity of complexes of the respiratory chain in isolated pancreatic islets. These dysfunctions were associated with a down-regulation of the expression of the glucose transporter Glut2 and of Kir6.2, a key component of the K(ATP) channel. Our findings establish that p43 is an important regulator of glucose homeostasis and pancreatic beta-cell function and provide evidence for the first time of a physiological role for a mitochondrial endocrine receptor.-Blanchet, E., Bertrand, C., Annicotte, J. S., Schlernitzauer, A., Pessemesse, L., Levin, J., Fouret, G., Feillet-Coudray, C., Bonafos, B., Fajas, L., Cabello, G., Wrutniak-Cabello, C., Casas, F. Mitochondrial T3 receptor p43 regulates insulin secretion and glucose homeostasis. FASEB J. 26, 40-50 (2012). www.fasebj.org	[Bertrand, Christelle; Schlernitzauer, Audrey; Pessemesse, Laurence; Levin, Jonathan; Fouret, Gilles; Feillet-Coudray, Christine; Bonafos, Beatrice; Wrutniak-Cabello, Chantal; Casas, Francois] Univ Montpellier 1, INRA, Dynam Musculaire & Metab UMR866, F-34060 Montpellier, France; [Bertrand, Christelle; Schlernitzauer, Audrey; Pessemesse, Laurence; Levin, Jonathan; Fouret, Gilles; Feillet-Coudray, Christine; Bonafos, Beatrice; Wrutniak-Cabello, Chantal; Casas, Francois] Univ Montpellier 2, F-34095 Montpellier 5, France; [Blanchet, Emilie; Annicotte, Jean Sebastien; Fajas, Lluis; Cabello, Gerard] Univ Montpellier 1, Inst Rech Clin Montreal, Inst Rech Cancerol Montpellier, Inst Natl Sante & Rech Med INSERM U896, F-34060 Montpellier, France	INRAE; Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Casas, F (corresponding author), Univ Montpellier 1, INRA, Dynam Musculaire & Metab UMR866, 2 Pl Viala, F-34060 Montpellier, France.	casasf@supagro.inra.fr	Coll, Lluis Fajas/C-8567-2014; BERTRAND-GADAY, Christelle/ABA-8619-2021; Annicotte, Jean-Sébastien/H-4641-2018; Levin, Jonathan/N-3189-2018	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; Annicotte, Jean-Sébastien/0000-0002-2109-4849; Fajas, Lluis/0000-0002-1283-9503; Francois, Casas/0000-0002-5535-8195	Institut National de la Recherche Agronomique; ANR MitHyCal; Societe Francophone du Diabete-Novartis	Institut National de la Recherche Agronomique; ANR MitHyCal(French National Research Agency (ANR)); Societe Francophone du Diabete-Novartis	The authors are grateful to J. Samarut (ENS, Lyon, France) for providing plasmid alpha 8BS, T. Lamonerie (ENS, Lyon, France) for vector pT102, and L. Lecam (Institut de Genetique Moleculaire de Montpellier, Montpellier, France) for ES cells. The authors thank the animal staff for animal care. This work was supported by grants from the Institut National de la Recherche Agronomique, ANR MitHyCal, and Societe Francophone du Diabete-Novartis.	Annicotte JS, 2009, NAT CELL BIOL, V11, P1017, DOI 10.1038/ncb1915; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BARIS O, 2007, FEBS ADV LECT SERIES, P14; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2006, MOL ENDOCRINOL, V20, P749, DOI 10.1210/me.2005-0074; Casas F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005631; Casas F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002501; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Crunkhorn S, 2008, THYROID, V18, P227, DOI 10.1089/thy.2007.0249; Fajas L, 2004, J CLIN INVEST, V113, P1288, DOI 10.1172/JCI200418555; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Grandemange S, 2005, CANCER RES, V65, P4282, DOI 10.1158/0008-5472.CAN-04-3652; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873; Koenig R., 1988, P NATL ACAD SCI USA, V85, P531; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Maechler P, 2010, ADV EXP MED BIOL, V654, P193, DOI 10.1007/978-90-481-3271-3_9; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Seyer P, 2006, J CELL PHYSIOL, V207, P75, DOI 10.1002/jcp.20539; Seyer P, 2011, EXP CELL RES, V317, P2059, DOI 10.1016/j.yexcr.2011.05.020; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Wharton DC., 1967, METHOD ENZYMOL, P245; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067	37	35	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					40	50		10.1096/fj.11-186841	http://dx.doi.org/10.1096/fj.11-186841			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21914860				2022-12-28	WOS:000299202200006
J	Hara-Chikuma, M; Sugiyama, Y; Kabashima, K; Sohara, E; Uchida, S; Sasaki, S; Inoue, S; Miyachi, Y				Hara-Chikuma, Mariko; Sugiyama, Yoshinori; Kabashima, Kenji; Sohara, Eisei; Uchida, Shinichi; Sasaki, Sei; Inoue, Shintaro; Miyachi, Yoshiki			Involvement of aquaporin-7 in the cutaneous primary immune response through modulation of antigen uptake and migration in dendritic cells	FASEB JOURNAL			English	Article						macropinocytosis; phagocytosis; chemotaxis	LANGERHANS CELLS; CONTACT HYPERSENSITIVITY; GENE DISRUPTION; DOWN-REGULATION; WATER CHANNEL; LYMPH-NODES; MACROPINOCYTOSIS; EXPRESSION; GLYCEROL; PROLIFERATION	Dendritic cells (DCs) have the ability to present antigen and play a critical role in the induction of the acquired immune response. Skin DCs uptake antigen and subsequently migrate to regional draining lymph nodes (LNs), where they activate naive T cells. Here we show that the water/glycerol channel protein aquaporin 7 (AQP7) is expressed on epidermal and dermal DCs and involved in the initiation of primary immune responses. AQP7-deficient DCs showed a decreased cellular uptake of low-molecular-mass compounds (fluorescein isothiocyanate and Lucifer yellow) and high-molecular-mass substances (ovalbumin and dextran), suggesting that AQP7 is involved in antigen uptake. AQP7-deficient DCs also exhibited reduced chemokine-dependent cell migration in comparison to wild-type DCs. Consistent with these in vitro results, AQP7-deficient mice demonstrated a reduced accumulation of antigen-retaining DCs in the LNs after antigen application to the skin, which could be attributed to decreased antigen uptake and migration. Coincidentally, AQP7-deficient mice had impaired antigen-induced sensitization in a contact hypersensitivity model. These observations suggested that AQP7 in skin DCs is primarily involved in antigen uptake and in the subsequent migration of DCs and is responsible for antigen presentation and the promotion of downstream immune responses.-Hara-Chikuma, M., Sugiyama, Y., Kabashima, K., Sohara, E., Uchida, S., Sasaki, S., Inoue, S., Miyachi, Y. Involvement of aquaporin-7 in the cutaneous primary immune response through modulation of antigen uptake and migration in dendritic cells. FASEB J. 26, 211-218 (2012). www.fasebj.org	[Hara-Chikuma, Mariko] Kyoto Univ, Ctr Innovat Immunoregulat Technol & Therapeut, Grad Sch Med, Dept Dermatol,Sakyo Ku, Kyoto 6068501, Japan; [Hara-Chikuma, Mariko; Sugiyama, Yoshinori; Inoue, Shintaro] Kanebo Cosmet Inc, Innovat Beauty Sci Lab, Odawara, Kanagawa, Japan; [Sohara, Eisei; Uchida, Shinichi; Sasaki, Sei] Tokyo Med & Dent Univ, Dept Nephrol, Tokyo, Japan	Kyoto University; Kanebo Cosmetics Inc.; Tokyo Medical & Dental University (TMDU)	Hara-Chikuma, M (corresponding author), Kyoto Univ, Ctr Innovat Immunoregulat Technol & Therapeut, Grad Sch Med, Dept Dermatol,Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	haramari@kuhp.kyoto-u.ac.jp	Inoue, Shintaro/AAR-6767-2021; Uchida, Shinichi/D-1111-2013; Kabashima, Kenji/G-2521-2014	Inoue, Shintaro/0000-0002-4996-5693; Kabashima, Kenji/0000-0002-0773-0554	Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank Maiko Yusa and Kiiko Kumagai for mouse breeding, Dr. Yoshinori Fujiyoshi and Akiko Kamegawa for help with water transport measurement, and Dr. Shunsuke Chikuma for critical reading of the manuscript. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; CARBREY JM, 2009, HDB EXP PHARM, V190, P3, DOI DOI 10.1007/978-3-540-79885-9_; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; Dieu-Nosjean MC, 1999, J LEUKOCYTE BIOL, V66, P252, DOI 10.1002/jlb.66.2.252; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Hara-Chikuma M, 2008, J MOL MED-JMM, V86, P221, DOI 10.1007/s00109-007-0272-4; Hara-Chikuma M, 2008, MOL CELL BIOL, V28, P326, DOI 10.1128/MCB.01482-07; Honda T, 2010, J ALLERGY CLIN IMMUN, V125, P1154, DOI 10.1016/j.jaci.2009.12.005; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Martin SF, 2004, INT ARCH ALLERGY IMM, V134, P186, DOI 10.1159/000078765; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Moon C, 2004, AM J HEMATOL, V75, P128, DOI 10.1002/ajh.10476; Noordegraaf M, 2010, J INVEST DERMATOL, V130, P2752, DOI 10.1038/jid.2010.223; Norbury CC, 2006, IMMUNOLOGY, V117, P443, DOI 10.1111/j.1365-2567.2006.02335.x; Oliva R, 2010, P NATL ACAD SCI USA, V107, P4135, DOI 10.1073/pnas.0910632107; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Rojek A, 2008, ANNU REV PHYSIOL, V70, P301, DOI 10.1146/annurev.physiol.70.113006.100452; Romani N, 2010, IMMUNOL REV, V234, P120, DOI 10.1111/j.0105-2896.2009.00886.x; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Savage DF, 2003, PLOS BIOL, V1, P334, DOI 10.1371/journal.pbio.0000072; Savina A, 2007, IMMUNOL REV, V219, P143, DOI 10.1111/j.1600-065X.2007.00552.x; Sohara E, 2005, AM J PHYSIOL-RENAL, V289, pF1195, DOI 10.1152/ajprenal.00133.2005; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Verkman AS, 2008, SEMIN NEPHROL, V28, P217, DOI 10.1016/j.semnephrol.2008.03.004; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; Wang GF, 2008, CLIN EXP IMMUNOL, V153, P410, DOI 10.1111/j.1365-2249.2008.03702.x; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; Yang BX, 2006, FEBS LETT, V580, P6679, DOI 10.1016/j.febslet.2006.11.025	36	30	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					211	218		10.1096/fj.11-186627	http://dx.doi.org/10.1096/fj.11-186627			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21968069				2022-12-28	WOS:000299202200022
J	Kamper, N; Franken, S; Temme, S; Koch, S; Bieber, T; Koch, N				Kaemper, Nadine; Franken, Sebastian; Temme, Sebastian; Koch, Susanne; Bieber, Thomas; Koch, Norbert			gamma-Interferon-regulated chaperone governs human lymphocyte antigen class II expression	FASEB JOURNAL			English	Article						HLA class III-encoded BAT3; BAG6; class II transactivator; CIITA; HLA class II	B-ASSOCIATED TRANSCRIPT-3; TRANSACTIVATOR CIITA; NUCLEAR TRANSPORT; INVARIANT CHAIN; MHC; COMPLEX; SCYTHE; BINDING; HLA; APOPTOSIS	Antigen presentation by human lymphocyte antigen (HLA) class II peptide receptors alerts the immune system to infections. In antigen-presenting cells (APCs), HLA class II, HLA-DM, and associated invariant chain-encoding genes are exclusively regulated by the interferon gamma (IFN gamma)-inducible class II transactivator (CIITA). Control of CIITA expression could therefore govern expression of class II peptide receptors in the diverse group of APCs. We discovered that elevation of the HLA class III region encoded B-associated transcript 3 (BAT3) increases and depletion of BAT3 decreases expression of HLA class II, HLA-DM, and invariant chain. IFN gamma strongly elevates BAT3 transcription in various tumor cell lines and in primary macrophages. BAT3 chaperones the simultaneously IFN gamma-induced CIITA. Following IFN gamma-treatment, both CIITA and BAT3 translocate from the cytosol to the nucleus. The nuclear import of CIITA mediated by IFN gamma controls activation of HLA class II genes. BAT3 is a novel key regulator of components of the HLA class II processing pathway. We present a mechanism explaining how parallel IFN gamma-mediated regulation of CIITA and of its chaperone BAT3 controls the level of components of the HLA class II processing pathway.-Kamper, N., Franken, S., Temme, S., Koch, S., Bieber, T., Koch, K. gamma-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J. 26, 104-116 (2012). www.fasebj.org	[Koch, Norbert] Univ Bonn, Abt Immunbiol, Inst Genet, Div Immunobiol, D-53117 Bonn, Germany; [Franken, Sebastian] Univ Bonn, Inst Biochem, D-53117 Bonn, Germany; [Koch, Susanne; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-53117 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Koch, N (corresponding author), Univ Bonn, Abt Immunbiol, Inst Genet, Div Immunobiol, Romerstr 164, D-53117 Bonn, Germany.	norbert.koch@uni-bonn.de		Franken, Sebastian/0000-0003-4844-6389	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Dr. Endl and Mr. Wurst (Flow Cytometry Core Facility, Institute of Molecular Medicine and Experimental Immunology, Bonn, Germany) for cell sorting; Dr. Zinke (Bonn, Germany) for instructions on the PCR detection system; Dr. B. Dobberstein for valuable discussions; and T. Ebert, S. Herzog, S. Schnautz, and A. Konig for technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft.	BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Beck S, 1999, IMMUNOL REV, V167, P201, DOI 10.1111/j.1600-065X.1999.tb01393.x; Bhat KP, 2010, IMMUNOL CELL BIOL, V88, P807, DOI 10.1038/icb.2010.45; Bhat KP, 2010, J BIOL CHEM, V285, P25893, DOI 10.1074/jbc.M110.127746; Camacho-Carvajal MM, 2004, INT IMMUNOL, V16, P65, DOI 10.1093/intimm/dxh010; Corduan A, 2009, CELL MOL LIFE SCI, V66, P1998, DOI 10.1007/s00018-009-9198-z; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V36, P345; Desmots F, 2005, MOL CELL BIOL, V25, P10329, DOI 10.1128/MCB.25.23.10329-10337.2005; Desmots F, 2008, J BIOL CHEM, V283, P3264, DOI 10.1074/jbc.M706419200; Ensminger AW, 2010, INFECT IMMUN, V78, P3905, DOI 10.1128/IAI.00344-10; Favaloro V, 2010, J CELL SCI, V123, P1522, DOI 10.1242/jcs.055970; Hessa T, 2011, NATURE, V475, P394, DOI 10.1038/nature10181; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Kabbage M, 2008, CELL MOL LIFE SCI, V65, P1390, DOI 10.1007/s00018-008-7535-2; Kikukawa Y, 2005, FEBS J, V272, P6373, DOI 10.1111/j.1742-4658.2005.05032.x; Krawczyk M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000058; LAMPSON LA, 1980, J IMMUNOL, V125, P293; Lehner B, 2004, GENOMICS, V83, P153, DOI 10.1016/S0888-7543(03)00235-0; Leznicki P, 2010, J CELL SCI, V123, P2170, DOI 10.1242/jcs.066738; Manchen ST, 2001, BIOCHEM BIOPH RES CO, V287, P1075, DOI 10.1006/bbrc.2001.5701; Mariappan M, 2010, NATURE, V466, P1120, DOI 10.1038/nature09296; Minami R, 2007, BIOCHEM J, V405, P495, DOI 10.1042/BJ20061886; Minami R, 2010, J CELL BIOL, V190, P637, DOI 10.1083/jcb.200908092; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Neumann J, 2001, J BIOL CHEM, V276, P13469, DOI 10.1074/jbc.M010629200; Nguyen P, 2008, MOL CELL BIOL, V28, P6720, DOI 10.1128/MCB.00568-08; Pai RK, 2002, J IMMUNOL, V169, P1326, DOI 10.4049/jimmunol.169.3.1326; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; Sasaki T, 2007, GENE DEV, V21, P848, DOI 10.1101/gad.1534107; Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Strambio-De-Castillia C, 2010, NAT REV MOL CELL BIO, V11, P490, DOI 10.1038/nrm2928; Temme S, 2010, J IMMUNOL, V184, P236, DOI 10.4049/jimmunol.0902192; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Vandiedonck C, 2004, P NATL ACAD SCI USA, V101, P15464, DOI 10.1073/pnas.0406756101; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Wagstaff KM, 2009, TRAFFIC, V10, P1188, DOI 10.1111/j.1600-0854.2009.00937.x; Wang QY, 2011, MOL CELL, V42, P758, DOI 10.1016/j.molcel.2011.05.010; WATANABE M, 1983, TRANSPLANTATION, V36, P712, DOI 10.1097/00007890-198336060-00025; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787; Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007	45	25	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2012	26	1					104	116		10.1096/fj.11-189670	http://dx.doi.org/10.1096/fj.11-189670			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21940994				2022-12-28	WOS:000299202200012
J	Nassar, D; Droitcourt, C; Mathieu-d'Argent, E; Kim, MJ; Khosrotehrani, K; Aractingi, S				Nassar, Dany; Droitcourt, Catherine; Mathieu-d'Argent, Emmanuelle; Kim, Min Ji; Khosrotehrani, Kiarash; Aractingi, Selim			Fetal progenitor cells naturally transferred through pregnancy participate in inflammation and angiogenesis during wound healing	FASEB JOURNAL			English	Article						microchimerism; skin; VEGFa	MESENCHYMAL STEM-CELLS; MARROW-DERIVED CELLS; BONE-MARROW; MATERNAL TISSUE; BLOOD; SKIN; MICROCHIMERISM; CONTRIBUTE; ORIGIN; REPAIR	The phenotype and fate of fetal microchimeric cells transfered into the maternal circulation during pregnancy are not well described. Since progenitors from distal sites mobilize during wound healing, we analyzed the recruitment and plasticity of fetal progenitors into maternal wounds. Wounds were generated on normal and bleomycin-induced fibrotic skin of parous or pregnant wild-type females with fluorescent GFP(+) fetuses. Analyses were performed on skin and blood specimens through PCR, immunohistochemistry, and flow cytometry. Controls consisted of parous and pregnant females without wounds and virgin females with wounds. Fetal cells were detected in all skin specimens of parous mice as long as healing was not achieved. During early stages of wound healing, fetal cells expressed mainly leukocyte markers, while in later phases endothelial markers prevailed. Fetally derived vessels connected to maternal circulation were also found, demonstrating the transfer of fetal endothelial progenitor cells. Wounding mobilized fetal CD34(+) ckit(-) cells into the blood during pregnancy. Most of this population was CD11b(-)VEGFR2(-). Another part was CD11b(+) with a fraction expressing VEGFR2. VEGFa-spiked Matrigel plugs partially mimicked this fetal progenitor recruitment and mobilization into the blood. In summary, fetal cells that mobilize in response to wounding are mainly progenitor cells and participate in angiogenesis and inflammation.-Nassar, D., Droitcourt, C., Mathieu-d'Argent, E., Kim, M. J., Khosrotehrani, K., Aractingi, S. Fetal progenitor cells naturally transferred through pregnancy participate in inflammation and angiogenesis during wound healing. FASEB J. 26, 149-157 (2012). www.fasebj.org	[Nassar, Dany; Droitcourt, Catherine; Mathieu-d'Argent, Emmanuelle; Kim, Min Ji; Khosrotehrani, Kiarash; Aractingi, Selim] Univ Paris 06, UMR 938, F-75012 Paris, France; [Nassar, Dany; Droitcourt, Catherine; Mathieu-d'Argent, Emmanuelle; Kim, Min Ji; Khosrotehrani, Kiarash; Aractingi, Selim] St Antoine Res Ctr, U938, Inst Natl Sante & Rech Med INSERM, Paris, France; [Khosrotehrani, Kiarash] Univ Queensland, UQ Ctr Clin Res, Brisbane, Qld, Australia; [Aractingi, Selim] Hop Tenon, AP HP, Dept Dermatol, F-75970 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Queensland; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Nassar, D (corresponding author), Univ Paris 06, INSERM, UMR S 938, Ctr Rech St Antoine,Lab Cellules Souches Foetales, 27 Rue Chaligny, F-75012 Paris, France.	dany.nassar@inserm.fr	kim, minji/GRX-9996-2022; Khosrotehrani, Kiarash/M-8025-2015	Khosrotehrani, Kiarash/0000-0002-6406-4076; kim, Min Ji/0000-0002-1403-9331; Aractingi, Selim/0000-0002-7766-2673; Nassar, Dany/0000-0001-6780-0721	Pierre et Marie Curie University Paris 6; Societe Francaise de Dermatologie; ANR; Fondation Rene Touraine; STEM-Pole Ile-de-France; National Health and Medical Research Council [569822]	Pierre et Marie Curie University Paris 6; Societe Francaise de Dermatologie; ANR(French National Research Agency (ANR)); Fondation Rene Touraine; STEM-Pole Ile-de-France; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by Pierre et Marie Curie University Paris 6, the Societe Francaise de Dermatologie, and the ANR PHYSIO2007 funding. D.N. was supported by the Fondation Rene Touraine and STEM-Pole Ile-de-France. K. K. was supported by National Health and Medical Research Council project grant 569822. The authors thank Philippe Fontange (Plateforme d'Imagerie IFR65, Hopital Tenon) for providing technical support and access to confocal microscopy, and Anne-Marie Faussat (Plateforme de Cytometrie IFR65, Saint-Antoine Research Centre). The authors thank Edwige Roy for important advice on flow cytometry and Elke Seppanen for proofreading the manuscript. Author contributions: D.N.: collection and assembly of data, data analysis and interpretation, and manuscript writing; C. D.: collection and assembly of data; E. M.-D.: collection and assembly of data; M.J.K.: collection and assembly of data; K. K.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript; S. A.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript. The authors declare no conflicts of interest.	Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Awad O, 2005, STEM CELLS, V23, P575, DOI 10.1634/stemcells.2004-0185; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Droitcourt C, 2008, J EUR ACAD DERMATOL, V22, P1256, DOI 10.1111/j.1468-3083.2008.02602.x; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; Galiano RD, 2004, AM J PATHOL, V164, P1935, DOI 10.1016/S0002-9440(10)63754-6; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Hildbrand P, 2004, BLOOD, V104, P2010, DOI 10.1182/blood-2003-12-4219; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Hristov M, 2009, CYTOM PART A, V75A, P848, DOI 10.1002/cyto.a.20772; Huu SN, 2007, P NATL ACAD SCI USA, V104, P1871, DOI 10.1073/pnas.0606490104; Huu SN, 2009, AM J PATHOL, V174, P630, DOI 10.2353/ajpath.2009.080566; Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569; Khosrotehrani K, 2007, HUM REPROD, V22, P654, DOI 10.1093/humrep/del426; Khosrotehrani K, 2005, J CELL SCI, V118, P1559, DOI 10.1242/jcs.02332; Khosrotehrani K, 2005, J REPROD IMMUNOL, V66, P1, DOI 10.1016/j.jri.2005.02.001; Khosrotehrani K, 2004, HUM REPROD, V19, P2460, DOI 10.1093/humrep/deh445; Khosrotehrani K, 2004, JAMA-J AM MED ASSOC, V292, P75, DOI 10.1001/jama.292.1.75; Khosrotehrani K, 2008, J IMMUNOL, V180, P889, DOI 10.4049/jimmunol.180.2.889; O'Donoghue K, 2004, LANCET, V364, P179, DOI 10.1016/S0140-6736(04)16631-2; Parant O, 2009, LAB INVEST, V89, P915, DOI 10.1038/labinvest.2009.55; Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017; Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Tan XW, 2005, STEM CELLS, V23, P1443, DOI 10.1634/stemcells.2004-0169; Tepper OM, 2010, DIABETES, V59, P1974, DOI 10.2337/db09-0185; Wang Y, 2004, BIOCHEM BIOPH RES CO, V325, P961, DOI 10.1016/j.bbrc.2004.10.105; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Yamamoto T, 1999, J INVEST DERMATOL, V112, P456, DOI 10.1046/j.1523-1747.1999.00528.x; Yoder MC, 2010, ARTERIOSCL THROM VAS, V30, P1094, DOI 10.1161/ATVBAHA.109.191635	33	39	42	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					149	157		10.1096/fj.11-180695	http://dx.doi.org/10.1096/fj.11-180695			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21974929				2022-12-28	WOS:000299202200016
J	Wenzel, UA; Bank, E; Florian, C; Forster, S; Zimara, N; Steinacker, J; Klinger, M; Reiling, N; Ritter, U; van Zandbergen, G				Wenzel, Ulf Alexander; Bank, Elena; Florian, Christian; Foerster, Sabine; Zimara, Nicole; Steinacker, Jochen; Klinger, Matthias; Reiling, Norbert; Ritter, Uwe; van Zandbergen, Ger			Leishmania major parasite stage-dependent host cell invasion and immune evasion	FASEB JOURNAL			English	Article						human macrophages; neutrophils; amastigotes; promastigotes; axenic culture; endocytosis and phagocytosis	AXENIC AMASTIGOTES; GENE-EXPRESSION; MACROPHAGES; DONOVANI; PROMASTIGOTES; INFECTION; LIPOPHOSPHOGLYCAN; CHOLESTEROL; TEMPERATURE; CULTIVATION	Leishmania pathogenesis is primarily studied using the disease-inducing promastigote stage of Leishmania major. Despite many efforts, all attempts so far have failed to culture the disease-relevant multiplying amastigote stage of L. major. Here, we established a stably growing axenic L. major amastigote culture system that was characterized genetically, morphologically, and by stage-specific DsRed protein expression. We found parasite stage-specific disease development in resistant C57BL/6 mice. Human neutrophils, as first host cells for promastigotes, do not take up amastigotes. In human macrophages, we observed an amastigote-specific complement receptor 3-mediated, endocytotic entry mechanism, whereas promastigotes are taken up by complement receptor 1-mediated phagocytosis. Promastigote infection of macrophages induced the inflammatory mediators TNF, CCL3, and CCL4, whereas amastigote infection was silent and resulted in significantly increased parasite numbers: from 7.1 +/- 1.4 (after 3 h) to 20.1 +/- 7.9 parasites/cell (after 96 h). Our study identifies Leishmania stage-specific disease development, host cell preference, entry mechanism, and immune evasion. Since the amastigote stage is the disease-propagating form found in the infected mammalian host, the newly developed L. major axenic cultures will serve as an important tool in better understanding the amastigote-driven immune response in leishmaniasis.-Wenzel, U. A., Bank, E., Florian, C., Forster, S., Zimara, N., Steinacker, J., Klinger, M., Reiling, N., Ritter, U., van Zandbergen, G. Leishmania major parasite stage-dependent host cell invasion and immune evasion. FASEB J. 26, 29-39 (2012). www.fasebj.org	[Bank, Elena; Foerster, Sabine; van Zandbergen, Ger] Fed Inst Vaccines & Biomed, Div Immunol, Paul Ehrlich Inst, D-63225 Langen, Germany; [Wenzel, Ulf Alexander; Bank, Elena; Steinacker, Jochen; van Zandbergen, Ger] Univ Clin Ulm, Inst Med Microbiol & Hyg, Ulm, Germany; [Wenzel, Ulf Alexander] Univ Gothenburg, Dept Microbiol & Immunol, Sahlgrenska Acad, Mucosal Immunobiol & Vaccine Ctr MIVAC, Gothenburg, Sweden; [Florian, Christian; Zimara, Nicole; Ritter, Uwe] Univ Regensburg, Dept Immunol, Regensburg, Germany; [Klinger, Matthias] Univ Lubeck, Inst Anat, Lubeck, Germany; [Reiling, Norbert] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Div Microbial Interface Biol, Borstel, Germany	Paul Ehrlich Institute; Ulm University; University of Gothenburg; University of Regensburg; University of Lubeck; Forschungszentrum Borstel	van Zandbergen, G (corresponding author), Fed Inst Vaccines & Biomed, Div Immunol, Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	ger.zandbergen@pei.de	van Zandbergen, Ger/M-1571-2013; Reiling, Norbert/D-6796-2013; Förster, Sabine/I-4714-2012; Steinacker, Juergen M. M/E-6876-2015	Reiling, Norbert/0000-0001-6673-4291; Steinacker, Juergen M. M/0000-0001-8901-9450	German Research Foundation [VA204 2-1, ZA533 5-1, ZA533 7-1, SFB 415-C7]; Bundesministerium fur Bildung und Forschung [01KI0784]	German Research Foundation(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	The authors thank S. Diebold, S. Moller, L. Dost, and K. Strele for excellent technical help. The authors thank Dr. G. Schonian (Charite, Humboldt University, Berlin, Germany) for helping to establish the ITS1 analyses and Dr. G. Spath (Institute Pasteur, Paris, France) for kindly providing the anti-LPG antibody WIC79.3. This research is supported in part by grants from the German Research Foundation (VA204 2-1, ZA533 5-1, and ZA533 7-1 to G.V.Z.; and SFB 415-C7 to N.R.) and the Bundesministerium fur Bildung und Forschung, Project 01KI0784, WP D (to N.R.).	Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BERMAN JD, 1981, AM J TROP MED HYG, V30, P318, DOI 10.4269/ajtmh.1981.30.318; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; Bogdan C, 2000, J EXP MED, V191, P2121, DOI 10.1084/jem.191.12.2121; Charmoy M, 2007, J LEUKOCYTE BIOL, V82, P288, DOI 10.1189/jlb.0706440; Cohen-Freue G, 2007, INT J PARASITOL, V37, P1077, DOI 10.1016/j.ijpara.2007.04.011; Courret N, 2002, J CELL SCI, V115, P2303; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; DOYLE PS, 1991, EXP PARASITOL, V73, P326, DOI 10.1016/0014-4894(91)90104-5; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106; Gupta N, 2001, TRENDS PARASITOL, V17, P150, DOI 10.1016/S1471-4922(00)01811-0; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Leifso K, 2007, MOL BIOCHEM PARASIT, V152, P35, DOI 10.1016/j.molbiopara.2006.11.009; Lodge R, 2005, CLIN IMMUNOL, V114, P256, DOI 10.1016/j.clim.2004.07.018; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; Mizbani A, 2009, VACCINE, V28, P53, DOI 10.1016/j.vaccine.2009.09.114; Mordue DG, 1999, J EXP MED, V190, P1783, DOI 10.1084/jem.190.12.1783; Nasereddin A, 2010, ACTA TROP, V113, P72, DOI 10.1016/j.actatropica.2009.09.009; Neumann J, 2010, FASEB J, V24, P4599, DOI 10.1096/fj.10-160994; Ouakad M, 2007, PARASITOL RES, V101, P473, DOI 10.1007/s00436-007-0491-1; Ribeiro-Gomes FL, 2007, J IMMUNOL, V179, P3988, DOI 10.4049/jimmunol.179.6.3988; Ritter U, 2002, PARASITE IMMUNOL, V24, P295, DOI 10.1046/j.1365-3024.2002.00467.x; Rupp J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006020; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Schonian G, 2003, DIAGN MICR INFEC DIS, V47, P349, DOI 10.1016/S0732-8893(03)00093-2; Spath GF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000381; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; van Zandbergen G, 2006, P NATL ACAD SCI USA, V103, P13837, DOI 10.1073/pnas.0600843103; Veiga E, 2007, CELL HOST MICROBE, V2, P340, DOI 10.1016/j.chom.2007.10.001; Weiss R, 2007, VACCINE, V25, P25, DOI 10.1016/j.vaccine.2006.07.044; Willems E, 2008, ANAL BIOCHEM, V379, P127, DOI 10.1016/j.ab.2008.04.036; ZENIAN A, 1979, J CELL SCI, V39, P187; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	41	34	34	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					29	39		10.1096/fj.11-184895	http://dx.doi.org/10.1096/fj.11-184895			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21908716				2022-12-28	WOS:000299202200005
J	Gabibov, AG; Belogurov, AA; Lomakin, YA; Zakharova, MY; Avakyan, ME; Dubrovskaya, VV; Smirnov, IV; Ivanov, AS; Molnar, AA; Gurtsevitch, VE; Diduk, SV; Smirnova, KV; Avalle, B; Sharanova, SN; Tramontano, A; Friboulet, A; Boyko, AN; Ponomarenko, NA; Tikunova, NV				Gabibov, Alexander G.; Belogurov, Alexey A., Jr.; Lomakin, Yakov A.; Zakharova, Maria Yu; Avakyan, Marat E.; Dubrovskaya, Viktorya V.; Smirnov, Ivan V.; Ivanov, Alexis S.; Molnar, Andrey A.; Gurtsevitch, Vladimir E.; Diduk, Sergey V.; Smirnova, Ksenia V.; Avalle, Berangere; Sharanova, Svetlana N.; Tramontano, Alfonso; Friboulet, Alain; Boyko, Alexey N.; Ponomarenko, Natalia A.; Tikunova, Nina V.			Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen	FASEB JOURNAL			English	Article						Epstein-Barr virus; latent membrane protein 1; phage-display library	EPSTEIN-BARR-VIRUS; DISABILITY STATUS SCALE; CEREBROSPINAL-FLUID; B-CELLS; LATENT MEMBRANE-PROTEIN-1; CATALYTIC ANTIBODIES; IMMUNE-RESPONSE; MS; INFECTION; AUTOANTIBODIES	Multiple sclerosis (MS) is a widespread neurodegenerative autoimmune disease with unknown etiology. It is increasingly evident that, together with pathogenic T cells, autoreactive B cells are among the major players in MS development. The analysis of myelin neuroantigen-specific antibody repertoires and their possible cross-reactivity against environmental antigens, including viral proteins, could shed light on the mechanism of MS induction and progression. A phage display library of single-chain variable fragments (scFvs) was constructed from blood lymphocytes of patienst with MS as a potential source of representative MS autoantibodies. Structural alignment of 13 clones selected toward myelin basic protein (MBP), one of the major myelin antigens, showed high homology within variable regions with cerebrospinal fluid MS-associated antibodies as well as with antibodies toward Epstein-Barr latent membrane protein 1 (LMP1). Three scFv clones showed pronounced specificity to MBP fragments 65-92 and 130-156, similar to the serum MS antibodies. One of these clones, designated E2, in both scFv and full-size human antibody constructs, was shown to react with both MBP and LMP1 proteins in vitro, suggesting natural cross-reactivity. Thus, antibodies induced against LMP1 during Epstein-Barr virus infection might act as inflammatory trigger by reacting with MBP, suggesting molecular mimicry in the mechanism of MS pathogenesis.-Gabibov, A. G., Belogurov, A. A., Jr. Lomakin, Y. A., Zakharova, M. Y., Avakyan, M. E., Dubrovskaya, V. V., Smirnov, I. V., Ivanov, A. S., Molnar, A. A., Gurtsevitch, V. E., Diduk, S. V., Smirnova, K. V., Avalle, B., Sharanova, S. N., Tramontano, A., Friboulet, A., Boyko, A. N., Ponomarenko, N. A., Tikunova, N. V. Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. FASEB J. 25, 4211-4221 (2011). www.fasebj.org	[Gabibov, Alexander G.; Belogurov, Alexey A., Jr.; Lomakin, Yakov A.; Zakharova, Maria Yu; Avakyan, Marat E.; Smirnov, Ivan V.; Ponomarenko, Natalia A.] Russian Acad Sci, MM Shemyakin & YA Ovchinnikov Inst Bioorgan Chem, Moscow 117901, Russia; [Gabibov, Alexander G.; Belogurov, Alexey A., Jr.] Russian Acad Sci, Inst Gene Biol, Moscow 117901, Russia; [Dubrovskaya, Viktorya V.; Tikunova, Nina V.] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Novosibirsk, Russia; [Ivanov, Alexis S.; Molnar, Andrey A.] Russian Acad Med Sci, Inst Biomed Chem, Moscow, Russia; [Gurtsevitch, Vladimir E.; Diduk, Sergey V.; Smirnova, Ksenia V.] Russian Acad Med Sci, NN Blokhin Inst Carcinogenesis, Moscow, Russia; [Avalle, Berangere; Friboulet, Alain] Univ Technol Compiegne, CNRS, UMR 6022, F-60206 Compiegne, France; [Sharanova, Svetlana N.; Boyko, Alexey N.] Russian State Med Univ, Dept Neurol & Neurosurg, City Hosp 11, Moscow Multiple Sclerosis Ctr, Moscow 117437, Russia; [Tramontano, Alfonso] Univ Calif Davis, Sch Med, Davis, CA 95616 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Pirogov Russian National Research Medical University; University of California System; University of California Davis	Gabibov, AG (corresponding author), RAS, Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117901, Russia.	gabibov@mx.ibch.ru	Boyko, Alexey N/Z-2106-2018; Diduk, Sergey/AAV-2269-2021; Tikunova, Nina/J-5701-2014; Lomakin, Yakov/F-9700-2017; Belogurov, Alexey/L-5859-2017; Ivanov, Alexis S/B-7090-2012; Smirnov, Ivan/N-5635-2017; Lomakin, Yakov/ABF-7470-2020; Smirnov, Ivan V/B-2491-2014	Lomakin, Yakov/0000-0002-3514-5395; Belogurov, Alexey/0000-0002-2033-9621; Ivanov, Alexis S/0000-0002-7022-6748; Smirnov, Ivan/0000-0002-0384-6568; Lomakin, Yakov/0000-0002-3514-5395; Smirnov, Ivan V/0000-0002-0384-6568; Diduk, S.V./0000-0002-8415-9275; Smirnova, K.V./0000-0001-6209-977X; Ponomarenko, Natalia/0000-0003-3129-3515; Gurtsevitch, V.E./0000-0003-1840-4364; Boyko, Alexei/0000-0003-3306-9541	NATO [982833]; Russian Education Agency [N P1371]; PICS CNRS France-Russia [N 4238]; Russian Foundation for Basic Research [10.04.00673a, 07.04.92168]; Federal Special-Purpose Program, Research and Development in Priority Directions of Growth of Scientific-Technological Complex of Russia; ICGEB Scientific Schools [64658.2010]; Russian Academy of Sciences	NATO(NATO (North Atlantic Treaty Organisation)); Russian Education Agency; PICS CNRS France-Russia; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Federal Special-Purpose Program, Research and Development in Priority Directions of Growth of Scientific-Technological Complex of Russia; ICGEB Scientific Schools; Russian Academy of Sciences(Russian Academy of Sciences)	Anti-LMP1 monoclonal antibody (clone S12) and pSG5/LMP1 plasmid were a generous gift from Dr. Friedrich A. Grasser (Institute of Medical Microbiology, Virology, and Hygiene, Hamburg, Germany). Anti-MBP murine polyclonal serum antibodies were kindly provided by Dr. Dobroslav Melamed (Assaf Harofeh Medical Center, Zerifin, Israel). This research was performed in frames of the Skolkovo program and supported by NATO SfP#982833; Russian Education Agency contract N P1371; PICS CNRS N 4238 France-Russia; Russian Foundation for Basic Research grants 10.04.00673a and 07.04.92168; the Federal Special-Purpose Program, Research and Development in Priority Directions of Growth of Scientific-Technological Complex of Russia for 2007-2012; ICGEB Scientific Schools grant 64658.2010, Chemical Basis of Biocatalysis; and the Fundamental Science for Medicine and Molecular and Cellular Biology programs of the Russian Academy of Sciences.	Ascherio A, 2007, ANN NEUROL, V61, P288, DOI 10.1002/ana.21117; Belogurov AA, 2008, J IMMUNOL, V180, P1258, DOI 10.4049/jimmunol.180.2.1258; Belogurov A, 2009, BIOESSAYS, V31, P1161, DOI 10.1002/bies.200900020; Cepok S, 2005, J CLIN INVEST, V115, P1352, DOI 10.1172/JCI200523661; Chamczuk AJ, 2002, J IMMUNOL METHODS, V262, P21, DOI 10.1016/S0022-1759(01)00522-1; Diduk SV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1134, DOI 10.1134/S0006297908100106; Fang CY, 2007, INTERVIROLOGY, V50, P254, DOI 10.1159/000101996; Farrell RA, 2009, NEUROLOGY, V73, P32, DOI 10.1212/WNL.0b013e3181aa29fe; FRASER KB, 1979, LANCET, V2, P715; Haahr S, 2004, ACTA NEUROL SCAND, V109, P270, DOI 10.1046/j.1600-0404.2003.00221.x; Hauser SL, 2006, NEURON, V52, P61, DOI 10.1016/j.neuron.2006.09.011; Hikada Masaki, 2010, Nat Immunol, V11, P1065, DOI 10.1038/ni1210-1065; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Jafari N, 2010, J CLIN VIROL, V49, P26, DOI 10.1016/j.jcv.2010.06.007; Jaquiery E, 2010, EUR J IMMUNOL, V40, P878, DOI 10.1002/eji.200939761; KABAT EA, 1948, AM J MED, V4, P653, DOI 10.1016/S0002-9343(48)90389-1; Korn T, 2010, RESULTS PROBL CELL D, V51, P43, DOI 10.1007/400_2008_17; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lamboy JA, 2008, CHEMBIOCHEM, V9, P2846, DOI 10.1002/cbic.200800366; Lambracht-Washington D, 2007, J NEUROIMMUNOL, V186, P164, DOI 10.1016/j.jneuroim.2007.03.002; Levin LI, 2010, ANN NEUROL, V67, P824, DOI 10.1002/ana.21978; Libbey JE, 2010, RESULTS PROBL CELL D, V51, P21, DOI 10.1007/400_2008_12; Lindsey JW, 2010, EUR J NEUROL, V17, P1263, DOI 10.1111/j.1468-1331.2010.03005.x; Lunemann JD, 2007, J VIROL, V81, P6777, DOI 10.1128/JVI.00153-07; Lunemann JD, 2009, TRENDS IMMUNOL, V30, P243, DOI 10.1016/j.it.2009.03.007; Lycke J, 1996, J NEUROL, V243, P214, DOI 10.1007/BF00868517; Maghzi Amir-Hadi, 2011, Pathophysiology, V18, P13, DOI 10.1016/j.pathophys.2010.04.003; Meij P, 1999, J INFECT DIS, V179, P1108, DOI 10.1086/314704; Meij P, 2002, INT J CANCER, V99, P93, DOI 10.1002/ijc.10309; Meij P, 2002, J MED VIROL, V68, P370, DOI 10.1002/jmv.10213; Nociti V, 2010, J NEUROIMMUNOL, V225, P149, DOI 10.1016/j.jneuroim.2010.04.007; Pender MP, 2007, CURR ALLERGY ASTHM R, V7, P285, DOI 10.1007/s11882-007-0043-x; Pender MP, 2009, AUTOIMMUN REV, V8, P563, DOI 10.1016/j.autrev.2009.01.017; PESCE AJ, 1986, J IMMUNOL METHODS, V87, P21, DOI 10.1016/0022-1759(86)90339-X; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; Ponomarenko NA, 2002, J IMMUNOL METHODS, V269, P197, DOI 10.1016/S0022-1759(02)00324-1; Reindl M, 2010, RESULTS PROBL CELL D, V51, P99, DOI 10.1007/400_2008_16; Reindl M, 2006, J NEUROIMMUNOL, V180, P50, DOI 10.1016/j.jneuroim.2006.06.028; Sawcer S, 2010, ANN NEUROL, V67, P3, DOI 10.1002/ana.21911; Serafini B, 2007, J EXP MED, V204, P2899, DOI 10.1084/jem.20071030; Souza TA, 2005, P NATL ACAD SCI USA, V102, P18093, DOI 10.1073/pnas.0509311102; Stepanov AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020991; SUMAYA CV, 1980, ARCH NEUROL-CHICAGO, V37, P94, DOI 10.1001/archneur.1980.00500510052009; Thacker EL, 2006, ANN NEUROL, V59, P499, DOI 10.1002/ana.20820; von Budingen HC, 2008, EUR J IMMUNOL, V38, P2014, DOI 10.1002/eji.200737784; Vorob'ev I I, 2001, Bioorg Khim, V27, P257; XIAO BG, 1991, J NEUROIMMUNOL, V31, P91, DOI 10.1016/0165-5728(91)90014-X; Yu XL, 2011, J NEUROIMMUNOL, V233, P192, DOI 10.1016/j.jneuroim.2010.11.007; Yu XL, 2006, J NEUROIMMUNOL, V172, P121, DOI 10.1016/j.jneuroim.2005.11.010; Zhang YP, 2005, J CLIN IMMUNOL, V25, P254, DOI 10.1007/s10875-005-4083-5	51	47	54	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4211	4221		10.1096/fj.11-190769	http://dx.doi.org/10.1096/fj.11-190769			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21859892				2022-12-28	WOS:000298138100014
J	Jung, J; Coe, H; Michalak, M				Jung, Joanna; Coe, Helen; Michalak, Marek			Specialization of endoplasmic reticulum chaperones for the folding and function of myelin glycoproteins P0 and PMP22	FASEB JOURNAL			English	Article						calreticulin; calnexin; ERp57; myelin disease; protein folding; quality control	PROTEIN-ZERO; CALNEXIN DEFICIENCY; QUALITY-CONTROL; DISULFIDE BOND; CALRETICULIN; DOMAIN; ER; NEUROPATHY; STRESS; VIVO	Peripheral myelin protein 22 (PMP22) and protein 0 (P0) are major peripheral myelin glycoproteins, and mutations in these two proteins are associated with hereditary demyelinating peripheral neuropathies. Calnexin, calreticulin, and ERp57 are critical components of protein quality control responsible for proper folding of newly synthesized glycoproteins. Here, using confocal microscopy, we show that cell surface targeting of P0 and PMP22 is not affected in the absence of the endoplasmic reticulum chaperones. However, the folding and function (adhesiveness) of PMP22 and P0, measured using the adhesion assay, are affected significantly in the absence of calnexin but not in the absence of calreticulin. Deficiency in oxidoreductase ERp57 results in impaired folding and function of P0, a disulfide bond-containing protein, but does not have any effect on folding or function of PMP22 (a protein that does not contain a disulfide bond). We concluded that calnexin and ERp57, but not calreticulin, play an important role in the biology of peripheral myelin proteins PMP22 and P0, and, consequently, these chaperones may contribute to the pathogenesis of peripheral neuropathies and the diversity of these neurological disorders.-Jung, J., Coe, H., Michalak, M. Specialization of endoplasmic reticulum chaperones for the folding and function of myelin glycoproteins P0 and PMP22. FASEB J. 25, 3929-3937 (2011). www.fasebj.org	[Jung, Joanna; Coe, Helen; Michalak, Marek] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S7, Canada; [Coe, Helen; Michalak, Marek] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S7, Canada	University of Alberta; University of Alberta	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S7, Canada.	marek.michalak@ualberta.ca			Canadian Institutes of Health Research [MOP-15291]; Alberta Innovates-Health Solutions studentship awards	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Innovates-Health Solutions studentship awards	The authors thank Jody Groenendyk for technical help and valuable advice. The authors thank Monika Dabrowska, Alison Robinson, and Aleksandra Janowicz for superb technical help. The authors thank Dr. Lucia Notterpek (University of Florida, Gainesville, FL, USA) for anti-PMP22 antibodies. This work was supported by a grant to M.M. from the Canadian Institutes of Health Research (MOP-15291). J.J. and H.C. were supported by Alberta Innovates-Health Solutions studentship awards.	ADLKOFER K, 1995, NAT GENET, V11, P274, DOI 10.1038/ng1195-274; Aebi M, 2010, TRENDS BIOCHEM SCI, V35, P74, DOI 10.1016/j.tibs.2009.10.001; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; Caramelo JJ, 2008, J BIOL CHEM, V283, P10221, DOI 10.1074/jbc.R700048200; Coe H, 2010, J BIOL CHEM, V285, P6725, DOI 10.1074/jbc.M109.054015; Coe H, 2008, CELL STRESS CHAPERON, V13, P497, DOI 10.1007/s12192-008-0049-x; Dickson KM, 2002, P NATL ACAD SCI USA, V99, P9852, DOI 10.1073/pnas.152621799; Ekici AB, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-29; Fontanini A, 2005, J BIOL CHEM, V280, P2378, DOI 10.1074/jbc.M405104200; Fortun J, 2005, J NEUROCHEM, V92, P1531, DOI 10.1111/j.1471-4159.2004.02987.x; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Grandis M, 2008, HUM MOL GENET, V17, P1877, DOI 10.1093/hmg/ddn083; Guo L, 2003, J BIOL CHEM, V278, P50645, DOI 10.1074/jbc.M309497200; Hasse B, 2004, MOL CELL NEUROSCI, V27, P370, DOI 10.1016/j.mcn.2004.06.009; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Keskanokwong T, 2007, J BIOL CHEM, V282, P23205, DOI 10.1074/jbc.M702139200; Kraus A, 2010, J BIOL CHEM, V285, P18928, DOI 10.1074/jbc.M110.107201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maattanen P, 2010, SEMIN CELL DEV BIOL, V21, P500, DOI 10.1016/j.semcdb.2010.03.006; MARTINI R, 1995, J NEUROSCI, V15, P4488; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Mobley CK, 2007, BIOCHEMISTRY-US, V46, P11185, DOI 10.1021/bi700855j; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Pennuto M, 2008, NEURON, V57, P393, DOI 10.1016/j.neuron.2007.12.021; Pfend G, 2001, NEUROCHEM RES, V26, P503, DOI 10.1023/A:1010908828134; Plotkowski ML, 2007, BIOCHEMISTRY-US, V46, P12164, DOI 10.1021/bi701066h; Quarles RH, 2002, CELL MOL LIFE SCI, V59, P1851, DOI 10.1007/PL00012510; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; Shen Shuo, 2007, Methods Mol Biol, V379, P127; Solda T, 2006, J BIOL CHEM, V281, P6219, DOI 10.1074/jbc.M513595200; Suter DM, 2006, STEM CELLS, V24, P615, DOI 10.1634/stemcells.2005-0226; Wrabetz L, 2000, J CELL BIOL, V148, P1021, DOI 10.1083/jcb.148.5.1021; Yin X, 2000, J CELL BIOL, V148, P1009, DOI 10.1083/jcb.148.5.1009; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang K, 1998, J NEUROSCI RES, V53, P1, DOI 10.1002/(SICI)1097-4547(19980701)53:1<1::AID-JNR1>3.0.CO;2-F; ZHANG KJ, 1994, J NEUROCHEM, V63, P367; Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+	40	17	17	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3929	3937		10.1096/fj.11-184911	http://dx.doi.org/10.1096/fj.11-184911			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21831887				2022-12-28	WOS:000296723100017
J	Petersen, PS; Jin, CY; Madsen, AN; Rasmussen, M; Kuhre, R; Egerod, KL; Nielsen, LB; Schwartz, TW; Holst, B				Petersen, Pia Steen; Jin, Chunyu; Madsen, Andreas Nygaard; Rasmussen, Maria; Kuhre, Rune; Egerod, Kristoffer L.; Nielsen, Lars Bo; Schwartz, Thue W.; Holst, Birgitte			Deficiency of the GPR39 receptor is associated with obesity and altered adipocyte metabolism	FASEB JOURNAL			English	Article						7TM receptor signaling; lipolysis; high-fat diet	DIET-INDUCED THERMOGENESIS; BETA-ADRENERGIC-RECEPTORS; ADIPOSE-TISSUE; ENERGY-METABOLISM; SURROGATE INDEXES; PROTEIN; LIPOLYSIS; MICE; EXPRESSION; WHITE	GPR39, a constitutively active 7TM receptor important for glucose-induced insulin secretion and maturation of pancreatic beta-cell function, is up-regulated in adipose tissue on abstinence from food and chemically induced diabetes. In the present study, we investigated the effect of GPR39 deficiency on body weight and adipocyte metabolism. GPR39-deficient mice were subjected to a high-fat diet and body composition, glucose tolerance, insulin secretion, food intake, and energy expenditure were evaluated. The cell biology of adipocyte metabolism was studied on both mRNA and protein levels. A significant increase in body weight corresponding to a 2-fold selective increase in fat mass was observed in GPR39-deficient mice fed a high-fat diet as compared with wild-type littermate controls fed the same diet. The GPR39-deficient animals had similar food intake but displayed almost eliminated diet-induced thermogenesis, measured by the oxygen consumption rate (Vo(2)) on change from normal to high-fat diet. Analysis of the adipose tissue for lipolytic enzymes demonstrated decreased level of phosphorylated hormone-sensitive lipase (HSL) and a decreased level of adipose triglyceride lipase (ATGL) by 35 and 60%, respectively, after food withdrawal in the GPR39-deficient mice. Extracellular signal-regulated kinases (ERK1/2), a signaling pathway known to be important for lipolysis, was decreased by 56% in the GPR39-deficient mice. GPR39 deficiency is associated with increased fat accumulation on a high-fat diet, conceivably due to decreased energy expenditure and adipocyte lipolytic activity.-Petersen, P. S., Jin, C., Madsen, A. N., Rasmussen, M., Kuhre, R., L. Egerod, K. L., Nielsen, L. B., Schwartz. T. W., Holst, B. Deficiency of the GPR39 receptor is associated with obesity and altered adipocyte metabolism. FASEB J. 25, 3803-3814 (2011). www.fasebj.org	[Petersen, Pia Steen; Jin, Chunyu; Madsen, Andreas Nygaard; Rasmussen, Maria; Kuhre, Rune; Egerod, Kristoffer L.; Schwartz, Thue W.; Holst, Birgitte] Univ Copenhagen, Fac Hlth Sci, Mol Pharmacol Lab, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; [Nielsen, Lars Bo] Univ Copenhagen, Fac Hlth Sci, Dept Clin Biochem, DK-2200 Copenhagen, Denmark; [Schwartz, Thue W.; Holst, Birgitte] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Novo Nordisk Foundation; University of Copenhagen	Holst, B (corresponding author), Univ Copenhagen, Mol Pharmacol Lab, Dept Pharmacol, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.	holst@sund.ku.dk	Egerod, Kristoffer L/D-9481-2012; Kuhre, Rune Ehrenreich/Q-9415-2016	Egerod, Kristoffer L/0000-0003-2781-1594; Holst, Birgitte/0000-0001-7432-097X; Schwartz, Thue W./0000-0002-0261-6904; Kuhre, Rune Ehrenreich/0000-0003-4787-340X	Danish Medical Research Council; Novo Nordisk Foundation; Lundbeck Foundation; Alfred Benzon Foundation; Danish Ministry of Science, Technology, and Innovation	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Alfred Benzon Foundation; Danish Ministry of Science, Technology, and Innovation	The authors are grateful to Bente Friis and Line Olsen for expert technical assistance and to Dr. Helen Cox for critically reading the manuscript. The study was supported by research grant from the Danish Medical Research Council, the Novo Nordisk Foundation, the Lundbeck Foundation, and the Alfred Benzon Foundation and by a grant from the Novo Nordisk Foundation to the Novo Nordisk Foundation Center for Basic Metabolic Research. This work is carried out as a part of the research program of the UNIK: Food, Fitness & Pharma for Health and Disease. The UNIK project is supported by the Danish Ministry of Science, Technology, and Innovation.	Ahmadian M, 2009, DIABETES, V58, P855, DOI 10.2337/db08-1644; Ahmed K, 2010, CELL METAB, V11, P311, DOI 10.1016/j.cmet.2010.02.012; Ahmed K, 2009, TRENDS PHARMACOL SCI, V30, P557, DOI 10.1016/j.tips.2009.09.001; Armani A, 2010, J CELL BIOCHEM, V110, P564, DOI 10.1002/jcb.22598; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Cai TQ, 2008, BIOCHEM BIOPH RES CO, V377, P987, DOI 10.1016/j.bbrc.2008.10.088; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Dittmer S, 2008, J BIOL CHEM, V283, P7074, DOI 10.1074/jbc.M704323200; Egerod KL, 2007, MOL ENDOCRINOL, V21, P1685, DOI 10.1210/me.2007-0055; Gaidhu MP, 2010, AM J PHYSIOL-CELL PH, V298, pC961, DOI 10.1152/ajpcell.00547.2009; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harada K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1182, DOI 10.1152/ajpendo.00259.2003; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2007, ENDOCRINOLOGY, V148, P13, DOI 10.1210/en.2006-0933; Holst B, 2009, ENDOCRINOLOGY, V150, P2577, DOI 10.1210/en.2008-1250; Huijsman E, 2009, AM J PHYSIOL-ENDOC M, V297, pE505, DOI 10.1152/ajpendo.00190.2009; Jaworski K, 2009, NAT MED, V15, P159, DOI 10.1038/nm.1904; Jimenez M, 2002, FEBS LETT, V530, P37, DOI 10.1016/S0014-5793(02)03387-2; Lee S, 2008, AM J PHYSIOL-ENDOC M, V294, pE261, DOI 10.1152/ajpendo.00676.2007; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Lopez M, 2008, CELL METAB, V7, P389, DOI 10.1016/j.cmet.2008.03.006; Lowell BB, 2003, J BIOL CHEM, V278, P29385, DOI 10.1074/jbc.R300011200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Moechars D, 2006, GASTROENTEROLOGY, V131, P1131, DOI 10.1053/j.gastro.2006.07.009; Muniyappa R, 2009, AM J PHYSIOL-ENDOC M, V297, pE1023, DOI 10.1152/ajpendo.00397.2009; Nogueiras R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JCI31743; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Shklyaev S, 2003, P NATL ACAD SCI USA, V100, P14217, DOI 10.1073/pnas.2333912100; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Tremblay F, 2009, ENDOCRINOLOGY, V150, P2586, DOI 10.1210/en.2008-1251; VAUGHAN M, 1964, J BIOL CHEM, V239, P401; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wang YH, 2009, CELL METAB, V9, P287, DOI 10.1016/j.cmet.2009.01.013; White UA, 2010, MOL CELL ENDOCRINOL, V318, P10, DOI 10.1016/j.mce.2009.08.023; Wijers SLJ, 2009, OBES REV, V10, P218, DOI 10.1111/j.1467-789X.2008.00538.x; Woods SC, 2008, J CLIN ENDOCR METAB, V93, pS37, DOI 10.1210/jc.2008-1630; Woods SC, 2009, CELL METAB, V9, P489, DOI 10.1016/j.cmet.2009.04.007; Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003; Zechner R, 2009, NATURE, V458, P1118, DOI 10.1038/4581118a; Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200; Zigman JM, 2005, J CLIN INVEST, V115, P3564, DOI 10.1172/JCI26002; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	47	34	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3803	3814		10.1096/fj.11-184531	http://dx.doi.org/10.1096/fj.11-184531			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21784784				2022-12-28	WOS:000296723100006
J	Ekland, EH; Schneider, J; Fidock, DA				Ekland, Eric H.; Schneider, Jessica; Fidock, David A.			Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches	FASEB JOURNAL			English	Article						Plasmodium falciparum; delayed death; drug discovery	PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; MALARIA PARASITE; DRUG-RESISTANCE; FLOW-CYTOMETRY; GROWTH; AUTOFLUORESCENCE; AZITHROMYCIN; CHLOROQUINE; INHIBITION	Malarial parasites have evolved resistance to all previously used therapies, and recent evidence suggests emerging resistance to the first-line artemisinins. To identify antimalarials with novel mechanisms of action, we have developed a high-throughput screen targeting the apicoplast organelle of Plasmodium falciparum. Antibiotics known to interfere with this organelle, such as azithromycin, exhibit an unusual phenotype whereby the progeny of drug-treated parasites die. Our screen exploits this phenomenon by assaying for "delayed death" compounds that exhibit a higher potency after two cycles of intraerythrocytic development compared to one. We report a primary assay employing parasites with an integrated copy of a firefly luciferase reporter gene and a secondary flow cytometry-based assay using a nucleic acid stain paired with a mitochondrial vital dye. Screening of the U. S. National Institutes of Health Clinical Collection identified known and novel antimalarials including kitasamycin. This inexpensive macrolide, used for agricultural applications, exhibited an in vitro IC50 in the 50 nM range, comparable to the 30 nM activity of our control drug, azithromycin. Imaging and pharmacologic studies confirmed kitasamycin action against the apicoplast, and in vivo activity was observed in a murine malaria model. These assays provide the foundation for high-throughput campaigns to identify novel chemotypes for combination therapies to treat multidrug-resistant malaria.-Ekland, E. H., Schneider, J., Fidock, D. A. Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J. 25, 3583-3593 (2011). www.fasebj.org	[Fidock, David A.] Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, Hammer Hlth Sci Ctr, New York, NY 10032 USA; [Fidock, David A.] Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Fidock, DA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, Hammer Hlth Sci Ctr, Rm 1502,701 W 168th St, New York, NY 10032 USA.	ee2196@columbia.edu; df2260@columbia.edu		Fidock, David/0000-0001-6753-8938	U.S. National Insitutes of Health [R21 NS059500]; American Recovery and Investment Act; Life Sciences Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS059500] Funding Source: NIH RePORTER	U.S. National Insitutes of Health; American Recovery and Investment Act; Life Sciences Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Marcus Lee, Rich Eastman, Rebecca Muhle, Lindsie Goss, and Philipp Heinrich for experimental, technical, and computational assistance. The authors also thank Bamini Jayabalasingham and Andrea Ecker for constructive comments on the manuscript. The authors are grateful to Wesley C. Van Voorhis and Michael H. Gelb (University of Washington, Seattle, WA, USA) for providing BMS-388891. This work was funded in part by the U.S. National Insitutes of Health (R21 NS059500 to D.A.F.), including support as a competitive revision application funded by the American Recovery and Investment Act of 2009. E.H.E. gratefully acknowledges support from the Life Sciences Research Foundation as a Hoffmann-La Roche Fellow.	Alkadi HO, 2007, CHEMOTHERAPY, V53, P385, DOI 10.1159/000109767; Aregawi M., 2010, WORLD MALARIA REPORT, pxii; Baniecki ML, 2007, ANTIMICROB AGENTS CH, V51, P716, DOI 10.1128/AAC.01144-06; Barthel D, 2008, ANTIMICROB AGENTS CH, V52, P774, DOI 10.1128/AAC.00892-07; Barton MD, 2000, NUTR RES REV, V13, P279, DOI 10.1079/095442200108729106; Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Bhakdi SC, 2007, CYTOM PART A, V71A, P662, DOI 10.1002/cyto.a.20406; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Chico RM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-255; Dahl EL, 2008, TRENDS PARASITOL, V24, P279, DOI 10.1016/j.pt.2008.03.007; Dahl EL, 2006, ANTIMICROB AGENTS CH, V50, P3124, DOI 10.1128/AAC.00394-06; Dharia NV, 2010, GENOME RES, V20, P1534, DOI 10.1101/gr.105163.110; Dharia NV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r21; Di L, 2006, DRUG DISCOV TODAY, V11, P446, DOI 10.1016/j.drudis.2006.03.004; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Eastman R. T., 2011, AGENTS CHEMOTHER; Eastman RT, 2009, NAT REV MICROBIOL, V7, P864, DOI 10.1038/nrmicro2239; Ekland EH, 2008, INT J PARASITOL, V38, P743, DOI 10.1016/j.ijpara.2008.03.004; Friesen J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001058; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Goodman CD, 2007, MOL BIOCHEM PARASIT, V152, P181, DOI 10.1016/j.molbiopara.2007.01.005; Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Istvan ES, 2011, P NATL ACAD SCI USA, V108, P1627, DOI 10.1073/pnas.1011560108; Janbon M., 1963, GAZ MED FR S, V70, P9; Jimenez-Diaz MB, 2005, CYTOM PART A, V67A, P27, DOI 10.1002/cyto.a.20169; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kalanon M, 2010, BIOCHEM SOC T, V38, P775, DOI 10.1042/BST0380775; Kalilani L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001166; Kuo MR, 2003, J BIOL CHEM, V278, P20851, DOI 10.1074/jbc.M211968200; Luntamo M, 2010, AM J TROP MED HYG, V83, P1212, DOI 10.4269/ajtmh.2010.10-0264; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Muhle RA, 2009, INT J PARASITOL, V39, P1425, DOI 10.1016/j.ijpara.2009.05.001; Nallan L, 2005, J MED CHEM, V48, P3704, DOI 10.1021/jm0491039; Nkrumah LJ, 2006, NAT METHODS, V3, P615, DOI 10.1038/NMETH904; Noedl H, 2009, TRENDS PARASITOL, V25, P540, DOI 10.1016/j.pt.2009.09.001; Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011; Okamoto N, 2009, EUKARYOT CELL, V8, P128, DOI 10.1128/EC.00267-08; PETERS W, 1965, EXP PARASITOL, V17, P80, DOI 10.1016/0014-4894(65)90012-3; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Plowe Christopher V, 2009, Trans R Soc Trop Med Hyg, V103 Suppl 1, pS11, DOI 10.1016/j.trstmh.2008.11.002; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225; Schoepflin S, 2010, AM J TROP MED HYG, V82, P529, DOI 10.4269/ajtmh.2010.09-0334; Sidhu ABS, 2007, J BIOL CHEM, V282, P2494, DOI 10.1074/jbc.M608615200; Silvie O, 2008, CURR OPIN MICROBIOL, V11, P352, DOI 10.1016/j.mib.2008.06.005; Stanway RR, 2009, BIOL CELL, V101, P415, DOI 10.1042/BC20080202; Tan KR, 2011, AM J TROP MED HYG, V84, P517, DOI 10.4269/ajtmh.2011.10-0285; Tuma RS, 1999, ANAL BIOCHEM, V268, P278, DOI 10.1006/abio.1998.3067; VANDERHEYDE HC, 1995, CLIN DIAGN LAB IMMUN, V2, P417, DOI 10.1128/CDLI.2.4.417-425.1995; Vinetz J. M., 2011, GOODMAN GILMANS PHAR, P1383; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wells TN, 2010, DISCOV MED, V9, P389; WHO, 2010, WHO GUIDELINES TREAT, V2; Xie L, 2007, PARASITOLOGY, V134, P1151, DOI 10.1017/S0031182007002661; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	59	69	69	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3583	3593		10.1096/fj.11-187401	http://dx.doi.org/10.1096/fj.11-187401			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746861	Green Published			2022-12-28	WOS:000295356400028
J	Hong, MY; Kefaloyianni, E; Bao, L; Malester, B; Delaroche, D; Neubert, TA; Coetzee, WA				Hong, Miyoun; Kefaloyianni, Eirini; Bao, Li; Malester, Brian; Delaroche, Diane; Neubert, Thomas A.; Coetzee, William A.			Cardiac ATP-sensitive K+ channel associates with the glycolytic enzyme complex	FASEB JOURNAL			English	Article						sulfonylurea receptor; energy metabolism; Kir6.2; SUR2A	PIG VENTRICULAR CELLS; GUINEA-PIG; FUNCTIONAL COMPARTMENTALIZATION; RAT-HEART; METABOLISM; MEMBRANE; MODULATION; ACTIVATION; SECRETION; RELEASE	Being gated by high-energy nucleotides, cardiac ATP-sensitive potassium (K-ATP) channels are exquisitely sensitive to changes in cellular energy metabolism. An emerging view is that proteins associated with the K-ATP channel provide an additional layer of regulation. Using putative sulfonylurea receptor (SUR) coiled-coil domains as baits in a 2-hybrid screen against a rat cardiac cDNA library, we identified glycolytic enzymes (GAPDH and aldolase A) as putative interacting proteins. Interaction between aldolase and SUR was confirmed using GST pulldown assays and coimmunoprecipitation assays. Mass spectrometry of proteins from K-ATP channel immunoprecipitates of rat cardiac membranes identified glycolysis as the most enriched biological process. Coimmunoprecipitation assays confirmed interaction for several glycolytic enzymes throughout the glycolytic pathway. Immunocytochemistry colocalized many of these enzymes with K-ATP channel subunits in rat cardiac myocytes. The catalytic activities of aldolase and pyruvate kinase functionally modulate K-ATP channels in patch-clamp experiments, whereas D-glucose was without effect. Overall, our data demonstrate close physical association and functional interaction of the glycolytic process (particularly the distal ATP-generating steps) with cardiac K-ATP channels.- Hong, M., Kefaloyianni, E., Bao, L., Malester, B., Delaroche, D., Neubert, T. A., Coetzee, W. A. Cardiac ATP-sensitive K+ channel associates with the glycolytic enzyme complex. FASEB J. 25, 2456-2467 (2011). www.fasebj.org	[Neubert, Thomas A.] NYU, Sch Med, Skirball Inst, Struct Biol Program, New York, NY 10016 USA; [Coetzee, William A.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; [Neubert, Thomas A.; Coetzee, William A.] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; [Hong, Miyoun; Kefaloyianni, Eirini; Bao, Li; Malester, Brian; Delaroche, Diane; Coetzee, William A.] NYU, Sch Med, Dept Pediat, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Coetzee, WA (corresponding author), NYU, Sch Med, Dept Pediat Cardiol, New York, NY 10016 USA.	william.coetzee@med.nyu.edu	Kefalogianni, Eirini/T-6913-2019	Coetzee, William/0000-0003-1522-8326; Hong, Miyoun/0000-0003-4475-1140; Kefalogianni, Eirini/0000-0001-9132-3902	U.S. National Institutes of Health [HL-085820]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085820] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Dr. Hon-Chi Lee (Mayo Clinic, Rochester, MN, USA) for the generous gift of a rabbit polyclonal anti-Kir6.2 antibody, Dr. Asa Wahlander for mass spectrometry, and Dr. Guoan Zhang and Steven Blais for assistance with mass spectrometry data analysis. This work was supported by U.S. National Institutes of Health grant HL-085820 (to W. A. C. and T.A.N.).	Alekseev AE, 2005, J MOL CELL CARDIOL, V38, P895, DOI 10.1016/j.yjmcc.2005.02.022; Alekseev AE, 2010, CELL METAB, V11, P58, DOI 10.1016/j.cmet.2009.11.009; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Bao L, 2011, AM J PHYSIOL-HEART C, V300, pH262, DOI 10.1152/ajpheart.00857.2010; Bricknell O L, 1976, Recent Adv Stud Cardiac Struct Metab, V11, P509; COETZEE WA, 1995, AM J PHYSIOL-HEART C, V269, pH1625, DOI 10.1152/ajpheart.1995.269.5.H1625; DAVIDHEISER S, 1984, AM J PHYSIOL, V247, pC335, DOI 10.1152/ajpcell.1984.247.5.C335; Dhar-Chowdhury P, 2007, CELL MOL LIFE SCI, V64, P3069, DOI 10.1007/s00018-007-7332-3; Dhar-Chowdhury P, 2005, J BIOL CHEM, V280, P38464, DOI 10.1074/jbc.M508744200; Dizon J, 1998, AM J PHYSIOL-HEART C, V274, pH1082, DOI 10.1152/ajpheart.1998.274.4.H1082; Dubinsky WP, 1998, AM J PHYSIOL-CELL PH, V275, pC1653, DOI 10.1152/ajpcell.1998.275.6.C1653; GEISBUHLER T, 1984, CIRC RES, V54, P536, DOI 10.1161/01.RES.54.5.536; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HATAO K, 1985, Diabetes Research and Clinical Practice, V1, P49, DOI 10.1016/S0168-8227(85)80028-0; HEARSE DJ, 1995, CARDIOVASC RES, V30, P1; Jovanovic S, 2005, EMBO REP, V6, P848, DOI 10.1038/sj.embor.7400489; Kang GX, 2006, J PHYSIOL-LONDON, V573, P595, DOI 10.1113/jphysiol.2006.107391; Kang YH, 2004, J BIOL CHEM, V279, P47125, DOI 10.1074/jbc.M404954200; KORGE P, 1995, INT J SPORTS MED, V16, P172, DOI 10.1055/s-2007-972987; KRAMER JH, 1983, AM J PHYSIOL, V245, pH313, DOI 10.1152/ajpheart.1983.245.2.H313; Lei B, 2004, J MOL CELL CARDIOL, V36, P567, DOI 10.1016/j.yjmcc.2004.02.004; Lu M, 2007, J BIOL CHEM, V282, P24495, DOI 10.1074/jbc.M702598200; MALAISSE WJ, 1976, ACTA DIABETOL LAT, V13, P202, DOI 10.1007/BF02581118; NAKAMURA S, 1989, CARDIOVASC RES, V23, P286, DOI 10.1093/cvr/23.4.286; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Oe K, 1999, CARDIOVASC RES, V43, P125, DOI 10.1016/S0008-6363(99)00052-8; OPIE LH, 1980, J PHYSIOLOGY PARIS, V76, P821; PAUL RJ, 1983, AM J PHYSIOL, V244, pC399, DOI 10.1152/ajpcell.1983.244.5.C399; Pountney DJ, 2001, J MOL CELL CARDIOL, V33, P1541, DOI 10.1006/jmcc.2001.1407; Saegusa N, 2005, CARDIOVASC RES, V67, P60, DOI 10.1016/j.cardiores.2005.03.011; SCHAFFER SW, 1985, AM J MED, V79, P48, DOI 10.1016/S0002-9343(85)80007-3; Shigematsu S, 1997, CARDIOVASC RES, V35, P273, DOI 10.1016/S0008-6363(97)00092-8; Srivastava S, 2005, MOL CELL BIOL, V25, P3630, DOI 10.1128/MCB.25.9.3630-3638.2005; Suarez E, 2001, J BIOL CHEM, V276, P18257, DOI 10.1074/jbc.M008100200; Tsuchiya K, 1997, CIRCULATION, V96, P3129, DOI 10.1161/01.CIR.96.9.3129; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022	40	38	38	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2456	2467		10.1096/fj.10-176669	http://dx.doi.org/10.1096/fj.10-176669			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21482559	Green Published			2022-12-28	WOS:000292242200036
J	Vanderperre, B; Staskevicius, AB; Tremblay, G; Mccoy, M; O'Neill, MA; Cashman, NR; Roucou, X				Vanderperre, Benoit; Staskevicius, Antanas B.; Tremblay, Guillaume; McCoy, Marie; O'Neill, Megan A.; Cashman, Neil R.; Roucou, Xavier			An overlapping reading frame in the PRNP gene encodes a novel polypeptide distinct from the prion protein	FASEB JOURNAL			English	Article						alternative translation initiation; PrP; mitochondria	ENDOPLASMIC-RETICULUM STRESS; ALTERNATIVE TRANSLATION INITIATION; CULTURED-CELLS; SCRAPIE PRION; ER STRESS; PRP; DISEASES; BAX; PROTEASOME; CONVERSION	The prion protein gene PRNP directs the synthesis of one of the most intensively studied mammalian proteins, the prion protein (PrP). Yet the physiological function of PrP has remained elusive and has created controversies in the literature. We found a downstream alternative translation initiation AUG codon surrounded by an optimal Kozak sequence in the +3 reading frame of PRNP. The corresponding alternative open reading frame encodes a polypeptide termed alternative prion protein (AltPrP) with a completely different amino acid sequence from PrP. We introduced a hemagglutinin (HA) tag in frame with AltPrP in PrP cDNAs from different species to test the expression of this novel polypeptide using anti-HA antibodies. AltPrP is constitutively coexpressed with human, bovine, sheep, and deer PrP. AltPrP is localized at the mitochondria and is up-regulated by endoplasmic reticulum stress and proteasomal inhibition. Generation of anti-AltPrP antibodies allowed us to test for endogenous expression of AltPrP in wild-type human cells expressing PrP. By transfecting cells with siRNA against PrP mRNA, we repressed expression of both PrP and AltPrP, confirming endogenous expression of AltPrP from PRNP. AltPrP was also detected in human brain homogenate, primary neurons, and peripheral blood mononuclear cells. These results demonstrate an unexpected function for PRNP, which, in addition to plasma membrane-anchored PrP, also encodes a second polypeptide termed AltPrP.-Vanderperre, B., Staskevicius, A. B., Tremblay, G., McCoy, M., O'Neill, M. A., Cashman, N. R., Roucou, X. An overlapping reading frame in the PRNP gene encodes a novel polypeptide distinct from the prion protein. FASEB J. 25, 2373-2386 (2011). www.fasebj.org	[Vanderperre, Benoit; Staskevicius, Antanas B.; Tremblay, Guillaume; McCoy, Marie; Roucou, Xavier] Univ Sherbrooke, Dept Biochem, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; [O'Neill, Megan A.; Cashman, Neil R.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada	University of Sherbrooke; University of British Columbia	Roucou, X (corresponding author), Univ Sherbrooke, Dept Biochem, Fac Med, 3001 12Eme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	xavier.roucou@usherbrooke.ca		Vanderperre, Benoit/0000-0002-2111-1071	PrioNet Canada	PrioNet Canada	The authors thank Debbie McKenzie and Judd Aiken (Alberta Centre for Prion and Protein Folding Diseases, University of Alberta, Edmonton, AB, Canada) for their gift of the deer PrP cDNA clone, Michael Tranulis (Norwegian School of Veterinary Science, Institute of Basic Sciences and Aquatic Medicine, Oslo, Norway) for providing the sheep PrP cDNA clone, and David Fortin (Department of Surgery, Universite de Sherbrooke, QC, Canada) for the kind gift of the U-118 and U-87 cell lines. Human brain tissue was kindly provided by Dr. Cheryl Wellington (University of British Columbia, Vancouver, BC, Canada). The authors also thank Catherine Grenier for her technical help in the initial stages of this project, and Alireza Roostaee for critical review of the manuscript. This research was funded by PrioNet Canada. X. R. is a senior research scholar of the Fonds de la Recherche en Sante du Quebec. Nucleotide sequence data reported in Fig. 1 are available in the Third Party Annotation Section of the DDBJ/EMBL/GenBank databases under accession numbers TPA: BK007887-BK007890.	Aguzzi A, 2008, ANNU REV NEUROSCI, V31, P439, DOI 10.1146/annurev.neuro.31.060407.125620; Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; Beaudoin S, 2009, BBA-MOL CELL RES, V1793, P335, DOI 10.1016/j.bbamcr.2008.10.009; Branch AD, 2005, SEMIN LIVER DIS, V25, P105, DOI 10.1055/s-2005-864786; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Deriziotis P, 2008, BBA-MOL BASIS DIS, V1782, P713, DOI 10.1016/j.bbadis.2008.06.011; Ding QX, 2003, J ALZHEIMERS DIS, V5, P241, DOI 10.3233/JAD-2003-5307; Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P163, DOI 10.1089/ars.2006.8.163; Dubot A, 2004, BIOCHEM BIOPH RES CO, V313, P687, DOI 10.1016/j.bbrc.2003.12.013; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Harrison PM, 2010, GENOMICS, V95, P268, DOI 10.1016/j.ygeno.2010.02.008; Ho O, 2006, J IMMUNOL, V177, P8283, DOI 10.4049/jimmunol.177.12.8283; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Horowitz Michal, 2010, Front Biosci (Schol Ed), V2, P1068; Juanes ME, 2009, J BIOL CHEM, V284, P2787, DOI 10.1074/jbc.M804051200; Klemke M, 2001, EMBO J, V20, P3849, DOI 10.1093/emboj/20.14.3849; Kochetov AV, 2008, BIOESSAYS, V30, P683, DOI 10.1002/bies.20771; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Krakauer DC, 1998, J MOL EVOL, V47, P133, DOI 10.1007/PL00006370; Lee YY, 2009, J BIOL CHEM, V284, P6661, DOI 10.1074/jbc.M806735200; Lund C, 2009, J BIOL CHEM, V284, P19668, DOI 10.1074/jbc.M109.003566; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Martins VR, 2001, BRAZ J MED BIOL RES, V34, P585, DOI 10.1590/S0100-879X2001000500005; Mastrangelo P, 2001, BIOCHEM CELL BIOL, V79, P613, DOI 10.1139/bcb-79-5-613; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mead S, 2006, EUR J HUM GENET, V14, P273, DOI 10.1038/sj.ejhg.5201544; Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200; Premzl M, 2009, J MOL EVOL, V68, P205, DOI 10.1007/s00239-008-9176-3; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Roostaee A, 2009, J BIOL CHEM, V284, P30907, DOI 10.1074/jbc.M109.057950; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; Sakudo A, 2009, CURR MED CHEM, V16, P380, DOI 10.2174/092986709787002673; Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Steele AD, 2009, PRION, V3, P240, DOI 10.4161/pri.3.4.10135; Steinacker P, 2010, AM J PATHOL, V176, P1409, DOI 10.2353/ajpath.2010.090355; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yamasaki K, 1999, J VIROL, V73, P8519, DOI 10.1128/JVI.73.10.8519-8526.1999; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Zeng L, 2010, J IMMUNOL, V185, P2324, DOI 10.4049/jimmunol.0903052	50	35	40	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2373	2386		10.1096/fj.10-173815	http://dx.doi.org/10.1096/fj.10-173815			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478263				2022-12-28	WOS:000292242200029
J	Kim, SI; Yoon, JI; Tommasi, S; Besaratinia, A				Kim, Sang-In; Yoon, Jae-In; Tommasi, Stella; Besaratinia, Ahmad			New experimental data linking secondhand smoke exposure to lung cancer in nonsmokers	FASEB JOURNAL			English	Article						carcinogenesis; mutagenicity; tobacco; TP53 mutations	TOBACCO-SMOKE; DNA-DAMAGE; CIGARETTE-SMOKE; TRANSVERSION MUTATIONS; LABORATORY-ANIMALS; P53 MUTATIONS; GENE; ADDUCTS; TP53; MICE	Secondhand smoke (SHS) exposure is a known risk factor for lung cancer development in lifelong nonsmokers; however, the mechanistic involvement of SHS in the genesis of this malignancy remains elusive. The present study is the first comprehensive investigation of SHS mutagenicity in vivo, in which we have established the mutagenic effects of SHS in transgenic Big Blue mice, and subsequently found correlations between our experimental findings and those obtained from our analysis of the largest database of mutations in human TP53, which is the most frequently mutated gene in human lung cancer. We demonstrate that whole-body SHS exposure of mice for 5 h/d, 5 d/wk for a duration of 2 or 4 mo elicits a significant mutagenic response in the lung, trachea, and bladder of exposed animals, as reflected by the elevation of background cII mutant frequency in the respective organs. The organ-specific mutagenicity of SHS is most pronounced in the lung and remains persistent both in the lung and bladder of SHS-exposed animals after a 1-mo recovery in clean air. The induced cII mutagenesis in the lung of SHS-exposed mice perfectly recapitulates our analysis of the TP53 mutations in human lung cancer in nonsmokers. Remarkably, the relative frequencies of all types of mutations in the TP53 gene of nonsmokers' lung tumors and in the cII transgene of lung cellular DNA from SHS-exposed mice are indistinguishable from one another. We provide the first verification of a mechanistic mode of action for SHS of relevance for carcinogenesis and the first experimental evidence linking SHS exposure to lung cancer in nonsmokers.-Kim, S.-I., Yoon, J.-I., Tommasi, S., Besaratinia, A. New experimental data linking secondhand smoke exposure to lung cancer in nonsmokers. FASEB J. 26, 1845-1854 (2012). www.fasebj.org	[Kim, Sang-In; Yoon, Jae-In; Tommasi, Stella; Besaratinia, Ahmad] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Besaratinia, A (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ania@coh.org		Besaratinia, Ahmad/0000-0001-7231-228X; Tommasi, Stella/0000-0001-6897-4985	University of California [18KT-0040]	University of California(University of California System)	The authors thank Dr. Yong Jiang for technical assistance in the conduct of our experiments, Dr. Fong-Fong Chu for help with mouse breeding and colony expansion, Dr. Walter Tsark for helpful discussion on institutional animal care and use committee protocol preparation, and their department chair for general support. Special thanks to the dedicated staff and management of the City of Hope Animal Resources Center, in particular, Armando Amaya, Marie Prez, Lauren Ratcliffe, Yvonne Harper, Donna Isbell, Kenneth Golding, and Dr. Richard Ermel. This study was supported by a grant from the University of California Tobacco Related Disease Research Program (18KT-0040) to A. B. The authors declare no conflicts of interest.	ADAMS JD, 1987, CARCINOGENESIS, V8, P729, DOI 10.1093/carcin/8.5.729; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Besaratinia A, 2008, LANCET ONCOL, V9, P657, DOI 10.1016/S1470-2045(08)70172-4; Besaratinia A, 2008, FASEB J, V22, P2379, DOI 10.1096/fj.07-105437; Besaratinia A, 2006, CARCINOGENESIS, V27, P1526, DOI 10.1093/carcin/bgi311; Coggins CRE, 2007, INT J TOXICOL, V26, P331, DOI 10.1080/10915810701490190; De Flora S, 2005, EXP LUNG RES, V31, P19, DOI 10.1080/01902140490494986; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Guerin M.R., 1992, CHEM ENV TOBACCO SMO; Guo CX, 2009, CELL MOL LIFE SCI, V66, P2363, DOI 10.1007/s00018-009-0024-4; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hecht SS, 2005, CARCINOGENESIS, V26, P1488, DOI 10.1093/carcin/bgi148; Husgafvel-Pursiainen K, 2000, CANCER RES, V60, P2906; International Agency for Research on Cancer, 2004, TOB SMOK INV SMOK, V83; Kim SI, 2011, MUTAT RES-FUND MOL M, V716, P92, DOI 10.1016/j.mrfmmm.2011.08.008; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Lambert LB, 2005, MUTAT RES-REV MUTAT, V590, P1, DOI 10.1016/j.mrrev.2005.04.002; Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; [National Research Council Committee on Passive Smoking Board on Environmental Studies and Toxicology], 1986, ENV TOB SMOK MEAS EX, P25; Olivier Magali, 2004, IARC Sci Publ, P247; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; U.S. Environmental Protection Agency, 1992, EPA600690006F OFF HL; US Surgeon General, 2006, HLTH CONS INV EXP TO; Witschi Hanspeter, 2003, Methods Mol Med, V74, P441; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; World Health Organization, 2008, WHO REP GLOB TOB EP; Yoon JI, 2012, CANCER PREV RES, V5, P299, DOI 10.1158/1940-6207.CAPR-11-0309; Yoon JH, 2001, CANCER RES, V61, P7110	43	18	18	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1845	1854		10.1096/fj.11-199984	http://dx.doi.org/10.1096/fj.11-199984			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22318968	Green Submitted			2022-12-28	WOS:000303680800013
J	Khaperskyy, DA; Hatchette, TF; McCormick, C				Khaperskyy, Denys A.; Hatchette, Todd F.; McCormick, Craig			Influenza A virus inhibits cytoplasmic stress granule formation	FASEB JOURNAL			English	Article						PKR; interferon; translation; NS1; live imaging	DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; NS1 PROTEIN; INFECTED-CELLS; MESSENGER-RNA; RIG-I; BINDING; PHOSPHORYLATION; TRANSLATION; ACTIVATION	An important component of the mammalian stress response is the reprogramming of translation. A variety of stresses trigger abrupt polysome disassembly and the accumulation of stalled translation preinitiation complexes. These complexes nucleate cytoplasmic stress granules (SGs), sites of mRNA triage in which mRNAs from disassembling polysomes are sorted and the fates of individual transcripts are determined. Here, we demonstrate that influenza A virus (IAV) actively suppresses SG formation during infection, thereby allowing translation of viral mRNAs. Complete inhibition of SG formation is dependent on the function of the viral nonstructural protein 1 (NS1); at late times postinfection, cells infected with NS1-mutant viruses formed SGs in a double-stranded RNA-activated protein kinase (PKR)-dependent fashion. In these cells, SG formation correlated with inhibited viral protein synthesis. Together, these experiments demonstrate the antiviral potential of SGs and reveal a viral countermeasure that limits SG formation.-Khaperskyy, D. A., Hatchette, T. F., McCormick, C. Influenza A virus inhibits cytoplasmic stress granule formation. FASEB J. 26, 1629-1639 (2012). www.fasebj.org	[Khaperskyy, Denys A.; Hatchette, Todd F.; McCormick, Craig] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada; [Hatchette, Todd F.] Queen Elizabeth 2 Hlth Sci Ctr, Dept Pathol & Lab Med, Halifax, NS, Canada; [McCormick, Craig] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada	Dalhousie University; Queen Elizabeth II Health Sciences Centre	McCormick, C (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St,Rm 7F,POB 15000, Halifax, NS B3H 4R2, Canada.	mccormick@dal.ca	McCormick, Craig/AAH-9069-2019	McCormick, Craig/0000-0003-2794-3722; Hatchette, Todd/0000-0002-5377-2528; Khaperskyy, Denys/0000-0003-0583-7179	Canadian Institutes of Health Research; Nova Scotia Health Research Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Nova Scotia Health Research Foundation	The authors thank members of the C. M. laboratory for helpful discussions and critical manuscript review. The authors thank Dr. Paul Anderson (Harvard Medical School, Boston, MA, USA), Dr. John Bell (Ottawa Hospital Research Institute, Ottawa, ON, Canada), Dr. Adolfo Garcia-Sastre (Mount Sinai School of Medicine, New York, NY, USA), Dr. Garry Nolan (Stanford University, Stanford, CA, USA), Dr. Chris Richardson (Dalhousie University, Halifax, NS, Canada), and Dr. Richard Webby (St. Jude Children's Research Hospital, Memphis, TN, USA) for reagents. The authors thank Steven Whitefield for technical assistance with live fluorescence microscopy This work was supported by grants from the Canadian Institutes of Health Research and the Nova Scotia Health Research Foundation (to C.M.).	Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Detzer A, 2011, NUCLEIC ACIDS RES, V39, P2727, DOI 10.1093/nar/gkq1216; Donelan NR, 2003, J VIROL, V77, P13257, DOI 10.1128/JVI.77.24.13257-13266.2003; Egorov A, 1998, J VIROL, V72, P6437, DOI 10.1128/JVI.72.8.6437-6441.1998; Ehrhardt C, 2010, MICROBES INFECT, V12, P81, DOI 10.1016/j.micinf.2009.09.007; Eisinger-Mathason TSK, 2008, MOL CELL, V31, P722, DOI 10.1016/j.molcel.2008.06.025; Emara MM, 2007, P NATL ACAD SCI USA, V104, P9041, DOI 10.1073/pnas.0703348104; Gack MU, 2009, CELL HOST MICROBE, V5, P439, DOI 10.1016/j.chom.2009.04.006; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Hale BG, 2008, J GEN VIROL, V89, P2359, DOI 10.1099/vir.0.2008/004606-0; Hatada E, 1999, J VIROL, V73, P2425, DOI 10.1128/JVI.73.3.2425-2433.1999; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Kakugawa S, 2009, J VIROL, V83, P2510, DOI 10.1128/JVI.02416-08; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kim WJ, 2005, MOL CELL BIOL, V25, P2450, DOI 10.1128/MCB.25.6.2450-2462.2005; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Luig C, 2010, FASEB J, V24, P4068, DOI 10.1096/fj.10-158766; McInerney GM, 2005, MOL BIOL CELL, V16, P3753, DOI 10.1091/mbc.E05-02-0124; Min JY, 2006, P NATL ACAD SCI USA, V103, P7100, DOI 10.1073/pnas.0602184103; Montero H, 2008, J VIROL, V82, P1496, DOI 10.1128/JVI.01779-07; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Smith JA, 2006, J VIROL, V80, P2019, DOI 10.1128/JVI.80.4.2019-2033.2006; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Wang W, 1999, RNA, V5, P195, DOI 10.1017/S1355838299981621; White JP, 2007, CELL HOST MICROBE, V2, P295, DOI 10.1016/j.chom.2007.08.006; Yamasaki S, 2008, CURR OPIN CELL BIOL, V20, P222, DOI 10.1016/j.ceb.2008.01.013	32	97	100	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1629	1639		10.1096/fj.11-196915	http://dx.doi.org/10.1096/fj.11-196915			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22202676				2022-12-28	WOS:000302359700024
J	Mirakaj, V; Jennewein, C; Konig, K; Granja, T; Rosenberger, P				Mirakaj, Valbona; Jennewein, Carla; Koenig, Klemens; Granja, Tiago; Rosenberger, Peter			The guidance receptor neogenin promotes pulmonary inflammation during lung injury	FASEB JOURNAL			English	Article						axonal guidance; cytokine; neutrophil	INHIBITS LEUKOCYTE MIGRATION; ENDOTHELIAL-CELLS; IN-VIVO; NETRIN-1; MOLECULE; EXPRESSION; HYPOXIA; PROTEIN; MOUSE; ACTIVATION	Lung injury is marked by a persistent self-propagating inflammation within the pulmonary tissue that is initiated by the migration of leukocytes into the alveolar space. Recent work has demonstrated that neuronal guidance proteins are involved into the orchestration of leukocyte migration. Neogenin is a crucial guidance receptor for axonal migration, yet its role during leukocyte migration and acute inflammation is to date unknown. Here, we report that neogenin influences neutrophil migration across endothelial HMEC-1 and alveolar A549 monolayers in vitro. In vivo, Neo1(-/-) mice demonstrated 59% reduced cell count, 41% reduced TNF-alpha, and 76% reduced IL-6 levels within the alveolar space during lung injury. In studies employing chimeric animals, the presence of Neo1(-/-) bone marrow was associated with a 42% reduction of cell count and reduced inflammatory changes within pulmonary tissue during lung injury. The functional inhibition of neogenin through antibody injection confirmed these results and the role of neogenin for the inflammatory changes within the alveolar space. Previously unappreciated, the guidance receptor neogenin has a significant effect on the orchestration of leukocyte migration and the control of acute inflammation.-Mirakaj, V., Jennewein, C., Konig, K., Granja, T., Rosenberger, P. The guidance receptor neogenin promotes pulmonary inflammation during lung injury. FASEB J. 26, 1549-1558 (2012). www.fasebj.org	[Mirakaj, Valbona; Koenig, Klemens; Rosenberger, Peter] Univ Tubingen, Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, D-72076 Tubingen, Germany; [Mirakaj, Valbona; Jennewein, Carla; Koenig, Klemens; Granja, Tiago; Rosenberger, Peter] Goethe Univ Frankfurt, Univ Hosp, Clin Anesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Rosenberger, P (corresponding author), Univ Tubingen, Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	peter.rosenberger@medizin.uni-tuebingen.de	Granja, Tiago/O-2597-2019; Jennewein, Carla/C-2199-2013	Granja, Tiago/0000-0002-8137-1449; Mirakaj, Valbona/0000-0002-6907-6455	Deutsche Forschungsgemeinschaft (DFG) [DFG-RO 3671/5-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Stefanie Laucher and Dr. David Kohler for technical assistance during bone marrow transplantation. The authors thank Dr. Alexander Schaub for help with the performing experiments. This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) DFG-RO 3671/5-1 to P.R.	Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137; Aherne CM, 2012, GUT, V61, P695, DOI 10.1136/gutjnl-2011-300012; Bae GU, 2009, MOL BIOL CELL, V20, P4920, DOI 10.1091/mbc.E09-06-0491; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Conrad S, 2007, J BIOL CHEM, V282, P16423, DOI 10.1074/jbc.M610901200; Csiszar A, 2005, CIRCULATION, V111, P2364, DOI 10.1161/01.CIR.0000164201.40634.1D; Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH569, DOI 10.1152/ajpheart.00180.2008; Eckle T, 2008, AM J PHYSIOL-LUNG C, V295, pL718, DOI 10.1152/ajplung.90298.2008; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Fitzgerald DP, 2006, DEV DYNAM, V235, P1720, DOI 10.1002/dvdy.20744; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Grenz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014812; Hagihara M, 2011, J BIOL CHEM, V286, P5157, DOI 10.1074/jbc.M110.180919; Hata K, 2009, J CELL BIOL, V184, P737, DOI 10.1083/jcb.200807029; Henes J, 2009, FASEB J, V23, P4244, DOI 10.1096/fj.09-138693; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Larrieu-Lahargue F, 2010, BLOOD, V115, P5418, DOI 10.1182/blood-2009-11-252338; Ly NP, 2005, P NATL ACAD SCI USA, V102, P14729, DOI 10.1073/pnas.0506233102; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Mirakaj V, 2011, P NATL ACAD SCI USA, V108, P6555, DOI 10.1073/pnas.1015605108; Mirakaj V, 2011, J IMMUNOL, V186, P549, DOI 10.4049/jimmunol.1002671; Mirakaj V, 2010, AM J RESP CRIT CARE, V181, P815, DOI 10.1164/rccm.200905-0717OC; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Muramatsu R, 2011, NAT MED, V17, P488, DOI 10.1038/nm.2321; Nick JA, 1999, CHEST, V116, p54S, DOI 10.1378/chest.116.suppl_1.54S; Park KW, 2004, P NATL ACAD SCI USA, V101, P16210, DOI 10.1073/pnas.0405984101; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rosenberger P, 2007, FASEB J, V21, P2613, DOI 10.1096/fj.06-8004com; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Tsuchiya A, 2007, BRAIN RES, V1159, P1, DOI 10.1016/j.brainres.2006.12.096; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang WW, 2009, AM J NEPHROL, V30, P186, DOI 10.1159/000213503; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129; Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540; Zhou Z, 2008, J BONE MINER RES, V23, pS273; Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016	41	21	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1549	1558		10.1096/fj.11-200063	http://dx.doi.org/10.1096/fj.11-200063			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198383				2022-12-28	WOS:000302359700017
J	Rasmussen, P; Kim, YS; Krogh-Madsen, R; Lundby, C; Olsen, NV; Secher, NH; van Lieshout, JJ				Rasmussen, Peter; Kim, Yu-Sok; Krogh-Madsen, Rikke; Lundby, Carsten; Olsen, Niels V.; Secher, Niels H.; van Lieshout, Johannes J.			Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans	FASEB JOURNAL			English	Article						exercise; hypoxia; neuroprotective agents	RECOMBINANT-HUMAN-ERYTHROPOIETIN; BLOOD-FLOW VELOCITY; EXERCISE CAPACITY; AUTOREGULATION; HYPERTENSION; PRESSURE; ARTERIAL; OXYGENATION; ISCHEMIA; RELEASE	Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n = 8) and chronic (5000 IU/week for 13 wk; n = 8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 +/- 3.7 to 47.6 +/- 4.1% (P<0.01), whereas hematocrit was unaffected following acute EPO administration. Yet, the two EPO regimes increased arterial pressure similarly (by 8 +/- 4 and 7 +/- 3 mmHg, respectively; P=0.01) through reduced vascular conductance (by 7 +/- 3 and 5 +/- 2%; P<0.05). Also, both EPO regimes widened the arterial-to-jugular O-2 differences at rest as well as during normoxic and hypoxic exercise (P<0.01), which indicated reduced cerebral blood flow despite preserved dynamic cerebral autoregulation, and an increase in middle cerebral artery mean blood flow velocity (P<0.05), therefore, reflected vasoconstriction. Thus, administration of EPO to healthy humans lowers systemic and cerebral conductance independent of its effect on hematocrit.-Rasmussen, P., Kim, Y. S., Krogh-Madsen, R., Lundby, C., Olsen, N. V., Secher, N. H., van Lieshout, J. J. Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans. FASEB J. 26, 1343-1348 (2012). www.fasebj.org	[Rasmussen, Peter; Lundby, Carsten] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Rasmussen, Peter; Krogh-Madsen, Rikke; Lundby, Carsten; Secher, Niels H.] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; [Rasmussen, Peter; Olsen, Niels V.; Secher, Niels H.] Univ Copenhagen, Rigshosp, Dept Anesthesia, DK-2100 Copenhagen, Denmark; [Krogh-Madsen, Rikke] Univ Copenhagen, Rigshosp, Dept Infect Dis, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; [Lundby, Carsten] Univ Copenhagen, Dept Neurosci & Pharmacol, Copenhagen, Denmark; [Kim, Yu-Sok; van Lieshout, Johannes J.] Univ Amsterdam, Acad Med Ctr, AMC Ctr Heart Failure Res, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; [Kim, Yu-Sok; van Lieshout, Johannes J.] Univ Amsterdam, Acad Med Ctr, AMC Ctr Heart Failure Res, Lab Cardiovasc Physiol, NL-1105 AZ Amsterdam, Netherlands; [van Lieshout, Johannes J.] Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham, England	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Nottingham	Rasmussen, P (corresponding author), Univ Zurich, Zurich Ctr Integrat Human Physiol, Bldg 23,Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter@prec.dk	Ernst-Rasmussen, Peter Bonde/B-8203-2013; Van Lieshout, Johannes/P-5499-2019; van Lieshout, Johannes J/B-6674-2011	Ernst-Rasmussen, Peter Bonde/0000-0003-1761-4562; Van Lieshout, Johannes/0000-0002-3646-2122; van Lieshout, Johannes J/0000-0002-3646-2122; Krogh-Madsen, Rikke/0000-0003-4914-2715	Anti-Doping Denmark; Benzon Foundation; Lundbeck Foundation; Danish Cardiovascular Research Academy; Dutch Diabetes Research Foundation	Anti-Doping Denmark; Benzon Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Cardiovascular Research Academy; Dutch Diabetes Research Foundation	The authors acknowledge the skilled assistance of technician Merete Nielsen. The authors were funded through grants from Anti-Doping Denmark (P. R. and C. L.), the Benzon Foundation (C. L.), the Lundbeck Foundation (N.H.S.), the Danish Cardiovascular Research Academy (J.J.V.L.), and the Dutch Diabetes Research Foundation (Y.S.K.). The authors declare no conflicts of interest.	Ainslie PN, 2008, J PHYSIOL-LONDON, V586, P4005, DOI 10.1113/jphysiol.2008.158279; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; BODEBOGER SM, 1992, J CARDIOVASC PHARM, V20, pS25, DOI 10.1097/00005344-199204002-00009; CARLINI RG, 1993, KIDNEY INT, V43, P1010, DOI 10.1038/ki.1993.142; CIRILLO M, 1992, HYPERTENSION, V20, P319, DOI 10.1161/01.HYP.20.3.319; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Fisher JW, 2003, EXP BIOL MED, V228, P1; Frietsch T, 2007, J CEREBR BLOOD F MET, V27, P469, DOI 10.1038/sj.jcbfm.9600360; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Immink RV, 2004, CIRCULATION, V110, P2241, DOI 10.1161/01.CIR.0000144472.08647.40; Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057; Jellema WT, 1996, CLIN SCI, V91, P193, DOI 10.1042/cs0910193; Krapf R, 2009, CLIN J AM SOC NEPHRO, V4, P470, DOI 10.2215/CJN.05040908; Lundby C, 2008, J APPL PHYSIOL, V105, P581, DOI 10.1152/japplphysiol.90484.2008; Lundby C, 2007, J PHYSIOL-LONDON, V578, P309, DOI 10.1113/jphysiol.2006.122689; Lundby C, 2011, J PHYSIOL-LONDON, V589, P1265, DOI 10.1113/jphysiol.2010.195917; MCMAHON FG, 1990, BLOOD, V76, P1718; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089, DOI 10.1152/ajpheart.1999.277.3.H1089; Pott F, 1997, ACTA PHYSIOL SCAND, V160, P43, DOI 10.1046/j.1365-201X.1997.00126.x; Rasmussen P, 2010, J APPL PHYSIOL, V109, P476, DOI 10.1152/japplphysiol.00234.2010; Santhanam AVR, 2006, AM J PHYSIOL-HEART C, V291, pH781, DOI 10.1152/ajpheart.00045.2006; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Tseng MY, 2009, J NEUROSURG, V111, P171, DOI 10.3171/2009.3.JNS081332; van Lieshout JJ, 2003, J APPL PHYSIOL, V94, P833, DOI 10.1152/japplphysiol.00260.2002; Wilson MH, 2011, J CEREBR BLOOD F MET, V31, P2019, DOI 10.1038/jcbfm.2011.81	27	17	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1343	1348		10.1096/fj.11-193508	http://dx.doi.org/10.1096/fj.11-193508			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22159148				2022-12-28	WOS:000300949300036
J	Icardi, L; Lievens, S; Mori, R; Piessevaux, J; De Cauwer, L; De Bosscher, K; Tavernier, J				Icardi, Laura; Lievens, Sam; Mori, Raffaele; Piessevaux, Julie; De Cauwer, Lode; De Bosscher, Karolien; Tavernier, Jan			Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2	FASEB JOURNAL			English	Article						interferon signaling; trichostatin A; TSA; interferon-stimulated genes	NEGATIVE REGULATION; INTERFERON-GAMMA; GENE-EXPRESSION; ACTIVATION; ACETYLATION; GROWTH; BETA; IL-6; RESPONSES; RECEPTOR	The antiviral and antiproliferative responses mediated by type I interferons (IFNs) depend on JAK/STAT signaling and ISGF3 (STAT1:STAT2:IRF9)-dependent transcription. In addition, type I IFNs stimulate STAT3 activation in many cell types, an event generally associated with cell cycle progression, survival, and proliferation. To gather more insight into this functionally contradictive phenomenon, we studied the regulation of STAT3 transcriptional activity upon type I IFN treatment. We show that IFN alpha 2 stimulation strongly induces STAT3 phosphorylation, nuclear translocation, and promoter binding, yet the activation of transcription of a STAT3-dependent reporter and endogenous genes, such as SOCS3 and c-FOS, is impaired. Simultaneous treatment with IFN alpha 2 and trichostatin A, as well as combined HDAC1/HDAC2 silencing, restores STAT3-dependent reporter gene and endogenous gene expression, strongly suggesting that HDAC1 and HDAC2 are directly involved in repressing IFN alpha 2-activated STAT3. Of note, single silencing of only one of the two HDACs does not lead to enhanced STAT3 activity, supporting a functional redundancy between these two enzymes. In sharp contrast, HDAC1 and HDAC2 activities are required for ISGF3-dependent gene expression. We conclude that HDAC1 and HDAC2 differentially modulate STAT activity in response to IFN alpha 2: while they are required for the induction of ISGF3-responsive genes, they impair the transcription of STAT3-dependent genes.-Icardi, L., Lievens, S., Mori, R., Piessevaux, J., De Cauwer, L., De Bosscher, K., Tavernier, J. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J. 26, 240-249 (2012). www.fasebj.org	[Icardi, Laura; Lievens, Sam; Mori, Raffaele; Piessevaux, Julie; De Cauwer, Lode; De Bosscher, Karolien; Tavernier, Jan] Vlaams Inst Biotechnol, Dept Med Prot Res, B-9000 Ghent, Belgium; [Icardi, Laura; Lievens, Sam; Mori, Raffaele; Piessevaux, Julie; De Cauwer, Lode; De Bosscher, Karolien; Tavernier, Jan] Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Tavernier, J (corresponding author), Vlaams Inst Biotechnol, Dept Med Prot Res, B-9000 Ghent, Belgium.	jan.tavernier@vib-ugent.be	Tavernier, Jan/AAG-3636-2019	De Cauwer, Lode/0000-0002-6928-8271; De Bosscher, Karolien/0000-0001-5059-9718; Icardi, Laura/0000-0002-8936-1691	Ghent University; Interuniversity Attraction Pole-6 [P6:28]; ReceptEur FP6 Marie-Curie program; Fonds Wetenschappelijk Onderzoek-Vlaanderen	Ghent University(Ghent University); Interuniversity Attraction Pole-6; ReceptEur FP6 Marie-Curie program; Fonds Wetenschappelijk Onderzoek-Vlaanderen(FWO)	The authors thank Dr. Els Pattyn and Annick Verhee for their help in initiating this research project. This work was supported by grants from Ghent University, the Interuniversity Attraction Pole-6 (No. P6:28) and the ReceptEur FP6 Marie-Curie program. K.D.B. is a postdoctoral researcher at the Fonds Wetenschappelijk Onderzoek-Vlaanderen.	Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Gamero AM, 2006, J BIOL CHEM, V281, P16238, DOI 10.1074/jbc.M509516200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hou T, 2008, J BIOL CHEM, V283, P30725, DOI 10.1074/jbc.M805941200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Ohbayashi N, 2007, BIOL PHARM BULL, V30, P1860, DOI 10.1248/bpb.30.1860; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ray S, 2005, GASTROENTEROLOGY, V129, P1616, DOI 10.1053/j.gastro.2005.07.055; Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419; Regis G, 2009, LEUKEMIA, V23, P2102, DOI 10.1038/leu.2009.139; Regis G, 2008, SEMIN CELL DEV BIOL, V19, P351, DOI 10.1016/j.semcdb.2008.06.004; Sakamoto S, 2004, J BIOL CHEM, V279, P40362, DOI 10.1074/jbc.M406400200; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Segre CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Tanabe Y, 2005, J IMMUNOL, V174, P609, DOI 10.4049/jimmunol.174.2.609; Tang XL, 2007, CELL, V131, P93, DOI 10.1016/j.cell.2007.07.034; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Togi S, 2009, BIOCHEM BIOPH RES CO, V379, P616, DOI 10.1016/j.bbrc.2008.12.132; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; Van Schoubroeck B., 2012, METHODS MOL IN PRESS, V812; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166	41	34	34	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					240	249		10.1096/fj.11-191122	http://dx.doi.org/10.1096/fj.11-191122			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21957129				2022-12-28	WOS:000299202200025
J	Perez-Alvarez, A; Hernandez-Vivanco, A; McIntosh, JM; Albillos, A				Perez-Alvarez, Alberto; Hernandez-Vivanco, Alicia; McIntosh, J. Michael; Albillos, Almudena			Native alpha 6 beta 4* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland	FASEB JOURNAL			English	Article						patch clamp; acetylcholine; adrenaline; secretion	ALPHA-CONOTOXIN-MII; 3 BETA 2; VENTRAL TEGMENTAL AREA; RAT MEDIAL HABENULA; ACETYLCHOLINE-RECEPTORS; NOREPINEPHRINE RELEASE; PARKINSONS-DISEASE; NIGROSTRIATAL DAMAGE; SUBUNIT COMPOSITION; DOPAMINE NEURONS	In the present study, we have electro-physiologically characterized native nicotinic acetylcholine receptors (nAChRs) in human chromaffin cells of the adrenal gland as well as their contribution to the exocytotic process. alpha-Conotoxin AuIB blocked by 14 +/- 1% the acetylcholine (ACh)-induced nicotinic current. alpha-Conotoxin MII (alpha-Ctx MII) exhibited an almost full blockade of the nicotinic current at nanomolar concentrations (IC(50) = 21.6 nM). The alpha 6*-preferring alpha-Ctx MII mutant analogs, alpha-Ctx MII[H9A,L15A] and alpha-Ctx MII[S4A,E11A,L15A], blocked nAChR currents with an IC(50) of 217.8 and 33 nM, respectively. These data reveal that nAChRs in these cells include the alpha 6* subtype. The washout of the blockade exerted by alpha-conotoxin BuIA (alpha-Ctx BuIA; 1 mu M) on ACh-evoked currents was slight and slow, arguing in favor of the presence of a beta 4 subunit in the nAChR composition. Exocytosis was almost fully blocked by 1 mu M alpha-Ctx MII, its mutant analogs, or alpha-Ctx BuIA. Finally, the fluorescent analog Alexa Fluor 546-BuIA showed distinct staining in these cells. Our results reveal that alpha 6 beta 4* nAChRs are expressed and contribute to exocytosis in human chromaffin cells of the adrenal gland, the main source of adrenaline under stressful situations.-Perez-Alvarez, A., Hernandez-Vivanco, A., McIntosh, J. M., Albillos, A. Native alpha 6 beta 4* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland. FASEB J. 26, 346-354 (2012). www.fasebj.org	[Perez-Alvarez, Alberto; Hernandez-Vivanco, Alicia; Albillos, Almudena] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, E-28029 Madrid, Spain; [McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Autonomous University of Madrid; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Perez-Alvarez, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	a.perez@uam.es; almudena.albillos@uam.es	Albillos, Almudena/AAA-9098-2019	Perez-Alvarez, Alberto/0000-0002-5586-0927; ALBILLOS, ALMUDENA/0000-0003-3315-9715; Hernandez Vivanco, Alicia/0000-0001-7920-3588	Universidad Autonoma de Madrid; Ministerio de Ciencia y Tecnologia [BFU2008-01382/BFI]; U.S. National Institutes of Health [MH53631, GM48677]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER	Universidad Autonoma de Madrid; Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank the donors of the human adrenal glands and their relatives. The authors also thank Dr. Agustin Albillos and the Transplant Team of the Hospital Ramon y Cajal (Madrid, Spain) for their excellent coordination in supplying the human adrenal glands. A.H.-V. holds a fellowship award from the Universidad Autonoma de Madrid. This work was supported by grants from the Ministerio de Ciencia y Tecnologia (BFU2008-01382/BFI to A. A.) and the U.S. National Institutes of Health (MH53631 and GM48677 to J.M.M.). The authors declare no conflicts of interest.	Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; ALMAZAN G, 1984, BRIT J PHARMACOL, V81, P599, DOI 10.1111/j.1476-5381.1984.tb16124.x; Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Azam L, 2005, J PHARMACOL EXP THER, V312, P231, DOI 10.1124/jpet.104.071456; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Azam L, 2008, J BIOL CHEM, V283, P11625, DOI 10.1074/jbc.M710288200; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Azam L, 2010, FASEB J, V24, P5113, DOI 10.1096/fj.10-166272; Bibevski S, 2000, J NEUROSCI, V20, P5076; Bordia T, 2007, MOL PHARMACOL, V72, P52, DOI 10.1124/mol.107.035998; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; Colomer C, 2010, J NEUROSCI, V30, P6732, DOI 10.1523/JNEUROSCI.4997-09.2010; Colquhoun LM, 1997, J NEUROCHEM, V69, P2355; CONNOLLY JG, 1995, J PHYSIOL-LONDON, V484, P87, DOI 10.1113/jphysiol.1995.sp020650; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Di Angelantonio S, 2003, EUR J NEUROSCI, V17, P2313, DOI 10.1046/j.1460-9568.2003.02669.x; Dowell C, 2003, J NEUROSCI, V23, P8445; Fu YT, 1999, NEUROSCI LETT, V266, P113, DOI 10.1016/S0304-3940(99)00293-1; Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x; Genzen JR, 2001, J NEUROPHYSIOL, V86, P1773, DOI 10.1152/jn.2001.86.4.1773; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Gillis Kevin D., 1995, P155; Goldner FM, 1997, NEUROREPORT, V8, P2739; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Hone AJ, 2010, J NEUROCHEM, V114, P994, DOI 10.1111/j.1471-4159.2010.06819.x; Jackson KJ, 2009, J PHARMACOL EXP THER, V331, P547, DOI 10.1124/jpet.109.155457; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Lai A, 2005, MOL PHARMACOL, V67, P1639, DOI 10.1124/mol.104.006429; Lamar E., 1990, SOC NEUR ABSTR, V16, P2852; LANGE KW, 1993, J NEUROCHEM, V60, P197, DOI 10.1111/j.1471-4159.1993.tb05838.x; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LUETJE CW, 1991, J NEUROSCI, V11, P837; Luo SQ, 1998, J NEUROSCI, V18, P8571; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; Mousavi M, 2001, LIFE SCI, V70, P577, DOI 10.1016/S0024-3205(01)01427-8; Mugnaini M, 2006, NEUROSCIENCE, V137, P565, DOI 10.1016/j.neuroscience.2005.09.008; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Neher E, 2006, PFLUG ARCH EUR J PHY, V453, P261, DOI 10.1007/s00424-006-0143-9; PAPKE RL, 1994, MOL PHARMACOL, V45, P142; Perez-Alvarez A, 2008, PFLUG ARCH EUR J PHY, V456, P1149, DOI 10.1007/s00424-008-0492-7; Perez-Alvarez A, 2007, J NEUROCHEM, V103, P2281, DOI 10.1111/j.1471-4159.2007.04932.x; Perez-Alvarez A, 2012, BRIT J PHARMACOL, V165, P908, DOI 10.1111/j.1476-5381.2011.01596.x; Perez-Alvarez A, 2011, J NEUROCHEM, V116, P105, DOI 10.1111/j.1471-4159.2010.07089.x; Perez-Alvarez A, 2010, CELL MOL NEUROBIOL, V30, P1407, DOI 10.1007/s10571-010-9582-0; Perry DC, 2007, J PHARMACOL EXP THER, V322, P306, DOI 10.1124/jpet.107.121228; Quick MW, 1999, NEUROPHARMACOLOGY, V38, P769, DOI 10.1016/S0028-3908(99)00024-6; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Quik M, 2001, J NEUROSCI, V21, P5494, DOI 10.1523/JNEUROSCI.21-15-05494.2001; Sala F, 2008, ACTA PHYSIOL, V192, P203, DOI 10.1111/j.1748-1716.2007.01804.x; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; TAKIYYUDDIN MA, 1994, J AUTON PHARMACOL, V14, P187, DOI 10.1111/j.1474-8673.1994.tb00601.x; Tumkosit P, 2006, MOL PHARMACOL, V70, P1358, DOI 10.1124/mol.106.027326; Vailati S, 1999, MOL PHARMACOL, V56, P11, DOI 10.1124/mol.56.1.11; Walsh H, 2008, J BIOL CHEM, V283, P6022, DOI 10.1074/jbc.M703432200; WHITEHOUSE PJ, 1988, ARCH NEUROL-CHICAGO, V45, P722, DOI 10.1001/archneur.1988.00520310028012; Wu PC, 2010, J NEUROCHEM, V112, P1210, DOI 10.1111/j.1471-4159.2009.06533.x; Xiao C, 2011, BIOCHEM PHARMACOL, V82, P852, DOI 10.1016/j.bcp.2011.05.005; Yang KC, 2011, J NEUROSCI, V31, P2537, DOI 10.1523/JNEUROSCI.3003-10.2011; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9	66	23	23	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					346	354		10.1096/fj.11-190223	http://dx.doi.org/10.1096/fj.11-190223			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21917987	Green Published			2022-12-28	WOS:000299202200034
J	Lanthier, N; Molendi-Coste, O; Cani, PD; van Rooijen, N; Horsmans, Y; Leclercq, IA				Lanthier, Nicolas; Molendi-Coste, Olivier; Cani, Patrice D.; van Rooijen, Nico; Horsmans, Yves; Leclercq, Isabelle A.			Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet	FASEB JOURNAL			English	Article						macrophage; insulin resistance; steatosis; NAFLD; clodronate	HEPATIC INSULIN-RESISTANCE; ADIPOSE-TISSUE MACROPHAGES; PHOSPHATIDYLINOSITOL 3-KINASE; NONALCOHOLIC STEATOHEPATITIS; INDUCED OBESITY; LIVER-CELLS; FED RATS; STEATOSIS; ACTIVATION; EXPRESSION	We aimed to evaluate activation of macrophages in insulin-sensitive tissues (liver, adipose tissue, and muscles) under high-fat diet (HFD) and elucidate the role of Kupffer cells (KC) in HFD-induced insulin resistance. Tissue macrophage populations, insulin signaling, and sensitivity were evaluated in mice fed a HFD for 4 or 16 wk. Selective KC depletion was obtained by intravenous injections of liposome-encapsulated clodronate. Mice fed a HFD for 4 to 16 wk have hepatic and peripheral insulin resistance together with macrophage recruitment in the adipose tissue but not in the liver. Depletion of KC for the last 10 d of the 16 wk experiment fails to improve insulin sensitivity compared to PBS-treated animals. In contrast, preventive KC depletion prior to and during the 4 wk HFD attenuates the development of obesity, adiposity, adipose tissue inflammation (P<0.01 vs. PBS group), and insulin resistance (P<0.01). Interestingly, in mice fed a normal diet, prolonged KC depletion ameliorates insulin sensitivity and decreases adiposity without altering physiological body weight gain or food intake. Preventive and prolonged KC depletion ameliorates insulin sensitivity and prevents adipose tissue inflammation, suggesting a communication between the liver and the adipose tissue in the development of HFD-induced metabolic alterations.-Lanthier, N., Molendi-Coste, O., Cani, P. D., van Rooijen, N., Horsmans, Y., Leclercq, I. A. Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. FASEB J. 25, 4301-4311 (2011). www.fasebj.org	[Lanthier, Nicolas; Molendi-Coste, Olivier; Horsmans, Yves; Leclercq, Isabelle A.] Catholic Univ Louvain, Inst Rech Expt & Clin, Lab Gastroenterol, B-1200 Brussels, Belgium; [Cani, Patrice D.] Catholic Univ Louvain, Louvain Drug Res Inst, Metab & Nutr Res Grp, B-1200 Brussels, Belgium; [van Rooijen, Nico] Vrije Univ Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands	Universite Catholique Louvain; Universite Catholique Louvain; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Leclercq, IA (corresponding author), Catholic Univ Louvain, Inst Rech Expt & Clin, Lab Hepatogastroenterol, UCL GAEN 5379, Ave E Mounier 53, B-1200 Brussels, Belgium.	isabelle.leclercq@uclouvain.be	D., Cani Patrice/M-8055-2016; Lanthier, Nicolas/AAT-2930-2021; Van Rooijen, Nico/Z-1578-2019	D., Cani Patrice/0000-0003-2040-2448; Lanthier, Nicolas/0000-0002-7651-9314; Molendi-Coste, Olivier/0000-0002-0498-9456	Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FRS-FNRS) [3.4520.10, 3.4578.07, M.I.S.F.45.08.08]; University FSR; Fondation St Luc; Astra Zeneca; Roche	Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); University FSR; Fondation St Luc; Astra Zeneca(AstraZeneca); Roche(Roche Holding)	The authors are grateful to Martine Petit, Valerie Lebrun, and Jorge Abarca-Quinones for expert technical assistance. This work was supported by Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (FRS-FNRS) grants (3.4520.10, 3.4578.07, and M.I.S.F.45.08.08); University FSR grants to I.L.; and a Liver, Virus, and Diabetes research grant from the Fondation St Luc, Astra Zeneca, and Roche to I.L. and Y.H. I.L. and P.D.C. are FRS-FNRS research associates. The authors declare no conflicts of interest in relation to this work. The foundation Clodronate Liposomes (NVR) is a nonprofit foundation related to the Department of Molecular Cell Biology of Vrije Universiteit (Amsterdam, The Netherlands).	Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Baffy G, 2009, J HEPATOL, V51, P212, DOI 10.1016/j.jhep.2009.03.008; Bieghs V, 2010, GASTROENTEROLOGY, V138, P2477, DOI 10.1053/j.gastro.2010.02.051; BIEWENGA J, 1995, CELL TISSUE RES, V280, P189, DOI 10.1007/BF00304524; Cintra DE, 2008, J HEPATOL, V48, P628, DOI 10.1016/j.jhep.2007.12.017; Clementi AH, 2009, BBA-MOL BASIS DIS, V1792, P1062, DOI 10.1016/j.bbadis.2009.08.007; De Taeye BM, 2007, AM J PHYSIOL-ENDOC M, V293, pE713, DOI 10.1152/ajpendo.00194.2007; Deveaux V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005844; Ehses JA, 2010, DIABETOLOGIA, V53, P1795, DOI 10.1007/s00125-010-1747-3; Engel DR, 2008, J IMMUNOL, V181, P5579, DOI 10.4049/jimmunol.181.8.5579; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Hong EG, 2009, DIABETES, V58, P2525, DOI 10.2337/db08-1261; Huang W, 2010, DIABETES, V59, P347, DOI 10.2337/db09-0016; Kammoun HL, 2009, J CLIN INVEST, V119, P1201, DOI 10.1172/JCI37007; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Lanthier N, 2010, HEPATOLOGY, V51, P721, DOI 10.1002/hep.23455; Lanthier N, 2010, AM J PHYSIOL-GASTR L, V298, pG107, DOI 10.1152/ajpgi.00391.2009; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Leclercq IA, 2007, J HEPATOL, V47, P142, DOI 10.1016/j.jhep.2007.04.002; Leclercq IA, 2007, LAB INVEST, V87, P56, DOI 10.1038/labinvest.3700489; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Marchesini G, 2006, Minerva Cardioangiol, V54, P229; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Neyrinck AM, 2009, BIOCHEM BIOPH RES CO, V385, P351, DOI 10.1016/j.bbrc.2009.05.070; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Suganami T, 2007, BIOCHEM BIOPH RES CO, V354, P45, DOI 10.1016/j.bbrc.2006.12.190; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363; Wu J, 2010, IMMUNOLOGY, V129, P363, DOI 10.1111/j.1365-2567.2009.03179.x; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	46	84	86	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4301	4311		10.1096/fj.11-189472	http://dx.doi.org/10.1096/fj.11-189472			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21873555	Bronze			2022-12-28	WOS:000298138100022
J	Rahim, AA; Wong, AMS; Hoefer, K; Buckley, SMK; Mattar, CN; Cheng, SH; Chan, JKY; Cooper, JD; Waddington, SN				Rahim, Ahad A.; Wong, Andrew M. S.; Hoefer, Klemens; Buckley, Suzanne M. K.; Mattar, Citra N.; Cheng, Seng H.; Chan, Jerry K. Y.; Cooper, Jonathan D.; Waddington, Simon N.			Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system	FASEB JOURNAL			English	Article						targeted gene expression; perinatal gene therapy; neurodegenerative disease; peripheral nerves	NEURONAL CEROID-LIPOFUSCINOSIS; POSTTRANSCRIPTIONAL REGULATORY ELEMENT; GENE-THERAPY; ANATOMICAL CHARACTERIZATION; BRAIN DEVELOPMENT; IN-UTERO; MODEL; DELIVERY; STORAGE; ADULT	Several diseases of the nervous system are characterized by neurodegeneration and death in childhood. Conventional medicine is ineffective, but fetal or neonatal gene therapy may provide an alternative route to treatment. We evaluated the ability of single-stranded and self-complementary adeno-associated virus pseudotype 2/9 (AAV2/9) to transduce the nervous system and target gene expression to specific neural cell types following intravenous injection into fetal and neonatal mice, using control uninjected age-matched mice. Fetal and neonatal administration produced global delivery to the central (brain, spinal cord, and all layers of the retina) and peripheral (myenteric plexus and innervating nerves) nervous system but with different expression profiles within the brain; fetal and neonatal administration resulted in expression in neurons and protoplasmic astrocytes, respectively. Neither single-stranded nor self-complementary AAV2/9 triggered a microglia-mediated immune response following either administration. In summary, intravenous AAV2/9 targets gene expression to specific neural cell types dependent on developmental stage. This represents a powerful tool for studying nervous system development and disease. Furthermore, it may provide a therapeutic strategy for treatment of early lethal genetic diseases, such as Gaucher disease, and for disabling neuropathies, such as preterm brain injury.-Rahim, A. A., Wong, A. M. S., Hoefer, K., Buckley, S. M. K., Mattar, C. N., Cheng, S. H., Chan, J. K. Y., Cooper, J. D., Waddington, S. N. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of central nervous system cell types and extensive transduction of the nervous system. FASEB J. 25, 3505-3518 (2011). www.fasebj.org	[Rahim, Ahad A.; Buckley, Suzanne M. K.; Waddington, Simon N.] UCL, Inst Womens Hlth, Gene Transfer Technol Grp, London WC1E 6HX, England; [Wong, Andrew M. S.; Hoefer, Klemens; Cooper, Jonathan D.] Kings Coll London, Inst Psychiat, Pediat Storage Disorders Lab, London WC2R 2LS, England; [Mattar, Citra N.; Chan, Jerry K. Y.] Natl Univ Singapore, Dept Obstet & Gynaecol, Expt Fetal Med Grp, Singapore 117548, Singapore; [Cheng, Seng H.] Genzyme Corp, Framingham, MA 01701 USA; [Chan, Jerry K. Y.] Kandang Kerbau Womens & Childrens Hosp, Dept Reprod Med, Singapore, Singapore	University of London; University College London; University of London; King's College London; National University of Singapore; Sanofi-Aventis; Genzyme Corporation; KK Women's & Children's Hospital	Waddington, SN (corresponding author), UCL, Inst Womens Hlth, Gene Transfer Technol Grp, 86-96 Chenies Mews, London WC1E 6HX, England.	s.waddington@ucl.ac.uk	Cooper, Jonathan/V-9962-2019; rahim, abdul/AAC-6745-2021; Cheng, Seng H/AAC-6564-2022; Waddington, Simon/G-3778-2011; Cooper, Jonathan/C-8117-2009	Cooper, Jonathan/0000-0003-1339-4750; rahim, abdul/0000-0002-0269-9156; Waddington, Simon/0000-0003-4970-4730; Cooper, Jonathan/0000-0003-1339-4750; Buckley, Suzanne/0000-0003-1286-1003; Mattar, Citra Nurfarah/0000-0003-0068-6957	UK Medical Research Council [G1000709]; Wellcome Trust [WT089806MA, GR079491MA]; UK Gaucher Association; family of Ellie Carter; National Medical Research Council, Singapore [CSA/012/2009]; Batten Disease Family Association; Batten Disease Support and Research Association; Medical Research Council [G1000709] Funding Source: researchfish; MRC [G1000709] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); UK Gaucher Association; family of Ellie Carter; National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Batten Disease Family Association; Batten Disease Support and Research Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Gennadij Raivich (University College London) for advice and useful discussion. The authors thank Julie Johnson (University of Pennsylvania, Philadelphia, PA, USA) and the University of Pennsylvania Vector Core Facility (http://www.med.upenn.edu/gtp/vectorcore/) for provision of vectors. The authors also thank Takis Athanasopolous and Alberto Malerba (Royal Holloway, University of London, London, UK) for useful discussion and advice on vectorology. This work was funded by a UK Medical Research Council grant (G1000709) and a Wellcome Trust grant (WT089806MA). A.A.R. and S.N.W. have also received support from the UK Gaucher Association (funds donated by the family of Ellie Carter). J.K.Y.C. received support from the Clinician Scientist Award, National Medical Research Council, Singapore (CSA/012/2009). The Pediatric Storage Disorders Laboratory at King's College London is supported by The Wellcome Trust (GR079491MA), Batten Disease Family Association, and the Batten Disease Support and Research Association.	Akache B, 2006, J VIROL, V80, P9831, DOI 10.1128/JVI.00878-06; Bible E, 2004, NEUROBIOL DIS, V16, P346, DOI 10.1016/j.nbd.2004.02.010; Boksa P, 2010, BRAIN BEHAV IMMUN, V24, P881, DOI 10.1016/j.bbi.2010.03.005; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Coutelle C, 2005, GENE THER, V12, P1601, DOI 10.1038/sj.gt.3302632; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Donello JE, 1998, J VIROL, V72, P5085, DOI 10.1128/JVI.72.6.5085-5092.1998; Duque S, 2009, MOL THER, V17, P1187, DOI 10.1038/mt.2009.71; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; Foust KD, 2010, NAT BIOTECHNOL, V28, P271, DOI 10.1038/nbt.1610; Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515; Franklin K., 2007, MOUSE BRAIN STEREOTA; Fritchie K, 2009, ACTA NEUROPATHOL, V117, P201, DOI 10.1007/s00401-008-0426-7; Galvin N, 2008, PEDIATR DEVEL PATHOL, V11, P185, DOI 10.2350/07-03-0242.1; Guggenbuhl P, 2008, JOINT BONE SPINE, V75, P116, DOI 10.1016/j.jbspin.2007.06.006; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; Huang H, 2009, J NEUROSCI, V29, P4263, DOI 10.1523/JNEUROSCI.2769-08.2009; Kielar C, 2007, NEUROBIOL DIS, V25, P150, DOI 10.1016/j.nbd.2006.09.001; Lei B, 2010, ADV EXP MED BIOL, V664, P671, DOI 10.1007/978-1-4419-1399-9_77; Loeb JE, 1999, HUM GENE THER, V10, P2295, DOI 10.1089/10430349950016942; McCarty DM, 2008, MOL THER, V16, P1648, DOI 10.1038/mt.2008.171; Orvisky E, 2000, PEDIATR RES, V48, P233, DOI 10.1203/00006450-200008000-00018; Paterna JC, 2000, GENE THER, V7, P1304, DOI 10.1038/sj.gt.3301221; Rahim AA, 2009, GENE THER, V16, P509, DOI 10.1038/gt.2008.186; Roybal JL, 2010, SEMIN FETAL NEONAT M, V15, P46, DOI 10.1016/j.siny.2009.05.005; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Sharma A, 2010, EXP EYE RES, V91, P440, DOI 10.1016/j.exer.2010.06.020; Shen JS, 2004, J GENE MED, V6, P1206, DOI 10.1002/jgm.630; Shen JS, 2001, GENE THER, V8, P1081, DOI 10.1038/sj.gt.3301495; Shen S, 2011, J BIOL CHEM, V286, P13532, DOI 10.1074/jbc.M110.210922; Siintola E, 2006, BRAIN, V129, P1438, DOI 10.1093/brain/awl107; Sondhi D, 2008, EXP NEUROL, V213, P18, DOI 10.1016/j.expneurol.2008.04.022; Souweidane MM, 2010, J NEUROSURG-PEDIATR, V6, P115, DOI 10.3171/2010.4.PEDS09507; Tuchscherer M, 2002, VET IMMUNOL IMMUNOP, V86, P195, DOI 10.1016/S0165-2427(02)00035-1; Tyynela J, 2000, EMBO J, V19, P2786, DOI 10.1093/emboj/19.12.2786; Visigalli I, 2010, BLOOD, V116, P5130, DOI 10.1182/blood-2010-04-278234; Waddington SN, 2007, CURR OPIN MOL THER, V9, P432; Waddington SN, 2004, BLOOD, V104, P2714, DOI 10.1182/blood-2004-02-0627; Waddington SN, 2004, GENE THER, V11, pS92, DOI 10.1038/sj.gt.3302375; Waddington SN, 2003, BLOOD, V101, P1359, DOI 10.1182/blood-2002-03-0779; Wen Shi Wu, 2004, Semin Fetal Neonatal Med, V9, P429, DOI 10.1016/j.siny.2004.04.002; Worgall S, 2008, HUM GENE THER, V19, P463, DOI 10.1089/hum.2008.022; Yokoi K, 2007, INVEST OPHTH VIS SCI, V48, P3324, DOI 10.1167/iovs.06-1306; Zhang JY, 2005, NEUROIMAGE, V26, P1042, DOI 10.1016/j.neuroimage.2005.03.009; Zhang JY, 2003, NEUROIMAGE, V20, P1639, DOI 10.1016/S1053-8119(03)00410-5	45	70	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3505	3518		10.1096/fj.11-182311	http://dx.doi.org/10.1096/fj.11-182311			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746868				2022-12-28	WOS:000295356400021
J	Sinke, AP; Deen, PMT				Sinke, Anne P.; Deen, Peter M. T.			The physiological implication of novel proteins in systemic osmoregulation	FASEB JOURNAL			English	Review						water homeostasis; osmosensing; osmobalance; hyponatremia; hypernatremia	IDIOPATHIC HYPOTHALAMIC DYSFUNCTION; VASOPRESSIN TYPE-2 RECEPTOR; AQUAPORIN-2 WATER CHANNEL; NORMAL THIRST RESPONSES; RAT SUPRAOPTIC NUCLEUS; SUBFORNICAL ORGAN; MICE LACKING; ADIPSIC HYPERNATREMIA; GLYCINE RECEPTORS; PRIMARY-CARE	Maintenance of the osmobalance is important for life. In this process, in which brain and kidney act in concert, mammals have to cope with significant deviations as drinking water reduces plasma osmolality, whereas salty food increases it. To restore homeostasis, specialized nuclei within the hypothalamus play a pivotal role in detecting changes in plasma osmolality and initiating appropriate responses. These responses are accomplished by either changing the intake of water or the excretion of water by the kidney. In the past decade, several novel findings have made significant contributions to our insights in the process of systemic osmoregulation. Novel proteins have been identified in the brain as well as in the kidney that are fulfilling important roles in the process of systemic osmoregulation. In this review, recent evidence of the involvement of TRPV channels (TRPV1, TRPV2, and TRPV4) and proteins, such as sodium channels NALCN and Na-x, in neuronal osmoregulation, as well as; e.g., the purinergic P2Y2 receptor in renal osmoregulation, are discussed, and integrated with existing knowledge of systemic osmoregulation.-Sinke, A. P., Deen, P. M. T. The physiological implication of novel proteins in systemic osmoregulation. FASEB J. 25, 3279-3289 (2011). www.fasebj.org	[Sinke, Anne P.; Deen, Peter M. T.] RUNMC Nijmegen, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Deen, PMT (corresponding author), RUNMC Nijmegen, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.deen@fysiol.umcn.nl	Deen, P.M.T./H-8023-2014; Deen, Peter MT/B-9854-2013	Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Allen AM, 1998, BRAIN RES BULL, V47, P17, DOI 10.1016/S0361-9230(98)00039-2; ANTUNESRODRIGUES J, 1985, P NATL ACAD SCI USA, V82, P8720, DOI 10.1073/pnas.82.24.8720; Bappal B, 2006, SAUDI MED J, V27, P727; Baylis P, 2001, PRINCIPLES PRACTICE; Benabdesselam R, 2010, J NEUROSCI RES, V88, P324, DOI 10.1002/jnr.22198; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Boone M, 2011, AM J PHYSIOL-RENAL, V300, pF761, DOI 10.1152/ajprenal.00247.2010; Bourque CW, 2008, NAT REV NEUROSCI, V9, P519, DOI 10.1038/nrn2400; BOURQUE CW, 1994, FRONT NEUROENDOCRIN, V15, P231, DOI 10.1006/frne.1994.1010; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; Bres V, 2000, BRIT J PHARMACOL, V130, P1976, DOI 10.1038/sj.bjp.0703492; Cauble MS, 2001, J PEDIATR ENDOCR MET, V14, P1163; Ciura S, 2006, J NEUROSCI, V26, P9069, DOI 10.1523/JNEUROSCI.0877-06.2006; Clapham DE, 2007, CELL, V129, P220, DOI 10.1016/j.cell.2007.03.034; CONLEY SB, 1976, J PEDIATR-US, V89, P898, DOI 10.1016/S0022-3476(76)80593-8; Deen PMT, 1998, AM J MED SCI, V316, P300, DOI 10.1097/00000441-199811000-00003; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Deleuze C, 1998, J PHYSIOL-LONDON, V507, P463, DOI 10.1111/j.1469-7793.1998.463bt.x; Deleuze C, 2005, NEUROSCIENCE, V133, P175, DOI 10.1016/j.neuroscience.2005.01.060; DURIVAGE SK, 1985, PEDIATRICS, V75, P896; Ecelbarger CA, 2006, CURR HYPERTENS REP, V8, P158, DOI 10.1007/s11906-006-0013-z; Egan G, 2003, P NATL ACAD SCI USA, V100, P15241, DOI 10.1073/pnas.2136650100; ERIKSSON L, 1971, ACTA PHYSIOL SCAND, V83, P554, DOI 10.1111/j.1748-1716.1971.tb05113.x; Feldman BJ, 2005, NEW ENGL J MED, V352, P1884, DOI 10.1056/NEJMoa042743; Fitzsimons JT, 1998, PHYSIOL REV, V78, P583, DOI 10.1152/physrev.1998.78.3.583; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; HAYEK A, 1982, PEDIATRICS, V70, P275; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hiyama TY, 2010, NEURON, V66, P508, DOI 10.1016/j.neuron.2010.04.017; Hoorn EJ, 2006, NEPHROL DIAL TRANSPL, V21, P70, DOI 10.1093/ndt/gfi082; Hussy N, 1997, J PHYSIOL-LONDON, V502, P609, DOI 10.1111/j.1469-7793.1997.609bj.x; Ji LL, 2005, AM J PHYSIOL-REG I, V288, pR311, DOI 10.1152/ajpregu.00399.2004; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kengne FG, 2008, QJM-INT J MED, V101, P583, DOI 10.1093/qjmed/hcn061; Kinsella S, 2010, CLIN J AM SOC NEPHRO, V5, P275, DOI 10.2215/CJN.06120809; Knoers NVAM, 2001, PEDIATR NEPHROL, V16, P1146, DOI 10.1007/s004670100051; Liapi A, 2005, EUR J NEUROSCI, V22, P825, DOI 10.1111/j.1460-9568.2005.04270.x; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Lu BX, 2007, CELL, V129, P371, DOI 10.1016/j.cell.2007.02.041; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Massieu L, 2004, NEUROCHEM RES, V29, P73, DOI 10.1023/B:NERE.0000010435.06586.e2; MCKINLEY MJ, 1978, BRAIN RES, V141, P89, DOI 10.1016/0006-8993(78)90619-4; MCKINLEY MJ, 1994, BRAIN RES, V653, P305, DOI 10.1016/0006-8993(94)90405-7; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Morita H, 2004, AUTON NEUROSCI-BASIC, V113, P43, DOI 10.1016/j.autneu.2004.05.005; Muraki K, 2003, CIRC RES, V93, P829, DOI 10.1161/01.RES.0000097263.10220.0C; Naeini RS, 2006, NAT NEUROSCI, V9, P93, DOI 10.1038/nn1614; Nagakura A, 2010, NEUROSCI LETT, V472, P161, DOI 10.1016/j.neulet.2010.01.077; Nielsen S, 1997, J NEUROSCI, V17, P171; O'Shaughnessy KM, 2004, J CLIN INVEST, V113, P1075, DOI 10.1172/JCI200421560; OLDFIELD BJ, 1994, NEUROSCIENCE, V60, P255, DOI 10.1016/0306-4522(94)90219-4; Oliet SHR, 1996, NEURON, V16, P175, DOI 10.1016/S0896-6273(00)80034-3; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; Perkins Robert M, 2006, Clin Exp Nephrol, V10, P63, DOI 10.1007/s10157-005-0397-0; Richard D, 1995, J PHYSIOL-LONDON, V489, P567, DOI 10.1113/jphysiol.1995.sp021073; Rieg T, 2007, FASEB J, V21, P3717, DOI 10.1096/fj.07-8807com; Robben JH, 2006, AM J PHYSIOL-RENAL, V291, pF257, DOI 10.1152/ajprenal.00491.2005; Robben JH, 2009, P NATL ACAD SCI USA, V106, P12195, DOI 10.1073/pnas.0900130106; ROBERTSON GL, 1976, KIDNEY INT, V10, P25, DOI 10.1038/ki.1976.76; ROBERTSON GL, 1983, J LAB CLIN MED, V101, P351; Rutter AR, 2005, NEUROREPORT, V16, P1735, DOI 10.1097/01.wnr.0000185958.03841.0f; Sajadieh A, 2009, AM J MED, V122, P679, DOI 10.1016/j.amjmed.2008.11.033; Salas MM, 2009, EUR J NEUROSCI, V29, P1568, DOI 10.1111/j.1460-9568.2009.06702.x; SCHAAD U, 1979, HELV PAEDIATR ACTA, V34, P63; Shimizu H, 2007, NEURON, V54, P59, DOI 10.1016/j.neuron.2007.03.014; Shirreffs SM, 2004, BRIT J NUTR, V91, P951, DOI 10.1079/BJN20041149; SIBBALD JR, 1988, BRAIN RES, V461, P205, DOI 10.1016/0006-8993(88)90251-X; SIMPSON JB, 1978, SCIENCE, V201, P379, DOI 10.1126/science.663664; Sinke AP, 2011, PHYSIOL GENOMICS, V43, P265, DOI 10.1152/physiolgenomics.00188.2010; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309; Spital A, 1999, AM J NEPHROL, V19, P447, DOI 10.1159/000013496; Stricker EM, 2002, PHYSIOL BEHAV, V77, P731, DOI 10.1016/S0031-9384(02)00926-5; Sunn N, 2002, P NATL ACAD SCI USA, V99, P1701, DOI 10.1073/pnas.022647699; Taylor AC, 2008, AM J PHYSIOL-REG I, V294, pR1285, DOI 10.1152/ajpregu.00003.2008; THOMPSON CJ, 1986, CLIN SCI, V71, P651, DOI 10.1042/cs0710651; THRASHER TN, 1980, AM J PHYSIOL, V238, pR333, DOI 10.1152/ajpregu.1980.238.5.R333; THRASHER TN, 1982, FED PROC, V41, P2528; Tian W, 2009, P NATL ACAD SCI USA, V106, P14034, DOI 10.1073/pnas.0904084106; Upadhyay A, 2009, SEMIN NEPHROL, V29, P227, DOI 10.1016/j.semnephrol.2009.03.004; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Verbalis JG, 2010, J BONE MINER RES, V25, P554, DOI 10.1359/jbmr.090827; VERNEY EB, 1947, PROC R SOC SER B-BIO, V135, P25, DOI 10.1098/rspb.1947.0037; VIVAS L, 1990, BRAIN RES, V519, P294, DOI 10.1016/0006-8993(90)90091-O; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Wainwright A, 2004, J COMP NEUROL, V474, P24, DOI 10.1002/cne.20100; Wang Z, 2010, J HUM HYPERTENS, V24, P327, DOI 10.1038/jhh.2009.67; Wildman SSP, 2009, J AM SOC NEPHROL, V20, P1480, DOI 10.1681/ASN.2008070686; WILKIN LD, 1989, NEUROSCIENCE, V28, P573, DOI 10.1016/0306-4522(89)90006-7; Wu W, 2009, AM J PHYSIOL-RENAL, V297, pF210, DOI 10.1152/ajprenal.90260.2008; Zhang XF, 2008, EUR J NEUROSCI, V27, P605, DOI 10.1111/j.1460-9568.2008.06030.x; Zhang Y, 2008, AM J PHYSIOL-RENAL, V295, pF1715, DOI 10.1152/ajprenal.90311.2008	96	19	19	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3279	3289		10.1096/fj.11-188433	http://dx.doi.org/10.1096/fj.11-188433			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21737616				2022-12-28	WOS:000295356400001
J	Dobek, GL; Zhang, XJ; Balazs, DA; Godbey, WT				Dobek, Georgina L.; Zhang, Xiujuan; Balazs, Daniel A.; Godbey, W. T.			Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability	FASEB JOURNAL			English	Article						Cox-2; Her-2; survivin	TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER CELLS; ANTI-APOPTOSIS GENE; HUMAN COLON-CANCER; BREAST-CANCER; COLORECTAL-CANCER; URINARY-BLADDER; IN-VITRO; SURVIVIN; CYCLOOXYGENASE-2	Genes under the control of the cyclooxygenase- 2 (Cox-2), human epidermal growth factor receptor 2 (Her-2), and survivin promoters were constructed and delivered to murine and human carcinoma cells. It was found that (P)Cox-2-driven reporter expression was strong and correlated well with endogenous Cox-2 levels, while (P)Her-2 and (P)survivin yielded poor results, consistent with the three distinct expression mechanisms used by cancer cells to overexpress the endogenous versions of the selected genes. The (P)Cox-2 was then used to drive the expression of caspase genes both in vitro and in vivo to bring about targeted apoptosis of carcinoma cells successfully. The results led to the following conclusions. 1) When selecting a promoter/enhancer for expression-targeted gene delivery, it is not enough to perform a microarray on some tumor tissue and select the control element associated with the greatest amount of gene up-regulation vs. normal controls. The mechanism of expression for the particular gene should be taken into account to prevent lengthy and costly research trials. 2) When overexpression is due to activator binding, a predictive model based on endogenous gene expression levels, overall cell transfectability, and cell doubling rates can be used to predict expression-targeted gene delivery outcomes with significant accuracy.-Dobek, G. L., Zhang, X., Balazs, D. A., Godbey, W. T. Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability. FASEB J. 25, 3219-3228 (2011). www.fasebj.org	[Zhang, Xiujuan; Balazs, Daniel A.; Godbey, W. T.] Tulane Univ, Lab Gene Therapy & Cellular Engn, Dept Chem & Biomol Engn, New Orleans, LA 70118 USA; [Dobek, Georgina L.] Tulane Univ, Dept Comparat Med, New Orleans, LA 70118 USA	Tulane University; Tulane University	Godbey, WT (corresponding author), Tulane Univ, Lab Gene Therapy & Cellular Engn, Dept Chem & Biomol Engn, 6823 St Charles Ave,300 Lindy Boggs Ctr, New Orleans, LA 70118 USA.	godbey@tulane.edu	Godbey, W T/H-9407-2012	Dobek, Georgina/0000-0002-3383-7101	National Science Foundation [CBET-0846395]; Department of Comparative Medicine, Tulane University; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T35OD010991] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Department of Comparative Medicine, Tulane University; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. John C. Prindle, Jr. (Tulane University), for assistance with statistical analyses. The authors thank Ariad (Cambridge, MA, USA; http://www.ariad.com/regulationkits) for providing the AP20187. This work was funded by a National Science Foundation CAREER award (CBET-0846395) and the Department of Comparative Medicine, Tulane University. The authors declare no conflicts of interest associated with these investigations.	Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Benoit V, 2004, ONCOGENE, V23, P1631, DOI 10.1038/sj.onc.1207295; Bostrom PJ, 2001, PATHOLOGY, V33, P469, DOI 10.1080/00313020120083188; Box GE., 1978, STAT EXPT; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Dachs GU, 1997, ONCOL RES, V9, P313; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; Dobek GL, 2011, JOVE-J VIS EXP, DOI 10.3791/2535; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Ferrandez A, 2003, CURR PHARM DESIGN, V9, P2229, DOI 10.2174/1381612033454036; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Ghosh N, 2010, PHARMACOL REP, V62, P233, DOI 10.1016/S1734-1140(10)70262-0; Godbey WT, 2003, GENE THER, V10, P1519, DOI 10.1038/sj.gt.3302012; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Honma I, 2009, CANCER IMMUNOL IMMUN, V58, P1803, DOI 10.1007/s00262-009-0691-x; Hopfer O, 2007, EXP HEMATOL, V35, P712, DOI 10.1016/j.exphem.2007.01.054; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Hurst HC, 2001, BREAST CANCER RES, V3, P395, DOI 10.1186/bcr329; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Jiang MH, 2006, CLIN CANCER RES, V12, P6179, DOI 10.1158/1078-0432.CCR-06-0746; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kato J, 2001, INT J CANCER, V95, P92; Kawasaki H, 1998, CANCER RES, V58, P5071; Kikkawa K, 2009, UROLOGY, V74, P222, DOI 10.1016/j.urology.2008.12.045; Ku JH, 2010, BJU INT, V106, P1812, DOI 10.1111/j.1464-410X.2010.09259.x; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Ma AN, 2010, BIOCHEM BIOPH RES CO, V393, P592, DOI 10.1016/j.bbrc.2010.02.020; Macrinici V, 2010, CLIN BREAST CANCER, V10, pE38, DOI 10.3816/CBC.2010.s.006; Margulis V, 2008, WORLD J UROL, V26, P59, DOI 10.1007/s00345-007-0219-y; McCrann DJ, 2010, BLOOD, V116, P2192, DOI 10.1182/blood-2010-04-280420; Mohammed SI, 1999, CANCER RES, V59, P5647; Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Pandha HS, 1999, J CLIN ONCOL, V17, P2180, DOI 10.1200/JCO.1999.17.7.2180; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRESS MF, 1993, CANCER RES, V53, P4960; Rajnakova A, 2001, CANCER LETT, V172, P177, DOI 10.1016/S0304-3835(01)00645-0; Ristimaki A, 1997, CANCER RES, V57, P1276; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Ryan BM, 2009, CANCER TREAT REV, V35, P553, DOI 10.1016/j.ctrv.2009.05.003; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shariat SF, 2007, CANCER-AM CANCER SOC, V109, P1106, DOI 10.1002/cncr.22521; Shirahama T, 2001, CLIN CANCER RES, V7, P558; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Wang G, 2010, CANCER GENE THER, V17, P559, DOI 10.1038/cgt.2010.11; Yoshimura R, 2001, J UROLOGY, V165, P1468, DOI 10.1016/S0022-5347(05)66329-X; Zhang X, 2008, CANCER GENE THER, V15, P543, DOI 10.1038/cgt.2008.7; Zhang XJ, 2009, MOL BIOTECHNOL, V41, P236, DOI 10.1007/s12033-008-9133-9	59	3	3	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3219	3228		10.1096/fj.11-185421	http://dx.doi.org/10.1096/fj.11-185421			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21602450	Green Published			2022-12-28	WOS:000294435200034
J	Rat, D; Schmitt, U; Tippmann, F; Dewachter, I; Theunis, C; Wieczerzak, E; Postina, R; van Leuven, F; Fahrenholz, F; Kojro, E				Rat, Dorothea; Schmitt, Ulrich; Tippmann, Frank; Dewachter, Ilse; Theunis, Clara; Wieczerzak, Ewa; Postina, Rolf; van Leuven, Fred; Fahrenholz, Falk; Kojro, Elzbieta			Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice	FASEB JOURNAL			English	Article						PAC1 receptor; G-protein-coupled receptor; neuroprotection; nasal delivery	VASOACTIVE-INTESTINAL-PEPTIDE; BDNF MESSENGER-RNA; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; NEURONAL CELL-DEATH; FACTOR-KAPPA-B; ALPHA-SECRETASE; NEUROTROPHIC FACTOR; GENE-EXPRESSION; INTRANASAL DELIVERY	Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org	[Rat, Dorothea; Tippmann, Frank; Postina, Rolf; Kojro, Elzbieta] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, D-55128 Mainz, Germany; [Schmitt, Ulrich; Fahrenholz, Falk] Johannes Gutenberg Univ Mainz, Dept Psychiat & Psychotherapy, Univ Med Ctr, D-55128 Mainz, Germany; [Dewachter, Ilse; Theunis, Clara; van Leuven, Fred] Katholieke Univ Leuven, Expt Genet Grp, LEGTEGG, Louvain, Belgium; [Wieczerzak, Ewa] Univ Gdansk, Fac Chem, PL-80952 Gdansk, Poland	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; KU Leuven; Fahrenheit Universities; University of Gdansk	Kojro, E (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Becherweg 30, D-55128 Mainz, Germany.	kojro@uni-mainz.de	Wieczerzak, Ewa/AAA-9432-2021; Dewachter, Ilse/AAZ-5661-2020	Wieczerzak, Ewa/0000-0003-2539-5160; Dewachter, Ilse/0000-0001-7202-515X	Alzheimer Forschung Initiative e.V. (Dusseldorf, Germany) [07807]	Alzheimer Forschung Initiative e.V. (Dusseldorf, Germany)	The authors thank Dr. C. Haass (Ludwig Maximilians University Munich, Munich, Germany) for providing antibodies and H. Pearson for critically reading the manuscript. The authors also appreciate the technical help of A. Kanarek. This work was supported by a grant from the Alzheimer Forschung Initiative e.V. (Dusseldorf, Germany) to E. K and F. F (07807).	Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Almkvist O, 1997, ARCH NEUROL-CHICAGO, V54, P641, DOI 10.1001/archneur.1997.00550170111022; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Braas KM, 2007, PEPTIDES, V28, P1856, DOI 10.1016/j.peptides.2007.04.004; Caccamo A, 2006, NEURON, V49, P671, DOI 10.1016/j.neuron.2006.01.020; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Clement ME, 2006, BIOCHEM BIOPH RES CO, V342, P206, DOI 10.1016/j.bbrc.2006.01.137; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Delgado M, 2002, BIOCHEM BIOPH RES CO, V297, P1181, DOI 10.1016/S0006-291X(02)02305-7; Delgado M, 2001, J BIOL CHEM, V276, P369, DOI 10.1074/jbc.M006923200; Dewachter I, 2002, J NEUROSCI, V22, P3445; Doberer D, 2007, EUR J CLIN INVEST, V37, P665, DOI 10.1111/j.1365-2362.2007.01832.x; Donmez G, 2010, CELL, V142, P320, DOI 10.1016/j.cell.2010.06.020; Dufes C, 2003, INT J PHARMACEUT, V255, P87, DOI 10.1016/S0378-5173(03)00039-5; Fellgiebel A, 2009, J GERIATR PSYCH NEUR, V22, P3, DOI 10.1177/0891988708327810; Garzon DJ, 2007, J NEUROSCI, V27, P2628, DOI 10.1523/JNEUROSCI.5053-06.2007; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Hanson LR, 2007, J NEUROIMMUNE PHARM, V2, P81, DOI 10.1007/s11481-006-9039-x; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashimoto H, 2000, J NEUROCHEM, V74, P501, DOI 10.1046/j.1471-4159.2000.740501.x; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7; Illum L, 2006, J AEROSOL MED, V19, P92, DOI 10.1089/jam.2006.19.92; Illum L, 2002, J PHARMACOL EXP THER, V301, P391, DOI 10.1124/jpet.301.1.391; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Jarvis CI, 2010, EUR J NEUROSCI, V32, P1246, DOI 10.1111/j.1460-9568.2010.07426.x; Kojro E, 2006, FASEB J, V20, P512, DOI 10.1096/fj.05-4812fje; Kojro E, 2010, J ALZHEIMERS DIS, V20, P1215, DOI 10.3233/JAD-2010-091621; Kopp M, 1997, NEUROSCI LETT, V227, P145, DOI 10.1016/S0304-3940(97)00312-1; Kuhn PH, 2010, EMBO J, V29, P3020, DOI 10.1038/emboj.2010.167; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; Li M, 2007, PEPTIDES, V28, P1891, DOI 10.1016/j.peptides.2007.05.002; Li Songyun, 1996, Molecular Brain Research, V41, P157, DOI 10.1016/0169-328X(96)00086-1; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Masmoudi-Kouki O, 2007, PEPTIDES, V28, P1753, DOI 10.1016/j.peptides.2007.05.015; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Pellegri G, 1998, EUR J NEUROSCI, V10, P272, DOI 10.1046/j.1460-9568.1998.00052.x; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tippmann F, 2009, FASEB J, V23, P1643, DOI 10.1096/fj.08-121392; Tong LQ, 2004, J NEUROSCI, V24, P6799, DOI 10.1523/JNEUROSCI.5463-03.2004; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Wang G, 2005, FEBS LETT, V579, P4005, DOI 10.1016/j.febslet.2005.06.013; Wu ZL, 2006, NEUROBIOL AGING, V27, P377, DOI 10.1016/j.neurobiolaging.2005.02.010; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Zink M, 2004, NEUROSCI LETT, V360, P106, DOI 10.1016/j.neulet.2004.01.030	68	100	106	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					3208	3218		10.1096/fj.10-180133	http://dx.doi.org/10.1096/fj.10-180133			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21593432	Green Published			2022-12-28	WOS:000294435200033
J	Vanoevelen, J; Janssens, A; Huitema, LFA; Hammond, CL; Metz, JR; Flik, G; Voets, T; Schulte-Merker, S				Vanoevelen, Jo; Janssens, Annelies; Huitema, Leonie F. A.; Hammond, Christina L.; Metz, Juriaan R.; Flik, Gert; Voets, Thomas; Schulte-Merker, Stefan			Trpv5/6 is vital for epithelial calcium uptake and bone formation	FASEB JOURNAL			English	Article						zebrafish; osteogenesis	CA2+ CHANNEL; STANNIOCALCIN 1; ZEBRAFISH; RECEPTOR; KIDNEY; ABSORPTION; EXPRESSION; TRANSPORT; STANNIUS; MEDAKA	Calcium is an essential ion serving a multitude of physiological roles. Aside from its role as a second messenger, it is an essential component of the vertebrate bone matrix. Efficient uptake and storage of calcium are therefore indispensable for all vertebrates. Transient receptor potential family, vanilloid type (TRPV)5 and TRPV6 channels are known players in transcellular calcium uptake, but the exact contribution of this pathway is unclear. We used forward genetic screening in zebrafish (Danio rerio) to identify genes essential in bone formation and identified a lethal zebrafish mutant (matt-und-schlapp) with severe defects in bone formation, including lack of ossification of the vertebral column and craniofacial structures. Mutant embryos show a 68% reduction in calcium content, and systemic calcium homeostasis is disturbed when compared with siblings. The phenotype can be partially rescued by increasing ambient calcium levels to 25 mM. We identified the mutation as a loss-of-function mutation in the single orthologue of TRPV5 and 6, trpv5/6. Expression in HEK293 cells showed that Trpv5/6 is a calcium-selective channel capable of inward calcium transport at physiological concentrations whereas the mutant channel is not. Taken together, this study provides both genetic and functional evidence that transcellular epithelial calcium uptake is vital to sustain life and enable bone formation.-Vanoevelen, J., Janssens, A., Huitema, L. F. A., Hammond, C. L., Metz, J. R., Flik, G., Voets, T., Schulte-Merker, S. Trpv5/6 is vital for epithelial calcium uptake and bone formation. FASEB J. 25, 3197-3207 (2011). www.fasebj.org	[Vanoevelen, Jo; Huitema, Leonie F. A.; Hammond, Christina L.; Schulte-Merker, Stefan] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Vanoevelen, Jo; Huitema, Leonie F. A.; Hammond, Christina L.; Schulte-Merker, Stefan] Univ Med Ctr, Utrecht, Netherlands; [Janssens, Annelies; Voets, Thomas] Catholic Univ Louvain, Lab Ion Channel Res, Dept Mol Cell Biol, B-3000 Louvain, Belgium; [Metz, Juriaan R.; Flik, Gert] Radboud Univ Nijmegen, Inst Water & Wetland Res, Dept Anim Physiol, NL-6525 ED Nijmegen, Netherlands; [Schulte-Merker, Stefan] Wageningen Univ, Expt Zool Grp, Wageningen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; KU Leuven; Universite Catholique Louvain; Radboud University Nijmegen; Wageningen University & Research	Vanoevelen, J (corresponding author), Catholic Univ Louvain, Lab Cellular Transport Syst, Dept Mol Cell Biol, Herestr 49, B-3000 Louvain, Belgium.	jo.vanoevelen@med.kuleuven.be	Flik, Gert/C-8229-2011; Voets, Thomas/E-2466-2012; Metz, Juriaan R./A-3290-2012; Vanoevelen, Jo M/F-2686-2013; Hammond, Chrissy/D-6568-2013; Voets, Thomas/AAD-4389-2019	Flik, Gert/0000-0001-9285-7957; Voets, Thomas/0000-0001-5526-5821; Metz, Juriaan R./0000-0002-1515-1958; Vanoevelen, Jo M/0000-0003-1830-8858; Hammond, Chrissy/0000-0002-4935-6724; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248	SmartMix	SmartMix	The authors thank F. Wuytack, L. Raeymaekers, L. Lieben, G. Carmeliet and B. Nilius for helpful discussions. The authors acknowledge the Hubrecht Imaging Center for expert advice on imaging. The authors thank the Tubingen 2000 screen consortium for identifying the mus<SUP>t25927</SUP> allele; this mutant was identified while S. S-M was working at Artemis Pharmaceuticals/Exelixis Deutschland. S. S.-M. is supported by the Koninklijke Nederlandse Academie van Wetenschap-penand funding from SmartMix. J.V. is a Postdoctoral Fellow of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. The authors declare no conflicts of interest. The data reported in this study have been deposited in the GenBank database (accession no. HQ676591; http://www.ncbi.nlm.gov).	Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; Benn BS, 2008, ENDOCRINOLOGY, V149, P3196, DOI 10.1210/en.2007-1655; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; Brand Michael, 2002, P7; Bronner F, 2003, J NUTR, V133, P1426, DOI 10.1093/jn/133.5.1426; Bronner F, 2009, NUTR REV, V67, P109, DOI 10.1111/j.1753-4887.2008.00147.x; Chen YY, 2003, J EXP ZOOL PART A, V295A, P127, DOI 10.1002/jez.a.10195; Chou MY, 2002, J COMP PHYSIOL B, V172, P109, DOI 10.1007/s00360-001-0231-2; Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868; Deng HX, 2010, NAT GENET, V42, P165, DOI 10.1038/ng.509; Elizondo MR, 2010, ENDOCRINOLOGY, V151, P5700, DOI 10.1210/en.2010-0853; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Flik Gert, 1995, V14, P317; Greenwood MP, 2009, ENDOCRINOLOGY, V150, P3002, DOI 10.1210/en.2008-1758; Hammond CL, 2009, DEVELOPMENT, V136, P3991, DOI 10.1242/dev.042150; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Inohaya K, 2007, DEV DYNAM, V236, P3031, DOI 10.1002/dvdy.21329; ISHIHARA A, 1987, J EXP ZOOL, V242, P121, DOI 10.1002/jez.1402420202; Kawakami K, 1998, GENE, V225, P17, DOI 10.1016/S0378-1119(98)00537-X; KIKUCHI K, 1988, AM J PHYSIOL, V255, pG482, DOI 10.1152/ajpgi.1988.255.4.G482; Koushik SV, 2001, FASEB J, V15, P1209, DOI 10.1096/fj.00-0696fje; Krakow D, 2009, AM J HUM GENET, V84, P307, DOI 10.1016/j.ajhg.2009.01.021; Kutuzova GD, 2008, P NATL ACAD SCI USA, V105, P19655, DOI 10.1073/pnas.0810761105; LAFEBER FPJG, 1988, GEN COMP ENDOCR, V69, P19, DOI 10.1016/0016-6480(88)90048-2; Landoure G, 2010, NAT GENET, V42, P170, DOI 10.1038/ng.512; Lee GS, 2007, J BONE MINER RES, V22, P1968, DOI 10.1359/JBMR.070801; Liao BK, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-354; Lieben L, 2010, BONE, V47, P301, DOI 10.1016/j.bone.2010.04.595; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2003, PFLUG ARCH EUR J PHY, V445, P584, DOI 10.1007/s00424-002-0923-9; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Okunande GW, 2004, J BIOL CHEM, V279, P33742, DOI 10.1074/jbc.M404628200; Pan TC, 2005, AM J PHYSIOL-REG I, V289, pR1202, DOI 10.1152/ajpregu.00816.2004; PANG PKT, 1974, GEN COMP ENDOCR, V23, P239, DOI 10.1016/0016-6480(74)90133-6; PANSU D, 1993, J NUTR, V123, P1396; Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Perez AV, 2008, DIGESTION, V77, P22, DOI 10.1159/000116623; Qiu AD, 2004, GENE, V342, P113, DOI 10.1016/j.gene.2004.07.041; Renn J, 2006, PROTOPLASMA, V229, P209, DOI 10.1007/s00709-006-0215-x; Renn J, 2009, DEV DYNAM, V238, P241, DOI 10.1002/dvdy.21836; Rock MJ, 2008, NAT GENET, V40, P999, DOI 10.1038/ng.166; Schulte-Merker S., 2002, ZEBRAFISH PRACTICAL; Shahsavarani A, 2006, J EXP BIOL, V209, P1928, DOI 10.1242/jeb.02190; Spoorendonk KM, 2010, J APPL ICHTHYOL, V26, P219, DOI 10.1111/j.1439-0426.2010.01409.x; Suzuki Y, 2008, J BONE MINER RES, V23, P1249, DOI [10.1359/jbmr.080314, 10.1359/JBMR.080314]; Tseng DY, 2009, AM J PHYSIOL-REG I, V296, pR549, DOI 10.1152/ajpregu.90742.2008; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; Vangheluwe P, 2009, CHEM REV, V109, P4733, DOI 10.1021/cr900013m; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Vennekens R, 2008, CURR PHARM DESIGN, V14, P18; Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558; Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469-185X.2009.00077.x; Woudenberg-Vrenken TE, 2009, NAT REV NEPHROL, V5, P441, DOI 10.1038/nrneph.2009.100	59	45	48	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					3197	3207		10.1096/fj.11-183145	http://dx.doi.org/10.1096/fj.11-183145			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21670068	Green Submitted			2022-12-28	WOS:000294435200032
J	Alhouayek, M; Lambert, DM; Delzenne, NM; Cani, PD; Muccioli, GG				Alhouayek, Mireille; Lambert, Didier M.; Delzenne, Nathalie M.; Cani, Patrice D.; Muccioli, Giulio G.			Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation	FASEB JOURNAL			English	Article						monoacylglycerol lipase; fatty acid amide hydrolase; anandamide; endocannabinoid; lipopolysaccharide	CANNABINOID RECEPTOR 2; ACID AMIDE HYDROLASE; ULCERATIVE-COLITIS; BOWEL-DISEASE; MONOACYLGLYCEROL LIPASE; ENDOCANNABINOID SYSTEM; INTESTINAL PERMEABILITY; ANTAGONIST RIMONABANT; ALPHA PRODUCTION; GUT MICROBIOTA	Inflammatory bowel diseases (IBDs) are chronic inflammatory conditions for which new therapeutic approaches are needed. Genetic and pharmacological data point to a protective role of CB1 and CB2 cannabinoid receptor activation in IBD experimental models. Therefore, increasing the endogenous levels of 2-arachidonoylglycerol, the main full agonist of these receptors, should have beneficial effects on colitis. 2-Arachidonoylglycerol levels were raised in the trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model by inhibiting monoacylglycerol lipase (MAGL), the primary enzyme responsible for hydrolysis of 2-arachidonoylglycerol, using the selective inhibitor JZL184. MAGL inhibition in diseased mice increased 2-arachidonoylglycerol levels, leading to a reduction of macroscopic and histological colon alterations, as well as of colonic expression of proinflammatory cytokines. The restored integrity of the intestinal barrier function after MAGL inhibition resulted in reduced endotoxemia as well as reduced peripheral and brain inflammation. Coadministration of either CB1 (SR141716A) or CB2 (AM630) selective antagonists with JZL184 completely abolished the protective effect of MAGL inhibition on TNBS-induced colon alterations, thus demonstrating the involvement of both cannabinoid receptors. In conclusion, increasing 2-arachidonoylglycerol levels resulted in a dramatic reduction of colitis and of the related systemic and central inflammation. This could offer a novel pharmacological approach for the treatment of IBD based on the new protective role of 2-arachidonoylglycerol described here.-Alhouayek, M., Lambert, D. M., Delzenne, N. M., Cani, P. D., Muccioli, G. G. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 25, 2711-2721 (2011). www.fasebj.org	[Alhouayek, Mireille; Muccioli, Giulio G.] Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids Res Grp, CHAM7230, B-1200 Brussels, Belgium; [Alhouayek, Mireille; Lambert, Didier M.] Catholic Univ Louvain, Med Chem Grp, CMFA7340, Louvain Drug Res Inst, B-1200 Brussels, Belgium; [Delzenne, Nathalie M.; Cani, Patrice D.] Catholic Univ Louvain, Louvain Drug Res Inst, Metab & Nutr Res Grp, PMNT7369, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain	Muccioli, GG (corresponding author), Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids Res Grp, CHAM7230, Av E Mounier 72, B-1200 Brussels, Belgium.	giulio.muccioli@uclouvain.be	Alhouayek, Mireille/R-5058-2018; Delzenne, Nathalie/AAC-4628-2019; D., Cani Patrice/M-8055-2016	Alhouayek, Mireille/0000-0002-9193-0718; Delzenne, Nathalie/0000-0003-2115-6082; D., Cani Patrice/0000-0003-2040-2448; Muccioli, Giulio/0000-0002-1600-9259	Fonds Speciaux de Recherches (FSR; Universite Catholique de Louvain); Fonds National de la Recherche Scientifique, Belgium (FNRS) [FRFC 2.4555.08]	Fonds Speciaux de Recherches (FSR; Universite Catholique de Louvain); Fonds National de la Recherche Scientifique, Belgium (FNRS)(Fonds de la Recherche Scientifique - FNRS)	The authors thank Dr. Audrey Neyrinck, Owein Guillemot-Legris, and Damien Naslain for their skillful help. G.G.M. is the recipient of a subsidy from the Fonds Speciaux de Recherches (FSR; Universite Catholique de Louvain) and is also grateful to the Fonds National de la Recherche Scientifique, Belgium (FNRS; grant FRFC 2.4555.08). P.D.C. is a research associate with the Fonds de la Recherche Scientifique (FRS-FNRS).	Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753; Ameho CK, 1997, GUT, V41, P487, DOI 10.1136/gut.41.4.487; Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245; Bento AF, 2011, AM J PATHOL, V178, P1153, DOI 10.1016/j.ajpath.2010.11.052; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Brand S, 2009, GUT, V58, P1152, DOI 10.1136/gut.2008.163667; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; Croci T, 2007, BRIT J PHARMACOL, V150, P559, DOI 10.1038/sj.bjp.0707138; D'Argenio G, 2006, FASEB J, V20, P568, DOI 10.1096/fj.05-4943fje; D'Inca R, 1999, AM J GASTROENTEROL, V94, P2956, DOI 10.1111/j.1572-0241.1999.01444.x; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Duncan M, 2008, AM J PHYSIOL-GASTR L, V295, pG1255, DOI 10.1152/ajpgi.90500.2008; Engel MA, 2010, J PHYSIOL PHARMACOL, V61, P89; Engel MA, 2008, J PHYSIOL PHARMACOL, V59, P673; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; Fiorino G, 2010, CURR DRUG TARGETS, V11, P249, DOI 10.2174/138945010790309975; Galvez J, 2000, BRIT J PHARMACOL, V130, P1949, DOI 10.1038/sj.bjp.0703505; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; Geng DC, 2010, J BIOMED MATER RES A, V95A, P321, DOI 10.1002/jbm.a.32836; Ghafouri N, 2004, BRIT J PHARMACOL, V143, P774, DOI 10.1038/sj.bjp.0705948; Ghosh N, 2010, INT REV IMMUNOL, V29, P4, DOI 10.3109/08830180903437212; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Korzenik JR, 2006, NAT REV DRUG DISCOV, V5, P197, DOI 10.1038/nrd1986; Long JZ, 2009, P NATL ACAD SCI USA, V106, P20270, DOI 10.1073/pnas.0909411106; Long JZ, 2009, CHEM BIOL, V16, P744, DOI 10.1016/j.chembiol.2009.05.009; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; Marquez L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006893; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; Melmed GY, 2010, NAT REV GASTRO HEPAT, V7, P110, DOI 10.1038/nrgastro.2009.218; Muccio GG, 2008, ANAL BIOCHEM, V373, P220, DOI 10.1016/j.ab.2007.09.030; Muccioli GG, 2007, J NEUROSCI, V27, P2883, DOI 10.1523/JNEUROSCI.4830-06.2007; Muccioli GG, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.46; Muccioli GG, 2010, DRUG DISCOV TODAY, V15, P474, DOI 10.1016/j.drudis.2010.03.007; Nishimura M, 2009, ANN NY ACAD SCI, V1173, P350, DOI 10.1111/j.1749-6632.2009.04738.x; Obermeier F, 1999, CLIN EXP IMMUNOL, V116, P238; Rojo OP, 2007, INFLAMM BOWEL DIS, V13, P269, DOI 10.1002/ibd.20019; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rogler G, 2010, BEST PRACT RES CL GA, V24, P157, DOI 10.1016/j.bpg.2009.10.011; Schafer A, 2008, BRIT J PHARMACOL, V154, P1047, DOI 10.1038/bjp.2008.158; Shi DN, 2006, CELL RES, V16, P70, DOI 10.1038/sj.cr.7310009; Singh Udai P., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P111, DOI 10.2174/187153007780832109; Storr M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009453; Storr MA, 2008, J MOL MED, V86, P925, DOI 10.1007/s00109-008-0359-6; Storr MA, 2009, INFLAMM BOWEL DIS, V15, P1678, DOI 10.1002/ibd.20960; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Sugamura K, 2009, CIRCULATION, V119, P28, DOI 10.1161/CIRCULATIONAHA.108.811992; Suzuki K, 2007, PATHOL INT, V57, P413, DOI 10.1111/j.1440-1827.2007.02117.x; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Zhou F, 2010, J INT MED RES, V38, P2023, DOI 10.1177/147323001003800616	55	154	160	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2711	2721		10.1096/fj.10-176602	http://dx.doi.org/10.1096/fj.10-176602			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21551239				2022-12-28	WOS:000293337800020
J	Rauscher, AA; Simon, Z; Szollosi, GJ; Graf, L; Derenyi, I; Malnasi-Csizmadia, A				Rauscher, Anna A.; Simon, Zoltan; Szoellosi, Gergely J.; Graf, Laszlo; Derenyi, Imre; Malnasi-Csizmadia, Andras			Temperature dependence of internal friction in enzyme reactions	FASEB JOURNAL			English	Article						trypsin activation; rough energy landscape; Kramers' theory	SOLVENT VISCOSITY; ALPHA-CHYMOTRYPSIN; CONFORMATIONAL-CHANGES; CHEMICAL-REACTIONS; ENERGY LANDSCAPE; PROTEIN DYNAMICS; HUMAN TRYPSIN-4; LIGAND-BINDING; DIFFUSION; ACTIVATION	Our aim was to elucidate the physical background of internal friction of enzyme reactions by investigating the temperature dependence of internal viscosity. By rapid transient kinetic methods, we directly measured the rate constant of trypsin 4 activation, which is an interdomain conformational rearrangement, as a function of temperature and solvent viscosity. We found that the apparent internal viscosity shows an Arrhenius-like temperature dependence, which can be characterized by the activation energy of internal friction. Glycine and alanine mutations were introduced at a single position of the hinge of the interdomain region to evaluate how the flexibility of the hinge affects internal friction. We found that the apparent activation energies of the conformational change and the internal friction are interconvertible parameters depending on the protein flexibility. The more flexible a protein was, the greater proportion of the total activation energy of the reaction was observed as the apparent activation energy of internal friction. Based on the coupling of the internal and external movements of the protein during its conformational change, we constructed a model that quantitatively relates activation energy, internal friction, and protein flexibility.-Rauscher, A. A., Simon, Z., Szollosi, G. J., Graf, L., Derenyi, I., Malnasi-Csizmadia, A. Temperature dependence of internal friction in enzyme reactions. FASEB J. 25, 2804-2813 (2011). www.fasebj.org	[Rauscher, Anna A.; Simon, Zoltan; Graf, Laszlo; Malnasi-Csizmadia, Andras] Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; [Szoellosi, Gergely J.; Derenyi, Imre] Eotvos Lorand Univ, Dept Biol Phys, H-1117 Budapest, Hungary; [Simon, Zoltan] Delta Informat Inc, Budapest, Hungary	Eotvos Lorand University; Eotvos Lorand University	Malnasi-Csizmadia, A (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.	malna@elte.hu	Szollosi, Gergely/AAG-5760-2019; Derenyi, Imre/G-8087-2011; Rauscher, Anna Á/I-3941-2017; Csizmadia, András Málnási/K-7632-2018	Szollosi, Gergely/0000-0002-8556-845X; Derenyi, Imre/0000-0003-1171-1214; Rauscher, Anna Á/0000-0002-4062-960X; Csizmadia, András Málnási/0000-0002-2430-8398	European Research Council; European Union; European Social Fund [TAMOP-4.2.1/B-09/1/KMR]; OTKA [K60665]	European Research Council(European Research Council (ERC)European Commission); European Union(European Commission); European Social Fund(European Social Fund (ESF)); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	The authors thank Vilmosne Enekes for the preparation of the enzyme constructs. This work was supported by European Research Council IDEAS 2007 (to A.M.-C.), the European Union and the European Social Fund (TAMOP-4.2.1/B-09/1/KMR; to A.M.-C., I.D., and L.G.), and the OTKA (K60665; to I.D.).	AGMON N, 1983, J CHEM PHYS, V78, P6947, DOI 10.1063/1.444643; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Fenimore PW, 2004, P NATL ACAD SCI USA, V101, P14408, DOI 10.1073/pnas.0405573101; FERSHT AR, 1974, BIOCHEMISTRY-US, V13, P1416, DOI 10.1021/bi00704a016; FESTA R, 1978, PHYSICA A, V90, P229, DOI 10.1016/0378-4371(78)90111-5; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Gombos L, 2008, BIOCHEMISTRY-US, V47, P1675, DOI 10.1021/bi701454e; Hagen SJ, 2010, CURR PROTEIN PEPT SC, V11, P385; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HEREMANS L, 1989, BIOCHIM BIOPHYS ACTA, V999, P192, DOI 10.1016/0167-4838(89)90217-3; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Neuweiler H, 2009, P NATL ACAD SCI USA, V106, P18569, DOI 10.1073/pnas.0910860106; Nevo R, 2005, EMBO REP, V6, P482, DOI 10.1038/sj.embor.7400403; Pabit SA, 2004, BIOCHEMISTRY-US, V43, P12532, DOI 10.1021/bi048822m; Plaxco KW, 1998, P NATL ACAD SCI USA, V95, P13591, DOI 10.1073/pnas.95.23.13591; Qiu LL, 2004, J AM CHEM SOC, V126, P3398, DOI 10.1021/ja049966r; Rampp M, 2000, CARBOHYD RES, V328, P561, DOI 10.1016/S0008-6215(00)00141-5; STOESZ JD, 1978, BIOCHEMISTRY-US, V17, P3693, DOI 10.1021/bi00611a003; Suda H, 2001, LANGMUIR, V17, P6045, DOI 10.1021/la0106384; Toth J, 2006, J BIOL CHEM, V281, P12596, DOI 10.1074/jbc.M512301200; Toth J, 2007, PROTEINS, V67, P1119, DOI 10.1002/prot.21398; Verheyden G, 2004, PROTEIN SCI, V13, P2533, DOI 10.1110/ps.04709604; Viswanath D. S., 2007, VISCOSITY LIQUIDS; Wensley BG, 2010, NATURE, V463, P685, DOI 10.1038/nature08743; ZWANZIG R, 1988, P NATL ACAD SCI USA, V85, P2029, DOI 10.1073/pnas.85.7.2029; ZWANZIG R, 1992, J CHEM PHYS, V97, P3587, DOI 10.1063/1.462993	32	11	12	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2804	2813		10.1096/fj.11-180794	http://dx.doi.org/10.1096/fj.11-180794			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21555355				2022-12-28	WOS:000293337800028
J	Hellmann, J; Tang, YN; Kosuri, M; Bhatnagar, A; Spite, M				Hellmann, Jason; Tang, Yunan; Kosuri, Madhavi; Bhatnagar, Aruni; Spite, Matthew			Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice	FASEB JOURNAL			English	Article						lipid mediators; resolution of inflammation; obesity	INFLAMMATION; RESISTANCE; RESOLUTION; GLUCOSE; EXPRESSION; INTERLEUKIN-6; POLARIZATION; ADIPONECTIN; HOMEOSTASIS; ADIPOCYTES	Type 2 diabetes and obesity have emerged as global public health crises. Adipose tissue expansion in obesity promotes accumulation of classically activated macrophages that perpetuate chronic inflammation and sustain insulin resistance. Acute inflammation normally resolves in an actively orchestrated series of molecular and cellular events that ensures return to homeostasis after an inflammatory insult, a process regulated in part by endogenous lipid mediators such as the resolvins. In this study, we sought to determine whether stimulating resolution with resolvin D1 (RvD1) improves insulin sensitivity by resolving chronic inflammation associated with obesity. In male leptin receptor-deficient (db/db) mice, treatment with RvD1 (2 mu g/kg) improved glucose tolerance, decreased fasting blood glucose, and increased insulin-stimulated Akt phosphorylation in adipose tissue relative to vehicle-treated mice. Treatment with RvD1 increased adiponectin production, while expression of IL-6 in adipose tissue was decreased. The formation of crown-like structures rich in inflammatory F4/80(+)CD11c(+) macrophages was reduced by > 50% in adipose tissue by RvD1 and was associated with an increased percentage of F4/80(+) cells expressing macrophage galactose-type C-type lectin 1 (MGL-1), a marker of alternatively activated macrophages. These results suggest that stimulating resolution with the endogenous proresolving mediator RvD1 could provide a novel therapeutic strategy for treating obesity-induced diabetes.-Hellmann, J., Tang, Y., Kosuri, M., Bhatnagar, A., Spite, M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25, 2399-2407 (2011). www.fasebj.org	[Hellmann, Jason; Tang, Yunan; Kosuri, Madhavi; Bhatnagar, Aruni; Spite, Matthew] Univ Louisville, Diabet & Obes Ctr, Louisville, KY 40202 USA; [Spite, Matthew] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Spite, M (corresponding author), Univ Louisville, Diabet & Obes Ctr, 580 S Preston St,Rm 404F,Delia Baxter Bldg, Louisville, KY 40202 USA.	matthew.spite@louisville.edu	Spite, Matthew/B-3337-2010; Hellmann, Jason/B-9360-2012		U.S. National Institutes of Health [P20RR024489]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024489] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the U.S. National Institutes of Health-sponsored Diabetes and Obesity Center (P20RR024489).	Apovian CM, 2008, ARTERIOSCL THROM VAS, V28, P1654, DOI 10.1161/ATVBAHA.108.170316; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Fedor D, 2009, CURR OPIN CLIN NUTR, V12, P138, DOI 10.1097/MCO.0b013e3283218299; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Folco EJ, 2009, J BIOL CHEM, V284, P25569, DOI 10.1074/jbc.M109.019786; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Kristiansen OP, 2005, DIABETES, V54, pS114, DOI 10.2337/diabetes.54.suppl_2.S114; Leedom AJ, 2010, AM J PATHOL, V176, P74, DOI 10.2353/ajpath.2010.090678; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2007, AM J PHYSIOL-ENDOC M, V292, pE166, DOI 10.1152/ajpendo.00284.2006; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Sun YY, 2007, WAVE RANDOM COMPLEX, V17, P1, DOI 10.1080/17455030600791694; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; White PJ, 2010, DIABETES, V59, P3066, DOI 10.2337/db10-0054; Zuniga LA, 2010, J IMMUNOL, V185, P6947, DOI 10.4049/jimmunol.1001269	42	212	218	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2399	2407		10.1096/fj.10-178657	http://dx.doi.org/10.1096/fj.10-178657			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21478260	Green Published			2022-12-28	WOS:000292242200031
J	Fillatre, J; Delacour, D; Van Hove, L; Bagarre, T; Houssin, N; Soulika, M; Veitia, RA; Moreau, J				Fillatre, Jonathan; Delacour, Delphine; Van Hove, Lucie; Bagarre, Thomas; Houssin, Nathalie; Soulika, Marina; Veitia, Reiner A.; Moreau, Jacques			Dynamics of the subcellular localization of RalBP1/RLIP through the cell cycle: the role of targeting signals and of protein-protein interactions	FASEB JOURNAL			English	Article						NLS; actin; centrosome	RAL-BINDING PROTEIN-1; ACTIN CYTOSKELETON; RLIP76; DOMAIN; IDENTIFICATION; RECOGNITION; INVOLVEMENT; TRANSPORT; EFFECTOR; PATHWAY	The small G protein Ras regulates many cell processes, such as gene expression, proliferation, apoptosis, and cell differentiation. Its mutations are associated with one-third of all cancers. Ras functions are mediated, at least in part, by Ral proteins and their downstream effector the Ral-binding protein 1 (RalBP1). RalBP1 is involved in endocytosis and in regulating the dynamics of the actin cytoskeleton. It also regulates early development since it is required for the completion of gastrulation in Xenopus laevis. RalBP1 has also been reported to be the main transporter of glutathione electrophiles, and it is involved in multidrug resistance. Such a variety of functions could be explained by a differential regulation of RalBP1 localization. In this study, we have detected endogenous RalBP1 in the nucleus of interphasic cells. This nuclear targeting is mediated by nuclear localization sequences that map to the N-terminal third of the protein. Moreover, in X. laevis embryos, a C-terminal coiled-coil sequence mediates RalBP1 retention in the nucleus. We have also observed RalBP1 at the level of the actin cytoskeleton, a localization that depends on interaction of the protein with active Ral. During mitosis RalBP1 also associates with the mitotic spindle and the centrosome, a localization that could be negatively regulated by active Ral. Finally, we demonstrate the presence of post-transcriptional and post-translational isoforms of RalBP1 lacking the Ral-binding domain, which opens new possibilities for the existence of Ral-independent functions.-Fillatre, J., Delacour, D., Van Hove, L., Bagarre, T., Houssin, N., Soulika, M., Veitia, R. A., Moreau, J. Dynamics of the subcellular localization of RalBP1/RLIP through the cell cycle: the role of targeting signals and of protein-protein interactions. FASEB J. 26, 2164-2174 (2012). www.fasebj.org	[Moreau, Jacques] Univ Paris Diderot, CNRS, Inst Jacques Monod, UMR 7592, F-75205 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Moreau, J (corresponding author), Univ Paris Diderot, CNRS, Inst Jacques Monod, UMR 7592, 15 Rue Helen Brion, F-75205 Paris, France.	moreau.jacques@ijm.univ-paris-diderot.fr	Houssin, Nathalie/AAU-7200-2020	Van Hove, Lucie/0000-0002-8499-5396; Delacour, Delphine/0000-0001-8202-4425	Centre National de la Recherche Scientifique; Association pour la Recherche sur le Cancer; Groupement des Entreprises Francaises dans la Lutte contre le Cancer	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Groupement des Entreprises Francaises dans la Lutte contre le Cancer	The authors thank Anne-Lise Haenni and Valerie Doye for critical reading of this manuscript. This work was supported by the Centre National de la Recherche Scientifique, Association pour la Recherche sur le Cancer, and Groupement des Entreprises Francaises dans la Lutte contre le Cancer.	Andreou Artemisia M., 2009, Biotechnology Journal, V4, P1740, DOI 10.1002/biot.200900219; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2008, CLIN CANCER RES, V14, P4372, DOI 10.1158/1078-0432.CCR-08-0145; Boissel L, 2007, DEV BIOL, V312, P331, DOI 10.1016/j.ydbio.2007.09.027; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cocquet J, 2006, GENOMICS, V88, P127, DOI 10.1016/j.ygeno.2005.12.013; Gurdon J. B., 1967, METHODS DEV BIOL, P75; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; Han K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000187; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Imasaki T, 2007, MOL CELL, V28, P57, DOI 10.1016/j.molcel.2007.08.006; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; Lebreton S, 2003, J CELL SCI, V116, P4651, DOI 10.1242/jcs.00763; Moreau J, 1999, DEV BIOL, V209, P268, DOI 10.1006/dbio.1999.9254; Omerovic J, 2009, FEBS J, V276, P1817, DOI 10.1111/j.1742-4658.2009.06928.x; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Pechlivanis M, 2006, BBA-PROTEINS PROTEOM, V1764, P1914, DOI 10.1016/j.bbapap.2006.09.017; Philips MR, 2005, BIOCHEM SOC T, V33, P657, DOI 10.1042/BST0330657; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Quaroni A, 1999, J CELL SCI, V112, P707; Sato N, 2005, BIOCHEM BIOPH RES CO, V336, P617, DOI 10.1016/j.bbrc.2005.08.145; Singhal SS, 2009, BIOCHEM PHARMACOL, V77, P1074, DOI 10.1016/j.bcp.2008.11.013; Singhal SS, 2006, CANCER RES, V66, P2354, DOI 10.1158/0008-5472.CAN-05-3534	28	13	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					2164	2174		10.1096/fj.11-196451	http://dx.doi.org/10.1096/fj.11-196451			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22319010				2022-12-28	WOS:000303680800042
J	Barison, N; Lambers, J; Hurwitz, R; Kolbe, M				Barison, Nicola; Lambers, Jutta; Hurwitz, Robert; Kolbe, Michael			Interaction of MxiG with the cytosolic complex of the type III secretion system controls Shigella virulence	FASEB JOURNAL			English	Article						FHA domain; protein phosphorylation; Spa33; protein transport	EPITHELIAL-CELLS; NEEDLE COMPLEX; PROTEIN SECRETION; FLEXNERI; IPAB; MODEL; CONSERVATION; INVASINS; RELEASE; SIGNAL	Gram-negative bacteria use the type 3 secretion system (T3SS) to colonize host cells. T3SSs are ring-shaped macromolecular complexes specific for the transport of effector molecules into host cells. It was recently suggested that a cytosolic ring-shaped protein complex delivers effector molecules to the T3SS. However, how transport of effector proteins is regulated is not known. Here, we report the high-resolution X-ray crystal structure of the whole cytosolic domain of MxiG (MxiG(1-126)), a major component of the inner T3SS rings in Shigella flexneri. MxiG(1-126) folds as an FHA domain, which specifically binds phosphorylated threonines. Indeed, MxiG(1-126) binds to Spa33, a cytoplasmic-ring component of Shigella, as revealed in pulldown studies. Surface plasmon resonance analysis showed specific interaction of MxiG with a Spa33 peptide only if phosphorylated. In total, 24 copies of the MxiG(1-126) crystal structure were fitted into the cryo-EM map of the Shigella T3SS. The phosphoprotein binding site of each MxiG molecule faces the channel of the T3SS, allowing interaction with cytosolic binding partners. Secretion assays and host cell invasion studies of complemented Shigella knockout cells indicated that the phosphoprotein binding of MxiG is essential for bacterial virulence. Our findings suggest that MxiG is involved in T3SS regulation.-Barison, N., Lambers, J., Hurwitz, R., Kolbe, M. Interaction of MxiG with the cytosolic complex of the type III secretion system controls Shigella virulence. FASEB J. 26, 1717-1726 (2012). www.fasebj.org	[Barison, Nicola; Lambers, Jutta; Kolbe, Michael] Max Planck Inst Infect Biol, Dept Cellular Microbiol, D-10117 Berlin, Germany; [Hurwitz, Robert] Max Planck Inst Infect Biol, Prot Purificat Core Facil, D-10117 Berlin, Germany	Max Planck Society; Max Planck Society	Kolbe, M (corresponding author), Max Planck Inst Infect Biol, Dept Cellular Microbiol, Charitepl 1, D-10117 Berlin, Germany.	kolbe@mpiib-berlin.mpg.de						Akeda Y, 2005, NATURE, V437, P911, DOI 10.1038/nature03992; Akeda Y, 2004, J BACTERIOL, V186, P2402, DOI 10.1128/JB.186.8.2402-2412.2004; Alam A, 2011, INFECT IMMUN, V79, P1728, DOI 10.1128/IAI.01194-10; Alderwick LJ, 2006, P NATL ACAD SCI USA, V103, P2558, DOI 10.1073/pnas.0507766103; ALLAOUI A, 1995, MOL MICROBIOL, V17, P461, DOI 10.1111/j.1365-2958.1995.mmi_17030461.x; Blaylock B, 2006, J BACTERIOL, V188, P3525, DOI 10.1128/JB.188.10.3525-3534.2006; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Blocker AJ, 2008, P NATL ACAD SCI USA, V105, P6507, DOI 10.1073/pnas.0708344105; Botteaux A, 2010, MICROBIOL-SGM, V156, P2807, DOI 10.1099/mic.0.039651-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornelis GR, 2010, BIOL CHEM, V391, P745, DOI 10.1515/BC.2010.079; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLano WL, 2006, PYMOL INCENTIVE PROD; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Feldman MF, 2002, MOL MICROBIOL, V46, P1183, DOI 10.1046/j.1365-2958.2002.03241.x; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Grangeasse C, 2010, BBA-PROTEINS PROTEOM, V1804, P628, DOI 10.1016/j.bbapap.2009.08.018; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95; Hodgkinson JL, 2009, NAT STRUCT MOL BIOL, V16, P477, DOI 10.1038/nsmb.1599; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Johnson DL, 2007, J BACTERIOL, V189, P7549, DOI 10.1128/JB.00893-07; Johnson S, 2008, FEMS MICROBIOL LETT, V286, P274, DOI 10.1111/j.1574-6968.2008.01284.x; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kim DW, 2005, P NATL ACAD SCI USA, V102, P14046, DOI 10.1073/pnas.0504466102; Kleywegt GJ, 1997, J MOL BIOL, V273, P371, DOI 10.1006/jmbi.1997.1309; Lara-Tejero M, 2011, SCIENCE, V331, P1188, DOI 10.1126/science.1201476; Liang XY, 2008, ACCOUNTS CHEM RES, V41, P991, DOI 10.1021/ar700148u; Lunelli M, 2009, P NATL ACAD SCI USA, V106, P9661, DOI 10.1073/pnas.0812900106; Macek B, 2008, MOL CELL PROTEOMICS, V7, P299, DOI 10.1074/mcp.M700311-MCP200; Mahajan A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.151re12; Martinez-Argudo I, 2010, MOL MICROBIOL, V78, P1365, DOI 10.1111/j.1365-2958.2010.07413.x; McDowell MA, 2011, J BIOL CHEM, V286, P30606, DOI 10.1074/jbc.M111.243865; MENARD R, 1993, J BACTERIOL, V175, P5899; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; Morita-Ishihara T, 2006, J BIOL CHEM, V281, P599, DOI 10.1074/jbc.M509644200; Mougous JD, 2007, NAT CELL BIOL, V9, P797, DOI 10.1038/ncb1605; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Peng JP, 2010, SCI CHINA LIFE SCI, V53, P1284, DOI 10.1007/s11427-010-4089-y; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Poyraz O, 2010, NAT STRUCT MOL BIOL, V17, P788, DOI 10.1038/nsmb.1822; Schraidt O, 2011, SCIENCE, V331, P1192, DOI 10.1126/science.1199358; Schraidt O, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000824; Schroeder GN, 2008, CLIN MICROBIOL REV, V21, P134, DOI 10.1128/CMR.00032-07; Schuch R, 2001, INFECT IMMUN, V69, P2180, DOI 10.1128/IAI.69.4.2180-2189.2001; Smith B. J., 2002, PROTEIN PROTOCOLS HD, P237; Spreter T, 2009, NAT STRUCT MOL BIOL, V16, P468, DOI 10.1038/nsmb.1603; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438	51	18	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1717	1726		10.1096/fj.11-197160	http://dx.doi.org/10.1096/fj.11-197160			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22247334				2022-12-28	WOS:000302359700032
J	Clunes, LA; Davies, CM; Coakley, RD; Aleksandrov, AA; Henderson, AG; Zeman, KL; Worthington, EN; Gentzsch, M; Kreda, SM; Cholon, D; Bennett, WD; Riordan, JR; Boucher, RC; Tarran, R				Clunes, Lucy A.; Davies, Catrin M.; Coakley, Raymond D.; Aleksandrov, Andrei A.; Henderson, Ashley G.; Zeman, Kirby L.; Worthington, Erin N.; Gentzsch, Martina; Kreda, Silvia M.; Cholon, Deborah; Bennett, William D.; Riordan, John R.; Boucher, Richard C.; Tarran, Robert			Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration	FASEB JOURNAL			English	Article						aggresome; chronic bronchitis; ion channel; lung disease	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; ENDOCYTIC TRAFFICKING; AGGRESOME FORMATION; MUCUS CLEARANCE; IN-VITRO; PROTEASOME; INFLAMMATION; DEGRADATION; VIVO	Cigarette smoke (CS) exposure induces mucus obstruction and the development of chronic bronchitis (CB). While many of these responses are determined genetically, little is known about the effects CS can exert on pulmonary epithelia at the protein level. We, therefore, tested the hypothesis that CS exerts direct effects on the CFTR protein, which could impair airway hydration, leading to the mucus stasis characteristic of both cystic fibrosis and CB. In vivo and in vitro studies demonstrated that CS rapidly decreased CFTR activity, leading to airway surface liquid (ASL) volume depletion (i.e., dehydration). Further studies revealed that CS induced internalization of CFTR. Surprisingly, CS-internalized CFTR did not colocalize with lysosomal proteins. Instead, the bulk of CFTR shifted to a detergent-resistant fraction within the cell and colocalized with the intermediate filament vimentin, suggesting that CS induced CFTR movement into an aggresome-like, perinuclear compartment. To test whether airway dehydration could be reversed, we used hypertonic saline (HS) as an osmolyte to rehydrate ASL. HS restored ASL height in CS-exposed, dehydrated airway cultures. Similarly, inhaled HS restored mucus transport and increased clearance in patients with CB. Thus, we propose that CS exposure rapidly impairs CFTR function by internalizing CFTR, leading to ASL dehydration, which promotes mucus stasis and a failure of mucus clearance, leaving smokers at risk for developing CB. Furthermore, our data suggest that strategies to rehydrate airway surfaces may provide a novel form of therapy for patients with CB.-Clunes, L. A., Davies, C. M., Coakley, R. D., Aleksandrov, A. A., Henderson, A. G., Zeman, K. L., Worthington, E. N., Gentzsch, M., Kreda, S. M., Cholon, D., Bennett, W. D., Riordan, J. R., Boucher, R. C., Tarran, R. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J. 26, 533-545 (2012). www.fasebj.org	[Clunes, Lucy A.; Davies, Catrin M.; Coakley, Raymond D.; Aleksandrov, Andrei A.; Henderson, Ashley G.; Zeman, Kirby L.; Worthington, Erin N.; Gentzsch, Martina; Kreda, Silvia M.; Cholon, Deborah; Bennett, William D.; Riordan, John R.; Boucher, Richard C.; Tarran, Robert] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Tarran, R (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, 7125 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	robert_tarran@med.unc.edu	Gentzsch, Martina/AAY-1815-2021	Gentzsch, Martina/0000-0002-9435-0321	Cystic Fibrosis Foundation; U.S. National Institutes of Health (NIH) [5R01DK051870, 5R01DK051619]; NIH [HL084934, HL34332]; British American Tobacco; Novartis Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084934, R13HL034332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051870, R01DK051619] Funding Source: NIH RePORTER	Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); British American Tobacco; Novartis Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank the UNC CF Center Tissue and Histology Cores for isolating cells from donor lungs and for sectioning cultures, respectively. The assistance of L. A. Aleksandrov, J. E. Rasmussen, and M. J. Watson is gratefully acknowledged. R. D. C., M. G., and S. K. were funded by the Cystic Fibrosis Foundation. A. A. A., M. G., and J. R. were funded by the U.S. National Institutes of Health (NIH; 5R01DK051870, 5R01DK051619). R. C. B. was funded by NIH HL084934 and HL34332. R. T. was funded by NIH HL084934, a British American Tobacco research grant, and a Novartis Institute biomedical research grant.	Aleksandrov AA, 1998, FEBS LETT, V431, P97, DOI 10.1016/S0014-5793(98)00713-3; Ameen N, 2007, J CYST FIBROS, V6, P1, DOI 10.1016/j.jcf.2006.09.002; Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2; BARTON AD, 1976, J LAB CLIN MED, V88, P423; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Brody JS, 2011, ANNU REV PHYSIOL, V73, P437, DOI 10.1146/annurev-physiol-012110-142219; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Cantin AM, 2006, AM J PHYSIOL-CELL PH, V290, pC262, DOI 10.1152/ajpcell.00070.2005; Cantin AM, 2006, AM J RESP CRIT CARE, V173, P1139, DOI 10.1164/rccm.200508-1330OC; Chmiel JF, 2007, CLIN CHEST MED, V28, P331, DOI 10.1016/j.ccm.2007.02.002; Cholon DM, 2010, AM J PHYSIOL-LUNG C, V298, pL304, DOI 10.1152/ajplung.00016.2009; Clunes LA, 2008, J ANAL TOXICOL, V32, P201, DOI 10.1093/jat/32.3.201; Coakley RD, 2008, J CLIN INVEST, V118, P4025, DOI 10.1172/JCI33893; Collaco JM, 2008, JAMA-J AM MED ASSOC, V299, P417, DOI 10.1001/jama.299.4.417; Davis PB, 2006, AM J RESP CRIT CARE, V173, P475, DOI 10.1164/rccm.200505-840OE; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; French BA, 2001, EXP MOL PATHOL, V71, P241, DOI 10.1006/exmp.2001.2401; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gerald Lynn B, 2002, J Cardiopulm Rehabil, V22, P234, DOI 10.1097/00008483-200207000-00004; GOODMAN RM, 1978, AM REV RESPIR DIS, V117, P205; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; Hogg JC, 2009, ANNU REV PATHOL-MECH, V4, P435, DOI 10.1146/annurev.pathol.4.110807.092145; Incalzi R A, 1989, Compr Gerontol A, V3 Suppl, P65; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Leikauf GD, 2002, CHEST, V121, p166S, DOI 10.1378/chest.121.5_suppl.166S; MORTENSEN J, 1994, EUR J NUCL MED, V21, P953; Murphy TF, 2009, CURR OPIN PULM MED, V15, P138, DOI 10.1097/MCP.0b013e328321861a; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Okiyoneda T, 2010, SCIENCE, V329, P805, DOI 10.1126/science.1191542; Olzmann JA, 2008, CURR MED CHEM, V15, P47; PUCHELLE E, 1979, SCAND J RESPIR DIS, V60, P307; Rollins BM, 2008, AM J RESP CELL MOL, V39, P190, DOI 10.1165/rcmb.2007-0450OC; RUBIN BK, 1992, AM REV RESPIR DIS, V145, P545, DOI 10.1164/ajrccm/145.3.545; Sawyer K, 2007, J APPL PHYSIOL, V102, P1380, DOI 10.1152/japplphysiol.00269.2006; Schmid A, 2011, SUBCELL BIOCHEM, V55, P95, DOI 10.1007/978-94-007-1217-1_5; Sethi S, 2000, CHEST, V117, p286S, DOI 10.1378/chest.117.5_suppl_1.286S; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Svartengren M, 2005, EUR RESPIR J, V26, P609, DOI 10.1183/09031936.05.00002105; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Taylor L, 2006, PEDIATR PULM, V41, P839, DOI 10.1002/ppul.20451; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zeskind Julie E, 2008, Proc Am Thorac Soc, V5, P834, DOI 10.1513/pats.200807-074TH	48	183	187	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					533	545		10.1096/fj.11-192377	http://dx.doi.org/10.1096/fj.11-192377			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	21990373	Green Published			2022-12-28	WOS:000300485700007
J	Hone, AJ; Meyer, EL; McIntyre, M; McIntosh, JM				Hone, Arik J.; Meyer, Erin L.; McIntyre, Melissa; McIntosh, J. Michael			Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the alpha 6 beta 4*subtype	FASEB JOURNAL			English	Article						alpha-conotoxin; real-time RT-PCR; patch-clamp electrophysiology	VENTRAL TEGMENTAL AREA; INHIBITORY SYNAPTIC-TRANSMISSION; ALPHA-CONOTOXIN; CHOLINERGIC-RECEPTORS; DOPAMINE RELEASE; RAT RETINA; SUBUNIT; MODULATION; ACTIVATION; EXPRESSION	The alpha 6-containing nicotinic acetylcholine receptors (nAChRs) have recently been implicated in diseases of the central nervous system (CNS), including Parkinson's disease and substance abuse. In contrast, little is known about the role of alpha 6* nAChRs in the peripheral nervous system (where the asterisk denotes the possible presence of additional subunits). Dorsal root ganglia (DRG) neurons are known to express nAChRs with a pharmacology consistent with an alpha 7, alpha 3 beta 4*, and alpha 4 beta 2* composition. Here we present evidence that DRG neurons also express alpha 6* nAChRs. We used RT-PCR to show the presence of alpha 6 subunit transcripts and patch-clamp electrophysiology together with subtype-selective alpha-conotoxins to pharmacologically characterize the nAChRs in rat DRG neurons. alpha-Conotoxin BuIA (500 nM) blocked acetylcholine-gated currents (I-ACh) by 90.3 +/- 3.0%; the recovery from blockade was very slow, indicating a predominance of alpha(x)beta 4* nAChRs. Perfusion with either 300 nM BuIA[T5A;P6O] or 200 nM MII[E11A], alpha-conotoxins that target the alpha 6 beta 4* subtype, blocked I-ACh by 49.3 +/- 5 and 46.7 +/- 8%, respectively. In these neurons, I-ACh was relatively insensitive to 200 nM ArIB[V11L;V16D] (9.4 +/- 2.0% blockade) or 500 nM PnIA (23.0 +/- 4% blockade), alpha-conotoxins that target alpha 7 and alpha 3 beta 2*/alpha 6 beta 2* nAChRs, respectively. We conclude that alpha 6 beta 4* nAChRs are among the subtypes expressed by DRG, and to our knowledge, this is the first demonstration of alpha 6 beta 4* in neurons outside the CNS.-Hone, A.J., Meyer, E. L., McIntyre, M., McIntosh, J. M. Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the alpha 6 beta 4* subtype. FASEB J. 26, 917-926 (2012). www.fasebj.org	[Meyer, Erin L.; McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; [Hone, Arik J.; McIntosh, J. Michael] Univ Utah, Interdept Program Neurosci, Salt Lake City, UT 84132 USA; [Meyer, Erin L.; McIntyre, Melissa; McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntosh, JM (corresponding author), Univ Utah, Dept Psychiat, 50 North 1900 East, Salt Lake City, UT 84132 USA.	mcintosh.mike@gmail.com		Meyer, Erin/0000-0003-0704-5861	U.S. National Institutes of Health [MH-53631, GM-48677]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Dr. Daniel McGehee (University of Chicago, Chicago, IL, USA) and Dr. Doju Yoshikami (University of Utah) for critical consultation regarding DRG patch-clamp experiments, and the University of Utah Genomics Core facility for assistance with the RT-PCR experiments. This work was supported by U.S. National Institutes of Health grants MH-53631 and GM-48677 (to J.M.M). The authors declare no conflicts of interest.	Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Azam L, 2006, MOL PHARMACOL, V70, P967, DOI 10.1124/mol.106.024513; Azam L, 2010, FASEB J, V24, P5113, DOI 10.1096/fj.10-166272; Baddick CG, 2011, BIOCHEM PHARMACOL, V82, P828, DOI 10.1016/j.bcp.2011.04.019; Brunzell DH, 2010, NEUROPSYCHOPHARMACOL, V35, P665, DOI 10.1038/npp.2009.171; Carroll FI, 2010, J NAT PROD, V73, P306, DOI 10.1021/np9006124; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Cheng LZ, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-56; Cucchiaro G, 2008, ANESTHESIOLOGY, V109, P512, DOI 10.1097/ALN.0b013e3181834490; Drenan RM, 2010, J NEUROSCI, V30, P9877, DOI 10.1523/JNEUROSCI.2056-10.2010; Dube GR, 2005, NEUROSCI LETT, V376, P29, DOI 10.1016/j.neulet.2004.11.020; Everhart D, 2003, J PHARMACOL EXP THER, V306, P664, DOI 10.1124/jpet.103.051656; Exley R, 2011, P NATL ACAD SCI USA, V108, P7577, DOI 10.1073/pnas.1103000108; Fucile S, 2005, J PHYSIOL-LONDON, V565, P219, DOI 10.1113/jphysiol.2005.084871; Genzen JR, 2001, J NEUROPHYSIOL, V86, P1773, DOI 10.1152/jn.2001.86.4.1773; Gotti C, 2010, J NEUROSCI, V30, P5311, DOI 10.1523/JNEUROSCI.5095-09.2010; Grinevich VP, 2005, J PHARMACOL EXP THER, V312, P619, DOI 10.1124/jpet.104.075069; Haberberger RV, 2004, AUTON NEUROSCI-BASIC, V113, P32, DOI 10.1016/j.autneu.2004.05.008; Hone AJ, 2009, J NEUROCHEM, V111, P80, DOI 10.1111/j.1471-4159.2009.06299.x; Innocent N, 2008, J PHARMACOL EXP THER, V327, P529, DOI 10.1124/jpet.108.142943; Jackson KJ, 2009, J PHARMACOL EXP THER, V331, P547, DOI 10.1124/jpet.109.155457; LAMAR E, 1990, Society for Neuroscience Abstracts, V16, P681; LANGE KW, 1993, J NEUROCHEM, V60, P197, DOI 10.1111/j.1471-4159.1993.tb05838.x; Lee CH, 2011, BIOCHEM PHARMACOL, V82, P959, DOI 10.1016/j.bcp.2011.06.044; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; Luo SQ, 1998, J NEUROSCI, V18, P8571; Mao D, 2006, MOL PHARMACOL, V70, P1693, DOI 10.1124/mol.106.027458; Marritt AM, 2005, MOL PHARMACOL, V68, P1656, DOI 10.1124/mol.105.012380; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; Mikulski Z, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-133; Moretti M, 2004, MOL PHARMACOL, V66, P85, DOI 10.1124/mol.66.1.85; Papke RL, 2008, NEUROPHARMACOLOGY, V54, P1189, DOI 10.1016/j.neuropharm.2008.03.010; Papke RL, 2010, J PHARMACOL EXP THER, V333, P501, DOI 10.1124/jpet.109.164566; Parker SL, 2004, MOL PHARMACOL, V65, P611, DOI 10.1124/mol.65.3.611; Perez XA, 2010, MOL PHARMACOL, V78, P971, DOI 10.1124/mol.110.067561; Perez-Alvarez A, 2012, FASEB J, V26, P346, DOI 10.1096/fj.11-190223; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Quik M, 2006, J NEUROCHEM, V98, P1866, DOI 10.1111/j.1471-4159.2006.04078.x; Rau KK, 2005, J NEUROPHYSIOL, V93, P1358, DOI 10.1152/jn.00591.2004; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Simopoulos TT, 2008, PAIN PHYSICIAN, V11, P137; Takeda D, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-26; Van Boxem K, 2011, PAIN MED, V12, P1322, DOI 10.1111/j.1526-4637.2011.01202.x; Van Zundert J, 2007, PAIN, V127, P173, DOI 10.1016/j.pain.2006.09.002; Whiteaker P, 2007, BIOCHEMISTRY-US, V46, P6628, DOI 10.1021/bi7004202; WHITEHOUSE PJ, 1988, NEUROLOGY, V38, P720, DOI 10.1212/WNL.38.5.720; Yang KC, 2011, J NEUROSCI, V31, P2537, DOI 10.1523/JNEUROSCI.3003-10.2011; Yang KC, 2009, J PHYSIOL-LONDON, V587, P345, DOI 10.1113/jphysiol.2008.162743; Zheng GR, 2011, BIOORG MED CHEM LETT, V21, P2476, DOI 10.1016/j.bmcl.2011.02.043	51	51	52	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					917	926		10.1096/fj.11-195883	http://dx.doi.org/10.1096/fj.11-195883			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22024738	Green Published			2022-12-28	WOS:000300485700041
J	Hibino, N; Yi, T; Duncan, DR; Rathore, A; Dean, E; Naito, Y; Dardik, A; Kyriakides, T; Madri, J; Pober, JS; Shinoka, T; Breuer, CK				Hibino, Narutoshi; Yi, Tai; Duncan, Daniel R.; Rathore, Animesh; Dean, Ethan; Naito, Yuji; Dardik, Alan; Kyriakides, Themis; Madri, Joseph; Pober, Jordan S.; Shinoka, Toshiharu; Breuer, Christopher K.			A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts	FASEB JOURNAL			English	Article						monocytes; clodronate liposomes	ULTRASMALL SUPERPARAMAGNETIC PARTICLES; BONE-MARROW-CELLS; IN-VIVO; NEOINTIMAL FORMATION; PULMONARY-ARTERY; BLOOD-VESSELS; ANIMAL-MODEL; MOUSE MODEL; IRON-OXIDE; AUTOGRAFTS	The primary graft-related complication during the first clinical trial evaluating the use of tissue-engineered vascular grafts (TEVGs) was stenosis. We investigated the role of macrophages in the formation of TEVG stenosis in a murine model. We analyzed the natural history of TEVG macrophage infiltration at critical time points and evaluated the role of cell seeding on neovessel formation. To assess the function of infiltrating macrophages, we implanted TEVGs into mice that had been macrophage depleted using clodronate liposomes. To confirm this, we used a CD11b-diphtheria toxin-receptor (DTR) transgenic mouse model. Monocytes infiltrated the scaffold within the first few days and initially transformed into M1 macrophages. As the scaffold degraded, the macrophage infiltrate disappeared. Cell seeding decreased the incidence of stenosis (32% seeded, 64% unseeded, P=0.024) and the degree of macrophage infiltration at 2 wk. Unseeded TEVGs demonstrated conversion from M1 to M2 phenotype, whereas seeded grafts did not. Clodronate and DTR inhibited macrophage infiltration and decreased stenosis but blocked formation of vascular neotissue, evidenced by the absence of endothelial and smooth muscle cells and collagen. These findings suggest that macrophage infiltration is critical for neovessel formation and provides a strategy for predicting, detecting, and inhibiting stenosis in TEVGs.-Hibino, N., Yi, T., Duncan, D. R., Rathore, A., Dean, E., Naito, Y., Dardik, A., Kyriakides, T., Madri, J., Pober, J. S., Shinoka, T., Breuer, C. K. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 25, 4253-4263 (2011). www.fasebj.org	[Hibino, Narutoshi; Yi, Tai; Duncan, Daniel R.; Rathore, Animesh; Dean, Ethan; Naito, Yuji; Dardik, Alan; Kyriakides, Themis; Madri, Joseph; Pober, Jordan S.; Shinoka, Toshiharu; Breuer, Christopher K.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT USA	Yale University	Breuer, CK (corresponding author), 10 Amistad St,Amistad Bldg,Rm 301 C, New Haven, CT 06510 USA.	christopher.breuer@yale.edu		Breuer, Christopher/0000-0003-0987-3898; Duncan, Daniel/0000-0003-4771-8901	U.S. National Institutes of Health (NIH) [K08HL083980, NIH R01HL098228, NIH UL1RR024139, NIH P30DK072442, NIH P01HL070295]; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; Gunze Ltd.; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL083980, R01HL095498, P01HL070295, R01HL098228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072442] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Gunze Ltd.; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Research support was provided through the following grants: U.S. National Institutes of Health (NIH) K08HL083980, NIH R01HL098228, NIH UL1RR024139, NIH P30DK072442, and NIH P01HL070295; Howard Hughes Medical Institute; and the Doris Duke Charitable Foundation Clinical Scientist Development Award. Histological processing was done by the Yale Core Center for Musculoskeletal Disorders (NIH AR46032). Gunze Ltd. has provided research support for the clinical trial evaluating the use of tissue-engineered vascular grafts. None of the funding for the work done in this manuscript was provided by Gunze Ltd.	Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264; Bergmann CE, 2006, J LEUKOCYTE BIOL, V80, P59, DOI 10.1189/jlb.0206087; Brennan MP, 2008, ANN SURG, V248, P370, DOI 10.1097/SLA.0b013e318184dcbd; Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Danenberg HD, 2002, CIRCULATION, V106, P599, DOI 10.1161/01.CIR.0000023532.98469.48; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Hibino N, 2005, J THORAC CARDIOV SUR, V129, P1064, DOI 10.1016/j.jtcvs.2004.10.030; Hibino N, 2011, FASEB J, V25, P2731, DOI 10.1096/fj.11-182246; Hibino N, 2010, J THORAC CARDIOV SUR, V139, P431, DOI 10.1016/j.jtcvs.2009.09.057; Hyafil F, 2006, ARTERIOSCL THROM VAS, V26, P176, DOI 10.1161/01.ATV.0000194098.82677.57; Isomatsu Y, 2003, J THORAC CARDIOV SUR, V126, P1958, DOI 10.1016/S0022-5223(03)01042-0; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; Matsumura G, 2003, BIOMATERIALS, V24, P2303, DOI 10.1016/S0142-9612(03)00043-7; Matsumura G, 2006, TISSUE ENG, V12, P3075, DOI 10.1089/ten.2006.12.3075; Mirensky TL, 2008, PEDIATR RES, V63, P559, DOI 10.1203/01.pdr.0000305938.92695.b9; Mirensky TL, 2010, J PEDIATR SURG, V45, P1299, DOI 10.1016/j.jpedsurg.2010.02.102; Mirensky TL, 2009, J PEDIATR SURG, V44, P1127, DOI 10.1016/j.jpedsurg.2009.02.035; Mosser D. M., 2010, NAT REV IMMUNOL, V18, P958; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; Naito Y, 2003, J THORAC CARDIOV SUR, V125, P419, DOI 10.1067/mtc.2003.134; Nelson GN, 2008, ARCH SURG-CHICAGO, V143, P488, DOI 10.1001/archsurg.143.5.488; RATLIFF NB, 1989, ARCH PATHOL LAB MED, V113, P772; Roh JD, 2008, BIOMATERIALS, V29, P1454, DOI 10.1016/j.biomaterials.2007.11.041; Roh JD, 2010, P NATL ACAD SCI USA, V107, P4669, DOI 10.1073/pnas.0911465107; ROLL FJ, 1980, J CELL BIOL, V85, P597, DOI 10.1083/jcb.85.3.597; Ruehm SG, 2001, CIRCULATION, V103, P415; Schepers A, 2006, ARTERIOSCL THROM VAS, V26, P2063, DOI 10.1161/01.ATV.0000235694.69719.e2; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Shinoka T, 1998, J THORAC CARDIOV SUR, V115, P536, DOI 10.1016/S0022-5223(98)70315-0; Shinoka Toshiharu, 2008, Yale Journal of Biology and Medicine, V81, P161; Stark VK, 1997, ARTERIOSCL THROM VAS, V17, P1614, DOI 10.1161/01.ATV.17.8.1614; Stoneman V, 2007, CIRC RES, V100, P884, DOI 10.1161/01.RES.0000260802.75766.00; Tatewaki H, 2007, J VASC SURG, V45, P1236, DOI 10.1016/j.jvs.2007.01.066; Trivedi RA, 2004, STROKE, V35, P1631, DOI 10.1161/01.STR.0000131268.50418.b7; Truijers M, 2009, AM J ROENTGENOL, V193, pW437, DOI 10.2214/AJR.09.2619; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Watanabe M, 2001, TISSUE ENG, V7, P429, DOI 10.1089/10763270152436481	40	164	172	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4253	4263		10.1096/fj.11-186585	http://dx.doi.org/10.1096/fj.11-186585			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21865316	Green Published			2022-12-28	WOS:000298138100018
J	Serres, S; Mardiguian, S; Campbell, SJ; McAteer, MA; Akhtar, A; Krapitchev, A; Choudhury, RP; Anthony, DC; Sibson, NR				Serres, Sebastien; Mardiguian, Silvy; Campbell, Sandra J.; McAteer, Martina A.; Akhtar, Asim; Krapitchev, Alexandre; Choudhury, Robin P.; Anthony, Daniel C.; Sibson, Nicola R.			VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis	FASEB JOURNAL			English	Article						contrast agent; experimental autoimmune encephalomyelitis; molecular MRI; vascular cell adhesion molecule-1	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ADHESION MOLECULE; IRON-OXIDE; IFN-GAMMA; BRAIN; LESIONS; MRI; RESPONSES; INTEGRIN; RAT	Diagnosis of multiple sclerosis (MS) currently requires lesion identification by gadolinium (Gd)-enhanced or T(2)-weighted magnetic resonance imaging (MRI). However, these methods only identify late-stage pathology associated with blood-brain barrier breakdown. There is a growing belief that more widespread, but currently undetectable, pathology is present in the MS brain. We have previously demonstrated that an anti-VCAM-1 antibody conjugated to microparticles of iron oxide (VCAM-MPIO) enables in vivo detection of VCAM-1 by MRI. Here, in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, we have shown that presymptomatic lesions can be quantified using VCAM-MPIO when they are undetectable by Gd-enhancing MRI. Moreover, in symptomatic animals VCAM-MPIO binding was present in all regions showing Gd-DTPA enhancement and also in areas of no Gd-DTPA enhancement, which were confirmed histologically to be regions of leukocyte infiltration. VCAM-MPIO binding correlated significantly with increasing disability. Negligible MPIO-induced contrast was found in either EAE animals injected with an equivalent nontargeted contrast agent (IgG-MPIO) or in control animals injected with the VCAM-MPIO. These findings describe a highly sensitive molecular imaging tool that may enable detection of currently invisible pathology in MS, thus accelerating diagnosis, guiding treatment, and enabling quantitative disease assessment.-Serres, S., Mardiguian, S., Campbell, S. J., McAteer, M. A., Akhtar, A., Krapitchev, A., Choudhury, R. P., Anthony, D. C., Sibson, N. R. VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in amouse model of multiple sclerosis. FASEB J. 25, 4415-4422 (2011). www.fasebj.org	[Serres, Sebastien; Krapitchev, Alexandre; Sibson, Nicola R.] Churchill Hosp, Canc Res UK, MRC, Gray Inst Radiat Oncol & Biol,Dept Oncol, Oxford OX3 7LJ, England; [Mardiguian, Silvy; Campbell, Sandra J.; Anthony, Daniel C.] Univ Oxford, John Radcliffe Hosp, Dept Pharmacol, Oxford OX3 9DU, England; [McAteer, Martina A.; Akhtar, Asim; Choudhury, Robin P.] Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford; University of Oxford; University of Oxford	Sibson, NR (corresponding author), Churchill Hosp, Radiobiol Res Inst, Oxford OX3 7LJ, England.	nicola.sibson@oncology.ox.ac.uk	McAteer, Martina/AAD-8628-2022; Anthony, Daniel/F-7765-2010	Anthony, Daniel/0000-0003-1380-6655; serres, sebastien/0000-0002-1573-1581; McAteer (Duric), Martina/0000-0002-7350-4651	Medical Research Council [G0401438]; Wellcome Trust; MRC [G0401438] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Dr. Andrew Lowe for technical assistance. This work was supported by the Medical Research Council, research grant G0401438 (to N.S.) and by The Wellcome Trust (to R.C.). S.J.C., R.P.C., D.C.A., and N.R.S. are cofounders of a University of Oxford spinoff company, Oxford Contrast.	Allavena R, 2010, AM J PATHOL, V176, P556, DOI 10.2353/ajpath.2010.090437; Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Barkhof F, 2002, CURR OPIN NEUROL, V15, P239, DOI 10.1097/00019052-200206000-00003; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Giacomini PS, 2009, ARCH NEUROL-CHICAGO, V66, P375, DOI 10.1001/archneurol.2008.578; Graesser D, 2000, J NEUROIMMUNOL, V109, P121, DOI 10.1016/S0165-5728(00)00275-7; Hellings N, 2002, J NEUROIMMUNOL, V126, P143, DOI 10.1016/S0165-5728(02)00052-8; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; JUHLER M, 1984, BRAIN RES, V302, P347, DOI 10.1016/0006-8993(84)90249-X; Lees JR, 2008, J EXP MED, V205, P2633, DOI 10.1084/jem.20080155; McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631; Newman TA, 2001, BRAIN, V124, P2203, DOI 10.1093/brain/124.11.2203; Peterson JW, 2002, J NEUROPATH EXP NEUR, V61, P539, DOI 10.1093/jnen/61.6.539; Phillips LM, 1999, J NEUROIMMUNOL, V96, P218, DOI 10.1016/S0165-5728(99)00034-X; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Serres S, 2009, J NEUROSCI, V29, P4820, DOI 10.1523/JNEUROSCI.0406-09.2009; Sipkins DA, 2000, J NEUROIMMUNOL, V104, P1, DOI 10.1016/S0165-5728(99)00248-9; Tang KS, 2011, MOL IMAGING BIOL, V13, P819, DOI 10.1007/s11307-010-0437-3; Tedeschi G, 2005, NEUROL SCI, V26, pS209, DOI 10.1007/s10072-005-0516-4; van Kasteren SI, 2009, P NATL ACAD SCI USA, V106, P18, DOI 10.1073/pnas.0806787106; von zur Muhlen C, 2008, J CLIN INVEST, V118, P1198, DOI 10.1172/JCI33314; Yang YD, 2010, MAGN RESON MED, V63, P33, DOI 10.1002/mrm.22175; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	26	53	55	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4415	4422		10.1096/fj.11-183772	http://dx.doi.org/10.1096/fj.11-183772			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21908714	Green Accepted			2022-12-28	WOS:000298138100032
J	Huang, W; Andras, IE; Rha, GB; Hennig, B; Toborek, M				Huang, Wen; Andras, Ibolya E.; Rha, Geun Bae; Hennig, Bernhard; Toborek, Michal			PPAR alpha and PPAR gamma protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling	FASEB JOURNAL			English	Article						peroxisome proliferator-activated receptor; matrix metalloproteinase; human immunodeficiency virus-1; blood-brain barrier	HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; MATRIX-METALLOPROTEINASE; OXIDATIVE STRESS; TRANSENDOTHELIAL MIGRATION; HIV-1-ASSOCIATED DEMENTIA	Activation of matrix metalloproteinase-9 (MMP-9) is involved in HIV-1-induced disruption of the blood-brain barrier (BBB). In the present study, we hypothesize that peroxisome proliferator-activated receptor (PPAR)-alpha or PPAR gamma can protect against HIV-1-induced MMP-9 overexpression in brain endothelial cells (hCMEC cell line) by attenuating cellular oxidative stress and down-regulation of caveolae-associated redox signaling. Exposure to HIV-1-infected monocytes induced phosphorylation of ERK1/2 and Akt in hCMEC by 2.5- and 3.6-fold, respectively; however, these effects were attenuated by overexpression of PPAR alpha or PPAR gamma and by silencing of caveolin-1 (cav-1). Coculture of hCMEC with HIV-1-infected monocytes significantly induced MMP-9 promoter and enzyme activity by 3- to 3.5-fold. Promoter mutation studies indicated that SP-1 (g1940t_g1941t) is an essential transcription factor involved in induction of MMP-9 promoter by HIV-1. In addition, HIV-1-stimulated activity of MMP-9 promoter was inhibited by mutation of AP-1 site 2 (c1918t_a1919g) and both (but not individual) NF-kappa B binding sites (g1389c and g1664c). PPAR overexpression, ERK1/2 or Akt inhibition, and silencing of cav-1 all effectively protected against HIV-1-induced MMP-9 promoter activity, indicating a close relationship among HIV-1-induced cerebrovascular toxicity, redox-regulated mechanisms, and functional caveolae. Such a link was further confirmed in MMP-9-deficient mice exposed to PPAR alpha or PPAR gamma agonist and injected with the HIV-1-specific protein Tat into cerebral vasculature. Overall, our results indicate that ERK1/2, Akt, and cav-1 are involved in the regulatory mechanisms of PPAR-mediated protection against HIV-1-induced MMP-9 expression in brain endothelial cells.-Huang, W., Andras, I. E., Rha, G. B., Hennig, B., Toborek, M. PPAR alpha and PPAR gamma protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB J. 25, 3979-3988 (2011). www.fasebj.org	[Toborek, Michal] Univ Kentucky, Med Ctr, Dept Neurosurg, Mol Neurosci & Vasc Biol Lab, Lexington, KY 40536 USA; [Hennig, Bernhard] Univ Kentucky, Coll Agr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Toborek, M (corresponding author), Univ Kentucky, Med Ctr, Dept Neurosurg, Mol Neurosci & Vasc Biol Lab, 593 Wethington Bldg,900 S Limestone, Lexington, KY 40536 USA.	michal.toborek@uky.edu			U.S. National Institutes of Health [MH63022, MH072567, DA027569, ES07380, AHA09POST2060217]; National Center for Research Resources [P20 RR15592]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063022, R01MH072567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027569] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health grants MH63022, MH072567, DA027569, ES07380, and AHA09POST2060217. Tat was produced and provided by support from the National Center for Research Resources (grant P20 RR15592).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Andersson LM, 2001, J NEUROVIROL, V7, P542, DOI 10.1080/135502801753248123; Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003; Avison MJ, 2004, J NEUROIMMUNOL, V157, P140, DOI 10.1016/j.jneuroim.2004.08.025; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Buttner A, 1996, ACTA NEUROPATHOL, V92, P35, DOI 10.1007/s004010050486; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cho WJ, 2007, J CELL MOL MED, V11, P1069, DOI 10.1111/j.1582-4934.2007.00113.x; Ciborowski P, 2004, J NEUROIMMUNOL, V157, P11, DOI 10.1016/j.jneuroim.2004.08.033; Cokakli M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-65; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Dubuquoy L, 2009, PPAR RES, V2009, DOI 10.1155/2009/145124; Felicetti F, 2009, INT J CANCER, V125, P1514, DOI 10.1002/ijc.24451; Ghorpade A, 2001, J VIROL, V75, P6572, DOI 10.1128/JVI.75.14.6572-6583.2001; Gil L, 2003, PHARMACOL RES, V47, P217, DOI 10.1016/S1043-6618(02)00320-1; Hanley TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000981; Huang W, 2008, J NEUROCHEM, V107, P497, DOI 10.1111/j.1471-4159.2008.05626.x; Huang W, 2010, AM J PHYSIOL-HEART C, V298, pH1136, DOI 10.1152/ajpheart.01126.2009; Huang W, 2009, FASEB J, V23, P1596, DOI 10.1096/fj.08-121624; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kim HN, 2008, BMB REP, V41, P858, DOI 10.5483/BMBRep.2008.41.12.858; Kim J, 2009, CELL MOL LIFE SCI, V66, P1766, DOI 10.1007/s00018-009-9169-4; Kline ER, 2008, AM J PHYSIOL-HEART C, V294, pH2792, DOI 10.1152/ajpheart.91447.2007; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lim EJ, 2007, AM J PHYSIOL-HEART C, V293, pH3340, DOI 10.1152/ajpheart.00921.2007; Liuzzi GM, 2000, J NEUROVIROL, V6, P156, DOI 10.3109/13550280009013159; Lombardi A, 2008, ARTERIOSCL THROM VAS, V28, P718, DOI 10.1161/ATVBAHA.107.160713; Louboutin JP, 2010, J NEUROPATH EXP NEUR, V69, P801, DOI 10.1097/NEN.0b013e3181e8c96f; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; McCoig C, 2004, PEDIATR INFECT DIS J, V23, P114, DOI 10.1097/01.inf.0000109247.67480.7a; Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY; Melendez MM, 2008, CLIN INFECT DIS, V46, P775, DOI 10.1086/527563; Mendes SD, 2009, CELL SIGNAL, V21, P1109, DOI 10.1016/j.cellsig.2009.02.025; Murthy S, 2010, J BIOL CHEM, V285, P25062, DOI 10.1074/jbc.M109.099655; Park SK, 2009, CARCINOGENESIS, V30, P1225, DOI 10.1093/carcin/bgp111; Pascale JM, 1997, CLIN DIAGN LAB IMMUN, V4, P474, DOI 10.1128/CDLI.4.4.474-477.1997; Persidsky Y, 2001, J NEUROIMMUNOL, V114, P57, DOI 10.1016/S0165-5728(00)00454-9; Persidsky Y, 2000, J LEUKOCYTE BIOL, V68, P413; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Ramirez SH, 2008, J IMMUNOL, V180, P1854, DOI 10.4049/jimmunol.180.3.1854; REDDY MM, 1989, J CLIN LAB ANAL, V3, P199, DOI 10.1002/jcla.1860030402; Reddy VS, 2010, AM J PHYSIOL-HEART C, V299, pH1242, DOI 10.1152/ajpheart.00451.2010; Schroer N, 2011, CANCER RES, V71, P87, DOI 10.1158/0008-5472.CAN-10-2193; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; Sporer B, 2000, J NEUROIMMUNOL, V102, P125, DOI 10.1016/S0165-5728(99)00170-8; Sporer B, 1998, J INFECT DIS, V178, P854, DOI 10.1086/515342; Srivastava AK, 2007, J BIOL CHEM, V282, P35113, DOI 10.1074/jbc.M705329200; Suresh DR, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-61; Tahir AA, 2009, CANCER BIOL THER, V8, P2286; Toborek M., 2011, NEUROLOGY A IN PRESS, P207; Vihanto MM, 2006, J CELL SCI, V119, P2299, DOI 10.1242/jcs.02946; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305; Yang N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001758; Yao Z, 2009, BIOFACTORS, V35, P407, DOI 10.1002/biof.52; Zhang BF, 2007, CELL SIGNAL, V19, P1690, DOI 10.1016/j.cellsig.2007.03.005; Zhong Y, 2008, J NEUROSCI, V28, P7788, DOI 10.1523/JNEUROSCI.0061-08.2008	59	35	37	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3979	3988		10.1096/fj.11-188607	http://dx.doi.org/10.1096/fj.11-188607			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21840940	Green Published			2022-12-28	WOS:000296723100022
J	Veschini, L; Crippa, L; Dondossola, E; Doglioni, C; Corti, A; Ferrero, E				Veschini, Lorenzo; Crippa, Luca; Dondossola, Eleonora; Doglioni, Claudio; Corti, Angelo; Ferrero, Elisabetta			The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization	FASEB JOURNAL			English	Article						cell junctions; tip cells; stalk cells	DEPENDENT MECHANISM; ANGIOGENESIS; MICROENVIRONMENT; NORMALIZATION; EXPRESSION; GROWTH; MORPHOGENESIS; METASTASIS; BORTEZOMIB; THERAPY	The angiogenic switch is a fundamental process for many diseases and for tumor growth. The main proangiogenic stimulus is hypoxia, through activation of the hypoxia-inducible factor (HIF)-1 alpha pathway in endothelial cells (ECs). We have previously shown that the vasostatin-1 (VS-1) fragment of chromogranin A inhibits TNF-alpha-induced vessel permeability and VEGF-induced EC proliferation, together with migration and matrix invasion, which are all critical steps in angiogenesis. The present study was undertaken to investigate the effect of VS-1 on tumor angiogenesis. We found mouse mammary adenocarcinomas (TS/A), genetically engineered to secrete VS-1 (TS/A 1B8), to be characterized by reduced vascular density and more regular vessels, compared with nontransfected tumors [TS/A wild type (WT)]. Supernatants from TS/A WT cells, but not those from TS/A 1B8, generated tip cells and promoted the permeability of primary human umbilical vein ECs, via VE-cadherin redistribution and cytoskeletal disorganization. These effects were abrogated by mAb 5A8, a VS-1-blocking antibody. Furthermore, VS-1 inhibited hypoxia-driven EC morphological changes, VE-cadherin redistribution, intercellular gap formation, tube morphogenesis, and HIF-1 alpha nuclear translocation in vitro. Our findings highlight a previously undescribed function of VS-1 as a regulator of tumor vascularization.-Veschini, L., Crippa, L., Dondossola, E., Doglioni, C., Corti, A., Ferrero, E. The vasostatin-1 fragment of chromogranin a preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J. 25, 3906-3914 (2011). www.fasebj.org	[Veschini, Lorenzo; Ferrero, Elisabetta] Ist Sci San Raffaele, Myeloma Unit, I-20132 Milan, Italy; [Crippa, Luca; Dondossola, Eleonora; Corti, Angelo] Ist Sci San Raffaele, Tumor Biol & Vasc Targeting Unit, I-20132 Milan, Italy; [Crippa, Luca; Dondossola, Eleonora; Corti, Angelo] Ist Sci San Raffaele, Network Mol Neurosci, Italian Inst Technol, I-20132 Milan, Italy; [Doglioni, Claudio] Ist Sci San Raffaele, Pathol Unit, Div Mol Oncol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ferrero, E (corresponding author), Lymphoid Malignancies Lab, I-20132 Milan, Italy.	ferrero.elisabetta@hsr.it	Corti, Angelo/F-7046-2012; Ferrero, Elisabetta/G-5690-2013	Corti, Angelo/0000-0002-0893-6191; Subba, Rajkrishna/0000-0003-0051-0062; Veschini, Lorenzo/0000-0003-3820-7472; Ferrero, Elisabetta/0000-0003-2571-933X; DOGLIONI, Claudio/0000-0002-4969-5216	Associazione Italiana per la Ricerca sul Cancro; Alleanza Contro il Cancro of Italy	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Alleanza Contro il Cancro of Italy	The authors thank Michael John of the Vita-Salute San Raffaele University for the English revision of the manuscript. We also thank Ilenia Papa for her technical and competent contribution to immunohistochemical preparations. This work was supported by Associazione Italiana per la Ricerca sul Cancro and Alleanza Contro il Cancro of Italy.	Aird WC, 2008, PHARMACOL REP, V60, P139; Bautch VL, 2009, CELL, V136, P810, DOI 10.1016/j.cell.2009.02.021; Belloni D, 2007, FASEB J, V21, P3052, DOI 10.1096/fj.06-6829com; Belloni D, 2010, EXP CELL RES, V316, P1010, DOI 10.1016/j.yexcr.2009.11.005; BHAVANI SS, 2010, CELL MOL LIFE SCI, V67, P861; Calvani M, 2006, BLOOD, V107, P2705, DOI 10.1182/blood-2005-09-3541; Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64; Colombo B, 2002, CANCER RES, V62, P941; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 2010, CELL MOL NEUROBIOL, V30, P1163, DOI 10.1007/s10571-010-9587-8; Cowan CE, 2010, CIRC RES, V107, P959, DOI 10.1161/CIRCRESAHA.110.219592; De Bock K, 2009, J MOL MED, V87, P561, DOI 10.1007/s00109-009-0482-z; De Smet F, 2009, ARTERIOSCL THROM VAS, V29, P639, DOI 10.1161/ATVBAHA.109.185165; Di Comite G, 2011, J HYPERTENS, V29, P409, DOI 10.1097/HJH.0b013e328341a429; Ferrero E, 2004, FASEB J, V18, P554, DOI 10.1096/fj.03-0922fje; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Fukumura D, 2007, J CELL BIOCHEM, V101, P937, DOI 10.1002/jcb.21187; Gao JM, 2010, BLOOD, V115, P4130, DOI 10.1182/blood-2009-10-248526; Helle KB, 2010, CELL MOL NEUROBIOL, V30, P1145, DOI 10.1007/s10571-010-9552-6; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Langheim S, 2010, AM J PHYSIOL-HEART C, V298, pH746, DOI 10.1152/ajpheart.00617.2009; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Millan J, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-11; Moserle L, 2009, CURR MOL MED, V9, P935, DOI 10.2174/156652409789712800; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Ramella R, 2010, J CELL BIOCHEM, V110, P70, DOI 10.1002/jcb.22510; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Theurl M, 2010, CIRC RES, V107, P1326, DOI 10.1161/CIRCRESAHA.110.219493; Veschini L, 2007, BLOOD, V109, P2565, DOI 10.1182/blood-2006-06-032664	33	30	32	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3906	3914		10.1096/fj.11-182410	http://dx.doi.org/10.1096/fj.11-182410			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21825034				2022-12-28	WOS:000296723100015
J	Asparuhova, MB; Ferralli, J; Chiquet, M; Chiquet-Ehrismann, R				Asparuhova, Maria B.; Ferralli, Jacqueline; Chiquet, Matthias; Chiquet-Ehrismann, Ruth			The transcriptional regulator megakaryoblastic leukemia-1 mediates serum response factor-independent activation of tenascin-C transcription by mechanical stress	FASEB JOURNAL			English	Article						myocardin-related transcription factors; extracellular matrix; mechanotransduction	SCAFFOLD ATTACHMENT FACTOR; CYCLIC TENSILE STRAIN; HUMAN BREAST-CANCER; GENE-EXPRESSION; TUMOR PROGRESSION; SKELETAL-MUSCLE; BINDING DOMAIN; IN-VITRO; SAF-A; ACTIN	The extracellular matrix protein tenascin-C (TNC) is up-regulated in processes influenced by mechanical stress, such as inflammation, tissue remodeling, wound healing, and tumorigenesis. Cyclic strain-induced TNC expression depends on RhoA-actin signaling, the pathway that regulates transcriptional activity of serum response factor (SRF) by its coactivator megakaryoblastic leukemia-1 (MKL1). Therefore, we tested whether MKL1 controls TNC transcription. We demonstrate that overexpression of MKL1 strongly induces TNC expression in mouse NIH3T3 fibroblasts and normal HC11 and transformed 4T1 mammary epithelial cells. Part of the induction was dependant on SRF and a newly identified atypical CArG box in the TNC promoter. Another part was independent of SRF but required the SAP domain of MKL1. An MKL1 mutant incapable of binding to SRF still strongly induced TNC, while induction of the SRF target c-fos was abolished. Cyclic strain failed to induce TNC in MKL1-deficient but not in SRF-deficient fibroblasts, and strain-induced TNC expression strongly depended on the SAP domain of MKL1. Promoter-reporter and chromatin immunoprecipitation experiments unraveled a SAP-dependent, SRF-independent interaction of MKL1 with the proximal promoter region of TNC, attributing for the first time a functional role to the SAP domain of MKL1 in regulating gene expression.-Asparuhova, M. B., Ferralli, J., Chiquet, M., Chiquet-Ehrismann, R. The transcriptional regulator megakaryoblastic leukemia-1 mediates serum response factor-independent activation of tenascin-C transcription by mechanical stress. FASEB J. 25, 3477-3488 (2011). www.fasebj.org	[Asparuhova, Maria B.; Ferralli, Jacqueline; Chiquet-Ehrismann, Ruth] Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Chiquet, Matthias] Univ Bern, Dept Orthodont & Dentofacial Orthoped, Bern, Switzerland; [Chiquet-Ehrismann, Ruth] Univ Basel, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of Bern; University of Basel	Chiquet-Ehrismann, R (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	chiquet@fmi.ch		Chiquet, Matthias/0000-0001-7812-4853	Novartis Research Foundation; Swiss National Science Foundation [3100A0-120235]	Novartis Research Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by the Novartis Research Foundation and a grant from the Swiss National Science Foundation 3100A0-120235 to R.C.E. and M.C. The authors thank Silke Maier for her support in the cloning of an MKL1 cDNA, Hubertus Kohler for cell sorting, the Genomics Facility of the Friedrich Miescher Institute and Tim Roloff for the transcript profiling, and Richard P. Tucker for critical reading of the manuscript.	Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; AUFDERHEIDE E, 1988, J CELL BIOL, V107, P2341, DOI 10.1083/jcb.107.6.2341; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Brown THOMAS D., 2000, Comput Methods Biomech Biomed Engin, V3, P65, DOI 10.1080/10255840008915254; Busche S, 2008, J CELL SCI, V121, P1025, DOI 10.1242/jcs.014456; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chiquet M, 2004, BBA-MOL CELL RES, V1693, P193, DOI 10.1016/j.bbamcr.2004.08.001; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Chiquet-Ehrismann R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004960; Connelly JT, 2010, NAT CELL BIOL, V12, P711, DOI 10.1038/ncb2074; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Fluck M, 2000, J CELL SCI, V113, P3583; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059; Ishihara A, 1995, CLIN CANCER RES, V1, P1035; Iwasaki K, 2008, J BIOL CHEM, V283, P21230, DOI 10.1074/jbc.M710525200; Jarvinen TAH, 1999, J CELL SCI, V112, P3157; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kjaer M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003; Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; LIGHTNER VA, 1994, EXP CELL RES, V210, P177, DOI 10.1006/excr.1994.1027; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mackey AL, 2011, FASEB J, V25, P1943, DOI 10.1096/fj.10-176487; Magnusson SP, 2008, J PHYSIOL-LONDON, V586, P71, DOI 10.1113/jphysiol.2007.139105; Maier S, 2008, BBA-MOL CELL RES, V1783, P1150, DOI 10.1016/j.bbamcr.2008.01.013; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1; Mikic B, 2000, J ORTHOPAED RES, V18, P406, DOI 10.1002/jor.1100180312; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Morita T, 2007, EXP CELL RES, V313, P3432, DOI 10.1016/j.yexcr.2007.07.008; Sarasa-Renedo A, 2006, EXP CELL RES, V312, P1361, DOI 10.1016/j.yexcr.2005.12.025; Sasazuki T, 2002, J BIOL CHEM, V277, P28853, DOI 10.1074/jbc.M203190200; Scherberich A, 2005, ONCOGENE, V24, P1525, DOI 10.1038/sj.onc.1208342; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang JHC, 2007, GENE, V391, P1, DOI 10.1016/j.gene.2007.01.014; Webb CMB, 1997, J BONE MINER RES, V12, P52, DOI 10.1359/jbmr.1997.12.1.52; Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592; Zaromytidou AI, 2006, MOL CELL BIOL, V26, P4134, DOI 10.1128/MCB.01902-05; Zhao XH, 2007, J CELL SCI, V120, P1801, DOI 10.1242/jcs.001586; Zipprich JT, 2009, RNA, V15, P781, DOI 10.1261/rna.1448009	58	45	46	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3477	3488		10.1096/fj.11-187310	http://dx.doi.org/10.1096/fj.11-187310			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21705668				2022-12-28	WOS:000295356400018
J	Okamoto, M; Inoue, K; Iwamura, H; Terashima, K; Soya, H; Asashima, M; Kuwabara, T				Okamoto, Masahiro; Inoue, Koshiro; Iwamura, Hiroki; Terashima, Kazuyuki; Soya, Hideaki; Asashima, Makoto; Kuwabara, Tomoko			Reduction in paracrine Wnt3 factors during aging causes impaired adult neurogenesis	FASEB JOURNAL			English	Article						astrocytes; exercise; chromatin; retrotransposon	NEURAL STEM-CELLS; L1 RETROTRANSPOSITION; TREADMILL EXERCISE; DENTATE GYRUS; RAT; AGE; NEURONS; GENE; PROLIFERATION; HIPPOCAMPUS	The mammalian brain contains neural stem cells (NSCs) that enable continued neurogenesis throughout adulthood. However, NSC function and/or numbers decline with increasing age. Adult hippocampal neurogenesis is unique in that astrocytes secreting Wnt3 promote NSC differentiation in a paracrine manner. Here, we show that both the levels of Wnt3 protein and the number of Wnt3-secreting astrocytes influence the impairment of adult neurogenesis during aging. The age-associated reduction in Wnt3 levels affects the regulation of target genes, such as NeuroD1 and retrotransposon L1, as well as the expression of Dcx, which is located adjacent to the L1 loci. Interestingly, the decline in the extrinsic Wnt3 levels and in the intracellular expression of the target genes with aging was reversible. Exercise was found to significantly increase de novo expression of Wnt3 and thereby rescue impaired neurogenesis in aged animals. Furthermore, the chromatin state of NeuroD1, L1, and the L1 loci near Dcx changed relative to Wnt3 levels in an age-or stimulus-associated manner. These results suggest that the regulation of paracrine factors plays a critical role in hippocampal aging and neurogenesis.-Okamoto, M., Inoue, K., Iwamura, H., Terashima, K., Soya, H., Asashima, M., Kuwabara, T. Reduction in paracrine Wnt3 factors during aging causes impaired adult neurogenesis. FASEB J. 25, 3570 - 3582 (2011). www.fasebj.org	[Okamoto, Masahiro; Inoue, Koshiro; Iwamura, Hiroki; Terashima, Kazuyuki; Asashima, Makoto; Kuwabara, Tomoko] Natl Inst Adv Ind Sci & Technol, Res Ctr Stem Cell Engn, Tsukuba, Ibaraki 3058562, Japan; [Okamoto, Masahiro; Inoue, Koshiro; Iwamura, Hiroki; Soya, Hideaki] Univ Tsukuba, Lab Exercise Biochem, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058574, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba	Kuwabara, T (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Stem Cell Engn, Cent 4,1-1-4 Higashi, Tsukuba, Ibaraki 3058562, Japan.	hsoya@taiiku.tsukuba.ac.jp; t.warashina@aist.go.jp	Kuwabara, Tomoko/M-1639-2018	Kuwabara, Tomoko/0000-0002-7668-0896	Japan National Institute of Advanced Industrial Science and Technology; Grants-in-Aid for Scientific Research [23240091] Funding Source: KAKEN	Japan National Institute of Advanced Industrial Science and Technology; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Hideto Takimoto and Takahiro Numabe for providing assistance for the care of animals. T.K. and M.A. were supported by various grants from the Japan National Institute of Advanced Industrial Science and Technology. T.K. was partly supported by a Grant-in-Aid for Young Scientists (B) and a Grant-in-Aid for Scientific Research (A).	Campuzano R, 2002, EUR J MED RES, V7, P93; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Cuitino L, 2010, J NEUROSCI, V30, P8411, DOI 10.1523/JNEUROSCI.5736-09.2010; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; des Portes V, 1998, CELL, V92, P51; Driscoll I, 2005, REV NEUROSCIENCE, V16, P87, DOI 10.1515/REVNEURO.2005.16.2.87; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galvan V, 2007, CLIN INTERV AGING, V2, P605; Gao ZL, 2009, NAT NEUROSCI, V12, P1090, DOI 10.1038/nn.2385; Gogolla N, 2009, NEURON, V62, P510, DOI 10.1016/j.neuron.2009.04.022; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kim SE, 2010, EXP GERONTOL, V45, P357, DOI 10.1016/j.exger.2010.02.005; Kim YP, 2004, NEUROSCI LETT, V355, P152, DOI 10.1016/j.neulet.2003.11.005; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Lee SMK, 2000, DEVELOPMENT, V127, P457; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lugert S, 2010, CELL STEM CELL, V6, P445, DOI 10.1016/j.stem.2010.03.017; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Luo J, 2006, AGING CELL, V5, P139, DOI 10.1111/j.1474-9726.2006.00197.x; McKinnon PJ, 1996, BRAIN RES, V709, P27, DOI 10.1016/0006-8993(95)01224-9; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3; Muotri AR, 2010, NATURE, V468, P443, DOI 10.1038/nature09544; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Okamoto H, 2010, BIOL PSYCHIAT, V68, P521, DOI 10.1016/j.biopsych.2010.04.023; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Piens M, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-64; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Sheng JS, 2004, EUR J NEUROSCI, V20, P873, DOI 10.1111/j.1460-9568.2004.03567.x; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang CY, 2011, NEUROSCI LETT, V497, P122, DOI 10.1016/j.neulet.2011.04.044; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493	45	106	110	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3570	3582		10.1096/fj.11-184697	http://dx.doi.org/10.1096/fj.11-184697			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21746862				2022-12-28	WOS:000295356400027
J	Moran-Salvador, E; Lopez-Parra, M; Garcia-Alonso, V; Titos, E; Martinez-Clemente, M; Gonzalez-Periz, A; Lopez-Vicario, C; Barak, Y; Arroyo, V; Claria, J				Moran-Salvador, Eva; Lopez-Parra, Marta; Garcia-Alonso, Veronica; Titos, Esther; Martinez-Clemente, Marcos; Gonzalez-Periz, Ana; Lopez-Vicario, Cristina; Barak, Yaacov; Arroyo, Vicente; Claria, Joan			Role for PPAR gamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts	FASEB JOURNAL			English	Article						nuclear receptors; liver cells; nonalcoholic fatty liver disease	ACTIVATED RECEPTOR-GAMMA; FATTY LIVER IMPROVEMENT; INSULIN-RESISTANCE; GENE-EXPRESSION; NONALCOHOLIC STEATOHEPATITIS; MOUSE MODEL; MICE; ROSIGLITAZONE; MUSCLE; ALPHA	Peroxisome proliferator-activated receptor (PPAR) gamma is a nuclear receptor central to glucose and lipid homeostasis. PPAR gamma role in nonalcoholic fatty liver disease is controversial because PPAR gamma overexpression is a general property of steatotic livers, but its activation by thiazolidinediones reduces hepatic steatosis. Here, we investigated hepatic PPAR gamma function by using Cre-loxP technology to generate hepatocyte (PPAR gamma(Delta hep))- and macrophage (PPAR gamma(Delta mac))-specific PPAR gamma-knockout mice. Targeted deletion of PPAR gamma in hepatocytes, and to a lesser extent in macrophages, protected mice against high-fat diet-induced hepatic steatosis. Down-regulated expression of genes involved in lipogenesis (SCD1, SREBP-1c, and ACC), lipid transport (CD36/FAT, L-FABP, and MTP), and beta-oxidation (PPAR alpha and ACO) was observed in PPAR gamma(Delta hep) mice. Moreover, PPAR gamma(Delta hep) mice showed improved glucose tolerance and reduced PEPCK expression without changes in Pcx, Fbp1, and G6Pc expression and CREB and JNK phosphorylation. In precision-cut liver slices (PCLSs) and hepatocytes, rosiglitazone either alone or in combination with oleic acid increased triglyceride accumulation, an effect that was blocked by the PPAR gamma antagonist biphenol A diglycidyl ether (BADGE). PCLSs and hepatocytes from PPAR gamma(Delta hep) mice showed blunted responses to rosiglitazone and oleic acid, whereas the response to these compounds remained intact in PCLSs from PPAR gamma(Delta mac) mice. Collectively, these findings establish PPAR gamma expression in hepatocytes as a prosteatotic factor in fatty liver disease.-Moran-Salvador, E., Lopez-Parra, M., Garcia-Alonso, V., Titos, E., Martinez-Clemente, M., Gonzalez-Periz, A., Lopez-Vicario, C., Barak, Y., Arroyo, V., Claria, J. Role for PPAR gamma in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J. 25, 2538-2550 (2011). www.fasebj.org	[Moran-Salvador, Eva; Lopez-Parra, Marta; Garcia-Alonso, Veronica; Titos, Esther; Martinez-Clemente, Marcos; Gonzalez-Periz, Ana; Lopez-Vicario, Cristina; Claria, Joan] Univ Barcelona, Hosp Clin, Dept Biochem & Mol Genet, Esther Koplowitz Ctr,IDIBAPS, E-08036 Barcelona, Spain; [Arroyo, Vicente] Univ Barcelona, Hosp Clin, Liver Unit, Esther Koplowitz Ctr,IDIBAPS, E-08036 Barcelona, Spain; [Titos, Esther; Gonzalez-Periz, Ana; Arroyo, Vicente; Claria, Joan] Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Area Temat Enfermedades Hep, Esther Koplowitz Ctr,IDIBAPS, E-08036 Barcelona, Spain; [Barak, Yaacov] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst, Pittsburgh, PA USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Claria, J (corresponding author), Univ Barcelona, Hosp Clin, Dept Biochem & Mol Genet, Esther Koplowitz Ctr,IDIBAPS, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Arroyo, Vicente/F-9189-2015; Claria, Joan/M-7772-2019; Titos, Esther/AAA-5394-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Lopez-Vicario, Cristina/0000-0002-6609-8501; Claria, Joan/0000-0003-4333-7749	Ministerio de Ciencia e Innovacion (MICINN) [SAF 09/08767, AP2007-02004]; Instituto de Salud Carlos III; IDIBAPS	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); IDIBAPS	Supported by a grant from the Ministerio de Ciencia e Innovacion (MICINN; SAF 09/08767). CIBERehd is funded by the Instituto de Salud Carlos III. The authors' laboratory is a consolidated research group recognized by the Generalitat de Catalunya (2009SGR1484). This work was carried out, in part, at the Esther Koplowitz Center (Barcelona, Spain). E.M.-S. (contract AP2007-02004) was supported by MICINN. E.T. and A.G.-P. had contracts with CIBERehd. C.L.-V. and V.G.-A. were supported by IDIBAPS and MICINN, respectively.	Barak Y, 2007, PPAR RES, V2007, DOI 10.1155/2007/12781; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; Brunt EM, 2010, WORLD J GASTROENTERO, V16, P5286, DOI 10.3748/wjg.v16.i42.5286; Ceni E, 2006, GASTROENTEROLOGY, V131, P1235, DOI 10.1053/j.gastro.2006.08.009; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheung O, 2008, SEMIN LIVER DIS, V28, P351, DOI 10.1055/s-0028-1091979; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Clementi AH, 2009, BBA-MOL BASIS DIS, V1792, P1062, DOI 10.1016/j.bbadis.2009.08.007; Edvardsson U, 2006, BIOCHEM BIOPH RES CO, V340, P111, DOI 10.1016/j.bbrc.2005.12.008; Edvardsson U, 1999, J LIPID RES, V40, P1177; Enomoto N, 2003, J PHARMACOL EXP THER, V306, P846, DOI 10.1124/jpet.102.047217; Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561; Huang W, 2010, DIABETES, V59, P347, DOI 10.2337/db09-0016; Jou J, 2008, SEMIN LIVER DIS, V28, P370, DOI 10.1055/s-0028-1091981; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Klassen LW, 2008, BIOCHEM PHARMACOL, V76, P426, DOI 10.1016/j.bcp.2008.05.012; Lanthier N, 2010, AM J PHYSIOL-GASTR L, V298, pG107, DOI 10.1152/ajpgi.00391.2009; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Martinez-Clemente M, 2010, HEPATOLOGY, V51, P817, DOI 10.1002/hep.23463; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Planaguma A, 2005, FASEB J, V19, P1120, DOI 10.1096/fj.04-2753fje; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; Ramadori G, 2008, J PHYSIOL PHARMACOL, V59, P107; Ratziu V, 2008, GASTROENTEROLOGY, V135, P100, DOI 10.1053/j.gastro.2008.03.078; Ratziu V, 2010, HEPATOLOGY, V51, P445, DOI 10.1002/hep.23270; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Sugii S, 2009, P NATL ACAD SCI USA, V106, P22504, DOI 10.1073/pnas.0912487106; Tsukamoto H, 2008, J GASTROEN HEPATOL, V23, pS104, DOI 10.1111/j.1440-1746.2007.05294.x; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Yu J, 2010, INT J BIOCHEM CELL B, V42, P948, DOI 10.1016/j.biocel.2010.02.006; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhang YL, 2006, J BIOL CHEM, V281, P37603, DOI 10.1074/jbc.M604709200	41	286	294	2	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2538	2550		10.1096/fj.10-173716	http://dx.doi.org/10.1096/fj.10-173716			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21507897				2022-12-28	WOS:000293337800005
J	Han, YJ; Ma, SF; Yourek, G; Park, YD; Garcia, JGN				Han, Yoo Jeong; Ma, Shwu Fan; Yourek, Gregory; Park, Yoon-Dong; Garcia, Joe G. N.			A transcribed pseudogene of MYLK promotes cell proliferation	FASEB JOURNAL			English	Article						myosin light chain kinase; human cancers; gene duplication; RNA stability	LIGHT-CHAIN KINASE; HUMAN GENOME; MESSENGER-RNA; MOUSE OOCYTES; IN-VIVO; MYOSIN; GENE; EXPRESSION; PROTEIN; DNA	Pseudogenes are considered nonfunctional genomic artifacts of catastrophic pathways. Recent evidence, however, indicates novel roles for pseudogenes as regulators of gene expression. We tested the functionality of myosin light chain kinase pseudogene (MYLKP1) in human cells and tissues by RT-PCR, promoter activity, and cell proliferation assays. MYLKP1 is partially duplicated from the original MYLK gene that encodes nonmuscle and smooth muscle myosin light chain kinase (smMLCK) isoforms and regulates cell contractility and cytokinesis. Despite strong homology with the smMLCK promoter (similar to 89.9%), the MYLKP1 promoter is minimally active in normal bronchial epithelial cells but highly active in lung adenocarcinoma cells. Moreover, MYLKP1 and smMLCK exhibit negatively correlated transcriptional patterns in normal and cancer cells with MYLKP1 strongly expressed in cancer cells and smMLCK highly expressed in non-neoplastic cells. For instance, expression of smMLCK decreased (19.5 +/- 4.7 fold) in colon carcinoma tissues compared to normal colon tissues. Mechanistically, MYLKP1 overexpression inhibits smMLCK expression in cancer cells by decreasing RNA stability, leading to increased cell proliferation. These studies provide strong evidence for the functional involvement of pseudogenes in carcinogenesis and suggest MYLKP1 as a potential novel diagnostic or therapeutic target in human cancers.-Han, Y. J., Ma, S. F., Yourek, G., Park, Y.-D., Garcia, J. G. N. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 25, 2305-2312 (2011). www.fasebj.org	[Park, Yoon-Dong; Garcia, Joe G. N.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Han, Yoo Jeong; Ma, Shwu Fan] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Han, Yoo Jeong; Yourek, Gregory] Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; [Garcia, Joe G. N.] Univ Illinois, Inst Personalized Resp Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Garcia, JGN (corresponding author), Univ Illinois, Dept Med, 1737 W Polk St,305D AOB, Chicago, IL 60612 USA.	jggarcia@uic.edu	Yourek, Gregory/I-6758-2019	Yourek, Gregory/0000-0001-8008-7967	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL058064] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balakirev ES, 2003, ANNU REV GENET, V37, P123, DOI 10.1146/annurev.genet.37.040103.103949; Brand-Arpon V, 1999, GENOMICS, V56, P98, DOI 10.1006/geno.1998.5690; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Endoh A, 1998, MOL CELL ENDOCRINOL, V137, P13, DOI 10.1016/S0303-7207(97)00224-4; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gerstein M, 2006, SCI AM, V295, P48, DOI 10.1038/scientificamerican0806-48; Goncalves I, 2000, GENOME RES, V10, P672, DOI 10.1101/gr.10.5.672; Han YJ, 2008, AM J HYPERTENS, V21, P860, DOI 10.1038/ajh.2008.199; Han YJ, 2008, MOL CELL BIOL, V28, P863, DOI 10.1128/MCB.00960-07; Han YJ, 2006, MOL BIOL CELL, V17, P4039, DOI 10.1091/mbc.E06-04-0353; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; JACQ C, 1977, CELL, V12, P109, DOI 10.1016/0092-8674(77)90189-1; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Korbel JO, 2008, CURR OPIN STRUC BIOL, V18, P366, DOI 10.1016/j.sbi.2008.02.005; Korneev S, 2002, MOL BIOL EVOL, V19, P1228, DOI 10.1093/oxfordjournals.molbev.a004183; Korneev SA, 1999, J NEUROSCI, V19, P7711; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Minamiya Y, 2005, TUMOR BIOL, V26, P153, DOI 10.1159/000086487; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; PROUDFOOT N, 1980, NATURE, V286, P840, DOI 10.1038/286840a0; Puget N, 2002, AM J HUM GENET, V70, P858, DOI 10.1086/339434; Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; Yin F, 2006, AM J PHYSIOL-CELL PH, V290, pC1599, DOI 10.1152/ajpcell.00289.2005; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	35	64	68	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2305	2312		10.1096/fj.10-177808	http://dx.doi.org/10.1096/fj.10-177808			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21441351	Green Published			2022-12-28	WOS:000292242200022
J	Wu, F; Christen, P; Gehring, H				Wu, Fang; Christen, Philipp; Gehring, Heinz			A novel approach to inhibit intracellular vitamin B-6-dependent enzymes: proof of principle with human and plasmodium ornithine decarboxylase and human histidine decarboxylase	FASEB JOURNAL			English	Review						coenzyme-substrate-conjugate inhibitors; drug development; multisubstrate inhibitors; polyamines; pyridoxal-5 '-phosphate-dependent enzymes	TARGETING POLYAMINE METABOLISM; SPORADIC COLORECTAL ADENOMAS; CRYSTAL-STRUCTURE; HYDROGEN-SULFIDE; ALANINE RACEMASE; ALPHA-DIFLUOROMETHYLORNITHINE; THERAPEUTIC TARGET; TRYPANOSOMA-BRUCEI; DRUG DISCOVERY; CANCER-THERAPY	Pyridoxal-5'-phosphate (vitamin B-6)-dependent enzymes play central roles in the metabolism of amino acids. Moreover, the synthesis of polyamines, which are essential for cell growth, and of biogenic amines, such as histamine and other signal transmitters, relies on these enzymes. Certain B-6 enzymes thus are prime targets for pharmacotherapeutic intervention. We have devised a novel, in principle generally applicable strategy for obtaining small-molecule cell-permeant inhibitors of specific B-6 enzymes. The imine adduct of pyridoxal-5'-phosphate and the specific amino acid substrate, the first intermediate in all pyridoxal-5'-phosphate-dependent reactions of amino acids, was reduced to a stable secondary amine. This coenzyme-substrate-conjugate was modified further to make it membrane-permeant and, guided by structure-based modeling, to boost its affinity to the apoform of the target enzyme. Inhibitors of this type effectively decreased the respective intracellular enzymatic activity (IC50 in low micromolar range), providing lead compounds for inhibitors of human ornithine decarboxylase (hODC), plasmodium ornithine decarboxylase, and human histidine decarboxylase. The inhibitors of hODC interfere with the metabolism of polyamines and efficiently prevent the proliferation of tumor cell lines (IC50 similar to 25 mu M). This approach to specific inhibition of intracellular B-6 enzymes might be applied in a straightforward manner to other B-6 enzymes of emerging medicinal interest.-Wu, F., Christen, P., Gehring, H. A novel approach to inhibit intracellular vitamin B-6-dependent enzymes: proof of principle with human and plasmodium ornithine decarboxylase and human histidine decarboxylase. FASEB J. 25, 2109-2122 (2011). www.fasebj.org	[Wu, Fang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, Shanghai 200030, Peoples R China; [Christen, Philipp; Gehring, Heinz] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	Shanghai Jiao Tong University; University of Zurich	Gehring, H (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gehring@bioc.uzh.ch	Wu, Fang/B-1945-2008	Wu, Fang/0000-0002-4194-2243				Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; Amadasi A, 2007, CURR MED CHEM, V14, P1291, DOI 10.2174/092986707780597899; Anderson AC, 2003, CHEM BIOL, V10, P787, DOI 10.1016/j.chembiol.2003.09.002; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bagdanoff JT, 2009, J MED CHEM, V52, P3941, DOI 10.1021/jm900278w; Bailey HH, 2010, CANCER PREV RES, V3, P35, DOI 10.1158/1940-6207.CAPR-09-0096; Becker JVW, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-235; Bianca RDD, 2009, P NATL ACAD SCI USA, V106, P4513, DOI 10.1073/pnas.0807974105; Birkholtz L, 2003, PROTEINS, V50, P464, DOI 10.1002/prot.10274; Casero RA, 2005, P W PHARMACOL SOC, V48, P24; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; Congreve M, 2005, DRUG DISCOV TODAY, V10, P895, DOI 10.1016/S1359-6446(05)03484-7; COWARD JK, 1987, ADV ENZYME REGUL, V26, P107, DOI 10.1016/0065-2571(87)90008-2; DEGRAW JI, 1977, J MED CHEM, V20, P1671, DOI 10.1021/jm00222a027; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Fenn TD, 2003, BIOCHEMISTRY-US, V42, P5775, DOI 10.1021/bi027022d; FERSHT A, 1999, STRUCTURE MECH PROTE, P345; Fitzpatrick TB, 2010, CHEMBIOCHEM, V11, P1185, DOI 10.1002/cbic.201000084; FLAMIGNI F, 1984, BIOCHIM BIOPHYS ACTA, V802, P245, DOI 10.1016/0304-4165(84)90168-5; Fleming JV, 2004, BIOCHEM J, V379, P253, DOI 10.1042/BJ20031525; Gelb MH, 2007, CURR OPIN CHEM BIOL, V11, P440, DOI 10.1016/j.cbpa.2007.05.038; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Heby O, 2007, AMINO ACIDS, V33, P359, DOI 10.1007/s00726-007-0537-9; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; Hoffman HE, 2009, J MED CHEM, V52, P6032, DOI 10.1021/jm900775q; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Hui AM, 2004, CANCER RES, V64, P9115, DOI 10.1158/0008-5472.CAN-04-2740; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; JENKINS WT, 1985, TRANSAMINASES, P216; Kabil O, 2010, J BIOL CHEM, V285, P21903, DOI 10.1074/jbc.R110.128363; KELLEY JL, 1977, J MED CHEM, V20, P506, DOI 10.1021/jm00214a009; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; Kim PM, 2010, P NATL ACAD SCI USA, V107, P3175, DOI 10.1073/pnas.0914706107; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Koomoa DLT, 2008, CANCER RES, V68, P9825, DOI 10.1158/0008-5472.CAN-08-1865; Lan L, 2000, CANCER RES, V60, P5696; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LeMagueres P, 2005, BIOCHEMISTRY-US, V44, P1471, DOI 10.1021/bi0486583; Liang YC, 2002, NUTR CANCER, V42, P217, DOI 10.1207/S15327914NC422_11; Maeda K, 1998, EXP HEMATOL, V26, P325; MANCARDI D, 2009, BIOCH BIOPHYS ACTA; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATTSSON M, 1982, AGENTS ACTIONS, V12, P177; McLaren CE, 2008, CANCER PREV RES, V1, P514, DOI 10.1158/1940-6207.CAPR-08-0074; Medina MA, 2003, CRIT REV BIOCHEM MOL, V38, P23, DOI 10.1080/713609209; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; Messing E, 2006, J UROLOGY, V176, P500, DOI 10.1016/j.juro.2006.03.061; METZLER DE, 2003, BIOCH CHEM REACTIONS, V2, P737; Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042; Miles E.W., 1985, TRANSAMINASES, P470; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; Milligan DL, 2007, J BACTERIOL, V189, P8381, DOI 10.1128/JB.01201-07; Moya-Garcia AA, 2009, BRIT J PHARMACOL, V157, P4, DOI 10.1111/j.1476-5381.2009.00219.x; Moya-Garcia AA, 2005, BIOESSAYS, V27, P57, DOI 10.1002/bies.20174; Muller IB, 2008, MOL BIOCHEM PARASIT, V160, P1, DOI 10.1016/j.molbiopara.2008.03.008; Muller IB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004406; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; OBENRADER MF, 1977, J BIOL CHEM, V252, P2860; OGIER G, 1993, BIOCHEM PHARMACOL, V45, P1631, DOI 10.1016/0006-2952(93)90304-F; Origanti S, 2007, CANCER RES, V67, P4834, DOI 10.1158/0008-5472.CAN-06-4627; Osterman AL, 1997, BIOCHEMISTRY-US, V36, P4558, DOI 10.1021/bi962916h; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Panatier A, 2006, CELL, V125, P775, DOI 10.1016/j.cell.2006.02.051; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; Raul F, 2007, INT J ONCOL, V31, P89; Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Robertson JG, 2007, CURR OPIN STRUC BIOL, V17, P674, DOI 10.1016/j.sbi.2007.08.008; Robertson JG, 2005, BIOCHEMISTRY-US, V44, P5561, DOI 10.1021/bi050247e; ROBSON LC, 1980, VITAMIN B6 METABOLIS, P205; Rodriguez-Caso C, 2003, EUR J BIOCHEM, V270, P4376, DOI 10.1046/j.1432-1033.2003.03834.x; Rodriguez-Caso C, 2003, CELL MOL LIFE SCI, V60, P1760, DOI 10.1007/s00018-003-3135-3; Rounbehler RJ, 2009, CANCER RES, V69, P547, DOI 10.1158/0008-5472.CAN-08-2968; Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799; SEELY JE, 1982, BIOCHEMISTRY-US, V21, P3394, DOI 10.1021/bi00257a023; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; Shapiro J, 2005, Skin Therapy Lett, V10, P1; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Silverman RB, 2008, ANGEW CHEM INT EDIT, V47, P3500, DOI 10.1002/anie.200704280; Simmons KJ, 2010, NAT REV MICROBIOL, V8, P501, DOI 10.1038/nrmicro2349; Singh V, 2005, J BIOL CHEM, V280, P18265, DOI 10.1074/jbc.M414472200; Smith MA, 2010, J BIOL CHEM, V285, P12873, DOI 10.1074/jbc.M109.050062; Smithson DC, 2010, J BIOL CHEM, V285, P16771, DOI 10.1074/jbc.M109.081588; Snyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Sporn MB, 2008, NAT CLIN PRACT ONCOL, V5, P628, DOI 10.1038/ncponc1221; Sun QX, 2009, J BIOL CHEM, V284, P3076, DOI 10.1074/jbc.M805459200; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; van Brummelen AC, 2009, J BIOL CHEM, V284, P4635, DOI 10.1074/jbc.M807085200; Vlastos AT, 2005, CLIN CANCER RES, V11, P390; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wood JM, 2003, BIOCHEM BIOPH RES CO, V308, P698, DOI 10.1016/S0006-291X(03)01451-7; Wrenger C, 2001, J BIOL CHEM, V276, P29651, DOI 10.1074/jbc.M100578200; Wu F, 2008, FASEB J, V22, P890, DOI 10.1096/fj.07-9566com; Wu F, 2007, MOL CANCER THER, V6, P1831, DOI 10.1158/1535-7163.MCT-07-0045; Wu F, 2009, FASEB J, V23, P565, DOI 10.1096/fj.08-115121; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Yoshimura T, 2008, FEBS J, V275, P3527, DOI 10.1111/j.1742-4658.2008.06516.x; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407; ZHANG ZM, 1992, ARCH BIOCHEM BIOPHYS, V294, P394, DOI 10.1016/0003-9861(92)90701-W; ZHANG ZM, 1993, MEMBRANE BIOCHEM, V10, P53, DOI 10.3109/09687689309150252; Zhao CM, 2003, REGUL PEPTIDES, V114, P21, DOI 10.1016/S0167-0115(03)00063-6; Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120	112	18	18	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2109	2122		10.1096/fj.10-174383	http://dx.doi.org/10.1096/fj.10-174383			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21454364				2022-12-28	WOS:000292242200003
J	Gad, AKB; Ronnlund, D; Spaar, A; Savchenko, AA; Petranyi, G; Blom, H; Szekely, L; Widengren, J; Aspenstrom, P				Gad, Annica K. B.; Ronnlund, Daniel; Spaar, Alexander; Savchenko, Andrii A.; Petranyi, Gabor; Blom, Hans; Szekely, Laszlo; Widengren, Jerker; Aspenstrom, Pontus			Rho GTPases link cellular contractile force to the density and distribution of nanoscale adhesions	FASEB JOURNAL			English	Article						traction force microscopy; STED microscopy	LIGHT-CHAIN KINASE; CYTOSKELETAL DYNAMICS; TRACTION FORCES; FOCAL ADHESIONS; STED MICROSCOPY; TENSION; FIBROBLASTS; CELLS; RAC; ACTIVATION	The ability of cells to adhere and to exert contractile forces governs their capacity to move within an organism. The cytoskeletal regulators of the Rho GTPase proteins are involved in control of the contractile forces of cells. To elucidate the basis of cell migration, we analyzed contractile forces and nanoscale adhesion-related particles in single cells expressing constitutively active variants of Rho GTPases by using traction-force microscopy and ultra-high-resolution stimulated emission depletion microscopy, respectively. RhoAV14 induced large increases in the contractile forces of single cells, with Rac1L61 and RhoDV26 having more moderate effects. The RhoAV14- and RhoDV26-induced forces showed similar spatial distributions and were accompanied by reduced or unaltered cell spreading. In contrast, the Rac1L61-induced force had different, scattered, force distributions that were linked to increased cell spreading. All three of these Rho GTPase activities caused a loss of thick stress fibers and focal adhesions and a more homogenous distribution of nanoscale adhesion-related particles over the ventral surface of the cells. Interestingly, only RhoAV14 increased the density of these particles. Our data suggest a Rac1-specific mode for cells to generate contractile forces. Importantly, increased density and a more homogenous distribution of these small adhesion-related particles promote cellular contractile forces.-Gad, A. K. B., Ronnlund, D., Spaar, A., Savchenko, A. A., Petranyi, G., Blom, H., Szekely, L., Widengren, J., Aspenstrom, P. Rho GTPases link cellular contractile force to the density and distribution of nanoscale adhesions. FASEB J. 26, 2374-2382 (2012). www.fasebj.org	[Gad, Annica K. B.; Savchenko, Andrii A.; Petranyi, Gabor; Szekely, Laszlo; Aspenstrom, Pontus] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Ronnlund, Daniel; Blom, Hans; Widengren, Jerker] AlbaNova Univ Ctr, Royal Inst Technol, Sch Engn Sci, Dept Biomol Phys, Stockholm, Sweden	Karolinska Institutet; Royal Institute of Technology	Gad, AKB (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Nobels 16,Box 280, SE-17177 Stockholm, Sweden.	annica.gad@ki.se	Gad, Annica/X-8294-2018; Gad, Annica/H-8758-2017; Szekely, Laszlo/B-1268-2009	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Szekely, Laszlo/0000-0001-6144-6573; Widengren, Jerker/0000-0003-3200-0374	Swedish Research Council; Karolinska Institutet; Alex and Eva Wallstrom Foundation; O. E. and Edla Johansson Foundation; Magnus Bergvall Foundation; Swedish Society for Medical Research; Swedish Cancer Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet(Karolinska Institutet); Alex and Eva Wallstrom Foundation; O. E. and Edla Johansson Foundation; Magnus Bergvall Foundation; Swedish Society for Medical Research; Swedish Cancer Foundation	The authors thank Dr. Anna Perols [Biotech, Kungliga Tekniska Hogskolan (KTH), Stockholm, Sweden], and Dr. Michael Way (London Research Institute, Cancer Research UK, London, UK), for providing reagents, and Dr. H. Brismar, (KTH and Karolinska Institutet, Stockholm, Sweden) for the use of the Zeiss LSM 510 META microscope. A. G. was supported through a postdoctoral position from the Swedish Research Council. The authors are grateful for the financial support from the Karolinska Institutet (to A. G. and P. A.), the Alex and Eva Wallstrom Foundation (to A. G.), the O. E. and Edla Johansson Foundation (to A. G.), the Magnus Bergvall Foundation (to A. G.), the Swedish Society for Medical Research (to A. G.), the Swedish Cancer Foundation (to P. A. and J. W.), and the Swedish Research Council (to P. A., J. W., and H. B.).	Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Beningo KA, 2002, TRENDS CELL BIOL, V12, P79, DOI 10.1016/S0962-8924(01)02205-X; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Beningo KA, 2006, ARCH BIOCHEM BIOPHYS, V456, P224, DOI 10.1016/j.abb.2006.09.025; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Blom H, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-16; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Buckers J, 2011, OPT EXPRESS, V19, P3130, DOI 10.1364/OE.19.003130; Butler JP, 2002, AM J PHYSIOL-CELL PH, V282, pC595, DOI 10.1152/ajpcell.00270.2001; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; Gad A, 2004, J BIOL CHEM, V279, P13640, DOI 10.1074/jbc.M314300200; Grashoff C, 2010, NATURE, V466, P263, DOI 10.1038/nature09198; Grinnell F, 2010, ANNU REV CELL DEV BI, V26, P335, DOI 10.1146/annurev.cellbio.042308.113318; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kekre H.B., 2010, INT J COMPUT THEORY, P695, DOI DOI 10.7763/IJCTE.2010.V2.227; Ladwein M, 2008, FEBS LETT, V582, P2066, DOI 10.1016/j.febslet.2008.04.033; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Munevar S, 2001, MOL BIOL CELL, V12, P3947, DOI 10.1091/mbc.12.12.3947; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Okamura Y, 2011, BIOPHYS J, V100, P1855, DOI 10.1016/j.bpj.2011.02.052; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Patla I, 2010, NAT CELL BIOL, V12, P909, DOI 10.1038/ncb2095; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; Ruusala A, 2008, MOL CELL BIOL, V28, P1802, DOI 10.1128/MCB.00201-07; Sabass B, 2008, BIOPHYS J, V94, P207, DOI 10.1529/biophysj.107.113670; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Saras J, 2004, EXP CELL RES, V299, P356, DOI 10.1016/j.yexcr.2004.05.029; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Vasiliev JM, 2004, P NATL ACAD SCI USA, V101, P12526, DOI 10.1073/pnas.0404723101; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicente-Manzanares M, 2008, J CELL BIOL, V183, P543, DOI 10.1083/jcb.200806030; Wildanger D, 2008, OPT EXPRESS, V16, P9614, DOI 10.1364/OE.16.009614; Wu YI, 2009, NATURE, V461, P104, DOI 10.1038/nature08241	38	15	16	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2374	2382		10.1096/fj.11-195800	http://dx.doi.org/10.1096/fj.11-195800			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22371528				2022-12-28	WOS:000305017200015
J	Hayashi, H; Nakagami, H; Takeichi, M; Shimamura, M; Koibuchi, N; Oiki, E; Sato, N; Koriyama, H; Mori, M; Araujo, RG; Maeda, A; Morishita, R; Tamai, K; Kaneda, Y				Hayashi, Hiroki; Nakagami, Hironori; Takeichi, Makiko; Shimamura, Munehisa; Koibuchi, Nobutaka; Oiki, Eiji; Sato, Naoyuki; Koriyama, Hiroshi; Mori, Masaki; Araujo, Rodriguez Gerardo; Maeda, Akito; Morishita, Ryuichi; Tamai, Katsuto; Kaneda, Yasufumi			HIG1, a novel regulator of mitochondrial gamma-secretase, maintains normal mitochondrial function	FASEB JOURNAL			English	Article						Alzheimer's disease; hypoxia; neuron; oxidative stress; intracellular A beta	AMYLOID PRECURSOR PROTEIN; INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; A-BETA; PEPTIDE PRODUCTION; OXIDATIVE STRESS; PRESENILIN; COMPLEX; NOTCH; INHIBITORS	The gamma-secretase complex (which contains presenilins, nicastrin, anterior pharynx defective-1, and presenilin enhancer-2) cleaves type I transmembrane proteins, including Notch and amyloid precursor protein. Dysregulated gamma-secretase activity has been implicated in the pathogenesis of Alzheimer's disease, stroke, atherosclerosis, and cancer. Tight regulation of gamma-secretase activity is required for normal physiology. Here, we isolated HIG1 (hypoxia inducible gene 1, domain member 1A) from a functional screen of gamma-secretase inhibitory genes. HIG1 was highly expressed in the brain. Interestingly, HIG1 was localized to the mitochondria and was directly bound to gamma-secretase components on the mitochondrial membrane in SK-N-SH neuroblastoma cells. Overexpresssion of HIG1 attenuated hypoxia-induced gamma-secretase activation on the mitochondrial membrane and the accumulation of intracellular amyloid beta. This accumulation was accompanied by hypoxia-induced mitochondrial dysfunction. The latter half domain of HIG1 was required for binding to the gamma-secretase complex and suppression of gamma-secretase activity. Moreover, depletion of HIG1 increased gamma-secretase activation and enhanced hypoxia-induced mitochondrial dysfunction. In summary, HIG1 is a novel modulator of the mitochondrial gamma-secretase complex, and may play a role in the maintenance of normal mitochondrial function.-Hayashi, H., Nakagami, H., Takeichi, M., Shimamura, M., Koibuchi, N., Oiki, E., Sato, N., Koriyama, H., Mori, M., Gerardo Araujo, R., Maeda, A., Morishita, R., Tamai, K., Kaneda, Y. HIG1, a novel regulator of mitochondrial gamma-secretase, maintains normal mitochondrial function. FASEB J. 26, 2306-2317 (2012). www.fasebj.org	[Hayashi, Hiroki; Nakagami, Hironori; Takeichi, Makiko; Mori, Masaki; Araujo, Rodriguez Gerardo; Tamai, Katsuto; Kaneda, Yasufumi] Osaka Univ, United Grad Sch Child Dev, Div Gene Therapy Sci, Suita, Osaka 5650871, Japan; [Nakagami, Hironori; Shimamura, Munehisa; Morishita, Ryuichi] Osaka Univ, United Grad Sch Child Dev, Div Vasc Med & Epigenet, Suita, Osaka 5650871, Japan; [Shimamura, Munehisa; Sato, Naoyuki; Koriyama, Hiroshi] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy Sci, Suita, Osaka 5650871, Japan; [Oiki, Eiji] Osaka Univ, Grad Sch Med, Ctr Med Res & Educ, Suita, Osaka 5650871, Japan; [Maeda, Akito] Osaka Univ, PIAS Collaborat Res, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan; [Koibuchi, Nobutaka] Univ Tokyo, Grad Sch Med, Dept Adv Clin Sci & Therapeut, Tokyo, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; University of Tokyo	Nakagami, H (corresponding author), Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nakagami@gts.med.osaka-u.ac.jp; kaneday@gts.med.osaka-u.ac.jp	Maeda, Akito/AAX-6252-2020; Nakagami, Hironori/GLU-0570-2022	Nakagami, Hironori/0000-0003-4494-3601	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank Prof. Noriaki Mitsuda (Ehime University, Ehime, Japan) for providing the human neuroblastoma cell line, SK-N-SH. pCS2 + Notch1 ICV 6mt (6 myc-tagged Notch1 intracellular domain) and pCS2 + Notch1 Delta ETM 6mt (6 myc-tagged Notch1 extracellular transmembrane domain) were kind gifts from Dr. Raphael Kopan (Washington University, St. Louis, MO, USA). This work was supported, in part, by the Japan Society for the Promotion of Science.	Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Aoyama T, 2009, BIOCHEM BIOPH RES CO, V383, P216, DOI 10.1016/j.bbrc.2009.03.154; Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chen X, 2006, IUBMB LIFE, V58, P686, DOI 10.1080/15216540601047767; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Evin G, 2005, BIOCHEMISTRY-US, V44, P4332, DOI 10.1021/bi0481702; Falkevall A, 2006, J BIOL CHEM, V281, P29096, DOI 10.1074/jbc.M602532200; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200; Hayashi H, 2007, BIOCHEM BIOPH RES CO, V363, P584, DOI 10.1016/j.bbrc.2007.09.003; Hayashi H, 2009, ARTERIOSCL THROM VAS, V29, P909, DOI 10.1161/ATVBAHA.108.178541; Hwang DY, 2005, NEUROCHEM RES, V30, P1171, DOI 10.1007/s11064-005-7952-7; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Koibuchi N, 2007, CIRC RES, V100, P850, DOI 10.1161/01.RES.0000261693.13269.bf; Leissring MA, 2004, BIOCHEM J, V383, P439, DOI 10.1042/BJ20041081; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Meunier C, 2002, J BIOL CHEM, V277, P9139, DOI 10.1074/jbc.M105970200; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Mracek T, 2009, ARCH BIOCHEM BIOPHYS, V481, P30, DOI 10.1016/j.abb.2008.10.011; Nilsson R, 2006, CELL SIGNAL, V18, P1713, DOI 10.1016/j.cellsig.2006.01.010; Nishikawa T, 2006, HUM GENE THER, V17, P470, DOI 10.1089/hum.2006.17.470; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; Shaw RW, 2006, FASEB J, V20, pA898, DOI 10.1096/fj.05-4055fje; Sheng BY, 2009, FREE RADICAL BIO MED, V46, P1362, DOI 10.1016/j.freeradbiomed.2009.02.018; Shi J, 2000, BRAIN RES, V853, P1, DOI 10.1016/S0006-8993(99)02113-7; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Shimamura M, 2007, STROKE, V38, P3251, DOI 10.1161/STROKEAHA.107.485045; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Tanahashi H, 2008, NEUROSCI LETT, V439, P293, DOI 10.1016/j.neulet.2008.05.039; Wang J, 2006, P NATL ACAD SCI USA, V103, P10636, DOI 10.1073/pnas.0604194103; Wang RS, 2006, FASEB J, V20, P1275, DOI 10.1096/fj.06-5839fje; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Zhang J, 2006, NEUROSCIENCE, V143, P63, DOI 10.1016/j.neuroscience.2006.07.023; Zhou SX, 2005, P NATL ACAD SCI USA, V102, P7499, DOI 10.1073/pnas.0502768102; Zuin A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002842	44	33	33	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2306	2317		10.1096/fj.11-196063	http://dx.doi.org/10.1096/fj.11-196063			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22355194				2022-12-28	WOS:000305017200009
J	Keimling, M; Deniz, M; Varga, D; Stahl, A; Schrezenmeier, H; Kreienberg, R; Hoffmann, I; Konig, J; Wiesmuller, L				Keimling, Marlen; Deniz, Miriam; Varga, Dominic; Stahl, Andreea; Schrezenmeier, Hubert; Kreienberg, Rolf; Hoffmann, Isabell; Koenig, Jochem; Wiesmueller, Lisa			The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility	FASEB JOURNAL			English	Article						error-prone DNA repair; functional biomarker; single-strand annealing	HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; MICRONUCLEUS FREQUENCIES; FUNCTIONAL ASSAYS; GENES; BRCA1; LYMPHOCYTES; MUTATION; CELLS; RISK	Most presently known breast cancer susceptibility genes have been linked to DSB repair. To identify novel markers that may serve as indicators for breast cancer risk, we performed DSB repair analyses using a case-control design. Thus, we examined 35 women with defined familial history of breast and/or ovarian cancer (first case group), 175 patients with breast cancer (second case group), and 245 healthy women without previous cancer or family history of breast cancer (control group). We analyzed DSB repair in peripheral blood lymphocytes (PBLs) by a GFP-based test system using 3 pathway-specific substrates. We found increases of microhomology-mediated nonhomologous end joining (mmNHEJ) and nonconservative single-strand annealing (SSA) in women with familial risk vs. controls (P=0.0001-0.0022) and patients with breast cancer vs. controls (P=0.0004-0.0042). Young age (<50) at initial diagnosis of breast cancer, which could be indicative of genetic predisposition, was associated with elevated SSA using two different substrates, amounting to similar odds ratios (ORs=2.54-4.46, P=0.0059-0.0095) as for familial risk (ORs=2.61-4.05, P=0.0007-0.0045). These findings and supporting validation data underscore the great potential of detecting distinct DSB repair activities in PBLs as method to estimate breast cancer susceptibility beyond limitations of genotyping and to predict responsiveness to therapeutics targeting DSB repair-dysfunctional tumors.-Keimling, M., Deniz, M., Varga, D., Stahl, A., Schrezenmeier, H., Kreienberg, R., Hoffmann, I., Konig, J., Wiesmuller, L. The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. FASEB J. 26, 2094-2104 (2012). www.fasebj.org	[Keimling, Marlen; Deniz, Miriam; Varga, Dominic; Stahl, Andreea; Kreienberg, Rolf; Wiesmueller, Lisa] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany; [Schrezenmeier, Hubert] Inst Klin Transfus Med & Immungenet Ulm, Ulm, Germany; [Hoffmann, Isabell; Koenig, Jochem] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, D-6500 Mainz, Germany	Ulm University; Johannes Gutenberg University of Mainz	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@uni-ulm.de	König, Jochem/T-3500-2019	König, Jochem/0000-0003-4683-0360	Ministry for Education and Research [Bundesministerium fur Bildung und Forschung (BMBF)], Germany (BRENDA) [012P0505]; German Cancer Foundation (Deutsche Krebshilfe) [107744]; Deutsche Forschungsgemeinschaft (DFG; Klinische Forschergruppe 167: Apoptoseregulation und ihre Storungen bei Krankheiten) [WI 3099/7-1, WI 3099/7 -2]	Ministry for Education and Research [Bundesministerium fur Bildung und Forschung (BMBF)], Germany (BRENDA); German Cancer Foundation (Deutsche Krebshilfe)(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG; Klinische Forschergruppe 167: Apoptoseregulation und ihre Storungen bei Krankheiten)	The authors cordially thank Marina Wager, Heike Goggerle, and Julia Kaufmann for expert technical assistance and Kathrin Kuhr for initial statistical evaluations. This work was supported by the Ministry for Education and Research [Bundesministerium fur Bildung und Forschung (BMBF)], Germany (BRENDA, 012P0505), the German Cancer Foundation (Deutsche Krebshilfe, 107744), and the Deutsche Forschungsgemeinschaft (DFG; Klinische Forschergruppe 167: Apoptoseregulation und ihre Storungen bei Krankheiten, WI 3099/7-1 and -2).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Bonassi S, 2001, ENVIRON MOL MUTAGEN, V37, P31; Broeks A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1668; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; Carvalho MA, 2007, INT J BIOCHEM CELL B, V39, P298, DOI 10.1016/j.biocel.2006.08.002; Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Decottignies A, 2007, GENETICS, V176, P1403, DOI 10.1534/genetics.107.071621; Dohrn L, 2012, BIOCHEM J, V441, P919, DOI 10.1042/BJ20110314; Farrugia DJ, 2008, CANCER RES, V68, P3523, DOI 10.1158/0008-5472.CAN-07-1587; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fu YP, 2003, CANCER RES, V63, P2440; Ganzinelli M, 2011, EUR J CANCER, V47, P1086, DOI 10.1016/j.ejca.2010.11.029; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Jaspers JE, 2009, BBA-REV CANCER, V1796, P266, DOI 10.1016/j.bbcan.2009.07.001; Jerry DJ, 2010, CELL MOL LIFE SCI, V67, P1017, DOI 10.1007/s00018-009-0244-7; Keimling M, 2008, INT J CANCER, V123, P730, DOI 10.1002/ijc.23551; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Keimling M, 2009, CARCINOGENESIS, V30, P1260, DOI 10.1093/carcin/bgp117; Kenyon J, 2007, NUCLEIC ACIDS RES, V35, P7557, DOI 10.1093/nar/gkm1064; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Megnin-Chanet F, 2010, CELL MOL LIFE SCI, V67, P3649, DOI 10.1007/s00018-010-0490-8; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Nippert Irmgard, 2003, Community Genet, V6, P249, DOI 10.1159/000079387; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Rothfuss A, 2000, CANCER RES, V60, P390; Salih AK, 2001, CANCER TREAT REV, V27, P261, DOI 10.1053/ctrv.2001.0235; Speit G, 2004, CYTOGENET GENOME RES, V104, P325, DOI 10.1159/000077511; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Szpirer C, 2007, MAMM GENOME, V18, P817, DOI 10.1007/s00335-007-9073-x; Terry PD, 2006, CANCER EPIDEM BIOMAR, V15, P602, DOI 10.1158/1055-9965.EPI-05-0853; Trainer AH, 2010, NAT REV CLIN ONCOL, V7, P708, DOI 10.1038/nrclinonc.2010.175; Uhl M., 2010, ENCY BREAST CANC, P675; Varga D, 2006, MUTAGENESIS, V21, P313, DOI 10.1093/mutage/gel035; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Willers H, 2009, MOL CANCER RES, V7, P1304, DOI 10.1158/1541-7786.MCR-09-0149; Wockel A, 2008, BREAST CARE, V3, P82, DOI 10.1159/000127509	44	31	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					2094	2104		10.1096/fj.11-200790	http://dx.doi.org/10.1096/fj.11-200790			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22278937				2022-12-28	WOS:000303680800035
J	Durgadoss, L; Nidadavolu, P; Valli, RK; Saeed, U; Mishra, M; Seth, P; Ravindranath, V				Durgadoss, Lalitha; Nidadavolu, Prakash; Valli, Rupanagudi Khader; Saeed, Uzma; Mishra, Mamata; Seth, Pankaj; Ravindranath, Vijayalakshmi			Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt	FASEB JOURNAL			English	Article						protein thiol; glutaredoxin; thiol antioxidants; protein phosphatase 2A	PROTEIN-KINASE; OXIDATIVE STRESS; CELL-SURVIVAL; PARKINSONS-DISEASE; NEGATIVE REGULATOR; ACTIVATION; APOPTOSIS; DEATH; PHOSPHORYLATION; GLUTAREDOXIN	Impairment of Akt phosphorylation, a critical survival signal, has been implicated in the degeneration of dopaminergic neurons in Parkinson's disease. However, the mechanism underlying pAkt loss is unclear. In the current study, we demonstrate pAkt loss in ventral midbrain of mice treated with dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), when compared to ventral midbrain of control mice treated with vehicle alone. Thiol residues of the critical cysteines in Akt are oxidized to a greater degree in mice treated with MPTP, which is reflected as a 40% loss of reduced Akt. Association of oxidatively modified Akt with the phosphatase PP2A, which can lead to enhanced dephosphorylation of pAkt, was significantly stronger after MPTP treatment. Maintaining the protein thiol homeostasis by thiol antioxidants prevented loss of reduced Akt, decreased association with PP2A, and maintained pAkt levels. Overexpression of glutaredoxin, a protein disulfide oxidoreductase, in human primary neurons helped sustain reduced state of Akt and abolished MPP+-mediated pAkt loss. We demonstrate for the first time the selective loss of Akt activity, in vivo, due to oxidative modification of Akt and provide mechanistic insight into oxidative stress-induced down-regulation of cell survival pathway in mouse midbrain following exposure to MPTP.-Durgadoss, L., Nidadavolu, P., Khader Valli, R., Saeed, U., Mishra, M., Seth, P., Ravindranath, R. Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt. FASEB J. 26, 1473-1483 (2012). www.fasebj.org	[Nidadavolu, Prakash; Ravindranath, Vijayalakshmi] Indian Inst Sci, Ctr Neurosci, Bangalore 560012, Karnataka, India; [Durgadoss, Lalitha; Nidadavolu, Prakash; Valli, Rupanagudi Khader; Saeed, Uzma; Mishra, Mamata; Seth, Pankaj; Ravindranath, Vijayalakshmi] Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Nainwal Mode, Manesar, India	Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Ravindranath, V (corresponding author), Indian Inst Sci, Ctr Neurosci, CV Raman Ave, Bangalore 560012, Karnataka, India.	viji@cns.iisc.ernet.in	MISHRA, MAMATA/AAL-4321-2021	MISHRA, MAMATA/0000-0003-3797-7133; Seth, Pankaj/0000-0003-1021-7839	Department of Science and Technology, India; National Brain Research Centre (NBRC), India; Council of Scientific and Industrial Research, India	Department of Science and Technology, India(Department of Science & Technology (India)); National Brain Research Centre (NBRC), India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by grants from the Department of Science and Technology, India to V. R. and a core grant of the National Brain Research Centre (NBRC), India. L. D. was supported by the Council of Scientific and Industrial Research, India. The authors also thank Ms. Neha Sehgal and Mr. Ajit Ray for their help with some experiments.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Cheng HC, 2011, J NEUROSCI, V31, P2125, DOI 10.1523/JNEUROSCI.5519-10.2011; Chung CY, 2007, J NEUROSCI, V27, P8314, DOI 10.1523/JNEUROSCI.1972-07.2007; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Astous M, 2006, MOL PHARMACOL, V69, P1492, DOI 10.1124/mol.105.018671; D'Astous M, 2005, NEUROENDOCRINOLOGY, V82, P111, DOI 10.1159/000091206; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Doo AR, 2010, J ETHNOPHARMACOL, V131, P433, DOI 10.1016/j.jep.2010.07.008; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Karunakaran S, 2007, FASEB J, V21, P2226, DOI 10.1096/fj.06-7580com; Karunakaran S, 2008, J NEUROSCI, V28, P12500, DOI 10.1523/JNEUROSCI.4511-08.2008; Kenchappa RS, 2004, FASEB J, V18, P1102, DOI 10.1096/fj.03-1075fje; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Leak RK, 2006, J NEUROCHEM, V99, P1151, DOI 10.1111/j.1471-4159.2006.04149.x; Li M, 1998, METH MOL B, V93, P59; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010; Malagelada C, 2008, J NEUROSCI, V28, P14363, DOI 10.1523/JNEUROSCI.3928-08.2008; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mieyal JJ, 2008, ANTIOXID REDOX SIGN, V10, P1941, DOI 10.1089/ars.2008.2089; Mishra M, 2008, ANN NEUROL, V63, P366, DOI 10.1002/ana.21292; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Panigrahi M, 1996, BRAIN RES, V717, P184, DOI 10.1016/0006-8993(96)00009-1; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Quesada A, 2008, DEV NEUROBIOL, V68, P632, DOI 10.1002/dneu.20609; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ries V, 2006, P NATL ACAD SCI USA, V103, P18757, DOI 10.1073/pnas.0606401103; Rodriguez-Blanco J, 2008, J NEUROCHEM, V107, P127, DOI 10.1111/j.1471-4159.2008.05588.x; Saeed U, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002459; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schoenebeck B, 2005, MOL CELL NEUROSCI, V30, P249, DOI 10.1016/j.mcn.2005.07.017; SIM ATR, 1991, MOL NEUROBIOL, V5, P229, DOI 10.1007/BF02935548; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tasaki Y, 2010, BRAIN RES, V1344, P25, DOI 10.1016/j.brainres.2010.04.085; Timmons S, 2009, NEUROSCI LETT, V467, P30, DOI 10.1016/j.neulet.2009.09.055; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Urata Y, 2006, J BIOL CHEM, V281, P13092, DOI 10.1074/jbc.M601984200; van der Heide LP, 2006, PROG NEUROBIOL, V79, P205, DOI 10.1016/j.pneurobio.2006.06.003; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Wu Y, 2007, APOPTOSIS, V12, P1365, DOI 10.1007/s10495-007-0065-9; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Zeevalk GD, 2007, EXP NEUROL, V203, P512, DOI 10.1016/j.expneurol.2006.09.004; Zhang J, 2007, CELL SIGNAL, V19, P2194, DOI 10.1016/j.cellsig.2007.06.022	57	36	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1473	1483		10.1096/fj.11-194100	http://dx.doi.org/10.1096/fj.11-194100			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198382				2022-12-28	WOS:000302359700010
J	Engel, T; Gomez-Villafuertes, R; Tanaka, K; Mesuret, G; Sanz-Rodriguez, A; Garcia-Huerta, P; Miras-Portugal, MT; Henshall, DC; Diaz-Hernandez, M				Engel, Tobias; Gomez-Villafuertes, Rosa; Tanaka, Katsuhiro; Mesuret, Guillaume; Sanz-Rodriguez, Amaya; Garcia-Huerta, Paula; Teresa Miras-Portugal, M.; Henshall, David C.; Diaz-Hernandez, Miguel			Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice	FASEB JOURNAL			English	Article						anticonvulsant; ATP; pharmacoresistance; temporal lobe epilepsy	TEMPORAL-LOBE EPILEPSY; C-FOS EXPRESSION; P2X(7) RECEPTORS; MICROGLIAL ACTIVATION; GLUTAMATE RELEASE; ATP; HIPPOCAMPUS; RAT; PATHOPHYSIOLOGY; INHIBITION	Prolonged seizures [status epilepticus (SE)] constitute a neurological emergency that can permanently damage the brain. SE results from a failure of the normal mechanisms to terminate seizures; in particular, gamma-amino butyric acid-mediated inhibition, and benzodiazepine anticonvulsants are often incompletely effective. ATP acts as a fast neurotransmitter via ionotropic ligand-gated P2X receptors. Here we report that SE induced by intra-amygdala kainic acid in mice selectively increased hippocampal levels of P2X7 receptors relative to other P2X receptors. Using transgenic P2X7 reporter mice expressing enhanced green fluorescent protein, we identify dentate granule neurons as the major cell population transcribing the P2X7 receptor after SE. Pretreatment of mice with an intracerebroventricular microinjection of 1.75 nmol A438079, a P2X7 receptor antagonist, reduced seizure duration by 58% and reduced seizure-induced neuronal death by 61%. Injection of brilliant blue G (1 pmol), another selective antagonist, reduced seizure duration by 48% and was also neuroprotective. A438079 was seizure-suppressive when injected shortly after induction of SE, and coinjection of A438079 with lorazepam 60 min after triggering SE, when electrographic seizure-responsiveness to lorazepam had decreased, also terminated SE. Our results suggest that P2X7 receptor antagonists may be a promising class of drug for seizure abrogation and neuroprotection in SE.-Engel, T., Gomez-Villafuertes, R., Tanaka, K., Mesuret, G., SanzRodriguez, A., Garcia-Huerta, P., Miras-Portugal, M. T., Henshall, D. C., Diaz-Hernandez, M. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 26, 1616-1628 (2012). www.fasebj.org	[Engel, Tobias; Tanaka, Katsuhiro; Mesuret, Guillaume; Sanz-Rodriguez, Amaya; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Gomez-Villafuertes, Rosa; Garcia-Huerta, Paula; Teresa Miras-Portugal, M.; Diaz-Hernandez, Miguel] Univ Complutense Madrid, Fac Vet, Dept Biochem & Mol Biol 4, Madrid, Spain; [Gomez-Villafuertes, Rosa; Garcia-Huerta, Paula; Teresa Miras-Portugal, M.; Diaz-Hernandez, Miguel] Univ Complutense Madrid, Inst Neuroquim UCM, Madrid, Spain; [Gomez-Villafuertes, Rosa; Garcia-Huerta, Paula; Teresa Miras-Portugal, M.; Diaz-Hernandez, Miguel] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain; [Tanaka, Katsuhiro] Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan	Royal College of Surgeons - Ireland; Complutense University of Madrid; Complutense University of Madrid; Mie University	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Gomez-Villafuertes, Rosa/L-7181-2014; Miras-Portugal, Maria Teresa/L-7137-2014	Gomez-Villafuertes, Rosa/0000-0002-7064-0906; Diaz-Hernandez, Miguel/0000-0002-1952-4600; Pintor, Jesus/0000-0002-9191-7679; Engel, Tobias/0000-0001-9137-0637; Henshall, David/0000-0001-6237-9632	Health Research Board Ireland [HRA_POR/2010/123, PD/2009/31]; Science Foundation Ireland [08/IN1/B1875]; Comunidad de Madrid [S-SAL-0253-2006]; Spanish Ministry of Science and Education [BFU2008-02699]; Fundacion Marcelino Botin; Consolider SICI Spanish Ion Channel Initiative [CSD2008-00005]; UCM-Santander Central Hispano Bank [911585-670]	Health Research Board Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Comunidad de Madrid(Comunidad de Madrid); Spanish Ministry of Science and Education(Spanish Government); Fundacion Marcelino Botin; Consolider SICI Spanish Ion Channel Initiative; UCM-Santander Central Hispano Bank	The authors thank Dr. Maiken Nedergaard (University of Rochester, Rochester, NY, USA) for kindly providing the P2rx7-EGFP mice. This work was supported by grants from Health Research Board Ireland (HRA_POR/2010/123 and PD/2009/31), Science Foundation Ireland (08/IN1/B1875), Comunidad de Madrid (S-SAL-0253-2006), Spanish Ministry of Science and Education (BFU2008-02699), Fundacion Marcelino Botin, Consolider SICI Spanish Ion Channel Initiative (CSD2008-00005), and a grant from UCM-Santander Central Hispano Bank (911585-670).	Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Avignone E, 2008, J NEUROSCI, V28, P9133, DOI 10.1523/JNEUROSCI.1820-08.2008; BENARI Y, 1980, NEUROSCIENCE, V5, P515, DOI 10.1016/0306-4522(80)90049-4; Bernardino L, 2008, J NEUROCHEM, V106, P271, DOI 10.1111/j.1471-4159.2008.05387.x; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Cho JH, 2010, NEUROREPORT, V21, P865, DOI 10.1097/WNR.0b013e32833d9142; Choi HK, 2012, NEUROL SCI, V33, P515, DOI 10.1007/s10072-011-0740-z; Coddou C, 2011, PHARMACOL REV, V63, P641, DOI 10.1124/pr.110.003129; Csolle C, 2010, J NEUROIMMUNOL, V219, P38, DOI 10.1016/j.jneuroim.2009.11.011; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; DELORENZO RJ, 2006, STATUS EPILEPTICUS M, P17; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Diaz-Hernandez M, 2001, EUR J NEUROSCI, V14, P918, DOI 10.1046/j.0953-816x.2001.01703.x; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Diez-Zaera M, 2011, MOL BIOL CELL, V22, P1014, DOI 10.1091/mbc.E10-09-0740; Dona F, 2009, EPILEPSY RES, V83, P157, DOI 10.1016/j.eplepsyres.2008.10.008; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Fabene PF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001105; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; FOLBERGROVA J, 1981, J NEUROCHEM, V37, P1228, DOI 10.1111/j.1471-4159.1981.tb04673.x; Gomez-Villafuertes R, 2009, FEBS J, V276, P5307, DOI 10.1111/j.1742-4658.2009.07228.x; Green SM, 2009, ANN EMERG MED, V54, P181, DOI 10.1016/j.annemergmed.2008.10.003; Gualix J, 2003, J NEUROCHEM, V87, P160, DOI 10.1046/j.1471-4159.2003.01975.x; Harvey BD, 2005, J COMP NEUROL, V488, P442, DOI 10.1002/cne.20594; Iglesias R, 2008, AM J PHYSIOL-CELL PH, V295, pC752, DOI 10.1152/ajpcell.00228.2008; Jun DJ, 2007, J BIOL CHEM, V282, P37350, DOI 10.1074/jbc.M707915200; Kapur J, 1995, ANN NEUROL, V38, P893, DOI 10.1002/ana.410380609; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khakh BS, 2003, J NEUROSCI, V23, P7426; Kim JE, 2011, J CLIN INVEST, V121, P2037, DOI 10.1172/JCI44818; Labrousse VF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006006; Le Feuvre RA, 2003, J CEREBR BLOOD F MET, V23, P381, DOI 10.1097/01.WCB.0000048519.34839.97; Lowenstein DH, 2005, CURR OPIN PHARMACOL, V5, P334, DOI 10.1016/j.coph.2005.04.003; Marchi N, 2009, NEUROBIOL DIS, V33, P171, DOI 10.1016/j.nbd.2008.10.002; Mazarati AM, 1999, NEUROSCI LETT, V265, P187, DOI 10.1016/S0304-3940(99)00238-4; Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Murphy BM, 2010, CELL DEATH DIFFER, V17, P459, DOI 10.1038/cdd.2009.134; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e; Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; Papp L, 2004, NEUROREPORT, V15, P2387, DOI 10.1097/00001756-200410250-00017; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Rappold PM, 2006, BRAIN RES, V1089, P171, DOI 10.1016/j.brainres.2006.03.040; Ravizza T, 2006, EPILEPSIA, V47, P1160, DOI 10.1111/j.1528-1167.2006.00590.x; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; Sanchez-Nogueiro J, 2005, FEBS LETT, V579, P3783, DOI 10.1016/j.febslet.2005.05.073; Sloviter RS, 2007, EPILEPSIA, V48, P6, DOI 10.1111/j.1528-1167.2007.01335.x; Sloviter RS, 2005, CR BIOL, V328, P143, DOI 10.1016/j.crvi.2004.10.010; Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007; Thompson RJ, 2008, SCIENCE, V322, P1555, DOI 10.1126/science.1165209; Ubogu EE, 2003, EPILEPSY BEHAV, V4, P70, DOI 10.1016/S1525-5050(02)00643-1; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vianna EPM, 2002, EPILEPSIA, V43, P227, DOI 10.1046/j.1528-1157.43.s.5.26.x; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WASTERLAIN CG, 2006, STATUS EPILEPTICUS M, P11; Wasterlain CG, 2009, EPILEPSIA, V50, P16, DOI 10.1111/j.1528-1167.2009.02375.x; Wasterlain CG, 2008, EPILEPSIA, V49, P63, DOI 10.1111/j.1528-1167.2008.01928.x; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	67	143	157	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1616	1628		10.1096/fj.11-196089	http://dx.doi.org/10.1096/fj.11-196089			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198387	Bronze			2022-12-28	WOS:000302359700023
J	Kemaladewi, DU; de Gorter, DJJ; Aartsma-Rus, A; van Ommen, GJ; ten Dijke, P; 't Hoen, PAC; Hoogaars, WM				Kemaladewi, Dwi U.; de Gorter, David J. J.; Aartsma-Rus, Annemieke; van Ommen, Gert-Jan; ten Dijke, Peter; 't Hoen, Peter A. C.; Hoogaars, Willem M.			Cell-type specific regulation of myostatin signaling	FASEB JOURNAL			English	Article						myoblast; TGF-beta signaling; ALK4; ALK5; coreceptor	TRANSFORMING-GROWTH-FACTOR; GROSS MUSCLE HYPERTROPHY; TGF-BETA; ACTIVIN; GENE; CRIPTO; DIFFERENTIATION; MICE; MASS; TRANSDUCTION	The transforming growth factor (TGF)-beta family member myostatin is an important regulator of myoblast, adipocyte, and fibroblast growth and differentiation, but the signaling mechanisms remain to be established. We therefore determined the contribution of myostatin type I receptors activin receptor-like kinase-4 (ALK4) and -5 (ALK5) and different coreceptors in C2C12 myoblasts, C3H10T1/2 mesenchymal stem cells, and 3T3-L1 fibroblasts, as well as in primary myoblast and fibroblasts. We performed siRNA-mediated knockdown of each receptor and measured signaling activity using Smad3-dependent luciferase and Smad2 phosphorylation assays with nontargeting siRNA as control. We find that myostatin utilizes ALK4 in myoblasts, whereas it has a preference for ALK5 in nonmyogenic cells. Notably, our results show that coreceptor Cripto is expressed in myoblasts but not in the nonmyogenic cells and that it regulates myostatin activity. More specifically, myostatin requires Cripto in myoblasts, whereas Cripto represses activin activity and TGF-beta signaling is Cripto independent. Cripto-mediated myostatin signaling is dependent on both epidermal growth factor (EGF)-like and Cripto-FRL1-cryptic (CFC) domains, whereas activin signaling is solely conferred by the CFC domain. Furthermore, Cripto down-regulation enhances myoblast differentiation, showing its importance in myostatin signaling. Together, our results identify a molecular mechanism that explains the cell-type specific aspects of signaling by myostatin and other TGF-beta family members.-Kemaladewi, D. U., de Gorter, D. J. J., Aartsma-Rus, A., van Ommen, G.-J. ten Dijke, P., 't Hoen, P. A., Hoogaars, W. M. Cell-type specific regulation of myostatin signaling. FASEB J. 26, 1462-1472 (2012). www.fasebj.org	[Kemaladewi, Dwi U.; Aartsma-Rus, Annemieke; van Ommen, Gert-Jan; 't Hoen, Peter A. C.; Hoogaars, Willem M.] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, NL-2300 RC Leiden, Netherlands; [Kemaladewi, Dwi U.; de Gorter, David J. J.; ten Dijke, Peter] Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	't Hoen, PAC (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Postzone S4-P,POB 9600, NL-2300 RC Leiden, Netherlands.	p.a.c.hoen@lumc.nl	Hoen, Peter A 't/D-3950-2018; Hoogaars, Willem/AAL-1657-2021; Dijke, Peter ten/AAG-4660-2021	Hoen, Peter A 't/0000-0003-4450-3112; Dijke, Peter ten/0000-0002-7234-342X; Hoogaars, Willem/0000-0001-6061-2576; Aartsma-Rus, Annemieke/0000-0003-1565-654X; Kemaladewi, Dwi/0000-0002-0747-4589	Dutch Duchenne Parent's Project; Netherlands Organization for Scientific Research; Centre for Biomedical Genetics	Dutch Duchenne Parent's Project; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Centre for Biomedical Genetics	The authors thank Dr. Peter C. Gray (Salk Institute for Biological Studies, La Jolla, CA, USA) for providing the Cripto plasmids and the Cripto antibody. The authors are grateful to Maarten van Dinther, Midory Thorikay, and Long Zhang (Molecular Cell Biology Department, Leiden University Medical Center) for the expert technical assistance. This study is supported by the Dutch Duchenne Parent's Project (to W. M. H. H and P. A. C. H), the Netherlands Organization for Scientific Research (to P. T. D), and the Centre for Biomedical Genetics (to P. T. D and G.J.V.O).	Aartsma-Rus A, 2003, HUM MOL GENET, V12, P907, DOI 10.1093/hmg/ddg100; Andersson O, 2007, DEV BIOL, V311, P500, DOI 10.1016/j.ydbio.2007.08.060; Artaza JN, 2008, J ENDOCRINOL, V196, P235, DOI 10.1677/JOE-07-0408; Bianco C, 2010, EXPERT OPIN THER PAT, V20, P1739, DOI 10.1517/13543776.2010.530659; Blanchet MH, 2008, EMBO J, V27, P2580, DOI 10.1038/emboj.2008.174; Bogdanovich S, 2005, FASEB J, V19, P543, DOI 10.1096/fj.04-2796com; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Ciarmela P, 2011, J CLIN ENDOCR METAB, V96, P755, DOI 10.1210/jc.2010-0501; Ciarmela P, 2009, ENDOCRINOLOGY, V150, P906, DOI 10.1210/en.2008-0880; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dumonceaux J, 2010, MOL THER, V18, P881, DOI 10.1038/mt.2009.322; Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gray PC, 2006, MOL CELL BIOL, V26, P9268, DOI 10.1128/MCB.01168-06; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kang JK, 2011, MOL THER, V19, P159, DOI 10.1038/mt.2010.212; Kelber JA, 2008, J BIOL CHEM, V283, P4490, DOI 10.1074/jbc.M704960200; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Li ZB, 2008, J BIOL CHEM, V283, P19371, DOI 10.1074/jbc.M802585200; Liu CM, 2008, GENE THER, V15, P155, DOI 10.1038/sj.gt.3303016; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Magee TR, 2006, J GENE MED, V8, P1171, DOI 10.1002/jgm.946; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Miura T, 2006, BIOCHEM BIOPH RES CO, V340, P675, DOI 10.1016/j.bbrc.2005.12.060; Moustakas A, 2001, J CELL SCI, V114, P4359; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; Pistilli EE, 2011, AM J PATHOL, V178, P1287, DOI 10.1016/j.ajpath.2010.11.071; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Shelton GD, 2007, NEUROMUSCULAR DISORD, V17, P721, DOI 10.1016/j.nmd.2007.06.008; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souza TA, 2008, MOL ENDOCRINOL, V22, P2689, DOI 10.1210/me.2008-0290; Watanabe K, 2007, J BIOL CHEM, V282, P35772, DOI 10.1074/jbc.M707351200; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Zhu J, 2007, J BIOL CHEM, V282, P25852, DOI 10.1074/jbc.M704146200	49	48	49	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1462	1472		10.1096/fj.11-191189	http://dx.doi.org/10.1096/fj.11-191189			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22202673				2022-12-28	WOS:000302359700009
J	Gentil, BJ; Minotti, S; Beange, M; Baloh, RH; Julien, JP; Durham, HD				Gentil, Benoit J.; Minotti, Sandra; Beange, Madeleine; Baloh, Robert H.; Julien, Jean-Pierre; Durham, Heather D.			Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease	FASEB JOURNAL			English	Article						NFL; axonal trafficking; neuropathy; fusion	CU/ZN-SUPEROXIDE-DISMUTASE; DOMINANT OPTIC ATROPHY; AXONAL-TRANSPORT; INTERMEDIATE-FILAMENTS; HIPPOCAMPAL-NEURONS; MITOFUSIN 2; MUTATIONS; COMPLEMENTATION; NETWORK; MODEL	Intermediate filaments serve important structural roles, but other cellular functions are increasingly recognized. This study demonstrated normal function of the low-molecular-weight neurofilament protein (NFL) in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease (CMT) due to mutations in the Nefl gene. In motor neurons of spinal cord cultured from Nefl-knockout mice, mitochondrial length and the rate of fusion were decreased concomitant with increased motility. These parameters were normalized after expression of NFLwt on the Nefl(-/-) background, but not by overexpression of the profusion protein, mitofusin 2 (MFN2). The effects of CMT-causing NFL mutants bore similarities to and differences from Nefl knockout. In the early phase of toxicity before disruption of the neurofilament network, NFLQ333P and NFLP8R integrated into neurofilaments and had effects on mitochondria similar to those with Nefl knockout. The reduction of fusion rate by NFLQ333P was partly due to interference with the function of the profusion protein MFN2, which is mutated in CMT2A, functionally linking these forms of CMT. In the later phase of toxicity, mitochondria essentially stopped moving in neurons expressing NFL mutants, probably a consequence of cytoskeletal disruption. Overall, the data point to important functions of neurofilaments in mitochondrial dynamics as well as primary involvement in CMT2E/1F.-Gentil, B. J. Minotti, S., Beange, M., Baloh, R. H., Julien, J.-P., Durham, H. D. Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease. FASEB J. 26, 1194-1203 (2012). www.fasebj.org	[Gentil, Benoit J.; Minotti, Sandra; Beange, Madeleine; Durham, Heather D.] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; [Gentil, Benoit J.; Minotti, Sandra; Beange, Madeleine; Durham, Heather D.] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Baloh, Robert H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Baloh, Robert H.] Washington Univ, Sch Med, Hope Ctr Neurol Dis, St Louis, MO USA; [Julien, Jean-Pierre] Univ Laval, Ctr Rech, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada	McGill University; McGill University; Washington University (WUSTL); Washington University (WUSTL); Laval University	Gentil, BJ (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St,Room 649, Montreal, PQ H3A 2B4, Canada.	benoit.gentil@mcgill.ca; heather.durham@mcgill.ca	GENTIL, Benoit/B-9459-2012	GENTIL, Benoit/0000-0003-2022-1890	Canadian Institutes of Health Research [86725]; Muscular Dystrophy Association USA [MDA93897]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Muscular Dystrophy Association USA(Muscular Dystrophy Association)	The authors thank Dr. Celine Amiez for assistance with statistical analyses, Dr. Claire Brown (McGill University Imaging Center) for valuable comments on confocal imaging, Dr. Heidi McBride (McGill University) for pcDNA-pOCT-EGFP, and Dr. R. Youle (U.S. National Institutes of Health, Bethesda, MD, USA) for pcDNA3-PA-OCT-EGFP. This work was supported by the Canadian Institutes of Health Research (grant 86725 to H. D. D.) and the Muscular Dystrophy Association USA (grant MDA93897 to H. D. D.). The authors declare no conflicts of interest.	Ackerley S, 2006, HUM MOL GENET, V15, P347, DOI 10.1093/hmg/ddi452; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007; Bearer EL, 1999, J NEUROCYTOL, V28, P85, DOI 10.1023/A:1007025421849; Brownlees J, 2002, HUM MOL GENET, V11, P2837, DOI 10.1093/hmg/11.23.2837; Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; Carter J, 1998, J BIOL CHEM, V273, P5101, DOI 10.1074/jbc.273.9.5101; Chen S, 2007, MOL CELL NEUROSCI, V36, P472, DOI 10.1016/j.mcn.2007.08.004; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; FIFKOVA E, 1982, J CELL BIOL, V95, P345, DOI 10.1083/jcb.95.1.345; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Herzig S, 2008, CURR MOL MED, V8, P131, DOI 10.2174/156652408783769625; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Kumemura H, 2008, BIOCHEM BIOPH RES CO, V367, P33, DOI 10.1016/j.bbrc.2007.12.116; Ligon LA, 2000, J COMP NEUROL, V427, P340, DOI 10.1002/1096-9861(20001120)427:3<340::AID-CNE2>3.0.CO;2-Y; Mironov SL, 2006, SYNAPSE, V59, P403, DOI 10.1002/syn.20256; Misko A, 2010, J NEUROSCI, V30, P4232, DOI 10.1523/JNEUROSCI.6248-09.2010; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087; Niemann A, 2009, NEUROBIOL DIS, V36, P509, DOI 10.1016/j.nbd.2009.09.011; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; Pathak D., J NEUROSCI, V30, P8984; Perez-Olle R, 2002, J CELL SCI, V115, P4937, DOI 10.1242/jcs.00148; Perez-Olle R, 2004, HUM MOL GENET, V13, P2207, DOI 10.1093/hmg/ddh236; Perrot R, 2009, FASEB J, V23, P3213, DOI 10.1096/fj.09-129585; Rao MV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017087; Rintoul GL, 2010, BBA-MOL BASIS DIS, V1802, P143, DOI 10.1016/j.bbadis.2009.09.005; Roy J, 1998, J NEUROSCI, V18, P9673; Shen HL, 2011, HUM MOL GENET, V20, P2535, DOI 10.1093/hmg/ddr152; Tang HL, 2008, BIOCHEM J, V410, P141, DOI 10.1042/BJ20071072; Tradewell ML, 2009, J NEUROPATH EXP NEUR, V68, P642, DOI 10.1097/NEN.0b013e3181a5deeb; Wagner OI, 2003, J NEUROSCI, V23, P9046; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	44	44	45	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1194	1203		10.1096/fj.11-196345	http://dx.doi.org/10.1096/fj.11-196345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22155564				2022-12-28	WOS:000300949300022
J	Omary, MB; Offhaus, H; Kunkel, SL				Omary, M. Bishr; Offhaus, Heather; Kunkel, Steven L.			Two strikes: limited NIH R55 and R56 retooling funds and abolishment of the A2 grant mechanism	FASEB JOURNAL			English	Article						bridge funding; research retooling		The U. S. National Institutes of Health (NIH) are facing significant budgetary challenges as a result of the current economic climate. The recent sunset of investigator-initiated R01-type research grants after one revised submission, coupled with the present lack of an NIH retooling funding mechanism for such grant applicants, creates a concerning risk that talented and well-trained investigators may be forced to give up their research careers. Existing NIH retooling mechanisms include the R55 Shannon Award, which was established in 1991 and was essentially replaced in 2005 by the R56 award. There is an urgent need to either significantly expand the R55/R56 mechanisms and definition of NIH grant bridging/retooling support for unfunded meritorious proposals or introduce a new mechanism that provides specific support to investigators with competitive but unfunded R01 revised grants. An expanded retooling funding mechanism deserves implementation during continuing assessment of whether allowance of only one revision of research proposals has achieved its initial intended goals.-Omary, M. B., Offhaus, H., Kunkel, S. L. Two strikes: limited NIH R55 and R56 retooling funds and abolishment of the A2 grant mechanism. FASEB J. 25, 4108-4110 (2011). www.fasebj.org	[Omary, M. Bishr] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Omary, M. Bishr] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; [Offhaus, Heather; Kunkel, Steven L.] Univ Michigan, Sch Med, Res Off, Ann Arbor, MI 48109 USA; [Kunkel, Steven L.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Omary, MB (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 1137 E Catherine St, Ann Arbor, MI 48109 USA.	mbishr@umich.edu		Omary, Bishr/0000-0002-8624-2347				Fang FC, 2009, INFECT IMMUN, V77, P929, DOI 10.1128/IAI.01567-08; Garnett C., 2004, NIH RECORD      0608; Rockey S., 2011, PAYLINES PERCENTILES; Rockey S., 2011, EARLY DATA A2 SUNSET; U.S. National Institute of Diabetes and Digestive and Kidney Diseases, RES NEW NIDDK INV; U.S. National Institutes of Health, ARCH FIN NIAID PAYL; U.S. National Institutes of Health, RES PROJ SUCC RAT NI; U.S. National Institutes of Health, NIH ALM; U.S. National Institutes of Health, ACT NIH R01 EQ SUCC; U.S. National Institutes of Health, NIH FISC POL GRANT A; U.S. National Institutes of Health, NIH POL SUBM RES AM; U.S. National Institutes of Health, TYP GRANT PROGR; U.S. National Institutes of Health, NIH RES GRANTS AW TO; U.S. National Institutes of Health, ANN FY 2008 NIH DIR; U.S. National Institutes of Health, 1991, NIH GUID GRANTS CONT, V20; U.S. National Institutes of Health, RES PORTF ONL REP TO	16	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4108	4110		10.1096/fj.11-188052	http://dx.doi.org/10.1096/fj.11-188052			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21974930	Green Submitted			2022-12-28	WOS:000298138100005
J	Allen, MD; Neumann, S; Gershengorn, MC				Allen, Michael D.; Neumann, Susanne; Gershengorn, Marvin C.			Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling	FASEB JOURNAL			English	Article						GPCR; inositolphosphates; IP1; G(q/11) coupling	PHOSPHOLIPASE-C; FLUORESCENT PROTEIN; CYTOSOLIC CA-2+; PHARMACOLOGY; DIMERIZATION; TRANSDUCIN; MUTATIONS; RHODOPSIN; FAMILIES; PEPTIDE	The thyroid-stimulating hormone (TSH) receptor signals via Gs to produce cAMP and via G(q/11) to produce inositol-1,4,5-trisphosphate, which is degraded to inositol monophosphate (IP1; phosphoinositide signaling). The potency of TSH for cAMP signaling is higher than for phosphoinositide signaling, and it was suggested that there are "spare receptors" for cAMP signaling. In a human embryonic kidney macrophage scavenger receptor-expressing (HEK-EM) 293 model system, there are no spare receptors, but the cells still exhibited 100-fold differences in potencies. Dose responses for TSH-stimulated dissociation of prebound 125I-TSH (negative cooperativity; EC50 = 70 mU/ml), which requires TSH binding to both sites of the TSH receptor (TSHR) homodimer, and TSH-stimulated IP1 production (EC50 = 50 mU/ml) were indistinguishable. Fluorescence resonance energy transfer (FRET) using tagged receptors showed that TSHR formed homodimers and heterodimers with two binding-deficient mutant TSHRs, L252P and C41S. When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production. The slopes of linear regression analyses comparing fold stimulation by TSH of IP1 vs. cAMP production were 0.044 +/- 0.0047, 0.0043 +/- 0.0041, and 0.0059 +/- 0.0014 for cells expressing TSHR alone, TSHR and L252P, or TSHR and C41S, respectively. We suggest that TSHR coupling to phosphoinositide signaling is dependent on binding 2 molecules of TSH to TSHR homodimer, causing a conformational change allowing coupling to G(q/11).Allen, M. D., Neumann, S., Gershengorn, M. C. Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. FASEB J. 25, 3687-3694 (2011). www.fasebj.org	[Allen, Michael D.; Neumann, Susanne; Gershengorn, Marvin C.] NIDDK, CEB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), NIDDK, CEB, NIH, 50 South Dr, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov			National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health [Z01-DK011006]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011006] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Stefano Costanzi and Jurgen Wess for helpful comments. This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases (Z01-DK011006), U.S. National Institutes of Health.	CORDA D, 1985, J BIOL CHEM, V260, P9230; Dalrymple MB, 2008, PHARMACOL THERAPEUT, V118, P359, DOI 10.1016/j.pharmthera.2008.03.004; Damian M, 2006, EMBO J, V25, P5693, DOI 10.1038/sj.emboj.7601449; De Meyts P, 2009, ANN NY ACAD SCI, V1160, P45, DOI 10.1111/j.1749-6632.2009.03837.x; Deflorian F, 2008, PROTEINS, V71, P783, DOI 10.1002/prot.21763; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Ernst OP, 2007, P NATL ACAD SCI USA, V104, P10859, DOI 10.1073/pnas.0701967104; Gao F, 2009, MOL PHARMACOL, V76, P264, DOI 10.1124/mol.109.055756; Gurevich VV, 2008, TRENDS PHARMACOL SCI, V29, P234, DOI 10.1016/j.tips.2008.02.004; Han Y, 2009, NAT CHEM BIOL, V5, P688, DOI 10.1038/nchembio.199; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x; Neumann S, 2009, P NATL ACAD SCI USA, V106, P12471, DOI 10.1073/pnas.0904506106; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5; Rivero-Muller A, 2010, P NATL ACAD SCI USA, V107, P2319, DOI 10.1073/pnas.0906695106; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Springael JY, 2007, PHARMACOL THERAPEUT, V115, P410, DOI 10.1016/j.pharmthera.2007.06.004; Tonacchera M, 2004, J CLIN ENDOCR METAB, V89, P5787, DOI 10.1210/jc.2004-1243; TRIMBLE ER, 1986, BIOCHEM J, V239, P257, DOI 10.1042/bj2390257; Urizar E, 2005, EMBO J, V24, P1954, DOI 10.1038/sj.emboj.7600686; White JF, 2007, P NATL ACAD SCI USA, V104, P12199, DOI 10.1073/pnas.0705312104; Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200	27	49	50	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3687	3694		10.1096/fj.11-188961	http://dx.doi.org/10.1096/fj.11-188961			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21705666	Green Published			2022-12-28	WOS:000295356400037
J	Creighton, J; Jian, MY; Sayner, S; Alexeyev, M; Insel, PA				Creighton, Judy; Jian, MingYuan; Sayner, Sarah; Alexeyev, Mikhail; Insel, Paul A.			Adenosine monophosphate-activated kinase alpha 1 promotes endothelial barrier repair	FASEB JOURNAL			English	Article						cadherins; calcium; capillary; caveolin; microdomains	PROTEIN-COUPLED-RECEPTORS; CELL-CELL CONTACTS; LIPID RAFTS; METABOLIC-DISORDERS; HEART-DISEASE; GAP FORMATION; CA2+ ENTRY; MIGRATION; LUNG; CAVEOLAE	The vascular endothelium responds to damage through activation of multiple signaling events that restore cell-cell adhesion and vascular integrity. However, the molecular mechanisms that integrate these events are not clearly defined. Herein, we identify a previously unexpected role for adenosine monophosphate-activated protein kinase (AMPK) in pulmonary microvascular endothelial cell (PMVEC) repair. PMVECs selectively express the AMPK alpha 1 catalytic subunit, pharmacological and short hairpin RNA-mediated inhibition of which attenuates Ca(2+) entry in these cells induced by the inflammatory Ca(2+)-signaling mimetic thapsigargin. We find that AMPK alpha 1 activity is required for the formation of PMVEC cell-cell networks in a prorepair environment and for monolayer resealing after wounding. Decreasing AMPK alpha 1 expression reduces barrier resistance in PMVEC monolayers, results consistent with a role for AMPK alpha 1 in cell-cell adhesion. AMPK alpha 1 colocalizes and coimmunoprecipitates with the adherens junction protein N-cadherin and cofractionates with proteins selectively expressed in caveolar membranes. Assessment of permeability, by measuring the filtration coefficient (K(f)) in isolated perfused lungs, confirmed that AMPK activation contributes to barrier repair in vivo. Our findings thus provide novel evidence for AMPK alpha 1 in Ca(2+) influx-mediated signaling and wound repair in the endothelium.-Creighton, J., Jian, M., Sayner, S., Alexeyev, M., Insel, P. A. Adenosine monophosphate-activated kinase alpha 1 promotes endothelial barrier repair. FASEB J. 25, 3356-3365 (2011). www.fasebj.org	[Insel, Paul A.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Creighton, Judy; Jian, MingYuan] Univ Alabama, Dept Anesthesiol, Birmingham, AL USA; [Sayner, Sarah; Alexeyev, Mikhail] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688 USA; [Sayner, Sarah; Alexeyev, Mikhail] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of South Alabama; University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, Mail Code 0636 UCSD,9500 Gilman Dr, La Jolla, CA 92093 USA.	pinsel@ucsd.edu			U.S. National Institutes of Health [HL102296, RR031286, HL007261]; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR031286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL091651, R01HL102296, T32HL007261, P01HL066299, R03HL110803] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R01OD010944] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Troy Stevens (University of South Alabama College of Medicine, Mobile, AL, USA) for providing cells. This work was supported by U.S. National Institutes of Health grants HL102296 (to J.C.), RR031286 (to M.A.), and HL007261 (to P.A.I.).	Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19; Anderson RGW, 2008, NAT BIOTECHNOL, V26, P380, DOI 10.1038/nbt0408-380; Benz PM, 2008, J CELL BIOL, V180, P205, DOI 10.1083/jcb.200709181; Causeret M, 2005, MOL BIOL CELL, V16, P2168, DOI 10.1091/mbc.E04-09-0829; Chen ZH, 2010, P NATL ACAD SCI US; Cioffi DL, 2002, J CELL BIOL, V157, P1267, DOI 10.1083/jcb.200204022; Cioffi DL, 2006, MICROCIRCULATION, V13, P709, DOI 10.1080/10739680600930354; Colombo SL, 2009, BIOCHEM J, V421, P163, DOI 10.1042/BJ20090613; Creighton JR, 2003, AM J PHYSIOL-LUNG C, V284, pL100, DOI 10.1152/ajplung.00083.2002; Creighton J, 2008, J CELL SCI, V121, P110, DOI 10.1242/jcs.011692; Crossthwaite AJ, 2005, J BIOL CHEM, V280, P6380, DOI 10.1074/jbc.M411987200; Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019; Fisslthaler B, 2009, CIRC RES, V105, P114, DOI 10.1161/CIRCRESAHA.109.201590; Fuhs SR, 2011, J BIOL CHEM, V286, P14830, DOI 10.1074/jbc.M110.214270; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007; Hardie DG, 2008, FEBS LETT, V582, P81, DOI 10.1016/j.febslet.2007.11.018; Hardie DG, 2011, BIOCHEM SOC T, V39, P1, DOI 10.1042/BST0390001; Hutchinson DS, 2008, PHARMACOL THERAPEUT, V119, P291, DOI 10.1016/j.pharmthera.2008.05.008; Insel PA, 2005, BIOCHEM SOC T, V33, P1131, DOI 10.1042/BST0331131; Insel PA, 2009, CURR OPIN NEPHROL HY, V18, P50, DOI 10.1097/MNH.0b013e3283186f82; King J, 2004, MICROVASC RES, V67, P139, DOI 10.1016/j.mvr.2003.11.006; Ko KS, 2001, J CELL SCI, V114, P1155; Liao YY, 2009, P NATL ACAD SCI USA, V106, P3202, DOI 10.1073/pnas.0813346106; Louis M, 2008, J CELL SCI, V121, P3951, DOI 10.1242/jcs.037218; Marrs GS, 2009, MOL CELL NEUROSCI, V40, P390, DOI 10.1016/j.mcn.2008.12.007; Martini A, 2010, ACTA PHYSIOL, V198, P449, DOI 10.1111/j.1748-1716.2009.02070.x; Meoli DF, 2009, AM J PHYSIOL-LUNG C, V297, pL706, DOI 10.1152/ajplung.90598.2008; Nakao S, 2008, J CELL BIOL, V182, P395, DOI 10.1083/jcb.200802069; Ofori-Acquah SF, 2008, MICROVASC RES, V75, P391, DOI 10.1016/j.mvr.2007.10.006; Pani B, 2009, CELL CALCIUM, V45, P625, DOI 10.1016/j.ceca.2009.02.009; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119; Taulet N, 2009, J BIOL CHEM, V284, P23137, DOI 10.1074/jbc.M109.017665; Townsley MI, 2006, MICROCIRCULATION, V13, P725, DOI 10.1080/10739680600930362; Viollet B, 2007, DIABETES METAB, V33, P395, DOI 10.1016/j.diabet.2007.10.004; Witczak CA, 2008, CELL MOL LIFE SCI, V65, P3737, DOI 10.1007/s00018-008-8244-6; Wu SW, 2009, AM J PHYSIOL-LUNG C, V297, pL650, DOI 10.1152/ajplung.00015.2009; Yarrow JC, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-21; Zhang L, 2011, J BIOL CHEM, V286, P16879, DOI 10.1074/jbc.M110.186932; Zheng B, 2007, P NATL ACAD SCI USA, V104, P819, DOI 10.1073/pnas.0610157104; Zhou C, 2007, AM J PHYSIOL-LUNG C, V292, pL833, DOI 10.1152/ajplung.00377.2006; Zou MH, 2008, CLIN EXP PHARMACOL P, V35, P535, DOI 10.1111/j.1440-1681.2007.04851.x	45	32	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3356	3365		10.1096/fj.10-179218	http://dx.doi.org/10.1096/fj.10-179218			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21680893	Green Published			2022-12-28	WOS:000295356400008
J	Wang, Q; Downey, GP; McCulloch, CA				Wang, Qin; Downey, Gregory P.; McCulloch, Christopher A.			Focal adhesions and Ras are functionally and spatially integrated to mediate IL-1 activation of ERK	FASEB JOURNAL			English	Article						fibroblasts; collagen; integrin	TYROSINE PHOSPHATASE-ALPHA; R-RAS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; RAS/RAF/MEK/ERK PATHWAY; RHEUMATOID-ARTHRITIS; SMALL GTPASE; MAP KINASE; PROTEIN; MATRIX	In connective tissue cells, IL-1-induced ERK activation leading to matrix metalloproteinase (MMP)-3 expression is dependent on cooperative interactions between focal adhesions and the endoplasmic reticulum (ER). As Ras can be activated on the ER, we investigated the role of Ras in IL-1 signaling and focal adhesion formation. We found that constitutively active H-Ras, K-Ras or N-Ras enhanced focal adhesion maturation and beta 1-integrin activation. IL-1 promoted the accumulation of Ras isoforms in ER and focal adhesion fractions, as shown in cells cotransfected with GFP-tagged Ras isoforms and YFP-ER protein and by analysis of subcellular fractions enriched for ER or focal adhesion proteins. Dominant-negative H-Ras or K-Ras reduced accumulation of H-Ras and K-Ras in focal adhesions induced by IL-1 and also blocked ERK activation and focal adhesion maturation. Ras-GRF was enriched constitutively in focal adhesion fractions and was required for Ras recruitment to focal adhesions. We conclude that Ras activation and IL-1 signaling are interactive processes that regulate the maturation of focal adhesions, which, in turn, is required for ERK activation.-Wang, Q., Downey, G. P., McCulloch, C. A. Focal adhesions and Ras are functionally and spatially integrated to mediate IL-1 activation of ERK. FASEB J. 25, 3448-3464 (2011). www.fasebj.org	[Wang, Qin; McCulloch, Christopher A.] Univ Toronto, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada; [Downey, Gregory P.] Natl Jewish Hlth, Denver, CO USA	University of Toronto; National Jewish Health	McCulloch, CA (corresponding author), Univ Toronto, Matrix Dynam Grp, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Downey, Gregory P/0000-0003-3253-5862	Canadian Institutes of Health Research [MOP-84254]; U.S. National Institutes of Health [HL090669]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090669] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Canadian Institutes of Health Research operating grant MOP-84254 to C.A.M. and by U.S. National Institutes of Health grant HL090669 to G.P.D.	Abreu JRF, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2785; Ada-Nguema AS, 2006, J CELL SCI, V119, P1307, DOI 10.1242/jcs.02835; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Arora PD, 2008, MOL BIOL CELL, V19, P5032, DOI 10.1091/mbc.E08-04-0430; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Boeckeler K, 2010, J CELL SCI, V123, P2725, DOI 10.1242/jcs.062299; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fernandez-Medarde A, 2011, BBA-REV CANCER, V1815, P170, DOI 10.1016/j.bbcan.2010.11.001; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Furuhjelm J, 2003, J CELL SCI, V116, P3729, DOI 10.1242/jcs.00689; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Heo WD, 2003, CELL, V113, P315; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kwong L, 2003, MOL CELL BIOL, V23, P933, DOI 10.1128/MCB.23.3.933-949.2003; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lo SH, 2006, DEV BIOL, V294, P280, DOI 10.1016/j.ydbio.2006.03.029; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; McCulloch CA, 2006, NAT REV DRUG DISCOV, V5, P864, DOI 10.1038/nrd2109; McHugh BJ, 2010, J CELL SCI, V123, P51, DOI 10.1242/jcs.056424; Osada M, 1999, MOL CELL BIOL, V19, P6333; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Wang Q, 2006, J BIOL CHEM, V281, P31093, DOI 10.1074/jbc.M606392200; Wang Q, 2010, J BIOL CHEM, V285, P22308, DOI 10.1074/jbc.M110.102426; Wang Q, 2009, J BIOL CHEM, V284, P20763, DOI 10.1074/jbc.M808828200; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yao Z, 2009, BIOFACTORS, V35, P407, DOI 10.1002/biof.52; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	4	4	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3448	3464		10.1096/fj.11-183459	http://dx.doi.org/10.1096/fj.11-183459			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21719512	Green Published			2022-12-28	WOS:000295356400016
J	Che, MX; Jiang, YJ; Xie, YY; Jiang, LL; Hu, HY				Che, Mei-Xia; Jiang, Ya-Jun; Xie, Yuan-Yuan; Jiang, Lei-Lei; Hu, Hong-Yu			Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing	FASEB JOURNAL			English	Article						delocalization; amyotrophic lateral sclerosis; TDP-35; seeding; pre-mRNA splicing	AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; DNA-BINDING PROTEIN-43; NUCLEAR FACTOR TDP-43; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; MESSENGER-RNA; CFTR EXON-9; IN-VIVO; MUTATIONS	TAR DNA binding protein of 43 kDa (TDP-43) is a nuclear factor functioning in RNA processing. It is also a major deposited protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin (FTLD-U). To understand the mechanism underlying the inclusion body formation and possible functional alteration, we studied some TDP-43 fragments and their effects on RNA processing in cell models. The results show that the 35-kDa fragment of TDP-43 (namely TDP-35, residues 90-414), but not TDP-25A (184-414), is capable of forming cytoplasmic inclusion bodies and altering pre-mRNA splicing. The inclusions formed by TDP-35 can also recruit full-length TDP-43 to cytoplasmic deposition from functionally nuclear localization. The in vitro studies demonstrate that TDP-35, rather than TDP-43 and TDP-25A, is prone to aggregation, and it further serves as a seed to facilitate aggregation of full-length TDP-43. This suggests that fragmentation of TDP-43 leads to cellular redistribution, inclusion body formation, and altered RNA processing, which are implicated in the molecular pathogenesis of ALS and FTLD.-Che, M.-X., Jiang, Y.-J., Xie, Y.-Y., Jiang, L.-L., Hu, H.-Y. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J. 25, 2344-2353 (2011). www.fasebj.org	[Che, Mei-Xia; Jiang, Ya-Jun; Xie, Yuan-Yuan; Jiang, Lei-Lei; Hu, Hong-Yu] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hu, HY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	hyhu@sibs.ac.cn	Jiang, Yajun/AAE-7853-2020; Xie, Yuanyuan/F-1974-2017; Hu, Hong-Yu/AAQ-2633-2020; Che, Meixia/Q-2119-2019	Che, Meixia/0000-0002-4515-1414; Jiang, Yajun/0000-0002-0886-292X	National Basic Research Program of China [2006CB910305, 2006CB806508]; Sino-Swiss Joint Research Projects [GJHZ0909]; National Natural Science Foundation of China [30870485]	National Basic Research Program of China(National Basic Research Program of China); Sino-Swiss Joint Research Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors thank Dr. I. C. Eperon, (University of Leicester, Leicester, UK), for providing the plasmids of pTN23 and pTN24, and Drs. E. Buratti and F. E. Baralle (International Center for Genetic Engineering and Biotechnology, Trieste, Italy) for the TG13T5 minigene. The authors also thank Ms. J. J. Wu for technical assistance in purification of TDP-25A, and Drs. Z. H. Qin and J. Y. Hui for critical reading of the manuscript and informative discussion. This work was supported by grants from the National Basic Research Program of China (2006CB910305, 2006CB806508), Sino-Swiss Joint Research Projects (GJHZ0909), and the National Natural Science Foundation of China (30870485).	Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Ayala YM, 2008, J CELL SCI, V121, P3778, DOI 10.1242/jcs.038950; BARMADA SJ, 1943, J NEUROSCI, V30, P639; Bose JK, 2008, J BIOL CHEM, V283, P28852, DOI 10.1074/jbc.M805376200; Buratti E, 2005, J BIOL CHEM, V280, P37572, DOI 10.1074/jbc.M505557200; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2008, FRONT BIOSCI-LANDMRK, V13, P867, DOI 10.2741/2727; Colombrita C, 2009, J NEUROCHEM, V111, P1051, DOI 10.1111/j.1471-4159.2009.06383.x; D'Ambrogio A, 2009, NUCLEIC ACIDS RES, V37, P4116, DOI 10.1093/nar/gkp342; Daoud H, 2009, J MED GENET, V46, P112, DOI 10.1136/jmg.2008.062463; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Hoffner G, 2005, J NEUROCHEM, V95, P125, DOI 10.1111/j.1471-4159.2005.03348.x; Igaz LM, 2009, J BIOL CHEM, V284, P8516, DOI 10.1074/jbc.M809462200; Johnson BS, 2009, J BIOL CHEM, V284, P20329, DOI 10.1074/jbc.M109.010264; Kabashi E., HUM MOL GENET, V19, P671; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kuo PH, 2009, NUCLEIC ACIDS RES, V37, P1799, DOI 10.1093/nar/gkp013; Lagier-Tourenne C, 2009, CELL, V136, P1001, DOI 10.1016/j.cell.2009.03.006; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Liscic RM, 2008, EUR J NEUROL, V15, P772, DOI 10.1111/j.1468-1331.2008.02195.x; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; NISHIMOTO Y, 1943, J BIOL CHEM, V285, P608; Nonaka T, 2009, HUM MOL GENET, V18, P3353, DOI 10.1093/hmg/ddp275; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Pesiridis GS, 2009, HUM MOL GENET, V18, pR156, DOI 10.1093/hmg/ddp303; Rohn TT, 2008, BRAIN RES, V1228, P189, DOI 10.1016/j.brainres.2008.06.094; Rohn TT, 2009, HISTOL HISTOPATHOL, V24, P1081, DOI 10.14670/HH-24.1081; Rutherford NJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000193; Shearman MS, 1999, METHOD ENZYMOL, V309, P716; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; STRONG MJ, J NEUROL SCI, V288, P1; Wang IF, 2008, TRENDS MOL MED, V14, P479, DOI 10.1016/j.molmed.2008.09.001; Wegorzewska I, 2009, P NATL ACAD SCI USA, V106, P18809, DOI 10.1073/pnas.0908767106; Winton MJ, 2008, J BIOL CHEM, V283, P13302, DOI 10.1074/jbc.M800342200; XIE YY, FASEB J, V24, P196; Zhang YJ, 2007, J NEUROSCI, V27, P10530, DOI 10.1523/JNEUROSCI.3421-07.2007; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P7607, DOI 10.1073/pnas.0900688106	41	56	56	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2011	25	7					2344	2353		10.1096/fj.10-174482	http://dx.doi.org/10.1096/fj.10-174482			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21450909				2022-12-28	WOS:000292242200026
J	Janfelt, C; Wellner, N; Leger, PL; Kokesch-Himmelreich, J; Hansen, SH; Charriaut-Marlangue, C; Hansen, HS				Janfelt, Christian; Wellner, Niels; Leger, Pierre-Louis; Kokesch-Himmelreich, Julia; Hansen, Steen Honore; Charriaut-Marlangue, Christiane; Hansen, Harald Severin			Visualization by mass spectrometry of 2-dimensional changes in rat brain lipids, including N-acylphosphatidylethanolamines, during neonatal brain ischemia	FASEB JOURNAL			English	Article						N-palmitoylethanolamine; free fatty acids; sodium/potassium pump; docosahexaenoic acid; arachidonic acid; desorption electrospray ionization	ACYL-ETHANOLAMINE PHOSPHOLIPIDS; FOCAL CEREBRAL-ISCHEMIA; FREE FATTY-ACID; P-31 NMR; ACYLETHANOLAMINES; ACCUMULATION; ANANDAMIDE; 2-ARACHIDONOYLGLYCEROL; PALMITOYLETHANOLAMIDE; NEUROPROTECTION	Spatial synthesis of N-acyl-phosphatidylethanolamines (NAPEs) and N-acylethanolamines (NAEs) during ischemia-reperfusion in neonatal rats has been investigated and compared to the spatial degradation of other phospholipids. Ischemia was induced in anesthetized Wistar P7 rat pups by left middle cerebral artery electrocoagulation combined with a transient and concomitant occlusion of both common carotid arteries. Pups were sacrificed after 24 and 48 h. Sham-treated animals were sacrificed after 48 h. The frozen brains were sliced and subjected to desorption electrospray ionization imaging mass spectrometry. There was a remarkable increase in the levels of many species of NAPEs in the whole injured area at both time points, and a clear but minor increase in selected NAEs. In the ischemic area, the sodium adducts of phosphatidylcholine and of lyso-phosphatidylcholine accumulated and the potassium adduct of phosphatidylcholine disappeared, indicating breakdown of the Na+/K+ pump. Free fatty acids, e. g., arachidonic and docosahexaenoic acids, tended to be more abundant in the periphery than in the center of the ischemic area and showed different spatial distribution. NAPEs are synthesized in the whole ischemic area where the cells seem to be dead and other phospholipids are degraded. Free fatty acids can be found in the periphery of the ischemic area.-Janfelt, C., Wellner, N., Leger, P.-L., Kokesch-Himmelreich, J., Hansen, S. H., Charriaut-Marlangue, C., Hansen, H. S. Visualization by mass spectrometry of 2-dimensional changes in rat brain lipids, including N-acylphosphatidylethanolamines, during neonatal brain ischemia. FASEB J. 26, 2667-2673 (2012). www.fasebj.org	[Wellner, Niels; Hansen, Harald Severin] Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, DK-2100 Copenhagen O, Denmark; [Janfelt, Christian; Hansen, Steen Honore] Univ Copenhagen, Dept Pharmaceut & Analyt Chem, Fac Pharmaceut Sci, DK-2100 Copenhagen O, Denmark; [Leger, Pierre-Louis; Charriaut-Marlangue, Christiane] Univ Paris 07, INSERM, U676, Hop Robert Debre, Paris, France; [Kokesch-Himmelreich, Julia] Univ Giessen, Inst Phys Chem, D-6300 Giessen, Germany	University of Copenhagen; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Justus Liebig University Giessen	Hansen, HS (corresponding author), Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, Univ Pk 2, DK-2100 Copenhagen O, Denmark.	hsh@farma.ku.dk	, CHARRIAUT-MARLANGUE/H-3249-2019	Hansen, Harald S./0000-0001-7360-7418; Janfelt, Christian/0000-0002-4626-3426	Novo Nordisk Foundation; Carlsberg Foundation; Danish Council for Independent Research, Natural Sciences; Novo Nordisk Fonden [NNF11OC1015218] Funding Source: researchfish	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Carlsberg Foundation(Carlsberg Foundation); Danish Council for Independent Research, Natural Sciences(Det Frie Forskningsrad (DFF)); Novo Nordisk Fonden(Novo Nordisk Foundation)	The study has been supported by grants from the Novo Nordisk Foundation (H. S. H.), the Carlsberg Foundation (C. J.), and the Danish Council for Independent Research, Natural Sciences (C. J.).	Alger BE, 2011, TRENDS NEUROSCI, V34, P304, DOI 10.1016/j.tins.2011.03.003; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bonnin P, 2011, J NEUROSCI METH, V198, P103, DOI 10.1016/j.jneumeth.2011.02.030; Chen CT, 2008, J LIPID RES, V49, P147, DOI 10.1194/jlr.M700386-JLR200; Coulon D, 2012, BIOCHIMIE, V94, P75, DOI 10.1016/j.biochi.2011.04.023; Degn M, 2007, J NEUROCHEM, V103, P1907, DOI 10.1111/j.1471-4159.2007.04892.x; Deutsch J, 1997, NEUROCHEM RES, V22, P759, DOI 10.1023/A:1022030306359; Diep TA, 2011, FASEB J, V25, P765, DOI 10.1096/fj.10-166595; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Franklin A, 2003, J NEUROSCI, V23, P7767; Galan-Rodriguez B, 2009, NEUROPHARMACOLOGY, V56, P653, DOI 10.1016/j.neuropharm.2008.11.006; Garg P, 2010, NEUROSCIENCE, V166, P252, DOI 10.1016/j.neuroscience.2009.11.069; Gillum MP, 2008, CELL, V135, P813, DOI 10.1016/j.cell.2008.10.043; Goto-Inoue N, 2011, BBA-MOL CELL BIOL L, V1811, P961, DOI 10.1016/j.bbalip.2011.03.004; Guan XL, 2006, FASEB J, V20, P1152, DOI 10.1096/fj.05-5362com; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Hansen HS, 2010, EXP NEUROL, V224, P48, DOI 10.1016/j.expneurol.2010.03.022; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Hansen HS, 1997, J NEUROCHEM, V69, P753; Hansen HS, 2002, PHARMACOL THERAPEUT, V95, P119, DOI 10.1016/S0163-7258(02)00251-6; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Harkewicz R, 2007, J BIOL CHEM, V282, P2899, DOI 10.1074/jbc.M610067200; Ji RR, 2011, TRENDS NEUROSCI, V34, P599, DOI 10.1016/j.tins.2011.08.005; Kilaru A., 2010, J GLYCOM LIPIDOM, V1, P101; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Maccarrone M, 2010, ANNU REV NUTR, V30, P423, DOI 10.1146/annurev.nutr.012809.104701; Manicke NE, 2010, J MASS SPECTROM, V45, P223, DOI 10.1002/jms.1707; Moesgaard B, 1999, J LIPID RES, V40, P515; Moesgaard B, 2000, J LIPID RES, V41, P985; Murikinati S, 2010, FASEB J, V24, P788, DOI 10.1096/fj.09-141275; Murphy RC, 2011, J BIOL CHEM, V286, P25427, DOI 10.1074/jbc.R111.233478; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Ong WY, 2010, CURR MED CHEM, V17, P2746, DOI 10.2174/092986710791859289; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Rodriguez de Fonseca F., 2001, NATURE, V414, P209, DOI DOI 10.1038/35102582; Saito M, 2010, J NEUROCHEM, V115, P168, DOI 10.1111/j.1471-4159.2010.06913.x; Sapirstein A, 2000, NEUROCHEM RES, V25, P745, DOI 10.1023/A:1007583708713; Schomacher M, 2008, BRAIN RES, V1240, P213, DOI 10.1016/j.brainres.2008.09.019; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Sun Y, 2007, BRIT J PHARMACOL, V152, P734, DOI 10.1038/sj.bjp.0707478; Swamy MJ, 2010, CHEM PHYS LIPIDS, V163, P266, DOI 10.1016/j.chemphyslip.2010.01.002; Takats Z, 2004, SCIENCE, V306, P471, DOI 10.1126/science.1104404; Terova B, 2005, BBA-BIOMEMBRANES, V1715, P49, DOI 10.1016/j.bbamem.2005.07.004; Thunig J, 2011, ANAL CHEM, V83, P3256, DOI 10.1021/ac2004967; Tsuboi K, 2011, BBA-MOL CELL BIOL L, V1811, P565, DOI 10.1016/j.bbalip.2011.07.009; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Wellner N, 2011, BBA-MOL CELL BIOL L, V1811, P508, DOI 10.1016/j.bbalip.2011.06.020; Wiseman JM, 2006, ANGEW CHEM INT EDIT, V45, P7188, DOI 10.1002/anie.200602449	54	48	48	3	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2667	2673		10.1096/fj.11-201152	http://dx.doi.org/10.1096/fj.11-201152			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22389441				2022-12-28	WOS:000305017200042
J	Bosmann, M; Sarma, JV; Atefi, G; Zetoune, FS; Ward, PA				Bosmann, Markus; Sarma, J. Vidya; Atefi, Gelareh; Zetoune, Firas S.; Ward, Peter A.			Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis	FASEB JOURNAL			English	Article						macrophages; interleukin-10; C5L2; endotoxic shock	CELL-DIFFERENTIATION; ESCHERICHIA-COLI; IL-17 PRODUCTION; DENDRITIC CELLS; REGULATORY ROLE; IFN-GAMMA; RECEPTOR; COMPLEMENT; ANAPHYLATOXIN; DRIVES	There is growing evidence that the complement activation product C5a positively or negatively regulates inflammatory functions. The studies presented here report that C5a exerts anti-inflammatory effects by altering production of the cytokines IL-17A and IL-23 during endotoxic shock in young adult male C57BL/6J mice and has similar effects on macrophages from the same mice. IL-17A and IL-23 both appeared in plasma during endotoxemia, and their neutralization improved survival. The relevant sources of IL-17A during endotoxemia were not CD4(+) cells, gamma delta T cells, or NK cells but CD11b(+)F4/80(+) macrophages. The addition in vitro of C5a to lipopolysaccharide-activated peritoneal macrophages dose dependently antagonized the production of IL-17A (IC50, 50-100 nM C5a) and IL-23 (IC50, 10 nM C5a). This suppression required the receptor C5aR, but was independent of the second C5a receptor, C5L2. Genetic absence of C5aR was associated with much higher levels of IL-17A and IL-23 during endotoxic shock. Mechanistically, C5a mediated its effects on the IL-17A/IL-23 axis in a 2-step process. C5a caused activation of the PI3K-Akt and MEK1/2-ERK1/2 pathways, resulting in induction of IL-10, which powerfully inhibited production of IL-17A and IL-23. These data identify previously unknown mechanisms by which the anaphylatoxin C5a limits acute inflammation and antagonizes the IL-17A/IL-23 axis.-Bosmann, M., Sarma, J. V., Atefi, G., Zetoune, F. S., Ward, P. A. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB J. 26, 1640-1651 (2012). www.fasebj.org	[Bosmann, Markus; Sarma, J. Vidya; Atefi, Gelareh; Zetoune, Firas S.; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu		Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health [GM-29507, GM-61656]; Deutsche Forschungsgemeinschaft [571701, BO 3482/1-1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029507, R01GM061656, R37GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the U.S. National Institutes of Health, grants GM-29507 and GM-61656 (to P. A. W.), along with the Deutsche Forschungsgemeinschaft, project 571701, BO 3482/1-1 (to M. B.). The authors cordially thank Beverly Schumann, Sue Scott, and Robin Kunkel for assistance in the preparation of the manuscript.	Atefi G, 2011, FASEB J, V25, P2500, DOI 10.1096/fj.11-183236; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Bosmann M, 2011, FASEB J, V25, P4222, DOI 10.1096/fj.11-191205; Bosmann M, 2011, SHOCK, V36, P396, DOI 10.1097/SHK.0b013e3182295f5f; Chen NJ, 2007, NATURE, V446, P203, DOI 10.1038/nature05559; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Da Silva CA, 2008, J IMMUNOL, V181, P4279, DOI 10.4049/jimmunol.181.6.4279; Fang CY, 2009, BLOOD, V114, P1005, DOI 10.1182/blood-2009-01-198283; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Gu Y, 2008, EUR J IMMUNOL, V38, P1807, DOI 10.1002/eji.200838331; Guo RF, 2006, J LEUKOCYTE BIOL, V80, P1575, DOI 10.1189/jlb.0106065; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Hollmann TJ, 2008, MOL IMMUNOL, V45, P1907, DOI 10.1016/j.molimm.2007.10.037; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lalli PN, 2008, BLOOD, V112, P1759, DOI 10.1182/blood-2008-04-151068; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liu JB, 2008, J IMMUNOL, V180, P5882, DOI 10.4049/jimmunol.180.9.5882; Liu XKK, 2005, MOL CELLS, V20, P339; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Peerschke EI, 2010, MOL IMMUNOL, V47, P2170, DOI 10.1016/j.molimm.2010.05.009; Ramos TN, 2009, NEUROSCI LETT, V467, P234, DOI 10.1016/j.neulet.2009.10.045; Reiman R, 2002, EUR J IMMUNOL, V32, P1157, DOI 10.1002/1521-4141(200204)32:4<1157::AID-IMMU1157>3.3.CO;2-D; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Riedemann NC, 2003, IMMUNITY, V19, P193, DOI 10.1016/S1074-7613(03)00206-1; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Takahashi N, 2008, J EXP MED, V205, P1755, DOI 10.1084/jem.20080588; Taylor FB, 2001, CRIT CARE MED, V29, pS78, DOI 10.1097/00003246-200107001-00026; Taylor FB, 2006, ADV EXP MED BIOL, V586, P203; Tidball JG, 2007, J PHYSIOL-LONDON, V578, P327, DOI 10.1113/jphysiol.2006.118265; Weaver DJ, 2010, EUR J IMMUNOL, V40, P710, DOI 10.1002/eji.200939333; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Wittmann M, 1999, J IMMUNOL, V162, P6763; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636	50	55	56	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1640	1651		10.1096/fj.11-199216	http://dx.doi.org/10.1096/fj.11-199216			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22202675	Green Published, Green Submitted			2022-12-28	WOS:000302359700025
J	Chen, SH; Dallas, MR; Balzer, EM; Konstantopoulos, K				Chen, Shih-Hsun; Dallas, Matthew R.; Balzer, Eric M.; Konstantopoulos, Konstantinos			Mucin 16 is a functional selectin ligand on pancreatic cancer cells	FASEB JOURNAL			English	Article						MUC16; metastasis; shear stress	COLON-CARCINOMA CELLS; P-SELECTIN; TUMOR-CELLS; EXTRACELLULAR SUPERSTRUCTURE; CARCINOEMBRYONIC ANTIGEN; VASCULAR INTERACTIONS; VARIANT ISOFORMS; CA-125 GENE; ADHESION; METASTASIS	Selectins promote metastasis by mediating specific interactions between selectin ligands on tumor cells and selectin-expressing host cells in the microvasculature. Using affinity chromatography in conjunction with tandem mass spectrometry and bioinformatics tools, we identified mucin 16 (MUC16) as a novel selectin ligand expressed by metastatic pancreatic cancer cells. While up-regulated in many pancreatic cancers, the biological function of sialofucosylated MUC16 has yet to be fully elucidated. To address this, we employed blot rolling and cell-free flow-based adhesion assays using MUC16 immunopurified from pancreatic cancer cells and found that it efficiently binds E-and L-but not P-selectin. The selectin-binding determinants are sialofucosylated structures displayed on O- and N-linked glycans. Silencing MUC16 expression by RNAi markedly reduces pancreatic cancer cell binding to E-and L-selectin under flow. These findings provide a novel integrated perspective on the enhanced metastatic potential associated with MUC16 overexpression and the role of selectins in metastasis.-Chen, S.-H., Dallas, M. R., Balzer, E. M., Konstantopoulos, K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 26, 1349-1359 (2012). www.fasebj.org	[Chen, Shih-Hsun; Dallas, Matthew R.; Balzer, Eric M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Dallas, Matthew R.; Balzer, Eric M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Dallas, Matthew R.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Canc Nanotechnol Training Ctr, Baltimore, MD 21218 USA; [Balzer, Eric M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	konstant@jhu.edu	Konstantopoulos, Konstantinos/A-7045-2011		U.S. National Cancer Institute [U54-CA143868, RO1-CA101135]; NATIONAL CANCER INSTITUTE [R01CA101135, U54CA143868, T32CA130840] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Drs. Robert Cole and Tatiana Boronina, who performed the peptide analysis and protein identification in the Mass Spectrometry and Proteomics Facility at Johns Hopkins School of Medicine with support from the Institute for Cell Engineering. The authors also thank Dr. Anirban Maitra (Department of Pathology, Johns Hopkins School of Medicine) for the generous gift of the Pa03C pancreatic carcinoma cell line. This work was supported by grants from the U.S. National Cancer Institute (awards U54-CA143868 and RO1-CA101135).	Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Belisle J. A., MOL CANC, V9, P118; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2004, AM J PHYSIOL-CELL PH, V287, pC539, DOI 10.1152/ajpcell.00450.2003; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Burdick MM, 2001, IEEE ENG MED BIOL, V20, P86, DOI 10.1109/51.932731; CAPSTICK V, 1991, International Journal of Biological Markers, V6, P129; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gadducci A, 2004, BIOMED PHARMACOTHER, V58, P24, DOI 10.1016/j.biopha.2003.11.003; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2004, J CELL SCI, V117, P2503, DOI 10.1242/jcs.01088; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Haridas D., PLOS ONE, V6; Hayashi N, 2004, PATHOBIOLOGY, V71, P26, DOI 10.1159/000072959; Ho S B, 1991, Semin Cancer Biol, V2, P389; Hosono J, 1998, J SURG ONCOL, V67, P77, DOI 10.1002/(SICI)1096-9098(199802)67:2<77::AID-JSO2>3.0.CO;2-I; Jadhav S, 2002, AM J PHYSIOL-CELL PH, V283, pC1133, DOI 10.1152/ajpcell.00104.2002; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; Kishimoto T, 1996, INT J CANCER, V69, P290, DOI 10.1002/(SICI)1097-0215(19960822)69:4<290::AID-IJC9>3.0.CO;2-S; Konstantopoulos K, 1997, J CLIN INVEST, V100, pS19; Konstantopoulos K, 2009, ANNU REV BIOMED ENG, V11, P177, DOI 10.1146/annurev-bioeng-061008-124949; Laubli H, 2006, CANCER RES, V66, P1536, DOI 10.1158/0008-5472.CAN-05-3121; MANNORI G, 1995, CANCER RES, V55, P4425; Mannori G, 1997, AM J PATHOL, V151, P233; MATSUOKA Y, 1990, CANCER, V65, P506, DOI 10.1002/1097-0142(19900201)65:3<506::AID-CNCR2820650322>3.0.CO;2-0; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McCarty OJT, 2002, BIOPHYS J, V83, P836, DOI 10.1016/S0006-3495(02)75212-0; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Napier SL, 2007, J BIOL CHEM, V282, P3433, DOI 10.1074/jbc.M607219200; Nimrichter L, 2008, BLOOD, V112, P3744, DOI 10.1182/blood-2008-04-149641; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Rump A, 2004, J BIOL CHEM, V279, P9190, DOI 10.1074/jbc.M312372200; SATOMURA Y, 1991, PANCREAS, V6, P448, DOI 10.1097/00006676-199107000-00012; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Takahashi S, 2001, PATHOBIOLOGY, V69, P127, DOI 10.1159/000048767; Thomas SN, 2008, J BIOL CHEM, V283, P15647, DOI 10.1074/jbc.M800543200; Thomas SN, 2009, AM J PHYSIOL-CELL PH, V296, pC505, DOI 10.1152/ajpcell.00472.2008; Varki A, 1997, J CLIN INVEST, V100, pS31; Wirtz D., NAT REV CANC, V11, P512; Wong NK, 2003, J BIOL CHEM, V278, P28619, DOI 10.1074/jbc.M302741200; Zeimet AG, 1998, TUMOR BIOL, V19, P275, DOI 10.1159/000030018	50	49	50	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1349	1359		10.1096/fj.11-195669	http://dx.doi.org/10.1096/fj.11-195669			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22159147	Green Published			2022-12-28	WOS:000300949300037
J	Yuen, B; Boncompagni, S; Feng, W; Yang, TZ; Lopez, JR; Matthaei, KI; Goth, SR; Protasi, F; Franzini-Armstrong, C; Allen, PD; Pessah, IN				Yuen, Benjamin; Boncompagni, Simona; Feng, Wei; Yang, Tianzhong; Lopez, Jose R.; Matthaei, Klaus I.; Goth, Samuel R.; Protasi, Feliciano; Franzini-Armstrong, Clara; Allen, Paul D.; Pessah, Isaac N.			Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage	FASEB JOURNAL			English	Article						Ca2+ regulation; ryanodine receptor mutation; anesthesia; heat stress	KNOCK-IN MICE; TYPE-1 RYANODINE RECEPTOR; CALCIUM-RELEASE UNITS; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; INTERDOMAIN INTERACTIONS; CONGENITAL MYOPATHY; POSTULATED ROLE; HEAT-STROKE	Mutation T4825I in the type 1 ryanodine receptor (RYR1(T4825I/+)) confers human malignant hyperthermia susceptibility (MHS). We report a knock-in mouse line that expresses the isogenetic mutation T4826I. Heterozygous RYR1(T4826I/+) (Het) or homozygous RYR1(T4826I/T4826I) (Hom) mice are fully viable under typical rearing conditions but exhibit genotype- and sex-dependent susceptibility to environmental conditions that trigger MH. Hom mice maintain higher core temperatures than WT in the home cage, have chronically elevated myoplasmic[Ca2+](rest), and present muscle damage in soleus with a strong sex bias. Mice subjected to heat stress in an enclosed 37 degrees C chamber fail to trigger MH regardless of genotype, whereas heat stress at 41 degrees C invariably triggers fulminant MH in Hom, but not Het, mice within 20 min. WT and Het female mice fail to maintain euthermic body temperature when placed atop a bed whose surface is 37 degrees C during halothane anesthesia (1.75%) and have no hyperthermic response, whereas 100% Hom mice of either sex and 17% of the Het males develop fulminant MH. WT mice placed on a 41 degrees C bed maintain body temperature while being administered halothane, and 40% of the Het females and 100% of the Het males develop fulminant MH within 40 min. Myopathic alterations in soleus were apparent by 12 mo, including abnormally distributed and enlarged mitochondria, deeply infolded sarcolemma, and frequent Z-line streaming regions, which were more severe in males. These data demonstrate that an MHS mutation within the S4-S5 cytoplasmic linker of RYR1 confers genotype- and sex-dependent susceptibility to pharmacological and environmental stressors that trigger fulminant MH and promote myopathy.-Yuen, B., Boncompagni, S., Feng, W., Yang, T., Lopez, J. R., Matthaei, K. I., Goth, S. R., Protasi, F., Franzini-Armstrong, C., Allen, P. D., Pessah, I. N. Mice expressing T4826I-RYR1 are viable but exhibit sex-and genotype-dependent susceptibility to malignant hyperthermia and muscle damage. FASEB J. 26, 1311-1322 (2012). www.fasebj.org	[Yuen, Benjamin; Feng, Wei; Goth, Samuel R.; Pessah, Isaac N.] Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA; [Boncompagni, Simona; Protasi, Feliciano] Univ G DAnnunzio, Ctr Res Aging, Chieti, Italy; [Boncompagni, Simona; Protasi, Feliciano] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Yang, Tianzhong; Lopez, Jose R.; Allen, Paul D.] Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; [Matthaei, Klaus I.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Franzini-Armstrong, Clara] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of California System; University of California Davis; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Harvard University; Brigham & Women's Hospital; Australian National University; John Curtin School of Medical Research; University of Pennsylvania	Pessah, IN (corresponding author), Univ Calif Davis, Dept Mol Biosci, 1 Shield Ave, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	U.S. National Institutes of Health [1P01 AR52354-05, 3R01 AR043140-15, 1R01 ES014901]; J. B. Johnson Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140, P01AR052354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014901] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); J. B. Johnson Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The work was supported by U.S. National Institutes of Health grants 1P01 AR52354-05 (to C. F. A., I.N.P., and P. D. A.), 3R01 AR043140-15 (to P. D. A. and I.N.P.), and 1R01 ES014901 (to I.N.P.), and an unrestricted gift grant from the J. B. Johnson Foundation (to I.N.P.).	Andronache Z, 2009, P NATL ACAD SCI USA, V106, P4531, DOI 10.1073/pnas.0812661106; Bannister RA, 2010, J GEN PHYSIOL, V135, P629, DOI 10.1085/jgp.200910329; Boncompagni S, 2006, J GERONTOL A-BIOL, V61, P995, DOI 10.1093/gerona/61.10.995; Boncompagni S, 2010, AGING CELL, V9, P958, DOI 10.1111/j.1474-9726.2010.00623.x; Boncompagni S, 2009, P NATL ACAD SCI USA, V106, P21996, DOI 10.1073/pnas.0911496106; Boncompagni S, 2009, MOL BIOL CELL, V20, P1058, DOI 10.1091/mbc.E08-07-0783; Brady JE, 2009, ANESTH ANALG, V109, P1162, DOI 10.1213/ane.0b013e3181ac1548; Brown RL, 2000, HUM MOL GENET, V9, P1515, DOI 10.1093/hmg/9.10.1515; Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360; Campbell HD, 2002, MOL CELL BIOL, V22, P3518, DOI 10.1128/MCB.22.10.3518-3526.2002; Carpenter D, 2009, BRIT J ANAESTH, V103, P538, DOI 10.1093/bja/aep204; Carpenter D, 2009, MUSCLE NERVE, V40, P633, DOI 10.1002/mus.21397; Carpenter D, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-104; Chelu MG, 2006, FASEB J, V20, P329, DOI 10.1096/fj.05-4497fje; Cherednichenko G, 2008, MOL PHARMACOL, V73, P1203, DOI 10.1124/mol.107.043299; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042; Eltit JM, 2010, J BIOL CHEM, V285, P13781, DOI 10.1074/jbc.M110.107300; Eltit JM, 2011, P NATL ACAD SCI USA, V108, P7046, DOI 10.1073/pnas.1018380108; Feng W, 2010, BIOPHYS J, V98, p511A, DOI 10.1016/j.bpj.2009.12.2780; Feng W, 2011, MOL PHARMACOL, V79, P420, DOI 10.1124/mol.110.067959; Franzini-Armstrong C, 2005, ANN NY ACAD SCI, V1047, P76, DOI 10.1196/annals.1341.007; Giulivi C, 2011, J BIOL CHEM, V286, P99, DOI 10.1074/jbc.M110.153247; Groom L, 2011, ANESTHESIOLOGY, V115, P938, DOI 10.1097/ALN.0b013e3182320068; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Jurkat-Rott K, 2002, J NEUROL, V249, P1493, DOI 10.1007/s00415-002-0871-5; Kobayashi S, 2005, J BIOL CHEM, V280, P6580, DOI 10.1074/jbc.M408375200; KRIPPENDORF BB, 1994, ANAT RECORD, V238, P304, DOI 10.1002/ar.1092380304; Litman RS, 2005, JAMA-J AM MED ASSOC, V293, P2918, DOI 10.1001/jama.293.23.2918; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Loy RE, 2011, J GEN PHYSIOL, V137, P43, DOI 10.1085/jgp.201010523; Lynch PJ, 1997, ANESTHESIOLOGY, V86, P620, DOI 10.1097/00000542-199703000-00014; Monnier N, 2002, ANESTHESIOLOGY, V97, P1067, DOI 10.1097/00000542-200211000-00007; Murayama T, 2005, AM J PHYSIOL-CELL PH, V288, pC1222, DOI 10.1152/ajpcell.00415.2004; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NEWHAM DJ, 1983, J NEUROL SCI, V61, P109, DOI 10.1016/0022-510X(83)90058-8; Parness J, 2009, ANESTH ANALG, V109, P1054, DOI 10.1213/ane.0b013e3181a7c8e5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 2009, J PHYSIOL-LONDON, V587, P3095, DOI 10.1113/jphysiol.2009.171967; Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356; Rueffert H, 2001, BRIT J ANAESTH, V87, P240, DOI 10.1093/bja/87.2.240; Samso M, 2009, PLOS BIOL, V7, P980, DOI 10.1371/journal.pbio.1000085; Sato K, 2010, ANESTHESIOLOGY, V112, P1350, DOI 10.1097/ALN.0b013e3181d69283; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; SZABO P, 1994, DEVELOPMENT, V120, P1651; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Tung CC, 2010, NATURE, V468, P585, DOI 10.1038/nature09471; Wang RW, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.194316; Yamamoto T, 2000, J BIOL CHEM, V275, P11618, DOI 10.1074/jbc.275.16.11618; Yang TZ, 2006, ANESTHESIOLOGY, V105, P1164, DOI 10.1097/00000542-200612000-00016; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; Zhou H, 2007, BRAIN, V130, P2024, DOI 10.1093/brain/awm096; Zhou J, 2010, MILLERS ANESTHESIA, P1171; Zvaritch E, 2009, P NATL ACAD SCI USA, V106, P21813, DOI 10.1073/pnas.0912126106	57	45	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					1311	1322		10.1096/fj.11-197582	http://dx.doi.org/10.1096/fj.11-197582			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22131268	Green Published			2022-12-28	WOS:000300949300033
J	Bian, WN; Bursac, N				Bian, Weining; Bursac, Nenad			Soluble miniagrin enhances contractile function of engineered skeletal muscle	FASEB JOURNAL			English	Article						synaptogenesis; myogenesis; twitch force; acetylcholine receptors	RECEPTOR EPSILON-SUBUNIT; ACETYLCHOLINE-RECEPTORS; AGRIN; EXPRESSION; DYSTROPHIN; UTROPHIN; MYOTUBES; FIBERS; CA2+; DYSTROGLYCAN	Neural agrin plays a pleiotropic role in skeletal muscle innervation and maturation, but its specific effects on the contractile function of aneural engineered muscle remain unknown. In this study, neonatal rat skeletal myoblasts cultured within 3-dimensional engineered muscle tissue constructs were treated with 10 nM soluble recombinant miniagrin and assessed using histological, biochemical, and functional assays. Depending on the treatment duration and onset time relative to the stage of myogenic differentiation, miniagrin was found to induce up to 1.7-fold increase in twitch and tetanus force amplitude. This effect was associated with the 2.3-fold up-regulation of dystrophin gene expression at 6 d after agrin removal and enhanced ACh receptor (AChR) cluster formation, but no change in cell number, expression of muscle myosin, or important aspects of intracellular Ca2+ handling. In muscle constructs with endogenous ACh levels suppressed by the application of alpha-NETA, miniagrin increased AChR clustering and twitch force amplitude but failed to improve intracellular Ca2+ handling and increase tetanus-to-twitch ratio. Overall, our studies suggest that besides its synaptogenic function that could promote integration of engineered muscle constructs in vivo, neural agrin can directly promote the contractile function of aneural engineered muscle via mechanisms distinct from those involving endogenous ACh.-Bian, W., Bursac, N. Soluble miniagrin enhances contractile function of engineered skeletal muscle. FASEB J. 26, 955-965 (2012). www.fasebj.org	[Bursac, Nenad] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Bian, Weining] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesia & Med, Boston, MA 02115 USA; [Bian, Weining] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	Duke University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bursac, N (corresponding author), Duke Univ, Dept Biomed Engn, 3000 Sci Dr,Hudson Hall 136, Durham, NC 27708 USA.	nbursac@duke.edu	Bursac, Nenad/AAU-5548-2021	Bursac, Nenad/0000-0002-5688-6061	Center for Biomolecular and Tissue Engineering at Duke University; U.S. National Institutes of Health from the National Institute of Arthritis and Musculoskeletal and Skin Disease [AR055226]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055226] Funding Source: NIH RePORTER	Center for Biomolecular and Tissue Engineering at Duke University; U.S. National Institutes of Health from the National Institute of Arthritis and Musculoskeletal and Skin Disease; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Robert Dennis (University of North Carolina, Chapel Hill, NC, USA) for providing the force transducer and Dr. Hyung-Suk Kim (University of North Carolina, Chapel Hill) for designing qRT-PCR gene expression assays. The authors also acknowledge invaluable technical assistance from Mark Juhas, Dr. Wayne Pfeiler, and Dr. Dennis Himmel. This work was supported by Lew's fellowship from the Center for Biomolecular and Tissue Engineering at Duke University to W. B. and U.S. National Institutes of Health grant AR055226 from the National Institute of Arthritis and Musculoskeletal and Skin Disease to N.B.	Bach AD, 2003, CELL TISSUE RES, V314, P263, DOI 10.1007/s00441-003-0757-6; Badie N, 2009, BIOPHYS J, V96, P3873, DOI 10.1016/j.bpj.2009.02.019; Bandi E, 2005, J PHYSIOL-LONDON, V568, P171, DOI 10.1113/jphysiol.2005.091439; Bandi E, 2008, AM J PHYSIOL-CELL PH, V294, pC66, DOI 10.1152/ajpcell.00248.2007; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Bezakova G, 2001, J CELL BIOL, V153, P1441, DOI 10.1083/jcb.153.7.1441; Bian WN, 2009, NAT PROTOC, V4, P1522, DOI 10.1038/nprot.2009.155; Bian WN, 2009, BIOMATERIALS, V30, P1401, DOI 10.1016/j.biomaterials.2008.11.015; Bloch RJ, 2003, EXERC SPORT SCI REV, V31, P73, DOI 10.1097/00003677-200304000-00004; Brandon EP, 2003, J NEUROSCI, V23, P539, DOI 10.1523/JNEUROSCI.23-02-00539.2003; BRANDT PW, 1980, P NATL ACAD SCI-BIOL, V77, P4717, DOI 10.1073/pnas.77.8.4717; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; COGNARD C, 1993, DEVELOPMENT, V117, P1153; Deconinck N, 1998, NEUROMUSCULAR DISORD, V8, P362, DOI 10.1016/S0960-8966(98)00048-0; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DiEdwardo CA, 1999, CLIN PLAST SURG, V26, P647; ENTWISTLE A, 1988, J CELL BIOL, V106, P1703, DOI 10.1083/jcb.106.5.1703; Fedorov VV, 2007, HEART RHYTHM, V4, P619, DOI 10.1016/j.hrthm.2006.12.047; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Gramolini AO, 1998, J BIOL CHEM, V273, P736, DOI 10.1074/jbc.273.2.736; Hamann M, 1995, J PHYSIOL-LONDON, V489, P791, DOI 10.1113/jphysiol.1995.sp021092; Herbst R, 2002, DEVELOPMENT, V129, P5449, DOI 10.1242/dev.00112; Hinds S, 2011, BIOMATERIALS, V32, P3575, DOI 10.1016/j.biomaterials.2011.01.062; Hopf C, 1996, J BIOL CHEM, V271, P5231; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jones G, 1996, P NATL ACAD SCI USA, V93, P5985, DOI 10.1073/pnas.93.12.5985; Jurdana M, 2009, CELL MOL NEUROBIOL, V29, P123, DOI 10.1007/s10571-008-9304-z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larkin LM, 2006, IN VITRO CELL DEV-AN, V42, P75; Lin S, 2000, DEV BRAIN RES, V119, P289, DOI 10.1016/S0165-3806(99)00165-0; Lin S, 2008, P NATL ACAD SCI USA, V105, P11406, DOI 10.1073/pnas.0801683105; MacIntosh BR, 2003, NEWS PHYSIOL SCI, V18, P222, DOI 10.1152/nips.01456.2003; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Midrio M, 2006, EUR J APPL PHYSIOL, V98, P1, DOI 10.1007/s00421-006-0256-z; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; Radojevic V, 2000, CELL TISSUE RES, V300, P447, DOI 10.1007/s004410000213; Rimer M, 1997, MOL CELL NEUROSCI, V9, P254, DOI 10.1006/mcne.1997.0622; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SASTRY BVR, 1988, J PHARMACOL EXP THER, V245, P72; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sharp PS, 2011, MOL THER, V19, P165, DOI 10.1038/mt.2010.213; Stavropoulos M. E., 2009, CURR PROTOC STEM CEL; Tourovskaia A, 2008, BIOPHYS J, V95, P3009, DOI 10.1529/biophysj.107.128173; Walker JS, 2010, J MUSCLE RES CELL M, V31, P59, DOI 10.1007/s10974-010-9208-7	50	41	41	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					955	965		10.1096/fj.11-187575	http://dx.doi.org/10.1096/fj.11-187575			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22075647	Green Published			2022-12-28	WOS:000300485700045
J	Boulter, E; Estrach, S; Garcia-Mata, R; Feral, CC				Boulter, Etienne; Estrach, Soline; Garcia-Mata, Rafael; Feral, Chloe C.			Off the beaten paths: alternative and crosstalk regulation of Rho GTPases	FASEB JOURNAL			English	Review						RhoGEF; isoprenylation; SUMOylation; post-translational modification; phosphorylation	GUANINE-NUCLEOTIDE-EXCHANGE; VASCULAR SMOOTH-MUSCLE; GTP-BINDING PROTEINS; PLASMA-MEMBRANE; BIOLOGICAL-ACTIVITY; REDOX REGULATION; CELL PLASTICITY; FAMILY GTPASE; RAS PROTEINS; CAAX MOTIF	Rho proteins are small GTPases of the Ras superfamily that regulate a wide variety of biological processes, ranging from gene expression to cell migration. Mechanistically, the major Rho GTPases function as molecular switches cycling between an inactive GDP-bound and an active GTP-bound conformation, although several Rho proteins spontaneously exchange nucleotides or are simply devoid of GTPase activity. For over a decade, RhoGEFs and RhoGAPs have been established as the mainstream regulators of Rho proteins, respectively flipping the switch on or off. However, regulation by GEFs and GAPs leaves several fundamental questions on the operation of the Rho switch unanswered, indicating that the regulation of Rho proteins does not rely exclusively on RhoGEFs and RhoGAPs. Recent evidence indeed suggests that Rho GTPases are finely tuned by multiple alternative regulatory mechanisms, including post-translational modifications and protein degradation, as well as crosstalk mechanisms between Rho proteins. Here we review these alternative mechanisms and discuss how they alter Rho protein function and signaling. We also envision how the classic binary Rho switch may indeed function more like a switchboard with multiple switches and dials that can all contribute to the regulation of Rho protein function.-Boulter, E., Estrach, S., Garcia-Mata, R., Feral, C. C. Off the beaten paths: alternative and crosstalk regulation of Rho GTPases. FASEB J. 26, 469-479 (2012). www.fasebj.org	[Boulter, Etienne] Univ Nice Sophia Antipolis, INSERM, U634, Fac Med,Avenir Team, F-06107 Nice 2, France; [Garcia-Mata, Rafael] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of North Carolina; University of North Carolina Chapel Hill	Boulter, E (corresponding author), Univ Nice Sophia Antipolis, INSERM, U634, Fac Med,Avenir Team, 28 Ave Valombrose, F-06107 Nice 2, France.	boulter@unice.fr	Boulter, Etienne/R-1737-2016; FERAL, Chloe/AAB-6111-2020; Estrach, Soline/D-4226-2017; Estrach, Soline/GYA-4499-2022; Feral, Chloe C/O-5781-2016	Boulter, Etienne/0000-0001-6597-9086; FERAL, Chloe/0000-0001-9756-2082; Feral, Chloe C/0000-0001-9756-2082; estrach, soline/0000-0003-2088-5988; Garcia-Mata, Rafael/0000-0002-7116-4411	city of Nice (France); European Union [276945]; CDD Jeune Chercheur from INSERM; Allocation INSERM InCa/AVENIR [R08227AS]	city of Nice (France); European Union(European Commission); CDD Jeune Chercheur from INSERM; Allocation INSERM InCa/AVENIR	The authors thank the reviewers for their very detailed and insightful comments and suggestions. E. B. is supported by a fellowship from the city of Nice (France) and a Marie Curie International Reintegration Grant from the European Union Seventh Framework Program under grant agreement 276945. S. E. is supported by a CDD Jeune Chercheur from INSERM. C.F. is supported by an Allocation INSERM InCa/AVENIR (R08227AS).	ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Aktories K, 2011, NAT REV MICROBIOL, V9, P487, DOI 10.1038/nrmicro2592; Alan JK, 2010, MOL CELL BIOL, V30, P4324, DOI 10.1128/MCB.01646-09; Albertinazzi C, 2003, MOL BIOL CELL, V14, P1295, DOI 10.1091/mbc.E02-07-0406; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Berzat AC, 2005, J BIOL CHEM, V280, P33055, DOI 10.1074/jbc.M507362200; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Boquet P, 2003, TRENDS CELL BIOL, V13, P238, DOI 10.1016/S0962-8924(03)00037-0; Boulter Etienne, 2010, Small GTPases, V1, P65; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Boyer L, 2006, MOL BIOL CELL, V17, P2489, DOI 10.1091/mbc.E05-09-0876; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004; Chenette EJ, 2005, J BIOL CHEM, V280, P13784, DOI 10.1074/jbc.M411300200; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cushman I, 2009, J BIOL CHEM, V284, P27964, DOI 10.1074/jbc.M109.025296; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Fairn GD, 2011, NAT CELL BIOL, V13, P1424, DOI 10.1038/ncb2351; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Guilluy C, 2011, TRENDS CELL BIOL, V21, P718, DOI 10.1016/j.tcb.2011.08.002; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Heo J, 2005, J BIOL CHEM, V280, P31003, DOI 10.1074/jbc.M504768200; Heo JY, 2006, BIOCHEMISTRY-US, V45, P14481, DOI 10.1021/bi0610101; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kovacic HN, 2001, J BIOL CHEM, V276, P45856, DOI 10.1074/jbc.M107925200; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lane KT, 2006, J LIPID RES, V47, P681, DOI 10.1194/jlr.R600002-JLR200; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nethe M, 2010, J CELL SCI, V123, P1948, DOI 10.1242/jcs.062919; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2005, EMBO J, V24, P1170, DOI 10.1038/sj.emboj.7600612; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rosenfeldt Hans, 2006, J Mol Signal, V1, P8, DOI 10.1186/1750-2187-1-8; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Savoia C, 2005, J HYPERTENS, V23, P1037, DOI 10.1097/01.hjh.0000166845.49850.39; Schwamborn JC, 2007, EMBO J, V26, P1410, DOI 10.1038/sj.emboj.7601580; Sorg I, 2001, INFECT IMMUN, V69, P7535, DOI 10.1128/IAI.69.12.7535-7543.2001; Stamatakis K, 2002, J BIOL CHEM, V277, P49389, DOI 10.1074/jbc.M204049200; Stevens Ellen V, 2011, Small GTPases, V2, P202; Tillement V, 2008, EXP CELL RES, V314, P2811, DOI 10.1016/j.yexcr.2008.06.011; Tkachenko E, 2011, NAT CELL BIOL, V13, P660, DOI 10.1038/ncb2231; Tu S, 2003, J BIOL CHEM, V278, P49293, DOI 10.1074/jbc.M307021200; Visvikis O, 2010, BIOL CELL, V102, P377, DOI 10.1042/BC20090151; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wherlock M, 2002, J CELL SCI, V115, P239; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Zimmerman ES, 2010, CURR OPIN STRUC BIOL, V20, P714, DOI 10.1016/j.sbi.2010.08.010	88	28	29	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					469	479		10.1096/fj.11-192252	http://dx.doi.org/10.1096/fj.11-192252			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038046				2022-12-28	WOS:000300485700001
J	Pessemesse, L; Schlernitzauer, A; Sar, C; Levin, J; Grandemange, S; Seyer, P; Favier, FB; Kaminski, S; Cabello, G; Wrutniak-Cabello, C; Casas, F				Pessemesse, Laurence; Schlernitzauer, Audrey; Sar, Chamroeun; Levin, Jonathan; Grandemange, Stephanie; Seyer, Pascal; Favier, Francois B.; Kaminski, Sandra; Cabello, Gerard; Wrutniak-Cabello, Chantal; Casas, Francois			Depletion of the p43 mitochondrial T3 receptor in mice affects skeletal muscle development and activity	FASEB JOURNAL			English	Article						metabolism; thyroid hormone	REGULATES MYOBLAST DIFFERENTIATION; MYOSIN ISOFORM EXPRESSION; HEAVY-CHAIN ISOFORMS; RESPIRATORY-CHAIN; PROTEIN-SYNTHESIS; OVEREXPRESSION; EXERCISE; SOLEUS; RNA	In vertebrates, skeletal muscle myofibers display different contractile and metabolic properties associated with different mitochondrial content and activity. We have previously identified a mitochondrial triiodothyronine receptor (p43) regulating mitochondrial transcription and mitochondrial biogenesis. When overexpressed in skeletal muscle, it increases mitochondrial DNA content, stimulates mitochondrial respiration, and induces a shift in the metabolic and contractile features of muscle fibers toward a slower and more oxidative phenotype. Here we show that a p43 depletion in mice decreases mitochondrial DNA replication and respiratory chain activity in skeletal muscle in association with the induction of a more glycolytic muscle phenotype and a decrease of capillary density. In addition, p43(-/-) mice displayed a significant increase in muscle mass relative to control animals and had an improved ability to use lipids. Our findings establish that the p43 mitochondrial receptor strongly affects muscle mass and the metabolic and contractile features of myofibers and provides evidence that this receptor mediates, in part, the influence of thyroid hormone in skeletal muscle.-Pessemesse, L., Schlernitzauer, A., Sar, C., Levin, J., Grandemange, S., Seyer, P., Favier, F. B., Kaminski, S., Cabello, G., Wrutniak-Cabello, C., Casas, F. Depletion of the p43 mitochondrial T3 receptor in mice affects skeletal muscle development and activity. FASEB J. 26, 748-756 (2012). www.fasebj.org	[Pessemesse, Laurence; Schlernitzauer, Audrey; Levin, Jonathan; Grandemange, Stephanie; Seyer, Pascal; Favier, Francois B.; Kaminski, Sandra; Cabello, Gerard; Wrutniak-Cabello, Chantal; Casas, Francois] INRA, UMR 866 Dynam Musculaire & Metab, Unite Mixte Rech, F-34060 Montpellier, France; [Pessemesse, Laurence; Schlernitzauer, Audrey; Sar, Chamroeun; Levin, Jonathan; Grandemange, Stephanie; Seyer, Pascal; Favier, Francois B.; Kaminski, Sandra; Cabello, Gerard; Wrutniak-Cabello, Chantal; Casas, Francois] Univ Montpellier I, Montpellier, France; [Pessemesse, Laurence; Schlernitzauer, Audrey; Sar, Chamroeun; Levin, Jonathan; Grandemange, Stephanie; Seyer, Pascal; Favier, Francois B.; Kaminski, Sandra; Cabello, Gerard; Wrutniak-Cabello, Chantal; Casas, Francois] Univ Montpellier 2, F-34060 Montpellier, France; [Sar, Chamroeun] INSERM, Hopital St Eloi 80, Inst Neurosci Montpellier, Montpellier, France	INRAE; Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Casas, F (corresponding author), INRA, UMR 866 Dynam Musculaire & Metab, Unite Mixte Rech, 2 Pl Viala, F-34060 Montpellier, France.	casasf@supagro.inra.fr	Grandemange, Stéphanie/G-7928-2015; Kaminski, Sandra/AAM-6134-2021; Levin, Jonathan/N-3189-2018	Favier, Francois/0000-0002-9084-4797; Francois, Casas/0000-0002-5535-8195	Institut National de la Recherche Agronomique; Agence Nationale de la Recherche (ANR MitHyCal); Association Francaise contre les Myopathies	Institut National de la Recherche Agronomique; Agence Nationale de la Recherche (ANR MitHyCal)(French National Research Agency (ANR)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	The authors thank the animal staff for animal care. The authors thank Chantal Cazevieille (Clinical Research Imaging Centre, Montpellier, France) for technical assistance and interpreting data concerning ultrastructural evaluation. This work was supported by grants from the Institut National de la Recherche Agronomique, Agence Nationale de la Recherche (ANR MitHyCal), and Association Francaise contre les Myopathies.	AUSONI S, 1990, J NEUROSCI, V10, P153; Blanchet E, 2012, FASEB J, V26, P40, DOI 10.1096/fj.11-186841; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BUTLERBROWNE GS, 1984, FEBS LETT, V166, P71, DOI 10.1016/0014-5793(84)80047-2; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005631; Casas F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002501; ENGLAND JM, 1978, J MOL BIOL, V119, P455, DOI 10.1016/0022-2836(78)90226-7; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873; KING DB, 1987, J EXP ZOOL, P291; LANSMAN RA, 1975, J MOL BIOL, V99, P777, DOI 10.1016/S0022-2836(75)80184-7; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MATHIEUCOSTELLO O, 1991, AM J PHYSIOL, V261, pH1617, DOI 10.1152/ajpheart.1991.261.5.H1617; MCDONALD KS, 1992, J APPL PHYSIOL, V73, P1135, DOI 10.1152/jappl.1992.73.3.1135; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Pelletier P, 2008, ENDOCRINOLOGY, V149, P6471, DOI 10.1210/en.2008-0718; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Seyer P, 2006, J CELL PHYSIOL, V207, P75, DOI 10.1002/jcp.20539; Seyer P, 2011, EXP CELL RES, V317, P2059, DOI 10.1016/j.yexcr.2011.05.020; SUGIE H, 1985, MUSCLE NERVE, V8, P654, DOI 10.1002/mus.880080805; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wharton DC., 1967, METHOD ENZYMOL, P245; Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067; Yu FS, 2000, AM J PHYSIOL-REG I, V278, pR1545, DOI 10.1152/ajpregu.2000.278.6.R1545; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	33	40	40	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					748	756		10.1096/fj.11-195933	http://dx.doi.org/10.1096/fj.11-195933			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22109994	Green Submitted			2022-12-28	WOS:000300485700026
J	Jang, C; Choi, JK; Na, YJ; Jang, B; Wasco, W; Buxbaum, JD; Kim, YS; Choi, EK				Jang, Changhwan; Choi, Jin-Kyu; Na, Yeo-Jung; Jang, Byungki; Wasco, Wilma; Buxbaum, Joseph D.; Kim, Yong-Sun; Choi, Eun-Kyoung			Calsenilin regulates presenilin 1/gamma-secretase-mediated N-cadherin epsilon-cleavage and beta-catenin signaling	FASEB JOURNAL			English	Article						adhesion molecule; SH-SY5Y neuroblastoma cells	GAMMA-SECRETASE COMPLEX; CELL-CELL ADHESION; AMYLOID PRECURSOR PROTEIN; TRANS-GOLGI NETWORK; C-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REPRESSOR; NUCLEAR TRANSLOCATION; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE	Presenilin 1 (PS1) is a component of the gamma-secretase complex that cleaves a variety of type I membrane proteins, including the beta-amyloid precursor protein (beta-APP), Notch, and neuronal (N)- and epithelial (E)-cadherins. N-cadherin is an essential adhesion molecule that forms a complex with, and is cleaved by, PS1/gamma-secretase and beta-catenin in the plasma membrane. The purpose of this study was to determine whether calsenilin, a presenilin-interacting protein, has a functional role in PS1/gamma-secretase-mediated N-cadherin epsilon-cleavage using Western blot analysis, RT-PCR, immunoprecipitation, subcellular fractionation, biotinylation, and a luciferase reporter assay in SH-SY5Y neuroblastoma cells. Here, we demonstrate that the expression of calsenilin leads to a disruption of PS1/gamma-secretase-mediated epsilon-cleavage of N-cadherin, which results in the significant accumulation of N-cadherin C-terminal fragment 1 (Ncad/CTF1), the reduction of cytoplasmic Ncad/CTF2 release, and a deceleration of PS1-CTF delivery to the cell surface. Interestingly, we also found that the expression of calsenilin is associated with the redistribution of beta-catenin from the cell surface to a cytoplasmic pool, as well as with the negative regulation of genes that are targets of T-cell factor/beta-catenin nuclear signaling. Taken together, our findings suggest that calsenilin is a novel negative regulator of N-cadherin processing that plays an important role in beta-catenin signaling.-Jang, C., Choi, J.-K., Na, Y.-J., Jang, B., Wasco, W., Buxbaum, J. D., Kim, Y.-S., Choi, E.-K. Calsenilin regulates presenilin 1/gamma-secretase-mediated N-cadherin epsilon-cleavage and beta-catenin signaling. FASEB J. 25, 4174-4183 (2011). www.fasebj.org	[Choi, Eun-Kyoung] Hallym Univ, Ilsong Inst Life Sci, Lab Cellular Aging & Neurodegenerat, Anyang 431060, Gyeonggi Do, South Korea; [Jang, Changhwan; Kim, Yong-Sun] Hallym Univ, Coll Med, Dept Microbiol, Chunchon, South Korea; [Wasco, Wilma] Harvard Univ, Sch Med, Mass Gen Inst Neurodegenerat Dis, Massachusetts Gen Hosp,Genet & Aging Res Unit,Dep, Charlestown, MA USA; [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat & Neurobiol, Lab Mol Neuropsychiat, New York, NY USA	Hallym University; Hallym University; Harvard University; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai	Choi, EK (corresponding author), Hallym Univ, Ilsong Inst Life Sci, Lab Cellular Aging & Neurodegenerat, 1605-4 Gwanyang Dong, Anyang 431060, Gyeonggi Do, South Korea.	ekchoi@hallym.ac.kr	Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313	National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0006204]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	The authors thank Dr. J. H. Boo (Seoul National University, Seoul, Korea) and Dr. H. G. Lee (Case Western Reserve University, Cleveland, OH, USA) for technical advice and helpful discussions. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0006204).	Abe K, 2007, NEURON, V53, P387, DOI 10.1016/j.neuron.2007.01.016; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Bamji SX, 2003, NEURON, V40, P719, DOI 10.1016/S0896-6273(03)00718-9; Bard L, 2008, J NEUROSCI, V28, P5879, DOI 10.1523/JNEUROSCI.5331-07.2008; Bekirov IH, 2008, HIPPOCAMPUS, V18, P349, DOI 10.1002/hipo.20395; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Caspi E, 2008, MOL BIOL CELL, V19, P4660, DOI 10.1091/mbc.E07-10-1046; Chen Q, 2005, J NEUROSCI, V25, P281, DOI 10.1523/JNEUROSCI.3692-04.2005; Choi EK, 2001, J BIOL CHEM, V276, P19197, DOI 10.1074/jbc.M008597200; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dries DR, 2008, CURR ALZHEIMER RES, V5, P132, DOI 10.2174/156720508783954695; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fontan-Lozano A, 2009, CURR BIOL, V19, P54, DOI 10.1016/j.cub.2008.11.056; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Grimm HS, 2003, J BIOL CHEM, V278, P13077, DOI 10.1074/jbc.M210380200; Hong YM, 2003, NEUROSCI LETT, V340, P33, DOI 10.1016/S0304-3940(03)00067-3; Huntley GW, 2002, CELL, V108, P1, DOI 10.1016/S0092-8674(01)00631-6; Jang C, 2011, BIOCHEM BIOPH RES CO, V405, P180, DOI 10.1016/j.bbrc.2010.12.137; Jang YN, 2009, J NEUROSCI, V29, P5974, DOI 10.1523/JNEUROSCI.6178-08.2009; Jin JK, 2005, NEUROREPORT, V16, P451, DOI 10.1097/00001756-200504040-00007; Jo DG, 2005, NEUROSCI LETT, V378, P59, DOI 10.1016/j.neulet.2004.12.078; Jo DG, 2004, J NEUROCHEM, V88, P604, DOI 10.1046/j.1471-4159.2003.02159.x; Jo DG, 2001, FASEB J, V15, P589; Kashiwa A, 2000, J NEUROCHEM, V75, P109, DOI 10.1046/j.1471-4159.2000.0750109.x; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kim BH, 2005, NEUROREPORT, V16, P425, DOI 10.1097/00001756-200504040-00002; Kiss A, 2008, MOL BIOL CELL, V19, P4042, DOI 10.1091/mbc.E08-04-0394; Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kouchi Z, 2009, J BIOL CHEM, V284, P1954, DOI 10.1074/jbc.M806250200; Lilliehook C, 2003, J NEUROSCI, V23, P9097; Lilliehook C, 2002, MOL CELL NEUROSCI, V19, P552, DOI 10.1006/mcne.2001.1096; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Namekata K, 2004, J BIOL CHEM, V279, P14331, DOI 10.1074/jbc.M311275200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Polakis P, 2000, GENE DEV, V14, P1837; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Rubio ME, 2005, MOL CELL NEUROSCI, V30, P118, DOI 10.1016/j.mcn.2005.06.005; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2008, J BIOL CHEM, V283, P34677, DOI 10.1074/jbc.M709067200; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Uemura K, 2006, NEUROSCI LETT, V402, P278, DOI 10.1016/j.neulet.2006.04.018; Uemura K, 2006, BIOCHEM BIOPH RES CO, V345, P951, DOI 10.1016/j.bbrc.2006.04.157; Uemura K, 2009, J NEUROCHEM, V108, P350, DOI 10.1111/j.1471-4159.2008.05760.x; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Zaidi NF, 2004, J NEUROCHEM, V89, P593, DOI 10.1046/j.1471-4159.2004.02362.x	67	22	22	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4174	4183		10.1096/fj.11-185926	http://dx.doi.org/10.1096/fj.11-185926			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21852538				2022-12-28	WOS:000298138100011
J	Alejandro, EU; Lim, GE; Mehran, AE; Hu, XK; Taghizadeh, F; Pelipeychenko, D; Baccarini, M; Johnson, JD				Alejandro, Emilyn U.; Lim, Gareth E.; Mehran, Arya E.; Hu, Xiaoke; Taghizadeh, Farnaz; Pelipeychenko, Dmytro; Baccarini, Manuela; Johnson, James D.			Pancreatic beta-cell Raf-1 is required for glucose tolerance, insulin secretion, and insulin 2 transcription	FASEB JOURNAL			English	Article						knockout mouse models; diabetes; growth factor signaling	PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-TRANSCRIPTION; C-RAF-1 GENE; MICE LACKING; SYNAPSIN-I; APOPTOSIS; EXPRESSION; GROWTH; ACTIVATION	Regulation of glucose homeostasis by insulin depends on pancreatic beta-cell growth, survival, and function. Raf-1 kinase is a major downstream target of several growth factors that promote proliferation and survival of many cell types, including the pancreatic beta cells. We have previously reported that insulin protects beta cells from apoptosis and promotes proliferation by activating Raf-1 signaling in cultured human islets, mouse islets, and MIN6 cells. As Raf-1 activity is critical for basal apoptosis and insulin secretion in vitro, we hypothesized that Raf-1 may play an important role in glucose homeostasis in vivo. To test this hypothesis, we utilized the Cre-loxP recombination system to obtain a pancreatic beta-cell-specific ablation of Raf-1 kinase gene (RIPCre(+/+):Raf-1(flox/flox)) and a complete set of littermate controls (RIPCre(+/+):Raf-1(wt/wt)). RIPCre(+/+):Raf-1(flox/flox) mice were viable, and no effects on weight gain were observed. RIPCre(+/+):Raf-1(flox/flox) mice had increased fasting blood glucose levels and impaired glucose tolerance but normal insulin tolerance compared to littermate controls. Insulin secretion in vivo and in isolated islets was markedly impaired, but there was no apparent effect on the exocytosis machinery. However, islet insulin protein and insulin 2 mRNA, but not insulin 1 mRNA, were dramatically reduced in Raf-1-knockout mice. Analysis of insulin 2 knockout mice demonstrated that this reduction in mRNA was sufficient to impair in vivo insulin secretion. Our data further indicate that Raf-1 specifically and acutely regulates insulin 2 mRNA via negative action on Foxo1, which has been shown to selectively control the insulin 2 gene. This work provides the first direct evidence that Raf-1 signaling is essential for the regulation of basal insulin transcription and the supply of releasable insulin in vivo.-Alejandro, E. U., Lim, G. E., Mehran, A. E., Hu, X., Taghizadeh, F., Pelipeychenko, D., Baccarini, M., Johnson, J. D. Pancreatic beta-cell Raf-1 is required for glucose tolerance, insulin secretion, and insulin 2 transcription. FASEB J. 25, 3884-3895 (2011). www.fasebj.org	[Alejandro, Emilyn U.; Lim, Gareth E.; Mehran, Arya E.; Hu, Xiaoke; Taghizadeh, Farnaz; Pelipeychenko, Dmytro; Johnson, James D.] Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Lab Mol Signalling Diabet, Vancouver, BC V6T 1Z3, Canada; [Alejandro, Emilyn U.; Lim, Gareth E.; Mehran, Arya E.; Hu, Xiaoke; Taghizadeh, Farnaz; Pelipeychenko, Dmytro; Johnson, James D.] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1Z3, Canada; [Baccarini, Manuela] Univ Vienna, Max F Perutz Labs, Vienna, Austria	University of British Columbia; University of British Columbia; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Johnson, JD (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Diabet Res Grp, Lab Mol Signalling Diabet, 5358 Life Sci Bldg,2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	jimjohn@interchange.ubc.ca	Baccarini, Manuela/B-6481-2014; Lim, Gareth/G-9143-2017	Baccarini, Manuela/0000-0002-3033-391X; Alejandro, Emilyn/0000-0002-7941-8439; Lim, Gareth/0000-0003-3850-3757	Juvenile Research Foundation (JDRF); Canadian Diabetes Association; Canadian Institutes for Health Research (CIHR); U.S. National Institutes of Health [F31DK079346]; University of British Columbia; Michael Smith Foundation for Health Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK079346] Funding Source: NIH RePORTER	Juvenile Research Foundation (JDRF)(Juvenile Diabetes Research Foundation); Canadian Diabetes Association; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of British Columbia; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Rong Liang for technical assistance. This work was supported by a regular research grant from the Juvenile Research Foundation (JDRF). J.D.J. was supported by salary awards from the JDRF, Canadian Diabetes Association, and the Canadian Institutes for Health Research (CIHR). E.U.A. was supported by scholarships from the U.S. National Institutes of Health (F31DK079346) and the University of British Columbia. G.E.L. was supported by fellowships from the CIHR and the Michael Smith Foundation for Health Research. E.U.A and G.E.L. performed the experiments, analyzed data, and wrote and edited the manuscript. F.T., A.E.M., X.H., and D.P. performed experiments and analyzed the data. M.B. contributed to discussion and edited the manuscript. J.D.J. conceived the study and wrote and edited the manuscript.	Alejandro EU, 2008, J BIOL CHEM, V283, P2407, DOI 10.1074/jbc.M703612200; Alejandro EU, 2010, ENDOCRINOLOGY, V151, P502, DOI 10.1210/en.2009-0678; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Beith JL, 2008, ENDOCRINOLOGY, V149, P2251, DOI 10.1210/en.2007-1557; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bernal-Mizrachi E, 2004, J CLIN INVEST, V114, P928, DOI 10.1172/JCI200420016; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Dror V, 2007, DIABETOLOGIA, V50, P2504, DOI 10.1007/s00125-007-0835-5; Duan LL, 2010, P NATL ACAD SCI USA, V107, P22314, DOI 10.1073/pnas.1016630108; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Elghazi L, 2007, DIABETES OBES METAB, V9, P147, DOI 10.1111/j.1463-1326.2007.00783.x; Fex M, 2007, J ENDOCRINOL, V194, P551, DOI 10.1677/JOE-07-0161; Fontes G, 2009, DIABETES, V58, P2048, DOI 10.2337/db08-0579; Galabova-Kovacs G, 2006, CELL CYCLE, V5, P1514, DOI 10.4161/cc.5.14.2981; Gu CY, 2010, CELL METAB, V11, P298, DOI 10.1016/j.cmet.2010.03.006; Hay CW, 2006, DIABETES, V55, P3201, DOI 10.2337/db06-0788; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Jeffrey KD, 2008, P NATL ACAD SCI USA, V105, P8452, DOI 10.1073/pnas.0711232105; Johnson JD, 2008, CELL CYCLE, V7, P1343, DOI 10.4161/cc.7.10.5865; Johnson JD, 2006, P NATL ACAD SCI USA, V103, P19575, DOI 10.1073/pnas.0604208103; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kaneko K, 2010, CELL METAB, V12, P619, DOI 10.1016/j.cmet.2010.11.005; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kowluru A, 2010, DIABETES, V59, P967, DOI 10.2337/db09-1334; Lawrence MC, 2005, J BIOL CHEM, V280, P26751, DOI 10.1074/jbc.M503158200; Lawrence MC, 2008, P NATL ACAD SCI USA, V105, P13315, DOI 10.1073/pnas.0806465105; Lee JY, 2006, J BIOL CHEM, V281, P2649, DOI 10.1074/jbc.M512373200; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Leibiger IB, 2008, ANNU REV NUTR, V28, P233, DOI 10.1146/annurev.nutr.28.061807.155530; Leroux L, 2001, DIABETES, V50, pS150, DOI 10.2337/diabetes.50.2007.S150; Longuet C, 2005, ENDOCRINOLOGY, V146, P643, DOI 10.1210/en.2004-0841; Luciani DS, 2005, MOL CELL ENDOCRINOL, V241, P88, DOI 10.1016/j.mce.2005.06.006; Madadi G, 2008, BIOCHEM BIOPH RES CO, V376, P694, DOI 10.1016/j.bbrc.2008.09.054; Matsumoto K, 1999, J BIOL CHEM, V274, P2053, DOI 10.1074/jbc.274.4.2053; MEUR G, J BIOL CHEM, V286, P13647; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Montiel C, 2003, J NEUROSCI RES, V71, P353, DOI 10.1002/jnr.10499; Nelson JD, 2011, DIABETES, V60, P127, DOI 10.2337/db09-1806; Niault T, 2009, J CELL BIOL, V187, P335, DOI 10.1083/jcb.200906178; Okada T, 2007, P NATL ACAD SCI USA, V104, P8977, DOI 10.1073/pnas.0608703104; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Ueki K, 2006, NAT GENET, V38, P583, DOI 10.1038/ng1787; Wang HJ, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-66; Wang ZX, 2009, J CELL SCI, V122, P893, DOI 10.1242/jcs.034355; Wicksteed B, 2010, DIABETES, V59, P3090, DOI 10.2337/db10-0624; Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317; Yokomaku D, 2003, MOL ENDOCRINOL, V17, P831, DOI 10.1210/me.2002-0314; Ziegler CG, 2008, ENDOCRINOLOGY, V149, P320, DOI 10.1210/en.2007-0645	52	31	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3884	3895		10.1096/fj.10-180349	http://dx.doi.org/10.1096/fj.10-180349			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21817126	Green Published			2022-12-28	WOS:000296723100013
J	Cohen, B; Dai, MJ; Ogorodnikov, D; Laurens, J; Raphan, T; Muller, P; Athanasios, A; Edmaier, J; Grossenbacher, T; Stadtmuller, K; Brugger, U; Hauser, G; Straumann, D				Cohen, Bernard; Dai, Mingjia; Ogorodnikov, Dmitri; Laurens, Jean; Raphan, Theodore; Mueller, Philippe; Athanasios, Alexiou; Edmaier, Juergen; Grossenbacher, Thomas; Stadtmueller, Klaus; Brugger, Ueli; Hauser, Gerald; Straumann, Dominik			Motion sickness on tilting trains	FASEB JOURNAL			English	Article						linear acceleration; angular acceleration; roll while rotating	VESTIBULOOCULAR REFLEX; ROLL OSCILLATION	Trains that tilt on curves can go faster, but passengers complain of motion sickness. We studied the control signals and tilts to determine why this occurs and how to maintain speed while eliminating motion sickness. Accelerometers and gyros monitored train and passenger yaw and roll, and a survey evaluated motion sickness. The experimental train had 3 control configurations: an untilted mode, a reactive mode that detected curves from sensors on the front wheel set, and a predictive mode that determined curves from the train's position on the tracks. No motion sickness was induced in the untilted mode, but the train ran 21% slower than when it tilted 8 degrees in either the reactive or predictive modes (113 vs. 137 km/h). Roll velocities rose and fell faster in the predictive than the reactive mode when entering and leaving turns (0.4 vs. 0.8 s for a 4 degrees/s roll tilt, P<0.001). Concurrently, motion sickness was greater (P<0.001) in the reactive mode. We conclude that the slower rise in roll velocity during yaw rotations on entering and leaving curves had induced the motion sickness. Adequate synchronization of roll tilt with yaw velocity on curves will reduce motion sickness and improve passenger comfort on tilting trains.-Cohen, B., Dai, M., Ogorodnikov, D., Laurens, J., Raphan, T., Muller, P., Athanasios, A., Edmaier, J., Grossenbacher, T., Stadtmuller, K., Brugger, U., Hauser, G., Straumann, D. Motion sickness on tilting trains. FASEB J. 25, 3765-3774 (2011). www.fasebj.org	[Cohen, Bernard; Dai, Mingjia; Ogorodnikov, Dmitri] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Laurens, Jean; Straumann, Dominik] Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland; [Raphan, Theodore] CUNY Brooklyn Coll, Dept Comp & Informat Sci, Brooklyn, NY 11210 USA; [Mueller, Philippe; Athanasios, Alexiou; Edmaier, Juergen; Grossenbacher, Thomas; Stadtmueller, Klaus] Schweizer Bundesbahnen, Bern, Switzerland; [Brugger, Ueli; Hauser, Gerald] Alstom Schienenfahrzeuge AG, Neuhausen, Switzerland	Icahn School of Medicine at Mount Sinai; University of Zurich; University Zurich Hospital; City University of New York (CUNY) System; Brooklyn College (CUNY); Alstom	Cohen, B (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1135,1 Gustav L Levy Pl, New York, NY 10029 USA.	bernard.cohen@mssm.edu			Schweizerische Bundes-bahnen; U.S. National Institute on Deafness and Other Communciation Disorders [DC007847, DC05204]; Swiss National Science Foundation; Center for Integrative Human Physiology, University of Zurich; Koetser Foundation for Brain Research; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC005204, R01DC007847] Funding Source: NIH RePORTER	Schweizerische Bundes-bahnen; U.S. National Institute on Deafness and Other Communciation Disorders; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Center for Integrative Human Physiology, University of Zurich; Koetser Foundation for Brain Research; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This study was supported by the Schweizerische Bundes-bahnen; U.S. National Institute on Deafness and Other Communciation Disorders grants DC007847 and DC05204; the Swiss National Science Foundation; the Center for Integrative Human Physiology, University of Zurich; and the Koetser Foundation for Brain Research. The authors thank the following colleagues for their help in performing these experiments and preparing the manuscript: Christopher J. Bockisch (Department of Neurology, Otolaryngology, and Ophthalmology, Zurich University Hospital, Zurich, Switzerland) and Marco Penner (Department of Neurology, Zurich University Hospital). The authors also thank Mildred Mora and Sergey Tarasenko for their technical support.	Andersson E, 1995, P I MECH ENG F-J RAI, V209, P93, DOI 10.1243/PIME_PROC_1995_209_261_02; Andersson E, 1996, VEHICLE SYST DYN, V25, P37, DOI 10.1080/00423119608969186; Barnett R., 1992, 113 U CAL TRANSP CTR; Cohen B., 2010, J VESTIBUL RES-EQUIL, V20, P212; Dai MJ, 2011, EXP BRAIN RES, V210, P503, DOI 10.1007/s00221-011-2548-8; Dai MJ, 2010, EXP BRAIN RES, V204, P207, DOI 10.1007/s00221-010-2305-4; Dai MJ, 2009, EXP BRAIN RES, V195, P553, DOI 10.1007/s00221-009-1825-2; Dai MJ, 2003, EXP BRAIN RES, V151, P173, DOI 10.1007/s00221-003-1479-4; Donohew B. E., 2008, AVIAT SPACE ENV MED, V75, P649; Donohew BE, 2010, AVIAT SPACE ENVIR MD, V81, P22, DOI 10.3357/ASEM.2555.2010; Donohew BE, 2009, AVIAT SPACE ENVIR MD, V80, P94, DOI 10.3357/ASEM.2345.2009; Ebeling K., 2005, JAPAN RAILWAY TRANSP, V40, P36; Forstberg J, 1998, BRAIN RES BULL, V47, P525, DOI 10.1016/S0361-9230(98)00097-5; Forstberg J, 2000, MOTION RELATED COMFO; Forstberg J., 2005, NORDIC FIELD TEST TI; Golding JF, 1997, AVIAT SPACE ENVIR MD, V68, P396; GOLDING JF, 1995, AVIAT SPACE ENVIR MD, V66, P1046; Golding JF, 2005, CURR OPIN NEUROL, V18, P29, DOI 10.1097/00019052-200502000-00007; GOLDING JF, 1992, AVIAT SPACE ENVIR MD, V63, P491; Goodall R.M., 2000, P RAILW TECHN C IMEC, P231; Guedry F. E., 1974, VESTIBULAR SYSTEM PA, VVI, P3; Hauser G, 2006, LERAIL, V129, P6; Joseph JA, 2007, AVIAT SPACE ENVIR MD, V78, P944, DOI 10.3357/ASEM.2043.2007; Kortum W., 1993, MECHANTRONIC DEV RAI; Lyne L., 1997, THESIS MIT BOSTON; MILLER EF, 1970, ACTA OTO-LARYNGOL, P1; MILLER EF, 1970, AEROSPACE MED, V41, P1180; Neimer J, 2001, CURR BIOL, V11, pR549, DOI 10.1016/S0960-9822(01)00339-6; Persson R., 2008, 614A VTI; Raphan T, 2002, EXP BRAIN RES, V145, P1, DOI 10.1007/s00221-002-1067-z; Raphan T, 1996, ANN NY ACAD SCI, V781, P348, DOI 10.1111/j.1749-6632.1996.tb15712.x; Sasaki K., 2000, RAILWAY TECH RES I, V41, P11; Union Internationale des Chemins de Fer, 1998, TILT TRAIN TECHN STA; Wearne S, 1999, J NEUROPHYSIOL, V81, P2175, DOI 10.1152/jn.1999.81.5.2175; Young LR, 2003, J VESTIBUL RES-EQUIL, V13, P65; Young-Jae Han, 2008, 2008 International Conference on Control, Automation and Systems (ICCAS), P1518, DOI 10.1109/ICCAS.2008.4694382; Zaidi K., 2007, TEMP J SCI TECH ENV, V26, P301; Zolotas A, 2006, P AMER CONTR CONF, V1-12, P1796, DOI 10.1109/ACC.2006.1656480	38	12	12	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3765	3774		10.1096/fj.11-184887	http://dx.doi.org/10.1096/fj.11-184887			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21788449	Green Published			2022-12-28	WOS:000296723100003
J	Millson, SH; Chua, CS; Roe, SM; Polier, S; Solovieva, S; Pearl, LH; Sim, TS; Prodromou, C; Piper, PW				Millson, Stefan H.; Chua, Chun-Song; Roe, S. Mark; Polier, Sigrun; Solovieva, Svetlana; Pearl, Laurence H.; Sim, Tiow-Suan; Prodromou, Chrisostomos; Piper, Peter W.			Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90	FASEB JOURNAL			English	Article						cancer drug resistance; yeast; Plasmodium falciparum; TRAP1; macbecin	SHOCK-PROTEIN 90; MOLECULAR CHAPERONE; NAD(P)H-QUINONE OXIDOREDUCTASE-1; BENZOQUINONE ANSAMYCINS; STRUCTURAL BASIS; INHIBITORS; EXPRESSION; CANCER; CELLS; YEAST	Much attention is focused on the benzoquinone ansamycins as anticancer agents, with several derivatives of the natural product geldanamycin (GdA) now in clinical trials. These drugs are selective inhibitors of Hsp90, a molecular chaperone vital for many of the activities that drive cancer progression. Mutational changes to their interaction site, the extremely conserved ATP binding site of Hsp90, would mostly be predicted to inactivate the chaperone. As a result, drug resistance should not arise readily this way. Nevertheless, Streptomyces hygroscopicus, the actinomycete that produces GdA, has evolved an Hsp90 family protein (HtpG) that lacks GdA binding. It is altered in certain of the highly conserved amino acids making contacts to this antibiotic in crystal structures of GdA bound to eukaryotic forms of Hsp90. Two of these amino acid changes, located on one side of the nucleotide-binding cleft, weakened GdA/Hsp90 binding and conferred partial GdA resistance when inserted into the endogenous Hsp90 of yeast cells. Crystal structures revealed their main effect to be a weakening of interactions with the C-12 methoxy group of the GdA ansamycin ring. This is the first study to demonstrate that partial GdA resistance is possible by mutation within the ATP binding pocket of Hsp90.-Millson, S. H., Chua, C.-S., Roe, S. M., Polier, S., Solovieva, S., Pearl, L. H., Sim, T.-S., Prodromou, C., Piper, P. W. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90. FASEB J. 25, 3828-3837 (2011). www.fasebj.org	[Piper, Peter W.] Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [Chua, Chun-Song; Sim, Tiow-Suan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore; [Roe, S. Mark; Polier, Sigrun; Pearl, Laurence H.; Prodromou, Chrisostomos] Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sheffield; National University of Singapore; University of Sussex	Piper, PW (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	chris.prodromou@sussex.ac.uk; peter.piper@sheffield.ac.uk	Prodromou, Chrisostomos/ABA-9133-2021	Prodromou, Chrisostomos/0000-0003-4320-1147; Millson, Stefan/0000-0001-5989-5759; Roe, Mark/0000-0002-7371-9855; Piper, Peter William/0000-0003-4019-2329; Pearl, Laurence/0000-0002-6910-1809	Cancer Research UK [C28248/A9058, C309/A8274]; Sir Stewart Halley Trust; Yorkshire Cancer Research	Cancer Research UK(Cancer Research UK); Sir Stewart Halley Trust; Yorkshire Cancer Research	This work was supported by Cancer Research UK project (C28248/A9058, C309/A8274) grants, the Sir Stewart Halley Trust, and Yorkshire Cancer Research. The authors are indebted to Swee Sharp and Paul Workman (Institute of Cancer Research, London, UK) for providing NVP-AUY922 and VER49009.	Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h; Chen B, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-156; Corbett KD, 2010, PROTEINS, V78, P2738, DOI 10.1002/prot.22799; David CL, 2003, CELL STRESS CHAPERON, V8, P93, DOI 10.1379/1466-1268(2003)8<93:EOAUDH>2.0.CO;2; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Gaspar N, 2009, CANCER RES, V69, P1966, DOI 10.1158/0008-5472.CAN-08-3131; Guo WC, 2005, CANCER RES, V65, P10006, DOI 10.1158/0008-5472.CAN-05-2029; Guo WC, 2006, MOL PHARMACOL, V70, P1194, DOI 10.1124/mol.106.025643; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kang MJ, 2010, J IND MICROBIOL BIOT, V37, P35, DOI 10.1007/s10295-009-0641-9; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Krissinel EB, 2004, ACTA CRYSTALLOGR D, V60, P2250, DOI 10.1107/S0907444904027167; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; Martin CJ, 2008, J MED CHEM, V51, P2853, DOI 10.1021/jm701558c; McCollum AK, 2008, CANCER RES, V68, P7419, DOI 10.1158/0008-5472.CAN-07-5175; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; McDonald E, 2006, CURR TOP MED CHEM, V6, P1193, DOI 10.2174/156802606777812086; McDonald E, 2006, CURR TOP MED CHEM, V6, P1091, DOI 10.2174/156802606777812004; Millson SH, 2010, BIOCHEM PHARMACOL, V79, P1581, DOI 10.1016/j.bcp.2010.01.031; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; PARDO JM, 1985, J GEN MICROBIOL, V131, P1289; Piper PW, 2003, GENE, V302, P165, DOI 10.1016/S0378-1119(02)01102-2; Porter JR, 2009, CURR TOP MED CHEM, V9, P1386, DOI 10.2174/156802609789895719; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2009, ACS CHEM BIOL, V4, P289, DOI 10.1021/cb9000316; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SASAKI K, 1979, J ANTIBIOT, V32, P849, DOI 10.7164/antibiotics.32.849; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Taldone T, 2008, CURR OPIN PHARMACOL, V8, P370, DOI 10.1016/j.coph.2008.06.015; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Zhang H, 2010, INT J CANCER, V126, P1226, DOI 10.1002/ijc.24825; Zurawska A, 2010, BBA-MOL CELL RES, V1803, P575, DOI 10.1016/j.bbamcr.2010.03.002	41	22	23	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3828	3837		10.1096/fj.11-188821	http://dx.doi.org/10.1096/fj.11-188821			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21778327				2022-12-28	WOS:000296723100008
J	Schulze, T; Golfier, S; Tabeling, C; Rabel, K; Graler, MH; Witzenrath, M; Lipp, M				Schulze, Tobias; Golfier, Sven; Tabeling, Christoph; Raebel, Katrin; Graeler, Markus H.; Witzenrath, Martin; Lipp, Martin			Sphingosine-1-phospate receptor 4 (S1P(4)) deficiency profoundly affects dendritic cell function and T(H)17-cell differentiation in a murine model	FASEB JOURNAL			English	Article						G-protein-coupled receptor; T-cell polarization; animal model	PROTEIN-COUPLED RECEPTOR; CD4 T-CELLS; 1-PHOSPHATE RECEPTOR; AIRWAY HYPERRESPONSIVENESS; LYMPHOCYTE EGRESS; TRANSGENIC MICE; ALLERGIC-ASTHMA; CHEMOTAXIS; MIGRATION; RESPONSES	Although predominantly expressed on lymphocytic and hematopoietic cells, the role of sphingosine-1-phospate receptor 4 (S1P(4)) in immune homeo-stasis is still poorly understood. In this report, we used a S1P(4)-deficient murine model to characterize the biological role of S1P(4)-mediated S1P signaling in the immune system. S1p(4)(-/-) animals showed normal peripheral lymphocyte numbers and a regular architecture of secondary lymphoid organs. Interestingly, S1P4 only marginally affects T-cell function in vivo. In contrast, dendritic cell (DC) migration and cytokine secretion are profoundly affected by S1P(4) deficiency. Lack of S1P(4) expression on DCs significantly reduces T(H)17 differentiation of T-H cells. Furthermore, in various in vivo models of T(H)1- or T(H)2-dominated immune reactions, S1P(4) deficiency consistently increased the amplitude of T(H)2-dominated immune responses, while those depending on T(H)1-dominated mechanisms were diminished. Finally, S1p(4)(-/-) mice showed decreased pathology in a model of dextran sulfate sodium-induced colitis. In summary, for the first time, we show that S1P(4) signaling is involved in the regulation of DC function and T(H)17 T-cell differentiation. S1P(4)-mediated S1P signaling also modifies the course of various immune diseases in a murine model. We propose that S1P(4) may constitute an interesting target to influence the course of various autoimmune pathologies.-Schulze, T., Golfier, S., Tabeling, C., Rabel, K., Graler, M. H., Witzenrath, M., Lipp, M. Sphingosine-1-phospate receptor 4 (S1P(4)) deficiency profoundly affects dendritic cell function and T(H)17-cell differentiation in a murine model. FASEB J. 25, 4024-4036 (2011). www.fasebj.org	[Schulze, Tobias; Golfier, Sven; Raebel, Katrin; Graeler, Markus H.; Lipp, Martin] MDC, Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13125 Berlin, Germany; [Tabeling, Christoph; Witzenrath, Martin] Charite, Dept Internal Med Infect Dis & Pulm Med, D-13353 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lipp, M (corresponding author), MDC, Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, Robert Rossle Str 10, D-13125 Berlin, Germany.	mlipp@mdc-berlin.de	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849; Tabeling, Christoph/0000-0001-9189-4318; Lipp, Martin/0000-0002-0087-2672	Deutsche Krebshilfe (German Cancer Aid) [FKZ 106952]	Deutsche Krebshilfe (German Cancer Aid)(Deutsche Krebshilfe)	The authors thank Gerd Mueller and Uta Hoepken for helpful discussions and critical reading of the manuscript. The authors are grateful to Jenny Grobe, Ulrike Keitel, and Heike Schwede for technical assistance. This work was supported by Deutsche Krebshilfe (German Cancer Aid) grant FKZ 106952.	Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Choi JW, 2008, BBA-MOL CELL BIOL L, V1781, P531, DOI 10.1016/j.bbalip.2008.03.004; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Czeloth N, 2007, J IMMUNOL, V179, P5855, DOI 10.4049/jimmunol.179.9.5855; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Egger B, 2000, DIGESTION, V62, P240, DOI 10.1159/000007822; Fukata M, 2008, J IMMUNOL, V180, P1886, DOI 10.4049/jimmunol.180.3.1886; Girkontaite I, 2004, J EXP MED, V200, P1491, DOI 10.1084/jem.20041483; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Golfier S, 2010, FASEB J, V24, P4701, DOI 10.1096/fj.09-141473; Gollmann G, 2008, INT IMMUNOL, V20, P911, DOI 10.1093/intimm/dxn050; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Grahler MH, 2005, J IMMUNOL, V174, P1997; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Haberberger RV, 2009, J ALLERGY CLIN IMMUN, V124, P933, DOI 10.1016/j.jaci.2009.06.034; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; Huang MC, 2007, J IMMUNOL, V178, P6806, DOI 10.4049/jimmunol.178.11.6806; Idzko M, 2002, FASEB J, V16, P625, DOI 10.1096/fj.01-0625fje; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kabashima K, 2006, J EXP MED, V203, P2683, DOI 10.1084/jem.20061289; Kohno T, 2003, GENES CELLS, V8, P685, DOI 10.1046/j.1365-2443.2003.00667.x; Kurashima Y, 2007, J IMMUNOL, V179, P1577, DOI 10.4049/jimmunol.179.3.1577; Kveberg L, 2002, EUR J IMMUNOL, V32, P1856, DOI 10.1002/1521-4141(200207)32:7<1856::AID-IMMU1856>3.0.CO;2-B; Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323; Lan YY, 2008, TRANSPL IMMUNOL, V20, P88, DOI 10.1016/j.trim.2008.07.004; Liao JJ, 2007, J IMMUNOL, V178, P5425, DOI 10.4049/jimmunol.178.9.5425; Maeda Y, 2007, J IMMUNOL, V178, P3437, DOI 10.4049/jimmunol.178.6.3437; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Matsuyuki H, 2006, CELL MOL IMMUNOL, V3, P429; Muller H, 2005, EUR J IMMUNOL, V35, P533, DOI 10.1002/eji.200425556; Osorio F, 2008, EUR J IMMUNOL, V38, P3274, DOI 10.1002/eji.200838950; Pabst R, 2002, J ALLERGY CLIN IMMUN, V110, P209, DOI 10.1067/mai.2002.126836; Rahaman M, 2006, AM J RESP CELL MOL, V34, P233, DOI 10.1165/rcmb.2005-0126OC; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Roviezzo F, 2004, P NATL ACAD SCI USA, V101, P11170, DOI 10.1073/pnas.0401439101; Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC; Roviezzo F, 2010, AM J RESP CELL MOL, V42, P572, DOI 10.1165/rcmb.2009-0108OC; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Skeritzian CA, 2007, PHARMACOL THERAPEUT, V115, P390, DOI 10.1016/j.pharmthera.2007.05.011; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Tang AM, 1996, J IMMUNOL, V157, P117; Wang WG, 2007, J IMMUNOL, V178, P4885, DOI 10.4049/jimmunol.178.8.4885; Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje; Witzenrath M, 2006, EUR RESPIR J, V28, P370, DOI 10.1183/09031936.06.00080105; Witzenrath M, 2006, AM J PHYSIOL-LUNG C, V291, pL466, DOI 10.1152/ajplung.00011.2005; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978	49	81	82	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					4024	4036		10.1096/fj.10-179028	http://dx.doi.org/10.1096/fj.10-179028			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21825036				2022-12-28	WOS:000296723100026
J	Carnini, C; Accomazzo, MR; Borroni, E; Vitellaro-Zuccarello, L; Durand, T; Folco, G; Rovati, GE; Capra, V; Sala, A				Carnini, Chiara; Accomazzo, Maria Rosa; Borroni, Emanuele; Vitellaro-Zuccarello, Laura; Durand, Thierry; Folco, Giancarlo; Rovati, G. Enrico; Capra, Valerie; Sala, Angelo			Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT(2) receptor	FASEB JOURNAL			English	Article						intracellular Ca2+; signal transduction; microsomal glutathione S-transferase-II	ISCHEMIA-REPERFUSION INJURY; TRANSCELLULAR BIOSYNTHESIS; C-4 SYNTHASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; MYOCARDIAL-INFARCTION; LIGAND-BINDING; IN-VIVO; EXPRESSION; INHIBITOR	The purpose of this study was to characterize enzyme, receptor, and signaling involved in the synthesis and the activity of cysteinyl leukotrienes (cys-LTs) in human umbilical vein endothelial cells (HUVECs). We used primary cultures of HUVECs and evaluated the formation of cys-LTs by RP-HPLC. Suicide inactivation and subcellular localization of the enzyme responsible for the conversion of leukotriene (LT) A(4) into LTC4 were studied by repeated incubations with LTA(4) and immunogold electron microscopy. The CysLT(2) receptor in HUVECs was characterized by equilibrium binding studies, Western blot analysis, and immunohistochemistry. Concentration-response curves in HUVECs and in transfected COS-7 cells were used to characterize a novel specific CysLT(2) receptor antagonist (pA(2) of 8.33 and 6.79 against CysLT(2) and CysLT(1) receptors, respectively). The results obtained provide evidence that the mGST-II synthesizing LTC4 in HUVECs is pharmacologically distinguishable from the LTC4-synthase (IC50 of MK886 <5 mu M for LTC4-synthase and >30 mu M for mGST-II), is not suicide-inactivated and is strategically located on endothelial transport vesicles. The CysLT(2) receptor is responsible for the increase in intracellular Ca2+ following exposure of HUVECs to cys-LTs and is coupled to a pertussis toxin-insensitive G(q) protein. The synthesis of cys-LTs from LTA(4) by endothelial cells is directly associated with the activation of the CysLT(2) receptor (EC50 0.64 mu M) in a typical autocrine fashion.-Carnini, C., Accomazzo, M. R., Borroni, E., Vitellaro-Zuccarello, L., Durand, T., Folco, G., Rovati, G. E., Capra, V., Sala, S. Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT(2) receptor. FASEB J. 25, 3519-3528 (2011). www.fasebj.org	[Carnini, Chiara; Accomazzo, Maria Rosa; Borroni, Emanuele; Folco, Giancarlo; Rovati, G. Enrico; Capra, Valerie; Sala, Angelo] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; [Vitellaro-Zuccarello, Laura] Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; [Durand, Thierry] Univ Montpellier, CNRS, IBMM, Fac Pharm,UMR 5247,UM 1,UM 2, F-34059 Montpellier, France	University of Milan; University of Milan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier	Sala, A (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	angelo.sala@unimi.it	Sala, Angelo/H-5478-2019; Capra, Valérie/B-6225-2008	Capra, Valérie/0000-0003-3956-0833; Sala, Angelo/0000-0001-9290-0257; Rovati, G.Enrico/0000-0002-8788-9783	European Community [LSHM-CT-2004-005033]; Italian Ministry of University and Research	European Community(European Commission); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR))	The authors thank Dr. Alberto Prada (Azienda Ospedaliera, Garbagnate Milanese, Milan, Italy), Dr. Alberto Zanini (Ospedale Fatebenefratelli, Erba, Italy), and Prof. Luciana Mussoni (Universita di Milano, Milan, Italy) for the collaboration in obtaining the umbilical cords; informed consent was obtained from donors of the umbilical cords. This work was carried out with the support of the European Community (LSHM-CT-2004-005033 to A.S., G.E.R., and G.F.), and of the Italian Ministry of University and Research (FIRB 2001 to G.F. and A.S.; PRIN 2005 to A.S.).	Capra V, 1998, MOL PHARMACOL, V53, P750, DOI 10.1124/mol.53.4.750; Capra V, 2005, J CELL SCI, V118, P5625, DOI 10.1242/jcs.02668; Capra V, 2003, PROSTAG OTH LIPID M, V71, P235, DOI 10.1016/S1098-8823(03)00045-5; Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; De Caterina R, 2010, EUR J CLIN INVEST, V40, P258, DOI 10.1111/j.1365-2362.2010.02261.x; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FITZPATRICK FA, 1994, ANN NY ACAD SCI, V744, P31, DOI 10.1111/j.1749-6632.1994.tb52721.x; Folco G, 2000, AM J RESP CRIT CARE, V161, pS112, DOI 10.1164/ajrccm.161.supplement_1.ltta-22; GORDON PB, 1983, IN VITRO CELL DEV B, V19, P661; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hakonarson H, 2005, JAMA-J AM MED ASSOC, V293, P2245, DOI 10.1001/jama.293.18.2245; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Helgadottir A, 2005, AM J HUM GENET, V76, P505, DOI 10.1086/428066; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Iovannisci DM, 2007, ARTERIOSCL THROM VAS, V27, P394, DOI 10.1161/01.ATV.0000252680.72734.10; Jiang W, 2008, AM J PATHOL, V172, P592, DOI 10.2353/ajpath.2008.070834; Kamohara M, 2001, BIOCHEM BIOPH RES CO, V287, P1088, DOI 10.1006/bbrc.2001.5695; LAM BK, 1989, J BIOL CHEM, V264, P12885; Lefer A M, 1988, Prog Clin Biol Res, V264, P101; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; Mechiche H, 2004, J CARDIOVASC PHARM, V43, P113, DOI 10.1097/00005344-200401000-00017; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; PATSCHEKE H, 1981, HAEMOSTASIS, V10, P14; Poeckel D, 2010, CARDIOVASC RES, V86, P243, DOI 10.1093/cvr/cvq016; Riccioni G, 2008, J LEUKOCYTE BIOL, V84, P1374, DOI 10.1189/jlb.0808476; Rossoni G, 1996, J PHARMACOL EXP THER, V276, P335; Rovati GE, 2007, THESCIENTIFICWORLDJO, V7, P1375, DOI 10.1100/tsw.2007.185; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; Sala A, 1997, BIOCHEM J, V328, P225, DOI 10.1042/bj3280225; Sala A, 2000, CIRCULATION, V101, P1436, DOI 10.1161/01.CIR.101.12.1436; Schroder O, 2003, BIOCHEM BIOPH RES CO, V312, P271, DOI 10.1016/j.bbrc.2003.10.115; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tardif JC, 2010, CIRC-CARDIOVASC IMAG, V3, P298, DOI 10.1161/CIRCIMAGING.110.937169; Uzonyi B, 2006, P NATL ACAD SCI USA, V103, P6326, DOI 10.1073/pnas.0601223103; Welt K, 2000, EXP TOXICOL PATHOL, V52, P27, DOI 10.1016/S0940-2993(00)80012-3; Woszczek G, 2007, J IMMUNOL, V178, P5262, DOI 10.4049/jimmunol.178.8.5262; Yuan YM, 2009, J PHARMACOL SCI, V109, P285, DOI 10.1254/jphs.08321FP; Zarini S, 2009, P NATL ACAD SCI USA, V106, P8296, DOI 10.1073/pnas.0903851106; Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099; Zhou GY, 2009, VASC PHARMACOL, V50, P171, DOI 10.1016/j.vph.2009.01.006	52	25	25	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2011	25	10					3519	3528		10.1096/fj.10-177030	http://dx.doi.org/10.1096/fj.10-177030			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21753081				2022-12-28	WOS:000295356400022
J	Kisko, K; Brozzo, MS; Missimer, J; Schleier, T; Menzel, A; Leppanen, VM; Alitalo, K; Walzthoeni, T; Aebersold, R; Ballmer-Hofer, K				Kisko, Kaisa; Brozzo, Maurice S.; Missimer, John; Schleier, Thomas; Menzel, Andreas; Leppanen, Veli-Matti; Alitalo, Kari; Walzthoeni, Thomas; Aebersold, Ruedi; Ballmer-Hofer, Kurt			Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering	FASEB JOURNAL			English	Article						SAXS; VEGF; cross-linking; mass spectrometry; receptor tyrosine kinase	CRYSTAL-STRUCTURE; RECEPTOR ACTIVATION; PROTEIN STRUCTURES; VEGF; BINDING; IDENTIFICATION; RESOLUTION; CONTACTS	Receptor tyrosine kinases play essential roles in tissue development and homeostasis, and aberrant signaling by these molecules is the basis of many diseases. Understanding the activation mechanism of these receptors is thus of high clinical relevance. We investigated vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs), which regulate blood and lymph vessel formation. We analyzed the structural changes in the extracellular receptor domain that were induced by ligand binding and that represent the initial step in transmembrane signaling, culminating in the activation of the intracellular receptor kinase domain. High-resolution structural information for the ligand binding domain became available recently, but the flexibility of the extracellular domain and inhomogeneous glycosylation of VEGFRs have prevented the production of highly diffracting crystals of the entire extracellular domain so far. Therefore, we chose to further investigate VEGFR structure by small-angle X-ray scattering in solution (SAXS). SAXS data were combined with independent distance restraint determination obtained by mass spectrometric analysis of chemically cross-linked ligand/receptor complexes. With these data, we constructed a structural model of the entire extracellular receptor domain in the unbound form and in complex with VEGF.-Kisko, K., Brozzo, M. S., Missimer, J., Schleier, T., Menzel, A., Leppanen, V.-M., Alitalo, K., Walzthoeni, T., Aebersold, R., Ballmer-Hofer, K. Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering. FASEB J. 25, 2980-2986 (2011). www.fasebj.org	[Kisko, Kaisa; Brozzo, Maurice S.; Missimer, John; Schleier, Thomas; Menzel, Andreas; Ballmer-Hofer, Kurt] Paul Scherrer Inst, CH-5232 Villigen, Switzerland; [Leppanen, Veli-Matti; Alitalo, Kari] Univ Helsinki, Haartman Inst, Dept Pathol, Biomedicum Helsinki,Mol Canc Biol Program, Helsinki, Finland; [Leppanen, Veli-Matti; Alitalo, Kari] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Walzthoeni, Thomas; Aebersold, Ruedi] ETH, Inst Mol Syst Biol, Dept Biol, Zurich, Switzerland; [Walzthoeni, Thomas] Univ Zurich, ETH Zurich, Mol Life Sci Program, Zurich, Switzerland; [Aebersold, Ruedi] Univ Zurich, Fac Sci, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Zurich	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	kurt.ballmer@psi.ch	Menzel, Andreas/C-4388-2012; Alitalo, Kari K/J-5013-2014	Menzel, Andreas/0000-0002-0489-609X; Alitalo, Kari K/0000-0002-7331-0902; Leppanen, Veli-Matti/0000-0001-7100-965X; Ballmer-Hofer, Kurt/0000-0002-3800-9129	Swiss National Science Foundation [3100A-116507]; Oncosuisse [OC2 01200-08-2007]; European Union [HEALTH-F4-2008-201648]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Oncosuisse; European Union(European Commission)	The authors thank the Swiss National Science Foundation (grant 3100A-116507) and Oncosuisse (grant OC2 01200-08-2007) for continuous support of their work. This work was supported, in part, by funding from the European Union Seventh Framework Program PROSPECTS (Proteomics Specification in Space and Time grant HEALTH-F4-2008-201648). The authors also thank all members of the X12SA beamline at SLS for their support during data acquisition; and Drs. D. Svergun and M. Roessler (European Molecular Biology Laboratory, Hamburg, Germany) for access to the X33 SAXS beamline at Deutsches Elektronen-Synchrotron (DESY; Hamburg, Germany) and for their competent assistance in establishing SAXS data analysis in the startup phase of this project.	Bernado P, 2010, EUR BIOPHYS J BIOPHY, V39, P769, DOI 10.1007/s00249-009-0549-3; Bohn S, 2010, P NATL ACAD SCI USA, V107, P20992, DOI 10.1073/pnas.1015530107; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827; Dosch DD, 2010, FASEB J, V24, P32, DOI 10.1096/fj.09-132670; HUANG TC, 1993, J APPL CRYSTALLOGR, V26, P180, DOI 10.1107/S0021889892009762; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Iyer S, 2006, J MOL BIOL, V359, P76, DOI 10.1016/j.jmb.2006.03.002; Koch MHJ, 2003, Q REV BIOPHYS, V36, P147, DOI 10.1017/S0033583503003871; Leitner A, 2010, MOL CELL PROTEOMICS, V9, P1634, DOI 10.1074/mcp.R000001-MCP201; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Leppanen VM, 2011, BLOOD, V117, P1507, DOI 10.1182/blood-2010-08-301549; Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107; Mertens HDT, 2010, J STRUCT BIOL, V172, P128, DOI 10.1016/j.jsb.2010.06.012; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Nagy P, 2010, P NATL ACAD SCI USA, V107, P16524, DOI 10.1073/pnas.1002642107; Petoukhov MV, 2007, J APPL CRYSTALLOGR, V40, pS223, DOI 10.1107/S0021889807002853; Pieren M, 2006, J BIOL CHEM, V281, P19578, DOI 10.1074/jbc.M601842200; Putnam CD, 2007, Q REV BIOPHYS, V40, P191, DOI 10.1017/S0033583507004635; Rinner O, 2008, NAT METHODS, V5, P315, DOI [10.1038/nmeth.1192, 10.1038/NMETH.1192]; Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202; Scheidegger P, 1999, BIOL CHEM, V380, P1449, DOI 10.1515/BC.1999.187; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stuttfeld E, 2009, IUBMB LIFE, V61, P915, DOI 10.1002/iub.234; Tvorogov D, 2010, CANCER CELL, V18, P630, DOI 10.1016/j.ccr.2010.11.001; Von Castelmur E, 2008, P NATL ACAD SCI USA, V105, P1186, DOI 10.1073/pnas.0707163105; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wriggers W, 2001, J APPL CRYSTALLOGR, V34, P773, DOI 10.1107/S0021889801012869; Yang Y, 2008, P NATL ACAD SCI USA, V105, P7681, DOI 10.1073/pnas.0802896105; Yang Y, 2010, P NATL ACAD SCI USA, V107, P1906, DOI 10.1073/pnas.0914052107; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055	31	31	32	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2011	25	9					2980	2986		10.1096/fj.11-185397	http://dx.doi.org/10.1096/fj.11-185397			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21613573				2022-12-28	WOS:000294435200013
J	Boutte, AM; Friedman, DB; Bogyo, M; Min, YF; Yang, L; Lin, PC				Boutte, Angela M.; Friedman, David B.; Bogyo, Matthew; Min, Yongfen; Yang, Li; Lin, P. Charles			Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis	FASEB JOURNAL			English	Article						cathepsin; angiogenesis; lymphanogenesis; NGP	CATHEPSIN-B; BREAST-CANCER; STEFIN-A; TUMOR; ANGIOGENESIS; ASSOCIATION; DEGRADATION; PROGRESSION; MEMBRANE; MICE	Myeloid-derived suppressor cells (MDSCs) are significantly increased in cancer patients and tumor bearing-animals. MDSCs infiltrate into tumors and promote tumor invasion and metastasis. To identify the mediator responsible for the prometastatic property of MDSCs, we used proteomics. We found neutrophilic granule protein (NGP) was decreased > 2-fold in MDSCs from metastatic 4T1 tumor-bearing mice compared to nonmetastatic 67NR controls. NGP mRNA levels were decreased in bone marrow and in tumor-infiltrating MDSCs by 45 and 66%, respectively, in 4T1 tumor-bearing mice compared to 67NR controls. Interestingly, 4T1-conditioned medium reduced myeloid cell NGP expression by similar to 40%, suggesting that a secreted factor mediates gene reduction. Sequence analysis shows a putative cystatin domain in NGP, and biochemical analysis confirms NGP a novel cathepsin inhibitor. It inhibited cathepsin B activity by nearly 40% in vitro. NGP expression in 4T1 tumor cells suppressed cell invasion, delayed primary tumor growth, and greatly reduced lung metastasis in vivo. A 2.8-fold reduction of cathepsin activity was found in tumors expressing NGP compared to controls. NGP significantly reduced tumor angiogenesis to 12.6 from 19.6 and lymphangiogenesis to 4.6 from 9.1 vessels/field. Necrosis was detectable only in NGP-expressing tumors, and the number of apoptotic cells increased to 22.4 from 8.3 in controls. Taken together, this study identifies a negative regulator of tumor metastasis in MDSCs, NGP, which is down-regulated in metastatic conditions. The finding suggests that malignant tumors promote invasion/metastasis not only through up-regulation of proteases but also down-regulation of protease inhibitors.-Boutte, A. M., Friedman, D. B., Bogyo, M., Min, Y., Yang, L., Lin, P. C. Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis. FASEB J. 25, 2626-2637 (2011). www.fasebj.org	[Min, Yongfen; Yang, Li; Lin, P. Charles] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Friedman, David B.] Vanderbilt Univ, Dept Biochem, Med Ctr, Nashville, TN 37232 USA; [Boutte, Angela M.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; [Bogyo, Matthew] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Vanderbilt University; Stanford University	Lin, PC (corresponding author), NCI, 1050 Boyles St,Bldg 560,Rm 12-32, Frederick, MD 21702 USA.	p.lin@nih.edu		Bogyo, Matthew/0000-0003-3753-4412	U.S. National Institutes of Health [1F32CA136118, UL1 RR 024975, CA108856, NS45888, AR053718]; NATIONAL CANCER INSTITUTE [F32CA136118, ZIABC011390, R01CA108856] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Drs. Lynn Matrisian and Barbara Fingleton at Vanderbilt University Medical Center for critical comments on the manuscript. The authors thank Dr. Kelli Boyd for analysis of tumor histology and Dr. Swati Biswas for her expertise in mouse models of cancer at Vanderbilt University Medical Center. This work is supported in part by U.S. National Institutes of Health grants to A.M.B. (1F32CA136118 and UL1 RR 024975) and P.C.L. (CA108856, NS45888, and AR053718).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363; Blum G, 2007, NAT CHEM BIOL, V3, P668, DOI 10.1038/nchembio.2007.26; Cavallo-Medved D, 2009, EXP CELL RES, V315, P1234, DOI 10.1016/j.yexcr.2009.01.021; Chang SH, 2009, CANCER RES, V69, P4537, DOI 10.1158/0008-5472.CAN-08-4539; Chen XB, 2010, BIOCHEM BIOPH RES CO, V391, P1070, DOI 10.1016/j.bbrc.2009.12.022; Colbert JD, 2009, TRAFFIC, V10, P425, DOI 10.1111/j.1600-0854.2009.00881.x; Cox JL, 2009, FRONT BIOSCI-LANDMRK, V14, P463, DOI 10.2741/3255; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Ekstrom U, 2008, FEBS J, V275, P4571, DOI 10.1111/j.1742-4658.2008.06600.x; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Friedman David B., 2008, V428, P93; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gombart AF, 2003, BLOOD, V101, P3265, DOI 10.1182/blood-2002-04-1039; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Kioulafa M, 2009, INT J CANCER, V125, P2887, DOI 10.1002/ijc.24686; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Moscinski LC, 1995, J CELL BIOCHEM, V59, P431, DOI 10.1002/jcb.240590404; Niedergethmann M, 2004, PANCREAS, V29, P204, DOI 10.1097/00006676-200410000-00005; Parker BS, 2008, J PATHOL, V214, P337, DOI 10.1002/path.2265; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Sinha AA, 2002, CANCER-AM CANCER SOC, V94, P3141, DOI 10.1002/cncr.10604; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Wegiel B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007953; Wu CH, 2006, NUCLEIC ACIDS RES, V34, pD187, DOI 10.1093/nar/gkj161; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004	30	20	23	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2626	2637		10.1096/fj.10-180604	http://dx.doi.org/10.1096/fj.10-180604			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21518852	Green Published			2022-12-28	WOS:000293337800013
J	Srivastava, S; Kashiwaya, Y; King, MT; Baxa, U; Tam, J; Niu, G; Chen, XY; Clarke, K; Veech, RL				Srivastava, Shireesh; Kashiwaya, Yoshihiro; King, M. Todd; Baxa, Ulrich; Tam, Joseph; Niu, Gang; Chen, Xiaoyuan; Clarke, Kieran; Veech, Richard L.			Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet	FASEB JOURNAL			English	Article						brown fat; electron transport chain; sympathetic activity; insulin sensitivity; energy expenditure	HYPOTHALAMIC MALONYL-COA; KETOGENIC DIET; HIGH-FAT; SKELETAL-MUSCLE; GENE-EXPRESSION; INDUCED OBESITY; ADULT HUMANS; PPAR-GAMMA; RAT; METABOLISM	We measured the effects of a diet in which D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester [ketone ester (KE)] replaced equicaloric amounts of carbohydrate on 8-wk-old male C57BL/6J mice. Diets contained equal amounts of fat, protein, and micronutrients. The KE group was fed ad libitum, whereas the control (Ctrl) mice were pair-fed to the KE group. Blood D-beta-hydroxybutyrate levels in the KE group were 3-5 times those reported with high-fat ketogenic diets. Voluntary food intake was reduced dose dependently with the KE diet. Feeding the KE diet for up to 1 mo increased the number of mitochondria and doubled the electron transport chain proteins, uncoupling protein 1, and mitochondrial biogenesis-regulating proteins in the interscapular brown adipose tissue (IBAT). [F-18]-Fluorodeoxyglucose uptake in IBAT of the KE group was twice that in IBAT of the Ctrl group. Plasma leptin levels of the KE group were more than 2-fold those of the Ctrl group and were associated with increased sympathetic nervous system activity to IBAT. The KE group exhibited 14% greater resting energy expenditure, but the total energy expenditure measured over a 24-h period or body weights was not different. The quantitative insulin-sensitivity check index was 73% higher in the KE group. These results identify KE as a potential antiobesity supplement.-Srivastava, S., Kashiwaya, Y., King, M. T. Baxa, U., Tam, J., Niu, G., Chen, X., Clarke, K., Veech, R. L. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J. 26, 2351-2362 (2012). www.fasebj.org	[Srivastava, Shireesh; Kashiwaya, Yoshihiro; King, M. Todd; Veech, Richard L.] NIAAA, Lab Metab Control, NIH, Rockville, MD 20852 USA; [Baxa, Ulrich] NCI, Electron Microscopy Lab, Adv Technol Program, SAIC Frederick Inc,Natl Inst Hlth, Frederick, MD 21701 USA; [Tam, Joseph] NIAAA, Lab Physiol Studies, NIH, Rockville, MD 20852 USA; [Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD USA; [Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); University of Oxford	Veech, RL (corresponding author), NIAAA, Lab Metab Control, NIH, 5625 Fishers Ln,Room 2S-28, Rockville, MD 20852 USA.	rveech@mail.nih.gov	Chen, Xiaoyuan/D-1860-2014	Chen, Xiaoyuan/0000-0002-9622-0870	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZIAEB000073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000110] Funding Source: NIH RePORTER; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); British Heart Foundation(British Heart Foundation)		Balietti M, 2010, AGEING RES REV, V9, P273, DOI 10.1016/j.arr.2010.02.003; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Butler AA, 2010, DIABETES, V59, P323, DOI 10.2337/db09-1471; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2011, J EXP BIOL, V214, P242, DOI 10.1242/jeb.050989; Cha SH, 2006, P NATL ACAD SCI USA, V103, P15410, DOI 10.1073/pnas.0607334103; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Dahlin M, 2005, EPILEPSY RES, V64, P115, DOI 10.1016/j.eplepsyres.2005.03.008; Dashti HM, 2007, MOL CELL BIOCHEM, V302, P249, DOI 10.1007/s11010-007-9448-z; ENDEMANN G, 1987, BIOCHEM CELL BIOL, V65, P989, DOI 10.1139/o87-129; Franko A, 2008, MOL CELL BIOL, V28, P2446, DOI 10.1128/MCB.00980-07; Fueger BJ, 2006, J NUCL MED, V47, P999; GEELEN MJH, 1983, FEBS LETT, V163, P269, DOI 10.1016/0014-5793(83)80833-3; Ghorbani M, 1997, BIOCHEM PHARMACOL, V54, P121, DOI 10.1016/S0006-2952(97)00162-7; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; Henderson ST, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-31; Himms-Hagen J, 2001, Rev Endocr Metab Disord, V2, P395, DOI 10.1023/A:1011856617047; Jornayvaz FR, 2010, AM J PHYSIOL-ENDOC M, V299, pE808, DOI 10.1152/ajpendo.00361.2010; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kashiwaya Y, 2010, J BIOL CHEM, V285, P25950, DOI 10.1074/jbc.M110.138198; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; KOLANOWSKI J, 1994, METABOLISM, V43, P180, DOI 10.1016/0026-0495(94)90242-9; Kozak LP, 2010, CELL METAB, V11, P263, DOI 10.1016/j.cmet.2010.03.009; Kwiterovich PO, 2003, JAMA-J AM MED ASSOC, V290, P912, DOI 10.1001/jama.290.7.912; Madsen L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011391; Murphy P, 2005, PEDIATR RES, V57, P353, DOI 10.1203/01.PDR.0000150804.18038.79; Nagashima K, 2011, METHODS MOL BIOL, V697, P83, DOI 10.1007/978-1-60327-198-1_8; Nedergaard J, 2005, BBA-MOL BASIS DIS, V1740, P293, DOI 10.1016/j.bbadis.2005.02.003; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; Petrovic N, 2008, AM J PHYSIOL-ENDOC M, V295, pE287, DOI 10.1152/ajpendo.00035.2008; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Rahmouni K, 2007, HYPERTENSION, V49, P647, DOI 10.1161/01.HYP.0000254827.59792.b2; Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512; Rim JS, 2002, J BIOL CHEM, V277, P34589, DOI 10.1074/jbc.M108866200; Rogovik AL, 2010, CAN FAM PHYSICIAN, V56, P540; ROTHWELL NJ, 1985, METABOLISM, V34, P474, DOI 10.1016/0026-0495(85)90214-8; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; Samaha Frederick F, 2007, Curr Atheroscler Rep, V9, P441, DOI 10.1007/s11883-007-0059-7; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Stephens M, 2011, CLIN ENDOCRINOL, V74, P661, DOI 10.1111/j.1365-2265.2011.04018.x; Tam J, 2010, J CLIN INVEST, V120, P2953, DOI 10.1172/JCI42551; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; VanItallie TB, 2005, NEUROLOGY, V64, P728, DOI 10.1212/01.WNL.0000152046.11390.45; Veech RL, 2001, IUBMB LIFE, V51, P241; Vercauteren K, 2006, MOL CELL BIOL, V26, P7409, DOI 10.1128/MCB.00585-06; Vernochet C, 2010, DRUG NEWS PERSPECT, V23, P409, DOI 10.1358/dnp.2010.23.7.1487083; Wolfgang MJ, 2007, P NATL ACAD SCI USA, V104, P19285, DOI 10.1073/pnas.0709778104; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	57	81	82	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2351	2362		10.1096/fj.11-200410	http://dx.doi.org/10.1096/fj.11-200410			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362892	Green Published			2022-12-28	WOS:000305017200013
J	Ramer, R; Bublitz, K; Freimuth, N; Merkord, J; Rohde, H; Haustein, M; Borchert, P; Schmuhl, E; Linnebacher, M; Hinz, B				Ramer, Robert; Bublitz, Katharina; Freimuth, Nadine; Merkord, Jutta; Rohde, Helga; Haustein, Maria; Borchert, Philipp; Schmuhl, Ellen; Linnebacher, Michael; Hinz, Burkhard			Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1	FASEB JOURNAL			English	Article						cannabinoids; tissue inhibitor of metalloproteinases-1; experimental metastasis; ICAM-1	REGULATES ICAM-1 EXPRESSION; VASCULAR ENDOTHELIAL-CELLS; FACTOR-KAPPA-B; TISSUE INHIBITOR; GENE-EXPRESSION; UP-REGULATION; MATRIX METALLOPROTEINASES-1; DIFFERENTIAL EXPRESSION; CANNABINOIDS INHIBIT; LYMPHOCYTE ADHESION	Cannabinoids inhibit cancer cell invasion via increasing tissue inhibitor of matrix metallo-proteinases-1 (TIMP-1). This study investigates the role of intercellular adhesion molecule-1 (ICAM-1) within this action. In the lung cancer cell lines A549, H358, and H460, cannabidiol (CBD; 0.001-3 mu M) elicited concentration-dependent ICAM-1 up-regulation compared to vehicle via cannabinoid receptors, transient receptor potential vanilloid 1, and p42/44 mitogen-activated protein kinase. Up-regulation of ICAM-1 mRNA by CBD in A549 was 4-fold at 3 mu M, with significant effects already evident at 0.01 mu M. ICAM-1 induction became significant after 2 h, whereas significant TIMP-1 mRNA increases were observed only after 48 h. Inhibition of ICAM-1 by antibody or siRNA approaches reversed the anti-invasive and TIMP-1-upregulating action of CBD and the likewise ICAM-1-inducing cannabinoids Delta(9)-tetrahydrocannabinol and R(+)-methanandamide when compared to isotype or nonsilencing siRNA controls. ICAM-1-dependent antiinvasive cannabinoid effects were confirmed in primary tumor cells from a lung cancer patient. In athymic nude mice, CBD elicited a 2.6- and 3.0-fold increase of ICAM-1 and TIMP-1 protein in A549 xenografts, as compared to vehicle-treated animals, and an antimetastatic effect that was fully reversed by a neutralizing antibody against ICAM-1 [% metastatic lung nodules vs. isotype control (100%): 47.7% for CBD + isotype antibody and 106.6% for CBD + ICAM-1 antibody]. Overall, our data indicate that cannabinoids induce ICAM-1, thereby conferring TIMP-1 induction and subsequent decreased cancer cell invasiveness.-Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., Borchert, P., Schmuhl, E., Linnebacher, M., Hinz, B. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule- 1. FASEB J. 26, 1535-1548 (2012). www.fasebj.org	[Ramer, Robert; Bublitz, Katharina; Freimuth, Nadine; Merkord, Jutta; Rohde, Helga; Haustein, Maria; Borchert, Philipp; Schmuhl, Ellen; Hinz, Burkhard] Univ Rostock, Inst Pharmacol & Toxicol, D-18057 Rostock, Germany; [Linnebacher, Michael] Univ Rostock, Sect Mol Oncol & Immunotherapy, Dept Gen Surg, D-18057 Rostock, Germany	University of Rostock; University of Rostock	Hinz, B (corresponding author), Univ Rostock, Inst Pharmacol & Toxicol, Schillingallee 70, D-18057 Rostock, Germany.	burkhard.hinz@med.uni-rostock.de	Linnebacher, Michael/AAT-3763-2021	Linnebacher, Michael/0000-0001-8054-1402	Deutsche Forschungsgemeinschaft [Hi 813/6-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study was supported by a grant from the Deutsche Forschungsgemeinschaft (Hi 813/6-1).	ALTOMONTE M, 1993, CANCER RES, V53, P3343; Bissett D, 2005, J CLIN ONCOL, V23, P842, DOI 10.1200/JCO.2005.03.170; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Blazquez C, 2008, CANCER RES, V68, P1945, DOI 10.1158/0008-5472.CAN-07-5176; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P517, DOI 10.1016/0091-3057(91)90357-8; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; Fujihara Tomofumi, 1999, Gastric Cancer, V2, P221, DOI 10.1007/s101200050067; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Hinz B, 2005, FASEB J, V19, P1929, DOI 10.1096/fj.04-3626fje; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hosch S B, 1997, J Gastrointest Surg, V1, P316, DOI 10.1016/S1091-255X(97)80051-0; Huang WC, 2004, CARCINOGENESIS, V25, P1925, DOI 10.1093/carcin/bgh211; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Izzo AA, 2009, TRENDS PHARMACOL SCI, V30, P515, DOI 10.1016/j.tips.2009.07.006; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; KELLY CP, 1992, AM J PHYSIOL, V263, pG864, DOI 10.1152/ajpgi.1992.263.6.G864; Kogan NM, 2006, MOL PHARMACOL, V70, P51, DOI 10.1124/mol.105.021089; Koyama Y, 1996, J IMMUNOL, V157, P5097; Lawson C, 1999, J IMMUNOL, V162, P2990; Lee HM, 2008, EUR J PHARMACOL, V579, P260, DOI 10.1016/j.ejphar.2007.10.001; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Lin YC, 2006, CLIN CANCER RES, V12, P7165, DOI 10.1158/1078-0432.CCR-06-1393; Maeda K, 2002, ONCOL REP, V9, P511; Massi P, 2004, J PHARMACOL EXP THER, V308, P838, DOI 10.1124/jpet.103.061002; McAllister SD, 2007, MOL CANCER THER, V6, P2921, DOI 10.1158/1535-7163.MCT-07-0371; McKallip RJ, 2006, MOL PHARMACOL, V70, P897, DOI 10.1124/mol.106.023937; Melis M, 1996, EUR RESPIR J, V9, P1831, DOI 10.1183/09031936.96.09091831; MIELE ME, 1994, EXP CELL RES, V214, P231, DOI 10.1006/excr.1994.1253; Mukhopadhyay P, 2010, FREE RADICAL BIO MED, V48, P457, DOI 10.1016/j.freeradbiomed.2009.11.022; NATALI P, 1990, CANCER RES, V50, P1271; Nithipatikom K, 2004, CANCER RES, V64, P8826, DOI 10.1158/0008-5472.CAN-04-3136; Ogawa Y, 1998, CLIN CANCER RES, V4, P31; Pisanti S, 2007, J CELL PHYSIOL, V211, P495, DOI 10.1002/jcp.20954; Preet A, 2008, ONCOGENE, V27, P339, DOI 10.1038/sj.onc.1210641; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rajesh M, 2007, AM J PHYSIOL-HEART C, V293, pH610, DOI 10.1152/ajpheart.00236.2007; Ramer R, 2007, ONCOGENE, V26, P5822, DOI 10.1038/sj.onc.1210358; Ramer R, 2008, J NATL CANCER I, V100, P59, DOI 10.1093/jnci/djm268; Ramer R, 2010, PHARM RES-DORDR, V27, P2162, DOI 10.1007/s11095-010-0219-2; Ramer R, 2010, BIOCHEM PHARMACOL, V79, P955, DOI 10.1016/j.bcp.2009.11.007; Rog DJ, 2007, CLIN THER, V29, P2068, DOI 10.1016/j.clinthera.2007.09.013; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sano H, 1998, BIOCHEM BIOPH RES CO, V250, P694, DOI 10.1006/bbrc.1998.9385; Sapna S, 2007, MOL CELL BIOCHEM, V303, P259, DOI 10.1007/s11010-007-9475-9; Sawada T, 2006, Adv Med Sci, V51, P60; Scaldaferri F, 2009, EUR J IMMUNOL, V39, P290, DOI 10.1002/eji.200838316; Shepherd FA, 2002, J CLIN ONCOL, V20, P4434, DOI 10.1200/JCO.2002.02.108; Shin Hun Sub, 2004, Korean Journal of Internal Medicine, V19, P48; Sunami T, 2000, JPN J CANCER RES, V91, P925, DOI 10.1111/j.1349-7006.2000.tb01036.x; VANKY F, 1990, CANCER IMMUNOL IMMUN, V31, P19, DOI 10.1007/BF01742491; Xian XS, 2010, J CELL BIOCHEM, V110, P321, DOI 10.1002/jcb.22540; Yu MH, 2008, CANCER SCI, V99, P391, DOI 10.1111/j.1349-7006.2008.00696.x	59	101	105	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2012	26	4					1535	1548		10.1096/fj.11-198184	http://dx.doi.org/10.1096/fj.11-198184			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22198381				2022-12-28	WOS:000302359700016
J	Bruzzone, S; Ameri, P; Briatore, L; Mannino, E; Basile, G; Andraghetti, G; Grozio, A; Magnone, M; Guida, L; Scarfi, S; Salis, A; Damonte, G; Sturla, L; Nencioni, A; Fenoglio, D; Fiory, F; Miele, C; Beguinot, F; Ruvolo, V; Bormioli, M; Colombo, G; Maggi, D; Murialdo, G; Cordera, R; De Flora, A; Zocchi, E				Bruzzone, Santina; Ameri, Pietro; Briatore, Lucia; Mannino, Elena; Basile, Giovanna; Andraghetti, Gabriella; Grozio, Alessia; Magnone, Mirko; Guida, Lucrezia; Scarfi, Sonia; Salis, Annalisa; Damonte, Gianluca; Sturla, Laura; Nencioni, Alessio; Fenoglio, Daniela; Fiory, Francesca; Miele, Claudia; Beguinot, Francesco; Ruvolo, Vittorio; Bormioli, Mariano; Colombo, Giuseppe; Maggi, Davide; Murialdo, Giovanni; Cordera, Renzo; De Flora, Antonio; Zocchi, Elena			The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts	FASEB JOURNAL			English	Article						insulin; oral glucose tolerance test; glucose uptake; GLP-1; GLUT-4	HUMAN PANCREATIC-ISLETS; CYCLIC ADP-RIBOSE; KAPPA-B KINASE; INSULIN-RESISTANCE; RISK; INFLAMMATION; MUSCLE	The plant hormone abscisic acid (ABA) is released from glucose-challenged human pancreatic beta cells and stimulates insulin secretion. We investigated whether plasma ABA increased during oral and intravenous glucose tolerance tests (OGTTs and IVGTTs) in healthy human subjects. In all subjects undergoing OGTTs (n = 8), plasma ABA increased over basal values (in a range from 2- to 9-fold). A positive correlation was found between the ABA area under the curve (AUC) and the glucose AUC. In 4 out of 6 IVGTTs, little or no increase of ABA levels was observed. In the remaining subjects, the ABA increase was similar to that recorded during OGTTs. GLP-1 stimulated ABA release from an insulinoma cell line and from human islets, by similar to 10- and 2-fold in low and high glucose, respectively. Human adipose tissue also released ABA in response to high glucose. Nanomolar ABA stimulated glucose uptake, similarly to insulin, in rat L6 myoblasts and in murine 3T3-L1 cells differentiated to adipocytes, by increasing GLUT-4 translocation to the plasma membrane. Demonstration that a glucose load in humans is followed by a physiological rise of plasma ABA, which can enhance glucose uptake by adipose tissues and muscle cells, identifies ABA as a new mammalian hormone involved in glucose metabolism.-Bruzzone, S., Ameri, P., Briatore, L., Mannino, E., Basile, G., Andraghetti, G., Grozio, A., Magnone, M., Guida, L., Scarf, S., Salis, A., Damonte, G., Sturla, L., Nencioni, A., Fenoglio, D., Fiory, F., Miele, C., Beguinot, F., Ruvolo, V., Bormioli, M., Colombo, G., Maggi, D., Murialdo, G., Cordera, R., De Flora, A., Zocchi, E. The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J. 26, 1251-1260 (2012). www.fasebj.org	[Zocchi, Elena] Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; [Bruzzone, Santina; Mannino, Elena; Basile, Giovanna; Grozio, Alessia; Magnone, Mirko; Guida, Lucrezia; Scarfi, Sonia; Salis, Annalisa; Damonte, Gianluca; Sturla, Laura; De Flora, Antonio; Zocchi, Elena] Univ Genoa, Ctr Excellence Biomed Res CEBR, I-16132 Genoa, Italy; [Ameri, Pietro; Briatore, Lucia; Andraghetti, Gabriella; Maggi, Davide; Murialdo, Giovanni; Cordera, Renzo] Univ Genoa, Dept Endocrinol & Med Sci, I-16132 Genoa, Italy; [Nencioni, Alessio; Fenoglio, Daniela] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; [Bruzzone, Santina; Scarfi, Sonia; Zocchi, Elena] Adv Biotechnol Ctr CBA, Genoa, Italy; [Fiory, Francesca; Miele, Claudia; Beguinot, Francesco] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Naples, Italy; [Ruvolo, Vittorio; Bormioli, Mariano; Colombo, Giuseppe] Santa Corona Hosp, Pietra Ligure, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; University of Naples Federico II	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV 1, I-16132 Genoa, Italy.	ezocchi@unige.it	Scarfi, Sonia/AAJ-2387-2020; Nencioni, Alessio/K-3692-2018; Cordera, Renzo/I-7229-2017; Fenoglio, Daniela/I-7220-2018; Bruzzone, Santina/A-4264-2015; maggi, davide/AAL-4687-2020; Ameri, Pietro/K-8556-2016; Salis, Annalisa/R-9241-2018	Scarfi, Sonia/0000-0002-7079-6919; Cordera, Renzo/0000-0002-5280-9691; Fenoglio, Daniela/0000-0001-9532-6473; Bruzzone, Santina/0000-0003-2034-3716; Ameri, Pietro/0000-0001-7167-7287; Salis, Annalisa/0000-0002-3082-2908; NENCIONI, ALESSIO/0000-0001-5068-8884; MAGGI, DAVIDE CARLO/0000-0003-3928-1295	Juvenile Diabetes Research Foundation [31-2008-413]; Italian Ministry of Education, University and Scientific Research; University of Genova; Fondazione CARIGE; Compagnia di S. Paolo; Regione Liguria	Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Italian Ministry of Education, University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); University of Genova; Fondazione CARIGE(Fondazione Carige); Compagnia di S. Paolo(Compagnia di San Paolo); Regione Liguria(Regione Liguria)	Human islets were provided through the Juvenile Diabetes Research Foundation, award 31-2008-413 (ECIT Islet for Basic Research program). The authors are indebted to all the volunteers collaborating on this study. This work was supported in part by the Italian Ministry of Education, University and Scientific Research, by the University of Genova, by the Fondazione CARIGE, by the Compagnia di S. Paolo, and by Regione Liguria.	Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; Bodrato N, 2009, J BIOL CHEM, V284, P14777, DOI 10.1074/jbc.M802604200; Bruzzone S, 2008, J BIOL CHEM, V283, P32188, DOI 10.1074/jbc.M802603200; Bruzzone S, 2007, P NATL ACAD SCI USA, V104, P5759, DOI 10.1073/pnas.0609379104; Bruzzone S, 2012, J CELL PHYSIOL, V227, P2502, DOI 10.1002/jcp.22987; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Deng YF, 2010, ANN NY ACAD SCI, V1212, pE1, DOI 10.1111/j.1749-6632.2010.05875.x; Donnelly D, 2012, BRIT J PHARMACOL, V166, P27, DOI 10.1111/j.1476-5381.2011.01687.x; Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799; Espinola-Klein C, 2011, FRONT BIOSCI-LANDMRK, V16, P1663, DOI 10.2741/3812; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Guri AJ, 2007, CLIN NUTR, V26, P107, DOI 10.1016/j.clnu.2006.07.008; Hey SJ, 2010, ANN BOT-LONDON, V105, P197, DOI 10.1093/aob/mcp285; Ishiki M, 2005, ENDOCRINOLOGY, V146, P5071, DOI 10.1210/en.2005-0850; Magnone M, 2009, J BIOL CHEM, V284, P17808, DOI 10.1074/jbc.M809546200; Muoio DM, 2008, NAT REV MOL CELL BIO, V9, P193, DOI 10.1038/nrm2327; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Raghavendra AS, 2010, TRENDS PLANT SCI, V15, P395, DOI 10.1016/j.tplants.2010.04.006; Rook F, 2006, PLANT CELL ENVIRON, V29, P426, DOI 10.1111/j.1365-3040.2005.01477.x; Sturla L, 2009, J BIOL CHEM, V284, P28045, DOI 10.1074/jbc.M109.035329; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Velasquez DA, 2010, VITAM HORM, V84, P303, DOI [10.1016/B978-0-12-381517-0.00011-4, 10.1016/S0083-6729(10)84007-5]; Wasilewska A, 2008, MOL PLANT, V1, P198, DOI 10.1093/mp/ssm022; Zhan TZ, 2011, J CELL BIOCHEM, V112, P849, DOI 10.1002/jcb.22984	26	65	69	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1251	1260		10.1096/fj.11-190140	http://dx.doi.org/10.1096/fj.11-190140			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22075645				2022-12-28	WOS:000300949300027
J	Hsieh, TH; Tsai, CF; Hsu, CY; Kuo, PL; Lee, JN; Chai, CY; Wang, SC; Tsai, EM				Hsieh, Tsung-Hua; Tsai, Cheng-Fang; Hsu, Chia-Yi; Kuo, Po-Lin; Lee, Jau-Nan; Chai, Chee-Yin; Wang, Shao-Chun; Tsai, Eing-Mei			Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway	FASEB JOURNAL			English	Article						environmental hormone; aryl hydrocarbon receptor; histone deacetylase 6; ER-negative; nongenomic	ARYL-HYDROCARBON RECEPTOR; AH RECEPTOR; IN-VITRO; UP-REGULATION; CELLS; HDAC6; EXPRESSION; TARGET; IDENTIFICATION; TUMORIGENESIS	The environmentally present group of chemical phthalates, or phthalate esters, has been recognized as a rising threat to public health, including cancer. While most studies have addressed the estrogenic effects of phthalates in malignancies of the breast and the prostate, little is known about their role in the etiology of hormone-independent cancer. Here we show that treatments with the phthalates n-butyl benzyl phthalate (BBP) and dibutyl phthalate (DBP) at 1 mu M induced proliferation (BBP, 3.2-fold; DBP, 3.2-fold), migration (BBP, 2.6-fold; DBP, 2.6-fold), invasion (BBP, 2.7-fold; DBP, 3.1-fold), and tumor formation (EC50: BBP, 0.12 mu M; DBP, 0.22 mu M) in estrogen receptor (ER)-negative breast cancer cells (MDA-MB-231). We further demonstrate that phthalates stimulated the cell surface aryl hydrocarbon receptor (AhR) and triggered the downstream cyclic AMP (cAMP)-PKA-CREB1 signaling cascade. The pathway led to increased expression of HDAC6, which facilitated nuclear assembly of the beta-catenin-LEF1/TCF4 transcriptional complex and transactivation of the c-Myc oncogene. This nongenomic pathway emanated from the phthalate-induced AhR promoted tumorigenesis of ER-negative breast cancer. Collectively, our findings revealed a novel oncogenic mechanism of phthalates in breast cancer independent from their estrogenic activities.-Hsieh, T.-H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., Lee, J.-N., Chai, C.-Y., Wang, S.-C., Tsai, E.-M. Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J. 26, 778 -787 (2012). www.fasebj.org	[Hsieh, Tsung-Hua; Tsai, Cheng-Fang; Hsu, Chia-Yi; Tsai, Eing-Mei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Grad Inst Med, Kaohsiung, Taiwan; [Kuo, Po-Lin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Inst Clin Med, Coll Med, Kaohsiung, Taiwan; [Kuo, Po-Lin; Lee, Jau-Nan; Chai, Chee-Yin; Tsai, Eing-Mei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Excellence Environm Med, Kaohsiung, Taiwan; [Lee, Jau-Nan; Tsai, Eing-Mei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Chai, Chee-Yin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol, Kaohsiung, Taiwan; [Wang, Shao-Chun] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University System of Ohio; University of Cincinnati	Tsai, EM (corresponding author), Kaohsiung Med Univ, Grad Inst Med, 100 Zihyou 1st Rd, Kaohsiung 807, Taiwan.	tsaieing@yahoo.com; wangsc@ucmail.uc.edu	Hsieh, Tsung-Hua/B-2132-2013; Wang, Shao-Chun/P-9904-2019	Wang, Shao-Chun/0000-0002-5477-1682; Hsu, ChiaYi/0000-0001-6809-2165; Chai, Chee-Yin/0000-0003-0486-9742	National Science Council, Taiwan [MY3, 99-2628-B-037-009-MY3]; Ministry of Education, Taiwan [KMU-EM-99-3]; Kaohsiung Medical University (Hospital) [KMUH 97-7R08, KMUH 98-8R19, KMUH 99-9I04, KMUH 99-9R30, KMUER-004]; Susan Komen Breast Cancer Research Award [KG080540]; University of Cincinnati	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Education, Taiwan(Ministry of Education, Taiwan); Kaohsiung Medical University (Hospital); Susan Komen Breast Cancer Research Award; University of Cincinnati	The authors thank the Center for Resources, Research, and Development of Kaohsiung Medical University for support with instrumentation, the Laboratory Animal Center of Kaohsiung Medical University for assistance with animal experiments, and the National RNAi Core Facility for providing the shRNAs. The authors also thank Dr. Shau-Ku Huang and Kazunari K. Yokoyama for critical review and valuable suggestions. This work was supported in part by the National Science Council, Taiwan (grants MY3, 99-2628-B-037-009-MY3), the Ministry of Education, Taiwan (grant KMU-EM-99-3), and the Kaohsiung Medical University (Hospital) Research Fund (grants KMUH 97-7R08, KMUH 98-8R19, KMUH 99-9I04, KMUH 99-9R30, and KMUER-004; to E. M. T). This study was also supported by the Susan Komen Breast Cancer Research Award (KG080540) and the startup fund of the University of Cincinnati (to S.C.W).	Agas D, 2007, J CELL BIOCHEM, V101, P543, DOI 10.1002/jcb.21212; Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; Azuma K, 2009, CANCER RES, V69, P2935, DOI 10.1158/0008-5472.CAN-08-3458; Barhoover MA, 2010, MOL PHARMACOL, V77, P195, DOI 10.1124/mol.109.059675; Du BH, 2005, CANCER RES, V65, P5982, DOI 10.1158/0008-5472.CAN-05-0628; Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200; Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.1289/ehp.97105802; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ishida M, 2010, CARCINOGENESIS, V31, P287, DOI 10.1093/carcin/bgp222; Janjua NR, 2007, ENVIRON SCI TECHNOL, V41, P5564, DOI 10.1021/es0628755; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; Kim IY, 2004, J TOXICOL ENV HEAL A, V67, P2025, DOI 10.1080/15287390490514750; Lee JE, 2000, TOXICOL SCI, V58, P235, DOI 10.1093/toxsci/58.2.235; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Li Y, 2008, J BIOL CHEM, V283, P12686, DOI 10.1074/jbc.C700185200; Liao H, 2010, J BIOL CHEM, V285, P14791, DOI 10.1074/jbc.M110.116905; Lin CI, 2008, J BIOMED SCI, V15, P833, DOI 10.1007/s11373-008-9267-6; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Matsumura F, 2009, BIOCHEM PHARMACOL, V77, P608, DOI 10.1016/j.bcp.2008.10.013; Miller ME, 2005, CLIN EXP METASTAS, V22, P149, DOI 10.1007/s10585-005-6536-x; Monteiro P, 2008, MOL PHARMACOL, V73, P769, DOI 10.1124/mol.107.043125; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Reck-Peterson S. L., 2010, COLD SPRING HARB PRO, DOI 10/1101/pdb.top73; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Singletary K, 1997, CARCINOGENESIS, V18, P1669, DOI 10.1093/carcin/18.8.1669; Tan KP, 2010, MOL PHARMACOL, V78, P175, DOI 10.1124/mol.110.065078; Wang KH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-288; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1006/toxs.1998.2505; Zhang S, 2009, ENDOCR-RELAT CANCER, V16, P835, DOI 10.1677/ERC-09-0054; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	34	118	125	1	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					778	787		10.1096/fj.11-191742	http://dx.doi.org/10.1096/fj.11-191742			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22049059				2022-12-28	WOS:000300485700029
J	Mohamed, JS; Boriek, AM				Mohamed, Junaith S.; Boriek, Aladin M.			Loss of desmin triggers mechanosensitivity and up-regulation of Ankrd1 expression through Akt-NF-kappa B signaling pathway in smooth muscle cells	FASEB JOURNAL			English	Article						ankyrin repeat protein 1; cytoskeleton; signal transduction; mechanotransduction	ANKYRIN REPEAT PROTEIN; MICE LACKING DESMIN; INTERMEDIATE-FILAMENT PROTEIN; SPINAL MUSCULAR-ATROPHY; SKELETAL-MUSCLE; CONGENITAL MYOPATHY; GENE-EXPRESSION; TRANSCRIPTION; CARP; PHOSPHORYLATION	Muscle cells, including human airway smooth muscle cells (HASMCs) express ankyrin repeat protein 1 (Ankrd1), a member of ankyrin repeat protein family. Ankrd1 efficiently interacts with the type III intermediate filament desmin. Our earlier study showed that desmin is an intracellular load-bearing protein that influences airway compliance, lung recoil, and airway contractile responsiveness. These results suggest that Ankrd1 and desmin may play important roles on ASMC homeostasis. Here we show that small interfering (si) RNA-mediated knockdown of the desmin gene in HASMCs, recombinant HASMCs (reHASMCs), up-regulates Ankrd1 expression. Moreover, loss of desmin in HASMCs increases the phosphorylation of Akt, inhibitor of kappa B kinase (IKK)-alpha, and inhibitor of kappa B (I kappa B)-alpha proteins, leading to NF-kappa B activation. Treatment of reHASMCs with Akt, IKK alpha, I kappa B alpha, or NF-kappa B inhibitor inhibits the loss of desmin-induced Ankrd1 up-regulation, suggesting Akt/NF-kappa B-mediated Ankrd1 regulation. Transfection of reHASMCs with siRNA specific for p50 or p65 corroborates the NF-kappa B-mediated Ankrd1 regulation. Luciferase reporter assays show that NF-kappa B directly binds on Ankrd1 promoter and up-regulates Ankrd1 levels. Overall, our data provide a new link between desmin and Ankrd1 regulation, which may be important for ASMC homeostasis.-Mohamed, J. S., Boriek, A. M. Loss of desmin triggers mechanosensitivity and up-regulation of Ankrd1 expression through Akt-NF-kappa B signaling pathway in smooth muscle cells. FASEB J. 26, 757-765 (2012). www.fasebj.org	[Mohamed, Junaith S.; Boriek, Aladin M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	boriek@bcm.tmc.edu	Mohamed, Junaith/AAC-4050-2020		National Science Foundation; Keck Foundation	National Science Foundation(National Science Foundation (NSF)); Keck Foundation(W.M. Keck Foundation)	This work was supported by the National Science Foundation and the Keck Foundation.	Aihara Y, 2000, HYPERTENSION, V36, P48, DOI 10.1161/01.HYP.36.1.48; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Balogh J, 2002, CARDIOVASC RES, V53, P439, DOI 10.1016/S0008-6363(01)00500-4; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Chen BC, 2009, MOL IMMUNOL, V46, P1179, DOI 10.1016/j.molimm.2008.11.006; Chen YW, 2002, J PHYSIOL-LONDON, V545, P27, DOI 10.1113/jphysiol.2002.021220; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Costa ML, 2004, BRAZ J MED BIOL RES, V37, P1819, DOI 10.1590/S0100-879X2004001200007; de Waard V, 2003, ARTERIOSCL THROM VAS, V23, P64, DOI 10.1161/01.ATV.0000042218.13101.50; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Kanai H, 2001, CIRC RES, V88, P30, DOI 10.1161/01.RES.88.1.30; KAPANCI Y, 1992, J HISTOCHEM CYTOCHEM, V40, P1955, DOI 10.1177/40.12.1333502; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kuo HC, 1999, DEVELOPMENT, V126, P4223; Lee IT, 2010, AM J PATHOL, V176, P1671, DOI 10.2353/ajpath.2010.090714; Loufrani L, 2001, FASEB J, V15, P117, DOI 10.1096/fj.01-0505fje; Maeda T, 2002, GENE, V297, P1, DOI 10.1016/S0378-1119(02)00924-1; Matsuura K, 2007, HUM PATHOL, V38, P410, DOI 10.1016/j.humpath.2006.09.006; Milner DJ, 1999, J MOL CELL CARDIOL, V31, P2063, DOI 10.1006/jmcc.1999.1037; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Mohamed JS, 2010, FASEB J, V24, P3330, DOI 10.1096/fj.10-158386; Nakada C, 2004, PATHOBIOLOGY, V71, P43, DOI 10.1159/000072961; Nakada C, 2003, PATHOL INT, V53, P653, DOI 10.1046/j.1440-1827.2003.01541.x; Paramio JM, 2002, BIOESSAYS, V24, P836, DOI 10.1002/bies.10140; Pardo PS, 2008, AM J PHYSIOL-CELL PH, V294, pC1056, DOI 10.1152/ajpcell.00270.2007; PARK S, 1986, J BIOL CHEM, V261, P5734; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Shardonofsky FR, 2006, AM J PHYSIOL-LUNG C, V290, pL890, DOI 10.1152/ajplung.00397.2005; Sjuve R, 1998, J MUSCLE RES CELL M, V19, P415, DOI 10.1023/A:1005353805699; Slats AM, 2008, J ALLERGY CLIN IMMUN, V121, P1196, DOI 10.1016/j.jaci.2008.02.017; Torrado M, 2004, EUR J HEART FAIL, V6, P161, DOI 10.1016/j.ejheart.2003.11.004; Wede OK, 2002, J PHYSIOL-LONDON, V540, P941, DOI 10.1113/jphysiol.2001.014910; Witt SH, 2005, J MUSCLE RES CELL M, V26, P401, DOI 10.1007/s10974-005-9022-9; Yamada M, 2005, J HISTOCHEM CYTOCHEM, V53, P735, DOI 10.1369/jhc.4A6483.2005; Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366; Zolk O, 2003, CARDIOVASC RES, V59, P563, DOI 10.1016/S0008-6363(03)00476-0; Zolk O, 2002, BIOCHEM BIOPH RES CO, V293, P1377, DOI 10.1016/S0006-291X(02)00387-X	43	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					757	765		10.1096/fj.10-160291	http://dx.doi.org/10.1096/fj.10-160291			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22085644				2022-12-28	WOS:000300485700027
J	Terashima, T; Kojima, H; Chan, L				Terashima, Tomoya; Kojima, Hideto; Chan, Lawrence			Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion	FASEB JOURNAL			English	Article						dorsal root ganglion; DRG; polyploid; proinsulin; oxidative stress; TNF-alpha	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INSULIN-PRODUCING CELLS; PURKINJE NEURONS; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; DEFICIENT MICE; STEM-CELLS; ACTIVATION; INFLAMMATION	Diabetic neuropathy is the most common diabetic complication. The pathogenetic pathways include oxidative stress, advanced glycation end product (AGE) formation, protein kinase C, and NF-kappa B activation, as well as increased polyol flux. These metabolic perturbations affect neurons, Schwann cells, and vasa nervorum, which are held to be the primary cell types involved. We hypothesize that diabetes induces the appearance of abnormal bone marrow-derived cells (BMDCs) that fuse with neurons in the dorsal root ganglia (DRG) of mice, leading to diabetic neuropathy. Neuronal poly(ADP-ribose) polymerase-1 (PARP-1) activation in diabetes is known to generate free radical and oxidant-induced injury and poly(ADP-ribose) polymer formation, resulting in neuronal death and dysfunction, culminating in neuropathy. We further hypothesize that BM-specific PARP expression plays a determining role in disease pathogenesis. Here we show that bone marrow transplantation (BMT) of PARP-knockout (PARPKO) cells to wild-type mice protects against, whereas BMT of wild-type cells to PARPKO mice, which are normally "neuropathy-resistant," confers susceptibility to, diabetic neuropathy. The pathogenetic process involving hyperglycemia, BMDCs, and BMDC-neuron fusion can be recapitulated in vitro. Incubation in high, but not low, glucose confers fusogenicity to BMDCs, which are characterized by proinsulin (PI) and TNF-alpha coexpression; coincubation of isolated DRG neurons with PI-BMDCs in high glucose leads to spontaneous fusion between the 2 cell types, while the presence of a PARP inhibitor or use of PARPKO BMDCs in the incubation protects against BMDC-neuron fusion. These complementary in vivo and in vitro experiments indicate that BMDC-PARP expression promotes diabetic neuropathy via BMDC-neuron fusion.-Terashima, T., Kojima, H., Chan, L. Bone marrow expression of poly(ADPribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion. FASEB J. 26, 295-308 (2012). www.fasebj.org	[Terashima, Tomoya; Chan, Lawrence] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Kojima, Hideto; Chan, Lawrence] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Kojima, Hideto; Chan, Lawrence] Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; [Chan, Lawrence] St Lukes Episcopal Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saint Lukes Episcopal Hospital	Chan, L (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	lchan@bcm.tmc.edu			U.S. National Institutes of Health [HL-51586, P30DK079638]; St. Luke's Episcopal Hospital; T. T. & W. F. Chao Global Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Luke's Episcopal Hospital; T. T. & W. F. Chao Global Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Manami Hara (University of Chicago, Chicago, IL, USA) for providing MIP-GFP mice, Eric Buras for intellectual and technical assistance, Weiqin Chen for histochemical analysis, and Leslie Wu and Yu-Chih Ku for manuscript preparation. This study was supported by U.S. National Institutes of Health grants HL-51586 (to L. C.) and P30DK079638 for the Diabetes and Endocrinology Research Center at Baylor College of Medicine. L. C. was also supported by the Betty Rutherford Chair for Diabetes Research from St. Luke's Episcopal Hospital and the T. T. & W. F. Chao Global Foundation.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Andrabi SA, 2008, ANN NY ACAD SCI, V1147, P233, DOI 10.1196/annals.1427.014; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Brownlee M, 2008, WILLIAMS TXB ENDOCRI, P1417; Calcutt NA, 2009, NAT REV DRUG DISCOV, V8, P417, DOI 10.1038/nrd2476; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Chan Lawrence, 2006, Trans Am Clin Climatol Assoc, V117, P341; David KK, 2009, FRONT BIOSCI-LANDMRK, V14, P1116, DOI 10.2741/3297; Davies PS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006530; Drel VR, 2010, ENDOCRINOLOGY, V151, P2547, DOI 10.1210/en.2009-1342; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Edwards JL, 2008, PHARMACOL THERAPEUT, V120, P1, DOI 10.1016/j.pharmthera.2008.05.005; Espejel S, 2009, ANN NEUROL, V66, P100, DOI 10.1002/ana.21670; Figueroa-Romero C, 2008, REV ENDOCR METAB DIS, V9, P301, DOI 10.1007/s11154-008-9104-2; Fujimiya M, 2007, P NATL ACAD SCI USA, V104, P4030, DOI 10.1073/pnas.0700220104; Gonzalez F, 2006, J ENDOCRINOL, V188, P521, DOI 10.1677/joe.1.06579; Gonzalez-Clemente JM, 2005, CLIN ENDOCRINOL, V63, P525, DOI 10.1111/j.1365-2265.2005.02376.x; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Ilnytska O, 2006, DIABETES, V55, P1686, DOI 10.2337/db06-0067; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Kemp K, 2011, NEUROPATH APPL NEURO, V37, P166, DOI 10.1111/j.1365-2990.2010.01122.x; Kojima H, 2004, P NATL ACAD SCI USA, V101, P2458, DOI 10.1073/pnas.0308690100; Larsson LI, 2008, HISTOCHEM CELL BIOL, V129, P551, DOI 10.1007/s00418-008-0411-1; Li F, 2005, DIABETES, V54, P1514, DOI 10.2337/diabetes.54.5.1514; Lluis F, 2010, J CELL PHYSIOL, V223, P6, DOI 10.1002/jcp.22003; Magrassi L, 2007, J NEUROSCI, V27, P9885, DOI 10.1523/JNEUROSCI.2539-07.2007; Mitsui Y, 1999, BRAIN RES, V844, P192, DOI 10.1016/S0006-8993(99)01830-2; Nagley P, 2010, BBA-MOL BASIS DIS, V1802, P167, DOI 10.1016/j.bbadis.2009.09.004; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Obrosova IG, 2005, DIABETES, V54, P3435, DOI 10.2337/diabetes.54.12.3435; Obrosova IG, 2004, DIABETES, V53, P711, DOI 10.2337/diabetes.53.3.711; Obrosova IG, 2009, BBA-MOL BASIS DIS, V1792, P931, DOI 10.1016/j.bbadis.2008.11.005; Oh SH, 2004, LAB INVEST, V84, P607, DOI 10.1038/labinvest.3700074; Okamoto K, 2001, EXP NEUROL, V169, P386, DOI 10.1006/exnr.2001.7677; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Peters SO, 2002, J IMMUNOL METHODS, V260, P109, DOI 10.1016/S0022-1759(01)00525-7; Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pugatsch T, 1996, BONE MARROW TRANSPL, V17, P273; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Singec I, 2008, NAT CELL BIOL, V10, P503, DOI 10.1038/ncb0508-503; Skundric Dusanka S, 2003, Exp Diabesity Res, V4, P303, DOI 10.1155/EDR.2003.303; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; Sorkin LS, 1997, NEUROSCIENCE, V81, P255, DOI 10.1016/S0306-4522(97)00147-4; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Szabo C, 2005, PHARMACOL RES, V52, P60, DOI 10.1016/j.phrs.2005.02.015; Szabo C, 2002, CIRCULATION, V106, P2680, DOI 10.1161/01.CIR.0000038365.78031.9C; TANAKA S, 1992, CLIN IMMUNOL IMMUNOP, V62, P258, DOI 10.1016/0090-1229(92)90100-3; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Terashima T, 2005, P NATL ACAD SCI USA, V102, P12525, DOI 10.1073/pnas.0505717102; Tesfaye S, 2010, DIABETES CARE, V33, P2285, DOI 10.2337/dc10-1303; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306-4522(96)00127-3; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wiersema A, 2008, STEM CELL RES, V1, P150, DOI 10.1016/j.scr.2008.02.001; Yasuda H, 2003, PROG NEUROBIOL, V69, P229, DOI 10.1016/S0301-0082(03)00034-0; Zerfaoui M, 2010, J IMMUNOL, V185, P1894, DOI 10.4049/jimmunol.1000646; Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960; Zochodne DW, 2008, CURR OPIN NEUROL, V21, P527, DOI 10.1097/WCO.0b013e32830b84cb	66	16	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					295	308		10.1096/fj.11-186262	http://dx.doi.org/10.1096/fj.11-186262			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21978940	Green Published			2022-12-28	WOS:000299202200030
J	Garstka, MA; Fritzsche, S; Lenart, I; Hein, Z; Jankevicius, G; Boyle, LH; Elliott, T; Trowsdale, J; Antoniou, AN; Zacharias, M; Springer, S				Garstka, Malgorzata Anna; Fritzsche, Susanne; Lenart, Izabela; Hein, Zeynep; Jankevicius, Gytis; Boyle, Louise H.; Elliott, Tim; Trowsdale, John; Antoniou, Antony N.; Zacharias, Martin; Springer, Sebastian			Tapasin dependence of major histocompatibility complex class I molecules correlates with their conformational flexibility	FASEB JOURNAL			English	Article						peptide binding; quality control; ligand binding; natively unstructured proteins	PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; TAP COMPLEX; HETERODIMER; DYNAMICS; PATHWAY; IMMUNODOMINANCE; TRANSPORTERS; ASSOCIATION; SIMULATION	Major histocompatibility complex (MHC) class I molecules present cell internally derived peptides at the plasma membrane for surveillance by cytotoxic T lymphocytes. The surface expression of most class I molecules at least partially depends on the endoplasmic reticulum protein, tapasin, which helps them to bind peptides of the right length and sequence. To determine what makes a class I molecule dependent on support by tapasin, we have conducted in silico molecular dynamics (MD) studies and laboratory experiments to assess the conformational state of tapasin-dependent and -independent class I molecules. We find that in the absence of peptide, the region around the F pocket of the peptide binding groove of the tapasin-dependent molecule HLA-B*44:02 is in a disordered conformational state and that it is converted to a conformationally stable state by tapasin. This novel chaperone function of tapasin has not been described previously. We demonstrate that the disordered state of class I is caused by the presence of two adjacent acidic residues in the bottom of the F pocket of class I, and we suggest that conformational disorder is a common feature of tapasin-dependent class I molecules, making them essentially unable to bind peptides on their own. MD simulations are a useful tool to predict such conformational disorder of class I molecules.-Garstka, M. A., Fritzsche, S., Lenart, I., Hein, Z., Jankevicius, G., Boyle, L. H., Elliott, T., Trowsdale, J., Antoniou, A. N., Zacharias, M., Springer, S. Tapasin dependence of major histocompatibility complex class I molecules correlates with their conformational flexibility. FASEB J. 25, 3989-3998 (2011). www.fasebj.org	[Garstka, Malgorzata Anna; Fritzsche, Susanne; Hein, Zeynep; Jankevicius, Gytis; Springer, Sebastian] Jacobs Univ Bremen, D-28759 Bremen, Germany; [Lenart, Izabela; Antoniou, Antony N.] UCL, Dept Immunol & Mol Pathol, London, England; [Boyle, Louise H.; Trowsdale, John] Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; [Elliott, Tim] Univ Southampton, Sch Med, Southampton, Hants, England; [Zacharias, Martin] Tech Univ Munich, Phys Dept T38, Munich, Germany	Jacobs University; University of London; University College London; University of Cambridge; University of Southampton; Technical University of Munich	Springer, S (corresponding author), Jacobs Univ Bremen, Campus Ring 1, D-28759 Bremen, Germany.	sebastian.springer@queens.oxon.org	Boyle, Louise/AFU-1885-2022; Jankevicius, Gytis/C-7126-2015; Springer, Sebastian/AAJ-7036-2021; Garstka, Malgorzata A./AAU-4401-2020	Jankevicius, Gytis/0000-0002-0212-3923; Springer, Sebastian/0000-0002-5527-6149; Garstka, Malgorzata A./0000-0003-2896-7275; Elliott, Tim/0000-0003-1097-0222; Boyle, Louise/0000-0002-3105-6555; Antoniou, Antony/0000-0002-6536-7781	Deutsche Forschungsgemeinschaft [SP583/2-3]; Fritz Thyssen Foundation; Arthritis Research UK [15293, 17868]; Wellcome Trust; Cancer Research UK; Versus Arthritis [18440] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fritz Thyssen Foundation; Arthritis Research UK(Versus Arthritis); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); Versus Arthritis(Versus Arthritis)	The authors thank Tobias Dick and Lars Ellgaard for discussions; Peter van Endert (Universite Paris Descartes, Paris, France), Robert Tampe (Biocenter, Frankfurt University, Frankfurt, Germany), Ping Wang (University of London, London, UK), and David Williams (University of Toronto, Toronto, ON, Canada) for reagents; and Ute Claus and Ursula Wellbrock for technical assistance. The work was supported by the Deutsche Forschungsgemeinschaft (SP583/2-3 to S.S.), the Fritz Thyssen Foundation (Z.H.), Arthritis Research UK (fellowship 15293 to A.N.A. and studentship 17868 to I.L.), the Wellcome Trust (L.B. and J.T.), and Cancer Research UK (T.E.).	Boulanger DSM, 2010, J IMMUNOL, V184, P73, DOI 10.4049/jimmunol.0803489; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; CASE DA, 2004, AMBER 8; Chen MN, 2007, EMBO J, V26, P1681, DOI 10.1038/sj.emboj.7601624; Dong G, 2009, IMMUNITY, V30, P21, DOI 10.1016/j.immuni.2008.10.018; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Elliott T, 1997, IMMUNOL TODAY, V18, P375, DOI 10.1016/S0167-5699(97)01097-9; FRECH C, 1995, J MOL BIOL, V251, P135, DOI 10.1006/jmbi.1995.0421; Fussell H, 2008, ARTHRITIS RHEUM, V58, P3419, DOI 10.1002/art.23990; Garstka M, 2007, J BIOL CHEM, V282, P30680, DOI 10.1074/jbc.M701721200; Howe C, 2009, EMBO J, V28, P3730, DOI 10.1038/emboj.2009.296; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kienast A, 2007, NAT IMMUNOL, V8, P864, DOI 10.1038/ni1483; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Neisig A, 1996, J IMMUNOL, V156, P3196; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 2000, J IMMUNOL, V164, P292, DOI 10.4049/jimmunol.164.1.292; Powis SJ, 2009, J IMMUNOL METHODS, V340, P81, DOI 10.1016/j.jim.2008.09.006; Praveen PVK, 2010, EUR J IMMUNOL, V40, P214, DOI 10.1002/eji.200939342; Sandhu KS, 2007, PROTEINS, V68, P109, DOI 10.1002/prot.21328; Schneeweiss C, 2009, MOL IMMUNOL, V46, P2054, DOI 10.1016/j.molimm.2009.02.032; Sieker F, 2008, MOL IMMUNOL, V45, P3714, DOI 10.1016/j.molimm.2008.06.009; Sieker F, 2007, PROTEIN SCI, V16, P299, DOI 10.1110/ps.062568407; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; STAM NJ, 1986, J IMMUNOL, V137, P2299; Thammavongsa V, 2006, J IMMUNOL, V177, P3150, DOI 10.4049/jimmunol.177.5.3150; Thirdborough SM, 2008, EUR J IMMUNOL, V38, P364, DOI 10.1002/eji.200737832; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Van Hateren A, 2010, TISSUE ANTIGENS, V76, P428, DOI 10.1111/j.1399-0039.2010.01577.x; Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485; Wearsch PA, 2011, P NATL ACAD SCI USA, V108, P4950, DOI 10.1073/pnas.1102524108; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yaneva R, 2010, MOL IMMUNOL, V47, P649, DOI 10.1016/j.molimm.2009.10.008; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287	42	59	59	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3989	3998		10.1096/fj.11-190249	http://dx.doi.org/10.1096/fj.11-190249			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21836024	Bronze			2022-12-28	WOS:000296723100023
J	Leitao, BB; Jones, MC; Brosens, JJ				Leitao, Beatriz B.; Jones, Marius C.; Brosens, Jan J.			The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death	FASEB JOURNAL			English	Article						endometrium; apoptosis; c-Jun	ENDOMETRIAL STROMAL CELLS; C-JUN; TRANSCRIPTIONAL REPRESSION; PROTEIN INHIBITOR; CROSS-TALK; KINASE; SUMOYLATION; PATHWAY; STAT1; APOPTOSIS	Human endometrial stromal cells (HESCs) exposed to reactive oxygen species (ROS) mount a hypersumoylation response in a c-Jun N-terminal kinase (JNK)-dependent manner. The mechanism that couples JNK signaling to the small ubiquitin-related modifier (SUMO) pathway and its functional consequences are not understood. We show that ROS-dependent JNK activation converges on the SUMO pathway via PIAS1 (protein inhibitor of activated STAT1). Unexpectedly, PIAS1 knockdown not only prevented ROS-dependent hypersumoylation but also enhanced JNK signaling in HESCs. Conversely, PIAS overexpression increased sumoylation of various substrates, including c-Jun, yet inhibited basal and ROS-dependent JNK activity independently of its SUMO ligase function. Expression profiling demonstrated that PIAS1 knockdown enhances and profoundly modifies the transcriptional response to oxidative stress signals. Using a cutoff of 2-fold change or more, a total of 250 ROS-sensitive genes were identified, 97 of which were not dependent on PIAS1. PIAS1 knockdown abolished the regulation of 43 genes but also sensitized 110 other genes to ROS. Importantly, PIAS1 silencing was obligatory for the induction of several cellular defense genes in response to oxidative stress. In agreement, PIAS1 knockdown attenuated ROS-dependent caspase-3/7 activation and subsequent apoptosis. Thus, PIAS1 determines the level of JNK activity in HESCs, couples ROS signaling to the SUMO pathway, and promotes oxidative cell death.-Leitao, B. B., Jones, M. C., Brosens, J. J. The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death. FASEB J. 25, 3416-3425 (2011). www.fasebj.org	[Leitao, Beatriz B.; Jones, Marius C.; Brosens, Jan J.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England	Imperial College London	Brosens, JJ (corresponding author), Univ Warwick, Clin Sci Res Inst, Div Reprod Hlth, Coventry CV2 2DX, W Midlands, England.	j.j.brosens@warwick.ac.uk		Brosens, Jan/0000-0003-0116-9329	Wellcome Trust [084336]; Genesis Trust; UK National Institute for Health Research Biomedical Research Centre	Wellcome Trust(Wellcome TrustEuropean Commission); Genesis Trust; UK National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR))	The authors are indebted to all the women and clinicians who participated in this study. This work was supported by the Wellcome Trust (084336), the Genesis Trust, and the UK National Institute for Health Research Biomedical Research Centre funding scheme. The authors declare no conflicts of interest.	ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bin L, 2008, TRENDS PHARMACOL SCI, V29, P505, DOI 10.1016/j.tips.2008.07.008; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Brosens JJ, 2006, J MOL ENDOCRINOL, V36, P389, DOI 10.1677/jme.1.02060; Brosens JJ, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.11.037; Cheng JK, 2005, J BIOL CHEM, V280, P14492, DOI 10.1074/jbc.M412185200; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; Cloke B, 2008, ENDOCRINOLOGY, V149, P4462, DOI 10.1210/en.2008-0356; Fukuda I, 2009, CHEM BIOL, V16, P133, DOI 10.1016/j.chembiol.2009.01.009; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gellersen B, 2003, J ENDOCRINOL, V178, P357, DOI 10.1677/joe.0.1780357; Gellersen B, 2007, SEMIN REPROD MED, V25, P445, DOI 10.1055/s-2007-991042; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jauniaux E, 2006, HUM REPROD UPDATE, V12, P747, DOI 10.1093/humupd/dml016; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Jones MC, 2006, P NATL ACAD SCI USA, V103, P16272, DOI 10.1073/pnas.0603002103; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Lee JH, 2009, MOL CELL, V35, P806, DOI 10.1016/j.molcel.2009.07.021; Leitao B, 2010, FASEB J, V24, P1541, DOI 10.1096/fj.09-149153; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu B, 2007, CELL, V129, P903, DOI 10.1016/j.cell.2007.03.056; Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Stehmeier P, 2009, MOL CELL, V33, P400, DOI 10.1016/j.molcel.2009.01.013; Takano M, 2007, MOL ENDOCRINOL, V21, P2334, DOI 10.1210/me.2007-0058; Wang Y, 2008, PHYTOMEDICINE, V15, P923, DOI 10.1016/j.phymed.2008.09.003; Weber S, 2009, GENE DEV, V23, P118, DOI 10.1101/gad.489409; Xu Z, 2008, FASEB J, V22, P127, DOI 10.1096/fj.06-7871com; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, CELL CYCLE, V2, P528, DOI 10.4161/cc.2.6.597	38	46	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3416	3425		10.1096/fj.11-186346	http://dx.doi.org/10.1096/fj.11-186346			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21676946	Green Published			2022-12-28	WOS:000295356400013
J	Rasmussen, P; Wyss, MT; Lundby, C				Rasmussen, Peter; Wyss, Matthias T.; Lundby, Carsten			Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans	FASEB JOURNAL			English	Review						adrenaline; exercise; energy metabolism; neuroenergetics; blood flow; transcranial ultrasound Doppler	BETA-ADRENERGIC-BLOCKADE; NONOXIDATIVE CARBOHYDRATE CONSUMPTION; BRAIN ENERGY-METABOLISM; KETY-SCHMIDT TECHNIQUE; AUGMENTS BLOOD-FLOW; TO-PYRUVATE RATIO; PROLONGED EXERCISE; OXYGEN-CONSUMPTION; MAXIMAL EXERCISE; STRENUOUS EXERCISE	At rest, the brain takes up oxygen and carbohydrate at an similar to 6:1 ratio. Exercise increases systemic lactate availability reducing this to as little as 1.7:1 despite a similar to 20% increase in cerebral metabolic rate for oxygen (CMRO(2)), thus indicating a disproportionate increase of carbohydrate metabolism. Underlining mechanisms and metabolic fate for the augmented lactate uptake are unknown. This meta-analysis examines whether adrenergic activation explains the increased lactate uptake, cerebral lactate release following cerebral activation compensates for the extra carbohydrate uptake during exercise, and cerebral lactate uptake spares glucose as fuel. Ten studies (n = 96) measuring arteriovenous differences for lactate, glucose, and oxygen and cerebral blood flow were included. Cerebral lactate uptake increased during brain activation by whole-body exercise compared to the resting state. Unlike glucose, lactate uptake is proportional to its arterial concentration but is unaffected by sympathetic activity. Following exercise, significant cerebral lactate released as arterial lactate levels decreased, which may balance the surplus lactate uptake in the brain during physical activity in the long term. Finally, cerebral glucose uptake was reduced by similar to 25% in relation to CMRO(2) when cerebral lactate uptake increased, suggesting, in part, preferential lactate consumption during activation. This meta-analysis favors the notion that cerebral lactate uptake is mainly passively governed by its availability, but when lactate is available, lactate supplements glucose and supports an increase in cerebral energy metabolism in an activity-dependent manner.-Rasmussen, P., Wyss, M. T., Lundby, C. Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J. 25, 2865-2873 (2011). www.fasebj.org	[Rasmussen, Peter; Lundby, Carsten] Univ Zurich, Zurich Ctr Integrat Human Physiol, Dept Physiol, CH-8057 Zurich, Switzerland; [Wyss, Matthias T.] Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich	Rasmussen, P (corresponding author), Univ Zurich, Zurich Ctr Integrat Human Physiol, Dept Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter@prec.dk	Wyss, Matthias T/A-9659-2012; Wyss, Matthias/F-4095-2011; Ernst-Rasmussen, Peter Bonde/B-8203-2013	Wyss, Matthias T/0000-0002-2037-3424; Ernst-Rasmussen, Peter Bonde/0000-0003-1761-4562				Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Ball KK, 2010, J CEREBR BLOOD F MET, V30, P162, DOI 10.1038/jcbfm.2009.206; BERNTMAN L, 1978, ACTA PHYSIOL SCAND, V104, P101, DOI 10.1111/j.1748-1716.1978.tb06255.x; BLOMQVIST G, 1991, EUR J NUCL MED, V18, P834; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Caesar K, 2008, J PHYSIOL-LONDON, V586, P1337, DOI 10.1113/jphysiol.2007.144154; CARLSSON C, 1977, BRAIN RES, V119, P223, DOI 10.1016/0006-8993(77)90102-0; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Dager SR, 1999, ARCH GEN PSYCHIAT, V56, P70, DOI 10.1001/archpsyc.56.1.70; Dalsgaard MK, 2006, J CEREBR BLOOD F MET, V26, P731, DOI 10.1038/sj.jcbfm.9600256; Dalsgaard MK, 2004, J PHYSIOL-LONDON, V554, P571, DOI 10.1113/jphysiol.2003.055053; Dalsgaard MK, 2002, J PHYSIOL-LONDON, V540, P681, DOI 10.1113/jphysiol.2001.013062; Delp MD, 2001, J PHYSIOL-LONDON, V533, P849, DOI 10.1111/j.1469-7793.2001.t01-1-00849.x; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P1895, DOI 10.1038/jcbfm.2010.151; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Fukuyama H, 1997, NEUROSCI LETT, V228, P183, DOI 10.1016/S0304-3940(97)00381-9; Gam CMB, 2009, CLIN PHYSIOL FUNCT I, V29, P420, DOI 10.1111/j.1475-097X.2009.00889.x; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; HASSELBALCH SG, 1994, J CEREBR BLOOD F MET, V14, P125, DOI 10.1038/jcbfm.1994.17; HEMMINGSEN R, 1979, ACTA PHYSIOL SCAND, V105, P274, DOI 10.1111/j.1748-1716.1979.tb06342.x; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; Ide K, 1999, J APPL PHYSIOL, V87, P1604, DOI 10.1152/jappl.1999.87.5.1604; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; Ido Y, 2004, P NATL ACAD SCI USA, V101, P653, DOI 10.1073/pnas.0307458100; Ido Y, 2001, FASEB J, V15, P1419, DOI 10.1096/fj.00-0652fje; Jorgensen L G, 1995, Acta Physiol Scand Suppl, V625, P1; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; Kemppainen J, 2005, J PHYSIOL-LONDON, V568, P323, DOI 10.1113/jphysiol.2005.091355; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; LAMANNA JC, 1985, BRAIN RES, V326, P299, DOI 10.1016/0006-8993(85)90039-3; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Lin AL, 2010, P NATL ACAD SCI USA, V107, P8446, DOI 10.1073/pnas.0909711107; LOSSNER B, 1984, BIOMED BIOCHIM ACTA, V43, P775; MADSEN PL, 1992, J APPL PHYSIOL, V73, P420, DOI 10.1152/jappl.1992.73.2.420; MADSEN PL, 1993, J CEREBR BLOOD F MET, V13, P646, DOI 10.1038/jcbfm.1993.83; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; MADSEN PL, 1995, J CEREB BLOOD FLOW M, V15, pS77; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mintun MA, 2004, P NATL ACAD SCI USA, V101, P659, DOI 10.1073/pnas.0307457100; Nybo L, 2005, J PHYSIOL-LONDON, V563, P285, DOI 10.1113/jphysiol.2004.075838; Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285; Nybo L, 2003, ACTA PHYSIOL SCAND, V179, P67, DOI 10.1046/j.1365-201X.2003.01175.x; Nybo L, 2003, J APPL PHYSIOL, V95, P1125, DOI 10.1152/japplphysiol.00241.2003; Nybo L, 2007, EXERC SPORT SCI REV, V35, P110, DOI 10.1097/jes.0b013e3180a031ec; OLESEN J, 1971, BRAIN, V94, P646; Pott F, 1996, ACTA PHYSIOL SCAND, V158, P349, DOI 10.1046/j.1365-201X.1996.564325000.x; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Rasmussen P, 2006, EUR J APPL PHYSIOL, V96, P299, DOI 10.1007/s00421-005-0079-3; Rasmussen P, 2011, ACTA PHYSIOL, V201, P475, DOI 10.1111/j.1748-1716.2010.02223.x; Rasmussen P, 2010, J PHYSIOL-LONDON, V588, P1985, DOI 10.1113/jphysiol.2009.186767; Rasmussen P, 2010, INT J IND ERGONOM, V40, P190, DOI 10.1016/j.ergon.2008.06.002; Rasmussen P, 2007, J CEREBR BLOOD F MET, V27, P1082, DOI 10.1038/sj.jcbfm.9600416; Rasmussen P, 2006, J APPL PHYSIOL, V101, P1406, DOI 10.1152/japplphysiol.00423.2006; Rasmussen P, 2010, J CEREBR BLOOD F MET, V30, P1240, DOI 10.1038/jcbfm.2010.25; Rasmussen P, 2009, J APPL PHYSIOL, V107, P1799, DOI 10.1152/japplphysiol.00468.2009; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; RICHTER EA, 1982, AM J PHYSIOL, V242, pE25, DOI 10.1152/ajpendo.1982.242.1.E25; Schmalbruch IK, 2002, STROKE, V33, P251, DOI 10.1161/hs0102.101233; SCHMOLL D, 1995, EUR J BIOCHEM, V227, P308, DOI 10.1111/j.1432-1033.1995.tb20390.x; Seifert T, 2009, AM J PHYSIOL-REG I, V297, pR867, DOI 10.1152/ajpregu.00277.2009; Seifert T, 2009, ACTA PHYSIOL, V196, P295, DOI 10.1111/j.1748-1716.2008.01946.x; Seifert T, 2010, AM J PHYSIOL-REG I, V298, pR372, DOI 10.1152/ajpregu.00525.2009; Seifert TS, 2009, J PHYSIOL-LONDON, V587, P285, DOI 10.1113/jphysiol.2008.162073; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vlassenko AG, 2006, P NATL ACAD SCI USA, V103, P1964, DOI 10.1073/pnas.0510632103; Vlassenko AG, 2006, NEUROIMAGE, V33, P1036, DOI 10.1016/j.neuroimage.2006.06.065; Volianitis S, 2008, J PHYSIOL-LONDON, V586, P107, DOI 10.1113/jphysiol.2007.142273; Wiesinger H, 1997, GLIA, V21, P22, DOI 10.1002/(SICI)1098-1136(199709)21:1<22::AID-GLIA3>3.0.CO;2-3; Zielke HR, 2007, J NEUROCHEM, V101, P9, DOI 10.1111/j.1471-4159.2006.04335.x	73	59	59	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2011	25	9					2865	2873		10.1096/fj.11-183822	http://dx.doi.org/10.1096/fj.11-183822			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	814GD	21602451	Bronze			2022-12-28	WOS:000294435200003
J	Brecht, K; Weigert, A; Hu, J; Popp, R; Fisslthaler, B; Korff, T; Fleming, I; Geisslinger, G; Brune, B				Brecht, Kerstin; Weigert, Andreas; Hu, Jiong; Popp, Ruediger; Fisslthaler, Beate; Korff, Thomas; Fleming, Ingrid; Geisslinger, Gerd; Bruene, Bernhard			Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E-2	FASEB JOURNAL			English	Article						lipid signaling; cancer; cell death; myeloid cells	WOUND-HEALING DEFECT; SPHINGOSINE KINASE 2; TUMOR ANGIOGENESIS; MOUSE MODEL; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; GROWTH; CYCLOOXYGENASE-2; PHAGOCYTOSIS; SUPPRESSOR	Macrophages contribute to tissue homeostasis in the developing as well as the adult organism. They promote tissue regeneration and remodeling after injury, which requires efficient neoangiogenesis. Signaling pathways activating an angiogenic program in macrophages are still poorly defined. We report that apoptotic cells (ACs), which originate from stressed or damaged tissues, can induce angiogenic properties in primary human macrophages. The signal originating from ACs is the lipid mediator sphingosine-1-phosphate (S1P), which activates S1P1/3 on macrophages to up-regulate cyclooxygenase-2. The formation and liberation of prostaglandin E-2 (PGE(2)) then stimulates migration of endothelial cells. This is demonstrated by using PGE(2) receptor antagonists or a neutralizing PGE(2) antibody in vitro, thereby attenuating endothelial cell migration using a Boyden chamber assay. In vivo, neutralization of PGE(2) from proangiogenic macrophage supernatants blocked vessel formation into Matrigel plugs. In particular, apoptotic cancer cells shifted prostanoid formation in macrophages selectively toward PGE(2) by up-regulating cyclooxygenase-2 and microsomal prostaglandin E synthase-1 (mPGES1), while down-regulating the PGE(2)-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or prostaglandin-D synthase (PGDS). Angiogenic programming of macrophages by ACs, therefore, may control responses to tissue stress such as in tumors, where macrophages support cancer progression.-Brecht, K., Weigert, A., Hu, J., Popp, R., Fisslthaler, B., Korff, T., Fleming, I., Geisslinger, G., Brune, B. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E-2. FASEB J. 25, 2408-2417 (2011). www.fasebj.org	[Brecht, Kerstin] Goethe Univ Frankfurt, Inst Bio Chem 1, ZAFES, D-60590 Frankfurt, Germany; [Hu, Jiong; Popp, Ruediger; Fisslthaler, Beate; Fleming, Ingrid] Goethe Univ Frankfurt, Inst Vasc Signaling, D-60590 Frankfurt, Germany; [Geisslinger, Gerd] Goethe Univ Frankfurt, Inst Clin Pharmacol, D-60590 Frankfurt, Germany; [Korff, Thomas; Geisslinger, Gerd] Heidelberg Univ, Inst Physiol & Pathophysiol, Heidelberg, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Ruprecht Karls University Heidelberg	Brecht, K (corresponding author), Goethe Univ Frankfurt, Inst Bio Chem 1, ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@pathobiochemie1.de	Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014; Weigert, Andreas/E-6540-2010	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Weigert, Andreas/0000-0002-7529-1952; Hu, Jiong/0000-0001-8266-0886	Deutsche Forschungsgemeinschaft [Br 999, FOG 784, Ge 695, Exzellenzcluster 147]; Sander Foundation; Hans Kroner-Graduiertenkolleg (HKG); Loewe Lipid Signaling Forschungszentrum Frankfurt (LiFF); Deutsche Krebshilfe	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Sander Foundation; Hans Kroner-Graduiertenkolleg (HKG); Loewe Lipid Signaling Forschungszentrum Frankfurt (LiFF); Deutsche Krebshilfe(Deutsche Krebshilfe)	The authors thank Franz Josef Streb, Margarethe Wiebe, and Ender Serbest for excellent technical assistance. The authors thank Dr. C. J. S. Edgell (University of North Carolina, Chapel Hill, NC, USA) for providing the human EC line EA.hy926. This work was supported by grants from Deutsche Forschungsgemeinschaft (Br 999; FOG 784; Ge 695; and Exzellenzcluster 147, Cardio-Pulmonary Systems), the Sander Foundation, Hans Kroner-Graduiertenkolleg (HKG), the Loewe Lipid Signaling Forschungszentrum Frankfurt (LiFF), and Deutsche Krebshilfe (to B.B.).	Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Coste O, 2008, J CELL MOL MED, V12, P995, DOI 10.1111/j.1582-4934.2008.00160.x; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eruslanov E, 2010, J LEUKOCYTE BIOL, V88, P839, DOI 10.1189/jlb.1209821; Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135; Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Goren I, 2009, AM J PATHOL, V175, P132, DOI 10.2353/ajpath.2009.081002; Gough MJ, 2001, CANCER RES, V61, P7240; Herr B, 2009, BLOOD, V114, P2140, DOI 10.1182/blood-2009-01-201889; Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569; Johann AM, 2008, J IMMUNOL, V180, P1239, DOI 10.4049/jimmunol.180.2.1239; Kamata H, 2010, BIOMED PHARMACOTHER, V64, P409, DOI 10.1016/j.biopha.2010.01.017; Kawanabe T, 2007, J DERMATOL SCI, V48, P53, DOI 10.1016/j.jdermsci.2007.06.002; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Korff T, 1999, J CELL SCI, V112, P3249; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Linke B, 2009, J PROTEOME RES, V8, P4851, DOI 10.1021/pr900106v; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; Meszaros AJ, 1999, J LEUKOCYTE BIOL, V65, P35, DOI 10.1002/jlb.65.1.35; Mirza R, 2009, AM J PATHOL, V175, P2454, DOI 10.2353/ajpath.2009.090248; Murata T, 2008, P NATL ACAD SCI USA, V105, P20009, DOI 10.1073/pnas.0805171105; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Peter C, 2010, APOPTOSIS, V15, P1007, DOI 10.1007/s10495-010-0472-1; Peters T, 2005, EMBO J, V24, P3400, DOI 10.1038/sj.emboj.7600809; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sindrilaru A, 2009, BLOOD, V113, P5266, DOI 10.1182/blood-2008-07-166702; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Wang J, 2011, MED ONCOL, V28, pS577, DOI 10.1007/s12032-010-9734-6; Weigert A, 2007, MOL BIOL CELL, V18, P3810, DOI 10.1091/mbc.E06-12-1096; Weigert A, 2006, BLOOD, V108, P1635, DOI 10.1182/blood-2006-04-014852; Weigert A, 2010, BLOOD, V115, P3531, DOI 10.1182/blood-2009-10-243444; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005	45	55	57	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2011	25	7					2408	2417		10.1096/fj.10-179473	http://dx.doi.org/10.1096/fj.10-179473			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	785PY	21450910				2022-12-28	WOS:000292242200032
J	Levin, RI; Fishman, GI				Levin, Richard I.; Fishman, Glenn I.			The power of Pasteur's quadrant: cardiovascular disease at the turn of the century	FASEB JOURNAL			English	Review						cardiology history; atherosclerosis; heart failure-regenerative medicine; methods of science	CORONARY-HEART-DISEASE; MORTALITY; FAILURE; RISK; RNAS	During the life span of The FASEB Journal, the decline in cardiovascular mortality was astonishing as the fundamental bases of the complex syndromes of cardiovascular disease were illuminated. In this Silver Anniversary Review, we highlight a few pivotal advances in the field and relate them to research in Pasteur's quadrant, the region of investigation driven by both a desire for fundamental understanding and the consideration of its use. In the second half of the 20th century, we advanced from little pathophysiologic understanding to a near-complete understanding and effective, evidence-based therapeutics for vascular disorders and a similar development of pharmacotherapy to address heart failure, primarily through agents that antagonize the excessive concentration of circulating neurohumoral agents. In the current era, we have witnessed "the rise of the machines," from stents to cardiac resynchronization therapy. The next wave of treatments will build on an increasingly sophisticated understanding of the molecular determinants of cardiovascular disorders. We briefly consider the promise of regenerative medicine and are intrigued by the possibility for the direct reprogramming of resident cardiac fibroblasts into cardiomyocytes. As for the future, genomic profiling should help physicians recommend individualized risk factor modification targeted to prevent specific manifestations of cardiovascular disease. Transcriptional and biomarker analyses will almost surely be used individually to tailor therapy for those at risk of or experiencing cardiovascular disease. Given the ongoing exponential expansion of scientific knowledge, all of human ingenuity will be needed to fully utilize the power of Pasteur's quadrant and to unleash another quarter century in cardiology as scientifically fruitful and effective on human health as the last.-Levin, R. I., Fishman, G. I. The power of Pasteur's quadrant: cardiovascular disease at the turn of the century. FASEB J. 25, 1788-1792 (2011). www.fasebj.org	[Levin, Richard I.] McGill Univ, Fac Med, Montreal, PQ, Canada; [Fishman, Glenn I.] NYU, Sch Med, Leon H Charney Div Cardiol, New York, NY 10016 USA	McGill University; New York University	Levin, RI (corresponding author), McGill Fac Med, 3640 Rue Montagne, Montreal, PQ H3G 2M1, Canada.	richard.levin@mcgill.ca; glenn.fishman@med.nyu.edu		Fishman, Glenn/0000-0002-2366-8527	U.S. National Institutes of Health [R01HL82727, R01HL081336, R01ES008681]; New York State Stem Cell Science (NYSTEM) [C024327]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082727, R01HL081336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York State Stem Cell Science (NYSTEM); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The work of the authors is supported by U.S. National Institutes of Health grants R01HL82727, R01HL081336, and R01ES008681 and New York State Stem Cell Science (NYSTEM) grant C024327. The authors thank Laurence Miall and Deanna Cowan (McGill University) for technical assistance.	[Anonymous], OMIM ONLINE MENDELIA; Boilson BA, 2010, CURR PROB CARDIOLOGY, V35, P8, DOI 10.1016/j.cpcardiol.2009.09.001; Braunwald E, 2003, J AM COLL CARDIOL, V42, P2031, DOI 10.1016/j.jacc.2003.08.025; BRESLOW JL, 1995, ADV EXP MED BIOL, V369, P65; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DINSMORE CE, 1992, HIST REGENERATION RE; Fox CS, 2004, CIRCULATION, V110, P522, DOI 10.1161/01.CIR.0000136993.34344.41; Heberden W., 1772, MED T COLL PHYSICIAN, V2, P59; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HUNT JA, 1958, BIOCHIM BIOPHYS ACTA, V28, P546, DOI 10.1016/0006-3002(58)90517-1; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; King SB, 2000, CIRCULATION, V102, P81; KRONZON I, 1993, PROG CARDIOVASC DIS, V36, P39, DOI 10.1016/0033-0620(93)90021-5; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Levin RI, 2009, J AM COLL CARDIOL, V53, P2068, DOI 10.1016/j.jacc.2009.03.011; Lewis T, 1933, DIS HEART; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lopshire JC, 2009, CIRCULATION, V120, P286, DOI 10.1161/CIRCULATIONAHA.108.812412; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCALISTER FA, 2007, JAMA-J AM MED ASSOC, V297, P2504; McNamara Dennis M, 2010, Heart Fail Clin, V6, P35, DOI 10.1016/j.hfc.2009.08.004; Moodie RL., 1923, PALEOPATHOLOGY INTRO; OBERPRILLER JO, 1974, J EXP ZOOL, V187, P249, DOI 10.1002/jez.1401870208; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Pencina MJ, 2009, CIRCULATION, V119, P3078, DOI 10.1161/CIRCULATIONAHA.108.816694; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Price D.S., 1951, ARCH INTERNATIONALES, V14, P85; RENTROP KP, 1984, NEW ENGL J MED, V311, P1457, DOI 10.1056/NEJM198412063112301; Rosenzweig A, 2010, NEW ENGL J MED, V363, P1471, DOI 10.1056/NEJMe1007902; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruff CT, 2011, NAT REV CARDIOL, V8, P140, DOI 10.1038/nrcardio.2010.199; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SIEGLER MG, 2010, TECH CRUNCH     0804; Slaughter MS, 2009, NEW ENGL J MED, V361, P2241, DOI 10.1056/NEJMoa0909938; STOKES D, 1997, PASTEURS QUADRANT BA, P58; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Topol EJ, 2005, J AM COLL CARDIOL, V46, P1456, DOI 10.1016/j.jacc.2005.06.064; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; Wang Q, 2004, AM J HUM GENET, V74, P262, DOI 10.1086/381560; Weissmann Gerald, 2011, FASEB J, V25, P1, DOI 10.1096/fj.11-0101ufm; Withering W, 1785, ACCOUNT FOXGLOVE SOM	49	0	0	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1788	1792		10.1096/fj.11-0604ufm	http://dx.doi.org/10.1096/fj.11-0604ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21622696	Green Published			2022-12-28	WOS:000291023800003
J	Frolova, EG; Sopko, N; Blech, L; Popovic, ZB; Li, JB; Vasanji, A; Drumm, C; Krukovets, I; Jain, MK; Penn, MS; Plow, EF; Stenina, OI				Frolova, Ella G.; Sopko, Nikolai; Blech, Lauren; Popovic, Zoran B.; Li, Jianbo; Vasanji, Amit; Drumm, Carla; Krukovets, Irene; Jain, Mukesh K.; Penn, Marc S.; Plow, Edward F.; Stenina, Olga I.			Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload	FASEB JOURNAL			English	Article						heart hypertrophy; extracellular matrix; transverse aortic constriction	GROWTH-FACTOR-BETA; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; ENDOTHELIAL-CELLS; HEART-FAILURE; UP-REGULATION; MICE; ANGIOGENESIS; TRANSITION; BONE	Thrombospondin-4 (TSP-4) expression increases dramatically in hypertrophic and failing hearts in rodent models and in humans. The aim of this study was to address the function of TSP-4 in the heart. TSP-4-knockout (Thbs4(-/-)) and wild-type (WT) mice were subjected to transverse aortic constriction (TAC) to increase left ventricle load. After 2 wk, Thbs4(-/-) mice had a significantly higher heart weight/body weight ratio than WT mice. The additional increase in the heart weight in TAC Thbs4(-/-) mice was due to increased deposition of extracellular matrix (ECM). The levels of interstitial collagens were higher in the knockout mice, but the size of cardiomyocytes and apoptosis in the myocardium was unaffected by TSP-4 deficiency, suggesting that increased reactive fibrosis was the primary cause of the higher heart weight. The increased ECM deposition in Thbs4(-/-) mice was accompanied by changes in functional parameters of the heart and decreased vessel density. The expression of inflammatory and fibrotic genes known to be influential in myocardial remodeling changed as a result of TSP-4 deficiency in vivo and as a result of incubation of cells with recombinant TSP-4 in vitro. Thus, TSP-4 is involved in regulating the adaptive responses of the heart to pressure overload, suggesting its important role in myocardial remodeling. Our study showed a direct influence of TSP-4 on heart function and to identify the mechanism of its effects on heart remodeling.-Frolova, E. G., Sopko, N., Blech, L., Popovic, Z. B., Li, J., Vasanji, A., Drumm, C., Krukovets, I., Jain, M. K., Penn, M. S., Plow, E. F., Stenina, O. I. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 26, 2363-2373 (2012). www.fasebj.org	[Plow, Edward F.; Stenina, Olga I.] Case Western Reserve Univ, Sch Med, Cleveland Clin, Dept Mol Cardiol,Lerner Res Inst, Cleveland, OH 44195 USA; [Frolova, Ella G.; Blech, Lauren; Drumm, Carla; Krukovets, Irene; Plow, Edward F.; Stenina, Olga I.] Case Western Reserve Univ, Sch Med, Cleveland Clin, Joseph J Jacob Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; [Sopko, Nikolai; Penn, Marc S.] Case Western Reserve Univ, Sch Med, Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA; [Popovic, Zoran B.; Li, Jianbo] Case Western Reserve Univ, Sch Med, Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Vasanji, Amit] Case Western Reserve Univ, Sch Med, Cleveland Clin, Biomed Imaging & Anal Core, Cleveland, OH 44195 USA; [Jain, Mukesh K.] Case Western Reserve Univ, Sch Med, Cleveland Clin, Case Cardiovasc Res Inst, Cleveland, OH 44195 USA	Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	Plow, EF (corresponding author), Case Western Reserve Univ, Sch Med, Cleveland Clin, Dept Mol Cardiol,Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	plowe@ccf.org; stenino@ccf.org	Sopko, Nikolai/AAL-2036-2020	Sopko, Nikolai/0000-0003-4913-0570; popovic, zoran/0000-0001-5692-2299; , Olga/0000-0002-1256-0545	U.S. National Institutes of Health [P50 HL077107, R01 DK067532]	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Drs. Judy Drazba and Satyamangla Prasad (Cleveland Clinic) for helpful discussions. This work was supported by U.S. National Institutes of Health grants (P50 HL077107 to E. F. P. and R01 DK067532 to O.I.S.).	Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Alford AI, 2006, BONE, V38, P749, DOI 10.1016/j.bone.2005.11.017; Bonnefoy A, 2008, CELL MOL LIFE SCI, V65, P713, DOI 10.1007/s00018-007-7487-y; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bradshaw AD, 2009, CIRCULATION, V119, P269, DOI 10.1161/CIRCULATIONAHA.108.773424; Chatila Khaled, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P21; Cingolani OH, 2011, CIRC RES, V109, P1410, DOI 10.1161/CIRCRESAHA.111.256743; Collins KA, 2001, AM J PHYSIOL-HEART C, V280, pH1954, DOI 10.1152/ajpheart.2001.280.5.H1954; Creemers EE, 2011, CARDIOVASC RES, V89, P265, DOI 10.1093/cvr/cvq308; Dorn GW, 2008, J MOL MED, V86, P1085, DOI 10.1007/s00109-008-0362-y; Frangogiannis NG, 2005, CIRCULATION, V111, P2935, DOI 10.1161/CIRCULATIONAHA.104.510354; Frolova EG, 2010, CIRC RES, V107, P1313, DOI 10.1161/CIRCRESAHA.110.232371; Gabrielsen A, 2007, J MOL CELL CARDIOL, V42, P870, DOI 10.1016/j.yjmcc.2006.12.016; Ghosh AK, 2010, CIRCULATION, V122, P1200, DOI 10.1161/CIRCULATIONAHA.110.955245; Hankenson KD, 2005, MATRIX BIOL, V24, P362, DOI 10.1016/j.matbio.2005.05.008; Hankenson KD, 2005, MOL CELL BIOL, V25, P5599, DOI 10.1128/MCB.25.13.5599-5606.2005; Izumiya Y, 2006, HYPERTENSION, V47, P887, DOI 10.1161/01.HYP.0000215207.54689.31; Krady MM, 2008, AM J PATHOL, V173, P879, DOI 10.2353/ajpath.2008.080128; Kyriakides TR, 2001, AM J PATHOL, V159, P1255, DOI 10.1016/S0002-9440(10)62512-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mirochnik Y, 2008, CURR DRUG TARGETS, V9, P851, DOI 10.2174/138945008785909347; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Mustonen E, 2008, BIOCHEM BIOPH RES CO, V373, P186, DOI 10.1016/j.bbrc.2008.05.164; Pluskota E, 2005, BLOOD, V106, P3970, DOI 10.1182/blood-2005-03-1292; Popovic ZB, 2005, J PHYSIOL-LONDON, V568, P255, DOI 10.1113/jphysiol.2005.090779; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; ROBINSON TF, 1986, SCI AM, V254, P84, DOI 10.1038/scientificamerican0686-84; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rysa J, 2005, HYPERTENSION, V45, P927, DOI 10.1161/01.HYP.0000161873.27088.4c; Salcedo L, 2011, INT J COLORECTAL DIS, V26, P1577, DOI 10.1007/s00384-011-1269-6; Schroen B, 2004, CIRC RES, V95, P515, DOI 10.1161/01.RES.0000141019.20332.3e; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; Sezaki S, 2005, EXP BIOL MED, V230, P621; Spinale FG, 2004, CIRC RES, V95, P446, DOI 10.1161/01.RES.0000142315.88477.42; Stenina OI, 2005, FASEB J, V19, P1893, DOI 10.1096/fj.05-3712fje; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Tan FL, 2002, P NATL ACAD SCI USA, V99, P11387, DOI 10.1073/pnas.162370099; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; WEBER KT, 1993, CARDIOVASC RES, V27, P341, DOI 10.1093/cvr/27.3.341; Xia Y, 2009, HISTOCHEM CELL BIOL, V131, P471, DOI 10.1007/s00418-008-0541-5	42	98	102	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2363	2373		10.1096/fj.11-190728	http://dx.doi.org/10.1096/fj.11-190728			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22362893	Green Published			2022-12-28	WOS:000305017200014
J	Kahali, S; Sarcar, B; Prabhu, A; Seto, E; Chinnaiyan, P				Kahali, Soumen; Sarcar, Bhaswati; Prabhu, Antony; Seto, Edward; Chinnaiyan, Prakash			Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response	FASEB JOURNAL			English	Article						HDAC inhibitor; GRP78; acetylation	CHAPERONE FUNCTION; CANCER CELLS; ER STRESS; ACETYLATION; ACTIVATION; INHIBITORS; EXPRESSION; GROWTH; DOMAIN; ATF6	Post-translational modification through protein acetylation is emerging as an important mode of cellular regulation. We have previously demonstrated the role that glucose-regulated protein 78 kDa (GRP78) acetylation and subsequent activation of the unfolded protein response (UPR) play in the antitumor activity of class I histone deacetylase (HDAC) inhibitors, which primarily target class I HDACs. In this study, we explored the contributory role these class I HDACs may play in UPR regulation. Binding studies were performed using immunoprecipitation/immunoblotting following dual-transfection with HA-tagged GRP78 and FLAG-tagged HDACs. Subcellular localization was performed using Western blot of fractionated cell lysates and confocal microscopy. Individual HDACs were inhibited using RNA interference. We identified the potential of HDACs 1, 2, and 3 to bind to GRP78. These HDACs colocalized with GRP78 in the endoplasmic reticulum (ER). Inhibition of individual HDACs resulted in GRP78 acetylation and selective activation of the UPR. Although traditionally viewed as nuclear enzymes, we demonstrate that Class I HDACs localize to the ER, bind to GRP78, and selectively activate the UPR, representing a novel mode of UPR regulation and mechanism of action of HDAC inhibitors.-Kahali, S., Sarcar, B., Prabhu, A., Seto, E., Chinnaiyan, P. Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J. 26, 2437-2445 (2012). www.fasebj.org	[Kahali, Soumen; Sarcar, Bhaswati; Prabhu, Antony; Chinnaiyan, Prakash] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA; [Kahali, Soumen; Sarcar, Bhaswati; Prabhu, Antony; Chinnaiyan, Prakash] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut, Tampa, FL 33612 USA; [Seto, Edward] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chinnaiyan, P (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol & Expt Therapeut, SRB3,12902 Magnolia Dr, Tampa, FL 33612 USA.	prakash.chinnaiyan@moffitt.org	Dayalan, Antony Herold Prabhu Packiam/J-8625-2019	Dayalan, Antony Herold Prabhu Packiam/0000-0003-2401-0118	American Cancer Society [RSG-11-029-01-CSM]; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge Joseph Johnson (Moffitt Imaging Core Facility, H. Lee Moffitt Cancer Center) for assistance with confocal microscopy. This work was funded by the American Cancer Society (RSG-11-029-01-CSM).	Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Dangond F, 2001, INT J ONCOL, V19, P773; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Kahali S, 2011, METHOD ENZYMOL, V490, P159, DOI 10.1016/B978-0-12-385114-7.00010-6; Kahali S, 2010, NEOPLASIA, V12, P80, DOI 10.1593/neo.91422; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Lee HK, 2008, NEURO-ONCOLOGY, V10, P236, DOI 10.1215/15228517-2008-006; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; MacDonald VE, 2009, EPIGENETICS-US, V4, P139, DOI 10.4161/epi.4.3.8484; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Ni M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006868; Park JJ, 2007, J GEN VIROL, V88, P3214, DOI 10.1099/vir.0.83171-0; Rao R, 2010, MOL CANCER THER, V9, P942, DOI 10.1158/1535-7163.MCT-09-0988; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yu XD, 2002, J NATL CANCER I, V94, P504; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	35	34	34	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2437	2445		10.1096/fj.11-193706	http://dx.doi.org/10.1096/fj.11-193706			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22389438	Green Published			2022-12-28	WOS:000305017200021
J	Smits, M; Wurdinger, T; van het Hof, B; Drexhage, JAR; Geerts, D; Wesseling, P; Noske, DP; Vandertop, WP; de Vries, HE; Reijerkerk, A				Smits, Michiel; Wurdinger, Thomas; van het Hof, Bert; Drexhage, Joost A. R.; Geerts, Dirk; Wesseling, Pieter; Noske, David P.; Vandertop, W. Peter; de Vries, Helga E.; Reijerkerk, Arie			Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma	FASEB JOURNAL			English	Article						brain cancer; brain endothelial cell	ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; SAF-1 TRANSCRIPTION FACTOR; GENE-EXPRESSION; FUNCTIONAL COOPERATION; SIGNALING PATHWAY; SYNOVIOCYTE CELLS; BRAIN-TUMORS; FACTOR-I; INDUCTION	In patients with glioblastomas, vascular endothelial growth factor (VEGF) is a key mediator of tumor-associated angiogenesis. Glioblastomas are notorious for their capacity to induce neovascularization, driving continued tumor growth. Here we report that miR-125b is down-regulated in glioblastoma-associated endothelial cells, resulting in increased expression of its target, myc-associated zinc finger protein (MAZ), a transcription factor that regulates VEGF. The down-regulation of miR-125b was also observed on exposure of endothelial cells to glioblastoma-conditioned medium or VEGF, resulting in increased MAZ expression. Further analysis revealed that inhibition of MAZ accumulation by miR-125b, or by MAZ-specific shRNAs, attenuated primary human brain endothelial cell migration and tubule formation in vitro, phenomena considered to mimick angiogenic processes in vitro. Moreover, MAZ expression was elevated in brain blood vessels of glioblastoma patients. Altogether these results demonstrate a functional feed-forward loop in glioblastoma-related angiogenesis, in which VEGF inhibits the expression of miR-125b, resulting in increased expression of MAZ, which in its turn causes transcriptional activation of VEGF. This loop is functionally impeded by the VEGF receptor inhibitor vandetanib, and our results may contribute to the further development of inhibitors of tumor-angiogenesis.-Smits, M., Wurdinger, T., van het Hof, B., Drexhage, J. A. R., Geerts, D., Wesseling, P., Noske, D. P., Vandertop, W. P., de Vries, H. E., Reijerkerk, A. Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. FASEB J. 26, 2639-2647 (2012). www.fasebj.org	[van het Hof, Bert; Drexhage, Joost A. R.; de Vries, Helga E.; Reijerkerk, Arie] Vrije Univ Med Ctr, Blood Brain Barrier Res Grp, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; [Smits, Michiel; Wurdinger, Thomas; Noske, David P.; Vandertop, W. Peter] Vrije Univ Med Ctr, Neurooncol Res Grp, Dept Neurosurg, Canc Ctr Amsterdam, NL-1007 MB Amsterdam, Netherlands; [Wesseling, Pieter] Vrije Univ Med Ctr, Neurooncol Res Grp, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; [Wurdinger, Thomas] Harvard Univ, Sch Med, Dept Neurol, Mol Neurogenet Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Wurdinger, Thomas] Harvard Univ, Sch Med, Dept Radiol, Mol Neurogenet Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Wurdinger, Thomas] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; [Geerts, Dirk] Erasmus Univ, Dept Pediat Oncol & Hematol, Sophia Childrens Hosp, Med Ctr, Rotterdam, Netherlands; [Wesseling, Pieter] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Vandertop, W. Peter] Univ Amsterdam, Acad Med Ctr, Neurosurg Ctr Amsterdam, NL-1105 AZ Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam	Reijerkerk, A (corresponding author), Vrije Univ Med Ctr, Blood Brain Barrier Res Grp, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands.	t.wurdinger@vumc.nl; a.reijerkerk@vumc.nl	Wesseling, P./H-8114-2014; Vandertop, William P./K-9288-2018; Wurdinger, Thomas/AAA-5645-2022; Geerts, Dirk/K-8260-2015	Wesseling, P./0000-0001-5453-5201; Geerts, Dirk/0000-0002-6386-8187; Vandertop, William/0000-0001-5417-0265; de Vries, Helga/0000-0001-7904-7124; Noske, David/0000-0001-5992-4468	Stichting Translational Research Cancer Center Amsterdam/Vrije Universiteit Medical Center; Nederlandse Organisatie voor Wetenschappelijk Onderzoek-VIDI; Netherlands Genomics Initiative	Stichting Translational Research Cancer Center Amsterdam/Vrije Universiteit Medical Center; Nederlandse Organisatie voor Wetenschappelijk Onderzoek-VIDI(Netherlands Organization for Scientific Research (NWO)); Netherlands Genomics Initiative	This work was supported by Stichting Translational Research Cancer Center Amsterdam/Vrije Universiteit Medical Center and Nederlandse Organisatie voor Wetenschappelijk Onderzoek-VIDI (T. W.) and Netherlands Genomics Initiative (A. R. and J. A. R. D.). M. S., T. W., and A. R. performed the expression analysis, target analysis, endothelial migration, and Matrigel experiments, wrote the manuscript, and designed the experiments; D. G. provided the shRNA constructs; P. W., D. P. N., W. P. V., and H. E. V. assisted in concept design and writing.	Alpini G, 2011, J HEPATOL, V55, P1339, DOI 10.1016/j.jhep.2011.04.015; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dudas J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-92; Fischer I, 2005, BRAIN PATHOL, V15, P297; Giannopoulos K, 2006, INT J ONCOL, V29, P95; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hennequin LF, 2002, J MED CHEM, V45, P1300, DOI 10.1021/jm011022e; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; Knowles Jonathan, 2005, Current Vascular Pharmacology, V3, P309, DOI 10.2174/157016105774329462; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee OH, 2008, ONCOGENE, V27, P1310, DOI 10.1038/sj.onc.1210731; Lia D, 2010, J HYPERTENS, V28, P1646, DOI 10.1097/HJH.0b013e32833a4922; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Miebach S, 2006, J NEURO-ONCOL, V76, P39, DOI 10.1007/s11060-005-3674-6; Parks CL, 1996, J BIOL CHEM, V271, P4417; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 2005, J IMMUNOL, V175, P4039, DOI 10.4049/jimmunol.175.6.4039; Ray A, 2003, ARTHRITIS RHEUM, V48, P134, DOI 10.1002/art.10706; Ray A, 2003, J BIOL CHEM, V278, P22586, DOI 10.1074/jbc.M300705200; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Ray A, 2011, MOL CANCER RES, V9, P1030, DOI 10.1158/1541-7786.MCR-10-0598; Ray BK, 2007, J IMMUNOL, V178, P1774, DOI 10.4049/jimmunol.178.3.1774; Ray BK, 2004, CIRC RES, V95, P1082, DOI 10.1161/01.RES.0000150046.48115.80; Reardon DA, 2011, J NATL COMPR CANC NE, V9, P414, DOI 10.6004/jnccn.2011.0038; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Smits M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016282; Sohl M, 2009, GENE, V437, P54, DOI 10.1016/j.gene.2009.02.017; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Wang X, 2008, BREAST CANCER RES TR, V111, P103, DOI 10.1007/s10549-007-9765-7; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Wurdinger T, 2009, CELL ADHES MIGR, V3, P230, DOI 10.4161/cam.3.2.7910; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177; Yin JH, 2000, BIOCHEM BIOPH RES CO, V279, P30, DOI 10.1006/bbrc.2000.3896; Zaytseva YY, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-90; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337; Zundel W, 2000, GENE DEV, V14, P391	50	76	76	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2639	2647		10.1096/fj.11-202820	http://dx.doi.org/10.1096/fj.11-202820			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415301				2022-12-28	WOS:000305017200039
J	Zheng, M; Kim, SK; Joe, Y; Back, SH; Cho, HR; Kim, HP; Ignarro, LJ; Chung, HT				Zheng, Min; Kim, Seul-Ki; Joe, Yeonsoo; Back, Sung Hoon; Cho, Hong R.; Kim, Hong Pyo; Ignarro, Louis J.; Chung, Hun-Taeg			Sensing endoplasmic reticulum stress by protein kinase RNA-like endoplasmic reticulum kinase promotes adaptive mitochondrial DNA biogenesis and cell survival via heme oxygenase-1/carbon monoxide activity	FASEB JOURNAL			English	Article						unfolded protein response; nuclear factor E2-related factor2; Nrf2; nuclear respiratory factor-1; NRF-1; mitochondrial transcription factor A; TFAM	NITRIC-OXIDE; MUSCLE-CELLS; DIFFERENTIATION; APOPTOSIS; INDUCTION	Endoplasmic reticulum (ER) stress activates the adaptive unfolded protein response, allowing cells to recover folding capacity in the organelle. However, the overwhelming response to severe damage results in apoptotic cell death. Because of the physical proximity between ER and mitochondria, a functional interrelationship between these two organelles, including mitochondrial ATP production and apoptosis, has been suggested. The adaptive response to ER stress includes the maintenance of cellular energetics, which eventually determines cell fate. We previously demonstrated that heme oxygenase-1 (HO-1) activity protects cells against ER stress in a protein kinase RNA-like endoplasmic reticulum kinase (PERK)-dependent pathway. Here, we provide evidence that PERK-mediated induction of HO-1 in murine macrophages, RAW264.7, relays ER stress to mitochondrial DNA (mtDNA) replication and function. ER stress induced by thapsigargin treatments (10-100 nM) resulted in a 2-fold increase in mtDNA contents compared with that in the untreated control. HO-1 activity on ER stress is proven to be critical for mitochondrial integrity because chemical inhibition (zinc protoporphyrin, 5-20 mu M) and genetic depletion of HO-1 by small interference RNA transfection suppress the activation of transcription factors for mitochondrial biogenesis. Carbon monoxide (CO), an enzymatic by-product of HO-1 activity is responsible for the function of HO-1. Limited bioavailability of CO by hemoglobin treatment triggers cell death with a concomitant decline in ATP production. Approximately 78.1% of RAW264.7 cells were damaged in the presence of hemoglobin compared with the percentage of injured cells (26.9%) under ER stress alone. Mitochondrial generation of ATP levels significantly declined when CO availability was limited under prolonged ER stress. Taken together, these results suggest that the cellular HO-1/CO system conveys ER stress to cell survival signals from mitochondria via both the activation of transcriptional factors and functional integrity of mtDNA.-Zheng, M., Kim, S.-K., Joe, Y., Back, S. H., Cho, H. R., Kim, H. P., Ignarro, L. J., Chung, H.-T. Sensing endoplasmic reticulum stress by protein kinase RNA-like endoplasmic reticulum kinase promotes adaptive mitochondrial DNA biogenesis and cell survival via heme oxygenase-1/carbon monoxide activity. FASEB J. 26, 2558-2568 (2012). www.fasebj.org	[Zheng, Min; Cho, Hong R.] Univ Ulsan, Dept Surg, Ulsan Univ Hosp, World Class Univ, Ulsan 680749, South Korea; [Zheng, Min; Cho, Hong R.] Univ Ulsan, Sch Med, World Class Univ, Ulsan 680749, South Korea; [Kim, Seul-Ki; Joe, Yeonsoo; Back, Sung Hoon; Kim, Hong Pyo; Chung, Hun-Taeg] Univ Ulsan, Sch Biol Sci, World Class Univ, Ulsan 680749, South Korea; [Ignarro, Louis J.] Konkuk Univ, Sch Med, Seoul, South Korea	University of Ulsan; Ulsan University Hospital; University of Ulsan; University of Ulsan; Konkuk University; Konkuk University Medical Center	Zheng, M (corresponding author), Univ Ulsan, Dept Surg, Ulsan Univ Hosp, World Class Univ, Ulsan 680749, South Korea.	chung@ulsan.ac.kr			Korea Research Foundation; Korean Government (MOEHRD) [BRL-2010-0001199]	Korea Research Foundation(National Research Foundation of Korea); Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government)	This work was supported by grants from the Korea Research Foundation, funded by the Korean Government (MOEHRD; BRL-2010-0001199). Author contributions: H. P. K., L. J. I., and H.-T. C. designed research; M. Z., S.-K. K., and Y. J. performed research; S. H. B. and H. R. C. analyzed data; and H. P. K., L. J. I., and H. T. C. wrote the article.	Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bravo R, 2011, J CELL SCI, V124, P2143, DOI 10.1242/jcs.080762; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Burgess A, 2010, HYPERTENSION, V56, P1124, DOI 10.1161/HYPERTENSIONAHA.110.151423; Choi BM, 2004, BIOCHEM BIOPH RES CO, V321, P132, DOI 10.1016/j.bbrc.2004.06.120; Choumar A, 2011, ANTIOXID REDOX SIGN, V15, P2837, DOI 10.1089/ars.2010.3713; Chung J, 2011, MOL IMMUNOL, V48, P1793, DOI 10.1016/j.molimm.2011.05.014; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Jahnke VE, 2009, AM J PHYSIOL-CELL PH, V296, pC1185, DOI 10.1152/ajpcell.00377.2008; Kaufman RJ, 2010, DIABETES OBES METAB, V12, P99, DOI 10.1111/j.1463-1326.2010.01281.x; Kim DH, 2008, J PHARMACOL EXP THER, V325, P833, DOI 10.1124/jpet.107.135285; Kim HP, 2011, BIOCHEM BIOPH RES CO, V404, P1, DOI 10.1016/j.bbrc.2010.11.067; Kim KM, 2007, CIRC RES, V101, P919, DOI 10.1161/CIRCRESAHA.107.154781; Lira VA, 2010, J PHYSIOL-LONDON, V588, P3551, DOI 10.1113/jphysiol.2010.194035; Lu TH, 2011, TOXICOL LETT, V201, P15, DOI 10.1016/j.toxlet.2010.11.019; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138; Ozcan L, 2009, CELL METAB, V9, P35, DOI 10.1016/j.cmet.2008.12.004; Park YC, 1996, IMMUNOLOGY, V87, P296, DOI 10.1046/j.1365-2567.1996.456544.x; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Seimon TA, 2010, CELL METAB, V12, P467, DOI 10.1016/j.cmet.2010.09.010; Suliman HB, 2007, J CLIN INVEST, V117, P3730, DOI 10.1172/JCI32967; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	28	33	34	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2558	2568		10.1096/fj.11-199604	http://dx.doi.org/10.1096/fj.11-199604			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22391129				2022-12-28	WOS:000305017200032
J	Cottrell, EC; Holmes, MC; Livingstone, DE; Kenyon, CJ; Seckl, JR				Cottrell, Elizabeth C.; Holmes, Megan C.; Livingstone, Dawn E.; Kenyon, Christopher J.; Seckl, Jonathan R.			Reconciling the nutritional and glucocorticoid hypotheses of fetal programming	FASEB JOURNAL			English	Article						low-protein diet; 11 beta-hydroxysteroid dehydrogenase-2; hypothalamo-pituitary-adrenal axis	11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; BETA-HYDROXYSTEROID DEHYDROGENASE; MESSENGER-RIBONUCLEIC-ACID; CHORIOCARCINOMA JEG-3 CELLS; PITUITARY-ADRENAL AXIS; MATERNAL UNDERNUTRITION; PLACENTAL TROPHOBLAST; GROWTH-RETARDATION; ADULT DISEASE; BIRTH-WEIGHT	Fetal growth restriction associates with increased risk of adult cardiometabolic and neuropsychiatric disorders. Both maternal malnutrition [notably a low-protein (LP) diet] and stress/glucocorticoid exposure reduce fetal growth and cause persisting abnormalities (programming) in adult offspring. Deficiency of placental 11 beta-hydroxysteroid dehydrogenase-2 (11 beta-HSD2), which inactivates glucocorticoids, is reduced by an LP diet and has been proposed as a unifying mechanism. Here, we explored the importance of glucocorticoids and placental 11 beta-HSD2 in dietary programming. Pregnant mice were fed a control or isocaloric LP diet throughout gestation. The LP diet first elevated fetal glucocorticoid levels, then reduced placental growth, and finally decreased fetal weight near term by 17%. Whereas the LP diet reduced placental 11 beta-HSD2 activity near term by similar to 25%, consistent with previous reports, activity was increased between 20 and 40% at earlier ages, implying that glucocorticoid overexposure in LP fetuses occurs via 11 beta-HSD2-independent mechanisms. Consistent with this, heterozygous 11 beta-HSD2(+/-) crosses showed that although both LP and 11 beta-HSD2 deficiency reduced fetal growth, LP indeed acted independently of 11 beta-HSD2. Instead, the LP diet induced the fetal hypothalamic-pituitary-adrenal axis per se. Thus, maternal malnutrition and placental 11 beta-HSD2 deficiency act via distinct processes to retard fetal growth, both involving fetoplacental overexposure to glucocorticoids but from distinct sources.-Cottrell, E. C., Holmes, M. C., Livingstone, D. E., Keynon, C. J., Seckl, J. R. Reconciling the nutritional and glucocorticoid hypotheses of fetal programming. FASEB J. 26, 1866-1874 (2012). www.fasebj.org	[Cottrell, Elizabeth C.; Holmes, Megan C.; Livingstone, Dawn E.; Kenyon, Christopher J.; Seckl, Jonathan R.] Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland	University of Edinburgh	Cottrell, EC (corresponding author), Univ Manchester, Fac Human & Med Sci, Manchester M13 9PT, Lancs, England.	elizabeth.cottrell@manchester.ac.uk	Seckl, Jonathan R/C-3555-2013	Cottrell, Elizabeth/0000-0002-0888-4707	Human Frontier Science Program [RGP0039/2006-C]	Human Frontier Science Program(Human Frontier Science Program)	The authors are grateful to Alan Borthwick and Laraine Wells for their technical support, and to Dr. Caitlin Wyrwoll and Professor Karen Chapman for expert advice. This study was supported in part by a Human Frontier Science Program grant (RGP0039/2006-C) to J.R.S. The authors declare no conflicts of interest.	Audette MC, 2010, PLACENTA, V31, P97, DOI 10.1016/j.placenta.2009.11.016; Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BAXTER RC, 1995, J CLIN ENDOCR METAB, V80, P2700, DOI 10.1210/jc.80.9.2700; Benediktsson R, 1997, CLIN ENDOCRINOL, V46, P161, DOI 10.1046/j.1365-2265.1997.1230939.x; Bertram C, 2001, ENDOCRINOLOGY, V142, P2841, DOI 10.1210/en.142.7.2841; Bhasin KKS, 2009, DIABETES, V58, P559, DOI 10.2337/db07-1530; Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803; Bloomfield FH, 2003, ENDOCRINOLOGY, V144, P2933, DOI 10.1210/en.2003-0189; Carroll JA, 2001, DOMEST ANIM ENDOCRIN, V21, P97, DOI 10.1016/S0739-7240(01)00107-2; Chisaka H, 2005, J SOC GYNECOL INVEST, V12, P303, DOI 10.1016/j.jsgi.2005.02.003; Coan PM, 2008, J PHYSIOL-LONDON, V586, P4567, DOI 10.1113/jphysiol.2008.156133; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Condon J, 1997, MOL CELL ENDOCRINOL, V127, P121, DOI 10.1016/S0303-7207(97)04000-8; Constancia M, 2005, P NATL ACAD SCI USA, V102, P19219, DOI 10.1073/pnas.0504468103; Cottrell EC, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.019.2009; Dave-Sharma S, 1998, J CLIN ENDOCR METAB, V83, P2244, DOI 10.1210/jc.83.7.2244; Diederich S, 2002, J CLIN ENDOCR METAB, V87, P5695, DOI 10.1210/jc.2002-020970; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; Edwards CRW, 1996, STEROIDS, V61, P263, DOI 10.1016/0039-128X(96)00033-5; Fowden AL, 2009, J PHYSIOL-LONDON, V587, P3459, DOI 10.1113/jphysiol.2009.173013; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Harris HJ, 2001, ENDOCRINOLOGY, V142, P114, DOI 10.1210/en.142.1.114; Holmes MC, 2006, J NEUROSCI, V26, P3840, DOI 10.1523/JNEUROSCI.4464-05.2006; Langdown ML, 2001, MOL CELL ENDOCRINOL, V185, P109, DOI 10.1016/S0303-7207(01)00629-3; LangleyEvans SC, 1997, J HYPERTENS, V15, P537, DOI 10.1097/00004872-199715050-00010; LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5; Lesage J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/en.142.5.1692; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; Ma XH, 2003, AM J OBSTET GYNECOL, V188, P13, DOI 10.1067/mob.2003.62; Mairesse J, 2007, AM J PHYSIOL-ENDOC M, V292, pE1526, DOI 10.1152/ajpendo.00574.2006; McInnes KJ, 2004, J BIOL CHEM, V279, P22908, DOI 10.1074/jbc.M402822200; MONTANO MM, 1993, J REPROD FERTIL, V99, P283; Murphy VE, 2002, J CLIN ENDOCR METAB, V87, P1660, DOI 10.1210/jc.87.4.1660; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; Roseboom TJ, 2011, PLACENTA, V32, P395, DOI 10.1016/j.placenta.2011.03.001; Sarkar S, 2001, AM J PHYSIOL-REG I, V281, pR1966, DOI 10.1152/ajpregu.2001.281.6.R1966; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; Sharma A, 2009, ENDOCRINOLOGY, V150, P4278, DOI 10.1210/en.2009-0479; Staud F, 2006, PLACENTA, V27, P171, DOI 10.1016/j.placenta.2005.01.001; Stein AD, 2004, INT J EPIDEMIOL, V33, P831, DOI 10.1093/ije/dyh083; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; Talge NM, 2007, J CHILD PSYCHOL PSYC, V48, P245, DOI 10.1111/j.1469-7610.2006.01714.x; Tremblay J, 1999, BIOL REPROD, V60, P541, DOI 10.1095/biolreprod60.3.541; Tzschoppe A, 2011, EUR J OBSTET GYN R B, V156, P50, DOI 10.1016/j.ejogrb.2011.01.008; van Beek JP, 2004, J CLIN ENDOCR METAB, V89, P5614, DOI 10.1210/jc.2004-0113; Welberg LAM, 2000, EUR J NEUROSCI, V12, P1047, DOI 10.1046/j.1460-9568.2000.00958.x; Whorwood CB, 2001, ENDOCRINOLOGY, V142, P2854, DOI 10.1210/en.142.7.2854; Wyrwoll CS, 2009, ENDOCRINOLOGY, V150, P1287, DOI 10.1210/en.2008-1100	49	78	78	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1866	1874		10.1096/fj.12-203489	http://dx.doi.org/10.1096/fj.12-203489			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22321728				2022-12-28	WOS:000303680800015
J	Brast, S; Grabner, A; Sucic, S; Sitte, HH; Hermann, E; Pavenstadt, H; Schlatter, E; Ciarimboli, G				Brast, Sabine; Grabner, Alexander; Sucic, Sonja; Sitte, Harald H.; Hermann, Edwin; Pavenstaedt, Hermann; Schlatter, Eberhard; Ciarimboli, Giuliano			The cysteines of the extracellular loop are crucial for trafficking of human organic cation transporter 2 to the plasma membrane and are involved in oligomerization	FASEB JOURNAL			English	Article						hOCT2; site-directed mutagenesis; regulation	TRANSMEMBRANE ALPHA-HELICES; HUMAN SEROTONIN TRANSPORTER; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; INTERACTION DOMAIN; EXTRUSION FAMILY; LIVING CELLS; RAT-KIDNEY; CISPLATIN; IDENTIFICATION	Human organic cation transporter 2 (hOCT2) is involved in transport of many endogenous and exogenous organic cations, mainly in kidney and brain cells. Because the quaternary structure of transmembrane proteins plays an essential role for their cellular trafficking and function, we investigated whether hOCT2 forms oligomeric complexes, and if so, which part of the transporter is involved in the oligomerization. A yeast 2-hybrid mating-based split-ubiquitin system (mbSUS), fluorescence resonance energy transfer, Western blot analysis, cross-linking experiments, immunofluorescence, and uptake measurements of the fluorescent organic cation 4-(4-(dimethylamino) styryl)-N-methylpyridinium were applied to human embryonic kidney 293 (HEK293) cells transfected with hOCT2 and partly also to freshly isolated human proximal tubules. The role of cysteines for oligomerization and trafficking of the transporter to the plasma membranes was investigated in cysteine mutants of hOCT2. hOCT2 formed oligomers both in the HEK293 expression system and in native human kidneys. The cysteines of the large extracellular loop are important to enable correct folding, oligomeric assembly, and plasma membrane insertion of hOCT2. Mutation of the first and the last cysteines of the loop at positions 51 and 143 abolished oligomer formation. Thus, the cysteines of the extracellular loop are important for correct trafficking of the transporter to the plasma membrane and for its oligomerization.-Brast, S., Grabner, A., Sucic, S., Sitte, H. H., Hermann, E., Pavenstadt, H., Schlatter, E., and Ciarimboli, G. The cysteines of the extracellular loop are crucial for trafficking of human organic cation transporter 2 to the plasma membrane and are involved in oligomerization. FASEB J. 26, 976-986 (2012). www.fasebj.org	[Brast, Sabine; Grabner, Alexander; Pavenstaedt, Hermann; Schlatter, Eberhard; Ciarimboli, Giuliano] Univ Klinikum Munster, Med Klin & Poliklin D, D-48149 Munster, Germany; [Hermann, Edwin] Univ Klinikum Munster, Klin & Poliklin Urol, D-48149 Munster, Germany; [Sucic, Sonja; Sitte, Harald H.] Med Univ Wien, Inst Pharmakol, Vienna, Austria	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; Medical University of Vienna	Ciarimboli, G (corresponding author), Univ Klinikum Munster, Med Klin & Poliklin D, Domagkstr 3A, D-48149 Munster, Germany.	gciari@uni-muenster.de	Sitte, Harald/O-7025-2019; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Sucic, Sonja/0000-0001-5136-8022; Ciarimboli, Giuliano/0000-0002-4365-3656	Deutsche Forschungsgemeinschaft [CI 107/4-1, CI 107/4-2]; Austrian Science Foundation [SFB35]; Austrian Science Fund (FWF) [F 3506] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Austrian Science Foundation(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors are grateful to Rita Schroter, Bernadette Gelschefarth, and Ute Neugebauer for excellent technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft (CI 107/4-1 to 2) and the Austrian Science Foundation (SFB35 to H.H.S.).	Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; Biermann J, 2006, AM J PHYSIOL-CELL PH, V290, pC1521, DOI 10.1152/ajpcell.00622.2005; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Busch AE, 1998, MOL PHARMACOL, V54, P342, DOI 10.1124/mol.54.2.342; Chen Y, 2007, J PHARMACOL EXP THER, V322, P695, DOI 10.1124/jpet.107.123554; Ciarimboli G, 2005, AM J PATHOL, V167, P1477, DOI 10.1016/S0002-9440(10)61234-5; Ciarimboli G, 2005, J AM SOC NEPHROL, V16, P1562, DOI 10.1681/ASN.2004040256; Ciarimboli G, 2005, PFLUG ARCH EUR J PHY, V449, P423, DOI 10.1007/s00424-004-1355-5; Ciarimboli G, 2011, MOL PHARMACEUT, V8, P270, DOI 10.1021/mp100329u; Ciarimboli G, 2010, AM J PATHOL, V176, P1169, DOI 10.2353/ajpath.2010.090610; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Feige JN, 2005, MICROSC RES TECHNIQ, V68, P51, DOI 10.1002/jemt.20215; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Gorbunov D, 2008, MOL PHARMACOL, V73, P50, DOI 10.1124/mol.107.040170; Grefen C., 2007, CURR PROTOC NEUROSCI, V41, P5271; Grefen C, 2008, MOL PLANT, V1, P308, DOI 10.1093/mp/ssm015; Hong M, 2005, J BIOL CHEM, V280, P32285, DOI 10.1074/jbc.M501447200; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; Kao LY, 2008, J BIOL CHEM, V283, P26782, DOI 10.1074/jbc.M804006200; Keller T, 2008, BIOCHEMISTRY-US, V47, P4552, DOI 10.1021/bi800060w; Kimura N, 2005, PHARM RES-DORDR, V22, P255, DOI 10.1007/s11095-004-1193-3; Kimura Naoko, 2005, Drug Metab Pharmacokinet, V20, P379, DOI 10.2133/dmpk.20.379; Koepsell H, 2004, REV PHYSIOL BIOCH P, V150, P36, DOI 10.1007/s10254-003-0017-x; Lazar A, 2006, CLIN EXP HYPERTENS, V28, P645, DOI 10.1080/10641960600946411; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; More SS, 2010, MOL CANCER THER, V9, P1058, DOI 10.1158/1535-7163.MCT-09-1084; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Neuhoff S, 2003, PHARMACEUT RES, V20, P1141, DOI 10.1023/A:1025032511040; Ogasawara M, 2006, J PHARMACOL SCI, V101, P24, DOI 10.1254/jphs.FMJ06001X6; Pelis RM, 2006, AM J PHYSIOL-RENAL, V290, pF1118, DOI 10.1152/ajprenal.00462.2005; Pelis RM, 2006, J BIOL CHEM, V281, P35272, DOI 10.1074/jbc.M606561200; Pietig G, 2001, J BIOL CHEM, V276, P33741, DOI 10.1074/jbc.M104617200; PIETRUCK F, 1995, KIDNEY INT, V47, P1647, DOI 10.1038/ki.1995.229; ROHLICEK V, 1994, RENAL PHYSIOL BIOCH, V17, P57; Salazar G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005896; Sallinen R, 2010, ANN MED, V42, P296, DOI 10.3109/07853891003777109; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Sitte HH, 2004, MOL INTERV, V4, P38, DOI 10.1124/mi.4.1.38; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Taubert D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000385; Walter JK, 2009, CELL MOL LIFE SCI, V66, P3655, DOI 10.1007/s00018-009-0150-z; Wilde S, 2009, CELL MOL LIFE SCI, V66, P1729, DOI 10.1007/s00018-009-9145-z; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yonezawa A, 2006, J PHARMACOL EXP THER, V319, P879, DOI 10.1124/jpet.106.110346	45	39	40	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2012	26	3					976	986		10.1096/fj.11-180679	http://dx.doi.org/10.1096/fj.11-180679			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22085643	Green Accepted			2022-12-28	WOS:000300949300003
J	Gronholm, J; Kaustio, M; Myllymaki, H; Kallio, J; Saarikettu, J; Kronhamn, J; Valanne, S; Silvennoinen, O; Ramet, M				Gronholm, Juha; Kaustio, Meri; Myllymaki, Henna; Kallio, Jenni; Saarikettu, Juha; Kronhamn, Jesper; Valanne, Susanna; Silvennoinen, Olli; Ramet, Mika			Not4 enhances JAK/STAT pathway-dependent gene expression in Drosophila and in human cells	FASEB JOURNAL			English	Article						Ccr4-Not complex; cytokine signaling; Stat92E; stress response	TRANSCRIPTIONAL ACTIVATION; CCR4-NOT COMPLEX; PROTEIN; IDENTIFICATION; P300/CBP; STAT6; YEAST; COOPERATION; INDUCTION; REGULATOR	The JAK/STAT pathway is essential for organogenesis, innate immunity, and stress responses in Drosophila melanogaster. The JAK/STAT pathway and its associated regulators have been highly conserved in evolution from flies to humans. We have used a genome-wide RNAi screen in Drosophila S2 cells to identify regulators of the JAK/STAT pathway, and here we report the characterization of Not4 as a positive regulator of the JAK/STAT pathway. Overexpression of Not4 enhanced Stat92E-mediated gene responses in vitro and in vivo in Drosophila. Specifically, Not4 increased Stat92E-mediated reporter gene activation in S2 cells; and in flies, Not4 overexpression resulted in an 8-fold increase in Turandot M (TotM) and in a 4-fold increase in Turandot A (TotA) stress gene activation when compared to wild-type flies. Drosophila Not4 is structurally related to human CNOT4, which was found to regulate interferon-gamma- and interleukin-4-induced STAT-mediated gene responses in human HeLa cells. Not4 was found to coimmunoprecipitate with Stat92E but not to affect tyrosine phosphorylation of Stat92E in Drosophila cells. However, Not4 is required for binding of Stat92E to its DNA recognition sequence in the TotM gene promoter. In summary, Not4/CNOT4 is a novel positive regulator of the JAK/STAT pathway in Drosophila and in humans.-Gronholm, J., Kaustio, M., Myllymaki, H., Kallio, J., Saarikettu, J., Kronhamn, J., Valanne, S., Silvennoinen, O., Ramet, M. Not4 enhances JAK/STAT pathway-dependent gene expression in Drosophila and in human cells. FASEB J. 26, 1239-1250 (2012). www.fasebj.org	[Gronholm, Juha; Saarikettu, Juha; Silvennoinen, Olli] Univ Tampere, Inst Biomed Technol, Lab Mol Immunol & Cytokine Receptor Signaling, FIN-33101 Tampere, Finland; [Kaustio, Meri; Myllymaki, Henna; Kallio, Jenni; Valanne, Susanna; Ramet, Mika] Univ Tampere, Inst Biomed Technol, Expt Immunol Lab, FIN-33101 Tampere, Finland; [Silvennoinen, Olli] Tampere Univ Hosp, Ctr Sci, Ctr Lab Med, Tampere, Finland; [Ramet, Mika] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Kronhamn, Jesper] Umea Univ, Dept Mol Biol, Umea, Sweden	Tampere University; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Umea University	Ramet, M (corresponding author), Tampere Univ, Inst Biomed Technol, FIN-33014 Tampere, Finland.	mika.ramet@uta.fi	Grönholm, Juha/Q-4078-2017; Valanne, Susanna/GZK-2381-2022	Grönholm, Juha/0000-0002-4190-0000; Valanne, Susanna/0000-0003-0898-8423; Myllymaki, Henna/0000-0002-6936-4879	Academy of Finland; Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Pirkanmaa Hospital District; Centre of Laboratory Medicine of the Tampere University Hospital; Finnish Cancer Foundation; Maire Lisko Foundation; Emil Aaltonen Foundation; Finnish Cultural Foundation; Biocenter Finland	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Tampere Tuberculosis Foundation; Pirkanmaa Hospital District; Centre of Laboratory Medicine of the Tampere University Hospital; Finnish Cancer Foundation; Maire Lisko Foundation; Emil Aaltonen Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Biocenter Finland	This research was supported by grants from the Academy of Finland, the Sigrid Juselius Foundation (to M. R and O.S.); the Tampere Tuberculosis Foundation (to M. R., S. V., and O.S.); Competitive Research Funding of the Pirkanmaa Hospital District (to M. R. and S. V.); Competitive Research Funding and Centre of Laboratory Medicine of the Tampere University Hospital, the Finnish Cancer Foundation, and the Maire Lisko Foundation (to O.S.); the Emil Aaltonen Foundation (to M. R. and J.G.); and the Finnish Cultural Foundation (to J.G.). The fly work was done at the University of Tampere Drosophila Core Facility, funded by Biocenter Finland. PG-13-luc and p53 plasmid constructs were kind gifts from Dr. Marikki Laiho (Haartman Institute, University of Helsinki, Helsinki, Finland). The authors thank Leena Makinen, Paula Kosonen, and Merja Lehtinen for excellent technical assistance. All authors approved the final version of the text.	Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Agaisse Herve, 2004, Immunol Rev, V198, P72, DOI 10.1111/j.0105-2896.2004.0133.x; Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown S, 2003, DEVELOPMENT, V130, P3077, DOI 10.1242/dev.00535; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Ekengren S, 2001, BIOCHEM BIOPH RES CO, V284, P998, DOI 10.1006/bbrc.2001.5067; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Gronholm J, 2010, J INNATE IMMUN, V2, P618, DOI 10.1159/000318676; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Henriksen MA, 2002, GENE DEV, V16, P2379, DOI 10.1101/gad.1020702; Hombria JCG, 2005, DEV BIOL, V288, P420, DOI 10.1016/j.ydbio.2005.09.040; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Kallio J, 2005, MICROBES INFECT, V7, P811, DOI 10.1016/j.micinf.2005.03.014; Kallio J, 2010, FASEB J, V24, P4467, DOI 10.1096/fj.10-162784; Kruk JA, 2011, GENE DEV, V25, P581, DOI 10.1101/gad.2020911; Laribee RN, 2007, P NATL ACAD SCI USA, V104, P5836, DOI 10.1073/pnas.0607996104; Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Malik S, 2010, FEBS J, V277, P1805, DOI 10.1111/j.1742-4658.2010.07607.x; Mersman DP, 2009, GENE DEV, V23, P951, DOI 10.1101/gad.1769209; Muller P, 2005, NATURE, V436, P871, DOI 10.1038/nature03869; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Pesu M, 2003, EUR J IMMUNOL, V33, P1727, DOI 10.1002/eji.200323680; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Singh SR, 2005, CELL RES, V15, P1, DOI 10.1038/sj.cr.7290255; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Temme C, 2010, RNA, V16, P1356, DOI 10.1261/rna.2145110; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Valineva T, 2005, J BIOL CHEM, V280, P14989, DOI 10.1074/jbc.M410465200; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	52	21	22	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2012	26	3					1239	1250		10.1096/fj.11-195875	http://dx.doi.org/10.1096/fj.11-195875			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	901FY	22159038				2022-12-28	WOS:000300949300026
J	Bucciantini, M; Nosi, D; Forzan, M; Russo, E; Calamai, M; Pieri, L; Formigli, L; Quercioli, F; Soria, S; Pavone, F; Savistchenko, J; Melki, R; Stefani, M				Bucciantini, Monica; Nosi, Daniele; Forzan, Mario; Russo, Edda; Calamai, Martino; Pieri, Laura; Formigli, Lucia; Quercioli, Franco; Soria, Silvia; Pavone, Francesco; Savistchenko, Jimmy; Melki, Ronald; Stefani, Massimo			Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1	FASEB JOURNAL			English	Article						Sup35; cytotoxicity; fibrillar assemblies; lipid rafts; prion; apoptosis	PRION-LIKE FACTOR; LIPID RAFTS; ALPHA-SYNUCLEIN; PROTEIN AGGREGATION; MISFOLDING DISEASES; ALZHEIMERS-DISEASE; MAMMALIAN-CELLS; BETA OLIGOMERS; LIVING CELLS; IN-VITRO	The interaction of amyloid aggregates with the cell plasma membrane is currently considered among the basic mechanisms of neuronal dysfunction in amyloid neurodegeneration. We used amyloid oligomers and fibrils grown from the yeast prion Sup35p, responsible for the specific prion trait [PSI+], to investigate how membrane lipids modulate fibril interaction with the membranes of cultured H-END cells and cytotoxicity. Sup35p shares no homology with endogenous mammalian polypeptide chains. Thus, the generic toxicity of amyloids and the molecular events underlying cell degeneration can be investigated without interference with analogous polypeptides encoded by the cell genome. Sup35 fibrils bound to the cell membrane without increasing its permeability to Ca2+. Fibril binding resulted in structural reorganization and aggregation of membrane rafts, with GM1 clustering and alteration of its mobility. Sup35 fibril binding was affected by GM1 or its sialic acid moiety, but not by cholesterol membrane content, with complete inhibition after treatment with fumonisin B1 or neuraminidase. Finally, cell impairment resulted from caspase-8 activation after Fas receptor translocation on fibril binding to the plasmamembrane. Our observations suggest that amyloid fibrils induce abnormal accumulation and overstabilization of raft domains in the cell membrane and provide a reasonable, although not unique, mechanistic and molecular explanation for fibril toxicity.-Bucciantini, M., Nosi, D., Forzan, M., Russo, E., Calamai, M., Pieri, L., Formigli, L., Quercioli, F., Soria, S., Pavone, F., Savistchenko, J., Melki, R., Stefani, M. Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J. 26, 818-831 (2012). www.fasebj.org	[Pieri, Laura; Savistchenko, Jimmy; Melki, Ronald] CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; [Bucciantini, Monica; Russo, Edda; Stefani, Massimo] Univ Florence, Dept Biochem Sci, Florence, Italy; [Bucciantini, Monica; Stefani, Massimo] Univ Florence, Res Ctr Mol Basis Neurodegenerat, Florence, Italy; [Nosi, Daniele; Formigli, Lucia] Univ Florence, Dept Anat Histol & Forens Med, Florence, Italy; [Forzan, Mario; Melki, Ronald] Univ Pisa, Dept Anim Pathol Food Prophylaxis & Hyg, Pisa, Italy; [Calamai, Martino; Pavone, Francesco] Univ Florence, European Lab Nonlinear Spect LENS, Florence, Italy; [Quercioli, Franco] Consiglio Nazl Ric Florence Res Area, Natl Opt Inst, Florence, Italy; [Soria, Silvia] Consiglio Nazl Ric Florence Res Area, Nello Carrara Inst Appl Phys, Florence, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Florence; University of Florence; University of Florence; University of Pisa; University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisica Applicata "Nello Carrara" (IFAC-CNR)	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	melki@lebs.cnrs-gif.fr	Calamai, Martino/AAY-8441-2020; Soria, Silvia/A-3508-2013	Calamai, Martino/0000-0002-4031-7235; Soria, Silvia/0000-0002-4838-2197; Forzan, Mario/0000-0003-2474-8219; , Laura/0000-0003-0779-9014; QUERCIOLI, FRANCO/0000-0002-7844-4686; bucciantini, monica/0000-0002-5243-9301; Russo, Edda/0000-0003-3141-1091; pavone, francesco saverio/0000-0002-0675-3981; STEFANI, MASSIMO/0000-0002-4490-1922	Ente Cassa di Risparmio di Firenze; Agence Nationale de la Recherche [ANR-06-BLAN-0266, ANR08-PCVI-0022-02]; European Community [PIEF-GA-2009-254791]; Human Frontier program; EraNet Neuron (Miprotran) program; Centre National de la Recherche Scientifique	Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Agence Nationale de la Recherche(French National Research Agency (ANR)); European Community(European Commission); Human Frontier program; EraNet Neuron (Miprotran) program; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	This work was supported by grants from the Ente Cassa di Risparmio di Firenze, the Agence Nationale de la Recherche (ANR-06-BLAN-0266 and ANR08-PCVI-0022-02), the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement PIEF-GA-2009-254791, the Human Frontier and the EraNet Neuron (Miprotran) programs, and the Centre National de la Recherche Scientifique.	Abe K, 1996, J NEUROCHEM, V67, P2074; Ahmad B, 2010, BBA-PROTEINS PROTEOM, V1804, P223, DOI 10.1016/j.bbapap.2009.10.005; Bannai H, 2006, NAT PROTOC, V1, P2628, DOI 10.1038/nprot.2006.429; Bhat RA, 2005, P NATL ACAD SCI USA, V102, P3135, DOI 10.1073/pnas.0500012102; Bolognesi B, 2010, ACS CHEM BIOL, V5, P735, DOI 10.1021/cb1001203; Bonneau S, 2005, IEEE T IMAGE PROCESS, V14, P1384, DOI 10.1109/TIP.2005.852794; Brundin P, 2010, NAT REV MOL CELL BIO, V11, P301, DOI 10.1038/nrm2873; Bucciantini M, 2004, FASEB J, V18, P437, DOI 10.1096/fj.04-3086fje; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cecchi C, 2005, J CELL SCI, V118, P3459, DOI 10.1242/jcs.02473; Cecchi C, 2009, BBA-BIOMEMBRANES, V1788, P2204, DOI 10.1016/j.bbamem.2009.07.019; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cheung ZH, 2011, J NEUROCHEM, V118, P317, DOI 10.1111/j.1471-4159.2011.07314.x; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cho WJ, 2009, J MOL BIOL, V393, P765, DOI 10.1016/j.jmb.2009.08.055; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Diomede L, 2010, NEUROBIOL DIS, V40, P424, DOI 10.1016/j.nbd.2010.07.002; Ehrensperger MV, 2007, BIOPHYS J, V92, P3706, DOI 10.1529/biophysj.106.095596; Filimonenko M, 2010, MOL CELL, V38, P265, DOI 10.1016/j.molcel.2010.04.007; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Gharibyan AL, 2007, J MOL BIOL, V365, P1337, DOI 10.1016/j.jmb.2006.10.101; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Halfmann R, 2010, SCIENCE, V330, P629, DOI 10.1126/science.1191081; Hansen C, 2011, J CLIN INVEST, V121, P715, DOI 10.1172/JCI43366; Herrera Federico, 2011, PLoS Curr, V3, pRRN1210, DOI 10.1371/currents.RRN1210; Jang H, 2010, J MOL BIOL, V404, P917, DOI 10.1016/j.jmb.2010.10.025; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kawai-Noma S, 2006, GENES CELLS, V11, P1085, DOI 10.1111/j.1365-2443.2006.01004.x; Kawai-Noma S, 2010, J CELL BIOL, V190, P223, DOI 10.1083/jcb.201002149; Kelly BL, 2007, NEUROSCIENCE, V147, P60, DOI 10.1016/j.neuroscience.2007.03.047; Kim SI, 2006, J CELL BIOCHEM, V99, P878, DOI 10.1002/jcb.20978; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kordower JH, 2009, NEUROPSYCHOPHARMACOL, V34, P254, DOI 10.1038/npp.2008.161; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Krzewska J, 2007, J BIOL CHEM, V282, P1679, DOI 10.1074/jbc.M608110200; Lettau M, 2008, CURR MED CHEM, V15, P1684, DOI 10.2174/092986708784872384; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lleres D, 2009, J CELL BIOL, V187, P481, DOI 10.1083/jcb.200907029; Mercatelli R, 2010, OPT EXPRESS, V18, P20505, DOI 10.1364/OE.18.020505; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P381; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Mossuto MF, 2010, J MOL BIOL, V402, P783, DOI 10.1016/j.jmb.2010.07.005; Naiki H, 2009, J BIOCHEM, V146, P751, DOI 10.1093/jb/mvp119; Nakazawa Y, 2009, CHEM PHYS LIPIDS, V158, P54, DOI 10.1016/j.chemphyslip.2008.12.001; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Novitskaya V, 2006, J BIOL CHEM, V281, P13828, DOI 10.1074/jbc.M511174200; Okada T, 2008, J MOL BIOL, V382, P1066, DOI 10.1016/j.jmb.2008.07.072; Okada T, 2007, J MOL BIOL, V371, P481, DOI 10.1016/j.jmb.2007.05.069; Park EK, 2009, J PATHOL, V218, P337, DOI 10.1002/path.2531; Picone P, 2009, BIOPHYS J, V96, P4200, DOI 10.1016/j.bpj.2008.11.056; Pieri L, 2006, J BIOL CHEM, V281, P15337, DOI 10.1074/jbc.M511647200; Ren PH, 2009, NAT CELL BIOL, V11, P219, DOI 10.1038/ncb1830; Renner M, 2010, NEURON, V66, P739, DOI 10.1016/j.neuron.2010.04.029; Riedel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008753; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Rushworth J. V., 2010, INT J ALZHEIMERS DIS, V2011; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Seevaratnam R, 2009, J BIOCHEM, V145, P791, DOI 10.1093/jb/mvp037; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stefani M, 2010, FEBS J, V277, P4602, DOI 10.1111/j.1742-4658.2010.07889.x; Stefani Massimo, 2006, Ital J Biochem, V55, P194; Taguchi H, 2010, FEBS J, V277, P1359, DOI 10.1111/j.1742-4658.2010.07569.x; van Rooijen BD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014292; Wang SSS, 2001, J BIOL CHEM, V276, P42027, DOI 10.1074/jbc.M102834200; Weise K, 2010, CHEMBIOCHEM, V11, P1280, DOI 10.1002/cbic.201000039; Wen Y, 2008, NEURON, V57, P680, DOI 10.1016/j.neuron.2008.02.024; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Williamson R, 2008, FASEB J, V22, P1552, DOI 10.1096/fj.07-9766com	69	99	99	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					818	831		10.1096/fj.11-189381	http://dx.doi.org/10.1096/fj.11-189381			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22071505				2022-12-28	WOS:000300485700033
J	Courtial, N; Smink, JJ; Kuvardina, ON; Leutz, A; Gothert, JR; Lausen, J				Courtial, Nadine; Smink, Jeske J.; Kuvardina, Olga N.; Leutz, Achim; Goethert, Joachim R.; Lausen, Joern			Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP	FASEB JOURNAL			English	Article						hematopoiesis; transcription; gene regulation	MICROPHTHALMIA TRANSCRIPTION FACTOR; GENE-EXPRESSION; STEM-CELLS; BONE; SCL; NFATC1; HEMATOPOIESIS; PU.1; MEGAKARYOPOIESIS; DEGRADATION	The balance between bone-forming osteoblasts and bone-resorbing osteoclasts is crucial to bone homeostasis, an equilibrium that is disturbed in many bone diseases. The transcription factor Tal1 is involved in the establishment of hematopoietic stem cells in the embryo and is a master regulator of hematopoietic gene expression in the adult. Here, we show that Tal1 is expressed in osteoclasts and that loss of Tal1 in osteoclast progenitors leads to altered expression of >1200 genes. We found that DC-STAMP, a key regulator of osteoclast cell fusion, is a direct target gene of Tal1 and show that Tal1 represses DC-STAMP expression by counteracting the activating function of the transcription factors PU. 1 and MITF. The identification of Tal1 as a factor involved in cell fusion contributes to the understanding of osteoclast-associated diseases, including osteoporosis.-Courtial, N., Smink, J. J., Kuvardina, O. N., Leutz, A., Gothert, J. R., Lausen, J. Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP. FASEB J. 26, 523-532 (2012). www.fasebj.org	[Courtial, Nadine; Kuvardina, Olga N.; Lausen, Joern] Inst Biomed Res, D-60596 Frankfurt, Germany; [Smink, Jeske J.; Leutz, Achim] Max Delbruck Ctr Mol Med, Berlin, Germany; [Smink, Jeske J.; Leutz, Achim] Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [Goethert, Joachim R.] Univ Duisburg Essen, Dept Hematol, Essen, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Duisburg Essen	Lausen, J (corresponding author), Inst Biomed Res, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	lausen@em.uni-frankfurt.de	Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; Gothert, Joachim/0000-0001-8957-6732	LOEWE initiative Onkogene Signaltransduktion Frankfurt; LOEWE Center for Cell and Gene Therapy Frankfurt (Hessisches Ministerium fur Wissenschaft und Kunst [III L 4-518/55.004, III L 4-518/17004]; Elsbeth-Bonhoff-Stiftung (Berlin)	LOEWE initiative Onkogene Signaltransduktion Frankfurt; LOEWE Center for Cell and Gene Therapy Frankfurt (Hessisches Ministerium fur Wissenschaft und Kunst; Elsbeth-Bonhoff-Stiftung (Berlin)	The authors thank Takeshi Miyamoto (Keio University School of Medicine, Tokyo, Japan), Dr. Nicholas Meadows (University of Queensland, Brisbane, QLD, Australia), and Dr. Manuel Grez (Georg-Speyer-Haus, Frankfurt, Germany) for providing material. J.L. is supported by the LOEWE initiative Onkogene Signaltransduktion Frankfurt and the LOEWE Center for Cell and Gene Therapy Frankfurt (Hessisches Ministerium fur Wissenschaft und Kunst, III L 4-518/55.004 and III L 4-518/17004). This work was supported by a grant to J.L. from the Elsbeth-Bonhoff-Stiftung (Berlin).	Anract P, 1998, INT ORTHOP, V22, P19, DOI 10.1007/s002640050201; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023; Bloor AJC, 2002, J HEMATOTH STEM CELL, V11, P195, DOI 10.1089/152581602753658402; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623-198769010-00018; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Dey S, 2010, MOL CELL BIOL, V30, P2181, DOI 10.1128/MCB.01441-09; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Elefanty AG, 1998, P NATL ACAD SCI USA, V95, P11897, DOI 10.1073/pnas.95.20.11897; Gekas C, 2009, BLOOD, V113, P3461, DOI 10.1182/blood-2008-07-167577; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375; Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005; Hu R, 2007, MOL CELL BIOL, V27, P4018, DOI 10.1128/MCB.01839-06; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Ida-Yonemochi H, 2004, EUR J ORAL SCI, V112, P148, DOI 10.1111/j.0909-8836.2004.00109.x; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishii M, 2008, MOD RHEUMATOL, V18, P220, DOI 10.1007/s10165-008-0051-2; Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood-2006-09-048249; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518; Lecuyer E, 2004, EXP HEMATOL, V32, P11, DOI 10.1016/j.exphem.2003.10.010; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Mensah K. A., J CELL PHYSL, V223, P76; Mizoguchi F, 2010, J CELL BIOCHEM, V109, P866, DOI 10.1002/jcb.22228; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Nie L, 2008, J BIOL CHEM, V283, P684, DOI 10.1074/jbc.M704981200; Novack DV, 2008, ANNU REV PATHOL-MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431; Pimanda JE, 2006, MOL CELL BIOL, V26, P2615, DOI 10.1128/MCB.26.7.2615-2625.2006; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140-6736(06)68891-0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Smink JJ, 2009, EMBO J, V28, P1769, DOI 10.1038/emboj.2009.127; Smink JJ, 2003, OSTEOARTHR CARTILAGE, V11, P864, DOI 10.1016/S1063-4584(03)00187-0; Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood-2010-10-311415; Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Terme JM, 2009, BLOOD, V113, P6695, DOI 10.1182/blood-2008-07-166835; Tsuneto M, 2005, STEM CELLS, V23, P134, DOI 10.1634/stemcells.2004-0154; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401; Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774-006-0697-9; Yamane T, 2000, EXP HEMATOL, V28, P833, DOI 10.1016/S0301-472X(00)00175-2; Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593	58	32	33	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					523	532		10.1096/fj.11-190850	http://dx.doi.org/10.1096/fj.11-190850			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	21990371				2022-12-28	WOS:000300485700006
J	Salani, B; Maffioli, S; Hamoudane, M; Parodi, A; Ravera, S; Passalacqua, M; Alama, A; Nhiri, M; Cordera, R; Maggi, D				Salani, Barbara; Maffioli, Sara; Hamoudane, Meriem; Parodi, Alessia; Ravera, Silvia; Passalacqua, Mario; Alama, Angela; Nhiri, Mohamed; Cordera, Renzo; Maggi, Davide			Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells	FASEB JOURNAL			English	Article						NSCLC; AKT; FOXO3a; OCT1	ACTIVATED PROTEIN-KINASE; IN-VITRO; TRANSCRIPTION FACTORS; DIABETES-MELLITUS; GROWTH; INSULIN; RECEPTOR; EXPRESSION; THERAPY; PATHWAY	Metformin causes an AMP/ATP ratio increase and AMP-activated protein kinase (AMPK) activation. Since caveolin-1 (Cav-1) plays a role in AMPK activation and energy balance, we investigated whether Cav-1 could participate in metformin's inhibitory effect on IGF1 signaling. The effect of metformin was studied in two non-small-cell lung cancer (NSCLC) cell lines, Calu-1 and Calu-6, expressing higher and lower amounts of Cav-1, respectively. In Calu-1, but not in Calu-6 cells, metformin reduced phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR) substrates Akt and Forkhead transcription factor 3a (FOXO3a), inhibited IGF1-dependent FOXO3a nuclear exit, and decreased IGF1-dependent cell proliferation. Here, we show that sensitivity of NSCLC cells to metformin was dependent on Cav-1 expression and that metformin required Cav-1 to induce AMPK phosphorylation and AMP/ATP ratio increase. Cav-1 silencing in Calu-1 and overexpression in Calu-6 reduced and improved, respectively, the inhibitory effect of metformin on IGF1-dependent Akt phosphorylation. Prolonged metformin treatment in Calu-6 cells induced a dose-dependent expression increase of Cav-1 and OCT1, a metformin transporter. Cav-1 and OCT1 expression was associated with the antiproliferative effect of metformin in Calu-6 cells (IC50 = 18 mM). In summary, these data suggest that Cav-1 is required for metformin action in NSCLC cells.-Salani, B., Maffioli, S., Hamoudane, M., Parodi, A., Ravera, S., Passalacqua, M., Alama, A., Nhiri, M., Cordera, R., Maggi, D. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 26, 788-798 (2012). www.fasebj.org	[Salani, Barbara; Maffioli, Sara; Hamoudane, Meriem; Cordera, Renzo; Maggi, Davide] Univ Genoa, Dept Endocrinol & Med, I-16132 Genoa, Italy; [Parodi, Alessia] Univ Genoa, Dept Internal Med & Med Specialties, I-16132 Genoa, Italy; [Ravera, Silvia] Univ Genoa, Dept Biol, I-16132 Genoa, Italy; [Passalacqua, Mario] Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; [Passalacqua, Mario] Univ Genoa, Italian Inst Biostruct & Biosyst, I-16132 Genoa, Italy; [Hamoudane, Meriem; Nhiri, Mohamed] Univ Abdelmalek Essaadi, Fac Sci & Tech Tangier, Tangier, Morocco; [Alama, Angela] Natl Inst Canc Res, Lung Canc Unit, Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; University of Genoa; Abdelmalek Essaadi University of Tetouan; University of Genoa; IRCCS AOU San Martino IST	Maggi, D (corresponding author), Univ Genoa, Dept Endocrinol & Med, Viale Benedetto 15-6, I-16132 Genoa, Italy.	davide.maggi@unige.it	Alama, Angela/AAE-7203-2019; Passalacqua, Mario/W-1973-2019; Ravera, Silvia/AAA-7982-2019; Cordera, Renzo/I-7229-2017; maggi, davide/AAL-4687-2020	Alama, Angela/0000-0002-9726-201X; Passalacqua, Mario/0000-0003-2779-6259; Ravera, Silvia/0000-0002-0803-1042; Cordera, Renzo/0000-0002-5280-9691; MAGGI, DAVIDE CARLO/0000-0003-3928-1295	Programma di Ricerca di Rilevante Interesse Nazionale; Fondazione Carige; University of Genoa	Programma di Ricerca di Rilevante Interesse Nazionale; Fondazione Carige(Fondazione Carige); University of Genoa	The authors thank Maria Rosa Dagnino for her skillful administrative assistance. This work was supported by grants from Programma di Ricerca di Rilevante Interesse Nazionale, Fondazione Carige, and the University of Genoa.	Alexander GC, 2008, ARCH INTERN MED, V168, P2088, DOI 10.1001/archinte.168.19.2088; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bosch M, 2011, CURR BIOL, V21, P681, DOI 10.1016/j.cub.2011.03.030; Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Cohen AW, 2005, DIABETES, V54, P679, DOI 10.2337/diabetes.54.3.679; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Fang LA, 2011, TOXICOL APPL PHARM, V251, P8, DOI 10.1016/j.taap.2010.11.007; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Gallagher EJ, 2010, TRENDS ENDOCRIN MET, V21, P610, DOI 10.1016/j.tem.2010.06.007; Gualberto A, 2010, CLIN CANCER RES, V16, P4654, DOI 10.1158/1078-0432.CCR-10-0089; Hartog H, 2007, EUR J CANCER, V43, P1895, DOI 10.1016/j.ejca.2007.05.021; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Iwasa T, 2009, CLIN CANCER RES, V15, P5117, DOI 10.1158/1078-0432.CCR-09-0478; Kikuchi R, 2012, ANN SURG ONCOL, V19, pS412, DOI 10.1245/s10434-011-1878-x; KORNBERG A, 1951, J BIOL CHEM, V193, P481; Levine YC, 2007, J BIOL CHEM, V282, P20351, DOI 10.1074/jbc.M702182200; Li D, 2011, J DIABETES, V10, P649; Linnerth NM, 2009, NEOPLASIA, V11, P672, DOI 10.1593/neo.09310; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Moreno-Navarrete JM, 2011, DIABETES, V60, P168, DOI 10.2337/db10-0805; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Miller RA, 2010, J CLIN INVEST, V120, P2267, DOI 10.1172/JCI43661; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Pal SK, 2010, MOL CANCER THER, V9, P1931, DOI 10.1158/1535-7163.MCT-10-0239; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Raposio E, 2008, CELL PROLIFERAT, V41, P739, DOI 10.1111/j.1365-2184.2008.00547.x; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Razani B, 2001, J BIOL CHEM, V276, P38121; Reitman ML, 2007, J CLIN INVEST, V117, P1226, DOI 10.1172/JCI32133; Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243; Roussel E, 2004, ANTI-CANCER DRUG, V15, P961, DOI 10.1097/00001813-200411000-00005; Salani B, 2008, ENDOCRINOLOGY, V149, P461, DOI 10.1210/en.2007-0312; Salani B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014157; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shukla S, 2009, INT J ONCOL, V34, P1613, DOI 10.3892/ijo_00000291; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18	57	54	58	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					788	798		10.1096/fj.11-192088	http://dx.doi.org/10.1096/fj.11-192088			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22038047				2022-12-28	WOS:000300485700030
J	Kang, K; Schmahl, J; Lee, JM; Garcia, K; Patil, K; Chen, A; Keene, M; Murphy, A; Sleeman, MW				Kang, Kihwa; Schmahl, Jennifer; Lee, Jong-Min; Garcia, Karen; Patil, Ketan; Chen, Amelia; Keene, Michelle; Murphy, Andrew; Sleeman, Mark W.			Mouse ghrelin-O-acyltransferase (GOAT) plays a critical role in bile acid reabsorption	FASEB JOURNAL			English	Article						intestine; ISBT; metabolomics	STIMULATES INSULIN-SECRETION; DES-ACYL GHRELIN; BETA-CELLS; FOOD-INTAKE; RAT ISLETS; ENDOCRINE; GLUCOSE; HORMONE; MICE; PANCREAS	Ghrelin is a unique peptide gut hormone that requires post-translational modification to stimulate both feeding and growth hormone release. Ghrelin O-acyltransferase (GOAT) was identified as a specific acyl-transferase for ghrelin, and recent genetic deletion studies of the Goat gene (Goat(-/-)) uncovered the role of ghrelin in the regulation of glucose homeostasis. To further understand the physiological functions of the GOAT/ghrelin system, we have conducted a metabolomic and microarray profile of Goat-null mice, as well as determined Goat expression in different tissues using the lacZ reporter gene. Serum metabolite profile analysis revealed that Goat(-/-) mice exhibited increased secondary bile acids > 2.5-fold. This was attributed to increased mRNA and protein expression of the ileal sodium-dependent bile acid transporter (ISBT) in the intestinal and biliary tract. Increased expression of additional solute carrier proteins, including Slc5a12 (> 10-fold) were also detected in the small intestine and bile duct. Goat staining was consistently observed in the pituitary glands, stomach, and intestines, and to a lesser extent in the gallbladder and pancreatic duct. This is the first report that the GOAT/ghrelin system regulates bile acid metabolism, and these findings suggest a novel function of GOAT in the regulation of intestinal bile acid reabsorption.-Kang, K., Schmahl, J., Lee, J. -M., Garcia, K., Patil, K., Chen, A., Keene, M., Murphy, A., Sleeman, M. W. Mouse ghrelin-O-acyltransferase (GOAT) plays a critical role in bile acid reabsorption. FASEB J. 26, 259-271 (2012). www.fasebj.org	[Kang, Kihwa; Schmahl, Jennifer; Garcia, Karen; Patil, Ketan; Chen, Amelia; Keene, Michelle; Murphy, Andrew; Sleeman, Mark W.] Regeneron Pharmaceut, Tarrytown, NY USA; [Lee, Jong-Min] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA	Regeneron; Harvard University; Massachusetts General Hospital	Kang, K (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	kihwa.kang@regeneron.com; mark.sleeman@regeneron.com						Adeghate E, 2002, J NEUROENDOCRINOL, V14, P555, DOI 10.1046/j.1365-2826.2002.00811.x; Akamizu T, 2004, EUR J ENDOCRINOL, V150, P447, DOI 10.1530/eje.0.1500447; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Barnett BP, 2010, SCIENCE, V330, P1689, DOI 10.1126/science.1196154; Chen CY, 2005, GASTROENTEROLOGY, V129, P8, DOI 10.1053/j.gastro.2005.04.015; Colombo M, 2003, PANCREAS, V27, P161, DOI 10.1097/00006676-200308000-00009; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; Dawson PA, 2009, J LIPID RES, V50, P2340, DOI 10.1194/jlr.R900012-JLR200; Dezaki K, 2004, DIABETES, V53, P3142, DOI 10.2337/diabetes.53.12.3142; Dezaki K, 2006, DIABETES, V55, P3486, DOI 10.2337/db06-0878; Doi A, 2006, P NATL ACAD SCI USA, V103, P885, DOI 10.1073/pnas.0502470102; Gahete MD, 2010, MOL CELL ENDOCRINOL, V317, P154, DOI 10.1016/j.mce.2009.12.023; Granata R, 2007, ENDOCRINOLOGY, V148, P512, DOI 10.1210/en.2006-0266; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Inui A, 2004, FASEB J, V18, P439, DOI 10.1096/fj.03-0641rev; Irako T, 2006, DIABETOLOGIA, V49, P1264, DOI 10.1007/s00125-006-0226-3; Kang K, 2011, PEPTIDES, V32, P2236, DOI 10.1016/j.peptides.2011.04.028; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lawton KA, 2008, PHARMACOGENOMICS, V9, P383, DOI 10.2217/14622416.9.4.383; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007; Poueymirou WT, 2007, NAT BIOTECHNOL, V25, P91, DOI 10.1038/nbt1263; Prado CL, 2004, P NATL ACAD SCI USA, V101, P2924, DOI 10.1073/pnas.0308604100; Roberts RE, 2011, CLIN ENDOCRINOL, V74, P67, DOI 10.1111/j.1365-2265.2010.03886.x; Sakata I, 2009, AM J PHYSIOL-ENDOC M, V297, pE134, DOI 10.1152/ajpendo.90859.2008; Shneider BL, 2001, J PEDIATR GASTR NUTR, V32, P407, DOI 10.1097/00005176-200104000-00002; Srinivas SR, 2005, BIOCHEM J, V392, P655, DOI 10.1042/BJ20050927; Sun YX, 2007, NEUROENDOCRINOLOGY, V86, P215, DOI 10.1159/000109094; Teramae H, 2010, BIOMED RES-TOKYO, V31, P239, DOI 10.2220/biomedres.31.239; Toshinai K, 2006, ENDOCRINOLOGY, V147, P2306, DOI 10.1210/en.2005-1357; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wierup N, 2004, J HISTOCHEM CYTOCHEM, V52, P301, DOI 10.1177/002215540405200301; Wierup N, 2002, REGUL PEPTIDES, V107, P63, DOI 10.1016/S0167-0115(02)00067-8; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; Zhang WZ, 2008, ENDOCRINOLOGY, V149, P4710, DOI 10.1210/en.2008-0263; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107; Zigman JM, 2005, J CLIN INVEST, V115, P3564, DOI 10.1172/JCI26002	43	23	25	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					259	271		10.1096/fj.11-191460	http://dx.doi.org/10.1096/fj.11-191460			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965605				2022-12-28	WOS:000299202200027
J	Lim, JH; Park, SY; Kim, SY; Kim, DJ; Choi, JE; Kim, MH; Choi, JS; Kim, MY; Yang, JH; Ryu, HM				Lim, Ji Hyae; Park, So Yeon; Kim, Shin Young; Kim, Do Jin; Choi, Ji Eun; Kim, Min Hyoung; Choi, Jun Seek; Kim, Moon Young; Yang, Jae Hyug; Ryu, Hyun Mee			Effective detection of fetal sex using circulating fetal DNA in first-trimester maternal plasma	FASEB JOURNAL			English	Article						epigenetic biomarker; methylation-specific PCR; multiplex quantitative PCR; phosphodiesterases gene	NONINVASIVE PRENATAL-DIAGNOSIS; REAL-TIME PCR; HYPERMETHYLATED RASSF1A; QUANTITATIVE-ANALYSIS; BLOOD; QUANTIFICATION; AMNIOCENTESIS; RELIABILITY; EXTRACTION; PREDICTION	The aim of this study was to develop a simple and effective method for noninvasively detecting fetal sex using circulating fetal DNA from first-trimester maternal plasma. A study was conducted with maternal plasma collected from 203 women between 5 and 12 wk of gestation. The presence of circulating fetal DNA was confirmed by a quantitative methylation-specific polymerase chain reaction of the unmethylated-PDE9A gene (U-PDE9A). Multiplex real-time PCR was used to simultaneously quantify the amount of DYS14 and GAPDH in maternal plasma. The results were confirmed by phenotype at birth. Pregnancy outcomes and U-PDE9A concentrations were obtained in all cases, including 99 male-bearing and 104 female-bearing participants. At equivalent specificity (100%), the false-negative rate was 9.1% for DYS14 quantification cycle, 7.1% for DYS14 concentration, and 0.0% for the concentration ratio of DYS14/GAPDH, respectively. In male-bearing participants, DYS14, U-PDE9A, and GAPDH concentrations were significantly lower in the false-negative case than in correct case (P<0.001 in all). Moreover, DYS14, U-PDE9A, and GAPDH concentrations showed significantly positive associations with each other (P <= 0.001 in all). The ratio of DYS14/GAPDH in maternal plasma was an effective biomarker for noninvasive fetal sex detection during the first trimester, indicating that it could be useful for clinical application.-Lim, J. H., Park, S. Y., Kim, S. Y., Kim, D. J., Choi, J. E., Kim, M. H., Choi, J. S., Kim, M. Y., Yang, J. H., Ryu, H. M. Effective detection of fetal sex using circulating fetal DNA in first-trimester maternal plasma. FASEB J. 26, 250-258 (2012). www.fasebj.org	[Ryu, Hyun Mee] KwanDong Univ, Sch Med, Dept Obstet & Gynecol, Cheil Gen Hosp & Womens Healthcare Ctr,Coll Med, Seoul 100380, South Korea; [Lim, Ji Hyae; Park, So Yeon; Kim, Shin Young; Kim, Do Jin; Choi, Ji Eun; Ryu, Hyun Mee] KwanDong Univ, Cheil Gen Hosp & Womens Healthcare Ctr, Coll Med, Lab Med Genet,Med Res Inst, Seoul 100380, South Korea	Catholic Kwandong University; Catholic Kwandong University	Ryu, HM (corresponding author), KwanDong Univ, Sch Med, Dept Obstet & Gynecol, Cheil Gen Hosp & Womens Healthcare Ctr,Coll Med, 1-19 Mookjung Dong, Seoul 100380, South Korea.	hmryu@yahoo.com	Lim, Ji Hyae/N-4634-2013	Lim, Ji Hyae/0000-0002-1105-7235	Life Insurance Philanthropy Foundation	Life Insurance Philanthropy Foundation	This study was supported by a research grant of the Life Insurance Philanthropy Foundation. The authors thank the following physicians and their associated staff who took the time and effort to participate in this study: Dr. Joung Yeol Han, Dr. Hyun Kyong Ahn, Dr. Jin Hoon Chung, Dr. Si Won Lee, Dr. Da Eun Lee, Jin Woo Kim, Bom Yi Lee, Mi Jin Kim, Ju Yeon Park, Eun Young Choi, Yeon Woo Lee, Ah Rum Oh, Shin Yeong Lee, and So Min Seo. The authors thank Dr. Sung Won Park, Dr. Daehun Peah, and Dr. In Soo Kang for statistical analysis of the data.	Alberry M, 2007, PRENATAL DIAG, V27, P415, DOI 10.1002/pd.1700; Bustamante-Aragones A, 2010, EXPERT REV MOL DIAGN, V10, P197, DOI [10.1586/erm.09.86, 10.1586/ERM.09.86]; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chan KCA, 2006, CLIN CHEM, V52, P2211, DOI 10.1373/clinchem.2006.074997; Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893; Chim SSC, 2008, CLIN CHEM, V54, P500, DOI 10.1373/clinchem.2007.098731; Chiu RWK, 2001, CLIN CHEM, V47, P1607; Clausen FB, 2007, PRENATAL DIAG, V27, P6, DOI 10.1002/pd.1605; Costa JM, 2002, NEW ENGL J MED, V346, P1502, DOI 10.1056/NEJM200205093461918; Dhallan R, 2004, JAMA-J AM MED ASSOC, V291, P1114, DOI 10.1001/jama.291.9.1114; Finning KM, 2008, SEMIN FETAL NEONAT M, V13, P69, DOI 10.1016/j.siny.2007.12.007; Honda H, 2002, HUM GENET, V110, P75, DOI 10.1007/s00439-001-0649-3; Johnson KL, 2004, CLIN CHEM, V50, P516, DOI 10.1373/clinchem.2003.024380; Legler TJ, 2007, PRENATAL DIAG, V27, P824, DOI 10.1002/pd.1783; Lim JH, 2008, OBSTET GYNECOL, V111, P1403, DOI 10.1097/AOG.0b013e3181719b7a; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Mujezinovic F, 2007, OBSTET GYNECOL, V110, P687, DOI 10.1097/01.AOG.0000278820.54029.e3; Odeh M, 2009, OBSTET GYNECOL SURV, V64, P50, DOI 10.1097/OGX.0b013e318193299b; Page-Christiaens GCML, 2006, ANN NY ACAD SCI, V1075, P123, DOI 10.1196/annals.1368.016; Picchiassi E, 2008, PRENATAL DIAG, V28, P525, DOI 10.1002/pd.2018; Scheffer PG, 2010, OBSTET GYNECOL, V115, P117, DOI 10.1097/AOG.0b013e3181c3c938; TABOR A, 1986, LANCET, V1, P1287; Tjoa ML, 2006, AM J PATHOL, V169, P400, DOI 10.2353/ajpath.2006.060161; Tong YK, 2006, CLIN CHEM, V52, P2194, DOI 10.1373/clinchem.2006.076851; Wright CF, 2009, HUM REPROD UPDATE, V15, P139, DOI 10.1093/humupd/dmn047; Zejskova L, 2010, EXP MOL PATHOL, V89, P241, DOI 10.1016/j.yexmp.2010.09.002; Zimmermann B, 2005, CLIN CHEM, V51, P1598, DOI 10.1373/clinchem.2005.051235	28	9	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					250	258		10.1096/fj.11-191429	http://dx.doi.org/10.1096/fj.11-191429			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21965598				2022-12-28	WOS:000299202200026
J	Zheng, ZX; Li, L; Liu, XY; Wang, DL; Tu, B; Wang, LN; Wang, HY; Zhu, WG				Zheng, Zhixing; Li, Lian; Liu, Xiangyu; Wang, Donglai; Tu, Bo; Wang, Lina; Wang, Haiying; Zhu, Wei-Guo			5-Aza-2 '-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins	FASEB JOURNAL			English	Article						MDM2; histone modification	INHIBIT CELL-PROLIFERATION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER CELLS; RETINOBLASTOMA PROTEIN; DNA-DAMAGE; PHOSPHATASE 2A; HISTONE DEACETYLASE; MDM2; METHYLATION; P53	Not only does 5-aza-2'-deoxycytidine (5-aza-CdR) induce the reexpression of silenced genes through the demethylation of CpG islands, but it increases the expression of unmethylated genes. However, the mechanism by which 5-aza-CdR activates the expression of genes is not completely understood. Here, we report that the pRb pocket proteins pRb, p107, and p130 were degraded in various cancer cell lines in response to 5-aza-CdR treatment, and this effect was dependent on the proteasome pathway. Mouse double minute 2 (MDM2) played a critical role in this 5-aza-CdR-induced degradation of pRb. Furthermore, PP2A phosphatase-induced MDM2 dephosphorylation at S260 was found to be essential for MDM2 binding to pRb in the presence of 5-aza-CdR. pRb degradation resulted in the significant reexpression of several genes, including methylated CDKN2A, RASFF1A, and unmethylated CDKN2D. Finally, knockdown of pRb pocket proteins by either RNAi or 5-aza-CdR treatment induced a significant decrease in the recruitment of SUV39H1 and an increase in the enrichment of KDM3B and KDM4A to histones around the promoter of RASFF1A and thus reduced H3K9 di- and trimethylation, by which RASFF1A expression is activated. Our data reveal a novel mechanism by which 5-aza-CdR induces the expression of both methylated and unmethylated genes by degrading pRb pocket proteins.-Zheng, Z., Li, L., Liu, X., Wang, D., Tu, B., Wang, L., Wang, H., Zhu, W.-G. 5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J. 26, 449-459 (2012). www.fasebj.org	[Zhu, Wei-Guo] Peking Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China; Peking Univ, Peking Univ Tsiinghua Univ Joint Ctr Life Sci, Beijing 100191, Peoples R China	Peking University; Peking University	Zhu, WG (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, 38 Xuanyuan Rd, Beijing 100191, Peoples R China.	zhuweiguo@bjmu.edu.cn	zhu, wei-guo/E-1334-2012; liu, xiangyu/D-8213-2014	Zhu, Wei-Guo/0000-0001-8385-6581; Wang, Haiying/0000-0001-7729-0649	National Natural Science Foundation of China [90919030, 31070691, 31071117, 30921062]; Ministry of Education of China; Ministry of Science and Technology of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This study is supported by National Natural Science Foundation of China grants 90919030, 31070691, 31071117, 30921062; 111 Project from the Ministry of Education of China; and grants from the Ministry of Science and Technology of China.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chai GL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002445; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; GLAZER RI, 1984, MOL PHARMACOL, V26, P381; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Jang YJ, 2007, J BIOL CHEM, V282, P2473, DOI 10.1074/jbc.M605480200; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; JUVEN T, 1993, ONCOGENE, V8, P3411; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Link PA, 2008, CANCER RES, V68, P9358, DOI 10.1158/0008-5472.CAN-08-1860; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2003, MOL CANCER RES, V1, P1017; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; VESELY J, 1977, CANCER RES, V37, P3684; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang DJ, 2009, CANCER RES, V69, P8200, DOI 10.1158/0008-5472.CAN-09-1976; Wang H, 2008, J BIOL CHEM, V283, P2564, DOI 10.1074/jbc.M702454200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07; Xing YN, 2008, CELL, V133, P154, DOI 10.1016/j.cell.2008.02.041; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	48	19	21	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2012	26	1					449	459		10.1096/fj.11-190025	http://dx.doi.org/10.1096/fj.11-190025			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	877SF	21990374				2022-12-28	WOS:000299202200044
J	Bae, HB; Zmijewski, JW; Deshane, JS; Tadie, JM; Chaplin, DD; Takashima, S; Abraham, E				Bae, Hong-Beom; Zmijewski, Jaroslaw W.; Deshane, Jessy S.; Tadie, Jean-Marc; Chaplin, David D.; Takashima, Seiji; Abraham, Edward			AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils	FASEB JOURNAL			English	Article						inflammation; phagocytosis; efferocytosis; cytoskeleton	ACUTE LUNG INJURY; RECEPTOR-MEDIATED PHAGOCYTOSIS; RESPIRATORY COMPLEX-I; HYDROGEN-PEROXIDE; MUSCLE-CELLS; RHO GTPASES; BINDING; CLIP-170; MICROTUBULES; MECHANISM	Although AMPK plays well-established roles in the modulation of energy balance, recent studies have shown that AMPK activation has potent anti-inflammatory effects. In the present experiments, we examined the role of AMPK in phagocytosis. We found that ingestion of Escherichia coli or apoptotic cells by macrophages increased AMPK activity. AMPK activation increased the ability of neutrophils or macrophages to ingest bacteria (by 46 +/- 7.8 or 85 +/- 26%, respectively, compared to control, P<0.05) and the ability of macrophages to ingest apoptotic cells (by 21 +/- 1.4%, P<0.05 compared to control). AMPK activation resulted in cytoskeletal reorganization, including enhanced formation of actin and microtubule networks. Activation of PAK1/2 and WAVE2, which are downstream effectors of Rac1, accompanied AMPK activation. AMPK activation also induced phosphorylation of CLIP-170, a protein that participates in microtubule synthesis. The increase in phagocytosis was reversible by the specific AMPK inhibitor compound C, siRNA to AMPK alpha 1, Rac1 inhibitors, or agents that disrupt actin or microtubule networks. In vivo, AMPK activation resulted in enhanced phagocytosis of bacteria in the lungs by 75 +/- 5% vs. control (P<0.05). These results demonstrate a novel function for AMPK in enhancing the phagocytic activity of neutrophils and macrophages.-Bae, H. -B., Zmijewski, J. W., Deshane, J. S., Tadie, J. -M., Chaplin, D. D., Takashima, S., Abraham, E. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 25, 4358-4368 (2011). www.fasebj.org	[Zmijewski, Jaroslaw W.] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA; [Zmijewski, Jaroslaw W.; Chaplin, David D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Bae, Hong-Beom] Chonnam Natl Univ, Sch Med, Dept Anesthesiol & Pain Med, Kwangju, South Korea; [Takashima, Seiji] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Chonnam National University; Osaka University	Abraham, E (corresponding author), Wake Forest Baptist Med Ctr, Wake Forest Sch Med, 10th Floor,Richard Janeway Clin Sci Tower,Med Ctr, Winston Salem, NC 27157 USA.	zmijewsk@uab.edu; eabraham@wakehealth.edu		Chaplin, David/0000-0002-1354-3069	U.S. National Institutes of Health [HL76206, GM87748]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087748] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by U.S. National Institutes of Health grants HL76206 and GM87748 to E.A. The authors declare no conflicts of interest.	Abou Kheir W, 2005, J CELL SCI, V118, P5369, DOI 10.1242/jcs.02638; Aoki C, 2010, J ATHEROSCLER THROMB, V17, P503, DOI 10.5551/jat.3392; Binker MG, 2007, J IMMUNOL, V179, P3780, DOI 10.4049/jimmunol.179.6.3780; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; DeFife KM, 1999, FASEB J, V13, P823, DOI 10.1096/fasebj.13.8.823; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; Dupuy AG, 2008, J CELL SCI, V121, P1773, DOI 10.1242/jcs.018036; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Folker ES, 2005, MOL BIOL CELL, V16, P5373, DOI 10.1091/mbc.E04-12-1106; Friggeri A, 2011, J IMMUNOL, V186, P6191, DOI 10.4049/jimmunol.1004134; Friggeri A, 2010, AM J PHYSIOL-CELL PH, V299, pC1267, DOI 10.1152/ajpcell.00152.2010; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Iseli TJ, 2008, J BIOL CHEM, V283, P4799, DOI 10.1074/jbc.M708298200; Jeong HW, 2009, AM J PHYSIOL-ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008; Jhun BS, 2004, BIOCHEM BIOPH RES CO, V318, P372, DOI 10.1016/j.bbrc.2004.04.035; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Khandani A, 2007, J LEUKOCYTE BIOL, V82, P417, DOI 10.1189/jlb.0706469; Labuzek K, 2010, N-S ARCH PHARMACOL, V381, P171, DOI 10.1007/s00210-009-0477-x; Lebensohn AM, 2009, MOL CELL, V36, P512, DOI 10.1016/j.molcel.2009.10.024; Lee YM, 2008, J BIOL CHEM, V283, P33969, DOI 10.1074/jbc.M804469200; Levine YC, 2007, J BIOL CHEM, V282, P20351, DOI 10.1074/jbc.M702182200; Lewkowicz E, 2008, J CELL BIOL, V183, P1287, DOI 10.1083/jcb.200807023; Lorne E, 2008, AM J PHYSIOL-CELL PH, V294, pC985, DOI 10.1152/ajpcell.00454.2007; Machuy N, 2007, J MOL BIOL, V370, P620, DOI 10.1016/j.jmb.2007.04.080; McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008; McGee K, 2003, FEBS LETT, V533, P35, DOI 10.1016/S0014-5793(02)03745-6; Nakano A, 2010, NAT CELL BIOL, V12, P583, DOI 10.1038/ncb2060; NEWMAN SL, 1990, J CLIN INVEST, V85, P223, DOI 10.1172/JCI114416; Niedergang F, 2004, CURR OPIN CELL BIOL, V16, P422, DOI 10.1016/j.ceb.2004.06.006; Peralta C, 2001, HEPATOLOGY, V34, P1164, DOI 10.1053/jhep.2001.29197; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Steenport M, 2009, J IMMUNOL, V183, P8119, DOI 10.4049/jimmunol.0901925; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Stuart LM, 2008, NAT REV IMMUNOL, V8, P131, DOI 10.1038/nri2240; Sulahian TH, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-59; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Tsoyi K., 2010, BRIT J PHARMACOL, V162, P1498; Tsuruta Y, 2007, J IMMUNOL, V179, P7079, DOI 10.4049/jimmunol.179.10.7079; Turner N, 2008, DIABETES, V57, P1414, DOI 10.2337/db07-1552; Vidal C, 2002, BLOOD, V100, P4462, DOI 10.1182/blood.V100.13.4462; WAN CP, 1993, J IMMUNOL METHODS, V162, P1, DOI 10.1016/0022-1759(93)90400-2; Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008; Zmijewski JW, 2008, AM J RESP CRIT CARE, V178, P168, DOI 10.1164/rccm.200710-1602OC; Zmijewski JW, 2007, AM J PHYSIOL-CELL PH, V293, pC255, DOI 10.1152/ajpcell.00618.2006; Zmijewski JW, 2010, J BIOL CHEM, V285, P33154, DOI 10.1074/jbc.M110.143685; Zmijewski JW, 2009, AM J RESP CRIT CARE, V179, P694, DOI 10.1164/rccm.200806-851OC	54	97	98	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4358	4368		10.1096/fj.11-190587	http://dx.doi.org/10.1096/fj.11-190587			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885655	Green Published			2022-12-28	WOS:000298138100027
J	Jenei, ZA; Warren, GZL; Hasan, M; Zammit, VA; Dixon, AM				Jenei, Zsuzsanna A.; Warren, Gemma Z. L.; Hasan, Muhammad; Zammit, Victor A.; Dixon, Ann M.			Packing of transmembrane domain 2 of carnitine palmitoyltransferase-1A affects oligomerization and malonyl-CoA sensitivity of the mitochondrial outer membrane protein	FASEB JOURNAL			English	Article						fatty acid metabolism; diabetes; GXXXG motif; analytical ultracentrifugation; GALLEX assay	C-TERMINAL DOMAIN; CONTACT SITES; CARNITINE-PALMITOYLTRANSFERASE-1; ULTRACENTRIFUGATION; ASSOCIATION	The purpose of this study was to investigate the sequence-dependence of oligomerization of transmembrane domain 2 (TM2) of rat carnitine palmitoyltransferase 1A (rCPT1A), to elucidate the role of this domain in the function of the full-length enzyme. Oligomerization of TM2 was studied qualitatively using complementary genetic assays that facilitate measurement of helix-helix interactions in the Escherichia coli inner membrane, and multiple quantitative biophysical methods. The effects of TM2-mutations on oligomerization and malonyl-CoA inhibition of the full-length enzyme (expressed in the yeast Pichia pastoris) were quantified. Changes designed to disrupt close-packing of the GXXXG(A) motifs reduced the oligomeric state of the corresponding TM2 peptides from hexamer to trimer (or lower), a reduction also observed on mutation of the TM2 sequence in the full-length enzyme. Disruption of these GXXXG(A) motifs had a parallel effect on the malonyl-CoA sensitivity of rCPT1A, reducing the IC50 from 30.3 +/- 5.0 to 3.0 +/- 0.6 mu M. For all measurements, wild-type rCPT1A was used as a control alongside various appropriate (e. g., molecular mass) standards. Our results suggest that sequence-determined, TM2-mediated oligomerization is likely to be involved in the modulation of malonyl-CoA inhibition of CPT1A in response to short-and long-term changes in protein-protein and protein-lipid interactions that occur in vivo. -Jenei, Z. A., Warren, G. Z. L., Hasan, M., Zammit, V. A., Dixon, A. M. Packing of transmembrane domain 2 of carnitine palmitoyltransferase-1A affects oligomerization and malonyl-CoA sensitivity of the mitochondrial outer membrane protein. FASEB J. 25, 4522-4530 (2011). www.fasebj.org	[Jenei, Zsuzsanna A.; Dixon, Ann M.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; [Warren, Gemma Z. L.; Zammit, Victor A.] Univ Warwick, Div Metab & Vasc Hlth, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Hasan, Muhammad] Univ Warwick, MOAC Doctoral Training Ctr, Coventry CV4 7AL, W Midlands, England	University of Warwick; University of Warwick; University of Warwick	Dixon, AM (corresponding author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.	ann.dixon@warwick.ac.uk	Hasan, Muhammad/AAQ-4243-2020; Dixon, Ann M/I-3696-2012	Hasan, Muhammad/0000-0003-3201-7184; Dixon, Ann M/0000-0002-5261-304X	Diabetes UK; British Heart Foundation [PG/08/087/25872]; Warwick University	Diabetes UK(Diabetes UK); British Heart Foundation(British Heart Foundation); Warwick University	The authors thank J. Crawford (HHMI Keck Facility, Yale University, New Haven, CT, USA) for peptide synthesis, R. Parslow (University of Birmingham, Birmingham, UK) and Dr. D. Staunton (Oxford University, Oxford, UK) for assistance with analytical ultracentrifugation, and Prof. A. Rodger (University of Warwick, Coventry, UK) for access to CD instrumentation. This work was supported by a Diabetes UK grant to V.A.Z. and A. M. D., a British Heart Foundation grant (PG/08/087/25872) to V.A.Z. and A. M. D. to support G.Z.L.W., and a Warwick University Postgraduate Research Fellowship to support Z.A.J.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; Dixon AM, 2006, BIOCHEMISTRY-US, V45, P5228, DOI 10.1021/bi052112e; Faye A, 2005, BIOCHEM J, V387, P67, DOI 10.1042/BJ20041533; Faye A, 2007, J BIOL CHEM, V282, P26908, DOI 10.1074/jbc.M705418200; Fraser F, 2001, J BIOL CHEM, V276, P20182, DOI 10.1074/jbc.M101078200; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 1999, BIOCHEM J, V341, P483, DOI 10.1042/0264-6021:3410483; Jenei ZA, 2009, J BIOL CHEM, V284, P6988, DOI 10.1074/jbc.M808487200; King G, 2010, MOL BIOSYST, V6, P1650, DOI 10.1039/c002241a; Kochendoerfer GG, 1999, BIOCHEMISTRY-US, V38, P11905, DOI 10.1021/bi990720m; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee KK, 2011, J BIOL CHEM; Lopez-Vinas E, 2007, J BIOL CHEM, V282, P18212, DOI 10.1074/jbc.M700885200; Oates J, 2008, BIOCHEMISTRY-US, V47, P8985, DOI 10.1021/bi8006252; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zammit VA, 2008, IUBMB LIFE, V60, P347, DOI 10.1002/iub.78	26	9	10	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4522	4530		10.1096/fj.11-192005	http://dx.doi.org/10.1096/fj.11-192005			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21917985				2022-12-28	WOS:000298138100042
J	Russell, R; Gori, I; Pellegrini, C; Kumar, R; Achtari, C; Canny, GO				Russell, Ronan; Gori, Ilaria; Pellegrini, Chiara; Kumar, Rajesh; Achtari, Chahin; Canny, Geraldine O.			Lipoxin A(4) is a novel estrogen receptor modulator	FASEB JOURNAL			English	Article						endometrium; eicosanoids; hormones; estradiol	ARYL-HYDROCARBON RECEPTOR; ASPIRIN-TRIGGERED LIPOXIN; FORMYL PEPTIDE RECEPTORS; ALPHA-KNOCKOUT MOUSE; PROTEIN-KINASE-C; PROGESTERONE-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; HUMAN NEUTROPHILS; STEROID-HORMONES	Inflammation is intimately linked with naturally occurring remodeling events in the endometrium. Lipoxins comprise a group of short-lived, non-classic eicosanoids possessing potent anti-inflammatory and proresolution properties. In the present study, we investigated the role of lipoxin A(4) (LXA(4)) in the endometrium and demonstrated that 15-LOX-2, an enzyme necessary for LX biosynthesis, is expressed in this tissue. Our results establish that LXA(4) possesses robust estrogenic activity through its capacity to alter ERE transcriptional activity, as well as expression of estrogen-regulated genes, alkaline phosphatase activity, and proliferation in human endometrial epithelial cells. Interestingly, LXA(4) also demonstrated antiestrogenic potential, significantly attenuating E2-induced activity. This estrogenic activity was directly mediated through estrogen receptors (ERs). Subsequent investigations determined that the actions of LXA(4) are exclusively mediated through ER alpha and closely mimic those of the potent estrogen 17 beta-estradiol (E2). In binding assays, LXA(4) competed with E2 for ER binding, with an IC50 of 46 nM. Furthermore, LXA(4) exhibited estrogenic activity in vivo, increasing uterine wet weight and modulating E2-regulated gene expression. These findings reveal a previously unappreciated facet of LXA(4) bioactions, implicating this lipid mediator in novel immunoendocrine crosstalk mechanisms.-Russell R., Gori, I., Pellegrini, C., Kumar, R., Achtari, C., Canny, G. O. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J. 25, 4326-4337 (2011). www.fasebj.org	[Canny, Geraldine O.] Univ Hosp Ctr, Dept Gynecol Obstet & Med Genet, Mucosal Immun Lab, CH-1011 Lausanne, Switzerland; Univ Lausanne, CH-1011 Lausanne, Switzerland	University of Lausanne	Canny, GO (corresponding author), Univ Hosp Ctr, Dept Gynecol Obstet & Med Genet, Mucosal Immun Lab, Ave Pierre Decker 2, CH-1011 Lausanne, Switzerland.	geraldine.canny@chuv.ch	Kumar, Rajesh/F-6579-2014; Kumar, Rajesh/I-5668-2019; Russell, Ronan/AAD-8418-2019	Achtari, Chahin/0000-0001-9265-9395; Canny, Geraldine/0000-0003-0632-7365; Kumar, Rajesh/0000-0002-0211-7195	Swiss National Science Foundation; Roche Research Foundation; Department of Gynecology and Obstetrics, CHUV (Lausanne, Switzerland); Swiss Confederation scholarship	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Roche Research Foundation; Department of Gynecology and Obstetrics, CHUV (Lausanne, Switzerland); Swiss Confederation scholarship	The authors thank Dr. Dela Golshayan for kindly facilitating in vivo experiments, and Carile Steinacher for assistance with immunohistochemistry, as well as Charles Serhan, Donald McDonnell, Karsten Gronert, and Sean Colgan for helpful discussions. Thanks also to Patrick Hohlfeld, Alan Baird, Stephen Keely, and Jane Irwin for their support. This work was funded by grants to G.O.C. from the Swiss National Science Foundation, Roche Research Foundation, and funds from the Department of Gynecology and Obstetrics, CHUV (Lausanne, Switzerland). R.R. was the recipient of a Swiss Confederation scholarship. The authors declare no conflicts of interest.	Abdelrahim M, 2006, CANCER RES, V66, P2459, DOI 10.1158/0008-5472.CAN-05-3132; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Amita M, 2010, ENDOCRINOLOGY, V151, P394, DOI 10.1210/en.2009-0721; Baker N, 2009, J IMMUNOL, V182, P3819, DOI 10.4049/jimmunol.0803175; Beischlag TV, 2005, J BIOL CHEM, V280, P21607, DOI 10.1074/jbc.C500090200; Boney-Montoya J, 2010, MOL ENDOCRINOL, V24, P346, DOI 10.1210/me.2009-0429; Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105, DOI 10.1042/bse0400105; Brannstrom M, 2002, J REPROD IMMUNOL, V57, P47, DOI 10.1016/S0165-0378(02)00009-8; Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cezar-De-Mello PFT, 2008, BRIT J PHARMACOL, V153, P956, DOI 10.1038/sj.bjp.0707650; Cezar-de-Mello PFT, 2006, ONCOGENE, V25, P122, DOI 10.1038/sj.onc.1209002; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Chungaon KO, 1996, BRIT J PHARMACOL, V117, P1334, DOI 10.1111/j.1476-5381.1996.tb16733.x; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; CLARK JH, 1984, J STEROID BIOCHEM, V20, P1005, DOI 10.1016/0022-4731(84)90011-6; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Diel P, 2002, J CHROMATOGR B, V777, P191, DOI 10.1016/S1570-0232(02)00494-4; EDWIN SS, 1994, J LIPID MEDIAT CELL, V9, P291; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; FIORE S, 1993, BLOOD, V81, P3395; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hernandez-Ochoa I, 2009, BIOCHEM PHARMACOL, V77, P547, DOI 10.1016/j.bcp.2008.09.037; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; HOLINKA CF, 1986, CANCER RES, V46, P2771; Jabbour HN, 2009, REPRODUCTION, V138, P903, DOI 10.1530/REP-09-0247; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570-0232(02)00493-2; JORDAN VC, 1985, ENVIRON HEALTH PERSP, V61, P97, DOI 10.2307/3430064; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Khau T, 2011, FASEB J, V25, P483, DOI 10.1096/fj.09-154096; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Kure I, 2010, J PHARMACOL EXP THER, V332, P541, DOI 10.1124/jpet.109.159046; Kurita T, 2001, BIOL REPROD, V64, P272, DOI 10.1095/biolreprod64.1.272; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li QX, 2004, J BIOL CHEM, V279, P11570, DOI 10.1074/jbc.M311773200; Lousse JC, 2010, HUM REPROD, V25, P734, DOI 10.1093/humrep/dep408; Macdonald LJ, 2011, REPRODUCTION, V142, P345, DOI 10.1530/REP-11-0021; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Maldonado-Perez D, 2011, FASEB J, V25, P569, DOI 10.1096/fj.10-170340; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMahon B, 2000, J BIOL CHEM, V275, P27566; MEDLOCK KL, 1991, J RECEPTOR RES, V11, P743, DOI 10.3109/10799899109064677; Melamed M, 1997, MOL ENDOCRINOL, V11, P1868, DOI 10.1210/me.11.12.1868; Migeotte I, 2006, CYTOKINE GROWTH F R, V17, P501, DOI 10.1016/j.cytogfr.2006.09.009; Mitchell D, 2007, J BIOL CHEM, V282, P15606, DOI 10.1074/jbc.M611004200; Motohashi E, 2005, BIOMED PHARMACOTHER, V59, P330, DOI 10.1016/j.biopha.2005.05.005; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Malley BW, 2005, MOL ENDOCRINOL, V19, P1402, DOI 10.1210/me.2004-0480; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pearce ST, 2004, CANCER RES, V64, P2889, DOI 10.1158/0008-5472.CAN-03-1770; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Santagati S, 1997, MOL ENDOCRINOL, V11, P938, DOI 10.1210/me.11.7.938; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; SERHAN CN, 1989, ADV PROSTAG THROMB L, V19, P116; SERHAN CN, 1986, J BIOL CHEM, V261, P6340; Shipley JM, 2006, TOXICOL APPL PHARM, V213, P87, DOI 10.1016/j.taap.2005.09.011; SIMCHOWITZ L, 1994, AM J PHYSIOL-CELL PH, V267, pC1525, DOI 10.1152/ajpcell.1994.267.6.C1525; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; STENKE L, 1991, BIOCHEM BIOPH RES CO, V180, P255, DOI 10.1016/S0006-291X(05)81285-9; WAKELING AE, 1991, CANCER RES, V51, P3867; Wallace AE, 2010, J ENDOCRINOL, V206, P141, DOI 10.1677/JOE-10-0072; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Willett P, 2006, DRUG DISCOV TODAY, V11, P1046, DOI 10.1016/j.drudis.2006.10.005; Winuthayanon W, 2010, P NATL ACAD SCI USA, V107, P19272, DOI 10.1073/pnas.1013226107	75	53	55	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4326	4337		10.1096/fj.11-187658	http://dx.doi.org/10.1096/fj.11-187658			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885654				2022-12-28	WOS:000298138100024
J	Salanova, M; Bortoloso, E; Schiffl, G; Gutsmann, M; Belavy, DL; Felsenberg, D; Furlan, S; Volpe, P; Blottner, D				Salanova, Michele; Bortoloso, Elena; Schiffl, Gudrun; Gutsmann, Martina; Belavy, Daniel L.; Felsenberg, Dieter; Furlan, Sandra; Volpe, Pompeo; Blottner, Dieter			Expression and regulation of Homer in human skeletal muscle during neuromuscular junction adaptation to disuse and exercise	FASEB JOURNAL			English	Article						bedrest; countermeasure; postsynaptic signaling; NFAT	METABOTROPIC GLUTAMATE RECEPTORS; BED-REST; RYANODINE RECEPTOR-TYPE-1; DECEREBRATE CAT; SOLEUS MUSCLES; VIBRATION; PROTEINS; ACTIVATION; FIBERS; CELLS	Protein calcium sensors of the Homer family have been proposed to modulate the activity of various ion channels and nuclear factor of activated T cells (NFAT), the transcription factor modulating skeletal muscle differentiation. We monitored Homer expression and subcellular localization in human skeletal muscle biopsies following 60 d of bedrest [Second Berlin Bedrest Study (BBR2-2)]. Soleus (SOL) and vastus lateralis (VL) biopsies were taken at start (pre) and at end (end) of bedrest from healthy male volunteers of a control group without exercise (CTR; n=9), a resistive-only exercise group (RE; n=7), and a combined resistive/ vibration exercise group (RVE; n=7). Confocal analysis showed Homer immunoreactivity at the postsynaptic microdomain of the neuromuscular junction (NMJ) at bedrest start. After bedrest, Homer immunoreactivity decreased (CTR), remained unchanged (RE), or increased (RVE) at the NMJ. Homer2 mRNA and protein were differently regulated in a muscle-specific way. Activated NFATc1 translocates from cytoplasm to nucleus; increased amounts of NFATc1-immunopositive slow-type myonuclei were found in RVE myofibers of both muscles. Pulldown assays identified NFATc1 and Homer as molecular partners in skeletal muscle. A direct motor nerve control of Homer2 was confirmed in rat NMJs by in vivo denervation. Homer2 is localized at the NMJ and is part of the calcineurin-NFATc1 signaling pathway. RVE has additional benefit over RE as countermeasure preventing disuse-induced neuromuscular maladaptation during bedrest.-Salanova, M., Bortoloso, E., Schiffl, G., Gutsmann, M., Belavy, D. L., Felsenberg, D., Furlan, S., Volpe, P., Blottner, D. Expression and regulation of Homer in human skeletal muscle during neuromuscular junction adaptation to disuse and exercise. FASEB J. 25, 4312-4325 (2011). www.fasebj.org	[Salanova, Michele; Schiffl, Gudrun; Gutsmann, Martina; Blottner, Dieter] Charite, Neuromuscular Grp, Inst Anat, Ctr Space Med Berlin, D-10115 Berlin, Germany; [Belavy, Daniel L.; Felsenberg, Dieter] Charite, Ctr Muscle & Bone Res ZMK, D-10115 Berlin, Germany; [Bortoloso, Elena; Furlan, Sandra; Volpe, Pompeo] Univ Padua, Dipartimento Sci Biomed Sperimentali, Padua, Italy; [Furlan, Sandra; Volpe, Pompeo] CNR, Inst Neurosci, Padua, Italy	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Salanova, M (corresponding author), Charite, Neuromuscular Grp, Inst Anat, Ctr Space Med Berlin, Campus Charite Mitte,Philippstr 12, D-10115 Berlin, Germany.	michele.salanova@charite.de	Belavy, Daniel/P-4947-2016	Belavy, Daniel/0000-0002-9307-832X; Blottner, Dieter/0000-0003-0355-3340	European Space Agency (ESA) [14431/02/NL/SH2]; German Aerospace Center (DLR) [50WB0821, 50WB0720]; Novotec Medical; Charite Universitatsmedizin Berlin; Siemens; Osteomedical Group; Wyeth Pharma; Servier Deutschland; PG; Kubivent; Seca; Astra-Zeneka; General Electric; Italian Space Agency (ASI); Alexander von Humboldt Foundation, Germany	European Space Agency (ESA)(European Space AgencyEuropean Commission); German Aerospace Center (DLR)(Helmholtz AssociationGerman Aerospace Centre (DLR)); Novotec Medical; Charite Universitatsmedizin Berlin; Siemens(Siemens AG); Osteomedical Group; Wyeth Pharma(Wyeth); Servier Deutschland; PG; Kubivent; Seca; Astra-Zeneka; General Electric(General Electric); Italian Space Agency (ASI)(Agenzia Spaziale Italiana (ASI)); Alexander von Humboldt Foundation, Germany(Alexander von Humboldt Foundation)	The authors are indebted to Dr. Vincenzo Sorrentino (University of Siena, Siena, Italy) for the GST-Homer constructs and Dr. Paul Rosenberg (Duke University, Durham, NC, USA) for the Homer2-V5 construct. The Second Berlin Bedrest Study (BBR2-2) was supported by grant 14431/02/NL/SH2 from the European Space Agency (ESA) and German Aerospace Center (DLR), grant 50WB0821 (D.B.), and grant 50WB0720 (D.F.). The BBR2-2 was also sponsored by Novotec Medical, Charite Universitatsmedizin Berlin, Siemens, Osteomedical Group, Wyeth Pharma, Servier Deutschland, P&G, Kubivent, Seca, Astra-Zeneka and General Electric. This work was also supported by funds from Italian Space Agency (ASI; to P.V). D.L.B. was supported by a postdoctoral fellowship from the Alexander von Humboldt Foundation, Germany. Special thanks are due to the volunteers, the staff of the Radiology Department at the Charite Campus Benjamin Franklin (CBF) Hospital, Drs. S. Krasnici and J. Fakler (Traumatology Unit, Charite CBF, Berlin), and all participants in the BBR2-2 study.	Ajima R, 2007, BIOCHEM BIOPH RES CO, V356, P851, DOI 10.1016/j.bbrc.2007.03.060; Alkner BA, 2004, EUR J APPL PHYSIOL, V93, P294, DOI 10.1007/s00421-004-1172-8; Belavy DL, 2010, J MUSCULOSKEL NEURON, V10, P207; Belavy DL, 2009, J MUSCULOSKEL NEURON, V9, P225; Blottner D, 2006, EUR J APPL PHYSIOL, V97, P261, DOI 10.1007/s00421-006-0160-6; Bortoloso E, 2006, AM J PHYSIOL-CELL PH, V290, pC711, DOI 10.1152/ajpcell.00217.2005; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN MC, 1967, J PHYSIOL-LONDON, V192, P773, DOI 10.1113/jphysiol.1967.sp008330; BURKE D, 1976, J PHYSIOL-LONDON, V261, P695, DOI 10.1113/jphysiol.1976.sp011581; Cochrane DJ, 2009, MUSCLE NERVE, V40, P420, DOI 10.1002/mus.21330; Convertino V A, 1991, Physiologist, V34, pS125; Costelli P, 2005, INT J BIOCHEM CELL B, V37, P2134, DOI 10.1016/j.biocel.2005.03.010; Deschenes MR, 2006, NEUROSCIENCE, V137, P1277, DOI 10.1016/j.neuroscience.2005.10.042; Deschenes MR, 2005, MUSCLE NERVE, V31, P468, DOI 10.1002/mus.20277; Deschenes MR, 2000, MUSCLE NERVE, V23, P1576, DOI 10.1002/1097-4598(200010)23:10<1576::AID-MUS15>3.3.CO;2-A; Edgerton V R, 1994, Adv Space Biol Med, V4, P33; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Gallagher P, 2005, ACTA PHYSIOL SCAND, V185, P61, DOI 10.1111/j.1365-201X.2005.01457.x; Gasperini R, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-29; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRANIT R, 1956, ACTA PHYSIOL SCAND, V37, P114, DOI 10.1111/j.1748-1716.1956.tb01347.x; HOMMA S, 1971, JPN J PHYSIOL, V21, P405; Huang GN, 2008, SCIENCE, V319, P476, DOI 10.1126/science.1151227; Huang G, 2007, J BIOL CHEM, V282, P14283, DOI 10.1074/jbc.M611529200; Hwang SY, 2003, CELL CALCIUM, V34, P177, DOI 10.1016/S0143-4160(03)00082-4; Ingalls CP, 2001, AVIAT SPACE ENVIR MD, V72, P471; Ingalls CP, 1999, J APPL PHYSIOL, V87, P386, DOI 10.1152/jappl.1999.87.1.386; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kim Jeong-Hwan, 2006, Genomics & Informatics, V4, P1; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MATTHEWS PB, 1966, NATURE, V209, P204, DOI 10.1038/209204b0; Max N, 2001, MELANOMA RES, V11, P371, DOI 10.1097/00008390-200108000-00007; MCGRATH GJ, 1973, J PHYSIOL-LONDON, V235, P371, DOI 10.1113/jphysiol.1973.sp010392; Millino C, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-14; Pouliquin P, 2009, EUR BIOPHYS J BIOPHY, V39, P91, DOI 10.1007/s00249-009-0494-1; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; ROLL JP, 1982, EXP BRAIN RES, V47, P177; Rudnick J, 2004, FASEB J, V18, P1228, DOI 10.1096/fj.03-0792fje; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; Salanova M, 2002, CELL CALCIUM, V32, P193, DOI 10.1016/S0143416002001549; Salanova M, 2008, HISTOCHEM CELL BIOL, V130, P105, DOI 10.1007/s00418-008-0399-6; Salanova M, 2009, HISTOCHEM CELL BIOL, V132, P383, DOI 10.1007/s00418-009-0624-y; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Schredelseker J, 2005, P NATL ACAD SCI USA, V102, P17219, DOI 10.1073/pnas.0508710102; Shiraishi-Yamaguchi Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-206; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Stiber JA, 2005, DEV BIOL, V287, P213, DOI 10.1016/j.ydbio.2005.06.030; Stiber JA, 2008, MOL CELL BIOL, V28, P2637, DOI 10.1128/MCB.01601-07; Tothova J, 2006, J CELL SCI, V119, P1604, DOI 10.1242/jcs.02875; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Volpe P, 2004, BIOCHEM BIOPH RES CO, V316, P884, DOI 10.1016/j.bbrc.2004.02.132; Ward CW, 2004, J BIOL CHEM, V279, P5781, DOI 10.1074/jbc.M311422200; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Worley PF, 2007, CELL CALCIUM, V42, P363, DOI 10.1016/j.ceca.2007.05.007	54	37	37	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2011	25	12					4312	4325		10.1096/fj.11-186049	http://dx.doi.org/10.1096/fj.11-186049			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21885651	Green Submitted			2022-12-28	WOS:000298138100023
J	Keimling, M; Volcic, M; Csernok, A; Wieland, B; Dork, T; Wiesmuller, L				Keimling, Marlen; Volcic, Meta; Csernok, Andreea; Wieland, Britta; Doerk, Thilo; Wiesmueller, Lisa			Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways	FASEB JOURNAL			English	Article						breast cancer; Nibrin; BRCA1	HOMOLOGOUS RECOMBINATION; GENE-MUTATIONS; CANCER-RISK; CELLS; BRCA1; INHIBITION; PHOSPHORYLATION; PROTEINS; MISSENSE; DEFECTS	Ataxia telangiectasia mutated (ATM) has multiple functions in homologous recombination (HR) and nonhomologous end joining (NHEJ), which lead to conflicting data regarding its DNA double-strand break-repair (DSBR) functions in previous studies. To explore the effect of clinically relevant ATM mutations, we characterized DSBR between mutated EGFP genes and ATM kinase signaling in 9 lymphoblastoid cell lines (LCLs) derived from patients with ataxia telangiectasia (AT) with defined vs. 3 control LCLs without ATM mutations. Our study revealed that the DSBR phenotype in AT cells is not uniform but appears to depend on the mutation, causing up to 32-fold increased or up to 3-fold decreased activities in particular pathways. Comparison with a further 10 LCLs mutated in downstream factors (BRCA1, BRCA2, Nibrin, Rad50, and Chk2) showed that the most diametrically opposed DSBR patterns in AT cells phenocopied NBN/RAD50 or BRCA1 mutations. Notably, reexpressing wild-type ATM reversed these defects by 2.3- to 3.5-fold. Our data suggest that ATM stimulates repair proteins such as Nibrin, which execute HR, single-strand annealing (SSA), and NHEJ. Concomitantly, ATM minimizes error-prone repair (SSA and NHEJ) through activation of surveillance factors such as BRCA1. Since the outcome of the individual defect can be diametrically opposed, distinguishing repair patterns in patients with ATM mutations may also be relevant regarding therapeutic responses.-Keimling, M., Volcic, M., Csernok, A., Wieland, B., Dork, T., Wiesmuller, L. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways. FASEB J. 25, 3849-3860 (2011). www.fasebj.org	[Keimling, Marlen; Volcic, Meta; Csernok, Andreea; Wiesmueller, Lisa] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany; [Wieland, Britta; Doerk, Thilo] Hannover Med Sch, Gynecol Res Unit, D-3000 Hannover, Germany; [Wieland, Britta] Hannover Med Sch, Dept Radiat Oncol, D-3000 Hannover, Germany	Ulm University; Hannover Medical School; Hannover Medical School	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@uni-ulm.de	Dörk, Thilo/J-8620-2012	Dörk, Thilo/0000-0002-9458-0282	Deutsche Krebshilfe [107744]; Bundesministerium fur Bildung und Forschung, Germany (BRENDA) [012P0505]; Deutsche Forschungsgemeinschaft (DFG) [167, WI 3099/7-1, WI 3099/7-2]	Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung, Germany (BRENDA)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors are grateful to Yosef Shiloh (Tel Aviv University, Tel Aviv, Israel) for providing the ATM expression vector. The authors cordially thank Natalia Bogdanova (Hannover Medical School), for performing mutational studies on CHEK2 and for providing material of mutation carriers, as well as Lisa Dohrn and Annabelle Schwan (Ulm University), for help with the DSBR analyses in HeLa cell lines. The authors gratefully acknowledge Peter Hillemanns and Rolf Kreienberg for the continuous support of their molecular oncological studies. The authors thank the Deutsche Krebshilfe (grant 107744), the Bundesministerium fur Bildung und Forschung, Germany (BRENDA, grant 012P0505), and the Deutsche Forschungsgemeinschaft (DFG Klinische Forschergruppe 167: Apoptoseregulation und ihre Storungen bei Krankheiten, grants WI 3099/7-1 and -2) for financial support.	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albert MH, 2010, BONE MARROW TRANSPL, V45, P622, DOI 10.1038/bmt.2009.207; Alterman N, 2007, AM J MED GENET A, V143A, P1827, DOI 10.1002/ajmg.a.31853; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Barone G, 2009, HUM MUTAT, V30, P1222, DOI 10.1002/humu.21034; Bishop AJR, 2000, CANCER RES, V60, P395; Bogdanova N, 2005, INT J CANCER, V116, P263, DOI 10.1002/ijc.21022; Bogdanova N, 2009, BREAST CANCER RES TR, V118, P207, DOI 10.1007/s10549-008-0189-9; Callen E, 2007, ONCOGENE, V26, P7759, DOI 10.1038/sj.onc.1210873; Cavaciuti E, 2005, GENE CHROMOSOME CANC, V42, P1, DOI 10.1002/gcc.20101; Choi S, 2010, CELL CYCLE, V9, P4052, DOI 10.4161/cc.9.20.13471; Demuth I, 2007, ONCOGENE, V26, P7792, DOI 10.1038/sj.onc.1210876; Dork T, 2004, AM J MED GENET A, V126A, P272, DOI 10.1002/ajmg.a.20601; Dork T, 2001, CANCER RES, V61, P7608; Drexler GA, 2004, DNA REPAIR, V3, P1345, DOI 10.1016/j.dnarep.2004.05.001; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gatz SA, 2008, CARCINOGENESIS, V29, P519, DOI 10.1093/carcin/bgm283; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Howlett NG, 2006, DNA REPAIR, V5, P251, DOI 10.1016/j.dnarep.2005.10.004; Joubert A, 2008, INT J RADIAT BIOL, V84, P107, DOI 10.1080/09553000701797039; Keimling M, 2008, INT J CANCER, V123, P730, DOI 10.1002/ijc.23551; Kim MS, 2009, J BIOL CHEM, V284, P9733, DOI 10.1074/jbc.M808097200; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lavin MF, 2007, BRIT MED BULL, V81-82, P129, DOI 10.1093/bmb/ldm012; Lavin MF, 2004, DNA REPAIR, V3, P1197, DOI 10.1016/j.dnarep.2004.03.011; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Restle A, 2008, NUCLEIC ACIDS RES, V36, P5362, DOI 10.1093/nar/gkn503; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Sandoval N, 1999, HUM MOL GENET, V8, P69, DOI 10.1093/hmg/8.1.69; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Speit G, 2000, CYTOGENET CELL GENET, V91, P261, DOI 10.1159/000056855; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Steinmann D, 2001, BRIT J CANCER, V85, P850, DOI 10.1054/bjoc.2001.2016; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Uhl M, 2010, DNA REPAIR, V9, P383, DOI 10.1016/j.dnarep.2009.12.020; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Waltes R, 2009, AM J HUM GENET, V84, P605, DOI 10.1016/j.ajhg.2009.04.010; Wang HC, 2004, ONCOGENE, V23, P824, DOI 10.1038/sj.onc.1207168; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Watrin E, 2006, EXP CELL RES, V312, P2687, DOI 10.1016/j.yexcr.2006.06.024; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; White JS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000758; Williams RS, 2009, CELL, V139, P87, DOI 10.1016/j.cell.2009.07.033; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhuang J, 2009, J BIOL CHEM, V284, P30565, DOI 10.1074/jbc.M109.059444; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	52	44	44	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2011	25	11					3849	3860		10.1096/fj.11-185546	http://dx.doi.org/10.1096/fj.11-185546			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21778326				2022-12-28	WOS:000296723100010
J	Wang, P; Zhu, F; Tong, ZQ; Konstantopoulos, K				Wang, Pu; Zhu, Fei; Tong, ZiQiu; Konstantopoulos, Konstantinos			Response of chondrocytes to shear stress: antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1	FASEB JOURNAL			English	Article						interleukin-6; mPGES-1; L-PGDS	PROTEIN-KINASE-A; OSTEOARTHRITIC CHONDROCYTES; INTERLEUKIN-6 EXPRESSION; PROSTAGLANDIN D-2; NITRIC-OXIDE; CROSS-TALK; PATHWAY; CARTILAGE; MAPK; INFLAMMATION	Osteoarthritis (OA) is often a consequence of excessive mechanical loading of cartilage, which produces hydrostatic stress, tensile strain, and fluid flow. Application of high fluid shear to chondrocytes recapitulates the earmarks of OA, as evidenced by the induction of cyclooxygenase-2, prostaglandins (PGs), and interleukin-6 (IL-6). Here, we delineated the signaling pathway by which high fluid shear mediates the temporal regulation of IL-6 synthesis in human chondrocytes. We determined that Toll-like receptor 4 (TLR4) and caveolin-1 are binding partners in chondrocytes. Their expression is temporally regulated by fluid shear via the sequential up-regulation of microsomal PGE synthase-1 (mPGES-1) and L-PGDS. High shear stress rapidly induces an 8-fold up-regulation of TLR4 expression via an mPGES-1-dependent pathway, whereas prolonged shear exposure concurrently down-regulates TLR4 by >4-fold and up-regulates caveolin-1 expression by > 2.5-fold in an L-PGDS-dependent manner. TLR4 and caveolin-1 exert opposing effects on the activation of ERK1/2, PI3-K and PKA signaling pathways, which, in turn, regulate the NF-kappa B-dependent IL-6 synthesis in a time-dependent fashion. Reconstructing the signaling network regulating shear-induced IL-6 expression in chondrocytes may provide insights for developing therapeutic strategies to combat osteoarthritis.-Wang, P., Zhu, F., Tong, Z., Konstantopoulos, K. Response of chondrocytes to shear stress: antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1. FASEB J. 25, 3401-3415 (2011). www.fasebj.org	[Wang, Pu; Zhu, Fei; Tong, ZiQiu; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	konstant@jhu.edu	Tong, Ziqiu/AAR-6182-2020; Konstantopoulos, Konstantinos/A-7045-2011	Tong, Ziqiu/0000-0003-4183-1858; 	U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases [RO1 AR053358]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053358] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases grant RO1 AR053358.	Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Bobacz K, 2007, ARTHRITIS RHEUM-US, V56, P1880, DOI 10.1002/art.22637; Bokmann S, 2003, EUR J CANCER PREV, V12, P469, DOI [10.1097/01.cej.0000102800.33147.d9, 10.1097/00008469-200312000-00005]; Brenn D, 2007, ARTHRITIS RHEUM, V56, P351, DOI 10.1002/art.22282; Buckwalter JA, 2006, BIORHEOLOGY, V43, P603; Dai SM, 2006, ARTHRITIS RHEUM-US, V54, P818, DOI 10.1002/art.21639; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goldring MB, 2004, METH MOLEC MED, V100, P37; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; He Q, 2010, AM J PHYSIOL-HEART C, V298, pH136, DOI 10.1152/ajpheart.00251.2009; Healy ZR, 2008, AM J PHYSIOL-CELL PH, V294, pC1146, DOI 10.1152/ajpcell.00542.2007; Healy ZR, 2005, P NATL ACAD SCI USA, V102, P14010, DOI 10.1073/pnas.0506620102; Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002; Li XF, 2005, J RHEUMATOL, V32, P887; Mohtai M, 1996, J ORTHOP RES, V14, P67, DOI 10.1002/jor.1100140112; Muller G, 1999, CELL MOL LIFE SCI, V56, P945, DOI 10.1007/s000180050485; Palmer CD, 2008, BLOOD, V111, P1781, DOI 10.1182/blood-2007-07-102343; Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848; Pelletier JP, 2001, ARTHRITIS RHEUM-US, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Qian YG, 2009, J CANCER RES CLIN, V135, P379, DOI 10.1007/s00432-008-0478-z; Razani B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241, DOI 10.1152/ajpcell.2001.281.4.C1241; Schuligoi R, 2005, BIOCHEM BIOPH RES CO, V335, P684, DOI 10.1016/j.bbrc.2005.07.130; Shan ZZ, 2004, J BIOL CHEM, V279, P37939, DOI 10.1074/jbc.M402424200; Song JM, 2007, PLOS PATHOG, V3, P541, DOI 10.1371/journal.ppat.0030060; Starkman BG, 2005, BIOCHEM J, V389, P723, DOI 10.1042/BJ20041636; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wang P, 2010, J BIOL CHEM, V285, P24793, DOI 10.1074/jbc.M110.110320; Wang P, 2010, AM J PHYSIOL-CELL PH, V298, pC1445, DOI 10.1152/ajpcell.00508.2009; Wang XM, 2009, J IMMUNOL, V182, P3809, DOI 10.4049/jimmunol.0712437; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Yudoh K, 2009, INT J RHEUM DIS, V12, P90, DOI 10.1111/j.1756-185X.2009.01390.x; Zayed N, 2008, ARTHRITIS RHEUM-US, V58, P3530, DOI 10.1002/art.23958; Zayed N, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2581; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13; Zhu F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015174	39	64	66	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3401	3415		10.1096/fj.11-184861	http://dx.doi.org/10.1096/fj.11-184861			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21715681	Green Published			2022-12-28	WOS:000295356400012
J	Selvais, C; D'Auria, L; Tyteca, D; Perrot, G; Lemoine, P; Troeberg, L; Dedieu, S; Noel, A; Nagase, H; Henriet, P; Courtoy, PJ; Marbaix, E; Emonard, H				Selvais, Charlotte; D'Auria, Ludovic; Tyteca, Donatienne; Perrot, Gwenn; Lemoine, Pascale; Troeberg, Linda; Dedieu, Stephane; Noel, Agnes; Nagase, Hideaki; Henriet, Patrick; Courtoy, Pierre J.; Marbaix, Etienne; Emonard, Herve			Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function	FASEB JOURNAL			English	Article						ADAM; MMP; endocytosis; plasma membrane; raft	EPIDERMAL-GROWTH-FACTOR; LIPID RAFTS; ADAM METALLOPROTEINASES; ENDOCYTIC CLEARANCE; CYTOPLASMIC DOMAIN; HUMAN ENDOMETRIUM; OVARIAN-STEROIDS; PLASMA-MEMBRANE; UP-REGULATION; GELATINASE-A	Low-density lipoprotein receptor-related protein-1 (LRP-1) is a plasma membrane scavenger and signaling receptor, composed of a large ligand-binding subunit (515-kDa alpha-chain) linked to a shorter transmembrane subunit (85-kDa beta-chain). LRP-1 cell-surface level and function are controlled by proteolytic shedding of its ectodomain. Here, we identified ectodomain sheddases in human HT1080 cells and demonstrated regulation of the cleavage by cholesterol by comparing the classical fibroblastoid type with a spontaneous epithelioid variant, enriched similar to 2-fold in cholesterol. Two membrane-associated metalloproteinases were involved in LRP-1 shedding: a disintegrin and metalloproteinase-12 (ADAM-12) and membrane-type 1 matrix metalloproteinase (MT1-MMP). Although both variants expressed similar levels of LRP-1, ADAM-12, MT1-MMP, and specific tissue inhibitor of metalloproteinases-2 (TIMP-2), LRP-1 shedding from epithelioid cells was similar to 4-fold lower than from fibroblastoid cells. Release of the ectodomain was triggered by cholesterol depletion in epithelioid cells and impaired by cholesterol overload in fibroblastoid cells. Modulation of LRP-1 shedding on clearance was reflected by accumulation of gelatinases (MMP-2 and MMP-9) in the medium. We conclude that cholesterol exerts an important control on LRP-1 levels and function at the plasma membrane by modulating shedding of its ectodomain, and therefore represents a novel regulator of extracellular proteolytic activities.-Selvais, C., D'Auria, L., Tyteca, D., Perrot, G, Lemoine, P., Troeberg, L., Dedieu, S., Noel, A., Nagase, H., Henriet, P., Courtoy, P. J., Marbaix, E., Emonard, H. Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J. 25, 2770-2781 (2011). www.fasebj.org	[Selvais, Charlotte; D'Auria, Ludovic; Tyteca, Donatienne; Lemoine, Pascale; Henriet, Patrick; Courtoy, Pierre J.; Marbaix, Etienne] Duve Inst, Cell Biol Lab, B-1200 Brussels, Belgium; [Selvais, Charlotte; D'Auria, Ludovic; Tyteca, Donatienne; Lemoine, Pascale; Henriet, Patrick; Courtoy, Pierre J.; Marbaix, Etienne] Catholic Univ Louvain, B-1200 Brussels, Belgium; [Perrot, Gwenn; Dedieu, Stephane; Emonard, Herve] Univ Reims, Fac Med, Reims, France; [Perrot, Gwenn; Dedieu, Stephane; Emonard, Herve] Univ Reims, Ctr Natl Rech Sci CNRS, Unite Mixte Rech UMR 6237, Reims, France; [Troeberg, Linda; Nagase, Hideaki] Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London, England; [Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl Canc, Liege, Belgium	Universite Catholique Louvain; Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Imperial College London; University of Oxford; University of Liege	Marbaix, E (corresponding author), Duve Inst, Cell Biol Lab, UCL-75-41,75 Ave Hippocrate, B-1200 Brussels, Belgium.	etienne.marbaix@uclouvain.be	Emonard, Herve/R-9718-2019; Emonard, Hervé/AAD-5432-2019	/0000-0003-0939-4651; Henriet, Patrick/0000-0003-4602-8888; d'auria, ludovic/0000-0001-6270-7739; Dedieu, Stephane/0000-0003-1447-5640; Noel, Agnes/0000-0002-7670-6179	Centre National de la Recherche Scientifique; Fonds National pour la Sante ACI; U.S. National Institutes of Health [AR40994]; Belgian Fonds de la Recherche Scientifique (FRS/FNRS); Fondation contre le Cancer and the Direction Generale des Technologies, de la Recherche et de l'Energie from the Region Wallonne; Fonds Special de la Recherche of the Universite Catholique de Louvain; Fonds de la Recherche Scientifique Medicale; Concerted Research Actions of Communaute Francaise de Belgique; Interuniversity Attraction Poles Program; Belgian FRS/FNRS-Televie; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Fonds National pour la Sante ACI; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Belgian Fonds de la Recherche Scientifique (FRS/FNRS)(Fonds de la Recherche Scientifique - FNRS); Fondation contre le Cancer and the Direction Generale des Technologies, de la Recherche et de l'Energie from the Region Wallonne; Fonds Special de la Recherche of the Universite Catholique de Louvain; Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Concerted Research Actions of Communaute Francaise de Belgique; Interuniversity Attraction Poles Program(Belgian Federal Science Policy Office); Belgian FRS/FNRS-Televie(Fonds de la Recherche Scientifique - FNRS); Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture(Fonds de la Recherche Scientifique - FNRS); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank E. Konradowski and D. Delapiere for excellent technical support, as well as Prof. Mark Rider (de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium) for editorial assistance. The work was supported by grants from Centre National de la Recherche Scientifique, Contrat de Projets Etat-Region 2007-2013, and Fonds National pour la Sante ACI 2008 (Canceropole Grand-Est Project) (to G.P., S.D. and H.E.); by U.S. National Institutes of Health grant AR40994 (to L.T. and H.N.); by the Belgian Fonds de la Recherche Scientifique (FRS/FNRS), the Fondation contre le Cancer and the Direction Generale des Technologies, de la Recherche et de l'Energie from the Region Wallonne (to A.N.); and by Fonds Special de la Recherche of the Universite Catholique de Louvain, Fonds de la Recherche Scientifique Medicale, Concerted Research Actions of Communaute Francaise de Belgique, and Interuniversity Attraction Poles Program (to P. H., P.J.C., and E. M.). C.S. was a recipient of a grant from Belgian FRS/FNRS-Televie. L.D.A. was a recipient of a grant from the Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture. P.H. is a research associate at FRS/FNRS.	Anderegg U, 2009, J INVEST DERMATOL, V129, P1471, DOI 10.1038/jid.2008.323; Atkinson SJ, 2004, FEBS LETT, V566, P65, DOI 10.1016/j.febslet.2004.04.040; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Berton A, 2001, J BIOL CHEM, V276, P20458, DOI 10.1074/jbc.M011664200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Byfield FJ, 2004, BIOPHYS J, V87, P3336, DOI 10.1529/biophysj.104.040634; Ceschin DG, 2009, J CELL BIOCHEM, V106, P372, DOI 10.1002/jcb.22014; Cornet PB, 2005, J CLIN ENDOCR METAB, V90, P1001, DOI 10.1210/jc.2004-1277; Dedieu S, 2008, MOL CELL BIOL, V28, P2980, DOI 10.1128/MCB.02238-07; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Emonard H, 2005, BIOCHIMIE, V87, P369, DOI 10.1016/j.biochi.2004.11.013; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; Fabre-Lafay S, 2005, J BIOL CHEM, V280, P19543, DOI 10.1074/jbc.M410943200; Foca C, 2000, MOL HUM REPROD, V6, P921, DOI 10.1093/molehr/6.10.921; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Frohlich C, 2006, CLIN CANCER RES, V12, P7359, DOI 10.1158/1078-0432.CCR-06-1066; Gingras D, 2010, BBA-MOL CELL RES, V1803, P142, DOI 10.1016/j.bbamcr.2009.04.011; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Jacobsen J, 2008, BIOCHEMISTRY-US, V47, P537, DOI 10.1021/bi701629c; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Liu Q, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-17; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Moss ML, 2007, J BIOL CHEM, V282, P35712, DOI 10.1074/jbc.M703231200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Okada A, 2008, ARTHRITIS RHEUM-US, V58, P778, DOI 10.1002/art.23262; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Selvais C, 2009, ENDOCRINOLOGY, V150, P3792, DOI 10.1210/en.2009-0015; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Tamaki C, 2007, MOL PHARMACOL, V72, P850, DOI 10.1124/mol.107.036913; Tanaka M, 2004, J BIOL CHEM, V279, P41950, DOI 10.1074/jbc.M400086200; Tanida S, 2004, GASTROENTEROLOGY, V127, P559, DOI 10.1053/j.gastro.2004.05.017; Thevenard J, 2010, INT J CANCER, V126, P1055, DOI 10.1002/ijc.24688; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Tyteca D, 2010, BBA-BIOMEMBRANES, V1798, P909, DOI 10.1016/j.bbamem.2010.01.021; Vassilev V, 2005, J CLIN ENDOCR METAB, V90, P5848, DOI 10.1210/jc.2005-0762; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Webb DJ, 2000, J CELL SCI, V113, P123; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596	59	63	64	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2011	25	8					2770	2781		10.1096/fj.10-169508	http://dx.doi.org/10.1096/fj.10-169508			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21518850	Green Published, Green Submitted			2022-12-28	WOS:000293337800025
J	McKay, BR; Ogborn, DI; Bellamy, LM; Tarnopolsky, MA; Parise, G				McKay, Bryon R.; Ogborn, Daniel I.; Bellamy, Leeann M.; Tarnopolsky, Mark A.; Parise, Gianni			Myostatin is associated with age-related human muscle stem cell dysfunction	FASEB JOURNAL			English	Article						Pax7; GDF-8; aging; fiber type-specific	SKELETAL-MUSCLE; SATELLITE-CELL; OLDER MEN; GENE-EXPRESSION; FLOW-CYTOMETRY; YOUNG; SARCOPENIA; WOMEN; MICE; MASS	Human aging is accompanied by a progressive loss of muscle mass (sarcopenia). We tested the hypothesis that older males (OMs, 70 +/- 4 yr, n = 9) would have a blunted myogenic response to a physiological stimulus compared to younger controls (21 +/- 3 yr, n = 9). Subjects completed an acute bout of intense unilateral muscle loading. Young healthy males matched for body mass and activity level served as the control group. Muscle biopsies and blood were obtained before and at 3, 24, and 48 h after muscle loading. The muscle stem cell response was analyzed using flow cytometry, immunofluorescent microscopy, and standard protein and mRNA analysis. OMs had 35% fewer basal stem cells and a type II fiber-specific impairment in stem cell content and proliferation. Myogenic determination factor staining and cell cycle analysis illustrated a severely blunted progression through the myogenic program. Myostatin protein and mRNA were 2-fold higher in OMs. Stem cell-specific myostatin levels were not different at baseline; however, there were 67% more myostatin-positive type II-associated stem cells in OMs at 24 h. These data illustrate an age-related impairment of stem cell function in a fiber type-specific manner. The greater colocalization of myostatin with stem cells provides a mechanism for the impaired myogenic capacity of aged muscle.-McKay, B. R., Ogborn, D. I., Bellamy, L. M., Tarnopolsky, M. A., Parise, G. Myostatin is associated with age-related human muscle stem cell dysfunction. FASEB J. 26, 2509-2521 (2012). www.fasebj.org	[McKay, Bryon R.; Bellamy, Leeann M.; Parise, Gianni] McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada; [Ogborn, Daniel I.] McMaster Univ, Dept Hlth Sci, Hamilton, ON L8S 4L8, Canada; [Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat & Med Phys, Hamilton, ON L8S 4L8, Canada; [Parise, Gianni] McMaster Univ, Dept Appl Radiat Sci, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Parise, G (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada.	pariseg@mcmaster.ca			National Institute of Child Health and Human Development	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors acknowledge Nicole MacFarlane and Dr. Doug Boreham for their technical assistance with the flow cytometry. The Pax7 hybridoma cells, developed by Dr. A. Kawakami, and the A4.951 and 5.1H11 hybridoma cells, developed by Dr. H. Blau, were obtained from the Developmental Studies Hybridoma Bank under the auspices of the National Institute of Child Health and Human Development and maintained by the University of Iowa, Department of Biology (Iowa City, IA, USA). Contributions: B. R. M. and G. P. conceived the project; B. R. M., D. I. O., M. A. T., and G. P. contributed to the experimental design, exercise testing, and tissue collection; B. R. M. was responsible for IHC/IF, RNA, and primary myoblast experiments; D. I. O. and L. M. B. were responsible for RNA isolation and RT reactions; D. I. O. was responsible for the protein analysis. The manuscript was largely written by B. R. M. and G. P. All authors were involved with the writing and final approval of the manuscript.	Alexander CM, 2009, CELL STEM CELL, V5, P579, DOI 10.1016/j.stem.2009.11.008; Bish LT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010230; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; Day K, 2010, DEV BIOL, V340, P330, DOI 10.1016/j.ydbio.2010.01.006; Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Huang ZQ, 2011, CELL SIGNAL, V23, P1441, DOI 10.1016/j.cellsig.2011.05.003; Jejurikar SS, 2006, EXP GERONTOL, V41, P828, DOI 10.1016/j.exger.2006.06.053; Jespersen JG, 2011, SCAND J MED SCI SPOR, V21, P215, DOI 10.1111/j.1600-0838.2009.01044.x; Kadi F, 2004, MUSCLE NERVE, V29, P120, DOI 10.1002/mus.10510; Kim JS, 2005, J APPL PHYSIOL, V99, P2149, DOI 10.1152/japplphysiol.00513.2005; Kim JS, 2005, AM J PHYSIOL-ENDOC M, V288, pE1110, DOI 10.1152/ajpendo.00464.2004; Kovacheva EL, 2010, ENDOCRINOLOGY, V151, P628, DOI 10.1210/en.2009-1177; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2010, MOL ENDOCRINOL, V24, P1998, DOI 10.1210/me.2010-0127; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Leger B, 2008, REJUV RES, V11, P163, DOI 10.1089/rej.2007.0588; LEXELL J, 1983, MUSCLE NERVE, V6, P588, DOI 10.1002/mus.880060809; Lindstrom M, 2009, HISTOCHEM CELL BIOL, V132, P141, DOI 10.1007/s00418-009-0606-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McFarlane C, 2011, AM J PHYSIOL-CELL PH, V301, pC195, DOI 10.1152/ajpcell.00012.2011; McKay BR, 2010, J PHYSIOL-LONDON, V588, P3307, DOI 10.1113/jphysiol.2010.190876; Mckay BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006027; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Melton LJ, 2000, J AM GERIATR SOC, V48, P625; Morissette MR, 2009, AGING CELL, V8, P573, DOI 10.1111/j.1474-9726.2009.00508.x; Raue U, 2006, J APPL PHYSIOL, V101, P53, DOI 10.1152/japplphysiol.01616.2005; Roth SM, 2000, ANAT REC, V260, P351, DOI 10.1002/1097-0185(200012)260:4<350::AID-AR30>3.0.CO;2-6; Roubenoff R, 1999, J NUTR, V129, p256S, DOI 10.1093/jn/129.1.256S; Sajko S, 2004, J HISTOCHEM CYTOCHEM, V52, P179, DOI 10.1177/002215540405200205; Shefer G, 2006, DEV BIOL, V294, P50, DOI 10.1016/j.ydbio.2006.02.022; Siriett V, 2006, J CELL PHYSIOL, V209, P866, DOI 10.1002/jcp.20778; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Verdijk LB, 2007, AM J PHYSIOL-ENDOC M, V292, pE151, DOI 10.1152/ajpendo.00278.2006; Yarasheski K E, 2002, J Nutr Health Aging, V6, P343; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	44	118	119	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2509	2521		10.1096/fj.11-198663	http://dx.doi.org/10.1096/fj.11-198663			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22403007				2022-12-28	WOS:000305017200027
J	Cooper, WN; Khulan, B; Owens, S; Elks, CE; Seidel, V; Prentice, AM; Belteki, G; Ong, KK; Affara, NA; Constancia, M; Dunger, DB				Cooper, Wendy N.; Khulan, Batbayar; Owens, Stephen; Elks, Cathy E.; Seidel, Veronica; Prentice, Andrew M.; Belteki, Gusztav; Ong, Ken K.; Affara, Nabeel A.; Constancia, Miguel; Dunger, David B.			DNA methylation profiling at imprinted loci after periconceptional micronutrient supplementation in humans: results of a pilot randomized controlled trial	FASEB JOURNAL			English	Article						fetal programming; maternal nutrition; epigenetics	BECKWITH-WIEDEMANN-SYNDROME; PRENATAL EXPOSURE; SEASONAL-VARIATIONS; GENE-EXPRESSION; GAMBIAN WOMEN; DUTCH FAMINE; IGF2 GENE; GROWTH; DISEASE; MOUSE	Intrauterine exposures mediated by maternal diet may affect risk of cardiovascular disease, obesity, and type 2 diabetes. Recent evidence, primarily from animal studies and observational data in humans, suggests that the epigenome can be altered by maternal diet during the periconceptional period and that these programming events may underlie later disease risk. A randomized controlled trial of periconceptional micronutrient supplementation in The Gambia, where seasonal nutritional variations affect fetal growth and postnatal outcomes, provided a unique opportunity to test this hypothesis. Specifically, we targeted imprinted genes, which play important roles in allocation of maternal resources while being epigenetically regulated. DNA methylation at 12 differentially methylated regions (DMRs) was analyzed in cord blood samples from 58 offspring of women participating in a double-blind randomized-controlled trial of pre- and periconceptional micronutrient supplementation (including folate, zinc, and vitamins A, B, C, and D). We observed sex-specific effects of micronutrient supplementation, reducing methylation levels at two of the DMRs analyzed, IGF2R in girls and GTL2-2 in boys. This pilot study is the first to analyze DNA methylation in the context of a randomized controlled trial, and it provides suggestive evidence that periconceptional maternal nutrition alters offspring methylation at imprinted loci.-Cooper, W. N., Khulan, B., Owens, S., Elks, C. E., Seidel, V., Prentice, A. M., Belteki, G., Ong, K. K., Affara, N. A., Constancia, M., Dunger, D. B. DNA methylation profiling at imprinted loci after periconceptional micronutrient supplementation in humans: results of a pilot randomized controlled trial. FASEB J. 26, 1782-1790 (2012). www.fasebj.org	[Belteki, Gusztav; Ong, Ken K.; Dunger, David B.] Univ Cambridge, Dept Paediat, Cambridge CB2 0QQ, England; [Cooper, Wendy N.; Khulan, Batbayar; Seidel, Veronica; Constancia, Miguel] Univ Cambridge, Dept Obstet & Gynaecol, Metab Res Labs, Cambridge CB2 0QQ, England; [Khulan, Batbayar; Affara, Nabeel A.] Univ Cambridge, Dept Pathol, Cambridge CB2 0QQ, England; [Constancia, Miguel] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 0QQ, England; [Owens, Stephen; Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1, England; [Elks, Cathy E.; Ong, Ken K.] Inst Metab Sci, Epidemiol Unit, MRC, Cambridge, England; [Belteki, Gusztav] Cambridge Univ Hosp NHS Fdn Trust, Rosie Hosp, Neonatal Intens Care Unit, Cambridge, England; [Constancia, Miguel; Dunger, David B.] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge; University of Cambridge; University of Cambridge	Dunger, DB (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Box 116,Level 8, Cambridge CB2 0QQ, England.	dbd25@cam.ac.uk	Belteki, Gusztav/B-8956-2008; Constancia, Miguel/F-6654-2013; Prentice, Andrew/AAG-1961-2019	Belteki, Gusztav/0000-0002-2974-2011; Dunger, Professor David/0000-0002-2566-9304; Constancia, Miguel/0000-0002-8976-1679	Biotechnology and Biological Sciences Research Council; European Union Epigenome Network or Excellence; UK National Institute for Health Research (Cambridge Comprehensive Biomedical Research Centre); Spanish Instituto de Salud Carlos III; BBSRC [BB/D01235X/2, BB/F02293X/1, BB/D01235X/1] Funding Source: UKRI; MRC [G0600717, MC_U123292700, MC_U123292699, MC_U106179472] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01235X/1, BB/D01235X/2, BB/F02293X/1] Funding Source: researchfish; Medical Research Council [MC_U106179472, G0600717B, G0600717, MC_U123292700, MC_U123292699] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10274] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Union Epigenome Network or Excellence; UK National Institute for Health Research (Cambridge Comprehensive Biomedical Research Centre); Spanish Instituto de Salud Carlos III(Instituto de Salud Carlos III); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by the Biotechnology and Biological Sciences Research Council; European Union Epigenome Network or Excellence (FP6); and the UK National Institute for Health Research (Cambridge Comprehensive Biomedical Research Centre). V. S. is supported by a Rio Hortega research fellowship from the Spanish Instituto de Salud Carlos III. The authors declare no conflicts of interest.	Barker D, 1986, LANCET, V327, P1077, DOI DOI 10.1016/S0140-6736(86)91340-1; Barker D.J., 1989, LANCET, V334, P577, DOI [10.1016/S0140-6736(89)90710-1, DOI 10.1016/S0140-6736(89)90710-1]; BATES CJ, 1994, EUR J CLIN NUTR, V48, P660; BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2; Bourc'his D, 2008, MOL CELL ENDOCRINOL, V282, P87, DOI 10.1016/j.mce.2007.11.025; BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133, DOI 10.1080/02724936.1993.11747637; Constancia M, 2005, P NATL ACAD SCI USA, V102, P19219, DOI 10.1073/pnas.0504468103; Erickson RP, 1997, BIOESSAYS, V19, P1027, DOI 10.1002/bies.950191113; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629; Gulati R, 2009, EUR J CLIN NUTR, V63, P970, DOI 10.1038/ejcn.2009.11; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Kobayashi S, 2006, CURR BIOL, V16, P166, DOI 10.1016/j.cub.2005.11.071; KRCO CJ, 1976, SCIENCE, V193, P1134, DOI 10.1126/science.959826; Kwong WY, 2006, REPRODUCTION, V132, P265, DOI 10.1530/rep.1.01038; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; MITTWOCH U, 1969, NATURE, V221, P446, DOI 10.1038/221446a0; Moore SE, 2004, INT J EPIDEMIOL, V33, P137, DOI 10.1093/ije/dyh007; Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245; Painter RC, 2006, AM J CLIN NUTR, V84, P322; PERGAMENT E, 1994, HUM REPROD, V9, P1730, DOI 10.1093/oxfordjournals.humrep.a138783; POWERS HJ, 1987, T ROY SOC TROP MED H, V81, P421, DOI 10.1016/0035-9203(87)90157-X; RAY PF, 1995, J REPROD FERTIL, V104, P165; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Roberfroid D, 2010, AM J CLIN NUTR, V91, P1649, DOI 10.3945/ajcn.2009.28855; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252; Zhang S, 2010, FASEB J, V24, P2772, DOI 10.1096/fj.09-154294	35	87	90	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1782	1790		10.1096/fj.11-192708	http://dx.doi.org/10.1096/fj.11-192708			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22267336				2022-12-28	WOS:000303680800006
J	Rao, A; Richards, TL; Simmons, D; Zahniser, NR; Sorkin, A				Rao, Anjali; Richards, Toni L.; Simmons, Diana; Zahniser, Nancy R.; Sorkin, Alexander			Epitope-tagged dopamine transporter knock-in mice reveal rapid endocytic trafficking and filopodia targeting of the transporter in dopaminergic axons	FASEB JOURNAL			English	Article						endocytosis; fluorescence imaging; amphetamine; endosome	NUCLEUS-ACCUMBENS; CELL-LINES; NEURONS; INTERNALIZATION; AMPHETAMINE; COCAINE; UBIQUITINATION; LOCALIZATION; MECHANISMS; MEMBRANES	The plasma membrane dopamine (DA) transporter (DAT) is essential for reuptake of extracellular DA. DAT function in heterologous cells is regulated by subcellular targeting, endocytosis, and intracellular trafficking, but the mechanisms regulating neuronal DAT remain poorly understood. Hence, we generated a knock-in mouse expressing a hemagglutinin (HA)-epitope-tagged DAT to study endogenous transporter trafficking. Introduction of the HA tag into the second extracellular loop of mouse DAT did not perturb its expression level, distribution pattern, or substrate uptake kinetics. Live-cell fluorescence microscopy imaging using fluorescently labeled HA-specific antibody and a quantitative HA-antibody endocytosis assay demonstrated that in axons HA-DAT was primarily located in the plasma membrane and internalized mostly in growth cones and varicosities, where synaptic vesicle markers were also concentrated. Formation of varicosities was frequently preceded or accompanied by highly dynamic filopodia-like membrane protrusions. Remarkably, HA-DAT often concentrated at the tips of these filopodia. This pool of HA-DATs exhibited low lateral membrane mobility. Thus, DAT-containing filopodia may be involved in synaptogenesis in developing DA neurons. Treatment of neurons with amphetamine increased mobility of filopodial HA-DAT and accelerated HA-DAT endocytosis in axons, suggesting that chronic amphetamine may interfere with DA synapse development. Interestingly, phorbol esters did not accelerate endocytosis of axonal DAT.-Rao, A., Richards, T. L., Simmons, D., Zahniser, N. R., Sorkin, A. Epitope-tagged dopamine transporter knock-in mice reveal rapid endocytic trafficking and filopodia targeting of the transporter in dopaminergic axons. FASEB J. 26, 1921-1933 (2012). www.fasebj.org	[Sorkin, Alexander] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; [Rao, Anjali; Richards, Toni L.; Simmons, Diana; Zahniser, Nancy R.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus	Sorkin, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S368 Biomed Sci Tower S,3500 Terrace St, Pittsburgh, PA 15261 USA.	sorkin@pitt.edu		Sorkin, Alexander/0000-0002-4446-1920	U.S. National Institutes of Health [R01 DA014204, F32 DA029357, K05 DA015050, T32 AA007464]; Transgenic Vectors Core of Rocky Mountain Neurological Disorders Core Center [University of Colorado-Anschutz Medical Campus (UC-AMC)];  [P30 NS048154]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS048154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204, K05DA015050, F32DA029357] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Transgenic Vectors Core of Rocky Mountain Neurological Disorders Core Center [University of Colorado-Anschutz Medical Campus (UC-AMC)]; ; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health grants R01 DA014204 (A. S., N.R.Z.), F32 DA029357 (A. R.), K05 DA015050 (N.R.Z.), and T32 AA007464 (D. S.), and the Transgenic Vectors Core of Rocky Mountain Neurological Disorders Core Center [University of Colorado-Anschutz Medical Campus (UC-AMC)], supported by P30 NS048154. The authors also thank Wallace Chick for help with making the HA-DAT mice, Dr. Rytis Prekeris (UC-AMC) for the Syntaxin13 antibody, and Dr. Trevor Williams (UC-AMC) for the beta-actin cre mice.	Chiu SL, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-7; Cremona ML, 2011, NAT NEUROSCI, V14, P469, DOI 10.1038/nn.2781; Daniel JA, 2009, J NEUROSCI, V29, P14670, DOI 10.1523/JNEUROSCI.1349-09.2009; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Drees F, 2008, CURR OPIN NEUROBIOL, V18, P53, DOI 10.1016/j.conb.2008.05.007; Eriksen J, 2010, J BIOL CHEM, V285, P27289, DOI 10.1074/jbc.M110.131003; Eriksen J, 2009, J NEUROSCI, V29, P6794, DOI 10.1523/JNEUROSCI.4177-08.2009; Fog JU, 2006, NEURON, V51, P417, DOI 10.1016/j.neuron.2006.06.028; Gallo G, 2011, DEV NEUROBIOL, V71, P201, DOI 10.1002/dneu.20852; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; Li PP, 2011, MOL BIOL CELL, V22, P2480, DOI 10.1091/mbc.E11-03-0198; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Matteoli M, 2004, TRENDS CELL BIOL, V14, P133, DOI 10.1016/j.tcb.2004.01.007; Melikian HE, 2004, PHARMACOL THERAPEUT, V104, P17, DOI 10.1016/j.pharmthera.2004.07.006; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miranda M, 2007, MOL INTERV, V7, P157, DOI 10.1124/mi.7.3.7; Niell CM, 2004, NAT NEUROSCI, V7, P254, DOI 10.1038/nn1191; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rao A, 2011, MOL CELL NEUROSCI, V46, P148, DOI 10.1016/j.mcn.2010.08.016; Richards TL, 2009, J NEUROCHEM, V108, P1575, DOI 10.1111/j.1471-4159.2009.05910.x; Riddle EL, 2005, AAPS J, V7, pE847, DOI 10.1208/aapsj070481; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Sorkina T, 2009, J NEUROSCI, V29, P1361, DOI 10.1523/JNEUROSCI.3250-08.2009; Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010; YGUERABIDE J, 1982, BIOPHYS J, V40, P69, DOI 10.1016/S0006-3495(82)84459-7; Yoshihara Y, 2009, CURR OPIN NEUROBIOL, V19, P146, DOI 10.1016/j.conb.2009.05.013; Zahniser NR, 2009, SEMIN CELL DEV BIOL, V20, P411, DOI 10.1016/j.semcdb.2009.01.004	34	30	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1921	1933		10.1096/fj.11-196113	http://dx.doi.org/10.1096/fj.11-196113			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22267337	Green Published			2022-12-28	WOS:000303680800020
J	Grosse, J; Wehland, M; Pietsch, J; Ma, X; Ulbrich, C; Schulz, H; Saar, K; Hubner, N; Hauslage, J; Hemmersbach, R; Braun, M; van Loon, J; Vagt, N; Infanger, M; Eilles, C; Egli, M; Richter, P; Baltz, T; Einspanier, R; Sharbati, S; Grimm, D				Grosse, Jirka; Wehland, Markus; Pietsch, Jessica; Ma, Xiao; Ulbrich, Claudia; Schulz, Herbert; Saar, Katrin; Huebner, Norbert; Hauslage, Jens; Hemmersbach, Ruth; Braun, Markus; van Loon, Jack; Vagt, Nicole; Infanger, Manfred; Eilles, Christoph; Egli, Marcel; Richter, Peter; Baltz, Theo; Einspanier, Ralf; Sharbati, Soroush; Grimm, Daniela			Short-term weightlessness produced by parabolic flight maneuvers altered gene expression patterns in human endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; cytoskeleton; integrins; microgravity	LEFT-VENTRICULAR HYPERTROPHY; FIBROBLAST-GROWTH-FACTOR; NF-KAPPA-B; SIMULATED MICROGRAVITY; F-ACTIN; ADHESION MOLECULE-1; MAMMALIAN-CELLS; GELSOLIN; APOPTOSIS; GRAVITY	This study focused on the effects of short-term microgravity (22 s) on the gene expression and morphology of endothelial cells (ECs) and evaluated gravisensitive signaling elements. ECs were investigated during four German Space Agency (Deutsches Zentrum fur Luft-und Raumfahrt) parabolic flight campaigns. Hoechst 33342 and acridine orange/ethidium bromide staining showed no signs of cell death in ECs after 31 parabolas (P31). Gene array analysis revealed 320 significantly regulated genes after the first parabola (P1) and P31. COL4A5, COL8A1, ITGA6, ITGA10, and ITGB3 mRNAs were down-regulated after P1. EDN1 and TNFRSF12A mRNAs were up-regulated. ADAM19, CARD8, CD40, GSN, PRKCA (all down-regulated after P1), and PRKAA1 (AMPK alpha 1) mRNAs (up-regulated) provide a very early protective mechanism of cell survival induced by 22 s microgravity. The ABL2 gene was significantly up-regulated after P1 and P31, TUBB was slightly induced, but ACTA2 and VIM mRNAs were not changed. beta-Tubulin immunofluorescence revealed a cytoplasmic rearrangement. Vibration had no effect. Hypergravity reduced CARD8, NOS3, VASH1, SERPINH1 (all P1), CAV2, ADAM19, TNFRSF12A, CD40, and ITGA6 (P31) mRNAs. These data suggest that microgravity alters the gene expression patterns and the cytoskeleton of ECs very early. Several gravisensitive signaling elements, such as AMPK alpha 1 and integrins, are involved in the reaction of ECs to altered gravity.-Grosse, J., Wehland, M., Pietsch, J., Ma, X., Ulbrich, C., Schulz, H., Saar, K., Hubner, N., Hauslage, J., Hemmersbach, R., Braun, M., van Loon, J., Vagt, N., Infanger, M., Eilles, C., Egli, M., Richter, P., Baltz, T., Einspanier, R., Sharbati, S., Grimm, D. Short-term weightlessness produced by parabolic flight maneuvers altered gene expression patterns in human endothelial cells. FASEB J. 26, 639-655 (2012). www.fasebj.org	[Ma, Xiao; Grimm, Daniela] Aarhus Univ, Inst Biomed, DK-8000 Aarhus C, Denmark; [Grosse, Jirka; Eilles, Christoph] Univ Regensburg, Dept Nucl Med, Regensburg, Germany; [Wehland, Markus; Pietsch, Jessica; Infanger, Manfred; Grimm, Daniela] Univ Magdeburg, Clin Plast Aesthet & Hand Surg, D-39106 Magdeburg, Germany; [Ulbrich, Claudia] Univ Hohenheim, Inst Zool, D-7000 Stuttgart, Germany; [Schulz, Herbert; Saar, Katrin; Huebner, Norbert] Max Delbruck Ctr Mol Med, Berlin, Germany; [Hauslage, Jens; Hemmersbach, Ruth] German Aerosp Ctr, Inst Aerosp Med, Cologne, Germany; [Braun, Markus; Vagt, Nicole] Univ Bonn, Inst Mol Physiol & Biotechnol Plants, Bonn, Germany; [van Loon, Jack] ACTA Free Univ, Dept Oral Cell Biol, Dutch Expt Support Ctr, Amsterdam, Netherlands; [Egli, Marcel] ETH, Space Biol Grp, Zurich, Switzerland; [Richter, Peter] Univ Erlangen Nurnberg, Erlangen, Germany; [Baltz, Theo] Univ Bordeaux 2, Dept Mol Parasitol & Mycol, F-33076 Bordeaux, France; [Einspanier, Ralf; Sharbati, Soroush] Free Univ Berlin, Inst Vet Biochem, Berlin, Germany	Aarhus University; University of Regensburg; Otto von Guericke University; University Hohenheim; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; German Aerospace Centre (DLR); University of Bonn; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Erlangen Nuremberg; UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin	Grimm, D (corresponding author), Aarhus Univ, Inst Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.	daniela.grimm@farm.au.dk	van Loon, Jack JJWA/A-4250-2013; Koch, Claudia/AAH-1421-2019; Koch, Claudia/D-6350-2017; Sharbati, Soroush/D-2548-2014	Koch, Claudia/0000-0001-8630-9700; Saar, Kathrin/0000-0002-4483-1557; van Loon, Jack/0000-0001-9051-6016; Sharbati, Soroush/0000-0003-3338-7654; Grimm, Daniela/0000-0002-4991-3105; Hauslage, Jens/0000-0003-2184-7000; Wehland, Markus/0000-0002-8160-859X	Deutsches Zentrum fur Luft- und Raumfahrt (BMWi) [50WB0824]; Eidgenossische Technische Hochschule Zurich (Zurich, Switzerland); Aarhus University (Aarhus, Denmark); Freie Universitat Berlin (Berlin, Germany); University of Regensburg (Regensburg, Germany); Netherlands Organisation for Scientific Research Earth and Life Sciences via the Netherlands Space Office [MG-057]	Deutsches Zentrum fur Luft- und Raumfahrt (BMWi); Eidgenossische Technische Hochschule Zurich (Zurich, Switzerland); Aarhus University (Aarhus, Denmark); Freie Universitat Berlin (Berlin, Germany); University of Regensburg (Regensburg, Germany); Netherlands Organisation for Scientific Research Earth and Life Sciences via the Netherlands Space Office	The authors thank the team of Proof-Reading-Service.com (Letchworth Garden City, UK; http://www.proof-reading-service.com) for academic proofreading of the article. This study was supported by the Deutsches Zentrum fur Luft- und Raumfahrt (BMWi grant 50WB0824 to D.G.), Eidgenossische Technische Hochschule Zurich (Zurich, Switzerland; M. E.), Aarhus University (Aarhus, Denmark; D. G.), Freie Universitat Berlin (Berlin, Germany; R. E.), and University of Regensburg (Regensburg, Germany; J.G.). J.V.L. is supported by grant MG-057 from the Netherlands Organisation for Scientific Research Earth and Life Sciences via the Netherlands Space Office.	Alliegro MC, 2001, CELL BIOL INT, V220, P2077; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; Borst AG, 2009, MICROGRAVITY SCI TEC, V21, P287, DOI 10.1007/s12217-008-9043-2; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; Buravkova L, 2005, ACTA ASTRONAUT, V57, P67, DOI 10.1016/j.actaastro.2005.03.012; Carlsson SIM, 2003, BBA-MOL CELL RES, V1642, P173, DOI 10.1016/j.bbamcr.2003.08.003; Chhabra D, 2005, PROTEOMICS, V5, P3131, DOI 10.1002/pmic.200401127; Colombo SL, 2009, BIOCHEM J, V421, P163, DOI 10.1042/BJ20090613; Cotrupi S, 2005, BBA-MOL CELL RES, V1746, P163, DOI 10.1016/j.bbamcr.2005.10.002; Dosaka-Akita H, 1998, CANCER RES, V58, P322; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01-0673fje; Grimm D, 2002, CARDIOVASC PATHOL, V11, P229, DOI 10.1016/S1054-8807(01)00116-8; Grimm D, 2011, EXPERT REV PROTEOMIC, V8, P13, DOI 10.1586/EPR.10.105; Grimm D, 2010, TISSUE ENG PT A, V16, P1559, DOI [10.1089/ten.tea.2009.0524, 10.1089/ten.TEA.2009.0524]; Grimm D, 2009, TISSUE ENG PT A, V15, P2267, DOI 10.1089/ten.tea.2008.0576; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Infanger M, 2006, APOPTOSIS, V11, P749, DOI 10.1007/s10495-006-5697-7; Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001; Infanger M, 2007, J CELL BIOCHEM, V101, P1439, DOI 10.1002/jcb.21261; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kang CY, 2011, EUR J APPL PHYSIOL, V111, P2131, DOI 10.1007/s00421-011-1844-0; Kossmehl P, 2005, J MOL MED, V83, P626, DOI 10.1007/s00109-005-0642-8; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; Lewis Marian L, 2002, Adv Space Biol Med, V8, P77; Liu GH, 2010, PROTEINS, V78, P1326, DOI 10.1002/prot.22656; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Malik N, 1996, J IMMUNOL, V156, P3952; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Miller AL, 2004, J CELL BIOL, V165, P407, DOI 10.1083/jcb.200308055; MORTON LF, 1983, THROMB RES, V32, P545, DOI 10.1016/0049-3848(83)90056-7; Pearson JD, 2000, LUPUS, V9, P183, DOI 10.1191/096120300678828299; Pietsch J, 2011, CURR MOL MED, V11, P350, DOI 10.2174/156652411795976600; Plenz GAM, 2003, ATHEROSCLEROSIS, V166, P1, DOI 10.1016/S0021-9150(01)00766-3; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Riecke K, 2002, ARCH TOXICOL, V76, P360, DOI 10.1007/s00204-002-0338-6; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Romanov Y, 2000, J Gravit Physiol, V7, pP77; Rothermund L, 2002, AM J HYPERTENS, V15, P644, DOI 10.1016/S0895-7061(02)02956-4; Russell FD, 1999, BRIT J PHARMACOL, V126, P391, DOI 10.1038/sj.bjp.0702315; Sangha DS, 2001, J APPL PHYSIOL, V91, P789, DOI 10.1152/jappl.2001.91.2.789; SCHIFFRIN EL, 1994, CLIN INVEST MED, V17, P602; Schmidt W, 2004, MICROGRAVITY SCI TEC, V15, P42, DOI 10.1007/BF02870951; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Sowa G, 2008, BIOCHEMISTRY-US, V47, P101, DOI 10.1021/bi701709s; Spisni E, 2003, J CELL PHYSIOL, V197, P198, DOI 10.1002/jcp.10344; Sun RJ, 2002, EUR BIOPHYS J BIOPHY, V30, P605, DOI 10.1007/s00249-001-0195-x; TANAKA M, 1995, CANCER RES, V55, P3228; Ulbrich C, 2008, J CELL BIOCHEM, V104, P1324, DOI 10.1002/jcb.21710; Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730; Ulbrich C, 2010, CELL PHYSIOL BIOCHEM, V25, P551, DOI 10.1159/000303059; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Versari S, 2007, BBA-MOL CELL RES, V1773, P1645, DOI 10.1016/j.bbamcr.2007.05.014; Wagener C, 2000, EXP CELL RES, V261, P19, DOI 10.1006/excr.2000.5038; Wang YX, 2001, P NATL ACAD SCI USA, V98, P14865, DOI 10.1073/pnas.251249298; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Younes A, 1999, INT J BIOL MARKER, V14, P135, DOI 10.1177/172460089901400303; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	75	64	65	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2012	26	2					639	655		10.1096/fj.11-194886	http://dx.doi.org/10.1096/fj.11-194886			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22024737				2022-12-28	WOS:000300485700017
J	Nakao, S; Zandi, S; Faez, S; Kohno, R; Hafezi-Moghadam, A				Nakao, Shintaro; Zandi, Souska; Faez, Sepideh; Kohno, Ri-ichiro; Hafezi-Moghadam, Ali			Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots	FASEB JOURNAL			English	Article						lymphangiogenesis; VE-cadherin; imaging; leukocyte recruitment	LYMPHEDEMA-DISTICHIASIS; LYMPHANGIOGENESIS; GROWTH; ANGIOGENESIS; VESSELS; NEOVASCULARIZATION; ENDOTHELIUM; MACROPHAGES; HYALURONAN; INDUCTION	LYVE-1(+) corneal lymphatics contribute to drainage and immunity. LYVE-1 is widely accepted as the most reliable lymphatic marker because of its continuous expression in lymphatic endothelium. LYVE-1 expression in corneal lymphatics has not been examined. In this study, we report intact CD31(+) corneal lymphatic capillary endothelial cells that do not express LYVE-1. The number of LYVE-1(-) gaps initially increased until 8 wk of age but was significantly reduced in aged mice. C57BL/6 mice showed a notably higher number of the LYVE-1(-)/CD31(+) lymphatic regions than BALB/c mice, which suggests a genetic predisposition for this histological feature. The LYVE-1(-) lymphatic gaps expressed podoplanin and VE-cadherin but not alpha SMA or FOXC2. Interestingly, the number of LYVE-1(-) gaps in FGF-2, but not VEGF-A, implanted corneas was significantly lower than in untreated corneas. Over 70% of the CD45(+) leukocytes were found in the proximity of the LYVE-1(-) gaps. Using a novel in vivo imaging technique for visualization of leukocyte migration into and out of corneal stroma, we showed reentry of extravasated leukocytes from angiogenic vessels into newly grown corneal lymphatics. This process was inhibited by VE-cadherin blockade. To date, existence of lymphatic valves in cornea is unknown. Electron microscopy showed overlapping lymphatic endothelial ends, reminiscent of microvalves in corneal lymphatics. This work introduces a novel corneal endothelial lymphatic phenotype that lacks LYVE-1. LYVE-1(-) lymphatic endothelium could serve as microvalves, supporting unidirectional flow, as well as immunological hot spots that facilitate reentry of stromal macropahges.-Nakao, S., Zandi, S., Faez, S., Kohno, R., Hafezi-Moghadam, A. Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots. FASEB J. 26, 808-817 (2012). www.fasebj.org	[Nakao, Shintaro; Zandi, Souska; Hafezi-Moghadam, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA; [Nakao, Shintaro; Zandi, Souska; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Nakao, Shintaro; Zandi, Souska; Faez, Sepideh; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02115 USA; [Nakao, Shintaro; Kohno, Ri-ichiro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Kyushu University	Hafezi-Moghadam, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, 221 Longwood Ave,3rd Floor, Boston, MA 02115 USA.	ahm@bwh.harvard.edu		Zandi, Souska/0000-0001-9351-4278; Hafezi-Moghadam, Ali/0000-0002-5336-0697	U.S. National Institutes of Health NIH [AI050775]; Bausch Lomb; Japan Eye Bank Association; Tear Film and Ocular Surface Society; Young Investigator Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	U.S. National Institutes of Health NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bausch Lomb; Japan Eye Bank Association; Tear Film and Ocular Surface Society; Young Investigator Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by U.S. National Institutes of Health NIH grants AI050775 (A.H.-M.), an overseas Research Fellowship Award from Bausch & Lomb, a Fellowship Award from the Japan Eye Bank Association and Tear Film and Ocular Surface Society, and a Young Investigator Fellowship (to S.N. under the mentorship of A.H.-M.). The authors thank the Malaysian Palm Oil Board and the American Health Assistance Foundation. The authors thank Alexander Schering and Rebecca C. Garland for their help with the preparation of the manuscript and Dr. David Jackson and Dr. Takayuki Hattori for helpful suggestions. S.N. and A.H.-M. designed research and organized the experiments; S.N., S.Z., S. F., and R. K. performed research and analyzed data; S.N. and A.H.-M. wrote the paper. The authors declare no conflicts of interest.	Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Chen L, 2004, NAT MED, V10, P813, DOI 10.1038/nm1078; COLLIN HB, 1970, INVEST OPHTH VISUAL, V9, P146; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; Hagendoorn J, 2004, CIRC RES, V95, P204, DOI 10.1161/01.RES.0000135549.72828.24; Hos D, 2008, EXP EYE RES, V87, P427, DOI 10.1016/j.exer.2008.07.013; Johnson LA, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702889200; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Makinen T, 2005, GENE DEV, V19, P397, DOI 10.1101/gad.330105; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Nakao S, 2007, AM J PATHOL, V171, P1058, DOI 10.2353/ajpath.2007.070172; Nakao S, 2011, BLOOD, V117, P1081, DOI 10.1182/blood-2010-02-267427; Nakao S, 2010, FASEB J, V24, P504, DOI 10.1096/fj.09-134056; Petrova TV, 2004, NAT MED, V10, P974, DOI 10.1038/nm1094; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Singh D, 2003, J CATARACT REFR SURG, V29, P632, DOI 10.1016/S0886-3350(03)00161-5; SZEGHY G, 1963, LANCET, V1, P832; Tammela T, 2007, NAT MED, V13, P1458, DOI 10.1038/nm1689; Trzewik J, 2001, FASEB J, V15, P1711, DOI 10.1096/fj.01-0067com; Watari K, 2008, BIOCHEM BIOPH RES CO, V377, P826, DOI 10.1016/j.bbrc.2008.10.077; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505	24	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2012	26	2					808	817		10.1096/fj.11-183897	http://dx.doi.org/10.1096/fj.11-183897			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	895HA	22090317	Green Published			2022-12-28	WOS:000300485700032
J	Shum, MSY; Pasquier, E; Po'uha, ST; O'Neill, GM; Chaponnier, C; Gunning, PW; Kavallaris, M				Shum, Michael S. Y.; Pasquier, Eddy; Po'uha, Sela T.; O'Neill, Geraldine M.; Chaponnier, Christine; Gunning, Peter W.; Kavallaris, Maria			gamma-Actin regulates cell migration and modulates the ROCK signaling pathway	FASEB JOURNAL			English	Article						cytoskeleton; focal adhesion; motility; polarity; beta-actin; paxillin	BETA-ACTIN; POLARITY PROTEINS; CDC42 CONTROLS; ISOFORMS; EXPRESSION; ADHESION; MYOSIN; IMMUNOLOCALIZATION; ARGINYLATION; CYTOSKELETON	Cell migration plays a crucial role in numerous cellular functions, and alterations in the regulation of cell migration are required for invasive transformation of a tumor cell. While the mechanistic process of actin-based migration has been well documented, little is known as to the specific function of the nonmuscle actin isoforms in mammalian cells. Here, we present a comprehensive examination of gamma-actin's role in cell migration using an RNAi approach. The partial suppression of gamma-actin expression in SH-EP neuroblastoma cells resulted in a significant decrease in wound healing and transwell migration. Similarly, the knockdown of gamma-actin significantly reduced speed of motility and severely affected the cell's ability to explore, which was, in part, due to a loss of cell polarity. Moreover, there was a significant increase in the size and number of paxillin-containing focal adhesions, coupled with a significant decrease in phosphorylated paxillin in gamma-actin-knockdown cells. In addition, there was a significant increase in the phosphorylation of cofilin and myosin regulatory light chain, suggesting an overactivated Rhoassociated kinase (ROCK) signaling pathway in gamma-actin-knockdown cells. The alterations in the phosphorylation of paxillin and myosin regulatory light chain were unique to gamma-actin and not beta-actin knockdown. Inhibition of the ROCK pathway with the inhibitor Y-27632 restored the ability of gamma-actin-knockdown cells to migrate. This study demonstrates gamma-actin as a potential upstream regulator of ROCK mediated cell migration.-Shum, M. S. Y., Pasquier, E., Po'uha, S. T., O'Neill, G. M., Chaponnier, C., Gunning, P. W., Kavallaris, M. gamma-Actin regulates cell migration and modulates the ROCK signaling pathway. FASEB J. 25, 4423-4433 (2011). www.fasebj.org	[Shum, Michael S. Y.; Pasquier, Eddy; Po'uha, Sela T.; Kavallaris, Maria] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Sydney, NSW, Australia; [Gunning, Peter W.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Oncol Res Unit, Sydney, NSW, Australia; [O'Neill, Geraldine M.] Childrens Hosp Westmead, Kids Res Inst, Focal Adhes Biol Grp, Westmead, NSW, Australia; [O'Neill, Geraldine M.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Chaponnier, Christine] Univ Geneva, Fac Med, Dept Pathol Immunol, Geneva, Switzerland	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Geneva	Kavallaris, M (corresponding author), UNSW, Lowy Canc Res Ctr, Childrens Canc Inst Australia, POB 81, Randwick, NSW 2031, Australia.	m.kavallaris@ccia.unsw.edu.au	Gunning, Peter W/E-9058-2010; O'Neill, Geraldine/F-3112-2014; Pasquier, Eddy/A-8112-2018; Kavallaris, Maria/J-5240-2014	Pasquier, Eddy/0000-0003-2824-5002; O'Neill, Geraldine/0000-0001-9997-8794; Gunning, Peter/0000-0003-0833-3128	Children's Cancer Institute Australia for Medical Research; Australian Postgraduate Award; Swiss National Foundation; National Health and Medical Research Council (NHMRC); Oncology Children's Foundation; NHMRC	Children's Cancer Institute Australia for Medical Research; Australian Postgraduate Award(Australian Government); Swiss National Foundation(Swiss National Science Foundation (SNSF)); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Oncology Children's Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Ms. Frances Byrne for insightful discussions. This work was supported by Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and the Sydney Children's Hospital, and funding from an Australian Postgraduate Award (M.S.Y.S.), grants from the Swiss National Foundation (C.C.), the National Health and Medical Research Council (NHMRC; M.K. and P.W.G.), the Oncology Children's Foundation, and NHMRC Senior and Principal Research Fellowships to M. K. and P. W. G., respectively.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bach CTT, 2009, MOL CELL BIOL, V29, P1506, DOI 10.1128/MCB.00857-08; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Bryan KE, 2006, J BIOL CHEM, V281, P20129, DOI 10.1074/jbc.M601514200; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; Dugina V, 2009, J CELL SCI, V122, P2980, DOI 10.1242/jcs.041970; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; Kouvroukoglou S, 2000, BIOMATERIALS, V21, P1725, DOI 10.1016/S0142-9612(99)00205-7; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; OTEY CA, 1988, CELL MOTIL CYTOSKEL, V9, P337, DOI 10.1002/cm.970090406; OTEY CA, 1986, J CELL BIOL, V102, P1726, DOI 10.1083/jcb.102.5.1726; OTEY CA, 1987, J CELL BIOCHEM, V34, P113, DOI 10.1002/jcb.240340205; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Pasquier E, 2010, MOL CANCER THER, V9, P1408, DOI 10.1158/1535-7163.MCT-09-0894; Pourroy B, 2006, CANCER RES, V66, P3256, DOI 10.1158/0008-5472.CAN-05-3885; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; SCHEVZOV G, 1995, DNA CELL BIOL, V14, P689, DOI 10.1089/dna.1995.14.689; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Watanabe H, 1998, J CELL SCI, V111, P1287; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701; Zhu M, 2003, AM J HUM GENET, V73, P1082, DOI 10.1086/379286	41	48	50	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2011	25	12					4423	4433		10.1096/fj.11-185447	http://dx.doi.org/10.1096/fj.11-185447			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	863BP	21908715	Green Published			2022-12-28	WOS:000298138100033
J	Sylvius, N; Bonne, G; Straatman, K; Reddy, T; Gant, TW; Shackleton, S				Sylvius, Nicolas; Bonne, Gisele; Straatman, Kees; Reddy, Thimma; Gant, Timothy W.; Shackleton, Sue			MicroRNA expression profiling in patients with lamin A/C-associated muscular dystrophy	FASEB JOURNAL			English	Article						cardiac and skeletal muscle; laminopathy; fetal genes	RNA-POLYMERASE-II; SKELETAL-MUSCLE DEVELOPMENT; CELL-CYCLE PROGRESSION; HEART-FAILURE; DILATED CARDIOMYOPATHY; GENE-EXPRESSION; TRANSCRIPTION FACTOR; NUCLEAR-ENVELOPE; MIRNA EXPRESSION; IN-VIVO	Mutations in the lamin A/C gene (LMNA) cause several disorders referred to as laminopathies, which include premature aging syndromes, lipodystrophy, and striated muscle disorders. There is evidence that lamin A/C plays a role in gene expression. MicroRNAs (miRNAs) are short noncoding RNAs regulating mRNAs involved in various biological processes, including the pathophysiology of striated muscles. Here, we profiled the expression of the miRNA transcriptome in skeletal muscle from patients with LMNA-related muscular dystrophy. Results show that control and patient groups can be distinguished based on their miRNA expression profile. Sixteen miRNAs are significantly dysregulated in patients compared with controls. Pathway enrichment analysis in the predicted targets of these miRNAs revealed pathways involved in muscle repair, such as MAPK, transforming growth factor-beta, and Wnt signaling. Interestingly, 9 of these miRNAs (hsa-miR-100, -127-3p, -148a, -136*, -192, -335, -376c, -489, and -502-3p) are highly expressed in fetal muscle, suggesting that the fetal miRNA gene program mediates a regenerative process. Overexpression of these miRNAs in C2C12 mouse myoblasts revealed that 3 of them (miR-100, -192, and -335) participate in muscle proliferation and differentiation. We identified target genes that likely mediate this effect, which include the calcineurin gene PPP3CA. Our findings are the first to demonstrate that miRNA expression is affected in laminopathies.-Sylvius, N., Bonne, G., Straatman, K., Reddy, T., Gant, T. W., Shackleton, S. MicroRNA expression profiling in patients with lamin A/C-associated muscular dystrophy. FASEB J. 25, 3966-3978 (2011). www.fasebj.org	[Sylvius, Nicolas; Gant, Timothy W.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; [Sylvius, Nicolas; Reddy, Thimma; Shackleton, Sue] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Straatman, Kees] Univ Leicester, Ctr Core Biotechnol Serv, Leicester LE1 7RH, Leics, England; [Bonne, Gisele] INSERM, U974, Paris, France; [Bonne, Gisele] Univ Paris 06, CNRS, UM 76, Inst Myol,UMR7215,IFR14, Paris, France; [Bonne, Gisele] Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Serv Biochim Metab, UF Cardiogenet & Myogenet, F-75634 Paris, France	University of Leicester; University of Leicester; University of Leicester; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Sylvius, N (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	ns249@le.ac.uk; ss115@le.ac.uk	Bonne, Gisèle/G-3121-2013	Bonne, Gisèle/0000-0002-2516-3258; Gant, Timothy/0000-0001-9057-4937; Sylvius, Nicolas/0000-0002-3470-3711; Straatman, Kornelis/0000-0002-9812-492X	Wellcome Trust; Institut National de la Sante et de la Recherche Medicale; Universite Pierre et Marie Curie Paris 06; Universite de la Mediterranee; Centre National de la Recherche Scientifique; Association Francaise contre les Myopathies	Wellcome Trust(Wellcome TrustEuropean Commission); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Pierre et Marie Curie Paris 06; Universite de la Mediterranee; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies)	This work was supported by a Wellcome Trust Value in People grant (to N.S.), Institut National de la Sante et de la Recherche Medicale, Universite Pierre et Marie Curie Paris 06, Universite de la Mediterranee, Centre National de la Recherche Scientifique, and Association Francaise contre les Myopathies. The authors sincerely thank clinicians R. Ben Yaou (Institut de Myologie, Universite Pierre et Marie Curie, Paris, France), P. Laforet (Institut de Myologie, Groupe Hospitalier Pitie-Salpetriere, Paris, France), and D. Duboc (Universite Paris Descartes, Hopital Cochin, Paris, France) for providing patient samples. The authors also acknowledge L. Demay and P. Richard for help in the LMNA mutation screening, M. Beuvin and N.B. Romero for help in the process of patient biopsies, N. Vignier (Institut de Myologie, Paris, France) for critical review of the manuscript, and Jinli Luo (Medical Research Council Toxicology Unit, Leicester, UK) for help in analyzing GO terms.	Arimura T, 2005, HUM MOL GENET, V14, P155, DOI 10.1093/hmg/ddi017; Astejada M N, 2007, Acta Myol, V26, P159; Bakay M, 2006, BRAIN, V129, P996, DOI 10.1093/brain/awl023; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Brack AS, 2009, DEV BIOL, V335, P93, DOI 10.1016/j.ydbio.2009.08.014; Calura E, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-630; Charniot JC, 2003, HUM MUTAT, V21, P473, DOI 10.1002/humu.10170; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen JF, 2008, P NATL ACAD SCI USA, V105, P2111, DOI 10.1073/pnas.0710228105; Csoka AB, 2004, AGING CELL, V3, P235, DOI 10.1111/j.1474-9728.2004.00105.x; Dorner D, 2006, J CELL BIOL, V173, P83, DOI 10.1083/jcb.200511149; Dreuillet C, 2002, NUCLEIC ACIDS RES, V30, P4634, DOI 10.1093/nar/gkf587; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Fang H, 2009, METHODS MOL BIOL, V563, P379, DOI 10.1007/978-1-60761-175-2_20; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Greco S, 2009, FASEB J, V23, P3335, DOI 10.1096/fj.08-128579; Gueneau L, 2009, AM J HUM GENET, V85, P338, DOI 10.1016/j.ajhg.2009.07.015; Helbling-Leclerc A, 2002, EUR J HUM GENET, V10, P157, DOI 10.1038/sj.ejhg.5200744; Ikeda S, 2007, PHYSIOL GENOMICS, V31, P367, DOI 10.1152/physiolgenomics.00144.2007; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kaab S, 2004, J MOL MED, V82, P308, DOI 10.1007/s00109-004-0527-2; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Kollias HD, 2008, J APPL PHYSIOL, V104, P579, DOI 10.1152/japplphysiol.01091.2007; Kumaran RI, 2002, J CELL BIOL, V159, P783, DOI 10.1083/jcb.200204149; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Liang WC, 2011, ANN NEUROL, V69, P1005, DOI 10.1002/ana.22338; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Malhas A, 2010, CELL CYCLE, V9, P531, DOI 10.4161/cc.9.3.10511; Matkovich SJ, 2009, CIRCULATION, V119, P1263, DOI 10.1161/CIRCULATIONAHA.108.813576; McDaneld TG, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-77; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Mestroni L, 1999, EUR HEART J, V20, P93, DOI 10.1053/euhj.1998.1145; Muchir A, 2007, J CLIN INVEST, V117, P1282, DOI 10.1172/JCI29042; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Otto A, 2008, J CELL SCI, V121, P2939, DOI 10.1242/jcs.026534; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Prasad SVN, 2009, J BIOL CHEM, V284, P27487, DOI 10.1074/jbc.M109.036541; Reichart B, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-12; Saenz A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003750; Shaklai S, 2007, FEBS J, V274, P1383, DOI 10.1111/j.1742-4658.2007.05697.x; Spann TP, 2002, J CELL BIOL, V156, P603, DOI 10.1083/jcb.200112047; Stierle VN, 2003, BIOCHEMISTRY-US, V42, P4819, DOI 10.1021/bi020704g; Sucharov C, 2008, J MOL CELL CARDIOL, V45, P185, DOI 10.1016/j.yjmcc.2008.04.014; SUNADOME K, DEV CELL, V20, P192; Sylvius N, 2005, J MED GENET, V42, P639, DOI 10.1136/jmg.2004.023283; Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947; van Berlo JH, 2004, EUR HEART J, V25, P812, DOI 10.1016/j.ehj.2004.03.007; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vytopil M, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.12.e132; Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	55	34	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2011	25	11					3966	3978		10.1096/fj.11-182915	http://dx.doi.org/10.1096/fj.11-182915			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	844BT	21840938				2022-12-28	WOS:000296723100021
J	Kim, HK; Kim, HY; Schneewind, O; Missiakas, D				Kim, Hwan Keun; Kim, Hye-Young; Schneewind, Olaf; Missiakas, Dominique			Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses	FASEB JOURNAL			English	Article						genetic vaccinology; protein A; sortase A; clumping factor; fibrinogen-binding protein; SdrD	SURFACE-PROTEINS; VACCINE; SORTASE; MUTANT; TUBERCULOSIS; INFECTIONS; RESISTANCE; DELETION; ANCHORS; MICE	Staphylococcus aureus infections result in abscesses as well as septicemia. Even with therapy, abscesses can persist or even reoccur, as staphylococcal infections fail to induce protective immune responses. Here, we show that prior infection with certain attenuated strains may elicit protective immunity. A closer examination reveals that protection correlates with antibody responses elicited on exposure to particular attenuated variants. Linear regression analysis was used to compare reduction in staphylococcal disease and antibody responses to infection with wild-type and attenuated variants. This analysis identified protective antigens that, when tested as vaccines in mice, elicited disease protection. Protection afforded by attenuated strains correlates in part with the ability of Staphylococcus aureus to modulate B cell responses via protein A (spa encoded). We designate this approach "genetic vaccinology," since it exploits genetic variants to draw a correlation between disease protection and humoral immune responses for the deduction of vaccine antigens. Genetic vaccinology is particularly useful for microbes that do not elicit natural protective immunity during infection.-Kim, H. K., Kim, H.-Y., Schneewind, O., Missiakas, D. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 25, 3605-3612 (2011). www.fasebj.org	[Kim, Hwan Keun; Kim, Hye-Young; Schneewind, Olaf; Missiakas, Dominique] Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA	University of Chicago	Missiakas, D (corresponding author), Univ Chicago, Dept Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	dmissiak@bsd.uchicago.edu		Kim, Hwan Keun/0000-0003-2095-9705	U.S. National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Branch [AI52747, AI92711, AI75258]; Region V Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (National Institutes of Health) [1-U54-AI-057153]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153, R01AI075258, RC4AI092711, R41AI052747] Funding Source: NIH RePORTER	U.S. National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Branch(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Region V Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank members of their laboratory for experimental assistance and critical discussion. This work was supported by grants from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Branch (AI52747 and AI92711 to O.S. and AI75258 to D. M.). D.M. and O.S. acknowledge membership within and support from the Region V Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (National Institutes of Health award 1-U54-AI-057153).	Adhikari RP, 2008, MICROBIOL-SGM, V154, P949, DOI 10.1099/mic.0.2007/012245-0; Bae T, 2006, PLASMID, V55, P58, DOI 10.1016/j.plasmid.2005.05.005; Bae T, 2004, P NATL ACAD SCI USA, V101, P12312, DOI 10.1073/pnas.0404728101; Behring EV., 1890, DEUT MED WOCHENSCHR, V49, P1113; Bordet J, 1923, BMJ-BRIT MED J, V1923, P175; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Chambers HF, 2005, NEW ENGL J MED, V352, P1485, DOI 10.1056/NEJMe058023; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; Chen PR, 2006, NAT CHEM BIOL, V2, P591, DOI 10.1038/nchembio820; Cheng AG, 2009, FASEB J, V23, P3393, DOI 10.1096/fj.09-135467; Fattom A, 2004, VACCINE, V23, P656, DOI 10.1016/j.vaccine.2004.06.043; Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x; FORSGREN A, 1968, J IMMUNOL, V100, P927; FORSGREN A, 1976, EUR J IMMUNOL, V6, P207, DOI 10.1002/eji.1830060312; Goodyear CS, 2004, P NATL ACAD SCI USA, V101, P11392, DOI 10.1073/pnas.0404382101; Goodyear CS, 2003, J EXP MED, V197, P1125, DOI 10.1084/jem.20020552; JENSEN KLAUS, 1958, ACTA PATHOL ET MICROBIOL SCAND, V44, P421; Kernodle DS, 2010, CLIN INFECT DIS, V51, P177, DOI 10.1086/653533; Kim HK, 2010, J EXP MED, V207, P1863, DOI 10.1084/jem.20092514; Kim HK, 2010, VACCINE, V28, P6382, DOI 10.1016/j.vaccine.2010.02.097; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Kuklin NA, 2006, INFECT IMMUN, V74, P2215, DOI 10.1128/IAI.74.4.2215-2223.2006; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; McKenney D, 1999, SCIENCE, V284, P1523, DOI 10.1126/science.284.5419.1523; Menzies BE, 1996, INFECT IMMUN, V64, P1839, DOI 10.1128/IAI.64.5.1839-1841.1996; Novick RP, 2008, ANNU REV GENET, V42, P541, DOI 10.1146/annurev.genet.42.110807.091640; Projan SJ, 2006, CURR OPIN PHARMACOL, V6, P473, DOI 10.1016/j.coph.2006.04.005; Rampone H, 1996, CAN J VET RES, V60, P237; Rogers D. E., 1965, ANN NY ACAD SCI, V128, P45; Sambandamurthy VK, 2006, VACCINE, V24, P6309, DOI 10.1016/j.vaccine.2006.05.097; Silverman GJ, 2006, NAT REV IMMUNOL, V6, P465, DOI 10.1038/nri1853; Simeone R, 2009, CURR OPIN MICROBIOL, V12, P4, DOI 10.1016/j.mib.2008.11.003; Smith T, 1907, J MED RES, V16, P359; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Thammavongsa V, 2009, J EXP MED, V206, P2417, DOI 10.1084/jem.20090097; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208	42	55	58	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3605	3612		10.1096/fj.11-187963	http://dx.doi.org/10.1096/fj.11-187963			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21753082	Green Published			2022-12-28	WOS:000295356400030
J	Zhou, P; Fan, L; Yu, KD; Zhao, MW; Li, XX				Zhou, Peng; Fan, Lei; Yu, Ke-Da; Zhao, Ming-Wei; Li, Xiao-Xin			Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity	FASEB JOURNAL			English	Article						age-related macular degeneration; double-stranded RNA	MACULAR DEGENERATION; FUNCTIONAL ANALYSES; POLYMORPHISMS	The genetic association between a variant in the Toll-like receptor 3 (TLR3) gene (C1234T in mRNA, L412F in protein, Reference SNP Cluster Report rs3775291) and geographic atrophy (GA; also called advanced "dry" age-related macular degeneration) was controversial in previous studies. We performed a meta-analysis by pooling the current evidence in literature and found that the T allele of the TLR3 C1234T variant showed a summary odds ratio of 0.753 (95% confidence interval: 0.612-0.927; P=0.007). Further experiments were performed to analyze how this mutant influences the function of TLR3. We found that this SNP did not affect mRNA, protein, or surface expression of TLR3. However, the binding capacity of L412F mutation of TLR3 for double-stranded RNA in the TLR3 protein was only 51.12 +/- 3.96% (P<0.001) of the wild-type level. There was a consistently reduced TLR3-mediated NF-kappa B activation. Therefore, TLR3 C1234T (L412F in the protein) may protect against GA by reduced binding capacity of TLR3 to dsRNA. This study may provide a better understanding of the genetic architecture underlying disease susceptibility and may advance the potential for preclinical prediction in future genetic testing.-Zhou, P., Fan, L., Yu, K. -D., Zhao, M. -W., Li, X. -X. Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity, FASEB J. 25, 3489-3495 (2011). www.fasebj.org	[Zhou, Peng; Zhao, Ming-Wei; Li, Xiao-Xin] Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China; [Zhou, Peng; Zhao, Ming-Wei; Li, Xiao-Xin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China; [Zhou, Peng] Fudan Univ, Eye & Ear Nose & Throat Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China; [Fan, Lei; Yu, Ke-Da] Fudan Univ, Dept Breast Surg, Ctr Canc, Inst Canc, Shanghai 200433, Peoples R China	Peking University; Fudan University; Fudan University	Li, XX (corresponding author), Peking Univ Peoples Hosp, Dept Ophthalmol, 11 S Ave XiZhiMen, Beijing 100044, Peoples R China.	drxiaoxinli@gmail.com	Zhou, Peng/C-6054-2008	Zhou, Peng/0000-0002-1744-5167	National Basic Research Program of China (973 Program) [2011CB510200]	National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This research was supported by National Basic Research Program of China (973 Program) grant 2011CB510200.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Allikmets R, 2009, NEW ENGL J MED, V360, P2252; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688; Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378; Edwards AO, 2009, NEW ENGL J MED, V360, P2254; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012; Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P17696, DOI 10.1074/jbc.M700209200; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437; Yu KD, 2011, BREAST CANCER RES TR, V126, P365, DOI 10.1007/s10549-010-0937-5; Yu KD, 2010, BREAST CANCER RES TR, V123, P219, DOI 10.1007/s10549-010-0753-y; Yu KD, 2010, BREAST CANCER RES TR, V122, P853, DOI 10.1007/s10549-010-0738-x	20	42	45	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2011	25	10					3489	3495		10.1096/fj.11-189258	http://dx.doi.org/10.1096/fj.11-189258			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	826LU	21712495				2022-12-28	WOS:000295356400019
J	Doyle, T; Chen, ZM; Muscoli, C; Obeid, LM; Salvemini, D				Doyle, Tim; Chen, Zhoumou; Muscoli, Carolina; Obeid, Lina M.; Salvemini, Daniela			Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-kappa B- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E-2 pathway	FASEB JOURNAL			English	Article						pain; sphingolipid; sphingosine-1-phosphate; COX inhibitor; NS-398	NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASES; PRIMARY SENSORY NEURONS; NERVE GROWTH-FACTOR; GENE-EXPRESSION; PROSTAGLANDIN SYNTHESIS; ENDOPLASMIC-RETICULUM; SIGNALING PATHWAYS; PHOSPHOLIPASE A(2); INFLAMMATORY PAIN	Inflammatory pain represents an important unmet clinical need with important socioeconomic implications. Ceramide, a potent proinflammatory sphingolipid, has been shown to elicit mechanical hyperalgesia, but the mechanisms remain largely unknown. We now demonstrate that, in addition to mechanical hyperalgesia, intraplantar injection of ceramide (10 mu g) led to the development of thermal hyperalgesia that was dependent on induction of the inducible cyclooxygenase (COX-2) and subsequent increase of prostaglandin E-2 (PGE(2)). The development of mechanical and thermal hyperalgesia and increased production of PGE(2) was blocked by NS-398 (15-150 ng), a selective COX-2 inhibitor. The importance of the COX-2 to PGE(2) pathway in ceramide signaling was underscored by the findings that intraplantar injection of a monoclonal PGE(2) antibody (4 mu g) blocked the development of hyperalgesia. Our results further revealed that COX-2 induction is regulated by NF-kappa B and p38 kinase activation, since intraplantar injection of SC-514 (0.1-1 mu g) or SB 203580 (1-10 mu g), well-characterized inhibitors of NF-kappa B and p38 kinase activation, respectively, blocked COX-2 induction and increased formation of PGE(2) and thermal hyperalgesia in a dose-dependent manner. Moreover, activation of NF-kappa B was dependent on upstream activation of p38 MAPK, since SB 203580 (10 mu g) blocked p65 phosphorylation, whereas p38 kinase phosphorylation was unaffected by NF-kappa B inhibition by SC-514 (1 mu g). Our findings not only provide mechanistic insight into the signaling pathways engaged by ceramide in the development of hyperalgesia, but also provide a potential pharmacological basis for developing inhibitors targeting the ceramide metabolic-to-COX-2 pathway as novel analgesics.-Doyle, T., Chen, Z., Muscoli, C., Obeid, L. M., Salvemini, D. Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-kappa B- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E-2 pathway. FASEB J. 25, 2782-2791 (2011). www.fasebj.org	[Doyle, Tim; Chen, Zhoumou; Muscoli, Carolina; Salvemini, Daniela] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; [Muscoli, Carolina] Magna Graecia Univ Catanzaro, Fac Pharm, Catanzaro, Italy; [Muscoli, Carolina] Ist Ricovero & Cura Carattere Sci San Raffaele La, Rome, Italy; [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Saint Louis University; Magna Graecia University of Catanzaro; Medical University of South Carolina	Salvemini, D (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	salvemd@slu.edu	Muscoli, Carolina/G-2773-2011	Muscoli, Carolina/0000-0002-1047-4467; obeid, lina/0000-0002-0734-0847	U.S. National Institutes of Health (NIH) [R01 DA024074, R21 DA023056, RO1 GM062887]; U.S. Department of Veterans Affairs; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA023056, R01DA024074] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Amanda Finley (Department of Pharmacological and Physiological Science, St. Louis University School of Medicine) for her help in performing p38 Western blot analysis. This study was supported by U.S. National Institutes of Health (NIH) grants R01 DA024074 and R21 DA023056 to D.S. and a U.S. Department of Veterans Affairs Merit Award and NIH grant RO1 GM062887 to L.O. The authors declare no conflicts of interest.	Ardail D, 2002, BBA-MOL CELL BIOL L, V1583, P305, DOI 10.1016/S1388-1981(02)00252-4; Arthur JSC, 2008, FRONT BIOSCI-LANDMRK, V13, P5866, DOI 10.2741/3122; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Bischof LJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000176; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bryant L, 2009, NEUROSCI LETT, V463, P49, DOI 10.1016/j.neulet.2009.07.051; Camandola S, 2005, J BIOL CHEM, V280, P22287, DOI 10.1074/jbc.M410923200; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Centers for Disease Control and Prevention (CDC), 2010, MMWR Morb Mortal Wkly Rep, V59, P1261; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; Chen CL, 2008, BLOOD, V111, P4365, DOI 10.1182/blood-2007-08-106336; Cheng JK, 2008, NEUROCHEM RES, V33, P1970, DOI 10.1007/s11064-008-9711-z; Chi XX, 2010, J NEUROPHYSIOL, V104, P2741, DOI 10.1152/jn.00709.2010; Cohen S, 2010, CURR OPIN RHEUMATOL, V22, P330, DOI 10.1097/BOR.0b013e3283378e6f; COLLIER HOJ, 1972, NATURE-NEW BIOL, V236, P141, DOI 10.1038/newbio236141a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS KD, 1993, J NEUROPHYSIOL, V69, P1071, DOI 10.1152/jn.1993.69.4.1071; Delgado A, 2006, BBA-BIOMEMBRANES, V1758, P1957, DOI 10.1016/j.bbamem.2006.08.017; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FERREIRA SH, 1978, PROSTAGLANDINS, V16, P31, DOI 10.1016/0090-6980(78)90199-5; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Gutierrez G, 2007, ANTI-CANCER DRUG, V18, P149, DOI 10.1097/CAD.0b013e3280115111; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; Hootman JM, 2006, ARTHRITIS RHEUM-US, V54, P226, DOI 10.1002/art.21562; Huang CY, 2010, J CELL PHYSIOL, V224, P475, DOI 10.1002/jcp.22145; Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Joo JH, 2008, J BIOL CHEM, V283, P16391, DOI 10.1074/jbc.M800945200; Joseph EK, 2004, EUR J NEUROSCI, V20, P2896, DOI 10.1111/j.1460-9568.2004.03750.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; KHASAR SG, 1995, NEUROSCIENCE, V67, P189, DOI 10.1016/0306-4522(94)00632-F; Kim HJ, 2006, TOXICOLOGY, V225, P36, DOI 10.1016/j.tox.2006.04.053; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kitano M, 2006, ARTHRITIS RHEUM-US, V54, P742, DOI 10.1002/art.21668; Lei XY, 2007, BIOCHEMISTRY-US, V46, P10170, DOI 10.1021/bi700017z; Li NX, 2000, METHOD ENZYMOL, V319, P273; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; MARTIN HA, 1987, NEUROSCIENCE, V22, P651, DOI 10.1016/0306-4522(87)90360-5; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Mitchell JA, 2006, NAT REV DRUG DISCOV, V5, P75, DOI 10.1038/nrd1929; MONCADA S, 1975, EUR J PHARMACOL, V31, P250, DOI 10.1016/0014-2999(75)90047-3; Muscoli C, 2010, J NEUROSCI, V30, P15400, DOI 10.1523/JNEUROSCI.2391-10.2010; Ndengele MM, 2008, FASEB J, V22, P3154, DOI 10.1096/fj.08-108159; Ndengele MM, 2009, J PHARMACOL EXP THER, V329, P64, DOI 10.1124/jpet.108.146290; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722; Oliveira MS, 2008, EPILEPSY RES, V79, P14, DOI 10.1016/j.eplepsyres.2007.12.008; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Reber L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004393; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; RUEFF A, 1993, NEUROSCIENCE, V54, P527, DOI 10.1016/0306-4522(93)90272-H; Saha RN, 2007, J IMMUNOL, V179, P7101, DOI 10.4049/jimmunol.179.10.7101; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Sauane M, 2010, J CELL PHYSIOL, V222, P546, DOI 10.1002/jcp.21969; Schafers M, 2008, NEUROSCIENCE, V157, P414, DOI 10.1016/j.neuroscience.2008.08.067; Schafers M, 2003, J NEUROSCI, V23, P3028; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Senkal CE, 2010, FASEB J, V24, P296, DOI 10.1096/fj.09-135087; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; TAIWO YO, 1991, NEUROSCIENCE, V44, P131, DOI 10.1016/0306-4522(91)90255-M; TAIWO YO, 1990, NEUROSCIENCE, V38, P757, DOI 10.1016/0306-4522(90)90068-F; Tang N, 2009, J OROFAC PAIN, V23, P167; Toth B, 2006, J BIOL CHEM, V281, P36369, DOI 10.1074/jbc.M604935200; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200; Wang ZY, 2010, PAIN, V151, P194, DOI 10.1016/j.pain.2010.07.006; Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Wilcox CM, 2006, CLIN GASTROENTEROL H, V4, P1082, DOI 10.1016/j.cgh.2006.04.010; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; WILLIS AL, 1973, PROSTAG OTH LIPID M, V3, P353, DOI 10.1016/0090-6980(73)90073-7; Zhang YH, 2006, J PHYSIOL-LONDON, V575, P101, DOI 10.1113/jphysiol.2006.111575; Zhang YH, 2006, J NEUROPHYSIOL, V96, P1042, DOI 10.1152/jn.00120.2006; Zhang YH, 2004, NEUROSCI LETT, V366, P187, DOI 10.1016/j.neulet.2004.05.042; Zhang YH, 2002, J PHYSIOL-LONDON, V544, P385, DOI 10.1113/jphysiol.2002.024265	88	24	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2011	25	8					2782	2791		10.1096/fj.10-178095	http://dx.doi.org/10.1096/fj.10-178095			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	800CV	21551240	Green Published			2022-12-28	WOS:000293337800026
